APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com



APPROVED DRUG PRODUCTS

WITH

THERAPEUTIC EQUIVALENCE EVALUATIONS

40th EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2020

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2019.

40th EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2020

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

CONTENTS

PAGE

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

PREFACE TO FORTIETH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products in the Orange Book is independent of any current regulatory action being taken administratively or judicially against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs)under the provisions of Section 505 of the FD&C Act and FDA regulations at that time.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate corrections and additions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments amended the FD&C Act to establish, among other things, the 505(b)(2) and 505(j) approval pathways. The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that have qualified under the FD&C Act for periods of exclusivity and provides patent information concerning the approved drug products in the Orange Book. The *Addendum* also provides additional information that may be helpful to those submitting an NDA under section 505(b) of the FD&C Act or an abbreviated new drug application (ANDA) under section 505(j) of the FD&C Act to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Central Document Room, Attn: Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn from sale for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.[1] This publication also includes indices of prescription and OTC drug products by proprietary name (brand name or trade name) or, if no proprietary name exists, established name of the active ingredient and by applicant name, which have been abbreviated for this publication. Established names for active ingredients generally conform to compendial names or ***United States Adopted Names*** (USAN) as described in 21 CFR 299.4(e). A list of uniform terms is provided in Appendix C.

The ***Addendum*** contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list. In addition, we note that Section 505(x) of the FD&C Act affects the date of approval for certain drug products subject to scheduling under the Controlled Substances Act. The Agency will list the drug product in the Orange Book and the date of approval as determined under Section 505(x).

The Orange Book identifies the application holder of a drug product and does not identify distributors or repackagers.

[1] Generally, newly approved products are added to the Active Section of the Orange Book (i.e., the Prescription Drug Product List or the Over-the-Counter Drug Product List), depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication. See Section 1.12.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Pharmaceutical equivalents are drug products in identical dosage forms and route(s) of administration that contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified-release dosage forms that require a reservoir or overage or such forms as prefilled syringes where the residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; do not necessarily contain the same inactive ingredients; and meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[2] They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form, or the same salt or ester (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules).[3] Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[4] Different dosage forms and strengths within a product line by a single manufacturer are pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Approved drug products are considered to be therapeutic equivalents if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.[5]

FDA classifies as therapeutically equivalent those drug products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the identical active drug ingredient in the identical dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable ***in vitro*** standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. The concept of therapeutic equivalence applies only to drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain). Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug

[2] 21 CFR 314.3(b).
[3] See 21 CFR 314.3(b).
[4] 21 CFR 314.3(b).
[5] 21 CFR 314.3(b).

product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product when administered to patients under the conditions specified in the labeling.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (***e.g.***, weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (***e.g.***, weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (***e.g.***, certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).[6] Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.[7]

[6] 21 CFR 314.3(b).
[7] 21 CFR 314.3(b).

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.[8] Section 505(j)(8)(B) of the FD&C Act describes certain conditions under which a test drug and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> (i) the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> (ii) the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid ***in vivo*** or ***in vitro*** test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an ***in vitro*** bioequivalence standard, especially when such an ***in vitro*** test has been correlated with human ***in vivo*** bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.[9]

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.[10]

[8] 21 CFR 314.3(b).
[9] 21 CFR 320.24.
[10] We note that prior to the 36th edition of the Orange Book, the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance d/////ocuments for additional information regarding bioequivalence and bioavailability. See generally 21 CFR part 320. See FDA Drugs guidance Web page at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs and FDA Drugs guidance (Product-Specific Guidances for Generic Drug Development) Web page at https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development.

1.4 Reference Listed Drug and Reference Standard

A reference listed drug is the listed drug[11] identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.[12] Generally, a reference listed drug is a drug product approved in a new drug application under Section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.[13]

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an ***in vivo*** bioequivalence study required for approval.[14] FDA generally selects a single reference standard that ANDA applicants must use in ***in vivo*** bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances, the reference listed drug and the reference standard may be different. For example, where the reference listed drug has been withdrawn from sale FDA may select an ANDA as the reference standard.

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

In some instances when FDA has not designated a listed drug as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may submit a controlled correspondence to the Office of Generic Drugs to ask FDA to designate a reference listed drug for that drug product. Section 1.7, ***Therapeutic Equivalence Evaluations Codes*** (***products meeting necessary bioequivalence requirements***) explains the character coding system (e.g., **AB, AB1, AB2, AB3**...) for multisource drug products listed under the same heading with two or more reference listed drugs.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any ***in vivo*** bioequivalence studies required for approval.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated,

---

[11] A "listed drug" is a new drug product that has been approved under section 505(c) of the FD&C Act for safety and effectiveness or under section 505(j) of the FD&C Act, which has not been withdrawn or suspended under section 505(e)(1) through (5) or section 505(j)(6) of the FD&C Act, and which has not been withdrawn from sale for what FDA has determined are reasons of safety or effectiveness. Listed drug status is evidenced by the drug product's identification in the current edition of FDA's "Approved Drug Products With Therapeutic Equivalence Evaluations" (the list) as an approved drug. A drug product is deemed to be a listed drug on the date of approval for the NDA or ANDA for that drug product (21 CFR 314.3(b)).

[12] 21 CFR 314.3(b).

[13] 21 CFR 314.94(a)(3)(i).

[14] 21 CFR 314.3(b).

e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an ***in vivo*** bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, e.g., reducing the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. However, these products may differ in other characteristics that are not required by statute or regulation to be the same, such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion, e.g., due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be patient-specific allergic reactions in rare cases due to a coloring or a preservative ingredient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the practitioner's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different

characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products (particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code generally is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by the applicant or some other person authorized by the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book. The details of therapeutic equivalence codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. Products listed in the Orange Book are identified by the applicant's name (firm name on the Form FDA 356h in the application). Where the applicant's name does not appear on the label, a person wishing to relate a specific product to the applicant name in the Orange Book may refer to FDA's NDC Directory[15] and match its search terms to information on the label, such as the NDC Code if available.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an NDA or ANDA that has been approved and that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may, however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly

[15] https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory.

whether the Agency has evaluated a particular approved product (e.g., a particular strength of an approved drug) as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX**, or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an **"A"** code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable *in vitro* approach is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through ***in vivo*** and/or ***in vitro*** studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA's determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, ***Description of Certain Special Situations***. For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

For example, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical

alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate ***in vitro*** bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, ***Therapeutic Equivalence-Related Terms, Strength)*** generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. If a study is submitted that demonstrates bioequivalence to a reference listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered

therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon ***in vitro*** methodology, if bioequivalence needs to be demonstrated by ***in vivo*** methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these

products are on the market without FDA approval and FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms,* the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.[16] In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as x mg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as x mg/vial.

However, FDA subsequently realized that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book displays the strength of all new approvals of parenteral solutions. Previously (i.e., prior to 2003), we would have displayed only the concentration of an approved parenteral solution, e.g. 50 mg/mL. For example, if this application had a 20 mL and 60 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1 gm/20 mL (50 mg/mL) and 3 gm/60 mL (50 mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of ***in vivo*** bioequivalence has been granted, or the application contains adequate scientific evidence establishing through an ***in vitro*** approach the bioequivalence of the product to a selected reference product, and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence and for which a waiver of ***in vivo*** bioequivalence has not been granted, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate ***in vivo*** bioequivalence data, and **BT** in the absence of such data.

[16] The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a **"B"** code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the **"B"** sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been

submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is

available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was

submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, ***all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.*** A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium.[17] Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[18]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS

[17] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.
[18] The chart is current as of the date of publication of the annual edition. See the most current monthly cumulative supplement for updates to this information available at https://www.fda.gov/media/72973/download. Please consult the Active Section for information on other strengths.

AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[19]	MYLAN	0.3MG	A076187	–	RS

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient in a fixed-combination drug product, or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to Section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA seeking approval of a drug that is the same as a drug product approved in a petitioned ANDA should use as its reference listed drug, the reference listed drug that served as the basis for the approved suitability petition, and use the drug product approved in the petitioned ANDA as its reference standard for conducting an ***in vivo*** bioequivalence study required for approval. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.[20] (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, FDA will not accept for review and/or will not approve a 505(b)(2) application or an ANDA under Section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity.[21] If the listed drug is also protected by one or more

[19] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

[20] If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

[21] See Patent and Exclusivity Information Addendum in the Orange Book.

patents, the approval date for the ANDA or 505(b)(2) application will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all ANDAs and 505(b)(2) applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its exclusivity, qualified ANDAs or 505(b)(2) applications may be accepted for review and/or approved, as applicable. An NDA for which the holder has waived its exclusivity as to all ANDAs and 505(b)(2) applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific active ingredient and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is generally an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the ***Federal Register*** of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**". The determinations listed in the Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.[22] Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book Staff of any changes or corrections, including any change in ownership or a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that under Section 506I(a) of the FD&C Act, applicants must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that applicants notify the Agency in writing within 180

[22] See, e.g., Section 506I(d) of the FD&C Act.

days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1 or 2 of the Orange Book (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update.

In addition, the FDA Orange Book Staff generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already listed in the Orange Book, but rather intends to apply the change prospectively to drug products as they are added to the Orange Book.

You can contact the Orange Book Staff by email at orangebook@fda.hhs.gov.

1.13 Availability of the Edition

The Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the Orange Book home page by clicking on Publications. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, https://www.gpo.gov/.

2.0 HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with **"A"** and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant *(Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT



*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **A")** AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE ***INTRODUCTION.***



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA		AUROBINDO PHARMA LTD	**EQ 20MG BASE/ML**	**A077950**	**001**	Mar 14, 2018
AA		HETERO LABS LTD III	**EQ 20MG BASE/ML**	**A201107**	**001**	Sep 26, 2016

ZIAGEN

AA	**+!**	VIIV HLTHCARE	**EQ 20MG BASE/ML**	**N020978**	**001**	Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATE

AB		APOTEX INC	**EQ 300MG BASE**	**A201570**	**001**	Dec 17, 2012
AB		AUROBINDO PHARMA LTD	**EQ 300MG BASE**	**A077844**	**001**	Dec 17, 2012
AB		CIPLA	**EQ 300MG BASE**	**A078119**	**001**	Nov 21, 2017
AB		HETERO LABS LTD III	**EQ 300MG BASE**	**A091560**	**001**	Sep 13, 2013
AB		MYLAN PHARMS INC	**EQ 300MG BASE**	**A091294**	**001**	Jun 18, 2012
AB		STRIDES PHARMA	**EQ 300MG BASE**	**A091050**	**001**	Oct 28, 2016

ZIAGEN

AB	**+!**	VIIV HLTHCARE	**EQ 300MG BASE**	**N020977**	**001**	Dec 17, 1998

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

	+!	VIIV HLTHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551	001	Aug 22, 2014

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		AUROBINDO PHARMA LTD	**EQ 600MG BASE;300MG**	**A090159**	**001**	Nov 15, 2018
AB			**EQ 600MG BASE;300MG**	**A206151**	**001**	Mar 28, 2017
AB		CIPLA	**EQ 600MG BASE;300MG**	**A091144**	**001**	Mar 28, 2017
AB		LUPIN LTD	**EQ 600MG BASE;300MG**	**A204990**	**001**	Mar 28, 2017
AB		TEVA PHARMS USA	**EQ 600MG BASE;300MG**	**A079246**	**001**	Sep 29, 2016

EPZICOM

AB	**+!**	VIIV HLTHCARE	**EQ 600MG BASE;300MG**	**N021652**	**001**	Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

AB		LUPIN LTD	**EQ 300MG BASE;150MG;300MG**	**A202912**	**001**	Dec 05, 2013

TRIZIVIR

AB	**+!**	VIIV HLTHCARE	**EQ 300MG BASE;150MG;300MG**	**N021205**	**001**	Nov 14, 2000

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

	+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017

ABEMACICLIB

TABLET;ORAL

VERZENIO

	+	ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017
	+		100MG	N208716	002	Sep 28, 2017
	+		150MG	N208716	003	Sep 28, 2017
	+!		200MG	N208716	004	Sep 28, 2017

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		AMNEAL PHARMS	**250MG**	**A208327**	**001**	Jan 07, 2019
AB		APOTEX	**250MG**	**A208453**	**001**	Oct 31, 2018
AB		GLENMARK PHARMS	**250MG**	**A209227**	**001**	Oct 16, 2019
AB		HIKMA PHARMS	**250MG**	**A208339**	**001**	Oct 31, 2018
AB		MSN	**250MG**	**A210686**	**001**	Jul 10, 2019
AB		MYLAN	**250MG**	**A208446**	**001**	Oct 31, 2018
AB		QILU	**250MG**	**A212462**	**001**	Sep 27, 2019
AB		RISING	**250MG**	**A208371**	**001**	Feb 25, 2019
AB		TEVA PHARMS USA	**250MG**	**A208432**	**001**	Oct 31, 2018
AB		WOCKHARDT BIO AG	**250MG**	**A208380**	**001**	Feb 27, 2019

ZYTIGA

AB	**+**	JANSSEN BIOTECH	**250MG**	**N202379**	**001**	Apr 28, 2011

YONSA

	+!	SUN PHARMA GLOBAL	125MG	N210308	001	May 22, 2018

ABIRATERONE ACETATE
TABLET;ORAL
ZYTIGA

	+!	JANSSEN BIOTECH	500MG	N202379	002	Apr 14, 2017

ACALABRUTINIB
CAPSULE;ORAL
CALQUENCE

	+!	ASTRAZENECA	100MG	N210259	001	Oct 31, 2017

ACAMPROSATE CALCIUM
TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM

AB	**!**	GLENMARK GENERICS	**333MG**	**A202229**	**001**	Jul 16, 2013
AB		MYLAN	**333MG**	**A200142**	**001**	Mar 11, 2014
AB		ZYDUS PHARMS	**333MG**	**A205995**	**001**	May 26, 2017

ACARBOSE
TABLET;ORAL
ACARBOSE

AB		EMCURE PHARMS LTD	**25MG**	**A202271**	**001**	Feb 07, 2012
AB			**50MG**	**A202271**	**002**	Feb 07, 2012
AB			**100MG**	**A202271**	**003**	Feb 07, 2012
AB		HIKMA	**25MG**	**A078470**	**001**	May 07, 2008
AB			**50MG**	**A078470**	**002**	May 07, 2008
AB			**100MG**	**A078470**	**003**	May 07, 2008
AB		IMPAX LABS	**25MG**	**A078441**	**001**	May 14, 2009
AB			**50MG**	**A078441**	**002**	May 14, 2009
AB			**100MG**	**A078441**	**003**	May 14, 2009
AB	**!**	STRIDES PHARMA	**25MG**	**A090912**	**001**	Jul 27, 2011
AB			**50MG**	**A090912**	**002**	Jul 27, 2011
AB			**100MG**	**A090912**	**003**	Jul 27, 2011
AB		VIRTUS PHARM	**25MG**	**A091343**	**001**	Oct 17, 2013
AB			**50MG**	**A091343**	**002**	Oct 17, 2013
AB			**100MG**	**A091343**	**003**	Oct 17, 2013
AB		WATSON LABS	**25MG**	**A077532**	**001**	May 07, 2008
AB			**50MG**	**A077532**	**002**	May 07, 2008
AB			**100MG**	**A077532**	**003**	May 07, 2008

ACEBUTOLOL HYDROCHLORIDE
CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE

AB	**!**	AMNEAL PHARM	**EQ 200MG BASE**	**A075047**	**001**	Dec 30, 1999
AB	**!**		**EQ 400MG BASE**	**A075047**	**002**	Dec 30, 1999
AB		MYLAN	**EQ 200MG BASE**	**A074288**	**001**	Apr 24, 1995
AB			**EQ 400MG BASE**	**A074288**	**002**	Apr 24, 1995

ACETAMINOPHEN
SOLUTION;INTRAVENOUS
ACETAMINOPHEN

AP		CUSTOPHARM INC	**1GM/100ML (10MG/ML)**	**A202605**	**001**	Jun 13, 2016
AP		SANDOZ INC	**1GM/100ML (10MG/ML)**	**A204052**	**001**	Mar 22, 2016

OFIRMEV

AP	**+!**	MALLINCKRODT HOSP	**1GM/100ML (10MG/ML)**	**N022450**	**001**	Nov 02, 2010

ACETAMINOPHEN

		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE
TABLET;ORAL
APADAZ

	+	KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019
	+		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018
	+!		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019

ACETAMINOPHEN; BUTALBITAL
CAPSULE;ORAL
BUTALBITAL AND ACETAMINOPHEN

AA		GRANULES PHARMS	**300MG;50MG**	**A213115**	**001**	Nov 22, 2019
AA	**!**	MAYNE PHARMA INC	**300MG;50MG**	**A207313**	**001**	Dec 27, 2017

TABLET;ORAL
BUTALBITAL AND ACETAMINOPHEN

AA		CNTY LINE PHARMS	**300MG;50MG**	**A207635**	**001**	Jun 05, 2017
AA			**325MG;50MG**	**A205120**	**001**	Oct 30, 2015
AA		LARKEN LABS INC	**325MG;50MG**	**A203484**	**002**	Dec 04, 2015
AA		MIKART	**300MG;50MG**	**A207386**	**001**	Nov 15, 2016
AA	**!**	NEXGEN PHARMA	**300MG;50MG**	**A090956**	**001**	Aug 23, 2011

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTAPAP

AA	**!**	MIKART	**325MG;50MG**	**A089987**	**001**	Oct 26, 1992

ALLZITAL

	!	LARKEN LABS INC	325MG;25MG	A203484	001	Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		AUROLIFE PHARMA LLC	**325MG;50MG;40MG**	**A204733**	**001**	Sep 26, 2018
AA		LANNETT CO INC	**300MG;50MG;40MG**	**A212082**	**001**	Dec 17, 2019
AA			**325MG;50MG;40MG**	**A212083**	**001**	Dec 17, 2019
AA		MAYNE PHARMA INC	**300MG;50MG;40MG**	**A210817**	**001**	Dec 17, 2019
AA	**!**		**325MG;50MG;40MG**	**A089007**	**001**	Mar 17, 1986
AA	**!**	NEXGEN PHARMA	**300MG;50MG;40MG**	**A040885**	**001**	Nov 16, 2009
AA		NUVO PHARMS INC	**300MG;50MG;40MG**	**A207118**	**001**	Oct 28, 2016
AA		WRASER PHARMS LLC	**300MG;50MG;40MG**	**A206615**	**001**	Aug 04, 2017

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	!	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		ABHAI LLC	**325MG;50MG;40MG**	**A211106**	**001**	Sep 26, 2018
AA		ACTAVIS LABS UT INC	**325MG;50MG;40MG**	**A088616**	**001**	Nov 09, 1984
AA		CNTY LINE PHARMS	**325MG;50MG;40MG**	**A204984**	**001**	Jan 10, 2017
AA		HIKMA PHARMS	**325MG;50MG;40MG**	**A089718**	**001**	Jun 12, 1995
AA		LANNETT CO INC	**325MG;50MG;40MG**	**A200243**	**001**	Sep 13, 2012
AA		MIKART	**325MG;50MG;40MG**	**A089175**	**001**	Jan 21, 1987
AA		NEXGEN PHARMA INC	**325MG;50MG;40MG**	**A209587**	**001**	Oct 31, 2018
AA		SPECGX LLC	**325MG;50MG;40MG**	**A087804**	**001**	Jan 24, 1985
AA	**!**	VINTAGE PHARMS	**325MG;50MG;40MG**	**A040511**	**001**	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		NEXGEN PHARMA INC	**325MG;50MG;40MG;30MG**	**A076560**	**001**	Jun 10, 2004
AB		VINTAGE PHARMS	**325MG;50MG;40MG;30MG**	**A075929**	**001**	Apr 22, 2002

FIORICET W/ CODEINE

AB	**+!**	ACTAVIS LABS UT INC	**325MG;50MG;40MG;30MG**	**N020232**	**001**	Jul 30, 1992

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

		NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

		WRASER PHARMS LLC	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

		LARKEN LABS INC	325MG;30MG;16MG	A204209	001	Sep 30, 2016

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		ANDA REPOSITORY	**120MG/5ML;12MG/5ML**	**A089450**	**001**	Oct 27, 1992
AA		HI TECH PHARMA	**120MG/5ML;12MG/5ML**	**A040119**	**001**	Apr 26, 1996
AA	**!**	PHARM ASSOC	**120MG/5ML;12MG/5ML**	**A087508**	**001**	
AA		WOCKHARDT BIO AG	**120MG/5ML;12MG/5ML**	**A087006**	**001**	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS NY	**300MG;30MG**	**A040779**	**001**	May 29, 2008
AA		AUROLIFE PHARMA LLC	**300MG;15MG**	**A202800**	**001**	Apr 15, 2013
AA			**300MG;30MG**	**A202800**	**002**	Apr 15, 2013
AA			**300MG;60MG**	**A202800**	**003**	Apr 15, 2013
AA		ELITE LABS INC	**300MG;15MG**	**A212418**	**001**	Sep 10, 2019
AA			**300MG;30MG**	**A212418**	**002**	Sep 10, 2019
AA			**300MG;60MG**	**A212418**	**003**	Sep 10, 2019
AA		EYWA	**300MG;15MG**	**A211610**	**001**	Jun 27, 2019
AA			**300MG;30MG**	**A211610**	**002**	Jun 27, 2019
AA			**300MG;60MG**	**A211610**	**003**	Jun 27, 2019
AA	**!**	SPECGX LLC	**300MG;15MG**	**A040419**	**001**	May 31, 2001
AA			**300MG;30MG**	**A040419**	**002**	May 31, 2001
AA			**300MG;60MG**	**A040419**	**003**	May 31, 2001
AA		SUN PHARM INDS LTD	**300MG;30MG**	**A085868**	**001**	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA			**300MG;60MG**	**A087083**	**001**	
AA		TEVA	**300MG;15MG**	**A088627**	**001**	Mar 06, 1985
AA			**300MG;30MG**	**A088628**	**001**	Mar 06, 1985
AA	!		**300MG;60MG**	**A088629**	**001**	Mar 06, 1985
AA		VINTAGE	**300MG;15MG**	**A089990**	**001**	Sep 30, 1988
AA			**300MG;30MG**	**A089805**	**001**	Sep 30, 1988
AA		VINTAGE PHARMS	**300MG;60MG**	**A089828**	**001**	Sep 30, 1988

TYLENOL W/ CODEINE NO. 3

AA	!	JANSSEN PHARMS	**300MG;30MG**	**A085055**	**003**	

TYLENOL W/ CODEINE NO. 4

AA		JANSSEN PHARMS	**300MG;60MG**	**A085055**	**004**	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	!	ANDA REPOSITORY	**325MG/15ML;7.5MG/15ML**	**A040482**	**001**	Sep 25, 2003
AA		GENUS	**325MG/15ML;7.5MG/15ML**	**A040894**	**001**	Jul 19, 2011
AA		PHARM ASSOC	**325MG/15ML;7.5MG/15ML**	**A040838**	**001**	May 10, 2013
AA		VISTAPHARM	**325MG/15ML;7.5MG/15ML**	**A200343**	**001**	Jan 25, 2012
AA		WES PHARMA INC	**325MG/15ML;7.5MG/15ML**	**A211023**	**001**	Mar 08, 2019
	!	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
	!	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

AA		SPECGX LLC	**325MG;5MG**	**A040409**	**001**	Oct 20, 2000

ANEXSIA 7.5/325

AA		SPECGX LLC	**325MG;7.5MG**	**A040405**	**001**	Sep 08, 2000

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ABHAI LLC	**300MG;5MG**	**A209036**	**001**	Jun 21, 2017
AA			**300MG;7.5MG**	**A209036**	**002**	Jun 21, 2017
AA			**300MG;10MG**	**A209036**	**003**	Jun 21, 2017
AA			**325MG;5MG**	**A209037**	**001**	Jun 21, 2017
AA			**325MG;7.5MG**	**A209037**	**002**	Jun 21, 2017
AA			**325MG;10MG**	**A209037**	**003**	Jun 21, 2017
AA		ACTAVIS LABS FL INC	**300MG;5MG**	**A206470**	**001**	Jun 02, 2016
AA			**300MG;7.5MG**	**A206470**	**002**	Jun 02, 2016
AA			**300MG;10MG**	**A206470**	**003**	Jun 02, 2016
AA		AMNEAL PHARMS	**300MG;10MG**	**A207137**	**001**	Nov 29, 2016
AA		AMNEAL PHARMS NY	**300MG;5MG**	**A206869**	**001**	Jun 23, 2017
AA			**325MG;5MG**	**A040736**	**001**	Aug 25, 2006
AA			**325MG;7.5MG**	**A040746**	**002**	May 10, 2016
AA			**325MG;10MG**	**A040746**	**001**	Aug 25, 2006
AA	!	ANDA REPOSITORY	**325MG;2.5MG**	**A040846**	**001**	Jun 09, 2010
AA			**325MG;7.5MG**	**A040432**	**001**	Jan 22, 2003
AA		ASCENT PHARMS INC	**325MG;2.5MG**	**A211487**	**001**	Nov 07, 2018
AA			**325MG;5MG**	**A211487**	**002**	Nov 07, 2018
AA			**325MG;7.5MG**	**A211487**	**003**	Nov 07, 2018
AA			**325MG;10MG**	**A211487**	**004**	Nov 07, 2018
AA		AUROLIFE PHARMA LLC	**300MG;5MG**	**A207709**	**001**	Sep 13, 2018
AA			**300MG;7.5MG**	**A207709**	**002**	Sep 13, 2018
AA			**300MG;10MG**	**A207709**	**003**	Sep 13, 2018
AA			**325MG;5MG**	**A201013**	**001**	Apr 11, 2012
AA			**325MG;7.5MG**	**A201013**	**002**	Apr 11, 2012
AA			**325MG;10MG**	**A201013**	**003**	Apr 11, 2012
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203863**	**001**	Mar 30, 2018
AA			**325MG;7.5MG**	**A203863**	**002**	Mar 30, 2018
AA			**325MG;10MG**	**A203863**	**003**	Mar 30, 2018
AA		GRANULES PHARMS	**325MG;5MG**	**A211729**	**001**	Jan 03, 2020
AA			**325MG;7.5MG**	**A211729**	**002**	Jan 03, 2020
AA			**325MG;10MG**	**A211729**	**003**	Jan 03, 2020
AA	!	MIKART	**300MG;5MG**	**A040658**	**001**	Jan 19, 2006
AA	!		**300MG;7.5MG**	**A040658**	**002**	Mar 24, 2006
AA	!		**300MG;10MG**	**A040658**	**003**	Jun 23, 2004
AA		NOVEL LABS INC	**300MG;5MG**	**A206142**	**001**	Nov 14, 2016
AA			**300MG;7.5MG**	**A206142**	**002**	Nov 14, 2016
AA			**300MG;10MG**	**A206142**	**003**	Nov 14, 2016
AA			**325MG;5MG**	**A206245**	**001**	Dec 01, 2016
AA			**325MG;7.5MG**	**A206245**	**002**	Dec 01, 2016
AA			**325MG;10MG**	**A206245**	**003**	Dec 01, 2016
AA		PAR PHARM	**300MG;5MG**	**A205001**	**001**	Jul 05, 2016

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		**300MG;7.5MG**	**A205001**	**002**	Jul 05, 2016
AA		**300MG;10MG**	**A205001**	**003**	Jul 05, 2016
AA		**325MG;5MG**	**A202935**	**002**	Jun 15, 2016
AA		**325MG;7.5MG**	**A202935**	**003**	Jun 15, 2016
AA		**325MG;10MG**	**A202935**	**004**	Jun 15, 2016
AA	RHODES PHARMS	**300MG;5MG**	**A207808**	**001**	Mar 30, 2018
AA		**300MG;7.5MG**	**A207808**	**002**	Mar 30, 2018
AA		**300MG;10MG**	**A207808**	**003**	Mar 30, 2018
AA		**325MG;5MG**	**A202991**	**001**	Apr 12, 2016
AA		**325MG;7.5MG**	**A202991**	**002**	Apr 12, 2016
AA		**325MG;10MG**	**A202991**	**003**	Apr 12, 2016
AA	SPECGX LLC	**300MG;5MG**	**A206718**	**001**	Mar 31, 2017
AA		**300MG;7.5MG**	**A206718**	**002**	Mar 31, 2017
AA		**300MG;10MG**	**A206718**	**003**	Mar 31, 2017
AA		**325MG;10MG**	**A040400**	**001**	Jul 26, 2000
AA	SUN PHARM INDS INC	**325MG;5MG**	**A090118**	**001**	Dec 23, 2008
AA		**325MG;7.5MG**	**A090118**	**002**	Dec 23, 2008
AA		**325MG;10MG**	**A090118**	**003**	Dec 23, 2008
AA	TRIS PHARMA INC	**300MG;5MG**	**A202214**	**004**	Mar 15, 2016
AA		**300MG;7.5MG**	**A202214**	**005**	Mar 15, 2016
AA		**300MG;10MG**	**A202214**	**006**	Mar 15, 2016
AA		**325MG;5MG**	**A202214**	**001**	Mar 27, 2013
AA		**325MG;7.5MG**	**A202214**	**002**	Mar 27, 2013
AA		**325MG;10MG**	**A202214**	**003**	Mar 27, 2013
AA	VINTAGE PHARMS	**300MG;5MG**	**A090415**	**001**	Jan 24, 2011
AA		**300MG;7.5MG**	**A090415**	**002**	Jan 24, 2011
AA		**300MG;10MG**	**A090415**	**003**	Jan 24, 2011
AA		**325MG;5MG**	**A040655**	**001**	Jan 19, 2006
AA		**325MG;7.5MG**	**A040656**	**001**	Jan 19, 2006
AA		**325MG;10MG**	**A040355**	**001**	May 31, 2000
AA	WES PHARMA INC	**300MG;5MG**	**A207509**	**001**	Oct 29, 2018
AA		**300MG;7.5MG**	**A207509**	**002**	Oct 29, 2018
AA		**300MG;10MG**	**A207509**	**003**	Oct 29, 2018
AA		**325MG;5MG**	**A210211**	**001**	Oct 30, 2017
AA		**325MG;7.5MG**	**A210211**	**002**	Oct 30, 2017
AA		**325MG;10MG**	**A210211**	**003**	Oct 30, 2017

NORCO

AA	APIL	**325MG;2.5MG**	**A040148**	**004**	Jul 07, 2014
AA !		**325MG;5MG**	**A040099**	**001**	Jun 25, 1997
AA		**325MG;5MG**	**A040148**	**005**	Jul 07, 2014
AA !		**325MG;7.5MG**	**A040148**	**003**	Sep 12, 2000
AA !		**325MG;10MG**	**A040148**	**001**	Feb 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

!	ABHAI LLC	325MG/5ML;5MG/5ML	A211499	001	Dec 31, 2018

TABLET;ORAL

OXYCET

AA	SPECGX LLC	**325MG;5MG**	**A087463**	**001**	Dec 07, 1983

OXYCODONE AND ACETAMINOPHEN

AA	ABHAI LLC	**325MG;2.5MG**	**A210644**	**001**	Feb 09, 2018
AA		**325MG;5MG**	**A210644**	**002**	Feb 09, 2018
AA		**325MG;7.5MG**	**A210644**	**003**	Feb 09, 2018
AA		**325MG;10MG**	**A210644**	**004**	Feb 09, 2018
AA	ACTAVIS ELIZABETH	**325MG;2.5MG**	**A201447**	**001**	Apr 12, 2013
AA		**325MG;5MG**	**A201447**	**002**	Apr 12, 2013
AA		**325MG;7.5MG**	**A201447**	**003**	Apr 12, 2013
AA		**325MG;10MG**	**A201447**	**004**	Apr 12, 2013
AA	ALVOGEN	**325MG;5MG**	**A202677**	**003**	Mar 08, 2016
AA		**325MG;7.5MG**	**A202677**	**001**	Jul 26, 2012
AA		**325MG;10MG**	**A202677**	**002**	Jul 26, 2012
AA	AMNEAL PHARMS	**325MG;5MG**	**A040777**	**001**	Nov 27, 2007
AA	AMNEAL PHARMS NY	**325MG;7.5MG**	**A040778**	**002**	Jun 27, 2014
AA		**325MG;10MG**	**A040778**	**001**	Nov 27, 2007
AA	ANDA REPOSITORY	**325MG;5MG**	**A207834**	**001**	Aug 15, 2019
AA		**325MG;7.5MG**	**A207834**	**002**	Aug 15, 2019
AA		**325MG;10MG**	**A207834**	**003**	Aug 15, 2019
AA	ASCENT PHARMS INC	**325MG;2.5MG**	**A207419**	**001**	Mar 22, 2017
AA		**325MG;5MG**	**A207419**	**002**	Mar 22, 2017

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA			**325MG;7.5MG**	**A207419**	**003**	Mar 22, 2017
AA			**325MG;10MG**	**A207419**	**004**	Mar 22, 2017
AA		AUROLIFE PHARMA LLC	**325MG;2.5MG**	**A201972**	**001**	Jul 15, 2013
AA			**325MG;5MG**	**A201972**	**002**	Jul 15, 2013
AA			**325MG;7.5MG**	**A201972**	**003**	Jul 15, 2013
AA			**325MG;10MG**	**A201972**	**004**	Jul 15, 2013
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203864**	**001**	Jul 02, 2018
AA			**325MG;7.5MG**	**A203864**	**002**	Jul 02, 2018
AA			**325MG;10MG**	**A203864**	**003**	Jul 02, 2018
AA		GRANULES PHARMS	**325MG;2.5MG**	**A211708**	**001**	Oct 31, 2019
AA			**325MG;5MG**	**A211708**	**002**	Oct 31, 2019
AA			**325MG;7.5MG**	**A211708**	**003**	Oct 31, 2019
AA			**325MG;10MG**	**A211708**	**004**	Oct 31, 2019
AA		LANNETT CO INC	**325MG;5MG**	**A207333**	**001**	Sep 25, 2017
AA			**325MG;10MG**	**A207333**	**002**	Sep 25, 2017
AA		MAYNE PHARMA INC	**325MG;2.5MG**	**A090177**	**001**	Oct 20, 2008
AA			**325MG;5MG**	**A090177**	**002**	Oct 20, 2008
AA			**325MG;7.5MG**	**A090177**	**003**	Oct 20, 2008
AA			**325MG;10MG**	**A090177**	**004**	Oct 20, 2008
AA		NESHER PHARMS	**325MG;2.5MG**	**A210079**	**001**	Dec 28, 2017
AA			**325MG;5MG**	**A210079**	**002**	Dec 28, 2017
AA			**325MG;7.5MG**	**A210079**	**003**	Dec 28, 2017
AA			**325MG;10MG**	**A210079**	**004**	Dec 28, 2017
AA		NOSTRUM LABS INC	**325MG;5MG**	**A209385**	**001**	Jul 02, 2018
AA			**325MG;7.5MG**	**A209385**	**002**	Jul 02, 2018
AA			**325MG;10MG**	**A209385**	**003**	Jul 02, 2018
AA		NOVEL LABS INC	**325MG;2.5MG**	**A204407**	**001**	Feb 24, 2017
AA			**325MG;5MG**	**A204407**	**002**	Feb 24, 2017
AA			**325MG;7.5MG**	**A204407**	**003**	Feb 24, 2017
AA			**325MG;10MG**	**A204407**	**004**	Feb 24, 2017
AA		RHODES PHARMS	**325MG;5MG**	**A201278**	**001**	Aug 28, 2014
AA			**325MG;7.5MG**	**A201278**	**002**	Aug 28, 2014
AA			**325MG;10MG**	**A201278**	**003**	Aug 28, 2014
AA		SPECGX LLC	**325MG;7.5MG**	**A040545**	**001**	Jun 30, 2004
AA			**325MG;10MG**	**A040545**	**002**	Jun 30, 2004
AA		SUN PHARM INDS INC	**325MG;2.5MG**	**A090535**	**001**	Dec 26, 2013
AA			**325MG;5MG**	**A090535**	**002**	Dec 26, 2013
AA			**325MG;7.5MG**	**A090535**	**003**	Dec 26, 2013
AA			**325MG;10MG**	**A090535**	**004**	Dec 26, 2013
AA		VINTAGE PHARMS	**325MG;2.5MG**	**A090733**	**001**	Jul 11, 2013
AA			**325MG;5MG**	**A040105**	**001**	Jul 30, 1996
AA			**325MG;7.5MG**	**A090734**	**001**	Jul 11, 2013
AA			**325MG;10MG**	**A090734**	**002**	Jul 11, 2013
AA		WATSON LABS	**325MG;5MG**	**A040171**	**001**	Oct 30, 1997
AA			**325MG;7.5MG**	**A040535**	**001**	Sep 05, 2003
AA			**325MG;10MG**	**A040535**	**002**	Sep 05, 2003
AA		WES PHARMA INC	**325MG;5MG**	**A207510**	**001**	Mar 21, 2018
AA			**325MG;7.5MG**	**A207510**	**002**	Mar 21, 2018
AA			**325MG;10MG**	**A207510**	**003**	Mar 21, 2018
AA		XIROMED	**325MG;5MG**	**A207574**	**001**	Dec 13, 2016

PERCOCET

AA	**!**	VINTAGE PHARMS LLC	**325MG;2.5MG**	**A040330**	**001**	Jun 25, 1999
AA	**!**		**325MG;5MG**	**A040330**	**002**	Jun 25, 1999
AA	**!**		**325MG;7.5MG**	**A040330**	**003**	Nov 23, 2001
AA	**!**		**325MG;10MG**	**A040330**	**004**	Nov 23, 2001

ROXICET

AA		HIKMA	**325MG;5MG**	**A087003**	**001**	

OXYCODONE AND ACETAMINOPHEN

	!	MIKART	300MG;2.5MG	A040608	001	Dec 30, 2005
	!		300MG;5MG	A040608	002	Dec 30, 2005
	!		300MG;7.5MG	A040608	003	Dec 30, 2005
	!		300MG;10MG	A040608	004	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ALKEM LABS LTD	**325MG;37.5MG**	**A202076**	**001**	Mar 30, 2012
AB		AMNEAL PHARMS	**325MG;37.5MG**	**A090485**	**001**	Dec 09, 2009
AB		APOTEX	**325MG;37.5MG**	**A078778**	**001**	Apr 07, 2014
AB		AUROBINDO PHARMA	**325MG;37.5MG**	**A207152**	**001**	Mar 22, 2017

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

		LTD				
AB		MACLEODS PHARMS LTD	**325MG;37.5MG**	**A206885**	**001**	May 02, 2017
AB		MICRO LABS LTD INDIA	**325MG;37.5MG**	**A201952**	**001**	Dec 14, 2012
AB		MYLAN	**325MG;37.5MG**	**A077858**	**001**	Sep 26, 2008
AB		SUN PHARM INDS INC	**325MG;37.5MG**	**A077184**	**001**	Dec 16, 2005
AB		ZYDUS PHARMS USA INC	**325MG;37.5MG**	**A090460**	**001**	Sep 06, 2012

ULTRACET

AB	**+!**	JANSSEN PHARMS	**325MG;37.5MG**	**N021123**	**001**	Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		ALEMBIC PHARMS LTD	**500MG**	**A210423**	**001**	Feb 19, 2019
AB		CADILA	**500MG**	**A205301**	**001**	Jan 16, 2019
AB		HERITAGE PHARMA	**500MG**	**A040904**	**001**	Dec 10, 2008
AB	**!**	HERITAGE PHARMS INC	**500MG**	**A090779**	**001**	Jul 14, 2011
AB		NOSTRUM LABS INC	**500MG**	**A204691**	**001**	Mar 29, 2016
AB		NOVAST LABS	**500MG**	**A203434**	**001**	Sep 30, 2016

TABLET;ORAL

ACETAZOLAMIDE

AB		EYWA PHARMA	**125MG**	**A211556**	**001**	Oct 18, 2019
AB			**250MG**	**A211556**	**002**	Oct 18, 2019
AB		HERITAGE PHARMA	**125MG**	**A205530**	**001**	Oct 27, 2016
AB			**250MG**	**A205530**	**002**	Oct 27, 2016
AB		LANNETT	**250MG**	**A084840**	**001**	
AB		NOVITIUM PHARMA	**125MG**	**A210588**	**001**	Oct 17, 2019
AB			**250MG**	**A210588**	**002**	Oct 17, 2019
AB		STRIDES PHARMA	**125MG**	**A209734**	**001**	Nov 20, 2017
AB			**250MG**	**A209734**	**002**	Nov 20, 2017
AB		TARO	**125MG**	**A040195**	**001**	May 28, 1997
AB	**!**		**250MG**	**A040195**	**002**	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		MYLAN ASI	**EQ 500MG BASE/VIAL**	**A200880**	**001**	May 09, 2012
AP		WEST-WARD PHARMS INT	**EQ 500MG BASE/VIAL**	**A040089**	**001**	Feb 28, 1995
AP	**!**	X GEN PHARMS	**EQ 500MG BASE/VIAL**	**A040784**	**001**	Dec 10, 2008
AP		ZYDUS PHARMS	**EQ 500MG BASE/VIAL**	**A206533**	**001**	Apr 15, 2019

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		B BRAUN	**250MG/100ML**	**N018161**	**001**	
AT		BAXTER HLTHCARE	**250MG/100ML**	**N018523**	**001**	Feb 19, 1982
AT	**+!**	ICU MEDICAL INC	**250MG/100ML**	**N017656**	**001**	

SOLUTION/DROPS;OTIC

ACETIC ACID

AT		MLV	**2%**	**A040607**	**001**	Feb 24, 2005
AT		RISING	**2%**	**A207280**	**001**	Mar 09, 2018
AT		TARO	**2%**	**A088638**	**001**	Sep 06, 1984
AT	**!**	WOCKHARDT BIO AG	**2%**	**A040166**	**001**	Jul 26, 1996

VOSOL

AT		HI TECH PHARMA	**2%**	**N012179**	**001**	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT		TARO PHARM INDS LTD	**2%;1%**	**A088759**	**001**	Mar 04, 1985
AT		VINTAGE	**2%;1%**	**A040609**	**001**	Feb 06, 2006

VOSOL HC

AT	**+!**	HI TECH PHARMA	**2%;1%**	**N012770**	**001**	

ACETOHYDROXAMIC ACID

TABLET;ORAL

LITHOSTAT

	+!	MISSION PHARMA	250MG	N018749	001	May 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

	+!	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

AP	**+!**	CUMBERLAND PHARMS	**6GM/30ML (200MG/ML)**	**N021539**	**001**	Jan 23, 2004

ACETYLCYSTEINE

AP		AKORN INC	**6GM/30ML (200MG/ML)**	**A203173**	**001**	Mar 24, 2015
AP		AUROBINDO PHARMA LTD	**6GM/30ML (200MG/ML)**	**A207358**	**001**	Feb 29, 2016
AP		FRESENIUS KABI USA	**6GM/30ML (200MG/ML)**	**A200644**	**001**	Nov 07, 2012
AP		SAGENT PHARMS INC	**6GM/30ML (200MG/ML)**	**A091684**	**001**	Oct 31, 2017
AP		ZYDUS PHARMS	**6GM/30ML (200MG/ML)**	**A208166**	**001**	Jul 20, 2018

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN		ALVOGEN INC	**10%**	**A204674**	**001**	Feb 11, 2014
AN			**20%**	**A203853**	**001**	Jun 21, 2012
AN		HOSPIRA	**10%**	**A073664**	**001**	Aug 30, 1994
AN			**20%**	**A074037**	**001**	Aug 30, 1994
AN	**!**	LUITPOLD	**10%**	**A072489**	**001**	Jul 28, 1995
AN	**!**		**20%**	**A072547**	**001**	Jul 28, 1995

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB		BARR LABS INC	**10MG**	**A091455**	**001**	Apr 04, 2013
AB			**25MG**	**A091455**	**002**	Apr 04, 2013
AB		IMPAX LABS INC	**10MG**	**A202552**	**001**	Dec 23, 2015
AB			**17.5MG**	**A202552**	**002**	Dec 23, 2015
AB			**22.5MG**	**A202552**	**003**	Dec 23, 2015
AB			**25MG**	**A202552**	**004**	Dec 23, 2015
AB		MYLAN	**10MG**	**A202148**	**001**	Sep 10, 2015
AB			**25MG**	**A202148**	**002**	Sep 10, 2015
AB		SIGMAPHARM LABS LLC	**10MG**	**A204633**	**001**	May 22, 2015
AB			**17.5MG**	**A204633**	**002**	May 22, 2015
AB			**22.5MG**	**A204633**	**003**	May 22, 2015
AB			**25MG**	**A204633**	**004**	May 22, 2015
AB		TEVA PHARMS USA	**17.5MG**	**A202897**	**001**	Apr 04, 2013
AB			**22.5MG**	**A202897**	**002**	Apr 04, 2013

SORIATANE

AB	**+**	STIEFEL LABS INC	**10MG**	**N019821**	**001**	Oct 28, 1996
AB	**+!**		**25MG**	**N019821**	**002**	Oct 28, 1996

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+!	CIRCASSIA	0.4MG/INH	N202450	001	Jul 23, 2012

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

		CIRCASSIA	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

	+!	AUXILIUM PHARMS LLC	8MG;60MG	N019806	001	Mar 25, 1994

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	**!**	APOTEX	**200MG**	**A075677**	**001**	Sep 28, 2005
AB		CADILA	**200MG**	**A204313**	**001**	Mar 25, 2016
AB		CADILA PHARMS LTD	**200MG**	**A201445**	**001**	Mar 06, 2014
AB		CARLSBAD TECHNOLOGY	**200MG**	**A206261**	**001**	Aug 16, 2017
AB		DAVA PHARMS INC	**200MG**	**A074833**	**001**	Apr 22, 1997
AB		HERITAGE PHARMS INC	**200MG**	**A074889**	**001**	Oct 31, 1997
AB		KENTON	**200MG**	**A075090**	**001**	Jan 26, 1999

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB		TEVA	**200MG**	**A074578**	**001**	Apr 22, 1997

CREAM;TOPICAL

ACYCLOVIR

AB		PERRIGO UK FINCO	**5%**	**A208702**	**001**	Feb 04, 2019

ZOVIRAX

AB	**+!**	BAUSCH	**5%**	**N021478**	**001**	Dec 30, 2002

OINTMENT;TOPICAL

ACYCLOVIR

AB		ACP NIMBLE	**5%**	**A205591**	**001**	Nov 13, 2017
AB		ALEMBIC PHARMS LTD	**5%**	**A209000**	**001**	Apr 06, 2018
AB		AMNEAL PHARMS	**5%**	**A204605**	**001**	Jun 18, 2014
AB		APOTEX	**5%**	**A210774**	**001**	Sep 06, 2019
AB		CADILA	**5%**	**A205974**	**001**	Mar 15, 2019
AB		CIPLA	**5%**	**A211794**	**001**	Jan 18, 2019
AB		FOUGERA PHARMS INC	**5%**	**A206633**	**001**	May 11, 2016
AB		GLENMARK PHARMS SA	**5%**	**A205510**	**001**	Jul 31, 2017
AB		MYLAN PHARMS INC	**5%**	**A202459**	**001**	Apr 03, 2013
AB		TARO	**5%**	**A205469**	**001**	Dec 21, 2016
AB		TOLMAR	**5%**	**A206437**	**001**	Jul 31, 2017
AB		TORRENT	**5%**	**A209971**	**001**	Jan 11, 2019

ZOVIRAX

AB	**+!**	BAUSCH	**5%**	**N018604**	**001**	Mar 29, 1982

SUSPENSION;ORAL

ACYCLOVIR

AB		ACTAVIS MID ATLANTIC	**200MG/5ML**	**A074738**	**001**	Apr 28, 1997
AB		HI TECH PHARMA	**200MG/5ML**	**A077026**	**001**	Jun 07, 2005

ZOVIRAX

AB	**+!**	MYLAN	**200MG/5ML**	**N019909**	**001**	Dec 22, 1989

TABLET;BUCCAL

SITAVIG

	+!	EPI HLTH	50MG	N203791	001	Apr 12, 2013

TABLET;ORAL

ACYCLOVIR

AB		APOTEX INC	**400MG**	**A077309**	**001**	Sep 29, 2005
AB			**800MG**	**A077309**	**002**	Sep 29, 2005
AB		CADILA PHARMS LTD	**400MG**	**A202168**	**001**	Nov 15, 2013
AB			**800MG**	**A202168**	**002**	Nov 15, 2013
AB		CARLSBAD	**400MG**	**A075382**	**001**	Apr 30, 1999
AB			**800MG**	**A075382**	**002**	Apr 30, 1999
AB		DAVA PHARMS INC	**400MG**	**A074946**	**001**	Nov 19, 1997
AB			**800MG**	**A074946**	**002**	Nov 19, 1997
AB		HERITAGE PHARMS INC	**400MG**	**A074891**	**001**	Oct 31, 1997
AB			**800MG**	**A074891**	**002**	Oct 31, 1997
AB		HETERO LABS LTD V	**400MG**	**A203834**	**001**	Oct 29, 2013
AB			**800MG**	**A203834**	**002**	Oct 29, 2013
AB		SQUARE PHARMS LTD	**400MG**	**A209366**	**001**	Oct 07, 2019
AB			**800MG**	**A209366**	**002**	Oct 07, 2019
AB		TEVA	**400MG**	**A074556**	**002**	Apr 22, 1997
AB			**800MG**	**A074556**	**003**	Apr 22, 1997
AB		YILING PHARM LTD	**400MG**	**A210401**	**001**	Mar 07, 2018
AB			**800MG**	**A210401**	**002**	Mar 07, 2018
AB		ZYDUS PHARMS	**400MG**	**A204314**	**001**	Aug 19, 2014
AB			**800MG**	**A204314**	**002**	Aug 19, 2014

ZOVIRAX

AB	**+**	MYLAN	**400MG**	**N020089**	**001**	Apr 30, 1991
AB	**+!**		**800MG**	**N020089**	**002**	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

AP		AUROBINDO PHARMA LTD	**EQ 50MG BASE/ML**	**A203701**	**001**	Oct 11, 2013
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A074930**	**001**	May 13, 1998
	!	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018
	!		EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018

ACYCLOVIR; HYDROCORTISONE

CREAM;TOPICAL

XERESE

	+!	BAUSCH	5%;1%	N022436	001	Jul 31, 2009

ADAPALENE

CREAM;TOPICAL

ADAPALENE

AB		FOUGERA PHARMS	**0.1%**	**A090824**	**001**	Jun 30, 2010

DIFFERIN

AB	**+!**	GALDERMA LABS LP	**0.1%**	**N020748**	**001**	May 26, 2000

GEL;TOPICAL

ADAPALENE

AB		ACTAVIS MID ATLANTIC	**0.3%**	**A201000**	**001**	Oct 27, 2014
AB		GLENMARK GENERICS	**0.1%**	**A091314**	**001**	Jul 01, 2010
AB		P AND L	**0.1%**	**A090962**	**001**	Jun 02, 2010
AB		TARO	**0.3%**	**A208322**	**001**	Jun 23, 2016
AB		TOLMAR	**0.3%**	**A200298**	**001**	Jun 14, 2012

DIFFERIN

AB	**+!**	GALDERMA LABS LP	**0.3%**	**N021753**	**001**	Jun 19, 2007

LOTION;TOPICAL

DIFFERIN

	+!	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010

SOLUTION;TOPICAL

ADAPALENE

AB		CALL INC	**0.1%**	**A203981**	**001**	Sep 23, 2016
AB			**0.1%**	**A204593**	**001**	Jan 05, 2016

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB		ACTAVIS MID ATLANTIC	**0.1%;2.5%**	**A203790**	**001**	Sep 30, 2015
AB		GLENMARK PHARMS LTD	**0.1%;2.5%**	**A208108**	**001**	Nov 08, 2019
AB		PERRIGO UK FINCO	**0.1%;2.5%**	**A205033**	**001**	Jan 23, 2018
AB		TARO	**0.1%;2.5%**	**A206959**	**001**	Jan 24, 2018
AB		TOLMAR	**0.1%;2.5%**	**A206164**	**001**	May 23, 2018

EPIDUO

AB	**+!**	GALDERMA LABS LP	**0.1%;2.5%**	**N022320**	**001**	Dec 08, 2008

EPIDUO FORTE

AB	**+!**	GALDERMA LABS	**0.3%;2.5%**	**N207917**	**001**	Jul 15, 2015

ADEFOVIR DIPIVOXIL

TABLET;ORAL

ADEFOVIR DIPIVOXIL

AB		APOTEX	**10MG**	**A205459**	**001**	Jul 06, 2018
AB		SIGMAPHARM LABS LLC	**10MG**	**A202051**	**001**	Aug 29, 2013

HEPSERA

AB	**+!**	GILEAD	**10MG**	**N021449**	**001**	Sep 20, 2002

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP	**!**	AKORN	**3MG/ML**	**A078076**	**001**	Oct 31, 2008
AP		FRESENIUS KABI USA	**3MG/ML**	**A077133**	**001**	Apr 27, 2005
AP			**3MG/ML**	**A205568**	**001**	Apr 16, 2018
AP		GLAND PHARMA LTD	**3MG/ML**	**A077283**	**001**	Jun 14, 2007
AP			**3MG/ML**	**A206778**	**001**	Feb 16, 2018
AP		MYLAN LABS LTD	**3MG/ML**	**A078640**	**001**	Mar 21, 2014
AP			**3MG/ML**	**A078686**	**001**	May 13, 2009
AP		WEST-WARD PHARMS INT	**3MG/ML**	**A076404**	**001**	Jun 16, 2004
AP			**3MG/ML**	**A076500**	**001**	Jun 16, 2004

SOLUTION;INTRAVENOUS

ADENOSINE

AP		AKORN	**60MG/20ML (3MG/ML)**	**A090450**	**001**	Oct 02, 2014
AP			**90MG/30ML (3MG/ML)**	**A090450**	**002**	Oct 02, 2014
AP		AUROBINDO PHARMA LTD	**60MG/20ML (3MG/ML)**	**A205331**	**001**	Nov 02, 2017
AP			**90MG/30ML (3MG/ML)**	**A205331**	**002**	Nov 02, 2017
AP		FRESENIUS KABI USA	**60MG/20ML (3MG/ML)**	**A077897**	**001**	Nov 27, 2017
AP			**90MG/30ML (3MG/ML)**	**A077897**	**002**	Nov 27, 2017
AP		HOSPIRA INC	**60MG/20ML (3MG/ML)**	**A203883**	**001**	Mar 24, 2014
AP			**90MG/30ML (3MG/ML)**	**A203883**	**002**	Mar 24, 2014

ADENOSINE							
SOLUTION;INTRAVENOUS							
ADENOSINE							
AP		MYLAN ASI	**60MG/20ML (3MG/ML)**	**A090212**	**001**	Mar 28, 2014
AP			**90MG/30ML (3MG/ML)**	**A090212**	**002**	Mar 28, 2014
AP	**!**	TEVA PHARMS USA	**60MG/20ML (3MG/ML)**	**A077425**	**001**	Aug 29, 2013
AP	**!**		**90MG/30ML (3MG/ML)**	**A077425**	**002**	Aug 29, 2013
AFAMELANOTIDE							
IMPLANT;SUBCUTANEOUS							
SCENESSE							
	+!	CLIVUNEL INC	16MG	N210797	001	Oct 08, 2019
AFATINIB DIMALEATE							
TABLET;ORAL							
GILOTRIF							
	+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013
	+		EQ 30MG BASE	N201292	002	Jul 12, 2013
	+!		EQ 40MG BASE	N201292	003	Jul 12, 2013
AIR POLYMER-TYPE A							
FOAM;INTRAUTERINE							
EXEM FOAM KIT							
	+!	GISKIT	10ML	N212279	001	Nov 07, 2019
ALBENDAZOLE							
TABLET;ORAL							
ALBENDAZOLE							
AB		ACTAVIS ELIZABETH	**200MG**	**A208094**	**001**	May 20, 2019
AB		CIPLA LTD	**200MG**	**A210434**	**001**	Sep 21, 2018
AB		EDENBRIDGE PHARMS	**200MG**	**A211117**	**001**	May 14, 2019
AB		STRIDES PHARMA	**200MG**	**A210011**	**001**	Dec 07, 2018
AB		ZYDUS PHARMS	**200MG**	**A208979**	**001**	Dec 14, 2018
ALBENZA							
AB	**+!**	IMPAX LABS INC	**200MG**	**N020666**	**001**	Jun 11, 1996
ALBUMIN HUMAN							
INJECTABLE;INJECTION							
OPTISON							
	+!	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997
ALBUMIN IODINATED I-125 SERUM							
INJECTABLE;INJECTION							
JEANATOPE							
	+	ISO TEX	100uCi/10ML (10uCi/ML)	N017836	003	Jun 08, 2004
	+		500uCi/0.5ML	N017836	001	
	+!		1,000uCi/ML	N017836	002	
ALBUMIN IODINATED I-131 SERUM							
INJECTABLE;INJECTION							
MEGATOPE							
	+!	ISO TEX	0.5mCi/VIAL	N017837	001	
	+!		1mCi/VIAL	N017837	002	
ALBUTEROL SULFATE							
AEROSOL, METERED;INHALATION							
PROAIR HFA							
BX	+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004
PROVENTIL-HFA							
BX	+!	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996
VENTOLIN HFA							
BX	+!	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001
POWDER, METERED;INHALATION							
PROAIR DIGIHALER							
	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018
PROAIR RESPICLICK							
	+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015
SOLUTION;INHALATION							
ACCUNEB							
AN	**+!**	MYLAN SPECIALITY LP	**EQ 0.021% BASE**	**N020949**	**002**	Apr 30, 2001
AN	**+!**		**EQ 0.042% BASE**	**N020949**	**001**	Apr 30, 2001
ALBUTEROL SULFATE							
AN		AUROBINDO PHARMA LTD	**EQ 0.083% BASE**	**A206224**	**001**	Oct 17, 2017
AN	**!**	BAUSCH AND LOMB	**EQ 0.5% BASE**	**A075050**	**001**	Jun 18, 1998
AN		HI TECH PHARMA	**EQ 0.5% BASE**	**A074543**	**001**	Jan 15, 1998

ALBUTEROL SULFATE						
SOLUTION;INHALATION						
ALBUTEROL SULFATE						
AN		NEPHRON	**EQ 0.021% BASE**	**A076355**	**002**	Mar 31, 2010
AN			**EQ 0.042% BASE**	**A076355**	**001**	Jun 28, 2004
AN	!		**EQ 0.083% BASE**	**A074880**	**001**	Sep 17, 1997
AN			**EQ 0.5% BASE**	**A075664**	**001**	Jun 26, 2001
AN		RITEDOSE CORP	**EQ 0.083% BASE**	**A077839**	**001**	Dec 16, 2008
AN		SUN PHARM	**EQ 0.083% BASE**	**A207857**	**001**	Jul 21, 2017
AN		WATSON LABS	**EQ 0.021% BASE**	**A077772**	**001**	Sep 25, 2007
AN			**EQ 0.042% BASE**	**A077772**	**002**	Sep 25, 2007
SYRUP;ORAL						
ALBUTEROL SULFATE						
AA		AMNEAL PHARMS	**EQ 2MG BASE/5ML**	**A079241**	**001**	May 12, 2010
AA		COSETTE	**EQ 2MG BASE/5ML**	**A074454**	**001**	Sep 25, 1995
AA		HI TECH PHARMA	**EQ 2MG BASE/5ML**	**A074749**	**001**	Jan 30, 1998
AA		LANNETT CO INC	**EQ 2MG BASE/5ML**	**A078105**	**001**	Dec 27, 2006
AA		QUAGEN	**EQ 2MG BASE/5ML**	**A212197**	**001**	Sep 06, 2019
AA	!	TEVA	**EQ 2MG BASE/5ML**	**A073419**	**001**	Mar 30, 1992
AA		VISTAPHARM	**EQ 2MG BASE/5ML**	**A077788**	**001**	Jun 26, 2007
TABLET;ORAL						
ALBUTEROL SULFATE						
AB		AMNEAL PHARMS CO	**EQ 2MG BASE**	**A208804**	**001**	May 21, 2018
AB			**EQ 4MG BASE**	**A208804**	**002**	May 21, 2018
AB		APPCO	**EQ 2MG BASE**	**A207046**	**001**	Jun 29, 2018
AB			**EQ 4MG BASE**	**A207046**	**002**	Jun 29, 2018
AB		ARISE	**EQ 2MG BASE**	**A210948**	**001**	Mar 15, 2019
AB			**EQ 4MG BASE**	**A210948**	**002**	Mar 15, 2019
AB		MYLAN	**EQ 2MG BASE**	**A072894**	**002**	Jan 17, 1991
AB	!		**EQ 4MG BASE**	**A072894**	**001**	Jan 17, 1991
AB		SUN PHARM INDUSTRIES	**EQ 2MG BASE**	**A072637**	**002**	Dec 05, 1989
AB			**EQ 4MG BASE**	**A072637**	**001**	Dec 05, 1989
AB		VIRTUS PHARM	**EQ 2MG BASE**	**A211397**	**001**	Oct 26, 2018
AB			**EQ 4MG BASE**	**A211397**	**002**	Oct 26, 2018
TABLET, EXTENDED RELEASE;ORAL						
ALBUTEROL SULFATE						
AB		MYLAN	**EQ 4MG BASE**	**A078092**	**002**	Jan 29, 2007
VOSPIRE ER						
AB		DAVA PHARMS INC	**EQ 4MG BASE**	**A076130**	**002**	Sep 26, 2002
ALBUTEROL SULFATE						
	!	MYLAN	EQ 8MG BASE	A078092	001	Jan 29, 2007
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE						
SOLUTION;INHALATION						
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE						
AN		CIPLA	**EQ 0.083% BASE;0.017%**	**A077559**	**001**	Dec 31, 2007
AN		NEPHRON	**EQ 0.083% BASE;0.017%**	**A076749**	**001**	Dec 31, 2007
AN		RITEDOSE CORP	**EQ 0.083% BASE;0.017%**	**A202496**	**001**	Oct 01, 2012
AN		SUN PHARM	**EQ 0.083% BASE;0.017%**	**A207875**	**001**	Aug 07, 2017
AN		WATSON LABS TEVA	**EQ 0.083% BASE;0.017%**	**A077063**	**001**	Dec 31, 2007
SPRAY, METERED;INHALATION						
COMBIVENT RESPIMAT						
	+!	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011
ALCAFTADINE						
SOLUTION/DROPS;OPHTHALMIC						
LASTACAFT						
	+!	ALLERGAN	0.25%	N022134	001	Jul 28, 2010
ALCLOMETASONE DIPROPIONATE						
CREAM;TOPICAL						
ALCLOMETASONE DIPROPIONATE						
AB	!	FOUGERA PHARMS	**0.05%**	**A076973**	**001**	Jul 12, 2005
AB		GLENMARK GENERICS	**0.05%**	**A079061**	**001**	Jun 23, 2009
AB		TARO	**0.05%**	**A076587**	**001**	Sep 15, 2005
OINTMENT;TOPICAL						
ALCLOMETASONE DIPROPIONATE						
AB	!	FOUGERA PHARMS	**0.05%**	**A076884**	**001**	Jul 18, 2005
AB		GLENMARK GENERICS	**0.05%**	**A079227**	**001**	Jul 30, 2009
AB		TARO	**0.05%**	**A076730**	**001**	Jul 29, 2004

ALCOHOL						
SOLUTION;INTRA-ARTERIAL						
ABLYSINOL						
+	BELCHER PHARMS LLC	99% (1ML)		N207987	001	Jun 21, 2018
+!		99% (5ML)		N207987	002	Jun 21, 2018
ALECTINIB HYDROCHLORIDE						
CAPSULE;ORAL						
ALECENSA						
+!	HOFFMANN-LA ROCHE	EQ 150MG BASE		N208434	001	Dec 11, 2015
ALENDRONATE SODIUM						
SOLUTION;ORAL						
ALENDRONATE SODIUM						
!	HIKMA	EQ 70MG BASE/75ML		A090520	001	Feb 25, 2013
TABLET;ORAL						
ALENDRONATE SODIUM						
AB	APOTEX	**EQ 5MG BASE**		**A077982**	**001**	Aug 04, 2008
AB		**EQ 10MG BASE**		**A077982**	**002**	Aug 04, 2008
AB		**EQ 35MG BASE**		**A077982**	**003**	Aug 04, 2008
AB		**EQ 70MG BASE**		**A077982**	**004**	Aug 04, 2008
AB	AUROBINDO PHARMA	**EQ 10MG BASE**		**A090124**	**001**	Aug 04, 2008
AB		**EQ 35MG BASE**		**A090124**	**002**	Aug 04, 2008
AB		**EQ 70MG BASE**		**A090124**	**003**	Aug 04, 2008
AB	CIPLA	**EQ 5MG BASE**		**A076768**	**001**	Aug 04, 2008
AB		**EQ 10MG BASE**		**A076768**	**002**	Aug 04, 2008
AB		**EQ 35MG BASE**		**A076768**	**003**	Aug 04, 2008
AB		**EQ 40MG BASE**		**A076768**	**004**	Aug 04, 2008
AB		**EQ 70MG BASE**		**A076768**	**005**	Aug 04, 2008
AB	HANGZHOU BINJIANG	**EQ 5MG BASE**		**A090258**	**001**	Sep 24, 2009
AB		**EQ 10MG BASE**		**A090258**	**002**	Sep 24, 2009
AB		**EQ 35MG BASE**		**A090258**	**003**	Sep 24, 2009
AB		**EQ 70MG BASE**		**A090258**	**004**	Sep 24, 2009
AB	IMPAX LABS INC	**EQ 5MG BASE**		**A075710**	**001**	Feb 06, 2008
AB		**EQ 10MG BASE**		**A075710**	**002**	Feb 06, 2008
AB		**EQ 35MG BASE**		**A075710**	**003**	Feb 06, 2008
AB		**EQ 40MG BASE**		**A075710**	**004**	Feb 06, 2008
AB		**EQ 70MG BASE**		**A075710**	**005**	Feb 06, 2008
AB	JUBILANT CADISTA	**EQ 5MG BASE**		**A090557**	**001**	Feb 18, 2010
AB		**EQ 10MG BASE**		**A090557**	**002**	Feb 18, 2010
AB		**EQ 35MG BASE**		**A090557**	**003**	Feb 18, 2010
AB		**EQ 70MG BASE**		**A090557**	**004**	Feb 18, 2010
AB	NEOPHARMA	**EQ 5MG BASE**		**A079049**	**003**	Aug 04, 2008
AB		**EQ 10MG BASE**		**A079049**	**004**	Aug 04, 2008
AB		**EQ 35MG BASE**		**A079049**	**001**	Aug 04, 2008
AB		**EQ 70MG BASE**		**A079049**	**002**	Aug 04, 2008
AB	SUN PHARM	**EQ 5MG BASE**		**A090022**	**001**	Sep 10, 2008
AB		**EQ 10MG BASE**		**A090022**	**002**	Sep 10, 2008
AB		**EQ 35MG BASE**		**A090022**	**003**	Sep 10, 2008
AB		**EQ 70MG BASE**		**A090022**	**004**	Sep 10, 2008
AB	WATSON LABS	**EQ 35MG BASE**		**A076984**	**001**	Aug 04, 2008
AB		**EQ 40MG BASE**		**A076984**	**002**	Aug 04, 2008
AB		**EQ 70MG BASE**		**A076984**	**003**	Aug 04, 2008
FOSAMAX						
AB **+!**	MERCK AND CO INC	**EQ 70MG BASE**		**N020560**	**005**	Oct 20, 2000
TABLET, EFFERVESCENT;ORAL						
BINOSTO						
+!	ASCEND THERAPS US	EQ 70MG BASE		N202344	001	Mar 12, 2012
ALENDRONATE SODIUM; CHOLECALCIFEROL						
TABLET;ORAL						
FOSAMAX PLUS D						
+	MERCK	EQ 70MG BASE;2,800 IU		N021762	001	Apr 07, 2005
+!		EQ 70MG BASE;5,600 IU		N021762	002	Apr 26, 2007
ALFENTANIL HYDROCHLORIDE						
INJECTABLE;INJECTION						
ALFENTA						
AP **+!**	AKORN	**EQ 0.5MG BASE/ML**		**N019353**	**001**	Dec 29, 1986
ALFENTANIL						
AP	HOSPIRA	**EQ 0.5MG BASE/ML**		**A075221**	**001**	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB		APOTEX INC	**10MG**	**A079013**	**001**	Jul 18, 2011
AB		AUROBINDO PHARMA LTD	**10MG**	**A079060**	**001**	Aug 30, 2012
AB		INVAGEN PHARMS	**10MG**	**A090284**	**001**	Jan 17, 2012
AB		SUN PHARM	**10MG**	**A079057**	**001**	Jul 18, 2011
AB		TORRENT PHARMS	**10MG**	**A079054**	**001**	Jul 18, 2011
AB		UNICHEM LABS LTD	**10MG**	**A203192**	**001**	Jan 28, 2016

UROXATRAL

AB	**+!**	CONCORDIA	**10MG**	**N021287**	**001**	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET;ORAL

ALISKIREN HEMIFUMARATE

AB		ANCHEN PHARMS	**EQ 150MG BASE**	**A206665**	**001**	Mar 22, 2019
AB			**EQ 300MG BASE**	**A206665**	**002**	Mar 22, 2019

TEKTURNA

AB	**+**	NODEN PHARMA	**EQ 150MG BASE**	**N021985**	**001**	Mar 05, 2007
AB	**+!**		**EQ 300MG BASE**	**N021985**	**002**	Mar 05, 2007

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

+	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008
+		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008
+!		EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008
+!		EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008

ALITRETINOIN

GEL;TOPICAL

PANRETIN

+!	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		ACCORD HLTHCARE	**100MG**	**A203154**	**001**	May 06, 2013
AB			**300MG**	**A203154**	**002**	May 06, 2013
AB		APOTEX INC	**100MG**	**A077353**	**001**	Sep 08, 2005
AB			**300MG**	**A077353**	**002**	Sep 08, 2005
AB		INDOCO REMEDIES	**100MG**	**A204467**	**001**	Jul 28, 2016
AB			**300MG**	**A204467**	**002**	Jul 28, 2016
AB		IPCA LABS LTD	**100MG**	**A090637**	**001**	Mar 16, 2011
AB			**300MG**	**A090637**	**002**	Mar 16, 2011
AB		MYLAN	**100MG**	**A018659**	**001**	Oct 24, 1986
AB			**300MG**	**A018659**	**002**	Oct 24, 1986
AB		NORTHSTAR HLTHCARE	**100MG**	**A078253**	**001**	Sep 11, 2007
AB			**300MG**	**A078253**	**002**	Sep 11, 2007
AB		SUN PHARM INDUSTRIES	**100MG**	**A071450**	**002**	Jan 09, 1987
AB			**300MG**	**A071450**	**001**	Jan 09, 1987
AB		UNICHEM LABS LTD	**100MG**	**A211820**	**001**	Mar 12, 2019
AB			**300MG**	**A211820**	**002**	Mar 12, 2019
AB		VINTAGE PHARMS	**100MG**	**A075798**	**001**	Jun 27, 2003
AB			**300MG**	**A075798**	**002**	Jun 27, 2003
AB		WATSON LABS	**100MG**	**N018832**	**002**	Sep 28, 1984
AB			**300MG**	**N018877**	**001**	Sep 28, 1984
AB		ZYDUS PHARMS	**100MG**	**A210117**	**001**	Oct 12, 2017
AB			**300MG**	**A210117**	**002**	Oct 12, 2017

LOPURIN

AB		DR REDDYS LA	**100MG**	**A071586**	**001**	Apr 02, 1987
AB			**300MG**	**A071587**	**001**	Apr 02, 1987

ZYLOPRIM

AB	**+**	CASPER PHARMA LLC	**100MG**	**N016084**	**001**	
AB	**+!**		**300MG**	**N016084**	**002**	

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALLOPURINOL SODIUM

AP		WEST-WARD PHARMS INT	**EQ 500MG BASE/VIAL**	**A076870**	**001**	Aug 26, 2004

ALOPRIM

AP	**+!**	MYLAN INSTITUTIONAL	**EQ 500MG BASE/VIAL**	**N020298**	**001**	May 17, 1996

PRESCRIPTION DRUG PRODUCT LIST

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB		AJANTA PHARMA LTD	**EQ 6.25MG BASE**	**A205523**	**001**	Mar 03, 2016
AB	**!**		**EQ 12.5MG BASE**	**A205523**	**002**	Mar 03, 2016
AB		MYLAN	**EQ 6.25MG BASE**	**A205171**	**001**	Nov 09, 2015
AB			**EQ 12.5MG BASE**	**A205171**	**002**	Nov 09, 2015
AB		TEVA PHARMS USA	**EQ 6.25MG BASE**	**A078027**	**001**	Jul 07, 2015
AB			**EQ 12.5MG BASE**	**A078027**	**002**	Jul 07, 2015

ALOGLIPTIN BENZOATE

TABLET;ORAL

NESINA

+	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013
+		EQ 12.5MG BASE	N022271	002	Jan 25, 2013
+!		EQ 25MG BASE	N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013
+!		EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

OSENI

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013
+		EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013
+		EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013
+!		EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB		AMNEAL PHARMS	**EQ 0.5MG BASE**	**A206647**	**001**	Dec 22, 2016
AB			**EQ 1MG BASE**	**A206647**	**002**	Dec 22, 2016
AB		EYWA PHARMA	**EQ 0.5MG BASE**	**A211621**	**001**	Sep 16, 2019
AB			**EQ 1MG BASE**	**A211621**	**002**	Sep 16, 2019
AB		HIKMA	**EQ 0.5MG BASE**	**A200652**	**001**	May 04, 2015
AB			**EQ 1MG BASE**	**A200652**	**002**	May 04, 2015
AB		PAR PHARM INC	**EQ 0.5MG BASE**	**A206113**	**001**	Feb 23, 2018
AB			**EQ 1MG BASE**	**A206113**	**002**	Feb 23, 2018
AB		RISING	**EQ 0.5MG BASE**	**A209180**	**001**	Jan 14, 2019
AB			**EQ 1MG BASE**	**A209180**	**002**	Jan 14, 2019

LOTRONEX

AB	**+**	SEBELA IRELAND LTD	**EQ 0.5MG BASE**	**N021107**	**002**	Dec 23, 2003
AB	**+!**		**EQ 1MG BASE**	**N021107**	**001**	Feb 09, 2000

ALPELISIB

TABLET;ORAL

PIQRAY

+	NOVARTIS	50MG	N212526	001	May 24, 2019
+		150MG	N212526	002	May 24, 2019
+!		200MG	N212526	003	May 24, 2019

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

+!	SANDOZ CANADA INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N021163	001	May 18, 2000
+!		2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	N021163	002	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE;ORAL

ALPRAZOLAM

	!	HIKMA	1MG/ML	A074312	001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.25MG**	**A074342**	**001**	Oct 31, 1993
AB			**0.5MG**	**A074342**	**002**	Oct 31, 1993
AB			**1MG**	**A074342**	**003**	Oct 31, 1993
AB			**2MG**	**A074342**	**004**	Oct 31, 1993
AB		APOTEX INC	**0.25MG**	**A077741**	**001**	Jan 19, 2007
AB			**0.5MG**	**A077741**	**002**	Jan 19, 2007
AB			**1MG**	**A077741**	**003**	Jan 19, 2007
AB			**2MG**	**A077741**	**004**	Jan 19, 2007
AB		AUROBINDO PHARMA LTD	**0.25MG**	**A203346**	**001**	Jul 31, 2015
AB			**0.5MG**	**A203346**	**002**	Jul 31, 2015
AB			**1MG**	**A203346**	**003**	Jul 31, 2015
AB			**2MG**	**A203346**	**004**	Jul 31, 2015
AB		BRECKENRIDGE	**0.25MG**	**A207507**	**001**	Jul 09, 2018
AB			**0.5MG**	**A207507**	**002**	Jul 09, 2018
AB			**1MG**	**A207507**	**003**	Jul 09, 2018
AB			**2MG**	**A207507**	**004**	Jul 09, 2018
AB		DAVA INTL INC	**0.25MG**	**A074174**	**001**	Oct 19, 1993
AB			**0.5MG**	**A074174**	**002**	Oct 19, 1993
AB			**1MG**	**A074174**	**003**	Oct 19, 1993
AB			**2MG**	**A074174**	**004**	Oct 19, 1993
AB		MYLAN	**0.25MG**	**A074215**	**001**	Jan 27, 1994
AB			**0.5MG**	**A074215**	**002**	Jan 27, 1994
AB			**1MG**	**A074215**	**003**	Jan 27, 1994
AB			**2MG**	**A074215**	**004**	Jan 27, 1994
AB		NATCO PHARMA LTD	**0.25MG**	**A200739**	**001**	Apr 15, 2015
AB			**0.5MG**	**A200739**	**002**	Apr 15, 2015
AB			**1MG**	**A200739**	**003**	Apr 15, 2015
AB			**2MG**	**A200739**	**004**	Apr 15, 2015
AB		OXFORD PHARMS	**0.25MG**	**A078491**	**001**	Sep 25, 2008
AB			**0.5MG**	**A078491**	**002**	Sep 25, 2008
AB			**1MG**	**A078491**	**003**	Sep 25, 2008
AB			**2MG**	**A078491**	**004**	Dec 12, 2008
AB		SANDOZ	**0.25MG**	**A074112**	**001**	Dec 29, 1995
AB			**0.5MG**	**A074112**	**002**	Dec 29, 1995
AB			**1MG**	**A074112**	**003**	Dec 29, 1995
AB			**2MG**	**A074909**	**001**	Mar 25, 1998
AB		SUN PHARM	**0.25MG**	**A090082**	**001**	Jun 17, 2010
AB			**0.5MG**	**A090082**	**002**	Jun 17, 2010
AB			**1MG**	**A090082**	**003**	Jun 17, 2010
AB			**2MG**	**A090082**	**004**	Jun 17, 2010
AB		VINTAGE PHARMS	**0.25MG**	**A090248**	**001**	Sep 17, 2010
AB			**0.5MG**	**A090248**	**002**	Sep 17, 2010
AB			**1MG**	**A090248**	**003**	Sep 17, 2010
AB			**2MG**	**A090248**	**004**	Sep 17, 2010

XANAX

AB	**+**	PHARMACIA AND UPJOHN	**0.25MG**	**N018276**	**001**	
AB	**+**		**0.5MG**	**N018276**	**002**	
AB	**+!**		**1MG**	**N018276**	**003**	
AB	**+**		**2MG**	**N018276**	**004**	Nov 27, 1985

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.5MG**	**A078056**	**001**	Feb 13, 2007
AB			**1MG**	**A078056**	**002**	Feb 13, 2007
AB			**2MG**	**A078056**	**003**	Feb 13, 2007
AB			**3MG**	**A078056**	**004**	Feb 13, 2007
AB		AMNEAL PHARMS NY	**0.5MG**	**A078387**	**001**	May 30, 2008
AB			**1MG**	**A078387**	**002**	May 30, 2008
AB			**2MG**	**A078387**	**003**	May 30, 2008
AB			**3MG**	**A078387**	**004**	May 30, 2008
AB		ANCHEN PHARMS	**0.5MG**	**A078469**	**001**	Sep 29, 2011
AB			**1MG**	**A078469**	**002**	Sep 29, 2011
AB			**2MG**	**A078469**	**003**	Sep 29, 2011
AB			**3MG**	**A078469**	**004**	Sep 29, 2011
AB		APOTEX INC	**0.5MG**	**A078449**	**001**	Nov 12, 2008
AB			**1MG**	**A078449**	**004**	Dec 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB			**2MG**	**A078449**	**002**	Nov 12, 2008
AB			**3MG**	**A078449**	**003**	Nov 12, 2008
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A090871**	**001**	Jun 07, 2011
AB			**1MG**	**A090871**	**002**	Jun 07, 2011
AB			**2MG**	**A090871**	**003**	Jun 07, 2011
AB			**3MG**	**A090871**	**004**	Jun 07, 2011

XANAX XR

AB	**+**	PHARMACIA AND UPJOHN	**0.5MG**	**N021434**	**001**	Jan 17, 2003
AB	**+**		**1MG**	**N021434**	**002**	Jan 17, 2003
AB	**+**		**2MG**	**N021434**	**003**	Jan 17, 2003
AB	**+!**		**3MG**	**N021434**	**004**	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.25MG**	**A078561**	**001**	Mar 16, 2010
AB			**0.5MG**	**A078561**	**002**	Mar 16, 2010
AB			**1MG**	**A078561**	**003**	Mar 16, 2010
AB			**2MG**	**A078561**	**004**	Mar 16, 2010
AB		PAR PHARM	**0.25MG**	**A078088**	**001**	Jan 09, 2009
AB			**0.5MG**	**A078088**	**002**	Jan 09, 2009
AB	**!**		**1MG**	**A078088**	**003**	Jan 09, 2009
AB			**2MG**	**A078088**	**004**	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

AP		TEVA PHARMS USA	**0.5MG/ML**	**A075196**	**001**	Apr 30, 1999
AP		WEST-WARD PHARMS INT	**0.5MG/ML**	**A074815**	**001**	Jan 20, 1998

CAVERJECT

AP	**+**	PHARMACIA AND UPJOHN	**0.01MG/VIAL**	**N020379**	**001**	Jul 06, 1995
AP	**+!**		**0.02MG/VIAL**	**N020379**	**002**	Jul 06, 1995
AP	**+!**		**0.04MG/VIAL**	**N020379**	**004**	May 19, 1997

EDEX

AP	**+**	AUXILIUM PHARMS LLC	**0.01MG/VIAL**	**N020649**	**002**	Jun 12, 1997
AP	**+**		**0.02MG/VIAL**	**N020649**	**003**	Jun 12, 1997
AP	**+!**		**0.04MG/VIAL**	**N020649**	**004**	Jun 12, 1997

PROSTIN VR PEDIATRIC

AP	**+!**	PHARMACIA AND UPJOHN	**0.5MG/ML**	**N018484**	**001**	

CAVERJECT IMPULSE

		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001	Jun 11, 2002
			0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

	+!	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649	005	Jul 30, 1998
	+!		0.02MG/VIAL	N020649	006	Jul 30, 1998
	+!		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY;URETHRAL

MUSE

	+!	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996
	+!		0.25MG	N020700	002	Nov 19, 1996
	+!		0.5MG	N020700	003	Nov 19, 1996
	+!		1MG	N020700	004	Nov 19, 1996

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

AB		WATSON LABS TEVA	**12MG**	**A208295**	**001**	Dec 19, 2019

ENTEREG

AB	**+!**	CUBIST PHARMS	**12MG**	**N021775**	**001**	May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**100MG**	**A208966**	**001**	Jun 21, 2017
AB		BIONPHARMA INC	**100MG**	**A078720**	**001**	May 29, 2008
AB		HERITAGE PHARMA	**100MG**	**A209171**	**001**	Jun 12, 2017
AB		INVAGEN PHARMS	**100MG**	**A207570**	**001**	Sep 30, 2016
AB	**!**	SANDOZ	**100MG**	**A071293**	**001**	Feb 18, 1987

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		STRIDES PHARMA	**100MG**	**A209047**	**001**	Jun 07, 2017
AB		UPSHER SMITH LABS	**100MG**	**A070589**	**001**	Aug 05, 1986
AB		WATSON LABS INC	**100MG**	**A208107**	**001**	Dec 06, 2016
AB		ZYDUS PHARMS	**100MG**	**A208278**	**001**	May 31, 2016

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

	+	ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	**!**	ANDA REPOSITORY	**50MG/5ML**	**A074028**	**001**	Jun 28, 1993
AA	**!**	CMP PHARMA INC	**50MG/5ML**	**A075819**	**001**	Sep 11, 2002
AA	**!**	HI TECH PHARMA	**50MG/5ML**	**A074170**	**001**	Oct 28, 1994
AA	**!**	PHARM ASSOC	**50MG/5ML**	**A074509**	**001**	Jul 17, 1995
AA	**!**	WOCKHARDT BIO AG	**50MG/5ML**	**A075060**	**001**	Dec 24, 1998

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB		INVAGEN PHARMS	**100MG**	**A207571**	**001**	Jan 31, 2017
AB		JUBILANT GENERICS	**100MG**	**A210403**	**001**	Feb 07, 2018
AB		STRIDES PHARMA	**100MG**	**A209035**	**001**	Jun 09, 2017
AB	**!**	UPSHER SMITH LABS	**100MG**	**A076186**	**001**	Dec 16, 2002
AB		WATSON LABS INC	**100MG**	**A208096**	**001**	Dec 15, 2016

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

	+	OSMOTICA PHARM	EQ 129MG BASE	N209410	001	Feb 16, 2018
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018
	+!		EQ 258MG BASE	N209410	003	Feb 16, 2018

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

AB		CIPLA	**5MG**	**A210715**	**001**	Apr 26, 2019
AB			**10MG**	**A210715**	**002**	Apr 26, 2019
AB		MYLAN	**5MG**	**A208441**	**001**	Mar 28, 2019
AB			**10MG**	**A208441**	**002**	Mar 28, 2019
AB		PAR PHARM INC	**5MG**	**A209509**	**001**	Apr 10, 2019
AB			**10MG**	**A209509**	**002**	Apr 10, 2019
AB		SIGMAPHARM LABS LLC	**5MG**	**A208354**	**001**	Apr 10, 2019
AB			**10MG**	**A208354**	**002**	Apr 10, 2019
AB		SUN PHARM	**5MG**	**A210784**	**001**	Mar 28, 2019
AB			**10MG**	**A210784**	**002**	Mar 28, 2019
AB		WATSON LABS INC	**5MG**	**A208252**	**001**	Mar 28, 2019
AB			**10MG**	**A208252**	**002**	Mar 28, 2019
AB		ZYDUS PHARMS	**5MG**	**A210058**	**001**	Mar 28, 2019
AB			**10MG**	**A210058**	**002**	Mar 28, 2019

LETAIRIS

AB	**+**	GILEAD	**5MG**	**N022081**	**001**	Jun 15, 2007
AB	**+!**		**10MG**	**N022081**	**002**	Jun 15, 2007

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

AB	**!**	FOUGERA PHARMS	**0.1%**	**A076065**	**001**	May 15, 2003
AB		TARO PHARM INDS	**0.1%**	**A076229**	**001**	May 31, 2002

LOTION;TOPICAL

AMCINONIDE

	!	FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002

OINTMENT;TOPICAL

AMCINONIDE

AB	**!**	FOUGERA PHARMS	**0.1%**	**A076096**	**001**	Nov 19, 2002
AB		TARO PHARM INDS	**0.1%**	**A076367**	**001**	Mar 19, 2003

AMIFAMPRIDINE

TABLET;ORAL

RUZURGI

	+!	JACOBUS PHARM CO INC	10MG	N209321	001	May 06, 2019

AMIFAMPRIDINE PHOSPHATE

TABLET;ORAL

FIRDAPSE

+!	CATALYST PHARMS	EQ 10MG BASE	N208078	001	Nov 28, 2018

AMIFOSTINE

INJECTABLE;INJECTION

AMIFOSTINE

AP	MYLAN LABS LTD	**500MG/VIAL**	**A204363**	**001**	Jul 17, 2017
AP	SUN PHARM	**500MG/VIAL**	**A077126**	**001**	Mar 14, 2008

ETHYOL

AP **+!**	CLINIGEN	**500MG/VIAL**	**N020221**	**001**	Dec 08, 1995

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

AP **!**	EMCURE PHARMS LTD	**EQ 250MG BASE/ML**	**A204040**	**001**	Dec 12, 2013
AP	FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A205605**	**001**	Dec 09, 2015
AP		**EQ 250MG BASE/ML**	**A205604**	**001**	Dec 09, 2015
AP	SAGENT PHARMS INC	**EQ 250MG BASE/ML**	**A203323**	**001**	May 12, 2016
AP **!**	WEST-WARD PHARMS INT	**EQ 50MG BASE/ML**	**A063313**	**001**	Apr 11, 1994
AP		**EQ 250MG BASE/ML**	**A063315**	**001**	Apr 11, 1994

SUSPENSION, LIPOSOMAL;INHALATION

ARIKAYCE KIT

+!	INSMED INC	EQ 590MG BASE/8.4ML	N207356	001	Sep 28, 2018

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB **!**	PAR PHARM	**5MG**	**A070346**	**001**	Jan 22, 1986
AB	SIGMAPHARM LABS LLC	**5MG**	**A079133**	**001**	Jan 30, 2009
AB	WINDLAS HLTHCARE	**5MG**	**A204180**	**001**	Aug 07, 2015

MIDAMOR

AB **+**	PADDOCK LLC	**5MG**	**N018200**	**001**	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	BARR	**EQ 5MG ANHYDROUS;50MG**	**A071111**	**001**	May 10, 1988
AB **!**	MYLAN	**EQ 5MG ANHYDROUS;50MG**	**A073209**	**001**	Oct 31, 1991

AMINO ACIDS

INJECTABLE;INJECTION

AMINO ACIDS

	B BRAUN	15%(150GM/1000ML)	A091112	001	Apr 13, 2012
		15%(300GM/2000ML)	A091112	002	Apr 13, 2012

AMINOSYN II 10% IN PLASTIC CONTAINER

	ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991

AMINOSYN II 15% IN PLASTIC CONTAINER

	ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991

AMINOSYN-PF 10%

	ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986

AMINOSYN-PF 7%

	ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

	BAXTER HLTHCARE	15% (15GM/100ML)	A020512	001	Aug 30, 1996

FREAMINE HBC 6.9%

	B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983

FREAMINE III 10%

	B BRAUN	10% (10GM/100ML)	N016822	005	

FREAMINE III 8.5%

	B BRAUN	8.5% (8.5GM/100ML)	N016822	004	

HEPATAMINE 8%

	B BRAUN	8% (8GM/100ML)	N018676	001	Aug 03, 1982

NEPHRAMINE 5.4%

	B BRAUN	5.4% (5.4GM/100ML)	N017766	001	

PREMASOL 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	10% (10GM/100ML)	A075880	002	Jun 19, 2003

PREMASOL 6% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	6% (6GM/100ML)	A075880	001	Jun 19, 2003

PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	20% (20GM/100ML)	N020849	001	Aug 26, 1998

TRAVASOL 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	10% (10MG/100ML)	N018931	003	Aug 23, 1984

AMINO ACIDS

INJECTABLE;INJECTION

TRAVASOL 5.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984

TRAVASOL 8.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931	002	Aug 23, 1984

TROPHAMINE

+!	B BRAUN	6% (6GM/100ML)	N019018	001	Jul 20, 1984

TROPHAMINE 10%

+!	B BRAUN	10% (10GM/100ML)	N019018	003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PROCALAMINE

	B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582	001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997

CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997

CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)	N200656	005	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)	N200656	006	Aug 25, 2014
+!		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)	N200656	007	Aug 25, 2014

PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1440ML)	N200656	001	Aug 25, 2014
+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1920ML)	N200656	002	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;10GM/100ML	N020734	002	Sep 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;25GM/100ML	N020734	005	Sep 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;5GM/100ML	N020734	001	Sep 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;10GM/100ML	N020734	008	Sep 29, 1997

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;20GM/100ML	N020734	010	Sep 29, 1997

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;25GM/100ML	N020734	011	Sep 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;5GM/100ML	N020734	007	Sep 29, 1997

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;10GM/100ML	N020734	014	Sep 29, 1997

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;15GM/100ML	N020734	015	Sep 29, 1997

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;20GM/100ML	N020734	016	Sep 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;25GM/100ML	N020734	017	Sep 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;35GM/100ML	N020734	018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTABLE

FREAMINE III 8.5% W/ ELECTROLYTES

	B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

FREAMINE III 3% W/ ELECTROLYTES

	B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822	003	

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

AP		LUITPOLD	**250MG/ML**	**A071192**	**001**	Dec 01, 1987

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	**!**	HOSPIRA	**250MG/ML**	**A070010**	**001**	Mar 09, 1987

SYRUP;ORAL

AMICAR

AA	**+!**	CLOVER PHARMS	**1.25GM/5ML**	**N015230**	**002**	

AMINOCAPROIC ACID

AA		AMNEAL PHARMS LLC	**1.25GM/5ML**	**A212780**	**001**	Aug 23, 2019

TABLET;ORAL

AMICAR

AB	**+**	CLOVER PHARMS	**500MG**	**N015197**	**001**	
AB	**+**		**1GM**	**N015197**	**002**	Jun 24, 2004

AMINOCAPROIC ACID

AB		AMNEAL	**500MG**	**A212492**	**001**	Nov 26, 2019
AB		SUNNY PHARMTECH INC	**500MG**	**A209060**	**001**	Nov 27, 2018
AB	**!**		**1GM**	**A209060**	**002**	Nov 27, 2018

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL						
GLEOLAN						
	+!	NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017
GEL;TOPICAL						
AMELUZ						
	+!	BIOFRONTERA	10%	N208081	001	May 10, 2016
SOLUTION;TOPICAL						
LEVULAN						
	+!	DUSA	20%	N020965	001	Dec 03, 1999

AMINOPHYLLINE

INJECTABLE;INJECTION						
AMINOPHYLLINE						
	!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE;ORAL						
PASER						
	!	JACOBUS	4GM/PACKET	A074346	001	Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION						
AMIODARONE HYDROCHLORIDE						
AP		AUROBINDO PHARMA LTD	**50MG/ML**	**A204550**	**001**	Oct 25, 2017
AP	**!**	FRESENIUS KABI USA	**50MG/ML**	**A075761**	**001**	Oct 15, 2002
AP	**!**	GLAND PHARMA LTD	**50MG/ML**	**A077161**	**001**	Apr 20, 2005
AP		HIKMA FARMACEUTICA	**50MG/ML**	**A077234**	**001**	Feb 25, 2008
AP	**!**	HOSPIRA	**50MG/ML**	**A075955**	**001**	Oct 18, 2002
AP		HOSPIRA INC	**50MG/ML**	**A203884**	**001**	Nov 25, 2013
AP			**50MG/ML**	**A203885**	**001**	Nov 25, 2013
AP	**!**	MYLAN INSTITUTIONAL	**50MG/ML**	**A076217**	**001**	Oct 15, 2002
AP		WOCKHARDT	**50MG/ML**	**A077610**	**001**	Oct 30, 2008
AP			**50MG/ML**	**A077834**	**001**	Oct 30, 2008
NEXTERONE						
	+!	BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010
	+!		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010
TABLET;ORAL						
AMIODARONE HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**200MG**	**A204742**	**001**	Jun 03, 2016
AB		MAYNE PHARMA INC	**100MG**	**A075389**	**002**	Dec 28, 2017
AB			**200MG**	**A075389**	**001**	Jan 25, 2001
AB			**400MG**	**A075389**	**003**	Dec 28, 2017
AB		MURTY PHARMS	**100MG**	**A077069**	**003**	Oct 04, 2016
AB			**200MG**	**A077069**	**001**	Apr 08, 2005
AB			**400MG**	**A077069**	**002**	Apr 08, 2005
AB		RUBICON	**200MG**	**A078578**	**001**	Nov 06, 2008
AB	**!**	SANDOZ	**200MG**	**A075315**	**001**	Dec 23, 1998
AB			**400MG**	**A075315**	**002**	Jun 30, 2000
AB		TARO	**100MG**	**A075424**	**002**	Dec 18, 2002
AB			**200MG**	**A075424**	**001**	Mar 30, 2001
AB			**400MG**	**A076362**	**001**	Nov 29, 2002
AB		TEVA PHARMS	**200MG**	**A074739**	**001**	Nov 30, 1998
AB		ZYDUS PHARMS USA INC	**200MG**	**A079029**	**001**	Sep 16, 2008
PACERONE						
AB		UPSHER SMITH LABS	**100MG**	**A075135**	**002**	Apr 12, 2005
AB			**200MG**	**A075135**	**001**	Apr 30, 1998
AMIODARONE HYDROCHLORIDE						
		TARO	300MG	A076362	002	Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL						
AMITRIPTYLINE HYDROCHLORIDE						
AB		ACCORD HLTHCARE	**10MG**	**A202446**	**001**	Jun 04, 2014
AB			**25MG**	**A202446**	**002**	Jun 04, 2014
AB			**50MG**	**A202446**	**003**	Jun 04, 2014
AB			**75MG**	**A202446**	**004**	Jun 04, 2014
AB			**100MG**	**A202446**	**005**	Jun 04, 2014
AB			**150MG**	**A202446**	**006**	Jun 04, 2014
AB		MYLAN	**10MG**	**A086009**	**002**	
AB			**25MG**	**A086009**	**003**	
AB			**50MG**	**A086009**	**001**	

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB			**75MG**	**A086009**	**004**	
AB			**100MG**	**A086009**	**005**	
AB			**150MG**	**A086009**	**006**	
AB		SANDOZ	**10MG**	**A085969**	**001**	
AB	**!**		**25MG**	**A085966**	**001**	
AB			**50MG**	**A085968**	**001**	
AB			**75MG**	**A085971**	**001**	
AB			**100MG**	**A085967**	**001**	
AB			**150MG**	**A085970**	**001**	
AB		SUN PHARM INDS INC	**10MG**	**A089399**	**002**	Jul 14, 1987
AB			**25MG**	**A089399**	**001**	Jul 14, 1987
AB			**50MG**	**A089399**	**003**	Jul 14, 1987
AB			**75MG**	**A089399**	**004**	Jul 14, 1987
AB			**100MG**	**A089399**	**005**	Jul 14, 1987
AB			**150MG**	**A089399**	**006**	Jul 14, 1987
AB		VINTAGE PHARMS	**10MG**	**A040218**	**001**	Sep 11, 1997
AB			**25MG**	**A040218**	**002**	Sep 11, 1997
AB			**50MG**	**A040218**	**003**	Sep 11, 1997
AB			**75MG**	**A040218**	**004**	Sep 11, 1997
AB			**100MG**	**A040218**	**005**	Sep 11, 1997
AB			**150MG**	**A040218**	**006**	Sep 11, 1997
AB		ZYDUS PHARMS	**10MG**	**A210086**	**001**	Oct 06, 2017
AB			**25MG**	**A210086**	**002**	Oct 06, 2017
AB			**50MG**	**A210086**	**003**	Oct 06, 2017
AB			**75MG**	**A210086**	**004**	Oct 06, 2017
AB			**100MG**	**A210086**	**005**	Oct 06, 2017
AB			**150MG**	**A210086**	**006**	Oct 06, 2017

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
!		25MG;2MG	A071443	004	Nov 10, 1988
!		25MG;4MG	A071443	005	Nov 10, 1988
!		50MG;4MG	A071443	001	Nov 10, 1988

AMLODIPINE BENZOATE

SUSPENSION;ORAL

KATERZIA

+!	SILVERGATE PHARMS	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB		ACCORD HLTHCARE	**EQ 2.5MG BASE**	**A202553**	**001**	Apr 29, 2013
AB			**EQ 5MG BASE**	**A202553**	**002**	Apr 29, 2013
AB			**EQ 10MG BASE**	**A202553**	**003**	Apr 29, 2013
AB		ALKEM	**EQ 2.5MG BASE**	**A078925**	**001**	May 04, 2009
AB			**EQ 5MG BASE**	**A078925**	**002**	May 04, 2009
AB			**EQ 10MG BASE**	**A078925**	**003**	May 04, 2009
AB		APOTEX	**EQ 2.5MG BASE**	**A076719**	**001**	May 23, 2007
AB			**EQ 5MG BASE**	**A076719**	**002**	May 23, 2007
AB			**EQ 10MG BASE**	**A076719**	**003**	May 23, 2007
AB		AUROBINDO PHARMA	**EQ 2.5MG BASE**	**A078021**	**001**	Jul 17, 2007
AB			**EQ 5MG BASE**	**A078021**	**002**	Jul 17, 2007
AB			**EQ 10MG BASE**	**A078021**	**003**	Jul 17, 2007
AB		CHINA RESOURCES	**EQ 2.5MG BASE**	**A090752**	**003**	May 16, 2016
AB			**EQ 5MG BASE**	**A090752**	**001**	Apr 15, 2011
AB			**EQ 10MG BASE**	**A090752**	**002**	Apr 15, 2011
AB		CIPLA	**EQ 2.5MG BASE**	**A077073**	**001**	Sep 26, 2007
AB			**EQ 5MG BASE**	**A077073**	**002**	Sep 26, 2007
AB			**EQ 10MG BASE**	**A077073**	**003**	Sep 26, 2007
AB		EPIC PHARMA LLC	**EQ 2.5MG BASE**	**A078552**	**001**	Apr 08, 2009
AB			**EQ 5MG BASE**	**A078552**	**002**	Apr 08, 2009

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB		**EQ 10MG BASE**	**A078552**	**003**	Apr 08, 2009
AB	HEBEI CHANGSHAN	**EQ 2.5MG BASE**	**A076692**	**001**	Jul 20, 2007
AB		**EQ 5MG BASE**	**A076692**	**002**	Jul 20, 2007
AB		**EQ 10MG BASE**	**A076692**	**003**	Jul 20, 2007
AB	HIKMA	**EQ 2.5MG BASE**	**A077262**	**001**	Jul 09, 2007
AB		**EQ 5MG BASE**	**A077262**	**002**	Jul 09, 2007
AB		**EQ 10MG BASE**	**A077262**	**003**	Jul 09, 2007
AB	HIKMA PHARMS	**EQ 2.5MG BASE**	**A077771**	**001**	Apr 12, 2011
AB		**EQ 5MG BASE**	**A077771**	**002**	Apr 12, 2011
AB		**EQ 10MG BASE**	**A077771**	**003**	Apr 12, 2011
AB	INVAGEN PHARMS	**EQ 2.5MG BASE**	**A077955**	**001**	Aug 28, 2007
AB		**EQ 2.5MG BASE**	**A206367**	**001**	Dec 10, 2015
AB		**EQ 5MG BASE**	**A077955**	**002**	Aug 28, 2007
AB		**EQ 5MG BASE**	**A206367**	**002**	Dec 10, 2015
AB		**EQ 10MG BASE**	**A077955**	**003**	Aug 28, 2007
AB		**EQ 10MG BASE**	**A206367**	**003**	Dec 10, 2015
AB	LUPIN	**EQ 2.5MG BASE**	**A078043**	**001**	Jul 12, 2007
AB		**EQ 5MG BASE**	**A078043**	**002**	Jul 12, 2007
AB		**EQ 10MG BASE**	**A078043**	**003**	Jul 12, 2007
AB	MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A201380**	**001**	Apr 13, 2012
AB		**EQ 10MG BASE**	**A201380**	**002**	Apr 13, 2012
AB	MYLAN	**EQ 2.5MG BASE**	**A076418**	**001**	Oct 03, 2005
AB		**EQ 5MG BASE**	**A076418**	**002**	Oct 03, 2005
AB		**EQ 10MG BASE**	**A076418**	**003**	Oct 03, 2005
AB	ORCHID HLTHCARE	**EQ 2.5MG BASE**	**A078453**	**001**	Jul 02, 2009
AB		**EQ 5MG BASE**	**A078453**	**002**	Jul 02, 2009
AB		**EQ 10MG BASE**	**A078453**	**003**	Jul 02, 2009
AB	OXFORD PHARMS	**EQ 2.5MG BASE**	**A078414**	**001**	Apr 07, 2010
AB		**EQ 5MG BASE**	**A078414**	**002**	Apr 07, 2010
AB		**EQ 10MG BASE**	**A078414**	**003**	Apr 07, 2010
AB	POLYGEN PHARMS	**EQ 2.5MG BASE**	**A207821**	**001**	Jul 11, 2016
AB		**EQ 5MG BASE**	**A207821**	**002**	Jul 11, 2016
AB		**EQ 10MG BASE**	**A207821**	**003**	Jul 11, 2016
AB	STRIDES PHARMA	**EQ 2.5MG BASE**	**A077516**	**001**	Jul 11, 2007
AB		**EQ 5MG BASE**	**A077516**	**002**	Jul 11, 2007
AB		**EQ 10MG BASE**	**A077516**	**003**	Jul 11, 2007
AB	SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A077974**	**001**	Jul 09, 2007
AB		**EQ 5MG BASE**	**A077974**	**002**	Jul 09, 2007
AB		**EQ 10MG BASE**	**A077974**	**003**	Jul 09, 2007
AB	TORRENT PHARMS	**EQ 2.5MG BASE**	**A078573**	**001**	Sep 22, 2008
AB		**EQ 5MG BASE**	**A078573**	**002**	Sep 22, 2008
AB		**EQ 10MG BASE**	**A078573**	**003**	Sep 22, 2008
AB	UNICHEM LABS LTD	**EQ 2.5MG BASE**	**A203245**	**001**	Oct 21, 2013
AB		**EQ 5MG BASE**	**A203245**	**002**	Oct 21, 2013
AB		**EQ 10MG BASE**	**A203245**	**003**	Oct 21, 2013
AB	UPSHER SMITH LABS	**EQ 2.5MG BASE**	**A077759**	**001**	Jul 09, 2007
AB		**EQ 5MG BASE**	**A077759**	**002**	Jul 09, 2007
AB		**EQ 10MG BASE**	**A077759**	**003**	Jul 09, 2007
AB	WATSON LABS	**EQ 2.5MG BASE**	**A077671**	**001**	Jul 19, 2007
AB		**EQ 5MG BASE**	**A077671**	**002**	Jul 19, 2007
AB		**EQ 10MG BASE**	**A077671**	**003**	Jul 19, 2007
AB	WOCKHARDT	**EQ 2.5MG BASE**	**A078500**	**001**	Sep 06, 2007
AB		**EQ 5MG BASE**	**A078500**	**002**	Sep 06, 2007
AB		**EQ 10MG BASE**	**A078500**	**003**	Sep 06, 2007
AB	ZYDUS PHARMS USA	**EQ 2.5MG BASE**	**A078226**	**001**	Jul 09, 2007
AB		**EQ 5MG BASE**	**A078226**	**002**	Jul 09, 2007
AB		**EQ 10MG BASE**	**A078226**	**003**	Jul 09, 2007

NORVASC

AB	**+** PFIZER	**EQ 2.5MG BASE**	**N019787**	**001**	Jul 31, 1992
AB	**+**	**EQ 5MG BASE**	**N019787**	**002**	Jul 31, 1992
AB	**+!**	**EQ 10MG BASE**	**N019787**	**003**	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	APOTEX	**EQ 5MG BASE;EQ 10MG BASE**	**A205199**	**001**	Nov 18, 2019
AB		**EQ 5MG BASE;EQ 20MG BASE**	**A205199**	**002**	Nov 18, 2019
AB		**EQ 5MG BASE;EQ 40MG BASE**	**A205199**	**003**	Nov 18, 2019
AB		**EQ 5MG BASE;EQ 80MG BASE**	**A205199**	**004**	Nov 18, 2019
AB		**EQ 10MG BASE;EQ 10MG BASE**	**A205199**	**005**	Nov 18, 2019

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB			EQ 10MG BASE;EQ 20MG BASE	A205199	006	Nov 18, 2019
AB			EQ 10MG BASE;EQ 40MG BASE	A205199	007	Nov 18, 2019
AB			EQ 10MG BASE;EQ 80MG BASE	A205199	008	Nov 18, 2019
AB		DR REDDYS	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014
AB			EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014
AB			EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014
AB			EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014
AB			EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014
AB			EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014
AB			EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014
AB			EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014
AB			EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014
AB			EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014
AB			EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014
AB		MYLAN	EQ 2.5MG BASE;EQ 10MG BASE	A200465	001	Nov 29, 2013
AB			EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013
AB			EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013
AB			EQ 5MG BASE;EQ 10MG BASE	A200465	004	Nov 29, 2013
AB			EQ 5MG BASE;EQ 20MG BASE	A200465	005	Nov 29, 2013
AB			EQ 5MG BASE;EQ 40MG BASE	A200465	006	Nov 29, 2013
AB			EQ 5MG BASE;EQ 80MG BASE	A200465	007	Nov 29, 2013
AB			EQ 10MG BASE;EQ 10MG BASE	A200465	008	Nov 29, 2013
AB			EQ 10MG BASE;EQ 20MG BASE	A200465	009	Nov 29, 2013
AB			EQ 10MG BASE;EQ 40MG BASE	A200465	010	Nov 29, 2013
AB			EQ 10MG BASE;EQ 80MG BASE	A200465	011	Nov 29, 2013

CADUET

AB	+	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004
AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004
AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004
AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004
AB	+!		EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		APOTEX	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013
AB			EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013
AB			EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013
AB			EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013
AB			EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013
AB			EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013
AB		AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239	001	Sep 05, 2012
AB			EQ 5MG BASE;10MG	A202239	002	Sep 05, 2012
AB			EQ 5MG BASE;20MG	A202239	003	Sep 05, 2012
AB			EQ 5MG BASE;40MG	A202239	004	Sep 05, 2012
AB			EQ 10MG BASE;20MG	A202239	005	Sep 05, 2012
AB			EQ 10MG BASE;40MG	A202239	006	Sep 05, 2012
AB		DR REDDYS LABS INC	EQ 2.5MG BASE;10MG	A077183	001	Apr 15, 2010
AB			EQ 5MG BASE;10MG	A077183	002	Apr 15, 2010
AB			EQ 5MG BASE;20MG	A077183	003	Apr 15, 2010
AB			EQ 5MG BASE;40MG	A090149	001	Jul 05, 2011
AB			EQ 10MG BASE;20MG	A077183	004	Apr 15, 2010
AB			EQ 10MG BASE;40MG	A090149	002	Jul 05, 2011
AB		LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466	001	Feb 05, 2010
AB			EQ 5MG BASE;10MG	A078466	002	Feb 05, 2010
AB			EQ 5MG BASE;20MG	A078466	003	Feb 05, 2010
AB			EQ 5MG BASE;40MG	A078466	005	Jul 05, 2011
AB			EQ 10MG BASE;20MG	A078466	004	Feb 05, 2010
AB			EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011
AB		PAR PHARM	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010
AB			EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010
AB			EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010
AB			EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB			**EQ 10MG BASE;20MG**	**A078381**	**004**	Jul 29, 2010
AB			**EQ 10MG BASE;40MG**	**A078381**	**006**	Jul 29, 2010
AB		WATSON LABS	**EQ 2.5MG BASE;10MG**	**A077890**	**001**	Oct 14, 2010
AB			**EQ 5MG BASE;10MG**	**A077890**	**002**	Oct 14, 2010
AB			**EQ 5MG BASE;20MG**	**A077890**	**003**	Oct 14, 2010
AB			**EQ 10MG BASE;20MG**	**A077890**	**004**	Oct 14, 2010
AB		WATSON LABS INC	**EQ 5MG BASE;40MG**	**A090364**	**001**	Jul 05, 2011
AB			**EQ 10MG BASE;40MG**	**A090364**	**002**	Jul 05, 2011

LOTREL

AB	**+**	NOVARTIS	**EQ 2.5MG BASE;10MG**	**N020364**	**002**	Mar 03, 1995
AB	**+**		**EQ 5MG BASE;10MG**	**N020364**	**003**	Mar 03, 1995
AB	**+**		**EQ 5MG BASE;20MG**	**N020364**	**004**	Mar 03, 1995
AB	**+**		**EQ 5MG BASE;40MG**	**N020364**	**007**	Apr 11, 2006
AB	**+**		**EQ 10MG BASE;20MG**	**N020364**	**005**	Jun 20, 2002
AB	**+!**		**EQ 10MG BASE;40MG**	**N020364**	**006**	Apr 11, 2006

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

	+	COEPTIS	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018
	+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018
	+!		EQ 10MG BASE;200MG	N210045	003	May 31, 2018

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB		PAR PHARM INC	**EQ 5MG BASE;12.5MG;20MG**	**A206137**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;12.5MG;40MG**	**A206137**	**002**	Oct 26, 2016
AB			**EQ 5MG BASE;25MG;40MG**	**A206137**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;12.5MG;40MG**	**A206137**	**004**	Oct 26, 2016
AB			**EQ 10MG BASE;25MG;40MG**	**A206137**	**005**	Oct 26, 2016
AB		TORRENT	**EQ 5MG BASE;12.5MG;20MG**	**A203580**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;12.5MG;40MG**	**A203580**	**002**	Oct 26, 2016
AB			**EQ 5MG BASE;25MG;40MG**	**A203580**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;12.5MG;40MG**	**A203580**	**004**	Oct 26, 2016
AB			**EQ 10MG BASE;25MG;40MG**	**A203580**	**005**	Oct 26, 2016

TRIBENZOR

AB	**+**	DAIICHI SANKYO	**EQ 5MG BASE;12.5MG;20MG**	**N200175**	**001**	Jul 23, 2010
AB	**+**		**EQ 5MG BASE;12.5MG;40MG**	**N200175**	**002**	Jul 23, 2010
AB	**+**		**EQ 5MG BASE;25MG;40MG**	**N200175**	**003**	Jul 23, 2010
AB	**+**		**EQ 10MG BASE;12.5MG;40MG**	**N200175**	**004**	Jul 23, 2010
AB	**+!**		**EQ 10MG BASE;25MG;40MG**	**N200175**	**005**	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA LTD	**5MG;12.5MG;160MG**	**A206180**	**001**	Dec 19, 2017
AB			**5MG;25MG;160MG**	**A206180**	**002**	Dec 19, 2017
AB			**10MG;12.5MG;160MG**	**A206180**	**003**	Dec 19, 2017
AB			**10MG;25MG;160MG**	**A206180**	**004**	Dec 19, 2017
AB			**10MG;25MG;320MG**	**A206180**	**005**	Dec 19, 2017
AB		LUPIN LTD	**5MG;12.5MG;160MG**	**A200797**	**001**	Jun 03, 2015
AB			**5MG;25MG;160MG**	**A200797**	**002**	Jun 03, 2015
AB			**10MG;12.5MG;160MG**	**A200797**	**003**	Jun 03, 2015
AB			**10MG;25MG;160MG**	**A200797**	**004**	Jun 03, 2015
AB			**10MG;25MG;320MG**	**A200797**	**005**	Jun 03, 2015
AB		PAR PHARM	**5MG;12.5MG;160MG**	**A201087**	**001**	Jun 01, 2015
AB			**5MG;25MG;160MG**	**A201087**	**002**	Jun 01, 2015
AB			**10MG;12.5MG;160MG**	**A201087**	**003**	Jun 01, 2015
AB			**10MG;25MG;160MG**	**A201087**	**004**	Jun 01, 2015
AB			**10MG;25MG;320MG**	**A201087**	**005**	Jun 01, 2015

EXFORGE HCT

AB	**+**	NOVARTIS	**5MG;12.5MG;160MG**	**N022314**	**001**	Apr 30, 2009
AB	**+**		**5MG;25MG;160MG**	**N022314**	**002**	Apr 30, 2009
AB	**+**		**10MG;12.5MG;160MG**	**N022314**	**003**	Apr 30, 2009
AB	**+**		**10MG;25MG;160MG**	**N022314**	**004**	Apr 30, 2009
AB	**+!**		**10MG;25MG;320MG**	**N022314**	**005**	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	AJANTA PHARMA LTD	**EQ 5MG BASE;20MG**	**A207216**	**001**	Oct 28, 2016
AB		**EQ 5MG BASE;40MG**	**A207216**	**002**	Oct 28, 2016
AB		**EQ 10MG BASE;20MG**	**A207216**	**003**	Oct 28, 2016
AB		**EQ 10MG BASE;40MG**	**A207216**	**004**	Oct 28, 2016
AB	ALEMBIC PHARMS LTD	**EQ 5MG BASE;20MG**	**A207073**	**001**	Jul 17, 2017
AB		**EQ 5MG BASE;40MG**	**A207073**	**002**	Jul 17, 2017
AB		**EQ 10MG BASE;20MG**	**A207073**	**003**	Jul 17, 2017
AB		**EQ 10MG BASE;40MG**	**A207073**	**004**	Jul 17, 2017
AB	ALKEM LABS LTD	**EQ 5MG BASE;20MG**	**A209042**	**001**	Aug 14, 2017
AB		**EQ 5MG BASE;40MG**	**A209042**	**002**	Aug 14, 2017
AB		**EQ 10MG BASE;20MG**	**A209042**	**003**	Aug 14, 2017
AB		**EQ 10MG BASE;40MG**	**A209042**	**004**	Aug 14, 2017
AB	AUROBINDO PHARMA LTD	**EQ 5MG BASE;20MG**	**A206906**	**001**	May 15, 2017
AB		**EQ 5MG BASE;40MG**	**A206906**	**002**	May 15, 2017
AB		**EQ 10MG BASE;20MG**	**A206906**	**003**	May 15, 2017
AB		**EQ 10MG BASE;40MG**	**A206906**	**004**	May 15, 2017
AB	GLENMARK PHARMS LTD	**EQ 5MG BASE;20MG**	**A207807**	**001**	Jul 05, 2017
AB		**EQ 5MG BASE;40MG**	**A207807**	**002**	Jul 05, 2017
AB		**EQ 10MG BASE;20MG**	**A207807**	**003**	Jul 05, 2017
AB		**EQ 10MG BASE;40MG**	**A207807**	**004**	Jul 05, 2017
AB	JUBILANT GENERICS	**EQ 5MG BASE;20MG**	**A207450**	**001**	May 15, 2017
AB		**EQ 5MG BASE;40MG**	**A207450**	**002**	May 15, 2017
AB		**EQ 10MG BASE;20MG**	**A207450**	**003**	May 15, 2017
AB		**EQ 10MG BASE;40MG**	**A207450**	**004**	May 15, 2017
AB	MACLEODS PHARMS LTD	**EQ 5MG BASE;20MG**	**A206884**	**001**	Oct 26, 2016
AB		**EQ 5MG BASE;40MG**	**A206884**	**003**	Oct 26, 2016
AB		**EQ 10MG BASE;20MG**	**A206884**	**002**	Oct 26, 2016
AB		**EQ 10MG BASE;40MG**	**A206884**	**004**	Oct 26, 2016
AB	MICRO LABS	**EQ 5MG BASE;20MG**	**A207435**	**001**	Nov 02, 2017
AB		**EQ 5MG BASE;40MG**	**A207435**	**002**	Nov 02, 2017
AB		**EQ 10MG BASE;20MG**	**A207435**	**003**	Nov 02, 2017
AB		**EQ 10MG BASE;40MG**	**A207435**	**004**	Nov 02, 2017
AB	SCIEGEN PHARMS INC	**EQ 5MG BASE;20MG**	**A209010**	**001**	Dec 03, 2018
AB		**EQ 5MG BASE;40MG**	**A209010**	**002**	Dec 03, 2018
AB		**EQ 10MG BASE;20MG**	**A209010**	**003**	Dec 03, 2018
AB		**EQ 10MG BASE;40MG**	**A209010**	**004**	Dec 03, 2018
AB	TORRENT	**EQ 5MG BASE;20MG**	**A202933**	**001**	Nov 25, 2016
AB		**EQ 5MG BASE;40MG**	**A202933**	**002**	Nov 25, 2016
AB		**EQ 10MG BASE;20MG**	**A202933**	**003**	Nov 25, 2016
AB		**EQ 10MG BASE;40MG**	**A202933**	**004**	Nov 25, 2016
AB	ZYDUS PHARMS	**EQ 5MG BASE;20MG**	**A207771**	**001**	Sep 22, 2017
AB		**EQ 5MG BASE;40MG**	**A207771**	**002**	Sep 22, 2017
AB		**EQ 10MG BASE;20MG**	**A207771**	**003**	Sep 22, 2017
AB		**EQ 10MG BASE;40MG**	**A207771**	**004**	Sep 22, 2017

AZOR

AB	**+** DAIICHI SANKYO	**EQ 5MG BASE;20MG**	**N022100**	**001**	Sep 26, 2007
AB	**+**	**EQ 5MG BASE;40MG**	**N022100**	**002**	Sep 26, 2007
AB	**+**	**EQ 10MG BASE;20MG**	**N022100**	**003**	Sep 26, 2007
AB	**+!**	**EQ 10MG BASE;40MG**	**N022100**	**004**	Sep 26, 2007

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015
+!		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

AB	ALEMBIC PHARMS LTD	**EQ 5MG BASE;40MG**	**A205234**	**001**	Nov 17, 2016
AB		**EQ 5MG BASE;80MG**	**A205234**	**003**	Nov 17, 2016
AB		**EQ 10MG BASE;40MG**	**A205234**	**002**	Nov 17, 2016
AB		**EQ 10MG BASE;80MG**	**A205234**	**004**	Nov 17, 2016
AB	LUPIN LTD	**EQ 5MG BASE;40MG**	**A201586**	**001**	Jan 08, 2014
AB		**EQ 5MG BASE;80MG**	**A201586**	**003**	Jan 08, 2014
AB		**EQ 10MG BASE;40MG**	**A201586**	**002**	Jan 08, 2014
AB		**EQ 10MG BASE;80MG**	**A201586**	**004**	Jan 08, 2014
AB	MYLAN	**EQ 5MG BASE;40MG**	**A202516**	**001**	Aug 26, 2014
AB		**EQ 5MG BASE;80MG**	**A202516**	**003**	Aug 26, 2014

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

AB			**EQ 10MG BASE;40MG**	**A202516**	**002**	Aug 26, 2014
AB			**EQ 10MG BASE;80MG**	**A202516**	**004**	Aug 26, 2014
AB		TORRENT	**EQ 5MG BASE;40MG**	**A202517**	**001**	Jan 08, 2014
AB			**EQ 5MG BASE;80MG**	**A202517**	**003**	Jan 08, 2014
AB			**EQ 10MG BASE;40MG**	**A202517**	**002**	Jan 08, 2014
AB			**EQ 10MG BASE;80MG**	**A202517**	**004**	Jan 08, 2014

TWYNSTA

AB	+	BOEHRINGER INGELHEIM	**EQ 5MG BASE;40MG**	**N022401**	**001**	Oct 16, 2009
AB	+		**EQ 5MG BASE;80MG**	**N022401**	**003**	Oct 16, 2009
AB	+		**EQ 10MG BASE;40MG**	**N022401**	**002**	Oct 16, 2009
AB	+!		**EQ 10MG BASE;80MG**	**N022401**	**004**	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		ALEMBIC PHARMS LTD	**EQ 5MG BASE;160MG**	**A202713**	**001**	Apr 03, 2015
AB			**EQ 5MG BASE;320MG**	**A202713**	**003**	Apr 03, 2015
AB			**EQ 10MG BASE;160MG**	**A202713**	**002**	Apr 03, 2015
AB			**EQ 10MG BASE;320MG**	**A202713**	**004**	Apr 03, 2015
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE;160MG**	**A206512**	**001**	Apr 22, 2016
AB			**EQ 5MG BASE;320MG**	**A206512**	**002**	Apr 22, 2016
AB			**EQ 10MG BASE;160MG**	**A206512**	**003**	Apr 22, 2016
AB			**EQ 10MG BASE;320MG**	**A206512**	**004**	Apr 22, 2016
AB		INVAGEN PHARMS	**EQ 5MG BASE;160MG**	**A205137**	**001**	Sep 16, 2016
AB			**EQ 5MG BASE;320MG**	**A205137**	**003**	Sep 16, 2016
AB			**EQ 10MG BASE;160MG**	**A205137**	**002**	Sep 16, 2016
AB			**EQ 10MG BASE;320MG**	**A205137**	**004**	Sep 16, 2016
AB		LUPIN	**EQ 5MG BASE;160MG**	**A090245**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090245**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090245**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090245**	**004**	Mar 30, 2015
AB		MYLAN	**EQ 5MG BASE;160MG**	**A090483**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090483**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090483**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090483**	**004**	Mar 30, 2015
AB		NOVEL LABS INC	**EQ 5MG BASE;160MG**	**A202829**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A202829**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A202829**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A202829**	**004**	Mar 30, 2015
AB		PAR PHARM INC	**EQ 5MG BASE;160MG**	**A090011**	**001**	Mar 28, 2013
AB			**EQ 5MG BASE;320MG**	**A090011**	**003**	Mar 28, 2013
AB			**EQ 10MG BASE;160MG**	**A090011**	**002**	Mar 28, 2013
AB			**EQ 10MG BASE;320MG**	**A090011**	**004**	Mar 28, 2013

EXFORGE

AB	+	NOVARTIS	**EQ 5MG BASE;160MG**	**N021990**	**002**	Jun 20, 2007
AB	+		**EQ 5MG BASE;320MG**	**N021990**	**004**	Jun 20, 2007
AB	+!		**EQ 10MG BASE;160MG**	**N021990**	**003**	Jun 20, 2007
AB	+!		**EQ 10MG BASE;320MG**	**N021990**	**005**	Jun 20, 2007

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		3D IMAGING DRUG	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203779**	**001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)**	**A204352**	**001**	May 01, 2015
AP		BRIGHAM WOMENS HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203783**	**001**	Oct 30, 2014
AP		CARDINAL HEALTH 414	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203700**	**001**	Feb 25, 2013
AP		DECATUR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204465**	**001**	Oct 23, 2014
AP	+!	FEINSTEIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**N022119**	**001**	Aug 23, 2007
AP		GEN HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A207025**	**001**	Feb 03, 2016
AP		IONETIX	**22.5mCi-225mCi/6ML (3.75-37.5mCi/ML)**	**A210524**	**001**	Dec 21, 2018
AP		JOHNS HOPKINS UNIV	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204514**	**001**	Aug 19, 2014
AP		KREITCHMAN PET CTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203938**	**001**	Dec 09, 2013
AP		MCPRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203321**	**001**	Feb 25, 2013
AP		MIDWEST MEDCL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204457**	**001**	Nov 18, 2015
AP		MIPS CRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204535**	**001**	Nov 20, 2014
AP		PETNET	**30mCi-300mCi (3.75-37.5mCi/ML)**	**A204510**	**001**	Nov 02, 2015
AP		SOFIE	**18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)**	**A204667**	**001**	Apr 22, 2015
AP		SPECTRON MRC LLC	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204455**	**001**	Apr 23, 2015

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	UCLA BIOMEDICAL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203812**	**001**	Jun 27, 2013
AP	UCSF RODIOPHARM	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204496**	**001**	Mar 28, 2014
AP	UNIV TX SW MEDCTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A209507**	**001**	Nov 01, 2019
AP	WA UNIV SCH MED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204506**	**001**	Feb 07, 2014
	ESSENTIAL ISOTOPES	3.75-260mCi/ML	A205687	001	Dec 17, 2015
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366	001	Sep 19, 2014
	SOFIE	3.75-260mCi/ML	A203543	001	Dec 14, 2012
	WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356	001	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

!	HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	! PERRIGO ISRAEL	**EQ 12% BASE**	**A075774**	**001**	May 01, 2002
AB	TARO	**EQ 12% BASE**	**A075883**	**001**	Apr 10, 2003
AB	WATSON LABS INC	**EQ 12% BASE**	**A076829**	**001**	Feb 07, 2006

LOTION;TOPICAL

AMMONIUM LACTATE

AB	! PERRIGO ISRAEL	**EQ 12% BASE**	**A075570**	**001**	Jun 23, 2004
AB	TARO	**EQ 12% BASE**	**A076216**	**001**	May 28, 2004
AB	WATSON LABS INC	**EQ 12% BASE**	**A075575**	**001**	Jun 11, 2002

AMOXAPINE

TABLET;ORAL

AMOXAPINE

	WATSON LABS	25MG	A072691	002	Aug 28, 1992
		50MG	A072691	003	Aug 28, 1992
		100MG	A072691	004	Aug 28, 1992
!		150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	**250MG**	**A062058**	**001**	
AB		**500MG**	**A062058**	**002**	
AB	AUROBINDO	**250MG**	**A065271**	**001**	Nov 09, 2005
AB		**500MG**	**A065271**	**002**	Nov 09, 2005
AB	DAVA PHARMS INC	**250MG**	**A062884**	**001**	Feb 25, 1988
AB		**500MG**	**A062881**	**001**	Feb 25, 1988
AB	HIKMA PHARMS	**250MG**	**A065291**	**001**	Feb 05, 2007
AB		**500MG**	**A065291**	**002**	Feb 05, 2007
AB	SANDOZ	**250MG**	**A064076**	**001**	Sep 30, 1994
AB		**500MG**	**A064076**	**002**	Sep 30, 1994
AB	TEVA	**250MG**	**A061926**	**001**	
AB	!	**500MG**	**A061926**	**003**	

AMOXIL

AB	NEOPHARMA	**250MG**	**A062216**	**001**	
AB		**500MG**	**A062216**	**004**	

FOR SUSPENSION;ORAL

AMOXICILLIN

AB	AUROBINDO	**200MG/5ML**	**A065334**	**001**	Dec 28, 2006
AB		**400MG/5ML**	**A065334**	**002**	Dec 28, 2006
AB	AUROBINDO PHARMA LTD	**125MG/5ML**	**A204030**	**001**	Sep 15, 2014
AB		**250MG/5ML**	**A204030**	**002**	Sep 15, 2014
AB	DAVA PHARMS INC	**125MG/5ML**	**A062927**	**001**	Nov 25, 1988
AB		**250MG/5ML**	**A062927**	**002**	Nov 25, 1988
AB	HIKMA	**125MG/5ML**	**A065322**	**002**	Jun 19, 2006
AB		**200MG/5ML**	**A065325**	**002**	Jun 19, 2006
AB		**250MG/5ML**	**A065322**	**001**	Jun 19, 2006
AB		**400MG/5ML**	**A065325**	**001**	Jun 19, 2006
AB	SANDOZ	**125MG/5ML**	**A065387**	**001**	Mar 26, 2007
AB		**200MG/5ML**	**A065378**	**001**	Mar 26, 2007
AB		**250MG/5ML**	**A065387**	**002**	Mar 26, 2007
AB		**400MG/5ML**	**A065378**	**002**	Mar 26, 2007
AB	TEVA	**200MG/5ML**	**A065119**	**001**	Dec 04, 2002

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

AB	**!**		**250MG/5ML**	**A061931**	**002**	
AB	**!**		**400MG/5ML**	**A065119**	**002**	Dec 04, 2002
AB		WOCKHARDT BIO AG	**400MG/5ML**	**A065319**	**002**	Jun 18, 2007

AMOXICILLIN PEDIATRIC

AB		TEVA	**50MG/ML**	**A061931**	**003**	Dec 01, 1982

AMOXIL

AB		NEOPHARMA	**50MG/ML**	**A062226**	**005**	
AB			**125MG/5ML**	**A062226**	**001**	
AB			**250MG/5ML**	**A062226**	**002**	

LAROTID

AB		NEOPHARMA	**125MG/5ML**	**A062226**	**003**	
AB			**250MG/5ML**	**A062226**	**004**	

TABLET;ORAL

AMOXICILLIN

AB		AUROBINDO	**500MG**	**A065256**	**001**	Nov 09, 2005
AB			**875MG**	**A065256**	**002**	Nov 09, 2005
AB		HIKMA	**875MG**	**A065255**	**001**	Mar 29, 2006
AB		SANDOZ	**500MG**	**A065228**	**001**	Jul 13, 2005
AB			**875MG**	**A065228**	**002**	Jul 13, 2005
AB		TEVA	**500MG**	**A065056**	**001**	Sep 18, 2000
AB	**!**		**875MG**	**A065056**	**002**	Sep 18, 2000

TABLET, CHEWABLE;ORAL

AMOXICILLIN

		TEVA	125MG	A064013	002	Sep 11, 1995
	!		250MG	A064013	001	Dec 22, 1992

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	**!**	RISING	**500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG**	**A206006**	**001**	Oct 07, 2016
AB		SANDOZ INC	**500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG**	**A202588**	**001**	Mar 04, 2014

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

	+!	CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	**125MG/5ML;EQ 31.25MG BASE/5ML**	**A209371**	**001**	Apr 19, 2019
AB			**200MG/5ML;EQ 28.5MG BASE/5ML**	**A201090**	**001**	Dec 20, 2011
AB			**250MG/5ML;EQ 62.5MG BASE/5ML**	**A209371**	**002**	Apr 19, 2019
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A201090**	**002**	Dec 20, 2011
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A201091**	**001**	Dec 20, 2011
AB		HIKMA PHARMS	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065191**	**002**	Jan 25, 2005
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065191**	**001**	Jan 25, 2005
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065373**	**001**	Nov 09, 2007
AB		SANDOZ	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065066**	**001**	Jun 05, 2002
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065066**	**002**	Jun 05, 2002
AB		SANDOZ INC	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065098**	**001**	Dec 16, 2002
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065098**	**002**	Dec 16, 2002
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065358**	**001**	Aug 13, 2007
AB		TEVA	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065089**	**001**	May 25, 2004
AB	**!**		**400MG/5ML;EQ 57MG BASE/5ML**	**A065089**	**002**	May 25, 2004
AB	**!**		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065162**	**001**	Mar 12, 2004
AB		WOCKHARDT BIO AG	**250MG/5ML;EQ 62.5MG BASE/5ML**	**A065431**	**001**	Nov 25, 2008
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065420**	**001**	Dec 02, 2013

AUGMENTIN '125'

AB	**+**	NEOPHARMA	**125MG/5ML;EQ 31.25MG BASE/5ML**	**N050575**	**001**	Aug 06, 1984

AUGMENTIN '250'

AB	**+!**	NEOPHARMA	**250MG/5ML;EQ 62.5MG BASE/5ML**	**N050575**	**002**	Aug 06, 1984

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	**250MG;EQ 125MG BASE**	**A091569**	**001**	Jan 20, 2012
AB			**500MG;EQ 125MG BASE**	**A091569**	**002**	Jan 20, 2012
AB			**875MG;EQ 125MG BASE**	**A091568**	**001**	Jan 20, 2012

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		HIKMA PHARMS	**875MG;EQ 125MG BASE**	**A203824**	**001**	Aug 23, 2016
AB		MICRO LABS LTD INDIA	**250MG;EQ 125MG BASE**	**A205707**	**001**	Dec 30, 2016
AB			**500MG;EQ 125MG BASE**	**A205707**	**002**	Dec 30, 2016
AB			**875MG;EQ 125MG BASE**	**A204755**	**003**	Dec 30, 2016
AB	**!**	SANDOZ	**250MG;EQ 125MG BASE**	**A065189**	**001**	Aug 23, 2005
AB			**500MG;EQ 125MG BASE**	**A065064**	**001**	Mar 15, 2002
AB	**!**		**875MG;EQ 125MG BASE**	**A065063**	**001**	Mar 14, 2002
AB	**!**	SANDOZ INC	**500MG;EQ 125MG BASE**	**A065117**	**001**	Nov 27, 2002
AB			**875MG;EQ 125MG BASE**	**A065093**	**001**	Nov 21, 2002
AB		TEVA	**500MG;EQ 125MG BASE**	**A065101**	**001**	Oct 30, 2002
AB		TEVA PHARMS USA	**875MG;EQ 125MG BASE**	**A065096**	**001**	Oct 29, 2002

AUGMENTIN '875'

AB	**+**	NEOPHARMA	**875MG;EQ 125MG BASE**	**N050720**	**001**	Feb 13, 1996

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

		TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005
	!		400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		SANDOZ	**1GM;EQ 62.5MG BASE**	**A090227**	**001**	Apr 21, 2010

AUGMENTIN XR

AB	**+!**	NEOPHARMA	**1GM;EQ 62.5MG BASE**	**N050785**	**001**	Sep 25, 2002

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE;ORAL

TALICIA

	+!	REDHILL	250MG;EQ 10MG BASE;12.5MG	N213004	001	Nov 01, 2019

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

ADZENYS ER

	+!	NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017

DYANAVEL XR

	+!	TRIS PHARMA INC	EQ 2.5MG BASE/ML	N208147	001	Oct 19, 2015

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

	+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016
	+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016
	+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016
	+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016
	+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016
	+!		EQ 18.8MG BASE	N204326	006	Jan 27, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 10

AB	**+**	SHIRE	**2.5MG;2.5MG;2.5MG;2.5MG**	**N021303**	**001**	Oct 11, 2001

ADDERALL XR 15

AB	**+**	SHIRE	**3.75MG;3.75MG;3.75MG;3.75MG**	**N021303**	**006**	May 22, 2002

ADDERALL XR 20

AB	**+**	SHIRE	**5MG;5MG;5MG;5MG**	**N021303**	**002**	Oct 11, 2001

ADDERALL XR 25

AB	**+**	SHIRE	**6.25MG;6.25MG;6.25MG;6.25MG**	**N021303**	**004**	May 22, 2002

ADDERALL XR 30

AB	**+!**	SHIRE	**7.5MG;7.5MG;7.5MG;7.5MG**	**N021303**	**003**	Oct 11, 2001

ADDERALL XR 5

AB	**+**	SHIRE	**1.25MG;1.25MG;1.25MG;1.25MG**	**N021303**	**005**	May 22, 2002

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A077302**	**001**	Jun 22, 2012
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A077302**	**002**	Jun 22, 2012
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A077302**	**003**	Jun 22, 2012
AB			**5MG;5MG;5MG;5MG**	**A077302**	**004**	Jun 22, 2012
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A077302**	**005**	Jun 22, 2012
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A077302**	**006**	Jun 22, 2012
AB		AMERIGEN PHARMS LTD	**1.25MG;1.25MG;1.25MG;1.25MG**	**A205401**	**001**	Jan 22, 2019
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A205401**	**002**	Jan 22, 2019
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A205401**	**003**	Jan 22, 2019
AB			**5MG;5MG;5MG;5MG**	**A205401**	**004**	Jan 22, 2019
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A205401**	**005**	Jan 22, 2019

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019
AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019
AB		5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019
AB	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019
AB		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019
AB		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019
AB		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019
AB	SUNGEN PHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A212037	003	Dec 11, 2019
AB		5MG;5MG;5MG;5MG	A212037	004	Dec 11, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A212037	005	Dec 11, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A212037	006	Dec 11, 2019
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536	001	Feb 12, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076536	002	Feb 12, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076536	003	Feb 12, 2013
AB		5MG;5MG;5MG;5MG	A076536	004	Feb 12, 2013
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb 12, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb 12, 2013

MYDAYIS

+	SHIRE DEV LLC	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017
+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017
+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017
+!		12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016
AB	ALVOGEN	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017
AB	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424	001	Nov 27, 2013
AB		1.875MG;1.875MG;1.875MG;1.875MG	A202424	002	Nov 27, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A202424	003	Nov 27, 2013
AB		3.125MG;3.125MG;3.125MG;3.125MG	A202424	004	Nov 27, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A202424	005	Nov 27, 2013
AB		5MG;5MG;5MG;5MG	A202424	006	Nov 27, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A202424	007	Nov 27, 2013
AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	A040422	001	Feb 11, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040422	005	Mar 19, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040422	002	Feb 11, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040422	006	Mar 19, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040422	007	Mar 19, 2003
AB		5MG;5MG;5MG;5MG	A040422	003	Feb 11, 2002
AB	!	7.5MG;7.5MG;7.5MG;7.5MG	A040422	004	Feb 11, 2002
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002
AB	MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015
AB		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017
AB	NUVO PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A209799	001	Dec 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A209799	002	Dec 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A209799	003	Dec 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A209799	004	Dec 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A209799	005	Dec 28, 2017
AB		5MG;5MG;5MG;5MG	A209799	006	Dec 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A209799	007	Dec 28, 2017
AB	SANDOZ	1.25MG;1.25MG;1.25MG;1.25MG	A040439	004	Sep 27, 2002
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040439	001	Jun 14, 2002
AB		5MG;5MG;5MG;5MG	A040439	002	Jun 14, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040439	003	Jun 14, 2002
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003
AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A040480	001	Sep 09, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040480	002	Sep 09, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040480	003	Sep 09, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003
AB		5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003
AB	SUNGEN PHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018
AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018
AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018
AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE						
TABLET;ORAL						
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A211352**	**007**	Dec 07, 2018
AMPHETAMINE SULFATE						
TABLET;ORAL						
AMPHETAMINE SULFATE						
AA		AMNEAL PHARMS	**5MG**	**A211139**	**001**	Sep 26, 2018
AA			**10MG**	**A211139**	**002**	Sep 26, 2018
AA		AUROLIFE PHARMA LLC	**5MG**	**A211639**	**001**	Apr 17, 2019
AA			**10MG**	**A211639**	**002**	Apr 17, 2019
AA		BIONPHARMA INC	**5MG**	**A212919**	**001**	Nov 22, 2019
AA			**10MG**	**A212919**	**002**	Nov 22, 2019
AA		GRANULES PHARMS	**5MG**	**A212619**	**001**	Aug 05, 2019
AA			**10MG**	**A212619**	**002**	Aug 05, 2019
EVEKEO						
AA		ARBOR PHARMS LLC	**5MG**	**A200166**	**001**	Aug 09, 2012
AA	**!**		**10MG**	**A200166**	**002**	Aug 09, 2012
TABLET, ORALLY DISINTEGRATING;ORAL						
EVEKEO ODT						
	+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019
	+		10MG	N209905	002	Jan 30, 2019
	+		15MG	N209905	003	Jan 30, 2019
	+		20MG	N209905	004	Jan 30, 2019
AMPHOTERICIN B						
INJECTABLE;INJECTION						
AMPHOTERICIN B						
	!	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992
INJECTABLE, LIPID COMPLEX;INJECTION						
ABELCET						
	+!	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995
INJECTABLE, LIPOSOMAL;INJECTION						
AMBISOME						
	+!	ASTELLAS	50MG/VIAL	N050740	001	Aug 11, 1997
AMPICILLIN SODIUM						
INJECTABLE;INJECTION						
AMPICILLIN SODIUM						
AP		ACS DOBFAR SPA	**EQ 10GM BASE/VIAL**	**A090889**	**001**	Apr 03, 2013
AP		ANTIBIOTICE	**EQ 250MG BASE/VIAL**	**A090354**	**001**	Dec 28, 2009
AP			**EQ 500MG BASE/VIAL**	**A090354**	**002**	Dec 28, 2009
AP			**EQ 1GM BASE/VIAL**	**A090354**	**003**	Dec 28, 2009
AP			**EQ 2GM BASE/VIAL**	**A090354**	**004**	Dec 28, 2009
AP		AUROBINDO PHARMA	**EQ 250MG BASE/VIAL**	**A065499**	**002**	Aug 17, 2010
AP			**EQ 500MG BASE/VIAL**	**A065499**	**003**	Aug 17, 2010
AP			**EQ 1GM BASE/VIAL**	**A065499**	**004**	Aug 17, 2010
AP			**EQ 2GM BASE/VIAL**	**A065499**	**005**	Aug 17, 2010
AP			**EQ 10GM BASE/VIAL**	**A065493**	**001**	Aug 17, 2010
AP		HANFORD GC	**EQ 250MG BASE/VIAL**	**A062772**	**006**	Apr 15, 1993
AP			**EQ 500MG BASE/VIAL**	**A062772**	**007**	Apr 15, 1993
AP			**EQ 1GM BASE/VIAL**	**A062772**	**001**	Apr 15, 1993
AP			**EQ 2GM BASE/VIAL**	**A062772**	**003**	Apr 15, 1993
AP			**EQ 10GM BASE/VIAL**	**A063142**	**001**	Apr 15, 1993
AP		ISTITUTO BIO ITA SPA	**EQ 10GM BASE/VIAL**	**A201404**	**001**	Dec 20, 2013
AP			**EQ 250MG BASE/VIAL**	**A062719**	**001**	May 12, 1987
AP			**EQ 500MG BASE/VIAL**	**A062719**	**003**	May 12, 1987
AP			**EQ 1GM BASE/VIAL**	**A062719**	**002**	May 12, 1987
AP			**EQ 2GM BASE/VIAL**	**A062797**	**002**	Jul 12, 1993
AP		MYLAN LABS LTD	**EQ 250MG BASE/VIAL**	**A201025**	**001**	Apr 09, 2014
AP			**EQ 500MG BASE/VIAL**	**A201025**	**002**	Apr 09, 2014
AP			**EQ 1GM BASE/VIAL**	**A201025**	**003**	Apr 09, 2014
AP			**EQ 2GM BASE/VIAL**	**A201025**	**004**	Apr 09, 2014
AP			**EQ 10GM BASE/VIAL**	**A202198**	**001**	Apr 07, 2014
AP		SAGENT PHARMS INC	**EQ 125MG BASE/VIAL**	**A090583**	**001**	Nov 27, 2015
AP			**EQ 250MG BASE/VIAL**	**A090583**	**002**	Nov 27, 2015
AP			**EQ 500MG BASE/VIAL**	**A090583**	**003**	Nov 27, 2015
AP			**EQ 1GM BASE/VIAL**	**A090583**	**004**	Nov 27, 2015
AP			**EQ 2GM BASE/VIAL**	**A090583**	**005**	Nov 27, 2015
AP			**EQ 10GM BASE/VIAL**	**A090581**	**001**	Oct 20, 2015
AP	**!**	SANDOZ	**EQ 125MG BASE/VIAL**	**A061395**	**001**	

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	**!**		**EQ 250MG BASE/VIAL**	**A061395**	**002**	
AP	**!**		**EQ 500MG BASE/VIAL**	**A061395**	**003**	
AP	**!**		**EQ 1GM BASE/VIAL**	**A061395**	**004**	
AP	**!**		**EQ 2GM BASE/VIAL**	**A061395**	**005**	
AP	**!**		**EQ 10GM BASE/VIAL**	**A061395**	**006**	

POWDER;INTRAVENOUS

AMPICILLIN SODIUM

AP	**!**	SANDOZ	**EQ 1GM BASE/VIAL**	**A062738**	**001**	Feb 19, 1987
AP	**!**		**EQ 2GM BASE/VIAL**	**A062738**	**002**	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065406**	**001**	Dec 22, 2009
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065406**	**002**	Dec 22, 2009
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065403**	**001**	Dec 23, 2009
AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A201406**	**001**	Dec 07, 2015
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A201406**	**002**	Dec 07, 2015
AP		ASTRAL	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090579**	**001**	Jan 08, 2016
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090579**	**002**	Jan 08, 2016
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A090578**	**001**	Jan 11, 2016
AP		AUROBINDO PHARMA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090340**	**001**	Sep 20, 2010
AP			**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090349**	**001**	Sep 20, 2010
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090340**	**002**	Sep 20, 2010
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090349**	**002**	Sep 20, 2010
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A090339**	**001**	Sep 20, 2010
AP		HANFORD GC	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065176**	**001**	Nov 30, 2005
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065176**	**002**	Nov 30, 2005
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065188**	**001**	Nov 25, 2005
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065222**	**001**	Nov 29, 2005
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065222**	**002**	Nov 29, 2005
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065314**	**001**	Nov 27, 2006
AP		MYLAN LABS LTD	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A201024**	**001**	Apr 07, 2014
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A201024**	**002**	Apr 07, 2014
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A202197**	**001**	Apr 07, 2014
AP		SANDOZ	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065241**	**001**	Jul 25, 2006
AP			**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065310**	**001**	Jul 25, 2006
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065241**	**002**	Jul 25, 2006
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065310**	**002**	Jul 25, 2006
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065240**	**001**	Jul 25, 2006
AP		WEST-WARD PHARMS INT	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065074**	**001**	Mar 19, 2002
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065074**	**002**	Mar 19, 2002
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065076**	**001**	Mar 19, 2002

UNASYN

AP	**!**	PFIZER	**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A062901**	**002**	Feb 27, 1992
AP	**!**		**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A062901**	**001**	Nov 23, 1988
AP	**+!**		**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**N050608**	**002**	Dec 31, 1986
AP	**+!**		**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**N050608**	**001**	Dec 31, 1986
AP	**+!**		**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**N050608**	**005**	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

AB		DAVA PHARMS INC	**EQ 250MG BASE**	**A062883**	**001**	Feb 25, 1988
AB	**!**		**EQ 500MG BASE**	**A062882**	**001**	Feb 25, 1988
AB		SANDOZ	**EQ 250MG BASE**	**A064082**	**001**	Aug 29, 1995
AB			**EQ 500MG BASE**	**A064082**	**002**	Aug 29, 1995

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE

		DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989
	!		EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

AB		SHIRE LLC	**EQ 0.5MG BASE**	**N020333**	**001**	Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

AB		BARR	**EQ 0.5MG BASE**	**A076530**	**001**	Apr 18, 2005
AB			**EQ 1MG BASE**	**A076530**	**002**	Apr 18, 2005

ANAGRELIDE HYDROCHLORIDE						
CAPSULE;ORAL						
ANAGRELIDE HYDROCHLORIDE						
AB		IMPAX LABS	**EQ 0.5MG BASE**	**A076910**	**001**	Apr 18, 2005
AB			**EQ 1MG BASE**	**A076910**	**002**	Apr 18, 2005
AB		IVAX SUB TEVA PHARMS	**EQ 0.5MG BASE**	**A076468**	**001**	Apr 18, 2005
AB	**!**		**EQ 1MG BASE**	**A076468**	**002**	Apr 18, 2005
AB		TORRENT	**EQ 0.5MG BASE**	**A209151**	**001**	Jun 30, 2017
AB			**EQ 1MG BASE**	**A209151**	**002**	Jun 30, 2017
ANASTROZOLE						
TABLET;ORAL						
ANASTROZOLE						
AB		ACCORD HLTHCARE	**1MG**	**A090568**	**001**	Jun 28, 2010
AB		APOTEX INC	**1MG**	**A200654**	**001**	May 11, 2012
AB		BEIJING YILING	**1MG**	**A206037**	**001**	Nov 09, 2018
AB		CIPLA	**1MG**	**A091164**	**001**	Jun 28, 2010
AB		FRESENIUS KABI USA	**1MG**	**A090088**	**001**	Jun 28, 2010
AB		HIKMA	**1MG**	**A078485**	**001**	Jun 28, 2010
AB		KENTON	**1MG**	**A078944**	**001**	Jun 28, 2010
AB		MYLAN	**1MG**	**A091051**	**001**	Jun 28, 2010
AB		NATCO PHARMA LTD	**1MG**	**A079220**	**001**	Jun 28, 2010
AB		NEOPHARMA	**1MG**	**A090732**	**001**	Jun 28, 2010
AB		TEVA PHARMS	**1MG**	**A078058**	**001**	Jun 28, 2010
AB		ZYDUS PHARMS USA INC	**1MG**	**A078921**	**001**	Jun 28, 2010
ARIMIDEX						
AB	**+!**	ANI PHARMS INC	**1MG**	**N020541**	**001**	Dec 27, 1995
ANGIOTENSIN II ACETATE						
SOLUTION;INTRAVENOUS						
GIAPREZA						
	+!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017
ANIDULAFUNGIN						
POWDER;INTRAVENOUS						
ERAXIS						
	+!	VICURON	50MG/VIAL	N021632	001	Feb 17, 2006
	+!		100MG/VIAL	N021632	002	Nov 14, 2006
APALUTAMIDE						
TABLET;ORAL						
ERLEADA						
	+!	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018
APIXABAN						
TABLET;ORAL						
APIXABAN						
AB		MICRO LABS	**2.5MG**	**A210013**	**001**	Dec 23, 2019
AB			**5MG**	**A210013**	**002**	Dec 23, 2019
AB		MYLAN	**2.5MG**	**A210128**	**001**	Dec 23, 2019
AB			**5MG**	**A210128**	**002**	Dec 23, 2019
ELIQUIS						
AB	**+**	BRISTOL MYERS SQUIBB	**2.5MG**	**N202155**	**001**	Dec 28, 2012
AB	**+!**		**5MG**	**N202155**	**002**	Dec 28, 2012
APOMORPHINE HYDROCHLORIDE						
INJECTABLE;SUBCUTANEOUS						
APOKYN						
	+!	US WORLDMEDS	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004
APRACLONIDINE HYDROCHLORIDE						
SOLUTION/DROPS;OPHTHALMIC						
APRACLONIDINE HYDROCHLORIDE						
AT		AKORN INC	**EQ 0.5% BASE**	**A077764**	**001**	Mar 12, 2009
IOPIDINE						
AT	**+!**	NOVARTIS	**EQ 0.5% BASE**	**N020258**	**001**	Jul 30, 1993
	+!		EQ 1% BASE	N019779	001	Dec 31, 1987

APREMILAST							
TABLET;ORAL							
OTEZLA							
	+	AMGEN INC	10MG	N205437	001	Mar 21, 2014
	+		20MG	N205437	002	Mar 21, 2014
	+!		30MG	N205437	003	Mar 21, 2014
APREPITANT							
CAPSULE;ORAL							
APREPITANT							
AB		GLENMARK PHARMS SA	**40MG**	**A207777**	**001**	Oct 12, 2017
AB			**80MG**	**A207777**	**002**	Oct 12, 2017
AB			**125MG**	**A207777**	**003**	Oct 12, 2017
AB		SANDOZ	**40MG**	**A090999**	**001**	Sep 24, 2012
AB			**80MG**	**A090999**	**002**	Sep 24, 2012
AB			**125MG**	**A090999**	**003**	Sep 24, 2012
EMEND							
AB	**+**	MERCK	**80MG**	**N021549**	**001**	Mar 26, 2003
AB	**+!**		**125MG**	**N021549**	**002**	Mar 26, 2003
EMULSION;INTRAVENOUS							
CINVANTI							
	+!	HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296	001	Nov 09, 2017
FOR SUSPENSION;ORAL							
EMEND							
	+!	MSD MERCK CO	125MG/KIT	N207865	001	Dec 17, 2015
ARFORMOTEROL TARTRATE							
SOLUTION;INHALATION							
BROVANA							
	+!	SUNOVION	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006
ARGATROBAN							
INJECTABLE;INJECTION							
ARGATROBAN							
AP		AMNEAL PHARMS CO	**250MG/2.5ML (100MG/ML)**	**A206698**	**001**	Jan 26, 2018
AP		FRESENIUS KABI USA	**250MG/2.5ML (100MG/ML)**	**N201811**	**001**	Mar 23, 2015
AP		HIKMA PHARM CO LTD	**250MG/2.5ML (100MG/ML)**	**N203049**	**001**	Jan 05, 2012
AP		HOSPIRA INC	**250MG/2.5ML (100MG/ML)**	**A204120**	**001**	Sep 21, 2016
AP		MYLAN INSTITUTIONAL	**250MG/2.5ML (100MG/ML)**	**A202626**	**001**	Jun 30, 2014
AP	**+!**	NOVARTIS	**250MG/2.5ML (100MG/ML)**	**N020883**	**001**	Jun 30, 2000
AP		PAR STERILE PRODUCTS	**250MG/2.5ML (100MG/ML)**	**A091665**	**001**	Jun 30, 2014
	+!	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016
INJECTABLE;INTRAVENOUS							
ARGATROBAN IN SODIUM CHLORIDE							
AP		GLAND PHARMA LTD	**125MG/125ML (1MG/ML)**	**A205570**	**001**	May 22, 2017
AP	**+!**	SANDOZ	**125MG/125ML (1MG/ML)**	**N022485**	**001**	May 09, 2011
ARGATROBAN IN 0.9% SODIUM CHLORIDE							
		TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014
ARGATROBAN IN SODIUM CHLORIDE							
	+!	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011
SOLUTION;INTRAVENOUS							
ARGATROBAN IN SODIUM CHLORIDE							
		AUROBINDO PHARMA LTD	50MG/50ML (1MG/ML)	N209552	001	Nov 27, 2018
ARGININE HYDROCHLORIDE							
INJECTABLE;INJECTION							
R-GENE 10							
	+!	PHARMACIA AND UPJOHN	10GM/100ML	N016931	001	
ARIPIPRAZOLE							
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR							
ABILIFY MAINTENA KIT							
	+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013
	+		300MG	N202971	003	Sep 29, 2014
	+!		400MG/VIAL	N202971	002	Feb 28, 2013
	+		400MG	N202971	004	Sep 29, 2014
SOLUTION;ORAL							
ARIPIPRAZOLE							
AA	**!**	AMNEAL PHARMS	**1MG/ML**	**A203906**	**001**	Aug 14, 2015
AA		APOTEX INC	**1MG/ML**	**A204094**	**001**	Sep 30, 2015
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A210479**	**001**	Jan 29, 2019
AA		LANNETT CO INC	**1MG/ML**	**A204171**	**001**	Aug 14, 2015

ARIPIPRAZOLE

SOLUTION;ORAL

ARIPIPRAZOLE

AA		VISTAPHARM	**1MG/ML**	**A212870**	**001**	Dec 26, 2019

TABLET;ORAL

ABILIFY

AB	**+**	OTSUKA	**2MG**	**N021436**	**006**	Nov 15, 2002
AB	**+!**		**5MG**	**N021436**	**005**	Nov 15, 2002
AB	**+!**		**10MG**	**N021436**	**001**	Nov 15, 2002
AB	**+**		**15MG**	**N021436**	**002**	Nov 15, 2002
AB	**+**		**20MG**	**N021436**	**003**	Nov 15, 2002
AB	**+**		**30MG**	**N021436**	**004**	Nov 15, 2002

ARIPIPRAZOLE

AB		ACCORD HLTHCARE	**2MG**	**A206251**	**001**	Dec 07, 2016
AB			**5MG**	**A206251**	**002**	Dec 07, 2016
AB			**10MG**	**A206251**	**003**	Dec 07, 2016
AB			**15MG**	**A206251**	**004**	Dec 07, 2016
AB			**20MG**	**A206251**	**005**	Dec 07, 2016
AB			**30MG**	**A206251**	**006**	Dec 07, 2016
AB		AJANTA PHARMA LTD	**2MG**	**A206174**	**001**	Sep 12, 2016
AB			**5MG**	**A206174**	**002**	Sep 12, 2016
AB			**10MG**	**A206174**	**003**	Sep 12, 2016
AB			**15MG**	**A206174**	**004**	Sep 12, 2016
AB			**20MG**	**A206174**	**005**	Sep 12, 2016
AB			**30MG**	**A206174**	**006**	Sep 12, 2016
AB		ALEMBIC PHARMS LTD	**2MG**	**A202101**	**001**	Apr 28, 2015
AB			**5MG**	**A202101**	**002**	Apr 28, 2015
AB			**10MG**	**A202101**	**003**	Apr 28, 2015
AB			**15MG**	**A202101**	**004**	Apr 28, 2015
AB			**20MG**	**A202101**	**005**	Apr 28, 2015
AB			**30MG**	**A202101**	**006**	Apr 28, 2015
AB		ALKEM LABS LTD	**2MG**	**A207105**	**001**	Feb 21, 2019
AB			**5MG**	**A207105**	**002**	Feb 21, 2019
AB			**10MG**	**A207105**	**003**	Feb 21, 2019
AB			**15MG**	**A207105**	**004**	Feb 21, 2019
AB			**20MG**	**A207105**	**005**	Feb 21, 2019
AB			**30MG**	**A207105**	**006**	Feb 21, 2019
AB		AMNEAL PHARMS	**2MG**	**A204838**	**001**	Jun 17, 2016
AB			**5MG**	**A204838**	**002**	Jun 17, 2016
AB			**10MG**	**A204838**	**003**	Jun 17, 2016
AB			**15MG**	**A204838**	**004**	Jun 17, 2016
AB			**20MG**	**A204838**	**005**	Jun 17, 2016
AB			**30MG**	**A204838**	**006**	Jun 17, 2016
AB		APOTEX INC	**2MG**	**A078583**	**001**	Jul 24, 2015
AB			**5MG**	**A078583**	**002**	Jul 24, 2015
AB			**10MG**	**A078583**	**003**	Jul 24, 2015
AB			**15MG**	**A078583**	**004**	Jul 24, 2015
AB			**20MG**	**A078583**	**005**	Jul 24, 2015
AB			**30MG**	**A078583**	**006**	Jul 24, 2015
AB		AUROBINDO PHARMA LTD	**2MG**	**A203908**	**001**	Oct 08, 2015
AB			**5MG**	**A203908**	**002**	Oct 08, 2015
AB			**10MG**	**A203908**	**003**	Oct 08, 2015
AB			**15MG**	**A203908**	**004**	Oct 08, 2015
AB			**20MG**	**A203908**	**005**	Oct 08, 2015
AB			**30MG**	**A203908**	**006**	Oct 08, 2015
AB		BOSCOGEN	**2MG**	**A091279**	**001**	Jan 09, 2017
AB			**5MG**	**A091279**	**002**	Jan 09, 2017
AB			**10MG**	**A091279**	**003**	Jan 09, 2017
AB			**15MG**	**A091279**	**004**	Jan 09, 2017
AB			**20MG**	**A091279**	**005**	Jan 09, 2017
AB			**30MG**	**A091279**	**006**	Jan 09, 2017
AB		HETERO LABS LTD V	**2MG**	**A205064**	**001**	Apr 28, 2015
AB			**5MG**	**A205064**	**002**	Apr 28, 2015
AB			**10MG**	**A205064**	**003**	Apr 28, 2015
AB			**15MG**	**A205064**	**004**	Apr 28, 2015
AB			**20MG**	**A205064**	**005**	Apr 28, 2015
AB			**30MG**	**A205064**	**006**	Apr 28, 2015
AB		MACLEODS PHARMS LTD	**2MG**	**A204111**	**001**	Oct 07, 2016
AB			**5MG**	**A204111**	**002**	Oct 07, 2016
AB			**10MG**	**A204111**	**003**	Oct 07, 2016
AB			**15MG**	**A204111**	**004**	Oct 07, 2016
AB			**20MG**	**A204111**	**005**	Oct 07, 2016

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

AB			**30MG**	**A204111**	**006**	Oct 07, 2016
AB		ORCHID HLTHCARE	**2MG**	**A202683**	**001**	May 23, 2017
AB			**5MG**	**A202683**	**002**	May 23, 2017
AB			**10MG**	**A202683**	**003**	May 23, 2017
AB			**15MG**	**A202683**	**004**	May 23, 2017
AB			**20MG**	**A202683**	**005**	May 23, 2017
AB			**30MG**	**A202683**	**006**	May 23, 2017
AB		PRINSTON INC	**2MG**	**A205363**	**001**	Dec 04, 2017
AB			**5MG**	**A205363**	**002**	Dec 04, 2017
AB			**10MG**	**A205363**	**003**	Dec 04, 2017
AB			**15MG**	**A205363**	**004**	Dec 04, 2017
AB			**20MG**	**A205363**	**005**	Dec 04, 2017
AB			**30MG**	**A205363**	**006**	Dec 04, 2017
AB		SCIEGEN PHARMS INC	**2MG**	**A206383**	**001**	Sep 29, 2016
AB			**5MG**	**A206383**	**002**	Sep 29, 2016
AB			**10MG**	**A206383**	**003**	Sep 29, 2016
AB			**15MG**	**A206383**	**004**	Sep 29, 2016
AB			**20MG**	**A206383**	**005**	Sep 29, 2016
AB			**30MG**	**A206383**	**006**	Sep 29, 2016
AB		TORRENT	**2MG**	**A201519**	**001**	Apr 28, 2015
AB			**10MG**	**A201519**	**003**	Apr 28, 2015
AB			**5MG**	**A201519**	**002**	Apr 28, 2015
AB			**15MG**	**A201519**	**004**	Apr 28, 2015
AB			**20MG**	**A201519**	**005**	Apr 28, 2015
AB			**30MG**	**A201519**	**006**	Apr 28, 2015
	ABILIFY MYCITE KIT					
	+	OTSUKA PHARM CO LTD	2MG	N207202	001	Nov 13, 2017
	+!		5MG	N207202	002	Nov 13, 2017
	+		10MG	N207202	003	Nov 13, 2017
	+		15MG	N207202	004	Nov 13, 2017
	+		20MG	N207202	005	Nov 13, 2017
	+		30MG	N207202	006	Nov 13, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

ARIPIPRAZOLE

AB	**!**	ALEMBIC PHARMS LTD	**10MG**	**A202102**	**001**	Apr 28, 2015
AB			**15MG**	**A202102**	**002**	Apr 28, 2015
AB		ORCHID HLTHCARE	**10MG**	**A202547**	**001**	Dec 11, 2017
AB			**15MG**	**A202547**	**002**	Dec 11, 2017
AB		SCIEGEN PHARMS INC	**10MG**	**A207240**	**001**	Apr 18, 2018
AB			**15MG**	**A207240**	**002**	Apr 18, 2018
AB		ZYDUS PHARMS	**10MG**	**A090165**	**001**	Aug 28, 2018
AB			**15MG**	**A090165**	**002**	Aug 28, 2018
			20MG	A090165	003	Aug 28, 2018
			30MG	A090165	004	Aug 28, 2018

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA					
+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
+		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
+!		882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015
+		1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017
ARISTADA INITIO KIT					
+	ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB		AUROBINDO PHARMA LTD	**50MG**	**A206069**	**001**	Mar 06, 2018
AB			**150MG**	**A206069**	**002**	Mar 06, 2018
AB			**200MG**	**A206069**	**004**	Dec 07, 2018
AB			**250MG**	**A206069**	**003**	Mar 06, 2018
AB		LUPIN LTD	**50MG**	**A200751**	**001**	Nov 28, 2016
AB			**150MG**	**A200751**	**003**	Nov 28, 2016
AB			**200MG**	**A200751**	**004**	Nov 28, 2016
AB			**250MG**	**A200751**	**005**	Nov 28, 2016
AB		MYLAN PHARMS INC	**50MG**	**A200043**	**001**	Jun 01, 2012
AB			**100MG**	**A200043**	**004**	May 09, 2019
AB			**150MG**	**A200043**	**002**	Jun 01, 2012
AB			**200MG**	**A200043**	**005**	May 09, 2019

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL						
AB			**250MG**	**A200043**	**003**	Jun 01, 2012
AB		NATCO PHARMA LTD	**50MG**	**A202768**	**001**	Nov 28, 2016
AB			**100MG**	**A202768**	**004**	Sep 28, 2017
AB			**150MG**	**A202768**	**002**	Nov 28, 2016
AB			**200MG**	**A202768**	**005**	Sep 28, 2017
AB			**250MG**	**A202768**	**003**	Nov 28, 2016
NUVIGIL						
AB	+	CEPHALON	**50MG**	**N021875**	**001**	Jun 15, 2007
AB	+		**150MG**	**N021875**	**003**	Jun 15, 2007
AB	+		**200MG**	**N021875**	**005**	Mar 26, 2009
AB	+!		**250MG**	**N021875**	**004**	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE						
AP		AMRING PHARMS	**1MG/ML**	**A210802**	**001**	Nov 13, 2018
AP		FRESENIUS KABI USA	**1MG/ML**	**A208231**	**001**	Aug 31, 2018
AP		INGENUS PHARMS LLC	**1MG/ML**	**A209315**	**001**	Nov 15, 2018
AP		NEXUS PHARMS	**1MG/ML**	**A209780**	**001**	Nov 15, 2018
AP		STI PHARMA LLC	**1MG/ML**	**A209873**	**001**	May 06, 2019
AP		ZYDUS PHARMS	**1MG/ML**	**A206228**	**001**	Nov 13, 2018
AP			**2MG/ML**	**A206228**	**002**	Aug 30, 2019
TRISENOX						
AP	+!	CEPHALON	**2MG/ML**	**N021248**	**002**	Oct 13, 2017

ARTEMETHER; LUMEFANTRINE

TABLET;ORAL

COARTEM						
	+!	NOVARTIS	20MG;120MG	N022268	001	Apr 07, 2009

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

SEPTOCAINE						
AP	+!	DEPROCO	**4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)**	**N022010**	**001**	Mar 30, 2006
AP	+!		**4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)**	**N020971**	**001**	Apr 03, 2000
ULTACAN						
AP		HANSAMED INC	**4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)**	**A201751**	**001**	Jul 11, 2017
ULTACAN FORTE						
AP		HANSAMED INC	**4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)**	**A201750**	**001**	Jul 11, 2017
ORABLOC						
	+	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010
	+!		4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010

ASCORBIC ACID

SOLUTION;INTRAVENOUS

ASCOR						
	+!	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC						
	+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL HYDROCHLORIDE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)						
	+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS

M.V.I. PEDIATRIC

+!	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001	Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;INTRAVENOUS

M.V.I. ADULT

+!	HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001	Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+!	HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

MOVIPREP

AA	**+!**	SALIX PHARMS	**4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM**	**N021881**	**001**	Aug 02, 2006

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

AA		NOVEL LABS INC	**4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM**	**A090145**	**001**	Jan 25, 2012

PLENVU

	+!	SALIX	7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	N209381	001	May 04, 2018

ASENAPINE

SYSTEM;TRANSDERMAL

SECUADO

+	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019
+		5.7MG/24HR	N212268	002	Oct 11, 2019
+!		7.6MG/24HR	N212268	003	Oct 11, 2019

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

+	ALLERGAN	EQ 2.5 BASE	N022117	003	Mar 12, 2015
+		EQ 5MG BASE	N022117	001	Aug 13, 2009
+!		EQ 10MG BASE	N022117	002	Aug 13, 2009

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

+!	ESPERO	162.5MG	N200671	001	Sep 04, 2015

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

FIORINAL

AA	**+!**	ALLERGAN	**325MG;50MG;40MG**	**N017534**	**005**	Apr 16, 1986

LANORINAL

AA		LANNETT	**325MG;50MG;40MG**	**A086996**	**002**	Oct 11, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	**!**	HIKMA INTL PHARMS	**325MG;50MG;40MG**	**A086162**	**002**	Feb 16, 1984
AA		PII	**325MG;50MG;40MG**	**A204195**	**001**	Sep 22, 2016

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB		MAYNE PHARMA INC	**325MG;50MG;40MG;30MG**	**A203335**	**001**	Oct 30, 2015
AB		NEXGEN PHARMA INC	**325MG;50MG;40MG;30MG**	**A075231**	**001**	Nov 30, 2001
AB		STEVENS J	**325MG;50MG;40MG;30MG**	**A074951**	**001**	Aug 31, 1998

FIORINAL W/CODEINE

AB	**+!**	ALLERGAN	**325MG;50MG;40MG;30MG**	**N019429**	**003**	Oct 26, 1990

PRESCRIPTION DRUG PRODUCT LIST

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

AB	**!**	HERITAGE PHARMS INC	**325MG;200MG**	**A089594**	**001**	Mar 31, 1989
AB		NOVAST LABS	**325MG;200MG**	**A040832**	**001**	Jan 07, 2010
AB		SANDOZ	**325MG;200MG**	**A040116**	**001**	Apr 25, 1996

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		INGENUS PHARMS NJ	**325MG;200MG;16MG**	**A040860**	**001**	Jan 07, 2010
AB	**!**	SANDOZ	**325MG;200MG;16MG**	**A040118**	**001**	Apr 16, 1996

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

AGGRENOX

AB	**+!**	BOEHRINGER INGELHEIM	**25MG;200MG**	**N020884**	**001**	Nov 22, 1999

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	**25MG;200MG**	**A206392**	**001**	Mar 08, 2016
AB		BARR	**25MG;200MG**	**A078804**	**001**	Aug 14, 2009
AB		DR REDDYS	**25MG;200MG**	**A209048**	**001**	Oct 10, 2018
AB		GLENMARK PHARMS SA	**25MG;200MG**	**A210318**	**001**	May 24, 2019
AB		LANNETT CO INC	**25MG;200MG**	**A204552**	**001**	Mar 20, 2019
AB		PAR PHARM INC	**25MG;200MG**	**A207944**	**001**	Jan 18, 2017
AB		SANDOZ INC	**25MG;200MG**	**A206739**	**001**	Jan 18, 2017
AB		SUN PHARM	**25MG;200MG**	**A208572**	**001**	Aug 21, 2018
AB		ZYDUS PHARMS	**25MG;200MG**	**A206753**	**001**	Aug 29, 2017

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

	!	STEVENS J	325MG;400MG	A081145	001	Jan 31, 1995

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

	+	GENUS LIFESCIENCES	81MG;40MG	N205103	001	Sep 14, 2016
	+!		325MG;40MG	N205103	002	Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA		ACTAVIS LABS FL INC	**325MG;4.8355MG**	**A090084**	**001**	Mar 22, 2011
AA		MAYNE PHARMA INC	**325MG;4.8355MG**	**A091670**	**001**	Mar 16, 2011

PERCODAN

AA	**+!**	ENDO PHARMS	**325MG;4.8355MG**	**N007337**	**007**	Aug 05, 2005

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB		AUROBINDO PHARMA LTD	**EQ 100MG BASE**	**A204806**	**001**	Jun 25, 2018
AB			**EQ 150MG BASE**	**A204806**	**002**	Jun 25, 2018
AB			**EQ 200MG BASE**	**A204806**	**003**	Jun 25, 2018
AB			**EQ 300MG BASE**	**A204806**	**004**	Jun 25, 2018
AB		CIPLA	**EQ 100MG BASE**	**A200626**	**001**	Aug 09, 2018
AB			**EQ 150MG BASE**	**A200626**	**002**	Aug 09, 2018
AB			**EQ 200MG BASE**	**A200626**	**003**	Aug 09, 2018
AB			**EQ 300MG BASE**	**A200626**	**004**	Aug 09, 2018
AB		MYLAN	**EQ 150MG BASE**	**A208177**	**001**	Sep 24, 2018
AB			**EQ 200MG BASE**	**A208177**	**002**	Sep 24, 2018
AB			**EQ 300MG BASE**	**A208177**	**003**	Sep 24, 2018
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A091673**	**001**	Apr 22, 2014
AB			**EQ 150MG BASE**	**A091673**	**002**	Apr 22, 2014
AB			**EQ 200MG BASE**	**A091673**	**003**	Apr 22, 2014
AB			**EQ 300MG BASE**	**A091673**	**004**	Apr 22, 2014

REYATAZ

AB	**+**	BRISTOL MYERS SQUIBB	**EQ 150MG BASE**	**N021567**	**002**	Jun 20, 2003
AB	**+**		**EQ 200MG BASE**	**N021567**	**003**	Jun 20, 2003
AB	**+!**		**EQ 300MG BASE**	**N021567**	**004**	Oct 16, 2006

POWDER;ORAL

REYATAZ

	+!	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

+!	BRISTOL-MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN	**25MG**	**A072304**	**002**	Jul 31, 1992
AB		**50MG**	**A072304**	**003**	Jul 18, 1988
AB		**100MG**	**A072304**	**001**	Jul 15, 1988
AB	AUROBINDO PHARMA	**25MG**	**A078512**	**001**	Oct 31, 2007
AB		**50MG**	**A078512**	**002**	Oct 31, 2007
AB		**100MG**	**A078512**	**003**	Oct 31, 2007
AB	DAVA PHARMS INC	**50MG**	**A073542**	**001**	Dec 19, 1991
AB		**100MG**	**A073543**	**001**	Dec 19, 1991
AB	HLTHCARE	**25MG**	**A074052**	**001**	May 01, 1992
AB		**50MG**	**A073025**	**001**	Sep 17, 1991
AB		**100MG**	**A073026**	**001**	Sep 17, 1991
AB	IPCA LABS LTD	**25MG**	**A077877**	**001**	Dec 27, 2006
AB		**50MG**	**A077877**	**002**	Dec 27, 2006
AB		**100MG**	**A077877**	**003**	Dec 27, 2006
AB	MYLAN	**25MG**	**A073457**	**002**	Apr 26, 1999
AB		**50MG**	**A073457**	**003**	Jan 24, 1992
AB		**100MG**	**A073457**	**001**	Jan 24, 1992
AB	TEVA	**25MG**	**A074056**	**003**	Jul 19, 2004
AB		**50MG**	**A074056**	**001**	Jan 18, 1995
AB		**100MG**	**A074056**	**002**	Jan 18, 1995
AB	UNICHEM LABS LTD	**25MG**	**A213136**	**001**	Nov 21, 2019
AB		**50MG**	**A213136**	**002**	Nov 21, 2019
AB		**100MG**	**A213136**	**003**	Nov 21, 2019
AB	UNIQUE PHARM LABS	**25MG**	**A077443**	**001**	Sep 13, 2006
AB		**50MG**	**A077443**	**002**	Sep 13, 2006
AB		**100MG**	**A077443**	**003**	Sep 13, 2006
AB	ZYDUS PHARMS USA	**25MG**	**A076900**	**001**	Jan 28, 2005
AB		**50MG**	**A076900**	**002**	Jan 28, 2005
AB		**100MG**	**A076900**	**003**	Jan 28, 2005

TENORMIN

AB	**+** ALVOGEN	**25MG**	**N018240**	**004**	Apr 09, 1990
AB	**+**	**50MG**	**N018240**	**001**	
AB	**+!**	**100MG**	**N018240**	**002**	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN	**50MG;25MG**	**A072302**	**002**	May 31, 1990
AB		**100MG;25MG**	**A072302**	**001**	May 31, 1990
AB	MYLAN	**50MG;25MG**	**A074203**	**001**	Oct 31, 1993
AB		**100MG;25MG**	**A074203**	**002**	Oct 31, 1993
AB	WATSON LABS	**50MG;25MG**	**A073665**	**001**	Jul 02, 1992
AB		**100MG;25MG**	**A073665**	**002**	Jul 02, 1992
AB	ZYDUS PHARMS	**50MG;25MG**	**A210028**	**001**	Mar 08, 2019
AB		**100MG;25MG**	**A210028**	**002**	Mar 08, 2019

TENORETIC 100

AB	**+!** ALVOGEN	**100MG;25MG**	**N018760**	**001**	Jun 08, 1984

TENORETIC 50

AB	**+** ALVOGEN	**50MG;25MG**	**N018760**	**002**	Jun 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	APOTEX	**10MG**	**A078983**	**001**	May 30, 2017
AB		**18MG**	**A078983**	**002**	May 30, 2017
AB		**25MG**	**A078983**	**003**	May 30, 2017
AB		**40MG**	**A078983**	**004**	May 30, 2017
AB		**60MG**	**A078983**	**005**	May 30, 2017
AB		**80MG**	**A078983**	**006**	May 30, 2017
AB		**100MG**	**A078983**	**007**	May 30, 2017
AB	AUROBINDO PHARMA LTD	**10MG**	**A079016**	**001**	May 30, 2017
AB		**18MG**	**A079016**	**002**	May 30, 2017
AB		**25MG**	**A079016**	**003**	May 30, 2017
AB		**40MG**	**A079016**	**004**	May 30, 2017

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB			**60MG**	**A079016**	**005**	May 30, 2017
AB			**80MG**	**A079016**	**006**	May 30, 2017
AB			**100MG**	**A079016**	**007**	May 30, 2017
AB		DR REDDYS LABS LTD	**10MG**	**A090609**	**001**	Feb 23, 2018
AB			**18MG**	**A090609**	**002**	Feb 23, 2018
AB			**25MG**	**A090609**	**003**	Feb 23, 2018
AB			**40MG**	**A090609**	**004**	Feb 23, 2018
AB			**60MG**	**A090609**	**005**	Feb 23, 2018
AB			**80MG**	**A090609**	**006**	Feb 23, 2018
AB			**100MG**	**A090609**	**007**	Feb 23, 2018
AB		GLENMARK PHARMS LTD	**10MG**	**A079019**	**001**	May 30, 2017
AB			**18MG**	**A079019**	**002**	May 30, 2017
AB			**25MG**	**A079019**	**003**	May 30, 2017
AB			**40MG**	**A079019**	**004**	May 30, 2017
AB			**60MG**	**A079019**	**005**	May 30, 2017
AB			**80MG**	**A079019**	**006**	May 30, 2017
AB			**100MG**	**A079019**	**007**	May 30, 2017
AB		TEVA PHARMS USA	**10MG**	**A079022**	**001**	May 30, 2017
AB			**18MG**	**A079022**	**002**	May 30, 2017
AB			**25MG**	**A079022**	**003**	May 30, 2017
AB			**40MG**	**A079022**	**004**	May 30, 2017
AB			**60MG**	**A079022**	**005**	May 30, 2017
AB			**80MG**	**A079022**	**006**	May 30, 2017
AB			**100MG**	**A079022**	**007**	May 30, 2017
AB		ZYDUS PHARMS USA INC	**18MG**	**A079017**	**001**	Sep 17, 2010
AB			**25MG**	**A079017**	**002**	Sep 17, 2010
AB			**40MG**	**A079017**	**003**	Sep 17, 2010
AB			**60MG**	**A079017**	**004**	Sep 17, 2010
AB			**80MG**	**A079017**	**005**	Sep 17, 2010
AB			**100MG**	**A079017**	**006**	Sep 17, 2010

STRATTERA

AB	+	LILLY	**10MG**	**N021411**	**002**	Nov 26, 2002
AB	+		**18MG**	**N021411**	**003**	Nov 26, 2002
AB	+		**25MG**	**N021411**	**004**	Nov 26, 2002
AB	+		**40MG**	**N021411**	**005**	Nov 26, 2002
AB	+!		**60MG**	**N021411**	**006**	Nov 26, 2002
AB	+		**80MG**	**N021411**	**007**	Feb 14, 2005
AB	+		**100MG**	**N021411**	**008**	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ACCORD HLTHCARE	**EQ 10MG BASE**	**A207687**	**001**	Mar 30, 2018
AB			**EQ 20MG BASE**	**A207687**	**002**	Mar 30, 2018
AB			**EQ 40MG BASE**	**A207687**	**003**	Mar 30, 2018
AB			**EQ 80MG BASE**	**A207687**	**004**	Mar 30, 2018
AB		APOTEX INC	**EQ 10MG BASE**	**A090548**	**001**	May 29, 2012
AB			**EQ 20MG BASE**	**A090548**	**002**	May 29, 2012
AB			**EQ 40MG BASE**	**A090548**	**003**	May 29, 2012
AB			**EQ 80MG BASE**	**A090548**	**004**	May 29, 2012
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A091650**	**001**	Jul 17, 2012
AB			**EQ 20MG BASE**	**A091650**	**002**	Jul 17, 2012
AB			**EQ 40MG BASE**	**A091650**	**003**	Jul 17, 2012
AB			**EQ 80MG BASE**	**A202357**	**001**	Jul 17, 2012
AB		GRAVITI PHARMS	**EQ 10MG BASE**	**A209912**	**001**	Jun 18, 2018
AB			**EQ 20MG BASE**	**A209912**	**002**	Jun 18, 2018
AB			**EQ 40MG BASE**	**A209912**	**003**	Jun 18, 2018
AB			**EQ 80MG BASE**	**A209912**	**004**	Jun 18, 2018
AB		INVAGEN PHARMS	**EQ 10MG BASE**	**A204846**	**001**	Jan 09, 2017
AB			**EQ 20MG BASE**	**A204846**	**002**	Jan 09, 2017
AB			**EQ 40MG BASE**	**A204846**	**003**	Jan 09, 2017
AB			**EQ 80MG BASE**	**A204846**	**004**	Jan 09, 2017
AB		LANNETT CO INC	**EQ 10MG BASE**	**A091624**	**001**	Apr 05, 2013
AB			**EQ 20MG BASE**	**A091624**	**002**	Apr 05, 2013
AB			**EQ 40MG BASE**	**A091624**	**003**	Apr 05, 2013
AB			**EQ 80MG BASE**	**A091624**	**004**	Apr 05, 2013
AB		MICRO LABS LTD INDIA	**EQ 10MG BASE**	**A205945**	**001**	Nov 07, 2019
AB			**EQ 20MG BASE**	**A205945**	**002**	Nov 07, 2019

PRESCRIPTION DRUG PRODUCT LIST

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB			**EQ 40MG BASE**	**A205945**	**003**	Nov 07, 2019
AB			**EQ 80MG BASE**	**A205945**	**004**	Nov 07, 2019
AB		MSN	**EQ 10MG BASE**	**A211933**	**001**	Feb 08, 2019
AB			**EQ 20MG BASE**	**A211933**	**002**	Feb 08, 2019
AB			**EQ 40MG BASE**	**A211933**	**003**	Feb 08, 2019
AB			**EQ 80MG BASE**	**A211933**	**004**	Feb 08, 2019
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A091226**	**001**	May 29, 2012
AB			**EQ 20MG BASE**	**A091226**	**002**	May 29, 2012
AB			**EQ 40MG BASE**	**A091226**	**003**	May 29, 2012
AB			**EQ 80MG BASE**	**A091226**	**004**	May 29, 2012
AB		SANDOZ INC	**EQ 10MG BASE**	**A077575**	**001**	May 29, 2012
AB			**EQ 20MG BASE**	**A077575**	**002**	May 29, 2012
AB			**EQ 40MG BASE**	**A077575**	**003**	May 29, 2012
AB			**EQ 80MG BASE**	**A077575**	**004**	May 29, 2012
AB		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A205519**	**001**	May 19, 2016
AB			**EQ 20MG BASE**	**A205519**	**002**	May 19, 2016
AB			**EQ 40MG BASE**	**A205519**	**003**	May 19, 2016
AB			**EQ 80MG BASE**	**A205519**	**004**	May 19, 2016
AB		SUN PHARM INDS LTD	**EQ 10MG BASE**	**A076477**	**001**	Nov 30, 2011
AB			**EQ 20MG BASE**	**A076477**	**002**	Nov 30, 2011
AB			**EQ 40MG BASE**	**A076477**	**003**	Nov 30, 2011
AB			**EQ 80MG BASE**	**A076477**	**004**	Nov 30, 2011
AB		TEVA PHARMS USA	**EQ 10MG BASE**	**A205300**	**001**	Mar 27, 2017
AB			**EQ 20MG BASE**	**A205300**	**002**	Mar 27, 2017
AB			**EQ 40MG BASE**	**A205300**	**003**	Mar 27, 2017
AB			**EQ 80MG BASE**	**A205300**	**004**	Mar 27, 2017
AB		THEPHARMANETWORK LLC	**EQ 10MG BASE**	**A209288**	**001**	Dec 21, 2018
AB			**EQ 20MG BASE**	**A209288**	**002**	Dec 21, 2018
AB			**EQ 40MG BASE**	**A209288**	**003**	Dec 21, 2018
AB			**EQ 80MG BASE**	**A209288**	**004**	Dec 21, 2018
AB		ZYDUS PHARMS	**EQ 10MG BASE**	**A206536**	**001**	Nov 20, 2018
AB			**EQ 20MG BASE**	**A206536**	**002**	Nov 20, 2018
AB			**EQ 40MG BASE**	**A206536**	**003**	Nov 20, 2018
AB			**EQ 80MG BASE**	**A206536**	**004**	Nov 20, 2018

LIPITOR

AB	**+**	PFIZER	**EQ 10MG BASE**	**N020702**	**001**	Dec 17, 1996
AB	**+**		**EQ 20MG BASE**	**N020702**	**002**	Dec 17, 1996
AB	**+**		**EQ 40MG BASE**	**N020702**	**003**	Dec 17, 1996
AB	**+!**		**EQ 80MG BASE**	**N020702**	**004**	Apr 07, 2000

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB		ABHAI LLC	**750MG/5ML**	**A210510**	**001**	May 31, 2019
AB		AMNEAL PHARMS	**750MG/5ML**	**A202960**	**001**	Mar 18, 2014
AB		APOTEX	**750MG/5ML**	**A209750**	**001**	Oct 11, 2017
AB		GLENMARK PHARMS	**750MG/5ML**	**A209685**	**001**	Nov 21, 2018
AB		HETERO LABS LTD III	**750MG/5ML**	**A210692**	**001**	Oct 11, 2018
AB		LUPIN LTD	**750MG/5ML**	**A209105**	**001**	Sep 11, 2018
AB		PADDOCK LLC	**750MG/5ML**	**A207833**	**001**	Apr 28, 2017

MEPRON

AB	**+!**	GLAXOSMITHKLINE LLC	**750MG/5ML**	**N020500**	**001**	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	**62.5MG;25MG**	**A091211**	**002**	Apr 06, 2015
AB			**250MG;100MG**	**A091211**	**001**	Jan 12, 2011
AB		MYLAN	**62.5MG;25MG**	**A202362**	**001**	May 27, 2014
AB			**250MG;100MG**	**A202362**	**002**	May 27, 2014

MALARONE

AB	**+!**	GLAXOSMITHKLINE	**250MG;100MG**	**N021078**	**001**	Jul 14, 2000

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

MALARONE PEDIATRIC

AB	**+**	GLAXOSMITHKLINE	**62.5MG;25MG**	**N021078**	**002**	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A206011**	**001**	Apr 08, 2015
AP		HOSPIRA INC	**10MG/ML**	**A090761**	**001**	Oct 18, 2012
AP		MEITHEAL	**10MG/ML**	**A091489**	**001**	Feb 17, 2012
AP	**!**	WEST-WARD PHARMS INT	**10MG/ML**	**A074901**	**001**	Jul 18, 1997

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A206010**	**001**	Apr 08, 2015
AP		HOSPIRA INC	**10MG/ML**	**A090782**	**001**	Oct 18, 2012
AP		MEITHEAL	**10MG/ML**	**A091488**	**001**	Feb 17, 2012
AP	**!**	WEST-WARD PHARMS INT	**10MG/ML**	**A074900**	**001**	Jul 18, 1997

ATROPINE

SOLUTION;INTRAMUSCULAR

ATROPEN

+!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
+!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
+!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
+!		EQ 2MG SULFATE/0.7ML	N017106	001	

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE

+!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017
+!		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001
+!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

+!	AKORN	1%	N206289	001	Jul 18, 2014

ISOPTO ATROPINE

	ALCON LABS INC	1%	N208151	001	Dec 01, 2016

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

+!	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

!	HIKMA	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		ANI PHARMS INC	**0.025MG;2.5MG**	**A086727**	**001**	
AA		BAYSHORE PHARMS LLC	**0.025MG;2.5MG**	**A210819**	**001**	Nov 13, 2018
AA		LANNETT	**0.025MG;2.5MG**	**A085372**	**001**	
AA		MYLAN	**0.025MG;2.5MG**	**A085762**	**001**	
AA		PAR PHARM	**0.025MG;2.5MG**	**A040357**	**001**	May 02, 2000
AA		UPSHER SMITH LABS	**0.025MG;2.5MG**	**A210571**	**001**	Aug 31, 2018

LOMOTIL

AA	**+!**	GD SEARLE LLC	**0.025MG;2.5MG**	**N012462**	**001**	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR

DUODOTE

+!	MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML	N021983	001	Sep 28, 2006

AURANOFIN
CAPSULE;ORAL
RIDAURA
+! SEBELA IRELAND LTD 3MG N018689 001 May 24, 1985

AVANAFIL
TABLET;ORAL
STENDRA
+ METUCHEN PHARMS 50MG N202276 001 Apr 27, 2012
+ 100MG N202276 002 Apr 27, 2012
+! 200MG N202276 003 Apr 27, 2012

AVATROMBOPAG MALEATE
TABLET;ORAL
DOPTELET
+! AKARX INC EQ 20MG BASE N210238 001 May 21, 2018

AVIBACTAM SODIUM; CEFTAZIDIME
POWDER;IV (INFUSION)
AVYCAZ
+! ALLERGAN EQ 0.5GM BASE;2GM/VIAL N206494 001 Feb 25, 2015

AXITINIB
TABLET;ORAL
INLYTA
+ PF PRISM CV 1MG N202324 001 Jan 27, 2012
+! 5MG N202324 002 Jan 27, 2012

AZACITIDINE
POWDER;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE
AP ACCORD HLTHCARE **100MG/VIAL** **A207475 001** Jul 02, 2018
AP ACTAVIS LLC **100MG/VIAL** **N208216 001** Apr 29, 2016
AP CIPLA **100MG/VIAL** **A209540 001** May 04, 2018
AP DR REDDYS **100MG/VIAL** **A201537 001** Sep 16, 2013
AP MYLAN INSTITUTIONAL **100MG/VIAL** **A204949 001** Apr 28, 2016
AP NATCO PHARMA LTD **100MG/VIAL** **A207234 001** Jun 23, 2017
AP SHILPA MEDICARE **100MG/VIAL** **A207518 001** Sep 29, 2016
VIDAZA
AP **+!** CELGENE **100MG/VIAL** **N050794 001** May 19, 2004

AZATHIOPRINE
TABLET;ORAL
AZASAN
AB AAIPHARMA LLC **25MG** **A075252 002** Feb 03, 2003
AB **50MG** **A075252 001** Jun 07, 1999
AB **75MG** **A075252 003** Feb 03, 2003
AB **100MG** **A075252 004** Feb 03, 2003
AZATHIOPRINE
AB AMNEAL PHARMS LLC **50MG** **A074069 001** Feb 16, 1996
AB MYLAN **50MG** **A075568 001** Dec 13, 1999
AB ZYDUS PHARMS USA **25MG** **A077621 002** Sep 05, 2008
AB **50MG** **A077621 001** Mar 15, 2007
AB **75MG** **A077621 003** Sep 05, 2008
AB **100MG** **A077621 004** Sep 05, 2008
IMURAN
AB **+!** SEBELA IRELAND LTD **50MG** **N016324 001**

AZATHIOPRINE SODIUM
INJECTABLE;INJECTION
AZATHIOPRINE SODIUM
! WEST-WARD PHARMS INT EQ 100MG BASE/VIAL A074419 001 Mar 31, 1995

AZELAIC ACID
AEROSOL, FOAM;TOPICAL
FINACEA
+! LEO PHARMA AS 15% N207071 001 Jul 29, 2015
CREAM;TOPICAL
AZELEX
+! ALMIRALL 20% N020428 001 Sep 13, 1995
GEL;TOPICAL
AZELAIC ACID
AB ACTAVIS LABS UT INC **15%** **A208011 001** Nov 19, 2018
AB GLENMARK PHARMS **15%** **A204637 001** Nov 19, 2018
AB TARO **15%** **A210549 001** Aug 23, 2019
AB TOLMAR **15%** **A208724 001** Nov 19, 2018

AZELAIC ACID

GEL;TOPICAL

FINACEA

AB	**+!**	LEO PHARMA AS	**15%**	**N021470**	**001**	Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		AKORN	**0.05%**	**A203660**	**001**	Nov 08, 2016
AT		ALEMBIC PHARMS LTD	**0.05%**	**A209620**	**001**	Mar 20, 2019
AT		APOTEX INC	**0.05%**	**A078621**	**001**	Aug 03, 2009
AT	!	SANDOZ INC	**0.05%**	**A202305**	**001**	May 31, 2012
AT		SOMERSET THERAPS LLC	**0.05%**	**A207411**	**001**	Mar 29, 2019
AT		SUN PHARM	**0.05%**	**A078738**	**001**	Jun 21, 2010

SPRAY, METERED;NASAL

ASTELIN

AB	**+!**	MYLAN SPECIALITY LP	**EQ 0.125MG BASE/SPRAY**	**N020114**	**001**	Nov 01, 1996

ASTEPRO

AB	**+!**	MYLAN SPECIALITY LP	**EQ 0.1876MG BASE/SPRAY**	**N022203**	**002**	Aug 31, 2009

AZELASTINE HYDROCHLORIDE

AB		ALKEM LABS LTD	**EQ 0.125MG BASE/SPRAY**	**A208156**	**001**	Aug 18, 2017
AB		AMNEAL PHARMS LLC	**EQ 0.125MG BASE/SPRAY**	**A204660**	**001**	Aug 28, 2017
AB			**EQ 0.1876MG BASE/SPRAY**	**A208199**	**001**	Dec 15, 2017
AB		APOTEX INC	**EQ 0.125MG BASE/SPRAY**	**A077954**	**001**	Apr 30, 2009
AB			**EQ 0.1876MG BASE/SPRAY**	**A201846**	**001**	Aug 31, 2012
AB		BRECKENRIDGE	**EQ 0.125MG BASE/SPRAY**	**A090176**	**001**	Jul 28, 2015
AB		HI TECH	**EQ 0.125MG BASE/SPRAY**	**A207610**	**001**	May 17, 2019
AB			**EQ 0.1876MG BASE/SPRAY**	**A210032**	**001**	Aug 23, 2019
AB		HIKMA	**EQ 0.125MG BASE/SPRAY**	**A091444**	**001**	Oct 24, 2014
AB			**EQ 0.1876MG BASE/SPRAY**	**A207243**	**001**	Sep 22, 2017
AB		PERRIGO ISRAEL	**EQ 0.1876MG BASE/SPRAY**	**A202743**	**001**	May 08, 2014
AB		SUN PHARM	**EQ 0.125MG BASE/SPRAY**	**A090423**	**001**	May 23, 2012
AB		UPSHER SMITH LABS	**EQ 0.125MG BASE/SPRAY**	**A202609**	**001**	Mar 17, 2017
AB		ZYDUS PHARMS	**EQ 0.125MG BASE/SPRAY**	**A091409**	**001**	Aug 14, 2017

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		APOTEX	**EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY**	**A207712**	**001**	Apr 28, 2017

DYMISTA

AB	**+!**	MYLAN SPECIALITY LP	**EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY**	**N202236**	**001**	May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

	+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011
	+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

	+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011
	+!		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB		AMNEAL PHARMS LLC	**EQ 100MG BASE/5ML**	**A205666**	**001**	Jul 19, 2018
AB			**EQ 200MG BASE/5ML**	**A205666**	**002**	Jul 19, 2018
AB		AUROBINDO PHARMA LTD	**EQ 100MG BASE/5ML**	**A209201**	**001**	Oct 09, 2018
AB			**EQ 200MG BASE/5ML**	**A209201**	**002**	Oct 09, 2018
AB		EPIC PHARMA LLC	**EQ 100MG BASE/5ML**	**A207531**	**001**	Apr 09, 2018
AB			**EQ 200MG BASE/5ML**	**A207531**	**002**	Apr 09, 2018
AB		PLIVA	**EQ 100MG BASE/5ML**	**A065246**	**002**	Jul 05, 2006
AB			**EQ 200MG BASE/5ML**	**A065246**	**001**	Jul 05, 2006
AB		TARO	**EQ 200MG BASE/5ML**	**A211521**	**001**	Dec 11, 2019
AB		TEVA PHARMS	**EQ 100MG BASE/5ML**	**A065419**	**001**	Jun 24, 2008
AB			**EQ 200MG BASE/5ML**	**A065419**	**002**	Jun 24, 2008
AB		ZYDUS	**EQ 100MG BASE/5ML**	**A211147**	**001**	Jul 31, 2018
AB			**EQ 200MG BASE/5ML**	**A211147**	**002**	Jul 31, 2018

ZITHROMAX

AB	**+**	PFIZER	**EQ 100MG BASE/5ML**	**N050710**	**001**	Oct 19, 1995
AB	**+!**		**EQ 200MG BASE/5ML**	**N050710**	**002**	Oct 19, 1995

AZITHROMYCIN						
FOR SUSPENSION;ORAL						
ZITHROMAX						
	+!		EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994
INJECTABLE;INJECTION						
AZITHROMYCIN						
AP		AUROBINDO PHARMA LTD	**EQ 500MG BASE/VIAL**	**A203294**	**001**	Jun 19, 2015
AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A065179**	**001**	Dec 13, 2005
AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A065501**	**001**	Nov 09, 2009
AP		HAINAN POLY PHARM	**EQ 500MG BASE/VIAL**	**A203412**	**001**	Oct 09, 2018
AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A065500**	**001**	Jun 26, 2009
AP			**EQ 500MG BASE/VIAL**	**A065511**	**001**	Jun 26, 2009
AP		MYLAN ASI	**EQ 500MG BASE/VIAL**	**A065506**	**001**	Mar 24, 2009
AP		MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A204732**	**001**	Jan 26, 2017
AP		SUN PHARM INDS LTD	**EQ 500MG BASE/VIAL**	**A090923**	**001**	Apr 02, 2013
ZITHROMAX						
AP	**+!**	PFIZER	**EQ 500MG BASE/VIAL**	**N050733**	**001**	Jan 30, 1997
SOLUTION/DROPS;OPHTHALMIC						
AZASITE						
	+!	OAK PHARMS INC	1%	N050810	001	Apr 27, 2007
TABLET;ORAL						
AZITHROMYCIN						
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A207370**	**001**	Jul 05, 2018
AB			**EQ 500MG BASE**	**A207398**	**001**	Jul 05, 2018
AB		BIONPHARMA INC	**EQ 250MG BASE**	**A210000**	**001**	Feb 26, 2019
AB			**EQ 500MG BASE**	**A210001**	**001**	Feb 26, 2019
AB			**EQ 600MG BASE**	**A209999**	**001**	Dec 26, 2018
AB		CSPC OUYI	**EQ 250MG BASE**	**A208250**	**001**	Apr 17, 2019
AB			**EQ 500MG BASE**	**A208249**	**001**	Oct 25, 2018
AB			**EQ 600MG BASE**	**A207566**	**001**	Sep 24, 2018
AB		LUPIN LTD	**EQ 250MG BASE**	**A065398**	**001**	May 15, 2015
AB			**EQ 500MG BASE**	**A065399**	**001**	May 15, 2015
AB			**EQ 600MG BASE**	**A065400**	**001**	May 15, 2015
AB		MYLAN	**EQ 600MG BASE**	**A065360**	**001**	Jan 08, 2007
AB		PLIVA	**EQ 250MG BASE**	**A065225**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065223**	**001**	Nov 14, 2005
AB	**!**		**EQ 600MG BASE**	**A065218**	**001**	Nov 14, 2005
AB		SANDOZ	**EQ 250MG BASE**	**A065211**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065212**	**001**	Nov 14, 2005
AB			**EQ 600MG BASE**	**A065209**	**001**	Nov 14, 2005
AB		SUNSHINE LAKE	**EQ 250MG BASE**	**A209045**	**001**	Dec 07, 2018
AB			**EQ 500MG BASE**	**A209044**	**001**	Dec 07, 2018
AB			**EQ 600MG BASE**	**A209043**	**001**	Dec 06, 2018
AB		TEVA	**EQ 500MG BASE**	**A065193**	**001**	Nov 14, 2005
AB		WOCKHARDT	**EQ 250MG BASE**	**A065404**	**001**	Feb 11, 2008
AB			**EQ 500MG BASE**	**A065405**	**001**	Feb 11, 2008
AB			**EQ 600MG BASE**	**A065302**	**003**	Feb 11, 2008
ZITHROMAX						
AB	**+**	PFIZER	**EQ 250MG BASE**	**N050711**	**001**	Jul 18, 1996
AB	**+**		**EQ 500MG BASE**	**N050784**	**001**	May 24, 2002
AZTREONAM						
FOR SOLUTION;INHALATION						
CAYSTON						
	+!	GILEAD	75MG/VIAL	N050814	001	Feb 22, 2010
INJECTABLE;INJECTION						
AZACTAM						
AP	**+!**	BRISTOL MYERS SQUIBB	**1GM/VIAL**	**N050580**	**002**	Dec 31, 1986
AP	**+!**		**2GM/VIAL**	**N050580**	**003**	Dec 31, 1986
AZTREONAM						
AP		FRESENIUS KABI USA	**1GM/VIAL**	**A065439**	**002**	Jun 18, 2010
AP			**2GM/VIAL**	**A065439**	**003**	Jun 18, 2010
			500MG/VIAL	A065439	001	Jun 18, 2010
BACITRACIN						
INJECTABLE;INJECTION						
BACIIM						
AP		X GEN PHARMS	**50,000 UNITS/VIAL**	**A064153**	**001**	May 09, 1997
BACITRACIN						
AP		AKORN	**50,000 UNITS/VIAL**	**A206719**	**001**	Oct 20, 2017
AP		FRESENIUS KABI USA	**50,000 UNITS/VIAL**	**A065116**	**001**	Dec 03, 2002

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

AP	**!**	PHARMACIA AND UPJOHN	**50,000 UNITS/VIAL**	**A060733**	**002**	
AP		XELLIA PHARMS APS	**50,000 UNITS/VIAL**	**A203177**	**001**	Aug 25, 2014

OINTMENT;OPHTHALMIC

BACITRACIN

	!	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001	

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	!	PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT		AKORN	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A065213**	**001**	Jul 25, 2012
AT	**!**	BAUSCH AND LOMB	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064068**	**001**	Oct 30, 1995

OINTMENT;TOPICAL

CORTISPORIN

	+!	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		AKORN	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A065088**	**001**	Feb 06, 2004
AT	**!**	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064064**	**001**	Oct 30, 1995
AT		PERRIGO CO TENNESSEE	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A060764**	**002**	

NEOSPORIN

AT	**+**	CASPER PHARMA LLC	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**N050417**	**001**	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	**500 UNITS/GM;10,000 UNITS/GM**	**A064028**	**001**	Jan 30, 1995
AT	**!**	BAUSCH AND LOMB	**500 UNITS/GM;10,000 UNITS/GM**	**A064046**	**001**	Jan 26, 1995
AT		PERRIGO CO TENNESSEE	**500 UNITS/GM;10,000 UNITS/GM**	**A065022**	**001**	Feb 27, 2002

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP		EMERALD INTL LTD	**0.05MG/ML**	**A091193**	**001**	May 03, 2016
AP			**0.5MG/ML**	**A091193**	**002**	May 03, 2016
AP			**2MG/ML**	**A091193**	**003**	May 03, 2016
AP		MAIA PHARMS INC	**0.5MG/ML**	**A210048**	**001**	Sep 11, 2019
AP			**1MG/ML**	**A210315**	**001**	Jul 30, 2019
AP			**2MG/ML**	**A210048**	**002**	Sep 11, 2019
AP		MYLAN LABS LTD	**0.5MG/ML**	**A209592**	**001**	Mar 21, 2018
AP			**1MG/ML**	**A209594**	**001**	Mar 06, 2018
AP			**2MG/ML**	**A209592**	**002**	Mar 21, 2018

GABLOFEN

AP		PIRAMAL CRITICAL	**0.05MG/ML**	**N022462**	**001**	Nov 19, 2010
AP			**0.5MG/ML**	**N022462**	**002**	Nov 19, 2010
AP	**+!**		**1MG/ML**	**N022462**	**004**	Jun 22, 2012
AP			**2MG/ML**	**N022462**	**003**	Nov 19, 2010

LIORESAL

AP	**+!**	SAOL THERAPS RES LTD	**0.05MG/ML**	**N020075**	**003**	Nov 07, 1996
AP	**+!**		**0.5MG/ML**	**N020075**	**001**	Jun 17, 1992
AP	**+!**		**2MG/ML**	**N020075**	**002**	Jun 17, 1992

SOLUTION;ORAL

OZOBAX

	+!	METACEL PHARMS LLC	5MG/5ML	N208193	001	Sep 18, 2019

BACLOFEN							
TABLET;ORAL							
BACLOFEN							
AB		EYWA PHARMA	**10MG**	**A211555**	**001**	Feb 01, 2019
AB			**20MG**	**A211555**	**002**	Feb 01, 2019
AB		IMPAX LABS	**10MG**	**A077971**	**001**	Oct 26, 2007
AB			**20MG**	**A077971**	**002**	Oct 26, 2007
AB		IVAX SUB TEVA PHARMS	**10MG**	**A072234**	**001**	Jul 21, 1988
AB	**!**		**20MG**	**A072235**	**001**	Jul 21, 1988
AB		LANNETT CO INC	**10MG**	**A077241**	**002**	Jul 06, 2007
AB			**20MG**	**A077241**	**001**	Dec 20, 2005
AB		MYLAN	**20MG**	**A077121**	**002**	Jul 29, 2005
AB		MYLAN PHARMS INC	**10MG**	**A090334**	**001**	Feb 18, 2010
AB			**20MG**	**A090334**	**002**	Feb 18, 2010
AB		NORTHSTAR HLTHCARE	**10MG**	**A078401**	**002**	Sep 18, 2009
AB			**20MG**	**A078401**	**001**	Sep 18, 2009
AB		OXFORD PHARMS	**10MG**	**A077088**	**002**	Oct 31, 2007
AB			**20MG**	**A077088**	**001**	Oct 31, 2007
AB		RUBICON	**10MG**	**A209102**	**002**	Nov 28, 2017
AB			**20MG**	**A209102**	**003**	Nov 28, 2017
AB		UPSHER SMITH LABS	**10MG**	**A074584**	**001**	Aug 19, 1996
AB			**20MG**	**A074584**	**002**	Aug 19, 1996
AB		VINTAGE PHARMS	**10MG**	**A077068**	**002**	Aug 30, 2005
AB			**20MG**	**A077068**	**001**	Aug 30, 2005
AB		ZYDUS	**10MG**	**A211659**	**001**	Nov 23, 2018
AB			**20MG**	**A211659**	**002**	Nov 23, 2018
		RUBICON	5MG	A209102	001	Nov 28, 2017
BALOXAVIR MARBOXIL							
TABLET;ORAL							
XOFLUZA							
	+	GENENTECH INC	20MG	N210854	001	Oct 24, 2018
	+!		40MG	N210854	002	Oct 24, 2018
BALSALAZIDE DISODIUM							
CAPSULE;ORAL							
BALSALAZIDE DISODIUM							
AB		APOTEX INC	**750MG**	**A077883**	**001**	Dec 28, 2007
AB		HIKMA	**750MG**	**A077806**	**001**	Dec 28, 2007
COLAZAL							
AB	**+!**	VALEANT PHARMS INTL	**750MG**	**N020610**	**001**	Jul 18, 2000
BARICITINIB							
TABLET;ORAL							
OLUMIANT							
	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019
	+!		2MG	N207924	001	May 31, 2018
BARIUM SULFATE							
FOR SUSPENSION;ORAL							
E-Z-HD							
	+!	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016
E-Z-PAQUE							
	+!	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017
VARIBAR THIN LIQUID							
	+!	BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019
PASTE;ORAL							
VARIBAR PUDDING							
		BRACCO	40%	N208844	001	Oct 14, 2016
SUSPENSION;ORAL							
LIQUID E-Z-PAQUE							
	+!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017
READI-CAT 2							
	+!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016
READI-CAT 2 SMOOTHIE							
	+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016
TAGITOL V							
	+!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017
VARIBAR HONEY							
	+!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018
VARIBAR NECTAR							
	+!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017

BARIUM SULFATE
SUSPENSION;ORAL
VARIBAR THIN HONEY

+!	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
TABLET;ORAL
DUAVEE

+!	WYETH PHARMS	EQ 20MG BASE;0.45MG	N022247	001	Oct 03, 2013

BECLOMETHASONE DIPROPIONATE
AEROSOL, METERED;INHALATION
QVAR REDIHALER

+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017
+		0.08MG/INH	N207921	002	Aug 03, 2017

AEROSOL, METERED;NASAL
QNASL

+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014
+!		0.08MG/ACTUATION	N202813	001	Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE
SPRAY, METERED;NASAL
BECONASE AQ

+!	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389	001	Jul 27, 1987

BEDAQUILINE FUMARATE
TABLET;ORAL
SIRTURO

+!	JANSSEN THERAP	EQ 100MG BASE	N204384	001	Dec 28, 2012

BELINOSTAT
POWDER;INTRAVENOUS
BELEODAQ

+!	ACROTECH	500MG/VIAL	N206256	001	Jul 03, 2014

BENAZEPRIL HYDROCHLORIDE
TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS	**5MG**	**A076820**	**001**	Feb 03, 2006
AB			**10MG**	**A076820**	**002**	Feb 03, 2006
AB			**20MG**	**A076820**	**003**	Feb 03, 2006
AB			**40MG**	**A076820**	**004**	Feb 03, 2006
AB		APOTEX	**5MG**	**A077128**	**001**	Mar 08, 2006
AB			**10MG**	**A077128**	**002**	Mar 08, 2006
AB			**20MG**	**A077128**	**003**	Mar 08, 2006
AB			**40MG**	**A077128**	**004**	Mar 08, 2006
AB		AUROBINDO PHARMA	**10MG**	**A078212**	**001**	May 22, 2008
AB			**20MG**	**A078212**	**002**	May 22, 2008
AB			**40MG**	**A078212**	**003**	May 22, 2008
AB		CASI PHARMS INC	**5MG**	**A076402**	**001**	Feb 11, 2004
AB			**10MG**	**A076402**	**002**	Feb 11, 2004
AB			**20MG**	**A076402**	**003**	Feb 11, 2004
AB			**40MG**	**A076402**	**004**	Feb 11, 2004
AB		MYLAN	**5MG**	**A076430**	**001**	Feb 11, 2004
AB			**10MG**	**A076430**	**002**	Feb 11, 2004
AB			**20MG**	**A076430**	**003**	Feb 11, 2004
AB			**40MG**	**A076430**	**004**	Feb 11, 2004
AB		PRINSTON INC	**5MG**	**A076118**	**001**	Feb 11, 2004
AB			**10MG**	**A076118**	**002**	Feb 11, 2004
AB			**20MG**	**A076118**	**003**	Feb 11, 2004
AB			**40MG**	**A076118**	**004**	Feb 11, 2004
AB		SUN PHARM INDS LTD	**5MG**	**A076344**	**001**	Feb 11, 2004
AB			**10MG**	**A076344**	**002**	Feb 11, 2004
AB			**20MG**	**A076344**	**003**	Feb 11, 2004
AB			**40MG**	**A076344**	**004**	Feb 11, 2004
AB		TEVA	**5MG**	**A076211**	**001**	Feb 11, 2004
AB			**10MG**	**A076211**	**002**	Feb 11, 2004
AB			**20MG**	**A076211**	**003**	Feb 11, 2004
AB			**40MG**	**A076211**	**004**	Feb 11, 2004
AB		ZYDUS PHARMS USA	**5MG**	**A078848**	**001**	May 23, 2008
AB			**10MG**	**A078848**	**002**	May 23, 2008
AB			**20MG**	**A078848**	**003**	May 23, 2008
AB			**40MG**	**A078848**	**004**	May 23, 2008

LOTENSIN

AB	**+**	US PHARMS HOLDINGS	**5MG**	**N019851**	**001**	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

LOTENSIN

		I				
AB	**+**		**10MG**	**N019851**	**002**	Jun 25, 1991
AB	**+**		**20MG**	**N019851**	**003**	Jun 25, 1991
AB	**+!**		**40MG**	**N019851**	**004**	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		APOTEX	**5MG;6.25MG**	**A078794**	**001**	Aug 21, 2014
AB			**10MG;12.5MG**	**A078794**	**002**	Aug 21, 2014
AB			**20MG;12.5MG**	**A078794**	**003**	Aug 21, 2014
AB			**20MG;25MG**	**A078794**	**004**	Aug 21, 2014
AB		MYLAN	**5MG;6.25MG**	**A076688**	**001**	Feb 11, 2004
AB			**10MG;12.5MG**	**A076688**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076688**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076688**	**004**	Feb 11, 2004
AB		SANDOZ	**5MG;6.25MG**	**A076631**	**001**	Feb 11, 2004
AB			**10MG;12.5MG**	**A076631**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076631**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076631**	**004**	Feb 11, 2004

LOTENSIN HCT

AB	**+**	US PHARMS HOLDINGS I	**10MG;12.5MG**	**N020033**	**002**	May 19, 1992
AB	**+**		**20MG;12.5MG**	**N020033**	**004**	May 19, 1992
AB	**+!**		**20MG;25MG**	**N020033**	**003**	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

TREANDA

+!	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009
+!		100MG/VIAL	N022249	001	Mar 20, 2008

SOLUTION;IV (INFUSION)

BELRAPZO

+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018

BENDEKA

+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

CORZIDE

AB	**+**	KING PHARMS LLC	**5MG;40MG**	**N018647**	**001**	May 25, 1983
AB	**+!**		**5MG;80MG**	**N018647**	**002**	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

AB		IMPAX LABS	**5MG;40MG**	**A077833**	**001**	Mar 30, 2007
AB			**5MG;80MG**	**A077833**	**002**	Mar 30, 2007

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALTAFLUOR BENOX

+!	ALTAIRE PHARMS INC	0.4%;0.25%	N208582	001	Dec 14, 2017

BENZNIDAZOLE

TABLET;ORAL

BENZNIDAZOLE

+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017
+!		100MG	N209570	002	Aug 29, 2017

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		APOTEX INC	**100MG**	**A091310**	**001**	Jan 16, 2015
AA			**200MG**	**A091310**	**002**	Jan 16, 2015
AA		ASCENT PHARMS INC	**100MG**	**A211518**	**001**	Feb 22, 2019
AA			**150MG**	**A211518**	**002**	Feb 22, 2019
AA			**200MG**	**A211518**	**003**	Feb 22, 2019
AA		BIONPHARMA INC	**100MG**	**A081297**	**001**	Jan 29, 1993
AA			**200MG**	**A081297**	**002**	Oct 30, 2007
AA		CSPC OUYI	**100MG**	**A202765**	**002**	Aug 25, 2017
AA			**200MG**	**A202765**	**001**	Jul 31, 2015
AA		MIKART	**100MG**	**A040851**	**001**	Nov 09, 2009
AA			**150MG**	**A040851**	**002**	Nov 09, 2009
AA			**200MG**	**A040851**	**003**	Nov 09, 2009
AA		ORIT LABS LLC	**100MG**	**A040682**	**001**	Jul 30, 2007

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA			**200MG**	**A040682**	**002**	Jul 30, 2007
AA		PURACAP PHARM LLC	**100MG**	**A206948**	**001**	Dec 19, 2018
AA			**200MG**	**A206948**	**002**	Dec 19, 2018
AA		QINGDAO BAHEAL PHARM	**100MG**	**A210562**	**001**	Nov 09, 2018
AA			**150MG**	**A210562**	**002**	Nov 09, 2018
AA			**200MG**	**A210562**	**003**	Nov 09, 2018
AA		STRIDES PHARMA	**100MG**	**A091133**	**001**	Jul 30, 2015
AA			**200MG**	**A091133**	**002**	Jul 30, 2015
AA	!	THEPHARMANETWORK LLC	**100MG**	**A040627**	**001**	Mar 30, 2007
AA	!		**150MG**	**A201209**	**001**	Sep 24, 2014
AA	!		**200MG**	**A040749**	**001**	Jul 25, 2007
AA		ZYDUS PHARMS USA	**100MG**	**A040597**	**001**	Jun 08, 2007
AA			**200MG**	**A040597**	**002**	Jun 08, 2007

TESSALON

AA	+	PFIZER	**100MG**	**N011210**	**001**	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

AB	+!	BAUSCH	**2.5%;EQ 1.2% BASE**	**N050819**	**001**	Oct 23, 2008

BENZACLIN

AB	+!	BAUSCH	**5%;EQ 1% BASE**	**N050756**	**001**	Dec 21, 2000

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		ACTAVIS LABS UT INC	**2.5%;EQ 1.2% BASE**	**A205128**	**001**	Jun 19, 2015
AB		GLENMARK PHARMS	**5%;EQ 1% BASE**	**A209252**	**001**	Mar 14, 2019
AB		MYLAN PHARMS INC	**5%;EQ 1% BASE**	**A065443**	**001**	Aug 11, 2009
AB		PERRIGO ISRAEL	**2.5%;EQ 1.2% BASE**	**A205397**	**001**	Sep 09, 2019
AB			**5%;1.2%**	**A090979**	**001**	Jun 26, 2012
AB		PERRIGO UK FINCO	**5%;EQ 1% BASE**	**A202440**	**001**	Sep 21, 2015
AB		TARO	**2.5%;EQ 1.2% BASE**	**A206575**	**001**	Aug 19, 2019
AB			**5%;EQ 1% BASE**	**A208776**	**001**	May 25, 2018
AB		TARO PHARMS	**5%;1.2%**	**A206218**	**001**	Dec 15, 2017
AB		TOLMAR	**5%;EQ 1% BASE**	**A204087**	**001**	Jun 27, 2017
AB			**5%;1.2%**	**A203688**	**001**	Aug 25, 2016
AB		ZYDUS PHARMS	**5%;1.2%**	**A210794**	**001**	Dec 28, 2018

DUAC

AB	+!	STIEFEL	**5%;1.2%**	**N050741**	**001**	Aug 26, 2002

ONEXTON

	+!	BAUSCH	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

BENZAMYCIN

AB	+!	VALEANT INTL	**5%;3%**	**N050557**	**001**	Oct 26, 1984

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB		LYNE	**5%;3%**	**A065385**	**001**	Sep 18, 2015
AB		TOLMAR	**5%;3%**	**A065112**	**001**	Mar 29, 2004

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		ANDA REPOSITORY	**50MG**	**A090473**	**002**	Sep 15, 2010
AA		EMCURE PHARMS LTD	**50MG**	**A202061**	**001**	Jan 27, 2012
AA		EPIC PHARMA LLC	**50MG**	**A090346**	**001**	Dec 15, 2015
AA	!	KVK TECH	**50MG**	**A090968**	**001**	Jul 20, 2010
AA		SPECGX LLC	**50MG**	**A040773**	**001**	Apr 25, 2007
AA		TWI PHARMS	**50MG**	**A040578**	**001**	Apr 17, 2006
		ANDA REPOSITORY	25MG	A090473	001	Sep 15, 2010

BENZTROPINE MESYLATE

INJECTABLE;INJECTION

BENZTROPINE MESYLATE

AP		FRESENIUS KABI USA	**1MG/ML**	**A090233**	**001**	Jul 28, 2009
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A090287**	**001**	Aug 31, 2009
AP		NAVINTA LLC	**1MG/ML**	**A091525**	**001**	Feb 05, 2013

COGENTIN

AP	+!	OAK PHARMS AKORN	**1MG/ML**	**N012015**	**001**	

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA	**!**	ASPEN GLOBAL INC	**0.5MG**	**A204713**	**001**	Apr 14, 2015
AA	**!**		**1MG**	**A204713**	**002**	Apr 14, 2015
AA	**!**		**2MG**	**A204713**	**003**	Apr 14, 2015
AA		EPIC PHARMA LLC	**0.5MG**	**A072264**	**001**	Feb 27, 1989
AA			**1MG**	**A072265**	**001**	Feb 27, 1989
AA			**2MG**	**A072266**	**001**	Feb 27, 1989
AA		INVAGEN PHARMS	**0.5MG**	**A090294**	**001**	Mar 29, 2010
AA			**1MG**	**A090294**	**002**	Mar 29, 2010
AA			**2MG**	**A090294**	**003**	Mar 29, 2010
AA		LEADING PHARMA LLC	**0.5MG**	**A090168**	**001**	Nov 28, 2012
AA			**1MG**	**A090168**	**002**	Nov 28, 2012
AA			**2MG**	**A090168**	**003**	Nov 28, 2012
AA		PLIVA	**0.5MG**	**A089058**	**001**	Aug 10, 1988
AA			**1MG**	**A089059**	**001**	Aug 10, 1988
AA			**2MG**	**A089060**	**001**	Aug 10, 1988
AA		VINTAGE	**0.5MG**	**A040715**	**001**	Aug 27, 2007
AA			**1MG**	**A040715**	**002**	Aug 27, 2007
AA			**2MG**	**A040715**	**003**	Aug 27, 2007

BENZYLPENICILLOYL POLYLYSINE

INJECTABLE;INJECTION

PRE-PEN

	+!	ALLERQUEST	60UMOLAR	N050114	001	

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT		MYLAN	**1.5%**	**A206220**	**001**	Mar 18, 2019

BEPREVE

AT	**+!**	BAUSCH AND LOMB INC	**1.5%**	**N022288**	**001**	Sep 08, 2009

BERACTANT

SUSPENSION;INTRATRACHEAL

SURVANTA

	+!	ABBVIE	25MG/ML	N020032	001	Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BESIVANCE

	+!	BAUSCH AND LOMB	EQ 0.6% BASE	N022308	001	May 28, 2009

BETAINE

FOR SOLUTION;ORAL

CYSTADANE

	+!	ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB		LUITPOLD	**3MG/ML;EQ 3MG BASE/ML**	**A090747**	**001**	Jul 31, 2009

CELESTONE SOLUSPAN

AB	**+!**	MERCK SHARP DOHME	**3MG/ML;EQ 3MG BASE/ML**	**N014602**	**001**	

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACP NIMBLE	**EQ 0.05% BASE**	**A210217**	**001**	Oct 12, 2018
AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A070885**	**001**	Feb 03, 1987
AB	**+!**	FOUGERA PHARMS	**EQ 0.05% BASE**	**N019137**	**001**	Jun 26, 1984
AB		TARO	**EQ 0.05% BASE**	**A073552**	**001**	Apr 30, 1992
AB		ZYDUS PHARMS	**EQ 0.05% BASE**	**A208885**	**001**	Jan 11, 2019

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ANDA REPOSITORY	**EQ 0.05% BASE**	**A076603**	**001**	Jan 23, 2004
AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A076215**	**001**	Dec 09, 2003
AB		GLENMARK GENERICS	**EQ 0.05% BASE**	**A078930**	**001**	Sep 23, 2008
AB		PERRIGO ISRAEL	**EQ 0.05% BASE**	**A076592**	**001**	Dec 09, 2003
AB		TARO	**EQ 0.05% BASE**	**A076543**	**001**	Dec 09, 2003

DIPROLENE AF

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05% BASE**	**N019555**	**001**	Apr 27, 1987

BETAMETHASONE DIPROPIONATE

GEL, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	**!**	FOUGERA PHARMS	**EQ 0.05% BASE**	**A075276**	**001**	May 13, 2003
AB		TARO	**EQ 0.05% BASE**	**A076508**	**001**	Dec 02, 2003

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACP NIMBLE	**EQ 0.05% BASE**	**A071467**	**001**	Aug 10, 1987
AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A070281**	**001**	Jul 31, 1985
AB	**!**	FOUGERA PHARMS INC	**EQ 0.05% BASE**	**A070275**	**001**	Aug 12, 1985
AB		HI TECH	**EQ 0.05% BASE**	**A209896**	**001**	Feb 06, 2018
AB		PERRIGO NEW YORK	**EQ 0.05% BASE**	**A072538**	**001**	Jan 31, 1990

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A077111**	**001**	May 21, 2007
AB		HI TECH	**EQ 0.05% BASE**	**A208849**	**001**	Oct 11, 2019
AB	**!**	TARO	**EQ 0.05% BASE**	**A077477**	**001**	May 21, 2007
AB		TELIGENT PHARMA INC	**EQ 0.05% BASE**	**A206389**	**001**	Feb 13, 2018

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A071012**	**001**	Feb 03, 1987
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.05% BASE**	**N019141**	**001**	Sep 04, 1984
AB		TARO	**EQ 0.05% BASE**	**A074271**	**001**	Sep 15, 1994

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A074304**	**001**	Aug 31, 1995
AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A075373**	**001**	Jun 22, 1999
AB		LUPIN LTD	**EQ 0.05% BASE**	**A209106**	**001**	Dec 18, 2019
AB		TARO	**EQ 0.05% BASE**	**A076753**	**001**	Oct 12, 2004
AB		TELIGENT PHARMA INC	**EQ 0.05% BASE**	**A206118**	**001**	Nov 09, 2017

DIPROLENE

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05% BASE**	**N018741**	**001**	Jul 27, 1983

SPRAY;TOPICAL

SERNIVO

	+!	ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

ENSTILAR

	+!	LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		PERRIGO UK FINCO	**0.064%;0.005%**	**A200174**	**001**	Dec 12, 2014
AB		TOLMAR	**0.064%;0.005%**	**A201615**	**001**	Jan 14, 2013

TACLONEX

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N021852**	**001**	Jan 09, 2006

SUSPENSION;TOPICAL

TACLONEX

	+!	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE;1%**	**A076002**	**001**	Aug 02, 2002
AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A075502**	**001**	Jun 05, 2001
AB		GLENMARK PHARMS	**EQ 0.05% BASE;1%**	**A202894**	**001**	Oct 30, 2015
AB		TARO	**EQ 0.05% BASE;1%**	**A075673**	**001**	May 29, 2001

LOTRISONE

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05% BASE;1%**	**N018827**	**001**	Jul 10, 1984

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A076516**	**001**	Jun 16, 2005
AB		TARO	**EQ 0.05% BASE;1%**	**A076493**	**001**	Jul 28, 2004

LOTRISONE

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05% BASE;1%**	**N020010**	**001**	Dec 08, 2000

BETAMETHASONE VALERATE						
AEROSOL, FOAM;TOPICAL						
BETAMETHASONE VALERATE						
AB		PERRIGO UK FINCO	**0.12%**	**A078337**	**001**	Nov 26, 2012
AB		RICONPHARMA LLC	**0.12%**	**A207144**	**001**	May 24, 2017
AB		TARO	**0.12%**	**A208204**	**001**	May 24, 2017
LUXIQ						
AB	**+!**	MYLAN	**0.12%**	**N020934**	**001**	Feb 28, 1999
CREAM;TOPICAL						
BETA-VAL						
AB		ACP NIMBLE	**EQ 0.1% BASE**	**N018642**	**001**	Mar 24, 1983
BETAMETHASONE VALERATE						
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018861**	**001**	Aug 31, 1983
DERMABET						
AB		TARO	**EQ 0.1% BASE**	**A072041**	**001**	Jan 06, 1988
VALNAC						
AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070050**	**001**	Oct 10, 1984
LOTION;TOPICAL						
BETAMETHASONE VALERATE						
AB		ANIMA	**EQ 0.1% BASE**	**A070052**	**001**	Jul 31, 1985
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018866**	**001**	Aug 31, 1983
OINTMENT;TOPICAL						
BETA-VAL						
AB		ACP NIMBLE	**EQ 0.1% BASE**	**A070069**	**001**	Dec 19, 1985
BETAMETHASONE VALERATE						
AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070051**	**001**	Oct 10, 1984
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018865**	**001**	Aug 31, 1983
BETAXOLOL HYDROCHLORIDE						
SOLUTION/DROPS;OPHTHALMIC						
BETAXOLOL HYDROCHLORIDE						
AT		AKORN	**EQ 0.5% BASE**	**A075386**	**001**	Jun 30, 2000
AT		MEDIMETRIKS PHARMS	**EQ 0.5% BASE**	**A075630**	**001**	Apr 12, 2001
AT		WOCKHARDT	**EQ 0.5% BASE**	**A078694**	**001**	Nov 16, 2009
BETOPTIC						
AT	**+!**	SANDOZ INC	**EQ 0.5% BASE**	**N019270**	**001**	Aug 30, 1985
SUSPENSION/DROPS;OPHTHALMIC						
BETOPTIC S						
	+!	NOVARTIS	EQ 0.25% BASE	N019845	001	Dec 29, 1989
TABLET;ORAL						
BETAXOLOL HYDROCHLORIDE						
AB		EPIC PHARMA	**10MG**	**A075541**	**001**	Oct 22, 1999
AB	**!**		**20MG**	**A075541**	**002**	Oct 22, 1999
AB		KVK TECH	**10MG**	**A078962**	**001**	Jun 27, 2008
AB			**20MG**	**A078962**	**002**	Jun 27, 2008
BETHANECHOL CHLORIDE						
TABLET;ORAL						
BETHANECHOL CHLORIDE						
AA		AMNEAL PHARM	**5MG**	**A040855**	**001**	Nov 21, 2007
AA			**10MG**	**A040855**	**002**	Nov 21, 2007
AA			**25MG**	**A040855**	**003**	Nov 21, 2007
AA			**50MG**	**A040855**	**004**	Nov 21, 2007
AA		ECI PHARMS LLC	**5MG**	**A040728**	**002**	Oct 26, 2007
AA			**10MG**	**A040728**	**003**	Oct 26, 2007
AA			**25MG**	**A040728**	**004**	Oct 26, 2007
AA			**50MG**	**A040728**	**001**	Oct 26, 2007
AA		HERITAGE PHARMA	**5MG**	**A091256**	**001**	May 04, 2010
AA			**10MG**	**A091256**	**002**	May 04, 2010
AA			**25MG**	**A091256**	**003**	May 04, 2010
AA			**50MG**	**A091256**	**004**	May 04, 2010
AA		LANNETT CO INC	**5MG**	**A040677**	**002**	Mar 27, 2008
AA			**10MG**	**A040677**	**003**	Mar 27, 2008
AA			**25MG**	**A040677**	**004**	Mar 27, 2008
AA			**50MG**	**A040677**	**001**	Mar 27, 2008
AA		UPSHER SMITH LABS	**5MG**	**A040633**	**001**	Jun 01, 2005
AA			**10MG**	**A040634**	**001**	Jun 01, 2005
AA			**25MG**	**A040635**	**001**	Jun 01, 2005
AA			**50MG**	**A040636**	**001**	Jun 01, 2005
AA		WOCKHARDT	**5MG**	**A040532**	**001**	Sep 29, 2003
AA			**10MG**	**A040533**	**001**	Sep 29, 2003
AA			**25MG**	**A040534**	**001**	Sep 29, 2003

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA			**50MG**	**A040518**	**001**	Sep 29, 2003

DUVOID

AA		CHARTWELL RX	**10MG**	**A086262**	**001**	
AA			**25MG**	**A086263**	**001**	
AA			**50MG**	**A085882**	**003**	

URECHOLINE

AA	**!**	ODYSSEY PHARMS	**5MG**	**A089095**	**001**	Dec 19, 1985
AA	**!**		**10MG**	**A088440**	**001**	May 29, 1984
AA	**!**		**25MG**	**A088441**	**001**	May 29, 1984
AA	**!**		**50MG**	**A089096**	**001**	Dec 19, 1985

BETRIXABAN

CAPSULE;ORAL

BEVYXXA

	+	PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017
	+!		80MG	N208383	002	Jun 23, 2017

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB		AMERIGEN PHARMS LTD	**75MG**	**A209861**	**001**	May 08, 2018
AB		AMNEAL PHARMS NY	**75MG**	**A210105**	**001**	Sep 04, 2018
AB		BIONPHARMA INC	**75MG**	**A203174**	**001**	Aug 12, 2014
AB		UPSHER SMITH LABS	**75MG**	**A209886**	**001**	Jul 25, 2018

TARGRETIN

AB	**+!**	VALEANT LUXEMBOURG	**75MG**	**N021055**	**001**	Dec 29, 1999

GEL;TOPICAL

TARGRETIN

	+!	BAUSCH	1%	N021056	001	Jun 28, 2000

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		ACCORD HLTHCARE	**50MG**	**A078917**	**001**	Jul 06, 2009
AB		APOTEX INC	**50MG**	**A200274**	**001**	May 21, 2015
AB		KENTON	**50MG**	**A091011**	**001**	Jun 10, 2015
AB		MYLAN	**50MG**	**A079185**	**001**	Jul 06, 2009
AB		SANDOZ	**50MG**	**A078575**	**001**	Jul 06, 2009
AB		SUN PHARM	**50MG**	**A079110**	**001**	Jul 06, 2009
AB		WATSON LABS TEVA	**50MG**	**A078634**	**001**	Aug 28, 2009
AB		ZYDUS PHARMS USA INC	**50MG**	**A079089**	**001**	Jul 06, 2009

CASODEX

AB	**+!**	ANI PHARMS INC	**50MG**	**N020498**	**001**	Oct 04, 1995

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

BIKTARVY

	+!	GILEAD SCIENCES INC	EQ 50MG BASE;200MG;EQ 25MG BASE	N210251	001	Feb 07, 2018

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT		ALEMBIC PHARMS LTD	**0.03%**	**A210263**	**001**	Apr 12, 2019
AT		APOTEX INC	**0.03%**	**A090449**	**001**	Jul 20, 2015
AT		GLAND PHARMA LTD	**0.03%**	**A210126**	**001**	Mar 22, 2019
AT	**!**	LUPIN LTD	**0.03%**	**A203991**	**001**	Feb 20, 2015
AT		SANDOZ INC	**0.03%**	**A202565**	**001**	May 05, 2015
AT		SOMERSET THERAPS LLC	**0.03%**	**A207601**	**001**	Jun 19, 2019

LUMIGAN

	+!	ALLERGAN	0.01%	N022184	001	Aug 31, 2010

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT		APOTEX INC	**0.03%**	**A201894**	**001**	Dec 01, 2014
AT		HI TECH	**0.03%**	**A203051**	**001**	Oct 09, 2018
AT		SANDOZ INC	**0.03%**	**A202719**	**001**	Apr 19, 2016

LATISSE

AT	**+!**	ALLERGAN	**0.03%**	**N022369**	**001**	Dec 24, 2008

BINIMETINIB

TABLET;ORAL

MEKTOVI

+!	ARRAY BIOPHARMA INC	15MG	N210498	001	Jun 27, 2018

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

PYLERA

+!	ALLERGAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

!	AILEX PHARMS LLC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB		AUROBINDO PHARMA	**5MG**	**A077910**	**001**	Dec 27, 2006
AB			**10MG**	**A077910**	**002**	Dec 27, 2006
AB		CASI PHARMS INC	**5MG**	**A075643**	**001**	Nov 16, 2000
AB			**10MG**	**A075643**	**002**	Nov 16, 2000
AB		FRONTIDA BIOPHARM	**5MG**	**A075474**	**001**	Oct 25, 2002
AB			**10MG**	**A075474**	**002**	Oct 25, 2002
AB		ORIT LABS LLC	**5MG**	**A204891**	**001**	Jan 11, 2017
AB			**10MG**	**A204891**	**002**	Jan 11, 2017
AB		TEVA PHARMS	**5MG**	**A075644**	**001**	Jun 26, 2001
AB			**10MG**	**A075644**	**002**	Jun 26, 2001
AB		UNICHEM PHARMS (USA)	**5MG**	**A078635**	**001**	Aug 18, 2009
AB	**!**		**10MG**	**A078635**	**002**	Aug 18, 2009

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB		SANDOZ	**2.5MG;6.25MG**	**A075579**	**001**	Sep 25, 2000
AB			**5MG;6.25MG**	**A075579**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075579**	**003**	Sep 25, 2000
AB		UNICHEM	**2.5MG;6.25MG**	**A079106**	**001**	Jul 28, 2010
AB			**5MG;6.25MG**	**A079106**	**002**	Jul 28, 2010
AB			**10MG;6.25MG**	**A079106**	**003**	Jul 28, 2010

ZIAC

AB	**+**	TEVA BRANDED PHARM	**2.5MG;6.25MG**	**N020186**	**003**	Mar 26, 1993
AB	**+**		**5MG;6.25MG**	**N020186**	**001**	Mar 26, 1993
AB	**+!**		**10MG;6.25MG**	**N020186**	**002**	Mar 26, 1993

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAX

AP	**+!**	SANDOZ INC	**250MG/VIAL**	**N020873**	**001**	Dec 15, 2000

BIVALIRUDIN

AP		ACCORD HLTHCARE	**250MG/VIAL**	**A206551**	**001**	Nov 22, 2017
AP		APOTEX	**250MG/VIAL**	**A204876**	**001**	Jul 06, 2017
AP		AUROBINDO PHARMA LTD	**250MG/VIAL**	**A205962**	**001**	Jul 27, 2018
AP		CIPLA	**250MG/VIAL**	**A091602**	**001**	Jul 16, 2018
AP		DR REDDYS LABS LTD	**250MG/VIAL**	**A201577**	**001**	May 26, 2017
AP		FRESENIUS KABI USA	**250MG/VIAL**	**A090189**	**001**	Oct 28, 2016
AP		HOSPIRA INC	**250MG/VIAL**	**A090811**	**001**	Jul 14, 2015
AP			**250MG/VIAL**	**A090816**	**001**	Jul 14, 2015
AP		MYLAN INSTITUTIONAL	**250MG/VIAL**	**A202471**	**001**	Jun 01, 2018
AP		SHUANGCHENG	**250MG/VIAL**	**A210031**	**001**	Oct 23, 2019

SOLUTION;INTRAVENOUS

ANGIOMAX RTU

+!	MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001	Jul 25, 2019

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017
+!		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP		CIPLA	**EQ 15 UNITS BASE/VIAL**	**A209439**	**001**	Mar 11, 2019
AP	**!**	FRESENIUS KABI USA	**EQ 15 UNITS BASE/VIAL**	**A065185**	**001**	Jan 28, 2008
AP	**!**		**EQ 30 UNITS BASE/VIAL**	**A065185**	**002**	Jan 28, 2008
AP		HOSPIRA	**EQ 15 UNITS BASE/VIAL**	**A065031**	**001**	Mar 10, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065031**	**002**	Mar 10, 2000
AP		MEITHEAL	**EQ 15 UNITS BASE/VIAL**	**A205030**	**001**	Apr 20, 2018
AP			**EQ 30 UNITS BASE/VIAL**	**A205030**	**002**	Apr 20, 2018
AP		TEVA PHARMS USA	**EQ 15 UNITS BASE/VIAL**	**A065033**	**001**	Jun 27, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065033**	**002**	Jun 27, 2000
AP		WEST-WARD PHARMS INT	**EQ 15 UNITS BASE/VIAL**	**A065042**	**002**	Oct 17, 2001
AP			**EQ 30 UNITS BASE/VIAL**	**A065042**	**001**	Oct 17, 2001

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

VELCADE

+!	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003

POWDER;INTRAVENOUS

BORTEZOMIB

	DR REDDYS LABS LTD	3.5MG/VIAL	N206927	001	Oct 04, 2019
	FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017

BOSENTAN

TABLET;ORAL

BOSENTAN

AB		AMNEAL PHARMS CO	**62.5MG**	**A209742**	**001**	Apr 26, 2019
AB			**125MG**	**A209742**	**002**	Apr 26, 2019
AB		CIPLA	**62.5MG**	**A210342**	**001**	Jan 03, 2020
AB			**125MG**	**A210342**	**002**	Jan 03, 2020
AB		HIKMA	**62.5MG**	**A208695**	**001**	Apr 26, 2019
AB			**125MG**	**A208695**	**002**	Apr 26, 2019
AB		MYLAN	**62.5MG**	**A205173**	**001**	Jan 15, 2020
AB			**125MG**	**A205173**	**002**	Jan 15, 2020
AB		NATCO PHARMA LTD	**62.5MG**	**A206987**	**001**	Apr 26, 2019
AB			**125MG**	**A206987**	**002**	Apr 26, 2019
AB		PAR PHARM INC	**62.5MG**	**A205699**	**001**	Apr 26, 2019
AB			**125MG**	**A205699**	**002**	Apr 26, 2019
AB		SUN PHARM	**62.5MG**	**A209324**	**001**	Apr 26, 2019
AB			**125MG**	**A209324**	**002**	Apr 26, 2019
AB		WATSON LABS INC	**62.5MG**	**A207110**	**001**	Apr 26, 2019
AB			**125MG**	**A207110**	**002**	Apr 26, 2019
AB		ZYDUS PHARMS	**62.5MG**	**A207760**	**001**	Apr 26, 2019
AB			**125MG**	**A207760**	**002**	Apr 26, 2019

TRACLEER

AB	**+**	ACTELION PHARMS LTD	**62.5MG**	**N021290**	**001**	Nov 20, 2001
AB	**+!**		**125MG**	**N021290**	**002**	Nov 20, 2001

TABLET, FOR SUSPENSION;ORAL

TRACLEER

+!	ACTELION PHARMS	32MG	N209279	001	Sep 05, 2017

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

+!	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012
+		EQ 400MG BASE	N203341	003	Oct 27, 2017
+		EQ 500MG BASE	N203341	002	Sep 04, 2012

BREMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+!	AMAG PHARMS INC	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

!	BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018

BREXANOLONE						
SOLUTION;INTRAVENOUS						
ZULRESSO						
	+!	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019
BREXPIPRAZOLE						
TABLET;ORAL						
REXULTI						
	+	OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015
	+		0.5MG	N205422	002	Jul 10, 2015
	+		1MG	N205422	003	Jul 10, 2015
	+!		2MG	N205422	004	Jul 10, 2015
	+		3MG	N205422	005	Jul 10, 2015
	+		4MG	N205422	006	Jul 10, 2015
BRIGATINIB						
TABLET;ORAL						
ALUNBRIG						
	+	ARIAD	30MG	N208772	001	Apr 28, 2017
	+		90MG	N208772	002	Apr 28, 2017
	+!		180MG	N208772	003	Oct 02, 2017
BRILLIANT BLUE G						
SOLUTION;OPHTHALMIC						
TISSUEBLUE						
	+!	DUTCH OPHTHALMIC	0.025%	N209569	001	Dec 20, 2019
BRIMONIDINE TARTRATE						
GEL;TOPICAL						
MIRVASO						
	+!	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013
SOLUTION/DROPS;OPHTHALMIC						
ALPHAGAN P						
AT	**+!**	ALLERGAN	**0.15%**	**N021262**	**001**	Mar 16, 2001
BRIMONIDINE TARTRATE						
AT		AKORN	**0.2%**	**A076439**	**001**	Mar 14, 2006
AT	**!**	BAUSCH AND LOMB	**0.2%**	**A076260**	**001**	May 28, 2003
AT		INDOCO REMEDIES	**0.2%**	**A091691**	**001**	Nov 18, 2014
AT		SANDOZ INC	**0.2%**	**A076254**	**001**	Sep 16, 2003
AT			**0.2%**	**A078075**	**001**	Jan 30, 2008
AT		SOMERSET THERAPS LLC	**0.2%**	**A208992**	**001**	Mar 11, 2019
QOLIANA						
AT		SANDOZ INC	**0.15%**	**N021764**	**001**	May 22, 2006
ALPHAGAN P						
	+!	ALLERGAN	0.1%	N021770	001	Aug 19, 2005
BRIMONIDINE TARTRATE; BRINZOLAMIDE						
SUSPENSION/DROPS;OPHTHALMIC						
SIMBRINZA						
	+!	NOVARTIS	0.2%;1%	N204251	001	Apr 19, 2013
BRIMONIDINE TARTRATE; TIMOLOL MALEATE						
SOLUTION/DROPS;OPHTHALMIC						
COMBIGAN						
	+!	ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007
BRINZOLAMIDE						
SUSPENSION/DROPS;OPHTHALMIC						
AZOPT						
	+!	NOVARTIS	1%	N020816	001	Apr 01, 1998
BRIVARACETAM						
SOLUTION;INTRAVENOUS						
BRIVIACT						
	+!	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016
SOLUTION;ORAL						
BRIVIACT						
	+!	UCB INC	10MG/ML	N205838	001	May 12, 2016
TABLET;ORAL						
BRIVIACT						
	+	UCB INC	10MG	N205836	001	May 12, 2016
	+		25MG	N205836	002	May 12, 2016
	+		50MG	N205836	003	May 12, 2016
	+		75MG	N205836	004	May 12, 2016
	+!		100MG	N205836	005	May 12, 2016

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT2		ALEMBIC PHARMS LTD	**EQ 0.09% ACID**	**A210560**	**001**	Jun 21, 2019
AT2	**!**	HI TECH	**EQ 0.09% ACID**	**A203395**	**001**	Jan 22, 2014
AT2		MYLAN	**EQ 0.09% ACID**	**A203368**	**001**	Jun 03, 2019

BROMSITE

	+!	SUN PHARMA GLOBAL	EQ 0.075% ACID	N206911	001	Apr 08, 2016

PROLENSA

	+!	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB	**!**	MYLAN	**EQ 5MG BASE**	**A077226**	**001**	Apr 04, 2005
AB		ZYDUS PHARMS USA INC	**EQ 5MG BASE**	**A078899**	**001**	Jul 30, 2008

PARLODEL

AB	**+**	US PHARMS HOLDINGS I	**EQ 5MG BASE**	**N017962**	**002**	Mar 01, 1982

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB		MYLAN	**EQ 2.5MG BASE**	**A076962**	**001**	Sep 24, 2004
AB	**!**	PADDOCK LLC	**EQ 2.5MG BASE**	**A077646**	**001**	Oct 01, 2008
AB		SANDOZ INC	**EQ 2.5MG BASE**	**A074631**	**001**	Jan 13, 1998

PARLODEL

AB	**+**	US PHARMS HOLDINGS I	**EQ 2.5MG BASE**	**N017962**	**001**	

CYCLOSET

	+!	VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	**!**	WOCKHARDT BIO AG	**2MG/5ML;10MG/5ML;30MG/5ML**	**A088811**	**001**	Jun 07, 1985

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		ACELLA	**2MG/5ML;10MG/5ML;30MG/5ML**	**A203375**	**001**	Sep 20, 2016
AA		MAYNE PHARMA INC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A207676**	**001**	Dec 04, 2018
AA		PADDOCK LLC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205292**	**001**	Jul 15, 2014
AA		TARO	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205112**	**001**	Feb 27, 2017

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

	+!	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014

CAPSULE;ORAL

BUDESONIDE

AB		ALVOGEN	**3MG**	**A206724**	**001**	Nov 23, 2016
AB		AMNEAL PHARMS	**3MG**	**A206200**	**001**	Jul 31, 2017
AB		APPCO	**3MG**	**A207367**	**001**	Apr 07, 2017
AB		BARR LABS DIV TEVA	**3MG**	**A090379**	**001**	Apr 02, 2014
AB		MAYNE PHARMA	**3MG**	**A206623**	**001**	Apr 08, 2016
AB		MYLAN	**3MG**	**A090410**	**001**	May 16, 2011
AB		SCIECURE PHARMA INC	**3MG**	**A209041**	**001**	Sep 28, 2017
AB		ZYDUS PHARMS	**3MG**	**A206134**	**001**	May 04, 2017

ENTOCORT EC

AB	**+!**	PERRIGO PHARMA INTL	**3MG**	**N021324**	**001**	Oct 02, 2001

CAPSULE, EXTENDED RELEASE;ORAL

ORTIKOS

	+	SUN PHARMA GLOBAL	6MG	N211929	001	Jun 13, 2019
	+!		9MG	N211929	002	Jun 13, 2019

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

	+	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006
	+!		0.16MG/INH	N021949	002	Jul 12, 2006

SUSPENSION;INHALATION

BUDESONIDE

AN		CIPLA	**0.25MG/2ML**	**A205710**	**001**	Nov 16, 2017
AN			**0.5MG/2ML**	**A205710**	**002**	Nov 16, 2017
AN			**1MG/2ML**	**A205710**	**003**	Nov 16, 2017
AN		IMPAX LABS INC	**0.25MG/2ML**	**A078404**	**001**	Jul 31, 2012
AN			**0.5MG/2ML**	**A078404**	**002**	Jul 31, 2012
AN		LUPIN ATLANTIS	**0.5MG/2ML**	**A210897**	**001**	Nov 09, 2018
AN		NEPHRON	**0.25MG/2ML**	**A078202**	**001**	Mar 30, 2009

BUDESONIDE

SUSPENSION;INHALATION

BUDESONIDE

AN			**0.5MG/2ML**	**A078202**	**002**	Mar 30, 2009
AN		SANDOZ INC	**0.25MG/2ML**	**A201966**	**003**	Sep 27, 2013
AN			**0.5MG/2ML**	**A201966**	**002**	Sep 27, 2013
AN			**1MG/2ML**	**A201966**	**001**	Sep 27, 2013
AN		TEVA PHARMS	**0.25MG/2ML**	**A077519**	**001**	Nov 18, 2008
AN			**0.5MG/2ML**	**A077519**	**002**	Nov 18, 2008
AN		TEVA PHARMS USA	**1MG/2ML**	**A204548**	**001**	Mar 08, 2016

PULMICORT RESPULES

AN	**+**	ASTRAZENECA PHARMS	**0.25MG/2ML**	**N020929**	**001**	Aug 08, 2000
AN	**+**		**0.5MG/2ML**	**N020929**	**002**	Aug 08, 2000
AN	**+!**		**1MG/2ML**	**N020929**	**003**	Aug 08, 2000

TABLET, EXTENDED RELEASE;ORAL

BUDESONIDE

AB		ACTAVIS LABS FL INC	**9MG**	**A205457**	**001**	Jul 03, 2018

UCERIS

AB	**+!**	SALIX	**9MG**	**N203634**	**001**	Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

SYMBICORT

+!	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006
+!		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP		HOSPIRA	**0.25MG/ML**	**A074332**	**001**	Oct 31, 1994
AP	**!**	WEST-WARD PHARMS INT	**0.25MG/ML**	**A079196**	**001**	Apr 30, 2008

TABLET;ORAL

BUMETANIDE

AB		AMNEAL PHARMS CO	**0.5MG**	**A209724**	**001**	Oct 18, 2017
AB			**1MG**	**A209724**	**002**	Oct 18, 2017
AB			**2MG**	**A209724**	**003**	Oct 18, 2017
AB		CEYONE	**0.5MG**	**A212019**	**001**	Dec 12, 2019
AB			**1MG**	**A212019**	**002**	Dec 12, 2019
AB			**2MG**	**A212019**	**003**	Dec 12, 2019
AB		HERITAGE PHARMA	**0.5MG**	**A074225**	**001**	Apr 24, 1995
AB			**1MG**	**A074225**	**002**	Apr 24, 1995
AB			**2MG**	**A074225**	**003**	Apr 24, 1995
AB		SANDOZ	**0.5MG**	**A074700**	**001**	Nov 21, 1996
AB			**1MG**	**A074700**	**002**	Nov 21, 1996
AB	**!**		**2MG**	**A074700**	**003**	Nov 21, 1996
AB		UPSHER SMITH LABS	**0.5MG**	**A209916**	**001**	Jan 23, 2018
AB			**1MG**	**A209916**	**002**	Jan 23, 2018
AB			**2MG**	**A209916**	**003**	Jan 23, 2018
AB		ZYDUS PHARMS	**0.5MG**	**A202900**	**001**	Apr 30, 2018
AB			**1MG**	**A202900**	**002**	Apr 30, 2018
AB			**2MG**	**A202900**	**003**	Apr 30, 2018

BUMEX

AB	**+**	VALIDUS PHARMS	**0.5MG**	**N018225**	**002**	Feb 28, 1983
AB	**+**		**1MG**	**N018225**	**001**	Feb 28, 1983
AB	**+**		**2MG**	**N018225**	**003**	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

EXPAREL

+!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001 Oct 28, 2011
+!		266MG/20ML (13.3MG/ML)	N022496 002 Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	**0.25%**	**A207183**	**001**	May 13, 2016
AP			**0.5%**	**A207183**	**002**	May 13, 2016
AP		HOSPIRA	**0.25%**	**A070583**	**001**	Feb 17, 1987
AP			**0.25%**	**A070586**	**001**	Mar 03, 1987
AP			**0.25%**	**A070590**	**001**	Feb 17, 1987
AP			**0.25%**	**N018053**	**002**	
AP			**0.5%**	**A070584**	**001**	Feb 17, 1986
AP			**0.5%**	**A070597**	**001**	Mar 03, 1987

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE							
AP			**0.5%**	**A070609**	**001**	Mar 03, 1987	
AP			**0.5%**	**N018053**	**001**		
AP			**0.75%**	**A070585**	**001**	Mar 03, 1987	
AP			**0.75%**	**N018053**	**003**		
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP		AUROBINDO PHARMA LTD	**0.25%**	**A203895**	**001**	Nov 05, 2013	
AP			**0.5%**	**A203895**	**002**	Nov 05, 2013	
AP			**0.75%**	**A203895**	**003**	Nov 05, 2013	
MARCAINE HYDROCHLORIDE							
AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**001**		
AP	**+!**		**0.5%**	**N016964**	**006**		
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**012**		
AP	**+!**		**0.5%**	**N016964**	**005**		
AP	**+!**		**0.75%**	**N016964**	**009**		
SENSORCAINE							
AP		FRESENIUS KABI USA	**0.25%**	**A070552**	**001**	May 21, 1986	
AP			**0.25%**	**N018304**	**001**		
AP			**0.5%**	**A070553**	**001**	May 21, 1986	
AP			**0.5%**	**N018304**	**002**		
AP			**0.75%**	**A070554**	**001**	May 21, 1986	
AP			**0.75%**	**N018304**	**003**		

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE							
AP		B BRAUN MEDICAL INC	**0.75%**	**A209087**	**001**	Apr 02, 2019	
AP		BAXTER HLTHCARE CORP	**0.75%**	**A207266**	**001**	Jul 25, 2016	
AP		HOSPIRA	**0.75%**	**A071810**	**001**	Dec 11, 1987	
AP		HUONS	**0.75%**	**A212822**	**001**	Dec 30, 2019	
MARCAINE							
AP	**+!**	HOSPIRA	**0.75%**	**N018692**	**001**	May 04, 1984	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE							
AP	**!**	HOSPIRA	**0.5%;0.005MG/ML**	**A071168**	**001**	Jun 16, 1988	
AP			**0.5%;0.005MG/ML**	**A071170**	**001**	Jun 16, 1988	
	!		0.25%;0.005MG/ML	A071165	001	Jun 16, 1988	
			0.25%;0.005MG/ML	A071167	001	Jun 16, 1988	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE							
AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**004**		
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**008**		
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE							
AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**013**		
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**007**		
AP	**+!**		**0.75%;0.0091MG/ML**	**N016964**	**010**		
SENSORCAINE							
AP		FRESENIUS KABI USA	**0.25%;0.0091MG/ML**	**A070966**	**001**	Oct 13, 1987	
AP			**0.25%;0.0091MG/ML**	**A070967**	**001**	Oct 13, 1987	
AP			**0.5%;0.0091MG/ML**	**A070968**	**001**	Oct 13, 1987	
AP			**0.5%;0.0091MG/ML**	**N018304**	**004**	Sep 02, 1983	
AP			**0.75%;0.0091MG/ML**	**N018304**	**005**	Sep 02, 1983	
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE							
	!	SEPTODONT	0.5%;0.0091MG/ML	A077250	001	Sep 27, 2006	

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE							
AB		WATSON LABS TEVA	**5MCG/HR**	**A204937**	**001**	Nov 20, 2018	
AB			**10MCG/HR**	**A204937**	**002**	Nov 20, 2018	
AB			**15MCG/HR**	**A204937**	**003**	Nov 20, 2018	
AB			**20MCG/HR**	**A204937**	**004**	Nov 20, 2018	
BUTRANS							
AB	**+**	PURDUE PHARMA LP	**5MCG/HR**	**N021306**	**001**	Jun 30, 2010	
AB	**+**		**10MCG/HR**	**N021306**	**002**	Jun 30, 2010	
AB	**+**		**15MCG/HR**	**N021306**	**004**	Jul 25, 2013	
AB	**+!**		**20MCG/HR**	**N021306**	**003**	Jun 30, 2010	

BUPRENORPHINE						
FILM, EXTENDED RELEASE;TRANSDERMAL						
BUTRANS						
	+		7.5MCG/HR	N021306	005	Jun 30, 2014
SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS						
SUBLOCADE						
	+	INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017
	+!		300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017
BUPRENORPHINE HYDROCHLORIDE						
FILM;BUCCAL						
BELBUCA						
	+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015
	+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015
	+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015
	+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015
	+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015
	+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015
	+!		EQ 0.9MG BASE	N207932	007	Oct 23, 2015
IMPLANT;IMPLANTATION						
PROBUPHINE						
	+!	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016
INJECTABLE;INJECTION						
BUPRENEX						
AP	**+!**	INDIVIOR INC	**EQ 0.3MG BASE/ML**	**N018401**	**001**	
BUPRENORPHINE HYDROCHLORIDE						
AP		AM REGENT	**EQ 0.3MG BASE/ML**	**A078331**	**001**	Mar 27, 2007
AP		HOSPIRA	**EQ 0.3MG BASE/ML**	**A074137**	**001**	Jun 03, 1996
AP		PAR STERILE PRODUCTS	**EQ 0.3MG BASE/ML**	**A206586**	**001**	Jul 28, 2015
AP		WEST-WARD PHARMS INT	**EQ 0.3MG BASE/ML**	**A076931**	**001**	Mar 02, 2005
TABLET;SUBLINGUAL						
BUPRENORPHINE HYDROCHLORIDE						
AB		ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090819**	**001**	Feb 19, 2015
AB			**EQ 8MG BASE**	**A090819**	**002**	Feb 19, 2015
AB		CASI PHARMS INC	**EQ 2MG BASE**	**A090279**	**001**	Jun 10, 2015
AB			**EQ 8MG BASE**	**A090279**	**002**	Jun 10, 2015
AB		ETHYPHARM	**EQ 2MG BASE**	**A090622**	**001**	Sep 24, 2010
AB			**EQ 8MG BASE**	**A090622**	**002**	Sep 24, 2010
AB		HIKMA	**EQ 2MG BASE**	**A078633**	**001**	Oct 08, 2009
AB	**!**		**EQ 8MG BASE**	**A078633**	**002**	Oct 08, 2009
AB		RHODES PHARMS	**EQ 2MG BASE**	**A207276**	**001**	Mar 27, 2017
AB			**EQ 8MG BASE**	**A207276**	**002**	Mar 27, 2017
AB		SUN PHARM	**EQ 2MG BASE**	**A201760**	**001**	Jan 29, 2016
AB			**EQ 8MG BASE**	**A201760**	**002**	Jan 29, 2016
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE						
FILM;BUCCAL						
BUNAVAIL						
	+	BDSI	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001	Jun 06, 2014
	+		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002	Jun 06, 2014
	+!		EQ 6.3MG BASE;EQ 1MG BASE	N205637	003	Jun 06, 2014
FILM;BUCCAL, SUBLINGUAL						
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
AB		ALVOGEN PINE BROOK	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205954**	**001**	Jan 24, 2019
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205954**	**002**	Jan 24, 2019
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205954**	**003**	Jan 24, 2019
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205954**	**004**	Jan 24, 2019
AB		DR REDDYS LABS SA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205299**	**001**	Jun 14, 2018
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205806**	**001**	Jun 14, 2018
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205299**	**002**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205806**	**002**	Jun 14, 2018
AB		MYLAN TECHNOLOGIES	**EQ 8MG BASE;EQ 2MG BASE**	**A207607**	**001**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A207607**	**002**	Jun 14, 2018
SUBOXONE						
AB	**+**	INDIVIOR INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**N022410**	**001**	Aug 30, 2010
AB	**+**		**EQ 4MG BASE;EQ 1MG BASE**	**N022410**	**003**	Aug 10, 2012
AB	**+**		**EQ 8MG BASE;EQ 2MG BASE**	**N022410**	**002**	Aug 30, 2010
AB	**+!**		**EQ 12MG BASE;EQ 3MG BASE**	**N022410**	**004**	Aug 10, 2012
TABLET;SUBLINGUAL						
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
AB		ACTAVIS ELIZABETH	**EQ 2MG BASE;EQ 0.5MG BASE**	**A091422**	**001**	Feb 22, 2013
AB	**!**		**EQ 8MG BASE;EQ 2MG BASE**	**A091422**	**002**	Feb 22, 2013

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203136**	**001**	Feb 22, 2013
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A203136**	**002**	Feb 22, 2013
AB	ETHYPHARM USA CORP	**EQ 2MG BASE;EQ 0.5MG BASE**	**A204431**	**001**	Oct 16, 2015
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A204431**	**002**	Oct 16, 2015
AB	HIKMA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203326**	**001**	Jun 27, 2014
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A203326**	**002**	Jun 27, 2014
AB	LANNETT CO INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205022**	**001**	Sep 19, 2016
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A205022**	**002**	Sep 19, 2016
AB	SPECGX LLC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A207000**	**001**	Dec 13, 2017
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A207000**	**002**	Dec 13, 2017
AB	SUN PHARM	**EQ 2MG BASE;EQ 0.5MG BASE**	**A201633**	**001**	Aug 05, 2016
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A201633**	**002**	Aug 05, 2016

ZUBSOLV

+	OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006	Oct 04, 2016
+		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013
+		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013
+		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014
+!		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008
+		348MG	N022108	002	Apr 23, 2008
+!		522MG	N022108	003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	**75MG**	**A203013**	**001**	Jun 08, 2018
AB		**100MG**	**A203013**	**002**	Jun 08, 2018
AB	APNAR PHARMA LP	**75MG**	**A075584**	**001**	Feb 07, 2000
AB		**100MG**	**A075584**	**002**	Feb 07, 2000
AB	APOTEX INC	**75MG**	**A076143**	**001**	Jan 17, 2006
AB !		**100MG**	**A076143**	**002**	Jan 17, 2006
AB	HERITAGE PHARMA	**75MG**	**A206975**	**001**	Aug 19, 2016
AB		**100MG**	**A206975**	**002**	Aug 19, 2016
AB	INVAGEN PHARMS	**75MG**	**A207389**	**001**	Sep 18, 2017
AB		**100MG**	**A207389**	**002**	Sep 18, 2017
AB	MYLAN	**75MG**	**A075491**	**001**	Apr 17, 2000
AB		**100MG**	**A075491**	**002**	Apr 17, 2000

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ACTAVIS LABS FL INC	**100MG**	**A079095**	**001**	Mar 24, 2009
AB1		**150MG**	**A079095**	**002**	Mar 24, 2009
AB1		**200MG**	**A079095**	**003**	Mar 24, 2009
AB1	ANCHEN PHARMS	**100MG**	**A091459**	**001**	Jun 09, 2011
AB1		**150MG**	**A091459**	**002**	Jun 09, 2011
AB1		**200MG**	**A091459**	**003**	Jun 09, 2011
AB1	IMPAX LABS	**100MG**	**A075913**	**001**	Jan 28, 2004
AB1		**150MG**	**A075913**	**002**	Mar 22, 2004
AB1		**200MG**	**A076711**	**001**	Dec 03, 2004
AB1	INVAGEN PHARMS	**100MG**	**A206674**	**001**	Feb 09, 2016
AB1		**150MG**	**A206674**	**002**	Feb 09, 2016
AB1		**200MG**	**A206674**	**003**	Feb 09, 2016
AB1	JUBILANT GENERICS	**100MG**	**A202774**	**001**	Oct 11, 2013
AB1		**150MG**	**A202774**	**002**	Oct 11, 2013
AB1		**200MG**	**A202774**	**003**	Oct 11, 2013
AB1	PRINSTON INC	**100MG**	**A202304**	**001**	May 26, 2015
AB1		**150MG**	**A202304**	**002**	May 26, 2015
AB1		**200MG**	**A202304**	**003**	May 26, 2015
AB1	SANDOZ	**100MG**	**A075932**	**001**	Nov 25, 2003
AB1		**150MG**	**A075932**	**002**	Mar 22, 2004
AB1		**200MG**	**A075932**	**003**	Jun 22, 2005
AB1	SCIEGEN PHARMS INC	**100MG**	**A205794**	**001**	Mar 01, 2016
AB1		**150MG**	**A205794**	**002**	Mar 01, 2016
AB1		**200MG**	**A205794**	**003**	Mar 01, 2016
AB1	SUN PHARM	**100MG**	**A078866**	**001**	Apr 06, 2010
AB1		**150MG**	**A078866**	**002**	Apr 06, 2010

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1			**200MG**	**A078866**	**003**	Apr 06, 2010
AB1		TORRENT	**100MG**	**A203969**	**001**	Oct 31, 2014
AB1			**150MG**	**A203969**	**002**	Oct 31, 2014
AB1			**200MG**	**A203969**	**003**	Oct 31, 2014
AB1		WATSON LABS INC	**100MG**	**A077455**	**001**	Jul 19, 2010
AB1			**150MG**	**A077455**	**002**	Mar 12, 2008
AB1			**200MG**	**A077455**	**003**	Jul 19, 2010

WELLBUTRIN SR

AB1	**+**	GLAXOSMITHKLINE	**100MG**	**N020358**	**002**	Oct 04, 1996
AB1	**+**		**150MG**	**N020358**	**003**	Oct 04, 1996
AB1	**+!**		**200MG**	**N020358**	**004**	Jun 14, 2002

BUPROPION HYDROCHLORIDE

AB2	**!**	ACTAVIS LABS FL INC	**150MG**	**A079094**	**001**	Mar 24, 2009
AB2		ANCHEN PHARMS	**150MG**	**A091520**	**001**	Jun 09, 2011
AB2		IMPAX LABS	**150MG**	**A075914**	**001**	May 27, 2004
AB2		JUBILANT GENERICS	**150MG**	**A202775**	**001**	Oct 11, 2013
AB2		SANDOZ INC	**150MG**	**A077475**	**001**	Mar 12, 2008
AB2		SCIEGEN PHARMS INC	**150MG**	**A206122**	**001**	Aug 17, 2016
AB3		ACCORD HLTHCARE	**150MG**	**A210497**	**001**	Oct 31, 2018
AB3			**300MG**	**A210497**	**002**	Oct 31, 2018
AB3		ACTAVIS LABS FL INC	**150MG**	**A077715**	**001**	Nov 26, 2008
AB3		ANBISON LAB	**150MG**	**A207224**	**001**	Jun 30, 2017
AB3			**300MG**	**A207224**	**002**	Jun 30, 2017
AB3		ANCHEN PHARMS	**150MG**	**A077284**	**001**	Dec 14, 2006
AB3			**300MG**	**A077284**	**002**	Dec 14, 2006
AB3		GRAVITI PHARMS	**150MG**	**A211020**	**001**	Jan 28, 2019
AB3			**300MG**	**A211020**	**002**	Jan 28, 2019
AB3		IMPAX LABS	**150MG**	**A077415**	**001**	Nov 26, 2008
AB3		INVAGEN PHARMS	**150MG**	**A206556**	**001**	Aug 26, 2016
AB3			**300MG**	**A206556**	**002**	Aug 26, 2016
AB3		JUBILANT GENERICS	**150MG**	**A207459**	**001**	Jun 30, 2017
AB3			**300MG**	**A207459**	**002**	Jun 30, 2017
AB3		LUPIN LTD	**150MG**	**A090693**	**001**	Apr 06, 2017
AB3			**300MG**	**A090693**	**002**	Apr 06, 2017
AB3		SCIEGEN PHARMS INC	**150MG**	**A207479**	**001**	Apr 12, 2017
AB3			**300MG**	**A207479**	**002**	Apr 12, 2017
AB3		SINOTHERAPEUTICS INC	**150MG**	**A208652**	**001**	Aug 21, 2017
AB3			**300MG**	**A208652**	**002**	Aug 21, 2017
AB3		TWI PHARMS	**150MG**	**A210081**	**001**	Nov 03, 2017
AB3			**300MG**	**A210081**	**002**	Nov 03, 2017
AB3		WATSON LABS INC	**150MG**	**A077285**	**001**	Nov 26, 2008
AB3			**300MG**	**A077285**	**002**	Aug 15, 2008
AB3		WOCKHARDT LTD	**150MG**	**A202189**	**001**	Nov 21, 2012
AB3		YICHANG HUMANWELL	**150MG**	**A210015**	**001**	Jun 14, 2018
AB3			**300MG**	**A210015**	**002**	Jun 14, 2018
AB3		ZHEJIANG JUTAI PHARM	**300MG**	**A211200**	**001**	Sep 05, 2019
AB3		ZYDUS PHARMS	**150MG**	**A201567**	**002**	Jul 23, 2018
AB3			**300MG**	**A201567**	**001**	Jan 17, 2014

WELLBUTRIN XL

AB3	**+**	VALEANT INTL	**150MG**	**N021515**	**001**	Aug 28, 2003
AB3	**+!**		**300MG**	**N021515**	**002**	Aug 28, 2003

FORFIVO XL

	+!	ALVOGEN	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

	+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A202557**	**001**	Dec 30, 2014
AB			**7.5MG**	**A202557**	**002**	Dec 30, 2014
AB			**10MG**	**A202557**	**003**	Dec 30, 2014
AB			**15MG**	**A202557**	**004**	Dec 30, 2014
AB			**30MG**	**A202557**	**005**	Dec 30, 2014
AB		AMNEAL PHARMS CO	**5MG**	**A208829**	**001**	May 24, 2017
AB			**7.5MG**	**A208829**	**002**	May 24, 2017

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB			**10MG**	**A208829**	**003**	May 24, 2017
AB			**15MG**	**A208829**	**004**	May 24, 2017
AB			**30MG**	**A208829**	**005**	May 24, 2017
AB		AUROBINDO PHARMA LTD	**5MG**	**A078246**	**001**	Feb 27, 2009
AB			**10MG**	**A078246**	**002**	Feb 27, 2009
AB			**15MG**	**A078246**	**003**	Feb 27, 2009
AB			**30MG**	**A078246**	**004**	Feb 27, 2009
AB		EPIC PHARMA LLC	**5MG**	**A208972**	**001**	Apr 16, 2019
AB			**7.5MG**	**A208972**	**002**	Apr 16, 2019
AB			**10MG**	**A208972**	**003**	Apr 16, 2019
AB			**15MG**	**A208972**	**004**	Apr 16, 2019
AB			**30MG**	**A208972**	**005**	Apr 16, 2019
AB		HERITAGE PHARMA	**5MG**	**A204582**	**001**	Sep 18, 2015
AB			**10MG**	**A204582**	**002**	Sep 18, 2015
AB			**15MG**	**A204582**	**003**	Sep 18, 2015
AB			**30MG**	**A204582**	**004**	Sep 18, 2015
AB		IMPAX LABS INC	**5MG**	**A074253**	**001**	Mar 28, 2001
AB			**10MG**	**A074253**	**002**	Mar 28, 2001
AB			**15MG**	**A074253**	**003**	Mar 13, 2002
AB		INVENTIA HLTHCARE	**5MG**	**A209696**	**001**	May 03, 2018
AB			**7.5MG**	**A209696**	**002**	May 03, 2018
AB			**10MG**	**A209696**	**003**	May 03, 2018
AB			**15MG**	**A209696**	**004**	May 03, 2018
AB			**30MG**	**A209696**	**005**	May 03, 2018
AB		MYLAN	**5MG**	**A076008**	**003**	Mar 01, 2002
AB			**7.5MG**	**A075467**	**002**	Mar 28, 2001
AB			**7.5MG**	**A076008**	**002**	Jul 08, 2013
AB			**10MG**	**A076008**	**004**	Mar 01, 2002
AB			**15MG**	**A076008**	**005**	Mar 28, 2001
AB			**30MG**	**A076008**	**001**	Jun 28, 2001
AB		OXFORD PHARMS	**30MG**	**A078302**	**001**	Dec 17, 2007
AB		STRIDES PHARMA	**5MG**	**A202330**	**001**	Aug 25, 2014
AB			**7.5MG**	**A202330**	**005**	Feb 17, 2017
AB			**10MG**	**A202330**	**002**	Aug 25, 2014
AB			**15MG**	**A202330**	**003**	Aug 25, 2014
AB			**30MG**	**A202330**	**004**	Aug 25, 2014
AB		TEVA	**5MG**	**A075022**	**001**	Feb 28, 2002
AB			**10MG**	**A075022**	**002**	Feb 28, 2002
AB	**!**		**15MG**	**A075022**	**003**	Feb 28, 2002
AB			**30MG**	**A075022**	**004**	Mar 25, 2004
AB		UNICHEM LABS LTD	**5MG**	**A210907**	**001**	Nov 14, 2019
AB			**10MG**	**A210907**	**002**	Nov 14, 2019
AB			**15MG**	**A210907**	**003**	Nov 14, 2019
AB			**30MG**	**A210907**	**004**	Nov 14, 2019
AB		YILING PHARM LTD	**5MG**	**A202087**	**001**	Dec 16, 2015
AB			**10MG**	**A202087**	**002**	Dec 16, 2015
AB			**15MG**	**A202087**	**003**	Dec 16, 2015
AB			**30MG**	**A202087**	**004**	Dec 16, 2015
AB		ZYDUS PHARMS	**5MG**	**A078888**	**001**	Feb 07, 2014
AB			**10MG**	**A078888**	**002**	Feb 07, 2014
AB			**15MG**	**A078888**	**003**	Feb 07, 2014
AB			**30MG**	**A078888**	**004**	Feb 07, 2014

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP		ACCORD HLTHCARE INC	**6MG/ML**	**A210148**	**001**	Feb 22, 2019
AP		ACTAVIS LLC	**6MG/ML**	**A205139**	**001**	Dec 08, 2017
AP		AMNEAL	**6MG/ML**	**A209580**	**001**	Dec 18, 2017
AP		APOTEX	**6MG/ML**	**A210448**	**001**	May 07, 2019
AP		ATHENEX INC	**6MG/ML**	**A205106**	**001**	Sep 21, 2018
AP		HOSPIRA INC	**6MG/ML**	**A205672**	**001**	Jul 31, 2018
AP		LUITPOLD	**6MG/ML**	**A202259**	**001**	Dec 22, 2015
AP		MYLAN LABS LTD	**6MG/ML**	**A205184**	**001**	Jul 13, 2018
AP		NEXUS PHARMS	**6MG/ML**	**A207794**	**001**	Jan 14, 2019
AP		PHARMASCIENCE INC	**6MG/ML**	**A207050**	**001**	Mar 24, 2017
AP		SHILPA MEDICARE LTD	**6MG/ML**	**A210931**	**001**	Apr 18, 2019

BUSULFEX

AP	**+!**	OTSUKA PHARM	**6MG/ML**	**N020954**	**001**	Feb 04, 1999

BUSULFAN
INJECTABLE;INJECTION
MYLERAN

AP		MYLAN INSTITUTIONAL	**6MG/ML**	**A208536**	**001**	Nov 20, 2017

TABLET;ORAL
MYLERAN

	+!	ASPEN GLOBAL	2MG	N009386	001

BUTABARBITAL SODIUM
TABLET;ORAL
BUTISOL SODIUM

	+!	MYLAN SPECIALITY LP	30MG	N000793	004

BUTENAFINE HYDROCHLORIDE
CREAM;TOPICAL
MENTAX

	+!	MYLAN	1%	N020524	001	Oct 18, 1996

BUTOCONAZOLE NITRATE
CREAM;VAGINAL
GYNAZOLE-1

	!	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012

BUTORPHANOL TARTRATE
INJECTABLE;INJECTION
BUTORPHANOL TARTRATE

AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078400**	**001**	May 01, 2009
AP			**2MG/ML**	**A078400**	**002**	May 01, 2009
AP		WEST-WARD PHARMS INT	**2MG/ML**	**A075046**	**001**	Aug 12, 1998

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	**!**	HOSPIRA	**1MG/ML**	**A074626**	**001**	Jan 23, 1997
AP	**!**		**2MG/ML**	**A074626**	**002**	Jan 23, 1997
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A075045**	**001**	Aug 12, 1998
AP			**2MG/ML**	**A075045**	**002**	Aug 12, 1998

SPRAY, METERED;NASAL
BUTORPHANOL TARTRATE

AB		APOTEX INC	**1MG/SPRAY**	**A075499**	**001**	Dec 04, 2002
AB		HIKMA	**1MG/SPRAY**	**A075824**	**001**	Mar 12, 2002
AB	**!**	MYLAN	**1MG/SPRAY**	**A075759**	**001**	Aug 08, 2001

CABAZITAXEL
SOLUTION;INTRAVENOUS
JEVTANA KIT

	+!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010

CABERGOLINE
TABLET;ORAL
CABERGOLINE

AB		INGENUS PHARMS LLC	**0.5MG**	**A204735**	**001**	Aug 01, 2018
AB		IVAX SUB TEVA PHARMS	**0.5MG**	**A077750**	**001**	Mar 07, 2007
AB		MYLAN	**0.5MG**	**A202947**	**001**	Dec 02, 2013
AB	**!**	PAR PHARM	**0.5MG**	**A076310**	**001**	Dec 29, 2005

CABOZANTINIB S-MALATE
CAPSULE;ORAL
COMETRIQ

	+!	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012
	+		EQ 80MG BASE	N203756	002	Nov 29, 2012

TABLET;ORAL
CABOMETYX

	+	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016
	+		EQ 40MG BASE	N208692	002	Apr 25, 2016
	+!		EQ 60MG BASE	N208692	003	Apr 25, 2016

CAFFEINE CITRATE
SOLUTION;INTRAVENOUS
CAFCIT

AP	**+!**	HIKMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793**	**001**	Sep 21, 1999

CAFFEINE CITRATE

AP		AUROBINDO PHARMA LTD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A205013**	**001**	Sep 22, 2015
AP		EXELA PHARMA SCIENCE	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077233**	**001**	Sep 21, 2006
AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077997**	**001**	Jul 20, 2007

CAFFEINE CITRATE							
SOLUTION;INTRAVENOUS							
CAFFEINE CITRATE							
AP		LUITPOLD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077906**	**001**	May 15, 2007
AP		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A207400**	**001**	Dec 14, 2017
AP		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090827**	**001**	Aug 29, 2012
AP		SUN PHARM	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090077**	**001**	Sep 30, 2009
SOLUTION;ORAL							
CAFCIT							
AA	**+!**	HIKMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793**	**002**	Apr 12, 2000
CAFFEINE CITRATE							
AA		EXELA PHARMA SCS LLC	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077304**	**001**	Sep 21, 2006
AA		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A078002**	**001**	Jan 31, 2008
AA		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A213202**	**001**	Dec 16, 2019
AA		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A091102**	**001**	Aug 29, 2012
AA		SUN PHARM	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090357**	**001**	Sep 30, 2009
CAFFEINE; ERGOTAMINE TARTRATE							
SUPPOSITORY;RECTAL							
MIGERGOT							
	!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983
TABLET;ORAL							
CAFERGOT							
AA	**!**	SANDOZ	**100MG;1MG**	**A084294**	**001**		
ERGOTAMINE TARTRATE AND CAFFEINE							
AA		HIKMA INTL PHARMS	**100MG;1MG**	**A040510**	**001**	Sep 17, 2004
AA		MIKART	**100MG;1MG**	**A040590**	**001**	Sep 16, 2005
CALCIFEDIOL							
CAPSULE, EXTENDED RELEASE;ORAL							
RAYALDEE							
	+!	OPKO IRELAND GLOBAL	0.03MG	N208010	001	Jun 17, 2016
CALCIPOTRIENE							
AEROSOL, FOAM;TOPICAL							
SORILUX							
	+!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010
CREAM;TOPICAL							
CALCIPOTRIENE							
AB		GLENMARK PHARMS	**0.005%**	**A205772**	**001**	Jun 09, 2015
AB		TOLMAR	**0.005%**	**A200935**	**001**	May 30, 2012
DOVONEX							
AB	**+!**	LEO PHARMA AS	**0.005%**	**N020554**	**001**	Jul 22, 1996
OINTMENT;TOPICAL							
CALCIPOTRIENE							
	!	GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010
SOLUTION;TOPICAL							
CALCIPOTRIENE							
AT		ACP NIMBLE	**0.005%**	**A078468**	**001**	Mar 24, 2011
AT		FOUGERA PHARMS	**0.005%**	**A078305**	**001**	May 06, 2008
AT		HI TECH PHARMA	**0.005%**	**A077579**	**001**	Nov 19, 2009
AT		NOVEL LABS INC	**0.005%**	**A207163**	**001**	Dec 26, 2017
AT	**!**	TOLMAR	**0.005%**	**A077029**	**001**	Nov 20, 2009
CALCITONIN SALMON							
INJECTABLE;INJECTION							
MIACALCIN							
	+!	MYLAN IRELAND LTD	200 IU/ML	N017808	002	Mar 29, 1991
SPRAY, METERED;NASAL							
CALCITONIN-SALMON							
AB	**!**	APOTEX INC	**200 IU/SPRAY**	**A076396**	**001**	Nov 17, 2008
AB		PAR PHARM	**200 IU/SPRAY**	**A076979**	**001**	Jun 08, 2009
CALCITRIOL							
CAPSULE;ORAL							
CALCITRIOL							
AB		AMNEAL PHARMS	**0.25MCG**	**A203289**	**002**	Jun 14, 2017
AB			**0.5MCG**	**A203289**	**001**	Jun 14, 2017
AB		BIONPHARMA INC	**0.25MCG**	**A091174**	**001**	May 24, 2013
AB			**0.5MCG**	**A091174**	**002**	May 24, 2013
AB		HIKMA	**0.25MCG**	**A076917**	**001**	Mar 27, 2006
AB		STRIDES PHARMA	**0.25MCG**	**A091356**	**001**	Dec 12, 2014
AB			**0.5MCG**	**A091356**	**002**	Dec 12, 2014
AB		TEVA	**0.25MCG**	**A075765**	**001**	Oct 12, 2001

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB			**0.5MCG**	**A075765**	**002**	Oct 12, 2001

ROCALTROL

AB	**+**	VALIDUS PHARMS	**0.25MCG**	**N018044**	**001**	
AB	**+!**		**0.5MCG**	**N018044**	**002**	

INJECTABLE;INJECTION

CALCITRIOL

	!	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008

OINTMENT;TOPICAL

VECTICAL

	+!	GALDERMA LABS LP	3MCG/GM	N022087	001	Jan 23, 2009

SOLUTION;ORAL

CALCITRIOL

AA		ELYSIUM	**1MCG/ML**	**A209798**	**001**	Nov 21, 2018
AA		HIKMA	**1MCG/ML**	**A076242**	**001**	Jul 18, 2003

ROCALTROL

AA	**+!**	VALIDUS PHARMS	**1MCG/ML**	**N021068**	**001**	Nov 20, 1998

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB		AMNEAL PHARMS	**667MG**	**A201658**	**001**	Oct 06, 2014
AB		CHARTWELL RX	**667MG**	**A091312**	**001**	Jun 01, 2012
AB		HERITAGE PHARMS INC	**667MG**	**A202315**	**001**	Jun 29, 2015
AB		HIKMA	**667MG**	**A077728**	**001**	Feb 26, 2008
AB		INVAGEN PHARMS	**667MG**	**A203135**	**001**	Feb 07, 2013
AB		LOTUS PHARM CO LTD	**667MG**	**A203298**	**001**	Jul 26, 2016
AB		LUPIN LTD	**667MG**	**A202127**	**001**	Jul 09, 2015
AB		NOSTRUM LABS INC	**667MG**	**A203179**	**001**	Oct 26, 2015

PHOSLO GELCAPS

AB	**+!**	FRESENIUS MEDCL	**667MG**	**N021160**	**003**	Apr 02, 2001

SOLUTION;ORAL

PHOSLYRA

	+!	FRESENIUS MEDCL	667MG/5ML	N022581	001	Apr 18, 2011

TABLET;ORAL

CALCIUM ACETATE

AB		CHARTWELL MOLECULAR	**667MG**	**A202420**	**001**	Feb 05, 2013
AB		HERITAGE PHARMS INC	**667MG**	**A202885**	**001**	Jan 22, 2015
AB	**!**	PADDOCK LLC	**667MG**	**A091561**	**001**	Apr 13, 2011

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP		AM REGENT	**100MG/ML**	**A209088**	**001**	Jul 27, 2017
AP		INTL MEDICATION SYS	**100MG/ML**	**A203477**	**001**	May 09, 2018
AP		MEDEFIL INC	**100MG/ML**	**A211553**	**001**	May 01, 2019

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**100MG/ML**	**N021117**	**001**	Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

BSS PLUS

	+!	ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N018469	001	

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**001**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**004**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**001**	Aug 19, 1992

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**002**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**005**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**002**	Aug 19, 1992

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**003**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**006**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	**18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**003**	Aug 19, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**001**	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**002**	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**004**	Dec 04, 1992

DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**012**	Jan 10, 1989

DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**013**	Jul 11, 1990

DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**014**	Jul 11, 1990

DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**015**	Jul 11, 1990

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**004**	
AT	+		**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**001**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**005**	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**		**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**002**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**006**	
AT	**+**		**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**003**	Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

ELLIOTTS B SOLUTION

	+!	LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	**+**	ICU MEDICAL INC	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017608**	**001**	

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019634**	**003**	Feb 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016679**	**001**	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**006**	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**004**	Apr 05, 1985
AP			**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**005**	Apr 05, 1985
AP	**+**	ICU MEDICAL INC	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019685**	**002**	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**007**	Apr 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**008**	Apr 05, 1985

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

		B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG/100ML;160MG/100ML	N019634	001	Feb 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

		BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	002	Apr 05, 1985
			20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367	003	Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

		BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	001	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+!	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N018895	001	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

BALANCED SALT

AT		AKORN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A075503**	**001**	Sep 27, 2006
AT		B BRAUN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A091387**	**001**	Feb 03, 2010

BSS

AT	**+!**	ALCON	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**N020742**	**001**	Dec 10, 1997

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;3.05GM/1000ML;0.314GM/100 0ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/10	N207026	001	Jan 13, 2015

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**A075323**	**001**	Apr 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	**+!**	HOSPIRA	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**N018608**	**001**	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N020002**	**001**	Apr 17, 1992
AP		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N016693**	**001**	
AP		ICU MEDICAL INC	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018251**	**001**	

SOLUTION;IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018156**	**001**	
AT		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018495**	**001**	Feb 19, 1982
AT		ICU MEDICAL INC	**33MG/100ML;30MG/100ML;860MG/100ML**	**N017635**	**001**	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019632**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016682**	**001**	
AP		FRESENIUS KABI USA	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**A209338**	**001**	Jan 28, 2019
AP		ICU MEDICAL INC	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017641**	**001**	

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	**+!**	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018681**	**001**	Dec 27, 1982
AT		BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018494**	**001**	Feb 19, 1982
AT	**+!**		**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018921**	**001**	Apr 03, 1984
AT	**+!**	ICU MEDICAL INC	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019416**	**001**	Jan 17, 1986

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017
+!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017
+!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017

CALCIUM GLUCONATE IN SODIUM CHLORIDE

+!	HQ SPCLT PHARMA	1GM/50ML (20MG/ML)	N210906	001	Oct 29, 2018
+!		2GM/100ML (20MG/ML)	N210906	002	Oct 29, 2018

CALFACTANT

SUSPENSION;INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+!	ONY	35MG/ML	N020521	001	Jul 01, 1998

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

+	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
+!		300MG	N204042	002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

INVOKAMET

+	JANSSEN PHARMS	50MG;500MG	N204353	001	Aug 08, 2014
+		50MG;1GM	N204353	002	Aug 08, 2014
+		150MG;500MG	N204353	003	Aug 08, 2014
+!		150MG;1GM	N204353	004	Aug 08, 2014

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

+	JANSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016
+		50MG;1GM	N205879	002	Sep 20, 2016
+		150MG;500MG	N205879	003	Sep 20, 2016
+!		150MG;1GM	N205879	004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET;ORAL

ATACAND

AB	**+**	ANI PHARMS INC	**4MG**	**N020838**	**001**	Jun 04, 1998
AB	**+**		**8MG**	**N020838**	**002**	Jun 04, 1998
AB	**+**		**16MG**	**N020838**	**003**	Jun 04, 1998
AB	**+!**		**32MG**	**N020838**	**004**	Jun 04, 1998

CANDESARTAN CILEXETIL

AB		ALEMBIC PHARMS LTD	**4MG**	**A210302**	**001**	Dec 04, 2018
AB			**8MG**	**A210302**	**002**	Dec 04, 2018
AB			**16MG**	**A210302**	**003**	Dec 04, 2018
AB			**32MG**	**A209119**	**001**	Jun 20, 2017
AB		MACLEODS PHARMS LTD	**4MG**	**A203813**	**001**	Dec 05, 2016
AB			**8MG**	**A203813**	**002**	Dec 05, 2016
AB			**16MG**	**A203813**	**003**	Dec 05, 2016
AB			**32MG**	**A203813**	**004**	Dec 05, 2016
AB		MYLAN	**4MG**	**A078702**	**001**	May 03, 2013
AB			**8MG**	**A078702**	**002**	May 03, 2013
AB			**16MG**	**A078702**	**003**	May 03, 2013
AB			**32MG**	**A078702**	**004**	May 03, 2013
AB		ZYDUS PHARMS	**4MG**	**A091390**	**001**	Aug 23, 2017
AB			**8MG**	**A091390**	**002**	Aug 23, 2017
AB			**16MG**	**A091390**	**003**	Aug 23, 2017
AB			**32MG**	**A091390**	**004**	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ATACAND HCT

AB	**+**	ANI PHARMS INC	**16MG;12.5MG**	**N021093**	**001**	Sep 05, 2000
AB	**+**		**32MG;12.5MG**	**N021093**	**002**	Sep 05, 2000
AB	**+!**		**32MG;25MG**	**N021093**	**003**	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		DR REDDYS LABS LTD	**16MG;12.5MG**	**A202965**	**001**	Jun 03, 2013
AB			**32MG;12.5MG**	**A202965**	**002**	Jun 03, 2013
AB			**32MG;25MG**	**A202965**	**003**	Jun 03, 2013
AB		MACLEODS PHARMS LTD	**16MG;12.5MG**	**A204100**	**001**	Feb 27, 2015
AB			**32MG;12.5MG**	**A204100**	**002**	Feb 27, 2015
AB			**32MG;25MG**	**A204100**	**003**	Feb 27, 2015
AB		MYLAN	**16MG;12.5MG**	**A090704**	**001**	Dec 04, 2012
AB			**32MG;12.5MG**	**A090704**	**002**	Dec 04, 2012
AB			**32MG;25MG**	**A090704**	**003**	Dec 04, 2012
AB		PRINSTON INC	**16MG;12.5MG**	**A207455**	**001**	Apr 11, 2018
AB			**32MG;12.5MG**	**A207455**	**002**	Apr 11, 2018
AB			**32MG;25MG**	**A207455**	**003**	Apr 11, 2018
AB		ZYDUS PHARMS	**16MG;12.5MG**	**A203466**	**001**	Nov 27, 2017
AB			**32MG;12.5MG**	**A203466**	**002**	Nov 27, 2017
AB			**32MG;25MG**	**A203466**	**003**	Nov 27, 2017

CANGRELOR

POWDER;INTRAVENOUS

KENGREAL

+!	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015

CANNABIDIOL

SOLUTION;ORAL

EPIDIOLEX

+!	GW RES LTD	100MG/ML	N210365	001	Sep 28, 2018

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		ACCORD HLTHCARE	**150MG**	**A202593**	**001**	Apr 23, 2015
AB			**500MG**	**A202593**	**002**	Apr 23, 2015
AB		ALKEM LABS LTD	**150MG**	**A207652**	**001**	Nov 24, 2017
AB			**500MG**	**A207652**	**002**	Nov 24, 2017
AB		AMNEAL PHARMS	**150MG**	**A204741**	**001**	Feb 28, 2017
AB			**500MG**	**A204741**	**002**	Feb 28, 2017
AB		EUGIA PHARMA	**150MG**	**A210604**	**001**	Apr 17, 2018
AB			**500MG**	**A210604**	**002**	Apr 17, 2018
AB		HIKMA	**150MG**	**A200483**	**001**	Jul 14, 2016
AB			**500MG**	**A200483**	**002**	Jul 14, 2016
AB		MSN	**150MG**	**A209365**	**001**	Jul 02, 2018
AB			**500MG**	**A209365**	**002**	Jul 02, 2018
AB		MYLAN	**150MG**	**A090943**	**001**	Aug 08, 2014
AB			**500MG**	**A090943**	**002**	Aug 08, 2014
AB		SHILPA MEDICARE LTD	**150MG**	**A207456**	**001**	Dec 12, 2016
AB			**500MG**	**A207456**	**002**	Dec 12, 2016
AB		SUN PHARM	**150MG**	**A204668**	**001**	Jun 21, 2019
AB			**500MG**	**A204668**	**002**	Jun 21, 2019
AB		TEVA PHARMS USA	**150MG**	**A091649**	**001**	Sep 16, 2013
AB			**500MG**	**A091649**	**002**	Sep 16, 2013

XELODA

AB	**+**	HOFFMANN LA ROCHE	**150MG**	**N020896**	**001**	Apr 30, 1998
AB	**+!**		**500MG**	**N020896**	**002**	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION

CAPASTAT SULFATE

AP	**+!**	AKORN	**EQ 1GM BASE/VIAL**	**N050095**	**001**	

CAPREOMYCIN SULFATE

AP		HISUN PHARM HANGZHOU	**EQ 1GM BASE/VIAL**	**A204796**	**001**	Oct 18, 2018
AP		MYLAN LABS LTD	**EQ 1GM BASE/VIAL**	**A202634**	**001**	Nov 27, 2017

CAPSAICIN

PATCH;TOPICAL

QUTENZA

	+!	AVERITAS	8%	N022395	001	Nov 16, 2009

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB		AJANTA PHARMA LTD	**12.5MG**	**A212809**	**001**	Dec 13, 2019
AB			**25MG**	**A212809**	**002**	Dec 13, 2019
AB			**50MG**	**A212809**	**003**	Dec 13, 2019
AB			**100MG**	**A212809**	**004**	Dec 13, 2019
AB		BOSCOGEN	**12.5MG**	**A074677**	**004**	May 30, 1997
AB			**25MG**	**A074677**	**002**	May 30, 1997
AB			**50MG**	**A074677**	**001**	May 30, 1997
AB			**100MG**	**A074677**	**003**	May 30, 1997
AB		HIKMA INTL PHARMS	**12.5MG**	**A074505**	**001**	Feb 13, 1996
AB			**25MG**	**A074505**	**002**	Feb 13, 1996
AB			**50MG**	**A074505**	**003**	Feb 13, 1996
AB			**100MG**	**A074505**	**004**	Feb 13, 1996
AB		MYLAN	**12.5MG**	**A074434**	**001**	Feb 13, 1996
AB			**25MG**	**A074434**	**002**	Feb 13, 1996
AB			**50MG**	**A074434**	**003**	Feb 13, 1996
AB	**!**		**100MG**	**A074434**	**004**	Feb 13, 1996
AB		PRINSTON INC	**12.5MG**	**A074477**	**001**	Feb 13, 1996
AB			**25MG**	**A074477**	**002**	Feb 13, 1996
AB			**50MG**	**A074477**	**003**	Feb 13, 1996
AB			**100MG**	**A074477**	**004**	Feb 13, 1996
AB		SETON PHARMS	**12.5MG**	**A212223**	**001**	Oct 30, 2019
AB			**25MG**	**A212223**	**002**	Oct 30, 2019
AB			**50MG**	**A212223**	**003**	Oct 30, 2019
AB			**100MG**	**A212223**	**004**	Oct 30, 2019
AB		TEVA	**12.5MG**	**A074322**	**001**	Feb 13, 1996
AB			**25MG**	**A074322**	**002**	Feb 13, 1996
AB			**50MG**	**A074322**	**003**	Feb 13, 1996
AB			**100MG**	**A074322**	**004**	Feb 13, 1996
AB		WATSON LABS	**12.5MG**	**A074386**	**001**	May 23, 1996
AB			**25MG**	**A074386**	**002**	May 23, 1996

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB			**50MG**	**A074386**	**003**	May 23, 1996
AB			**100MG**	**A074386**	**004**	May 23, 1996
AB		WOCKHARDT LTD	**12.5MG**	**A074532**	**001**	Mar 28, 1997
AB			**25MG**	**A074532**	**002**	Mar 28, 1997
AB			**50MG**	**A074532**	**003**	Mar 28, 1997
AB			**100MG**	**A074532**	**004**	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	MYLAN	25MG;15MG	A074896	001	Dec 29, 1997
!		25MG;25MG	A074896	002	Dec 29, 1997
!		50MG;15MG	A074896	004	Dec 29, 1997
		50MG;25MG	A074896	003	Dec 29, 1997

CARBACHOL

SOLUTION;INTRAOCULAR

MIOSTAT

+!	ALCON	0.01%	N016968	001	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		APOTEX INC	**100MG**	**A078986**	**001**	Nov 25, 2011
AB			**200MG**	**A078986**	**002**	Nov 25, 2011
AB			**300MG**	**A078986**	**003**	Nov 25, 2011
AB		TARO	**100MG**	**A201106**	**001**	Jun 21, 2013
AB			**200MG**	**A201106**	**002**	Jun 21, 2013
AB			**300MG**	**A201106**	**003**	Jun 21, 2013
AB		TEVA PHARMS	**100MG**	**A078592**	**001**	Sep 20, 2012
AB			**200MG**	**A078592**	**002**	Sep 20, 2012
AB			**300MG**	**A078592**	**003**	Sep 20, 2012

CARBATROL

AB	**+**	SHIRE DEV LLC	**100MG**	**N020712**	**003**	Sep 30, 1997
AB	**+**		**200MG**	**N020712**	**001**	Sep 30, 1997
AB	**+!**		**300MG**	**N020712**	**002**	Sep 30, 1997

EQUETRO

	+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004
	+		200MG	N021710	002	Dec 10, 2004
	+!		300MG	N021710	003	Dec 10, 2004

SUSPENSION;ORAL

CARBAMAZEPINE

AB		WOCKHARDT BIO AG	**100MG/5ML**	**A075714**	**001**	Jun 05, 2002

TEGRETOL

AB	**+!**	NOVARTIS	**100MG/5ML**	**N018927**	**001**	Dec 18, 1987

TERIL

AB		TARO	**100MG/5ML**	**A076729**	**001**	Sep 20, 2004

TABLET;ORAL

CARBAMAZEPINE

AB		APOTEX INC	**200MG**	**A075948**	**001**	Feb 27, 2002
AB		TARO	**200MG**	**A074649**	**001**	Oct 03, 1996
AB		TORRENT PHARMS	**200MG**	**A077272**	**002**	Dec 07, 2005

EPITOL

AB		TEVA	**200MG**	**A070541**	**001**	Sep 17, 1986

TEGRETOL

AB	**+!**	NOVARTIS	**200MG**	**N016608**	**001**	

CARBAMAZEPINE

		TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005
			300MG	A077272	003	Dec 07, 2005
			400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

AB		TARO PHARM INDS	**100MG**	**A075687**	**001**	Oct 24, 2000
AB		TORRENT PHARMS	**100MG**	**A075712**	**001**	Jul 05, 2001

EPITOL

AB		TEVA	**100MG**	**A073524**	**001**	Jul 29, 1992

TEGRETOL

AB	**+!**	NOVARTIS	**100MG**	**N018281**	**001**	

CARBAMAZEPINE

	!	TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

CARBAMAZEPINE

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		TARO	**100MG**	**A078115**	**001**	Mar 31, 2009
AB			**200MG**	**A078115**	**002**	Mar 31, 2009
AB			**400MG**	**A078115**	**003**	Mar 31, 2009
AB		ZYDUS PHARMS	**100MG**	**A205571**	**001**	Feb 07, 2019
AB			**200MG**	**A205571**	**002**	Feb 07, 2019
AB			**400MG**	**A205571**	**003**	Feb 07, 2019

TEGRETOL-XR

AB	**+**	NOVARTIS	**100MG**	**N020234**	**001**	Mar 25, 1996
AB	**+**		**200MG**	**N020234**	**002**	Mar 25, 1996
AB	**+!**		**400MG**	**N020234**	**003**	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB		ALVOGEN	**25MG**	**A204291**	**001**	Jan 08, 2016
AB		AMERIGEN PHARMS LTD	**25MG**	**A203261**	**001**	Mar 10, 2014
AB		AUROBINDO PHARMA LTD	**25MG**	**A211055**	**001**	Oct 21, 2019
AB		EDENBRIDGE PHARMS	**25MG**	**A205304**	**001**	Feb 17, 2016
AB		NOVEL LABS INC	**25MG**	**A204763**	**001**	Oct 20, 2017
AB		ZYDUS PHARMS	**25MG**	**A209910**	**001**	May 07, 2018

LODOSYN

AB	**+!**	ATON	**25MG**	**N017830**	**001**	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		SUN PHARM	**25MG;200MG;100MG**	**A079085**	**001**	May 10, 2012
AB			**37.5MG;200MG;150MG**	**A079085**	**002**	May 10, 2012

STALEVO 100

AB	**+**	ORION PHARMA	**25MG;200MG;100MG**	**N021485**	**002**	Jun 11, 2003

STALEVO 150

AB	**+**	ORION PHARMA	**37.5MG;200MG;150MG**	**N021485**	**003**	Jun 11, 2003

STALEVO 125

	+	ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008

STALEVO 200

	+!	ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007

STALEVO 50

	+!	ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003

STALEVO 75

	+	ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

RYTARY

	+	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015
	+		36.25MG;145MG	N203312	002	Jan 07, 2015
	+		48.75MG;195MG	N203312	003	Jan 07, 2015
	+!		61.25MG;245MG	N203312	004	Jan 07, 2015

SUSPENSION;ENTERAL

DUOPA

	+!	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015

TABLET;ORAL

CARBIDOPA AND LEVODOPA

AB		ACTAVIS ELIZABETH	**10MG;100MG**	**A074260**	**001**	Sep 03, 1993
AB			**25MG;100MG**	**A074260**	**002**	Sep 03, 1993
AB			**25MG;250MG**	**A074260**	**003**	Sep 03, 1993
AB		APOTEX INC	**10MG;100MG**	**A077120**	**001**	Jun 02, 2008
AB			**25MG;100MG**	**A077120**	**002**	Jun 02, 2008
AB			**25MG;250MG**	**A077120**	**003**	Jun 02, 2008
AB		MAYNE PHARMA	**10MG;100MG**	**A073618**	**001**	Aug 28, 1992
AB			**25MG;100MG**	**A073589**	**001**	Aug 28, 1992
AB			**25MG;250MG**	**A073607**	**001**	Aug 28, 1992
AB		MYLAN	**10MG;100MG**	**A090324**	**001**	Sep 28, 2009
AB			**25MG;100MG**	**A090324**	**002**	Sep 28, 2009
AB			**25MG;250MG**	**A090324**	**003**	Sep 28, 2009
AB		SUN PHARM INDS	**10MG;100MG**	**A078536**	**001**	Oct 28, 2008
AB			**25MG;100MG**	**A078536**	**002**	Oct 28, 2008
AB			**25MG;250MG**	**A078536**	**003**	Oct 28, 2008

SINEMET

AB	**+**	MERCK SHARP DOHME	**10MG;100MG**	**N017555**	**001**	

CARBIDOPA; LEVODOPA

TABLET;ORAL

SINEMET

AB	**+**		**25MG;100MG**	**N017555**	**003**	
AB	**+!**		**25MG;250MG**	**N017555**	**002**	

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB		ACCORD HLTHCARE	**25MG;100MG**	**A202323**	**001**	Feb 08, 2013
AB			**50MG;200MG**	**A202323**	**002**	Feb 08, 2013
AB		ALEMBIC PHARMS LTD	**25MG;100MG**	**A210341**	**001**	Jun 05, 2019
AB			**50MG;200MG**	**A210341**	**002**	Jun 05, 2019
AB		APOTEX	**25MG;100MG**	**A076212**	**001**	Jun 16, 2004
AB			**50MG;200MG**	**A076212**	**002**	Jun 16, 2004
AB		IMPAX LABS	**25MG;100MG**	**A076521**	**001**	May 14, 2004
AB			**50MG;200MG**	**A076521**	**002**	May 14, 2004
AB		MYLAN	**25MG;100MG**	**A075091**	**002**	Apr 21, 2000
AB			**50MG;200MG**	**A075091**	**001**	Sep 30, 1999
AB		SUN PHARM INDS	**25MG;100MG**	**A077828**	**001**	Aug 23, 2007
AB	**!**		**50MG;200MG**	**A077828**	**002**	Aug 23, 2007

SINEMET CR

AB	**+**	MERCK SHARP DOHME	**25MG;100MG**	**N019856**	**002**	Dec 24, 1992

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

AB		MYLAN	**10MG;100MG**	**A078893**	**001**	Sep 18, 2008
AB			**25MG;100MG**	**A078893**	**002**	Sep 18, 2008
AB	**!**		**25MG;250MG**	**A078893**	**003**	Sep 18, 2008
AB		SUN PHARM	**10MG;100MG**	**A078690**	**001**	Jul 31, 2009
AB			**25MG;100MG**	**A078690**	**002**	Jul 31, 2009
AB			**25MG;250MG**	**A078690**	**003**	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

	!	MIKART	4MG/5ML	A040458	001	Apr 25, 2003

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

	+!	AYTU	4MG/5ML	N022556	001	Mar 28, 2013

TABLET;ORAL

CARBINOXAMINE MALEATE

AA		INVAGEN PHARMS	**4MG**	**A090435**	**001**	Apr 15, 2010
AA	**!**	MIKART	**4MG**	**A040442**	**001**	Mar 19, 2003
AA		MISSION PHARMACAL CO	**4MG**	**A090756**	**001**	May 27, 2011
	!	MIKART	6MG	A207484	001	May 31, 2016

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP		ACCORD HLTHCARE	**50MG/5ML (10MG/ML)**	**A206775**	**001**	Feb 09, 2017
AP			**150MG/15ML (10MG/ML)**	**A206775**	**002**	Feb 09, 2017
AP			**450MG/45ML (10MG/ML)**	**A206775**	**003**	Feb 09, 2017
AP			**600MG/60ML (10MG/ML)**	**A206775**	**004**	Feb 09, 2017
AP		AKORN	**50MG/5ML (10MG/ML)**	**A090475**	**001**	Jul 29, 2009
AP			**150MG/15ML (10MG/ML)**	**A090475**	**002**	Jul 29, 2009
AP			**450MG/45ML (10MG/ML)**	**A090475**	**003**	Jul 29, 2009
AP			**600MG/60ML (10MG/ML)**	**A091268**	**002**	Jul 28, 2010
AP		CIPLA LTD	**50MG/5ML (10MG/ML)**	**A077861**	**001**	Jan 18, 2007
AP			**150MG/15ML (10MG/ML)**	**A077861**	**002**	Jan 18, 2007
AP			**450MG/45ML (10MG/ML)**	**A077861**	**003**	Jan 18, 2007
AP			**600MG/60ML (10MG/ML)**	**A077861**	**004**	Jan 18, 2007
AP		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A205487**	**001**	Mar 28, 2016
AP			**150MG/15ML (10MG/ML)**	**A205487**	**002**	Mar 28, 2016
AP			**450MG/45ML (10MG/ML)**	**A205487**	**003**	Mar 28, 2016
AP		FRESENIUS KABI USA	**450MG/45ML (10MG/ML)**	**A077247**	**003**	Oct 21, 2004
AP			**450MG/45ML (10MG/ML)**	**A077266**	**003**	Feb 15, 2006
AP			**600MG/60ML (10MG/ML)**	**A077266**	**004**	Feb 15, 2006
AP		GLAND PHARMA LTD	**150MG/15ML (10MG/ML)**	**A207324**	**002**	Feb 15, 2017
AP			**450MG/45ML (10MG/ML)**	**A207324**	**003**	Feb 15, 2017
AP			**600MG/60ML (10MG/ML)**	**A207324**	**004**	Feb 15, 2017
AP		HOSPIRA	**50MG/5ML (10MG/ML)**	**A076517**	**001**	Oct 14, 2004
AP			**150MG/15ML (10MG/ML)**	**A076517**	**002**	Oct 14, 2004
AP			**450MG/45ML (10MG/ML)**	**A076517**	**003**	Oct 14, 2004
AP			**600MG/60ML (10MG/ML)**	**A077059**	**001**	Nov 23, 2004
AP		INGENUS PHARMS LLC	**50MG/5ML (10MG/ML)**	**A208487**	**001**	Apr 26, 2017

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP			**150MG/15ML (10MG/ML)**	**A208487**	**002**	Apr 26, 2017
AP			**450MG/45ML (10MG/ML)**	**A208487**	**003**	Apr 26, 2017
AP			**600MG/60ML (10MG/ML)**	**A208487**	**004**	Apr 26, 2017
AP		MEITHEAL	**50MG/5ML (10MG/ML)**	**A077096**	**001**	Jun 14, 2005
AP			**150MG/15ML (10MG/ML)**	**A077096**	**002**	Jun 14, 2005
AP			**450MG/45ML (10MG/ML)**	**A077096**	**003**	Jun 14, 2005
AP			**600MG/60ML (10MG/ML)**	**A077096**	**004**	Jun 03, 2013
AP	!	PHARMACHEMIE BV	**50MG/5ML (10MG/ML)**	**A077269**	**001**	Oct 14, 2004
AP	!		**150MG/15ML (10MG/ML)**	**A077269**	**002**	Oct 14, 2004
AP	!		**450MG/45ML (10MG/ML)**	**A077269**	**003**	Oct 14, 2004
AP	!		**600MG/60ML (10MG/ML)**	**A077269**	**004**	Dec 28, 2007
AP		PLIVA LACHEMA	**50MG/5ML (10MG/ML)**	**A078631**	**001**	Dec 02, 2008
AP			**150MG/15ML (10MG/ML)**	**A078631**	**002**	Dec 02, 2008
AP			**450MG/45ML (10MG/ML)**	**A078631**	**003**	Dec 02, 2008
AP			**600MG/60ML (10MG/ML)**	**A078631**	**004**	Dec 02, 2008
AP		SANDOZ INC	**50MG/5ML (10MG/ML)**	**A078280**	**001**	May 08, 2008
AP			**150MG/15ML (10MG/ML)**	**A078280**	**002**	May 08, 2008
AP			**450MG/45ML (10MG/ML)**	**A078280**	**003**	May 08, 2008
AP		SUN PHARM	**50MG/5ML (10MG/ML)**	**A077926**	**001**	Sep 19, 2008
AP			**150MG/15ML (10MG/ML)**	**A077926**	**002**	Sep 19, 2008
AP			**450MG/45ML (10MG/ML)**	**A077926**	**003**	Sep 19, 2008
AP	!	TEVA PHARMS USA	**50MG/5ML (10MG/ML)**	**A077139**	**001**	Sep 21, 2005
AP	!		**150MG/15ML (10MG/ML)**	**A077139**	**002**	Sep 21, 2005
AP	!		**450MG/45ML (10MG/ML)**	**A077139**	**003**	Sep 21, 2005
AP	!		**600MG/60ML (10MG/ML)**	**A077139**	**004**	Sep 21, 2005
AP		WEST-WARD PHARMS INT	**50MG/5ML (10MG/ML)**	**A077244**	**001**	Oct 15, 2004
AP			**150MG/15ML (10MG/ML)**	**A077244**	**002**	Oct 15, 2004
AP			**450MG/45ML (10MG/ML)**	**A077244**	**003**	Oct 15, 2004
AP			**600MG/60ML (10MG/ML)**	**A077244**	**004**	Jan 20, 2006

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP		GLAND PHARMA LTD	**50MG/5ML (10MG/ML)**	**A207324**	**001**	Feb 15, 2017

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP		DR REDDYS LABS LTD	**EQ 0.25MG BASE/ML**	**A211941**	**001**	Jul 02, 2019

HEMABATE

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 0.25MG BASE/ML**	**N017989**	**001**	

CARFILZOMIB

POWDER;INTRAVENOUS

CARFILZOMIB

AP		DR REDDYS	**60MG/VIAL**	**A209422**	**001**	Sep 09, 2019

KYPROLIS

AP	**+!**	ONYX THERAP	**60MG/VIAL**	**N202714**	**001**	Jul 20, 2012
	+		10MG/VIAL	N202714	003	Jun 07, 2018
	+		30MG/VIAL	N202714	002	Jun 03, 2016

CARGLUMIC ACID

TABLET;ORAL

CARBAGLU

	+!	RECORDATI RARE	200MG	N022562	001	Mar 18, 2010

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

VRAYLAR

	+	ALLERGAN	EQ 1.5MG BASE	N204370	001	Sep 17, 2015
	+		EQ 3MG BASE	N204370	002	Sep 17, 2015
	+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015
	+!		EQ 6MG BASE	N204370	004	Sep 17, 2015

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA		ACCELRX LABS	**350MG**	**A040576**	**001**	Jun 07, 2005
AA		ALLIED	**350MG**	**A040245**	**001**	Sep 08, 1997
AA		AUROBINDO PHARMA	**350MG**	**A040792**	**001**	Aug 06, 2009
AA		HIKMA INTL PHARMS	**350MG**	**A040124**	**001**	Jan 24, 1996
AA		NATCO PHARMA LTD	**350MG**	**A090988**	**001**	Oct 28, 2014

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA		NOVAST LABS	**350MG**	**A040823**	**001**	Oct 22, 2008
AA		ORIENT PHARMA CO LTD	**350MG**	**A205085**	**001**	Oct 28, 2014
AA		SCIEGEN PHARMS INC	**350MG**	**A203374**	**001**	Jan 27, 2014
AA		STRIDES PHARMA	**350MG**	**A205513**	**002**	Nov 12, 2015
AA		WATSON LABS	**350MG**	**A087499**	**001**	Apr 20, 1982
AA		WILSHIRE PHARMS INC	**350MG**	**A205126**	**002**	Jul 08, 2015

SOMA

AA	**+**	MYLAN SPECIALITY LP	**350MG**	**N011792**	**001**	

CARISOPRODOL

AB		AUROBINDO PHARMA	**250MG**	**A040792**	**002**	Nov 08, 2016
AB		NOSTRUM LABS INC	**250MG**	**A207237**	**001**	May 11, 2017
AB		STRIDES PHARMA	**250MG**	**A205513**	**001**	Nov 12, 2015
AB		WILSHIRE PHARMS INC	**250MG**	**A205126**	**001**	Jul 08, 2015

SOMA

AB	**+!**	MYLAN SPECIALITY LP	**250MG**	**N011792**	**004**	Sep 13, 2007

CARMUSTINE

IMPLANT;INTRACRANIAL

GLIADEL

	+!	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996

INJECTABLE;INJECTION

BICNU

AP	**+!**	EMCURE PHARMS LTD	**100MG/VIAL**	**N017422**	**001**	

CARMUSTINE

AP		AMNEAL	**100MG/VIAL**	**A211229**	**001**	Oct 16, 2018
AP		NAVINTA LLC	**100MG/VIAL**	**A210179**	**001**	Sep 11, 2018
AP		STI PHARMA LLC	**100MG/VIAL**	**A209278**	**001**	Apr 02, 2019

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

	!	SANDOZ INC	1%	A075476	001	Jan 03, 2000

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB		AUROBINDO PHARMA	**3.125MG**	**A078332**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078332**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078332**	**003**	Sep 05, 2007
AB			**25MG**	**A078332**	**004**	Sep 05, 2007
AB		BEXIMCO USA	**3.125MG**	**A078384**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078384**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078384**	**003**	Sep 05, 2007
AB			**25MG**	**A078384**	**004**	Sep 05, 2007
AB		CHARTWELL MOLECULAR	**3.125MG**	**A077474**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077474**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077474**	**003**	Sep 05, 2007
AB			**25MG**	**A077474**	**004**	Sep 05, 2007
AB		DR REDDYS LABS LTD	**3.125MG**	**A076649**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076649**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076649**	**003**	Sep 05, 2007
AB			**25MG**	**A076649**	**004**	Sep 05, 2007
AB		GLENMARK GENERICS	**3.125MG**	**A078251**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078251**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078251**	**003**	Sep 05, 2007
AB			**25MG**	**A078251**	**004**	Sep 05, 2007
AB		LUPIN	**3.125MG**	**A078217**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078217**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078217**	**003**	Sep 05, 2007
AB			**25MG**	**A078217**	**004**	Sep 05, 2007
AB		MYLAN	**3.125MG**	**A077316**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077316**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077316**	**003**	Sep 05, 2007
AB			**25MG**	**A077316**	**004**	Sep 05, 2007
AB		RUBICON	**3.125MG**	**A078165**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078165**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078165**	**003**	Sep 05, 2007
AB			**25MG**	**A078165**	**004**	Sep 05, 2007
AB		SANDOZ	**3.125MG**	**A078227**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078227**	**002**	Sep 05, 2007

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB			**12.5MG**	**A078227**	**003**	Sep 05, 2007
AB			**25MG**	**A078227**	**004**	Sep 05, 2007
AB		SUN PHARM INDS LTD	**3.125MG**	**A076989**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076989**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076989**	**003**	Sep 05, 2007
AB			**25MG**	**A076989**	**004**	Sep 05, 2007
AB		TARO	**3.125MG**	**A077780**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077780**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077780**	**003**	Sep 05, 2007
AB			**25MG**	**A077780**	**004**	Sep 05, 2007
AB		TEVA	**3.125MG**	**A076373**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076373**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076373**	**003**	Sep 05, 2007
AB			**25MG**	**A076373**	**004**	Sep 05, 2007
AB		ZYDUS PHARMS USA INC	**3.125MG**	**A077614**	**004**	Sep 05, 2007
AB			**6.25MG**	**A077614**	**001**	Sep 05, 2007
AB			**12.5MG**	**A077614**	**002**	Sep 05, 2007
AB			**25MG**	**A077614**	**003**	Sep 05, 2007

COREG

AB	+	SMITHKLINE BEECHAM	**3.125MG**	**N020297**	**004**	May 29, 1997
AB	+		**6.25MG**	**N020297**	**003**	Sep 14, 1995
AB	+!		**12.5MG**	**N020297**	**002**	Sep 14, 1995
AB	+		**25MG**	**N020297**	**001**	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

CARVEDILOL PHOSPHATE

AB		IMPAX LABS INC	**10MG**	**A204717**	**001**	May 07, 2018
AB			**20MG**	**A204717**	**002**	May 07, 2018
AB			**40MG**	**A204717**	**003**	May 07, 2018
AB			**80MG**	**A204717**	**004**	May 07, 2018
AB		SUN PHARM INDUSTRIES	**10MG**	**A090132**	**001**	Oct 25, 2017
AB			**20MG**	**A090132**	**002**	Oct 25, 2017
AB			**40MG**	**A090132**	**003**	Oct 25, 2017
AB			**80MG**	**A090132**	**004**	Oct 25, 2017

COREG CR

AB	+	SMITHKLINE BEECHAM	**10MG**	**N022012**	**001**	Oct 20, 2006
AB	+		**20MG**	**N022012**	**002**	Oct 20, 2006
AB	+!		**40MG**	**N022012**	**003**	Oct 20, 2006
AB	+		**80MG**	**N022012**	**004**	Oct 20, 2006

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CANCIDAS

AP	+!	MERCK	**50MG/VIAL**	**N021227**	**001**	Jan 26, 2001
AP	+!		**70MG/VIAL**	**N021227**	**002**	Jan 26, 2001

CASPOFUNGIN ACETATE

AP		FRESENIUS KABI USA	**50MG/VIAL**	**N206110**	**001**	Dec 30, 2016
AP			**70MG/VIAL**	**N206110**	**002**	Dec 30, 2016
AP		GLAND PHARMA LTD	**50MG/VIAL**	**A207092**	**001**	Sep 29, 2017
AP			**70MG/VIAL**	**A207092**	**002**	Sep 29, 2017
AP		JIANGSU HENGRUI MED	**50MG/VIAL**	**A200833**	**001**	Jun 28, 2018
AP			**70MG/VIAL**	**A200833**	**002**	Jun 28, 2018
AP		MYLAN LABS LTD	**50MG/VIAL**	**A207650**	**001**	Sep 29, 2017
AP			**70MG/VIAL**	**A207650**	**002**	Sep 29, 2017
AP		XELLIA PHARMS APS	**50MG/VIAL**	**A205923**	**001**	Jul 02, 2018
AP			**70MG/VIAL**	**A205923**	**002**	Jul 02, 2018

CEFACLOR

CAPSULE;ORAL

CEFACLOR

AB		HIKMA	**EQ 250MG BASE**	**A065350**	**001**	Apr 03, 2007
AB	!		**EQ 500MG BASE**	**A065350**	**002**	Apr 03, 2007
AB		YUNG SHIN PHARM	**EQ 250MG BASE**	**A065146**	**001**	Jan 22, 2004
AB			**EQ 500MG BASE**	**A065146**	**002**	Jan 22, 2004

FOR SUSPENSION;ORAL

CEFACLOR

	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012
		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012

CEFACLOR

FOR SUSPENSION;ORAL

CEFACLOR

		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012
	!	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012

TABLET, EXTENDED RELEASE;ORAL

CEFACLOR

	TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
	!	EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A065352**	**001**	Jan 25, 2007
AB		HIKMA	**EQ 500MG BASE**	**A065311**	**001**	Feb 07, 2006
AB		LUPIN	**EQ 500MG BASE**	**A065392**	**001**	May 29, 2007
AB		ORCHID HLTHCARE	**EQ 500MG BASE**	**A065309**	**001**	Sep 18, 2006
AB	**!**	TEVA PHARMS	**EQ 500MG BASE**	**A065282**	**001**	Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXIL

AB		AUROBINDO	**EQ 250MG BASE/5ML**	**A065349**	**001**	Apr 25, 2013
AB			**EQ 500MG BASE/5ML**	**A065349**	**002**	Apr 25, 2013
AB		HIKMA PHARMS	**EQ 250MG BASE/5ML**	**A091036**	**001**	Nov 28, 2012
AB			**EQ 500MG BASE/5ML**	**A091036**	**002**	Nov 28, 2012
AB		LUPIN	**EQ 250MG BASE/5ML**	**A065396**	**001**	Feb 21, 2008
AB	**!**		**EQ 500MG BASE/5ML**	**A065396**	**002**	Feb 21, 2008
AB		ORCHID HLTHCARE	**EQ 250MG BASE/5ML**	**A065307**	**002**	Oct 16, 2006
AB			**EQ 500MG BASE/5ML**	**A065307**	**003**	Oct 16, 2006

TABLET;ORAL

CEFADROXIL

AB		HIKMA	**EQ 1GM BASE**	**A065260**	**001**	Mar 30, 2006
AB		ORCHID HLTHCARE	**EQ 1GM BASE**	**A065301**	**001**	Sep 18, 2006
	!	TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065303**	**001**	Oct 22, 2008
AP			**EQ 1GM BASE/VIAL**	**A065303**	**002**	Oct 22, 2008
AP			**EQ 10GM BASE/VIAL**	**A065306**	**001**	Oct 22, 2008
AP	**!**	HIKMA FARMACEUTICA	**EQ 500MG BASE/VIAL**	**A065047**	**001**	Sep 18, 2001
AP	**!**		**EQ 1GM BASE/VIAL**	**A065047**	**002**	Sep 18, 2001
AP			**EQ 10GM BASE/VIAL**	**A065143**	**001**	Oct 18, 2004
AP		QILU	**EQ 1GM BASE/VIAL**	**A203661**	**001**	Dec 28, 2015
AP	**!**		**EQ 10GM BASE/VIAL**	**A209217**	**001**	Oct 17, 2018
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A062831**	**001**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A062831**	**002**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A065345**	**001**	May 09, 2007
AP			**EQ 10GM BASE/VIAL**	**A062831**	**003**	Sep 25, 1992

ANCEF IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A063002	002	Mar 28, 1991

CEFAZOLIN AND DEXTROSE

+!	B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
+		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012

CEFAZOLIN SODIUM

!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014
!	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
!		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

	BAXTER HLTHCARE CORP	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015

CEFDINIR

CAPSULE;ORAL

CEFDINIR

AB		AUROBINDO PHARMA	**300MG**	**A065434**	**001**	Jan 07, 2008
AB		LUPIN	**300MG**	**A065264**	**001**	May 19, 2006
AB		ORCHID HLTHCARE	**300MG**	**A065418**	**001**	Jul 18, 2007
AB	**!**	SANDOZ	**300MG**	**A065330**	**001**	Apr 06, 2007
AB		TEVA PHARMS	**300MG**	**A065368**	**001**	May 09, 2007

FOR SUSPENSION;ORAL

CEFDINIR

AB		AUROBINDO PHARMA	**125MG/5ML**	**A065473**	**001**	Dec 14, 2007

CEFDINIR

FOR SUSPENSION;ORAL

CEFDINIR

AB			**250MG/5ML**	**A065473**	**002**	Dec 14, 2007
AB		LUPIN	**125MG/5ML**	**A065259**	**001**	May 31, 2006
AB			**250MG/5ML**	**A065259**	**002**	May 07, 2007
AB		ORCHID HLTHCARE	**125MG/5ML**	**A065429**	**001**	Jul 18, 2007
AB			**250MG/5ML**	**A065429**	**002**	Jul 18, 2007
AB		SANDOZ	**125MG/5ML**	**A065337**	**001**	Apr 06, 2007
AB	**!**		**250MG/5ML**	**A065337**	**002**	Apr 06, 2007
AB		TEVA PHARMS	**125MG/5ML**	**A065332**	**001**	May 04, 2007
AB			**250MG/5ML**	**A065332**	**002**	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065441**	**001**	Mar 20, 2008
AP			**EQ 2GM BASE/VIAL**	**A065441**	**002**	Mar 20, 2008
AP		QILU	**EQ 500MG BASE/VIAL**	**A203704**	**001**	Feb 01, 2016
AP			**EQ 1GM BASE/VIAL**	**A203704**	**002**	Feb 01, 2016
AP			**EQ 2GM BASE/VIAL**	**A203704**	**003**	Feb 01, 2016
AP		SAGENT PHARMS INC	**EQ 1GM BASE/VIAL**	**A091048**	**001**	Jan 04, 2017
AP			**EQ 2GM BASE/VIAL**	**A091048**	**002**	Jan 04, 2017

MAXIPIME

AP	**+!**	HOSPIRA INC	**EQ 500MG BASE/VIAL**	**N050679**	**001**	Jan 18, 1996
AP	**+!**		**EQ 1GM BASE/VIAL**	**N050679**	**002**	Jan 18, 1996
AP	**+!**		**EQ 2GM BASE/VIAL**	**N050679**	**003**	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008

POWDER;INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018

CEFIDEROCOL SULFATE TOSYLATE

POWDER;INTRAVENOUS

FETROJA

+!	SHIONOGI INC	EQ 1GM BASE/VIAL	N209445	001	Nov 14, 2019

CEFIXIME

CAPSULE;ORAL

CEFIXIME

AB		ALKEM LABS LTD	**400MG**	**A210574**	**001**	Oct 09, 2018

SUPRAX

AB	**+!**	LUPIN LTD	**400MG**	**N203195**	**001**	Jun 01, 2012

FOR SUSPENSION;ORAL

CEFIXIME

AB		AUROBINDO PHARMA LTD	**100MG/5ML**	**A204835**	**001**	Apr 14, 2015
AB			**200MG/5ML**	**A204835**	**002**	Apr 14, 2015
AB		BELCHER PHARMS LLC	**100MG/5ML**	**A206938**	**001**	Feb 06, 2017
AB			**200MG/5ML**	**A206938**	**002**	Feb 06, 2017
AB			**500MG/5ML**	**A206939**	**001**	Feb 06, 2017

SUPRAX

AB	**+!**	LUPIN LTD	**500MG/5ML**	**N202091**	**001**	Feb 20, 2013
AB		LUPIN PHARMS	**100MG/5ML**	**A065129**	**001**	Feb 23, 2004
AB	**!**		**200MG/5ML**	**A065355**	**001**	Apr 10, 2007

TABLET;ORAL

SUPRAX

!	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004

TABLET, CHEWABLE;ORAL

SUPRAX

	LUPIN LTD	100MG	A065380	001	Oct 25, 2010
		150MG	A065380	002	Oct 25, 2010
!		200MG	A065380	003	Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME

	!	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002
	!		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002
	!		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002
	!		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

AP	**+**	TELIGENT	**EQ 1GM BASE/VIAL**	**N050588**	**001**	Dec 27, 1985
AP	**+**		**EQ 2GM BASE/VIAL**	**N050588**	**002**	Dec 27, 1985

CEFOTETAN

AP	**!**	FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A065374**	**001**	Aug 09, 2007
AP	**!**		**EQ 2GM BASE/VIAL**	**A065374**	**002**	Aug 09, 2007
AP		HIKMA	**EQ 1GM BASE/VIAL**	**A091031**	**001**	Oct 26, 2011
AP			**EQ 2GM BASE/VIAL**	**A091031**	**002**	Oct 26, 2011

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

	+!	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007
	+!		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE;INJECTION

CEFOXITIN

AP	**!**	ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065414**	**001**	Jun 12, 2009
AP	**!**		**EQ 2GM BASE/VIAL**	**A065414**	**002**	Jun 12, 2009
AP	**!**		**EQ 10GM BASE/VIAL**	**A065415**	**001**	May 19, 2010
AP		HIKMA FARMACEUTICA	**EQ 1GM BASE/VIAL**	**A065238**	**001**	Mar 12, 2010
AP			**EQ 2GM BASE/VIAL**	**A065238**	**002**	Mar 12, 2010
AP			**EQ 10GM BASE/VIAL**	**A065239**	**001**	Mar 02, 2010
AP		WEST-WARD PHARMS INT	**EQ 1GM BASE/VIAL**	**A065051**	**001**	Sep 11, 2000
AP			**EQ 2GM BASE/VIAL**	**A065051**	**002**	Sep 11, 2000
AP			**EQ 10GM BASE/VIAL**	**A065050**	**001**	Sep 11, 2000

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 1GM BASE/VIAL**	**N065214**	**001**	Mar 10, 2006
AP	**+!**		**EQ 2GM BASE/VIAL**	**N065214**	**002**	Mar 10, 2006

MEFOXIN IN PLASTIC CONTAINER

	!	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
	!		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993

POWDER;INTRAVENOUS

CEFOXITIN IN PLASTIC CONTAINER

		SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

		AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007
	!		EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007

TABLET;ORAL

CEFPODOXIME PROXETIL

AB		AUROBINDO PHARMA	**EQ 100MG BASE**	**A065370**	**001**	Jun 11, 2007
AB			**EQ 200MG BASE**	**A065370**	**002**	Jun 11, 2007
AB		ORCHID HLTHCARE	**EQ 100MG BASE**	**A065388**	**001**	Nov 14, 2007
AB			**EQ 200MG BASE**	**A065388**	**002**	Nov 14, 2007
AB		SANDOZ	**EQ 100MG BASE**	**A065462**	**001**	May 28, 2008
AB	**!**		**EQ 200MG BASE**	**A065462**	**002**	May 28, 2008

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

AB		APOTEX INC	**125MG/5ML**	**A065351**	**001**	Feb 29, 2012
AB			**250MG/5ML**	**A065351**	**002**	Feb 29, 2012
AB		AUROBINDO PHARMA	**125MG/5ML**	**A065381**	**001**	Jan 30, 2007
AB			**250MG/5ML**	**A065381**	**002**	Jan 30, 2007
AB		LUPIN	**125MG/5ML**	**A065261**	**001**	Dec 19, 2005
AB	**!**		**250MG/5ML**	**A065261**	**002**	Dec 19, 2005
AB		ORCHID HLTHCARE	**125MG/5ML**	**A065284**	**002**	Dec 30, 2005
AB			**250MG/5ML**	**A065284**	**001**	Dec 30, 2005
AB		SANDOZ	**125MG/5ML**	**A065257**	**001**	Dec 08, 2005
AB			**250MG/5ML**	**A065257**	**002**	Dec 08, 2005
AB		TEVA PHARMS	**125MG/5ML**	**A065236**	**001**	Dec 08, 2005
AB			**250MG/5ML**	**A065236**	**002**	Dec 08, 2005

CEFPROZIL

TABLET;ORAL

CEFPROZIL

AB		APOTEX INC	**250MG**	**A065327**	**001**	Mar 26, 2008
AB			**500MG**	**A065327**	**002**	Mar 26, 2008
AB		AUROBINDO PHARMA LTD	**250MG**	**A065340**	**001**	May 24, 2007
AB			**500MG**	**A065340**	**002**	May 24, 2007
AB		CASI PHARMS INC	**250MG**	**A065235**	**001**	Nov 14, 2005
AB			**500MG**	**A065235**	**002**	Nov 14, 2005
AB		LUPIN	**250MG**	**A065276**	**001**	Dec 08, 2005
AB	!		**500MG**	**A065276**	**002**	Dec 08, 2005
AB		ORCHID HLTHCARE	**250MG**	**A065267**	**001**	Dec 19, 2005
AB			**500MG**	**A065267**	**002**	Dec 19, 2005
AB		TEVA	**250MG**	**A065208**	**001**	Dec 06, 2005
AB			**500MG**	**A065208**	**002**	Dec 06, 2005
AB		WOCKHARDT	**250MG**	**A065428**	**001**	Jun 14, 2007
AB			**500MG**	**A065428**	**002**	Jun 14, 2007

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS

TEFLARO

	+	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010
	+!		600MG/VIAL	N200327	002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE;INJECTION

CEFTAZIDIME

AP		ACS DOBFAR	**1GM/VIAL**	**A062640**	**002**	Nov 20, 1985
AP			**2GM/VIAL**	**A062640**	**003**	Nov 20, 1985
AP			**6GM/VIAL**	**A062640**	**004**	Feb 03, 1992
AP		WOCKHARDT	**1GM/VIAL**	**A065196**	**001**	Oct 15, 2008

FORTAZ

AP	**+!**	TELIGENT	**500MG/VIAL**	**N050578**	**001**	Jul 19, 1985
AP	**+!**		**1GM/VIAL**	**N050578**	**002**	Jul 19, 1985
AP	**+!**		**2GM/VIAL**	**N050578**	**003**	Jul 19, 1985
AP	**+!**		**6GM/VIAL**	**N050578**	**004**	Jul 19, 1985

TAZICEF

AP		HOSPIRA	**500MG/VIAL**	**A062662**	**001**	Mar 06, 1986
AP			**1GM/VIAL**	**A062662**	**002**	Mar 06, 1986
AP			**1GM/VIAL**	**A064032**	**001**	Oct 31, 1993
AP			**2GM/VIAL**	**A062662**	**003**	Mar 06, 1986
AP			**2GM/VIAL**	**A064032**	**002**	Oct 31, 1993
AP			**6GM/VIAL**	**A062662**	**004**	Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

	+	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011
	+!		EQ 2GM BASE	N050823	002	Jun 13, 2011

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;INTRAVENOUS

ZERBAXA

	+!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065329**	**001**	Jul 24, 2008
AP			**EQ 1GM BASE/VIAL**	**A065329**	**002**	Jul 24, 2008
AP			**EQ 2GM BASE/VIAL**	**A065329**	**003**	Jul 24, 2008
AP			**EQ 10GM BASE/VIAL**	**A065328**	**001**	Jul 24, 2008
AP		HOSPIRA INC	**EQ 10GM BASE/VIAL**	**A065232**	**001**	Aug 02, 2005
AP		QILU	**EQ 10GM BASE/VIAL**	**A209218**	**001**	Oct 17, 2018
AP	!	SANDOZ	**EQ 10GM BASE/VIAL**	**A065168**	**001**	May 17, 2005
AP	!	SANDOZ INC	**EQ 1GM BASE/VIAL**	**A065204**	**001**	May 03, 2005
AP	!		**EQ 2GM BASE/VIAL**	**A065204**	**002**	May 03, 2005
AP		WOCKHARDT	**EQ 1GM BASE/VIAL**	**A065180**	**001**	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 1GM BASE/VIAL**	**N050796**	**001**	Apr 20, 2005
AP	**+!**		**EQ 2GM BASE/VIAL**	**N050796**	**002**	Apr 20, 2005

CEFTRIAXONE SODIUM

AP		ASTRAL	**EQ 10GM BASE/VIAL**	**A091117**	**001**	Jan 20, 2017
AP		HIKMA	**EQ 10GM BASE/VIAL**	**A090701**	**001**	Oct 04, 2017

CEFTRIAXONE

		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224 001	Aug 23, 2005
	!		EQ 40MG BASE/ML	A065224 002	Aug 23, 2005

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP		AKORN INC	**EQ 250MG BASE/VIAL**	**A065305 001**	Jan 11, 2008
AP			**EQ 500MG BASE/VIAL**	**A065305 002**	Jan 11, 2008
AP			**EQ 1GM BASE/VIAL**	**A065305 003**	Jan 11, 2008
AP			**EQ 2GM BASE/VIAL**	**A065305 004**	Jan 11, 2008
AP		ASTRAL	**EQ 250MG BASE/VIAL**	**A091049 001**	Jun 11, 2018
AP			**EQ 500MG BASE/VIAL**	**A091049 002**	Jun 11, 2018
AP			**EQ 1GM BASE/VIAL**	**A091049 003**	Jun 11, 2018
AP			**EQ 2GM BASE/VIAL**	**A091049 004**	Jun 11, 2018
AP		HIKMA FARMACEUTICA	**EQ 250MG BASE/VIAL**	**A065342 001**	Jan 10, 2008
AP			**EQ 500MG BASE/VIAL**	**A065342 002**	Jan 10, 2008
AP			**EQ 1GM BASE/VIAL**	**A065342 003**	Jan 10, 2008
AP			**EQ 2GM BASE/VIAL**	**A065342 004**	Jan 10, 2008
AP		LUPIN	**EQ 250MG BASE/VIAL**	**A065125 001**	Sep 30, 2003
AP			**EQ 500MG BASE/VIAL**	**A065125 002**	Sep 30, 2003
AP			**EQ 1GM BASE/VIAL**	**A065125 003**	Sep 30, 2003
AP			**EQ 2GM BASE/VIAL**	**A065125 004**	Sep 30, 2003
AP		QILU	**EQ 250MG BASE/VIAL**	**A203702 001**	Jun 29, 2016
AP			**EQ 500MG BASE/VIAL**	**A203702 002**	Jun 29, 2016
AP			**EQ 1GM BASE/VIAL**	**A203702 003**	Jun 29, 2016
AP			**EQ 2GM BASE/VIAL**	**A203702 004**	Jun 29, 2016
AP	!	SANDOZ	**EQ 250MG BASE/VIAL**	**A065169 001**	May 09, 2005
AP	!		**EQ 500MG BASE/VIAL**	**A065169 002**	May 09, 2005
AP	!		**EQ 1GM BASE/VIAL**	**A065169 003**	May 09, 2005
AP	!		**EQ 2GM BASE/VIAL**	**A065169 004**	May 09, 2005
AP		WOCKHARDT	**EQ 250MG BASE/VIAL**	**A065391 001**	Apr 12, 2007
AP			**EQ 500MG BASE/VIAL**	**A065391 002**	Apr 12, 2007
AP			**EQ 2GM BASE/VIAL**	**A065391 003**	Apr 12, 2007

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB		ALKEM LABS LTD	**EQ 250MG BASE**	**A065496 001**	Jun 07, 2010
AB			**EQ 500MG BASE**	**A065496 002**	Jun 07, 2010
AB		APOTEX	**EQ 250MG BASE**	**A065069 001**	Oct 02, 2002
AB			**EQ 500MG BASE**	**A065069 002**	Oct 02, 2002
AB		AUROBINDO PHARMA LTD	**EQ 125MG BASE**	**A065308 001**	Mar 29, 2006
AB			**EQ 250MG BASE**	**A065308 002**	Mar 29, 2006
AB			**EQ 500MG BASE**	**A065308 003**	Mar 29, 2006
AB		LUPIN	**EQ 250MG BASE**	**A065135 001**	Jul 25, 2003
AB	!		**EQ 500MG BASE**	**A065135 002**	Jul 25, 2003
AB		ORCHID HLTHCARE	**EQ 125MG BASE**	**A065359 001**	Feb 15, 2008
AB			**EQ 250MG BASE**	**A065359 002**	Feb 15, 2008
AB			**EQ 500MG BASE**	**A065359 003**	Feb 15, 2008
AB		WOCKHARDT	**EQ 125MG BASE**	**A065166 001**	Jul 29, 2005
AB			**EQ 250MG BASE**	**A065166 002**	Jul 29, 2005
AB			**EQ 500MG BASE**	**A065166 003**	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 750MG BASE/VIAL**	**N050780 001**	Feb 21, 2001
AP	**+!**		**EQ 1.5GM BASE/VIAL**	**N050780 002**	Feb 21, 2001

CEFUROXIME SODIUM

AP		ACS DOBFAR SPA	**EQ 1.5GM BASE/VIAL**	**A064125 002**	May 30, 1997
AP			**EQ 7.5GM BASE/VIAL**	**A064124 001**	May 30, 1997
AP		HIKMA FARMACEUTICA	**EQ 1.5GM BASE/VIAL**	**A065048 002**	Jan 09, 2004
AP			**EQ 7.5GM BASE/VIAL**	**A065046 001**	Jan 09, 2004

ZINACEF

AP	**+!**	TELIGENT	**EQ 1.5GM BASE/VIAL**	**N050558 003**	Oct 19, 1983
AP	**+!**		**EQ 7.5GM BASE/VIAL**	**N050558 004**	Oct 23, 1986

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB		ACS DOBFAR SPA	**EQ 750MG BASE/VIAL**	**A064125 001**	May 30, 1997
AB		HIKMA FARMACEUTICA	**EQ 750MG BASE/VIAL**	**A065048 001**	Jan 09, 2004

CEFUROXIME SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB	**+!**	TELIGENT	**EQ 750MG BASE/VIAL**	**N050558**	**002**	Oct 19, 1983

CELECOXIB

CAPSULE;ORAL

CELEBREX

AB	**+**	GD SEARLE	**50MG**	**N020998**	**004**	Dec 15, 2006
AB	**+**		**100MG**	**N020998**	**001**	Dec 31, 1998
AB	**+**		**200MG**	**N020998**	**002**	Dec 31, 1998
AB	**+!**		**400MG**	**N020998**	**003**	Aug 29, 2002

CELECOXIB

AB		ALEMBIC PHARMS LTD	**50MG**	**A204519**	**001**	Aug 21, 2015
AB			**100MG**	**A204519**	**002**	Aug 21, 2015
AB			**200MG**	**A204519**	**003**	Aug 21, 2015
AB			**400MG**	**A204519**	**004**	Aug 21, 2015
AB		AMNEAL PHARMS	**50MG**	**A208833**	**001**	May 31, 2018
AB			**100MG**	**A208833**	**002**	May 31, 2018
AB			**200MG**	**A208833**	**003**	May 31, 2018
AB			**400MG**	**A208833**	**004**	May 31, 2018
AB		APOTEX INC	**50MG**	**A204197**	**001**	Jun 02, 2015
AB			**100MG**	**A204197**	**002**	Jun 02, 2015
AB			**200MG**	**A204197**	**003**	Jun 02, 2015
AB		AUROBINDO PHARMA LTD	**50MG**	**A206827**	**001**	Feb 01, 2016
AB			**100MG**	**A206827**	**002**	Feb 01, 2016
AB			**200MG**	**A206827**	**003**	Feb 01, 2016
AB			**400MG**	**A206827**	**004**	Feb 01, 2016
AB		CADILA PHARMS LTD	**50MG**	**A208701**	**001**	Nov 14, 2019
AB			**100MG**	**A208701**	**002**	Nov 14, 2019
AB			**200MG**	**A208701**	**003**	Nov 14, 2019
AB			**400MG**	**A208701**	**004**	Nov 14, 2019
AB		CIPLA	**50MG**	**A207446**	**001**	Sep 23, 2015
AB			**100MG**	**A207446**	**002**	Sep 23, 2015
AB			**200MG**	**A207446**	**003**	Sep 23, 2015
AB			**400MG**	**A207446**	**004**	Sep 23, 2015
AB		CSPC OUYI	**50MG**	**A210071**	**001**	Jan 23, 2018
AB			**100MG**	**A210071**	**002**	Jan 23, 2018
AB			**200MG**	**A210071**	**003**	Jan 23, 2018
AB		JUBILANT GENERICS	**50MG**	**A207061**	**001**	Apr 04, 2017
AB			**100MG**	**A207061**	**002**	Apr 04, 2017
AB			**200MG**	**A207061**	**003**	Apr 04, 2017
AB			**400MG**	**A207061**	**004**	Apr 04, 2017
AB		LUPIN LTD	**50MG**	**A202240**	**001**	Oct 29, 2014
AB			**100MG**	**A202240**	**002**	Jun 09, 2015
AB			**200MG**	**A202240**	**003**	Jun 09, 2015
AB			**400MG**	**A202240**	**004**	Jun 09, 2015
AB		MACLEODS PHARMS LTD	**50MG**	**A204590**	**001**	Mar 16, 2016
AB			**100MG**	**A204590**	**002**	Mar 16, 2016
AB			**200MG**	**A204590**	**003**	Mar 16, 2016
AB			**400MG**	**A204590**	**004**	Mar 16, 2016
AB		MICRO LABS	**50MG**	**A204776**	**001**	Apr 30, 2018
AB			**100MG**	**A204776**	**002**	Apr 30, 2018
AB			**200MG**	**A204776**	**003**	Apr 30, 2018
AB			**400MG**	**A204776**	**004**	Apr 30, 2018
AB		MYLAN	**50MG**	**A078857**	**001**	May 30, 2014
AB			**100MG**	**A078857**	**002**	Feb 11, 2015
AB			**200MG**	**A078857**	**003**	Feb 11, 2015
AB			**400MG**	**A078857**	**004**	Feb 11, 2015
AB		QINGDAO BAHEAL PHARM	**50MG**	**A208856**	**001**	Aug 07, 2019
AB			**100MG**	**A208856**	**002**	Aug 07, 2019
AB			**200MG**	**A208856**	**003**	Aug 07, 2019
AB			**400MG**	**A208856**	**004**	Aug 07, 2019
AB		TEVA	**50MG**	**A076898**	**001**	May 30, 2014
AB			**100MG**	**A076898**	**002**	May 30, 2014
AB			**200MG**	**A076898**	**003**	May 30, 2014
AB			**400MG**	**A076898**	**004**	May 30, 2014
AB		TORRENT	**50MG**	**A207677**	**001**	Dec 23, 2015
AB			**100MG**	**A207677**	**002**	Dec 23, 2015
AB			**200MG**	**A207677**	**003**	Dec 23, 2015
AB			**400MG**	**A207677**	**004**	Dec 23, 2015

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	WATSON LABS INC	**50MG**	**A200562**	**001**	Feb 11, 2015
AB		**100MG**	**A200562**	**002**	Feb 11, 2015
AB		**200MG**	**A200562**	**003**	Feb 11, 2015
AB		**400MG**	**A200562**	**004**	Feb 11, 2015

TABLET;ORAL

CELECOXIB

AB	UMEDICA LABS PVT LTD	**50MG**	**A210628**	**001**	Nov 27, 2019
AB		**100MG**	**A210628**	**002**	Nov 27, 2019
AB		**200MG**	**A210628**	**003**	Nov 27, 2019
AB		**400MG**	**A210628**	**004**	Nov 27, 2019

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	ALKEM LABS LTD	**EQ 250MG BASE**	**A090836**	**001**	Dec 20, 2010
AB		**EQ 500MG BASE**	**A090836**	**002**	Dec 20, 2010
AB		**EQ 750MG BASE**	**A090836**	**004**	Mar 29, 2013
AB	AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A065253**	**001**	Nov 16, 2005
AB		**EQ 500MG BASE**	**A065253**	**002**	Nov 16, 2005
AB	BELCHER PHARMS	**EQ 250MG BASE**	**A062713**	**001**	Jul 15, 1988
AB		**EQ 500MG BASE**	**A062713**	**002**	Jul 15, 1988
AB	HIKMA	**EQ 250MG BASE**	**A065215**	**001**	Jan 24, 2006
AB		**EQ 500MG BASE**	**A065215**	**002**	Jan 24, 2006
AB	LUPIN	**EQ 250MG BASE**	**A065229**	**001**	Nov 25, 2005
AB		**EQ 500MG BASE**	**A065229**	**002**	Nov 25, 2005
AB	ORCHID HLTHCARE	**EQ 250MG BASE**	**A065248**	**001**	Jun 28, 2005
AB		**EQ 500MG BASE**	**A065248**	**002**	Jun 28, 2005
AB	TEVA	**EQ 250MG BASE**	**A062702**	**001**	Feb 13, 1987
AB		**EQ 500MG BASE**	**A062702**	**002**	Feb 13, 1987
AB	YUNG SHIN PHARM	**EQ 250MG BASE**	**A065152**	**001**	Feb 24, 2005
AB		**EQ 500MG BASE**	**A065152**	**002**	Feb 24, 2005

KEFLEX

AB	**+** PRAGMA	**EQ 250MG BASE**	**N050405**	**002**	
AB	**+**	**EQ 500MG BASE**	**N050405**	**003**	
AB	**+!**	**EQ 750MG BASE**	**N050405**	**005**	May 12, 2006

CEPHALEXIN

	ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013

FOR SUSPENSION;ORAL

CEPHALEXIN

AB	ALKEM LABS LTD	**EQ 125MG BASE/5ML**	**A210221**	**001**	Mar 26, 2019
AB		**EQ 250MG BASE/5ML**	**A210221**	**002**	Mar 26, 2019
AB	LUPIN	**EQ 125MG BASE/5ML**	**A065234**	**001**	Aug 17, 2005
AB		**EQ 250MG BASE/5ML**	**A065234**	**002**	Aug 17, 2005
AB	ORCHID HLTHCARE	**EQ 125MG BASE/5ML**	**A065326**	**001**	Jul 10, 2006
AB		**EQ 250MG BASE/5ML**	**A065326**	**002**	Jul 10, 2006
AB	TEVA	**EQ 125MG BASE/5ML**	**A062703**	**001**	Feb 13, 1987
AB	**!**	**EQ 250MG BASE/5ML**	**A062703**	**002**	Feb 13, 1987
AB	YUNG SHIN PHARM	**EQ 125MG BASE/5ML**	**A065336**	**001**	Jul 25, 2007
AB		**EQ 250MG BASE/5ML**	**A065336**	**002**	Jul 25, 2007

TABLET;ORAL

CEPHALEXIN

	TEVA	EQ 250MG BASE	A063023	001	Jan 12, 1989
	!	EQ 500MG BASE	A063024	001	Jan 12, 1989

CERITINIB

TABLET;ORAL

ZYKADIA

	+! NOVARTIS	150MG	N211225	001	Mar 18, 2019

CETIRIZINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

QUZYTTIR

	+! JDP	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019

SOLUTION/DROPS;OPHTHALMIC

ZERVIATE

	+! EYEVANCE	EQ 0.24% BASE	N208694	001	May 30, 2017

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	**5MG/5ML**	**A090766**	**001**	Oct 07, 2009

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA		BRECKENRIDGE	**5MG/5ML**	**A078488**	**001**	Oct 06, 2008
AA		LANNETT CO INC	**5MG/5ML**	**A078876**	**001**	May 11, 2012
AA		MLV	**5MG/5ML**	**A090191**	**001**	Nov 12, 2009
AA	!	PERRIGO PHARMS CO	**5MG/5ML**	**A078398**	**001**	Jun 17, 2008
AA		TARO	**5MG/5ML**	**A076601**	**001**	Jun 20, 2008
AA		TEVA PHARMS	**5MG/5ML**	**A077279**	**001**	May 27, 2008

CETRORELIX

INJECTABLE;INJECTION

CETROTIDE

	+!	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197	001	Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB		HIKMA	**30MG**	**A091591**	**001**	Jul 08, 2013
AB		NOVEL LABS INC	**30MG**	**A204746**	**001**	Dec 30, 2016
AB		RISING	**30MG**	**A203775**	**001**	Jun 04, 2014

EVOXAC

AB	**+!**	DAIICHI SANKYO INC	**30MG**	**N020989**	**002**	Jan 11, 2000

CHENODIOL

TABLET;ORAL

CHENODIOL

	!	NEXGEN PHARMA	250MG	A091019	001	Oct 22, 2009

CHLORAMBUCIL

TABLET;ORAL

LEUKERAN

	+!	ASPEN GLOBAL INC	2MG	N010669	002	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB		BARR	**5MG**	**A084768**	**001**	
AB			**10MG**	**A083116**	**001**	
AB			**25MG**	**A084769**	**001**	

LIBRIUM

AB		VALEANT PHARM INTL	**5MG**	**A085461**	**001**	
AB			**10MG**	**A085472**	**001**	
AB	!		**25MG**	**A085475**	**001**	

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

LIBRAX

	+!	VALEANT PHARMS	5MG;2.5MG	N012750	001	

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT		HI TECH PHARMA	**0.12%**	**A074356**	**001**	May 07, 1996
AT		LYNE	**0.12%**	**A074291**	**001**	Dec 28, 1995
AT		PHARM ASSOC	**0.12%**	**A074522**	**001**	Dec 15, 1995
AT		WOCKHARDT BIO AG	**0.12%**	**A075006**	**001**	Mar 03, 2004
AT		XTTRIUM	**0.12%**	**A077789**	**001**	Jun 18, 2009

PAROEX

AT		SUNSTAR AMERICAS	**0.12%**	**A076434**	**001**	Nov 29, 2005

PERIDEX

AT	**+!**	3M	**0.12%**	**N019028**	**001**	Aug 13, 1986

PERIOGARD

AT		COLGATE PALMOLIVE CO	**0.12%**	**A073695**	**001**	Jan 14, 1994
AT		COLGATE-PALMOLIVE CO	**0.12%**	**A203212**	**001**	Jan 28, 2016

TABLET;DENTAL

PERIOCHIP

	+!	DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE						
INJECTABLE;INJECTION						
CHLOROPROCAINE HYDROCHLORIDE						
AP		HOSPIRA	**2%**	**A087447**	**001**	Apr 16, 1982
AP			**3%**	**A087446**	**001**	Apr 16, 1982
AP		WEST-WARD PHARMS INT	**2%**	**A040273**	**001**	Sep 09, 1998
AP			**3%**	**A040273**	**002**	Sep 09, 1998
NESACAINE						
AP	**+**	FRESENIUS KABI USA	**2%**	**N009435**	**002**	
NESACAINE-MPF						
AP	**+!**	FRESENIUS KABI USA	**2%**	**N009435**	**006**	May 02, 1996
AP	**+!**		**3%**	**N009435**	**007**	May 02, 1996
NESACAINE						
	+!	FRESENIUS KABI USA	1%	N009435	001	
SOLUTION;INTRATHECAL						
CLOROTEKAL						
	+	B BRAUN MEDICAL INC	50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017
CHLOROQUINE PHOSPHATE						
TABLET;ORAL						
CHLOROQUINE PHOSPHATE						
AA	**!**	HIKMA PHARMS	**EQ 150MG BASE**	**A083082**	**001**	
AA			**EQ 300MG BASE**	**A083082**	**002**	Sep 17, 1999
AA		IPCA LABS LTD	**EQ 150MG BASE**	**A090610**	**001**	Dec 03, 2009
AA			**EQ 300MG BASE**	**A090249**	**001**	Dec 03, 2009
AA		NATCO PHARMA LTD	**EQ 150MG BASE**	**A091621**	**001**	Jan 21, 2011
AA	**!**		**EQ 300MG BASE**	**A090612**	**001**	Jan 21, 2011
CHLOROTHIAZIDE						
SUSPENSION;ORAL						
DIURIL						
	+!	SALIX PHARMS	250MG/5ML	N011870	001	
TABLET;ORAL						
CHLOROTHIAZIDE						
	!	MYLAN	250MG	A084217	002	
			500MG	A084217	001	
CHLOROTHIAZIDE SODIUM						
INJECTABLE;INJECTION						
CHLOROTHIAZIDE SODIUM						
AP		AM REGENT	**EQ 500MG BASE/VIAL**	**A202561**	**001**	Apr 22, 2013
AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090896**	**001**	Oct 16, 2009
AP		MYLAN INSTITUTIONAL	**EQ 500MG BASE/VIAL**	**A202493**	**001**	Jun 18, 2014
AP		SAGENT PHARMS INC	**EQ 500MG BASE/VIAL**	**A202462**	**001**	May 29, 2015
AP		SUN PHARM	**EQ 500MG BASE/VIAL**	**A091546**	**001**	Jul 26, 2011
DIURIL						
AP	**+!**	OAK PHARMS AKORN	**EQ 500MG BASE/VIAL**	**N011145**	**005**	
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE						
TABLET, EXTENDED RELEASE;ORAL						
TUXARIN ER						
		MAINPOINTE	8MG;54.3MG	N206323	001	Jun 22, 2015
CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE						
SOLUTION;ORAL						
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
	!	PADDOCK LLC	4MG/5ML;5MG/5ML;60MG/5ML	A204627	001	Apr 29, 2014
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX						
SUSPENSION, EXTENDED RELEASE;ORAL						
TUZISTRA XR						
	+!	AYTU	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015
CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX						
CAPSULE, EXTENDED RELEASE;ORAL						
TUSSICAPS						
		ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007
	!		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007
SUSPENSION, EXTENDED RELEASE;ORAL						
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX						
AB		TRIS PHARMA INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**A091632**	**001**	Oct 01, 2010
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX						
AB	**!**	NEOS THERAP INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**A091671**	**001**	Jun 29, 2012

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	!	WEST-WARD PHARMS INT	25MG/ML	A083329	001	

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		AMNEAL PHARMS CO	**10MG**	**A209755**	**001**	Sep 10, 2018
AB			**25MG**	**A209755**	**002**	Sep 10, 2018
AB			**50MG**	**A209755**	**003**	Sep 10, 2018
AB			**100MG**	**A209755**	**004**	Sep 10, 2018
AB			**200MG**	**A209755**	**005**	Sep 10, 2018
AB		UPSHER SMITH LABS	**10MG**	**A083386**	**001**	
AB	!		**25MG**	**A084112**	**001**	
AB			**50MG**	**A084113**	**001**	
AB	!		**100MG**	**A084114**	**001**	
AB			**200MG**	**A084115**	**001**	

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		AMNEAL PHARMS CO	**25MG**	**A207204**	**001**	Jul 01, 2019
AB			**50MG**	**A207204**	**002**	Jul 01, 2019
AB		ARISE	**25MG**	**A210742**	**001**	Oct 12, 2018
AB			**50MG**	**A210742**	**002**	Oct 12, 2018
AB		ATHEM	**25MG**	**A211063**	**001**	Feb 26, 2019
AB			**50MG**	**A211063**	**002**	Feb 26, 2019
AB		MYLAN	**25MG**	**A086831**	**002**	
AB	!		**50MG**	**A086831**	**001**	
AB		RICONPHARMA LLC	**25MG**	**A206904**	**001**	Mar 30, 2017
AB			**50MG**	**A206904**	**002**	Mar 30, 2017
AB		SUN PHARM INDUSTRIES	**25MG**	**A089286**	**002**	Jul 21, 1986
AB			**50MG**	**A089286**	**001**	Jul 21, 1986
AB		UMEDICA LABS PVT LTD	**25MG**	**A207222**	**001**	May 24, 2018
AB			**50MG**	**A207222**	**002**	May 24, 2018
AB		UNICHEM LABS LTD	**25MG**	**A211627**	**001**	Aug 06, 2019
AB			**50MG**	**A211627**	**002**	Aug 06, 2019
AB		ZYDUS PHARMS	**25MG**	**A207813**	**001**	May 10, 2019
AB			**50MG**	**A207813**	**002**	May 10, 2019

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA		NOVITIUM PHARMA	**500MG**	**A212254**	**001**	Sep 12, 2019
AA	!	WATSON LABS	**500MG**	**A089859**	**001**	May 04, 1988
AB	!	MIKART	**375MG**	**A040861**	**001**	Jun 01, 2010
AB	!		**750MG**	**A040861**	**002**	Jun 01, 2010
AB		NOVITIUM PHARMA	**375MG**	**A212253**	**001**	Nov 27, 2019
AB			**750MG**	**A212253**	**002**	Nov 27, 2019
	!	MIKART	250MG	A207483	001	Jun 24, 2016

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		ANI PHARMS INC	**EQ 4GM RESIN/PACKET**	**A074554**	**001**	Oct 02, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074554**	**002**	Oct 02, 1996
AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077204**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077204**	**002**	Aug 26, 2005
AB	!	SANDOZ	**EQ 4GM RESIN/PACKET**	**A074557**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074557**	**002**	Aug 15, 1996
AB		ZYDUS PHARMS	**EQ 4GM RESIN/SCOOPFUL**	**A202901**	**001**	Jul 02, 2018

CHOLESTYRAMINE LIGHT

AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077203**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077203**	**002**	Aug 26, 2005
AB	!	SANDOZ	**EQ 4GM RESIN/PACKET**	**A074558**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074558**	**002**	Aug 15, 1996
AB		ZYDUS PHARMS	**EQ 4GM RESIN/SCOOPFUL**	**A202902**	**001**	Apr 25, 2017

PREVALITE

AB		UPSHER SMITH LABS	**EQ 4GM RESIN/PACKET**	**A073263**	**001**	Feb 22, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A073263**	**002**	Oct 30, 1997

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

+	RTRX	50MG	N205750	001	Mar 17, 2015
+!		250MG	N205750	002	Mar 17, 2015

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

AP	DECATUR	**4-33.1mCi/ML**	**A206319**	**001**	Nov 13, 2015
AP +!	MCPRF	**4-33.1mCi/ML**	**N203155**	**001**	Sep 12, 2012
AP	UCSF RODIOPHARM	**4-33.1mCi/ML**	**A208444**	**001**	Nov 20, 2017
AP	WA UNIV SCH MED	**4-33.1mCi/ML**	**A208413**	**001**	Jan 10, 2017
	UNIV TX MD ANDERSON	4-100mCi/ML	A205690	001	Oct 29, 2015

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB	ACTAVIS ELIZABETH	**EQ 45MG FENOFIBRIC ACID**	**A200920**	**001**	Oct 07, 2015
AB		**EQ 135MG FENOFIBRIC ACID**	**A200920**	**002**	Oct 07, 2015
AB	ALEMBIC PHARMS LTD	**EQ 45MG FENOFIBRIC ACID**	**A208705**	**001**	May 12, 2017
AB		**EQ 135MG FENOFIBRIC ACID**	**A208705**	**002**	May 12, 2017
AB	ANCHEN PHARMS	**EQ 45MG FENOFIBRIC ACID**	**A201573**	**002**	Jul 18, 2013
AB		**EQ 135MG FENOFIBRIC ACID**	**A201573**	**001**	Jul 18, 2013
AB	AUROBINDO PHARMA LTD	**EQ 45MG FENOFIBRIC ACID**	**A212598**	**001**	Jul 25, 2019
AB		**EQ 135MG FENOFIBRIC ACID**	**A212598**	**002**	Jul 25, 2019
AB	GRAVITI PHARMS	**EQ 45MG FENOFIBRIC ACID**	**A211626**	**001**	Jul 18, 2019
AB		**EQ 135MG FENOFIBRIC ACID**	**A211626**	**002**	Jul 18, 2019
AB	IMPAX LABS INC	**EQ 45MG FENOFIBRIC ACID**	**A200264**	**001**	Sep 07, 2016
AB		**EQ 135MG FENOFIBRIC ACID**	**A200264**	**002**	Sep 07, 2016
AB	LUPIN LTD	**EQ 45MG FENOFIBRIC ACID**	**A200750**	**001**	Dec 04, 2013
AB		**EQ 135MG FENOFIBRIC ACID**	**A200750**	**002**	Dec 04, 2013

TRILIPIX

AB +	ABBVIE	**EQ 45MG FENOFIBRIC ACID**	**N022224**	**001**	Dec 15, 2008
AB +!		**EQ 135MG FENOFIBRIC ACID**	**N022224**	**002**	Dec 15, 2008

CHORIOGONADOTROPIN ALFA

INJECTABLE;SUBCUTANEOUS

OVIDREL

+!	EMD SERONO	EQ 0.25MG /0.5ML	N021149	002	Oct 06, 2003

CHROMIC CHLORIDE

INJECTABLE;INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+!	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

+!	COVIS PHARMA BV	0.08MG/INH	N021658	002	Jan 10, 2008
+!		0.16MG/INH	N021658	003	Jan 10, 2008

AEROSOL, METERED;NASAL

ZETONNA

+!	COVIS PHARMA BV	0.037MG/INH	N202129	001	Jan 20, 2012

SPRAY, METERED;NASAL

OMNARIS

+!	COVIS PHARMA BV	0.05MG/INH	N022004	001	Oct 20, 2006

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

AB	ACP NIMBLE	**0.77%**	**A078463**	**001**	Dec 20, 2010
AB	FOUGERA PHARMS	**0.77%**	**A076435**	**001**	Dec 29, 2004
AB	GLENMARK PHARMS	**0.77%**	**A090273**	**001**	Nov 10, 2009
AB	PERRIGO ISRAEL	**0.77%**	**A077364**	**001**	Mar 03, 2006
AB	TARO	**0.77%**	**A076790**	**001**	Apr 12, 2005

LOPROX

AB +!	MEDIMETRIKS PHARMS	**0.77%**	**N018748**	**001**	Dec 30, 1982

GEL;TOPICAL

CICLOPIROX

AB +!	CNTY LINE PHARMS	**0.77%**	**N020519**	**001**	Jul 21, 1997
AB	FOUGERA PHARMS	**0.77%**	**A077896**	**001**	Jun 10, 2008
AB	GLENMARK GENERICS	**0.77%**	**A091595**	**001**	Feb 29, 2012
AB	PADDOCK LLC	**0.77%**	**A078266**	**001**	Jan 07, 2009

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

AT		ACTAVIS MID ATLANTIC	**1%**	**A090490**	**001**	Nov 24, 2009
AT		FOUGERA PHARMS	**1%**	**A090146**	**001**	May 25, 2010
AT		PERRIGO CO	**1%**	**A078594**	**001**	Feb 16, 2010
AT		TARO	**1%**	**A090269**	**001**	Feb 23, 2011
AT		TELIGENT PHARMA INC	**1%**	**A209975**	**001**	Apr 05, 2018

LOPROX

AT	**+!**	BAUSCH	**1%**	**N021159**	**001**	Feb 28, 2003

SOLUTION;TOPICAL

CICLOPIROX

AT		ACELLA	**8%**	**A078172**	**001**	Sep 18, 2007
AT		ACP NIMBLE	**8%**	**A078233**	**001**	Sep 18, 2007
AT		ACTAVIS MID ATLANTIC	**8%**	**A078046**	**001**	Sep 18, 2007
AT		AKORN	**8%**	**A078975**	**001**	Feb 17, 2010
AT		ANDA REPOSITORY	**8%**	**A077687**	**001**	Sep 18, 2007
AT		HI TECH PHARMA	**8%**	**A078270**	**001**	Sep 18, 2007
AT		NOVAST LABS	**8%**	**A078124**	**001**	Sep 18, 2007
AT		PERRIGO NEW YORK	**8%**	**A077623**	**001**	Sep 18, 2007
AT		TARO PHARM INDS	**8%**	**A078144**	**001**	Sep 18, 2007

PENLAC

AT	**+!**	VALEANT BERMUDA	**8%**	**N021022**	**001**	Dec 17, 1999

SUSPENSION;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A076422**	**001**	Aug 06, 2004
AB		PERRIGO NEW YORK	**0.77%**	**A077676**	**001**	Dec 15, 2006
AB		TARO	**0.77%**	**A077092**	**001**	Aug 10, 2005

LOPROX

AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N019824**	**001**	Dec 30, 1988

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP		EMCURE PHARMS LTD	**EQ 75MG BASE/ML**	**A202501**	**001**	Jul 26, 2012
AP	**!**	MYLAN INSTITUTIONAL	**EQ 75MG BASE/ML**	**A201276**	**001**	Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

IMIPENEM AND CILASTATIN

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A090577**	**002**	Dec 21, 2011
AP		HQ SPCLT PHARMA	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A207594**	**001**	Dec 12, 2019

PRIMAXIN

AP	**+!**	MERCK	**EQ 500MG BASE/VIAL;500MG/VIAL**	**N050587**	**002**	Nov 26, 1985

IMIPENEM AND CILASTATIN

	!	ACS DOBFAR	EQ 250MG BASE/VIAL;250MG/VIAL	A090577	001	Dec 21, 2011

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

POWDER;INTRAVENOUS

RECARBRIO

	+!	MSD MERCK CO	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	N212819	001	Jul 16, 2019

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

AB		APOTEX INC	**50MG**	**A077030**	**001**	Dec 10, 2004
AB			**100MG**	**A077030**	**002**	Dec 10, 2004
AB		BRECKENRIDGE PHARM	**50MG**	**A077708**	**001**	Sep 28, 2009
AB			**100MG**	**A077708**	**002**	Sep 28, 2009
AB		CASI PHARMS INC	**50MG**	**A077310**	**001**	Nov 08, 2005
AB			**100MG**	**A077021**	**001**	Nov 23, 2004
AB		CHARTWELL RX	**50MG**	**A077722**	**001**	Sep 24, 2012
AB			**100MG**	**A077831**	**001**	Sep 24, 2012
AB		HIKMA	**50MG**	**A077024**	**001**	May 17, 2005
AB			**100MG**	**A077024**	**002**	May 17, 2005
AB		SLATE	**50MG**	**A077208**	**002**	Mar 29, 2006
AB			**100MG**	**A077208**	**001**	Mar 29, 2006
AB	**!**	TEVA	**50MG**	**A077027**	**001**	Nov 24, 2004
AB	**!**		**100MG**	**A077027**	**002**	Nov 24, 2004

CIMETIDINE

TABLET;ORAL

CIMETIDINE

AB		HIKMA	**200MG**	**A074890**	**001**	Dec 18, 1998
AB			**300MG**	**A074890**	**002**	Dec 18, 1998
AB			**400MG**	**A074890**	**003**	Dec 18, 1998
AB			**800MG**	**A074890**	**004**	Dec 18, 1998
AB		MYLAN	**200MG**	**A074246**	**001**	May 17, 1994
AB			**300MG**	**A074246**	**002**	May 17, 1994
AB			**400MG**	**A074246**	**003**	May 17, 1994
AB	!		**800MG**	**A074246**	**004**	May 17, 1994
AB		PLIVA	**800MG**	**A074566**	**001**	Feb 27, 1997
AB		TEVA	**200MG**	**A074151**	**001**	May 17, 1994
AB			**300MG**	**A074151**	**002**	May 17, 1994
AB			**400MG**	**A074151**	**003**	May 17, 1994
AB			**800MG**	**A074463**	**001**	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

	DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA	!	HI TECH PHARMA	**EQ 300MG BASE/5ML**	**A074664**	**001**	Oct 28, 1997
AA		PHARM ASSOC	**EQ 300MG BASE/5ML**	**A074553**	**001**	Jan 27, 1997
AA		WOCKHARDT BIO AG	**EQ 300MG BASE/5ML**	**A074757**	**001**	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB		ALKEM LABS LTD	**EQ 30MG BASE**	**A210570**	**001**	May 17, 2019
AB			**EQ 60MG BASE**	**A210570**	**002**	May 17, 2019
AB			**EQ 90MG BASE**	**A210570**	**003**	May 17, 2019
AB		AUROBINDO PHARMA LTD	**EQ 30MG BASE**	**A206125**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A206125**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A206125**	**003**	Mar 08, 2018
AB		CIPLA	**EQ 30MG BASE**	**A208915**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A208915**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A208915**	**003**	Mar 08, 2018
AB		LUPIN LTD	**EQ 30MG BASE**	**A210548**	**001**	Jun 28, 2019
AB			**EQ 60MG BASE**	**A210548**	**002**	Jun 28, 2019
AB			**EQ 90MG BASE**	**A210548**	**003**	Jun 28, 2019
AB		MYLAN	**EQ 30MG BASE**	**A203422**	**001**	Oct 16, 2018
AB			**EQ 60MG BASE**	**A203422**	**002**	Oct 16, 2018
AB			**EQ 90MG BASE**	**A203422**	**003**	Oct 16, 2018
AB		PIRAMAL HLTHCARE UK	**EQ 30MG BASE**	**A210207**	**001**	Aug 01, 2018
AB			**EQ 60MG BASE**	**A210207**	**002**	Aug 01, 2018
AB			**EQ 90MG BASE**	**A210207**	**003**	Aug 01, 2018
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209226**	**001**	Apr 30, 2018
AB			**EQ 60MG BASE**	**A209226**	**002**	Apr 30, 2018
AB			**EQ 90MG BASE**	**A209226**	**003**	Apr 30, 2018
AB		SUN PHARM	**EQ 30MG BASE**	**A207008**	**001**	Oct 11, 2018
AB			**EQ 60MG BASE**	**A207008**	**002**	Oct 11, 2018
AB			**EQ 90MG BASE**	**A207008**	**003**	Oct 11, 2018
AB		WATSON LABS TEVA	**EQ 30MG BASE**	**A204377**	**001**	Dec 27, 2018
AB			**EQ 60MG BASE**	**A204377**	**002**	Dec 27, 2018
AB			**EQ 90MG BASE**	**A204377**	**003**	Dec 27, 2018

SENSIPAR

AB	+	AMGEN	**EQ 30MG BASE**	**N021688**	**001**	Mar 08, 2004
AB	+		**EQ 60MG BASE**	**N021688**	**002**	Mar 08, 2004
AB	+!		**EQ 90MG BASE**	**N021688**	**003**	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

+	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997
+!		500MG/5ML	N020780	002	Sep 26, 1997

INJECTABLE;INJECTION

CIPROFLOXACIN

AP	!	BAXTER HLTHCARE CORP	**200MG/20ML (10MG/ML)**	**A078062**	**001**	Apr 29, 2008
AP	!		**400MG/40ML (10MG/ML)**	**A078062**	**002**	Apr 29, 2008
AP		HIKMA FARMACEUTICA	**200MG/20ML (10MG/ML)**	**A076717**	**001**	Dec 22, 2009

CIPROFLOXACIN						
INJECTABLE;INJECTION						
CIPROFLOXACIN						
AP			**400MG/40ML (10MG/ML)**	**A076717**	**002**	Dec 22, 2009
AP		HOSPIRA	**200MG/20ML (10MG/ML)**	**A077245**	**001**	Aug 28, 2006
AP			**400MG/40ML (10MG/ML)**	**A077245**	**002**	Aug 28, 2006
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE CORP	**200MG/100ML**	**A078024**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078024**	**002**	Mar 18, 2008
AP		HIKMA FARMACEUTICA	**400MG/200ML**	**A078431**	**001**	Nov 18, 2009
AP	**!**	HOSPIRA	**200MG/100ML**	**A077753**	**001**	Mar 18, 2008
AP	**!**		**400MG/200ML**	**A077753**	**002**	Mar 18, 2008
AP		INFORLIFE	**200MG/100ML**	**A078252**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078252**	**002**	Mar 18, 2008
INJECTABLE, SUSPENSION;OTIC						
OTIPRIO						
	+!	OTONOMY INC	6% (60MG/ML)	N207986	001	Dec 10, 2015
CIPROFLOXACIN HYDROCHLORIDE						
OINTMENT;OPHTHALMIC						
CILOXAN						
	+!	NOVARTIS	EQ 0.3% BASE	N020369	001	Mar 30, 1998
SOLUTION/DROPS;OPHTHALMIC						
CILOXAN						
AT	**+!**	NOVARTIS	**EQ 0.3% BASE**	**N019992**	**001**	Dec 31, 1990
CIPROFLOXACIN HYDROCHLORIDE						
AT		AKORN INC	**EQ 0.3% BASE**	**A076555**	**001**	Dec 11, 2008
AT		ALTAIRE PHARMS INC	**EQ 0.3% BASE**	**A204613**	**001**	May 03, 2018
AT		FDC LTD	**EQ 0.3% BASE**	**A077568**	**001**	Jun 30, 2008
AT		RISING	**EQ 0.3% BASE**	**A077689**	**001**	Dec 13, 2006
AT		TELIGENT	**EQ 0.3% BASE**	**A076754**	**001**	Jun 09, 2004
AT		WATSON LABS INC	**EQ 0.3% BASE**	**A076673**	**001**	Jan 21, 2005
SOLUTION/DROPS;OTIC						
CETRAXAL						
	+!	WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009
TABLET;ORAL						
CIPRO						
AB	**+**	BAYER HLTHCARE	**EQ 250MG BASE**	**N019537**	**002**	Oct 22, 1987
AB	**+!**		**EQ 500MG BASE**	**N019537**	**003**	Oct 22, 1987
CIPROFLOXACIN HYDROCHLORIDE						
AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A077859**	**001**	Apr 26, 2007
AB			**EQ 500MG BASE**	**A077859**	**002**	Apr 26, 2007
AB			**EQ 750MG BASE**	**A077859**	**003**	Apr 26, 2007
AB		CARLSBAD	**EQ 250MG BASE**	**A076126**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A076126**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A076126**	**004**	Jun 09, 2004
AB		CHARTWELL	**EQ 250MG BASE**	**A076896**	**001**	Nov 04, 2004
AB			**EQ 500MG BASE**	**A076896**	**002**	Nov 04, 2004
AB			**EQ 750MG BASE**	**A076896**	**003**	Nov 04, 2004
AB		DR REDDYS LABS LTD	**EQ 100MG BASE**	**A075593**	**002**	Jun 09, 2004
AB			**EQ 250MG BASE**	**A075593**	**003**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A075593**	**004**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A075593**	**001**	Jun 09, 2004
AB		HIKMA	**EQ 250MG BASE**	**A076558**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A076558**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A076558**	**004**	Jun 09, 2004
AB		IVAX SUB TEVA PHARMS	**EQ 250MG BASE**	**A076089**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A076089**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A076089**	**004**	Jun 09, 2004
AB		MYLAN	**EQ 500MG BASE**	**A075817**	**003**	Jun 09, 2004
AB		TARO	**EQ 100MG BASE**	**A076912**	**001**	Feb 18, 2005
AB			**EQ 250MG BASE**	**A076912**	**002**	Oct 06, 2004
AB			**EQ 500MG BASE**	**A076912**	**003**	Oct 06, 2004
AB			**EQ 750MG BASE**	**A076912**	**004**	Oct 06, 2004
AB		UNIQUE PHARM LABS	**EQ 250MG BASE**	**A076639**	**001**	Sep 10, 2004
AB			**EQ 500MG BASE**	**A076639**	**002**	Sep 10, 2004
AB			**EQ 750MG BASE**	**A076639**	**003**	Sep 10, 2004
AB		WATSON LABS	**EQ 100MG BASE**	**A076794**	**001**	Feb 10, 2005
AB			**EQ 250MG BASE**	**A076794**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**	**A076794**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**	**A076794**	**004**	Jun 09, 2004

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB		YILING PHARM LTD	**EQ 250MG BASE**	**A208921**	**001**	Jun 22, 2018
AB			**EQ 500MG BASE**	**A208921**	**002**	Jun 22, 2018

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS;OTIC

OTOVEL

	+!	LABORATORIOS SALVAT	EQ 0.3% BASE;0.025%	N208251	001	Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

	+!	NOVARTIS	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	**!**	ANCHEN PHARMS	**425.2MG;EQ 574.9MG BASE**	**A078166**	**001**	Nov 27, 2007
AB		DR REDDYS LABS LTD	**425.2MG;EQ 574.9MG BASE**	**A077701**	**001**	Mar 26, 2007
	!	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

	+!	NOVARTIS	0.3%;0.1%	N021537	001	Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203183**	**001**	Feb 26, 2015
AP		HOSPIRA INC	**EQ 2MG BASE/ML**	**A203236**	**001**	Mar 30, 2018
AP			**EQ 10MG BASE/ML**	**A203236**	**002**	Mar 30, 2018
AP		JIANGSU HENGRUI MED	**EQ 2MG BASE/ML**	**A209334**	**001**	Aug 30, 2017
AP		MEITHEAL	**EQ 2MG BASE/ML**	**A211668**	**001**	Apr 25, 2019
AP			**EQ 2MG BASE/ML**	**A211669**	**001**	Apr 25, 2019
AP			**EQ 10MG BASE/ML**	**A211668**	**002**	Apr 25, 2019
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200159**	**001**	Feb 03, 2012
AP		SOMERSET	**EQ 2MG BASE/ML**	**A209132**	**001**	Apr 24, 2019
AP		ZYDUS PHARMS	**EQ 2MG BASE/ML**	**A212171**	**001**	Nov 04, 2019
AP			**EQ 10MG BASE/ML**	**A212171**	**002**	Nov 04, 2019

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203182**	**001**	Feb 26, 2015
AP			**EQ 10MG BASE/ML**	**A203182**	**002**	Feb 26, 2015
AP		JIANGSU HENGRUI MED	**EQ 2MG BASE/ML**	**A204960**	**001**	Jan 27, 2017
AP			**EQ 10MG BASE/ML**	**A204960**	**002**	Sep 19, 2017
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200154**	**001**	Feb 03, 2012
AP			**EQ 10MG BASE/ML**	**A200154**	**002**	Feb 03, 2012
AP		SOMERSET THERAPS LLC	**EQ 2MG BASE/ML**	**A206791**	**001**	Feb 20, 2019
AP			**EQ 10MG BASE/ML**	**A206791**	**002**	Feb 20, 2019

NIMBEX

AP	**+!**	ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**001**	Dec 15, 1995

NIMBEX PRESERVATIVE FREE

AP	**+!**	ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**003**	Dec 15, 1995
AP	**+!**		**EQ 10MG BASE/ML**	**N020551**	**002**	Dec 15, 1995

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP		ACCORD HLTHCARE	**1MG/ML**	**A206774**	**001**	Aug 18, 2015
AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A074735**	**001**	Jul 16, 1999
AP		GLAND PHARMA LTD	**1MG/ML**	**A207323**	**001**	Mar 17, 2017
AP	**+**	HQ SPCLT PHARMA	**1MG/ML**	**N018057**	**004**	Nov 08, 1988
AP		PHARMACHEMIE BV	**1MG/ML**	**A074656**	**001**	May 16, 2000
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A075036**	**001**	Nov 07, 2000

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA		AUROBINDO PHARMA LTD	**EQ 10MG BASE/5ML**	**A077812**	**001**	Aug 28, 2006
AA		HETERO LABS LTD III	**EQ 10MG BASE/5ML**	**A201450**	**001**	Dec 15, 2015
AA	**!**	HIKMA	**EQ 10MG BASE/5ML**	**A077043**	**001**	Dec 13, 2004

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA		LANNETT CO INC	**EQ 10MG BASE/5ML**	**A077629**	**001**	Jun 15, 2006

TABLET;ORAL

CELEXA

AB	**+**	ALLERGAN	**EQ 10MG BASE**	**N020822**	**001**	Apr 27, 2000
AB	**+**		**EQ 20MG BASE**	**N020822**	**002**	Jul 17, 1998
AB	**+!**		**EQ 40MG BASE**	**N020822**	**003**	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

AB		ACP NIMBLE	**EQ 10MG BASE**	**A077048**	**001**	Nov 16, 2004
AB			**EQ 20MG BASE**	**A077048**	**002**	Nov 16, 2004
AB			**EQ 40MG BASE**	**A077048**	**003**	Nov 16, 2004
AB		AMNEAL PHARMS NY	**EQ 10MG BASE**	**A077289**	**001**	Nov 30, 2006
AB			**EQ 20MG BASE**	**A077289**	**002**	Nov 30, 2006
AB			**EQ 40MG BASE**	**A077289**	**003**	Nov 30, 2006
AB		APOTEX INC	**EQ 10MG BASE**	**A077046**	**001**	Nov 24, 2004
AB		AUROBINDO	**EQ 10MG BASE**	**A077031**	**001**	Oct 28, 2004
AB			**EQ 20MG BASE**	**A077031**	**002**	Oct 28, 2004
AB			**EQ 40MG BASE**	**A077031**	**003**	Oct 28, 2004
AB		CHARTWELL MOLECULAR	**EQ 10MG BASE**	**A077044**	**001**	Nov 05, 2004
AB			**EQ 20MG BASE**	**A077044**	**002**	Nov 05, 2004
AB			**EQ 40MG BASE**	**A077044**	**003**	Nov 05, 2004
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A077038**	**001**	Oct 28, 2004
AB			**EQ 20MG BASE**	**A077038**	**002**	Oct 28, 2004
AB			**EQ 40MG BASE**	**A077038**	**003**	Oct 28, 2004
AB		EPIC PHARMA	**EQ 10MG BASE**	**A077045**	**003**	Apr 29, 2005
AB			**EQ 20MG BASE**	**A077045**	**002**	Apr 29, 2005
AB			**EQ 40MG BASE**	**A077045**	**001**	Apr 29, 2005
AB		GLENMARK GENERICS	**EQ 10MG BASE**	**A077654**	**001**	Feb 27, 2009
AB			**EQ 20MG BASE**	**A077654**	**002**	Feb 27, 2009
AB			**EQ 40MG BASE**	**A077654**	**003**	Feb 27, 2009
AB		INVAGEN PHARMS	**EQ 10MG BASE**	**A077534**	**001**	Oct 03, 2006
AB			**EQ 20MG BASE**	**A077534**	**002**	Oct 03, 2006
AB			**EQ 40MG BASE**	**A077534**	**003**	Oct 03, 2006
AB		JUBILANT GENERICS	**EQ 10MG BASE**	**A205407**	**001**	Dec 23, 2015
AB			**EQ 20MG BASE**	**A205407**	**002**	Dec 23, 2015
AB			**EQ 40MG BASE**	**A205407**	**003**	Dec 23, 2015
AB		MYLAN	**EQ 10MG BASE**	**A077042**	**001**	Nov 05, 2004
AB			**EQ 20MG BASE**	**A077042**	**002**	Nov 05, 2004
AB			**EQ 40MG BASE**	**A077042**	**003**	Nov 05, 2004
AB		TORPHARM	**EQ 20MG BASE**	**A077046**	**002**	Nov 24, 2004
AB			**EQ 40MG BASE**	**A077046**	**003**	Nov 24, 2004
AB		TORRENT PHARMS	**EQ 10MG BASE**	**A078216**	**001**	Mar 27, 2007
AB			**EQ 20MG BASE**	**A078216**	**002**	Mar 27, 2007
AB			**EQ 40MG BASE**	**A078216**	**003**	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

	+!	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML;3.177GM/100ML	N019481	001	Oct 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION;ORAL

CLENPIQ

	+!	FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

	+!	EXALENZ BIOSCIENCE	N/A,4GM;75MG,N/A	N021314	001	Dec 17, 2002

CLADRIBINE

INJECTABLE;INJECTION

CLADRIBINE

AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A076571**	**001**	Apr 22, 2004
AP		HISUN PHARM HANGZHOU	**1MG/ML**	**A210856**	**001**	Nov 25, 2019
AP		MYLAN LABS LTD	**1MG/ML**	**A200510**	**001**	Oct 06, 2011
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A075405**	**001**	Feb 28, 2000

TABLET;ORAL

MAVENCLAD

	+!	EMD SERONO INC	10MG	N022561	001	Mar 29, 2019

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

AB		SANDOZ	**125MG/5ML**	**A065283**	**002**	Sep 04, 2007
AB	**!**		**250MG/5ML**	**A065283**	**003**	Sep 04, 2007

TABLET;ORAL

CLARITHROMYCIN

AB	**!**	AUROBINDO	**250MG**	**A065489**	**001**	Jul 25, 2012
AB	**!**		**500MG**	**A065489**	**002**	Jul 25, 2012
AB		CHARTWELL	**250MG**	**A065384**	**001**	Aug 20, 2007
AB			**500MG**	**A065384**	**002**	Aug 20, 2007
AB		HEC PHARM	**250MG**	**A203584**	**001**	Sep 28, 2015
AB			**500MG**	**A203584**	**002**	Sep 28, 2015
AB		HIKMA	**250MG**	**A065178**	**002**	May 25, 2004
AB			**500MG**	**A065178**	**001**	May 25, 2004
AB		SANDOZ	**250MG**	**A065144**	**001**	Oct 18, 2005
AB			**500MG**	**A065136**	**001**	Aug 25, 2005
AB		STRIDES PHARMA	**250MG**	**A202710**	**001**	Jun 10, 2013
AB			**500MG**	**A202710**	**002**	Jun 10, 2013
AB		TEVA	**250MG**	**A065155**	**001**	May 31, 2005
AB			**500MG**	**A065155**	**002**	May 31, 2005
AB		WOCKHARDT	**250MG**	**A065266**	**001**	May 31, 2006
AB			**500MG**	**A065266**	**002**	May 31, 2006

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		ACTAVIS LABS FL INC	**500MG**	**A065145**	**001**	Jun 24, 2004
AB	**!**	MAYNE PHARMA	**500MG**	**A065154**	**001**	May 18, 2005
AB		NOSTRUM LABS INC	**500MG**	**A203243**	**001**	Feb 29, 2016
AB		SUNSHINE LAKE	**500MG**	**A208987**	**001**	Jul 09, 2018

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

	!	TEVA	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994

TABLET;ORAL

CLEMASTINE FUMARATE

	!	TEVA	2.68MG	A073283	001	Jan 31, 1992

CLEVIDIPINE

EMULSION;INTRAVENOUS

CLEVIPREX

	+!	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
	+!		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLEOCIN HYDROCHLORIDE

AB	**+**	PHARMACIA AND UPJOHN	**EQ 75MG BASE**	**N050162**	**001**	
AB	**+**		**EQ 150MG BASE**	**N050162**	**002**	
AB	**+!**		**EQ 300MG BASE**	**N050162**	**003**	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

AB		ACP NIMBLE	**EQ 150MG BASE**	**A063029**	**001**	Sep 20, 1989
AB			**EQ 300MG BASE**	**A063029**	**002**	Aug 05, 2005
AB		AUROBINDO PHARMA	**EQ 150MG BASE**	**A065442**	**001**	Aug 26, 2009
AB			**EQ 300MG BASE**	**A065442**	**002**	Aug 26, 2009
AB		EPIC PHARMA LLC	**EQ 150MG BASE**	**A065194**	**001**	Mar 22, 2004
AB			**EQ 300MG BASE**	**A065194**	**002**	Mar 22, 2004
AB		LANNETT CO INC	**EQ 75MG BASE**	**A065243**	**002**	Aug 12, 2005
AB			**EQ 150MG BASE**	**A065243**	**003**	Aug 12, 2005
AB			**EQ 300MG BASE**	**A065243**	**001**	Aug 12, 2005
AB		MICRO LABS	**EQ 75MG BASE**	**A207402**	**001**	Nov 05, 2018
AB			**EQ 150MG BASE**	**A207402**	**002**	Nov 05, 2018
AB			**EQ 300MG BASE**	**A207402**	**003**	Nov 05, 2018
AB		SUN PHARM INDS LTD	**EQ 150MG BASE**	**A065061**	**001**	Feb 02, 2001
AB			**EQ 300MG BASE**	**A065061**	**002**	Feb 02, 2001
AB		WATSON LABS	**EQ 150MG BASE**	**A063083**	**001**	Jul 31, 1991
AB			**EQ 300MG BASE**	**A063083**	**002**	Mar 18, 2003
AB		ZYDUS PHARMS USA	**EQ 75MG BASE**	**A065217**	**001**	Jan 31, 2005
AB			**EQ 150MG BASE**	**A065217**	**002**	Jan 31, 2005
AB			**EQ 300MG BASE**	**A065217**	**003**	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

AA	**!**	PHARMACIA AND UPJOHN	**EQ 75MG BASE/5ML**	**A062644**	**001**	Apr 07, 1986

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		AMNEAL PHARMS	**EQ 75MG BASE/5ML**	**A203513**	**001**	Mar 13, 2014
AA		AUROBINDO PHARMA LTD	**EQ 75MG BASE/5ML**	**A202409**	**001**	Apr 30, 2013
AA		HERITAGE PHARMS INC	**EQ 75MG BASE/5ML**	**A207047**	**001**	May 11, 2018
AA		LYNE	**EQ 75MG BASE/5ML**	**A201821**	**001**	Aug 28, 2012
AA		ORIT LABS LLC	**EQ 75MG BASE/5ML**	**A206958**	**001**	May 05, 2017
AA		PADDOCK LLC	**EQ 75MG BASE/5ML**	**A090902**	**001**	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		PERRIGO UK FINCO	**1%**	**A090785**	**001**	Mar 31, 2010

EVOCLIN

AT	**+!**	MYLAN	**1%**	**N050801**	**001**	Oct 22, 2004

CREAM;VAGINAL

CLEOCIN

AB	**+!**	PHARMACIA AND UPJOHN	**EQ 2% BASE**	**N050680**	**002**	Mar 02, 1998

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	**EQ 2% BASE**	**A065139**	**001**	Dec 27, 2004

CLINDESSE

	+!	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004

GEL;TOPICAL

CLEOCIN T

AB	**+!**	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050615**	**001**	Jan 07, 1987

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	**EQ 1% BASE**	**A064160**	**001**	Jan 28, 2000

CLINDAGEL

BT	+!	BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

AP		PHARMACIA AND UPJOHN	**EQ 150MG BASE/ML**	**A062803**	**001**	Oct 16, 1987
AP	**+!**		**EQ 150MG BASE/ML**	**N050441**	**001**	

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 6MG BASE/ML**	**N050639**	**001**	Aug 30, 1989
AP	**+!**		**EQ 12MG BASE/ML**	**N050639**	**002**	Aug 30, 1989
AP	**+!**		**EQ 18MG BASE/ML**	**N050639**	**003**	Apr 10, 1991

CLINDAMYCIN PHOSPHATE

AP		ALVOGEN INC	**EQ 150MG BASE/ML**	**A062800**	**001**	Jul 24, 1987
AP			**EQ 150MG BASE/ML**	**A062801**	**001**	Jul 24, 1987
AP			**EQ 150MG BASE/ML**	**A062943**	**001**	Sep 29, 1988
AP		FRESENIUS KABI USA	**EQ 150MG BASE/ML**	**A065346**	**001**	Mar 29, 2007
AP			**EQ 150MG BASE/ML**	**A065347**	**001**	May 09, 2007
AP		MYLAN LABS LTD	**EQ 150MG BASE/ML**	**A204748**	**001**	Oct 10, 2017
AP			**EQ 150MG BASE/ML**	**A204749**	**001**	Oct 10, 2017
AP		SAGENT PHARMS INC	**EQ 150MG BASE/ML**	**A090108**	**001**	Sep 30, 2011
AP			**EQ 150MG BASE/ML**	**A090109**	**001**	Sep 30, 2011
AP		WEST-WARD PHARMS INT	**EQ 150MG BASE/ML**	**A062889**	**001**	Apr 25, 1988
AP			**EQ 150MG BASE/ML**	**A065206**	**001**	Sep 24, 2004

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		AKORN INC	**EQ 6MG BASE/ML**	**A203048**	**001**	Apr 04, 2013
AP			**EQ 12MG BASE/ML**	**A203048**	**002**	Apr 04, 2013
AP			**EQ 18MG BASE/ML**	**A203048**	**003**	Apr 04, 2013
AP		BAXTER HLTHCARE CORP	**EQ 6MG BASE/ML**	**A208084**	**001**	Jun 28, 2017
AP			**EQ 12MG BASE/ML**	**A208084**	**002**	Jun 28, 2017
AP			**EQ 18MG BASE/ML**	**A208084**	**003**	Jun 28, 2017
AP		SANDOZ INC	**EQ 6MG BASE/ML**	**A201692**	**001**	May 31, 2012
AP			**EQ 12MG BASE/ML**	**A201692**	**002**	May 31, 2012
AP			**EQ 18MG BASE/ML**	**A201692**	**003**	May 31, 2012

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

	+!	ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989

CLINDAMYCIN PHOSPHATE

LOTION;TOPICAL

CLEOCIN T

AB	**+!**	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050600**	**001**	May 31, 1989

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	**EQ 1% BASE**	**A065067**	**001**	Jan 31, 2002

SOLUTION;INTRAVENOUS

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017
	+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017
	+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017

SOLUTION;TOPICAL

CLEOCIN T

AT	**+!**	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050537**	**001**	

CLINDA-DERM

AT		PADDOCK LLC	**EQ 1% BASE**	**A063329**	**001**	Sep 30, 1992

CLINDAMYCIN PHOSPHATE

AT		CADILA	**EQ 1% BASE**	**A208767**	**001**	Jul 16, 2018
AT		ENCUBE ETHICALS	**EQ 1% BASE**	**A209914**	**001**	Jan 28, 2019
AT		FOUGERA PHARMS	**EQ 1% BASE**	**A065254**	**001**	Feb 14, 2006
AT		FOUGERA PHARMS INC	**EQ 1% BASE**	**A064159**	**001**	Jun 05, 1997
AT		G AND W LABS INC	**EQ 1% BASE**	**A062811**	**001**	Sep 01, 1988
AT		GLASSHOUSE PHARMS	**EQ 1% BASE**	**A209846**	**001**	Feb 08, 2018
AT		PERRIGO NEW YORK	**EQ 1% BASE**	**A064050**	**001**	Nov 30, 1995
AT		TARO PHARM INDS	**EQ 1% BASE**	**A065184**	**001**	Mar 31, 2004
AT		TELIGENT PHARMA INC	**EQ 1% BASE**	**A206945**	**001**	Dec 30, 2016
AT		VINTAGE PHARMS	**EQ 1% BASE**	**A203343**	**001**	May 29, 2015

SUPPOSITORY;VAGINAL

CLEOCIN

	+!	PHARMACIA AND UPJOHN	100MG	N050767	001	Aug 13, 1999

SWAB;TOPICAL

CLEOCIN

AT	**+**	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050537**	**002**	Feb 22, 1994

CLINDAMYCIN PHOSPHATE

AT		AKORN	**EQ 1% BASE**	**A065513**	**001**	Jun 17, 2010
AT		PERRIGO NEW YORK	**EQ 1% BASE**	**A065049**	**001**	May 25, 2000

CLINDETS

AT		PERRIGO CO	**EQ 1% BASE**	**A064136**	**001**	Sep 30, 1996

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB		ACTAVIS MID ATLANTIC	**1.2%;0.025%**	**A202564**	**001**	Jun 12, 2015

ZIANA

AB	**+!**	MEDICIS	**1.2%;0.025%**	**N050802**	**001**	Nov 07, 2006

VELTIN

BX	+!	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010

CLOBAZAM

FILM;ORAL

SYMPAZAN

	+	AQUESTIVE THERAP	5MG	N210833	001	Nov 01, 2018
	+		10MG	N210833	002	Nov 01, 2018
	+!		20MG	N210833	003	Nov 01, 2018

SUSPENSION;ORAL

CLOBAZAM

AB		AMNEAL PHARMS LLC	**2.5MG/ML**	**A210039**	**001**	Oct 22, 2018
AB		BIONPHARMA INC	**2.5MG/ML**	**A208819**	**001**	Oct 22, 2018
AB		HIKMA	**2.5MG/ML**	**A209715**	**001**	Oct 22, 2018
AB		LUPIN LTD	**2.5MG/ML**	**A210546**	**001**	Dec 28, 2018
AB		MYLAN	**2.5MG/ML**	**A211259**	**001**	Oct 22, 2018
AB		UPSHER SMITH LABS	**2.5MG/ML**	**A210569**	**001**	Oct 22, 2018
AB		VISTAPHARM	**2.5MG/ML**	**A210746**	**001**	Jul 10, 2019

ONFI

AB	**+!**	LUNDBECK PHARMS LLC	**2.5MG/ML**	**N203993**	**001**	Dec 14, 2012

TABLET;ORAL

CLOBAZAM

AB		ALKEM LABS LTD	**10MG**	**A212714**	**001**	Sep 06, 2019
AB			**20MG**	**A212714**	**002**	Sep 06, 2019

CLOBAZAM

TABLET;ORAL

CLOBAZAM

AB	AMNEAL PHARMS CO	**10MG**	**A209718**	**001**	Oct 22, 2018
AB		**20MG**	**A209718**	**002**	Oct 22, 2018
AB	BIONPHARMA INC	**10MG**	**A208825**	**001**	Oct 22, 2018
AB		**20MG**	**A208825**	**002**	Oct 22, 2018
AB	BRECKENRIDGE	**10MG**	**A209308**	**001**	Oct 22, 2018
AB		**20MG**	**A209308**	**002**	Oct 22, 2018
AB	HETERO LABS LTD III	**10MG**	**A209795**	**001**	Oct 22, 2018
AB		**20MG**	**A209795**	**002**	Oct 22, 2018
AB	HIKMA	**10MG**	**A208785**	**001**	Oct 22, 2018
AB		**20MG**	**A208785**	**002**	Oct 22, 2018
AB	LANNETT CO INC	**10MG**	**A212092**	**001**	Oct 30, 2019
AB		**20MG**	**A212092**	**002**	Oct 30, 2019
AB	LUPIN LTD	**10MG**	**A210545**	**001**	Dec 14, 2018
AB		**20MG**	**A210545**	**002**	Dec 14, 2018
AB	MICRO LABS	**10MG**	**A211711**	**001**	Jan 30, 2019
AB		**20MG**	**A211711**	**002**	Jan 30, 2019
AB	PIRAMAL HLTHCARE UK	**10MG**	**A209808**	**001**	Oct 22, 2018
AB		**20MG**	**A209808**	**002**	Oct 22, 2018
AB	UPSHER SMITH LABS	**10MG**	**A209687**	**001**	Oct 22, 2018
AB		**20MG**	**A209687**	**002**	Oct 22, 2018
AB	ZYDUS PHARMS	**10MG**	**A211449**	**001**	Oct 22, 2018
AB		**20MG**	**A211449**	**002**	Oct 22, 2018

ONFI

AB	+	LUNDBECK PHARMS LLC	**10MG**	**N202067**	**002**	Oct 21, 2011
AB	+!		**20MG**	**N202067**	**003**	Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	GLENMARK PHARMS LTD	**0.05%**	**A210809**	**001**	Feb 15, 2019
AB1	INGENUS PHARMS LLC	**0.05%**	**A206805**	**001**	Jul 31, 2017
AB1	PERRIGO ISRAEL	**0.05%**	**A077763**	**001**	Mar 10, 2008
AB1	TARO	**0.05%**	**A208779**	**001**	Oct 04, 2018

OLUX

AB1	+!	MYLAN	**0.05%**	**N021142**	**001**	May 26, 2000

CLOBETASOL PROPIONATE

AB2	GLENMARK PHARMS LTD	**0.05%**	**A211450**	**001**	Sep 09, 2019
AB2	PERRIGO UK FINCO	**0.05%**	**A201402**	**001**	Aug 14, 2012

OLUX E

AB2	+!	MYLAN	**0.05%**	**N022013**	**001**	Jan 12, 2007

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	ACP NIMBLE	**0.05%**	**A074139**	**001**	Aug 03, 1994
AB1	AMNEAL PHARMS LLC	**0.05%**	**A211256**	**001**	Dec 26, 2018
AB1	FOUGERA PHARMS INC	**0.05%**	**A074392**	**001**	Sep 30, 1996
AB1	GLENMARK PHARMS	**0.05%**	**A209095**	**001**	May 10, 2018
AB1	LUPIN LTD	**0.05%**	**A210208**	**001**	Jan 30, 2018
AB1	MYLAN	**0.05%**	**A075338**	**001**	Feb 09, 2001
AB1	RISING	**0.05%**	**A211401**	**001**	Jan 11, 2019
AB1	TARO	**0.05%**	**A074249**	**001**	Jul 08, 1996
AB1	TELIGENT PHARMA INC	**0.05%**	**A209974**	**001**	Apr 17, 2018
AB1	TORRENT	**0.05%**	**A211836**	**001**	Dec 30, 2019
AB1	XIROMED	**0.05%**	**A210034**	**001**	Jun 15, 2018
AB1	ZYDUS PHARMS	**0.05%**	**A211074**	**001**	Oct 15, 2018

CORMAX

AB1	!	HI TECH PHARMA	**0.05%**	**A074220**	**001**	May 16, 1997

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	!	FOUGERA PHARMS	**0.05%**	**A075430**	**001**	May 26, 1999
AB2		NOVAST LABS	**0.05%**	**A075733**	**001**	Aug 22, 2001
AB2		TARO	**0.05%**	**A075633**	**001**	May 17, 2000
AB2		TELIGENT PHARMA INC	**0.05%**	**A209411**	**001**	Aug 21, 2017

EMBELINE E

AB2		HI TECH PHARMA	**0.05%**	**A075325**	**001**	Dec 24, 1998

IMPOYZ

	+!	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	!	FOUGERA PHARMS	**0.05%**	**A075368**	**001**	Feb 15, 2000
AB		PERRIGO CO	**0.05%**	**A075027**	**001**	Oct 31, 1997
AB		TARO	**0.05%**	**A075279**	**001**	May 28, 1999

CLOBETASOL PROPIONATE

GEL;TOPICAL

CLOBETASOL PROPIONATE						
AB		TELIGENT PHARMA INC	**0.05%**	**A208881**	**001**	Mar 06, 2017
EMBELINE						
AB		HI TECH PHARMA	**0.05%**	**A076141**	**001**	Apr 12, 2002

LOTION;TOPICAL

CLOBETASOL PROPIONATE						
AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078223**	**001**	Dec 04, 2008
AB		CADILA	**0.05%**	**A205249**	**001**	Sep 24, 2019
AB		LUPIN LTD	**0.05%**	**A209147**	**001**	Sep 22, 2017
AB		TARO	**0.05%**	**A200302**	**001**	Jul 02, 2012
AB		TELIGENT PHARMA INC	**0.05%**	**A208667**	**001**	Nov 29, 2016
CLOBEX						
AB	**+!**	GALDERMA LABS LP	**0.05%**	**N021535**	**001**	Jul 24, 2003

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE						
AB		ACP NIMBLE	**0.05%**	**A074089**	**001**	Feb 16, 1994
AB		ALEOR DERMACEUTICALS	**0.05%**	**A211800**	**001**	Mar 04, 2019
AB		ENCUBE	**0.05%**	**A211295**	**001**	Nov 15, 2019
AB	**!**	FOUGERA PHARMS	**0.05%**	**A074407**	**001**	Feb 23, 1996
AB		GLENMARK PHARMS	**0.05%**	**A208933**	**001**	Mar 20, 2017
AB		MYLAN	**0.05%**	**A075057**	**001**	Aug 12, 1998
AB		NOVEL LABS INC	**0.05%**	**A208841**	**001**	May 04, 2018
AB		TARO	**0.05%**	**A074248**	**001**	Jul 12, 1996
AB		TELIGENT PHARMA INC	**0.05%**	**A208589**	**001**	Jan 23, 2019
AB		TORRENT	**0.05%**	**A212926**	**001**	Oct 25, 2019
AB		XIROMED	**0.05%**	**A209701**	**001**	Apr 17, 2018
AB		ZYDUS PHARMS	**0.05%**	**A210199**	**001**	Oct 27, 2017
EMBELINE						
AB		HI TECH PHARMA	**0.05%**	**A074221**	**001**	Mar 31, 1995

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE						
AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078854**	**001**	Jun 07, 2011
AB		HI TECH	**0.05%**	**A209871**	**001**	Oct 27, 2017
AB		PERRIGO ISRAEL	**0.05%**	**A090974**	**001**	Aug 09, 2012
CLOBEX						
AB	**+!**	GALDERMA LABS	**0.05%**	**N021644**	**001**	Feb 05, 2004

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE						
AT		ACP NIMBLE	**0.05%**	**A074331**	**001**	Dec 15, 1995
AT		ALEOR DERMACEUTICALS	**0.05%**	**A212881**	**001**	Oct 21, 2019
AT		FOUGERA PHARMS	**0.05%**	**A075391**	**001**	Feb 08, 1999
AT		GLENMARK PHARMS LTD	**0.05%**	**A210190**	**001**	Apr 18, 2018
AT		MACLEODS PHARMS LTD	**0.05%**	**A209361**	**001**	Oct 25, 2017
AT		NOVEL LABS INC	**0.05%**	**A206075**	**001**	Nov 23, 2015
AT		SAPTALIS PHARMS	**0.05%**	**A211494**	**001**	Oct 02, 2019
AT		TARO	**0.05%**	**A075224**	**001**	Nov 16, 1998
AT			**0.05%**	**A075363**	**001**	Dec 29, 2000
AT		TOLMAR	**0.05%**	**A076977**	**001**	Aug 05, 2005
AT		WOCKHARDT BIO AG	**0.05%**	**A075205**	**001**	Nov 13, 1998
EMBELINE						
AT	**!**	HI TECH PHARMA	**0.05%**	**A074222**	**001**	Dec 06, 1995

SPRAY;TOPICAL

CLOBETASOL PROPIONATE						
AT		AKORN	**0.05%**	**A207218**	**001**	Apr 28, 2017
AT		ALEOR DERMACEUTICALS	**0.05%**	**A211191**	**001**	Oct 02, 2019
AT		GLENMARK PHARMS	**0.05%**	**A209004**	**001**	Mar 26, 2018
AT		LUPIN LTD	**0.05%**	**A208125**	**001**	Mar 26, 2018
AT		PADDOCK LLC	**0.05%**	**A090898**	**001**	Jun 16, 2011
AT		TARO	**0.05%**	**A208842**	**001**	Mar 26, 2018
AT		ZYDUS PHARMS	**0.05%**	**A206378**	**001**	Feb 16, 2017
CLOBEX						
AT	**+!**	GALDERMA LABS LP	**0.05%**	**N021835**	**001**	Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLODERM

+!	EPI HLTH	0.1%	N017765	001		

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP	ABON PHARMS LLC	**20MG/20ML (1MG/ML)**	**A204029**	**001**	May 09, 2017
AP	ACCORD HLTHCARE	**20MG/20ML (1MG/ML)**	**A212034**	**001**	Feb 22, 2019
AP	AMNEAL	**20MG/20ML (1MG/ML)**	**A208857**	**001**	Nov 06, 2017
AP	DR REDDYS LABS LTD	**20MG/20ML (1MG/ML)**	**A205375**	**001**	Nov 06, 2017
AP	GLAND PHARMA LTD	**20MG/20ML (1MG/ML)**	**A207831**	**001**	Oct 31, 2018
AP	INGENUS PHARMS LLC	**20MG/20ML (1MG/ML)**	**A210270**	**001**	Sep 14, 2018
AP	MSN	**20MG/20ML (1MG/ML)**	**A209775**	**001**	Dec 06, 2017
AP	MYLAN LABS LTD	**20MG/20ML (1MG/ML)**	**A208860**	**001**	Nov 06, 2017

CLOLAR

AP	**+!** GENZYME	**20MG/20ML (1MG/ML)**	**N021673**	**001**	Dec 28, 2004

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMIPHENE CITRATE

!	PAR PHARM	50MG	A075528	001	Aug 30, 1999

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

ANAFRANIL

AB	**+!** SPECGX LLC	**25MG**	**N019906**	**001**	Dec 29, 1989
AB	**+**	**50MG**	**N019906**	**002**	Dec 29, 1989
AB	**+**	**75MG**	**N019906**	**003**	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	**25MG**	**A208632**	**001**	Oct 31, 2018
AB		**50MG**	**A208632**	**002**	Oct 31, 2018
AB		**75MG**	**A208632**	**003**	Oct 31, 2018
AB	JUBILANT CADISTA	**25MG**	**A212218**	**001**	Oct 21, 2019
AB		**50MG**	**A212218**	**002**	Oct 21, 2019
AB		**75MG**	**A212218**	**003**	Oct 21, 2019
AB	LUPIN LTD	**25MG**	**A209294**	**001**	Nov 21, 2018
AB		**50MG**	**A209294**	**002**	Nov 21, 2018
AB		**75MG**	**A209294**	**003**	Nov 21, 2018
AB	MYLAN	**25MG**	**A074947**	**001**	Apr 30, 1998
AB		**50MG**	**A074947**	**002**	Apr 30, 1998
AB		**75MG**	**A074947**	**003**	Apr 30, 1998
AB	SANDOZ	**25MG**	**A074364**	**001**	Mar 29, 1996
AB		**25MG**	**A074953**	**001**	Jun 25, 1997
AB		**50MG**	**A074364**	**002**	Mar 29, 1996
AB		**50MG**	**A074953**	**002**	Jun 25, 1997
AB		**75MG**	**A074364**	**003**	Mar 29, 1996
AB		**75MG**	**A074953**	**003**	Jun 25, 1997
AB	TARO	**25MG**	**A074694**	**001**	Dec 31, 1996
AB		**50MG**	**A074694**	**002**	Dec 31, 1996
AB		**75MG**	**A074694**	**003**	Dec 31, 1996
AB	TEVA	**25MG**	**A074958**	**001**	Aug 26, 1997
AB		**50MG**	**A074958**	**002**	Aug 26, 1997
AB		**75MG**	**A074958**	**003**	Aug 26, 1997
AB	ZYDUS PHARMS	**25MG**	**A208961**	**001**	Dec 27, 2017
AB		**50MG**	**A208961**	**002**	Dec 27, 2017
AB		**75MG**	**A208961**	**003**	Dec 27, 2017

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB	ACCORD HLTHCARE	**0.5MG**	**A077147**	**001**	May 02, 2005
AB		**1MG**	**A077147**	**002**	May 02, 2005
AB		**2MG**	**A077147**	**003**	May 02, 2005
AB	ACTAVIS ELIZABETH	**0.5MG**	**A074869**	**001**	Oct 31, 1996
AB		**1MG**	**A074869**	**002**	Oct 31, 1996
AB		**2MG**	**A074869**	**003**	Oct 31, 1996
AB	MYLAN	**0.5MG**	**A075150**	**001**	Oct 05, 1998
AB		**1MG**	**A075150**	**002**	Oct 05, 1998
AB		**2MG**	**A075150**	**003**	Oct 05, 1998
AB	PRINSTON INC	**0.5MG**	**A077856**	**001**	Jun 28, 2006
AB		**1MG**	**A077856**	**002**	Jun 28, 2006
AB		**2MG**	**A077856**	**003**	Jun 28, 2006

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB		SANDOZ	**0.5MG**	**A074979**	**001**	Aug 29, 1997
AB			**1MG**	**A074979**	**002**	Aug 29, 1997
AB			**2MG**	**A074979**	**003**	Aug 29, 1997
AB		TEVA	**0.5MG**	**A074569**	**001**	Sep 10, 1996
AB			**1MG**	**A074569**	**002**	Sep 10, 1996
AB			**2MG**	**A074569**	**003**	Sep 10, 1996
AB		WATSON LABS	**0.5MG**	**A074964**	**001**	Dec 30, 1997
AB			**1MG**	**A074964**	**002**	Dec 30, 1997
AB			**2MG**	**A074964**	**003**	Dec 30, 1997

KLONOPIN

AB	**+**	ROCHE	**0.5MG**	**N017533**	**001**
AB	**+!**		**1MG**	**N017533**	**002**
AB	**+**		**2MG**	**N017533**	**003**

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

AB		ALEMBIC PHARMS LTD	**0.125MG**	**A211033**	**001**	Jun 28, 2019
AB			**0.25MG**	**A211033**	**002**	Jun 28, 2019
AB			**0.5MG**	**A211033**	**003**	Jun 28, 2019
AB			**1MG**	**A211033**	**004**	Jun 28, 2019
AB			**2MG**	**A211033**	**005**	Jun 28, 2019
AB		BARR	**0.125MG**	**A077194**	**001**	Aug 10, 2005
AB			**0.25MG**	**A077194**	**002**	Aug 10, 2005
AB			**0.5MG**	**A077194**	**003**	Aug 10, 2005
AB			**1MG**	**A077194**	**004**	Aug 10, 2005
AB			**2MG**	**A077194**	**005**	Aug 10, 2005
AB		PAR PHARM	**0.125MG**	**A077171**	**001**	Aug 03, 2005
AB			**0.25MG**	**A077171**	**002**	Aug 03, 2005
AB			**0.5MG**	**A077171**	**003**	Aug 03, 2005
AB	**!**		**1MG**	**A077171**	**004**	Aug 03, 2005
AB			**2MG**	**A077171**	**005**	Aug 03, 2005
AB		SUN PHARM INDS INC	**0.125MG**	**A078654**	**001**	Aug 27, 2014
AB			**0.25MG**	**A078654**	**002**	Aug 27, 2014
AB			**0.5MG**	**A078654**	**003**	Aug 27, 2014
AB			**1MG**	**A078654**	**004**	Aug 27, 2014
AB			**2MG**	**A078654**	**005**	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CATAPRES-TTS-1

AB	**+**	BOEHRINGER INGELHEIM	**0.1MG/24HR**	**N018891**	**001**	Oct 10, 1984

CATAPRES-TTS-2

AB	**+**	BOEHRINGER INGELHEIM	**0.2MG/24HR**	**N018891**	**002**	Oct 10, 1984

CATAPRES-TTS-3

AB	**+!**	BOEHRINGER INGELHEIM	**0.3MG/24HR**	**N018891**	**003**	Oct 10, 1984

CLONIDINE

AB		ACTAVIS LABS UT INC	**0.1MG/24HR**	**A090873**	**001**	May 06, 2014
AB			**0.2MG/24HR**	**A090873**	**002**	May 06, 2014
AB			**0.3MG/24HR**	**A090873**	**003**	May 06, 2014
AB		AVEVA	**0.1MG/24HR**	**A076157**	**001**	Aug 18, 2009
AB			**0.2MG/24HR**	**A076157**	**002**	Aug 18, 2009
AB			**0.3MG/24HR**	**A076157**	**003**	Aug 18, 2009
AB		MAYNE PHARMA	**0.1MG/24HR**	**A079090**	**001**	Aug 20, 2010
AB			**0.2MG/24HR**	**A079090**	**002**	Aug 20, 2010
AB			**0.3MG/24HR**	**A079090**	**003**	Aug 20, 2010
AB		MYLAN TECHNOLOGIES	**0.1MG/24HR**	**A076166**	**001**	Jul 16, 2010
AB			**0.2MG/24HR**	**A076166**	**002**	Jul 16, 2010
AB			**0.3MG/24HR**	**A076166**	**003**	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/10ML (0.1MG/ML)**	**A200673**	**001**	Jul 08, 2011
AP			**5MG/10ML (0.5MG/ML)**	**A200673**	**002**	Jul 08, 2011
AP		HIKMA FARMACEUTICA	**1MG/10ML (0.1MG/ML)**	**A200300**	**001**	Jan 26, 2011
AP			**5MG/10ML (0.5MG/ML)**	**A200300**	**002**	Jan 26, 2011
AP		X-GEN PHARMS INC	**1MG/10ML (0.1MG/ML)**	**A203167**	**001**	Oct 29, 2013
AP			**5MG/10ML (0.5MG/ML)**	**A203167**	**002**	Oct 29, 2013
AP		ZYDUS PHARMS	**1MG/10ML (0.1MG/ML)**	**A202601**	**001**	Feb 20, 2014

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP			**5MG/10ML (0.5MG/ML)**	**A202601**	**002**	Feb 20, 2014

DURACLON

AP	+	MYLAN INSTITUTIONAL	**1MG/10ML (0.1MG/ML)**	**N020615**	**001**	Oct 02, 1996
AP	+!		**5MG/10ML (0.5MG/ML)**	**N020615**	**002**	Apr 27, 1999

TABLET;ORAL

CATAPRES

AB	+	BOEHRINGER INGELHEIM	**0.1MG**	**N017407**	**001**	
AB	+		**0.2MG**	**N017407**	**002**	
AB	+!		**0.3MG**	**N017407**	**003**	

CLONIDINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**0.1MG**	**A070974**	**001**	Dec 16, 1986
AB			**0.2MG**	**A070975**	**001**	Dec 16, 1986
AB			**0.3MG**	**A070976**	**001**	Dec 16, 1986
AB		ALEMBIC PHARMS LTD	**0.1MG**	**A091368**	**001**	Dec 06, 2011
AB			**0.2MG**	**A091368**	**002**	Dec 06, 2011
AB			**0.3MG**	**A091368**	**003**	Dec 06, 2011
AB		FRONTIDA BIOPHARM	**0.1MG**	**A070923**	**003**	Sep 04, 1987
AB			**0.2MG**	**A070923**	**002**	Sep 04, 1987
AB			**0.3MG**	**A070923**	**001**	Sep 04, 1987
AB		IMPAX LABS	**0.1MG**	**A078099**	**001**	Aug 27, 2009
AB			**0.2MG**	**A078099**	**002**	Aug 27, 2009
AB			**0.3MG**	**A078099**	**003**	Aug 27, 2009
AB		MYLAN	**0.1MG**	**A070317**	**002**	Jul 09, 1987
AB			**0.2MG**	**A070317**	**003**	Jun 09, 1987
AB			**0.3MG**	**A070317**	**001**	Jun 09, 1987
AB		PRINSTON INC	**0.1MG**	**A077901**	**001**	Mar 09, 2007
AB			**0.2MG**	**A077901**	**002**	Mar 09, 2007
AB			**0.3MG**	**A077901**	**003**	Mar 09, 2007
AB		UNICHEM	**0.1MG**	**A078895**	**001**	Aug 26, 2009
AB			**0.2MG**	**A078895**	**002**	Aug 26, 2009
AB			**0.3MG**	**A078895**	**003**	Aug 26, 2009
AB		YUNG SHIN PHARM	**0.1MG**	**A202297**	**001**	Jun 13, 2013
AB			**0.2MG**	**A202297**	**002**	Jun 13, 2013
AB			**0.3MG**	**A202297**	**003**	Jun 13, 2013

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1		ACTAVIS ELIZABETH	**0.1MG**	**A203320**	**001**	May 15, 2015
AB1		AJANTA PHARMA LTD	**0.1MG**	**A209686**	**001**	Nov 20, 2017
AB1		AMNEAL PHARMS NY	**0.1MG**	**A210052**	**001**	Nov 20, 2017
AB1		ANCHEN PHARMS	**0.1MG**	**A202984**	**001**	Sep 30, 2013
AB1		JUBILANT GENERICS	**0.1MG**	**A210338**	**001**	Jan 29, 2018
AB1		LUPIN LTD	**0.1MG**	**A209285**	**001**	Oct 23, 2017
AB1		MAYNE PHARMA INC	**0.1MG**	**A210680**	**001**	Apr 30, 2018
AB1		NOVAST LABS	**0.1MG**	**A209675**	**001**	Mar 05, 2019
AB1		XIAMEN LP PHARM CO	**0.1MG**	**A209757**	**001**	Nov 20, 2017

KAPVAY

AB1	+!	CONCORDIA PHARMS INC	**0.1MG**	**N022331**	**003**	Sep 28, 2010

CLONIDINE HYDROCHLORIDE

AB2		ACTAVIS ELIZABETH	**0.1MG**	**A202792**	**001**	May 15, 2015

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB		ACCORD HLTHCARE	**EQ 75MG BASE**	**A202925**	**001**	Mar 27, 2013
AB			**EQ 300MG BASE**	**A202925**	**002**	Mar 27, 2013
AB		ACME LABS	**EQ 75MG BASE**	**A078004**	**001**	May 17, 2012
AB		AMNEAL PHARMS	**EQ 75MG BASE**	**A203751**	**001**	Apr 11, 2014
AB		APOTEX INC	**EQ 75MG BASE**	**A076274**	**001**	May 17, 2012
AB			**EQ 300MG BASE**	**A076274**	**002**	Mar 04, 2014
AB		AUROBINDO PHARMA LTD	**EQ 75MG BASE**	**A090540**	**001**	May 17, 2012
AB		CELLTRION	**EQ 75MG BASE**	**A202266**	**001**	Aug 14, 2012
AB			**EQ 300MG BASE**	**A202266**	**002**	Nov 20, 2012
AB		CSPC OUYI	**EQ 75MG BASE**	**A204359**	**001**	Feb 02, 2017
AB		DR REDDYS LABS INC	**EQ 75MG BASE**	**A076273**	**001**	Jan 14, 2008
AB		DR REDDYS LABS LTD	**EQ 300MG BASE**	**A091023**	**001**	May 17, 2012
AB		MACLEODS PHARMS LTD	**EQ 75MG BASE**	**A202928**	**001**	Feb 10, 2014
AB		PRINSTON INC	**EQ 75MG BASE**	**A206376**	**001**	May 07, 2018

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB			**EQ 300MG BASE**	**A206376**	**002**	May 07, 2018
AB		SCIEGEN PHARMS INC	**EQ 75MG BASE**	**A204165**	**001**	Sep 15, 2014
AB			**EQ 300MG BASE**	**A204165**	**002**	Sep 15, 2014
AB		SUN PHARM	**EQ 75MG BASE**	**A090494**	**001**	May 17, 2012
AB		TEVA	**EQ 75MG BASE**	**A076999**	**001**	May 17, 2012
AB		TORRENT PHARMS LTD	**EQ 75MG BASE**	**A090844**	**001**	May 17, 2012

PLAVIX

AB	+	SANOFI AVENTIS US	**EQ 75MG BASE**	**N020839**	**001**	Nov 17, 1997
AB	+!		**EQ 300MG BASE**	**N020839**	**002**	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB		MYLAN	**3.75MG**	**A071858**	**002**	Jul 17, 1987
AB			**7.5MG**	**A071858**	**003**	Jul 17, 1987
AB	!		**15MG**	**A071858**	**001**	Jul 17, 1987
AB		TARO	**3.75MG**	**A075731**	**003**	Apr 27, 2000
AB			**7.5MG**	**A075731**	**002**	Apr 27, 2000
AB			**15MG**	**A075731**	**001**	Apr 27, 2000

GEN-XENE

AB		ALRA	**3.75MG**	**A071787**	**001**	Apr 26, 1988
AB			**7.5MG**	**A071788**	**001**	Apr 26, 1988
AB			**15MG**	**A071789**	**001**	Apr 26, 1988

TRANXENE

AB	+	RECORDATI RARE	**7.5MG**	**N017105**	**007**	

CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE

AB		FOUGERA PHARMS	**1%**	**A078338**	**001**	Sep 02, 2008
AB		GLENMARK PHARMS	**1%**	**A090219**	**001**	Aug 03, 2010
AB	!	TARO	**1%**	**A072640**	**001**	Aug 31, 1993

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT		NOVITIUM PHARMA	**1%**	**A209815**	**001**	Feb 14, 2019
AT	!	TARO	**1%**	**A074580**	**001**	Jul 29, 1996
AT		TASMAN PHARMA	**1%**	**A212281**	**001**	Jul 25, 2019
AT		TEVA	**1%**	**A073306**	**001**	Feb 28, 1995

TROCHE/LOZENGE;ORAL

CLOTRIMAZOLE

AB	!	HIKMA	**10MG**	**A076387**	**001**	Jul 29, 2004
AB		PADDOCK LLC	**10MG**	**A076763**	**001**	Oct 28, 2005

CLOZAPINE

SUSPENSION;ORAL

VERSACLOZ

	+!	TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013

TABLET;ORAL

CLOZAPINE

AB		ACCORD HLTHCARE	**25MG**	**A202873**	**001**	Nov 25, 2015
AB			**100MG**	**A202873**	**002**	Nov 25, 2015
AB		AUROBINDO PHARMA LTD	**25MG**	**A206433**	**001**	Nov 29, 2016
AB			**50MG**	**A206433**	**002**	Nov 29, 2016
AB			**100MG**	**A206433**	**003**	Nov 29, 2016
AB			**200MG**	**A206433**	**004**	Nov 29, 2016
AB		IVAX SUB TEVA PHARMS	**25MG**	**A074949**	**001**	Nov 26, 1997
AB			**50MG**	**A074949**	**004**	Apr 25, 2005
AB			**50MG**	**A076809**	**003**	Dec 16, 2005
AB			**100MG**	**A074949**	**002**	Nov 26, 1997
AB			**100MG**	**A076809**	**002**	Dec 16, 2005
AB			**200MG**	**A076809**	**001**	Dec 16, 2005
AB		MAYNE PHARMA	**25MG**	**A203807**	**001**	Sep 17, 2015
AB			**50MG**	**A203807**	**003**	Aug 22, 2017
AB			**100MG**	**A203807**	**002**	Sep 17, 2015
AB			**200MG**	**A203807**	**004**	Aug 22, 2017
AB		MYLAN	**25MG**	**A075417**	**001**	May 27, 1999
AB			**50MG**	**A075417**	**004**	Apr 15, 2010
AB			**100MG**	**A075417**	**002**	May 27, 1999
AB			**200MG**	**A075417**	**005**	Apr 15, 2010

CLOZAPINE

TABLET;ORAL

CLOZAPINE

AB		SUN PHARM INDS INC	**25MG**	**A075713**	**001**	Nov 15, 2002
AB			**50MG**	**A075713**	**003**	Aug 19, 2005
AB			**100MG**	**A075713**	**002**	Nov 15, 2002
AB			**200MG**	**A075713**	**004**	Nov 07, 2017

CLOZARIL

AB	**+**	HERITAGE LIFE	**25MG**	**N019758**	**001**	Sep 26, 1989
AB	**+**		**50MG**	**N019758**	**003**	May 20, 2019
AB	**+!**		**100MG**	**N019758**	**002**	Sep 26, 1989
AB	**+**		**200MG**	**N019758**	**004**	May 20, 2019

CLOZAPINE

	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB		BARR LABS INC	**25MG**	**A090308**	**001**	Nov 25, 2015
AB	**!**		**100MG**	**A090308**	**002**	Nov 25, 2015
AB		MYLAN	**25MG**	**A201824**	**002**	Sep 15, 2015
AB			**100MG**	**A201824**	**003**	Sep 15, 2015
		BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018
		TEVA PHARMS USA	150MG	A203039	001	Nov 25, 2015
			200MG	A203039	002	Nov 25, 2015

COBICISTAT

TABLET;ORAL

TYBOST

	+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014

COBICISTAT; DARUNAVIR

TABLET;ORAL

PREZCOBIX

	+!	JANSSEN PRODS	150MG;800MG	N205395	001	Jan 29, 2015

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

SYMTUZA

	+!	JANSSEN PRODS	150MG;800MG;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

GENVOYA

	+!	GILEAD SCIENCES INC	150MG;150MG;200MG;EQ 10MG BASE	N207561	001	Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

	+!	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100	001	Aug 27, 2012

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

	+!	GENENTECH INC	EQ 20MG BASE	N206192	001	Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

	+!	GENUS LIFESCIENCES	4%	N209963	001	Dec 14, 2017

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		VINTAGE	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040660**	**001**	Dec 07, 2006

PROMETH VC W/ CODEINE

AA	**!**	ACTAVIS MID ATLANTIC	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A088764**	**001**	Oct 31, 1984

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		HI-TECH PHARMA CO	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040674**	**001**	Dec 23, 2014

PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AMNEAL PHARMS	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A200963**	**001**	Aug 26, 2015

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	**!**	ACTAVIS MID ATLANTIC	**10MG/5ML;6.25MG/5ML**	**A088763**	**001**	Oct 31, 1984
AA		AMNEAL PHARMS	**10MG/5ML;6.25MG/5ML**	**A200894**	**001**	Apr 24, 2013
AA		HI TECH PHARMA	**10MG/5ML;6.25MG/5ML**	**A040151**	**001**	Aug 26, 1997
AA		NOSTRUM LABS INC	**10MG/5ML;6.25MG/5ML**	**A090180**	**001**	Mar 17, 2010
AA		TRIS PHARMA INC	**10MG/5ML;6.25MG/5ML**	**A200386**	**001**	Jun 29, 2012
AA		WOCKHARDT BIO AG	**10MG/5ML;6.25MG/5ML**	**A088875**	**001**	Dec 17, 1984

PROMETHAZINE WITH CODEINE

AA		VINTAGE	**10MG/5ML;6.25MG/5ML**	**A040650**	**001**	Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

	!	STI PHARMA LLC	10MG/5ML;30MG/5ML;1.25MG/5ML	A088704	001	Mar 22, 1985

CODEINE SULFATE

TABLET;ORAL

CODEINE SULFATE

AB	**+**	HIKMA	**15MG**	**N022402**	**001**	Jul 16, 2009
AB	**+**		**30MG**	**N022402**	**002**	Jul 16, 2009
AB	**+!**		**60MG**	**N022402**	**003**	Jul 16, 2009
AB		LANNETT CO INC	**15MG**	**A203046**	**001**	Jun 13, 2014
AB			**30MG**	**A203046**	**002**	Jun 13, 2014
AB			**60MG**	**A203046**	**003**	Jun 13, 2014

COLCHICINE

CAPSULE;ORAL

MITIGARE

	+!	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014

SOLUTION;ORAL

GLOPERBA

	+!	AVION PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019

TABLET;ORAL

COLCHICINE

AB		ALKEM LABS LTD	**0.6MG**	**A211250**	**001**	Feb 08, 2019
AB		DR REDDYS	**0.6MG**	**A209876**	**001**	Sep 06, 2019
AB		MYLAN	**0.6MG**	**A209470**	**001**	Sep 16, 2019
AB		WATSON LABS INC	**0.6MG**	**A204461**	**001**	Jul 31, 2019

COLCRYS

AB	**+!**	TAKEDA PHARMS USA	**0.6MG**	**N022352**	**001**	Jul 29, 2009

COLCHICINE; PROBENECID

TABLET;ORAL

COL-PROBENECID

AB	**!**	WATSON LABS	**0.5MG;500MG**	**A084279**	**001**	

PROBENECID AND COLCHICINE

AB		NOVAST LABS	**0.5MG;500MG**	**A040618**	**001**	May 13, 2008

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL

WELCHOL

	+!	DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	**3.75GM/PACKET**	**A210316**	**001**	May 06, 2019
AB		GLENMARK PHARMS LTD	**3.75GM/PACKET**	**A202190**	**002**	Jul 16, 2018

WELCHOL

AB	**+!**	DAIICHI SANKYO	**3.75GM/PACKET**	**N022362**	**002**	Oct 02, 2009

COLESEVELAM HYDROCHLORIDE

		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	**625MG**	**A209038**	**001**	Oct 05, 2018
AB		BIONPHARMA INC	**625MG**	**A208670**	**001**	Sep 13, 2019
AB		DR REDDYS	**625MG**	**A210889**	**001**	Oct 05, 2018
AB		GLENMARK PHARMS LTD	**625MG**	**A203480**	**001**	May 18, 2018
AB		IMPAX LABS INC	**625MG**	**A091600**	**001**	May 16, 2018
AB		ZYDUS PHARMS	**625MG**	**A207765**	**001**	Oct 07, 2019

WELCHOL

AB	**+!**	DAIICHI SANKYO	**625MG**	**N021176**	**001**	May 26, 2000

COLESTIPOL HYDROCHLORIDE							
GRANULE;ORAL							
COLESTID							
AB	**+**	PHARMACIA UPJOHN	**5GM/SCOOPFUL**	**N017563**	**003**	Sep 22, 1995	
AB	**+!**		**5GM/PACKET**	**N017563**	**004**	Sep 22, 1995	
COLESTIPOL HYDROCHLORIDE							
AB		IMPAX LABS	**5GM/SCOOPFUL**	**A077277**	**001**	May 02, 2006	
AB			**5GM/PACKET**	**A077277**	**002**	May 02, 2006	
FLAVORED COLESTID							
	+	PHARMACIA UPJOHN	5GM/PACKET	N017563	001		
	+		5GM/SCOOPFUL	N017563	002		
TABLET;ORAL							
COLESTID							
AB	**+!**	PHARMACIA UPJOHN	**1GM**	**N020222**	**001**	Jul 19, 1994	
COLESTIPOL HYDROCHLORIDE							
AB		IMPAX LABS	**1GM**	**A077510**	**001**	Oct 24, 2006	
COLISTIMETHATE SODIUM							
INJECTABLE;INJECTION							
COLISTIMETHATE SODIUM							
AP		EMCURE PHARMS LTD	**EQ 150MG BASE/VIAL**	**A202359**	**001**	Sep 28, 2012	
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A065364**	**001**	Apr 17, 2008	
AP		NEXUS PHARMS	**EQ 150MG BASE/VIAL**	**A065177**	**001**	Mar 19, 2004	
AP		SAGENT PHARMS INC	**EQ 150MG BASE/VIAL**	**A201365**	**001**	Feb 19, 2014	
AP		X GEN PHARMS	**EQ 150MG BASE/VIAL**	**A064216**	**001**	Feb 26, 1999	
AP		XELLIA PHARMS APS	**EQ 150MG BASE/VIAL**	**A205356**	**001**	May 29, 2015	
COLY-MYCIN M							
AP	**+!**	PAR STERILE PRODUCTS	**EQ 150MG BASE/VIAL**	**N050108**	**002**		
COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE							
SUSPENSION/DROPS;OTIC							
COLY-MYCIN S							
	+!	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001		
CONIVAPTAN HYDROCHLORIDE							
INJECTABLE;INTRAVENOUS							
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER							
	+!	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	
COPANLISIB DIHYDROCHLORIDE							
POWDER;INTRAVENOUS							
ALIQOPA							
	+!	BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017	
COPPER							
INTRAUTERINE DEVICE;INTRAUTERINE							
PARAGARD T 380A							
	+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984	
CORTICORELIN OVINE TRIFLUTATE							
INJECTABLE;INJECTION							
ACTHREL							
	+!	FERRING	EQ 0.1MG BASE/VIAL	N020162	001	May 23, 1996	
CORTICOTROPIN							
INJECTABLE;INJECTION							
H.P. ACTHAR GEL							
	+!	MALLINCKRODT ARD	80 UNITS/ML	N008372	008		
CORTISONE ACETATE							
TABLET;ORAL							
CORTISONE ACETATE							
	!	HIKMA INTL PHARMS	25MG	A080776	002		
COSYNTROPIN							
INJECTABLE;INJECTION							
CORTROSYN							
AP	**+!**	AMPHASTAR PHARMS INC	**0.25MG/VIAL**	**N016750**	**001**		
COSYNTROPIN							
AP		MYLAN INSTITUTIONAL	**0.25MG/VIAL**	**A090574**	**001**	Dec 17, 2009	
AP		SANDOZ	**0.25MG/VIAL**	**A202147**	**001**	Jun 29, 2012	

CRISABOROLE
OINTMENT;TOPICAL
EUCRISA

+!	ANACOR PHARMS INC	2%	N207695	001	Dec 14, 2016

CRIZOTINIB
CAPSULE;ORAL
XALKORI

+	PF PRISM CV	200MG	N202570	001	Aug 26, 2011
+!		250MG	N202570	002	Aug 26, 2011

CROFELEMER
TABLET, DELAYED RELEASE;ORAL
MYTESI

+!	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012

CROMOLYN SODIUM
CONCENTRATE;ORAL
CROMOLYN SODIUM

AA		AILEX PHARMS LLC	**100MG/5ML**	**A209264**	**001**	Oct 16, 2017
AA		MICRO LABS LTD INDIA	**100MG/5ML**	**A202745**	**001**	Apr 04, 2013
AA		RISING	**100MG/5ML**	**A202583**	**001**	Oct 27, 2011

GASTROCROM

AA	**+!**	MYLAN SPECIALITY LP	**100MG/5ML**	**N020479**	**001**	Feb 29, 1996

SOLUTION;INHALATION
CROMOLYN SODIUM

AN		AILEX PHARMS LLC	**10MG/ML**	**A209453**	**001**	Oct 16, 2017
AN	**!**	TEVA PHARMS	**10MG/ML**	**A075271**	**001**	Jan 18, 2000
AN		WOCKHARDT BIO AG	**10MG/ML**	**A075346**	**001**	Oct 25, 1999

SOLUTION/DROPS;OPHTHALMIC
CROMOLYN SODIUM

AT	**!**	AKORN	**4%**	**A074706**	**001**	Apr 29, 1998
AT		SANDOZ INC	**4%**	**A075282**	**001**	Jun 16, 1999

CROTAMITON
LOTION;TOPICAL
CROTAN

AT		MARNEL PHARMS	**10%**	**A087204**	**001**	

EURAX

AT	**+!**	SUN PHARM INDS INC	**10%**	**N009112**	**003**	

CUPRIC CHLORIDE
INJECTABLE;INJECTION
CUPRIC CHLORIDE IN PLASTIC CONTAINER

+!	HOSPIRA	EQ 0.4MG COPPER/ML	N018960	001	Jun 26, 1986

CYANOCOBALAMIN
INJECTABLE;INJECTION
CYANOCOBALAMIN

AP	**+!**	AM REGENT	**1MG/ML**	**A080737**	**001**	
AP		MYLAN LABS LTD	**1MG/ML**	**A204829**	**001**	Jun 05, 2017
AP		SOMERSET THERAPS LLC	**1MG/ML**	**A206503**	**001**	Dec 11, 2015
AP			**1MG/ML**	**A209429**	**001**	Dec 18, 2018
AP		VITRUVIAS THERAP	**1MG/ML**	**A209255**	**001**	Dec 18, 2018
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A080515**	**002**	

VIBISONE

AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A080557**	**003**	

SPRAY, METERED;NASAL
NASCOBAL

+!	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
AMRIX

AB	**+**	TEVA PHARMS INTL	**15MG**	**N021777**	**001**	Feb 01, 2007
AB	**+!**		**30MG**	**N021777**	**002**	Feb 01, 2007

CYCLOBENZAPRINE HYDROCHLORIDE

AB		APOTEX	**15MG**	**A206703**	**001**	Jul 24, 2018
AB			**30MG**	**A206703**	**002**	Jul 24, 2018
AB		TWI PHARMS INC	**15MG**	**A091281**	**001**	Jan 31, 2013
AB			**30MG**	**A091281**	**002**	Jan 31, 2013

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**5MG**	**A071611**	**002**	Feb 03, 2006
AB			**7.5MG**	**A071611**	**003**	Feb 03, 2006
AB			**10MG**	**A071611**	**001**	May 03, 1989
AB		ANDA REPOSITORY	**5MG**	**A073541**	**002**	Apr 06, 2006
AB			**10MG**	**A073541**	**001**	May 23, 1995
AB		AUROBINDO PHARMA	**5MG**	**A078643**	**001**	Sep 26, 2008
AB			**10MG**	**A078643**	**002**	Sep 26, 2008
AB		INVAGEN PHARMS	**5MG**	**A090478**	**001**	Jul 23, 2010
AB			**10MG**	**A090478**	**002**	Jul 23, 2010
AB		JUBILANT CADISTA	**5MG**	**A077563**	**001**	Apr 19, 2006
AB			**7.5MG**	**A077563**	**003**	Aug 25, 2017
AB			**10MG**	**A077563**	**002**	Apr 19, 2006
AB		KVK TECH	**5MG**	**A078048**	**001**	Feb 28, 2011
AB			**10MG**	**A078048**	**002**	Feb 28, 2011
AB		MYLAN PHARMS INC	**5MG**	**A073144**	**002**	Feb 03, 2006
AB			**7.5MG**	**A073144**	**003**	Mar 25, 2013
AB	**!**		**10MG**	**A073144**	**001**	May 30, 1991
AB		ORIT LABS LLC	**5MG**	**A078218**	**002**	Jun 19, 2015
AB			**10MG**	**A078218**	**001**	Apr 18, 2008
AB		OXFORD PHARMS	**5MG**	**A077209**	**002**	Feb 03, 2006
AB			**10MG**	**A077209**	**001**	Oct 04, 2005
AB		PLIVA	**10MG**	**A074421**	**001**	Sep 29, 1995
AB		PRINSTON INC	**5MG**	**A077797**	**001**	Feb 28, 2007
AB			**10MG**	**A077797**	**002**	Feb 28, 2007
AB		RUBICON	**5MG**	**A208170**	**001**	May 31, 2017
AB			**7.5MG**	**A208170**	**002**	May 31, 2017
AB			**10MG**	**A208170**	**003**	May 31, 2017
AB		SUN PHARM INDS LTD	**5MG**	**A078722**	**001**	May 12, 2008
AB			**7.5MG**	**A078722**	**002**	May 12, 2008
AB			**10MG**	**A078722**	**003**	May 12, 2008

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPENTOLATE

AT		AKORN	**1%**	**A040164**	**001**	Jan 13, 1997

CYCLOGYL

AT	**!**	ALCON LABS INC	**0.5%**	**A084109**	**001**	
AT	**!**		**1%**	**A084110**	**001**	

CYCLOPENTOLATE HYDROCHLORIDE

AT		AKORN INC	**0.5%**	**A205937**	**001**	Dec 09, 2015

PENTOLAIR

AT		BAUSCH AND LOMB	**1%**	**A040075**	**001**	Apr 29, 1994

CYCLOGYL

	!	ALCON LABS INC	2%	A084108	001	

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOMYDRIL

	!	ALCON LABS INC	0.2%;1%	A084300	001	

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

AB		AMERIGEN PHARMS LTD	**25MG**	**A207014**	**001**	Mar 19, 2018
AB			**50MG**	**A207014**	**002**	Mar 19, 2018
AB		CIPLA	**25MG**	**A211608**	**001**	Jan 18, 2019
AB			**50MG**	**A211608**	**002**	Jan 18, 2019
AB	**+**	HIKMA	**25MG**	**N203856**	**001**	Sep 16, 2013
AB	**+!**		**50MG**	**N203856**	**002**	Sep 16, 2013
AB		STI PHARMA LLC	**25MG**	**A209872**	**001**	May 07, 2018
AB			**50MG**	**A209872**	**002**	May 07, 2018

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

AP		AMNEAL	**500MG/VIAL**	**A210046**	**001**	May 25, 2018
AP			**1GM/VIAL**	**A210046**	**002**	May 25, 2018
AP			**2GM/VIAL**	**A210046**	**003**	May 25, 2018
AP	**!**	BAXTER HLTHCARE	**500MG/VIAL**	**A040745**	**001**	May 21, 2008
AP	**!**		**1GM/VIAL**	**A040745**	**002**	May 21, 2008
AP	**!**		**2GM/VIAL**	**A040745**	**003**	May 21, 2008
AP		JIANGSU HENGRUI MED	**500MG/VIAL**	**A204555**	**001**	Oct 31, 2014
AP			**1GM/VIAL**	**A204555**	**002**	Oct 31, 2014

CYCLOPHOSPHAMIDE						
INJECTABLE;INJECTION						
CYCLOPHOSPHAMIDE						
AP			**2GM/VIAL**	**A204555**	**003**	Oct 31, 2014
CYCLOSERINE						
CAPSULE;ORAL						
SEROMYCIN						
	!	PURDUE	250MG	A060593	001	
CYCLOSPORINE						
CAPSULE;ORAL						
CYCLOSPORINE						
AB1		APOTEX	**25MG**	**A210721**	**001**	Jul 10, 2019
AB1			**50MG**	**A210721**	**002**	Jul 10, 2019
AB1			**100MG**	**A210721**	**003**	Jul 10, 2019
AB1		IVAX SUB TEVA PHARMS	**25MG**	**A065110**	**003**	Mar 29, 2005
AB1			**50MG**	**A065110**	**001**	Mar 29, 2005
AB1			**100MG**	**A065110**	**002**	Mar 29, 2005
AB1		MAYNE PHARMA	**25MG**	**A065044**	**002**	Dec 20, 2000
AB1			**100MG**	**A065044**	**001**	Dec 20, 2000
AB1		SANDOZ	**25MG**	**A065017**	**002**	Jan 13, 2000
AB1			**100MG**	**A065017**	**001**	Jan 13, 2000
GENGRAF						
AB1		ABBVIE	**25MG**	**A065003**	**001**	May 12, 2000
AB1			**100MG**	**A065003**	**003**	May 12, 2000
NEORAL						
AB1	**+**	NOVARTIS	**25MG**	**N050715**	**001**	Jul 14, 1995
AB1	**+!**		**100MG**	**N050715**	**002**	Jul 14, 1995
CYCLOSPORINE						
AB2		APOTEX	**25MG**	**A065040**	**001**	May 09, 2002
AB2			**100MG**	**A065040**	**002**	May 09, 2002
SANDIMMUNE						
AB2	**+**	NOVARTIS	**25MG**	**N050625**	**001**	Mar 02, 1990
AB2	**+!**		**100MG**	**N050625**	**002**	Mar 02, 1990
BX	+		50MG	N050625	003	Nov 23, 1992
EMULSION;OPHTHALMIC						
RESTASIS						
	+!	ALLERGAN	0.05%	N050790	001	Dec 23, 2002
RESTASIS MULTIDOSE						
	+!	ALLERGAN	0.05%	N050790	002	Oct 27, 2016
INJECTABLE;INJECTION						
CYCLOSPORINE						
AP		AM REGENT	**50MG/ML**	**A065151**	**001**	Oct 07, 2003
AP		WEST-WARD PHARMS INT	**50MG/ML**	**A065004**	**001**	Oct 29, 1999
SANDIMMUNE						
AP	**+!**	NOVARTIS	**50MG/ML**	**N050573**	**001**	Nov 14, 1983
SOLUTION;OPHTHALMIC						
CEQUA						
	+!	SUN PHARMA GLOBAL	0.09%	N210913	001	Aug 14, 2018
SOLUTION;ORAL						
CYCLOSPORINE						
AB1		ABBVIE	**100MG/ML**	**A065025**	**001**	Mar 03, 2000
AB1		IVAX SUB TEVA PHARMS	**100MG/ML**	**A065078**	**001**	Mar 25, 2005
AB1		MAYNE PHARMA	**100MG/ML**	**A065054**	**001**	Dec 18, 2001
NEORAL						
AB1	**+!**	NOVARTIS	**100MG/ML**	**N050716**	**001**	Jul 14, 1995
CYCLOSPORINE						
AB2		WOCKHARDT BIO AG	**100MG/ML**	**A065133**	**001**	Sep 17, 2004
SANDIMMUNE						
AB2	**+!**	NOVARTIS	**100MG/ML**	**N050574**	**001**	Nov 14, 1983
CYPROHEPTADINE HYDROCHLORIDE						
SYRUP;ORAL						
CYPROHEPTADINE HYDROCHLORIDE						
AA		ANDA REPOSITORY	**2MG/5ML**	**A204823**	**001**	Dec 27, 2016
AA		ELYSIUM	**2MG/5ML**	**A209108**	**001**	Oct 16, 2018
AA		LANNETT CO INC	**2MG/5ML**	**A203191**	**001**	Jul 13, 2017
AA	**!**	LYNE	**2MG/5ML**	**A040668**	**001**	Jun 28, 2006
AA		PHARM ASSOC	**2MG/5ML**	**A091295**	**001**	Mar 28, 2013
AA		QUAGEN	**2MG/5ML**	**A212423**	**001**	May 22, 2019

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		APEX PHARMS INC	**4MG**	**A207783**	**001**	Dec 29, 2016
AA		BEXIMCO PHARMS USA	**4MG**	**A206676**	**001**	Apr 12, 2019
AA		BOSCOGEN	**4MG**	**A040644**	**001**	May 30, 2006
AA		ELYSIUM	**4MG**	**A207555**	**001**	Jan 31, 2017
AA	**!**	HERITAGE PHARMA	**4MG**	**A087056**	**001**	
AA		MOUNTAIN	**4MG**	**A040537**	**001**	Sep 30, 2003
AA		NOVAST LABS	**4MG**	**A205087**	**001**	Sep 23, 2015
AA		PAR PHARM	**4MG**	**A087129**	**001**	
AA		STRIDES PHARMA	**4MG**	**A209172**	**001**	Apr 11, 2018
AA		TWI PHARMS	**4MG**	**A206553**	**001**	Nov 29, 2016
AA		ZYDUS PHARMS	**4MG**	**A208938**	**001**	May 19, 2017

CYSTEAMINE BITARTRATE

CAPSULE;ORAL

CYSTAGON

+		MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+!			EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

+		HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013
+!			EQ 75MG BASE	N203389	002	Apr 30, 2013

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTARAN

+!		LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ELCYS

+!		EXELA PHARMA SCS LLC	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019

NOURESS

		AVADEL LEGACY	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP	**!**	FRESENIUS KABI USA	**100MG/ML**	**A076512**	**001**	Jan 15, 2004
AP		GLAND PHARMA LTD	**100MG/VIAL**	**A211937**	**001**	Dec 23, 2019
AP			**2GM/VIAL**	**A211938**	**001**	Dec 23, 2019
AP	**!**	HOSPIRA	**20MG/ML**	**A071868**	**001**	Jun 04, 1990
AP	**!**		**20MG/ML**	**A072168**	**001**	Aug 31, 1990
AP	**!**		**20MG/ML**	**A072945**	**001**	Feb 28, 1994
AP			**100MG/ML**	**A075383**	**001**	Nov 22, 1999
AP		MEITHEAL	**20MG/ML**	**A206190**	**001**	Nov 09, 2017
AP			**100MG/ML**	**A205696**	**001**	Jul 17, 2018
AP		MYLAN LABS LTD	**20MG/ML**	**A200914**	**001**	Dec 13, 2011
AP			**20MG/ML**	**A200915**	**001**	Dec 13, 2011
AP			**100MG/ML**	**A201784**	**001**	Jan 30, 2012
AP		WEST-WARD PHARMS INT	**100MG/VIAL**	**A071471**	**001**	Aug 02, 1989
AP	**!**		**2GM/VIAL**	**A074245**	**002**	Aug 31, 1994
	!		500MG/VIAL	A071472	001	Aug 02, 1989
	!		1GM/VIAL	A074245	001	Aug 31, 1994

CYTARABINE; DAUNORUBICIN

POWDER;INTRAVENOUS

VYXEOS

+!		CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

PRADAXA

+		BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010
+			EQ 110MG BASE	N022512	003	Nov 20, 2015
+!			EQ 150MG BASE	N022512	002	Oct 19, 2010

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

+	NOVARTIS	EQ 50MG BASE	N202806	001	May 29, 2013
+!		EQ 75MG BASE	N202806	002	May 29, 2013

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

AP	**!**	FRESENIUS KABI USA	**200MG/VIAL**	**A075371**	**002**	Aug 27, 1999
AP		HOSPIRA	**200MG/VIAL**	**A075940**	**001**	Oct 18, 2001
AP		TEVA PHARMS USA	**200MG/VIAL**	**A075259**	**002**	Aug 27, 1998
AP	**!**		**500MG/VIAL**	**A075259**	**001**	Sep 22, 2000
AP		WEST-WARD PHARMS INT	**200MG/VIAL**	**A075812**	**001**	Jun 15, 2001
AP			**500MG/VIAL**	**A075812**	**002**	Oct 31, 2002
	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999

DACOMITINIB

TABLET;ORAL

VIZIMPRO

+	PFIZER INC	15MG	N211288	001	Sep 27, 2018
+		30MG	N211288	002	Sep 27, 2018
+!		45MG	N211288	003	Sep 27, 2018

DACTINOMYCIN

INJECTABLE;INJECTION

COSMEGEN

AP	**+!**	RECORDATI RARE	**0.5MG/VIAL**	**N050682**	**001**	

DACTINOMYCIN

AP		HISUN PHARM HANGZHOU	**0.5MG/VIAL**	**A207232**	**001**	Jul 16, 2019
AP		MYLAN LABS LTD	**0.5MG/VIAL**	**A203385**	**001**	Nov 09, 2017
AP		X-GEN PHARMS INC	**0.5MG/VIAL**	**A203999**	**001**	May 20, 2019

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

DALVANCE

+!	ALLERGAN	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA

AB	**+!**	ACORDA	**10MG**	**N022250**	**001**	Jan 22, 2010

DALFAMPRIDINE

AB		ACCORD HLTHCARE	**10MG**	**A206863**	**001**	Jul 11, 2018
AB		ACTAVIS LABS FL INC	**10MG**	**A206836**	**001**	Jan 23, 2017
AB		ALKEM LABS LTD	**10MG**	**A206765**	**001**	Jul 30, 2018
AB		AUROBINDO PHARMA LTD	**10MG**	**A206811**	**001**	Jan 23, 2017
AB		HIKMA	**10MG**	**A206646**	**001**	Oct 24, 2018
AB		MICRO LABS	**10MG**	**A210158**	**001**	Mar 11, 2019
AB		SUN PHARM	**10MG**	**A208292**	**001**	May 21, 2019

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE;INTRAVENOUS

SYNERCID

+!	KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

FRAGMIN

+	PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994
+		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996
+		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002
+		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998
+		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007
+		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007
+		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007
+!		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002

DANAZOL

CAPSULE;ORAL

DANAZOL

AB		BARR	**50MG**	**A074582**	**003**	May 29, 1998
AB			**100MG**	**A074582**	**002**	May 29, 1998
AB	**!**		**200MG**	**A074582**	**001**	Aug 09, 1996
AB		LANNETT CO INC	**50MG**	**A077246**	**002**	Apr 19, 2007
AB			**100MG**	**A077246**	**003**	Apr 19, 2007
AB			**200MG**	**A077246**	**001**	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE;ORAL

DANTRIUM

AB	**+**	PAR STERILE PRODUCTS	**25MG**	**N017443**	**001**	
AB	**+**		**50MG**	**N017443**	**003**	
AB	**+!**		**100MG**	**N017443**	**002**	

DANTROLENE SODIUM

AB		ELITE LABS INC	**25MG**	**A076686**	**001**	Oct 24, 2005
AB			**50MG**	**A076686**	**002**	Oct 24, 2005
AB			**100MG**	**A076686**	**003**	Oct 24, 2005
AB		IMPAX LABS	**25MG**	**A076856**	**001**	Mar 01, 2005
AB			**50MG**	**A076856**	**002**	Mar 01, 2005
AB			**100MG**	**A076856**	**003**	Mar 01, 2005

FOR SUSPENSION;INTRAVENOUS

RYANODEX

+!	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014

INJECTABLE;INJECTION

DANTRIUM

AP	**+!**	PAR STERILE PRODUCTS	**20MG/VIAL**	**N018264**	**001**	

DANTROLENE SODIUM

AP		HIKMA PHARMS	**20MG/VIAL**	**A204762**	**001**	Jun 19, 2017

REVONTO

AP		US WORLDMEDS	**20MG/VIAL**	**A078378**	**001**	Jul 24, 2007

DAPAGLIFLOZIN

TABLET;ORAL

FARXIGA

+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014
+!		10MG	N202293	002	Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

XIGDUO XR

+	ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017
+		5MG;500MG	N205649	001	Oct 29, 2014
+		5MG;1GM	N205649	002	Oct 29, 2014
+		10MG;500MG	N205649	003	Oct 29, 2014
+!		10MG;1GM	N205649	004	Oct 29, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

QTERNMET XR

+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019
+		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019
+		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019
+!		10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

QTERN

+	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019
+!		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017

DAPSONE

GEL;TOPICAL

ACZONE

AB	**+!**	ALLERGAN	**5%**	**N021794**	**001**	Jul 07, 2005

DAPSONE

AB		TARO	**5%**	**A209506**	**001**	Oct 16, 2017

ACZONE

+!	ALMIRALL	7.5%	N207154	001	Feb 24, 2016

DAPSONE

TABLET;ORAL

DAPSONE

AB		ACTAVIS LLC	**25MG**	**A204380**	**001**	Mar 23, 2017
AB			**100MG**	**A204380**	**002**	Mar 23, 2017
AB		ALVOGEN	**25MG**	**A205429**	**001**	Jan 07, 2016
AB			**100MG**	**A205429**	**002**	Jan 07, 2016
AB		JACOBUS	**25MG**	**A086841**	**001**	
AB	**!**		**100MG**	**A086842**	**001**	
AB		NOSTRUM LABS INC	**25MG**	**A203887**	**001**	May 06, 2016
AB			**100MG**	**A203887**	**002**	May 06, 2016
AB		NOVITIUM PHARMA	**25MG**	**A206505**	**001**	Dec 01, 2016
AB			**100MG**	**A206505**	**002**	Dec 01, 2016
AB		SAI LIFE SCIENCES	**100MG**	**A207165**	**001**	May 08, 2019
AB		VIRTUS PHARMS	**25MG**	**A204074**	**001**	May 10, 2016
AB			**100MG**	**A204074**	**002**	May 10, 2016

DAPTOMYCIN

POWDER;INTRAVENOUS

CUBICIN

AP	**+!**	CUBIST PHARMS LLC	**500MG/VIAL**	**N021572**	**002**	Sep 12, 2003

DAPTOMYCIN

AP		ACCORD HLTHCARE	**500MG/VIAL**	**A211961**	**001**	Jun 24, 2019
AP		BE PHARMS	**500MG/VIAL**	**A212513**	**001**	Jun 26, 2019
AP		DR REDDYS	**500MG/VIAL**	**A208375**	**001**	May 01, 2019
AP		FRESENIUS KABI USA	**500MG/VIAL**	**A206077**	**001**	Apr 11, 2018
AP		HOSPIRA INC	**500MG/VIAL**	**A202857**	**001**	Sep 12, 2014
AP		JIANGSU HENGRUI MED	**500MG/VIAL**	**A212022**	**001**	Aug 22, 2019
AP		MYLAN LABS LTD	**500MG/VIAL**	**A205037**	**001**	Jun 05, 2018
AP		SAGENT PHARMS INC	**500MG/VIAL**	**A207104**	**001**	Nov 15, 2019
AP		TEVA PHARMS USA	**500MG/VIAL**	**A091039**	**001**	Mar 25, 2016
AP		XELLIA PHARMS APS	**500MG/VIAL**	**A206005**	**001**	Jun 15, 2016

CUBICIN RF

	+!	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016

POWDER;IV (INFUSION)

DAPTOMYCIN

AP		ACCORD HLTHCARE	**350MG/VIAL**	**A212667**	**001**	Jul 12, 2019
AP	**+!**	SAGENT PHARMS INC	**350MG/VIAL**	**N208385**	**001**	Sep 12, 2017
	+!	XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN

AB		MACLEODS PHARMS LTD	**EQ 7.5MG BASE**	**A207302**	**001**	Jul 28, 2017
AB			**EQ 15MG BASE**	**A207302**	**002**	Jul 28, 2017

DARIFENACIN HYDROBROMIDE

AB		ALAN LABS INC	**EQ 7.5MG BASE**	**A209571**	**002**	Oct 22, 2019
AB			**EQ 15MG BASE**	**A209571**	**001**	Oct 22, 2019
AB		ALEMBIC PHARMS LTD	**EQ 7.5MG BASE**	**A207681**	**001**	Dec 08, 2017
AB			**EQ 15MG BASE**	**A207681**	**002**	Dec 08, 2017
AB		ANCHEN PHARMS	**EQ 7.5MG BASE**	**A091190**	**001**	Mar 13, 2015
AB			**EQ 15MG BASE**	**A091190**	**002**	Mar 13, 2015
AB		AUROBINDO PHARMA LTD	**EQ 7.5MG BASE**	**A206743**	**001**	Sep 19, 2016
AB			**EQ 15MG BASE**	**A206743**	**002**	Sep 19, 2016
AB		CIPLA	**EQ 7.5MG BASE**	**A207664**	**001**	Sep 01, 2016
AB			**EQ 15MG BASE**	**A207664**	**002**	Sep 01, 2016
AB		JUBILANT GENERICS	**EQ 7.5MG BASE**	**A205550**	**001**	Oct 12, 2016
AB			**EQ 15MG BASE**	**A205550**	**002**	Oct 12, 2016
AB		POLYGEN PHARMS	**EQ 7.5MG BASE**	**A211045**	**001**	Jan 06, 2020
AB			**EQ 15MG BASE**	**A211045**	**002**	Jan 06, 2020
AB		TORRENT	**EQ 7.5MG BASE**	**A205209**	**001**	Nov 17, 2016
AB			**EQ 15MG BASE**	**A205209**	**002**	Nov 17, 2016

ENABLEX

AB	**+**	APIL	**EQ 7.5MG BASE**	**N021513**	**001**	Dec 22, 2004
AB	**+!**		**EQ 15MG BASE**	**N021513**	**002**	Dec 22, 2004

DAROLUTAMIDE

TABLET;ORAL

NUBEQA

	+!	BAYER HEALTHCARE	300MG	N212099	001	Jul 30, 2019

DARUNAVIR

SUSPENSION;ORAL

PREZISTA

+!	JANSSEN PRODS	100MG/ML	N202895	001	Dec 16, 2011

TABLET;ORAL

DARUNAVIR

AB		TEVA PHARMS USA	**600MG**	**A202118**	**001**	Nov 21, 2017

PREZISTA

AB	**+**	JANSSEN PRODS	**600MG**	**N021976**	**002**	Feb 25, 2008
	+		75MG	N021976	004	Dec 18, 2008
	+		150MG	N021976	005	Dec 18, 2008
	+!		800MG	N021976	006	Nov 09, 2012

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET;ORAL

VIEKIRA PAK (COPACKAGED)

+!	ABBVIE INC	EQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG	N206619	001	Dec 19, 2014

DASATINIB

TABLET;ORAL

SPRYCEL

+	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006
+		50MG	N021986	002	Jun 28, 2006
+		70MG	N021986	003	Jun 28, 2006
+		80MG	N021986	005	Oct 28, 2010
+!		100MG	N021986	004	May 30, 2008
+		140MG	N021986	006	Oct 28, 2010

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

CERUBIDINE

AP	**!**	WEST-WARD PHARMS INT	**EQ 20MG BASE/VIAL**	**A064103**	**001**	Feb 03, 1995

DAUNORUBICIN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 20MG BASE/VIAL**	**A065000**	**001**	May 25, 1999
AP		HISUN PHARM HANGZHOU	**EQ 5MG BASE/ML**	**A208759**	**001**	Apr 12, 2019
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A065035**	**001**	Jan 24, 2000
AP	**+!**	WEST-WARD PHARMS INT	**EQ 5MG BASE/ML**	**N050731**	**001**	Jan 30, 1998
		FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

AP	**+!**	OTSUKA PHARM CO LTD	**50MG/VIAL**	**N021790**	**001**	May 02, 2006

DECITABINE

AP		ACCORD HLTHCARE	**50MG/VIAL**	**A203475**	**001**	Feb 27, 2017
AP		CHEMI SPA	**50MG/VIAL**	**A206033**	**001**	Sep 22, 2017
AP		CIPLA	**50MG/VIAL**	**A208601**	**001**	Nov 16, 2017
AP		DR REDDYS	**50MG/VIAL**	**A203131**	**001**	Jul 11, 2013
AP		INGENUS PHARMS LLC	**50MG/VIAL**	**A210984**	**001**	Sep 16, 2019
AP		LUPIN LTD	**50MG/VIAL**	**A210756**	**001**	Nov 09, 2018
AP		MSN	**50MG/VIAL**	**A212265**	**001**	Aug 28, 2019
AP		PHARMASCIENCE INC	**50MG/VIAL**	**A204607**	**001**	May 31, 2017
AP		SAGENT PHARMS INC	**50MG/VIAL**	**A207100**	**001**	Mar 16, 2018
AP		SANDOZ INC	**50MG/VIAL**	**A202969**	**001**	Aug 28, 2014
AP		WOCKHARDT BIO AG	**50MG/VIAL**	**A209056**	**001**	Apr 09, 2019

POWDER;INTRAVENOUS

DECITABINE

+!	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014

DEFERASIROX

GRANULE;ORAL

JADENU SPRINKLE

+	NOVARTIS	90MG	N207968	001	May 18, 2017
+		180MG	N207968	002	May 18, 2017
+!		360MG	N207968	003	May 18, 2017

TABLET;ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	**90MG**	**A208697**	**001**	Dec 13, 2019
AB			**180MG**	**A208697**	**002**	Dec 13, 2019
AB			**360MG**	**A208697**	**003**	Dec 13, 2019
AB		ALEMBIC PHARMS LTD	**90MG**	**A211824**	**001**	Nov 20, 2019

DEFERASIROX

TABLET;ORAL

DEFERASIROX

AB			**360MG**	**A211824**	**002**	Nov 20, 2019
AB		AMNEAL PHARMS CO	**90MG**	**A210727**	**001**	Dec 27, 2019
AB			**360MG**	**A210727**	**002**	Dec 27, 2019
AB		MSN	**90MG**	**A210945**	**001**	Nov 20, 2019
AB			**360MG**	**A210945**	**002**	Nov 20, 2019
AB		PIRAMAL HLTHCARE UK	**90MG**	**A212995**	**001**	Dec 30, 2019
AB			**360MG**	**A212995**	**002**	Dec 30, 2019
AB		SUN PHARM	**90MG**	**A211641**	**001**	Jan 02, 2020
AB			**360MG**	**A211641**	**002**	Jan 02, 2020
AB		TEVA PHARMS USA	**90MG**	**A209223**	**001**	Nov 25, 2019
AB			**360MG**	**A209223**	**002**	Nov 25, 2019
AB		ZYDUS PHARMS	**90MG**	**A211383**	**001**	Nov 20, 2019
AB			**360MG**	**A211383**	**002**	Nov 20, 2019

JADENU

AB	**+**	NOVARTIS PHARMS CORP	**90MG**	**N206910**	**001**	Mar 30, 2015
AB	**+**		**180MG**	**N206910**	**002**	Mar 30, 2015
AB	**+!**		**360MG**	**N206910**	**003**	Mar 30, 2015

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	**125MG**	**A203560**	**001**	Jan 26, 2016
AB			**250MG**	**A203560**	**002**	Jan 26, 2016
AB			**500MG**	**A203560**	**003**	Jan 26, 2016
AB		ALEMBIC PHARMS LTD	**125MG**	**A210060**	**001**	Nov 20, 2019
AB			**250MG**	**A210060**	**002**	Nov 20, 2019
AB			**500MG**	**A210060**	**003**	Nov 20, 2019
AB		ALKEM LABS LTD	**125MG**	**A210519**	**001**	Nov 20, 2019
AB			**250MG**	**A210519**	**002**	Nov 20, 2019
AB			**500MG**	**A210519**	**003**	Nov 20, 2019
AB		BIONPHARMA INC	**125MG**	**A210920**	**001**	Nov 20, 2019
AB			**250MG**	**A210920**	**002**	Nov 20, 2019
AB			**500MG**	**A210920**	**003**	Nov 20, 2019
AB		ICHNOS	**125MG**	**A209433**	**001**	Jan 06, 2020
AB			**250MG**	**A209433**	**002**	Jan 06, 2020
AB			**500MG**	**A209433**	**003**	Jan 06, 2020
AB		MSN	**125MG**	**A209878**	**001**	Nov 20, 2019
AB			**250MG**	**A209878**	**002**	Nov 20, 2019
AB			**500MG**	**A209878**	**003**	Nov 20, 2019
AB		SUN PHARM	**125MG**	**A209782**	**001**	Nov 20, 2019
AB			**250MG**	**A209782**	**002**	Nov 20, 2019
AB			**500MG**	**A209782**	**003**	Nov 20, 2019

EXJADE

AB	**+**	NOVARTIS	**125MG**	**N021882**	**001**	Nov 02, 2005
AB	**+**		**250MG**	**N021882**	**002**	Nov 02, 2005
AB	**+!**		**500MG**	**N021882**	**003**	Nov 02, 2005

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

	+	APOPHARMA INC	80MG/ML	N208030	002	Apr 20, 2018
	+!		100MG/ML	N208030	001	Sep 09, 2015

TABLET;ORAL

FERRIPROX

	+!	APOPHARMA INC	500MG	N021825	001	Oct 14, 2011
	+		1GM	N021825	002	Jul 25, 2019

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

AP		FRESENIUS KABI USA	**500MG/VIAL**	**A078718**	**001**	Sep 15, 2009
AP			**2GM/VIAL**	**A078718**	**002**	Sep 15, 2009
AP		GLAND PHARMA LTD	**500MG/VIAL**	**A207384**	**001**	Sep 29, 2017
AP			**2GM/VIAL**	**A207384**	**002**	Sep 29, 2017
AP		HOSPIRA	**500MG/VIAL**	**A076019**	**001**	Mar 17, 2004
AP			**2GM/VIAL**	**A076019**	**002**	Mar 17, 2004
AP		WEST-WARD PHARMS INT	**500MG/VIAL**	**A078086**	**001**	May 30, 2007
AP			**2GM/VIAL**	**A078086**	**002**	May 30, 2007

DESFERAL

AP	**+!**	NOVARTIS	**500MG/VIAL**	**N016267**	**001**	
AP	**+!**		**2GM/VIAL**	**N016267**	**002**	May 25, 2000

DEFIBROTIDE SODIUM

SOLUTION;INTRAVENOUS

DEFITELIO

+!	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016

DEFLAZACORT

SUSPENSION;ORAL

EMFLAZA

+!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017

TABLET;ORAL

EMFLAZA

+	PTC THERAP	6MG	N208684	001	Feb 09, 2017
+		18MG	N208684	002	Feb 09, 2017
+		30MG	N208684	003	Feb 09, 2017
+!		36MG	N208684	004	Feb 09, 2017

DEGARELIX ACETATE

POWDER;SUBCUTANEOUS

FIRMAGON

+	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
+!		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAFLOXACIN MEGLUMINE

POWDER;INTRAVENOUS

BAXDELA

+!	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017

TABLET;ORAL

BAXDELA

+!	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017

DELAVIRDINE MESYLATE

TABLET;ORAL

RESCRIPTOR

+!	VIIV HLTHCARE	200MG	N020705	002	Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB	AKORN	**150MG**	**A065389**	**001**	Dec 01, 2008
AB		**300MG**	**A065389**	**002**	Dec 01, 2008
AB	AMNEAL PHARM	**150MG**	**A065425**	**001**	Feb 27, 2008
AB **!**		**300MG**	**A065425**	**002**	Feb 27, 2008
AB	BARR	**150MG**	**A065171**	**001**	Dec 13, 2004
AB		**300MG**	**A065171**	**002**	Dec 13, 2004
AB	EPIC PHARMA LLC	**150MG**	**A065447**	**001**	Aug 18, 2015
AB		**300MG**	**A065447**	**002**	Aug 18, 2015

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

KYBELLA

+!	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015

DESFLURANE

LIQUID;INHALATION

DESFLURANE

AN	SHANGHAI HENGRUI	**100%**	**A208234**	**001**	Feb 26, 2018

SUPRANE

AN	**+!** BAXTER HLTHCARE	**100%**	**N020118**	**001**	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB	ACTAVIS TOTOWA	**10MG**	**A074430**	**001**	Feb 09, 1996
AB		**25MG**	**A071601**	**001**	Jun 05, 1987
AB		**50MG**	**A071588**	**001**	Jun 05, 1987
AB		**75MG**	**A071602**	**001**	Oct 05, 1987
AB		**100MG**	**A071766**	**001**	Oct 05, 1987
AB		**150MG**	**A074430**	**002**	Feb 09, 1996
AB	AMNEAL PHARMS CO	**10MG**	**A208105**	**001**	Mar 17, 2016
AB		**25MG**	**A208105**	**002**	Mar 17, 2016
AB		**50MG**	**A208105**	**003**	Mar 17, 2016
AB		**75MG**	**A208105**	**004**	Mar 17, 2016
AB		**100MG**	**A208105**	**005**	Mar 17, 2016
AB		**150MG**	**A208105**	**006**	Mar 17, 2016
AB	ANI PHARMS INC	**10MG**	**A205153**	**001**	Oct 28, 2016
AB		**25MG**	**A205153**	**002**	Oct 28, 2016

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB			**50MG**	**A205153**	**003**	Oct 28, 2016
AB			**75MG**	**A205153**	**004**	Oct 28, 2016
AB			**100MG**	**A205153**	**005**	Oct 28, 2016
AB			**150MG**	**A205153**	**006**	Oct 28, 2016
AB		HERITAGE PHARMS INC	**10MG**	**A207433**	**001**	May 05, 2016
AB			**25MG**	**A207433**	**002**	May 05, 2016
AB			**50MG**	**A207433**	**003**	May 05, 2016
AB			**75MG**	**A207433**	**004**	May 05, 2016
AB			**100MG**	**A207433**	**005**	May 05, 2016
AB			**150MG**	**A207433**	**006**	May 05, 2016
AB		NOVAST LABS	**10MG**	**A204963**	**001**	Dec 26, 2017
AB			**25MG**	**A204963**	**002**	Dec 26, 2017
AB			**50MG**	**A204963**	**003**	Dec 26, 2017
AB			**75MG**	**A204963**	**004**	Dec 26, 2017
AB			**100MG**	**A204963**	**005**	Dec 26, 2017
AB			**150MG**	**A204963**	**006**	Dec 26, 2017
AB		SANDOZ	**10MG**	**A072099**	**001**	May 24, 1988
AB			**25MG**	**A072100**	**001**	May 24, 1988
AB			**50MG**	**A072101**	**001**	May 24, 1988
AB			**75MG**	**A072102**	**001**	Jun 20, 1988
AB			**100MG**	**A072103**	**001**	Jun 20, 1988
AB			**150MG**	**A072104**	**001**	Jun 20, 1988

NORPRAMIN

AB	+	US PHARM HOLDINGS	**10MG**	**N014399**	**007**	Feb 11, 1982
AB	+		**25MG**	**N014399**	**001**	
AB	+		**50MG**	**N014399**	**003**	
AB	+		**75MG**	**N014399**	**004**	
AB	+!		**100MG**	**N014399**	**005**	
AB	+		**150MG**	**N014399**	**006**	

DESLORATADINE

SOLUTION;ORAL

CLARINEX

AA	+!	MERCK SHARP DOHME	**0.5MG/ML**	**N021300**	**001**	Sep 01, 2004

DESLORATADINE

AA		TARO	**0.5MG/ML**	**A202936**	**001**	May 26, 2016
AA		TARO PHARM INDS LTD	**0.5MG/ML**	**A202592**	**001**	Jun 30, 2015

TABLET;ORAL

CLARINEX

AB	+!	MERCK SHARP DOHME	**5MG**	**N021165**	**001**	Dec 21, 2001

DESLORATADINE

AB		BELCHER PHARMS	**5MG**	**A078355**	**001**	Apr 19, 2012
AB		DR REDDYS LABS LTD	**5MG**	**A078365**	**001**	Mar 08, 2011
AB		LUPIN PHARMS	**5MG**	**A078352**	**001**	Oct 25, 2010
AB		ORCHID HLTHCARE	**5MG**	**A078357**	**001**	Feb 19, 2010
AB		PERRIGO	**5MG**	**A078361**	**001**	Dec 22, 2011
AB		SANDOZ	**5MG**	**A078364**	**001**	Dec 03, 2010
AB		SUN PHARM INDS	**5MG**	**A078359**	**001**	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

CLARINEX

AB	+	MERCK SHARP DOHME	**2.5MG**	**N021312**	**002**	Jul 14, 2005
AB	+!		**5MG**	**N021312**	**001**	Jun 26, 2002

DESLORATADINE

AB		REDDYS	**2.5MG**	**A078367**	**001**	Jul 12, 2010
AB			**5MG**	**A078367**	**002**	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARINEX D 24 HOUR

AB	+!	MERCK SHARP DOHME	**5MG;240MG**	**N021605**	**001**	Mar 03, 2005

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB		DR REDDYS LABS LTD	**5MG;240MG**	**A078366**	**001**	Apr 26, 2011

CLARINEX-D 12 HOUR

	+!	MERCK SHARP DOHME	2.5MG;120MG	N021313	001	Feb 01, 2006

DESMOPRESSIN ACETATE						
INJECTABLE;INJECTION						
DDAVP						
AP	**+!**	FERRING PHARMS INC	**0.004MG/ML**	**N018938**	**001**	Mar 30, 1984
DESMOPRESSIN ACETATE						
AP		AM REGENT	**0.004MG/ML**	**A091374**	**001**	Feb 14, 2019
AP		SAGENT PHARMS INC	**0.004MG/ML**	**A204695**	**001**	Aug 22, 2017
AP			**0.004MG/ML**	**A204751**	**001**	Aug 22, 2017
AP		SUN PHARM INDS LTD	**0.004MG/ML**	**A091280**	**001**	Jan 25, 2013
AP		TEVA PHARMS USA	**0.004MG/ML**	**A074888**	**001**	Oct 15, 1997
SOLUTION;NASAL						
DDAVP						
	+!	FERRING PHARMS INC	0.01%	N017922	001	
SPRAY, METERED;NASAL						
DDAVP (NEEDS NO REFRIGERATION)						
AB	**+!**	FERRING PHARMS INC	**0.01MG/SPRAY**	**N017922**	**003**	Aug 07, 1996
DESMOPRESSIN ACETATE						
AB	**!**	BAUSCH AND LOMB	**0.01MG/SPRAY**	**A074830**	**001**	Jan 25, 1999
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)						
AB		APOTEX INC	**0.01MG/SPRAY**	**A076703**	**001**	Jan 27, 2005
AB		SUN PHARM	**0.01MG/SPRAY**	**A078271**	**001**	Dec 23, 2013
AB		ZYDUS PHARMS	**0.01MG/SPRAY**	**A091345**	**001**	Oct 03, 2017
MINIRIN						
AB	**+!**	FERRING	**0.01MG/SPRAY**	**N021333**	**001**	Sep 16, 2002
STIMATE (NEEDS NO REFRIGERATION)						
	+!	FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007
TABLET;ORAL						
DDAVP						
AB	**+**	FERRING PHARMS INC	**0.1MG**	**N019955**	**001**	Sep 06, 1995
AB	**+!**		**0.2MG**	**N019955**	**002**	Sep 06, 1995
DESMOPRESSIN ACETATE						
AB		ABHAI LLC	**0.1MG**	**A210371**	**001**	Jan 28, 2019
AB			**0.2MG**	**A210371**	**002**	Jan 28, 2019
AB		ACTAVIS LABS FL INC	**0.1MG**	**A076470**	**001**	Jul 01, 2005
AB			**0.2MG**	**A076470**	**002**	Jul 01, 2005
AB		APOTEX INC	**0.1MG**	**A077414**	**001**	Mar 07, 2006
AB			**0.2MG**	**A077414**	**002**	Mar 07, 2006
AB		GLENMARK PHARMS LTD	**0.1MG**	**A201831**	**001**	May 28, 2015
AB			**0.2MG**	**A201831**	**002**	May 28, 2015
AB		HERITAGE PHARMA	**0.1MG**	**A207880**	**001**	May 26, 2017
AB			**0.2MG**	**A207880**	**002**	May 26, 2017
AB		IMPAX LABS INC	**0.1MG**	**A077122**	**001**	Jan 25, 2006
AB			**0.2MG**	**A077122**	**002**	Jan 25, 2006
AB		MYLAN	**0.1MG**	**A200653**	**001**	Jun 27, 2014
AB			**0.2MG**	**A200653**	**002**	Jun 27, 2014
AB		NOVAST LABS	**0.1MG**	**A208357**	**001**	Jun 06, 2019
AB			**0.2MG**	**A208357**	**002**	Jun 06, 2019
TABLET;SUBLINGUAL						
NOCDURNA						
	+	FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018
	+!		0.0553MG	N022517	002	Jun 21, 2018
DESOGESTREL; ETHINYL ESTRADIOL						
TABLET;ORAL-28						
BEKYREE						
AB		LUPIN LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202226**	**001**	Aug 12, 2015
CYCLESSA						
AB	**+!**	ASPEN GLOBAL INC	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**N021090**	**001**	Dec 20, 2000
DESOGESTREL AND ETHINYL ESTRADIOL						
AB		ACCORD HLTHCARE	**0.15MG,N/A;0.02MG,0.01MG**	**A209170**	**001**	Jun 05, 2017
AB		AUROBINDO PHARMA LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A206853**	**001**	Mar 22, 2017
AB	**!**	DURAMED PHARMS BARR	**0.15MG;0.03MG**	**A075256**	**002**	Aug 12, 1999
AB		MAYNE PHARMA	**0.15MG,N/A;0.02MG,0.01MG**	**A076916**	**001**	Dec 29, 2008
AB			**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A077182**	**001**	Jan 24, 2006
AB		MYLAN LABS LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202296**	**001**	Aug 30, 2013
AB			**0.15MG;0.03MG**	**A202085**	**001**	May 20, 2015
AB		NOVAST LABS	**0.15MG;0.03MG**	**A091234**	**001**	Jul 12, 2013
AB		WATSON LABS	**0.15MG;0.03MG**	**A076915**	**001**	Jul 29, 2005
EMOQUETTE						
AB		VINTAGE PHARMS LLC	**0.15MG;0.03MG**	**A076675**	**001**	Feb 25, 2011

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

ENSKYCE

AB		LUPIN LTD	**0.15MG;0.03MG**	**A201887**	**001**	Mar 07, 2013

ISIBLOOM

AB		XIROMED	**0.15MG;0.03MG**	**A202789**	**001**	Aug 12, 2015

KALLIGA

AB		AUROBINDO PHARMA LTD	**0.15MG;0.03MG**	**A207081**	**001**	May 17, 2017

KARIVA

AB	**!**	BARR	**0.15MG,N/A;0.02MG,0.01MG**	**A075863**	**001**	Apr 05, 2002

KIMIDESS

AB		VINTAGE PHARMS	**0.15MG,N/A;0.02MG,0.01MG**	**A076681**	**001**	Apr 30, 2015

PIMTREA

AB		NOVAST LABS	**0.15MG,N/A;0.02MG,0.01MG**	**A091247**	**001**	Aug 01, 2013

VELIVET

AB		DURAMED PHARMS BARR	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A076455**	**001**	Feb 24, 2004

VIORELE

AB		GLENMARK GENERICS	**0.15MG,N/A;0.02MG,0.01MG**	**A091346**	**001**	Apr 02, 2012

VOLNEA

AB		XIROMED	**0.15MG,N/A;0.02MG,0.01MG**	**A202689**	**001**	Sep 09, 2016

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

	+!	ALMIRALL	0.05%	N021978	001	Sep 19, 2006

CREAM;TOPICAL

DESONIDE

AB		ACP NIMBLE	**0.05%**	**A074027**	**001**	Sep 28, 1992
AB		CADILA	**0.05%**	**A210198**	**001**	Nov 20, 2019
AB		GLENMARK PHARMS	**0.05%**	**A209729**	**001**	Jul 24, 2017
AB	**+!**	PERRIGO NEW YORK	**0.05%**	**N017010**	**001**	
AB		TARO	**0.05%**	**A073548**	**001**	Jun 30, 1992

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**N019048**	**001**	Dec 14, 1984

GEL;TOPICAL

DESONATE

	+!	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006

LOTION;TOPICAL

DESONIDE

AB		FOUGERA PHARMS	**0.05%**	**A075860**	**001**	Mar 19, 2002
AB		GLENMARK PHARMS	**0.05%**	**A209494**	**001**	Sep 26, 2017
AB		TARO	**0.05%**	**A202161**	**001**	Oct 31, 2014
AB		TELIGENT PHARMA INC	**0.05%**	**A207855**	**001**	Sep 28, 2017

DESOWEN

AB	**!**	GALDERMA LABS LP	**0.05%**	**A072354**	**001**	Jan 24, 1992

OINTMENT;TOPICAL

DESONIDE

AB		ALEOR DERMACEUTICALS	**0.05%**	**A212473**	**001**	Oct 23, 2019
AB		ENCUBE ETHICALS	**0.05%**	**A210998**	**001**	Jan 30, 2019
AB		FOUGERA PHARMS	**0.05%**	**A075751**	**001**	Mar 12, 2001
AB		GLENMARK PHARMS LTD	**0.05%**	**A209996**	**001**	Sep 15, 2017
AB		HI TECH	**0.05%**	**A208836**	**001**	Mar 27, 2017
AB	**+!**	PERRIGO NEW YORK	**0.05%**	**N017426**	**001**	
AB		TARO	**0.05%**	**A074254**	**001**	Aug 03, 1994
AB		TELIGENT PHARMA INC	**0.05%**	**A212002**	**001**	Mar 12, 2019

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**A071425**	**001**	Jun 15, 1988

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A205082**	**001**	Sep 04, 2015
AB		AKORN	**0.05%**	**A203787**	**001**	Jan 06, 2017
AB			**0.25%**	**A203234**	**001**	Jun 12, 2015
AB		FOUGERA PHARMS	**0.25%**	**A078369**	**001**	Jun 29, 2010
AB		LUPIN ATLANTIS	**0.05%**	**A208163**	**001**	Jan 10, 2017
AB			**0.25%**	**A208164**	**001**	Jan 09, 2017
AB		PERRIGO NEW YORK	**0.25%**	**A076510**	**001**	Jul 01, 2003
AB		RISING	**0.05%**	**A210980**	**001**	Dec 21, 2018
AB			**0.25%**	**A205594**	**001**	Jul 02, 2018

DESOXIMETASONE

CREAM;TOPICAL

TOPICORT

AB	**!**	TARO PHARM INDS LTD	**0.05%**	**A073210**	**001**	Nov 30, 1990
AB	**!**		**0.25%**	**A073193**	**001**	Nov 30, 1990

GEL;TOPICAL

DESOXIMETASONE

AB		AKORN	**0.05%**	**A090727**	**001**	Mar 10, 2011
AB		PERRIGO NEW YORK	**0.05%**	**A077552**	**001**	Jan 09, 2006
AB		RISING	**0.05%**	**A204675**	**001**	Aug 12, 2016

TOPICORT

AB	**!**	TARO PHARM INDS LTD	**0.05%**	**A074904**	**001**	Jul 14, 1998

OINTMENT;TOPICAL

DESOXIMETASONE

AB		ACP NIMBLE	**0.25%**	**A206740**	**001**	Dec 23, 2016
AB		ACTAVIS MID ATLANTIC	**0.25%**	**A204965**	**001**	Nov 07, 2016
AB		AKORN	**0.25%**	**A201005**	**001**	Apr 24, 2014
AB		FOUGERA PHARMS	**0.25%**	**A078657**	**001**	Sep 28, 2012
AB		GLENMARK GENERICS	**0.25%**	**A202838**	**001**	Sep 20, 2013
AB		LUPIN ATLANTIS	**0.05%**	**A208044**	**001**	Dec 12, 2016
AB			**0.25%**	**A208104**	**001**	Dec 01, 2016
AB		NOVEL LABS INC	**0.25%**	**A206792**	**001**	May 10, 2016
AB		PERRIGO ISRAEL	**0.25%**	**A077770**	**001**	Apr 20, 2015
AB		RISING	**0.25%**	**A204272**	**001**	Nov 30, 2016
AB		TELIGENT PHARMA INC	**0.05%**	**A209973**	**001**	Oct 23, 2018
AB			**0.25%**	**A208101**	**001**	Feb 25, 2016
AB		ZYDUS PHARMS	**0.25%**	**A205206**	**001**	Sep 19, 2017

TOPICORT

AB	**+!**	TARO PHARM INDS LTD	**0.05%**	**N018594**	**001**	Jan 17, 1985
AB	**!**		**0.25%**	**A074286**	**001**	Jun 07, 1996

SPRAY;TOPICAL

DESOXIMETASONE

AT		LUPIN ATLANTIS	**0.25%**	**A208124**	**001**	Mar 16, 2018
AT		PERRIGO ISRAEL	**0.25%**	**A206441**	**001**	Jan 20, 2017

TOPICORT

AT	**+!**	TARO PHARMS	**0.25%**	**N204141**	**001**	Apr 11, 2013

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

	+!	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
	+!		100MG	N204150	002	Mar 04, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		ACTAVIS LABS FL	**EQ 25MG BASE**	**A204065**	**001**	Jul 29, 2016
AB			**EQ 50MG BASE**	**A204065**	**002**	Jul 29, 2016
AB			**EQ 100MG BASE**	**A204065**	**003**	Jul 29, 2016
AB		ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A204003**	**003**	Sep 14, 2018
AB			**EQ 50MG BASE**	**A204003**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204003**	**002**	Jun 29, 2015
AB		CASI PHARMS INC	**EQ 50MG BASE**	**A204028**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204028**	**002**	Jun 29, 2015
AB		HIKMA	**EQ 25MG BASE**	**A204082**	**002**	Aug 28, 2017
AB			**EQ 50MG BASE**	**A204082**	**001**	Feb 16, 2016
AB			**EQ 100MG BASE**	**A204083**	**001**	Feb 16, 2016
AB		INTELLIPHARMACEUTICS	**EQ 50MG BASE**	**A204805**	**001**	May 07, 2019
AB			**EQ 100MG BASE**	**A204805**	**002**	May 07, 2019
AB		LUPIN LTD	**EQ 50MG BASE**	**A204172**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204172**	**002**	Jun 29, 2015
AB		MYLAN	**EQ 50MG BASE**	**A204095**	**001**	Jun 29, 2015
AB		ZYDUS PHARMS	**EQ 50MG BASE**	**A204020**	**001**	Oct 11, 2017
AB			**EQ 100MG BASE**	**A204020**	**002**	Oct 11, 2017

PRISTIQ

AB	**+**	PF PRISM CV	**EQ 25MG BASE**	**N021992**	**003**	Aug 20, 2014
AB	**+!**		**EQ 50MG BASE**	**N021992**	**001**	Feb 29, 2008
AB	**+!**		**EQ 100MG BASE**	**N021992**	**002**	Feb 29, 2008

DEUTETRABENAZINE

TABLET;ORAL

AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
+		9MG	N208082	002	Apr 03, 2017
+!		12MG	N208082	003	Apr 03, 2017

DEXAMETHASONE

CONCENTRATE;ORAL

DEXAMETHASONE INTENSOL

!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR;ORAL

DEXAMETHASONE

AA	**!**	ANIMA	**0.5MG/5ML**	**A084754**	**001**	
AA		LANNETT CO INC	**0.5MG/5ML**	**A091188**	**001**	May 11, 2011
AA		LYNE	**0.5MG/5ML**	**A090891**	**001**	Jul 12, 2011
AA		WOCKHARDT BIO AG	**0.5MG/5ML**	**A088254**	**001**	Jul 27, 1983

IMPLANT;INTRAVITREAL

OZURDEX

+!	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009

INSERT;OPHTHALMIC

DEXTENZA

+!	OCULAR THERAPEUTIX	0.4MG	N208742	001	Nov 30, 2018

SOLUTION;ORAL

DEXAMETHASONE

!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION;INTRAOCULAR

DEXYCU KIT

+!	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

+!	NOVARTIS	0.1%	N013422	001	

TABLET;ORAL

DEXAMETHASONE

AB		ECR	**1.5MG**	**A040700**	**001**	Aug 15, 2008
AB		HIKMA	**1.5MG**	**A084610**	**001**	
AB		LARKEN LABS INC	**1.5MG**	**A201270**	**001**	Jul 17, 2017
BP		FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983
BP			0.75MG	A088481	003	Apr 28, 1983
BP			4MG	A088481	004	Apr 28, 1983
BP			6MG	A088481	001	Nov 28, 1983
BP		HIKMA	0.5MG	A084611	001	
BP			0.75MG	A084613	001	
BP			1MG	A088306	001	Sep 15, 1983
BP			2MG	A087916	001	Aug 26, 1982
BP			4MG	A084612	001	
BP	!		6MG	A088316	001	Sep 15, 1983
BP		XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983

HEMADY

+!	DEXCEL PHARMA	20MG	N211379	001	Oct 03, 2019

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		AMNEAL	**EQ 4MG PHOSPHATE/ML**	**A208689**	**001**	Aug 22, 2018
AP		AUROBINDO PHARMA LTD	**EQ 4MG PHOSPHATE/ML**	**A206781**	**001**	Dec 01, 2015
AP	**!**	FRESENIUS KABI USA	**EQ 4MG PHOSPHATE/ML**	**A084916**	**001**	
AP			**EQ 4MG PHOSPHATE/ML**	**A203129**	**001**	Sep 30, 2015
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A040572**	**001**	Apr 22, 2005
AP			**EQ 10MG PHOSPHATE/ML**	**A209192**	**001**	Jul 06, 2018
AP		MYLAN LABS LTD	**EQ 4MG PHOSPHATE/ML**	**A040803**	**001**	Aug 29, 2008
AP			**EQ 10MG PHOSPHATE/ML**	**A040802**	**001**	Aug 29, 2008
AP		SOMERSET	**EQ 4MG PHOSPHATE/ML**	**A207521**	**001**	Jun 08, 2018
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A211036**	**001**	May 10, 2019
AP		WEST-WARD PHARMS INT	**EQ 4MG PHOSPHATE/ML**	**A084282**	**001**	
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A087702**	**001**	Sep 07, 1982

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP		AMNEAL	**EQ 10MG PHOSPHATE/ML**	**A208690**	**001**	Aug 22, 2018
AP	**!**	FRESENIUS KABI USA	**EQ 10MG PHOSPHATE/ML**	**A040491**	**001**	Apr 11, 2003
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A207442**	**001**	Apr 19, 2018

DEXAMETHASONE SODIUM PHOSPHATE						
SOLUTION/DROPS;OPHTHALMIC, OTIC						
DEXAMETHASONE SODIUM PHOSPHATE						
	!	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
OINTMENT;OPHTHALMIC						
MAXITROL						
AT	**+!**	NOVARTIS	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**N050065**	**002**	
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE						
AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064063**	**001**	Jul 25, 1994
AT		PERRIGO CO TENNESSEE	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A062938**	**001**	Jul 31, 1989
SUSPENSION/DROPS;OPHTHALMIC						
DEXASPORIN						
AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064135**	**001**	Sep 13, 1995
MAXITROL						
AT	**+!**	NOVARTIS	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N050023**	**002**	
AT		SANDOZ INC	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062341**	**001**	May 22, 1984
DEXAMETHASONE; TOBRAMYCIN						
OINTMENT;OPHTHALMIC						
TOBRADEX						
	+!	NOVARTIS	0.1%;0.3%	N050616	001	Sep 28, 1988
SUSPENSION/DROPS;OPHTHALMIC						
TOBRADEX						
AB	**+!**	NOVARTIS	**0.1%;0.3%**	**N050592**	**001**	Aug 18, 1988
TOBRAMYCIN AND DEXAMETHASONE						
AB		BAUSCH AND LOMB	**0.1%;0.3%**	**A064134**	**001**	Oct 27, 1999
TOBRADEX ST						
	+!	NOVARTIS	0.05%;0.3%	N050818	001	Feb 13, 2009
DEXCHLORPHENIRAMINE MALEATE						
SYRUP;ORAL						
DEXCHLORPHENIRAMINE MALEATE						
AA	**!**	WOCKHARDT BIO AG	**2MG/5ML**	**A088251**	**001**	Mar 23, 1984
POLMON						
AA		CAPELLON PHARMS LLC	**2MG/5ML**	**A202520**	**001**	Jul 16, 2018
DEXLANSOPRAZOLE						
CAPSULE, DELAYED RELEASE;ORAL						
DEXILANT						
AB	**+!**	TAKEDA PHARMS USA	**60MG**	**N022287**	**002**	Jan 30, 2009
DEXLANSOPRAZOLE						
AB		PAR PHARM INC	**60MG**	**A202294**	**001**	Apr 19, 2017
DEXILANT						
	+	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009
DEXMEDETOMIDINE HYDROCHLORIDE						
INJECTABLE;INJECTION						
DEXMEDETOMIDINE HYDROCHLORIDE						
AP		ACCORD HLTHCARE	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204023**	**001**	Feb 09, 2016
AP		ACTAVIS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204686**	**001**	Oct 17, 2016
AP		AKORN INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202585**	**001**	Nov 24, 2014
AP		AUROBINDO PHARMA LTD	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205867**	**001**	Mar 17, 2016
AP		BAXTER HLTHCARE CORP	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208532**	**001**	Aug 21, 2018
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208532**	**002**	Aug 21, 2018
AP		FRESENIUS KABI USA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A208129**	**001**	Nov 29, 2018
AP			**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A201072**	**001**	Sep 18, 2015
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208129**	**002**	Nov 29, 2018
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208129**	**003**	Nov 29, 2018
AP		JIANGSU HENGRUI MED	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A209065**	**001**	Sep 19, 2017
AP		MYLAN INSTITUTIONAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202881**	**001**	Aug 18, 2014
AP		PAR STERILE PRODUCTS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A203972**	**001**	Aug 18, 2014
AP		SANDOZ INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A091465**	**001**	Jun 14, 2016
AP		SLAYBACK PHARMA LLC	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212791**	**001**	Dec 04, 2019
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212791**	**002**	Dec 04, 2019
AP		SUN PHARM INDS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202126**	**001**	Aug 20, 2015
AP		TEVA PHARMS USA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205272**	**001**	Nov 28, 2017
AP		WEST-WARD PHARMS INT	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205046**	**001**	Apr 26, 2017
AP		ZYDUS PHARMS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A206798**	**001**	Feb 27, 2018

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRECEDEX

AP	**+!**	HOSPIRA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**N021038**	**004**	Nov 14, 2014
AP	**+!**		**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**N021038**	**001**	Dec 17, 1999
AP	**+!**		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**N021038**	**002**	Mar 13, 2013
AP	**+!**		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**N021038**	**003**	Mar 13, 2013

SOLUTION;INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

+!	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015
+		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018
+		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ADARE PHARMS INC	**5MG**	**A210279**	**001**	Oct 09, 2018
AB			**10MG**	**A210279**	**002**	Oct 09, 2018
AB			**15MG**	**A210279**	**003**	Oct 09, 2018
AB			**20MG**	**A210279**	**004**	Oct 09, 2018
AB			**25MG**	**A210279**	**005**	Oct 09, 2018
AB			**30MG**	**A210279**	**006**	Oct 09, 2018
AB			**35MG**	**A210279**	**007**	Oct 09, 2018
AB			**40MG**	**A210279**	**008**	Oct 09, 2018
AB		IMPAX LABS INC	**5MG**	**A079108**	**001**	Aug 05, 2015
AB			**10MG**	**A079108**	**002**	Aug 05, 2015
AB			**15MG**	**A079108**	**003**	May 19, 2014
AB			**20MG**	**A079108**	**004**	Dec 21, 2015
AB			**25MG**	**A203614**	**001**	Jul 05, 2017
AB			**30MG**	**A079108**	**005**	Nov 21, 2013
AB			**35MG**	**A203614**	**002**	Jul 05, 2017
AB		INTELLIPHARMACEUTICS	**15MG**	**A078992**	**003**	Nov 18, 2013
AB			**30MG**	**A078992**	**004**	Nov 18, 2013
AB		MYLAN	**5MG**	**A204266**	**001**	Aug 25, 2015
AB			**10MG**	**A204266**	**002**	Aug 25, 2015
AB			**15MG**	**A204266**	**003**	Aug 25, 2015
AB			**20MG**	**A204266**	**004**	Dec 21, 2015
AB			**30MG**	**A202580**	**001**	Aug 28, 2013
AB			**40MG**	**A204266**	**007**	Aug 25, 2015
AB		PAR PHARM INC	**5MG**	**A202842**	**001**	Nov 30, 2016
AB			**10MG**	**A202842**	**002**	Nov 30, 2016
AB			**15MG**	**A202842**	**003**	Nov 30, 2016
AB			**20MG**	**A202842**	**004**	Nov 30, 2016
AB			**25MG**	**A202842**	**005**	Nov 30, 2016
AB			**30MG**	**A202842**	**006**	Nov 30, 2016
AB			**35MG**	**A202842**	**007**	Nov 30, 2016
AB			**40MG**	**A202842**	**008**	Nov 30, 2016
AB		TEVA PHARMS USA	**5MG**	**A078908**	**001**	Nov 19, 2013
AB			**10MG**	**A078908**	**002**	Nov 19, 2013
AB			**15MG**	**A078908**	**004**	May 19, 2014
AB			**20MG**	**A078908**	**003**	Nov 19, 2013
AB			**25MG**	**A202731**	**001**	Jul 05, 2017
AB			**30MG**	**A202731**	**003**	May 19, 2014
AB			**35MG**	**A202731**	**004**	Jul 05, 2017
AB			**40MG**	**A202731**	**002**	Nov 19, 2013

FOCALIN XR

AB	**+**	NOVARTIS	**5MG**	**N021802**	**001**	May 26, 2005
AB	**+**		**10MG**	**N021802**	**002**	May 26, 2005
AB	**+**		**15MG**	**N021802**	**004**	Aug 01, 2006
AB	**+**		**20MG**	**N021802**	**003**	May 26, 2005
AB	**+**		**25MG**	**N021802**	**008**	Apr 21, 2011
AB	**+**		**30MG**	**N021802**	**005**	Oct 23, 2009
AB	**+**		**35MG**	**N021802**	**007**	Apr 21, 2011
AB	**+!**		**40MG**	**N021802**	**006**	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	**2.5MG**	**A206931**	**001**	Dec 04, 2015
AB			**5MG**	**A206931**	**002**	Dec 04, 2015
AB			**10MG**	**A206931**	**003**	Dec 04, 2015
AB		ALKEM LABS LTD	**2.5MG**	**A212631**	**001**	Jul 19, 2019
AB			**5MG**	**A212631**	**002**	Jul 19, 2019

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB			**10MG**	**A212631**	**003**	Jul 19, 2019
AB		CEDIPROF INC	**5MG**	**A209211**	**001**	Sep 19, 2018
AB			**10MG**	**A209211**	**002**	Sep 19, 2018
AB		NOVEL LABS INC	**2.5MG**	**A204534**	**001**	Dec 04, 2015
AB			**5MG**	**A204534**	**002**	Dec 04, 2015
AB			**10MG**	**A204534**	**003**	Dec 04, 2015
AB		RHODES PHARMS	**2.5MG**	**A208756**	**001**	Nov 20, 2017
AB			**5MG**	**A208756**	**002**	Nov 20, 2017
AB			**10MG**	**A208756**	**003**	Nov 20, 2017
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A201231**	**001**	Sep 24, 2015
AB			**5MG**	**A201231**	**002**	Sep 24, 2015
AB			**10MG**	**A201231**	**003**	Sep 24, 2015
AB		TRIS PHARMA INC	**2.5MG**	**A207901**	**001**	Aug 26, 2016
AB			**5MG**	**A207901**	**002**	Aug 26, 2016
AB			**10MG**	**A207901**	**003**	Aug 26, 2016

FOCALIN

AB	**+**	NOVARTIS	**2.5MG**	**N021278**	**001**	Nov 13, 2001
AB	**+**		**5MG**	**N021278**	**002**	Nov 13, 2001
AB	**+!**		**10MG**	**N021278**	**003**	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP		GLAND PHARMA LTD	**EQ 250MG BASE/VIAL**	**A207321**	**002**	Dec 16, 2019
AP			**EQ 500MG BASE/VIAL**	**A207321**	**001**	Nov 28, 2016
AP		MYLAN INSTITUTIONAL	**EQ 250MG BASE/VIAL**	**A200752**	**001**	Oct 19, 2011
AP			**EQ 500MG BASE/VIAL**	**A200752**	**002**	Oct 19, 2011
AP		WEST-WARD PHARMS INT	**EQ 250MG BASE/VIAL**	**A076068**	**001**	Sep 28, 2004
AP			**EQ 500MG BASE/VIAL**	**A076068**	**002**	Sep 28, 2004

ZINECARD

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 250MG BASE/VIAL**	**N020212**	**001**	May 26, 1995
AP	**+!**		**EQ 500MG BASE/VIAL**	**N020212**	**002**	May 26, 1995

TOTECT

	+!	CLINIGEN	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE

AB	**+**	IMPAX LABS INC	**5MG**	**N017078**	**001**	
AB	**+**		**10MG**	**N017078**	**002**	
AB	**+!**		**15MG**	**N017078**	**003**	

DEXTROAMPHETAMINE SULFATE

AB		ACTAVIS ELIZABETH	**5MG**	**A203901**	**001**	Nov 30, 2012
AB			**10MG**	**A203901**	**002**	Nov 30, 2012
AB			**15MG**	**A203901**	**003**	Nov 30, 2012
AB		MAYNE PHARMA	**5MG**	**A076137**	**001**	Jan 18, 2002
AB			**10MG**	**A076137**	**002**	Jan 18, 2002
AB			**15MG**	**A076137**	**003**	Jan 18, 2002
AB		NESHER PHARMS	**5MG**	**A209111**	**001**	Jun 27, 2017
AB			**10MG**	**A209111**	**002**	Jun 27, 2017
AB			**15MG**	**A209111**	**003**	Jun 27, 2017
AB		PII	**5MG**	**A205077**	**001**	Jun 21, 2019
AB			**10MG**	**A205077**	**002**	Jun 21, 2019
AB			**15MG**	**A205077**	**003**	Jun 21, 2019
AB		SPECGX LLC	**5MG**	**A076353**	**001**	May 06, 2003
AB			**10MG**	**A076353**	**002**	May 06, 2003
AB			**15MG**	**A076353**	**003**	May 06, 2003
AB		VINTAGE PHARMS	**5MG**	**A205673**	**001**	Oct 31, 2017
AB			**10MG**	**A205673**	**002**	Oct 31, 2017
AB			**15MG**	**A205673**	**003**	Oct 31, 2017

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	**!**	OUTLOOK PHARMS	**5MG/5ML**	**A040776**	**001**	Jan 29, 2008
AA		TRIS PHARMA INC	**5MG/5ML**	**A203644**	**001**	May 29, 2013

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		ARBOR PHARMS LLC	**5MG**	**A090533**	**002**	Oct 25, 2011
AA			**10MG**	**A090533**	**004**	Oct 25, 2011

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		AUROLIFE PHARMA LLC	**5MG**	**A202893**	**001**	Jul 31, 2013
AA			**10MG**	**A202893**	**002**	Jul 31, 2013
AA		AVANTHI INC	**5MG**	**A203548**	**001**	Nov 23, 2015
AA			**10MG**	**A203548**	**002**	Nov 23, 2015
AA		BARR	**5MG**	**A040361**	**001**	Jan 31, 2001
AA	!		**10MG**	**A040361**	**002**	Jan 31, 2001
AA		NESHER PHARMS	**5MG**	**A206588**	**001**	Mar 28, 2016
AA			**10MG**	**A206588**	**002**	Mar 28, 2016
AA		NOVEL LABS INC	**5MG**	**A204330**	**001**	Mar 16, 2016
AA			**10MG**	**A204330**	**002**	Mar 16, 2016
AA		NUVO PHARM	**5MG**	**A210059**	**001**	Oct 18, 2017
AA			**10MG**	**A210059**	**002**	Oct 18, 2017
AA		SPECGX LLC	**5MG**	**A040436**	**001**	Jan 29, 2002
AA			**10MG**	**A040436**	**002**	Jan 29, 2002
		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		HI TECH PHARMA	**15MG/5ML;6.25MG/5ML**	**A040027**	**001**	Jul 31, 1996

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		WOCKHARDT BIO AG	**15MG/5ML;6.25MG/5ML**	**A088864**	**001**	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB		ACTAVIS ELIZABETH	**20MG;10MG**	**A202934**	**001**	Oct 10, 2017

NUEDEXTA

AB	**+!**	AVANIR PHARMS	**20MG;10MG**	**N021879**	**001**	Oct 29, 2010

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**10GM/100ML**	**N019626**	**004**	Feb 02, 1988
AP	**+!**	BAXTER HLTHCARE	**10GM/100ML**	**N016694**	**001**	
AP		FRESENIUS KABI USA	**10GM/100ML**	**A209448**	**001**	Jul 16, 2018
AP	**+!**	ICU MEDICAL INC	**10GM/100ML**	**N018080**	**001**	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**50MG/ML**	**N016730**	**002**	
AP	**+!**		**5GM/100ML**	**N016730**	**001**	
AP	**+!**		**5GM/100ML**	**N019626**	**002**	Feb 02, 1988
AP	**+!**	BAXTER HLTHCARE	**50MG/ML**	**N016673**	**003**	Oct 30, 1985
AP	**+!**		**50MG/ML**	**N020179**	**002**	Dec 07, 1992
AP	**+!**		**5GM/100ML**	**N016673**	**001**	
AP	**+!**		**5GM/100ML**	**N020179**	**001**	Dec 07, 1992
AP		FRESENIUS KABI USA	**50MG/ML**	**A207449**	**001**	Oct 21, 2016
AP	**+!**	HOSPIRA	**5GM/100ML**	**N019466**	**001**	Jul 15, 1985
AP	**+!**		**5GM/100ML**	**N019479**	**001**	Sep 17, 1985
AP	**+!**	ICU MEDICAL INC	**50MG/ML**	**N016367**	**002**	

DEXTROSE 50% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**50GM/100ML**	**N020047**	**001**	Jul 02, 1991
AP	**+!**	ICU MEDICAL INC	**50GM/100ML**	**N018563**	**001**	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**70GM/100ML**	**N019626**	**005**	Feb 18, 2015
AP	**+!**	BAXTER HLTHCARE	**70GM/100ML**	**N020047**	**003**	Jul 02, 1991
AP	**+!**	ICU MEDICAL INC	**70GM/100ML**	**N018561**	**001**	Mar 23, 1982
AP	**+!**		**70GM/100ML**	**N019893**	**001**	Dec 26, 1989
		DEXTROSE 20% IN PLASTIC CONTAINER				
	+!	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982
		DEXTROSE 25%				
	+!	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998
		DEXTROSE 30% IN PLASTIC CONTAINER				
	+!	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985
		DEXTROSE 40% IN PLASTIC CONTAINER				
	+!	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 50%

+	HOSPIRA	500MG/ML	N019445	003	Sep 03, 2014

DEXTROSE 50% IN PLASTIC CONTAINER

+	HOSPIRA	500MG/ML	N019445	001	Jun 03, 1986

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019873	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017609	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML**	**N017634**	**001**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML**	**N017634**	**003**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML**	**N017634**	**002**	

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML**	**N019699**	**004**	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML**	**N019699**	**006**	Sep 29, 1989

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634	004	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371	001	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**006**	Apr 13, 1982
AP			**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**007**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**004**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**008**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**001**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**005**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**009**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**002**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**003**	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;330MG/100ML**	**N018629 005**	Mar 23, 1982
AP		**5GM/100ML;150MG/100ML;330MG/100ML**	**N018629 002**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;330MG/100ML**	**N018629 003**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;330MG/100ML**	**N018629 004**	Mar 23, 1982
AP		**5GM/100ML;300MG/100ML;330MG/100ML**	**N018629 006**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;330MG/100ML**	**N018629 007**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;330MG/100ML**	**N018629 008**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;330MG/100ML**	**N018629 001**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;450MG/100ML**	**N018008 010**		

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;75MG/100ML;200MG/100ML**	**N019630 008**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;75MG/100ML;330MG/100ML**	**N019630 014**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;75MG/100ML;450MG/100ML**	**N019630 020**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;75MG/100ML;900MG/100ML**	**N019630 026**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;150MG/100ML;200MG/100ML**	**N019630 010**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;150MG/100ML;330MG/100ML**	**N019630 016**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;150MG/100ML;450MG/100ML**	**N019630 022**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;150MG/100ML;900MG/100ML**	**N019630 028**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML;200MG/100ML**	**N019630 012**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML;330MG/100ML**	**N019630 018**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML;450MG/100ML**	**N019630 024**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML;900MG/100ML**	**N019630 030**	Feb 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;450MG/100ML**	**N018008 005**	Apr 28, 1982
AP		**5GM/100ML;150MG/100ML;450MG/100ML**	**N018008 006**	Apr 28, 1982
AP	**+!** ICU MEDICAL INC	**5GM/100ML;74.5MG/100ML;450MG/100ML**	**N018362 009**	Jul 05, 1983
AP	**+!**	**5GM/100ML;149MG/100ML;450MG/100ML**	**N018362 005**	Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;450MG/100ML**	**N018008 007**	Apr 28, 1982
AP	**+!** ICU MEDICAL INC	**5GM/100ML;149MG/100ML;450MG/100ML**	**N018362 010**	Jul 05, 1983

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;900MG/100ML**	**N019308 005**	Apr 05, 1985
AP	**+!** ICU MEDICAL INC	**5GM/100ML;149MG/100ML;900MG/100ML**	**N019691 005**	Mar 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;450MG/100ML**	**N018008 008**	Apr 28, 1982
AP	**+!** ICU MEDICAL INC	**5GM/100ML;224MG/100ML;450MG/100ML**	**N018362 002**		

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;450MG/100ML**	**N018008 009**	Apr 28, 1982
AP	**+!** ICU MEDICAL INC	**5GM/100ML;298MG/100ML;450MG/100ML**	**N018362 003**		

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;900MG/100ML**	**N019308 007**	Apr 05, 1985
AP	**+!** ICU MEDICAL INC	**5GM/100ML;298MG/100ML;900MG/100ML**	**N019691 009**	Mar 24, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007	Feb 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630 019	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630 025	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630 032	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630 038	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630 044	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630 049	May 07, 1992
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630 002	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630 033	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;450MG/100ML	N019630 039	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML;900MG/100ML	N019630 045	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;110MG/100ML;300MG/100ML	N019630 050	May 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;110MG/100ML	N019630 003	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;200MG/100ML	N019630 009	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;330MG/100ML	N019630 015	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;450MG/100ML	N019630 021	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML;900MG/100ML	N019630 027	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;150MG/100ML;200MG/100ML	N019630 034	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;150MG/100ML;450MG/100ML	N019630 040	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;150MG/100ML;900MG/100ML	N019630 046	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;150MG/100ML;300MG/100ML	N019630 051	May 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;150MG/100ML;110MG/100ML	N019630 004	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;220MG/100ML;200MG/100ML	N019630 035	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;220MG/100ML;450MG/100ML	N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML	N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML	N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML	N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML	N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML	N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML	N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML	N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML	N019630 053	May 07, 1992

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML	N019630	006	Feb 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308	004	Apr 05, 1985
		5GM/100ML;150MG/100ML;900MG/100ML	N019308	002	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+	ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308	003	Apr 05, 1985

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308	006	Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008	004	

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308	001	Apr 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**2.5GM/100ML;450MG/100ML**	**N019631**	**004**	Feb 24, 1988
AP	**+!** BAXTER HLTHCARE	**2.5GM/100ML;450MG/100ML**	**N016697**	**001**	
AP	FRESENIUS KABI USA	**2.5GM/100ML;450MG/100ML**	**A211190**	**001**	Dec 20, 2019

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;200MG/100ML**	**N019631**	**007**	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;330MG/100ML**	**N019631**	**008**	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;450MG/100ML**	**N019631**	**009**	Feb 24, 1988
AP	**+** ICU MEDICAL INC	**5GM/100ML;450MG/100ML**	**N017607**	**001**	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;900MG/100ML**	**N019631**	**010**	Feb 24, 1988
AP	**+!** ICU MEDICAL INC	**5GM/100ML;900MG/100ML**	**N017585**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;200MG/100ML**	**N016689**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;330MG/100ML**	**N016687**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;450MG/100ML**	**N016683**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;900MG/100ML**	**N016678**	**001**	

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;110MG/100ML	N019631	011	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;200MG/100ML	N019631	012	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;330MG/100ML	N019631	013	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;450MG/100ML	N019631	014	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;900MG/100ML	N019631	015	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;110MG/100ML	N019631	001	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;200MG/100ML	N019631	002	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;330MG/100ML	N019631	003	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;900MG/100ML	N019631	005	Feb 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML	N019631	016	Jan 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML	N019631	006	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	5GM/100ML;225MG/100ML	N017606	001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001	

DIATRIZOATE MEGLUMINE							
SOLUTION;URETHRAL							
CYSTOGRAFIN							
	+	BRACCO	30%	N010040	018		
CYSTOGRAFIN DILUTE							
	+	BRACCO	18%	N010040	022	Nov 09, 1982	
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM							
SOLUTION;ORAL, RECTAL							
GASTROGRAFIN							
AA	**+!**	BRACCO	**66%;10%**	**N011245**	**003**		
MD-GASTROVIEW							
AA		LIEBEL-FLARSHEIM	**66%;10%**	**A087388**	**001**		
DIAZEPAM							
CONCENTRATE;ORAL							
DIAZEPAM							
AA		LANNETT CO INC	**5MG/ML**	**A204433**	**001**	Apr 14, 2014	
DIAZEPAM INTENSOL							
AA	**!**	HIKMA	**5MG/ML**	**A071415**	**001**	Apr 03, 1987	
GEL;RECTAL							
DIASTAT							
	+	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	
DIASTAT ACUDIAL							
	+	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	
	+!		20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	
INJECTABLE;INJECTION							
DIAZEPAM							
AP		BELOTECA INC	**10MG/2ML (5MG/ML)**	**A210363**	**001**	Mar 18, 2019	
AP			**50MG/10ML (5MG/ML)**	**A211998**	**001**	Dec 26, 2019	
AP	**!**	HOSPIRA	**10MG/2ML (5MG/ML)**	**A072079**	**001**	Dec 20, 1988	
AP	**!**		**50MG/10ML (5MG/ML)**	**A071583**	**001**	Oct 13, 1987	
SOLUTION;ORAL							
DIAZEPAM							
AA	**!**	HIKMA	**5MG/5ML**	**A070928**	**001**	Apr 03, 1987	
AA		LANNETT CO INC	**5MG/5ML**	**A206477**	**001**	Jun 24, 2016	
TABLET;ORAL							
DIAZEPAM							
AB		BARR	**2MG**	**A070152**	**001**	Nov 01, 1985	
AB			**10MG**	**A070154**	**001**	Nov 01, 1985	
AB		IVAX SUB TEVA PHARMS	**2MG**	**A071307**	**001**	Dec 10, 1986	
AB			**5MG**	**A071321**	**001**	Dec 10, 1986	
AB			**10MG**	**A071322**	**001**	Dec 10, 1986	
AB		MAYNE PHARMA	**2MG**	**A071134**	**001**	Feb 03, 1987	
AB			**5MG**	**A071135**	**001**	Feb 03, 1987	
AB			**10MG**	**A071136**	**001**	Feb 03, 1987	
AB		MYLAN	**2MG**	**A070325**	**002**	Sep 04, 1985	
AB			**5MG**	**A070325**	**003**	Sep 04, 1985	
AB			**10MG**	**A070325**	**001**	Sep 04, 1985	
AB		VINTAGE PHARMS	**2MG**	**A077749**	**001**	Mar 31, 2006	
AB			**5MG**	**A077749**	**002**	Mar 31, 2006	
AB			**10MG**	**A077749**	**003**	Mar 31, 2006	
VALIUM							
AB	**+**	ROCHE	**2MG**	**N013263**	**002**		
AB	**+**		**5MG**	**N013263**	**004**		
AB	**+!**		**10MG**	**N013263**	**006**		
DIAZOXIDE							
SUSPENSION;ORAL							
DIAZOXIDE							
AB		E5 PHARMA INC	**50MG/ML**	**A211050**	**001**	Dec 20, 2019	
PROGLYCEM							
AB	**+!**	TEVA BRANDED PHARM	**50MG/ML**	**N017453**	**001**		
DICHLORPHENAMIDE							
TABLET;ORAL							
KEVEYIS							
	+!	STRONGBRIDGE US	50MG	N011366	002	Aug 07, 2015	

DICLOFENAC

CAPSULE;ORAL

ZORVOLEX

	+	ZYLA	18MG	N204592	001	Oct 18, 2013
	+!		35MG	N204592	002	Oct 18, 2013

DICLOFENAC EPOLAMINE

PATCH;TOPICAL

FLECTOR

	+!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB		BIONPHARMA INC	**25MG**	**A204648**	**001**	Feb 23, 2016
AB		STRIDES PHARMA	**25MG**	**A210078**	**001**	Dec 03, 2019

ZIPSOR

AB	**+!**	ASSERTIO	**25MG**	**N022202**	**001**	Jun 16, 2009

FOR SOLUTION;ORAL

CAMBIA

AB	**+!**	ASSERTIO	**50MG**	**N022165**	**001**	Jun 17, 2009

DICLOFENAC POTASSIUM

AB		PAR FORM	**50MG**	**A202964**	**001**	May 02, 2016

TABLET;ORAL

DICLOFENAC POTASSIUM

AB		AMICI	**50MG**	**A076561**	**001**	Mar 18, 2004
AB		CASI PHARMS INC	**50MG**	**A075229**	**001**	Nov 20, 1998
AB	**!**	MYLAN	**50MG**	**A075463**	**001**	Jul 26, 1999
AB		TEVA	**50MG**	**A075219**	**001**	Aug 06, 1998

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB		ACTAVIS MID ATLANTIC	**3%**	**A206493**	**001**	Dec 02, 2015
AB		AMNEAL PHARMS	**1%**	**A208077**	**001**	Mar 18, 2016
AB		CIPLA	**1%**	**A209903**	**001**	Aug 03, 2018
AB		GLENMARK PHARMS LTD	**3%**	**A208301**	**001**	Sep 13, 2016
AB		HI TECH	**1%**	**A209484**	**001**	Nov 21, 2018
AB		MYLAN	**1%**	**A204306**	**001**	May 06, 2019
AB		PERRIGO UK FINCO	**1%**	**A211253**	**001**	May 16, 2019
AB			**3%**	**A210893**	**001**	Jul 27, 2018
AB		TARO	**3%**	**A206298**	**001**	Apr 28, 2016
AB		TOLMAR	**3%**	**A200936**	**001**	Oct 28, 2013

SOLARAZE

AB	**+!**	FOUGERA PHARMS	**3%**	**N021005**	**001**	Oct 16, 2000

VOLTAREN

AB	**+!**	GLAXOSMITHKLINE CONS	**1%**	**N022122**	**001**	Oct 17, 2007

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT		AMNEAL PHARMS	**1.5%**	**A206116**	**001**	Sep 02, 2016
AT	**!**	APOTEX INC	**1.5%**	**A202027**	**001**	May 27, 2014
AT		CADILA	**1.5%**	**A206411**	**001**	Apr 17, 2018
AT		LUPIN LTD	**1.5%**	**A204132**	**001**	Aug 20, 2015
AT		NOVEL LABS INC	**1.5%**	**A205878**	**001**	Dec 09, 2015
AT		TARO	**1.5%**	**A203818**	**001**	Nov 26, 2014
AT		TELIGENT PHARMA INC	**1.5%**	**A202769**	**001**	Jul 08, 2015
AT		TWI PHARMS	**1.5%**	**A202393**	**001**	Nov 24, 2014
AT		WATSON LABS INC	**1.5%**	**A202852**	**001**	Nov 24, 2014

PENNSAID

	+!	HORIZON	2%	N204623	001	Jan 16, 2014

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT		AKORN	**0.1%**	**A077845**	**001**	Apr 17, 2008
AT		ALTAIRE PHARMS INC	**0.1%**	**A203383**	**001**	Nov 16, 2015
AT		BAUSCH AND LOMB	**0.1%**	**A078792**	**001**	Dec 28, 2007
AT		RISING	**0.1%**	**A078553**	**001**	Dec 28, 2007
AT		SANDOZ INC	**0.1%**	**A078031**	**001**	Feb 06, 2008

VOLTAREN

AT	**+!**	NOVARTIS	**0.1%**	**N020037**	**001**	Mar 28, 1991

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB		ACTAVIS ELIZABETH	**50MG**	**A074514**	**001**	Mar 26, 1996

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB			**75MG**	**A074514**	**002**	Mar 26, 1996
AB		CARLSBAD	**25MG**	**A075185**	**002**	Nov 13, 1998
AB			**50MG**	**A075185**	**003**	Nov 13, 1998
AB			**75MG**	**A075185**	**001**	Nov 13, 1998
AB		MYLAN PHARMS INC	**50MG**	**A075281**	**002**	Feb 12, 2002
AB			**75MG**	**A075281**	**003**	Feb 12, 2002
AB	!	UNIQUE PHARM LABS	**25MG**	**A090066**	**001**	Dec 01, 2010
AB	!		**50MG**	**A090066**	**002**	Dec 01, 2010
AB	!		**75MG**	**A077863**	**003**	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	!	DEXCEL LTD	**100MG**	**A076201**	**001**	Nov 06, 2002
AB		VPNA	**100MG**	**A075492**	**001**	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

AB	+	GD SEARLE LLC	**50MG;0.2MG**	**N020607**	**001**	Dec 24, 1997
AB	+!		**75MG;0.2MG**	**N020607**	**002**	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

AB		ACTAVIS LABS FL INC	**50MG;0.2MG**	**A201089**	**001**	Jul 09, 2012
AB			**75MG;0.2MG**	**A201089**	**002**	Jul 09, 2012
AB		AMNEAL PHARMS	**50MG;0.2MG**	**A203995**	**001**	Nov 25, 2016
AB			**75MG;0.2MG**	**A203995**	**002**	Nov 25, 2016
AB		SANDOZ	**50MG;0.2MG**	**A200158**	**001**	May 09, 2013
AB			**75MG;0.2MG**	**A200158**	**002**	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

AB		SANDOZ	**EQ 250MG BASE**	**A061454**	**001**	
AB	!		**EQ 500MG BASE**	**A061454**	**003**	
AB		TEVA	**EQ 250MG BASE**	**A062286**	**001**	Jun 03, 1982
AB			**EQ 500MG BASE**	**A062286**	**002**	Jun 03, 1982
		SANDOZ	EQ 125MG BASE	A061454	002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB	!	LANNETT	**10MG**	**A084285**	**001**	
AB		MYLAN	**10MG**	**A040319**	**001**	Sep 07, 1999
AB		WATSON LABS	**10MG**	**A085082**	**001**	Jun 19, 1986
AB		WEST WARD	**10MG**	**A040204**	**001**	Feb 28, 1997

INJECTABLE;INJECTION

BENTYL

AP	+!	ALLERGAN	**10MG/ML**	**N008370**	**001**	Oct 15, 1984

BENTYL PRESERVATIVE FREE

AP	+!	ALLERGAN	**10MG/ML**	**N008370**	**002**	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

AP		AKORN INC	**10MG/ML**	**A207084**	**001**	May 04, 2018
AP		AM REGENT	**10MG/ML**	**A208353**	**001**	Feb 17, 2017
AP		CUSTOPHARM INC	**10MG/ML**	**A210788**	**001**	Feb 11, 2019
AP		FOSUN PHARMA	**10MG/ML**	**A210979**	**001**	Jul 02, 2018
AP		FRESENIUS KABI USA	**10MG/ML**	**A210257**	**001**	Jan 25, 2019
AP		NEXUS PHARMS	**10MG/ML**	**A206468**	**001**	Feb 01, 2019
AP		SLATE	**10MG/ML**	**A207076**	**001**	Nov 02, 2018
AP		SUNGEN PHARMA	**10MG/ML**	**A212058**	**001**	Apr 26, 2019

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

AP		WEST-WARD PHARMS INT	**10MG/ML**	**A040465**	**001**	Jun 30, 2003

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

	!	GENERICS	10MG/5ML	A040169	001	Mar 24, 2005

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

AB		HIKMA PHARMS	**20MG**	**A040161**	**001**	Oct 01, 1996
AB		LANNETT	**20MG**	**A040230**	**001**	Feb 26, 1999
AB		MYLAN	**20MG**	**A040317**	**001**	Sep 07, 1999
AB	!	WATSON LABS	**20MG**	**A085223**	**001**	Jul 30, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

AB		AUROBINDO PHARMA	**125MG**	**A090094**	**001**	Sep 24, 2008
AB			**200MG**	**A090094**	**002**	Sep 24, 2008
AB			**250MG**	**A090094**	**003**	Sep 24, 2008
AB			**400MG**	**A090094**	**004**	Sep 24, 2008

VIDEX EC

AB	+	BRISTOL MYERS SQUIBB	**125MG**	**N021183**	**001**	Oct 31, 2000
AB	+		**200MG**	**N021183**	**002**	Oct 31, 2000
AB	+		**250MG**	**N021183**	**003**	Oct 31, 2000
AB	+!		**400MG**	**N021183**	**004**	Oct 31, 2000

FOR SOLUTION;ORAL

VIDEX

	+!	BRISTOL-MYERS SQUIBB	10MG/ML	N020156	001	Oct 09, 1991

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

	+!	BAYER HLTHCARE	N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A	N022252	001	May 06, 2010

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

AA		AVANTHI INC	**25MG**	**A201212**	**001**	Dec 22, 2010
AA	!	LANNETT CO INC	**25MG**	**A200177**	**001**	Jul 18, 2011

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

AB	!	LANNETT CO INC	**75MG**	**A091680**	**001**	Oct 24, 2011

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX	!	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002
BX	!	TARO	0.05%	A075508	001	Apr 24, 2000

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		AKORN	**0.05%**	**A206572**	**001**	Jul 24, 2015
AB		FOUGERA PHARMS	**0.05%**	**A075374**	**001**	Apr 27, 1999
AB		RISING	**0.05%**	**A207440**	**001**	Feb 27, 2017
AB	!	TARO	**0.05%**	**A075331**	**001**	May 14, 1999
AB		TELIGENT PHARMA INC	**0.05%**	**A210753**	**001**	Jun 12, 2018

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	**500MG**	**A202845**	**001**	Mar 08, 2012
AB	!	TEVA	**500MG**	**A073673**	**001**	Jul 31, 1992
AB		ZYDUS PHARMS	**500MG**	**A203547**	**001**	Jun 16, 2017

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DUREZOL

	+!	NOVARTIS	0.05%	N022212	001	Jun 23, 2008

DIGOXIN

ELIXIR;ORAL

DIGOXIN

AA	+!	HIKMA	**0.05MG/ML**	**N021648**	**001**	Aug 26, 2004
AA		VISTAPHARM	**0.05MG/ML**	**A213000**	**001**	Oct 04, 2019

INJECTABLE;INJECTION

DIGOXIN

AP		SANDOZ INC	**0.25MG/ML**	**A040481**	**001**	Aug 21, 2003
AP		WEST-WARD PHARMS INT	**0.25MG/ML**	**A083391**	**001**	

LANOXIN

AP	+!	COVIS PHARMA BV	**0.25MG/ML**	**N009330**	**002**	

LANOXIN PEDIATRIC

	+!	COVIS PHARMA BV	0.1MG/ML	N009330	004	

TABLET;ORAL

DIGOXIN

AB		HIKMA INTL PHARMS	**0.125MG**	**A077002**	**002**	Oct 30, 2007
AB			**0.25MG**	**A077002**	**001**	Oct 30, 2007
AB		IMPAX LABS	**0.125MG**	**A078556**	**001**	Jul 20, 2009

DIGOXIN

TABLET;ORAL

DIGOXIN

AB			**0.25MG**	**A078556**	**002**	Jul 20, 2009
AB		MYLAN PHARMS INC	**0.125MG**	**A040282**	**001**	Dec 23, 1999
AB			**0.25MG**	**A040282**	**002**	Dec 23, 1999
AB		STEVENS J	**0.125MG**	**A076268**	**001**	Jul 26, 2002
AB			**0.25MG**	**A076268**	**002**	Jul 26, 2002
AB		SUN PHARM INDS INC	**0.125MG**	**A076363**	**001**	Jan 31, 2003
AB			**0.25MG**	**A076363**	**002**	Jan 31, 2003

LANOXIN

AB	**+**	CONCORDIA	**0.125MG**	**N020405**	**002**	Sep 30, 1997
AB	**+!**		**0.25MG**	**N020405**	**004**	Sep 30, 1997
	+		0.0625MG	N020405	001	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

D.H.E. 45

AP	**+!**	BAUSCH	**1MG/ML**	**N005929**	**001**	

DIHYDROERGOTAMINE MESYLATE

AP		APOLLO	**1MG/ML**	**A212046**	**001**	Jan 07, 2020
AP		HIKMA PHARMS	**1MG/ML**	**A206621**	**001**	Sep 15, 2017
AP		PADDOCK LLC	**1MG/ML**	**A040475**	**001**	Apr 28, 2003
AP		SAGENT PHARMS INC	**1MG/ML**	**A207264**	**001**	Jul 11, 2018
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A040453**	**001**	Jun 09, 2003

SPRAY, METERED;NASAL

MIGRANAL

	+!	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB2		APOTEX	**180MG**	**A074943**	**002**	Dec 19, 2000
AB2	**!**		**240MG**	**A074943**	**001**	Aug 06, 1998

CARDIZEM CD

AB3	**+**	BAUSCH	**120MG**	**N020062**	**001**	Aug 10, 1992
AB3	**+**		**180MG**	**N020062**	**002**	Dec 27, 1991
AB3	**+**		**240MG**	**N020062**	**003**	Dec 27, 1991
AB3	**+**		**300MG**	**N020062**	**004**	Dec 27, 1991
AB3	**+!**		**360MG**	**N020062**	**005**	Aug 24, 1999

CARTIA XT

AB3		ACTAVIS LABS FL INC	**120MG**	**A074752**	**002**	Jul 09, 1998
AB3			**180MG**	**A074752**	**001**	Jul 09, 1998
AB3			**240MG**	**A074752**	**003**	Jul 09, 1998
AB3			**300MG**	**A074752**	**004**	Jul 09, 1998

DILTIAZEM HYDROCHLORIDE

AB3		ACTAVIS ELIZABETH	**360MG**	**A202463**	**001**	Dec 07, 2012
AB3		NOVAST LABS	**120MG**	**A208783**	**001**	Jun 14, 2019
AB3			**180MG**	**A208783**	**002**	Jun 14, 2019
AB3			**240MG**	**A208783**	**003**	Jun 14, 2019
AB3			**300MG**	**A208783**	**004**	Jun 14, 2019
AB3			**360MG**	**A208783**	**005**	Jun 14, 2019
AB3		PAR PHARM	**120MG**	**A074984**	**001**	Dec 20, 1999
AB3			**180MG**	**A074984**	**002**	Dec 20, 1999
AB3			**240MG**	**A074984**	**003**	Dec 20, 1999
AB3			**300MG**	**A074984**	**004**	Dec 20, 1999
AB3		SUN PHARM	**120MG**	**A090492**	**001**	Oct 28, 2011
AB3			**120MG**	**A203023**	**001**	Jun 08, 2017
AB3			**180MG**	**A090492**	**002**	Oct 28, 2011
AB3			**180MG**	**A203023**	**002**	Jun 08, 2017
AB3			**240MG**	**A090492**	**003**	Oct 28, 2011
AB3			**240MG**	**A203023**	**003**	Jun 08, 2017
AB3			**300MG**	**A090492**	**004**	Oct 28, 2011
AB3			**300MG**	**A203023**	**004**	Jun 08, 2017
AB3			**360MG**	**A090492**	**005**	Oct 28, 2011
AB3			**360MG**	**A203023**	**005**	Jun 08, 2017
AB3		TWI PHARMS	**120MG**	**A205231**	**001**	Aug 30, 2018
AB3			**180MG**	**A205231**	**002**	Aug 30, 2018
AB3			**240MG**	**A205231**	**003**	Aug 30, 2018
AB3			**300MG**	**A205231**	**004**	Aug 30, 2018
AB3			**360MG**	**A205231**	**005**	Aug 30, 2018
AB3		VALEANT PHARMS NORTH	**120MG**	**A075116**	**001**	Dec 23, 1999

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB3			**180MG**	**A075116**	**002**	Dec 23, 1999
AB3			**240MG**	**A075116**	**003**	Dec 23, 1999
AB3			**300MG**	**A075116**	**004**	Dec 23, 1999
AB3		ZYDUS PHARMS	**120MG**	**A206534**	**001**	Aug 08, 2017
AB3			**180MG**	**A206534**	**002**	Aug 08, 2017
AB3			**240MG**	**A206534**	**003**	Aug 08, 2017
AB3			**300MG**	**A206534**	**004**	Aug 08, 2017
AB3			**360MG**	**A206534**	**005**	Aug 08, 2017
AB4		SANDOZ	**120MG**	**A091022**	**001**	Sep 28, 2012
AB4			**180MG**	**A091022**	**002**	Sep 28, 2012
AB4			**240MG**	**A091022**	**003**	Sep 28, 2012
AB4			**300MG**	**A091022**	**004**	Sep 28, 2012
AB4			**360MG**	**A091022**	**005**	Sep 28, 2012
AB4			**420MG**	**A091022**	**006**	Sep 28, 2012
AB4		SUN PHARM	**120MG**	**A090421**	**001**	Nov 15, 2010
AB4			**180MG**	**A090421**	**002**	Nov 15, 2010
AB4			**240MG**	**A090421**	**003**	Nov 15, 2010
AB4			**300MG**	**A090421**	**004**	Nov 15, 2010
AB4			**360MG**	**A090421**	**005**	Nov 15, 2010
AB4		ZYDUS PHARMS	**120MG**	**A206641**	**001**	Aug 11, 2017
AB4			**180MG**	**A206641**	**002**	Aug 11, 2017
AB4			**240MG**	**A206641**	**003**	Aug 11, 2017
AB4			**300MG**	**A206641**	**004**	Aug 11, 2017
AB4			**360MG**	**A206641**	**005**	Aug 11, 2017
AB4			**420MG**	**A206641**	**006**	Aug 11, 2017

DILTZAC

AB4		APOTEX INC	**120MG**	**A076395**	**001**	Feb 01, 2006
AB4			**180MG**	**A076395**	**002**	Feb 01, 2006
AB4			**240MG**	**A076395**	**003**	Feb 01, 2006
AB4			**300MG**	**A076395**	**004**	Feb 01, 2006
AB4			**360MG**	**A076395**	**005**	Feb 01, 2006

TAZTIA XT

AB4		ACTAVIS LABS FL INC	**120MG**	**A075401**	**001**	Apr 10, 2003
AB4			**180MG**	**A075401**	**002**	Apr 10, 2003
AB4			**240MG**	**A075401**	**003**	Apr 10, 2003
AB4			**300MG**	**A075401**	**004**	Apr 10, 2003
AB4			**360MG**	**A075401**	**005**	Apr 10, 2003

TIAZAC

AB4	**+**	BAUSCH	**120MG**	**N020401**	**001**	Sep 11, 1995
AB4	**+**		**180MG**	**N020401**	**002**	Sep 11, 1995
AB4	**+**		**240MG**	**N020401**	**003**	Sep 11, 1995
AB4	**+**		**300MG**	**N020401**	**004**	Sep 11, 1995
AB4	**+**		**360MG**	**N020401**	**005**	Sep 11, 1995
AB4	**+!**		**420MG**	**N020401**	**006**	Oct 16, 1998

DILTIAZEM HYDROCHLORIDE

BC	!	MYLAN	120MG	A074910	003	May 02, 1997
		APOTEX	120MG	A074943	003	Dec 19, 2000
		MYLAN	60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		AKORN INC	**5MG/ML**	**A075086**	**001**	Apr 09, 1998
AP	**!**	ATHENEX INC	**5MG/ML**	**A074617**	**001**	Feb 28, 1996
AP		HIKMA FARMACEUTICA	**5MG/ML**	**A202651**	**001**	Aug 09, 2012
AP		HOSPIRA	**5MG/ML**	**A074941**	**001**	Apr 15, 1998
AP		INTL MEDICATION	**5MG/ML**	**A075749**	**001**	Nov 21, 2001
AP		WEST-WARD PHARMS INT	**5MG/ML**	**A078538**	**001**	Dec 17, 2008
	!	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002

TABLET;ORAL

CARDIZEM

AB	**+**	BAUSCH	**30MG**	**N018602**	**001**	Nov 05, 1982
AB	**+**		**60MG**	**N018602**	**002**	Nov 05, 1982
AB	**+**		**90MG**	**N018602**	**003**	Dec 08, 1986
AB	**+!**		**120MG**	**N018602**	**004**	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

AB		EDENBRIDGE PHARMS	**30MG**	**A211596**	**001**	Nov 18, 2019
AB			**60MG**	**A211596**	**002**	Nov 18, 2019
AB			**90MG**	**A211596**	**003**	Nov 18, 2019
AB			**120MG**	**A211596**	**004**	Nov 18, 2019

DILTIAZEM HYDROCHLORIDE

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

AB		MYLAN	**30MG**	**A072838**	**004**	Nov 05, 1992
AB			**60MG**	**A072838**	**003**	Nov 05, 1992
AB			**90MG**	**A072838**	**002**	Nov 05, 1992
AB			**120MG**	**A072838**	**001**	Nov 05, 1992
AB		TEVA	**30MG**	**A074185**	**001**	May 31, 1995
AB			**60MG**	**A074185**	**002**	May 31, 1995
AB			**90MG**	**A074185**	**003**	May 31, 1995
AB			**120MG**	**A074185**	**004**	May 31, 1995

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

AB	+	BAUSCH	**120MG**	**N021392**	**001**	Feb 06, 2003
AB	+		**180MG**	**N021392**	**002**	Feb 06, 2003
AB	+		**240MG**	**N021392**	**003**	Feb 06, 2003
AB	+		**300MG**	**N021392**	**004**	Feb 06, 2003
AB	+		**360MG**	**N021392**	**005**	Feb 06, 2003
AB	+!		**420MG**	**N021392**	**006**	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**120MG**	**A077686**	**006**	Mar 15, 2010
AB			**180MG**	**A077686**	**005**	Mar 15, 2010
AB			**240MG**	**A077686**	**004**	Mar 15, 2010
AB			**300MG**	**A077686**	**003**	Mar 15, 2010
AB			**360MG**	**A077686**	**002**	Mar 15, 2010
AB			**420MG**	**A077686**	**001**	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

!	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004

DIMERCAPROL

INJECTABLE;INJECTION

BAL

+!	AKORN	10%	N005939	001	

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

TECFIDERA

+	BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013
+!		240MG	N204063	002	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

RIMSO-50

+!	MYLAN INSTITUTIONAL	50%	N017788	001	

DINOPROSTONE

GEL;ENDOCERVICAL

PREPIDIL

+!	PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992

INSERT, EXTENDED RELEASE;VAGINAL

CERVIDIL

+!	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995

SUPPOSITORY;VAGINAL

PROSTIN E2

+!	PHARMACIA AND UPJOHN	20MG	N017810	001	

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP		APP PHARMS	**50MG/ML**	**A040466**	**001**	May 28, 2002
AP		HOSPIRA	**50MG/ML**	**A040140**	**001**	Nov 20, 1998
AP		MICRO LABS	**50MG/ML**	**A205723**	**001**	Aug 22, 2018
AP		MYLAN INSTITUTIONAL	**50MG/ML**	**A040498**	**001**	Jul 12, 2005
AP	!	WEST-WARD PHARMS INT	**50MG/ML**	**A080817**	**002**	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**50MG/ML**	**A091526**	**001**	Mar 26, 2013

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	**!**	ATHENEX INC	**5MG/ML**	**A074939**	**001**	Apr 13, 1998
AP		FRESENIUS KABI USA	**5MG/ML**	**A074956**	**001**	Sep 30, 1998
AP		WEST-WARD PHARMS INT	**5MG/ML**	**A074521**	**001**	Oct 18, 1996

TABLET;ORAL

DIPYRIDAMOLE

AB		BARR	**25MG**	**A087184**	**001**	Oct 03, 1990
AB			**50MG**	**A087716**	**001**	Oct 03, 1990
AB			**75MG**	**A087717**	**001**	Oct 03, 1990
AB		IMPAX LABS	**25MG**	**A040782**	**001**	Jul 18, 2007
AB			**50MG**	**A040782**	**002**	Jul 18, 2007
AB			**75MG**	**A040782**	**003**	Jul 18, 2007
AB		MURTY PHARMS	**25MG**	**A040733**	**001**	Feb 13, 2007
AB			**50MG**	**A040733**	**002**	Feb 13, 2007
AB			**75MG**	**A040733**	**003**	Feb 13, 2007
AB		ZYDUS PHARMS USA INC	**25MG**	**A040874**	**001**	Jan 28, 2008
AB			**50MG**	**A040874**	**002**	Jan 28, 2008
AB			**75MG**	**A040874**	**003**	Jan 28, 2008

PERSANTINE

AB	**+**	BOEHRINGER INGELHEIM	**25MG**	**N012836**	**003**	Dec 22, 1986
AB	**+**		**50MG**	**N012836**	**004**	Feb 06, 1987
AB	**+!**		**75MG**	**N012836**	**005**	Feb 06, 1987

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

VUMERITY

	+!	BIOGEN	231MG	N211855	001	Oct 29, 2019

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

AB		MAYNE PHARMA	**EQ 100MG BASE**	**A070173**	**001**	May 31, 1985
AB			**EQ 150MG BASE**	**A070173**	**002**	May 31, 1985
AB		TEVA	**EQ 100MG BASE**	**A070101**	**001**	Feb 22, 1985
AB			**EQ 150MG BASE**	**A070102**	**001**	Feb 22, 1985

NORPACE

AB	**+**	GD SEARLE LLC	**EQ 100MG BASE**	**N017447**	**001**	
AB	**+!**		**EQ 150MG BASE**	**N017447**	**002**	

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

	+	GD SEARLE LLC	EQ 100MG BASE	N018655	001	Jul 20, 1982
	+!		EQ 150MG BASE	N018655	002	Jul 20, 1982

DISULFIRAM

TABLET;ORAL

ANTABUSE

AB		ODYSSEY PHARMS	**250MG**	**A088482**	**001**	Dec 08, 1983
AB	**!**		**500MG**	**A088483**	**001**	Dec 08, 1983

DISULFIRAM

AB		ALVOGEN	**250MG**	**A091681**	**001**	Aug 08, 2013
AB		CHARTWELL MOLECULES	**250MG**	**A091563**	**001**	Dec 31, 2012
AB			**500MG**	**A091563**	**002**	Dec 31, 2012
AB		HIKMA	**250MG**	**A202652**	**001**	Feb 05, 2014
AB			**500MG**	**A202652**	**002**	Feb 05, 2014
AB		SIGMAPHARM LABS LLC	**250MG**	**A091619**	**001**	Mar 28, 2011
AB			**500MG**	**A091619**	**002**	Mar 28, 2011

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DEPAKOTE

AB	**+!**	ABBVIE	**EQ 125MG VALPROIC ACID**	**N019680**	**001**	Sep 12, 1989

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078979**	**001**	Jan 23, 2009
AB		MYLAN	**EQ 125MG VALPROIC ACID**	**A090407**	**001**	Mar 28, 2011
AB		ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A078919**	**001**	Jan 27, 2009

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

AB	**+**	ABBVIE	**EQ 125MG VALPROIC ACID**	**N018723**	**003**	Oct 26, 1984
AB	**+**		**EQ 250MG VALPROIC ACID**	**N018723**	**001**	Mar 10, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

	DEPAKOTE					
AB	**+!**	**EQ 500MG VALPROIC ACID**	**N018723**	**002**	Mar 10, 1983	
	DIVALPROEX SODIUM					
AB	ACTAVIS LABS FL INC	**EQ 500MG VALPROIC ACID**	**A079080**	**001**	Feb 25, 2011	
AB	ANCHEN PHARMS	**EQ 500MG VALPROIC ACID**	**A078411**	**001**	Nov 03, 2008	
AB	APOTEX	**EQ 125MG VALPROIC ACID**	**A077615**	**003**	Jul 29, 2008	
AB		**EQ 250MG VALPROIC ACID**	**A077615**	**002**	Jul 29, 2008	
AB		**EQ 500MG VALPROIC ACID**	**A077615**	**001**	Jul 29, 2008	
AB	AUROBINDO PHARMA LTD	**EQ 125MG VALPROIC ACID**	**A090554**	**001**	Apr 21, 2011	
AB		**EQ 250MG VALPROIC ACID**	**A090554**	**002**	Apr 21, 2011	
AB		**EQ 500MG VALPROIC ACID**	**A090554**	**003**	Apr 21, 2011	
AB	CELLTRION	**EQ 125MG VALPROIC ACID**	**A077296**	**001**	Jul 31, 2008	
AB		**EQ 250MG VALPROIC ACID**	**A077296**	**002**	Jul 31, 2008	
AB		**EQ 500MG VALPROIC ACID**	**A077296**	**003**	Jul 31, 2008	
AB	DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078755**	**001**	Jul 29, 2008	
AB		**EQ 250MG VALPROIC ACID**	**A078755**	**002**	Jul 29, 2008	
AB		**EQ 500MG VALPROIC ACID**	**A078755**	**003**	Jul 29, 2008	
AB	INVATECH	**EQ 125MG VALPROIC ACID**	**A078290**	**003**	Jul 29, 2008	
AB		**EQ 250MG VALPROIC ACID**	**A078290**	**002**	Jul 29, 2008	
AB		**EQ 500MG VALPROIC ACID**	**A078290**	**001**	Jul 29, 2008	
AB	LUPIN	**EQ 125MG VALPROIC ACID**	**A078790**	**001**	Jul 29, 2008	
AB		**EQ 250MG VALPROIC ACID**	**A078790**	**002**	Jul 29, 2008	
AB		**EQ 500MG VALPROIC ACID**	**A078790**	**003**	Jul 29, 2008	
AB	MYLAN	**EQ 125MG VALPROIC ACID**	**A090062**	**001**	Mar 17, 2009	
AB		**EQ 250MG VALPROIC ACID**	**A090062**	**002**	Mar 17, 2009	
AB		**EQ 500MG VALPROIC ACID**	**A090062**	**003**	Mar 17, 2009	
AB	ORCHID HLTHCARE	**EQ 125MG VALPROIC ACID**	**A078853**	**001**	Nov 25, 2008	
AB		**EQ 250MG VALPROIC ACID**	**A078853**	**002**	Nov 25, 2008	
AB		**EQ 500MG VALPROIC ACID**	**A078853**	**003**	Nov 25, 2008	
AB	PRINSTON INC	**EQ 125MG VALPROIC ACID**	**A090210**	**001**	Nov 30, 2009	
AB		**EQ 250MG VALPROIC ACID**	**A090210**	**002**	Nov 30, 2009	
AB		**EQ 500MG VALPROIC ACID**	**A090210**	**003**	Nov 30, 2009	
AB	SUN PHARM INDS	**EQ 125MG VALPROIC ACID**	**A078597**	**001**	Jul 29, 2008	
AB		**EQ 250MG VALPROIC ACID**	**A078597**	**002**	Jul 29, 2008	
AB		**EQ 500MG VALPROIC ACID**	**A078597**	**003**	Jul 29, 2008	
AB	UNICHEM LABS LTD	**EQ 125MG VALPROIC ACID**	**A079163**	**001**	Apr 05, 2011	
AB		**EQ 250MG VALPROIC ACID**	**A079163**	**002**	Apr 05, 2011	
AB		**EQ 500MG VALPROIC ACID**	**A079163**	**003**	Apr 05, 2011	
AB	UPSHER SMITH LABS	**EQ 125MG VALPROIC ACID**	**A078182**	**001**	Jul 29, 2008	
AB		**EQ 250MG VALPROIC ACID**	**A078182**	**002**	Jul 29, 2008	
AB		**EQ 500MG VALPROIC ACID**	**A078182**	**003**	Jul 29, 2008	
AB	ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A077100**	**001**	Mar 05, 2009	
AB		**EQ 250MG VALPROIC ACID**	**A077100**	**002**	Mar 05, 2009	
AB		**EQ 500MG VALPROIC ACID**	**A077100**	**003**	Mar 05, 2009	

TABLET, EXTENDED RELEASE;ORAL

	DEPAKOTE ER					
AB	**+** ABBVIE	**EQ 250MG VALPROIC ACID**	**N021168**	**002**	May 31, 2002	
AB	**+!**	**EQ 500MG VALPROIC ACID**	**N021168**	**001**	Aug 04, 2000	
	DIVALPROEX SODIUM					
AB	AMNEAL PHARMS	**EQ 250MG VALPROIC ACID**	**A203730**	**001**	May 29, 2015	
AB		**EQ 500MG VALPROIC ACID**	**A203730**	**002**	May 29, 2015	
AB	AUROBINDO PHARMA LTD	**EQ 250MG VALPROIC ACID**	**A202419**	**001**	Jun 02, 2014	
AB		**EQ 500MG VALPROIC ACID**	**A202419**	**002**	Jun 02, 2014	
AB	DR REDDYS LABS LTD	**EQ 250MG VALPROIC ACID**	**A090161**	**001**	Mar 15, 2012	
AB	IMPAX LABS	**EQ 250MG VALPROIC ACID**	**A078791**	**001**	May 06, 2009	
AB		**EQ 500MG VALPROIC ACID**	**A078791**	**002**	Aug 04, 2009	
AB	LUPIN LTD	**EQ 250MG VALPROIC ACID**	**A209286**	**001**	Oct 18, 2019	
AB		**EQ 500MG VALPROIC ACID**	**A209286**	**002**	Oct 18, 2019	
AB	MYLAN	**EQ 250MG VALPROIC ACID**	**A077567**	**001**	Jan 29, 2009	
AB		**EQ 500MG VALPROIC ACID**	**A077567**	**002**	Jan 29, 2009	
AB	REDDYS	**EQ 500MG VALPROIC ACID**	**A090070**	**001**	Mar 12, 2012	
AB	WOCKHARDT	**EQ 250MG VALPROIC ACID**	**A078705**	**002**	Feb 10, 2009	
AB		**EQ 500MG VALPROIC ACID**	**A078705**	**001**	Aug 04, 2009	
AB	ZYDUS PHARMS USA INC	**EQ 250MG VALPROIC ACID**	**A078239**	**001**	Feb 27, 2009	
AB		**EQ 500MG VALPROIC ACID**	**A078239**	**002**	Aug 04, 2009	

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

AP		HOSPIRA	EQ 12.5MG BASE/ML	A074086	001	Nov 29, 1993
AP	!		EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995
AP		WEST-WARD PHARMS INT	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	EQ 50MG BASE/100ML	N020255	001	Oct 19, 1993
AP	+!		EQ 100MG BASE/100ML	N020255	003	Oct 19, 1993
AP	+!		EQ 200MG BASE/100ML	N020255	004	Oct 19, 1993
AP	+!		EQ 400MG BASE/100ML	N020255	005	Oct 19, 1993
AP	+!	HOSPIRA	EQ 50MG BASE/100ML	N020201	003	Oct 19, 1993
AP	+!		EQ 100MG BASE/100ML	N020201	002	Oct 19, 1993
AP	+!		EQ 200MG BASE/100ML	N020201	001	Oct 19, 1993
AP	+!		EQ 400MG BASE/100ML	N020201	006	Jul 07, 1994

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	+	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195	003	Apr 20, 2012
AP	+		80MG/4ML (20MG/ML)	N201195	004	Apr 20, 2012
AP	+!		160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012
AP		ACTAVIS LLC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013
AP			80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013
AP			160MG/8ML (20MG/ML)	N203551	004	Sep 21, 2015
AP		AMNEAL	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018
AP			80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018
AP			160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018
AP		DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017
AP			80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017
AP		DR REDDYS LABS LTD	20MG/ML (20MG/ML)	A204193	001	Nov 05, 2014
AP			80MG/4ML (20MG/ML)	A204193	002	Nov 05, 2014
AP	+!	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011
AP	+!		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011
AP	+!		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011
AP		INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017
AP			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017
AP			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017
AP		JIANGSU HENGRUI MED	20MG/ML (20MG/ML)	A207252	001	Aug 09, 2017
AP			80MG/4ML (20MG/ML)	A207252	002	Aug 09, 2017
AP			160MG/8ML (20MG/ML)	A207252	003	Aug 09, 2017
AP		MYLAN LABS LTD	20MG/2ML (10MG/ML)	A210072	001	Jul 02, 2018
AP			80MG/8ML (10MG/ML)	A210848	001	Jul 06, 2018
AP			160MG/8ML (20MG/ML)	A208137	001	Apr 01, 2019
AP		SANDOZ	20MG/2ML (10MG/ML)	N201525	001	Jun 29, 2011
AP			80MG/8ML (10MG/ML)	N201525	002	Jun 29, 2011
AP			160MG/16ML (10MG/ML)	N201525	003	Jun 29, 2011
AP		TEIKOKU PHARMA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015
AP			80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015
AP			160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015

TAXOTERE

AP	+!	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010
AP	+!		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010
AP	+!		160MG/8ML (20MG/ML)	N020449	005	Apr 13, 2012

DOCETAXEL

		ACTAVIS LLC	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013
		DFB ONCOLOGY LTD	200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017
	+	HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016
	+		80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016
	+		160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017
	!	JIANGSU HENGRUI MED	40MG/ML	A203170	001	Feb 15, 2017

SOLUTION;INTRAVENOUS

DOCETAXEL

AP		SUN PHARMA GLOBAL	20MG/ML (20MG/ML)	N022534	003	Jan 08, 2019
AP			80MG/4ML (20MG/ML)	N022534	004	Jan 08, 2019
AP			160MG/8ML (20MG/ML)	N022534	005	Jan 08, 2019

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL						
AP		MYLAN LABS LTD	**160MG/16ML (10MG/ML)**	**A208859**	**001**	Apr 30, 2018

DOFETILIDE

CAPSULE;ORAL

DOFETILDE						
AB		AUROBINDO PHARMA LTD	**0.125MG**	**A210740**	**001**	Jan 22, 2019
AB			**0.25MG**	**A210740**	**002**	Jan 22, 2019
AB			**0.5MG**	**A210740**	**003**	Jan 22, 2019
DOFETILIDE						
AB		BIONPHARMA INC	**0.125MG**	**A208625**	**001**	Apr 10, 2018
AB			**0.25MG**	**A208625**	**002**	Apr 10, 2018
AB			**0.5MG**	**A208625**	**003**	Apr 10, 2018
AB		MAYNE PHARMA INC	**0.125MG**	**A207058**	**001**	Jun 06, 2016
AB			**0.25MG**	**A207058**	**002**	Jun 06, 2016
AB			**0.5MG**	**A207058**	**003**	Jun 06, 2016
AB		PAR PHARM INC	**0.125MG**	**A208519**	**001**	Oct 09, 2018
AB			**0.25MG**	**A208519**	**002**	Oct 09, 2018
AB			**0.5MG**	**A208519**	**003**	Oct 09, 2018
AB		PRINSTON INC	**0.125MG**	**A211223**	**001**	Dec 17, 2019
AB			**0.25MG**	**A211223**	**002**	Dec 17, 2019
AB			**0.5MG**	**A211223**	**003**	Dec 17, 2019
AB		RICONPHARMA LLC	**0.125MG**	**A212410**	**001**	Dec 27, 2019
AB			**0.25MG**	**A212410**	**002**	Dec 27, 2019
AB			**0.5MG**	**A212410**	**003**	Dec 27, 2019
AB		SIGMAPHARM LABS LLC	**0.125MG**	**A207746**	**001**	Mar 26, 2018
AB			**0.25MG**	**A207746**	**002**	Mar 26, 2018
AB			**0.5MG**	**A207746**	**003**	Mar 26, 2018
AB		SUN PHARM	**0.125MG**	**A210466**	**001**	Oct 09, 2018
AB			**0.25MG**	**A210466**	**002**	Oct 09, 2018
AB			**0.5MG**	**A210466**	**003**	Oct 09, 2018
TIKOSYN						
AB	**+**	PFIZER	**0.125MG**	**N020931**	**001**	Oct 01, 1999
AB	**+**		**0.25MG**	**N020931**	**002**	Oct 01, 1999
AB	**+!**		**0.5MG**	**N020931**	**003**	Oct 01, 1999

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY						
	+	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016
	+		EQ 25MG BASE	N204790	003	Jun 09, 2016
	+!		EQ 50MG BASE	N204790	001	Aug 12, 2013

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

DOVATO						
	+!	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

JULUCA						
	+!	VIIV HLTHCARE	EQ 50MG BASE;EQ 25MG BASE	N210192	001	Nov 21, 2017

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

ARICEPT						
AB	**+**	EISAI INC	**5MG**	**N020690**	**002**	Nov 25, 1996
AB	**+!**		**10MG**	**N020690**	**001**	Nov 25, 1996
AB	**+!**		**23MG**	**N022568**	**001**	Jul 23, 2010
DONEPEZIL HYDROCHLORIDE						
AB		ACI HEALTHCARE LTD	**5MG**	**A078662**	**001**	May 31, 2011
AB			**10MG**	**A078662**	**002**	May 31, 2011
AB		ACTAVIS ELIZABETH	**23MG**	**A202415**	**001**	Dec 17, 2015
AB		ALEMBIC PHARMS LTD	**5MG**	**A201724**	**001**	Feb 25, 2013
AB			**10MG**	**A201724**	**002**	Feb 25, 2013
AB		AUROBINDO	**5MG**	**A090056**	**001**	May 31, 2011
AB			**10MG**	**A090056**	**002**	May 31, 2011
AB		CADILA	**5MG**	**A090100**	**001**	Oct 24, 2012
AB			**10MG**	**A090100**	**002**	Oct 24, 2012
AB		CADILA PHARMS LTD	**5MG**	**A204609**	**001**	Sep 19, 2017
AB			**10MG**	**A204609**	**002**	Sep 19, 2017
AB		CIPLA LTD	**5MG**	**A077518**	**001**	May 31, 2011

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB			**10MG**	**A077518**	**002**	May 31, 2011
AB		CSPC OUYI	**5MG**	**A202114**	**001**	Jul 05, 2013
AB			**10MG**	**A202114**	**002**	Jul 05, 2013
AB		DEXCEL PHARMA	**23MG**	**A203713**	**001**	Feb 19, 2016
AB		DR REDDYS	**23MG**	**A202723**	**001**	Jul 24, 2013
AB		DR REDDYS LABS LTD	**5MG**	**A201001**	**001**	May 31, 2011
AB			**10MG**	**A201001**	**002**	May 31, 2011
AB		HERITAGE PHARMA	**5MG**	**A077344**	**001**	May 31, 2011
AB			**10MG**	**A077344**	**002**	May 31, 2011
AB		HETERO LABS LTD V	**5MG**	**A203034**	**001**	Jan 30, 2015
AB			**10MG**	**A203034**	**002**	Jan 30, 2015
AB		HISUN PHARM HANGZHOU	**23MG**	**A202410**	**001**	Mar 24, 2017
AB		INDICUS PHARMA	**5MG**	**A201634**	**001**	Jun 13, 2012
AB			**10MG**	**A201634**	**002**	Jun 13, 2012
AB			**23MG**	**A203419**	**001**	Apr 12, 2016
AB		JUBILANT GENERICS	**5MG**	**A090768**	**001**	May 31, 2011
AB			**10MG**	**A090768**	**002**	May 31, 2011
AB		LUPIN LTD	**23MG**	**A202782**	**001**	Oct 30, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A201146**	**001**	Aug 17, 2012
AB			**10MG**	**A201146**	**002**	Aug 17, 2012
AB			**23MG**	**A202631**	**001**	Jan 22, 2014
AB		MYLAN	**23MG**	**A202656**	**001**	Oct 22, 2015
AB		MYLAN PHARMS INC	**5MG**	**A090521**	**001**	May 31, 2011
AB			**10MG**	**A090521**	**002**	May 31, 2011
AB		PLIVA HRVATSKA DOO	**5MG**	**A090425**	**001**	May 31, 2011
AB			**10MG**	**A090425**	**002**	May 31, 2011
AB		PRINSTON INC	**5MG**	**A200292**	**001**	May 31, 2011
AB			**10MG**	**A200292**	**002**	May 31, 2011
AB		SANDOZ	**5MG**	**A090290**	**001**	May 31, 2011
AB			**10MG**	**A090290**	**002**	May 31, 2011
AB		SCIEGEN PHARMS INC	**5MG**	**A203907**	**001**	Oct 29, 2014
AB			**10MG**	**A203907**	**002**	Oct 29, 2014
AB		STRIDES PHARMA	**5MG**	**A090551**	**001**	May 31, 2011
AB			**10MG**	**A090551**	**002**	May 31, 2011
AB		SUN PHARM INDS	**5MG**	**A090493**	**001**	May 31, 2011
AB			**10MG**	**A090493**	**002**	May 31, 2011
AB		TORRENT PHARMS	**5MG**	**A090686**	**001**	May 31, 2011
AB			**10MG**	**A090686**	**002**	May 31, 2011
AB		TWI PHARMS	**23MG**	**A203104**	**001**	Oct 29, 2014
AB		UNICHEM LABS LTD	**5MG**	**A203656**	**001**	Jun 23, 2016
AB			**10MG**	**A203656**	**002**	Jun 23, 2016
AB		ZYDUS PHARMS	**23MG**	**A203162**	**001**	Aug 31, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

AB		HISUN PHARM HANGZHOU	**5MG**	**A205269**	**001**	Jul 27, 2018
AB			**10MG**	**A205269**	**002**	Jul 27, 2018
AB		MACLEODS PHARMS LTD	**5MG**	**A201787**	**001**	Dec 14, 2012
AB			**10MG**	**A201787**	**002**	Dec 14, 2012
AB		SANDOZ	**5MG**	**A091198**	**001**	May 10, 2011
AB	**!**		**10MG**	**A091198**	**002**	May 10, 2011
AB		UNICHEM LABS LTD	**5MG**	**A204831**	**001**	Nov 10, 2016
AB			**10MG**	**A204831**	**002**	Nov 10, 2016

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

+	ALLERGAN	10MG;7MG	N206439	003	Jul 18, 2016
+		10MG;14MG	N206439	001	Dec 23, 2014
+		10MG;21MG	N206439	004	Jul 18, 2016
+!		10MG;28MG	N206439	002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

AP		HIKMA INTL PHARMS	**40MG/ML**	**A207707**	**001**	Apr 11, 2018
AP			**80MG/ML**	**A207707**	**002**	Apr 11, 2018
AP	**+!**	HOSPIRA	**40MG/ML**	**N018132**	**001**	
AP	**+!**		**80MG/100ML**	**N018132**	**002**	Feb 04, 1982
AP	**+!**		**80MG/ML**	**N018132**	**004**	Jul 09, 1982

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

AP	**+!**		**160MG/100ML**	**N018132**	**003**	Feb 04, 1982

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

AP	**+!**	B BRAUN	**80MG/100ML**	**N019099**	**002**	Oct 15, 1986
AP	**+!**		**320MG/100ML**	**N019099**	**004**	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**160MG/100ML**	**N019099**	**003**	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**80MG/100ML**	**N019615**	**001**	Mar 27, 1987
AP	**+!**		**160MG/100ML**	**N019615**	**002**	Mar 27, 1987
AP	**+!**		**320MG/100ML**	**N019615**	**003**	Mar 27, 1987
AP	**+!**	HOSPIRA	**80MG/100ML**	**N018826**	**001**	Sep 30, 1983
AP	**+!**		**160MG/100ML**	**N018826**	**002**	Sep 30, 1983
AP	**+!**		**320MG/100ML**	**N018826**	**003**	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

	+!	B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987

DORAVIRINE

TABLET;ORAL

PIFELTRO

	+!	MSD MERCK CO	100MG	N210806	001	Aug 30, 2018

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

DELSTRIGO

	+!	MSD MERCK CO	100MG;300MG;300MG	N210807	001	Aug 30, 2018

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		ALEMBIC PHARMS LTD	**EQ 2% BASE**	**A212639**	**001**	Aug 09, 2019
AT		BAUSCH AND LOMB	**EQ 2% BASE**	**A090143**	**001**	Jun 25, 2009
AT		FDC LTD	**EQ 2% BASE**	**A205294**	**001**	Jan 24, 2019
AT		HI TECH PHARMA	**EQ 2% BASE**	**A077846**	**001**	Oct 28, 2008
AT		MICRO LABS	**EQ 2% BASE**	**A204778**	**001**	Nov 08, 2019
AT		SANDOZ INC	**EQ 2% BASE**	**A078748**	**001**	Nov 06, 2008
AT			**EQ 2% BASE**	**A078981**	**001**	Apr 13, 2009

TRUSOPT

AT	**+!**	MERCK	**EQ 2% BASE**	**N020408**	**001**	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT	**+!**	OAK PHARMS INC	**EQ 2% BASE;EQ 0.5% BASE**	**N020869**	**001**	Apr 07, 1998

COSOPT PF

AT	**+!**	OAK PHARMS INC	**EQ 2% BASE;EQ 0.5% BASE**	**N202667**	**001**	Feb 01, 2012

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT		AKORN INC	**EQ 2% BASE;EQ 0.5% BASE**	**A203058**	**001**	Sep 22, 2014
AT		AUROBINDO PHARMA LTD	**EQ 2% BASE;EQ 0.5% BASE**	**A207630**	**001**	Jul 24, 2018
AT		BAUSCH AND LOMB	**EQ 2% BASE;EQ 0.5% BASE**	**A090037**	**001**	Jul 14, 2009
AT		HI TECH PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**A077847**	**001**	Oct 28, 2008
AT		SANDOZ	**EQ 2% BASE;EQ 0.5% BASE**	**A078749**	**001**	Nov 06, 2008
AT		SANDOZ INC	**EQ 2% BASE;EQ 0.5% BASE**	**A090604**	**001**	Nov 18, 2009
AT		SOMERSET	**EQ 2% BASE;EQ 0.5% BASE**	**A207523**	**001**	Jun 25, 2019
AT		TEVA PHARMS	**EQ 2% BASE;EQ 0.5% BASE**	**A078704**	**001**	Sep 28, 2009

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	**+!**	HIKMA	**20MG/ML**	**N014879**	**001**	

DOXAPRAM HYDROCHLORIDE

AP		ATHENEX INC	**20MG/ML**	**A076266**	**001**	Jan 10, 2003

DOXAZOSIN MESYLATE

TABLET;ORAL

CARDURA

AB	**+!**	PFIZER	**EQ 1MG BASE**	**N019668**	**001**	Nov 02, 1990
AB	**+**		**EQ 2MG BASE**	**N019668**	**002**	Nov 02, 1990
AB	**+**		**EQ 4MG BASE**	**N019668**	**003**	Nov 02, 1990
AB	**+**		**EQ 8MG BASE**	**N019668**	**004**	Nov 02, 1990

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB	ACCORD HLTHCARE	**EQ 1MG BASE**	**A202824**	**001**	Jun 11, 2014
AB		**EQ 2MG BASE**	**A202824**	**002**	Jun 11, 2014
AB		**EQ 4MG BASE**	**A202824**	**003**	Jun 11, 2014
AB		**EQ 8MG BASE**	**A202824**	**004**	Jun 11, 2014
AB	ANI PHARMS INC	**EQ 1MG BASE**	**A075432**	**001**	Oct 18, 2000
AB		**EQ 2MG BASE**	**A075432**	**002**	Oct 18, 2000
AB		**EQ 4MG BASE**	**A075432**	**003**	Oct 18, 2000
AB		**EQ 8MG BASE**	**A075432**	**004**	Oct 18, 2000
AB	APOTEX	**EQ 1MG BASE**	**A075580**	**001**	Oct 18, 2000
AB		**EQ 2MG BASE**	**A075580**	**002**	Oct 18, 2000
AB		**EQ 4MG BASE**	**A075580**	**003**	Oct 18, 2000
AB		**EQ 8MG BASE**	**A075580**	**004**	Oct 18, 2000
AB	DAVA PHARMS INC	**EQ 1MG BASE**	**A076161**	**001**	Jun 10, 2004
AB		**EQ 2MG BASE**	**A076161**	**002**	Jun 10, 2004
AB		**EQ 4MG BASE**	**A076161**	**003**	Jun 10, 2004
AB		**EQ 8MG BASE**	**A076161**	**004**	Jun 10, 2004
AB	HERITAGE PHARMA	**EQ 1MG BASE**	**A205210**	**001**	Feb 13, 2018
AB		**EQ 2MG BASE**	**A205210**	**002**	Feb 13, 2018
AB		**EQ 4MG BASE**	**A205210**	**003**	Feb 13, 2018
AB		**EQ 8MG BASE**	**A205210**	**004**	Feb 13, 2018
AB	MYLAN	**EQ 1MG BASE**	**A075509**	**001**	Oct 19, 2000
AB		**EQ 2MG BASE**	**A075509**	**002**	Oct 19, 2000
AB		**EQ 4MG BASE**	**A075509**	**003**	Oct 19, 2000
AB		**EQ 8MG BASE**	**A075509**	**004**	Oct 19, 2000
AB	PLIVA	**EQ 1MG BASE**	**A075750**	**001**	Jun 08, 2001
AB		**EQ 2MG BASE**	**A075750**	**002**	Jun 08, 2001
AB		**EQ 4MG BASE**	**A075750**	**003**	Jun 08, 2001
AB		**EQ 8MG BASE**	**A075750**	**004**	Jun 08, 2001
AB	TEVA	**EQ 1MG BASE**	**A075536**	**001**	Oct 18, 2000
AB		**EQ 2MG BASE**	**A075536**	**002**	Oct 18, 2000
AB		**EQ 4MG BASE**	**A075536**	**003**	Oct 18, 2000
AB		**EQ 8MG BASE**	**A075536**	**004**	Oct 18, 2000
AB	UPSHER SMITH LABS	**EQ 1MG BASE**	**A209013**	**001**	Apr 17, 2018
AB		**EQ 2MG BASE**	**A209013**	**002**	Apr 17, 2018
AB		**EQ 4MG BASE**	**A209013**	**003**	Apr 17, 2018
AB		**EQ 8MG BASE**	**A209013**	**004**	Apr 17, 2018
AB	ZYDUS PHARMS	**EQ 1MG BASE**	**A208719**	**001**	Jul 07, 2017
AB		**EQ 2MG BASE**	**A208719**	**002**	Jul 07, 2017
AB		**EQ 4MG BASE**	**A208719**	**003**	Jul 07, 2017
AB		**EQ 8MG BASE**	**A208719**	**004**	Jul 07, 2017

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+	PFIZER	EQ 4MG BASE	N021269	001	Feb 22, 2005
+!		EQ 8MG BASE	N021269	002	Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	AJANTA PHARMA LTD	**EQ 10MG BASE**	**A212624**	**001**	Sep 13, 2019
AB		**EQ 25MG BASE**	**A212624**	**002**	Sep 13, 2019
AB		**EQ 50MG BASE**	**A212624**	**003**	Sep 13, 2019
AB		**EQ 75MG BASE**	**A212624**	**004**	Sep 13, 2019
AB		**EQ 100MG BASE**	**A212624**	**005**	Sep 13, 2019
AB	AMNEAL PHARMS CO	**EQ 10MG BASE**	**A207482**	**001**	Jun 28, 2017
AB		**EQ 25MG BASE**	**A207482**	**002**	Jun 28, 2017
AB		**EQ 50MG BASE**	**A207482**	**003**	Jun 28, 2017
AB		**EQ 75MG BASE**	**A207482**	**004**	Jun 28, 2017
AB		**EQ 100MG BASE**	**A207482**	**005**	Jun 28, 2017
AB	AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A211603**	**001**	Mar 27, 2019
AB		**EQ 25MG BASE**	**A211603**	**002**	Mar 27, 2019
AB		**EQ 50MG BASE**	**A211603**	**003**	Mar 27, 2019
AB		**EQ 75MG BASE**	**A211603**	**004**	Mar 27, 2019
AB		**EQ 100MG BASE**	**A211603**	**005**	Mar 27, 2019
AB	MYLAN PHARMS INC	**EQ 10MG BASE**	**A070791**	**002**	May 13, 1986
AB !		**EQ 25MG BASE**	**A070791**	**003**	May 13, 1986
AB		**EQ 50MG BASE**	**A070791**	**001**	May 13, 1986
AB		**EQ 75MG BASE**	**A070791**	**004**	May 13, 1986
AB !		**EQ 100MG BASE**	**A070791**	**005**	May 13, 1986
AB	PAR PHARM	**EQ 10MG BASE**	**A071422**	**002**	Nov 09, 1987

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB			**EQ 25MG BASE**	**A071422**	**003**	Nov 09, 1987
AB			**EQ 50MG BASE**	**A071422**	**004**	Nov 09, 1987
AB			**EQ 75MG BASE**	**A071422**	**005**	Nov 09, 1987
AB			**EQ 100MG BASE**	**A071422**	**001**	Nov 09, 1987
	!		EQ 150MG BASE	A071422	006	Nov 09, 1987

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

AA		LANNETT CO INC	**EQ 10MG BASE/ML**	**A074721**	**001**	Dec 29, 1998
AA	**!**	TEVA PHARMS	**EQ 10MG BASE/ML**	**A071609**	**001**	Nov 09, 1987
AA		WOCKHARDT BIO AG	**EQ 10MG BASE/ML**	**A071918**	**001**	Jul 20, 1988

CREAM;TOPICAL

ZONALON

	+!	MYLAN	5%	N020126	001	Apr 01, 1994

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 3MG BASE**	**A201951**	**001**	Jul 26, 2013
AB			**EQ 6MG BASE**	**A201951**	**002**	Jul 26, 2013

SILENOR

AB	**+**	CURRAX	**EQ 3MG BASE**	**N022036**	**001**	Mar 17, 2010
AB	**+!**		**EQ 6MG BASE**	**N022036**	**002**	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB		HIKMA	**0.5MCG**	**A091433**	**001**	Sep 23, 2011
AB			**1MCG**	**A091433**	**002**	Jan 14, 2014
AB			**2.5MCG**	**A091433**	**003**	Jan 14, 2014
AB		RISING	**0.5MCG**	**A201518**	**001**	Sep 09, 2016
AB			**1MCG**	**A201518**	**002**	Sep 09, 2016
AB			**2.5MCG**	**A201518**	**003**	Sep 09, 2016

HECTOROL

AB	**+**	SANOFI	**0.5MCG**	**N020862**	**002**	Apr 23, 2004
AB	**+**		**1MCG**	**N020862**	**003**	Jul 13, 2009
AB	**+!**		**2.5MCG**	**N020862**	**001**	Jun 09, 1999

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		AKORN INC	**2MCG/ML (2MCG/ML)**	**A203929**	**002**	Mar 28, 2016
AP			**4MCG/2ML (2MCG/ML)**	**A203929**	**001**	May 07, 2015
AP		AMNEAL	**2MCG/ML (2MCG/ML)**	**A208974**	**001**	May 24, 2017
AP			**4MCG/2ML (2MCG/ML)**	**A208974**	**002**	May 24, 2017
AP			**4MCG/2ML (2MCG/ML)**	**A208975**	**001**	May 24, 2017
AP		GLAND PHARMA LTD	**4MCG/2ML (2MCG/ML)**	**A210452**	**001**	Sep 26, 2019
AP		HIKMA PHARMS	**4MCG/2ML (2MCG/ML)**	**A091101**	**001**	Aug 30, 2013
AP	**+**	HOSPIRA INC	**4MCG/2ML (2MCG/ML)**	**N208614**	**001**	Jul 24, 2018
AP		LUPIN LTD	**4MCG/2ML (2MCG/ML)**	**A210801**	**001**	Nov 01, 2018
AP		SANDOZ INC	**4MCG/2ML (2MCG/ML)**	**A091333**	**001**	May 05, 2014
AP			**4MCG/2ML (2MCG/ML)**	**A200926**	**001**	Feb 04, 2014
AP		SUN PHARM	**2MCG/ML (2MCG/ML)**	**A203875**	**001**	Nov 14, 2019
AP			**4MCG/2ML (2MCG/ML)**	**A203875**	**002**	Nov 14, 2019

HECTOROL

AP	**+**	SANOFI	**2MCG/ML (2MCG/ML)**	**N021027**	**002**	Apr 06, 2000
AP	**+!**		**4MCG/2ML (2MCG/ML)**	**N021027**	**001**	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		ACTAVIS INC	**2MG/ML**	**A203622**	**001**	Jun 27, 2014
AP			**200MG/100ML**	**A203622**	**002**	Jun 27, 2014
AP		AMNEAL	**20MG/VIAL**	**A208888**	**001**	Feb 17, 2017
AP			**50MG/VIAL**	**A208888**	**002**	Feb 17, 2017
AP		FRESENIUS KABI USA	**2MG/ML**	**A063277**	**001**	Oct 26, 1995
AP		GLAND PHARMA LTD	**2MG/ML**	**A209825**	**001**	Aug 11, 2017
AP		MYLAN LABS LTD	**50MG/VIAL**	**A200170**	**002**	Oct 28, 2011
AP		PHARMACHEMIE BV	**2MG/ML**	**A063336**	**001**	Feb 28, 1995
AP			**10MG/VIAL**	**A063097**	**001**	May 21, 1990
AP			**20MG/VIAL**	**A063097**	**002**	May 21, 1990
AP			**50MG/VIAL**	**A063097**	**003**	May 21, 1990
AP			**200MG/100ML**	**A063336**	**004**	Feb 28, 1995
AP	**+!**	PHARMACIA AND UPJOHN	**2MG/ML**	**N050629**	**001**	Dec 23, 1987
AP	**+!**		**200MG/100ML**	**N050629**	**002**	May 03, 1988

PRESCRIPTION DRUG PRODUCT LIST

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		SAGENT PHARMS	2MG/ML	A091495	001	Mar 18, 2013
AP		SUN PHARM INDS	2MG/ML	A091418	001	Feb 15, 2012
AP		TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995
AP			200MG/100ML	A064140	002	Jul 28, 1995
AP		WEST-WARD PHARMS INT	2MG/ML	A062975	001	Mar 17, 1989
AP	!		10MG/VIAL	A062921	001	Mar 17, 1989
AP	!		20MG/VIAL	A062921	002	Mar 17, 1989
AP	!		50MG/VIAL	A062921	003	Mar 17, 1989
AP			200MG/100ML	A064097	001	Sep 13, 1994
	+	PHARMACIA AND UPJOHN	150MG/75ML	N050629	003	Mar 28, 2011

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL (LIPOSOMAL)

AB	+	BAXTER HLTHCARE CORP	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017
AB			50MG/25ML (2MG/ML)	A208657	002	May 15, 2017
AB	!	SUN PHARM	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013
AB	!		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		ACP NIMBLE	EQ 50MG BASE	A204446	001	May 28, 2015
AB			EQ 75MG BASE	A204446	002	May 28, 2015
AB			EQ 100MG BASE	A204446	003	May 28, 2015
AB		ALEMBIC PHARMS LTD	EQ 75MG BASE	A209165	001	Jul 28, 2017
AB			EQ 100MG BASE	A209165	002	Jul 28, 2017
AB		IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011
AB		LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014
AB			EQ 75MG BASE	A204234	002	Mar 05, 2014
AB			EQ 100MG BASE	A204234	003	Mar 05, 2014
AB		MAYNE PHARMA INC	EQ 50MG BASE	A209396	001	Sep 29, 2017
AB			EQ 75MG BASE	A209396	002	Sep 29, 2017
AB			EQ 100MG BASE	A209396	003	Sep 29, 2017
AB		MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012
AB		PAR PHARM	EQ 50MG BASE	A065055	001	Dec 01, 2000
AB			EQ 100MG BASE	A065055	002	Dec 01, 2000
AB	!		EQ 150MG BASE	A065055	003	Jul 15, 2005
AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000
AB			EQ 75MG BASE	A065053	003	Sep 10, 2003
AB	!		EQ 100MG BASE	A065053	002	Nov 22, 2000
AB		ZYDUS PHARMS	EQ 50MG BASE	A205115	001	Feb 18, 2016
AB			EQ 75MG BASE	A205115	002	Feb 18, 2016
AB			EQ 100MG BASE	A205115	003	Feb 18, 2016

ORACEA

	+!	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB		CHARTWELL LIFE SCI	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008
AB		LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013

VIBRAMYCIN

AB	+!	PFIZER	EQ 25MG BASE/5ML	N050006	001	

TABLET;ORAL

DOXYCYCLINE

AB		HERITAGE PHARMS INC	EQ 50MG BASE	A091605	001	Dec 20, 2011
AB			EQ 75MG BASE	A091605	002	Dec 20, 2011
AB			EQ 100MG BASE	A091605	003	Dec 20, 2011
AB	!		EQ 150MG BASE	A091605	004	Dec 20, 2011
AB		LANNETT CO INC	EQ 50MG BASE	A065285	001	Dec 08, 2005
AB			EQ 75MG BASE	A065285	003	Jul 30, 2008
AB			EQ 100MG BASE	A065285	002	Dec 08, 2005
AB			EQ 150MG BASE	A065285	004	Jul 30, 2008
AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006
AB			EQ 75MG BASE	A065356	002	May 31, 2006
AB			EQ 100MG BASE	A065356	003	May 31, 2006
AB			EQ 150MG BASE	A065356	004	Jul 29, 2010

DOXYCYCLINE

TABLET;ORAL

DOXYCYCLINE

AB		ZYDUS PHARMS	**EQ 50MG BASE**	**A209582**	**001**	Sep 28, 2017
AB			**EQ 75MG BASE**	**A209582**	**002**	Sep 28, 2017
AB			**EQ 100MG BASE**	**A209582**	**003**	Sep 28, 2017
AB			**EQ 150MG BASE**	**A209582**	**004**	Sep 28, 2017

DOXYCYCLINE CALCIUM

SUSPENSION;ORAL

VIBRAMYCIN

	+!	PFIZER	EQ 50MG BASE/5ML	N050480	001	

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		ACTAVIS LABS FL INC	**EQ 50MG BASE**	**A062031**	**002**	Oct 13, 1982
AB			**EQ 100MG BASE**	**A062031**	**001**	
AB		ALEMBIC PHARMS LTD	**EQ 50MG BASE**	**A210527**	**001**	Jun 13, 2018
AB			**EQ 100MG BASE**	**A210527**	**002**	Jun 13, 2018
AB		AMNEAL PHARMS	**EQ 100MG BASE**	**A207289**	**001**	Jun 27, 2016
AB		CHANGZHOU PHARM	**EQ 100MG BASE**	**A209402**	**001**	Oct 07, 2019
AB		CHARTWELL LIFE SCI	**EQ 50MG BASE**	**A062500**	**001**	Sep 11, 1984
AB			**EQ 100MG BASE**	**A062500**	**002**	Sep 11, 1984
AB		HIKMA INTL PHARMS	**EQ 50MG BASE**	**A062396**	**002**	Nov 07, 1984
AB			**EQ 100MG BASE**	**A062396**	**001**	May 07, 1984
AB		SUN PHARM INDUSTRIES	**EQ 50MG BASE**	**A062676**	**002**	Jul 10, 1986
AB			**EQ 100MG BASE**	**A062676**	**001**	Jul 10, 1986
AB		ZYDUS PHARMS	**EQ 50MG BASE**	**A207774**	**001**	May 31, 2018
AB			**EQ 100MG BASE**	**A207774**	**002**	May 31, 2018

VIBRAMYCIN

AB	**+!**	PFIZER	**EQ 100MG BASE**	**N050007**	**002**	

INJECTABLE;INJECTION

DOXY 100

AP	**!**	FRESENIUS KABI USA	**EQ 100MG BASE/VIAL**	**A062475**	**001**	Dec 09, 1983

DOXY 200

AP	**!**	FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A062475**	**002**	Dec 09, 1983

DOXYCYCLINE

AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A091406**	**001**	Aug 21, 2012
AP	**!**	WEST-WARD PHARMS INT	**EQ 100MG BASE/VIAL**	**A062569**	**001**	Mar 09, 1988
AP		ZYDUS PHARMS	**EQ 100MG BASE/VIAL**	**A207757**	**001**	Sep 28, 2017
AP			**EQ 200MG BASE/VIAL**	**A207757**	**002**	Sep 28, 2017

SYSTEM, EXTENDED RELEASE;PERIODONTAL

ATRIDOX

	+!	TOLMAR	50MG	N050751	001	Sep 03, 1998

TABLET;ORAL

ACTICLATE

AB	**+**	ALMIRALL	**EQ 75MG BASE**	**N205931**	**001**	Jul 25, 2014
AB	**+!**		**EQ 150MG BASE**	**N205931**	**002**	Jul 25, 2014

DOXYCYCLINE HYCLATE

AB		ACTAVIS LABS FL INC	**EQ 100MG BASE**	**A062421**	**001**	Feb 02, 1983
AB		AMNEAL PHARMS CO	**EQ 75MG BASE**	**A209372**	**001**	Oct 06, 2017
AB			**EQ 150MG BASE**	**A209372**	**002**	Oct 06, 2017
AB		APOTEX	**EQ 75MG BASE**	**A209243**	**001**	Apr 15, 2019
AB			**EQ 150MG BASE**	**A209243**	**002**	Apr 15, 2019
AB		CADILA	**EQ 100MG BASE**	**A207773**	**001**	Oct 30, 2017
AB		CARIBE HOLDINGS	**EQ 100MG BASE**	**A062269**	**002**	Nov 08, 1982
AB		CHANGZHOU PHARM	**EQ 100MG BASE**	**A211343**	**001**	Oct 09, 2019
AB		CHARTWELL LIFE SCI	**EQ 100MG BASE**	**A062505**	**001**	Sep 11, 1984
AB		EMCURE PHARMS LTD	**EQ 100MG BASE**	**A209969**	**001**	Nov 09, 2018
AB		EPIC PHARMA LLC	**EQ 20MG BASE**	**A065182**	**001**	May 13, 2005
AB		HERITAGE PHARMA	**EQ 20MG BASE**	**A065163**	**001**	May 13, 2005
AB	**!**	HIKMA INTL PHARMS	**EQ 100MG BASE**	**A065095**	**001**	Jul 02, 2003
AB	**!**	LANNETT CO INC	**EQ 20MG BASE**	**A065277**	**001**	Nov 10, 2005
AB		LARKEN LABS	**EQ 20MG BASE**	**A065287**	**001**	Feb 28, 2006
AB		LUPIN LTD	**EQ 75MG BASE**	**A208818**	**001**	Sep 27, 2017
AB			**EQ 150MG BASE**	**A208818**	**002**	Sep 27, 2017
AB		MAYNE PHARMA INC	**EQ 75MG BASE**	**A208765**	**001**	Jun 14, 2017
AB			**EQ 150MG BASE**	**A208765**	**002**	Jun 14, 2017
AB		MYLAN	**EQ 100MG BASE**	**A062432**	**001**	Feb 15, 1983
AB		NOVEL LABS INC	**EQ 100MG BASE**	**A207558**	**001**	Sep 06, 2017
AB		SUN PHARM	**EQ 20MG BASE**	**A065134**	**001**	May 13, 2005

DOXYCYCLINE HYCLATE

TABLET;ORAL

DOXYCYCLINE HYCLATE

		INDUSTRIES				
AB			**EQ 100MG BASE**	**A062677**	**001**	Jul 10, 1986
		CARIBE HOLDINGS	EQ 50MG BASE	A062269	003	Oct 05, 1983

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	+	MAYNE PHARMA	**EQ 50MG BASE**	**N050795**	**006**	Dec 19, 2014
AB	+		**EQ 75MG BASE**	**N050795**	**001**	May 06, 2005
AB	+		**EQ 100MG BASE**	**N050795**	**002**	May 06, 2005
AB	+		**EQ 150MG BASE**	**N050795**	**003**	Jun 20, 2008
AB	+!		**EQ 200MG BASE**	**N050795**	**005**	Apr 11, 2013

DOXYCYCLINE HYCLATE

AB		ACTAVIS ELIZABETH	**EQ 50MG BASE**	**A090134**	**003**	May 22, 2018
AB			**EQ 75MG BASE**	**A090134**	**001**	Dec 14, 2011
AB			**EQ 100MG BASE**	**A090134**	**002**	Dec 14, 2011
AB			**EQ 200MG BASE**	**A090134**	**004**	May 22, 2018
AB		HERITAGE PHARMS INC	**EQ 75MG BASE**	**A200856**	**001**	Apr 30, 2013
AB			**EQ 100MG BASE**	**A200856**	**002**	Apr 30, 2013
AB			**EQ 150MG BASE**	**A200856**	**003**	Apr 30, 2013
AB			**EQ 200MG BASE**	**A200856**	**004**	Nov 13, 2018
AB		MYLAN	**EQ 50MG BASE**	**A090431**	**003**	May 23, 2016
AB		PRINSTON INC	**EQ 150MG BASE**	**A207494**	**001**	Nov 15, 2016
AB			**EQ 200MG BASE**	**A207494**	**002**	Nov 15, 2016

DORYX MPC

	+!	MAYNE PHARMA	EQ 120MG BASE	N050795	008	May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

AB	+!	DUCHESNAY	**10MG;10MG**	**N021876**	**001**	Apr 08, 2013

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**10MG;10MG**	**A205811**	**001**	Aug 19, 2016
AB		PAR PHARM INC	**10MG;10MG**	**A208518**	**001**	Dec 06, 2017

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

	+!	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB		AKORN INC	**2.5MG**	**A079217**	**001**	Jun 20, 2014
AB			**5MG**	**A079217**	**002**	Jun 20, 2014
AB			**10MG**	**A079217**	**003**	Jun 20, 2014
AB		LANNETT CO INC	**2.5MG**	**A201463**	**001**	May 18, 2018
AB			**5MG**	**A201463**	**002**	May 18, 2018
AB			**10MG**	**A201463**	**003**	May 18, 2018
AB		SVC PHARMA	**2.5MG**	**A078292**	**001**	Jun 27, 2008
AB			**5MG**	**A078292**	**002**	Jun 27, 2008
AB			**10MG**	**A078292**	**003**	Jun 27, 2008

MARINOL

AB	+	ABBVIE	**2.5MG**	**N018651**	**001**	May 31, 1985
AB	+!		**5MG**	**N018651**	**002**	May 31, 1985
AB	+		**10MG**	**N018651**	**003**	May 31, 1985

SOLUTION;ORAL

SYNDROS

	+!	INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

MULTAQ

	+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

AP		EUROHLTH INTL SARL	**2.5MG/ML**	**A208197**	**001**	Dec 14, 2017
AP		HOSPIRA	**2.5MG/ML**	**A071981**	**001**	Feb 29, 1988
AP		LUITPOLD	**2.5MG/ML**	**A072123**	**001**	Oct 24, 1988

INAPSINE

AP	+!	AKORN INC	**2.5MG/ML**	**N016796**	**001**	

DROSPIRENONE

TABLET;ORAL

SLYND

	+!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

	+	BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012
	+!		0.5MG;1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		ANDA REPOSITORY	**3MG;0.02MG**	**A203291**	**001**	Jul 18, 2017
AB		BARR	**3MG;0.02MG**	**A078515**	**001**	Mar 30, 2009
AB		GLENMARK PHARMS LTD	**3MG;0.02MG**	**A204296**	**001**	Aug 17, 2015
AB		HETERO LABS LTD	**3MG;0.02MG**	**A211944**	**001**	Mar 22, 2019
AB		JUBILANT CADISTA	**3MG;0.02MG**	**A209423**	**001**	Dec 22, 2017
AB		MYLAN LABS LTD	**3MG;0.02MG**	**A202594**	**001**	Oct 22, 2015
AB		WATSON LABS	**3MG;0.02MG**	**A078833**	**001**	Nov 28, 2011

KYRA

AB		SUN PHARM	**3MG;0.02MG**	**A202318**	**001**	Jul 23, 2019

LO-ZUMANDIMINE

AB		AUROBINDO PHARMA LTD	**3MG;0.02MG**	**A209632**	**001**	Feb 27, 2018

LORYNA

AB		XIROMED	**3MG;0.02MG**	**A079221**	**001**	Mar 28, 2011

MELAMISA

AB		NOVAST LABS	**3MG;0.02MG**	**A202016**	**001**	Jan 26, 2016

NIKKI

AB		LUPIN LTD	**3MG;0.02MG**	**A201661**	**001**	May 27, 2014

YAZ

AB	**+!**	BAYER HLTHCARE	**3MG;0.02MG**	**N021676**	**001**	Mar 16, 2006

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		ACCORD HLTHCARE	**3MG;0.03MG**	**A207245**	**001**	Nov 22, 2016
AB		APOTEX	**3MG;0.03MG**	**A205876**	**001**	Sep 21, 2016
AB		BARR	**3MG;0.03MG**	**A077527**	**001**	May 09, 2008
AB		GLENMARK PHARMS LTD	**3MG;0.03MG**	**A204848**	**001**	Mar 25, 2016
AB		JUBILANT CADISTA	**3MG;0.03MG**	**A210017**	**001**	Sep 10, 2018
AB		LUPIN LTD	**3MG;0.03MG**	**A201663**	**001**	Dec 18, 2012
AB		MAYNE PHARMA	**3MG;0.03MG**	**A090081**	**001**	Sep 07, 2010
AB		MYLAN LABS LTD	**3MG;0.03MG**	**A202131**	**001**	May 04, 2015

KEMEYA

AB		SUN PHARM	**3MG;0.03MG**	**A202138**	**001**	Mar 13, 2019

SYEDA

AB		XIROMED	**3MG;0.03MG**	**A090114**	**001**	Mar 28, 2011

YAELA

AB		NOVAST LABS	**3MG;0.03MG**	**A202015**	**001**	Nov 19, 2014

YASMIN

AB	**+!**	BAYER HLTHCARE	**3MG;0.03MG**	**N021098**	**001**	May 11, 2001

ZUMANDIMINE

AB		AUROBINDO PHARMA LTD	**3MG;0.03MG**	**A209407**	**001**	Mar 26, 2018

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ

AB		BAYER HLTHCARE	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**N022532**	**001**	Sep 24, 2010

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB		LUPIN LTD	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A205947**	**001**	Jun 13, 2018
AB		WATSON LABS INC	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A203593**	**001**	Oct 11, 2016
AB			**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A203594**	**001**	Oct 11, 2016

SAFYRAL

AB	**+!**	BAYER HLTHCARE	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**N022574**	**001**	Dec 16, 2010

TYDEMY

AB		LUPIN LTD	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A205948**	**001**	Dec 12, 2017

DROXIDOPA

CAPSULE;ORAL

NORTHERA

+	LUNDBECK NA LTD	100MG		N203202	001	Feb 18, 2014
+		200MG		N203202	002	Feb 18, 2014
+!		300MG		N203202	003	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

AB	**+**	LILLY	**EQ 20MG BASE**	**N021427**	**001**	Aug 03, 2004
AB	**+**		**EQ 30MG BASE**	**N021427**	**002**	Aug 03, 2004
AB	**+!**		**EQ 60MG BASE**	**N021427**	**004**	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	**EQ 20MG BASE**	**A090776**	**001**	Dec 17, 2013
AB		**EQ 30MG BASE**	**A090776**	**002**	Dec 17, 2013
AB		**EQ 60MG BASE**	**A090776**	**003**	Dec 17, 2013
AB	AJANTA PHARMA LTD	**EQ 20MG BASE**	**A208706**	**001**	Jan 06, 2017
AB		**EQ 30MG BASE**	**A208706**	**002**	Jan 06, 2017
AB		**EQ 40MG BASE**	**A208706**	**004**	Mar 11, 2019
AB		**EQ 60MG BASE**	**A208706**	**003**	Jan 06, 2017
AB	ALEMBIC PHARMS LTD	**EQ 20MG BASE**	**A202949**	**001**	Jun 09, 2014
AB		**EQ 30MG BASE**	**A202949**	**002**	Jun 09, 2014
AB		**EQ 60MG BASE**	**A202949**	**003**	Jun 09, 2014
AB	ALKEM LABS LTD	**EQ 20MG BASE**	**A203197**	**001**	Aug 26, 2015
AB		**EQ 30MG BASE**	**A203197**	**002**	Aug 26, 2015
AB		**EQ 60MG BASE**	**A203197**	**003**	Aug 26, 2015
AB	ANCHEN PHARMS	**EQ 20MG BASE**	**A090780**	**001**	Oct 28, 2015
AB		**EQ 30MG BASE**	**A090780**	**002**	Oct 28, 2015
AB		**EQ 60MG BASE**	**A090780**	**003**	Oct 28, 2015
AB	APOTEX	**EQ 20MG BASE**	**A202045**	**001**	Jun 11, 2014
AB		**EQ 30MG BASE**	**A202045**	**002**	Jun 11, 2014
AB		**EQ 60MG BASE**	**A202045**	**003**	Jun 11, 2014
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A090778**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090778**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090778**	**003**	Dec 11, 2013
AB	BRECKENRIDGE	**EQ 20MG BASE**	**A203088**	**001**	Jun 11, 2014
AB		**EQ 30MG BASE**	**A203088**	**002**	Jun 11, 2014
AB		**EQ 40MG BASE**	**A203088**	**004**	May 18, 2018
AB		**EQ 60MG BASE**	**A203088**	**003**	Jun 11, 2014
AB	CSPC OUYI	**EQ 20MG BASE**	**A211310**	**001**	Oct 16, 2018
AB		**EQ 30MG BASE**	**A211310**	**002**	Oct 16, 2018
AB		**EQ 60MG BASE**	**A211310**	**003**	Oct 16, 2018
AB	HETERO LABS LTD III	**EQ 20MG BASE**	**A204343**	**001**	Aug 03, 2016
AB		**EQ 30MG BASE**	**A204343**	**002**	Aug 03, 2016
AB		**EQ 60MG BASE**	**A204343**	**003**	Aug 03, 2016
AB	INVENTIA	**EQ 20MG BASE**	**A202336**	**001**	Oct 28, 2015
AB		**EQ 30MG BASE**	**A202336**	**002**	Oct 28, 2015
AB		**EQ 60MG BASE**	**A202336**	**003**	Oct 28, 2015
AB	LUPIN LTD	**EQ 20MG BASE**	**A090694**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090694**	**002**	Dec 11, 2013
AB		**EQ 40MG BASE**	**A090694**	**003**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090694**	**004**	Dec 11, 2013
AB	MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204815**	**001**	Mar 23, 2017
AB		**EQ 30MG BASE**	**A204815**	**002**	Mar 23, 2017
AB		**EQ 60MG BASE**	**A204815**	**003**	Mar 23, 2017
AB	MARKSANS PHARMA	**EQ 20MG BASE**	**A090723**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090723**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090723**	**003**	Dec 11, 2013
AB	PRINSTON INC	**EQ 20MG BASE**	**A206653**	**001**	May 18, 2017
AB		**EQ 30MG BASE**	**A206653**	**002**	May 18, 2017
AB		**EQ 60MG BASE**	**A206653**	**003**	May 18, 2017
AB	QINGDAO BAHEAL PHARM	**EQ 20MG BASE**	**A210599**	**001**	Apr 17, 2019
AB		**EQ 30MG BASE**	**A210599**	**002**	Apr 17, 2019
AB		**EQ 60MG BASE**	**A210599**	**003**	Apr 17, 2019
AB	SUN PHARM	**EQ 20MG BASE**	**A090745**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090745**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090745**	**003**	Dec 11, 2013
AB	TORRENT	**EQ 20MG BASE**	**A090774**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090774**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090774**	**003**	Dec 11, 2013

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB		YAOPHARMA CO LTD	**EQ 20MG BASE**	**A207219**	**001**	Aug 16, 2019
AB			**EQ 30MG BASE**	**A207219**	**002**	Aug 16, 2019
AB			**EQ 60MG BASE**	**A207219**	**003**	Aug 16, 2019
AB		ZYDUS HLTHCARE	**EQ 20MG BASE**	**A090739**	**001**	Jan 08, 2014
AB			**EQ 30MG BASE**	**A090739**	**002**	Jan 08, 2014
AB			**EQ 60MG BASE**	**A090739**	**003**	Jan 08, 2014
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A090728**	**001**	Jan 08, 2014
AB			**EQ 30MG BASE**	**A090728**	**002**	Jan 08, 2014
AB			**EQ 60MG BASE**	**A090728**	**003**	Jan 08, 2014

CAPSULE, DELAYED RELEASE;ORAL

DRIZALMA SPRINKLE

	+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019
	+		EQ 30MG BASE	N212516	002	Jul 19, 2019
	+		EQ 40MG BASE	N212516	003	Jul 19, 2019
	+!		EQ 60MG BASE	N212516	004	Jul 19, 2019

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	**+!**	GLAXOSMITHKLINE	**0.5MG**	**N021319**	**001**	Nov 20, 2001

DUTASTERIDE

AB		ACTAVIS LABS FL INC	**0.5MG**	**A202808**	**001**	Nov 20, 2015
AB		AMNEAL PHARMS	**0.5MG**	**A203118**	**001**	Nov 20, 2015
AB		APOTEX INC	**0.5MG**	**A204292**	**001**	Nov 24, 2015
AB		ASCENT PHARMS INC	**0.5MG**	**A206574**	**001**	Oct 21, 2016
AB		AUROLIFE PHARMA LLC	**0.5MG**	**A202660**	**001**	Nov 20, 2015
AB		BARR	**0.5MG**	**A090095**	**001**	Dec 21, 2010
AB		BIONPHARMA INC	**0.5MG**	**A200899**	**001**	Nov 20, 2015
AB		CADILA	**0.5MG**	**A204373**	**001**	Oct 04, 2017
AB		HERITAGE PHARMS INC	**0.5MG**	**A207935**	**001**	Oct 13, 2017
AB		HIKMA	**0.5MG**	**A202204**	**001**	Nov 23, 2015
AB		HUMANWELL PURACAP	**0.5MG**	**A209909**	**001**	Nov 21, 2017
AB		INTERGEL PHARMS INC	**0.5MG**	**A206373**	**001**	Mar 17, 2016
AB		MARKSANS PHARMA	**0.5MG**	**A204376**	**001**	Apr 07, 2017
AB		STRIDES PHARMA	**0.5MG**	**A204262**	**001**	Nov 20, 2015
AB		VINTAGE PHARMS LLC	**0.5MG**	**A202421**	**001**	Nov 20, 2015

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**0.5MG;0.4MG**	**A202975**	**001**	Nov 20, 2015
AB		ANCHEN PHARMS	**0.5MG;0.4MG**	**A202509**	**001**	Feb 26, 2014
AB		ZYDUS PHARMS	**0.5MG;0.4MG**	**A207769**	**001**	May 24, 2018

JALYN

AB	**+!**	GLAXOSMITHKLINE	**0.5MG;0.4MG**	**N022460**	**001**	Jun 14, 2010

DUVELISIB

CAPSULE;ORAL

COPIKTRA

	+	VERASTEM INC	15MG	N211155	001	Sep 24, 2018
	+!		25MG	N211155	002	Sep 24, 2018

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL

DYCLOPRO

	!	NOVOCOL INC	0.5%	A200480	001	Nov 20, 2018
	!		1%	A200480	002	Nov 20, 2018

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

	+!	WYETH PHARMS	0.125%	N011963	001	

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

	+!	GLENMARK	1%	N205175	001	Oct 24, 2013

CREAM;TOPICAL

ECONAZOLE NITRATE

AB		MYLAN	**1%**	**A210364**	**001**	Apr 18, 2018
AB	**!**	PERRIGO ISRAEL	**1%**	**A076479**	**001**	Jun 23, 2004
AB		TARO	**1%**	**A076005**	**001**	Nov 26, 2002

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB		TELIGENT PHARMA INC	**1%**	**A076574**	**001**	Dec 17, 2004

SPECTAZOLE

AB	**+**	ALVOGEN	**1%**	**N018751**	**001**	Dec 23, 1982

EDARAVONE

SOLUTION;INTRAVENOUS

RADICAVA

	+!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001 May 05, 2017
	+!		60MG/100ML (0.6MG/ML)	N209176	002 Nov 15, 2018

EDETATE CALCIUM DISODIUM

INJECTABLE;INJECTION

CALCIUM DISODIUM VERSENATE

	+!	MEDICIS	200MG/ML	N008922	001

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

	+	DAIICHI SANKYO INC	EQ 15MG BASE	N206316	001 Jan 08, 2015
	+		EQ 30MG BASE	N206316	002 Jan 08, 2015
	+!		EQ 60MG BASE	N206316	003 Jan 08, 2015

EFAVIRENZ

CAPSULE;ORAL

EFAVIRENZ

AB		AUROBINDO PHARMA LTD	**50MG**	**A078064**	**001**	Dec 15, 2017
AB			**200MG**	**A078064**	**003**	Dec 15, 2017

SUSTIVA

AB	**+**	BRISTOL MYERS SQUIBB	**50MG**	**N020972**	**001**	Sep 17, 1998
AB	**+!**		**200MG**	**N020972**	**003**	Sep 17, 1998

EFAVIRENZ

		AUROBINDO PHARMA LTD	100MG	A078064	002 Dec 15, 2017

TABLET;ORAL

EFAVIRENZ

AB		AUROBINDO PHARMA LTD	**600MG**	**A077673**	**001**	Sep 21, 2018
AB			**600MG**	**A205322**	**001**	Aug 30, 2018
AB		CIPLA	**600MG**	**A204766**	**001**	Jun 15, 2018
AB		HETERO LABS LTD III	**600MG**	**A078886**	**001**	Apr 27, 2018
AB		MYLAN	**600MG**	**A091471**	**001**	Feb 17, 2016
AB		STRIDES PHARMA	**600MG**	**A204869**	**001**	Mar 12, 2018

SUSTIVA

AB	**+!**	BRISTOL MYERS SQUIBB	**600MG**	**N021360**	**002**	Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

ATRIPLA

AB	**+!**	GILEAD SCIENCES	**600MG;200MG;300MG**	**N021937**	**001**	Jul 12, 2006

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	**600MG;200MG;300MG**	**A203041**	**001**	Sep 04, 2018
AB		CIPLA	**600MG;200MG;300MG**	**A206894**	**001**	Jun 03, 2019

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

SYMFI

	+!	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001 Mar 22, 2018

SYMFI LO

	+!	MYLAN	400MG;300MG;300MG	N208255	001 Feb 05, 2018

EFINACONAZOLE

SOLUTION;TOPICAL

JUBLIA

	+!	BAUSCH	10%	N203567	001 Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

+!	SKINMEDICA	13.9%	N021145	001	Jul 27, 2000

ELAGOLIX SODIUM

TABLET;ORAL

ORILISSA

+	ABBVIE INC	EQ 150MG BASE	N210450	001	Jul 23, 2018
+!		EQ 200MG BASE	N210450	002	Jul 23, 2018

ELBASVIR; GRAZOPREVIR

TABLET;ORAL

ZEPATIER

+!	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB	AJANTA PHARMA LTD	**EQ 20MG BASE**	**A205186**	**001**	Aug 29, 2017
AB		**EQ 40MG BASE**	**A205186**	**002**	Aug 29, 2017
AB	AMNEAL PHARMS CO	**EQ 20MG BASE**	**A206787**	**001**	May 25, 2018
AB		**EQ 40MG BASE**	**A206787**	**002**	May 25, 2018
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A210708**	**001**	Jan 15, 2019
AB		**EQ 40MG BASE**	**A210708**	**002**	Jan 15, 2019
AB	MYLAN	**EQ 20MG BASE**	**A205152**	**001**	Aug 11, 2017
AB		**EQ 40MG BASE**	**A205152**	**002**	Aug 11, 2017
AB	TEVA PHARMS USA	**EQ 20MG BASE**	**A202040**	**001**	Jun 27, 2017
AB		**EQ 40MG BASE**	**A202040**	**002**	Jun 27, 2017
AB	ZYDUS PHARMS	**EQ 20MG BASE**	**A206409**	**001**	Jun 16, 2017
AB		**EQ 40MG BASE**	**A206409**	**002**	Jun 16, 2017

RELPAX

AB	**+**	PFIZER IRELAND	**EQ 20MG BASE**	**N021016**	**001**	Dec 26, 2002
AB	**+!**		**EQ 40MG BASE**	**N021016**	**002**	Dec 26, 2002

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET, TABLET;ORAL

TRIKAFTA (COPACKAGED)

+!	VERTEX PHARMS INC	100MG,75MG,50MG;N/A,150MG,N/A	N212273	001	Oct 21, 2019

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

CERDELGA

+!	GENZYME CORP	EQ 84MG BASE	N205494	001	Aug 19, 2014

ELTROMBOPAG OLAMINE

FOR SUSPENSION;ORAL

PROMACTA KIT

+	NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018
+!		EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015

TABLET;ORAL

PROMACTA

+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011
+		EQ 25MG ACID	N022291	001	Nov 20, 2008
+		EQ 50MG ACID	N022291	002	Nov 20, 2008
+!		EQ 75MG ACID	N022291	003	Sep 08, 2009

ELUXADOLINE

TABLET;ORAL

VIBERZI

+	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015
+!		100MG	N206940	002	May 27, 2015

EMPAGLIFLOZIN

TABLET;ORAL

JARDIANCE

+	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014
+!		25MG	N204629	002	Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET;ORAL

GLYXAMBI

+	BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015
+!		25MG;5MG	N206073	002	Jan 30, 2015

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SYNJARDY

+	BOEHRINGER INGELHEIM	5MG;500MG	N206111	001	Aug 26, 2015
+		5MG;1GM	N206111	002	Aug 26, 2015
+		12.5MG;500MG	N206111	003	Aug 26, 2015
+!		12.5MG;1GM	N206111	004	Aug 26, 2015

TABLET, EXTENDED RELEASE;ORAL

SYNJARDY XR

+	BOEHRINGER INGELHEIM	5MG;1GM	N208658	001	Dec 09, 2016
+		10MG;1GM	N208658	002	Dec 09, 2016
+		12.5MG;1GM	N208658	003	Dec 09, 2016
+!		25MG;1GM	N208658	004	Dec 09, 2016

EMTRICITABINE

CAPSULE;ORAL

EMTRICITABINE

AB		CIPLA	**200MG**	**A091168**	**001**	Jul 02, 2018

EMTRIVA

AB	**+!**	GILEAD	**200MG**	**N021500**	**001**	Jul 02, 2003

SOLUTION;ORAL

EMTRIVA

	+!	GILEAD	10MG/ML	N021896	001	Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

ODEFSEY

	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

COMPLERA

	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

DESCOVY

	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	**200MG;300MG**	**A090513**	**001**	Jan 26, 2018
AB		MYLAN	**200MG;300MG**	**A206436**	**001**	Apr 09, 2018
AB		TEVA PHARMS USA	**200MG;300MG**	**A090894**	**001**	Jun 08, 2017

TRUVADA

AB	**+!**	GILEAD	**200MG;300MG**	**N021752**	**001**	Aug 02, 2004
	+		100MG;150MG	N021752	002	Mar 10, 2016
	+		133MG;200MG	N021752	003	Mar 10, 2016
	+		167MG;250MG	N021752	004	Mar 10, 2016

ENALAPRIL MALEATE

SOLUTION;ORAL

EPANED

	+!	SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016

TABLET;ORAL

ENALAPRIL MALEATE

AB		HERITAGE PHARMA	**2.5MG**	**A075479**	**001**	Aug 22, 2000
AB			**5MG**	**A075479**	**002**	Aug 22, 2000
AB			**10MG**	**A075479**	**003**	Aug 22, 2000
AB			**20MG**	**A075479**	**004**	Aug 22, 2000
AB		NOSTRUM LABS INC	**2.5MG**	**A075178**	**002**	Mar 23, 2001
AB			**5MG**	**A075178**	**001**	Mar 23, 2001
AB			**10MG**	**A075178**	**003**	Mar 23, 2001
AB			**20MG**	**A075178**	**004**	Mar 23, 2001
AB		SANDOZ INC	**2.5MG**	**A075496**	**001**	Aug 22, 2000
AB			**5MG**	**A075496**	**002**	Aug 22, 2000

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

AB			**10MG**	**A075459**	**001**	Aug 22, 2000
AB			**20MG**	**A075459**	**002**	Aug 22, 2000
AB		TARO	**2.5MG**	**A075657**	**001**	Jan 23, 2001
AB			**5MG**	**A075657**	**002**	Jan 23, 2001
AB			**10MG**	**A075657**	**003**	Jan 23, 2001
AB			**20MG**	**A075657**	**004**	Jan 23, 2001
AB		WOCKHARDT LTD	**2.5MG**	**A075483**	**001**	Aug 22, 2000
AB			**5MG**	**A075483**	**002**	Aug 22, 2000
AB			**10MG**	**A075483**	**003**	Aug 22, 2000
AB			**20MG**	**A075483**	**004**	Aug 22, 2000

VASOTEC

AB	**+**	BAUSCH	**2.5MG**	**N018998**	**005**	Jul 26, 1988
AB	**+**		**5MG**	**N018998**	**001**	Dec 24, 1985
AB	**+**		**10MG**	**N018998**	**002**	Dec 24, 1985
AB	**+!**		**20MG**	**N018998**	**003**	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		ACP NIMBLE	**5MG;12.5MG**	**A075727**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075727**	**002**	Sep 18, 2001
AB		DR REDDYS LABS LTD	**5MG;12.5MG**	**A075909**	**001**	Oct 15, 2001
AB			**10MG;25MG**	**A075909**	**002**	Oct 15, 2001
AB		MYLAN	**5MG;12.5MG**	**A075624**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075624**	**002**	Sep 18, 2001
AB		NOSTRUM LABS INC	**5MG;12.5MG**	**A076486**	**001**	Oct 27, 2004
AB			**10MG;25MG**	**A076486**	**002**	Oct 27, 2004
AB		TARO PHARM INDS	**5MG;12.5MG**	**A075788**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075788**	**002**	Sep 18, 2001

VASERETIC

AB	**+**	BAUSCH	**5MG;12.5MG**	**N019221**	**003**	Jul 12, 1995
AB	**+!**		**10MG;25MG**	**N019221**	**001**	Oct 31, 1986

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP	**!**	ATHENEX INC	**1.25MG/ML**	**A075634**	**001**	Aug 22, 2000
AP		DR REDDYS	**1.25MG/ML**	**A075578**	**001**	Aug 22, 2000
AP		HIKMA FARMACEUTICA	**1.25MG/ML**	**A078687**	**001**	Dec 23, 2008
AP	**!**	HOSPIRA	**1.25MG/ML**	**A075458**	**001**	Aug 22, 2000

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

	+	CELGENE CORP	EQ 50MG BASE	N209606	001	Aug 01, 2017
	+!		EQ 100MG BASE	N209606	002	Aug 01, 2017

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

	+!	ARRAY BIOPHARMA INC	75MG	N210496	002	Jun 27, 2018

ENFUVIRTIDE

INJECTABLE;SUBCUTANEOUS

FUZEON

	+!	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB		AMPHASTAR PHARMS INC	**300MG/3ML (100MG/ML)**	**A208600**	**001**	Mar 14, 2019
AB		SANDOZ INC	**300MG/3ML (100MG/ML)**	**A078660**	**001**	Nov 28, 2011

LOVENOX

AB	**+**	SANOFI AVENTIS US	**300MG/3ML (100MG/ML)**	**N020164**	**009**	Jan 23, 2003

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP		AMPHASTAR PHARM	**30MG/0.3ML (100MG/ML)**	**A076684**	**001**	Sep 19, 2011
AP			**40MG/0.4ML (100MG/ML)**	**A076684**	**002**	Sep 19, 2011
AP			**60MG/0.6ML (100MG/ML)**	**A076684**	**003**	Sep 19, 2011
AP			**80MG/0.8ML (100MG/ML)**	**A076684**	**004**	Sep 19, 2011
AP			**100MG/ML (100MG/ML)**	**A076684**	**005**	Sep 19, 2011
AP			**120MG/0.8ML (150MG/ML)**	**A076684**	**006**	Sep 19, 2011

ENOXAPARIN SODIUM						
INJECTABLE;SUBCUTANEOUS						
ENOXAPARIN SODIUM (PRESERVATIVE FREE)						
AP			**150MG/ML (150MG/ML)**	**A076684**	**007**	Sep 19, 2011
AP		APOTEX INC	**30MG/0.3ML (100MG/ML)**	**A078990**	**001**	Sep 28, 2018
AP			**40MG/0.4ML (100MG/ML)**	**A078990**	**002**	Sep 28, 2018
AP			**60MG/0.6ML (100MG/ML)**	**A078990**	**003**	Sep 28, 2018
AP			**80MG/0.8ML (100MG/ML)**	**A078990**	**004**	Sep 28, 2018
AP			**100MG/ML (100MG/ML)**	**A078990**	**005**	Sep 28, 2018
AP			**120MG/0.8ML (150MG/ML)**	**A078990**	**006**	Sep 28, 2018
AP			**150MG/ML (150MG/ML)**	**A078990**	**007**	Sep 28, 2018
AP		NANJING KING-FRIEND	**30MG/0.3ML (100MG/ML)**	**A206834**	**001**	Nov 29, 2019
AP			**40MG/0.4ML (100MG/ML)**	**A206834**	**002**	Nov 29, 2019
AP			**60MG/0.6ML (100MG/ML)**	**A206834**	**003**	Nov 29, 2019
AP			**80MG/0.8ML (100MG/ML)**	**A206834**	**004**	Nov 29, 2019
AP			**100MG/ML (100MG/ML)**	**A206834**	**005**	Nov 29, 2019
AP			**120MG/0.8ML (150MG/ML)**	**A206834**	**006**	Nov 29, 2019
AP			**150MG/ML (150MG/ML)**	**A206834**	**007**	Nov 29, 2019
AP		SANDOZ	**30MG/0.3ML (100MG/ML)**	**A077857**	**002**	Jul 23, 2010
AP			**40MG/0.4ML (100MG/ML)**	**A077857**	**003**	Jul 23, 2010
AP			**60MG/0.6ML (100MG/ML)**	**A077857**	**004**	Jul 23, 2010
AP			**80MG/0.8ML (100MG/ML)**	**A077857**	**005**	Jul 23, 2010
AP			**100MG/ML (100MG/ML)**	**A077857**	**001**	Jul 23, 2010
AP			**120MG/0.8ML (150MG/ML)**	**A077857**	**006**	Jul 23, 2010
AP			**150MG/ML (150MG/ML)**	**A077857**	**007**	Jul 23, 2010
AP		TEVA	**30MG/0.3ML (100MG/ML)**	**A076726**	**001**	Jun 23, 2014
AP			**40MG/0.4ML (100MG/ML)**	**A076726**	**002**	Jun 23, 2014
AP			**60MG/0.6ML (100MG/ML)**	**A076726**	**003**	Jun 23, 2014
AP			**80MG/0.8ML (100MG/ML)**	**A076726**	**004**	Jun 23, 2014
AP			**100MG/ML (100MG/ML)**	**A076726**	**005**	Jun 23, 2014
AP			**120MG/0.8ML (150MG/ML)**	**A076726**	**006**	Jun 23, 2014
AP			**150MG/ML (150MG/ML)**	**A076726**	**007**	Jun 23, 2014
LOVENOX (PRESERVATIVE FREE)						
AP	+	SANOFI AVENTIS US	**30MG/0.3ML (100MG/ML)**	**N020164**	**001**	Mar 29, 1993
AP	+		**40MG/0.4ML (100MG/ML)**	**N020164**	**002**	Jan 30, 1998
AP	+		**60MG/0.6ML (100MG/ML)**	**N020164**	**003**	Mar 27, 1998
AP	+		**80MG/0.8ML (100MG/ML)**	**N020164**	**004**	Mar 27, 1998
AP	+!		**100MG/ML (100MG/ML)**	**N020164**	**005**	Mar 27, 1998
AP	+		**120MG/0.8ML (150MG/ML)**	**N020164**	**007**	Jun 02, 2000
AP	+		**150MG/ML (150MG/ML)**	**N020164**	**008**	Jun 02, 2000
ENTACAPONE						
TABLET;ORAL						
COMTAN						
AB	+!	ORION PHARMA	**200MG**	**N020796**	**001**	Oct 19, 1999
ENTACAPONE						
AB		AJANTA PHARMA LTD	**200MG**	**A205792**	**001**	Aug 31, 2017
AB		AUROBINDO PHARMA LTD	**200MG**	**A203437**	**001**	Jun 19, 2015
AB		MACLEODS PHARMS LTD	**200MG**	**A207210**	**001**	Jun 05, 2017
AB		SUN PHARM	**200MG**	**A090690**	**001**	Jul 16, 2012
AB		SUNSHINE LAKE	**200MG**	**A206669**	**001**	Oct 03, 2018
AB		WOCKHARDT LTD	**200MG**	**A078941**	**001**	Aug 16, 2012
ENTECAVIR						
SOLUTION;ORAL						
BARACLUDE						
	+!	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005
TABLET;ORAL						
BARACLUDE						
AB	+	BRISTOL MYERS SQUIBB	**0.5MG**	**N021797**	**001**	Mar 29, 2005
AB	+!		**1MG**	**N021797**	**002**	Mar 29, 2005
ENTECAVIR						
AB		ACCORD HLTHCARE	**0.5MG**	**A205824**	**001**	Aug 25, 2017
AB			**1MG**	**A205824**	**002**	Aug 25, 2017
AB		AMNEAL PHARMS	**0.5MG**	**A206652**	**001**	Nov 12, 2015
AB			**1MG**	**A206652**	**002**	Nov 12, 2015
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A206217**	**001**	Aug 26, 2015
AB			**1MG**	**A206217**	**002**	Aug 26, 2015
AB		BRECKENRIDGE	**0.5MG**	**A208721**	**001**	Mar 15, 2018
AB			**1MG**	**A208721**	**002**	Mar 15, 2018

ENTECAVIR							
TABLET;ORAL							
ENTECAVIR							
AB		BRIGHTGENE	**0.5MG**	**A212126**	**001**	Sep 25, 2019
AB			**1MG**	**A212126**	**002**	Sep 25, 2019
AB		CASI PHARMS INC	**0.5MG**	**A206672**	**001**	May 11, 2017
AB			**1MG**	**A206672**	**002**	May 11, 2017
AB		CIPLA	**0.5MG**	**A206872**	**001**	Dec 06, 2016
AB			**1MG**	**A206872**	**002**	Dec 06, 2016
AB		HETERO LABS LTD V	**0.5MG**	**A205740**	**001**	Aug 21, 2015
AB			**1MG**	**A205740**	**002**	Aug 21, 2015
AB		MYLAN	**0.5MG**	**A206226**	**001**	Mar 26, 2019
AB			**1MG**	**A206226**	**002**	Mar 26, 2019
AB		PRINSTON INC	**0.5MG**	**A208782**	**001**	Oct 10, 2017
AB			**1MG**	**A208782**	**002**	Oct 10, 2017
AB		TEVA PHARMS USA	**0.5MG**	**A202122**	**001**	Aug 26, 2014
AB			**1MG**	**A202122**	**002**	Aug 26, 2014
AB		YAOPHARMA CO LTD	**0.5MG**	**A212201**	**001**	Nov 04, 2019
AB			**1MG**	**A212201**	**002**	Nov 04, 2019
AB		ZYDUS PHARMS	**0.5MG**	**A206745**	**001**	Jun 23, 2017
AB			**1MG**	**A206745**	**002**	Jun 23, 2017
ENTRECTINIB							
CAPSULE;ORAL							
ROZLYTREK							
	+	GENENTECH INC	100MG	N212725	001	Aug 15, 2019
	+!		200MG	N212725	002	Aug 15, 2019
ENZALUTAMIDE							
CAPSULE;ORAL							
XTANDI							
	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012
EPHEDRINE SULFATE							
SOLUTION;INTRAVENOUS							
AKOVAZ							
AP	**+!**	AVADEL LEGACY	**50MG/ML (50MG/ML)**	**N208289**	**001**	Apr 29, 2016
CORPHEDRA							
AP		PAR STERILE PRODUCTS	**50MG/ML (50MG/ML)**	**N208943**	**001**	Jan 27, 2017
EPHEDRINE SULFATE							
AP		AKORN INC	**50MG/ML (50MG/ML)**	**N208609**	**001**	Mar 01, 2017
AP		AMNEAL	**50MG/ML (50MG/ML)**	**A212932**	**001**	Oct 23, 2019
AP		SANDOZ INC	**50MG/ML (50MG/ML)**	**A209784**	**001**	Aug 23, 2017
EPINASTINE HYDROCHLORIDE							
SOLUTION/DROPS;OPHTHALMIC							
ELESTAT							
AT	**+!**	ALLERGAN	**0.05%**	**N021565**	**001**	Oct 16, 2003
EPINASTINE HYDROCHLORIDE							
AT		AKORN	**0.05%**	**A204055**	**001**	May 05, 2017
AT		APOTEX	**0.05%**	**A090919**	**001**	Oct 31, 2011
AT		BRECKENRIDGE	**0.05%**	**A090870**	**001**	Mar 14, 2011
AT		SOMERSET THERAPS LLC	**0.05%**	**A090951**	**001**	Oct 31, 2011
EPINEPHRINE							
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS							
EPINEPHRINE (AUTOINJECTOR)							
AB		TEVA PHARMS USA	**0.15MG/DELIVERY**	**A090589**	**002**	Aug 16, 2018
AB			**0.3MG/DELIVERY**	**A090589**	**001**	Aug 16, 2018
EPIPEN							
AB	**+!**	MYLAN SPECIALITY LP	**0.3MG/DELIVERY**	**N019430**	**001**	Dec 22, 1987
EPIPEN JR.							
AB	**+!**	MYLAN SPECIALITY LP	**0.15MG/DELIVERY**	**N019430**	**002**	Dec 22, 1987
ADRENACLICK							
BX	+!	IMPAX	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009
BX	+!		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
ADRENALIN							
	+!	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012
	+!		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

AUVI-Q

BX	+!	KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012
BX	+		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012
	+		EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017

SYMJEPI

	+!	ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534	002	Sep 27, 2018
	+!		0.3MG/0.3ML (0.3MG/0.3ML)	N207534	001	Jun 15, 2017

SOLUTION;INTRAVENOUS

EPINEPHRINE (COPACKAGED)

	+!	HOSPIRA INC	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

	+!	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIGNOSPAN FORTE

	!	DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985

LIGNOSPAN STANDARD

	!	DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CITANEST FORTE DENTAL

AP	**+!**	DENTSPLY PHARM	**0.005MG/ML;4%**	**N021383**	**001**	

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		SEPTODONT INC	**0.005MG/ML;4%**	**A078959**	**001**	Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP		HOSPIRA	**0.005MG/ML;0.5%**	**A089635**	**001**	Jun 21, 1988
AP			**0.005MG/ML;1.5%**	**A088571**	**001**	Sep 13, 1985
AP			**0.005MG/ML;1.5%**	**A089645**	**001**	Jun 21, 1988
AP			**0.005MG/ML;2%**	**A089651**	**001**	Jun 21, 1988
AP			**0.01MG/ML;1%**	**A089644**	**001**	Jun 21, 1988
AP	**!**		**0.01MG/ML;2%**	**A089646**	**001**	Jun 21, 1988

XYLOCAINE W/ EPINEPHRINE

AP	**+!**	FRESENIUS KABI USA	**0.005MG/ML;0.5%**	**N006488**	**012**	
AP	**+!**		**0.005MG/ML;1.5%**	**N006488**	**017**	
AP	**+!**		**0.005MG/ML;2%**	**N006488**	**019**	Nov 13, 1986
AP	**+!**		**0.01MG/ML;1%**	**N006488**	**004**	
AP	**+!**		**0.02MG/ML;2%**	**N006488**	**005**	
	+!		0.005MG/ML;1%	N006488	018	Nov 13, 1986

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

ELLENCE

AP	**+!**	PFIZER INC	**200MG/100ML (2MG/ML)**	**N050778**	**001**	Sep 15, 1999
AP	**+**		**50MG/25ML (2MG/ML)**	**N050778**	**002**	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP		ACTAVIS TOTOWA	**50MG/25ML (2MG/ML)**	**A065445**	**002**	Sep 18, 2008
AP			**200MG/100ML (2MG/ML)**	**A065445**	**003**	Sep 18, 2008
AP		AKORN INC	**50MG/25ML (2MG/ML)**	**A090163**	**001**	Jun 24, 2009
AP		CIPLA LTD	**50MG/25ML (2MG/ML)**	**A065361**	**001**	Oct 22, 2007
AP			**200MG/100ML (2MG/ML)**	**A065361**	**002**	Oct 22, 2007
AP		FRESENIUS KABI USA	**50MG/25ML (2MG/ML)**	**A065408**	**002**	Oct 15, 2007
AP			**200MG/100ML (2MG/ML)**	**A065408**	**004**	Oct 15, 2007
AP		HISUN PHARM HANGZHOU	**50MG/25ML (2MG/ML)**	**A090075**	**001**	Mar 25, 2010
AP			**200MG/100ML (2MG/ML)**	**A090075**	**002**	Mar 25, 2010
AP		IMPAX LABS INC	**50MG/25ML (2MG/ML)**	**A065331**	**001**	Aug 09, 2007
AP			**200MG/100ML (2MG/ML)**	**A065331**	**002**	Aug 09, 2007
AP		WEST-WARD PHARMS INT	**50MG/25ML (2MG/ML)**	**A065289**	**001**	Jun 27, 2007
AP			**200MG/100ML (2MG/ML)**	**A065289**	**002**	Jun 27, 2007
		FRESENIUS KABI USA	10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007
			150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007

EPLERENONE

TABLET;ORAL

EPLERENONE

AB		ACCORD HLTHCARE	**25MG**	**A206922**	**001**	Jul 13, 2017
AB			**50MG**	**A206922**	**002**	Jul 13, 2017
AB		APOTEX	**25MG**	**A078482**	**001**	Jul 30, 2008
AB			**50MG**	**A078482**	**002**	Jul 30, 2008
AB		BRECKENRIDGE	**25MG**	**A208283**	**001**	Sep 14, 2018
AB			**50MG**	**A208283**	**002**	Sep 14, 2018
AB		MYLAN	**25MG**	**A203896**	**001**	Feb 02, 2017
AB			**50MG**	**A203896**	**002**	Feb 02, 2017
AB		SANDOZ	**25MG**	**A078510**	**001**	Aug 01, 2008
AB			**50MG**	**A078510**	**002**	Aug 01, 2008

INSPRA

AB	**+**	GD SEARLE LLC	**25MG**	**N021437**	**001**	Sep 27, 2002
AB	**+!**		**50MG**	**N021437**	**002**	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP		TEVA PHARMS USA	**EQ 0.5MG BASE/VIAL**	**A078396**	**001**	Apr 23, 2008
AP			**EQ 1.5MG BASE/VIAL**	**A078396**	**002**	Apr 23, 2008

FLOLAN

AP	**+!**	GLAXOSMITHKLINE LLC	**EQ 0.5MG BASE/VIAL**	**N020444**	**001**	Sep 20, 1995
AP	**+!**		**EQ 1.5MG BASE/VIAL**	**N020444**	**002**	Sep 20, 1995

VELETRI

	+	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012
	+!		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET;ORAL

EPROSARTAN MESYLATE

AB		MYLAN PHARMS INC	**EQ 400MG BASE**	**A202012**	**001**	Nov 16, 2011
AB	**!**		**EQ 600MG BASE**	**A202012**	**002**	Nov 16, 2011

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP		ACCORD HLTHCARE	**2MG/ML**	**A205557**	**001**	Nov 06, 2017
AP			**75MG/100ML**	**A205557**	**002**	Nov 06, 2017
AP		AKORN	**2MG/ML**	**A204589**	**001**	Apr 18, 2017
AP			**75MG/100ML**	**A204589**	**002**	Apr 18, 2017
AP		AMNEAL PHARMS	**2MG/ML**	**A205581**	**001**	Dec 08, 2016
AP			**75MG/100ML**	**A205581**	**002**	Dec 08, 2016
AP		AUROBINDO PHARMA LTD	**2MG/ML**	**A206127**	**001**	Dec 08, 2015
AP			**75MG/100ML**	**A206127**	**002**	Dec 08, 2015
AP		BAXTER HLTHCARE CORP	**2MG/ML**	**A208554**	**001**	Nov 23, 2018
AP			**75MG/100ML**	**A208554**	**002**	Nov 23, 2018
AP		HAINAN POLY PHARM	**2MG/ML**	**A209864**	**001**	Jan 25, 2019
AP			**75MG/100ML**	**A209864**	**002**	Jan 25, 2019
AP		MYLAN LABS LTD	**2MG/ML**	**A203258**	**001**	Jul 20, 2018
AP			**75MG/100ML**	**A203258**	**002**	Jul 20, 2018
AP		SAGENT PHARMS INC	**2MG/ML**	**A204693**	**001**	Mar 07, 2018
AP			**75MG/100ML**	**A204693**	**002**	Mar 07, 2018
AP		TEVA PHARMS USA	**2MG/ML**	**A090854**	**001**	Jun 12, 2015

INTEGRILIN

AP	**+!**	SCHERING	**2MG/ML**	**N020718**	**001**	May 18, 1998
AP	**+!**		**75MG/100ML**	**N020718**	**002**	May 18, 1998

ERAVACYCLINE DIHYDROCHLORIDE

POWDER;INTRAVENOUS

XERAVA

	+!	TETRAPHASE PHARMS	EQ 50MG BASE/VIAL	N211109	001	Aug 27, 2018

ERDAFITINIB

TABLET;ORAL

BALVERSA

	+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019
	+		4MG	N212018	002	Apr 12, 2019
	+!		5MG	N212018	003	Apr 12, 2019

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL						
AA	**+!**	US PHARM HOLDINGS	**50,000 IU**	**N003444**	**001**	
ERGOCALCIFEROL						
AA		ORIT LABS LLC	**50,000 IU**	**A040833**	**001**	May 20, 2009
AA		PURACAP PHARM LLC	**50,000 IU**	**A204276**	**001**	Dec 07, 2018
AA		SIGMAPHARM LABS LLC	**50,000 IU**	**A091004**	**001**	Jul 14, 2010
AA		STRIDES PHARMA	**50,000 IU**	**A090455**	**001**	Aug 03, 2010
AA		SUN PHARM INDS INC	**50,000 IU**	**A040865**	**001**	Dec 29, 2009
VITAMIN D						
AA		BIONPHARMA INC	**50,000 IU**	**A080704**	**001**	

ERGOLOID MESYLATES

TABLET;ORAL

ERGOLOID MESYLATES						
	!	SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOMAR						
	!	TERSERA THERAPS LLC	2MG	A087693	001	Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

HALAVEN						
	+!	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE						
AB		APOTEX	**EQ 25MG BASE**	**A208396**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A208396**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A208396**	**003**	Nov 05, 2019
AB		MYLAN	**EQ 25MG BASE**	**A091002**	**001**	Jun 11, 2014
AB			**EQ 100MG BASE**	**A091002**	**002**	Jun 11, 2014
AB			**EQ 150MG BASE**	**A091002**	**003**	Jun 11, 2014
AB		NATCO PHARMA LTD	**EQ 25MG BASE**	**A208488**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A208488**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A208488**	**003**	Nov 05, 2019
AB		SHILPA MEDICARE LTD	**EQ 25MG BASE**	**A211960**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A211960**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A211960**	**003**	Nov 05, 2019
AB		SUN PHARM	**EQ 25MG BASE**	**A210300**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A210300**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A210300**	**003**	Nov 05, 2019
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A091059**	**002**	Aug 28, 2015
AB			**EQ 150MG BASE**	**A091059**	**003**	Aug 28, 2015
TARCEVA						
AB	**+**	OSI PHARMS	**EQ 25MG BASE**	**N021743**	**001**	Nov 18, 2004
AB	**+**		**EQ 100MG BASE**	**N021743**	**002**	Nov 18, 2004
AB	**+!**		**EQ 150MG BASE**	**N021743**	**003**	Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM						
AP		ACS DOBFAR SPA	**EQ 1GM BASE/VIAL**	**A208790**	**001**	Apr 16, 2018
AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A209133**	**001**	Jun 25, 2018
AP		SAVIOR LIFETEC CORP	**EQ 1GM BASE/VIAL**	**A207647**	**001**	Mar 19, 2019
INVANZ						
AP	**+!**	MERCK SHARP DOHME	**EQ 1GM BASE/VIAL**	**N021337**	**001**	Nov 21, 2001

ERTUGLIFLOZIN

TABLET;ORAL

STEGLATRO						
	+	MERCK SHARP DOHME	5MG	N209803	001	Dec 19, 2017
	+!		15MG	N209803	002	Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SEGLUROMET

+	MERCK SHARP DOHME	2.5MG;500MG	N209806	001	Dec 19, 2017
+		2.5MG;1GM	N209806	002	Dec 19, 2017
+		7.5MG;500MG	N209806	003	Dec 19, 2017
+!		7.5MG;1GM	N209806	004	Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

+	MERCK SHARP DOHME	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017
+!		15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

AB	**+!**	MAYNE PHARMA	**250MG**	**N050536**	**001**	

ERYTHROMYCIN

AB		ARBOR PHARMS LLC	**250MG**	**A062746**	**001**	Dec 22, 1986

GEL;TOPICAL

ERYGEL

AT	**+!**	MYLAN	**2%**	**N050617**	**001**	Oct 21, 1987

ERYTHROMYCIN

AT		FOUGERA PHARMS	**2%**	**A064184**	**001**	Sep 30, 1997
AT		PERRIGO CO	**2%**	**A063211**	**001**	Jan 29, 1993
AT		TELIGENT PHARMA INC	**2%**	**A208154**	**001**	Jul 19, 2017

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT		AKORN	**0.5%**	**A064030**	**001**	Jul 18, 1996
AT		BAUSCH AND LOMB	**0.5%**	**A064067**	**001**	Jul 29, 1994
AT	**!**	PERRIGO CO TENNESSEE	**0.5%**	**A062447**	**001**	Sep 26, 1983

SOLUTION;TOPICAL

ERYTHROMYCIN

AT	**!**	PERRIGO NEW YORK	**2%**	**A063038**	**001**	Jan 11, 1991
AT		TELIGENT PHARMA INC	**2%**	**A208100**	**001**	Nov 20, 2017
AT		WOCKHARDT BIO AG	**2%**	**A062825**	**001**	Oct 23, 1987

SWAB;TOPICAL

ERYTHROMYCIN

AT		AKORN	**2%**	**A090215**	**001**	May 12, 2010
AT	**!**	PERRIGO CO	**2%**	**A064126**	**001**	Jul 03, 1996

TABLET;ORAL

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	**250MG**	**A209720**	**001**	Mar 09, 2018
AB			**500MG**	**A209720**	**002**	Mar 09, 2018
AB		ARBOR PHARMS LLC	**250MG**	**A061621**	**001**	
AB	**!**		**500MG**	**A061621**	**002**	

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB		ARBOR PHARMS LLC	**250MG**	**A062298**	**001**	
AB			**333MG**	**A062298**	**003**	Mar 29, 1982
AB	**!**		**500MG**	**A062298**	**002**	

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	**250MG**	**A210954**	**001**	Jul 02, 2019
AB			**333MG**	**A210954**	**002**	Jul 02, 2019
AB			**500MG**	**A210954**	**003**	Jul 02, 2019

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

AB	**+**	ARBOR PHARMS LLC	**EQ 200MG BASE/5ML**	**N050207**	**001**	

ERYPED

AB	**+**	ARBOR PHARMS LLC	**EQ 200MG BASE/5ML**	**N050207**	**003**	Mar 30, 1987
AB	**+!**		**EQ 400MG BASE/5ML**	**N050207**	**002**	

ERYTHROMYCIN ETHYLSUCCINATE

AB		AMNEAL PHARMS	**EQ 200MG BASE/5ML**	**A211204**	**001**	Nov 01, 2019
AB			**EQ 400MG BASE/5ML**	**A211204**	**002**	Nov 01, 2019
AB		ANI PHARMS INC	**EQ 200MG BASE/5ML**	**A062055**	**001**	
AB			**EQ 200MG BASE/5ML**	**A062055**	**003**	Nov 02, 2018
AB			**EQ 400MG BASE/5ML**	**A062055**	**002**	Nov 02, 2018
AB		PAR PHARM INC	**EQ 200MG BASE/5ML**	**A211991**	**001**	Oct 23, 2019
AB			**EQ 400MG BASE/5ML**	**A211991**	**002**	Oct 23, 2019

ERYTHROMYCIN ETHYLSUCCINATE						
TABLET;ORAL						
E.E.S. 400						
BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061905	002	Aug 12, 1982
ERYTHROMYCIN ETHYLSUCCINATE						
BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061904	001	
ERYTHROMYCIN LACTOBIONATE						
INJECTABLE;INJECTION						
ERYTHROCIN						
AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A062638**	**001**	Oct 31, 1986
AP	**+!**		**EQ 500MG BASE/VIAL**	**N050609**	**001**	Sep 24, 1986
ERYTHROMYCIN STEARATE						
TABLET;ORAL						
ERYTHROCIN STEARATE						
	!	ARBOR PHARMS LLC	EQ 250MG BASE	A060359	001	
ESCITALOPRAM OXALATE						
SOLUTION;ORAL						
ESCITALOPRAM OXALATE						
AA		ALLIED	**EQ 5MG BASE/5ML**	**A203967**	**001**	May 26, 2015
AA		AMNEAL PHARMS	**EQ 5MG BASE/5ML**	**A202227**	**001**	Mar 14, 2012
AA		AUROBINDO PHARMA LTD	**EQ 5MG BASE/5ML**	**A079062**	**001**	Apr 02, 2012
AA		HETERO LABS LTD III	**EQ 5MG BASE/5ML**	**A202221**	**001**	Jun 12, 2012
AA		LANNETT CO INC	**EQ 5MG BASE/5ML**	**A090477**	**001**	Jun 12, 2013
AA		MACLEODS PHARMS LTD	**EQ 5MG BASE/5ML**	**A202754**	**001**	Mar 31, 2016
AA		TARO	**EQ 5MG BASE/5ML**	**A079121**	**001**	May 03, 2012
LEXAPRO						
AA	**+!**	ALLERGAN	**EQ 5MG BASE/5ML**	**N021365**	**001**	Nov 27, 2002
TABLET;ORAL						
ESCITALOPRAM OXALATE						
AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A202389**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202389**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202389**	**003**	Sep 11, 2012
AB		AMNEAL PHARMS	**EQ 5MG BASE**	**A205619**	**001**	May 17, 2017
AB			**EQ 10MG BASE**	**A205619**	**002**	May 17, 2017
AB			**EQ 20MG BASE**	**A205619**	**003**	May 17, 2017
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A090432**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A090432**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090432**	**003**	Sep 11, 2012
AB		CADILA	**EQ 5MG BASE**	**A077734**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A077734**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A077734**	**003**	Sep 11, 2012
AB		GRAVITI PHARMS	**EQ 5MG BASE**	**A078777**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078777**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078777**	**003**	Sep 11, 2012
AB		HIKMA PHARMS	**EQ 5MG BASE**	**A078766**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078766**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078766**	**003**	Sep 11, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078604**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078604**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078604**	**003**	Sep 11, 2012
AB		JUBILANT GENERICS	**EQ 5MG BASE**	**A202280**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A202280**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A202280**	**003**	Sep 12, 2012
AB		LUPIN LTD	**EQ 5MG BASE**	**A078169**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078169**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078169**	**003**	Sep 11, 2012
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A202210**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202210**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202210**	**003**	Sep 11, 2012
AB		PHARM ASSOC	**EQ 5MG BASE**	**A077512**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A077512**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A077512**	**003**	Sep 12, 2012
AB		PRINSTON INC	**EQ 5MG BASE**	**A078032**	**001**	Aug 28, 2015
AB			**EQ 10MG BASE**	**A078032**	**002**	Aug 28, 2015
AB			**EQ 20MG BASE**	**A078032**	**003**	Aug 28, 2015
AB		TEVA PHARMS USA	**EQ 5MG BASE**	**A076765**	**001**	Mar 14, 2012
AB			**EQ 10MG BASE**	**A076765**	**002**	Mar 14, 2012
AB			**EQ 20MG BASE**	**A076765**	**003**	Mar 14, 2012
AB		TORRENT PHARMS LTD	**EQ 5MG BASE**	**A090939**	**001**	Sep 11, 2012

ESCITALOPRAM OXALATE						
TABLET;ORAL						
ESCITALOPRAM OXALATE						
AB			**EQ 10MG BASE**	**A090939**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090939**	**003**	Sep 11, 2012
LEXAPRO						
AB	**+**	ALLERGAN	**EQ 5MG BASE**	**N021323**	**001**	Aug 14, 2002
AB	**+**		**EQ 10MG BASE**	**N021323**	**002**	Aug 14, 2002
AB	**+!**		**EQ 20MG BASE**	**N021323**	**003**	Aug 14, 2002
ESKETAMINE HYDROCHLORIDE						
SPRAY;NASAL						
SPRAVATO						
	+!	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019
ESLICARBAZEPINE ACETATE						
TABLET;ORAL						
APTIOM						
	+	SUNOVION PHARMS INC	200MG	N022416	001	Nov 08, 2013
	+		400MG	N022416	002	Nov 08, 2013
	+		600MG	N022416	003	Nov 08, 2013
	+!		800MG	N022416	004	Nov 08, 2013
ESMOLOL HYDROCHLORIDE						
INJECTABLE;INJECTION						
BREVIBLOC						
AP	**+!**	BAXTER HLTHCARE	**10MG/ML**	**N019386**	**006**	Feb 25, 2003
ESMOLOL HYDROCHLORIDE						
AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A205520**	**001**	Jul 23, 2015
AP		FRESENIUS KABI USA	**10MG/ML**	**A076573**	**001**	May 02, 2005
AP		GLAND PHARMA LTD	**10MG/ML**	**A208538**	**001**	Aug 14, 2019
AP		MYLAN INSTITUTIONAL	**10MG/ML**	**A076474**	**001**	May 02, 2005
AP		MYLAN LABS LTD	**10MG/ML**	**A206608**	**001**	Jun 08, 2018
AP			**20MG/ML**	**A206608**	**002**	Jun 08, 2018
AP		SAGENT PHARMS INC	**10MG/ML**	**A207107**	**001**	Jun 08, 2018
AP			**20MG/ML**	**A207107**	**002**	Jun 08, 2018
AP		WEST-WARD PHARMS INT	**10MG/ML**	**A076323**	**001**	Aug 10, 2004
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003
BREVIBLOC IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001
SOLUTION;INTRAVENOUS						
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER						
	+!	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER						
	+!	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016
ESOMEPRAZOLE MAGNESIUM						
CAPSULE, DELAYED REL PELLETS;ORAL						
ESOMEPRAZOLE MAGNESIUM						
AB		ALKEM LABS LTD	**EQ 20MG BASE**	**A208333**	**001**	Oct 20, 2017
AB			**EQ 40MG BASE**	**A208333**	**002**	Oct 20, 2017
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A205606**	**001**	Apr 21, 2016
AB			**EQ 40MG BASE**	**A205606**	**002**	Apr 21, 2016
AB		DR REDDYS LABS LTD	**EQ 20MG BASE**	**A078279**	**001**	Sep 25, 2015
AB			**EQ 40MG BASE**	**A078279**	**002**	Sep 25, 2015
AB		GLENMARK PHARMS	**EQ 20MG BASE**	**A209495**	**001**	May 10, 2019
AB			**EQ 40MG BASE**	**A209495**	**002**	May 10, 2019
AB		HETERO LABS LTD III	**EQ 20MG BASE**	**A202784**	**001**	Sep 21, 2015
AB			**EQ 40MG BASE**	**A202784**	**002**	Sep 21, 2015
AB		IVAX SUB TEVA PHARMS	**EQ 20MG BASE**	**A078003**	**001**	Jan 26, 2015
AB			**EQ 40MG BASE**	**A078003**	**002**	Jan 26, 2015
AB		LANNETT CO INC	**EQ 20MG BASE**	**A205563**	**001**	Sep 01, 2017
AB			**EQ 40MG BASE**	**A205563**	**002**	Sep 01, 2017
AB		MYLAN	**EQ 20MG BASE**	**A078936**	**001**	Aug 02, 2015
AB			**EQ 40MG BASE**	**A078936**	**002**	Aug 03, 2015
AB		SUN PHARM	**EQ 20MG BASE**	**A209735**	**001**	Apr 30, 2018
AB			**EQ 40MG BASE**	**A209735**	**002**	Apr 30, 2018
AB		TORRENT	**EQ 20MG BASE**	**A203636**	**001**	Oct 19, 2015
AB			**EQ 40MG BASE**	**A203636**	**002**	Oct 19, 2015
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A206296**	**001**	May 22, 2019

PRESCRIPTION DRUG PRODUCT LIST

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB			**EQ 40MG BASE**	**A206296**	**002**	May 22, 2019

NEXIUM

AB	**+**	ASTRAZENECA PHARMS	**EQ 20MG BASE**	**N021153**	**001**	Feb 20, 2001
AB	**+!**		**EQ 40MG BASE**	**N021153**	**002**	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE;ORAL

NEXIUM

+	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011
+		EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011
+		EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008
+		EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006
+!		EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

VIMOVO

+	HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010
+!		EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		ACCORD HLTHCARE	**EQ 40MG BASE/VIAL**	**A205379**	**001**	Sep 25, 2015
AP	**!**	AUROBINDO PHARMA LTD	**EQ 40MG BASE/VIAL**	**A204657**	**002**	Aug 10, 2016
AP		DEVA HOLDING AS	**EQ 40MG BASE/VIAL**	**A207181**	**001**	Mar 06, 2017
AP		MYLAN LABS LTD	**EQ 40MG BASE/VIAL**	**A202686**	**002**	May 17, 2017
AP		SUN PHARMA GLOBAL	**EQ 40MG BASE/VIAL**	**A200882**	**002**	Mar 18, 2013

NEXIUM IV

AP	**+!**	ASTRAZENECA PHARMS	**EQ 40MG BASE/VIAL**	**N021689**	**002**	Mar 31, 2005

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

AB		MAYNE PHARMA	**1MG**	**A074921**	**001**	Jul 10, 1997
AB	**!**		**2MG**	**A074921**	**002**	Jul 10, 1997
AB		PAR PHARM	**1MG**	**A074826**	**001**	Jul 03, 1997
AB			**2MG**	**A074826**	**002**	Jul 03, 1997
AB		WATSON LABS	**1MG**	**A074818**	**001**	Aug 19, 1997
AB			**2MG**	**A074818**	**002**	Aug 19, 1997

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	**!**	ALLERGAN	**0.01%**	**A086069**	**001**	Jan 31, 1984

ESTRADIOL

AB		ALVOGEN PINE BROOK	**0.01%**	**A209767**	**001**	Mar 05, 2018
AB		MYLAN	**0.01%**	**A208788**	**001**	Dec 29, 2017
AB		PERRIGO UK FINCO	**0.01%**	**A210194**	**001**	Jan 22, 2018
AB		TEVA PHARMS USA	**0.01%**	**A210488**	**001**	Mar 30, 2018

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB	**+**	BAYER HLTHCARE	**0.06MG/24HR**	**N020375**	**006**	May 27, 2003

ESTRADIOL

AB		MYLAN TECHNOLOGIES	**0.06MG/24HR**	**A075182**	**005**	Jul 20, 2006
AB1		AMNEAL PHARMS LLC	**0.025MG/24HR**	**A211293**	**001**	Feb 04, 2019
AB1			**0.0375MG/24HR**	**A211293**	**002**	Feb 04, 2019
AB1			**0.05MG/24HR**	**A211293**	**003**	Feb 04, 2019
AB1			**0.075MG/24HR**	**A211293**	**004**	Feb 04, 2019
AB1			**0.1MG/24HR**	**A211293**	**005**	Feb 04, 2019
AB1		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A201675**	**001**	Dec 19, 2014
AB1			**0.0375MG/24HR**	**A201675**	**002**	Dec 19, 2014
AB1			**0.05MG/24HR**	**A201675**	**003**	Dec 19, 2014
AB1			**0.075MG/24HR**	**A201675**	**004**	Dec 19, 2014
AB1			**0.1MG/24HR**	**A201675**	**005**	Dec 19, 2014

VIVELLE-DOT

AB1	**+**	NOVARTIS	**0.025MG/24HR**	**N020538**	**009**	May 03, 2002
AB1	**+**		**0.0375MG/24HR**	**N020538**	**005**	Jan 08, 1999
AB1	**+**		**0.05MG/24HR**	**N020538**	**006**	Jan 08, 1999
AB1	**+**		**0.075MG/24HR**	**N020538**	**007**	Jan 08, 1999
AB1	**+!**		**0.1MG/24HR**	**N020538**	**008**	Jan 08, 1999

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB2	+	BAYER HLTHCARE	**0.025MG/24HR**	**N020375**	**004**	Mar 05, 1999
AB2	+		**0.0375MG/24HR**	**N020375**	**005**	May 27, 2003
AB2	+		**0.05MG/24HR**	**N020375**	**001**	Dec 22, 1994
AB2	+		**0.075MG/24HR**	**N020375**	**003**	Mar 23, 1998
AB2	+!		**0.1MG/24HR**	**N020375**	**002**	Dec 22, 1994

ESTRADIOL

AB2		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A075182**	**003**	Jan 26, 2005
AB2			**0.0375MG/24HR**	**A075182**	**004**	Jul 20, 2006
AB2			**0.05MG/24HR**	**A075182**	**006**	Feb 24, 2000
AB2			**0.075MG/24HR**	**A075182**	**002**	Jan 26, 2005
AB2			**0.1MG/24HR**	**A075182**	**001**	Feb 24, 2000
AB3			**0.025MG/24HR**	**A206685**	**001**	Aug 15, 2018
AB3			**0.0375MG/24HR**	**A206685**	**002**	Aug 15, 2018
AB3			**0.05MG/24HR**	**A206685**	**003**	Aug 15, 2018
AB3			**0.075MG/24HR**	**A206685**	**004**	Aug 15, 2018
AB3			**0.1MG/24HR**	**A206685**	**005**	Aug 15, 2018

MINIVELLE

AB3	+	NOVEN	**0.025MG/24HR**	**N203752**	**005**	Sep 23, 2014
AB3	+		**0.0375MG/24HR**	**N203752**	**001**	Oct 29, 2012
AB3	+		**0.05MG/24HR**	**N203752**	**003**	Oct 29, 2012
AB3	+		**0.075MG/24HR**	**N203752**	**002**	Oct 29, 2012
AB3	+!		**0.1MG/24HR**	**N203752**	**004**	Oct 29, 2012

ALORA

BX		ALLERGAN	0.025MG/24HR	N020655	004	Apr 05, 2002
BX			0.05MG/24HR	N020655	001	Dec 20, 1996
BX			0.075MG/24HR	N020655	002	Dec 20, 1996
BX			0.1MG/24HR	N020655	003	Dec 20, 1996

MENOSTAR

	+!	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004

GEL;TRANSDERMAL

DIVIGEL

	+!	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007

GEL, METERED;TRANSDERMAL

ELESTRIN

	+!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006

ESTROGEL

	+!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004

INSERT;VAGINAL

IMVEXXY

	+	THERAPEUTICSMD INC	0.004MG	N208564	001	May 29, 2018
	+!		0.01MG	N208564	002	May 29, 2018

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

	+!	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996

SPRAY;TRANSDERMAL

EVAMIST

	+!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007

TABLET;ORAL

ESTRADIOL

AB		BARR LABS INC	**0.5MG**	**A040197**	**001**	Oct 22, 1997
AB			**1MG**	**A040197**	**002**	Oct 22, 1997
AB	!		**2MG**	**A040197**	**003**	Oct 22, 1997
AB		EPIC PHARMA INC	**0.5MG**	**A040275**	**001**	Dec 29, 1998
AB			**1MG**	**A040275**	**002**	Dec 29, 1998
AB			**2MG**	**A040275**	**003**	Dec 29, 1998
AB		MAYNE PHARMA	**0.5MG**	**A040114**	**003**	Mar 14, 1996
AB			**1MG**	**A040114**	**001**	Mar 14, 1996
AB			**2MG**	**A040114**	**002**	Mar 14, 1996
AB		MYLAN	**0.5MG**	**A040326**	**001**	Apr 21, 1999
AB			**1MG**	**A040326**	**002**	Apr 21, 1999
AB			**2MG**	**A040326**	**003**	Apr 21, 1999

TABLET;VAGINAL

ESTRADIOL

AB		AMNEAL PHARMS	**10MCG**	**A205256**	**001**	May 29, 2015
AB		GLENMARK PHARMS LTD	**10MCG**	**A210264**	**001**	Sep 14, 2018
AB		TEVA PHARMS USA	**10MCG**	**A206388**	**001**	Jul 21, 2017

VAGIFEM

AB	+!	NOVO NORDISK INC	**10MCG**	**N020908**	**002**	Nov 25, 2009

ESTRADIOL ACETATE							
INSERT, EXTENDED RELEASE;VAGINAL							
FEMRING							
	+	MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
	+!		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003
ESTRADIOL CYPIONATE							
INJECTABLE;INJECTION							
DEPO-ESTRADIOL							
	!	PHARMACIA AND UPJOHN	5MG/ML	A085470	003	
ESTRADIOL VALERATE							
INJECTABLE;INJECTION							
DELESTROGEN							
AO	**+!**	PAR STERILE PRODUCTS	**20MG/ML**	**N009402**	**004**	
AO	**+!**		**40MG/ML**	**N009402**	**003**	
ESTRADIOL VALERATE							
AO		AM REGENT	**20MG/ML**	**A090920**	**001**	Jan 19, 2010
AO			**40MG/ML**	**A090920**	**002**	Jan 19, 2010
DELESTROGEN							
	+!	PAR STERILE PRODUCTS	10MG/ML	N009402	002	
ESTRADIOL; LEVONORGESTREL							
FILM, EXTENDED RELEASE;TRANSDERMAL							
CLIMARA PRO							
	+!	BAYER HLTHCARE	0.045MG/24HR;0.015MG/24HR	N021258	001	Nov 21, 2003
ESTRADIOL; NORETHINDRONE ACETATE							
FILM, EXTENDED RELEASE;TRANSDERMAL							
COMBIPATCH							
	+	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998
	+!		0.05MG/24HR;0.25MG/24HR	N020870	002	Aug 07, 1998
TABLET;ORAL							
ACTIVELLA							
AB	**+**	AMNEAL PHARMS LLC	**0.5MG;0.1MG**	**N020907**	**002**	Dec 28, 2006
AB	**+!**		**1MG;0.5MG**	**N020907**	**001**	Nov 18, 1998
AMABELZ							
AB		LUPIN LTD	**0.5MG;0.1MG**	**A203339**	**001**	Jun 20, 2016
AB			**1MG;0.5MG**	**A203339**	**002**	Jun 20, 2016
ESTRADIOL AND NORETHINDRONE ACETATE							
AB		BARR	**1MG;0.5MG**	**A079193**	**001**	May 11, 2010
AB		BRECKENRIDGE PHARM	**0.5MG;0.1MG**	**A078324**	**002**	Jun 09, 2011
AB			**1MG;0.5MG**	**A078324**	**001**	Apr 17, 2008
AB		MYLAN LABS LTD	**0.5MG;0.1MG**	**A207261**	**001**	Feb 10, 2017
AB			**1MG;0.5MG**	**A207261**	**002**	Feb 10, 2017
AB		NOVAST LABS	**0.5MG;0.1MG**	**A210612**	**001**	Apr 03, 2019
AB			**1MG;0.5MG**	**A210612**	**002**	Apr 03, 2019
AB		TEVA PHARMS USA	**0.5MG;0.1MG**	**A200747**	**001**	Mar 08, 2012
ESTRADIOL; NORGESTIMATE							
TABLET;ORAL							
ESTRADIOL AND NORGESTIMATE							
	!	BARR	1MG,1MG;N/A,0.09MG	A076812	001	Apr 29, 2005
ESTRADIOL; PROGESTERONE							
CAPSULE;ORAL							
BIJUVA							
	+!	THERAPEUTICSMD INC	1MG;100MG	N210132	001	Oct 28, 2018
ESTRAMUSTINE PHOSPHATE SODIUM							
CAPSULE;ORAL							
EMCYT							
	+!	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001	
ESTROGENS, CONJUGATED							
CREAM;TOPICAL, VAGINAL							
PREMARIN							
	+!	WYETH PHARMS	0.625MG/GM	N020216	001	
INJECTABLE;INJECTION							
PREMARIN							
	+!	WYETH PHARMS	25MG/VIAL	N010402	001	

ESTROGENS, CONJUGATED						
TABLET;ORAL						
PREMARIN						
+	WYETH PHARMS	0.3MG		N004782	003	
+		0.45MG		N004782	006	Jul 16, 2003
+!		0.625MG		N004782	004	
+!		0.9MG		N004782	005	Jan 26, 1984
+!		1.25MG		N004782	001	
ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE						
TABLET;ORAL-28						
PREMPHASE 14/14						
+!	WYETH PHARMS	0.625MG,0.625MG;N/A,5MG		N020527	002	Nov 17, 1995
PREMPRO						
+!	WYETH PHARMS	0.3MG;1.5MG		N020527	005	Jun 04, 2003
+!		0.45MG;1.5MG		N020527	004	Mar 12, 2003
+!		0.625MG;2.5MG		N020527	001	Nov 17, 1995
+!		0.625MG;5MG		N020527	003	Jan 09, 1998
ESTROGENS, ESTERIFIED						
TABLET;ORAL						
MENEST						
	MONARCH PHARMS	0.3MG		A084951	001	
		0.625MG		A084948	001	
		1.25MG		A084950	001	
!		2.5MG		A084949	001	
ESTROPIPATE						
TABLET;ORAL						
ESTROPIPATE						
	MYLAN	0.75MG		A040359	001	Aug 26, 1999
		1.5MG		A040359	002	Aug 26, 1999
OGEN 5						
	PHARMACIA AND UPJOHN	6MG		A083220	004	
ESZOPICLONE						
TABLET;ORAL						
ESZOPICLONE						
AB	AURO BINDO PHARMA LTD	**1MG**		**A208451**	**001**	Sep 15, 2016
AB		**2MG**		**A208451**	**002**	Sep 15, 2016
AB		**3MG**		**A208451**	**003**	Sep 15, 2016
AB	DR REDDYS LABS LTD	**1MG**		**A091024**	**001**	Apr 15, 2014
AB		**2MG**		**A091024**	**002**	Apr 15, 2014
AB		**3MG**		**A091024**	**003**	Apr 15, 2014
AB	GLENMARK GENERICS	**1MG**		**A091166**	**001**	Apr 15, 2014
AB		**2MG**		**A091166**	**002**	Apr 15, 2014
AB		**3MG**		**A091166**	**003**	Apr 15, 2014
AB	HIKMA	**1MG**		**A091153**	**001**	Apr 15, 2014
AB		**2MG**		**A091153**	**002**	Apr 15, 2014
AB		**3MG**		**A091153**	**003**	Apr 15, 2014
AB	LUPIN LTD	**1MG**		**A091124**	**001**	Sep 13, 2011
AB		**2MG**		**A091124**	**002**	Sep 13, 2011
AB		**3MG**		**A091124**	**003**	Sep 13, 2011
AB	MACLEODS PHARMS LTD	**1MG**		**A202929**	**001**	Jan 30, 2015
AB		**2MG**		**A202929**	**002**	Jan 30, 2015
AB		**3MG**		**A202929**	**003**	Jan 30, 2015
AB	MYLAN PHARMS INC	**1MG**		**A091151**	**001**	Mar 26, 2013
AB		**2MG**		**A091151**	**002**	Mar 26, 2013
AB		**3MG**		**A091151**	**003**	Mar 26, 2013
AB	ORCHID HLTHCARE	**1MG**		**A091113**	**001**	Jun 10, 2014
AB		**2MG**		**A091113**	**002**	Jun 10, 2014
AB		**3MG**		**A091113**	**003**	Jun 10, 2014
AB	SUN PHARM	**1MG**		**A091103**	**001**	Apr 03, 2013
AB		**2MG**		**A091103**	**002**	Apr 03, 2013
AB		**3MG**		**A091103**	**003**	Apr 03, 2013
AB	TEVA	**1MG**		**A091169**	**001**	May 23, 2011
AB		**2MG**		**A091169**	**002**	May 23, 2011
AB		**3MG**		**A091169**	**003**	May 23, 2011
LUNESTA						
AB +	SUNOVION PHARMS INC	**1MG**		**N021476**	**001**	Dec 15, 2004
AB +		**2MG**		**N021476**	**002**	Dec 15, 2004
AB +!		**3MG**		**N021476**	**003**	Dec 15, 2004

ETELCALCETIDE
SOLUTION;INTRAVENOUS
PARSABIV

	+!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017
	+!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017
	+!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017

ETEPLIRSEN
SOLUTION;INTRAVENOUS
EXONDYS 51

	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016
	+!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016

ETHACRYNATE SODIUM
INJECTABLE;INJECTION

EDECRIN						
AP	**+!**	BAUSCH	**EQ 50MG BASE/VIAL**	**N016093**	**001**	
ETHACRYNATE SODIUM						
AP		MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A204634**	**001**	Aug 23, 2016
AP		PAR STERILE PRODUCTS	**EQ 50MG BASE/VIAL**	**A205473**	**001**	Jul 29, 2015
AP		ZYDUS PHARMS	**EQ 50MG BASE/VIAL**	**A207758**	**001**	Nov 17, 2017

ETHACRYNIC ACID
TABLET;ORAL

EDECRIN						
AB	**+!**	BAUSCH	**25MG**	**N016092**	**001**	
ETHACRYNIC ACID						
AB		AGNITIO	**25MG**	**A211809**	**001**	Jul 12, 2019
AB		ALVOGEN	**25MG**	**A205709**	**001**	Jul 24, 2018
AB		AMNEAL PHARMS CO	**25MG**	**A208805**	**001**	May 08, 2018
AB		EDENBRIDGE PHARMS	**25MG**	**A205609**	**001**	Jun 30, 2016
AB		HIKMA	**25MG**	**A207262**	**001**	Feb 23, 2017
AB		LUPIN LTD	**25MG**	**A211719**	**001**	Sep 06, 2019
AB		PAR PHARM INC	**25MG**	**A208501**	**001**	Jul 21, 2017
AB		SCIEGEN PHARMS INC	**25MG**	**A211232**	**001**	Aug 27, 2019

ETHAMBUTOL HYDROCHLORIDE
TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE						
AB		AKORN	**100MG**	**A075095**	**001**	Nov 30, 1999
AB			**400MG**	**A075095**	**002**	Nov 30, 1999
AB		BARR	**400MG**	**A076057**	**001**	Nov 26, 2001
AB		LUPIN	**100MG**	**A078939**	**001**	Jun 17, 2009
AB			**400MG**	**A078939**	**002**	Jun 17, 2009
MYAMBUTOL						
AB	**+**	STI PHARMA LLC	**100MG**	**N016320**	**001**	
AB	**+!**		**400MG**	**N016320**	**003**	

ETHANOLAMINE OLEATE
INJECTABLE;INJECTION
ETHAMOLIN

	+!	QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE
TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL						
AB		MYLAN LABS LTD	**0.035MG;1MG**	**A204703**	**001**	Jul 28, 2016
AB			**0.05MG;1MG**	**A204704**	**001**	Feb 09, 2016
KELNOR						
AB		BARR	**0.035MG;1MG**	**A076785**	**001**	May 23, 2005
LO-MALMOREDE						
AB		NOVAST LABS	**0.035MG;1MG**	**A209548**	**001**	Feb 11, 2019
MALMOREDE						
AB		NOVAST LABS	**0.05MG;1MG**	**A209547**	**001**	Jul 25, 2018
ZOVIA 1/35E-28						
AB		MAYNE PHARMA	**0.035MG;1MG**	**A072721**	**001**	Dec 30, 1991
ZOVIA 1/50E-28						
AB	**!**	WATSON LABS	**0.05MG;1MG**	**A072723**	**001**	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

		ELURYNG				
AB		AMNEAL PHARMS LLC	**0.015MG/24HR;0.12MG/24HR**	**A210830**	**001**	Dec 11, 2019
		NUVARING				
AB	**+!**	ORGANON SUB MERCK	**0.015MG/24HR;0.12MG/24HR**	**N021187**	**001**	Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

		ASHLYNA				
AB		GLENMARK GENERICS	**0.03MG,0.01MG;0.15MG,N/A**	**A203163**	**001**	Feb 23, 2015
		DAYSEE				
AB		LUPIN LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A091467**	**001**	Apr 10, 2013
		FAYOSIM				
AB		LUPIN LTD	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**A205943**	**001**	Mar 29, 2016
		ICLEVIA				
AB		AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206850**	**001**	Jun 29, 2018
		INTROVALE				
AB		XIROMED	**0.03MG;0.15MG**	**A079064**	**001**	Sep 27, 2010
		JAIMIESS				
AB		XIROMED	**0.03MG,0.01MG;0.15MG,N/A**	**A203770**	**001**	Dec 27, 2017
		LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB		AMNEAL PHARMS	**0.03MG;0.15MG**	**A203871**	**001**	Nov 13, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A203872**	**001**	Dec 22, 2015
AB		GLENMARK GENERICS	**0.02MG;0.09MG**	**A202791**	**001**	Apr 09, 2015
AB		GLENMARK PHARMS LTD	**0.03MG;0.15MG**	**A203164**	**001**	Jun 12, 2015
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091440**	**001**	Oct 23, 2012
AB		MYLAN LABS LTD	**0.03MG;0.15MG**	**A200490**	**001**	Apr 21, 2015
AB	**!**	WATSON LABS	**0.02MG;0.09MG**	**A079218**	**001**	Jun 06, 2011
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL				
AB		LUPIN LTD	**0.02MG,0.1MG;0.01MG,N/A**	**A091674**	**001**	Oct 26, 2011
AB		MAYNE PHARMA	**0.02MG,0.1MG;0.01MG,N/A**	**A200407**	**001**	Oct 25, 2011
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A078834**	**001**	May 31, 2011
AB		MYLAN LABS LTD	**0.02MG,0.15MG; 0.025MG,0.15MG;0.03MG,0.15MG;**	**A206053**	**001**	Oct 02, 2017
AB			**0.02MG,0.1MG;0.01MG,N/A**	**A200493**	**001**	Jun 17, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A200492**	**001**	May 27, 2015
AB		XIROMED	**0.02MG,0.1MG;0.01MG,N/A**	**A205131**	**001**	Dec 14, 2017
		LO SIMPESSE				
AB		AUROBINDO PHARMA LTD	**0.02MG,0.1MG;0.01MG,N/A**	**A206852**	**001**	Apr 28, 2017
		LOSEASONIQUE				
AB		TEVA BRANDED PHARM	**0.02MG,0.1MG;0.01MG,N/A**	**N022262**	**001**	Oct 24, 2008
		QUARTETTE				
AB	**+!**	TEVA BRANDED PHARM	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**N204061**	**001**	Mar 28, 2013
		QUASENSE				
AB		WATSON LABS	**0.03MG;0.15MG**	**A077101**	**001**	Sep 06, 2006
		SEASONALE				
AB	**+!**	TEVA BRANDED PHARM	**0.03MG;0.15MG**	**N021544**	**001**	Sep 05, 2003
		SEASONIQUE				
AB	**+!**	TEVA BRANDED PHARM	**0.03MG,0.01MG;0.15MG,N/A**	**N021840**	**001**	May 25, 2006
		SETLAKIN				
AB		NOVAST LABS	**0.03MG;0.15MG**	**A090716**	**001**	Sep 15, 2014
		SIMPESSE				
AB		AUROBINDO PHARMA LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A206851**	**001**	Apr 07, 2017
		SYLEVIA				
AB		SUN PHARM	**0.03MG;0.15MG**	**A202988**	**001**	Feb 06, 2019
		BALCOLTRA				
		AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018

TABLET;ORAL-28

		ALTAVERA				
AB		XIROMED	**0.03MG;0.15MG**	**A079102**	**001**	Aug 03, 2010
		AYUNA				
AB		AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206866**	**001**	Sep 23, 2016
		ELIFEMME				
AB		XIROMED	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A202507**	**001**	Dec 04, 2015
		ENPRESSE-28				
AB		DURAMED PHARMS BARR	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A075809**	**002**	Jul 16, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

	KURVELO					
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091408**	**001**	Oct 17, 2012
	LEVONEST					
AB		NOVAST LABS LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A090719**	**001**	Dec 29, 2010
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB		AMNEAL PHARMS	**0.03MG;0.15MG**	**A201095**	**001**	Dec 08, 2014
AB		LUPIN LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A200248**	**001**	Nov 19, 2015
AB		MYLAN LABS LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A202970**	**001**	Mar 23, 2018
AB			**0.03MG;0.15MG**	**A091663**	**001**	Dec 21, 2012
	LEVORA 0.15/30-28					
AB	!	MAYNE PHARMA	**0.03MG;0.15MG**	**A073594**	**001**	Dec 13, 1993
	MARLISSA					
AB		GLENMARK GENERICS	**0.03MG;0.15MG**	**A091452**	**001**	Feb 29, 2012
	MYZILRA					
AB		VINTAGE PHARMS LLC	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A077502**	**001**	Nov 23, 2011
	PORTIA-28					
AB		BARR	**0.03MG;0.15MG**	**A075866**	**002**	May 23, 2002
	TRIVORA-28					
AB	!	MAYNE PHARMA	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A074538**	**002**	Dec 18, 1997
	AFIRMELLE					
AB1		AUROBINDO PHARMA LTD	**0.02MG;0.1MG**	**A206886**	**001**	Nov 14, 2016
	AVIANE-28					
AB1		DURAMED PHARMS BARR	**0.02MG;0.1MG**	**A075796**	**001**	Apr 30, 2001
	CERINTA					
AB1		SUN PHARM	**0.02MG;0.1MG**	**A202817**	**001**	Jan 07, 2019
	FALMINA					
AB1		NOVAST LABS LTD	**0.02MG;0.1MG**	**A090721**	**001**	Mar 28, 2012
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1		AMNEAL PHARMS	**0.02MG;0.1MG**	**A201108**	**001**	Feb 05, 2014
AB1		LUPIN LTD	**0.02MG;0.1MG**	**A091425**	**001**	Jan 18, 2013
AB1	!	MAYNE PHARMA	**0.02MG;0.1MG**	**A076625**	**001**	Nov 18, 2004
AB1		MYLAN LABS LTD	**0.02MG;0.1MG**	**A200245**	**001**	Oct 09, 2013
	ORSYTHIA					
AB1		VINTAGE PHARMS LLC	**0.02MG;0.1MG**	**A077099**	**001**	May 11, 2011
	VIENVA					
AB1		XIROMED	**0.02MG;0.1MG**	**A201088**	**001**	May 21, 2015
	LESSINA-28					
AB2		BARR	**0.02MG;0.1MG**	**A075803**	**002**	Mar 20, 2002
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB2	!	MAYNE PHARMA	**0.02MG;0.1MG**	**A077681**	**001**	May 31, 2006

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

	XULANE					
	!	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

	NORINYL 1+35 21-DAY					
AB		ALLERGAN	**0.035MG;1MG**	**N017565**	**001**	
	NORTREL 1/35-21					
AB		BARR	**0.035MG;1MG**	**A072693**	**001**	Feb 28, 1992
	NORTREL 7/7/7					
		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET;ORAL-28

	ALYACEN 1/35					
AB		GLENMARK GENERICS	**0.035MG;1MG**	**A091634**	**001**	Jan 19, 2012
	ALYACEN 7/7/7					
AB		GLENMARK GENERICS	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A091636**	**001**	Jan 19, 2012
	ARANELLE					
AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**A076783**	**001**	Sep 29, 2004
	BALZIVA-28					
AB	!	BARR	**0.035MG;0.4MG**	**A076238**	**001**	Apr 22, 2004

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

BREVICON 28-DAY						
AB		ALLERGAN	**0.035MG;0.5MG**	**N017743**	**001**	
BRIELLYN						
AB		GLENMARK GENERICS	**0.035MG;0.4MG**	**A090538**	**001**	Mar 22, 2011
CYCLAFEM 0.5/35						
AB		VINTAGE PHARMS	**0.035MG;0.5MG**	**A203413**	**001**	Dec 16, 2015
CYCLAFEM 1/35						
AB		VINTAGE PHARMS LLC	**0.035MG;1MG**	**A076337**	**001**	Nov 12, 2010
CYCLAFEM 7/7/7						
AB		VINTAGE PHARMS LLC	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A076338**	**001**	Nov 16, 2010
CYONANZ						
AB		AUROBINDO PHARMA LTD	**0.035MG;0.5MG**	**A207055**	**001**	Oct 21, 2016
DASETTA 1/35						
AB		NOVAST LABS LTD	**0.035MG;1MG**	**A090948**	**001**	Dec 22, 2011
DASETTA 7/7/7						
AB		NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A090946**	**001**	Dec 22, 2011
GILDAGIA						
AB		VINTAGE PHARMS	**0.035MG;0.4MG**	**A078376**	**001**	Nov 06, 2012
NORETHINDRONE AND ETHINYL ESTRADIOL						
AB		ACCORD HLTHCARE	**0.035MG;1MG**	**A206864**	**001**	Apr 28, 2017
AB		MAYNE PHARMA	**0.035MG;0.5MG**	**A070686**	**001**	Jan 29, 1987
AB		WATSON LABS	**0.035MG;0.4MG**	**A078323**	**001**	Feb 04, 2010
AB		WATSON LABS TEVA	**0.035MG;1MG**	**A070687**	**001**	Jan 29, 1987
NORINYL 1+35 28-DAY						
AB		ALLERGAN	**0.035MG;1MG**	**N017565**	**002**	
NORTREL 0.5/35-28						
AB		BARR	**0.035MG;0.5MG**	**A072695**	**001**	Feb 28, 1992
NORTREL 1/35-28						
AB	**!**	BARR	**0.035MG;1MG**	**A072696**	**001**	Feb 28, 1992
NORTREL 7/7/7						
AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A075478**	**002**	Aug 30, 2002
NYLIA 1/35						
AB		AUROBINDO PHARMA LTD	**0.035MG;1MG**	**A207056**	**001**	Oct 21, 2016
NYLIA 7/7/7						
AB		AUROBINDO PHARMA LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A207054**	**001**	Oct 21, 2016
ORTHO-NOVUM 7/7/7-28						
AB	**+!**	JANSSEN PHARMS	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**N018985**	**002**	Apr 04, 1984
PHILITH						
AB		NOVAST LABS LTD	**0.035MG;0.4MG**	**A090947**	**001**	Dec 22, 2011
PIRMELLA 1/35						
AB		LUPIN LTD	**0.035MG;1MG**	**A201512**	**001**	Apr 24, 2013
PIRMELLA 7/7/7						
AB		LUPIN LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A201510**	**001**	Apr 24, 2013
TRI-NORINYL 28-DAY						
AB	**+!**	MAYNE PHARMA	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**N018977**	**002**	Apr 13, 1984
VYFEMLA						
AB		LUPIN LTD	**0.035MG;0.4MG**	**A201886**	**001**	Sep 26, 2013
WERA						
AB	**!**	NOVAST LABS LTD	**0.035MG;0.5MG**	**A091204**	**001**	Mar 27, 2012
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)						
		WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988

TABLET, CHEWABLE;ORAL

KAITLIB FE						
AB		LUPIN LTD	**0.025MG;0.8MG**	**A203448**	**001**	Dec 17, 2015
NEXESTA FE						
AB		AUROBINDO PHARMA LTD	**0.035MG;0.4MG**	**A207535**	**001**	Feb 02, 2017
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB		ACCORD HLTHCARE	**0.035MG;0.4MG**	**A207066**	**001**	Mar 29, 2017
AB		AMNEAL PHARMS	**0.035MG;0.4MG**	**A078892**	**001**	Sep 26, 2011
AB	**+!**	APIL	**0.025MG;0.8MG**	**N022573**	**001**	Dec 22, 2010
AB		BARR	**0.035MG;0.4MG**	**A078965**	**001**	Aug 05, 2010
AB		LUPIN LTD	**0.035MG;0.4MG**	**A091332**	**001**	Mar 23, 2016
AB		MYLAN LABS LTD	**0.025MG;0.8MG**	**A203371**	**001**	Apr 23, 2014

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	**!**		**0.035MG;0.4MG**	**A202086**	**001**	Apr 01, 2015

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

TAYTULLA

	+!	APIL	0.02MG;1MG	N204426	001	Apr 19, 2013

TABLET;ORAL

AUROVELA 24 FE

AB		AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207504**	**001**	Jun 15, 2017

BLISOVI 24 FE

AB		LUPIN LTD	**0.02MG;1MG**	**A091398**	**001**	Oct 28, 2015

FEMHRT

AB		APIL	**0.0025MG;0.5MG**	**N021065**	**001**	Jan 14, 2005

FYAVOLV

AB		LUPIN LTD	**0.005MG;1MG**	**A204213**	**002**	Dec 10, 2015
AB			**0.0025MG;0.5MG**	**A204213**	**001**	Dec 10, 2015

GILDESS 24 FE

AB		VINTAGE PHARMS	**0.02MG;1MG**	**A090293**	**001**	Dec 01, 2014

LARIN 24 FE

AB		NOVAST LABS	**0.02MG;1MG**	**A202994**	**001**	Feb 18, 2015

LERIBANE

AB		NOVAST LABS	**0.0025MG;0.5MG**	**A203435**	**002**	Jun 03, 2016
AB			**0.005MG;1MG**	**A203435**	**001**	Jun 03, 2016

LOESTRIN 24 FE

AB	**+**	APIL	**0.02MG;1MG**	**N021871**	**001**	Feb 17, 2006

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	**!**	BARR LABS INC	**0.005MG;1MG**	**A076221**	**001**	Nov 06, 2009
AB		GLENMARK GENERICS	**0.0025MG;0.5MG**	**A203038**	**001**	Apr 02, 2015
AB			**0.005MG;1MG**	**A203038**	**002**	Apr 02, 2015
AB		MYLAN LABS LTD	**0.0025MG;0.5MG**	**A207260**	**001**	Feb 02, 2017
AB			**0.005MG;1MG**	**A207259**	**001**	Dec 27, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	**!**	AMNEAL PHARMS	**0.02MG;1MG**	**A078267**	**001**	Sep 01, 2009
AB		BARR LABS INC	**0.02MG;1MG**	**A090938**	**001**	Dec 01, 2014
AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A204847**	**001**	Nov 17, 2017
AB		MYLAN LABS LTD	**0.02MG;1MG**	**A202742**	**001**	Oct 30, 2014

LO LOESTRIN FE

	+!	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010

TABLET;ORAL-21

AUROVELA 1.5/30

AB		AUROBINDO PHARMA LTD	**0.03MG;1.5MG**	**A207581**	**001**	Jun 26, 2017

AUROVELA 1/20

AB		AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207506**	**001**	Jun 16, 2017

GILDESS 1.5/30

AB		VINTAGE PHARMS LLC	**0.03MG;1.5MG**	**A077075**	**002**	Jul 24, 2012

GILDESS 1/20

AB		VINTAGE PHARMS LLC	**0.02MG;1MG**	**A077077**	**002**	Jul 24, 2012

HAILEY 1.5/30

AB		GLENMARK PHARMS	**0.03MG;1.5MG**	**A209297**	**001**	Jun 05, 2018

JUNEL 1.5/30

AB		BARR	**0.03MG;1.5MG**	**A076381**	**001**	May 30, 2003

JUNEL 1/20

AB		BARR	**0.02MG;1MG**	**A076380**	**001**	May 30, 2003

LARIN 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A202996**	**001**	Mar 20, 2014

LARIN 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A202995**	**001**	Dec 04, 2013

LOESTRIN 21 1.5/30

AB	**+**	APIL	**0.03MG;1.5MG**	**N017875**	**001**	

LOESTRIN 21 1/20

AB	**+**	APIL	**0.02MG;1MG**	**N017876**	**001**	

LOESTRIN FE 1.5/30

AB	**+!**	APIL	**0.03MG;1.5MG**	**N017355**	**001**	

MICROGESTIN 1.5/30

AB		MAYNE PHARMA	**0.03MG;1.5MG**	**A075548**	**002**	Jul 30, 2003

MICROGESTIN 1/20

AB		MAYNE PHARMA	**0.02MG;1MG**	**A075647**	**002**	Jul 30, 2003

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206969**	**001**	Jan 20, 2016
AB		MYLAN LABS LTD	**0.02MG;1MG**	**A202771**	**001**	Nov 06, 2013
AB			**0.03MG;1.5MG**	**A202770**	**001**	Feb 19, 2015

TRI-LEGEST 21

		BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076405	001	Oct 26, 2007

TABLET;ORAL-28

AUROVELA FE 1.5/30

AB		AUROBINDO PHARMA LTD	**0.03MG;1.5MG**	**A207580**	**001**	Jun 15, 2017

AUROVELA FE 1/20

AB		AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207505**	**001**	Jun 16, 2017

BLISOVI FE 1.5/30

AB		LUPIN LTD	**0.03MG;1.5MG**	**A201585**	**001**	Nov 18, 2015

BLISOVI FE 1/20

AB		LUPIN LTD	**0.02MG;1MG**	**A201584**	**001**	Nov 18, 2015

ESTROSTEP FE

AB	**+!**	APIL	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**N020130**	**002**	Oct 09, 1996

GILDESS FE 1.5/30

AB		VINTAGE PHARMS LLC	**0.03MG;1.5MG**	**A077075**	**001**	Apr 28, 2005

GILDESS FE 1/20

AB		VINTAGE PHARMS LLC	**0.02MG;1MG**	**A077077**	**001**	May 20, 2005

HAILEY FE 1.5/30

AB		GLENMARK PHARMS	**0.03MG;1.5MG**	**A209031**	**001**	Jun 05, 2018

HAILEY FE 1/20

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206597**	**001**	Nov 21, 2017

JUNEL FE 1.5/30

AB		BARR	**0.03MG;1.5MG**	**A076064**	**001**	Sep 18, 2003

JUNEL FE 1/20

AB		BARR	**0.02MG;1MG**	**A076081**	**001**	Sep 18, 2003

LARIN FE 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A091453**	**001**	Aug 23, 2013

LARIN FE 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A091454**	**001**	Aug 26, 2013

LOESTRIN FE 1/20

AB	**+**	APIL	**0.02MG;1MG**	**N017354**	**001**	

MICROGESTIN FE 1.5/30

AB		MAYNE PHARMA	**0.03MG;1.5MG**	**A075548**	**001**	Feb 05, 2001

MICROGESTIN FE 1/20

AB		MAYNE PHARMA	**0.02MG;1MG**	**A075647**	**001**	Feb 05, 2001

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		MAYNE PHARMA	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076629**	**001**	Mar 18, 2010
AB		MYLAN LABS LTD	**0.02MG;1MG**	**A202772**	**001**	Nov 14, 2013
AB			**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A205069**	**001**	Jun 22, 2018
AB			**0.03MG;1.5MG**	**A202741**	**001**	Feb 20, 2015

TRI-LEGEST FE

AB		BARR	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076105**	**001**	Oct 26, 2007

TABLET, CHEWABLE;ORAL

MIBELAS 24 FE

AB		LUPIN ATLANTIS	**0.02MG;1MG**	**A206287**	**001**	May 24, 2016

MINASTRIN 24 FE

AB	**+!**	APIL	**0.02MG;1MG**	**N203667**	**001**	May 08, 2013

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	**0.02MG;1MG**	**A207514**	**001**	Sep 11, 2017
AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A210369**	**001**	Dec 26, 2017
AB		XIROMED	**0.02MG;1MG**	**A209609**	**001**	Jul 16, 2018

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

ESTARYLLA

AB		XIROMED	**0.035MG;0.25MG**	**A090794**	**001**	Jan 30, 2013

MILI

AB		AUROBINDO PHARMA LTD	**0.035MG;0.25MG**	**A205449**	**001**	Jul 07, 2016

MONO-LINYAH

AB		NOVAST LABS LTD	**0.035MG;0.25MG**	**A090523**	**001**	May 23, 2012

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		AMNEAL PHARMS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A203870**	**001**	Nov 12, 2015
AB			**0.035MG;0.25MG**	**A203865**	**001**	Oct 27, 2015
AB			**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,**	**A203873**	**001**	May 12, 2016

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL						
		0.25MG				
AB	GLENMARK GENERICS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A200494**	**001**	Jun 17, 2011
AB		**0.035MG;0.25MG**	**A200538**	**001**	Apr 05, 2012
AB	GLENMARK PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A204057**	**001**	Feb 23, 2016
AB	LUPIN LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205588**	**001**	Apr 26, 2016
AB		**0.035MG;0.25MG**	**A205630**	**001**	Oct 27, 2016
AB	LUPIN PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A200541**	**001**	Jun 25, 2012
AB	MYLAN LABS LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A201897**	**001**	Jan 27, 2016
AB		**0.035MG;0.25MG**	**A201896**	**001**	Jan 27, 2016
AB	NAARI PTE LTD	**0.035MG;0.035MG;0.035MG;0.18MG;0.215MG; 0.25MG**	**A200383**	**001**	Apr 07, 2015
AB		**0.035MG;0.25MG**	**A200384**	**001**	Apr 07, 2015
ORTHO TRI-CYCLEN						
AB **+!**	JANSSEN PHARMS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**N019697**	**001**	Jul 03, 1992
ORTHO TRI-CYCLEN LO						
AB **+!**	JANSSEN PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**N021241**	**001**	Aug 22, 2002
PREVIFEM						
AB	VINTAGE PHARMS LLC	**0.035MG;0.25MG**	**A076334**	**001**	Jan 09, 2004
SPRINTEC						
AB **!**	BARR	**0.035MG;0.25MG**	**A075804**	**001**	Sep 25, 2002
TRI LO SPRINTEC						
AB	BARR LABS INC	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A076784**	**001**	Jun 29, 2009
TRI-ESTARYLLA						
AB	XIROMED	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090793**	**001**	Jan 30, 2013
TRI-LINYAH						
AB	NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090524**	**001**	May 30, 2012
TRI-LO-ESTARYLLA						
AB	XIROMED	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A091232**	**001**	Jun 29, 2015
TRI-LO-MILI						
AB	AUROBINDO PHARMA LTD	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A205762**	**001**	Nov 04, 2016
TRI-MILI						
AB	AUROBINDO PHARMA LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205441**	**001**	Jul 06, 2016
TRI-PREVIFEM						
AB	VINTAGE PHARMS LLC	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A076335**	**001**	Mar 26, 2004
TRI-SPRINTEC						
AB	BARR	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A075808**	**001**	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

CRYSELLE					
AB	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**001**	Nov 30, 2001

TABLET;ORAL-28

CRYSELLE					
AB	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**002**	Nov 30, 2001
ELINEST					
AB	NOVAST LABS LTD	**0.03MG;0.3MG**	**A091105**	**001**	Mar 28, 2012
LOW-OGESTREL-28					
AB	MAYNE PHARMA	**0.03MG;0.3MG**	**A075288**	**002**	Jul 28, 1999
OGESTREL 0.5/50-28					
!	WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA					
+!	THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

	+!	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001	

ETHIONAMIDE

TABLET;ORAL

TRECATOR

	+!	WYETH PHARMS	250MG	N013026	002	

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB		AKORN	**250MG**	**A040686**	**001**	May 28, 2008
AB		BIONPHARMA INC	**250MG**	**A040430**	**001**	Oct 28, 2002
AB		HERITAGE PHARMS INC	**250MG**	**A200892**	**001**	Sep 25, 2012
AB		STRIDES PHARMA	**250MG**	**A211928**	**001**	Feb 19, 2019

ZARONTIN

AB	**+!**	PARKE DAVIS	**250MG**	**N012380**	**001**	

SYRUP;ORAL

ETHOSUXIMIDE

AA		MIKART	**250MG/5ML**	**A040506**	**001**	Dec 22, 2003
AA		PHARM ASSOC	**250MG/5ML**	**A040253**	**001**	Nov 22, 2000

ZARONTIN

AA	**!**	PARKE-DAVIS	**250MG/5ML**	**A080258**	**001**	

ETHOTOIN

TABLET;ORAL

PEGANONE

	+!	RECORDATI RARE	250MG	N010841	001	

ETODOLAC

CAPSULE;ORAL

ETODOLAC

AB		ANI PHARMS INC	**200MG**	**A075126**	**001**	Sep 16, 1999
AB			**300MG**	**A075126**	**002**	Sep 16, 1999
AB		APOTEX	**200MG**	**A075419**	**001**	Jul 28, 2000
AB			**300MG**	**A075419**	**002**	Jul 28, 2000
AB		TARO	**200MG**	**A075078**	**001**	Apr 30, 1998
AB	**!**		**300MG**	**A075078**	**002**	Apr 30, 1998

TABLET;ORAL

ETODOLAC

AB		AMNEAL PHARMS CO	**400MG**	**A208834**	**001**	Jun 07, 2018
AB			**500MG**	**A208834**	**002**	Jun 07, 2018
AB		APOTEX INC	**400MG**	**A076004**	**001**	Dec 03, 2002
AB			**500MG**	**A076004**	**002**	Dec 03, 2002
AB		EDENBRIDGE PHARMS	**400MG**	**A209888**	**001**	Nov 30, 2018
AB			**500MG**	**A209888**	**002**	Nov 30, 2018
AB		SANDOZ	**400MG**	**A074903**	**001**	Apr 11, 1997
AB			**500MG**	**A074903**	**002**	Apr 19, 1999
AB		TARO PHARM INDS	**400MG**	**A075074**	**001**	Mar 11, 1998
AB	**!**		**500MG**	**A075074**	**002**	Apr 25, 2000
AB		TEVA	**400MG**	**A075009**	**001**	Nov 26, 1997
AB			**500MG**	**A075009**	**002**	Dec 28, 1999

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

AB		TARO	**400MG**	**A076174**	**001**	Mar 13, 2003
AB			**500MG**	**A076174**	**002**	Mar 13, 2003
AB			**600MG**	**A076174**	**003**	Mar 13, 2003
AB		TEVA	**400MG**	**A075665**	**003**	Feb 05, 2001
AB			**500MG**	**A075665**	**002**	Jul 31, 2000
AB	**!**		**600MG**	**A075665**	**001**	Jul 31, 2000
AB		ZYDUS PHARMS	**400MG**	**A091134**	**001**	Jan 23, 2014
AB			**500MG**	**A091134**	**002**	Jan 23, 2014
AB			**600MG**	**A091134**	**003**	Jan 23, 2014

ETOMIDATE

INJECTABLE;INJECTION

AMIDATE

AP	**+!**	HOSPIRA	**2MG/ML**	**N018227**	**001**	Sep 07, 1982

ETOMIDATE

AP		AUROBINDO PHARMA LTD	**2MG/ML**	**A206126**	**001**	Feb 24, 2017
AP		EMCURE PHARMS LTD	**2MG/ML**	**A204618**	**001**	Aug 13, 2014

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP		GLAND PHARMA LTD	**2MG/ML**	**A209058**	**001**	Apr 18, 2017
AP		HIKMA	**2MG/ML**	**A202354**	**001**	Feb 25, 2016
AP		MYLAN LABS LTD	**2MG/ML**	**A078289**	**001**	Jan 02, 2009
AP			**2MG/ML**	**A201044**	**001**	Feb 07, 2017
AP		WEST-WARD PHARMS INT	**2MG/ML**	**A074593**	**001**	Nov 04, 1996
AP		ZYDUS PHARMS	**2MG/ML**	**A202360**	**001**	Jul 18, 2014

ETONOGESTREL

IMPLANT;IMPLANTATION

NEXPLANON

	+!	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011

ETOPOSIDE

CAPSULE;ORAL

ETOPOSIDE

	!	MYLAN	50MG	A075635	001	Sep 19, 2001

INJECTABLE;INJECTION

ETOPOSIDE

AP		ACCORD HLTHCARE	**20MG/ML**	**A074513**	**001**	Mar 14, 1996
AP	**!**	FRESENIUS KABI USA	**20MG/ML**	**A074983**	**001**	Sep 30, 1998
AP		MYLAN LABS LTD	**20MG/ML**	**A203507**	**001**	Nov 20, 2017
AP			**20MG/ML**	**A204927**	**001**	Oct 31, 2017
AP		TEVA PHARMS USA	**20MG/ML**	**A074529**	**001**	Jul 24, 1996
AP		WEST-WARD PHARMS INT	**20MG/ML**	**A074290**	**001**	Jul 17, 1995

ETOPOSIDE PHOSPHATE

INJECTABLE;INJECTION

ETOPOPHOS PRESERVATIVE FREE

	+!	CHEPLAPHARM	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996

ETRAVIRINE

TABLET;ORAL

INTELENCE

	+	JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012
	+		100MG	N022187	001	Jan 18, 2008
	+!		200MG	N022187	002	Dec 22, 2010

EVEROLIMUS

TABLET;ORAL

AFINITOR

AB	**+**	NOVARTIS	**2.5MG**	**N022334**	**003**	Jul 09, 2010
AB	**+!**		**5MG**	**N022334**	**001**	Mar 30, 2009
AB	**+**		**7.5MG**	**N022334**	**004**	Mar 30, 2012
AB	**+**		**10MG**	**N022334**	**002**	Mar 30, 2009

EVEROLIMUS

AB		HIKMA	**0.25MG**	**A206133**	**001**	Apr 12, 2018
AB			**0.5MG**	**A206133**	**002**	Apr 12, 2018
AB			**0.75MG**	**A206133**	**003**	Apr 12, 2018
AB		PAR PHARM	**2.5MG**	**A207934**	**001**	Dec 09, 2019
AB			**5MG**	**A207934**	**002**	Dec 09, 2019
AB			**7.5MG**	**A207934**	**003**	Dec 09, 2019
AB		TEVA PHARMS USA	**2.5MG**	**A210050**	**001**	Dec 09, 2019
AB			**5MG**	**A210050**	**002**	Dec 09, 2019
AB			**7.5MG**	**A210050**	**003**	Dec 09, 2019
AB			**10MG**	**A210050**	**004**	Dec 09, 2019

ZORTRESS

AB	**+**	NOVARTIS	**0.25MG**	**N021560**	**001**	Apr 20, 2010
AB	**+**		**0.5MG**	**N021560**	**002**	Apr 20, 2010
AB	**+!**		**0.75MG**	**N021560**	**003**	Apr 20, 2010
	+		1MG	N021560	004	Aug 10, 2018

TABLET, FOR SUSPENSION;ORAL

AFINITOR DISPERZ

	+	NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012
	+		3MG	N203985	002	Aug 29, 2012
	+!		5MG	N203985	003	Aug 29, 2012

EXEMESTANE

TABLET;ORAL

AROMASIN

AB	**+!**	PHARMACIA AND UPJOHN	**25MG**	**N020753**	**001**	Oct 21, 1999

EXEMESTANE

AB		ALVOGEN	**25MG**	**A200898**	**001**	Jul 28, 2014
AB		BRECKENRIDGE	**25MG**	**A211031**	**001**	Feb 21, 2019
AB		CIPLA	**25MG**	**A210323**	**001**	Apr 27, 2018
AB		HIKMA	**25MG**	**A077431**	**001**	Apr 01, 2011
AB		MAYNE PHARMA INC	**25MG**	**A208764**	**001**	Aug 08, 2019
AB		MYLAN	**25MG**	**A203315**	**001**	Mar 10, 2017
AB		UPSHER SMITH LABS	**25MG**	**A209208**	**001**	Jul 26, 2017
AB		ZYDUS PHARMS	**25MG**	**A202602**	**001**	Oct 03, 2018

EXENATIDE

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE

	+!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON

	+!	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012

BYDUREON PEN

	+!	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014

INJECTABLE;SUBCUTANEOUS

BYETTA

	+!	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
	+!		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005

EZETIMIBE

TABLET;ORAL

EZETIMIBE

AB		ACCORD HLTHCARE	**10MG**	**A211550**	**001**	Oct 26, 2018
AB		ALKEM LABS LTD	**10MG**	**A209234**	**001**	Dec 21, 2017
AB		AMNEAL PHARMS CO	**10MG**	**A208803**	**001**	Jun 12, 2017
AB		APOTEX	**10MG**	**A208332**	**001**	Jun 12, 2017
AB		AUROBINDO PHARMA LTD	**10MG**	**A209838**	**001**	Aug 25, 2017
AB		GLENMARK PHARMS LTD	**10MG**	**A078560**	**001**	Jun 26, 2015
AB		MYLAN	**10MG**	**A201790**	**001**	Apr 26, 2019
AB		OHM LABS INC	**10MG**	**A207311**	**001**	Jun 12, 2017
AB		SANDOZ INC	**10MG**	**A203931**	**001**	Jun 12, 2017
AB		TEVA PHARMS USA	**10MG**	**A078724**	**001**	Jun 12, 2017
AB		WATSON LABS INC	**10MG**	**A200831**	**001**	Jun 12, 2017
AB		ZYDUS PHARMS	**10MG**	**A204331**	**001**	Jun 12, 2017

ZETIA

AB	**+!**	MSD INTL GMBH	**10MG**	**N021445**	**001**	Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB		ALKEM LABS LTD	**10MG;10MG**	**A209222**	**001**	Dec 22, 2017
AB			**10MG;20MG**	**A209222**	**002**	Dec 22, 2017
AB			**10MG;40MG**	**A209222**	**003**	Dec 22, 2017
AB			**10MG;80MG**	**A209222**	**004**	Dec 22, 2017
AB		AMNEAL PHARMS CO	**10MG;10MG**	**A208831**	**001**	Nov 21, 2017
AB			**10MG;20MG**	**A208831**	**002**	Nov 21, 2017
AB			**10MG;40MG**	**A208831**	**003**	Nov 21, 2017
AB			**10MG;80MG**	**A208831**	**004**	Nov 21, 2017
AB		ANI PHARMS INC	**10MG;10MG**	**A201890**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A201890**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A201890**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A201890**	**004**	Apr 26, 2017
AB		DR REDDYS LABS SA	**10MG;10MG**	**A200909**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A200909**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A200909**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A200909**	**004**	Apr 26, 2017
AB		GLENMARK PHARMS LTD	**10MG;10MG**	**A208699**	**001**	Jun 27, 2019
AB			**10MG;20MG**	**A208699**	**002**	Jun 27, 2019
AB			**10MG;40MG**	**A208699**	**003**	Jun 27, 2019
AB			**10MG;80MG**	**A208699**	**004**	Jun 27, 2019
AB		WATSON LABS INC	**10MG;10MG**	**A202968**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A202968**	**002**	Apr 26, 2017

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB			**10MG;40MG**	**A202968**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A202968**	**004**	Apr 26, 2017

VYTORIN

AB	+	MSD INTL	**10MG;10MG**	**N021687**	**001**	Jul 23, 2004
AB	+		**10MG;20MG**	**N021687**	**002**	Jul 23, 2004
AB	+		**10MG;40MG**	**N021687**	**003**	Jul 23, 2004
AB	+!		**10MG;80MG**	**N021687**	**004**	Jul 23, 2004

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

AB		APOTEX	**125MG**	**A091480**	**001**	Jul 22, 2011
AB			**250MG**	**A091480**	**002**	Jul 22, 2011
AB			**500MG**	**A091480**	**003**	Jul 22, 2011
AB		AUROBINDO PHARMA LTD	**125MG**	**A091114**	**001**	Mar 21, 2011
AB			**250MG**	**A091114**	**002**	Mar 21, 2011
AB			**500MG**	**A091114**	**003**	Mar 21, 2011
AB		CIPLA	**125MG**	**A078278**	**001**	Mar 21, 2011
AB			**250MG**	**A078278**	**002**	Mar 21, 2011
AB			**500MG**	**A078278**	**003**	Mar 21, 2011
AB		HETERO LABS LTD V	**125MG**	**A202438**	**001**	Sep 10, 2014
AB			**250MG**	**A202438**	**002**	Sep 10, 2014
AB			**500MG**	**A202438**	**003**	Sep 10, 2014
AB		HIKMA	**125MG**	**A090128**	**001**	Mar 21, 2011
AB			**250MG**	**A090128**	**002**	Mar 21, 2011
AB			**500MG**	**A090128**	**003**	Mar 21, 2011
AB		MACLEODS PHARMS LTD	**125MG**	**A201022**	**001**	Jan 12, 2012
AB			**250MG**	**A201022**	**002**	Jan 12, 2012
AB			**500MG**	**A201022**	**003**	Jan 12, 2012
AB		MYLAN	**125MG**	**A201333**	**001**	Mar 24, 2011
AB			**250MG**	**A201333**	**002**	Mar 24, 2011
AB			**500MG**	**A201333**	**003**	Mar 24, 2011
AB		TEVA PHARMS	**125MG**	**A077487**	**001**	Aug 24, 2007
AB			**250MG**	**A077487**	**002**	Aug 24, 2007
AB	!		**500MG**	**A077487**	**003**	Aug 24, 2007

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB		HI-TECH PHARMA CO	**40MG/5ML**	**A201995**	**001**	May 30, 2014
AB	!	LUPIN LTD	**40MG/5ML**	**A090440**	**001**	Jun 29, 2010
AB		NAVINTA LLC	**40MG/5ML**	**A091020**	**001**	May 27, 2010
AB		NOVEL LABS INC	**40MG/5ML**	**A201695**	**001**	Dec 17, 2012

INJECTABLE;INJECTION

FAMOTIDINE

AP		ATHENEX INC	**10MG/ML**	**A075651**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075684**	**001**	Apr 16, 2001
AP		FRESENIUS KABI USA	**10MG/ML**	**A075709**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078641**	**001**	Jun 25, 2008
AP	!	WEST-WARD PHARMS INT	**10MG/ML**	**A075488**	**001**	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

AP		ATHENEX INC	**10MG/ML**	**A075622**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075825**	**001**	Apr 17, 2001
AP		FRESENIUS KABI USA	**10MG/ML**	**A075813**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078642**	**001**	Jun 25, 2008
AP	!	WEST-WARD PHARMS INT	**10MG/ML**	**A075486**	**001**	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001

TABLET;ORAL

FAMOTIDINE

AB		ALEMBIC PHARMS LTD	**20MG**	**A078916**	**001**	May 22, 2009
AB			**40MG**	**A078916**	**002**	May 22, 2009
AB		APOTEX	**20MG**	**A075611**	**001**	Jul 23, 2001
AB			**40MG**	**A075611**	**002**	Jul 23, 2001
AB		AUROBINDO PHARMA LTD	**20MG**	**A206530**	**001**	Dec 22, 2015
AB			**40MG**	**A206530**	**002**	Dec 22, 2015
AB		CARLSBAD	**20MG**	**A075805**	**001**	Apr 16, 2001

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

AB			**40MG**	**A075805**	**002**	Apr 16, 2001
AB		CELLTRION	**20MG**	**A075786**	**001**	Apr 16, 2001
AB			**40MG**	**A075786**	**002**	Apr 16, 2001
AB		DR REDDYS LABS LTD	**20MG**	**A075718**	**001**	Apr 16, 2001
AB			**40MG**	**A075718**	**002**	Apr 16, 2001
AB		IVAX SUB TEVA PHARMS	**20MG**	**A075511**	**001**	Apr 16, 2001
AB			**40MG**	**A075511**	**002**	Apr 16, 2001
AB		MYLAN	**20MG**	**A075704**	**001**	Apr 16, 2001
AB		PERRIGO R AND D	**20MG**	**A077352**	**002**	Jul 27, 2005
AB			**40MG**	**A077352**	**001**	Jul 27, 2005
AB		TEVA	**20MG**	**A075311**	**001**	Apr 16, 2001
AB			**40MG**	**A075311**	**002**	Apr 16, 2001

PEPCID

AB	**+**	VALEANT PHARMS NORTH	**20MG**	**N019462**	**001**	Oct 15, 1986
AB	**+!**		**40MG**	**N019462**	**002**	Oct 15, 1986

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

DUEXIS

	+!	HORIZON	26.6MG;800MG	N022519	001	Apr 23, 2011

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB		ALEMBIC PHARMS LTD	**40MG**	**A205421**	**001**	Jul 01, 2019
AB			**80MG**	**A205421**	**002**	Jul 01, 2019
AB		HIKMA	**40MG**	**A205414**	**001**	Oct 15, 2019
AB			**80MG**	**A205414**	**002**	Oct 15, 2019
AB		INDOCO REMEDIES	**40MG**	**A210292**	**001**	Dec 30, 2019
AB			**80MG**	**A210292**	**002**	Dec 30, 2019
AB		MSN	**40MG**	**A210461**	**001**	Dec 30, 2019
AB			**80MG**	**A210461**	**002**	Dec 30, 2019
AB		MYLAN	**40MG**	**A205385**	**001**	Jul 01, 2019
AB			**80MG**	**A205385**	**002**	Jul 01, 2019
AB		SUN PHARM	**40MG**	**A205467**	**001**	Jul 01, 2019
AB			**80MG**	**A205467**	**002**	Jul 01, 2019

ULORIC

AB	**+**	TAKEDA PHARMS USA	**40MG**	**N021856**	**001**	Feb 13, 2009
AB	**+!**		**80MG**	**N021856**	**002**	Feb 13, 2009

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL

INREBIC

	+!	IMPACT	EQ 100MG BASE	N212327	001	Aug 16, 2019

FELBAMATE

SUSPENSION;ORAL

FELBAMATE

AB		AMNEAL PHARMS	**600MG/5ML**	**A202385**	**001**	Dec 16, 2011
AB		TARO	**600MG/5ML**	**A206314**	**001**	Jun 16, 2017
AB		VISTAPHARM	**600MG/5ML**	**A211333**	**001**	May 31, 2019

FELBATOL

AB	**+!**	MYLAN SPECIALITY LP	**600MG/5ML**	**N020189**	**003**	Jul 29, 1993

TABLET;ORAL

FELBAMATE

AB		ALVOGEN	**400MG**	**A204595**	**001**	Jan 11, 2016
AB			**600MG**	**A204595**	**002**	Jan 11, 2016
AB		AMNEAL PHARMS	**400MG**	**A201680**	**001**	Sep 13, 2011
AB			**600MG**	**A201680**	**002**	Sep 13, 2011
AB		ANI PHARMS INC	**400MG**	**A202284**	**001**	Nov 04, 2015
AB			**600MG**	**A202284**	**002**	Nov 04, 2015
AB		CADILA	**400MG**	**A208970**	**001**	May 30, 2017
AB			**600MG**	**A208970**	**002**	May 30, 2017
AB		TARO	**400MG**	**A207093**	**001**	Apr 20, 2017
AB			**600MG**	**A207093**	**002**	Apr 20, 2017

FELBATOL

AB	**+**	MYLAN SPECIALITY LP	**400MG**	**N020189**	**001**	Jul 29, 1993
AB	**+!**		**600MG**	**N020189**	**002**	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		AUROBINDO PHARMA LTD	2.5MG	A203417	001	Jan 17, 2013
AB			5MG	A203417	002	Jan 17, 2013
AB			10MG	A203417	003	Jan 17, 2013
AB		GLENMARK GENERICS	2.5MG	A090365	001	Dec 17, 2010
AB			5MG	A090365	002	Dec 17, 2010
AB			10MG	A090365	003	Dec 17, 2010
AB		HERITAGE PHARMS INC	2.5MG	A201964	001	Nov 08, 2013
AB			5MG	A201964	002	Nov 08, 2013
AB			10MG	A201964	003	Nov 08, 2013
AB		JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016
AB			5MG	A203983	002	Aug 19, 2016
AB			10MG	A203983	003	Aug 19, 2016
AB		ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015
AB			5MG	A203032	002	May 21, 2015
AB			10MG	A203032	003	May 21, 2015
AB		SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013
AB			5MG	A091200	002	Dec 13, 2013
AB			10MG	A091200	003	Dec 13, 2013
AB		SUN PHARM INDUSTRIES	2.5MG	A075896	001	Nov 02, 2004
AB			5MG	A075896	002	Nov 02, 2004
AB			10MG	A075896	003	Nov 02, 2004
AB		TORRENT PHARMS LTD	2.5MG	A202170	001	Nov 28, 2011
AB			5MG	A202170	002	Nov 28, 2011
AB	!		10MG	A202170	003	Nov 28, 2011
AB		VINTAGE PHARMS LLC	2.5MG	A200815	001	Oct 28, 2011
AB			5MG	A200815	002	Oct 28, 2011
AB			10MG	A200815	003	Oct 28, 2011
AB		YILING PHARM LTD	2.5MG	A210847	001	Oct 26, 2018
AB			5MG	A210847	002	Oct 26, 2018
AB			10MG	A210847	003	Oct 26, 2018
AB		YUNG SHIN PHARM	2.5MG	A204800	001	Apr 29, 2019
AB			5MG	A204800	002	Apr 29, 2019
AB			10MG	A204800	003	Apr 29, 2019

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

AB	+	LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004
AB	+!		130MG	N021695	003	Nov 30, 2004

FENOFIBRATE

AB		SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014
AB			130MG	A201748	002	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

AB		AJANTA PHARMA LTD	67MG	A210705	001	Sep 10, 2018
AB			134MG	A210705	002	Sep 10, 2018
AB			200MG	A210705	003	Sep 10, 2018
AB		AMERIGEN PHARMS LTD	67MG	A209504	001	Apr 30, 2018
AB			134MG	A209504	002	Apr 30, 2018
AB			200MG	A209504	003	Apr 30, 2018
AB		APOTEX	43MG	A202252	001	Jul 26, 2013
AB			130MG	A202252	002	Jul 26, 2013
AB		AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017
AB			134MG	A207805	002	Nov 16, 2017
AB			200MG	A207805	003	Nov 16, 2017
AB		DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012
AB			130MG	A090859	002	Mar 01, 2012
AB		GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017
AB			134MG	A205566	002	Apr 07, 2017
AB			200MG	A205566	003	Apr 07, 2017
AB		IMPAX LABS	67MG	A075868	001	Oct 27, 2003
AB			134MG	A075868	002	Oct 27, 2003
AB	!		200MG	A075868	003	Oct 27, 2003
AB		INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017
AB			134MG	A207378	002	Mar 28, 2017
AB			200MG	A207378	003	Mar 28, 2017
AB		MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013
AB			67MG	A202676	001	Oct 23, 2012
AB			130MG	A202579	002	Jan 10, 2013

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB			**134MG**	**A202676**	**002**	Oct 23, 2012
AB			**200MG**	**A202676**	**003**	Oct 23, 2012
AB		RHODES PHARMS	**67MG**	**A075753**	**001**	Sep 03, 2002
AB			**134MG**	**A075753**	**002**	Apr 09, 2002
AB			**200MG**	**A075753**	**003**	Apr 09, 2002
AB		TORRENT	**67MG**	**A210782**	**001**	Jun 26, 2018
AB			**134MG**	**A210782**	**002**	Jun 26, 2018
AB			**200MG**	**A210782**	**003**	Jun 26, 2018

ANTARA (MICRONIZED)

	+	LUPIN ATLANTIS	30MG	N021695	004	Oct 18, 2013
	+		90MG	N021695	005	Oct 18, 2013

LIPOFEN

	+	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
	+!		150MG	N021612	003	Jan 11, 2006

TABLET;ORAL

FENOFIBRATE

AB		AJANTA PHARMA LTD	**54MG**	**A210138**	**001**	Jul 23, 2018
AB			**160MG**	**A210138**	**002**	Jul 23, 2018
AB		ALEMBIC PHARMS LTD	**48MG**	**A210476**	**001**	Aug 09, 2019
AB			**145MG**	**A210476**	**002**	Aug 09, 2019
AB		AMNEAL PHARMS LLC	**48MG**	**A209951**	**001**	Feb 09, 2018
AB			**54MG**	**A209950**	**001**	Mar 19, 2018
AB			**145MG**	**A209951**	**002**	Feb 09, 2018
AB			**160MG**	**A209950**	**002**	Mar 19, 2018
AB		AUROBINDO PHARMA LTD	**48MG**	**A205118**	**001**	May 05, 2016
AB			**145MG**	**A205118**	**002**	May 05, 2016
AB		AUSTARPHARMA	**54MG**	**A207803**	**001**	Dec 19, 2017
AB			**160MG**	**A207803**	**002**	Dec 19, 2017
AB		CIPLA	**48MG**	**A208709**	**001**	Dec 15, 2016
AB			**145MG**	**A208709**	**002**	Dec 15, 2016
AB		HETERO LABS LTD III	**48MG**	**A204598**	**001**	Jul 12, 2016
AB			**145MG**	**A204598**	**002**	Jul 12, 2016
AB		IMPAX LABS	**54MG**	**A076509**	**001**	Mar 26, 2008
AB	!		**160MG**	**A076509**	**002**	Mar 26, 2008
AB		LUPIN LTD	**48MG**	**A090856**	**001**	Dec 23, 2011
AB			**54MG**	**A204019**	**001**	Aug 17, 2015
AB			**145MG**	**A090856**	**002**	Dec 23, 2011
AB			**160MG**	**A204019**	**002**	Aug 17, 2015
AB		MYLAN	**40MG**	**A204475**	**001**	Jun 23, 2016
AB			**54MG**	**A076520**	**001**	Oct 25, 2007
AB			**120MG**	**A204475**	**002**	Jun 23, 2016
AB			**160MG**	**A076520**	**003**	Oct 25, 2007
AB		MYLAN PHARMS INC	**48MG**	**A202856**	**001**	Dec 07, 2012
AB			**145MG**	**A202856**	**002**	Dec 07, 2012
AB		NUVO PHARM	**54MG**	**A210670**	**001**	Sep 06, 2019
AB			**160MG**	**A210670**	**002**	Sep 06, 2019
AB		ORIT LABS LLC	**54MG**	**A209660**	**001**	Feb 11, 2019
AB			**160MG**	**A209660**	**002**	Feb 11, 2019
AB		PRINSTON INC	**48MG**	**A211080**	**001**	Aug 28, 2018
AB			**145MG**	**A211080**	**002**	Aug 28, 2018
AB		RHODES PHARMS	**54MG**	**A076433**	**001**	May 13, 2005
AB			**160MG**	**A076433**	**002**	May 13, 2005
AB		SUN PHARM	**48MG**	**A200884**	**001**	Sep 07, 2017
AB			**145MG**	**A200884**	**002**	Sep 07, 2017
AB		SUN PHARM INDS LTD	**54MG**	**A076635**	**001**	Oct 31, 2005
AB			**160MG**	**A076635**	**003**	Oct 31, 2005
AB		VALEANT PHARMS NORTH	**48MG**	**A090715**	**001**	Apr 05, 2012
AB			**145MG**	**A090715**	**002**	Apr 05, 2012

FENOGLIDE

AB	+	SALIX	**40MG**	**N022118**	**001**	Aug 10, 2007
AB	+!		**120MG**	**N022118**	**002**	Aug 10, 2007

TRICOR

AB	+	ABBVIE	**48MG**	**N021656**	**001**	Nov 05, 2004
AB	+!		**145MG**	**N021656**	**002**	Nov 05, 2004

TRIGLIDE

BX	+	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005

FENOFIBRATE						
TABLET;ORAL						
FENOFIBRATE						
		SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005
FENOFIBRIC ACID						
TABLET;ORAL						
FIBRICOR						
	+	ATHENA	35MG	N022418	001	Aug 14, 2009
	+!		105MG	N022418	002	Aug 14, 2009
FENOLDOPAM MESYLATE						
INJECTABLE;INJECTION						
CORLOPAM						
AP	**+!**	HOSPIRA	**EQ 10MG BASE/ML**	**N019922**	**001**	Sep 23, 1997
FENOLDOPAM MESYLATE						
AP		SANDOZ INC	**EQ 10MG BASE/ML**	**A077155**	**001**	Feb 15, 2005
AP		WEST-WARD PHARMS INT	**EQ 10MG BASE/ML**	**A076582**	**001**	Oct 12, 2004
FENOPROFEN CALCIUM						
CAPSULE;ORAL						
NALFON						
	+	XSPIRE PHARMA	EQ 200MG BASE	N017604	003	
	+!		EQ 400MG BASE	N017604	004	Jul 21, 2009
TABLET;ORAL						
FENOPROFEN CALCIUM						
	!	XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988
FENTANYL						
FILM, EXTENDED RELEASE;TRANSDERMAL						
DURAGESIC-100						
AB	**+**	JANSSEN PHARMS	**100MCG/HR**	**N019813**	**001**	Aug 07, 1990
DURAGESIC-12						
AB	**+**	JANSSEN PHARMS	**12.5MCG/HR**	**N019813**	**005**	Feb 04, 2005
DURAGESIC-25						
AB	**+!**	JANSSEN PHARMS	**25MCG/HR**	**N019813**	**004**	Aug 07, 1990
DURAGESIC-37						
AB	**+**	JANSSEN PHARMS	**37.5MCG/HR**	**N019813**	**006**	Jan 24, 2018
DURAGESIC-50						
AB	**+**	JANSSEN PHARMS	**50MCG/HR**	**N019813**	**003**	Aug 07, 1990
DURAGESIC-75						
AB	**+**	JANSSEN PHARMS	**75MCG/HR**	**N019813**	**002**	Aug 07, 1990
FENTANYL-100						
AB		3M DRUG DELIVERY	**100MCG/HR**	**A202097**	**005**	Nov 04, 2016
AB		AVEVA	**100MCG/HR**	**A077449**	**004**	Oct 20, 2008
AB		LAVIPHARM LABS	**100MCG/HR**	**A077051**	**004**	Aug 04, 2006
AB		MYLAN TECHNOLOGIES	**100MCG/HR**	**A076258**	**004**	Jan 28, 2005
AB		SPECGX LLC	**100MCG/HR**	**A077154**	**004**	Feb 09, 2011
FENTANYL-12						
AB		3M DRUG DELIVERY	**12.5MCG/HR**	**A202097**	**001**	Nov 04, 2016
AB		AVEVA	**12.5MCG/HR**	**A077449**	**005**	Sep 11, 2015
AB		MYLAN TECHNOLOGIES	**12.5MCG/HR**	**A076258**	**005**	Jan 23, 2007
AB		SPECGX LLC	**12.5MCG/HR**	**A077154**	**005**	Jun 11, 2015
FENTANYL-25						
AB		3M DRUG DELIVERY	**25MCG/HR**	**A202097**	**002**	Nov 04, 2016
AB		AVEVA	**25MCG/HR**	**A077449**	**001**	Oct 20, 2008
AB		LAVIPHARM LABS	**25MCG/HR**	**A077051**	**001**	Aug 04, 2006
AB		MYLAN TECHNOLOGIES	**25MCG/HR**	**A076258**	**001**	Jan 28, 2005
AB		SPECGX LLC	**25MCG/HR**	**A077154**	**001**	Feb 09, 2011
FENTANYL-37						
AB		AVEVA	**37.5MCG/HR**	**A077449**	**006**	Dec 06, 2017
AB		MYLAN TECHNOLOGIES	**37.5MCG/HR**	**A076258**	**006**	Dec 29, 2014
FENTANYL-50						
AB		3M DRUG DELIVERY	**50MCG/HR**	**A202097**	**003**	Nov 04, 2016
AB		AVEVA	**50MCG/HR**	**A077449**	**002**	Oct 20, 2008
AB		LAVIPHARM LABS	**50MCG/HR**	**A077051**	**002**	Aug 04, 2006
AB		MYLAN TECHNOLOGIES	**50MCG/HR**	**A076258**	**002**	Jan 28, 2005
AB		SPECGX LLC	**50MCG/HR**	**A077154**	**002**	Feb 09, 2011
FENTANYL-62						
AB		AVEVA	**62.5MCG/HR**	**A077449**	**007**	Dec 06, 2017
FENTANYL-75						
AB		3M DRUG DELIVERY	**75MCG/HR**	**A202097**	**004**	Nov 04, 2016
AB		AVEVA	**75MCG/HR**	**A077449**	**003**	Oct 20, 2008
AB		LAVIPHARM LABS	**75MCG/HR**	**A077051**	**003**	Aug 04, 2006

FENTANYL						
FILM, EXTENDED RELEASE;TRANSDERMAL						
FENTANYL-75						
AB		MYLAN TECHNOLOGIES	**75MCG/HR**	**A076258**	**003**	Jan 28, 2005
AB		SPECGX LLC	**75MCG/HR**	**A077154**	**003**	Feb 09, 2011
FENTANYL-87						
AB		AVEVA	**87.5MCG/HR**	**A077449**	**008**	Dec 06, 2017
FENTANYL-62						
		MYLAN TECHNOLOGIES	62.5MCG/HR	A076258	007	Dec 29, 2014
FENTANYL-87						
		MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014
SPRAY;SUBLINGUAL						
SUBSYS						
	+	BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012
	+		0.2MG	N202788	002	Jan 04, 2012
	+!		0.4MG	N202788	003	Jan 04, 2012
	+		0.6MG	N202788	004	Jan 04, 2012
	+		0.8MG	N202788	005	Jan 04, 2012
	+		1.2MG	N202788	006	Aug 30, 2012
	+		1.6MG	N202788	007	Aug 30, 2012
FENTANYL CITRATE						
INJECTABLE;INJECTION						
FENTANYL CITRATE						
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**N019115**	**001**	Jan 12, 1985
FENTANYL CITRATE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A210762**	**001**	May 03, 2019
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A072786**	**001**	Sep 24, 1991
AP	**+!**	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**N019101**	**001**	Jul 11, 1984
SUBLIMAZE PRESERVATIVE FREE						
AP	**+!**	AKORN	**EQ 0.05MG BASE/ML**	**N016619**	**001**	
SPRAY, METERED;NASAL						
LAZANDA						
	+	BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
	+!		EQ 0.4MG BASE	N022569	002	Jun 30, 2011
TABLET;BUCCAL, SUBLINGUAL						
FENTORA						
	+	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006
	+!		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006
	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006
TROCHE/LOZENGE;TRANSMUCOSAL						
ACTIQ						
AB	**+**	CEPHALON	**EQ 0.2MG BASE**	**N020747**	**001**	Nov 04, 1998
AB	**+!**		**EQ 0.4MG BASE**	**N020747**	**002**	Nov 04, 1998
AB	**+**		**EQ 0.6MG BASE**	**N020747**	**003**	Nov 04, 1998
AB	**+**		**EQ 0.8MG BASE**	**N020747**	**004**	Nov 04, 1998
AB	**+**		**EQ 1.2MG BASE**	**N020747**	**005**	Nov 04, 1998
AB	**+**		**EQ 1.6MG BASE**	**N020747**	**006**	Nov 04, 1998
FENTANYL CITRATE						
AB		SPECGX LLC	**EQ 0.2MG BASE**	**A078907**	**001**	Oct 30, 2009
AB			**EQ 0.4MG BASE**	**A078907**	**002**	Oct 30, 2009
AB			**EQ 0.6MG BASE**	**A078907**	**003**	Oct 30, 2009
AB			**EQ 0.8MG BASE**	**A078907**	**004**	Oct 30, 2009
AB			**EQ 1.2MG BASE**	**A078907**	**005**	Oct 30, 2009
AB			**EQ 1.6MG BASE**	**A078907**	**006**	Oct 30, 2009
FERRIC CARBOXYMALTOSE						
INJECTABLE;INTRAVENOUS						
INJECTAFER						
	+!	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013
FERRIC CITRATE						
TABLET;ORAL						
AURYXIA						
	+!	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014

FERRIC HEXACYANOFERRATE(II)

CAPSULE;ORAL

RADIOGARDASE (PRUSSIAN BLUE)

	+!	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003

FERRIC MALTOL

CAPSULE;ORAL

ACCRUFER

	+!	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS

TRIFERIC

	+!	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016

SOLUTION;INTRAVENOUS

TRIFERIC

	+!	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015

FERUMOXYTOL

SOLUTION;INTRAVENOUS

FERAHEME

	+!	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

AB		AUROBINDO PHARMA LTD	**4MG**	**A205007**	**001**	Feb 17, 2017
AB			**8MG**	**A205007**	**002**	Feb 17, 2017
AB		DR REDDYS LABS LTD	**4MG**	**A204975**	**001**	Aug 13, 2019
AB			**8MG**	**A204975**	**002**	Aug 13, 2019
AB		ZYDUS PHARMS	**4MG**	**A204946**	**001**	Oct 03, 2017
AB			**8MG**	**A204946**	**002**	Oct 03, 2017

TOVIAZ

AB	**+**	PFIZER	**4MG**	**N022030**	**001**	Oct 31, 2008
AB	**+!**		**8MG**	**N022030**	**002**	Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

AB		BARR	**30MG**	**A076191**	**001**	Aug 31, 2005
AB			**60MG**	**A076191**	**002**	Aug 31, 2005
AB			**180MG**	**A076191**	**003**	Aug 31, 2005
AB		DR REDDYS LABS LTD	**30MG**	**A076502**	**001**	Apr 11, 2006
AB			**60MG**	**A076502**	**002**	Apr 11, 2006
AB			**180MG**	**A076502**	**003**	Apr 11, 2006
AB		MYLAN	**60MG**	**A077081**	**003**	Apr 11, 2008
AB			**180MG**	**A077081**	**001**	Apr 16, 2007
AB		TEVA	**30MG**	**A076447**	**001**	Sep 01, 2005
AB			**60MG**	**A076447**	**002**	Sep 01, 2005
AB			**180MG**	**A076447**	**003**	Sep 01, 2005

FIDAXOMICIN

TABLET;ORAL

DIFICID

	+!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB		ACCORD HLTHCARE	**1MG**	**A091643**	**001**	Nov 05, 2013
AB			**5MG**	**A090121**	**001**	Feb 23, 2010
AB		ACTAVIS TOTOWA	**1MG**	**A078371**	**001**	Nov 05, 2013
AB		ACTAVIS TOTOWA TEVA	**5MG**	**A077914**	**001**	Mar 28, 2007
AB		ALKEM LABS LTD	**1MG**	**A207750**	**001**	Jan 06, 2017
AB			**5MG**	**A204304**	**001**	Jan 05, 2017
AB		AUROBINDO PHARMA	**5MG**	**A078341**	**001**	Oct 30, 2007
AB		AUROBINDO PHARMA LTD	**1MG**	**A203687**	**001**	Nov 05, 2013
AB		CIPLA	**1MG**	**A077335**	**001**	Nov 20, 2014
AB		DR REDDYS LABS INC	**1MG**	**A076436**	**001**	Jul 28, 2006
AB		DR REDDYS LABS LTD	**5MG**	**A076437**	**001**	Feb 28, 2007
AB		HETERO LABS LTD III	**1MG**	**A090060**	**001**	Jul 01, 2013
AB			**5MG**	**A090061**	**001**	Jun 07, 2010
AB		SUN PHARM	**1MG**	**A090508**	**001**	Jul 01, 2013

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB			**5MG**	**A090507**	**001**	Aug 16, 2011
AB		TEVA	**1MG**	**A076905**	**001**	Nov 05, 2013
AB			**5MG**	**A076511**	**001**	Dec 15, 2006
AB		ZYDUS PHARMS USA INC	**5MG**	**A078900**	**001**	Dec 28, 2009

PROPECIA

AB	**+!**	MERCK	**1MG**	**N020788**	**001**	Dec 19, 1997

PROSCAR

AB	**+!**	MERCK	**5MG**	**N020180**	**001**	Jun 19, 1992

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB		BIOCON LTD	**EQ 0.5MG BASE**	**A207979**	**001**	Dec 04, 2019
AB		HEC PHARM CO LTD	**EQ 0.5MG BASE**	**A207939**	**001**	Dec 04, 2019
AB		SUN PHARM	**EQ 0.5MG BASE**	**A208014**	**001**	Dec 04, 2019

GILENYA

AB	**+!**	NOVARTIS	**EQ 0.5MG BASE**	**N022527**	**001**	Sep 21, 2010
	+		EQ 0.25MG BASE	N022527	002	May 11, 2018

FISH OIL TRIGLYCERIDES

EMULSION;INTRAVENOUS

OMEGAVEN

+!	FRESENIUS KABI USA	5GM/50ML (0.1GM/ML)	N210589	001	Jul 27, 2018
+!		10GM/100ML (0.1GM/ML)	N210589	002	Jul 27, 2018

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

SMOFLIPID 20%

+!	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648	001	Jul 13, 2016
+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648	002	Jul 13, 2016
+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648	003	Jul 13, 2016
+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (1000ML)	N207648	004	Aug 10, 2018

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

AB		EPIC PHARMA	**100MG**	**A076835**	**001**	Nov 30, 2005
AB	**!**	PADDOCK LLC	**100MG**	**A076831**	**001**	Dec 16, 2004

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB		AMNEAL PHARM	**50MG**	**A075442**	**001**	Jul 31, 2001
AB			**100MG**	**A075442**	**002**	Jul 31, 2001
AB			**150MG**	**A075442**	**003**	Jul 31, 2001
AB		ANI PHARMS INC	**50MG**	**A075882**	**001**	Oct 28, 2002
AB			**100MG**	**A075882**	**002**	Oct 28, 2002
AB			**150MG**	**A075882**	**003**	Oct 28, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A202821**	**001**	Nov 03, 2017
AB			**100MG**	**A202821**	**002**	Nov 03, 2017
AB			**150MG**	**A202821**	**003**	Nov 03, 2017
AB		HIKMA	**50MG**	**A076278**	**001**	Jan 14, 2003
AB			**100MG**	**A076278**	**002**	Jan 14, 2003
AB	**!**		**150MG**	**A076278**	**003**	Jan 14, 2003
AB		SUN PHARM INDS LTD	**50MG**	**A076421**	**001**	Mar 28, 2003
AB			**100MG**	**A076421**	**002**	Mar 28, 2003
AB			**150MG**	**A076421**	**003**	Mar 28, 2003

TAMBOCOR

AB	**+**	CNTY LINE PHARMS	**50MG**	**N018830**	**004**	Aug 23, 1988
AB	**+**		**100MG**	**N018830**	**001**	Oct 31, 1985
AB	**+**		**150MG**	**N018830**	**003**	Jun 03, 1988

FLIBANSERIN
TABLET;ORAL
ADDYI

+!	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015

FLORBETABEN F-18
SOLUTION;INTRAVENOUS
NEURACEQ

+!	LIFE MOLECULAR	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014

FLORBETAPIR F-18
SOLUTION;INTRAVENOUS
AMYVID

+!	AVID RADIOPHARMS INC	10-30ML (13.5-51mCi/ML)	N202008	002	Apr 06, 2012
+!		10-50ML (13.5-51mCi/ML)	N202008	003	Apr 06, 2012

FLOXURIDINE
INJECTABLE;INJECTION
FLOXURIDINE

AP		FRESENIUS KABI USA	**500MG/VIAL**	**A075837**	**001**	Feb 22, 2001
AP	**!**	WEST-WARD PHARMS INT	**500MG/VIAL**	**A075387**	**001**	Apr 16, 2000

FLUCICLOVINE F-18
SOLUTION;INTRAVENOUS
AXUMIN

+!	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016

FLUCONAZOLE
FOR SUSPENSION;ORAL
DIFLUCAN

AB	**+**	PFIZER	**50MG/5ML**	**N020090**	**001**	Dec 23, 1993
AB	**+!**		**200MG/5ML**	**N020090**	**002**	Dec 23, 1993

FLUCONAZOLE

AB		AUROBINDO PHARMA LTD	**50MG/5ML**	**A079150**	**001**	Sep 18, 2009
AB			**200MG/5ML**	**A079150**	**002**	Sep 18, 2009
AB		HIKMA	**50MG/5ML**	**A076246**	**001**	Jul 29, 2004
AB			**200MG/5ML**	**A076246**	**002**	Jul 29, 2004

INJECTABLE;INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078764**	**001**	Jan 30, 2012
AP			**400MG/200ML (2MG/ML)**	**A078764**	**002**	Jan 30, 2012
AP	**!**	HOSPIRA	**200MG/100ML (2MG/ML)**	**A076304**	**001**	Jul 29, 2004
AP	**!**		**400MG/200ML (2MG/ML)**	**A076304**	**002**	Jul 29, 2004
AP		WOODWARD	**200MG/100ML (2MG/ML)**	**A077988**	**001**	May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077988**	**002**	May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		BAXTER HLTHCARE CORP	**200MG/100ML (2MG/ML)**	**A077947**	**001**	May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077947**	**002**	May 26, 2010
AP		FRESENIUS KABI USA	**200MG/100ML (2MG/ML)**	**A076145**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076145**	**002**	Jul 29, 2004
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A076736**	**001**	Aug 23, 2005
AP		WEST-WARD PHARMS INT	**200MG/100ML (2MG/ML)**	**A076087**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076087**	**003**	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**200MG/100ML (2MG/ML)**	**A076766**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076766**	**002**	Jul 29, 2004
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078698**	**001**	Jan 30, 2012
AP			**400MG/200ML (2MG/ML)**	**A078698**	**002**	Jan 30, 2012
AP		HOSPIRA	**200MG/100ML (2MG/ML)**	**A076303**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076303**	**002**	Jul 29, 2004
AP	**!**	INFORLIFE	**200MG/100ML (2MG/ML)**	**A079104**	**001**	Jul 30, 2009
AP	**!**		**400MG/200ML (2MG/ML)**	**A079104**	**002**	Jul 30, 2009
AP		WEST-WARD PHARMS INT	**200MG/100ML (2MG/ML)**	**A078107**	**001**	Jul 30, 2008
AP			**400MG/200ML (2MG/ML)**	**A078107**	**002**	Jul 30, 2008
AP		WOODWARD	**200MG/100ML (2MG/ML)**	**A077909**	**001**	May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077909**	**002**	May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		WOODWARD	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015

TABLET;ORAL

DIFLUCAN

AB	**+**	PFIZER	**50MG**	**N019949**	**001**	Jan 29, 1990
AB	**+**		**100MG**	**N019949**	**002**	Jan 29, 1990
AB	**+**		**150MG**	**N019949**	**004**	Jun 30, 1994
AB	**+!**		**200MG**	**N019949**	**003**	Jan 29, 1990

FLUCONAZOLE

AB		AUROBINDO PHARMA	**50MG**	**A077731**	**001**	Oct 07, 2008
AB			**100MG**	**A077731**	**002**	Oct 07, 2008
AB			**150MG**	**A077731**	**003**	Oct 07, 2008
AB			**200MG**	**A077731**	**004**	Oct 07, 2008
AB		CHARTWELL	**50MG**	**A076665**	**001**	Jul 29, 2004
AB			**100MG**	**A076665**	**002**	Jul 29, 2004
AB			**150MG**	**A076665**	**003**	Jul 29, 2004
AB			**200MG**	**A076665**	**004**	Jul 29, 2004
AB		DR REDDYS LABS INC	**50MG**	**A076658**	**001**	Jul 29, 2004
AB			**100MG**	**A076658**	**002**	Jul 29, 2004
AB			**150MG**	**A076658**	**003**	Jul 29, 2004
AB			**200MG**	**A076658**	**004**	Jul 29, 2004
AB		GLENMARK GENERICS	**50MG**	**A077253**	**001**	Jan 25, 2006
AB			**100MG**	**A077253**	**002**	Jan 25, 2006
AB			**150MG**	**A077253**	**003**	Jan 25, 2006
AB			**200MG**	**A077253**	**004**	Jan 25, 2006
AB		HARRIS PHARM	**50MG**	**A078423**	**001**	Mar 07, 2011
AB			**100MG**	**A078423**	**002**	Mar 07, 2011
AB			**150MG**	**A078423**	**003**	Mar 07, 2011
AB			**200MG**	**A078423**	**004**	Mar 07, 2011
AB		IVAX SUB TEVA PHARMS	**50MG**	**A076077**	**001**	Jul 29, 2004
AB			**100MG**	**A076077**	**002**	Jul 29, 2004
AB			**150MG**	**A076077**	**003**	Jul 29, 2004
AB			**200MG**	**A076077**	**004**	Jul 29, 2004
AB		MYLAN	**50MG**	**A076351**	**001**	Jul 29, 2004
AB			**100MG**	**A076351**	**002**	Jul 29, 2004
AB			**150MG**	**A076351**	**003**	Jul 29, 2004
AB			**200MG**	**A076351**	**004**	Jul 29, 2004
AB		TARO	**50MG**	**A076507**	**001**	Jul 29, 2004
AB			**100MG**	**A076507**	**002**	Jul 29, 2004
AB			**150MG**	**A076507**	**003**	Jul 29, 2004
AB			**200MG**	**A076507**	**004**	Jul 29, 2004
AB		TEVA	**50MG**	**A074681**	**001**	Jul 29, 2004
AB			**100MG**	**A074681**	**002**	Jul 29, 2004
AB			**150MG**	**A074681**	**003**	Jul 29, 2004
AB			**200MG**	**A074681**	**004**	Jul 29, 2004
AB		UNIQUE PHARM LABS	**50MG**	**A076957**	**001**	Sep 28, 2005
AB			**100MG**	**A076957**	**002**	Sep 28, 2005
AB			**150MG**	**A076957**	**004**	Feb 27, 2017
AB			**200MG**	**A076957**	**003**	Sep 28, 2005
AB		ZYDUS PHARMS	**50MG**	**A208963**	**001**	Feb 16, 2017
AB			**100MG**	**A208963**	**002**	Feb 16, 2017
AB			**150MG**	**A208963**	**003**	Feb 16, 2017
AB			**200MG**	**A208963**	**004**	Feb 16, 2017

FLUCYTOSINE

CAPSULE;ORAL

ANCOBON

AB	**+**	BAUSCH	**250MG**	**N017001**	**001**	
AB	**+!**		**500MG**	**N017001**	**002**	

FLUCYTOSINE

AB		HIKMA	**250MG**	**A206550**	**001**	Oct 17, 2017
AB			**500MG**	**A206550**	**002**	Oct 17, 2017
AB		NOVEL LABS INC	**250MG**	**A204652**	**001**	Jul 07, 2017
AB			**500MG**	**A204652**	**002**	Jul 07, 2017
AB		RECIPHARM	**250MG**	**A207536**	**001**	Jun 18, 2018
AB			**500MG**	**A207536**	**002**	Jun 18, 2018
AB		SIGMAPHARM LABS LLC	**250MG**	**A201566**	**001**	Jun 28, 2011
AB			**500MG**	**A201566**	**002**	Jun 28, 2011

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP		ACTAVIS LLC	**50MG/2ML (25MG/ML)**	**A203738**	**001**	Feb 28, 2017
AP		ACTAVIS TOTOWA	**50MG/VIAL**	**A078610**	**001**	Feb 11, 2009
AP		AREVA PHARMS	**50MG/2ML (25MG/ML)**	**A090724**	**001**	Sep 27, 2010
AP		CUSTOPHARM INC	**50MG/VIAL**	**A076349**	**001**	Aug 28, 2003
AP	**!**	FRESENIUS KABI USA	**50MG/2ML (25MG/ML)**	**A078393**	**001**	Oct 15, 2007
AP			**50MG/VIAL**	**A078544**	**001**	Oct 15, 2007
AP	**!**	HOSPIRA	**50MG/VIAL**	**A077790**	**001**	Apr 06, 2007
AP		MYLAN LABS LTD	**50MG/VIAL**	**A200648**	**001**	Oct 16, 2012
AP		SAGENT PHARMS INC	**50MG/2ML (25MG/ML)**	**A076661**	**001**	Apr 28, 2004
AP	**+!**	SANDOZ	**50MG/2ML (25MG/ML)**	**N022137**	**001**	Sep 21, 2007

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		3D IMAGING DRUG	**20-300mCi/ML**	**A203778**	**001**	Oct 30, 2015
AP		BIOMEDCL RES FDN	**20-300mCi/ML**	**A203710**	**001**	May 01, 2015
AP			**20-300mCi/ML**	**A203837**	**001**	May 01, 2015
AP		BRIGHAM WOMENS	**20-300mCi/ML**	**A203816**	**001**	Oct 30, 2014
AP		CARDINAL HEALTH 414	**20-300mCi/ML**	**A203603**	**001**	Nov 13, 2015
AP		CHILDRENS HOSP MI	**20-300mCi/ML**	**A204385**	**001**	Oct 29, 2014
AP		CPDC	**20-300mCi/ML**	**A204525**	**001**	Oct 29, 2014
AP		DECATUR	**20-300mCi/ML**	**A204463**	**001**	Oct 21, 2014
AP		ESSENTIAL ISOTOPES	**20-300mCi/ML**	**A203946**	**001**	Feb 05, 2014
AP	**+!**	FEINSTEIN	**20-400mCi/ML**	**N021870**	**002**	Nov 21, 2008
AP		JUBILANT DRAXIMAGE	**20-300mCi/ML**	**A203920**	**001**	Jun 23, 2015
AP		KETTERING MEDCTR	**4-40mCi/ML**	**A204759**	**001**	Oct 27, 2015
AP		KREITCHMAN PET CTR	**10-100mCi/ML**	**A203942**	**001**	Apr 11, 2016
AP		LANTHEUS MEDICAL	**20-200mCi/ML**	**A203664**	**001**	Feb 04, 2014
AP		MA GENERAL HOSP	**20-300mCi/ML**	**A204333**	**001**	Sep 25, 2014
AP		MCPRF	**20-240mCi/ML**	**A203612**	**001**	Aug 05, 2013
AP		MEM SLOAN-KETTERING	**20-300mCi/ML**	**A208679**	**001**	Dec 08, 2016
AP		METHODIST HOSP RES	**20-300mCi/ML**	**A203904**	**001**	Apr 23, 2015
AP		MIPS CRF	**20-300mCi/ML**	**A204472**	**001**	Sep 11, 2015
AP		NCM USA BRONX LLC	**20-300mCi/ML**	**A204512**	**001**	Jan 07, 2015
AP	**!**	PETNET	**20-200mCi/ML**	**A079086**	**001**	Feb 25, 2011
AP	**!**	QUEEN HAMAMATSU PET	**10-100mCi/ML**	**A203771**	**001**	Aug 31, 2015
AP		SHERTECH LABS LLC	**20-300mCi/ML**	**A204264**	**001**	Dec 18, 2014
AP		SOFIE	**20-300mCi/ML**	**A203591**	**001**	Aug 31, 2015
AP	**!**		**20-500mCi/ML**	**A203665**	**001**	Feb 14, 2013
AP		TRUSTEES UNIV PA	**20-200mCi/ML**	**A203801**	**001**	Oct 29, 2014
AP	**!**	UCLA BIOMEDICAL	**4-40mCi/ML**	**A203811**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**20-300mCi/ML**	**A203902**	**001**	May 09, 2014
AP		UIHC PET IMAGING	**20-300mCi/ML**	**A203990**	**001**	Aug 06, 2014
AP		UNIV MICHIGAN	**20-300mCi/ML**	**A204531**	**001**	Jul 17, 2015
AP		UNIV TX MD ANDERSON	**20-300mCi/ML**	**A203246**	**002**	Jan 13, 2014
AP		UNIV UTAH CYCLOTRON	**20-300mCi/ML**	**A204498**	**001**	Jun 23, 2015
AP		WI MEDCL CYCLOTRON	**20-500mCi/ML**	**A203709**	**001**	Oct 23, 2013
AP		WUSM CYCLOTRON	**20-300mCi/ML**	**A203935**	**001**	Feb 05, 2014
		HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
		NORTHLAND	4-500mCi/ML	A203994	001	Feb 04, 2015
		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015
		SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015
		UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB		BARR	**0.1MG**	**A040425**	**001**	Jan 21, 2003
AB		HIKMA PHARMS	**0.1MG**	**A091302**	**001**	Jul 22, 2011
AB	**!**	IMPAX LABS	**0.1MG**	**A040431**	**001**	Mar 18, 2002

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		FRESENIUS KABI USA	**0.5MG/5ML (0.1MG/ML)**	**A076955**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076955**	**001**	Oct 12, 2004
AP		HIKMA FARMACEUTICA	**0.5MG/5ML (0.1MG/ML)**	**A078527**	**001**	Mar 23, 2009
AP	**!**		**1MG/10ML (0.1MG/ML)**	**A078527**	**002**	Mar 23, 2009
AP		MYLAN LABS LTD	**0.5MG/5ML (0.1MG/ML)**	**A078595**	**001**	May 13, 2008
AP		SAGENT PHARMS	**0.5MG/5ML (0.1MG/ML)**	**A090584**	**001**	Aug 28, 2012
AP			**1MG/10ML (0.1MG/ML)**	**A090584**	**002**	Aug 28, 2012

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		SANDOZ INC	**0.5MG/5ML (0.1MG/ML)**	**A077071**	**001**	May 03, 2005
AP			**1MG/10ML (0.1MG/ML)**	**A077071**	**002**	May 03, 2005
AP		WEST-WARD PHARMS INT	**0.5MG/5ML (0.1MG/ML)**	**A076256**	**002**	Oct 12, 2004
AP			**0.5MG/5ML (0.1MG/ML)**	**A076787**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076256**	**001**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076787**	**001**	Oct 12, 2004

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

AB	**!**	BAUSCH AND LOMB	**0.025MG/SPRAY**	**A074805**	**001**	Feb 20, 2002
AB		HI TECH PHARMA CO	**0.025MG/SPRAY**	**A077704**	**001**	Aug 03, 2006

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

AT		ACP NIMBLE	**0.01%**	**A089526**	**001**	Jul 26, 1988
AT			**0.025%**	**A210747**	**001**	Nov 05, 2018
AT		FOUGERA PHARMS INC	**0.01%**	**A088170**	**001**	Dec 16, 1982
AT			**0.025%**	**A088169**	**001**	Dec 16, 1982
AT		TARO	**0.025%**	**A087104**	**001**	Apr 27, 1982

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N012787**	**004**	
AT	**+!**		**0.025%**	**N012787**	**002**	
AT	**+!**		**0.025%**	**N012787**	**005**	

IMPLANT;INTRAVITREAL

ILUVIEN

	+!	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014

RETISERT

	+!	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005

YUTIQ

	+!	EYEPOINT PHARMS	0.18MG	N210331	001	Oct 12, 2018

OIL;TOPICAL

DERMA-SMOOTHE/FS

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**001**	Feb 03, 1988
AT	**+!**		**0.01%**	**N019452**	**002**	Nov 09, 2005

FLUCINOLONE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A210556**	**001**	Oct 25, 2018

FLUOCINOLONE ACETONIDE

AT		AKORN	**0.01%**	**A091514**	**001**	Jun 25, 2015
AT		IDENTI PHARMS INC	**0.01%**	**A201759**	**001**	Oct 17, 2011
AT			**0.01%**	**A201764**	**001**	Oct 17, 2011
AT		LYNE	**0.01%**	**A090982**	**001**	Apr 25, 2016
AT			**0.01%**	**A203377**	**001**	Apr 25, 2016
AT		PERRIGO ISRAEL	**0.01%**	**A202847**	**001**	Aug 09, 2013
AT			**0.01%**	**A202848**	**001**	Aug 09, 2013
AT		TARO	**0.01%**	**A202368**	**001**	May 19, 2016
AT			**0.01%**	**A209336**	**001**	May 19, 2016

FLUOCINONIDE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A210539**	**001**	Oct 26, 2018

OIL/DROPS;OTIC

DERMOTIC

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**003**	Nov 09, 2005

FLAC

AT		ANDA REPOSITORY	**0.01%**	**A210736**	**001**	Apr 11, 2018

FLUOCINOLONE ACETONIDE

AT		AKORN	**0.01%**	**A202705**	**001**	Sep 09, 2016
AT		IDENTI PHARMS INC	**0.01%**	**A091306**	**001**	Oct 17, 2011
AT		LYNE	**0.01%**	**A203378**	**001**	Apr 25, 2016
AT		PERRIGO ISRAEL	**0.01%**	**A202849**	**001**	Jul 17, 2017

FLUOCINONIDE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A211815**	**001**	Dec 14, 2018

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT		ACP NIMBLE	**0.025%**	**A089524**	**001**	Jul 26, 1988
AT		FOUGERA PHARMS INC	**0.025%**	**A088168**	**001**	Dec 16, 1982
AT		TARO	**0.025%**	**A040041**	**001**	Sep 15, 1994

FLUOCINOLONE ACETONIDE

OINTMENT;TOPICAL

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.025%**	**N013960**	**001**	

SHAMPOO;TOPICAL

CAPEX

	+!	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		ENCUBE ETHICALS	**0.01%**	**A209913**	**001**	Feb 13, 2019
AT		FOUGERA PHARMS INC	**0.01%**	**A088167**	**001**	Dec 16, 1982
AT		GLASSHOUSE PHARMS	**0.01%**	**A209596**	**001**	Dec 26, 2017
AT		LUPIN	**0.01%**	**A206422**	**001**	Sep 02, 2015
AT		TARO	**0.01%**	**A089124**	**001**	Sep 11, 1985

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N015296**	**001**	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM;TOPICAL

TRI-LUMA

	+!	GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

	!	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001	

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB		AMNEAL PHARMS LLC	**0.1%**	**A211111**	**001**	Jun 04, 2018
AB		FOUGERA PHARMS INC	**0.1%**	**A200735**	**001**	Jul 14, 2014
AB		GLENMARK GENERICS	**0.1%**	**A091282**	**001**	Jul 14, 2014
AB		PERRIGO ISRAEL	**0.1%**	**A090256**	**001**	Jan 14, 2014
AB		TARO	**0.1%**	**A200734**	**001**	Jul 14, 2014
AB		TELIGENT PHARMA INC	**0.1%**	**A211758**	**001**	Apr 03, 2019

VANOS

AB	**+!**	MEDICIS	**0.1%**	**N021758**	**001**	Feb 11, 2005

FLUOCINONIDE

AB1		ACP NIMBLE	**0.05%**	**A073085**	**001**	Feb 14, 1992
AB1		FOUGERA PHARMS INC	**0.05%**	**A073030**	**001**	Oct 17, 1994
AB1		TARO	**0.05%**	**A071500**	**001**	Jun 10, 1987
AB1	**+!**		**0.05%**	**N019117**	**001**	Jun 26, 1984
AB1		TELIGENT PHARMA INC	**0.05%**	**A211410**	**001**	Oct 16, 2018
AB1		TEVA	**0.05%**	**A072488**	**001**	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

AB2		ACP NIMBLE	**0.05%**	**A074204**	**001**	Jun 13, 1995
AB2		FOUGERA PHARMS	**0.05%**	**A076586**	**001**	Jun 23, 2004
AB2	**!**	TARO PHARM INDS LTD	**0.05%**	**A072494**	**001**	Jan 19, 1989
AB2		TEVA	**0.05%**	**A072490**	**001**	Feb 07, 1989

LIDEX-E

AB2	**+**	CNTY LINE PHARMS	**0.05%**	**N016908**	**003**	

GEL;TOPICAL

FLUOCINONIDE

AB		ACP NIMBLE	**0.05%**	**A072537**	**001**	Feb 07, 1989
AB	**+**	CNTY LINE PHARMS	**0.05%**	**N017373**	**001**	
AB		FOUGERA PHARMS INC	**0.05%**	**A072933**	**001**	Dec 30, 1994
AB	**!**	TARO	**0.05%**	**A074935**	**001**	Jul 29, 1997
AB		TELIGENT PHARMA INC	**0.05%**	**A209030**	**001**	Jun 19, 2018

OINTMENT;TOPICAL

FLUOCINONIDE

AB		FOUGERA PHARMS	**0.05%**	**A074905**	**001**	Aug 26, 1997
AB		NOVEL LABS INC	**0.05%**	**A207538**	**001**	Jul 31, 2017
AB	**!**	TARO	**0.05%**	**A075008**	**001**	Jun 30, 1999
AB		TELIGENT PHARMA INC	**0.05%**	**A207680**	**001**	Sep 28, 2018
AB		TEVA	**0.05%**	**A073481**	**001**	Dec 27, 1991
AB		XIROMED	**0.05%**	**A212976**	**001**	Nov 26, 2019

LIDEX

AB	**+**	CNTY LINE PHARMS	**0.05%**	**N016909**	**002**	

SOLUTION;TOPICAL

FLUOCINONIDE

AT		ACP NIMBLE	**0.05%**	**A071535**	**001**	Dec 02, 1988
AT		ENCUBE ETHICALS	**0.05%**	**A209699**	**001**	Nov 29, 2018
AT		FOUGERA PHARMS INC	**0.05%**	**A072934**	**001**	Feb 27, 1995

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINONIDE							
SOLUTION;TOPICAL							
FLUOCINONIDE							
AT		GLASSHOUSE PHARMS	**0.05%**	**A209118**	**001**	Apr 23, 2018
AT		MACLEODS PHARMS LTD	**0.05%**	**A209283**	**001**	Apr 23, 2018
AT		NOVEL LABS INC	**0.05%**	**A206003**	**001**	Jul 21, 2017
AT	**!**	TARO	**0.05%**	**A074799**	**001**	Dec 31, 1996
AT		TELIGENT PHARMA INC	**0.05%**	**A207554**	**001**	Mar 18, 2019
AT		TEVA	**0.05%**	**A072511**	**001**	Feb 07, 1989
AT		ZYDUS PHARMS	**0.05%**	**A208948**	**001**	Jul 17, 2018
LIDEX							
AT	**+**	CNTY LINE PHARMS	**0.05%**	**N018849**	**001**	Apr 06, 1984
FLUORESCEIN SODIUM							
INJECTABLE;INTRAVENOUS							
AK-FLUOR 10%							
AP	**+**	AKORN	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N022186**	**001**	Aug 08, 2008
FLUORESCITE							
AP	**+!**	ALCON LABS INC	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N021980**	**001**	Mar 28, 2006
AK-FLUOR 25%							
	+!	AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008
FLUORODOPA F-18							
SOLUTION;INTRAVENOUS							
FLUORODOPA F18							
	+!	FEINSTEIN	0.42-8.33mCi/ML	N200655	001	Oct 10, 2019
FLUOROMETHOLONE							
OINTMENT;OPHTHALMIC							
FML							
	+!	ALLERGAN	0.1%	N017760	001	Sep 04, 1985
SUSPENSION/DROPS;OPHTHALMIC							
FML							
	+!	ALLERGAN	0.1%	N016851	002	Jul 28, 1982
FML FORTE							
	+!	ALLERGAN	0.25%	N019216	001	Apr 23, 1986
FLUOROMETHOLONE ACETATE							
SUSPENSION/DROPS;OPHTHALMIC							
FLAREX							
	+!	EYEVANCE	0.1%	N019079	001	Feb 11, 1986
FLUOROURACIL							
CREAM;TOPICAL							
CARAC							
AB	**+!**	VALEANT PHARMS NORTH	**0.5%**	**N020985**	**001**	Oct 27, 2000
EFUDEX							
AB	**+!**	BAUSCH	**5%**	**N016831**	**003**	
FLUOROURACIL							
AB		MAYNE PHARMA	**5%**	**A077524**	**001**	Apr 11, 2008
AB		MYLAN	**0.5%**	**A203122**	**001**	Apr 20, 2015
AB		TARO	**5%**	**A090368**	**001**	Mar 05, 2010
FLUOROPLEX							
	+!	ALMIRALL	1%	N016988	001	
TOLAK							
	+!	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015
INJECTABLE;INJECTION							
FLUOROURACIL							
AP	**!**	ACCORD HLTHCARE	**500MG/10ML (50MG/ML)**	**A040743**	**002**	Apr 26, 2007
AP	**!**		**1GM/20ML (50MG/ML)**	**A040743**	**001**	Apr 26, 2007
AP	**!**		**2.5GM/50ML (50MG/ML)**	**A040798**	**002**	Apr 26, 2007
AP	**!**		**5GM/100ML (50MG/ML)**	**A040798**	**001**	Apr 26, 2007
AP	**!**	FRESENIUS KABI USA	**500MG/10ML (50MG/ML)**	**A040279**	**002**	Sep 30, 1998
AP	**!**		**1GM/20ML (50MG/ML)**	**A040279**	**001**	Sep 30, 1998
AP	**!**		**2.5GM/50ML (50MG/ML)**	**A040278**	**001**	Sep 30, 1998
AP	**!**		**5GM/100ML (50MG/ML)**	**A040278**	**002**	Sep 30, 1998
AP		GLAND PHARMA LTD	**500MG/10ML (50MG/ML)**	**A210123**	**001**	Oct 27, 2017
AP			**1GM/20ML (50MG/ML)**	**A210123**	**002**	Oct 27, 2017
AP			**2.5GM/50ML (50MG/ML)**	**A210124**	**001**	Dec 26, 2017
AP			**5GM/100ML (50MG/ML)**	**A210124**	**002**	Dec 26, 2017
AP		INGENUS PHARMS LLC	**500MG/10ML (50MG/ML)**	**A209219**	**001**	Dec 12, 2019
AP			**500MG/10ML (50MG/ML)**	**A209271**	**001**	Dec 11, 2019
AP			**1GM/20ML (50MG/ML)**	**A209219**	**002**	Dec 12, 2019
AP			**2.5GM/50ML (50MG/ML)**	**A209271**	**002**	Dec 11, 2019

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP		MYLAN LABS LTD	**2.5GM/50ML (50MG/ML)**	**A202669**	**001**	Jul 17, 2012
AP			**5GM/100ML (50MG/ML)**	**A202669**	**002**	Jul 17, 2012
AP		SAGENT PHARMS INC	**500MG/10ML (50MG/ML)**	**A203608**	**001**	May 11, 2017
AP			**1GM/20ML (50MG/ML)**	**A203608**	**002**	May 11, 2017
AP			**2.5GM/50ML (50MG/ML)**	**A203609**	**001**	Feb 17, 2016
AP			**5GM/100ML (50MG/ML)**	**A203609**	**002**	Feb 17, 2016
AP	!	TEVA PHARMS USA	**500MG/10ML (50MG/ML)**	**A040333**	**001**	Jan 27, 2000
AP	!		**2.5GM/50ML (50MG/ML)**	**A040334**	**001**	Feb 25, 2000
AP	!		**5GM/100ML (50MG/ML)**	**A040334**	**002**	Feb 25, 2000

SOLUTION;TOPICAL

EFUDEX

AT	+!	BAUSCH	**2%**	**N016831**	**001**	
AT	+!		**5%**	**N016831**	**002**	

FLUOROURACIL

AT		TARO	**2%**	**A076526**	**001**	Nov 05, 2003
AT			**5%**	**A076526**	**002**	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 40MG BASE**	**A090223**	**003**	Mar 19, 2009
AB		APNAR PHARMA LP	**EQ 40MG BASE**	**A075049**	**003**	Jan 29, 2002
AB		AUROBINDO PHARMA	**EQ 40MG BASE**	**A078619**	**003**	Jan 31, 2008
AB		CADILA PHARMS LTD	**EQ 40MG BASE**	**A206993**	**003**	May 23, 2019
AB		IVAX SUB TEVA PHARMS	**EQ 40MG BASE**	**A075245**	**003**	Sep 28, 2004
AB		MARKSANS PHARMA	**EQ 40MG BASE**	**A075465**	**003**	Aug 02, 2001
AB		SCIEGEN PHARMS INC	**EQ 40MG BASE**	**A204597**	**003**	Mar 16, 2015
AB		SUN PHARM INDS LTD	**EQ 40MG BASE**	**A076990**	**001**	Dec 13, 2004
AB		TEVA	**EQ 40MG BASE**	**A075452**	**003**	Jan 29, 2002

PROZAC

AB	+!	ELI LILLY AND CO	**EQ 40MG BASE**	**N018936**	**003**	Jun 15, 1999

FLUOXETINE HYDROCHLORIDE

AB1		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A090223**	**001**	Mar 19, 2009
AB1			**EQ 20MG BASE**	**A090223**	**002**	Mar 19, 2009
AB1		APNAR PHARMA LP	**EQ 10MG BASE**	**A075049**	**001**	Aug 02, 2001
AB1			**EQ 20MG BASE**	**A075049**	**002**	Jan 29, 2002
AB1		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078619**	**001**	Jan 31, 2008
AB1			**EQ 20MG BASE**	**A078619**	**002**	Jan 31, 2008
AB1		BARR	**EQ 10MG BASE**	**A074803**	**002**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A074803**	**001**	Aug 02, 2001
AB1		CADILA PHARMS LTD	**EQ 10MG BASE**	**A206993**	**001**	May 23, 2019
AB1			**EQ 20MG BASE**	**A206993**	**002**	May 23, 2019
AB1		IVAX SUB TEVA PHARMS	**EQ 10MG BASE**	**A075245**	**002**	Jan 31, 2002
AB1			**EQ 20MG BASE**	**A075245**	**001**	Jan 31, 2002
AB1		LANDELA PHARM	**EQ 10MG BASE**	**A075464**	**001**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A075464**	**002**	Jan 30, 2002
AB1		MARKSANS PHARMA	**EQ 10MG BASE**	**A075465**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075465**	**002**	Jan 29, 2002
AB1		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A204597**	**001**	Mar 16, 2015
AB1			**EQ 20MG BASE**	**A204597**	**002**	Mar 16, 2015
AB1		SPECGX LLC	**EQ 10MG BASE**	**A075658**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075658**	**002**	Jan 29, 2002
AB1		TEVA	**EQ 10MG BASE**	**A075452**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075452**	**002**	Jan 29, 2002
AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A076001**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A076001**	**002**	Jan 29, 2002

PROZAC

AB1	+	ELI LILLY AND CO	**EQ 10MG BASE**	**N018936**	**006**	Dec 23, 1992
AB1	+		**EQ 20MG BASE**	**N018936**	**001**	Dec 29, 1987

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

	!	DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA		LANNETT CO INC	**EQ 20MG BASE/5ML**	**A077849**	**001**	Feb 09, 2007
AA	!	PHARM ASSOC	**EQ 20MG BASE/5ML**	**A076015**	**001**	Jan 30, 2002
AA		SPECGX LLC	**EQ 20MG BASE/5ML**	**A075920**	**001**	Jan 29, 2002
AA		TEVA	**EQ 20MG BASE/5ML**	**A075506**	**001**	Aug 02, 2001

FLUOXETINE HYDROCHLORIDE

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA		WOCKHARDT BIO AG	**EQ 20MG BASE/5ML**	**A075514**	**001**	Aug 29, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A208698**	**001**	Apr 05, 2017
AB			**EQ 20MG BASE**	**A208698**	**002**	Apr 05, 2017
AB	**+!**	ALVOGEN	**EQ 60MG BASE**	**N202133**	**001**	Oct 06, 2011
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A076006**	**001**	Jan 30, 2002
AB			**EQ 20MG BASE**	**A076006**	**002**	Apr 23, 2018
AB			**EQ 60MG BASE**	**A211721**	**001**	Jan 25, 2019
AB		G AND W LABS INC	**EQ 60MG BASE**	**A212191**	**001**	Jul 05, 2019
AB		INVENTIA HLTHCARE	**EQ 60MG BASE**	**A209695**	**001**	Nov 20, 2017
AB		LUPIN LTD	**EQ 10MG BASE**	**A211653**	**001**	Apr 15, 2019
AB			**EQ 20MG BASE**	**A211653**	**002**	Apr 15, 2019
AB			**EQ 60MG BASE**	**A211632**	**001**	Feb 08, 2019
AB		MYLAN	**EQ 10MG BASE**	**A075755**	**001**	Aug 02, 2001
AB	**!**		**EQ 20MG BASE**	**A075755**	**002**	Aug 02, 2001
AB		PAR FORM	**EQ 10MG BASE**	**A203836**	**001**	Aug 19, 2016
AB			**EQ 20MG BASE**	**A203836**	**002**	Aug 19, 2016
AB		PAR PHARM INC	**EQ 60MG BASE**	**A209419**	**001**	Nov 16, 2017
AB		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A210935**	**001**	Mar 20, 2019
AB			**EQ 20MG BASE**	**A210935**	**002**	Mar 20, 2019
AB			**EQ 60MG BASE**	**A211282**	**001**	Jan 10, 2019
AB		TARO	**EQ 60MG BASE**	**A211477**	**001**	Nov 21, 2018
AB		TEVA	**EQ 10MG BASE**	**A075872**	**001**	Jan 29, 2002
AB			**EQ 20MG BASE**	**A075872**	**002**	Jan 04, 2019
AB		TEVA PHARMS USA	**EQ 60MG BASE**	**A211051**	**001**	Dec 03, 2018
AB		UPSHER SMITH LABS	**EQ 10MG BASE**	**A211696**	**001**	Jan 30, 2019
AB			**EQ 20MG BASE**	**A211696**	**002**	Jan 30, 2019
AB1		TORRENT	**EQ 10MG BASE**	**A206937**	**001**	Oct 21, 2016
AB1			**EQ 20MG BASE**	**A206937**	**002**	Oct 21, 2016

SARAFEM

AB1	**+**	APIL	**EQ 10MG BASE**	**N021860**	**001**	May 19, 2006
AB1	**+**		**EQ 15MG BASE**	**N021860**	**002**	May 19, 2006
AB1	**+!**		**EQ 20MG BASE**	**N021860**	**003**	May 19, 2006

SELFEMRA

AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A200151**	**001**	Feb 03, 2014
AB1			**EQ 15MG BASE**	**A200151**	**002**	Feb 03, 2014
AB1			**EQ 20MG BASE**	**A200151**	**003**	Feb 03, 2014

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		PAR PHARM	**EQ 25MG BASE;EQ 3MG BASE**	**A077742**	**001**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077742**	**002**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077742**	**003**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077742**	**004**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077742**	**005**	Nov 02, 2012
AB		SANDOZ	**EQ 25MG BASE;EQ 3MG BASE**	**A078901**	**005**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A078901**	**001**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A078901**	**003**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A078901**	**002**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A078901**	**004**	Nov 16, 2012
AB		TEVA PHARMS	**EQ 25MG BASE;EQ 3MG BASE**	**A202074**	**001**	Mar 25, 2013
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077528**	**001**	Jun 19, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077528**	**002**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077528**	**003**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077528**	**004**	Jun 19, 2012

SYMBYAX

AB	**+**	LILLY	**EQ 25MG BASE;EQ 3MG BASE**	**N021520**	**001**	Apr 09, 2007
AB	**+**		**EQ 25MG BASE;EQ 6MG BASE**	**N021520**	**002**	Dec 24, 2003
AB	**+**		**EQ 25MG BASE;EQ 12MG BASE**	**N021520**	**004**	Dec 24, 2003
AB	**+!**		**EQ 50MG BASE;EQ 6MG BASE**	**N021520**	**003**	Dec 24, 2003
AB	**+**		**EQ 50MG BASE;EQ 12MG BASE**	**N021520**	**005**	Dec 24, 2003

FLUOXYMESTERONE
TABLET;ORAL
FLUOXYMESTERONE

	!	UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983

FLUPHENAZINE DECANOATE
INJECTABLE;INJECTION
FLUPHENAZINE DECANOATE

AO		AUROBINDO PHARMA LTD	**25MG/ML**	**A207739**	**001**	Oct 17, 2017
AO	**!**	FRESENIUS KABI USA	**25MG/ML**	**A071413**	**001**	Jul 14, 1987
AO		MYLAN LABS LTD	**25MG/ML**	**A075918**	**001**	Aug 17, 2001
AO		PAR STERILE PRODUCTS	**25MG/ML**	**A203732**	**001**	Jul 03, 2014
AO		WEST-WARD PHARMS INT	**25MG/ML**	**A074531**	**001**	Aug 30, 1996

FLUPHENAZINE HYDROCHLORIDE
CONCENTRATE;ORAL
FLUPHENAZINE HYDROCHLORIDE

	!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996

ELIXIR;ORAL
FLUPHENAZINE HYDROCHLORIDE

	!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996

INJECTABLE;INJECTION
FLUPHENAZINE HYDROCHLORIDE

	!	FRESENIUS KABI USA	2.5MG/ML	A089556	001	Apr 16, 1987

TABLET;ORAL
FLUPHENAZINE HYDROCHLORIDE

AB		LANNETT CO INC	**1MG**	**A089743**	**002**	Aug 25, 1988
AB			**2.5MG**	**A089743**	**003**	Aug 25, 1988
AB			**5MG**	**A089743**	**004**	Aug 25, 1988
AB	**!**		**10MG**	**A089743**	**001**	Aug 25, 1988
AB		MYLAN	**1MG**	**A089804**	**002**	Aug 12, 1988
AB			**2.5MG**	**A089804**	**003**	Aug 12, 1988
AB			**5MG**	**A089804**	**004**	Aug 12, 1988
AB			**10MG**	**A089804**	**001**	Aug 12, 1988
AB		SANDOZ	**1MG**	**A089586**	**002**	Oct 16, 1987
AB			**2.5MG**	**A089586**	**003**	Oct 16, 1987
AB			**5MG**	**A089586**	**004**	Oct 16, 1987
AB			**10MG**	**A089586**	**001**	Oct 16, 1987

FLURANDRENOLIDE
CREAM;TOPICAL
CORDRAN SP

AT	**+!**	ALMIRALL	**0.05%**	**N012806**	**002**	

FLURANDRENOLIDE

AT		CINTEX SVCS	**0.05%**	**A205342**	**001**	Apr 13, 2016

CORDRAN SP

	+!	ALMIRALL	0.025%	N012806	003	

LOTION;TOPICAL
CORDRAN

AT	**+!**	ALMIRALL	**0.05%**	**N013790**	**001**	

FLURANDRENOLIDE

AT		CINTEX SVCS	**0.05%**	**A205343**	**001**	Dec 22, 2016
AT		PERRIGO UK FINCO	**0.05%**	**A207133**	**001**	Aug 30, 2016

OINTMENT;TOPICAL
CORDRAN

AT	**+!**	ALMIRALL	**0.05%**	**N012806**	**001**	

FLURANDRENOLIDE

AT		TELIGENT PHARMA INC	**0.05%**	**A207851**	**001**	Dec 30, 2016

TAPE;TOPICAL
CORDRAN

	+!	ALMIRALL	0.004MG/SQ CM	N016455	001	

FLURAZEPAM HYDROCHLORIDE
CAPSULE;ORAL
FLURAZEPAM HYDROCHLORIDE

		MYLAN PHARMS INC	15MG	A070345	002	Nov 27, 1985
	!		30MG	A070345	001	Nov 27, 1985

FLURBIPROFEN
TABLET;ORAL
FLURBIPROFEN

AB	**!**	MYLAN	**100MG**	**A074358**	**002**	Jun 20, 1994
AB		TEVA	**100MG**	**A074431**	**001**	May 31, 1995
		MYLAN	50MG	A074358	001	Jun 20, 1994

FLURBIPROFEN SODIUM
SOLUTION/DROPS;OPHTHALMIC
FLURBIPROFEN SODIUM

AT		BAUSCH AND LOMB	**0.03%**	**A074447**	**001**	Jan 04, 1995

OCUFEN

AT	**+!**	ALLERGAN	**0.03%**	**N019404**	**001**	Dec 31, 1986

FLUTAMIDE
CAPSULE;ORAL
FLUTAMIDE

AB	**!**	CIPLA	**125MG**	**A075780**	**001**	Sep 19, 2001
AB		PAR PHARM	**125MG**	**A075298**	**001**	Sep 18, 2001

FLUTEMETAMOL F-18
INJECTABLE;INTRAVENOUS
VIZAMYL

	+!	GE HEALTHCARE	121.5mCi/30ML (4.05mCi/ML)	N203137	002	Oct 25, 2013

FLUTICASONE FUROATE
POWDER;INHALATION
ARNUITY ELLIPTA

	+!	GLAXOSMITHKLINE	0.05MG/INH	N205625	003	May 17, 2018
	+!		0.1MG/INH	N205625	001	Aug 20, 2014
	+!		0.2MG/INH	N205625	002	Aug 20, 2014

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
POWDER;INHALATION
TRELEGY ELLIPTA

	+!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	001	Sep 18, 2017

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE
POWDER;INHALATION
BREO ELLIPTA

	+!	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013
	+!		0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015

FLUTICASONE PROPIONATE
AEROSOL, METERED;INHALATION
FLOVENT HFA

	+!	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
	+!		0.11MG/INH	N021433	002	May 14, 2004
	+!		0.22MG/INH	N021433	001	May 14, 2004

CREAM;TOPICAL
FLUTICASONE PROPIONATE

AB		ACP NIMBLE	**0.05%**	**A077055**	**001**	Jun 30, 2006
AB		ANDA REPOSITORY	**0.05%**	**A076633**	**001**	May 14, 2004
AB		FOUGERA PHARMS	**0.05%**	**A076451**	**001**	May 14, 2004
AB	**!**	PERRIGO ISRAEL	**0.05%**	**A076793**	**001**	May 14, 2004

LOTION;TOPICAL
CUTIVATE

AB	**+!**	FOUGERA PHARMS	**0.05%**	**N021152**	**001**	Mar 31, 2005

FLUTICASONE PROPIONATE

AB		GLENMARK GENERICS	**0.05%**	**A090759**	**001**	May 02, 2011
AB		PERRIGO ISRAEL	**0.05%**	**A091553**	**001**	Jul 30, 2013

OINTMENT;TOPICAL
FLUTICASONE PROPIONATE

AB		ACP NIMBLE	**0.005%**	**A077168**	**001**	Mar 03, 2006
AB	**!**	PERRIGO NEW YORK	**0.005%**	**A076668**	**001**	May 14, 2004

POWDER;INHALATION
FLOVENT DISKUS 100

	+!	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000

FLOVENT DISKUS 250

	+!	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000

FLOVENT DISKUS 50

	+!	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000

SPRAY, METERED;NASAL
FLUTICASONE PROPIONATE

AB		APOTEX INC	**0.05MG/SPRAY**	**A077538**	**001**	Sep 12, 2007

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

AB		HI TECH PHARMA	**0.05MG/SPRAY**	**A077570**	**001**	Jan 16, 2008
AB	**!**	HIKMA	**0.05MG/SPRAY**	**A076504**	**001**	Feb 22, 2006
AB		WOCKHARDT BIO AG	**0.05MG/SPRAY**	**A078492**	**001**	Jan 09, 2012

XHANCE

	+!	OPTINOSE US INC	0.093MG	N209022	001	Sep 18, 2017

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED;INHALATION

ADVAIR HFA

	+!	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
	+!		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
	+!		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER;INHALATION

ADVAIR DISKUS 100/50

AB	**+!**	GLAXO GRP LTD	**0.1MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**001**	Aug 24, 2000

ADVAIR DISKUS 250/50

AB	**+!**	GLAXO GRP LTD	**0.25MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**002**	Aug 24, 2000

ADVAIR DISKUS 500/50

AB	**+!**	GLAXO GRP LTD	**0.5MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**003**	Aug 24, 2000

WIXELA INHUB

AB		MYLAN	**0.1MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**001**	Jan 30, 2019
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**002**	Jan 30, 2019
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**003**	Jan 30, 2019

AIRDUO DIGIHALER

	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019
	+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019
	+		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019

AIRDUO RESPICLICK

	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017
	+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017
	+!		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017

FLUVASTATIN SODIUM

CAPSULE;ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090595**	**001**	Apr 11, 2012
AB	**!**		**EQ 40MG BASE**	**A090595**	**002**	Apr 11, 2012
AB		TEVA PHARMS	**EQ 20MG BASE**	**A078407**	**001**	Jun 12, 2012
AB			**EQ 40MG BASE**	**A078407**	**002**	Jun 12, 2012

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB		TEVA PHARMS USA	**EQ 80MG BASE**	**A079011**	**001**	Jan 27, 2016

LESCOL XL

AB	**+!**	NOVARTIS	**EQ 80MG BASE**	**N021192**	**001**	Oct 06, 2000

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB		ACTAVIS ELIZABETH	**100MG**	**A091482**	**001**	Apr 23, 2013
AB	**!**		**150MG**	**A091482**	**002**	Nov 18, 2013
AB		ANCHEN PHARMS	**100MG**	**A091476**	**001**	Mar 13, 2013
AB			**150MG**	**A091476**	**002**	Mar 13, 2013
AB		TORRENT	**100MG**	**A203240**	**001**	Oct 31, 2014
AB			**150MG**	**A203240**	**002**	Oct 31, 2014

TABLET;ORAL

FLUVOXAMINE MALEATE

AB		APOTEX	**25MG**	**A075902**	**001**	May 07, 2001
AB			**50MG**	**A075902**	**002**	May 07, 2001
AB			**100MG**	**A075902**	**003**	May 07, 2001
AB		TEVA	**25MG**	**A075893**	**001**	Sep 10, 2002
AB			**50MG**	**A075893**	**002**	Sep 10, 2002
AB			**100MG**	**A075893**	**003**	Sep 10, 2002
AB		UPSHER SMITH LABS	**25MG**	**A075888**	**001**	Nov 29, 2000
AB			**50MG**	**A075888**	**002**	Nov 29, 2000
AB	**!**		**100MG**	**A075888**	**003**	Nov 29, 2000

LUVOX

AB		ANI PHARMS	**25MG**	**N021519**	**001**	Dec 20, 2007
AB			**50MG**	**N021519**	**002**	Dec 20, 2007
AB			**100MG**	**N021519**	**003**	Dec 20, 2007

PRESCRIPTION DRUG PRODUCT LIST

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

AP		EXELA PHARMA SCS LLC	**5MG/ML**	**A202522**	**001**	Nov 06, 2019
AP	**!**	FRESENIUS KABI USA	**5MG/ML**	**A089202**	**001**	Feb 18, 1986

TABLET;ORAL

FOLIC ACID

AA	**!**	AMNEAL PHARM	**1MG**	**A040625**	**001**	Jul 21, 2005
AA		ATHEM	**1MG**	**A211064**	**001**	Mar 08, 2019
AA		CADILA PHARMS LTD	**1MG**	**A202437**	**001**	Jan 27, 2014
AA		CHARTWELL MOLECULAR	**1MG**	**A090035**	**001**	Jun 09, 2009
AA		HIKMA PHARMS	**1MG**	**A080600**	**001**	
AA		LEADING PHARMA LLC	**1MG**	**A040796**	**001**	Jan 12, 2009
AA		NUVO PHARMS INC	**1MG**	**A204418**	**001**	Jul 28, 2015
AA		QINGDAO BAHEAL PHARM	**1MG**	**A091145**	**001**	Jul 12, 2013
AA		VINTAGE	**1MG**	**A040756**	**001**	Jun 04, 2010
AA	**!**	WATSON LABS	**1MG**	**A080680**	**001**	

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

FOLLISTIM AQ

+!	ORGANON USA INC	300 IU/0.36ML	N021211	001	Mar 23, 2004
+!		600 IU/0.72ML	N021211	002	Mar 23, 2004
+!		900 IU/1.08ML	N021211	004	Feb 11, 2005

GONAL-F

+!	EMD SERONO	450 IU/VIAL	N020378	005	Mar 26, 2004
+		1,050 IU/VIAL	N020378	004	Feb 28, 2001

GONAL-F RFF

+!	EMD SERONO	75 IU/VIAL	N021765	002	Mar 25, 2004

GONAL-F RFF REDI-JECT

+!	EMD SERONO	150 IU/0.25ML	N021684	004	Nov 25, 2019
+!		300 IU/0.5ML	N021684	001	May 25, 2004
+!		450 IU/0.75ML	N021684	002	May 25, 2004
+!		900 IU/1.5ML	N021684	003	May 25, 2004

FOMEPIZOLE

INJECTABLE;INJECTION

FOMEPIZOLE

AP		AM REGENT	**1.5GM/1.5ML (1GM/ML)**	**A078368**	**001**	Dec 14, 2007
AP	**!**	MYLAN INSTITUTIONAL	**1.5GM/1.5ML (1GM/ML)**	**A078639**	**001**	Mar 03, 2008
AP		NAVINTA LLC	**1.5GM/1.5ML (1GM/ML)**	**A078537**	**001**	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

ARIXTRA

AP	**+!**	MYLAN IRELAND LTD	**2.5MG/0.5ML**	**N021345**	**001**	Dec 07, 2001
AP	**+!**		**5MG/0.4ML**	**N021345**	**002**	May 28, 2004
AP	**+!**		**7.5MG/0.6ML**	**N021345**	**003**	May 28, 2004
AP	**+!**		**10MG/0.8ML**	**N021345**	**004**	May 28, 2004

FONDAPARINUX SODIUM

AP	AUROBINDO PHARMA LTD	**2.5MG/0.5ML**	**A206918**	**001**	Dec 26, 2017
AP		**5MG/0.4ML**	**A206918**	**002**	Dec 26, 2017
AP		**7.5MG/0.6ML**	**A206918**	**003**	Dec 26, 2017
AP		**10MG/0.8ML**	**A206918**	**004**	Dec 26, 2017
AP	DR REDDYS LABS LTD	**2.5MG/0.5ML**	**A091316**	**001**	Jul 11, 2011
AP		**5MG/0.4ML**	**A091316**	**002**	Jul 11, 2011
AP		**7.5MG/0.6ML**	**A091316**	**003**	Jul 11, 2011
AP		**10MG/0.8ML**	**A091316**	**004**	Jul 11, 2011
AP	JIANGSU HENGRUI MED	**2.5MG/0.5ML**	**A206812**	**001**	May 15, 2018
AP		**5MG/0.4ML**	**A206812**	**002**	May 15, 2018
AP		**7.5MG/0.6ML**	**A206812**	**003**	May 15, 2018
AP		**10MG/0.8ML**	**A206812**	**004**	May 15, 2018
AP	SCINOPHARM TAIWAN	**2.5MG/0.5ML**	**A208615**	**001**	Nov 14, 2018
AP		**5MG/0.4ML**	**A208615**	**002**	Nov 14, 2018
AP		**7.5MG/0.6ML**	**A208615**	**003**	Nov 14, 2018
AP		**10MG/0.8ML**	**A208615**	**004**	Nov 14, 2018

FORMOTEROL FUMARATE
SOLUTION;INHALATION
PERFOROMIST

+!	MYLAN SPECLT	0.02MG/2ML	N022007	001	May 11, 2007

FORMOTEROL FUMARATE; GLYCOPYRROLATE
AEROSOL, METERED;INHALATION
BEVESPI AEROSPHERE

+!	ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016

FORMOTEROL FUMARATE; MOMETASONE FUROATE
AEROSOL, METERED;INHALATION
DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019
+!		0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010
+!		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM
SUSPENSION;ORAL
LEXIVA

+!	VIIV HLTHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007

TABLET;ORAL

FOSAMPRENAVIR CALCIUM						
AB		MYLAN	**EQ 700MG BASE**	**A204060**	**001**	Apr 15, 2016
AB		SUN PHARM	**EQ 700MG BASE**	**A204024**	**001**	Nov 20, 2019
LEXIVA						
AB	**+!**	VIIV HLTHCARE	**EQ 700MG BASE**	**N021548**	**001**	Oct 20, 2003

FOSAPREPITANT DIMEGLUMINE
POWDER;INTRAVENOUS

EMEND						
AP	**+!**	MERCK AND CO INC	**EQ 150MG BASE/VIAL**	**N022023**	**002**	Nov 12, 2010
FOSAPREPITANT DIMEGLUMINE						
AP		APOTEX	**EQ 150MG BASE/VIAL**	**A205020**	**001**	Sep 05, 2019
AP		BAXTER HLTHCARE CORP	**EQ 150MG BASE/VIAL**	**A211860**	**001**	Sep 05, 2019
AP		BE PHARMS	**EQ 150MG BASE/VIAL**	**A212309**	**001**	Sep 05, 2019
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A206197**	**001**	Jun 09, 2016
AP		LUPIN LTD	**EQ 150MG BASE/VIAL**	**A210689**	**001**	Sep 05, 2019
AP		MSN	**EQ 150MG BASE/VIAL**	**A209965**	**001**	Sep 05, 2019
AP		MYLAN LABS LTD	**EQ 150MG BASE/VIAL**	**A204015**	**002**	Sep 05, 2019
AP		SUNGEN PHARMA	**EQ 150MG BASE/VIAL**	**A211624**	**001**	Sep 05, 2019
		MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019
		TEVA PHARMS USA	EQ 150MG BASE/VIAL	N210064	001	Sep 05, 2019

FOSCARNET SODIUM
INJECTABLE;INJECTION
FOSCAVIR

+!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991

FOSFOMYCIN TROMETHAMINE
FOR SOLUTION;ORAL
MONUROL

+!	ZAMBON SPA	EQ 3GM BASE/PACKET	N050717	001	Dec 19, 1996

FOSINOPRIL SODIUM
TABLET;ORAL

FOSINOPRIL SODIUM						
AB		APOTEX INC	**10MG**	**A076906**	**001**	May 17, 2005
AB			**20MG**	**A076906**	**002**	May 17, 2005
AB			**40MG**	**A076906**	**003**	May 17, 2005
AB		AUROBINDO PHARMA LTD	**10MG**	**A091163**	**001**	Mar 30, 2011
AB			**20MG**	**A091163**	**002**	Mar 30, 2011
AB			**40MG**	**A091163**	**003**	Mar 30, 2011
AB		INVAGEN PHARMS	**10MG**	**A077222**	**001**	Apr 20, 2005
AB			**20MG**	**A077222**	**002**	Apr 20, 2005
AB			**40MG**	**A077222**	**003**	Apr 20, 2005
AB		PRINSTON INC	**10MG**	**A205670**	**001**	Aug 29, 2016
AB			**20MG**	**A205670**	**002**	Aug 29, 2016
AB			**40MG**	**A205670**	**003**	Aug 29, 2016
AB		TEVA	**10MG**	**A076139**	**001**	Nov 25, 2003
AB			**20MG**	**A076139**	**002**	Nov 25, 2003
AB	**!**		**40MG**	**A076139**	**003**	Nov 25, 2003
AB		UPSHER SMITH LABS	**10MG**	**A076483**	**001**	Apr 23, 2004
AB			**20MG**	**A076483**	**002**	Apr 23, 2004

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

AB			**40MG**	**A076483**	**003**	Apr 23, 2004

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**10MG;12.5MG**	**A079245**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A079245**	**002**	Jul 09, 2009
AB		EMCURE PHARMS LTD	**10MG;12.5MG**	**A079025**	**001**	Sep 17, 2010
AB	**!**		**20MG;12.5MG**	**A079025**	**002**	Sep 17, 2010
AB		INVAGEN PHARMS	**10MG;12.5MG**	**A090228**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A090228**	**002**	Jul 09, 2009
AB		SANDOZ	**10MG;12.5MG**	**A076961**	**001**	Sep 28, 2005
AB			**20MG;12.5MG**	**A076961**	**002**	Sep 28, 2005

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER;INTRAVENOUS

AKYNZEO

	+!	HELSINN HLTHCARE	EQ 235MG BASE;EQ 0.25MG BASE	N210493	001	Apr 19, 2018

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

CEREBYX

AP	**+!**	PARKE DAVIS	**EQ 50MG PHENYTOIN NA/ML**	**N020450**	**001**	Aug 05, 1996

FOSPHENYTOIN SODIUM

AP		AMNEAL	**EQ 50MG PHENYTOIN NA/ML**	**A078476**	**001**	Mar 18, 2008
AP		FRESENIUS KABI USA	**EQ 50MG PHENYTOIN NA/ML**	**A078052**	**001**	Aug 06, 2007
AP		HIKMA FARMACEUTICA	**EQ 50MG PHENYTOIN NA/ML**	**A078765**	**001**	Dec 02, 2009
AP		MYLAN LABS LTD	**EQ 50MG PHENYTOIN NA/ML**	**A078736**	**001**	Jun 08, 2010
AP		SUN PHARM	**EQ 50MG PHENYTOIN NA/ML**	**A078417**	**001**	Mar 18, 2008
AP		WEST-WARD PHARMS INT	**EQ 50MG PHENYTOIN NA/ML**	**A077481**	**001**	Aug 06, 2007
AP			**EQ 50MG PHENYTOIN NA/ML**	**A077989**	**001**	Aug 06, 2007
AP		WOCKHARDT	**EQ 50MG PHENYTOIN NA/ML**	**A078137**	**001**	Aug 06, 2007

FOSTAMATINIB DISODIUM

TABLET;ORAL

TAVALISSE

	+	RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018
	+!		EQ 150MG BASE	N209299	002	Apr 17, 2018

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVA

AB	**+!**	ENDO PHARMS	**EQ 2.5MG BASE**	**N021006**	**001**	Nov 08, 2001

FROVATRIPTAN SUCCINATE

AB		AMNEAL PHARMS CO	**EQ 2.5MG BASE**	**A211292**	**001**	Nov 06, 2018
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**	**A204730**	**001**	Mar 11, 2016
AB		MYLAN	**EQ 2.5MG BASE**	**A202931**	**001**	Aug 28, 2014

FULVESTRANT

INJECTABLE;INTRAMUSCULAR

FASLODEX

AO	**+!**	ASTRAZENECA	**50MG/ML**	**N021344**	**001**	Apr 25, 2002

FULVESTRANT

AO		AMNEAL	**50MG/ML**	**A210044**	**001**	Mar 04, 2019
AO		GLENMARK PHARMS INC	**50MG/ML**	**A207754**	**001**	Aug 22, 2019
AO		HBT LABS INC	**50MG/ML**	**A209714**	**001**	Nov 21, 2019
AO		MYLAN INSTITUTIONAL	**50MG/ML**	**A208811**	**001**	Jul 23, 2019
AO		SAGENT PHARMS INC	**50MG/ML**	**A205871**	**001**	Aug 22, 2019
AO		SANDOZ INC	**50MG/ML**	**A205935**	**001**	May 14, 2019

SOLUTION;INTRAMUSCULAR

FULVESTRANT

		FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019
		TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		AMNEAL PHARMS CO	**10MG/ML**	**A207552**	**001**	Jul 20, 2016
AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A212174**	**001**	May 03, 2019
AP	**!**	BAXTER HLTHCARE CORP	**10MG/ML**	**A202747**	**001**	Jan 27, 2014

FUROSEMIDE							
INJECTABLE;INJECTION							
FUROSEMIDE							
AP		EMCURE PHARMS LTD	**10MG/ML**	**A203428**	**001**	Aug 26, 2014
AP		FRESENIUS KABI USA	**10MG/ML**	**N018902**	**001**	May 22, 1984
AP		HOSPIRA	**10MG/ML**	**A075241**	**001**	May 28, 1999
AP			**10MG/ML**	**N018667**	**001**	May 28, 1982
AP		WOCKHARDT	**10MG/ML**	**A077941**	**001**	Mar 22, 2007
SOLUTION;ORAL							
FUROSEMIDE							
AA	!	HIKMA	**10MG/ML**	**A070434**	**001**	Apr 22, 1987
AA		WOCKHARDT BIO AG	**10MG/ML**	**A070655**	**001**	Oct 02, 1987
		HIKMA	40MG/5ML	A070433	001	Apr 22, 1987
TABLET;ORAL							
FUROSEMIDE							
AB		AVET	**20MG**	**N018413**	**001**	Nov 30, 1983
AB			**40MG**	**N018413**	**002**	Nov 30, 1983
AB		HIKMA	**20MG**	**N018823**	**001**	Nov 10, 1983
AB			**40MG**	**N018823**	**002**	Nov 10, 1983
AB			**80MG**	**A070086**	**001**	Jan 24, 1986
AB		IPCA LABS LTD	**20MG**	**A078010**	**001**	Sep 18, 2006
AB			**40MG**	**A078010**	**002**	Sep 18, 2006
AB			**80MG**	**A078010**	**003**	Sep 18, 2006
AB		LEADING PHARMA LLC	**20MG**	**A077293**	**001**	Nov 09, 2005
AB			**40MG**	**A077293**	**002**	Nov 09, 2005
AB			**80MG**	**A077293**	**003**	Nov 09, 2005
AB		MYLAN	**20MG**	**N018487**	**001**	
AB			**40MG**	**N018487**	**002**	
AB			**80MG**	**A070082**	**001**	Oct 29, 1986
AB		PRINSTON INC	**20MG**	**A076796**	**001**	Mar 26, 2004
AB			**40MG**	**A076796**	**002**	Mar 26, 2004
AB			**80MG**	**A076796**	**003**	Mar 26, 2004
AB		SANDOZ	**20MG**	**N018569**	**002**	
AB			**40MG**	**N018569**	**001**	
AB			**80MG**	**N018569**	**005**	Aug 14, 1984
LASIX							
AB	+	US PHARM HOLDINGS	**20MG**	**N016273**	**002**	
AB	+		**40MG**	**N016273**	**001**	
AB	+!		**80MG**	**N016273**	**003**	
GABAPENTIN							
CAPSULE;ORAL							
GABAPENTIN							
AB		ACI HEALTHCARE LTD	**100MG**	**A206943**	**001**	May 14, 2018
AB			**300MG**	**A206943**	**002**	May 14, 2018
AB			**400MG**	**A206943**	**003**	May 14, 2018
AB		ACTAVIS ELIZABETH	**100MG**	**A075350**	**001**	Sep 12, 2003
AB			**300MG**	**A075350**	**002**	Sep 12, 2003
AB			**400MG**	**A075350**	**003**	Sep 12, 2003
AB		ALKEM	**100MG**	**A090858**	**001**	Dec 17, 2010
AB			**300MG**	**A090858**	**002**	Dec 17, 2010
AB			**400MG**	**A090858**	**003**	Dec 17, 2010
AB		AMNEAL PHARMS NY	**100MG**	**A078428**	**001**	Jul 25, 2007
AB			**300MG**	**A078428**	**002**	Jul 25, 2007
AB			**400MG**	**A078428**	**003**	Jul 25, 2007
AB		AUROBINDO PHARMA LTD	**100MG**	**A078787**	**001**	Jan 31, 2008
AB			**300MG**	**A078787**	**002**	Jan 31, 2008
AB			**400MG**	**A078787**	**003**	Jan 31, 2008
AB		EPIC PHARMA LLC	**100MG**	**A207099**	**001**	Mar 24, 2017
AB			**300MG**	**A207099**	**002**	Mar 24, 2017
AB			**400MG**	**A207099**	**003**	Mar 24, 2017
AB		GRANULES INDIA LTD	**100MG**	**A075360**	**001**	Apr 06, 2005
AB			**300MG**	**A075360**	**002**	Apr 06, 2005
AB			**400MG**	**A075360**	**003**	Apr 06, 2005
AB		INVAGEN PHARMS	**100MG**	**A090705**	**001**	Dec 30, 2009
AB			**300MG**	**A090705**	**002**	Dec 30, 2009
AB			**400MG**	**A090705**	**003**	Dec 30, 2009
AB		JIANGSU HENGRUI MED	**100MG**	**A091008**	**001**	Oct 26, 2017
AB			**300MG**	**A091008**	**002**	Oct 26, 2017
AB			**400MG**	**A091008**	**003**	Oct 26, 2017
AB		MARKSANS PHARMA	**100MG**	**A090007**	**001**	Jul 21, 2011
AB			**300MG**	**A090007**	**002**	Jul 21, 2011

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN						
AB		**400MG**	**A090007**	**003**	Jul 21, 2011
AB	MYLAN	**100MG**	**A090158**	**001**	Feb 14, 2011
AB		**300MG**	**A090158**	**002**	Feb 14, 2011
AB		**400MG**	**A090158**	**003**	Feb 14, 2011
AB	SCIEGEN PHARMS INC	**100MG**	**A204989**	**001**	Feb 18, 2016
AB		**300MG**	**A204989**	**002**	Feb 18, 2016
AB		**400MG**	**A204989**	**003**	Feb 18, 2016
AB	STRIDES PHARMA	**100MG**	**A211314**	**001**	Oct 16, 2018
AB		**300MG**	**A211314**	**002**	Oct 16, 2018
AB		**400MG**	**A211314**	**003**	Oct 16, 2018
AB	SUN PHARM INDS LTD	**100MG**	**A077242**	**001**	Aug 24, 2006
AB		**300MG**	**A077242**	**002**	Aug 24, 2006
AB		**400MG**	**A077242**	**003**	Aug 24, 2006
AB	TARO	**100MG**	**A077261**	**001**	Aug 02, 2013
AB		**300MG**	**A077261**	**002**	Aug 02, 2013
AB		**400MG**	**A077261**	**003**	Aug 02, 2013
AB	TEVA PHARMS	**100MG**	**A075435**	**001**	Oct 08, 2004
AB		**300MG**	**A075435**	**002**	Oct 08, 2004
AB		**400MG**	**A075435**	**003**	Oct 08, 2004
NEURONTIN					
AB +	PFIZER PHARMS	**100MG**	**N020235**	**001**	Dec 30, 1993
AB +		**300MG**	**N020235**	**002**	Dec 30, 1993
AB +!		**400MG**	**N020235**	**003**	Dec 30, 1993

SOLUTION;ORAL

GABAPENTIN					
AA	ACELLA PHARMS LLC	**250MG/5ML**	**A076403**	**001**	May 01, 2012
AA	AMNEAL PHARMS	**250MG/5ML**	**A202024**	**001**	Mar 23, 2012
AA	HI TECH PHARMA	**250MG/5ML**	**A078974**	**001**	Feb 18, 2011
AA	TARO	**250MG/5ML**	**A076672**	**001**	Jul 03, 2013
AA	TRIS PHARMA INC	**250MG/5ML**	**A091286**	**001**	Mar 14, 2016
AA	VISTAPHARM	**250MG/5ML**	**A211330**	**001**	Dec 03, 2019
NEURONTIN					
AA +!	PARKE DAVIS	**250MG/5ML**	**N021129**	**001**	Mar 02, 2000

TABLET;ORAL

GABAPENTIN					
AB	ACI HEALTHCARE LTD	**600MG**	**A203244**	**002**	Jul 12, 2013
AB		**800MG**	**A203244**	**001**	Jul 12, 2013
AB	ACTAVIS ELIZABETH	**600MG**	**A075694**	**001**	Oct 21, 2004
AB		**800MG**	**A075694**	**002**	Oct 21, 2004
AB	ALKEM LABS LTD	**600MG**	**A206402**	**001**	Dec 23, 2015
AB		**800MG**	**A206402**	**002**	Dec 23, 2015
AB	APOTEX INC	**100MG**	**A077894**	**001**	Oct 10, 2006
AB		**300MG**	**A077894**	**002**	Oct 10, 2006
AB		**400MG**	**A077894**	**003**	Oct 10, 2006
AB	AUROBINDO PHARMA LTD	**600MG**	**A200651**	**001**	Oct 06, 2011
AB		**800MG**	**A200651**	**002**	Oct 06, 2011
AB	CSPC OUYI	**600MG**	**A207057**	**001**	Oct 26, 2017
AB		**800MG**	**A207057**	**002**	Oct 26, 2017
AB	GLENMARK PHARMS LTD	**600MG**	**A077662**	**001**	Aug 18, 2006
AB		**800MG**	**A077662**	**002**	Aug 18, 2006
AB	INVAGEN PHARMS	**600MG**	**A202764**	**001**	Oct 16, 2012
AB		**800MG**	**A202764**	**002**	Oct 16, 2012
AB	IVAX SUB TEVA PHARMS	**100MG**	**A076017**	**001**	Apr 28, 2004
AB		**300MG**	**A076017**	**002**	Apr 28, 2004
AB		**400MG**	**A076017**	**003**	Apr 28, 2004
AB	MYLAN PHARMS INC	**600MG**	**A090335**	**001**	Jun 01, 2010
AB		**800MG**	**A090335**	**002**	Jun 01, 2010
AB	RUBICON	**600MG**	**A077661**	**004**	Sep 13, 2006
AB		**800MG**	**A077661**	**005**	Sep 13, 2006
AB	SCIEGEN PHARMS INC	**600MG**	**A205101**	**001**	Feb 04, 2016
AB		**800MG**	**A205101**	**002**	Feb 04, 2016
AB	SUN PHARM INDS LTD	**600MG**	**A077525**	**001**	Aug 24, 2006
AB		**800MG**	**A077525**	**002**	Aug 24, 2006
AB	TEVA PHARMS USA	**600MG**	**A205807**	**001**	Mar 10, 2017
AB		**800MG**	**A205807**	**002**	Mar 10, 2017
AB	ZYDUS PHARMS USA INC	**600MG**	**A078926**	**001**	Feb 11, 2011
AB		**800MG**	**A078926**	**002**	Feb 11, 2011

GABAPENTIN

TABLET;ORAL

NEURONTIN

AB	**+**	PFIZER PHARMS	**600MG**	**N020882**	**001**	Oct 09, 1998
AB	**+!**		**800MG**	**N020882**	**002**	Oct 09, 1998

GRALISE

BX	+!	ASSERTIO	300MG	N022544	001	Jan 28, 2011
BX	+!		600MG	N022544	002	Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL

HORIZANT

	+	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011
	+!		600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE;INTRAVENOUS

MULTIHANCE

	+!	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
	+!		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
	+!		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
	+!		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

	+!	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
	+!		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION;INTRAVENOUS

GADAVIST

	+!	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006	Dec 18, 2013
	+!		4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011
	+!		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011
	+!		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011
	+!		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011
	+!		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011

GADODIAMIDE

INJECTABLE;INJECTION

OMNISCAN

	+!	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
	+!		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

CLARISCAN

AP		GE HEALTHCARE	**7.538GM/20ML (376.9MG/ML)**	**A210016**	**003**	Nov 01, 2019
AP			**3.769GM/10ML (376.9MG/ML)**	**A210016**	**001**	Nov 01, 2019
AP			**5.6535GM/15ML (376.9MG/ML)**	**A210016**	**002**	Nov 01, 2019

DOTAREM

AP	**+!**	GUERBET	**3.769GM/10ML (376.9MG/ML)**	**N204781**	**002**	Mar 20, 2013
AP	**+!**		**5.6535GM/15ML (376.9MG/ML)**	**N204781**	**003**	Mar 20, 2013
AP	**+!**		**7.538GM/20ML (376.9MG/ML)**	**N204781**	**004**	Mar 20, 2013
	+!		37.69GM/100ML (376.9MG/ML)	N204781	001	Mar 20, 2013
	+!		1.8845GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017

GADOTERIDOL

INJECTABLE;INJECTION

PROHANCE

	+!	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992

PROHANCE MULTIPACK

	+!	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003

GADOXETATE DISODIUM

SOLUTION;INTRAVENOUS

EOVIST

	+!	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001	Jul 03, 2008
	+		2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	**EQ 8MG BASE**	**A204895**	**001**	Aug 05, 2016
AB			**EQ 16MG BASE**	**A204895**	**002**	Aug 05, 2016
AB			**EQ 24MG BASE**	**A204895**	**003**	Aug 05, 2016
AB		BARR	**EQ 8MG BASE**	**A078189**	**001**	Sep 15, 2008
AB			**EQ 16MG BASE**	**A078189**	**002**	Sep 15, 2008

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB			**EQ 24MG BASE**	**A078189**	**003**	Sep 15, 2008
AB		SUN PHARM	**EQ 8MG BASE**	**A090178**	**001**	Feb 02, 2011
AB			**EQ 16MG BASE**	**A090178**	**002**	Feb 02, 2011
AB			**EQ 24MG BASE**	**A090178**	**003**	Feb 02, 2011
AB		WATSON LABS	**EQ 8MG BASE**	**A079028**	**001**	Dec 15, 2008
AB			**EQ 16MG BASE**	**A079028**	**002**	Dec 15, 2008
AB			**EQ 24MG BASE**	**A079028**	**003**	Dec 15, 2008

RAZADYNE ER

AB	**+!**	JANSSEN PHARMS	**EQ 8MG BASE**	**N021615**	**001**	Apr 01, 2005
AB	**+**		**EQ 16MG BASE**	**N021615**	**002**	Apr 01, 2005
AB	**+**		**EQ 24MG BASE**	**N021615**	**003**	Apr 01, 2005

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

	!	HIKMA	4MG/ML	A078185	001	Jan 30, 2009

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB		APOTEX INC	**EQ 4MG BASE**	**A077781**	**001**	Sep 27, 2011
AB			**EQ 8MG BASE**	**A077781**	**002**	Sep 27, 2011
AB			**EQ 12MG BASE**	**A077781**	**003**	Sep 27, 2011
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A090957**	**001**	Mar 29, 2011
AB			**EQ 8MG BASE**	**A090957**	**002**	Mar 29, 2011
AB			**EQ 12MG BASE**	**A090957**	**003**	Mar 29, 2011
AB		BARR	**EQ 4MG BASE**	**A077605**	**001**	Aug 28, 2008
AB			**EQ 8MG BASE**	**A077605**	**002**	Aug 28, 2008
AB			**EQ 12MG BASE**	**A077605**	**003**	Aug 28, 2008
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A077593**	**001**	Sep 11, 2008
AB			**EQ 8MG BASE**	**A077593**	**002**	Sep 11, 2008
AB			**EQ 12MG BASE**	**A077593**	**003**	Sep 11, 2008
AB		HIKMA	**EQ 4MG BASE**	**A077608**	**001**	Feb 11, 2009
AB			**EQ 8MG BASE**	**A077608**	**002**	Feb 11, 2009
AB			**EQ 12MG BASE**	**A077608**	**003**	Feb 11, 2009
AB		SANDOZ	**EQ 4MG BASE**	**A077589**	**001**	Jun 22, 2009
AB			**EQ 8MG BASE**	**A077589**	**002**	Jun 22, 2009
AB			**EQ 12MG BASE**	**A077589**	**003**	Jun 22, 2009
AB		YABAO PHARM	**EQ 4MG BASE**	**A077604**	**001**	Feb 06, 2009
AB			**EQ 8MG BASE**	**A077604**	**002**	Feb 06, 2009
AB			**EQ 12MG BASE**	**A077604**	**003**	Feb 06, 2009
AB		ZYDUS PHARMS USA INC	**EQ 4MG BASE**	**A078898**	**001**	Feb 17, 2011
AB			**EQ 8MG BASE**	**A078898**	**002**	Feb 17, 2011
AB			**EQ 12MG BASE**	**A078898**	**003**	Feb 17, 2011

RAZADYNE

AB	**+!**	JANSSEN PHARMS	**EQ 4MG BASE**	**N021169**	**001**	Feb 28, 2001
AB	**+**		**EQ 8MG BASE**	**N021169**	**002**	Feb 28, 2001
AB	**+**		**EQ 12MG BASE**	**N021169**	**003**	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS		CURIUM	2mCi/ML	N018058	001	
BS		LANTHEUS MEDCL	2mCi/ML	N017478	001	

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

	+!	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016

GALLIUM DOTATOC GA-68

SOLUTION;INTRAVENOUS

GALLIUM DOTATOC GA 68

	+!	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

	+!	BAUSCH AND LOMB	0.15%	N022211	001	Sep 15, 2009

GANCICLOVIR

SOLUTION;INTRAVENOUS

GANZYK-RTU

	+!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347 001	Feb 17, 2017

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

CYTOVENE

AP	**+!**	CHEPLAPHARM	**EQ 500MG BASE/VIAL**	**N019661 001**	Jun 23, 1989

GANCICLOVIR SODIUM

AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090658 001**	Jun 21, 2010
AP		HAINAN POLY PHARM	**EQ 500MG BASE/VIAL**	**A204204 001**	Nov 08, 2018
AP		MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A204560 001**	Nov 17, 2017
AP		PAR STERILE PRODUCTS	**EQ 500MG BASE/VIAL**	**A204950 001**	Dec 06, 2016
AP		PHARMASCIENCE INC	**EQ 500MG BASE/VIAL**	**A207645 001**	Dec 08, 2017

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

AP	**+!**	ORGANON USA INC	**250MCG/0.5ML**	**N021057 001**	Jul 29, 1999
AP		SUN PHARM	**250MCG/0.5ML**	**A204246 001**	Nov 30, 2018

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

AT		HI-TECH PHARMA CO	**0.5%**	**A203189 001**	Sep 03, 2014
AT		LUPIN LTD	**0.5%**	**A202653 001**	Aug 28, 2013
AT		MYLAN	**0.5%**	**A206446 001**	Jun 08, 2018
AT		SANDOZ INC	**0.5%**	**A204227 001**	Jul 11, 2016

ZYMAXID

AT	**+!**	ALLERGAN	**0.5%**	**N022548 001**	May 18, 2010

ZYMAR

	+!	ALLERGAN	0.3%	N021493 001	Mar 28, 2003

GEFITINIB

TABLET;ORAL

IRESSA

	+!	ASTRAZENECA PHARMS	250MG	N206995 001	Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 200MG BASE/VIAL**	**A091594 001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091594 002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A091594 003**	Jul 25, 2011
AP		APOTEX	**200MG/5.26ML (38MG/ML)**	**A206776 001**	May 23, 2017
AP			**1GM/26.3ML (38MG/ML)**	**A206776 002**	May 23, 2017
AP			**2GM/52.6ML (38MG/ML)**	**A206776 003**	May 23, 2017
AP		CIPLA	**EQ 200MG BASE/VIAL**	**A078759 001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078759 002**	Jul 25, 2011
AP		DR REDDYS LABS LTD	**EQ 200MG BASE/VIAL**	**A091365 001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091365 002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A202997 001**	May 07, 2013
AP		EMCURE PHARMS LTD	**EQ 200MG BASE/VIAL**	**A202063 001**	Sep 11, 2012
AP			**EQ 1GM BASE/VIAL**	**A202063 002**	Sep 11, 2012
AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A090799 001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A090799 002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A090242 003**	May 16, 2011
AP			**EQ 2GM BASE/VIAL**	**A090799 003**	May 16, 2011
AP		GLAND PHARMA LTD	**EQ 200MG BASE/VIAL**	**A204520 001**	Jan 05, 2016
AP			**EQ 1GM BASE/VIAL**	**A204520 002**	Jan 05, 2016
AP		HOSPIRA	**EQ 200MG BASE/VIAL**	**A078339 001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078339 002**	Jul 25, 2011
AP	**+!**	HOSPIRA INC	**200MG/5.26ML (38MG/ML)**	**N200795 001**	Aug 04, 2011
AP	**+!**		**1GM/26.3ML (38MG/ML)**	**N200795 002**	Aug 04, 2011
AP	**!**		**EQ 2GM BASE/VIAL**	**A079183 001**	Nov 15, 2010
AP	**+!**		**2GM/52.6ML (38MG/ML)**	**N200795 003**	Aug 04, 2011
AP		JIANGSU HANSOH PHARM	**EQ 200MG BASE/VIAL**	**A202485 001**	May 07, 2013
AP			**EQ 1GM BASE/VIAL**	**A202485 002**	May 07, 2013
AP		MYLAN LABS LTD	**EQ 200MG BASE/VIAL**	**A200145 001**	Jul 25, 2011
AP			**200MG/5.26ML (38MG/ML)**	**A205242 001**	Dec 06, 2017
AP			**EQ 1GM BASE/VIAL**	**A200145 002**	Jul 25, 2011

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP			**1GM/26.3ML (38MG/ML)**	**A205242**	**002**	Dec 06, 2017
AP			**EQ 2GM BASE/VIAL**	**A200145**	**003**	Jul 25, 2011
AP			**2GM/52.6ML (38MG/ML)**	**A205242**	**003**	Dec 06, 2017
AP		SAGENT PHARMS INC	**200MG/5.26ML (38MG/ML)**	**A209077**	**001**	Jul 20, 2018
AP			**1GM/26.3ML (38MG/ML)**	**A209077**	**002**	Jul 20, 2018
AP			**2GM/52.6ML (38MG/ML)**	**A209077**	**003**	Jul 20, 2018
AP		SHILPA MEDICARE LTD	**200MG/5.26ML (38MG/ML)**	**A210991**	**001**	Oct 04, 2019
AP			**1GM/26.3ML (38MG/ML)**	**A210991**	**002**	Oct 04, 2019
AP			**2GM/52.6ML (38MG/ML)**	**A210991**	**003**	Oct 04, 2019
AP		SUN PHARM	**EQ 200MG BASE/VIAL**	**A078433**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078433**	**002**	Jul 25, 2011
AP		TEVA PHARMS	**EQ 200MG BASE/VIAL**	**A077983**	**002**	Jan 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A077983**	**001**	Jan 25, 2011

GEMZAR

AP	**+!**	LILLY	**EQ 200MG BASE/VIAL**	**N020509**	**001**	May 15, 1996
AP	**+!**		**EQ 1GM BASE/VIAL**	**N020509**	**002**	May 15, 1996

SOLUTION;INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

+!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017
+!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017
+!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017
+!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017

INFUGEM

+!	SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018
+!		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018
+!		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018
+!		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018
+!		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018
+!		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018
+!		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018
+!		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018
+!		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018
+!		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB		APOTEX	**600MG**	**A075034**	**001**	Jul 20, 1998
AB		AUROBINDO PHARMA LTD	**600MG**	**A202726**	**001**	Sep 16, 2015
AB		CADILA PHARMS LTD	**600MG**	**A203266**	**001**	Jun 17, 2016
AB		CARIBE HOLDINGS	**600MG**	**A078012**	**001**	Mar 26, 2007
AB		CHARTWELL MOLECULES	**600MG**	**A074270**	**001**	Sep 27, 1993
AB		HIKMA PHARMS	**600MG**	**A078599**	**001**	Aug 16, 2010
AB		IMPAX PHARMS	**600MG**	**A078207**	**001**	Jun 01, 2007
AB		INVAGEN PHARMS	**600MG**	**A077836**	**001**	Jul 27, 2006
AB		NORTHSTAR HLTHCARE	**600MG**	**A079072**	**001**	Sep 13, 2010
AB		TEVA	**600MG**	**A074256**	**001**	Oct 31, 1993
AB		ZYDUS PHARMS	**600MG**	**A204189**	**001**	Aug 28, 2018

LOPID

AB	**+!**	PFIZER PHARMS	**600MG**	**N018422**	**003**	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB	**+!**	LG CHEM LTD	**EQ 320MG BASE**	**N021158**	**001**	Apr 04, 2003

GEMIFLOXACIN MESYLATE

AB		ORCHID HLTHCARE	**EQ 320MG BASE**	**A090466**	**001**	Jun 15, 2015

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT		ACP NIMBLE	**EQ 0.1% BASE**	**A064056**	**001**	Apr 29, 1994
AT	**!**	PERRIGO NEW YORK	**EQ 0.1% BASE**	**A062307**	**001**	
AT		TELIGENT PHARMA INC	**EQ 0.1% BASE**	**A209304**	**001**	Oct 18, 2019

INJECTABLE;INJECTION

GENTAMICIN SULFATE

AP	**!**	FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A062366**	**002**	Feb 06, 1986
AP	**!**		**EQ 40MG BASE/ML**	**A062366**	**001**	Aug 04, 1983
AP		HOSPIRA	**EQ 10MG BASE/ML**	**A062420**	**001**	Aug 15, 1983
AP			**EQ 10MG BASE/ML**	**A062612**	**004**	Feb 20, 1986

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE

AP			**EQ 40MG BASE/ML**	**A062420**	**002**	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**EQ 1.2MG BASE/ML**	**A062373**	**007**	Sep 07, 1982
AP			**EQ 1.6MG BASE/ML**	**A062373**	**008**	Sep 07, 1982
AP			**EQ 80MG BASE/100ML**	**A062373**	**002**	Sep 07, 1982
AP			**EQ 100MG BASE/100ML**	**A062373**	**005**	Sep 07, 1982
AP		HOSPIRA	**EQ 1.2MG BASE/ML**	**A062414**	**001**	Aug 15, 1983
AP			**EQ 1.6MG BASE/ML**	**A062414**	**003**	Aug 15, 1983
AP			**EQ 80MG BASE/100ML**	**A062414**	**008**	Aug 15, 1983
AP			**EQ 100MG BASE/100ML**	**A062414**	**010**	Aug 15, 1983
	!	BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373	009	Sep 07, 1982
	!		EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

AT	**!**	AKORN	**EQ 0.3% BASE**	**A064093**	**001**	Aug 31, 1995
AT		FERA PHARMS LLC	**EQ 0.3% BASE**	**A065024**	**001**	Jul 30, 2004

OINTMENT;TOPICAL

GENTAMICIN SULFATE

AT		ACP NIMBLE	**EQ 0.1% BASE**	**A064054**	**001**	Apr 29, 1994
AT		FOUGERA PHARMS INC	**EQ 0.1% BASE**	**A062533**	**001**	Oct 05, 1984
AT	**!**	PERRIGO NEW YORK	**EQ 0.1% BASE**	**A062351**	**001**	Feb 18, 1982
AT		TARO	**EQ 0.1% BASE**	**A062477**	**001**	Dec 23, 1983
AT		TELIGENT PHARMA INC	**EQ 0.1% BASE**	**A209233**	**001**	Dec 31, 2018

SOLUTION/DROPS;OPHTHALMIC

GENOPTIC

AT	**!**	ALLERGAN	**EQ 0.3% BASE**	**A062452**	**001**	Oct 10, 1984

GENTAK

AT		AKORN	**EQ 0.3% BASE**	**A064163**	**001**	Oct 12, 2001

GENTAMICIN SULFATE

AT		AKORN	**EQ 0.3% BASE**	**A062635**	**001**	Jan 08, 1987
AT		BAUSCH AND LOMB	**EQ 0.3% BASE**	**A064048**	**001**	May 11, 1994
AT		PERRIGO CO TENNESSEE	**EQ 0.3% BASE**	**A065121**	**001**	Jan 30, 2004
AT		SANDOZ INC	**EQ 0.3% BASE**	**A062196**	**001**	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

PRED-G

	+!	ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989

SUSPENSION/DROPS;OPHTHALMIC

PRED-G

	+!	ALLERGAN	EQ 0.3% BASE;1%	N050586	001	Jun 10, 1988

GILTERITINIB FUMARATE

TABLET;ORAL

XOSPATA

	+!	ASTELLAS	EQ 40MG BASE	N211349	001	Nov 28, 2018

GIVOSIRAN SODIUM

SOLUTION;SUBCUTANEOUS

GIVLAARI

	+!	ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)	N212194	001	Nov 20, 2019

GLASDEGIB MALEATE

TABLET;ORAL

DAURISMO

	+	PFIZER INC	EQ 25MG BASE	N210656	001	Nov 21, 2018
	+!		EQ 100MG BASE	N210656	002	Nov 21, 2018

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	**+!**	TEVA PHARMS USA	**20MG/ML**	**N020622**	**002**	Feb 12, 2002
AP	**+!**		**40MG/ML**	**N020622**	**003**	Jan 28, 2014

GLATIRAMER ACETATE

AP		MYLAN	**20MG/ML**	**A091646**	**001**	Oct 03, 2017
AP			**40MG/ML**	**A206936**	**001**	Oct 03, 2017

GLATOPA

AP		SANDOZ INC	**20MG/ML**	**A090218**	**001**	Apr 16, 2015
AP			**40MG/ML**	**A206921**	**001**	Feb 12, 2018

GLECAPREVIR; PIBRENTASVIR							
TABLET;ORAL							
MAVYRET							
	+!	ABBVIE INC	100MG;40MG		N209394	001	Aug 03, 2017
GLIMEPIRIDE							
TABLET;ORAL							
AMARYL							
AB	**+!**	SANOFI AVENTIS US	**1MG**		**N020496**	**001**	Nov 30, 1995
AB	**+**		**2MG**		**N020496**	**002**	Nov 30, 1995
AB	**+**		**4MG**		**N020496**	**003**	Nov 30, 1995
GLIMEPIRIDE							
AB		ACCORD HLTHCARE	**1MG**		**A078181**	**001**	Aug 23, 2007
AB			**2MG**		**A078181**	**002**	Aug 23, 2007
AB			**4MG**		**A078181**	**003**	Aug 23, 2007
AB		AUROBINDO PHARMA LTD	**1MG**		**A202759**	**001**	Jun 29, 2012
AB			**2MG**		**A202759**	**002**	Jun 29, 2012
AB			**4MG**		**A202759**	**003**	Jun 29, 2012
AB		CARLSBAD	**1MG**		**A077911**	**001**	Sep 22, 2009
AB			**2MG**		**A077911**	**002**	Sep 22, 2009
AB			**4MG**		**A077911**	**003**	Sep 22, 2009
AB		DR REDDYS LABS LTD	**1MG**		**A077091**	**001**	Oct 06, 2005
AB			**2MG**		**A077091**	**002**	Oct 06, 2005
AB			**4MG**		**A077091**	**003**	Oct 06, 2005
AB		INDOCO REMEDIES	**1MG**		**A202112**	**001**	Apr 17, 2013
AB			**2MG**		**A202112**	**002**	Apr 17, 2013
AB			**4MG**		**A202112**	**003**	Apr 17, 2013
AB		INVAGEN PHARMS	**1MG**		**A077295**	**001**	Oct 06, 2005
AB			**2MG**		**A077295**	**002**	Oct 06, 2005
AB			**4MG**		**A077295**	**003**	Oct 06, 2005
AB		MICRO LABS	**1MG**		**A091220**	**001**	Jun 29, 2012
AB			**2MG**		**A091220**	**002**	Jun 29, 2012
AB			**4MG**		**A091220**	**004**	Jun 29, 2012
AB			**8MG**		**A091220**	**006**	Jun 29, 2012
AB		MYLAN	**1MG**		**A077624**	**001**	Nov 28, 2005
AB			**2MG**		**A077624**	**002**	Nov 28, 2005
AB			**4MG**		**A077624**	**003**	Nov 28, 2005
AB		PRINSTON INC	**1MG**		**A077370**	**001**	Dec 23, 2005
AB			**2MG**		**A077370**	**002**	Dec 23, 2005
AB			**4MG**		**A077370**	**003**	Dec 23, 2005
AB			**8MG**		**A077370**	**004**	Dec 23, 2005
		MICRO LABS	3MG		A091220	003	Jun 29, 2012
			6MG		A091220	005	Jun 29, 2012
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE							
TABLET;ORAL							
DUETACT							
AB	**+!**	TAKEDA PHARMS USA	**2MG;30MG**		**N021925**	**001**	Jul 28, 2006
AB	**+**		**4MG;30MG**		**N021925**	**002**	Jul 28, 2006
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE							
AB		SANDOZ	**2MG;30MG**		**A201049**	**001**	Jan 04, 2013
AB			**4MG;30MG**		**A201049**	**002**	Jan 04, 2013
GLIPIZIDE							
TABLET;ORAL							
GLIPIZIDE							
AB		ACCORD HLTHCARE	**5MG**		**A074550**	**001**	Sep 11, 1997
AB			**10MG**		**A074550**	**002**	Sep 11, 1997
AB		APOTEX	**5MG**		**A075795**	**001**	Jun 13, 2001
AB			**10MG**		**A075795**	**002**	Jun 13, 2001
AB		MYLAN	**5MG**		**A074226**	**001**	May 10, 1994
AB			**10MG**		**A074226**	**002**	May 10, 1994
AB		SANDOZ	**5MG**		**A074305**	**001**	Apr 07, 1995
AB			**10MG**		**A074305**	**002**	Apr 07, 1995
AB		SUN PHARM INDS INC	**5MG**		**A077820**	**001**	Jul 11, 2006
AB			**10MG**		**A077820**	**002**	Jul 11, 2006
AB		WATSON LABS TEVA	**5MG**		**A074223**	**001**	Feb 27, 1995
AB			**10MG**		**A074223**	**002**	Feb 27, 1995
GLUCOTROL							
AB	**+**	PFIZER	**5MG**		**N017783**	**001**	May 08, 1984
AB	**+!**		**10MG**		**N017783**	**002**	May 08, 1984

GLIPIZIDE

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB		AUROBINDO PHARMA LTD	**2.5MG**	**A206928**	**001**	May 12, 2017
AB			**5MG**	**A206928**	**002**	May 12, 2017
AB			**10MG**	**A206928**	**003**	May 12, 2017
AB		PAR PHARM	**5MG**	**A076159**	**002**	Sep 20, 2013
AB			**10MG**	**A076159**	**001**	Sep 20, 2013
AB		UNIQUE PHARM LABS	**2.5MG**	**A204720**	**001**	Dec 29, 2016
AB			**5MG**	**A204720**	**002**	Dec 29, 2016
AB			**10MG**	**A204720**	**003**	Dec 29, 2016
AB		WATSON LABS	**2.5MG**	**A076467**	**003**	Mar 27, 2006
AB			**5MG**	**A076467**	**001**	Sep 08, 2003
AB			**10MG**	**A076467**	**002**	Nov 07, 2003
AB		ZYDUS PHARMS	**2.5MG**	**A203499**	**001**	Jul 16, 2018
AB			**5MG**	**A203499**	**002**	Jul 16, 2018
AB			**10MG**	**A203499**	**003**	Jul 16, 2018

GLUCOTROL XL

AB	**+**	PFIZER	**2.5MG**	**N020329**	**003**	Aug 10, 1999
AB	**+**		**5MG**	**N020329**	**001**	Apr 26, 1994
AB	**+!**		**10MG**	**N020329**	**002**	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		EPIC PHARMA LLC	**2.5MG;250MG**	**A077507**	**001**	Oct 27, 2005
AB			**2.5MG;500MG**	**A077507**	**002**	Oct 27, 2005
AB			**5MG;500MG**	**A077507**	**003**	Oct 27, 2005
AB		HERITAGE PHARMS INC	**2.5MG;250MG**	**A078728**	**001**	Jun 23, 2010
AB			**2.5MG;500MG**	**A078728**	**002**	Jun 23, 2010
AB			**5MG;500MG**	**A078728**	**003**	Jun 23, 2010
AB		TEVA PHARMS	**2.5MG;250MG**	**A077270**	**001**	Oct 28, 2005
AB			**2.5MG;500MG**	**A077270**	**002**	Oct 28, 2005
AB	**!**		**5MG;500MG**	**A077270**	**003**	Oct 28, 2005
AB		ZYDUS PHARMS USA INC	**2.5MG;250MG**	**A078905**	**001**	Jan 31, 2011
AB			**2.5MG;500MG**	**A078905**	**002**	Jan 31, 2011
AB			**5MG;500MG**	**A078905**	**003**	Jan 31, 2011

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

+!	LILLY	1MG/VIAL	N020928	001	Sep 11, 1998

POWDER;NASAL

BAQSIMI

+!	ELI LILLY AND CO	3MG	N210134	001	Jul 24, 2019

SOLUTION;SUBCUTANEOUS

GVOKE HYPOPEN

+!	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	003	Sep 10, 2019
+!		1MG/0.2ML (1MG/0.2ML)	N212097	004	Sep 10, 2019

GVOKE PFS

+!	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019
+!		1MG/0.2ML (1MG/0.2ML)	N212097	002	Sep 10, 2019

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGEN

+!	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

AB		DAVA PHARMS INC	**1.5MG**	**A074591**	**001**	Dec 22, 1997
AB			**3MG**	**A074591**	**002**	Dec 22, 1997
AB			**4.5MG**	**A074591**	**003**	Dec 22, 1997
AB			**6MG**	**A074591**	**004**	Dec 22, 1997
AB		HIKMA	**1.5MG**	**A075890**	**001**	Jul 31, 2003
AB			**3MG**	**A075890**	**002**	Jul 31, 2003
AB			**6MG**	**A075890**	**003**	Jul 31, 2003
AB		MYLAN	**1.5MG**	**A074792**	**001**	Jun 26, 1998
AB			**3MG**	**A074792**	**002**	Jun 26, 1998

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

AB			**6MG**	**A074792**	**003**	Aug 17, 1999
AB		TEVA	**1.5MG**	**A074686**	**001**	Apr 20, 1999
AB			**3MG**	**A074686**	**002**	Apr 20, 1999
AB			**4.5MG**	**A074686**	**003**	Apr 20, 1999
AB			**6MG**	**A074686**	**004**	Apr 20, 1999

GLYNASE

AB	+	PHARMACIA AND UPJOHN	**1.5MG**	**N020051**	**001**	Mar 04, 1992
AB	+		**3MG**	**N020051**	**002**	Mar 04, 1992
AB	+!		**6MG**	**N020051**	**004**	Sep 24, 1993

GLYBURIDE

AB1		AUROBINDO PHARMA	**1.25MG**	**A077537**	**001**	Oct 18, 2007
AB1			**2.5MG**	**A077537**	**002**	Oct 18, 2007
AB1			**5MG**	**A077537**	**003**	Oct 18, 2007
AB1		CADILA PHARMS LTD	**1.25MG**	**A203379**	**001**	Jan 04, 2019
AB1			**2.5MG**	**A203379**	**002**	Jan 04, 2019
AB1			**5MG**	**A203379**	**003**	Jan 04, 2019
AB1		EPIC PHARMA LLC	**1.25MG**	**A076257**	**001**	Jun 27, 2002
AB1			**2.5MG**	**A076257**	**002**	Jun 27, 2002
AB1			**5MG**	**A076257**	**003**	Jun 27, 2002
AB1		HERITAGE PHARMS INC	**1.25MG**	**A090937**	**001**	Feb 28, 2011
AB1			**2.5MG**	**A090937**	**002**	Feb 28, 2011
AB1			**5MG**	**A090937**	**003**	Feb 28, 2011
AB1		PHARMADAX INC	**1.25MG**	**A203581**	**001**	Apr 14, 2016
AB1			**2.5MG**	**A203581**	**002**	Apr 14, 2016
AB1			**5MG**	**A203581**	**003**	Apr 14, 2016
AB1		TEVA	**1.25MG**	**A074388**	**001**	Aug 29, 1995
AB1			**2.5MG**	**A074388**	**002**	Aug 29, 1995
AB1	!		**5MG**	**A074388**	**003**	Aug 29, 1995
AB1		ZYDUS PHARMS	**1.25mg**	**A206749**	**001**	May 10, 2016
AB1			**2.5mg**	**A206749**	**002**	May 10, 2016
AB1			**5MG**	**A206749**	**003**	May 10, 2016

DIABETA

AB2	+	SANOFI AVENTIS US	**1.25MG**	**N017532**	**001**	May 01, 1984
AB2	+		**2.5MG**	**N017532**	**002**	May 01, 1984
AB2	+!		**5MG**	**N017532**	**003**	May 01, 1984

GLYBURIDE

AB2		IMPAX LABS INC	**1.25MG**	**A206079**	**001**	Sep 30, 2015
AB2			**2.5MG**	**A206079**	**002**	Sep 30, 2015
AB2			**5MG**	**A206079**	**003**	Sep 30, 2015

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**1.25MG;250MG**	**A076716**	**001**	Jun 28, 2005
AB			**2.5MG;500MG**	**A076716**	**002**	Jun 28, 2005
AB			**5MG;500MG**	**A076716**	**003**	Jun 28, 2005
AB		AUROBINDO PHARMA	**1.25MG;250MG**	**A077870**	**001**	Nov 14, 2007
AB	!		**2.5MG;500MG**	**A077870**	**002**	Nov 14, 2007
AB			**5MG;500MG**	**A077870**	**003**	Nov 14, 2007
AB		IMPAX LABS INC	**1.25MG;250MG**	**A076345**	**001**	Feb 18, 2004
AB			**2.5MG;500MG**	**A076345**	**002**	Feb 18, 2004
AB			**5MG;500MG**	**A076345**	**003**	Feb 18, 2004
AB		ZYDUS PHARMS	**1.25MG;250MG**	**A206748**	**001**	Feb 29, 2016
AB			**2.5MG;500MG**	**A206748**	**002**	Feb 29, 2016
AB			**5MG;500MG**	**A206748**	**003**	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

	+!	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013

GLYCINE

SOLUTION;IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	+!	BAXTER HLTHCARE	**1.5GM/100ML**	**N017865**	**001**	

GLYCINE 1.5% IN PLASTIC CONTAINER

AT		B BRAUN	**1.5GM/100ML**	**N016784**	**001**	
AT		ICU MEDICAL INC	**1.5GM/100ML**	**N018315**	**001**	

GLYCOPYRROLATE							
INJECTABLE;INJECTION							
GLYCOPYRROLATE							
AP		AM REGENT	**0.2MG/ML**	**A089335**	**001**	Jul 23, 1986
AP		AMNEAL	**0.2MG/ML**	**A208973**	**001**	Jun 15, 2017
AP		APOTEX	**0.2MG/ML**	**A210246**	**001**	Oct 29, 2019
AP		AUROBINDO PHARMA LTD	**0.2MG/ML**	**A210244**	**001**	Nov 28, 2018
AP		CAPLIN	**0.2MG/ML**	**A211705**	**001**	Mar 20, 2019
AP		FRESENIUS KABI USA	**0.2MG/ML**	**A209024**	**001**	Oct 31, 2018
AP			**0.2MG/ML**	**A209328**	**001**	Oct 27, 2017
AP		GLAND PHARMA LTD	**0.2MG/ML**	**A212612**	**001**	Sep 30, 2019
AP	!	HIKMA FARMACEUTICA	**0.2MG/ML**	**A090963**	**001**	Sep 21, 2011
AP		PIRAMAL CRITICAL	**0.2MG/ML**	**A210842**	**001**	Oct 25, 2018
AP		PRINSTON INC	**0.2MG/ML**	**A210927**	**001**	Oct 31, 2018
AP		SANDOZ INC	**0.2MG/ML**	**A211334**	**001**	May 14, 2019
AP		SOMERSET THERAPS LLC	**0.2MG/ML**	**A207639**	**001**	Jun 23, 2017
POWDER;INHALATION							
SEEBRI							
	+!	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015
SOLUTION;INHALATION							
LONHALA MAGNAIR KIT							
	+!	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017
SOLUTION;INTRAMUSCULAR, INTRAVENOUS							
GLYRX-PF							
		EXELA PHARMA SCS LLC	0.2MG/ML (0.2MG/ML)	N210997	001	Jul 11, 2018
			0.4MG/2ML (0.2MG/ML)	N210997	002	Jul 11, 2018
SOLUTION;ORAL							
CUVPOSA							
	+!	MERZ PHARMS	1MG/5ML	N022571	001	Jul 28, 2010
TABLET;ORAL							
GLYCOPYRROLATE							
AA		AUROLIFE PHARMA LLC	**1MG**	**A202675**	**001**	Apr 15, 2013
AA			**2MG**	**A202675**	**002**	Oct 30, 2018
AA		DR REDDYS LABS LTD	**1MG**	**A040847**	**001**	Mar 21, 2008
AA			**2MG**	**A040847**	**002**	Mar 21, 2008
AA		HERITAGE PHARMS INC	**1MG**	**A207201**	**001**	Jan 03, 2017
AA			**2MG**	**A207201**	**002**	Jan 03, 2017
AA		KENTON	**1MG**	**A091182**	**001**	Feb 03, 2014
AA			**2MG**	**A091182**	**002**	Feb 03, 2014
AA		LEADING PHARMA LLC	**1MG**	**A090195**	**001**	Sep 21, 2012
AA			**2MG**	**A090195**	**002**	Sep 21, 2012
AA		NATCO PHARMA LTD	**1MG**	**A091413**	**001**	Jun 20, 2016
AA			**2MG**	**A091413**	**002**	Jun 20, 2016
AA		ORIT LABS LLC	**1MG**	**A203657**	**001**	Nov 30, 2018
AA			**2MG**	**A203657**	**002**	Nov 30, 2018
AA		OXFORD PHARMS	**1MG**	**A090020**	**001**	Oct 19, 2011
AA			**2MG**	**A090020**	**002**	Oct 19, 2011
AA	!	PAR PHARM	**1MG**	**A040653**	**001**	Aug 31, 2006
AA	!		**2MG**	**A040653**	**002**	Aug 31, 2006
AA		RISING	**1MG**	**A040821**	**001**	Dec 29, 2008
AA			**2MG**	**A040821**	**002**	Dec 29, 2008
AA		SUN PHARM INDS LTD	**1MG**	**A040844**	**001**	Aug 18, 2009
AA			**2MG**	**A040844**	**002**	Aug 18, 2009
		NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012
GLYCOPYRROLATE ; INDACATEROL MALEATE							
POWDER;INHALATION							
UTIBRON							
	+!	SUNOVION PHARMS INC	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015
GLYCOPYRRONIUM TOSYLATE							
CLOTH;TOPICAL							
QBREXZA							
	+!	DERMIRA INC	EQ 2.4% BASE	N210361	001	Jun 28, 2018

GOLODIRSEN

SOLUTION;INTRAVENOUS

VYONDYS 53

	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N211970	001	Dec 12, 2019

GONADOTROPIN, CHORIONIC

INJECTABLE;INJECTION

CHORIONIC GONADOTROPIN

AP	**+!**	FERRING	**10,000 UNITS/VIAL**	**N017016**	**007**	
AP	**+!**	FRESENIUS KABI USA	**10,000 UNITS/VIAL**	**N017067**	**002**	

PREGNYL

AP	**+!**	ORGANON USA INC	**10,000 UNITS/VIAL**	**N017692**	**001**	

CHORIONIC GONADOTROPIN

	+!	FERRING	5,000 UNITS/VIAL	N017016	006	

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

	+!	TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT		AMRING PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A065187**	**001**	Oct 28, 2005
AT	**!**	BAUSCH AND LOMB	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A064047**	**001**	Jan 31, 1996

NEOSPORIN

AT	**!**	MONARCH PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A060582**	**001**	

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

	+!	KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008

INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

SUSTOL

	+!	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP		AKORN INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A079119**	**001**	Sep 10, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A079078**	**001**	Sep 14, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A079078**	**002**	Sep 14, 2009
AP		AUROBINDO PHARMA LTD	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A204238**	**001**	Jul 06, 2016
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204238**	**002**	Jul 06, 2016
AP		BIONPHARMA INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078863**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078880**	**001**	Jun 30, 2008
AP		CIPLA LTD	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078262**	**001**	Dec 31, 2007
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078258**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078258**	**002**	Jun 30, 2008
AP	**!**	DR REDDYS	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078392**	**001**	Dec 31, 2007
AP	**!**		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077297**	**001**	Jun 30, 2008
AP		FRESENIUS KABI USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078522**	**001**	Dec 31, 2007
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078090**	**001**	Jun 30, 2008
AP		HIKMA FARMACEUTICA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078629**	**001**	Dec 23, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078629**	**002**	Dec 23, 2009
AP		MYLAN ASI	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A091136**	**001**	Apr 09, 2010
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A091136**	**002**	Apr 09, 2010
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A091137**	**002**	Apr 09, 2010
AP		MYLAN LABS LTD	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A203454**	**001**	Apr 04, 2017
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A203454**	**002**	Apr 04, 2017
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A203453**	**001**	Jan 31, 2017
AP		SANDOZ INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078534**	**001**	Apr 30, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078531**	**001**	Apr 30, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078835**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078531**	**002**	Apr 30, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078835**	**002**	Jun 30, 2008
AP		WEST-WARD PHARMS INT	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A077913**	**001**	Jun 26, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077186**	**001**	Jun 30, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A077187**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077177**	**001**	Dec 31, 2007

GRANISETRON HYDROCHLORIDE						
INJECTABLE;INJECTION						
GRANISETRON HYDROCHLORIDE						
AP		WOCKHARDT USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078566**	**001**	Feb 29, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078564**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078565**	**001**	Jun 30, 2008
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP		BIONPHARMA INC	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078863**	**002**	Jun 30, 2008
AP	**!**	FRESENIUS KABI USA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078096**	**001**	Jun 30, 2008
TABLET;ORAL						
GRANISETRON HYDROCHLORIDE						
AB		APOTEX INC	**EQ 1MG BASE**	**A078843**	**001**	Feb 27, 2008
AB		CHARTWELL MOLECULAR	**EQ 1MG BASE**	**A078037**	**001**	Feb 27, 2008
AB		DR REDDYS LABS LTD	**EQ 1MG BASE**	**A078846**	**001**	Feb 27, 2009
AB	**!**	HIKMA	**EQ 1MG BASE**	**A077842**	**001**	Dec 31, 2007
AB		MYLAN	**EQ 1MG BASE**	**A078725**	**001**	Jan 30, 2008
AB		NATCO PHARMA	**EQ 1MG BASE**	**A078969**	**001**	Jun 22, 2009
AB		ORCHID HLTHCARE	**EQ 1MG BASE**	**A078678**	**001**	Feb 13, 2008
AB		TARO	**EQ 1MG BASE**	**A090817**	**001**	May 28, 2010
GRISEOFULVIN, MICROSIZE						
SUSPENSION;ORAL						
GRISEOFULVIN						
AB	**!**	ACTAVIS MID ATLANTIC	**125MG/5ML**	**A065394**	**001**	Jul 06, 2007
AB		CHARTWELL RX	**125MG/5ML**	**A065200**	**001**	Mar 02, 2005
AB		CIPLA	**125MG/5ML**	**A065354**	**001**	Sep 10, 2007
AB		VINTAGE PHARMS	**125MG/5ML**	**A065438**	**001**	Oct 08, 2010
TABLET;ORAL						
GRISEOFULVIN						
AB	**!**	SANDOZ INC	**500MG**	**A091592**	**002**	Aug 07, 2013
AB		SIGMAPHARM LABS LLC	**500MG**	**A202482**	**001**	Oct 22, 2012
		SANDOZ INC	250MG	A091592	001	Aug 07, 2013
GRISEOFULVIN, ULTRAMICROSIZE						
TABLET;ORAL						
GRIS-PEG						
AB	**+**	VALEANT PHARMS INC	**125MG**	**N050475**	**001**	
AB	**+!**		**250MG**	**N050475**	**002**	
GRISEOFULVIN, ULTRAMICROSIZE						
AB		MOUNTAIN	**125MG**	**A204371**	**001**	Jan 09, 2014
AB			**250MG**	**A204371**	**002**	Jan 09, 2014
AB		SANDOZ INC	**125MG**	**A202805**	**001**	Dec 26, 2018
AB			**250MG**	**A202805**	**002**	Dec 26, 2018
GRISEOFULVIN,ULTRAMICROSIZE						
AB		SIGMAPHARM LABS LLC	**125MG**	**A202545**	**001**	Oct 22, 2012
AB			**250MG**	**A202545**	**002**	Oct 22, 2012
GUANFACINE HYDROCHLORIDE						
TABLET;ORAL						
GUANFACINE HYDROCHLORIDE						
AB		AMNEAL PHARM	**EQ 1MG BASE**	**A075109**	**001**	Nov 25, 1998
AB			**EQ 2MG BASE**	**A075109**	**002**	Nov 25, 1998
AB		EPIC PHARMA LLC	**EQ 1MG BASE**	**A074673**	**001**	Feb 28, 1997
AB			**EQ 2MG BASE**	**A074673**	**002**	Feb 28, 1997
AB		MYLAN	**EQ 1MG BASE**	**A074796**	**001**	Jan 27, 1997
AB	**!**		**EQ 2MG BASE**	**A074796**	**002**	Jan 27, 1997
AB		WATSON LABS	**EQ 1MG BASE**	**A074145**	**001**	Oct 17, 1995
AB			**EQ 2MG BASE**	**A074145**	**002**	Oct 17, 1995
TABLET, EXTENDED RELEASE;ORAL						
GUANFACINE HYDROCHLORIDE						
AB		ACTAVIS ELIZABETH	**EQ 1MG BASE**	**A200881**	**001**	Oct 05, 2012
AB			**EQ 2MG BASE**	**A200881**	**002**	Oct 05, 2012
AB			**EQ 3MG BASE**	**A200881**	**003**	Oct 05, 2012
AB			**EQ 4MG BASE**	**A200881**	**004**	Oct 05, 2012
AB		APOTEX	**EQ 1MG BASE**	**A205430**	**001**	Jul 25, 2018
AB			**EQ 2MG BASE**	**A205430**	**002**	Jul 25, 2018
AB			**EQ 3MG BASE**	**A205430**	**003**	Jul 25, 2018
AB			**EQ 4MG BASE**	**A205430**	**004**	Jul 25, 2018
AB		SANDOZ INC	**EQ 1MG BASE**	**A202568**	**001**	Jun 03, 2015
AB			**EQ 2MG BASE**	**A202568**	**002**	Jun 03, 2015
AB			**EQ 3MG BASE**	**A202568**	**003**	Jun 03, 2015
AB			**EQ 4MG BASE**	**A202568**	**004**	Jun 03, 2015
AB		SUN PHARM	**EQ 1MG BASE**	**A205689**	**001**	Nov 16, 2017

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB			**EQ 2MG BASE**	**A205689**	**002**	Nov 16, 2017
AB			**EQ 3MG BASE**	**A205689**	**003**	Nov 16, 2017
AB			**EQ 4MG BASE**	**A205689**	**004**	Nov 16, 2017
AB		TEVA PHARMS USA	**EQ 1MG BASE**	**A201382**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201382**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201382**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201382**	**004**	Jun 02, 2015
AB		TWI PHARMS	**EQ 1MG BASE**	**A201408**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201408**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201408**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201408**	**004**	Jun 02, 2015

INTUNIV

AB	**+**	SHIRE	**EQ 1MG BASE**	**N022037**	**001**	Sep 02, 2009
AB	**+**		**EQ 2MG BASE**	**N022037**	**002**	Sep 02, 2009
AB	**+**		**EQ 3MG BASE**	**N022037**	**003**	Sep 02, 2009
AB	**+!**		**EQ 4MG BASE**	**N022037**	**004**	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET;ORAL

GUANIDINE HYDROCHLORIDE

		MERCK SHARP DOHME	125MG	N001546	001

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

AB		MYLAN	**0.1%**	**A211027**	**001**	Aug 12, 2019

HALOG

AB	**+!**	SUN PHARM INDS INC	**0.1%**	**N017556**	**001**	

OINTMENT;TOPICAL

HALOG

	+!	SUN PHARM INDS INC	0.1%	N017824	001	

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

LEXETTE

	+!	MAYNE PHARMA	0.05%	N210566	001	May 24, 2018

CREAM;TOPICAL

HALOBETASOL PROPIONATE

AB	**!**	ACP NIMBLE	**0.05%**	**A078162**	**001**	Apr 24, 2007
AB		FOUGERA PHARMS	**0.05%**	**A077001**	**001**	Dec 16, 2004
AB		PERRIGO ISRAEL	**0.05%**	**A077123**	**001**	Dec 16, 2004
AB		TARO	**0.05%**	**A077227**	**001**	Aug 04, 2005

LOTION;TOPICAL

BRYHALI

	+!	BAUSCH	0.01%	N209355	001	Nov 06, 2018

ULTRAVATE

	+!	SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

AB		ACP NIMBLE	**0.05%**	**A077109**	**001**	Jun 14, 2005
AB	**!**		**0.05%**	**A077721**	**001**	Sep 07, 2006
AB		PERRIGO ISRAEL	**0.05%**	**A076872**	**001**	Dec 16, 2004
AB		TARO	**0.05%**	**A076994**	**001**	Dec 16, 2004
AB		TELIGENT PHARMA INC	**0.05%**	**A209978**	**001**	Mar 20, 2018

ULTRAVATE

AB	**+**	SUN PHARM INDS INC	**0.05%**	**N019968**	**001**	Dec 17, 1990

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL

DUOBRII

	+!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	APPCO	**0.5MG**	**A211061**	**001**	Jan 08, 2020
AB		**1MG**	**A211061**	**002**	Jan 08, 2020
AB		**2MG**	**A211061**	**003**	Jan 08, 2020
AB		**5MG**	**A211061**	**004**	Jan 08, 2020
AB		**10MG**	**A211061**	**005**	Jan 08, 2020
AB		**20MG**	**A211061**	**006**	Jan 08, 2020

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB		INNOGENIX	0.5MG	A071173	002	Jan 02, 1987
AB			1MG	A071173	003	Jan 02, 1987
AB			2MG	A071173	004	Jan 02, 1987
AB			5MG	A071173	005	Jan 07, 1988
AB			10MG	A071173	001	Jan 07, 1988
AB			20MG	A071173	006	Jan 07, 1988
AB		MYLAN	0.5MG	A070278	006	Jun 10, 1986
AB			1MG	A070278	004	Jun 10, 1986
AB	!		2MG	A070278	001	Jun 10, 1986
AB			5MG	A070278	005	Jun 10, 1986
AB			10MG	A070278	002	Jul 16, 2009
AB			20MG	A070278	003	Jul 16, 2009
AB		SANDOZ	0.5MG	A071206	001	Nov 17, 1986
AB			1MG	A071207	001	Nov 17, 1986
AB			5MG	A071209	001	Nov 17, 1986
AB			10MG	A071210	001	Mar 11, 1988
AB			20MG	A071211	001	Mar 11, 1988
AB		ZYDUS PHARMS USA	5MG	A077580	003	Nov 29, 2007
AB			10MG	A077580	004	Nov 29, 2007
AB			20MG	A077580	005	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALDOL

AO	+!	JANSSEN PHARMS	EQ 50MG BASE/ML	N018701	001	Jan 14, 1986
AO	+!		EQ 100MG BASE/ML	N018701	002	Jan 31, 1997

HALOPERIDOL DECANOATE

AO		FRESENIUS KABI USA	EQ 50MG BASE/ML	A074893	001	Dec 19, 1997
AO			EQ 100MG BASE/ML	A074893	002	Dec 19, 1997
AO		GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017
AO			EQ 100MG BASE/ML	A205241	002	May 12, 2017
AO		MYLAN LABS LTD	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000
AO			EQ 100MG BASE/ML	A075440	002	Feb 28, 2000
AO		SOMERSET THERAPS LLC	EQ 50MG BASE/ML	A209101	001	Jul 03, 2018
AO			EQ 100MG BASE/ML	A209101	002	Jul 03, 2018
AO		TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999
AO			EQ 100MG BASE/ML	A075393	002	May 11, 1999
AO		WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998
AO			EQ 100MG BASE/ML	A075305	001	Sep 28, 1998
AO		ZYDUS PHARMS	EQ 50MG BASE/ML	A211180	001	Oct 22, 2019
AO			EQ 100MG BASE/ML	A211180	002	Oct 22, 2019

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL

AA		LANNETT CO INC	EQ 2MG BASE/ML	A073364	001	Sep 28, 1993
AA	!	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993

INJECTABLE;INJECTION

HALDOL

AP	+!	JANSSEN PHARMS	EQ 5MG BASE/ML	N015923	001	

HALOPERIDOL

AP		AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017
AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A075689	001	Mar 09, 2001
AP		GLAND PHARMA LTD	EQ 5MG BASE/ML	A076774	001	Aug 25, 2004
AP		MYLAN LABS LTD	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009
AP		SAGENT PHARMS	EQ 5MG BASE/ML	A091637	001	Sep 02, 2011
AP			EQ 5MG BASE/ML	A200742	001	Sep 02, 2011
AP		TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001
AP		WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP		CASI PHARMS INC	5,000 UNITS/ML	A091659	001	Jun 08, 2011
AP	+!	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	001	
AP			5,000 UNITS/ML	A206552	001	Jun 10, 2016
AP	+!		5,000 UNITS/ML	N017651	006	
AP	+!		10,000 UNITS/ML	N017029	003	

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM						
AP	**+!**		**20,000 UNITS/ML**	**N017029**	**004**	
AP		GLAND PHARMA LTD	**5,000 UNITS/ML**	**A205323**	**001**	Feb 06, 2017
AP	**+!**	HIKMA	**1,000 UNITS/ML**	**N017037**	**001**	
AP	**+!**		**5,000 UNITS/ML**	**N017037**	**002**	
AP	**+!**		**10,000 UNITS/ML**	**N017037**	**003**	
AP		HOSPIRA INC	**1,000 UNITS/ML**	**A090571**	**001**	Aug 31, 2009
AP			**5,000 UNITS/ML**	**A090571**	**002**	Aug 31, 2009
AP			**10,000 UNITS/ML**	**A090571**	**003**	Aug 31, 2009
AP		MYLAN LABS LTD	**1,000 UNITS/ML**	**A203851**	**001**	Nov 30, 2017
AP			**5,000 UNITS/ML**	**A203851**	**002**	Nov 30, 2017
AP			**10,000 UNITS/ML**	**A203851**	**003**	Nov 30, 2017
AP			**20,000 UNITS/ML**	**A203852**	**001**	Nov 30, 2017
AP		NANJING KING-FRIEND	**1,000 UNITS/ML**	**A211005**	**001**	Dec 14, 2018
AP			**1,000 UNITS/ML**	**A211007**	**001**	May 28, 2019
AP			**5,000 UNITS/ML**	**A211007**	**002**	May 28, 2019
AP			**10,000 UNITS/ML**	**A211007**	**003**	May 28, 2019
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090808**	**001**	Jun 30, 2010
AP			**5,000 UNITS/ML**	**A090808**	**002**	Jun 30, 2010
AP			**10,000 UNITS/ML**	**A090808**	**003**	Jun 30, 2010
AP			**20,000 UNITS/ML**	**A090809**	**001**	Jun 30, 2010
AP		SANDOZ	**1,000 UNITS/ML**	**A091682**	**001**	Jun 08, 2011
AP			**5,000 UNITS/ML**	**A091682**	**002**	Jun 08, 2011
AP			**10,000 UNITS/ML**	**A201002**	**001**	Jun 08, 2011
AP		SHENZHEN TECHDOW	**1,000 UNITS/ML**	**A202957**	**001**	Jun 12, 2014
AP			**5,000 UNITS/ML**	**A202733**	**001**	Jun 12, 2014
AP			**5,000 UNITS/ML**	**A202957**	**002**	Jun 12, 2014
AP			**10,000 UNITS/ML**	**A203198**	**001**	Jun 12, 2014
AP			**20,000 UNITS/ML**	**A203198**	**002**	Jun 12, 2014
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**001**	Apr 28, 1982
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	**+!**	B BRAUN	**200 UNITS/100ML**	**N019953**	**001**	Jul 20, 1992
AP	**+!**	HOSPIRA	**200 UNITS/100ML**	**N018916**	**010**	Jun 23, 1989
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		HOSPIRA	**10,000 UNITS/100ML**	**N019339**	**003**	Mar 27, 1985
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**002**	Apr 28, 1982
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	**+!**	HOSPIRA	**200 UNITS/100ML**	**N018916**	**011**	Jun 23, 1989
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	**+!**	B BRAUN	**4,000 UNITS/100ML**	**N019952**	**001**	Jul 20, 1992
AP		HOSPIRA	**4,000 UNITS/100ML**	**N019805**	**001**	Jan 25, 1989
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	**+!**	B BRAUN	**5,000 UNITS/100ML**	**N019952**	**004**	Jul 20, 1992
AP	**+!**		**10,000 UNITS/100ML**	**N019952**	**005**	Jul 20, 1992
AP		HOSPIRA	**5,000 UNITS/100ML**	**N019339**	**004**	Mar 27, 1985
AP			**5,000 UNITS/100ML**	**N019805**	**002**	Jan 25, 1989
AP			**10,000 UNITS/100ML**	**N019339**	**002**	Mar 27, 1985
HEPARIN SODIUM IN PLASTIC CONTAINER						
AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**013**	Dec 05, 1985
AP	**+!**		**5,000 UNITS/ML**	**N017029**	**014**	Dec 05, 1985
AP	**+!**		**10,000 UNITS/ML**	**N017029**	**015**	Dec 05, 1985
AP	**+!**		**20,000 UNITS/ML**	**N017029**	**016**	Dec 05, 1985
HEPARIN SODIUM PRESERVATIVE FREE						
AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**010**	Apr 28, 1986
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090810**	**001**	Jun 30, 2010
AP		SHENZHEN TECHDOW	**1,000 UNITS/ML**	**A202732**	**001**	Jun 12, 2014
HEPARIN SODIUM						
		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018
	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
	!	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983
	+!	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
	+!		5,000 UNITS/ML	N201370	002	Jul 21, 2011
	+!		10,000 UNITS/ML	N201370	003	Jul 21, 2011
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
		HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
		HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
			10,000 UNITS/100ML	N018916	008	Jan 31, 1984

HEPARIN SODIUM PRESERVATIVE FREE

	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010
	!	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987
	+!	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENE

SPONGE;TOPICAL

PRE-OP

AT	**+!**	DAVIS AND GECK	**480MG**	**N017433**	**001**	

PRE-OP II

AT	**+**	DAVIS AND GECK	**480MG**	**N017433**	**002**	

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION;INTRAVESICAL

CYSVIEW KIT

	+!	PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010

HISTRELIN ACETATE

IMPLANT;SUBCUTANEOUS

SUPPRELIN LA

	+!	ENDO PHARM	50MG	N022058	001	May 03, 2007

VANTAS

	+!	ENDO PHARM	50MG	N021732	001	Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYCODAN

AA	**+**	GENUS	**1.5MG/5ML;5MG/5ML**	**N005213**	**002**	Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ABHAI LLC	**1.5MG/5ML;5MG/5ML**	**A207487**	**001**	Feb 21, 2017
AA		ACTAVIS MID ATLANTIC	**1.5MG/5ML;5MG/5ML**	**A088017**	**001**	Jul 05, 1983
AA	**!**	HI TECH PHARMA	**1.5MG/5ML;5MG/5ML**	**A040613**	**001**	Feb 08, 2008
AA		NOVEL LABS INC	**1.5MG/5ML;5MG/5ML**	**A203535**	**001**	Feb 13, 2017
AA		PADDOCK LLC	**1.5MG/5ML;5MG/5ML**	**A205731**	**001**	Feb 15, 2017
AA		WOCKHARDT BIO AG	**1.5MG/5ML;5MG/5ML**	**A088008**	**001**	Mar 03, 1983

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA		AVANTHI INC	**1.5MG;5MG**	**A207176**	**001**	Aug 07, 2017
AA		NOVEL LABS INC	**1.5MG;5MG**	**A091528**	**001**	Apr 20, 2011

TUSSIGON

AA	**!**	KING PHARMS	**1.5MG;5MG**	**A088508**	**001**	Jul 30, 1985

HYALURONIDASE

INJECTABLE;INJECTION

AMPHADASE

	+!	AMPHASTAR PHARM	150 UNITS/ML	N021665	001	Oct 26, 2004

VITRASE

	+!	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE;INJECTION

HYLENEX RECOMBINANT

	+!	HALOZYME THERAP	150 UNITS/ML	N021859	001	Dec 02, 2005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	**!**	AKORN	**20MG/ML**	**A040730**	**001**	Apr 21, 2009
AP		FRESENIUS KABI USA	**20MG/ML**	**A040388**	**001**	Mar 13, 2001
AP		MYLAN INSTITUTIONAL	**20MG/ML**	**A204680**	**001**	Apr 28, 2016
AP		NAVINTA LLC	**20MG/ML**	**A202938**	**001**	Mar 28, 2013
AP		X-GEN PHARMS INC	**20MG/ML**	**A203110**	**001**	Jun 29, 2015

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		ALKEM LABS LTD	**10MG**	**A200737**	**001**	Dec 07, 2012
AA			**25MG**	**A200737**	**002**	Dec 07, 2012
AA			**50MG**	**A200737**	**003**	Dec 07, 2012
AA			**100MG**	**A200737**	**004**	Dec 07, 2012
AA		CADILA PHARMS LTD	**25MG**	**A203845**	**001**	Sep 18, 2014
AA			**50MG**	**A203845**	**002**	Sep 18, 2014

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA			**100MG**	**A203845**	**003**	Sep 18, 2014
AA		GLENMARK PHARMS LTD	**10MG**	**A090527**	**001**	May 27, 2009
AA			**25MG**	**A090527**	**002**	May 27, 2009
AA			**50MG**	**A090527**	**003**	May 27, 2009
AA			**100MG**	**A090527**	**004**	May 27, 2009
AA		HERITAGE PHARMS INC	**10MG**	**A086242**	**001**	Feb 04, 2010
AA			**25MG**	**A086242**	**003**	
AA			**50MG**	**A086242**	**002**	
AA			**100MG**	**A086242**	**004**	Feb 04, 2010
AA		HETERO LABS LTD III	**10MG**	**A040901**	**001**	Sep 12, 2008
AA			**25MG**	**A040901**	**002**	Sep 12, 2008
AA			**50MG**	**A040901**	**003**	Sep 12, 2008
AA			**100MG**	**A040901**	**004**	Sep 12, 2008
AA		INVAGEN PHARMS	**10MG**	**A090255**	**001**	Dec 15, 2008
AA			**25MG**	**A090255**	**002**	Dec 15, 2008
AA			**50MG**	**A090255**	**003**	Dec 15, 2008
AA			**100MG**	**A090255**	**004**	Dec 15, 2008
AA		PAR PHARM	**10MG**	**A087836**	**001**	Oct 05, 1982
AA			**25MG**	**A086961**	**002**	
AA			**50MG**	**A086962**	**001**	
AA			**100MG**	**A088391**	**001**	Sep 27, 1983
AA	**!**	PLIVA	**10MG**	**A089097**	**001**	Dec 18, 1985
AA	**!**		**25MG**	**A088467**	**001**	May 01, 1984
AA	**!**		**50MG**	**A088468**	**001**	May 01, 1984
AA	**!**		**100MG**	**A089098**	**001**	Dec 18, 1985
AA		SCIEGEN PHARMS INC	**10MG**	**A205236**	**001**	May 26, 2017
AA			**25MG**	**A205236**	**002**	May 26, 2017
AA			**50MG**	**A205236**	**003**	May 26, 2017
AA			**100MG**	**A205236**	**004**	May 26, 2017
AA		STRIDES PHARMA	**10MG**	**A200770**	**004**	Jun 25, 2019
AA			**25MG**	**A200770**	**001**	May 03, 2013
AA			**50MG**	**A200770**	**002**	May 03, 2013
AA			**100MG**	**A200770**	**003**	May 03, 2013
AA		UPSHER SMITH LABS	**10MG**	**A209251**	**001**	Jul 09, 2018
AA			**25MG**	**A209251**	**002**	Jul 09, 2018
AA			**50MG**	**A209251**	**003**	Jul 09, 2018
AA			**100MG**	**A209251**	**004**	Jul 09, 2018

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

		PAR PHARM	25MG;25MG	A088957	001	Oct 21, 1985
	!		50MG;50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

BIDIL

	+!	ARBOR PHARMS LLC	37.5MG;20MG	N020727	001	Jun 23, 2005

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG**	**A200645**	**001**	Nov 30, 2010
AB		AUROBINDO PHARMA	**12.5MG**	**A078164**	**001**	Sep 18, 2007
AB		IPCA LABS LTD	**12.5MG**	**A079237**	**001**	Apr 02, 2009
AB		IVAX SUB TEVA PHARMS	**12.5MG**	**A077005**	**001**	Jul 13, 2005
AB		JUBILANT CADISTA	**12.5MG**	**A078391**	**001**	Feb 11, 2008
AB		MYLAN	**12.5MG**	**A075640**	**001**	Jan 28, 2000
AB		PRINSTON INC	**12.5MG**	**A075907**	**001**	Sep 17, 2002
AB		SCIEGEN PHARMS INC	**12.5MG**	**A203561**	**001**	Jan 14, 2019
AB		SUN PHARM INDS INC	**12.5MG**	**A090651**	**001**	Apr 07, 2014
AB		UNICHEM	**12.5MG**	**A090510**	**001**	Jan 19, 2010

MICROZIDE

AB	**+!**	ALLERGAN	**12.5MG**	**N020504**	**001**	Dec 27, 1996

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB	**!**	ACCORD HLTHCARE	**12.5MG**	**A202556**	**001**	Sep 24, 2012
AB			**25MG**	**A202556**	**002**	Sep 24, 2012
AB			**50MG**	**A202556**	**003**	Sep 24, 2012
AB		ACTAVIS ELIZABETH	**12.5MG**	**A040707**	**001**	Feb 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	25MG	A040780	001	Jul 20, 2007
AB			50MG	A040780	002	Jul 20, 2007
AB		HERITAGE PHARMS INC	25MG	A085182	002	
AB			50MG	A085182	001	
AB		HIKMA INTL PHARMS	50MG	A084878	001	
AB		IPCA LABS LTD	12.5MG	A040807	001	Jul 20, 2007
AB			25MG	A040807	002	Jul 20, 2007
AB			50MG	A040807	003	Jul 20, 2007
AB		IVAX SUB TEVA PHARMS	25MG	A083177	001	
AB	!		50MG	A083177	002	
AB		LEADING PHARMA LLC	12.5MG	A040702	003	May 10, 2017
AB			25MG	A040702	001	Mar 16, 2007
AB			50MG	A040702	002	Mar 16, 2007
AB		MYLAN PHARMS INC	25MG	A040735	002	Jan 23, 2007
AB			50MG	A040735	003	Jan 23, 2007
AB		OXFORD PHARMS	25MG	A087059	001	
AB			50MG	A087068	001	
AB		PRINSTON INC	25MG	A040412	001	Mar 29, 2002
AB			50MG	A040412	002	Mar 29, 2002
AB		SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014
AB			50MG	A203018	002	Jul 23, 2014
AB		UNICHEM	25MG	A040907	001	Aug 15, 2008
AB			50MG	A040907	002	Aug 15, 2008

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

AB	+!	SANOFI AVENTIS US	12.5MG;150MG	N020758	002	Sep 30, 1997
AB	+!		12.5MG;300MG	N020758	003	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG;150MG	A091370	001	Oct 15, 2012
AB			12.5MG;300MG	A091370	002	Oct 15, 2012
AB			25MG;300MG	A091370	003	Oct 12, 2016
AB		AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013
AB			12.5MG;300MG	A203630	002	Feb 22, 2013
AB			25MG;300MG	A203630	003	Mar 31, 2016
AB		DR REDDYS LABS LTD	12.5MG;150MG	A203500	001	Sep 27, 2012
AB			12.5MG;300MG	A203500	002	Sep 27, 2012
AB		HIKMA	12.5MG;150MG	A090351	001	Oct 15, 2012
AB			12.5MG;300MG	A090351	002	Oct 15, 2012
AB			25MG;300MG	A090351	003	Jun 08, 2017
AB		HISUN PHARM HANGZHOU	12.5MG;150MG	A207896	001	Oct 14, 2016
AB			12.5MG;300MG	A207896	002	Oct 14, 2016
AB		LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013
AB			12.5MG;300MG	A201524	002	Feb 27, 2013
AB		MACLEODS PHARMS LTD	12.5MG;150MG	A202414	001	Sep 27, 2012
AB			12.5MG;300MG	A202414	002	Sep 27, 2012
AB		PRINSTON INC	12.5MG;150MG	A203072	001	May 09, 2014
AB			12.5MG;300MG	A203072	002	May 09, 2014
AB		SANDOZ	12.5MG;150MG	A077446	001	Sep 27, 2012
AB			12.5MG;300MG	A077446	002	Sep 27, 2012
AB		TEVA	12.5MG;150MG	A077369	001	Mar 30, 2012
AB			12.5MG;300MG	A077369	002	Mar 30, 2012
AB		UNICHEM LABS LTD	12.5MG;150MG	A207018	001	Sep 19, 2017
AB			12.5MG;300MG	A207018	002	Sep 19, 2017

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO	12.5MG;10MG	A077606	001	Mar 14, 2006
AB			12.5MG;20MG	A077606	002	Mar 14, 2006
AB			25MG;20MG	A077606	003	Mar 14, 2006
AB		HIKMA INTL PHARMS	12.5MG;10MG	A076265	001	Jul 08, 2002
AB			12.5MG;20MG	A076265	002	Jul 08, 2002
AB			25MG;20MG	A076265	003	Jul 08, 2002
AB		INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017
AB			12.5MG;20MG	A204058	002	May 23, 2017
AB			25MG;20MG	A204058	003	May 23, 2017

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		LUPIN	12.5MG;10MG	A077912	001	Sep 27, 2006
AB			12.5MG;20MG	A077912	002	Sep 27, 2006
AB			25MG;20MG	A077912	003	Sep 27, 2006
AB		PRINSTON INC	12.5MG;10MG	A076230	001	Jul 01, 2002
AB			12.5MG;20MG	A076230	002	Jul 01, 2002
AB			25MG;20MG	A076230	003	Jul 01, 2002
AB		SANDOZ	12.5MG;10MG	A076262	001	Jul 01, 2002
AB			12.5MG;20MG	A076262	002	Jul 01, 2002
AB			25MG;20MG	A076262	003	Jul 01, 2002
AB		SUN PHARM INDS LTD	12.5MG;10MG	A076007	001	Jul 01, 2002
AB			12.5MG;20MG	A076007	002	Jul 01, 2002
AB			25MG;20MG	A076007	003	Jul 01, 2002
AB		WATSON LABS	12.5MG;10MG	A076194	003	Jul 01, 2002
AB			12.5MG;20MG	A076194	001	Jul 01, 2002
AB			25MG;20MG	A076194	002	Jul 01, 2002

ZESTORETIC

AB	+	ALVOGEN	12.5MG;10MG	N019888	003	Nov 18, 1993
AB	+!		12.5MG;20MG	N019888	001	Sep 20, 1990
AB	+!		25MG;20MG	N019888	002	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR

AB	+	MERCK SHARP DOHME	12.5MG;100MG	N020387	003	Oct 20, 2005

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG;50MG	A091617	001	Feb 17, 2012
AB			12.5MG;100MG	A091617	002	Feb 17, 2012
AB			25MG;100MG	A091617	003	Feb 17, 2012
AB		AUROBINDO PHARMA	12.5MG;50MG	A091629	001	Oct 06, 2010
AB			12.5MG;100MG	A091629	002	Oct 06, 2010
AB	!		25MG;100MG	A091629	003	Jan 06, 2010
AB		CADISTA PHARMS	12.5MG;50MG	A201845	001	Sep 18, 2012
AB			12.5MG;100MG	A201845	002	Sep 18, 2012
AB			25MG;100MG	A201845	003	Sep 18, 2012
AB		HIKMA	12.5MG;50MG	A077732	002	Oct 06, 2010
AB			12.5MG;100MG	A077732	001	Apr 06, 2010
AB			25MG;100MG	A077732	003	Oct 06, 2010
AB		IPCA LABS LTD	12.5MG;50MG	A201682	001	Mar 01, 2013
AB			12.5MG;100MG	A201682	002	Mar 01, 2013
AB			25MG;100MG	A201682	003	Mar 01, 2013
AB		LUPIN LTD	12.5MG;50MG	A078245	001	Oct 06, 2010
AB			12.5MG;100MG	A078245	002	May 21, 2010
AB			25MG;100MG	A078245	003	Oct 06, 2010
AB		MACLEODS PHARMS LTD	12.5MG;50MG	A202289	001	Aug 09, 2012
AB			12.5MG;100MG	A202289	002	Aug 09, 2012
AB			25MG;100MG	A202289	003	Aug 09, 2012
AB		MYLAN	12.5MG;50MG	A091652	001	Oct 06, 2010
AB			12.5MG;100MG	A091652	002	Apr 06, 2010
AB			25MG;100MG	A091652	003	Oct 06, 2010
AB		PRINSTON INC	12.5MG;50MG	A204901	001	Nov 06, 2017
AB			12.5MG;100MG	A204901	002	Nov 06, 2017
AB			25MG;100MG	A204901	003	Nov 06, 2017
AB		SANDOZ	12.5MG;50MG	A077948	001	Oct 06, 2010
AB			12.5MG;100MG	A077948	003	Aug 19, 2010
AB			25MG;100MG	A077948	002	Oct 06, 2010
AB		TEVA PHARMS	12.5MG;50MG	A077157	001	Apr 06, 2010
AB			12.5MG;100MG	A077157	002	Apr 06, 2010
AB			25MG;100MG	A077157	003	Apr 06, 2010
AB		TORRENT PHARMS	12.5MG;50MG	A090528	001	Oct 06, 2010
AB			12.5MG;100MG	A090528	003	Apr 06, 2010
AB			25MG;100MG	A090528	002	Oct 06, 2010
AB		UNICHEM LABS LTD	12.5MG;50MG	A204832	001	Jul 21, 2017
AB			12.5MG;100MG	A204832	002	Jul 21, 2017
AB			25MG;100MG	A204832	003	Jul 21, 2017
AB		ZYDUS PHARMS USA INC	12.5MG;50MG	A078385	001	Oct 06, 2010
AB			25MG;100MG	A078385	002	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

		MYLAN	15MG;250MG	A070265	002	Jan 23, 1986
	!		25MG;250MG	A070265	001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

	+	CONCORDIA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
	+		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
	+!		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

AB	**+**	US PHARMS HOLDINGS I	**25MG;50MG**	**N018303**	**001**	Dec 31, 1984
AB	**+!**		**25MG;100MG**	**N018303**	**002**	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**25MG;50MG**	**A202870**	**001**	Nov 06, 2013
AB			**25MG;100MG**	**A202870**	**002**	Nov 06, 2013
AB			**50MG;100MG**	**A202870**	**003**	Nov 06, 2013
AB		MYLAN	**25MG;50MG**	**A076792**	**001**	Aug 20, 2004
AB			**25MG;100MG**	**A076792**	**002**	Aug 20, 2004
AB			**50MG;100MG**	**A076792**	**003**	Aug 20, 2004
AB		SUN PHARM INDS	**25MG;50MG**	**A090654**	**001**	Jan 19, 2012
AB			**25MG;100MG**	**A090654**	**002**	Jan 19, 2012
AB			**50MG;100MG**	**A090654**	**003**	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		GLENMARK PHARMS	**12.5MG;7.5MG**	**A090718**	**001**	Mar 17, 2010
AB			**12.5MG;15MG**	**A090718**	**002**	Mar 17, 2010
AB			**25MG;15MG**	**A090718**	**003**	Mar 17, 2010
AB		HERITAGE PHARMS INC	**12.5MG;7.5MG**	**A202150**	**001**	Mar 07, 2014
AB			**12.5MG;15MG**	**A202150**	**002**	Mar 07, 2014
AB			**25MG;15MG**	**A202150**	**003**	Mar 07, 2014
AB		TEVA	**12.5MG;7.5MG**	**A076980**	**001**	Mar 07, 2007
AB			**12.5MG;15MG**	**A076980**	**003**	Mar 07, 2007
AB	**!**		**25MG;15MG**	**A076980**	**002**	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR HCT

AB	**+**	DAIICHI SANKYO	**12.5MG;20MG**	**N021532**	**002**	Jun 05, 2003
AB	**+**		**12.5MG;40MG**	**N021532**	**003**	Jun 05, 2003
AB	**+!**		**25MG;40MG**	**N021532**	**005**	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;20MG**	**A204233**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A204233**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A204233**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA LTD	**12.5MG;20MG**	**A205391**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A205391**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A205391**	**003**	Apr 24, 2017
AB		PRINSTON INC	**12.5MG;20MG**	**A207804**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A207804**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A207804**	**003**	Apr 24, 2017
AB		TEVA PHARMS USA	**12.5MG;40MG**	**A200532**	**002**	Apr 24, 2017
AB		TORRENT	**12.5MG;20MG**	**A206515**	**001**	May 03, 2017
AB			**12.5MG;40MG**	**A206515**	**002**	May 03, 2017
AB			**25MG;40MG**	**A206515**	**003**	May 03, 2017
AB		UMEDICA LABS PVT LTD	**12.5MG;20MG**	**A208847**	**001**	Sep 17, 2019
AB			**12.5MG;40MG**	**A208847**	**003**	Sep 17, 2019
AB			**25MG;40MG**	**A208847**	**002**	Sep 17, 2019

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	**!**	MYLAN	**25MG;80MG**	**A070947**	**001**	Apr 01, 1987
	!		25MG;40MG	A070947	002	Mar 04, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCURETIC

AB	**+**	PFIZER PHARMS	**12.5MG;EQ 10MG BASE**	**N020125**	**001**	Dec 28, 1999
AB	**+**		**12.5MG;EQ 20MG BASE**	**N020125**	**002**	Dec 28, 1999
AB	**+!**		**25MG;EQ 20MG BASE**	**N020125**	**003**	Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		APOTEX CORP	**12.5MG;EQ 10MG BASE**	**A091524**	**001**	Mar 12, 2013
AB			**12.5MG;EQ 20MG BASE**	**A091524**	**002**	Mar 12, 2013
AB			**25MG;EQ 20MG BASE**	**A091524**	**003**	Mar 12, 2013
AB		AUROBINDO PHARMA	**12.5MG;EQ 10MG BASE**	**A078450**	**001**	Aug 24, 2007
AB			**12.5MG;EQ 20MG BASE**	**A078450**	**002**	Aug 24, 2007
AB			**25MG;EQ 20MG BASE**	**A078450**	**003**	Aug 24, 2007
AB		INVAGEN PHARMS	**12.5MG;EQ 10MG BASE**	**A201356**	**001**	Apr 20, 2011
AB			**12.5MG;EQ 20MG BASE**	**A201356**	**002**	Apr 20, 2011
AB			**25MG;EQ 20MG BASE**	**A201356**	**003**	Apr 20, 2011

QUINARETIC

AB		LUPIN	**12.5MG;EQ 10MG BASE**	**A076374**	**001**	Mar 31, 2004
AB			**12.5MG;EQ 20MG BASE**	**A076374**	**002**	Mar 31, 2004
AB			**25MG;EQ 20MG BASE**	**A076374**	**003**	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

ALDACTAZIDE

AB	**+**	GD SEARLE LLC	**25MG;25MG**	**N012616**	**004**	Dec 30, 1982

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	**25MG;25MG**	**A086513**	**001**	
AB		SUN PHARM INDUSTRIES	**25MG;25MG**	**A089534**	**001**	Jul 02, 1987

ALDACTAZIDE

	+!	GD SEARLE LLC	50MG;50MG	N012616	005	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT

AB	**+**	BOEHRINGER INGELHEIM	**12.5MG;40MG**	**N021162**	**001**	Nov 17, 2000
AB	**+**		**12.5MG;80MG**	**N021162**	**002**	Nov 17, 2000
AB	**+!**		**25MG;80MG**	**N021162**	**003**	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;40MG**	**A203010**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A203010**	**002**	Feb 25, 2014
AB			**25MG;80MG**	**A203010**	**003**	Feb 25, 2014
AB		AUROBINDO PHARMA LTD	**12.5MG;40MG**	**A208727**	**001**	Dec 15, 2016
AB			**12.5MG;80MG**	**A208727**	**002**	Dec 15, 2016
AB			**25MG;80MG**	**A208727**	**003**	Dec 15, 2016
AB		GLENMARK PHARMS LTD	**12.5MG;40MG**	**A202544**	**001**	Mar 04, 2019
AB			**12.5MG;80MG**	**A202544**	**002**	Mar 04, 2019
AB			**25MG;80MG**	**A202544**	**003**	Mar 04, 2019
AB		LUPIN LTD	**12.5MG;40MG**	**A091351**	**001**	Aug 07, 2014
AB			**12.5MG;80MG**	**A091351**	**002**	Aug 07, 2014
AB			**25MG;80MG**	**A091351**	**003**	Aug 07, 2014
AB		MACLEODS PHARMS LTD	**12.5MG;40MG**	**A204169**	**001**	Nov 02, 2015
AB			**12.5MG;80MG**	**A204169**	**002**	Nov 02, 2015
AB			**25MG;80MG**	**A204169**	**003**	Nov 02, 2015
AB		MYLAN	**12.5MG;40MG**	**A091648**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A091648**	**002**	Feb 25, 2014
AB			**25MG;80MG**	**A091648**	**003**	Feb 25, 2014
AB		PRINSTON INC	**12.5MG;40MG**	**A209028**	**001**	Nov 06, 2017
AB			**12.5MG;80MG**	**A209028**	**002**	Nov 06, 2017
AB			**25MG;80MG**	**A209028**	**003**	Nov 06, 2017
AB		TORRENT	**12.5MG;40MG**	**A201192**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A201192**	**002**	Feb 25, 2014
AB			**25MG;80MG**	**A201192**	**003**	Feb 25, 2014
AB		ZYDUS PHARMS	**12.5MG;40MG**	**A204221**	**001**	Aug 15, 2017
AB			**12.5MG;80MG**	**A204221**	**002**	Aug 15, 2017
AB			**25MG;80MG**	**A204221**	**003**	Aug 15, 2017

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

DYAZIDE

AB	**+!**	GLAXOSMITHKLINE LLC	**25MG;37.5MG**	**N016042**	**003**	Mar 03, 1994

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		DURAMED PHARMS BARR	**25MG;37.5MG**	**A075052**	**001**	Jun 18, 1999
AB		LANNETT CO INC	**25MG;37.5MG**	**A201407**	**001**	Dec 09, 2011
AB		MYLAN	**25MG;37.5MG**	**A074701**	**001**	Jun 07, 1996
AB		SANDOZ	**25MG;37.5MG**	**A074821**	**001**	Jun 05, 1997
AB		ZYDUS PHARMS	**25MG;37.5MG**	**A208358**	**001**	Feb 11, 2019

TABLET;ORAL

MAXZIDE

AB	**+!**	MYLAN PHARMS INC	**50MG;75MG**	**N019129**	**001**	Oct 22, 1984

MAXZIDE-25

AB	**+**	MYLAN PHARMS INC	**25MG;37.5MG**	**N019129**	**003**	May 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	**25MG;37.5MG**	**A071251**	**002**	May 05, 1998
AB			**50MG;75MG**	**A071251**	**001**	Apr 17, 1988
AB		PLIVA	**25MG;37.5MG**	**A074026**	**001**	Apr 26, 1996
AB		SANDOZ	**25MG;37.5MG**	**A073281**	**001**	Apr 30, 1992
AB			**50MG;75MG**	**A072011**	**001**	Jun 17, 1988
AB		WATSON LABS	**25MG;37.5MG**	**A073449**	**001**	Sep 23, 1993
AB			**50MG;75MG**	**A071851**	**001**	Nov 30, 1988
AB		ZYDUS PHARMS	**25MG;37.5MG**	**A208360**	**001**	Jun 29, 2018
AB			**50MG;75MG**	**A208360**	**002**	Jun 29, 2018

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

DIOVAN HCT

AB	**+**	NOVARTIS	**12.5MG;80MG**	**N020818**	**001**	Mar 06, 1998
AB	**+**		**12.5MG;160MG**	**N020818**	**002**	Mar 06, 1998
AB	**+**		**12.5MG;320MG**	**N020818**	**004**	Apr 28, 2006
AB	**+**		**25MG;160MG**	**N020818**	**003**	Jan 17, 2002
AB	**+!**		**25MG;320MG**	**N020818**	**005**	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;80MG**	**A201662**	**001**	Mar 21, 2013
AB			**12.5MG;160MG**	**A201662**	**002**	Mar 21, 2013
AB			**12.5MG;320MG**	**A201662**	**003**	Mar 21, 2013
AB			**25MG;160MG**	**A201662**	**004**	Mar 21, 2013
AB			**25MG;320MG**	**A201662**	**005**	Mar 21, 2013
AB		AUROBINDO PHARMA LTD	**12.5MG;80MG**	**A202519**	**001**	Mar 21, 2013
AB			**12.5MG;160MG**	**A202519**	**002**	Mar 21, 2013
AB			**12.5MG;320MG**	**A202519**	**003**	Mar 21, 2013
AB			**25MG;160MG**	**A202519**	**004**	Mar 21, 2013
AB			**25MG;320MG**	**A202519**	**005**	Mar 21, 2013
AB		LUPIN LTD	**12.5MG;80MG**	**A078946**	**003**	Mar 21, 2013
AB			**12.5MG;160MG**	**A078946**	**004**	Mar 21, 2013
AB			**12.5MG;320MG**	**A078946**	**001**	Mar 21, 2013
AB			**25MG;160MG**	**A078946**	**005**	Mar 21, 2013
AB			**25MG;320MG**	**A078946**	**002**	Mar 21, 2013
AB		MACLEODS PHARMS LTD	**12.5MG;80MG**	**A203145**	**001**	Apr 19, 2013
AB			**12.5MG;160MG**	**A203145**	**002**	Apr 19, 2013
AB			**12.5MG;320MG**	**A203145**	**003**	Apr 19, 2013
AB			**25MG;160MG**	**A203145**	**004**	Apr 19, 2013
AB			**25MG;320MG**	**A203145**	**005**	Apr 19, 2013
AB		MYLAN PHARMS INC	**12.5MG;80MG**	**A078020**	**001**	Sep 21, 2012
AB			**12.5MG;160MG**	**A078020**	**002**	Sep 21, 2012
AB			**12.5MG;320MG**	**A078020**	**004**	Sep 21, 2012
AB			**25MG;160MG**	**A078020**	**003**	Sep 21, 2012
AB			**25MG;320MG**	**A078020**	**005**	Sep 21, 2012
AB		PRINSTON INC	**12.5MG;80MG**	**A206083**	**001**	Feb 08, 2016
AB			**12.5MG;160MG**	**A206083**	**002**	Feb 08, 2016
AB			**12.5MG;320MG**	**A206083**	**003**	Feb 08, 2016
AB			**25MG;160MG**	**A206083**	**004**	Feb 08, 2016
AB			**25MG;320MG**	**A206083**	**005**	Feb 08, 2016

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+!	PERSION	10MG	N202880	001	Oct 25, 2013
+		15MG	N202880	002	Oct 25, 2013
+		20MG	N202880	003	Oct 25, 2013
+		30MG	N202880	004	Oct 25, 2013

HYDROCODONE BITARTRATE						
CAPSULE, EXTENDED RELEASE;ORAL						
ZOHYDRO ER						
+		40MG		N202880	005	Oct 25, 2013
+		50MG		N202880	006	Oct 25, 2013
TABLET, EXTENDED RELEASE;ORAL						
HYSINGLA ER						
+!	PURDUE PHARMA LP	20MG		N206627	001	Nov 20, 2014
+		30MG		N206627	002	Nov 20, 2014
+		40MG		N206627	003	Nov 20, 2014
+		60MG		N206627	004	Nov 20, 2014
+		80MG		N206627	005	Nov 20, 2014
+		100MG		N206627	006	Nov 20, 2014
+		120MG		N206627	007	Nov 20, 2014
HYDROCODONE BITARTRATE; IBUPROFEN						
TABLET;ORAL						
HYDROCODONE BITARTRATE AND IBUPROFEN						
AB	ACTAVIS LABS FL INC	**7.5MG;200MG**		**A076604**	**001**	Dec 31, 2003
AB	AMNEAL PHARMS NY	**5MG;200MG**		**A076642**	**002**	Mar 18, 2004
AB !		**7.5MG;200MG**		**A076642**	**001**	Oct 12, 2004
AB	AUROLIFE PHARMA LLC	**7.5MG;200MG**		**A204575**	**001**	Jun 02, 2016
AB	VINTAGE PHARMS	**5MG;200MG**		**A077727**	**001**	Nov 06, 2006
AB		**7.5MG;200MG**		**A077723**	**001**	Nov 06, 2006
AB		**10MG;200MG**		**A077723**	**002**	Nov 06, 2006
REPREXAIN						
AB	AMNEAL PHARMS NY	**10MG;200MG**		**A076642**	**004**	Oct 19, 2007
		2.5MG;200MG		A076642	003	Oct 19, 2007
HYDROCORTISONE						
CREAM;TOPICAL						
ALA-CORT						
AT	CROWN LABS	**2.5%**		**A080706**	**007**	Jan 05, 2016
AT		**1%**		**A080706**	**006**	
ANUSOL HC						
AT	SALIX PHARMS	**2.5%**		**A088250**	**001**	Jun 06, 1984
HYDROCORTISONE						
AT	ACTAVIS MID ATLANTIC	**1%**		**A087795**	**001**	May 03, 1983
AT		**2.5%**		**A089682**	**001**	Mar 10, 1988
AT !	FOUGERA PHARMS INC	**1%**		**A080693**	**003**	
AT !		**2.5%**		**A089414**	**001**	Dec 16, 1986
AT	LANNETT CO INC	**2.5%**		**A040503**	**001**	Mar 12, 2004
AT	PERRIGO NEW YORK	**2.5%**		**A085025**	**001**	
AT	RISING	**2.5%**		**A040879**	**001**	Aug 20, 2010
AT	TARO PHARM INDS LTD	**2.5%**		**A088799**	**001**	Nov 09, 1984
AT	TELIGENT PHARMA INC	**2.5%**		**A203810**	**001**	Jul 23, 2018
ENEMA;RECTAL						
COLOCORT						
AB	PADDOCK LLC	**100MG/60ML**		**A075172**	**001**	Dec 03, 1999
CORTENEMA						
AB +!	ANI PHARMS	**100MG/60ML**		**N016199**	**001**	
HYDROCORTISONE						
AB	TEVA PHARMS	**100MG/60ML**		**A074171**	**001**	May 27, 1994
LOTION;TOPICAL						
HYDROCORTISONE						
AT !	FOUGERA PHARMS	**2.5%**		**A040351**	**001**	Jul 25, 2000
AT	LANNETT CO INC	**2.5%**		**A040417**	**001**	Jul 30, 2003
AT	TARO	**2.5%**		**A040247**	**001**	Jul 23, 1999
AT	TELIGENT PHARMA INC	**2.5%**		**A203804**	**001**	Jul 27, 2018
STIE-CORT						
AT	PERRIGO CO	**2.5%**		**A089074**	**001**	Nov 26, 1985
ALA-SCALP						
	MARNEL PHARMS	2%		A083231	001	
OINTMENT;TOPICAL						
HYDROCORTISONE						
AT	ACTAVIS MID ATLANTIC	**1%**		**A087796**	**001**	Oct 13, 1982
AT !	FOUGERA PHARMS	**1%**		**A080692**	**001**	
AT !	FOUGERA PHARMS INC	**2.5%**		**A081203**	**001**	May 28, 1993
AT	PERRIGO NEW YORK	**2.5%**		**A085027**	**001**	
AT	TARO	**1%**		**A086257**	**001**	

HYDROCORTISONE

OINTMENT;TOPICAL

HYDROCORTISONE IN ABSORBASE

AT		CMP PHARMA INC	**1%**	**A088138**	**001**	Sep 06, 1985

SOLUTION;TOPICAL

TEXACORT

	!	MISSION PHARMA	2.5%	A081271	001	Apr 17, 1992

TABLET;ORAL

CORTEF

AB	**+**	PHARMACIA AND UPJOHN	**5MG**	**N008697**	**003**	
AB	**+**		**10MG**	**N008697**	**001**	
AB	**+!**		**20MG**	**N008697**	**002**	

HYDROCORTISONE

AB		HIKMA INTL PHARMS	**5MG**	**A083365**	**002**	Feb 23, 2015
AB			**10MG**	**A083365**	**003**	Feb 23, 2015
AB			**20MG**	**A083365**	**001**	
AB		IMPAX LABS INC	**5MG**	**A040646**	**001**	Mar 30, 2007
AB			**10MG**	**A040646**	**002**	Mar 30, 2007
AB			**20MG**	**A040646**	**003**	Mar 30, 2007
AB		PII	**5MG**	**A207029**	**001**	Apr 27, 2017
AB			**10MG**	**A207029**	**002**	Apr 27, 2017
AB			**20MG**	**A207029**	**003**	Apr 27, 2017
AB		VINTAGE	**5MG**	**A040761**	**001**	Jul 16, 2007
AB			**10MG**	**A040761**	**002**	Jul 16, 2007
AB			**20MG**	**A040761**	**003**	Jul 16, 2007

HYDROCORTISONE ACETATE

AEROSOL, METERED;RECTAL

CORTIFOAM

	+!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982

CREAM;TOPICAL

MICORT-HC

		SEBELA IRELAND LTD	2.5%	A040396	001	Feb 27, 2001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL

CORTISPORIN

	+!	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL

EPIFOAM

BX		MYLAN SPECIALITY LP	1%;1%	A086457	001	

PROCTOFOAM HC

BX		MYLAN SPECIALITY LP	1%;1%	A086195	001	

CREAM;TOPICAL

PRAMOSONE

		SEBELA IRELAND LTD	0.5%;1%	A083778	001	
			1%;1%	A085368	001	

LOTION;TOPICAL

PRAMOSONE

		SEBELA IRELAND LTD	1%;1%	A085980	001	
			2.5%;1%	A085979	001	

HYDROCORTISONE ACETATE; UREA

CREAM;TOPICAL

U-CORT

		TARO	1%;10%	A089472	001	Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

HYDROCORTISONE BUTYRATE

AB1		TARO PHARM INDS	**0.1%**	**A076654**	**001**	Aug 03, 2005

LOCOID

AB1	**+!**	BAUSCH	**0.1%**	**N018514**	**001**	Mar 31, 1982

HYDROCORTISONE BUTYRATE

AB2		ACTAVIS MID ATLANTIC	**0.1%**	**A205134**	**001**	Dec 08, 2017
AB2		GLENMARK GENERICS	**0.1%**	**A202145**	**001**	Sep 27, 2013

LOCOID LIPOCREAM

AB2	**+!**	PRECISION DERMAT	**0.1%**	**N020769**	**001**	Sep 08, 1997

LOTION;TOPICAL

HYDROCORTISONE BUTYRATE

AB		LUPIN LTD	**0.1%**	**A210209**	**001**	Aug 17, 2018

HYDROCORTISONE BUTYRATE

LOTION;TOPICAL

HYDROCORTISONE BUTYRATE

AB		TELIGENT PHARMA INC	**0.1%**	**A209556**	**001**	Nov 21, 2017

LOCOID

AB	**+!**	BAUSCH	**0.1%**	**N022076**	**001**	May 18, 2007

OINTMENT;TOPICAL

HYDROCORTISONE BUTYRATE

AB		TARO	**0.1%**	**A076842**	**001**	Dec 27, 2004

LOCOID

AB	**+!**	PRECISION DERMAT	**0.1%**	**N018652**	**001**	Oct 29, 1982

SOLUTION;TOPICAL

HYDROCORTISONE BUTYRATE

AT		TARO PHARM INDS	**0.1%**	**A076364**	**001**	Jan 14, 2004

LOCOID

AT	**+!**	BAUSCH	**0.1%**	**N019116**	**001**	Feb 25, 1987

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL

PANDEL

	+!	FOUGERA PHARMS	0.1%	N020453	001	Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

SOLU-CORTEF

	+!	PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001	
	+!		EQ 250MG BASE/VIAL	N009866	002	
	+!		EQ 500MG BASE/VIAL	N009866	003	
	+!		EQ 1GM BASE/VIAL	N009866	004	

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

AB		GLENMARK PHARMS LTD	**0.2%**	**A211129**	**001**	Oct 12, 2018
AB		LUPIN LTD	**0.2%**	**A210307**	**001**	Aug 15, 2019
AB		PERRIGO ISRAEL	**0.2%**	**A075666**	**001**	May 24, 2000
AB	**!**	TARO	**0.2%**	**A075042**	**001**	Aug 25, 1998

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

AB		GLENMARK PHARMS LTD	**0.2%**	**A211750**	**001**	Dec 14, 2018
AB	**!**	TARO	**0.2%**	**A075043**	**001**	Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	**!**	BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064053**	**001**	Dec 29, 1995
AT		SANDOZ INC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062423**	**001**	Aug 25, 1983

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

	!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988

SUSPENSION/DROPS;OTIC

CASPORYN HC

AT	**+!**	CASPER PHARMA LLC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N060613**	**001**	

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT		AMRING PHARMS	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A065219**	**001**	May 01, 2006
AT		SANDOZ INC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062488**	**001**	Nov 06, 1985

OTICAIR

AT		BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064065**	**001**	Aug 28, 1996

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

AP	**+!**	FRESENIUS KABI USA	**1MG/ML**	**N019034**	**003**	Apr 30, 2009
AP	**+!**		**2MG/ML**	**N019034**	**004**	Apr 30, 2009

HYDROMORPHONE HYDROCHLORIDE

AP		AKORN	**10MG/ML**	**A078228**	**001**	Apr 14, 2010
AP			**10MG/ML**	**A078261**	**001**	Apr 14, 2010
AP		BARR	**10MG/ML**	**A076444**	**001**	Apr 25, 2003
AP		EUROHLTH INTL SARL	**2MG/ML**	**A202159**	**001**	Apr 27, 2018
AP		HOSPIRA INC	**1MG/ML**	**N200403**	**001**	Dec 01, 2011
AP			**2MG/ML**	**N200403**	**002**	Dec 01, 2011
AP			**4MG/ML**	**N200403**	**003**	Dec 01, 2011
AP			**10MG/ML**	**A078591**	**001**	Jun 17, 2008

HYDROMORPHONE HYDROCHLORIDE

SOLUTION;ORAL

DILAUDID

AA	**+!**	RHODES PHARMS	**5MG/5ML**	**N019891**	**001**	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

AA		ASCENT PHARMS INC	**5MG/5ML**	**A210176**	**001**	Oct 27, 2017
AA		HIKMA	**5MG/5ML**	**A074653**	**001**	Jul 29, 1998

TABLET;ORAL

DILAUDID

AB	**+**	RHODES PHARMS	**2MG**	**N019892**	**003**	Nov 09, 2007
AB	**+**		**4MG**	**N019892**	**002**	Nov 09, 2007
AB	**+!**		**8MG**	**N019892**	**001**	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**2MG**	**A210506**	**001**	Jan 17, 2018
AB			**4MG**	**A210506**	**002**	Jan 17, 2018
AB			**8MG**	**A210506**	**003**	Jan 17, 2018
AB		AUROLIFE PHARMA LLC	**2MG**	**A205814**	**001**	May 13, 2016
AB			**4MG**	**A205814**	**002**	May 13, 2016
AB			**8MG**	**A205814**	**003**	May 13, 2016
AB		ELITE LABS	**8MG**	**A076723**	**001**	Oct 18, 2005
AB		HIKMA	**4MG**	**A074597**	**003**	May 29, 2009
AB			**8MG**	**A074597**	**001**	Jul 29, 1998
AB		LANNETT CO INC	**2MG**	**A077471**	**002**	Dec 09, 2009
AB			**4MG**	**A077471**	**003**	Dec 09, 2009
AB			**8MG**	**A077471**	**001**	Dec 09, 2009
AB		SPECGX LLC	**2MG**	**A076855**	**002**	Sep 19, 2007
AB			**4MG**	**A076855**	**003**	Sep 19, 2007
AB			**8MG**	**A076855**	**001**	Dec 23, 2004

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		OSMOTICA	**8MG**	**A205629**	**001**	Jul 07, 2016
AB			**12MG**	**A205629**	**002**	Jul 07, 2016
AB			**16MG**	**A205629**	**003**	Jul 07, 2016
AB	**!**		**32MG**	**A205629**	**004**	Jul 07, 2016
AB		PADDOCK LLC	**8MG**	**A204278**	**001**	Apr 06, 2015
AB			**12MG**	**A204278**	**002**	Apr 06, 2015
AB			**16MG**	**A204278**	**003**	Apr 06, 2015
AB			**32MG**	**A204278**	**004**	Sep 20, 2017

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

	+!	SERB SA	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011

HYDROXOCOBALAMIN

	!	ACTAVIS LLC	1MG/ML	A085998	001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

PAREMYD

	+!	AKORN	1%;0.25%	N019261	001	Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB		ALKALOIDA ZRT	**200MG**	**A201691**	**001**	May 08, 2018
AB		AMNEAL PHARMS CO	**200MG**	**A210577**	**001**	May 15, 2018
AB		HIKMA PHARMS	**200MG**	**A040760**	**001**	Aug 15, 2007
AB		IPCA LABS LTD	**200MG**	**A040766**	**001**	Jun 14, 2007
AB		MYLAN	**200MG**	**A040274**	**001**	May 29, 1998
AB		SANDOZ	**200MG**	**A040104**	**001**	Nov 30, 1995
AB		TEVA PHARMS	**200MG**	**A040081**	**001**	Sep 30, 1994
AB		TWI PHARMS	**200MG**	**A210441**	**001**	May 01, 2018
AB		WATSON LABS	**200MG**	**A040133**	**001**	Nov 30, 1995
AB		ZYDUS PHARMS USA INC	**200MG**	**A040657**	**001**	Sep 21, 2007

PLAQUENIL

AB	**+!**	CONCORDIA	**200MG**	**N009768**	**001**	

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

AP		AM REGENT	**250MG/ML (250MG/ML)**	**A210723**	**001**	Jun 21, 2018
AP		ASPEN	**250MG/ML (250MG/ML)**	**A211777**	**001**	Aug 08, 2019
AP		EUGIA PHARMA	**250MG/ML (250MG/ML)**	**A211071**	**001**	Apr 16, 2019
AP		SLAYBACK PHARMA LLC	**250MG/ML (250MG/ML)**	**A210877**	**001**	Mar 22, 2019

HYDROXYPROGESTERONE CAPROATE						
SOLUTION;INTRAMUSCULAR						
MAKENA PRESERVATIVE FREE						
AP	**+!**	AMAG PHARMA USA	**250MG/ML (250MG/ML)**	**N021945**	**002**	Feb 19, 2016
HYDROXYPROGESTERON CAPROATE						
AP1		AM REGENT	**1250MG/5ML (250MG/ML)**	**A210724**	**001**	Aug 09, 2019
HYDROXYPROGESTERONE CAPROATE						
AP1		EUGIA PHARMA	**1250MG/5ML (250MG/ML)**	**A211070**	**001**	Apr 16, 2019
AP1		SLAYBACK PHARMA LLC	**1250MG/5ML (250MG/ML)**	**A210618**	**001**	Dec 28, 2018
AP1		SUN PHARM	**1250MG/5ML (250MG/ML)**	**A208381**	**001**	Apr 09, 2019
MAKENA						
AP1	**+!**	AMAG PHARMA USA	**1250MG/5ML (250MG/ML)**	**N021945**	**001**	Feb 03, 2011
HYDROXYPROGESTERONE CAPROATE						
	!	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015
SOLUTION;SUBCUTANEOUS						
MAKENA (AUTOINJECTOR)						
	+!	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018
HYDROXYPROPYL CELLULOSE						
INSERT;OPHTHALMIC						
LACRISERT						
	+!	VALEANT PHARMS INTL	5MG	N018771	001	
HYDROXYUREA						
CAPSULE;ORAL						
HYDREA						
AB	**+!**	BRISTOL MYERS SQUIBB	**500MG**	**N016295**	**001**	
HYDROXYUREA						
AB		BARR	**500MG**	**A075143**	**001**	Oct 16, 1998
AB		PAR PHARM	**500MG**	**A075340**	**001**	Feb 24, 1999
DROXIA						
	+	BRISTOL MYERS SQUIBB	200MG	N016295	002	Feb 25, 1998
	+		300MG	N016295	003	Feb 25, 1998
	+		400MG	N016295	004	Feb 25, 1998
TABLET;ORAL						
SIKLOS						
	+	ADDMEDICA SAS	100MG	N208843	001	Dec 21, 2017
	+		1GM	N208843	002	Dec 21, 2017
HYDROXYZINE HYDROCHLORIDE						
INJECTABLE;INJECTION						
HYDROXYZINE HYDROCHLORIDE						
	!	LUITPOLD	25MG/ML	A087408	001	
	!		50MG/ML	A087408	002	
SYRUP;ORAL						
HYDROXYZINE HYDROCHLORIDE						
AA	**!**	HI TECH PHARMA	**10MG/5ML**	**A040010**	**001**	Oct 28, 1994
AA		LANNETT CO INC	**10MG/5ML**	**A201674**	**001**	Aug 21, 2013
AA	**!**	VINTAGE PHARMS	**10MG/5ML**	**A040391**	**001**	Apr 10, 2002
AA	**!**	WOCKHARDT BIO AG	**10MG/5ML**	**A087294**	**001**	Apr 12, 1982
TABLET;ORAL						
HYDROXYZINE HYDROCHLORIDE						
AB		AMNEAL PHARM	**10MG**	**A040808**	**001**	Sep 24, 2008
AB			**25MG**	**A040808**	**002**	Sep 24, 2008
AB			**50MG**	**A040808**	**003**	Sep 24, 2008
AB		ECI PHARMS LLC	**10MG**	**A040804**	**001**	Jun 30, 2008
AB			**25MG**	**A040804**	**002**	Jun 30, 2008
AB			**50MG**	**A040804**	**003**	Jun 30, 2008
AB		EPIC PHARMA LLC	**10MG**	**A040604**	**002**	Dec 28, 2004
AB			**25MG**	**A040604**	**003**	Dec 28, 2004
AB			**50MG**	**A040604**	**001**	Dec 28, 2004
AB		HERITAGE PHARMA	**10MG**	**A204279**	**001**	Aug 20, 2014
AB			**25MG**	**A204279**	**002**	Aug 20, 2014
AB			**50MG**	**A204279**	**003**	Aug 20, 2014
AB		HETERO LABS LTD III	**10MG**	**A040805**	**001**	May 29, 2008
AB			**25MG**	**A040805**	**002**	May 29, 2008
AB			**50MG**	**A040805**	**003**	May 29, 2008
AB		INVAGEN PHARMS	**10MG**	**A040812**	**001**	Mar 12, 2008
AB			**25MG**	**A040812**	**002**	Mar 12, 2008
AB			**50MG**	**A040812**	**003**	Mar 12, 2008
AB		KVK TECH	**10MG**	**A040786**	**001**	Mar 20, 2007
AB			**25MG**	**A040786**	**002**	Mar 20, 2007

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE						
AB			**50MG**	**A040786**	**003**	Mar 20, 2007
AB		NORTHSTAR HLTHCARE	**10MG**	**A040840**	**002**	Mar 31, 2008
AB			**25MG**	**A040840**	**003**	Mar 31, 2008
AB			**50MG**	**A040840**	**001**	Mar 31, 2008
AB		NUVO PHARM	**10MG**	**A207120**	**001**	Mar 29, 2017
AB			**50MG**	**A207122**	**001**	Mar 29, 2017
AB		NUVO PHARMS INC	**25MG**	**A207121**	**001**	Mar 29, 2017
AB	!	PLIVA	**10MG**	**A088617**	**001**	Jan 10, 1986
AB	!		**25MG**	**A088618**	**001**	Jan 10, 1986
AB	!		**50MG**	**A088619**	**001**	Jan 10, 1986
AB		PRINSTON INC	**10MG**	**A040579**	**001**	May 27, 2005
AB			**25MG**	**A040574**	**001**	May 27, 2005
AB			**50MG**	**A040580**	**001**	May 27, 2005

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE						
AB		BARR	**EQ 25MG HYDROCHLORIDE**	**A088496**	**001**	Jun 15, 1984
AB			**EQ 50MG HYDROCHLORIDE**	**A088487**	**001**	Jun 15, 1984
AB		HERITAGE PHARMA	**EQ 25MG HYDROCHLORIDE**	**A201507**	**001**	Jun 03, 2013
AB			**EQ 50MG HYDROCHLORIDE**	**A201507**	**002**	Jun 03, 2013
AB		IMPAX LABS INC	**EQ 25MG HYDROCHLORIDE**	**A040156**	**001**	Jul 15, 1996
AB			**EQ 50MG HYDROCHLORIDE**	**A040156**	**002**	Jul 15, 1996
AB		SANDOZ	**EQ 25MG HYDROCHLORIDE**	**A087479**	**001**	
AB	!		**EQ 50MG HYDROCHLORIDE**	**A086183**	**001**	
		BARR	EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA						
AP	**+!**	ROCHE	**EQ 3MG BASE/3ML**	**N021858**	**001**	Jan 06, 2006
IBANDRONATE SODIUM						
AP		ACCORD HLTHCARE	**EQ 3MG BASE/3ML**	**A206058**	**001**	Feb 05, 2016
AP		APOTEX	**EQ 3MG BASE/3ML**	**A204222**	**001**	Oct 16, 2015
AP		AUROBINDO PHARMA LTD	**EQ 3MG BASE/3ML**	**A205332**	**001**	Aug 19, 2015
AP		MYLAN LABS LTD	**EQ 3MG BASE/3ML**	**A202671**	**001**	Sep 02, 2014
AP		SAGENT PHARMS INC	**EQ 3MG BASE/3ML**	**A202235**	**001**	Sep 02, 2014
AP		SUN PHARM	**EQ 3MG BASE/3ML**	**A090853**	**001**	Feb 14, 2014

TABLET;ORAL

BONIVA						
AB	**+!**	HOFFMANN LA ROCHE	**EQ 150MG BASE**	**N021455**	**002**	Mar 24, 2005
IBANDRONATE SODIUM						
AB		APOTEX INC	**EQ 150MG BASE**	**A078948**	**001**	Mar 19, 2012
AB		AUROBINDO PHARMA LTD	**EQ 150MG BASE**	**A204502**	**001**	Mar 11, 2016
AB		DR REDDYS LABS LTD	**EQ 150MG BASE**	**A078997**	**001**	Apr 30, 2012
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A206887**	**001**	Oct 31, 2017
AB		ORCHID HLTHCARE	**EQ 150MG BASE**	**A078998**	**001**	Mar 19, 2012
AB		WATSON LABS TEVA	**EQ 150MG BASE**	**A079003**	**001**	Mar 20, 2012

IBRUTINIB

CAPSULE;ORAL

IMBRUVICA						
	+	PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017
	+!		140MG	N205552	001	Nov 13, 2013

TABLET;ORAL

IMBRUVICA						
	+	PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018
	+		280MG	N210563	002	Feb 16, 2018
	+		420MG	N210563	003	Feb 16, 2018
	+!		560MG	N210563	004	Feb 16, 2018

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR						
	+!	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009
	+!		800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019

SUSPENSION;ORAL

IBUPROFEN						
AB	!	ACTAVIS MID ATLANTIC	**100MG/5ML**	**A074978**	**001**	Mar 25, 1998

IBUPROFEN							
SUSPENSION;ORAL							
IBUPROFEN							
AB		HI TECH	**100MG/5ML**	**A205647**	**001**	Nov 03, 2016
AB		L PERRIGO CO	**100MG/5ML**	**A076925**	**001**	Sep 23, 2004
AB		TARO	**100MG/5ML**	**A209204**	**001**	Jun 23, 2017
		AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018
TABLET;ORAL							
IBU-TAB							
AB		ALRA	**400MG**	**A071058**	**001**	Aug 11, 1988
AB			**600MG**	**A071059**	**001**	Aug 11, 1988
IBUPROFEN							
AB		AMNEAL PHARMS NY	**400MG**	**A071334**	**001**	Nov 25, 1986
AB			**400MG**	**A078558**	**001**	Jun 18, 2007
AB			**600MG**	**A071335**	**001**	Nov 25, 1986
AB			**600MG**	**A078558**	**002**	Jun 18, 2007
AB			**800MG**	**A071935**	**001**	Oct 13, 1987
AB			**800MG**	**A078558**	**003**	Jun 18, 2007
AB		CONTRACT PHARMACAL	**400MG**	**A071268**	**002**	Oct 15, 1986
AB			**600MG**	**A071268**	**001**	Oct 15, 1986
AB			**800MG**	**A071268**	**003**	Jul 01, 1988
AB		DR REDDYS LA	**400MG**	**A075682**	**001**	Nov 14, 2001
AB			**600MG**	**A075682**	**002**	Nov 14, 2001
AB	**!**		**800MG**	**A075682**	**003**	Nov 14, 2001
AB		DR REDDYS LABS INC	**400MG**	**A076112**	**001**	Oct 31, 2001
AB			**600MG**	**A076112**	**002**	Oct 31, 2001
AB			**800MG**	**A076112**	**003**	Oct 31, 2001
AB		GRANULES INDIA LTD	**400MG**	**A091625**	**001**	Sep 15, 2015
AB			**600MG**	**A091625**	**002**	Sep 15, 2015
AB			**800MG**	**A091625**	**003**	Sep 15, 2015
AB		MARKSANS PHARMA	**400MG**	**A090796**	**001**	Dec 21, 2010
AB			**600MG**	**A090796**	**002**	Dec 21, 2010
AB			**800MG**	**A090796**	**003**	Dec 21, 2010
AB		PERRIGO PHARMS CO	**400MG**	**A077114**	**001**	Jul 18, 2005
AB			**600MG**	**A077114**	**002**	Jul 18, 2005
AB			**800MG**	**A077114**	**003**	Jul 18, 2005
AB		SHANDONG XINHUA	**400MG**	**A202413**	**001**	Nov 23, 2016
AB			**600MG**	**A202413**	**002**	Nov 23, 2016
AB			**800MG**	**A202413**	**003**	Nov 23, 2016
AB		STRIDES PHARMA	**400MG**	**A078329**	**001**	Feb 05, 2009
AB			**600MG**	**A078329**	**002**	Feb 05, 2009
AB			**800MG**	**A078329**	**003**	Feb 05, 2009
AB		VINTAGE PHARMS	**400MG**	**A071644**	**001**	Feb 01, 1988
IBUPROFEN LYSINE							
INJECTABLE;INTRAVENOUS							
IBUPROFEN LYSINE							
AP		X-GEN PHARMS INC	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**A202402**	**001**	Mar 30, 2016
NEOPROFEN							
AP	**+!**	RECORDATI RARE	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**N021903**	**001**	Apr 13, 2006
IBUPROFEN; OXYCODONE HYDROCHLORIDE							
TABLET;ORAL							
OXYCODONE HYDROCHLORIDE AND IBUPROFEN							
AB		ACTAVIS ELIZABETH	**400MG;5MG**	**A078769**	**001**	Jan 04, 2008
AB	**!**	BARR LABS INC	**400MG;5MG**	**A078316**	**001**	Nov 29, 2007
IBUTILIDE FUMARATE							
INJECTABLE;INJECTION							
CORVERT							
AP	**+!**	PHARMACIA AND UPJOHN	**0.1MG/ML**	**N020491**	**001**	Dec 28, 1995
IBUTILIDE FUMARATE							
AP		MYLAN INSTITUTIONAL	**0.1MG/ML**	**A090643**	**001**	Jan 11, 2010
ICATIBANT ACETATE							
INJECTABLE;SUBCUTANEOUS							
FIRAZYR							
AP	**+!**	SHIRE ORPHAN THERAP	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N022150**	**001**	Aug 25, 2011
ICATIBANT ACETATE							
AP		TEVA PHARMS USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A210118**	**001**	Jul 15, 2019

ICODEXTRIN
SOLUTION;INTRAPERITONEAL
EXTRANEAL

	+!	BAXTER HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002

ICOSAPENT ETHYL
CAPSULE;ORAL
VASCEPA

	+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017
	+!		1GM	N202057	001	Jul 26, 2012

IDARUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
IDAMYCIN PFS

AP	**+!**	PHARMACIA AND UPJOHN	**1MG/ML**	**N050734**	**001**	Feb 17, 1997

IDARUBICIN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/ML**	**A065440**	**001**	Aug 04, 2009
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A065275**	**001**	Dec 14, 2006
AP			**1MG/ML**	**A065288**	**001**	May 15, 2007

IDARUBICIN HYDROCHLORIDE PFS

AP		TEVA PHARMS USA	**1MG/ML**	**A065036**	**001**	May 01, 2002

IDELALISIB
TABLET;ORAL
ZYDELIG

	+	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014
	+!		150MG	N205858	002	Jul 23, 2014

IFOSFAMIDE
INJECTABLE;INJECTION
IFEX

AP	**+**	BAXTER HLTHCARE	**1GM/VIAL**	**N019763**	**001**	Dec 30, 1988
AP	**+**		**3GM/VIAL**	**N019763**	**002**	Dec 30, 1988

IFOSFAMIDE

AP	**!**	FRESENIUS KABI USA	**1GM/VIAL**	**A076078**	**001**	May 28, 2002
AP	**!**		**3GM/VIAL**	**A076078**	**002**	May 28, 2002
AP	**!**	TEVA PHARMS USA	**1GM/20ML (50MG/ML)**	**A076657**	**001**	Apr 04, 2007
AP	**!**		**3GM/60ML (50MG/ML)**	**A076657**	**002**	Apr 04, 2007
AP		WEST-WARD PHARMS INT	**1GM/20ML (50MG/ML)**	**A076619**	**001**	Jun 29, 2011
AP			**3GM/60ML (50MG/ML)**	**A076619**	**002**	Jun 29, 2011

ILOPERIDONE
TABLET;ORAL
FANAPT

	+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009
	+		2MG	N022192	002	May 06, 2009
	+		4MG	N022192	003	May 06, 2009
	+		6MG	N022192	004	May 06, 2009
	+		8MG	N022192	005	May 06, 2009
	+		10MG	N022192	006	May 06, 2009
	+		12MG	N022192	007	May 06, 2009

ILOPROST
SOLUTION;INHALATION
VENTAVIS

	+!	ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
	+!		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009

IMATINIB MESYLATE
TABLET;ORAL
GLEEVEC

AB	**+**	NOVARTIS	**EQ 100MG BASE**	**N021588**	**001**	Apr 18, 2003
AB	**+!**		**EQ 400MG BASE**	**N021588**	**002**	Apr 18, 2003

IMATINIB MESYLATE

AB		APOTEX	**EQ 100MG BASE**	**A079179**	**001**	Aug 05, 2016
AB			**EQ 400MG BASE**	**A079179**	**002**	Aug 05, 2016
AB		BRECKENRIDGE	**EQ 100MG BASE**	**A205990**	**001**	Feb 08, 2019
AB			**EQ 400MG BASE**	**A205990**	**002**	Feb 08, 2019
AB		DR REDDYS	**EQ 100MG BASE**	**A206547**	**001**	Aug 13, 2018
AB			**EQ 400MG BASE**	**A206547**	**002**	Aug 13, 2018
AB		HIKMA	**EQ 100MG BASE**	**A207586**	**001**	Jul 13, 2018
AB			**EQ 400MG BASE**	**A207586**	**002**	Jul 13, 2018
AB		MYLAN	**EQ 100MG BASE**	**A204644**	**001**	Jun 21, 2017

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB		**EQ 400MG BASE**	**A204644**	**002**	Jun 21, 2017
AB	NATCO PHARMA LTD	**EQ 100MG BASE**	**A207818**	**001**	Mar 01, 2019
AB		**EQ 400MG BASE**	**A207818**	**002**	Mar 01, 2019
AB	SHILPA MEDICARE LTD	**EQ 100MG BASE**	**A208302**	**001**	Jan 17, 2019
AB		**EQ 400MG BASE**	**A208302**	**002**	Jan 17, 2019
AB	SUN PHARM	**EQ 100MG BASE**	**A078340**	**001**	Dec 03, 2015
AB		**EQ 400MG BASE**	**A078340**	**002**	Dec 03, 2015
AB	TEVA PHARMS USA	**EQ 100MG BASE**	**A204285**	**001**	Aug 04, 2016
AB		**EQ 400MG BASE**	**A204285**	**002**	Aug 04, 2016
AB	WOCKHARDT BIO AG	**EQ 100MG BASE**	**A208429**	**001**	Jan 17, 2019
AB		**EQ 400MG BASE**	**A208429**	**002**	Jan 17, 2019

IMIGLUCERASE

INJECTABLE;INJECTION

CEREZYME

+	GENZYME	200 UNITS/VIAL	N020367	001	May 23, 1994
+!		400 UNITS/VIAL	N020367	002	Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB	LEADING PHARMA LLC	**10MG**	**A040903**	**001**	Oct 24, 2012
AB		**25MG**	**A040903**	**002**	Oct 24, 2012
AB		**50MG**	**A040903**	**003**	Oct 24, 2012
AB	PAR PHARM	**10MG**	**A088292**	**001**	Oct 21, 1983
AB		**25MG**	**A088262**	**001**	Oct 21, 1983
AB		**50MG**	**A088276**	**001**	Oct 21, 1983
AB	SANDOZ	**10MG**	**A084936**	**002**	
AB		**25MG**	**A083745**	**001**	
AB		**50MG**	**A084937**	**001**	
AB	SPECGX LLC	**10MG**	**A087846**	**002**	May 22, 1984
AB		**25MG**	**A087846**	**003**	May 22, 1984
AB	SUN PHARM INDUSTRIES	**10MG**	**A081048**	**001**	Jun 05, 1990
AB		**25MG**	**A081049**	**001**	Jun 05, 1990
AB		**50MG**	**A081050**	**001**	Jun 05, 1990

TOFRANIL

AB	**!** SPECGX LLC	**50MG**	**A087846**	**001**	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

AB	**!** HIKMA	**EQ 75MG HYDROCHLORIDE**	**A091099**	**001**	Apr 16, 2010
AB		**EQ 100MG HYDROCHLORIDE**	**A091099**	**002**	Apr 16, 2010
AB		**EQ 125MG HYDROCHLORIDE**	**A091099**	**003**	Apr 16, 2010
AB		**EQ 150MG HYDROCHLORIDE**	**A091099**	**004**	Apr 16, 2010
AB	LUPIN LTD	**EQ 75MG HYDROCHLORIDE**	**A090444**	**001**	Apr 16, 2010
AB		**EQ 100MG HYDROCHLORIDE**	**A090444**	**002**	Apr 16, 2010
AB		**EQ 125MG HYDROCHLORIDE**	**A090444**	**003**	Apr 16, 2010
AB		**EQ 150MG HYDROCHLORIDE**	**A090444**	**004**	Apr 16, 2010

IMIQUIMOD

CREAM;TOPICAL

ALDARA

AB	**+!** BAUSCH	**5%**	**N020723**	**001**	Feb 27, 1997

IMIQUIMOD

AB	ANDA REPOSITORY	**5%**	**A091044**	**001**	Feb 28, 2011
AB	APOTEX INC	**5%**	**A091308**	**001**	Apr 06, 2012
AB	FOUGERA PHARMS	**5%**	**A078548**	**001**	Feb 25, 2010
AB	GLENMARK GENERICS	**5%**	**A201994**	**001**	Mar 06, 2012
AB	PERRIGO ISRAEL	**5%**	**A078837**	**001**	Sep 07, 2010
AB	TARO	**5%**	**A200173**	**001**	Apr 15, 2011

ZYCLARA

+!	BAUSCH	2.5%	N022483	002	Jul 15, 2011
+!		3.75%	N022483	001	Mar 25, 2010

INAMRINONE LACTATE						
INJECTABLE;INJECTION						
AMRINONE LACTATE						
	!	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075513	001	May 09, 2000
INDACATEROL MALEATE						
POWDER;INHALATION						
ARCAPTA NEOHALER						
	+!	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011
INDAPAMIDE						
TABLET;ORAL						
INDAPAMIDE						
AB		ACTAVIS ELIZABETH	**1.25MG**	**A074722**	**001**	Jun 17, 1996
AB			**2.5MG**	**A074722**	**002**	Jun 17, 1996
AB		AMERIGEN PHARMS LTD	**1.25MG**	**A075201**	**001**	Dec 04, 1998
AB			**2.5MG**	**A075201**	**002**	Dec 04, 1998
AB		ANI PHARMS INC	**1.25MG**	**A074299**	**002**	Apr 29, 1996
AB			**2.5MG**	**A074299**	**001**	Jul 27, 1995
AB		MYLAN	**1.25MG**	**A074461**	**002**	Mar 26, 1997
AB	**!**		**2.5MG**	**A074461**	**001**	Mar 27, 1996
INDINAVIR SULFATE						
CAPSULE;ORAL						
CRIXIVAN						
	+	MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996
	+!		EQ 400MG BASE	N020685	001	Mar 13, 1996
INDIUM IN-111 CHLORIDE						
INJECTABLE;INJECTION						
INDIUM IN 111 CHLORIDE						
	+!	CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994
INDIUM IN-111 OXYQUINOLINE						
INJECTABLE;INJECTION						
INDIUM IN 111 OXYQUINOLINE						
AP		BWXT ITG	**1mCi/ML**	**A202586**	**001**	Jul 25, 2018
AP	**+!**	GE HEALTHCARE	**1mCi/ML**	**N019044**	**001**	Dec 24, 1985
INDIUM IN-111 PENTETATE DISODIUM						
INJECTABLE;INTRATHECAL						
MPI INDIUM DTPA IN 111						
	+!	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982
INDIUM IN-111 PENTETREOTIDE KIT						
INJECTABLE;INJECTION						
OCTREOSCAN						
	+!	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994
INDOCYANINE GREEN						
INJECTABLE;INJECTION						
IC-GREEN						
AP	**+!**	AKORN	**25MG/VIAL**	**N011525**	**001**	
INDOCYANINE GREEN						
AP		DIAGNOSTIC GREEN	**25MG/VIAL**	**A040811**	**001**	Nov 21, 2007
POWDER;INTRAVENOUS, INTERSTITIAL						
SPY AGENT GREEN KIT						
	+!	NOVADAQ TECH	25MG/VIAL	N211580	001	Nov 21, 2018
INDOMETHACIN						
CAPSULE;ORAL						
INDOMETHACIN						
AB		CADILA	**25MG**	**A090403**	**001**	Nov 15, 2010
AB			**50MG**	**A090403**	**002**	Nov 15, 2010
AB		GLENMARK GENERICS	**25MG**	**A091276**	**001**	Dec 22, 2010
AB	**!**		**50MG**	**A091276**	**002**	Dec 22, 2010
AB		HERITAGE PHARMA	**25MG**	**A070719**	**001**	Feb 12, 1986
AB			**50MG**	**A070756**	**001**	Feb 12, 1986
AB		HERITAGE PHARMS INC	**25MG**	**N018851**	**001**	May 18, 1984
AB			**50MG**	**N018851**	**002**	May 18, 1984
AB		HETERO LABS LTD III	**25MG**	**A091240**	**001**	Apr 12, 2011
AB			**50MG**	**A091240**	**002**	Apr 12, 2011
AB		JUBILANT GENERICS	**25MG**	**A205215**	**001**	Aug 25, 2017
AB			**50MG**	**A205215**	**002**	Aug 25, 2017
AB		SANDOZ	**25MG**	**A070673**	**001**	Apr 29, 1987
AB			**50MG**	**A070674**	**001**	Apr 29, 1987

INDOMETHACIN							
CAPSULE;ORAL							
TIVORBEX							
	+	GENUS	20MG	N204768	001	Feb 24, 2014
	+!		40MG	N204768	002	Feb 24, 2014
CAPSULE, EXTENDED RELEASE;ORAL							
INDOMETHACIN							
AB		AMNEAL PHARMS	**75MG**	**A091549**	**001**	Dec 01, 2010
AB		AUROBINDO PHARMA LTD	**75MG**	**A204243**	**001**	Dec 27, 2016
AB		AVANTHI INC	**75MG**	**A079175**	**001**	Mar 06, 2009
AB		CHARTWELL RX	**75MG**	**A200529**	**001**	Nov 30, 2010
AB		GLENMARK PHARMS LTD	**75MG**	**A203501**	**001**	Jun 22, 2017
AB		HETERO LABS LTD III	**75MG**	**A201807**	**001**	Sep 28, 2012
AB		JUBILANT GENERICS	**75MG**	**A202706**	**001**	Oct 05, 2015
AB		MYLAN	**75MG**	**A202139**	**001**	Mar 20, 2014
AB		NOVAST LABS	**75MG**	**A204853**	**001**	May 08, 2017
AB	**!**	SANDOZ	**75MG**	**A074464**	**001**	May 28, 1998
AB		ZYDUS PHARMS	**75MG**	**A202711**	**001**	Sep 25, 2017
INJECTABLE;INJECTION							
INDOMETHACIN							
	+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N022536	001	Mar 17, 2010
SUPPOSITORY;RECTAL							
INDOMETHACIN							
	!	ACP NIMBLE	50MG	A073314	001	Aug 31, 1992
SUSPENSION;ORAL							
INDOCIN							
	+!	EGALET	25MG/5ML	N018332	001	Oct 10, 1985
INDOMETHACIN SODIUM							
INJECTABLE;INJECTION							
INDOCIN							
AP	**+!**	RECORDATI RARE	**EQ 1MG BASE/VIAL**	**N018878**	**001**	Jan 30, 1985
INDOMETHACIN SODIUM							
AP		HOSPIRA INC	**EQ 1MG BASE/VIAL**	**A204118**	**001**	Apr 19, 2016
AP		NAVINTA LLC	**EQ 1MG BASE/VIAL**	**A206561**	**001**	Jul 19, 2017
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/VIAL**	**A078713**	**001**	Jul 16, 2008
INGENOL MEBUTATE							
GEL;TOPICAL							
INGENOL MEBUTATE							
AB		PERRIGO UK FINCO	**0.015%**	**A209018**	**001**	Jan 07, 2019
AB			**0.05%**	**A209019**	**001**	Jan 09, 2019
PICATO							
AB	**+!**	LEO LABS	**0.015%**	**N202833**	**001**	Jan 23, 2012
AB	**+!**		**0.05%**	**N202833**	**002**	Jan 23, 2012
INOTERSEN SODIUM							
SOLUTION;SUBCUTANEOUS							
TEGSEDI							
	+!	AKCEA THERAPS	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)	N211172	001	Oct 05, 2018
INSULIN ASPART							
SOLUTION;INTRAVENOUS, SUBCUTANEOUS							
FIASP							
	+!	NOVO	1000 UNITS/10ML (100 UNITS/ML)	N208751	001	Sep 29, 2017
SOLUTION;SUBCUTANEOUS							
FIASP FLEXTOUCH							
	+!	NOVO	300 UNITS/3ML (100 UNITS/ML)	N208751	002	Sep 29, 2017
FIASP PENFILL							
	+!	NOVO	300 UNITS/3ML (100 UNITS/ML)	N208751	003	Sep 24, 2018
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT							
INJECTABLE;SUBCUTANEOUS							
NOVOLOG MIX 70/30							
	+!	NOVO NORDISK INC	700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)	N021172	001	Nov 01, 2001
NOVOLOG MIX 70/30 FLEXPEN							
	+!	NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	004	May 03, 2002

INSULIN ASPART RECOMBINANT					
INJECTABLE;SUBCUTANEOUS					
NOVOLOG					
+!	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N020986	001	Jun 07, 2000
NOVOLOG FLEXPEN					
+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	003	Jan 19, 2001
NOVOLOG PENFILL					
+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	002	Jun 07, 2000
INSULIN DEGLUDEC					
SOLUTION;SUBCUTANEOUS					
TRESIBA					
+	NOVO	300 UNITS/3ML (100 UNITS/ML)	N203314	001	Sep 25, 2015
+!		600 UNITS/3ML (200 UNITS/ML)	N203314	002	Sep 25, 2015
		1000 UNITS/10ML (100 UNITS/ML)	N203314	003	Nov 21, 2018
INSULIN DEGLUDEC; LIRAGLUTIDE					
SOLUTION;SUBCUTANEOUS					
XULTOPHY 100/3.6					
+!	NOVO	300 UNITS/3ML;10.8MG/3ML (100 UNITS/ML;3.6MG/ML)	N208583	001	Nov 21, 2016
INSULIN DETEMIR RECOMBINANT					
INJECTABLE;SUBCUTANEOUS					
LEVEMIR					
+!	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N021536	001	Jun 16, 2005
LEVEMIR FLEXTOUCH					
+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013
INSULIN GLARGINE					
SOLUTION;SUBCUTANEOUS					
BASAGLAR					
	ELI LILLY AND CO	300 UNITS/3ML (100 UNITS/ML)	N205692	001	Dec 16, 2015
INSULIN GLARGINE RECOMBINANT					
INJECTABLE;INJECTION					
LANTUS					
+!	SANOFI AVENTIS US	100 UNITS/ML	N021081	001	Apr 20, 2000
LANTUS SOLOSTAR					
+!	SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081	002	Apr 27, 2007
SOLUTION;SUBCUTANEOUS					
TOUJEO MAX SOLOSTAR					
+!	SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N206538	002	Mar 26, 2018
TOUJEO SOLOSTAR					
+!	SANOFI US SERVICES	450 UNITS/1.5ML (300 UNITS/ML)	N206538	001	Feb 25, 2015
INSULIN GLARGINE; LIXISENATIDE					
SOLUTION;SUBCUTANEOUS					
SOLIQUA 100/33					
+!	SANOFI-AVENTIS US	300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML)	N208673	001	Nov 21, 2016
INSULIN GLULISINE RECOMBINANT					
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS					
APIDRA					
+!	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629	001	Apr 16, 2004
INJECTABLE;SUBCUTANEOUS					
APIDRA SOLOSTAR					
+	SANOFI AVENTIS US	300 UNITS/3ML	N021629	003	Feb 24, 2009
INSULIN HUMAN					
SOLUTION;INTRAVENOUS					
MYXREDLIN					
+!	BAXTER HLTHCARE CORP	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019
SOLUTION;SUBCUTANEOUS					
HUMULIN R					
+!	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994
HUMULIN R KWIKPEN					
+!	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015

INSULIN LISPRO					
SOLUTION;INTRAVENOUS, SUBCUTANEOUS					
ADMELOG					
+	SANOFI-AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N209196	003	Oct 19, 2018
+		1000 UNITS/10ML (100 UNITS/ML)	N209196	001	Dec 11, 2017
ADMELOG SOLOSTAR					
+	SANOFI-AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N209196	002	Dec 11, 2017
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT					
INJECTABLE;INJECTION					
HUMALOG MIX 50/50					
+!	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	001	Dec 22, 1999
HUMALOG MIX 50/50 KWIKPEN					
+!	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	002	Sep 06, 2007
HUMALOG MIX 75/25					
+!	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	001	Dec 22, 1999
HUMALOG MIX 75/25 KWIKPEN					
+!	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	002	Sep 06, 2007
INSULIN LISPRO RECOMBINANT					
INJECTABLE;INJECTION					
HUMALOG					
+!	LILLY	100 UNITS/ML	N020563	001	Jun 14, 1996
HUMALOG KWIKPEN					
+!	LILLY	100 UNITS/ML	N020563	003	Sep 06, 2007
+!		200UNITS/ML	N020563	004	Nov 15, 2019
HUMALOG TEMPO PEN					
+!	LILLY	100UNITS/ML	N020563	005	Nov 15, 2019
SOLUTION;SUBCUTANEOUS					
HUMALOG KWIKPEN					
+!	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015
INSULIN RECOMBINANT HUMAN					
POWDER;INHALATION					
AFREZZA					
+	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014
+!		8 UNITS/INH	N022472	002	Jun 27, 2014
+		12 UNITS/INH	N022472	003	Apr 17, 2015
IOBENGUANE I-131					
SOLUTION;INTRAVENOUS					
AZEDRA					
+!	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018
IOBENGUANE SULFATE I-123					
SOLUTION;INTRAVENOUS					
ADREVIEW					
+!	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290	001	Sep 19, 2008
IODIXANOL					
INJECTABLE;INJECTION					
VISIPAQUE 270					
+!	GE HEALTHCARE	55%	N020351	001	Mar 22, 1996
VISIPAQUE 320					
+!	GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996
		65.2%	N020808	002	Aug 29, 1997
IOFLUPANE I-123					
SOLUTION;INTRAVENOUS					
DATSCAN					
+!	GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454	001	Jan 14, 2011
IOHEXOL					
FOR SOLUTION;ORAL					
ORALTAG					
	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015
INJECTABLE;INJECTION					
OMNIPAQUE 140					
+!	GE HEALTHCARE	30.2%	N018956	005	Nov 30, 1988
SOLUTION;INJECTION, ORAL					
OMNIPAQUE 350					
+!	GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985
		75.5%	N020608	003	Oct 24, 1995

IOHEXOL						
SOLUTION;INJECTION, ORAL, RECTAL						
OMNIPAQUE 180						
+!	GE HEALTHCARE	38.8%	N018956	001	Dec 26, 1985	
OMNIPAQUE 240						
+!	GE HEALTHCARE	51.8%	N018956	002	Dec 26, 1985	
OMNIPAQUE 300						
+!	GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985	
		64.7%	N020608	002	Oct 24, 1995	
SOLUTION;ORAL						
OMNIPAQUE 12						
+!	GE HEALTHCARE	2.6%	N018956	009	Apr 17, 2018	
OMNIPAQUE 9						
+!	GE HEALTHCARE	1.9%	N018956	008	Apr 17, 2018	
IOPAMIDOL						
INJECTABLE;INJECTION						
ISOVUE-300						
AP **+!**	BRACCO	**61%**	**N018735**	**002**	Dec 31, 1985	
ISOVUE-370						
AP **+!**	BRACCO	**76%**	**N018735**	**003**	Dec 31, 1985	
SCANLUX-300						
AP	SANOCHEMIA CORP USA	**61%**	**A090394**	**001**	Jun 18, 2010	
SCANLUX-370						
AP	SANOCHEMIA CORP USA	**76%**	**A090394**	**002**	Jun 18, 2010	
ISOVUE-200						
+!	BRACCO	41%	N018735	006	Jul 07, 1987	
ISOVUE-250						
+!	BRACCO	51%	N018735	007	Jul 06, 1992	
+!		51%	N020327	002	Oct 12, 1994	
ISOVUE-300						
+!	BRACCO	61%	N020327	003	Oct 12, 1994	
ISOVUE-370						
+!	BRACCO	76%	N020327	004	Oct 12, 1994	
ISOVUE-M 200						
+!	BRACCO	41%	N018735	001	Dec 31, 1985	
ISOVUE-M 300						
+!	BRACCO	61%	N018735	004	Dec 31, 1985	
IOPROMIDE						
INJECTABLE;INJECTION						
ULTRAVIST (PHARMACY BULK)						
+!	BAYER HLTHCARE	62.3%	N021425	001	Sep 20, 2002	
+!		76.9%	N021425	002	Sep 20, 2002	
ULTRAVIST 300						
+!	BAYER HLTHCARE	62.3%	N020220	002	May 10, 1995	
ULTRAVIST 370						
+!	BAYER HLTHCARE	76.9%	N020220	001	May 10, 1995	
IOTHALAMATE MEGLUMINE						
INJECTABLE;INJECTION						
CONRAY						
+!	LIEBEL-FLARSHEIM	60%	N013295	001		
SOLUTION;INTRAVESICAL						
CYSTO-CONRAY II						
	LIEBEL-FLARSHEIM	17.2%	N017057	002		
IOTHALAMATE SODIUM I-125						
INJECTABLE;INJECTION						
GLOFIL-125						
	ISOTEX	250-300uCi/ML	N017279	001		
IOVERSOL						
INJECTABLE;INJECTION						
OPTIRAY 240						
+!	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	
OPTIRAY 300						
+!	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	
+!		64%	N020923	004	May 13, 1999	
OPTIRAY 320						
+!	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	
+!		68%	N020923	002	May 29, 1998	
OPTIRAY 350						
+!	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	
+!		74%	N020923	003	May 28, 1998	

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

ATROVENT HFA

	+!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004

SOLUTION;INHALATION

IPRATROPIUM BROMIDE

AN		AUROBINDO PHARMA LTD	**0.02%**	**A206543**	**001**	Oct 27, 2016
AN		LANDELA PHARM	**0.02%**	**A077072**	**001**	Jul 19, 2005
AN		NEPHRON	**0.02%**	**A075562**	**001**	Sep 27, 2001
AN	!	RITEDOSE CORP	**0.02%**	**A075693**	**001**	Jan 26, 2001
AN		SUN PHARM	**0.02%**	**A207903**	**001**	Jan 03, 2017
AN		WATSON LABS	**0.02%**	**A076291**	**001**	May 09, 2005

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

AB		APOTEX INC	**0.042MG/SPRAY**	**A076155**	**001**	Apr 18, 2003
AB		BAUSCH AND LOMB	**0.021MG/SPRAY**	**A076025**	**001**	Mar 31, 2003
AB			**0.042MG/SPRAY**	**A076103**	**001**	Mar 31, 2003
AB	!	HIKMA	**0.021MG/SPRAY**	**A076664**	**001**	Nov 05, 2003
AB	!		**0.042MG/SPRAY**	**A076598**	**001**	Nov 05, 2003

IRBESARTAN

TABLET;ORAL

AVAPRO

AB	+	SANOFI AVENTIS US	**75MG**	**N020757**	**001**	Sep 30, 1997
AB	+		**150MG**	**N020757**	**002**	Sep 30, 1997
AB	+!		**300MG**	**N020757**	**003**	Sep 30, 1997

IRBESARTAN

AB		ALEMBIC PHARMS LTD	**75MG**	**A091236**	**001**	Oct 15, 2012
AB			**150MG**	**A091236**	**002**	Oct 15, 2012
AB			**300MG**	**A091236**	**003**	Oct 15, 2012
AB		AMNEAL PHARMS	**75MG**	**A204740**	**001**	Apr 17, 2018
AB			**150MG**	**A204740**	**002**	Apr 17, 2018
AB			**300MG**	**A204740**	**003**	Apr 17, 2018
AB		AUROBINDO PHARMA LTD	**75MG**	**A203081**	**001**	Sep 27, 2012
AB			**150MG**	**A203081**	**002**	Sep 27, 2012
AB			**300MG**	**A203081**	**003**	Sep 27, 2012
AB		CHARTWELL MOLECULAR	**75MG**	**A077205**	**001**	Nov 14, 2012
AB			**150MG**	**A077205**	**002**	Nov 14, 2012
AB			**300MG**	**A077205**	**003**	Nov 14, 2012
AB		HETERO LABS LTD V	**75MG**	**A202910**	**001**	Sep 27, 2012
AB			**150MG**	**A202910**	**002**	Sep 27, 2012
AB			**300MG**	**A202910**	**003**	Sep 27, 2012
AB		HIKMA	**75MG**	**A090201**	**001**	Oct 15, 2012
AB			**150MG**	**A090201**	**002**	Oct 15, 2012
AB			**300MG**	**A090201**	**003**	Oct 15, 2012
AB		HISUN PHARM HANGZHOU	**75MG**	**A206194**	**001**	Jun 14, 2016
AB			**150MG**	**A206194**	**002**	Jun 14, 2016
AB			**300MG**	**A206194**	**003**	Jun 14, 2016
AB		JUBILANT GENERICS	**75MG**	**A203534**	**001**	Feb 23, 2015
AB			**150MG**	**A203534**	**002**	Feb 23, 2015
AB			**300MG**	**A203534**	**003**	Feb 23, 2015
AB		LUPIN LTD	**75MG**	**A201531**	**001**	Oct 15, 2012
AB			**150MG**	**A201531**	**002**	Oct 15, 2012
AB			**300MG**	**A201531**	**003**	Oct 15, 2012
AB		MACLEODS PHARMS LTD	**75MG**	**A202254**	**001**	Oct 03, 2012
AB			**150MG**	**A202254**	**002**	Oct 03, 2012
AB			**300MG**	**A202254**	**003**	Oct 03, 2012
AB		NEOPHARMA	**75MG**	**A203161**	**001**	Sep 27, 2012
AB			**150MG**	**A203161**	**002**	Sep 27, 2012
AB			**300MG**	**A203161**	**003**	Sep 27, 2012
AB		PRINSTON INC	**75MG**	**A203071**	**001**	Sep 27, 2012
AB			**150MG**	**A203071**	**002**	Sep 27, 2012
AB			**300MG**	**A203071**	**003**	Sep 27, 2012
AB		SANDOZ	**75MG**	**A077466**	**001**	Sep 27, 2012
AB			**150MG**	**A077466**	**002**	Sep 27, 2012
AB			**300MG**	**A077466**	**003**	Sep 27, 2012
AB		SCIEGEN PHARMS INC	**75MG**	**A204774**	**001**	Dec 07, 2015
AB			**150MG**	**A204774**	**002**	Dec 07, 2015
AB			**300MG**	**A204774**	**003**	Dec 07, 2015
AB		TEVA PHARMS	**75MG**	**A077159**	**001**	Mar 30, 2012

IRBESARTAN

TABLET;ORAL

IRBESARTAN

AB		**150MG**	**A077159**	**002**	Mar 30, 2012
AB		**300MG**	**A077159**	**003**	Mar 30, 2012
AB	UNICHEM LABS LTD	**75MG**	**A203020**	**001**	Dec 07, 2015
AB		**150MG**	**A203020**	**002**	Dec 07, 2015
AB		**300MG**	**A203020**	**003**	Dec 07, 2015
AB	ZYDUS PHARMS USA INC	**75MG**	**A079213**	**001**	Sep 27, 2012
AB		**150MG**	**A079213**	**002**	Sep 27, 2012
AB		**300MG**	**A079213**	**003**	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

CAMPTOSAR

AP	**+!**	PFIZER INC	**40MG/2ML (20MG/ML)**	**N020571**	**001**	Jun 14, 1996
AP	**+!**		**100MG/5ML (20MG/ML)**	**N020571**	**002**	Jun 14, 1996
AP	**+!**		**300MG/15ML (20MG/ML)**	**N020571**	**003**	Aug 05, 2010

IRINOTECAN HYDROCHLORIDE

AP		ACCORD HLTHCARE	**40MG/2ML (20MG/ML)**	**A079068**	**001**	Nov 21, 2008
AP			**100MG/5ML (20MG/ML)**	**A079068**	**002**	Nov 21, 2008
AP		ACTAVIS TOTOWA	**40MG/2ML (20MG/ML)**	**A078589**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A078589**	**002**	Feb 27, 2008
AP			**500MG/25ML (20MG/ML)**	**A078589**	**003**	Nov 18, 2015
AP		AKORN	**40MG/2ML (20MG/ML)**	**A090726**	**001**	Sep 16, 2009
AP			**100MG/5ML (20MG/ML)**	**A090726**	**002**	Sep 16, 2009
AP		CIPLA LTD	**40MG/2ML (20MG/ML)**	**A077219**	**001**	Feb 20, 2008
AP			**100MG/5ML (20MG/ML)**	**A077219**	**002**	Feb 20, 2008
AP		EMCURE PHARMS LTD	**40MG/2ML (20MG/ML)**	**A200771**	**001**	Feb 14, 2012
AP			**100MG/5ML (20MG/ML)**	**A200771**	**002**	Feb 14, 2012
AP		FRESENIUS KABI USA	**40MG/2ML (20MG/ML)**	**A077776**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077776**	**002**	Feb 27, 2008
AP		GLAND PHARMA LTD	**40MG/2ML (20MG/ML)**	**A212993**	**001**	Nov 18, 2019
AP			**100MG/5ML (20MG/ML)**	**A212993**	**002**	Nov 18, 2019
AP		HIKMA FARMACEUTICA	**40MG/2ML (20MG/ML)**	**A091032**	**001**	Dec 20, 2010
AP			**100MG/5ML (20MG/ML)**	**A091032**	**002**	Dec 20, 2010
AP		HISUN PHARM HANGZHOU	**40MG/2ML (20MG/ML)**	**A090016**	**001**	Jan 28, 2009
AP			**100MG/5ML (20MG/ML)**	**A090016**	**002**	Jan 28, 2009
AP		HOSPIRA	**40MG/2ML (20MG/ML)**	**A077915**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077915**	**002**	Feb 27, 2008
AP	**!**		**500MG/25ML (20MG/ML)**	**A078796**	**001**	Feb 27, 2008
AP		INGENUS PHARMS LLC	**40MG/2ML (20MG/ML)**	**A206935**	**001**	May 26, 2017
AP			**100MG/5ML (20MG/ML)**	**A206935**	**002**	May 26, 2017
AP		INTAS PHARMS USA	**40MG/2ML (20MG/ML)**	**A203054**	**001**	Aug 31, 2017
AP			**100MG/5ML (20MG/ML)**	**A203054**	**002**	Aug 31, 2017
AP		JIANGSU HENGRUI MED	**40MG/2ML (20MG/ML)**	**A090675**	**002**	Dec 16, 2011
AP			**100MG/5ML (20MG/ML)**	**A090675**	**001**	Dec 16, 2011
AP		NEOPHARMA	**40MG/2ML (20MG/ML)**	**A078953**	**001**	Apr 15, 2010
AP			**100MG/5ML (20MG/ML)**	**A078953**	**002**	Apr 15, 2010
AP		PLIVA LACHEMA	**40MG/2ML (20MG/ML)**	**A078122**	**001**	Oct 31, 2008
AP			**100MG/5ML (20MG/ML)**	**A078122**	**002**	Oct 31, 2008
AP		QILU	**40MG/2ML (20MG/ML)**	**A203380**	**001**	May 03, 2016
AP			**100MG/5ML (20MG/ML)**	**A203380**	**002**	May 03, 2016
AP			**300MG/15ML (20MG/ML)**	**A203380**	**003**	May 03, 2016
AP		SHILPA MEDICARE LTD	**40MG/2ML (20MG/ML)**	**A208718**	**001**	Dec 28, 2018
AP			**100MG/5ML (20MG/ML)**	**A208718**	**002**	Dec 28, 2018
AP		TEVA PHARMS USA	**40MG/2ML (20MG/ML)**	**A090101**	**002**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A090101**	**003**	Feb 27, 2008
AP			**500MG/25ML (20MG/ML)**	**A090101**	**001**	Nov 26, 2008
AP		WEST-WARD PHARMS INT	**40MG/2ML (20MG/ML)**	**A078753**	**001**	Dec 24, 2008
AP			**100MG/5ML (20MG/ML)**	**A078753**	**002**	Dec 24, 2008
AP		ZENNOVA	**40MG/2ML (20MG/ML)**	**A090393**	**002**	May 13, 2011
AP			**100MG/5ML (20MG/ML)**	**A090393**	**003**	May 13, 2011

INJECTABLE, LIPOSOMAL;INTRAVENOUS

ONIVYDE

	+!	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015

IRON DEXTRAN
INJECTABLE;INJECTION
INFED

BP	+!	ALLERGAN	EQ 50MG IRON/ML	N017441	001	

IRON SUCROSE
INJECTABLE;INTRAVENOUS
VENOFER

	+	AM REGENT	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005
	+!		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000
	+		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007

ISAVUCONAZONIUM SULFATE
CAPSULE;ORAL
CRESEMBA

	+!	ASTELLAS	186MG	N207500	001	Mar 06, 2015

POWDER;INTRAVENOUS
CRESEMBA

	+!	ASTELLAS	372MG	N207501	001	Mar 06, 2015

ISOCARBOXAZID
TABLET;ORAL
MARPLAN

	+!	VALIDUS PHARMS INC	10MG	N011961	001	

ISOFLURANE
LIQUID;INHALATION

	FORANE					
AN	**+!**	BAXTER HLTHCARE	**99.9%**	**N017624**	**001**	
	ISOFLURANE					
AN		HALOCARBON PRODS	**99.9%**	**A075225**	**001**	Oct 20, 1999
AN		PIRAMAL CRITICAL	**99.9%**	**A074416**	**001**	Sep 30, 1994
AN		PIRAMAL ENT	**99.9%**	**A074502**	**001**	Jun 27, 1995

ISONIAZID
INJECTABLE;INJECTION
ISONIAZID

	!	SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005

SYRUP;ORAL
ISONIAZID

	!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983

TABLET;ORAL

	ISONIAZID					
AA		ANDA REPOSITORY	**100MG**	**A040090**	**001**	Jun 26, 1997
AA			**300MG**	**A040090**	**002**	Jun 26, 1997
AA	**!**	BARR	**100MG**	**A080936**	**001**	
AA	**!**		**300MG**	**A080937**	**002**	
AA		THEPHARMANETWORK LLC	**100MG**	**A202610**	**001**	Oct 29, 2014
AA			**300MG**	**A202610**	**002**	Oct 29, 2014

ISONIAZID; PYRAZINAMIDE; RIFAMPIN
TABLET;ORAL
RIFATER

	+!	SANOFI AVENTIS US	50MG;300MG;120MG	N050705	001	May 31, 1994

ISONIAZID; RIFAMPIN
CAPSULE;ORAL
RIFAMATE

	!	SANOFI AVENTIS US	150MG;300MG	A061884	001	

ISOPROTERENOL HYDROCHLORIDE
INJECTABLE;INJECTION

	ISOPROTERENOL HYDROCHLORIDE					
AP		AMNEAL	**0.2MG/ML**	**A210576**	**001**	Oct 17, 2018
AP		AMPHASTAR PHARMS INC	**0.2MG/ML**	**A210106**	**001**	Jun 18, 2018
AP		CIPLA	**0.2MG/ML**	**A210322**	**001**	Jun 12, 2018
AP			**0.2MG/ML**	**A211738**	**001**	Jun 28, 2019
AP		NEXUS PHARMS	**0.2MG/ML**	**A206961**	**001**	Aug 02, 2017
	ISUPREL					
AP	**+!**	BAUSCH	**0.2MG/ML**	**N010515**	**001**	

ISOSORBIDE DINITRATE							
CAPSULE, EXTENDED RELEASE;ORAL							
DILATRATE-SR							
	+!	AUXILIUM PHARMS LLC	40MG		N019790	001	Sep 02, 1988
TABLET;ORAL							
ISORDIL							
AB	**+**	BAUSCH	**5MG**		**N012093**	**007**	Jul 29, 1988
AB	**+!**		**40MG**		**N012093**	**001**	Jul 29, 1988
ISOSORBIDE DINITRATE							
AB		HIKMA INTL PHARMS	**5MG**		**A086067**	**001**	Oct 29, 1987
AB			**10MG**		**A086066**	**001**	Oct 29, 1987
AB			**20MG**		**A088088**	**001**	Nov 02, 1987
AB			**30MG**		**A040591**	**001**	Jan 10, 2007
AB		PAR PHARM	**5MG**		**A086923**	**001**	Mar 12, 1987
AB			**10MG**		**A086925**	**001**	Mar 12, 1987
AB			**20MG**		**A087537**	**001**	Oct 02, 1987
AB	**!**		**30MG**		**A087946**	**001**	Jan 12, 1988
AB		SANDOZ	**5MG**		**A086221**	**001**	Jan 07, 1988
AB			**10MG**		**A086223**	**001**	Jan 07, 1988
AB			**20MG**		**A089367**	**001**	Apr 07, 1988
AB		ZYDUS	**5MG**		**A213057**	**001**	Nov 20, 2019
AB			**10MG**		**A213057**	**002**	Nov 20, 2019
AB			**20MG**		**A213057**	**003**	Nov 20, 2019
AB			**30MG**		**A213057**	**004**	Nov 20, 2019
AB			**40MG**		**A213057**	**005**	Nov 20, 2019
TABLET, EXTENDED RELEASE;ORAL							
ISOSORBIDE DINITRATE							
	!	SUN PHARM INDS INC	40MG		A040009	001	Dec 30, 1998
ISOSORBIDE MONONITRATE							
TABLET;ORAL							
ISOSORBIDE MONONITRATE							
AB		ACTAVIS ELIZABETH	**10MG**		**A075037**	**002**	Oct 30, 1998
AB			**20MG**		**A075037**	**001**	Oct 30, 1998
AB		HIKMA PHARMS	**20MG**		**A075361**	**001**	Oct 05, 2000
MONOKET							
AB	**+**	LANNETT CO INC	**10MG**		**N020215**	**002**	Jun 30, 1993
AB	**+!**		**20MG**		**N020215**	**001**	Jun 30, 1993
TABLET, EXTENDED RELEASE;ORAL							
ISOSORBIDE MONONITRATE							
AB		DEXCEL LTD	**30MG**		**A075522**	**002**	Sep 20, 2016
AB			**60MG**		**A075522**	**001**	Apr 17, 2000
AB			**120MG**		**A210822**	**001**	Aug 29, 2018
AB		HIKMA INTL PHARMS	**30MG**		**A076813**	**002**	Mar 30, 2006
AB			**60MG**		**A076813**	**001**	Jan 07, 2005
AB		LANNETT CO INC	**30MG**		**A075155**	**002**	Jan 13, 2000
AB			**60MG**		**A075155**	**001**	Oct 30, 1998
AB	**!**		**120MG**		**A075155**	**003**	Aug 04, 2000
AB		NESHER PHARMS	**30MG**		**A075395**	**001**	Mar 16, 2000
AB			**60MG**		**A075395**	**002**	Mar 16, 2000
AB			**120MG**		**A075395**	**003**	Mar 16, 2000
AB		RICONPHARMA LLC	**30MG**		**A210918**	**001**	Nov 05, 2018
AB			**60MG**		**A210918**	**002**	Nov 05, 2018
AB			**120MG**		**A210918**	**003**	Nov 05, 2018
AB		TORRENT PHARMS	**30MG**		**A200270**	**001**	Jun 03, 2011
AB			**60MG**		**A200495**	**001**	Jun 03, 2011
AB			**120MG**		**A200495**	**002**	Jun 03, 2011
AB		VINTAGE PHARMS	**30MG**		**A090598**	**001**	Aug 11, 2010
AB			**60MG**		**A090598**	**002**	Aug 11, 2010
AB			**120MG**		**A090598**	**003**	Aug 11, 2010
ISOSULFAN BLUE							
INJECTABLE;INJECTION							
ISOSULFAN BLUE							
AP		AUROBINDO PHARMA LTD	**1%**		**A206831**	**001**	Feb 02, 2016
AP	**!**	MYLAN INSTITUTIONAL	**1%**		**A090874**	**001**	Jul 20, 2010

ISOTRETINOIN

CAPSULE;ORAL

AMNESTEEM						
AB		MYLAN PHARMS INC	**10MG**	**A075945**	**001**	Nov 08, 2002
AB			**20MG**	**A075945**	**002**	Nov 08, 2002
AB			**40MG**	**A075945**	**003**	Nov 08, 2002
CLARAVIS						
AB		TEVA PHARMS USA	**10MG**	**A076356**	**001**	Apr 11, 2003
AB			**20MG**	**A076135**	**002**	Apr 11, 2003
AB			**30MG**	**A076135**	**003**	May 11, 2006
AB	**!**		**40MG**	**A076135**	**001**	Apr 11, 2003
ISOTRETINOIN						
AB		AMNEAL PHARMS NY	**10MG**	**A207792**	**001**	Sep 29, 2017
AB			**20MG**	**A207792**	**002**	Sep 29, 2017
AB			**30MG**	**A207792**	**003**	Sep 29, 2017
AB			**40MG**	**A207792**	**004**	Sep 29, 2017
MYORISAN						
AB		DOUGLAS PHARMS	**10MG**	**A076485**	**001**	Jan 19, 2012
AB			**20MG**	**A076485**	**002**	Jan 19, 2012
AB			**30MG**	**A076485**	**004**	Aug 25, 2015
AB			**40MG**	**A076485**	**003**	Jan 19, 2012
ZENATANE						
AB		DR REDDYS LABS LTD	**10MG**	**A202099**	**001**	Mar 25, 2013
AB			**20MG**	**A202099**	**002**	Mar 25, 2013
AB			**30MG**	**A202099**	**004**	Feb 23, 2015
AB			**40MG**	**A202099**	**003**	Mar 25, 2013
ABSORICA						
BX	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012
BX	+		20MG	N021951	002	May 25, 2012
BX	+		30MG	N021951	003	May 25, 2012
BX	+!		40MG	N021951	004	May 25, 2012
	+		25MG	N021951	005	Aug 15, 2014
	+		35MG	N021951	006	Aug 15, 2014
ABSORICA LD						
	+	SUN PHARM	8MG	N211913	001	Nov 05, 2019
	+		16MG	N211913	002	Nov 05, 2019
	+		20MG	N211913	003	Nov 05, 2019
	+		24MG	N211913	004	Nov 05, 2019
	+		28MG	N211913	005	Nov 05, 2019
	+!		32MG	N211913	006	Nov 05, 2019

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE						
AB		ELITE LABS INC	**2.5MG**	**A077169**	**001**	Apr 24, 2006
AB			**5MG**	**A077169**	**002**	Apr 24, 2006
AB		WATSON LABS TEVA	**2.5MG**	**A077317**	**001**	Jan 05, 2006
AB	**!**		**5MG**	**A077317**	**002**	Jan 05, 2006

ISTRADEFYLLINE

TABLET;ORAL

NOURIANZ						
	+	KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019
	+!		40MG	N022075	002	Aug 27, 2019

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE						
AB		ACCORD HLTHCARE	**100MG**	**A205991**	**001**	May 26, 2016
AB		ALEMBIC PHARMS LTD	**100MG**	**A206741**	**001**	Dec 13, 2016
AB		ALKEM LABS LTD	**100MG**	**A208591**	**001**	Jun 12, 2017
AB		AMNEAL PHARMS	**100MG**	**A205080**	**001**	Sep 26, 2016
AB		JUBILANT GENERICS	**100MG**	**A203445**	**001**	Feb 23, 2017
AB		MYLAN PHARMS INC	**100MG**	**A200463**	**001**	Jul 20, 2012
AB		PAR PHARM INC	**100MG**	**A205724**	**001**	Dec 13, 2016
AB		PII	**100MG**	**A206410**	**001**	Jul 02, 2019
AB		SANDOZ	**100MG**	**A076104**	**001**	May 28, 2004
AB		TORRENT	**100MG**	**A209460**	**001**	Aug 24, 2018
AB		ZYDUS PHARMS	**100MG**	**A204672**	**001**	Sep 19, 2017
SPORANOX						
AB	**+!**	JANSSEN PHARMS	**100MG**	**N020083**	**001**	Sep 11, 1992
TOLSURA						
	+!	MAYNE PHARMA INTL	65MG	N208901	001	Dec 11, 2018

ITRACONAZOLE
SOLUTION;ORAL
ITRACONAZOLE

AA		AMNEAL PHARMS	**10MG/ML**	**A205573**	**001**	Oct 30, 2015
AA		APOTEX	**10MG/ML**	**A208481**	**001**	Aug 02, 2019

SPORANOX

AA	**+!**	JANSSEN PHARMS	**10MG/ML**	**N020657**	**001**	Feb 21, 1997

TABLET;ORAL
ONMEL

+!	SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010

IVABRADINE
SOLUTION;ORAL
CORLANOR

+!	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019

IVABRADINE HYDROCHLORIDE
TABLET;ORAL
CORLANOR

+	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015
+!		EQ 7.5MG BASE	N206143	002	Apr 15, 2015

IVACAFTOR
GRANULE;ORAL
KALYDECO

+	VERTEX PHARMS INC	25MG/PACKET	N207925	003	Apr 29, 2019
+		50MG/PACKET	N207925	001	Mar 17, 2015
+!		75MG/PACKET	N207925	002	Mar 17, 2015

TABLET;ORAL
KALYDECO

+	VERTEX PHARMS	75MG	N203188	002	May 20, 2019
+!		150MG	N203188	001	Jan 31, 2012

IVACAFTOR; IVACAFTOR, TEZACAFTOR
TABLET, TABLET;ORAL
SYMDEKO (COPACKAGED)

+	VERTEX PHARMS INC	75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019
+!		150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018

IVACAFTOR; LUMACAFTOR
GRANULE;ORAL
ORKAMBI

+	VERTEX PHARMS INC	125MG/PACKET;100MG/PACKET	N211358	001	Aug 07, 2018
+!		188MG/PACKET;150MG/PACKET	N211358	002	Aug 07, 2018

TABLET;ORAL
ORKAMBI

+	VERTEX PHARMS INC	125MG;100MG	N206038	002	Sep 28, 2016
+!		125MG;200MG	N206038	001	Jul 02, 2015

IVERMECTIN
CREAM;TOPICAL
IVERMECTIN

AB		TEVA PHARMS USA	**1%**	**A210019**	**001**	Sep 13, 2019

SOOLANTRA

AB	**+!**	GALDERMA LABS LP	**1%**	**N206255**	**001**	Dec 19, 2014

LOTION;TOPICAL
SKLICE

+!	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012

TABLET;ORAL
IVERMECTIN

AB		EDENBRIDGE PHARMS	**3MG**	**A204154**	**001**	Oct 24, 2014

STROMECTOL

AB	**+!**	MERCK SHARP DOHME	**3MG**	**N050742**	**002**	Oct 08, 1998

IVOSIDENIB
TABLET;ORAL
TIBSOVO

+!	AGIOS PHARMS INC	250MG	N211192	001	Jul 20, 2018

IXABEPILONE
INJECTABLE;INTRAVENOUS
IXEMPRA KIT

+!	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007
+!		45MG/VIAL	N022065	002	Oct 16, 2007

IXAZOMIB CITRATE						
CAPSULE;ORAL						
NINLARO						
	+	MILLENNIUM PHARMS	EQ 2.3MG BASE	N208462	001	Nov 20, 2015
	+		EQ 3MG BASE	N208462	002	Nov 20, 2015
	+!		EQ 4MG BASE	N208462	003	Nov 20, 2015
KETAMINE HYDROCHLORIDE						
INJECTABLE;INJECTION						
KETALAR						
AP	**+!**	PAR STERILE PRODUCTS	**EQ 10MG BASE/ML**	**N016812**	**001**	
AP	**+!**		**EQ 50MG BASE/ML**	**N016812**	**002**	
AP	**+!**		**EQ 100MG BASE/ML**	**N016812**	**003**	
KETAMINE HYDROCHLORIDE						
AP		HOSPIRA	**EQ 50MG BASE/ML**	**A074549**	**001**	Jun 27, 1996
AP			**EQ 100MG BASE/ML**	**A074549**	**002**	Jun 27, 1996
AP		MYLAN INSTITUTIONAL	**EQ 10MG BASE/ML**	**A076092**	**001**	Sep 30, 2008
AP			**EQ 50MG BASE/ML**	**A076092**	**002**	Dec 28, 2001
AP			**EQ 100MG BASE/ML**	**A076092**	**003**	Oct 25, 2002
AP		WEST-WARD PHARMS INT	**EQ 50MG BASE/ML**	**A074524**	**001**	Mar 22, 1996
AP			**EQ 100MG BASE/ML**	**A074524**	**002**	Mar 22, 1996
KETOCONAZOLE						
AEROSOL, FOAM;TOPICAL						
EXTINA						
AT	**+!**	MYLAN	**2%**	**N021738**	**001**	Jun 12, 2007
KETOCONAZOLE						
AT		PERRIGO ISRAEL	**2%**	**A091550**	**001**	Aug 25, 2011
CREAM;TOPICAL						
KETOCONAZOLE						
AB		FOUGERA PHARMS	**2%**	**A076294**	**001**	Apr 28, 2004
AB	**!**	TEVA	**2%**	**A075581**	**001**	Apr 25, 2000
KETOZOLE						
AB		TARO	**2%**	**A075638**	**001**	Dec 18, 2002
GEL;TOPICAL						
XOLEGEL						
	+!	ALMIRALL	2%	N021946	001	Jul 28, 2006
SHAMPOO;TOPICAL						
KETOCONAZOLE						
AB		PERRIGO ISRAEL	**2%**	**A076419**	**001**	Jan 07, 2004
AB		TOLMAR	**2%**	**A076942**	**001**	Apr 11, 2005
NIZORAL						
AB	**+!**	JANSSEN PHARMS	**2%**	**N019927**	**001**	Aug 31, 1990
TABLET;ORAL						
KETOCONAZOLE						
AB		MYLAN	**200MG**	**A075597**	**001**	Dec 23, 1999
AB		STRIDES PHARMA	**200MG**	**A210457**	**001**	Jun 18, 2018
AB	**!**	TARO	**200MG**	**A075319**	**001**	Jun 15, 1999
KETOPROFEN						
CAPSULE;ORAL						
KETOPROFEN						
AB		HERITAGE PHARMS INC	**50MG**	**A074014**	**002**	Jan 29, 1993
AB			**75MG**	**A074014**	**003**	Jan 29, 1993
AB		TEVA	**50MG**	**A073516**	**001**	Dec 22, 1992
AB	**!**		**75MG**	**A073517**	**001**	Dec 22, 1992
		HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993
CAPSULE, EXTENDED RELEASE;ORAL						
KETOPROFEN						
	!	MYLAN	200MG	A075679	001	Feb 20, 2002
KETOROLAC TROMETHAMINE						
INJECTABLE;INJECTION						
KETOROLAC TROMETHAMINE						
AP		AMPHASTAR PHARM	**15MG/ML**	**A076209**	**001**	Jul 21, 2004
AP			**30MG/ML**	**A076209**	**002**	Jul 21, 2004
AP		BAXTER HLTHCARE CORP	**15MG/ML**	**A209900**	**002**	Jul 25, 2018
AP			**30MG/ML**	**A209900**	**001**	Sep 15, 2017
AP		FRESENIUS KABI USA	**15MG/ML**	**A075784**	**001**	Jan 11, 2002
AP			**15MG/ML**	**A203242**	**001**	Oct 07, 2015
AP			**30MG/ML**	**A075784**	**002**	Jan 11, 2002
AP			**30MG/ML**	**A203242**	**002**	Oct 07, 2015

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP		GLAND PHARMA LTD	**15MG/ML**	**A204216**	**001**	Nov 01, 2016
AP			**30MG/ML**	**A204216**	**002**	Nov 01, 2016
AP	!	HOSPIRA	**15MG/ML**	**A074802**	**001**	Jun 05, 1997
AP			**15MG/ML**	**A074993**	**001**	Jan 27, 1999
AP	!		**30MG/ML**	**A074802**	**002**	Jun 05, 1997
AP			**30MG/ML**	**A074993**	**002**	Jan 27, 1999
AP		SAGENT PHARMS INC	**15MG/ML**	**A091065**	**001**	Nov 27, 2013
AP			**30MG/ML**	**A091065**	**002**	Nov 27, 2013
AP		SANDOZ INC	**30MG/ML**	**A076271**	**002**	Oct 06, 2004
AP		WEST-WARD PHARMS INT	**15MG/ML**	**A075772**	**001**	Jul 21, 2004
AP			**30MG/ML**	**A075772**	**002**	Jul 21, 2004
AP		WOCKHARDT	**15MG/ML**	**A077942**	**001**	Mar 27, 2007
AP			**30MG/ML**	**A077942**	**002**	Mar 27, 2007

SOLUTION/DROPS;OPHTHALMIC

ACULAR

AT	+!	ALLERGAN	**0.5%**	**N019700**	**001**	Nov 09, 1992

ACULAR LS

AT	+!	ALLERGAN	**0.4%**	**N021528**	**001**	May 30, 2003

KETOROLAC TROMETHAMINE

AT		AKORN	**0.4%**	**A078399**	**001**	Nov 05, 2009
AT			**0.5%**	**A078434**	**001**	Nov 05, 2009
AT		APOTEX INC	**0.4%**	**A077308**	**001**	Nov 05, 2009
AT			**0.5%**	**A076109**	**001**	Nov 05, 2009
AT		MICRO LABS LTD INDIA	**0.5%**	**A203410**	**001**	Apr 05, 2019
AT		SANDOZ INC	**0.5%**	**A076583**	**001**	Nov 05, 2009
AT		SUN PHARM	**0.5%**	**A090017**	**001**	Nov 05, 2009

ACUVAIL

	+!	ALLERGAN	0.45%	N022427	001	Jul 22, 2009

SPRAY, METERED;NASAL

SPRIX

	+!	ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010

TABLET;ORAL

KETOROLAC TROMETHAMINE

AB		CYCLE PHARMS LTD	**10MG**	**A210616**	**001**	Aug 16, 2018
AB	!	MYLAN	**10MG**	**A074761**	**001**	May 16, 1997
AB		PLIVA	**10MG**	**A075284**	**001**	Jun 23, 1999
AB		TEVA	**10MG**	**A074754**	**001**	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

AT		LUPIN LTD	**EQ 0.3% BASE;EQ 1% BASE**	**A210183**	**001**	Jul 01, 2019

OMIDRIA

AT	+!	OMEROS	**EQ 0.3% BASE;EQ 1% BASE**	**N205388**	**001**	May 30, 2014

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

	+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP		AKORN INC	**5MG/ML**	**A075431**	**001**	Nov 29, 1999
AP		GLAND PHARMA LTD	**5MG/ML**	**A090699**	**001**	Apr 03, 2012
AP	!	HOSPIRA	**5MG/ML**	**A075239**	**001**	Nov 29, 1999
AP	!		**5MG/ML**	**A075240**	**001**	Nov 29, 1999
AP		WEST-WARD PHARMS INT	**5MG/ML**	**A075303**	**001**	May 28, 1999

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB		ATHEM	**100MG**	**A207863**	**001**	Feb 04, 2019
AB			**200MG**	**A207863**	**002**	Feb 04, 2019
AB			**300MG**	**A207863**	**003**	Feb 04, 2019
AB		CADILA PHARMS LTD	**100MG**	**A211325**	**001**	May 13, 2019
AB			**200MG**	**A211325**	**002**	May 13, 2019
AB			**300MG**	**A211325**	**003**	May 13, 2019
AB		INNOGENIX	**100MG**	**A075215**	**001**	Jul 29, 1999
AB			**200MG**	**A075215**	**002**	Jul 29, 1999

LABETALOL HYDROCHLORIDE

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB			**300MG**	**A075215**	**003**	Jul 29, 1999
AB		PAR FORM	**100MG**	**A200908**	**001**	Jul 10, 2012
AB			**200MG**	**A200908**	**002**	Jul 10, 2012
AB			**300MG**	**A200908**	**003**	Jul 10, 2012
AB		SANDOZ	**100MG**	**A075113**	**001**	Aug 04, 1998
AB	**!**		**200MG**	**A075113**	**002**	Aug 04, 1998
AB			**300MG**	**A075113**	**003**	Aug 04, 1998
AB		TWI PHARMS	**100MG**	**A209603**	**001**	Jun 20, 2018
AB			**200MG**	**A209603**	**002**	Jun 20, 2018
AB			**300MG**	**A209603**	**003**	Jun 20, 2018
AB		WATSON LABS	**100MG**	**A075133**	**001**	Aug 03, 1998
AB			**200MG**	**A075133**	**002**	Aug 03, 1998
AB			**300MG**	**A075133**	**003**	Aug 03, 1998
AB		ZYDUS PHARMS	**100MG**	**A207743**	**001**	Sep 19, 2017
AB			**200MG**	**A207743**	**002**	Sep 19, 2017
AB			**300MG**	**A207743**	**003**	Sep 19, 2017

TRANDATE

AB	**+**	CNTY LINE PHARMS	**100MG**	**N018716**	**001**	May 24, 1985
AB	**+**		**200MG**	**N018716**	**002**	Aug 01, 1984
AB	**+**		**300MG**	**N018716**	**003**	Aug 01, 1984

LACOSAMIDE

SOLUTION;INTRAVENOUS

VIMPAT

+!	UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008

SOLUTION;ORAL

VIMPAT

+!	UCB INC	10MG/ML	N022255	001	Apr 20, 2010

TABLET;ORAL

VIMPAT

+	UCB INC	50MG	N022253	001	Oct 28, 2008
+		100MG	N022253	002	Oct 28, 2008
+		150MG	N022253	003	Oct 28, 2008
+!		200MG	N022253	004	Oct 28, 2008

LACTULOSE

FOR SOLUTION;ORAL

LACTULOSE

!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997
!		20GM/PACKET	A074712	002	Dec 10, 1997

SOLUTION;ORAL

CONSTILAC

AA		ALRA	**10GM/15ML**	**A071054**	**001**	Jul 26, 1988

LACTULOSE

AA		FRESENIUS KABI	**10GM/15ML**	**A090503**	**001**	Jan 25, 2012
AA	**!**	HI TECH PHARMA	**10GM/15ML**	**A074076**	**001**	Jul 03, 1995
AA		HIKMA	**10GM/15ML**	**A073591**	**001**	May 29, 1992
AA		LANNETT CO INC	**10GM/15ML**	**A075993**	**001**	Jul 26, 2001
AA		LIFEPHARMA	**10GM/15ML**	**A209517**	**001**	Nov 23, 2018
AA		PHARM ASSOC	**10GM/15ML**	**A074623**	**001**	Jul 30, 1996
AA		VISTAPHARM	**10GM/15ML**	**A074138**	**001**	Sep 30, 1992
AA		WOCKHARDT BIO AG	**10GM/15ML**	**A074602**	**001**	Nov 14, 1996
AA		XTTRIUM LABS INC	**10GM/15ML**	**A075911**	**001**	Feb 21, 2002

SOLUTION;ORAL, RECTAL

CHOLAC

AA		ALRA	**10GM/15ML**	**A071331**	**001**	Jul 26, 1988

ENULOSE

AA	**!**	ACTAVIS MID ATLANTIC	**10GM/15ML**	**A071548**	**001**	Aug 15, 1988

GENERLAC

AA		WOCKHARDT BIO AG	**10GM/15ML**	**A074603**	**001**	Oct 31, 1996

LACTULOSE

AA		FRESENIUS KABI	**10GM/15ML**	**A090502**	**001**	Jan 25, 2012
AA		HI TECH PHARMA	**10GM/15ML**	**A074077**	**001**	Jul 03, 1995

LAMIVUDINE							
SOLUTION;ORAL							
EPIVIR							
AA	**+!**	VIIV HLTHCARE	**10MG/ML**	**N020596**	**001**	Nov 17, 1995	
LAMIVUDINE							
AA		AUROBINDO PHARMA LTD	**10MG/ML**	**A077695**	**001**	Nov 21, 2016	
AA		LANNETT CO INC	**10MG/ML**	**A203564**	**001**	Oct 31, 2014	
EPIVIR-HBV							
	+!	GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998	
TABLET;ORAL							
EPIVIR							
AB	**+**	VIIV HLTHCARE	**150MG**	**N020564**	**001**	Nov 17, 1995	
AB	**+!**		**300MG**	**N020564**	**003**	Jun 24, 2002	
EPIVIR-HBV							
AB	**+!**	GLAXOSMITHKLINE	**100MG**	**N021003**	**001**	Dec 08, 1998	
LAMIVUDINE							
AB		ANNORA	**100MG**	**A211306**	**001**	Mar 21, 2019	
AB		APOTEX	**100MG**	**A202941**	**001**	Jan 02, 2014	
AB			**150MG**	**A091606**	**001**	Dec 02, 2011	
AB			**300MG**	**A091606**	**002**	Dec 02, 2011	
AB		ARISE	**150MG**	**A206974**	**001**	Nov 21, 2016	
AB			**300MG**	**A206974**	**002**	Nov 21, 2016	
AB		AUROBINDO PHARMA LTD	**150MG**	**A077464**	**001**	Nov 21, 2016	
AB			**150MG**	**A202032**	**001**	Nov 17, 2011	
AB			**300MG**	**A077464**	**002**	Nov 21, 2016	
AB			**300MG**	**A202032**	**002**	Nov 17, 2011	
AB		CIPLA	**150MG**	**A077221**	**001**	Mar 03, 2017	
AB			**300MG**	**A077221**	**002**	Mar 03, 2017	
AB		ECI PHARMS LLC	**150MG**	**A203586**	**001**	Nov 21, 2016	
AB		HETERO LABS LTD V	**100MG**	**A203260**	**001**	Jan 02, 2014	
AB			**150MG**	**A203277**	**001**	Jan 06, 2014	
AB			**300MG**	**A203277**	**002**	Jan 06, 2014	
AB		LUPIN LTD	**150MG**	**A205217**	**001**	Dec 18, 2014	
AB			**300MG**	**A205217**	**002**	Dec 18, 2014	
AB		MACLEODS PHARMS LTD	**150MG**	**A090198**	**001**	May 01, 2019	
AB			**300MG**	**A090198**	**002**	May 01, 2019	
AB		MYLAN LABS LTD	**150MG**	**A078545**	**001**	Mar 05, 2019	
AB			**300MG**	**A078545**	**002**	Mar 05, 2019	
AB		STRIDES PHARMA	**150MG**	**A090457**	**001**	Apr 19, 2018	
AB			**300MG**	**A090457**	**002**	Apr 19, 2018	
LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE							
TABLET;ORAL							
CIMDUO							
	+!	MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018	
TEMIXYS							
		CELLTRION	300MG;300MG	N211284	001	Nov 16, 2018	
LAMIVUDINE; ZIDOVUDINE							
TABLET;ORAL							
COMBIVIR							
AB	**+!**	VIIV HLTHCARE	**150MG;300MG**	**N020857**	**001**	Sep 26, 1997	
LAMIVUDINE AND ZIDOVUDINE							
AB		ANDA REPOSITORY	**150MG;300MG**	**A206375**	**001**	Apr 10, 2018	
AB		AUROBINDO PHARMA LTD	**150MG;300MG**	**A077558**	**001**	May 05, 2017	
AB			**150MG;300MG**	**A202418**	**001**	May 15, 2012	
AB		CIPLA	**150MG;300MG**	**A077411**	**001**	Sep 07, 2018	
AB		HETERO LABS LTD III	**150MG;300MG**	**A079124**	**001**	Sep 17, 2015	
AB		HETERO LABS LTD V	**150MG;300MG**	**A203259**	**001**	Feb 03, 2014	
AB		LUPIN LTD	**150MG;300MG**	**A090246**	**001**	May 15, 2012	
AB		MACLEODS PHARMS LTD	**150MG;300MG**	**A090679**	**001**	Aug 29, 2018	
AB		STRIDES PHARMA	**150MG;300MG**	**A079128**	**001**	May 13, 2015	
LAMOTRIGINE							
TABLET;ORAL							
LAMICTAL							
AB	**+!**	GLAXOSMITHKLINE LLC	**25MG**	**N020241**	**005**	Dec 27, 1994	
AB	**+**		**100MG**	**N020241**	**001**	Dec 27, 1994	
AB	**+**		**150MG**	**N020241**	**002**	Dec 27, 1994	
AB	**+**		**200MG**	**N020241**	**003**	Dec 27, 1994	

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

AB	ALEMBIC PHARMS LTD	**25MG**	**A090607**	**001**	Jan 13, 2011
AB		**100MG**	**A090607**	**002**	Jan 13, 2011
AB		**150MG**	**A090607**	**003**	Jan 13, 2011
AB		**200MG**	**A090607**	**004**	Jan 13, 2011
AB	ALKEM LABS LTD	**25MG**	**A200694**	**001**	Jun 14, 2013
AB		**100MG**	**A200694**	**002**	Jun 14, 2013
AB		**150MG**	**A200694**	**003**	Jun 14, 2013
AB		**200MG**	**A200694**	**004**	Jun 14, 2013
AB	AUROBINDO PHARMA	**25MG**	**A078956**	**001**	Jan 27, 2009
AB		**100MG**	**A078956**	**002**	Jan 27, 2009
AB		**150MG**	**A078956**	**003**	Jan 27, 2009
AB		**200MG**	**A078956**	**004**	Jan 27, 2009
AB	CIPLA	**25MG**	**A077783**	**001**	Nov 01, 2010
AB		**100MG**	**A077783**	**002**	Nov 01, 2010
AB		**150MG**	**A077783**	**003**	Nov 01, 2010
AB		**200MG**	**A077783**	**004**	Nov 01, 2010
AB	DR REDDYS LABS LTD	**25MG**	**A076708**	**001**	Jan 27, 2009
AB		**100MG**	**A076708**	**002**	Jan 27, 2009
AB		**150MG**	**A076708**	**003**	Jan 27, 2009
AB		**200MG**	**A076708**	**004**	Jan 27, 2009
AB	GLENMARK GENERICS	**25MG**	**A090169**	**001**	May 12, 2012
AB		**100MG**	**A090169**	**002**	May 12, 2012
AB		**150MG**	**A090169**	**003**	May 12, 2012
AB		**200MG**	**A090169**	**004**	May 12, 2012
AB	JUBILANT CADISTA	**25MG**	**A079132**	**001**	Jan 27, 2009
AB		**100MG**	**A079132**	**002**	Jan 27, 2009
AB		**150MG**	**A079132**	**003**	Jan 27, 2009
AB		**200MG**	**A079132**	**004**	Jan 27, 2009
AB	LUPIN LTD	**25MG**	**A078691**	**001**	Jun 01, 2010
AB		**100MG**	**A078691**	**002**	Jun 01, 2010
AB		**150MG**	**A078691**	**003**	Jun 01, 2010
AB		**200MG**	**A078691**	**004**	Jun 01, 2010
AB	MYLAN	**25MG**	**A077420**	**001**	Jan 27, 2009
AB		**100MG**	**A077420**	**002**	Jan 27, 2009
AB		**150MG**	**A077420**	**003**	Jan 27, 2009
AB		**200MG**	**A077420**	**004**	Jan 27, 2009
AB	RUBICON	**25MG**	**A078625**	**001**	Jan 27, 2009
AB		**100MG**	**A078625**	**002**	Jan 27, 2009
AB		**150MG**	**A078625**	**003**	Jan 27, 2009
AB		**200MG**	**A078625**	**004**	Jan 27, 2009
AB	TARO PHARM INDS	**25MG**	**A078525**	**001**	Jan 27, 2009
AB		**100MG**	**A078525**	**002**	Jan 27, 2009
AB		**150MG**	**A078525**	**003**	Jan 27, 2009
AB		**200MG**	**A078525**	**004**	Jan 27, 2009
AB	TORRENT PHARMS	**25MG**	**A078947**	**001**	Jan 27, 2009
AB		**100MG**	**A078947**	**002**	Jan 27, 2009
AB		**150MG**	**A078947**	**003**	Jan 27, 2009
AB		**200MG**	**A078947**	**004**	Jan 27, 2009
AB	UNICHEM LABS LTD	**25MG**	**A090170**	**001**	Oct 06, 2011
AB		**100MG**	**A090170**	**002**	Oct 06, 2011
AB		**150MG**	**A090170**	**003**	Oct 06, 2011
AB		**200MG**	**A090170**	**004**	Oct 06, 2011
AB	ZYDUS PHARMS USA	**25MG**	**A077633**	**001**	Jan 27, 2009
AB		**100MG**	**A077633**	**003**	Jan 27, 2009
AB		**150MG**	**A077633**	**004**	Jan 27, 2009
AB		**200MG**	**A077633**	**005**	Jan 27, 2009
		50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE;ORAL

LAMICTAL CD

AB	+	GLAXOSMITHKLINE LLC	**2MG**	**N020764**	**004**	Sep 08, 2000
AB	+		**5MG**	**N020764**	**001**	Aug 24, 1998
AB	+!		**25MG**	**N020764**	**002**	Aug 24, 1998

LAMOTRIGINE

AB	ALEMBIC PHARMS LTD	**5MG**	**A201168**	**001**	Jun 12, 2014
AB		**25MG**	**A201168**	**002**	Jun 12, 2014
AB	AUROBINDO PHARMA	**5MG**	**A090401**	**002**	Nov 04, 2009
AB		**25MG**	**A090401**	**003**	Nov 04, 2009
AB	DR REDDYS LABS LTD	**5MG**	**A076701**	**001**	Jan 22, 2009

LAMOTRIGINE

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

AB			**25MG**	**A076701**	**002**	Jan 22, 2009
AB		GLENMARK PHARMS LTD	**5MG**	**A079099**	**001**	Feb 19, 2009
AB			**25MG**	**A079099**	**002**	Feb 19, 2009
AB		JUBILANT GENERICS	**5MG**	**A200220**	**001**	Feb 28, 2011
AB			**25MG**	**A200220**	**002**	Feb 28, 2011
AB		TARO	**5MG**	**A079204**	**001**	Feb 04, 2009
AB			**25MG**	**A079204**	**002**	Feb 04, 2009
AB		WATSON LABS	**2MG**	**A076928**	**001**	Jan 22, 2009
AB			**5MG**	**A076928**	**002**	Jan 22, 2009
AB			**25MG**	**A076928**	**003**	Jan 22, 2009
AB		ZYDUS PHARMS USA INC	**5MG**	**A078009**	**002**	Jan 22, 2009
AB			**25MG**	**A078009**	**003**	Jan 22, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	+	GLAXOSMITHKLINE LLC	**25MG**	**N022115**	**001**	May 29, 2009
AB	+!		**50MG**	**N022115**	**002**	May 29, 2009
AB	+		**100MG**	**N022115**	**003**	May 29, 2009
AB	+!		**200MG**	**N022115**	**004**	May 29, 2009
AB	+		**250MG**	**N022115**	**006**	Jun 21, 2011
AB	+		**300MG**	**N022115**	**005**	Apr 14, 2010

LAMOTRIGINE

AB		ACTAVIS ELIZABETH	**100MG**	**A200672**	**003**	Oct 17, 2013
AB			**200MG**	**A200672**	**004**	Oct 17, 2013
AB			**25MG**	**A200672**	**001**	Oct 17, 2013
AB			**50MG**	**A200672**	**002**	Oct 17, 2013
AB			**250MG**	**A203733**	**001**	Nov 13, 2013
AB			**300MG**	**A200672**	**005**	Oct 17, 2013
AB		AMNEAL PHARMS	**25MG**	**A207497**	**001**	Nov 30, 2018
AB			**50MG**	**A207497**	**002**	Nov 30, 2018
AB			**100MG**	**A207497**	**003**	Nov 30, 2018
AB			**200MG**	**A207497**	**004**	Nov 30, 2018
AB			**250MG**	**A207497**	**005**	Nov 30, 2018
AB			**300MG**	**A207497**	**006**	Nov 30, 2018
AB		ANCHEN PHARMS	**25MG**	**A201374**	**001**	Dec 26, 2012
AB			**50MG**	**A201374**	**002**	Dec 26, 2012
AB			**100MG**	**A201374**	**003**	Dec 26, 2012
AB			**200MG**	**A201374**	**004**	Dec 26, 2012
AB			**250MG**	**A201374**	**005**	Dec 26, 2012
AB			**300MG**	**A201374**	**006**	Dec 26, 2012
AB		DR REDDYS LABS LTD	**25MG**	**A202383**	**001**	Jun 19, 2013
AB			**50MG**	**A202383**	**002**	Jun 19, 2013
AB			**100MG**	**A202383**	**003**	Jun 19, 2013
AB			**200MG**	**A202383**	**004**	Jun 19, 2013
AB			**300MG**	**A202383**	**005**	Jun 19, 2013
AB		PAR PHARM	**25MG**	**A201791**	**001**	Jan 18, 2013
AB			**50MG**	**A201791**	**002**	Jan 18, 2013
AB			**100MG**	**A201791**	**003**	Jan 18, 2013
AB			**200MG**	**A201791**	**004**	Jan 18, 2013
AB			**250MG**	**A201791**	**005**	Jan 18, 2013
AB			**300MG**	**A201791**	**006**	Jan 18, 2013
AB		RUBICON	**100MG**	**A202887**	**003**	Jun 17, 2013
AB			**200MG**	**A202887**	**004**	Jun 17, 2013
AB		TORRENT	**25MG**	**A203370**	**001**	Dec 23, 2013
AB			**50MG**	**A203370**	**002**	Dec 23, 2013
AB			**100MG**	**A203370**	**003**	Dec 23, 2013
AB			**200MG**	**A203370**	**004**	Dec 23, 2013
AB		WOCKHARDT LTD	**25MG**	**A202498**	**001**	Jan 04, 2013
AB			**50MG**	**A202498**	**002**	Jan 04, 2013
AB			**100MG**	**A202498**	**003**	Jan 04, 2013
AB			**200MG**	**A202498**	**004**	Jan 04, 2013
AB			**300MG**	**A202498**	**005**	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

AB	+	GLAXOSMITHKLINE LLC	**25MG**	**N022251**	**001**	May 08, 2009
AB	+!		**50MG**	**N022251**	**002**	May 08, 2009
AB	+		**100MG**	**N022251**	**003**	May 08, 2009
AB	+		**200MG**	**N022251**	**004**	May 08, 2009

LAMOTRIGINE

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB		IMPAX LABS INC	**25MG**	**A200828**	**001**	Jul 15, 2013
AB			**50MG**	**A200828**	**002**	Jul 15, 2013
AB			**100MG**	**A200828**	**003**	Jul 15, 2013
AB			**200MG**	**A200828**	**004**	Jul 15, 2013
AB		PAR PHARM	**25MG**	**A204158**	**001**	Oct 27, 2015
AB			**50MG**	**A204158**	**002**	Oct 27, 2015
AB			**100MG**	**A204158**	**003**	Oct 27, 2015
AB			**200MG**	**A204158**	**004**	Oct 27, 2015
AB		SCIEGEN PHARMS INC	**25MG**	**A206382**	**001**	Jun 17, 2016
AB			**50MG**	**A206382**	**002**	Jun 17, 2016
AB			**100MG**	**A206382**	**003**	Jun 17, 2016
AB			**200MG**	**A206382**	**004**	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

	+!	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074 001	Aug 30, 2007
	+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074 002	Aug 30, 2007
	+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074 003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB		ALKEM LABS LTD	**15MG**	**A207394**	**001**	Jan 18, 2019
AB			**30MG**	**A207394**	**002**	Jan 18, 2019
AB		DR REDDYS LABS LTD	**15MG**	**A091269**	**001**	Oct 15, 2010
AB			**30MG**	**A091269**	**002**	Oct 15, 2010
AB		INVENTIA	**15MG**	**A205868**	**001**	Aug 30, 2017
AB			**30MG**	**A205868**	**002**	Aug 30, 2017
AB		LANNETT CO INC	**15MG**	**A207156**	**001**	Sep 28, 2017
AB			**30MG**	**A207156**	**002**	Sep 28, 2017
AB		MYLAN PHARMS INC	**15MG**	**A090763**	**001**	Nov 10, 2009
AB			**30MG**	**A090763**	**002**	Nov 10, 2009
AB		NATCO PHARMA LTD	**15MG**	**A201921**	**001**	Dec 18, 2012
AB			**30MG**	**A201921**	**002**	Dec 18, 2012
AB		SANDOZ	**15MG**	**A090331**	**001**	Apr 23, 2010
AB			**30MG**	**A090331**	**002**	Apr 23, 2010
AB		SUN PHARM	**15MG**	**A202637**	**001**	Sep 13, 2013
AB			**30MG**	**A091509**	**001**	Sep 13, 2013
AB		TEVA PHARMS	**15MG**	**A077255**	**001**	Nov 10, 2009
AB			**30MG**	**A077255**	**002**	Nov 10, 2009
AB		WOCKHARDT USA	**15MG**	**A202176**	**001**	Sep 14, 2012
AB			**30MG**	**A202176**	**002**	Sep 14, 2012
AB		XIROMED	**15MG**	**A203203**	**001**	Jul 25, 2016
AB			**30MG**	**A203203**	**002**	Jul 25, 2016
AB		ZYDUS HLTHCARE	**15MG**	**A202366**	**001**	Aug 19, 2013
AB			**30MG**	**A202366**	**002**	Aug 19, 2013

PREVACID

AB	**+**	TAKEDA PHARMS USA	**15MG**	**N020406**	**001**	May 10, 1995
AB	**+!**		**30MG**	**N020406**	**002**	May 10, 1995

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

AB		MYLAN	**15MG**	**A202396**	**001**	Nov 28, 2018
AB			**30MG**	**A202396**	**002**	Nov 28, 2018
AB		TEVA PHARMS USA	**15MG**	**A208784**	**001**	Sep 21, 2017
AB			**30MG**	**A208784**	**002**	Sep 21, 2017
AB		ZYDUS PHARMS	**15MG**	**A200816**	**001**	Nov 27, 2018
AB			**30MG**	**A200816**	**002**	Nov 27, 2018

PREVACID

AB	**+**	TAKEDA PHARMS USA	**15MG**	**N021428**	**001**	Aug 30, 2002
AB	**+!**		**30MG**	**N021428**	**002**	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

+	SHIRE DEV LLC	EQ 750MG BASE	N204734 001	Sep 24, 2014
+!		EQ 1GM BASE	N204734 002	Sep 24, 2014

TABLET, CHEWABLE;ORAL

FOSRENOL

AB	**+**	SHIRE LLC	**EQ 500MG BASE**	**N021468**	**002**	Oct 26, 2004

LANTHANUM CARBONATE						
TABLET, CHEWABLE;ORAL						
FOSRENOL						
AB	**+**		**EQ 750MG BASE**	**N021468**	**003**	Nov 23, 2005
AB	**+!**		**EQ 1GM BASE**	**N021468**	**004**	Nov 23, 2005
LANTHANUM CARBONATE						
AB		NATCO PHARMA LTD	**EQ 500MG BASE**	**A090978**	**001**	Aug 11, 2017
AB			**EQ 750MG BASE**	**A090978**	**002**	Aug 11, 2017
AB			**EQ 1GM BASE**	**A090978**	**003**	Aug 11, 2017
LAPATINIB DITOSYLATE						
TABLET;ORAL						
TYKERB						
	+!	NOVARTIS	EQ 250MG BASE	N022059	001	Mar 13, 2007
LAROTRECTINIB SULFATE						
CAPSULE;ORAL						
VITRAKVI						
	+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018
	+!		EQ 100MG BASE	N210861	002	Nov 26, 2018
SOLUTION;ORAL						
VITRAKVI						
	+!	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018
LATANOPROST						
EMULSION;OPHTHALMIC						
XELPROS						
	+!	SUN PHARMA GLOBAL	0.005%	N206185	001	Sep 12, 2018
SOLUTION/DROPS;OPHTHALMIC						
LATANOPROST						
AT		AKORN	**0.005%**	**A090887**	**001**	Jul 19, 2011
AT		AMRING PHARMS	**0.005%**	**A200925**	**001**	Mar 22, 2011
AT		AUROBINDO PHARMA LTD	**0.005%**	**A206519**	**001**	Sep 03, 2019
AT		BAUSCH AND LOMB	**0.005%**	**A201006**	**001**	Mar 22, 2011
AT		DR REDDYS LABS LTD	**0.005%**	**A202077**	**001**	Feb 11, 2013
AT		FDC LTD	**0.005%**	**A202442**	**001**	Apr 22, 2016
AT		SANDOZ INC	**0.005%**	**A091449**	**001**	Mar 22, 2011
AT		SOMERSET	**0.005%**	**A201786**	**001**	Mar 22, 2011
XALATAN						
AT	**+!**	PHARMACIA AND UPJOHN	**0.005%**	**N020597**	**001**	Jun 05, 1996
LATANOPROST; NETARSUDIL DIMESYLATE						
SOLUTION/DROPS;OPHTHALMIC						
ROCKLATAN						
	+!	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019
LATANOPROSTENE BUNOD						
SOLUTION/DROPS;OPHTHALMIC						
VYZULTA						
	+!	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017
LEDIPASVIR; SOFOSBUVIR						
PELLETS;ORAL						
HARVONI						
	+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477	001	Aug 28, 2019
	+!		45MG;200MG/PACKET	N212477	002	Aug 28, 2019
TABLET;ORAL						
HARVONI						
	+	GILEAD SCIENCES INC	45MG;200MG	N205834	002	Aug 28, 2019
	+!		90MG;400MG	N205834	001	Oct 10, 2014
LEFAMULIN ACETATE						
SOLUTION;INTRAVENOUS						
XENLETA						
	+!	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019
TABLET;ORAL						
XENLETA						
	+!	NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019

LEFLUNOMIDE

TABLET;ORAL

ARAVA

AB	**+**	SANOFI AVENTIS US	**10MG**	**N020905**	**001**	Sep 10, 1998
AB	**+!**		**20MG**	**N020905**	**002**	Sep 10, 1998

LEFLUNOMIDE

AB		ABHAI LLC	**10MG**	**A212453**	**001**	Jun 03, 2019
AB			**20MG**	**A212453**	**002**	Jun 03, 2019
AB		ALEMBIC PHARMS LTD	**10MG**	**A091369**	**001**	Nov 21, 2011
AB			**20MG**	**A091369**	**002**	Nov 21, 2011
AB		APOTEX INC	**10MG**	**A077090**	**001**	Sep 13, 2005
AB			**20MG**	**A077090**	**002**	Sep 13, 2005
AB		BARR	**10MG**	**A077083**	**001**	Sep 13, 2005
AB			**20MG**	**A077083**	**002**	Sep 13, 2005
AB		HERITAGE PHARMS INC	**10MG**	**A077086**	**001**	Sep 13, 2005
AB			**20MG**	**A077086**	**002**	Sep 13, 2005
AB		TEVA PHARMS	**10MG**	**A077084**	**001**	Sep 13, 2005
AB			**20MG**	**A077084**	**002**	Sep 13, 2005
AB		ZYDUS	**10MG**	**A212308**	**001**	Apr 24, 2019
AB			**20MG**	**A212308**	**002**	Apr 24, 2019

ARAVA

	+!	SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998

LENALIDOMIDE

CAPSULE;ORAL

REVLIMID

	+	CELGENE	2.5MG	N021880	005	Dec 21, 2011
	+		5MG	N021880	001	Dec 27, 2005
	+		10MG	N021880	002	Dec 27, 2005
	+		15MG	N021880	003	Jun 29, 2006
	+		20MG	N021880	006	Jun 05, 2013
	+!		25MG	N021880	004	Jun 29, 2006

LENVATINIB MESYLATE

CAPSULE;ORAL

LENVIMA

	+	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015
	+!		EQ 10MG BASE	N206947	002	Feb 13, 2015

LETERMOVIR

SOLUTION;INTRAVENOUS

PREVYMIS

	+!	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017
	+!		480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017

TABLET;ORAL

PREVYMIS

	+	MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017
	+!		480MG	N209939	002	Nov 08, 2017

LETROZOLE

TABLET;ORAL

FEMARA

AB	**+!**	NOVARTIS PHARMS	**2.5MG**	**N020726**	**001**	Jul 25, 1997

LETROZOLE

AB		ACCORD HLTHCARE	**2.5MG**	**A090934**	**001**	Jun 03, 2011
AB		APOTEX INC	**2.5MG**	**A091303**	**001**	Apr 19, 2012
AB		BEIJING YILING	**2.5MG**	**A205869**	**001**	Nov 14, 2018
AB		DR REDDYS LABS LTD	**2.5MG**	**A091191**	**001**	Jun 03, 2011
AB		EUGIA PHARMA	**2.5MG**	**A211717**	**001**	Jan 11, 2019
AB		HIKMA	**2.5MG**	**A090838**	**001**	Jun 03, 2011
AB		HIKMA PHARMS	**2.5MG**	**A203796**	**001**	Jun 03, 2016
AB		INDICUS PHARMA	**2.5MG**	**A201804**	**001**	Jun 03, 2011
AB		JIANGSU HENGRUI MED	**2.5MG**	**A202716**	**001**	May 16, 2013
AB		NATCO PHARMA LTD	**2.5MG**	**A200161**	**001**	Jun 03, 2011
AB		TEVA PHARMS	**2.5MG**	**A090289**	**001**	Jun 03, 2011
AB		VINTAGE PHARMS LLC	**2.5MG**	**A090789**	**001**	Jun 03, 2011

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

	+!	NOVARTIS	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A207226**	**001**	Jul 27, 2018
AP		TEVA PHARMS USA	**EQ 100MG BASE/VIAL**	**A081277**	**001**	Sep 28, 1993
AP			**EQ 350MG BASE/VIAL**	**A040174**	**001**	Jun 12, 1997
AP	!	WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A089384**	**001**	Sep 14, 1987
AP	!		**EQ 100MG BASE/VIAL**	**A089717**	**001**	Mar 28, 1988

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A040258**	**001**	Feb 26, 1999
AP	!		**EQ 500MG BASE/VIAL**	**A040286**	**001**	Feb 26, 1999
AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A203800**	**001**	May 19, 2017
AP			**EQ 200MG BASE/VIAL**	**A203800**	**002**	May 19, 2017
AP			**EQ 350MG BASE/VIAL**	**A203800**	**003**	May 19, 2017
AP		SAGENT PHARMS	**EQ 50MG BASE/VIAL**	**A200753**	**001**	Sep 06, 2012
AP			**EQ 100MG BASE/VIAL**	**A200753**	**002**	Sep 06, 2012
AP			**EQ 200MG BASE/VIAL**	**A200753**	**003**	Sep 06, 2012
AP			**EQ 350MG BASE/VIAL**	**A200855**	**001**	Sep 06, 2012
AP		SAGENT PHARMS INC	**EQ 500MG BASE/VIAL**	**A209110**	**001**	Oct 26, 2017
AP	!	WEST-WARD PHARMS INT	**EQ 10MG BASE/ML**	**A040347**	**001**	Apr 25, 2000
AP	!		**EQ 200MG BASE/VIAL**	**A040056**	**001**	May 23, 1995
AP	!		**EQ 350MG BASE/VIAL**	**A040335**	**001**	Apr 20, 2000

LEUCOVORIN CALCIUM

		FRESENIUS KABI USA	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018

TABLET;ORAL

LEUCOVORIN CALCIUM

AB		BARR	**EQ 5MG BASE**	**A071198**	**001**	Sep 24, 1987
AB			**EQ 25MG BASE**	**A071199**	**001**	Sep 24, 1987
AB		HIKMA	**EQ 5MG BASE**	**A072733**	**001**	Feb 22, 1993
AB	!		**EQ 25MG BASE**	**A072736**	**001**	Feb 22, 1993
			EQ 10MG BASE	A072734	001	Feb 22, 1993
			EQ 15MG BASE	A072735	001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE;INJECTION

LEUPROLIDE ACETATE

AP	!	SANDOZ	**1MG/0.2ML**	**A074728**	**001**	Aug 04, 1998
AP		SUN PHARM	**1MG/0.2ML**	**A078885**	**001**	Mar 09, 2009
AP		TEVA PHARMS USA	**1MG/0.2ML**	**A075471**	**001**	Oct 25, 2000

LUPRON DEPOT

	+!	ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995
	+!		7.5MG/VIAL	N019732	001	Jan 26, 1989
	+!		11.25MG/VIAL	N020708	001	Mar 07, 1997
	+		22.5MG/VIAL	N020517	001	Dec 22, 1995
	+!		30MG/VIAL	N020517	002	May 30, 1997
	+!		45MG/VIAL	N020517	003	Jun 17, 2011

LUPRON DEPOT-PED

	+!	ABBVIE ENDOCRINE INC	7.5MG/VIAL	N020263	002	Apr 16, 1993
	+!		11.25MG/VIAL	N020263	005	Jan 21, 1994
	+!		11.25MG/VIAL	N020263	007	Aug 15, 2011
	+!		15MG/VIAL	N020263	006	Jan 21, 1994
	+!		30MG/VIAL	N020263	008	Aug 15, 2011

INJECTABLE;SUBCUTANEOUS

ELIGARD

	+!	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002
	+!		22.5MG/VIAL	N021379	001	Jul 24, 2002
	+!		30MG/VIAL	N021488	001	Feb 13, 2003
	+!		45MG/VIAL	N021731	001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET;INTRAMUSCULAR, ORAL

LUPANETA PACK

	+	ABBVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N203696	001	Dec 14, 2012
	+!		11.25MG/VIAL,N/A;N/A,5MG	N203696	002	Dec 14, 2012

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		AUROBINDO PHARMA LTD	**EQ 0.25% BASE**	**A207628**	**001**	Jan 31, 2017
AN			**EQ 0.0103% BASE**	**A207625**	**001**	Dec 30, 2016
AN			**EQ 0.021% BASE**	**A207625**	**002**	Dec 30, 2016
AN			**EQ 0.042% BASE**	**A207625**	**003**	Dec 30, 2016
AN		CIPLA	**EQ 0.021% BASE**	**A078171**	**002**	Dec 13, 2013
AN			**EQ 0.042% BASE**	**A078171**	**003**	Dec 13, 2013
AN			**EQ 0.0103% BASE**	**A078171**	**001**	Dec 13, 2013
AN		IMPAX LABS INC	**EQ 0.0103% BASE**	**A077756**	**003**	Apr 09, 2008
AN			**EQ 0.021% BASE**	**A077756**	**001**	Apr 09, 2008
AN			**EQ 0.042% BASE**	**A077756**	**002**	Apr 09, 2008
AN		MYLAN SPECIALITY LP	**EQ 0.25% BASE**	**A078309**	**001**	Mar 20, 2009
AN		RITEDOSE CORP	**EQ 0.0103% BASE**	**A203653**	**001**	Mar 22, 2016
AN			**EQ 0.021% BASE**	**A203653**	**002**	Mar 22, 2016
AN			**EQ 0.042% BASE**	**A203653**	**003**	Mar 22, 2016
AN		SUN PHARM	**EQ 0.0103% BASE**	**A207820**	**001**	Nov 05, 2018
AN			**EQ 0.021% BASE**	**A207820**	**002**	Nov 05, 2018
AN			**EQ 0.042% BASE**	**A207820**	**003**	Nov 05, 2018
AN		TEVA PARENTERAL	**EQ 0.25% BASE**	**A200875**	**001**	Sep 11, 2014
AN		TEVA PHARMS USA	**EQ 0.0103% BASE**	**A090297**	**001**	Apr 26, 2013
AN			**EQ 0.021% BASE**	**A090297**	**002**	Apr 26, 2013
AN			**EQ 0.042% BASE**	**A090297**	**003**	Apr 26, 2013

XOPENEX

AN	**+!**	OAK PHARMS INC	**EQ 0.0103% BASE**	**N020837**	**003**	Jan 30, 2002
AN	**+!**		**EQ 0.021% BASE**	**N020837**	**001**	Mar 25, 1999
AN	**+!**		**EQ 0.042% BASE**	**N020837**	**002**	Mar 25, 1999
AN	**+!**		**EQ 0.25% BASE**	**N020837**	**004**	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED;INHALATION

XOPENEX HFA

	+!	SUNOVION	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005

LEVAMLODIPINE MALEATE

TABLET;ORAL

CONJUPRI

	+	CSPC OUYI	EQ 1.25MG BASE	N212895	001	Dec 19, 2019
	+		EQ 2.5MG BASE	N212895	002	Dec 19, 2019
	+!		EQ 5MG BASE	N212895	003	Dec 19, 2019

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

KEPPRA

AP	**+!**	UCB INC	**500MG/5ML (100MG/ML)**	**N021872**	**001**	Jul 31, 2006

LEVETIRACETAM

AP		AUROBINDO PHARMA LTD	**500MG/5ML (100MG/ML)**	**A204312**	**001**	Feb 01, 2016
AP		FRESENIUS KABI USA	**500MG/5ML (100MG/ML)**	**A090813**	**001**	May 26, 2010
AP			**500MG/5ML (100MG/ML)**	**A090876**	**001**	Aug 13, 2015
AP		HAINAN POLY PHARM	**500MG/5ML (100MG/ML)**	**A209781**	**001**	Mar 20, 2018
AP		HIKMA FARMACEUTICA	**500MG/5ML (100MG/ML)**	**A090981**	**001**	Oct 13, 2011
AP		HOSPIRA INC	**500MG/5ML (100MG/ML)**	**A202869**	**001**	Apr 06, 2012
AP		JUBILANT GENERICS	**500MG/5ML (100MG/ML)**	**A206838**	**001**	Jun 02, 2016
AP		MICRO LABS	**500MG/5ML (100MG/ML)**	**A211954**	**001**	Aug 09, 2019
AP		MYLAN LABS LTD	**500MG/5ML (100MG/ML)**	**A203308**	**001**	Sep 16, 2016
AP		SAGENT PHARMS	**500MG/5ML (100MG/ML)**	**A091627**	**001**	Jun 26, 2013
AP		SUN PHARM INDS LTD	**500MG/5ML (100MG/ML)**	**A090754**	**001**	Jun 16, 2010
AP		X GEN PHARMS	**500MG/5ML (100MG/ML)**	**A091485**	**001**	Aug 05, 2011

LEVETIRACETAM IN SODIUM CHLORIDE

AP		AUROBINDO PHARMA LTD	**500MG/100ML (5MG/ML)**	**A207160**	**001**	Jan 04, 2017
AP			**1000MG/100ML (10MG/ML)**	**A207160**	**002**	Jan 04, 2017
AP			**1500MG/100ML (15MG/ML)**	**A207160**	**003**	Jan 04, 2017
AP		GLAND PHARMA LTD	**500MG/100ML (5MG/ML)**	**A206880**	**001**	Oct 25, 2017
AP			**1000MG/100ML (10MG/ML)**	**A206880**	**002**	Oct 25, 2017
AP			**1500MG/100ML (15MG/ML)**	**A206880**	**003**	Oct 25, 2017
AP	**+!**	HQ SPECIALITY PHARMA	**500MG/100ML (5MG/ML)**	**N202543**	**001**	Nov 09, 2011
AP	**+!**		**1000MG/100ML (10MG/ML)**	**N202543**	**002**	Nov 09, 2011
AP	**+!**		**1500MG/100ML (15MG/ML)**	**N202543**	**003**	Nov 09, 2011

LEVETIRACETAM

SOLUTION;ORAL

	KEPPRA						
AA	**+!**	UCB INC	**100MG/ML**	**N021505**	**001**	Jul 15, 2003	
	LEVETIRACETAM						
AA		ACTAVIS MID ATLANTIC	**100MG/ML**	**A078976**	**001**	Jan 15, 2009	
AA		AMNEAL PHARMS	**100MG/ML**	**A090992**	**001**	Oct 27, 2009	
AA		ANDA REPOSITORY	**100MG/ML**	**A079107**	**001**	Jan 15, 2009	
AA		AUROBINDO PHARMA LTD	**100MG/ML**	**A079063**	**001**	Jan 15, 2009	
AA		BRECKENRIDGE	**100MG/ML**	**A079120**	**001**	Jan 16, 2009	
AA		HETERO LABS LTD III	**100MG/ML**	**A203052**	**001**	Feb 28, 2013	
AA		HI-TECH PHARMACAL	**100MG/ML**	**A090601**	**001**	Feb 28, 2012	
AA		LANNETT CO INC	**100MG/ML**	**A090079**	**001**	Apr 11, 2012	
AA			**100MG/ML**	**A090263**	**001**	Apr 03, 2009	
AA		LUPIN LTD	**100MG/ML**	**A090893**	**001**	Oct 17, 2011	
AA		ORIT LABS LLC	**100MG/ML**	**A203067**	**001**	May 09, 2013	
AA		PHARM ASSOC	**100MG/ML**	**A201157**	**001**	Jun 04, 2015	
AA		TARO	**100MG/ML**	**A078774**	**001**	Feb 10, 2009	
AA		TRIS PHARMA INC	**100MG/ML**	**A090461**	**001**	Sep 30, 2010	
AA		WOCKHARDT BIO AG	**100MG/ML**	**A090028**	**001**	Mar 03, 2010	

TABLET;ORAL

	KEPPRA						
AB	**+**	UCB INC	**250MG**	**N021035**	**001**	Nov 30, 1999	
AB	**+**		**500MG**	**N021035**	**002**	Nov 30, 1999	
AB	**+**		**750MG**	**N021035**	**003**	Nov 30, 1999	
AB	**+!**		**1GM**	**N021035**	**004**	Jan 06, 2006	
	LEVETIRACETAM						
AB		ACCORD HLTHCARE	**250MG**	**A090843**	**001**	Feb 14, 2011	
AB			**500MG**	**A090843**	**002**	Feb 14, 2011	
AB			**750MG**	**A090843**	**003**	Feb 14, 2011	
AB			**1GM**	**A090843**	**004**	Feb 14, 2011	
AB		ACI HEALTHCARE LTD	**250MG**	**A078042**	**001**	Jan 15, 2009	
AB			**500MG**	**A078042**	**002**	Jan 15, 2009	
AB			**750MG**	**A078042**	**003**	Jan 15, 2009	
AB			**1GM**	**A078042**	**004**	Jan 15, 2009	
AB		ACIC PHARMS	**250MG**	**A090767**	**001**	Jul 28, 2010	
AB			**500MG**	**A090767**	**002**	Jul 28, 2010	
AB			**750MG**	**A090767**	**003**	Jul 28, 2010	
AB			**1GM**	**A090767**	**004**	Jul 28, 2010	
AB		APOTEX INC	**250MG**	**A078869**	**001**	Mar 13, 2009	
AB			**500MG**	**A078869**	**002**	Mar 13, 2009	
AB			**750MG**	**A078869**	**003**	Mar 13, 2009	
AB			**1GM**	**A078869**	**004**	Mar 13, 2009	
AB		AUROBINDO PHARMA	**250MG**	**A078993**	**001**	Jan 15, 2009	
AB			**500MG**	**A078993**	**002**	Jan 15, 2009	
AB			**750MG**	**A078993**	**003**	Jan 15, 2009	
AB			**1GM**	**A078993**	**004**	Jan 15, 2009	
AB		BRECKENRIDGE PHARM	**250MG**	**A090511**	**001**	Aug 18, 2011	
AB			**500MG**	**A090511**	**002**	Aug 18, 2011	
AB			**750MG**	**A090511**	**003**	Aug 18, 2011	
AB			**1GM**	**A090511**	**004**	Aug 18, 2011	
AB		CHARTWELL RX	**250MG**	**A201293**	**001**	Jun 14, 2011	
AB			**500MG**	**A201293**	**002**	Jun 14, 2011	
AB			**750MG**	**A201293**	**003**	Jun 14, 2011	
AB			**1GM**	**A201293**	**004**	Jun 14, 2011	
AB		DR REDDYS LABS LTD	**250MG**	**A076920**	**001**	Jan 15, 2009	
AB			**500MG**	**A076920**	**002**	Jan 15, 2009	
AB			**750MG**	**A076920**	**003**	Jan 15, 2009	
AB			**1GM**	**A078904**	**001**	Jan 15, 2009	
AB		HETERO LABS LTD III	**250MG**	**A090515**	**001**	Oct 08, 2010	
AB			**500MG**	**A090515**	**002**	Oct 08, 2010	
AB			**750MG**	**A090515**	**003**	Oct 08, 2010	
AB			**1GM**	**A090515**	**004**	Oct 08, 2010	
AB		INVAGEN PHARMS	**250MG**	**A078234**	**001**	Jan 15, 2009	
AB			**500MG**	**A078234**	**002**	Jan 15, 2009	
AB			**750MG**	**A078234**	**003**	Jan 15, 2009	
AB		LOTUS PHARM CO LTD	**250MG**	**A090906**	**002**	Oct 31, 2016	
AB			**500MG**	**A090906**	**001**	Nov 05, 2010	
AB			**750MG**	**A090906**	**003**	Oct 31, 2016	
AB			**1GM**	**A090906**	**004**	Oct 31, 2016	
AB		LUPIN	**250MG**	**A078154**	**001**	Jan 15, 2009	

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

AB		500MG	A078154	002	Jan 15, 2009
AB		750MG	A078154	003	Jan 15, 2009
AB		1GM	A090025	001	Jan 15, 2009
AB	MYLAN	250MG	A076919	001	Nov 04, 2008
AB		500MG	A076919	002	Nov 04, 2008
AB		750MG	A076919	003	Nov 04, 2008
AB		1GM	A090261	001	Dec 08, 2009
AB	ORCHID HLTHCARE	250MG	A078526	001	Jan 15, 2009
AB		500MG	A078526	002	Jan 15, 2009
AB		750MG	A078526	003	Jan 15, 2009
AB		1GM	A090484	001	Aug 05, 2010
AB	OXFORD PHARMS	250MG	A077319	001	Mar 20, 2009
AB		500MG	A077319	002	Mar 20, 2009
AB		750MG	A077319	003	Mar 20, 2009
AB	PRINSTON INC	250MG	A078106	001	Feb 10, 2009
AB		500MG	A078106	002	Feb 10, 2009
AB		750MG	A078106	003	Feb 10, 2009
AB		1GM	A078106	004	Feb 10, 2009
AB	SECAN PHARMS	500MG	A205102	004	Dec 16, 2015
AB		1GM	A205102	003	Dec 16, 2015
AB	TARO	250MG	A078960	004	Feb 01, 2010
AB		500MG	A078960	003	Feb 01, 2010
AB		750MG	A078960	002	Feb 01, 2010
AB		1GM	A078960	001	Feb 01, 2010
AB	TEVA PHARMS	250MG	A078101	001	Jan 15, 2009
AB		500MG	A078101	002	Jan 15, 2009
AB		750MG	A078101	003	Jan 15, 2009
AB		1GM	A078101	004	Jan 15, 2009
AB	TORRENT PHARMS	250MG	A078858	001	Jan 15, 2009
AB		500MG	A078858	002	Jan 15, 2009
AB		750MG	A078858	003	Jan 15, 2009
AB		1GM	A078858	004	Jan 15, 2009
AB	VINTAGE PHARMS	250MG	A091491	001	Dec 14, 2010
AB		500MG	A091491	002	Dec 14, 2010
AB		750MG	A091491	003	Dec 14, 2010
AB		1GM	A091491	004	Dec 14, 2010
AB	WOCKHARDT	250MG	A079042	001	Jan 15, 2009
AB		500MG	A079042	002	Jan 15, 2009
AB		750MG	A079042	003	Jan 15, 2009
AB		1GM	A079042	004	Jan 15, 2009
AB	ZYDUS PHARMS USA INC	250MG	A078918	001	Apr 29, 2009
AB		1GM	A078918	002	Apr 29, 2009

TABLET, EXTENDED RELEASE;ORAL

KEPPRA XR

AB	+	UCB INC	500MG	N022285	001	Sep 12, 2008
AB	+!		750MG	N022285	002	Feb 12, 2009

LEVETIRACETAM

AB	ACTAVIS ELIZABETH	500MG	A091557	001	Sep 12, 2011
AB		750MG	A091557	002	Sep 12, 2011
AB	ACTAVIS LABS FL INC	500MG	A091093	001	Sep 12, 2011
AB		750MG	A091093	002	Sep 12, 2011
AB	ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011
AB		750MG	A091360	002	Oct 04, 2011
AB	ANDA REPOSITORY	500MG	A204511	001	Feb 23, 2016
AB		750MG	A204511	002	Feb 23, 2016
AB	APOTEX INC	500MG	A091261	001	Sep 12, 2011
AB		750MG	A091261	002	Sep 12, 2011
AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015
AB		750MG	A202167	002	Sep 04, 2015
AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016
AB		750MG	A204754	002	Aug 26, 2016
AB	HISUN PHARM HANGZHOU	500MG	A207175	001	Sep 28, 2017
AB		750MG	A207175	002	Sep 28, 2017
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016
AB		750MG	A202095	001	Jun 06, 2016
AB	LUPIN LTD	500MG	A091399	001	Sep 12, 2011
AB		750MG	A091399	002	Sep 12, 2011
AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012

LEVETIRACETAM

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

AB			**750MG**	**A201464**	**002**	May 25, 2012
AB		PRINSTON INC	**500MG**	**A202533**	**001**	Jul 20, 2012
AB			**500MG**	**A203468**	**001**	May 21, 2015
AB			**750MG**	**A202533**	**002**	Jul 20, 2012
AB			**750MG**	**A203468**	**002**	May 21, 2015
AB		ROUSES POINT PHARMS	**500MG**	**A202524**	**001**	Aug 27, 2012
AB			**750MG**	**A202524**	**002**	Aug 27, 2012
AB		SUN PHARM	**500MG**	**A203059**	**001**	Sep 09, 2013
AB			**750MG**	**A203059**	**002**	Sep 09, 2013
AB		TEVA PHARMS	**500MG**	**A091430**	**001**	Sep 12, 2011
AB			**750MG**	**A091430**	**002**	Sep 12, 2011
AB		TORRENT PHARMS LTD	**500MG**	**A091338**	**001**	May 29, 2012
AB			**750MG**	**A091338**	**002**	May 29, 2012

ELEPSIA XR

	+	SPARC	1GM	N204417	001	Dec 20, 2018
	+!		1.5GM	N204417	002	Dec 20, 2018

LEVETIRACETAM

		APOTEX	1GM	A202958	001	Feb 25, 2015

TABLET, FOR SUSPENSION;ORAL

SPRITAM

	+	APRECIA PHARMS	250MG	N207958	001	Jul 31, 2015
	+		500MG	N207958	002	Jul 31, 2015
	+		750MG	N207958	003	Jul 31, 2015
	+!		1GM	N207958	004	Jul 31, 2015

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

AT		AKORN	**0.25%**	**A074779**	**001**	Oct 29, 1996
AT			**0.5%**	**A074780**	**001**	Oct 29, 1996

BETAGAN

AT	**+!**	ALLERGAN	**0.25%**	**N019814**	**001**	Jun 28, 1989
AT	**+!**		**0.5%**	**N019219**	**002**	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

AT		BAUSCH AND LOMB	**0.5%**	**A074326**	**001**	Mar 04, 1994

LEVOCARNITINE

INJECTABLE;INJECTION

CARNITOR

AP	**+!**	LEADIANT BIOSCI INC	**200MG/ML**	**N020182**	**001**	Dec 16, 1992

LEVOCARNITINE

AP		LUITPOLD	**200MG/ML**	**A075861**	**001**	Jun 22, 2001
AP		WEST-WARD PHARMS INT	**200MG/ML**	**A075567**	**001**	Mar 29, 2001

SOLUTION;ORAL

CARNITOR

AA	**+!**	LEADIANT BIOSCI INC	**1GM/10ML**	**N019257**	**001**	Apr 10, 1986

CARNITOR SF

AA	**+**	LEADIANT BIOSCI INC	**1GM/10ML**	**N019257**	**002**	Mar 28, 2007

LEVOCARNITINE

AA		HI TECH PHARMA	**1GM/10ML**	**A077399**	**001**	Oct 25, 2007
AA		LYNE	**1GM/10ML**	**A076851**	**001**	Aug 10, 2004
AA		NOVITIUM PHARMA	**1GM/10ML**	**A211676**	**001**	Aug 14, 2019

LEVOCARNITINE SF

AA		NOVITIUM PHARMA	**1GM/10ML**	**A211676**	**002**	Aug 14, 2019

TABLET;ORAL

CARNITOR

AB	**+!**	LEADIANT BIOSCI INC	**330MG**	**N018948**	**001**	Dec 27, 1985

LEVOCARNITINE

AB		RISING	**330MG**	**A076858**	**001**	Sep 20, 2004

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		APOTEX	**2.5MG/5ML**	**A202915**	**001**	Aug 21, 2014
AA	**!**	L PERRIGO CO	**2.5MG/5ML**	**A091263**	**001**	Nov 07, 2011
AA		LANNETT CO INC	**2.5MG/5ML**	**A204599**	**001**	May 15, 2017
AA		TARO PHARM INDS LTD	**2.5MG/5ML**	**A202673**	**001**	Jul 26, 2013

LEVOCETIRIZINE HYDROCHLORIDE

AA		HETERO LABS LTD III	**2.5MG/5ML**	**A210914**	**001**	Apr 01, 2019

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL

AA	**+**	SANOFI AVENTIS US	**2.5MG/5ML**	**N022157**	**001**	Jan 28, 2008

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		APOTEX	**5MG**	**A203027**	**001**	Feb 13, 2015
AB		DR REDDYS LABS LTD	**5MG**	**A090392**	**001**	Feb 24, 2011
AB		GLENMARK GENERICS	**5MG**	**A090385**	**001**	Feb 24, 2011
AB		HETERO LABS LTD III	**5MG**	**A091264**	**001**	Jun 29, 2012
AB		MACLEODS PHARMS LTD	**5MG**	**A205564**	**001**	Jan 11, 2016
AB		MICRO LABS LTD INDIA	**5MG**	**A202046**	**001**	Sep 17, 2013
AB		NEOPHARMA	**5MG**	**A204323**	**001**	Dec 20, 2016
AB		SCIEGEN PHARMS INC	**5MG**	**A203646**	**001**	Sep 09, 2014
AB		SUN PHARM	**5MG**	**A090362**	**001**	Jan 31, 2013
AB		SUN PHARM INDS LTD	**5MG**	**A201653**	**001**	Jun 26, 2015
AB		SYNTHON PHARMS	**5MG**	**A090229**	**001**	Nov 26, 2010
AB		TEVA PHARMS	**5MG**	**A090199**	**001**	Aug 22, 2011

XYZAL

AB	**+!**	SANOFI AVENTIS US	**5MG**	**N022064**	**001**	May 25, 2007

LEVODOPA

POWDER;INHALATION

INBRIJA

	+!	ACORDA	42MG	N209184	001	Dec 21, 2018

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP		AKORN	**EQ 500MG/20ML (EQ 25MG/ML)**	**A091644**	**001**	Jun 20, 2011
AP			**EQ 750MG/30ML (EQ 25MG/ML)**	**A091644**	**002**	Jun 20, 2011
AP	**!**	AUROBINDO PHARMA LTD	**EQ 500MG/20ML (EQ 25MG/ML)**	**A202328**	**001**	Jan 24, 2013
AP	**!**		**EQ 750MG/30ML (EQ 25MG/ML)**	**A202328**	**002**	Jan 24, 2013
AP		BAXTER HLTHCARE CORP	**EQ 500MG/20ML (EQ 25MG/ML)**	**A091436**	**001**	Jun 05, 2013

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		AUROBINDO PHARMA LTD	**EQ 250MG/50ML (EQ 5MG/ML)**	**A206919**	**001**	Feb 10, 2016
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A206919**	**002**	Feb 10, 2016
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A206919**	**003**	Feb 10, 2016
AP		BAXTER HLTHCARE CORP	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091397**	**001**	Aug 08, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091397**	**002**	Aug 08, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091397**	**003**	Aug 08, 2013
AP		FRESENIUS KABI USA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A200674**	**001**	Jun 19, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A200674**	**002**	Jun 19, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A200674**	**003**	Jun 19, 2013
AP		HIKMA FARMACEUTICA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091375**	**001**	Sep 16, 2011
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091375**	**002**	Sep 16, 2011
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091375**	**003**	Sep 16, 2011
AP		HOSPIRA INC	**EQ 250MG/50ML (EQ 5MG/ML)**	**A078579**	**001**	Sep 03, 2015
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A078579**	**002**	Sep 03, 2015
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A078579**	**003**	Sep 03, 2015
AP	**!**	INFORLIFE	**EQ 250MG/50ML (EQ 5MG/ML)**	**A090343**	**001**	Jul 07, 2011
AP	**!**		**EQ 500MG/100ML (EQ 5MG/ML)**	**A090343**	**002**	Jul 07, 2011
AP	**!**		**EQ 750MG/150ML (EQ 5MG/ML)**	**A090343**	**003**	Jul 07, 2011

SOLUTION;ORAL

LEVOFLOXACIN

AA	**!**	HI TECH PHARMA	**250MG/10ML**	**A091678**	**001**	Jun 20, 2011
AA		LANNETT CO INC	**250MG/10ML**	**A205222**	**001**	May 25, 2018

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT		AKORN	**0.5%**	**A090268**	**001**	Dec 20, 2010
AT		MYLAN LABS LTD	**0.5%**	**A204899**	**001**	Dec 08, 2017
AT	**!**	RISING	**0.5%**	**A077700**	**001**	Dec 20, 2010
AT		WATSON LABS TEVA	**0.5%**	**A076826**	**001**	Feb 10, 2011
		MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019

TABLET;ORAL

LEVOFLOXACIN

AB		APOTEX INC	**250MG**	**A090787**	**001**	Sep 29, 2011
AB			**500MG**	**A090787**	**002**	Sep 29, 2011
AB			**750MG**	**A090787**	**003**	Sep 29, 2011

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN

AB		AUROBINDO PHARMA LTD	**250MG**	**A201043**	**001**	Jun 20, 2011
AB			**500MG**	**A201043**	**002**	Jun 20, 2011
AB	**!**		**750MG**	**A201043**	**003**	Jun 20, 2011
AB		CELLTRION	**250MG**	**A090367**	**001**	Jun 20, 2011
AB			**500MG**	**A090367**	**002**	Jun 20, 2011
AB			**750MG**	**A090367**	**003**	Jun 20, 2011
AB		CIPLA LTD	**250MG**	**A076890**	**001**	Mar 30, 2012
AB			**500MG**	**A076890**	**002**	Mar 30, 2012
AB			**750MG**	**A076890**	**003**	Mar 30, 2012
AB		DR REDDYS LABS INC	**250MG**	**A076710**	**001**	Jun 20, 2011
AB			**500MG**	**A076710**	**002**	Jun 20, 2011
AB			**750MG**	**A076710**	**003**	Jun 20, 2011
AB		GLENMARK GENERICS	**250MG**	**A200250**	**001**	Jun 20, 2011
AB			**500MG**	**A200250**	**002**	Jun 20, 2011
AB			**750MG**	**A200250**	**003**	Jun 20, 2011
AB		HEC PHARM	**250MG**	**A204968**	**001**	Feb 05, 2019
AB			**500MG**	**A204968**	**002**	Feb 05, 2019
AB			**750MG**	**A204968**	**003**	Feb 05, 2019
AB		HETERO LABS LTD V	**250MG**	**A202801**	**001**	Jan 08, 2015
AB			**500MG**	**A202801**	**002**	Jan 08, 2015
AB			**750MG**	**A202801**	**003**	Jan 08, 2015
AB		JUBILANT GENERICS	**250MG**	**A203613**	**001**	Jun 19, 2015
AB			**500MG**	**A203613**	**002**	Jun 19, 2015
AB		LUPIN	**250MG**	**A078424**	**001**	Jun 20, 2011
AB			**500MG**	**A078424**	**002**	Jun 20, 2011
AB			**750MG**	**A078424**	**003**	Jun 20, 2011
AB		MACLEODS PHARMS LTD	**250MG**	**A200839**	**001**	Mar 22, 2012
AB			**500MG**	**A200839**	**002**	Mar 22, 2012
AB			**750MG**	**A200839**	**003**	Mar 22, 2012
AB		ORCHID HLTHCARE	**250MG**	**A202200**	**001**	Jan 30, 2012
AB			**500MG**	**A202200**	**002**	Jan 30, 2012
AB			**750MG**	**A202200**	**003**	Jan 30, 2012
AB		SANDOZ	**250MG**	**A077438**	**001**	Jun 20, 2011
AB			**500MG**	**A077438**	**002**	Jun 20, 2011
AB			**750MG**	**A077438**	**003**	Jun 20, 2011
AB		TEVA	**250MG**	**A076361**	**001**	Jun 20, 2011
AB			**500MG**	**A076361**	**002**	Jun 20, 2011
AB			**750MG**	**A076361**	**003**	Jun 20, 2011
AB		TORRENT PHARMS	**250MG**	**A090722**	**001**	Jun 20, 2011
AB			**500MG**	**A090722**	**002**	Jun 20, 2011
AB			**750MG**	**A090722**	**003**	Jun 20, 2011
AB		ZYDUS PHARMS USA INC	**250MG**	**A077652**	**001**	Sep 07, 2012
AB			**500MG**	**A077652**	**002**	Sep 07, 2012
AB			**750MG**	**A077652**	**003**	Sep 07, 2012

LEVOLEUCOVORIN

POWDER;INTRAVENOUS

KHAPZORY

	+!	ACROTECH	175MG/VIAL	N211226	001	Oct 19, 2018
	+!		300MG/VIAL	N211226	002	Oct 19, 2018

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

FUSILEV

AP	**+!**	ACROTECH	**EQ 50MG BASE/VIAL**	**N020140**	**001**	Mar 07, 2008

LEVOLEUCOVORIN CALCIUM

AP		ACTAVIS LLC	**EQ 50MG BASE/VIAL**	**A206516**	**001**	Feb 13, 2017
AP		AMNEAL	**EQ 50MG BASE/VIAL**	**A207547**	**001**	Feb 13, 2017
AP		MEITHEAL	**EQ 50MG BASE/VIAL**	**A211003**	**001**	Aug 22, 2019
AP		WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A206263**	**001**	Jun 16, 2016

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP		AMNEAL	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A207548**	**001**	Sep 08, 2017
AP		GLAND PHARMA LTD	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A210892**	**001**	Sep 14, 2018
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A210892**	**002**	Sep 14, 2018
AP		INGENUS PHARMS LLC	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A210623**	**001**	May 03, 2018
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A210623**	**002**	May 03, 2018
AP		MEITHEAL	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A211002**	**001**	Aug 16, 2019

LEVOLEUCOVORIN CALCIUM							
SOLUTION;INTRAVENOUS							
LEVOLEUCOVORIN CALCIUM							
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A211002**	**002**	Aug 16, 2019
AP		SANDOZ INC	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A203563**	**001**	Mar 09, 2015
AP	**!**		**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A203563**	**002**	Mar 09, 2015
LEVOMILNACIPRAN HYDROCHLORIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
FETZIMA							
	+	ALLERGAN	EQ 20MG BASE	N204168	001	Jul 25, 2013
	+		EQ 40MG BASE	N204168	002	Jul 25, 2013
	+		EQ 80MG BASE	N204168	003	Jul 25, 2013
	+!		EQ 120MG BASE	N204168	004	Jul 25, 2013
LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
SCANDONEST L							
	!	DEPROCO	0.05MG/ML;2%	A088388	001	Oct 10, 1984
LEVONORGESTREL							
INTRAUTERINE DEVICE;INTRAUTERINE							
KYLEENA							
	+!	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016
LILETTA							
		MEDICINES360	52MG	N206229	001	Feb 26, 2015
MIRENA							
	+!	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000
SKYLA							
	+!	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013
TABLET;ORAL							
LEVONORGESTREL							
AB	**!**	L PERRIGO CO	**0.75MG**	**A090740**	**001**	Dec 30, 2010
AB		MYLAN LABS LTD	**0.75MG**	**A202740**	**001**	Sep 02, 2016
LEVORPHANOL TARTRATE							
TABLET;ORAL							
LEVORPHANOL TARTRATE							
AB	**!**	SENTYNL THERAPS INC	**2MG**	**A074278**	**001**	Mar 31, 2000
AB		SPECGX LLC	**2MG**	**A212024**	**001**	Dec 13, 2019
AB		VIRTUS PHARMS	**2MG**	**A211484**	**001**	Dec 13, 2018
	!	SENTYNL THERAPS INC	3MG	A074278	003	Jun 18, 2018
LEVOTHYROXINE SODIUM							
CAPSULE;ORAL							
TIROSINT							
	+	INSTITUT BIOCHIMIQUE	0.013MG	N021924	013	Aug 01, 2007
	+		0.025MG	N021924	002	Oct 13, 2006
	+		0.05MG	N021924	003	Oct 13, 2006
	+		0.075MG	N021924	004	Oct 13, 2006
	+		0.088MG	N021924	010	Oct 02, 2009
	+		0.1MG	N021924	005	Oct 13, 2006
	+		0.112MG	N021924	008	Oct 02, 2009
	+		0.125MG	N021924	006	Oct 13, 2006
	+		0.137MG	N021924	009	Oct 02, 2009
	+		0.15MG	N021924	007	Oct 13, 2006
	+		0.175MG	N021924	011	Apr 25, 2017
	+!		0.200MG	N021924	012	Apr 25, 2017
POWDER;INTRAVENOUS							
LEVOTHYROXINE SODIUM							
AP	**+!**	FRESENIUS KABI USA	**100MCG/VIAL**	**N202231**	**001**	Jun 24, 2011
AP	**+!**		**200MCG/VIAL**	**N202231**	**002**	Jun 24, 2011
AP	**+!**		**500MCG/VIAL**	**N202231**	**003**	Jun 24, 2011
AP		MAIA PHARMS INC	**100MCG/VIAL**	**A208749**	**001**	Dec 21, 2018
AP			**200MCG/VIAL**	**A208749**	**002**	Dec 21, 2018
AP			**500MCG/VIAL**	**A208749**	**003**	Dec 21, 2018
AP		PIRAMAL CRITICAL	**100MCG/VIAL**	**A206163**	**001**	Jun 29, 2016
AP			**500MCG/VIAL**	**A206163**	**002**	Jun 29, 2016
SOLUTION;INTRAVENOUS							
LEVOTHYROXINE SODIUM							
	+!	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019
	+!		200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019
	+!		500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019

LEVOTHYROXINE SODIUM
SOLUTION;ORAL
TIROSINT-SOL

+	INSTITUT BIOCHIMIQUE	13MCG/ML		N206977 001	Dec 15, 2016
+		25MCG/ML		N206977 002	Dec 15, 2016
+		50MCG/ML		N206977 003	Dec 15, 2016
+		75MCG/ML		N206977 004	Dec 15, 2016
+		88MCG/ML		N206977 005	Dec 15, 2016
+		100MCG/ML		N206977 006	Dec 15, 2016
+		112MCG/ML		N206977 007	Dec 15, 2016
+		125MCG/ML		N206977 008	Dec 15, 2016
+		137MCG/ML		N206977 009	Dec 15, 2016
+		150MCG/ML		N206977 010	Dec 15, 2016
+		175MCG/ML		N206977 011	Dec 15, 2016
+!		200MCG/ML		N206977 012	Dec 15, 2016

LEVOTHYROXINE SODIUM **
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL
SYNTHROID

-->	+	ABBVIE	--> AB1,AB2	0.025MG	N021402 001	Jul 24, 2002
-->	+		--> AB1,AB2	0.05MG	N021402 002	Jul 24, 2002
-->	+		--> AB1,AB2	0.075MG	N021402 003	Jul 24, 2002
-->	+		--> AB1,AB2	0.088MG	N021402 004	Jul 24, 2002
-->	+		--> AB1,AB2	0.1MG	N021402 005	Jul 24, 2002
-->	+		--> AB1,AB2	0.112MG	N021402 006	Jul 24, 2002
-->	+		--> AB1,AB2	0.125MG	N021402 007	Jul 24, 2002
-->	+		--> AB1,AB2	0.137MG	N021402 008	Jul 24, 2002
-->	+		--> AB1,AB2	0.15MG	N021402 009	Jul 24, 2002
-->	+		--> AB1,AB2	0.175MG	N021402 010	Jul 24, 2002
-->	+		--> AB1,AB2	0.2MG	N021402 012	Jul 24, 2002
-->	+!		--> AB1,AB2	0.3MG	N021402 011	Jul 24, 2002

LEVO-T

-->	CEDIPROF INC	--> AB1,AB2,AB3	0.025MG	N021342 001	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.05MG	N021342 002	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.075MG	N021342 003	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.088MG	N021342 004	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.1MG	N021342 005	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.112MG	N021342 006	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.125MG	N021342 007	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.137MG	N021342 012	Dec 08, 2003
-->		--> AB1,AB2,AB3	0.15MG	N021342 008	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.175MG	N021342 009	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.2MG	N021342 010	Mar 01, 2002
-->		--> AB1,AB2,AB3	0.3MG	N021342 011	Mar 01, 2002

LEVOTHYROXINE SODIUM

-->	LUPIN ATLANTIS	--> AB1,AB2,AB3	0.025MG	A209713 001	Jan 18, 2019
-->		--> AB1,AB2,AB3	0.05MG	A209713 002	Jan 18, 2019
-->		--> AB1,AB2,AB3	0.075MG	A209713 003	Jan 18, 2019
-->		--> AB1,AB2,AB3	0.088MG	A209713 004	Jan 18, 2019
-->		--> AB1,AB2,AB3	0.1MG	A209713 005	Jan 18, 2019
-->		--> AB1,AB2,AB3	0.112MG	A209713 006	Jan 18, 2019
-->		--> AB1,AB2,AB3	0.125MG	A209713 007	Jan 18, 2019
-->		--> AB1,AB2,AB3	0.137MG	A209713 008	Jan 18, 2019
-->		--> AB1,AB2,AB3	0.15MG	A209713 009	Jan 18, 2019

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

	LEVOTHYROXINE SODIUM						
-->			--> AB1,AB2,AB3	0.175MG	A209713	010	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.2MG	A209713	011	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.3MG	A209713	012	Jan 18, 2019
	UNITHROID						
-->	+	STEVENS J	--> AB1,AB2,AB3	0.025MG	N021210	001	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.05MG	N021210	002	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.075MG	N021210	003	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.088MG	N021210	004	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.1MG	N021210	005	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.112MG	N021210	006	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.125MG	N021210	007	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.137MG	N021210	012	Feb 08, 2008
-->	+		--> AB1,AB2,AB3	0.15MG	N021210	008	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.175MG	N021210	009	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.2MG	N021210	010	Aug 21, 2000
-->	+!		--> AB1,AB2,AB3	0.3MG	N021210	011	Aug 21, 2000
	LEVOTHYROXINE SODIUM						
-->		MYLAN	--> AB1,AB2,AB3,AB4	0.025MG	A076187	001	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.05MG	A076187	002	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.075MG	A076187	003	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.088MG	A076187	004	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.1MG	A076187	005	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.112MG	A076187	006	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.125MG	A076187	007	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.137MG	A076187	012	Dec 13, 2006
-->			--> AB1,AB2,AB3,AB4	0.15MG	A076187	008	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.175MG	A076187	009	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.2MG	A076187	010	Jun 05, 2002
-->	!		--> AB1,AB2,AB3,AB4	0.3MG	A076187	011	Jun 05, 2002
	LEVOXYL						
-->	+	KING PHARMS	--> AB1,AB3	0.025MG	N021301	001	May 25, 2001
-->	+		--> AB1,AB3	0.05MG	N021301	002	May 25, 2001
-->	+		--> AB1,AB3	0.075MG	N021301	003	May 25, 2001
-->	+		--> AB1,AB3	0.088MG	N021301	004	May 25, 2001
-->	+		--> AB1,AB3	0.1MG	N021301	005	May 25, 2001
-->	+		--> AB1,AB3	0.112MG	N021301	006	May 25, 2001
-->	+		--> AB1,AB3	0.125MG	N021301	007	May 25, 2001
-->	+		--> AB1,AB3	0.137MG	N021301	008	May 25, 2001
-->	+		--> AB1,AB3	0.15MG	N021301	009	May 25, 2001
-->	+		--> AB1,AB3	0.175MG	N021301	010	May 25, 2001
-->	+!		--> AB1,AB3	0.2MG	N021301	011	May 25, 2001
	EUTHYROX						
AB2		PROVELL	0.025MG		N021292	001	May 31, 2002
AB2			0.05MG		N021292	002	May 31, 2002
AB2			0.075MG		N021292	003	May 31, 2002
AB2			0.088MG		N021292	004	May 31, 2002
AB2			0.1MG		N021292	005	May 31, 2002

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

EUTHYROX

AB2			**0.112MG**		**N021292 006**	May 31, 2002
AB2			**0.125MG**		**N021292 007**	May 31, 2002
AB2			**0.137MG**		**N021292 008**	May 31, 2002
AB2			**0.15MG**		**N021292 009**	May 31, 2002
AB2			**0.175MG**		**N021292 010**	May 31, 2002
AB2			**0.2MG**		**N021292 011**	May 31, 2002

THYRO-TABS

-->	**+**	ALVOGEN	**--> AB2,AB4**	**0.025MG**	N021116 001	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.05MG**	N021116 002	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.075MG**	N021116 003	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.088MG**	N021116 010	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.1MG**	N021116 004	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.112MG**	N021116 011	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.125MG**	N021116 005	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.137MG**	N021116 012	Dec 07, 2004
-->	**+**		**--> AB2,AB4**	**0.15MG**	N021116 006	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.175MG**	N021116 007	Oct 24, 2002
-->	**+**		**--> AB2,AB4**	**0.2MG**	N021116 008	Oct 24, 2002
-->	**+!**		**--> AB2,AB4**	**0.3MG**	N021116 009	Oct 24, 2002

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT		ACP NIMBLE	**5%**		**A211019 001**	Dec 12, 2018
AT		ALEOR DERMACEUTICALS	**5%**		**A211469 001**	Nov 23, 2018
AT		ALKEM LABS LTD	**5%**		**A207810 001**	Mar 10, 2017
AT		AMNEAL PHARMS	**5%**		**A206297 001**	Aug 07, 2015
AT	**!**	FOUGERA PHARMS INC	**5%**		**A080198 001**	
AT		GLENMARK PHARMS LTD	**5%**		**A206498 001**	Sep 09, 2016
AT		NOVAST LABS	**5%**		**A208604 001**	Sep 20, 2017
AT		SEPTODONT INC	**5%**		**A040911 001**	May 23, 2011
AT		STRIDES PHARMA	**5%**		**A210958 001**	Dec 11, 2018
AT		SUNGEN PHARMA	**5.0%**		**A212486 001**	Oct 17, 2019
AT		TARO	**5%**		**A086724 001**	
AT		TELIGENT PHARMA INC	**5%**		**A205318 001**	Feb 01, 2016
AT		TEVA PHARMS USA	**5%**		**A210256 001**	Jan 16, 2018
AT		VITRUVIAS THERAP	**5%**		**A208822 001**	Sep 25, 2017

PATCH;TOPICAL

LIDOCAINE

AB		ACTAVIS LABS UT INC	**5%**		**A200675 001**	Aug 23, 2012
AB		MYLAN TECHNOLOGIES	**5%**		**A202346 001**	Aug 07, 2015

LIDODERM

AB	**+!**	TEIKOKU PHARMA USA	**5%**		**N020612 001**	Mar 19, 1999

ZTLIDO

	+!	SCILEX PHARMS INC	1.8%		N207962 001	Feb 28, 2018

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

AKTEN

	+!	AKORN	3.5%		N022221 001	Oct 07, 2008

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	**1%**		**A207182 001**	Oct 30, 2017
AP			**2%**		**A207182 002**	Oct 30, 2017
AP		B BRAUN MEDICAL INC	**1%**		**A208474 001**	Aug 03, 2018
AP		FRESENIUS KABI USA	**1%**		**A080404 002**	
AP			**2%**		**A080404 003**	
AP		HOSPIRA	**0.5%**		**A088328 001**	May 17, 1984
AP	**!**		**1%**		**A083158 001**	
AP			**1%**		**A088329 001**	May 17, 1984
AP			**2%**		**A040078 001**	Jun 23, 1995
AP	**!**		**2%**		**A083158 002**	
AP			**2%**		**A088294 001**	May 17, 1984
AP		INTL MEDICATION	**1%**		**A083173 001**	
AP			**2%**		**A083173 002**	
AP		SPECTRA MDCL DEVICES	**1%**		**A208017 001**	Apr 18, 2018

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**200MG/100ML**	**N019830**	**002**	Apr 08, 1992
AP		BAXTER HLTHCARE	**200MG/100ML**	**N018461**	**002**	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**400MG/100ML**	**N019830**	**003**	Apr 08, 1992
AP		BAXTER HLTHCARE	**400MG/100ML**	**N018461**	**003**	

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**800MG/100ML**	**N019830**	**004**	Apr 08, 1992
AP		BAXTER HLTHCARE	**800MG/100ML**	**N018461**	**004**	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**1%**	**A088586**	**001**	Jul 24, 1985
AP		HOSPIRA	**0.5%**	**A088325**	**001**	Jul 31, 1984
AP			**1%**	**A088299**	**001**	Jul 31, 1984
AP			**2%**	**A088327**	**001**	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	**1%**	**A203040**	**001**	Mar 14, 2013
AP			**1%**	**A203082**	**001**	Mar 14, 2013
AP			**2%**	**A203040**	**002**	Mar 14, 2013
AP			**2%**	**A203082**	**002**	Mar 14, 2013
AP		FRESENIUS KABI USA	**2%**	**N017584**	**001**	
AP			**4%**	**N017584**	**002**	
AP		HOSPIRA	**1%**	**A080408**	**001**	
AP			**1.5%**	**A080408**	**002**	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

AP		HOSPIRA	**1%**	**A040302**	**001**	Sep 28, 1998
AP			**2%**	**A040302**	**002**	Sep 28, 1998

XYLOCAINE

AP	**+!**	FRESENIUS KABI USA	**0.5%**	**N006488**	**008**	
AP	**+!**		**1%**	**N006488**	**007**	
AP	**+!**		**1.5%**	**N006488**	**010**	
AP	**+!**		**2%**	**N006488**	**002**	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

	!	HOSPIRA	4%	A088295	001	May 17, 1984

INJECTABLE;SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

	!	HOSPIRA	5%	A083914	001	

JELLY;TOPICAL

GLYDO

AT		SAGENT PHARMS INC	**2%**	**A201094**	**001**	Apr 28, 2014

LIDOCAINE HYDROCHLORIDE

AT		AKORN	**2%**	**A040433**	**001**	Feb 12, 2003
AT		INTL MEDICATION	**2%**	**A086283**	**001**	

XYLOCAINE

AT	**+!**	OAK PHARMS	**2%**	**N008816**	**001**	

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE

AT		HI TECH PHARMA	**2%**	**A040014**	**001**	Jul 10, 1995
AT		WOCKHARDT BIO AG	**2%**	**A087872**	**001**	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	**!**	LANNETT CO INC	**2%**	**A040708**	**001**	Feb 27, 2007

LIDOCAINE VISCOUS

AT		HIKMA	**2%**	**A088802**	**001**	Apr 26, 1985

SOLUTION;TOPICAL

LARYNG-O-JET KIT

AT		INTL MEDICATION	**4%**	**A086364**	**001**	

LIDOCAINE HYDROCHLORIDE

AT	**!**	HIKMA	**4%**	**A088803**	**001**	Apr 03, 1985
AT		LANNETT CO INC	**4%**	**A040710**	**001**	Feb 27, 2007
AT		TELIGENT PHARMA INC	**4%**	**A204494**	**001**	Mar 12, 2014

SYSTEM;INTRADERMAL

ZINGO

		POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

EMLA

AB	**+!**	TEVA BRANDED PHARM	**2.5%;2.5%**	**N019941**	**001**	Dec 30, 1992

LIDOCAINE AND PRILOCAINE

AB		FOUGERA PHARMS	**2.5%;2.5%**	**A076453**	**001**	Aug 18, 2003
AB		HI TECH PHARMA	**2.5%;2.5%**	**A076290**	**001**	Sep 25, 2003

LIDOCAINE; PRILOCAINE						
CREAM;TOPICAL						
LIDOCAINE AND PRILOCAINE						
AB		TELIGENT PHARMA INC	**2.5%;2.5%**	**A205887**	**001**	Jun 29, 2018
AB		TOLMAR	**2.5%;2.5%**	**A076320**	**001**	Aug 27, 2003
GEL;PERIODONTAL						
ORAQIX						
	+!	DENTSPLY PHARM	2.5%;2.5%	N021451	001	Dec 19, 2003
LIDOCAINE; TETRACAINE						
CREAM;TOPICAL						
PLIAGLIS						
	+!	TARO PHARMS	7%;7%	N021717	001	Jun 29, 2006
PATCH;TOPICAL						
SYNERA						
	+!	GALEN SPECIALTY	70MG;70MG	N021623	001	Jun 23, 2005
LIFITEGRAST						
SOLUTION/DROPS;OPHTHALMIC						
XIIDRA						
	+!	NOVARTIS	5%	N208073	001	Jul 11, 2016
LINACLOTIDE						
CAPSULE;ORAL						
LINZESS						
	+!	ALLERGAN	72MCG	N202811	003	Jan 25, 2017
	+!		145MCG	N202811	001	Aug 30, 2012
	+		290MCG	N202811	002	Aug 30, 2012
LINAGLIPTIN						
TABLET;ORAL						
TRADJENTA						
	+!	BOEHRINGER INGELHEIM	5MG	N201280	001	May 02, 2011
LINAGLIPTIN; METFORMIN HYDROCHLORIDE						
TABLET;ORAL						
JENTADUETO						
	+	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012
	+		2.5MG;850MG	N201281	002	Jan 30, 2012
	+!		2.5MG;1GM	N201281	003	Jan 30, 2012
TABLET, EXTENDED RELEASE;ORAL						
JENTADUETO XR						
	+	BOEHRINGER INGELHEIM	2.5MG;1GM	N208026	001	May 27, 2016
	+!		5MG;1GM	N208026	002	May 27, 2016
LINCOMYCIN HYDROCHLORIDE						
INJECTABLE;INJECTION						
LINCOCIN						
AP	**+!**	PHARMACIA AND UPJOHN	**EQ 300MG BASE/ML**	**N050317**	**001**	
LINCOMYCIN						
AP		X-GEN PHARMS INC	**EQ 300MG BASE/ML**	**A201746**	**001**	Jun 04, 2015
LINDANE						
LOTION;TOPICAL						
LINDANE						
	!	OLTA PHARMS	1%	A087313	001	
SHAMPOO;TOPICAL						
LINDANE						
AT		OLTA PHARMS	**1%**	**A087266**	**001**	
AT	**!**	WOCKHARDT BIO AG	**1%**	**A088191**	**001**	Sep 18, 1984
LINEZOLID						
FOR SUSPENSION;ORAL						
LINEZOLID						
AB		HIKMA	**100MG/5ML**	**A200068**	**001**	Jun 03, 2015
ZYVOX						
AB	**+!**	PHARMACIA AND UPJOHN	**100MG/5ML**	**N021132**	**001**	Apr 18, 2000
SOLUTION;INTRAVENOUS						
LINEZOLID						
AP		AUROBINDO PHARMA LTD	**600MG/300ML (2MG/ML)**	**A206917**	**001**	Aug 04, 2016
AP		FRESENIUS KABI USA	**600MG/300ML (2MG/ML)**	**A204764**	**001**	Mar 15, 2016
AP		HOSPIRA INC	**600MG/300ML (2MG/ML)**	**A205442**	**001**	Jul 07, 2015

PRESCRIPTION DRUG PRODUCT LIST

LINEZOLID						
SOLUTION;INTRAVENOUS						
LINEZOLID						
AP		HQ SPCLT PHARMA	**200MG/100ML (2MG/ML)**	**A207001**	**001**	Jul 07, 2017
AP			**600MG/300ML (2MG/ML)**	**A207001**	**002**	Jul 07, 2017
AP		MYLAN LABS LTD	**200MG/100ML (2MG/ML)**	**A205154**	**001**	Dec 06, 2017
AP			**600MG/300ML (2MG/ML)**	**A205154**	**002**	Dec 06, 2017
AP		NANG KUANG PHARM CO	**200MG/100ML (2MG/ML)**	**A207354**	**001**	Dec 20, 2016
AP			**600MG/300ML (2MG/ML)**	**A207354**	**002**	Dec 20, 2016
AP		SAGENT PHARMS INC	**200MG/100ML (2MG/ML)**	**A204696**	**001**	Mar 02, 2017
AP			**600MG/300ML (2MG/ML)**	**A204696**	**002**	Mar 02, 2017
AP		SANDOZ INC	**200MG/100ML (2MG/ML)**	**A200904**	**001**	Jul 16, 2015
AP			**600MG/300ML (2MG/ML)**	**A200904**	**002**	Jul 16, 2015
AP		TEVA PHARMS	**600MG/300ML (2MG/ML)**	**A200222**	**001**	Jun 27, 2012
ZYVOX						
AP	**+**	PHARMACIA AND UPJOHN	**200MG/100ML (2MG/ML)**	**N021131**	**001**	Apr 18, 2000
AP	**+!**		**600MG/300ML (2MG/ML)**	**N021131**	**003**	Apr 18, 2000
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	+!	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015
TABLET;ORAL						
LINEZOLID						
AB		ALEMBIC PHARMS LTD	**600MG**	**A205233**	**001**	Dec 21, 2015
AB		ALKEM LABS LTD	**600MG**	**A205517**	**001**	Dec 21, 2015
AB		AMNEAL PHARMS	**600MG**	**A204536**	**001**	Dec 21, 2015
AB		CELLTRION	**600MG**	**A210702**	**001**	Apr 25, 2019
AB		GATE PHARMS	**600MG**	**A091210**	**001**	Feb 05, 2016
AB		GLENMARK PHARMS	**600MG**	**A078987**	**001**	Dec 21, 2015
AB		HETERO LABS LTD V	**600MG**	**A204239**	**001**	Dec 21, 2015
AB		NOVEL LABS INC	**600MG**	**A207526**	**001**	Aug 22, 2016
AB		TEVA PHARMS USA	**600MG**	**A078061**	**001**	May 18, 2015
AB		ZYDUS PHARMS	**600MG**	**A206097**	**001**	Feb 22, 2017
ZYVOX						
AB	**+!**	PHARMACIA AND UPJOHN	**600MG**	**N021130**	**002**	Apr 18, 2000
LIOTHYRONINE SODIUM						
INJECTABLE;INJECTION						
LIOTHYRONINE SODIUM						
AP		X GEN PHARMS	**EQ 0.01MG BASE/ML**	**A076923**	**001**	Aug 17, 2005
TRIOSTAT						
AP	**+!**	PAR STERILE PRODUCTS	**EQ 0.01MG BASE/ML**	**N020105**	**001**	Dec 31, 1991
TABLET;ORAL						
CYTOMEL						
AB	**+**	KING PHARMS	**EQ 0.005MG BASE**	**N010379**	**001**	
AB	**+**		**EQ 0.025MG BASE**	**N010379**	**002**	
AB	**+**		**EQ 0.05MG BASE**	**N010379**	**003**	
LIOTHYRONINE SODIUM						
AB		MAYNE PHARMA INC	**EQ 0.005MG BASE**	**A090097**	**001**	Mar 20, 2009
AB			**EQ 0.025MG BASE**	**A090097**	**002**	Mar 20, 2009
AB			**EQ 0.05MG BASE**	**A090097**	**003**	Mar 20, 2009
AB		SIGMAPHARM LABS LLC	**EQ 0.005MG BASE**	**A200295**	**001**	Nov 29, 2012
AB			**EQ 0.025MG BASE**	**A200295**	**002**	Nov 29, 2012
AB	**!**		**EQ 0.05MG BASE**	**A200295**	**003**	Nov 29, 2012
LIRAGLUTIDE RECOMBINANT						
SOLUTION;SUBCUTANEOUS						
SAXENDA						
	+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014
VICTOZA						
	+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010
LISDEXAMFETAMINE DIMESYLATE						
CAPSULE;ORAL						
VYVANSE						
	+	SHIRE DEVELOPMENT	10MG	N021977	007	Oct 30, 2014
	+		20MG	N021977	004	Dec 10, 2007
	+		30MG	N021977	001	Feb 23, 2007
	+		40MG	N021977	005	Dec 10, 2007
	+		50MG	N021977	002	Feb 23, 2007
	+		60MG	N021977	006	Dec 10, 2007
	+!		70MG	N021977	003	Feb 23, 2007

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE;ORAL

VYVANSE

+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017
+		20MG	N208510	002	Jan 28, 2017
+		30MG	N208510	003	Jan 28, 2017
+		40MG	N208510	004	Jan 28, 2017
+		50MG	N208510	005	Jan 28, 2017
+!		60MG	N208510	006	Jan 28, 2017

LISINOPRIL

SOLUTION;ORAL

QBRELIS

+!	SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016

TABLET;ORAL

LISINOPRIL

AB	ACCORD HLTHCARE	**2.5MG**	**A202554**	**001**	Jul 30, 2013
AB		**5MG**	**A202554**	**002**	Jul 30, 2013
AB		**10MG**	**A202554**	**003**	Jul 30, 2013
AB		**20MG**	**A202554**	**004**	Jul 30, 2013
AB		**30MG**	**A202554**	**005**	Jul 30, 2013
AB		**40MG**	**A202554**	**006**	Jul 30, 2013
AB	APOTEX INC	**2.5MG**	**A076102**	**001**	Sep 30, 2002
AB		**5MG**	**A076102**	**002**	Sep 30, 2002
AB		**10MG**	**A076102**	**003**	Sep 30, 2002
AB		**20MG**	**A076102**	**004**	Sep 30, 2002
AB		**30MG**	**A076102**	**005**	Sep 30, 2002
AB		**40MG**	**A076102**	**006**	Sep 30, 2002
AB	AUROBINDO	**2.5MG**	**A077622**	**001**	Feb 22, 2006
AB		**5MG**	**A077622**	**002**	Feb 22, 2006
AB		**10MG**	**A077622**	**003**	Feb 22, 2006
AB		**20MG**	**A077622**	**004**	Feb 22, 2006
AB		**30MG**	**A077622**	**005**	Feb 22, 2006
AB		**40MG**	**A077622**	**006**	Feb 22, 2006
AB	CASI PHARMS INC	**2.5MG**	**A075994**	**001**	Jul 01, 2002
AB		**5MG**	**A075994**	**002**	Jul 01, 2002
AB		**10MG**	**A075994**	**003**	Jul 01, 2002
AB		**20MG**	**A075994**	**004**	Jul 01, 2002
AB		**30MG**	**A075994**	**005**	Jul 01, 2002
AB		**40MG**	**A075994**	**006**	Jul 01, 2002
AB	INVAGEN PHARMS	**2.5MG**	**A203508**	**001**	Oct 29, 2013
AB		**5MG**	**A203508**	**002**	Oct 29, 2013
AB		**10MG**	**A203508**	**003**	Oct 29, 2013
AB		**20MG**	**A203508**	**004**	Oct 29, 2013
AB		**30MG**	**A203508**	**005**	Oct 29, 2013
AB		**40MG**	**A203508**	**006**	Oct 29, 2013
AB	LUPIN	**2.5MG**	**A077321**	**001**	Sep 09, 2005
AB		**5MG**	**A077321**	**002**	Sep 09, 2005
AB		**10MG**	**A077321**	**003**	Sep 09, 2005
AB		**20MG**	**A077321**	**004**	Sep 09, 2005
AB		**30MG**	**A077321**	**005**	Sep 09, 2005
AB		**40MG**	**A077321**	**006**	Sep 09, 2005
AB	PRINSTON INC	**2.5MG**	**A075743**	**001**	Jul 01, 2002
AB		**2.5MG**	**A076180**	**001**	Jul 01, 2002
AB		**5MG**	**A075743**	**002**	Jul 01, 2002
AB		**5MG**	**A076180**	**002**	Jul 01, 2002
AB		**10MG**	**A075743**	**003**	Jul 01, 2002
AB		**10MG**	**A076180**	**003**	Jul 01, 2002
AB		**20MG**	**A075743**	**004**	Jul 01, 2002
AB		**20MG**	**A076164**	**001**	Jul 01, 2002
AB		**30MG**	**A075743**	**005**	Jul 01, 2002
AB		**30MG**	**A076164**	**002**	Jul 01, 2002
AB		**40MG**	**A075743**	**006**	Jul 01, 2002
AB		**40MG**	**A076164**	**003**	Jul 01, 2002
AB	SUN PHARM INDS LTD	**2.5MG**	**A075944**	**001**	Jul 01, 2002
AB		**5MG**	**A075944**	**002**	Jul 01, 2002
AB		**10MG**	**A075944**	**003**	Jul 01, 2002
AB		**20MG**	**A075944**	**004**	Jul 01, 2002
AB		**30MG**	**A075944**	**006**	Feb 11, 2003
AB		**40MG**	**A075944**	**005**	Jul 01, 2002
AB	WATSON LABS	**2.5MG**	**A076059**	**001**	Jul 01, 2002
AB		**5MG**	**A076059**	**002**	Jul 01, 2002
AB		**10MG**	**A076059**	**003**	Jul 01, 2002

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB			**20MG**	**A076059**	**004**	Jul 01, 2002
AB			**30MG**	**A076059**	**005**	Jul 01, 2002
AB			**40MG**	**A076059**	**006**	Jul 01, 2002
AB		WOCKHARDT	**2.5MG**	**A078402**	**001**	Apr 19, 2007
AB			**5MG**	**A078402**	**002**	Apr 19, 2007
AB			**10MG**	**A078402**	**003**	Apr 19, 2007
AB			**20MG**	**A078402**	**004**	Apr 19, 2007
AB			**30MG**	**A078402**	**005**	Apr 19, 2007
AB			**40MG**	**A078402**	**006**	Apr 19, 2007

PRINIVIL

AB		MERCK	**5MG**	**N019558**	**001**	Dec 29, 1987
AB			**40MG**	**N019558**	**004**	Oct 25, 1988

ZESTRIL

AB	**+**	ALVOGEN	**2.5MG**	**N019777**	**005**	Apr 29, 1993
AB	**+**		**5MG**	**N019777**	**001**	May 19, 1988
AB	**+**		**10MG**	**N019777**	**002**	May 19, 1988
AB	**+**		**20MG**	**N019777**	**003**	May 19, 1988
AB	**+**		**30MG**	**N019777**	**006**	Jan 20, 1999
AB	**+!**		**40MG**	**N019777**	**004**	May 19, 1988

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		ALEMBIC LTD	**150MG**	**A079159**	**001**	Jan 12, 2009
AB			**300MG**	**A079159**	**002**	Jan 12, 2009
AB			**600MG**	**A079159**	**003**	Jan 12, 2009
AB		GLENMARK GENERICS	**150MG**	**A079139**	**001**	Feb 03, 2009
AB			**300MG**	**A079139**	**002**	Feb 03, 2009
AB			**600MG**	**A079139**	**003**	Feb 03, 2009
AB		HETERO LABS LTD III	**150MG**	**A090702**	**001**	Sep 25, 2009
AB			**300MG**	**A090702**	**002**	Sep 25, 2009
AB			**600MG**	**A090702**	**003**	Sep 25, 2009
AB	**+**	HIKMA	**150MG**	**N017812**	**002**	Jan 28, 1987
AB	**+**		**300MG**	**N017812**	**001**	
AB	**+!**		**600MG**	**N017812**	**003**	Jan 28, 1987
AB		MYLAN	**150MG**	**A076243**	**002**	Feb 24, 2003
AB			**300MG**	**A076243**	**001**	Jun 27, 2002

TABLET;ORAL

LITHIUM CARBONATE

AB	**+!**	HIKMA	**300MG**	**N018558**	**001**	Jan 29, 1982
AB		SUN PHARM INDS INC	**300MG**	**A091027**	**001**	Jun 24, 2010

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		ALEMBIC PHARMS LTD	**300MG**	**A204445**	**001**	Jun 10, 2015
AB		GLENMARK GENERICS	**450MG**	**A091616**	**001**	Feb 14, 2011
AB		GLENMARK PHARMS INC	**300MG**	**A091544**	**001**	Dec 27, 2010
AB		HERITAGE PHARMA	**300MG**	**A205532**	**001**	Sep 29, 2016
AB		HIKMA	**300MG**	**A076832**	**001**	Oct 28, 2004
AB	**!**		**450MG**	**A076691**	**001**	Jan 05, 2004
AB		MYLAN PHARMS INC	**300MG**	**A202288**	**001**	Jun 29, 2012
AB			**450MG**	**A202219**	**001**	Aug 08, 2012
AB		UNIQUE PHARM LABS	**300MG**	**A204779**	**001**	Jul 27, 2015
AB			**450MG**	**A205663**	**001**	Jun 05, 2017

LITHOBID

AB	**+!**	ANI PHARMS INC	**300MG**	**N018027**	**001**	

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	**+!**	HIKMA	**EQ 300MG CARBONATE/5ML**	**N018421**	**001**	
AA		WOCKHARDT BIO AG	**EQ 300MG CARBONATE/5ML**	**A070755**	**001**	May 21, 1986

LIXISENATIDE

SOLUTION;SUBCUTANEOUS

ADLYXIN

	+!	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016
	+!		0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016

LODOXAMIDE TROMETHAMINE						
SOLUTION/DROPS;OPHTHALMIC						
ALOMIDE						
	+!	NOVARTIS	EQ 0.1% BASE	N020191	001	Sep 23, 1993
LOFEXIDINE HYDROCHLORIDE						
TABLET;ORAL						
LUCEMYRA						
	+!	US WORLDMEDS LLC	EQ 0.18MG BASE	N209229	001	May 16, 2018
LOMITAPIDE MESYLATE						
CAPSULE;ORAL						
JUXTAPID						
	+	AEGERION	EQ 5MG BASE	N203858	001	Dec 21, 2012
	+		EQ 10MG BASE	N203858	002	Dec 21, 2012
	+		EQ 20MG BASE	N203858	003	Dec 21, 2012
	+		EQ 30MG BASE	N203858	004	Apr 23, 2015
	+		EQ 40MG BASE	N203858	005	Apr 23, 2015
	+!		EQ 60MG BASE	N203858	006	Apr 23, 2015
LOMUSTINE						
CAPSULE;ORAL						
GLEOSTINE						
	+	CORDEN PHARMA	10MG	N017588	001	
	+		40MG	N017588	002	
	+!		100MG	N017588	003	
LOPERAMIDE HYDROCHLORIDE						
CAPSULE;ORAL						
LOPERAMIDE HYDROCHLORIDE						
AB	**!**	MYLAN	**2MG**	**A072741**	**001**	Sep 18, 1991
AB		TEVA	**2MG**	**A073192**	**001**	Apr 30, 1992
LOPINAVIR; RITONAVIR						
SOLUTION;ORAL						
KALETRA						
AA	**+!**	ABBVIE	**80MG/ML;20MG/ML**	**N021251**	**001**	Sep 15, 2000
LOPINAVIR AND RITONAVIR						
AA		LANNETT CO INC	**80MG/ML;20MG/ML**	**A207407**	**001**	Dec 27, 2016
TABLET;ORAL						
KALETRA						
	+	ABBVIE	100MG;25MG	N021906	002	Nov 09, 2007
	+!		200MG;50MG	N021906	001	Oct 28, 2005
LORAZEPAM						
CONCENTRATE;ORAL						
LORAZEPAM						
AA		AMNEAL PHARMS	**2MG/ML**	**A091383**	**001**	Dec 23, 2009
AA		HI-TECH PHARMA CO	**2MG/ML**	**A200169**	**001**	Jan 30, 2012
AA		LANNETT CO INC	**2MG/ML**	**A079244**	**001**	Apr 28, 2009
AA		LUPIN LTD	**2MG/ML**	**A091407**	**001**	Feb 19, 2013
AA		PHARM ASSOC	**2MG/ML**	**A090260**	**001**	Jun 15, 2010
LORAZEPAM INTENSOL						
AA	**!**	HIKMA	**2MG/ML**	**A072755**	**001**	Jun 28, 1991
INJECTABLE;INJECTION						
ATIVAN						
AP	**+!**	HIKMA	**2MG/ML**	**N018140**	**001**	
AP	**+!**		**4MG/ML**	**N018140**	**002**	
LORAZEPAM						
AP		AKORN	**2MG/ML**	**A075025**	**001**	Jul 23, 1998
AP		HOSPIRA	**2MG/ML**	**A074243**	**001**	Apr 12, 1994
AP			**2MG/ML**	**A074282**	**001**	May 27, 1994
AP			**4MG/ML**	**A074243**	**002**	Apr 12, 1994
AP			**4MG/ML**	**A074282**	**002**	May 27, 1994
AP		INTL MEDICATION SYS	**2MG/ML**	**A076150**	**001**	Nov 15, 2004
TABLET;ORAL						
ATIVAN						
AB	**+**	BAUSCH	**0.5MG**	**N017794**	**001**	
AB	**+**		**1MG**	**N017794**	**002**	
AB	**+!**		**2MG**	**N017794**	**003**	
LORAZEPAM						
AB		AMNEAL PHARMS	**0.5MG**	**A078826**	**001**	Jun 23, 2010
AB			**1MG**	**A078826**	**002**	Jun 23, 2010
AB			**2MG**	**A078826**	**003**	Jun 23, 2010
AB		AUROLIFE PHARMA LLC	**0.5MG**	**A203572**	**001**	Dec 22, 2017

LORAZEPAM						
TABLET;ORAL						
LORAZEPAM						
AB		**1MG**	**A203572**	**002**	Dec 22, 2017
AB		**2MG**	**A203572**	**003**	Dec 22, 2017
AB	LEADING PHARMA LLC	**0.5MG**	**A078203**	**001**	Jul 30, 2007
AB		**1MG**	**A078203**	**002**	Jul 30, 2007
AB		**2MG**	**A078203**	**003**	Jul 30, 2007
AB	MYLAN	**0.5MG**	**A077657**	**001**	Mar 16, 2006
AB		**1MG**	**A077657**	**002**	Mar 16, 2006
AB		**2MG**	**A077657**	**003**	Mar 16, 2006
AB	OXFORD PHARMS	**0.5MG**	**A077754**	**001**	May 10, 2006
AB		**1MG**	**A077754**	**002**	May 10, 2006
AB		**2MG**	**A077754**	**003**	May 10, 2006
AB	SANDOZ	**0.5MG**	**A071141**	**002**	Apr 21, 1987
AB		**1MG**	**A071141**	**003**	Apr 21, 1987
AB		**2MG**	**A071141**	**001**	Apr 21, 1987
AB	WATSON LABS	**0.5MG**	**A072926**	**001**	Oct 31, 1991
AB		**1MG**	**A072927**	**001**	Oct 31, 1991
AB		**2MG**	**A072928**	**001**	Oct 31, 1991
LORCASERIN HYDROCHLORIDE						
TABLET;ORAL						
BELVIQ						
+!	EISAI INC	10MG	N022529	001	Jun 27, 2012	
TABLET, EXTENDED RELEASE;ORAL						
BELVIQ XR						
+!	EISAI INC	20MG	N208524	001	Jul 15, 2016	
LORLATINIB						
TABLET;ORAL						
LORBRENA						
+	PFIZER INC	25MG	N210868	001	Nov 02, 2018	
+!		100MG	N210868	002	Nov 02, 2018	
LOSARTAN POTASSIUM						
TABLET;ORAL						
COZAAR						
AB	**+!** MERCK SHARP DOHME	**100MG**	**N020386**	**003**	Oct 13, 1998	
LOSARTAN POTASSIUM						
AB	ALEMBIC PHARMS LTD	**25MG**	**A090428**	**001**	Oct 06, 2010
AB		**50MG**	**A090428**	**002**	Oct 06, 2010
AB		**100MG**	**A090428**	**003**	Oct 06, 2010
AB	AUROBINDO PHARMA	**25MG**	**A090083**	**001**	Oct 06, 2010
AB		**50MG**	**A090083**	**002**	Oct 06, 2010
AB		**100MG**	**A090083**	**003**	Oct 06, 2010
AB	CADISTA PHARMS	**25MG**	**A201170**	**001**	Sep 18, 2012
AB		**50MG**	**A201170**	**002**	Sep 18, 2012
AB		**100MG**	**A201170**	**003**	Sep 18, 2012
AB	HETERO LABS LTD V	**25MG**	**A203835**	**001**	Aug 12, 2015
AB		**50MG**	**A203835**	**002**	Aug 12, 2015
AB		**100MG**	**A203835**	**003**	Aug 12, 2015
AB	HIKMA	**25MG**	**A077459**	**001**	Oct 06, 2010
AB		**50MG**	**A077459**	**002**	Oct 06, 2010
AB		**100MG**	**A077459**	**003**	Oct 06, 2010
AB	IPCA LABS LTD	**25MG**	**A200290**	**001**	Aug 30, 2013
AB		**50MG**	**A200290**	**002**	Aug 30, 2013
AB		**100MG**	**A200290**	**003**	Aug 30, 2013
AB	LUPIN LTD	**25MG**	**A078232**	**001**	Oct 06, 2010
AB		**50MG**	**A078232**	**002**	Oct 06, 2010
AB		**100MG**	**A078232**	**003**	Oct 06, 2010
AB	MACLEODS PHARMS LTD	**25MG**	**A202230**	**001**	May 30, 2012
AB		**50MG**	**A202230**	**002**	May 30, 2012
AB		**100MG**	**A202230**	**003**	May 30, 2012
AB	MICRO LABS	**25MG**	**A091541**	**001**	Sep 24, 2012
AB		**50MG**	**A091541**	**002**	Sep 24, 2012
AB		**100MG**	**A091541**	**003**	Sep 24, 2012
AB	MYLAN	**25MG**	**A091590**	**001**	Oct 06, 2010
AB		**50MG**	**A091590**	**002**	Oct 06, 2010
AB		**100MG**	**A091590**	**003**	Oct 06, 2010
AB	PRINSTON INC	**25MG**	**A091497**	**001**	Jun 06, 2011
AB		**50MG**	**A091497**	**002**	Jun 06, 2011
AB		**100MG**	**A091497**	**003**	Jun 06, 2011
AB	SANDOZ	**25MG**	**A077424**	**001**	Oct 06, 2010

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB			**50MG**	**A077424**	**002**	Oct 06, 2010
AB			**100MG**	**A077424**	**003**	Oct 06, 2010
AB		STRIDES PHARMA	**25MG**	**A090382**	**001**	Oct 06, 2010
AB			**50MG**	**A090382**	**002**	Oct 06, 2010
AB			**100MG**	**A090382**	**003**	Oct 06, 2010
AB		TORRENT PHARMS	**25MG**	**A090467**	**001**	Oct 06, 2010
AB			**50MG**	**A090467**	**002**	Oct 06, 2010
AB			**100MG**	**A090467**	**003**	Oct 06, 2010
AB		UNICHEM LABS LTD	**25MG**	**A203030**	**001**	Oct 14, 2015
AB			**50MG**	**A203030**	**002**	Oct 14, 2015
AB			**100MG**	**A203030**	**003**	Oct 14, 2015
AB		UPSHER SMITH LABS	**25MG**	**A090544**	**001**	Oct 06, 2010
AB			**50MG**	**A090544**	**002**	Oct 06, 2010
AB			**100MG**	**A090544**	**003**	Oct 06, 2010
AB		WATSON LABS	**25MG**	**A091129**	**001**	Oct 06, 2010
AB			**50MG**	**A091129**	**002**	Oct 06, 2010
AB			**100MG**	**A091129**	**003**	Oct 06, 2010
AB		ZYDUS PHARMS USA INC	**25MG**	**A078243**	**001**	Oct 06, 2010
AB			**50MG**	**A078243**	**002**	Oct 06, 2010
AB			**100MG**	**A078243**	**003**	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

	+!	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012

LOTEMAX SM

	+!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019

OINTMENT;OPHTHALMIC

LOTEMAX

	+!	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011

SUSPENSION/DROPS;OPHTHALMIC

LOTEMAX

AB	**+!**	BAUSCH AND LOMB	**0.5%**	**N020583**	**001**	Mar 09, 1998

LOTEPREDNOL ETABONATE

AB		HI TECH	**0.5%**	**A207609**	**001**	Apr 17, 2019

ALREX

	+!	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998

INVELTYS

	+!	KALA PHARMS INC	1%	N210565	001	Aug 22, 2018

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

ZYLET

	+!	BAUSCH AND LOMB	0.5%;0.3%	N050804	001	Dec 14, 2004

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		ACTAVIS ELIZABETH	**10MG**	**A075828**	**001**	Dec 17, 2001
AB			**20MG**	**A075828**	**002**	Dec 17, 2001
AB			**40MG**	**A075828**	**003**	Dec 17, 2001
AB		APOTEX INC	**10MG**	**A077748**	**001**	Feb 28, 2007
AB			**20MG**	**A077748**	**002**	Feb 28, 2007
AB			**40MG**	**A077748**	**003**	Feb 28, 2007
AB		BEXIMCO PHARMS USA	**10MG**	**A075300**	**001**	Dec 17, 2001
AB			**20MG**	**A075300**	**002**	Dec 17, 2001
AB			**40MG**	**A075300**	**003**	Dec 17, 2001
AB		CARLSBAD	**10MG**	**A075991**	**001**	Jun 05, 2002
AB			**20MG**	**A075991**	**002**	Jun 05, 2002
AB	**!**		**40MG**	**A075991**	**003**	Jun 05, 2002
AB		LUPIN	**10MG**	**A078296**	**001**	Mar 14, 2008
AB			**20MG**	**A078296**	**002**	Nov 01, 2007
AB			**40MG**	**A078296**	**003**	Nov 01, 2007
AB		SANDOZ	**10MG**	**A075636**	**001**	Dec 17, 2001
AB			**20MG**	**A075636**	**002**	Dec 17, 2001
AB			**40MG**	**A075636**	**003**	Dec 17, 2001
AB		TEVA	**10MG**	**A075551**	**003**	Dec 17, 2001
AB			**20MG**	**A075551**	**002**	Dec 17, 2001
AB			**40MG**	**A075551**	**001**	Dec 17, 2001

LOVASTATIN
TABLET, EXTENDED RELEASE;ORAL
ALTOPREV

+	COVIS PHARMA BV	20MG	N021316	002	Jun 26, 2002
+		40MG	N021316	003	Jun 26, 2002
+!		60MG	N021316	004	Jun 26, 2002

LOXAPINE
POWDER;INHALATION
ADASUVE

+!	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012

LOXAPINE SUCCINATE
CAPSULE;ORAL
LOXAPINE SUCCINATE

AB	ELITE LABS INC	**EQ 5MG BASE**	**A076868**	**001**	Aug 04, 2005
AB		**EQ 10MG BASE**	**A076868**	**002**	Aug 04, 2005
AB		**EQ 25MG BASE**	**A076868**	**003**	Aug 04, 2005
AB		**EQ 50MG BASE**	**A076868**	**004**	Aug 04, 2005
AB	LANNETT CO INC	**EQ 5MG BASE**	**A090695**	**001**	Sep 26, 2011
AB		**EQ 10MG BASE**	**A090695**	**002**	Sep 26, 2011
AB		**EQ 25MG BASE**	**A090695**	**003**	Sep 26, 2011
AB		**EQ 50MG BASE**	**A090695**	**004**	Sep 26, 2011
AB	MYLAN	**EQ 5MG BASE**	**A076762**	**001**	Nov 01, 2004
AB		**EQ 10MG BASE**	**A076762**	**002**	Nov 01, 2004
AB		**EQ 25MG BASE**	**A076762**	**003**	Nov 01, 2004
AB		**EQ 50MG BASE**	**A076762**	**004**	Nov 01, 2004
AB	WATSON LABS	**EQ 5MG BASE**	**A072204**	**001**	Jun 15, 1988
AB		**EQ 10MG BASE**	**A072205**	**001**	Jun 15, 1988
AB	**!**	**EQ 25MG BASE**	**A072206**	**001**	Jun 15, 1988
AB		**EQ 50MG BASE**	**A072062**	**001**	Jun 15, 1988

LUBIPROSTONE
CAPSULE;ORAL
AMITIZA

+	SUCAMPO PHARMA LLC	8MCG	N021908	002	Apr 29, 2008
+!		24MCG	N021908	001	Jan 31, 2006

LULICONAZOLE
CREAM;TOPICAL
LUZU

+!	MEDICIS	1%	N204153	001	Nov 14, 2013

LUMATEPERONE TOSYLATE
CAPSULE;ORAL
CAPLYTA

+!	INTRA-CELLULAR	EQ 42MG BASE	N209500	001	Dec 20, 2019

LURASIDONE HYDROCHLORIDE
TABLET;ORAL
LATUDA

AB	**+**	SUNOVION PHARMS INC	**20MG**	**N200603**	**003**	Dec 07, 2011
AB	**+!**		**40MG**	**N200603**	**001**	Oct 28, 2010
AB	**+**		**60MG**	**N200603**	**005**	Jul 12, 2013
AB	**+**		**80MG**	**N200603**	**002**	Oct 28, 2010
AB	**+**		**120MG**	**N200603**	**004**	Apr 26, 2012
	LURASIDONE HYDROCHLORIDE					
AB		ACCORD HLTHCARE	**20MG**	**A208049**	**001**	Jan 03, 2019
AB			**40MG**	**A208049**	**002**	Jan 03, 2019
AB			**60MG**	**A208049**	**003**	Jan 03, 2019
AB			**80MG**	**A208049**	**004**	Jan 03, 2019
AB			**120MG**	**A208049**	**005**	Jan 03, 2019
AB		SUN PHARM	**20MG**	**A208066**	**001**	Jan 04, 2019
AB			**40MG**	**A208066**	**002**	Jan 04, 2019
AB			**60MG**	**A208066**	**003**	Jan 04, 2019
AB			**80MG**	**A208066**	**004**	Jan 04, 2019
AB			**120MG**	**A208066**	**005**	Jan 04, 2019

LUSUTROMBOPAG
TABLET;ORAL
MULPLETA

+!	SHIONOGI INC	3MG	N210923	001	Jul 31, 2018

LUTETIUM DOTATATE LU-177							
SOLUTION;INTRAVENOUS							
LUTATHERA							
	+!	AAA USA INC	10mCi/ML		N208700	001	Jan 26, 2018
MACIMORELIN ACETATE							
FOR SOLUTION;ORAL							
MACRILEN							
	+!	NOVO	EQ 60MG BASE/POUCH		N205598	001	Dec 20, 2017
MACITENTAN							
TABLET;ORAL							
OPSUMIT							
	+!	ACTELION PHARMS LTD	10MG		N204410	001	Oct 18, 2013
MAFENIDE ACETATE							
CREAM;TOPICAL							
SULFAMYLON							
	+!	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM		N016763	001	
FOR SOLUTION;TOPICAL							
MAFENIDE ACETATE							
AT		NOVAST LABS	**5%**		**A206716**	**001**	Jul 31, 2017
AT		PAR FORM	**5%**		**A201511**	**001**	Feb 12, 2013
SULFAMYLON							
AT	**+!**	MYLAN INSTITUTIONAL	**5%**		**N019832**	**003**	Jun 05, 1998
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE							
INJECTABLE;INJECTION							
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER							
	+!	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML		N019696	001	Sep 29, 1989
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE							
INJECTABLE;INJECTION							
ISOLYTE S IN PLASTIC CONTAINER							
		B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML		N019711	001	Sep 29, 1989
NORMOSOL-R IN PLASTIC CONTAINER							
		ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML		N017586	001	
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER							
	+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML		N017378	001	
PLASMA-LYTE A IN PLASTIC CONTAINER							
	+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML		N017378	002	Nov 22, 1982
SOLUTION;IRRIGATION							
PHYSIOLYTE IN PLASTIC CONTAINER							
		B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML		N019024	001	Jun 08, 1984
PHYSIOSOL IN PLASTIC CONTAINER							
		ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML		N017637	002	Jul 08, 1982
MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE							
SOLUTION;INJECTION							
NORMOCARB HF 25							
	+!	DIALYSIS SUPS	0.21GM/100ML;2.8GM/100ML;9.07GM/100ML		N021910	001	Jul 26, 2006
NORMOCARB HF 35							
	+!	DIALYSIS SUPS	0.21GM/100ML;3.97GM/100ML;8.3GM/100ML		N021910	002	Jul 26, 2006
MAGNESIUM SULFATE							
INJECTABLE;INJECTION							
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP		FRESENIUS KABI USA	**1GM/100ML**		**A206486**	**001**	Mar 07, 2016
AP	**+!**	HOSPIRA	**1GM/100ML**		**N020488**	**001**	Jul 11, 1995
AP		HQ SPCLT PHARMA	**1GM/100ML**		**A207349**	**001**	Mar 02, 2016
AP		MYLAN LABS LTD	**1GM/100ML**		**A209932**	**001**	Sep 10, 2018
MAGNESIUM SULFATE IN PLASTIC CONTAINER							
AP		FRESENIUS KABI USA	**4GM/100ML (40MG/ML)**		**A206485**	**001**	Mar 15, 2016
AP			**4GM/50ML (80MG/ML)**		**A206485**	**002**	Mar 15, 2016
AP			**2GM/50ML (40MG/ML)**		**A206485**	**003**	Mar 15, 2016
AP			**20GM/500ML (40MG/ML)**		**A206485**	**004**	Mar 15, 2016
AP			**40GM/1000ML (40MG/ML)**		**A206485**	**005**	Mar 15, 2016
AP	**+**	HOSPIRA	**2GM/50ML (40MG/ML)**		**N020309**	**003**	Jan 26, 2007
AP	**+!**		**4GM/100ML (40MG/ML)**		**N020309**	**001**	Jun 24, 1994

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	**+!**		**4GM/50ML (80MG/ML)**	**N020309**	**002**	Jun 24, 1994
AP	**+**		**20GM/500ML (40MG/ML)**	**N020309**	**004**	Jan 18, 1995
AP	**+**		**40GM/1000ML (40MG/ML)**	**N020309**	**005**	Jan 18, 1995
AP		HQ SPCLT PHARMA	**2GM/50ML (40MG/ML)**	**A207350**	**001**	Dec 06, 2017
AP			**4GM/100ML (40MG/ML)**	**A207350**	**002**	Dec 06, 2017
AP			**4GM/50ML (80MG/ML)**	**A207350**	**003**	Dec 06, 2017
AP			**20GM/500ML (40MG/ML)**	**A207350**	**004**	Dec 06, 2017
AP			**40GM/1000ML (40MG/ML)**	**A207350**	**005**	Dec 06, 2017
AP		MYLAN LABS LTD	**2GM/50ML (40MG/ML)**	**A209911**	**001**	Sep 14, 2018
AP			**4GM/100ML (40MG/ML)**	**A209911**	**002**	Sep 14, 2018

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+!	HOSPIRA	2GM/100ML	N020488	002	Jul 11, 1995

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP		EXELA PHARMA SCS LLC	**5GM/10ML (500MG/ML)**	**A206039**	**001**	Dec 18, 2014
AP	**+!**	FRESENIUS KABI USA	**5GM/10ML (500MG/ML)**	**N019316**	**001**	Sep 08, 1986
AP	**+!**		**10GM/20ML (500MG/ML)**	**N019316**	**003**	Jan 29, 2016
AP	**!**	HOSPIRA	**5GM/10ML (500MG/ML)**	**A075151**	**001**	Apr 25, 2000
AP		HOSPIRA INC	**10GM/20ML (500MG/ML)**	**A202411**	**001**	May 14, 2015
	+!	FRESENIUS KABI USA	25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

	+!	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

TIS-U-SOL

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018508**	**001**	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018336**	**001**	

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA		NOVEL LABS INC	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A202511**	**001**	Feb 23, 2017

SUPREP BOWEL PREP KIT

AA	**+!**	BRAINTREE LABS	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**N022372**	**001**	Aug 05, 2010

MALATHION

LOTION;TOPICAL

MALATHION

	!	SUVEN LIFE	0.5%	A091559	001	May 23, 2012

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	+!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP		B BRAUN	**10GM/100ML**	**N020006**	**002**	Jul 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP		B BRAUN	**15GM/100ML**	**N020006**	**003**	Jul 26, 1993

MANNITOL 20% IN PLASTIC CONTAINER

AP		B BRAUN	**20GM/100ML**	**N020006**	**004**	Jul 26, 1993
AP		ICU MEDICAL INC	**20GM/100ML**	**N019603**	**004**	Jan 08, 1990

MANNITOL 25%

AP		FRESENIUS KABI USA	**12.5GM/50ML**	**A080677**	**001**	
AP		HOSPIRA	**12.5GM/50ML**	**N016269**	**006**	Aug 25, 1994
AP		INTL MEDICATION	**12.5GM/50ML**	**A083051**	**001**	

MANNITOL 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N020006**	**001**	Jul 26, 1993

OSMITROL 10% IN WATER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**002**	

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**006**	

MANNITOL
INJECTABLE;INJECTION
OSMITROL 15% IN WATER
AP BAXTER HLTHCARE **15GM/100ML** **N013684 004**
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **15GM/100ML** **N013684 008**
OSMITROL 20% IN WATER
AP BAXTER HLTHCARE **20GM/100ML** **N013684 003**
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **20GM/100ML** **N013684 007**
OSMITROL 5% IN WATER
AP BAXTER HLTHCARE **5GM/100ML** **N013684 001**
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML** **N013684 005**
POWDER;INHALATION
ARIDOL KIT
+! PHARMAXIS LTD N/A,5MG,10MG,20MG,40MG N022368 001 Oct 05, 2010
SOLUTION;IRRIGATION
RESECTISOL IN PLASTIC CONTAINER
B BRAUN 5GM/100ML N016772 002

MANNITOL; SORBITOL
SOLUTION;IRRIGATION
SORBITOL-MANNITOL IN PLASTIC CONTAINER
+! ICU MEDICAL INC 540MG/100ML;2.7GM/100ML N018316 001

MAPROTILINE HYDROCHLORIDE
TABLET;ORAL
MAPROTILINE HYDROCHLORIDE
MYLAN 25MG A072285 002 Oct 03, 1988
! 50MG A072285 001 Oct 03, 1988
75MG A072285 003 Oct 03, 1988

MARAVIROC
SOLUTION;ORAL
SELZENTRY
+! VIIV HLTHCARE 20MG/ML N208984 001 Nov 04, 2016
TABLET;ORAL
SELZENTRY
+ VIIV HLTHCARE 25MG N022128 003 Nov 04, 2016
+ 75MG N022128 004 Nov 04, 2016
+ 150MG N022128 001 Aug 06, 2007
+! 300MG N022128 002 Aug 06, 2007

MEBENDAZOLE
TABLET, CHEWABLE;ORAL
EMVERM
! IMPAX LABS INC 100MG A073580 001 Jan 04, 1995

MECAMYLAMINE HYDROCHLORIDE
TABLET;ORAL
MECAMYLAMINE HYDROCHLORIDE
! NEXGEN PHARMA 2.5MG A204054 001 Mar 19, 2013

MECASERMIN RECOMBINANT
INJECTABLE;SUBCUTANEOUS
INCRELEX
+! IPSEN INC 40MG/4ML (10MG/ML) N021839 001 Aug 30, 2005

MECHLORETHAMINE HYDROCHLORIDE
GEL;TOPICAL
VALCHLOR
+! HELSINN EQ 0.016% BASE N202317 001 Aug 23, 2013

MECLIZINE HYDROCHLORIDE
TABLET;ORAL
ANTIVERT
AA **+** CASPER PHARMA LLC **12.5MG** **N010721 006**
AA **+** **25MG** **N010721 004**
AA **+** **50MG** **N010721 001** Jan 20, 1982
MECLIZINE HYDROCHLORIDE
AA **!** AMNEAL PHARMS **12.5MG** **A201451 001** Feb 23, 2011
AA **!** **25MG** **A201451 002** Feb 23, 2011
AA AUREX **12.5MG** **A087127 001**
AA **25MG** **A087128 001**
AA EPIC PHARMA LLC **12.5MG** **A200294 001** Apr 13, 2012

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA			**25MG**	**A200294**	**002**	Apr 13, 2012
AA		INDICUS PHARMA	**12.5MG**	**A205136**	**001**	Feb 22, 2019
AA			**25MG**	**A205136**	**002**	Feb 22, 2019
AA		INVATECH	**25MG**	**A084092**	**003**	May 22, 1989
AA		JUBILANT CADISTA	**12.5MG**	**A040659**	**001**	Jun 04, 2010
AA			**25MG**	**A040659**	**002**	Jun 04, 2010
AA		MYLAN PHARMS INC	**12.5MG**	**A202640**	**001**	Sep 17, 2012
AA			**25MG**	**A202640**	**002**	Sep 17, 2012
AA		SANDOZ	**12.5MG**	**A084843**	**002**	May 22, 1989
		INDICUS PHARMA	50MG	A205136	003	Feb 22, 2019

TABLET, CHEWABLE;ORAL

ANTIVERT

AA	**+**	CASPER PHARMA LLC	**25MG**	**N010721**	**005**	

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

		MYLAN	EQ 50MG BASE	A071081	002	Sep 03, 1986
	!		EQ 100MG BASE	A071081	001	Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

DEPO-PROVERA

AB	**+!**	PHARMACIA AND UPJOHN	**150MG/ML**	**N020246**	**001**	Oct 29, 1992

MEDROXYPROGESTERONE ACETATE

AB		AMPHASTAR PHARMS INC	**150MG/ML**	**A077235**	**001**	Nov 28, 2017
AB			**150MG/ML**	**A077334**	**001**	Nov 28, 2017
AB		MYLAN LABS LTD	**150MG/ML**	**A210227**	**001**	Oct 12, 2018
AB		SUN PHARM	**150MG/ML**	**A210760**	**001**	May 01, 2019
AB			**150MG/ML**	**A210761**	**001**	Apr 24, 2019
AB		TEVA PHARMS USA	**150MG/ML**	**A076553**	**001**	Jul 28, 2004

DEPO-PROVERA

	+!	PHARMACIA AND UPJOHN	400MG/ML	N012541	003	

INJECTABLE;SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

	+!	PHARMACIA AND UPJOHN	104MG/0.65ML	N021583	001	Dec 17, 2004

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

AB		BARR	**2.5MG**	**A040159**	**001**	Aug 09, 1996
AB			**5MG**	**A040159**	**002**	Aug 09, 1996
AB			**10MG**	**A040159**	**003**	Aug 09, 1996

PROVERA

AB	**+**	PHARMACIA AND UPJOHN	**2.5MG**	**N011839**	**001**	
AB	**+**		**5MG**	**N011839**	**003**	
AB	**+!**		**10MG**	**N011839**	**004**	

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

AB		BELCHER PHARMS LLC	**250MG**	**A091608**	**001**	Jun 02, 2014
AB		LUPIN LTD	**250MG**	**A091322**	**001**	Jul 22, 2011
AB		MICRO LABS	**250MG**	**A090562**	**001**	Nov 19, 2010

PONSTEL

AB	**+!**	SHIONOGI INC	**250MG**	**N015034**	**003**	

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

AB	**!**	BARR	**250MG**	**A076392**	**001**	Dec 29, 2003
AB		HIKMA	**250MG**	**A076523**	**001**	Oct 01, 2004

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	**+!**	ENDO PHARMS INC	**125MG/ML**	**N021778**	**001**	Jul 05, 2005

MEGESTROL ACETATE

AB		BRECKENRIDGE	**125MG/ML**	**A204688**	**001**	Dec 01, 2017
AB		HI TECH	**40MG/ML**	**A203960**	**001**	Jun 09, 2017

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGESTROL ACETATE

AB	**!**	HIKMA	**40MG/ML**	**A075997**	**001**	Feb 15, 2002
AB		PAR PHARM	**40MG/ML**	**A075671**	**001**	Jul 25, 2001
AB		TEVA PHARMS	**40MG/ML**	**A075681**	**001**	May 05, 2003
AB		TWI PHARMS	**125MG/ML**	**A203139**	**001**	Aug 27, 2014
AB		WOCKHARDT BIO AG	**40MG/ML**	**A076721**	**001**	Nov 01, 2004

TABLET;ORAL

MEGESTROL ACETATE

AB		BARR	**20MG**	**A074621**	**002**	Aug 16, 1996
AB			**40MG**	**A074621**	**001**	Nov 30, 1995
AB		HIKMA	**20MG**	**A074458**	**001**	Sep 29, 1995
AB			**40MG**	**A074458**	**002**	Sep 29, 1995
AB		PAR PHARM	**20MG**	**A072422**	**001**	Aug 08, 1988
AB	**!**		**40MG**	**A072423**	**001**	Aug 08, 1988

MELOXICAM

CAPSULE;ORAL

VIVLODEX

	+	ZYLA	5MG	N207233	001	Oct 22, 2015
	+!		10MG	N207233	002	Oct 22, 2015

TABLET;ORAL

MELOXICAM

AB		APOTEX INC	**7.5MG**	**A077882**	**001**	Jul 20, 2006
AB			**15MG**	**A077882**	**002**	Jul 20, 2006
AB		AUROBINDO PHARMA	**7.5MG**	**A078008**	**001**	Oct 02, 2006
AB			**15MG**	**A078008**	**002**	Oct 02, 2006
AB		BRECKENRIDGE PHARM	**7.5MG**	**A077920**	**001**	Jul 19, 2006
AB			**15MG**	**A077920**	**002**	Jul 19, 2006
AB		CIPLA	**7.5MG**	**A077929**	**001**	Jul 19, 2006
AB			**15MG**	**A077929**	**002**	Jul 19, 2006
AB		DR REDDYS LABS INC	**7.5MG**	**A077931**	**001**	Jul 25, 2006
AB			**15MG**	**A077931**	**002**	Jul 25, 2006
AB		GLENMARK GENERICS	**7.5MG**	**A077932**	**001**	Jul 19, 2006
AB			**15MG**	**A077932**	**002**	Jul 19, 2006
AB		LUPIN PHARMS	**7.5MG**	**A077944**	**001**	Jul 19, 2006
AB			**15MG**	**A077944**	**002**	Jul 19, 2006
AB		PURACAP PHARM	**7.5MG**	**A077938**	**001**	Jul 19, 2006
AB			**15MG**	**A077938**	**002**	Jul 19, 2006
AB		STRIDES PHARMA	**7.5MG**	**A077928**	**001**	May 13, 2009
AB			**15MG**	**A077928**	**002**	May 13, 2009
AB		TARO	**7.5MG**	**A078102**	**001**	Nov 07, 2006
AB			**15MG**	**A078102**	**002**	Nov 07, 2006
AB		UNICHEM	**7.5MG**	**A077927**	**001**	Dec 20, 2006
AB			**15MG**	**A077927**	**002**	Dec 20, 2006
AB		YUNG SHIN PHARM	**7.5MG**	**A077918**	**001**	Dec 07, 2006
AB			**15MG**	**A077918**	**002**	Dec 07, 2006
AB		ZYDUS PHARMS USA	**7.5MG**	**A077921**	**001**	Jul 19, 2006
AB			**15MG**	**A077921**	**002**	Jul 19, 2006

MOBIC

AB	**+**	BOEHRINGER INGELHEIM	**7.5MG**	**N020938**	**001**	Apr 13, 2000
AB	**+!**		**15MG**	**N020938**	**002**	Aug 23, 2000

TABLET, ORALLY DISINTEGRATING;ORAL

QMIIZ ODT

	+	TERSERA THERAPS LLC	7.5MG	N211210	001	Oct 19, 2018
	+!		15MG	N211210	002	Oct 19, 2018

MELPHALAN

TABLET;ORAL

ALKERAN

AB	**+!**	APOTEX	**2MG**	**N014691**	**002**	

MELPHALAN

AB		ALVOGEN	**2MG**	**A207809**	**001**	Mar 22, 2017

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

AP	**+**	APOTEX	**EQ 50MG BASE/VIAL**	**N020207**	**001**	Nov 18, 1992

MELPHALAN HYDROCHLORIDE

AP		ACTAVIS LLC	**EQ 50MG BASE/VIAL**	**A206018**	**001**	Dec 19, 2016
AP		ALVOGEN INC	**EQ 50MG BASE/VIAL**	**A204817**	**001**	May 17, 2019
AP		DR REDDYS LABS LTD	**EQ 50MG BASE/VIAL**	**A203655**	**001**	Dec 08, 2017

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A203393**	**001**	Dec 22, 2017
AP		GLAND PHARMA LTD	**EQ 50MG BASE/VIAL**	**A209826**	**001**	May 28, 2019
AP	!	MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A090270**	**001**	Jun 09, 2009
AP		NORATECH	**EQ 50MG BASE/VIAL**	**A211463**	**001**	Sep 13, 2019
AP		PAR STERILE PRODUCTS	**EQ 50MG BASE/VIAL**	**A204773**	**001**	Aug 22, 2016
AP		SAGENT PHARMS INC	**EQ 50MG BASE/VIAL**	**A201379**	**001**	Feb 28, 2017
AP		WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A090303**	**001**	Oct 28, 2010

POWDER;INTRAVENOUS

EVOMELA

	+!	ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	**7MG**	**A205825**	**001**	Oct 12, 2016
AB			**14MG**	**A205825**	**002**	Oct 12, 2016
AB			**21MG**	**A205825**	**003**	Oct 12, 2016
AB			**28MG**	**A205825**	**004**	Oct 12, 2016
AB		ANCHEN PHARMS	**7MG**	**A205784**	**001**	Jun 09, 2017
AB			**14MG**	**A205784**	**002**	Jun 09, 2017
AB			**21MG**	**A205784**	**003**	Jun 09, 2017
AB			**28MG**	**A205784**	**004**	Jun 09, 2017
AB		APOTEX	**7MG**	**A206135**	**001**	Nov 22, 2016
AB			**14MG**	**A206135**	**002**	Nov 22, 2016
AB			**21MG**	**A206135**	**003**	Nov 22, 2016
AB			**28MG**	**A206135**	**004**	Nov 22, 2016
AB		LUPIN LTD	**7MG**	**A206028**	**001**	Sep 28, 2016
AB			**14MG**	**A206028**	**002**	Sep 28, 2016
AB			**21MG**	**A206028**	**003**	Sep 28, 2016
AB			**28MG**	**A206028**	**004**	Sep 28, 2016
AB		MYLAN	**7MG**	**A206032**	**001**	Sep 28, 2016
AB			**14MG**	**A206032**	**002**	Sep 28, 2016
AB			**21MG**	**A206032**	**003**	Sep 28, 2016
AB			**28MG**	**A206032**	**004**	Sep 28, 2016
AB		SUN PHARM	**7MG**	**A205905**	**001**	Sep 28, 2016
AB			**14MG**	**A205905**	**002**	Sep 28, 2016
AB			**21MG**	**A205905**	**003**	Sep 28, 2016
AB			**28MG**	**A205905**	**004**	Sep 28, 2016
AB		ZYDUS PHARMS	**7MG**	**A203293**	**001**	Aug 03, 2017
AB			**14MG**	**A203293**	**002**	Aug 03, 2017
AB			**21MG**	**A203293**	**003**	Aug 03, 2017
AB			**28MG**	**A203293**	**004**	Aug 03, 2017

NAMENDA XR

AB	+	FOREST LABS LLC	**7MG**	**N022525**	**001**	Jun 21, 2010
AB	+		**14MG**	**N022525**	**002**	Jun 21, 2010
AB	+		**21MG**	**N022525**	**003**	Jun 21, 2010
AB	+!		**28MG**	**N022525**	**004**	Jun 21, 2010

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX	**2MG/ML**	**A209955**	**001**	Feb 09, 2018
AA	!	LANNETT CO INC	**2MG/ML**	**A204033**	**001**	Oct 13, 2015
AA		MACLEODS PHARMS LTD	**2MG/ML**	**A202790**	**001**	Oct 13, 2015

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**5MG**	**A206528**	**001**	Nov 30, 2015
AB			**10MG**	**A206528**	**002**	Nov 30, 2015
AB		ALEMBIC PHARMS LTD	**5MG**	**A200891**	**001**	Oct 13, 2015
AB			**10MG**	**A200891**	**002**	Oct 13, 2015
AB		AMNEAL PHARMS	**5MG**	**A090041**	**001**	Apr 10, 2015
AB			**10MG**	**A090041**	**002**	Apr 10, 2015
AB		AUROBINDO PHARMA LTD	**5MG**	**A203175**	**001**	Oct 13, 2015
AB			**10MG**	**A203175**	**002**	Oct 13, 2015
AB		CADILA	**5MG**	**A090961**	**001**	Jul 10, 2017
AB			**10MG**	**A090961**	**002**	Jul 10, 2017
AB		CELLTRION	**5MG**	**A090073**	**001**	Sep 04, 2015
AB			**10MG**	**A090073**	**002**	Sep 04, 2015
AB		CSPC OUYI	**5MG**	**A209527**	**001**	May 07, 2018

MEMANTINE HYDROCHLORIDE

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB			**10MG**	**A209527**	**002**	May 07, 2018
AB		DR REDDYS LABS LTD	**5MG**	**A090048**	**001**	Apr 14, 2010
AB			**10MG**	**A090048**	**002**	Apr 14, 2010
AB		JUBILANT GENERICS	**5MG**	**A091585**	**001**	Oct 13, 2015
AB			**10MG**	**A091585**	**002**	Oct 13, 2015
AB		LANNETT CO INC	**5MG**	**A207236**	**001**	Nov 10, 2016
AB			**10MG**	**A207236**	**002**	Nov 10, 2016
AB		LUPIN LTD	**5MG**	**A090051**	**001**	Apr 10, 2015
AB			**10MG**	**A090051**	**002**	Apr 10, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A202840**	**001**	Oct 13, 2015
AB			**10MG**	**A202840**	**002**	Oct 13, 2015
AB		PURACAP PHARM LLC	**5MG**	**A206855**	**001**	Nov 17, 2015
AB			**10MG**	**A206855**	**002**	Nov 17, 2015
AB		STRIDES PHARMA	**5MG**	**A202350**	**001**	May 23, 2017
AB			**10MG**	**A202350**	**002**	May 23, 2017
AB		SUN PHARM	**5MG**	**A090058**	**001**	May 05, 2010
AB			**10MG**	**A090058**	**002**	May 05, 2010
AB		TEVA PHARMS	**5MG**	**A090052**	**001**	Oct 25, 2011
AB			**10MG**	**A090052**	**002**	Oct 25, 2011
AB		TORRENT	**5MG**	**A200155**	**001**	Oct 13, 2015
AB			**10MG**	**A200155**	**002**	Oct 13, 2015
AB		UNICHEM LABS LTD	**5MG**	**A200022**	**001**	Oct 13, 2015
AB			**10MG**	**A200022**	**002**	Oct 13, 2015
AB		UPSHER SMITH LABS	**5MG**	**A090043**	**001**	Jul 31, 2015
AB			**10MG**	**A090043**	**002**	Jul 31, 2015

NAMENDA

AB	**+**	ALLERGAN	**5MG**	**N021487**	**001**	Oct 16, 2003
AB	**+!**		**10MG**	**N021487**	**002**	Oct 16, 2003

MENOTROPINS (FSH;LH)

INJECTABLE;SUBCUTANEOUS

MENOPUR

	+!	FERRING	75 IU/VIAL;75 IU/VIAL	N021663	001	Oct 29, 2004

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

AP	**+!**	HOSPIRA	**25MG/ML**	**N021171**	**001**	
AP	**+!**		**50MG/ML**	**N021171**	**002**	
AP	**+!**		**75MG/ML**	**N021171**	**003**	
AP	**+!**		**100MG/ML**	**N021171**	**004**	

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	**25MG/ML**	**A080445**	**001**	
AP			**25MG/ML**	**A080455**	**007**	
AP			**50MG/ML**	**A080445**	**002**	
AP			**50MG/ML**	**A080455**	**008**	
AP			**75MG/ML**	**A080445**	**003**	
AP			**75MG/ML**	**A080455**	**009**	
AP			**100MG/ML**	**A080445**	**004**	
AP			**100MG/ML**	**A080455**	**010**	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

	!	WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993

SYRUP;ORAL

MEPERIDINE HYDROCHLORIDE

	!	HIKMA	50MG/5ML	A088744	001	Jan 30, 1985

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

AA		EPIC PHARMA	**50MG**	**A040331**	**001**	May 28, 1999
AA			**100MG**	**A040331**	**002**	May 28, 1999
AA	**!**	HIKMA	**50MG**	**A040110**	**001**	Mar 12, 1997
AA	**!**		**100MG**	**A040110**	**002**	Mar 12, 1997
AA		VINTAGE PHARMS	**50MG**	**A040191**	**001**	Dec 17, 1998
AA			**100MG**	**A040191**	**002**	Dec 17, 1998

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CARBOCAINE

AP	**+!**	HOSPIRA	**1%**	**N012250**	**001**		
AP	**+!**		**1.5%**	**N012250**	**005**		
AP	**+!**		**2%**	**N012250**	**002**		

POLOCAINE

AP		FRESENIUS KABI USA	**1%**	**A089407**	**001**	Dec 01, 1986	
AP			**2%**	**A089410**	**001**	Dec 01, 1986	

POLOCAINE-MPF

AP		FRESENIUS KABI USA	**1%**	**A089406**	**001**	Dec 01, 1986	
AP			**1.5%**	**A089408**	**001**	Dec 01, 1986	
AP			**2%**	**A089409**	**001**	Dec 01, 1986	

SCANDONEST PLAIN

AP	**!**	DEPROCO	**3%**	**A088387**	**001**	Oct 10, 1984	

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA		ALEMBIC PHARMS LTD	**200MG**	**A090122**	**001**	Feb 18, 2009	
AA			**400MG**	**A090122**	**002**	Feb 18, 2009	
AA		INVAGEN PHARMS	**200MG**	**A040797**	**001**	Feb 27, 2008	
AA			**400MG**	**A040797**	**002**	Feb 27, 2008	
AA	**!**	WATSON LABS	**200MG**	**A083304**	**001**		
AA	**!**		**400MG**	**A083308**	**001**		

MERCAPTOPURINE

SUSPENSION;ORAL

PURIXAN

	+!	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	

TABLET;ORAL

MERCAPTOPURINE

AB		DR REDDYS LABS SA	**50MG**	**A040461**	**001**	Feb 11, 2004	
AB	**!**	HIKMA	**50MG**	**A040528**	**001**	Feb 13, 2004	
AB		MYLAN	**50MG**	**A040594**	**001**	Jul 01, 2005	

PURINETHOL

AB	**+**	STASON PHARMS	**50MG**	**N009053**	**002**		

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP		ACS DOBFAR	**500MG/VIAL**	**A091404**	**001**	Oct 26, 2011	
AP			**1GM/VIAL**	**A091404**	**002**	Oct 26, 2011	
AP		ACS DOBFAR SPA	**500MG/VIAL**	**A204139**	**001**	Jun 09, 2016	
AP			**1GM/VIAL**	**A204139**	**002**	Jun 09, 2016	
AP		AMNEAL PHARMS	**500MG/VIAL**	**A205883**	**001**	Apr 12, 2016	
AP			**1GM/VIAL**	**A205883**	**002**	Apr 12, 2016	
AP		AUROBINDO PHARMA LTD	**500MG/VIAL**	**A205835**	**001**	Mar 27, 2017	
AP			**1GM/VIAL**	**A205835**	**002**	Mar 27, 2017	
AP		DAEWOONG PHARM CO	**500MG/VIAL**	**A204854**	**001**	Dec 18, 2015	
AP			**1GM/VIAL**	**A204854**	**002**	Dec 18, 2015	
AP		GLAND PHARMA LTD	**500MG/VIAL**	**A206141**	**001**	Jun 08, 2016	
AP			**1GM/VIAL**	**A206141**	**002**	Jun 08, 2016	
AP		HQ SPCLT PHARMA	**500MG/VIAL**	**A210773**	**001**	Aug 16, 2019	
AP			**1GM/VIAL**	**A210773**	**002**	Aug 16, 2019	
AP		SAVIOR LIFETEC CORP	**500MG/VIAL**	**A206086**	**001**	Apr 19, 2016	
AP			**1GM/VIAL**	**A206086**	**002**	Apr 19, 2016	

MERREM

AP	**+!**	PFIZER	**500MG/VIAL**	**N050706**	**003**	Jun 21, 1996	
AP	**+!**		**1GM/VIAL**	**N050706**	**001**	Jun 21, 1996	

POWDER;INTRAVENOUS

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

		B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	
			1GM/VIAL	N202106	002	Apr 30, 2015	

MEROPENEM; VABORBACTAM

POWDER;INTRAVENOUS

VABOMERE

	+!	REMPEX PHARMS	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017	

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL

DELZICOL

AB	**+!**	APIL	**400MG**	**N204412**	**001**	Feb 01, 2013

MESALAMINE

AB		TEVA PHARMS USA	**400MG**	**A207873**	**001**	May 09, 2019

CAPSULE, EXTENDED RELEASE;ORAL

APRISO

AB	**+!**	VALEANT PHARMS INTL	**375MG**	**N022301**	**001**	Oct 31, 2008

MESALAMINE

AB		MYLAN	**375MG**	**A207271**	**001**	Nov 20, 2019

PENTASA

	+	SHIRE	250MG	N020049	001	May 10, 1993
	+!		500MG	N020049	002	Jul 08, 2004

ENEMA;RECTAL

MESALAMINE

AB		PERRIGO ISRAEL	**4GM/60ML**	**A076751**	**001**	Sep 17, 2004

ROWASA

AB	**+!**	MYLAN SPECIALITY LP	**4GM/60ML**	**N019618**	**001**	Dec 24, 1987

SFROWASA

AB	**+**	MYLAN SPECIALITY LP	**4GM/60ML**	**N019618**	**002**	Jun 20, 2008

SUPPOSITORY;RECTAL

CANASA

AB	**+!**	ALLERGAN	**1GM**	**N021252**	**002**	Nov 05, 2004

MESALAMINE

AB		AMNEAL PHARMS LLC	**1GM**	**A210509**	**001**	Jan 02, 2020
AB		AMRING PHARMS	**1GM**	**A208362**	**001**	Jun 21, 2019
AB		MYLAN	**1GM**	**A204354**	**001**	Nov 24, 2015
AB		PHARM SOURCING	**1GM**	**A207448**	**001**	Apr 19, 2019
AB		SANDOZ INC	**1GM**	**A202065**	**001**	Jun 12, 2019

TABLET, DELAYED RELEASE;ORAL

ASACOL HD

AB	**+!**	APIL	**800MG**	**N021830**	**001**	May 29, 2008

LIALDA

AB	**+!**	SHIRE	**1.2GM**	**N022000**	**001**	Jan 16, 2007

MESALAMINE

AB		ACTAVIS LABS FL	**1.2GM**	**A203817**	**001**	Mar 23, 2018
AB		MYLAN	**1.2GM**	**A203574**	**001**	Nov 20, 2018
AB		SUN PHARM	**1.2GM**	**A211858**	**001**	Jan 25, 2019
AB		ZYDUS PHARMS	**800MG**	**A203286**	**001**	Jul 21, 2017
AB			**1.2GM**	**A091640**	**001**	Jun 05, 2017

MESNA

INJECTABLE;INTRAVENOUS

MESNA

AP		FRESENIUS KABI USA	**100MG/ML**	**A075811**	**001**	Apr 26, 2001
AP		GLAND PHARMA LTD	**100MG/ML**	**A206992**	**001**	Dec 18, 2017
AP		SAGENT PHARMS INC	**100MG/ML**	**A090913**	**001**	Apr 13, 2010
AP		TEVA PHARMS USA	**100MG/ML**	**A075764**	**001**	Apr 27, 2001
AP		WEST-WARD PHARMS INT	**100MG/ML**	**A075739**	**001**	Jan 09, 2004

MESNEX

AP	**+!**	BAXTER HLTHCARE	**100MG/ML**	**N019884**	**001**	Dec 30, 1988

TABLET;ORAL

MESNEX

	+!	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

	!	LANNETT CO INC	10MG/5ML	A073632	001	Jul 22, 1992

METAXALONE

TABLET;ORAL

METAXALONE

AB		ACTAVIS LABS FL INC	**800MG**	**A203695**	**001**	Jun 15, 2017
AB		AMNEAL PHARMS	**800MG**	**A203399**	**001**	Jun 21, 2013
AB		APPCO	**800MG**	**A208774**	**001**	Sep 24, 2018
AB		LANNETT CO INC	**800MG**	**A204770**	**001**	Nov 22, 2016
AB		SANDOZ	**800MG**	**A040445**	**001**	Mar 31, 2010
AB		SCIEGEN PHARMS INC	**800MG**	**A207466**	**001**	Aug 31, 2017

SKELAXIN

AB	**+!**	KING PHARMS	**800MG**	**N013217**	**003**	Aug 30, 2002

METAXALONE
TABLET;ORAL
METAXALONE

	MOUNTAIN	400MG		A040486	001	Feb 27, 2015

METFORMIN HYDROCHLORIDE
FOR SUSPENSION, EXTENDED RELEASE;ORAL
RIOMET ER

+!	SUN PHARM	500MG/5ML		N212595	001	Aug 29, 2019

SOLUTION;ORAL
RIOMET

+!	SUN PHARM INDS LTD	500MG/5ML		N021591	001	Sep 11, 2003

TABLET;ORAL
METFORMIN HYDROCHLORIDE

AB	ALKEM	**500MG**		**A091184**	**001**	Nov 01, 2010
AB		**850MG**		**A091184**	**002**	Nov 01, 2010
AB		**1GM**		**A091184**	**003**	Nov 01, 2010
AB	AMNEAL PHARMS NY	**500MG**		**A077880**	**001**	Jun 05, 2006
AB		**850MG**		**A077880**	**002**	Jun 05, 2006
AB		**1GM**		**A077880**	**003**	Jun 05, 2006
AB	APOTEX	**500MG**		**A075984**	**001**	Apr 23, 2002
AB		**500MG**		**A090666**	**001**	Dec 07, 2011
AB		**850MG**		**A075984**	**002**	Apr 23, 2002
AB		**850MG**		**A090666**	**002**	Dec 07, 2011
AB		**1GM**		**A075984**	**003**	Apr 23, 2002
AB		**1GM**		**A090666**	**003**	Dec 07, 2011
AB	ATLAS PHARMS LLC	**500MG**		**A076033**	**001**	Jan 24, 2002
AB		**850MG**		**A076033**	**002**	Jan 24, 2002
AB		**1GM**		**A076033**	**003**	Jan 24, 2002
AB	AUROBINDO	**500MG**		**A077095**	**001**	Jan 14, 2005
AB		**850MG**		**A077095**	**002**	Jan 14, 2005
AB		**1GM**		**A077095**	**003**	Jan 14, 2005
AB	CHARTWELL LIFE SCI	**500MG**		**A075972**	**001**	Jan 24, 2002
AB		**850MG**		**A075972**	**002**	Jan 24, 2002
AB		**1GM**		**A075972**	**003**	Jan 24, 2002
AB	CSPC OUYI	**500MG**		**A205096**	**001**	Jul 11, 2016
AB		**850MG**		**A205096**	**002**	Jul 11, 2016
AB		**1GM**		**A205096**	**003**	Jul 11, 2016
AB	DR REDDYS LABS INC	**500MG**		**A077787**	**001**	Aug 23, 2006
AB		**850MG**		**A077787**	**002**	Aug 23, 2006
AB		**1GM**		**A077787**	**003**	Aug 23, 2006
AB	GLENMARK GENERICS	**500MG**		**A078170**	**001**	May 23, 2008
AB		**850MG**		**A078170**	**002**	May 23, 2008
AB		**1GM**		**A078170**	**003**	May 23, 2008
AB	GRANULES INDIA	**500MG**		**A090564**	**001**	Apr 22, 2010
AB		**850MG**		**A090564**	**002**	Apr 22, 2010
AB !		**1GM**		**A090564**	**003**	Apr 22, 2010
AB	HERITAGE PHARMA	**500MG**		**A075978**	**001**	Jan 25, 2002
AB		**850MG**		**A075978**	**002**	Jan 25, 2002
AB		**1GM**		**A075978**	**003**	Nov 05, 2002
AB	INDICUS PHARMA	**500MG**		**A079148**	**001**	Nov 25, 2008
AB		**850MG**		**A079148**	**002**	Nov 25, 2008
AB		**1GM**		**A079148**	**003**	Nov 25, 2008
AB	LAURUS LABS LTD	**500MG**		**A209882**	**001**	Aug 27, 2018
AB		**850MG**		**A209882**	**002**	Aug 27, 2018
AB		**1GM**		**A209882**	**003**	Aug 27, 2018
AB	MACLEODS PHARMS LTD	**500MG**		**A205330**	**001**	Oct 31, 2017
AB		**850MG**		**A205330**	**002**	Oct 31, 2017
AB		**1GM**		**A205330**	**003**	Oct 31, 2017
AB	MARKSANS PHARMA	**500MG**		**A090888**	**001**	Mar 12, 2012
AB		**850MG**		**A090888**	**002**	Mar 12, 2012
AB		**1GM**		**A090888**	**003**	Mar 12, 2012
AB	MYLAN	**500MG**		**A075973**	**001**	Jan 25, 2002
AB		**500MG**		**A075976**	**001**	Jan 24, 2002
AB		**850MG**		**A075973**	**002**	Jan 25, 2002
AB		**850MG**		**A075976**	**002**	Jan 24, 2002
AB		**1GM**		**A075973**	**003**	Jan 25, 2002
AB		**1GM**		**A075976**	**003**	Jan 24, 2002
AB	SANDOZ	**500MG**		**A075965**	**001**	Jan 25, 2002
AB		**850MG**		**A075965**	**002**	Jan 25, 2002
AB		**1GM**		**A075965**	**003**	Jan 25, 2002
AB	SCIEGEN PHARMS INC	**500MG**		**A203769**	**001**	Sep 11, 2013
AB		**850MG**		**A203769**	**002**	Sep 11, 2013

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB			**1GM**	**A203769**	**003**	Sep 11, 2013
AB		SUN PHARM INDS INC	**500MG**	**A075967**	**001**	Jan 29, 2002
AB			**850MG**	**A075967**	**002**	Jan 29, 2002
AB			**1GM**	**A075967**	**003**	Jan 29, 2002
AB		TORRENT PHARMS	**500MG**	**A077711**	**001**	Jan 24, 2007
AB			**850MG**	**A077711**	**002**	Jan 24, 2007
AB			**1GM**	**A077711**	**003**	Jan 24, 2007
AB		ZYDUS HLTHCARE	**500MG**	**A203686**	**001**	Aug 28, 2014
AB			**850MG**	**A203686**	**002**	Aug 28, 2014
AB			**1GM**	**A203686**	**003**	Aug 28, 2014
AB		ZYDUS PHARMS USA	**500MG**	**A077064**	**001**	Apr 18, 2005
AB			**850MG**	**A077064**	**002**	Apr 18, 2005
AB			**1GM**	**A077064**	**003**	Apr 18, 2005
		CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
			750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**750MG**	**A076869**	**001**	Apr 12, 2005
AB		ALKEM LABS LTD	**750MG**	**A206145**	**002**	Oct 22, 2018
AB	!	AMNEAL PHARMS NY	**750MG**	**A078596**	**002**	Jan 03, 2008
AB		APOTEX	**750MG**	**A076706**	**002**	Dec 29, 2005
AB		AUROBINDO PHARMA LTD	**750MG**	**A079118**	**002**	Jul 20, 2012
AB		BARR	**750MG**	**A076863**	**001**	Oct 14, 2004
AB		BEXIMCO PHARMS USA	**750MG**	**A207427**	**002**	Dec 13, 2016
AB		CADILA	**750MG**	**A077078**	**001**	Apr 21, 2005
AB		CSPC OUYI	**750MG**	**A078321**	**002**	Apr 17, 2008
AB		GRANULES INDIA LTD	**750MG**	**A209313**	**002**	Mar 16, 2018
AB		INTELLIPHARMACEUTICS	**750MG**	**A202306**	**002**	Feb 23, 2017
AB		MACLEODS PHARMS LTD	**750MG**	**A206955**	**002**	Dec 07, 2016
AB		MARKSANS PHARMA	**750MG**	**A090295**	**002**	Apr 29, 2016
AB		NOSTRUM PHARMS LLC	**750MG**	**A076756**	**002**	Dec 12, 2011
AB		PRINSTON INC	**750MG**	**A208880**	**002**	Sep 10, 2018
AB		SUN PHARM INDS (IN)	**750MG**	**A077336**	**002**	Feb 09, 2006
AB		TEVA	**750MG**	**A076864**	**001**	Apr 12, 2005
AB1		ACTAVIS LABS FL INC	**500MG**	**A076172**	**001**	Jun 16, 2004
AB1		ALIGNSCIENCE PHARMA	**500MG**	**A209303**	**001**	Mar 19, 2018
AB1		ALKEM LABS LTD	**500MG**	**A206145**	**001**	Oct 22, 2018
AB1		AMNEAL PHARMS NY	**500MG**	**A078596**	**001**	Jan 03, 2008
AB1		APOTEX	**500MG**	**A076706**	**001**	Dec 14, 2004
AB1		AUROBINDO PHARMA LTD	**500MG**	**A079118**	**001**	Jul 20, 2012
AB1		BEXIMCO PHARMS USA	**500MG**	**A207427**	**001**	Dec 13, 2016
AB1		CADILA	**500MG**	**A077060**	**001**	Apr 20, 2005
AB1		CSPC OUYI	**500MG**	**A078321**	**001**	Apr 17, 2008
AB1		GRANULES INDIA LTD	**500MG**	**A209313**	**001**	Mar 16, 2018
AB1		INTELLIPHARMACEUTICS	**500MG**	**A202306**	**001**	Feb 23, 2017
AB1		INVENTIA	**500MG**	**A201991**	**001**	Jan 18, 2012
AB1		MACLEODS PHARMS LTD	**500MG**	**A206955**	**001**	Dec 07, 2016
AB1		MARKSANS PHARMA	**500MG**	**A090295**	**001**	Apr 29, 2016
AB1		NOSTRUM PHARMS LLC	**500MG**	**A076756**	**001**	Jul 26, 2006
AB1		PRINSTON INC	**500MG**	**A208880**	**001**	Sep 10, 2018
AB1		SANDOZ	**500MG**	**A076873**	**001**	Dec 14, 2004
AB1		SUN PHARM INDS (IN)	**500MG**	**A077336**	**001**	Feb 09, 2006
AB1		TEVA	**500MG**	**A076269**	**001**	Jun 18, 2004
AB1		TORRENT	**500MG**	**A090014**	**001**	Dec 30, 2009
AB2		LUPIN LTD	**500MG**	**A090692**	**001**	Jun 29, 2011
AB2	!		**1GM**	**A090692**	**002**	Jun 29, 2011
AB2		MYLAN PHARMS INC	**500MG**	**A200690**	**001**	Aug 01, 2012
AB2			**1GM**	**A200690**	**002**	Aug 01, 2012
AB2		NOSTRUM LABS INC	**500MG**	**A203832**	**001**	Dec 26, 2017
AB2			**1GM**	**A203832**	**002**	Dec 26, 2017
AB2		NOVAST LABS	**500MG**	**A209674**	**001**	Nov 02, 2018
AB2			**1GM**	**A209674**	**002**	Nov 02, 2018
AB2		QINGDAO BAHEAL PHARM	**500MG**	**A209993**	**001**	Dec 27, 2018
AB2			**1GM**	**A209993**	**002**	Dec 27, 2018

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GLUMETZA

AB3	+	SANTARUS INC	**500MG**	**N021748**	**001**	Jun 03, 2005
AB3	+!		**1GM**	**N021748**	**002**	Jun 03, 2005

METFORMIN HYDROCHLORIDE

AB3		ACTAVIS LABS FL INC	**500MG**	**A203755**	**001**	Aug 01, 2016
AB3			**1GM**	**A203755**	**002**	Aug 01, 2016
AB3		GLENMARK PHARMS LTD	**500MG**	**A212969**	**001**	Nov 25, 2019
AB3			**1GM**	**A212969**	**002**	Nov 25, 2019
AB3		LUPIN LTD	**500MG**	**A091664**	**001**	Jul 19, 2013
AB3			**1GM**	**A091664**	**002**	Jul 19, 2013
AB3		SUN PHARM	**500MG**	**A202917**	**001**	Aug 01, 2016
AB3			**1GM**	**A202917**	**002**	Aug 01, 2016

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

AB	+	TAKEDA PHARMS USA	**500MG;EQ 15MG BASE**	**N021842**	**001**	Aug 29, 2005
AB	+!		**850MG;EQ 15MG BASE**	**N021842**	**002**	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**500MG;EQ 15MG BASE**	**A200823**	**001**	Feb 13, 2013
AB			**850MG;EQ 15MG BASE**	**A200823**	**002**	Feb 13, 2013
AB		MACLEODS PHARMS LTD	**500MG;EQ 15MG BASE**	**A204802**	**001**	Nov 05, 2015
AB			**850MG;EQ 15MG BASE**	**A204802**	**002**	Nov 05, 2015
AB		SANDOZ	**500MG;EQ 15MG BASE**	**A091273**	**001**	Apr 16, 2013
AB			**850MG;EQ 15MG BASE**	**A091273**	**002**	Apr 16, 2013
AB		TEVA PHARMS USA	**500MG;EQ 15MG BASE**	**A091155**	**001**	Mar 10, 2014
AB			**850MG;EQ 15MG BASE**	**A091155**	**002**	Mar 10, 2014
AB		TORRENT PHARMS LTD	**500MG;EQ 15MG BASE**	**A202001**	**001**	Feb 13, 2013
AB			**850MG;EQ 15MG BASE**	**A202001**	**002**	Feb 13, 2013

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

+	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010
+		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
+!		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007
+!		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012
+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012
+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+!	METHAPHARM	100MG/VIAL	N019193	001	Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA		HIKMA	**10MG/ML**	**A040180**	**001**	Apr 30, 1998
AA		PHARM ASSOC	**10MG/ML**	**A207368**	**001**	Aug 22, 2019
AA		VISTAPHARM	**10MG/ML**	**A040088**	**001**	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

AA		HIKMA	**10MG/ML**	**A089897**	**001**	Sep 06, 1988

METHADOSE

AA	+!	SPECGX LLC	**10MG/ML**	**N017116**	**002**

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

AP		AKORN	**10MG/ML**	**A208306**	**001**	Oct 27, 2017
AP	+!	MYLAN INSTITUTIONAL	**10MG/ML**	**N021624**	**001**	

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA	!	HIKMA	**5MG/5ML**	**A087393**	**001**	
AA	!		**10MG/5ML**	**A087997**	**001**	Aug 30, 1982
AA		PHARM ASSOC	**5MG/5ML**	**A207537**	**001**	Oct 02, 2019

METHADONE HYDROCHLORIDE

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA			**10MG/5ML**	**A207537**	**002**	Oct 01, 2019
AA		VISTAPHARM	**5MG/5ML**	**A090707**	**001**	Jun 30, 2010
AA			**10MG/5ML**	**A090707**	**002**	Jun 30, 2010

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

AA	**+!**	HIKMA	**5MG**	**N006134**	**002**	
AA	**+!**		**10MG**	**N006134**	**010**	

METHADONE HYDROCHLORIDE

AA		ASCENT PHARMS INC	**5MG**	**A211228**	**001**	Jan 03, 2019
AA			**10MG**	**A211228**	**002**	Jan 03, 2019
AA		AUROLIFE PHARMA LLC	**5MG**	**A203502**	**001**	Aug 31, 2015
AA			**10MG**	**A203502**	**002**	Aug 31, 2015
AA		ELITE LABS INC	**5MG**	**A210484**	**001**	Aug 02, 2018
AA			**10MG**	**A210484**	**002**	Aug 02, 2018
AA		EPIC PHARMA LLC	**5MG**	**A090065**	**001**	Aug 18, 2015
AA			**10MG**	**A090065**	**002**	Aug 18, 2015
AA		SPECGX LLC	**5MG**	**A040517**	**001**	Apr 27, 2004
AA			**10MG**	**A040517**	**002**	Apr 27, 2004
AA		SUN PHARM INDUSTRIES	**5MG**	**A208305**	**001**	Mar 30, 2018
AA			**10MG**	**A208305**	**002**	Mar 30, 2018
AA		THEPHARMANETWORK LLC	**10MG**	**A090635**	**001**	Nov 25, 2009
AA		VISTAPHARM	**10MG**	**A040241**	**002**	May 29, 1998

METHADOSE

AA		SPECGX LLC	**5MG**	**A040050**	**001**	Apr 15, 1993
AA			**10MG**	**A040050**	**002**	Apr 15, 1993

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	**+!**	HIKMA	**40MG**	**N017058**	**001**	
AA		SPECGX LLC	**40MG**	**A077142**	**001**	Jul 12, 2005
AA		VISTAPHARM	**40MG**	**A075082**	**001**	Mar 25, 1998

METHADOSE

AA		SPECGX LLC	**40MG**	**A074184**	**001**	Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

AA	**+!**	RECORDATI RARE	**5MG**	**N005378**	**002**	

METHAMPHETAMINE HYDROCHLORIDE

AA		HIKMA	**5MG**	**A203846**	**001**	Nov 17, 2015
AA		MAYNE PHARMA INC	**5MG**	**A091189**	**001**	Apr 21, 2010

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB		ANI PHARMS INC	**25MG**	**A040001**	**001**	Jun 30, 1993
AB			**50MG**	**A040001**	**002**	Jun 30, 1993
AB		MIKART	**25MG**	**A040062**	**001**	Jan 27, 1994
AB	**!**		**50MG**	**A040062**	**002**	Jan 27, 1994
AB		SANDOZ	**25MG**	**A040036**	**001**	Jun 30, 1993
AB			**50MG**	**A040036**	**002**	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	**+!**	US PHARM HOLDINGS	**1GM**	**N017681**	**001**	

METHENAMINE HIPPURATE

AB		AUROBINDO PHARMA LTD	**1GM**	**A205661**	**001**	Jul 05, 2016
AB		IMPAX LABS INC	**1GM**	**A076411**	**001**	Jun 20, 2003
AB		MICRO LABS	**1GM**	**A212172**	**001**	Aug 01, 2019

UREX

AB		CNTY LINE PHARMS	**1GM**	**N016151**	**001**	

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		CASI PHARMS INC	**5MG**	**A040411**	**001**	Mar 27, 2001
AB			**10MG**	**A040411**	**002**	Mar 27, 2001
AB		ECI PHARMS LLC	**5MG**	**A040547**	**001**	Feb 18, 2005
AB			**10MG**	**A040547**	**002**	Feb 18, 2005

METHIMAZOLE						
TABLET;ORAL						
METHIMAZOLE						
AB		HERITAGE PHARMA	**5MG**	**A040734**	**001**	Dec 14, 2007
AB			**10MG**	**A040734**	**002**	Dec 14, 2007
AB		MYLAN	**5MG**	**A040350**	**001**	Mar 29, 2000
AB	!		**10MG**	**A040350**	**002**	Mar 29, 2000
AB		RISING	**5MG**	**A202068**	**001**	Mar 07, 2012
AB			**10MG**	**A202068**	**002**	Mar 07, 2012
TAPAZOLE						
AB		KING PHARMS LLC	**5MG**	**A040320**	**001**	Mar 31, 2000
AB			**10MG**	**A040320**	**002**	Mar 31, 2000
METHOCARBAMOL						
SOLUTION;IM-IV						
METHOCARBAMOL						
AP		AM REGENT	**1GM/10ML (100MG/ML)**	**A207496**	**001**	Jun 22, 2017
AP		AUROBINDO PHARMA LTD	**1GM/10ML (100MG/ML)**	**A206128**	**001**	May 27, 2016
AP		FRESENIUS KABI USA	**1GM/10ML (100MG/ML)**	**A209331**	**001**	Apr 17, 2018
AP		GLAND PHARMA LTD	**1GM/10ML (100MG/ML)**	**A211504**	**001**	Oct 26, 2018
AP		MONTEREY PHARMS LLC	**1GM/10ML (100MG/ML)**	**A205354**	**001**	Oct 27, 2016
AP		MYLAN INSTITUTIONAL	**1GM/10ML (100MG/ML)**	**A204404**	**001**	Dec 05, 2014
AP		NAVINTA LLC	**1GM/10ML (100MG/ML)**	**A206071**	**001**	Nov 24, 2017
AP		SAGENT PHARMS INC	**1GM/10ML (100MG/ML)**	**A205404**	**001**	Jul 18, 2017
AP		SLATE	**1GM/10ML (100MG/ML)**	**A208116**	**001**	Jan 19, 2017
AP		SOMERSET THERAPS LLC	**1GM/10ML (100MG/ML)**	**A207522**	**001**	Jul 31, 2017
ROBAXIN						
AP	+!	HIKMA	**1GM/10ML (100MG/ML)**	**N011790**	**001**	
TABLET;ORAL						
METHOCARBAMOL						
AA		AUSTARPHARMA LLC	**500MG**	**A200958**	**001**	Oct 21, 2011
AA			**750MG**	**A200958**	**002**	Oct 21, 2011
AA		BEXIMCO PHARMS USA	**500MG**	**A208507**	**001**	Jul 21, 2017
AA			**750MG**	**A208507**	**002**	Jul 21, 2017
AA		DBL PHARMS	**500MG**	**A203550**	**001**	Feb 08, 2017
AA			**750MG**	**A203550**	**002**	Feb 08, 2017
AA	!	GRANULES INDIA LTD	**500MG**	**A209312**	**001**	May 07, 2018
AA			**750MG**	**A209312**	**002**	May 07, 2018
AA		HETERO LABS LTD III	**500MG**	**A090200**	**001**	Nov 06, 2009
AA			**750MG**	**A090200**	**002**	Nov 06, 2009
AA		HIKMA INTL PHARMS	**500MG**	**A085159**	**001**	
AA			**750MG**	**A085123**	**001**	
AA		OXFORD PHARMS	**500MG**	**A040489**	**001**	Jan 29, 2003
AA			**750MG**	**A040489**	**002**	Jan 29, 2003
AA		PRINSTON INC	**500MG**	**A086989**	**001**	
AA			**750MG**	**A086988**	**001**	
ROBAXIN-750						
AA	+!	AUXILIUM PHARMS LLC	**750MG**	**N011011**	**006**	
METHOHEXITAL SODIUM						
INJECTABLE;INJECTION						
BREVITAL SODIUM						
	+!	PAR STERILE PRODUCTS	500MG/VIAL	N011559	001	
	+!		2.5GM/VIAL	N011559	002	
METHOTREXATE						
SOLUTION;SUBCUTANEOUS						
OTREXUP						
	+!	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
	+!		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016
	+!		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
	+!		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016
	+!		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013
	+!		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016
	+!		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013
RASUVO						
	+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
	+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
	+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
	+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
	+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014

METHOTREXATE						
SOLUTION;SUBCUTANEOUS						
RASUVO						
	+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
	+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
	+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
	+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014
REDITREX						
		CUMBERLAND PHARMS	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019
			10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019
			12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019
			15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019
			17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019
			20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019
			22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019
			25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019
METHOTREXATE SODIUM						
INJECTABLE;INJECTION						
METHOTREXATE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	**EQ 25MG BASE/ML**	**A040265**	**001**	Feb 26, 1999
AP			**EQ 1GM BASE/VIAL**	**A040266**	**001**	Feb 26, 1999
METHOTREXATE SODIUM						
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040263**	**001**	Feb 26, 1999
AP	**+!**	HOSPIRA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**N011719**	**010**	Dec 15, 2004
AP	**!**	WEST-WARD PHARMS INT	**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A089341**	**001**	Sep 16, 1986
METHOTREXATE SODIUM PRESERVATIVE FREE						
AP	**!**	ACCORD HLTHCARE	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040767**	**001**	Apr 30, 2007
AP	**!**		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040768**	**001**	Apr 30, 2007
AP	**!**		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040716**	**001**	Apr 30, 2007
AP	**+!**	HOSPIRA	**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**N011719**	**012**	Apr 13, 2005
AP		MYLAN LABS LTD	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A201529**	**001**	Mar 29, 2012
AP			**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A201529**	**002**	Mar 29, 2012
AP			**EQ 200MG BASE/8ML (EQ 25MG BASE/ML)**	**A201529**	**003**	Mar 29, 2012
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A201529**	**004**	Mar 29, 2012
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A201530**	**001**	Mar 29, 2012
AP		PHARMACHEMIE BV	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040843**	**002**	Jan 11, 2010
AP			**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A040843**	**003**	Feb 27, 2012
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040843**	**004**	Jan 11, 2010
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040843**	**001**	Jan 11, 2010
AP		SAGENT PHARMS INC	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A203407**	**001**	Aug 09, 2018
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A203407**	**002**	Aug 09, 2018
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A203407**	**003**	Aug 09, 2018
AP		SANDOZ INC	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A090039**	**001**	Mar 31, 2009
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A090039**	**002**	Mar 31, 2009
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A090029**	**001**	Mar 31, 2009
AP	**!**	WEST-WARD PHARMS INT	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A089340**	**001**	Sep 16, 1986
AP	**!**		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A089343**	**001**	Sep 16, 1986
METHOTREXATE SODIUM						
	!	WEST-WARD PHARMS INT	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
METHOTREXATE SODIUM PRESERVATIVE FREE						
	!	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005
SOLUTION;ORAL						
XATMEP						
	+!	SILVERGATE PHARMS	EQ 2MG BASE/ML	N208400	001	Apr 25, 2017
TABLET;ORAL						
METHOTREXATE SODIUM						
AB		AMNEAL PHARMS	**EQ 2.5MG BASE**	**A210040**	**001**	Dec 22, 2017
AB		BARR	**EQ 2.5MG BASE**	**A081099**	**001**	Oct 15, 1990
AB	**+!**	DAVA PHARMS INC	**EQ 2.5MG BASE**	**N008085**	**002**	
AB		HIKMA	**EQ 2.5MG BASE**	**A040054**	**001**	Aug 01, 1994
AB		MYLAN	**EQ 2.5MG BASE**	**A081235**	**001**	May 15, 1992
AB		SUN PHARM	**EQ 2.5MG BASE**	**A201749**	**001**	May 21, 2015
AB		ZYDUS PHARMS	**EQ 2.5MG BASE**	**A207812**	**001**	Jan 13, 2017
TREXALL						
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	!		EQ 15MG BASE	A040385	004	Mar 21, 2001

METHOXSALEN

CAPSULE;ORAL

METHOXSALEN

AB		ACTAVIS INC	**10MG**	**A202603**	**001**	Jun 09, 2015
AB		STRIDES PHARMA	**10MG**	**A202687**	**001**	Jun 05, 2014

OXSORALEN-ULTRA

AB	**+!**	BAUSCH	**10MG**	**N019600**	**001**	Oct 30, 1986

INJECTABLE;INJECTION

UVADEX

	+!	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

		BAYSHORE PHARMS LLC	2.5MG	A200602	001	Sep 24, 2012
	!		5MG	A200602	002	Sep 24, 2012

METHSUXIMIDE

CAPSULE;ORAL

CELONTIN

	+!	PARKE DAVIS	300MG	N010596	008	

METHYLDOPA

TABLET;ORAL

METHYLDOPA

AB		ACCORD HLTHCARE	**250MG**	**A070084**	**001**	Oct 15, 1985
AB			**500MG**	**A070085**	**001**	Oct 15, 1985
AB		HERITAGE PHARMA	**250MG**	**A070098**	**001**	Feb 20, 1986
AB			**500MG**	**A070343**	**001**	Feb 20, 1986
AB		MYLAN	**250MG**	**A070076**	**002**	Apr 18, 1985
AB	**!**		**500MG**	**A070076**	**001**	Apr 18, 1985
AB		WATSON LABS	**500MG**	**A070625**	**001**	Jun 06, 1986

METHYLENE BLUE

SOLUTION;INTRAVENOUS

PROVAYBLUE

	+!	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016

METHYLERGONOVINE MALEATE

INJECTABLE;INJECTION

METHERGINE

AP	**+!**	EDISON THERAPS LLC	**0.2MG/ML**	**N006035**	**004**	

METHYLERGONOVINE MALEATE

AP		BRECKENRIDGE	**0.2MG/ML**	**A040889**	**001**	Sep 13, 2010
AP		LUITPOLD	**0.2MG/ML**	**A090193**	**001**	Nov 24, 2008

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB		AMNEAL PHARMS	**0.2MG**	**A211483**	**001**	Sep 10, 2018
AB		GRANULES PHARMS	**0.2MG**	**A210424**	**001**	May 15, 2018
AB	**!**	NOVEL LABS INC	**0.2MG**	**A091577**	**001**	May 02, 2011
AB		TEVA PHARMS USA	**0.2MG**	**A211455**	**001**	Mar 20, 2019

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS

RELISTOR

	+!	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010

TABLET;ORAL

RELISTOR

	+!	SALIX	150MG	N208271	001	Jul 19, 2016

METHYLPHENIDATE

FILM, EXTENDED RELEASE;TRANSDERMAL

DAYTRANA

	+	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006
	+		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006
	+		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006
	+!		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT

	+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017
	+		17.3MG	N205489	002	Jun 19, 2017
	+		25.9MG	N205489	003	Jun 19, 2017

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE							
AB1		BARR LABS INC	**10MG**	**A079031**	**004**	Oct 15, 2014
AB1			**20MG**	**A079031**	**001**	Jul 13, 2012
AB1			**30MG**	**A079031**	**002**	Jul 13, 2012
AB1			**40MG**	**A079031**	**003**	Jul 13, 2012
AB1		GRANULES PHARMS	**10MG**	**A211796**	**001**	May 23, 2019
AB1			**20MG**	**A211796**	**002**	May 23, 2019
AB1			**30MG**	**A211796**	**003**	May 23, 2019
AB1			**40MG**	**A211796**	**004**	May 23, 2019
AB1			**60MG**	**A211796**	**005**	May 23, 2019
AB1		MAYNE PHARMA	**10MG**	**A200886**	**001**	Feb 26, 2018
AB1			**20MG**	**A078458**	**001**	Dec 01, 2011
AB1			**30MG**	**A078458**	**002**	Dec 01, 2011
AB1			**40MG**	**A078458**	**003**	Dec 01, 2011
AB1	!		**60MG**	**A078458**	**004**	Jun 23, 2016
RITALIN LA							
AB1	+	NOVARTIS	**10MG**	**N021284**	**004**	Apr 10, 2004
AB1	+		**20MG**	**N021284**	**001**	Jun 05, 2002
AB1	+		**30MG**	**N021284**	**002**	Jun 05, 2002
AB1	+		**40MG**	**N021284**	**003**	Jun 05, 2002
METADATE CD							
AB2	+	LANNETT CO INC	**10MG**	**N021259**	**003**	May 27, 2003
AB2	+		**20MG**	**N021259**	**001**	Apr 03, 2001
AB2	+		**30MG**	**N021259**	**002**	Jun 19, 2003
AB2	+		**40MG**	**N021259**	**004**	Feb 19, 2006
AB2	+		**50MG**	**N021259**	**005**	Feb 19, 2006
AB2	+!		**60MG**	**N021259**	**006**	Feb 19, 2006
METHYLPHENIDATE HYDROCHLORIDE							
AB2		IMPAX LABS INC	**10MG**	**A205105**	**001**	Jul 28, 2016
AB2			**20MG**	**A205105**	**002**	Jul 28, 2016
AB2			**30MG**	**A205105**	**003**	Jul 28, 2016
AB2			**40MG**	**A205105**	**004**	Jul 28, 2016
AB2			**50MG**	**A205105**	**005**	Jul 28, 2016
AB2			**60MG**	**A205105**	**006**	Jul 28, 2016
AB2		SPECGX LLC	**10MG**	**A203583**	**001**	Sep 29, 2015
AB2			**20MG**	**A203583**	**002**	Sep 29, 2015
AB2			**30MG**	**A203583**	**003**	Sep 29, 2015
AB2			**40MG**	**A203583**	**004**	Sep 29, 2015
AB2			**50MG**	**A203583**	**005**	Sep 29, 2015
AB2			**60MG**	**A203583**	**006**	Sep 29, 2015
AB2		TEVA PHARMS	**10MG**	**A077707**	**001**	Jul 19, 2012
AB2			**20MG**	**A077707**	**002**	Jul 19, 2012
AB2			**30MG**	**A077707**	**003**	Jul 19, 2012
AB2			**40MG**	**A078873**	**001**	Jul 19, 2012
AB2			**50MG**	**A078873**	**002**	Jul 19, 2012
AB2			**60MG**	**A078873**	**003**	Jul 19, 2012
APTENSIO XR							
AB3	+	RHODES PHARMS	**10MG**	**N205831**	**001**	Apr 17, 2015
AB3	+		**15MG**	**N205831**	**002**	Apr 17, 2015
AB3	+		**20MG**	**N205831**	**003**	Apr 17, 2015
AB3	+		**30MG**	**N205831**	**004**	Apr 17, 2015
AB3	+		**40MG**	**N205831**	**005**	Apr 17, 2015
AB3	+		**50MG**	**N205831**	**006**	Apr 17, 2015
AB3	+!		**60MG**	**N205831**	**007**	Apr 17, 2015
METHYLPHENIDATE HYDROCHLORIDE							
AB3		ACTAVIS ELIZABETH	**10MG**	**A208861**	**001**	Dec 13, 2018
AB3			**15MG**	**A208861**	**002**	Dec 13, 2018
AB3			**20MG**	**A208861**	**003**	Dec 13, 2018
AB3			**30MG**	**A208861**	**004**	Dec 13, 2018
AB3			**40MG**	**A208861**	**005**	Dec 13, 2018
AB3			**50MG**	**A208861**	**006**	Dec 13, 2018
AB3			**60MG**	**A208861**	**007**	Dec 13, 2018
ADHANSIA XR							
	+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019
	+		35MG	N212038	002	Feb 27, 2019
	+		45MG	N212038	003	Feb 27, 2019
	+		55MG	N212038	004	Feb 27, 2019
	+		70MG	N212038	005	Feb 27, 2019
	+		85MG	N212038	006	Feb 27, 2019

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

JORNAY PM

	+	IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018
	+		40MG	N209311	002	Aug 08, 2018
	+		60MG	N209311	003	Aug 08, 2018
	+		80MG	N209311	004	Aug 08, 2018
	+		100MG	N209311	005	Aug 08, 2018

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

	+!	NEXTWAVE	5MG/ML	N202100	001	Sep 27, 2012

SOLUTION;ORAL

METHYLIN

AA	**+!**	SPECGX LLC	**5MG/5ML**	**N021419**	**001**	Dec 19, 2002
AA	**+!**		**10MG/5ML**	**N021419**	**002**	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

AA		ABHAI LLC	**5MG/5ML**	**A207485**	**001**	Nov 18, 2016
AA			**10MG/5ML**	**A207485**	**002**	Nov 18, 2016
AA		BRECKENRIDGE	**5MG/5ML**	**A201466**	**001**	Nov 12, 2013
AA			**10MG/5ML**	**A201466**	**002**	Nov 12, 2013
AA		NOVEL LABS INC	**5MG/5ML**	**A204602**	**001**	Aug 14, 2015
AA			**10MG/5ML**	**A204602**	**002**	Aug 14, 2015
AA		NOVELGENIX THERAPS	**5MG/5ML**	**A210139**	**001**	Oct 03, 2018
AA			**10MG/5ML**	**A210139**	**002**	Oct 03, 2018
AA		TRIS PHARMA INC	**5MG/5ML**	**A091601**	**001**	Jul 23, 2010
AA			**10MG/5ML**	**A091601**	**002**	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	**5MG**	**A206932**	**001**	May 11, 2017
AB			**10MG**	**A206932**	**002**	May 11, 2017
AB			**20MG**	**A206932**	**003**	May 11, 2017
AB		ACTAVIS LABS FL INC	**5MG**	**A040220**	**001**	Aug 29, 1997
AB			**10MG**	**A040220**	**002**	Aug 29, 1997
AB			**20MG**	**A040220**	**003**	Aug 29, 1997
AB		ALKEM LABS LTD	**5MG**	**A211779**	**001**	Oct 04, 2019
AB			**10MG**	**A211779**	**002**	Oct 04, 2019
AB			**20MG**	**A211779**	**003**	Oct 04, 2019
AB		ASCENT PHARMS INC	**5MG**	**A207416**	**001**	Sep 22, 2015
AB			**10MG**	**A207416**	**002**	Sep 22, 2015
AB			**20MG**	**A207416**	**003**	Sep 22, 2015
AB		BIONPHARMA INC	**5MG**	**A209753**	**001**	Mar 02, 2018
AB			**10MG**	**A209753**	**002**	Mar 02, 2018
AB			**20MG**	**A209753**	**003**	Mar 02, 2018
AB		BRECKENRIDGE	**5MG**	**A207587**	**001**	Mar 03, 2017
AB			**10MG**	**A207587**	**002**	Mar 03, 2017
AB			**20MG**	**A207587**	**003**	Mar 03, 2017
AB		MOUNTAIN	**5MG**	**A091159**	**001**	Mar 12, 2014
AB			**10MG**	**A091159**	**002**	Mar 12, 2014
AB			**20MG**	**A091159**	**003**	Mar 12, 2014
AB		NOVEL LABS INC	**5MG**	**A207884**	**001**	Nov 13, 2015
AB			**10MG**	**A207884**	**002**	Nov 13, 2015
AB			**20MG**	**A207884**	**003**	Nov 13, 2015
AB		OXFORD PHARMS	**5MG**	**A202892**	**001**	Sep 23, 2014
AB			**10MG**	**A202892**	**002**	Sep 23, 2014
AB			**20MG**	**A202892**	**003**	Sep 23, 2014
AB		SPECGX LLC	**5MG**	**A040300**	**001**	Nov 27, 1998
AB			**10MG**	**A040300**	**002**	Nov 27, 1998
AB			**20MG**	**A040300**	**003**	Nov 27, 1998
AB		SUN PHARM INDS INC	**5MG**	**A090710**	**001**	Mar 15, 2012
AB			**10MG**	**A090710**	**002**	Mar 15, 2012
AB			**20MG**	**A090710**	**003**	Mar 15, 2012

RITALIN

AB	**+**	NOVARTIS	**5MG**	**N010187**	**003**	
AB	**+**		**10MG**	**N010187**	**006**	
AB	**+!**		**20MG**	**N010187**	**010**	

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**2.5MG**	**A210354**	**001**	Dec 29, 2017
AB			**5MG**	**A210354**	**002**	Dec 29, 2017
AB			**10MG**	**A210354**	**003**	Dec 29, 2017
AB		BRECKENRIDGE	**2.5MG**	**A204954**	**001**	Jan 26, 2017
AB			**5MG**	**A204954**	**002**	Jan 26, 2017

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB			**10MG**	**A204954**	**003**	Jan 26, 2017
AB		NOVEL LABS INC	**2.5MG**	**A204115**	**001**	Feb 25, 2015
AB			**5MG**	**A204115**	**002**	Feb 25, 2015
AB	**!**		**10MG**	**A204115**	**003**	Feb 25, 2015
AB		RISING	**2.5MG**	**A205756**	**001**	Nov 07, 2016
AB			**5MG**	**A205756**	**002**	Nov 07, 2016
AB			**10MG**	**A205756**	**003**	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

AB	**+**	JANSSEN PHARMS	**18MG**	**N021121**	**001**	Aug 01, 2000
AB	**+**		**27MG**	**N021121**	**004**	Apr 01, 2002
AB	**+**		**36MG**	**N021121**	**002**	Aug 01, 2000
AB	**+!**		**54MG**	**N021121**	**003**	Dec 08, 2000

METHYLIN ER

AB		SPECGX LLC	**10MG**	**A075629**	**001**	May 09, 2000
AB			**20MG**	**A075629**	**002**	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI LLC	**10MG**	**A207488**	**001**	Jun 09, 2015
AB	**!**		**20MG**	**A207488**	**002**	Jun 09, 2015
AB		ACTAVIS LABS FL	**18MG**	**A076772**	**001**	Mar 22, 2018
AB			**27MG**	**A076772**	**002**	Mar 22, 2018
AB			**36MG**	**A076772**	**003**	Mar 22, 2018
AB			**54MG**	**A076655**	**001**	Mar 21, 2018
AB		ALVOGEN PINE BROOK	**18MG**	**A210818**	**001**	Nov 30, 2018
AB			**27MG**	**A210818**	**002**	Nov 30, 2018
AB			**36MG**	**A210818**	**003**	Nov 30, 2018
AB			**54MG**	**A210818**	**004**	Nov 30, 2018
AB		AMNEAL PHARMS	**18MG**	**A207515**	**001**	Feb 01, 2018
AB			**27MG**	**A207515**	**002**	Feb 01, 2018
AB			**36MG**	**A207515**	**003**	Feb 01, 2018
AB			**54MG**	**A207515**	**004**	Feb 01, 2018
AB		ANDOR PHARMS	**18MG**	**A211918**	**001**	Apr 24, 2019
AB			**27MG**	**A211918**	**002**	Apr 24, 2019
AB			**36MG**	**A211918**	**003**	Apr 24, 2019
AB			**54MG**	**A211918**	**004**	Apr 24, 2019
AB		ANI PHARMS INC	**18MG**	**A208607**	**001**	Jul 14, 2017
AB			**27MG**	**A208607**	**002**	Jul 14, 2017
AB			**36MG**	**A208607**	**003**	Jul 14, 2017
AB			**54MG**	**A208607**	**004**	Jul 14, 2017
AB		ASCENT PHARMS INC	**18MG**	**A211009**	**001**	Sep 03, 2019
AB			**27MG**	**A211009**	**002**	Sep 03, 2019
AB			**36MG**	**A211009**	**003**	Sep 03, 2019
AB			**54MG**	**A211009**	**004**	Sep 03, 2019
AB		CNTY LINE PHARMS	**10MG**	**A204772**	**001**	Feb 29, 2016
AB			**20MG**	**A204772**	**002**	Feb 29, 2016
AB		GRANULES PHARMS	**10MG**	**A210992**	**001**	Nov 21, 2018
AB			**20MG**	**A210992**	**002**	Nov 21, 2018
AB		MYLAN	**18MG**	**A206726**	**001**	Oct 21, 2016
AB			**27MG**	**A206726**	**002**	Oct 21, 2016
AB			**36MG**	**A206726**	**003**	Oct 21, 2016
AB			**54MG**	**A206726**	**004**	Oct 21, 2016
AB		OSMOTICA	**18MG**	**A205327**	**001**	Jul 28, 2017
AB			**27MG**	**A205327**	**002**	Jul 28, 2017
AB			**36MG**	**A205327**	**003**	Jul 28, 2017
AB			**54MG**	**A205327**	**004**	Jul 28, 2017
BX		LANNETT CO INC	18MG	A091695	001	Jul 09, 2013
BX			27MG	A091695	002	Jul 09, 2013
BX			36MG	A091695	003	Sep 23, 2013
BX			54MG	A091695	004	Sep 23, 2013
BX		SPECGX LLC	27MG	A202608	001	Dec 28, 2012
BX			36MG	A202608	002	Dec 28, 2012
BX			54MG	A202608	003	Dec 28, 2012
	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER

	+	NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015
	+		30MG	N207960	002	Dec 04, 2015
	+!		40MG	N207960	003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	+	PHARMACIA AND UPJOHN	**2MG**	**N011153**	**002**		
AB	+		**4MG**	**N011153**	**001**		
AB	+		**8MG**	**N011153**	**004**		
AB	+		**16MG**	**N011153**	**003**		
AB	+!		**32MG**	**N011153**	**006**		

METHYLPREDNISOLONE

AB	DURAMED PHARMS BARR	**4MG**	**A088497**	**001**	Feb 21, 1984
AB	JUBILANT CADISTA	**4MG**	**A040189**	**001**	Oct 31, 1997
AB		**8MG**	**A040189**	**002**	Oct 31, 1997
AB		**16MG**	**A040189**	**003**	Jul 20, 2007
AB		**32MG**	**A040189**	**004**	Jul 20, 2007
AB	SANDOZ	**4MG**	**A040194**	**001**	Oct 31, 1997
AB	SUNGEN PHARMA	**4MG**	**A212262**	**001**	Jun 27, 2019
AB	TIANJIN TIANYAO	**4MG**	**A204072**	**001**	May 14, 2018
AB	VINTAGE PHARMS	**4MG**	**A040183**	**001**	Dec 22, 1998
AB	WATSON LABS	**4MG**	**A040232**	**001**	Oct 16, 1997
AB	ZYDUS PHARMS	**4MG**	**A206751**	**001**	Apr 23, 2018
AB		**8MG**	**A206751**	**002**	Apr 23, 2018
AB		**16MG**	**A206751**	**003**	Apr 23, 2018
AB		**32MG**	**A206751**	**004**	Apr 23, 2018

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

AB	+!	PHARMACIA AND UPJOHN	**20MG/ML**	**N011757**	**002**		
AB	+!		**40MG/ML**	**N011757**	**001**		
AB	+!		**80MG/ML**	**N011757**	**004**		

METHYLPREDNISOLONE ACETATE

AB	SAGENT PHARMS INC	**20MG/ML**	**A201835**	**001**	Jun 27, 2018
AB		**40MG/ML**	**A201835**	**002**	Jun 27, 2018
AB		**80MG/ML**	**A201835**	**003**	Jun 27, 2018
AB	SANDOZ INC	**40MG/ML**	**A040719**	**001**	Jan 29, 2009
AB		**40MG/ML**	**A040794**	**001**	Mar 05, 2009
AB		**80MG/ML**	**A040719**	**002**	Jan 29, 2009
AB		**80MG/ML**	**A040794**	**002**	Mar 05, 2009
AB	TEVA PHARMS USA	**40MG/ML**	**A040557**	**001**	Feb 23, 2005
AB		**40MG/ML**	**A040620**	**001**	Oct 27, 2006
AB		**80MG/ML**	**A040557**	**002**	Feb 23, 2005
AB		**80MG/ML**	**A040620**	**002**	Oct 27, 2006

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	AMNEAL	**EQ 40MG BASE/VIAL**	**A207549**	**001**	Nov 09, 2016
AP		**EQ 125MG BASE/VIAL**	**A207549**	**002**	Nov 09, 2016
AP	AUROBINDO PHARMA LTD	**EQ 40MG BASE/VIAL**	**A207667**	**001**	Dec 15, 2015
AP		**EQ 125MG BASE/VIAL**	**A207667**	**002**	Dec 15, 2015
AP		**EQ 500MG BASE/VIAL**	**A207667**	**003**	Dec 15, 2015
AP		**EQ 2GM BASE/VIAL**	**A207667**	**004**	Dec 15, 2015
AP	FRESENIUS KABI USA	**EQ 40MG BASE/VIAL**	**A040583**	**001**	Jul 30, 2004
AP		**EQ 125MG BASE/VIAL**	**A040583**	**002**	Jul 30, 2004
AP		**EQ 1GM BASE/VIAL**	**A040612**	**001**	Aug 12, 2004
AP	HIKMA	**EQ 500MG BASE/VIAL**	**A202691**	**001**	Feb 16, 2016
AP		**EQ 1GM BASE/VIAL**	**A202691**	**002**	Feb 16, 2016
AP	SAGENT PHARMS INC	**EQ 40MG BASE/VIAL**	**A040888**	**001**	Jul 18, 2011
AP		**EQ 125MG BASE/VIAL**	**A040888**	**002**	Jul 18, 2011
AP		**EQ 500MG BASE/VIAL**	**A040888**	**003**	Jul 18, 2011
AP		**EQ 1GM BASE/VIAL**	**A040888**	**004**	Jul 18, 2011
AP		**EQ 2GM BASE/VIAL**	**A040888**	**005**	Jul 18, 2011

SOLU-MEDROL

AP	+!	PHARMACIA AND UPJOHN	**EQ 40MG BASE/VIAL**	**N011856**	**003**		
AP	+!		**EQ 125MG BASE/VIAL**	**N011856**	**004**		
AP	+!		**EQ 500MG BASE/VIAL**	**N011856**	**005**		
AP	+!		**EQ 1GM BASE/VIAL**	**N011856**	**006**		
AP	+!		**EQ 2GM BASE/VIAL**	**N011856**	**007**	Feb 27, 1985	

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

AB		IMPAX LABS INC	**10MG**	**A204851**	**001**	Sep 21, 2015

TESTRED

AB	**!**	VALEANT PHARM INTL	**10MG**	**A083976**	**001**	

TABLET;ORAL

ANDROID 25

BP		VALEANT PHARM INTL	25MG	A087147	001	

METHYLTESTOSTERONE

BP		IMPAX LABS	10MG	A080767	002	

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE

AP		EMCURE PHARMS LTD	**EQ 5MG BASE/ML**	**A204756**	**001**	Dec 20, 2013

METOCLOPRAMIDE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 5MG BASE/ML**	**A091392**	**001**	Apr 19, 2013
AP	**!**	HOSPIRA	**EQ 5MG BASE/ML**	**A073118**	**001**	Jan 17, 1991
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A073135**	**001**	Nov 27, 1991

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA		ANI PHARMS	**EQ 5MG BASE/5ML**	**A071402**	**001**	Jun 25, 1993
AA		PHARM ASSOC	**EQ 5MG BASE/5ML**	**A072744**	**001**	May 28, 1991
AA		VISTAPHARM	**EQ 5MG BASE/5ML**	**A075051**	**001**	Jan 26, 2001
AA	**!**	WOCKHARDT BIO AG	**EQ 5MG BASE/5ML**	**A074703**	**001**	Oct 31, 1997

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB		IMPAX LABS INC	**EQ 5MG BASE**	**A071250**	**002**	Dec 28, 1995
AB			**EQ 10MG BASE**	**A071250**	**001**	Feb 03, 1988
AB		IPCA LABS LTD	**EQ 5MG BASE**	**A078807**	**001**	Jun 12, 2008
AB			**EQ 10MG BASE**	**A078807**	**002**	Jun 12, 2008
AB		PAR PHARM INC	**EQ 10MG BASE**	**A070581**	**001**	Oct 17, 1985
AB		TEVA	**EQ 5MG BASE**	**A072801**	**001**	Jun 15, 1993
AB			**EQ 10MG BASE**	**A070184**	**001**	Jul 29, 1985
AB		VINTAGE PHARMS	**EQ 5MG BASE**	**A077878**	**001**	Aug 28, 2006
AB			**EQ 10MG BASE**	**A077878**	**002**	Aug 28, 2006

REGLAN

AB	**+**	ANI PHARMS	**EQ 5MG BASE**	**N017854**	**002**	May 05, 1987
AB	**+!**		**EQ 10MG BASE**	**N017854**	**001**	

TABLET, ORALLY DISINTEGRATING;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

		NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014
	!		EQ 10MG BASE	A202191	002	Aug 15, 2014

METOLAZONE

TABLET;ORAL

METOLAZONE

AB		MYLAN	**2.5MG**	**A076698**	**001**	Dec 23, 2003
AB			**5MG**	**A076698**	**002**	Oct 19, 2004
AB			**10MG**	**A076698**	**003**	Oct 19, 2004
AB		SANDOZ	**2.5MG**	**A076732**	**001**	Dec 19, 2003
AB			**5MG**	**A076466**	**001**	Dec 19, 2003
AB			**10MG**	**A076466**	**002**	Dec 19, 2003

ZAROXOLYN

AB	**+**	LANNETT CO INC	**2.5MG**	**N017386**	**001**	
AB	**+!**		**5MG**	**N017386**	**002**	
AB	**+!**		**10MG**	**N017386**	**003**	

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE

	+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018
	+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018
	+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018
	+!		EQ 200MG TARTRATE	N210428	004	Jan 26, 2018

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB		ACTAVIS ELIZABETH	**EQ 25MG TARTRATE**	**A204161**	**001**	Nov 25, 2016
AB			**EQ 50MG TARTRATE**	**A204161**	**002**	Nov 25, 2016
AB			**EQ 100MG TARTRATE**	**A204161**	**003**	Nov 25, 2016
AB			**EQ 200MG TARTRATE**	**A204161**	**004**	Nov 25, 2016
AB		ACTAVIS LABS FL INC	**EQ 25MG TARTRATE**	**A076862**	**002**	Aug 03, 2009
AB			**EQ 50MG TARTRATE**	**A076862**	**001**	Aug 03, 2009

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB			**EQ 100MG TARTRATE**	**A077298**	**001**	Apr 15, 2010
AB			**EQ 200MG TARTRATE**	**A077298**	**002**	Apr 15, 2010
AB		CIPLA	**EQ 50MG TARTRATE**	**A207465**	**001**	Oct 26, 2018
AB			**EQ 100MG TARTRATE**	**A207465**	**002**	Oct 26, 2018
AB			**EQ 200MG TARTRATE**	**A207465**	**003**	Oct 26, 2018
AB		DR REDDYS LABS LTD	**EQ 25MG TARTRATE**	**A090617**	**001**	Aug 01, 2012
AB			**EQ 50MG TARTRATE**	**A090617**	**002**	Aug 01, 2012
AB		MYLAN PHARMS INC	**EQ 25MG TARTRATE**	**A202033**	**001**	Dec 15, 2011
AB			**EQ 50MG TARTRATE**	**A202033**	**002**	Dec 15, 2011
AB			**EQ 100MG TARTRATE**	**A202033**	**003**	Dec 15, 2011
AB			**EQ 200MG TARTRATE**	**A202033**	**004**	Dec 15, 2011
AB		NOVAST LABS	**EQ 25MG TARTRATE**	**A204106**	**001**	Feb 06, 2018
AB			**EQ 50MG TARTRATE**	**A204106**	**002**	Feb 06, 2018
AB			**EQ 100MG TARTRATE**	**A204106**	**003**	Feb 06, 2018
AB			**EQ 200MG TARTRATE**	**A204106**	**004**	Feb 06, 2018
AB		REDDYS	**EQ 100MG TARTRATE**	**A078889**	**001**	Aug 15, 2012
AB			**EQ 200MG TARTRATE**	**A078889**	**002**	Aug 15, 2012
AB		TWI PHARMS	**EQ 25MG TARTRATE**	**A207206**	**001**	Dec 19, 2018
AB			**EQ 50MG TARTRATE**	**A207206**	**002**	Dec 19, 2018
AB			**EQ 100MG TARTRATE**	**A207206**	**003**	Dec 19, 2018
AB			**EQ 200MG TARTRATE**	**A207206**	**004**	Dec 19, 2018
AB		WOCKHARDT	**EQ 25MG TARTRATE**	**A090615**	**001**	Jul 22, 2010
AB			**EQ 50MG TARTRATE**	**A090615**	**002**	Jul 22, 2010
AB			**EQ 100MG TARTRATE**	**A090615**	**003**	Jul 22, 2010
AB			**EQ 200MG TARTRATE**	**A090615**	**004**	Jul 22, 2010
AB		ZYDUS PHARMS	**EQ 25MG TARTRATE**	**A203894**	**001**	Mar 23, 2018
AB			**EQ 50MG TARTRATE**	**A203894**	**002**	Mar 23, 2018
AB			**EQ 100MG TARTRATE**	**A203894**	**003**	Mar 23, 2018
AB			**EQ 200MG TARTRATE**	**A203894**	**004**	Mar 23, 2018

TOPROL-XL

AB	**+**	TOPROL	**EQ 25MG TARTRATE**	**N019962**	**004**	Feb 05, 2001
AB	**+!**		**EQ 50MG TARTRATE**	**N019962**	**001**	Jan 10, 1992
AB	**+**		**EQ 100MG TARTRATE**	**N019962**	**002**	Jan 10, 1992
AB	**+!**		**EQ 200MG TARTRATE**	**N019962**	**003**	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		BAXTER HLTHCARE CORP	**1MG/ML**	**A078950**	**001**	Apr 29, 2013
AP		FRESENIUS KABI USA	**1MG/ML**	**A091045**	**001**	Oct 25, 2010
AP		GLAND PHARMA LTD	**1MG/ML**	**A204205**	**001**	Aug 27, 2014
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A077761**	**001**	May 30, 2007
AP		HOSPIRA	**1MG/ML**	**A074133**	**001**	Dec 21, 1993
AP			**1MG/ML**	**A075160**	**001**	Jul 06, 1998
AP	**!**		**1MG/ML**	**A078085**	**001**	Apr 29, 2008
AP		MYLAN ASI	**1MG/ML**	**A090317**	**001**	Apr 19, 2010
AP		SANDOZ INC	**1MG/ML**	**A077360**	**001**	Oct 02, 2007
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A076495**	**001**	Jul 07, 2003

TABLET;ORAL

LOPRESSOR

AB	**+**	US PHARMS HOLDINGS I	**50MG**	**N017963**	**001**	
AB	**+**		**100MG**	**N017963**	**002**	

METOPROLOL TARTRATE

AB		ALEMBIC PHARMS LTD	**25MG**	**A202871**	**001**	May 28, 2013
AB			**50MG**	**A202871**	**002**	May 28, 2013
AB			**100MG**	**A202871**	**003**	May 28, 2013
AB		AUROBINDO PHARMA	**25MG**	**A077739**	**001**	Sep 11, 2007
AB			**50MG**	**A077739**	**002**	Sep 11, 2007
AB			**100MG**	**A077739**	**003**	Sep 11, 2007
AB		HERITAGE PHARMA	**50MG**	**A074141**	**001**	Jan 31, 1995
AB			**100MG**	**A074141**	**002**	Jan 31, 1995
AB		IPCA LABS LTD	**25MG**	**A078459**	**001**	Jun 17, 2008
AB			**50MG**	**A078459**	**002**	Jun 17, 2008
AB			**100MG**	**A078459**	**003**	Jun 17, 2008
AB		MYLAN	**25MG**	**A076704**	**001**	Jan 16, 2004
AB			**37.5MG**	**A076704**	**004**	Mar 18, 2015
AB			**50MG**	**A076704**	**002**	Jan 16, 2004

METOPROLOL TARTRATE						
TABLET;ORAL						
METOPROLOL TARTRATE						
AB			**75MG**	**A076704**	**005**	Mar 18, 2015
AB	**!**		**100MG**	**A076704**	**003**	Jan 16, 2004
AB		RUBICON	**25MG**	**A200981**	**001**	Oct 28, 2014
AB			**37.5MG**	**A200981**	**004**	Aug 21, 2019
AB			**50MG**	**A200981**	**002**	Oct 28, 2014
AB			**75MG**	**A200981**	**005**	Aug 21, 2019
AB			**100MG**	**A200981**	**003**	Oct 28, 2014
AB		SUN PHARM INDS INC	**25MG**	**A076670**	**001**	Jan 15, 2004
AB			**50MG**	**A074644**	**001**	Dec 10, 1996
AB			**100MG**	**A074644**	**002**	Dec 10, 1996
METRONIDAZOLE						
CAPSULE;ORAL						
FLAGYL						
AB	**+!**	GD SEARLE LLC	**375MG**	**N020334**	**001**	May 03, 1995
METRONIDAZOLE						
AB		ALEMBIC PHARMS LTD	**375MG**	**A079065**	**001**	Jun 23, 2009
AB		PAR PHARM	**375MG**	**A076522**	**001**	Jan 29, 2004
CREAM;TOPICAL						
METROCREAM						
AB	**+!**	GALDERMA LABS LP	**0.75%**	**N020531**	**001**	Sep 20, 1995
METRONIDAZOLE						
AB		ACP NIMBLE	**0.75%**	**A077549**	**001**	Dec 19, 2007
AB		FOUGERA PHARMS	**0.75%**	**A076408**	**001**	May 28, 2004
NORITATE						
	+!	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997
GEL;TOPICAL						
METROGEL						
AB	**+!**	GALDERMA LABS LP	**0.75%**	**N019737**	**001**	Nov 22, 1988
AB	**+!**		**1%**	**N021789**	**001**	Jun 30, 2005
METRONIDAZOLE						
AB		ACP NIMBLE	**0.75%**	**A078178**	**001**	Jan 19, 2011
AB		FOUGERA PHARMS	**0.75%**	**A077018**	**001**	Jun 06, 2006
AB		TARO	**0.75%**	**A077819**	**001**	Jul 18, 2006
AB			**1%**	**A204651**	**001**	Mar 14, 2017
AB		TOLMAR	**0.75%**	**A077547**	**001**	Jul 13, 2006
AB			**1%**	**A090903**	**001**	Jul 22, 2011
GEL;VAGINAL						
METROGEL-VAGINAL						
AB	**+!**	BAUSCH	**0.75%**	**N020208**	**001**	Aug 17, 1992
METRONIDAZOLE						
AB		PERRIGO UK FINCO	**0.75%**	**A211786**	**001**	Jul 02, 2019
AB		TOLMAR	**0.75%**	**A077264**	**001**	Oct 31, 2006
VANDAZOLE						
BX		TEVA PHARMS	0.75%	N021806	001	May 20, 2005
NUVESSA						
	+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014
INJECTABLE;INJECTION						
FLAGYL I.V. RTU IN PLASTIC CONTAINER						
AP	**+!**	BAXTER HLTHCARE	**500MG/100ML**	**N018657**	**001**	
METRO I.V. IN PLASTIC CONTAINER						
AP	**+!**	B BRAUN	**500MG/100ML**	**N018900**	**001**	Sep 29, 1983
METRONIDAZOLE IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE CORP	**500MG/100ML**	**A078084**	**001**	Mar 31, 2008
AP	**+!**	HOSPIRA	**500MG/100ML**	**N018890**	**002**	Nov 18, 1983
AP		INFORLIFE	**500MG/100ML**	**A206191**	**001**	Feb 25, 2019
AP		MYLAN LABS LTD	**500MG/100ML**	**A205531**	**001**	May 09, 2017
LOTION;TOPICAL						
METROLOTION						
AB	**+!**	GALDERMA LABS LP	**0.75%**	**N020901**	**001**	Nov 24, 1998
METRONIDAZOLE						
AB		FOUGERA PHARMS	**0.75%**	**A077197**	**001**	May 24, 2006
TABLET;ORAL						
FLAGYL						
AB	**+**	GD SEARLE LLC	**250MG**	**N012623**	**001**	
AB	**+!**		**500MG**	**N012623**	**003**	
METRONIDAZOLE						
AB		ALEMBIC PHARMS LTD	**250MG**	**A079067**	**001**	Mar 13, 2009

METRONIDAZOLE
TABLET;ORAL
METRONIDAZOLE

AB			**500MG**	**A079067**	**002**	Mar 13, 2009
AB		AUROBINDO PHARMA LTD	**250MG**	**A203974**	**001**	May 29, 2015
AB			**500MG**	**A203974**	**002**	May 29, 2015
AB		CADILA	**250MG**	**A206560**	**001**	Nov 16, 2016
AB			**500MG**	**A206560**	**002**	Nov 16, 2016
AB		CADILA PHARMS LTD	**250MG**	**A209794**	**001**	Dec 12, 2017
AB			**500MG**	**A209794**	**002**	Dec 12, 2017
AB		FLAMINGO PHARMS	**250MG**	**A207309**	**001**	May 16, 2016
AB			**500MG**	**A207309**	**002**	May 16, 2016
AB		HERITAGE PHARMS INC	**250MG**	**A205245**	**001**	Sep 23, 2015
AB			**500MG**	**A205245**	**002**	Sep 23, 2015
AB		INNOGENIX	**250MG**	**A070772**	**001**	Jul 16, 1986
AB			**500MG**	**A070772**	**002**	Jul 16, 1986
AB		LUPIN LTD	**250MG**	**A209096**	**001**	Sep 12, 2017
AB			**500MG**	**A209096**	**002**	Sep 12, 2017
AB		ORIT LABS LLC	**250MG**	**A208681**	**001**	Jun 20, 2017
AB			**500MG**	**A208681**	**002**	Jun 20, 2017
AB		PLIVA	**500MG**	**A070033**	**001**	Dec 06, 1984
AB		STRIDES PHARMA	**250MG**	**A070040**	**001**	Jan 29, 1985
AB			**250MG**	**A208162**	**001**	May 25, 2016
AB			**500MG**	**A070039**	**001**	Jan 29, 1985
AB			**500MG**	**A208162**	**002**	May 25, 2016
AB		TEVA PHARMS USA	**250MG**	**A070027**	**001**	Nov 06, 1984
AB		UNICHEM LABS LTD	**250MG**	**A203458**	**001**	Jan 22, 2014
AB			**500MG**	**A203458**	**002**	Jan 22, 2014
AB		WATSON LABS	**250MG**	**A070035**	**001**	Dec 20, 1984
AB		WATSON LABS INC	**500MG**	**A070044**	**001**	Feb 08, 1985

METYRAPONE
CAPSULE;ORAL
METOPIRONE

+!	HRA PHARMA	250MG	N012911	002	Aug 09, 1996

METYROSINE
CAPSULE;ORAL
DEMSER

+!	BAUSCH	250MG	N017871	001	

MEXILETINE HYDROCHLORIDE
CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

	TEVA	150MG	A074377	001	May 16, 1995
		200MG	A074377	002	May 16, 1995
!		250MG	A074377	003	May 16, 1995

MICAFUNGIN SODIUM
INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

AP		FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A207344**	**001**	May 17, 2019
AP			**EQ 100MG BASE/VIAL**	**A207344**	**002**	May 17, 2019
MYCAMINE						
AP	**+!**	ASTELLAS	**EQ 50MG BASE/VIAL**	**N021506**	**002**	Mar 16, 2005
AP	**+!**		**EQ 100MG BASE/VIAL**	**N021506**	**003**	Jun 27, 2006

MICONAZOLE
TABLET;BUCCAL
ORAVIG

+!	FORTOVIA	50MG	N022404	001	Apr 16, 2010

MICONAZOLE NITRATE
SUPPOSITORY;VAGINAL
MICONAZOLE NITRATE

AB		ACTAVIS PHARMA	**200MG**	**A073508**	**001**	Nov 19, 1993
MONISTAT 3						
AB	**+!**	MEDTECH PRODUCTS	**200MG**	**N018888**	**001**	Aug 15, 1984

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

+!	MYLAN	0.25%;81.35%;15%	N021026	001	Feb 16, 2006

MIDAZOLAM

SPRAY;NASAL

NAYZILAM

+!	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		AKORN INC	**EQ 1MG BASE/ML**	**A075494**	**001**	Jun 30, 2000
AP			**EQ 5MG BASE/ML**	**A075494**	**002**	Jun 30, 2000
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075154**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075154**	**001**	Jun 20, 2000
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A090696**	**001**	Feb 29, 2012
AP			**EQ 5MG BASE/ML**	**A090850**	**001**	Jan 25, 2012
AP	!	HOSPIRA	**EQ 1MG BASE/ML**	**A075293**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075856**	**001**	Jun 13, 2002
AP	!		**EQ 5MG BASE/ML**	**A075293**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075856**	**002**	Jun 13, 2002
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/ML**	**A075243**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075247**	**002**	Jun 23, 2000
AP			**EQ 1MG BASE/ML**	**A075324**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075421**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075243**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075247**	**001**	Jun 23, 2000
AP			**EQ 5MG BASE/ML**	**A075324**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075421**	**001**	Jun 20, 2000

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A203460**	**001**	Aug 22, 2014
AP			**EQ 5MG BASE/ML**	**A203460**	**002**	Aug 22, 2014
AP	!	HOSPIRA	**EQ 1MG BASE/ML**	**A075857**	**001**	Jul 22, 2002
AP	!		**EQ 5MG BASE/ML**	**A075857**	**002**	Jul 22, 2002
AP		MYLAN ASI	**EQ 1MG BASE/ML**	**A090315**	**001**	Nov 29, 2010
AP			**EQ 5MG BASE/ML**	**A090315**	**002**	Nov 29, 2010

MIDAZOLAM HYDROCHLORIDE

	FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017

SOLUTION;INTRAMUSCULAR

SEIZALAM

+!	MERIDIAN MEDCL TECHN	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

AA		HI TECH PHARMA	**EQ 2MG BASE/ML**	**A075958**	**001**	Sep 04, 2003
AA	!	HIKMA	**EQ 2MG BASE/ML**	**A075873**	**001**	Apr 30, 2002
AA		PADDOCK LLC	**EQ 2MG BASE/ML**	**A076379**	**001**	May 02, 2005

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB		APOTEX	**2.5MG**	**A077746**	**001**	Sep 12, 2006
AB			**5MG**	**A077746**	**002**	Sep 12, 2006
AB			**10MG**	**A077746**	**003**	Sep 12, 2006
AB		IMPAX PHARMS	**2.5MG**	**A076449**	**001**	May 27, 2004
AB			**5MG**	**A076449**	**002**	May 27, 2004
AB			**10MG**	**A076449**	**003**	Dec 16, 2005
AB		MYLAN PHARMS INC	**2.5MG**	**A076577**	**001**	Sep 10, 2003
AB			**5MG**	**A076577**	**002**	Sep 10, 2003
AB			**10MG**	**A076577**	**003**	Sep 10, 2003
AB		PAR PHARM INC	**2.5MG**	**A207169**	**001**	Oct 29, 2018
AB			**5MG**	**A207169**	**002**	Oct 29, 2018
AB			**10MG**	**A207169**	**003**	Oct 29, 2018
AB		RUBICON	**2.5MG**	**A212543**	**001**	Aug 19, 2019
AB			**5MG**	**A212543**	**002**	Aug 19, 2019
AB			**10MG**	**A212543**	**003**	Aug 19, 2019
AB		UNIQUE PHARM LABS	**2.5MG**	**A207613**	**001**	Nov 02, 2018
AB			**5MG**	**A207613**	**002**	Nov 02, 2018
AB			**10MG**	**A207613**	**003**	Nov 02, 2018

ORVATEN

AB		UPSHER SMITH LABS	**2.5MG**	**A076725**	**001**	Nov 03, 2004

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

ORVATEN

AB	**!**		**5MG**	**A076725**	**002**	Nov 03, 2004
AB			**10MG**	**A076725**	**003**	Nov 03, 2004

MIDOSTAURIN

CAPSULE;ORAL

RYDAPT

+!	NOVARTIS	25MG	N207997	001	Apr 28, 2017

MIFEPRISTONE

TABLET;ORAL

MIFEPREX

AB	**+!**	DANCO LABS LLC	**200MG**	**N020687**	**001**	Sep 28, 2000

MIFEPRISTONE

AB		GENBIOPRO	**200MG**	**A091178**	**001**	Apr 11, 2019

KORLYM

+!	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012

MIGALASTAT HYDROCHLORIDE

CAPSULE;ORAL

GALAFOLD

+!	AMICUS THERAPS US	EQ 123MG BASE	N208623	001	Aug 10, 2018

MIGLITOL

TABLET;ORAL

GLYSET

AB	**+!**	PHARMACIA AND UPJOHN	**25MG**	**N020682**	**001**	Dec 18, 1996
AB	**+**		**50MG**	**N020682**	**002**	Dec 18, 1996
AB	**+**		**100MG**	**N020682**	**003**	Dec 18, 1996

MIGLITOL

AB		ORIENT PHARMA CO LTD	**25MG**	**A203965**	**001**	Feb 24, 2015
AB			**50MG**	**A203965**	**002**	Feb 24, 2015
AB			**100MG**	**A203965**	**003**	Feb 24, 2015

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

AB		AMERIGEN PHARMS LTD	**100MG**	**A208342**	**001**	Apr 17, 2018

ZAVESCA

AB	**+!**	ACTELION PHARMS LTD	**100MG**	**N021348**	**001**	Jul 31, 2003

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

SAVELLA

+	ALLERGAN	12.5MG	N022256	001	Jan 14, 2009
+		25MG	N022256	002	Jan 14, 2009
+!		50MG	N022256	003	Jan 14, 2009
+		100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075936**	**001**	May 28, 2002
AP	**!**	HIKMA FARMACEUTICA	**EQ 1MG BASE/ML**	**A077966**	**001**	Dec 03, 2010
AP		HOSPIRA INC	**EQ 1MG BASE/ML**	**A203280**	**001**	Sep 03, 2014
AP		INTL MEDICATED	**EQ 1MG BASE/ML**	**A076013**	**001**	Aug 02, 2002
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/ML**	**A075530**	**001**	May 28, 2002
AP			**EQ 1MG BASE/ML**	**A075660**	**001**	May 28, 2002

MILRINONE LACTATE IN DEXTROSE 5%

AP		WOODWARD	**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A077151**	**002**	Jul 20, 2005

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**!**	BAXTER HLTHCARE	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075834**	**001**	May 28, 2002
AP	**!**		**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075834**	**002**	May 28, 2002
AP		HOSPIRA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075885**	**001**	May 28, 2002
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075885**	**002**	May 28, 2002
AP		WEST-WARD PHARMS INT	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A078113**	**001**	May 21, 2008
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A078113**	**002**	May 21, 2008

MILRINONE LACTATE IN PLASTIC CONTAINER

AP		HIKMA FARMACEUTICA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A090038**	**001**	Jan 21, 2010
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A090038**	**002**	Jan 21, 2010

MILTEFOSINE
CAPSULE;ORAL
IMPAVIDO
+! KNIGHT THERAPS 50MG N204684 001 Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE
AEROSOL, FOAM;TOPICAL
AMZEEQ
+! FOAMIX EQ 4% BASE N212379 001 Oct 18, 2019
CAPSULE;ORAL
DYNACIN
AB CNTY LINE PHARMS **EQ 50MG BASE** **A063067 003** Aug 14, 1990
AB **EQ 75MG BASE** **A063067 002** Sep 15, 1999
AB **EQ 100MG BASE** **A063067 001** Jul 31, 1990
MINOCIN
AB + BAUSCH **EQ 50MG BASE** **N050649 001** May 31, 1990
AB + **EQ 100MG BASE** **N050649 002** May 31, 1990
MINOCYCLINE HYDROCHLORIDE
AB AUROBINDO PHARMA **EQ 50MG BASE** **A065470 001** Mar 11, 2008
AB **EQ 75MG BASE** **A065470 002** Mar 11, 2008
AB **EQ 100MG BASE** **A065470 003** Mar 11, 2008
AB IMPAX LABS **EQ 50MG BASE** **A065005 001** Mar 23, 1999
AB **EQ 75MG BASE** **A065005 003** Apr 18, 2001
AB **EQ 100MG BASE** **A065005 002** Mar 23, 1999
AB SUN PHARM INDS INC **EQ 50MG BASE** **A090867 001** May 13, 2013
AB **EQ 75MG BASE** **A090867 002** May 13, 2013
AB **EQ 100MG BASE** **A090867 003** May 13, 2013
AB TORRENT **EQ 50MG BASE** **A065062 001** Nov 30, 2000
AB **EQ 75MG BASE** **A065062 002** Nov 30, 2000
AB **EQ 100MG BASE** **A065062 003** Nov 30, 2000
AB WATSON LABS **EQ 75MG BASE** **A063065 002** Jun 10, 1999
AB **EQ 100MG BASE** **A063065 001** Dec 30, 1991
AB WATSON LABS TEVA **EQ 50MG BASE** **A063181 001** Dec 30, 1991
AB ZYDUS **EQ 50MG BASE** **A063011 001** Mar 02, 1992
AB **EQ 75MG BASE** **A063009 002** Aug 12, 2003
AB ! **EQ 100MG BASE** **A063009 001** Mar 02, 1992
CAPSULE, EXTENDED RELEASE;ORAL
XIMINO
SUN PHARM INDS INC EQ 45MG BASE N201922 001 Jul 11, 2012
EQ 90MG BASE N201922 003 Jul 11, 2012
EQ 135MG BASE N201922 005 Jul 11, 2012
INJECTABLE;INJECTION
MINOCIN
+! REMPEX PHARMS EQ 100MG BASE/VIAL N050444 001
POWDER, EXTENDED RELEASE;DENTAL
ARESTIN
+! ORAPHARMA EQ 1MG BASE N050781 001 Feb 16, 2001
TABLET;ORAL
MINOCYCLINE HYDROCHLORIDE
AB DR REDDYS LABS LTD **EQ 50MG BASE** **A065436 001** Dec 26, 2007
AB **EQ 75MG BASE** **A065436 002** Dec 26, 2007
AB **EQ 100MG BASE** **A065436 003** Dec 26, 2007
AB PAR PHARM **EQ 50MG BASE** **A065131 001** Apr 16, 2003
AB **EQ 75MG BASE** **A065131 002** Apr 16, 2003
AB ! **EQ 100MG BASE** **A065131 003** Apr 16, 2003
AB SUN PHARM INDUSTRIES **EQ 50MG BASE** **A090217 001** Jan 29, 2016
AB **EQ 75MG BASE** **A090217 002** Jan 29, 2016
AB **EQ 100MG BASE** **A090217 003** Jan 29, 2016
AB TORRENT **EQ 50MG BASE** **A065156 001** Jan 06, 2004
AB **EQ 75MG BASE** **A065156 002** Jan 06, 2004
AB **EQ 100MG BASE** **A065156 003** Jan 06, 2004
TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE
AB ALKEM LABS LTD **EQ 45MG BASE** **A204453 001** Sep 28, 2016
AB **EQ 55MG BASE** **A204453 008** Dec 19, 2019
AB **EQ 65MG BASE** **A204453 006** Mar 16, 2018
AB **EQ 80MG BASE** **A204453 002** Sep 28, 2016
AB **EQ 90MG BASE** **A204453 003** Sep 28, 2016
AB **EQ 105MG BASE** **A204453 004** Sep 28, 2016
AB **EQ 115MG BASE** **A204453 007** Mar 16, 2018
AB **EQ 135MG BASE** **A204453 005** Sep 28, 2016
AB AUROBINDO PHARMA **EQ 45MG BASE** **A202261 001** Nov 19, 2012

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

		LTD				
AB			**EQ 55MG BASE**	**A202261**	**008**	Aug 21, 2019
AB			**EQ 65MG BASE**	**A202261**	**002**	Sep 28, 2018
AB			**EQ 80MG BASE**	**A202261**	**006**	Jun 13, 2016
AB			**EQ 90MG BASE**	**A202261**	**003**	Nov 19, 2012
AB			**EQ 105MG BASE**	**A202261**	**007**	Jun 13, 2016
AB			**EQ 115MG BASE**	**A202261**	**004**	Sep 28, 2018
AB			**EQ 135MG BASE**	**A202261**	**005**	Nov 19, 2012
AB		BARR LABS INC	**EQ 65MG BASE**	**A065485**	**004**	May 18, 2012
AB			**EQ 80MG BASE**	**A065485**	**007**	Apr 26, 2017
AB			**EQ 105MG BASE**	**A065485**	**008**	Apr 26, 2017
AB			**EQ 115MG BASE**	**A065485**	**005**	May 18, 2012
AB		LUPIN LTD	**EQ 45MG BASE**	**A091424**	**001**	Nov 30, 2011
AB			**EQ 55MG BASE**	**A091424**	**002**	Nov 30, 2011
AB			**EQ 90MG BASE**	**A091424**	**003**	Nov 30, 2011
AB			**EQ 135MG BASE**	**A091424**	**004**	Nov 30, 2011
AB		MYLAN	**EQ 80MG BASE**	**A203443**	**002**	Aug 22, 2014
AB			**EQ 105MG BASE**	**A203443**	**003**	Aug 22, 2014
AB		SANDOZ	**EQ 45MG BASE**	**A090422**	**001**	Aug 13, 2009
AB			**EQ 90MG BASE**	**A090422**	**002**	Aug 13, 2009
AB	**!**		**EQ 135MG BASE**	**A090422**	**003**	Aug 13, 2009
AB		SIDMAK LABS INDIA	**EQ 45MG BASE**	**A204394**	**001**	Dec 30, 2015
AB			**EQ 80MG BASE**	**A204394**	**004**	Dec 30, 2015
AB			**EQ 105MG BASE**	**A204394**	**005**	Dec 30, 2015
AB			**EQ 135MG BASE**	**A204394**	**007**	Dec 30, 2015
AB		SUN PHARM INDS LTD	**EQ 45MG BASE**	**A091118**	**001**	Sep 25, 2014
AB			**EQ 65MG BASE**	**A091118**	**003**	Dec 03, 2019
AB			**EQ 80MG BASE**	**A091118**	**004**	Sep 25, 2014
AB			**EQ 90MG BASE**	**A091118**	**005**	Sep 25, 2014
AB			**EQ 105MG BASE**	**A091118**	**006**	Sep 25, 2014
AB			**EQ 115MG BASE**	**A091118**	**007**	Dec 03, 2019
AB			**EQ 135MG BASE**	**A091118**	**008**	Sep 25, 2014
AB		ZYDUS PHARMS	**EQ 45MG BASE**	**A203553**	**001**	Nov 16, 2017
AB			**EQ 80MG BASE**	**A203553**	**004**	Nov 16, 2017
AB			**EQ 90MG BASE**	**A203553**	**005**	Nov 16, 2017
AB			**EQ 105MG BASE**	**A203553**	**006**	Nov 16, 2017
AB			**EQ 135MG BASE**	**A203553**	**008**	Nov 16, 2017

SOLODYN

AB	**+**	MEDICIS	**EQ 55MG BASE**	**N050808**	**008**	Aug 27, 2010
AB	**+**		**EQ 65MG BASE**	**N050808**	**004**	Jul 23, 2009
AB	**+**		**EQ 80MG BASE**	**N050808**	**007**	Aug 27, 2010
AB	**+**		**EQ 105MG BASE**	**N050808**	**006**	Aug 27, 2010
AB	**+!**		**EQ 115MG BASE**	**N050808**	**005**	Jul 23, 2009
		MINOLIRA				
		EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017
			EQ 135MG BASE	N209269	002	May 08, 2017

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB		PAR PHARM	**2.5MG**	**A071826**	**001**	Nov 14, 1988
AB			**10MG**	**A071839**	**001**	Nov 14, 1988
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A072709**	**002**	Dec 14, 1995
AB			**10MG**	**A072709**	**001**	Dec 14, 1995
AB		WATSON LABS	**2.5MG**	**A071344**	**001**	Mar 03, 1987
AB	**!**		**10MG**	**A071345**	**001**	Mar 03, 1987

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

AB		SAWAI USA	**25MG**	**A209446**	**001**	Dec 27, 2019

MYRBETRIQ

AB	**+!**	APGDI	**25MG**	**N202611**	**001**	Jun 28, 2012
	+!		50MG	N202611	002	Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		APOTEX INC	**15MG**	**A077666**	**001**	Aug 22, 2007
AB			**30MG**	**A077666**	**002**	Aug 22, 2007
AB			**45MG**	**A077666**	**003**	Aug 22, 2007
AB		AUROBINDO	**7.5MG**	**A076921**	**001**	Oct 22, 2004
AB			**15MG**	**A076921**	**002**	Oct 22, 2004
AB			**30MG**	**A076921**	**003**	Oct 22, 2004
AB			**45MG**	**A076921**	**004**	Oct 22, 2004
AB		MYLAN	**15MG**	**A076122**	**001**	Jun 19, 2003
AB			**30MG**	**A076122**	**002**	Jun 19, 2003
AB			**45MG**	**A076122**	**003**	Jun 19, 2003
AB		SUN PHARM INDS INC	**7.5MG**	**A076541**	**004**	Apr 22, 2004
AB			**15MG**	**A076541**	**001**	Apr 22, 2004
AB			**30MG**	**A076541**	**002**	Apr 22, 2004
AB			**45MG**	**A076541**	**003**	Apr 22, 2004
AB		TEVA	**15MG**	**A076119**	**001**	Jan 24, 2003
AB			**30MG**	**A076119**	**002**	Jan 24, 2003
AB			**45MG**	**A076119**	**003**	Jun 19, 2003
AB		UPSHER SMITH LABS	**15MG**	**A076219**	**001**	Jun 19, 2003
AB			**30MG**	**A076219**	**002**	Jun 19, 2003
AB			**45MG**	**A076219**	**003**	Jun 19, 2003

REMERON

AB	**+!**	ORGANON USA INC	**15MG**	**N020415**	**001**	Jun 14, 1996
AB	**+**		**30MG**	**N020415**	**002**	Jun 14, 1996

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB		AUROBINDO PHARMA LTD	**15MG**	**A077376**	**002**	Dec 08, 2005
AB			**30MG**	**A077376**	**003**	Dec 08, 2005
AB			**45MG**	**A077376**	**004**	Feb 28, 2006
AB		IMPAX LABS INC	**15MG**	**A076901**	**001**	Jun 28, 2005
AB			**30MG**	**A076901**	**002**	Jun 28, 2005
AB			**45MG**	**A076901**	**003**	Jun 28, 2005
AB		ZYDUS PHARMS	**15MG**	**A205798**	**001**	Jun 01, 2017
AB			**30MG**	**A205798**	**002**	Jun 01, 2017
AB			**45MG**	**A205798**	**003**	Jun 01, 2017

REMERON SOLTAB

AB	**+!**	ORGANON USA INC	**15MG**	**N021208**	**001**	Jan 12, 2001
AB	**+**		**30MG**	**N021208**	**002**	Jan 12, 2001
AB	**+**		**45MG**	**N021208**	**003**	Jan 12, 2001

MISOPROSTOL

TABLET;ORAL

CYTOTEC

AB	**+**	GD SEARLE LLC	**0.1MG**	**N019268**	**003**	Sep 21, 1990
AB	**+!**		**0.2MG**	**N019268**	**001**	Dec 27, 1988

MISOPROSTOL

AB		NOVEL LABS INC	**0.1MG**	**A091667**	**001**	Jul 25, 2012
AB			**0.2MG**	**A091667**	**002**	Jul 25, 2012

MITOMYCIN

FOR SOLUTION;TOPICAL

MITOSOL

	+!	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012

INJECTABLE;INJECTION

MITOMYCIN

AP	**!**	ACCORD HLTHCARE	**5MG/VIAL**	**A064144**	**001**	Apr 30, 1998
AP	**!**		**20MG/VIAL**	**A064144**	**002**	Apr 30, 1998
AP	**!**		**40MG/VIAL**	**A064144**	**003**	Aug 11, 2009
AP		MYLAN LABS LTD	**5MG/VIAL**	**A202670**	**001**	Oct 13, 2017
AP			**20MG/VIAL**	**A202670**	**002**	Oct 13, 2017
AP			**40MG/VIAL**	**A203386**	**001**	Oct 13, 2017
AP		WEST-WARD PHARMS INT	**5MG/VIAL**	**A064180**	**001**	Dec 23, 1999
AP			**20MG/VIAL**	**A064117**	**002**	Apr 19, 1995
AP			**20MG/VIAL**	**A064180**	**002**	Dec 23, 1999
AP			**40MG/VIAL**	**A064117**	**003**	Jun 02, 1999

MITOTANE
TABLET;ORAL
LYSODREN

+!	HRA PHARMA	500MG	N016885	001		

MITOXANTRONE HYDROCHLORIDE
INJECTABLE;INJECTION
MITOXANTRONE HYDROCHLORIDE

AP	FRESENIUS KABI USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077496**	**001**	Apr 11, 2006	
AP		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077496**	**002**	Apr 11, 2006	
AP		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077496**	**003**	Apr 11, 2006	
AP !	HOSPIRA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076871**	**001**	Apr 11, 2006	
AP !		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076871**	**002**	Apr 11, 2006	
AP !		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076871**	**003**	Apr 11, 2006	
AP	TEVA PHARMS USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077356**	**001**	Apr 11, 2006	
AP		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077356**	**002**	Apr 11, 2006	
AP		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077356**	**003**	Apr 11, 2006	
AP	WEST-WARD PHARMS INT	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076611**	**001**	Apr 11, 2006	
AP		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076611**	**002**	Apr 11, 2006	
AP		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076611**	**003**	Apr 11, 2006	

MODAFINIL
TABLET;ORAL
MODAFINIL

AB	ALEMBIC PHARMS LTD	**100MG**	**A202700**	**001**	Oct 18, 2012	
AB		**200MG**	**A202700**	**002**	Oct 18, 2012	
AB	APOTEX INC	**100MG**	**A077667**	**001**	Feb 03, 2014	
AB		**200MG**	**A077667**	**002**	Feb 03, 2014	
AB	APPCO	**100MG**	**A207196**	**001**	Aug 16, 2017	
AB		**200MG**	**A207196**	**002**	Aug 16, 2017	
AB	AUROBINDO PHARMA LTD	**100MG**	**A202566**	**001**	Sep 27, 2012	
AB		**200MG**	**A202566**	**002**	Sep 27, 2012	
AB	CADILA	**100MG**	**A209966**	**001**	Sep 14, 2017	
AB		**200MG**	**A209966**	**002**	Sep 14, 2017	
AB	MYLAN PHARMS INC	**100MG**	**A076594**	**001**	Jul 16, 2012	
AB		**200MG**	**A076594**	**002**	Jul 16, 2012	
AB	ORCHID HLTHCARE	**100MG**	**A078963**	**001**	Sep 26, 2012	
AB		**200MG**	**A078963**	**002**	Sep 26, 2012	
AB	WATSON LABS INC	**100MG**	**A076715**	**001**	Nov 01, 2012	
AB		**200MG**	**A076715**	**002**	Nov 01, 2012	

PROVIGIL

AB +	CEPHALON	**100MG**	**N020717**	**001**	Dec 24, 1998	
AB +!		**200MG**	**N020717**	**002**	Dec 24, 1998	

MOEXIPRIL HYDROCHLORIDE
TABLET;ORAL
MOEXIPRIL HYDROCHLORIDE

AB	APOTEX INC	**7.5MG**	**A078454**	**001**	Jun 02, 2008	
AB		**15MG**	**A078454**	**002**	Jun 02, 2008	
AB	CHARTWELL RX	**7.5MG**	**A077536**	**001**	Nov 30, 2006	
AB		**15MG**	**A077536**	**002**	Nov 30, 2006	
AB	GLENMARK GENERICS	**7.5MG**	**A090416**	**001**	Mar 30, 2010	
AB		**15MG**	**A090416**	**002**	Mar 30, 2010	
AB	TEVA	**7.5MG**	**A076204**	**001**	May 08, 2003	
AB !		**15MG**	**A076204**	**002**	May 08, 2003	

MOLINDONE HYDROCHLORIDE
TABLET;ORAL
MOLINDONE HYDROCHLORIDE

	EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015	
		10MG	A090453	002	Mar 20, 2015	
!		25MG	A090453	003	Mar 20, 2015	

MOMETASONE FUROATE
AEROSOL, METERED;INHALATION
ASMANEX HFA

+	MERCK SHARP DOHME	0.05MG/INH	N205641	003	Aug 12, 2019	
+		0.10MG/INH	N205641	001	Apr 25, 2014	
+!		0.20MG/INH	N205641	002	Apr 25, 2014	

CREAM;TOPICAL
MOMETASONE FUROATE

AB	ACP NIMBLE	**0.1%**	**A077447**	**001**	May 22, 2006	
AB	ANDA REPOSITORY	**0.1%**	**A076591**	**001**	Apr 18, 2007	

PRESCRIPTION DRUG PRODUCT LIST

MOMETASONE FUROATE

CREAM;TOPICAL

MOMETASONE FUROATE

AB		FOUGERA PHARMS	**0.1%**	**A076171**	**001**	Apr 08, 2005
AB	!	GLENMARK GENERICS	**0.1%**	**A078541**	**001**	May 28, 2008
AB		TARO	**0.1%**	**A076679**	**001**	Dec 21, 2004

IMPLANT;IMPLANTATION

SINUVA

	+	INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017

LOTION;TOPICAL

ELOCON

AB	+!	MERCK SHARP DOHME	**0.1%**	**N019796**	**001**	Mar 30, 1989

MOMETASONE FUROATE

AB		ACP NIMBLE	**0.1%**	**A077678**	**001**	Nov 21, 2007
AB		ANDA REPOSITORY	**0.1%**	**A076499**	**001**	Nov 21, 2007
AB		FOUGERA PHARMS	**0.1%**	**A075919**	**001**	Nov 29, 2007
AB		GLENMARK GENERICS	**0.1%**	**A090506**	**001**	Aug 09, 2010
AB		PERRIGO ISRAEL	**0.1%**	**A077180**	**001**	Apr 06, 2005
AB		TARO	**0.1%**	**A076788**	**001**	Mar 15, 2006

OINTMENT;TOPICAL

MOMETASONE FUROATE

AB		ACP NIMBLE	**0.1%**	**A077401**	**001**	Jun 20, 2006
AB		ANDA REPOSITORY	**0.1%**	**A076481**	**001**	Nov 14, 2003
AB		FOUGERA PHARMS	**0.1%**	**A077061**	**001**	Mar 28, 2005
AB	!	GLENMARK GENERICS	**0.1%**	**A078571**	**001**	May 28, 2008
AB		PERRIGO NEW YORK	**0.1%**	**A076067**	**001**	Mar 18, 2002
AB		TORRENT	**0.1%**	**A207899**	**001**	Jul 13, 2018

POWDER;INHALATION

ASMANEX TWISTHALER

	+	MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008
	+!		0.22MG/INH	N021067	001	Mar 30, 2005

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB		AMNEAL PHARMS	**EQ 0.05MG BASE/SPRAY**	**A207989**	**001**	Apr 03, 2017
AB		APOTEX INC	**EQ 0.05MG BASE/SPRAY**	**A091161**	**001**	Mar 22, 2016

NASONEX

AB	+!	MERCK SHARP DOHME	**EQ 0.05MG BASE/SPRAY**	**N020762**	**001**	Oct 01, 1997

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	**EQ 4MG BASE/PACKET**	**A203438**	**001**	Jul 31, 2015
AB		DR REDDYS LABS LTD	**EQ 4MG BASE/PACKET**	**A202906**	**001**	Sep 17, 2012
AB		TEVA PHARMS	**EQ 4MG BASE/PACKET**	**A090955**	**001**	Aug 03, 2012
AB		TORRENT	**EQ 4MG BASE/PACKET**	**A210431**	**001**	Jul 31, 2018

SINGULAIR

AB	+!	MERCK	**EQ 4MG BASE/PACKET**	**N021409**	**001**	Jul 26, 2002

TABLET;ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	**EQ 10MG BASE**	**A202717**	**001**	Sep 21, 2012
AB		AJANTA PHARMA LTD	**EQ 10MG BASE**	**A203432**	**001**	Jul 31, 2015
AB		AMNEAL PHARMS	**EQ 10MG BASE**	**A204604**	**001**	Sep 04, 2015
AB		ANBISON LAB	**EQ 10MG BASE**	**A205683**	**001**	Jan 12, 2016
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A202468**	**001**	Aug 03, 2012
AB		CIPLA	**EQ 10MG BASE**	**A207463**	**001**	Oct 28, 2016
AB		CSPC OUYI	**EQ 10MG BASE**	**A209012**	**001**	Apr 24, 2017
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A201582**	**001**	Aug 06, 2012
AB		GLENMARK GENERICS	**EQ 10MG BASE**	**A090926**	**001**	Aug 03, 2012
AB		HETERO LABS LTD V	**EQ 10MG BASE**	**A202843**	**001**	Sep 10, 2014
AB		HIKMA	**EQ 10MG BASE**	**A090655**	**001**	Aug 03, 2012
AB		L PERRIGO CO	**EQ 10MG BASE**	**A206112**	**001**	Apr 26, 2017
AB		LANNETT CO INC	**EQ 10MG BASE**	**A201522**	**001**	Aug 03, 2012
AB		MACLEODS PHARMS LTD	**EQ 10MG BASE**	**A203366**	**001**	Sep 11, 2014
AB		SANDOZ INC	**EQ 10MG BASE**	**A200889**	**001**	Aug 03, 2012
AB		TEVA PHARMS	**EQ 10MG BASE**	**A078605**	**001**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 10MG BASE**	**A201515**	**001**	Aug 03, 2012
AB		UNICHEM LABS LTD	**EQ 10MG BASE**	**A204290**	**001**	Oct 08, 2015
AB		UNIMARK REMEDIES LTD	**EQ 10MG BASE**	**A202859**	**001**	Oct 30, 2014

SINGULAIR

AB	+!	MSD MERCK CO	**EQ 10MG BASE**	**N020829**	**002**	Feb 20, 1998

PRESCRIPTION DRUG PRODUCT LIST

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015
AB			EQ 5MG BASE	A203328	002	Jul 31, 2015
AB		ANBISON LAB	EQ 4MG BASE	A205695	001	Nov 05, 2015
AB			EQ 5MG BASE	A205695	002	Nov 05, 2015
AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096	001	Aug 03, 2012
AB			EQ 5MG BASE	A202096	002	Aug 03, 2012
AB		CIPLA	EQ 4MG BASE	A207464	001	Dec 06, 2018
AB			EQ 5MG BASE	A207464	002	Dec 06, 2018
AB		CSPC OUYI	EQ 4MG BASE	A209011	001	Apr 18, 2017
AB			EQ 5MG BASE	A209011	002	Apr 18, 2017
AB		DR REDDYS LABS LTD	EQ 4MG BASE	A201581	001	Aug 06, 2012
AB			EQ 5MG BASE	A201581	002	Aug 06, 2012
AB		HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015
AB			EQ 5MG BASE	A204093	002	May 22, 2015
AB		HIKMA	EQ 4MG BASE	A091128	001	Aug 03, 2012
AB			EQ 5MG BASE	A091128	002	Aug 03, 2012
AB		JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015
AB			EQ 5MG BASE	A203795	002	Feb 27, 2015
AB		LANNETT CO INC	EQ 4MG BASE	A200405	001	Aug 03, 2012
AB			EQ 5MG BASE	A200405	002	Aug 03, 2012
AB		MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015
AB			EQ 5MG BASE	A203582	002	Mar 12, 2015
AB		SANDOZ INC	EQ 4MG BASE	A091414	001	Aug 03, 2012
AB			EQ 5MG BASE	A091414	002	Aug 03, 2012
AB		TEVA PHARMS	EQ 4MG BASE	A078723	001	Aug 03, 2012
AB			EQ 5MG BASE	A078723	002	Aug 03, 2012
AB		TORRENT PHARMS LTD	EQ 4MG BASE	A090984	001	Aug 03, 2012
AB			EQ 5MG BASE	A090984	002	Aug 03, 2012
AB		UNICHEM LABS LTD	EQ 4MG BASE	A208621	001	Jul 02, 2018
AB			EQ 5MG BASE	A208621	002	Jul 02, 2018
AB		UNIMARK REMEDIES LTD	EQ 4MG BASE	A203037	001	Oct 30, 2014
AB			EQ 5MG BASE	A203037	002	Oct 30, 2014

SINGULAIR

AB	+	MSD MERCK CO	EQ 4MG BASE	N020830	002	Mar 03, 2000
AB	+!		EQ 5MG BASE	N020830	001	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

AB	+!	ALLERGAN	10MG	N020616	008	Apr 20, 2007
AB	+		20MG	N020616	001	Jul 03, 1996
AB	+		30MG	N020616	004	Mar 09, 2001
AB	+		40MG	N020616	009	Jul 09, 2012
AB	+		50MG	N020616	002	Jul 03, 1996
AB	+		60MG	N020616	005	Mar 09, 2001
AB	+		70MG	N020616	010	Jul 09, 2012
AB	+		80MG	N020616	006	Oct 27, 2006
AB	+!		100MG	N020616	003	Jul 03, 1996

MORPHINE SULFATE

AB		IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016
AB			30MG	A200411	002	Apr 12, 2016
AB			40MG	A200411	007	Jul 25, 2018
AB			50MG	A200411	003	Apr 12, 2016
AB			60MG	A200411	004	Apr 12, 2016
AB			80MG	A200411	005	Apr 12, 2016
AB			100MG	A200411	006	Apr 12, 2016
AB		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011
AB			30MG	A200812	002	Nov 10, 2011
AB			50MG	A200812	003	Nov 10, 2011
AB			60MG	A200812	004	Nov 10, 2011
AB			80MG	A200812	005	Nov 10, 2011
AB			100MG	A200812	006	Nov 10, 2011
AB		TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014
AB			30MG	A202718	002	Dec 29, 2014
AB			40MG	A202718	007	Jun 03, 2015
AB			50MG	A202718	003	Dec 29, 2014
AB			60MG	A202718	004	Dec 29, 2014
AB			70MG	A202718	008	Jun 03, 2015

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB			**80MG**	**A202718**	**005**	Dec 29, 2014
AB			**100MG**	**A202718**	**006**	Dec 29, 2014
AB		UPSHER SMITH LABS	**10MG**	**A202104**	**001**	Jun 03, 2013
AB			**20MG**	**A202104**	**002**	Jun 03, 2013
AB			**30MG**	**A202104**	**003**	Jun 03, 2013
AB			**50MG**	**A202104**	**004**	Jun 03, 2013
AB			**60MG**	**A202104**	**005**	Jun 03, 2013
AB			**80MG**	**A202104**	**006**	Jun 03, 2013
AB			**100MG**	**A202104**	**007**	Jun 03, 2013

KADIAN

	+	ALLERGAN	130MG	N020616	011	Jul 09, 2012
	+		150MG	N020616	012	Jul 09, 2012
	+!		200MG	N020616	007	Feb 27, 2007

MORPHINE SULFATE

		ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
			45MG	A079040	002	Jan 16, 2013
			60MG	A079040	003	Jan 16, 2013
			75MG	A079040	004	Jan 16, 2013
			90MG	A079040	005	Jan 16, 2013
	!		120MG	A079040	006	Jan 16, 2013

INJECTABLE;INJECTION

DURAMORPH PF

AP	**+!**	WEST-WARD PHARMS INT	**0.5MG/ML**	**N018565**	**001**	Sep 18, 1984
AP	**+!**		**1MG/ML**	**N018565**	**002**	Sep 18, 1984

INFUMORPH

AP	**+!**	WEST-WARD PHARMS INT	**10MG/ML**	**N018565**	**003**	Jul 19, 1991
AP	**+!**		**25MG/ML**	**N018565**	**004**	Jul 19, 1991

MITIGO

AP		PIRAMAL CRITICAL	**10MG/ML**	**A204393**	**001**	Jul 16, 2018
AP			**25MG/ML**	**A204393**	**002**	Jul 16, 2018

MORPHINE SULFATE

AP		EUROHLTH INTL SARL	**4MG/ML**	**A205758**	**001**	May 21, 2015
AP			**8MG/ML**	**A205758**	**002**	May 21, 2015
AP			**10MG/ML**	**A205758**	**003**	May 21, 2015
AP		HOSPIRA	**0.5MG/ML**	**A071849**	**001**	May 11, 1988
AP			**0.5MG/ML**	**A073509**	**001**	Sep 30, 1992
AP			**1MG/ML**	**A071850**	**001**	May 11, 1988
AP			**1MG/ML**	**A073510**	**001**	Sep 30, 1992
AP	**+!**	HOSPIRA INC	**4MG/ML**	**N202515**	**002**	Nov 14, 2011
AP	**+!**		**8MG/ML**	**N202515**	**003**	Nov 14, 2011
AP	**+!**		**10MG/ML**	**N202515**	**004**	Nov 14, 2011
AP	**+!**	ICU MEDICAL INC	**1MG/ML**	**N019916**	**001**	Oct 30, 1992
	+!	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011
	+!	MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

	+!	FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
	+!		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
	+!		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
	+!		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
	+!		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013

SOLUTION;ORAL

MORPHINE SULFATE

AA		ANI PHARMS INC	**10MG/5ML**	**A205509**	**001**	Apr 17, 2018
AA			**20MG/5ML**	**A205509**	**002**	Apr 17, 2018
AA			**100MG/5ML**	**A205509**	**003**	Apr 17, 2018
AA		HI TECH	**100MG/5ML**	**A208809**	**001**	Jul 06, 2017
AA	**+**	HIKMA	**10MG/5ML**	**N022195**	**001**	Mar 17, 2008
AA	**+**		**20MG/5ML**	**N022195**	**002**	Mar 17, 2008
AA	**+!**		**100MG/5ML**	**N022195**	**003**	Jan 25, 2010
AA		NOSTRUM LABS INC	**10MG/5ML**	**A201011**	**001**	Feb 05, 2014
AA			**20MG/5ML**	**A201011**	**002**	Feb 05, 2014
AA			**100MG/5ML**	**A201011**	**003**	Oct 06, 2016
AA		PADDOCK LLC	**100MG/5ML**	**A201574**	**001**	Aug 06, 2012
AA		PHARM ASSOC	**100MG/5ML**	**A206573**	**001**	Nov 14, 2016
AA		RHODES PHARMS	**10MG/5ML**	**A206308**	**001**	Jun 22, 2017
AA			**20MG/5ML**	**A206420**	**001**	Jul 12, 2016

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

AA			**100MG/5ML**	**A206308**	**002**	Jun 22, 2017
AA		SPECGX LLC	**100MG/5ML**	**A202348**	**001**	Jul 15, 2011
AA		TRIS PHARMA INC	**10MG/5ML**	**A203518**	**001**	May 12, 2015
AA			**20MG/5ML**	**A203519**	**001**	May 18, 2016
AA			**100MG/5ML**	**A203518**	**002**	May 12, 2015

TABLET;ORAL

MORPHINE SULFATE

AB	+	HIKMA	**15MG**	**N022207**	**001**	Mar 17, 2008
AB	+!		**30MG**	**N022207**	**002**	Mar 17, 2008
AB		UPSHER SMITH LABS	**15MG**	**A210610**	**001**	Jul 22, 2019
AB			**30MG**	**A210610**	**002**	Jul 22, 2019

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	**15MG**	**A203849**	**001**	Apr 06, 2015
AB			**30MG**	**A203849**	**002**	Apr 06, 2015
AB			**60MG**	**A203849**	**003**	Apr 06, 2015
AB			**100MG**	**A203849**	**004**	Apr 06, 2015
AB			**200MG**	**A203849**	**005**	Apr 06, 2015
AB		DAVA PHARMS INC	**15MG**	**A075407**	**001**	Jan 28, 2000
AB		MAYNE PHARMA INC	**15MG**	**A205386**	**001**	Oct 28, 2016
AB			**30MG**	**A205386**	**002**	Oct 28, 2016
AB			**60MG**	**A205386**	**003**	Oct 28, 2016
AB			**100MG**	**A205386**	**004**	Oct 28, 2016
AB		NESHER PHARMS	**15MG**	**A076733**	**001**	May 19, 2004
AB			**30MG**	**A076720**	**002**	Dec 23, 2005
AB			**60MG**	**A076720**	**001**	May 19, 2004
AB			**100MG**	**A077855**	**001**	Sep 27, 2007
AB			**200MG**	**A077855**	**002**	Sep 27, 2007
AB		NOVEL LABS INC	**15MG**	**A203602**	**001**	Dec 16, 2015
AB			**30MG**	**A203602**	**002**	Dec 16, 2015
AB			**60MG**	**A203602**	**003**	Dec 16, 2015
AB			**100MG**	**A203602**	**004**	Dec 16, 2015
AB			**200MG**	**A203602**	**005**	Dec 16, 2015
AB		RHODES PHARMS	**15MG**	**A074862**	**001**	Jul 07, 1998
AB			**30MG**	**A074862**	**002**	Jul 07, 1998
AB			**60MG**	**A074862**	**003**	Jul 07, 1998
AB			**100MG**	**A074769**	**001**	Jul 02, 1998
AB			**200MG**	**A074769**	**002**	Jul 02, 1998
AB		SPECGX LLC	**15MG**	**A076412**	**001**	Jul 31, 2003
AB			**30MG**	**A076412**	**002**	Jul 31, 2003
AB			**60MG**	**A076412**	**003**	Jul 31, 2003
AB			**100MG**	**A076438**	**001**	Jul 03, 2003
AB			**200MG**	**A076438**	**002**	Jul 03, 2003
AB		SUN PHARM INDS LTD	**15MG**	**A078761**	**001**	May 11, 2012
AB			**30MG**	**A078761**	**002**	May 11, 2012
AB			**60MG**	**A078761**	**003**	May 11, 2012
AB			**100MG**	**A078761**	**004**	May 11, 2012
AB			**200MG**	**A078761**	**005**	May 11, 2012
AB		VINTAGE PHARMS LLC	**15MG**	**A075295**	**001**	Oct 28, 1998
AB			**30MG**	**A075295**	**002**	Oct 28, 1998
AB			**60MG**	**A075295**	**003**	Oct 28, 1998
AB			**100MG**	**A075295**	**004**	Sep 15, 2000
AB			**200MG**	**A075295**	**005**	Sep 15, 2000

MS CONTIN

AB	+	PURDUE PHARMA LP	**15MG**	**N019516**	**003**	Sep 12, 1989
AB	+		**30MG**	**N019516**	**001**	May 29, 1987
AB	+		**60MG**	**N019516**	**002**	Apr 08, 1988
AB	+!		**100MG**	**N019516**	**004**	Jan 16, 1990
AB	+		**200MG**	**N019516**	**005**	Nov 08, 1993

MORPHABOND ER

	+	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015
	+		30MG	N206544	002	Oct 02, 2015
	+		60MG	N206544	003	Oct 02, 2015
	+!		100MG	N206544	004	Oct 02, 2015

MOXIDECTIN						
TABLET;ORAL						
MOXIDECTIN						
	+!	MDGH	2MG	N210867	001	Jun 13, 2018
MOXIFLOXACIN HYDROCHLORIDE						
SOLUTION;INTRAVENOUS						
MOXIFLOXACIN HYDROCHLORIDE						
	+!	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER						
	!	MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017
SOLUTION/DROPS;OPHTHALMIC						
MOXIFLOXACIN HYDROCHLORIDE						
AT1		AKORN	**EQ 0.5% BASE**	**A202916**	**001**	Nov 09, 2017
AT1		ALEMBIC PHARMS LTD	**EQ 0.5% BASE**	**A209469**	**001**	Feb 13, 2019
AT1		APOTEX	**EQ 0.5% BASE**	**A090080**	**001**	Jun 30, 2017
AT1		AUROBINDO PHARMA LTD	**EQ 0.5% BASE**	**A206242**	**001**	Oct 04, 2017
AT1		LUPIN LTD	**EQ 0.5% BASE**	**A202867**	**001**	Sep 04, 2014
AT1		WATSON LABS INC	**EQ 0.5% BASE**	**A202525**	**001**	Mar 06, 2015
VIGAMOX						
AT1	**+!**	NOVARTIS	**EQ 0.5% BASE**	**N021598**	**001**	Apr 15, 2003
MOXEZA						
AT2	**+!**	NOVARTIS	**EQ 0.5% BASE**	**N022428**	**001**	Nov 19, 2010
MOXIFLOXACIN HYDROCHLORIDE						
AT2		LUPIN LTD	**EQ 0.5% BASE**	**A204079**	**001**	May 28, 2015
TABLET;ORAL						
AVELOX						
AB	**+!**	BAYER HLTHCARE	**EQ 400MG BASE**	**N021085**	**001**	Dec 10, 1999
MOXIFLOXACIN HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**EQ 400MG BASE**	**A202632**	**001**	Mar 04, 2014
AB		CROSSMEDIKA SA	**EQ 400MG BASE**	**A205348**	**001**	Jan 14, 2016
AB		DR REDDYS LABS LTD	**EQ 400MG BASE**	**A076938**	**001**	Mar 04, 2014
AB		MSN	**EQ 400MG BASE**	**A208682**	**001**	Sep 22, 2017
AB		NOVEL LABS INC	**EQ 400MG BASE**	**A207285**	**001**	Feb 13, 2017
AB		TEVA PHARMS USA	**EQ 400MG BASE**	**A077437**	**001**	Feb 18, 2014
AB		TORRENT	**EQ 400MG BASE**	**A200160**	**001**	Apr 03, 2014
MUPIROCIN						
OINTMENT;TOPICAL						
MUPIROCIN						
AB		FOUGERA PHARMS	**2%**	**A065192**	**001**	Nov 30, 2005
AB		GLENMARK PHARMS	**2%**	**A090480**	**001**	Jun 08, 2011
AB	**!**	PERRIGO ISRAEL	**2%**	**A065123**	**001**	Nov 07, 2003
AB		TARO	**2%**	**A065170**	**001**	Sep 23, 2005
AB		TEVA	**2%**	**A065085**	**001**	Nov 07, 2003
CENTANY						
BX		PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002
MUPIROCIN CALCIUM						
CREAM;TOPICAL						
MUPIROCIN						
	!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013
MYCOPHENOLATE MOFETIL						
CAPSULE;ORAL						
CELLCEPT						
AB	**+!**	ROCHE PALO	**250MG**	**N050722**	**001**	May 03, 1995
MYCOPHENOLATE MOFETIL						
AB		ACCORD HLTHCARE	**250MG**	**A090253**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**250MG**	**A200197**	**001**	Jun 13, 2013
AB		CONCORD BIOTECH LTD	**250MG**	**A210181**	**001**	Jan 08, 2019
AB		HIKMA	**250MG**	**A065410**	**001**	Jul 29, 2008
AB		MYLAN	**250MG**	**A065520**	**001**	May 04, 2009
AB		SANDOZ	**250MG**	**A065379**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**250MG**	**A090055**	**001**	Jun 10, 2010
AB		TEVA PHARMS	**250MG**	**A065491**	**001**	May 06, 2009
AB		VINTAGE PHARMS LLC	**250MG**	**A090111**	**001**	Dec 22, 2009
AB		ZHEJIANG HISUN PHARM	**250MG**	**A204077**	**001**	Nov 13, 2017
SUSPENSION;ORAL						
CELLCEPT						
AB	**+!**	ROCHE PALO	**200MG/ML**	**N050759**	**001**	Oct 01, 1998

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB		ALKEM LABS LTD	**200MG/ML**	**A203005**	**001**	Nov 14, 2014
AB		VISTAPHARM	**200MG/ML**	**A210370**	**001**	Feb 12, 2019

TABLET;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**500MG**	**N050723**	**001**	Jun 19, 1997

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	**500MG**	**A065416**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**500MG**	**A091249**	**001**	Nov 04, 2011
AB		HIKMA	**500MG**	**A065413**	**001**	Jul 29, 2008
AB		MYLAN	**500MG**	**A065521**	**001**	May 04, 2009
AB		SANDOZ	**500MG**	**A065451**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**500MG**	**A090456**	**001**	Jun 10, 2010
AB		ZHEJIANG HISUN PHARM	**500MG**	**A204076**	**001**	Nov 16, 2017

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

CELLCEPT

AP	**+!**	ROCHE PALO	**500MG/VIAL**	**N050758**	**001**	Aug 12, 1998

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		AKORN INC	**500MG/VIAL**	**A204043**	**001**	Feb 28, 2017
AP		MYLAN LABS LTD	**500MG/VIAL**	**A203859**	**001**	Mar 31, 2017
AP		PAR STERILE PRODUCTS	**500MG/VIAL**	**A203575**	**001**	Oct 28, 2016
AP		ZYDUS PHARMS	**500MG/VIAL**	**A204473**	**001**	Aug 31, 2017

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

AB		ACCORD HLTHCARE	**180MG**	**A202555**	**001**	Aug 23, 2017
AB			**360MG**	**A202555**	**002**	Aug 23, 2017
AB		APOTEX INC	**180MG**	**A091558**	**001**	Aug 21, 2012
AB			**360MG**	**A091558**	**002**	Aug 19, 2014
AB		CONCORD BIOTECH LTD	**180MG**	**A211173**	**001**	Dec 13, 2019
AB			**360MG**	**A211173**	**002**	Dec 13, 2019
AB		MYLAN	**180MG**	**A091248**	**002**	Jan 08, 2014
AB			**360MG**	**A091248**	**001**	Jan 08, 2014
AB		TEVA PHARMS USA	**180MG**	**A202720**	**001**	Oct 30, 2014
AB			**360MG**	**A202720**	**002**	Oct 30, 2014

MYFORTIC

AB	**+**	NOVARTIS	**180MG**	**N050791**	**001**	Feb 27, 2004
AB	**+!**		**360MG**	**N050791**	**002**	Feb 27, 2004

NABILONE

CAPSULE;ORAL

CESAMET

	+!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985

NABUMETONE

TABLET;ORAL

NABUMETONE

AB		CASI PHARMS INC	**500MG**	**A075280**	**001**	Feb 25, 2002
AB			**750MG**	**A075280**	**002**	Feb 25, 2002
AB		CHARTWELL MOLECULES	**500MG**	**A076009**	**001**	Jan 24, 2003
AB			**750MG**	**A076009**	**002**	Jan 24, 2003
AB		IMPAX LABS INC	**500MG**	**A075189**	**001**	May 26, 2000
AB	**!**		**750MG**	**A075189**	**002**	Sep 24, 2001
AB		INVAGEN PHARMS	**500MG**	**A078671**	**001**	Mar 07, 2008
AB			**750MG**	**A078671**	**002**	Mar 07, 2008
AB		LUPIN LTD	**500MG**	**A090445**	**001**	Jan 12, 2011
AB			**750MG**	**A090445**	**002**	Jan 12, 2011
AB		MYLAN PHARMS INC	**500MG**	**A090516**	**001**	Jul 12, 2010
AB			**750MG**	**A090516**	**002**	Jul 12, 2010
AB		NEXGEN PHARMA INC	**500MG**	**A203166**	**001**	Aug 30, 2019
AB			**750MG**	**A203166**	**002**	Aug 30, 2019
AB		NOSTRUM LABS INC	**500MG**	**A090427**	**001**	Dec 30, 2011
AB			**750MG**	**A090427**	**002**	Dec 30, 2011
AB		SCIEGEN PHARMS INC	**500MG**	**A078420**	**001**	Sep 24, 2008
AB			**750MG**	**A078420**	**002**	Sep 24, 2008
AB		WATSON LABS	**500MG**	**A091083**	**001**	Jun 13, 2011
AB			**750MG**	**A091083**	**002**	Jun 13, 2011
		NEXGEN PHARMA INC	1GM	A203166	003	Aug 30, 2019

NADOLOL

TABLET;ORAL

CORGARD

AB	**+**	US WORLDMEDS LLC	**20MG**	**N018063**	**005**	Oct 28, 1986
AB	**+**		**40MG**	**N018063**	**001**	
AB	**+!**		**80MG**	**N018063**	**002**	

NADOLOL

AB		AMNEAL PHARMS CO	**20MG**	**A208832**	**001**	Jun 02, 2017
AB			**40MG**	**A208832**	**002**	Jun 02, 2017
AB			**80MG**	**A208832**	**003**	Jun 02, 2017
AB		AUROBINDO PHARMA LTD	**40MG**	**A201893**	**001**	Sep 16, 2015
AB			**80MG**	**A201893**	**002**	Sep 16, 2015
AB		BEXIMCO PHARMS USA	**20MG**	**A210955**	**001**	Jul 23, 2018
AB			**40MG**	**A210955**	**002**	Jul 23, 2018
AB			**80MG**	**A210955**	**003**	Jul 23, 2018
AB		HERITAGE PHARMA	**20MG**	**A074229**	**001**	Aug 30, 1996
AB			**40MG**	**A074229**	**002**	Aug 30, 1996
AB			**80MG**	**A074255**	**001**	Jan 24, 1996
AB		INVAGEN PHARMS	**20MG**	**A203455**	**001**	Dec 18, 2015
AB			**40MG**	**A203455**	**002**	Dec 18, 2015
AB			**80MG**	**A203455**	**003**	Dec 18, 2015
AB		LUPIN LTD	**20MG**	**A209309**	**001**	Oct 05, 2017
AB			**40MG**	**A209309**	**002**	Oct 05, 2017
AB			**80MG**	**A209309**	**003**	Oct 05, 2017
AB		MYLAN	**20MG**	**A074172**	**001**	Oct 31, 1993
AB			**40MG**	**A074172**	**002**	Oct 31, 1993
AB			**80MG**	**A074172**	**003**	Oct 31, 1993
AB		NOVAST LABS	**20MG**	**A210786**	**001**	Jun 01, 2018
AB			**40MG**	**A210786**	**002**	Jun 01, 2018
AB			**80MG**	**A210786**	**003**	Jun 01, 2018
AB		SANDOZ	**20MG**	**A074501**	**001**	Nov 09, 1995
AB			**40MG**	**A074501**	**002**	Nov 09, 1995
AB			**80MG**	**A074501**	**003**	Nov 09, 1995
AB		VGYAAN	**20MG**	**A212856**	**001**	Sep 13, 2019
AB			**40MG**	**A212856**	**002**	Sep 13, 2019
AB			**80MG**	**A212856**	**003**	Sep 13, 2019
AB		ZYDUS PHARMS	**20MG**	**A207761**	**001**	Jul 28, 2017
AB			**40MG**	**A207761**	**002**	Jul 28, 2017
AB			**80MG**	**A207761**	**003**	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

	+!	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL**	**A090560**	**001**	Oct 03, 2011
AP			**EQ 2GM BASE/VIAL**	**A090560**	**002**	Oct 03, 2011
AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A091613**	**001**	Dec 26, 2012
AP			**EQ 2GM BASE/VIAL**	**A091613**	**002**	Dec 26, 2012
AP			**EQ 10GM BASE/VIAL**	**A091614**	**001**	Dec 26, 2012
AP		FRESENIUS	**EQ 1GM BASE/VIAL**	**A206682**	**001**	Dec 10, 2019
AP			**EQ 2GM BASE/VIAL**	**A206682**	**002**	Dec 10, 2019
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL**	**A090002**	**001**	Jun 30, 2011
AP			**EQ 2GM BASE/VIAL**	**A090002**	**002**	Jun 30, 2011
AP			**EQ 10GM BASE/VIAL**	**A090005**	**001**	Apr 20, 2011
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A090582**	**001**	Aug 24, 2012
AP			**EQ 2GM BASE/VIAL**	**A090582**	**002**	Aug 24, 2012
AP			**EQ 10GM BASE/VIAL**	**A090580**	**001**	Aug 24, 2012
AP	**!**	SANDOZ	**EQ 1GM BASE/VIAL**	**A062527**	**002**	Aug 02, 1984
AP	**!**		**EQ 1GM BASE/VIAL**	**A062732**	**001**	Dec 23, 1986
AP	**!**		**EQ 2GM BASE/VIAL**	**A062527**	**003**	Aug 02, 1984
AP	**!**		**EQ 2GM BASE/VIAL**	**A062732**	**002**	Dec 23, 1986
AP	**!**		**EQ 10GM BASE/VIAL**	**A062527**	**004**	Aug 02, 1984

NALLPEN IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+!		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE							
CREAM;TOPICAL							
NAFTIFINE HYDROCHLORIDE							
AB		TARO PHARMS	**2%**	**A206901**	**001**	Jan 06, 2016
AB		TOLMAR	**2%**	**A206960**	**001**	Apr 10, 2017
NAFTIN							
AB	**+!**	SEBELA IRELAND LTD	**2%**	**N019599**	**002**	Jan 13, 2012
NAFTIFINE HYDROCHLORIDE							
	!	TARO PHARMS	1%	A205975	001	Sep 08, 2016
GEL;TOPICAL							
NAFTIFINE HYDROCHLORIDE							
AB		TOLMAR	**1%**	**A206165**	**001**	Mar 20, 2019
NAFTIN							
AB	**+!**	SEBELA IRELAND LTD	**1%**	**N019356**	**001**	Jun 18, 1990
AB	**+!**		**2%**	**N204286**	**001**	Jun 27, 2013
NALBUPHINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
NALBUPHINE HYDROCHLORIDE							
AP	**!**	HOSPIRA	**10MG/ML**	**A070914**	**001**	Feb 03, 1989
AP	**!**		**10MG/ML**	**A070915**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML**	**A070916**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML**	**A070918**	**001**	Feb 03, 1989
AP		MYLAN LABS LTD	**10MG/ML**	**A206506**	**001**	Feb 06, 2019
AP			**10MG/ML**	**A207595**	**001**	Jan 11, 2019
AP			**20MG/ML**	**A206506**	**002**	Feb 06, 2019
AP			**20MG/ML**	**A207595**	**002**	Jan 11, 2019
NALDEMEDINE TOSYLATE							
TABLET;ORAL							
SYMPROIC							
	+!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017
NALOXEGOL OXALATE							
TABLET;ORAL							
MOVANTIK							
	+	ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014
	+!		EQ 25MG BASE	N204760	002	Sep 16, 2014
NALOXONE HYDROCHLORIDE							
INJECTABLE;INJECTION							
NALOXONE							
AP		WEST-WARD PHARMS INT	**0.4MG/ML**	**A070299**	**001**	Sep 24, 1986
NALOXONE HYDROCHLORIDE							
AP		AKORN	**0.4MG/ML**	**A208871**	**001**	Feb 28, 2017
AP			**0.4MG/ML**	**A208872**	**001**	Mar 14, 2017
AP		AUROBINDO PHARMA LTD	**0.4MG/ML**	**A212455**	**001**	Oct 15, 2019
AP			**0.4MG/ML**	**A212456**	**001**	Nov 04, 2019
AP	**!**	HOSPIRA	**0.4MG/ML**	**A070172**	**001**	Sep 24, 1986
AP	**!**		**0.4MG/ML**	**A070254**	**001**	Jan 07, 1987
AP	**!**		**0.4MG/ML**	**A070256**	**001**	Jan 07, 1987
AP	**!**		**0.4MG/ML**	**A070257**	**001**	Jan 07, 1987
AP		INTL MEDICATION	**0.4MG/ML**	**A070639**	**001**	Sep 24, 1986
AP		MYLAN INSTITUTIONAL	**0.4MG/ML**	**A204997**	**001**	Mar 06, 2014
AP			**0.4MG/ML**	**A205014**	**001**	Jun 29, 2016
AP		SOMERSET THERAPS LLC	**0.4MG/ML**	**A207633**	**001**	Aug 08, 2017
AP			**0.4MG/ML**	**A207634**	**001**	Jul 26, 2017
	!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS							
EVZIO (AUTOINJECTOR)							
	+!	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016
SPRAY, METERED;NASAL							
NARCAN							
	+!	ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015
NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE							
TABLET;ORAL							
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE							
AB		LUPIN	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075735**	**001**	Jul 11, 2001
AB		SUN PHARM INDS LTD	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075523**	**001**	Mar 17, 2000
AB	**!**	WATSON LABS	**EQ 0.5MG BASE;EQ 50MG BASE**	**A074736**	**001**	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

VIVITROL

	+!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A091205**	**001**	Aug 17, 2011
AB		APOTEX	**50MG**	**A207905**	**001**	Jul 21, 2017
AB		BARR	**50MG**	**A074918**	**001**	May 08, 1998
AB		ELITE LABS	**50MG**	**A075274**	**001**	May 26, 1999
AB	!	SPECGX LLC	**50MG**	**A076264**	**002**	Mar 22, 2002
AB		SUN PHARM	**50MG**	**A090356**	**001**	Feb 24, 2012
		SPECGX LLC	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB	+	ATNAHS PHARMA US	**25MG/ML**	**N018965**	**001**	Mar 23, 1987

NAPROXEN

AB	!	HIKMA	**25MG/ML**	**A074190**	**001**	Mar 30, 1994

TABLET;ORAL

NAPROSYN

AB	+!	ATNAHS PHARMA US	**500MG**	**N017581**	**004**	Apr 15, 1982

NAPROXEN

AB		AMNEAL PHARMS NY	**250MG**	**A075927**	**001**	Dec 18, 2001
AB			**375MG**	**A075927**	**002**	Dec 18, 2001
AB			**500MG**	**A075927**	**003**	Dec 18, 2001
AB		AUROBINDO PHARMA LTD	**250MG**	**A200429**	**001**	Nov 08, 2011
AB			**375MG**	**A200429**	**002**	Nov 08, 2011
AB			**500MG**	**A200429**	**003**	Nov 08, 2011
AB		GLENMARK GENERICS	**250MG**	**A078250**	**001**	Mar 28, 2007
AB			**375MG**	**A078250**	**002**	Mar 28, 2007
AB			**500MG**	**A078250**	**003**	Mar 28, 2007
AB		INVAGEN PHARMS	**250MG**	**A091305**	**001**	Aug 24, 2011
AB			**375MG**	**A091305**	**002**	Aug 24, 2011
AB			**500MG**	**A091305**	**003**	Aug 24, 2011
AB		MARKSANS PHARMA	**250MG**	**A091416**	**001**	Feb 14, 2011
AB			**375MG**	**A091416**	**002**	Feb 14, 2011
AB			**500MG**	**A091416**	**003**	Feb 14, 2011
AB		MYLAN	**250MG**	**A074121**	**001**	Dec 21, 1993
AB			**375MG**	**A074121**	**002**	Dec 21, 1993
AB			**500MG**	**A074121**	**003**	Dec 21, 1993
AB		PERRIGO PHARMS CO	**250MG**	**A077339**	**001**	Apr 27, 2005
AB			**375MG**	**A077339**	**002**	Apr 27, 2005
AB			**500MG**	**A077339**	**003**	Apr 27, 2005
AB		TEVA	**250MG**	**A074201**	**001**	Dec 21, 1993
AB			**375MG**	**A074201**	**002**	Dec 21, 1993
AB			**500MG**	**A074201**	**003**	Dec 21, 1993
AB		ZYDUS PHARMS USA	**250MG**	**A078620**	**001**	Jun 07, 2007
AB			**375MG**	**A078620**	**002**	Jun 07, 2007
AB			**500MG**	**A078620**	**003**	Jun 07, 2007

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

AB	+!	ATNAHS PHARMA US	**375MG**	**N020067**	**002**	Oct 14, 1994
AB	+!		**500MG**	**N020067**	**003**	Oct 14, 1994

NAPROXEN

AB		PLIVA	**375MG**	**A075337**	**001**	May 26, 1999
AB			**500MG**	**A075337**	**002**	May 26, 1999
AB		SUNRISE PHARM INC	**375MG**	**A091432**	**001**	Sep 19, 2011
AB			**500MG**	**A091432**	**002**	Sep 19, 2011
AB		TEVA	**375MG**	**A075227**	**001**	Jun 30, 1998
AB			**500MG**	**A075227**	**002**	Jun 30, 1998

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX DS

AB	+!	ATNAHS PHARMA US	**EQ 500MG BASE**	**N018164**	**003**	Sep 30, 1987

NAPROXEN SODIUM

AB		AMNEAL PHARMS NY	**EQ 250MG BASE**	**A078432**	**001**	Apr 25, 2007
AB			**EQ 500MG BASE**	**A078432**	**002**	Apr 25, 2007

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A200629**	**001**	Oct 31, 2011
AB			**EQ 500MG BASE**	**A200629**	**002**	Oct 31, 2011
AB		DR REDDYS LABS LTD	**EQ 250MG BASE**	**A078486**	**001**	Jul 26, 2007
AB			**EQ 500MG BASE**	**A078486**	**002**	Jul 26, 2007
AB		GLENMARK PHARMS LTD	**EQ 250MG BASE**	**A078314**	**001**	Apr 27, 2007
AB			**EQ 500MG BASE**	**A078314**	**002**	Apr 27, 2007
AB		SCIEGEN PHARMS INC	**EQ 250MG BASE**	**A212199**	**001**	Oct 30, 2019
AB			**EQ 500MG BASE**	**A212199**	**002**	Oct 30, 2019
AB		TEVA	**EQ 250MG BASE**	**A074198**	**001**	Dec 21, 1993
AB			**EQ 500MG BASE**	**A074198**	**002**	Dec 21, 1993

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

AB	**+**	ALVOGEN	**EQ 375MG BASE**	**N020353**	**001**	Jan 05, 1996
AB	**+**		**EQ 500MG BASE**	**N020353**	**002**	Jan 05, 1996
AB	**+!**		**EQ 750MG BASE**	**N020353**	**003**	Jan 05, 1996

NAPROXEN SODIUM

AB		ACTAVIS LABS FL INC	**EQ 375MG BASE**	**A075416**	**002**	Apr 23, 2003
AB			**EQ 500MG BASE**	**A075416**	**001**	Aug 27, 2002
AB			**EQ 750MG BASE**	**A075416**	**003**	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB		AUROBINDO PHARMA LTD	**500MG;EQ 85MG BASE**	**A207457**	**001**	Feb 15, 2018
AB		MYLAN	**500MG;EQ 85MG BASE**	**A090872**	**001**	Sep 04, 2018
AB		SUN PHARM	**500MG;EQ 85MG BASE**	**A202803**	**001**	Jul 20, 2018

TREXIMET

AB	**+!**	CURRAX	**500MG;EQ 85MG BASE**	**N021926**	**001**	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

AMERGE

AB	**+**	GLAXOSMITHKLINE LLC	**EQ 1MG BASE**	**N020763**	**002**	Feb 10, 1998
AB	**+!**		**EQ 2.5MG BASE**	**N020763**	**001**	Feb 10, 1998

NARATRIPTAN

AB		HERITAGE PHARMS INC	**EQ 1MG BASE**	**A200502**	**001**	Feb 28, 2011
AB			**EQ 2.5MG BASE**	**A200502**	**002**	Feb 28, 2011
AB		HIKMA	**EQ 1MG BASE**	**A090381**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A090381**	**002**	Jul 07, 2010
AB		ORCHID HLTHCARE	**EQ 1MG BASE**	**A091441**	**001**	Apr 30, 2012
AB			**EQ 2.5MG BASE**	**A091441**	**002**	Apr 30, 2012
AB		PADDOCK LLC	**EQ 1MG BASE**	**A091326**	**001**	Jul 08, 2010
AB			**EQ 2.5MG BASE**	**A091326**	**002**	Jul 08, 2010
AB		SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A091552**	**001**	Feb 14, 2011

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

	+!	NOVARTIS	5%	N050514	001	

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

AB		ALVOGEN	**60MG**	**A205055**	**001**	Dec 11, 2015
AB			**120MG**	**A205055**	**002**	Dec 11, 2015
AB		CADILA PHARMS LTD	**60MG**	**A206432**	**001**	Apr 19, 2019
AB			**120MG**	**A206432**	**002**	Apr 19, 2019
AB		DR REDDYS LABS LTD	**60MG**	**A077461**	**001**	Sep 09, 2009
AB			**120MG**	**A077461**	**002**	Sep 09, 2009
AB		PAR PHARM	**60MG**	**A077463**	**001**	Sep 09, 2009
AB			**120MG**	**A077463**	**002**	Sep 09, 2009
AB		WATSON LABS	**60MG**	**A077462**	**001**	Mar 30, 2011
AB			**120MG**	**A077462**	**002**	Mar 30, 2011
AB		WILSHIRE PHARMS INC	**60MG**	**A205544**	**001**	Jun 18, 2018
AB			**120MG**	**A205544**	**002**	Jun 18, 2018
AB		ZYDUS PHARMS	**60MG**	**A205248**	**001**	Jul 06, 2016
AB	**!**		**120MG**	**A205248**	**002**	Jul 06, 2016

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

AB	**+**	ALLERGAN	**EQ 2.5MG BASE**	**N021742**	**002**	Dec 17, 2007
AB	**+**		**EQ 5MG BASE**	**N021742**	**003**	Dec 17, 2007
AB	**+**		**EQ 10MG BASE**	**N021742**	**004**	Dec 17, 2007
AB	**+!**		**EQ 20MG BASE**	**N021742**	**005**	Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALOCRIL

AT	**+!**	ALLERGAN	**2%**	**N021009**	**001**	Dec 08, 1999

NEDOCROMIL SODIUM

AT		AKORN	**2%**	**A090638**	**001**	Aug 22, 2012

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

		TEVA	50MG	A076037	001	Sep 16, 2003
			100MG	A076037	002	Sep 16, 2003
			150MG	A076037	003	Sep 16, 2003
			200MG	A076037	004	Sep 16, 2003
	!		250MG	A076037	005	Sep 16, 2003

NELARABINE

INJECTABLE;INTRAVENOUS

ARRANON

	+!	NOVARTIS	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005

NELFINAVIR MESYLATE

TABLET;ORAL

VIRACEPT

	+!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997
	+!		EQ 625MG BASE	N021503	001	Apr 30, 2003

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA		BRECKENRIDGE	**500MG**	**A065468**	**001**	Mar 29, 2010
AA	**!**	TEVA	**500MG**	**A060304**	**001**	
AA		X GEN PHARMS	**500MG**	**A065220**	**001**	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		X GEN PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065106**	**001**	Jan 31, 2006
AT			**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065108**	**001**	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	**!**	MONARCH PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A060707**	**001**	

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

AP	**+!**	AVADEL LEGACY	**5MG/10ML (0.5MG/ML)**	**N204078**	**001**	May 31, 2013
AP	**+!**		**10MG/10ML (1MG/ML)**	**N204078**	**002**	May 31, 2013

NEOSTIGMINE METHYLSULFATE

AP		AM REGENT	**5MG/10ML (0.5MG/ML)**	**A209182**	**001**	May 04, 2018
AP			**10MG/10ML (1MG/ML)**	**A209182**	**002**	May 04, 2018
AP		AMNEAL	**5MG/10ML (0.5MG/ML)**	**A210051**	**001**	Jun 15, 2018
AP			**10MG/10ML (1MG/ML)**	**A210051**	**002**	Jun 15, 2018
AP		AMPHASTAR PHARMS INC	**5MG/10ML (0.5MG/ML)**	**A209933**	**001**	Sep 25, 2017
AP			**10MG/10ML (1MG/ML)**	**A209933**	**002**	Sep 25, 2017
AP		AMRING PHARMS	**5MG/10ML (0.5MG/ML)**	**A210989**	**001**	Aug 22, 2018
AP			**10MG/10ML (1MG/ML)**	**A210989**	**002**	Aug 22, 2018
AP		BE PHARMS	**5MG/10ML (0.5MG/ML)**	**A212512**	**001**	May 13, 2019
AP			**10MG/10ML (1MG/ML)**	**A212512**	**002**	May 13, 2019
AP		DR REDDYS	**5MG/10ML (0.5MG/ML)**	**A209135**	**001**	Jul 10, 2018
AP			**10MG/10ML (1MG/ML)**	**A209135**	**002**	Jul 10, 2018
AP		EUROHLTH INTL SARL	**5MG/10ML (0.5MG/ML)**	**A207042**	**001**	Dec 28, 2015
AP			**10MG/10ML (1MG/ML)**	**A207042**	**002**	Dec 28, 2015
AP		GLAND PHARMA LTD	**5MG/10ML (0.5MG/ML)**	**A212968**	**001**	Oct 16, 2019
AP			**10MG/10ML (1MG/ML)**	**A212968**	**002**	Oct 16, 2019
AP		PAR STERILE PRODUCTS	**5MG/10ML (0.5MG/ML)**	**A208405**	**001**	Apr 26, 2017
AP			**10MG/10ML (1MG/ML)**	**A208405**	**002**	Apr 26, 2017

NEOSTIGMINE METHYLSULFATE
SOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

	FRESENIUS KABI USA	3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018
		5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015
		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015

NEPAFENAC
SUSPENSION/DROPS;OPHTHALMIC
ILEVRO

+!	NOVARTIS	0.3%	N203491	001	Oct 16, 2012

NEVANAC

+!	NOVARTIS	0.1%	N021862	001	Aug 19, 2005

NERATINIB MALEATE
TABLET;ORAL
NERLYNX

+!	PUMA BIOTECH	EQ 40MG BASE	N208051	001	Jul 17, 2017

NETARSUDIL DIMESYLATE
SOLUTION/DROPS;OPHTHALMIC
RHOPRESSA

+!	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017

NETUPITANT; PALONOSETRON HYDROCHLORIDE
CAPSULE;ORAL
AKYNZEO

+!	HELSINN HLTHCARE	300MG;EQ 0.5MG BASE	N205718	001	Oct 10, 2014

NEVIRAPINE
SUSPENSION;ORAL
NEVIRAPINE

AA		AUROBINDO	**50MG/5ML**	**A077702**	**001**	May 22, 2012
AA		CIPLA	**50MG/5ML**	**A207684**	**001**	Aug 03, 2017

VIRAMUNE

AA	**+!**	BOEHRINGER INGELHEIM	**50MG/5ML**	**N020933**	**001**	Sep 11, 1998

TABLET;ORAL
NEVIRAPINE

AB		AUROBINDO	**200MG**	**A077521**	**001**	May 22, 2012
AB		CIPLA	**200MG**	**A077956**	**001**	May 22, 2012
AB		HETERO LABS LTD III	**200MG**	**A078584**	**001**	May 22, 2012
AB		MACLEODS PHARMS LTD	**200MG**	**A090688**	**001**	Jan 14, 2019
AB		MICRO LABS LTD	**200MG**	**A203080**	**001**	May 22, 2012
AB		MYLAN LABS	**200MG**	**A078864**	**001**	May 22, 2012
AB		MYLAN PHARMS INC	**200MG**	**A202523**	**001**	May 22, 2012
AB		PRINSTON INC	**200MG**	**A078644**	**001**	May 22, 2012
AB		STRIDES PHARMA	**200MG**	**A078195**	**001**	May 22, 2012

VIRAMUNE

AB	**+!**	BOEHRINGER INGELHEIM	**200MG**	**N020636**	**001**	Jun 21, 1996

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

AB		ALVOGEN	**100MG**	**A204621**	**002**	Nov 09, 2015
AB			**400MG**	**A204621**	**001**	Jul 10, 2015
AB		AUROBINDO PHARMA LTD	**100MG**	**A208616**	**001**	Nov 23, 2016
AB			**400MG**	**A207698**	**001**	Feb 28, 2017
AB		MACLEODS PHARMS LTD	**400MG**	**A206879**	**001**	Oct 06, 2017
AB		MYLAN	**400MG**	**A205651**	**001**	Oct 27, 2014
AB		SANDOZ INC	**400MG**	**A203411**	**001**	Apr 03, 2014

VIRAMUNE XR

AB	**+**	BOEHRINGER INGELHEIM	**100MG**	**N201152**	**002**	Nov 08, 2012
AB	**+!**		**400MG**	**N201152**	**001**	Mar 25, 2011

NIACIN
TABLET;ORAL
NIACIN

AA		WOCKHARDT	**500MG**	**A081134**	**001**	Apr 28, 1992

NIACOR

AA	**!**	AVONDALE PHARMS	**500MG**	**A040378**	**001**	May 03, 2000

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB		AMNEAL PHARMS	**500MG**	**A203578**	**001**	Jul 24, 2015
AB			**750MG**	**A204178**	**001**	Dec 11, 2015

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB			**1GM**	**A203578**	**002**	Jul 24, 2015
AB		AUROBINDO PHARMA LTD	**500MG**	**A209236**	**001**	Feb 01, 2018
AB			**750MG**	**A209236**	**002**	Feb 01, 2018
AB			**1GM**	**A209236**	**003**	Feb 01, 2018
AB		BARR	**500MG**	**A076378**	**001**	Apr 26, 2005
AB			**750MG**	**A076378**	**002**	Apr 26, 2005
AB			**1GM**	**A076250**	**001**	Apr 14, 2005
AB		JUBILANT GENERICS	**500MG**	**A209156**	**001**	May 14, 2018
AB			**750MG**	**A209156**	**002**	May 14, 2018
AB			**1GM**	**A209156**	**003**	May 14, 2018
AB		LANNETT CO INC	**500MG**	**A203899**	**001**	Jun 16, 2017
AB			**1GM**	**A203899**	**002**	Jun 16, 2017
AB		LUPIN LTD	**500MG**	**A090860**	**001**	Mar 20, 2014
AB			**750MG**	**A090892**	**001**	Mar 20, 2014
AB			**1GM**	**A090446**	**001**	Mar 20, 2014
AB		MYLAN	**1GM**	**A203742**	**003**	Feb 22, 2019
AB			**500MG**	**A203742**	**001**	Feb 22, 2019
AB			**750MG**	**A203742**	**002**	Feb 22, 2019
AB		SUN PHARM	**500MG**	**A200484**	**001**	Apr 23, 2014
AB			**750MG**	**A201273**	**001**	Apr 23, 2014
AB			**1GM**	**A200484**	**002**	Apr 23, 2014

NIASPAN

AB	**+**	ABBVIE	**500MG**	**N020381**	**002**	Jul 28, 1997
AB	**+!**		**750MG**	**N020381**	**003**	Jul 28, 1997
AB	**+!**		**1GM**	**N020381**	**004**	Jul 28, 1997

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		EPIC PHARMA	**20MG**	**A074928**	**001**	Mar 19, 1998
AB			**30MG**	**A074928**	**002**	Mar 19, 1998
AB		MYLAN	**20MG**	**A074642**	**001**	Jul 18, 1996
AB	**!**		**30MG**	**A074642**	**002**	Jul 18, 1996

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

	EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+!	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+!	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+!	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008

NICOTINE

INHALANT;ORAL

NICOTROL

+!	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997

SPRAY, METERED;NASAL

NICOTROL

+!	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		ACTAVIS ELIZABETH	**10MG**	**A072579**	**001**	Jan 08, 1991
AB			**20MG**	**A072556**	**001**	Sep 20, 1990
AB		HERITAGE PHARMA	**10MG**	**A202644**	**001**	Apr 25, 2013
AB			**20MG**	**A202644**	**002**	Apr 25, 2013
AB		INTERGEL PHARM	**10MG**	**A072781**	**001**	Jul 30, 1993
AB		LEADING PHARMA LLC	**10MG**	**A073250**	**001**	Oct 08, 1991
AB			**20MG**	**A074045**	**001**	Apr 30, 1992

PROCARDIA

AB	**+!**	PFIZER	**10MG**	**N018482**	**001**	

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

AB1	**+**	ALVOGEN	**30MG**	**N020198**	**001**	Apr 21, 1993
AB1	**+!**		**60MG**	**N020198**	**002**	Apr 21, 1993

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

AB1	**+!**		**90MG**	**N020198**	**003**	Apr 21, 1993

NIFEDIPINE

AB1		MYLAN	**30MG**	**A201071**	**001**	Dec 03, 2010
AB1			**60MG**	**A201071**	**002**	Dec 03, 2010
AB1			**90MG**	**A201071**	**003**	Dec 03, 2010
AB1		NOVAST LABS	**30MG**	**A202987**	**001**	Aug 25, 2016
AB1			**60MG**	**A202987**	**002**	Aug 25, 2016
AB1			**90MG**	**A202987**	**003**	Aug 25, 2016
AB1		PAR PHARM	**30MG**	**A077899**	**001**	Dec 13, 2006
AB1			**60MG**	**A077899**	**002**	Dec 13, 2006
AB1			**90MG**	**A077899**	**003**	May 25, 2012
AB1		VALEANT PHARMS NORTH	**30MG**	**A075269**	**001**	Dec 04, 2000
AB1			**60MG**	**A075269**	**002**	Dec 04, 2000
AB1			**90MG**	**A076070**	**001**	Aug 16, 2002
AB1		ZYDUS PHARMS	**30MG**	**A210184**	**001**	Jun 29, 2018
AB1			**60MG**	**A210184**	**002**	Jun 29, 2018
AB1			**90MG**	**A210184**	**003**	Jun 29, 2018
AB2		NOVAST LABS	**30MG**	**A210614**	**001**	Mar 12, 2019
AB2			**60MG**	**A210614**	**002**	Mar 12, 2019
AB2			**90MG**	**A210614**	**003**	Mar 12, 2019
AB2		OSMOTICA PHARM US	**30MG**	**A077127**	**001**	Nov 21, 2005
AB2			**60MG**	**A077127**	**002**	Nov 21, 2005
AB2			**90MG**	**A077127**	**003**	Oct 03, 2007
AB2		SPIL	**30MG**	**A210838**	**001**	Apr 16, 2019
AB2			**60MG**	**A210838**	**002**	Apr 16, 2019
AB2			**90MG**	**A210838**	**003**	Apr 16, 2019
AB2		TWI PHARMS	**30MG**	**A203126**	**001**	Apr 03, 2014
AB2			**60MG**	**A203126**	**002**	Apr 03, 2014
AB2			**90MG**	**A203126**	**003**	Apr 03, 2014
AB2		VALEANT PHARMS NORTH	**30MG**	**A075289**	**002**	Feb 06, 2001
AB2			**60MG**	**A075289**	**001**	Sep 27, 2000
AB2		ZYDUS PHARMS	**30MG**	**A210012**	**001**	Dec 19, 2017
AB2			**60MG**	**A210012**	**002**	Dec 19, 2017
AB2			**90MG**	**A210012**	**003**	Dec 19, 2017

PROCARDIA XL

AB2	**+**	PFIZER	**30MG**	**N019684**	**001**	Sep 06, 1989
AB2	**+**		**60MG**	**N019684**	**002**	Sep 06, 1989
AB2	**+!**		**90MG**	**N019684**	**003**	Sep 06, 1989

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

TASIGNA

+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018
+		EQ 150MG BASE	N022068	002	Jun 17, 2010
+!		EQ 200MG BASE	N022068	001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

AB	**+!**	CONCORDIA	**150MG**	**N020169**	**002**	Apr 30, 1999

NILUTAMIDE

AB		ANI PHARMS INC	**150MG**	**A207631**	**001**	Jul 15, 2016

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	**!**	BIONPHARMA INC	**30MG**	**A076740**	**001**	Jan 17, 2008
AB		HERITAGE PHARMS INC	**30MG**	**A077811**	**001**	May 02, 2007
AB		SOFGEN PHARMS	**30MG**	**A201832**	**001**	Jul 24, 2015
AB		THEPHARMANETWORK LLC	**30MG**	**A090103**	**001**	Apr 07, 2014

SOLUTION;ORAL

NYMALIZE

+!	ARBOR PHARMS LLC	60MG/20ML	N203340	001	May 10, 2013

NINTEDANIB ESYLATE						
CAPSULE;ORAL						
OFEV						
	+	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014
	+!		EQ 150MG BASE	N205832	002	Oct 15, 2014
NIRAPARIB TOSYLATE						
CAPSULE;ORAL						
ZEJULA						
	+!	TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017
NISOLDIPINE						
TABLET, EXTENDED RELEASE;ORAL						
NISOLDIPINE						
AB		MYLAN	**8.5MG**	**A091001**	**001**	Jan 26, 2011
AB			**17MG**	**A091001**	**002**	Jan 26, 2011
AB			**34MG**	**A091001**	**004**	Jan 26, 2011
SULAR						
AB	**+!**	COVIS PHARMA BV	**8.5MG**	**N020356**	**008**	Jan 02, 2008
AB	**+!**		**17MG**	**N020356**	**007**	Jan 02, 2008
AB	**+!**		**34MG**	**N020356**	**005**	Jan 02, 2008
NISOLDIPINE						
		MYLAN	20MG	A079051	001	Jul 25, 2008
			25.5MG	A091001	003	Jan 26, 2011
	!		30MG	A079051	002	Jul 25, 2008
	!		40MG	A079051	003	Jul 25, 2008
NITAZOXANIDE						
FOR SUSPENSION;ORAL						
ALINIA						
	+!	ROMARK	100MG/5ML	N021498	001	Nov 22, 2002
TABLET;ORAL						
ALINIA						
	+!	ROMARK	500MG	N021497	001	Jul 21, 2004
NITISINONE						
CAPSULE;ORAL						
NITISINONE						
AB		NOVITIUM PHARMA	**2MG**	**A211041**	**001**	Aug 26, 2019
AB			**5MG**	**A211041**	**002**	Aug 26, 2019
AB			**10MG**	**A211041**	**003**	Aug 26, 2019
ORFADIN						
AB	**+**	SWEDISH ORPHAN	**2MG**	**N021232**	**001**	Jan 18, 2002
AB	**+**		**5MG**	**N021232**	**002**	Jan 18, 2002
AB	**+**		**10MG**	**N021232**	**003**	Jan 18, 2002
	+!		20MG	N021232	004	Jun 13, 2016
SUSPENSION;ORAL						
ORFADIN						
	+!	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016
TABLET;ORAL						
NITYR						
	+	CYCLE PHARMS LTD	2MG	N209449	001	Jul 26, 2017
	+		5MG	N209449	002	Jul 26, 2017
	+!		10MG	N209449	003	Jul 26, 2017
NITRIC OXIDE						
GAS;INHALATION						
INOMAX						
AA	**+!**	MALLINCKRODT HOSP	**800PPM**	**N020845**	**003**	Dec 23, 1999
NOXIVENT						
AA		PRAXAIR DISTRIBUTION	**800PPM**	**A207141**	**002**	Oct 02, 2018
GENOSYL						
	+!	VERO BIOTECH	800PPM	N202860	001	Dec 20, 2019
NOXIVENT						
		PRAXAIR DISTRIBUTION	100PPM	A207141	001	Oct 02, 2018
NITROFURANTOIN						
SUSPENSION;ORAL						
FURADANTIN						
AB	**+!**	CASPER PHARMA LLC	**25MG/5ML**	**N009175**	**001**	
NITROFURANTOIN						
AB		ACTAVIS MID ATLANTIC	**25MG/5ML**	**A205180**	**001**	May 03, 2016

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

AB		AMNEAL PHARMS	**25MG/5ML**	**A201679**	**001**	May 11, 2011
AB		NOSTRUM LABS INC	**25MG/5ML**	**A201355**	**001**	Aug 14, 2013
AB		NOVEL LABS INC	**25MG/5ML**	**A201693**	**001**	Sep 08, 2014

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

AB	**+**	ALVOGEN	**25MG**	**N016620**	**003**	
AB	**+**		**50MG**	**N016620**	**001**	
AB	**+!**		**100MG**	**N016620**	**002**	

NITROFURANTOIN

AB		ACTAVIS LABS FL INC	**25MG**	**A091095**	**001**	Jun 18, 2015
AB			**50MG**	**A091095**	**002**	Jun 18, 2015
AB			**100MG**	**A091095**	**003**	Jun 18, 2015
AB		IMPAX LABS INC	**50MG**	**A073671**	**001**	Jan 28, 1993
AB			**100MG**	**A073652**	**001**	Jan 28, 1993
AB		NOVEL LABS INC	**50MG**	**A203233**	**001**	Jul 09, 2018
AB			**100MG**	**A203233**	**002**	Jul 09, 2018
AB		SUN PHARM INDUSTRIES	**25MG**	**A201722**	**001**	Feb 16, 2016
AB			**50MG**	**A201722**	**002**	Feb 16, 2016
AB			**100MG**	**A201722**	**003**	Feb 16, 2016
AB		ZYDUS PHARMS	**50MG**	**A205005**	**001**	Dec 12, 2017
AB			**100MG**	**A205005**	**002**	Dec 12, 2017

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

AB	**+!**	ALVOGEN	**75MG;25MG**	**N020064**	**001**	Dec 24, 1991

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		AMNEAL PHARMS	**75MG;25MG**	**A207372**	**001**	May 15, 2017
AB		MYLAN	**75MG;25MG**	**A076648**	**001**	Mar 22, 2004
AB		SANDOZ	**75MG;25MG**	**A077066**	**001**	Apr 05, 2005
AB		SUNNY PHARMTECH INC	**75MG;25MG**	**A208516**	**001**	May 24, 2018
AB		WATSON LABS INC	**75MG;25MG**	**A202250**	**001**	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL

NITROMIST

	+!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006

FILM, EXTENDED RELEASE;TRANSDERMAL

NITROGLYCERIN

AB2		HERCON PHARM	**0.1MG/HR**	**A089885**	**002**	Oct 30, 2017
AB2			**0.2MG/HR**	**A089884**	**001**	Oct 30, 1998
AB2			**0.4MG/HR**	**A089885**	**001**	Oct 30, 1998
AB2			**0.6MG/HR**	**A089886**	**001**	Oct 30, 1998
AB2	**!**	MYLAN TECHNOLOGIES	**0.1MG/HR**	**A074559**	**004**	Feb 06, 1998
AB2	**!**		**0.2MG/HR**	**A074559**	**003**	Aug 30, 1996
AB2	**!**		**0.4MG/HR**	**A074559**	**002**	Aug 30, 1996
AB2	**!**		**0.6MG/HR**	**A074559**	**001**	Aug 30, 1996

NITRO-DUR

	+!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995
	+!		0.2MG/HR	N020145	002	Apr 04, 1995
	+!		0.3MG/HR	N020145	003	Apr 04, 1995
	+!		0.4MG/HR	N020145	004	Apr 04, 1995
	+!		0.6MG/HR	N020145	005	Apr 04, 1995
	+!		0.8MG/HR	N020145	006	Apr 04, 1995

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	**+!**	BAXTER HLTHCARE	**10MG/100ML**	**N019970**	**001**	Dec 29, 1989
AP	**+!**		**20MG/100ML**	**N019970**	**002**	Dec 29, 1989
AP	**+!**		**40MG/100ML**	**N019970**	**003**	Dec 29, 1989

NITROGLYCERIN

	!	LUITPOLD	5MG/ML	A072034	001	May 24, 1988

OINTMENT;INTRA-ANAL

RECTIV

	+!	ALLERGAN	0.4%	N021359	001	Jun 21, 2011

OINTMENT;TRANSDERMAL

NITROGLYCERIN

	!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988

NITROGLYCERIN						
POWDER;SUBLINGUAL						
GONITRO						
	+!	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016
SPRAY, METERED;SUBLINGUAL						
NITROGLYCERIN						
AB		PERRIGO ISRAEL	**0.4MG/SPRAY**	**A091496**	**001**	Sep 20, 2013
NITROLINGUAL PUMPSPRAY						
AB	**+!**	POHL BOSKAMP	**0.4MG/SPRAY**	**N018705**	**002**	Jan 10, 1997
TABLET;SUBLINGUAL						
NITROGLYCERIN						
AB		ACTAVIS LABS FL INC	**0.3MG**	**A203693**	**001**	Oct 16, 2017
AB			**0.4MG**	**A203693**	**002**	Oct 16, 2017
AB			**0.6MG**	**A203693**	**003**	Oct 16, 2017
AB		ALVOGEN	**0.3MG**	**A211604**	**001**	Apr 30, 2019
AB			**0.4MG**	**A211604**	**002**	Apr 30, 2019
AB			**0.6MG**	**A211604**	**003**	Apr 30, 2019
AB		DR REDDYS	**0.3MG**	**A208191**	**001**	Aug 26, 2016
AB			**0.4MG**	**A208191**	**002**	Aug 26, 2016
AB			**0.6MG**	**A208191**	**003**	Aug 26, 2016
AB		GLENMARK PHARMS SA	**0.3MG**	**A206391**	**001**	Sep 19, 2017
AB			**0.4MG**	**A206391**	**002**	Sep 19, 2017
AB			**0.6MG**	**A206391**	**003**	Sep 19, 2017
AB		SIGMAPHARM LABS LLC	**0.3MG**	**A207745**	**001**	May 07, 2018
AB			**0.4MG**	**A207745**	**002**	May 07, 2018
AB			**0.6MG**	**A207745**	**003**	May 07, 2018
NITROSTAT						
AB	**+**	PFIZER PHARMS	**0.3MG**	**N021134**	**001**	May 01, 2000
AB	**+**		**0.4MG**	**N021134**	**002**	May 01, 2000
AB	**+!**		**0.6MG**	**N021134**	**003**	May 01, 2000
NIZATIDINE						
CAPSULE;ORAL						
NIZATIDINE						
AB		DR REDDYS LABS LTD	**150MG**	**A077314**	**001**	Sep 15, 2005
AB			**300MG**	**A077314**	**002**	Sep 15, 2005
AB		GLENMARK GENERICS	**150MG**	**A090618**	**001**	Jul 15, 2011
AB			**300MG**	**A090618**	**002**	Jul 15, 2011
AB		MYLAN PHARMS INC	**150MG**	**A075806**	**001**	Jul 05, 2002
AB	**!**		**300MG**	**A075806**	**002**	Jul 05, 2002
AB		SANDOZ	**150MG**	**A076178**	**001**	Jul 05, 2002
AB			**300MG**	**A076178**	**002**	Jul 05, 2002
AB		WATSON LABS	**150MG**	**A075616**	**001**	Jul 09, 2002
AB			**300MG**	**A075616**	**002**	Jul 09, 2002
SOLUTION;ORAL						
NIZATIDINE						
	!	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009
NOREPINEPHRINE BITARTRATE						
INJECTABLE;INJECTION						
LEVOPHED						
AP	**+!**	HOSPIRA	**EQ 1MG BASE/ML**	**N007513**	**001**	
NOREPINEPHRINE BITARTRATE						
AP		AMNEAL	**EQ 1MG BASE/ML**	**A210839**	**001**	Dec 17, 2018
AP		BAXTER HLTHCARE CORP	**EQ 1MG BASE/ML**	**A040859**	**001**	Mar 27, 2012
AP		HIKMA	**EQ 1MG BASE/ML**	**A203662**	**001**	Nov 07, 2018
AP		MYLAN LABS LTD	**EQ 1MG BASE/ML**	**A211242**	**001**	Oct 04, 2018
AP		SANDOZ INC	**EQ 1MG BASE/ML**	**A211359**	**001**	Oct 18, 2018
AP		TEVA PHARMS USA	**EQ 1MG BASE/ML**	**A040455**	**001**	Mar 03, 2003
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/ML**	**A040462**	**001**	Oct 31, 2003
NORETHINDRONE						
TABLET;ORAL-28						
CAMILA						
AB1		MAYNE PHARMA	**0.35MG**	**A076177**	**001**	Oct 21, 2002
HEATHER						
AB1		GLENMARK GENERICS	**0.35MG**	**A090454**	**001**	Apr 23, 2010
INCASSIA						
AB1		AUROBINDO PHARMA LTD	**0.35MG**	**A207304**	**001**	Sep 23, 2016
NOR-QD						
AB1	**+!**	APIL	**0.35MG**	**N017060**	**001**	

NORETHINDRONE

TABLET;ORAL-28

NORETHINDRONE

AB1		ACCORD HLTHCARE	**0.35MG**	**A206807**	**001**	Dec 13, 2016
AB1		AMNEAL PHARMS	**0.35MG**	**A202260**	**001**	Aug 01, 2013
AB1		LUPIN LTD	**0.35MG**	**A091325**	**001**	Sep 19, 2011
AB1		MYLAN LABS LTD	**0.35MG**	**A201483**	**001**	Jun 24, 2013
AB1		NOVAST LABS	**0.35MG**	**A202014**	**001**	Sep 13, 2013

ERRIN

AB2		MAYNE PHARMA	**0.35MG**	**A076225**	**001**	Oct 21, 2002

JENCYCLA

AB2		LUPIN LTD	**0.35MG**	**A091323**	**001**	Mar 28, 2013

NORETHINDRONE

AB2		GLENMARK GENERICS	**0.35MG**	**A091209**	**001**	Jul 22, 2010
AB2	!	MYLAN LABS LTD	**0.35MG**	**A200980**	**001**	Jun 12, 2013
AB2		NOVAST LABS	**0.35MG**	**A200961**	**001**	Sep 13, 2013

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB		AMNEAL PHARMS	**5MG**	**A200275**	**001**	Jul 30, 2012
AB	!	BARR	**5MG**	**A075951**	**001**	May 25, 2001
AB		GLENMARK GENERICS	**5MG**	**A091090**	**001**	Jul 21, 2010
AB		MYLAN LABS LTD	**5MG**	**A205278**	**001**	Nov 10, 2016
AB		NOVAST LABS	**5MG**	**A206490**	**001**	Nov 05, 2018

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB		MAYNE PHARMA	**EQ 10MG BASE**	**A073556**	**002**	Mar 30, 1992
AB			**EQ 25MG BASE**	**A073556**	**003**	Mar 30, 1992
AB			**EQ 50MG BASE**	**A073556**	**004**	Mar 30, 1992
AB			**EQ 75MG BASE**	**A073556**	**001**	Mar 30, 1992
AB		TARO	**EQ 10MG BASE**	**A075520**	**004**	May 08, 2000
AB			**EQ 25MG BASE**	**A075520**	**003**	May 08, 2000
AB			**EQ 50MG BASE**	**A075520**	**001**	May 08, 2000
AB			**EQ 75MG BASE**	**A075520**	**002**	May 08, 2000
AB		TEVA	**EQ 10MG BASE**	**A074132**	**001**	Mar 27, 1995
AB			**EQ 25MG BASE**	**A074132**	**002**	Mar 27, 1995
AB			**EQ 50MG BASE**	**A074132**	**003**	Mar 27, 1995
AB			**EQ 75MG BASE**	**A074132**	**004**	Mar 27, 1995

PAMELOR

AB	+	SPECGX LLC	**EQ 10MG BASE**	**N018013**	**001**	
AB	+		**EQ 25MG BASE**	**N018013**	**002**	
AB	+		**EQ 50MG BASE**	**N018013**	**004**	
AB	+!		**EQ 75MG BASE**	**N018013**	**003**	

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A075606**	**001**	Aug 28, 2000
AA		TARO	**EQ 10MG BASE/5ML**	**A077965**	**001**	Jun 20, 2006

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

SPINRAZA

	+!	BIOGEN IDEC	12MG/5ML (2.4MG/ML)	N209531	001	Dec 23, 2016

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		ACP NIMBLE	**100,000 UNITS/GM**	**A061966**	**001**	
AT		ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062949**	**001**	Jun 13, 1988
AT		CROWN LABS INC	**100,000 UNITS/GM**	**A207733**	**001**	Sep 26, 2017
AT		FOUGERA PHARMS	**100,000 UNITS/GM**	**A062129**	**001**	
AT		PERRIGO NEW YORK	**100,000 UNITS/GM**	**A062225**	**001**	
AT	!	TARO	**100,000 UNITS/GM**	**A064022**	**001**	Jan 29, 1993
AT		TORRENT	**100,000 UNITS/GM**	**A212557**	**001**	Jul 24, 2019
AT		VINTAGE	**100,000 UNITS/GM**	**A065315**	**001**	May 31, 2006

OINTMENT;TOPICAL

NYSTATIN

AT		ACP NIMBLE	**100,000 UNITS/GM**	**A209114**	**001**	Oct 06, 2017
AT		ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062840**	**001**	Nov 13, 1987
AT		CADILA	**100,000 UNITS/GM**	**A207767**	**001**	May 25, 2018
AT	!	FOUGERA PHARMS	**100,000 UNITS/GM**	**A062124**	**002**	Sep 23, 1982

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

AT		LYNE	**100,000 UNITS/GM**	**A209082**	**001**	May 21, 2018
AT		PERRIGO NEW YORK	**100,000 UNITS/GM**	**A062472**	**001**	Feb 13, 1984
AT		TORRENT	**100,000 UNITS/GM**	**A211838**	**001**	Jan 28, 2019

POWDER;TOPICAL

NYSTATIN

AT		EPIC PHARMA LLC	**100,000 UNITS/GM**	**A210532**	**001**	Apr 30, 2018
AT		LUPIN	**100,000 UNITS/GM**	**A065138**	**001**	Jul 23, 2004
AT		LYNE	**100,000 UNITS/GM**	**A208838**	**001**	May 30, 2017
AT	!	MAYNE PHARMA INC	**100,000 UNITS/GM**	**A065203**	**001**	Jul 15, 2004
AT		NESHER PHARMS	**100,000 UNITS/GM**	**A208581**	**001**	Jun 08, 2017
AT		UPSHER SMITH LABS	**100,000 UNITS/GM**	**A065183**	**001**	May 03, 2005
AT		X GEN PHARMS	**100,000 UNITS/GM**	**A065175**	**001**	Dec 17, 2004

NYSTOP

AT		PADDOCK LLC	**100,000 UNITS/GM**	**A064118**	**001**	Aug 16, 1996

SUSPENSION;ORAL

NYSTATIN

AA		FOUGERA PHARMS INC	**100,000 UNITS/ML**	**A062517**	**001**	Jun 07, 1984
AA		HI TECH PHARMA	**100,000 UNITS/ML**	**A064042**	**001**	Feb 28, 1994
AA		LANNETT CO INC	**100,000 UNITS/ML**	**A065148**	**001**	Jun 28, 2005
AA		PHARM ASSOC	**100,000 UNITS/ML**	**A203621**	**001**	Jan 07, 2016
AA		TARO	**100,000 UNITS/ML**	**A062876**	**001**	Feb 29, 1988
AA		VISTAPHARM	**100,000 UNITS/ML**	**A064142**	**001**	Jun 25, 1998
AA			**100,000 UNITS/ML**	**A065422**	**001**	Mar 07, 2011
AA	!	WOCKHARDT BIO AG	**100,000 UNITS/ML**	**A062512**	**001**	Oct 29, 1984

TABLET;ORAL

NYSTATIN

AA		HERITAGE PHARMS INC	**500,000 UNITS**	**A062474**	**001**	Dec 22, 1983
AA		SUN PHARM INDUSTRIES	**500,000 UNITS**	**A062838**	**001**	Dec 22, 1988
AA	!	TEVA	**500,000 UNITS**	**A062506**	**001**	Jan 16, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT		ACP NIMBLE	**100,000 UNITS/GM;0.1%**	**A062367**	**001**	May 28, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		AMNEAL PHARMS LLC	**100,000 UNITS/GM;0.1%**	**A209990**	**001**	Feb 15, 2018
AT		CROWN LABS INC	**100,000 UNITS/GM;0.1%**	**A207730**	**001**	Dec 26, 2017
AT		DR REDDYS	**100,000 UNITS/GM;0.1%**	**A208326**	**001**	Oct 26, 2016
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062599**	**001**	Oct 08, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208136**	**001**	Oct 24, 2016
AT		LUPIN LTD	**100,000 UNITS/GM;0.1%**	**A208205**	**001**	May 31, 2018
AT		PERRIGO UK FINCO	**100,000 UNITS/GM;0.1%**	**A208479**	**001**	Aug 14, 2017
AT	!	TARO	**100,000 UNITS/GM;0.1%**	**A062364**	**001**	Dec 22, 1987

OINTMENT;TOPICAL

MYKACET

AT		ACP NIMBLE	**100,000 UNITS/GM;0.1%**	**A062733**	**001**	Mar 06, 1987

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		AKORN	**100,000 UNITS/GM;0.1%**	**A207217**	**001**	Aug 04, 2017
AT		DR REDDYS	**100,000 UNITS/GM;0.1%**	**A207741**	**001**	Jan 31, 2017
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062602**	**001**	Oct 09, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208300**	**001**	Jun 23, 2016
AT		PERRIGO UK FINCO	**100,000 UNITS/GM;0.1%**	**A207380**	**001**	Dec 20, 2016
AT		RISING	**100,000 UNITS/GM;0.1%**	**A206785**	**001**	Dec 29, 2016
AT		STRIDES PHARMA	**100,000 UNITS/GM;0.1%**	**A210077**	**001**	Jan 29, 2018
AT	!	TARO	**100,000 UNITS/GM;0.1%**	**A063305**	**001**	Mar 29, 1993
AT		TELIGENT PHARMA INC	**100,000 UNITS/GM;0.1%**	**A208287**	**001**	Dec 30, 2016
AT		VITRUVIAS THERAP	**100000 UNITS/GM;0.1%**	**A207316**	**001**	Nov 18, 2019

OBETICHOLIC ACID

TABLET;ORAL

OCALIVA

	+	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016
	+!		10MG	N207999	002	May 27, 2016

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP		FRESENIUS KABI USA	**EQ 0.2MG BASE/ML**	**A077450**	**001**	Feb 10, 2006
AP			**EQ 1MG BASE/ML**	**A077450**	**002**	Feb 10, 2006
AP		HERITAGE PHARMS INC	**EQ 0.05MG BASE/ML**	**A204669**	**001**	Dec 27, 2018
AP			**EQ 0.1MG BASE/ML**	**A204669**	**002**	Dec 27, 2018
AP			**EQ 0.5MG BASE/ML**	**A204669**	**003**	Dec 27, 2018
AP		SAGENT PHARMS INC	**EQ 0.2MG BASE/ML**	**A091041**	**001**	Nov 12, 2013
AP			**EQ 1MG BASE/ML**	**A091041**	**002**	Nov 12, 2013
AP		TEVA PHARMS USA	**EQ 0.05MG BASE/ML**	**A075957**	**001**	Oct 03, 2005
AP			**EQ 0.1MG BASE/ML**	**A075957**	**002**	Oct 03, 2005
AP			**EQ 0.2MG BASE/ML**	**A075959**	**001**	Nov 21, 2005
AP			**EQ 0.5MG BASE/ML**	**A075957**	**003**	Oct 03, 2005
AP			**EQ 1MG BASE/ML**	**A075959**	**002**	Nov 21, 2005
AP	**!**	WEST-WARD PHARMS INT	**EQ 0.2MG BASE/ML**	**A076330**	**001**	Apr 08, 2005
AP	**!**		**EQ 1MG BASE/ML**	**A076330**	**002**	Apr 08, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A077457**	**001**	Feb 10, 2006
AP			**EQ 0.1MG BASE/ML**	**A077457**	**002**	Feb 10, 2006
AP			**EQ 0.5MG BASE/ML**	**A077457**	**003**	Feb 10, 2006
AP		MYLAN INSTITUTIONAL	**EQ 0.05MG BASE/ML**	**A079198**	**001**	Feb 10, 2011
AP			**EQ 0.1MG BASE/ML**	**A079198**	**002**	Feb 10, 2011
AP			**EQ 0.5MG BASE/ML**	**A079198**	**003**	Feb 10, 2011
AP		SAGENT PHARMS INC	**EQ 0.05MG BASE/ML**	**A090834**	**001**	Nov 12, 2013
AP			**EQ 0.1MG BASE/ML**	**A090834**	**002**	Nov 12, 2013
AP			**EQ 0.5MG BASE/ML**	**A090834**	**003**	Nov 12, 2013
AP	**!**	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**A076313**	**001**	Mar 28, 2005
AP	**!**		**EQ 0.1MG BASE/ML**	**A076313**	**003**	Mar 28, 2005
AP	**!**		**EQ 0.5MG BASE/ML**	**A076313**	**002**	Mar 28, 2005

SANDOSTATIN

AP	**+!**	NOVARTIS	**EQ 0.05MG BASE/ML**	**N019667**	**001**	Oct 21, 1988
AP	**+!**		**EQ 0.1MG BASE/ML**	**N019667**	**002**	Oct 21, 1988
AP	**+!**		**EQ 0.2MG BASE/ML**	**N019667**	**004**	Jun 12, 1991
AP	**+!**		**EQ 0.5MG BASE/ML**	**N019667**	**003**	Oct 21, 1988
AP	**+!**		**EQ 1MG BASE/ML**	**N019667**	**005**	Jun 12, 1991

SANDOSTATIN LAR

	+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
	+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
	+!		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OCUFLOX

AT	**+!**	ALLERGAN	**0.3%**	**N019921**	**001**	Jul 30, 1993

OFLOXACIN

AT		AKORN	**0.3%**	**A076407**	**001**	Apr 15, 2008
AT		ALTAIRE PHARMS INC	**0.3%**	**A202692**	**001**	Apr 29, 2013
AT		ALVOGEN	**0.3%**	**A076830**	**001**	Aug 31, 2004
AT		APOTEX INC	**0.3%**	**A076513**	**001**	May 14, 2004
AT		BAUSCH AND LOMB	**0.3%**	**A076622**	**001**	May 14, 2004
AT		FDC LTD	**0.3%**	**A078559**	**001**	Feb 25, 2009
AT		HI TECH PHARMA	**0.3%**	**A076615**	**001**	May 14, 2004

SOLUTION/DROPS;OTIC

OFLOXACIN

AT		AMNEAL	**0.3%**	**A211525**	**001**	Aug 30, 2019
AT		APOTEX INC	**0.3%**	**A076527**	**001**	Sep 28, 2007
AT	**!**	BAUSCH AND LOMB	**0.3%**	**A076128**	**001**	Mar 17, 2008
AT		HI TECH PHARMA	**0.3%**	**A076616**	**001**	Mar 17, 2008

TABLET;ORAL

OFLOXACIN

AB		CADILA PHARMS LTD	**200MG**	**A091656**	**001**	Sep 18, 2014
AB			**300MG**	**A091656**	**002**	Sep 18, 2014
AB			**400MG**	**A091656**	**003**	Sep 18, 2014
AB		DR REDDYS LABS LTD	**200MG**	**A077098**	**001**	Feb 10, 2006
AB			**300MG**	**A077098**	**002**	Feb 10, 2006
AB			**400MG**	**A077098**	**003**	Feb 10, 2006
AB		TEVA	**200MG**	**A076182**	**001**	Sep 02, 2003
AB			**300MG**	**A076182**	**002**	Sep 02, 2003
AB	**!**		**400MG**	**A076182**	**003**	Sep 02, 2003

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP		AM REGENT	**10MG/VIAL**	**A201741**	**001**	Mar 20, 2012
AP		SANDOZ INC	**10MG/VIAL**	**A201588**	**001**	Oct 24, 2011

ZYPREXA

AP	**+!**	LILLY	**10MG/VIAL**	**N021253**	**001**	Mar 29, 2004

TABLET;ORAL

OLANZAPINE

AB		ALKEM LABS LTD	**2.5MG**	**A202295**	**001**	Oct 20, 2015
AB			**5MG**	**A202295**	**002**	Oct 20, 2015
AB			**7.5MG**	**A202295**	**003**	Oct 20, 2015
AB			**10MG**	**A202295**	**004**	Oct 20, 2015
AB			**15MG**	**A202295**	**005**	Oct 20, 2015
AB			**20MG**	**A202295**	**006**	Oct 20, 2015
AB		APOTEX INC	**2.5MG**	**A090798**	**001**	Apr 23, 2012
AB			**5MG**	**A090798**	**002**	Apr 23, 2012
AB			**7.5MG**	**A090798**	**003**	Apr 23, 2012
AB			**10MG**	**A090798**	**004**	Apr 23, 2012
AB			**15MG**	**A090798**	**005**	Apr 23, 2012
AB			**20MG**	**A090798**	**006**	Apr 23, 2012
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A202050**	**001**	Apr 23, 2012
AB			**5MG**	**A202050**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202050**	**003**	Apr 23, 2012
AB			**10MG**	**A202050**	**004**	Apr 23, 2012
AB			**15MG**	**A202050**	**005**	Apr 23, 2012
AB			**20MG**	**A202050**	**006**	Apr 23, 2012
AB		DR REDDYS LABS LTD	**2.5MG**	**A076255**	**001**	Apr 23, 2012
AB			**5MG**	**A076255**	**002**	Apr 23, 2012
AB			**7.5MG**	**A076255**	**003**	Apr 23, 2012
AB			**10MG**	**A076255**	**004**	Apr 23, 2012
AB			**15MG**	**A076133**	**001**	Apr 23, 2012
AB			**20MG**	**A076133**	**002**	Oct 24, 2011
AB		HIKMA PHARMS	**2.5MG**	**A204866**	**001**	Jun 16, 2017
AB			**5MG**	**A204866**	**002**	Jun 16, 2017
AB			**7.5MG**	**A204866**	**003**	Jun 16, 2017
AB			**10MG**	**A204866**	**004**	Jun 16, 2017
AB			**15MG**	**A204866**	**005**	Jun 16, 2017
AB			**20MG**	**A204866**	**006**	Jun 16, 2017
AB		INVAGEN PHARMS	**2.5MG**	**A203333**	**001**	Mar 15, 2016
AB			**5MG**	**A203333**	**002**	Mar 15, 2016
AB			**7.5MG**	**A203333**	**003**	Mar 15, 2016
AB			**10MG**	**A203333**	**004**	Mar 15, 2016
AB			**15MG**	**A203333**	**005**	Mar 15, 2016
AB			**20MG**	**A203333**	**006**	Mar 15, 2016
AB		IVAX PHARMS INC	**20MG**	**A077301**	**001**	Apr 29, 2015
AB		JIANGSU HANSOH PHARM	**2.5MG**	**A209399**	**001**	Sep 24, 2018
AB			**5MG**	**A209399**	**002**	Sep 24, 2018
AB			**10MG**	**A209399**	**003**	Sep 24, 2018
AB		MACLEODS PHARMS LTD	**2.5MG**	**A202862**	**001**	Aug 15, 2014
AB			**5MG**	**A202862**	**002**	Aug 15, 2014
AB			**7.5MG**	**A202862**	**003**	Aug 15, 2014
AB			**10MG**	**A202862**	**004**	Aug 15, 2014
AB			**15MG**	**A202862**	**005**	Aug 15, 2014
AB			**20MG**	**A202862**	**006**	Aug 15, 2014
AB		ORCHID HLTHCARE	**2.5MG**	**A202287**	**001**	Apr 23, 2012
AB			**5MG**	**A202287**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202287**	**003**	Apr 23, 2012
AB			**10MG**	**A202287**	**004**	Apr 23, 2012
AB			**15MG**	**A202287**	**005**	Apr 23, 2012
AB			**20MG**	**A202287**	**006**	Apr 23, 2012
AB		QILU	**2.5MG**	**A204319**	**001**	Jan 27, 2016
AB			**5MG**	**A204319**	**002**	Jan 27, 2016
AB			**7.5MG**	**A204319**	**003**	Jan 27, 2016
AB			**10MG**	**A204319**	**004**	Jan 27, 2016
AB			**15MG**	**A204319**	**005**	Jan 27, 2016
AB			**20MG**	**A204319**	**006**	Jan 27, 2016
AB		SUN PHARM INDS	**2.5MG**	**A091038**	**001**	Apr 23, 2012
AB			**5MG**	**A091038**	**002**	Apr 23, 2012
AB			**7.5MG**	**A091038**	**003**	Apr 23, 2012
AB			**10MG**	**A091038**	**004**	Apr 23, 2012

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB			**15MG**	**A091038**	**005**	Apr 23, 2012
AB			**20MG**	**A091038**	**006**	Apr 23, 2012
AB		TEVA PHARMS	**2.5MG**	**A076000**	**001**	Oct 24, 2011
AB			**5MG**	**A076000**	**002**	Oct 24, 2011
AB			**7.5MG**	**A076000**	**003**	Oct 24, 2011
AB			**10MG**	**A076000**	**004**	Oct 24, 2011
AB			**15MG**	**A076000**	**005**	Oct 24, 2011
AB		TORRENT PHARMS LTD	**2.5MG**	**A091434**	**001**	Apr 23, 2012
AB			**5MG**	**A091434**	**002**	Apr 23, 2012
AB			**7.5MG**	**A091434**	**003**	Apr 23, 2012
AB			**10MG**	**A091434**	**004**	Apr 23, 2012
AB			**15MG**	**A091434**	**005**	Apr 23, 2012
AB			**20MG**	**A091434**	**006**	Apr 23, 2012
AB		ZYDUS PHARMS	**2.5MG**	**A090459**	**001**	Jul 16, 2018
AB			**5MG**	**A090459**	**002**	Jul 16, 2018
AB			**7.5MG**	**A090459**	**003**	Jul 16, 2018
AB			**10MG**	**A090459**	**004**	Jul 16, 2018
AB			**15MG**	**A090459**	**005**	Jul 16, 2018
AB			**20MG**	**A090459**	**006**	Jul 16, 2018

ZYPREXA

AB	+	LILLY	**2.5MG**	**N020592**	**001**	Sep 30, 1996
AB	+!		**5MG**	**N020592**	**002**	Sep 30, 1996
AB	+		**7.5MG**	**N020592**	**003**	Sep 30, 1996
AB	+		**10MG**	**N020592**	**004**	Sep 30, 1996
AB	+		**15MG**	**N020592**	**005**	Sep 09, 1997
AB	+		**20MG**	**N020592**	**006**	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB		APOTEX INC	**5MG**	**A091265**	**001**	Oct 24, 2011
AB			**10MG**	**A091265**	**002**	Oct 24, 2011
AB			**15MG**	**A091265**	**003**	Oct 24, 2011
AB			**20MG**	**A091265**	**004**	Oct 24, 2011
AB		AUROBINDO PHARMA LTD	**5MG**	**A203708**	**001**	May 15, 2014
AB			**10MG**	**A203708**	**002**	May 15, 2014
AB			**15MG**	**A203708**	**003**	May 15, 2014
AB			**20MG**	**A203708**	**004**	May 15, 2014
AB		BARR LABS INC	**5MG**	**A077243**	**001**	Jan 30, 2012
AB			**10MG**	**A077243**	**002**	Jan 30, 2012
AB			**15MG**	**A077243**	**003**	Jan 30, 2012
AB			**20MG**	**A077243**	**004**	Jan 30, 2012
AB		DR REDDYS LABS LTD	**5MG**	**A076534**	**001**	Oct 24, 2011
AB			**10MG**	**A076534**	**002**	Oct 24, 2011
AB			**15MG**	**A076534**	**003**	Oct 24, 2011
AB			**20MG**	**A076534**	**004**	Oct 24, 2011
AB		INVAGEN PHARMS	**5MG**	**A203456**	**001**	Mar 16, 2016
AB			**10MG**	**A203456**	**002**	Mar 16, 2016
AB			**15MG**	**A203456**	**003**	Mar 16, 2016
AB			**20MG**	**A203456**	**004**	Mar 16, 2016
AB		JUBILANT GENERICS	**5MG**	**A200221**	**001**	Sep 12, 2012
AB			**10MG**	**A200221**	**002**	Sep 12, 2012
AB			**15MG**	**A200221**	**003**	Sep 12, 2012
AB			**20MG**	**A200221**	**004**	Sep 12, 2012
AB		MACLEODS PHARMS LTD	**5MG**	**A203044**	**001**	Feb 20, 2015
AB			**10MG**	**A203044**	**002**	Feb 20, 2015
AB			**15MG**	**A203044**	**003**	Feb 20, 2015
AB			**20MG**	**A203044**	**004**	Feb 20, 2015
AB		MYLAN	**5MG**	**A202285**	**001**	May 12, 2014
AB			**10MG**	**A202285**	**002**	May 12, 2014
AB			**15MG**	**A202285**	**003**	May 12, 2014
AB			**20MG**	**A202285**	**004**	May 12, 2014
AB		ORCHID HLTHCARE	**5MG**	**A202937**	**001**	Mar 02, 2015
AB			**10MG**	**A202937**	**002**	Mar 02, 2015
AB			**15MG**	**A202937**	**003**	Mar 02, 2015
AB			**20MG**	**A202937**	**004**	Mar 02, 2015
AB		PAR PHARM	**5MG**	**A078109**	**001**	Oct 24, 2011
AB			**10MG**	**A078109**	**002**	Oct 24, 2011
AB			**15MG**	**A078109**	**003**	Oct 24, 2011
AB			**20MG**	**A078109**	**004**	Oct 24, 2011
AB		SUN PHARM INDS	**5MG**	**A090881**	**001**	Feb 28, 2012

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB			**10MG**	**A090881**	**002**	Feb 28, 2012
AB			**15MG**	**A090881**	**003**	Feb 28, 2012
AB			**20MG**	**A090881**	**004**	Feb 28, 2012
AB		TORRENT PHARMS LLC	**5MG**	**A091415**	**001**	Oct 25, 2011
AB			**10MG**	**A091415**	**002**	Oct 25, 2011
AB			**15MG**	**A091415**	**003**	Oct 25, 2011
AB			**20MG**	**A091415**	**004**	Oct 25, 2011

ZYPREXA ZYDIS

AB	**+!**	LILLY	**5MG**	**N021086**	**001**	Apr 06, 2000
AB	**+**		**10MG**	**N021086**	**002**	Apr 06, 2000
AB	**+**		**15MG**	**N021086**	**003**	Apr 06, 2000
AB	**+**		**20MG**	**N021086**	**004**	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

+	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+!		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLAPARIB

CAPSULE;ORAL

LYNPARZA

+!	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014

TABLET;ORAL

LYNPARZA

+	ASTRAZENECA PHARMS	100MG	N208558	001	Aug 17, 2017
+!		150MG	N208558	002	Aug 17, 2017

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

CLINOLIPID 20%

+!	BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

AB	**+**	DAIICHI SANKYO	**5MG**	**N021286**	**001**	Apr 25, 2002
AB	**+**		**20MG**	**N021286**	**003**	Apr 25, 2002
AB	**+!**		**40MG**	**N021286**	**004**	Apr 25, 2002

OLMESARTAN MEDOXOMIL

AB		ACCORD HLTHCARE	**5MG**	**A207662**	**001**	Apr 24, 2017
AB			**20MG**	**A207662**	**002**	Apr 24, 2017
AB			**40MG**	**A207662**	**003**	Apr 24, 2017
AB		ALEMBIC PHARMS LTD	**5MG**	**A203012**	**001**	Apr 24, 2017
AB			**20MG**	**A203012**	**002**	Apr 24, 2017
AB			**40MG**	**A203012**	**003**	Apr 24, 2017
AB		ALKEM LABS LTD	**5MG**	**A206763**	**001**	Apr 24, 2017
AB			**20MG**	**A206763**	**002**	Apr 24, 2017
AB			**40MG**	**A206763**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA LTD	**5MG**	**A204798**	**001**	Apr 24, 2017
AB			**20MG**	**A204798**	**002**	Apr 24, 2017
AB			**40MG**	**A204798**	**003**	Apr 24, 2017
AB		GLENMARK PHARMS LTD	**5MG**	**A203281**	**001**	May 25, 2017
AB			**20MG**	**A203281**	**002**	May 25, 2017
AB			**40MG**	**A203281**	**003**	May 25, 2017
AB		JUBILANT GENERICS	**5MG**	**A205482**	**001**	Apr 24, 2017
AB			**20MG**	**A205482**	**002**	Apr 24, 2017
AB			**40MG**	**A205482**	**003**	Apr 24, 2017
AB		LUPIN LTD	**5MG**	**A206631**	**001**	Apr 27, 2017
AB			**20MG**	**A206631**	**002**	Apr 27, 2017
AB			**40MG**	**A206631**	**003**	Apr 27, 2017
AB		MACLEODS PHARMS LTD	**5MG**	**A204814**	**001**	Apr 24, 2017
AB			**20MG**	**A204814**	**002**	Apr 24, 2017
AB			**40MG**	**A204814**	**003**	Apr 24, 2017
AB		MICRO LABS	**5MG**	**A206372**	**001**	Sep 17, 2019
AB			**20MG**	**A206372**	**002**	Sep 17, 2019
AB			**40MG**	**A206372**	**003**	Sep 17, 2019
AB		MYLAN	**5MG**	**A078276**	**001**	Oct 26, 2016
AB			**20MG**	**A078276**	**002**	Oct 26, 2016

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB		**40MG**	**A078276**	**003**	Oct 26, 2016
AB	QILU	**5MG**	**A210552**	**001**	Jan 10, 2019
AB		**20MG**	**A210552**	**002**	Jan 10, 2019
AB		**40MG**	**A210552**	**003**	Jan 10, 2019
AB	SCIEGEN PHARMS INC	**5MG**	**A208130**	**001**	Jun 29, 2018
AB		**20MG**	**A208130**	**002**	Jun 29, 2018
AB		**40MG**	**A208130**	**003**	Jun 29, 2018
AB	SUNSHINE LAKE	**5MG**	**A211049**	**001**	Feb 22, 2019
AB		**20MG**	**A211049**	**002**	Feb 22, 2019
AB		**40MG**	**A211049**	**003**	Feb 22, 2019
AB	TORRENT	**5MG**	**A202375**	**001**	Apr 24, 2017
AB		**20MG**	**A202375**	**002**	Apr 24, 2017
AB		**40MG**	**A202375**	**003**	Apr 24, 2017
AB	UMEDICA LABS PVT LTD	**5MG**	**A207135**	**001**	Jul 18, 2019
AB		**20MG**	**A207135**	**002**	Jul 18, 2019
AB		**40MG**	**A207135**	**003**	Jul 18, 2019
AB	ZYDUS PHARMS	**5MG**	**A205192**	**001**	Apr 24, 2017
AB		**20MG**	**A205192**	**002**	Apr 24, 2017
AB		**40MG**	**A205192**	**003**	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION

STRIVERDI RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	AKORN	**EQ 0.2% BASE**	**A204723**	**001**	Dec 05, 2017
AT	AKORN INC	**EQ 0.1% BASE**	**A204532**	**001**	Jan 10, 2017
AT	ALEMBIC PHARMS LTD	**EQ 0.1% BASE**	**A209919**	**001**	Dec 07, 2018
AT		**EQ 0.2% BASE**	**A209420**	**001**	Apr 29, 2019
AT	APOTEX	**EQ 0.1% BASE**	**A078350**	**001**	Dec 07, 2015
AT	APOTEX INC	**EQ 0.2% BASE**	**A090918**	**001**	Dec 05, 2017
AT	AUROBINDO PHARMA LTD	**EQ 0.1% BASE**	**A204812**	**001**	Dec 18, 2015
AT		**EQ 0.2% BASE**	**A209995**	**001**	Apr 04, 2019
AT	BARR LABS INC	**EQ 0.2% BASE**	**A090848**	**001**	Jul 13, 2015
AT	CIPLA	**EQ 0.1% BASE**	**A206046**	**001**	Jul 26, 2017
AT		**EQ 0.2% BASE**	**A206087**	**001**	Dec 05, 2017
AT	FDC LTD	**EQ 0.1% BASE**	**A209282**	**001**	Sep 26, 2019
AT	GLAND PHARMA LTD	**EQ 0.1% BASE**	**A209619**	**001**	Aug 02, 2019
AT	MYLAN	**EQ 0.1% BASE**	**A204392**	**001**	Mar 21, 2018
AT	SOMERSET THERAPS LLC	**EQ 0.1% BASE**	**A206306**	**001**	Dec 07, 2015
AT	USV	**EQ 0.1% BASE**	**A203152**	**001**	Dec 07, 2015
AT	WOCKHARDT LTD	**EQ 0.1% BASE**	**A200810**	**001**	Jun 28, 2017

PATADAY

AT	**+!**	NOVARTIS	**EQ 0.2% BASE**	**N021545**	**001**	Dec 22, 2004

PATANOL

AT	**+!**	NOVARTIS	**EQ 0.1% BASE**	**N020688**	**001**	Dec 18, 1996

PAZEO

+!	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	APOTEX INC	**0.665MG/SPRAY**	**A091572**	**001**	Oct 08, 2014
AB	PERRIGO ISRAEL	**0.665MG/SPRAY**	**A202853**	**001**	Jan 31, 2017

PATANASE

AB	**+!**	NOVARTIS	**0.665MG/SPRAY**	**N021861**	**001**	Apr 15, 2008

OLSALAZINE SODIUM
CAPSULE;ORAL
DIPENTUM
+! MYLAN SPECIALITY LP 250MG N019715 001 Jul 31, 1990

OMACETAXINE MEPESUCCINATE
POWDER;SUBCUTANEOUS
SYNRIBO
+! TEVA PHARMS INTL 3.5MG/VIAL N203585 001 Oct 26, 2012

OMADACYCLINE TOSYLATE
POWDER;INTRAVENOUS
NUZYRA
+! PARATEK PHARMS INC EQ 100MG BASE/VIAL N209817 001 Oct 02, 2018
TABLET;ORAL
NUZYRA
+! PARATEK PHARMS INC EQ 150MG BASE N209816 001 Oct 02, 2018

OMEGA-3-ACID ETHYL ESTERS
CAPSULE;ORAL
LOVAZA

AB	**+!**	SMITHKLINE BEECHAM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**N021654**	**001**	Nov 10, 2004

OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A204940**	**001**	Nov 27, 2015
AB		APOTEX	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A090973**	**001**	Sep 30, 2014
AB		ASCENT PHARMS INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A207420**	**001**	Feb 25, 2019
AB		BIONPHARMA INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A206455**	**001**	Aug 07, 2019
AB		STRIDES PHARMA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A203893**	**001**	Sep 19, 2017
AB		SUN PHARM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A210834**	**001**	Jan 09, 2020
AB		TEVA PHARMS USA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A091028**	**001**	Apr 07, 2014

OMEPRAZOLE
CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB		ACTAVIS LABS FL INC	**10MG**	**A075347**	**001**	May 30, 2008
AB			**20MG**	**A075347**	**002**	May 30, 2008
AB			**40MG**	**A075347**	**003**	May 30, 2008
AB		APOTEX	**10MG**	**A076048**	**001**	Oct 22, 2007
AB			**20MG**	**A076048**	**002**	Oct 22, 2007
AB			**40MG**	**A076048**	**003**	Jan 21, 2009
AB		AUROBINDO PHARMA LTD	**10MG**	**A203270**	**001**	Aug 19, 2015
AB			**20MG**	**A203270**	**002**	Aug 19, 2015
AB			**40MG**	**A203270**	**003**	Aug 19, 2015
AB		BRECKENRIDGE	**10MG**	**A203481**	**001**	Jul 03, 2017
AB			**20MG**	**A203481**	**002**	Jul 03, 2017
AB			**40MG**	**A203481**	**003**	Jul 03, 2017
AB		DR REDDYS LABS LTD	**10MG**	**A075576**	**003**	Oct 22, 2007
AB			**10MG**	**A078490**	**002**	Mar 16, 2009
AB			**20MG**	**A075576**	**002**	Oct 22, 2007
AB			**20MG**	**A078490**	**003**	Mar 16, 2009
AB			**40MG**	**A075576**	**001**	Jan 21, 2009
AB			**40MG**	**A078490**	**001**	Apr 17, 2009
AB		GLENMARK GENERICS	**10MG**	**A091672**	**001**	Oct 31, 2014
AB			**20MG**	**A091672**	**002**	Oct 31, 2014
AB			**40MG**	**A091672**	**003**	Oct 31, 2014
AB		HETERO LABS LTD III	**10MG**	**A204012**	**001**	Sep 26, 2019
AB			**20MG**	**A204012**	**002**	Sep 26, 2019
AB		IMPAX LABS	**10MG**	**A075785**	**001**	Oct 22, 2007
AB			**20MG**	**A075785**	**002**	Oct 22, 2007
AB			**40MG**	**A075785**	**003**	Jan 21, 2009
AB		LANNETT CO INC	**10MG**	**A075410**	**001**	Nov 01, 2002
AB			**20MG**	**A075410**	**002**	Nov 01, 2002
AB			**40MG**	**A075410**	**003**	Jan 23, 2009
AB		MYLAN	**10MG**	**A205070**	**001**	Jun 29, 2018
AB			**20MG**	**A075876**	**002**	May 29, 2003
AB			**20MG**	**A205070**	**002**	Jun 29, 2018
AB			**40MG**	**A205070**	**003**	Jun 29, 2018

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB		SANDOZ	**10MG**	**A075757**	**001**	Jan 28, 2003
AB	**!**		**20MG**	**A075757**	**002**	Jan 28, 2003
AB	**!**		**40MG**	**A076515**	**001**	Jan 21, 2009
AB		TEVA PHARMS USA	**20MG**	**A204661**	**001**	Jun 13, 2017
AB			**40MG**	**A204661**	**002**	Jun 13, 2017
AB		ZYDUS PHARMS USA INC	**10MG**	**A091352**	**001**	Nov 19, 2012
AB			**20MG**	**A091352**	**002**	Nov 19, 2012
AB			**40MG**	**A091352**	**003**	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

	+	COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
	+!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG;1.1GM**	**A204228**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204228**	**002**	Jul 15, 2016
AB		AUROLIFE PHARMA LLC	**20MG;1.1GM**	**A204922**	**001**	Aug 19, 2016
AB			**40MG;1.1GM**	**A204922**	**002**	Aug 19, 2016
AB		DR REDDYS LABS LTD	**20MG;1.1GM**	**A204068**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204068**	**002**	Jul 15, 2016
AB		SCIEGEN PHARMS INC	**20MG;1.1GM**	**A207476**	**001**	Dec 06, 2016
AB			**40MG;1.1GM**	**A207476**	**002**	Dec 06, 2016
AB		ZYDUS PHARMS	**20MG;1.1GM**	**A203290**	**001**	May 25, 2018
AB			**40MG;1.1GM**	**A203290**	**002**	May 25, 2018

ZEGERID

AB	**+**	SALIX	**20MG;1.1GM**	**N021849**	**001**	Feb 27, 2006
AB	**+!**		**40MG;1.1GM**	**N021849**	**002**	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG/PACKET;1.68GM/PACKET**	**A205545**	**001**	Jul 27, 2016
AB			**40MG/PACKET;1.68GM/PACKET**	**A205545**	**002**	Jul 27, 2016
AB		PAR PHARM	**20MG/PACKET;1.68GM/PACKET**	**A079182**	**001**	Apr 19, 2013
AB			**40MG/PACKET;1.68GM/PACKET**	**A079182**	**002**	Apr 19, 2013

ZEGERID

AB	**+**	SALIX	**20MG/PACKET;1.68GM/PACKET**	**N021636**	**001**	Jun 15, 2004
AB	**+!**		**40MG/PACKET;1.68GM/PACKET**	**N021636**	**002**	Dec 21, 2004

ONDANSETRON

FILM;ORAL

ZUPLENZ

	+	MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010
	+!		8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		AUROBINDO PHARMA	**4MG**	**A090469**	**001**	Apr 12, 2010
AB			**8MG**	**A090469**	**002**	Apr 12, 2010
AB		BARR	**4MG**	**A076693**	**001**	Jun 25, 2007
AB			**8MG**	**A076693**	**002**	Jun 25, 2007
AB		GLENMARK GENERICS	**4MG**	**A078152**	**001**	Jun 27, 2007
AB			**8MG**	**A078152**	**002**	Jun 27, 2007
AB		MYLAN	**4MG**	**A078139**	**001**	Jun 25, 2007
AB			**8MG**	**A078139**	**002**	Jun 25, 2007
AB		SANDOZ	**4MG**	**A078050**	**001**	Aug 13, 2007
AB			**8MG**	**A078050**	**002**	Aug 13, 2007
AB		SUN PHARM INDS	**4MG**	**A077557**	**001**	Aug 02, 2007
AB			**8MG**	**A077557**	**002**	Aug 02, 2007
AB		SUN PHARM INDS LTD	**4MG**	**A078602**	**001**	Feb 24, 2011
AB			**8MG**	**A078602**	**002**	Feb 24, 2011
AB		TEVA	**4MG**	**A076810**	**001**	Jun 25, 2007
AB			**8MG**	**A076810**	**002**	Jun 25, 2007

ZOFRAN ODT

AB	**+**	NOVARTIS	**4MG**	**N020781**	**001**	Jan 27, 1999
AB	**+!**		**8MG**	**N020781**	**002**	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206846**	**001**	Jul 13, 2015
AP		AUROBINDO PHARMA LTD	**EQ 2MG BASE/ML**	**A202599**	**001**	Dec 21, 2012
AP	!	BAXTER HLTHCARE CORP	**EQ 2MG BASE/ML**	**A078288**	**001**	Feb 22, 2013
AP		EMCURE PHARMS	**EQ 2MG BASE/ML**	**A090424**	**001**	Apr 16, 2010
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076974**	**001**	Dec 26, 2006
AP		GLAND PHARMA LTD	**EQ 2MG BASE/ML**	**A079224**	**001**	Sep 25, 2009
AP			**EQ 2MG BASE/ML**	**A090648**	**001**	Jun 15, 2012
AP		HIKMA FARMACEUTICA	**EQ 2MG BASE/ML**	**A076781**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077473**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077840**	**001**	Jan 19, 2007
AP		MYLAN LABS LTD	**EQ 2MG BASE/ML**	**A204906**	**001**	Jul 31, 2017
AP		QILU	**EQ 2MG BASE/ML**	**A203711**	**001**	Sep 08, 2014
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A077430**	**001**	Jun 27, 2007
AP		TEVA	**EQ 2MG BASE/ML**	**A076876**	**001**	Nov 22, 2006
AP		WEST-WARD PHARMS INT	**EQ 2MG BASE/ML**	**A076967**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077365**	**001**	Dec 26, 2006
AP		WOCKHARDT	**EQ 2MG BASE/ML**	**A077577**	**001**	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206845**	**001**	Mar 10, 2016
AP		AUROBINDO PHARMA LTD	**EQ 2MG BASE/ML**	**A202600**	**001**	Dec 21, 2012
AP	!	BAXTER HLTHCARE CORP	**EQ 2MG BASE/ML**	**A078287**	**001**	Feb 22, 2013
AP		EMCURE PHARMS LTD	**EQ 2MG BASE/ML**	**A078945**	**001**	Jan 03, 2013
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076972**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A202253**	**001**	Jul 19, 2013
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077548**	**001**	Dec 26, 2006
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A077551**	**001**	Jun 27, 2007
AP		WEST-WARD PHARMS INT	**EQ 2MG BASE/ML**	**A077011**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077541**	**001**	Dec 26, 2006
AP		WOCKHARDT	**EQ 2MG BASE/ML**	**A077716**	**001**	Dec 26, 2006

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA		AMNEAL PHARMS	**EQ 4MG BASE/5ML**	**A091483**	**001**	Jan 31, 2011
AA		AUROBINDO PHARMA	**EQ 4MG BASE/5ML**	**A078776**	**001**	Nov 28, 2007
AA		HIKMA	**EQ 4MG BASE/5ML**	**A076960**	**001**	Dec 26, 2006
AA		LANNETT CO INC	**EQ 4MG BASE/5ML**	**A091342**	**001**	Jan 27, 2011
AA		PHARM ASSOC	**EQ 4MG BASE/5ML**	**A078127**	**001**	Jun 25, 2007
AA		TARO	**EQ 4MG BASE/5ML**	**A077009**	**001**	Nov 30, 2007

ZOFRAN

AA	**+!**	NOVARTIS	**EQ 4MG BASE/5ML**	**N020605**	**001**	Jan 24, 1997

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB		APOTEX	**EQ 4MG BASE**	**A077306**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077306**	**002**	Jun 25, 2007
AB		AUROBINDO PHARMA	**EQ 4MG BASE**	**A078539**	**001**	Jul 31, 2007
AB			**EQ 8MG BASE**	**A078539**	**002**	Jul 31, 2007
AB			**EQ 24MG BASE**	**A078539**	**003**	Jul 31, 2007
AB		CASI PHARMS INC	**EQ 4MG BASE**	**A077517**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077517**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A077517**	**003**	Jun 25, 2007
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A076183**	**003**	Dec 26, 2006
AB			**EQ 8MG BASE**	**A076183**	**002**	Dec 26, 2006
AB			**EQ 24MG BASE**	**A076183**	**001**	Dec 26, 2006
AB		GLENMARK GENERICS	**EQ 4MG BASE**	**A077535**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077535**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A077535**	**003**	Jun 25, 2007
AB		IPCA LABS LTD	**EQ 4MG BASE**	**A203761**	**001**	Jan 23, 2014
AB			**EQ 8MG BASE**	**A203761**	**002**	Jan 23, 2014
AB		MYLAN	**EQ 4MG BASE**	**A076930**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A076930**	**002**	Jun 25, 2007
AB		NATCO PHARMA LTD	**EQ 4MG BASE**	**A077851**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077851**	**002**	Jun 25, 2007
AB		PLIVA HRVATSKA DOO	**EQ 4MG BASE**	**A077112**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077112**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A077112**	**003**	Jun 25, 2007
AB		SUN PHARM INDS (IN)	**EQ 4MG BASE**	**A077050**	**001**	Jun 25, 2007

ONDANSETRON HYDROCHLORIDE						
TABLET;ORAL						
ONDANSETRON HYDROCHLORIDE						
AB			**EQ 8MG BASE**	**A077050**	**002**	Jun 25, 2007
AB		TEVA	**EQ 4MG BASE**	**A076252**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A076252**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A076252**	**003**	Jun 25, 2007
ZOFRAN						
AB	**+**	NOVARTIS	**EQ 4MG BASE**	**N020103**	**001**	Dec 31, 1992
AB	**+**		**EQ 8MG BASE**	**N020103**	**002**	Dec 31, 1992
AB	**+!**		**EQ 24MG BASE**	**N020103**	**003**	Aug 27, 1999
ONDANSETRON HYDROCHLORIDE						
		DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006
ORITAVANCIN DIPHOSPHATE						
POWDER;INTRAVENOUS						
ORBACTIV						
	+!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014
ORLISTAT						
CAPSULE;ORAL						
XENICAL						
	+!	CHEPLAPHARM	120MG	N020766	001	Apr 23, 1999
ORPHENADRINE CITRATE						
INJECTABLE;INJECTION						
ORPHENADRINE CITRATE						
AP	**!**	AKORN	**30MG/ML**	**A040484**	**001**	May 24, 2006
AP		SAGENT PHARMS	**30MG/ML**	**A090585**	**001**	Aug 30, 2011
AP		WATSON LABS	**30MG/ML**	**A084779**	**001**	Mar 15, 1982
AP		WEST-WARD PHARMS INT	**30MG/ML**	**A040463**	**001**	Mar 04, 2003
TABLET, EXTENDED RELEASE;ORAL						
ORPHENADRINE CITRATE						
AB		ANDA REPOSITORY	**100MG**	**A040249**	**001**	Jan 29, 1999
AB		IMPAX PHARMS	**100MG**	**A040368**	**001**	Jun 23, 2000
AB		INVAGEN PHARMS	**100MG**	**A091158**	**001**	Jul 27, 2012
AB		LUPIN	**100MG**	**A040284**	**001**	Jun 19, 1998
AB	**!**	SANDOZ	**100MG**	**A040327**	**001**	Feb 15, 2000
OSELTAMIVIR PHOSPHATE						
CAPSULE;ORAL						
OSELTAMIVIR PHOSPHATE						
AB		ALEMBIC PHARMS LTD	**EQ 30MG BASE**	**A211823**	**001**	Jun 24, 2019
AB			**EQ 45MG BASE**	**A211823**	**002**	Jun 24, 2019
AB			**EQ 75MG BASE**	**A211823**	**003**	Jun 24, 2019
AB		AMNEAL PHARMS	**EQ 30MG BASE**	**A209093**	**001**	May 17, 2017
AB			**EQ 45MG BASE**	**A209093**	**002**	May 17, 2017
AB			**EQ 75MG BASE**	**A209093**	**003**	May 17, 2017
AB		HETERO LABS LTD III	**EQ 30MG BASE**	**A209438**	**001**	Feb 23, 2018
AB			**EQ 45MG BASE**	**A209438**	**002**	Feb 23, 2018
AB			**EQ 75MG BASE**	**A209438**	**003**	Feb 23, 2018
AB		LUPIN ATLANTIS	**EQ 30MG BASE**	**A208348**	**001**	Jan 09, 2018
AB			**EQ 45MG BASE**	**A208348**	**002**	Jan 09, 2018
AB			**EQ 75MG BASE**	**A208348**	**003**	Jan 09, 2018
AB		MACLEODS PHARMS LTD	**EQ 30MG BASE**	**A207211**	**001**	Sep 14, 2017
AB			**EQ 45MG BASE**	**A207211**	**002**	Sep 14, 2017
AB			**EQ 75MG BASE**	**A207211**	**003**	Sep 14, 2017
AB		NATCO PHARMA LTD	**EQ 30MG BASE**	**A202595**	**001**	Aug 03, 2016
AB			**EQ 45MG BASE**	**A202595**	**002**	Aug 03, 2016
AB			**EQ 75MG BASE**	**A202595**	**003**	Aug 03, 2016
AB		NESHER PHARMS	**EQ 30MG BASE**	**A208578**	**001**	Feb 24, 2017
AB			**EQ 45MG BASE**	**A208578**	**002**	Feb 24, 2017
AB			**EQ 75MG BASE**	**A208578**	**003**	Feb 24, 2017
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209421**	**001**	Jun 08, 2018
AB			**EQ 45MG BASE**	**A209421**	**002**	Jun 08, 2018
AB			**EQ 75MG BASE**	**A209421**	**003**	Jun 08, 2018
TAMIFLU						
AB	**+**	ROCHE	**EQ 30MG BASE**	**N021087**	**003**	Jul 02, 2007
AB	**+**		**EQ 45MG BASE**	**N021087**	**002**	Jul 02, 2007
AB	**+!**		**EQ 75MG BASE**	**N021087**	**001**	Oct 27, 1999
FOR SUSPENSION;ORAL						
OSELTAMIVIR PHOSPHATE						
AB		ALVOGEN PINE BROOK	**EQ 6MG BASE/ML**	**A208823**	**001**	Oct 31, 2017
AB		AMNEAL PHARMS NY	**EQ 6MG BASE/ML**	**A210186**	**001**	Feb 27, 2018

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		LUPIN ATLANTIS	**EQ 6MG BASE/ML**	**A208347**	**001**	Feb 20, 2018
AB		NESHER PHARMS	**EQ 6MG BASE/ML**	**A209113**	**001**	Sep 14, 2017
AB		TEVA PHARMS USA	**EQ 6MG BASE/ML**	**A211125**	**001**	Feb 27, 2019

TAMIFLU

AB	**+!**	ROCHE	**EQ 6MG BASE/ML**	**N021246**	**002**	Mar 21, 2011

OSIMERTINIB MESYLATE

TABLET;ORAL

TAGRISSO

	+	ASTRAZENECA PHARMS	EQ 40MG BASE	N208065	001	Nov 13, 2015
	+!		EQ 80MG BASE	N208065	002	Nov 13, 2015

OSPEMIFENE

TABLET;ORAL

OSPHENA

	+!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A201539**	**001**	Jan 18, 2013
AP			**EQ 2GM BASE/VIAL**	**A201539**	**002**	Jan 18, 2013
AP			**EQ 10GM BASE/VIAL**	**A201538**	**001**	Jan 18, 2013
AP		PIRAMAL CRITICAL	**EQ 1GM BASE/VIAL**	**A206681**	**001**	Sep 11, 2017
AP			**EQ 2GM BASE/VIAL**	**A206681**	**002**	Sep 11, 2017
AP			**EQ 10GM BASE/VIAL**	**A206760**	**001**	Oct 26, 2017
AP	**!**	SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A091246**	**001**	Mar 30, 2012
AP	**!**		**EQ 2GM BASE/VIAL**	**A091246**	**002**	Mar 30, 2012
AP	**!**		**EQ 10GM BASE/VIAL**	**A091245**	**001**	Mar 30, 2012
AP		WOCKHARDT BIO AG	**EQ 1GM BASE/VIAL**	**A207147**	**001**	Jul 31, 2017
AP			**EQ 2GM BASE/VIAL**	**A207147**	**002**	Jul 31, 2017
AP			**EQ 10GM BASE/VIAL**	**A207148**	**001**	Nov 24, 2017

BACTOCILL IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989
	+!		EQ 40MG BASE/ML	N050640	002	Oct 26, 1989

OXALIPLATIN

INJECTABLE;INTRAVENOUS

ELOXATIN

AP	**+!**	SANOFI AVENTIS US	**50MG/10ML (5MG/ML)**	**N021759**	**001**	Jan 31, 2005
AP	**+!**		**100MG/20ML (5MG/ML)**	**N021759**	**002**	Jan 31, 2005

OXALIPLATIN

AP		ACCORD HLTHCARE	**50MG/10ML (5MG/ML)**	**A207474**	**001**	Mar 21, 2017
AP			**100MG/20ML (5MG/ML)**	**A207474**	**002**	Mar 21, 2017
AP			**200MG/40ML (5MG/ML)**	**A207474**	**003**	Mar 21, 2017
AP		ACTAVIS LLC	**50MG/10ML (5MG/ML)**	**A204880**	**001**	Mar 05, 2018
AP			**100MG/20ML (5MG/ML)**	**A204880**	**002**	Mar 05, 2018
AP	**!**	ACTAVIS TOTOWA	**50MG/VIAL**	**A078803**	**001**	Aug 08, 2012
AP	**!**		**100MG/VIAL**	**A078803**	**002**	Aug 08, 2012
AP		CIPLA	**50MG/10ML (5MG/ML)**	**A208523**	**001**	Feb 10, 2017
AP			**100MG/20ML (5MG/ML)**	**A208523**	**002**	Feb 10, 2017
AP		EUGIA PHARMA	**50MG/10ML (5MG/ML)**	**A205529**	**001**	Sep 06, 2017
AP			**100MG/20ML (5MG/ML)**	**A205529**	**002**	Sep 06, 2017
AP		FRESENIUS KABI USA	**50MG/10ML (5MG/ML)**	**A078811**	**001**	Jun 10, 2010
AP			**100MG/20ML (5MG/ML)**	**A078811**	**002**	Jun 10, 2010
AP			**50MG/VIAL**	**A078819**	**001**	Jun 02, 2010
AP			**50MG/10ML (5MG/ML)**	**A090030**	**001**	Jan 31, 2017
AP			**100MG/VIAL**	**A078819**	**002**	Jun 02, 2010
AP			**100MG/20ML (5MG/ML)**	**A090030**	**002**	Jan 31, 2017
AP			**200MG/40ML (5MG/ML)**	**A090030**	**003**	Jan 31, 2017
AP		GLAND PHARMA LTD	**50MG/10ML (5MG/ML)**	**A207325**	**001**	Feb 10, 2017
AP			**50MG/VIAL**	**A207385**	**001**	May 23, 2017
AP			**100MG/20ML (5MG/ML)**	**A207325**	**002**	Feb 10, 2017
AP			**100MG/VIAL**	**A207385**	**002**	May 23, 2017
AP			**200MG/40ML (5MG/ML)**	**A207325**	**003**	Oct 18, 2017
AP		HOSPIRA WORLDWIDE	**50MG/10ML (5MG/ML)**	**A078813**	**001**	Aug 07, 2009
AP			**100MG/20ML (5MG/ML)**	**A078813**	**002**	Aug 07, 2009
AP		INGENUS PHARMS LLC	**50MG/10ML (5MG/ML)**	**A207562**	**001**	Oct 16, 2018
AP			**100MG/20ML (5MG/ML)**	**A207562**	**002**	Oct 16, 2018
AP		JIANGSU HENGRUI MED	**50MG/10ML (5MG/ML)**	**A203869**	**001**	Jun 18, 2014
AP			**100MG/20ML (5MG/ML)**	**A203869**	**002**	Jun 18, 2014

OXALIPLATIN						
INJECTABLE;INTRAVENOUS						
OXALIPLATIN						
AP		MYLAN LABS LTD	**50MG/10ML (5MG/ML)**	**A091358**	**001**	Aug 07, 2012
AP			**100MG/20ML (5MG/ML)**	**A091358**	**002**	Aug 07, 2012
AP		QILU	**50MG/10ML (5MG/ML)**	**A204368**	**001**	Jun 07, 2016
AP			**50MG/VIAL**	**A204616**	**001**	May 11, 2016
AP			**100MG/20ML (5MG/ML)**	**A204368**	**002**	Jun 07, 2016
AP			**100MG/VIAL**	**A204616**	**002**	May 11, 2016
AP	!		**200MG/40ML (5MG/ML)**	**A204368**	**003**	Jun 07, 2016
AP		SANDOZ	**50MG/10ML (5MG/ML)**	**A078817**	**001**	Jan 24, 2011
AP			**100MG/20ML (5MG/ML)**	**A078817**	**002**	Jan 24, 2011
AP	+!	TEVA PHARMS	**50MG/10ML (5MG/ML)**	**N022160**	**001**	Aug 07, 2009
AP	+!		**100MG/20ML (5MG/ML)**	**N022160**	**002**	Aug 07, 2009
OXANDROLONE						
TABLET;ORAL						
OXANDROLONE						
AB		PAR PHARM	**2.5MG**	**A077827**	**001**	Jun 22, 2007
AB	!		**10MG**	**A077827**	**002**	Jun 22, 2007
AB		UPSHER SMITH LABS	**2.5MG**	**A076761**	**001**	Dec 01, 2006
AB			**10MG**	**A078033**	**001**	Mar 22, 2007
OXAPROZIN						
TABLET;ORAL						
DAYPRO						
AB	+!	GD SEARLE	**600MG**	**N018841**	**004**	Oct 29, 1992
OXAPROZIN						
AB		AMNEAL PHARMS CO	**600MG**	**A208633**	**001**	May 04, 2017
AB		APOTEX INC	**600MG**	**A075987**	**001**	Sep 02, 2004
AB		DR REDDYS LABS LTD	**600MG**	**A075855**	**001**	Jan 31, 2001
AB		IVAX SUB TEVA PHARMS	**600MG**	**A075846**	**001**	May 13, 2002
AB		SANDOZ	**600MG**	**A075845**	**001**	Jan 31, 2001
AB		TEVA	**600MG**	**A075849**	**001**	Jul 03, 2002
OXAZEPAM						
CAPSULE;ORAL						
OXAZEPAM						
AB		ACTAVIS ELIZABETH	**10MG**	**A072253**	**002**	Apr 14, 1988
AB			**15MG**	**A072253**	**003**	Apr 14, 1988
AB	!		**30MG**	**A072253**	**001**	Apr 14, 1988
AB		SANDOZ	**10MG**	**A071813**	**001**	Apr 19, 1988
AB			**15MG**	**A071756**	**001**	Apr 19, 1988
AB			**30MG**	**A071814**	**001**	Apr 19, 1988
OXCARBAZEPINE						
SUSPENSION;ORAL						
OXCARBAZEPINE						
AB		AMNEAL PHARMS	**300MG/5ML**	**A202961**	**001**	Sep 17, 2012
AB		HIKMA	**300MG/5ML**	**A201193**	**001**	Oct 03, 2012
AB		SUN PHARM INDS LTD	**300MG/5ML**	**A078734**	**001**	Jun 26, 2009
TRILEPTAL						
AB	+!	NOVARTIS	**300MG/5ML**	**N021285**	**001**	May 25, 2001
TABLET;ORAL						
OXCARBAZEPINE						
AB		BRECKENRIDGE PHARM	**150MG**	**A078069**	**001**	Jan 11, 2008
AB			**300MG**	**A078069**	**002**	Jan 11, 2008
AB			**600MG**	**A078069**	**003**	Jan 11, 2008
AB		GLENMARK PHARMS LTD	**150MG**	**A077802**	**001**	Oct 09, 2007
AB			**300MG**	**A077802**	**002**	Oct 09, 2007
AB			**600MG**	**A077802**	**003**	Oct 09, 2007
AB		HIKMA	**150MG**	**A077795**	**001**	Oct 09, 2007
AB			**300MG**	**A077795**	**002**	Oct 09, 2007
AB			**600MG**	**A077795**	**003**	Oct 09, 2007
AB		RUBICON	**150MG**	**A077747**	**001**	Apr 09, 2008
AB			**300MG**	**A077747**	**002**	Apr 09, 2008
AB			**600MG**	**A077747**	**003**	Apr 09, 2008
AB		SUN PHARM INDS	**150MG**	**A077794**	**001**	Oct 09, 2007
AB			**300MG**	**A077794**	**002**	Oct 09, 2007
AB			**600MG**	**A077794**	**003**	Oct 09, 2007
AB		TARO	**150MG**	**A077801**	**001**	Nov 15, 2007
AB			**300MG**	**A077801**	**002**	Nov 15, 2007
AB			**600MG**	**A077801**	**003**	Nov 15, 2007

OXCARBAZEPINE

TABLET;ORAL

TRILEPTAL

AB	**+**	NOVARTIS	**150MG**	**N021014**	**001**	Jan 14, 2000
AB	**+**		**300MG**	**N021014**	**002**	Jan 14, 2000
AB	**+!**		**600MG**	**N021014**	**003**	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL

OXTELLAR XR

+	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
+		300MG	N202810	002	Oct 19, 2012
+!		600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB		TARO PHARMS	**EQ 1% BASE**	**A205076**	**001**	Mar 07, 2016

OXISTAT

AB	**+!**	FOUGERA PHARMS	**EQ 1% BASE**	**N019828**	**001**	Dec 30, 1988

LOTION;TOPICAL

OXISTAT

+!	FOUGERA PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

+!	ALLERGAN	3.9MG/24HR	N021351	002	Feb 26, 2003

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

+!	ALLERGAN	10% (100MG/PACKET)	N022204	001	Jan 27, 2009

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		LANNETT CO INC	**5MG/5ML**	**A074520**	**001**	Mar 29, 1996
AA		PHARM ASSOC	**5MG/5ML**	**A075137**	**001**	Dec 18, 1998
AA	**!**	WOCKHARDT BIO AG	**5MG/5ML**	**A074868**	**001**	Feb 12, 1997

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB		ABHAI LLC	**5MG**	**A209335**	**001**	Dec 22, 2017
AB		ARISE	**5MG**	**A209025**	**001**	Dec 21, 2017
AB		ATHEM	**5MG**	**A211062**	**001**	Feb 06, 2019
AB		EMCURE PHARMS LTD	**5MG**	**A211682**	**001**	May 10, 2019
AB		NOVAST LABS	**5MG**	**A210611**	**001**	Oct 30, 2019
AB		NOVITIUM PHARMA	**5MG**	**A209823**	**001**	Oct 23, 2017
AB		TEVA PHARMS USA	**5MG**	**A071655**	**001**	Nov 14, 1988
AB		TULEX PHARMS INC	**5MG**	**A210125**	**001**	Sep 06, 2018
AB		UPSHER SMITH LABS	**5MG**	**A074625**	**001**	Jul 31, 1996
AB	**!**	VINTAGE PHARMS	**5MG**	**A075079**	**001**	Oct 31, 1997

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

AB	**+**	JANSSEN PHARMS	**5MG**	**N020897**	**001**	Dec 16, 1998
AB	**+**		**10MG**	**N020897**	**002**	Dec 16, 1998

OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A207138**	**001**	Feb 29, 2016
AB			**10MG**	**A207138**	**002**	Feb 29, 2016
AB	**!**		**15MG**	**A207138**	**003**	Feb 29, 2016
AB		AJANTA PHARMA LTD	**5MG**	**A211655**	**001**	Feb 28, 2019
AB			**10MG**	**A211655**	**002**	Feb 28, 2019
AB			**15MG**	**A211655**	**003**	Feb 28, 2019
AB		AMNEAL PHARMS	**5MG**	**A204010**	**001**	Nov 23, 2015
AB			**10MG**	**A204010**	**002**	Nov 23, 2015
AB			**15MG**	**A204010**	**003**	Nov 23, 2015
AB		BIONPHARMA INC	**5MG**	**A210717**	**001**	Dec 17, 2019
AB			**10MG**	**A210717**	**002**	Dec 17, 2019
AB			**15MG**	**A210717**	**003**	Dec 17, 2019
AB		IMPAX PHARMS	**5MG**	**A076745**	**002**	May 09, 2007
AB			**10MG**	**A076745**	**003**	May 09, 2007
AB			**15MG**	**A076745**	**001**	Nov 09, 2006
AB		MYLAN PHARMS INC	**10MG**	**A076644**	**001**	Nov 09, 2006
AB			**15MG**	**A076644**	**002**	May 10, 2007
AB		OSMOTICA PHARM US	**5MG**	**A078503**	**001**	Feb 04, 2009
AB			**10MG**	**A078503**	**002**	Feb 04, 2009
AB			**15MG**	**A078503**	**003**	Feb 04, 2009
AB		UNIQUE PHARM LABS	**5MG**	**A206121**	**001**	May 27, 2016

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB			**10MG**	**A206121**	**002**	May 27, 2016
AB			**15MG**	**A206121**	**003**	May 27, 2016
AB		ZYDUS PHARMS	**5MG**	**A202332**	**001**	Jun 26, 2017
AB			**10MG**	**A202332**	**002**	Jun 26, 2017
AB			**15MG**	**A202332**	**003**	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

+	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
+		13.5MG	N208090	002	Apr 26, 2016
+		18MG	N208090	003	Apr 26, 2016
+		27MG	N208090	004	Apr 26, 2016
+!		36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB		ANI PHARMS INC	**5MG**	**A205177**	**001**	Mar 31, 2016
AB		AVANTHI INC	**5MG**	**A202773**	**001**	Aug 17, 2015
AB	**+!**	GENUS LIFESCIENCES	**5MG**	**N200534**	**001**	Oct 20, 2010
AB		LANNETT CO INC	**5MG**	**A203823**	**001**	Aug 01, 2014
AB		MAYNE PHARMA INC	**5MG**	**A203107**	**001**	Jul 26, 2012
AB		NOVEL LABS INC	**5MG**	**A204752**	**001**	Aug 24, 2015

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA		ABHAI LLC	**5MG/5ML**	**A208593**	**001**	Jul 21, 2017
AA			**100MG/5ML**	**A208593**	**002**	Jul 21, 2017
AA		ALKEM LABS LTD	**5MG/5ML**	**A211748**	**001**	Feb 07, 2019
AA			**100MG/5ML**	**A211749**	**001**	Feb 04, 2019
AA		ANI PHARMS INC	**5MG/5ML**	**A204979**	**001**	Jun 01, 2015
AA			**100MG/5ML**	**A203447**	**001**	Aug 30, 2017
AA		ASCENT PHARMS INC	**5MG/5ML**	**A209021**	**001**	Nov 09, 2017
AA			**100MG/5ML**	**A209021**	**002**	Nov 09, 2017
AA		EYWA	**5MG/5ML**	**A207511**	**001**	Nov 23, 2016
AA			**100MG/5ML**	**A209897**	**001**	Sep 06, 2017
AA	**+**	GENUS LIFESCIENCES	**5MG/5ML**	**N200535**	**002**	Aug 22, 2013
AA	**+!**		**100MG/5ML**	**N200535**	**001**	Oct 20, 2010
AA		HI TECH	**5MG/5ML**	**A208817**	**001**	Aug 10, 2017
AA			**100MG/5ML**	**A208795**	**001**	Aug 07, 2017
AA		HIKMA	**5MG/5ML**	**A204037**	**001**	Jul 15, 2013
AA			**100MG/5ML**	**A203208**	**001**	Jul 12, 2013
AA		MAYNE PHARMA INC	**100MG/5ML**	**A204092**	**001**	Jun 05, 2014
AA		NOVEL LABS INC	**100MG/5ML**	**A204603**	**001**	Apr 29, 2015
AA		PHARM ASSOC	**5MG/5ML**	**A206914**	**001**	Feb 01, 2019
AA			**100MG/5ML**	**A206822**	**001**	Aug 15, 2017
AA		SPECGX LLC	**5MG/5ML**	**A210758**	**001**	Apr 30, 2018
AA			**100MG/5ML**	**A210758**	**002**	Apr 30, 2018
AA	**+!**	VISTAPHARM	**5MG/5ML**	**N201194**	**001**	Jan 12, 2012
AA			**100MG/5ML**	**A202537**	**001**	Jul 30, 2012
AA		WOCKHARDT BIO AG	**5MG/5ML**	**A206456**	**001**	Jun 16, 2015

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**5MG**	**A076636**	**003**	Apr 07, 2015
AB			**15MG**	**A076636**	**001**	Feb 06, 2004
AB			**30MG**	**A076636**	**002**	Feb 06, 2004
AB		ALVOGEN	**5MG**	**A202116**	**001**	Dec 30, 2011
AB			**15MG**	**A202116**	**002**	Dec 30, 2011
AB			**30MG**	**A202116**	**003**	Dec 30, 2011
AB		AMNEAL PHARMS	**5MG**	**A203638**	**001**	Jun 03, 2014
AB			**10MG**	**A203638**	**002**	Jun 03, 2014
AB			**15MG**	**A203638**	**003**	Jun 03, 2014
AB			**20MG**	**A203638**	**004**	Jun 03, 2014
AB			**30MG**	**A203638**	**005**	Jun 03, 2014
AB		ASCENT PHARMS INC	**15MG**	**A207418**	**001**	Aug 07, 2017
AB			**30MG**	**A207418**	**002**	Aug 07, 2017
AB		AUROLIFE PHARMA LLC	**5MG**	**A202160**	**001**	Nov 19, 2012
AB			**15MG**	**A202160**	**002**	Nov 19, 2012
AB			**30MG**	**A202160**	**003**	Nov 19, 2012
AB		AVANTHI INC	**5MG**	**A091393**	**001**	Aug 31, 2009

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	**!**		**10MG**	**A091393**	**002**	Aug 31, 2009
AB			**15MG**	**A091393**	**003**	Aug 31, 2009
AB			**20MG**	**A091393**	**004**	Aug 31, 2009
AB			**30MG**	**A091393**	**005**	Aug 31, 2009
AB		EPIC PHARMA LLC	**5MG**	**A090895**	**001**	Aug 24, 2009
AB			**5MG**	**A202662**	**001**	Sep 22, 2015
AB			**10MG**	**A202662**	**002**	Sep 22, 2015
AB			**15MG**	**A090895**	**002**	Aug 24, 2009
AB			**15MG**	**A202662**	**003**	Sep 22, 2015
AB			**20MG**	**A202662**	**005**	Apr 27, 2017
AB			**30MG**	**A090895**	**003**	Aug 24, 2009
AB			**30MG**	**A202662**	**004**	Sep 22, 2015
AB		MAYNE PHARMA INC	**5MG**	**A091313**	**001**	Feb 18, 2011
AB			**10MG**	**A091313**	**004**	Apr 29, 2016
AB			**15MG**	**A091313**	**002**	Feb 18, 2011
AB			**20MG**	**A091313**	**005**	Apr 29, 2016
AB			**30MG**	**A091313**	**003**	Feb 18, 2011
AB		NESHER PHARMS	**5MG**	**A077290**	**001**	Dec 08, 2005
AB			**10MG**	**A077290**	**002**	Dec 08, 2005
AB			**15MG**	**A077290**	**003**	Dec 08, 2005
AB			**20MG**	**A077290**	**004**	Dec 08, 2005
AB			**30MG**	**A077290**	**005**	Dec 08, 2005
AB		NOVEL LABS INC	**5MG**	**A204021**	**001**	Jun 12, 2017
AB			**10MG**	**A204021**	**002**	Jun 12, 2017
AB			**15MG**	**A204021**	**003**	Jun 12, 2017
AB			**20MG**	**A204021**	**004**	Jun 12, 2017
AB			**30MG**	**A204021**	**005**	Jun 12, 2017
AB		NUVO PHARM	**5MG**	**A207119**	**001**	Apr 12, 2016
AB			**10MG**	**A207119**	**002**	Apr 12, 2016
AB			**15MG**	**A207119**	**003**	Apr 12, 2016
AB			**20MG**	**A207119**	**004**	Apr 12, 2016
AB			**30MG**	**A207119**	**005**	Apr 12, 2016
AB		RHODES PHARMS	**5MG**	**A091490**	**001**	Mar 09, 2011
AB			**10MG**	**A091490**	**002**	Mar 09, 2011
AB			**15MG**	**A091490**	**003**	Mar 09, 2011
AB			**20MG**	**A091490**	**004**	Mar 09, 2011
AB			**30MG**	**A091490**	**005**	Mar 09, 2011
AB		SPECGX LLC	**5MG**	**A076758**	**003**	Mar 19, 2007
AB			**15MG**	**A076758**	**001**	Jun 30, 2004
AB			**30MG**	**A076758**	**002**	Jun 30, 2004
AB		SUN PHARM INDS INC	**5MG**	**A090659**	**001**	Apr 10, 2009
AB			**10MG**	**A090659**	**005**	Nov 06, 2012
AB			**15MG**	**A090659**	**002**	Apr 10, 2009
AB			**20MG**	**A090659**	**004**	Nov 06, 2012
AB			**30MG**	**A090659**	**003**	Apr 10, 2009

ROXICODONE

AB	**+**	SPECGX LLC	**5MG**	**N021011**	**003**	May 15, 2009
AB	**+!**		**15MG**	**N021011**	**001**	Aug 31, 2000
AB	**+**		**30MG**	**N021011**	**002**	Aug 31, 2000

OXAYDO

		ZYLA	5MG	N202080	001	Jun 17, 2011
			7.5MG	N202080	002	Jun 17, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYCONTIN

	+	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
	+		15MG	N022272	002	Apr 05, 2010
	+		20MG	N022272	003	Apr 05, 2010
	+		30MG	N022272	004	Apr 05, 2010
	+!		40MG	N022272	005	Apr 05, 2010
	+		60MG	N022272	006	Apr 05, 2010
	+		80MG	N022272	007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADE

	+!	EPI HLTH	1%	N208552	001	Jan 18, 2017

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

+!	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+!	MYLAN SPECIALITY LP	50MG	N016848	001	

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**5MG**	**A210175**	**001**	Feb 02, 2018
AB			**10MG**	**A210175**	**002**	Feb 02, 2018
AB		AUROLIFE PHARMA LLC	**5MG**	**A204459**	**001**	Apr 26, 2016
AB			**10MG**	**A204459**	**002**	Apr 26, 2016
AB		AVANTHI INC	**5MG**	**A203601**	**001**	Jan 30, 2013
AB	**!**		**10MG**	**A203601**	**002**	Jan 30, 2013
AB		EPIC PHARMA LLC	**5MG**	**A201187**	**001**	Dec 15, 2014
AB			**10MG**	**A201187**	**002**	Dec 15, 2014
AB		HIKMA	**5MG**	**A090964**	**001**	Sep 27, 2010
AB			**10MG**	**A090964**	**002**	Sep 27, 2010
AB		SPECGX LLC	**5MG**	**A202321**	**001**	Apr 25, 2013
AB			**10MG**	**A202321**	**002**	Apr 25, 2013
AB		TEVA	**5MG**	**A091443**	**002**	Feb 15, 2011
AB			**10MG**	**A091443**	**001**	Feb 15, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**5MG**	**A079046**	**003**	Jul 11, 2013
AB			**7.5MG**	**A079046**	**001**	Dec 13, 2010
AB			**10MG**	**A079046**	**004**	Jul 11, 2013
AB			**15MG**	**A079046**	**002**	Dec 13, 2010
AB			**20MG**	**A079046**	**005**	Jul 11, 2013
AB			**30MG**	**A079046**	**006**	Jul 11, 2013
AB			**40MG**	**A079046**	**007**	Jul 11, 2013
AB		HIKMA	**5MG**	**A200822**	**002**	Jul 15, 2013
AB			**7.5MG**	**A200822**	**003**	Jul 15, 2013
AB			**10MG**	**A200822**	**004**	Jul 15, 2013
AB			**15MG**	**A200822**	**005**	Jul 15, 2013
AB			**20MG**	**A200822**	**006**	Jul 15, 2013
AB			**30MG**	**A200822**	**007**	Jul 15, 2013
AB			**40MG**	**A200822**	**001**	Jul 15, 2013
AB		IMPAX LABS	**5MG**	**A079087**	**001**	Jun 14, 2010
AB			**7.5MG**	**A079087**	**002**	Dec 21, 2010
AB			**10MG**	**A079087**	**003**	Jun 14, 2010
AB			**15MG**	**A079087**	**004**	Dec 21, 2010
AB			**20MG**	**A079087**	**005**	Jun 14, 2010
AB			**30MG**	**A079087**	**006**	Jul 22, 2010
AB		SPECGX LLC	**5MG**	**A202946**	**001**	Jun 27, 2014
AB			**7.5MG**	**A202946**	**002**	Jun 27, 2014
AB			**10MG**	**A202946**	**003**	Jun 27, 2014
AB			**15MG**	**A202946**	**004**	Jun 27, 2014
AB			**20MG**	**A202946**	**005**	Jun 27, 2014
AB			**30MG**	**A202946**	**006**	Jun 27, 2014
AB			**40MG**	**A202946**	**007**	Jun 27, 2014
	!	IMPAX LABS	40MG	A079087	007	Jun 14, 2010

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	**+!**	FRESENIUS KABI USA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018248**	**001**	
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018248**	**002**	
AP		HIKMA FARMACEUTICA	**10USP UNITS/ML (10USP UNITS/ML)**	**A200219**	**001**	Feb 13, 2013
AP		SAGENT PHARMS INC	**10USP UNITS/ML (10USP UNITS/ML)**	**A091676**	**001**	Jul 13, 2018
AP			**100USP UNITS/10ML (10USP UNITS/ML)**	**A091676**	**002**	Jul 13, 2018
AP	**+!**	WEST-WARD PHARMS INT	**10USP UNITS/ML (10USP UNITS/ML)**	**N018243**	**001**	
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018243**	**002**	Jan 10, 2007

PITOCIN

AP	**+!**	PAR STERILE PRODUCTS	**10USP UNITS/ML (10USP UNITS/ML)**	**N018261**	**001**	
AP	**+**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018261**	**002**	Jul 27, 2007

OXYTOCIN							
INJECTABLE;INJECTION							
OXYTOCIN							
	+!	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248	003	Jul 27, 2007
PITOCIN							
	+	PAR STERILE PRODUCTS	500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012
OZENOXACIN							
CREAM;TOPICAL							
XEPI							
	+!	FERRER INTERNACIONAL	1%	N208945	001	Dec 11, 2017
PACLITAXEL							
FOR SUSPENSION;IV (INFUSION)							
ABRAXANE							
	+!	ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005
INJECTABLE;INJECTION							
PACITAXEL							
AP		GLAND PHARMA LTD	**6MG/ML**	**A207326**	**001**	Aug 23, 2016
PACLITAXEL							
AP		ACTAVIS TOTOWA	**6MG/ML**	**A090130**	**001**	Dec 09, 2009
AP		FRESENIUS KABI USA	**6MG/ML**	**A077574**	**001**	Nov 27, 2006
AP	**!**	HOSPIRA	**6MG/ML**	**A076131**	**001**	May 08, 2002
AP		MYLAN LABS LTD	**6MG/ML**	**A091540**	**001**	Sep 29, 2011
AP		TEVA PHARMS	**6MG/ML**	**A075184**	**001**	Jan 25, 2002
AP		WEST-WARD PHARMS INT	**6MG/ML**	**A075190**	**001**	Jan 28, 2002
PALBOCICLIB							
CAPSULE;ORAL							
IBRANCE							
	+	PFIZER INC	75MG	N207103	001	Feb 03, 2015
	+		100MG	N207103	002	Feb 03, 2015
	+!		125MG	N207103	003	Feb 03, 2015
TABLET;ORAL							
IBRANCE							
	+	PFIZER INC	75MG	N212436	001	Nov 01, 2019
	+		100MG	N212436	002	Nov 01, 2019
	+!		125MG	N212436	003	Nov 01, 2019
PALIPERIDONE							
TABLET, EXTENDED RELEASE;ORAL							
INVEGA							
AB	**+**	JANSSEN PHARMS	**1.5MG**	**N021999**	**006**	Aug 26, 2008
AB	**+**		**3MG**	**N021999**	**001**	Dec 19, 2006
AB	**+!**		**6MG**	**N021999**	**002**	Dec 19, 2006
AB	**+**		**9MG**	**N021999**	**003**	Dec 19, 2006
PALIPERIDONE							
AB		ACTAVIS LABS FL INC	**1.5MG**	**A202645**	**001**	Aug 03, 2015
AB			**3MG**	**A202645**	**002**	Aug 03, 2015
AB			**6MG**	**A202645**	**003**	Aug 03, 2015
AB			**9MG**	**A202645**	**004**	Aug 03, 2015
AB		AMNEAL PHARMS	**1.5MG**	**A204707**	**001**	Sep 23, 2019
AB			**3MG**	**A204707**	**002**	Sep 23, 2019
AB			**6MG**	**A204707**	**003**	Sep 23, 2019
AB			**9MG**	**A204707**	**004**	Sep 23, 2019
AB		INVENTIA	**1.5MG**	**A204452**	**001**	Jun 12, 2019
AB			**3MG**	**A204452**	**002**	Jun 12, 2019
AB			**6MG**	**A204452**	**003**	Jun 12, 2019
AB			**9MG**	**A204452**	**004**	Jun 12, 2019
AB		MYLAN	**1.5MG**	**A203802**	**001**	Sep 24, 2015
AB			**3MG**	**A203802**	**002**	Sep 24, 2015
AB			**6MG**	**A203802**	**003**	Sep 24, 2015
AB			**9MG**	**A203802**	**004**	Sep 24, 2015
AB		SUN PHARM	**1.5mg**	**A205618**	**001**	Apr 06, 2018
AB			**3MG**	**A205618**	**002**	Apr 06, 2018
AB			**6MG**	**A205618**	**003**	Apr 06, 2018
AB			**9MG**	**A205618**	**004**	Apr 06, 2018

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

INVEGA TRINZA

+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015
+		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015
+		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015
+!		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

ALOXI

AP	**+!**	HELSINN HLTHCARE	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**N021372**	**002**	Feb 29, 2008
AP	**+!**		**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**N021372**	**001**	Jul 25, 2003

PALONOSETRON HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204702**	**001**	Nov 06, 2018
AP		CIPLA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206396**	**001**	Sep 19, 2018
AP		DR REDDYS LABS LTD	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A201533**	**002**	Apr 21, 2016
AP		FRESENIUS KABI USA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206801**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206802**	**001**	Sep 19, 2018
AP		HOSPIRA INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A207005**	**001**	Sep 19, 2018
AP			**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**A207005**	**002**	Sep 19, 2018
AP		MYLAN INSTITUTIONAL	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206416**	**001**	Sep 19, 2018
AP		QILU	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**A205648**	**002**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205648**	**001**	Sep 19, 2018
AP		SAGENT PHARMS INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204289**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205870**	**001**	Sep 19, 2018
AP		SANDOZ INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202521**	**001**	Oct 13, 2015
AP		TEVA PHARMS USA	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**A090713**	**002**	Mar 23, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A090713**	**001**	Mar 23, 2018
AP		VIRTUS PHARM	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A209287**	**001**	Sep 19, 2018

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

+		FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017
		HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP		AREVA PHARMS	**30MG/VIAL**	**A077433**	**001**	Nov 26, 2008
AP			**90MG/VIAL**	**A077433**	**003**	Nov 26, 2008
AP		DR REDDYS	**30MG/10ML (3MG/ML)**	**A078156**	**001**	Aug 19, 2008
AP			**60MG/10ML (6MG/ML)**	**A078156**	**002**	Aug 19, 2008
AP			**90MG/10ML (9MG/ML)**	**A078156**	**003**	Aug 19, 2008
AP		FRESENIUS KABI USA	**30MG/VIAL**	**A075773**	**001**	May 06, 2002
AP			**30MG/10ML (3MG/ML)**	**A076207**	**001**	May 17, 2002
AP			**90MG/VIAL**	**A075773**	**002**	May 06, 2002
AP			**90MG/10ML (9MG/ML)**	**A076207**	**002**	May 17, 2002
AP	**!**	HOSPIRA	**30MG/10ML (3MG/ML)**	**A075841**	**001**	Jun 27, 2002
AP	**!**		**60MG/10ML (6MG/ML)**	**A075841**	**002**	Jun 27, 2002
AP	**!**		**90MG/10ML (9MG/ML)**	**A075841**	**003**	Jun 27, 2002
AP		MYLAN LABS LTD	**30MG/10ML (3MG/ML)**	**A078520**	**001**	Oct 31, 2008
AP			**90MG/10ML (9MG/ML)**	**A078520**	**002**	Oct 31, 2008
AP		SAGENT PHARMS INC	**30MG/10ML (3MG/ML)**	**A078373**	**001**	Dec 23, 2008
AP			**90MG/10ML (9MG/ML)**	**A078373**	**002**	Dec 23, 2008
AP		TEVA PHARMS USA	**30MG/10ML (3MG/ML)**	**A076153**	**001**	Mar 27, 2002
AP			**90MG/10ML (9MG/ML)**	**A076153**	**002**	Mar 27, 2002
AP		WEST-WARD PHARMS INT	**30MG/VIAL**	**A075290**	**001**	Apr 30, 2001
AP	**+!**		**30MG/10ML (3MG/ML)**	**N021113**	**001**	Mar 04, 2002
AP			**90MG/VIAL**	**A075290**	**003**	Apr 30, 2001
AP	**+!**		**90MG/10ML (9MG/ML)**	**N021113**	**002**	Mar 04, 2002
		AREVA PHARMS	60MG/VIAL	A077433	002	Nov 26, 2008

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

CREON

+	ABBVIE	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009
+		15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725	004	Jul 12, 2011
+		30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009
+		180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725	005	Mar 14, 2013
+!		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009

PANCREAZE

+	VIVUS INC	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523	005	Mar 07, 2014
+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010
+!		98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010

PERTZYE

+	DIGESTIVE CARE INC	30,250USP UNITS;8,000USP UNITS;28,750USP UNITS	N022175	001	May 17, 2012
+!		60,500USP UNITS;16,000USP UNITS;57,500USP UNITS	N022175	002	May 17, 2012
+		15,125USP UNITS;4,000USP UNITS;14,375USP UNITS	N022175	003	Oct 06, 2016
+		90,750USP UNITS;24,000USP UNITS;86,250USP UNITS	N022175	004	Jul 13, 2017

ZENPEP

+	ZENPEP	168,000USP UNITS;40,000USP UNITS;126,000USP UNITS	N022210	007	Mar 25, 2014
+		14,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011
+		24,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009
+		42,000USP UNITS;10,000USP UNITS;32,000USP UNITS	N022210	002	Aug 27, 2009
+		63,000USP UNITS;15,000USP UNITS;47,000USP UNITS	N022210	003	Aug 27, 2009
+		84,000USP UNITS;20,000USP UNITS;63,000USP UNITS	N022210	004	Aug 27, 2009
+!		105,000USP UNITS;25,000USP UNITS;79,000USP UNITS	N022210	006	Jul 13, 2011

TABLET;ORAL

VIOKACE

+	VIOKACE	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012
+!		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

AP	**!**	DR REDDYS	**1MG/ML**	**A072759**	**001**	Jul 31, 1990
AP		HOSPIRA	**1MG/ML**	**A072320**	**001**	Jan 19, 1989
	!	DR REDDYS	2MG/ML	A072760	001	Jul 31, 1990

PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

+	SECURA	EQ 10MG BASE	N205353	001	Feb 23, 2015
+		EQ 15MG BASE	N205353	002	Feb 23, 2015
+!		EQ 20MG BASE	N205353	003	Feb 23, 2015

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PROTONIX

+!	WYETH PHARMS	EQ 40MG BASE	N022020	001	Nov 14, 2007

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	AKORN INC	**EQ 40MG BASE/VIAL**	**A079197**	**001**	Nov 08, 2012
AP	AUROBINDO PHARMA LTD	**EQ 40MG BASE/VIAL**	**A205675**	**001**	Mar 30, 2016
AP	SANDOZ INC	**EQ 40MG BASE/VIAL**	**A090296**	**001**	Jul 14, 2015

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

AP		SUN PHARM	**EQ 40MG BASE/VIAL**	**A077674**	**001**	Aug 19, 2019

PROTONIX IV

AP	**+!**	WYETH PHARMS	**EQ 40MG BASE/VIAL**	**N020988**	**001**	Mar 22, 2001

POWDER;IV (INFUSION)

PANTOPRAZOLE SODIUM

	+!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		ACTAVIS TOTOWA	**EQ 20MG BASE**	**A090797**	**001**	Feb 07, 2011
AB			**EQ 40MG BASE**	**A090797**	**002**	Feb 07, 2011
AB		AMNEAL PHARMS	**EQ 20MG BASE**	**A205119**	**001**	Jan 26, 2016
AB			**EQ 40MG BASE**	**A205119**	**002**	Jan 26, 2016
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A202038**	**001**	Sep 28, 2012
AB			**EQ 40MG BASE**	**A202038**	**002**	Sep 28, 2012
AB		DR REDDYS LABS LTD	**EQ 20MG BASE**	**A077619**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A077619**	**002**	Jan 19, 2011
AB		HETERO LABS LTD V	**EQ 20MG BASE**	**A202882**	**001**	Sep 10, 2014
AB			**EQ 40MG BASE**	**A202882**	**002**	Sep 10, 2014
AB		INGENUS PHARMS LLC	**EQ 40MG BASE**	**A211368**	**001**	Mar 01, 2019
AB		JUBILANT GENERICS	**EQ 20MG BASE**	**A090901**	**001**	Aug 30, 2011
AB			**EQ 40MG BASE**	**A090901**	**002**	Aug 30, 2011
AB		L PERRIGO CO	**EQ 20MG BASE**	**A203024**	**001**	May 07, 2014
AB		LANNETT CO INC	**EQ 20MG BASE**	**A078281**	**001**	Jan 20, 2011
AB			**EQ 40MG BASE**	**A078281**	**002**	Jan 20, 2011
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A200821**	**001**	Feb 16, 2012
AB			**EQ 40MG BASE**	**A200821**	**002**	Feb 16, 2012
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090970**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A090970**	**002**	Jan 19, 2011
AB		ORCHID HLTHCARE	**EQ 20MG BASE**	**A202052**	**001**	Dec 02, 2014
AB			**EQ 40MG BASE**	**A202052**	**002**	Dec 02, 2014
AB		RUBICON	**EQ 20MG BASE**	**A090807**	**001**	May 02, 2012
AB			**EQ 40MG BASE**	**A090807**	**002**	May 02, 2012
AB		TEVA	**EQ 20MG BASE**	**A077056**	**001**	Aug 02, 2007
AB			**EQ 40MG BASE**	**A077056**	**002**	Aug 02, 2007
AB		TORRENT PHARMS	**EQ 20MG BASE**	**A090074**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A090074**	**002**	Jan 19, 2011
AB		WOCKHARDT	**EQ 20MG BASE**	**A091231**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A091231**	**002**	Jan 19, 2011

PROTONIX

AB	**+**	WYETH PHARMS	**EQ 20MG BASE**	**N020987**	**002**	Jun 12, 2001
AB	**+!**		**EQ 40MG BASE**	**N020987**	**001**	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB		AMNEAL PHARMS	**1MCG**	**A204327**	**001**	Jan 13, 2016
AB			**2MCG**	**A204327**	**002**	Jan 13, 2016
AB			**4MCG**	**A204327**	**003**	Jan 13, 2016
AB		AUROBINDO PHARMA LTD	**1MCG**	**A207672**	**001**	Jan 14, 2016
AB			**2MCG**	**A207672**	**002**	Jan 14, 2016
AB			**4MCG**	**A207672**	**003**	Jan 14, 2016
AB		BIONPHARMA INC	**1MCG**	**A202539**	**001**	Mar 27, 2014
AB			**2MCG**	**A202539**	**002**	Mar 27, 2014
AB			**4MCG**	**A202539**	**003**	Mar 27, 2014
AB		DR REDDYS LABS LTD	**1MCG**	**A091412**	**001**	Jun 24, 2014
AB			**2MCG**	**A091412**	**002**	Jun 24, 2014
AB			**4MCG**	**A091412**	**003**	Jun 24, 2014
AB		MARKSANS PHARMA	**1MCG**	**A204948**	**001**	Oct 07, 2016
AB			**2MCG**	**A204948**	**002**	Oct 07, 2016
AB			**4MCG**	**A204948**	**003**	Oct 07, 2016
AB		RISING	**1MCG**	**A202124**	**001**	Jun 24, 2014
AB			**2MCG**	**A202124**	**002**	Jun 24, 2014
AB			**4MCG**	**A202124**	**003**	Jun 24, 2014
AB		TEVA PHARMS USA	**1MCG**	**A090829**	**001**	Sep 27, 2013
AB			**2MCG**	**A090829**	**002**	Sep 27, 2013
AB	**!**		**4MCG**	**A090829**	**003**	Sep 27, 2013

ZEMPLAR

AB	**+**	ABBVIE	**1MCG**	**N021606**	**001**	May 26, 2005

PARICALCITOL

CAPSULE;ORAL

ZEMPLAR

AB	**+**		**2MCG**	**N021606**	**002**	May 26, 2005

SOLUTION;INTRAVENOUS

PARICALCITOL

AP		ACCORD HLTHCARE	**0.002MG/ML (0.002MG/ML)**	**N207174**	**001**	Feb 04, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**N207174**	**002**	Feb 04, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**N207174**	**003**	Feb 04, 2016
AP		AKORN	**0.005MG/ML (0.005MG/ML)**	**A207692**	**001**	Oct 16, 2017
AP		AMNEAL PHARMS CO	**0.002MG/ML (0.002MG/ML)**	**A206699**	**001**	Mar 09, 2017
AP			**0.005MG/ML (0.005MG/ML)**	**A206699**	**002**	Mar 09, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A206699**	**003**	Mar 09, 2017
AP		AUROBINDO PHARMA LTD	**0.002MG/ML (0.002MG/ML)**	**A205982**	**001**	Oct 09, 2018
AP			**0.005MG/ML (0.005MG/ML)**	**A205982**	**002**	Oct 09, 2018
AP			**0.01MG/2ML (0.005MG/ML)**	**A205982**	**003**	Oct 09, 2018
AP		DR REDDYS	**0.002MG/ML (0.002MG/ML)**	**A204910**	**001**	Aug 17, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**A204910**	**002**	Aug 17, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**A204910**	**003**	Aug 17, 2016
AP		HIKMA PHARMS	**0.002MG/ML (0.002MG/ML)**	**N205917**	**001**	Nov 18, 2014
AP			**0.005MG/ML (0.005MG/ML)**	**N205917**	**002**	Nov 18, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N205917**	**003**	Nov 18, 2014
AP		HOSPIRA INC	**0.002MG/ML (0.002MG/ML)**	**N201657**	**001**	Oct 21, 2014
AP			**0.005MG/ML (0.005MG/ML)**	**N201657**	**002**	Oct 21, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N201657**	**003**	Oct 21, 2014
AP		MYLAN LABS LTD	**0.002MG/ML (0.002MG/ML)**	**A203897**	**001**	Nov 02, 2017
AP			**0.005MG/ML (0.005MG/ML)**	**A203897**	**002**	Nov 02, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A203897**	**003**	Nov 02, 2017
AP		SANDOZ INC	**0.002MG/ML (0.002MG/ML)**	**A091108**	**001**	Jul 27, 2011
AP			**0.005MG/ML (0.005MG/ML)**	**A091108**	**002**	Jul 27, 2011
AP			**0.01MG/2ML (0.005MG/ML)**	**A091108**	**003**	Jul 27, 2011

ZEMPLAR

AP	**+!**	ABBVIE	**0.002MG/ML (0.002MG/ML)**	**N020819**	**002**	Feb 01, 2000
AP	**+!**		**0.005MG/ML (0.005MG/ML)**	**N020819**	**001**	Apr 17, 1998
AP	**+!**		**0.01MG/2ML (0.005MG/ML)**	**N020819**	**003**	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE;ORAL

PAROMOMYCIN SULFATE

AA		HERITAGE PHARMS INC	**EQ 250MG BASE**	**A065173**	**001**	Dec 14, 2007
AA	**!**	SUN PHARM INDS INC	**EQ 250MG BASE**	**A064171**	**001**	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAXIL

	+!	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997

TABLET;ORAL

PAROXETINE

AB		PRINSTON INC	**EQ 10MG BASE**	**A203854**	**001**	Oct 31, 2014
AB			**EQ 20MG BASE**	**A203854**	**002**	Oct 31, 2014
AB			**EQ 30MG BASE**	**A203854**	**003**	Oct 31, 2014
AB			**EQ 40MG BASE**	**A203854**	**004**	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

AB		APOTEX	**EQ 10MG BASE**	**A075356**	**001**	Jul 30, 2003
AB			**EQ 20MG BASE**	**A075356**	**002**	Jul 30, 2003
AB			**EQ 30MG BASE**	**A075356**	**003**	Jul 30, 2003
AB			**EQ 40MG BASE**	**A075356**	**004**	Jul 30, 2003
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078406**	**001**	Jul 25, 2007
AB			**EQ 20MG BASE**	**A078406**	**002**	Jul 25, 2007
AB			**EQ 30MG BASE**	**A078406**	**003**	Jul 25, 2007
AB			**EQ 40MG BASE**	**A078406**	**004**	Jul 25, 2007
AB		JUBILANT GENERICS	**EQ 10MG BASE**	**A205528**	**001**	Nov 27, 2015
AB			**EQ 20MG BASE**	**A205528**	**002**	Nov 27, 2015
AB			**EQ 30MG BASE**	**A205528**	**003**	Nov 27, 2015
AB			**EQ 40MG BASE**	**A205528**	**004**	Nov 27, 2015
AB		MYLAN	**EQ 10MG BASE**	**A078902**	**001**	Mar 13, 2008
AB			**EQ 20MG BASE**	**A078902**	**002**	Mar 13, 2008
AB			**EQ 30MG BASE**	**A078902**	**003**	Mar 13, 2008
AB			**EQ 40MG BASE**	**A078902**	**004**	Mar 13, 2008
AB		OXFORD PHARMS	**EQ 10MG BASE**	**A076968**	**001**	Jun 21, 2010
AB			**EQ 20MG BASE**	**A076968**	**002**	Jun 21, 2010
AB			**EQ 30MG BASE**	**A076968**	**003**	Jun 21, 2010
AB			**EQ 40MG BASE**	**A076968**	**004**	Jun 21, 2010

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

AB		TEVA	**EQ 10MG BASE**	**A076618**	**001**	Aug 15, 2005
AB			**EQ 20MG BASE**	**A076618**	**002**	Aug 15, 2005
AB			**EQ 30MG BASE**	**A076618**	**003**	Aug 15, 2005
AB			**EQ 40MG BASE**	**A076618**	**004**	Aug 15, 2005
AB		ZYDUS PHARMS USA	**EQ 10MG BASE**	**A077584**	**001**	Mar 07, 2007
AB			**EQ 20MG BASE**	**A077584**	**002**	Mar 07, 2007
AB			**EQ 30MG BASE**	**A077584**	**003**	Mar 07, 2007
AB			**EQ 40MG BASE**	**A077584**	**004**	Mar 07, 2007

PAXIL

AB	**+**	APOTEX TECHNOLOGIES	**EQ 10MG BASE**	**N020031**	**001**	Dec 29, 1992
AB	**+**		**EQ 20MG BASE**	**N020031**	**002**	Dec 29, 1992
AB	**+**		**EQ 30MG BASE**	**N020031**	**003**	Dec 29, 1992
AB	**+!**		**EQ 40MG BASE**	**N020031**	**005**	Dec 29, 1992

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB		LANNETT CO INC	**EQ 12.5MG BASE**	**A204744**	**001**	Jun 10, 2016
AB			**EQ 25MG BASE**	**A204744**	**002**	Jun 10, 2016
AB			**EQ 37.5MG BASE**	**A204744**	**003**	Jun 10, 2016
AB		LUPIN LTD	**EQ 12.5MG BASE**	**A204134**	**001**	Jan 20, 2017
AB			**EQ 25MG BASE**	**A204134**	**002**	Jan 20, 2017
AB			**EQ 37.5MG BASE**	**A204134**	**003**	Jan 20, 2017
AB		MYLAN	**EQ 12.5MG BASE**	**A077873**	**001**	Jun 29, 2007
AB			**EQ 25MG BASE**	**A077873**	**002**	Jun 29, 2007
AB			**EQ 37.5MG BASE**	**A091427**	**001**	Apr 14, 2011
AB		SCIECURE PHARMA INC	**EQ 12.5MG BASE**	**A209293**	**001**	Jun 12, 2018
AB			**EQ 25MG BASE**	**A209293**	**002**	Jun 12, 2018
AB			**EQ 37.5MG BASE**	**A209293**	**003**	Jun 12, 2018

PAXIL CR

AB	**+**	APOTEX TECHNOLOGIES	**EQ 12.5MG BASE**	**N020936**	**001**	Feb 16, 1999
AB	**+**		**EQ 25MG BASE**	**N020936**	**002**	Feb 16, 1999
AB	**+!**		**EQ 37.5MG BASE**	**N020936**	**003**	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

AB	**+!**	SEBELA IRELAND LTD	**EQ 7.5MG BASE**	**N204516**	**001**	Jun 28, 2013

PAROXETINE MESYLATE

AB		ACTAVIS LABS FL INC	**EQ 7.5MG BASE**	**A207139**	**001**	Jun 20, 2017
AB		PRINSTON INC	**EQ 7.5MG BASE**	**A207188**	**001**	Aug 18, 2017

TABLET;ORAL

PEXEVA

	+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003
	+		EQ 20MG BASE	N021299	002	Jul 03, 2003
	+		EQ 30MG BASE	N021299	003	Jul 03, 2003
	+!		EQ 40MG BASE	N021299	004	Jul 03, 2003

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS

SIGNIFOR

	+	NOVARTIS	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012
	+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012
	+!		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012

PASIREOTIDE PAMOATE

FOR SUSPENSION;INTRAMUSCULAR

SIGNIFOR LAR KIT

	+	NOVARTIS	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018
	+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014
	+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018
	+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014
	+!		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014

PATIROMER SORBITEX CALCIUM

POWDER;ORAL

VELTASSA

	+	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015
	+		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015
	+!		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015

PATISIRAN SODIUM
SOLUTION;INTRAVENOUS
ONPATTRO

	+!	ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N210922	001	Aug 10, 2018

PAZOPANIB HYDROCHLORIDE
TABLET;ORAL
VOTRIENT

	+!	NOVARTIS	EQ 200MG BASE	N022465	001	Oct 19, 2009

PEGAPTANIB SODIUM
INJECTABLE;INTRAVITREAL
MACUGEN

	+!	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004

PEGVISOMANT
INJECTABLE;SUBCUTANEOUS
SOMAVERT

	+!	PHARMACIA AND UPJOHN	10MG/VIAL	N021106	001	Mar 25, 2003
	+!		15MG/VIAL	N021106	002	Mar 25, 2003
	+!		20MG/VIAL	N021106	003	Mar 25, 2003
	+!		25MG/VIAL	N021106	004	Jul 31, 2014
	+!		30MG/VIAL	N021106	005	Jul 31, 2014

PEMETREXED DISODIUM
POWDER;INTRAVENOUS
ALIMTA

	+!	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007
	+!		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004

PENCICLOVIR
CREAM;TOPICAL
DENAVIR

	+!	MYLAN	1%	N020629	001	Sep 24, 1996

PENICILLAMINE
CAPSULE;ORAL
CUPRIMINE

AB	**+!**	VALEANT PHARMS INTL	**250MG**	**N019853**	**001**	

PENICILLAMINE

AB		AMERIGEN PHARMS LTD	**250MG**	**A209921**	**001**	May 07, 2019
AB		PAR PHARM INC	**250MG**	**A211231**	**001**	Dec 23, 2019
AB		WATSON LABS INC	**250MG**	**A210976**	**001**	Jun 24, 2019

TABLET;ORAL
DEPEN

AB	**+!**	MYLAN SPECIALITY LP	**250MG**	**N019854**	**001**	

PENICILLAMINE

AB		PAR PHARM INC	**250MG**	**A211196**	**001**	Dec 23, 2019

PENICILLIN G BENZATHINE
INJECTABLE;INJECTION
BICILLIN L-A

BC	+!	KING PHARMS LLC	600,000 UNITS/ML	N050141	001	

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE
INJECTABLE;INJECTION
BICILLIN C-R

	+!	KING PHARMS LLC	300,000 UNITS/ML;300,000 UNITS/ML	N050138	001	

BICILLIN C-R 900/300

	+!	KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003	

PENICILLIN G POTASSIUM
INJECTABLE;INJECTION
PENICILLIN G POTASSIUM

AP		ACS DOBFAR SPA	**20,000,000 UNITS/VIAL**	**A205043**	**002**	Oct 26, 2018
AP			**5,000,000 UNITS/VIAL**	**A205043**	**001**	Oct 26, 2018
AP		HANFORD GC	**5,000,000 UNITS/VIAL**	**A065149**	**002**	Jul 23, 2009
AP			**20,000,000 UNITS/VIAL**	**A065149**	**003**	Jul 23, 2009
AP		ISTITUTO BIO ITA SPA	**5,000,000 UNITS/VIAL**	**A065448**	**001**	Aug 18, 2009
AP			**20,000,000 UNITS/VIAL**	**A065448**	**002**	Aug 18, 2009
AP		SANDOZ	**5,000,000 UNITS/VIAL**	**A065079**	**002**	Aug 30, 2002
AP			**20,000,000 UNITS/VIAL**	**A065079**	**003**	Aug 30, 2002

PFIZERPEN

AP	**!**	PFIZER	**5,000,000 UNITS/VIAL**	**A060657**	**002**	
AP	**!**		**20,000,000 UNITS/VIAL**	**A060657**	**003**	

PENICILLIN G POTASSIUM
INJECTABLE;INJECTION
PENICILLIN G POTASSIUM

	HANFORD GC	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	20,000 UNITS/ML	N050638	001	Jun 25, 1990
+!		40,000 UNITS/ML	N050638	002	Jun 25, 1990
+!		60,000 UNITS/ML	N050638	003	Jun 25, 1990

PENICILLIN G PROCAINE
INJECTABLE;INJECTION
PENICILLIN G PROCAINE

!	KING PHARMS LLC	300,000 UNITS/ML	A060101	002	
!		600,000 UNITS/ML	A060101	001	

PENICILLIN G SODIUM
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
PENICILLIN G SODIUM

!	SANDOZ	5,000,000 UNITS/VIAL	A065068	001	Feb 26, 2001

PENICILLIN V POTASSIUM
FOR SOLUTION;ORAL
PENICILLIN V POTASSIUM

AA		DAVA PHARMS INC	**EQ 125MG BASE/5ML**	**A062981**	**001**	Feb 10, 1989
AA			**EQ 250MG BASE/5ML**	**A062981**	**002**	Feb 10, 1989

PENICILLIN-VK

AA		TEVA	**EQ 125MG BASE/5ML**	**A060456**	**001**	
AA	**!**		**EQ 250MG BASE/5ML**	**A060456**	**002**	

TABLET;ORAL
PENICILLIN V POTASSIUM

AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A065435**	**001**	Apr 29, 2008
AB			**EQ 500MG BASE**	**A065435**	**002**	Apr 29, 2008
AB		DAVA PHARMS INC	**EQ 250MG BASE**	**A062936**	**001**	Nov 25, 1988
AB			**EQ 500MG BASE**	**A062935**	**001**	Nov 23, 1988
AB		HIKMA PHARMS	**EQ 250MG BASE**	**A090549**	**001**	Oct 11, 2013
AB			**EQ 500MG BASE**	**A090549**	**002**	Oct 11, 2013
AB		SANDOZ	**EQ 250MG BASE**	**A064071**	**001**	Nov 30, 1995
AB	**!**		**EQ 500MG BASE**	**A064071**	**002**	Nov 30, 1995

PENICILLIN-VK

AB		TEVA	**EQ 250MG BASE**	**A060711**	**002**	
AB			**EQ 500MG BASE**	**A060711**	**003**	

PENTAMIDINE ISETHIONATE
FOR SOLUTION;INHALATION
NEBUPENT

AN	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019887**	**001**	Jun 15, 1989

PENTAMIDINE ISETHIONATE

AN		SETON PHARMS	**300MG/VIAL**	**A206667**	**001**	Apr 24, 2019

INJECTABLE;INJECTION
PENTAM

AP	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019264**	**001**	Oct 16, 1984

PENTAMIDINE ISETHIONATE

AP		SETON PHARMS	**300MG/VIAL**	**A206666**	**001**	Sep 28, 2017

PENTETATE CALCIUM TRISODIUM
SOLUTION;INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

+!	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004

PENTETATE ZINC TRISODIUM
SOLUTION;INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

+!	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004

PENTOBARBITAL SODIUM
INJECTABLE;INJECTION
NEMBUTAL SODIUM

AP	**!**	OAK PHARMS	**50MG/ML**	**A083246**	**001**	

PENTOBARBITAL SODIUM

AP		ATHENEX	**50MG/ML**	**A206677**	**001**	Nov 27, 2017
AP		CUSTOPHARM INC	**50MG/ML**	**A203619**	**001**	Nov 13, 2017
AP		SAGENT PHARMS INC	**50MG/ML**	**A206404**	**001**	May 23, 2016

PENTOSAN POLYSULFATE SODIUM

CAPSULE;ORAL

ELMIRON

+!	JANSSEN PHARMS	100MG	N020193	001	Sep 26, 1996

PENTOSTATIN

INJECTABLE;INJECTION

NIPENT

AP	**+!**	HOSPIRA INC	**10MG/VIAL**	**N020122**	**001**	Oct 11, 1991

PENTOSTATIN

AP	WEST-WARD PHARMS INT	**10MG/VIAL**	**A077841**	**001**	Aug 07, 2007

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB	**!**	APOTEX	**400MG**	**A075191**	**001**	Jun 09, 1999
AB		VALEANT PHARMS	**400MG**	**A075028**	**001**	Jul 20, 1998

PENTOXIL

AB		UPSHER SMITH LABS	**400MG**	**A074962**	**001**	Mar 31, 1999

PERAMIVIR

SOLUTION;INTRAVENOUS

RAPIVAB

+!	BIOCRYST	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014

PERAMPANEL

SUSPENSION;ORAL

FYCOMPA

+!	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016

TABLET;ORAL

FYCOMPA

+	EISAI INC	2MG	N202834	001	Oct 22, 2012
+		4MG	N202834	002	Oct 22, 2012
+		6MG	N202834	003	Oct 22, 2012
+		8MG	N202834	004	Oct 22, 2012
+		10MG	N202834	005	Oct 22, 2012
+!		12MG	N202834	006	Oct 22, 2012

PERFLUTREN

INJECTABLE;INTRAVENOUS

DEFINITY

+!	LANTHEUS MEDCL	6.52MG/ML	N021064	001	Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

AB		AUROBINDO PHARMA	**2MG**	**A079070**	**001**	Nov 10, 2009
AB			**4MG**	**A079070**	**002**	Nov 10, 2009
AB	**!**		**8MG**	**A079070**	**003**	Nov 10, 2009
AB		HIKMA	**2MG**	**A090072**	**001**	Nov 10, 2009
AB			**4MG**	**A090072**	**002**	Nov 10, 2009
AB			**8MG**	**A090072**	**003**	Nov 10, 2009

PERMETHRIN

CREAM;TOPICAL

ELIMITE

AB	**+!**	MYLAN	**5%**	**N019855**	**001**	Aug 25, 1989

PERMETHRIN

AB		ACTAVIS LABS	**5%**	**A074806**	**001**	Jan 23, 1998
AB		ENCUBE ETHICALS	**5%**	**A211303**	**001**	Apr 03, 2019
AB		PERRIGO ISRAEL	**5%**	**A076369**	**001**	Apr 21, 2003

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB		MYLAN	**2MG**	**A206691**	**001**	Apr 14, 2017
AB			**4MG**	**A206691**	**002**	Apr 14, 2017
AB			**8MG**	**A206691**	**003**	Apr 14, 2017
AB			**16MG**	**A206691**	**004**	Apr 14, 2017
AB		RISING	**2MG**	**A205056**	**001**	Mar 01, 2019
AB			**4MG**	**A205056**	**002**	Mar 01, 2019
AB			**8MG**	**A205056**	**003**	Mar 01, 2019
AB			**16MG**	**A205056**	**004**	Mar 01, 2019
AB		SANDOZ	**2MG**	**A089685**	**002**	Dec 08, 1988
AB			**4MG**	**A089685**	**003**	Dec 08, 1988
AB			**8MG**	**A089685**	**001**	Dec 08, 1988

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB	**!**		**16MG**	**A089685**	**004**	Dec 08, 1988
AB		VINTAGE PHARMS	**2MG**	**A040226**	**001**	Dec 31, 1998
AB			**4MG**	**A040226**	**002**	Dec 31, 1998
AB			**8MG**	**A040226**	**003**	Dec 31, 1998
AB			**16MG**	**A040226**	**004**	Dec 31, 1998
AB		WATSON LABS INC	**2MG**	**A207582**	**001**	Oct 17, 2016
AB			**4MG**	**A207582**	**002**	Oct 17, 2016
AB			**8MG**	**A207582**	**003**	Oct 17, 2016
AB			**16MG**	**A207582**	**004**	Oct 17, 2016
AB		WILSHIRE PHARMS INC	**2MG**	**A205973**	**001**	Dec 17, 2015
AB			**4MG**	**A205973**	**002**	Dec 17, 2015
AB			**8MG**	**A205973**	**003**	Dec 17, 2015
AB			**16MG**	**A205973**	**004**	Dec 17, 2015

PEXIDARTINIB HYDROCHLORIDE

CAPSULE;ORAL

TURALIO

	+!	DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENDIMETRAZINE TARTRATE

	+!	VIRTUS PHARMS	105MG	N018074	001	

TABLET;ORAL

BONTRIL PDM

AA	**!**	VALEANT	**35MG**	**A085272**	**001**	

PHENDIMETRAZINE TARTRATE

AA		ELITE LABS INC	**35MG**	**A040762**	**001**	Jan 28, 2008
AA			**35MG**	**A203600**	**001**	Dec 27, 2017
AA		KVK TECH	**35MG**	**A091042**	**001**	Aug 31, 2010
AA		MIKART	**35MG**	**A089452**	**001**	Oct 30, 1991
AA		VIRTUS PHARMS	**35MG**	**A085588**	**001**	

PHENELZINE SULFATE

TABLET;ORAL

NARDIL

AB	**+!**	PARKE DAVIS	**EQ 15MG BASE**	**N011909**	**002**	

PHENELZINE SULFATE

AB		NOVEL LABS INC	**EQ 15MG BASE**	**A200181**	**001**	Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB		HIKMA	**10MG**	**A201050**	**001**	Jul 16, 2012
AB	**!**	PAR PHARM INC	**10MG**	**A204522**	**001**	Jan 24, 2017

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

ADIPEX-P

AA	**!**	TEVA	**37.5MG**	**A088023**	**001**	Aug 02, 1983

PHENTERMINE HYDROCHLORIDE

AA		AUROLIFE PHARMA LLC	**15MG**	**A204318**	**001**	Nov 09, 2016
AA			**30MG**	**A204318**	**002**	Nov 09, 2016
AA		BARR	**15MG**	**A090591**	**001**	Mar 18, 2010
AA			**30MG**	**A090591**	**002**	Mar 18, 2010
AA		ELITE LABS	**15MG**	**A202248**	**001**	Sep 28, 2012
AA			**30MG**	**A202248**	**002**	Sep 28, 2012
AA		ELITE LABS INC	**37.5MG**	**A040228**	**001**	Jun 19, 1997
AA		INVAGEN PHARMS	**15MG**	**A202858**	**001**	Feb 14, 2014
AA			**30MG**	**A202858**	**002**	Feb 14, 2014
AA			**30MG**	**A204414**	**001**	May 05, 2014
AA			**37.5MG**	**A202846**	**001**	Feb 05, 2014
AA		KVK TECH	**15MG**	**A040886**	**002**	Mar 31, 2008
AA			**30MG**	**A040875**	**001**	Mar 21, 2008
AA			**30MG**	**A040886**	**001**	Mar 31, 2008
AA			**37.5MG**	**A040887**	**001**	Apr 24, 2008
AA		LANNETT	**15MG**	**A087022**	**002**	Jan 20, 2012
AA			**30MG**	**A087022**	**001**	Feb 03, 1983
AA		LANNETT CO INC	**37.5MG**	**A201961**	**001**	Jul 20, 2011
AA		NUVO PHARM	**15MG**	**A205019**	**001**	Dec 05, 2014
AA			**30MG**	**A205019**	**002**	Dec 05, 2014
AA			**37.5MG**	**A205017**	**001**	Sep 25, 2014

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA	**!**	SANDOZ	**15MG**	**A087190**	**002**	
AA	**!**		**30MG**	**A086945**	**001**	Jul 20, 1983
AA	**!**		**30MG**	**A087190**	**001**	
AA		SUN PHARM INDUSTRIES	**30MG**	**A040525**	**001**	Oct 23, 2003

TABLET;ORAL

ADIPEX-P

AA	**!**	TEVA	**37.5MG**	**A085128**	**001**	

LOMAIRA

AA	**!**	AVANTHI INC	**8MG**	**A203495**	**001**	Sep 12, 2016

PHENTERMINE HYDROCHLORIDE

AA		AUROLIFE PHARMA LLC	**37.5MG**	**A203068**	**001**	Aug 06, 2014
AA		BARR	**37.5MG**	**A090470**	**001**	Aug 31, 2009
AA		ELITE LABS	**37.5MG**	**A200272**	**001**	Jan 31, 2011
AA		ELITE LABS INC	**37.5MG**	**A040190**	**001**	May 30, 1997
AA		INVAGEN PHARMS	**37.5MG**	**A202942**	**001**	Feb 05, 2014
AA		KVK TECH	**37.5MG**	**A040876**	**001**	Mar 31, 2008
AA		KVK TECH INC	**8MG**	**A203436**	**001**	Mar 17, 2017
AA		LANNETT	**37.5MG**	**A040555**	**001**	Apr 15, 2005
AA		NUVO PHARM	**37.5MG**	**A205008**	**001**	Sep 25, 2014
AA		POLYGEN PHARMS	**37.5MG**	**A206342**	**001**	Nov 18, 2016
AA		PRINSTON INC	**37.5MG**	**A040377**	**001**	Jan 04, 2002
AA		SUN PHARM INDUSTRIES	**37.5MG**	**A040526**	**001**	Oct 23, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

PHENTERMINE HYDROCHLORIDE

	ZYDUS PHARMS	15MG	A204663	001	Jun 28, 2017
		30MG	A204663	002	Jun 28, 2017
		37.5MG	A204663	003	Jun 28, 2017

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QSYMIA

	+	VIVUS	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012
	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012
	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012
	+!		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

PHENTOLAMINE MESYLATE

AP		PRECISION DOSE INC	**5MG/VIAL**	**A207686**	**001**	Jul 14, 2017
AP	**!**	WEST-WARD PHARMS INT	**5MG/VIAL**	**A040235**	**001**	Mar 11, 1998

ORAVERSE

	+!	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1		AMNEAL	**10MG/ML (10MG/ML)**	**A211079**	**001**	Jul 05, 2018
AP1			**50MG/5ML (10MG/ML)**	**A211078**	**001**	Jul 19, 2018
AP1			**100MG/10ML (10MG/ML)**	**A211078**	**002**	Jul 19, 2018
AP1		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A210666**	**001**	Jan 30, 2019
AP1			**100MG/10ML (10MG/ML)**	**A210666**	**002**	Jan 30, 2019
AP1		MEITHEAL	**50MG/5ML (10MG/ML)**	**A210333**	**001**	Apr 27, 2018
AP1			**100MG/10ML (10MG/ML)**	**A210333**	**002**	Apr 27, 2018
AP1		PAR STERILE PRODUCTS	**10MG/ML (10MG/ML)**	**A210025**	**001**	Dec 21, 2018
AP1			**50MG/5ML (10MG/ML)**	**A210025**	**002**	Dec 21, 2018
AP1			**100MG/10ML (10MG/ML)**	**A210025**	**003**	Dec 21, 2018
AP1		SANDOZ INC	**10MG/ML (10MG/ML)**	**A208905**	**001**	Jan 31, 2019
AP1			**50MG/5ML (10MG/ML)**	**A208905**	**002**	Jan 31, 2019
AP1			**100MG/10ML (10MG/ML)**	**A208905**	**003**	Jan 31, 2019

VAZCULEP

AP1	**+!**	AVADEL LEGACY	**10MG/ML (10MG/ML)**	**N204300**	**001**	Jun 27, 2014
AP1	**+!**		**50MG/5ML (10MG/ML)**	**N204300**	**002**	Jun 27, 2014
AP1	**+!**		**100MG/10ML (10MG/ML)**	**N204300**	**003**	Jun 27, 2014

PHENYLEPHRINE HYDROCHLORIDE

AP2		FRESENIUS KABI USA	**10MG/ML (10MG/ML)**	**A210665**	**001**	Jan 29, 2019
AP2		MEITHEAL	**10MG/ML (10MG/ML)**	**A210334**	**001**	Apr 27, 2018
AP2	**+!**	WEST WARD PHARM	**10MG/ML (10MG/ML)**	**N203826**	**001**	Dec 20, 2012

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

		CORP				
AP2	**+!**		**50MG/5ML (10MG/ML)**	**N203826**	**002**	Jun 19, 2019
AP2	**+!**		**100MG/10ML (10MG/ML)**	**N203826**	**003**	Jun 19, 2019
		BIORPHEN				
	+!	ETON PHARMS	0.1MG/ML (0.1MG/ML)	N212909	001	Oct 21, 2019

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	**+!**	AKORN INC	**2.5%**	**N207926**	**001**	Jan 15, 2015
AT	**+!**		**10%**	**N207926**	**002**	Jan 15, 2015
AT	**+!**	PARAGON BIOTECK	**2.5%**	**N203510**	**001**	Mar 21, 2013
AT	**+!**		**10%**	**N203510**	**002**	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA		HI TECH	**5MG/5ML;6.25MG/5ML**	**A040675**	**001**	Dec 23, 2014
AA	**!**	VINTAGE	**5MG/5ML;6.25MG/5ML**	**A040654**	**001**	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**5MG/5ML;6.25MG/5ML**	**A040902**	**001**	Aug 25, 2009

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	**+!**	PARKE DAVIS	**125MG/5ML**	**N008762**	**001**	

PHENYTOIN

AB		TARO	**125MG/5ML**	**A040521**	**001**	Mar 08, 2004
AB		VISTAPHARM	**125MG/5ML**	**A040342**	**001**	Jan 31, 2001
AB			**125MG/5ML**	**A040610**	**001**	Aug 18, 2005
AB		WOCKHARDT BIO AG	**125MG/5ML**	**A040420**	**001**	Apr 19, 2002

TABLET, CHEWABLE;ORAL

DILANTIN

AB	**!**	PFIZER	**50MG**	**A084427**	**001**	

PHENYTOIN

AB		EPIC PHARMA LLC	**50MG**	**A040884**	**001**	Nov 28, 2014
AB		MYLAN PHARMS INC	**50MG**	**A200691**	**001**	Dec 26, 2012
AB		TARO	**50MG**	**A200565**	**001**	Apr 17, 2014

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

AB	**!**	PARKE-DAVIS	**100MG EXTENDED**	**A084349**	**002**	

EXTENDED PHENYTOIN SODIUM

AB		AMNEAL PHARMS NY	**100MG EXTENDED**	**A040765**	**001**	Nov 12, 2008
AB		LUPIN LTD	**100MG EXTENDED**	**A211633**	**001**	Sep 30, 2019
AB		MYLAN	**100MG EXTENDED**	**A040298**	**001**	Dec 28, 1998
AB		SUN PHARM INDS	**200MG EXTENDED**	**A040731**	**001**	Jun 30, 2008
AB			**300MG EXTENDED**	**A040731**	**002**	Jun 30, 2008
AB		TARO	**100MG EXTENDED**	**A040684**	**001**	Sep 05, 2006

PHENYTEK

AB		MYLAN	**200MG EXTENDED**	**A040298**	**002**	Dec 06, 2001
AB	**!**		**300MG EXTENDED**	**A040298**	**003**	Dec 06, 2001

PHENYTOIN SODIUM

AB		AUROBINDO PHARMA LTD	**100MG EXTENDED**	**A204309**	**001**	Jun 10, 2015
		DILANTIN				
	!	PARKE-DAVIS	30MG EXTENDED	A084349	001	

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP		ACELLA	**50MG/ML**	**A040573**	**001**	Sep 13, 2006
AP	**!**	WEST-WARD PHARMS INT	**50MG/ML**	**A084307**	**001**	

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

AB		DR REDDYS LABS LTD	**10MG/ML**	**A207719**	**001**	May 22, 2019

VITAMIN K1

AB	**!**	HOSPIRA	**10MG/ML**	**A087955**	**001**	Jul 25, 1983
		PHYTONADIONE				
BP	!	INTL MEDICATION	1MG/0.5ML	A083722	001	

PHYTONADIONE
INJECTABLE;INJECTION
VITAMIN K1

BP	!	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983

TABLET;ORAL

MEPHYTON						
AB	**+!**	BAUSCH	**5MG**	**N010104**	**003**	
PHYTONADIONE						
AB		AMNEAL PHARMS CO	**5MG**	**A209373**	**001**	May 11, 2018
AB		ZYDUS	**5MG**	**A210189**	**001**	Feb 20, 2019

PILOCARPINE HYDROCHLORIDE
SOLUTION;OPHTHALMIC

ISOPTO CARPINE						
AT	**+**	NOVARTIS	**1%**	**N200890**	**001**	Jun 22, 2010
AT	**+**		**2%**	**N200890**	**002**	Jun 22, 2010
AT	**+!**		**4%**	**N200890**	**003**	Jun 22, 2010
PILOCARPINE HYDROCHLORIDE						
AT		AKORN INC	**1%**	**A204398**	**001**	Sep 27, 2017
AT			**2%**	**A204398**	**002**	Sep 27, 2017
AT			**4%**	**A204398**	**003**	Sep 27, 2017
AT		SOMERSET THERAPS LLC	**1%**	**A210384**	**001**	Nov 25, 2019
AT			**2%**	**A210384**	**002**	Nov 25, 2019
AT			**4%**	**A210384**	**003**	Nov 25, 2019

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**5MG**	**A212377**	**001**	Aug 13, 2019
AB			**7.5MG**	**A212377**	**002**	Aug 13, 2019
AB		IMPAX LABS	**5MG**	**A077248**	**001**	Mar 31, 2006
AB			**7.5MG**	**A077248**	**002**	Mar 31, 2006
AB		INNOGENIX	**5MG**	**A076963**	**001**	Dec 22, 2004
AB			**7.5MG**	**A076963**	**002**	Feb 27, 2007
AB		LANNETT CO INC	**5MG**	**A077220**	**001**	Oct 14, 2005
AB			**7.5MG**	**A077220**	**002**	May 06, 2009
AB		PERRIGO PHARMA INTL	**5MG**	**A076746**	**001**	Nov 16, 2004
SALAGEN						
AB	**+**	CONCORDIA	**5MG**	**N020237**	**001**	Mar 22, 1994
AB	**+!**		**7.5MG**	**N020237**	**002**	Apr 18, 2003

PIMAVANSERIN TARTRATE
CAPSULE;ORAL
NUPLAZID

	+!	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018

TABLET;ORAL
NUPLAZID

	+!	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018

PIMECROLIMUS
CREAM;TOPICAL

ELIDEL						
AB	**+!**	BAUSCH	**1%**	**N021302**	**001**	Dec 13, 2001
PIMECROLIMUS						
AB		ACTAVIS LABS UT INC	**1%**	**A209345**	**001**	Dec 27, 2018
AB		GLENMARK PHARMS LTD	**1%**	**A211769**	**001**	Aug 29, 2019

PIMOZIDE
TABLET;ORAL
PIMOZIDE

		PAR PHARM	1MG	A204521	001	Sep 28, 2015
	!		2MG	A204521	002	Sep 28, 2015

PINDOLOL
TABLET;ORAL
PINDOLOL

AB		ANI PHARMS INC	**5MG**	**A073609**	**002**	Mar 29, 1993
AB			**10MG**	**A073609**	**001**	Mar 29, 1993
AB		BAYSHORE PHARMS LLC	**5MG**	**A211712**	**001**	Aug 01, 2019
AB			**10MG**	**A211712**	**002**	Aug 01, 2019
AB		MYLAN PHARMS INC	**5MG**	**A074019**	**001**	Sep 03, 1992
AB	**!**		**10MG**	**A074019**	**002**	Sep 03, 1992
AB		NOSTRUM LABS INC	**5MG**	**A205415**	**001**	Jan 13, 2016
AB			**10MG**	**A205415**	**002**	Jan 13, 2016
AB		SUN PHARM	**5MG**	**A074063**	**001**	Jan 27, 1994

PINDOLOL

TABLET;ORAL

PINDOLOL

		INDUSTRIES				
AB			**10MG**	**A074063**	**002**	Jan 27, 1994

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOS

AB	**+**	TAKEDA PHARMS USA	**EQ 15MG BASE**	**N021073**	**001**	Jul 15, 1999
AB	**+**		**EQ 30MG BASE**	**N021073**	**002**	Jul 15, 1999
AB	**+!**		**EQ 45MG BASE**	**N021073**	**003**	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 15MG BASE**	**A200044**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200044**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200044**	**003**	Feb 13, 2013
AB		AUROBINDO PHARMA LTD	**EQ 15MG BASE**	**A200268**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200268**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200268**	**003**	Feb 13, 2013
AB		BRECKENRIDGE	**EQ 15MG BASE**	**A078472**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A078472**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A078472**	**003**	Feb 13, 2013
AB		CELLTRION	**EQ 15MG BASE**	**A076798**	**001**	Oct 26, 2012
AB			**EQ 30MG BASE**	**A076798**	**002**	Oct 26, 2012
AB			**EQ 45MG BASE**	**A076798**	**003**	Oct 26, 2012
AB		LUPIN LTD	**EQ 15MG BASE**	**A204133**	**001**	Apr 07, 2014
AB			**EQ 30MG BASE**	**A204133**	**002**	Apr 07, 2014
AB			**EQ 45MG BASE**	**A204133**	**003**	Apr 07, 2014
AB		MACLEODS PHARMS LTD	**EQ 15MG BASE**	**A202467**	**001**	Feb 06, 2013
AB			**EQ 30MG BASE**	**A202467**	**002**	Feb 06, 2013
AB			**EQ 45MG BASE**	**A202467**	**003**	Feb 06, 2013
AB		MYLAN PHARMS INC	**EQ 15MG BASE**	**A076801**	**001**	Aug 17, 2012
AB			**EQ 30MG BASE**	**A076801**	**002**	Aug 17, 2012
AB			**EQ 45MG BASE**	**A076801**	**003**	Aug 17, 2012
AB		NEOPHARMA	**EQ 15MG BASE**	**A078383**	**001**	Mar 12, 2013
AB			**EQ 30MG BASE**	**A078383**	**002**	Mar 12, 2013
AB			**EQ 45MG BASE**	**A078383**	**003**	Mar 12, 2013
AB		PRINSTON INC	**EQ 15MG BASE**	**A207806**	**001**	Apr 17, 2018
AB			**EQ 30MG BASE**	**A207806**	**002**	Apr 17, 2018
AB			**EQ 45MG BASE**	**A207806**	**003**	Apr 17, 2018
AB		PURACAP PHARM LLC	**EQ 15MG BASE**	**A206738**	**001**	Oct 06, 2017
AB			**EQ 30MG BASE**	**A206738**	**002**	Oct 06, 2017
AB			**EQ 45MG BASE**	**A206738**	**003**	Oct 06, 2017
AB		SANDOZ	**EQ 15MG BASE**	**A078670**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A078670**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A078670**	**003**	Feb 13, 2013
AB		TEVA PHARMS USA	**EQ 15MG BASE**	**A077210**	**001**	Jan 10, 2014
AB			**EQ 30MG BASE**	**A077210**	**002**	Jan 10, 2014
AB			**EQ 45MG BASE**	**A077210**	**003**	Jan 10, 2014
AB		TORRENT PHARMS LTD	**EQ 15MG BASE**	**A091298**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A091298**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A091298**	**003**	Feb 13, 2013
AB		ZYDUS PHARMS USA INC	**EQ 15MG BASE**	**A202456**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A202456**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A202456**	**003**	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

	!	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
	!		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
	!		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
	!		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		APOLLO	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A207847**	**001**	Jan 13, 2017
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A207847**	**002**	Jan 13, 2017
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207848**	**002**	Jan 13, 2017
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A207847**	**003**	Jan 13, 2017

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP			**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A207848**	**001**	May 11, 2018
AP		AUROBINDO PHARMA LTD	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065498**	**001**	May 23, 2011
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065498**	**002**	May 23, 2011
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065498**	**003**	May 23, 2011
AP		FRESENIUS KABI	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A203719**	**001**	May 18, 2018
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A203719**	**002**	May 18, 2018
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A203719**	**003**	May 18, 2018
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A203720**	**001**	May 11, 2018
AP		FRESENIUS KABI USA	**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A206204**	**001**	May 11, 2018
AP		ISTITUTO BIO ITA SPA	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065523**	**001**	May 31, 2011
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065523**	**002**	May 31, 2011
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065523**	**003**	May 31, 2011
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A090498**	**001**	May 31, 2011
AP		MYLAN LABS LTD	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065458**	**001**	Aug 15, 2014
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065458**	**002**	Aug 15, 2014
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065458**	**003**	Aug 15, 2014
AP		QILU	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A204959**	**001**	Aug 10, 2018
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A204959**	**002**	Aug 10, 2018
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A204959**	**003**	Aug 10, 2018
AP		SANDOZ	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065362**	**001**	Oct 21, 2010
AP			**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065363**	**001**	Oct 21, 2010
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065362**	**002**	Oct 21, 2010
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065363**	**002**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065362**	**003**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065363**	**003**	Oct 21, 2010
AP		SANDOZ INC	**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A203557**	**001**	Oct 29, 2014
AP		WOCKHARDT BIO AG	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A206996**	**001**	Mar 22, 2017
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A206996**	**002**	Mar 22, 2017
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A206996**	**003**	Mar 22, 2017
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207146**	**001**	Mar 17, 2017

ZOSYN

AP	**+!**	WYETH PHARMS	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**N050684**	**001**	Oct 22, 1993
AP	**+!**		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**N050684**	**002**	Oct 22, 1993
AP	**+!**		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**N050684**	**003**	Oct 22, 1993
AP	**+!**		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**N050684**	**004**	Oct 22, 1993

ZOSYN IN PLASTIC CONTAINER

+!	WYETH PHARMS	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

+!	GENENTECH INC	267MG	N022535	001	Oct 15, 2014

TABLET;ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017
+!		801MG	N208780	003	Jan 11, 2017

PIROXICAM

CAPSULE;ORAL

FELDENE

AB	**+**	PFIZER	**10MG**	**N018147**	**002**	Apr 06, 1982
AB	**+!**		**20MG**	**N018147**	**003**	Apr 06, 1982

PIROXICAM

AB		CADILA	**10MG**	**A205585**	**001**	Jul 17, 2018
AB			**20MG**	**A205585**	**002**	Jul 17, 2018
AB		FLAMINGO PHARMS	**10MG**	**A207938**	**001**	Sep 09, 2016
AB			**20MG**	**A207938**	**002**	Sep 09, 2016
AB		HIKMA PHARMS	**10MG**	**A209256**	**001**	Aug 11, 2017
AB			**20MG**	**A209256**	**002**	Aug 11, 2017
AB		MICRO LABS	**10MG**	**A206152**	**001**	Dec 29, 2017
AB			**20MG**	**A206152**	**002**	Dec 29, 2017
AB		NOSTRUM LABS INC	**10MG**	**A074116**	**001**	Jun 15, 1993
AB			**20MG**	**A074118**	**001**	Jun 15, 1993
AB		PII	**10MG**	**A206136**	**001**	Jun 20, 2017
AB			**20MG**	**A206136**	**002**	Jun 20, 2017
AB		STRIDES PHARMA	**10MG**	**A210347**	**001**	Jan 26, 2018
AB			**20MG**	**A210347**	**002**	Jan 26, 2018

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB		TEVA	**10MG**	**A074131**	**001**	Dec 11, 1992
AB			**20MG**	**A074131**	**002**	Dec 11, 1992
AB		UNICHEM LABS LTD	**10MG**	**A208340**	**001**	Apr 13, 2017
AB			**20MG**	**A208340**	**002**	Apr 13, 2017

PITAVASTATIN CALCIUM

TABLET;ORAL

LIVALO

AB	**+**	KOWA CO	**EQ 1MG BASE**	**N022363**	**001**	Aug 03, 2009
AB	**+**		**EQ 2MG BASE**	**N022363**	**002**	Aug 03, 2009
AB	**+!**		**EQ 4MG BASE**	**N022363**	**003**	Aug 03, 2009

PITAVASTATIN CALCIUM

AB		AUROBINDO PHARMA LTD	**EQ 1MG BASE**	**A206015**	**001**	Dec 20, 2016
AB			**EQ 2MG BASE**	**A206015**	**002**	Dec 20, 2016
AB			**EQ 4MG BASE**	**A206015**	**003**	Dec 20, 2016
AB		ORIENT PHARMA CO LTD	**EQ 1MG BASE**	**A205932**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205932**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205932**	**003**	Feb 03, 2017
AB		SAWAI USA	**EQ 1MG BASE**	**A205955**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205955**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205955**	**003**	Feb 03, 2017

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

+	MEDICURE	EQ 2MG BASE	N208379	002	Jul 14, 2017
+!		EQ 4MG BASE	N208379	003	Jul 14, 2017

PITOLISANT HYDROCHLORIDE

TABLET;ORAL

WAKIX

+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019
+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019

PLAZOMICIN SULFATE

SOLUTION;INTRAVENOUS

ZEMDRI

+!	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018

PLECANATIDE

TABLET;ORAL

TRULANCE

+!	SALIX	3MG	N208745	001	Jan 19, 2017

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

MOZOBIL

+!	GENZYME	24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008

PODOFILOX

GEL;TOPICAL

CONDYLOX

+!	ALLERGAN	0.5%	N020529	001	Mar 13, 1997

SOLUTION;TOPICAL

CONDYLOX

AT	**+!**	ALLERGAN	**0.5%**	**N019795**	**001**	Dec 13, 1990

PODOFILOX

AT		PADDOCK LLC	**0.5%**	**A075600**	**001**	Jan 29, 2002

POLIDOCANOL

SOLUTION;INTRAVENOUS

ASCLERA

+	CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201	001	Mar 30, 2010
+!		20MG/2ML (10MG/ML)	N021201	002	Mar 30, 2010

VARITHENA

+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017
+!		180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

LAX-LYTE WITH FLAVOR PACKS

AA		PADDOCK LLC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A079232**	**001**	Feb 25, 2010

NULYTELY

AA	**+!**	BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**001**	Apr 22, 1991

NULYTELY-FLAVORED

AA	**+!**	BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**002**	Nov 18, 1994

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA		BRECKENRIDGE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A202060**	**001**	Mar 08, 2017
AA		NOVEL LABS INC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A090019**	**001**	May 27, 2009
AA		STRIDES PHARMA	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A204559**	**001**	Apr 13, 2015

TRILYTE

AA		MYLAN	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A076491**	**001**	Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE WITH FLAVOR PACKS

AA		MYLAN SPECIALITY LP	**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**N018983**	**012**	Oct 08, 1998

GOLYTELY

AA	**+!**	BRAINTREE	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**N019011**	**001**	Jul 13, 1984

PEG 3350 AND ELECTROLYTES

AA		NOVEL LABS INC	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A090231**	**001**	Jun 01, 2009
AA			**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**A090186**	**001**	Jun 01, 2009

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

AA		STRIDES PHARMA	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A204558**	**001**	Dec 21, 2018

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP		AUROBINDO PHARMA LTD	**EQ 500,000 UNITS BASE/VIAL**	**A206589**	**001**	Apr 04, 2016
AP		FRESENIUS KABI USA	**EQ 500,000 UNITS BASE/VIAL**	**A065372**	**001**	Jan 10, 2008
AP	**!**	GLAND PHARMA LTD	**EQ 500,000 UNITS BASE/VIAL**	**A207322**	**001**	Apr 14, 2016
AP		MYLAN ASI	**EQ 500,000 UNITS BASE/VIAL**	**A090110**	**001**	Jun 29, 2011
AP		X GEN PHARMS	**EQ 500,000 UNITS BASE/VIAL**	**A063000**	**001**	Sep 30, 1994
AP		XELLIA PHARMS APS	**EQ 500,000 UNITS BASE/VIAL**	**A202766**	**001**	Jan 15, 2014

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

POLYTRIM

AT	**+!**	ALLERGAN	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**N050567**	**001**	Oct 20, 1988

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		AKORN INC	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A065006**	**001**	Dec 17, 1998
AT		BAUSCH AND LOMB	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064120**	**001**	Feb 14, 1997
AT		SANDOZ INC	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064211**	**001**	Apr 13, 1998

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

	+	CELGENE	1MG	N204026	001	Feb 08, 2013
	+		2MG	N204026	002	Feb 08, 2013
	+		3MG	N204026	003	Feb 08, 2013
	+!		4MG	N204026	004	Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

	+	ARIAD	EQ 15MG BASE	N203469	001	Dec 14, 2012
	+		EQ 30MG BASE	N203469	003	Apr 23, 2015
	+!		EQ 45MG BASE	N203469	002	Dec 14, 2012

PORACTANT ALFA
SUSPENSION;INTRATRACHEAL
CUROSURF

	+!	CHIESI USA INC	80MG/ML	N020744	001	Nov 18, 1999

PORFIMER SODIUM
INJECTABLE;INJECTION
PHOTOFRIN

		PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995

POSACONAZOLE
SOLUTION;INTRAVENOUS
NOXAFIL

	+!	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014

SUSPENSION;ORAL
NOXAFIL

	+!	SCHERING	40MG/ML	N022003	001	Sep 15, 2006

TABLET, DELAYED RELEASE;ORAL
NOXAFIL

AB	**+!**	MERCK SHARP DOHME	**100MG**	**N205053**	**001**	Nov 25, 2013

POSACONAZOLE

AB		SINOTHERAPEUTICS INC	**100MG**	**A212411**	**001**	Aug 21, 2019

POTASSIUM ACETATE
INJECTABLE;INJECTION
POTASSIUM ACETATE

AP		EXELA PHARMA SCS LLC	**2MEQ/ML**	**A206203**	**001**	Dec 29, 2015
AP	**+!**	HOSPIRA	**2MEQ/ML**	**N018896**	**001**	Jul 20, 1984

POTASSIUM CHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
KLOR-CON

AB		UPSHER SMITH LABS	**8MEQ**	**A203106**	**001**	Jul 10, 2015
AB			**10MEQ**	**A203106**	**002**	Jul 10, 2015

MICRO-K

AB	**+**	NESHER PHARMS	**8MEQ**	**N018238**	**001**	

MICRO-K 10

AB	**+**	NESHER PHARMS	**10MEQ**	**N018238**	**002**	May 14, 1984

POTASSIUM CHLORIDE

AB		ACTAVIS LABS FL INC	**8MEQ**	**A077419**	**001**	Jun 02, 2008
AB	**!**		**10MEQ**	**A077419**	**002**	Jun 02, 2008
AB		ADARE PHARMS INC	**8MEQ**	**A208864**	**001**	Mar 17, 2017
AB			**10MEQ**	**A208864**	**002**	Mar 17, 2017
AB		AMNEAL PHARMS	**10MEQ**	**A202128**	**001**	Feb 22, 2013
AB		ANCHEN PHARMS	**8MEQ**	**A202886**	**001**	Dec 26, 2013
AB			**10MEQ**	**A202886**	**002**	Dec 26, 2013
AB		GLENMARK PHARMS LTD	**10MEQ**	**A202868**	**001**	Jan 19, 2016
AB		LANNETT CO INC	**8MEQ**	**A204210**	**001**	Mar 28, 2016
AB			**10MEQ**	**A204210**	**002**	Mar 28, 2016
AB		LUPIN LTD	**8MEQ**	**A203002**	**001**	Dec 18, 2015
AB			**10MEQ**	**A203002**	**002**	Dec 18, 2015
AB		NOVEL LABS INC	**8MEQ**	**A204828**	**001**	Aug 16, 2016
AB			**10MEQ**	**A204828**	**002**	Aug 16, 2016
AB		PADDOCK LLC	**8MEQ**	**A200185**	**001**	May 18, 2011
AB			**10MEQ**	**A200185**	**002**	May 18, 2011
AB		PII	**8MEQ**	**A205549**	**001**	Dec 08, 2015
AB			**10MEQ**	**A205549**	**002**	Dec 08, 2015
AB		PRINSTON INC	**8MEQ**	**A209026**	**001**	Jun 11, 2019
AB			**10MEQ**	**A209026**	**002**	Jun 11, 2019
AB		TRIS PHARMA INC	**8MEQ**	**A201944**	**001**	Mar 04, 2016
AB			**10MEQ**	**A201944**	**002**	Mar 04, 2016
AB		ZYDUS PHARMS	**8MEQ**	**A208445**	**001**	Mar 11, 2019
AB			**10MEQ**	**A208445**	**002**	Mar 11, 2019

FOR SOLUTION;ORAL
KLOR-CON

AA		UPSHER SMITH LABS	**20MEQ**	**A209662**	**001**	Oct 23, 2017

POTASSIUM CHLORIDE

AA		AMNEAL PHARMS LLC	**20MEQ**	**A210902**	**001**	May 23, 2019
AA		BELCHER PHARMS LLC	**20MEQ**	**A212183**	**001**	May 06, 2019
AA		EPIC PHARMA LLC	**20MEQ**	**A210200**	**001**	Nov 23, 2018
AA		NOVEL LABS INC	**20MEQ**	**A210241**	**001**	Nov 21, 2018
AA	**+!**	PHARMA RES SOFTWARE	**20MEQ**	**N208019**	**001**	Aug 19, 2015

POTASSIUM CHLORIDE							
INJECTABLE;INJECTION							
POTASSIUM CHLORIDE							
AP		B BRAUN	**2MEQ/ML**	**A085870**	**001**		
AP		FRESENIUS KABI USA	**2MEQ/ML**	**A080225**	**001**		
AP	!	HOSPIRA	**2MEQ/ML**	**A080205**	**001**		
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER							
AP	+!	BAXTER HLTHCARE	**14.9MG/ML**	**N019904**	**001**	Dec 26, 1989	
AP	+!		**746MG/100ML**	**N019904**	**005**	Dec 17, 1990	
AP	+	ICU MEDICAL INC	**14.9MG/ML**	**N020161**	**005**	Nov 30, 1992	
AP	+		**745MG/100ML**	**N020161**	**001**	Nov 30, 1992	
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER							
AP	+!	BAXTER HLTHCARE	**29.8MG/ML**	**N019904**	**002**	Dec 26, 1989	
AP	+!		**1.49GM/100ML**	**N019904**	**006**	Dec 17, 1990	
AP	+!	ICU MEDICAL INC	**29.8MG/ML**	**N020161**	**006**	Aug 11, 1998	
AP	+		**1.49GM/100ML**	**N020161**	**002**	Nov 30, 1992	
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER							
AP	+!	BAXTER HLTHCARE	**2.98GM/100ML**	**N019904**	**004**	Dec 26, 1989	
AP	+!	ICU MEDICAL INC	**2.98GM/100ML**	**N020161**	**004**	Aug 11, 1998	
POTASSIUM CHLORIDE IN PLASTIC CONTAINER							
AP		FRESENIUS KABI USA	**2MEQ/ML**	**A088901**	**001**	Jan 25, 1985	
AP			**2MEQ/ML**	**A088908**	**001**	Jan 25, 1985	
POTASSIUM CHLORIDE							
	!	FRESENIUS KABI USA	3MEQ/ML	A080225	003		
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER							
	+!	BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989	
SOLUTION;ORAL							
POTASSIUM CHLORIDE							
AA		AMNEAL PHARMS LLC	**20MEQ/15ML**	**A210041**	**001**	Jul 19, 2018	
AA			**40MEQ/15ML**	**A210041**	**002**	Jul 19, 2018	
AA		APOTEX	**20MEQ/15ML**	**A211067**	**001**	Aug 08, 2018	
AA			**40MEQ/15ML**	**A211067**	**002**	Aug 08, 2018	
AA	+	GENUS LIFESCIENCES	**20MEQ/15ML**	**N206814**	**001**	Dec 22, 2014	
AA	+!		**40MEQ/15ML**	**N206814**	**002**	Dec 22, 2014	
AA		NOVEL LABS INC	**20MEQ/15ML**	**A209786**	**001**	Aug 29, 2018	
AA			**40MEQ/15ML**	**A209786**	**002**	Aug 29, 2018	
AA		PHARM ASSOC	**20MEQ/15ML**	**A210766**	**001**	Mar 29, 2019	
AA			**40MEQ/15ML**	**A210766**	**002**	Mar 29, 2019	
TABLET, EXTENDED RELEASE;ORAL							
KLOR-CON M10							
AB1		UPSHER SMITH LABS	**10MEQ**	**A074726**	**002**	Aug 09, 2000	
KLOR-CON M15							
AB1		UPSHER SMITH LABS	**15MEQ**	**A074726**	**003**	Jun 06, 2003	
KLOR-CON M20							
AB1	!	UPSHER SMITH LABS	**20MEQ**	**A074726**	**001**	Nov 20, 1998	
POTASSIUM CHLORIDE							
AB1		ACTAVIS LABS FL INC	**10MEQ**	**A075604**	**001**	Apr 10, 2002	
AB1			**20MEQ**	**A075604**	**002**	Apr 10, 2002	
AB1		ADARE PHARMS INC	**10MEQ**	**A076368**	**002**	Jun 05, 2019	
AB1			**20MEQ**	**A076368**	**001**	Aug 18, 2004	
AB1		GLENMARK PHARMS LTD	**10MEQ**	**A203562**	**001**	Jul 26, 2016	
AB1			**20MEQ**	**A203562**	**002**	Jul 26, 2016	
AB1		NOVEL LABS INC	**10MEQ**	**A206347**	**001**	Jan 21, 2016	
AB1			**20MEQ**	**A206347**	**002**	Jan 21, 2016	
AB1		PRINSTON INC	**10MEQ**	**A209922**	**001**	Apr 30, 2019	
AB1			**15MEQ**	**A209922**	**002**	Apr 30, 2019	
AB1			**20MEQ**	**A209922**	**003**	Apr 30, 2019	
KLOR-CON							
AB2	+	UPSHER SMITH LABS	**8MEQ**	**N019123**	**001**	Apr 17, 1986	
AB2	+!		**10MEQ**	**N019123**	**002**	Apr 17, 1986	
POTASSIUM CHLORIDE							
AB2		AUROBINDO PHARMA LTD	**8MEQ**	**A210921**	**001**	Dec 19, 2018	
AB2			**10MEQ**	**A210921**	**002**	Dec 19, 2018	
AB2		MYLAN	**8MEQ**	**A204662**	**001**	Aug 21, 2014	
AB2			**10MEQ**	**A204662**	**002**	Aug 21, 2014	
AB2		NOVEL LABS INC	**8MEQ**	**A206759**	**001**	Aug 09, 2016	
AB2			**10MEQ**	**A206759**	**002**	Aug 09, 2016	
AB2		PADDOCK LLC	**8MEQ**	**A205993**	**001**	Nov 05, 2015	
AB2			**10MEQ**	**A205993**	**002**	Nov 05, 2015	
AB2		SIGMAPHARM LABS LLC	**8MEQ**	**A207528**	**001**	Aug 19, 2016	
AB2			**10MEQ**	**A207528**	**002**	Aug 19, 2016	
AB2		STRIDES PHARMA	**8MEQ**	**A210733**	**001**	Aug 31, 2018	

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE							
AB2			**10MEQ**	**A210733**	**002**	Aug 31, 2018
AB2		YICHANG HUMANWELL	**8MEQ**	**A209314**	**001**	Jun 22, 2018
AB2			**10MEQ**	**A209314**	**002**	Jun 22, 2018
K-TAB							
AB3	+	ABBVIE	**10MEQ**	**N018279**	**001**	
AB3	+!		**20MEQ**	**N018279**	**003**	Nov 25, 2013
POTASSIUM CHLORIDE							
AB3		VITRUVIAS THERAP	**10MEQ**	**A209688**	**001**	Jan 12, 2018
AB3			**20MEQ**	**A209688**	**002**	Jan 12, 2018
AB3		YICHANG HUMANWELL	**10MEQ**	**A212561**	**001**	Sep 30, 2019
AB3			**20MEQ**	**A212561**	**002**	Sep 30, 2019
K-TAB							
BC	+	ABBVIE	8MEQ	N018279	002	Aug 01, 1988

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	**149MG/100ML;450MG/100ML**	**A078446**	**001**	Sep 10, 2008
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	**+!**	BAXTER HLTHCARE	**150MG/100ML;450MG/100ML**	**N017648**	**005**	Nov 26, 2002
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		B BRAUN	**150MG/100ML;900MG/100ML**	**N019708**	**004**	Sep 29, 1989
AP	+	BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N017648**	**001**	
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	+	BAXTER HLTHCARE	**300MG/100ML;900MG/100ML**	**N017648**	**002**	
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	**149MG/100ML;900MG/100ML**	**N019686**	**001**	Oct 17, 1988
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	**298MG/100ML;900MG/100ML**	**N019686**	**002**	Oct 17, 1988

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE							
AB		ANI PHARMS INC	**10MEQ**	**A212779**	**001**	Jan 14, 2020
AB			**15MEQ**	**A212779**	**002**	Jan 14, 2020
AB		MOUNTAIN	**5MEQ**	**A077440**	**001**	Jun 09, 2006
AB			**10MEQ**	**A077440**	**002**	Jun 09, 2006
AB		STRIDES PHARMA	**5MEQ**	**A206813**	**001**	Sep 11, 2017
AB			**10MEQ**	**A206813**	**002**	Sep 11, 2017
AB			**15MEQ**	**A206813**	**003**	Sep 11, 2017
AB		TEVA PHARMS USA INC	**5MEQ**	**A209758**	**001**	Mar 05, 2018
AB			**10MEQ**	**A209758**	**002**	Mar 05, 2018
AB			**15MEQ**	**A209758**	**003**	Mar 05, 2018
AB		ZYDUS PHARMS	**5MEQ**	**A203546**	**001**	Aug 06, 2014
AB			**10MEQ**	**A203546**	**002**	Aug 06, 2014
AB			**15MEQ**	**A203546**	**003**	Aug 06, 2014
UROCIT-K							
AB	+	MISSION PHARMA	**5MEQ**	**N019071**	**001**	Aug 30, 1985
AB	+		**10MEQ**	**N019071**	**002**	Aug 31, 1992
AB	+!		**15MEQ**	**N019071**	**003**	Dec 30, 2009

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

+!	CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019
+!	FRESENIUS KABI USA	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	N212832	001	Nov 26, 2019
+!		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	N212832	002	Nov 26, 2019
+!		11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)	N212832	003	Nov 26, 2019

POVIDONE-IODINE

SOLUTION/DROPS;OPHTHALMIC

BETADINE

+!	ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PRALIDOXIME CHLORIDE

+!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983

PROTOPAM CHLORIDE

+!	BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

MIRAPEX

AB	**+**	BOEHRINGER INGELHEIM	**0.125MG**	**N020667**	**001**	Jul 01, 1997
AB	**+!**		**0.25MG**	**N020667**	**002**	Jul 01, 1997
AB	**+**		**0.5MG**	**N020667**	**006**	Feb 12, 1998
AB	**+**		**0.75MG**	**N020667**	**007**	Jul 30, 2007
AB	**+**		**1MG**	**N020667**	**003**	Jul 01, 1997
AB	**+**		**1.5MG**	**N020667**	**005**	Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**0.125MG**	**A078894**	**001**	Oct 08, 2010
AB			**0.25MG**	**A078894**	**002**	Oct 08, 2010
AB			**0.5MG**	**A078894**	**003**	Oct 08, 2010
AB			**1MG**	**A078894**	**004**	Oct 08, 2010
AB			**1.5MG**	**A078894**	**005**	Oct 08, 2010
AB		APOTEX INC	**0.125MG**	**A090151**	**001**	Apr 30, 2012
AB			**0.25MG**	**A090151**	**002**	Apr 30, 2012
AB			**0.5MG**	**A090151**	**003**	Apr 30, 2012
AB			**0.75MG**	**A090151**	**006**	Apr 30, 2012
AB			**1MG**	**A090151**	**004**	Apr 30, 2012
AB			**1.5MG**	**A090151**	**005**	Apr 30, 2012
AB		AUROBINDO PHARMA LTD	**0.125MG**	**A202633**	**001**	Oct 26, 2012
AB			**0.25MG**	**A202633**	**002**	Oct 26, 2012
AB			**0.5MG**	**A202633**	**003**	Oct 26, 2012
AB			**0.75MG**	**A202633**	**004**	Oct 26, 2012
AB			**1MG**	**A202633**	**005**	Oct 26, 2012
AB			**1.5MG**	**A202633**	**006**	Oct 26, 2012
AB		BRECKENRIDGE PHARM	**0.125MG**	**A091450**	**001**	Oct 08, 2010
AB			**0.25MG**	**A091450**	**002**	Oct 08, 2010
AB			**0.5MG**	**A091450**	**003**	Oct 08, 2010
AB			**1MG**	**A091450**	**004**	Oct 08, 2010
AB			**1.5MG**	**A091450**	**005**	Oct 08, 2010
AB		CSPC OUYI	**0.25MG**	**A211088**	**001**	Oct 03, 2018
AB			**0.5MG**	**A211088**	**002**	Oct 03, 2018
AB			**0.75MG**	**A211088**	**003**	Oct 03, 2018
AB			**1MG**	**A211088**	**004**	Oct 03, 2018
AB			**1.5MG**	**A211088**	**005**	Oct 03, 2018
AB		GLENMARK GENERICS	**0.125MG**	**A090781**	**001**	Oct 08, 2010
AB			**0.25MG**	**A090781**	**002**	Oct 08, 2010
AB			**0.5MG**	**A090781**	**003**	Oct 08, 2010
AB			**0.75MG**	**A090781**	**006**	Sep 11, 2015
AB			**1MG**	**A090781**	**004**	Oct 08, 2010
AB			**1.5MG**	**A090781**	**005**	Oct 08, 2010
AB		HERITAGE PHARMA	**0.125MG**	**A077724**	**001**	Feb 19, 2008
AB			**0.25MG**	**A077724**	**002**	Feb 19, 2008
AB			**0.5MG**	**A077724**	**003**	Feb 19, 2008
AB			**1MG**	**A077724**	**004**	Feb 19, 2008
AB			**1.5MG**	**A077724**	**005**	Feb 19, 2008
AB		MACLEODS PHARMS LTD	**0.125MG**	**A202164**	**001**	Sep 20, 2012
AB			**0.25MG**	**A202164**	**002**	Sep 20, 2012
AB			**0.5MG**	**A202164**	**003**	Sep 20, 2012
AB			**1MG**	**A202164**	**004**	Sep 20, 2012
AB			**1.5MG**	**A202164**	**005**	Sep 20, 2012
AB		MYLAN	**0.125MG**	**A077854**	**001**	Oct 08, 2010
AB			**0.25MG**	**A077854**	**002**	Oct 08, 2010
AB			**0.5MG**	**A077854**	**003**	Oct 08, 2010
AB			**0.75MG**	**A090764**	**001**	Apr 09, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB			**1MG**	**A077854**	**004**	Oct 08, 2010
AB			**1.5MG**	**A077854**	**005**	Oct 08, 2010
AB		SCIEGEN PHARMS INC	**0.125MG**	**A203855**	**001**	Oct 28, 2014
AB			**0.25MG**	**A203855**	**002**	Oct 28, 2014
AB			**0.5MG**	**A203855**	**003**	Oct 28, 2014
AB			**0.75MG**	**A203855**	**004**	Oct 28, 2014
AB			**1MG**	**A203855**	**005**	Oct 28, 2014
AB			**1.5MG**	**A203855**	**006**	Oct 28, 2014
AB		STRIDES PHARMA	**0.125MG**	**A202702**	**001**	Jun 03, 2014
AB			**0.25MG**	**A202702**	**002**	Jun 03, 2014
AB			**0.5MG**	**A202702**	**003**	Jun 03, 2014
AB			**0.75MG**	**A202702**	**004**	Jun 03, 2014
AB			**1MG**	**A202702**	**005**	Jun 03, 2014
AB			**1.5MG**	**A202702**	**006**	Jun 03, 2014
AB		TORRENT PHARMS	**0.125MG**	**A090865**	**001**	Oct 08, 2010
AB			**0.25MG**	**A090865**	**002**	Oct 08, 2010
AB			**0.5MG**	**A090865**	**003**	Oct 08, 2010
AB			**0.75MG**	**A090865**	**004**	Oct 08, 2010
AB			**1MG**	**A090865**	**005**	Oct 08, 2010
AB			**1.5MG**	**A090865**	**006**	Oct 08, 2010
AB		UNICHEM LABS LTD	**0.125MG**	**A207011**	**001**	Dec 19, 2018
AB			**0.25MG**	**A207011**	**002**	Dec 19, 2018
AB			**0.5MG**	**A207011**	**003**	Dec 19, 2018
AB			**0.75MG**	**A207011**	**004**	Dec 19, 2018
AB			**1MG**	**A207011**	**005**	Dec 19, 2018
AB			**1.5MG**	**A207011**	**006**	Dec 19, 2018
AB		ZYDUS PHARMS USA INC	**0.125MG**	**A078920**	**001**	Jul 06, 2010
AB			**0.25MG**	**A078920**	**002**	Jul 06, 2010
AB			**0.5MG**	**A078920**	**003**	Jul 06, 2010
AB			**1MG**	**A078920**	**004**	Jul 06, 2010
AB			**1.5MG**	**A078920**	**005**	Jul 06, 2010

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

AB	**+!**	BOEHRINGER INGELHEIM	**0.375MG**	**N022421**	**001**	Feb 19, 2010
AB	**+**		**0.75MG**	**N022421**	**002**	Feb 19, 2010
AB	**+**		**1.5MG**	**N022421**	**003**	Feb 19, 2010
AB	**+**		**2.25MG**	**N022421**	**006**	Jun 17, 2011
AB	**+**		**3MG**	**N022421**	**004**	Feb 19, 2010
AB	**+**		**3.75MG**	**N022421**	**007**	Jun 17, 2011
AB	**+**		**4.5MG**	**N022421**	**005**	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**0.375MG**	**A201963**	**001**	Apr 21, 2016
AB			**0.75MG**	**A201963**	**002**	Apr 21, 2016
AB			**1.5MG**	**A201963**	**003**	Apr 21, 2016
AB			**2.25MG**	**A203615**	**001**	Oct 14, 2016
AB			**3MG**	**A201963**	**004**	Apr 21, 2016
AB			**3.75MG**	**A203615**	**002**	Jan 03, 2017
AB			**4.5MG**	**A201963**	**005**	Apr 21, 2016
AB		ALEMBIC PHARMS LTD	**0.375MG**	**A204518**	**001**	Jan 02, 2019
AB			**0.75MG**	**A204518**	**002**	Jan 02, 2019
AB			**1.5MG**	**A204518**	**003**	Jan 02, 2019
AB			**2.25MG**	**A204518**	**004**	Jan 02, 2019
AB			**3MG**	**A204518**	**005**	Jan 02, 2019
AB			**3.75MG**	**A204518**	**006**	Jan 02, 2019
AB			**4.5MG**	**A204518**	**007**	Jan 02, 2019
AB		ANCHEN PHARMS	**0.375MG**	**A202206**	**001**	Feb 06, 2014
AB			**0.75MG**	**A202206**	**002**	Feb 06, 2014
AB			**1.5MG**	**A202206**	**003**	Feb 06, 2014
AB			**2.25MG**	**A202206**	**004**	Feb 06, 2014
AB			**3MG**	**A202206**	**005**	Feb 06, 2014
AB			**3.75MG**	**A202206**	**006**	Feb 06, 2014
AB			**4.5MG**	**A202206**	**007**	Feb 06, 2014
AB		DR REDDYS	**0.375MG**	**A203354**	**001**	Aug 07, 2015
AB			**0.75MG**	**A203354**	**002**	Aug 07, 2015
AB			**1.5MG**	**A203354**	**003**	Aug 07, 2015
AB			**3MG**	**A203354**	**004**	Aug 07, 2015
AB			**4.5MG**	**A203354**	**005**	Aug 07, 2015
AB		MACLEODS PHARMS LTD	**0.375MG**	**A206156**	**001**	Jun 24, 2016

PRAMIPEXOLE DIHYDROCHLORIDE						
TABLET, EXTENDED RELEASE;ORAL						
PRAMIPEXOLE DIHYDROCHLORIDE						
AB			**0.75MG**	**A206156**	**002**	Jun 24, 2016
AB			**1.5MG**	**A206156**	**003**	Jun 24, 2016
AB			**2.25MG**	**A206156**	**004**	Jun 24, 2016
AB			**3MG**	**A206156**	**005**	Jun 24, 2016
AB			**3.75MG**	**A206156**	**007**	Jan 23, 2017
AB			**4.5MG**	**A206156**	**006**	Jun 24, 2016
AB		SANDOZ INC	**0.375MG**	**A202353**	**001**	Dec 04, 2014
AB			**0.75MG**	**A202353**	**002**	Dec 04, 2014
AB			**1.5MG**	**A202353**	**003**	Dec 04, 2014
AB			**3MG**	**A202353**	**004**	Dec 04, 2014
AB			**4.5MG**	**A202353**	**005**	Dec 04, 2014
AB		ZYDUS PHARMS	**0.375MG**	**A202891**	**001**	Dec 12, 2017
AB			**0.75MG**	**A202891**	**002**	Dec 12, 2017
AB			**1.5MG**	**A202891**	**003**	Dec 12, 2017
AB			**2.25MG**	**A202891**	**004**	Dec 12, 2017
AB			**3MG**	**A202891**	**005**	Dec 12, 2017
AB			**3.75MG**	**A202891**	**006**	Dec 12, 2017
AB			**4.5MG**	**A202891**	**007**	Dec 12, 2017
PRAMLINTIDE ACETATE						
INJECTABLE;SUBCUTANEOUS						
SYMLIN						
	+	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
	+!		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007
PRASTERONE						
INSERT;VAGINAL						
INTRAROSA						
	+!	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016
PRASUGREL HYDROCHLORIDE						
TABLET;ORAL						
EFFIENT						
AB	**+**	ELI LILLY AND CO	**EQ 5MG BASE**	**N022307**	**001**	Jul 10, 2009
AB	**+!**		**EQ 10MG BASE**	**N022307**	**002**	Jul 10, 2009
PRASUGREL						
AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A205987**	**001**	Feb 02, 2018
AB			**EQ 10MG BASE**	**A205987**	**002**	Feb 02, 2018
AB		AMNEAL PHARMS	**EQ 5MG BASE**	**A205913**	**001**	Jun 19, 2018
AB			**EQ 10MG BASE**	**A205913**	**002**	Jun 19, 2018
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A205888**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205888**	**002**	Oct 16, 2017
AB		HEC PHARM	**EQ 5MG BASE**	**A206021**	**001**	Jan 16, 2019
AB			**EQ 10MG BASE**	**A206021**	**002**	Jan 16, 2019
AB		MYLAN	**EQ 5MG BASE**	**A205927**	**001**	Jul 12, 2017
AB			**EQ 10MG BASE**	**A205927**	**002**	Jul 12, 2017
AB		PANACEA BIOTEC LTD	**EQ 5MG BASE**	**A205897**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205897**	**002**	Oct 16, 2017
AB		USPHARMA WINDLAS	**EQ 5MG BASE**	**A205790**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205790**	**002**	Oct 16, 2017
PRAVASTATIN SODIUM						
TABLET;ORAL						
PRAVACHOL						
AB	**+**	BRISTOL MYERS SQUIBB	**20MG**	**N019898**	**003**	Oct 31, 1991
AB	**+**		**40MG**	**N019898**	**004**	Mar 22, 1993
AB	**+!**		**80MG**	**N019898**	**008**	Dec 18, 2001
PRAVASTATIN SODIUM						
AB		ACCORD HLTHCARE	**10MG**	**A207068**	**001**	Nov 17, 2016
AB			**20MG**	**A207068**	**002**	Nov 17, 2016
AB			**40MG**	**A207068**	**003**	Nov 17, 2016
AB			**80MG**	**A207068**	**004**	Nov 17, 2016
AB		APNAR PHARMA LP	**10MG**	**A077491**	**002**	Oct 23, 2006
AB			**20MG**	**A077491**	**003**	Oct 23, 2006
AB			**40MG**	**A077491**	**004**	Oct 23, 2006
AB			**80MG**	**A077491**	**001**	Feb 11, 2008
AB		APOTEX	**10MG**	**A076341**	**001**	Oct 23, 2006
AB			**20MG**	**A076341**	**002**	Oct 23, 2006
AB			**40MG**	**A076341**	**003**	Oct 23, 2006
AB			**80MG**	**A076341**	**004**	Dec 28, 2007

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB		AUROBINDO PHARMA LTD	**10MG**	**A203367**	**001**	Feb 02, 2017
AB			**20MG**	**A203367**	**002**	Feb 02, 2017
AB			**40MG**	**A203367**	**003**	Feb 02, 2017
AB			**80MG**	**A203367**	**004**	Feb 02, 2017
AB		CHARTWELL RX	**10MG**	**A209869**	**001**	Apr 13, 2018
AB			**20MG**	**A209869**	**002**	Apr 13, 2018
AB			**40MG**	**A209869**	**003**	Apr 13, 2018
AB			**80MG**	**A209869**	**004**	Apr 13, 2018
AB		CIPLA	**10MG**	**A077904**	**001**	Oct 23, 2006
AB			**20MG**	**A077904**	**002**	Oct 23, 2006
AB			**40MG**	**A077904**	**003**	Oct 23, 2006
AB			**80MG**	**A077904**	**004**	Mar 22, 2016
AB		DR REDDYS LABS INC	**10MG**	**A076714**	**001**	Oct 23, 2006
AB			**20MG**	**A076714**	**002**	Oct 23, 2006
AB			**40MG**	**A076714**	**003**	Oct 23, 2006
AB			**80MG**	**A076714**	**004**	Dec 28, 2007
AB		GLENMARK GENERICS	**10MG**	**A077987**	**001**	May 11, 2007
AB			**20MG**	**A077987**	**002**	May 11, 2007
AB			**40MG**	**A077987**	**003**	May 11, 2007
AB			**80MG**	**A077987**	**004**	Dec 28, 2007
AB		HISUN PHARM HANGZHOU	**20MG**	**A206061**	**001**	Nov 23, 2018
AB			**40MG**	**A206061**	**002**	Nov 23, 2018
AB			**80MG**	**A206061**	**003**	Nov 23, 2018
AB		LUPIN PHARMS	**10MG**	**A077917**	**001**	Jan 08, 2008
AB			**20MG**	**A077917**	**002**	Jan 08, 2008
AB			**40MG**	**A077917**	**003**	Jan 08, 2008
AB			**80MG**	**A077917**	**004**	Jan 08, 2008
AB		MYLAN PHARMS INC	**10MG**	**A079187**	**001**	May 27, 2010
AB			**20MG**	**A079187**	**002**	May 27, 2010
AB			**40MG**	**A079187**	**003**	May 27, 2010
AB			**80MG**	**A079187**	**004**	May 27, 2010
AB		TEVA	**10MG**	**A076056**	**001**	Apr 24, 2006
AB			**20MG**	**A076056**	**002**	Apr 24, 2006
AB			**40MG**	**A076056**	**003**	Apr 24, 2006
AB		TEVA PHARMS	**80MG**	**A077793**	**001**	Jan 15, 2008
AB		WATSON LABS	**10MG**	**A076939**	**004**	Oct 23, 2006
AB			**20MG**	**A076939**	**003**	Oct 23, 2006
AB			**40MG**	**A076939**	**002**	Oct 23, 2006
AB			**80MG**	**A076939**	**001**	Dec 28, 2007
AB		ZYDUS PHARMS USA	**10MG**	**A077751**	**001**	Apr 30, 2008
AB			**20MG**	**A077751**	**002**	Apr 30, 2008
AB			**40MG**	**A077751**	**003**	Apr 30, 2008
AB			**80MG**	**A077751**	**004**	Apr 30, 2008

PRAZIQUANTEL

TABLET;ORAL

BILTRICIDE

AB	**+!**	BAYER HLTHCARE	**600MG**	**N018714**	**001**	Dec 29, 1982

PRAZIQUANTEL

AB		PAR PHARM INC	**600MG**	**A208820**	**001**	Nov 27, 2017

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

MINIPRESS

AB	**+**	PFIZER	**EQ 1MG BASE**	**N017442**	**002**	
AB	**+!**		**EQ 2MG BASE**	**N017442**	**003**	
AB	**+**		**EQ 5MG BASE**	**N017442**	**001**	

PRAZOSIN HYDROCHLORIDE

AB		MYLAN	**EQ 1MG BASE**	**A072575**	**003**	May 16, 1989
AB			**EQ 2MG BASE**	**A072575**	**002**	May 16, 1989
AB			**EQ 5MG BASE**	**A072575**	**001**	May 16, 1989
AB		NOVITIUM PHARMA	**EQ 1MG BASE**	**A210971**	**001**	Oct 03, 2018
AB			**EQ 2MG BASE**	**A210971**	**002**	Oct 03, 2018
AB			**EQ 5MG BASE**	**A210971**	**003**	Oct 03, 2018
AB		TEVA PHARMS	**EQ 1MG BASE**	**A071745**	**002**	Sep 12, 1988
AB			**EQ 2MG BASE**	**A071745**	**003**	Sep 12, 1988
AB			**EQ 5MG BASE**	**A071745**	**001**	Sep 12, 1988

PREDNICARBATE

CREAM;TOPICAL

DERMATOP E EMOLLIENT

AB	**+!**	VALEANT BERMUDA	**0.1%**	**N020279**	**001**	Oct 29, 1993

PREDNICARBATE

AB		FOUGERA PHARMS	**0.1%**	**A077287**	**001**	Sep 19, 2006

OINTMENT;TOPICAL

DERMATOP

AB	**+!**	VALEANT PHARMS NORTH	**0.1%**	**N019568**	**001**	Sep 23, 1991

PREDNICARBATE

AB		FOUGERA PHARMS	**0.1%**	**A077236**	**001**	Mar 09, 2007

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	**!**	HI TECH PHARMA CO	**15MG/5ML**	**A040401**	**001**	Feb 27, 2003
AA		LANNETT CO INC	**15MG/5ML**	**A040775**	**001**	Sep 21, 2007
AA		PHARM ASSOC	**15MG/5ML**	**A040399**	**001**	Mar 05, 2003
AA		VISTAPHARM	**15MG/5ML**	**A040323**	**001**	May 13, 1999
AA		WOCKHARDT BIO AG	**15MG/5ML**	**A040313**	**001**	Sep 10, 2003

PRELONE

AA		TEVA	**15MG/5ML**	**A089081**	**001**	Feb 04, 1986

TABLET;ORAL

PREDNISOLONE

	!	WATSON LABS	5MG	A080354	001	

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

AB		NOVARTIS	**1%**	**N017469**	**001**	

PRED FORTE

AB	**+!**	ALLERGAN	**1%**	**N017011**	**001**	

PRED MILD

	+!	ALLERGAN	0.12%	N017100	001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC

BLEPHAMIDE S.O.P.

	!	ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986

SUSPENSION;OPHTHALMIC

BLEPHAMIDE

	+!	ALLERGAN	0.2%;10%	N012813	002	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PEDIAPRED

AA	**+!**	SETON PHARM	**EQ 5MG BASE/5ML**	**N019157**	**001**	May 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

AA		CHARTWELL RX	**EQ 5MG BASE/5ML**	**A075988**	**001**	May 25, 2004
AA		EDENBRIDGE PHARMS	**EQ 10MG BASE/5ML**	**A203559**	**001**	Dec 20, 2016
AA			**EQ 20MG BASE/5ML**	**A203559**	**002**	Dec 20, 2016
AA		HI TECH PHARMA	**EQ 5MG BASE/5ML**	**A075183**	**001**	Mar 26, 2003
AA	**!**	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A078465**	**001**	Mar 07, 2008
AA			**EQ 15MG BASE/5ML**	**A076913**	**001**	Apr 25, 2005
AA	**!**		**EQ 20MG BASE/5ML**	**A078988**	**001**	Jun 09, 2008
AA		VINTAGE	**EQ 15MG BASE/5ML**	**A079010**	**001**	May 26, 2009
AA		WOCKHARDT BIO AG	**EQ 5MG BASE/5ML**	**A075099**	**001**	Jun 28, 2002
AA	**!**		**EQ 15MG BASE/5ML**	**A076895**	**001**	Oct 04, 2004
	!	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

AB	**+**	CONCORDIA PHARMS INC	**EQ 10MG BASE**	**N021959**	**001**	Jun 01, 2006
AB	**+**		**EQ 15MG BASE**	**N021959**	**002**	Jun 01, 2006
AB	**+!**		**EQ 30MG BASE**	**N021959**	**003**	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE

AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A202179**	**001**	Apr 10, 2013
AB			**EQ 15MG BASE**	**A202179**	**002**	Apr 10, 2013
AB			**EQ 30MG BASE**	**A202179**	**003**	Apr 10, 2013

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM							
SOLUTION/DROPS;OPHTHALMIC							
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE							
	!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%		A074449	001	Dec 29, 1995
PREDNISONE							
SOLUTION;ORAL							
PREDNISONE							
	!	HIKMA	5MG/5ML		A088703	001	Nov 08, 1984
PREDNISONE INTENSOL							
	!	HIKMA	5MG/ML		A088810	001	Feb 20, 1985
TABLET;ORAL							
PREDNISONE							
AB		GENEYORK PHARMS	**1MG**		**A211496**	**001**	Dec 28, 2018
AB			**2.5MG**		**A211495**	**001**	Dec 07, 2018
AB			**5MG**		**A211495**	**002**	Dec 07, 2018
AB			**10MG**		**A210525**	**001**	Dec 04, 2018
AB			**20MG**		**A210525**	**002**	Dec 04, 2018
AB			**50MG**		**A210525**	**003**	Dec 04, 2018
AB	**!**	HIKMA	**1MG**		**A087800**	**001**	Apr 22, 1982
AB	**!**		**2.5MG**		**A087801**	**001**	Apr 22, 1982
AB	**!**		**5MG**		**A080352**	**001**	
AB	**!**		**10MG**		**A084122**	**001**	
AB	**!**		**20MG**		**A087342**	**001**	
AB	**!**		**50MG**		**A084283**	**001**	
AB		HIKMA PHARMS	**50MG**		**A088465**	**001**	Jun 01, 1984
AB		JUBILANT CADISTA	**1MG**		**A040611**	**001**	Jun 06, 2005
AB			**5MG**		**A040362**	**002**	Aug 29, 2001
AB			**10MG**		**A040362**	**001**	Aug 29, 2001
AB			**20MG**		**A040362**	**003**	Jun 29, 2005
AB		MYLAN	**5MG**		**A080292**	**001**	
AB			**10MG**		**A088832**	**001**	Dec 04, 1985
AB			**20MG**		**A083677**	**001**	
AB		NOVITIUM PHARMA	**2.5MG**		**A211575**	**001**	Nov 15, 2019
AB			**5MG**		**A211575**	**002**	Nov 15, 2019
AB			**10MG**		**A211575**	**003**	Nov 15, 2019
AB			**20MG**		**A211575**	**004**	Nov 15, 2019
AB			**50MG**		**A211575**	**005**	Nov 15, 2019
AB		SUN PHARM INDUSTRIES	**5MG**		**A089247**	**002**	Dec 04, 1985
AB			**10MG**		**A089247**	**003**	Dec 04, 1985
AB			**20MG**		**A089247**	**001**	Dec 04, 1985
AB		VINTAGE PHARMS	**1MG**		**A040584**	**001**	Dec 21, 2004
AB			**2.5MG**		**A040581**	**001**	Dec 21, 2004
AB			**5MG**		**A040256**	**001**	Jul 12, 2002
AB			**10MG**		**A040256**	**002**	Jul 12, 2002
AB			**20MG**		**A040392**	**001**	Feb 12, 2003
AB		WATSON LABS	**5MG**		**A080356**	**001**	
AB			**10MG**		**A085162**	**001**	
AB			**20MG**		**A085161**	**001**	
TABLET, DELAYED RELEASE;ORAL							
PREDNISONE							
AB		ACTAVIS LABS FL INC	**1MG**		**A204867**	**001**	Apr 25, 2017
AB			**2MG**		**A204867**	**002**	Apr 25, 2017
AB			**5MG**		**A204867**	**003**	Apr 25, 2017
RAYOS							
AB	**+**	HORIZON PHARMA USA	**1MG**		**N202020**	**001**	Jul 26, 2012
AB	**+**		**2MG**		**N202020**	**002**	Jul 26, 2012
AB	**+!**		**5MG**		**N202020**	**003**	Jul 26, 2012
PREGABALIN							
CAPSULE;ORAL							
LYRICA							
AB	**+**	PF PRISM CV	**25MG**		**N021446**	**001**	Dec 30, 2004
AB	**+**		**50MG**		**N021446**	**002**	Dec 30, 2004
AB	**+**		**75MG**		**N021446**	**003**	Dec 30, 2004
AB	**+**		**100MG**		**N021446**	**004**	Dec 30, 2004
AB	**+**		**150MG**		**N021446**	**005**	Dec 30, 2004
AB	**+**		**200MG**		**N021446**	**006**	Dec 30, 2004
AB	**+**		**225MG**		**N021446**	**007**	Dec 30, 2004
AB	**+!**		**300MG**		**N021446**	**008**	Dec 30, 2004
PREGABALIN							
AB		ALEMBIC PHARMS LTD	**25MG**		**A203459**	**001**	Jul 19, 2019
AB			**50MG**		**A203459**	**002**	Jul 19, 2019

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		75MG	A203459	003	Jul 19, 2019
AB		100MG	A203459	004	Jul 19, 2019
AB		150MG	A203459	005	Jul 19, 2019
AB		200MG	A203459	006	Jul 19, 2019
AB		225MG	A203459	007	Jul 19, 2019
AB		300MG	A203459	008	Jul 19, 2019
AB	ALKEM LABS LTD	25MG	A211177	001	Sep 30, 2019
AB		50MG	A211177	002	Sep 30, 2019
AB		75MG	A207799	001	Jul 19, 2019
AB		100MG	A207799	002	Jul 19, 2019
AB		150MG	A207799	003	Jul 19, 2019
AB		200MG	A207799	004	Jul 19, 2019
AB		225MG	A207799	005	Jul 19, 2019
AB		300MG	A207799	006	Jul 19, 2019
AB	AMNEAL PHARMS CO	25MG	A209743	001	Jul 19, 2019
AB		50MG	A209743	002	Jul 19, 2019
AB		75MG	A209743	003	Jul 19, 2019
AB		100MG	A209743	004	Jul 19, 2019
AB		150MG	A209743	005	Jul 19, 2019
AB		200MG	A209743	006	Jul 19, 2019
AB		225MG	A209743	007	Jul 19, 2019
AB		300MG	A209743	008	Jul 19, 2019
AB	CIPLA	25MG	A212280	001	Jan 10, 2020
AB		50MG	A212280	002	Jan 10, 2020
AB		75MG	A212280	003	Jan 10, 2020
AB		100MG	A212280	004	Jan 10, 2020
AB		150MG	A212280	005	Jan 10, 2020
AB		200MG	A212280	006	Jan 10, 2020
AB		225MG	A212280	007	Jan 10, 2020
AB		300MG	A212280	008	Jan 10, 2020
AB	CSPC OUYI	50MG	A210585	001	Dec 26, 2019
AB		75MG	A210585	002	Dec 26, 2019
AB		100MG	A210585	003	Dec 26, 2019
AB		150MG	A210585	004	Dec 26, 2019
AB		200MG	A210585	005	Dec 26, 2019
AB		300MG	A210585	006	Dec 26, 2019
AB	DR REDDYS	25MG	A209664	001	Jul 19, 2019
AB		50MG	A209664	002	Jul 19, 2019
AB		75MG	A209664	003	Jul 19, 2019
AB		100MG	A209664	004	Jul 19, 2019
AB		150MG	A209664	005	Jul 19, 2019
AB		200MG	A209664	006	Jul 19, 2019
AB		225MG	A209664	007	Jul 19, 2019
AB		300MG	A209664	008	Jul 19, 2019
AB	HETERO LABS LTD III	25MG	A206912	001	Oct 08, 2019
AB		50MG	A206912	002	Oct 08, 2019
AB		75MG	A206912	003	Oct 08, 2019
AB		100MG	A206912	004	Oct 08, 2019
AB		150MG	A206912	005	Oct 08, 2019
AB		200MG	A206912	006	Oct 08, 2019
AB		225MG	A206912	007	Oct 08, 2019
AB		300MG	A206912	008	Oct 08, 2019
AB	INVAGEN PHARMS	25MG	A211384	001	Jul 19, 2019
AB		50MG	A211384	002	Jul 19, 2019
AB		75MG	A211384	003	Jul 19, 2019
AB		100MG	A211384	004	Jul 19, 2019
AB		150MG	A211384	005	Jul 19, 2019
AB		200MG	A211384	006	Jul 19, 2019
AB		225MG	A211384	007	Jul 19, 2019
AB		300MG	A211384	008	Jul 19, 2019
AB	MSN	25MG	A209357	001	Jul 19, 2019
AB		50MG	A209357	002	Jul 19, 2019
AB		75MG	A209357	003	Jul 19, 2019
AB		100MG	A209357	004	Jul 19, 2019
AB		150MG	A209357	005	Jul 19, 2019
AB		200MG	A209357	006	Jul 19, 2019
AB		225MG	A209357	007	Jul 19, 2019
AB		300MG	A209357	008	Jul 19, 2019
AB	MYLAN	25MG	A091228	001	Sep 20, 2019

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		**50MG**	**A091228**	**002**	Sep 20, 2019
AB		**75MG**	**A091228**	**003**	Sep 20, 2019
AB		**100MG**	**A091228**	**004**	Sep 20, 2019
AB		**150MG**	**A091228**	**005**	Sep 20, 2019
AB		**200MG**	**A091228**	**006**	Sep 20, 2019
AB		**225MG**	**A091228**	**007**	Sep 20, 2019
AB		**300MG**	**A091228**	**008**	Sep 20, 2019
AB	RISING	**25MG**	**A210432**	**001**	Jul 19, 2019
AB		**50MG**	**A210432**	**002**	Jul 19, 2019
AB		**75MG**	**A210432**	**003**	Jul 19, 2019
AB		**100MG**	**A210432**	**004**	Jul 19, 2019
AB		**150MG**	**A210432**	**005**	Jul 19, 2019
AB		**200MG**	**A210432**	**006**	Jul 19, 2019
AB		**225MG**	**A210432**	**007**	Jul 19, 2019
AB		**300MG**	**A210432**	**008**	Jul 19, 2019
AB	SCIEGEN PHARMS INC	**25MG**	**A208677**	**001**	Jul 19, 2019
AB		**50MG**	**A208677**	**002**	Jul 19, 2019
AB		**75MG**	**A208677**	**003**	Jul 19, 2019
AB		**100MG**	**A208677**	**004**	Jul 19, 2019
AB		**150MG**	**A208677**	**005**	Jul 19, 2019
AB		**200MG**	**A208677**	**006**	Jul 19, 2019
AB		**225MG**	**A208677**	**007**	Jul 19, 2019
AB		**300MG**	**A208677**	**008**	Jul 19, 2019
AB	SHUANGCHENG	**75MG**	**A210891**	**001**	Sep 30, 2019
AB		**300MG**	**A210891**	**002**	Sep 30, 2019
AB	SUN PHARM	**25MG**	**A091157**	**001**	Nov 29, 2019
AB		**50MG**	**A091157**	**002**	Nov 29, 2019
AB		**75MG**	**A091157**	**003**	Nov 29, 2019
AB		**100MG**	**A091157**	**004**	Nov 29, 2019
AB		**150MG**	**A091157**	**005**	Nov 29, 2019
AB		**200MG**	**A091157**	**006**	Nov 29, 2019
AB		**225MG**	**A091157**	**007**	Nov 29, 2019
AB		**300MG**	**A091157**	**008**	Nov 29, 2019
AB	TEVA PHARMS	**25MG**	**A091219**	**001**	Jul 19, 2019
AB		**50MG**	**A091219**	**002**	Jul 19, 2019
AB		**75MG**	**A091224**	**001**	Jul 19, 2019
AB		**100MG**	**A091224**	**002**	Jul 19, 2019
AB		**150MG**	**A091224**	**003**	Jul 19, 2019
AB		**200MG**	**A091224**	**004**	Jul 19, 2019
AB		**225MG**	**A091224**	**005**	Jul 19, 2019
AB		**300MG**	**A091224**	**006**	Jul 19, 2019

SOLUTION;ORAL

LYRICA

AA	**+!**	PF PRISM CV	**20MG/ML**	**N022488**	**001**	Jan 04, 2010

PREGABALIN

AA		ALKEM LABS LTD	**20MG/ML**	**A207623**	**001**	Jul 19, 2019

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

+	PF PRISM CV	82.5MG	N209501	001	Oct 11, 2017
+		165MG	N209501	002	Oct 11, 2017
+!		330MG	N209501	003	Oct 11, 2017

PRETOMANID

TABLET;ORAL

PRETOMANID

+!	MYLAN IRELAND LTD	200MG	N212862	001	Aug 14, 2019

PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRILOCAINE HYDROCHLORIDE

!	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE

AB	**+!**	SANOFI AVENTIS US	**EQ 15MG BASE**	**N008316**	**001**	

PRIMAQUINE PHOSPHATE

AB		ALVOGEN INC	**EQ 15MG BASE**	**A203924**	**001**	Feb 03, 2014
AB		BAYSHORE PHARMS LLC	**EQ 15MG BASE**	**A204476**	**001**	Feb 25, 2014
AB		NOVAST LABS	**EQ 15MG BASE**	**A206043**	**001**	Jun 23, 2016

PRIMIDONE
TABLET;ORAL
MYSOLINE

AB	**+!**	VALEANT	**50MG**	**N009170**	**003**	
AB	**+**		**250MG**	**N009170**	**002**	

PRIMIDONE

AB		AMNEAL PHARM	**50MG**	**A040866**	**001**	Apr 23, 2008
AB			**250MG**	**A040866**	**002**	Apr 23, 2008
AB		ANDA REPOSITORY	**50MG**	**A040626**	**001**	Sep 29, 2005
AB			**250MG**	**A040626**	**002**	Sep 29, 2005
AB		HIKMA INTL PHARMS	**250MG**	**A040667**	**002**	Jul 27, 2006
AB		LANNETT	**50MG**	**A084903**	**002**	May 24, 2001
AB			**250MG**	**A084903**	**001**	
AB		OXFORD PHARMS	**50MG**	**A040586**	**001**	Feb 24, 2005
AB			**250MG**	**A040586**	**002**	Feb 24, 2005
AB		WATSON LABS	**250MG**	**A083551**	**001**	

PROBENECID
TABLET;ORAL
PROBALAN

AB		LANNETT	**500MG**	**A080966**	**001**	

PROBENECID

AB		MYLAN	**500MG**	**A084211**	**002**	
	!	WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

AP	**!**	HOSPIRA	**100MG/ML**	**A089069**	**001**	Feb 12, 1986
AP		INTL MEDICATION	**100MG/ML**	**A088636**	**001**	Jul 31, 1984
AP		NEXUS PHARMS	**100MG/ML**	**A206332**	**001**	Oct 13, 2017
AP			**500MG/ML**	**A206332**	**002**	Oct 13, 2017
	!	HOSPIRA	500MG/ML	A089070	001	Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE
CAPSULE;ORAL
MATULANE

	+!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001	

PROCHLORPERAZINE
SUPPOSITORY;RECTAL
COMPRO

AB		PADDOCK LLC	**25MG**	**A040246**	**001**	Jun 28, 2000

PROCHLORPERAZINE

AB	**!**	ACP NIMBLE	**25MG**	**A040058**	**001**	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE
INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP		ATHENEX INC	**EQ 5MG BASE/ML**	**A040540**	**001**	May 28, 2004
AP	**!**	EMCURE PHARMS LTD	**EQ 5MG BASE/ML**	**A204147**	**001**	Oct 15, 2013
AP		MYLAN LABS LTD	**EQ 5MG BASE/ML**	**A210710**	**001**	Oct 25, 2018
AP		NEXUS PHARMS	**EQ 5MG BASE/ML**	**A204860**	**001**	Feb 15, 2019
AP		WEST-WARD PHARMS INT	**EQ 5MG BASE/ML**	**A089903**	**001**	Aug 29, 1989

PROCHLORPERAZINE MALEATE
TABLET;ORAL
PROCHLORPERAZINE MALEATE

AB		MYLAN	**EQ 5MG BASE**	**A040185**	**002**	Oct 28, 1996
AB			**EQ 10MG BASE**	**A040185**	**001**	Oct 28, 1996
AB		SANDOZ	**EQ 5MG BASE**	**A040101**	**001**	Jul 19, 1996
AB	**!**		**EQ 10MG BASE**	**A040101**	**002**	Jul 19, 1996

PROCOMP

AB		JUBILANT CADISTA	**EQ 5MG BASE**	**A040268**	**001**	Feb 27, 1998
AB			**EQ 10MG BASE**	**A040268**	**002**	Feb 27, 1998

PROGESTERONE
CAPSULE;ORAL
PROGESTERONE

AB		AMNEAL PHARMS NY	**100MG**	**A207724**	**001**	Sep 07, 2017
AB			**200MG**	**A207724**	**002**	Sep 07, 2017
AB		BIONPHARMA INC	**100MG**	**A200900**	**001**	Aug 16, 2013
AB			**200MG**	**A200900**	**002**	Aug 16, 2013
AB		DR REDDYS	**100MG**	**A208801**	**001**	Feb 28, 2017
AB			**200MG**	**A208801**	**002**	Feb 28, 2017

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE						
AB		EUGIA PHARMA	**100MG**	**A211285**	**001**	Oct 26, 2018
AB			**200MG**	**A211285**	**002**	Oct 26, 2018
AB		SOFGEN PHARMS	**100MG**	**A200456**	**001**	Sep 28, 2012
AB			**200MG**	**A200456**	**002**	Sep 28, 2012
AB		XIROMED	**100MG**	**A205229**	**001**	Oct 20, 2017
AB			**200MG**	**A205229**	**002**	Oct 20, 2017
PROMETRIUM						
AB	+	VIRTUS PHARMS	**100MG**	**N019781**	**001**	May 14, 1998
AB	+!		**200MG**	**N019781**	**002**	Oct 15, 1999

GEL;VAGINAL

CRINONE					
	+!	ALLERGAN	4%	N020701	001 Jul 31, 1997
	+!		8%	N020701	002 Jul 31, 1997

INJECTABLE;INJECTION

PROGESTERONE						
AO	+!	ACTAVIS LABS UT INC	**50MG/ML**	**N017362**	**002**	
AO		EUGIA PHARMA	**50MG/ML**	**A210965**	**001**	Dec 06, 2018
AO		FRESENIUS KABI USA	**50MG/ML**	**A075906**	**001**	Apr 25, 2001
AO		HIKMA FARMACEUTICA	**50MG/ML**	**A091033**	**001**	Oct 28, 2010

INSERT;VAGINAL

ENDOMETRIN						
	+!	FERRING	100MG	N022057	001	Jun 21, 2007

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE						
AP	!	WEST-WARD PHARMS INT	**25MG/ML**	**A083312**	**001**	
AP	!		**50MG/ML**	**A083312**	**002**	
AP		X-GEN PHARMS	**25MG/ML**	**A040737**	**001**	Apr 24, 2008
AP			**50MG/ML**	**A040737**	**002**	Apr 24, 2008

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE						
AB		ACP NIMBLE	**12.5MG**	**A040428**	**002**	Mar 31, 2003
AB	!		**25MG**	**A040428**	**001**	Feb 05, 2002
AB		PERRIGO ISRAEL	**12.5MG**	**A040500**	**001**	Jun 30, 2003
AB			**25MG**	**A040500**	**002**	Jun 30, 2003
AB		TARO	**12.5MG**	**A040603**	**001**	Oct 26, 2006
AB			**25MG**	**A040603**	**002**	Oct 26, 2006
AB		WATSON LABS INC	**12.5MG**	**A040479**	**001**	Jun 24, 2003
AB			**25MG**	**A040479**	**002**	Jun 24, 2003
PROMETHEGAN						
	!	ACP NIMBLE	50MG	A087165	001	Aug 14, 1987

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE						
AA		AMNEAL PHARMS	**6.25MG/5ML**	**A040882**	**001**	Dec 30, 2009
AA		HI TECH PHARMA	**6.25MG/5ML**	**A040026**	**001**	Sep 25, 1998
AA		NOSTRUM LABS INC	**6.25MG/5ML**	**A040891**	**001**	Mar 13, 2009
AA		TARO	**6.25MG/5ML**	**A040718**	**001**	Apr 04, 2007
AA		TRIS PHARMA INC	**6.25MG/5ML**	**A091675**	**001**	Jun 28, 2012
AA		VINTAGE	**6.25MG/5ML**	**A040643**	**001**	Apr 26, 2006
PROMETHAZINE PLAIN						
AA	!	WOCKHARDT BIO AG	**6.25MG/5ML**	**A087953**	**001**	Nov 15, 1982

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE						
AB		AMNEAL PHARMS NY	**12.5MG**	**A091179**	**001**	Dec 13, 2010
AB			**25MG**	**A091179**	**002**	Dec 13, 2010
AB			**50MG**	**A091179**	**003**	Dec 13, 2010
AB		KVK TECH	**12.5MG**	**A040712**	**002**	May 04, 2007
AB			**25MG**	**A040712**	**001**	Jul 31, 2006
AB			**50MG**	**A040712**	**003**	Jul 31, 2006
AB		PRINSTON INC	**12.5MG**	**A040622**	**001**	Jul 18, 2006
AB			**25MG**	**A040622**	**002**	Jul 18, 2006
AB			**50MG**	**A040622**	**003**	Jul 18, 2006
AB		QUAGEN	**12.5MG**	**A040673**	**001**	Mar 05, 2008
AB			**25MG**	**A040673**	**002**	Mar 05, 2008
AB			**50MG**	**A040673**	**003**	Mar 05, 2008
AB		SANDOZ	**25MG**	**A084176**	**003**	
AB	!		**50MG**	**A084176**	**001**	
AB		STRIDES PHARMA	**12.5MG**	**A209177**	**001**	Jun 30, 2017

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		**25MG**	**A209177**	**002**	Jun 30, 2017
AB		**50MG**	**A209177**	**003**	Jun 30, 2017
AB	SUN PHARM INDS INC	**12.5MG**	**A040863**	**001**	Dec 30, 2008
AB		**25MG**	**A040863**	**002**	Dec 30, 2008
AB		**50MG**	**A040863**	**003**	Dec 30, 2008
AB	WATSON LABS	**25MG**	**A083426**	**001**	
AB		**50MG**	**A083711**	**001**	
AB	ZYDUS PHARMS USA	**12.5MG**	**A040596**	**001**	Nov 18, 2005
AB		**25MG**	**A040596**	**002**	Nov 18, 2005
AB		**50MG**	**A040596**	**003**	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	**225MG**	**A205268**	**001**	Sep 08, 2017
AB		**325MG**	**A205268**	**002**	Sep 08, 2017
AB		**425MG**	**A205268**	**003**	Sep 08, 2017
AB	MYLAN	**225MG**	**A203803**	**001**	Apr 29, 2016
AB		**325MG**	**A203803**	**002**	Apr 29, 2016
AB		**425MG**	**A203803**	**003**	Apr 29, 2016
AB	PAR PHARM	**225MG**	**A078540**	**001**	Oct 18, 2010
AB		**325MG**	**A078540**	**002**	Oct 18, 2010
AB		**425MG**	**A078540**	**003**	Oct 18, 2010
AB	SINOTHERAPEUTICS INC	**225MG**	**A210339**	**001**	Jan 04, 2019
AB		**325MG**	**A210339**	**002**	Jan 04, 2019
AB		**425MG**	**A210339**	**003**	Jan 04, 2019
AB	WATSON LABS INC	**225MG**	**A202688**	**001**	Aug 24, 2015
AB		**325MG**	**A202688**	**002**	Aug 24, 2015
AB		**425MG**	**A202688**	**003**	Aug 24, 2015
AB	WILSHIRE PHARMS INC	**225MG**	**A205956**	**001**	Jul 02, 2018
AB		**325MG**	**A205956**	**002**	Jul 02, 2018
AB		**425MG**	**A205956**	**003**	Jul 02, 2018

RYTHMOL SR

AB	**+** GLAXOSMITHKLINE LLC	**225MG**	**N021416**	**001**	Sep 04, 2003
AB	**+**	**325MG**	**N021416**	**002**	Sep 04, 2003
AB	**+!**	**425MG**	**N021416**	**003**	Sep 04, 2003

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB	ANI PHARMS INC	**150MG**	**A076550**	**001**	Apr 23, 2004
AB		**225MG**	**A076550**	**002**	Apr 23, 2004
AB		**300MG**	**A076550**	**003**	Apr 23, 2004
AB	AUROBINDO PHARMA LTD	**150MG**	**A202445**	**001**	May 11, 2016
AB		**225MG**	**A202445**	**002**	May 11, 2016
AB		**300MG**	**A202445**	**003**	May 11, 2016
AB	SUN PHARM INDUSTRIES	**150MG**	**A075998**	**001**	Nov 29, 2001
AB		**225MG**	**A075998**	**002**	Nov 29, 2001
AB		**300MG**	**A075998**	**003**	Nov 29, 2001
AB	VINTAGE PHARMS	**150MG**	**A075938**	**001**	Oct 17, 2002
AB		**225MG**	**A075938**	**002**	Oct 17, 2002
AB	**!**	**300MG**	**A075938**	**003**	Oct 17, 2002
AB	WATSON LABS	**150MG**	**A075203**	**001**	Oct 24, 2000
AB		**225MG**	**A075203**	**002**	Oct 24, 2000

PROPANTHELINE BROMIDE

TABLET;ORAL

PROPANTHELINE BROMIDE

	! HIKMA	15MG	A080927	002	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

AT	ALCON LABS INC	**0.5%**	**A080027**	**001**	

PROPARACAINE HYDROCHLORIDE

AT	**!** AKORN INC	**0.5%**	**A040277**	**001**	Mar 16, 2000
AT	BAUSCH AND LOMB	**0.5%**	**A040074**	**001**	Sep 29, 1995

PROPOFOL

INJECTABLE;INJECTION

DIPRIVAN

AB	**+!**	FRESENIUS KABI USA	**10MG/ML**	**N019627**	**002**	Jun 11, 1996

PROPOFOL

AB		DR REDDYS	**10MG/ML**	**A205067**	**001**	Nov 15, 2018
AB		HOSPIRA	**10MG/ML**	**A077908**	**001**	Mar 17, 2006
AB		SAGENT PHARMS INC	**10MG/ML**	**A075102**	**001**	Jan 04, 1999
AB		WATSON LABS INC	**10MG/ML**	**A205307**	**001**	Dec 22, 2015

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

AB	**+**	ANI PHARMS INC	**60MG**	**N018553**	**004**	Mar 18, 1987
AB	**+**		**80MG**	**N018553**	**002**	Apr 19, 1983
AB	**+**		**120MG**	**N018553**	**003**	Apr 19, 1983
AB	**+!**		**160MG**	**N018553**	**001**	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**60MG**	**A078494**	**001**	Aug 10, 2007
AB			**80MG**	**A078494**	**002**	Aug 10, 2007
AB			**120MG**	**A078494**	**003**	Aug 10, 2007
AB			**160MG**	**A078494**	**004**	Aug 10, 2007
AB		ADARE PHARMS INC	**60MG**	**A078703**	**001**	Jul 15, 2011
AB			**80MG**	**A078703**	**002**	Jul 15, 2011
AB			**120MG**	**A078703**	**003**	Jul 15, 2011
AB			**160MG**	**A078703**	**004**	Jul 15, 2011
AB		AMTA	**60MG**	**A212026**	**001**	Jan 06, 2020
AB			**80MG**	**A212026**	**002**	Jan 06, 2020
AB			**120MG**	**A212026**	**003**	Jan 06, 2020
AB			**160MG**	**A212026**	**004**	Jan 06, 2020
AB		NORTEC DEV ASSOC	**60MG**	**A078065**	**001**	Jan 26, 2007
AB			**80MG**	**A078065**	**002**	Jan 26, 2007
AB			**120MG**	**A078065**	**003**	Jan 26, 2007
AB			**160MG**	**A078065**	**004**	Jan 26, 2007
AB		ZYDUS PHARMS USA INC	**60MG**	**A090321**	**001**	Mar 25, 2011
AB			**80MG**	**A090321**	**002**	Mar 25, 2011
AB			**120MG**	**A090321**	**003**	Mar 25, 2011
AB			**160MG**	**A090321**	**004**	Mar 25, 2011

INNOPRAN XL

BX	+	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003
BX	+!		120MG	N021438	002	Mar 12, 2003

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP		ATHENEX INC	**1MG/ML**	**A075792**	**001**	Aug 29, 2000
AP		FRESENIUS KABI USA	**1MG/ML**	**A075826**	**001**	Aug 31, 2001
	!	HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008

SOLUTION;ORAL

HEMANGEOL

	+!	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

	!	HIKMA	20MG/5ML	A070979	001	May 15, 1987
	!		40MG/5ML	A070690	001	May 15, 1987

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		IMPAX LABS INC	**10MG**	**A071972**	**001**	Apr 06, 1988
AB			**20MG**	**A071972**	**002**	Apr 06, 1988
AB			**40MG**	**A071972**	**003**	Apr 06, 1988
AB			**60MG**	**A071976**	**002**	May 13, 1986
AB	**!**		**80MG**	**A071976**	**001**	Apr 06, 1988
AB		INNOGENIX	**10MG**	**A070322**	**002**	Oct 22, 1985
AB			**20MG**	**A070322**	**003**	Oct 22, 1985
AB			**40MG**	**A070322**	**004**	Oct 22, 1985
AB			**60MG**	**A070322**	**005**	Sep 24, 1986
AB			**80MG**	**A070322**	**001**	Aug 04, 1986
AB		IPCA LABS LTD	**10MG**	**A078955**	**001**	Jun 02, 2008
AB			**20MG**	**A078955**	**002**	Jun 02, 2008
AB			**40MG**	**A078955**	**003**	Jun 02, 2008
AB			**60MG**	**A078955**	**004**	Jun 02, 2008
AB			**80MG**	**A078955**	**005**	Jun 02, 2008
AB		MYLAN	**10MG**	**A070213**	**002**	Nov 19, 1985
AB			**20MG**	**A070213**	**003**	Nov 19, 1985
AB			**40MG**	**A070213**	**001**	Nov 19, 1985

PROPRANOLOL HYDROCHLORIDE
TABLET;ORAL
PROPRANOLOL HYDROCHLORIDE

AB			**60MG**	**A070213**	**005**	Apr 08, 2011
AB			**80MG**	**A070213**	**004**	Nov 19, 1985
AB		NORTHSTAR HLTHCARE	**10MG**	**A078213**	**001**	Jan 10, 2008
AB			**20MG**	**A078213**	**002**	Jan 10, 2008
AB			**40MG**	**A078213**	**003**	Jan 10, 2008
AB			**60MG**	**A078213**	**004**	Jan 10, 2008
AB			**80MG**	**A078213**	**005**	Jan 10, 2008
AB		VINTAGE PHARMS	**10MG**	**A070221**	**002**	Aug 01, 1986
AB			**20MG**	**A070221**	**003**	Aug 01, 1986
AB			**40MG**	**A070219**	**001**	Aug 01, 1986
AB			**40MG**	**A070221**	**004**	Aug 01, 1986
AB			**60MG**	**A070221**	**005**	Sep 24, 1986
AB			**80MG**	**A070221**	**001**	Apr 14, 1986
AB		WATSON LABS	**10MG**	**A070175**	**001**	May 13, 1986
AB			**20MG**	**A070176**	**001**	May 13, 1986
AB			**40MG**	**A070177**	**001**	May 13, 1986
AB			**60MG**	**A070178**	**002**	Apr 23, 2018
AB			**80MG**	**A070178**	**001**	May 13, 1986

PROPYLTHIOURACIL
TABLET;ORAL
PROPYLTHIOURACIL

BD		ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+!	DAVA PHARMS INC	50MG	N006188	001	

PROTAMINE SULFATE
INJECTABLE;INJECTION
PROTAMINE SULFATE

	!	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987

PROTRIPTYLINE HYDROCHLORIDE
TABLET;ORAL
PROTRIPTYLINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	**5MG**	**A202220**	**001**	Nov 19, 2012
AB			**10MG**	**A202220**	**002**	Nov 19, 2012
AB		HIKMA	**5MG**	**A078913**	**001**	Sep 16, 2008
AB			**10MG**	**A078913**	**002**	Sep 16, 2008
AB		SIGMAPHARM LABS LLC	**5MG**	**A090462**	**001**	May 03, 2010
AB			**10MG**	**A090462**	**002**	May 03, 2010

VIVACTIL

AB		HERITAGE PHARMA	**5MG**	**A073644**	**001**	Aug 24, 1995
AB	**!**		**10MG**	**A073645**	**001**	Aug 24, 1995

PRUCALOPRIDE SUCCINATE
TABLET;ORAL
MOTEGRITY

	+	SHIRE DEV LLC	EQ 1MG BASE	N210166	001	Dec 14, 2018
	+!		EQ 2MG BASE	N210166	002	Dec 14, 2018

PYRAZINAMIDE
TABLET;ORAL
PYRAZINAMIDE

AB		AKORN	**500MG**	**A081319**	**001**	Jun 30, 1992
AB	**!**	DAVA PHARMS INC	**500MG**	**A080157**	**001**	

PYRIDOSTIGMINE BROMIDE
INJECTABLE;INJECTION
MESTINON

AP	**+!**	BAUSCH	**5MG/ML**	**N009830**	**001**	

REGONOL

AP		SANDOZ INC	**5MG/ML**	**N017398**	**001**	

SYRUP;ORAL
MESTINON

AA	**+!**	BAUSCH	**60MG/5ML**	**N015193**	**001**	

PYRIDOSTIGMINE BROMIDE

AA		AMNEAL PHARMS LLC	**60MG/5ML**	**A212702**	**001**	Jan 10, 2020
AA		INVATECH	**60MG/5ML**	**A208797**	**001**	Jan 09, 2020
AA		NOVITIUM PHARMA	**60MG/5ML**	**A211694**	**001**	Mar 08, 2019

TABLET;ORAL
MESTINON

AB	**+!**	BAUSCH	**60MG**	**N009829**	**002**	

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

AB		ELYSIUM	**60MG**	**A211181**	**001**	Jul 20, 2018
AB		IMPAX LABS	**60MG**	**A040502**	**001**	Apr 24, 2003
AB		ZYDUS PHARMS	**60MG**	**A205650**	**001**	Jun 22, 2015
		ELYSIUM	30MG	A211181	002	May 14, 2019

TABLET, EXTENDED RELEASE;ORAL

MESTINON

AB	**+!**	BAUSCH	**180MG**	**N011665**	**001**	

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN	**180MG**	**A204737**	**001**	Jun 26, 2015
AB		IMPAX LABS INC	**180MG**	**A203184**	**001**	Sep 15, 2015
AB		RISING	**180MG**	**A205464**	**001**	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

	!	FRESENIUS KABI USA	100MG/ML	A080618	001	

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

	+!	VYERA PHARMS LLC	25MG	N008578	001	

QUAZEPAM

TABLET;ORAL

DORAL

	+!	GALT PHARMS	15MG	N018708	001	Dec 27, 1985

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	**EQ 25MG BASE**	**A202152**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A202152**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A202152**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A202152**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A202152**	**005**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A202152**	**006**	Mar 27, 2012
AB		ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A203390**	**001**	Oct 28, 2014
AB			**EQ 50MG BASE**	**A203390**	**002**	Oct 28, 2014
AB			**EQ 100MG BASE**	**A203390**	**003**	Oct 28, 2014
AB			**EQ 200MG BASE**	**A203390**	**004**	Oct 28, 2014
AB			**EQ 300MG BASE**	**A203390**	**005**	Oct 28, 2014
AB			**EQ 400MG BASE**	**A203390**	**006**	Oct 28, 2014
AB		ALKEM LABS LTD	**EQ 25MG BASE**	**A201504**	**001**	Feb 12, 2013
AB			**EQ 50MG BASE**	**A201504**	**002**	Feb 12, 2013
AB			**EQ 100MG BASE**	**A201504**	**003**	Feb 12, 2013
AB			**EQ 150MG BASE**	**A201504**	**004**	Feb 12, 2013
AB			**EQ 200MG BASE**	**A201504**	**005**	Feb 12, 2013
AB			**EQ 300MG BASE**	**A201504**	**006**	Feb 12, 2013
AB			**EQ 400MG BASE**	**A201504**	**007**	Feb 12, 2013
AB		APOTEX INC	**EQ 25MG BASE**	**A090960**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A090960**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A090960**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A090960**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A090960**	**005**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A090960**	**006**	Mar 27, 2012
AB		AUROBINDO PHARMA LTD	**EQ 25MG BASE**	**A091388**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A091388**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A091388**	**003**	Mar 27, 2012
AB			**EQ 150MG BASE**	**A091388**	**004**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A091388**	**005**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A091388**	**006**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A091388**	**007**	Mar 27, 2012
AB		DR REDDYS LABS LTD	**EQ 25MG BASE**	**A077380**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A077380**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A077380**	**003**	Mar 27, 2012
AB			**EQ 150MG BASE**	**A077380**	**004**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A077380**	**005**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A077380**	**006**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A077380**	**007**	Mar 27, 2012
AB		HIKMA	**EQ 25MG BASE**	**A090120**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A090749**	**001**	Mar 27, 2012

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB		**EQ 100MG BASE**	**A090749**	**002**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A090749**	**003**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A090749**	**004**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A090749**	**005**	Mar 27, 2012
AB	JUBILANT GENERICS	**EQ 25MG BASE**	**A203150**	**001**	Nov 26, 2013
AB	LUPIN LTD	**EQ 25MG BASE**	**A201109**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A201109**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A201109**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A201109**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A201109**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A201109**	**006**	Mar 27, 2012
AB	MACLEODS PHARMS LTD	**EQ 25MG BASE**	**A203359**	**001**	May 17, 2016
AB		**EQ 50MG BASE**	**A203359**	**002**	May 17, 2016
AB		**EQ 100MG BASE**	**A203359**	**003**	May 17, 2016
AB		**EQ 200MG BASE**	**A203359**	**004**	May 17, 2016
AB		**EQ 300MG BASE**	**A203359**	**005**	May 17, 2016
AB		**EQ 400MG BASE**	**A203359**	**006**	May 17, 2016
AB	SANDOZ	**EQ 25MG BASE**	**A078679**	**001**	Dec 14, 2012
AB		**EQ 50MG BASE**	**A078679**	**002**	Dec 14, 2012
AB		**EQ 100MG BASE**	**A078679**	**003**	Dec 14, 2012
AB		**EQ 150MG BASE**	**A078679**	**004**	Dec 14, 2012
AB		**EQ 200MG BASE**	**A078679**	**005**	Dec 14, 2012
AB		**EQ 300MG BASE**	**A078679**	**006**	Dec 14, 2012
AB		**EQ 400MG BASE**	**A078679**	**007**	Dec 14, 2012
AB	SUN PHARM	**EQ 25MG BASE**	**A201190**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A201190**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A201190**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A201190**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A201190**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A201190**	**006**	Mar 27, 2012
AB	TEVA PHARMS	**EQ 25MG BASE**	**A077745**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A077745**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A077745**	**003**	Mar 27, 2012
AB		**EQ 150MG BASE**	**A077745**	**004**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A077745**	**005**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A077745**	**006**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A077745**	**007**	Mar 27, 2012
AB	TORRENT PHARMS LTD	**EQ 25MG BASE**	**A200363**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A200363**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A200363**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A200363**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A200363**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A200363**	**006**	Mar 27, 2012
AB	UNICHEM LABS LTD	**EQ 25MG BASE**	**A202674**	**001**	Mar 08, 2016
AB		**EQ 50MG BASE**	**A202674**	**002**	Mar 08, 2016
AB		**EQ 100MG BASE**	**A202674**	**003**	Mar 08, 2016
AB		**EQ 200MG BASE**	**A202674**	**004**	Mar 08, 2016
AB		**EQ 300MG BASE**	**A202674**	**005**	Mar 08, 2016
AB		**EQ 400MG BASE**	**A202674**	**006**	Mar 08, 2016

SEROQUEL

AB	**+!**	ASTRAZENECA PHARMS	**EQ 25MG BASE**	**N020639**	**001**	Sep 26, 1997
AB	**+**		**EQ 50MG BASE**	**N020639**	**007**	Oct 04, 2005
AB	**+**		**EQ 100MG BASE**	**N020639**	**002**	Sep 26, 1997
AB	**+**		**EQ 200MG BASE**	**N020639**	**003**	Sep 26, 1997
AB	**+!**		**EQ 300MG BASE**	**N020639**	**005**	Jul 26, 2000
AB	**+**		**EQ 400MG BASE**	**N020639**	**006**	Oct 04, 2005

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	**EQ 50MG BASE**	**A206252**	**001**	Nov 29, 2017
AB		**EQ 150MG BASE**	**A090681**	**001**	May 09, 2017
AB		**EQ 200MG BASE**	**A090681**	**002**	May 09, 2017
AB		**EQ 300MG BASE**	**A090681**	**003**	May 09, 2017
AB		**EQ 400MG BASE**	**A090681**	**004**	Nov 01, 2016
AB	ALIGNSCIENCE PHARMA	**EQ 150MG BASE**	**A209497**	**001**	Sep 28, 2018
AB		**EQ 200MG BASE**	**A209497**	**002**	Sep 28, 2018
AB	ANCHEN PHARMS	**EQ 150MG BASE**	**A090757**	**001**	Dec 01, 2017
AB		**EQ 200MG BASE**	**A090757**	**002**	Dec 01, 2017
AB		**EQ 300MG BASE**	**A090757**	**003**	Dec 01, 2017
AB		**EQ 400MG BASE**	**A090757**	**004**	Dec 01, 2017

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB		AUROBINDO PHARMA LTD	**EQ 50MG BASE**	**A207655**	**001**	Nov 29, 2017
AB			**EQ 150MG BASE**	**A207655**	**002**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A207655**	**003**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A207655**	**004**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A207655**	**005**	Nov 29, 2017
AB		INTELLIPHARMACEUTICS	**EQ 50MG BASE**	**A202939**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A202939**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A202939**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A202939**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A202939**	**005**	May 09, 2017
AB		LUPIN LTD	**EQ 50MG BASE**	**A204203**	**001**	May 17, 2017
AB			**EQ 150MG BASE**	**A204203**	**002**	May 17, 2017
AB			**EQ 200MG BASE**	**A204203**	**003**	May 17, 2017
AB			**EQ 300MG BASE**	**A204203**	**004**	May 17, 2017
AB			**EQ 400MG BASE**	**A204203**	**005**	May 17, 2017
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A204253**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A204253**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A204253**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A204253**	**004**	Nov 29, 2017
AB		NOVAST LABS	**EQ 50MG BASE**	**A208947**	**001**	Nov 29, 2017
AB			**EQ 150MG BASE**	**A208947**	**002**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A208947**	**003**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A208947**	**004**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A208947**	**005**	Nov 29, 2017
AB		PAR PHARM	**EQ 50MG BASE**	**A090482**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A090482**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A090482**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A090482**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A090482**	**005**	May 09, 2017
AB		PHARMADAX INC	**EQ 50MG BASE**	**A206260**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A206260**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A206260**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A206260**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A206260**	**005**	May 09, 2017
AB		SCIEGEN PHARMS INC	**EQ 50MG BASE**	**A209635**	**005**	Nov 16, 2018
AB			**EQ 150MG BASE**	**A209635**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A209635**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A209635**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A209635**	**004**	Nov 29, 2017

SEROQUEL XR

AB	+	ASTRAZENECA	**EQ 50MG BASE**	**N022047**	**001**	May 17, 2007
AB	+		**EQ 150MG BASE**	**N022047**	**005**	Aug 11, 2008
AB	+!		**EQ 200MG BASE**	**N022047**	**002**	May 17, 2007
AB	+		**EQ 300MG BASE**	**N022047**	**003**	May 17, 2007
AB	+		**EQ 400MG BASE**	**N022047**	**004**	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRIL

AB	+	PFIZER PHARMS	**EQ 5MG BASE**	**N019885**	**001**	Nov 19, 1991
AB	+		**EQ 10MG BASE**	**N019885**	**002**	Nov 19, 1991
AB	+		**EQ 20MG BASE**	**N019885**	**003**	Nov 19, 1991
AB	+!		**EQ 40MG BASE**	**N019885**	**004**	Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202725**	**001**	Apr 29, 2013
AB			**EQ 10MG BASE**	**A202725**	**002**	Apr 29, 2013
AB			**EQ 20MG BASE**	**A202725**	**003**	Apr 29, 2013
AB			**EQ 40MG BASE**	**A202725**	**004**	Apr 29, 2013
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078457**	**001**	Aug 24, 2007
AB			**EQ 10MG BASE**	**A078457**	**002**	Aug 24, 2007
AB			**EQ 20MG BASE**	**A078457**	**003**	Aug 24, 2007
AB			**EQ 40MG BASE**	**A078457**	**004**	Aug 24, 2007
AB		LUPIN	**EQ 5MG BASE**	**A077690**	**001**	Jun 20, 2006
AB			**EQ 10MG BASE**	**A077690**	**002**	Jun 20, 2006
AB			**EQ 20MG BASE**	**A077690**	**003**	Jun 20, 2006
AB			**EQ 40MG BASE**	**A077690**	**004**	Jun 20, 2006
AB		MYLAN	**EQ 5MG BASE**	**A076694**	**001**	Dec 23, 2004

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB			**EQ 10MG BASE**	**A076694**	**002**	Dec 23, 2004
AB			**EQ 20MG BASE**	**A076694**	**003**	Dec 23, 2004
AB			**EQ 40MG BASE**	**A076694**	**004**	Dec 23, 2004
AB		PRINSTON INC	**EQ 5MG BASE**	**A205823**	**001**	Sep 15, 2016
AB			**EQ 10MG BASE**	**A205823**	**002**	Sep 15, 2016
AB			**EQ 20MG BASE**	**A205823**	**003**	Sep 15, 2016
AB			**EQ 40MG BASE**	**A205823**	**004**	Sep 15, 2016

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

	!	SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

AB		SANDOZ	**200MG**	**A088072**	**002**	
AB			**300MG**	**A088072**	**001**	Sep 26, 1983
AB	**!**	WATSON LABS	**200MG**	**A083288**	**001**	
AB	**!**		**300MG**	**A085583**	**001**	

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

AB	**+!**	SUN PHARM INDUSTRIES	**324MG**	**N021799**	**001**	Aug 12, 2005

QUININE SULFATE

AB		AMNEAL PHARMS	**324MG**	**A203729**	**001**	Jul 15, 2015
AB		LUPIN LTD	**324MG**	**A203112**	**001**	Apr 24, 2015
AB		NOVAST LABS	**324MG**	**A204372**	**001**	Jul 22, 2015
AB		TEVA PHARMS	**324MG**	**A091661**	**001**	Sep 28, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

	+	AYTU	5MG	N204736	001	Mar 26, 2013
	+!		10MG	N204736	002	Mar 26, 2013

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

AB	**+!**	EISAI INC	**20MG**	**N020973**	**002**	Aug 19, 1999

RABEPRAZOLE SODIUM

AB		ALKEM LABS LTD	**20MG**	**A208644**	**001**	Apr 24, 2018
AB		AMNEAL PHARMS	**20MG**	**A204179**	**001**	Jul 31, 2015
AB		AUROBINDO PHARMA LTD	**20MG**	**A205761**	**001**	Feb 17, 2017
AB		DR REDDYS	**20MG**	**A076824**	**001**	Nov 08, 2013
AB		LANNETT CO INC	**20MG**	**A090678**	**001**	Nov 08, 2013
AB		LUPIN LTD	**20MG**	**A078964**	**001**	Nov 08, 2013
AB		RUBICON	**20MG**	**A204237**	**001**	Nov 18, 2015
AB		TEVA PHARMS USA	**20MG**	**A076822**	**001**	Nov 08, 2013
AB		TORRENT	**20MG**	**A202376**	**001**	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION;INTRAVENOUS

XOFIGO

	+!	BAYER HLTHCARE	162mCi/6ML (27mCi/ML)	N203971	001	May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB	**+!**	LILLY	**60MG**	**N020815**	**001**	Dec 09, 1997

RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	**60MG**	**A208206**	**001**	Apr 08, 2016
AB		AUROBINDO PHARMA LTD	**60MG**	**A204310**	**001**	Aug 28, 2015
AB		GLENMARK PHARMS LTD	**60MG**	**A204491**	**001**	Mar 22, 2016
AB		INVAGEN PHARMS	**60MG**	**A090842**	**001**	Sep 24, 2014
AB		SCIEGEN PHARMS INC	**60MG**	**A206384**	**001**	Oct 12, 2016
AB		TEVA PHARMS USA	**60MG**	**A078193**	**001**	Mar 04, 2014
AB		WATSON LABS INC	**60MG**	**A200825**	**001**	Jan 21, 2015

RALTEGRAVIR POTASSIUM

POWDER;ORAL						
ISENTRESS						
	+!	MERCK SHARP DOHME	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013
TABLET;ORAL						
ISENTRESS						
	+!	MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007
ISENTRESS HD						
	+!	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017
TABLET, CHEWABLE;ORAL						
ISENTRESS						
	+	MERCK SHARP DOHME	EQ 25MG BASE	N203045	001	Dec 21, 2011
	+!		EQ 100MG BASE	N203045	002	Dec 21, 2011

RAMELTEON

TABLET;ORAL						
RAMELTEON						
AB		ACTAVIS LABS FL INC	**8MG**	**A091610**	**001**	Aug 19, 2015
AB		DR REDDYS LABS SA	**8MG**	**A091693**	**001**	Jul 26, 2013
AB		ZYDUS PHARMS	**8MG**	**A211567**	**001**	Jul 22, 2019
ROZEREM						
AB	**+!**	TAKEDA PHARMS USA	**8MG**	**N021782**	**001**	Jul 22, 2005

RAMIPRIL

CAPSULE;ORAL						
ALTACE						
AB	+	KING PHARMS LLC	**1.25MG**	**N019901**	**001**	Jan 28, 1991
AB	+		**2.5MG**	**N019901**	**002**	Jan 28, 1991
AB	+		**5MG**	**N019901**	**003**	Jan 28, 1991
AB	+!		**10MG**	**N019901**	**004**	Jan 28, 1991
RAMIPRIL						
AB		ACCORD HLTHCARE	**1.25MG**	**A202392**	**001**	Apr 15, 2014
AB			**2.5MG**	**A202392**	**002**	Apr 15, 2014
AB			**5MG**	**A202392**	**003**	Apr 15, 2014
AB			**10MG**	**A202392**	**004**	Apr 15, 2014
AB		APOTEX	**1.25MG**	**A079116**	**001**	Jun 20, 2008
AB			**2.5MG**	**A079116**	**002**	Jun 20, 2008
AB			**5MG**	**A079116**	**003**	Jun 20, 2008
AB			**10MG**	**A079116**	**004**	Jun 20, 2008
AB		AUROBINDO PHARMA LTD	**1.25MG**	**A091604**	**001**	Jun 08, 2011
AB			**2.5MG**	**A091604**	**002**	Jun 08, 2011
AB			**5MG**	**A091604**	**003**	Jun 08, 2011
AB			**10MG**	**A091604**	**004**	Jun 08, 2011
AB		CHARTWELL MOLECULAR	**1.25MG**	**A078745**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078745**	**002**	Jun 18, 2008
AB			**5MG**	**A078745**	**003**	Jun 18, 2008
AB			**10MG**	**A078745**	**004**	Jun 18, 2008
AB		DR REDDYS LABS LTD	**1.25MG**	**A078191**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078191**	**002**	Jun 18, 2008
AB			**5MG**	**A078191**	**003**	Jun 18, 2008
AB			**10MG**	**A078191**	**004**	Jun 18, 2008
AB		HIKMA	**1.25MG**	**A077900**	**001**	Jun 18, 2008
AB			**2.5MG**	**A077900**	**002**	Jun 18, 2008
AB			**5MG**	**A077900**	**003**	Jun 18, 2008
AB			**10MG**	**A077900**	**004**	Jun 18, 2008
AB		LUPIN	**1.25MG**	**A077626**	**001**	Jun 09, 2008
AB			**2.5MG**	**A077626**	**002**	Jun 09, 2008
AB			**5MG**	**A077626**	**003**	Jun 09, 2008
AB			**10MG**	**A077626**	**004**	Jun 09, 2008
AB		TEVA PHARMS	**1.25MG**	**A077470**	**001**	Jun 18, 2008
AB			**2.5MG**	**A077470**	**002**	Jun 18, 2008
AB			**5MG**	**A077470**	**003**	Jun 18, 2008
AB			**10MG**	**A077470**	**004**	Jun 18, 2008
AB		WATSON LABS	**1.25MG**	**A076549**	**001**	Oct 24, 2005
AB			**2.5MG**	**A076549**	**002**	Oct 24, 2005
AB			**10MG**	**A076549**	**004**	Oct 24, 2005
AB		ZYDUS PHARMS USA	**1.25MG**	**A078832**	**001**	Sep 02, 2008
AB			**2.5MG**	**A078832**	**002**	Sep 02, 2008
AB			**5MG**	**A078832**	**003**	Sep 02, 2008
AB			**10MG**	**A078832**	**004**	Sep 02, 2008

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**EQ 150MG BASE**	**A209859**	**001**	Sep 27, 2018
AB			**EQ 300MG BASE**	**A209859**	**002**	Sep 27, 2018
AB		APPCO	**EQ 150MG BASE**	**A211893**	**001**	Apr 05, 2019
AB			**EQ 300MG BASE**	**A211893**	**002**	Apr 05, 2019
AB		AUROBINDO PHARMA LTD	**EQ 150MG BASE**	**A211058**	**001**	Jul 16, 2018
AB			**EQ 300MG BASE**	**A211058**	**002**	Jul 16, 2018
AB		DR REDDYS LABS LTD	**EQ 150MG BASE**	**A075742**	**001**	Nov 29, 2000
AB			**EQ 300MG BASE**	**A075742**	**002**	Nov 29, 2000
AB		NOVITIUM PHARMA	**EQ 150MG BASE**	**A210681**	**001**	Nov 23, 2018
AB			**EQ 300MG BASE**	**A210681**	**002**	Nov 23, 2018
AB		SANDOZ	**EQ 150MG BASE**	**A074655**	**001**	Oct 22, 1997
AB	**!**		**EQ 300MG BASE**	**A074655**	**002**	Oct 22, 1997

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP		MYLAN LABS LTD	**EQ 25MG BASE/ML**	**A079076**	**001**	Jun 09, 2016
AP		WEST-WARD PHARMS INT	**EQ 25MG BASE/ML**	**A074777**	**001**	Mar 02, 2005
AP			**EQ 25MG BASE/ML**	**A077458**	**001**	Feb 16, 2006
AP		ZYDUS PHARMS USA INC	**EQ 25MG BASE/ML**	**A091534**	**001**	Feb 22, 2013

ZANTAC

AP	**+!**	TELIGENT	**EQ 25MG BASE/ML**	**N019090**	**001**	Oct 19, 1984

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**EQ 15MG BASE/ML**	**A078312**	**001**	Sep 02, 2008
AA		ANDA REPOSITORY	**EQ 15MG BASE/ML**	**A090054**	**001**	Nov 15, 2010
AA		AUROBINDO PHARMA LTD	**EQ 15MG BASE/ML**	**A090623**	**001**	Jul 28, 2010
AA		BRECKENRIDGE	**EQ 15MG BASE/ML**	**A078684**	**001**	Aug 27, 2009
AA		HI TECH PHARMA	**EQ 15MG BASE/ML**	**A091078**	**001**	Mar 22, 2011
AA		LANNETT CO INC	**EQ 15MG BASE/ML**	**A078890**	**001**	Jul 01, 2010
AA			**EQ 15MG BASE/ML**	**A091288**	**001**	Dec 09, 2010
AA		NOSTRUM LABS INC	**EQ 15MG BASE/ML**	**A091091**	**001**	Sep 20, 2011
AA	**!**	PHARM ASSOC	**EQ 15MG BASE/ML**	**A077405**	**001**	Sep 21, 2007
AA		TARO	**EQ 15MG BASE/ML**	**A077476**	**001**	Jun 13, 2011

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB		ACIC PHARMS	**EQ 150MG BASE**	**A203694**	**001**	Nov 30, 2017
AB			**EQ 300MG BASE**	**A203694**	**002**	Nov 30, 2017
AB		AMNEAL PHARMS NY	**EQ 150MG BASE**	**A077824**	**001**	Oct 13, 2006
AB	**!**		**EQ 300MG BASE**	**A077824**	**002**	Oct 13, 2006
AB		APOTEX	**EQ 150MG BASE**	**A074680**	**001**	Sep 12, 1997
AB			**EQ 300MG BASE**	**A074680**	**002**	Sep 12, 1997
AB		DR REDDYS LABS INC	**EQ 150MG BASE**	**A076705**	**001**	Jul 27, 2005
AB			**EQ 300MG BASE**	**A076705**	**002**	Jul 27, 2005
AB		GLENMARK PHARMS INC	**EQ 150MG BASE**	**A078542**	**001**	Nov 19, 2008
AB			**EQ 300MG BASE**	**A078542**	**002**	Nov 19, 2008
AB		HERITAGE PHARMA	**EQ 150MG BASE**	**A075165**	**001**	Sep 30, 1998
AB			**EQ 300MG BASE**	**A075165**	**002**	Sep 30, 1998
AB		PAR PHARM	**EQ 150MG BASE**	**A075180**	**001**	Jan 28, 1999
AB			**EQ 300MG BASE**	**A075180**	**002**	Jan 28, 1999
AB		SANDOZ	**EQ 150MG BASE**	**A074467**	**001**	Aug 29, 1997
AB			**EQ 300MG BASE**	**A074467**	**002**	Aug 29, 1997
AB		STRIDES PHARMA	**EQ 150MG BASE**	**A205512**	**001**	Aug 22, 2016
AB			**EQ 150MG BASE**	**A210010**	**001**	Aug 01, 2018
AB			**EQ 300MG BASE**	**A205512**	**002**	Aug 22, 2016
AB			**EQ 300MG BASE**	**A210010**	**002**	Aug 01, 2018
AB		VKT PHARMA PVT LTD	**EQ 150MG BASE**	**A211289**	**001**	Jan 31, 2019
AB			**EQ 300MG BASE**	**A211289**	**002**	Jan 31, 2019
AB		WOCKHARDT LTD	**EQ 150MG BASE**	**A075208**	**001**	Dec 17, 1998
AB			**EQ 300MG BASE**	**A075208**	**002**	Dec 17, 1998

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

AB	**+**	GILEAD	**500MG**	**N021526**	**002**	Jan 27, 2006
AB	**+!**		**1GM**	**N021526**	**001**	Feb 12, 2007

RANOLAZINE

AB		ACTAVIS ELIZABETH	**500MG**	**A208862**	**001**	May 28, 2019
AB			**1GM**	**A208862**	**002**	May 28, 2019

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		AJANTA PHARMA LTD	**500MG**	**A210054**	**001**	May 28, 2019
AB			**1GM**	**A210054**	**002**	May 28, 2019
AB		AMERIGEN PHARMS LTD	**500MG**	**A210482**	**001**	Oct 29, 2019
AB			**1GM**	**A210482**	**002**	Oct 29, 2019
AB		CADILA	**500MG**	**A210188**	**001**	Aug 19, 2019
AB			**1GM**	**A210188**	**002**	Aug 19, 2019
AB		CIPLA	**500MG**	**A211291**	**001**	May 28, 2019
AB			**1GM**	**A211291**	**002**	May 28, 2019
AB		GLENMARK PHARMS LTD	**500MG**	**A211082**	**001**	Jul 05, 2019
AB			**1GM**	**A211082**	**002**	Jul 05, 2019
AB		LUPIN LTD	**500MG**	**A201046**	**001**	Jul 29, 2013
AB			**1GM**	**A201046**	**002**	Jul 29, 2013
AB		SCIEGEN PHARMS INC	**500MG**	**A211829**	**001**	Jun 04, 2019
AB			**1GM**	**A211829**	**002**	Jun 04, 2019
AB		SUN PHARM	**500MG**	**A211707**	**001**	May 28, 2019
AB			**1GM**	**A211707**	**002**	May 28, 2019

RASAGILINE MESYLATE

TABLET;ORAL

AZILECT

AB	**+**	TEVA	**EQ 0.5MG BASE**	**N021641**	**001**	May 16, 2006
AB	**+!**		**EQ 1MG BASE**	**N021641**	**002**	May 16, 2006

RASAGILINE MESYLATE

AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A201889**	**001**	Oct 30, 2017
AB			**EQ 1MG BASE**	**A201889**	**002**	Oct 30, 2017
AB		INDOCO REMEDIES	**EQ 0.5MG BASE**	**A206153**	**001**	Oct 04, 2019
AB			**EQ 1MG BASE**	**A206153**	**002**	Oct 04, 2019
AB		MICRO LABS	**EQ 0.5MG BASE**	**A207004**	**001**	Mar 29, 2019
AB			**EQ 1MG BASE**	**A207004**	**002**	Mar 29, 2019
AB		MYLAN	**EQ 0.5MG BASE**	**A201971**	**001**	May 15, 2017
AB			**EQ 1MG BASE**	**A201971**	**002**	May 15, 2017
AB		ORCHID HLTHCARE	**EQ 0.5MG BASE**	**A201970**	**001**	Mar 15, 2016
AB			**EQ 1MG BASE**	**A201970**	**002**	Mar 15, 2016
AB		SANDOZ INC	**EQ 0.5MG BASE**	**A201892**	**001**	Jul 27, 2018
AB			**EQ 1MG BASE**	**A201892**	**002**	Jul 27, 2018
AB		WATSON LABS INC	**EQ 0.5MG BASE**	**A201823**	**001**	Jul 01, 2013
AB			**EQ 1MG BASE**	**A201823**	**002**	Jul 01, 2013

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

	+!	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008

REGORAFENIB

TABLET;ORAL

STIVARGA

	+!	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/VIAL**	**A206223**	**001**	Jan 16, 2018
AP			**EQ 2MG BASE/VIAL**	**A206223**	**002**	Jan 16, 2018
AP			**EQ 5MG BASE/VIAL**	**A206223**	**003**	Jan 16, 2018

ULTIVA

AP	**+**	MYLAN INSTITUTIONAL	**EQ 1MG BASE/VIAL**	**N020630**	**001**	Jul 12, 1996
AP	**+**		**EQ 2MG BASE/VIAL**	**N020630**	**002**	Jul 12, 1996
AP	**+!**		**EQ 5MG BASE/VIAL**	**N020630**	**003**	Jul 12, 1996

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		ACTAVIS TOTOWA	**0.5MG**	**A090008**	**001**	Jan 22, 2014
AB			**1MG**	**A090008**	**002**	Jan 22, 2014
AB			**2MG**	**A090008**	**003**	Jan 22, 2014
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A203820**	**001**	Jan 22, 2014
AB			**1MG**	**A203820**	**002**	Jan 22, 2014
AB	**!**		**2MG**	**A203820**	**003**	Jan 22, 2014
AB		BOSCOGEN	**0.5MG**	**A091517**	**001**	Apr 24, 2015
AB			**1MG**	**A091517**	**002**	Apr 24, 2015
AB			**2MG**	**A091517**	**003**	Apr 24, 2015

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		CASI PHARMS INC	**0.5MG**	**A078555**	**001**	Nov 22, 2013
AB			**1MG**	**A078555**	**002**	Jan 22, 2014
AB			**2MG**	**A078555**	**003**	Jan 22, 2014
AB		PADDOCK LLC	**0.5MG**	**A201189**	**001**	Jul 17, 2013
AB			**1MG**	**A201189**	**002**	Jan 22, 2014
AB			**2MG**	**A201189**	**003**	Jan 22, 2014
AB		SUN PHARM INDS INC	**1MG**	**A077571**	**002**	Jul 11, 2013
AB			**2MG**	**A077571**	**003**	Jul 11, 2013

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

+!	ALMIRALL	1%	N022055	001	Apr 12, 2007

REVEFENACIN

SOLUTION;INHALATION

YUPELRI

+!	MYLAN IRELAND LTD	175MCG/3ML	N210598	001	Nov 09, 2018

RIBAVIRIN

CAPSULE;ORAL

REBETOL

AB	**+!**	MERCK SHARP DOHME	**200MG**	**N020903**	**002**	Jul 25, 2001

RIBASPHERE

AB		KADMON PHARMS LLC	**200MG**	**A076203**	**001**	Apr 06, 2004

RIBAVIRIN

AB		AUROBINDO PHARMA	**200MG**	**A079117**	**001**	Sep 17, 2009
AB		TEVA	**200MG**	**A076277**	**001**	Oct 04, 2004
AB		ZYDUS PHARMS USA	**200MG**	**A077224**	**001**	Oct 28, 2005

FOR SOLUTION;INHALATION

RIBAVIRIN

AN		NAVINTA LLC	**6GM/VIAL**	**A207366**	**001**	Oct 06, 2016

VIRAZOLE

AN	**+!**	VALEANT PHARM INTL	**6GM/VIAL**	**N018859**	**001**	Dec 31, 1985

TABLET;ORAL

RIBAVIRIN

AB		AUROBINDO PHARMA	**200MG**	**A079111**	**001**	Sep 17, 2009
AB		BEXIMCO PHARMS USA	**200MG**	**A202546**	**001**	Aug 12, 2014
AB			**400MG**	**A202546**	**002**	Aug 12, 2014
AB			**500MG**	**A202546**	**003**	Aug 12, 2014
AB			**600MG**	**A202546**	**004**	Aug 12, 2014
AB		KADMON PHARMS LLC	**200MG**	**A077456**	**001**	Dec 05, 2005
AB			**400MG**	**A077456**	**002**	Dec 05, 2005
AB	**!**		**600MG**	**A077456**	**003**	Dec 05, 2005
AB		SANDOZ	**200MG**	**A077743**	**001**	Oct 03, 2006
AB		ZYDUS PHARMS USA	**200MG**	**A077094**	**001**	Dec 05, 2005
AB			**400MG**	**A077094**	**002**	Mar 16, 2007
AB			**500MG**	**A077094**	**004**	Apr 18, 2008
AB			**600MG**	**A077094**	**003**	Mar 16, 2007

RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI

+!	NOVARTIS	EQ 200MG BASE	N209092	001	Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS;OPHTHALMIC

PHOTREXA

+!	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

+!	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016

RIFABUTIN

CAPSULE;ORAL

MYCOBUTIN

AB	**+!**	PHARMACIA AND UPJOHN	**150MG**	**N050689**	**001**	Dec 23, 1992

RIFABUTIN

AB		LUPIN LTD	**150MG**	**A090033**	**001**	Feb 24, 2014

RIFAMPIN

CAPSULE;ORAL

RIFADIN						
AB		SANOFI AVENTIS US	**150MG**	**A062303**	**001**	
AB	**+!**		**300MG**	**N050420**	**001**	
RIFAMPIN						
AB		AKORN	**150MG**	**A065028**	**001**	Mar 14, 2001
AB			**300MG**	**A065028**	**002**	Mar 14, 2001
AB		LANNETT CO INC	**150MG**	**A065390**	**001**	Mar 28, 2008
AB			**300MG**	**A065390**	**002**	Mar 28, 2008
AB		LUPIN PHARMS	**150MG**	**A090034**	**001**	Aug 21, 2013
AB			**300MG**	**A090034**	**002**	Aug 21, 2013
AB		SANDOZ	**150MG**	**A064150**	**002**	Jan 02, 1998
AB			**300MG**	**A064150**	**001**	May 28, 1997
RIMACTANE						
AB		OXFORD PHARMS	**300MG**	**N050429**	**001**	

INJECTABLE;INJECTION

RIFADIN						
AP	**+!**	SANOFI AVENTIS US	**600MG/VIAL**	**N050627**	**001**	May 25, 1989
RIFAMPIN						
AP		AKORN	**600MG/VIAL**	**A065502**	**001**	Sep 21, 2010
AP		EMCURE PHARMS LTD	**600MG/VIAL**	**A204101**	**001**	Aug 18, 2014
AP		FRESENIUS KABI USA	**600MG/VIAL**	**A091181**	**001**	Aug 21, 2014
AP		HIKMA PHARMS	**600MG/VIAL**	**A205039**	**001**	Mar 03, 2016
AP		MYLAN LABS LTD	**600MG/VIAL**	**A065421**	**001**	May 22, 2008
AP		WATSON PHARMS TEVA	**600MG/VIAL**	**A206736**	**001**	Jan 19, 2016
AP		WEST-WARD PHARMS INT	**600MG/VIAL**	**A064217**	**001**	Oct 29, 1999

RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE;ORAL

AEMCOLO						
	+!	REDHILL	EQ 194MG BASE	N210910	001	Nov 16, 2018

RIFAPENTINE

TABLET;ORAL

PRIFTIN						
	+!	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998

RIFAXIMIN

TABLET;ORAL

XIFAXAN						
	+!	SALIX PHARMS	200MG	N021361	001	May 25, 2004
	+!		550MG	N022554	001	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT						
	+!	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011

RILUZOLE

FILM;ORAL

EXSERVAN						
	+!	AQUESTIVE THERAP	50MG	N212640	001	Nov 22, 2019

SUSPENSION;ORAL

TIGLUTIK KIT						
	+!	ITALFARMACO SPA	50MG/10ML	N209080	001	Sep 05, 2018

TABLET;ORAL

RILUTEK						
AB	**+!**	COVIS PHARMA BV	**50MG**	**N020599**	**001**	Dec 12, 1995
RILUZOLE						
AB		ALKEM LABS LTD	**50MG**	**A204048**	**001**	Mar 30, 2016
AB		APOTEX CORP	**50MG**	**A091300**	**001**	Jun 18, 2013
AB		GLENMARK PHARMS LTD	**50MG**	**A091394**	**001**	Jun 18, 2013
AB		IMPAX LABS	**50MG**	**A076173**	**001**	Jan 29, 2003
AB		MYLAN PHARMS INC	**50MG**	**A203042**	**001**	Jul 01, 2013
AB		STANDARD CHEM PHARM	**50MG**	**A206045**	**001**	Dec 09, 2019
AB		SUN PHARM INDS LTD	**50MG**	**A091417**	**001**	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

FLUMADINE						
AB	**+!**	SUN PHARM INDS INC	**100MG**	**N019649**	**001**	Sep 17, 1993
RIMANTADINE HYDROCHLORIDE						
AB		IMPAX LABS	**100MG**	**A076132**	**001**	Aug 30, 2002

RIOCIGUAT

TABLET;ORAL

ADEMPAS

	+	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013
	+		1MG	N204819	002	Oct 08, 2013
	+		1.5MG	N204819	003	Oct 08, 2013
	+		2MG	N204819	004	Oct 08, 2013
	+!		2.5MG	N204819	005	Oct 08, 2013

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

AB	**+**	APIL	**5MG**	**N020835**	**002**	Apr 14, 2000
AB	**+**		**30MG**	**N020835**	**001**	Mar 27, 1998
AB	**+!**		**35MG**	**N020835**	**003**	May 25, 2002
AB	**+!**		**150MG**	**N020835**	**005**	Apr 22, 2008

RISEDRONATE SODIUM

AB		APOTEX INC	**35MG**	**A090877**	**001**	Nov 30, 2015
AB			**75MG**	**A090877**	**002**	Jun 10, 2014
AB			**150MG**	**A090877**	**003**	Jun 10, 2014
AB		AUROBINDO PHARMA LTD	**5MG**	**A200296**	**001**	Nov 30, 2015
AB			**30MG**	**A200296**	**002**	Nov 30, 2015
AB			**35MG**	**A200296**	**003**	Nov 30, 2015
AB			**150MG**	**A206768**	**001**	Oct 21, 2016
AB		MACLEODS PHARMS LTD	**5MG**	**A203533**	**001**	Dec 09, 2015
AB			**30MG**	**A203533**	**002**	Dec 09, 2015
AB			**35MG**	**A203533**	**003**	Nov 29, 2016
AB		ORCHID HLTHCARE	**30MG**	**A205280**	**001**	May 13, 2019
AB			**35MG**	**A205280**	**002**	May 13, 2019
AB		SUN PHARM	**5MG**	**A090886**	**001**	Nov 30, 2015
AB			**30MG**	**A090886**	**002**	Nov 30, 2015
AB			**35MG**	**A090886**	**003**	Nov 30, 2015
AB			**75MG**	**A090886**	**004**	Jun 10, 2014
AB			**150MG**	**A090886**	**005**	Jun 10, 2014
AB		TEVA PHARMS USA	**5MG**	**A077132**	**001**	Oct 05, 2007
AB			**30MG**	**A077132**	**002**	Oct 05, 2007
AB			**35MG**	**A077132**	**003**	Oct 05, 2007
AB			**150MG**	**A079215**	**001**	Jun 13, 2014

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	**+!**	APIL	**35MG**	**N022560**	**001**	Oct 08, 2010

RISEDRONATE SODIUM

AB		SUN PHARM	**35MG**	**A203925**	**001**	Jul 09, 2019
AB		TEVA PHARMS USA	**35MG**	**A203217**	**001**	May 18, 2015

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

	+	INDIVIOR INC	90MG	N210655	001	Jul 27, 2018
	+!		120MG	N210655	002	Jul 27, 2018

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
	+!		25MG/VIAL	N021346	001	Oct 29, 2003
	+		37.5MG/VIAL	N021346	002	Oct 29, 2003
	+		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION;ORAL

RISPERDAL

AA	**+!**	JANSSEN PHARMS	**1MG/ML**	**N020588**	**001**	Jun 10, 1996

RISPERIDONE

AA		AMNEAL PHARMS	**1MG/ML**	**A091384**	**001**	May 25, 2011
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A078452**	**001**	Sep 04, 2009
AA		HIKMA	**1MG/ML**	**A076904**	**001**	Jul 29, 2009
AA		LANNETT CO INC	**1MG/ML**	**A079158**	**001**	Dec 03, 2010
AA		PHARM ASSOC	**1MG/ML**	**A077719**	**001**	Jul 29, 2009
AA		TARO	**1MG/ML**	**A090347**	**001**	Feb 07, 2011
AA		TRIS PHARMA INC	**1MG/ML**	**A079059**	**001**	Dec 12, 2012

TABLET;ORAL

RISPERDAL

AB	**+**	JANSSEN PHARMS	**0.25MG**	**N020272**	**008**	May 10, 1999
AB	**+**		**0.5MG**	**N020272**	**007**	Jan 27, 1999
AB	**+!**		**1MG**	**N020272**	**001**	Dec 29, 1993

RISPERIDONE

TABLET;ORAL

RISPERDAL

AB	+		**2MG**	**N020272**	**002**	Dec 29, 1993
AB	+		**3MG**	**N020272**	**003**	Dec 29, 1993
AB	+		**4MG**	**N020272**	**004**	Dec 29, 1993

RISPERIDONE

AB	AJANTA PHARMA LTD	**0.25MG**	**A201003**	**001**	Aug 24, 2011
AB		**0.5MG**	**A201003**	**002**	Aug 24, 2011
AB		**1MG**	**A201003**	**003**	Aug 24, 2011
AB		**2MG**	**A201003**	**004**	Aug 24, 2011
AB		**3MG**	**A201003**	**005**	Aug 24, 2011
AB		**4MG**	**A201003**	**006**	Aug 24, 2011
AB	APOTEX INC	**0.25MG**	**A077953**	**001**	Sep 15, 2008
AB		**0.5MG**	**A077953**	**002**	Sep 15, 2008
AB		**1MG**	**A077953**	**003**	Sep 15, 2008
AB		**2MG**	**A077953**	**004**	Sep 15, 2008
AB		**3MG**	**A077953**	**005**	Sep 15, 2008
AB		**4MG**	**A077953**	**006**	Sep 15, 2008
AB	CELLTRION	**0.25MG**	**A078871**	**001**	Oct 09, 2008
AB		**0.5MG**	**A078871**	**002**	Oct 09, 2008
AB		**1MG**	**A078871**	**003**	Oct 09, 2008
AB		**2MG**	**A078871**	**004**	Oct 09, 2008
AB		**3MG**	**A078871**	**005**	Oct 09, 2008
AB		**4MG**	**A078871**	**006**	Oct 09, 2008
AB	CHARTWELL MOLECULAR	**0.25MG**	**A077543**	**001**	May 18, 2011
AB		**0.5MG**	**A077543**	**002**	May 18, 2011
AB		**1MG**	**A077543**	**003**	May 18, 2011
AB		**2MG**	**A077543**	**004**	May 18, 2011
AB		**3MG**	**A077543**	**005**	May 18, 2011
AB		**4MG**	**A077543**	**006**	May 18, 2011
AB	DR REDDYS LABS LTD	**0.25MG**	**A076879**	**001**	Oct 24, 2008
AB		**0.5MG**	**A076879**	**002**	Oct 24, 2008
AB		**1MG**	**A076879**	**003**	Oct 24, 2008
AB		**2MG**	**A076879**	**004**	Oct 24, 2008
AB		**3MG**	**A076879**	**005**	Oct 24, 2008
AB		**4MG**	**A076879**	**006**	Oct 24, 2008
AB	MYLAN	**0.25MG**	**A076288**	**001**	Sep 15, 2008
AB		**0.5MG**	**A076288**	**002**	Sep 15, 2008
AB		**1MG**	**A076288**	**003**	Sep 15, 2008
AB		**2MG**	**A076288**	**004**	Sep 15, 2008
AB		**3MG**	**A076288**	**005**	Sep 15, 2008
AB		**4MG**	**A076288**	**006**	Sep 15, 2008
AB	OXFORD PHARMS	**0.25MG**	**A078071**	**001**	Jun 17, 2009
AB		**0.5MG**	**A078071**	**002**	Jun 17, 2009
AB		**1MG**	**A078071**	**003**	Jun 17, 2009
AB		**2MG**	**A078071**	**004**	Jun 17, 2009
AB		**3MG**	**A078071**	**005**	Jun 17, 2009
AB		**4MG**	**A078071**	**006**	Jun 17, 2009
AB	PRINSTON INC	**0.25MG**	**A077493**	**001**	Nov 29, 2011
AB		**0.5MG**	**A077493**	**002**	Nov 29, 2011
AB		**1MG**	**A077493**	**003**	Nov 29, 2011
AB		**2MG**	**A077493**	**004**	Nov 29, 2011
AB		**3MG**	**A077493**	**005**	Nov 29, 2011
AB		**4MG**	**A077493**	**006**	Nov 29, 2011
AB	RENATA	**0.25MG**	**A078707**	**001**	Dec 29, 2008
AB		**0.5MG**	**A078707**	**002**	Dec 29, 2008
AB		**1MG**	**A078707**	**003**	Dec 29, 2008
AB		**2MG**	**A078707**	**004**	Dec 29, 2008
AB		**3MG**	**A078707**	**005**	Dec 29, 2008
AB		**4MG**	**A078707**	**006**	Dec 29, 2008
AB	RISING	**0.25MG**	**A078269**	**001**	Oct 08, 2008
AB		**0.5MG**	**A078269**	**002**	Oct 08, 2008
AB		**1MG**	**A078269**	**003**	Oct 08, 2008
AB		**2MG**	**A078269**	**004**	Oct 08, 2008
AB		**3MG**	**A078269**	**005**	Oct 08, 2008
AB		**4MG**	**A078269**	**006**	Oct 08, 2008
AB	SANDOZ	**0.25MG**	**A078528**	**001**	Oct 16, 2009
AB		**0.5MG**	**A078528**	**002**	Oct 16, 2009
AB		**1MG**	**A078528**	**003**	Oct 16, 2009
AB		**2MG**	**A078528**	**004**	Oct 16, 2009
AB		**3MG**	**A078528**	**005**	Oct 16, 2009

RISPERIDONE

TABLET;ORAL

RISPERIDONE

AB			**4MG**	**A078528**	**006**	Oct 16, 2009
AB		TORRENT PHARMS	**0.25MG**	**A079088**	**001**	Oct 30, 2008
AB			**0.5MG**	**A079088**	**002**	Oct 30, 2008
AB			**1MG**	**A079088**	**003**	Oct 30, 2008
AB			**2MG**	**A079088**	**004**	Oct 30, 2008
AB			**3MG**	**A079088**	**005**	Oct 30, 2008
AB			**4MG**	**A079088**	**006**	Oct 30, 2008
AB		ZYDUS PHARMS USA INC	**0.25MG**	**A078040**	**001**	Oct 16, 2008
AB			**0.5MG**	**A078040**	**002**	Oct 16, 2008
AB			**1MG**	**A078040**	**003**	Oct 16, 2008
AB			**2MG**	**A078040**	**004**	Oct 16, 2008
AB			**3MG**	**A078040**	**005**	Oct 16, 2008
AB			**4MG**	**A078040**	**006**	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERDAL

AB	+	JANSSEN PHARMS	**0.5MG**	**N021444**	**001**	Apr 02, 2003
AB	+!		**1MG**	**N021444**	**002**	Apr 02, 2003
AB	+		**2MG**	**N021444**	**003**	Apr 02, 2003
AB	+		**3MG**	**N021444**	**004**	Dec 23, 2004
AB	+		**4MG**	**N021444**	**005**	Dec 23, 2004

RISPERIDONE

AB		ACTAVIS LABS FL INC	**0.5MG**	**A076996**	**001**	Apr 19, 2011
AB			**1MG**	**A076996**	**002**	Apr 19, 2011
AB			**2MG**	**A076996**	**003**	Apr 19, 2011
AB			**3MG**	**A076996**	**004**	Apr 19, 2011
AB			**4MG**	**A076996**	**005**	Apr 19, 2011
AB		DR REDDYS LABS LTD	**0.5MG**	**A077328**	**001**	Feb 24, 2009
AB			**1MG**	**A077328**	**002**	Oct 05, 2009
AB			**2MG**	**A077328**	**003**	Feb 24, 2009
AB			**3MG**	**A077328**	**004**	Nov 30, 2009
AB			**4MG**	**A077328**	**005**	Nov 30, 2009
AB		HERITAGE PHARMA	**0.5MG**	**A076908**	**001**	Mar 12, 2012
AB			**1MG**	**A076908**	**002**	Mar 12, 2012
AB			**2MG**	**A076908**	**003**	Mar 12, 2012
AB		JUBILANT GENERICS	**0.5MG**	**A090839**	**001**	Nov 04, 2011
AB			**1MG**	**A090839**	**002**	Nov 04, 2011
AB			**2MG**	**A090839**	**003**	Nov 04, 2011
AB			**3MG**	**A090839**	**004**	Nov 04, 2011
AB			**4MG**	**A090839**	**005**	Nov 04, 2011
AB		PAR PHARM	**0.5MG**	**A077494**	**002**	Apr 30, 2009
AB			**1MG**	**A077494**	**003**	Oct 26, 2009
AB			**2MG**	**A077494**	**004**	Apr 30, 2009
AB			**3MG**	**A077494**	**005**	Apr 30, 2009
AB			**4MG**	**A077494**	**006**	Apr 30, 2009
AB		SANDOZ	**0.5MG**	**A078116**	**001**	Dec 22, 2009
AB			**1MG**	**A078116**	**002**	Dec 22, 2009
AB			**2MG**	**A078116**	**003**	Dec 22, 2009
AB			**3MG**	**A078116**	**004**	Dec 22, 2009
AB			**4MG**	**A078116**	**005**	Dec 22, 2009
AB		SUN PHARM INDS LTD	**0.5MG**	**A077542**	**001**	Aug 06, 2010
AB			**0.5MG**	**A078464**	**001**	Apr 08, 2013
AB			**1MG**	**A077542**	**002**	Aug 06, 2010
AB			**1MG**	**A078464**	**002**	Apr 08, 2013
AB			**2MG**	**A077542**	**003**	Aug 06, 2010
AB			**2MG**	**A078464**	**003**	Apr 08, 2013
AB			**3MG**	**A078464**	**004**	Apr 08, 2013
AB			**3MG**	**A078474**	**001**	Aug 06, 2010
AB			**4MG**	**A078464**	**005**	Apr 08, 2013
AB			**4MG**	**A078474**	**002**	Aug 06, 2010
AB		ZYDUS PHARMS USA	**0.5MG**	**A078516**	**001**	May 01, 2009
AB			**2MG**	**A078516**	**003**	May 01, 2009
		PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

RITONAVIR

POWDER;ORAL

NORVIR

	+!	ABBVIE INC	100MG/PACKET	N209512	001	Jun 07, 2017

SOLUTION;ORAL

NORVIR

	+!	ABBVIE	80MG/ML	N020659	001	Mar 01, 1996

TABLET;ORAL

NORVIR

AB	**+!**	ABBVIE	**100MG**	**N022417**	**001**	Feb 10, 2010

RITONAVIR

AB		AMNEAL PHARMS LLC	**100MG**	**A208890**	**001**	Sep 17, 2018
AB		AUROBINDO PHARMA LTD	**100MG**	**A206614**	**001**	Sep 17, 2018
AB		HETERO LABS LTD III	**100MG**	**A204587**	**001**	Sep 17, 2018
AB		HIKMA	**100MG**	**A202573**	**001**	Jan 15, 2015

RIVAROXABAN

TABLET;ORAL

XARELTO

	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018
	+		10MG	N022406	001	Jul 01, 2011
	+		15MG	N022406	002	Nov 04, 2011
	+!		20MG	N022406	003	Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

AB	**+**	NOVARTIS	**4.6MG/24HR**	**N022083**	**001**	Jul 06, 2007
AB	**+!**		**9.5MG/24HR**	**N022083**	**002**	Jul 06, 2007
AB	**+**		**13.3MG/24HR**	**N022083**	**005**	Aug 31, 2012

RIVASTIGMINE

AB		ALVOGEN	**4.6MG/24HR**	**A204403**	**001**	Sep 03, 2015
AB			**9.5MG/24HR**	**A204403**	**002**	Sep 03, 2015
AB			**13.3MG/24HR**	**A204403**	**003**	Aug 31, 2015
AB		AMNEAL PHARMS	**4.6MG/24HR**	**A207308**	**001**	Jan 08, 2019
AB			**9.5MG/24HR**	**A207308**	**002**	Jan 08, 2019
AB			**13.3MG/24HR**	**A207308**	**003**	Jan 08, 2019
AB		BRECKENRIDGE	**4.6MG/24HR**	**A209063**	**001**	Nov 26, 2019
AB			**9.5MG/24HR**	**A209063**	**002**	Nov 26, 2019
AB			**13.3MG/24HR**	**A209063**	**003**	Nov 26, 2019
AB		MYLAN TECHNOLOGIES	**4.6MG/24HR**	**A205622**	**001**	Jun 20, 2018
AB			**9.5MG/24HR**	**A205622**	**002**	Jun 20, 2018
AB			**13.3MG/24HR**	**A205622**	**003**	Jun 20, 2018
AB		ZYDUS NOVELTECH INC	**4.6MG/24HR**	**A206318**	**001**	Mar 04, 2019
AB			**9.5MG/24HR**	**A206318**	**002**	Mar 04, 2019
AB			**13.3MG/24HR**	**A206318**	**003**	Mar 04, 2019

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		ALEMBIC PHARMS LTD	**EQ 1.5MG BASE**	**A091689**	**001**	Jun 12, 2012
AB			**EQ 3MG BASE**	**A091689**	**002**	Jun 12, 2012
AB			**EQ 4.5MG BASE**	**A091689**	**003**	Jun 12, 2012
AB			**EQ 6MG BASE**	**A091689**	**004**	Jun 12, 2012
AB		APOTEX INC	**EQ 1.5MG BASE**	**A091072**	**001**	May 16, 2013
AB			**EQ 3MG BASE**	**A091072**	**002**	May 16, 2013
AB			**EQ 4.5MG BASE**	**A091072**	**003**	May 16, 2013
AB			**EQ 6MG BASE**	**A091072**	**004**	May 16, 2013
AB		AUROBINDO PHARMA LTD	**EQ 1.5MG BASE**	**A204572**	**001**	Mar 25, 2016
AB			**EQ 3MG BASE**	**A204572**	**002**	Mar 25, 2016
AB			**EQ 4.5MG BASE**	**A204572**	**003**	Mar 25, 2016
AB			**EQ 6MG BASE**	**A204572**	**004**	Mar 25, 2016
AB		CADILA PHARMS LTD	**EQ 1.5MG BASE**	**A203844**	**001**	Feb 13, 2017
AB			**EQ 3MG BASE**	**A203844**	**002**	Feb 13, 2017
AB			**EQ 4.5MG BASE**	**A203844**	**003**	Feb 13, 2017
AB			**EQ 6MG BASE**	**A203844**	**004**	Feb 13, 2017
AB		CHARTWELL RX	**EQ 1.5MG BASE**	**A207797**	**001**	Sep 28, 2017
AB			**EQ 3MG BASE**	**A207797**	**002**	Sep 28, 2017
AB			**EQ 4.5MG BASE**	**A207797**	**003**	Sep 28, 2017
AB			**EQ 6MG BASE**	**A207797**	**004**	Sep 28, 2017
AB	**!**	DR REDDYS LABS INC	**EQ 1.5MG BASE**	**A077130**	**001**	Oct 31, 2007
AB			**EQ 3MG BASE**	**A077130**	**002**	Oct 31, 2007

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE						
AB			**EQ 4.5MG BASE**	**A077130**	**003**	Oct 31, 2007
AB	**!**		**EQ 6MG BASE**	**A077130**	**004**	Oct 31, 2007
AB		MACLEODS PHARMS LTD	**EQ 1.5MG BASE**	**A203148**	**001**	Aug 22, 2014
AB			**EQ 3MG BASE**	**A203148**	**002**	Aug 22, 2014
AB			**EQ 4.5MG BASE**	**A203148**	**003**	Aug 22, 2014
AB			**EQ 6MG BASE**	**A203148**	**004**	Aug 22, 2014
AB		ORCHID HLTHCARE	**EQ 1.5MG BASE**	**A090879**	**001**	Jun 10, 2015
AB			**EQ 3MG BASE**	**A090879**	**002**	Jun 10, 2015
AB			**EQ 4.5MG BASE**	**A090879**	**003**	Jun 10, 2015
AB			**EQ 6MG BASE**	**A090879**	**004**	Jun 10, 2015
AB		SUN PHARM	**EQ 1.5MG BASE**	**A077131**	**001**	Oct 22, 2007
AB			**EQ 3MG BASE**	**A077131**	**002**	Oct 22, 2007
AB			**EQ 4.5MG BASE**	**A077131**	**003**	Oct 22, 2007
AB			**EQ 6MG BASE**	**A077131**	**004**	Oct 22, 2007
AB		WATSON LABS	**EQ 1.5MG BASE**	**A077129**	**001**	Jan 08, 2008
AB			**EQ 3MG BASE**	**A077129**	**002**	Jan 08, 2008
AB			**EQ 4.5MG BASE**	**A077129**	**003**	Jan 08, 2008
AB			**EQ 6MG BASE**	**A077129**	**004**	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT						
AB	**+!**	MERCK	**EQ 10MG BASE**	**N020864**	**002**	Jun 29, 1998
RIZATRIPTAN BENZOATE						
AB		ALKEM LABS LTD	**EQ 5MG BASE**	**A203269**	**001**	Feb 18, 2016
AB			**EQ 10MG BASE**	**A203269**	**002**	Feb 18, 2016
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202490**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A202490**	**002**	Dec 31, 2012
AB		CELLTRION	**EQ 5MG BASE**	**A077526**	**001**	Mar 26, 2013
AB			**EQ 10MG BASE**	**A077526**	**002**	Mar 26, 2013
AB		ECI PHARMS LLC	**EQ 5MG BASE**	**A202047**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A202047**	**002**	Dec 31, 2012
AB		EMCURE PHARMS LTD	**EQ 5MG BASE**	**A204090**	**001**	Nov 26, 2013
AB			**EQ 10MG BASE**	**A204090**	**002**	Nov 26, 2013
AB		GLENMARK GENERICS	**EQ 5MG BASE**	**A201967**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A201967**	**002**	Dec 31, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A204339**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A204339**	**002**	Jul 01, 2013
AB		JUBILANT GENERICS	**EQ 5MG BASE**	**A203252**	**001**	Dec 31, 2014
AB			**EQ 10MG BASE**	**A203252**	**002**	Dec 31, 2014
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203147**	**001**	Feb 11, 2014
AB			**EQ 10MG BASE**	**A203147**	**002**	Feb 11, 2014
AB		MYLAN PHARMS INC	**EQ 5MG BASE**	**A201993**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A201993**	**002**	Dec 31, 2012
AB		NATCO PHARMA LTD	**EQ 5MG BASE**	**A200482**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A200482**	**002**	Dec 31, 2012
AB		SANDOZ	**EQ 5MG BASE**	**A079230**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A079230**	**002**	Dec 31, 2012
AB		TEVA PHARMS	**EQ 5MG BASE**	**A077263**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A077263**	**002**	Dec 31, 2012
AB		UNICHEM LABS LTD	**EQ 5MG BASE**	**A207836**	**001**	Mar 07, 2017
AB			**EQ 10MG BASE**	**A207836**	**002**	Mar 07, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT						
AB	**+!**	MERCK	**EQ 10MG BASE**	**N020865**	**002**	Jun 29, 1998
RIZATRIPTAN BENZOATE						
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A203062**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203062**	**002**	Jul 01, 2013
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE**	**A201914**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A201914**	**002**	Jul 01, 2013
AB		JUBILANT GENERICS	**EQ 5MG BASE**	**A203334**	**001**	Oct 16, 2015
AB			**EQ 10MG BASE**	**A203334**	**002**	Oct 16, 2015
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203146**	**001**	Sep 19, 2014
AB			**EQ 10MG BASE**	**A203146**	**002**	Sep 19, 2014
AB		MYLAN PHARMS INC	**EQ 5MG BASE**	**A078173**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A078173**	**002**	Dec 31, 2012
AB		NATCO PHARMA LTD	**EQ 5MG BASE**	**A203478**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203478**	**002**	Jul 01, 2013

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB		PANACEA BIOTEC LTD	**EQ 5MG BASE**	**A204722**	**001**	Jan 11, 2017
AB			**EQ 10MG BASE**	**A204722**	**002**	Jan 11, 2017
AB		SANDOZ	**EQ 5MG BASE**	**A078739**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A078739**	**002**	Jul 01, 2013
AB		UNICHEM LABS LTD	**EQ 5MG BASE**	**A207835**	**001**	Mar 07, 2017
AB			**EQ 10MG BASE**	**A207835**	**002**	Mar 07, 2017

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		AUROBINDO PHARMA LTD	**50MG/5ML (10MG/ML)**	**A206206**	**001**	Apr 12, 2017
AP			**100MG/10ML (10MG/ML)**	**A206206**	**002**	Apr 12, 2017
AP		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A078651**	**001**	Dec 29, 2008
AP			**100MG/10ML (10MG/ML)**	**A078651**	**002**	Dec 29, 2008
AP		GLAND PHARMA LTD	**50MG/5ML (10MG/ML)**	**A205656**	**001**	Apr 04, 2018
AP			**100MG/10ML (10MG/ML)**	**A205656**	**002**	Apr 04, 2018
AP		HOSPIRA	**50MG/5ML (10MG/ML)**	**A078519**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A078519**	**002**	Nov 26, 2008
AP		MYLAN INSTITUTIONAL	**50MG/5ML (10MG/ML)**	**A079199**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A079199**	**002**	Nov 26, 2008
AP		SAGENT PHARMS INC	**50MG/5ML (10MG/ML)**	**A091458**	**001**	Jul 28, 2010
AP			**100MG/10ML (10MG/ML)**	**A091458**	**002**	Jul 28, 2010
AP	**!**	SANDOZ INC	**50MG/5ML (10MG/ML)**	**A079195**	**001**	Dec 05, 2008
AP	**!**		**100MG/10ML (10MG/ML)**	**A079195**	**002**	Dec 05, 2008
AP		SANOVEL ILAC	**50MG/5ML (10MG/ML)**	**A210437**	**001**	Aug 13, 2019
AP			**100MG/10ML (10MG/ML)**	**A210437**	**002**	Aug 13, 2019
AP		TAMARANG	**50MG/5ML (10MG/ML)**	**A091115**	**001**	Aug 27, 2012
AP			**100MG/10ML (10MG/ML)**	**A091115**	**002**	Aug 27, 2012
AP		TEVA PHARMS	**50MG/5ML (10MG/ML)**	**A078717**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A078717**	**002**	Nov 26, 2008
AP		WEST WARD PHARM CORP	**50MG/5ML (10MG/ML)**	**A204679**	**001**	Feb 28, 2017
AP			**100MG/10ML (10MG/ML)**	**A204679**	**002**	Feb 28, 2017

ROFLUMILAST

TABLET;ORAL

DALIRESP

AB	**+!**	ASTRAZENECA PHARMS	**500MCG**	**N022522**	**001**	Feb 28, 2011

ROFLUMILAST

AB		BRECKENRIDGE	**500MCG**	**A208236**	**001**	Oct 03, 2018
AB		HETERO LABS LTD III	**500MCG**	**A208213**	**001**	Nov 23, 2018
AB		MICRO LABS	**500MCG**	**A208180**	**001**	Mar 22, 2019
AB		TORRENT	**500MCG**	**A208272**	**001**	Aug 06, 2018

DALIRESP

	+	ASTRAZENECA PHARMS	250MCG	N022522	002	Jan 23, 2018

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL

VARUBI

	+!	TERSERA THERAPS LLC	EQ 90MG BASE	N206500	001	Sep 01, 2015

ROMIDEPSIN

POWDER;INTRAVENOUS

ISTODAX

	+!	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

REQUIP

AB	**+!**	GLAXOSMITHKLINE LLC	**EQ 0.25MG BASE**	**N020658**	**001**	Sep 19, 1997
AB	**+**		**EQ 0.5MG BASE**	**N020658**	**002**	Sep 19, 1997
AB	**+**		**EQ 1MG BASE**	**N020658**	**003**	Sep 19, 1997
AB	**+**		**EQ 2MG BASE**	**N020658**	**004**	Sep 19, 1997
AB	**+**		**EQ 3MG BASE**	**N020658**	**006**	Jan 27, 1999
AB	**+**		**EQ 4MG BASE**	**N020658**	**007**	Jan 27, 1999
AB	**+**		**EQ 5MG BASE**	**N020658**	**005**	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 0.25MG BASE**	**A204022**	**001**	Feb 28, 2017
AB			**EQ 0.5MG BASE**	**A204022**	**002**	Feb 28, 2017
AB			**EQ 1MG BASE**	**A204022**	**003**	Feb 28, 2017
AB			**EQ 2MG BASE**	**A204022**	**004**	Feb 28, 2017

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		EQ 3MG BASE	A204022	005	Feb 28, 2017
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017
AB	ALEMBIC LTD	EQ 0.25MG BASE	A090429	001	Mar 24, 2010
AB		EQ 0.5MG BASE	A090429	002	Mar 24, 2010
AB		EQ 1MG BASE	A090429	003	Mar 24, 2010
AB		EQ 2MG BASE	A090429	004	Mar 24, 2010
AB		EQ 3MG BASE	A090429	005	Mar 24, 2010
AB		EQ 4MG BASE	A090429	006	Mar 24, 2010
AB		EQ 5MG BASE	A090429	007	Mar 24, 2010
AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009
AB	CELLTRION	EQ 0.25MG BASE	A079050	001	May 29, 2008
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008
AB		EQ 1MG BASE	A079050	003	May 29, 2008
AB		EQ 2MG BASE	A079050	004	May 29, 2008
AB		EQ 3MG BASE	A079050	005	May 29, 2008
AB		EQ 4MG BASE	A079050	006	May 29, 2008
AB		EQ 5MG BASE	A079050	007	May 29, 2008
AB	GLENMARK GENERICS	EQ 0.25MG BASE	A090135	001	Feb 25, 2010
AB		EQ 0.5MG BASE	A090135	002	Feb 25, 2010
AB		EQ 1MG BASE	A090135	003	Feb 25, 2010
AB		EQ 2MG BASE	A090135	004	Feb 25, 2010
AB		EQ 3MG BASE	A090135	005	Feb 25, 2010
AB		EQ 4MG BASE	A090135	006	Feb 25, 2010
AB		EQ 5MG BASE	A090135	007	Feb 25, 2010
AB	HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008
AB		EQ 0.5MG BASE	A077852	002	May 05, 2008
AB		EQ 1MG BASE	A077852	003	May 05, 2008
AB		EQ 2MG BASE	A077852	004	May 05, 2008
AB		EQ 3MG BASE	A077852	005	May 05, 2008
AB		EQ 4MG BASE	A077852	006	May 05, 2008
AB		EQ 5MG BASE	A077852	007	May 19, 2008
AB	MLV	EQ 0.25MG BASE	A079165	001	Feb 07, 2012
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012
AB	MYLAN	EQ 0.25MG BASE	A078881	001	May 05, 2008
AB		EQ 0.5MG BASE	A078881	002	May 05, 2008
AB		EQ 1MG BASE	A078881	003	May 05, 2008
AB		EQ 2MG BASE	A078881	004	May 05, 2008
AB		EQ 3MG BASE	A078881	005	May 05, 2008
AB		EQ 4MG BASE	A078881	006	May 05, 2008
AB		EQ 5MG BASE	A078881	007	May 19, 2008
AB	ORCHID HLTHCARE	EQ 0.25MG BASE	A079229	001	Nov 28, 2012
AB		EQ 0.5MG BASE	A079229	002	Nov 28, 2012
AB		EQ 1MG BASE	A079229	003	Nov 28, 2012
AB		EQ 2MG BASE	A079229	004	Nov 28, 2012
AB		EQ 3MG BASE	A079229	005	Nov 28, 2012
AB		EQ 4MG BASE	A079229	006	Nov 28, 2012
AB		EQ 5MG BASE	A079229	007	Nov 28, 2012
AB	PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008
AB		EQ 0.5MG BASE	A078110	002	May 05, 2008
AB		EQ 1MG BASE	A078110	003	May 05, 2008
AB		EQ 2MG BASE	A078110	004	May 05, 2008
AB		EQ 3MG BASE	A078110	005	May 05, 2008
AB		EQ 4MG BASE	A078110	006	May 05, 2008
AB		EQ 5MG BASE	A078110	007	Jul 11, 2008

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

AB	+! GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

AB	+		**EQ 6MG BASE**	**N022008**	**006**	Apr 10, 2009
AB	+		**EQ 8MG BASE**	**N022008**	**004**	Jun 13, 2008
AB	+		**EQ 12MG BASE**	**N022008**	**005**	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090869**	**001**	May 17, 2012
AB		**EQ 4MG BASE**	**A090869**	**002**	May 17, 2012
AB		**EQ 6MG BASE**	**A090869**	**003**	May 17, 2012
AB		**EQ 8MG BASE**	**A090869**	**004**	May 17, 2012
AB		**EQ 12MG BASE**	**A090869**	**005**	May 17, 2012
AB	ALEMBIC PHARMS LTD	**EQ 2MG BASE**	**A202786**	**001**	Apr 22, 2013
AB		**EQ 4MG BASE**	**A202786**	**002**	Apr 22, 2013
AB		**EQ 6MG BASE**	**A202786**	**003**	Apr 22, 2013
AB		**EQ 8MG BASE**	**A202786**	**004**	Apr 22, 2013
AB		**EQ 12MG BASE**	**A202786**	**005**	Apr 22, 2013
AB	CELLTRION	**EQ 2MG BASE**	**A091395**	**001**	Aug 27, 2012
AB		**EQ 4MG BASE**	**A091395**	**002**	Aug 27, 2012
AB		**EQ 6MG BASE**	**A091395**	**003**	Aug 27, 2012
AB		**EQ 8MG BASE**	**A091395**	**004**	Aug 27, 2012
AB		**EQ 12MG BASE**	**A091395**	**005**	Aug 27, 2012
AB	DR REDDYS LABS LTD	**EQ 2MG BASE**	**A201576**	**001**	Jun 06, 2012
AB		**EQ 4MG BASE**	**A201576**	**002**	Jun 06, 2012
AB		**EQ 6MG BASE**	**A201576**	**003**	Jun 06, 2012
AB		**EQ 8MG BASE**	**A201576**	**004**	Jun 06, 2012
AB		**EQ 12MG BASE**	**A201576**	**005**	Jun 06, 2012
AB	SANDOZ INC	**EQ 2MG BASE**	**A201047**	**001**	Jun 06, 2012
AB		**EQ 4MG BASE**	**A201047**	**003**	Jun 06, 2012
AB		**EQ 6MG BASE**	**A201047**	**004**	Jun 06, 2012
AB		**EQ 8MG BASE**	**A201047**	**005**	Jun 06, 2012
AB		**EQ 12MG BASE**	**A201047**	**006**	Jun 06, 2012
AB	WATSON LABS INC	**EQ 2MG BASE**	**A200431**	**001**	Jun 06, 2012
AB		**EQ 4MG BASE**	**A200431**	**002**	Jun 06, 2012
AB		**EQ 6MG BASE**	**A200431**	**003**	Jun 06, 2012
AB		**EQ 8MG BASE**	**A200431**	**004**	Jun 06, 2012
AB		**EQ 12MG BASE**	**A200431**	**005**	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

AP	+ FRESENIUS KABI USA	**20MG/10ML (2MG/ML)**	**N020533**	**001**	May 01, 1998
AP	+	**40MG/20ML (2MG/ML)**	**N020533**	**002**	Sep 24, 1996
AP	+	**100MG/20ML (5MG/ML)**	**N020533**	**003**	May 01, 1998
AP	+	**100MG/10ML (10MG/ML)**	**N020533**	**005**	Sep 24, 1996
AP	+	**150MG/20ML (7.5MG/ML)**	**N020533**	**004**	Sep 24, 1996
AP	+	**150MG/30ML (5MG/ML)**	**N020533**	**008**	Sep 24, 1996
AP	+	**200MG/100ML (2MG/ML)**	**N020533**	**006**	Sep 24, 1996
AP	+!	**200MG/20ML (10MG/ML)**	**N020533**	**011**	Sep 24, 1996
AP	+	**400MG/200ML (2MG/ML)**	**N020533**	**007**	Sep 24, 1996
AP	+	**500MG/100ML (5MG/ML)**	**N020533**	**009**	Jan 04, 2011
AP	+	**1GM/200ML (5MG/ML)**	**N020533**	**010**	Jan 04, 2011

ROPIVACAINE HYDROCHLORIDE

AP	AKORN	**200MG/100ML (2MG/ML)**	**A204636**	**001**	Mar 16, 2018
AP		**400MG/200ML (2MG/ML)**	**A204636**	**002**	Mar 16, 2018
AP	AKORN INC	**150MG/30ML (5MG/ML)**	**A203955**	**001**	Apr 11, 2016
AP	AUROBINDO PHARMA LTD	**40MG/20ML (2MG/ML)**	**A205612**	**001**	Jul 13, 2016
AP		**100MG/20ML (5MG/ML)**	**A205612**	**003**	Jul 13, 2016
AP		**100MG/10ML (10MG/ML)**	**A205612**	**006**	Jul 13, 2016
AP		**150MG/30ML (5MG/ML)**	**A205612**	**004**	Jul 13, 2016
AP		**150MG/20ML (7.5MG/ML)**	**A205612**	**005**	Jul 13, 2016
AP		**200MG/100ML (2MG/ML)**	**A205612**	**002**	Jul 13, 2016
AP		**200MG/20ML (10MG/ML)**	**A205612**	**007**	Jul 13, 2016
AP	HOSPIRA	**20MG/10ML (2MG/ML)**	**A090194**	**001**	Sep 23, 2014
AP		**40MG/20ML (2MG/ML)**	**A090194**	**005**	Sep 23, 2014
AP		**100MG/10ML (10MG/ML)**	**A090194**	**004**	Sep 23, 2014
AP		**150MG/30ML (5MG/ML)**	**A090194**	**002**	Sep 23, 2014
AP		**150MG/20ML (7.5MG/ML)**	**A090194**	**003**	Sep 23, 2014
AP		**200MG/20ML (10MG/ML)**	**A090194**	**006**	Sep 23, 2014
AP	INFORLIFE	**200MG/100ML (2MG/ML)**	**A206166**	**001**	Jun 11, 2018
AP		**400MG/200ML (2MG/ML)**	**A206166**	**002**	Jun 11, 2018
AP		**500MG/100ML (5MG/ML)**	**A206166**	**003**	Jun 11, 2018

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP			**1GM/200ML (5MG/ML)**	**A206166**	**004**	Jun 11, 2018
AP		MYLAN ASI	**40MG/20ML (2MG/ML)**	**A090318**	**001**	Sep 23, 2014
AP			**150MG/30ML (5MG/ML)**	**A090318**	**002**	Sep 23, 2014
AP			**150MG/20ML (7.5MG/ML)**	**A090318**	**003**	Sep 23, 2014
AP			**200MG/20ML (10MG/ML)**	**A090318**	**004**	Sep 23, 2014
AP		NAVINTA LLC	**150MG/30ML (5MG/ML)**	**A078601**	**002**	Jul 17, 2014
AP			**200MG/20ML (10MG/ML)**	**A078601**	**003**	Jul 17, 2014
AP		SOMERSET THERAPS LLC	**20MG/10ML (2MG/ML)**	**A207636**	**001**	Jun 15, 2018
AP			**40MG/20ML (2MG/ML)**	**A207636**	**002**	Jun 15, 2018
AP			**100MG/20ML (5MG/ML)**	**A207636**	**003**	Jun 15, 2018
AP			**100MG/10ML (10MG/ML)**	**A207636**	**006**	Jun 15, 2018
AP			**150MG/30ML (5MG/ML)**	**A207636**	**004**	Jun 15, 2018
AP			**150MG/20ML (7.5MG/ML)**	**A207636**	**005**	Jun 15, 2018
AP			**200MG/20ML (10MG/ML)**	**A207636**	**007**	Jun 15, 2018

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

+		SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999
+			EQ 4MG BASE	N021071	003	May 25, 1999

ROSUVASTATIN CALCIUM

CAPSULE;ORAL

EZALLOR

+		SUN PHARMA GLOBAL	EQ 5MG BASE	N208647	001	Dec 18, 2018
+			EQ 10MG BASE	N208647	002	Dec 18, 2018
+			EQ 20MG BASE	N208647	003	Dec 18, 2018
+!			EQ 40MG BASE	N208647	004	Dec 18, 2018

TABLET;ORAL

CRESTOR

AB	**+**	IPR	**5MG**	**N021366**	**002**	Aug 12, 2003
AB	**+**		**10MG**	**N021366**	**003**	Aug 12, 2003
AB	**+**		**20MG**	**N021366**	**004**	Aug 12, 2003
AB	**+!**		**40MG**	**N021366**	**005**	Aug 12, 2003

ROSUVASTATIN CALCIUM

AB		ACCORD HLTHCARE	**5MG**	**A206434**	**001**	Oct 31, 2016
AB			**10MG**	**A206434**	**002**	Oct 31, 2016
AB			**20MG**	**A206434**	**003**	Oct 31, 2016
AB			**40MG**	**A206434**	**004**	Oct 31, 2016
AB		ALKEM LABS LTD	**5MG**	**A206465**	**001**	Mar 21, 2017
AB			**10MG**	**A206465**	**002**	Mar 21, 2017
AB			**20MG**	**A206465**	**003**	Mar 21, 2017
AB			**40MG**	**A206465**	**004**	Mar 21, 2017
AB		ALLIED	**5MG**	**A079168**	**001**	Jul 19, 2016
AB			**10MG**	**A079168**	**002**	Jul 19, 2016
AB			**20MG**	**A079168**	**003**	Jul 19, 2016
AB			**40MG**	**A079168**	**004**	Jul 19, 2016
AB		APOTEX INC	**5MG**	**A079145**	**001**	Jul 19, 2016
AB			**10MG**	**A079145**	**002**	Jul 19, 2016
AB			**20MG**	**A079145**	**003**	Jul 19, 2016
AB			**40MG**	**A079145**	**004**	Jul 19, 2016
AB		AUROBINDO PHARMA LTD	**5MG**	**A079170**	**001**	Jul 19, 2016
AB			**10MG**	**A079170**	**002**	Jul 19, 2016
AB			**20MG**	**A079170**	**003**	Jul 19, 2016
AB			**40MG**	**A079170**	**004**	Jul 19, 2016
AB		BIOCON LTD	**5MG**	**A207752**	**001**	Oct 31, 2016
AB			**10MG**	**A207752**	**002**	Oct 31, 2016
AB			**20MG**	**A207752**	**003**	Oct 31, 2016
AB			**40MG**	**A207752**	**004**	Oct 31, 2016
AB		CADILA PHARMS LTD	**5MG**	**A207453**	**001**	Nov 23, 2016
AB			**10MG**	**A207453**	**002**	Nov 23, 2016
AB			**20MG**	**A207453**	**003**	Nov 23, 2016
AB			**40MG**	**A207453**	**004**	Nov 23, 2016
AB		CHANGZHOU PHARM	**5MG**	**A207408**	**001**	Oct 31, 2016
AB			**10MG**	**A207408**	**002**	Oct 31, 2016
AB			**20MG**	**A207408**	**003**	Oct 31, 2016
AB			**40MG**	**A207408**	**004**	Oct 31, 2016
AB		GLENMARK PHARMS	**5MG**	**A079172**	**001**	Jul 19, 2016
AB			**10MG**	**A079172**	**002**	Jul 19, 2016

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB		**20MG**	**A079172**	**003**	Jul 19, 2016
AB		**40MG**	**A079172**	**004**	Jul 19, 2016
AB	HETERO LABS LTD V	**5MG**	**A207616**	**001**	Oct 31, 2016
AB		**10MG**	**A207616**	**002**	Oct 31, 2016
AB		**20MG**	**A207616**	**003**	Oct 31, 2016
AB		**40MG**	**A207616**	**004**	Oct 31, 2016
AB	JUBILANT GENERICS	**5MG**	**A207062**	**001**	Oct 31, 2016
AB		**10MG**	**A207062**	**002**	Oct 31, 2016
AB		**20MG**	**A207062**	**003**	Oct 31, 2016
AB		**40MG**	**A207062**	**004**	Oct 31, 2016
AB	LUPIN LTD	**5MG**	**A205587**	**001**	Jul 31, 2017
AB		**10MG**	**A205587**	**002**	Jul 31, 2017
AB		**20MG**	**A205587**	**003**	Jul 31, 2017
AB		**40MG**	**A205587**	**004**	Jul 31, 2017
AB	MSN	**5MG**	**A208898**	**001**	Nov 22, 2017
AB		**10MG**	**A208898**	**002**	Nov 22, 2017
AB		**20MG**	**A208898**	**003**	Nov 22, 2017
AB		**40MG**	**A208898**	**004**	Nov 22, 2017
AB	SANDOZ INC	**5MG**	**A079171**	**001**	Jul 19, 2016
AB		**10MG**	**A079171**	**002**	Jul 19, 2016
AB		**20MG**	**A079171**	**003**	Jul 19, 2016
AB		**40MG**	**A079171**	**004**	Jul 19, 2016
AB	SHANDONG	**5MG**	**A207375**	**001**	May 07, 2019
AB		**10MG**	**A207375**	**002**	May 07, 2019
AB		**20MG**	**A207375**	**003**	May 07, 2019
AB		**40MG**	**A207375**	**004**	May 07, 2019
AB	SUN PHARM	**5MG**	**A079169**	**001**	Jul 19, 2016
AB		**10MG**	**A079169**	**002**	Jul 19, 2016
AB		**20MG**	**A079169**	**003**	Jul 19, 2016
AB		**40MG**	**A079169**	**004**	Jul 19, 2016
AB	TORRENT	**5MG**	**A201619**	**001**	Oct 31, 2016
AB		**10MG**	**A201619**	**002**	Oct 31, 2016
AB		**20MG**	**A201619**	**003**	Oct 31, 2016
AB		**40MG**	**A201619**	**004**	Oct 31, 2016
AB	WATSON LABS INC	**5MG**	**A079167**	**001**	Apr 29, 2016
AB		**10MG**	**A079167**	**002**	Apr 29, 2016
AB		**20MG**	**A079167**	**003**	Apr 29, 2016
AB		**40MG**	**A079167**	**004**	Apr 29, 2016
AB	ZHEJIANG YONGTAI	**5MG**	**A212059**	**001**	Nov 04, 2019
AB		**10MG**	**A212059**	**002**	Nov 04, 2019
AB		**20MG**	**A212059**	**003**	Nov 04, 2019
AB		**40MG**	**A212059**	**004**	Nov 04, 2019

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NEUPRO

+	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+!		2MG/24HR	N021829	001	May 09, 2007
+		3MG/24HR	N021829	005	Apr 02, 2012
+		4MG/24HR	N021829	002	May 09, 2007
+		6MG/24HR	N021829	003	May 09, 2007
+		8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE;INJECTION

CARDIOGEN-82

	BRACCO	N/A	N019414	001	Dec 29, 1989

SOLUTION;INTRAVENOUS

RUBY-FILL

	JUBILANT DRAXIMAGE	N/A	N202153	001	Sep 30, 2016

RUCAPARIB CAMSYLATE

TABLET;ORAL

RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 200MG BASE	N209115	001	Dec 19, 2016
+		EQ 250MG BASE	N209115	003	May 01, 2017
+!		EQ 300MG BASE	N209115	002	Dec 19, 2016

RUFINAMIDE
SUSPENSION;ORAL

BANZEL						
AB	**+!**	EISAI INC	**40MG/ML**	**N201367**	**001**	Mar 03, 2011
RUFINAMIDE						
AB		BIONPHARMA INC	**40MG/ML**	**A211388**	**001**	Apr 23, 2019
AB		HIKMA	**40MG/ML**	**A207363**	**001**	Apr 23, 2019

TABLET;ORAL

BANZEL						
AB	**+**	EISAI INC	**200MG**	**N021911**	**002**	Nov 14, 2008
AB	**+!**		**400MG**	**N021911**	**003**	Nov 14, 2008
RUFINAMIDE						
AB		GLENMARK PHARMS LTD	**200MG**	**A205075**	**001**	May 16, 2016
AB			**400MG**	**A205075**	**002**	May 16, 2016
AB		HIKMA	**200MG**	**A204988**	**001**	May 16, 2016
AB			**400MG**	**A204988**	**002**	May 16, 2016

RUXOLITINIB PHOSPHATE
TABLET;ORAL

JAKAFI					
	+	INCYTE CORP	EQ 5MG BASE	N202192	001 Nov 16, 2011
	+		EQ 10MG BASE	N202192	002 Nov 16, 2011
	+		EQ 15MG BASE	N202192	003 Nov 16, 2011
	+		EQ 20MG BASE	N202192	004 Nov 16, 2011
	+!		EQ 25MG BASE	N202192	005 Nov 16, 2011

SACROSIDASE
SOLUTION;ORAL

SUCRAID					
	+!	QOL MEDCL	8,500 IU/ML	N020772	001 Apr 09, 1998

SACUBITRIL; VALSARTAN
TABLET;ORAL

ENTRESTO					
	+	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001 Jul 07, 2015
	+		49MG;51MG	N207620	002 Jul 07, 2015
	+!		97MG;103MG	N207620	003 Jul 07, 2015

SAFINAMIDE MESYLATE
TABLET;ORAL

XADAGO					
	+	US WORLDMEDS LLC	50MG	N207145	001 Mar 21, 2017
	+!		100MG	N207145	002 Mar 21, 2017

SALMETEROL XINAFOATE
POWDER;INHALATION

SEREVENT					
	+!	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001 Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
INJECTABLE;INJECTION

QUADRAMET					
	+!	LANTHEUS MEDICAL	50mCi/ML	N020570	001 Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE
POWDER;ORAL

KUVAN						
AB	**+!**	BIOMARIN PHARM	**100MG/PACKET**	**N205065**	**001**	Dec 19, 2013
SAPROPTERIN DIHYDROCHLORIDE						
AB		PAR PHARM INC	**100MG/PACKET**	**A207207**	**001**	Aug 20, 2019
KUVAN						
	+	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015

TABLET;ORAL

KUVAN					
	+!	BIOMARIN PHARM	100MG	N022181	001 Dec 13, 2007

SAQUINAVIR MESYLATE
TABLET;ORAL

INVIRASE					
	+!	HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785	001 Dec 17, 2004

SARECYCLINE HYDROCHLORIDE
TABLET;ORAL
SEYSARA

+	ALMIRALL	EQ 60MG BASE	N209521	001	Oct 01, 2018
+		EQ 100MG BASE	N209521	002	Oct 01, 2018
+!		EQ 150MG BASE	N209521	003	Oct 01, 2018

SAXAGLIPTIN HYDROCHLORIDE
TABLET;ORAL
ONGLYZA

+	ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009
+!		EQ 5MG BASE	N022350	002	Jul 31, 2009

SCOPOLAMINE
FILM, EXTENDED RELEASE;TRANSDERMAL
SCOPOLAMINE

AB	MYLAN TECHNOLOGIES	**1MG/72HR**	**A203753**	**001**	Jun 19, 2019
AB	PERRIGO PHARMS CO	**1MG/72HR**	**A078830**	**001**	Jan 30, 2015

TRANSDERM SCOP

AB	**+!** GLAXOSMITHKLINE CON	**1MG/72HR**	**N017874**	**001**	

SECNIDAZOLE
GRANULE;ORAL
SOLOSEC

+!	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017

SECOBARBITAL SODIUM
CAPSULE;ORAL
SECONAL SODIUM

!	VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983
!		100MG	A086101	002	Oct 03, 1983

SECRETIN SYNTHETIC HUMAN
FOR SOLUTION;INTRAVENOUS
CHIRHOSTIM

+!	CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
+		40MCG/VIAL	N021256	002	Jun 21, 2007

SELEGILINE
FILM, EXTENDED RELEASE;TRANSDERMAL
EMSAM

+!	SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
+		9MG/24HR	N021336	002	Feb 27, 2006
+		12MG/24HR	N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE
CAPSULE;ORAL
SELEGILINE HYDROCHLORIDE

AB	**!** APOTEX	**5MG**	**A075321**	**001**	Dec 04, 1998
AB	DAVA PHARMS INC	**5MG**	**A075352**	**001**	Nov 30, 1998
AB	RISING	**5MG**	**A206803**	**001**	Apr 02, 2019

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

AB	**!** APOTEX INC	**5MG**	**A074871**	**001**	Jun 06, 1997
AB	BOSCOGEN	**5MG**	**A074912**	**001**	Apr 30, 1998

TABLET, ORALLY DISINTEGRATING;ORAL
ZELAPAR

+!	BAUSCH	1.25MG	N021479	001	Jun 14, 2006

SELENIOUS ACID
SOLUTION;INTRAVENOUS
SELENIOUS ACID

+!	AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019

SELENIUM SULFIDE
LOTION/SHAMPOO;TOPICAL
SELENIUM SULFIDE

AT	**!** PERRIGO NEW YORK	**2.5%**	**A089996**	**001**	Jan 10, 1991
AT	WOCKHARDT BIO AG	**2.5%**	**A088228**	**001**	Sep 01, 1983

SELEXIPAG
TABLET;ORAL
UPTRAVI

+	ACTELION PHARMS LTD	0.2MG	N207947	001	Dec 21, 2015
+		0.4MG	N207947	002	Dec 21, 2015
+		0.6MG	N207947	003	Dec 21, 2015
+		0.8MG	N207947	004	Dec 21, 2015

SELEXIPAG						
TABLET;ORAL						
UPTRAVI						
+		1MG	N207947	005	Dec 21, 2015
+		1.2MG	N207947	006	Dec 21, 2015
+		1.4MG	N207947	007	Dec 21, 2015
+!		1.6MG	N207947	008	Dec 21, 2015
SELINEXOR						
TABLET;ORAL						
XPOVIO						
+!	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019
SEMAGLUTIDE						
SOLUTION;SUBCUTANEOUS						
OZEMPIC						
+!	NOVO	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017
TABLET;ORAL						
RYBELSUS						
+	NOVO	3MG	N213051	001	Sep 20, 2019
+		7MG	N213051	002	Sep 20, 2019
+!		14MG	N213051	003	Sep 20, 2019
SERTACONAZOLE NITRATE						
CREAM;TOPICAL						
ERTACZO						
+!	BAUSCH	2%	N021385	001	Dec 10, 2003
SERTRALINE HYDROCHLORIDE						
CONCENTRATE;ORAL						
SERTRALINE HYDROCHLORIDE						
AA	AUROBINDO PHARMA	**EQ 20MG BASE/ML**	**A078861**	**001**	Oct 31, 2008
ZOLOFT						
AA **+!**	PFIZER	**EQ 20MG BASE/ML**	**N020990**	**001**	Dec 07, 1999
TABLET;ORAL						
SERTRALINE HYDROCHLORIDE						
AB	ACCORD HLTHCARE	**EQ 25MG BASE**	**A202825**	**001**	Nov 07, 2014
AB		**EQ 50MG BASE**	**A202825**	**002**	Nov 07, 2014
AB		**EQ 100MG BASE**	**A202825**	**003**	Nov 07, 2014
AB	APOTEX INC	**EQ 25MG BASE**	**A076882**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A076882**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A076882**	**003**	Feb 06, 2007
AB	AUROBINDO PHARMA	**EQ 25MG BASE**	**A077206**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077206**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077206**	**003**	Feb 06, 2007
AB	AUSTARPHARMA LLC	**EQ 25MG BASE**	**A078677**	**001**	Mar 04, 2009
AB		**EQ 50MG BASE**	**A078677**	**002**	Mar 04, 2009
AB		**EQ 100MG BASE**	**A078677**	**003**	Mar 04, 2009
AB	INVAGEN PHARMS	**EQ 25MG BASE**	**A077397**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077397**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077397**	**003**	Feb 06, 2007
AB	LUPIN	**EQ 25MG BASE**	**A077670**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077670**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077670**	**003**	Feb 06, 2007
AB	OXFORD PHARMS	**EQ 25MG BASE**	**A078175**	**001**	Jul 21, 2010
AB		**EQ 50MG BASE**	**A078175**	**002**	Jul 21, 2010
AB		**EQ 100MG BASE**	**A078175**	**003**	Jul 21, 2010
AB	SUN PHARM INDS LTD	**EQ 25MG BASE**	**A077977**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077977**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077977**	**003**	Feb 06, 2007
AB	TORRENT PHARMS	**EQ 25MG BASE**	**A077765**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077765**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077765**	**003**	Feb 06, 2007
AB	WOCKHARDT	**EQ 25MG BASE**	**A078403**	**001**	Jan 08, 2008
AB		**EQ 50MG BASE**	**A078403**	**002**	Jan 08, 2008
AB		**EQ 100MG BASE**	**A078403**	**003**	Jan 08, 2008
ZOLOFT						
AB **+**	PFIZER	**EQ 25MG BASE**	**N019839**	**005**	Mar 06, 1996
AB **+**		**EQ 50MG BASE**	**N019839**	**001**	Dec 30, 1991
AB **+!**		**EQ 100MG BASE**	**N019839**	**002**	Dec 30, 1991
SERTRALINE HYDROCHLORIDE						
	SUN PHARM INDS LTD	EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007

SEVELAMER CARBONATE							
FOR SUSPENSION;ORAL							
RENVELA							
AB	**+**	GENZYME	**800MG/PACKET**	**N022318**	**001**	Aug 12, 2009
AB	**+!**		**2.4GM/PACKET**	**N022318**	**002**	Feb 18, 2009
SEVELAMER CARBONATE							
AB		AUROBINDO PHARMA LTD	**800MG/PACKET**	**A207624**	**001**	Jun 13, 2017
AB			**2.4GM/PACKET**	**A207624**	**002**	Jun 13, 2017
AB		DR REDDYS LABS LTD	**800MG/PACKET**	**A210464**	**001**	Oct 25, 2018
AB			**2.4GM/PACKET**	**A210464**	**002**	Oct 25, 2018
TABLET;ORAL							
RENVELA							
AB	**+!**	SANOFI	**800MG**	**N022127**	**001**	Oct 19, 2007
SEVELAMER CARBONATE							
AB		AMNEAL PHARMS CO	**800MG**	**A207288**	**001**	Nov 28, 2017
AB		AUROBINDO PHARMA LTD	**800MG**	**A207179**	**001**	Jul 17, 2017
AB		DR REDDYS LABS LTD	**800MG**	**A206094**	**001**	Sep 29, 2017
AB		IMPAX LABS INC	**800MG**	**A090975**	**001**	Oct 23, 2017
AB		INVAGEN PHARMS	**800MG**	**A203860**	**001**	Oct 26, 2017
AB		TWI PHARMS	**800MG**	**A200959**	**001**	Mar 20, 2018
AB		WILSHIRE PHARMS INC	**800MG**	**A204451**	**001**	Nov 29, 2018
SEVELAMER HYDROCHLORIDE							
TABLET;ORAL							
RENAGEL							
AB	**+**	GENZYME	**400MG**	**N021179**	**001**	Jul 12, 2000
AB	**+!**		**800MG**	**N021179**	**002**	Jul 12, 2000
SEVELAMER HYDROCHLORIDE							
AB		GLENMARK PHARMS LTD	**400MG**	**A204724**	**001**	Feb 08, 2019
AB			**800MG**	**A204724**	**002**	Feb 08, 2019
SEVOFLURANE							
LIQUID;INHALATION							
SEVOFLURANE							
AN		BAXTER HLTHCARE	**100%**	**A075895**	**001**	Jul 02, 2002
AN		HALOCARBON PRODS	**100%**	**A078650**	**001**	Nov 19, 2007
AN		SHANGHAI HENGRUI	**100%**	**A203793**	**001**	Nov 03, 2015
SOJOURN							
AN		PIRAMAL CRITICAL	**100%**	**A077867**	**001**	May 02, 2007
ULTANE							
AN	**+!**	ABBVIE	**100%**	**N020478**	**001**	Jun 07, 1995
SILDENAFIL CITRATE							
FOR SUSPENSION;ORAL							
REVATIO							
AB	**+!**	PFIZER	**EQ 10MG BASE/ML**	**N203109**	**001**	Aug 30, 2012
SILDENAFIL CITRATE							
AB		AJANTA PHARMA LTD	**EQ 10MG BASE/ML**	**A212883**	**001**	Nov 27, 2019
AB		ALKEM LABS LTD	**EQ 10MG BASE/ML**	**A212440**	**001**	Nov 27, 2019
AB		AMNEAL PHARMS	**EQ 10MG BASE/ML**	**A211092**	**001**	Nov 27, 2019
AB		NOVITIUM PHARMA	**EQ 10MG BASE/ML**	**A212260**	**001**	May 31, 2019
SOLUTION;INTRAVENOUS							
REVATIO							
AP	**+!**	PFIZER	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**N022473**	**001**	Nov 18, 2009
SILDENAFIL CITRATE							
AP		AUROBINDO PHARMA LTD	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**A203988**	**001**	Apr 01, 2015
TABLET;ORAL							
REVATIO							
AB	**+!**	PFIZER	**EQ 20MG BASE**	**N021845**	**001**	Jun 03, 2005
SILDENAFIL CITRATE							
AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A210394**	**001**	May 04, 2018
AB			**EQ 25MG BASE**	**A206401**	**001**	Oct 12, 2018
AB			**EQ 50MG BASE**	**A206401**	**002**	Oct 12, 2018
AB			**EQ 100MG BASE**	**A206401**	**003**	Oct 12, 2018
AB		AMNEAL PHARMS	**EQ 20MG BASE**	**A202025**	**001**	Feb 28, 2013
AB		AMNEAL PHARMS NY	**EQ 25MG BASE**	**A202023**	**001**	Jun 27, 2018
AB			**EQ 50MG BASE**	**A202023**	**002**	Jun 27, 2018
AB			**EQ 100MG BASE**	**A202023**	**003**	Jun 27, 2018
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A203963**	**001**	Nov 18, 2015
AB			**EQ 25MG BASE**	**A203962**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A203962**	**002**	Jun 11, 2018

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB			**EQ 100MG BASE**	**A203962**	**003**	Jun 11, 2018
AB		HEBEI CHANGSHAN	**EQ 20MG BASE**	**A202598**	**001**	Nov 06, 2012
AB		HETERO LABS LTD V	**EQ 20MG BASE**	**A203623**	**001**	Nov 26, 2014
AB			**EQ 25MG BASE**	**A202659**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A202659**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A202659**	**003**	Jun 11, 2018
AB		LUPIN LTD	**EQ 25MG BASE**	**A212051**	**001**	Mar 22, 2019
AB			**EQ 50MG BASE**	**A212051**	**002**	Mar 22, 2019
AB			**EQ 100MG BASE**	**A212051**	**003**	Mar 22, 2019
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A203814**	**001**	Dec 17, 2013
AB		MYLAN	**EQ 25MG BASE**	**A201171**	**001**	Mar 25, 2019
AB			**EQ 50MG BASE**	**A201171**	**002**	Mar 25, 2019
AB			**EQ 100MG BASE**	**A201171**	**003**	Mar 25, 2019
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A201150**	**001**	Nov 09, 2012
AB		RUBICON	**EQ 20MG BASE**	**A204883**	**001**	Jun 20, 2016
AB			**EQ 25MG BASE**	**A204882**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A204882**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A204882**	**003**	Jun 11, 2018
AB		TEVA	**EQ 25MG BASE**	**A077342**	**001**	Mar 09, 2016
AB			**EQ 50MG BASE**	**A077342**	**002**	Mar 09, 2016
AB			**EQ 100MG BASE**	**A077342**	**003**	Mar 09, 2016
AB		TEVA PHARMS	**EQ 20MG BASE**	**A078380**	**001**	Jan 07, 2013
AB		TORRENT	**EQ 25MG BASE**	**A091448**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A091448**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A091448**	**003**	Jun 11, 2018
AB		TORRENT PHARMS LTD	**EQ 20MG BASE**	**A091479**	**001**	Nov 06, 2012
AB		WATSON LABS INC	**EQ 20MG BASE**	**A202503**	**001**	Nov 06, 2012

VIAGRA

AB	**+**	PFIZER INC	**EQ 25MG BASE**	**N020895**	**001**	Mar 27, 1998
AB	**+**		**EQ 50MG BASE**	**N020895**	**002**	Mar 27, 1998
AB	**+!**		**EQ 100MG BASE**	**N020895**	**003**	Mar 27, 1998

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB	**+!**	ALLERGAN	**4MG**	**N022206**	**001**	Oct 08, 2008
AB	**+**		**8MG**	**N022206**	**002**	Oct 08, 2008

SILODOSIN

AB		AJANTA PHARMA LTD	**4MG**	**A211060**	**001**	Dec 03, 2018
AB			**8MG**	**A211060**	**002**	Dec 03, 2018
AB		ALEMBIC PHARMS LTD	**4MG**	**A211731**	**001**	Nov 22, 2019
AB			**8MG**	**A211731**	**002**	Nov 22, 2019
AB		AMNEAL PHARMS CO	**4MG**	**A209745**	**001**	Dec 03, 2018
AB			**8MG**	**A209745**	**002**	Dec 03, 2018
AB		AUROBINDO PHARMA LTD	**4MG**	**A210626**	**001**	Dec 10, 2018
AB			**8MG**	**A210626**	**002**	Dec 10, 2018
AB		LUPIN LTD	**4MG**	**A206541**	**001**	Dec 03, 2018
AB			**8MG**	**A206541**	**002**	Dec 03, 2018
AB		MACLEODS PHARMS LTD	**4MG**	**A211166**	**001**	Dec 03, 2018
AB			**8MG**	**A211166**	**002**	Dec 03, 2018
AB		MSN	**4MG**	**A210687**	**001**	Dec 03, 2018
AB			**8MG**	**A210687**	**002**	Dec 03, 2018
AB		SANDOZ INC	**4MG**	**A204726**	**001**	Mar 31, 2017
AB			**8MG**	**A204726**	**002**	Mar 31, 2017

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

AB	**+!**	KING PHARMS LLC	**1%**	**N017381**	**001**	

SSD

AB		DR REDDYS LA	**1%**	**N018578**	**001**	Feb 25, 1982

THERMAZENE

AB		THEPHARMANETWORK LLC	**1%**	**N018810**	**001**	Dec 23, 1985

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016
	+!		40MG/5ML	N206679	002	Apr 21, 2016

TABLET;ORAL

SIMVASTATIN

AB		ACCORD HLTHCARE	**5MG**	**A078155**	**005**	Apr 05, 2013
AB			**10MG**	**A078155**	**002**	Feb 26, 2008
AB			**20MG**	**A078155**	**003**	Feb 26, 2008
AB			**40MG**	**A078155**	**004**	Feb 26, 2008
AB			**80MG**	**A078155**	**001**	Feb 26, 2008
AB		AUROBINDO PHARMA	**5MG**	**A077691**	**001**	Dec 20, 2006
AB			**10MG**	**A077691**	**002**	Dec 20, 2006
AB			**20MG**	**A077691**	**003**	Dec 20, 2006
AB			**40MG**	**A077691**	**004**	Dec 20, 2006
AB			**80MG**	**A077691**	**005**	Dec 20, 2006
AB		BIOCON LIMITED	**5MG**	**A078034**	**001**	Dec 20, 2006
AB			**10MG**	**A078034**	**002**	Dec 20, 2006
AB			**20MG**	**A078034**	**003**	Dec 20, 2006
AB			**40MG**	**A078034**	**004**	Dec 20, 2006
AB			**80MG**	**A078034**	**005**	Dec 20, 2006
AB		DR REDDYS LABS INC	**5MG**	**A077752**	**005**	Jan 23, 2008
AB			**10MG**	**A077752**	**001**	Dec 20, 2006
AB			**20MG**	**A077752**	**002**	Dec 20, 2006
AB			**40MG**	**A077752**	**003**	Dec 20, 2006
AB			**80MG**	**A077752**	**004**	Dec 20, 2006
AB		HETERO LABS LTD III	**5MG**	**A200895**	**001**	Nov 25, 2014
AB			**10MG**	**A200895**	**002**	Nov 25, 2014
AB			**20MG**	**A200895**	**003**	Nov 25, 2014
AB			**40MG**	**A200895**	**004**	Nov 25, 2014
AB			**80MG**	**A200895**	**005**	Nov 25, 2014
AB		LUPIN	**5MG**	**A078103**	**005**	Apr 14, 2009
AB			**10MG**	**A078103**	**001**	May 11, 2007
AB			**20MG**	**A078103**	**002**	May 11, 2007
AB			**40MG**	**A078103**	**003**	May 11, 2007
AB			**80MG**	**A078103**	**004**	May 11, 2007
AB		MICRO LABS	**5MG**	**A090383**	**001**	Sep 16, 2011
AB			**10MG**	**A090383**	**002**	Sep 16, 2011
AB			**20MG**	**A090383**	**003**	Sep 16, 2011
AB			**40MG**	**A090383**	**004**	Sep 16, 2011
AB			**80MG**	**A090383**	**005**	Sep 16, 2011
AB		OXFORD PHARMS	**5MG**	**A078735**	**001**	Aug 30, 2010
AB			**10MG**	**A078735**	**002**	Aug 30, 2010
AB			**20MG**	**A078735**	**003**	Aug 30, 2010
AB			**40MG**	**A078735**	**004**	Aug 30, 2010
AB			**80MG**	**A078735**	**005**	Aug 30, 2010
AB		WATSON LABS TEVA	**5MG**	**A076685**	**001**	Dec 20, 2006
AB			**10MG**	**A076685**	**002**	Dec 20, 2006
AB			**20MG**	**A076685**	**003**	Dec 20, 2006
AB			**40MG**	**A076685**	**004**	Dec 20, 2006
AB			**80MG**	**A076685**	**005**	Dec 20, 2006
AB		ZYDUS PHARMS USA	**5MG**	**A077837**	**001**	Dec 20, 2006
AB			**10MG**	**A077837**	**002**	Dec 20, 2006
AB			**20MG**	**A077837**	**003**	Dec 20, 2006
AB			**40MG**	**A077837**	**004**	Dec 20, 2006
AB			**80MG**	**A077837**	**005**	Dec 20, 2006

ZOCOR

AB	**+**	MSD MERCK CO	**5MG**	**N019766**	**001**	Dec 23, 1991
AB	**+**		**10MG**	**N019766**	**002**	Dec 23, 1991
AB	**+**		**20MG**	**N019766**	**003**	Dec 23, 1991
AB	**+**		**40MG**	**N019766**	**004**	Dec 23, 1991
AB	**+!**		**80MG**	**N019766**	**005**	Jul 10, 1998

SINCALIDE

INJECTABLE;INJECTION

KINEVAC

+!	BRACCO	0.005MG/VIAL	N017697	001	

SINECATECHINS							
OINTMENT;TOPICAL							
VEREGEN							
	+!	FOUGERA PHARMS INC	15%		N021902	001	Oct 31, 2006
SIPONIMOD FUMARIC ACID							
TABLET;ORAL							
MAYZENT							
	+	NOVARTIS	EQ 0.25MG BASE		N209884	001	Mar 26, 2019
	+!		EQ 2MG BASE		N209884	002	Mar 26, 2019
SIROLIMUS							
SOLUTION;ORAL							
RAPAMUNE							
AA	**+!**	PF PRISM CV	**1MG/ML**		**N021083**	**001**	Sep 15, 1999
SIROLIMUS							
AA		AMNEAL PHARMS LLC	**1MG/ML**		**A211212**	**001**	Oct 18, 2019
AA		APOTEX	**1MG/ML**		**A211406**	**001**	Oct 22, 2019
AA		NOVITIUM PHARMA	**1MG/ML**		**A211040**	**001**	Jan 28, 2019
TABLET;ORAL							
RAPAMUNE							
AB	**+**	PF PRISM CV	**0.5MG**		**N021110**	**004**	Jan 25, 2010
AB	**+**		**1MG**		**N021110**	**001**	Aug 25, 2000
AB	**+!**		**2MG**		**N021110**	**002**	Aug 22, 2002
SIROLIMUS							
AB		DR REDDYS LABS LTD	**1MG**		**A201578**	**001**	Oct 27, 2014
AB			**2MG**		**A201578**	**002**	Oct 27, 2014
AB		ZYDUS PHARMS	**0.5MG**		**A201676**	**003**	Jan 08, 2014
SITAGLIPTIN PHOSPHATE							
TABLET;ORAL							
JANUVIA							
	+	MERCK SHARP DOHME	EQ 25MG BASE		N021995	001	Oct 16, 2006
	+		EQ 50MG BASE		N021995	002	Oct 16, 2006
	+!		EQ 100MG BASE		N021995	003	Oct 16, 2006
SODIUM ACETATE							
INJECTABLE;INJECTION							
SODIUM ACETATE							
		FRESENIUS KABI USA	4MEQ/ML		A206687	001	Oct 30, 2017
	+!	HOSPIRA	2MEQ/ML		N018893	001	May 04, 1983
SODIUM BENZOATE; SODIUM PHENYLACETATE							
SOLUTION;INTRAVENOUS							
AMMONUL							
AP	**+!**	MEDICIS	**10%;10% (5GM/50ML;5GM/50ML)**		**N020645**	**001**	Feb 17, 2005
SODIUM PHENYLACETATE AND SODIUM BENZOATE							
AP		AILEX PHARMS LLC	**10%;10% (5GM/50ML;5GM/50ML)**		**A207096**	**001**	Feb 24, 2016
AP		MAIA PHARMS INC	**10%;10% (5GM/50ML;5GM/50ML)**		**A208521**	**001**	May 08, 2017
AP		NAVINTA LLC	**10%;10% (5GM/50ML;5GM/50ML)**		**A205880**	**001**	Aug 04, 2016
SODIUM BICARBONATE							
INJECTABLE;INJECTION							
SODIUM BICARBONATE							
AP		EXELA PHARMA SCS LLC	**0.5MEQ/ML**		**A211091**	**001**	Jun 20, 2019
AP			**0.9MEQ/ML**		**A211091**	**002**	Jun 20, 2019
AP			**1MEQ/ML**		**A211091**	**003**	Jun 20, 2019
AP	**!**	HOSPIRA	**0.9MEQ/ML**		**A077394**	**001**	Nov 09, 2005
AP	**!**		**1MEQ/ML**		**A077394**	**002**	Nov 09, 2005
AP		HOSPIRA INC	**0.5MEQ/ML**		**A202981**	**001**	Mar 04, 2016
AP			**0.9MEQ/ML**		**A202494**	**001**	Mar 06, 2017
AP			**1MEQ/ML**		**A202432**	**001**	Sep 26, 2017
AP			**1MEQ/ML**		**A202494**	**002**	Mar 06, 2017
AP		INTL MEDICATION SYS	**1MEQ/ML**		**A203449**	**001**	Sep 19, 2017
		HOSPIRA INC	1MEQ/ML		A202495	001	Mar 06, 2017
SODIUM CHLORIDE							
INJECTABLE;INJECTION							
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		FRESENIUS KABI USA	**9MG/ML**		**A088911**	**001**	Feb 07, 1985
AP	**+!**	HOSPIRA	**9MG/ML**		**N018800**	**001**	Oct 29, 1982
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	**+**	B BRAUN	**450MG/100ML**		**N019635**	**001**	Mar 09, 1988
AP		BAXTER HLTHCARE	**450MG/100ML**		**N018016**	**001**	
AP		FRESENIUS KABI USA	**450MG/100ML**		**A208122**	**001**	Jul 23, 2018

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		HOSPIRA	**450MG/100ML**	**N019759**	**001**	Jun 08, 1988
AP	**+!**	ICU MEDICAL INC	**450MG/100ML**	**N018090**	**001**	

SODIUM CHLORIDE 0.9%

AP		SPECTRA MDCL DEVICES	**9MG/ML**	**A206171**	**001**	Jul 21, 2017
AP		WEST-WARD PHARMS INT	**9MG/ML**	**A201850**	**001**	Jan 20, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**900MG/100ML**	**N017464**	**001**	
AP	**+!**		**900MG/100ML**	**N019635**	**002**	Mar 09, 1988
AP	**+!**	BAXTER HLTHCARE	**9MG/ML**	**N016677**	**004**	Oct 30, 1985
AP	**+**		**9MG/ML**	**N020178**	**002**	Dec 07, 1992
AP	**+!**		**900MG/100ML**	**N016677**	**001**	
AP	**+!**		**900MG/100ML**	**N020178**	**001**	Dec 07, 1992
AP	**!**	FRESENIUS KABI USA	**9MG/ML**	**A088912**	**001**	Jan 10, 1985
AP			**900MG/100ML**	**A207310**	**001**	Sep 19, 2017
AP		FRESENIUS MEDCL	**900MG/100ML**	**A078177**	**001**	Apr 12, 2007
AP		HAEMONETICS	**900MG/100ML**	**A076316**	**001**	Oct 27, 2004
AP	**+!**	HOSPIRA	**9MG/ML**	**N018803**	**001**	Oct 29, 1982
AP	**+**		**9MG/ML**	**N019465**	**002**	Jul 15, 1985
AP	**+!**		**900MG/100ML**	**N019465**	**001**	Jul 15, 1985
AP	**+!**		**900MG/100ML**	**N019480**	**001**	Sep 17, 1985
AP	**+!**	ICU MEDICAL INC	**900MG/100ML**	**N016366**	**001**	
AP		JUBILANT CADISTA	**9MG/ML**	**A203352**	**001**	May 18, 2016
AP		LABORATORIOS GRIFOLS	**900MG/100ML**	**A207956**	**001**	May 25, 2017
AP	**!**	TARO	**9MG/ML**	**A077407**	**001**	Aug 11, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		B BRAUN	**3GM/100ML**	**N019635**	**003**	Mar 09, 1988
AP	**+!**	BAXTER HLTHCARE	**3GM/100ML**	**N019022**	**001**	Nov 01, 1983
AP		FRESENIUS KABI USA	**3GM/100ML**	**A209476**	**001**	Mar 13, 2019

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N019635**	**004**	Mar 09, 1988
AP	**+**	BAXTER HLTHCARE	**5GM/100ML**	**N019022**	**002**	Nov 01, 1983

SODIUM CHLORIDE 0.9%

	+	B BRAUN	9MG/10ML	N019635	005	Aug 11, 2016
	+	MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006

SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	**+!**	B BRAUN	**900MG/100ML**	**N016733**	**001**	
AT		BAXTER HLTHCARE	**900MG/100ML**	**N017427**	**001**	
AT			**900MG/100ML**	**N017867**	**001**	
AT		ICU MEDICAL INC	**900MG/100ML**	**N017514**	**001**	
AT			**900MG/100ML**	**N018314**	**001**	

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

		BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

FERRLECIT

AB	**+!**	SANOFI AVENTIS US	**62.5MG/5ML**	**N020955**	**001**	Feb 18, 1999

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		WEST-WARD PHARMS INT	**62.5MG/5ML**	**A078215**	**001**	Mar 31, 2011

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		3D IMAGING DRUG	**10-200mCi/ML**	**A203777**	**001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**10-200mCi/ML**	**A204351**	**001**	Jan 09, 2015
AP		CARDINAL HEALTH 414	**10-200mCi/ML**	**A203780**	**001**	Jul 30, 2015
AP		DECATUR	**10-200mCi/ML**	**A204464**	**001**	Oct 21, 2014
AP		ESSENTIAL ISOTOPES	**10-200mCi/ML**	**A204541**	**001**	Oct 29, 2014
AP		HOT SHOTS NM LLC	**10-200mCi/ML**	**A204530**	**001**	Jul 29, 2015

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		JUBILANT DRAXIMAGE	**10-200mCi/ML**	**A203968**	**001**	Oct 23, 2015
AP		KREITCHMAN PET CTR	**10-200mCi/ML**	**A203936**	**001**	May 19, 2016
AP		MIDWEST MEDCL	**10-200mCi/ML**	**A204440**	**001**	Nov 17, 2015
AP		MIPS CRF	**10-200mCi/ML**	**A204517**	**001**	Jul 21, 2015
AP		NCM USA BRONX LLC	**10-200mCi/ML**	**A204513**	**001**	Nov 28, 2014
AP		PETNET	**10-200mCi/ML**	**A203890**	**001**	Sep 28, 2015
AP		PRECISION NUCLEAR	**10-200mCi/ML**	**A204542**	**001**	Feb 27, 2015
AP		SHERTECH LABS LLC	**10-200mCi/ML**	**A204315**	**001**	Sep 22, 2014
AP		SOFIE	**10-200mCi/ML**	**A203592**	**001**	Aug 18, 2015
AP	**!**		**10-200mCi/ML**	**A203544**	**001**	Dec 26, 2012
AP		SPECTRON MRC LLC	**10-200mCi/ML**	**A203912**	**001**	Apr 22, 2015
AP		UCSF RODIOPHARM	**10-200mCi/ML**	**A204437**	**001**	Mar 13, 2014
AP		UNIV UTAH CYCLOTRON	**10-200mCi/ML**	**A204497**	**001**	Apr 20, 2015
	!	MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013
		THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	**+!**	CARDINAL HEALTH 418	**100uCi**	**N018671**	**001**	May 27, 1982
AA	**+!**		**200uCi**	**N018671**	**002**	May 27, 1982
AA		MALLINKRODT NUCLEAR	**100uCi**	**A071909**	**001**	Feb 28, 1989
AA			**200uCi**	**A071910**	**001**	Feb 28, 1989

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

	+	JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005

SOLUTION;ORAL

HICON

	+!	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011

SODIUM LACTATE

INJECTABLE;INJECTION

SODIUM LACTATE IN PLASTIC CONTAINER

	+!	HOSPIRA	5MEQ/ML	N018947	001	Sep 05, 1984

SODIUM NITRITE

SOLUTION;INTRAVENOUS

SODIUM NITRITE

	+!	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

NITHIODOTE

	+!	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML (250MG/ML)	N201444	001	Jan 14, 2011

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

NITROPRESS

AP	**!**	HOSPIRA	**25MG/ML**	**A071961**	**001**	Aug 01, 1988

SODIUM NITROPRUSSIDE

AP		AKORN	**25MG/ML**	**A208635**	**001**	May 04, 2017
AP		AMNEAL	**25MG/ML**	**A209493**	**001**	Nov 07, 2017
AP		AMPHASTAR PHARMS INC	**25MG/ML**	**A209832**	**001**	Dec 18, 2017
AP		CAPLIN	**25MG/ML**	**A211016**	**001**	Nov 29, 2019
AP		CIPLA	**25MG/ML**	**A210855**	**001**	Jul 16, 2018
AP		DR REDDYS LABS LTD	**25MG/ML**	**A210114**	**001**	Apr 10, 2019
AP		MEDICURE	**25MG/ML**	**A209584**	**001**	Aug 10, 2018
AP		MICRO LABS	**25MG/ML**	**A209352**	**001**	Dec 08, 2017
AP		MYLAN LABS LTD	**25MG/ML**	**A210763**	**001**	Apr 17, 2018
AP		NEXUS PHARMS	**25MG/ML**	**A207499**	**001**	May 25, 2017
AP		SAGENT PHARMS INC	**25MG/ML**	**A207426**	**001**	Dec 08, 2016
AP		SOMERSET THERAPS LLC	**25MG/ML**	**A210882**	**001**	Aug 17, 2018

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

	+!	EXELA PHARMA SCS LLC	20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018
	+!		50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

AA		HIKMA	**500MG/ML**	**A202090**	**001**	Jan 17, 2017

XYREM

AA	**+!**	JAZZ PHARMS	**500MG/ML**	**N021196**	**001**	Jul 17, 2002

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB	**+!**	HORIZON THERAP	**3GM/TEASPOONFUL**	**N020573**	**001**	Apr 30, 1996

SODIUM PHENYLBUTYRATE

AB		PAR PHARM	**3GM/TEASPOONFUL**	**A203918**	**001**	Jun 15, 2016
AB		SIGMAPHARM LABS LLC	**3GM/TEASPOONFUL**	**A202819**	**001**	Mar 22, 2013

TABLET;ORAL

BUPHENYL

AB	**+!**	HORIZON THERAP	**500MG**	**N020572**	**001**	May 13, 1996

SODIUM PHENYLBUTYRATE

AB		ALVOGEN	**500MG**	**A090910**	**001**	Nov 18, 2011
AB		PAR PHARM	**500MG**	**A204395**	**001**	Apr 15, 2016

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

OSMOPREP

	+!	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

	+!	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

AA	**!**	KVK TECH	**454GM/BOT**	**A040905**	**001**	Mar 30, 2009

KIONEX

AA		PADDOCK LLC	**454GM/BOT**	**A040029**	**001**	Feb 06, 1998

SODIUM POLYSTYRENE SULFONATE

AA		BELCHER PHARMS LLC	**454GM/BOT**	**A205727**	**001**	Feb 23, 2016
AA		CMP PHARMA INC	**454GM/BOT**	**A089910**	**001**	Jan 19, 1989
AA		ECI PHARMS LLC	**453.6GM/BOT**	**A090313**	**001**	Dec 21, 2011
AA		EPIC PHARMA LLC	**453.6GM/BOT**	**A202333**	**001**	Mar 19, 2014
AA		NOVELGENIX THERAPS	**454GM/BOT**	**A206815**	**001**	Feb 18, 2016
AA		NUVO PHARMS INC	**454GM/BOT**	**A204071**	**001**	Nov 28, 2014

KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015

SODIUM POLYSTYRENE SULFONATE

		NUVO PHARMS INC	15GM/BOT	A204071	002	Nov 28, 2014

SUSPENSION;ORAL, RECTAL

KIONEX

AA		PADDOCK LLC	**15GM/60ML**	**A040028**	**001**	Sep 17, 2007

SODIUM POLYSTYRENE SULFONATE

AA		HIKMA	**15GM/60ML**	**A089049**	**001**	Nov 17, 1986
AA		PADDOCK LLC	**15GM/60ML**	**A090590**	**001**	May 13, 2011

SPS

AA	**!**	CMP PHARMA INC	**15GM/60ML**	**A087859**	**001**	Dec 08, 1982

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

AP		CUSTOPHARM INC	**60MG/2ML (30MG/ML)**	**A209937**	**001**	Dec 09, 2019

SOTRADECOL

AP	**!**	MYLAN INSTITUTIONAL	**60MG/2ML (30MG/ML)**	**A040541**	**002**	Nov 12, 2004
	!		20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION;INTRAVENOUS

SODIUM THIOSULFATE

	+!	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

+	ASTRAZENECA PHARMS	5GM/PACKET	N207078	001	May 18, 2018
+!		10GM/PACKET	N207078	002	May 18, 2018

SOFOSBUVIR

PELLETS;ORAL

SOVALDI

+	GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019
+!		200MG/PACKET	N212480	002	Aug 28, 2019

TABLET;ORAL

SOVALDI

+	GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019
+!		400MG	N204671	001	Dec 06, 2013

SOFOSBUVIR; VELPATASVIR

TABLET;ORAL

EPCLUSA

+!	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET;ORAL

VOSEVI

+!	GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	AJANTA PHARMA LTD	**5MG**	**A205483**	**001**	May 20, 2019
AB		**10MG**	**A205483**	**002**	May 20, 2019
AB	ALEMBIC PHARMS LTD	**5MG**	**A205575**	**001**	May 20, 2019
AB		**10MG**	**A205575**	**002**	May 20, 2019
AB	ALKEM LABS LTD	**5MG**	**A210224**	**001**	May 20, 2019
AB		**10MG**	**A210224**	**002**	May 20, 2019
AB	AMNEAL PHARMS CO	**5MG**	**A209719**	**001**	May 20, 2019
AB		**10MG**	**A209719**	**002**	May 20, 2019
AB	BRECKENRIDGE	**5MG**	**A209818**	**001**	May 20, 2019
AB		**10MG**	**A209818**	**002**	May 20, 2019
AB	CELLTRION	**5MG**	**A210582**	**001**	May 20, 2019
AB		**10MG**	**A210582**	**002**	May 20, 2019
AB	CIPLA	**5MG**	**A209839**	**001**	May 20, 2019
AB		**10MG**	**A209839**	**002**	May 20, 2019
AB	CSPC OUYI	**5MG**	**A211423**	**001**	Dec 11, 2019
AB		**10MG**	**A211423**	**002**	Dec 11, 2019
AB	GLENMARK PHARMS INC	**5MG**	**A209239**	**001**	May 20, 2019
AB		**10MG**	**A209239**	**002**	May 20, 2019
AB	JIANGXI BOYA SEEHOT	**5MG**	**A210281**	**001**	May 20, 2019
AB		**10MG**	**A210281**	**002**	May 20, 2019
AB	MSN	**5MG**	**A210688**	**001**	May 20, 2019
AB		**10MG**	**A210688**	**002**	May 20, 2019
AB	QILU	**5MG**	**A209333**	**001**	May 20, 2019
AB		**10MG**	**A209333**	**002**	May 20, 2019
AB	SCIEGEN PHARMS INC	**5MG**	**A211657**	**001**	May 20, 2019
AB		**10MG**	**A211657**	**002**	May 20, 2019
AB	STRIDES PHARMA	**5MG**	**A212214**	**001**	Sep 26, 2019
AB		**10MG**	**A212214**	**002**	Sep 26, 2019
AB	TEVA PHARMS USA	**5MG**	**A091464**	**001**	Apr 02, 2014
AB		**10MG**	**A091464**	**002**	Apr 02, 2014
AB	UNICHEM LABS LTD	**5MG**	**A211701**	**001**	Aug 27, 2019
AB		**10MG**	**A211701**	**002**	Aug 27, 2019
AB	WATSON LABS INC	**5MG**	**A202551**	**001**	May 20, 2019
AB		**10MG**	**A202551**	**002**	May 20, 2019

VESICARE

AB	**+**	ASTELLAS	**5MG**	**N021518**	**001**	Nov 19, 2004
AB	**+!**		**10MG**	**N021518**	**002**	Nov 19, 2004

SOLRIAMFETOL

TABLET;ORAL

SUNOSI

+	JAZZ	75MG	N211230	001	Jun 17, 2019
+		150MG	N211230	002	Jun 17, 2019

SOMATROPIN

INJECTABLE;INJECTION

		GENOTROPIN				
BX	+!	PHARMACIA	5.8MG/VIAL	N020280	006	Aug 24, 1995
		NORDITROPIN FLEXPRO				
BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010
BX			10MG/1.5ML	N021148	009	Mar 01, 2010
		OMNITROPE				
BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006
BX			5MG/1.5ML	N021426	003	Jan 16, 2008
BX			5.8MG/VIAL	N021426	001	May 30, 2006
BX			10MG/1.5ML	N021426	004	Aug 25, 2008
		SAIZEN				
BX	+	EMD SERONO	5MG/VIAL	N019764	002	Oct 08, 1996
		SEROSTIM				
BX		EMD SERONO	5MG/VIAL	N020604	002	Aug 23, 1996
BX			6MG/VIAL	N020604	001	Aug 23, 1996
		ZOMACTON				
BX	+!	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002
		GENOTROPIN				
	+!	PHARMACIA	13.8MG/VIAL	N020280	007	Oct 23, 1996
		GENOTROPIN PRESERVATIVE FREE				
	+	PHARMACIA	0.2MG/VIAL	N020280	001	Jan 27, 1998
	+		0.4MG/VIAL	N020280	002	Jan 27, 1998
	+		0.6MG/VIAL	N020280	003	Jan 27, 1998
	+		0.8MG/VIAL	N020280	005	Jan 27, 1998
	+		1MG/VIAL	N020280	008	Jan 27, 1998
	+		1.2MG/VIAL	N020280	009	Jan 27, 1998
	+		1.4MG/VIAL	N020280	010	Jan 27, 1998
	+		1.6MG/VIAL	N020280	011	Jan 27, 1998
	+		1.8MG/VIAL	N020280	012	Jan 27, 1998
	+!		2MG/VIAL	N020280	013	Jan 27, 1998
		NORDITROPIN FLEXPRO				
		NOVO NORDISK INC	15MG/1.5ML	N021148	010	Mar 01, 2010
			30MG/3ML	N021148	011	Jan 23, 2015
		NUTROPIN AQ NUSPIN				
	+!	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
	+!		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008
	+!		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008
		SAIZEN				
	+!	EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
		SEROSTIM				
		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997
		ZOMACTON				
	+	FERRING	10MG/VIAL	N019774	003	Mar 07, 2012

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

		HUMATROPE				
BX	+!	LILLY	5MG/VIAL	N019640	004	Mar 08, 1987
BX	+		6MG/VIAL	N019640	005	Feb 04, 1999
	+!		12MG/VIAL	N019640	006	Feb 04, 1999
	+!		24MG/VIAL	N019640	007	Feb 04, 1999
		ZORBTIVE				
	+!	EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

		ODOMZO				
	+!	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015

SORAFENIB TOSYLATE

TABLET;ORAL

		NEXAVAR				
	+!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005

SORBITOL

SOLUTION;IRRIGATION

		SORBITOL 3% IN PLASTIC CONTAINER				
		BAXTER HLTHCARE	3GM/100ML	N017863	001	
		SORBITOL 3.3% IN PLASTIC CONTAINER				
		B BRAUN	3.3GM/100ML	N016741	001	

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

	+!	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009

SOLUTION;ORAL

SOTYLIZE

	+!	ARBOR PHARMS LLC	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014

TABLET;ORAL

BETAPACE

AB	**+**	COVIS PHARMA BV	**80MG**	**N019865**	**001**	Oct 30, 1992
AB	**+**		**120MG**	**N019865**	**005**	Apr 20, 1994
AB	**+!**		**160MG**	**N019865**	**002**	Oct 30, 1992
AB	**+**		**240MG**	**N019865**	**003**	Oct 30, 1992

BETAPACE AF

AB	**+**	COVIS PHARMA BV	**80MG**	**N021151**	**001**	Feb 22, 2000
AB	**+**		**120MG**	**N021151**	**002**	Feb 22, 2000
AB	**+!**		**160MG**	**N021151**	**003**	Feb 22, 2000

SORINE

AB		UPSHER SMITH LABS	**80MG**	**A075500**	**001**	Apr 27, 2001
AB			**120MG**	**A075500**	**004**	Apr 27, 2001
AB			**160MG**	**A075500**	**002**	Apr 27, 2001
AB			**240MG**	**A075500**	**003**	Apr 27, 2001

SOTALOL HYDROCHLORIDE

AB		APOTEX	**80MG**	**A076140**	**001**	Sep 26, 2002
AB			**80MG**	**A076214**	**001**	Aug 27, 2003
AB			**120MG**	**A076140**	**002**	Sep 26, 2002
AB			**120MG**	**A076214**	**002**	Aug 27, 2003
AB			**160MG**	**A076140**	**003**	Sep 26, 2002
AB			**160MG**	**A076214**	**003**	Aug 27, 2003
AB			**240MG**	**A076140**	**004**	Sep 26, 2002
AB		BEXIMCO PHARMS USA	**80MG**	**A207428**	**001**	Oct 21, 2016
AB			**80MG**	**A207429**	**001**	Nov 02, 2018
AB			**120MG**	**A207428**	**002**	Oct 21, 2016
AB			**120MG**	**A207429**	**002**	Nov 02, 2018
AB			**160MG**	**A207428**	**003**	Oct 21, 2016
AB			**160MG**	**A207429**	**003**	Nov 02, 2018
AB		EPIC PHARMA INC	**80MG**	**A077070**	**001**	Nov 04, 2005
AB			**120MG**	**A077070**	**002**	Nov 04, 2005
AB			**160MG**	**A077070**	**003**	Nov 04, 2005
AB		MYLAN	**80MG**	**A077616**	**001**	Feb 07, 2007
AB			**120MG**	**A077616**	**002**	Feb 07, 2007
AB			**160MG**	**A077616**	**003**	Feb 07, 2007
AB		OXFORD PHARMS	**80MG**	**A075563**	**001**	Nov 07, 2003
AB			**120MG**	**A075563**	**002**	Nov 07, 2003
AB			**160MG**	**A075563**	**003**	Nov 07, 2003
AB			**240MG**	**A075563**	**004**	Nov 07, 2003
AB		TEVA	**80MG**	**A075429**	**001**	May 01, 2000
AB			**120MG**	**A075429**	**002**	May 01, 2000
AB			**160MG**	**A075429**	**003**	May 01, 2000
AB			**240MG**	**A075429**	**004**	May 01, 2000

SOYBEAN OIL

INJECTABLE;INJECTION

INTRALIPID 10%

AP	**+!**	FRESENIUS	**10%**	**N017643**	**001**	

INTRALIPID 20%

AP	**+!**	FRESENIUS	**20%**	**N018449**	**001**	
AP	**+!**		**20%**	**N020248**	**001**	Aug 07, 1996

NUTRILIPID 10%

AP	**+!**	B BRAUN	**10%**	**N019531**	**001**	May 28, 1993

NUTRILIPID 20%

AP	**+!**	B BRAUN	**20%**	**N019531**	**002**	May 28, 1993

INTRALIPID 30%

	+!	FRESENIUS	30%	N019942	001	Dec 30, 1993

SPINOSAD

SUSPENSION;TOPICAL

NATROBA

	+!	PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011

SPIRONOLACTONE

SUSPENSION;ORAL

CAROSPIR

	+!	CMP DEV LLC	25MG/5ML	N209478	001	Aug 04, 2017

TABLET;ORAL

ALDACTONE

AB	**+**	GD SEARLE LLC	**25MG**	**N012151**	**009**	Dec 30, 1983
AB	**+**		**50MG**	**N012151**	**008**	Dec 30, 1982
AB	**+!**		**100MG**	**N012151**	**010**	Dec 30, 1983

SPIRONOLACTONE

AB		ACCORD HLTHCARE	**25MG**	**A203512**	**001**	Sep 19, 2016
AB			**50MG**	**A203512**	**002**	Sep 19, 2016
AB			**100MG**	**A203512**	**003**	Sep 19, 2016
AB		AMNEAL PHARMS	**25MG**	**A091426**	**001**	Jul 02, 2010
AB			**50MG**	**A091426**	**002**	Jul 02, 2010
AB			**100MG**	**A091426**	**003**	Jul 02, 2010
AB		JUBILANT GENERICS	**25MG**	**A203253**	**001**	Apr 23, 2014
AB			**50MG**	**A203253**	**002**	Apr 23, 2014
AB			**100MG**	**A203253**	**003**	Apr 23, 2014
AB		MYLAN	**25MG**	**A040424**	**001**	Aug 20, 2001
AB			**50MG**	**A040424**	**002**	Aug 20, 2001
AB			**100MG**	**A040424**	**003**	Aug 20, 2001
AB		OXFORD PHARMS	**25MG**	**A040750**	**001**	Aug 29, 2006
AB			**50MG**	**A040750**	**002**	Aug 29, 2006
AB			**100MG**	**A040750**	**003**	Aug 29, 2006
AB		SUN PHARM INDUSTRIES	**25MG**	**A089424**	**001**	Jul 23, 1986
AB			**50MG**	**A089424**	**002**	Aug 11, 1999
AB			**100MG**	**A089424**	**003**	Aug 11, 1999
AB		ZYDUS PHARMS	**25MG**	**A205936**	**001**	Jul 18, 2018
AB			**50MG**	**A205936**	**002**	Jul 18, 2018
AB			**100MG**	**A205936**	**003**	Jul 18, 2018

STAVUDINE

CAPSULE;ORAL

STAVUDINE

AB		AUROBINDO PHARMA	**15MG**	**A077672**	**003**	Dec 29, 2008
AB			**20MG**	**A077672**	**004**	Dec 29, 2008
AB			**30MG**	**A077672**	**001**	Dec 29, 2008
AB			**40MG**	**A077672**	**002**	Dec 29, 2008

ZERIT

AB	**+**	BRISTOL MYERS SQUIBB	**15MG**	**N020412**	**002**	Jun 24, 1994
AB	**+**		**20MG**	**N020412**	**003**	Jun 24, 1994
AB	**+**		**30MG**	**N020412**	**004**	Jun 24, 1994
AB	**+!**		**40MG**	**N020412**	**005**	Jun 24, 1994

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**100%**	**N018802**	**001**	Oct 27, 1982

STERILE WATER FOR INJECTION

AP		FRESENIUS KABI USA	**100%**	**A209689**	**001**	Nov 24, 2017
AP	**+!**	HOSPIRA	**100% (10ML)**	**N018801**	**002**	Oct 27, 1982
AP		MEDEFIL INC	**100% (10ML)**	**A211188**	**005**	Dec 02, 2019
AP		WEST-WARD PHARMS INT	**100% (10ML)**	**A206369**	**001**	Sep 02, 2015

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**100%**	**N019633**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**100%**	**N018632**	**001**	Jun 30, 1982
AP	**+!**		**100%**	**N018632**	**002**	Apr 19, 1988
AP		FRESENIUS KABI USA	**100%**	**A088400**	**001**	Jan 16, 1984
AP	**+!**	ICU MEDICAL INC	**100%**	**N018233**	**001**	
AP	**+!**		**100%**	**N019869**	**001**	Dec 26, 1989
AP		TARO	**100%**	**A077393**	**001**	Aug 11, 2006

STERILE WATER FOR INJECTION

	+!	HOSPIRA	100% (20ML)	N018801	003	Oct 27, 1982
	+!		100% (50ML)	N018801	004	Oct 27, 1982
	+!		100% (100ML)	N018801	005	Oct 27, 1982
		MEDEFIL INC	100% (1ML)	A211188	001	Dec 02, 2019
	!		100% (2.5ML)	A211188	002	Dec 02, 2019
	!		100% (3ML)	A211188	003	Dec 02, 2019
	!		100% (5ML)	A211188	004	Dec 02, 2019

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER

AT	**+**	BAXTER HLTHCARE	**100%**	**N017428**	**001**		

STERILE WATER IN PLASTIC CONTAINER

AT	**+**	B BRAUN	**100%**	**N016734**	**001**		
AT		BAXTER HLTHCARE	**100%**	**N017866**	**001**		
AT		ICU MEDICAL INC	**100%**	**N017513**	**001**		
AT			**100%**	**N018313**	**001**		

STIRIPENTOL

CAPSULE;ORAL

DIACOMIT

	+	BIOCODEX SA	250MG	N206709	001	Aug 20, 2018	
	+!		500MG	N206709	002	Aug 20, 2018	

FOR SUSPENSION;ORAL

DIACOMIT

	+	BIOCODEX SA	250MG/PACKET	N207223	001	Aug 20, 2018	
	+!		500MG/PACKET	N207223	002	Aug 20, 2018	

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

	!	X GEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998	

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

	+!	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON

AP	**+!**	Q BIOMED	**1mCi/ML**	**N020134**	**001**	Jun 18, 1993	

STRONTIUM CHLORIDE SR-89

AP		Q BIOMED	**1mCi/ML**	**A075941**	**001**	Jan 06, 2003	

SUCCIMER

CAPSULE;ORAL

CHEMET

	+!	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

AP	**+!**	SANDOZ INC	**20MG/ML**	**N008453**	**002**		

QUELICIN

AP	**+!**	HOSPIRA	**20MG/ML**	**N008845**	**006**		

SUCCINYLCHOLINE CHLORIDE

AP		AMNEAL	**20MG/ML**	**A211432**	**001**	Nov 16, 2018	
AP		AMRING PHARMS	**20MG/ML**	**A210231**	**001**	Jun 04, 2018	
AP		BRECKENRIDGE	**20MG/ML**	**A212638**	**001**	Oct 09, 2019	
AP		DR REDDYS	**20MG/ML**	**A210698**	**001**	Aug 02, 2019	
AP		SOMERSET THERAPS LLC	**20MG/ML**	**A211589**	**001**	Jan 15, 2020	
AP	**!**	ZYDUS PHARMS	**20MG/ML**	**A209467**	**001**	May 04, 2018	

SUCRALFATE

SUSPENSION;ORAL

CARAFATE

AB	**+!**	ALLERGAN	**1GM/10ML**	**N019183**	**001**	Dec 16, 1993	

SUCRALFATE

AB		AMNEAL PHARMS LLC	**1GM/10ML**	**A209356**	**001**	Dec 02, 2019	

TABLET;ORAL

CARAFATE

AB	**+!**	ALLERGAN	**1GM**	**N018333**	**001**		

SUCRALFATE

AB		TEVA	**1GM**	**A070848**	**001**	Mar 29, 1996	

SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE;ORAL

VELPHORO

	+!	VIFOR FRESENIUS	500MG	N205109	001	Nov 27, 2013	

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTA PRESERVATIVE FREE

AP	**+!**	AKORN	**EQ 0.05MG BASE/ML**	**N019050**	**001**	May 04, 1984

SUFENTANIL CITRATE

AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A074534**	**001**	Dec 11, 1996
AP		WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**A074413**	**001**	Dec 15, 1995

TABLET;SUBLINGUAL

DSUVIA

	+!	ACELRX PHARMS	EQ 0.03MG BASE	N209128	001	Nov 02, 2018

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

	+	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015
	+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015

SULCONAZOLE NITRATE

CREAM;TOPICAL

EXELDERM

	+!	JOURNEY	1%	N018737	001	Feb 28, 1989

SOLUTION;TOPICAL

EXELDERM

	+!	JOURNEY	1%	N018738	001	Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON

AB	**+!**	VALEANT PHARMS NORTH	**10%**	**N019931**	**001**	Dec 23, 1996

SULFACETAMIDE SODIUM

AB		FOUGERA PHARMS	**10%**	**A077015**	**001**	Nov 17, 2006
AB		PERRIGO CO TENNESSEE	**10%**	**A078649**	**001**	Mar 23, 2009
AB		TARO	**10%**	**A078668**	**001**	May 20, 2009

OINTMENT;OPHTHALMIC

SULFACETAMIDE SODIUM

	!	PERRIGO CO TENNESSEE	10%	A080029	001	

SOLUTION/DROPS;OPHTHALMIC

BLEPH-10

AT	**!**	ALLERGAN	**10%**	**A080028**	**001**	

SULFACETAMIDE SODIUM

AT		AKORN	**10%**	**A040215**	**001**	May 25, 1999
AT		BAUSCH AND LOMB	**10%**	**A040066**	**001**	Dec 28, 1994
AT		SANDOZ INC	**10%**	**A089560**	**001**	Oct 18, 1988

SULFADIAZINE

TABLET;ORAL

SULFADIAZINE

	!	SANDOZ	500MG	A040091	001	Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	**!**	MYLAN LABS LTD	**80MG/ML;16MG/ML**	**A206607**	**001**	Aug 30, 2017
AP		SOMERSET	**80MG/ML;16MG/ML**	**A212231**	**001**	Jun 26, 2019

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		ANI PHARMS INC	**200MG/5ML;40MG/5ML**	**A077612**	**001**	Nov 13, 2006
AB		AUROBINDO PHARMA	**200MG/5ML;40MG/5ML**	**A091348**	**001**	Jun 08, 2010
AB	**!**	HI TECH PHARMA	**200MG/5ML;40MG/5ML**	**A074650**	**001**	Dec 29, 1997
AB		LANNETT CO INC	**200MG/5ML;40MG/5ML**	**A077785**	**001**	Jan 24, 2007

SULFATRIM PEDIATRIC

AB		PHARM ASSOC	**200MG/5ML;40MG/5ML**	**N018615**	**001**	Jan 07, 1983

TABLET;ORAL

BACTRIM

AB	**+**	SUN PHARM INDUSTRIES	**400MG;80MG**	**N017377**	**001**	

BACTRIM DS

AB	**+!**	SUN PHARM INDUSTRIES	**800MG;160MG**	**N017377**	**002**	

SEPTRA

AB		MONARCH PHARMS	**400MG;80MG**	**N017376**	**001**	

PRESCRIPTION DRUG PRODUCT LIST

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SEPTRA DS

AB		MONARCH PHARMS	**800MG;160MG**	**N017376**	**002**	

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		AMNEAL PHARMS NY	**400MG;80MG**	**A076899**	**001**	Jan 27, 2005
AB			**800MG;160MG**	**A076899**	**002**	Jan 27, 2005
AB		AUROBINDO PHARMA	**400MG;80MG**	**A090624**	**001**	Feb 16, 2010
AB			**800MG;160MG**	**A090624**	**002**	Feb 16, 2010
AB		CHARTWELL MOLECULES	**400MG;80MG**	**A078060**	**002**	Jan 25, 2007
AB			**800MG;160MG**	**A078060**	**001**	Jan 25, 2007
AB		GLENMARK GENERICS	**400MG;80MG**	**A090828**	**002**	Dec 22, 2010
AB			**800MG;160MG**	**A090828**	**001**	Dec 22, 2010
AB		SUN PHARM INDUSTRIES	**400MG;80MG**	**A071017**	**002**	Aug 25, 1986
AB			**800MG;160MG**	**A071017**	**001**	Aug 25, 1986
AB		VISTA PHARMS	**400MG;80MG**	**A076817**	**001**	Oct 07, 2005
AB			**800MG;160MG**	**A076817**	**002**	Oct 07, 2005

SULFANILAMIDE

CREAM;VAGINAL

AVC

	+!	MYLAN SPECIALITY LP	15%	N006530	003	Jan 27, 1987

SULFASALAZINE

TABLET;ORAL

AZULFIDINE

AB	**+!**	PHARMACIA AND UPJOHN	**500MG**	**N007073**	**001**	

SULFASALAZINE

AB		VINTAGE PHARMS	**500MG**	**A040349**	**001**	Jan 11, 2002
AB		WATSON LABS	**500MG**	**A085828**	**001**	

TABLET, DELAYED RELEASE;ORAL

AZULFIDINE EN-TABS

AB	**+!**	PHARMACIA AND UPJOHN	**500MG**	**N007073**	**002**	Apr 06, 1983

SULFASALAZINE

AB		VINTAGE PHARMS	**500MG**	**A075339**	**001**	Jan 11, 2002

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION;INTRAVENOUS

LUMASON

	+!	BRACCO	60.7MG/25MG	N203684	001	Oct 15, 2014

SULINDAC

TABLET;ORAL

SULINDAC

AB		EPIC PHARMA	**150MG**	**A072710**	**001**	Mar 25, 1991
AB			**200MG**	**A072711**	**001**	Mar 25, 1991
AB		MYLAN	**150MG**	**A073039**	**002**	Jun 22, 1993
AB			**200MG**	**A073039**	**001**	Jun 22, 1993
AB		SUN PHARM INDUSTRIES	**150MG**	**A072050**	**001**	Apr 17, 1991
AB			**200MG**	**A072051**	**001**	Apr 17, 1991
AB		WATSON LABS	**150MG**	**A071891**	**001**	Apr 03, 1990
AB	**!**		**200MG**	**A071795**	**001**	Apr 03, 1990

SUMATRIPTAN

SPRAY;NASAL

IMITREX

AB	**+!**	GLAXOSMITHKLINE	**5MG/SPRAY**	**N020626**	**001**	Aug 26, 1997
AB	**+!**		**20MG/SPRAY**	**N020626**	**003**	Aug 26, 1997

SUMATRIPTAN

AB		LANNETT CO INC	**5MG/SPRAY**	**A204841**	**001**	Feb 19, 2016
AB			**20MG/SPRAY**	**A204841**	**002**	Feb 19, 2016

TOSYMRA

	+!	UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX STATDOSE

AB	**+!**	GLAXOSMITHKLINE	**EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)**	**N020080**	**002**	Feb 01, 2006
AB	**+!**		**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080**	**003**	Dec 23, 1996

SUMATRIPTAN SUCCINATE

AB		ANTARES PHARMA INC	**EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)**	**A078319**	**001**	Dec 10, 2015
AB			**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A078319**	**002**	Dec 10, 2015

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AB		DR REDDYS	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090495**	**001**	Jan 29, 2014
AB		SUN PHARM	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090358**	**001**	Jun 21, 2011

IMITREX

AP	**+!**	GLAXOSMITHKLINE	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080**	**001**	Dec 28, 1992

SUMATRIPTAN SUCCINATE

AP		AUROBINDO PHARMA LTD	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A202758**	**001**	Apr 23, 2013
AP		FRESENIUS KABI USA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079242**	**001**	Mar 02, 2009
AP		HIKMA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A200183**	**001**	Sep 16, 2013
AP		MYLAN ASI	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090314**	**001**	Jun 10, 2010
AP			**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090641**	**001**	Jul 28, 2010
AP		PAR PHARM	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A077332**	**001**	Oct 09, 2009
AP		WEST-WARD PHARMS INT	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079123**	**001**	Feb 06, 2009
AP		WOCKHARDT	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A078593**	**001**	Feb 06, 2009

POWDER;NASAL

ONZETRA XSAIL

	+!	CURRAX	EQ 11MG BASE	N206099	001	Jan 27, 2016

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

	+	UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016

TABLET;ORAL

IMITREX

AB	**+**	GLAXOSMITHKLINE	**EQ 25MG BASE**	**N020132**	**002**	Jun 01, 1995
AB	**+**		**EQ 50MG BASE**	**N020132**	**003**	Jun 01, 1995
AB	**+!**		**EQ 100MG BASE**	**N020132**	**001**	Jun 01, 1995

SUMATRIPTAN SUCCINATE

AB		APOTEX INC	**EQ 25MG BASE**	**A200263**	**001**	Jun 19, 2012
AB			**EQ 50MG BASE**	**A200263**	**002**	Jun 19, 2012
AB			**EQ 100MG BASE**	**A200263**	**003**	Jun 19, 2012
AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A078327**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078327**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078327**	**003**	Aug 10, 2009
AB		DR REDDYS LABS INC	**EQ 25MG BASE**	**A076847**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076847**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076847**	**003**	Aug 10, 2009
AB		MYLAN	**EQ 25MG BASE**	**A077744**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A077744**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A077744**	**003**	Aug 10, 2009
AB		ORCHID HLTHCARE	**EQ 25MG BASE**	**A078284**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078284**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078284**	**003**	Aug 10, 2009
AB		SUN PHARM INDS	**EQ 25MG BASE**	**A078295**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078295**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078295**	**003**	Aug 10, 2009
AB		SUN PHARM INDS LTD	**EQ 25MG BASE**	**A076554**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076554**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076572**	**001**	Feb 09, 2009
AB		WATSON LABS	**EQ 25MG BASE**	**A076933**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076933**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076933**	**003**	Aug 10, 2009

SUNITINIB MALATE

CAPSULE;ORAL

SUTENT

	+	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006
	+		EQ 25MG BASE	N021938	002	Jan 26, 2006
	+		EQ 37.5MG BASE	N021938	004	Mar 31, 2009
	+!		EQ 50MG BASE	N021938	003	Jan 26, 2006

SUVOREXANT

TABLET;ORAL

BELSOMRA

	+	MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014
	+		10MG	N204569	002	Aug 13, 2014
	+		15MG	N204569	003	Aug 13, 2014
	+!		20MG	N204569	004	Aug 13, 2014

TACROLIMUS

CAPSULE;ORAL

	PROGRAF						
AB	**+**	ASTELLAS	**EQ 0.5MG BASE**	**N050708**	**003**	Aug 24, 1998
AB	**+**		**EQ 1MG BASE**	**N050708**	**001**	Apr 08, 1994
AB	**+!**		**EQ 5MG BASE**	**N050708**	**002**	Apr 08, 1994
	TACROLIMUS						
AB		ACCORD HLTHCARE	**EQ 0.5MG BASE**	**A091195**	**001**	Aug 31, 2011
AB			**EQ 1MG BASE**	**A091195**	**002**	Aug 31, 2011
AB			**EQ 5MG BASE**	**A091195**	**003**	Aug 31, 2011
AB		BELCHER PHARMS LLC	**EQ 0.5MG BASE**	**A206651**	**001**	Nov 30, 2017
AB			**EQ 1MG BASE**	**A206651**	**002**	Nov 30, 2017
AB			**EQ 5MG BASE**	**A206651**	**003**	Nov 30, 2017
AB		DR REDDYS LABS LTD	**EQ 0.5MG BASE**	**A090509**	**001**	May 12, 2010
AB			**EQ 1MG BASE**	**A090509**	**002**	May 12, 2010
AB			**EQ 5MG BASE**	**A090509**	**003**	May 12, 2010
AB		MYLAN	**EQ 0.5MG BASE**	**A090596**	**001**	Sep 17, 2010
AB			**EQ 1MG BASE**	**A090596**	**002**	Sep 17, 2010
AB			**EQ 5MG BASE**	**A090596**	**003**	Sep 17, 2010
AB		PANACEA BIOTEC LTD	**EQ 0.5MG BASE**	**A090802**	**001**	Sep 28, 2012
AB			**EQ 1MG BASE**	**A090802**	**002**	Sep 28, 2012
AB			**EQ 5MG BASE**	**A090802**	**003**	Sep 28, 2012
AB		SANDOZ	**EQ 0.5MG BASE**	**A065461**	**001**	Aug 10, 2009
AB			**EQ 1MG BASE**	**A065461**	**002**	Aug 10, 2009
AB			**EQ 5MG BASE**	**A065461**	**003**	Aug 10, 2009
AB		STRIDES PHARMA	**EQ 0.5MG BASE**	**A090687**	**001**	Jul 22, 2014
AB			**EQ 1MG BASE**	**A090687**	**002**	Jul 22, 2014
AB			**EQ 5MG BASE**	**A090687**	**003**	Jul 22, 2014

CAPSULE, EXTENDED RELEASE;ORAL

	ASTAGRAF XL					
	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013
	+		EQ 1MG BASE	N204096	002	Jul 19, 2013
	+!		EQ 5MG BASE	N204096	003	Jul 19, 2013

FOR SUSPENSION;ORAL

	PROGRAF					
	+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018
	+!		EQ 1MG BASE/PACKET	N210115	002	May 24, 2018

INJECTABLE;INJECTION

	PROGRAF						
AP	**+!**	ASTELLAS	**EQ 5MG BASE/ML**	**N050709**	**001**	Apr 08, 1994
	TACROLIMUS						
AP		HOSPIRA INC	**EQ 5MG BASE/ML**	**A203900**	**001**	Aug 25, 2017

OINTMENT;TOPICAL

	PROTOPIC						
AB	**+!**	LEO PHARMA AS	**0.03%**	**N050777**	**001**	Dec 08, 2000
AB	**+!**		**0.1%**	**N050777**	**002**	Dec 08, 2000
	TACROLIMUS						
AB		ACCORD HLTHCARE	**0.03%**	**A211688**	**001**	Jan 31, 2019
AB			**0.1%**	**A211688**	**002**	Jan 31, 2019
AB		FOUGERA PHARMS INC	**0.03%**	**A200744**	**001**	Sep 09, 2014
AB			**0.1%**	**A200744**	**002**	Sep 09, 2014
AB		GLENMARK PHARMS LTD	**0.1%**	**A210393**	**001**	Apr 16, 2018

TABLET, EXTENDED RELEASE;ORAL

	ENVARSUS XR					
	+	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015
	+		EQ 1MG BASE	N206406	002	Jul 10, 2015
	+!		EQ 4MG BASE	N206406	003	Jul 10, 2015

TADALAFIL

TABLET;ORAL

	CIALIS						
AB	**+**	LILLY	**2.5MG**	**N021368**	**004**	Jan 07, 2008
AB	**+**		**5MG**	**N021368**	**001**	Nov 21, 2003
AB	**+**		**10MG**	**N021368**	**002**	Nov 21, 2003
	TADALAFIL						
AB		ACCORD HLTHCARE	**2.5MG**	**A209167**	**001**	Mar 26, 2019
AB			**5MG**	**A209167**	**002**	Mar 26, 2019
AB		AJANTA PHARMA LTD	**2.5MG**	**A209654**	**001**	Mar 26, 2019
AB			**5MG**	**A209654**	**002**	Mar 26, 2019
AB			**10MG**	**A209654**	**003**	Mar 26, 2019
AB		ALEMBIC PHARMS LTD	**2.5MG**	**A204809**	**001**	Mar 26, 2019
AB			**5MG**	**A204809**	**002**	Mar 26, 2019
AB			**10MG**	**A204809**	**003**	Mar 26, 2019

TADALAFIL

TABLET;ORAL

TADALAFIL						
AB	AMNEAL PHARMS CO	**2.5MG**	**A209744**	**001**	Mar 26, 2019
AB		**5MG**	**A209744**	**002**	Mar 26, 2019
AB		**10MG**	**A209744**	**003**	Mar 26, 2019
AB	AUROBINDO PHARMA LTD	**2.5MG**	**A206285**	**001**	Mar 26, 2019
AB		**5MG**	**A206285**	**002**	Mar 26, 2019
AB		**10MG**	**A206285**	**003**	Mar 26, 2019
AB	CIPLA	**2.5MG**	**A209539**	**001**	Mar 26, 2019
AB		**5MG**	**A209539**	**002**	Mar 26, 2019
AB		**10MG**	**A209539**	**003**	Mar 26, 2019
AB	DR REDDYS LABS LTD	**2.5MG**	**A210069**	**001**	Mar 26, 2019
AB		**5MG**	**A210069**	**002**	Mar 26, 2019
AB		**10MG**	**A210069**	**003**	Mar 26, 2019
AB	HETERO LABS LTD III	**2.5MG**	**A209908**	**001**	Mar 26, 2019
AB		**5MG**	**A209908**	**002**	Mar 26, 2019
AB		**10MG**	**A209908**	**003**	Mar 26, 2019
AB	LUPIN LTD	**2.5MG**	**A210567**	**001**	Mar 26, 2019
AB		**5MG**	**A210567**	**002**	Mar 26, 2019
AB		**10MG**	**A210567**	**003**	Mar 26, 2019
AB	MACLEODS PHARMS LTD	**2.5MG**	**A207244**	**001**	Oct 07, 2019
AB		**5MG**	**A207244**	**002**	Oct 07, 2019
AB		**10MG**	**A207244**	**003**	Oct 07, 2019
AB	MYLAN	**2.5MG**	**A206956**	**001**	Apr 29, 2019
AB		**5MG**	**A206957**	**001**	Apr 29, 2019
AB		**10MG**	**A206956**	**002**	Apr 29, 2019
AB	QILU	**2.5MG**	**A210420**	**001**	Mar 26, 2019
AB		**5MG**	**A210420**	**002**	Mar 26, 2019
AB		**10MG**	**A210420**	**003**	Mar 26, 2019
AB	SUN PHARM	**2.5MG**	**A208934**	**001**	Mar 26, 2019
AB		**5MG**	**A208934**	**002**	Mar 26, 2019
AB		**10MG**	**A208934**	**003**	Mar 26, 2019
AB	SUNSHINE LAKE	**2.5MG**	**A211335**	**001**	Mar 26, 2019
AB		**5MG**	**A211335**	**002**	Mar 26, 2019
AB		**10MG**	**A211335**	**003**	Mar 26, 2019
AB	TEVA PHARMS USA	**2.5MG**	**A090141**	**001**	May 22, 2018
AB		**5MG**	**A090141**	**002**	May 22, 2018
AB		**10MG**	**A090141**	**003**	May 22, 2018
AB	TORRENT	**2.5MG**	**A211839**	**001**	Mar 26, 2019
AB		**5MG**	**A211839**	**002**	Mar 26, 2019
AB		**10MG**	**A211839**	**003**	Mar 26, 2019
AB	UNICHEM LABS LTD	**2.5MG**	**A209250**	**001**	Mar 26, 2019
AB		**5MG**	**A209250**	**002**	Mar 26, 2019
AB		**10MG**	**A209250**	**003**	Mar 26, 2019
AB	ZYDUS PHARMS	**2.5MG**	**A206693**	**001**	Mar 26, 2019
AB		**5MG**	**A206693**	**002**	Mar 26, 2019
AB		**10MG**	**A206693**	**003**	Mar 26, 2019
CIALIS					
AB1 **+!**	LILLY	**20MG**	**N021368**	**003**	Nov 21, 2003
TADALAFIL					
AB1	ACCORD HLTHCARE	**20MG**	**A209167**	**004**	Mar 26, 2019
AB1	AJANTA PHARMA LTD	**20MG**	**A209654**	**004**	Mar 26, 2019
AB1	ALEMBIC PHARMS LTD	**20MG**	**A204809**	**004**	Mar 26, 2019
AB1	AMNEAL PHARMS CO	**20MG**	**A209744**	**004**	Mar 26, 2019
AB1	AUROBINDO PHARMA LTD	**20MG**	**A206285**	**004**	Mar 26, 2019
AB1	CIPLA	**20MG**	**A209539**	**004**	Mar 26, 2019
AB1	DR REDDYS LABS LTD	**20MG**	**A210069**	**004**	Mar 26, 2019
AB1	HETERO LABS LTD III	**20MG**	**A209908**	**004**	Mar 26, 2019
AB1	LUPIN LTD	**20MG**	**A210567**	**004**	Mar 26, 2019
AB1	MACLEODS PHARMS LTD	**20MG**	**A207244**	**004**	Oct 07, 2019
AB1	MYLAN	**20MG**	**A206956**	**003**	Apr 29, 2019
AB1	QILU	**20MG**	**A210420**	**004**	Mar 26, 2019
AB1	SUN PHARM	**20MG**	**A208934**	**004**	Mar 26, 2019
AB1	SUNSHINE LAKE	**20MG**	**A211335**	**004**	Mar 26, 2019
AB1	TEVA PHARMS USA	**20MG**	**A090141**	**004**	May 22, 2018
AB1	TORRENT	**20MG**	**A211839**	**004**	Mar 26, 2019
AB1	UNICHEM LABS LTD	**20MG**	**A209250**	**004**	Mar 26, 2019
AB1	ZYDUS PHARMS	**20MG**	**A206693**	**004**	Mar 26, 2019

TADALAFIL

TABLET;ORAL

ADCIRCA						
AB2	**+!**	ELI LILLY CO	**20MG**	**N022332**	**001**	May 22, 2009
ALYQ						
AB2		TEVA PHARMS USA	**20MG**	**A209942**	**001**	Feb 05, 2019
TADALAFIL						
AB2		AJANTA PHARMA LTD	**20MG**	**A210392**	**001**	Feb 05, 2019
AB2		AUROBINDO PHARMA LTD	**20MG**	**A206286**	**001**	Feb 05, 2019
AB2		CIPLA	**20MG**	**A210255**	**001**	Feb 05, 2019
AB2		DR REDDYS LABS LTD	**20MG**	**A210145**	**001**	Feb 05, 2019
AB2		HETERO LABS LTD III	**20MG**	**A209907**	**001**	Feb 05, 2019
AB2		LUPIN LTD	**20MG**	**A210572**	**001**	Feb 05, 2019
AB2		MACLEODS PHARMS LTD	**20MG**	**A207290**	**001**	Oct 16, 2019
AB2		MYLAN	**20MG**	**A200630**	**001**	Aug 03, 2018
AB2		TORRENT	**20MG**	**A212062**	**001**	Mar 26, 2019

TAFAMIDIS

CAPSULE;ORAL

VYNDAMAX						
	+!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL						
	+!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019

TAFENOQUINE SUCCINATE

TABLET;ORAL

ARAKODA						
	+!	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018
KRINTAFEL						
	+!	GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST						
AT		MICRO LABS	**0.0015%**	**A209051**	**001**	Aug 19, 2019
ZIOPTAN						
AT	**+!**	OAK PHARMS INC	**0.0015%**	**N202514**	**001**	Feb 10, 2012

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA						
	+	PFIZER INC	EQ 0.25MG BASE	N211651	001	Oct 16, 2018
	+!		EQ 1MG BASE	N211651	002	Oct 16, 2018

TALC

AEROSOL;INTRAPLEURAL

SCLEROSOL						
	+!	LYMOL MEDCL	4GM/SPRAY	N020587	001	Dec 24, 1997

POWDER;INTRAPLEURAL

STERITALC						
	+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017
	+		3GM/VIAL	N205555	002	May 01, 2017
	+!		4GM/VIAL	N205555	003	May 01, 2017
TALC						
	+!	LYMOL MEDCL	5GM/BOT	N021388	001	Dec 15, 2003

TALIGLUCERASE ALFA

POWDER;INTRAVENOUS

ELELYSO						
	+!	PFIZER	200 UNITS/VIAL	N022458	001	May 01, 2012

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX						
		FORTOVIA	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005

TABLET;ORAL

TAMOXIFEN CITRATE						
AB		ACTAVIS LABS FL INC	**EQ 10MG BASE**	**A070929**	**001**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A070929**	**002**	Feb 20, 2003
AB		APOTEX	**EQ 10MG BASE**	**A090878**	**001**	Sep 23, 2011
AB			**EQ 20MG BASE**	**A090878**	**002**	Sep 23, 2011
AB		MAYNE PHARMA	**EQ 10MG BASE**	**A075797**	**001**	Feb 20, 2003
AB	**!**		**EQ 20MG BASE**	**A075797**	**002**	Feb 20, 2003

TAMOXIFEN CITRATE						
TABLET;ORAL						
TAMOXIFEN CITRATE						
AB	MYLAN	**EQ 10MG BASE**	**A074732**	**002**	Feb 20, 2003
AB		**EQ 20MG BASE**	**A074732**	**001**	Feb 20, 2003
AB	ZYDUS PHARMS	**EQ 10MG BASE**	**A206694**	**001**	Oct 27, 2017
AB		**EQ 20MG BASE**	**A206694**	**002**	Oct 27, 2017
TAMSULOSIN HYDROCHLORIDE						
CAPSULE;ORAL						
FLOMAX						
AB **+!**	SANOFI AVENTIS US	**0.4MG**	**N020579**	**001**	Apr 15, 1997
TAMSULOSIN HYDROCHLORIDE						
AB	ALKEM LABS LTD	**0.4MG**	**A207405**	**001**	Aug 11, 2017
AB	ANBISON LAB	**0.4MG**	**A211885**	**001**	Oct 17, 2019
AB	ANCHEN PHARMS	**0.4MG**	**A202010**	**001**	Jan 04, 2013
AB	AUROBINDO PHARMA LTD	**0.4MG**	**A202433**	**001**	Apr 30, 2013
AB	IMPAX LABS	**0.4MG**	**A090377**	**001**	Mar 02, 2010
AB	MACLEODS PHARMS LTD	**0.4MG**	**A204645**	**001**	Jan 20, 2017
AB	SANDOZ	**0.4MG**	**A078015**	**001**	Apr 27, 2010
AB	SUN PHARM INDS LTD	**0.4MG**	**A090931**	**001**	Jul 15, 2010
AB	SYNTHON PHARMS	**0.4MG**	**A078801**	**001**	Apr 27, 2010
AB	TEVA PHARMS	**0.4MG**	**A077630**	**001**	Apr 27, 2010
AB	WOCKHARDT	**0.4MG**	**A078938**	**001**	Apr 27, 2010
AB	ZYDUS PHARMS USA INC	**0.4MG**	**A078225**	**001**	Apr 27, 2010
TAPENTADOL HYDROCHLORIDE						
TABLET;ORAL						
NUCYNTA						
+	DEPO NF	EQ 50MG BASE	N022304	001	Nov 20, 2008
+		EQ 75MG BASE	N022304	002	Nov 20, 2008
+!		EQ 100MG BASE	N022304	003	Nov 20, 2008
TABLET, EXTENDED RELEASE;ORAL						
NUCYNTA ER						
+	DEPO NF	EQ 50MG BASE	N200533	001	Aug 25, 2011
+		EQ 100MG BASE	N200533	002	Aug 25, 2011
+		EQ 150MG BASE	N200533	003	Aug 25, 2011
+		EQ 200MG BASE	N200533	004	Aug 25, 2011
+!		EQ 250MG BASE	N200533	005	Aug 25, 2011
TASIMELTEON						
CAPSULE;ORAL						
HETLIOZ						
+!	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014
TAVABOROLE						
SOLUTION;TOPICAL						
KERYDIN						
+!	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014
TAZAROTENE						
AEROSOL, FOAM;TOPICAL						
FABIOR						
+!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012
CREAM;TOPICAL						
AVAGE						
AB **+!**	ALLERGAN	**0.1%**	**N021184**	**003**	Sep 30, 2002
TAZAROTENE						
AB	ACP NIMBLE	**0.1%**	**A208662**	**001**	Dec 22, 2017
AB	TARO PHARMS	**0.1%**	**A208258**	**001**	Apr 03, 2017
TAZORAC						
AB **+!**	ALLERGAN	**0.1%**	**N021184**	**002**	Sep 29, 2000
+!		0.05%	N021184	001	Sep 29, 2000
GEL;TOPICAL						
TAZORAC						
+!	ALLERGAN	0.05%	N020600	001	Jun 13, 1997
+!		0.1%	N020600	002	Jun 13, 1997
LOTION;TOPICAL						
ARAZLO						
+!	BAUSCH	0.045%	N211882	001	Dec 18, 2019

PRESCRIPTION DRUG PRODUCT LIST

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
INJECTABLE;INJECTION
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS	+!	DRAXIMAGE	N/A	N017881	001	Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT
INJECTABLE;INJECTION
NEUROLITE

	+!	LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994

TECHNETIUM TC-99M EXAMETAZIME KIT
INJECTABLE;INJECTION
CERETEC

	+!	GE HEALTHCARE	N/A	N019829	001	Dec 30, 1988

POWDER;INTRAVENOUS
DRAX EXAMETAZIME

		JUBILANT DRAXIMAGE	N/A	N208870	001	Aug 17, 2017

TECHNETIUM TC-99M MEBROFENIN KIT
INJECTABLE;INJECTION
CHOLETEC

AP	**+!**	BRACCO	**N/A**	**N018963**	**001**	Jan 21, 1987

TECHNETIUM TC-99M MEBROFENIN

AP		PHARMALUCENCE	**N/A**	**A078242**	**001**	Jan 29, 2008

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-25

	+!	JUBILANT DRAXIMAGE	N/A	N018035	002	Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
CIS-MDP

		PHARMALUCENCE	N/A	N018124	001	

TECHNETIUM TC-99M MERTIATIDE KIT
INJECTABLE;INJECTION
TECHNESCAN MAG3

AP	**+!**	CURIUM	**N/A**	**N019882**	**001**	Jun 15, 1990

TECHNETIUM TC99M MERTIATIDE KIT

AP		PHARMALUCENCE	**N/A**	**A208994**	**001**	Jul 12, 2019

TECHNETIUM TC-99M OXIDRONATE KIT
INJECTABLE;INJECTION
TECHNESCAN

	+!	CURIUM	N/A	N018321	001	

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
DRAXIMAGE DTPA

	+!	JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
CIS-PYRO

AP		PHARMALUCENCE	**N/A**	**N019039**	**001**	Jun 30, 1987

TECHNESCAN PYP KIT

AP		CURIUM	**N/A**	**N017538**	**001**	

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
ULTRATAG

	+!	CURIUM	N/A	N019981	001	Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
CARDIOLITE

AP	**+!**	LANTHEUS MEDCL	**N/A**	**N019785**	**001**	Dec 21, 1990

TECHNETIUM TC 99M SESTAMIBI

AP		CARDINAL HEALTH 414	**N/A**	**A078809**	**001**	Apr 28, 2009
AP		JUBILANT DRAXIMAGE	**N/A**	**A078806**	**001**	Apr 29, 2009
AP		MALLINKRODT NUCLEAR	**N/A**	**A078098**	**001**	Sep 22, 2008
AP		PHARMALUCENCE	**10-30mCi**	**A079157**	**001**	Jul 10, 2009

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

TECHNELITE

+!	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014

ULTRA-TECHNEKOW FM

+!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014

SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC

RADIOGENIX SYSTEM

+	NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL

AN-SULFUR COLLOID

+!	PHARMALUCENCE	N/A	N017858	001	

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVIEW 30ML

+!	GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE;INJECTION

LYMPHOSEEK KIT

+!	CARDINAL HEALTH 414	N/A	N202207	001	Mar 13, 2013

TECOVIRIMAT

CAPSULE;ORAL

TPOXX

+!	SIGA TECHNOLOGIES	200MG	N208627	001	Jul 13, 2018

TEDIZOLID PHOSPHATE

POWDER;INTRAVENOUS

SIVEXTRO

+!	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014

TABLET;ORAL

SIVEXTRO

+!	CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014

TEDUGLUTIDE RECOMBINANT

POWDER;SUBCUTANEOUS

GATTEX KIT

+!	NPS PHARMS INC	5MG/VIAL	N203441	001	Dec 21, 2012

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

+!	ALFASIGMA	EQ 6MG BASE	N021200	002	Jul 24, 2002

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VIBATIV

+!	CUMBERLAND PHARMS	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009

TELMISARTAN

TABLET;ORAL

MICARDIS

AB	+	BOEHRINGER INGELHEIM	**20MG**	**N020850**	**003**	Apr 04, 2000
AB	+		**40MG**	**N020850**	**001**	Nov 10, 1998
AB	+!		**80MG**	**N020850**	**002**	Nov 10, 1998

TELMISARTAN

AB		ALEMBIC PHARMS LTD	**20MG**	**A202130**	**001**	Jul 07, 2014
AB			**40MG**	**A202130**	**002**	Jul 07, 2014
AB			**80MG**	**A202130**	**003**	Jul 07, 2014
AB		AMNEAL PHARMS	**20MG**	**A204415**	**001**	Sep 08, 2015
AB			**40MG**	**A204415**	**002**	Sep 08, 2015
AB			**80MG**	**A204415**	**003**	Sep 08, 2015
AB		AUROBINDO PHARMA LTD	**20MG**	**A206511**	**001**	Sep 03, 2015
AB			**40MG**	**A206511**	**002**	Sep 03, 2015
AB			**80MG**	**A206511**	**003**	Sep 03, 2015
AB		CADILA PHARMS LTD	**20MG**	**A208605**	**001**	Jul 25, 2017
AB			**40MG**	**A208605**	**002**	Jul 25, 2017
AB			**80MG**	**A208605**	**003**	Jul 25, 2017
AB		GLENMARK PHARMS LTD	**20MG**	**A090032**	**001**	Jul 07, 2014
AB			**40MG**	**A090032**	**002**	Jul 07, 2014
AB			**80MG**	**A090032**	**003**	Jul 07, 2014

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB		HETERO LABS LTD V	**20MG**	**A205901**	**001**	Apr 22, 2016
AB			**40MG**	**A205901**	**002**	Apr 22, 2016
AB			**80MG**	**A205901**	**003**	Apr 22, 2016
AB		INVENTIA	**20MG**	**A205150**	**001**	Oct 30, 2015
AB			**40MG**	**A205150**	**002**	Oct 30, 2015
AB			**80MG**	**A205150**	**003**	Oct 30, 2015
AB		JUBILANT GENERICS	**20MG**	**A204164**	**001**	Aug 22, 2016
AB			**40MG**	**A204164**	**002**	Aug 22, 2016
AB			**80MG**	**A204164**	**003**	Aug 22, 2016
AB		MYLAN	**20MG**	**A202397**	**001**	Jul 07, 2014
AB			**40MG**	**A202397**	**002**	Jul 07, 2014
AB			**80MG**	**A202397**	**003**	Jul 07, 2014
AB		PRINSTON INC	**20MG**	**A207882**	**001**	May 03, 2017
AB			**40MG**	**A207882**	**002**	May 03, 2017
AB			**80MG**	**A207882**	**003**	May 03, 2017
AB		SANDOZ INC	**20MG**	**A203867**	**001**	Nov 03, 2014
AB			**40MG**	**A203867**	**002**	Nov 03, 2014
AB			**80MG**	**A203867**	**003**	Nov 03, 2014
AB		TORRENT	**20MG**	**A203171**	**001**	Jul 07, 2014
AB			**40MG**	**A203171**	**002**	Jul 07, 2014
AB			**80MG**	**A203171**	**003**	Jul 07, 2014
AB		ZYDUS PHARMS	**20MG**	**A203325**	**001**	Aug 26, 2014
AB			**40MG**	**A203325**	**002**	Aug 26, 2014
AB			**80MG**	**A203325**	**003**	Aug 26, 2014

TELOTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

	+!	LEXICON PHARMS INC	EQ 250MG BASE	N208794	001	Feb 28, 2017

TEMAZEPAM

CAPSULE;ORAL

RESTORIL

AB	+	SPECGX LLC	**7.5MG**	**N018163**	**003**	Oct 25, 1991
AB	+		**15MG**	**N018163**	**001**	
AB	+		**22.5MG**	**N018163**	**004**	Nov 02, 2004
AB	+!		**30MG**	**N018163**	**002**	

TEMAZEPAM

AB		ACTAVIS ELIZABETH	**15MG**	**A071620**	**002**	Aug 07, 1987
AB			**30MG**	**A071620**	**001**	Aug 07, 1987
AB		ALEMBIC PHARMS LTD	**7.5MG**	**A211542**	**001**	Nov 23, 2018
AB			**15MG**	**A211542**	**002**	Nov 23, 2018
AB			**22.5MG**	**A211542**	**003**	Nov 23, 2018
AB			**30MG**	**A211542**	**004**	Nov 23, 2018
AB		AMNEAL PHARMS	**7.5MG**	**A203482**	**001**	May 23, 2016
AB			**15MG**	**A203482**	**002**	May 23, 2016
AB			**22.5MG**	**A203482**	**003**	May 23, 2016
AB			**30MG**	**A203482**	**004**	May 23, 2016
AB		MYLAN	**7.5MG**	**A070920**	**002**	May 21, 2010
AB			**15MG**	**A070920**	**004**	Jul 07, 1986
AB			**22.5MG**	**A070920**	**003**	Jun 12, 2009
AB			**30MG**	**A070920**	**001**	Jul 10, 1986
AB		NOVEL LABS INC	**7.5MG**	**A071457**	**002**	Jun 22, 2012
AB			**15MG**	**A071456**	**001**	Apr 21, 1987
AB			**22.5MG**	**A071457**	**003**	Jun 22, 2012
AB			**30MG**	**A071457**	**001**	Apr 21, 1987
AB		PRINSTON INC	**7.5MG**	**A201781**	**001**	Jun 04, 2015
AB			**15MG**	**A201781**	**002**	Jun 04, 2015
AB			**22.5MG**	**A201781**	**003**	Jun 04, 2015
AB			**30MG**	**A201781**	**004**	Jun 04, 2015
AB		SANDOZ	**15MG**	**A071427**	**001**	Jan 12, 1988
AB			**30MG**	**A071428**	**001**	Jan 12, 1988
AB		SUN PHARM INDUSTRIES	**7.5MG**	**A078581**	**001**	Sep 08, 2009
AB			**22.5MG**	**A071175**	**002**	Sep 14, 2009

TEMOZOLOMIDE

CAPSULE;ORAL

TEMODAR							
AB	+	MERCK SHARP DOHME	**5MG**	**N021029**	**001**	Aug 11, 1999
AB	+		**20MG**	**N021029**	**002**	Aug 11, 1999
AB	+		**100MG**	**N021029**	**003**	Aug 11, 1999
AB	+		**140MG**	**N021029**	**005**	Oct 19, 2006
AB	+		**180MG**	**N021029**	**006**	Oct 19, 2006
AB	+!		**250MG**	**N021029**	**004**	Aug 11, 1999
TEMOZOLOMIDE							
AB		ACCORD HLTHCARE	**5MG**	**A201528**	**001**	Feb 27, 2017
AB			**20MG**	**A201528**	**002**	Feb 27, 2017
AB			**100MG**	**A201528**	**003**	Feb 27, 2017
AB			**140MG**	**A201528**	**004**	Feb 27, 2017
AB			**180MG**	**A201528**	**005**	Feb 27, 2017
AB			**250MG**	**A201528**	**006**	Feb 27, 2017
AB		AMERIGEN PHARMS LTD	**5MG**	**A203490**	**001**	Jul 13, 2016
AB			**20MG**	**A203490**	**002**	Jul 13, 2016
AB			**100MG**	**A203490**	**003**	Jul 13, 2016
AB			**140MG**	**A203490**	**004**	Jul 13, 2016
AB			**180MG**	**A203490**	**005**	Jul 13, 2016
AB			**250MG**	**A203490**	**006**	Jul 13, 2016
AB		AMNEAL PHARMS	**5MG**	**A203691**	**001**	May 08, 2015
AB			**20MG**	**A203691**	**002**	May 08, 2015
AB			**100MG**	**A203691**	**003**	May 08, 2015
AB			**140MG**	**A203691**	**004**	May 08, 2015
AB			**180MG**	**A203691**	**005**	May 08, 2015
AB			**250MG**	**A203691**	**006**	May 08, 2015
AB		BARR	**5MG**	**A078879**	**001**	Mar 01, 2010
AB			**20MG**	**A078879**	**002**	Mar 01, 2010
AB			**100MG**	**A078879**	**003**	Mar 01, 2010
AB			**140MG**	**A078879**	**005**	Mar 01, 2010
AB			**180MG**	**A078879**	**006**	Mar 01, 2010
AB			**250MG**	**A078879**	**004**	Mar 01, 2010
AB		CHEMI SPA	**5MG**	**A204639**	**001**	Nov 23, 2016
AB			**20MG**	**A204639**	**002**	Nov 23, 2016
AB			**100MG**	**A204639**	**003**	Nov 23, 2016
AB			**140MG**	**A204639**	**004**	Nov 23, 2016
AB			**180MG**	**A204639**	**005**	Nov 23, 2016
AB			**250MG**	**A204639**	**006**	Nov 23, 2016
AB		DEVA HOLDING AS	**5MG**	**A207658**	**001**	Apr 26, 2017
AB			**20MG**	**A207658**	**002**	Apr 26, 2017
AB			**100MG**	**A207658**	**003**	Apr 26, 2017
AB			**140MG**	**A207658**	**004**	Apr 26, 2017
AB			**180MG**	**A207658**	**005**	Apr 26, 2017
AB			**250MG**	**A207658**	**006**	Apr 26, 2017
AB		IDT AUSTRALIA LTD	**5MG**	**A206413**	**001**	Apr 12, 2016
AB			**20MG**	**A206413**	**002**	Apr 12, 2016
AB			**100MG**	**A206413**	**003**	Apr 12, 2016
AB			**140MG**	**A206413**	**004**	Apr 12, 2016
AB			**180MG**	**A206413**	**005**	Apr 12, 2016
AB			**250MG**	**A206413**	**006**	Apr 12, 2016
AB		RISING	**5MG**	**A206309**	**001**	Apr 27, 2016
AB			**20MG**	**A206309**	**002**	Apr 27, 2016
AB			**100MG**	**A206309**	**003**	Apr 27, 2016
AB			**140MG**	**A206309**	**004**	Apr 27, 2016
AB			**180MG**	**A206309**	**005**	Apr 27, 2016
AB			**250MG**	**A206309**	**006**	Apr 27, 2016
AB		SUN PHARM	**5MG**	**A201742**	**001**	Feb 12, 2014
AB			**20MG**	**A201742**	**002**	Feb 12, 2014
AB			**100MG**	**A201742**	**003**	Feb 12, 2014
AB			**140MG**	**A201742**	**004**	Feb 12, 2014
AB			**180MG**	**A201742**	**005**	Feb 12, 2014
AB			**250MG**	**A201742**	**006**	Feb 12, 2014
AB		WATSON LABS TEVA	**5MG**	**A203959**	**001**	Apr 18, 2017
AB			**20MG**	**A203959**	**002**	Apr 18, 2017
AB			**100MG**	**A203959**	**003**	Apr 18, 2017
AB			**140MG**	**A203959**	**004**	Apr 18, 2017
AB			**250MG**	**A203959**	**005**	Apr 18, 2017
AB		ZYDUS PHARMS	**5MG**	**A206750**	**001**	Jul 31, 2017
AB			**20MG**	**A206750**	**002**	Jul 31, 2017
AB			**100MG**	**A206750**	**003**	Jul 31, 2017

TEMOZOLOMIDE
CAPSULE;ORAL
TEMOZOLOMIDE

AB			**140MG**	**A206750**	**004**	Jul 31, 2017
AB			**180MG**	**A206750**	**005**	Jul 31, 2017
AB			**250MG**	**A206750**	**006**	Jul 31, 2017

POWDER;INTRAVENOUS
TEMODAR

	+!	MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009

TEMSIROLIMUS
SOLUTION;INTRAVENOUS
TEMSIROLIMUS

AP		ACCORD HLTHCARE	**25MG/ML (25MG/ML)**	**A203153**	**001**	Jul 30, 2018
AP		GLAND PHARMA LTD	**25MG/ML (25MG/ML)**	**A207383**	**001**	Aug 16, 2019

TORISEL

AP	**+!**	PF PRISM CV	**25MG/ML (25MG/ML)**	**N022088**	**001**	May 30, 2007

TENAPANOR HYDROCHLORIDE
TABLET;ORAL
IBSRELA

	+!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019

TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
VEMLIDY

	+!	GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE
POWDER;ORAL
VIREAD

	+!	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	**150MG**	**A090647**	**001**	Jan 26, 2018
AB			**200MG**	**A090647**	**002**	Jan 26, 2018
AB			**250MG**	**A090647**	**003**	Jan 26, 2018
AB			**300MG**	**A090647**	**004**	Jan 26, 2018
AB		CASI PHARMS INC	**300MG**	**A209550**	**001**	Feb 26, 2018
AB		CIPLA	**300MG**	**A078800**	**001**	Jan 26, 2018
AB		HETERO LABS LTD III	**300MG**	**A090636**	**001**	Jan 26, 2018
AB		MACLEODS PHARMS LTD	**300MG**	**A203232**	**001**	Jan 26, 2018
AB		MYLAN	**150MG**	**A206569**	**001**	Nov 27, 2018
AB			**200MG**	**A206569**	**002**	Nov 27, 2018
AB			**250MG**	**A206569**	**003**	Nov 27, 2018
AB			**300MG**	**A206569**	**004**	Nov 27, 2018
AB		QILU	**200MG**	**A209498**	**001**	Mar 02, 2018
AB			**250MG**	**A209498**	**002**	Mar 02, 2018
AB			**300MG**	**A209498**	**003**	Mar 02, 2018
AB		STRIDES PHARMA	**300MG**	**A090742**	**001**	Jan 26, 2018
AB		TEVA PHARMS USA	**150MG**	**A091612**	**002**	Jan 26, 2018
AB			**200MG**	**A091612**	**003**	Jan 26, 2018
AB			**250MG**	**A091612**	**004**	Jan 26, 2018
AB			**300MG**	**A091612**	**001**	Mar 18, 2015

VIREAD

AB	**+**	GILEAD SCIENCES INC	**150MG**	**N021356**	**002**	Jan 18, 2012
AB	**+**		**200MG**	**N021356**	**003**	Jan 18, 2012
AB	**+**		**250MG**	**N021356**	**004**	Jan 18, 2012
AB	**+!**		**300MG**	**N021356**	**001**	Oct 26, 2001

TERAZOSIN HYDROCHLORIDE
CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE

AB		APNAR PHARMA LP	**EQ 1MG BASE**	**A074823**	**001**	Mar 30, 1998
AB	**!**		**EQ 2MG BASE**	**A074823**	**002**	Mar 30, 1998
AB			**EQ 5MG BASE**	**A074823**	**003**	Mar 30, 1998
AB			**EQ 10MG BASE**	**A074823**	**004**	Mar 30, 1998
AB		HERITAGE PHARMA	**EQ 1MG BASE**	**A075614**	**002**	Jan 30, 2001
AB			**EQ 2MG BASE**	**A075614**	**001**	Jan 30, 2001
AB			**EQ 5MG BASE**	**A075614**	**003**	Jan 30, 2001
AB			**EQ 10MG BASE**	**A075614**	**004**	Jan 30, 2001
AB		HIKMA	**EQ 1MG BASE**	**A075498**	**001**	Apr 12, 2001
AB			**EQ 2MG BASE**	**A075498**	**002**	Apr 12, 2001
AB			**EQ 5MG BASE**	**A075498**	**003**	Apr 12, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB			**EQ 10MG BASE**	**A075498**	**004**	Apr 12, 2001
AB		JUBILANT CADISTA	**EQ 1MG BASE**	**A075317**	**001**	Dec 20, 2004
AB			**EQ 2MG BASE**	**A075317**	**002**	Dec 20, 2004
AB			**EQ 5MG BASE**	**A075317**	**003**	Dec 20, 2004
AB			**EQ 10MG BASE**	**A075317**	**004**	Dec 20, 2004
AB		MYLAN	**EQ 1MG BASE**	**A075140**	**002**	Feb 11, 2000
AB			**EQ 2MG BASE**	**A075140**	**003**	Feb 11, 2000
AB			**EQ 5MG BASE**	**A075140**	**001**	Feb 11, 2000
AB			**EQ 10MG BASE**	**A075140**	**004**	Feb 11, 2000

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

LAMISIL

AB	**+!**	NOVARTIS	**EQ 250MG BASE**	**N020539**	**001**	May 10, 1996

TERBINAFINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A078297**	**001**	Jul 02, 2007
AB		BRECKENRIDGE PHARM	**EQ 250MG BASE**	**A077714**	**001**	Jun 04, 2010
AB		CIPLA	**EQ 250MG BASE**	**A077137**	**001**	Jul 02, 2007
AB		DR REDDYS LABS INC	**EQ 250MG BASE**	**A076390**	**001**	Jul 02, 2007
AB		GLENMARK GENERICS	**EQ 250MG BASE**	**A078157**	**001**	Jul 02, 2007
AB		HARRIS PHARM	**EQ 250MG BASE**	**A077919**	**001**	Jul 02, 2007
AB		HERITAGE PHARMA	**EQ 250MG BASE**	**A076377**	**001**	Jul 02, 2007
AB		INVAGEN PHARMS	**EQ 250MG BASE**	**A077533**	**001**	Jul 02, 2007
AB		ORCHID HLTHCARE	**EQ 250MG BASE**	**A078163**	**001**	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP		AKORN	**1MG/ML**	**A078151**	**001**	Jan 07, 2008
AP	**!**	ATHENEX INC	**1MG/ML**	**A076770**	**001**	Apr 23, 2004
AP		FRESENIUS KABI USA	**1MG/ML**	**A076887**	**001**	May 26, 2004
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078630**	**001**	May 20, 2009
AP		UNITED BIOMEDCL	**1MG/ML**	**A200122**	**001**	Nov 08, 2013

TABLET;ORAL

BRETHINE

AB	**+**	ANI PHARMS INC	**2.5MG**	**N017849**	**001**	
AB	**+**		**5MG**	**N017849**	**002**	

TERBUTALINE SULFATE

AB		IMPAX LABS	**2.5MG**	**A075877**	**001**	Jun 26, 2001
AB			**5MG**	**A075877**	**002**	Jun 26, 2001
AB		LANNETT CO INC	**2.5MG**	**A077152**	**001**	Mar 25, 2005
AB	**!**		**5MG**	**A077152**	**002**	Mar 25, 2005

TERCONAZOLE

CREAM;VAGINAL

TERCONAZOLE

AB		FOUGERA PHARMS	**0.4%**	**A076712**	**001**	Feb 18, 2005
AB	**!**	TARO	**0.4%**	**A076043**	**001**	Jan 19, 2005
BX	+!	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004
BX	!	TARO	0.8%	A075953	001	Apr 06, 2004

SUPPOSITORY;VAGINAL

TERCONAZOLE

AB	**!**	PERRIGO ISRAEL	**80MG**	**A077149**	**001**	Mar 17, 2006
AB		TARO	**80MG**	**A077553**	**001**	Mar 09, 2007

TERIFLUNOMIDE

TABLET;ORAL

AUBAGIO

AB	**+**	SANOFI AVENTIS US	**7MG**	**N202992**	**001**	Sep 12, 2012
AB	**+!**		**14MG**	**N202992**	**002**	Sep 12, 2012

TERIFLUNOMIDE

AB		ACCORD HLTHCARE	**7MG**	**A209690**	**001**	Jan 07, 2019
AB			**14MG**	**A209690**	**002**	Jan 07, 2019
AB		ALEMBIC PHARMS LTD	**7MG**	**A209572**	**001**	Apr 19, 2019
AB			**14MG**	**A209572**	**002**	Apr 19, 2019
AB		GLENMARK PHARMS	**7MG**	**A209663**	**001**	Nov 15, 2018
AB			**14MG**	**A209663**	**002**	Nov 15, 2018
AB		SANDOZ INC	**7MG**	**A209710**	**001**	Jan 03, 2019
AB			**14MG**	**A209710**	**002**	Jan 03, 2019

PRESCRIPTION DRUG PRODUCT LIST

TERIPARATIDE RECOMBINANT HUMAN							
INJECTABLE;SUBCUTANEOUS							
FORTEO							
	+!	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008
SOLUTION;SUBCUTANEOUS							
BONSITY							
		ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019
TESAMORELIN ACETATE							
POWDER;SUBCUTANEOUS							
EGRIFTA							
	+!	THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010
	+!		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011
TESTOSTERONE							
FILM, EXTENDED RELEASE;TRANSDERMAL							
ANDRODERM							
	+!	ALLERGAN	2MG/24HR	N020489	003	Oct 20, 2011
	+!		4MG/24HR	N020489	004	Oct 20, 2011
GEL;TRANSDERMAL							
ANDROGEL							
AB1	**+**	ABBVIE	**25MG/2.5GM PACKET**	**N021015**	**001**	Feb 28, 2000
AB1	**+!**		**50MG/5GM PACKET**	**N021015**	**002**	Feb 28, 2000
TESTOSTERONE							
AB1		ACTAVIS LABS UT INC	**25MG/2.5GM PACKET**	**A076737**	**001**	Jan 27, 2006
AB1			**50MG/5GM PACKET**	**A076737**	**002**	Jan 27, 2006
AB1		PAR PHARM	**50MG/5GM PACKET**	**A076744**	**002**	May 23, 2007
ANDROGEL							
AB2	**+**	ABBVIE	**1.62% (20.25MG/1.25GM PACKET)**	**N022309**	**002**	Sep 07, 2012
AB2	**+!**		**1.62% (40.5MG/2.5GM PACKET)**	**N022309**	**003**	Sep 07, 2012
TESTIM							
AB2	**+!**	AUXILIUM PHARMS LLC	**50MG/5GM PACKET**	**N021454**	**001**	Oct 31, 2002
TESTOSTERONE							
AB2		ACTAVIS LABS UT INC	**50MG/5GM PACKET**	**A091073**	**001**	Sep 18, 2017
AB2		PERRIGO UK FINCO	**1.62% (20.25MG/1.25GM PACKET)**	**A205781**	**001**	Jul 12, 2017
AB2			**1.62% (40.5MG/2.5GM PACKET)**	**A205781**	**002**	Jul 12, 2017
VOGELXO							
AB2		UPSHER SMITH LABS	**50MG/5GM PACKET**	**N204399**	**002**	Jun 04, 2014
GEL, METERED;NASAL							
NATESTO							
		ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014
GEL, METERED;TRANSDERMAL							
ANDROGEL							
AB	**+!**	ABBVIE	**1.62% (20.25MG/1.25GM ACTUATION)**	**N022309**	**001**	Apr 29, 2011
AB	**+!**		**12.5MG/1.25GM ACTUATION**	**N021015**	**003**	Sep 26, 2003
FORTESTA							
AB	**+!**	ENDO PHARMS	**10MG/0.5GM ACTUATION**	**N021463**	**001**	Dec 29, 2010
TESTOSTERONE							
AB		ACTAVIS LABS UT INC	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204570**	**001**	Apr 10, 2019
AB			**10MG/0.5GM ACTUATION**	**A204571**	**001**	Aug 05, 2015
AB			**12.5MG/1.25GM ACTUATION**	**A076737**	**003**	Mar 09, 2015
AB		AMNEAL PHARMS LLC	**1.62% (20.25MG/1.25GM ACTUATION)**	**A207373**	**001**	Apr 10, 2019
AB		DR REDDYS	**1.62% (20.25MG/1.25GM ACTUATION)**	**A208620**	**001**	Apr 10, 2019
AB		LUPIN ATLANTIS	**1.62% (20.25MG/1.25GM ACTUATION)**	**A208560**	**001**	Apr 10, 2019
AB		PERRIGO ISRAEL	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204268**	**001**	Aug 04, 2015
AB		TWI PHARMS	**1.62% (20.25MG/1.25GM ACTUATION)**	**A209390**	**001**	Sep 23, 2019
VOGELXO							
BX		UPSHER SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014
PELLET;IMPLANTATION							
TESTOPEL							
	!	AUXILIUM PHARMS INC	75MG	A080911	001	
SOLUTION, METERED;TRANSDERMAL							
TESTOSTERONE							
AT		ACTAVIS LABS UT INC	**30MG/1.5ML ACTUATION**	**A205328**	**001**	Aug 07, 2017
AT		CIPLA	**30MG/1.5ML ACTUATION**	**A209533**	**001**	Jan 29, 2018
AT		LUPIN LTD	**30MG/1.5ML ACTUATION**	**A208061**	**001**	Oct 23, 2017
AT	**!**	PERRIGO ISRAEL	**30MG/1.5ML ACTUATION**	**A204255**	**001**	Feb 28, 2017

TESTOSTERONE CYPIONATE							
INJECTABLE;INJECTION							
DEPO-TESTOSTERONE							
AO	**!**	PHARMACIA AND UPJOHN	**100MG/ML**	**A085635**	**002**		
AO	**!**		**200MG/ML**	**A085635**	**003**		
TESTOSTERONE CYPIONATE							
AO		AM REGENT	**200MG/ML**	**A207742**	**001**	Jun 16, 2017	
AO		CIPLA	**100MG/ML**	**A210362**	**001**	Jun 19, 2018	
AO			**200MG/ML**	**A210362**	**002**	Jun 19, 2018	
AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091244**	**001**	May 01, 2012	
AO		PADDOCK LLC	**200MG/ML**	**A040530**	**001**	Jan 31, 2005	
AO		SANDOZ INC	**100MG/ML**	**A040615**	**001**	Aug 10, 2006	
AO			**200MG/ML**	**A040615**	**002**	Aug 10, 2006	
AO		SUN PHARM INDS LTD	**100MG/ML**	**A201720**	**001**	Jun 03, 2013	
AO			**200MG/ML**	**A201720**	**002**	Jun 03, 2013	
AO		WATSON PHARMS INC	**200MG/ML**	**A086030**	**001**		
AO		WEST-WARD PHARMS INT	**100MG/ML**	**A090387**	**001**	Jul 15, 2010	
AO			**200MG/ML**	**A090387**	**002**	Jul 15, 2010	
AO		WILSHIRE PHARMS INC	**200MG/ML**	**A206368**	**001**	Apr 24, 2019	
TESTOSTERONE ENANTHATE							
INJECTABLE;INJECTION							
TESTOSTERONE ENANTHATE							
AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091120**	**001**	Sep 18, 2012	
AO		NEXUS PHARMS	**200MG/ML**	**A040575**	**001**	Jun 14, 2006	
AO	**!**	WATSON PHARMS INC	**200MG/ML**	**A085598**	**001**		
SOLUTION;SUBCUTANEOUS							
XYOSTED (AUTOINJECTOR)							
	+!	ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018	
	+!		75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018	
	+!		100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018	
TESTOSTERONE UNDECANOATE							
CAPSULE;ORAL							
JATENZO							
	+	CLARUS	158MG	N206089	001	Mar 27, 2019	
	+		198MG	N206089	002	Mar 27, 2019	
	+!		237MG	N206089	003	Mar 27, 2019	
INJECTABLE;INTRAMUSCULAR							
AVEED							
	+!	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014	
TETRABENAZINE							
TABLET;ORAL							
TETRABENAZINE							
AB		ACTAVIS LABS FL INC	**25MG**	**A206686**	**001**	Jul 07, 2017	
AB		BIONPHARMA INC	**12.5MG**	**A208826**	**001**	Dec 18, 2017	
AB			**25MG**	**A208826**	**002**	Dec 18, 2017	
AB		DR REDDYS	**12.5MG**	**A209284**	**001**	Jan 08, 2018	
AB			**25MG**	**A209284**	**002**	Jan 08, 2018	
AB		HETERO LABS LTD V	**12.5MG**	**A204574**	**001**	Feb 03, 2016	
AB			**25MG**	**A204574**	**002**	Feb 03, 2016	
AB		HIKMA	**12.5MG**	**A209739**	**001**	Apr 08, 2019	
AB			**25MG**	**A209739**	**002**	Apr 08, 2019	
AB		LUPIN LTD	**12.5MG**	**A210544**	**001**	Apr 20, 2018	
AB			**25MG**	**A210544**	**002**	Apr 20, 2018	
AB		MYLAN	**12.5MG**	**A207682**	**001**	Jan 31, 2017	
AB			**25MG**	**A207682**	**002**	Jan 31, 2017	
AB		SUN PHARM	**12.5MG**	**A206129**	**001**	Aug 17, 2015	
AB			**25MG**	**A206129**	**002**	Aug 17, 2015	
XENAZINE							
AB	**+**	VALEANT PHARMS NORTH	**12.5MG**	**N021894**	**001**	Aug 15, 2008	
AB	**+!**		**25MG**	**N021894**	**002**	Aug 15, 2008	
TETRACAINE HYDROCHLORIDE							
SOLUTION;OPHTHALMIC							
TETRACAINE HYDROCHLORIDE							
	+!	ALCON LABS	0.5%	N208135	001	Feb 29, 2016	
		BAUSCH	0.5%	N210821	001	Mar 12, 2019	

TETRACYCLINE HYDROCHLORIDE							
CAPSULE;ORAL							
ACHROMYCIN V							
AB	**+**	AVET	**250MG**	**N050278**	**003**		
AB	**+!**		**500MG**	**N050278**	**001**		
TETRACYCLINE HYDROCHLORIDE							
AB		AMNEAL PHARMS NY	**250MG**	**A210674**	**001**	Sep 18, 2018	
AB			**500MG**	**A210674**	**002**	Sep 18, 2018	
AB		BRECKENRIDGE	**250MG**	**A210662**	**001**	Nov 07, 2018	
AB			**500MG**	**A210662**	**002**	Nov 07, 2018	
AB		CHARTWELL TETRA	**250MG**	**A062752**	**001**	Aug 12, 1988	
AB			**500MG**	**A062752**	**002**	Aug 12, 1988	
AB		WATSON LABS	**250MG**	**A061837**	**001**		
AB			**500MG**	**A061837**	**002**		
TETRAHYDROZOLINE HYDROCHLORIDE							
SOLUTION;NASAL							
TYZINE							
	!	FOUGERA PHARMS	0.05%	A086576	002		
			0.1%	A086576	001		
SPRAY;NASAL							
TYZINE							
	!	FOUGERA PHARMS	0.1%	A086576	003		
THALIDOMIDE							
CAPSULE;ORAL							
THALOMID							
	+	CELGENE	50MG	N020785	001	Jul 16, 1998	
	+		100MG	N020785	002	Jan 17, 2003	
	+		150MG	N020785	004	Jan 10, 2007	
	+!		200MG	N020785	003	Jan 17, 2003	
THALLOUS CHLORIDE TL-201							
INJECTABLE;INJECTION							
THALLOUS CHLORIDE TL 201							
AP	**+!**	CURIUM	**1mCi/ML**	**N018150**	**001**		
AP	**+!**	GE HEALTHCARE	**1mCi/ML**	**N018110**	**002**	Feb 27, 1996	
AP	**+!**	LANTHEUS MEDCL	**1mCi/ML**	**N017806**	**001**		
THEOPHYLLINE							
CAPSULE, EXTENDED RELEASE;ORAL							
THEO-24							
		ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983	
	!	AUXILIUM PHARMS INC	400MG	A081034	001	Feb 28, 1992	
		AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	
			300MG	A087944	001	Aug 22, 1983	
INJECTABLE;INJECTION							
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER							
	+!	B BRAUN	40MG/100ML	N019826	001	Aug 14, 1992	
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER							
	+!	B BRAUN	80MG/100ML	N019826	002	Aug 14, 1992	
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER							
	+!	B BRAUN	160MG/100ML	N019826	003	Aug 14, 1992	
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER							
	+!	B BRAUN	320MG/100ML	N019826	006	Aug 14, 1992	
SOLUTION;ORAL							
THEOPHYLLINE							
AA	**!**	LANNETT CO INC	**80MG/15ML**	**A091156**	**001**	Apr 13, 2011	
AA		TRIS PHARMA INC	**80MG/15ML**	**A091586**	**001**	Jun 15, 2012	
SOLUTION, ELIXIR;ORAL							
ELIXOPHYLLIN							
AA	**!**	NOSTRUM LABS INC	**80MG/15ML**	**A085186**	**001**		
THEOPHYLLINE							
AA		PHARM ASSOC	**80MG/15ML**	**A206344**	**001**	Dec 16, 2016	
TABLET, EXTENDED RELEASE;ORAL							
THEOCHRON							
AB		NOSTRUM PHARMS LLC	**100MG**	**A087400**	**003**	Feb 21, 1985	
AB			**200MG**	**A087400**	**004**	Feb 21, 1985	
THEOPHYLLINE							
AB		ALEMBIC PHARMS LTD	**300MG**	**A090430**	**001**	Oct 27, 2010	
AB		GLENMARK GENERICS	**400MG**	**A090355**	**001**	Jul 13, 2010	
AB			**600MG**	**A090355**	**002**	Jul 13, 2010	
AB	**!**	HERITAGE PHARMA	**100MG**	**A089807**	**001**	Apr 30, 1990	
AB	**!**		**200MG**	**A089808**	**001**	Apr 30, 1990	

THEOPHYLLINE
TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB			**300MG**	**A089763**	**001**	Apr 30, 1990
AB		NOSTRUM LABS INC	**400MG**	**A040560**	**003**	Apr 21, 2006
AB	**!**		**600MG**	**A040560**	**002**	Apr 21, 2006
AB		RHODES PHARMS	**400MG**	**A040086**	**002**	Sep 01, 1982
AB			**600MG**	**A040086**	**001**	Apr 15, 1996
	!	ALEMBIC PHARMS LTD	450MG	A090430	002	Oct 27, 2010

THIAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
THIAMINE HYDROCHLORIDE

AP	**!**	FRESENIUS KABI USA	**100MG/ML**	**A080556**	**001**	
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091623**	**001**	Jun 25, 2012
AP		SAGENT PHARMS INC	**100MG/ML**	**A206106**	**001**	Dec 01, 2017

THIOGUANINE
TABLET;ORAL
THIOGUANINE

	+!	ASPEN GLOBAL INC	40MG	N012429	001	

THIORIDAZINE HYDROCHLORIDE
TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

		MYLAN	10MG	A088004	002	Mar 15, 1983
			25MG	A088004	003	Mar 15, 1983
			50MG	A088004	004	Mar 15, 1983
	!		100MG	A088004	001	Nov 18, 1983

THIOTEPA
INJECTABLE;INJECTION
THIOTEPA

AP		DR REDDYS	**15MG/VIAL**	**A210337**	**001**	May 04, 2018
AP		JIANGSU HENGRUI MED	**15MG/VIAL**	**A209150**	**001**	May 04, 2018
AP		STI PHARMA LLC	**15MG/VIAL**	**A208242**	**001**	Jan 10, 2020
AP	**!**	WEST-WARD PHARMS INT	**15MG/VIAL**	**A075547**	**001**	Apr 02, 2001

POWDER;INTRAVENOUS
TEPADINA

	+!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017
	+!		100MG/VIAL	N208264	002	Jan 26, 2017

THIOTHIXENE
CAPSULE;ORAL
THIOTHIXENE

AB		MYLAN	**1MG**	**A071093**	**002**	Jun 23, 1987
AB			**2MG**	**A071093**	**003**	Jun 23, 1987
AB			**5MG**	**A071093**	**004**	Jun 23, 1987
AB			**10MG**	**A071093**	**001**	Jun 23, 1987
AB		NOVITIUM PHARMA	**1MG**	**A211642**	**001**	Apr 05, 2019
AB			**2MG**	**A211642**	**002**	Apr 05, 2019
AB	**!**		**5MG**	**A211642**	**003**	Apr 05, 2019
AB			**10MG**	**A211642**	**004**	Apr 05, 2019

THYROTROPIN ALFA
INJECTABLE;INJECTION
THYROGEN

	+!	GENZYME	1.1MG/VIAL	N020898	001	Nov 30, 1998

TIAGABINE HYDROCHLORIDE
TABLET;ORAL
GABITRIL

AB	**+**	CEPHALON	**2MG**	**N020646**	**005**	Apr 16, 1999
AB	**+!**		**4MG**	**N020646**	**001**	Sep 30, 1997
AB	**+**		**12MG**	**N020646**	**002**	Sep 30, 1997
AB	**+**		**16MG**	**N020646**	**003**	Sep 30, 1997

TIAGABINE HYDROCHLORIDE

AB		AMNEAL PHARMS CO	**2MG**	**A208181**	**001**	Dec 08, 2017
AB			**4MG**	**A208181**	**002**	Dec 08, 2017
AB			**12MG**	**A208181**	**003**	Dec 08, 2017
AB			**16MG**	**A208181**	**004**	Dec 08, 2017
AB		SUN PHARM INDS	**2MG**	**A077555**	**001**	Nov 04, 2011
AB			**4MG**	**A077555**	**002**	Nov 04, 2011
AB		WILSHIRE PHARMS INC	**2MG**	**A206857**	**001**	Oct 13, 2017
AB			**4MG**	**A206857**	**002**	Oct 13, 2017

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

AB			**12MG**	**A206857**	**003**	Oct 13, 2017
AB			**16MG**	**A206857**	**004**	Oct 13, 2017

TICAGRELOR

TABLET;ORAL

BRILINTA

AB	**+!**	ASTRAZENECA PHARMS	**90MG**	**N022433**	**001**	Jul 20, 2011

TICAGRELOR

AB		HISUN PHARM HANGZHOU	**90MG**	**A208575**	**001**	Jan 23, 2019

BRILINTA

	+	ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

AB		APOTEX	**250MG**	**A075089**	**001**	Jul 01, 1999
AB	**!**	TEVA	**250MG**	**A075149**	**001**	Aug 20, 1999

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

AP		AMNEAL PHARMS LLC	**50MG/VIAL**	**N211158**	**001**	Aug 02, 2018
AP		APOTEX	**50MG/VIAL**	**A204439**	**001**	Dec 21, 2018
AP		AUROBINDO PHARMA LTD	**50MG/VIAL**	**A206335**	**001**	Jun 11, 2019
AP		FRESENIUS KABI USA	**50MG/VIAL**	**N205645**	**001**	Dec 01, 2016
AP		SANDOZ INC	**50MG/VIAL**	**A091620**	**001**	May 27, 2015
AP		XELLIA PHARMS APS	**50MG/VIAL**	**A205722**	**001**	Oct 18, 2019

TYGACIL

AP	**+!**	PF PRISM CV	**50MG/VIAL**	**N021821**	**001**	Jun 15, 2005

TIGECYCLINE

		ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

AT	**+!**	OAK PHARMS INC	**EQ 0.25% BASE**	**N020439**	**001**	Mar 31, 1995
AT	**+!**		**EQ 0.5% BASE**	**N020439**	**002**	Mar 31, 1995

TIMOLOL

AT		AKORN	**EQ 0.25% BASE**	**A205309**	**001**	Sep 30, 2016
AT			**EQ 0.5% BASE**	**A205309**	**002**	Sep 30, 2016

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB	**+!**	SANDOZ INC	**EQ 0.25% BASE**	**N020963**	**001**	Oct 21, 1998
AB	**+!**		**EQ 0.5% BASE**	**N020963**	**002**	Oct 21, 1998

TIMOPTIC-XE

AB	**+!**	VALEANT PHARMS LLC	**EQ 0.25% BASE**	**N020330**	**001**	Nov 04, 1993
AB	**+!**		**EQ 0.5% BASE**	**N020330**	**002**	Nov 04, 1993

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT		BAUSCH AND LOMB	**EQ 0.25% BASE**	**A074778**	**001**	Mar 25, 1997
AT		FDC LTD	**EQ 0.25% BASE**	**A077259**	**001**	Apr 30, 2008
AT		PACIFIC PHARMA	**EQ 0.25% BASE**	**A074746**	**001**	Mar 25, 1997
AT	**!**	SANDOZ INC	**EQ 0.25% BASE**	**A074261**	**001**	Apr 28, 1995
AT		WOCKHARDT	**EQ 0.25% BASE**	**A078771**	**001**	Sep 28, 2009

TIMOPTIC

AT	**+**	VALEANT PHARMS INTL	**EQ 0.25% BASE**	**N018086**	**001**	

TIMOLOL MALEATE

AT1		AKORN	**EQ 0.5% BASE**	**A074466**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A074516**	**001**	Mar 25, 1997
AT1		BAUSCH AND LOMB	**EQ 0.5% BASE**	**A074776**	**001**	Mar 25, 1997
AT1		FDC LTD	**EQ 0.5% BASE**	**A077259**	**002**	Apr 30, 2008
AT1		HI TECH PHARMA	**EQ 0.5% BASE**	**A075163**	**001**	Sep 10, 2002
AT1		PACIFIC PHARMA	**EQ 0.5% BASE**	**A074747**	**001**	Mar 25, 1997
AT1	**!**	SANDOZ INC	**EQ 0.5% BASE**	**A074262**	**001**	Apr 28, 1995
AT1		WOCKHARDT	**EQ 0.5% BASE**	**A078771**	**002**	Sep 28, 2009

TIMOPTIC

AT1	**+**	VALEANT PHARMS INTL	**EQ 0.5% BASE**	**N018086**	**002**	

TIMOLOL MALEATE						
SOLUTION/DROPS;OPHTHALMIC						
ISTALOL						
AT2	**+!**	BAUSCH AND LOMB	**EQ 0.5% BASE**	**N021516**	**001**	Jun 04, 2004
TIMOLOL MALEATE						
AT2		APOTEX	**EQ 0.5% BASE**	**A204936**	**001**	Apr 17, 2015
TIMOPTIC IN OCUDOSE						
	+!	VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986
	+!		EQ 0.5% BASE	N019463	002	Nov 05, 1986
TABLET;ORAL						
TIMOLOL MALEATE						
AB		ELYSIUM	**5MG**	**A207556**	**001**	May 02, 2019
AB			**10MG**	**A207556**	**002**	May 02, 2019
AB			**20MG**	**A207556**	**003**	May 02, 2019
AB		MYLAN	**5MG**	**A072668**	**002**	Jun 08, 1990
AB			**10MG**	**A072668**	**003**	Jun 08, 1990
AB	**!**		**20MG**	**A072668**	**001**	Jun 08, 1990
TINIDAZOLE						
TABLET;ORAL						
TINDAMAX						
AB	**+**	MISSION PHARMA	**250MG**	**N021618**	**001**	May 17, 2004
AB	**+!**		**500MG**	**N021618**	**002**	May 17, 2004
TINIDAZOLE						
AB		EDENBRIDGE PHARMS	**250MG**	**A203808**	**001**	Aug 04, 2015
AB			**500MG**	**A203808**	**002**	Aug 04, 2015
AB		HIKMA	**250MG**	**A201172**	**001**	Apr 30, 2012
AB			**500MG**	**A201172**	**002**	Apr 30, 2012
AB		NOVEL LABS INC	**250MG**	**A202044**	**001**	Apr 30, 2012
AB			**500MG**	**A202044**	**002**	Apr 30, 2012
AB		UNIQUE PHARM LABS	**250MG**	**A202489**	**001**	Oct 09, 2013
AB			**500MG**	**A202489**	**002**	Oct 09, 2013
TIOPRONIN						
TABLET;ORAL						
THIOLA						
	+!	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988
TABLET, DELAYED RELEASE;ORAL						
THIOLA EC						
	+	MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019
	+!		300MG	N211843	002	Jun 28, 2019
TIOTROPIUM BROMIDE						
POWDER;INHALATION						
SPIRIVA						
	+!	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004
SPRAY, METERED;INHALATION						
SPIRIVA RESPIMAT						
	+	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015
	+!		EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE						
TABLET;ORAL						
LONSURF						
	+	TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015
	+!		EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015
TIPRANAVIR						
CAPSULE;ORAL						
APTIVUS						
	+!	BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005
SOLUTION;ORAL						
APTIVUS						
	+!	BOEHRINGER INGELHEIM	100MG/ML	N022292	001	Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE;INJECTION

AGGRASTAT

+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002
+!		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000

SOLUTION;INJECTION

AGGRASTAT

+!	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	**EQ 2MG BASE**	**A213223**	**001**	Jan 13, 2020
AB		**EQ 4MG BASE**	**A213223**	**002**	Jan 13, 2020
AB		**EQ 6MG BASE**	**A213223**	**003**	Jan 13, 2020
AB	ALKEM LABS LTD	**EQ 2MG BASE**	**A212196**	**001**	Mar 27, 2019
AB		**EQ 4MG BASE**	**A212196**	**002**	Mar 27, 2019
AB		**EQ 6MG BASE**	**A212196**	**003**	Mar 27, 2019
AB	APOTEX INC	**EQ 2MG BASE**	**A078868**	**001**	Feb 03, 2012
AB		**EQ 4MG BASE**	**A078868**	**002**	Feb 03, 2012
AB		**EQ 6MG BASE**	**A078868**	**003**	Feb 03, 2012
AB	CADILA PHARMS LTD	**EQ 2MG BASE**	**A210021**	**001**	Mar 26, 2019
AB		**EQ 4MG BASE**	**A210021**	**002**	Mar 26, 2019
AB		**EQ 6MG BASE**	**A210021**	**003**	Mar 26, 2019
AB	JUBILANT GENERICS	**EQ 2MG BASE**	**A209605**	**001**	Aug 04, 2017
AB		**EQ 4MG BASE**	**A209605**	**002**	Aug 04, 2017
AB		**EQ 6MG BASE**	**A209605**	**003**	Aug 04, 2017
AB	MYLAN PHARMS INC	**EQ 2MG BASE**	**A091502**	**001**	Nov 09, 2012
AB		**EQ 4MG BASE**	**A091502**	**002**	Nov 09, 2012
AB		**EQ 6MG BASE**	**A091502**	**003**	Nov 09, 2012
AB	NOVAST LABS	**EQ 2MG BASE**	**A210267**	**001**	Mar 12, 2019
AB		**EQ 4MG BASE**	**A210267**	**002**	Mar 12, 2019
AB		**EQ 6MG BASE**	**A210267**	**003**	Mar 12, 2019
AB	PAR PHARM INC	**EQ 2MG BASE**	**A207199**	**001**	Mar 14, 2017
AB		**EQ 4MG BASE**	**A207199**	**002**	Mar 14, 2017
AB		**EQ 6MG BASE**	**A207199**	**003**	Mar 14, 2017
AB	ZYDUS PHARMS	**EQ 2MG BASE**	**A208622**	**001**	Mar 03, 2017
AB		**EQ 4MG BASE**	**A208622**	**002**	Mar 03, 2017
AB		**EQ 6MG BASE**	**A208622**	**003**	Mar 03, 2017

ZANAFLEX

AB	**+** COVIS PHARMA BV	**EQ 2MG BASE**	**N021447**	**001**	Aug 29, 2002
AB	**+**	**EQ 4MG BASE**	**N021447**	**002**	Aug 29, 2002
AB	**+!**	**EQ 6MG BASE**	**N021447**	**003**	Aug 29, 2002

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	**EQ 2MG BASE**	**A211798**	**001**	Jan 25, 2019
AB		**EQ 4MG BASE**	**A211798**	**002**	Jan 25, 2019
AB	APOTEX	**EQ 2MG BASE**	**A076533**	**001**	Jan 16, 2004
AB		**EQ 4MG BASE**	**A076533**	**002**	Jan 16, 2004
AB	CASI PHARMS INC	**EQ 2MG BASE**	**A076280**	**001**	Nov 26, 2002
AB		**EQ 4MG BASE**	**A076280**	**002**	Jun 27, 2002
AB	DR REDDYS LABS INC	**EQ 2MG BASE**	**A076286**	**001**	Jul 03, 2002
AB		**EQ 4MG BASE**	**A076286**	**002**	Jul 03, 2002
AB	EPIC PHARMA LLC	**EQ 2MG BASE**	**A076347**	**001**	Oct 11, 2002
AB		**EQ 4MG BASE**	**A076347**	**002**	Oct 11, 2002
AB	MYLAN	**EQ 2MG BASE**	**A076354**	**001**	Mar 28, 2003
AB		**EQ 4MG BASE**	**A076354**	**002**	Mar 28, 2003
AB	OXFORD PHARMS	**EQ 2MG BASE**	**A076281**	**001**	Oct 20, 2003
AB		**EQ 4MG BASE**	**A076281**	**002**	Oct 20, 2003
AB	SUN PHARM INDS INC	**EQ 2MG BASE**	**A076416**	**001**	Sep 29, 2003
AB		**EQ 4MG BASE**	**A076416**	**002**	Sep 29, 2003
AB	UNICHEM LABS LTD	**EQ 2MG BASE**	**A091283**	**001**	Nov 28, 2012
AB		**EQ 4MG BASE**	**A091283**	**002**	Nov 28, 2012
AB	ZYDUS PHARMS	**EQ 2MG BASE**	**A208187**	**001**	Mar 09, 2018
AB		**EQ 4MG BASE**	**A208187**	**002**	Mar 09, 2018

ZANAFLEX

AB	**+!** COVIS PHARMA BV	**EQ 4MG BASE**	**N020397**	**001**	Nov 27, 1996

TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBREX

	+!	NOVARTIS	0.3%	N050555	001	

POWDER;INHALATION

TOBI PODHALER

	+!	MYLAN SPECIALITY LP	28MG	N201688	001	Mar 22, 2013

SOLUTION;INHALATION

KITABIS PAK

AN		PULMOFLOW INC	**300MG/5ML**	**N205433**	**001**	Dec 02, 2014

TOBI

AN	**+!**	MYLAN SPECIALITY LP	**300MG/5ML**	**N050753**	**001**	Dec 22, 1997

TOBRAMYCIN

AN		AKORN INC	**300MG/5ML**	**A201422**	**001**	May 28, 2014
AN		AMNEAL PHARMS	**300MG/5ML**	**A205501**	**001**	Jul 13, 2015
AN		DR REDDYS LABS SA	**300MG/5ML**	**A207080**	**001**	Jul 09, 2018
AN		LUPIN	**300MG/5ML**	**A208964**	**001**	Mar 22, 2017
AN		MYLAN	**300MG/5ML**	**A209554**	**001**	Oct 13, 2017
AN		SUN PHARM	**300MG/5ML**	**A207136**	**001**	Dec 26, 2019
AN		TEVA PHARMS USA	**300MG/5ML**	**A091589**	**001**	Oct 10, 2013

BETHKIS

	+!	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012

SOLUTION/DROPS;OPHTHALMIC

AKTOB

AT		AKORN	**0.3%**	**A064096**	**001**	Jan 31, 1996

TOBRAMYCIN

AT		ALEMBIC PHARMS LTD	**0.3%**	**A211847**	**001**	Apr 19, 2019
AT		BAUSCH AND LOMB	**0.3%**	**A064052**	**001**	Nov 29, 1993
AT		FERA PHARMS	**0.3%**	**A065026**	**001**	Sep 11, 2001
AT		SOMERSET THERAPS LLC	**0.3%**	**A207444**	**001**	Jun 28, 2017

TOBREX

AT	**+!**	NOVARTIS	**0.3%**	**N050541**	**001**	
AT		SANDOZ INC	**0.3%**	**A062535**	**001**	Dec 13, 1984

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP		AKORN	**EQ 40MG BASE/ML**	**A205179**	**001**	Sep 16, 2014
AP		BAXTER HLTHCARE CORP	**EQ 40MG BASE/ML**	**A206965**	**001**	Jul 01, 2016
AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A065122**	**001**	Nov 29, 2002
AP	**!**		**EQ 40MG BASE/ML**	**A065122**	**002**	Nov 29, 2002
AP			**EQ 1.2GM BASE/VIAL**	**N050789**	**001**	Jul 13, 2004
AP	**!**	HOSPIRA	**EQ 10MG BASE/ML**	**A063112**	**001**	Apr 30, 1991
AP			**EQ 40MG BASE/ML**	**A063111**	**001**	Apr 30, 1991
AP		MYLAN LABS LTD	**EQ 40MG BASE/ML**	**A065407**	**001**	Mar 11, 2008
AP		TEVA PHARMS USA	**EQ 40MG BASE/ML**	**A063100**	**001**	Jan 30, 1992
AP		WEST-WARD PHARMS INT	**EQ 40MG BASE/ML**	**A063117**	**001**	Apr 26, 1991
AP	**!**	X GEN PHARMS	**EQ 1.2GM BASE/VIAL**	**A065013**	**001**	Aug 17, 2001
AP		XELLIA PHARMS APS	**EQ 1.2GM BASE/VIAL**	**A205685**	**001**	Sep 16, 2014

TOBRAMYCIN SULFATE (PHARMACY BULK)

	!	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	!	HOSPIRA	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990
	!		EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993
	!		EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012
	+!		EQ 10MG BASE	N203214	002	May 30, 2018

TABLET, EXTENDED RELEASE;ORAL

XELJANZ XR

	+!	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016
	+		EQ 22MG BASE	N208246	002	Dec 12, 2019

TOLAZAMIDE
TABLET;ORAL
TOLAZAMIDE

		MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986
	!		500MG	A070259	003	Mar 17, 1986

TOLBUTAMIDE
TABLET;ORAL
TOLBUTAMIDE

	!	MYLAN PHARMS INC	500MG	A086445	001	

TOLCAPONE
TABLET;ORAL
TASMAR

AB	**+!**	BAUSCH	**100MG**	**N020697**	**001**	Jan 29, 1998

TOLCAPONE

AB		MAYNE PHARMA	**100MG**	**A210095**	**001**	Aug 01, 2019
AB		NOVAST LABS	**100MG**	**A208937**	**001**	Aug 07, 2018
AB		PAR PHARM INC	**100MG**	**A204584**	**001**	Mar 26, 2015

TOLMETIN SODIUM
CAPSULE;ORAL
TOLMETIN SODIUM

AB		MYLAN	**EQ 400MG BASE**	**A073393**	**001**	May 27, 1993
AB	**!**	TEVA	**EQ 400MG BASE**	**A073290**	**001**	Nov 27, 1991

TABLET;ORAL
TOLMETIN SODIUM

	!	MYLAN	EQ 600MG BASE	A074473	001	Aug 30, 1994

TOLTERODINE TARTRATE
CAPSULE, EXTENDED RELEASE;ORAL
DETROL LA

AB	**+**	PHARMACIA AND UPJOHN	**2MG**	**N021228**	**001**	Dec 22, 2000
AB	**+!**		**4MG**	**N021228**	**002**	Dec 22, 2000

TOLTERODINE TARTRATE

AB		HETERO LABS LTD III	**2MG**	**A206419**	**001**	Dec 12, 2017
AB			**4MG**	**A206419**	**002**	Dec 12, 2017
AB		INVENTIA HLTHCARE	**2MG**	**A204562**	**001**	Aug 19, 2019
AB			**4MG**	**A204562**	**002**	Aug 19, 2019
AB		MYLAN	**2MG**	**A201486**	**001**	Oct 31, 2013
AB			**4MG**	**A201486**	**002**	Oct 31, 2013
AB		TEVA PHARMS USA	**2MG**	**A079141**	**001**	Nov 22, 2016
AB			**4MG**	**A079141**	**002**	Nov 22, 2016
AB		TORRENT	**2MG**	**A203016**	**001**	Aug 11, 2015
AB			**4MG**	**A203016**	**002**	Aug 11, 2015

TABLET;ORAL
DETROL

AB	**+**	PHARMACIA AND UPJOHN	**1MG**	**N020771**	**001**	Mar 25, 1998
AB	**+!**		**2MG**	**N020771**	**002**	Mar 25, 1998

TOLTERODINE TARTRATE

AB		INVATECH	**1MG**	**A210775**	**001**	Dec 30, 2019
AB			**2MG**	**A210775**	**002**	Dec 30, 2019
AB		IVAX SUB TEVA PHARMS	**1MG**	**A077006**	**001**	Feb 23, 2015
AB			**2MG**	**A077006**	**002**	Feb 23, 2015
AB		MACLEODS PHARMS LTD	**1MG**	**A203409**	**001**	Aug 31, 2015
AB			**2MG**	**A203409**	**002**	Aug 31, 2015
AB		MYLAN PHARMS INC	**1MG**	**A202641**	**001**	Nov 27, 2012
AB			**2MG**	**A202641**	**002**	Nov 27, 2012

TOLVAPTAN
TABLET;ORAL
JYNARQUE

	+	OTSUKA PHARM CO LTD	15MG	N204441	001	Apr 23, 2018
	+		30MG	N204441	002	Apr 23, 2018
	+!		45MG	N204441	003	Apr 23, 2018
	+		60MG	N204441	004	Apr 23, 2018
	+		90MG	N204441	005	Apr 23, 2018

SAMSCA

	+	OTSUKA AMERICA PHARM	15MG	N022275	001	May 19, 2009
	+!		30MG	N022275	002	May 19, 2009

TOPIRAMATE

CAPSULE;ORAL

TOPAMAX							
AB	**+**	JANSSEN PHARMS	**15MG**	**N020844**	**001**	Oct 26, 1998
AB	**+!**		**25MG**	**N020844**	**002**	Oct 26, 1998
TOPIRAMATE							
AB		TEVA	**15MG**	**A076575**	**001**	Apr 17, 2009
AB			**25MG**	**A076575**	**002**	Apr 17, 2009
AB		WATSON LABS	**15MG**	**A077868**	**001**	Apr 15, 2009
AB			**25MG**	**A077868**	**002**	Apr 15, 2009
AB		ZYDUS PHARMS USA INC	**15MG**	**A078877**	**001**	Oct 14, 2009
AB			**25MG**	**A078877**	**002**	Oct 14, 2009

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE							
AB		ZYDUS PHARMS	**25MG**	**A207382**	**001**	Nov 24, 2017
AB			**50MG**	**A207382**	**002**	Nov 24, 2017
AB			**100MG**	**A207382**	**003**	Nov 24, 2017
TROKENDI XR							
AB	**+**	SUPERNUS PHARMS	**25MG**	**N201635**	**001**	Aug 16, 2013
AB	**+**		**50MG**	**N201635**	**002**	Aug 16, 2013
AB	**+**		**100MG**	**N201635**	**003**	Aug 16, 2013
QUDEXY XR							
BC	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014
BC	+		50MG	N205122	002	Mar 11, 2014
BC	+		100MG	N205122	003	Mar 11, 2014
BC	+!		200MG	N205122	005	Mar 11, 2014
TROKENDI XR							
BC	+!	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013
QUDEXY XR							
	+	UPSHER SMITH LABS	150MG	N205122	004	Mar 11, 2014

TABLET;ORAL

TOPAMAX							
AB	**+**	JANSSEN PHARMS	**25MG**	**N020505**	**004**	Dec 24, 1996
AB	**+**		**50MG**	**N020505**	**005**	Dec 24, 1996
AB	**+!**		**100MG**	**N020505**	**001**	Dec 24, 1996
AB	**+**		**200MG**	**N020505**	**002**	Dec 24, 1996
TOPIRAMATE							
AB		ACCORD HLTHCARE	**25MG**	**A076311**	**001**	Mar 27, 2009
AB			**50MG**	**A076311**	**002**	Mar 27, 2009
AB			**100MG**	**A076311**	**003**	Mar 27, 2009
AB			**200MG**	**A076311**	**004**	Mar 27, 2009
AB		APOTEX INC	**25MG**	**A077733**	**001**	Mar 27, 2009
AB			**50MG**	**A077733**	**002**	Mar 27, 2009
AB			**100MG**	**A077733**	**003**	Mar 27, 2009
AB			**200MG**	**A077733**	**004**	Mar 27, 2009
AB		AUROBINDO PHARMA	**25MG**	**A078462**	**001**	Mar 27, 2009
AB			**50MG**	**A078462**	**002**	Mar 27, 2009
AB			**100MG**	**A078462**	**003**	Mar 27, 2009
AB			**200MG**	**A078462**	**004**	Mar 27, 2009
AB		CIPLA LTD	**25MG**	**A076343**	**001**	Mar 27, 2009
AB			**50MG**	**A076343**	**002**	Mar 27, 2009
AB			**100MG**	**A076343**	**003**	Mar 27, 2009
AB			**200MG**	**A076343**	**004**	Mar 27, 2009
AB		GLENMARK GENERICS	**25MG**	**A077627**	**001**	Mar 27, 2009
AB			**50MG**	**A077627**	**002**	Mar 27, 2009
AB			**100MG**	**A077627**	**003**	Mar 27, 2009
AB			**200MG**	**A077627**	**004**	Mar 27, 2009
AB		INVAGEN PHARMS	**25MG**	**A079162**	**001**	Mar 27, 2009
AB			**50MG**	**A079162**	**002**	Mar 27, 2009
AB			**100MG**	**A079162**	**003**	Mar 27, 2009
AB			**200MG**	**A079162**	**004**	Mar 27, 2009
AB		SUN PHARM	**25MG**	**A090278**	**001**	Mar 27, 2009
AB			**50MG**	**A090278**	**002**	Mar 27, 2009
AB			**100MG**	**A090278**	**003**	Mar 27, 2009
AB			**200MG**	**A090278**	**004**	Mar 27, 2009
AB		SUN PHARM INDS LTD	**25MG**	**A076327**	**001**	Mar 27, 2009
AB			**100MG**	**A076327**	**002**	Mar 27, 2009
AB			**200MG**	**A076327**	**003**	Mar 27, 2009
AB		TEVA	**25MG**	**A076317**	**001**	Mar 27, 2009
AB			**50MG**	**A076317**	**002**	Mar 27, 2009
AB			**100MG**	**A076317**	**003**	Mar 27, 2009
AB			**200MG**	**A076317**	**004**	Mar 27, 2009

TOPIRAMATE						
TABLET;ORAL						
TOPIRAMATE						
AB		TORRENT PHARMS	**25MG**	**A079153**	**001**	Mar 27, 2009
AB			**50MG**	**A079153**	**002**	Mar 27, 2009
AB			**100MG**	**A079153**	**003**	Mar 27, 2009
AB			**200MG**	**A079153**	**004**	Mar 27, 2009
AB		UNICHEM LABS LTD	**25MG**	**A090162**	**001**	Mar 27, 2009
AB			**50MG**	**A090162**	**002**	Mar 27, 2009
AB			**100MG**	**A090162**	**003**	Mar 27, 2009
AB			**200MG**	**A090162**	**004**	Feb 19, 2013
AB		UPSHER SMITH LABS	**25MG**	**A078499**	**001**	Jan 07, 2010
AB			**50MG**	**A078499**	**002**	Jan 07, 2010
AB			**100MG**	**A078499**	**003**	Jan 07, 2010
AB			**200MG**	**A078499**	**004**	Jan 07, 2010
AB		ZYDUS PHARMS USA INC	**25MG**	**A078235**	**001**	Mar 27, 2009
AB			**50MG**	**A078235**	**002**	Mar 27, 2009
AB			**100MG**	**A078235**	**003**	Mar 27, 2009
AB			**200MG**	**A078235**	**004**	Mar 27, 2009
TOPOTECAN HYDROCHLORIDE						
CAPSULE;ORAL						
HYCAMTIN						
	+	NOVARTIS	EQ 0.25MG BASE	N020981	001	Oct 11, 2007
	+!		EQ 1MG BASE	N020981	002	Oct 11, 2007
INJECTABLE;INJECTION						
HYCAMTIN						
AP	**+!**	NOVARTIS	**EQ 4MG BASE/VIAL**	**N020671**	**001**	May 28, 1996
TOPOTECAN HYDROCHLORIDE						
AP		ACCORD HLTHCARE	**EQ 4MG BASE/VIAL**	**A202351**	**001**	Jun 26, 2013
AP		ACTAVIS TOTOWA	**EQ 4MG BASE/VIAL**	**A090620**	**001**	Dec 02, 2010
AP		CIPLA	**EQ 4MG BASE/VIAL**	**A091199**	**001**	Dec 01, 2010
AP		DR REDDYS LABS LTD	**EQ 4MG BASE/VIAL**	**A201191**	**001**	Mar 09, 2011
AP		FRESENIUS KABI USA	**EQ 4MG BASE/VIAL**	**A091089**	**001**	Nov 29, 2010
AP		MEITHEAL	**EQ 4MG BASE/VIAL**	**A201166**	**001**	Aug 08, 2012
AP		NOVAST LABS	**EQ 4MG BASE/VIAL**	**A206962**	**001**	Nov 30, 2016
AP		SAGENT PHARMS	**EQ 4MG BASE/VIAL**	**A091284**	**001**	Jan 26, 2011
SOLUTION;INTRAVENOUS						
TOPOTECAN HYDROCHLORIDE						
AP		ACCORD HLTHCARE	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204406**	**002**	Jul 06, 2017
AP	**+!**	HOSPIRA INC	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N200582**	**001**	Feb 02, 2011
AP		MYLAN LABS LTD	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A206074**	**001**	Nov 24, 2017
AP		TEVA PHARMS USA	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N022453**	**001**	Dec 20, 2012
		ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017
TOREMIFENE CITRATE						
TABLET;ORAL						
FARESTON						
AB	**+!**	KYOWA KIRIN	**EQ 60MG BASE**	**N020497**	**001**	May 29, 1997
TOREMIFENE CITRATE						
AB		RISING	**EQ 60MG BASE**	**A208813**	**001**	Dec 04, 2018
TORSEMIDE						
TABLET;ORAL						
DEMADEX						
AB	**+**	MYLAN SPECIALITY LP	**5MG**	**N020136**	**001**	Aug 23, 1993
AB	**+**		**10MG**	**N020136**	**002**	Aug 23, 1993
AB	**+!**		**20MG**	**N020136**	**003**	Aug 23, 1993
AB	**+**		**100MG**	**N020136**	**004**	Aug 23, 1993
TORSEMIDE						
AB		APOTEX INC	**5MG**	**A076894**	**001**	May 31, 2005
AB			**10MG**	**A076894**	**002**	May 31, 2005
AB			**20MG**	**A076894**	**003**	May 31, 2005
AB			**100MG**	**A076894**	**004**	May 31, 2005
AB		AUROBINDO PHARMA	**5MG**	**A078249**	**001**	Oct 17, 2007
AB			**10MG**	**A078249**	**002**	Oct 17, 2007
AB			**20MG**	**A078249**	**003**	Oct 17, 2007
AB			**100MG**	**A078249**	**004**	Oct 17, 2007
AB		HETERO LABS LTD III	**5MG**	**A079234**	**001**	Jan 27, 2009
AB			**10MG**	**A079234**	**002**	Jan 27, 2009
AB			**20MG**	**A079234**	**003**	Jan 27, 2009
AB			**100MG**	**A079234**	**004**	Jan 27, 2009
AB		HIKMA	**5MG**	**A076943**	**001**	Mar 01, 2005

TORSEMIDE

TABLET;ORAL

TORSEMIDE

AB			**10MG**	**A076943**	**002**	Mar 01, 2005
AB			**20MG**	**A076943**	**003**	Mar 01, 2005
AB		PAR PHARM	**5MG**	**A076226**	**001**	May 27, 2003
AB			**10MG**	**A076226**	**002**	May 27, 2003
AB			**20MG**	**A076226**	**003**	May 27, 2003
AB			**100MG**	**A076226**	**004**	May 27, 2003
AB		PLIVA PHARM IND	**5MG**	**A076346**	**001**	May 30, 2003
AB			**10MG**	**A076346**	**002**	May 30, 2003
AB			**20MG**	**A076346**	**003**	May 30, 2003
AB			**100MG**	**A076346**	**004**	Oct 19, 2004
AB		TEVA	**5MG**	**A076110**	**001**	May 14, 2002
AB			**10MG**	**A076110**	**002**	May 14, 2002
AB			**20MG**	**A076110**	**003**	May 14, 2002
AB			**100MG**	**A076110**	**004**	May 14, 2002
AB		VINTAGE PHARMS	**5MG**	**A090613**	**001**	Mar 22, 2011
AB			**10MG**	**A090613**	**002**	Mar 22, 2011
AB			**20MG**	**A090613**	**003**	Mar 22, 2011
AB			**100MG**	**A090613**	**004**	Mar 22, 2011

TRABECTEDIN

POWDER;INTRAVENOUS

YONDELIS

	+!	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CONZIP

	+!	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
	+		150MG	N022370	004	Aug 01, 2011
	+		200MG	N022370	002	May 07, 2010
	+		300MG	N022370	003	May 07, 2010

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB		ACI HEALTHCARE LTD	**50MG**	**A202075**	**001**	Nov 28, 2011
AB		AMNEAL PHARMS	**50MG**	**A076003**	**001**	Jun 20, 2002
AB		APOTEX	**50MG**	**A075981**	**001**	Jul 10, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A203494**	**001**	Mar 31, 2014
AB		CSPC OUYI PHARM CO	**50MG**	**A091498**	**001**	Mar 29, 2013
AB		IPCA LABS LTD	**50MG**	**A201973**	**001**	Nov 16, 2012
AB		MACLEODS PHARMS LTD	**50MG**	**A205702**	**001**	Sep 25, 2015
AB		MYLAN	**50MG**	**A075986**	**001**	Jun 21, 2002
AB		PLIVA	**50MG**	**A075982**	**001**	Jul 01, 2002
AB		RUBICON	**50MG**	**A208708**	**001**	Jun 28, 2019
AB			**100MG**	**A208708**	**002**	Jun 28, 2019
AB		SUN PHARM INDS INC	**50MG**	**A075964**	**001**	Jun 19, 2002
AB		TEVA	**50MG**	**A075977**	**001**	Jun 19, 2002
AB		UNICHEM LABS LTD	**50MG**	**A211825**	**001**	Aug 09, 2019
AB		ZYDUS PHARMS USA INC	**50MG**	**A090404**	**001**	Jan 31, 2011

ULTRAM

AB	**+!**	JANSSEN PHARMS	**50MG**	**N020281**	**002**	Mar 03, 1995

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

AB1	**!**	LUPIN LTD	**100MG**	**A200503**	**001**	Aug 29, 2011
AB1			**200MG**	**A200503**	**002**	Aug 29, 2011
AB1			**300MG**	**A200503**	**003**	Aug 29, 2011
AB1		MYLAN	**100MG**	**A205257**	**001**	Dec 22, 2015
AB1			**200MG**	**A205257**	**002**	Dec 22, 2015
AB1			**300MG**	**A205257**	**003**	Dec 22, 2015
AB1		SUN PHARM	**100MG**	**A201384**	**001**	Dec 07, 2011
AB1			**200MG**	**A201384**	**002**	Dec 07, 2011
AB1			**300MG**	**A201384**	**003**	Dec 07, 2011
AB2		ACTAVIS ELIZABETH	**100MG**	**A091609**	**001**	Jun 27, 2012
AB2			**200MG**	**A091609**	**002**	Jun 27, 2012
AB2			**300MG**	**A091609**	**003**	Jun 27, 2012
AB2		ANCHEN PHARMS	**100MG**	**A200491**	**001**	Jun 27, 2012
AB2			**200MG**	**A200491**	**002**	Jun 27, 2012
AB2			**300MG**	**A200491**	**003**	Jun 27, 2012
AB2	**!**	SUN PHARM	**100MG**	**A091607**	**001**	Dec 30, 2011
AB2			**200MG**	**A091607**	**002**	Dec 30, 2011

TRAMADOL HYDROCHLORIDE							
TABLET, EXTENDED RELEASE;ORAL							
TRAMADOL HYDROCHLORIDE							
AB2			**300MG**	**A091607**	**003**	Dec 30, 2011	
TRAMETINIB DIMETHYL SULFOXIDE							
TABLET;ORAL							
MEKINIST							
+		NOVARTIS	EQ 0.5MG	N204114	001	May 29, 2013	
+!			EQ 2MG	N204114	003	May 29, 2013	
TRANDOLAPRIL							
TABLET;ORAL							
TRANDOLAPRIL							
AB		AUROBINDO PHARMA	**1MG**	**A078438**	**001**	Jun 12, 2007	
AB			**2MG**	**A078438**	**002**	Jun 12, 2007	
AB			**4MG**	**A078438**	**003**	Jun 12, 2007	
AB		EPIC PHARMA	**1MG**	**A078508**	**003**	Jun 18, 2008	
AB			**2MG**	**A078508**	**001**	Jun 18, 2008	
AB			**4MG**	**A078508**	**002**	Jun 18, 2008	
AB		LUPIN	**1MG**	**A077522**	**001**	Jun 12, 2007	
AB			**2MG**	**A077522**	**002**	Jun 12, 2007	
AB	!		**4MG**	**A077522**	**003**	Jun 12, 2007	
AB		TEVA PHARMS	**1MG**	**A077489**	**001**	Dec 12, 2006	
AB			**2MG**	**A077489**	**002**	Dec 12, 2006	
AB			**4MG**	**A077489**	**003**	Dec 12, 2006	
TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE							
TABLET, EXTENDED RELEASE;ORAL							
TARKA							
AB	+	ABBVIE	**2MG;180MG**	**N020591**	**001**	Oct 22, 1996	
AB	+		**2MG;240MG**	**N020591**	**004**	Oct 22, 1996	
AB	+!		**4MG;240MG**	**N020591**	**002**	Oct 22, 1996	
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE							
AB		GLENMARK GENERICS	**2MG;180MG**	**A079135**	**001**	May 26, 2010	
AB			**2MG;240MG**	**A079135**	**002**	May 26, 2010	
AB			**4MG;240MG**	**A079135**	**003**	May 05, 2010	
			1MG;240MG	A079135	004	Aug 30, 2010	
TRANEXAMIC ACID							
INJECTABLE;INJECTION							
CYKLOKAPRON							
AP	+!	PHARMACIA AND UPJOHN	**100MG/ML**	**N019281**	**001**	Dec 30, 1986	
TRANEXAMIC ACID							
AP		ACIC PHARMS	**100MG/ML**	**A202436**	**001**	Feb 11, 2014	
AP		AKORN	**100MG/ML**	**A202373**	**001**	Nov 17, 2011	
AP			**100MG/ML**	**A206594**	**001**	Sep 28, 2017	
AP			**100MG/ML**	**A206634**	**001**	Jun 09, 2016	
AP		AMNEAL PHARMS CO	**100MG/ML**	**A208840**	**001**	Feb 28, 2017	
AP		APOLLO	**100MG/ML**	**A212676**	**001**	Jul 17, 2019	
AP		APOTEX	**100MG/ML**	**A209860**	**001**	Jan 14, 2020	
AP		AUROBINDO PHARMA LTD	**100MG/ML**	**A205035**	**001**	Jan 14, 2016	
AP		CAPLIN	**100MG/ML**	**A212360**	**001**	Jul 17, 2019	
AP		EMCURE PHARMS LTD	**100MG/ML**	**A203521**	**001**	Aug 12, 2014	
AP		FRESENIUS KABI USA	**100MG/ML**	**A091596**	**001**	Mar 02, 2012	
AP		GLAND PHARMA LTD	**100MG/ML**	**A207239**	**001**	Feb 13, 2017	
AP		LUITPOLD	**100MG/ML**	**A201885**	**001**	Aug 10, 2011	
AP		MICRO LABS	**100MG/ML**	**A206713**	**001**	Jun 27, 2017	
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091657**	**001**	Nov 03, 2011	
AP		X-GEN PHARMS INC	**100MG/ML**	**A201580**	**001**	Jun 14, 2013	
AP		ZYDUS PHARMS	**100MG/ML**	**A205228**	**001**	Jul 17, 2017	
SOLUTION;INTRAVENOUS							
TRANEXAMIC ACID							
+!		EXELA PHARMA SCS LLC	1GM/100ML (10MG/ML)	N212020	001	Apr 15, 2019	
TABLET;ORAL							
LYSTEDA							
AB	+!	FERRING PHARMS INC	**650MG**	**N022430**	**001**	Nov 13, 2009	
TRANEXAMIC ACID							
AB		ACTAVIS LABS FL INC	**650MG**	**A202093**	**001**	Dec 27, 2012	
AB		APOTEX INC	**650MG**	**A202286**	**001**	Jan 27, 2014	
AB		MYLAN	**650MG**	**A205133**	**001**	Sep 21, 2015	

TRANYLCYPROMINE SULFATE

TABLET;ORAL

PARNATE

AB	**+!**	CONCORDIA	**EQ 10MG BASE**	**N012342**	**003**	Aug 16, 1985

TRANYLCYPROMINE SULFATE

AB		CNTY LINE PHARMS	**EQ 10MG BASE**	**A206856**	**001**	Apr 17, 2018
AB		PAR PHARM	**EQ 10MG BASE**	**A040640**	**001**	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

AT	**+!**	NOVARTIS	**0.004%**	**N021994**	**001**	Sep 21, 2006

TRAVOPROST

AT		APOTEX	**0.004%**	**A203431**	**001**	Jul 10, 2015
AT		MYLAN	**0.004%**	**A205050**	**001**	Jul 07, 2017
AT1		ALEMBIC PHARMS LTD	**0.004%**	**A210458**	**001**	Dec 20, 2019
AT1	**!**	PAR PHARM	**0.004%**	**A091340**	**001**	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A206923**	**001**	Sep 08, 2017
AB			**100MG**	**A206923**	**002**	Sep 08, 2017
AB			**150MG**	**A206923**	**003**	Sep 08, 2017
AB			**300MG**	**A206923**	**004**	Sep 08, 2017
AB		ALVOGEN	**50MG**	**A071636**	**001**	Apr 18, 1988
AB			**100MG**	**A071514**	**001**	Apr 18, 1988
AB		APOTEX	**50MG**	**A071258**	**001**	Mar 25, 1987
AB	**!**	APOTEX INC	**100MG**	**A071196**	**001**	Mar 25, 1987
AB			**150MG**	**A071196**	**002**	Apr 26, 1999
AB			**300MG**	**A071196**	**003**	Apr 26, 1999
AB		OXFORD PHARMS	**50MG**	**A072192**	**001**	Feb 02, 1989
AB			**100MG**	**A072193**	**001**	Feb 02, 1989
AB		PLIVA	**150MG**	**A071525**	**001**	Mar 09, 1988
AB		SUN PHARM INDUSTRIES	**50MG**	**A073137**	**002**	Mar 24, 1993
AB			**100MG**	**A073137**	**001**	Mar 24, 1993
AB			**150MG**	**A073137**	**003**	Dec 22, 1995
AB		TEVA PHARMS USA	**50MG**	**A071523**	**001**	Dec 11, 1987
AB			**100MG**	**A071524**	**001**	Dec 11, 1987
AB		TORRENT	**50MG**	**A202180**	**001**	Nov 27, 2013
AB			**100MG**	**A202180**	**002**	Nov 27, 2013
AB			**150MG**	**A202180**	**003**	Nov 27, 2013
AB			**300MG**	**A202180**	**004**	Nov 27, 2013
AB		ZYDUS PHARMS	**50MG**	**A205253**	**001**	Oct 10, 2017
AB			**100MG**	**A205253**	**002**	Oct 10, 2017
AB			**150MG**	**A205253**	**003**	Oct 10, 2017
AB			**300MG**	**A205253**	**004**	Oct 10, 2017

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

AP	**+!**	UNITED THERAP	**1MG/ML**	**N021272**	**001**	May 21, 2002
AP	**+!**		**2.5MG/ML**	**N021272**	**002**	May 21, 2002
AP	**+!**		**5MG/ML**	**N021272**	**003**	May 21, 2002
AP	**+!**		**10MG/ML**	**N021272**	**004**	May 21, 2002

TREPROSTINIL

AP		PAR STERILE PRODUCTS	**1MG/ML**	**A209382**	**001**	Sep 24, 2019
AP			**2.5MG/ML**	**A209382**	**002**	Sep 24, 2019
AP			**5MG/ML**	**A209382**	**003**	Sep 24, 2019
AP			**10MG/ML**	**A209382**	**004**	Sep 24, 2019
AP		SANDOZ INC	**1MG/ML**	**A203649**	**001**	Nov 30, 2017
AP			**2.5MG/ML**	**A203649**	**002**	Nov 30, 2017
AP			**5MG/ML**	**A203649**	**003**	Nov 30, 2017
AP			**10MG/ML**	**A203649**	**004**	Nov 30, 2017
AP		TEVA PHARMS USA	**1MG/ML**	**A206648**	**001**	Sep 26, 2019
AP			**2.5MG/ML**	**A206648**	**002**	Sep 26, 2019
AP			**5MG/ML**	**A206648**	**003**	Sep 26, 2019
AP			**10MG/ML**	**A206648**	**004**	Sep 26, 2019

SOLUTION;INHALATION

TYVASO

	+!	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009

TREPROSTINIL

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

REMODULIN

	UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018
		50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018
		100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018
		200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

+	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
+		EQ 0.25MG BASE	N203496	002	Dec 20, 2013
+!		EQ 1MG BASE	N203496	003	Dec 20, 2013
+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
+		EQ 5MG BASE	N203496	005	Oct 07, 2016

TRETINOIN

CAPSULE;ORAL

TRETINOIN

AB		ANCHEN PHARMS	**10MG**	**A201687**	**001**	Oct 24, 2012
AB	**!**	BARR LABS INC	**10MG**	**A077684**	**001**	Jun 22, 2007
AB		GLENMARK PHARMS LTD	**10MG**	**A208279**	**001**	Dec 23, 2016

CREAM;TOPICAL

AVITA

AB		MYLAN PHARMS INC	**0.025%**	**N020404**	**003**	Jan 14, 1997

RETIN-A

AB	**+!**	VALEANT BERMUDA	**0.025%**	**N019049**	**001**	Sep 16, 1988
AB	**+!**	VALEANT PHARMS NORTH	**0.1%**	**N017340**	**001**	

TRETINOIN

AB		PERRIGO PHARMA INTL	**0.025%**	**A075264**	**001**	Dec 24, 1998
AB			**0.1%**	**A075213**	**001**	Dec 24, 1998
AB		TARO PHARMS	**0.1%**	**A211645**	**001**	Jan 22, 2019

RETIN-A

AB1	**+!**	VALEANT BERMUDA	**0.05%**	**N017522**	**001**	

TRETINOIN

AB1		PERRIGO PHARMA INTL	**0.05%**	**A075265**	**001**	Dec 24, 1998
AB1		TARO PHARMS	**0.05%**	**A211644**	**001**	Jan 25, 2019

RENOVA

AB2	**+!**	VALEANT PHARMS NORTH	**0.05%**	**N019963**	**001**	Dec 29, 1995

TRETINOIN

AB2		ZO SKIN HEALTH	**0.05%**	**A076498**	**001**	Sep 15, 2005

RENOVA

	+!	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000

GEL;TOPICAL

ATRALIN

AB	**+!**	DOW PHARM	**0.05%**	**N022070**	**001**	Jul 26, 2007

RETIN-A

AB	**+!**	VALEANT INTL	**0.01%**	**N017955**	**001**	
AB	**+!**		**0.025%**	**N017579**	**002**	

RETIN-A MICRO

AB	**+!**	VALEANT INTL	**0.04%**	**N020475**	**002**	May 10, 2002
AB	**+!**		**0.1%**	**N020475**	**001**	Feb 07, 1997

TRETINOIN

AB		MYLAN	**0.04%**	**A202567**	**001**	Jul 17, 2013
AB			**0.05%**	**A207955**	**001**	Aug 13, 2015
AB			**0.1%**	**A202026**	**001**	Jul 17, 2013
AB		PERRIGO PHARMA INTL	**0.01%**	**A075589**	**001**	Jun 11, 2002
AB			**0.025%**	**A075529**	**001**	Feb 22, 2000

AVITA

BT		MYLAN	0.025%	N020400	001	Jan 29, 1998

RETIN-A-MICRO

	+!	VALEANT INTL	0.06%	N020475	004	Oct 23, 2017
	+!		0.08%	N020475	003	Jan 28, 2014

LOTION;TOPICAL

ALTRENO

	+!	DOW PHARM	0.05%	N209353	001	Aug 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		ACP NIMBLE	**0.025%**	**A089797**	**001**	May 31, 1991
AT			**0.1%**	**A089798**	**001**	May 31, 1991
AT		ALKEM LABS LTD	**0.025%**	**A207651**	**001**	Dec 26, 2017
AT			**0.1%**	**A207651**	**002**	Dec 26, 2017
AT			**0.5%**	**A207651**	**003**	Dec 26, 2017
AT	**!**	FOUGERA PHARMS	**0.025%**	**A085692**	**001**	
AT	**!**		**0.1%**	**A085692**	**003**	
AT	**!**		**0.5%**	**A085692**	**002**	
AT		GLENMARK PHARMS LTD	**0.1%**	**A207117**	**001**	Aug 05, 2016
AT		LUPIN ATLANTIS	**0.025%**	**A208763**	**001**	Feb 01, 2017
AT			**0.1%**	**A208763**	**002**	Feb 01, 2017
AT			**0.5%**	**A208763**	**003**	Feb 01, 2017
AT		MACLEODS PHARMS LTD	**0.025%**	**A209535**	**001**	May 18, 2018
AT			**0.1%**	**A209535**	**002**	May 18, 2018
AT			**0.5%**	**A209535**	**003**	May 18, 2018
AT		MLV	**0.025%**	**A040671**	**001**	Jun 09, 2006
AT			**0.1%**	**A040671**	**002**	Jun 09, 2006
AT	**+**	MYLAN	**0.025%**	**N011601**	**003**	
AT	**+**		**0.1%**	**N011601**	**006**	
AT		PERRIGO NEW YORK	**0.025%**	**A086413**	**002**	
AT			**0.1%**	**A086413**	**003**	
AT			**0.5%**	**A086413**	**001**	
AT		STRIDES PHARMA	**0.025%**	**A210346**	**001**	Feb 11, 2019
AT			**0.1%**	**A210346**	**002**	Feb 11, 2019
AT			**0.5%**	**A210346**	**003**	Feb 11, 2019
AT		TARO PHARM INDS LTD	**0.1%**	**A040039**	**001**	Nov 26, 1997
AT		TELIGENT PHARMA INC	**0.1%**	**A208848**	**001**	Sep 18, 2017

TRIDERM

AT		CROWN LABS	**0.025%**	**A088042**	**002**	Mar 25, 2015
AT			**0.1%**	**A088042**	**001**	Mar 19, 1984
AT			**0.5%**	**A088042**	**003**	Mar 25, 2015

FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

ZILRETTA

	+!	FLEXION THERAPS INC	32MG/VIAL	N208845	001	Oct 06, 2017

INJECTABLE;INJECTION

KENALOG-40

AB	**+!**	APOTHECON	**40MG/ML**	**N014901**	**001**	

TRIAMCINOLONE ACETONIDE

AB		AMNEAL	**40MG/ML**	**A207550**	**001**	Dec 11, 2017
AB		TEVA PHARMS USA	**40MG/ML**	**A209852**	**001**	Oct 05, 2018

KENALOG-10

	+	APOTHECON	10MG/ML	N012041	001	

KENALOG-80

	+!	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019

INJECTABLE;INTRAVITREAL

TRIESENCE

	+!	NOVARTIS	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		ACP NIMBLE	**0.1%**	**A089129**	**001**	Aug 14, 1986
AT		AKORN	**0.025%**	**A202374**	**001**	May 08, 2013
AT			**0.1%**	**A202374**	**002**	May 08, 2013
AT		ALLIED	**0.1%**	**A040672**	**002**	Dec 13, 2006
AT		FOUGERA PHARMS	**0.025%**	**A040467**	**001**	Apr 21, 2003
AT			**0.1%**	**A040467**	**002**	Apr 21, 2003
AT		TELIGENT PHARMA INC	**0.025%**	**A204608**	**001**	Jul 07, 2016
AT			**0.1%**	**A204606**	**001**	Jul 07, 2016
AT	**!**	WOCKHARDT BIO AG	**0.025%**	**A088450**	**001**	Apr 01, 1985
AT	**!**		**0.1%**	**A088451**	**001**	Apr 03, 1985

OINTMENT;TOPICAL

TRIAMCINOLONE ACETATE

AT		MACLEODS PHARMS LTD	**0.025%**	**A209828**	**001**	Nov 23, 2018
AT			**0.1%**	**A209828**	**002**	Nov 23, 2018
AT			**0.5%**	**A209828**	**003**	Nov 23, 2018

TRIAMCINOLONE ACETONIDE

AT		ACP NIMBLE	**0.025%**	**A089795**	**001**	Dec 23, 1988
AT			**0.1%**	**A089796**	**001**	Dec 23, 1988
AT			**0.5%**	**A208925**	**001**	Oct 06, 2017
AT		ENCUBE	**0.05%**	**A212384**	**001**	Nov 29, 2019

TRIAMCINOLONE ACETONIDE							
OINTMENT;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		FOUGERA PHARMS	**0.025%**	**A085691**	**001**		
AT			**0.1%**	**A085691**	**003**		
AT			**0.5%**	**A085691**	**002**		
AT		GLENMARK PHARMS	**0.1%**	**A208320**	**001**	Aug 22, 2017	
AT		GLENMARK PHARMS LTD	**0.5%**	**A206379**	**001**	Jul 22, 2016	
AT		NOVEL LABS INC	**0.1%**	**A207365**	**001**	Oct 12, 2018	
AT	!	PERRIGO NEW YORK	**0.025%**	**A087385**	**002**		
AT	!		**0.1%**	**A087385**	**003**		
AT	!		**0.5%**	**A087385**	**001**		
AT		TARO PHARM INDS LTD	**0.1%**	**A040037**	**001**	Sep 30, 1994	
AT		TELIGENT PHARMA INC	**0.1%**	**A205373**	**001**	May 13, 2016	
AT			**0.5%**	**A208590**	**001**	Mar 03, 2017	
TRIAMCINOLONE ACETONIDE IN ABSORBASE							
AT	!	CMP PHARMA INC	**0.05%**	**A089595**	**001**	Mar 23, 1995	
PASTE;DENTAL							
TRIAMCINOLONE ACETONIDE							
AT		ACP NIMBLE	**0.1%**	**A205592**	**001**	Jan 12, 2017	
AT		AKORN	**0.1%**	**A206312**	**001**	Aug 11, 2016	
AT		LYNE	**0.1%**	**A040771**	**001**	Jul 01, 2010	
AT	!	TARO	**0.1%**	**A070730**	**001**	Oct 01, 1986	
SPRAY;TOPICAL							
KENALOG							
AT	+!	SUN PHARM INDS INC	**0.147MG/GM**	**N012104**	**001**		
TRIAMCINOLONE ACETONIDE							
AT		AKORN	**0.147MG/GM**	**A207094**	**001**	Dec 07, 2016	
AT		PERRIGO UK FINCO	**0.147MG/GM**	**A205782**	**001**	Apr 13, 2015	
AT		RISING	**0.147MG/GM**	**A206786**	**001**	Sep 08, 2017	
TRIAMCINOLONE HEXACETONIDE							
INJECTABLE;INJECTION							
ARISTOSPAN							
	+!	SANDOZ INC	5MG/ML	N016466	001		
	+!		20MG/ML	N016466	002		
TRIAMTERENE							
CAPSULE;ORAL							
DYRENIUM							
AB	+	CONCORDIA	**50MG**	**N013174**	**001**		
AB	+!		**100MG**	**N013174**	**002**		
TRIAMTERENE							
AB		AGNITIO	**50MG**	**A211581**	**001**	Aug 19, 2019	
AB			**100MG**	**A211581**	**002**	Aug 19, 2019	
TRIAZOLAM							
TABLET;ORAL							
HALCION							
AB	+	PHARMACIA AND UPJOHN	**0.125MG**	**N017892**	**003**	Apr 26, 1985	
AB	+!		**0.25MG**	**N017892**	**001**	Nov 15, 1982	
TRIAZOLAM							
AB		HIKMA	**0.125MG**	**A074224**	**001**	Jun 01, 1994	
AB			**0.25MG**	**A074224**	**002**	Jun 01, 1994	
AB		MYLAN PHARMS INC	**0.125MG**	**A074031**	**001**	Mar 25, 1994	
AB			**0.25MG**	**A074031**	**002**	Mar 25, 1994	
TRICLABENDAZOLE							
TABLET;ORAL							
EGATEN							
	+!	NOVARTIS	250MG	N208711	001	Feb 13, 2019	
TRIENTINE HYDROCHLORIDE							
CAPSULE;ORAL							
CLOVIQUE							
AB		KADMON PHARMS LLC	**250MG**	**A209731**	**001**	Oct 21, 2019	
SYPRINE							
AB	+!	BAUSCH	**250MG**	**N019194**	**001**	Nov 08, 1985	
TRIENTINE HYDROCHLORIDE							
AB		AMNEAL PHARMS LLC	**250MG**	**A210619**	**001**	Feb 08, 2019	
AB		DR REDDYS LABS LTD	**250MG**	**A211076**	**001**	Jul 03, 2019	
AB		KADMON PHARMS LLC	**250MG**	**A209415**	**001**	Sep 16, 2019	
AB		MSN	**250MG**	**A211134**	**001**	May 22, 2019	
AB		NAVINTA LLC	**250MG**	**A211251**	**001**	Jan 16, 2019	

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB		PAR PHARM INC	**250MG**	**A210096**	**001**	Sep 25, 2019
AB		WATSON LABS TEVA	**250MG**	**A207567**	**001**	Feb 07, 2018
AB		ZYDUS PHARMS	**250MG**	**A211554**	**001**	Apr 26, 2019

TRIFAROTENE

CREAM;TOPICAL

AKLIEF

	+!	GALDERMA R AND D	0.005%	N211527	001	Oct 04, 2019

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

AB		MYLAN	**EQ 1MG BASE**	**A040209**	**001**	Jul 07, 1997
AB			**EQ 2MG BASE**	**A040209**	**002**	Jul 07, 1997
AB			**EQ 5MG BASE**	**A040209**	**003**	Jul 07, 1997
AB	**!**		**EQ 10MG BASE**	**A040209**	**004**	Jul 07, 1997
AB		SANDOZ	**EQ 1MG BASE**	**A085785**	**001**	
AB			**EQ 2MG BASE**	**A085786**	**001**	
AB			**EQ 5MG BASE**	**A085789**	**001**	
AB			**EQ 10MG BASE**	**A085788**	**001**	

TRIFLURIDINE

SOLUTION/DROPS;OPHTHALMIC

TRIFLURIDINE

AT		HI TECH	**1%**	**A205438**	**001**	Jul 28, 2017
AT		SANDOZ INC	**1%**	**A074311**	**001**	Oct 06, 1995

VIROPTIC

AT	**+!**	MONARCH PHARMS	**1%**	**N018299**	**001**	

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA		MIKART	**2MG/5ML**	**A040251**	**001**	Sep 27, 1999
AA	**!**	PHARM ASSOC	**2MG/5ML**	**A040177**	**001**	Apr 17, 1997

TABLET;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA		NATCO PHARMA LTD	**2MG**	**A091630**	**001**	Nov 17, 2010
AA			**5MG**	**A091630**	**002**	Nov 17, 2010
AA		NOVITIUM PHARMA	**2MG**	**A040254**	**001**	Dec 24, 1998
AA			**5MG**	**A040254**	**002**	Dec 24, 1998
AA	**!**	WATSON LABS	**2MG**	**A084363**	**001**	
AA	**!**		**5MG**	**A084364**	**001**	

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TIGAN

AB	**+!**	KING PHARMS LLC	**300MG**	**N017531**	**006**	Dec 13, 2001

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB		LUPIN	**300MG**	**A076546**	**001**	Aug 20, 2003
AB		SUN PHARM INDUSTRIES	**300MG**	**A076570**	**001**	Aug 28, 2003

INJECTABLE;INJECTION

TIGAN

	+!	PAR STERILE PRODUCTS	100MG/ML	N017530	001	

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

AB	**+!**	MAYNE PHARMA	**100MG**	**N018679**	**001**	Jul 30, 1982
AB		NOVEL LABS INC	**100MG**	**A091437**	**001**	Jun 15, 2011
AB		WATSON LABS	**100MG**	**A070049**	**001**	Jun 06, 1985

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

	+!	ALLEGIS	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB		CROSSMEDIKA SA	**EQ 25MG BASE**	**A208127**	**001**	Apr 15, 2016
AB	**!**		**EQ 50MG BASE**	**A208127**	**002**	Apr 15, 2016
AB			**EQ 100MG BASE**	**A208127**	**003**	Apr 15, 2016
AB		ELITE LABS INC	**EQ 25MG BASE**	**A077361**	**001**	Aug 02, 2006
AB			**EQ 50MG BASE**	**A077361**	**002**	Aug 02, 2006
AB			**EQ 100MG BASE**	**A077361**	**003**	Aug 02, 2006

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT

+!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017

INJECTABLE;INTRAMUSCULAR

TRELSTAR

+!	ALLERGAN	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000
+!		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001
+!		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

AT	**!**	NOVARTIS	**1%**	**A084306**	**001**	
AT	**!**	SANDOZ INC	**0.5%**	**A084305**	**001**	

TROPICACYL

AT		AKORN	**0.5%**	**A040314**	**001**	Sep 29, 2000
AT			**1%**	**A040315**	**001**	Sep 29, 2000

TROPICAMIDE

AT		BAUSCH AND LOMB	**0.5%**	**A040067**	**001**	Jul 27, 1994
AT			**1%**	**A040064**	**001**	Jul 27, 1994
AT		SOMERSET THERAPS LLC	**1%**	**A207524**	**001**	Dec 12, 2019

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

AB	**!**	ACTAVIS LABS FL INC	**60MG**	**A091289**	**001**	Oct 12, 2012
AB		PADDOCK LLC	**60MG**	**A201291**	**001**	May 24, 2013

TABLET;ORAL

TROSPIUM CHLORIDE

AB		APOTEX	**20MG**	**A091513**	**001**	Dec 06, 2011
AB	**!**	GLENMARK GENERICS	**20MG**	**A091575**	**001**	Aug 13, 2010
AB		HERITAGE PHARMS INC	**20MG**	**A204945**	**001**	Aug 30, 2016
AB		INVAGEN PHARMS	**20MG**	**A091688**	**001**	Aug 23, 2016
AB		PADDOCK LLC	**20MG**	**A091573**	**001**	Nov 17, 2010

TRYPAN BLUE

SOLUTION;OPHTHALMIC

MEMBRANEBLUE

+!	DORC	0.15%	N022278	001	Feb 20, 2009

VISIONBLUE

+!	DORC	0.06%	N021670	001	Dec 16, 2004

UBROGEPANT

TABLET;ORAL

UBRELVY

+	ALLERGAN	50MG	N211765	001	Dec 23, 2019
+!		100MG	N211765	002	Dec 23, 2019

ULIPRISTAL ACETATE

TABLET;ORAL

ELLA

AB	**+!**	LAB HRA PHARMA	**30MG**	**N022474**	**001**	Aug 13, 2010

LOGILIA

AB		TEVA PHARMS USA	**30MG**	**A207952**	**001**	Feb 13, 2017

UMECLIDINIUM BROMIDE

POWDER;INHALATION

INCRUSE ELLIPTA

+!	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001	Apr 30, 2014

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER;INHALATION

ANORO ELLIPTA

+!	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL

RINVOQ

+!	ABBVIE INC	15MG	N211675	001	Aug 16, 2019

UREA, C-14

CAPSULE;ORAL

PYTEST

+!	AVENT	1uCi	N020617	001	May 09, 1997

PYTEST KIT

+!	AVENT	1uCi	N020617	002	May 09, 1997

URIDINE TRIACETATE

GRANULE;ORAL

VISTOGARD

+!	WELLSTAT THERAP	10GM/PACKET	N208159	001	Dec 11, 2015

XURIDEN

+!	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	**+!**	ALLERGAN	**300MG**	**N019594**	**002**	Dec 31, 1987

URSODIOL

AB		ABHAI LLC	**300MG**	**A210707**	**001**	May 17, 2018
AB		AMNEAL PHARMS CO	**300MG**	**A211301**	**001**	Oct 16, 2018
AB		EPIC PHARMA	**300MG**	**A075517**	**001**	Mar 14, 2000
AB		EYWA PHARMA	**300MG**	**A212452**	**001**	Oct 30, 2019
AB		LANNETT CO INC	**300MG**	**A079082**	**001**	Dec 15, 2008
AB		MYLAN	**300MG**	**A090530**	**001**	Feb 17, 2010
AB		TEVA PHARMS	**300MG**	**A075592**	**001**	May 25, 2000

TABLET;ORAL

URSO 250

AB	**+**	ALLERGAN	**250MG**	**N020675**	**001**	Dec 10, 1997

URSO FORTE

AB	**+!**	ALLERGAN	**500MG**	**N020675**	**002**	Jul 21, 2004

URSODIOL

AB		GLENMARK GENERICS	**250MG**	**A090801**	**001**	Jul 12, 2011
AB			**500MG**	**A090801**	**002**	Jul 12, 2011
AB		IMPAX LABS INC	**250MG**	**A200826**	**001**	Dec 23, 2011
AB			**500MG**	**A200826**	**002**	Dec 23, 2011
AB		PAR PHARM	**250MG**	**A202540**	**001**	Feb 14, 2013
AB			**500MG**	**A202540**	**002**	Feb 14, 2013
AB		ZYDUS	**250MG**	**A211145**	**001**	Oct 30, 2018
AB			**500MG**	**A211145**	**002**	Oct 30, 2018

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	APOTEX	**EQ 500MG BASE**	**A090500**	**001**	Apr 04, 2014
AB		**EQ 1GM BASE**	**A090500**	**002**	Apr 04, 2014
AB	AUROBINDO PHARMA	**EQ 500MG BASE**	**A090682**	**001**	May 24, 2010
AB		**EQ 1GM BASE**	**A090682**	**002**	May 24, 2010
AB	CIPLA	**EQ 500MG BASE**	**A077135**	**001**	May 24, 2010
AB		**EQ 1GM BASE**	**A077135**	**002**	May 24, 2010
AB	HETERO LABS LTD V	**EQ 500MG BASE**	**A203047**	**001**	Apr 08, 2015
AB		**EQ 1GM BASE**	**A203047**	**002**	Apr 08, 2015
AB	HIKMA	**EQ 500MG BASE**	**A078656**	**001**	May 24, 2010
AB		**EQ 1GM BASE**	**A078656**	**002**	May 24, 2010
AB	JUBILANT GENERICS	**EQ 500MG BASE**	**A201506**	**001**	Apr 03, 2012
AB		**EQ 1GM BASE**	**A201506**	**002**	Apr 03, 2012
AB	MYLAN PHARMS INC	**EQ 500MG BASE**	**A078518**	**001**	May 24, 2010
AB		**EQ 1GM BASE**	**A078518**	**002**	May 24, 2010
AB	SANDOZ	**EQ 500MG BASE**	**A077478**	**001**	May 24, 2010
AB		**EQ 1GM BASE**	**A077478**	**002**	May 24, 2010
AB	SUN PHARM INDS LTD	**EQ 500MG BASE**	**A076588**	**001**	Jan 31, 2007
AB		**EQ 1GM BASE**	**A076588**	**002**	Jan 31, 2007
AB	TEVA PHARMS	**EQ 500MG BASE**	**A077655**	**001**	May 24, 2010
AB		**EQ 1GM BASE**	**A077655**	**002**	May 24, 2010

PRESCRIPTION DRUG PRODUCT LIST

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		TIME-CAP LABS INC	**EQ 500MG BASE**	**A079012**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A079012**	**002**	May 24, 2010
AB		WOCKHARDT	**EQ 500MG BASE**	**A090216**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090216**	**002**	May 24, 2010
AB		ZYDUS PHARMS	**EQ 500MG BASE**	**A079137**	**001**	Dec 29, 2017
AB			**EQ 1GM BASE**	**A079137**	**002**	Dec 29, 2017

VALTREX

AB	**+**	GLAXOSMITHKLINE	**EQ 500MG BASE**	**N020487**	**001**	Jun 23, 1995
AB	**+!**		**EQ 1GM BASE**	**N020487**	**002**	Jun 23, 1995

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

	+	NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017
	+!		EQ 80MG BASE	N209241	002	Oct 04, 2017

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	**+!**	HOFFMANN LA ROCHE	**50MG/ML**	**N022257**	**001**	Aug 28, 2009

VALGANCICLOVIR HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**50MG/ML**	**A205220**	**001**	Jul 18, 2016
AB		AJANTA PHARMA LTD	**50MG/ML**	**A212890**	**001**	Jan 13, 2020

TABLET;ORAL

VALCYTE

AB	**+!**	HOFFMANN LA ROCHE	**EQ 450MG BASE**	**N021304**	**001**	Mar 29, 2001

VALGANCICLOVIR HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**EQ 450MG BASE**	**A212234**	**001**	Dec 26, 2019
AB		AUROBINDO PHARMA LTD	**EQ 450MG BASE**	**A204750**	**001**	Mar 31, 2016
AB		CIPLA	**EQ 450MG BASE**	**A209672**	**001**	Nov 09, 2018
AB		DR REDDYS	**EQ 450MG BASE**	**A206876**	**001**	Dec 12, 2017
AB		DR REDDYS LABS LTD	**EQ 450MG BASE**	**A203511**	**001**	Nov 04, 2014
AB		ENDO PHARMS INC	**EQ 450MG BASE**	**A200790**	**001**	Nov 04, 2014
AB		HETERO LABS LTD V	**EQ 450MG BASE**	**A205166**	**001**	Mar 18, 2016

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

AP		ATHENEX INC	**EQ 100MG BASE/ML**	**A076295**	**001**	Nov 14, 2002
AP		FRESENIUS KABI USA	**EQ 100MG BASE/ML**	**A076539**	**001**	Jun 26, 2003
AP	**!**	HIKMA FARMACEUTICA	**EQ 100MG BASE/ML**	**A078523**	**001**	Feb 17, 2010

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	**!**	BIONPHARMA INC	**250MG**	**A073484**	**001**	Jun 29, 1993
AB		CATALENT	**250MG**	**A073229**	**001**	Oct 29, 1991
AB		NOVELGENIX THERAPS	**250MG**	**A207611**	**001**	Aug 05, 2019
AB		SUN PHARM INDS LTD	**250MG**	**A091037**	**001**	Feb 22, 2013

SYRUP;ORAL

VALPROIC ACID

AA		ECI PHARMS LLC	**250MG/5ML**	**A090517**	**001**	May 28, 2010
AA		HIGH TECH PHARMA	**250MG/5ML**	**A074060**	**001**	Jan 13, 1995
AA		LANNETT CO INC	**250MG/5ML**	**A077960**	**001**	Oct 13, 2006
AA	**!**	PHARM ASSOC	**250MG/5ML**	**A075379**	**001**	Dec 15, 2000
AA		VISTAPHARM	**250MG/5ML**	**A075782**	**001**	Dec 22, 2000
AA		WOCKHARDT BIO AG	**250MG/5ML**	**A070868**	**001**	Jul 01, 1986

VALRUBICIN

SOLUTION;INTRAVESICAL

VALRUBICIN

AO		CUSTOPHARM INC	**40MG/ML**	**A206430**	**001**	Apr 19, 2019

VALSTAR PRESERVATIVE FREE

AO	**+!**	ENDO PHARM	**40MG/ML**	**N020892**	**001**	Sep 25, 1998

VALSARTAN

TABLET;ORAL

DIOVAN

AB	**+**	NOVARTIS	**40MG**	**N021283**	**004**	Aug 14, 2002
AB	**+**		**80MG**	**N021283**	**001**	Jul 18, 2001
AB	**+**		**160MG**	**N021283**	**002**	Jul 18, 2001
AB	**+!**		**320MG**	**N021283**	**003**	Jul 18, 2001

VALSARTAN

TABLET;ORAL

VALSARTAN

AB	ALEMBIC PHARMS LTD	**40MG**	**A091367**	**001**	Jan 05, 2015
AB		**80MG**	**A091367**	**002**	Jan 05, 2015
AB		**160MG**	**A091367**	**003**	Jan 05, 2015
AB		**320MG**	**A091367**	**004**	Jan 05, 2015
AB	ALKEM LABS LTD	**40MG**	**A205536**	**001**	Mar 12, 2019
AB		**80MG**	**A205536**	**002**	Mar 12, 2019
AB		**160MG**	**A205536**	**003**	Mar 12, 2019
AB		**320MG**	**A205536**	**004**	Mar 12, 2019
AB	AMNEAL PHARMS	**40MG**	**A204011**	**001**	Jan 11, 2016
AB		**80MG**	**A204011**	**002**	Jan 11, 2016
AB		**160MG**	**A204011**	**003**	Jan 11, 2016
AB		**320MG**	**A204011**	**004**	Jan 11, 2016
AB	AUROBINDO PHARMA LTD	**40MG**	**A202223**	**001**	Jan 05, 2015
AB		**80MG**	**A202223**	**002**	Jan 05, 2015
AB		**160MG**	**A202223**	**003**	Jan 05, 2015
AB		**320MG**	**A202223**	**004**	Jan 05, 2015
AB	HETERO LABS LTD V	**40MG**	**A203311**	**001**	Jan 05, 2015
AB		**80MG**	**A203311**	**002**	Jan 05, 2015
AB		**160MG**	**A203311**	**003**	Jan 05, 2015
AB		**320MG**	**A203311**	**004**	Jan 05, 2015
AB	IVAX PHARMS	**40MG**	**A077530**	**001**	Jan 04, 2016
AB		**80MG**	**A077530**	**002**	Jan 04, 2016
AB		**160MG**	**A077530**	**003**	Jan 04, 2016
AB		**320MG**	**A077530**	**004**	Jan 04, 2016
AB	JUBILANT GENERICS	**40MG**	**A203536**	**001**	Jan 05, 2015
AB		**80MG**	**A203536**	**002**	Jan 05, 2015
AB		**160MG**	**A203536**	**003**	Jan 05, 2015
AB		**320MG**	**A203536**	**004**	Jan 05, 2015
AB	LUPIN LTD	**40MG**	**A201677**	**001**	Jan 05, 2015
AB		**80MG**	**A201677**	**002**	Jan 05, 2015
AB		**160MG**	**A201677**	**003**	Jan 05, 2015
AB		**320MG**	**A201677**	**004**	Jan 05, 2015
AB	MACLEODS PHARMS LTD	**40MG**	**A202696**	**001**	Sep 16, 2016
AB		**80MG**	**A202696**	**002**	Sep 16, 2016
AB		**160MG**	**A202696**	**003**	Sep 16, 2016
AB		**320MG**	**A202696**	**004**	Sep 16, 2016
AB	MYLAN	**40MG**	**A090866**	**001**	Jan 05, 2015
AB		**80MG**	**A090866**	**002**	Jan 05, 2015
AB		**160MG**	**A090866**	**003**	Jan 05, 2015
AB		**320MG**	**A090866**	**004**	Jan 05, 2015
AB	OHM LABS INC	**40MG**	**A077492**	**001**	Jun 26, 2014
AB		**80MG**	**A077492**	**002**	Jun 26, 2014
AB		**160MG**	**A077492**	**003**	Jun 26, 2014
AB		**320MG**	**A077492**	**004**	Jun 26, 2014
AB	PRINSTON INC	**40MG**	**A204821**	**001**	Jun 09, 2015
AB		**80MG**	**A204821**	**002**	Jun 09, 2015
AB		**160MG**	**A204821**	**003**	Jun 09, 2015
AB		**320MG**	**A204821**	**004**	Jun 09, 2015
AB	SQUARE PHARMS LTD	**40MG**	**A205347**	**001**	Apr 09, 2018
AB		**80MG**	**A205347**	**002**	Apr 09, 2018
AB		**160MG**	**A205347**	**003**	Apr 09, 2018
AB		**320MG**	**A205347**	**004**	Apr 09, 2018
AB	UNICHEM LABS LTD	**40MG**	**A209261**	**001**	May 04, 2018
AB		**80MG**	**A209261**	**002**	May 04, 2018
AB		**160MG**	**A209261**	**003**	May 04, 2018
AB		**320MG**	**A209261**	**004**	May 04, 2018

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOCIN HYDROCHLORIDE

AB	**+**	ANI PHARMS INC	**EQ 125MG BASE**	**N050606**	**001**	Apr 15, 1986
AB	**+!**		**EQ 250MG BASE**	**N050606**	**002**	Apr 15, 1986

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	**EQ 125MG BASE**	**A065478**	**001**	Apr 09, 2012
AB		**EQ 250MG BASE**	**A065478**	**002**	Apr 09, 2012
AB	LUPIN LTD	**EQ 125MG BASE**	**A090439**	**001**	Jan 28, 2015
AB		**EQ 250MG BASE**	**A090439**	**002**	Jan 28, 2015
AB	ORIENT PHARMA CO LTD	**EQ 125MG BASE**	**A210729**	**001**	Apr 29, 2019

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB			**EQ 250MG BASE**	**A210729**	**002**	Apr 29, 2019
AB		STRIDES PHARMA	**EQ 125MG BASE**	**A065490**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065490**	**002**	Apr 09, 2012
AB		WATSON LABS	**EQ 125MG BASE**	**A065510**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065510**	**002**	Apr 09, 2012

FOR SOLUTION;ORAL

FIRVANQ KIT

+!	RXMTM THERAPS LLC	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018
+!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018

VANCOCIN HYDROCHLORIDE

	ANI PHARMS INC	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	**EQ 500MG BASE/VIAL**	**A205780**	**001**	Mar 31, 2016
AP			**EQ 1GM BASE/VIAL**	**A205780**	**002**	Mar 31, 2016
AP			**EQ 5GM BASE/VIAL**	**A205779**	**001**	Mar 29, 2016
AP			**EQ 10GM BASE/VIAL**	**A205779**	**002**	Mar 29, 2016
AP	**!**	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A062663**	**001**	Mar 17, 1987
AP			**EQ 750MG BASE/VIAL**	**A062663**	**005**	Aug 17, 2016
AP	**!**		**EQ 1GM BASE/VIAL**	**A062663**	**002**	Jul 31, 1987
AP	**!**		**EQ 5GM BASE/VIAL**	**A062663**	**003**	Jun 03, 1988
AP	**!**		**EQ 10GM BASE/VIAL**	**A062663**	**004**	Nov 28, 1997
AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A205694**	**001**	Jan 21, 2016
AP			**EQ 1GM BASE/VIAL**	**A205694**	**002**	Jan 21, 2016
AP		HIKMA	**EQ 5GM BASE/VIAL**	**A204360**	**001**	Oct 15, 2018
AP			**EQ 10GM BASE/VIAL**	**A204360**	**002**	Oct 15, 2018
AP		HIKMA PHARMS	**EQ 750MG BASE/VIAL**	**A206616**	**001**	Oct 03, 2018
AP	**!**	HOSPIRA	**EQ 500MG BASE/VIAL**	**A062911**	**001**	Aug 04, 1988
AP	**!**		**EQ 500MG BASE/VIAL**	**A062931**	**001**	Oct 29, 1992
AP	**!**		**EQ 750MG BASE/VIAL**	**A062912**	**002**	Jan 07, 2009
AP	**!**		**EQ 750MG BASE/VIAL**	**A062933**	**002**	May 27, 2009
AP	**!**		**EQ 1GM BASE/VIAL**	**A062912**	**001**	Aug 04, 1988
AP	**!**		**EQ 1GM BASE/VIAL**	**A062933**	**001**	Oct 29, 1992
AP	**!**		**EQ 5GM BASE/VIAL**	**A063076**	**001**	Dec 21, 1990
AP		HOSPIRA INC	**EQ 10GM BASE/VIAL**	**A065455**	**001**	Apr 29, 2009
AP		MUSTAFA NEVZAT ILAC	**EQ 500MG BASE/VIAL**	**A065401**	**001**	Jun 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065401**	**002**	Jun 30, 2008
AP		MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A065397**	**001**	Dec 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065397**	**002**	Dec 30, 2008
AP			**EQ 5GM BASE/VIAL**	**A065432**	**001**	Dec 30, 2008
AP			**EQ 10GM BASE/VIAL**	**A091554**	**001**	Sep 19, 2011
AP		SAGENT PHARMS	**EQ 5GM BASE/VIAL**	**A200837**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A200837**	**002**	Sep 02, 2014
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A090250**	**001**	Apr 27, 2010
AP			**EQ 1GM BASE/VIAL**	**A090250**	**002**	Apr 27, 2010
AP		SANDOZ INC	**EQ 5GM BASE/VIAL**	**A201048**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A201048**	**002**	Aug 10, 2012
AP		XELLIA PHARMS APS	**EQ 5GM BASE/VIAL**	**A204125**	**001**	Dec 28, 2015
AP			**EQ 10GM BASE/VIAL**	**A204125**	**002**	Dec 28, 2015
AP			**EQ 500MG BASE/VIAL**	**A204107**	**001**	Dec 28, 2015
AP			**EQ 1GM BASE/VIAL**	**A204107**	**002**	Dec 28, 2015

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010
+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+!	MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481	001	Jul 10, 2018
+!		EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018
+!		EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018
+!		EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016

SOLUTION;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+!	XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019
+!		EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019
+!		EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019
+!		EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019

VANDETANIB

TABLET;ORAL

CAPRELSA

+	GENZYME CORP	100MG	N022405	001	Apr 06, 2011
+!		300MG	N022405	002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

AB	**+**	BAYER HLTHCARE	**5MG**	**N021400**	**001**	Aug 19, 2003
AB	**+**		**10MG**	**N021400**	**002**	Aug 19, 2003
AB	**+!**		**20MG**	**N021400**	**004**	Aug 19, 2003

VARDENAFIL HYDROCHLORIDE

AB		CROSSMEDIKA SA	**2.5MG**	**A209057**	**001**	Oct 31, 2018
AB			**5MG**	**A209057**	**002**	Oct 31, 2018
AB			**10MG**	**A209057**	**003**	Oct 31, 2018
AB			**20MG**	**A209057**	**004**	Oct 31, 2018
AB		MACLEODS PHARMS LTD	**2.5MG**	**A204632**	**001**	Oct 22, 2019
AB			**5MG**	**A204632**	**002**	Oct 22, 2019
AB			**10MG**	**A204632**	**003**	Oct 22, 2019
AB			**20MG**	**A204632**	**004**	Oct 22, 2019
AB		TEVA PHARMS	**2.5MG**	**A091347**	**001**	May 03, 2012
AB			**5MG**	**A091347**	**002**	May 03, 2012
AB			**10MG**	**A091347**	**003**	May 03, 2012
AB			**20MG**	**A091347**	**004**	May 03, 2012
AB		ZYDUS PHARMS	**2.5MG**	**A208960**	**001**	Oct 31, 2018
AB			**5MG**	**A208960**	**002**	Oct 31, 2018
AB			**10MG**	**A208960**	**003**	Oct 31, 2018
AB			**20MG**	**A208960**	**004**	Oct 31, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

AB	**+!**	BAYER HLTHCARE	**10MG**	**N200179**	**001**	Jun 17, 2010

VARDENAFIL HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**10MG**	**A208324**	**001**	Nov 16, 2018

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

+	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006
+!		EQ 1MG BASE	N021928	002	May 10, 2006

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

+!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014
+!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP		AUROBINDO PHARMA LTD	**10MG/VIAL**	**A206670**	**001**	Dec 20, 2018
AP			**20MG/VIAL**	**A206670**	**002**	Dec 20, 2018
AP		GLAND PHARMA LTD	**10MG/VIAL**	**A205390**	**001**	May 26, 2016
AP			**20MG/VIAL**	**A205390**	**002**	May 26, 2016
AP		HIKMA	**10MG/VIAL**	**A203725**	**001**	Jul 30, 2019
AP			**20MG/VIAL**	**A203725**	**002**	Jul 30, 2019
AP		HOSPIRA	**10MG/VIAL**	**A075164**	**001**	Oct 21, 1999
AP			**20MG/VIAL**	**A075164**	**002**	Oct 21, 1999
AP		MYLAN LABS LTD	**10MG/VIAL**	**A090243**	**001**	May 11, 2010
AP			**20MG/VIAL**	**A090243**	**002**	May 11, 2010
AP		SAGENT PHARMS INC	**10MG/VIAL**	**A078274**	**001**	Dec 29, 2008
AP			**20MG/VIAL**	**A078274**	**002**	Dec 29, 2008
AP	**!**	SUN PHARM	**10MG/VIAL**	**A079001**	**001**	Jun 17, 2009
AP	**!**		**20MG/VIAL**	**A079001**	**002**	Jun 17, 2009
AP		TEVA PHARMS USA	**10MG/VIAL**	**A074688**	**001**	Aug 25, 1999
AP			**20MG/VIAL**	**A074688**	**002**	Aug 25, 1999
AP		WEST-WARD PHARMS INT	**10MG/VIAL**	**A075549**	**001**	Jun 13, 2000
AP			**20MG/VIAL**	**A075549**	**002**	Jun 13, 2000

PRESCRIPTION DRUG PRODUCT LIST

VELAGLUCERASE ALFA

INJECTABLE;INTRAVENOUS

VPRIV

	SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010

VEMURAFENIB

TABLET;ORAL

ZELBORAF

+!	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011

VENETOCLAX

TABLET;ORAL

VENCLEXTA

+	ABBVIE INC	10MG	N208573	001	Apr 11, 2016
+		50MG	N208573	002	Apr 11, 2016
+!		100MG	N208573	003	Apr 11, 2016

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

AB	**+**	WYETH PHARMS	**EQ 37.5MG BASE**	**N020699**	**001**	Oct 20, 1997
AB	**+**		**EQ 75MG BASE**	**N020699**	**002**	Oct 20, 1997
AB	**+!**		**EQ 150MG BASE**	**N020699**	**004**	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

AB		ANNORA PHARMA	**EQ 37.5MG BASE**	**A212277**	**001**	Jul 08, 2019
AB			**EQ 75MG BASE**	**A212277**	**002**	Jul 08, 2019
AB			**EQ 150MG BASE**	**A212277**	**003**	Jul 08, 2019
AB		AUROBINDO PHARMA LTD	**EQ 37.5MG BASE**	**A200834**	**001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A200834**	**002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A200834**	**003**	Apr 14, 2011
AB		DR REDDYS LABS LTD	**EQ 37.5MG BASE**	**A078421**	**001**	May 06, 2011
AB			**EQ 75MG BASE**	**A078421**	**002**	May 06, 2011
AB			**EQ 150MG BASE**	**A078421**	**003**	May 06, 2011
AB		INTELLIPHARMACEUTICS	**EQ 37.5MG BASE**	**A201272**	**001**	Nov 23, 2018
AB			**EQ 75MG BASE**	**A201272**	**002**	Nov 23, 2018
AB			**EQ 150MG BASE**	**A201272**	**003**	Nov 23, 2018
AB		MACLEODS PHARMS LTD	**EQ 37.5MG BASE**	**A204889**	**001**	Oct 05, 2017
AB			**EQ 75MG BASE**	**A204889**	**002**	Oct 05, 2017
AB			**EQ 150MG BASE**	**A204889**	**003**	Oct 05, 2017
AB		ORCHID HLTHCARE	**EQ 37.5MG BASE**	**A091123**	**001**	Jul 11, 2011
AB			**EQ 75MG BASE**	**A091123**	**002**	Jul 11, 2011
AB			**EQ 150MG BASE**	**A091123**	**003**	Jul 11, 2011
AB		TEVA	**EQ 37.5MG BASE**	**A076565**	**001**	Jun 28, 2010
AB			**EQ 75MG BASE**	**A076565**	**002**	Jun 28, 2010
AB			**EQ 150MG BASE**	**A076565**	**003**	Jun 28, 2010
AB		TORRENT PHARMS LLC	**EQ 37.5MG BASE**	**A090899**	**001**	Jun 01, 2011
AB			**EQ 75MG BASE**	**A090899**	**002**	Jun 01, 2011
AB			**EQ 150MG BASE**	**A090899**	**003**	Jun 01, 2011
AB		VALEANT PHARMS NORTH	**EQ 37.5MG BASE**	**A090071**	**001**	Apr 15, 2011
AB			**EQ 75MG BASE**	**A090071**	**002**	Apr 15, 2011
AB			**EQ 150MG BASE**	**A090071**	**003**	Apr 15, 2011
AB		WOCKHARDT	**EQ 37.5MG BASE**	**A078865**	**001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A078865**	**002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A078865**	**003**	Apr 14, 2011
AB		ZYDUS PHARMS USA INC	**EQ 37.5MG BASE**	**A090174**	**001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A090174**	**002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A090174**	**003**	Apr 14, 2011

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A078932**	**001**	Dec 14, 2010
AB			**EQ 37.5MG BASE**	**A078932**	**002**	Dec 14, 2010
AB			**EQ 50MG BASE**	**A078932**	**003**	Dec 14, 2010
AB			**EQ 75MG BASE**	**A078932**	**004**	Dec 14, 2010
AB			**EQ 100MG BASE**	**A078932**	**005**	Dec 14, 2010
AB		AMNEAL PHARMS	**EQ 25MG BASE**	**A079098**	**001**	May 11, 2010
AB			**EQ 37.5MG BASE**	**A079098**	**002**	May 11, 2010
AB			**EQ 50MG BASE**	**A079098**	**003**	May 11, 2010
AB			**EQ 75MG BASE**	**A079098**	**004**	May 11, 2010
AB			**EQ 100MG BASE**	**A079098**	**005**	May 11, 2010
AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A090555**	**001**	Apr 07, 2010
AB			**EQ 37.5MG BASE**	**A090555**	**002**	Apr 07, 2010

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB			**EQ 50MG BASE**	**A090555**	**003**	Apr 07, 2010
AB			**EQ 75MG BASE**	**A090555**	**004**	Apr 07, 2010
AB			**EQ 100MG BASE**	**A090555**	**005**	Apr 07, 2010
AB		CADILA PHARMS LTD	**EQ 25MG BASE**	**A206250**	**001**	Nov 21, 2018
AB			**EQ 37.5MG BASE**	**A206250**	**002**	Nov 21, 2018
AB			**EQ 50MG BASE**	**A206250**	**003**	Nov 21, 2018
AB			**EQ 75MG BASE**	**A206250**	**004**	Nov 21, 2018
AB			**EQ 100MG BASE**	**A206250**	**005**	Nov 21, 2018
AB		DR REDDYS LABS LTD	**EQ 25MG BASE**	**A078301**	**001**	Jun 13, 2008
AB			**EQ 37.5MG BASE**	**A078301**	**002**	Jun 13, 2008
AB			**EQ 50MG BASE**	**A078301**	**003**	Jun 13, 2008
AB			**EQ 75MG BASE**	**A078301**	**004**	Jun 13, 2008
AB			**EQ 100MG BASE**	**A078301**	**005**	Jun 13, 2008
AB		HERITAGE PHARMS INC	**EQ 25MG BASE**	**A078554**	**001**	Jan 09, 2009
AB			**EQ 37.5MG BASE**	**A078554**	**002**	Jan 09, 2009
AB			**EQ 50MG BASE**	**A078554**	**003**	Jan 09, 2009
AB			**EQ 75MG BASE**	**A078554**	**004**	Jan 09, 2009
AB			**EQ 100MG BASE**	**A078554**	**005**	Jan 09, 2009
AB		MYLAN	**EQ 25MG BASE**	**A077166**	**001**	Jun 13, 2008
AB			**EQ 37.5MG BASE**	**A077166**	**002**	Jun 13, 2008
AB			**EQ 50MG BASE**	**A077166**	**003**	Jun 13, 2008
AB			**EQ 75MG BASE**	**A077166**	**004**	Jun 13, 2008
AB			**EQ 100MG BASE**	**A077166**	**005**	Jun 13, 2008
AB		SUN PHARM INDS INC	**EQ 25MG BASE**	**A078627**	**001**	Jun 13, 2008
AB			**EQ 37.5MG BASE**	**A078627**	**002**	Jun 13, 2008
AB			**EQ 50MG BASE**	**A078627**	**003**	Jun 13, 2008
AB			**EQ 75MG BASE**	**A078627**	**004**	Jun 13, 2008
AB			**EQ 100MG BASE**	**A078627**	**005**	Jun 13, 2008
AB		TEVA	**EQ 25MG BASE**	**A076690**	**001**	Aug 03, 2006
AB			**EQ 37.5MG BASE**	**A076690**	**002**	Aug 03, 2006
AB	**!**		**EQ 50MG BASE**	**A076690**	**003**	Aug 03, 2006
AB			**EQ 75MG BASE**	**A076690**	**004**	Aug 03, 2006
AB			**EQ 100MG BASE**	**A076690**	**005**	Aug 03, 2006
AB		YAOPHARMA CO LTD	**EQ 25MG BASE**	**A202036**	**001**	May 28, 2015
AB			**EQ 37.5MG BASE**	**A202036**	**002**	May 28, 2015
AB			**EQ 50MG BASE**	**A202036**	**003**	May 28, 2015
AB			**EQ 75MG BASE**	**A202036**	**004**	May 28, 2015
AB			**EQ 100MG BASE**	**A202036**	**005**	May 28, 2015
AB		ZYDUS PHARMS USA	**EQ 25MG BASE**	**A077653**	**001**	Jun 13, 2008
AB			**EQ 37.5MG BASE**	**A077653**	**002**	Jun 13, 2008
AB			**EQ 50MG BASE**	**A077653**	**003**	Jun 13, 2008
AB			**EQ 75MG BASE**	**A077653**	**004**	Jun 13, 2008
AB			**EQ 100MG BASE**	**A077653**	**005**	Jun 13, 2008

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		CADILA PHARMS LTD	**EQ 75MG BASE**	**A211323**	**001**	Aug 29, 2019
AB			**EQ 150MG BASE**	**A211323**	**002**	Aug 29, 2019
AB			**EQ 225MG BASE**	**A211323**	**003**	Aug 29, 2019
AB		DEXCEL PHARMA	**EQ 150MG BASE**	**A209193**	**001**	Oct 31, 2019
AB			**EQ 225MG BASE**	**A209193**	**002**	Oct 31, 2019
AB		NOSTRUM LABS INC	**EQ 150MG BASE**	**A205468**	**002**	Mar 24, 2017
AB			**EQ 225MG BASE**	**A205468**	**003**	Mar 24, 2017
AB	**+**	OSMOTICA PHARM	**EQ 37.5MG BASE**	**N022104**	**001**	May 20, 2008
AB	**+**		**EQ 75MG BASE**	**N022104**	**002**	May 20, 2008
AB	**+!**		**EQ 150MG BASE**	**N022104**	**003**	May 20, 2008
AB	**+**		**EQ 225MG BASE**	**N022104**	**004**	May 20, 2008
AB		SUN PHARM	**EQ 37.5MG BASE**	**A091272**	**001**	Aug 18, 2010
AB			**EQ 75MG BASE**	**A091272**	**002**	Aug 18, 2010
AB			**EQ 150MG BASE**	**A091272**	**003**	Aug 18, 2010
AB			**EQ 225MG BASE**	**A091272**	**004**	Jan 08, 2019

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB		MYLAN	**120MG**	**A075138**	**001**	Apr 20, 1999
AB			**180MG**	**A075138**	**002**	Apr 20, 1999
AB			**240MG**	**A075138**	**003**	Apr 20, 1999

VERELAN

AB	**+**	RECRO GAINESVILLE	**120MG**	**N019614**	**001**	May 29, 1990
AB	**+**		**180MG**	**N019614**	**003**	Jan 09, 1992

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	**+**		**240MG**	**N019614**	**002**	May 29, 1990
	+!		360MG	N019614	004	May 10, 1996

VERELAN PM

	+	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998
	+		200MG	N020943	002	Nov 25, 1998
	+!		300MG	N020943	003	Nov 25, 1998

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		AMNEAL	**5MG/2ML (2.5MG/ML)**	**A210994**	**001**	Jul 13, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A210994**	**002**	Jul 13, 2018
AP		EXELA PHARMA SCS LLC	**5MG/2ML (2.5MG/ML)**	**N018925**	**001**	Mar 30, 1984
AP			**10MG/4ML (2.5MG/ML)**	**N018925**	**002**	Apr 05, 2018
AP	**!**	HOSPIRA	**5MG/2ML (2.5MG/ML)**	**A070738**	**001**	May 06, 1987
AP	**!**		**5MG/2ML (2.5MG/ML)**	**A075136**	**001**	Oct 20, 1998
AP	**!**		**5MG/2ML (2.5MG/ML)**	**A070737**	**001**	May 06, 1987
AP	**!**		**10MG/4ML (2.5MG/ML)**	**A070737**	**002**	May 06, 1987
AP		MICRO LABS	**5MG/2ML (2.5MG/ML)**	**A211370**	**001**	Dec 28, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211370**	**002**	Dec 28, 2018
AP		SOMERSET	**5MG/2ML (2.5MG/ML)**	**A211035**	**001**	Jun 18, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211035**	**002**	Jun 18, 2018
AP		SOMERSET THERAPS LLC	**5MG/2ML (2.5MG/ML)**	**A211015**	**001**	Jun 18, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211015**	**002**	Jun 18, 2018

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB		HERITAGE PHARMS INC	**40MG**	**A071881**	**002**	Oct 14, 2015
AB			**80MG**	**A071881**	**003**	Apr 05, 1988
AB	**!**		**120MG**	**A071881**	**001**	Apr 05, 1988
AB		MYLAN	**80MG**	**A071483**	**002**	Feb 15, 1989
AB			**120MG**	**A071483**	**001**	Feb 15, 1989
AB		WATSON LABS	**40MG**	**A072924**	**001**	Jun 29, 1993
AB			**80MG**	**A070995**	**001**	Oct 01, 1986
AB			**120MG**	**A070994**	**001**	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

AB	**+!**	PFIZER	**120MG**	**N019152**	**003**	Mar 06, 1991
AB	**+!**		**240MG**	**N019152**	**001**	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

AB		CADILA PHARMS LTD	**180MG**	**A206173**	**001**	May 05, 2017
AB			**240MG**	**A206173**	**002**	May 05, 2017
AB		GLENMARK GENERICS	**120MG**	**A090700**	**001**	Aug 03, 2011
AB	**!**		**180MG**	**A090700**	**002**	Aug 03, 2011
AB			**240MG**	**A078906**	**001**	Sep 17, 2009
AB		IVAX SUB TEVA PHARMS	**120MG**	**A073568**	**002**	Oct 10, 1997
AB			**180MG**	**A074330**	**001**	Jan 31, 1994
AB			**240MG**	**A073568**	**001**	Jul 31, 1992
AB		MYLAN	**120MG**	**A074587**	**002**	Feb 21, 1997
AB			**180MG**	**A074587**	**003**	Sep 09, 1997
AB			**240MG**	**A074587**	**001**	Mar 23, 1996
AB		PAR PHARM	**120MG**	**A075072**	**001**	May 25, 1999
AB			**240MG**	**A075072**	**003**	May 25, 1999
AB		SUN PHARM INDS INC	**120MG**	**A090529**	**001**	Dec 30, 2011
AB			**180MG**	**A090529**	**002**	Dec 30, 2011
AB			**240MG**	**A090529**	**003**	Dec 30, 2011

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+!	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	**+!**	LUNDBECK PHARMS LLC	**500MG/PACKET**	**N022006**	**001**	Aug 21, 2009

VIGABATRIN

AA		AMNEAL PHARMS	**500MG/PACKET**	**A210155**	**001**	Mar 13, 2018
AA		DR REDDYS LABS LTD	**500MG/PACKET**	**A211481**	**001**	Nov 20, 2018
AA		INVAGEN PHARMS	**500MG/PACKET**	**A211592**	**001**	Dec 03, 2019
AA		PAR PHARM INC	**500MG/PACKET**	**A208218**	**001**	Apr 27, 2017

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

AA		TEVA PHARMS USA	**500MG/PACKET**	**A209824**	**001**	Apr 23, 2018

VIGADRONE

AA		AUCTA	**500MG/PACKET**	**A210196**	**001**	Jun 21, 2018

TABLET;ORAL

SABRIL

AB	**+!**	LUNDBECK PHARMS LLC	**500MG**	**N020427**	**001**	Aug 21, 2009

VIGABATRIN

AB		TEVA PHARMS USA	**500MG**	**A209822**	**001**	Jan 14, 2019

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

AB	**+!**	ALLERGAN	**10MG**	**N022567**	**001**	Jan 21, 2011
AB	**+**		**20MG**	**N022567**	**002**	Jan 21, 2011
AB	**+**		**40MG**	**N022567**	**003**	Jan 21, 2011

VILAZODONE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**10MG**	**A208202**	**001**	Jan 10, 2020
AB			**20MG**	**A208202**	**002**	Jan 10, 2020
AB			**40MG**	**A208202**	**003**	Jan 10, 2020
AB		TEVA PHARMS USA	**10MG**	**A208212**	**001**	Sep 30, 2019
AB			**20MG**	**A208212**	**002**	Sep 30, 2019
AB			**40MG**	**A208212**	**003**	Sep 30, 2019

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VINBLASTINE SULFATE

	!	FRESENIUS KABI USA	1MG/ML	A089515	001 Apr 29, 1987
	!	WEST-WARD PHARMS INT	10MG/VIAL	A089395	001 Apr 09, 1987

VINCRISTINE SULFATE

INJECTABLE;INJECTION

VINCRISTINE SULFATE PFS

	!	HOSPIRA	1MG/ML	A071484	001 Apr 19, 1988

INJECTABLE, LIPOSOMAL;INTRAVENOUS

MARQIBO KIT

	+!	ACROTECH	5MG/5ML (1MG/ML)	N202497	001 Aug 09, 2012

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	**EQ 10MG BASE/ML**	**A078011**	**001**	Jul 22, 2009
AP		DR REDDYS	**EQ 10MG BASE/ML**	**A202017**	**001**	Sep 12, 2013
AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A076849**	**001**	Apr 18, 2005
AP		JIANGSU HANSOH PHARM	**EQ 10MG BASE/ML**	**A091106**	**001**	Sep 26, 2012
AP		TEVA PHARMS USA	**EQ 10MG BASE/ML**	**A076028**	**001**	Feb 03, 2003
AP		WEST-WARD PHARMS INT	**EQ 10MG BASE/ML**	**A075992**	**001**	Jun 10, 2003
AP			**EQ 10MG BASE/ML**	**A076461**	**001**	Dec 11, 2003

VISMODEGIB

CAPSULE;ORAL

ERIVEDGE

	+!	GENENTECH	150MG	N203388	001	Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE;INJECTION

AQUASOL A

	+!	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001	

VORAPAXAR SULFATE

TABLET;ORAL

ZONTIVITY

	+!	TOPROL	EQ 2.08MG BASE	N204886	001	May 08, 2014

VORICONAZOLE

FOR SUSPENSION;ORAL

VFEND

AB	**+!**	PF PRISM CV	**200MG/5ML**	**N021630**	**001**	Dec 19, 2003

VORICONAZOLE

AB		AMNEAL PHARMS	**200MG/5ML**	**A205034**	**001**	Apr 13, 2016
AB		NOVEL LABS INC	**200MG/5ML**	**A206799**	**001**	May 31, 2016

VORICONAZOLE

INJECTABLE;INTRAVENOUS

VFEND

AP	**+!**	PF PRISM CV	**200MG/VIAL**	**N021267**	**001**	May 24, 2002

VORICONAZOLE

AP		ALVOGEN	**200MG/VIAL**	**A206398**	**001**	Mar 23, 2016
AP		HAINAN POLY PHARM	**200MG/VIAL**	**A211661**	**001**	Nov 30, 2018
AP		SANDOZ INC	**200MG/VIAL**	**A090862**	**001**	May 30, 2012
AP		ZYDUS PHARMS	**200MG/VIAL**	**A208983**	**001**	Jul 16, 2018

POWDER;INTRAVENOUS

VORICONAZOLE

AP		XELLIA PHARMS APS	**200MG/VIAL**	**N208562**	**001**	Mar 09, 2017

TABLET;ORAL

VFEND

AB	**+**	PF PRISM CV	**50MG**	**N021266**	**001**	May 24, 2002
AB	**+!**		**200MG**	**N021266**	**002**	May 24, 2002

VORICONAZOLE

AB		AJANTA PHARMA LTD	**50MG**	**A206181**	**001**	May 24, 2016
AB			**200MG**	**A206181**	**002**	May 24, 2016
AB		AKORN	**50MG**	**A207049**	**001**	Sep 07, 2016
AB			**200MG**	**A207049**	**002**	Sep 07, 2016
AB		APPCO	**50MG**	**A206762**	**001**	May 24, 2016
AB			**200MG**	**A206762**	**002**	May 24, 2016
AB		AUROBINDO PHARMA LTD	**50MG**	**A206837**	**001**	Jan 22, 2016
AB			**200MG**	**A206837**	**002**	Jan 22, 2016
AB		CADILA	**50MG**	**A206747**	**001**	May 24, 2016
AB			**200MG**	**A206747**	**002**	May 24, 2016
AB		GLENMARK PHARMS LTD	**50MG**	**A203503**	**001**	Sep 02, 2015
AB			**200MG**	**A203503**	**002**	Sep 02, 2015
AB		MYLAN PHARMS INC	**50MG**	**A090547**	**001**	Apr 22, 2010
AB			**200MG**	**A090547**	**002**	Apr 22, 2010
AB		NOVEL LABS INC	**50MG**	**A207371**	**001**	May 24, 2016
AB			**200MG**	**A207371**	**002**	May 24, 2016
AB		PRINSTON INC	**50MG**	**A206654**	**001**	Aug 08, 2016
AB			**200MG**	**A206654**	**002**	Aug 08, 2016
AB		SANDOZ INC	**50MG**	**A200265**	**001**	Dec 12, 2011
AB			**200MG**	**A200265**	**002**	Dec 12, 2011

VORINOSTAT

CAPSULE;ORAL

ZOLINZA

	+!	MERCK	100MG	N021991	001	Oct 06, 2006

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

	+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013
	+		EQ 10MG BASE	N204447	002	Sep 30, 2013
	+!		EQ 20MG BASE	N204447	004	Sep 30, 2013

VOXELOTOR

TABLET;ORAL

OXBRYTA

	+!	GLOBAL BLOOD THERAPS	500MG	N213137	001	Nov 25, 2019

WARFARIN SODIUM

TABLET;ORAL

COUMADIN

AB	**+**	BRISTOL MYERS SQUIBB	**1MG**	**N009218**	**022**	Mar 01, 1990
AB	**+**		**2MG**	**N009218**	**013**	
AB	**+**		**2.5MG**	**N009218**	**018**	
AB	**+**		**3MG**	**N009218**	**025**	Nov 18, 1996
AB	**+**		**4MG**	**N009218**	**023**	Aug 24, 1993
AB	**+**		**5MG**	**N009218**	**007**	
AB	**+**		**6MG**	**N009218**	**026**	Nov 18, 1996
AB	**+**		**7.5MG**	**N009218**	**016**	
AB	**+!**		**10MG**	**N009218**	**005**	

JANTOVEN

AB		UPSHER SMITH LABS	**1MG**	**A040416**	**001**	Oct 02, 2003
AB			**2MG**	**A040416**	**002**	Oct 02, 2003
AB			**2.5MG**	**A040416**	**003**	Oct 02, 2003
AB			**3MG**	**A040416**	**004**	Oct 02, 2003

WARFARIN SODIUM

TABLET;ORAL

JANTOVEN

AB		**4MG**	**A040416**	**005**	Oct 02, 2003
AB		**5MG**	**A040416**	**006**	Oct 02, 2003
AB		**6MG**	**A040416**	**007**	Oct 02, 2003
AB		**7.5MG**	**A040416**	**008**	Oct 02, 2003
AB		**10MG**	**A040416**	**009**	Oct 02, 2003

WARFARIN SODIUM

AB	AMNEAL PHARMS	**1MG**	**A202202**	**001**	Mar 04, 2013
AB		**2MG**	**A202202**	**002**	Mar 04, 2013
AB		**2.5MG**	**A202202**	**003**	Mar 04, 2013
AB		**3MG**	**A202202**	**004**	Mar 04, 2013
AB		**4MG**	**A202202**	**005**	Mar 04, 2013
AB		**5MG**	**A202202**	**006**	Mar 04, 2013
AB		**6MG**	**A202202**	**007**	Mar 04, 2013
AB		**7.5MG**	**A202202**	**008**	Mar 04, 2013
AB		**10MG**	**A202202**	**009**	Mar 04, 2013
AB	BARR	**1MG**	**A040145**	**001**	Mar 26, 1997
AB		**2MG**	**A040145**	**002**	Mar 26, 1997
AB		**2.5MG**	**A040145**	**003**	Mar 26, 1997
AB		**3MG**	**A040145**	**008**	Nov 05, 1998
AB		**4MG**	**A040145**	**004**	Mar 26, 1997
AB		**5MG**	**A040145**	**005**	Mar 26, 1997
AB		**6MG**	**A040145**	**009**	Nov 05, 1998
AB		**7.5MG**	**A040145**	**006**	Mar 26, 1997
AB		**10MG**	**A040145**	**007**	Mar 26, 1997
AB	INVAGEN PHARMS	**1MG**	**A090935**	**001**	May 25, 2011
AB		**2MG**	**A090935**	**002**	May 25, 2011
AB		**2.5MG**	**A090935**	**003**	May 25, 2011
AB		**3MG**	**A090935**	**004**	May 25, 2011
AB		**4MG**	**A090935**	**005**	May 25, 2011
AB		**5MG**	**A090935**	**006**	May 25, 2011
AB		**6MG**	**A090935**	**007**	May 25, 2011
AB		**7.5MG**	**A090935**	**008**	May 25, 2011
AB		**10MG**	**A090935**	**009**	May 25, 2011
AB	IPCA LABS LTD	**1MG**	**A200104**	**001**	Jun 27, 2013
AB		**2MG**	**A200104**	**002**	Jun 27, 2013
AB		**2.5MG**	**A200104**	**003**	Jun 27, 2013
AB		**3MG**	**A200104**	**004**	Jun 27, 2013
AB		**4MG**	**A200104**	**005**	Jun 27, 2013
AB		**5MG**	**A200104**	**006**	Jun 27, 2013
AB		**6MG**	**A200104**	**007**	Jun 27, 2013
AB		**7.5MG**	**A200104**	**008**	Jun 27, 2013
AB		**10MG**	**A200104**	**009**	Jun 27, 2013
AB	PLIVA	**1MG**	**A040616**	**009**	Jul 05, 2006
AB		**2MG**	**A040616**	**001**	Jul 05, 2006
AB		**2.5MG**	**A040616**	**002**	Jul 05, 2006
AB		**3MG**	**A040616**	**003**	Jul 05, 2006
AB		**4MG**	**A040616**	**004**	Jul 05, 2006
AB		**5MG**	**A040616**	**005**	Jul 05, 2006
AB		**6MG**	**A040616**	**006**	Jul 05, 2006
AB		**7.5MG**	**A040616**	**007**	Jul 05, 2006
AB		**10MG**	**A040616**	**008**	Jul 05, 2006
AB	TARO	**1MG**	**A040301**	**002**	Jul 15, 1999
AB		**2MG**	**A040301**	**003**	Jul 15, 1999
AB		**2.5MG**	**A040301**	**004**	Jul 15, 1999
AB		**3MG**	**A040301**	**005**	Jul 15, 1999
AB		**4MG**	**A040301**	**006**	Jul 15, 1999
AB		**5MG**	**A040301**	**007**	Jul 15, 1999
AB		**6MG**	**A040301**	**008**	Jul 15, 1999
AB		**7.5MG**	**A040301**	**009**	Jul 15, 1999
AB		**10MG**	**A040301**	**001**	Jul 15, 1999
AB	ZYDUS PHARMS USA	**1MG**	**A040663**	**001**	May 30, 2006
AB		**2MG**	**A040663**	**002**	May 30, 2006
AB		**2.5MG**	**A040663**	**003**	May 30, 2006
AB		**3MG**	**A040663**	**004**	May 30, 2006
AB		**4MG**	**A040663**	**005**	May 30, 2006
AB		**5MG**	**A040663**	**006**	May 30, 2006
AB		**6MG**	**A040663**	**007**	May 30, 2006
AB		**7.5MG**	**A040663**	**008**	May 30, 2006
AB		**10MG**	**A040663**	**009**	May 30, 2006

XENON XE-133
GAS;INHALATION
XENON XE 133

	CURIUM	10mCi/VIAL	N018327	001	Mar 09, 1982
		20mCi/VIAL	N018327	002	Mar 09, 1982
	LANTHEUS MEDCL	10mCi/VIAL	N017284	001	
		20mCi/VIAL	N017284	002	

ZAFIRLUKAST
TABLET;ORAL

ACCOLATE						
AB	**+** PAR PHARM INC	**10MG**	**N020547**	**003**	Sep 17, 1999
AB	**+!**	**20MG**	**N020547**	**001**	Sep 26, 1996
ZAFIRLUKAST					
AB	DR REDDYS LABS LTD	**10MG**	**A090372**	**001**	Nov 18, 2010
AB		**20MG**	**A090372**	**002**	Nov 18, 2010

ZALEPLON
CAPSULE;ORAL

SONATA						
AB	**+** PFIZER	**5MG**	**N020859**	**001**	Aug 13, 1999
AB	**+!**	**10MG**	**N020859**	**002**	Aug 13, 1999
ZALEPLON						
AB	AUROBINDO PHARMA	**5MG**	**A078829**	**001**	Jun 06, 2008
AB		**10MG**	**A078829**	**002**	Jun 06, 2008
AB	CIPLA LTD	**5MG**	**A077505**	**001**	Jun 20, 2008
AB		**10MG**	**A077505**	**002**	Jun 20, 2008
AB	HIKMA	**5MG**	**A077237**	**001**	Jun 06, 2008
AB		**10MG**	**A077237**	**002**	Jun 06, 2008
AB	HIKMA PHARMS	**5MG**	**A078147**	**001**	Nov 25, 2008
AB		**10MG**	**A078147**	**002**	Nov 25, 2008
AB	ORCHID HLTHCARE	**5MG**	**A090374**	**001**	Sep 17, 2009
AB		**10MG**	**A090374**	**002**	Sep 17, 2009
AB	TEVA PHARMS	**5MG**	**A077239**	**001**	Jun 06, 2008
AB		**10MG**	**A077239**	**002**	Jun 06, 2008
AB	UNICHEM	**5MG**	**A078989**	**001**	Jun 06, 2008
AB		**10MG**	**A078989**	**002**	Jun 06, 2008

ZANAMIVIR
POWDER;INHALATION
RELENZA

+!	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999

ZANUBRUTINIB
CAPSULE;ORAL
BRUKINSA

+!	BEIGENE	80MG	N213217	001	Nov 14, 2019

ZICONOTIDE ACETATE
INJECTABLE;INTRATHECAL
PRIALT

+!	TERSERA THERAPS LLC	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
+!		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004
+!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004

ZIDOVUDINE
CAPSULE;ORAL

RETROVIR						
AB	**+!** VIIV HLTHCARE	**100MG**	**N019655**	**001**	Mar 19, 1987
ZIDOVUDINE						
AB	AUROBINDO PHARMA LTD	**100MG**	**A078128**	**001**	Mar 27, 2006
AB	CIPLA LTD	**100MG**	**A078349**	**001**	May 23, 2007

INJECTABLE;INJECTION

RETROVIR						
AP	**+!** VIIV HLTHCARE	**10MG/ML**	**N019951**	**001**	Feb 02, 1990

SYRUP;ORAL

RETROVIR						
AA	**+!** VIIV HLTHCARE	**50MG/5ML**	**N019910**	**001**	Sep 28, 1989
ZIDOVUDINE						
AA	AUROBINDO	**50MG/5ML**	**A077268**	**001**	Sep 19, 2005
AA	CIPLA LTD	**50MG/5ML**	**A077981**	**001**	Jun 26, 2008

TABLET;ORAL

ZIDOVUDINE						
AB	AUROBINDO	**300MG**	**A077267**	**001**	Sep 19, 2005
AB	CIPLA	**300MG**	**A090561**	**001**	Oct 27, 2010

ZIDOVUDINE

TABLET;ORAL

ZIDOVUDINE

AB	**!**	HETERO LABS LTD III	**300MG**	**A090092**	**001**	Apr 25, 2008
AB		HIKMA	**300MG**	**A076844**	**001**	Sep 19, 2005
AB		MYLAN PHARMS INC	**300MG**	**A078922**	**001**	Feb 14, 2008

ZILEUTON

TABLET;ORAL

ZYFLO

	+!	CHIESI USA INC	600MG	N020471	003	Dec 09, 1996

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB		LUPIN LTD	**600MG**	**A211972**	**001**	Nov 05, 2019
AB		PAR PHARM INC	**600MG**	**A212670**	**001**	Dec 16, 2019
AB		RISING	**600MG**	**A204929**	**001**	Mar 17, 2017

ZYFLO CR

AB	**+!**	CHIESI USA INC	**600MG**	**N022052**	**001**	May 30, 2007

ZINC ACETATE

CAPSULE;ORAL

GALZIN

	+	TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997
	+!		EQ 50MG ZINC	N020458	002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

	+!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

	+!	AM REGENT	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019
	+!		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

AB	**+!**	PFIZER	**EQ 20MG BASE**	**N020825**	**001**	Feb 05, 2001
AB	**+**		**EQ 40MG BASE**	**N020825**	**002**	Feb 05, 2001
AB	**+**		**EQ 60MG BASE**	**N020825**	**003**	Feb 05, 2001
AB	**+**		**EQ 80MG BASE**	**N020825**	**004**	Feb 05, 2001

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX	**EQ 20MG BASE**	**A077561**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077561**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077561**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077561**	**004**	Mar 02, 2012
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A204117**	**001**	Dec 27, 2016
AB			**EQ 40MG BASE**	**A204117**	**002**	Dec 27, 2016
AB			**EQ 60MG BASE**	**A204117**	**003**	Dec 27, 2016
AB			**EQ 80MG BASE**	**A204117**	**004**	Dec 27, 2016
AB		DR REDDYS LABS INC	**EQ 20MG BASE**	**A077565**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077565**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077565**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077565**	**004**	Mar 02, 2012
AB		LUPIN PHARMS	**EQ 20MG BASE**	**A077560**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077560**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077560**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077560**	**004**	Mar 02, 2012
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204375**	**001**	Feb 17, 2017
AB			**EQ 40MG BASE**	**A204375**	**002**	Feb 17, 2017
AB			**EQ 60MG BASE**	**A204375**	**003**	Feb 17, 2017
AB			**EQ 80MG BASE**	**A204375**	**004**	Feb 17, 2017
AB		SANDOZ INC	**EQ 20MG BASE**	**A077562**	**001**	Jun 01, 2012
AB			**EQ 40MG BASE**	**A077562**	**002**	Jun 01, 2012
AB			**EQ 60MG BASE**	**A077562**	**003**	Jun 01, 2012
AB			**EQ 80MG BASE**	**A077562**	**004**	Jun 01, 2012
AB		WOCKHARDT LTD	**EQ 20MG BASE**	**A090348**	**001**	Sep 05, 2012
AB			**EQ 40MG BASE**	**A090348**	**002**	Sep 05, 2012
AB			**EQ 60MG BASE**	**A090348**	**003**	Sep 05, 2012
AB			**EQ 80MG BASE**	**A090348**	**004**	Sep 05, 2012

ZIPRASIDONE MESYLATE

INJECTABLE;INTRAMUSCULAR

GEODON

AP	**+!**	PFIZER	**EQ 20MG BASE/ML**	**N020919**	**001**	Jun 21, 2002

ZIPRASIDONE MESYLATE

AP		GLAND PHARMA LTD	**EQ 20MG BASE/ML**	**A211908**	**001**	Dec 26, 2019

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

RECLAST

AP	**+!**	NOVARTIS	**EQ 5MG BASE/100ML**	**N021817**	**001**	Apr 16, 2007

ZOLEDRONIC

AP		GLAND PHARMA LTD	**EQ 4MG BASE/100ML**	**A205749**	**001**	Jun 29, 2018

ZOLEDRONIC ACID

AP		ACCORD HLTHCARE	**EQ 4MG BASE/5ML**	**A205279**	**001**	Nov 28, 2016
AP		AKORN	**EQ 5MG BASE/100ML**	**A200918**	**001**	Aug 21, 2014
AP		AKORN INC	**EQ 4MG BASE/5ML**	**A202548**	**001**	May 22, 2014
AP		APOTEX	**EQ 5MG BASE/100ML**	**A204367**	**001**	Dec 24, 2015
AP		AUROBINDO PHARMA LTD	**EQ 4MG BASE/5ML**	**A207751**	**001**	Sep 26, 2016
AP			**EQ 5MG BASE/100ML**	**A209125**	**001**	Dec 08, 2017
AP		BPI LABS LLC	**EQ 4MG BASE/5ML**	**A207341**	**001**	Dec 29, 2017
AP		BRECKENRIDGE	**EQ 4MG BASE/5ML**	**A091170**	**001**	Mar 04, 2013
AP			**EQ 4MG BASE/5ML**	**A202571**	**001**	May 07, 2013
AP			**EQ 5MG BASE/100ML**	**A202163**	**001**	Aug 05, 2013
AP		CIPLA	**EQ 4MG BASE/100ML**	**A210174**	**001**	Oct 27, 2017
AP		DR REDDYS LABS LTD	**EQ 4MG BASE/5ML**	**A091186**	**001**	Mar 04, 2013
AP			**EQ 5MG BASE/100ML**	**A091363**	**001**	Mar 29, 2013
AP		EMCURE PHARMS LTD	**EQ 4MG BASE/5ML**	**A201783**	**001**	Mar 12, 2013
AP			**EQ 5MG BASE/100ML**	**A201801**	**001**	Mar 29, 2013
AP		FRESENIUS KABI USA	**EQ 4MG BASE/5ML**	**A091516**	**001**	Apr 23, 2015
AP		GLAND PHARMA LTD	**EQ 4MG BASE/5ML**	**A202930**	**001**	Aug 05, 2013
AP			**EQ 5MG BASE/100ML**	**A204217**	**001**	Aug 18, 2016
AP			**EQ 5MG BASE/100ML**	**A209578**	**001**	Aug 08, 2019
AP		HIKMA FARMACEUTICA	**EQ 4MG BASE/5ML**	**A202182**	**001**	Jun 03, 2013
AP		HOSPIRA INC	**EQ 4MG BASE/5ML**	**A090621**	**001**	Mar 19, 2015
AP			**EQ 5MG BASE/100ML**	**A202837**	**001**	Apr 05, 2013
AP		INFORLIFE	**EQ 4MG BASE/100ML**	**N203231**	**001**	Aug 02, 2013
AP			**EQ 5MG BASE/100ML**	**A202828**	**001**	Sep 23, 2013
AP		MYLAN LABS LTD	**EQ 4MG BASE/5ML**	**A202650**	**001**	Mar 04, 2013
AP			**EQ 5MG BASE/100ML**	**A203841**	**001**	Feb 14, 2017
AP			**EQ 5MG BASE/100ML**	**A205254**	**001**	Oct 27, 2017
AP		SAGENT PHARMS INC	**EQ 4MG BASE/5ML**	**A091493**	**001**	Nov 24, 2014
AP		USV	**EQ 4MG BASE/5ML**	**A202923**	**001**	Sep 04, 2014

ZOMETA

AP	**+!**	NOVARTIS	**EQ 4MG BASE/5ML**	**N021223**	**002**	Mar 07, 2003
AP	**+!**		**EQ 4MG BASE/100ML**	**N021223**	**003**	Jun 17, 2011

SOLUTION;INTRAVENOUS

ZOLEDRONIC ACID

		HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015

ZOLMITRIPTAN

SPRAY;NASAL

ZOMIG

	+	ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013
	+!		5MG/SPRAY	N021450	004	Sep 30, 2003

TABLET;ORAL

ZOLMITRIPTAN

AB		AJANTA PHARMA LTD	**2.5MG**	**A204041**	**001**	May 20, 2016
AB			**5MG**	**A204041**	**002**	May 20, 2016
AB		ALEMBIC PHARMS LTD	**2.5MG**	**A204232**	**001**	Sep 30, 2015
AB			**5MG**	**A204232**	**002**	Sep 30, 2015
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A207021**	**001**	May 11, 2016
AB			**5MG**	**A207021**	**002**	May 11, 2016
AB		GLENMARK GENERICS	**2.5MG**	**A201779**	**001**	May 14, 2013
AB			**5MG**	**A201779**	**002**	May 14, 2013
AB		INVAGEN PHARMS	**2.5MG**	**A204284**	**001**	Apr 09, 2014
AB			**5MG**	**A204284**	**002**	Apr 09, 2014
AB		JUBILANT GENERICS	**2.5MG**	**A202279**	**001**	Nov 20, 2014
AB			**5MG**	**A202279**	**002**	Nov 20, 2014
AB		ORCHID HLTHCARE	**2.5MG**	**A203726**	**001**	Oct 21, 2019
AB			**5MG**	**A203726**	**002**	Oct 21, 2019
AB		PLD ACQUISITIONS	**2.5MG**	**A207867**	**001**	Feb 27, 2017

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

		LLC				
AB			**5MG**	**A207867**	**002**	Feb 27, 2017
AB		TWI PHARMS	**2.5MG**	**A206973**	**001**	Jun 30, 2017
AB			**5MG**	**A206973**	**002**	Jun 30, 2017
AB		ZYDUS PHARMS	**2.5MG**	**A203019**	**001**	Jul 11, 2018
AB			**5MG**	**A203019**	**002**	Jul 11, 2018

ZOMIG

AB	+	IPR	**2.5MG**	**N020768**	**001**	Nov 25, 1997
AB	+!		**5MG**	**N020768**	**002**	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB		ALEMBIC PHARMS LTD	**2.5MG**	**A205074**	**001**	Dec 01, 2016
AB			**5MG**	**A205074**	**002**	Dec 01, 2016
AB		GLENMARK GENERICS	**2.5MG**	**A202560**	**001**	May 14, 2013
AB			**5MG**	**A202560**	**002**	May 14, 2013
AB		JUBILANT GENERICS	**2.5MG**	**A202956**	**001**	Sep 17, 2015
AB			**5MG**	**A202956**	**002**	Sep 17, 2015
AB		MYLAN	**2.5MG**	**A202855**	**001**	Sep 20, 2019
AB			**5MG**	**A202855**	**002**	Sep 20, 2019
AB		ZYDUS PHARMS USA INC	**2.5MG**	**A202890**	**001**	May 15, 2013
AB			**5MG**	**A202890**	**002**	May 15, 2013

ZOMIG-ZMT

AB	+	ASTRAZENECA	**2.5MG**	**N021231**	**001**	Feb 13, 2001
AB	+!		**5MG**	**N021231**	**002**	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

	+!	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008

TABLET;ORAL

AMBIEN

AB	+	SANOFI AVENTIS US	**5MG**	**N019908**	**001**	Dec 16, 1992
AB	+!		**10MG**	**N019908**	**002**	Dec 16, 1992

ZOLPIDEM TARTRATE

AB		ACME LABS	**5MG**	**A077214**	**001**	Apr 23, 2007
AB			**10MG**	**A077214**	**002**	Apr 23, 2007
AB		APOTEX INC	**5MG**	**A077884**	**001**	Apr 23, 2007
AB			**10MG**	**A077884**	**002**	Apr 23, 2007
AB		AUROBINDO PHARMA	**5MG**	**A078413**	**001**	May 04, 2007
AB			**10MG**	**A078413**	**002**	May 04, 2007
AB		CIPLA LTD	**5MG**	**A077388**	**001**	Jul 30, 2012
AB			**10MG**	**A077388**	**002**	Jul 30, 2012
AB		INVAGEN PHARMS	**5MG**	**A078184**	**001**	Sep 07, 2007
AB			**10MG**	**A078184**	**002**	Sep 07, 2007
AB		SANDOZ INC	**5MG**	**A077322**	**001**	Apr 23, 2007
AB			**10MG**	**A077322**	**002**	Apr 23, 2007
AB		TEVA	**5MG**	**A076410**	**001**	Apr 23, 2007
AB			**10MG**	**A076410**	**002**	Apr 23, 2007
AB		TORRENT PHARMS	**5MG**	**A077903**	**001**	Aug 17, 2007
AB			**10MG**	**A077903**	**002**	Aug 17, 2007
AB		VINTAGE	**5MG**	**A078616**	**001**	Nov 21, 2008
AB			**10MG**	**A078616**	**002**	Nov 21, 2008
AB		YUNG SHIN PHARM	**5MG**	**A077990**	**001**	Apr 23, 2007
AB			**10MG**	**A077990**	**002**	Apr 23, 2007

TABLET;SUBLINGUAL

EDLUAR

AB	+	MYLAN SPECIALITY LP	**5MG**	**N021997**	**001**	Mar 13, 2009
AB	+!		**10MG**	**N021997**	**002**	Mar 13, 2009

ZOLPIDEM TARTRATE

AB		DR REDDYS	**1.75MG**	**A204503**	**001**	Nov 18, 2016
AB			**3.5MG**	**A204503**	**002**	Nov 18, 2016
AB		MYLAN	**5MG**	**A202657**	**001**	Aug 08, 2016
AB			**10MG**	**A202657**	**002**	Aug 08, 2016
AB		NOVEL LABS INC	**1.75MG**	**A204299**	**001**	Jun 03, 2015
AB	!		**3.5MG**	**A204299**	**002**	Jun 03, 2015
AB		PAR FORM	**5MG**	**A201509**	**001**	Aug 01, 2016
AB			**10MG**	**A201509**	**002**	Aug 01, 2016
AB		PAR PHARM INC	**1.75MG**	**A204229**	**001**	Sep 11, 2017
AB			**3.5MG**	**A204229**	**002**	Sep 11, 2017

PRESCRIPTION DRUG PRODUCT LIST

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

AB	+	SANOFI AVENTIS US	**6.25MG**	**N021774**	**002**	Sep 02, 2005
AB	+!		**12.5MG**	**N021774**	**001**	Sep 02, 2005

ZOLPIDEM TARTRATE

AB		ACTAVIS ELIZABETH	**6.25MG**	**A078179**	**002**	Oct 13, 2010
AB			**12.5MG**	**A078179**	**001**	Jun 06, 2011
AB		ACTAVIS LABS FL INC	**6.25MG**	**A090153**	**001**	Mar 25, 2013
AB			**12.5MG**	**A090153**	**002**	Mar 25, 2013
AB		ANCHEN PHARMS	**6.25MG**	**A078148**	**002**	Apr 14, 2011
AB			**12.5MG**	**A078148**	**001**	Dec 03, 2010
AB		APOTEX INC	**6.25MG**	**A200266**	**001**	Sep 10, 2013
AB			**12.5MG**	**A200266**	**002**	Sep 10, 2013
AB		LUPIN LTD	**6.25MG**	**A078970**	**001**	Sep 11, 2013
AB			**12.5MG**	**A078970**	**002**	Sep 11, 2013
AB		SANDOZ	**6.25MG**	**A090107**	**001**	Jul 01, 2011
AB			**12.5MG**	**A090107**	**002**	Jul 01, 2011
AB		SUN PHARM	**6.25MG**	**A204170**	**001**	Jan 24, 2017
AB			**12.5MG**	**A204170**	**002**	Jan 24, 2017

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	+	SUNOVION PHARMS INC	**25MG**	**N020789**	**003**	Aug 22, 2003
AB	+!		**100MG**	**N020789**	**001**	Mar 27, 2000

ZONISAMIDE

AB		APOTEX INC	**25MG**	**A077642**	**001**	Dec 22, 2005
AB			**50MG**	**A077642**	**002**	Dec 22, 2005
AB			**100MG**	**A077642**	**003**	Dec 22, 2005
AB		BIONPHARMA INC	**25MG**	**A077813**	**001**	Aug 16, 2006
AB			**50MG**	**A077813**	**002**	Aug 16, 2006
AB			**100MG**	**A077813**	**003**	Aug 16, 2006
AB		CELLTRION	**25MG**	**A077636**	**003**	Jul 27, 2006
AB			**50MG**	**A077636**	**002**	Jul 27, 2006
AB			**100MG**	**A077636**	**001**	Dec 22, 2005
AB		GLENMARK GENERICS	**25MG**	**A077651**	**001**	Jan 30, 2006
AB			**50MG**	**A077651**	**002**	Jan 30, 2006
AB			**100MG**	**A077651**	**003**	Jan 30, 2006
AB		INVAGEN PHARMS	**25MG**	**A077869**	**001**	May 31, 2006
AB			**50MG**	**A077869**	**002**	May 31, 2006
AB			**100MG**	**A077869**	**003**	May 31, 2006
AB		SUN PHARM INDS (IN)	**25MG**	**A077634**	**001**	Mar 17, 2006
AB			**50MG**	**A077634**	**002**	Mar 17, 2006
AB			**100MG**	**A077634**	**003**	Mar 17, 2006
AB		ZYDUS PHARMS USA	**25MG**	**A077625**	**001**	Oct 16, 2006
AB			**50MG**	**A077625**	**002**	Oct 16, 2006
AB			**100MG**	**A077625**	**003**	Oct 16, 2006

ACETAMINOPHEN					
SUPPOSITORY;RECTAL					
ACEPHEN					
	ACP NIMBLE	120MG	N018060	001	
		325MG	A072344	001	Mar 27, 1992
		650MG	A072237	001	Mar 27, 1992
ACETAMINOPHEN					
	PERRIGO NEW YORK	120MG	A070607	001	Apr 06, 1987
		650MG	A070608	001	Dec 01, 1986
+	TARO PHARM INDS LTD	120MG	N018337	003	Sep 12, 1983
+		325MG	N018337	002	
+!		650MG	N018337	001	
INFANTS' FEVERALL					
+	TARO PHARM INDS LTD	80MG	N018337	004	Aug 26, 1992
NEOPAP					
	POLYMEDICA	120MG	N016401	001	
TABLET, EXTENDED RELEASE;ORAL					
ACETAMINOPHEN					
	AUROBINDO PHARMA LTD	650MG	A207229	001	Nov 09, 2016
	GRANULES INDIA LTD	650MG	A211544	001	Apr 16, 2019
	HERITAGE PHARMA	650MG	A207035	001	May 31, 2018
	OHM LABS	650MG	A076200	001	Mar 19, 2002
	PERRIGO	650MG	A075077	001	Feb 25, 2000
	SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011
TYLENOL					
+!	J AND J CONSUMER INC	650MG	N019872	001	Jun 08, 1994
+!		650MG	N019872	002	Jan 11, 2001
ACETAMINOPHEN; ASPIRIN; CAFFEINE					
TABLET;ORAL					
ACETAMINOPHEN, ASPIRIN AND CAFFEINE					
	PERRIGO	250MG;250MG;65MG	A075794	001	Nov 26, 2001
EXCEDRIN (MIGRAINE)					
+!	GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998
ADAPALENE					
GEL;TOPICAL					
ADAPALENE					
	GLENMARK GENERICS	0.1%	A091314	002	Jul 09, 2019
DIFFERIN					
+!	GALDERMA LABS LP	0.1%	N020380	002	Jul 08, 2016
ALCOHOL; CHLORHEXIDINE GLUCONATE					
SOLUTION;TOPICAL					
AVAGARD					
+!	3M	61%;1%	N021074	001	Jun 07, 2001
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE					
TABLET, CHEWABLE;ORAL					
GAVISCON					
+	SANOFI AVENTIS US	80MG;20MG	N018685	001	Dec 09, 1983
ASPIRIN					
CAPSULE;ORAL					
VAZALORE					
+!	PLX PHARMA	325MG	N203697	001	Jan 14, 2013
AVOBENZONE; ECAMSULE; OCTOCRYLENE					
CREAM;TOPICAL					
ANTHELIOS SX					
+!	LOREAL USA	2%;2%;10%	N021502	001	Jul 21, 2006
CAPITAL SOLEIL 15					
+!	LOREAL USA	2%;3%;10%	N021501	001	Oct 02, 2006
AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE					
CREAM;TOPICAL					
ANTHELIOS 20					
+!	LOREAL USA	2%;2%;10%;2%	N021471	001	Oct 05, 2006
ANTHELIOS 40					
+!	LOREAL USA	2%;3%;10%;5%	N022009	001	Mar 31, 2008
+!		2%;3%;10%;5%	N022009	002	Oct 29, 2009

BENTOQUATAM					
LOTION;TOPICAL					
IVY BLOCK					
+!	STAND HOMEOPATH	5%	N020532	001	Aug 26, 1996
BRIMONIDINE TARTRATE					
SOLUTION/DROPS;OPHTHALMIC					
LUMIFY					
+!	BAUSCH AND LOMB INC	0.025%	N208144	001	Dec 22, 2017
BUDESONIDE					
SPRAY, METERED;NASAL					
BUDESONIDE					
	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015
RHINOCORT ALLERGY					
+!	ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015
BUTENAFINE HYDROCHLORIDE					
CREAM;TOPICAL					
BUTENAFINE HYDROCHLORIDE					
	TARO PHARMS	1%	A205181	001	Nov 16, 2017
LOTRIMIN ULTRA					
+!	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001
CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE					
TABLET, CHEWABLE;ORAL					
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE					
	PERRIGO R AND D	800MG;10MG;165MG	A077355	001	Feb 06, 2008
		800MG;10MG;165MG	A204782	001	Aug 29, 2016
PEPCID COMPLETE					
+!	J AND J CONSUMER INC	800MG;10MG;165MG	N020958	001	Oct 16, 2000
CETIRIZINE HYDROCHLORIDE					
CAPSULE;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	APOTEX	10MG	A207235	001	Aug 12, 2016
	AUROBINDO PHARMA LTD	10MG	A209107	001	Jul 20, 2018
+	BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009
+!		10MG	N022429	004	Jul 23, 2009
	STRIDES PHARMA	10MG	A205291	001	Jul 21, 2017
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AUROBINDO PHARMA LTD	10MG	A209107	002	Jul 20, 2018
+	BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009
+!		10MG	N022429	002	Jul 23, 2009
SOLUTION;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	QUAGEN	5MG/5ML	A212266	001	May 16, 2019
SYRUP;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009
	ATHEM	5MG/5ML	A091327	001	Oct 17, 2011
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010
	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019
	LANNETT CO INC	5MG/5ML	A091130	001	Apr 22, 2011
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013
		5MG/5ML	A090254	002	Apr 09, 2008
	TARO	5MG/5ML	A090182	002	Apr 22, 2008
		5MG/5ML	A201546	001	May 20, 2011
	TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009
	ATHEM	5MG/5ML	A091327	002	Oct 17, 2011
	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010
	LANNETT CO INC	5MG/5ML	A091130	002	Apr 22, 2011
	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008
	TARO	5MG/5ML	A090182	001	Apr 22, 2008
		5MG/5ML	A201546	002	May 20, 2011
	TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012
CHILDREN'S ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL					
CHILDREN'S ZYRTEC HIVES RELIEF					
+!	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007
TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010
		10MG	A078780	004	Jan 21, 2010
	APOTEX INC	5MG	A078317	001	Dec 27, 2007
		10MG	A078317	002	Dec 27, 2007
	AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015
		10MG	A090760	003	Aug 05, 2015
	CIPLA LTD	5MG	A077318	001	Jul 25, 2013
		10MG	A077318	002	Jul 25, 2013
	CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
		10MG	A076047	002	Dec 27, 2007
	DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
		10MG	A078343	003	Jan 15, 2008
	GRANULES INDIA LTD	10MG	A209274	001	Dec 22, 2017
	IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
		10MG	A202277	004	Mar 11, 2014
	MARKSANS PHARMA	5MG	A078933	001	Jun 15, 2010
		10MG	A078933	002	Jun 15, 2010
	MYLAN	5MG	A076677	001	Dec 27, 2007
		10MG	A076677	002	Dec 27, 2007
	ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
		10MG	A078862	002	Feb 19, 2009
	PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
		10MG	A078336	002	Dec 27, 2007
	PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007
		10MG	A077946	002	Dec 27, 2007
	SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
		10MG	A077498	002	Dec 27, 2007
	TARO	5MG	A078072	001	Jul 22, 2009
		5MG	A078072	003	Jul 22, 2009
	TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
		10MG	A079191	004	Apr 15, 2010
	UNICHEM	5MG	A078680	003	Jun 26, 2009
		10MG	A078680	004	Jun 26, 2009
	UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
		10MG	A077829	004	Aug 26, 2009
	WOCKHARDT	5MG	A078427	003	Dec 28, 2007
		10MG	A078427	004	Dec 28, 2007
CETIRIZINE HYDROCHLORIDE HIVES					
	DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
		10MG	A078343	002	Jan 15, 2008
	IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
		10MG	A202277	003	Mar 11, 2014
	MARKSANS PHARMA	5MG	A078933	003	Jun 15, 2010
		10MG	A078933	004	Jun 15, 2010
	MYLAN	5MG	A076677	004	Dec 27, 2007
		10MG	A076677	003	Dec 27, 2007
	ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
		10MG	A078862	004	Feb 19, 2009
	PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
		10MG	A078336	004	Dec 27, 2007
	SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
		10MG	A077498	004	Dec 27, 2007
	UNICHEM	5MG	A078680	001	Jun 26, 2009
		10MG	A078680	002	Jun 26, 2009
	UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
!		10MG	A077829	002	Aug 26, 2009
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
		10MG	A078780	002	Jan 21, 2010
	AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
		10MG	A090760	004	Aug 05, 2015
	TARO	10MG	A078072	002	Jul 22, 2009
		10MG	A078072	004	Jul 22, 2009
	TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
		10MG	A079191	002	Apr 15, 2010
ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	10MG	N019835	004	Nov 16, 2007
TABLET, CHEWABLE;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015
		10MG	A091116	002	Feb 19, 2015
	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016
		10MG	A206793	002	Mar 08, 2016
	SANDOZ	5MG	A078692	001	Feb 14, 2008
!		10MG	A078692	002	Feb 14, 2008
	SUN PHARM	5MG	A090142	001	Aug 30, 2011
		10MG	A090142	002	Aug 30, 2011
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015
		10MG	A091116	004	Feb 19, 2015
	SUN PHARM	5MG	A090142	003	Aug 30, 2011
		10MG	A090142	004	Aug 30, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	PERRIGO R AND D	10MG	A205490	001	Sep 02, 2015
ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	10MG	N022578	001	Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
	PLD ACQUISITIONS	5MG;120MG	A077991	001	Mar 05, 2008
	SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR					
+!	J AND J CONSUMER INC	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL					
EXIDINE					
+!	XTTRIUM	4%	N019127	001	Dec 24, 1984
CLOTH;TOPICAL					
CHLORHEXIDINE GLUCONATE					
+!	SAGE PRODS	2%	N021669	001	Apr 25, 2005
READYPREP CHG					
	MEDLINE INDUSTRIES	2%	N207964	001	Nov 20, 2018
SOLUTION;TOPICAL					
BRIAN CARE					
	SOAPCO	4%	A071419	001	Dec 17, 1987
CHG SCRUB					
	ECOLAB	4%	N019258	002	Jul 22, 1986
CHLORHEXIDINE GLUCONATE					
	BAJAJ	0.75%	N020111	001	Sep 11, 1997
CIDA-STAT					
	ECOLAB	2%	N019258	001	Jul 22, 1986
EXIDINE					
+!	XTTRIUM	2%	N019422	001	Dec 17, 1985
		4%	N019125	001	Dec 24, 1984
HIBICLENS					
+!	MOLNLYCKE HLTH	4%	N017768	001	
HIBISTAT					
+!	MOLNLYCKE HLTH	0.5%	N018300	001	
SPONGE;TOPICAL					
BIOSCRUB					
	GRIFFEN	4%	N019822	001	Mar 31, 1989
CHLORHEXIDINE GLUCONATE					
!	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL					
SOLUTION;TOPICAL					
SOLUPREP					
+!	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018
SPONGE;TOPICAL					
CHLORAPREP ONE-STEP					
+!	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000
+!		2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+!		2%;70% (26ML)	N020832	006	Nov 21, 2006
+!		2%;70% (1ML)	N020832	008	Oct 23, 2008
CHLORAPREP ONE-STEP FREPP					
+!	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
CHLORAPREP WITH TINT					
+!	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005
+!		2%;70% (10.5ML)	N020832	005	Apr 03, 2006
+!		2%;70% (3ML)	N020832	007	Oct 10, 2006
SWAB;TOPICAL					
CHLORAPREP ONE-STEP SEPP					
+!	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
CHLORAPREP SINGLE SWABSTICK					
+!	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005
CHLORAPREP TRIPLE SWABSTICK					
+!	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009
PREVANTICS MAXI SWABSTICK					
+!	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
PREVANTICS SWAB					
+!	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
PREVANTICS SWABSTICK					
+!	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005
CHLORPHENIRAMINE MALEATE					
TABLET, EXTENDED RELEASE;ORAL					
CHLORPHENIRAMINE MALEATE					
!	AVANTHI INC	12MG	A040829	001	May 13, 2009
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE					
TABLET;ORAL					
ADVIL ALLERGY AND CONGESTION RELIEF					
+!	GLAXOSMITHKLINE	4MG;200MG;10MG	N022113	001	Dec 21, 2011
ADVIL MULTI-SYMPTOM COLD & FLU					
+!	GLAXOSMITHKLINE	4MG;200MG;10MG	N022113	002	Apr 28, 2017
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE					
SUSPENSION;ORAL					
CHILDREN'S ADVIL ALLERGY SINUS					
+!	GLAXOSMITHKLINE	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004
TABLET;ORAL					
ADVIL ALLERGY SINUS					
+!	GLAXOSMITHKLINE	2MG;200MG;30MG	N021441	001	Dec 19, 2002
CIMETIDINE					
TABLET;ORAL					
CIMETIDINE					
	APOTEX	100MG	A074948	001	Jun 19, 1998
		200MG	A074948	002	Jul 26, 2002
	IVAX SUB TEVA PHARMS	200MG	A075345	001	Jun 16, 1999
	L PERRIGO CO	200MG	A075285	001	Oct 29, 1998
TAGAMET HB					
+!	MEDTECH PRODUCTS	200MG	N020238	002	Aug 21, 1996
CLEMASTINE FUMARATE					
TABLET;ORAL					
CLEMASTINE FUMARATE					
!	L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995
CLOTRIMAZOLE					
CREAM;VAGINAL					
CLOTRIMAZOLE					
!	P AND L	1%	A074165	001	Jul 16, 1993
	TARO	1%	A072641	001	Dec 04, 1995
TRIVAGIZOLE 3					
	TARO	2%	N021143	001	Apr 12, 2000

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

!	BAUSCH AND LOMB	5.2MG/SPRAY	A075702	001	Jul 03, 2001
	PERRIGO	5.2MG/SPRAY	A075427	001	Dec 12, 2001

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015
		60MG;1.2GM	A091070	002	Aug 31, 2015
	AMNEAL PHARMS	30MG;600MG	A209692	001	Nov 01, 2018
		60MG;1.2GM	A209692	002	Nov 01, 2018
	AUROBINDO PHARMA LTD	30MG;600MG	A206941	001	Mar 17, 2017
		60MG;1.2GM	A206941	002	Mar 17, 2017
	PERRIGO R AND D	30MG;600MG	A207602	002	Mar 05, 2018
		60MG;1.2GM	A207602	001	Mar 05, 2018

MUCINEX DM

+	RB HLTH	30MG;600MG	N021620	002	Apr 29, 2004
+!		60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+!	RB HLTH	EQ 30MG HYDROBROMIDE/5ML	N018658	001	Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

	AMNEAL PHARMS LLC	EQ 30MG HYDROBROMIDE/5ML	A203133	001	Jul 28, 2017
	TRIS PHARMA INC	EQ 30MG HYDROBROMIDE/5ML	A091135	001	May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+!	GLAXOSMITHKLINE	38MG;200MG	N021394	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

	DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
	PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+!	GLAXOSMITHKLINE	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019
	BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010
	STRIDES PHARMA	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+!	BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

	AMNEAL PHARMS CO	25MG;220MG	A209726	001	Oct 23, 2018
	APOTEX	25MG;220MG	A211830	001	Aug 22, 2019
	PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019

DOCOSANOL

CREAM;TOPICAL

ABREVA

+!	GLAXOSMITHKLINE	10%	N020941	001	Jul 25, 2000

DOCOSANOL

	P AND L	10%	A208754	001	Nov 19, 2018

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

	LNK	25MG	A040564	001	Aug 27, 2004
	PERRIGO	25MG	A040167	001	Sep 18, 1996

UNISOM

+!	CHATTEM	25MG	N018066	001	

EPINEPHRINE

AEROSOL, METERED;INHALATION

PRIMATENE MIST

+!	ARMSTRONG PHARMS	0.125MG/INH	N205920	001	Nov 07, 2018

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019
	AURO BINDO PHARMA LTD	EQ 20MG BASE	A209339	001	Oct 16, 2017
	DR REDDYS LABS LTD	EQ 20MG BASE	A207673	001	May 15, 2018
	MYLAN	EQ 20MG BASE	A212376	001	Oct 16, 2019
	PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017

NEXIUM 24HR

+!	ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014

TABLET, DELAYED RELEASE;ORAL

NEXIUM 24HR

+!	ASTRAZENECA LP	EQ 20MG BASE	N207920	001	Nov 23, 2015

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	AURO BINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016
		20MG	A206531	002	Apr 26, 2016
	DR REDDYS LABS LTD	10MG	A075758	001	Aug 17, 2001
		20MG	A077367	001	Sep 25, 2006
	MYLAN	10MG	A075674	001	Dec 21, 2001
	P AND L	10MG	A075512	001	Jul 26, 2001
	PERRIGO	10MG	A075400	001	Mar 18, 2005
	PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006
	SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009
		20MG	A090283	002	Nov 17, 2009
	TEVA	10MG	A075312	001	May 31, 2001
	WOCKHARDT	10MG	A077146	001	Mar 07, 2005
		20MG	A090837	001	Aug 04, 2010

PEPCID AC

+	J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995
		10MG	N020902	001	Aug 05, 1999
+!		20MG	N020325	002	Sep 23, 2003

TABLET, CHEWABLE;ORAL

FAMOTIDINE

	PERRIGO	10MG	A075715	001	Aug 22, 2003

PEPCID AC

+!	J AND J CONSUMER INC	20MG	N020801	002	Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+!	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	P AND L	30MG/5ML	A203330	001	Nov 18, 2014

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

!	P AND L	30MG/5ML	A203330	002	Nov 18, 2014

TABLET;ORAL

ALLEGRA ALLERGY

+	SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011
+!		180MG	N020872	010	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	AUROLIFE PHARMA LLC	30MG	A202039	001	Nov 19, 2014
	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
	HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016
	SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
	TEVA	30MG	A076447	004	Apr 13, 2011
	WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
	SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
	TEVA	30MG	A076447	005	Apr 13, 2011
	WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014
	180MG	A202039	003	Nov 19, 2014
DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
	180MG	A076502	008	Apr 12, 2011
GRANULES INDIA LTD	60MG	A211075	001	Oct 18, 2019
	180MG	A211075	002	Oct 18, 2019
HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
	180MG	A204097	003	Aug 19, 2016
MYLAN	60MG	A077081	006	Jul 21, 2011
	180MG	A077081	008	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
	180MG	A204507	003	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
	180MG	A091567	006	Feb 06, 2012
TEVA	60MG	A076447	006	Apr 13, 2011
	180MG	A076447	008	Apr 13, 2011
UNIQUE PHARM LABS	180MG	A210137	001	Aug 13, 2018
WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
	180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
	180MG	A076502	009	Apr 12, 2011
MYLAN	60MG	A077081	007	Jul 21, 2011
	180MG	A077081	009	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
	180MG	A204507	005	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
	180MG	A091567	005	Feb 06, 2012
TEVA	60MG	A076447	007	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
	180MG	A079112	005	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+!	SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+!	SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	60MG;120MG	A209116	001	Oct 30, 2017
DR REDDYS LABS LTD	60MG;120MG	A076667	001	Nov 18, 2014
	180MG;240MG	A079043	002	Jun 22, 2011
SUN PHARM	60MG;120MG	A090818	001	Jan 29, 2015

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+!	GLAXOSMITHKLINE CONS	0.0275MG/SPRAY	N022051	002	Aug 02, 2016

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+!	GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014

FLUTICASONE PROPIONATE

APOTEX	0.05MG/SPRAY	A208150	001	Feb 29, 2016
HI TECH	0.05MG/SPRAY	A208024	001	Apr 17, 2019
HIKMA	0.05MG/SPRAY	A207957	001	May 26, 2016

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015
AMNEAL PHARMS	600MG	A207342	001	Jul 11, 2018
	1.2GM	A207342	002	Jul 11, 2018
AUROBINDO PHARMA LTD	600MG	A210453	001	Oct 21, 2019
	1.2GM	A210453	002	Oct 21, 2019
GUARDIAN DRUG	600MG	A209215	001	Sep 06, 2017
	1.2GM	A209215	002	Sep 06, 2017

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN					
	PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011
MUCINEX					
+	RB HLTH	600MG	N021282	001	Jul 12, 2002
+!		1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015
		1.2GM;120MG	A091071	002	May 27, 2015
	DR REDDYS LABS LTD	600MG;60MG	A208369	001	Dec 29, 2017
		1.2GM;120MG	A208369	002	Dec 29, 2017
MUCINEX D					
+	RB HLTH	600MG;60MG	N021585	001	Jun 22, 2004
+!		1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS					
+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995
ADVIL MIGRAINE LIQUI-GELS					
+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000
IBUPROFEN					
	AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011
	ASCENT PHARMS INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206999	001	Dec 21, 2017
	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018
	BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016
	MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009
	P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016
MIDOL LIQUID GELS					
+!	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL					
	GLAXOSMITHKLINE	100MG/5ML	N020589	001	Jun 27, 1996
CHILDREN'S ADVIL-FLAVORED					
	GLAXOSMITHKLINE	100MG/5ML	N020589	002	Nov 07, 1997
CHILDREN'S IBUPROFEN					
	PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998
CHILDREN'S MOTRIN					
+!	J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995
IBUPROFEN					
	APTAPHARMA INC	100MG/5ML	A210602	001	Nov 23, 2018
	ARISE	100MG/5ML	A200457	001	Aug 18, 2011
	AUROBINDO PHARMA LTD	100MG/5ML	A209179	001	Apr 17, 2018
	P AND L	100MG/5ML	A074916	001	Apr 30, 1999
	TARO	100MG/5ML	A209207	001	Jun 27, 2017

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN					
+!	J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996
IBUPROFEN					
	GUARDIAN DRUG	40MG/ML	A210755	001	Sep 26, 2018
	L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998
	TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009
INFANT'S ADVIL					
+!	GLAXOSMITHKLINE	50MG/1.25ML	N020812	002	Jan 12, 2000

TABLET;ORAL

ADVIL					
	GLAXOSMITHKLINE	200MG	N018989	001	May 18, 1984
IBU-TAB 200					
	ALRA	200MG	A071057	001	Aug 11, 1988
IBUPROFEN					
	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014
	AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
		200MG	A072199	001	May 23, 1988
	AUROBINDO PHARMA	200MG	A208865	001	Nov 08, 2017

IBUPROFEN

TABLET;ORAL

IBUPROFEN					
	LTD				
	AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003
	CONTRACT PHARMACAL	200MG	A072299	001	Jul 01, 1988
	DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
	DR REDDYS LABS INC	200MG	A076117	001	Nov 20, 2001
	GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
	GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016
	LNK	200MG	A075010	001	Mar 01, 1999
		200MG	A075139	001	Mar 01, 1999
	MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
		200MG	A091239	001	Feb 01, 2011
	MCNEIL	200MG	A073019	001	Mar 30, 1994
	MERRO PHARM	200MG	A070985	001	Oct 02, 1987
	OHM	200MG	A071163	001	Jul 15, 1986
	PAR PHARM	200MG	A070481	001	Sep 24, 1986
	PERRIGO	200MG	A072096	001	Dec 08, 1987
		200MG	A075995	001	Mar 14, 2002
!	PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
	SHANDONG XINHUA	200MG	A206990	001	Aug 21, 2018
		200MG	A207095	001	May 05, 2017
	STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011
		200MG	A091355	001	Apr 04, 2011
		200MG	A206989	001	Jun 29, 2018
		200MG	A207052	001	May 30, 2017
	ULTRATAB LABS INC	200MG	A209076	001	Jan 06, 2020
	VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
		200MG	A071639	001	Feb 02, 1988
JUNIOR STRENGTH ADVIL					
	GLAXOSMITHKLINE	100MG	N020267	002	Dec 13, 1996
JUNIOR STRENGTH IBUPROFEN					
	L PERRIGO CO	100MG	A075367	001	Apr 22, 1999
JUNIOR STRENGTH MOTRIN					
	J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996
MOTRIN IB					
+	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990
TAB-PROFEN					
	PERRIGO	200MG	A072095	001	Dec 08, 1987

TABLET, CHEWABLE;ORAL

CHILDREN'S ADVIL					
	GLAXOSMITHKLINE	50MG	N020944	001	Dec 18, 1998
IBUPROFEN					
!	PERRIGO	100MG	A076359	002	Jan 16, 2004
JUNIOR STRENGTH ADVIL					
	GLAXOSMITHKLINE	100MG	N020944	002	Dec 18, 1998

IBUPROFEN SODIUM

TABLET;ORAL

ADVIL					
+!	GLAXOSMITHKLINE	EQ 200MG BASE	N201803	001	Jun 12, 2012
IBUPROFEN SODIUM					
	PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL CONGESTION RELIEF					
+!	GLAXOSMITHKLINE	200MG;10MG	N022565	001	May 27, 2010
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE					
	PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

ADVIL COLD AND SINUS					
+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374	001	May 30, 2002
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	A209235	001	Dec 01, 2017

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL					
CHILDREN'S ADVIL COLD					
	GLAXOSMITHKLINE	100MG/5ML;15MG/5ML	N021373	001	Apr 18, 2002
CHILDREN'S MOTRIN COLD					
+!	J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	PERRIGO	100MG/5ML;15MG/5ML	A076478	001	Nov 05, 2003
TABLET;ORAL					
ADVIL COLD AND SINUS					
+!	GLAXOSMITHKLINE	200MG;30MG	N019771	001	Sep 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	DR REDDYS LABS LTD	200MG;30MG	A077628	001	Aug 14, 2006
IBUPROHM COLD AND SINUS					
	OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001
SINE-AID IB					
	J AND J CONSUMER INC	200MG;30MG	N019899	001	Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION					
HUMULIN R PEN					
+!	LILLY	100 UNITS/ML	N018780	005	Aug 06, 1998
NOVOLIN R					
+!	NOVO NORDISK INC	100 UNITS/ML	N019938	001	Jun 25, 1991

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION					
HUMULIN R					
+!	LILLY	100 UNITS/ML	N018780	001	Oct 28, 1982

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION					
HUMULIN 70/30					
+!	LILLY	30 UNITS/ML;70 UNITS/ML	N019717	001	Apr 25, 1989
HUMULIN 70/30 PEN					
+!	LILLY	30 UNITS/ML;70 UNITS/ML	N019717	002	Aug 06, 1998
NOVOLIN 70/30					
+!	NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019991	001	Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION					
HUMULIN N					
+!	LILLY	100 UNITS/ML	N018781	001	Oct 28, 1982
NOVOLIN N					
+!	NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL					
DURAPREP					
+!	3M	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006
+!		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006

KETOCONAZOLE

SHAMPOO;TOPICAL					
NIZORAL A-D					
+!	KRAMER	1%	N020310	001	Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC					
ALAWAY					
+!	BAUSCH AND LOMB	EQ 0.025% BASE	N021996	001	Dec 01, 2006
+		EQ 0.035% BASE	N021996	002	Feb 11, 2015
KETOTIFEN FUMARATE					
	AKORN	EQ 0.025% BASE	A077958	001	Jul 26, 2007
	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006
ZADITOR					
!	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL					
LANSOPRAZOLE					
	DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
	LANNETT CO INC	15MG	A207157	001	Sep 29, 2017
	MYLAN	15MG	A203187	001	Jun 01, 2016
	NATCO PHARMA LTD	15MG	A203306	001	Jan 13, 2016

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE					
	PERRIGO R AND D	15MG	A202319	001	May 18, 2012
	WOCKHARDT LTD	15MG	A202727	001	May 18, 2012
PREVACID 24 HR					
+!	PERRIGO PHARMA INTL	15MG	N022327	001	May 18, 2009

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE					
	DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR					
+!	SANOFI AVENTIS US	2.5MG/5ML	N209090	001	Jan 31, 2017

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE					
	DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018
	MICRO LABS	5MG	A211551	001	Nov 20, 2018
XYZAL ALLERGY 24HR					
+!	SANOFI AVENTIS US	5MG	N209089	001	Jan 31, 2017

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT					
	AUROBINDO PHARMA LTD	1.5MG	A206867	001	Dec 08, 2015
FALLBACK SOLO					
	LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014
HER STYLE					
	NOVAST LABS	1.5MG	A207976	001	Mar 11, 2016
LEVONORGESTREL					
	AMNEAL PHARMS	1.5MG	A204044	001	Jul 03, 2018
	GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010
	MYLAN LABS LTD	0.75MG	A202740	001	Sep 02, 2016
		1.5MG	A202739	001	Oct 31, 2014
	NAARI PTE LTD	1.5MG	A202380	001	May 29, 2015
	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
	PERRIGO R AND D	1.5MG	A202334	001	Aug 20, 2014
OPCICON ONE-STEP					
	SUN PHARM	1.5MG	A202635	001	Sep 11, 2014
PLAN B ONE-STEP					
+!	FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE					
+	BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005
+!		2MG	N021855	002	Aug 04, 2005

SOLUTION;ORAL

IMODIUM A-D					
+!	J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988
LOPERAMIDE HYDROCHLORIDE					
	HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
	PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997

SUSPENSION;ORAL

IMODIUM A-D					
+!	J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004
LOPERAMIDE HYDROCHLORIDE					
	PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011

TABLET;ORAL

IMODIUM A-D					
+!	J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015
	L PERRIGO CO	2MG	A075232	001	Jan 06, 2000
	LNK	2MG	A076497	001	Jun 10, 2003
	OHM LABS	2MG	A074091	001	Dec 10, 1992

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+!	J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

	PERRIGO R AND D	2MG;125MG	A209837	001	Sep 05, 2018
	SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006

TABLET, CHEWABLE;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

!	PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002

LORATADINE

CAPSULE;ORAL

CLARITIN

+!	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008

LORATADINE

	MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016
	STRIDES PHARMA	10MG	A211926	001	Jan 15, 2020

SUSPENSION;ORAL

LORATADINE

+!	TARO	1MG/ML	N021734	001	Oct 04, 2005

SYRUP;ORAL

CLARITIN

+!	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002

LORATADINE

	AUROBINDO PHARMA LTD	1MG/ML	A208931	001	Jun 29, 2018
	LANNETT CO INC	1MG/ML	A077421	001	Jun 29, 2006
	PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
	TARO	1MG/ML	A076805	001	Aug 20, 2004
		1MG/ML	A201865	001	Jul 31, 2015
	TEVA	1MG/ML	A075505	001	Nov 07, 2003
	WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004

TABLET;ORAL

CLARITIN

+!	BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002

CLARITIN HIVES RELIEF

+!	BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003

LORATADINE

	APOTEX INC	10MG	A076471	001	Feb 14, 2006
	AUROBINDO PHARMA LTD	10MG	A208314	001	Apr 16, 2018
	GRANULES INDIA LTD	10MG	A210722	001	Dec 23, 2019
	GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019
	MYLAN	10MG	A075790	001	Nov 07, 2008
		10MG	A076154	001	Aug 20, 2003
		10MG	A078447	001	Aug 12, 2011
	PERRIGO	10MG	A076301	001	Jun 25, 2004
	PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003
	SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+!	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006

CLARITIN

+	BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018

LORATADINE

	PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019
	SUN PHARM	5MG	A210088	001	Apr 16, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

ALAVERT

	GLAXOSMITHKLINE	10MG	N021375	001	Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+!	BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003

CLARITIN REDITABS

+!	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN REDITABS					
+!		10MG	N020704	002	Nov 27, 2002
LORATADINE					
	ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003
	AUROBINDO PHARMA LTD	10MG	A208477	001	Apr 11, 2018
	GLAXOSMITHKLINE	10MG	A075822	001	Feb 10, 2003
	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003
LORATADINE REDIDOSE					
	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D					
+!	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002
CLARITIN-D 24 HOUR					
+!	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
	P AND L	10MG;240MG	A075706	001	Feb 21, 2003
	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003
		10MG;240MG	A075989	001	Mar 04, 2004
	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS					
+!	HISAMITSU PHARM CO	3%;10%	N022029	001	Feb 20, 2008
+		3%;10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK					
	PERRIGO	2%,4%	A076357	001	Mar 30, 2004
MONISTAT 3 COMBINATION PACK					
+	MEDTECH PRODUCTS	2%,4%	N021261	003	Jun 17, 2003
MONISTAT 3 COMBINATION PACK (PREFILLED)					
+!	MEDTECH PRODUCTS	2%,4%	N021261	001	Feb 02, 2001

CREAM;VAGINAL

MICONAZOLE 3					
	TARO	4%	A076773	001	Mar 02, 2005
MICONAZOLE 7					
	P AND L	2%	A074164	001	Mar 29, 1996
MICONAZOLE NITRATE					
	ACP NIMBLE	2%	A074366	001	Feb 22, 1996
	PERRIGO	2%	A074760	001	May 15, 1997
	PERRIGO R AND D	4%	A091366	001	Jan 15, 2010
	TARO PHARMS	2%	A074444	001	Jan 13, 1997
MONISTAT 3					
+!	MEDTECH PRODUCTS	4%	N020827	001	Mar 30, 1998
MONISTAT 7					
+!	MEDTECH PRODUCTS	2%	N017450	002	Feb 15, 1991

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK					
	P AND L	2%,200MG	A074926	001	Apr 16, 1999
MICONAZOLE NITRATE					
	PERRIGO R AND D	2%,1.2GM	A079114	001	Jun 02, 2010
MICONAZOLE NITRATE COMBINATION PACK					
	PERRIGO	2%,200MG	A075329	001	Apr 20, 1999
MONISTAT 1 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,1.2GM	N021308	001	Jun 29, 2001
MONISTAT 3 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996
MONISTAT 7 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,100MG	N020288	002	Apr 26, 1993

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE					
	ACP NIMBLE	100MG	A074414	001	Apr 30, 1997
	P AND L	100MG	A073507	001	Nov 19, 1993
!	PERRIGO	100MG	A074395	001	Mar 20, 1997

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL					
MONISTAT 7					
+!	MEDTECH PRODUCTS	100MG	N018520	002	Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL					
MEN'S ROGAINE					
+!	JOHNSON AND JOHNSON	5%	N021812	001	Jan 20, 2006
MINOXIDIL					
	PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011
MINOXIDIL (FOR MEN)					
	P AND L	5%	A208092	001	Feb 17, 2017
	TARO	5%	A209074	001	Dec 31, 2018
MINOXIDIL (FOR WOMEN)					
	P AND L	5%	A208092	002	Jul 27, 2017
	TARO	5%	A209074	002	Apr 22, 2019
WOMEN'S ROGAINE					
+!	JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014
SOLUTION;TOPICAL					
MINOXIDIL (FOR MEN)					
	HI TECH PHARMA	2%	A074731	001	Dec 24, 1996
	L PERRIGO CO	2%	A075357	001	Jul 30, 1999
	P AND L	2%	A074588	001	Apr 05, 1996
	WOCKHARDT BIO AG	2%	A074767	001	Feb 28, 1997
MINOXIDIL (FOR WOMEN)					
	HI TECH PHARMA	2%	A074731	002	May 11, 2005
	L PERRIGO CO	2%	A075357	002	Jul 30, 1999
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
	AVACOR PRODS	5%	A075619	001	Nov 17, 2000
	P AND L	5%	A075518	001	Nov 17, 2000
	PERRIGO	5%	A075598	001	Jun 13, 2001
	PERRIGO NEW YORK	5%	A075737	001	Mar 15, 2002
	WOCKHARDT BIO AG	5%	A075438	001	Feb 27, 2003
ROGAINE (FOR MEN)					
+!	JOHNSON AND JOHNSON	2%	N019501	002	Feb 09, 1996
ROGAINE (FOR WOMEN)					
+!	JOHNSON AND JOHNSON	2%	N019501	003	Feb 09, 1996
ROGAINE EXTRA STRENGTH (FOR MEN)					
+!	JOHNSON AND JOHNSON	5%	N020834	001	Nov 14, 1997
THEROXIDIL					
	EI INC	2%	A078176	001	Nov 09, 2007
		5%	A076239	001	Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC					
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE					
	AKORN INC	0.025%;0.3%	A202795	001	Jan 24, 2013
	ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
NAPHCON-A					
+!	ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994
OPCON-A					
+!	BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994
VISINE					
+!	JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL					
NAPROXEN SODIUM					
+!	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006
	CATALENT	EQ 200MG BASE	A202807	001	Jan 04, 2019
	PURACAP PHARM LLC	EQ 200MG BASE	A208363	001	Mar 15, 2018
TABLET;ORAL					
ALEVE					
+!	BAYER	220MG	N020204	002	Jan 11, 1994
NAPROXEN SODIUM					
	AMNEAL PHARMS NY	220MG	A079096	001	Dec 16, 2008
	AUROBINDO PHARMA LTD	220MG	A205497	001	Mar 18, 2016
	CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997
	DR REDDYS LABS INC	220MG	A075168	001	Jul 28, 1998
	GRANULES INDIA	220MG	A091353	001	Sep 20, 2011
	LNK INTL INC	220MG	A204872	001	Jan 23, 2017
	MARKSANS PHARMA	220MG	A090545	001	Mar 16, 2011

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

	NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018
	PERRIGO	220MG	A074661	001	Jan 13, 1997
	SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011
	YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+!	BAYER	220MG;120MG	N021076	001	Nov 29, 1999

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS INC	220MG;120MG	A077381	001	Sep 27, 2006
	PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+		14MG/24HR	N020076	005	Nov 12, 1999
+!		21MG/24HR	N020076	006	Nov 12, 1999

NICODERM CQ

+	SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
+		14MG/24HR	N020165	005	Aug 02, 1996
+!		21MG/24HR	N020165	004	Aug 02, 1996

NICOTINE

	AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
		14MG/24HR	A074612	003	Oct 20, 1997
		21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
+		EQ 2MG BASE	N018612	004	Sep 25, 2000
+!		EQ 4MG BASE	N020066	002	Feb 09, 1996
+		EQ 4MG BASE	N020066	004	Sep 25, 2000

NICORETTE (MINT)

+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
+		EQ 4MG BASE	N020066	003	Dec 23, 1998

NICOTINE POLACRILEX

	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
		EQ 2MG BASE	A076776	001	Sep 16, 2004
		EQ 2MG BASE	A076777	001	Sep 16, 2004
		EQ 4MG BASE	A076778	001	Sep 16, 2004
		EQ 4MG BASE	A076779	001	Sep 16, 2004
		EQ 4MG BASE	A076789	001	Sep 16, 2004
	P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999
		EQ 2MG BASE	A076569	001	Jul 29, 2004
		EQ 2MG BASE	A078699	001	Dec 29, 2008
		EQ 2MG BASE	A079044	001	Jul 08, 2009
		EQ 2MG BASE	A079216	001	Jul 08, 2009
		EQ 2MG BASE	A204794	001	May 10, 2016
		EQ 4MG BASE	A074707	001	Mar 19, 1999
		EQ 4MG BASE	A076568	002	Jul 29, 2004
		EQ 4MG BASE	A078697	001	Dec 29, 2008
		EQ 4MG BASE	A079038	001	Jul 08, 2009
		EQ 4MG BASE	A079219	001	Jul 08, 2009
		EQ 4MG BASE	A204833	001	Feb 26, 2016
	PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
		EQ 2MG BASE	A078547	001	May 24, 2007
		EQ 2MG BASE	A078967	001	Apr 23, 2008
		EQ 2MG BASE	A091349	001	Jul 20, 2011
		EQ 2MG BASE	A206394	001	Dec 15, 2016
		EQ 4MG BASE	A078326	001	Oct 30, 2006
		EQ 4MG BASE	A078546	001	May 24, 2007
		EQ 4MG BASE	A078968	001	Apr 23, 2008
		EQ 4MG BASE	A091354	001	Jul 20, 2011
		EQ 4MG BASE	A206393	001	Dec 15, 2016

TROCHE/LOZENGE;ORAL

NICORETTE

+	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330	001	Oct 31, 2002

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL					
NICORETTE					
+		EQ 2MG BASE	N022360	001	May 18, 2009
+!		EQ 4MG BASE	N021330	002	Oct 31, 2002
+!		EQ 4MG BASE	N022360	002	May 18, 2009
NICOTINE POLACRILEX					
	DR REDDYS LABS SA	EQ 2MG BASE	A212796	001	Jan 08, 2020
		EQ 4MG BASE	A212796	002	Jan 08, 2020
	P AND L	EQ 2MG BASE	A208875	001	Oct 31, 2019
		EQ 2MG BASE	A209206	001	Jun 26, 2018
		EQ 2MG BASE	A209519	001	Jul 02, 2018
		EQ 2MG BASE	A209520	001	Oct 31, 2019
		EQ 2MG BASE	A210711	001	Oct 31, 2019
		EQ 2MG BASE	A210712	001	Sep 06, 2019
		EQ 2MG BASE	A212056	001	Jul 26, 2019
		EQ 4MG BASE	A208875	002	Oct 31, 2019
		EQ 4MG BASE	A209206	002	Jun 26, 2018
		EQ 4MG BASE	A209519	002	Jul 02, 2018
		EQ 4MG BASE	A209520	002	Oct 31, 2019
		EQ 4MG BASE	A210711	002	Oct 31, 2019
		EQ 4MG BASE	A210712	002	Sep 06, 2019
		EQ 4MG BASE	A212056	002	Jul 26, 2019
	PERRIGO R AND D	EQ 2MG BASE	A077007	001	Jan 31, 2006
		EQ 2MG BASE	A090711	001	Jul 10, 2009
		EQ 2MG BASE	A090821	001	Jul 10, 2009
		EQ 2MG BASE	A203690	001	Oct 09, 2012
		EQ 4MG BASE	A077007	002	Jan 31, 2006
		EQ 4MG BASE	A090711	002	Jul 10, 2009
		EQ 4MG BASE	A090821	002	Jul 10, 2009
		EQ 4MG BASE	A203690	002	Oct 09, 2012
	PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019
		EQ 4MG BASE	A207868	002	Feb 07, 2019

NIZATIDINE

TABLET;ORAL					
AXID AR					
+!	GLAXOSMITHKLINE	75MG	N020555	001	May 09, 1996

NONOXYNOL-9

SPONGE;VAGINAL					
TODAY					
+!	MAYER LABS INC	1GM	N018683	001	Apr 01, 1983

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE					
+!	DEXCEL PHARMA	20MG	N022032	001	Dec 04, 2007
	DR REDDYS	20MG	A207740	001	Nov 05, 2018
	SUN PHARM	20MG	A207891	001	Oct 12, 2018
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL					
OMEPRAZOLE					
+	DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
!	DR REDDYS LABS LTD	EQ 20MG BASE	A078878	001	Jun 05, 2009
	SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018
TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A206877	001	Jun 06, 2018
	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015
PRILOSEC OTC					
+!	ASTRAZENECA PHARMS	EQ 20MG BASE	N021229	001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL					
OMEPRAZOLE AND SODIUM BICARBONATE					
	ACTAVIS ELIZABETH	20MG;1.1GM	A204137	001	Jul 15, 2016
	AUROLIFE PHARMA LLC	20MG;1.1GM	A204923	001	Nov 07, 2016
	PAR PHARM	20MG;1.1GM	A201946	001	Jul 15, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361	001	Jul 15, 2016
	ZYDUS PHARMS	20MG;1.1GM	A203345	001	Mar 16, 2018

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL					
ZEGERID OTC					
+!	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009
FOR SUSPENSION;ORAL					
ZEGERID OTC					
+!	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013

ORLISTAT

CAPSULE;ORAL					
ALLI					
+!	GLAXOSMITHKLINE CONS	60MG	N021887	001	Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL					
OXYTROL FOR WOMEN					
+!	ALLERGAN	3.9MG/24HR	N202211	001	Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC					
VISINE L.R.					
+!	JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL					
NIX					
+!	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990
PERMETHRIN					
	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000
	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL					
MIRALAX					
+!	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006
POLYETHYLENE GLYCOL 3350					
	ANI PHARMS INC	17GM/SCOOPFUL	A202850	001	Dec 15, 2015
	AUROBINDO PHARMA LTD	17GM/SCOOPFUL	A209017	001	Apr 09, 2018
	MYLAN	17GM/PACKET	A078915	001	Oct 06, 2009
		17GM/SCOOPFUL	A078915	002	Oct 06, 2009
	NEXGEN PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
	NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
	NOVELGENIX THERAPS	17GM/SCOOPFUL	A202071	001	Dec 28, 2012
	NUVO PHARMS INC	17GM/SCOOPFUL	A206105	001	Oct 28, 2016
	PAR PHARM	17GM/SCOOPFUL	A079214	001	Jan 31, 2013
	PERRIGO R AND D	17GM/PACKET	A090685	001	Oct 06, 2009
		17GM/SCOOPFUL	A090685	002	Oct 06, 2009
	STRIDES PHARMA	17GM/SCOOPFUL	A203928	001	Aug 24, 2016
		17GM/PACKET	A203928	002	Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL					
POTASSIUM IODIDE					
	MISSION PHARMACAL CO	65MG/ML	A206211	001	Mar 24, 2016
THYROSHIELD					
!	ARCO PHARMS LLC	65MG/ML	A077218	001	Jan 12, 2005
TABLET;ORAL					
IOSAT					
+	ANBEX	65MG	N018664	002	May 12, 2011
+!		130MG	N018664	001	Oct 14, 1982
THYROSAFE					
!	RECIP	65MG	A076350	001	Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL					
POVIDONE IODINE					
+!	ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989
SPONGE;TOPICAL					
E-Z SCRUB 201					
+!	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985

POVIDONE-IODINE					
SPONGE;TOPICAL					
E-Z SCRUB 241					
+!	BECTON DICKINSON	10%	N019476	001	Jan 07, 1987
PSEUDOEPHEDRINE HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017
	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999
	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005
SUDAFED 12 HOUR					
!	MCNEIL CONS	120MG	A073585	001	Oct 31, 1991
SUDAFED 24 HOUR					
+!	J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992
PURIFIED WATER					
SOLUTION;OPHTHALMIC					
PUR-WASH					
+!	NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011
RANITIDINE HYDROCHLORIDE					
TABLET;ORAL					
RANITIDINE HYDROCHLORIDE					
	APOTEX INC	EQ 75MG BASE	A075167	001	May 04, 2000
		EQ 150MG BASE	A200172	001	May 31, 2012
	AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579	001	Nov 13, 2017
		EQ 150MG BASE	A207578	001	Nov 13, 2017
	DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
		EQ 150MG BASE	A078192	001	Aug 31, 2007
	GRANULES INDIA LTD	EQ 150MG BASE	A210243	001	Aug 20, 2018
		EQ 150MG BASE	A210243	002	Aug 20, 2018
	PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
	PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
		EQ 150MG BASE	A091429	002	May 11, 2011
	STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012
		EQ 75MG BASE	A209160	001	Mar 05, 2018
		EQ 150MG BASE	A200536	001	Jun 28, 2011
		EQ 150MG BASE	A209161	001	Feb 22, 2018
	UNIQUE PHARM LABS	EQ 75MG BASE	A210250	001	Aug 30, 2019
		EQ 150MG BASE	A210228	001	Aug 30, 2019
	WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
ZANTAC 150					
+!	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004
+		EQ 150MG BASE	N021698	002	Mar 13, 2007
ZANTAC 75					
+	SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995
SODIUM CHLORIDE					
AEROSOL, METERED;INHALATION					
BRONCHO SALINE					
+!	BLAIREX	0.9%	N019912	001	Sep 03, 1992
TERBINAFINE					
GEL;TOPICAL					
LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021958	001	Jul 24, 2006
TERBINAFINE HYDROCHLORIDE					
CREAM;TOPICAL					
LAMISIL					
+!	GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999
TERBINAFINE HYDROCHLORIDE					
	TARO	1%	A077511	001	Jul 02, 2007
SOLUTION;TOPICAL					
LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021124	001	Mar 17, 2000
SPRAY;TOPICAL					
LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021124	002	Mar 17, 2000

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE				
PERRIGO	6.5%	A075915	001	Nov 21, 2001
VAGISTAT-1				
+! COMBE	6.5%	N020676	001	Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR				
+! SANOFI AVENTIS US	0.055MG/SPRAY	N020468	002	Oct 11, 2013
TRIAMCINOLONE ACETONIDE				
PERRIGO ISRAEL	0.055MG/SPRAY	A078104	002	Nov 14, 2014

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

0.9% SODIUM CHLORIDE INJECTION USP SOLUTION		
INJECTABLE; INJECTION		
NONE		
FRESENIUS KABI AG	N125695	Sep 05, 2019
ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP		
INJECTABLE; INJECTION		
NONE		
HAEMONETICS MANUFACTURING INC	N760305	Jun 30, 1978
ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)		
INJECTABLE; INJECTION		
CITRA LABS LLC	N020037	Aug 26, 2003
ACD-A SOLUTION		
TERUMO BCT INC	A010228	Feb 25, 2002
ADSOL WITH ACD-A		
FENWAL INC	N000922	Aug 29, 2002
ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A		
HAEMONETICS CORP	A980728	Feb 06, 2002
AS3 SOLUTION/ACD-A		
TERUMO BCT INC	N001214	May 29, 2002
NONE		
HAEMONETICS MANUFACTURING INC	A710497	Nov 06, 1987
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP		
INJECTABLE; INJECTION		
NONE		
FENWAL INC	N160918	Mar 17, 1978
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)		
INJECTABLE; INJECTION		
NONE		
ARTERIOCYTE MEDICAL SYSTEMS, INC	N011057	May 11, 2012
ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)		
INJECTABLE; INJECTION		
CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3		
HAEMONETICS CORP	N000127	Jan 18, 2002
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION		
INJECTABLE; INJECTION		
NONE		
TERUMO MEDICAL CORP	N820528	Nov 03, 1982
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)		
INJECTABLE; INJECTION		
CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS		
FENWAL INC	N770420	May 12, 1978
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP		
INJECTABLE; INJECTION		
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER		
FENWAL INC	N940404	Jul 28, 1994

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS MANUFACTURING INC		N800077	Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC		N900223	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC		N900224	Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS		N040083	Nov 21, 2005

NONE

TERUMO BCT INC		A070025	Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N170401	Dec 06, 1977
		N811012	Jun 28, 1983
HAEMONETICS MANUFACTURING INC		N800222	Aug 23, 1982
TERUMO MEDICAL CORP		N781211	Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC		N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP		N880217	Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS MANUFACTURING INC	0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML	N820915	Oct 19, 1984

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS CORPORATION		N980123	Mar 03, 2000
LABORATORIES GRIFOIS, S.A.		A125697	Oct 25, 2019
TERUMO BCT		N125608	Jun 26, 2018

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL LABORATORIES INC		N010409	Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N770923	Jan 20, 1978
TERUMO MEDICAL CORP		N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA		N125552	Dec 21, 2016

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB		N830715	Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC	10GM/100ML;5GM/100ML	A720563	Oct 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	Oct 30, 1992

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
HOSPIRA INC	6GM/100ML;0.9GM/100ML	A740193	Jan 30, 1995
HESPAN IN PLASTIC CONTAINER			
B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N890105	Apr 04, 1991
NONE			
TEVA PARENTERAL MEDICINES INC	6GM/100ML;0.9GM/100ML	A740592	Nov 12, 1998

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

NONE			
B. BRAUN MEDICAL		A110013	Jan 09, 2015
VOLUVEN			
FRESENIUS KABI DEUTSCHLAND GMBH	6GM/100ML;0.9GM/100ML	N070012	Dec 27, 2007

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION			
HAEMONETICS CORP		N090067	Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL			
HAEMONETICS CORP		N110059	Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTION

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL			
CITRA LABS LLC		N950522	Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION			
FENWAL INC.	2.26G/500ML; 2.21G/500ML; 1.59G/500ML; 1.53G/500ML; 0.465G/500ML	N080041	Dec 09, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ABACAVIR SULFATE; LAMIVUDINE				
TABLET;ORAL				
ABACAVIR SULFATE AND LAMIVUDINE				
	ZYDUS PHARMS	EQ 600MG BASE;300MG	A208990 001	Nov 15, 2018
ABARELIX				
INJECTABLE;INTRAMUSCULAR				
PLENAXIS				
	SPECIALITY EUROPEAN	100MG/VIAL	N021320 001	Nov 25, 2003
ACAMPROSATE CALCIUM				
TABLET, DELAYED RELEASE;ORAL				
ACAMPROSATE CALCIUM				
	BARR LABS DIV TEVA	333MG	A200143 001	Nov 18, 2013
CAMPRAL				
+	FOREST LABS	333MG **	N021431 001	Jul 29, 2004
ACARBOSE				
TABLET;ORAL				
ACARBOSE				
	MYLAN	25MG	A091053 001	Jan 06, 2011
		50MG	A091053 002	Jan 06, 2011
		100MG	A091053 003	Jan 06, 2011
PRECOSE				
+	BAYER HLTHCARE	25MG	N020482 004	May 29, 1997
+		50MG	N020482 001	Sep 06, 1995
+		100MG	N020482 002	Sep 06, 1995
ACEBUTOLOL HYDROCHLORIDE				
CAPSULE;ORAL				
ACEBUTOLOL HYDROCHLORIDE				
	ANI PHARMS INC	EQ 200MG BASE	A074007 001	Oct 18, 1995
		EQ 400MG BASE	A074007 002	Oct 18, 1995
SECTRAL				
+	PROMIUS PHARMA	EQ 200MG BASE	N018917 001	Dec 28, 1984
+		EQ 400MG BASE	N018917 003	Dec 28, 1984
ACETAMINOPHEN				
INJECTABLE;INJECTION				
INJECTAPAP				
	ORTHO MCNEIL PHARM	100MG/ML	N017785 001	Mar 07, 1986
SUPPOSITORY;RECTAL				
ACEPHEN				
	ACP NIMBLE	120MG	A072218 001	Mar 27, 1992
		325MG	N018060 003	Dec 18, 1986
		650MG	N018060 002	
ACETAMINOPHEN				
	ABLE	120MG	A073106 001	Feb 27, 1995
		325MG	A073107 001	Feb 27, 1995
		650MG	A073108 001	Feb 27, 1995
	ACINO PRODS	120MG	A071010 001	May 12, 1987
		650MG	A071011 001	May 12, 1987
TYLENOL				
	J AND J CONSUMER INC	120MG	N017756 002	
		650MG	N017756 001	
TABLET, EXTENDED RELEASE;ORAL				
ACETAMINOPHEN				
	SUN PHARM INDS LTD	650MG	A090205 001	Nov 18, 2009
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE				
CAPSULE;ORAL				
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE				
	MIKART	150MG;180MG;15MG	A081095 001	Oct 26, 1990
		150MG;180MG;30MG	A081096 001	Oct 26, 1990
		150MG;180MG;60MG	A081097 001	Oct 26, 1990
CODEINE, ASPIRIN, APAP FORMULA NO. 2				
	SCHERER LABS	150MG;180MG;15MG	A085640 001	
CODEINE, ASPIRIN, APAP FORMULA NO. 3				
	SCHERER LABS	150MG;180MG;30MG	A085639 001	
CODEINE, ASPIRIN, APAP FORMULA NO. 4				
	SCHERER LABS	150MG;180MG;60MG	A085638 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BANCAP				
	FOREST PHARMS	325MG;50MG	A088889 001	Jan 16, 1986
BUCET				
	MALLINCKRODT	650MG;50MG	A088991 001	Jun 28, 1985
PHRENILIN FORTE				
	VALEANT	650MG;50MG	A088831 001	Jun 19, 1985
TENCON				
	MALLINCKRODT	650MG;50MG	A089405 001	May 15, 1990
TRIAPRIN				
	DUNHALL	325MG;50MG	A089268 001	Jul 02, 1987

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN				
	HALSEY	325MG;50MG	A089568 001	Oct 05, 1988
	WATSON LABS	325MG;50MG	A087550 001	Oct 19, 1984
BUTAPAP				
	MIKART	650MG;50MG	A089988 001	Oct 26, 1992
PHRENILIN				
	VALEANT	325MG;50MG **	A087811 001	Jun 19, 1985
SEDAPAP				
	MAYRAND	650MG;50MG	A088944 001	Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

ANOQUAN				
	SHIRE	325MG;50MG;40MG	A087628 001	Oct 01, 1986
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE				
	GILBERT LABS	325MG;50MG;40MG **	A088825 001	Dec 05, 1984
	GRAHAM DM	325MG;50MG;40MG	A088743 001	Jul 18, 1985
		325MG;50MG;40MG	A088765 001	Mar 27, 1985
		325MG;50MG;40MG	A089067 001	Apr 19, 1985
	HIKMA PHARMS	500MG;50MG;40MG	A040261 001	Oct 28, 1998
	MALLINCKRODT	325MG;50MG;40MG	A088758 001	Mar 27, 1985
ESGIC-PLUS				
	MIKART	500MG;50MG;40MG	A040085 001	Mar 28, 1996
FEMCET				
	MALLINCKRODT	325MG;50MG;40MG	A089102 001	Jun 19, 1985
MEDIGESIC PLUS				
	US CHEM	325MG;50MG;40MG	A089115 001	Jan 14, 1986
TRIAD				
	MALLINCKRODT	325MG;50MG;40MG	A089023 001	Jun 19, 1985

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE				
	ABLE	325MG;50MG;40MG	A040390 001	Jul 23, 2001
		500MG;50MG;40MG	A040394 001	Jul 23, 2001
	GILBERT LABS	325MG;50MG;40MG	A087629 001	Nov 13, 1984
	HIKMA PHARMS	500MG;50MG;40MG	A040336 001	Aug 18, 1999
	MIKART	750MG;50MG;40MG	A040496 001	Dec 23, 2003
	MIRROR PHARMS LLC	500MG;50MG;40MG	A040883 001	Dec 23, 2008
	NOVAST LABS	325MG;50MG;40MG	A040864 001	Dec 01, 2008
	SUN PHARM INDUSTRIES	325MG;50MG;40MG	A040601 001	Jul 29, 2005
	VINTAGE PHARMS	500MG;50MG;40MG	A040513 001	Aug 25, 2003
	WATSON LABS	325MG;50MG;40MG	A089536 001	Feb 16, 1988
		500MG;50MG;40MG	A040267 001	Jul 30, 1998
ESGIC				
	FOREST PHARMS	325MG;50MG;40MG	A089660 001	Dec 23, 1988
ESGIC-PLUS				
	MIKART	500MG;50MG;40MG	A089451 001	May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE				
	ABLE	325MG;50MG;40MG;30MG	A076528 001	Aug 21, 2003
	HIKMA INTL PHARMS	325MG;50MG;40MG;30MG	A075618 001	Mar 23, 2001
PHRENILIN WITH CAFFEINE AND CODEINE				
	VALEANT	325MG;50MG;40MG;30MG	A074911 001	Aug 22, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE				
CAPSULE;ORAL				
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE				
MIKART	356.4MG;30MG;16MG	A040109	001	Aug 26, 1997
WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007
DHC PLUS				
PHARM RES ASSOC	356.4MG;30MG;16MG	A088584	001	Mar 04, 1986
SYNALGOS-DC-A				
LEITNER PHARMS	356.4MG;30MG;16MG	A089166	001	May 14, 1986
TABLET;ORAL				
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE				
BOCA PHARMA LLC	712.8MG;60MG;32MG	A040701	001	Apr 03, 2007
MIKART	712.8MG;60MG;32MG	A040316	001	Apr 28, 1999
WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006
ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE				
TABLET;ORAL				
TAVIST ALLERGY/SINUS/HEADACHE				
NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082	001	Mar 01, 2001
ACETAMINOPHEN; CODEINE PHOSPHATE				
CAPSULE;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
TEVA	300MG;15MG	A088537	001	Jun 04, 1984
	300MG;30MG	A088324	001	Dec 29, 1983
	300MG;60MG	A088599	001	Jun 01, 1984
PHENAPHEN W/ CODEINE NO. 2				
ROBINS AH	325MG;15MG	A084444	001	
PHENAPHEN W/ CODEINE NO. 3				
ROBINS AH	325MG;30MG	A084445	001	
PHENAPHEN W/ CODEINE NO. 4				
ROBINS AH	325MG;60MG	A084446	001	
PROVAL #3				
SOLVAY	325MG;30MG	A085685	001	
TYLENOL W/ CODEINE NO. 3				
ORTHO MCNEIL PHARM	300MG;30MG	A087422	001	
TYLENOL W/ CODEINE NO. 4				
ORTHO MCNEIL PHARM	300MG;60MG	A087421	001	
SOLUTION;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
ACI HEALTHCARE LTD	120MG/5ML;12MG/5ML	A086366	001	
ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001	
DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098	001	Sep 20, 1996
LANNETT CO INC	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001	
SUSPENSION;ORAL				
CAPITAL AND CODEINE				
ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001	
VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001	
TABLET;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
ABLE	300MG;30MG	A040452	001	Aug 01, 2002
	300MG;60MG	A040459	001	Aug 01, 2002
AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987
	300MG;15MG	A089481	001	Mar 03, 1987
	300MG;30MG	A089479	001	Mar 03, 1987
	300MG;30MG	A089482	001	Mar 03, 1987
	300MG;60MG	A089480	001	Mar 03, 1987
	300MG;60MG	A089483	001	Mar 03, 1987
DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
	300MG;15MG	A088353	001	Feb 06, 1984
	300MG;30MG	A040223	002	Nov 18, 1997
	300MG;30MG	A088354	001	Feb 06, 1984
	300MG;60MG	A040223	003	Nov 18, 1997
	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992
	300MG;60MG	A081249	001	Jul 16, 1992
HALSEY	300MG;15MG	A083871	001	

ACETAMINOPHEN; CODEINE PHOSPHATE				
TABLET;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG **	A085363	001	
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;30MG	A089238	001	Feb 25, 1986
	300MG;60MG	A089244	001	Feb 25, 1986
	650MG;30MG	A089231	001	Mar 03, 1986
	650MG;60MG	A089363	001	Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;30MG	A085794	001	
	300MG;60MG	A087653	001	Apr 13, 1982
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
RHODES PHARMS	300MG;15MG	A089673	002	Feb 10, 1988
	300MG;30MG	A089673	003	Feb 10, 1988
	300MG;60MG	A089673	001	Feb 10, 1988
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	
SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
	300MG;30MG	A089184	001	Oct 18, 1985
	300MG;30MG	A089253	001	May 19, 1986
	300MG;60MG	A089185	001	Oct 18, 1985
	300MG;60MG	A089254	001	May 19, 1986
USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;15MG	A089997	001	Dec 28, 1994
	300MG;30MG	A087276	001	May 26, 1982
	300MG;30MG	A089998	001	Dec 28, 1994
	300MG;60MG	A087275	001	May 26, 1982
	300MG;60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
	300MG;30MG	A040443	002	Jan 22, 2003
	300MG;60MG	A040443	003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG;30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
	500MG;30MG	A040441	001	Mar 27, 2003
	500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG;30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4				
GLAXOSMITHKLINE	300MG;60MG	A083951	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE				
TABLET;ORAL				
PAPA-DEINE #3				
VANGARD	300MG;30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4				
VANGARD	300MG;60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
ROBINS AH	650MG;30MG	A085856	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056	001	
	325MG;15MG **	A085056	002	
	325MG;30MG **	A085056	003	
	325MG;60MG **	A085056	004	
TYLENOL W/ CODEINE NO. 1				
JANSSEN PHARMS	300MG;7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
JANSSEN PHARMS	300MG;15MG	A085055	002	
ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE				
TABLET, EXTENDED RELEASE;ORAL				
DRIXORAL PLUS				
SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987
ACETAMINOPHEN; HYDROCODONE BITARTRATE				
CAPSULE;ORAL				
ACETAMINOPHEN AND HYDROCODONE BITARTRATE				
CENT PHARMS	500MG;5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG;5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG;5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG;5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG;5MG	A088956	001	Jul 19, 1985
	500MG;5MG	A089006	001	Aug 09, 1985
MIKART	500MG;5MG	A081067	001	Nov 30, 1989
	500MG;5MG	A081068	001	Nov 30, 1989
	500MG;5MG	A081069	001	Nov 30, 1989
	500MG;5MG	A081070	001	Nov 30, 1989
	500MG;5MG	A089008	001	Feb 21, 1986
LORCET-HD				
MALLINCKRODT	500MG;5MG	A087336	001	Jul 08, 1982
SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418	001	Jun 27, 2001
MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003
MIKART	500MG/15ML;5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML;5MG/15ML	A089557	001	Apr 29, 1992
	500MG/15ML;7.5MG/15ML	A081051	001	Aug 28, 1992
NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002
PHARM ASSOC	500MG/15ML;7.5MG/15ML	A040182	001	Mar 13, 1998
VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	A040520	001	Oct 30, 2003
ZYFREL				
CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468	001	Apr 14, 2016
TABLET;ORAL				
ANEXSIA				
MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987
	750MG;10MG	A040468	001	Oct 31, 2002
ANEXSIA 7.5/650				
MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987
CO-GESIC				
UCB INC	500MG;5MG	A087757	001	May 03, 1982
DURADYNE DHC				
FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983
HY-PHEN				
ASCHER	500MG;5MG	A087677	001	May 03, 1982
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG;5MG	A040478	001	Nov 08, 2002
	325MG;7.5MG	A040464	001	Oct 23, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	325MG;10MG	A040464	002	Oct 23, 2002
	500MG;5MG	A040477	001	Nov 06, 2002
	500MG;7.5MG	A040490	001	May 21, 2003
	500MG;10MG	A040473	001	Nov 06, 2002
	650MG;7.5MG	A040474	001	Jan 02, 2003
	650MG;10MG	A040476	001	Oct 23, 2002
	750MG;7.5MG	A040469	001	Oct 25, 2002
ALVOGEN PINE BROOK	300MG;5MG	A208540	001	Nov 08, 2018
	300MG;7.5MG	A208540	002	Nov 08, 2018
	300MG;10MG	A208540	003	Nov 08, 2018
	325MG;2.5MG	A209958	001	Oct 24, 2018
	325MG;5MG	A209958	002	Oct 24, 2018
	325MG;7.5MG	A209958	003	Oct 24, 2018
	325MG;10MG	A209958	004	Oct 24, 2018
AMNEAL PHARMS NY	500MG;5MG	A040729	001	Aug 25, 2006
	500MG;7.5MG	A040748	001	Aug 25, 2006
	500MG;10MG	A040813	001	Feb 23, 2007
	650MG;7.5MG	A040754	001	Aug 25, 2006
	650MG;10MG	A040757	001	Aug 25, 2006
	750MG;7.5MG	A040769	001	Aug 28, 2006
APIL	500MG;10MG	A040148	002	Feb 14, 1997
BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017
	300MG;7.5MG	A207171	002	Jun 20, 2017
	300MG;10MG	A207171	003	Jun 20, 2017
	325MG;5MG	A207172	001	Jun 22, 2017
	325MG;7.5MG	A207172	002	Jun 22, 2017
	325MG;10MG	A207172	003	Jun 22, 2017
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
NOSTRUM LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018
	325MG;5MG	A209924	002	Nov 16, 2018
	325MG;7.5MG	A209924	003	Nov 16, 2018
	325MG;10MG	A209924	004	Nov 16, 2018
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE				
TABLET;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017
	325MG;7.5MG	A206484	002	Mar 24, 2017
	325MG;10MG	A206484	003	Mar 24, 2017
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996
	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	400MG;7.5MG	A040288	002	Nov 27, 1998
	400MG;10MG	A040288	003	Nov 27, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL					
OXYCODONE AND ACETAMINOPHEN					
	ACTAVIS ELIZABETH	500MG;5MG	A040199	001	Dec 30, 1998
	BARR	500MG;5MG	A040304	001	Oct 02, 2000
	DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999
	HALSEY	500MG;5MG	A089994	001	May 04, 1989
	MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998
	MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
	VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996
	VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999
	WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997
ROXILOX					
	ROXANE	500MG;5MG	A040061	001	Jul 03, 1995
TYLOX					
	JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984
TYLOX-325					
	ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984
SOLUTION;ORAL					
OXYCODONE AND ACETAMINOPHEN					
	MIKART INC	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018
	SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN					
	VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014
ROXICET					
	HIKMA	325MG/5ML;5MG/5ML	A089351	001	Dec 03, 1986
TABLET;ORAL					
OXYCODONE 2.5/APAP 500					
	BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	
OXYCODONE 5/APAP 500					
	BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	
OXYCODONE AND ACETAMINOPHEN					
	ACTAVIS ELIZABETH	325MG;5MG	A040203	001	Mar 15, 1999
		325MG;7.5MG	A040800	001	Apr 03, 2012
		325MG;10MG	A040800	002	Apr 03, 2012
	AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007
		650MG;10MG	A040789	002	Nov 27, 2007
	BARR	325MG;5MG	A087406	001	
	DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
	MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004
		650MG;10MG	A040550	002	Jun 30, 2004
	MAYNE PHARMA INC	500MG;7.5MG	A090177	005	Oct 20, 2008
		650MG;10MG	A090177	006	Oct 20, 2008
	MIKART	400MG;2.5MG	A040679	001	May 16, 2006
		400MG;5MG	A040687	001	Apr 27, 2006
		400MG;7.5MG	A040698	001	Apr 27, 2006
		400MG;10MG	A040692	001	Apr 27, 2006
		500MG;10MG	A040676	001	Apr 19, 2006
	WATSON LABS	500MG;7.5MG	A040371	001	Dec 29, 2000
		650MG;10MG	A040371	002	Dec 29, 2000
PERCOCET					
	VINTAGE PHARMS LLC	325MG;5MG	A085106	002	
		500MG;7.5MG	A040341	001	Jul 26, 1999
		650MG;10MG	A040341	002	Jul 26, 1999
ROXICET 5/500					
	ROXANE	500MG;5MG	A089775	001	Jan 12, 1989
TABLET, EXTENDED RELEASE;ORAL					
XARTEMIS XR					
+	MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE;ORAL					
TYLOX					
	ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE				
TABLET;ORAL				
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE				
	GAVIS PHARMS	650MG;EQ 25MG BASE	A076202 001	Aug 02, 2002
	WATSON LABS	650MG;EQ 25MG BASE	A074699 001	Mar 24, 2000
TALACEN				
	SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458 001	Sep 23, 1982
ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE				
TABLET;ORAL				
DARVOCET				
	AAIPHARMA LLC	325MG;32.5MG	N016844 001	
DOLENE AP-65				
	LEDERLE	650MG;65MG	A085100 001	
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN				
	MYLAN	325MG;32MG	A083689 001	
		650MG;65MG	A083978 001	
	SANDOZ	650MG;65MG	A089959 001	Jul 18, 1989
	VINTAGE PHARMS	650MG;65MG	A040507 001	Jul 30, 2003
	WATSON LABS	650MG;65MG	A040139 001	Dec 16, 1996
WYGESIC				
	CARACO	650MG;65MG	A084999 001	
ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE				
TABLET;ORAL				
DARVOCET A500				
	XANODYNE PHARM	500MG;100MG	A076429 001	Sep 10, 2003
DARVOCET-N 100				
	XANODYNE PHARM	650MG;100MG	N017122 002	
DARVOCET-N 50				
	XANODYNE PHARM	325MG;50MG	N017122 001	
PROPACET 100				
	TEVA	650MG;100MG	A070107 001	Jun 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
	ABLE	650MG;100MG	A075838 001	Jul 11, 2001
	ACTAVIS ELIZABETH	650MG;100MG	A070910 001	Jan 02, 1987
	CORNERSTONE	325MG;100MG	A076743 001	May 07, 2004
		500MG;100MG	A076750 001	Jun 28, 2004
	HALSEY	325MG;50MG	A072105 001	May 13, 1988
		650MG;100MG	A072106 001	May 13, 1988
	IVAX SUB TEVA PHARMS	650MG;100MG	A070146 001	Aug 02, 1985
	MALLINCKRODT	650MG;100MG	A075738 001	Feb 02, 2001
	MIRROR PHARMS	650MG;100MG	A077821 001	Feb 11, 2008
	MUTUAL PHARM	325MG;50MG	A070115 001	Jun 12, 1985
		650MG;100MG	A070116 001	Jun 12, 1985
		650MG;100MG	A070615 001	Mar 21, 1986
		650MG;100MG	A070771 001	Mar 21, 1986
		650MG;100MG	A070775 001	Mar 21, 1986
	MYLAN	650MG;100MG	A072195 001	Feb 16, 1988
	MYLAN PHARMS INC	650MG;100MG	A070145 001	Jun 12, 1985
	SANDOZ	650MG;100MG	A070443 001	Jan 23, 1986
	SUPERPHARM	650MG;100MG	A071319 001	Jan 06, 1987
	TEVA	650MG;100MG	A070732 001	Jan 03, 1986
		650MG;100MG	A074119 001	Dec 19, 1994
	VINTAGE PHARMS	325MG;50MG	A074843 002	Feb 15, 2001
		650MG;100MG	A074843 001	Feb 12, 1997
	WATSON LABS	325MG;50MG	A070398 001	Dec 18, 1986
		650MG;100MG	A070399 001	Dec 18, 1986
	WATSON LABS FLORIDA	500MG;100MG	A077196 001	Jun 28, 2005
		650MG;100MG	A076609 001	Nov 16, 2004
	WOCKHARDT LTD	325MG;50MG	A077677 001	Mar 16, 2007
		650MG;100MG	A077677 002	Mar 16, 2007
ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE				
TABLET;ORAL				
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN				
	CSPC OUYI	325MG;37.5MG	A076914 001	Jul 26, 2006
	PAR PHARM	325MG;37.5MG	A076475 001	Apr 21, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE				
	ACCORD HLTHCARE	500MG	A207659 001	Oct 18, 2018
	MYLAN	500MG	A203917 001	Jun 18, 2019
DIAMOX				
+	TEVA BRANDED PHARM	500MG	N012945 001	

TABLET;ORAL

ACETAZOLAMIDE				
	ALRA	250MG	A083320 001	
	ASCOT	250MG	A087686 001	Oct 20, 1982
	HERITAGE PHARMA	250MG	A088882 001	Oct 22, 1985
	SUN PHARM INDUSTRIES	125MG	A089753 002	Jun 22, 1988
		250MG	A089753 001	Jun 22, 1988
	VANGARD	250MG	A087654 001	Feb 05, 1982
	WATSON LABS	250MG	A084498 002	
DIAMOX				
+	TEVA BRANDED PHARM	125MG **	N008943 001	
+		250MG **	N008943 002	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM				
	EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202693 001	Dec 19, 2014
	HOSPIRA	EQ 500MG BASE/VIAL	A040108 001	Oct 30, 1995
	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358 001	Jun 20, 2017
DIAMOX				
+	TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388 001	

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETASOL				
	ACTAVIS MID ATLANTIC	2%	A087146 001	
ACETIC ACID				
	KV PHARM	2%	A085493 001	
ORLEX				
	WARNER CHILCOTT	2%	A086845 001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE				
	BAUSCH AND LOMB	2%;0.79%	A040063 001	Feb 25, 1994
BOROFAIR				
	PHARMAFAIR	2%;0.79%	A088606 001	Aug 21, 1985
DOMEBORO				
	BAYER PHARMS	2%;0.79%	A084476 001	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS;OTIC

TRIDESILON				
	BAYER PHARMS	2%;0.05%	N017914 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC				
	ACTAVIS MID ATLANTIC	2%;1%	A087143 001	Jan 13, 1982
ACETIC ACID W/ HYDROCORTISONE				
	KV PHARM	2%;1%	A085492 001	
HYDROCORTISONE AND ACETIC ACID				
	BAUSCH AND LOMB	2%;1%	A040097 001	Oct 31, 1994
	WOCKHARDT	2%;1%	A040168 001	Aug 30, 1996
ORLEX HC				
	WARNER CHILCOTT	2%;1%	A086844 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS;OTIC

NEO-CORT-DOME				
	BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETOHEXAMIDE					
TABLET;ORAL					
ACETOHEXAMIDE					
	ANI PHARMS INC	250MG	A070869	001	Feb 09, 1987
		500MG	A070870	001	Feb 09, 1987
	USL PHARMA	250MG	A070753	001	Nov 03, 1986
		500MG	A070754	001	Nov 03, 1986
	WATSON LABS TEVA	250MG	A071893	001	Nov 25, 1987
		500MG	A071894	001	Nov 25, 1987
DYMELOR					
	LILLY	250MG	N013378	002	
		500MG	N013378	001	
ACETOPHENAZINE MALEATE					
TABLET;ORAL					
TINDAL					
	SCHERING	20MG	N012254	002	
ACETRIZOATE SODIUM					
SOLUTION;INTRAUTERINE					
SALPIX					
	ORTHO MCNEIL PHARM	53%	N009008	001	
ACETYLCHOLINE CHLORIDE					
FOR SOLUTION;OPHTHALMIC					
MIOCHOL					
+	NOVARTIS	20MG/VIAL **	N016211	001	
ACETYLCYSTEINE					
INJECTABLE;INTRAVENOUS					
ACETYLCYSTEINE					
	MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015
SOLUTION;INHALATION, ORAL					
ACETYLCYSTEINE					
	HOSPIRA	10%	A071364	001	May 01, 1989
		20%	A071365	001	May 01, 1989
	ROXANE	10%	A072323	001	Apr 30, 1992
		10%	A072621	001	Sep 30, 1992
		20%	A072324	001	Apr 30, 1992
		20%	A072622	001	Sep 30, 1992
MUCOMYST					
+	APOTHECON	10% **	N013601	002	
+		20% **	N013601	001	
MUCOSIL-10					
	DEY	10%	A070575	001	Oct 14, 1986
MUCOSIL-20					
	DEY	20%	A070576	001	Oct 14, 1986
TABLET, EFFERVESCENT;ORAL					
CETYLEV					
+	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016
+		2.5GM	N207916	002	Jan 29, 2016
ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE					
SOLUTION;INHALATION					
MUCOMYST W/ ISOPROTERENOL					
	MEAD JOHNSON	10%;0.05%	N017366	001	
ACETYLDIGITOXIN					
TABLET;ORAL					
ACYLANID					
	NOVARTIS	0.1MG	N009436	001	
ACITRETIN					
CAPSULE;ORAL					
ACITRETIN					
	MYLAN	17.5MG	A203707	001	Sep 10, 2015
		22.5MG	A203707	002	Sep 10, 2015
SORIATANE					
+	STIEFEL LABS INC	17.5MG	N019821	003	Aug 06, 2009
+		22.5MG	N019821	004	Aug 06, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACRISORCIN

CREAM;TOPICAL

AKRINOL

SCHERING	2MG/GM	N012470	001	

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997
CHARTWELL MOLECULES	200MG	A074872	001	Apr 22, 1997
IVAX SUB TEVA PHARMS	200MG	A074674	001	Apr 22, 1997
LEK PHARM	200MG	A074750	001	Apr 22, 1997
MYLAN	200MG	A074727	001	Apr 22, 1997
	200MG	A074977	001	Apr 13, 1998
RANBAXY	200MG	A074975	001	Sep 30, 1998
ROXANE	200MG	A074570	002	Apr 22, 1997
TEVA	200MG	A074828	001	Apr 22, 1997
TEVA PHARMS	200MG	A074914	001	Nov 26, 1997
WATSON LABS	200MG	A075101	001	Apr 15, 1998

ZOVIRAX

+ MYLAN	200MG	N018828	001	Jan 25, 1985

OINTMENT;OPHTHALMIC

AVACLYR

+ FERA PHARMS LLC	3%	N202408	001	Mar 29, 2019

OINTMENT;TOPICAL

ACYCLOVIR

PERRIGO UK FINCO	5%	A205659	001	Feb 20, 2019

TABLET;ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
	800MG	A074870	002	Jun 05, 1997
CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997
	800MG	A074834	002	Apr 24, 1997
IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
	800MG	A074836	002	Apr 22, 1997
LEK PHARM	400MG	A074658	001	Apr 22, 1997
	800MG	A074658	002	Apr 22, 1997
MYLAN	400MG	A074976	001	Apr 13, 1998
	400MG	A075211	001	Sep 28, 1998
	800MG	A074976	002	Apr 13, 1998
	800MG	A075211	002	Sep 28, 1998
SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998
	800MG	A074980	002	Sep 30, 1998
TEVA	200MG **	A074556	001	Apr 22, 1997
TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
	800MG	A075021	002	Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR

ABBVIE	EQ 50MG BASE/ML	A075114	001	Jul 26, 1999

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
	EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997

ACYCLOVIR SODIUM

APOTHECON	EQ 500MG BASE/VIAL	A074897	001	Feb 27, 1998
	EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997
	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997
FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998
HIKMA PHARMS	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016
	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016
HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997
	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999
	EQ 500MG BASE/VIAL	A074663	001	Apr 22, 1997
	EQ 500MG BASE/VIAL	A074758	001	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074663	002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074758	002	Apr 22, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACYCLOVIR SODIUM					
INJECTABLE;INJECTION					
ACYCLOVIR SODIUM					
	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017
		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017
	TEVA PARENTERAL	EQ 50MG BASE/ML	A075627	001	Mar 28, 2001
		EQ 500MG BASE/VIAL	A074969	001	Aug 26, 1997
		EQ 1GM BASE/VIAL	A074969	002	Aug 26, 1997
	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017
		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017
ZOVIRAX					
+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N018603	003	Aug 30, 1983
+		EQ 500MG BASE/VIAL **	N018603	001	Oct 22, 1982
+		EQ 1GM BASE/VIAL **	N018603	002	Jun 29, 1989
ADAPALENE					
SOLUTION;TOPICAL					
DIFFERIN					
+	GALDERMA LABS LP	0.1% **	N020338	001	May 31, 1996
ADAPALENE; BENZOYL PEROXIDE					
GEL;TOPICAL					
ADAPALENE AND BENZOYL PEROXIDE					
	TARO	0.3%;2.5%	A209148	001	Oct 17, 2018
ADENOSINE					
INJECTABLE;INJECTION					
ADENOCARD					
+	ASTELLAS	3MG/ML **	N019937	002	Oct 30, 1989
ADENOSINE					
	LUITPOLD	3MG/ML	A090010	001	Apr 28, 2009
	TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004
		3MG/ML	A078676	001	Jul 31, 2008
	WEST-WARD PHARMS INT	3MG/ML	A076501	001	Jun 16, 2004
	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009
SOLUTION;INTRAVENOUS					
ADENOSCAN					
+	ASTELLAS	60MG/20ML (3MG/ML) **	N020059	001	May 18, 1995
+		90MG/30ML (3MG/ML) **	N020059	002	May 18, 1995
ADENOSINE					
	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014
		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014
ALATROFLOXACIN MESYLATE					
INJECTABLE;INJECTION					
TROVAN PRESERVATIVE FREE					
	PFIZER	EQ 200MG BASE/VIAL	N020760	001	Dec 18, 1997
		EQ 300MG BASE/VIAL	N020760	002	Dec 18, 1997
ALBENDAZOLE					
TABLET, CHEWABLE;ORAL					
ALBENZA					
	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015
ALBUMIN CHROMATED CR-51 SERUM					
INJECTABLE;INJECTION					
CHROMALBIN					
	ISO TEX	100uCi/VIAL	N017835	001	
		250uCi/VIAL	N017835	002	
		500uCi/VIAL	N017835	003	
ALBUMIN IODINATED I-125 SERUM					
INJECTABLE;INJECTION					
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)					
	BAYER PHARMS	2.5uCi/AMP	N017846	001	
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125					
	MALLINCKRODT	6.67uCi/ML	N017844	003	
		10uCi/ML	N017844	001	
		100uCi/ML	N017844	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALBUMIN IODINATED I-131 SERUM				
INJECTABLE;INJECTION				
MEGATOPE				
ISO TEX	2mCi/VIAL	N017837	003	
	5uCi/AMP	N017837	004	
	20uCi/AMP	N017837	005	
ALBUTEROL				
AEROSOL, METERED;INHALATION				
ALBUTEROL				
ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	
ALBUTEROL SULFATE				
CAPSULE;INHALATION				
VENTOLIN ROTACAPS				
GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988
SOLUTION;INHALATION				
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995
APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010
	EQ 0.042% BASE	A078623	002	Apr 05, 2010
	EQ 0.083% BASE	A075717	001	Feb 02, 2007
	EQ 0.5% BASE	A076391	001	Apr 01, 2003
BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999
LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006
MYLAN SPECLT	EQ 0.083% BASE **	A072652	001	Feb 21, 1992
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999
WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
PROVENTIL				
+ SCHERING	EQ 0.083% BASE **	N019243	002	Jan 14, 1987
+	EQ 0.5% BASE **	N019243	001	Jan 14, 1987
VENTOLIN				
+ GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773	001	Apr 23, 1992
	EQ 0.5% BASE **	N019269	002	Jan 16, 1987
SYRUP;ORAL				
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
+ SCHERING	EQ 2MG BASE/5ML **	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML **	N019621	001	Jun 10, 1987
TABLET;ORAL				
ALBUTEROL SULFATE				
AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072860	002	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989
PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
	EQ 4MG BASE	A072317	001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
	EQ 2MG BASE	A072779	001	Jun 25, 1993
	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989
	EQ 4MG BASE	A072780	001	Jun 25, 1993

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALBUTEROL SULFATE				
TABLET;ORAL				
ALBUTEROL SULFATE				
	EQ 4MG BASE		A072939 001	Mar 30, 1990
UCB INC	EQ 2MG BASE		A073120 001	Sep 29, 1992
	EQ 4MG BASE		A073121 001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE		A072817 001	Jan 09, 1990
	EQ 4MG BASE		A072818 001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE		A072629 001	Jan 31, 1991
	EQ 2MG BASE		A072764 001	Aug 28, 1991
	EQ 4MG BASE		A072630 001	Jan 31, 1991
	EQ 4MG BASE		A072765 001	Aug 28, 1991
YAOPHARMA CO LTD	EQ 2MG BASE		A072151 001	Dec 05, 1989
	EQ 4MG BASE		A072152 001	Dec 05, 1989
PROVENTIL				
+ SCHERING	EQ 2MG BASE **		N017853 001	May 07, 1982
+	EQ 4MG BASE **		N017853 002	May 07, 1982
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE		N019112 001	Jul 10, 1986
	EQ 4MG BASE		N019112 002	Jul 10, 1986
TABLET, EXTENDED RELEASE;ORAL				
PROVENTIL				
SCHERING	EQ 4MG BASE		N019383 001	Jul 13, 1987
VOLMAX				
MURO	EQ 4MG BASE		N019604 002	Dec 23, 1992
	EQ 8MG BASE		N019604 001	Dec 23, 1992
VOSPIRE ER				
DAVA PHARMS INC	EQ 8MG BASE		A076130 003	Sep 26, 2002
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE				
AEROSOL, METERED;INHALATION				
COMBIVENT				
BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH		N020291 001	Oct 24, 1996
SOLUTION;INHALATION				
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE				
APOTEX INC	EQ 0.083% BASE;0.017%		A077117 001	Dec 31, 2007
FOSUN PHARMA	EQ 0.083% BASE;0.017%		A076867 001	Dec 21, 2006
TEVA PHARMS	EQ 0.083% BASE;0.017%		A076724 001	Dec 31, 2007
DUONEB				
+ MYLAN SPECIALITY LP	EQ 0.083% BASE;0.017% **		N020950 001	Mar 21, 2001
ALCLOMETASONE DIPROPIONATE				
CREAM;TOPICAL				
ACLOVATE				
+ FOUGERA PHARMS	0.05% **		N018707 001	Dec 14, 1982
OINTMENT;TOPICAL				
ACLOVATE				
+ FOUGERA PHARMS	0.05% **		N018702 001	Dec 14, 1982
ALCOHOL				
INJECTABLE;INJECTION				
ALCOHOL 5% IN DEXTROSE 5%				
MILES	5ML/100ML		A083483 001	
ALCOHOL; DEXTROSE				
INJECTABLE;INJECTION				
ALCOHOL 10% AND DEXTROSE 5%				
B BRAUN	10ML/100ML;5GM/100ML		N004589 006	
ALCOHOL 5% AND DEXTROSE 5%				
B BRAUN	5ML/100ML;5GM/100ML		N004589 004	
ALCOHOL 5% IN D5-W				
HOSPIRA	5ML/100ML;5GM/100ML		A083263 001	
ALCOHOL 5% IN DEXTROSE 5% IN WATER				
BAXTER HLTHCARE	5ML/100ML;5GM/100ML		A083256 001	
ALENDRONATE SODIUM				
SOLUTION;ORAL				
FOSAMAX				
+ MERCK	EQ 70MG BASE/75ML **		N021575 001	Sep 17, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALENDRONATE SODIUM				
TABLET;ORAL				
ALENDRONATE SODIUM				
	MYLAN	EQ 5MG BASE	A076584 001	Aug 04, 2008
		EQ 10MG BASE	A076584 002	Aug 04, 2008
		EQ 35MG BASE	A076584 003	Aug 04, 2008
		EQ 35MG BASE	A078638 001	Aug 04, 2008
		EQ 70MG BASE	A076584 004	Aug 04, 2008
		EQ 70MG BASE	A078638 002	Aug 04, 2008
	TEVA PHARMS	EQ 35MG BASE	A076184 002	Aug 04, 2008
		EQ 70MG BASE	A076184 001	Feb 06, 2008
	UPSHER SMITH LABS	EQ 5MG BASE	A075871 001	Apr 22, 2009
		EQ 10MG BASE	A075871 002	Apr 22, 2009
		EQ 35MG BASE	A075871 004	Apr 22, 2009
		EQ 40MG BASE	A075871 003	Apr 22, 2009
		EQ 70MG BASE	A075871 005	Apr 22, 2009
FOSAMAX				
+	MERCK AND CO INC	EQ 5MG BASE **	N020560 003	Apr 25, 1997
+		EQ 10MG BASE **	N020560 001	Sep 29, 1995
+		EQ 35MG BASE **	N020560 004	Oct 20, 2000
+		EQ 40MG BASE **	N020560 002	Sep 29, 1995
ALFUZOSIN HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
ALFUZOSIN HYDROCHLORIDE				
	HERITAGE PHARMA	10MG	A079056 001	Jul 18, 2011
	MYLAN	10MG	A079014 001	Jul 18, 2011
	WOCKHARDT LTD	10MG	A090221 001	Aug 10, 2012
ALGLUCERASE				
INJECTABLE;INJECTION				
CEREDASE				
	GENZYME	10 UNITS/ML	N020057 004	May 08, 1992
		80 UNITS/ML	N020057 003	Apr 05, 1991
ALISKIREN HEMIFUMARATE				
CAPSULE, PELLET;ORAL				
TEKTURNA				
+	NODEN PHARMA	EQ 37.5MG BASE	N210709 001	Nov 14, 2017
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE				
TABLET;ORAL				
TEKAMLO				
	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545 001	Aug 26, 2010
		EQ 150MG BASE;EQ 10MG BASE	N022545 002	Aug 26, 2010
		EQ 300MG BASE;EQ 5MG BASE	N022545 003	Aug 26, 2010
		EQ 300MG BASE;EQ 10MG BASE	N022545 004	Aug 26, 2010
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
AMTURNIDE				
	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045 001	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045 002	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045 003	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045 004	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045 005	Dec 21, 2010
ALISKIREN HEMIFUMARATE; VALSARTAN				
TABLET;ORAL				
VALTURNA				
	NOVARTIS	EQ 150MG BASE;160MG	N022217 001	Sep 16, 2009
		EQ 300MG BASE;320MG	N022217 002	Sep 16, 2009
ALKAVERVIR				
TABLET;ORAL				
VERILOID				
	3M	2MG	N007336 002	
		3MG	N007336 003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALLOPURINOL				
TABLET;ORAL				
ALLOPURINOL				
	FOSUN PHARMA	100MG	A070268 001	Dec 31, 1985
	MUTUAL PHARM	100MG	A070466 001	Dec 24, 1985
		300MG	A070467 001	Dec 24, 1985
	PURACAP PHARM	100MG	A070150 001	Dec 10, 1985
		300MG	A070147 001	Dec 10, 1985
	PUREPAC PHARM	100MG	A070579 001	Apr 14, 1986
		300MG	A070580 001	Apr 14, 1986
	SANDOZ	300MG	A070269 001	Dec 31, 1985
	SUN PHARM INDS INC	100MG	A078390 001	Aug 30, 2007
		300MG	A078390 002	Aug 30, 2007
	SUPERPHARM	100MG	A070950 001	Nov 30, 1988
		300MG	A070951 001	Nov 30, 1988
	WATSON LABS	100MG	N018241 001	Nov 16, 1984
		100MG	N018785 001	Sep 28, 1984
		300MG	N018241 002	Nov 16, 1984
		300MG	N018785 002	Sep 28, 1984
LOPURIN				
	ABBOTT	100MG	N018297 001	
		300MG	N018297 002	
ALLOPURINOL; LESINURAD				
TABLET;ORAL				
DUZALLO				
+	IRONWOOD PHARMS INC	200MG;200MG	N209203 001	Aug 18, 2017
+		300MG;200MG	N209203 002	Aug 18, 2017
ALMOTRIPTAN MALATE				
TABLET;ORAL				
AXERT				
+	JANSSEN PHARMS	EQ 6.25MG BASE	N021001 001	May 07, 2001
+		EQ 12.5MG BASE	N021001 002	May 07, 2001
ALPRAZOLAM				
SOLUTION;ORAL				
ALPRAZOLAM				
	ROXANE	0.5MG/5ML	A074314 001	Oct 31, 1993
TABLET;ORAL				
ALPRAZOLAM				
	ANI PHARMS INC	0.25MG	A074085 001	Feb 16, 1994
		0.5MG	A074085 002	Feb 16, 1994
		1MG	A074085 003	Feb 16, 1994
		2MG	A074085 004	Feb 26, 1996
	IVAX SUB TEVA PHARMS	0.25MG	A074294 001	Jul 29, 1994
		0.5MG	A074294 002	Jul 29, 1994
		1MG	A074294 003	Jul 29, 1994
		2MG	A074294 004	Jul 29, 1994
	MYLAN PHARMS INC	0.25MG	A074046 001	Oct 19, 1993
		0.5MG	A074046 002	Oct 19, 1993
		1MG	A074046 003	Oct 19, 1993
		2MG	A074046 004	May 07, 1997
	ROXANE	0.25MG	A074199 001	Oct 19, 1993
		0.5MG	A074199 002	Oct 19, 1993
		1MG	A074199 003	Oct 19, 1993
	WATSON LABS	0.25MG	A074456 001	Aug 31, 1995
		0.25MG	A074479 001	Jan 21, 1997
		0.5MG	A074456 002	Aug 31, 1995
		0.5MG	A074479 002	Jan 21, 1997
		1MG	A074456 003	Aug 31, 1995
		1MG	A074479 003	Jan 21, 1997
TABLET, EXTENDED RELEASE;ORAL				
ALPRAZOLAM				
	ACTAVIS LABS FL INC	0.5MG	A077198 001	May 13, 2010
		1MG	A077198 002	May 13, 2010
		2MG	A077198 003	May 13, 2010
		3MG	A077198 004	May 13, 2010
	ANI PHARMS INC	0.5MG	A077725 001	Jul 31, 2006
		0.5MG	A077979 001	Feb 28, 2007
		1MG	A077725 002	Jul 31, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

		1MG	A077979	002	Feb 28, 2007
		2MG	A077725	004	Jul 31, 2006
		2MG	A077979	003	Feb 28, 2007
		3MG	A077725	003	Jul 31, 2006
		3MG	A077979	004	Feb 28, 2007
	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008
		1MG	A078489	002	Oct 17, 2008
		2MG	A078489	003	Oct 17, 2008
		3MG	A078489	004	Oct 17, 2008
	IMPAX LABS	0.5MG	A077968	004	May 24, 2007
		1MG	A077968	003	May 24, 2007
		2MG	A077968	002	May 24, 2007
		3MG	A077968	001	May 24, 2007
	IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007
		1MG	A077996	002	Jan 31, 2007
		2MG	A077996	003	Jan 31, 2007
		3MG	A077996	004	Jan 31, 2007
	MYLAN	0.5MG	A077391	002	Jan 26, 2006
		1MG	A077391	003	Jan 26, 2006
		2MG	A077391	004	Jan 26, 2006
		3MG	A077391	001	Jan 26, 2006
	SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006
		1MG	A077777	002	Jun 30, 2006
		2MG	A077777	003	Jun 30, 2006
		3MG	A077777	004	Jun 30, 2006
	VINTAGE PHARMS	0.5MG	A078442	001	Oct 15, 2007
		1MG	A078442	002	Oct 15, 2007
		2MG	A078442	003	Oct 15, 2007
		3MG	A078442	004	Oct 15, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

NIRAVAM

+	UCB INC	0.25MG **	N021726	001	Jan 19, 2005
+		0.5MG **	N021726	002	Jan 19, 2005
+		1MG **	N021726	003	Jan 19, 2005
+		2MG **	N021726	004	Jan 19, 2005

ALPROSTADIL

INJECTABLE;INJECTION

CAVERJECT

	PFIZER	0.005MG/ML	N020755	001	Oct 31, 1997
		0.01MG/ML	N020755	002	Oct 01, 1997
		0.02MG/ML	N020755	003	Oct 01, 1997
+	PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996

EDEX

	AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997

ALSEROXYLON

TABLET;ORAL

RAUTENSIN

	NOVARTIS	2MG	N009215	001	

RAUWILOID

	3M	2MG	N008867	001	

ALTRETAMINE

CAPSULE;ORAL

HEXALEN

+	EISAI INC	50MG	N019926	001	Dec 26, 1990

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

	PENNEX	80MG;20MG	A089449	001	Nov 27, 1987

FOAMCOAT

	GUARDIAN DRUG	80MG;20MG	A071793	001	Sep 04, 1987

FOAMICON

	NOVARTIS	80MG;20MG	A072687	001	Jun 28, 1989

GAVISCON

+	SANOFI AVENTIS US	160MG;40MG	N018685	002	Dec 09, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMANTADINE HYDROCHLORIDE				
CAPSULE;ORAL				
AMANTADINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006
LANNETT CO INC	100MG	A209221	001	Jun 15, 2017
WATSON LABS	100MG	A071382	001	Jan 21, 1987
SYMADINE				
SOLVAY	100MG	A071000	001	Sep 04, 1986
SYMMETREL				
+ ENDO PHARMS	100MG **	N016020	001	
SYRUP;ORAL				
AMANTADINE HYDROCHLORIDE				
G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990
LANNETT CO INC	50MG/5ML	A076352	001	Sep 10, 2004
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006
SYMMETREL				
+ ENDO PHARMS	50MG/5ML **	N016023	002	
TABLET;ORAL				
SYMMETREL				
+ ENDO PHARMS	100MG **	N018101	001	
AMBENONIUM CHLORIDE				
TABLET;ORAL				
MYTELASE				
SANOFI AVENTIS US	10MG	N010155	002	
AMCINONIDE				
CREAM;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.025%	N018116	001	
+	0.1%	N018116	002	
LOTION;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.1%	N019729	001	Jun 13, 1988
OINTMENT;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.1%	N018498	001	
AMDINOCILLIN				
INJECTABLE;INJECTION				
COACTIN				
ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984
	1GM/VIAL	N050565	003	Dec 21, 1984
AMIFOSTINE				
INJECTABLE;INJECTION				
ETHYOL				
CLINIGEN	375MG/VIAL	N020221	002	Sep 10, 1999
AMIKACIN SULFATE				
INJECTABLE;INJECTION				
AMIKACIN SULFATE				
ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993
WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMIKACIN SULFATE				
INJECTABLE;INJECTION				
AMIKIN				
APOTHECON	EQ 50MG BASE/ML	A062311	001	
	EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
+	EQ 50MG BASE/ML **	N050495	001	
	EQ 250MG BASE/ML	A062311	002	
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
+	EQ 250MG BASE/ML **	N050495	002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618	001	Nov 30, 1987
AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
TEVA	EQ 5MG ANHYDROUS;50MG	A070795	001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS;50MG	A073334	001	Jul 19, 1991
YAOPHARMA CO LTD	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991
HYDRO-RIDE				
PAR PHARM	EQ 5MG ANHYDROUS;50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50				
+ MERCK	EQ 5MG ANHYDROUS;50MG **	N018201	001	
AMINO ACIDS				
INJECTABLE;INJECTION				
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE				
HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984
AMINOSYN 10%				
ICU MEDICAL INC	10% (10GM/100ML)	N017673	003	
AMINOSYN 10% (PH6)				
ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985
AMINOSYN 3.5%				
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004	
AMINOSYN 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984
AMINOSYN 5%				
ICU MEDICAL INC	5% (5GM/100ML)	N017673	001	
AMINOSYN 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N017673	002	
AMINOSYN 7% (PH6)				
ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985
AMINOSYN 8.5%				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004	
AMINOSYN 8.5% (PH6)				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985
AMINOSYN II 10%				
ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986
AMINOSYN II 3.5%				
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986
AMINOSYN II 5%				
ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986
AMINOSYN II 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986
AMINOSYN II 8.5%				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986
AMINOSYN-HBC 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985
AMINOSYN-HBC 7% IN PLASTIC CONTAINER				
ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
AMINOSYN-HF 8%				
ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996
AMINOSYN-RF 5.2%				
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001	
BRANCHAMIN 4%				
BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984
FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML) **	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986
	3.5%;25GM/100ML	N019713	006	Sep 09, 1988
HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986
	3.5%;5GM/100ML	N019713	002	Sep 09, 1988
HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986
	4.25%;25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986
	5%;25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML ;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100M L;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019712	001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 003	Dec 16, 1986	
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 002	Nov 01, 1988	

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 002	Oct 23, 1995	

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 003	Oct 23, 1995	

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 004	Oct 23, 1995	

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 005	Oct 23, 1995	

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 001	Oct 23, 1995	

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147 007	Oct 23, 1995	

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147 008	Oct 23, 1995	

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147 009	Oct 23, 1995	

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147 010	Oct 23, 1995	

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147 006	Oct 23, 1995	

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789 003		

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018804 002	May 15, 1984	
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018875 002	Aug 08, 1984	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789 005		

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML	N019493 001	Oct 16, 1986	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

VEINAMINE 8%

HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38 8MG/100ML	N017957 001		

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
AMINOSYN II 10% W/ ELECTROLYTES				
	ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437 004	Apr 03, 1986
AMINOSYN II 7% W/ ELECTROLYTES				
	ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437 006	Apr 03, 1986
AMINOSYN II 8.5% W/ ELECTROLYTES				
	ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437 005	Apr 03, 1986
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC				
INJECTABLE;INJECTION				
AMINOSYN 8.5% W/ELECTROLYTES				
	ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML	N017673 009	Oct 25, 2002
AMINOSYN II 8.5% W/ELECTROLYTES				
	ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML;425MG/100ML	N019437 008	Oct 25, 2002
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE				
INJECTABLE;INJECTION				
AMINOSYN II 3.5% M				
	ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437 007	Apr 03, 1986
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177 001	Oct 23, 1995
TRAVASOL 3.5% W/ ELECTROLYTES				
	BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493 003	
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N020173 001	Oct 27, 1995
TRAVASOL 5.5% W/ ELECTROLYTES				
	BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493 001	
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173 002	Oct 27, 1995
TRAVASOL 8.5% W/ ELECTROLYTES				
	BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493 002	
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
AMINOSYN 7% W/ ELECTROLYTES				
	ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
AMINOSYN 8.5% W/ ELECTROLYTES				
	ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673 005	
AMINOCAPROIC ACID				
INJECTABLE;INJECTION				
AMICAR				
+	CLOVER PHARMS	250MG/ML **	N015229 002	
AMINOCAPROIC ACID				
	ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986
	BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982
	HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988
SYRUP;ORAL				
AMINOCAPROIC ACID				
	AKORN	1.25GM/5ML	A074759 001	Sep 02, 1998
TABLET;ORAL				
AMINOCAPROIC				
	AKORN	500MG	A075602 001	May 24, 2001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOGLUTETHIMIDE				
TABLET;ORAL				
CYTADREN				
NOVARTIS	250MG	N018202	001	
AMINOHIPPURATE SODIUM				
INJECTABLE;INJECTION				
AMINOHIPPURATE SODIUM				
MERCK	20%	N005619	001	
AMINOPHYLLINE				
ENEMA;RECTAL				
SOMOPHYLLIN				
FISONS	300MG/5ML	N018232	001	Apr 02, 1982
INJECTABLE;INJECTION				
AMINOPHYLLIN				
GD SEARLE LLC	25MG/ML	A087243	001	May 24, 1982
	25MG/ML	A087621	001	May 24, 1982
AMINOPHYLLINE				
ABRAXIS PHARM	25MG/ML	A084568	001	
	25MG/ML	A087200	001	
	25MG/ML	A087250	001	Jan 06, 1982
	25MG/ML	A087886	001	Aug 30, 1983
	25MG/ML	A088407	001	Jan 25, 1984
ELKINS SINN	25MG/ML	A087239	001	
HOSPIRA	25MG/ML	A087601	001	Jul 23, 1982
INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982
	25MG/ML	A087867	001	Nov 10, 1983
	25MG/ML	A087868	001	Nov 10, 1983
KING PHARMS	25MG/ML	A086606	001	
LUITPOLD	25MG/ML	A087240	001	
	25MG/ML	A087600	001	
LYPHOMED	25MG/ML	A087431	001	
PHARMA SERVE NY	25MG/ML	A087387	001	Jun 03, 1983
	25MG/ML	A087392	001	Dec 15, 1983
SMITH AND NEPHEW	25MG/ML	A088429	001	May 30, 1985
	25MG/ML	A088749	001	May 30, 1985
TEVA PARENTERAL	25MG/ML	A081142	001	Sep 25, 1991
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100MG/100ML	A088147	002	May 03, 1983
	200MG/100ML	A088147	003	May 03, 1983
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
HOSPIRA	100MG/100ML	N018924	001	Dec 12, 1984
	200MG/100ML	N018924	002	Dec 12, 1984
	400MG/100ML	N018924	003	Dec 12, 1984
	500MG/100ML	N018924	004	Dec 12, 1984
SOLUTION;ORAL				
AMINOPHYLLINE				
MORTON GROVE	105MG/5ML	A088156	001	Dec 05, 1983
ROXANE	105MG/5ML	A088126	001	Aug 19, 1983
AMINOPHYLLINE DYE FREE				
ACTAVIS MID ATLANTIC	105MG/5ML	A087727	001	Apr 16, 1982
SOMOPHYLLIN				
FISONS	105MG/5ML	A086466	001	
SOMOPHYLLIN-DF				
FISONS	105MG/5ML	A087045	001	
SUPPOSITORY;RECTAL				
TRUPHYLLINE				
ACP NIMBLE	250MG	A085498	001	Mar 23, 1983
	500MG	A085498	002	Jan 03, 1983
TABLET;ORAL				
AMINOPHYLLIN				
GD SEARLE LLC	100MG	N002386	002	
	200MG	N002386	003	
AMINOPHYLLINE				
ANI PHARMS INC	100MG	A085261	004	
	200MG	A085261	002	
ASCOT	100MG	A087522	001	Feb 12, 1982
	200MG	A087523	001	Feb 12, 1982
BARR	100MG	A088297	001	Aug 19, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOPHYLLINE				
TABLET;ORAL				
AMINOPHYLLINE				
	200MG		A088298 001	Aug 19, 1983
DURAMED PHARMS BARR	100MG		A088182 001	Mar 31, 1983
	200MG		A088183 001	Mar 31, 1983
HALSEY	100MG		A084674 001	
HIKMA INTL PHARMS	100MG		A084540 001	
	200MG		A085003 001	
IMPAX LABS	100MG		A084574 001	
	200MG		A084576 001	
KV PHARM	100MG		A085284 001	
	200MG		A085289 001	
LANNETT	100MG		A084588 001	
	200MG		A084588 002	
PAL PAK	100MG		A084533 001	
PANRAY	100MG		A084552 001	
	200MG		A084552 002	
PUREPAC PHARM	100MG		A084699 001	
	200MG		A085333 001	
ROXANE	100MG		A087500 001	Feb 09, 1982
	200MG		A087501 001	Feb 09, 1982
VALEANT PHARM INTL	200MG		A084563 001	
VANGARD	100MG		A088314 001	Oct 03, 1983
	200MG		A088319 001	Oct 03, 1983
VINTAGE PHARMS	100MG		A085409 001	
	200MG		A085410 001	
WATSON LABS	100MG		A085567 001	
	200MG		A085564 001	
TABLET, DELAYED RELEASE;ORAL				
AMINOPHYLLINE				
IMPAX LABS	100MG		A084577 001	
	200MG		A084575 001	
TABLICAPS	100MG		A084632 002	
VALE	100MG		A084531 001	
	200MG		A084530 001	
TABLET, EXTENDED RELEASE;ORAL				
PHYLLOCONTIN				
PHARM RES ASSOC	225MG		A086760 001	
AMINOSALICYLATE SODIUM				
POWDER;ORAL				
P.A.S. SODIUM				
CENTURY PHARMS	4GM/PACKET		A080947 001	
SODIUM AMINOSALICYLATE				
HEXCEL	100%		A080097 001	
TABLET;ORAL				
PARASAL SODIUM				
PANRAY	500MG		N006811 006	
	1GM		N006811 011	
SODIUM P.A.S.				
LANNETT	500MG		A080138 002	
TEEBACIN				
CONSOLIDATED MIDLAND	500MG		N007320 002	
AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID				
TABLET;ORAL				
NEOPASALATE				
MEDPOINTE PHARM HLC	846MG;112MG		A080059 002	
AMINOSALICYLIC ACID				
TABLET;ORAL				
PARASAL				
PANRAY	500MG		N006811 001	
	1GM		N006811 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOSALICYLIC ACID RESIN COMPLEX				
POWDER;ORAL				
REZIPAS				
BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM		N009052 001	
AMIODARONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
AMIODARONE HYDROCHLORIDE				
AKORN	50MG/ML		A076232 001	Jul 05, 2006
BEDFORD	50MG/ML		A076018 001	Oct 15, 2002
BEDFORD LABS	50MG/ML		A076299 001	Oct 24, 2002
BEN VENUE	50MG/ML		A076088 001	Oct 15, 2002
DR REDDYS	50MG/ML		A076163 001	Sep 05, 2003
HOSPIRA	50MG/ML		A076108 001	Oct 15, 2002
INTL MEDICATION SYS	50MG/ML		N021594 001	Feb 04, 2004
PAR STERILE PRODUCTS	50MG/ML		A076394 001	Apr 25, 2003
CORDARONE				
+ WYETH PHARMS INC	50MG/ML **		N020377 001	Aug 03, 1995
NEXTERONE				
+ BAXTER HLTHCARE	50MG/ML **		N022325 001	Dec 24, 2008
TABLET;ORAL				
AMIODARONE HYDROCHLORIDE				
MYLAN	200MG		A075188 001	Feb 24, 1999
TEVA	200MG		A074895 001	Apr 16, 1999
CORDARONE				
+ WYETH PHARMS	200MG **		N018972 001	Dec 24, 1985
AMITRIPTYLINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
ENDEP				
ROCHE	40MG/ML		A085749 001	
INJECTABLE;INJECTION				
AMITRIPTYLINE HYDROCHLORIDE				
WATSON LABS	10MG/ML		A085594 001	
ELAVIL				
ASTRAZENECA	10MG/ML		N012704 001	
TABLET;ORAL				
AMITID				
BRISTOL MYERS SQUIBB	10MG		A086454 001	
	25MG		A086454 002	
	50MG		A086454 003	
	75MG		A086454 004	
	100MG		A086454 005	
AMITRIL				
WARNER CHILCOTT	10MG		A083939 001	
	25MG		A083937 001	
	50MG		A083938 002	
	75MG		A084957 001	
	100MG		A085093 001	
	150MG		A086295 001	
AMITRIPTYLINE HYDROCHLORIDE				
AM THERAP	25MG		A088672 001	Nov 20, 1984
	50MG		A088673 001	Nov 20, 1984
	75MG		A088674 001	Nov 20, 1984
	100MG		A088675 001	Nov 20, 1984
ANI PHARMS INC	10MG		A085031 002	
	25MG		A085031 001	
	50MG		A085031 003	
	75MG		A085031 004	
COPLEY PHARM	10MG		A088421 001	Apr 30, 1984
	25MG		A088422 001	Apr 30, 1984
	50MG		A088423 001	Apr 30, 1984
	75MG		A088424 001	Apr 30, 1984
	100MG		A088425 001	Apr 30, 1984
	150MG		A088426 001	Apr 30, 1984
HALSEY	10MG		A085923 001	
	25MG		A085922 001	
	50MG		A085925 001	
	50MG		A087557 001	Mar 05, 1982
	75MG		A085926 001	May 20, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	100MG	A085927 001	May 20, 1983
LEDERLE	10MG	A086744 001	
	10MG	A087366 001	Jan 04, 1982
	25MG	A086746 001	
	25MG	A087367 001	May 03, 1982
	50MG	A086743 001	
	50MG	A087181 001	Jan 04, 1982
	75MG	A086745 001	
	75MG	A087369 001	Jan 04, 1982
	100MG	A086747 001	
	100MG	A087368 001	May 03, 1982
	150MG	A087370 001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744 001	
	25MG	A085627 001	
	50MG	A085745 001	
	75MG	A085743 001	
	100MG	A085742 002	May 11, 1982
	150MG	A089423 001	Feb 17, 1987
PAR PHARM	10MG	A088697 001	Sep 25, 1984
	25MG	A088698 001	Sep 25, 1984
	50MG	A088699 001	Sep 25, 1984
	75MG	A088700 001	Sep 25, 1984
	100MG	A088701 001	Sep 25, 1984
	150MG	A088702 001	Sep 25, 1984
PLIVA	10MG	A088883 001	Sep 26, 1984
	25MG	A088884 001	Sep 26, 1984
	50MG	A088885 001	Sep 26, 1984
	75MG	A088886 001	Sep 26, 1984
	100MG	A088887 001	Sep 26, 1984
	150MG	A088888 001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075 001	Sep 16, 1983
	10MG	A088084 001	Jul 18, 1983
	25MG	A088076 001	May 20, 1983
	25MG	A088085 001	Jul 18, 1983
	50MG	A088077 001	Sep 16, 1983
	50MG	A088105 001	Jul 18, 1983
	75MG	A088078 001	Sep 16, 1983
	75MG	A088106 001	Jul 18, 1983
	100MG	A088079 001	Sep 16, 1983
	100MG	A088107 001	Jul 18, 1983
ROXANE	10MG	A086002 001	
	10MG	A086144 001	
	25MG	A085944 001	
	25MG	A086145 001	
	50MG	A085945 001	
	50MG	A086143 001	
	75MG	A086004 001	
	75MG	A086147 001	
	100MG	A086003 001	
	100MG	A086146 001	
	150MG	A086090 001	
	150MG	A086148 001	
SUN PHARM INDS INC	10MG	A040816 002	Jun 27, 2008
	25MG	A040816 001	Jun 27, 2008
	50MG	A040816 003	Jun 27, 2008
	75MG	A040816 004	Jun 27, 2008
	100MG	A040816 005	Jun 27, 2008
	150MG	A040816 006	Jun 27, 2008
SUPERPHARM	10MG	A088853 001	Nov 13, 1984
	25MG	A088854 001	Nov 13, 1984
	50MG	A088855 001	Nov 13, 1984
	75MG	A088856 001	Nov 13, 1984
	100MG	A088857 001	Nov 13, 1984
TEVA	10MG	A086610 001	
	25MG	A086859 001	
	50MG	A086857 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	75MG	A086860 001		
	100MG	A085836 001		
	100MG	A086854 001		
	150MG	A086853 001		
UCB INC	10MG	A085864 001		
	25MG	A085935 001		
	50MG	A085936 001		
	75MG	A086337 001		
	100MG	A086336 001		
	150MG	A086335 001		
USL PHARMA	25MG	A087775 001	Feb 10, 1982	
VANGARD	10MG	A087632 001	Feb 01, 1982	
	50MG	A087616 001	Feb 08, 1982	
	75MG	A087617 001	Feb 05, 1982	
	100MG	A087639 001	Feb 08, 1982	
WATSON LABS	10MG	A085816 001		
	10MG	A088620 001	Mar 02, 1984	
	25MG	A085817 001		
	25MG	A088621 001	Mar 02, 1984	
	50MG	A085815 001		
	50MG	A088622 001	Mar 02, 1984	
	75MG	A085819 001		
	75MG	A088633 001	Mar 02, 1984	
	100MG	A085820 001		
	100MG	A088634 001	Mar 02, 1984	
	150MG	A085821 001		
	150MG	A088635 001	Mar 02, 1984	
WEST WARD	10MG	A087647 001	Mar 05, 1982	
	25MG	A087278 001		

ELAVIL

+ ASTRAZENECA	10MG **	N012703 001		
+	25MG **	N012703 003		
+	50MG **	N012703 004		
+	75MG **	N012703 005		
+	100MG **	N012703 006		
+	150MG **	N012703 007		

ENDEP

ROCHE	10MG	A083639 001		
	25MG	A083639 002		
	50MG	A083639 003		
	75MG	A083639 004		
	100MG	A083639 005		
	150MG	A085303 001		

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986	
	EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986	
HERITAGE PHARMA	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988	
	EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988	
PAR PHARM	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988	
	EQ 25MG BASE;10MG	A072278 001	May 09, 1988	
USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988	
	EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988	

LIMBITROL

+ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG **	N016949 001		

LIMBITROL DS

+ HERITAGE PHARMS INC	EQ 25MG BASE;10MG **	N016949 002		

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

ETRAFON 2-10

SCHERING	10MG;2MG **	N014713 007		

ETRAFON 2-25

SCHERING	25MG;2MG **	N014713 004		

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE				
TABLET;ORAL				
ETRAFON-A				
SCHERING	10MG;4MG **	N014713	002	
ETRAFON-FORTE				
SCHERING	25MG;4MG **	N014713	006	
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE				
FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987
	10MG;4MG	A071862	001	Dec 21, 1987
	25MG;2MG	A071063	001	Nov 27, 1987
	25MG;4MG	A071064	001	Nov 27, 1987
	50MG;4MG	A071863	001	Dec 21, 1987
HERITAGE PHARMA	10MG;2MG	A073007	001	Oct 17, 1991
	10MG;4MG	A073009	001	Oct 17, 1991
	25MG;2MG	A073008	001	Oct 17, 1991
	25MG;4MG	A073010	001	Oct 17, 1991
IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
	10MG;4MG	A070937	001	Sep 11, 1986
	25MG;2MG	A070936	001	Sep 11, 1986
	25MG;4MG	A070938	001	Sep 11, 1986
	50MG;4MG	A070939	001	Sep 12, 1986
PAR PHARM	10MG;2MG	A070565	001	Sep 11, 1986
	10MG;4MG	A070620	001	Sep 11, 1986
	25MG;2MG	A070621	001	Sep 11, 1986
	25MG;4MG	A070595	001	Sep 11, 1986
	50MG;4MG	A070574	001	Sep 11, 1986
SUN PHARM INDUSTRIES	10MG;2MG	A071077	001	Nov 12, 1986
	10MG;4MG	A071078	001	Nov 12, 1986
	25MG;2MG	A070297	001	Nov 12, 1986
	25MG;4MG	A071079	001	Nov 12, 1986
WATSON LABS	10MG;2MG	A070373	001	Aug 25, 1986
	10MG;2MG	A072539	001	Feb 15, 1989
	10MG;4MG	A070375	001	Aug 25, 1986
	10MG;4MG	A072540	001	Feb 15, 1989
	25MG;2MG	A070374	001	Aug 25, 1986
	25MG;2MG	A072541	001	Feb 15, 1989
	25MG;4MG	A070376	001	Aug 25, 1986
	25MG;4MG	A072134	001	Feb 15, 1989
	50MG;4MG	A070377	001	Nov 04, 1986
	50MG;4MG	A071558	001	Mar 02, 1987
	50MG;4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10				
NEW RIVER	10MG;2MG **	N014715	004	
TRIAVIL 2-25				
NEW RIVER	25MG;2MG **	N014715	002	
TRIAVIL 4-10				
NEW RIVER	10MG;4MG **	N014715	003	
TRIAVIL 4-25				
NEW RIVER	25MG;4MG **	N014715	005	
TRIAVIL 4-50				
NEW RIVER	50MG;4MG **	N014715	006	
AMLEXANOX				
PASTE;DENTAL				
APHTHASOL				
ULURU	5%	N020511	001	Dec 17, 1996
PATCH;TOPICAL				
AMLEXANOX				
ULURU	2MG	N021727	001	Sep 29, 2004
AMLODIPINE BESYLATE				
TABLET;ORAL				
AMLODIPINE BESYLATE				
AMNEAL PHARMS NY	EQ 2.5MG BASE	A078477	001	Jan 16, 2008
	EQ 5MG BASE	A078477	002	Jan 16, 2008
	EQ 10MG BASE	A078477	003	Jan 16, 2008
GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007
	EQ 5MG BASE	A077333	002	Jul 17, 2007
	EQ 10MG BASE	A077333	003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362	001	Jul 09, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	EQ 5MG BASE	A077362	002	Jul 09, 2007
	EQ 10MG BASE	A077362	003	Jul 09, 2007
MYLAN	EQ 2.5MG BASE	A078224	001	Feb 27, 2008
	EQ 5MG BASE	A078224	002	Feb 27, 2008
	EQ 10MG BASE	A078224	003	Feb 27, 2008
PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007
	EQ 5MG BASE	A078131	002	Sep 04, 2007
	EQ 10MG BASE	A078131	003	Sep 04, 2007
SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015
	EQ 5MG BASE	A204900	002	Jul 23, 2015
	EQ 10MG BASE	A204900	003	Jul 23, 2015
SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007
	EQ 5MG BASE	A078231	002	Nov 30, 2007
	EQ 10MG BASE	A078231	003	Nov 30, 2007
SUN PHARM INDUSTRIES	EQ 2.5MG BASE	A078081	001	Jan 31, 2008
	EQ 5MG BASE	A078081	002	Jan 31, 2008
	EQ 10MG BASE	A078081	003	Jan 31, 2008
SUNSHINE LAKE	EQ 2.5MG BASE	A206524	001	May 04, 2018
	EQ 5MG BASE	A206524	002	May 04, 2018
	EQ 10MG BASE	A206524	003	May 04, 2018
SYNTHON PHARMS	EQ 2.5MG BASE	A077080	001	Jun 27, 2007
	EQ 5MG BASE	A077080	002	Jun 27, 2007
	EQ 10MG BASE	A077080	003	Jun 27, 2007
TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007
	EQ 5MG BASE	A076846	002	Jun 28, 2007
	EQ 10MG BASE	A076846	003	Jun 28, 2007
YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007
	EQ 5MG BASE	A076859	002	Sep 10, 2007
	EQ 10MG BASE	A076859	003	Sep 10, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007
	EQ 5MG BASE	N022026	002	Sep 27, 2007
	EQ 10MG BASE	N022026	003	Sep 27, 2007

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019
	EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019
	EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019
	EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019
	EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019
	EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019
	EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019
	EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019
	EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019
	EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019
	EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018
	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018
	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018
	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018
MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010
	EQ 5MG BASE;10MG	A077375	002	May 21, 2010
	EQ 5MG BASE;20MG	A077375	003	May 21, 2010
	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011
	EQ 10MG BASE;20MG	A077375	004	May 21, 2010
	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011
TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007
	EQ 5MG BASE;10MG	A077179	002	May 18, 2007
	EQ 5MG BASE;20MG	A077179	003	May 18, 2007
	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE				
CAPSULE;ORAL				
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE				
	EQ 10MG BASE;20MG		A077179 004	May 18, 2007
	EQ 10MG BASE;40MG		A077179 006	Jul 05, 2011
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL				
TABLET;ORAL				
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE				
TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG		A202491 001	Nov 03, 2016
	EQ 5MG BASE;12.5MG;40MG		A202491 002	Nov 03, 2016
	EQ 5MG BASE;25MG;40MG		A202491 003	Nov 03, 2016
	EQ 10MG BASE;12.5MG;40MG		A202491 004	Nov 03, 2016
	EQ 10MG BASE;25MG;40MG		A202491 005	Nov 03, 2016
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN				
TABLET;ORAL				
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE				
TEVA PHARMS	5MG;12.5MG;160MG		A200435 001	Sep 25, 2012
	5MG;25MG;160MG		A200435 002	Sep 25, 2012
	10MG;12.5MG;160MG		A200435 005	Sep 25, 2012
	10MG;25MG;160MG		A200435 003	Sep 25, 2012
	10MG;25MG;320MG		A200435 004	Sep 25, 2012
TORRENT	5MG;12.5MG;160MG		A201593 001	Jun 03, 2015
	5MG;25MG;160MG		A201593 002	Jun 03, 2015
	10MG;12.5MG;160MG		A201593 003	Jun 03, 2015
	10MG;25MG;160MG		A201593 004	Jun 03, 2015
	10MG;25MG;320MG		A201593 005	Jun 03, 2015
AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL				
TABLET;ORAL				
AMLODIPINE AND OLMESARTAN MEDOXOMIL				
ACCORD HLTHCARE INC	EQ 5MG BASE;20MG		A209600 001	Aug 30, 2018
	EQ 5MG BASE;40MG		A209600 003	Aug 30, 2018
	EQ 10MG BASE;20MG		A209600 002	Aug 30, 2018
	EQ 10MG BASE;40MG		A209600 004	Aug 30, 2018
TEVA PHARMS USA	EQ 5MG BASE;20MG		A091154 001	Oct 26, 2016
	EQ 5MG BASE;40MG		A091154 002	Oct 26, 2016
	EQ 10MG BASE;20MG		A091154 003	Oct 26, 2016
	EQ 10MG BASE;40MG		A091154 004	Oct 26, 2016
AMLODIPINE BESYLATE; VALSARTAN				
TABLET;ORAL				
AMLODIPINE BESYLATE AND VALSARTAN				
TEVA PHARMS USA	EQ 5MG BASE;160MG		A091235 001	Mar 30, 2015
	EQ 5MG BASE;320MG		A091235 003	Mar 30, 2015
	EQ 10MG BASE;160MG		A091235 002	Mar 30, 2015
	EQ 10MG BASE;320MG		A091235 004	Mar 30, 2015
TORRENT	EQ 5MG BASE;160MG		A202377 001	Mar 30, 2015
	EQ 5MG BASE;320MG		A202377 002	Mar 30, 2015
	EQ 10MG BASE;160MG		A202377 003	Mar 30, 2015
	EQ 10MG BASE;320MG		A202377 004	Mar 30, 2015
AMLODIPINE MALEATE				
TABLET;ORAL				
AMVAZ				
DR REDDYS LABS INC	2.5MG		N021435 001	Oct 31, 2003
	5MG		N021435 002	Oct 31, 2003
	10MG		N021435 003	Oct 31, 2003
AMMONIA N-13				
INJECTABLE;INTRAVENOUS				
AMMONIA N 13				
CENTRAL RADIOPHARM	3.75-260mCi/ML		A204539 001	Jun 23, 2015
UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A203933 001	Jun 27, 2014
AMMONIUM CHLORIDE				
INJECTABLE;INJECTION				
AMMONIUM CHLORIDE				
ABBOTT	5MEQ/ML		A083130 001	
GD SEARLE LLC	3MEQ/ML		A086205 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMMONIUM CHLORIDE				
INJECTABLE;INJECTION				
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE				
MCGAW	900MG/100ML		N006580 001	
AMMONIUM CHLORIDE 2.14%				
B BRAUN	40MEQ/100ML		A085734 001	
AMMONIUM LACTATE				
CREAM;TOPICAL				
LAC-HYDRIN				
SUN PHARM INDS INC	EQ 12% BASE **		N020508 001	Aug 29, 1996
LOTION;TOPICAL				
LAC-HYDRIN				
+ SUN PHARM INDS INC	EQ 12% BASE **		N019155 001	Apr 24, 1985
AMODIAQUINE HYDROCHLORIDE				
TABLET;ORAL				
CAMOQUIN HYDROCHLORIDE				
PARKE DAVIS	EQ 200MG BASE		N006441 001	
AMOXAPINE				
TABLET;ORAL				
AMOXAPINE				
UPSHER SMITH LABS	25MG		A072943 001	Jun 28, 1991
	50MG		A072944 001	Jun 28, 1991
	100MG		A072878 001	Jun 28, 1991
	150MG		A072879 001	Jun 28, 1991
WATSON PHARMS TEVA	25MG		A072418 001	Aug 01, 1989
	50MG		A072419 001	Aug 01, 1989
	100MG		A072420 001	May 11, 1989
	150MG		A072421 001	May 11, 1989
ASENDIN				
LEDERLE	25MG		N018021 001	
	50MG		N018021 002	
	100MG		N018021 003	
	150MG		N018021 004	
AMOXICILLIN				
CAPSULE;ORAL				
AMOXICILLIN				
LABS ATRAL	250MG		A062528 001	Aug 07, 1985
	500MG		A062528 002	Aug 07, 1985
MYLAN	250MG		A062067 001	
	500MG		A062067 002	
SUN PHARM INDS LTD	250MG		A065016 001	Apr 08, 1999
	500MG		A065016 002	Apr 08, 1999
TEVA	250MG		A062853 001	Dec 22, 1987
	250MG		A063030 001	Feb 28, 1989
	500MG		A062854 001	Dec 22, 1987
	500MG		A063031 001	Feb 28, 1989
AMOXIL				
+ GLAXOSMITHKLINE	250MG **		N050459 001	
+	500MG **		N050459 002	
TRIMOX				
APOTHECON	250MG		A061885 001	
	250MG		A062098 001	
	250MG		A062152 001	
	250MG		A063099 001	Mar 20, 1992
	500MG		A061885 002	
	500MG		A062098 002	
	500MG		A062152 002	
	500MG		A063099 002	Mar 20, 1992
UTIMOX				
PARKE DAVIS	250MG		A062107 001	
	500MG		A062107 002	
WYMOX				
WYETH AYERST	250MG		A062120 001	
	500MG		A062120 002	
FOR SUSPENSION;ORAL				
AMOXICILLIN				
AM ANTIBIOTICS	125MG/5ML		A062059 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN					
		250MG/5ML	A062059	002	
	MYLAN	125MG/5ML	A062090	001	
		250MG/5ML	A062090	002	
	SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002
		400MG/5ML	A065113	002	Nov 29, 2002
	TEVA	125MG/5ML	A061931	001	
		125MG/5ML	A062946	001	Nov 01, 1988
		250MG/5ML	A063001	001	Jan 06, 1989
AMOXIL					
+	GLAXOSMITHKLINE	50MG/ML **	N050460	005	
+		125MG/5ML **	N050460	001	
+		250MG/5ML **	N050460	002	
+	NEOPHARMA	200MG/5ML **	N050760	001	Apr 15, 1999
+		400MG/5ML **	N050760	002	Apr 15, 1999
LAROTID					
+	GLAXOSMITHKLINE	50MG/ML **	N050460	006	
POLYMOX					
	APOTHECON	125MG/5ML	A061851	001	
		125MG/5ML	A062323	001	
		250MG/5ML	A061851	002	
		250MG/5ML	A062323	002	
TRIMOX					
	APOTHECON	50MG/ML	A061886	001	
		125MG/5ML	A061886	002	
		125MG/5ML	A062099	001	
		125MG/5ML	A062154	001	
		125MG/5ML	A062885	001	Mar 08, 1988
		250MG/5ML	A061886	003	
		250MG/5ML	A062099	002	
		250MG/5ML	A062154	002	
		250MG/5ML	A062885	002	Mar 08, 1988
UTIMOX					
	PARKE DAVIS	125MG/5ML	A062127	001	
		250MG/5ML	A062127	002	
WYMOX					
	WYETH AYERST	125MG/5ML	A062131	001	
		250MG/5ML	A062131	002	

TABLET;ORAL

AMOXICILLIN					
	DAVA PHARMS INC	875MG	A065344	001	Jan 15, 2009
	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000
		875MG	A065059	002	Nov 24, 2000
AMOXIL					
+	NEOPHARMA	500MG **	N050754	002	Jul 10, 1998
+		875MG **	N050754	001	Jul 10, 1998

TABLET, CHEWABLE;ORAL

AMOXICILLIN					
	APOTHECON	125MG	A064131	001	May 06, 1996
		250MG	A064131	002	May 06, 1996
	DAVA PHARMS INC	125MG	A064139	001	Jan 29, 1996
		250MG	A064139	002	Jan 29, 1996
	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999
		200MG	A065060	001	Nov 29, 2000
		250MG	A065021	002	Dec 23, 1999
		400MG	A065060	002	Nov 29, 2000
	TEVA	125MG	A064031	001	Dec 19, 1996
		250MG	A064031	002	Dec 19, 1996
AMOXIL					
+	NEOPHARMA	125MG **	N050542	002	
		200MG	N050761	001	Apr 15, 1999
+		250MG **	N050542	001	
		400MG	N050761	002	Apr 15, 1999

TABLET, EXTENDED RELEASE;ORAL

MOXATAG					
+	PRAGMA	775MG	N050813	001	Jan 23, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXICILLIN				
TABLET, FOR SUSPENSION;ORAL				
AMOXICILLIN				
AUROBINDO PHARMA LTD	200MG		A065324 001	Jan 17, 2007
	400MG		A065324 002	Jan 17, 2007
DISPERMOX				
RANBAXY LABS LTD	200MG		A065080 002	Aug 11, 2003
	400MG		A065080 001	Aug 11, 2003
	600MG		A065159 001	Dec 04, 2003
AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE				
CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL				
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN				
ANI PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG		A200218 001	Aug 30, 2013
PREVPAC				
+ TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG		N050757 001	Dec 02, 1997
AMOXICILLIN; CLAVULANATE POTASSIUM				
FOR SUSPENSION;ORAL				
AMOXICILLIN AND CLAVULANATE POTASSIUM				
SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML		A065132 001	Mar 19, 2003
	400MG/5ML;EQ 57MG BASE/5ML		A065132 002	Mar 19, 2003
	600MG/5ML;EQ 42.9MG BASE/5ML		A065207 002	Jan 30, 2007
AUGMENTIN '200'				
+ NEOPHARMA	200MG/5ML;EQ 28.5MG BASE/5ML		N050725 001	May 31, 1996
AUGMENTIN '400'				
+ NEOPHARMA	400MG/5ML;EQ 57MG BASE/5ML		N050725 002	May 31, 1996
AUGMENTIN ES-600				
+ NEOPHARMA	600MG/5ML;EQ 42.9MG BASE/5ML		N050755 001	Jun 22, 2001
TABLET;ORAL				
AMOXICILLIN AND CLAVULANATE POTASSIUM				
APOTEX INC	250MG;EQ 125MG BASE		A065333 001	Feb 24, 2009
	500MG;EQ 125MG BASE		A065333 002	Feb 24, 2009
	875MG;EQ 125MG BASE		A065317 003	Oct 20, 2008
SUN PHARM INDS LTD	500MG;EQ 125MG BASE		A065109 001	Nov 04, 2002
	875MG;EQ 125MG BASE		A065102 001	Sep 17, 2002
AUGMENTIN '250'				
+ NEOPHARMA	250MG;EQ 125MG BASE **		N050564 001	Aug 06, 1984
AUGMENTIN '500'				
+ NEOPHARMA	500MG;EQ 125MG BASE **		N050564 002	Aug 06, 1984
TABLET, CHEWABLE;ORAL				
AMOXICILLIN AND CLAVULANATE POTASSIUM				
SANDOZ	200MG;EQ 28.5MG BASE		A065065 001	Apr 18, 2002
	400MG;EQ 57MG BASE		A065065 002	Apr 18, 2002
SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE		A065161 001	Dec 03, 2003
	400MG;EQ 57MG BASE		A065161 002	Dec 03, 2003
AUGMENTIN '125'				
+ NEOPHARMA	125MG;EQ 31.25MG BASE **		N050597 001	Jul 22, 1985
AUGMENTIN '200'				
+ NEOPHARMA	200MG;EQ 28.5MG BASE		N050726 001	May 31, 1996
AUGMENTIN '250'				
+ NEOPHARMA	250MG;EQ 62.5MG BASE **		N050597 002	Jul 22, 1985
AUGMENTIN '400'				
+ NEOPHARMA	400MG;EQ 57MG BASE		N050726 002	May 31, 1996
AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE				
CAPSULE;ORAL				
DELCOBESE				
TEVA	1.25MG;1.25MG;1.25MG;1.25MG **		A083564 001	
	2.5MG;2.5MG;2.5MG;2.5MG **		A083564 002	
	3.75MG;3.75MG;3.75MG;3.75MG **		A083564 003	
	5MG;5MG;5MG;5MG **		A083564 004	
TABLET;ORAL				
DELCOBESE				
TEVA	1.25MG;1.25MG;1.25MG;1.25MG		A083563 004	
	2.5MG;2.5MG;2.5MG;2.5MG		A083563 003	
	3.75MG;3.75MG;3.75MG;3.75MG		A083563 002	
	5MG;5MG;5MG;5MG		A083563 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE					
CAPSULE, EXTENDED RELEASE;ORAL					
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019
		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019
		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019
		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019
		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019
		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019
TABLET;ORAL					
ADDERALL 10					
+	TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **	N011522	007	Feb 13, 1996
ADDERALL 12.5					
+	TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG **	N011522	012	Aug 31, 2000
ADDERALL 15					
+	TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **	N011522	013	Aug 31, 2000
ADDERALL 20					
+	TEVA WOMENS	5MG;5MG;5MG;5MG **	N011522	008	Feb 13, 1996
ADDERALL 30					
+	TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **	N011522	010	May 12, 1997
ADDERALL 5					
+	TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **	N011522	009	May 12, 1997
ADDERALL 7.5					
+	TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG **	N011522	011	Aug 31, 2000
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003
		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003
		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003
		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003
	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003
		2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003
		5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003
		7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003
AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX					
CAPSULE, EXTENDED RELEASE;ORAL					
BIPHETAMINE 12.5					
	UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093	007	
BIPHETAMINE 20					
	UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093	003	
BIPHETAMINE 7.5					
	UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093	009	
AMPHETAMINE SULFATE					
TABLET;ORAL					
AMPHETAMINE SULFATE					
	LANNETT	5MG	A083901	001	Aug 31, 1984
		10MG	A083901	002	Aug 31, 1984
AMPHOTERICIN B					
CREAM;TOPICAL					
FUNGIZONE					
	APOTHECON	3%	N050314	001	
INJECTABLE;INJECTION					
AMPHOTERICIN B					
	ABBOTT	50MG/VIAL	A064141	001	Dec 23, 1996
	ABRAXIS PHARM	50MG/VIAL	A062728	001	Apr 13, 1987
	TEVA PARENTERAL	50MG/VIAL	A064062	001	Mar 31, 1995
FUNGIZONE					
	APOTHECON	50MG/VIAL	A060517	001	
INJECTABLE, LIPID COMPLEX;INJECTION					
AMPHOTEC					
	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996
		100MG/VIAL	N050729	002	Nov 22, 1996
LOTION;TOPICAL					
FUNGIZONE					
	APOTHECON	3%	A060570	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPHOTERICIN B				
OINTMENT;TOPICAL				
FUNGIZONE				
APOTHECON	3%	N050313	001	
SUSPENSION;ORAL				
FUNGIZONE				
BRISTOL MYERS SQUIBB	100MG/ML	N050341	003	
AMPICILLIN SODIUM				
INJECTABLE;INJECTION				
AMPICILLIN SODIUM				
ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884	001	Apr 03, 2013
	EQ 1GM BASE/VIAL	A090884	002	Apr 03, 2013
	EQ 2GM BASE/VIAL	A090884	003	Apr 03, 2013
APOTHECON	EQ 125MG BASE/VIAL	A062860	001	Feb 05, 1988
	EQ 250MG BASE/VIAL	A062860	002	Feb 05, 1988
	EQ 500MG BASE/VIAL	A062860	003	Feb 05, 1988
	EQ 1GM BASE/VIAL	A062860	004	Feb 05, 1988
	EQ 2GM BASE/VIAL	A062860	005	Feb 05, 1988
AUROBINDO PHARMA	EQ 125MG BASE/VIAL	A065499	001	Aug 17, 2010
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	A061936	005	
	EQ 250MG BASE/VIAL	A061936	001	
	EQ 500MG BASE/VIAL	A061936	002	
	EQ 1GM BASE/VIAL	A061936	003	
	EQ 2GM BASE/VIAL	A061936	004	
HANFORD GC	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993
	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993
	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993
	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993
HOSPIRA INC	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015
	EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015
	EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015
	EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015
	EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015
INTL MEDICATION	EQ 1GM BASE/VIAL	A062634	002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634	003	Jan 09, 1987
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993
LILLY	EQ 500MG BASE/VIAL	A062565	001	Apr 04, 1985
	EQ 1GM BASE/VIAL	A062565	002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565	003	Jun 24, 1986
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816	001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816	002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816	003	Oct 24, 1988
	EQ 1GM BASE/VIAL	A062816	004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816	005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994	001	Sep 15, 1988
WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986
	EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986
OMNIPEN-N				
WYETH AYERST	EQ 125MG BASE/VIAL	A060626	001	
	EQ 125MG BASE/VIAL	A062718	001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626	002	
	EQ 250MG BASE/VIAL	A062718	002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626	003	
	EQ 500MG BASE/VIAL	A062718	003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626	004	
	EQ 1GM BASE/VIAL	A062718	004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626	005	
	EQ 2GM BASE/VIAL	A062718	005	Dec 16, 1986
PENBRITIN-S				
+ WYETH AYERST	EQ 125MG BASE/VIAL **	N050072	001	
+	EQ 250MG BASE/VIAL **	N050072	002	
+	EQ 500MG BASE/VIAL **	N050072	003	
+	EQ 1GM BASE/VIAL **	N050072	004	
+	EQ 2GM BASE/VIAL **	N050072	005	
+	EQ 4GM BASE/VIAL **	N050072	006	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN SODIUM				
INJECTABLE;INJECTION				
POLYCILLIN-N				
BRISTOL	EQ 125MG BASE/VIAL **	N050309	001	
	EQ 250MG BASE/VIAL **	N050309	002	
	EQ 500MG BASE/VIAL **	N050309	003	
	EQ 1GM BASE/VIAL **	N050309	004	
	EQ 2GM BASE/VIAL **	N050309	005	
TOTACILLIN-N				
GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677	001	
	EQ 250MG BASE/VIAL	A060677	002	
	EQ 500MG BASE/VIAL	A060677	003	
	EQ 1GM BASE/VIAL	A060677	004	
	EQ 1GM BASE/VIAL	A062727	001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677	005	
	EQ 2GM BASE/VIAL	A062727	002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677	006	
AMPICILLIN SODIUM; SULBACTAM SODIUM				
INJECTABLE;INJECTION				
AMPICILLIN AND SULBACTAM				
HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011
	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011
MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007
UNASYN				
PFIZER	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608	003	Dec 31, 1986
AMPICILLIN/AMPICILLIN TRIHYDRATE				
CAPSULE;ORAL				
AMCILL				
PARKE DAVIS	EQ 250MG BASE	A062041	001	
	EQ 500MG BASE	A062041	002	
AMPICILLIN TRIHYDRATE				
AM ANTIBIOTICS	EQ 250MG BASE	A061602	001	
	EQ 500MG BASE	A061602	002	
HERITAGE PHARMA	EQ 250MG BASE	A061502	001	
	EQ 500MG BASE	A061502	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765	001	
	EQ 500MG BASE	A060765	002	
LEDERLE	EQ 250MG BASE	A062208	001	
	EQ 500MG BASE	A062208	002	
MYLAN	EQ 250MG BASE	A061755	001	
	EQ 500MG BASE	A061755	002	
PUREPAC PHARM	EQ 250MG BASE	A061853	001	
	EQ 500MG BASE	A061853	002	
VITARINE	EQ 250MG BASE	A061387	001	
	EQ 500MG BASE	A061387	003	
OMNIPEN (AMPICILLIN)				
WYETH AYERST	250MG	A060624	001	
	500MG	A060624	002	
PENBRITIN				
WYETH AYERST	EQ 250MG BASE	A060908	001	
	EQ 500MG BASE	A060908	002	
PFIZERPEN-A				
PFIZER	EQ 250MG BASE	A062050	001	
	EQ 500MG BASE	A062050	002	
POLYCILLIN				
BRISTOL	EQ 250MG BASE	N050310	001	
	EQ 500MG BASE	N050310	002	
PRINCIPEN				
APOTHECON	EQ 250MG BASE	A062888	001	Mar 04, 1988
	EQ 500MG BASE	A062888	002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392	001	
	EQ 500MG BASE	A061392	002	
PRINCIPEN '250'				
APOTHECON	EQ 250MG BASE	A062157	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL			
PRINCIPEN '250'			
		EQ 250MG BASE	N050056 001
PRINCIPEN '500'			
	APOTHECON	EQ 500MG BASE	A062157 001
		EQ 500MG BASE	N050056 002
TOTACILLIN			
	GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001
		EQ 250MG BASE	A062212 001
		EQ 500MG BASE	A060060 002
		EQ 500MG BASE	A062212 002
FOR SUSPENSION;ORAL			
AMCILL			
	PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001
		EQ 250MG BASE/5ML	A062030 002
AMPICILLIN TRIHYDRATE			
	AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061601 001
		EQ 250MG BASE/5ML	A061601 002
	MYLAN	EQ 125MG BASE/5ML	A061829 002
		EQ 250MG BASE/5ML	A061829 001
	PUREPAC PHARM	EQ 125MG BASE/5ML	A061980 001
		EQ 250MG BASE/5ML	A061980 002
	TEVA	EQ 125MG BASE/5ML	A061370 001
		EQ 250MG BASE/5ML	A061370 002
OMNIPEN (AMPICILLIN)			
	WYETH AYERST	100MG/ML	A060625 001
		125MG/5ML	A060625 002
		250MG/5ML	A060625 003
		500MG/5ML	A060625 004
PENBRITIN			
	WYETH AYERST	EQ 100MG BASE/ML	N050019 001
		EQ 125MG BASE/5ML	N050019 002
		EQ 250MG BASE/5ML	N050019 003
PFIZERPEN-A			
	PFIZER	EQ 125MG BASE/5ML	A062049 001
		EQ 250MG BASE/5ML	A062049 002
POLYCILLIN			
	APOTHECON	EQ 125MG BASE/5ML	A062297 001
		EQ 250MG BASE/5ML	A062297 002
	BRISTOL	EQ 100MG BASE/ML	N050308 004
		EQ 125MG BASE/5ML	N050308 001
		EQ 250MG BASE/5ML	N050308 002
		EQ 500MG BASE/5ML	N050308 003
PRINCIPEN			
	APOTHECON	EQ 100MG BASE/ML	A061394 001
		EQ 125MG BASE/5ML	A061394 002
		EQ 250MG BASE/5ML	A061394 003
PRINCIPEN '125'			
	APOTHECON	EQ 125MG BASE/5ML	A060127 002
		EQ 125MG BASE/5ML	A062151 001
PRINCIPEN '250'			
	APOTHECON	EQ 250MG BASE/5ML	A060127 001
		EQ 250MG BASE/5ML	A062151 002
TOTACILLIN			
	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666 001
		EQ 125MG BASE/5ML	A062223 001
		EQ 250MG BASE/5ML	A060666 002
		EQ 250MG BASE/5ML	A062223 002
TABLET, CHEWABLE;ORAL			
POLYCILLIN			
	BRISTOL	EQ 125MG BASE	N050093 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL			
PRINCIPEN W/ PROBENECID			
	APOTHECON	EQ 389MG BASE;111MG	A062150 001
		EQ 389MG BASE;111MG	N050488 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID				
FOR SUSPENSION;ORAL				
POLYCILLIN-PRB				
APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898	001	
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457	001	
PROBAMPACIN				
ACP NIMBLE	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001	
AMPRENAVIR				
CAPSULE;ORAL				
AGENERASE				
GLAXOSMITHKLINE	50MG	N021007	001	Apr 15, 1999
	150MG	N021007	002	Apr 15, 1999
SOLUTION;ORAL				
AGENERASE				
+ GLAXOSMITHKLINE	15MG/ML **	N021039	001	Apr 15, 1999
ANAGRELIDE HYDROCHLORIDE				
CAPSULE;ORAL				
AGRYLIN				
+ SHIRE LLC	EQ 1MG BASE **	N020333	002	Mar 14, 1997
ANAGRELIDE HYDROCHLORIDE				
MYLAN	EQ 0.5MG BASE	A076811	001	Apr 18, 2005
	EQ 1MG BASE	A076811	002	Apr 18, 2005
MYLAN PHARMS INC	EQ 0.5MG BASE	A077613	001	Jun 27, 2006
	EQ 1MG BASE	A077613	002	Jun 27, 2006
ROXANE	EQ 0.5MG BASE	A076489	001	Apr 18, 2005
	EQ 1MG BASE	A076489	002	Apr 18, 2005
UPSHER SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005
	EQ 1MG BASE	A076683	002	Apr 18, 2005
WATSON LABS	EQ 0.5MG BASE	A076417	001	Apr 18, 2005
	EQ 1MG BASE	A076417	002	Apr 18, 2005
ANASTROZOLE				
TABLET;ORAL				
ANASTROZOLE				
IMPAX LABS INC	1MG	A091242	001	May 31, 2012
LANNETT CO INC	1MG	A091331	001	Jan 05, 2011
SANDOZ	1MG	A079007	001	Jun 28, 2010
SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011
SYNTHON PHARMS	1MG	A078322	001	Jun 28, 2010
WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010
ANGIOTENSIN II ACETATE				
SOLUTION;INTRAVENOUS				
GIAPREZA				
+ LA JOLLA PHARMA	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017
ANILERIDINE HYDROCHLORIDE				
TABLET;ORAL				
LERITINE				
MERCK	EQ 25MG BASE	N010585	002	
ANILERIDINE PHOSPHATE				
INJECTABLE;INJECTION				
LERITINE				
MERCK	25MG/ML	N010520	003	
ANISINDIONE				
TABLET;ORAL				
MIRADON				
SCHERING	50MG	N010909	003	
ANISOTROPINE METHYLBROMIDE				
TABLET;ORAL				
ANISOTROPINE METHYLBROMIDE				
WATSON LABS	50MG	A086046	001	
VALPIN 50				
ENDO PHARMS	50MG	N013428	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE					
SOLUTION/DROPS;OPHTHALMIC					
VASOCON-A					
	NOVARTIS	0.5%;0.05%	N018746	002	Jul 11, 1994
APOMORPHINE HYDROCHLORIDE					
INJECTABLE;SUBCUTANEOUS					
APOKYN					
	US WORLDMEDS	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004
APREPITANT					
CAPSULE;ORAL					
EMEND					
+	MERCK	40MG	N021549	003	Jun 30, 2006
APROTININ					
INJECTABLE;INJECTION					
TRASYLOL					
	BAYER HLTHCARE	10,000KIU/ML	N020304	001	Dec 29, 1993
ARBUTAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
GENESA					
	GENSIA AUTOMEDICS	0.05MG/ML	N020420	001	Sep 12, 1997
ARDEPARIN SODIUM					
INJECTABLE;INJECTION					
NORMIFLO					
+	PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML **	N020227	002	May 23, 1997
+		10,000 UNITS/0.5ML **	N020227	001	May 23, 1997
ARGATROBAN					
SOLUTION;INTRAVENOUS					
ARGATROBAN IN DEXTROSE					
	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011
ARIPIPRAZOLE					
INJECTABLE;INTRAMUSCULAR					
ABILIFY					
	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006
SOLUTION;ORAL					
ABILIFY					
+	OTSUKA	1MG/ML **	N021713	001	Dec 10, 2004
TABLET;ORAL					
ARIPIPRAZOLE					
	MYLAN	2MG	A206240	001	Sep 19, 2018
		5MG	A206240	002	Sep 19, 2018
		10MG	A206240	003	Sep 19, 2018
		15MG	A206240	004	Sep 19, 2018
		20MG	A206240	005	Sep 19, 2018
		30MG	A206240	006	Sep 19, 2018
	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015
		5MG	A078607	002	Apr 28, 2015
		10MG	A078608	001	Apr 28, 2015
		15MG	A078708	001	Apr 28, 2015
		20MG	A078708	002	Apr 28, 2015
		30MG	A078708	003	Apr 28, 2015
	ZYDUS PHARMS	2MG	A090472	001	Jan 07, 2019
		5MG	A090472	002	Jan 07, 2019
		10MG	A090472	003	Jan 07, 2019
		15MG	A090472	004	Jan 07, 2019
		20MG	A090472	005	Jan 07, 2019
		30MG	A090472	006	Jan 07, 2019
TABLET, ORALLY DISINTEGRATING;ORAL					
ABILIFY					
+	OTSUKA	10MG **	N021729	002	Jun 07, 2006
+		15MG **	N021729	003	Jun 07, 2006
+		20MG **	N021729	004	Jun 07, 2006
+		30MG **	N021729	005	Jun 07, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ARMODAFINIL					
TABLET;ORAL					
ARMODAFINIL					
	APOTEX INC	50MG	A201514	001	Mar 25, 2019
		150MG	A201514	002	Mar 25, 2019
		250MG	A201514	003	Mar 25, 2019
	WATSON LABS INC	100MG	A200156	002	Aug 29, 2012
		200MG	A200156	004	Aug 29, 2012
NUVIGIL					
+	CEPHALON	100MG **	N021875	002	Mar 26, 2009
ARSENIC TRIOXIDE					
INJECTABLE;INJECTION					
TRISENOX					
+	CEPHALON	1MG/ML **	N021248	001	Sep 25, 2000
ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE					
INJECTABLE;INJECTION					
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE					
	HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138	001	Jun 18, 2010
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E					
INJECTABLE;INJECTION					
BEROCCA PN					
	ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071	003	Oct 10, 1985
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E					
INJECTABLE;INJECTION					
M.V.C. 9+3					
	ABRAXIS PHARM	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018440	002	Aug 08, 1985
M.V.I.-12 ADULT					
	HOSPIRA	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N008809	004	Aug 08, 1985
+		20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809	006	Sep 09, 2004
MVC PLUS					
	WATSON LABS	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018439	002	Aug 08, 1985
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E					
INJECTABLE;INJECTION					
M.V.I.-12 ADULT					
	HOSPIRA	20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M	N008809	005	Apr 22, 2004
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E					
INJECTABLE;INJECTION					
M.V.I.-12 LYOPHILIZED					
	TELIGENT PHARMA INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E					
INJECTABLE;INJECTION					
VITAPED					
	HOSPIRA	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ	N020176	001	Dec 29, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

VITAPED

	BASE/10ML,N/A;7 IU/10ML,N/A			

ASPIRIN

TABLET;ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER	500MG	N021317	001	Oct 18, 2001

TABLET, EXTENDED RELEASE;ORAL

8-HOUR BAYER

BAYER	650MG	N016030	001	

MEASURIN

BAYER	650MG	N016030	002	

ASPIRIN; BUTALBITAL

TABLET;ORAL

AXOTAL

SAVAGE LABS	650MG;50MG	A088305	001	Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007
WATSON LABS	325MG;50MG;40MG	A086231	002	Feb 12, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983
FOSUN PHARMA	325MG;50MG;40MG	A086398	002	Apr 06, 1984
HALSEY	325MG;50MG;40MG	A089448	001	Dec 01, 1986
IVAX PHARMS	325MG;50MG;40MG	A085441	002	Oct 31, 1984
PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983
QUANTUM PHARMICS	325MG;50MG;40MG	A088972	001	Jun 18, 1985
WATSON LABS	325MG;50MG;40MG	A086237	002	Mar 23, 1984

FIORINAL

+	ALLERGAN	325MG;50MG;40MG **	N017534	003	Apr 16, 1986

LANORINAL

LANNETT	325MG;50MG;40MG	A086986	002	Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC	325MG;50MG;40MG;30MG	A075351	001	Mar 05, 1999
WATSON LABS	325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC

+	SUN PHARM INDUSTRIES	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

INVAGESIC

SANDOZ	385MG;30MG;25MG	A074817	001	Nov 27, 1996

INVAGESIC FORTE

SANDOZ	770MG;60MG;50MG	A074817	002	Nov 27, 1996

NORGESIC

+	MEDICIS	385MG;30MG;25MG **	N013416	003	Oct 27, 1982

NORGESIC FORTE

+	MEDICIS	770MG;60MG;50MG **	N013416	004	Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996
	770MG;60MG;50MG	A074654	002	Dec 31, 1996
STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999
	770MG;60MG;50MG	A074988	002	Apr 30, 1999

ORPHENGESIC

GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998

ORPHENGESIC FORTE

GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE				
CAPSULE;ORAL				
COMPOUND 65				
	ALRA	389MG;32.4MG;65MG	A084553 002	Aug 17, 1983
DARVON COMPOUND				
	XANODYNE PHARM	389MG;32.4MG;32MG	N010996 006	Mar 08, 1983
DARVON COMPOUND-65				
	XANODYNE PHARM	389MG;32.4MG;65MG	N010996 007	Mar 08, 1983
PROPOXYPHENE COMPOUND 65				
	IVAX SUB TEVA PHARMS	389MG;32.4MG;65MG	A083077 002	Dec 07, 1984
	SANDOZ	389MG;32.4MG;65MG	A080044 002	Sep 16, 1983
	TEVA	389MG;32.4MG;65MG	A089025 001	Mar 29, 1985
PROPOXYPHENE COMPOUND-65				
	SANDOZ	389MG;32.4MG;65MG	A083101 002	Jun 24, 1985
PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE				
	WATSON LABS	389MG;32.4MG;65MG	A085732 002	Sep 03, 1984
ASPIRIN; CARISOPRODOL				
TABLET;ORAL				
CARISOPRODOL AND ASPIRIN				
	OXFORD PHARMS	325MG;200MG	A040252 001	Dec 10, 1997
CARISOPRODOL COMPOUND				
	WATSON LABS	325MG;200MG	A088809 001	Oct 03, 1985
SOMA COMPOUND				
	MEDA PHARMS	325MG;200MG **	N012365 005	Jul 11, 1983
ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE				
TABLET;ORAL				
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE				
	OXFORD PHARMS	325MG;200MG;16MG	A040283 001	Dec 29, 1998
SOMA COMPOUND W/ CODEINE				
	MEDA PHARMS	325MG;200MG;16MG **	N012366 002	Jul 11, 1983
ASPIRIN; DIPYRIDAMOLE				
CAPSULE, EXTENDED RELEASE;ORAL				
ASPIRIN AND DIPYRIDAMOLE				
	ANI PHARMS INC	25MG;200MG	A206964 001	Jan 18, 2017
ASPIRIN; HYDROCODONE BITARTRATE				
TABLET;ORAL				
AZDONE				
	SCHWARZ PHARMA	500MG;5MG **	A089420 001	Jan 25, 1988
VICOPRIN				
	ABBOTT	500MG;5MG	A086333 001	Sep 14, 1983
ASPIRIN; MEPROBAMATE				
TABLET;ORAL				
EQUAGESIC				
	SUN PHARM INDUSTRIES	325MG;200MG	N011702 003	Dec 29, 1983
MEPRO-ASPIRIN				
	SANDOZ	325MG;200MG	A089127 001	Mar 02, 1987
MEPROBAMATE AND ASPIRIN				
	PAR PHARM	325MG;200MG	A089126 001	Aug 19, 1986
MICRAININ				
	MEDPOINTE PHARM HLC	325MG;200MG	A084978 001	
Q-GESIC				
	QUANTUM PHARMICS	325MG;200MG	A088740 001	Jun 01, 1984
ASPIRIN; METHOCARBAMOL				
TABLET;ORAL				
METHOCARBAMOL AND ASPIRIN				
	IVAX SUB TEVA PHARMS	325MG;400MG	A087211 001	Dec 22, 1982
	MCNEIL	325MG;400MG	A089193 001	Feb 12, 1986
	PAR PHARM	325MG;400MG	A089657 001	Nov 04, 1988
ROBAXISAL				
	ROBINS AH	325MG;400MG	N012281 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE					
TABLET;ORAL					
CODOXY					
	HALSEY	325MG;4.5MG;0.38MG	A087464	001	Jul 01, 1982
OXYCODONE AND ASPIRIN					
	ANI PHARMS INC	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998
	SUN PHARM INDUSTRIES	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998
		325MG;4.5MG;0.38MG	A087794	001	May 26, 1982
OXYCODONE AND ASPIRIN (HALF-STRENGTH)					
	ROXANE	325MG;2.25MG;0.19MG	A087742	001	Jun 04, 1982
PERCODAN					
	ENDO PHARMS	325MG;4.5MG;0.38MG **	N007337	006	
PERCODAN-DEMI					
	ENDO PHARMS	325MG;2.25MG;0.19MG **	N007337	005	
ROXIPRIN					
	ROXANE	325MG;4.5MG;0.38MG	A087743	001	Jun 04, 1982
ASPIRIN; PENTAZOCINE HYDROCHLORIDE					
TABLET;ORAL					
TALWIN COMPOUND					
+	SANOFI AVENTIS US	325MG;EQ 12.5MG BASE **	N016891	001	
ASPIRIN; PRAVASTATIN SODIUM					
TABLET, TABLET;ORAL					
PRAVIGARD PAC (COPACKAGED)					
	BRISTOL MYERS SQUIBB	325MG,N/A;N/A,80MG	N021387	006	Jun 24, 2003
TABLET, TABLET, TABLET;ORAL					
PRAVIGARD PAC (COPACKAGED)					
	BRISTOL MYERS SQUIBB	81MG,N/A;N/A,20MG	N021387	001	Jun 24, 2003
		81MG,N/A;N/A,40MG	N021387	002	Jun 24, 2003
		81MG,N/A;N/A,80MG	N021387	003	Jun 24, 2003
		325MG,N/A;N/A,20MG	N021387	004	Jun 24, 2003
		325MG,N/A;N/A,40MG	N021387	005	Jun 24, 2003
ASPIRIN; PROPOXYPHENE HYDROCHLORIDE					
CAPSULE;ORAL					
DARVON W/ ASA					
	XANODYNE PHARM	325MG;65MG	N010996	005	
ASPIRIN; PROPOXYPHENE NAPSYLATE					
CAPSULE;ORAL					
DARVON-N W/ ASA					
	AAIPHARMA LLC	325MG;100MG	N016829	001	
TABLET;ORAL					
DARVON-N W/ ASA					
	AAIPHARMA LLC	325MG;100MG	N016863	001	
ATAZANAVIR SULFATE					
CAPSULE;ORAL					
REYATAZ					
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE **	N021567	001	Jun 20, 2003
ATENOLOL					
INJECTABLE;INJECTION					
TENORMIN					
+	ASTRAZENECA	0.5MG/ML **	N019058	001	Sep 13, 1989
TABLET;ORAL					
ATENOLOL					
	ABLE	25MG	A076907	001	Jul 30, 2004
		50MG	A076907	002	Jul 30, 2004
		100MG	A076907	003	Jul 30, 2004
	APOTHECON	50MG	A073317	001	Mar 20, 1992
		100MG	A073318	001	Mar 20, 1992
	DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992
	INVATECH	25MG	A074265	001	Feb 28, 1994
		50MG	A074265	002	Feb 28, 1994
		100MG	A074265	003	Feb 28, 1994
	MYLAN	25MG	A074126	003	Aug 26, 1998
		50MG	A074126	001	Mar 23, 1994
		100MG	A074126	002	Mar 23, 1994
	NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009
		50MG	A078254	002	Sep 25, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATENOLOL

TABLET;ORAL

ATENOLOL

	100MG		A078254 003	Sep 25, 2009
NOSTRUM LABS	50MG		A074127 001	Feb 21, 1995
	100MG		A074127 002	Feb 21, 1995
PLIVA	25MG		A074101 001	Jul 17, 1997
	50MG		A074101 002	Jul 17, 1997
	100MG		A074101 003	Jul 17, 1997
SCS	50MG		A073676 001	Oct 30, 1992
	100MG		A073676 002	Oct 30, 1992
SUN PHARM INDS INC	25MG		A078210 001	Jul 10, 2007
	50MG		A078210 002	Jul 10, 2007
	100MG		A078210 003	Jul 10, 2007
SUN PHARM INDUSTRIES	25MG		A074499 001	Jul 30, 1997
	50MG		A073475 001	Mar 30, 1993
	100MG		A073476 001	Mar 30, 1993
TEVA	50MG		A073315 001	May 28, 1993
	100MG		A073316 001	May 28, 1993
TEVA PHARMS	50MG		A074120 001	Feb 24, 1995
	100MG		A074120 002	Feb 24, 1995
WATSON LABS	50MG		A073352 001	Dec 27, 1991
WATSON LABS TEVA	100MG		A073353 001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG;25MG		A074404 001	May 14, 1998
	100MG;25MG		A074404 002	May 14, 1998
PLIVA	50MG;25MG		A074107 001	Sep 24, 1997
	100MG;25MG		A074107 002	Sep 24, 1997
SUN PHARM INDUSTRIES	50MG;25MG		A073582 002	Apr 29, 1993
	100MG;25MG		A073582 001	Apr 29, 1993

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

STRATTERA

LILLY	5MG		N021411 001	Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

LUPIN LTD	EQ 10MG BASE		A204991 001	Mar 06, 2019
	EQ 20MG BASE		A204991 002	Mar 06, 2019
	EQ 40MG BASE		A204991 003	Mar 06, 2019
	EQ 80MG BASE		A204991 004	Mar 06, 2019
TEVA PHARMS	EQ 10MG BASE		A078773 001	May 29, 2012
	EQ 20MG BASE		A078773 002	May 29, 2012
	EQ 40MG BASE		A078773 003	May 29, 2012
	EQ 80MG BASE		A078773 004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

+ MERCK SHARP DOHME	EQ 10MG BASE;10MG **		N200153 001	May 03, 2013
+	EQ 20MG BASE;10MG **		N200153 002	May 03, 2013
+	EQ 40MG BASE;10MG **		N200153 003	May 03, 2013
+	EQ 80MG BASE;10MG **		N200153 004	May 03, 2013

ATOVAQUONE

TABLET;ORAL

MEPRON

+ GLAXOSMITHKLINE LLC	250MG **		N020259 001	Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE	10MG/ML		A074824 001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML		A074753 001	Jan 23, 1997
HOSPIRA	10MG/ML		A074632 001	Dec 23, 1996
	10MG/ML		A074740 001	Mar 28, 1997
MYLAN LABS LTD	10MG/ML		A206096 001	Jun 22, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ATRACURIUM BESYLATE				
INJECTABLE;INJECTION				
ATRACURIUM BESYLATE				
TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998
ATRACURIUM BESYLATE PRESERVATIVE FREE				
BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
	10MG/ML	A074639	001	Mar 25, 1997
	10MG/ML	A074741	001	Mar 28, 1997
MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017
WATSON LABS INC	10MG/ML	A074944	001	Jul 28, 1998
TRACRIUM				
+ HOSPIRA	10MG/ML **	N018831	002	Jun 20, 1985
TRACRIUM PRESERVATIVE FREE				
+ HOSPIRA	10MG/ML **	N018831	001	Nov 23, 1983
ATROPINE				
SOLUTION;INTRAMUSCULAR				
ATROPINE				
ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987
ATROPINE (AUTOINJECTOR)				
RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018
ATROPINE SULFATE				
AEROSOL, METERED;INHALATION				
ATROPINE SULFATE				
US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990
SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL				
ATROPINE SULFATE ANSYR PLASTIC SYRINGE				
+ HOSPIRA	0.5MG/5ML (0.1MG/ML) **	N021146	001	Jul 09, 2001
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE				
TABLET;ORAL				
MOTOFEN HALF-STRENGTH				
SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001	
ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE				
CAPSULE;ORAL				
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE				
SCHERER RP	0.025MG;2.5MG	A086440	001	
SOLUTION;ORAL				
COLONAID				
MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735	001	
LOMANATE				
ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746	001	
LOMOTIL				
GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001	
TABLET;ORAL				
COLONAID				
MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737	001	
DI-ATRO				
MD PHARM	0.025MG;2.5MG	A085266	001	
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE				
ABLE	0.025MG;2.5MG	A040395	001	Nov 27, 2000
ASCOT	0.025MG;2.5MG	A087934	001	Jul 19, 1983
FOSUN PHARMA	0.025MG;2.5MG	A086173	001	
HEATHER	0.025MG;2.5MG	A086798	001	
HIKMA PHARMS	0.025MG;2.5MG	A087765	001	Mar 15, 1982
INWOOD LABS	0.025MG;2.5MG	A085509	001	
KV PHARM	0.025MG;2.5MG	A085659	001	
LEDERLE	0.025MG;2.5MG	A086950	001	
PARKE DAVIS	0.025MG;2.5MG	A087131	001	
PVT FORM	0.025MG;2.5MG	A085766	001	
R AND S PHARMA	0.025MG;2.5MG	A085035	001	
ROXANE	0.025MG;2.5MG	A086057	001	
SUN PHARM INDUSTRIES	0.025MG;2.5MG	A085506	001	
USL PHARMA	0.025MG;2.5MG	A087842	001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG;2.5MG	A087195	001	Feb 16, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE					
TABLET;ORAL					
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE					
	WATSON LABS	0.025MG;2.5MG	A085876	001	
LO-TROL					
	VANGARD	0.025MG;2.5MG	A088009	001	Mar 25, 1983
LOGEN					
	SUPERPHARM	0.025MG;2.5MG	A088962	001	May 10, 1985
LONOX					
	FOSUN PHARMA	0.025MG;2.5MG	A085311	002	
LOW-QUEL					
	HALSEY	0.025MG;2.5MG	A085211	001	
ATROPINE SULFATE; EDROPHONIUM CHLORIDE					
INJECTABLE;INJECTION					
ENLON-PLUS					
	MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991
+		0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991
ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
ATROPINE AND DEMEROL					
	ABBVIE	0.4MG/ML;50MG/ML	A087853	001	Nov 26, 1982
		0.4MG/ML;75MG/ML	A087847	001	Nov 26, 1982
		0.4MG/ML;100MG/ML	A087848	001	Nov 26, 1982
MEPERIDINE AND ATROPINE SULFATE					
	WYETH AYERST	0.4MG/ML;50MG/ML	A085121	001	
		0.4MG/ML;75MG/ML	A085121	002	
		0.4MG/ML;100MG/ML	A085121	003	
ATROPINE; PRALIDOXIME CHLORIDE					
INJECTABLE;INTRAMUSCULAR					
ATNAA					
	US ARMY	2.1MG/0.7ML;600MG/2ML	N021175	001	Jan 17, 2002
AVOBENZONE; OCTINOXATE; OXYBENZONE					
LOTION;TOPICAL					
SHADE UVAGUARD					
+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992
AZACITIDINE					
POWDER;INTRAVENOUS, SUBCUTANEOUS					
AZACITIDINE					
	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019
AZATADINE MALEATE					
TABLET;ORAL					
OPTIMINE					
	SCHERING	1MG	N017601	001	
AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE					
TABLET, EXTENDED RELEASE;ORAL					
TRINALIN					
	SCHERING	1MG;120MG	N018506	001	Mar 23, 1982
AZATHIOPRINE					
TABLET;ORAL					
IMURAN					
+	SEBELA IRELAND LTD	25MG **	N016324	002	
AZATHIOPRINE SODIUM					
INJECTABLE;INJECTION					
IMURAN					
+	CASPER PHARMA LLC	EQ 100MG BASE/VIAL **	N017391	001	
AZELASTINE HYDROCHLORIDE					
SOLUTION/DROPS;OPHTHALMIC					
OPTIVAR					
+	MYLAN SPECIALITY LP	0.05% **	N021127	001	May 22, 2000
SPRAY, METERED;NASAL					
ASTEPRO					
	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AZITHROMYCIN					
CAPSULE;ORAL					
ZITHROMAX					
+	PFIZER	EQ 250MG BASE **	N050670	001	Nov 01, 1991
FOR SUSPENSION;ORAL					
AZITHROMYCIN					
	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015
		EQ 200MG BASE/5ML	A065488	002	May 15, 2015
	SANDOZ	EQ 100MG BASE/5ML	A065297	001	Sep 18, 2006
		EQ 200MG BASE/5ML	A065297	002	Sep 18, 2006
FOR SUSPENSION, EXTENDED RELEASE;ORAL					
ZMAX					
+	PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005
INJECTABLE;INJECTION					
AZITHROMYCIN					
	CSPC OUYI	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007
	TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809	001	Dec 19, 2006
		EQ 2.5GM BASE/VIAL	N050809	002	Dec 19, 2006
TABLET;ORAL					
AZITHROMYCIN					
	APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011
		EQ 500MG BASE	A065509	001	Jul 13, 2011
		EQ 600MG BASE	A065508	001	Jul 13, 2011
	MYLAN	EQ 250MG BASE	A065365	001	May 30, 2007
		EQ 500MG BASE	A065366	001	May 30, 2007
	TEVA	EQ 250MG BASE	A065153	001	Nov 14, 2005
		EQ 600MG BASE	A065150	001	Nov 14, 2005
ZITHROMAX					
+	PFIZER	EQ 600MG BASE **	N050730	001	Jun 12, 1996
AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE					
FOR SUSPENSION, TABLET;ORAL					
TROVAN/ZITHROMAX COMPLIANCE PAK					
	PFIZER	EQ 1GM BASE,N/A;N/A,EQ 100MG BASE	N050762	001	Dec 18, 1998
AZLOCILLIN SODIUM					
INJECTABLE;INJECTION					
AZLIN					
	BAYER PHARMS	EQ 2GM BASE/VIAL	A062388	001	Sep 08, 1982
		EQ 2GM BASE/VIAL	A062417	001	Oct 12, 1982
		EQ 2GM BASE/VIAL	N050562	001	Sep 03, 1982
		EQ 3GM BASE/VIAL	A062388	002	Sep 08, 1982
		EQ 3GM BASE/VIAL	A062417	002	Oct 12, 1982
		EQ 3GM BASE/VIAL	N050562	002	Sep 03, 1982
		EQ 4GM BASE/VIAL	A062388	003	Sep 08, 1982
		EQ 4GM BASE/VIAL	A062417	003	Oct 12, 1982
		EQ 4GM BASE/VIAL	N050562	003	Sep 03, 1982
AZTREONAM					
INJECTABLE;INJECTION					
AZACTAM					
	BRISTOL MYERS SQUIBB	500MG/VIAL	N050580	001	Dec 31, 1986
AZACTAM IN PLASTIC CONTAINER					
	BRISTOL MYERS SQUIBB	10MG/ML	N050632	003	May 24, 1989
+		20MG/ML	N050632	002	May 24, 1989
+		40MG/ML	N050632	001	May 24, 1989
AZTREONAM					
	WEST-WARD PHARMS INT	1GM/VIAL	A065286	001	Mar 23, 2011
		2GM/VIAL	A065286	002	Mar 23, 2011
BACAMPICILLIN HYDROCHLORIDE					
FOR SUSPENSION;ORAL					
SPECTROBID					
	PFIZER	125MG/5ML	N050556	001	Mar 23, 1982
TABLET;ORAL					
SPECTROBID					
	PFIZER	400MG	N050520	001	
		800MG	N050520	002	Sep 12, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BACITRACIN				
INJECTABLE;INJECTION				
BACITRACIN				
MYLAN ASI	50,000 UNITS/VIAL	A090211	001	May 11, 2010
PFIZER	50,000 UNITS/VIAL	A060282	001	
PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001	
OINTMENT;OPHTHALMIC				
BACIGUENT				
PHARMACIA AND UPJOHN	500 UNITS/GM	A060734	001	
BACITRACIN				
LILLY	500 UNITS/GM	A060687	001	
PHARMADERM	500 UNITS/GM	A062158	001	
PHARMAFAIR	500 UNITS/GM	A062453	001	Mar 28, 1984
OINTMENT;TOPICAL				
BACITRACIN				
COMBE	500 UNITS/GM	A062799	001	May 14, 1987
NASKA	500 UNITS/GM	A062857	001	Nov 13, 1987
POWDER;FOR RX COMPOUNDING				
BACI-RX				
X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001	
BACITRACIN				
APOTHEKERNES	5,000,000 UNITS/BOT	A061699	001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456	001	Jul 27, 1983
BACITRACIN ZINC				
POWDER;FOR RX COMPOUNDING				
ZIBA-RX				
X GEN PHARMS	500,000 UNITS/BOT	A061737	001	
BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
CORTISPORIN				
+ CASPER PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **	N050416	002	
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389	001	Jul 02, 1982
OINTMENT;TOPICAL				
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381	001	Sep 06, 1985
BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;TOPICAL				
LANABIOTIC				
COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499	001	Jun 03, 1985
BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386	001	Sep 09, 1982
BACITRACIN-NEOMYCIN-POLYMYXIN				
PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167	001	
NEO-POLYCIN				
DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647	001	
OINTMENT;TOPICAL				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833	001	Nov 09, 1987
BACITRACIN ZINC; POLYMYXIN B SULFATE				
AEROSOL;TOPICAL				
POLYSPORIN				
GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167	002	Mar 01, 1985
OINTMENT;OPHTHALMIC				
OCUMYCIN				
PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430	001	Apr 08, 1983
POLYSPORIN				
MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM **	A061229	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BACITRACIN ZINC; POLYMYXIN B SULFATE				
OINTMENT;TOPICAL				
BACITRACIN ZINC-POLYMYXIN B SULFATE				
	NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849 001	Nov 13, 1987
BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE				
	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731 002	
BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
MYCITRACIN				
	PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048 001	
BACITRACIN; POLYMYXIN B SULFATE				
DISC;TOPICAL				
LANABIOTIC				
	COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598 001	Sep 22, 1986
BACLOFEN				
TABLET;ORAL				
BACLOFEN				
	MYLAN	10MG	A077181 001	Jul 29, 2005
	SUN PHARM INDS INC	10MG	A077862 001	Aug 14, 2006
		20MG	A077862 002	Aug 14, 2006
	TEVA	10MG	A073043 001	Feb 27, 1992
		20MG	A073044 001	Feb 27, 1992
	USL PHARMA	10MG	A071260 001	May 06, 1988
		20MG	A071261 001	May 06, 1988
	WATSON LABS	10MG	A072824 001	Sep 18, 1991
		10MG	A073092 001	Jan 28, 1994
		10MG	A074698 001	Aug 20, 1996
		20MG	A072825 001	Sep 18, 1991
		20MG	A073093 001	Jan 28, 1994
		20MG	A074698 002	Aug 20, 1996
LIORESAL				
+	NOVARTIS	10MG **	N017851 001	
+		20MG **	N017851 003	Jan 20, 1982
TABLET, ORALLY DISINTEGRATING;ORAL				
KEMSTRO				
	UCB INC	10MG	N021589 001	Oct 30, 2003
		20MG	N021589 002	Oct 30, 2003
BALSALAZIDE DISODIUM				
CAPSULE;ORAL				
BALSALAZIDE DISODIUM				
	MYLAN	750MG	A077807 001	Dec 28, 2007
TABLET;ORAL				
BALSALAZIDE DISODIUM				
	PAR PHARM INC	1.1GM	A206336 001	Sep 08, 2015
GIAZO				
+	VALEANT PHARMS INTL	1.1GM	N022205 001	Feb 03, 2012
BARIUM SULFATE				
FOR SUSPENSION;ORAL				
E-Z-CAT DRY				
+	BRACCO	40% (9GM/POUCH)	N208036 003	Jan 03, 2017
BECLOMETHASONE DIPROPIONATE				
AEROSOL, METERED;INHALATION				
BECLOVENT				
	GLAXOSMITHKLINE	0.042MG/INH	N018153 001	
QVAR 40				
+	TEVA BRANDED PHARM	0.04MG/INH **	N020911 002	Sep 15, 2000
QVAR 80				
+	TEVA BRANDED PHARM	0.08MG/INH **	N020911 001	Sep 15, 2000
VANCERIL				
	SCHERING	0.042MG/INH	N017573 001	
VANCERIL DOUBLE STRENGTH				
	SCHERING	0.084MG/INH	N020486 001	Dec 24, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BECLOMETHASONE DIPROPIONATE				
AEROSOL, METERED;NASAL				
BECONASE				
GLAXOSMITHKLINE	0.042MG/INH	N018584	001	
VANCENASE				
SCHERING	0.042MG/INH	N018521	001	
BECLOMETHASONE DIPROPIONATE MONOHYDRATE				
SPRAY, METERED;NASAL				
VANCENASE AQ				
SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589	001	Dec 23, 1987
	EQ 0.084MG DIPROP/SPRAY	N020469	001	Jun 26, 1996
BENAZEPRIL HYDROCHLORIDE				
TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE				
ANI PHARMS INC	5MG	A076333	001	Feb 11, 2004
	10MG	A076333	002	Feb 11, 2004
	20MG	A076333	003	Feb 11, 2004
	40MG	A076333	004	Feb 11, 2004
GENPHARM	5MG	A076476	001	Feb 11, 2004
	10MG	A076476	002	Feb 11, 2004
	20MG	A076476	003	Feb 11, 2004
	40MG	A076476	004	Feb 11, 2004
HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004
	10MG	A076267	002	Feb 11, 2004
	20MG	A076267	003	Feb 11, 2004
	40MG	A076267	004	Feb 11, 2004
BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
ANI PHARMS INC	5MG;6.25MG	A076342	001	Feb 11, 2004
	5MG;6.25MG	A076348	001	Feb 11, 2004
	10MG;12.5MG	A076342	002	Feb 11, 2004
	10MG;12.5MG	A076348	002	Feb 11, 2004
	20MG;12.5MG	A076342	003	Feb 11, 2004
	20MG;12.5MG	A076348	003	Feb 11, 2004
	20MG;25MG	A076342	004	Feb 11, 2004
	20MG;25MG	A076348	004	Feb 11, 2004
MYLAN PHARMS INC	5MG;6.25MG	A076612	001	Feb 11, 2004
	10MG;12.5MG	A076612	002	Feb 11, 2004
	20MG;12.5MG	A076612	003	Feb 11, 2004
	20MG;25MG	A076612	004	Feb 11, 2004
SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005
	10MG;12.5MG	A077483	002	Sep 08, 2005
	20MG;12.5MG	A077483	003	Sep 08, 2005
	20MG;25MG	A077483	004	Sep 08, 2005
LOTENSIN HCT				
+ US PHARMS HOLDINGS I	5MG;6.25MG **	N020033	001	May 19, 1992
BENDAMUSTINE HYDROCHLORIDE				
SOLUTION;IV (INFUSION)				
TREANDA				
+ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013
+	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013
BENDROFLUMETHIAZIDE				
TABLET;ORAL				
NATURETIN-10				
APOTHECON	10MG	N012164	003	
NATURETIN-2.5				
APOTHECON	2.5MG	N012164	001	
NATURETIN-5				
APOTHECON	5MG	N012164	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BENDROFLUMETHIAZIDE; NADOLOL				
TABLET;ORAL				
NADOLOL AND BENDROFLUMETHIAZIDE				
	MYLAN	5MG;40MG	A078688 001	Feb 15, 2008
		5MG;80MG	A078688 002	Feb 15, 2008
BENOXINATE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
BENOXINATE HYDROCHLORIDE				
	SOLA BARNES HIND	0.4%	A084149 001	
BENTIROMIDE				
SOLUTION;ORAL				
CHYMEX				
	SAVAGE LABS	500MG/7.5ML	N018366 001	Dec 29, 1983
BENZONATATE				
CAPSULE;ORAL				
BENZONATATE				
	NESHER PHARMS	100MG	A040795 001	Oct 31, 2007
		200MG	A040795 002	Oct 31, 2007
	SUN PHARM INDS INC	100MG	A040587 001	Mar 19, 2008
		200MG	A040587 002	Mar 19, 2008
TESSALON				
+	PFIZER	200MG **	N011210 003	Jun 25, 1999
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE				
GEL;TOPICAL				
BENZACLIN				
	BAUSCH	5%;EQ 1% BASE	N050756 002	Apr 20, 2007
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE				
	ANDA REPOSITORY	2.5%;EQ 1.2% BASE	A207194 001	Aug 19, 2019
	TARO	3.75%;EQ 1.2% BASE	A208683 001	Jun 05, 2018
BENZOYL PEROXIDE; ERYTHROMYCIN				
GEL;TOPICAL				
AKTIPAK				
+	BIOFRONTERA	5%;3%	N050769 001	Nov 27, 2000
BENZPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
BENZPHETAMINE HYDROCHLORIDE				
	EPIC PHARMA LLC	50MG	A040714 001	Oct 29, 2007
	IMPAX LABS	50MG	A040845 001	Nov 18, 2008
	TEDOR PHARM	25MG	A040747 002	Nov 20, 2015
		50MG	A040747 001	Mar 30, 2007
DIDREX				
+	PHARMACIA AND UPJOHN	25MG **	N012427 003	
+		50MG **	N012427 002	
BENZQUINAMIDE HYDROCHLORIDE				
INJECTABLE;INJECTION				
EMETE-CON				
	PFIZER	EQ 50MG BASE/VIAL	N016820 001	
SUPPOSITORY;RECTAL				
EMETE-CON				
	ROERIG	EQ 100MG BASE	N016818 006	
BENZTHIAZIDE				
TABLET;ORAL				
AQUATAG				
	SOLVAY	25MG	N016001 001	
		50MG	N016001 002	
BENZTHIAZIDE				
	PVT FORM	50MG	A083206 001	
EXNA				
	AH ROBINS INC	50MG	N012489 001	
FOVANE				
	PFIZER	50MG	N012128 002	
URESE				
	PFIZER	25MG	N012128 003	

BENZTROPINE MESYLATE				
INJECTABLE;INJECTION				
BENZTROPINE MESYLATE				
LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010
TABLET;ORAL				
BENZTROPINE MESYLATE				
CHARTWELL RX	1MG	A081265	002	Jan 23, 1992
	2MG	A081265	001	Jan 23, 1992
LANNETT CO INC	0.5MG **	A088877	001	Apr 11, 1985
	1MG **	A088894	001	Apr 11, 1985
	2MG **	A088895	001	Apr 11, 1985
OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008
	1MG	A040706	003	Feb 14, 2008
	2MG	A040706	001	Feb 14, 2008
QUANTUM PHARMICS	0.5MG	A088514	001	Jan 31, 1984
	1MG	A088510	001	Jan 31, 1984
	2MG	A088511	001	Jan 31, 1984
UPSHER SMITH LABS	0.5MG	A040103	001	Dec 12, 1996
	1MG	A040103	002	Dec 12, 1996
	2MG	A040103	003	Dec 12, 1996
USL PHARMA	0.5MG	A089211	001	Jun 14, 1988
	1MG	A089212	001	Jun 14, 1988
	2MG	A089213	001	Jun 14, 1988
COGENTIN				
+ MERCK	0.5MG **	N009193	004	
+	1MG **	N009193	003	
+	2MG **	N009193	002	
BENZYL ALCOHOL				
LOTION;TOPICAL				
ULESFIA				
+ SHIONOGI INC	5%	N022129	001	Apr 09, 2009
BENZYL BENZOATE				
EMULSION;TOPICAL				
BENZYL BENZOATE				
LANNETT	50%	A084535	001	
BEPOTASTINE BESILATE				
SOLUTION/DROPS;OPHTHALMIC				
BEPOTASTINE BESILATE				
APOTEX	1.5%	A206066	001	Mar 05, 2019
BEPRIDIL HYDROCHLORIDE				
TABLET;ORAL				
BEPADIN				
MEDPOINTE PHARM HLC	200MG	N019001	001	Dec 28, 1990
	300MG	N019001	002	Dec 28, 1990
	400MG	N019001	003	Dec 28, 1990
VASCOR				
JOHNSON AND JOHNSON	200MG	N019002	001	Dec 28, 1990
	300MG	N019002	002	Dec 28, 1990
	400MG	N019002	003	Dec 28, 1990
BETA CAROTENE				
CAPSULE;ORAL				
SOLATENE				
ROCHE	30MG	N017589	001	
BETAMETHASONE				
CREAM;TOPICAL				
CELESTONE				
SCHERING	0.2%	N014762	001	
SYRUP;ORAL				
CELESTONE				
MERCK SHARP DOHME	0.6MG/5ML	N014215	002	
TABLET;ORAL				
CELESTONE				
SCHERING	0.6MG	N012657	003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETAMETHASONE BENZOATE				
CREAM;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%		N016998 002	
GEL;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%		N017244 001	
LOTION;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%		N017528 001	
OINTMENT;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%		N018089 001	
BETAMETHASONE DIPROPIONATE				
CREAM;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE		N019138 001	Jun 26, 1984
BETAMETHASONE DIPROPIONATE				
PERRIGO NEW YORK	EQ 0.05% BASE		A072536 001	Jan 31, 1990
	EQ 0.05% BASE		A074579 001	Nov 26, 1997
PHARMADERM	EQ 0.05% BASE		N019136 001	Jun 26, 1984
TARO	EQ 0.05% BASE		A071143 001	Jun 17, 1987
TEVA	EQ 0.05% BASE		A071476 001	Aug 10, 1987
DIPROSONE				
SCHERING	EQ 0.05% BASE		N017536 001	
CREAM, AUGMENTED;TOPICAL				
DIPROLENE				
SCHERING	EQ 0.05% BASE		N019408 001	Jan 31, 1986
DISC;TOPICAL				
DIPROSONE				
SCHERING	EQ 0.1% BASE		N017829 001	
GEL, AUGMENTED;TOPICAL				
DIPROLENE				
SCHERING	EQ 0.05% BASE		N019408 002	Nov 22, 1991
LOTION;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE		A070273 001	Aug 12, 1985
BETAMETHASONE DIPROPIONATE				
ACP NIMBLE	EQ 0.05% BASE		A071882 001	Jun 06, 1988
ALPHARMA US PHARMS	EQ 0.05% BASE		A071085 001	Feb 03, 1987
PHARMADERM	EQ 0.05% BASE		A070274 001	Aug 12, 1985
TARO	EQ 0.05% BASE		A072276 001	Aug 24, 1988
	EQ 0.05% BASE		A074272 001	Sep 30, 1994
DIPROSONE				
+ SCHERING	EQ 0.05% BASE **		N017781 001	
LOTION, AUGMENTED;TOPICAL				
DIPROLENE				
+ MERCK SHARP DOHME	EQ 0.05% BASE		N019716 001	Aug 01, 1988
OINTMENT;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE		N019143 001	Sep 04, 1984
BETAMETHASONE DIPROPIONATE				
PERRIGO NEW YORK	EQ 0.05% BASE		A072526 001	Jan 31, 1990
PHARMADERM	EQ 0.05% BASE		N019140 001	Sep 04, 1984
TEVA	EQ 0.05% BASE		A071477 001	Aug 10, 1987
DIPROSONE				
SCHERING	EQ 0.05% BASE		N017691 001	
BETAMETHASONE SODIUM PHOSPHATE				
INJECTABLE;INJECTION				
BETAMETHASONE SODIUM PHOSPHATE				
WATSON LABS	EQ 3MG BASE/ML		A085738 001	
CELESTONE				
+ SCHERING	EQ 3MG BASE/ML **		N017561 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETAMETHASONE VALERATE				
CREAM;TOPICAL				
BETADERM				
ROACO	EQ 0.1% BASE	N018839	001	Jun 30, 1983
BETAMETHASONE VALERATE				
PERRIGO NEW YORK	EQ 0.1% BASE	A070053	001	Jun 10, 1986
PHARMADERM	EQ 0.1% BASE	N018860	002	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070485	001	May 29, 1987
TARO	EQ 0.1% BASE	A070062	001	May 14, 1985
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018862	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.01% BASE	N016322	002	
	EQ 0.1% BASE	N016322	001	
LOTION;TOPICAL				
BETA-VAL				
ACP NIMBLE	EQ 0.1% BASE	A070072	001	Jun 27, 1985
BETAMETHASONE VALERATE				
PHARMADERM	EQ 0.1% BASE	N018870	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070484	001	May 29, 1987
TEVA PHARMS	EQ 0.1% BASE	A071883	001	Apr 22, 1988
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018867	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.1% BASE	N016932	001	
OINTMENT;TOPICAL				
BETAMETHASONE VALERATE				
PERRIGO NEW YORK	EQ 0.1% BASE	A071478	001	Dec 23, 1987
PHARMADERM	EQ 0.1% BASE	N018864	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070486	001	May 29, 1987
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018863	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.1% BASE	N016740	001	
BETAXOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
BETAXOLOL HYDROCHLORIDE				
APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000
TABLET;ORAL				
KERLONE				
SANOFI AVENTIS US	10MG **	N019507	001	Oct 27, 1989
	20MG **	N019507	002	Oct 27, 1989
BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE				
TABLET;ORAL				
KERLEDEX				
SANOFI AVENTIS US	5MG;12.5MG	N019807	001	Oct 30, 1992
	10MG;12.5MG	N019807	002	Oct 30, 1992
BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
BETOPTIC PILO				
ALCON	EQ 0.25% BASE;1.75%	N020619	001	Apr 17, 1997
BETAZOLE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HISTALOG				
LILLY	50MG/ML	N009344	001	
BETHANECHOL CHLORIDE				
INJECTABLE;INJECTION				
URECHOLINE				
+ ODYSSEY PHARMS	5MG/ML **	N006536	001	
TABLET;ORAL				
BETHANECHOL CHLORIDE				
ABLE	5MG	A040492	001	Jul 27, 2004
	10MG	A040483	001	Jul 27, 2004
	25MG	A040485	001	Jul 27, 2004
	50MG	A040509	001	Jul 27, 2004
ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004
	10MG	A040553	001	Oct 28, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETHANECHOL CHLORIDE					
TABLET;ORAL					
BETHANECHOL CHLORIDE					
		25MG	A040554	001	Oct 28, 2004
		50MG	A040551	001	Oct 28, 2004
	ASCOT	10MG	A088288	001	Jun 08, 1983
		25MG	A088289	001	Jun 08, 1983
	IMPAX LABS	5MG	A040721	001	Nov 01, 2006
		10MG	A040721	002	Nov 01, 2006
		25MG	A040721	003	Nov 01, 2006
		50MG	A040721	004	Nov 01, 2006
	IVAX SUB TEVA PHARMS	25MG	A084689	001	
	LANNETT	5MG	A084702	001	
		10MG	A084712	001	
		25MG	A084074	001	
	SANDOZ	5MG	A084353	001	
		10MG	A084378	001	
		10MG	A084379	001	
		25MG	A084383	001	
		25MG	A084384	001	
	SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009
		10MG	A040897	002	Apr 22, 2009
		25MG	A040897	003	Apr 22, 2009
		50MG	A040897	004	Apr 22, 2009
	WATSON LABS	5MG	A084402	001	
		5MG	A085230	002	
		5MG	A085841	001	
		10MG	A084408	001	
		10MG	A085228	001	
		10MG	A085842	001	
		25MG	A084441	001	
		25MG	A085229	001	
		25MG	A085839	001	
		50MG	A087397	001	
		50MG	A087444	001	
MYOTONACHOL					
	GLENWOOD	5MG	A084188	001	
		10MG	A084188	003	
		25MG	A084188	004	
URECHOLINE					
+	ODYSSEY PHARMS	5MG **	N006536	003	
+		10MG **	N006536	002	
+		25MG **	N006536	004	
+		50MG **	N006536	005	
BETHANIDINE SULFATE					
TABLET;ORAL					
TENATHAN					
	ROBINS AH	10MG	N017675	001	
		25MG	N017675	002	
BICALUTAMIDE					
TABLET;ORAL					
BICALUTAMIDE					
	FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010
	KUDCO IRELAND	50MG	A077995	001	Jul 06, 2009
	ROXANE	50MG	A078285	001	Mar 24, 2011
	SYNTHON PHARMS	50MG	A077973	001	Jul 06, 2009
	TEVA	50MG	A076932	001	Jul 06, 2009
BIMATOPROST					
SOLUTION/DROPS;OPHTHALMIC					
BIMATOPROST					
	HI-TECH PHARMA CO	0.03%	A203299	001	Nov 08, 2018
LUMIGAN					
+	ALLERGAN	0.03% **	N021275	001	Mar 16, 2001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL

AKINETON

	ABBVIE	2MG	N012003 001	

BIPERIDEN LACTATE

INJECTABLE;INJECTION

AKINETON

	ABBVIE	5MG/ML	N012418 002	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

HALFLYTELY

+	BRAINTREE	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM **	N021551 003	Jul 16, 2010

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

	NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM	A202217 001	Aug 20, 2014

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

+	CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG **	N050719 001	Aug 15, 1996

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

	MYLAN	5MG	A075831 001	Dec 14, 2005
		10MG	A075831 002	Dec 14, 2005

ZEBETA

+	TEVA WOMENS	5MG **	N019982 002	Jul 31, 1992
+		10MG **	N019982 001	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	ACTAVIS ELIZABETH	2.5MG;6.25MG	A075672 001	Sep 25, 2000
		5MG;6.25MG	A075672 002	Sep 25, 2000
		10MG;6.25MG	A075672 003	Sep 25, 2000
	APOTHECON	2.5MG;6.25MG	A075642 002	Dec 27, 2000
		5MG;6.25MG	A075642 001	Dec 27, 2000
		10MG;6.25MG	A075642 003	Dec 27, 2000
	IVAX SUB TEVA PHARMS	2.5MG;6.25MG	A075632 001	Sep 27, 2000
		5MG;6.25MG	A075632 002	Sep 27, 2000
		10MG;6.25MG	A075632 003	Sep 27, 2000
	MYLAN	2.5MG;6.25MG	A075768 001	Sep 25, 2000
		5MG;6.25MG	A075768 002	Sep 25, 2000
		10MG;6.25MG	A075768 003	Sep 25, 2000
	SANDOZ	2.5MG;6.25MG	A075527 001	Sep 25, 2000
		5MG;6.25MG	A075527 003	Sep 25, 2000
		10MG;6.25MG	A075527 002	Sep 25, 2000
	TEVA	2.5MG;6.25MG	A075686 001	Jan 19, 2001
		5MG;6.25MG	A075686 002	Jan 19, 2001
		10MG;6.25MG	A075686 003	Jan 19, 2001
	WATSON LABS TEVA	2.5MG;6.25MG	A075469 001	Sep 25, 2000
		5MG;6.25MG	A075469 002	Sep 25, 2000
		10MG;6.25MG	A075469 003	Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED;INHALATION

TORNALATE

	SANOFI AVENTIS US	0.37MG/INH	N018770 001	Dec 28, 1984

SOLUTION;INHALATION

TORNALATE

	SANOFI AVENTIS US	0.2%	N019548 001	Feb 19, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BLEOMYCIN SULFATE					
INJECTABLE;INJECTION					
BLENOXANE					
+	BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL **	N050443	001	
+		EQ 30 UNITS BASE/VIAL **	N050443	002	Sep 07, 1995
BLEOMYCIN SULFATE					
	PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007
	TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
		EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996
BOCEPREVIR					
CAPSULE;ORAL					
VICTRELIS					
	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011
BORTEZOMIB					
POWDER;INTRAVENOUS, SUBCUTANEOUS					
BORTEZOMIB					
+	HOSPIRA INC	1MG/VIAL	N209191	002	Dec 28, 2018
+		2.5MG/VIAL	N209191	001	Jul 12, 2018
BOSENTAN					
TABLET;ORAL					
BOSENTAN					
	ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019
		125MG	A206002	002	Apr 26, 2019
BRETYLIUM TOSYLATE					
INJECTABLE;INJECTION					
BRETYLIUM TOSYLATE					
	ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
		100MG/ML	A071298	001	Feb 13, 1987
	ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
		50MG/ML	A071152	001	Aug 10, 1987
		50MG/ML	A071153	001	Aug 10, 1987
	EUROHLTH INTL SARL	50MG/ML	A070546	001	May 14, 1986
+	HOSPIRA	50MG/ML **	N019030	001	Apr 29, 1986
		50MG/ML	N019033	001	Apr 29, 1986
	INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
	LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988
	WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5%					
	ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
		400MG/100ML	N019005	003	Apr 29, 1986
		800MG/100ML	N019005	001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
		200MG/100ML	N019121	002	Apr 29, 1986
		400MG/100ML	N019121	003	Apr 29, 1986
	BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
		400MG/100ML	N019837	001	Apr 12, 1989
	HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
		400MG/100ML	N019008	003	Apr 29, 1986
		800MG/100ML	N019008	001	Apr 29, 1986
BRETYLOL					
	HOSPIRA	50MG/ML	N017954	001	
BRIMONIDINE TARTRATE					
SOLUTION/DROPS;OPHTHALMIC					
ALPHAGAN					
+	ALLERGAN	0.2% **	N020613	001	Sep 06, 1996
		0.5%	N020490	001	Mar 13, 1997
BRIMONIDINE TARTRATE					
	TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004
BROMFENAC SODIUM					
SOLUTION/DROPS;OPHTHALMIC					
BROMDAY					
+	BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	002	Oct 16, 2010
BROMFENAC SODIUM					
	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013
	APOTEX	EQ 0.09% ACID	A202435	001	Jun 19, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

BROMFENAC SODIUM
SOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

	EQ 0.09% ACID	A202620	001	Jun 23, 2014
COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011
VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015

XIBROM

+	BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	001	Mar 24, 2005

BROMOCRIPTINE MESYLATE
CAPSULE;ORAL
BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998

BROMODIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE;ORAL
AMBODRYL

PARKE DAVIS	25MG	N007984	001	

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
SYRUP;ORAL
AMBENYL

FOREST LABS	12.5MG/5ML;10MG/5ML	N009319	006	Jan 10, 1984

BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343	001	Aug 15, 1984

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT	12.5MG/5ML;10MG/5ML	A088626	001	Oct 12, 1984

BROMPHENIRAMINE MALEATE
ELIXIR;ORAL
BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936	001	
KV PHARM	2MG/5ML	A085466	001	
PHARM ASSOC	2MG/5ML	A087517	001	
USL PHARMA	2MG/5ML	A087964	001	Jan 25, 1983

INJECTABLE;INJECTION
BROMPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A083821	001	
	100MG/ML	A083820	001	

DIMETANE-TEN

WYETH AYERST	10MG/ML	N011418	002	

TABLET;ORAL
BROMPHENIRAMINE MALEATE

BARR	4MG	A084468	001	
IVAX SUB TEVA PHARMS	4MG	A084351	001	
NEWTRON PHARMS	4MG	A086987	001	
NEXGEN PHARMA INC	4MG	A086187	001	
PAR PHARM	4MG	A087009	001	
PIONEER PHARMS	4MG	A088604	001	Jul 13, 1984
UPSHER SMITH LABS	4MG	A083215	001	
VITARINE	4MG	A085850	001	
WATSON LABS	4MG	A083123	001	
	4MG	A085769	001	

DIMETANE

WYETH CONS	4MG	N010799	003	

TABLET, EXTENDED RELEASE;ORAL
DIMETANE

WYETH CONS	8MG	N010799	010	Jun 10, 1983
	12MG	N010799	011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SYRUP;ORAL
BROMANATE DM

ALPHARMA US PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A088722	001	Mar 07, 1985

BROMFED-DM

WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A089681	001	Dec 22, 1988

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

VINTAGE PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202940	001	Jul 21, 2014

DIMETANE-DX

+	ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML **	N019279	001	Aug 24, 1984

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE				
ALZA	16MG;240MG	N019672	001	Mar 29, 1996
BUCLIZINE HYDROCHLORIDE				
TABLET;ORAL				
BUCLADIN-S				
STUART PHARMS	50MG	N010911	006	
BUDESONIDE				
AEROSOL, METERED;NASAL				
RHINOCORT				
ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994
POWDER, METERED;INHALATION				
PULMICORT				
ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
	0.32MG/INH	N020441	003	Jun 24, 1997
BUMETANIDE				
INJECTABLE;INJECTION				
BUMETANIDE				
ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995
HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997
BUMEX				
+ VALIDUS PHARMS	0.25MG/ML **	N018226	001	Feb 28, 1983
BUPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
BUPIVACAINE HYDROCHLORIDE				
HOSPIRA	0.75%	A070587	001	Mar 03, 1987
MYLAN ASI	0.25%	A091503	001	Oct 18, 2011
	0.5%	A091503	002	Oct 18, 2011
NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019
BUPIVACAINE HYDROCHLORIDE KIT				
HOSPIRA	0.075%	N019978	001	Sep 03, 1992
	0.114%	N019978	002	Sep 03, 1992
	0.23%	N019978	003	Sep 03, 1992
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE				
INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002
	0.5%	A076012	002	Jan 09, 2002
	0.75%	A076012	003	Jan 09, 2002
MYLAN ASI	0.25%	A091487	002	Oct 18, 2011
	0.5%	A091487	001	Oct 18, 2011
	0.75%	A091487	003	Oct 18, 2011
INJECTABLE;SPINAL				
SENSORCAINE				
FRESENIUS KABI USA	0.75%	A071202	001	Apr 15, 1987
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE				
INJECTABLE;INJECTION				
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE				
HOSPIRA	0.25%;0.005MG/ML	A071166	001	Jun 16, 1988
	0.5%;0.005MG/ML	A071169	001	Jun 16, 1988
	0.75%;0.005MG/ML	A071171	001	Jun 16, 1988
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE				
INJECTABLE;INJECTION				
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE				
+ HOSPIRA	0.5%;0.0091MG/ML	N022046	001	Jul 13, 1983
BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DUOCAINE				
AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUPRENORPHINE HYDROCHLORIDE					
TABLET;SUBLINGUAL					
BUPRENORPHINE HYDROCHLORIDE					
	BARR	EQ 2MG BASE	A090360	001	May 07, 2010
		EQ 8MG BASE	A090360	002	May 07, 2010
	MYLAN	EQ 2MG BASE	A201066	001	Mar 06, 2015
		EQ 8MG BASE	A201066	002	Mar 06, 2015
SUBUTEX					
+	INDIVIOR INC	EQ 2MG BASE **	N020732	002	Oct 08, 2002
+		EQ 8MG BASE **	N020732	003	Oct 08, 2002
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE					
FILM;SUBLINGUAL					
CASSIPA					
+	TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042	001	Sep 07, 2018
TABLET;SUBLINGUAL					
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014
		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014
SUBOXONE					
+	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE **	N020733	001	Oct 08, 2002
+		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002
BUPROPION HYDROCHLORIDE					
TABLET;ORAL					
BUPROPION HYDROCHLORIDE					
	HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999
		100MG	A075310	002	Nov 29, 1999
	INVATECH	75MG	A075613	002	Oct 10, 2000
		100MG	A075613	001	Oct 10, 2000
WELLBUTRIN					
+	GLAXOSMITHKLINE	50MG **	N018644	001	Dec 30, 1985
+		75MG **	N018644	002	Dec 30, 1985
+		100MG **	N018644	003	Dec 30, 1985
TABLET, EXTENDED RELEASE;ORAL					
BUPROPION HYDROCHLORIDE					
	ACTAVIS LABS FL INC	300MG	A077715	002	Jun 13, 2007
	IMPAX LABS	300MG	A077415	002	Dec 15, 2006
	MYLAN	100MG	A090325	001	Apr 08, 2010
		150MG	A090325	002	Apr 08, 2010
		150MG	A090941	001	May 03, 2010
		150MG	A090942	001	Jul 14, 2010
		200MG	A090325	003	Apr 08, 2010
		300MG	A090942	002	Jul 14, 2010
	SANDOZ	100MG	A076845	001	Jul 14, 2005
		150MG	A076834	001	Jul 14, 2005
		150MG	A076845	002	Jul 14, 2005
	SUN PHARM	150MG	A200695	001	Dec 18, 2014
	WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012
		150MG	A201331	002	Aug 30, 2012
		200MG	A201331	003	Aug 30, 2012
	YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018
		150MG	A211347	002	Oct 16, 2018
		200MG	A211347	003	Oct 16, 2018
WELLBUTRIN SR					
	GLAXOSMITHKLINE	50MG	N020358	001	Oct 04, 1996
ZYBAN					
	GLAXOSMITHKLINE	100MG	N020711	002	May 14, 1997
+		150MG	N020711	003	May 14, 1997
BUSPIRONE HYDROCHLORIDE					
CAPSULE;ORAL					
BUSPAR					
	BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000
		7.5MG	N021190	002	Dec 20, 2000
		10MG	N021190	003	Dec 20, 2000
		15MG	N021190	004	Dec 20, 2000
TABLET;ORAL					
BUSPAR					
+	BRISTOL MYERS SQUIBB	5MG **	N018731	001	Sep 29, 1986
+		10MG **	N018731	002	Sep 29, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUSPIRONE HYDROCHLORIDE				
TABLET;ORAL				
BUSPAR				
+	15MG **	N018731	003	Apr 22, 1996
+	30MG **	N018731	004	Apr 22, 1996
BUSPIRONE HYDROCHLORIDE				
EGIS	5MG	A075119	001	Mar 14, 2002
	10MG	A075119	002	Mar 14, 2002
	15MG	A075119	003	Jan 23, 2003
FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002
	10MG	A075413	002	Mar 19, 2002
	15MG	A075413	003	Mar 19, 2002
IVAX SUB TEVA PHARMS	5MG **	A075385	001	Mar 01, 2002
	10MG **	A075385	002	Mar 01, 2002
	15MG **	A075385	003	Mar 01, 2002
MYLAN	5MG	A075467	001	Feb 28, 2002
	10MG	A075467	003	Feb 28, 2002
	15MG	A075467	004	Feb 28, 2002
NESHER PHARMS	5MG	A075572	001	Feb 27, 2002
	10MG	A075572	002	Feb 27, 2002
	15MG	A075572	003	Feb 27, 2002
OXFORD PHARMS	5MG	A075388	001	May 09, 2002
	10MG	A075388	002	May 09, 2002
	15MG	A075388	003	May 09, 2002
RUBICON	5MG	A075521	001	Apr 05, 2002
	10MG	A075521	002	Apr 05, 2002
	15MG	A075521	003	Apr 05, 2002
BUTABARBITAL SODIUM				
CAPSULE;ORAL				
BUTICAPS				
MEDPOINTE PHARM HLC	15MG	A085381	001	
	30MG	A085381	002	
	50MG	A085381	003	
	100MG	A085381	004	
ELIXIR;ORAL				
BUTABARB				
ALPHARMA US PHARMS	30MG/5ML	A085873	001	
BUTABARBITAL SODIUM				
WOCKHARDT	30MG/5ML	A085383	001	
BUTALAN				
LANNETT	33.3MG/5ML	A085880	001	
BUTISOL SODIUM				
MEDA PHARMS	30MG/5ML	A085380	001	
SARISOL				
HALSEY	30MG/5ML	A084723	001	
TABLET;ORAL				
BUTABARBITAL				
BUNDY	30MG	A085550	001	
BUTABARBITAL SODIUM				
SANDOZ	15MG	A084292	003	Feb 09, 1982
	15MG	A085938	001	
	30MG	A084272	002	
	30MG	A085934	001	
SOLVAY	16.2MG	A083606	001	
	32.4MG	A083898	001	
	48.6MG	A083897	001	
	97.2MG	A083896	001	
TEVA	15MG	A088632	001	May 18, 1985
	30MG	A088631	001	May 01, 1985
WATSON LABS	15MG	A085764	001	
	30MG	A085772	001	
WHITEWORTH TOWN PLSN	15MG	A083325	002	
	30MG	A083337	001	
BUTISOL SODIUM				
MYLAN SPECIALITY LP	15MG	N000793	002	
	50MG	N000793	003	
	100MG	N000793	005	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUTABARBITAL SODIUM				
TABLET;ORAL				
SARISOL NO. 1				
HALSEY	15MG		A084719 001	
SARISOL NO. 2				
HALSEY	30MG		A084719 002	
SODIUM BUTABARBITAL				
HIKMA PHARMS	15MG		A085418 001	
	30MG		A085432 001	
IVAX SUB TEVA PHARMS	15MG		A083484 001	
	30MG		A084040 001	
LANNETT	15MG		A085849 001	
	30MG		A085866 001	
	100MG		A085881 001	
MARSHALL PHARMA	16.2MG		A083524 001	
	32.4MG		A083858 001	
BUTENAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
MENTAX-TC				
MYLAN	1%		N021408 001	Oct 17, 2002
BUTOCONAZOLE NITRATE				
CREAM;VAGINAL				
BUTOCONAZOLE NITRATE				
PERRIGO PHARMA INTL	2%		N019881 001	Feb 07, 1997
FEMSTAT				
ROCHE PALO	2%		N019215 001	Nov 25, 1985
FEMSTAT 3				
+ BAYER	2%		N020421 001	Dec 21, 1995
SUPPOSITORY;VAGINAL				
FEMSTAT				
ROCHE PALO	100MG		N019359 001	Nov 25, 1985
BUTORPHANOL TARTRATE				
INJECTABLE;INJECTION				
BUTORPHANOL TARTRATE				
BAXTER HLTHCARE CORP	2MG/ML		A075697 001	Oct 23, 2001
HIKMA FARMACEUTICA	2MG/ML		A078247 001	Apr 29, 2009
HOSPIRA	1MG/ML		A075342 001	Nov 04, 1999
	1MG/ML		A075559 001	Mar 20, 2000
	2MG/ML		A075342 002	Nov 04, 1999
	2MG/ML		A075559 002	Mar 20, 2000
BUTORPHANOL TARTRATE PRESERVATIVE FREE				
BAXTER HLTHCARE CORP	1MG/ML		A075695 001	Oct 23, 2001
	2MG/ML		A075695 002	Oct 23, 2001
HOSPIRA	1MG/ML		A074620 001	Jan 22, 1997
	1MG/ML		A075170 001	Sep 28, 1998
	2MG/ML		A074620 002	Jan 22, 1997
	2MG/ML		A075170 002	Sep 28, 1998
STADOL				
+ APOTHECON	2MG/ML **		N017857 004	
STADOL PRESERVATIVE FREE				
+ APOTHECON	1MG/ML **		N017857 001	
+	2MG/ML **		N017857 002	
SPRAY, METERED;NASAL				
STADOL				
BRISTOL MYERS SQUIBB	1MG/SPRAY **		N019890 001	Dec 12, 1991
CABERGOLINE				
TABLET;ORAL				
CABERGOLINE				
ACTAVIS LABS FL INC	0.5MG		A078035 001	Apr 21, 2008
APOTEX CORP	0.5MG		A201503 001	Mar 08, 2013
IMPAX LABS INC	0.5MG		A077843 001	Jul 03, 2007
DOSTINEX				
+ PHARMACIA AND UPJOHN	0.5MG **		N020664 001	Dec 23, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAFFEINE CITRATE					
SOLUTION;ORAL					
CAFFEINE CITRATE					
	LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009
CAFFEINE; ERGOTAMINE TARTRATE					
SUPPOSITORY;RECTAL					
CAFERGOT					
+	NOVARTIS	100MG;2MG **	N009000	002	
TABLET;ORAL					
CAFERGOT					
	NOVARTIS	100MG;1MG	N006620	001	
WIGRAINE					
	ORGANON USA INC	100MG;1MG	A086562	001	
CALCIFEDIOL					
CAPSULE;ORAL					
CALDEROL					
	ORGANON USA INC	0.02MG	N018312	001	
		0.05MG	N018312	002	
CALCIPOTRIENE					
OINTMENT;TOPICAL					
DOVONEX					
+	LEO PHARMA AS	0.005% **	N020273	001	Dec 29, 1993
SOLUTION;TOPICAL					
DOVONEX					
+	LEO PHARM	0.005% **	N020611	001	Mar 03, 1997
CALCITONIN HUMAN					
INJECTABLE;INJECTION					
CIBACALCIN					
	NOVARTIS	0.5MG/VIAL	N018470	001	Oct 31, 1986
CALCITONIN SALMON					
INJECTABLE;INJECTION					
CALCIMAR					
+	SANOFI AVENTIS US	200 IU/ML **	N017769	001	
		400 IU/VIAL	N017497	001	
CALCITONIN-SALMON					
	IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995
MIACALCIN					
+	MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986
SPRAY, METERED;NASAL					
MIACALCIN					
+	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995
CALCITONIN SALMON RECOMBINANT					
SPRAY, METERED;NASAL					
FORTICAL					
	UPSHER SMITH LABS	200 IU/SPRAY **	N021406	001	Aug 12, 2005
CALCITRIOL					
CAPSULE;ORAL					
CALCITRIOL					
	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019
		0.5MCG	A204556	002	Feb 21, 2019
INJECTABLE;INJECTION					
CALCIJEX					
+	ABBVIE	0.001MG/ML **	N018874	001	Sep 25, 1986
+		0.002MG/ML **	N018874	002	Sep 25, 1986
CALCITRIOL					
	AKORN	0.002MG/ML	A078066	002	Jan 29, 2008
	FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002
		0.002MG/ML	A075836	002	Dec 31, 2002
	FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003
		0.002MG/ML	A075766	002	Feb 20, 2003
	HOSPIRA	0.001MG/ML	A075816	001	Jan 16, 2004
		0.002MG/ML	A075816	002	Jan 16, 2004
	LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003
		0.002MG/ML	A075746	002	Sep 26, 2003
	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003
	SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CALCITRIOL
INJECTABLE;INJECTION
CALCITRIOL

TEVA PARENTERAL	0.001MG/ML	A075823	001	Mar 31, 2003
	0.002MG/ML	A075823	002	Mar 31, 2003

CALCIUM ACETATE
CAPSULE;ORAL
PHOSLO

FRESENIUS MEDCL	333.5MG	N021160	001	Apr 02, 2001
	667MG	N021160	002	Apr 02, 2001

TABLET;ORAL
CALCIUM ACETATE

HIKMA	667MG	A077693	001	Jan 30, 2008

ELIPHOS

CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008

PHOSLO

+ FRESENIUS MEDCL	667MG **	N019976	001	Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM
TABLET, TABLET;ORAL
ACTONEL WITH CALCIUM (COPACKAGED)

+ WARNER CHILCOTT	EQ 500MG BASE,N/A;N/A,35MG **	N021823	001	Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SOLUTION;IRRIGATION
METHOTREXATE SODIUM

AKORN	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N020079	001	Feb 26, 1999

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
INJECTABLE;INJECTION
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SOLUTION;IRRIGATION
NAVSTEL

ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864 001	Jun 10, 1993
B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N018271 001	

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019867 001	Dec 20, 1993
B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269 002	Jan 17, 1983

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML **	N017390 001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807 001	Aug 26, 1983
B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807 003	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807 002	Aug 26, 1983
B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807 004	Aug 26, 1983

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460 006	Jan 29, 1986

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460 001	

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460 003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379 002	

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379 003	

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379 007	Jun 24, 1988

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379 001	

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379 004	Jul 07, 1982

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379 005	Jul 07, 1982

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379 008	Jun 24, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE					
SOLUTION;INTRAPERITONEAL					
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	007	Jan 29, 1986
		26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	002	
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	005	Nov 02, 1983
		26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	008	Jan 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	009	Jan 29, 1986
		26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	004	
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	001	
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	003	
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	002	
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	001	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	002	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	003	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	004	Jun 13, 1994
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE					
INJECTABLE;INJECTION					
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018258	001	
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE					
INJECTABLE;INJECTION					
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER					
	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018254	001	
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018256	001	
		33MG/100ML;5GM/100ML;30MG/100ML;	N020000	001	Apr 17, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

	860MG/100ML			
BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N016695	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML	N019634	002	Feb 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017510	001	
MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018499	001	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988
+		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	008	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	004	Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395	001	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395	002	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395	003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399	001	Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899	001	Oct 31, 1983
	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718	001	Sep 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
ACETATED RINGER'S IN PLASTIC CONTAINER				
	B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018725 001	Nov 29, 1982
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
RINGER'S IN PLASTIC CONTAINER				
	B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721 001	Nov 09, 1982
SOLUTION;IRRIGATION				
RINGER'S IN PLASTIC CONTAINER				
	ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462 001	
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE				
INJECTABLE;INJECTION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019485 001	Oct 24, 1985
	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018023 001	
	MILES	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018417 001	
SOLUTION;IRRIGATION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019933 001	Aug 29, 1989
CALCIUM GLUCEPTATE				
INJECTABLE;INJECTION				
CALCIUM GLUCEPTATE				
	ABBOTT	EQ 90MG CALCIUM/5ML	A080001 001	
		EQ 90MG CALCIUM/5ML	A083159 001	
	ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373 001	Apr 30, 1987
	LILLY	EQ 90MG CALCIUM/5ML	N006470 001	
CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM				
INJECTABLE;INJECTION				
ISOPAQUE 440				
	GE HEALTHCARE	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N016847 001	
CALCIUM; MEGLUMINE; METRIZOIC ACID				
INJECTABLE;INJECTION				
ISOPAQUE 280				
	GE HEALTHCARE	0.35MG/ML;140.1MG/ML;461.8MG/ML	N017506 001	
CANDESARTAN CILEXETIL				
TABLET;ORAL				
CANDESARTAN CILEXETIL				
	APOTEX INC	4MG	A202079 001	Jan 10, 2014
		8MG	A202079 002	Jan 10, 2014
		16MG	A202079 003	Jan 10, 2014
		32MG	A202079 004	Jan 10, 2014
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE				
	APOTEX INC	16MG;12.5MG	A202884 001	Dec 04, 2012
		32MG;12.5MG	A202884 002	Dec 04, 2012
		32MG;25MG	A202884 003	Jun 03, 2013
CANDICIDIN				
OINTMENT;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	0.6MG/GM	A061596 001	
TABLET;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	3MG	A061613 001	

CAPTOPRIL

TABLET;ORAL

CAPOTEN

+	PAR PHARM	12.5MG **	N018343	005	Jan 17, 1985
+		25MG **	N018343	002	
+		37.5MG **	N018343	006	Sep 17, 1986
+		50MG **	N018343	001	
+		75MG **	N018343	007	Jun 13, 1995
+		100MG **	N018343	003	
+		150MG **	N018343	004	Jun 13, 1995

CAPTOPRIL

ACP NIMBLE	12.5MG	A074433	001	Feb 13, 1996
	12.5MG	A074462	001	Feb 13, 1996
	12.5MG	A074483	001	Feb 13, 1996
	25MG	A074433	002	Feb 13, 1996
	25MG	A074462	002	Feb 13, 1996
	25MG	A074483	002	Feb 13, 1996
	50MG	A074433	003	Feb 13, 1996
	50MG	A074462	003	Feb 13, 1996
	50MG	A074483	003	Feb 13, 1996
	100MG	A074433	004	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
	100MG	A074483	004	Feb 13, 1996
APOTEX	12.5MG	A074737	001	Oct 28, 1998
	25MG	A074737	002	Oct 28, 1998
	50MG	A074737	003	Oct 28, 1998
	100MG	A074737	004	Oct 28, 1998
APOTHECON	12.5MG	A074472	001	Mar 31, 1995
	25MG	A074472	002	Mar 31, 1995
	50MG	A074472	003	Mar 31, 1995
	100MG	A074472	004	Mar 31, 1995
DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996
	25MG	A074423	002	Feb 13, 1996
	50MG	A074423	003	Feb 13, 1996
	100MG	A074423	004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
G AND W LABS INC	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074590	003	Aug 30, 1996
OXFORD PHARMS	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996
PAR PHARM	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
WATSON LABS	12.5MG	A074451	001	Feb 13, 1996
	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074451	002	Feb 13, 1996
	25MG	A074576	002	Apr 23, 1996
	50MG	A074451	003	Feb 13, 1996
	50MG	A074576	003	Apr 23, 1996
	100MG	A074451	004	Feb 13, 1996
	100MG	A074576	004	Apr 23, 1996
YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995
	12.5MG	A074519	001	Feb 13, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAPTOPRIL				
TABLET;ORAL				
CAPTOPRIL				
	25MG	A074363	002	Nov 09, 1995
	25MG	A074519	002	Feb 13, 1996
	50MG	A074363	003	Nov 09, 1995
	50MG	A074519	003	Feb 13, 1996
	100MG	A074363	004	Nov 09, 1995
	100MG	A074519	004	Feb 13, 1996
CAPTOPRIL; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
CAPOZIDE 25/15				
+ APOTHECON	25MG;15MG **	N018709	001	Oct 12, 1984
CAPOZIDE 25/25				
+ APOTHECON	25MG;25MG **	N018709	002	Oct 12, 1984
CAPOZIDE 50/15				
+ APOTHECON	50MG;15MG **	N018709	004	Oct 12, 1984
CAPOZIDE 50/25				
+ APOTHECON	50MG;25MG **	N018709	003	Oct 12, 1984
CAPTOPRIL AND HYDROCHLOROTHIAZIDE				
ACP NIMBLE	25MG;15MG	A074827	001	Dec 29, 1997
	25MG;25MG	A074827	002	Dec 29, 1997
	50MG;15MG	A074827	004	Dec 29, 1997
	50MG;25MG	A074827	003	Dec 29, 1997
IVAX SUB TEVA PHARMS	25MG;15MG	A075055	001	Jun 18, 1998
	25MG;25MG	A075055	002	Jun 18, 1998
	50MG;15MG	A075055	004	Jun 18, 1998
	50MG;25MG	A075055	003	Jun 18, 1998
VINTAGE PHARMS LLC	25MG;15MG	A074788	001	Dec 29, 1997
	25MG;25MG	A074788	002	Dec 29, 1997
	50MG;15MG	A074788	004	Dec 29, 1997
	50MG;25MG	A074788	003	Dec 29, 1997
WATSON LABS	50MG;25MG	A074832	001	Dec 29, 1997
CARBACHOL				
SOLUTION;INTRAOCULAR				
CARBACHOL				
PHARMAFAIR	0.01%	A070292	001	May 21, 1986
CARBASTAT				
NOVARTIS	0.01%	A073677	001	Apr 28, 1995
CARBAMAZEPINE				
CAPSULE, EXTENDED RELEASE;ORAL				
CARBAMAZEPINE				
NOSTRUM LABS INC	100MG	A076697	001	May 20, 2011
	200MG	A076697	002	May 20, 2011
	300MG	A076697	003	May 20, 2011
SOLUTION;INTRAVENOUS				
CARNEXIV				
+ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016
SUSPENSION;ORAL				
CARBAMAZEPINE				
TARO	100MG/5ML	A075875	001	Dec 21, 2000
TABLET;ORAL				
CARBAMAZEPINE				
ACTAVIS ELIZABETH	200MG	A071696	001	Nov 09, 1987
INWOOD LABS	200MG	A070231	001	Aug 14, 1986
PLIVA	200MG	A071479	001	Jul 24, 1987
USL PHARMA	200MG	A070300	001	May 15, 1986
WARNER CHILCOTT	200MG	A070429	001	Jan 02, 1987
TERIL				
TARO	200MG	A076525	001	Sep 26, 2003
TABLET, CHEWABLE;ORAL				
CARBAMAZEPINE				
JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBENICILLIN DISODIUM				
INJECTABLE;INJECTION				
GEOPEN				
ROERIG	EQ 1GM BASE/VIAL	N050306 001		
	EQ 2GM BASE/VIAL	N050306 004		
	EQ 5GM BASE/VIAL	N050306 002		
	EQ 10GM BASE/VIAL	N050306 006		
	EQ 30GM BASE/VIAL	N050306 007		
PYOPEN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298 001		
	EQ 2GM BASE/VIAL	N050298 002		
	EQ 5GM BASE/VIAL	N050298 003		
	EQ 10GM BASE/VIAL	N050298 006		
	EQ 20GM BASE/VIAL	N050298 007		
CARBENICILLIN INDANYL SODIUM				
TABLET;ORAL				
GEOCILLIN				
PFIZER	EQ 382MG BASE	N050435 001		
CARBIDOPA; ENTACAPONE; LEVODOPA				
TABLET;ORAL				
CARBIDOPA, LEVODOPA AND ENTACAPONE				
WOCKHARDT LTD	12.5MG;200MG;50MG	A090786 001	Nov 20, 2012	
	18.75MG;200MG;75MG	A090833 001	Nov 20, 2012	
	25MG;200MG;100MG	A090833 002	Nov 20, 2012	
	31.25MG;200MG;125MG	A090833 003	Nov 20, 2012	
	37.5MG;200MG;150MG	A090833 004	Nov 20, 2012	
	50MG;200MG;200MG	A090833 005	Nov 20, 2012	
CARBIDOPA; LEVODOPA				
TABLET;ORAL				
CARBIDOPA AND LEVODOPA				
ANI PHARMS INC	10MG;100MG	A073587 002	Jun 29, 1995	
	25MG;100MG	A073587 001	Jun 29, 1995	
	25MG;250MG	A073587 003	Jun 29, 1995	
SCS	10MG;100MG	A074080 001	Mar 25, 1994	
	25MG;100MG	A074080 002	Mar 25, 1994	
	25MG;250MG	A074080 003	Mar 25, 1994	
WATSON LABS	10MG;100MG	A073381 001	Sep 28, 1993	
	25MG;100MG	A073382 001	Sep 28, 1993	
	25MG;250MG	A073383 001	Sep 28, 1993	
TABLET, EXTENDED RELEASE;ORAL				
CARBIDOPA AND LEVODOPA				
KV PHARM	50MG;200MG	A076663 001	Jun 24, 2004	
SINEMET CR				
+ MERCK SHARP DOHME	50MG;200MG	N019856 001	May 30, 1991	
TABLET, FOR SUSPENSION;ORAL				
CARBILEV				
RANBAXY	10MG;100MG	A076643 001	Jun 10, 2005	
	25MG;100MG	A076643 002	Jun 10, 2005	
	25MG;250MG	A076643 003	Jun 10, 2005	
TABLET, ORALLY DISINTEGRATING;ORAL				
CARBIDOPA AND LEVODOPA				
IMPAX LABS	10MG;100MG	A090631 001	Jun 08, 2010	
	25MG;100MG	A090631 002	Jun 08, 2010	
	25MG;250MG	A090631 003	Jun 08, 2010	
PARCOPA				
UCB INC	10MG;100MG **	A076699 001	Aug 27, 2004	
	25MG;100MG **	A076699 002	Aug 27, 2004	
	25MG;250MG **	A076699 003	Aug 27, 2004	
CARBINOXAMINE MALEATE				
ELIXIR;ORAL				
CLISTIN				
+ MCNEIL	4MG/5ML **	N008955 001		
SOLUTION;ORAL				
CARBINOXAMINE MALEATE				
CYPRESS PHARM	4MG/5ML	A090418 001	May 04, 2010	
VINTAGE PHARMS	4MG/5ML	A040814 001	Feb 26, 2008	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBINOXAMINE MALEATE					
TABLET;ORAL					
CARBINOXAMINE MALEATE					
	CYPRESS PHARM	4MG	A090417	001	Aug 23, 2010
	VINTAGE PHARMS	4MG	A040639	002	May 30, 2008
CLISTIN					
+	ORTHO MCNEIL PHARM	4MG **	N008915	001	
CARBOPLATIN					
INJECTABLE;INJECTION					
CARBOPLATIN					
	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006
		150MG/VIAL	A077383	002	Jan 27, 2006
		450MG/VIAL	A077383	003	Jan 27, 2006
	FRESENIUS KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004
		150MG/VIAL	A076235	002	Oct 14, 2004
		450MG/VIAL	A076235	003	Oct 14, 2004
	HOSPIRA	50MG/VIAL	A076473	001	Oct 27, 2004
		150MG/VIAL	A076473	002	Oct 27, 2004
		450MG/VIAL	A076473	003	Oct 27, 2004
	MYLAN LABS LTD	50MG/VIAL	A091510	001	May 29, 2012
		150MG/VIAL	A091510	002	May 29, 2012
		450MG/VIAL	A091510	003	May 29, 2012
	PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004
		150MG/VIAL	A076602	002	Nov 16, 2004
		450MG/VIAL	A076602	003	Nov 16, 2004
	SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005
		150MG/VIAL	A076959	002	Mar 18, 2005
		450MG/VIAL	A076959	003	Mar 18, 2005
	WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004
		150MG/VIAL	A076162	002	Oct 14, 2004
		450MG/VIAL	A076162	003	Oct 14, 2004
	WEST-WARD PHARMS INT	50MG/VIAL	A076099	001	Oct 14, 2004
		150MG/VIAL	A076099	002	Oct 14, 2004
		450MG/VIAL	A076099	003	Oct 14, 2004
PARAPLATIN					
+	CORDEN PHARMA	50MG/VIAL **	N019880	001	Mar 03, 1989
+		150MG/VIAL **	N019880	002	Mar 03, 1989
+		450MG/VIAL **	N019880	003	Mar 03, 1989
INJECTABLE;INTRAVENOUS					
CARBOPLATIN					
	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012
		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012
		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012
		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012
	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006
		150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006
		450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006
		50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004
		50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006
		150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004
		150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006
	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007
		150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007
		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007
	MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011
		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011
		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011
		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011
		1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011
	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009
		150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009
		450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009
	TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007
		150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
		450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007
PARAPLATIN					
+	CORDENPHARMA	50MG/5ML (10MG/ML) **	N020452	001	Jul 14, 2003
+		150MG/15ML (10MG/ML) **	N020452	002	Jul 14, 2003
+		450MG/45ML (10MG/ML) **	N020452	003	Jul 14, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBOPLATIN				
INJECTABLE;INTRAVENOUS				
PARAPLATIN				
+	600MG/60ML (10MG/ML) **	N020452	004	Jan 15, 2004
CARISOPRODOL				
CAPSULE;ORAL				
SOMA				
+ MYLAN SPECIALITY LP	250MG	N011792	003	
TABLET;ORAL				
CARISOPRODOL				
ABLE	350MG	A040421	001	Jun 21, 2001
EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000
FOSUN PHARMA	350MG	A081025	001	Apr 13, 1989
OXFORD PHARMS	350MG	A040188	001	Mar 07, 1997
PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
SANDOZ	350MG	A089566	001	Aug 30, 1988
SUN PHARM INDS LTD	350MG	A040755	001	Feb 27, 2007
SUN PHARM INDUSTRIES	350MG	A089346	001	Oct 17, 1991
WATSON LABS	350MG	A040152	001	Dec 03, 1996
	350MG	A085433	001	
WATSON LABS TEVA	350MG	A086179	001	
RELA				
SCHERING	350MG	N012155	001	
CARPHENAZINE MALEATE				
CONCENTRATE;ORAL				
PROKETAZINE				
WYETH AYERST	50MG/ML	N014173	001	
TABLET;ORAL				
PROKETAZINE				
WYETH AYERST	12.5MG	N012768	001	
	25MG	N012768	002	
	50MG	N012768	004	
CARPROFEN				
TABLET;ORAL				
RIMADYL				
ROCHE	100MG	N018550	002	Dec 31, 1987
	150MG	N018550	003	Dec 31, 1987
CARTEOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
CARTEOLOL HYDROCHLORIDE				
APOTEX INC	1%	A076097	001	Feb 06, 2002
BAUSCH AND LOMB	1%	A075546	001	Jan 20, 2000
OCUPRESS				
+ NOVARTIS	1% **	N019972	001	May 23, 1990
TABLET;ORAL				
CARTROL				
ABBVIE	2.5MG	N019204	001	Dec 28, 1988
	5MG	N019204	002	Dec 28, 1988
	10MG	N019204	003	Dec 28, 1988
CARVEDILOL				
TABLET;ORAL				
CARVEDILOL				
HIKMA	3.125MG	A077887	001	Sep 07, 2007
	6.25MG	A077887	002	Sep 07, 2007
	12.5MG	A077887	003	Sep 07, 2007
	25MG	A077887	004	Sep 07, 2007
PLIVA HRVATSKA DOO	3.125MG	A078240	001	Oct 30, 2007
	6.25MG	A078240	002	Oct 30, 2007
	12.5MG	A078240	003	Oct 30, 2007
	25MG	A078240	004	Oct 30, 2007
SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007
	6.25MG	A077346	001	Sep 05, 2007
	12.5MG	A077346	002	Sep 05, 2007
	25MG	A077346	003	Sep 05, 2007
WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009
	6.25MG	A078786	002	Dec 22, 2009
	12.5MG	A078786	003	Dec 22, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARVEDILOL				
TABLET;ORAL				
CARVEDILOL				
	25MG		A078786 004	Dec 22, 2009
CASPOFUNGIN ACETATE				
POWDER;INTRAVENOUS				
CASPOFUNGIN ACETATE				
CIPLA	50MG/VIAL		A209489 001	Jul 12, 2018
	70MG/VIAL		A209489 002	Jul 12, 2018
CEFACLOR				
CAPSULE;ORAL				
CECLOR				
+ LILLY	EQ 250MG BASE **		N050521 001	
+	EQ 500MG BASE **		N050521 002	
CEFACLOR				
CEPH INTL	EQ 250MG BASE		A062205 001	
	EQ 500MG BASE		A062205 002	
DAVA PHARMS INC	EQ 250MG BASE		A064107 001	Apr 27, 1995
	EQ 500MG BASE		A064107 002	Apr 27, 1995
HERITAGE PHARMA	EQ 250MG BASE		A064148 001	May 23, 1996
	EQ 500MG BASE		A064148 002	May 23, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE		A064061 001	Apr 27, 1995
	EQ 500MG BASE		A064061 002	Apr 27, 1995
RANBAXY	EQ 250MG BASE		A064156 001	Aug 28, 1997
	EQ 500MG BASE		A064156 002	Aug 28, 1997
TEVA	EQ 250MG BASE		A064081 001	Sep 16, 1996
	EQ 250MG BASE		A064145 001	Jun 24, 1996
	EQ 500MG BASE		A064081 002	Sep 16, 1996
	EQ 500MG BASE		A064145 002	Jun 24, 1996
FOR SUSPENSION;ORAL				
CECLOR				
+ LILLY	EQ 125MG BASE/5ML **		N050522 001	
+	EQ 250MG BASE/5ML **		N050522 002	
CEFACLOR				
DAVA PHARMS INC	EQ 125MG BASE/5ML		A064114 001	Apr 28, 1995
	EQ 187MG BASE/5ML		A064115 001	Apr 28, 1995
	EQ 250MG BASE/5ML		A064116 001	Apr 28, 1995
	EQ 375MG BASE/5ML		A064110 001	Apr 28, 1995
FACTA FARMA	EQ 125MG BASE/5ML		A062206 001	
	EQ 187MG BASE/5ML		A062206 003	Apr 20, 1988
	EQ 250MG BASE/5ML		A062206 002	
	EQ 375MG BASE/5ML		A062206 004	Apr 20, 1988
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML		A064087 001	Apr 28, 1995
	EQ 187MG BASE/5ML		A064086 001	Apr 28, 1995
	EQ 250MG BASE/5ML		A064085 001	Apr 28, 1995
	EQ 375MG BASE/5ML		A064070 001	Apr 28, 1995
RANBAXY	EQ 125MG BASE/5ML		A064166 001	Oct 02, 1997
	EQ 187MG BASE/5ML		A064165 001	Oct 02, 1997
	EQ 250MG BASE/5ML		A064164 001	Oct 02, 1997
	EQ 375MG BASE/5ML		A064155 001	Oct 02, 1997
WATSON LABS INC	EQ 125MG BASE/5ML		A064204 001	Feb 18, 1998
	EQ 187MG BASE/5ML		A064205 001	Feb 18, 1998
	EQ 250MG BASE/5ML		A064206 001	Feb 18, 1998
	EQ 375MG BASE/5ML		A064207 001	Feb 18, 1998
TABLET, CHEWABLE;ORAL				
RANICLOR				
RANBAXY LABS LTD	EQ 125MG BASE		A065092 001	Dec 22, 2003
	EQ 187MG BASE		A065092 002	Dec 22, 2003
	EQ 250MG BASE		A065092 003	Dec 22, 2003
	EQ 375MG BASE		A065092 004	Dec 22, 2003
TABLET, EXTENDED RELEASE;ORAL				
CECLOR CD				
LILLY	EQ 375MG BASE		N050673 001	Jun 28, 1996
	EQ 500MG BASE		N050673 002	Jun 28, 1996
CEFACLOR				
WORLD GEN	EQ 500MG BASE		A065057 001	Jan 05, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL				
CEFADROXIL				
	CSPC OUYI	EQ 500MG BASE	A205072 001	Jul 28, 2017
	IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001	Mar 03, 1987
	PUREPAC PHARM	EQ 500MG BASE	A063017 001	Jan 05, 1989
	RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999
	SANDOZ	EQ 500MG BASE	A062291 001	
	TEVA	EQ 500MG BASE	A062695 001	Feb 10, 1989
DURICEF				
	WARNER CHILCOTT	EQ 250MG BASE	N050512 002	
+		EQ 500MG BASE **	N050512 001	
ULTRACEF				
	BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982
FOR SUSPENSION;ORAL				
CEFADROXIL				
	ANI PHARMS INC	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
		EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
		EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006
		EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
		EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006
	APOTHECON	EQ 125MG BASE/5ML	A062334 001	
		EQ 250MG BASE/5ML	A062334 002	
		EQ 500MG BASE/5ML	A062334 003	
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115 001	Mar 26, 2003
		EQ 250MG BASE/5ML	A065115 002	Mar 26, 2003
		EQ 500MG BASE/5ML	A065115 003	Mar 26, 2003
DURICEF				
+	WARNER CHILCOTT	EQ 125MG BASE/5ML **	N050527 002	
+		EQ 250MG BASE/5ML **	N050527 003	
+		EQ 500MG BASE/5ML **	N050527 001	
ULTRACEF				
	BRISTOL	EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
		EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
		EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982
TABLET;ORAL				
CEFADROXIL				
	RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999
DURICEF				
+	WARNER CHILCOTT	EQ 1GM BASE **	N050528 001	
ULTRACEF				
	APOTHECON	EQ 1GM BASE	A062390 001	Jun 10, 1982
	BRISTOL	EQ 1GM BASE	A062408 001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE;INJECTION				
MANDOL				
	LILLY	EQ 500MG BASE/VIAL	N050504 001	
		EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
		EQ 1GM BASE/VIAL	N050504 002	
		EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
		EQ 2GM BASE/VIAL	N050504 003	
		EQ 10GM BASE/VIAL	N050504 004	

CEFAZOLIN SODIUM

INJECTABLE;INJECTION				
ANCEF				
+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461 001	
+		EQ 500MG BASE/VIAL	N050461 002	
+		EQ 1GM BASE/VIAL **	N050461 003	
+		EQ 5GM BASE/VIAL **	N050461 004	
+		EQ 10GM BASE/VIAL **	N050461 005	
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 004	Jun 08, 1983
ANCEF IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFAZOLIN SODIUM				
INJECTABLE;INJECTION				
CEFAZOLIN AND DEXTROSE				
B BRAUN	EQ 500MG BASE/VIAL	N050779	001	Jul 27, 2000
CEFAZOLIN SODIUM				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688	002	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062688	003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062688	005	Aug 03, 1987
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008
	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008
BEDFORD	EQ 250MG BASE/VIAL	A062894	001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894	002	Jul 21, 1988
	EQ 1GM BASE/VIAL	A062894	003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894	004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894	005	Jul 21, 1988
CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280	001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A065280	002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295	001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296	001	Mar 18, 2009
DR REDDYS	EQ 250MG BASE/VIAL	A062988	001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988	002	Dec 29, 1989
	EQ 1GM BASE/VIAL	A062988	003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989	001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989	002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989	003	Dec 29, 1989
FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991
	EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991
	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999
FRESENIUS KABI USA	EQ 500MG BASE/VIAL **	A064169	001	Aug 14, 1998
	EQ 1GM BASE/VIAL **	A064169	002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170	001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170	002	Mar 18, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033	001	Oct 31, 1993
HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005
	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005
	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005
	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016
	EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005
STERI PHARMA	EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991
TEVA PHARMS	EQ 250MG BASE/VIAL	A063016	001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016	002	Mar 14, 1989
	EQ 1GM BASE/VIAL	A063016	003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018	001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018	002	Mar 05, 1990
WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807	001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807	002	Jan 12, 1988
	EQ 1GM BASE/VIAL	A062807	003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988
KEFZOL				
ACS DOBFAR	EQ 250MG BASE/VIAL	A061773	001	
	EQ 500MG BASE/VIAL	A061773	002	
	EQ 1GM BASE/VIAL	A061773	003	
	EQ 10GM BASE/VIAL	A061773	004	
	EQ 20GM BASE/VIAL	A061773	005	Sep 08, 1987
LILLY	EQ 500MG BASE/VIAL	A062557	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557	002	Sep 10, 1985
CEFDINIR				
CAPSULE;ORAL				
OMNICEF				
+ ABBVIE	300MG **	N050739	001	Dec 04, 1997
FOR SUSPENSION;ORAL				
OMNICEF				
+ ABBVIE	125MG/5ML **	N050749	001	Dec 04, 1997
+	250MG/5ML **	N050749	002	Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFDITOREN PIVOXIL				
TABLET;ORAL				
SPECTRACEF				
VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001
	400MG	N021222	002	Jul 21, 2008
CEFEPIME HYDROCHLORIDE				
INJECTABLE;INJECTION				
CEFEPIME HYDROCHLORIDE				
FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010
	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010
	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007
	EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007
	EQ 1GM BASE/VIAL	A202268	001	Jul 30, 2012
	EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007
	EQ 2GM BASE/VIAL	A202268	002	Jul 30, 2012
CEFIXIME				
FOR SUSPENSION;ORAL				
CEFIXIME				
SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017
	200MG/5ML	A206144	002	Nov 17, 2017
SUPRAX				
+ LEDERLE	100MG/5ML **	N050622	001	Apr 28, 1989
TABLET;ORAL				
SUPRAX				
+ LEDERLE	200MG **	N050621	001	Apr 28, 1989
+	400MG **	N050621	002	Apr 28, 1989
CEFMENOXIME HYDROCHLORIDE				
INJECTABLE;INJECTION				
CEFMAX				
TAP PHARM	EQ 500MG BASE/VIAL	N050571	001	Dec 30, 1987
	EQ 1GM BASE/VIAL	N050571	002	Dec 30, 1987
	EQ 2GM BASE/VIAL	N050571	003	Dec 30, 1987
CEFMETAZOLE SODIUM				
INJECTABLE;INJECTION				
ZEFAZONE				
+ PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL **	N050637	001	Dec 11, 1989
+	EQ 2GM BASE/VIAL **	N050637	002	Dec 11, 1989
ZEFAZONE IN PLASTIC CONTAINER				
+ PHARMACIA AND UPJOHN	EQ 20MG BASE/ML **	N050683	001	Dec 29, 1992
+	EQ 40MG BASE/ML **	N050683	002	Dec 29, 1992
CEFONICID SODIUM				
INJECTABLE;INJECTION				
MONOCID				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579	001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295	001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579	002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579	003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579	004	May 23, 1984
CEFOPERAZONE SODIUM				
INJECTABLE;INJECTION				
CEFOBID				
PFIZER	EQ 1GM BASE/VIAL	A063333	001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551	001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333	002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551	002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551	003	Mar 05, 1990
CEFOBID IN PLASTIC CONTAINER				
PFIZER	EQ 20MG BASE/ML	N050613	002	Jul 31, 1987
	EQ 40MG BASE/ML	N050613	001	Jul 23, 1986

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFORANIDE

INJECTABLE;INJECTION

PRECEF

APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200	001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200	002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200	003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201	001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
WOCKHARDT	EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004

CEFOTAXIME SODIUM

AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006
	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016
	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006
	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006
	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016
	EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006
LUPIN	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003
	EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003
	EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003
WOCKHARDT	EQ 500MG BASE/VIAL	A065197	002	Jun 20, 2008
	EQ 2GM BASE/VIAL	A065197	003	Jun 20, 2008

CLAFORAN

	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987
		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987
+	US PHARM HOLDINGS	EQ 500MG BASE/VIAL **	N050547	001	
+		EQ 1GM BASE/VIAL **	N050547	002	
+		EQ 2GM BASE/VIAL **	N050547	003	
+		EQ 10GM BASE/VIAL **	N050547	004	Dec 29, 1983

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	EQ 40MG BASE/ML	N050596	004	May 20, 1985

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

TELIGENT	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993

CEFOTAN IN PLASTIC CONTAINER

TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFOTETAN DISODIUM				
INJECTABLE;INJECTION				
CEFOTETAN				
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007
WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011
CEFOTIAM HYDROCHLORIDE				
INJECTABLE;INJECTION				
CERADON				
TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988
CEFOXITIN SODIUM				
INJECTABLE;INJECTION				
CEFOXITIN				
ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011
	EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011
	EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011
FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012	001	Jul 03, 2000
	EQ 2GM BASE/VIAL **	A065012	002	Jul 03, 2000
	EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000
HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006
	EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006
	EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006
MEFOXIN				
MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
+	EQ 1GM BASE/VIAL **	N050517	001	
	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
+	EQ 2GM BASE/VIAL **	N050517	002	
+	EQ 10GM BASE/VIAL **	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ MERCK	EQ 20MG BASE/ML **	N050581	003	Sep 20, 1984
+	EQ 40MG BASE/ML **	N050581	004	Sep 20, 1984
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ MERCK	EQ 20MG BASE/ML **	N050581	002	Sep 20, 1984
+	EQ 40MG BASE/ML **	N050581	001	Sep 20, 1984
CEFPIRAMIDE SODIUM				
INJECTABLE;INJECTION				
CEFPIRAMIDE SODIUM				
WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989
CEFPODOXIME PROXETIL				
FOR SUSPENSION;ORAL				
BANAN				
SANKYO	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992
CEFPODOXIME PROXETIL				
SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009
	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009
SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002
	EQ 100MG BASE/5ML	A065082	002	May 31, 2002
VANTIN				
+ PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML **	N050675	001	Aug 07, 1992
+	EQ 100MG BASE/5ML **	N050675	002	Aug 07, 1992
TABLET;ORAL				
BANAN				
SANKYO	EQ 100MG BASE	N050687	001	Aug 07, 1992
	EQ 200MG BASE	N050687	002	Aug 07, 1992
CEFPODOXIME PROXETIL				
SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003
	EQ 200MG BASE	A065083	002	Aug 20, 2003
VANTIN				
+ PHARMACIA AND UPJOHN	EQ 100MG BASE **	N050674	001	Aug 07, 1992
+	EQ 200MG BASE **	N050674	002	Aug 07, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFPROZIL					
FOR SUSPENSION;ORAL					
CEFPROZIL					
	RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006
		250MG/5ML	A065202	002	Jun 30, 2006
CEFZIL					
+	CORDEN PHARMA	125MG/5ML **	N050665	001	Dec 23, 1991
+		250MG/5ML **	N050665	002	Dec 23, 1991
TABLET;ORAL					
CEFPROZIL					
	RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006
		500MG	A065198	002	Dec 13, 2006
CEFZIL					
+	CORDEN PHARMA	250MG **	N050664	001	Dec 23, 1991
+		500MG **	N050664	002	Dec 23, 1991
CEFTAZIDIME					
INJECTABLE;INJECTION					
CEFTAZIDIME					
	ACS DOBFAR	500MG/VIAL	A062640	001	Nov 20, 1985
	AUROBINDO PHARMA LTD	500MG/VIAL	A065481	001	May 28, 2010
		1GM/VIAL	A065481	002	May 28, 2010
		2GM/VIAL	A065481	003	May 28, 2010
		6GM/VIAL	A065482	001	May 28, 2010
CEPTAZ					
	GLAXOSMITHKLINE	500MG/VIAL	N050646	001	Sep 27, 1990
		1GM/VIAL	N050646	002	Sep 27, 1990
		2GM/VIAL	N050646	003	Sep 27, 1990
		10GM/VIAL	N050646	004	Sep 27, 1990
PENTACEF					
	GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
		1GM/VIAL	A064006	001	Mar 31, 1992
		2GM/VIAL	A063322	002	Nov 07, 1995
		2GM/VIAL	A064006	002	Mar 31, 1992
		6GM/VIAL	A064008	001	Mar 31, 1992
		10GM/VIAL	A064008	002	Mar 31, 1992
TAZIDIME					
	LILLY	1GM/VIAL	A062655	001	Nov 20, 1985
		2GM/VIAL	A062655	002	Nov 20, 1985
TAZIDIME IN PLASTIC CONTAINER					
	LILLY	1GM/VIAL	A062739	001	Jul 10, 1986
		2GM/VIAL	A062739	002	Jul 10, 1986
CEFTAZIDIME SODIUM					
INJECTABLE;INJECTION					
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221	001	Apr 29, 1993
		EQ 20MG BASE/ML	A063221	002	Apr 29, 1993
		EQ 40MG BASE/ML	A063221	003	Apr 29, 1993
FORTAZ IN PLASTIC CONTAINER					
	TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989
+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989
CEFTIBUTEN DIHYDRATE					
CAPSULE;ORAL					
CEDAX					
	SI PHARMS	EQ 400MG BASE	N050685	002	Dec 20, 1995
FOR SUSPENSION;ORAL					
CEDAX					
+	SI PHARMS	EQ 90MG BASE/5ML **	N050686	001	Dec 20, 1995
+		EQ 180MG BASE/5ML **	N050686	002	Dec 20, 1995
CEFTIZOXIME SODIUM					
INJECTABLE;INJECTION					
CEFIZOX					
	ASTELLAS	EQ 500MG BASE/VIAL	N050560	001	Sep 15, 1983
		EQ 1GM BASE/VIAL	A063294	002	Mar 31, 1994
		EQ 1GM BASE/VIAL	N050560	002	Sep 15, 1983
		EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
		EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFTIZOXIME SODIUM					
INJECTABLE;INJECTION					
CEFIZOX					
		EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER					
	ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
		EQ 40MG BASE/ML	N050589	002	Oct 03, 1984
CEFIZOX IN PLASTIC CONTAINER					
	ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
		EQ 40MG BASE/ML	N050589	004	Apr 13, 1995
CEFTRIAXONE SODIUM					
INJECTABLE;INJECTION					
CEFTRIAXONE					
	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013
	AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008
	BEDFORD	EQ 10GM BASE/VIAL	A065475	001	Aug 18, 2008
	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007
	FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252	001	Feb 15, 2006
	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005
		EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012
		EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005
		EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012
	LUPIN	EQ 10GM BASE/VIAL	A065263	001	Sep 12, 2006
	TEVA	EQ 10GM BASE/VIAL	A065274	001	May 01, 2006
ROCEPHIN					
	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993
		EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
		EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993
		EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
		EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993
		EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
+		EQ 10GM BASE/VIAL **	N050585	005	Dec 21, 1984
	ROCHE	EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
		EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
		EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
+	HOFFMANN LA ROCHE	EQ 10MG BASE/ML **	N050624	001	Feb 11, 1987
+		EQ 20MG BASE/ML **	N050624	002	Feb 11, 1987
+		EQ 40MG BASE/ML **	N050624	003	Feb 11, 1987
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
CEFTRIAXONE					
	AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
		EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
		EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
		EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008
	BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008
		EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008
		EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008
		EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008
	CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
		EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
		EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
		EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
	FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
		EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
		EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
		EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005
		EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005
		EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005
		EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005
	TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
		EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006
	TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
		EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CEFTRIAXONE SODIUM				
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
ROCEPHIN				
+	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL **	N050585 001	Dec 21, 1984
+		EQ 500MG BASE/VIAL **	N050585 002	Dec 21, 1984
+		EQ 1GM BASE/VIAL **	N050585 003	Dec 21, 1984
+		EQ 2GM BASE/VIAL **	N050585 004	Dec 21, 1984
CEFTRIAXONE SODIUM; LIDOCAINE				
INJECTABLE;INJECTION				
ROCEPHIN KIT				
	HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N050585 007	May 08, 1996
		EQ 1GM BASE/VIAL,N/A;N/A,1%	N050585 006	May 08, 1996
CEFUROXIME AXETIL				
FOR SUSPENSION;ORAL				
CEFTIN				
+	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672 001	Jun 30, 1994
+		EQ 250MG BASE/5ML	N050672 002	Apr 29, 1997
CEFUROXIME AXETIL				
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323 001	Feb 05, 2008
		EQ 250MG BASE/5ML	A065323 002	Feb 05, 2008
TABLET;ORAL				
CEFTIN				
+	GLAXOSMITHKLINE	EQ 125MG BASE **	N050605 001	Dec 28, 1987
+		EQ 250MG BASE **	N050605 002	Dec 28, 1987
+		EQ 500MG BASE **	N050605 003	Dec 28, 1987
CEFUROXIME AXETIL				
	ANI PHARMS INC	EQ 250MG BASE	A065190 001	Oct 18, 2004
		EQ 500MG BASE	A065190 002	Oct 18, 2004
	FOSUN PHARMA	EQ 250MG BASE	A065126 001	Oct 28, 2003
		EQ 500MG BASE	A065126 002	Oct 28, 2003
	RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002
		EQ 250MG BASE	A065043 002	Feb 15, 2002
		EQ 500MG BASE	A065043 001	Feb 15, 2002
	SUN PHARM INDS LTD	EQ 125MG BASE	A065118 001	Apr 25, 2003
		EQ 250MG BASE	A065118 002	Apr 25, 2003
		EQ 500MG BASE	A065118 003	Apr 25, 2003
CEFUROXIME SODIUM				
INJECTABLE;INJECTION				
CEFUROXIME SODIUM				
	FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001
		EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998
	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008
		EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008
		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008
	TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998
	WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035 002	Feb 26, 1993
		EQ 7.5GM BASE/VIAL	A064036 001	Feb 26, 1993
CEFUROXIME SODIUM IN PLASTIC CONTAINER				
	SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251 001	Dec 30, 2009
		EQ 225GM BASE/VIAL	A065251 002	Dec 30, 2009
KEFUROX				
	ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591 002	Jan 10, 1986
		EQ 7.5GM BASE/VIAL	A062591 003	Dec 17, 1987
	LILLY	EQ 1.5GM BASE/VIAL	A062592 002	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER				
	LILLY	EQ 1.5GM BASE/VIAL	A062590 002	Jan 10, 1986
ZINACEF IN PLASTIC CONTAINER				
	TELIGENT	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989
+		EQ 30MG BASE/ML	N050643 002	Apr 28, 1989
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
CEFUROXIME SODIUM				
	FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001
	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008
	TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998
		EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998
	WATSON LABS INC	EQ 750MG BASE/VIAL	A064035 001	Feb 26, 1993

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFUROXIME SODIUM				
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
KEFUROX				
ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986
INJECTABLE;INTRAVENOUS				
KEFUROX				
LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER				
LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986
CELLULOSE SODIUM PHOSPHATE				
POWDER;ORAL				
CALCIBIND				
MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
	300GM/BOT	N018757	003	Oct 16, 1984
CEPHALEXIN				
CAPSULE;ORAL				
CEPHALEXIN				
APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
	EQ 250MG BASE	A063063	001	Sep 29, 1989
	EQ 250MG BASE	A063186	001	Dec 30, 1994
	EQ 500MG BASE	A062974	001	Nov 23, 1988
	EQ 500MG BASE	A063063	002	Sep 29, 1989
	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118	001	
	EQ 500MG BASE	A062118	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
	EQ 500MG BASE	A061969	002	
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988
	EQ 500MG BASE	A062869	001	Mar 17, 1988
SUN PHARM INDS (IN)	EQ 250MG BASE	A062791	001	Jun 11, 1987
	EQ 500MG BASE	A062791	002	Jun 11, 1987
SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999
	EQ 500MG BASE	A065007	002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760	001	Apr 24, 1987
	EQ 250MG BASE	A062821	001	Feb 05, 1988
	EQ 500MG BASE	A062761	001	Apr 24, 1987
	EQ 500MG BASE	A062823	001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872	001	Jun 20, 1988
	EQ 500MG BASE	A062871	001	Jul 05, 1988
KEFLEX				
+ PRAGMA	EQ 333MG BASE **	N050405	004	May 12, 2006
FOR SUSPENSION;ORAL				
CEPHALEXIN				
APOTHECON	EQ 125MG BASE/5ML	A062986	001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987	001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778	001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777	001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML **	A062117	001	
	EQ 125MG BASE/5ML **	A062117	002	
	EQ 250MG BASE/5ML **	A062117	003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767	001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873	001	May 23, 1988
	EQ 250MG BASE/5ML	A062768	001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867	001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779	001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781	001	Dec 22, 1987
KEFLEX				
+ PRAGMA	EQ 100MG BASE/ML **	N050406	003	
+	EQ 125MG BASE/5ML **	N050406	001	
+	EQ 250MG BASE/5ML **	N050406	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHALEXIN				
TABLET;ORAL				
CEPHALEXIN				
BARR	EQ 250MG BASE	A062826	001	Aug 17, 1987
	EQ 500MG BASE	A062827	001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863	001	Aug 11, 1988
	EQ 500MG BASE	A062863	002	Aug 11, 1988
	EQ 1GM BASE	A062863	003	Aug 11, 1988
KEFLET				
LILLY	EQ 250MG BASE	A062745	001	Dec 01, 1986
	EQ 250MG BASE	N050440	003	Feb 26, 1987
	EQ 500MG BASE	A062745	002	Dec 01, 1986
	EQ 500MG BASE	N050440	001	
	EQ 1GM BASE	N050440	002	
TABLET, FOR SUSPENSION;ORAL				
PANIXINE DISPERDOSE				
RANBAXY LABS LTD	EQ 125MG BASE	A065100	002	Sep 11, 2003
	EQ 250MG BASE	A065100	001	Sep 11, 2003
CEPHALEXIN HYDROCHLORIDE				
TABLET;ORAL				
KEFTAB				
LILLY	EQ 250MG BASE	N050614	001	Oct 29, 1987
	EQ 333MG BASE	N050614	003	May 16, 1988
	EQ 500MG BASE	N050614	002	Oct 29, 1987
CEPHALOGLYCIN				
CAPSULE;ORAL				
KAFOCIN				
LILLY	250MG	N050219	001	
CEPHALOTHIN SODIUM				
INJECTABLE;INJECTION				
CEPHALOTHIN				
INTL MEDICATION	EQ 500MG BASE/VIAL	A062426	001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426	002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426	003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426	004	May 03, 1985
CEPHALOTHIN SODIUM				
ABBOTT	EQ 1GM BASE/VIAL	A062547	001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548	001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547	002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548	002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666	002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666	001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464	001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464	002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464	003	May 07, 1984
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422	005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730	001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422	004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730	002	Mar 05, 1987
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	002	Jan 31, 1984
KEFLIN				
LILLY	EQ 1GM BASE/VIAL	N050482	001	
	EQ 2GM BASE/VIAL	N050482	002	
	EQ 4GM BASE/VIAL	N050482	003	
	EQ 20GM BASE/VIAL	N050482	007	
KEFLIN IN PLASTIC CONTAINER				
LILLY	EQ 1GM BASE/VIAL	A062549	001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549	002	Sep 10, 1985
SEFFIN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435	001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435	002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435	003	Nov 15, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CEPHAPIRIN SODIUM				
INJECTABLE;INJECTION				
CEFADYL				
APOTHECON	EQ 500MG BASE/VIAL	A062961	001	Sep 20, 1988
	EQ 500MG BASE/VIAL	N050446	005	
	EQ 1GM BASE/VIAL	A061769	001	
	EQ 1GM BASE/VIAL	A062724	001	Dec 23, 1986
	EQ 1GM BASE/VIAL	A062961	002	Sep 20, 1988
	EQ 1GM BASE/VIAL	N050446	001	
	EQ 2GM BASE/VIAL	A061769	002	
	EQ 2GM BASE/VIAL	A062724	002	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446	002	
	EQ 4GM BASE/VIAL	A061769	003	
	EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446	003	
	EQ 20GM BASE/VIAL	N050446	004	
CEPHAPIRIN SODIUM				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
	EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
	EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986
WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987
	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987
	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987
CEPHRADINE				
CAPSULE;ORAL				
ANSPOR				
GLAXOSMITHKLINE	250MG	A061859	001	
	500MG	A061859	002	
CEPHRADINE				
BARR	250MG	A062850	001	Apr 22, 1988
	500MG	A062851	001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762	001	Mar 06, 1987
	500MG	A062762	002	Mar 06, 1987
TEVA	250MG	A062683	001	Jan 09, 1987
	500MG	A062683	002	Jan 09, 1987
VITARINE	250MG	A062813	001	Feb 25, 1988
	500MG	A062813	002	Feb 25, 1988
VELOSEF				
APOTHECON	250MG	A061764	001	
	500MG	A061764	002	
VELOSEF '250'				
ERSANA	250MG	N050548	001	
VELOSEF '500'				
ERSANA	500MG	N050548	002	
FOR SUSPENSION;ORAL				
ANSPOR				
GLAXOSMITHKLINE	125MG/5ML	A061866	001	
	250MG/5ML	A061866	002	
CEPHRADINE				
BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987
VELOSEF '125'				
APOTHECON	125MG/5ML	A061763	001	
VELOSEF '250'				
APOTHECON	250MG/5ML	A061763	002	
INJECTABLE;INJECTION				
VELOSEF				
APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHRADINE					
TABLET;ORAL					
VELOSEF					
	BRISTOL MYERS SQUIBB	1GM	N050530	001	
CERITINIB					
CAPSULE;ORAL					
ZYKADIA					
+	NOVARTIS	150MG	N205755	001	Apr 29, 2014
CERIVASTATIN SODIUM					
TABLET;ORAL					
BAYCOL					
	BAYER PHARMS	0.05MG	N020740	001	Jun 26, 1997
		0.1MG	N020740	002	Jun 26, 1997
		0.2MG	N020740	003	Jun 26, 1997
		0.3MG	N020740	004	Jun 26, 1997
		0.4MG	N020740	005	May 24, 1999
		0.8MG	N020740	006	Jul 24, 2000
CERULETIDE DIETHYLAMINE					
INJECTABLE;INJECTION					
TYMTRAN					
	PHARMACIA AND UPJOHN	0.02MG/ML	N018296	001	
CETIRIZINE HYDROCHLORIDE					
SYRUP;ORAL					
CETIRIZINE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010
	AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009
	LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009
	PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008
	RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008
	TORRENT	5MG/5ML	A078870	001	Apr 27, 2009
	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008
	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008
	PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008
	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008
	TORRENT	5MG/5ML	A090474	002	Mar 30, 2009
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008
	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008
	PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008
	RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008
	TORRENT	5MG/5ML	A090474	001	Mar 30, 2009
ZYRTEC					
	J AND J CONSUMER INC	5MG/5ML **	N020346	001	Sep 27, 1996
TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007
		10MG	A078615	004	Dec 28, 2007
	SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
		10MG	A077499	002	Dec 27, 2007
CETIRIZINE HYDROCHLORIDE HIVES					
	SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
		10MG	A077499	004	Dec 27, 2007
ZYRTEC ALLERGY					
+	J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007
ZYRTEC HIVES RELIEF					
+	J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007
+		10MG	N019835	006	Nov 16, 2007
TABLET, CHEWABLE;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	SUN PHARM INDS INC	5MG	A077631	004	Jan 11, 2008
		10MG	A077631	003	Jan 11, 2008
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	SUN PHARM INDS INC	5MG	A077631	001	Jan 11, 2008
		10MG	A077631	002	Jan 11, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CETIRIZINE HYDROCHLORIDE				
TABLET, CHEWABLE;ORAL				
CHILDREN'S ZYRTEC ALLERGY				
+	J AND J CONSUMER INC	5MG **	N021621 003	Nov 16, 2007
+		10MG **	N021621 004	Nov 16, 2007
CHILDREN'S ZYRTEC HIVES RELIEF				
+	J AND J CONSUMER INC	5MG **	N021621 005	Nov 16, 2007
+		10MG **	N021621 006	Nov 16, 2007
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
	PERRIGO R AND D	5MG;120MG	A210719 001	Nov 16, 2018
CETRORELIX				
INJECTABLE;INJECTION				
CETROTIDE				
	EMD SERONO INC	EQ 3MG BASE/ML	N021197 002	Aug 11, 2000
CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL				
FOR SUSPENSION;INTRATRACHEAL				
EXOSURF NEONATAL				
	GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N020044 001	Aug 02, 1990
CEVIMELINE HYDROCHLORIDE				
CAPSULE;ORAL				
CEVIMELINE HYDROCHLORIDE				
	APOTEX INC	30MG	A091260 001	Aug 25, 2011
CHENODIOL				
TABLET;ORAL				
CHENIX				
+	LEADIANT BIOSCI INC	250MG **	N018513 002	Jul 28, 1983
CHLOPHEDIANOL HYDROCHLORIDE				
SYRUP;ORAL				
ULO				
	3M	25MG/5ML	N012126 001	
CHLORAMPHENICOL				
CREAM;TOPICAL				
CHLOROMYCETIN				
	PARKE DAVIS	1%	N050183 001	
FOR SOLUTION;OPHTHALMIC				
CHLOROMYCETIN				
	PARKEDALE	25MG/VIAL	N050143 001	
INJECTABLE;INJECTION				
CHLOROMYCETIN				
	PARKE DAVIS	250MG/ML	N050153 001	
OINTMENT;OPHTHALMIC				
CHLORAMPHENICOL				
	ALTANA	1%	A060133 001	
CHLOROFAIR				
	PHARMAFAIR	1%	A062439 001	Apr 21, 1983
CHLOROMYCETIN				
	PARKEDALE	1%	N050156 001	
CHLOROPTIC S.O.P.				
	ALLERGAN	1%	A061187 001	
ECONOCHLOR				
	ALCON	1%	A061648 001	
SOLUTION/DROPS;OPHTHALMIC				
CHLORAMPHENICOL				
	AKORN	0.5%	A062042 001	
	ALCON	0.5%	A062628 001	Sep 25, 1985
CHLOROFAIR				
	PHARMAFAIR	0.5%	A062437 001	Apr 14, 1983
CHLOROPTIC				
	ALLERGAN	0.5%	N050091 001	
ECONOCHLOR				
	ALCON	0.5%	A061645 001	
OPHTHOCHLOR				
	PARKEDALE	0.5%	A061220 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORAMPHENICOL				
SOLUTION/DROPS;OPHTHALMIC				
OPTOMYCIN				
OPTOPICS	0.5%	A062171	001	Mar 31, 1982
SOLUTION/DROPS;OTIC				
CHLOROMYCETIN				
PARKEDALE	0.5%	N050205	001	
CHLORAMPHENICOL SODIUM SUCCINATE				
INJECTABLE;INJECTION				
CHLORAMPHENICOL				
ELKINS SINN	EQ 1GM BASE/VIAL	A062406	001	Nov 09, 1982
CHLORAMPHENICOL SODIUM SUCCINATE				
GRUPPO LEPETIT	EQ 1GM BASE/VIAL	A062278	001	
CHLOROMYCETIN				
+ PARKEDALE	EQ 1GM BASE/VIAL	N050155	001	
MYCHEL-S				
ANGUS	EQ 1GM BASE/VIAL	A060132	001	
CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN				
OINTMENT;TOPICAL				
ELASE-CHLOROMYCETIN				
+ PARKE DAVIS	10MG/GM;666 UNITS/GM;1 UNITS/GM	N050294	001	
CHLORAMPHENICOL; HYDROCORTISONE ACETATE				
FOR SUSPENSION;OPHTHALMIC				
CHLOROMYCETIN HYDROCORTISONE				
PARKEDALE	12.5MG/VIAL;25MG/VIAL	N050202	001	
CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
OPHTHOCORT				
PARKEDALE	10MG/GM;5MG/GM;10,000 UNITS/GM	N050201	002	
CHLORAMPHENICOL; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
CHLOROMYXIN				
PARKE DAVIS	1%;10,000 UNITS/GM	N050203	002	
CHLORAMPHENICOL; PREDNISOLONE				
OINTMENT;OPHTHALMIC				
CHLOROPTIC-P S.O.P.				
ALLERGAN	1%;0.5%	A061188	001	
CHLORDIAZEPOXIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
LIBRELEASE				
VALEANT PHARM INTL	30MG	N017813	001	Sep 12, 1983
TABLET;ORAL				
LIBRITABS				
VALEANT PHARM INTL	5MG	A085482	001	
	10MG	A085481	001	
	25MG	A085488	001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
CAPSULE;ORAL				
A-POXIDE				
ABBOTT	5MG	A085447	001	
	5MG	A085517	001	
	10MG	A085447	002	
	10MG	A085518	001	
	25MG	A085447	003	
	25MG	A085513	001	
CHLORDIAZACHEL				
RACHELLE	5MG	A085086	001	
	10MG	A084639	001	
	25MG	A085087	001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
ASCOT	5MG	A087525	001	Jan 07, 1982
	10MG	A087524	001	Jan 07, 1982
	25MG	A087512	001	Jan 07, 1982
FERRANTE	5MG	A085118	001	
	10MG	A085119	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL					
CHLORDIAZEPOXIDE HYDROCHLORIDE					
		25MG	A085120	001	
	HALSEY	5MG	A085340	001	
		10MG	A085339	001	
		25MG	A084685	001	
	IMPAX LABS	5MG	A086213	001	
		10MG	A085113	001	
		25MG	A086212	001	
	IVAX SUB TEVA PHARMS	5MG	A083741	001	
		10MG	A083742	001	
		25MG	A083570	001	
	LEDERLE	5MG	A086892	001	
		5MG	A087234	001	
		10MG	A086876	001	
		10MG	A087037	001	
		25MG	A086893	001	
		25MG	A087231	001	
	MAST MM	10MG	A086217	001	
	MYLAN	5MG	A084886	001	
		10MG	A084601	001	
		25MG	A084887	001	
	PARKE DAVIS	5MG	A085163	001	
		10MG	A084598	001	
		25MG	A085164	001	
	PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
		25MG	A089558	001	Jul 15, 1988
	PUREPAC PHARM	5MG	A085155	001	
		10MG	A084939	002	
		25MG	A085144	001	
	ROXANE	5MG	A084706	001	
		10MG	A084700	001	
		25MG	A084705	001	
	SUPERPHARM	5MG	A088987	001	Apr 25, 1985
		10MG	A088986	001	Apr 25, 1985
		25MG	A088988	001	Apr 25, 1985
	TEVA	5MG	A088705	001	Jan 18, 1985
		10MG	A088706	001	Jan 18, 1985
		25MG	A086494	001	
		25MG	A088707	001	Jan 18, 1985
	UPSHER SMITH LABS	5MG	A084678	001	
		5MG	A084919	001	
		10MG	A084041	001	
		10MG	A084920	001	
		25MG	A084679	002	
		25MG	A084823	001	
	USL PHARMA	5MG	A084644	001	
		10MG	A084623	001	
		25MG	A084645	001	
	VANGARD	5MG	A088129	001	Mar 28, 1983
		10MG	A088010	001	Mar 28, 1983
		25MG	A088130	001	Mar 28, 1983
	WATSON LABS	5MG	A086383	001	
		10MG	A086294	001	
		25MG	A086382	001	
	WEST WARD	5MG	A085014	001	
		10MG	A085000	001	
		25MG	A085294	001	
LIBRIUM					
+	VALEANT PHARM INTL	5MG **	N012249	002	
+		10MG **	N012249	001	
+		25MG **	N012249	003	
LYGEN					
	ALRA	5MG	A085107	001	
		10MG	A085009	001	
		25MG	A085108	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORDIAZEPOXIDE HYDROCHLORIDE				
INJECTABLE;INJECTION				
LIBRIUM				
BAUSCH	100MG/AMP	N012301 001		
CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED				
TABLET;ORAL				
MENRIUM 10-4				
ROCHE	10MG;0.4MG	N014740 006		
MENRIUM 5-2				
ROCHE	5MG;0.2MG	N014740 002		
MENRIUM 5-4				
ROCHE	5MG;0.4MG	N014740 004		
CHLORHEXIDINE GLUCONATE				
SOLUTION;DENTAL				
CHLORHEXIDINE GLUCONATE				
BAJAJ	0.12%	A075561 001	Nov 14, 2000	
SOLUTION;TOPICAL				
EXIDINE				
XTTRIUM	2.5%	N019421 001	Dec 17, 1985	
MICRODERM				
J AND J	4%	A072255 001	Apr 15, 1991	
PREVACARE R				
J AND J	0.5%	A072292 001	Jan 28, 1992	
STERI-STAT				
MATRIX MEDCL	4%	A070104 001	Jul 24, 1986	
SPONGE;TOPICAL				
CHLORHEXIDINE GLUCONATE				
KENDALL IL	4%	N019490 001	Mar 27, 1987	
E-Z SCRUB				
BECTON DICKINSON	4%	A073416 001	Mar 14, 2000	
HIBICLENS				
+ MOLNLYCKE HLTH	4% **	N018423 001		
MICRODERM				
J AND J	4%	A072295 001	Feb 28, 1991	
PHARMASEAL SCRUB CARE				
CAREFUSION 2200	4%	N019793 001	Dec 02, 1988	
CHLORMERODRIN HG-197				
INJECTABLE;INJECTION				
CHLORMERODRIN HG 197				
BRACCO	0.6-1.4mCi/ML	N017269 001		
CHLORMEZANONE				
TABLET;ORAL				
TRANCOPAL				
SANOFI AVENTIS US	100MG	N011467 003		
	200MG	N011467 005		
CHLOROPROCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NESACAINE-MPF				
FRESENIUS KABI USA	2%	N009435 003		
	3%	N009435 004		
CHLOROQUINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARALEN HYDROCHLORIDE				
SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002 002		
CHLOROQUINE PHOSPHATE				
TABLET;ORAL				
ARALEN				
+ SANOFI AVENTIS US	EQ 300MG BASE	N006002 001		
CHLOROQUINE PHOSPHATE				
IMPAX LABS	EQ 150MG BASE	A080880 001		
	EQ 300MG BASE	A040516 001	Aug 29, 2003	
MD PHARM	EQ 150MG BASE	A087228 001		
PUREPAC PHARM	EQ 150MG BASE	A080886 001		
TEVA	EQ 150MG BASE	A087504 001	Jan 13, 1982	
WATSON LABS	EQ 150MG BASE	A087979 001	Dec 21, 1982	
	EQ 300MG BASE	A088030 001	Dec 21, 1982	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE				
TABLET;ORAL				
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE				
	SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860 002	
CHLOROTHIAZIDE				
TABLET;ORAL				
CHLOROTHIAZIDE				
	ABC HOLDING	250MG	A085569 001	
	HIKMA INTL PHARMS	250MG	A086028 001	Jul 14, 1982
		500MG	A087736 001	Jul 14, 1982
	LEDERLE	250MG	A086940 001	
		500MG	A086938 001	
	SANDOZ	250MG	A085485 001	
	WATSON LABS	250MG	A085165 001	
		250MG	A085173 001	
		250MG	A086795 001	Aug 15, 1983
		500MG	A084026 001	Sep 01, 1982
		500MG	A086796 001	Aug 15, 1983
DIURIL				
+	OAK PHARMS AKORN	250MG **	N011145 004	
+		500MG **	N011145 002	
CHLOROTHIAZIDE; METHYLDOPA				
TABLET;ORAL				
ALDOCLOR-150				
	MERCK	150MG;250MG	N016016 001	
ALDOCLOR-250				
	MERCK	250MG;250MG	N016016 002	
METHYLDOPA AND CHLOROTHIAZIDE				
	PAR PHARM	150MG;250MG	A070783 001	Nov 06, 1987
		250MG;250MG	A070654 001	Nov 06, 1987
CHLOROTHIAZIDE; RESERPINE				
TABLET;ORAL				
CHLOROTHIAZIDE AND RESERPINE				
	HIKMA PHARMS	250MG;0.125MG	A088557 001	Dec 22, 1983
		500MG;0.125MG	A088365 001	Dec 22, 1983
CHLOROTHIAZIDE W/ RESERPINE				
	WATSON LABS	250MG;0.125MG	A084853 001	
		500MG;0.125MG	A088151 001	Jun 09, 1983
CHLOROTHIAZIDE-RESERPINE				
	MYLAN	250MG;0.125MG	A087744 001	May 06, 1982
		500MG;0.125MG	A087745 001	May 06, 1982
DIUPRES-250				
	MERCK	250MG;0.125MG	N011635 003	Aug 26, 1987
DIUPRES-500				
	MERCK	500MG;0.125MG	N011635 006	Aug 26, 1987
CHLOROTRIANISENE				
CAPSULE;ORAL				
CHLOROTRIANISENE				
	BANNER PHARMACAPS	12MG	A084652 001	
TACE				
	SANOFI AVENTIS US	12MG	N008102 004	
		25MG	N011444 001	
		72MG	N016235 001	
CHLOROXINE				
SHAMPOO;TOPICAL				
CAPITROL				
	WESTWOOD SQUIBB	2%	N017594 001	
CHLORPHENESIN CARBAMATE				
TABLET;ORAL				
MAOLATE				
	PAMLAB LLC	400MG	N014217 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CHLORPHENIRAMINE MALEATE					
CAPSULE, EXTENDED RELEASE;ORAL					
CHLORPHENIRAMINE MALEATE					
	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988
TELDRIN					
	GLAXOSMITHKLINE	8MG	N017369	001	
		12MG	N017369	002	
INJECTABLE;INJECTION					
CHLOR-TRIMETON					
	SCHERING PLOUGH	10MG/ML	N008826	001	
		100MG/ML	N008794	001	
CHLORPHENIRAMINE MALEATE					
	BEL MAR	10MG/ML	A080821	001	
	ELKINS SINN	10MG/ML	A080797	001	
	WATSON LABS	10MG/ML	A083593	001	
		10MG/ML	A086096	001	
		100MG/ML	A086095	001	
PYRIDAMAL 100					
	BEL MAR	100MG/ML	A083733	001	
SYRUP;ORAL					
CHLOR-TRIMETON					
	SCHERING	2MG/5ML	N006921	006	
CHLORPHENIRAMINE MALEATE					
	PHARM ASSOC	2MG/5ML	A087520	001	Feb 10, 1982
TABLET;ORAL					
ANTAGONATE					
	BAYER PHARMS	4MG	A083381	001	
CHLOR-TRIMETON					
	SCHERING	4MG	N006921	002	
CHLORPHENIRAMINE MALEATE					
	ANABOLIC	4MG	A083078	001	
	AUROLIFE PHARMA LLC	4MG	A080961	001	
	BELL PHARMA	4MG	A083062	001	
	ELKINS SINN	4MG	A080938	001	
	IMPAX LABS	4MG	A080809	001	
	IVAX SUB TEVA PHARMS	4MG	A080779	001	
	KV PHARM	4MG	A087164	001	
	LEDERLE	4MG	A086941	001	
	NEWTRON PHARMS	4MG	A086519	001	
	PANRAY	4MG	A083243	001	
	PHARMAVITE	4MG	A085104	001	
	PHARMERAL	4MG	A083753	001	
	PIONEER PHARMS	4MG	A088556	001	Jul 13, 1984
	PUREPAC PHARM	4MG	A086306	001	
	PVT FORM	4MG	A080786	001	
	ROXANE	4MG	A080626	001	
	SUN PHARM INDUSTRIES	4MG	A080700	001	
	VITARINE	4MG	A085837	001	
	WATSON LABS	4MG	A080696	001	
		4MG	A080791	001	
		4MG	A085139	001	
	WEST WARD	4MG	A083787	001	
KLOROMIN					
	HALSEY	4MG	A083629	001	
PHENETRON					
	LANNETT	4MG	A080846	001	
TABLET, EXTENDED RELEASE;ORAL					
CHLOR-TRIMETON					
+	BAYER HEALTHCARE LLC	8MG **	N007638	001	
+		12MG **	N007638	002	
EFIDAC 24 CHLORPHENIRAMINE MALEATE					
	ALZA	16MG	N019746	002	Nov 18, 1994
CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE					
SOLUTION;ORAL					
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE					
	ACELLA	4MG/5ML;5MG/5ML	A206891	001	Jun 09, 2017
	TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE				
SOLUTION;ORAL				
VITUZ				
+	PERSION	4MG/5ML;5MG/5ML	N204307 001	Feb 20, 2013
CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE				
SOLUTION;ORAL				
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657 001	Aug 03, 2015
	TORRENT	4MG/5ML;5MG/5ML;60MG/5ML	A206660 001	May 15, 2017
	TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A203838 001	Nov 26, 2014
ZUTRIPRO				
+	PERSION	4MG/5ML;5MG/5ML;60MG/5ML	N022439 001	Jun 08, 2011
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
COLD CAPSULE IV				
	GRAHAM DM	12MG;75MG	N018793 001	Apr 25, 1985
COLD CAPSULE V				
	GRAHAM DM	8MG;75MG	N018794 001	Apr 23, 1985
TABLET, EXTENDED RELEASE;ORAL				
TRIAMINIC-12				
	NOVARTIS	12MG;75MG	N018115 001	
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
CODIMAL-L.A. 12				
	SCHWARZ PHARMA	12MG;120MG	N018935 001	Apr 15, 1985
ISOCLOR				
	FISONS	8MG;120MG	N018747 001	Mar 06, 1986
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE				
	CENT PHARMS	8MG;120MG	N019428 001	Aug 02, 1988
	GRAHAM DM	8MG;120MG	N018844 001	Mar 20, 1985
		12MG;120MG	N018843 001	Mar 18, 1985
	KV PHARM	12MG;120MG	A071455 001	Mar 01, 1989
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE				
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+	BAYER HEALTHCARE LLC	8MG;120MG	N018397 001	
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX				
SUSPENSION, EXTENDED RELEASE;ORAL				
CODEPREX				
	LANNETT CO INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369 001	Jun 21, 2004
PENNTUSS				
	FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928 001	Aug 14, 1985
CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX				
SUSPENSION, EXTENDED RELEASE;ORAL				
TUSSIONEX PENNKINETIC				
+	UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **	N019111 001	Dec 31, 1987
CHLORPHENTERMINE HYDROCHLORIDE				
TABLET;ORAL				
PRE-SATE				
	PARKE DAVIS	EQ 65MG BASE	N014696 001	
CHLORPROMAZINE				
SUPPOSITORY;RECTAL				
THORAZINE				
+	GLAXOSMITHKLINE	25MG **	N009149 024	
+		100MG **	N009149 033	
CHLORPROMAZINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
THORAZINE				
	GLAXOSMITHKLINE	30MG	N011120 016	
		75MG	N011120 017	
		150MG	N011120 018	
		200MG	N011120 019	
		300MG	N011120 020	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROMAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	100MG/ML	A086863	001	
PHARM ASSOC	30MG/ML	A040231	001	Dec 30, 1999
	100MG/ML	A040224	001	Jan 26, 1999
WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982
	100MG/ML	A087053	001	
CHLORPROMAZINE HYDROCHLORIDE INTENSOL				
HIKMA	30MG/ML	A088157	001	Apr 27, 1983
	100MG/ML	A088158	001	Apr 27, 1983
SONAZINE				
FOSUN PHARMA	30MG/ML	A080983	004	
	100MG/ML	A080983	005	
THORAZINE				
+ GLAXOSMITHKLINE	30MG/ML **	N009149	032	
+	100MG/ML **	N009149	043	
INJECTABLE;INJECTION				
CHLORPROMAZINE HYDROCHLORIDE				
ABRAXIS PHARM	25MG/ML	A084911	001	
DR REDDYS	25MG/ML	A080365	001	
MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
WATSON LABS	25MG/ML	A085591	001	
WYETH AYERST	25MG/ML	A080370	001	
THORAZINE				
+ GLAXOSMITHKLINE	25MG/ML **	N009149	011	
SYRUP;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A086712	001	
SONAZINE				
FOSUN PHARMA	10MG/5ML	A083040	001	
THORAZINE				
+ GLAXOSMITHKLINE	10MG/5ML **	N009149	022	
TABLET;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
CYCLE PHARMS LTD	10MG	A085331	001	
	25MG	A085331	002	
	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
IVAX SUB TEVA PHARMS	10MG	A083549	001	
	25MG	A083549	002	
	50MG	A083549	003	
	100MG	A083574	001	
	200MG	A083575	001	
KV PHARM	10MG	A085750	002	Jan 04, 1982
	25MG	A085751	001	
	50MG	A085484	001	
	100MG	A085752	001	
	200MG	A085748	002	Jan 04, 1982
LEDERLE	10MG	A084803	001	
	25MG	A084801	001	
	50MG	A084800	001	
	100MG	A084789	001	
	200MG	A084802	001	
PUREPAC PHARM	10MG	A080403	004	
	25MG	A080403	001	
	50MG	A080403	002	
	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	
SANDOZ	10MG **	A080439	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	25MG **	A080439	002	
	50MG **	A080439	003	
	100MG **	A080439	004	
	200MG **	A080439	005	
VANGARD	10MG	A088038	001	Aug 16, 1982
	25MG	A087645	001	
	50MG	A087646	001	
WATSON LABS	10MG	A085959	001	
	25MG	A085956	001	
	50MG	A085960	001	
	100MG	A085957	001	
	200MG	A085958	001	
WEST WARD	10MG	A087783	001	Sep 16, 1982
	25MG	A087865	001	Sep 16, 1982
	50MG	A087878	001	Sep 15, 1982
	100MG	A087884	001	Sep 15, 1982
	200MG	A087880	001	Sep 16, 1982

PROMAPAR

PARKE DAVIS	10MG	A086886	001	
	25MG	A084423	001	
	50MG	A086887	001	
	100MG	A086888	001	
	200MG	A086885	001	

THORAZINE

GLAXOSMITHKLINE	10MG **	N009149	002	
	25MG **	N009149	007	
	50MG **	N009149	013	
	100MG **	N009149	018	
	200MG **	N009149	020	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984
	100MG	A088812	001	Oct 19, 1984
	100MG	A088840	001	Oct 25, 1984
	100MG	A088918	001	Oct 16, 1984
	100MG	A088921	001	Apr 12, 1985
	100MG	A089446	001	Nov 17, 1986
	250MG	A087353	001	
	250MG	A088813	001	Oct 19, 1984
	250MG	A088826	001	Sep 26, 1984
	250MG	A088919	001	Oct 16, 1984
	250MG	A088922	001	Apr 12, 1985
	250MG	A089447	001	Nov 17, 1986
AUROLIFE PHARMA LLC	100MG	A088725	001	Aug 31, 1984
	250MG	A088726	001	Aug 31, 1984
DAVA PHARMS INC	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
MYLAN	100MG	A088549	002	Jun 01, 1984
	250MG	A088549	001	Jun 01, 1984
PAR PHARM	100MG	A088175	001	Feb 27, 1984
	250MG	A088176	001	Feb 27, 1984
SANDOZ	250MG	A084669	001	
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A086865	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A086866	001	
	250MG	A088568	001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852	001	Sep 26, 1984

CHLORPROPAMIDE				
TABLET;ORAL				
DIABINESE				
+ PFIZER	100MG		N011641 003	
+	250MG		N011641 006	
GLUCAMIDE				
ANI PHARMS INC	250MG		A088641 001	Oct 11, 1984
CHLORPROTHIXENE				
CONCENTRATE;ORAL				
TARACTAN				
ROCHE	100MG/5ML		N016149 002	
INJECTABLE;INJECTION				
TARACTAN				
ROCHE	12.5MG/ML		N012487 001	
TABLET;ORAL				
TARACTAN				
ROCHE	10MG		N012486 005	
	25MG		N012486 004	
	50MG		N012486 003	
	100MG		N012486 001	
CHLORTETRACYCLINE HYDROCHLORIDE				
OINTMENT;OPHTHALMIC				
AUREOMYCIN				
LEDERLE	1%		N050404 001	
CHLORTHALIDONE				
TABLET;ORAL				
CHLORTHALIDONE				
ABBOTT	25MG		A087364 001	
	50MG		A087384 001	
ACP NIMBLE	50MG		A088651 001	May 30, 1985
ANI PHARMS INC	25MG		A087296 001	
	25MG		A087706 001	
	25MG		A088164 001	Jan 09, 1984
	50MG		A087689 001	
ASCOT	25MG		A087698 001	Oct 20, 1982
	50MG		A087699 001	Oct 20, 1982
BARR LABS INC	25MG		A088902 001	Sep 19, 1985
	50MG		A088903 001	Sep 19, 1985
DAVA PHARMS INC	25MG		A087451 001	
	50MG		A087450 001	
IVAX PHARMS	25MG		A087555 001	
	50MG		A087176 001	
	50MG		A087947 001	Feb 27, 1984
KV PHARM	25MG		A087311 001	
	50MG		A087312 001	
MUTUAL PHARM	25MG		A087292 001	
	25MG		A089738 001	Sep 19, 1988
	50MG		A087293 001	
	50MG		A089739 001	Sep 19, 1988
PIONEER PHARMS	50MG		A089591 001	Jul 21, 1988
PUREPAC PHARM	25MG		A088139 001	Jul 16, 1986
	50MG		A088140 001	Aug 11, 1983
SANDOZ	25MG		A087380 001	
	50MG		A087118 001	
	50MG		A087381 001	
SUPERPHARM	25MG		A087473 001	Feb 09, 1983
	50MG		A087247 001	Feb 09, 1983
USL PHARMA	25MG		A089051 001	Jun 01, 1987
	50MG		A089052 001	Jun 01, 1987
VANGARD	25MG		A088012 001	Jul 14, 1982
	50MG		A088073 001	Mar 25, 1983
WARNER CHILCOTT	25MG		A087515 001	Jan 24, 1983
	50MG		A087516 001	Feb 09, 1983
WATSON LABS	25MG		A087050 001	
	25MG		A087100 001	
	50MG		A087029 001	
	50MG		A087082 001	
	50MG		A087521 001	

CHLORTHALIDONE
TABLET;ORAL
HYGROTON
+ SANOFI AVENTIS US 25MG ** N012283 004
+ 50MG ** N012283 003
THALITONE
+ CASPER PHARMA LLC 15MG ** N019574 001 Dec 20, 1988
25MG N019574 002 Feb 12, 1992
MONARCH PHARMS 25MG A088051 001 Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
TABLET;ORAL
CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
PAR PHARM 15MG;0.1MG A071179 001 Dec 16, 1987
15MG;0.2MG A071178 001 Dec 16, 1987
15MG;0.3MG A071142 001 Dec 16, 1987
CLORPRES
MYLAN 15MG;0.1MG A071325 003 Feb 09, 1987
15MG;0.2MG A071325 002 Feb 09, 1987
15MG;0.3MG A071325 001 Feb 09, 1987
COMBIPRES
+ BOEHRINGER INGELHEIM 15MG;0.1MG ** N017503 001
+ 15MG;0.2MG ** N017503 002
+ 15MG;0.3MG ** N017503 003 Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE
CAPSULE;ORAL
LOPRESSIDONE
NOVARTIS 25MG;100MG N019451 001 Dec 31, 1987
25MG;200MG N019451 002 Dec 31, 1987

CHLORTHALIDONE; RESERPINE
TABLET;ORAL
DEMI-REGROTON
SANOFI AVENTIS US 25MG;0.125MG N015103 002
REGROTON
SANOFI AVENTIS US 50MG;0.25MG N015103 001

CHLORZOXAZONE
TABLET;ORAL
CHLORZOXAZONE
ACTAVIS ELIZABETH 250MG A088928 001 May 08, 1987
500MG A040113 001 Sep 29, 1995
AUROLIFE PHARMA LLC 250MG A089852 001 May 04, 1988
500MG A089853 001 May 04, 1988
BARR 500MG A089895 001 May 04, 1988
OHM LABS 250MG A081298 001 Dec 29, 1993
500MG A081299 001 Dec 29, 1993
PAR PHARM 250MG A087981 001 Sep 20, 1983
PIONEER PHARMS 250MG A089592 001 Jan 06, 1989
500MG A089948 001 Jan 06, 1989
SUN PHARM INDUSTRIES 500MG A089970 001 Sep 27, 1990
WATSON LABS 250MG A086901 001
250MG A086948 001 Aug 09, 1982
500MG A040137 001 Aug 09, 1996
500MG A081019 001 Jul 29, 1991
500MG A081040 001 Aug 22, 1989
PARAFLEX
+ ORTHO MCNEIL PHARM 250MG ** N011300 003
PARAFON FORTE DSC
+ JANSSEN R AND D 500MG ** N011529 002 Jun 15, 1987
STRIFON FORTE DSC
FERNDALE LABS 500MG A081008 001 Dec 23, 1988

CHOLESTYRAMINE
BAR, CHEWABLE;ORAL
CHOLYBAR
PARKE DAVIS EQ 4GM RESIN/BAR A071621 001 May 26, 1988
EQ 4GM RESIN/BAR A071739 001 May 26, 1988

CHOLESTYRAMINE				
POWDER;ORAL				
CHOLESTYRAMINE				
IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771	001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771	002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347	002	May 28, 1998
CHOLESTYRAMINE LIGHT				
TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998
LOCHOLEST				
SANDOZ	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996
LOCHOLEST LIGHT				
INVATECH	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996
QUESTRAN				
+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N016640	001	
+	EQ 4GM RESIN/SCOOPFUL **	N016640	003	
QUESTRAN LIGHT				
+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N019669	001	Dec 05, 1988
+	EQ 4GM RESIN/SCOOPFUL **	N019669	003	Dec 05, 1988
TABLET;ORAL				
QUESTRAN				
APOTHECON	EQ 800MG RESIN	A073403	002	Dec 27, 1999
	EQ 1GM RESIN	A073403	001	Apr 28, 1994
CHOLINE FENOFIBRATE				
CAPSULE, DELAYED RELEASE;ORAL				
FENOFIBRIC ACID				
MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013
	EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013
TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019
	EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019
CHORIOGONADOTROPIN ALFA				
INJECTABLE;INJECTION				
OVIDREL				
EMD SERONO	0.25MG/VIAL	N021149	001	Sep 20, 2000
CHROMIC CHLORIDE				
INJECTABLE;INJECTION				
CHROMIC CHLORIDE				
ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271	001	May 05, 1987
CHROMIC PHOSPHATE P-32				
INJECTABLE;INJECTION				
PHOSPHOCOL P32				
CURIUM	5mCi/ML	N017084	001	
CHYMOPAPAIN				
INJECTABLE;INJECTION				
CHYMODIACTIN				
CHART MEDCL	4,000 UNITS/VIAL	N018663	002	Aug 21, 1984
+	10,000 UNITS/VIAL **	N018663	001	Nov 10, 1982
DISCASE				
ABBOTT	12,500 UNITS/VIAL	N018625	001	Jan 18, 1984
CHYMOTRYPSIN				
FOR SOLUTION;OPHTHALMIC				
ALPHA CHYMAR				
SOLA BARNES HIND	750 UNITS/VIAL	N011837	001	
CATARASE				
CIBA	300 UNITS/VIAL	N016938	001	
NOVARTIS	150 UNITS/VIAL	N018121	001	
ZOLYSE				
ALCON	750 UNITS/VIAL	N011903	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CICLOPIROX					
SOLUTION;TOPICAL					
CICLOPIROX					
	MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007
	TEVA PHARMS	8%	A078079	001	Sep 18, 2007
CIDOFOVIR					
INJECTABLE;INJECTION					
VISTIDE					
+	GILEAD SCIENCES INC	EQ 75MG BASE/ML **	N020638	001	Jun 26, 1996
CILASTATIN SODIUM; IMIPENEM					
INJECTABLE;INJECTION					
PRIMAXIN					
	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	A062756	001	Jan 08, 1987
		EQ 500MG BASE/VIAL;500MG/VIAL	A062756	002	Jan 08, 1987
POWDER;INTRAMUSCULAR					
PRIMAXIN					
	MERCK	EQ 500MG BASE/VIAL;500MG/VIAL	N050630	001	Dec 14, 1990
		EQ 750MG BASE/VIAL;750MG/VIAL	N050630	002	Dec 14, 1990
POWDER;INTRAVENOUS					
IMIPENEM AND CILASTATIN					
	HOSPIRA INC	EQ 250MG BASE/VIAL;250MG/VIAL	A090825	001	Nov 16, 2011
		EQ 500MG BASE/VIAL;500MG/VIAL	A090825	002	Nov 16, 2011
		EQ 500MG BASE/VIAL;500MG/VIAL	A091007	001	Nov 16, 2011
PRIMAXIN					
+	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	N050587	001	Nov 26, 1985
CILOSTAZOL					
TABLET;ORAL					
CILOSTAZOL					
	ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004
	EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005
		100MG	A077022	001	Nov 23, 2004
	IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
	MYLAN	50MG	A077323	002	Apr 20, 2006
		100MG	A077323	001	Apr 20, 2006
	MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004
		100MG	A077019	002	Nov 23, 2004
	PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007
		100MG	A077898	002	Oct 29, 2007
PLETAL					
+	OTSUKA	50MG **	N020863	001	Jan 15, 1999
+		100MG **	N020863	002	Jan 15, 1999
CIMETIDINE					
SUSPENSION;ORAL					
TAGAMET HB 200					
	GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999
TABLET;ORAL					
CIMETIDINE					
	CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994
		300MG	A074329	003	May 17, 1994
		400MG	A074329	004	May 17, 1994
		800MG	A074329	001	May 17, 1994
	CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998
		200MG	A074963	001	Jun 19, 1998
	CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994
		400MG	A074361	002	Dec 23, 1994
		800MG	A074371	001	Dec 23, 1994
	DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995
		400MG	A074340	002	Jun 23, 1995
		800MG	A074339	001	Jun 23, 1995
	IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
		200MG	A074424	001	Jul 28, 1995
		300MG	A074401	002	May 30, 1995
		300MG	A074424	002	Jul 28, 1995
		400MG	A074401	003	May 30, 1995
		400MG	A074424	003	Jul 28, 1995
		800MG	A074402	001	May 30, 1995
		800MG	A074424	004	Jul 28, 1995

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIMETIDINE

TABLET;ORAL

CIMETIDINE

PERRIGO	100MG	A074972	001	Jun 19, 1998
PLIVA	200MG	A074568	001	Feb 27, 1997
	300MG	A074568	002	Feb 27, 1997
	400MG	A074568	003	Feb 27, 1997
SANDOZ INC	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995
	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995
	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995
UPSHER SMITH LABS	200MG	A074506	001	Jan 24, 1996
	300MG	A074506	002	Jan 24, 1996
	400MG	A074506	003	Jan 24, 1996
	800MG	A074506	004	Jan 24, 1996
WATSON LABS INC	200MG	A074349	001	Aug 30, 1996
	300MG	A074349	002	Aug 30, 1996
	400MG	A074349	003	Aug 30, 1996
	800MG	A074316	001	Feb 28, 1996
WATSON LABS TEVA	200MG	A075425	001	Jul 29, 1999
YAOPHARMA CO LTD	200MG	A074100	001	Jan 31, 1995
	300MG	A074100	002	Jan 31, 1995
	400MG	A074100	003	Jan 31, 1995
	800MG	A074100	004	Jan 31, 1995

TAGAMET

GLAXOSMITHKLINE	200MG **	N017920	002	
	300MG **	N017920	003	
	400MG **	N017920	004	Dec 14, 1983
	800MG **	N017920	005	Apr 30, 1986

TAGAMET HB

+ MEDTECH PRODUCTS	100MG **	N020238	001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422	001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353	001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252	001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468	005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML **	N017939	002	

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ GLAXOSMITHKLINE	EQ 6MG BASE/ML **	N019434	001	Oct 31, 1985

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996
	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994
LANNETT CO INC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994
PHARM ASSOC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CIMETIDINE HYDROCHLORIDE				
SOLUTION;ORAL				
TAGAMET				
	GLAXOSMITHKLINE	EQ 300MG BASE/5ML **	N017924 001	
CINOXACIN				
CAPSULE;ORAL				
CINOBAC				
	LILLY	250MG	N018067 001	
		500MG	N018067 002	
CINOXACIN				
	TEVA	250MG	A073005 001	Feb 28, 1992
		500MG	A073006 001	Feb 28, 1992
CIPROFLOXACIN				
FOR SUSPENSION;ORAL				
CIPROFLOXACIN				
	LUPIN LTD	250MG/5ML	A200563 001	Mar 05, 2014
		500MG/5ML	A200563 002	Mar 05, 2014
INJECTABLE;INJECTION				
CIPRO				
+	BAYER HLTHCARE	400MG/40ML (10MG/ML) **	N019847 001	Dec 26, 1990
+		200MG/20ML (10MG/ML) **	N019847 002	Dec 26, 1990
		1200MG/120ML (10MG/ML) **	N019847 003	Dec 26, 1990
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	BAYER HLTHCARE	200MG/100ML **	N019857 001	Dec 26, 1990
+		400MG/200ML **	N019857 002	Dec 26, 1990
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAYER PHARMS	200MG/100ML	N019858 001	Dec 26, 1990
CIPROFLOXACIN				
	BEDFORD LABS	200MG/20ML (10MG/ML)	A076992 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A076992 002	Aug 28, 2006
		1200MG/120ML (10MG/ML)	A076993 001	Aug 28, 2006
	DR REDDYS	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006
	FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A076484 002	Aug 28, 2006
CIPROFLOXACIN IN DEXTROSE 5%				
	HIKMA FARMACEUTICA	200MG/100ML	A076757 001	Apr 21, 2008
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008
		400MG/200ML	A077888 002	Mar 18, 2008
	BEDFORD	200MG/100ML	A078114 001	Mar 18, 2008
		400MG/200ML	A078114 002	Mar 18, 2008
	TEVA PHARMS	200MG/100ML	A077138 001	Mar 18, 2008
		400MG/200ML	A077138 002	Mar 18, 2008
CIPROFLOXACIN HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
CIPROFLOXACIN HYDROCHLORIDE				
	AMRING PHARMS	EQ 0.3% BASE	A078598 001	Jan 16, 2008
	RUBICON	EQ 0.3% BASE	A075928 001	Jun 09, 2004
TABLET;ORAL				
CIPRO				
+	BAYER HLTHCARE	EQ 100MG BASE **	N019537 001	Apr 08, 1996
+		EQ 750MG BASE **	N019537 004	Oct 22, 1987
CIPROFLOXACIN HYDROCHLORIDE				
	ANI PHARMS INC	EQ 100MG BASE	A075939 001	Mar 03, 2005
		EQ 250MG BASE	A075939 002	Jun 09, 2004
		EQ 500MG BASE	A075939 003	Jun 09, 2004
		EQ 750MG BASE	A075939 004	Jun 09, 2004
	BARR	EQ 250MG BASE	A074124 001	Jun 09, 2004
		EQ 500MG BASE	A074124 002	Jun 09, 2004
		EQ 750MG BASE	A074124 003	Jun 09, 2004
	FOSUN PHARMA	EQ 250MG BASE	A076593 002	Jun 09, 2004
		EQ 500MG BASE	A076593 003	Jun 09, 2004
		EQ 750MG BASE	A076593 004	Jun 09, 2004
	MYLAN	EQ 100MG BASE	A075817 001	Jun 25, 2007
		EQ 250MG BASE	A075685 002	Jun 09, 2004
		EQ 250MG BASE	A075817 002	Jun 09, 2004
		EQ 500MG BASE	A075685 003	Jun 09, 2004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIPROFLOXACIN HYDROCHLORIDE					
TABLET;ORAL					
CIPROFLOXACIN HYDROCHLORIDE					
		EQ 750MG BASE	A075685	001	Jun 09, 2004
		EQ 750MG BASE	A075817	004	Jun 09, 2004
	NOSTRUM LABS	EQ 250MG BASE	A076138	001	Jun 09, 2004
		EQ 500MG BASE	A076138	002	Jun 09, 2004
		EQ 750MG BASE	A076138	003	Jun 09, 2004
	PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005
		EQ 250MG BASE	A076426	002	Jun 15, 2005
		EQ 500MG BASE	A076426	003	Jun 15, 2005
		EQ 750MG BASE	A076426	004	Jun 15, 2005
	SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004
		EQ 500MG BASE	A075747	002	Jun 09, 2004
		EQ 750MG BASE	A075747	003	Jun 09, 2004
	TEVA	EQ 250MG BASE	A076136	001	Jun 09, 2004
		EQ 500MG BASE	A076136	002	Jun 09, 2004
		EQ 750MG BASE	A076136	003	Jun 09, 2004
TABLET, EXTENDED RELEASE;ORAL					
PROQUIN XR					
	DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
CIPRO XR					
	BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE **	N021473	001	Dec 13, 2002
		425.2MG;EQ 574.9MG BASE **	N021473	002	Aug 28, 2003
CIPROFLOXACIN EXTENDED RELEASE					
	ANI PHARMS INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010
		425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010
	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007
	FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007
	MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007
		425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007
CISAPRIDE MONOHYDRATE					
SUSPENSION;ORAL					
PROPULSID					
	JANSSEN PHARMS	EQ 1MG BASE/ML	N020398	001	Sep 15, 1995
TABLET;ORAL					
PROPULSID					
	JANSSEN PHARMS	EQ 10MG BASE	N020210	001	Jul 29, 1993
		EQ 20MG BASE	N020210	002	Dec 23, 1993
TABLET, ORALLY DISINTEGRATING;ORAL					
PROPULSID QUICKSOLV					
	JANSSEN PHARMA	EQ 20MG BASE	N020767	001	Nov 07, 1997
CISATRACURIUM BESYLATE					
INJECTABLE;INJECTION					
CISATRACURIUM BESYLATE					
	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017
	HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018
CISATRACURIUM BESYLATE PRESERVATIVE FREE					
	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017
		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017
CISPLATIN					
INJECTABLE;INJECTION					
CISPLATIN					
	BEDFORD	10MG/VIAL	A074713	001	Nov 14, 2000
		50MG/VIAL	A074713	002	Nov 14, 2000
	MYLAN LABS LTD	1MG/ML	A091062	001	Apr 18, 2012
	TEVA PHARMS USA	1MG/ML	A074814	001	May 16, 2000
PLATINOL					
+	HQ SPCLT PHARMA	10MG/VIAL	N018057	001	
+		50MG/VIAL	N018057	002	
PLATINOL-AQ					
+	HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CITALOPRAM HYDROBROMIDE				
CAPSULE;ORAL				
CITALOPRAM HYDROBROMIDE				
MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007
	EQ 20MG BASE	A077668	002	Feb 28, 2007
	EQ 40MG BASE	A077668	003	Feb 28, 2007
SOLUTION;ORAL				
CELEXA				
+ FOREST LABS	EQ 10MG BASE/5ML **	N021046	001	Dec 22, 1999
CITALOPRAM HYDROBROMIDE				
PHARM ASSOC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005
TABLET;ORAL				
CELEXA				
ALLERGAN	EQ 60MG BASE	N020822	004	Jul 17, 1998
CITALOPRAM HYDROBROMIDE				
EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004
	EQ 20MG BASE	A077036	002	Oct 28, 2004
	EQ 40MG BASE	A077036	003	Oct 28, 2004
FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004
	EQ 10MG BASE	A077040	001	Aug 17, 2005
	EQ 20MG BASE	A077035	002	Oct 28, 2004
	EQ 20MG BASE	A077040	002	Aug 17, 2005
	EQ 40MG BASE	A077035	003	Oct 28, 2004
	EQ 40MG BASE	A077040	003	Aug 17, 2005
HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004
	EQ 10MG BASE	A077034	001	Jun 30, 2005
	EQ 10MG BASE	A077213	001	Mar 31, 2006
	EQ 10MG BASE	A077232	001	Oct 31, 2005
	EQ 20MG BASE	A077033	002	Oct 28, 2004
	EQ 20MG BASE	A077034	002	Jun 30, 2005
	EQ 20MG BASE	A077213	002	Mar 31, 2006
	EQ 20MG BASE	A077232	002	Oct 31, 2005
	EQ 40MG BASE	A077033	003	Oct 28, 2004
	EQ 40MG BASE	A077034	003	Jun 30, 2005
	EQ 40MG BASE	A077213	003	Mar 31, 2006
	EQ 40MG BASE	A077232	003	Oct 31, 2005
MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005
	EQ 20MG BASE	A077039	002	Feb 03, 2005
	EQ 40MG BASE	A077039	003	Feb 03, 2005
MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004
	EQ 20MG BASE	A077037	002	Nov 05, 2004
	EQ 40MG BASE	A077037	003	Nov 05, 2004
NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008
	EQ 40MG BASE	A077141	001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004
	EQ 20MG BASE	A077041	002	Nov 23, 2004
	EQ 40MG BASE	A077041	003	Nov 23, 2004
SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004
	EQ 20MG BASE	A077032	002	Nov 12, 2004
	EQ 40MG BASE	A077032	003	Nov 12, 2004
SUN PHARM INDUSTRIES	EQ 10MG BASE	A077052	001	Jul 03, 2006
	EQ 20MG BASE	A077052	002	Jul 03, 2006
	EQ 40MG BASE	A077052	003	Jul 03, 2006
TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006
	EQ 20MG BASE	A077278	002	Mar 22, 2006
	EQ 40MG BASE	A077278	003	Mar 22, 2006
TABLET, ORALLY DISINTEGRATING;ORAL				
CITALOPRAM HYDROBROMIDE				
BIOVAIL LABS INTL	EQ 10MG BASE	N021763	001	Dec 20, 2005
	EQ 20MG BASE	N021763	002	Dec 20, 2005
	EQ 40MG BASE	N021763	003	Dec 20, 2005
CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE				
SOLUTION;IRRIGATION				
IRRIGATING SOLUTION G IN PLASTIC CONTAINER				
BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519	001	Jun 22, 1982
UROLOGIC G IN PLASTIC CONTAINER				
HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904	001	May 27, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE					
FOR SOLUTION;ORAL					
PREPOPIK					
+	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	N202535	001	Jul 16, 2012
CLADRIBINE					
INJECTABLE;INJECTION					
LEUSTATIN					
+	JANSSEN PHARMS	1MG/ML **	N020229	001	Feb 26, 1993
CLARITHROMYCIN					
FOR SUSPENSION;ORAL					
BIAXIN					
+	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993
		187MG/5ML	N050698	003	Sep 30, 1998
+		250MG/5ML	N050698	002	Dec 23, 1993
CLARITHROMYCIN					
	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007
		250MG/5ML	A065382	002	Aug 30, 2007
TABLET;ORAL					
BIAXIN					
+	ABBVIE	250MG **	N050662	001	Oct 31, 1991
+		500MG **	N050662	002	Oct 31, 1991
CLARITHROMYCIN					
	AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019
		500MG	A206714	002	Apr 25, 2019
	IVAX SUB TEVA PHARMS	250MG	A065137	001	May 31, 2005
		500MG	A065137	002	May 31, 2005
	MYLAN	250MG	A065195	001	Mar 11, 2005
		500MG	A065195	002	Mar 11, 2005
	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004
		500MG	A065174	002	Sep 24, 2004
TABLET, EXTENDED RELEASE;ORAL					
BIAXIN XL					
+	ABBVIE	500MG **	N050775	001	Mar 03, 2000
CLARITHROMYCIN					
	ANI PHARMS INC	500MG	A065250	001	Aug 25, 2005
	LUPIN LTD	500MG	A202532	001	Sep 15, 2015
	RANBAXY	1GM	A065210	001	Jan 26, 2005
CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM					
INJECTABLE;INJECTION					
TIMENTIN					
	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985
		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
TIMENTIN IN PLASTIC CONTAINER					
	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989
CLEMASTINE FUMARATE					
SYRUP;ORAL					
CLEMASTINE FUMARATE					
	ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993
	APOTEX INC	EQ 0.5MG BASE/5ML	A075703	001	Nov 27, 2000
	LANNETT CO INC	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997
	TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095	001	Apr 21, 1992
	WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998
TAVIST					
+	NOVARTIS	EQ 0.5MG BASE/5ML **	N018675	001	Jun 28, 1985
TABLET;ORAL					
CLEMASTINE FUMARATE					
	ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992
		1.34MG	A073282	002	Dec 03, 1992
	PLD ACQUISITIONS LLC	1.34MG	A073458	001	Oct 31, 1993
	SANDOZ	2.68MG	A073459	001	Oct 31, 1993
TAVIST					
+	NOVARTIS	2.68MG	N017661	001	
TAVIST-1					
+	GLAXOSMITHKLINE CONS	1.34MG	N020925	001	Aug 21, 1992
	NOVARTIS	1.34MG	N017661	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLEMASTINE FUMARATE				
TABLET;ORAL				
TAVIST-1				
	1.34MG		N017661 003	Aug 21, 1992
CLEVIDIPINE				
EMULSION;INTRAVENOUS				
CLEVIPREX				
+ CHIESI USA INC	125MG/250ML (0.5MG/ML)		N022156 003	Nov 08, 2013
CLIDINIUM BROMIDE				
CAPSULE;ORAL				
QUARZAN				
ROCHE	2.5MG		N010355 001	
	5MG		N010355 002	
CLINDAMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE		A061809 001	
	EQ 150MG BASE		A061809 002	
CLINDAMYCIN HYDROCHLORIDE				
MYLAN PHARMS INC	EQ 75MG BASE		A091225 001	May 31, 2011
	EQ 150MG BASE		A091225 002	May 31, 2011
	EQ 300MG BASE		A091225 003	May 31, 2011
TEVA	EQ 75MG BASE		A063027 001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE		A063082 001	Jul 31, 1991
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
FOR SOLUTION;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML **		A061827 001	
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
MYLAN	EQ 75MG BASE/5ML		A203063 001	May 25, 2016
CLINDAMYCIN PHOSPHATE				
CREAM;VAGINAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 2% BASE		N050680 001	Aug 11, 1992
INJECTABLE;INJECTION				
CLEOCIN PHOSPHATE				
PHARMACIA AND UPJOHN	EQ 150MG BASE/ML		A061839 001	
CLINDAMYCIN PHOSPHATE				
ABRAXIS PHARM	EQ 150MG BASE/ML		A062747 001	Jun 03, 1988
BEDFORD	EQ 150MG BASE/ML		A063163 001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML		A062908 001	Feb 01, 1989
IGI LABS INC	EQ 150MG BASE/ML		A062928 001	Feb 13, 1989
LOCH	EQ 150MG BASE/ML		A062905 001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML		A062913 001	Oct 20, 1988
SOLOPAK	EQ 150MG BASE/ML		A062819 001	Mar 15, 1988
	EQ 150MG BASE/ML		A062852 001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML		A063041 001	Dec 29, 1989
	EQ 150MG BASE/ML		A063282 001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML		A062900 001	Jun 08, 1988
	EQ 150MG BASE/ML		A063079 001	Mar 05, 1990
WEST-WARD PHARMS INT	EQ 150MG BASE/ML		A062806 001	Oct 15, 1987
	EQ 150MG BASE/ML		A062953 001	Apr 21, 1988
	EQ 150MG BASE/ML		A063068 001	Aug 28, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
ABRAXIS PHARM	EQ 12MG BASE/ML		N050636 001	Dec 22, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT LABS	EQ 6MG BASE/ML		A065027 001	Jun 29, 2001
	EQ 12MG BASE/ML		A065027 002	Jun 29, 2001
	EQ 18MG BASE/ML		A065027 003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML		N050648 001	Dec 29, 1989
	EQ 12MG BASE/ML		N050648 002	Dec 29, 1989
	EQ 900MG BASE/100ML		N050648 003	Dec 29, 1989
SOLUTION;TOPICAL				
CLEOCIN T				
PHARMACIA AND UPJOHN	EQ 1% BASE		A062363 001	Feb 08, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLINDAMYCIN PHOSPHATE

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989
NOVAST LABS	EQ 1% BASE	A064108	001	Sep 27, 1996
VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989
WOCKHARDT BIO AG	EQ 1% BASE	A063304	001	Jul 15, 1997

CLIOQUINOL; NYSTATIN

OINTMENT;TOPICAL

NYSTAFORM

BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235	001	

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

TARO	2.5MG/ML	A210978	001	Apr 15, 2019

TABLET;ORAL

CLOBAZAM

ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019
	20MG	A212398	002	May 23, 2019
TARO	10MG	A209440	001	Oct 22, 2018
	20MG	A209440	002	Oct 22, 2018

ONFI

LUNDBECK PHARMS LLC	5MG **	N202067	001	Oct 21, 2011

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019322	001	Dec 27, 1985

TEMOVATE E

+ FOUGERA PHARMS	0.05% **	N020340	001	Jun 17, 1994

GEL;TOPICAL

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N020337	001	Apr 29, 1994

LOTION;TOPICAL

CLOBETASOL PROPIONATE

HI TECH	0.05%	A211348	001	Oct 26, 2018

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019323	001	Dec 27, 1985

SOLUTION;TOPICAL

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019966	001	Feb 22, 1990

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

APOTEX	0.05%	A210446	001	Apr 17, 2018

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018

CLOFAZIMINE

CAPSULE;ORAL

LAMPRENE

+ NOVARTIS	50MG	N019500	002	Dec 15, 1986
	100MG	N019500	001	Dec 15, 1986

CLOFIBRATE

CAPSULE;ORAL

ATROMID-S

WYETH AYERST	500MG	N016099	002	

CLOFIBRATE

BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
SANDOZ	500MG	A072191	001	May 02, 1988
TEVA	500MG	A072600	001	Jul 25, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLOFIBRATE				
CAPSULE;ORAL				
CLOFIBRATE				
USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987
CLOMIPHENE CITRATE				
TABLET;ORAL				
CLOMID				
+ SANOFI AVENTIS US	50MG	N016131	002	
MILOPHENE				
MILEX	50MG	A072196	001	Dec 20, 1988
SEROPHENE				
EMD SERONO	50MG	N018361	001	Mar 22, 1982
CLOMIPRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
CLOMIPRAMINE HYDROCHLORIDE				
MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019
	50MG	A211767	002	Apr 08, 2019
	75MG	A211767	003	Apr 08, 2019
TEVA	25MG	A074849	001	Apr 04, 1997
	50MG	A074849	002	Apr 04, 1997
	75MG	A074849	003	Apr 04, 1997
WATSON LABS	25MG	A074600	001	Nov 27, 1996
	25MG	A074751	001	Sep 30, 1998
	50MG	A074600	002	Nov 27, 1996
	50MG	A074751	002	Sep 30, 1998
	75MG	A074600	003	Nov 27, 1996
	75MG	A074751	003	Sep 30, 1998
CLONAZEPAM				
TABLET;ORAL				
CLONAZEPAM				
MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997
	1MG	A074940	002	Oct 30, 1997
	2MG	A074940	003	Oct 30, 1997
RUBICON	0.5MG	A075468	001	Oct 06, 2000
	1MG	A075468	002	Oct 06, 2000
	2MG	A075468	003	Oct 06, 2000
SANDOZ	0.5MG	A074925	001	Sep 30, 1997
	1MG	A074925	002	Sep 30, 1997
	2MG	A074925	003	Sep 30, 1997
SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001
	1MG	A075423	002	Apr 27, 2001
	2MG	A075423	003	Apr 27, 2001
TEVA	0.5MG	A074920	001	Aug 04, 1998
	1MG	A074920	002	Aug 04, 1998
	2MG	A074920	003	Aug 04, 1998
KLONOPIN				
ROCHE	0.125MG	N017533	005	Apr 09, 1997
	0.25MG	N017533	006	Apr 09, 1997
TABLET, ORALLY DISINTEGRATING;ORAL				
KLONOPIN RAPIDLY DISINTEGRATING				
+ ROCHE	0.125MG **	N020813	001	Dec 23, 1997
+	0.25MG **	N020813	002	Dec 23, 1997
+	0.5MG **	N020813	003	Dec 23, 1997
+	1MG **	N020813	004	Dec 23, 1997
+	2MG **	N020813	005	Dec 23, 1997
CLONIDINE				
SUSPENSION, EXTENDED RELEASE;ORAL				
CLONIDINE				
TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009
TABLET, EXTENDED RELEASE;ORAL				
CLONIDINE				
TRIS PHARMA INC	EQ 0.17MG BASE	N022500	001	Dec 03, 2009
	EQ 0.26MG BASE	N022500	002	Dec 03, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLONIDINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
CLONIDINE HYDROCHLORIDE					
LUITPOLD	1MG/10ML (0.1MG/ML)		A091104	001	Oct 08, 2009
	5MG/10ML (0.5MG/ML)		A091104	002	Oct 08, 2009
TABLET;ORAL					
CLONIDINE HYDROCHLORIDE					
AM THERAP	0.1MG		A070881	001	Jul 08, 1986
	0.2MG		A070882	001	Jul 08, 1986
	0.3MG		A070883	001	Jul 08, 1986
AUROLIFE PHARMA LLC	0.1MG		A070886	002	Aug 31, 1988
	0.2MG		A070886	001	Aug 31, 1988
	0.3MG		A070886	003	Aug 31, 1988
CHARTWELL MOLECULES	0.1MG		A071785	002	Apr 05, 1988
	0.2MG		A071785	003	Apr 05, 1988
	0.3MG		A071785	001	Apr 05, 1988
DURAMED PHARMS BARR	0.1MG		A071103	001	Aug 14, 1986
	0.2MG		A071102	001	Aug 14, 1986
	0.3MG		A071101	001	Aug 14, 1986
INTERPHARM	0.1MG		A071252	001	Oct 01, 1986
	0.2MG		A071253	001	Oct 01, 1986
	0.3MG		A071254	001	Oct 01, 1986
PAR PHARM	0.1MG		A070461	001	Jul 08, 1986
	0.2MG		A070460	001	Jul 08, 1986
	0.3MG		A070459	001	Jul 08, 1986
SUN PHARM INDS INC	0.1MG		A090329	001	Jul 03, 2014
	0.2MG		A090329	002	Jul 03, 2014
	0.3MG		A090329	003	Jul 03, 2014
TEVA	0.1MG		A070747	001	Jul 08, 1986
	0.2MG		A070702	001	Jul 08, 1986
	0.3MG		A070659	001	Jul 08, 1986
WARNER CHILCOTT	0.1MG		A072138	001	Jun 13, 1988
	0.2MG		A072139	001	Jun 13, 1988
	0.3MG		A072140	001	Jun 13, 1988
WATSON LABS	0.1MG		A070395	001	Mar 23, 1987
	0.1MG		A070965	001	Jul 08, 1986
	0.2MG		A070396	001	Mar 23, 1987
	0.2MG		A070964	001	Jul 08, 1986
	0.3MG		A070397	001	Mar 23, 1987
	0.3MG		A070963	001	Jul 08, 1986
TABLET, EXTENDED RELEASE;ORAL					
CLONIDINE HYDROCHLORIDE					
ACTAVIS ELIZABETH	0.2MG		A202792	002	May 15, 2015
	0.2MG		A203320	002	May 15, 2015
ANCHEN PHARMS	0.1MG		A202983	001	Apr 02, 2014
	0.2MG		A202983	002	Apr 02, 2014
	0.2MG		A202984	002	Sep 30, 2013
UPSHER SMITH LABS	0.1MG		A211433	001	Oct 12, 2018
JENLOGA					
+ CONCORDIA PHARMS INC	0.1MG **		N022331	001	Sep 30, 2009
+	0.2MG **		N022331	002	May 25, 2010
KAPVAY					
+ CONCORDIA PHARMS INC	0.2MG **		N022331	004	Sep 28, 2010
CLOPIDOGREL BISULFATE					
TABLET;ORAL					
CLOPIDOGREL BISULFATE					
ACTAVIS TOTOWA	EQ 75MG BASE		A090307	001	May 28, 2013
ANI PHARMS INC	EQ 300MG BASE		A090625	001	May 17, 2012
	EQ 300MG BASE		A091216	001	May 17, 2012
CADILA	EQ 75MG BASE		A201686	001	Oct 10, 2012
MYLAN PHARMS INC	EQ 75MG BASE		A077665	001	May 17, 2012
	EQ 300MG BASE		A077665	002	May 17, 2012
SUN PHARM INDUSTRIES	EQ 75MG BASE		A078133	001	Jun 10, 2013

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777	001	Jul 14, 1987
	7.5MG	A071778	001	Jul 14, 1987
	15MG	A071779	001	Jul 14, 1987
AM THERAP	3.75MG	A071429	001	Jun 23, 1987
	7.5MG	A071430	001	Jun 23, 1987
	15MG	A071431	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017
	7.5MG	A072112	003	Aug 11, 2017
	15MG	A072112	001	Aug 26, 1988
DAVA PHARMS INC	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988

TRANXENE

RECORDATI RARE	3.75MG **	N017105	001	
	7.5MG **	N017105	002	
	15MG **	N017105	003	

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072514	002	May 11, 1990
	7.5MG	A072514	003	May 11, 1990
	15MG	A072514	001	May 11, 1990
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004
	7.5MG	A076911	002	Sep 29, 2004
	15MG	A076911	003	Sep 29, 2004
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
	7.5MG	A071853	001	Feb 09, 1988
	15MG	A071854	001	Feb 09, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLORAZEPATE DIPOTASSIUM				
TABLET;ORAL				
TRANXENE				
RECORDATI RARE	3.75MG **		N017105 006	
+	15MG **		N017105 008	
TRANXENE SD				
RECORDATI RARE	11.25MG **		N017105 005	
	22.5MG **		N017105 004	
CLOTRIMAZOLE				
CREAM;TOPICAL				
LOTRIMIN				
SCHERING PLOUGH	1% **		N017619 001	
MYCELEX				
BAYER HEALTHCARE LLC	1%		N018183 001	
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	1% **		N018052 002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	2%		N020574 001	Nov 24, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	1%		N018230 002	Dec 26, 1991
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,200MG		N020526 002	Jul 29, 1996
GYNE-LOTRIMIN COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,100MG		N020289 002	Apr 26, 1993
MYCELEX-7 COMBINATION PACK				
BAYER HEALTHCARE LLC	1%,100MG		N020389 002	Jun 23, 1994
LOTION;TOPICAL				
LOTRIMIN				
SCHERING	1%		N018813 001	Feb 17, 1984
SOLUTION;TOPICAL				
LOTRIMIN				
+ SCHERING PLOUGH	1% **		N017613 001	
MYCELEX				
+ BAYER HLTHCARE	1% **		N018181 001	
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	100MG		N017717 002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	200MG		N020525 001	Jul 29, 1996
GYNIX				
TEVA PHARMS	100MG		A073249 001	Feb 13, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	100MG		N018182 002	Dec 26, 1991
MYCELEX-G				
BAYER PHARMS	500MG		N019069 001	Apr 19, 1985
TROCHE/LOZENGE;ORAL				
MYCELEX				
+ BAYER HLTHCARE	10MG **		N018713 001	Jun 17, 1983
CLOXACILLIN SODIUM				
CAPSULE;ORAL				
CLOXACILLIN SODIUM				
APOTHECON	EQ 250MG BASE		A061452 001	
	EQ 500MG BASE		A061452 002	
TEVA	EQ 250MG BASE		A062240 001	
	EQ 500MG BASE		A062240 002	
CLOXAPEN				
GLAXOSMITHKLINE	EQ 250MG BASE		A061806 001	
	EQ 250MG BASE		A062233 001	
	EQ 500MG BASE		A061806 002	
	EQ 500MG BASE		A062233 002	
FOR SOLUTION;ORAL				
CLOXACILLIN SODIUM				
TEVA	EQ 125MG BASE/5ML		A062268 001	
	EQ 125MG BASE/5ML		A062978 001	Apr 06, 1989
TEGOPEN				
APOTHECON	EQ 125MG BASE/5ML		A061453 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CLOXACILLIN SODIUM

FOR SOLUTION;ORAL				
TEGOPEN				
	EQ 125MG BASE/5ML	N050192	001	

CLOZAPINE

TABLET;ORAL				
CLOZAPINE				
MYLAN	12.5MG	A075417	003	Apr 15, 2010
PAR PHARM	25MG	A075162	001	Apr 26, 2005
	100MG	A075162	002	Apr 26, 2005
SANDOZ	25MG	A074546	001	Aug 30, 1996
	100MG	A074546	002	Aug 30, 1996
ZYDUS PHARMS	25MG	A209480	001	Dec 06, 2017
	50MG	A209480	002	Dec 06, 2017
	100MG	A209480	003	Dec 06, 2017
	200MG	A209480	004	Dec 06, 2017
TABLET, ORALLY DISINTEGRATING;ORAL				
FAZACLO ODT				
+ JAZZ	12.5MG	N021590	004	May 30, 2007
+	25MG	N021590	001	Feb 10, 2004
	50MG	N021590	003	Jun 03, 2005
+	100MG	N021590	002	Feb 10, 2004
+	150MG	N021590	005	Jul 09, 2010
+	200MG	N021590	006	Jul 09, 2010

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A;N/A				
RUBRATOPE-57 KIT				
BRACCO	N/A;N/A;N/A;N/A	N016089	001	

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A;N/A				
RUBRATOPE-60 KIT				
BRACCO	N/A;N/A;N/A;N/A	N016090	001	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL				
PHENERGAN VC W/ CODEINE				
+ ANI PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML **	N008306	005	Apr 02, 1984
PHERAZINE VC W/ CODEINE				
HALSEY	10MG/5ML;5MG/5ML;6.25MG/5ML	A088870	001	Mar 02, 1987
PROMETHAZINE VC W/ CODEINE				
CENCI	10MG/5ML;5MG/5ML;6.25MG/5ML	A088816	001	Nov 22, 1985
WOCKHARDT	10MG/5ML;5MG/5ML;6.25MG/5ML	A088896	001	Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL				
PHENERGAN W/ CODEINE				
+ ANI PHARMS	10MG/5ML;6.25MG/5ML **	N008306	004	Apr 02, 1984
PHERAZINE W/ CODEINE				
HALSEY	10MG/5ML;6.25MG/5ML	A088739	001	Dec 23, 1988
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE				
PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988
PROMETHAZINE W/ CODEINE				
CENCI	10MG/5ML;6.25MG/5ML	A088814	001	Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL				
ACTIFED W/ CODEINE				
GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML	N012575	003	Apr 04, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE				
CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018	001	Jul 23, 1986
TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE				
WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833	001	Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL				
CODEINE SULFATE				
HIKMA	30MG/5ML	N202245	001	Jun 30, 2011

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

COLCHICINE				
CAPSULE;ORAL				
COLCHICINE				
PAR PHARM INC	0.6MG		A208678 001	Nov 29, 2018
TABLET;ORAL				
COLCHICINE				
AMNEAL PHARMS	0.6MG		A204711 001	Sep 28, 2016
ZYDUS PHARMS	0.6MG		A211519 001	Feb 19, 2019
COLCHICINE; PROBENECID				
TABLET;ORAL				
COLBENEMID				
+ MERCK	0.5MG;500MG **		N012383 001	
PROBEN-C				
WATSON LABS	0.5MG;500MG		A085552 001	
PROBENECID AND COLCHICINE				
ANI PHARMS INC	0.5MG;500MG		A083734 001	
BEECHAM	0.5MG;500MG		A084321 001	
IMPAX LABS	0.5MG;500MG		A083720 002	
SANDOZ	0.5MG;500MG		A086130 001	
PROBENECID W/ COLCHICINE				
LEDERLE	0.5MG;500MG		A086954 001	
WATSON LABS	0.5MG;500MG		A083221 001	
COLESEVELAM HYDROCHLORIDE				
CAPSULE;ORAL				
WELCHOL				
DAIICHI SANKYO	375MG		N021141 001	May 26, 2000
FOR SUSPENSION;ORAL				
WELCHOL				
+ DAIICHI SANKYO	1.875GM/PACKET		N022362 001	Oct 02, 2009
COLISTIN SULFATE				
SUSPENSION;ORAL				
COLY-MYCIN S				
PARKE DAVIS	EQ 25MG BASE/5ML		N050355 001	
CONIVAPTAN HYDROCHLORIDE				
INJECTABLE;INTRAVENOUS				
VAPRISOL				
CUMBERLAND PHARMS	20MG/4ML (5MG/ML)		N021697 001	Dec 29, 2005
COPPER				
INTRAUTERINE DEVICE;INTRAUTERINE				
CU-7				
GD SEARLE LLC	89MG		N017408 001	
TATUM-T				
GD SEARLE LLC	120MG		N018205 001	
CORTICOTROPIN				
INJECTABLE;INJECTION				
ACTH				
PARKEDALE	25 UNITS/VIAL		N008317 002	
	40 UNITS/VIAL		N008317 004	
ACTHAR				
SANOFI AVENTIS US	25 UNITS/VIAL		N007504 002	
	40 UNITS/VIAL		N007504 003	
CORTICOTROPIN				
ORGANICS LAGRANGE	40 UNITS/ML		N010831 001	
	80 UNITS/ML		N010831 002	
WATSON LABS	40 UNITS/VIAL		A088772 001	Nov 21, 1984
H.P. ACTHAR GEL				
MALLINCKRODT ARD	40 UNITS/ML		N008372 006	
PURIFIED CORTROPHIN GEL				
ANI PHARMS INC	40 UNITS/ML		N008975 001	
	80 UNITS/ML		N008975 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CORTICOTROPIN-ZINC HYDROXIDE				
INJECTABLE;INJECTION				
CORTROPHIN-ZINC				
	ANI PHARMS INC	40 UNITS/ML	N009854 001	
CORTISONE ACETATE				
INJECTABLE;INJECTION				
CORTISONE ACETATE				
	PHARMACIA AND UPJOHN	25MG/ML	N008126 002	
	WATSON LABS	25MG/ML	A083147 003	
		25MG/ML	A085677 001	
		50MG/ML	A083147 004	
		50MG/ML	A085677 002	
CORTONE				
	MERCK	25MG/ML	N007110 002	
		50MG/ML	N007110 003	
TABLET;ORAL				
CORTISONE ACETATE				
	BARR	25MG	A083471 001	
	ELKINS SINN	25MG	A080836 001	
	EVERYLIFE	25MG	A084246 001	
	HEATHER	25MG	A085736 001	
	IMPAX LABS	25MG	N009458 001	
	INWOOD LABS	25MG	A080731 001	
	IVAX SUB TEVA PHARMS	25MG	A080630 001	
		25MG	A083536 001	
	LANNETT	25MG	A080694 001	
	PANRAY	5MG	N008284 002	
		25MG	N008284 001	
	PHARMACIA AND UPJOHN	5MG	N008126 003	
		10MG	N008126 004	
		25MG	N008126 001	
	PUREPAC PHARM	25MG	A080493 001	
	VITARINE	25MG	A080333 001	
	WATSON LABS	25MG	A085884 001	
	WHITEWORTH TOWN PLSN	25MG	A080341 001	
CORTONE				
+	MERCK	25MG **	N007750 003	
COSYNTROPIN				
SOLUTION;INTRAVENOUS				
COSYNTROPIN				
	SANDOZ INC	0.25MG/ML (0.25MG/ML)	N022028 001	Feb 21, 2008
CROMOLYN SODIUM				
AEROSOL, METERED;INHALATION				
INTAL				
	KING PHARMS LLC	0.8MG/INH	N018887 001	Dec 05, 1985
CAPSULE;INHALATION				
INTAL				
+	SANOFI AVENTIS US	20MG **	N016990 001	
CAPSULE;ORAL				
GASTROCROM				
	UCB INC	100MG	N019188 001	Dec 22, 1989
CONCENTRATE;ORAL				
CROMOLYN SODIUM				
	GENERA PHARMS	100MG/5ML	A090954 001	Dec 18, 2009
SOLUTION;INHALATION				
CROMOLYN SODIUM				
	ACTAVIS MID ATLANTIC	10MG/ML	A075067 001	Jul 19, 1999
	BAUSCH AND LOMB	10MG/ML	A075585 001	Dec 21, 2000
	FERA PHARMS LLC	10MG/ML	A075437 001	Apr 21, 2000
	HIKMA	10MG/ML	A075333 001	Apr 30, 2002
	MYLAN SPECIALITY LP	10MG/ML	A074209 001	Apr 26, 1994
	ROXANE	10MG/ML	A075175 001	Sep 30, 1999
	WATSON LABS	10MG/ML	A076469 001	Jun 17, 2005
INTAL				
+	KING PHARMS LLC	10MG/ML **	N018596 001	May 28, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CROMOLYN SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
CROLOM				
BAUSCH AND LOMB	4%	A074443	001	Jan 30, 1995
CROMOLYN SODIUM				
APOTEX INC	4%	A075615	001	Jan 26, 2001
CROMOPTIC				
KING PHARMS	4%	A075088	001	Apr 27, 1999
OPTICROM				
+ ALLERGAN	4% **	N018155	001	Oct 03, 1984
SPRAY, METERED;NASAL				
CROMOLYN SODIUM				
ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001
HH AND P	5.2MG/SPRAY	A077976	001	Sep 07, 2007
NASALCROM				
+ BLACKSMITH BRANDS	5.2MG/SPRAY **	N020463	001	Jan 03, 1997
CROTAMITON				
CREAM;TOPICAL				
EURAX				
+ SUN PHARM INDS INC	10%	N006927	001	
CRYPTENAMINE ACETATES				
INJECTABLE;INJECTION				
UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814	001	
CRYPTENAMINE TANNATES				
TABLET;ORAL				
UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT	N009217	001	
CUPRIC SULFATE				
INJECTABLE;INJECTION				
CUPRIC SULFATE				
ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987
CYANOCOBALAMIN				
GEL, METERED;NASAL				
NASCOBAL				
PAR PHARM	0.5MG/INH	N019722	001	Nov 05, 1996
INJECTABLE;INJECTION				
BERUBIGEN				
PHARMACIA AND UPJOHN	1MG/ML	N006798	001	
BETALIN 12				
LILLY	0.1MG/ML	A080855	001	
	1MG/ML	A080855	002	
COBAVITE				
WATSON LABS	0.1MG/ML	A083013	001	
	1MG/ML	A083064	001	
CYANOCOBALAMIN				
ABRAXIS PHARM	0.03MG/ML	A080510	003	
	0.1MG/ML	A080510	001	
	1MG/ML	A080510	002	
AKORN	1MG/ML	A087969	001	Nov 10, 1983
DELL LABS	0.03MG/ML	A080689	001	
	0.1MG/ML	A080689	002	
	1MG/ML	A080689	003	
DR REDDYS	0.1MG/ML	A080573	002	
	1MG/ML	A080573	001	
FRESENIUS KABI USA	0.1MG/ML	A080557	002	
LUITPOLD	0.03MG/ML	A080668	001	
LYPHOMED	1MG/ML	A083075	001	
MYLAN INSTITUTIONAL	1MG/ML	A040451	001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564	001	
SOLOPAK	1MG/ML	A087551	001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085	002	
WATSON LABS	0.1MG/ML	A083120	001	
	1MG/ML	A083120	002	
WYETH AYERST	0.1MG/ML	A080554	001	
	1MG/ML	A080554	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYANOCOBALAMIN				
INJECTABLE;INJECTION				
DODEX				
	ACCORD HLTHCARE	1MG/ML	A083022 001	
REDISOL				
	MERCK	1MG/ML	N006668 010	
RUBIVITE				
	BEL MAR	0.03MG/ML	N010791 004	
		0.05MG/ML	N010791 001	
		0.1MG/ML	N010791 002	
		0.12MG/ML	N010791 005	
		1MG/ML	N010791 003	
RUBRAMIN PC				
	BRISTOL MYERS SQUIBB	0.1MG/ML	N006799 002	
+		1MG/ML **	N006799 004	
+		1MG/ML **	N006799 010	Apr 28, 1988
RUVITE				
	SAVAGE LABS	1MG/ML	A080570 002	
VI-TWEL				
	BAYER HLTHCARE	1MG/ML	N007012 002	
SPRAY, METERED;NASAL				
CALOMIST				
	PAR PHARM	25MCG/SPRAY	N022102 001	Jul 27, 2007
TABLET;ORAL				
CYANOCOBALAMIN				
	WEST WARD	1MG	A084264 001	
CYANOCOBALAMIN CO-57				
CAPSULE;ORAL				
RUBRATOPE-57				
	BRACCO	0.5-1uCi	N016089 002	
CYANOCOBALAMIN CO-60				
CAPSULE;ORAL				
RUBRATOPE-60				
	BRACCO	0.5-1uCi	N016090 002	
CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58				
N/A;N/A				
DICOPAC KIT				
	GE HEALTHCARE	N/A;N/A;N/A	N017406 001	
CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR				
N/A;N/A				
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT				
	MALLINCKRODT	0.1MG;0.5uCi;60MG	N016635 001	
CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE				
INJECTABLE;INJECTION				
DEPINAR				
	ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N011208 001	
CYCLACILLIN				
FOR SUSPENSION;ORAL				
CYCLAPEN-W				
	WYETH AYERST	125MG/5ML	N050508 001	
		250MG/5ML	N050508 002	
		500MG/5ML	N050508 003	
TABLET;ORAL				
CYCLACILLIN				
	TEVA	250MG	A062895 001	Aug 04, 1988
		500MG	A062895 002	Aug 04, 1988
CYCLAPEN-W				
	WYETH AYERST	250MG	N050509 001	
		500MG	N050509 002	
CYCLIZINE LACTATE				
INJECTABLE;INJECTION				
MAREZINE				
	GLAXOSMITHKLINE	50MG/ML	N009495 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYCLOBENZAPRINE HYDROCHLORIDE				
TABLET;ORAL				
CYCLOBENZAPRINE HYDROCHLORIDE				
SANDOZ	10MG	A073683	001	Feb 26, 1993
UPSHER SMITH LABS	5MG	A072854	002	Feb 03, 2006
	10MG	A072854	001	Nov 19, 1991
WATSON LABS	10MG	A073143	001	Nov 27, 1991
	10MG	A074436	001	Nov 30, 1994
FLEXERIL				
+ JANSSEN RES AND DEV	5MG **	N017821	001	
+	10MG **	N017821	002	
CYCLOPENTOLATE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
AK-PENTOLATE				
AKORN	1%	A085555	001	
AKPENTOLATE				
AKORN	2%	A040165	001	Jan 13, 1997
CYCLOPENTOLATE HYDROCHLORIDE				
ALCON PHARMS LTD	1%	A089162	001	Jan 24, 1991
SOLA BARNES HIND	1%	A084150	001	
	1%	A084863	001	
PENTOLAIR				
PHARMAFAIR	0.5%	A088643	001	Feb 09, 1987
	1%	A088150	001	Feb 25, 1983
CYCLOPHOSPHAMIDE				
INJECTABLE;INJECTION				
CYCLOPHOSPHAMIDE				
BAXTER HLTHCARE	100MG/VIAL	A088371	001	Jul 03, 1986
	200MG/VIAL	A088372	001	Jul 03, 1986
	500MG/VIAL	A088373	001	Jul 03, 1986
	1GM/VIAL	A088374	001	Sep 24, 1986
CYTOXAN				
+ BAXTER HLTHCARE	100MG/VIAL **	N012142	001	
+	200MG/VIAL **	N012142	002	
CYTOXAN (LYOPHILIZED)				
+ BAXTER HLTHCARE	500MG/VIAL	N012142	003	
+	500MG/VIAL **	N012142	008	Jan 04, 1984
+	1GM/VIAL	N012142	004	Aug 30, 1982
+	1GM/VIAL **	N012142	010	Sep 24, 1985
+	2GM/VIAL	N012142	005	Aug 30, 1982
+	2GM/VIAL **	N012142	009	Dec 10, 1985
LYOPHILIZED CYTOXAN				
+ BAXTER HLTHCARE	100MG/VIAL **	N012142	006	Dec 05, 1985
+	200MG/VIAL **	N012142	007	Dec 10, 1985
NEOSAR				
BEDFORD	100MG/VIAL	A087442	001	Feb 16, 1982
	200MG/VIAL	A087442	002	Feb 16, 1982
	500MG/VIAL	A087442	003	Feb 16, 1982
	1GM/VIAL	A087442	004	Jul 08, 1983
	2GM/VIAL	A087442	005	Mar 30, 1989
TEVA PARENTERAL	100MG/VIAL	A040015	001	Apr 29, 1993
	200MG/VIAL	A040015	002	Apr 29, 1993
	500MG/VIAL	A040015	003	Apr 29, 1993
	1GM/VIAL	A040015	004	Apr 29, 1993
	2GM/VIAL	A040015	005	Apr 29, 1993
TABLET;ORAL				
CYCLOPHOSPHAMIDE				
ROXANE	25MG	A040032	001	Aug 17, 1999
	50MG	A040032	002	Aug 17, 1999
CYTOXAN				
+ BAXTER HLTHCARE	25MG **	N012141	002	
+	50MG **	N012141	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYCLOSPORINE					
CAPSULE;ORAL					
GENGRAF					
	ABBVIE	50MG	A065003	002	May 12, 2000
NEORAL					
+	NOVARTIS	50MG **	N050715	003	Jul 14, 1995
SOLUTION;ORAL					
CYCLOSPORINE					
	PHARM ASSOC	100MG/ML	A065167	001	Jan 05, 2005
CYCLOTHIAZIDE					
TABLET;ORAL					
ANHYDRON					
	LILLY	2MG	N013157	002	
FLUIDIL					
	PHARMACIA AND UPJOHN	2MG	N018173	001	
CYCRIMINE HYDROCHLORIDE					
TABLET;ORAL					
PAGITANE					
	LILLY	1.25MG	N008951	001	
		2.5MG	N008951	002	
CYPROHEPTADINE HYDROCHLORIDE					
SYRUP;ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	2MG/5ML **	A086833	001	
	HALSEY	2MG/5ML	A089199	001	Jul 03, 1986
	MORTON GROVE	2MG/5ML	A087001	001	Nov 04, 1982
	NASKA	2MG/5ML	A089021	001	Dec 21, 1987
PERIACTIN					
+	MERCK	2MG/5ML **	N013220	002	
TABLET;ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
	AM THERAP	4MG	A088798	001	Feb 15, 1985
	ASCOT	4MG	A087685	001	Oct 25, 1982
	CHARTWELL RX	4MG	A088212	001	May 26, 1983
	DURAMED PHARMS BARR	4MG	A088232	001	Oct 25, 1983
	FOSUN PHARMA	4MG	A086808	001	
	HALSEY	4MG	A089057	001	Jul 03, 1986
	KV PHARM	4MG	A086737	001	
	MD PHARM	4MG	A087566	001	Nov 10, 1982
	MYLAN	4MG	A086678	001	
	PIONEER PHARMS	4MG	A087839	001	Feb 08, 1984
	PLIVA	4MG	A088205	001	Jul 26, 1983
	SUPERPHARM	4MG	A087405	001	
	VITARINE	4MG	A087284	001	
	WATSON LABS	4MG	A085245	001	
		4MG	A086165	001	
		4MG	A086580	001	
PERIACTIN					
+	MERCK	4MG **	N012649	001	
CYSTEINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
CYSTEINE HYDROCHLORIDE					
+	HOSPIRA	7.25% **	N019523	001	Oct 22, 1986
CYTARABINE					
INJECTABLE;INJECTION					
CYTARABINE					
	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011
+	TEVA PARENTERAL	100MG/VIAL **	N016793	001	
+		500MG/VIAL **	N016793	002	
+		1GM/VIAL **	N016793	003	Dec 21, 1987
+		2GM/VIAL **	N016793	004	Dec 21, 1987
CYTOSAR-U					
	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998
		500MG/VIAL	A075206	002	Dec 30, 1998
		1GM/VIAL	A075206	004	Dec 30, 1998
		2GM/VIAL	A075206	003	Dec 30, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYTARABINE					
INJECTABLE, LIPOSOMAL;INJECTION					
DEPOCYT					
+	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999
DACARBAZINE					
INJECTABLE;INJECTION					
DACARBAZINE					
	ABRAXIS PHARM	100MG/VIAL	A070962	001	Aug 28, 1986
		200MG/VIAL	A070990	001	Aug 28, 1986
DTIC-DOME					
+	BAYER HLTHCARE	100MG/VIAL **	N017575	001	
+		200MG/VIAL **	N017575	002	
DACLATASVIR DIHYDROCHLORIDE					
TABLET;ORAL					
DAKLINZA					
+	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015
+		EQ 60MG BASE	N206843	002	Jul 24, 2015
+		EQ 90MG BASE	N206843	003	Apr 13, 2016
DACTINOMYCIN					
INJECTABLE;INJECTION					
DACTINOMYCIN					
	AM REGENT	0.5MG/VIAL	A202562	001	Aug 23, 2013
	WEST-WARD PHARMS INT	0.5MG/VIAL	A090304	001	Mar 16, 2010
DALFOPRISTIN; QUINUPRISTIN					
INJECTABLE;INTRAVENOUS					
SYNERCID					
	KING PHARMS	420MG/VIAL;180MG/VIAL	N050748	002	Aug 24, 2000
DALTEPARIN SODIUM					
INJECTABLE;INJECTION					
FRAGMIN					
	PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002
INJECTABLE;SUBCUTANEOUS					
FRAGMIN					
	PFIZER INC	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007
		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002
DANAPAROID SODIUM					
INJECTABLE;INJECTION					
ORGARAN					
	ASPEN GLOBAL INC	750 UNITS/0.6ML	N020430	001	Dec 24, 1996
DANAZOL					
CAPSULE;ORAL					
DANAZOL					
	AM THERAP	200MG	A071569	001	Dec 30, 1987
DANOCRINE					
	SANOFI AVENTIS US	50MG **	N017557	003	
		100MG **	N017557	004	
		200MG **	N017557	002	
DANTROLENE SODIUM					
INJECTABLE;INJECTION					
DANTROLENE SODIUM					
	MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016
DAPIPRAZOLE HYDROCHLORIDE					
SOLUTION/DROPS;OPHTHALMIC					
DAPIPRAZOLE HYDROCHLORIDE					
	BARADAINA LLC	0.5%	A204902	001	May 30, 2019
+	FERA PHARMS	0.5% **	N019849	001	Dec 31, 1990
DAPSONE					
GEL;TOPICAL					
DAPSONE					
	TARO PHARMS	7.5%	A210191	001	Jun 26, 2019
TABLET;ORAL					
DAPSONE					
	TARO	25MG	A209430	001	Mar 01, 2019
		100MG	A209430	002	Mar 01, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DAPTOMYCIN					
POWDER;INTRAVENOUS					
CUBICIN					
	CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003
DARUNAVIR					
TABLET;ORAL					
PREZISTA					
+	JANSSEN PRODS	300MG **	N021976	001	Jun 23, 2006
+		400MG **	N021976	003	Oct 21, 2008
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR					
TABLET, EXTENDED RELEASE;ORAL					
VIEKIRA XR					
+	ABBVIE INC	EQ 200MG BASE;8.33MG;50MG;33.33MG	N208624	001	Jul 22, 2016
DASATINIB					
TABLET;ORAL					
DASATINIB					
	APOTEX INC	20MG	A202103	001	Jun 10, 2016
		50MG	A202103	002	Jun 10, 2016
		70MG	A202103	003	Jun 10, 2016
		100MG	A202103	004	Jun 10, 2016
DAUNORUBICIN CITRATE					
INJECTABLE, LIPOSOMAL;INJECTION					
DAUNOXOME					
	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996
DAUNORUBICIN HYDROCHLORIDE					
INJECTABLE;INJECTION					
CERUBIDINE					
	SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876	001	
	WYETH AYERST	EQ 20MG BASE/VIAL **	N050484	001	
DAUNORUBICIN HYDROCHLORIDE					
	HISUN PHARM HANGZHOU	EQ 20MG BASE/VIAL	A206195	001	Apr 25, 2019
	TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212	001	Jun 23, 1998
		EQ 50MG BASE/VIAL	A064212	002	May 03, 1999
DECAMETHONIUM BROMIDE					
INJECTABLE;INJECTION					
SYNCURINE					
	GLAXOSMITHKLINE	1MG/ML	N006931	002	
DEFERIPRONE					
TABLET;ORAL					
DEFERIPRONE					
	TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019
DEFEROXAMINE MESYLATE					
INJECTABLE;INJECTION					
DEFEROXAMINE MESYLATE					
	DR REDDYS	500MG/VIAL	A076806	001	Mar 31, 2006
		2GM/VIAL	A076806	002	Mar 31, 2006
DELAVIRDINE MESYLATE					
TABLET;ORAL					
RESCRIPTOR					
+	VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
DEMECARIUM BROMIDE					
SOLUTION/DROPS;OPHTHALMIC					
HUMORSOL					
	MERCK	0.125%	N011860	002	
		0.25%	N011860	001	
DEMECLOCYCLINE HYDROCHLORIDE					
CAPSULE;ORAL					
DECLOMYCIN					
	LEDERLE	150MG	N050262	001	
SYRUP;ORAL					
DECLOMYCIN					
	LEDERLE	75MG/5ML	N050257	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DEMECLOCYCLINE HYDROCHLORIDE
TABLET;ORAL
DECLOMYCIN

COREPHARMA	75MG	N050261	001	
	150MG	N050261	002	
	300MG	N050261	003	

DEMECLOCYCLINE HYDROCHLORIDE

IMPAX LABS	150MG	A065094	001	Mar 22, 2004
	300MG	A065094	002	Mar 22, 2004

DESERPIDINE
TABLET;ORAL
HARMONYL

ABBVIE	0.1MG	N010796	001	
	0.25MG	N010796	002	

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
ORETICYL 25

ABBVIE	0.125MG;25MG	N012148	001	

ORETICYL 50

ABBVIE	0.125MG;50MG	N012148	003	

ORETICYL FORTE

ABBVIE	0.25MG;25MG	N012148	002	

DESERPIDINE; METHYCLOTHIAZIDE
TABLET;ORAL
ENDURONYL

ABBOTT	0.25MG;5MG	N012775	001	

ENDURONYL FORTE

ABBOTT	0.5MG;5MG	N012775	002	

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS	0.25MG;5MG	A088486	001	Aug 10, 1984
	0.5MG;5MG	A088452	001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE
CAPSULE;ORAL
PERTOFRANE

SANOFI AVENTIS US	25MG	N013621	001	
	50MG	N013621	002	

TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987
	50MG	A071803	003	Dec 08, 1987
	75MG	A071803	004	Dec 08, 1987
	100MG	A071803	001	May 29, 1997
	150MG	A071803	005	May 29, 1997
USL PHARMA	25MG	A071864	001	Sep 09, 1987
	50MG	A071865	001	Sep 09, 1987
	75MG	A071866	001	Sep 09, 1987
	100MG	A071867	001	Sep 09, 1987

DESIRUDIN RECOMBINANT
INJECTABLE;SUBCUTANEOUS
IPRIVASK

+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003

DESLANOSIDE
INJECTABLE;INJECTION
CEDILANID-D

NOVARTIS	0.2MG/ML	N009282	002	

DESLORATADINE
TABLET;ORAL
DESLORATADINE

MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DESMOPRESSIN ACETATE					
INJECTABLE;INJECTION					
DDAVP					
	FERRING PHARMS INC	0.015MG/ML	N018938	002	Apr 25, 1995
DESMOPRESSIN ACETATE					
	BEDFORD	0.004MG/ML	A074575	001	Feb 18, 2000
	HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000
DESMOPRESSIN ACETATE PRESERVATIVE FREE					
	BEDFORD	0.004MG/ML	A074574	001	Feb 18, 2000
SOLUTION;NASAL					
CONCENTRAID					
	FERRING	0.01%	N019776	001	Dec 26, 1990
DESMOPRESSIN ACETATE					
	SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012
SPRAY, METERED;NASAL					
DDAVP					
+	FERRING PHARMS INC	0.01MG/SPRAY **	N017922	002	Feb 06, 1989
NOCTIVA					
+	ALYVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017
+		0.00166MG/SPRAY	N201656	002	Mar 03, 2017
STIMATE					
	FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994
TABLET;ORAL					
DESMOPRESSIN ACETATE					
	FERRING	0.1MG	N021795	001	May 08, 2008
		0.2MG	N021795	002	May 08, 2008
DESOGESTREL; ETHINYL ESTRADIOL					
TABLET;ORAL-21					
DESOGEN					
	ORGANON USA INC	0.15MG;0.03MG	N020071	001	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL					
	DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	001	Aug 12, 1999
ORTHO-CEPT					
	JANSSEN PHARMS	0.15MG;0.03MG	N020301	001	Dec 14, 1992
TABLET;ORAL-28					
DESOGEN					
	ORGANON USA INC	0.15MG;0.03MG	N020071	002	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL					
	ACCORD HLTHCARE	0.15MG;0.03MG	A207067	001	Sep 13, 2018
MIRCETTE					
+	TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG **	N020713	001	Apr 22, 1998
ORTHO-CEPT					
	JANSSEN PHARMS	0.15MG;0.03MG	N020301	002	Dec 14, 1992
DESOXIMETASONE					
CREAM;TOPICAL					
DESOXIMETASONE					
	CADILA	0.25%	A205620	001	Sep 28, 2018
TOPICORT					
+	TARO PHARM INDS LTD	0.25% **	N017856	001	
TOPICORT LP					
+	TARO PHARM INDS LTD	0.05% **	N018309	001	
GEL;TOPICAL					
TOPICORT					
+	TARO PHARM INDS LTD	0.05% **	N018586	001	Mar 29, 1982
OINTMENT;TOPICAL					
DESOXIMETASONE					
	ALTANA	0.25%	A073440	001	Apr 01, 1998
TOPICORT					
+	TARO PHARM INDS LTD	0.25% **	N018763	001	Sep 30, 1983
DESOXYCORTICOSTERONE ACETATE					
INJECTABLE;INJECTION					
DOCA					
	ORGANON USA INC	5MG/ML	N001104	001	
PELLET;IMPLANTATION					
PERCORTEN					
	NOVARTIS	125MG	N005151	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DESOXYCORTICOSTERONE PIVALATE				
INJECTABLE;INJECTION				
PERCORTEN				
	NOVARTIS	25MG/ML	N008822 001	
DESVENLAFAXINE				
TABLET, EXTENDED RELEASE;ORAL				
KHEDEZLA				
	OSMOTICA PHARM CORP	50MG	N204683 001	Jul 10, 2013
		100MG	N204683 002	Jul 10, 2013
DESVENLAFAXINE FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE				
+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583 001	Jan 28, 2014
+		EQ 100MG BASE	N205583 002	Jan 28, 2014
	TEVA PHARMS USA	EQ 50MG BASE	N205208 001	Oct 11, 2013
		EQ 100MG BASE	N205208 002	Oct 11, 2013
DESVENLAFAXINE SUCCINATE				
TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE SUCCINATE				
	MYLAN	EQ 100MG BASE	A204095 002	Jun 29, 2015
	YICHANG HUMANWELL	EQ 50MG BASE	A210014 001	Oct 01, 2018
		EQ 100MG BASE	A210014 002	Oct 01, 2018
DEXAMETHASONE				
AEROSOL;TOPICAL				
AEROSEB-DEX				
	ALLERGAN HERBERT	0.01% **	A083296 002	
DECASPRAY				
+	MERCK	0.04% **	N012731 002	
ELIXIR;ORAL				
DECADRON				
	MERCK	0.5MG/5ML	N012376 002	
DEXAMETHASONE				
	ALPHARMA US PHARMS	0.5MG/5ML	A088997 001	Oct 10, 1986
HEXADROL				
	ASPEN GLOBAL INC	0.5MG/5ML	N012674 001	
GEL;TOPICAL				
DECADERM				
	MERCK	0.1%	N013538 001	
SUSPENSION/DROPS;OPHTHALMIC				
DEXAMETHASONE				
	WATSON LABS	0.1%	A089170 001	May 09, 1989
TABLET;ORAL				
DECADRON				
+	MERCK	0.25MG **	N011664 004	
+		0.5MG **	N011664 001	
+		0.75MG **	N011664 002	
+		1.5MG **	N011664 003	
+		4MG **	N011664 005	
+		6MG **	N011664 006	Jul 30, 1982
DEXAMETHASONE				
	ANI PHARMS INC	0.75MG	A080399 001	
	HERITAGE PHARMA	1.5MG	A085456 001	
	IMPAX LABS	0.75MG	A085376 001	
	PAR PHARM	0.25MG	A088149 001	Apr 28, 1983
	PHOENIX LABS NY	0.75MG	A083806 001	
	PVT FORM	0.75MG	A083420 001	
	ROXANE	0.25MG	A084614 001	
	SUN PHARM INDUSTRIES	0.25MG	A084013 001	
		0.25MG	A084764 001	
		0.5MG	A084084 001	
		0.5MG	A084766 001	
		0.75MG	A084081 001	
		0.75MG	A084765 001	
		1.5MG	A084086 001	
		1.5MG	A084763 001	
	UPSHER SMITH	0.75MG	A087534 001	
		1.5MG	A087533 001	

DEXAMETHASONE				
TABLET;ORAL				
DEXAMETHASONE				
WATSON LABS	0.25MG	A085455	001	
	0.5MG	A085458	001	
	0.75MG	A080968	001	
	0.75MG	A084457	001	
	0.75MG	A085818	001	
	1.5MG	A085840	001	
WHITEWORTH TOWN PLSN	0.75MG	A084327	001	
DEXONE 0.5				
SOLVAY	0.5MG	A084991	001	
DEXONE 0.75				
SOLVAY	0.75MG	A084993	001	
DEXONE 1.5				
SOLVAY	1.5MG	A084990	001	
DEXONE 4				
SOLVAY	4MG	A084992	001	
HEXADROL				
ASPEN GLOBAL INC	0.5MG	N012675	004	
	0.75MG	N012675	007	
	1.5MG	N012675	009	
	4MG	N012675	010	
DEXAMETHASONE ACETATE				
INJECTABLE;INJECTION				
DECADRON-LA				
+ MERCK	EQ 8MG BASE/ML **	N016675	001	
DEXAMETHASONE ACETATE				
WATSON LABS	EQ 8MG BASE/ML	A084315	001	
WATSON LABS TEVA	EQ 16MG BASE/ML	A087711	001	May 24, 1982
DEXAMETHASONE SODIUM PHOSPHATE				
AEROSOL;NASAL				
DEXACORT				
UCB INC	EQ 0.1MG PHOSPHATE/INH	N014242	001	
AEROSOL, METERED;INHALATION				
DEXACORT				
UCB INC	EQ 0.1MG PHOSPHATE/INH	N013413	001	
CREAM;TOPICAL				
DECADRON				
MERCK	EQ 0.1% PHOSPHATE	N011983	002	
INJECTABLE;INJECTION				
DECADRON				
+ MERCK	EQ 4MG PHOSPHATE/ML **	N012071	002	
+	EQ 24MG PHOSPHATE/ML **	N012071	004	
DEXACEN-4				
CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342	001	
DEXAMETHASONE				
ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448	001	Jan 25, 1984
FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469	001	Jan 25, 1984
DEXAMETHASONE SODIUM PHOSPHATE				
AKORN	EQ 4MG PHOSPHATE/ML	A084493	001	
AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019
BEL MAR	EQ 4MG PHOSPHATE/ML	A084752	001	
DELL LABS	EQ 4MG PHOSPHATE/ML	A083161	001	
DR REDDYS	EQ 4MG PHOSPHATE/ML	A089169	001	Apr 09, 1986
INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522	001	Feb 17, 1984
LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982
LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065	001	
TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125	001	Aug 31, 1990
	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990
WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702	001	
	EQ 4MG PHOSPHATE/ML	A084355	001	
	EQ 10MG PHOSPHATE/ML	A087668	001	Jul 01, 1982
	EQ 24MG PHOSPHATE/ML	A085606	001	
WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641	001	
HEXADROL				
+ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML **	N014694	002	
+	EQ 10MG PHOSPHATE/ML **	N014694	003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXAMETHASONE SODIUM PHOSPHATE				
INJECTABLE;INJECTION				
HEXADROL				
	EQ 20MG PHOSPHATE/ML	N014694 004		
OINTMENT;OPHTHALMIC				
DECADRON				
MERCK	EQ 0.05% PHOSPHATE	N011977 001		
DEXAIR				
PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001	Dec 28, 1982	
MAXIDEX				
ALCON	EQ 0.05% PHOSPHATE	A083342 001		
SOLUTION/DROPS;OPHTHALMIC				
DEXAIR				
PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001	Dec 15, 1983	
DEXAMETHASONE SODIUM PHOSPHATE				
SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001		
	EQ 0.1% PHOSPHATE	A084173 001		
SOLUTION/DROPS;OPHTHALMIC, OTIC				
DECADRON				
+ MERCK	EQ 0.1% PHOSPHATE	N011984 001		
DEXAMETHASONE SODIUM PHOSPHATE				
SANDOZ INC	EQ 0.1% PHOSPHATE	A088771 001	Jan 16, 1985	
SOLUTION/DROPS;OTIC				
DEXAMETHASONE SODIUM PHOSPHATE				
AKORN	EQ 0.1% PHOSPHATE	A084855 001		
DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DECADRON W/ XYLOCAINE				
MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334 002		
DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE				
OINTMENT;OPHTHALMIC				
NEODECADRON				
MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324 001		
SOLUTION/DROPS;OPHTHALMIC				
NEODECADRON				
MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322 001		
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE				
BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055 001	Oct 30, 1995	
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE				
ALCON PHARMS LTD	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714 001	Jul 21, 1986	
PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539 001	Jan 10, 1985	
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
DEXACIDIN				
NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566 001	Feb 22, 1985	
DEXASPORIN				
PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411 001	May 16, 1983	
SUSPENSION/DROPS;OPHTHALMIC				
DEXACIDIN				
NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544 001	Oct 29, 1984	
DEXASPORIN				
PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428 001	May 18, 1983	
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE				
ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986	
DEXBROMPHENIRAMINE MALEATE				
SYRUP;ORAL				
DISOMER				
SCHERING	2MG/5ML	N011814 002		
TABLET;ORAL				
DISOMER				
SCHERING	2MG	N011814 001		

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE				
TABLET;ORAL				
DISOPHROL				
SCHERING	2MG;60MG	N012394	002	
TABLET, EXTENDED RELEASE;ORAL				
BROMPHERIL				
COPLEY PHARM	6MG;120MG	A089116	001	Jan 22, 1987
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE				
AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013
DISOBROM				
SANDOZ	6MG;120MG	A070770	001	Sep 30, 1991
DISOPHROL				
SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982
DRIXORAL				
+ SCHERING PLOUGH	6MG;120MG **	N013483	003	Sep 13, 1982
RESPORAL				
PIONEER PHARMS	6MG;120MG	A089139	001	Jun 16, 1988
DEXCHLORPHENIRAMINE MALEATE				
SYRUP;ORAL				
POLARAMINE				
SCHERING	2MG/5ML	A086837	001	Jul 19, 1982
TABLET;ORAL				
DEXCHLORPHENIRAMINE MALEATE				
ANI PHARMS INC	2MG	A088682	001	Jan 17, 1986
POLARAMINE				
SCHERING	2MG	A086835	001	
DEXLANSOPRAZOLE				
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
DEXILANT SOLUTAB				
+ TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016
DEXMEDETOMIDINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DEXMEDETOMIDINE HYDROCHLORIDE				
AM REGENT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017
CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019
DEXMETHYLPHENIDATE HYDROCHLORIDE				
TABLET;ORAL				
DEXMETHYLPHENIDATE HYDROCHLORIDE				
LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017
	5MG	A209468	002	Sep 25, 2017
	10MG	A209468	003	Sep 25, 2017
TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007
	5MG	A077107	001	Jan 29, 2007
	10MG	A077107	002	Jan 29, 2007
DEXTROAMPHETAMINE SULFATE				
CAPSULE;ORAL				
DEXAMPEX				
TEVA	15MG	A085355	001	
CAPSULE, EXTENDED RELEASE;ORAL				
DEXTROAMPHETAMINE SULFATE				
ABLE	5MG	A076814	001	Aug 25, 2004
	10MG	A076814	002	Aug 25, 2004
	15MG	A076814	003	Aug 25, 2004
MYLAN	5MG	A206735	001	Jan 27, 2016
	10MG	A206735	002	Jan 27, 2016
	15MG	A206735	003	Jan 27, 2016
ELIXIR;ORAL				
DEXEDRINE				
GLAXOSMITHKLINE	5MG/5ML **	A083902	001	
TABLET;ORAL				
DEXAMPEX				
TEVA	5MG	A083735	001	
	10MG	A083735	002	
DEXEDRINE				
GLAXOSMITHKLINE	5MG	A084935	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROAMPHETAMINE SULFATE				
TABLET;ORAL				
DEXTROAMPHETAMINE SULFATE				
ANI PHARMS INC	5MG	A085370	001	
EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014
	10MG	A090652	002	Mar 07, 2014
HALSEY	10MG	A083930	001	
LANNETT	5MG	A083903	001	
	10MG	A083903	003	
	15MG	A085652	001	
MAST MM	5MG	A086521	001	
NESHER PHARMS	5MG	A040365	001	Oct 31, 2002
	10MG	A040367	001	Oct 31, 2002
PUREPAC PHARM	5MG	A084125	001	
SANDOZ	10MG	A085371	001	
VINTAGE PHARMS LLC	5MG	A040299	001	May 13, 1999
VITARINE	5MG	A084986	001	
	10MG	A085892	001	
DEXTROSTAT				
SHIRE	5MG **	A084051	001	
	10MG **	A084051	002	
FERNDEX				
FERNDALE LABS	5MG	A084001	001	
DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE				
SYRUP;ORAL				
PHERAZINE DM				
HALSEY	15MG/5ML;6.25MG/5ML	A088913	001	Mar 02, 1987
PROMETH W/ DEXTROMETHORPHAN				
G AND W LABS INC	15MG/5ML;6.25MG/5ML **	A088762	001	Oct 31, 1984
PROMETHAZINE DM				
VINTAGE	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011
+ ANI PHARMS	15MG/5ML;6.25MG/5ML **	N011265	002	Apr 02, 1984
TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012
DEXTROSE				
INJECTABLE;INJECTION				
DEXTROSE 10% IN PLASTIC CONTAINER				
B BRAUN	10GM/100ML	N018046	001	
MILES	10GM/100ML	N018504	001	
DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	2.5GM/100ML	N018358	001	
	2.5GM/100ML	N019626	001	Feb 02, 1988
DEXTROSE 20% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	20GM/100ML **	N017521	004	
DEXTROSE 30% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	30GM/100ML	N017521	003	
DEXTROSE 38.5% IN PLASTIC CONTAINER				
ABBOTT	38.5GM/100ML	N018923	001	Sep 19, 1984
DEXTROSE 40% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	40GM/100ML	N017521	002	
DEXTROSE 5% IN PLASTIC CONTAINER				
DHL	5GM/100ML	N019971	001	Sep 28, 1995
+ ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984
DEXTROSE 50% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	50GM/100ML **	N017521	001	
ICU MEDICAL INC	50GM/100ML	N019894	001	Dec 26, 1989
DEXTROSE 60%				
B BRAUN	60GM/100ML	N017995	002	Sep 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER				
B BRAUN	60GM/100ML	N017995	001	
+ BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982
	60GM/100ML	N020047	002	Jul 02, 1991
HOSPIRA	60GM/100ML	N019346	001	Jan 25, 1985
DEXTROSE 7.7% IN PLASTIC CONTAINER				
B BRAUN	7.7GM/100ML	N019626	003	Feb 02, 1988
DEXTROSE 70% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	70GM/100ML	N017521	006	Mar 26, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML	N017385	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025	001	Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N019844	001	Jun 10, 1993

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019843	001	Aug 09, 1993

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274	001	

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;37MG/100ML	N019699	001	Sep 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML	N018744	001	Nov 09, 1982
	5GM/100ML;75MG/100ML	N019699	002	Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;110MG/100ML	N019699	003	Sep 29, 1989

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML	N018744	002	Nov 09, 1982

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982
	5GM/100ML;220MG/100ML	N019699	005	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML	N018744	004	Nov 09, 1982

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514	001	May 08, 1986

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML	N019870 001	Jun 10, 1993	
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML	N018270 001		

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG /100ML;220MG/100ML	N018840 001	Jun 29, 1983	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%				
B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268 009		
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268 004		
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268 005		
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268 006		
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268 011	Jan 18, 1986	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N018268 012	Jan 18, 1986	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N018268 013	Jan 18, 1986	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N018268 014	Jan 18, 1986	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%				
B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N018268 010		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N018268 001		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N018268 002		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N018268 003		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 003		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 001		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 002		
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365 002	Jul 05, 1983	
+	5GM/100ML;149MG/100ML;225MG/100ML	N018365 006	Mar 28, 1988	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 001	Jan 17, 1986	
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 006	Mar 28, 1988	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 002	Mar 24, 1988	
+	5GM/100ML;149MG/100ML;900MG/100ML	N019691 004	Mar 24, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365 008	Mar 28, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876 007	Mar 28, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362 006	Mar 28, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691 006	Mar 24, 1988	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N018365 009	Mar 28, 1988	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876 008	Mar 28, 1988	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	5GM/100ML;298MG/100ML;450MG/100ML	N018362 007	Mar 28, 1988	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	ICU MEDICAL INC	5GM/100ML;298MG/100ML;900MG/100ML	N019691 008	Mar 24, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691 007	Mar 24, 1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;225MG/100ML	N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;300MG/100ML	N018876 009	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 008	Mar 28, 1988
+		5GM/100ML;149MG/100ML;450MG/100ML	N018362 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 001	Mar 24, 1988
+		5GM/100ML;149MG/100ML;900MG/100ML	N019691 003	Mar 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;200MG/100ML	N018386 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;450MG/100ML	N018229 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;900MG/100ML	N018047 001	
	BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N016696 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;450MG/100ML	N018030 001	
	HOSPIRA	2.5GM/100ML;450MG/100ML	N018096 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;900MG/100ML	N018376 001	
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ABBOTT	3.3GM/100ML;300MG/100ML	N018055 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML	N018030 005	
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;200MG/100ML	N018030 004	
	MILES	5GM/100ML;200MG/100ML	N018399 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ABBOTT	5GM/100ML;225MG/100ML	N019482 001	Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ABBOTT	5GM/100ML;300MG/100ML	N019486 001	Oct 04, 1985
	MILES	5GM/100ML;300MG/100ML	N018501 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;330MG/100ML	N018030 003	
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	ABBOTT	5GM/100ML;450MG/100ML	N019484 001	Oct 04, 1985
	B BRAUN	5GM/100ML;450MG/100ML	N018030 002	
	MILES	5GM/100ML;450MG/100ML	N018400 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	ABBOTT	5GM/100ML;900MG/100ML	N019483 001	Oct 04, 1985
	B BRAUN	5GM/100ML;900MG/100ML	N018026 001	
	MILES	5GM/100ML;900MG/100ML	N018500 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROTHYROXINE SODIUM				
TABLET;ORAL				
CHOLOXIN				
ABBVIE	1MG	N012302 005		
	2MG	N012302 002		
	4MG	N012302 004		
	6MG	N012302 006		
DEZOCINE				
INJECTABLE;INJECTION				
DALGAN				
ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989	
	10MG/ML	N019082 002	Dec 29, 1989	
	15MG/ML	N019082 003	Dec 29, 1989	
DIATRIZOATE MEGLUMINE				
INJECTABLE;INJECTION				
ANGIOVIST 282				
BAYER HLTHCARE	60%	A087726 001	Sep 23, 1982	
CARDIOGRAFIN				
BRACCO	85%	N011620 002		
DIATRIZOATE MEGLUMINE				
BRACCO	76%	N010040 017		
HYPAQUE				
GE HEALTHCARE	30%	N016403 002		
	60%	N016403 001		
RENO-60				
BRACCO	60%	N010040 016		
RENO-DIP				
BRACCO	30%	N010040 012		
UROVIST MEGLUMINE DIU/CT				
BAYER HLTHCARE	30%	A087739 001	Sep 23, 1982	
SOLUTION;URETERAL				
RENO-30				
BRACCO	30%	N010040 021		
UROVIST CYSTO				
BAYER HLTHCARE	30%	A087729 001	Sep 23, 1982	
UROVIST CYSTO PEDIATRIC				
BAYER HLTHCARE	30%	A087731 001	Sep 23, 1982	
SOLUTION;URETHRAL				
HYPAQUE-CYSTO				
GE HEALTHCARE	30%	N016403 003		
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM				
INJECTABLE;INJECTION				
ANGIOVIST 292				
BAYER HLTHCARE	52%;8%	A087724 001	Sep 23, 1982	
ANGIOVIST 370				
BAYER HLTHCARE	66%;10%	A087723 001	Sep 23, 1982	
DIATRIZOATE-60				
INTL MEDICATION	52%;8%	A088166 001	Jun 17, 1983	
HYPAQUE-76				
GE HEALTHCARE	66%;10%	A086505 001		
HYPAQUE-M,75%				
GE HEALTHCARE	50%;25%	N010220 003		
HYPAQUE-M,90%				
GE HEALTHCARE	60%;30%	N010220 002		
MD-60				
MALLINCKRODT	52%;8%	A087074 001		
MD-76				
MALLINCKRODT	66%;10%	A087073 001		
MD-76R				
+ LIEBEL-FLARSHEIM	66%;10%	N019292 001	Sep 29, 1989	
RENOCAL-76				
BRACCO	66%;10%	A089347 001	Jun 01, 1988	
RENOGRAFIN-60				
BRACCO	52%;8%	N010040 006		
RENOGRAFIN-76				
+ BRACCO	66%;10%	N010040 001		

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM				
INJECTABLE;INJECTION				
RENOVIST				
	BRACCO	34.3%;35%	N010040 020	
RENOVIST II				
	BRACCO	28.5%;29.1%	N010040 019	
SOLUTION;ORAL, RECTAL				
GASTROVIST				
	BAYER HLTHCARE	66%;10%	A087728 001	Sep 23, 1982
DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE				
SOLUTION;INTRAUTERINE				
SINOGRAFIN				
+	BRACCO	52.7%;26.8%	N011324 002	
DIATRIZOATE SODIUM				
FOR SOLUTION;ORAL, RECTAL				
HYPAQUE				
	GE HEALTHCARE	100%	N011386 001	
INJECTABLE;INJECTION				
HYPAQUE				
	GE HEALTHCARE	25%	N009561 003	
		50%	N009561 001	
MD-50				
	MALLINCKRODT	50%	A087075 001	
UROVIST SODIUM 300				
	BAYER HLTHCARE	50%	A087725 001	Sep 23, 1982
SOLUTION;ORAL, RECTAL				
HYPAQUE				
	GE HEALTHCARE	40%	N011386 003	
SOLUTION;URETERAL				
HYPAQUE SODIUM 20%				
	GE HEALTHCARE	20%	N009561 002	
DIAZEPAM				
CAPSULE, EXTENDED RELEASE;ORAL				
VALRELEASE				
	ROCHE	15MG	N018179 001	
GEL;RECTAL				
DIASTAT				
+	BAUSCH	5MG/ML (5MG/ML) **	N020648 002	Jul 29, 1997
+		10MG/2ML (5MG/ML) **	N020648 003	Jul 29, 1997
+		15MG/3ML (5MG/ML) **	N020648 004	Jul 29, 1997
+		20MG/4ML (5MG/ML) **	N020648 005	Jul 29, 1997
INJECTABLE;INJECTION				
DIAZEPAM				
	ABRAXIS PHARM	5MG/ML	A070662 001	Jun 25, 1986
	HOSPIRA	5MG/ML	A071584 001	Oct 13, 1987
	MARSAM PHARMS LLC	5MG/ML	A072371 001	Jan 29, 1993
	PARENTA PHARMS	5MG/ML	A076815 001	Apr 15, 2004
	US ARMY	5MG/ML **	N020124 001	Dec 05, 1990
	WARNER CHILCOTT	5MG/ML	A071613 001	Oct 22, 1987
		5MG/ML	A071614 001	Oct 22, 1987
	WATSON LABS	5MG/ML	A070296 001	Feb 12, 1986
		5MG/ML	A070911 001	Aug 28, 1986
		5MG/ML	A070912 001	Aug 28, 1986
		5MG/ML	A070930 001	Dec 01, 1986
	WATSON LABS INC	5MG/ML	A072370 001	Jan 29, 1993
		5MG/ML	A072397 001	Jan 29, 1993
	WEST-WARD PHARMS INT	5MG/ML	A070311 001	Dec 16, 1985
		5MG/ML	A070312 001	Dec 16, 1985
		5MG/ML	A070313 001	Dec 16, 1985
		5MG/ML	A071308 001	Jul 17, 1987
		5MG/ML	A071309 001	Jul 17, 1987
		5MG/ML	A071310 001	Jul 17, 1987
DIZAC				
	PHARMACIA AND UPJOHN	5MG/ML **	N019287 001	Jun 18, 1993
VALIUM				
+	ROCHE	5MG/ML **	N016087 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIAZEPAM				
TABLET;ORAL				
DIAZEPAM				
ACTAVIS ELIZABETH	2MG	A070781	001	Mar 19, 1986
	5MG	A070706	001	Mar 19, 1986
	10MG	A070707	001	Mar 19, 1986
DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985
	5MG	A070228	003	Sep 26, 1985
	10MG	A070228	001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894	001	Aug 27, 1986
	5MG	A070895	001	Aug 27, 1986
	10MG	A070896	001	Aug 27, 1986
FERNDALE LABS	2MG	A070903	001	Apr 01, 1987
	5MG	A070904	001	Apr 01, 1987
	10MG	A070905	001	Apr 01, 1987
HALSEY	2MG	A070987	001	Aug 15, 1986
	5MG	A070996	001	Aug 15, 1986
	10MG	A070956	001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360	001	Sep 04, 1985
	5MG	A070361	001	Sep 04, 1985
	10MG	A070362	001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402	001	Apr 25, 1989
NUVO PHARM	10MG	A070464	001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
	5MG	A070788	001	Aug 02, 1988
	10MG	A070776	001	Aug 02, 1988
ROXANE	2MG	A070356	001	Jun 17, 1986
	5MG	A070357	001	Jun 17, 1986
	10MG	A070358	001	Jun 17, 1986
TEVA PHARMS	5MG	A070153	001	Nov 01, 1985
UPSHER SMITH LABS	2MG	A070302	001	Dec 20, 1985
	5MG	A070303	001	Dec 20, 1985
	10MG	A070304	001	Dec 20, 1985
VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986
	5MG	A070463	001	Feb 25, 1986
WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
	5MG	A070210	001	Sep 04, 1985
	10MG	A070222	001	Sep 04, 1985
WATSON LABS	2MG	A070456	001	Nov 01, 1985
	5MG	A070457	001	Nov 01, 1985
	10MG	A070458	001	Nov 01, 1985
Q-PAM				
QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
	2MG	A072431	001	Apr 29, 1988
	5MG	A070424	001	Dec 12, 1985
	5MG	A072432	001	Apr 29, 1988
	10MG	A070425	001	Dec 12, 1985
	10MG	A072433	001	Apr 29, 1988
DIAZOXIDE				
CAPSULE;ORAL				
PROGLYCEM				
TEVA BRANDED PHARM	50MG	N017425	001	
	100MG	N017425	002	
INJECTABLE;INJECTION				
DIAZOXIDE				
ABRAXIS PHARM	15MG/ML	A071519	001	Aug 26, 1987
HYPERSTAT				
SCHERING	15MG/ML	N016996	001	
DIBUCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HEAVY SOLUTION NUPERCAINE				
NOVARTIS	2.5MG/ML	N006203	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DICHLORPHENAMIDE

TABLET;ORAL

DARANIDE

+	STRONGBRIDGE US	50MG **	N011366	001	

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL

LICART

+	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018

DICLOFENAC POTASSIUM

TABLET;ORAL

CATAFLAM

+	NOVARTIS	25MG **	N020142	001	Nov 24, 1993
		50MG **	N020142	002	Nov 24, 1993

DICLOFENAC POTASSIUM

	SANDOZ	50MG	A075582	001	Feb 23, 2001
	SUN PHARM INDUSTRIES	50MG	A075470	001	Feb 21, 2002
	WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION;INTRAVENOUS

DICLOFENAC SODIUM

	MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019

DYLOJECT

+	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014

SOLUTION;TOPICAL

DICLOFENAC SODIUM

	RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017

PENNSAID

+	NUVO PHARMS INC	1.5% **	N020947	001	Nov 04, 2009

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

	APOTEX INC	0.1%	A077600	001	Nov 13, 2008
	FALCON PHARMS	0.1%	N020809	001	May 04, 1998

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

	ALLIED	50MG	A074986	001	Feb 26, 1999
		75MG	A074986	002	Feb 26, 1999
	CASI PHARMS INC	25MG	A074376	001	Sep 28, 1995
		50MG	A074376	002	Sep 28, 1995
		75MG	A074394	001	Nov 30, 1995
	PLIVA	50MG	A074432	002	Jul 29, 1999
		75MG	A074432	003	Jul 29, 1999
	ROXANE	25MG	A074391	001	Jun 29, 1995
		50MG	A074391	002	Jun 29, 1995
		75MG	A074391	003	Jun 29, 1995
	TEVA	50MG	A074723	001	Mar 30, 1999
		75MG	A074390	001	Aug 15, 1996
	TEVA PHARMS	25MG	A074459	001	Jun 25, 1997
		50MG	A074459	002	Jun 25, 1997
		75MG	A074459	003	Jun 25, 1997

VOLTAREN

+	NOVARTIS	25MG **	N019201	001	Jul 28, 1988
+		50MG **	N019201	002	Jul 28, 1988
+		75MG **	N019201	003	Jul 28, 1988

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002
	MYLAN	100MG	A076152	001	Dec 13, 2001

VOLTAREN-XR

+	NOVARTIS	100MG **	N020254	001	Mar 08, 1996

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

	EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014
		75MG;0.2MG	A200540	002	Mar 14, 2014

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DICLOXACILLIN SODIUM				
CAPSULE;ORAL				
DYCILL				
GLAXOSMITHKLINE	EQ 250MG BASE	A060254	002	
	EQ 250MG BASE	A062238	001	
	EQ 500MG BASE	A060254	003	
	EQ 500MG BASE	A062238	002	
PATHOCIL				
WYETH AYERST	EQ 250MG BASE	N050011	002	
	EQ 500MG BASE	N050011	003	Mar 28, 1983
FOR SUSPENSION;ORAL				
DICLOXACILLIN SODIUM				
APOTHECON	EQ 62.5MG BASE/5ML	A061455	001	
DYNAPEN				
APOTHECON	EQ 62.5MG BASE/5ML	N050337	002	
PATHOCIL				
WYETH AYERST	EQ 62.5MG BASE/5ML	N050092	001	
DICUMAROL				
CAPSULE;ORAL				
DICUMAROL				
LILLY	25MG	N005509	003	
	50MG	N005509	001	
TABLET;ORAL				
DICUMAROL				
ABBVIE	25MG	N005545	003	
	50MG	N005545	004	
	100MG	N005545	005	
DICYCLOMINE HYDROCHLORIDE				
CAPSULE;ORAL				
BENTYL				
+ ALLERGAN	10MG	N007409	003	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
PIONEER PHARMS	10MG	A089361	001	Jan 10, 1989
SUN PHARM INDUSTRIES	10MG	A084505	001	Oct 21, 1986
WATSON LABS	10MG	A083179	001	Feb 12, 1986
INJECTABLE;INJECTION				
DICYCLOMINE HYDROCHLORIDE				
DR REDDYS	10MG/ML	A080614	001	Feb 11, 1986
SYRUP;ORAL				
BENTYL				
+ APTALIS PHARMA US	10MG/5ML **	N007961	002	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A084479	001	
TABLET;ORAL				
BENTYL				
+ ALLERGAN	20MG	N007409	001	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
PIONEER PHARMS	20MG	A088585	001	Aug 20, 1986
SUN PHARM INDUSTRIES	20MG	A084600	001	Jul 29, 1985
WATSON LABS	20MG	A084361	001	Feb 06, 1986
DIDANOSINE				
CAPSULE, DELAYED REL PELLETS;ORAL				
DIDANOSINE				
BARR	200MG	A077167	001	Dec 03, 2004
	250MG	A077167	002	Dec 03, 2004
	400MG	A077167	003	Dec 03, 2004
MYLAN PHARMS INC	125MG	A090788	001	Apr 08, 2010
	200MG	A090788	002	Apr 08, 2010
	250MG	A090788	003	Apr 08, 2010
	400MG	A090788	004	Apr 08, 2010
FOR SOLUTION;ORAL				
DIDANOSINE				
AUROBINDO PHARMA	10MG/ML	A078112	001	Mar 08, 2007
VIDEX				
BRISTOL MYERS SQUIBB	100MG/PACKET	N020155	003	Oct 09, 1991
	167MG/PACKET	N020155	004	Oct 09, 1991
	250MG/PACKET	N020155	005	Oct 09, 1991
	375MG/PACKET	N020155	006	Oct 09, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIDANOSINE					
TABLET, CHEWABLE;ORAL					
VIDEX					
+	BRISTOL MYERS SQUIBB	25MG **	N020154	002	Oct 09, 1991
+		50MG **	N020154	003	Oct 09, 1991
+		100MG **	N020154	004	Oct 09, 1991
+		150MG **	N020154	005	Oct 09, 1991
+		200MG **	N020154	006	Oct 28, 1999
TABLET, FOR SUSPENSION;ORAL					
DIDANOSINE					
	AUROBINDO	100MG	A077275	001	Aug 14, 2012
		150MG	A077275	002	Aug 14, 2012
		200MG	A077275	003	Aug 14, 2012
DIENESTROL					
CREAM;VAGINAL					
DIENESTROL					
	ORTHO MCNEIL PHARM	0.01%	N006110	005	
DV					
	SANOFI AVENTIS US	0.01%	A083518	001	
ESTRAGUARD					
	SOLVAY	0.01%	A084436	001	
SUPPOSITORY;VAGINAL					
DV					
	SANOFI AVENTIS US	0.7MG	A083517	001	
DIETHYLCARBAMAZINE CITRATE					
TABLET;ORAL					
HETRAZAN					
	LEDERLE	50MG	N006459	001	
DIETHYLPROPION HYDROCHLORIDE					
TABLET;ORAL					
DIETHYLPROPION HYDROCHLORIDE					
	CHARTWELL RX	25MG	A088267	001	Aug 25, 1983
		25MG	A088268	001	Aug 25, 1983
	EPIC PHARMA LLC	25MG	A040828	001	Nov 05, 2008
	SANDOZ	25MG	A085916	001	
	TEVA	25MG	A088642	001	Sep 20, 1984
	UCB INC	25MG	A085544	001	
	WATSON LABS	25MG	A085741	001	
TENUATE					
	SANOFI AVENTIS US	25MG	N017668	001	
+	TEVA BRANDED PHARM	25MG	N011722	002	
TEPANIL					
	3M	25MG	N011673	001	
TABLET, EXTENDED RELEASE;ORAL					
TENUATE					
	SANOFI AVENTIS US	75MG	N017669	001	
TENUATE DOSPAN					
+	TEVA BRANDED PHARM	75MG	N012546	001	
TEPANIL TEN-TAB					
	3M	75MG	N017956	001	
DIETHYLSTILBESTROL					
INJECTABLE;INJECTION					
STILBESTROL					
	BRISTOL MYERS SQUIBB	0.2MG/ML	N004056	003	
		0.5MG/ML	N004056	004	
		1MG/ML	N004056	005	
		5MG/ML	N004056	006	
SUPPOSITORY;VAGINAL					
DIETHYLSTILBESTROL					
	LILLY	0.1MG	N004040	001	
		0.5MG	N004040	002	
STILBESTROL					
	BRISTOL MYERS SQUIBB	0.1MG	N004056	001	
		0.5MG	N004056	002	
TABLET;ORAL					
DIETHYLSTILBESTROL					
	LILLY	0.1MG	N004041	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIETHYLSTILBESTROL				
TABLET;ORAL				
DIETHYLSTILBESTROL				
	0.5MG		N004041 003	
	1MG		N004041 004	
	5MG		N004041 005	
STILBESTROL				
TABLICAPS	0.5MG		A083004 001	
	1MG		A083002 001	
	5MG		A083006 001	
STILBETIN				
BRISTOL MYERS SQUIBB	0.1MG		N004056 007	
	0.25MG		N004056 017	
	0.5MG		N004056 008	
	1MG		N004056 009	
	5MG		N004056 010	
TABLET, DELAYED RELEASE;ORAL				
DIETHYLSTILBESTROL				
LILLY	0.1MG		N004039 002	
	0.25MG		N004039 005	
	0.5MG		N004039 003	
	1MG		N004039 004	
	5MG		N004039 006	
STILBESTROL				
TABLICAPS	0.5MG		A083003 001	
	1MG		A083005 001	
	5MG		A083007 001	
STILBETIN				
BRISTOL MYERS SQUIBB	0.1MG		N004056 011	
	0.5MG		N004056 012	
	1MG		N004056 013	
	5MG		N004056 014	
DIETHYLSTILBESTROL DIPHOSPHATE				
INJECTABLE;INJECTION				
STILPHOSTROL				
BAYER PHARMS	250MG/5ML		N010010 001	
TABLET;ORAL				
STILPHOSTROL				
BAYER PHARMS	50MG		N010010 002	
DIFLORASONE DIACETATE				
CREAM;TOPICAL				
DIFLORASONE DIACETATE				
FOUGERA PHARMS	0.05%		A075187 001	Mar 30, 1998
FLORONE				
PHARMACIA AND UPJOHN	0.05% **		N017741 001	
FLORONE E				
PHARMACIA AND UPJOHN	0.05%		N019259 001	Aug 28, 1985
PSORCON				
+ TARO PHARMS NORTH	0.05% **		N020205 001	Nov 20, 1992
OINTMENT;TOPICAL				
PSORCON				
+ PHARMACIA AND UPJOHN	0.05%		N019260 001	Aug 28, 1985
PSORCON E				
PHARMACIA AND UPJOHN	0.05%		N017994 001	
DIFLUNISAL				
TABLET;ORAL				
DIFLUNISAL				
ANI PHARMS INC	500MG		A074604 001	Jun 10, 1996
PUREPAC PHARM	250MG		A074285 001	May 07, 1996
	500MG		A074285 002	May 07, 1996
SOCORRO	250MG		A073562 001	Nov 27, 1992
	500MG		A073563 001	Nov 27, 1992
TEVA	250MG		A073679 001	Jul 31, 1992
WATSON LABS	250MG		A074400 001	Jul 17, 1997
	500MG		A074400 002	Jul 17, 1997
DOLOBID				
+ MERCK	250MG **		N018445 001	Apr 19, 1982
+	500MG **		N018445 002	Apr 19, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIGITOXIN				
INJECTABLE;INJECTION				
CRYSTODIGIN				
LILLY	0.2MG/ML	A084100 005		
DIGOXIN				
CAPSULE;ORAL				
LANOXICAPS				
GLAXOSMITHKLINE LLC	0.05MG	N018118 002	Jul 26, 1982	
	0.1MG	N018118 003	Jul 26, 1982	
	0.15MG	N018118 004	Sep 24, 1984	
	0.2MG	N018118 001	Jul 26, 1982	
INJECTABLE;INJECTION				
DIGOXIN				
ABRAXIS PHARM	0.25MG/ML	A083217 001		
HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996	
	0.25MG/ML	A040206 001	Aug 28, 1998	
WYETH AYERST	0.25MG/ML	A084386 001		
DIGOXIN PEDIATRIC				
HOSPIRA	0.1MG/ML	A040092 001	Apr 25, 1996	
TABLET;ORAL				
LANOXIN				
+ CONCORDIA	0.1875MG	N020405 003	Sep 30, 1997	
	0.375MG	N020405 005	Sep 30, 1997	
	0.5MG	N020405 006	Sep 30, 1997	
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
EMBOLEX				
NOVARTIS	0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML	N018885 001	Nov 30, 1984	
	0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML	N018885 002	Nov 30, 1984	
DILTIAZEM HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
CARDIZEM SR				
+ BIOVAIL	60MG **	N019471 001	Jan 23, 1989	
+	90MG **	N019471 002	Jan 23, 1989	
+	120MG **	N019471 003	Jan 23, 1989	
+	180MG **	N019471 004	Jan 23, 1989	
DILACOR XR				
+ ALLERGAN	120MG **	N020092 001	May 29, 1992	
+	180MG **	N020092 002	May 29, 1992	
+	240MG **	N020092 003	May 29, 1992	
DILT-CD				
APOTEX	120MG	A076151 001	May 20, 2004	
	180MG	A076151 002	May 20, 2004	
	240MG	A076151 003	May 20, 2004	
	300MG	A076151 004	May 20, 2004	
DILTIAZEM HYDROCHLORIDE				
ACTAVIS LABS FL INC	120MG	A074852 001	Oct 10, 1997	
	180MG	A074852 002	Oct 10, 1997	
	240MG	A074852 003	Oct 10, 1997	
BIOVAIL	60MG	A074845 001	Sep 15, 1999	
	90MG	A074845 002	Sep 15, 1999	
	120MG	A074845 003	Sep 15, 1999	
	120MG	N020939 001	Jan 28, 2000	
	180MG	N020939 002	Jan 28, 2000	
	240MG	N020939 003	Jan 28, 2000	
	300MG	N020939 004	Jan 28, 2000	
	360MG	N020939 005	Sep 14, 2001	
	420MG	N020939 006	Sep 14, 2001	
MYLAN	120MG	A075124 002	Mar 18, 1998	
	180MG	A075124 003	Mar 18, 1998	
	240MG	A075124 001	Mar 18, 1998	
NESHER PHARMS	120MG	A076563 002	Sep 12, 2006	
	180MG	A076563 003	Sep 12, 2006	
	240MG	A076563 004	Sep 12, 2006	
	300MG	A076563 005	Sep 12, 2006	
	360MG	A076563 006	Sep 12, 2006	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DILTIAZEM HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
DILTIAZEM HYDROCHLORIDE				
	420MG		A076563 001	Sep 12, 2006
PAR PHARM	360MG		A209766 001	May 30, 2018
TEVA	60MG		A074079 001	Nov 30, 1993
	90MG		A074079 002	Nov 30, 1993
	120MG		A074079 003	Nov 30, 1993
INJECTABLE;INJECTION				
CARDIZEM				
BIOVAIL	100MG/VIAL **		N020792 001	Sep 05, 1997
+ BIOVAIL LABS INTL	5MG/ML **		N020027 001	Oct 24, 1991
+	25MG/VIAL **		N020027 003	Aug 18, 1995
DILTIAZEM HYDROCHLORIDE				
DR REDDYS	5MG/ML		A074894 001	Aug 26, 1997
HOSPIRA	5MG/ML		A075004 001	Feb 16, 2000
	5MG/ML		A075106 001	Apr 29, 1999
MYLAN LABS LTD	5MG/ML		A075375 001	Sep 30, 1999
TABLET;ORAL				
DILTIAZEM HYDROCHLORIDE				
APOTHECON	30MG		A074051 001	Mar 31, 1993
	60MG		A074051 002	Mar 31, 1993
	90MG		A074051 003	Mar 31, 1993
	120MG		A074051 004	Mar 31, 1993
CHARTWELL MOLECULES	30MG		A074093 001	Nov 05, 1992
	60MG		A074093 002	Nov 05, 1992
	90MG		A074093 003	Nov 05, 1992
	120MG		A074093 004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG		A074168 001	Mar 03, 1995
	60MG		A074168 002	Mar 03, 1995
	90MG		A074168 003	Mar 03, 1995
	120MG		A074168 004	Mar 03, 1995
TEVA	30MG		A074084 001	Feb 25, 1994
	60MG		A074084 002	Feb 25, 1994
TEVA PHARMS	30MG		A074067 001	Nov 05, 1992
	60MG		A074067 002	Nov 05, 1992
	90MG		A074067 003	Nov 05, 1992
	120MG		A074067 004	Nov 05, 1992
DILTIAZEM MALATE				
TABLET, EXTENDED RELEASE;ORAL				
TIAMATE				
MERCK	EQ 120MG HYDROCHLORIDE		N020506 001	Oct 04, 1996
	EQ 180MG HYDROCHLORIDE		N020506 002	Oct 04, 1996
	EQ 240MG HYDROCHLORIDE		N020506 003	Oct 04, 1996
DILTIAZEM MALATE; ENALAPRIL MALEATE				
TABLET, EXTENDED RELEASE;ORAL				
TECZEM				
BIOVAIL	EQ 180MG HYDROCHLORIDE;5MG		N020507 001	Oct 04, 1996
DIMENHYDRINATE				
INJECTABLE;INJECTION				
DIMENHYDRINATE				
BAXTER HLTHCARE	50MG/ML		A084767 001	
WATSON LABS	50MG/ML		A083531 001	
WATSON LABS TEVA	50MG/ML		A080615 001	
WYETH AYERST	50MG/ML		A084316 001	
LIQUID;ORAL				
DIMENHYDRINATE				
ALRA	12.5MG/4ML		A080715 001	
TABLET;ORAL				
DIMENHYDRINATE				
HEATHER	50MG		A080841 001	
NEXGEN PHARMA INC	50MG		A085985 001	
WATSON LABS	50MG		A085166 001	

DIMETHYL SULFOXIDE				
SOLUTION;INTRAVESICAL				
DIMETHYL SULFOXIDE				
MYLAN INSTITUTIONAL	50%	A076185	001	Nov 29, 2002
DIMYRISTOYL LECITHIN; PERFLEXANE				
INJECTABLE;INTRAVENOUS				
IMAGENT				
VESSELON SPV LLC	0.92MG/VIAL;0.092MG/VIAL	N021191	001	May 31, 2002
DINOPROST TROMETHAMINE				
INJECTABLE;INJECTION				
PROSTIN F2 ALPHA				
PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434	001	
DIPHEMANIL METHYLSULFATE				
TABLET;ORAL				
PRANTAL				
SCHERING	100MG	N008114	004	
DIPHENHYDRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
BENADRYL				
MCNEIL CONS	25MG	N005845	007	
	50MG	N005845	001	
DIPHENHYDRAMINE HYDROCHLORIDE				
ALRA	25MG	A080519	004	
	50MG	A080519	003	
ANABOLIC	50MG	A083275	001	
ELKINS SINN	25MG	A085701	001	
	50MG	A085701	002	
FOSUN PHARMA	25MG	A080832	001	
	25MG	A080845	002	
	50MG	A080832	002	
	50MG	A080845	001	
HALSEY	50MG	A087914	001	Jun 04, 1984
HEATHER	25MG	A084524	001	
	50MG	A083953	001	
HERITAGE PHARMA	50MG	A080727	001	
	50MG	A080738	001	
HIKMA INTL PHARMS	50MG	A083567	001	
IMPAX LABS	25MG	A080807	001	
	50MG	A080807	002	
IVAX SUB TEVA PHARMS	25MG	A080762	001	
	50MG	A080762	002	
LANNETT	25MG	A080868	001	
	50MG	A080868	002	
LEDERLE	25MG	A086874	001	
	50MG	A086875	001	
LNK	25MG	A087977	001	Jan 27, 1983
	50MG	A087978	001	Jan 27, 1983
MK LABS	25MG	A083087	001	
	50MG	A083087	002	
MUTUAL PHARM	25MG	A084506	001	
NEWTRON PHARMS	25MG	A086543	001	
	50MG	A086544	001	
NEXGEN PHARMA INC	25MG	A083634	001	
PERRIGO	25MG	A083061	001	
	50MG	A083061	002	
PIONEER PHARMS	25MG	A089101	001	Dec 20, 1985
	50MG	A088880	001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156	001	
	50MG	A085150	001	
PVT FORM	25MG	A083027	001	
	50MG	A083027	002	
ROXANE	50MG	A080635	001	
SUN PHARM INDUSTRIES	25MG	A089488	001	Jan 02, 1987
	50MG	A089489	001	Jan 02, 1987
SUPERPHARM	25MG	A089040	001	May 15, 1985
	50MG	A089041	001	May 15, 1985
TEVA	25MG	A085874	001	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
DIPHENHYDRAMINE HYDROCHLORIDE				
	50MG		A085874 002	
VALEANT PHARM INTL	25MG		A080596 001	
	50MG		A080592 001	
VANGARD	25MG		A088034 001	Oct 27, 1982
	50MG		A087630 001	
WATSON LABS	25MG		A080728 001	
	25MG		A083797 001	
	25MG		A085138 001	
	50MG		A083797 002	
	50MG		A085083 001	
WHITEWORTH TOWN PLSN	25MG		A083441 001	
	50MG		A080800 001	
ELIXIR;ORAL				
BELIX				
HALSEY	12.5MG/5ML		A086586 001	Oct 03, 1983
BENADRYL				
MCNEIL CONS	12.5MG/5ML		N005845 004	
DIBENIL				
CENCI	12.5MG/5ML		A088304 001	Dec 16, 1983
DIPHEN				
USL PHARMA	12.5MG/5ML		A084640 001	
DIPHENHYDRAMINE HYDROCHLORIDE				
BUNDY	12.5MG/5ML		A083674 001	
CENCI	12.5MG/5ML		A087941 001	Dec 17, 1982
KV PHARM	12.5MG/5ML		A085621 001	
LANNETT	12.5MG/5ML		A080939 002	
LEDERLE	12.5MG/5ML		A086937 001	
MK LABS	12.5MG/5ML		A083088 002	
NASKA	12.5MG/5ML		A088680 001	May 31, 1985
PERRIGO	12.5MG/5ML		A083063 001	
PUREPAC PHARM	12.5MG/5ML		A083237 001	Jan 25, 1982
PVT FORM	12.5MG/5ML		A085287 001	
ROXANE	12.5MG/5ML		A080643 001	
HYDRAMINE				
ALPHARMA US PHARMS	12.5MG/5ML		A080763 002	
INJECTABLE;INJECTION				
BENADRYL				
MCNEIL CONS	10MG/ML		N006146 001	
+	50MG/ML **		N006146 002	
BENADRYL PRESERVATIVE FREE				
+ MCNEIL CONS	50MG/ML **		N009486 001	
DIPHENHYDRAMINE HYDROCHLORIDE				
BEL MAR	10MG/ML		A080822 001	
DR REDDYS	10MG/ML		A080873 001	
	50MG/ML		A080873 002	
EUROHLTH INTL SARL	50MG/ML		A083183 001	
LYPHOMED	10MG/ML		A087066 001	
WATSON LABS	10MG/ML		A083533 001	
WYETH AYERST	50MG/ML		A080577 001	
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE				
ABRAXIS PHARM	50MG/ML		A080586 002	
DR REDDYS	50MG/ML		A080873 003	
INTL MEDICATION	50MG/ML		A084094 001	
SYRUP;ORAL				
ANTITUSSIVE				
PERRIGO	12.5MG/5ML		A071292 001	Apr 10, 1987
BELDIN				
HALSEY	12.5MG/5ML		A089179 001	Jun 05, 1986
BENYLIN				
PARKE DAVIS	12.5MG/5ML		N006514 004	
DIPHEN				
MORTON GROVE	12.5MG/5ML		A070118 001	Oct 01, 1985
DIPHENHYDRAMINE HYDROCHLORIDE				
ALPHARMA US PHARMS	12.5MG/5ML		A070497 001	Apr 25, 1989
CUMBERLAND SWAN	12.5MG/5ML		A073611 001	Aug 20, 1992
HI TECH PHARMA	12.5MG/5ML		A072416 001	Sep 28, 1990

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP;ORAL				
HYDRAMINE				
	ALPHARMA US PHARMS	12.5MG/5ML	A070205 001	Jan 28, 1986
SILPHEN				
	LANNETT CO INC	12.5MG/5ML	A072646 001	Feb 27, 1992
VICKS FORMULA 44				
	WARNER CHILCOTT	12.5MG/5ML	A070524 001	Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL				
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE				
	P AND L	25MG;220MG	A207597 001	Jan 25, 2019

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
BENYLIN				
	PARKE DAVIS	12.5MG/5ML;30MG/5ML	N019014 001	Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET;ORAL				
VONTROL				
	GLAXOSMITHKLINE	EQ 25MG BASE	N016033 001	

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
HISPRIL				
	GLAXOSMITHKLINE	5MG	N011945 001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
AKPRO				
	AKORN	0.1%	A074382 001	Sep 29, 1995
DIPIVEFRIN HYDROCHLORIDE				
	BAUSCH AND LOMB	0.1%	A074188 001	May 19, 1995
	FALCON PHARMS	0.1%	A073636 001	Jun 30, 1994
PROPINE				
	ALLERGAN	0.1%	N018239 001	

DIPYRIDAMOLE

INJECTABLE;INJECTION				
DIPYRIDAMOLE				
	DR REDDYS	5MG/ML	A074952 001	Nov 26, 1997
	HOSPIRA	5MG/ML	A074601 001	Dec 19, 1997
	MYLAN LABS LTD	5MG/ML	A075769 001	Nov 27, 2002
IV PERSANTINE				
+	BOEHRINGER INGELHEIM	5MG/ML **	N019817 001	Dec 13, 1990
TABLET;ORAL				
DIPYRIDAMOLE				
	ANI PHARMS INC	25MG	A086944 002	Apr 16, 1991
		50MG	A086944 001	Feb 25, 1992
		75MG	A086944 003	Feb 25, 1992
	GLENMARK GENERICS	25MG	A088999 001	Feb 05, 1991
		50MG	A089000 001	Feb 05, 1991
		75MG	A089001 001	Feb 05, 1991
	LANNETT CO INC	25MG	A040898 001	Apr 23, 2008
		50MG	A040898 002	Apr 23, 2008
		75MG	A040898 003	Apr 23, 2008
	OXFORD PHARMS	25MG	A040542 001	Apr 21, 2006
		50MG	A040542 002	Apr 21, 2006
		75MG	A040542 003	Apr 21, 2006
	PUREPAC PHARM	25MG	A089425 001	Jul 12, 1990
		50MG	A089426 001	Jul 12, 1990
		75MG	A089427 001	Jul 12, 1990
	WATSON LABS	50MG	A087160 001	Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL				
DYNABAC				
	LILLY RES LABS	250MG	N050678 001	Jun 19, 1995

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL				
DISOPYRAMIDE PHOSPHATE				
AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985
	EQ 150MG BASE	A070471	001	Dec 10, 1985
INTERPHARM	EQ 100MG BASE	A071190	001	Jan 15, 1987
	EQ 150MG BASE	A071191	001	Jan 15, 1987
IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186	001	Nov 18, 1985
	EQ 150MG BASE	A070187	001	Nov 18, 1985
MYLAN	EQ 100MG BASE	A070138	001	Jun 14, 1985
	EQ 150MG BASE	A070139	001	Jun 14, 1985
SUN PHARM INDUSTRIES	EQ 100MG BASE	A070351	001	Dec 17, 1985
	EQ 150MG BASE	A070352	001	Dec 17, 1985
SUPERPHARM	EQ 100MG BASE	A070940	001	Feb 09, 1987
	EQ 150MG BASE	A070941	001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240	001	Feb 02, 1986
	EQ 150MG BASE	A070241	001	Feb 02, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
DISOPYRAMIDE PHOSPHATE				
NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987

DISULFIRAM

TABLET;ORAL				
ANTABUSE				
+ TEVA WOMENS	250MG **	N007883	003	
+	500MG **	N007883	002	
DISULFIRAM				
MYLAN	250MG	A203916	001	Mar 04, 2015
	500MG	A203916	002	Mar 04, 2015
PAR PHARM	250MG	A088792	001	Aug 14, 1984
	500MG	A088793	001	Aug 14, 1984
WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A087974	001	Aug 05, 1983
WATSON LABS TEVA	500MG	A086890	001	

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL				
DEPAKOTE CP				
ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
	EQ 500MG BASE	N019794	002	Jul 11, 1990
DIVALPROEX SODIUM				
MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008
TEVA	EQ 125MG VALPROIC ACID	A076941	001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A076941	002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A076941	003	Jul 29, 2008
TABLET, EXTENDED RELEASE;ORAL				
DIVALPROEX SODIUM				
ACP NIMBLE	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009
ANCHEN PHARMS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009
	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DOBUTAMINE HYDROCHLORIDE				
BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
DR REDDYS	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
HOSPIRA	EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993
WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993
WATSON LABS INC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	EQ 50MG BASE/100ML	N020269	001	Oct 19, 1993
	EQ 100MG BASE/100ML	N020269	002	Oct 19, 1993
	EQ 200MG BASE/100ML	N020269	003	Oct 19, 1993

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOBUTAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
DOBUTREX					
+	LILLY	EQ 12.5MG BASE/ML	N017820	002	
DOCETAXEL					
INJECTABLE;INJECTION					
DOCEFREZ					
+	SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011
+		80MG/VIAL	N022534	002	May 03, 2011
DOCETAXEL					
+	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011
+		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011
	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012
		80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012
	CIPLA	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018
		80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018
		160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018
+	HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016
	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014
		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014
		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014
		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014
	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019
		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019
		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019
	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015
		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015
TAXOTERE					
+	SANOFI AVENTIS US	40MG/ML **	N020449	001	May 14, 1996
DOLASETRON MESYLATE					
INJECTABLE;INJECTION					
ANZEMET					
+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001
TABLET;ORAL					
ANZEMET					
+	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997
+		100MG	N020623	002	Sep 11, 1997
DONEPEZIL HYDROCHLORIDE					
SOLUTION;ORAL					
ARICEPT					
	EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004
TABLET;ORAL					
DONEPEZIL HYDROCHLORIDE					
	ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011
		10MG	A201335	002	Aug 29, 2011
	APOTEX	5MG	A078841	001	Jun 02, 2011
		10MG	A078841	002	Jun 02, 2011
	HIKMA PHARMS	5MG	A090247	001	May 31, 2011
		10MG	A090247	002	May 31, 2011
	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016
	PAR PHARM	23MG	A202542	001	Jul 24, 2013
	SUN PHARM	23MG	A204293	001	Jun 05, 2015
	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010
		10MG	A076786	002	Nov 26, 2010
	WOCKHARDT	5MG	A091267	001	May 31, 2011
		10MG	A091267	002	May 31, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
ARICEPT ODT					
+	EISAI INC	5MG	N021720	001	Oct 18, 2004
+		10MG	N021720	002	Oct 18, 2004
DONEPEZIL HYDROCHLORIDE					
	HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010
		10MG	A078388	001	Nov 26, 2010
	SUN PHARM INDUSTRIES	5MG	A077975	002	Dec 11, 2009
		10MG	A077975	001	Dec 11, 2009
	ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DONEPEZIL HYDROCHLORIDE
TABLET, ORALLY DISINTEGRATING;ORAL
DONEPEZIL HYDROCHLORIDE

	10MG	A090175	002	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017
	10MG;28MG	A208328	002	Jan 27, 2017

DOPAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
	80MG/ML	A070657	001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
	40MG/ML	A070058	001	Mar 20, 1985
	80MG/ML	A070013	001	Jun 12, 1985
	80MG/ML	A070059	001	Mar 20, 1985
	160MG/ML	A070364	001	Dec 04, 1985
AM REGENT	40MG/ML	A070799	001	Feb 11, 1987
	80MG/ML	A070820	001	Feb 11, 1987
	160MG/ML	A070826	001	Feb 11, 1987
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TELIGENT	40MG/ML	N018656	001	Jun 28, 1983
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995

INTROPIN

HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DORIPENEM
INJECTABLE;INTRAVENOUS
DORIBAX

+	SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010
+		500MG/VIAL	N022106	001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009
RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008
TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008
WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014
ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019
LANNETT CO INC	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014
RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008
WATSON LABS INC	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014
ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013

DOXACURIUM CHLORIDE
INJECTABLE;INJECTION
NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946	001	Mar 07, 1991

DOXAPRAM HYDROCHLORIDE
INJECTABLE;INJECTION
DOXAPRAM HYDROCHLORIDE

WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992

DOXAZOSIN MESYLATE
TABLET;ORAL
DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000
	EQ 2MG BASE	A075574	002	Oct 18, 2000
	EQ 4MG BASE	A075574	003	Oct 18, 2000
	EQ 8MG BASE	A075574	004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453	001	Oct 18, 2000
	EQ 2MG BASE	A075453	002	Oct 18, 2000
	EQ 4MG BASE	A075453	003	Oct 18, 2000
	EQ 8MG BASE	A075453	004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000
	EQ 2MG BASE	A075609	002	Oct 18, 2000
	EQ 4MG BASE	A075609	003	Oct 18, 2000
	EQ 8MG BASE	A075609	004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353	001	Jan 12, 2001
	EQ 2MG BASE	A075353	002	Jan 12, 2001
	EQ 4MG BASE	A075353	003	Jan 12, 2001
	EQ 8MG BASE	A075353	004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000
	EQ 2MG BASE	A075426	002	Oct 18, 2000
	EQ 4MG BASE	A075426	003	Oct 18, 2000
	EQ 8MG BASE	A075426	004	Oct 18, 2000
YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000
	EQ 2MG BASE	A075646	002	Oct 18, 2000
	EQ 4MG BASE	A075646	003	Oct 18, 2000
	EQ 8MG BASE	A075646	004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE
CAPSULE;ORAL
DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685	001	Jan 05, 1988
	EQ 25MG BASE	A071686	001	Jan 05, 1988
	EQ 50MG BASE	A071673	001	Jan 05, 1988
	EQ 75MG BASE	A071674	001	Jan 05, 1988
	EQ 100MG BASE	A071675	001	Jan 05, 1988
	EQ 150MG BASE	A071676	001	Jan 05, 1988
NEW RIVER	EQ 10MG BASE	N016987	001	
	EQ 25MG BASE	N016987	002	
	EQ 50MG BASE	N016987	003	
	EQ 75MG BASE	N016987	006	
	EQ 100MG BASE	N016987	004	
	EQ 150MG BASE	N016987	007	Apr 13, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054	001	Dec 28, 1990
	EQ 25MG BASE	A072109	001	Dec 28, 1990
	EQ 50MG BASE	A073055	001	Dec 28, 1990
	EQ 75MG BASE	A072386	001	Sep 08, 1988
	EQ 100MG BASE	A072110	001	Sep 08, 1988

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL				
DOXEPIN HYDROCHLORIDE				
	EQ 150MG BASE	A072387	001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972	001	Sep 29, 1987
	EQ 25MG BASE	A070973	001	Sep 29, 1987
	EQ 50MG BASE	A070931	001	Sep 29, 1987
	EQ 75MG BASE	A070932	001	Sep 29, 1987
	EQ 100MG BASE	A072375	001	Mar 15, 1989
	EQ 150MG BASE	A072376	001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487	001	Mar 02, 1987
	EQ 25MG BASE	A070827	001	May 15, 1986
	EQ 50MG BASE	A070828	001	May 15, 1986
	EQ 75MG BASE	A070825	001	May 15, 1986
	EQ 100MG BASE	A071562	001	Mar 02, 1987
SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502	001	Feb 18, 1988
	EQ 50MG BASE	A071653	001	Feb 18, 1988
	EQ 75MG BASE	A071654	001	Feb 18, 1988
	EQ 100MG BASE	A071521	001	Feb 18, 1988
WATSON LABS	EQ 10MG BASE	A070952	001	Mar 04, 1987
	EQ 10MG BASE	A071485	001	Apr 30, 1987
	EQ 10MG BASE	A072985	001	Mar 29, 1991
	EQ 25MG BASE	A070953	001	May 15, 1986
	EQ 25MG BASE	A071486	001	Apr 30, 1987
	EQ 25MG BASE	A072986	001	Mar 29, 1991
	EQ 50MG BASE	A070954	001	May 15, 1986
	EQ 50MG BASE	A071238	001	Apr 30, 1987
	EQ 75MG BASE	A071326	001	Apr 30, 1987
	EQ 75MG BASE	A071763	001	Feb 09, 1988
	EQ 100MG BASE	A070955	001	May 15, 1986
	EQ 100MG BASE	A071239	001	Apr 30, 1987
	EQ 150MG BASE	A071764	001	Feb 09, 1988
WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991
SINEQUAN				
+ PFIZER	EQ 10MG BASE **	N016798	003	
+	EQ 25MG BASE **	N016798	001	
+	EQ 50MG BASE **	N016798	002	
+	EQ 75MG BASE **	N016798	006	
+	EQ 100MG BASE **	N016798	005	
+	EQ 150MG BASE **	N016798	007	
CONCENTRATE;ORAL				
DOXEPIN HYDROCHLORIDE				
PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004
SINEQUAN				
+ PFIZER	EQ 10MG BASE/ML **	N017516	001	
TABLET;ORAL				
DOXEPIN HYDROCHLORIDE				
MYLAN	EQ 3MG BASE	A202337	001	Jan 20, 2016
	EQ 6MG BASE	A202337	002	Jan 20, 2016

DOXERCALCIFEROL

INJECTABLE;INJECTION				
DOXERCALCIFEROL				
+ HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION				
ADRIAMYCIN PFS				
PHARMACIA AND UPJOHN	2MG/ML	A063165	001	Jan 30, 1991
	200MG/100ML	A063165	002	Jan 30, 1991
DOXORUBICIN HYDROCHLORIDE				
ALVOGEN INC	2MG/ML	A065515	001	Nov 08, 2012
HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019
HLTHCARE	2MG/ML	A200146	001	Jul 18, 2012
MYLAN LABS LTD	2MG/ML	A200901	001	Feb 14, 2012
	10MG/VIAL	A200170	001	Oct 28, 2011
PHARMACIA AND UPJOHN	10MG/VIAL	N050467	001	
	20MG/VIAL	N050467	003	May 20, 1985
	50MG/VIAL	N050467	002	
	150MG/VIAL	N050467	004	Jul 22, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXORUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
RUBEX				
BRISTOL MYERS SQUIBB	10MG/VIAL	A062926	001	Apr 13, 1989
	50MG/VIAL	A062926	002	Apr 13, 1989
	100MG/VIAL	A062926	003	Apr 13, 1989
DOXYCYCLINE				
CAPSULE;ORAL				
DOXYCYCLINE				
PAR PHARM	EQ 75MG BASE	A065055	004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000
	EQ 100MG BASE	A065032	002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000
	EQ 100MG BASE	A065041	002	Apr 28, 2000
MONODOX				
+ ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992
+	EQ 75MG BASE	N050641	003	Oct 18, 2006
+	EQ 100MG BASE	N050641	001	Dec 29, 1989
FOR SUSPENSION;ORAL				
DOXYCHEL				
RACHELLE	EQ 25MG BASE/5ML	A061720	001	
TABLET;ORAL				
DOXYCYCLINE				
MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006
	EQ 75MG BASE	A065377	002	Nov 07, 2006
	EQ 100MG BASE	A065377	003	Nov 07, 2006
	EQ 150MG BASE	A065427	001	Jun 07, 2007
PAR PHARM	EQ 50MG BASE	A065070	001	Dec 15, 2000
	EQ 75MG BASE	A065070	003	Dec 30, 2002
	EQ 100MG BASE	A065070	002	Dec 15, 2000
	EQ 150MG BASE	A065070	004	Jul 14, 2005
SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006
	EQ 75MG BASE	A065353	002	Nov 27, 2006
	EQ 100MG BASE	A065353	003	Nov 27, 2006
SUN PHARM INDUSTRIES	EQ 50MG BASE	A065471	001	Apr 17, 2009
	EQ 75MG BASE	A065471	002	Apr 17, 2009
	EQ 100MG BASE	A065471	003	Apr 17, 2009
DOXYCYCLINE HYCLATE				
CAPSULE;ORAL				
ACTICLATE CAP				
+ ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016
DOXY-LEMMON				
TEVA	EQ 50MG BASE	A062497	001	Aug 23, 1984
	EQ 100MG BASE	A062497	002	Jun 15, 1984
DOXYCYCLINE HYCLATE				
AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018
	EQ 100MG BASE	A211012	002	Sep 24, 2018
HALSEY	EQ 50MG BASE	A062119	002	May 24, 1985
	EQ 100MG BASE	A062119	001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463	001	Dec 07, 1983
	EQ 100MG BASE	A062463	002	Dec 07, 1983
HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005
INTERPHARM	EQ 50MG BASE	A062763	001	Sep 02, 1988
	EQ 100MG BASE	A062763	002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418	001	Jan 28, 1983
	EQ 100MG BASE	A062418	002	Jan 28, 1983
MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982
	EQ 100MG BASE	A062337	002	Mar 29, 1982
PAR PHARM	EQ 50MG BASE	A062434	001	Oct 19, 1984
	EQ 100MG BASE	A062442	001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631	001	Jul 24, 1986
	EQ 100MG BASE	A062631	002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479	001	Dec 23, 1983
	EQ 100MG BASE	A062479	002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469	001	Oct 31, 1984
	EQ 100MG BASE	A062469	002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594	001	Dec 05, 1985
	EQ 100MG BASE	A062594	002	Dec 05, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXYCYCLINE HYCLATE

CAPSULE;ORAL				
DOXYCYCLINE HYCLATE				
WATSON LABS	EQ 50MG BASE	A061717	001	
	EQ 50MG BASE	A062142	001	
	EQ 100MG BASE	A061717	002	
	EQ 100MG BASE	A062142	002	
PERIOSTAT				
+ COLLAGENEX	EQ 20MG BASE **	N050744	001	Sep 30, 1998
VIBRAMYCIN				
+ PFIZER	EQ 50MG BASE **	N050007	001	
CAPSULE, COATED PELLETS;ORAL				
DOXYCYCLINE HYCLATE				
PLIVA	EQ 100MG BASE	A063187	001	Jun 30, 1992
CAPSULE, DELAYED RELEASE;ORAL				
DORYX				
+ MAYNE PHARMA INTL	EQ 75MG BASE	N050582	002	Aug 13, 2001
+	EQ 100MG BASE	N050582	001	Jul 22, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062653	001	Oct 30, 1985
DOXYCYCLINE HYCLATE				
MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005
	EQ 100MG BASE	A065281	002	Dec 21, 2005
INJECTABLE;INJECTION				
DOXYCHEL HYCLATE				
RACHELLE	EQ 100MG BASE/VIAL	A061953	001	
DOXYCYCLINE				
WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988
DOXYCYCLINE HYCLATE				
WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989
	EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989
VIBRAMYCIN				
+ PFIZER	EQ 100MG BASE/VIAL **	N050442	002	
+	EQ 200MG BASE/VIAL **	N050442	001	
TABLET;ORAL				
DOXY-LEMMON				
TEVA	EQ 100MG BASE	A062581	001	Mar 15, 1985
DOXYCYCLINE HYCLATE				
HEATHER	EQ 100MG BASE	A062462	001	May 11, 1983
INTERPHARM	EQ 100MG BASE	A062764	001	Sep 02, 1988
MUTUAL PHARM	EQ 100MG BASE	A062391	001	Sep 30, 1982
SUPERPHARM	EQ 100MG BASE	A062494	001	Feb 20, 1985
VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986
WARNER CHILCOTT	EQ 100MG BASE	A062593	001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392	001	Mar 31, 1983
	EQ 100MG BASE	A062392	002	Mar 31, 1983
LYMEPAK				
+ CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018
PERIOSTAT				
+ GALDERMA LABS LP	EQ 20MG BASE **	N050783	001	Feb 02, 2001
VIBRA-TABS				
+ PFIZER	EQ 100MG BASE **	N050533	001	
TABLET, DELAYED RELEASE;ORAL				
DORYX				
+ MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013
DORYX MPC				
+ MAYNE PHARMA	EQ 60MG BASE **	N050795	007	May 20, 2016
DOXYCYCLINE HYCLATE				
IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010
	EQ 100MG BASE	A090505	002	Dec 28, 2010
MYLAN	EQ 75MG BASE	A090431	001	Dec 28, 2010
	EQ 80MG BASE	A090431	004	Apr 29, 2016
	EQ 100MG BASE	A090431	002	Dec 28, 2010
	EQ 200MG BASE	A090431	005	May 19, 2016
MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012
ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018
	EQ 100MG BASE	A206772	002	Dec 21, 2018
	EQ 150MG BASE	A206772	003	Dec 21, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXYLAMINE SUCCINATE				
CAPSULE;ORAL				
UNISOM				
PFIZER	25MG	N019440	001	Feb 05, 1986
TABLET;ORAL				
DECAPRYN				
SANOFI AVENTIS US	12.5MG	N006412	015	
	25MG	N006412	014	
DOXY-SLEEP-AID				
PAR PHARM	25MG	A070156	001	Jul 02, 1987
DOXYLAMINE SUCCINATE				
COPLEY PHARM	25MG	A088900	002	Feb 12, 1988
QUANTUM PHARMICS	25MG	A088603	001	Aug 07, 1984
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
BENDECTIN				
SANOFI AVENTIS US	10MG;10MG **	N010598	002	
DROMOSTANOLONE PROPIONATE				
INJECTABLE;INJECTION				
DROLBAN				
LILLY	50MG/ML	N012936	001	
DRONABINOL				
CAPSULE;ORAL				
DRONABINOL				
INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011
	5MG	A078501	002	Aug 19, 2011
	10MG	A078501	003	Aug 19, 2011
DROPERIDOL				
INJECTABLE;INJECTION				
DROPERIDOL				
ABRAXIS PHARM	2.5MG/ML	A070992	001	Nov 17, 1986
	2.5MG/ML	A070993	001	Nov 17, 1986
ASTRAZENECA	2.5MG/ML	A072018	001	Oct 20, 1988
HOSPIRA	2.5MG/ML	A071645	001	Apr 07, 1988
	2.5MG/ML	A072272	001	Aug 31, 1995
IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988
	2.5MG/ML	A072020	001	Oct 19, 1988
	2.5MG/ML	A072021	001	Oct 19, 1988
LUITPOLD	2.5MG/ML	A072335	001	Oct 24, 1988
SMITH AND NEPHEW	2.5MG/ML	A071750	001	Sep 06, 1988
SOLOPAK	2.5MG/ML	A071754	001	Sep 06, 1988
	2.5MG/ML	A071755	001	Sep 06, 1988
WATSON LABS	2.5MG/ML	A073520	001	Nov 27, 1991
	2.5MG/ML	A073521	001	Nov 27, 1991
	2.5MG/ML	A073523	001	Nov 27, 1991
DROPERIDOL; FENTANYL CITRATE				
INJECTABLE;INJECTION				
FENTANYL CITRATE AND DROPERIDOL				
ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026	001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027	001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028	001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982	001	May 04, 1988
INNOVAR				
AKORN MFG	2.5MG/ML;EQ 0.05MG BASE/ML	N016049	001	
DULOXETINE HYDROCHLORIDE				
CAPSULE, DELAYED REL PELLETS;ORAL				
DULOXETINE HYDROCHLORIDE				
TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013
	EQ 30MG BASE	A090783	002	Dec 11, 2013
	EQ 60MG BASE	A090783	003	Dec 11, 2013

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DUTASTERIDE				
CAPSULE;ORAL				
DUTASTERIDE				
BRECKENRIDGE	0.5MG	A204705	001	Nov 20, 2015
MYLAN	0.5MG	A203241	001	Jun 14, 2016
PII	0.5MG	A208227	001	Jun 22, 2018
RISING	0.5MG	A202530	001	Nov 20, 2015
DYCLONINE HYDROCHLORIDE				
SOLUTION;TOPICAL				
DYCLONE				
+ ASTRAZENECA	0.5% **	N009925	002	
+	1% **	N009925	001	
DYDROGESTERONE				
TABLET;ORAL				
GYNOREST				
SOLVAY	5MG **	N017388	001	
	10MG **	N017388	002	
DYPHYLLINE				
ELIXIR;ORAL				
NEOTHYLLINE				
TEVA	160MG/15ML	N007794	003	
INJECTABLE;INJECTION				
NEOTHYLLINE				
TEVA	250MG/ML	N009088	001	
TABLET;ORAL				
DILOR				
SAVAGE LABS	200MG	A084514	001	
DILOR-400				
SAVAGE LABS	400MG	A084751	001	
LUFYLLIN				
MYLAN SPECIALITY LP	200MG	A084566	001	
	400MG	A084566	002	
NEOTHYLLINE				
TEVA	200MG	N007794	001	
	400MG	N007794	002	
ECHOTHIOPHATE IODIDE				
FOR SOLUTION;OPHTHALMIC				
PHOSPHOLINE IODIDE				
WYETH PHARMS	0.03%	N011963	002	
	0.06%	N011963	004	
	0.25%	N011963	003	
ECONAZOLE NITRATE				
CREAM;TOPICAL				
ECONAZOLE NITRATE				
CASI PHARMS INC	1%	A076075	001	Nov 26, 2002
EDETATE CALCIUM DISODIUM				
TABLET;ORAL				
CALCIUM DISODIUM VERSENATE				
MEDICIS	500MG	N008922	002	
EDROPHONIUM CHLORIDE				
INJECTABLE;INJECTION				
EDROPHONIUM CHLORIDE				
HOSPIRA	10MG/ML	A040131	001	Feb 24, 1998
WATSON LABS	10MG/ML	A040044	001	Mar 20, 1996
EDROPHONIUM CHLORIDE PRESERVATIVE FREE				
WATSON LABS	10MG/ML	A040043	001	Mar 20, 1996
ENLON				
MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985
REVERSOL				
ORGANON USA INC	10MG/ML	A089624	001	May 13, 1988
TENSILON				
+ TELIGENT	10MG/ML **	N007959	001	
TENSILON PRESERVATIVE FREE				
+ TELIGENT	10MG/ML **	N007959	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EFAVIRENZ					
CAPSULE;ORAL					
SUSTIVA					
+	BRISTOL MYERS SQUIBB	100MG **	N020972	002	Sep 17, 1998
TABLET;ORAL					
SUSTIVA					
+	BRISTOL MYERS SQUIBB	300MG **	N021360	001	Feb 01, 2002
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE					
	TEVA PHARMS USA	600MG;200MG;300MG	A091215	001	Nov 09, 2018
EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE					
	AUROBINDO PHARMA LTD	600MG;300MG;300MG	N022343	001	Aug 15, 2018
	MACLEODS PHARMS LTD	400MG;300MG;300MG	N210649	001	Mar 15, 2019
EFLORNITHINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
ORNIDYL					
	SANOFI AVENTIS US	200MG/ML	N019879	002	Nov 28, 1990
ELTROMBOPAG OLAMINE					
TABLET;ORAL					
PROMACTA					
+	NOVARTIS	EQ 100MG ACID	N022291	005	Nov 16, 2012
ELVITEGRAVIR					
TABLET;ORAL					
VITEKTA					
+	GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014
+		150MG	N203093	002	Sep 24, 2014
EMEDASTINE DIFUMARATE					
SOLUTION/DROPS;OPHTHALMIC					
EMADINE					
+	NOVARTIS	0.05%	N020706	001	Dec 29, 1997
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE					
	AMNEAL PHARMS CO	100MG;150MG	A209721	001	Aug 22, 2018
		133MG;200MG	A209721	002	Aug 22, 2018
		167MG;250MG	A209721	003	Aug 22, 2018
		200MG;300MG	A209721	004	Aug 22, 2018
	LAURUS LABS LTD	200MG;300MG	A212114	001	Jul 26, 2019
ENALAPRIL MALEATE					
FOR SOLUTION;ORAL					
EPANED KIT					
+	SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013
TABLET;ORAL					
ENALAPRIL MALEATE					
	APOTHECON	2.5MG	A075583	001	Aug 22, 2000
		5MG	A075583	002	Aug 22, 2000
		10MG	A075583	003	Aug 22, 2000
		20MG	A075583	004	Aug 22, 2000
	BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000
		5MG	A075621	002	Aug 22, 2000
		10MG	A075621	003	Aug 22, 2000
		20MG	A075621	004	Aug 22, 2000
	IVAX SUB TEVA PHARMS	2.5MG	A075482	001	Aug 22, 2000
		5MG	A075482	002	Aug 22, 2000
		10MG	A075482	003	Aug 22, 2000
		20MG	A075482	004	Aug 22, 2000
	KRKA DD NOVO MESTO	2.5MG	A075370	001	Aug 22, 2000
		5MG	A075370	002	Aug 22, 2000
		10MG	A075369	001	Aug 22, 2000
		20MG	A075369	002	Aug 22, 2000
	MYLAN	2.5MG	A075472	001	Aug 22, 2000
		2.5MG	A075480	001	Aug 22, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ENALAPRIL MALEATE					
TABLET;ORAL					
ENALAPRIL MALEATE					
		5MG	A075472	002	Aug 22, 2000
		5MG	A075480	002	Aug 22, 2000
		10MG	A075472	003	Aug 22, 2000
		10MG	A075480	003	Aug 22, 2000
		20MG	A075472	004	Aug 22, 2000
		20MG	A075480	004	Aug 22, 2000
	SANDOZ	2.5MG	A075048	001	Aug 22, 2000
		5MG	A075048	002	Aug 22, 2000
		10MG	A075048	003	Aug 22, 2000
		20MG	A075048	004	Aug 22, 2000
	SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000
		5MG	A075556	002	Aug 22, 2000
		10MG	A075556	003	Aug 22, 2000
		20MG	A075556	004	Aug 22, 2000
	WATSON LABS	2.5MG	A075501	001	Aug 22, 2000
		5MG	A075501	002	Aug 22, 2000
		10MG	A075501	003	Aug 22, 2000
		20MG	A075501	004	Aug 22, 2000
ENALAPRIL MALEATE; FELODIPINE					
TABLET, EXTENDED RELEASE;ORAL					
LEXXEL					
	ASTRAZENECA	5MG;2.5MG	N020668	002	Oct 28, 1998
		5MG;5MG	N020668	001	Dec 27, 1996
ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE					
TABLET;ORAL					
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE					
	IVAX SUB TEVA PHARMS	5MG;12.5MG	A075736	001	Mar 25, 2003
		10MG;25MG	A075736	002	Mar 25, 2003
	UPSHER SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001
		10MG;25MG	A076116	002	Sep 19, 2001
ENALAPRILAT					
INJECTABLE;INJECTION					
ENALAPRILAT					
	HOSPIRA	1.25MG/ML	A075456	001	Aug 22, 2000
		1.25MG/ML	A075571	001	Aug 22, 2000
VASOTEC					
+	BIOVAIL LABS INTL	1.25MG/ML **	N019309	001	Feb 09, 1988
ENCORAFENIB					
CAPSULE;ORAL					
BRAFTOVI					
+	ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018
ENFLURANE					
LIQUID;INHALATION					
ENFLURANE					
	ABBOTT	99.9%	A070803	001	Sep 08, 1987
	PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994
ETHRANE					
	BAXTER HLTHCARE	99.9%	N017087	001	
ENOXACIN					
TABLET;ORAL					
PENETREX					
	SANOFI AVENTIS US	200MG	N019616	004	Dec 31, 1991
		400MG	N019616	005	Dec 31, 1991
ENOXAPARIN SODIUM					
INJECTABLE;SUBCUTANEOUS					
LOVENOX (PRESERVATIVE FREE)					
+	SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **	N020164	006	Jun 02, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ENTACAPONE
TABLET;ORAL
ENTACAPONE

MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013

ENTECAVIR
TABLET;ORAL
ENTECAVIR

PAR PHARM INC	0.5MG	A206294	001	Nov 23, 2016
	1MG	A206294	002	Nov 23, 2016

EPINASTINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016
SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011

EPINEPHRINE
AEROSOL, METERED;INHALATION
BRONKAID MIST

STERLING	0.25MG/INH	N016803	001	

EPINEPHRINE

ARMSTRONG PHARMS	0.2MG/INH	A087907	001	May 23, 1984

PRIMATENE MIST

WYETH CONS	0.2MG/INH	N016126	001	

INJECTABLE;INJECTION
SUS-PHRINE SULFITE FREE

FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999
	5MG/ML	N007942	001	

INJECTABLE;INTRAMUSCULAR
EPI E Z PEN JR

MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	004	Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430	003	Aug 03, 1995

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
TWINJECT 0.15

IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004

TWINJECT 0.3

IMPAX	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018

EPINEPHRINE BITARTRATE
AEROSOL, METERED;INHALATION
BRONITIN MIST

WYETH CONS	0.3MG/INH	N016126	002	

MEDIHALER-EPI

3M	0.3MG/INH	N010374	003	

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
DURANEST

+ ASTRAZENECA	0.005MG/ML;1% **	N017751	006	
+	0.005MG/ML;1.5% **	N017751	007	
+ DENTSPLY PHARM	0.005MG/ML;1.5% **	N021384	001	

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CITANEST FORTE

ASTRAZENECA	0.005MG/ML;4%	N014763	008	

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
DURANEST

+ ASTRAZENECA	0.005MG/ML;0.5% **	N017751	004	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE				
CARLISLE	0.01MG/ML;2%	A084720	001	
	0.02MG/ML;2%	A084732	001	
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983
	0.02MG/ML;2%	A080504	005	Oct 19, 1983
EASTMAN KODAK	0.01MG/ML;2%	A040057	002	Feb 26, 1993
	0.02MG/ML;2%	A040057	001	Feb 26, 1993
HOSPIRA	0.005MG/ML;1%	A089649	001	Jun 21, 1988
	0.005MG/ML;1.5%	A089650	001	Jun 21, 1988
	0.01MG/ML;2%	A078772	001	May 12, 2008
	0.02MG/ML;2%	A078772	002	May 12, 2008
WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001	
	0.01MG/ML;2%	A080406	002	
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE				
ABBOTT	0.01MG/ML;1%	A083154	001	
BEL MAR	0.01MG/ML;1%	A080820	001	
	0.01MG/ML;2%	A080757	001	
DELL LABS	0.01MG/ML;1%	A083389	001	
	0.01MG/ML;2%	A083390	001	
INTL MEDICATION	0.01MG/ML;1%	A086402	001	
WATSON LABS	0.01MG/ML;1%	A080377	003	
	0.01MG/ML;1%	A085463	001	
	0.01MG/ML;2%	A080377	004	
LIDOCATON				
PHARMATON	0.01MG/ML;2%	A084729	001	Aug 17, 1983
	0.02MG/ML;2%	A084728	001	Aug 17, 1983
OCTOCAINE				
SEPTODONT	0.01MG/ML;2%	A084048	001	
	0.02MG/ML;2%	A084048	002	
XYLOCAINE DENTAL WITH EPINEPHRINE				
DENTSPLY PHARM	0.01MG/ML;2% **	N021381	001	
	0.02MG/ML;2% **	N021381	002	
XYLOCAINE W/ EPINEPHRINE				
ASTRAZENECA	0.005MG/ML;1%	N010418	006	
	0.005MG/ML;1.5%	N010418	010	
	0.005MG/ML;2%	N010418	008	
FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003	
PATCH;IONTOPHORESIS, TOPICAL				
LIDOSITE TOPICAL SYSTEM KIT				
VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504	001	May 06, 2004
SOLUTION;IONTOPHORESIS				
IONTOCAINE				
IOMED	0.01MG/ML;2%	N020530	001	Dec 21, 1995
SOLUTION;IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
EMPI	0.01MG/ML;2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PROCAINE HYDROCHLORIDE W/ EPINEPHRINE				
BEL MAR	0.02MG/ML;1%	A080758	001	
	0.02MG/ML;2%	A080759	001	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION				
EPIRUBICIN HYDROCHLORIDE				
ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008
EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
FRESENIUS KABI USA	200MG/100ML (2MG/ML)	A065411	001	Aug 20, 2007
	50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007
HOSPIRA	10MG/5ML (2MG/ML)	A065343	001	Apr 19, 2007
	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
	150MG/75ML (2MG/ML)	A065343	003	Apr 19, 2007
	200MG/100ML (2MG/ML)	A065343	004	Apr 19, 2007
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007
	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EPIRUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
EPIRUBICIN HYDROCHLORIDE				
MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012
	200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012
ZENNOVA	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011
POWDER;INTRAVENOUS				
EPIRUBICIN HYDROCHLORIDE				
HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006
	200MG/VIAL	N050807	002	Sep 15, 2006
EPLERENONE				
TABLET;ORAL				
INSPRA				
GD SEARLE LLC	100MG	N021437	003	Sep 27, 2002
EPROSARTAN MESYLATE				
TABLET;ORAL				
TEVETEN				
ABBVIE	EQ 300MG BASE	N020738	004	Dec 22, 1997
+	EQ 400MG BASE	N020738	005	Dec 22, 1997
+	EQ 600MG BASE	N020738	006	May 27, 1999
EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
TEVETEN HCT				
ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001
	600MG;25MG	N021268	002	Nov 01, 2001
EPTIFIBATIDE				
INJECTABLE;INJECTION				
EPTIFIBATIDE				
TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015
USV	2MG/ML	A204361	001	Mar 14, 2019
	2MG/ML	A204362	001	Mar 11, 2019
	75MG/100ML	A204361	002	Mar 14, 2019
ERGOCALCIFEROL				
CAPSULE;ORAL				
DELTALIN				
LILLY	50,000 IU	A080884	001	
VITAMIN D				
CHASE CHEM	50,000 IU	A080747	001	
EVERYLIFE	50,000 IU	A080956	001	
IMPAX LABS	50,000 IU	A080951	001	
LANNETT	50,000 IU	A080825	001	
VITARINE	50,000 IU	A084053	001	
WEST WARD	50,000 IU	A083102	001	
ERGOLOID MESYLATES				
CAPSULE;ORAL				
HYDERGINE LC				
NOVARTIS	1MG	N018706	001	Jan 18, 1983
SOLUTION;ORAL				
HYDERGINE				
NOVARTIS	1MG/ML	N018418	001	
TABLET;ORAL				
ERGOLOID MESYLATES				
MUTUAL PHARM	1MG	A088891	001	Nov 01, 1985
WATSON LABS	1MG	A086433	001	May 27, 1982
	1MG	A087244	001	Aug 16, 1982
GERIMAL				
WATSON LABS	1MG	A088207	001	Mar 22, 1984
HYDERGINE				
NOVARTIS	0.5MG	N017993	003	
+	1MG	N017993	001	
TABLET;SUBLINGUAL				
ALKERGOT				
SANDOZ	0.5MG	A085153	001	
	1MG	A087417	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ERGOLOID MESYLATES				
TABLET;SUBLINGUAL				
CIRCANOL				
3M	0.5MG		A084868 001	
	1MG		A085809 001	
DEAPRIL-ST				
BRISTOL MYERS SQUIBB	1MG		A085020 002	
ERGOLOID MESYLATES				
KV PHARM	0.5MG		A085899 001	
	0.5MG		A086265 001	
	1MG		A085900 001	
	1MG		A086264 001	
LEDERLE	0.5MG		A086984 001	
	1MG		A086985 001	
SUN PHARM INDUSTRIES	0.5MG		A087407 001	
	1MG		A087552 001	
SUPERPHARM	0.5MG		A089233 001	Sep 23, 1986
	1MG		A089234 001	Sep 23, 1986
VANGARD	0.5MG		A088013 001	Sep 20, 1982
	1MG		A088014 001	Sep 20, 1982
WATSON LABS	0.5MG		A084930 001	
	0.5MG		A087233 001	
	1MG		A085177 001	
	1MG		A087183 001	
GERIMAL				
WATSON LABS	0.5MG		A086189 001	
	1MG		A086188 001	
HYDERGINE				
NOVARTIS	0.5MG		N009087 002	
	1MG		N009087 001	
HYDROGENATED ERGOT ALKALOIDS				
IVAX PHARMS	0.5MG		A087186 001	
	1MG		A087185 001	
ERGOTAMINE TARTRATE				
AEROSOL, METERED;INHALATION				
MEDIHALER ERGOTAMINE				
3M	0.36MG/INH		N012102 001	
TABLET;SUBLINGUAL				
ERGOSTAT				
WATSON LABS INC	2MG		A088337 001	Jun 08, 1984
WIGRETTES				
ORGANON USA INC	2MG		A086750 001	Jul 29, 1982
ERYTHROMYCIN				
CAPSULE, DELAYED REL PELLETS;ORAL				
ERYC				
PARKE DAVIS	250MG		A062546 001	Jul 25, 1985
	250MG		A062618 001	Sep 25, 1985
WARNER CHILCOTT LLC	250MG		A062338 001	
ERYC 125				
PARKE DAVIS	125MG		A062648 001	Oct 24, 1985
ERYC SPRINKLES				
HOSPIRA	125MG		N050593 001	Jul 22, 1985
ERYTHROMYCIN				
BARR	250MG		A063098 001	May 04, 1989
GEL;TOPICAL				
E-GLADES				
MYLAN	2%		A065009 001	Mar 18, 2002
EMGEL				
ALTANA	2%		A063107 001	Aug 23, 1991
LOTION;TOPICAL				
E-SOLVE 2				
SYOSSET	2%		A062467 001	Jul 03, 1985
OINTMENT;OPHTHALMIC				
ERYTHROMYCIN				
PHARMADERM	5MG/GM		A062446 001	Sep 26, 1983
PHARMAFAIR	5MG/GM		A062481 001	Apr 05, 1984
ILOTYCIN				
DISTA	0.5%		N050368 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN

OINTMENT;TOPICAL					
AKNE-MYCIN					
+	BAUSCH	2%	N050584	001	Jan 10, 1985
POWDER;FOR RX COMPOUNDING					
ERYTHROMYCIN					
	PADDOCK LLC	100%	N050610	001	Nov 07, 1986
SOLUTION;TOPICAL					
A/T/S					
	TARO	2%	A062405	001	Nov 18, 1982
C-SOLVE-2					
	FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985
ERYDERM					
	ARBOR PHARMS INC	2%	A062290	001	
ERYMAX					
	MERZ PHARMS	2%	A062508	002	Jul 11, 1985
ERYTHRA-DERM					
	MLV	2%	A062687	001	Feb 05, 1988
ERYTHRO-STATIN					
	HI TECH PHARMA	2%	A064101	001	Oct 22, 1996
ERYTHROMYCIN					
	ALPHARMA US PHARMS	1.5%	A062328	001	Apr 19, 1982
		2%	A062326	001	Apr 19, 1982
		2%	A062327	001	Apr 19, 1982
		2%	A062342	001	Feb 25, 1982
		2%	A062957	001	Jul 21, 1988
	BAUSCH AND LOMB	2%	A064039	001	Jan 27, 1994
	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997
	LILLY	2%	N050532	001	
	PHARMAFAIR	1.5%	A062485	001	Jul 11, 1984
		2%	A062616	001	Jul 25, 1985
	RENAISSANCE PHARMA	2%	A064127	001	Feb 14, 1997
SANSAC					
	DOW PHARM	2%	A062522	001	Jan 24, 1985
STATICIN					
+	WESTWOOD SQUIBB	1.5% **	N050526	001	
T-STAT					
	WESTWOOD SQUIBB	2% **	A062436	001	Mar 09, 1983
SWAB;TOPICAL					
C-SOLVE-2					
	IVAX SUB TEVA PHARMS	2%	A062751	001	Jul 30, 1993
ERYCETTE					
+	JOHNSON AND JOHNSON	2% **	N050594	001	Feb 15, 1985
ERYTHROMYCIN					
	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006
	MYLAN	2%	A064128	001	Jul 03, 1996
T-STAT					
	WESTWOOD SQUIBB	2%	A062748	001	Jul 23, 1987
TABLET, COATED PARTICLES;ORAL					
PCE					
+	ARBOR PHARMS LLC	333MG	N050611	001	Sep 09, 1986
+		500MG	N050611	002	Aug 22, 1990
TABLET, DELAYED RELEASE;ORAL					
E-BASE					
	BARR	333MG	A063028	001	May 15, 1990
		333MG	A063086	001	May 15, 1990
		500MG	A062999	001	Nov 25, 1988
E-MYCIN					
	ARBOR PHARMS INC	250MG	A060272	001	
		333MG	A060272	002	
ILOTYCIN					
	DISTA	250MG	A061910	001	
R-P MYCIN					
	SOLVAY	250MG	A061659	001	
ROBIMYCIN					
	ROBINS AH	250MG	A061633	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN ESTOLATE				
CAPSULE;ORAL				
ERYTHROMYCIN ESTOLATE				
BARR	EQ 125MG BASE		A062162 001	
	EQ 250MG BASE		A062162 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE		A062237 001	
WATSON LABS	EQ 250MG BASE		A062087 001	
ILOSONE				
LILLY	EQ 125MG BASE		A061897 001	
	EQ 250MG BASE		A061897 002	
FOR SUSPENSION;ORAL				
ILOSONE				
DISTA	EQ 125MG BASE/5ML		A061893 001	
SUSPENSION;ORAL				
ERYTHROMYCIN ESTOLATE				
ACP NIMBLE	EQ 125MG BASE/5ML		A062169 001	Oct 17, 1990
	EQ 250MG BASE/5ML		A062169 002	Oct 17, 1990
ALPHARMA US PHARMS	EQ 125MG BASE/5ML		A062353 001	Nov 18, 1982
	EQ 250MG BASE/5ML		A062409 001	Dec 16, 1982
LIFE LABS	EQ 250MG BASE/5ML		A062362 001	Dec 17, 1982
ILOSONE				
LILLY	EQ 125MG BASE/5ML		A061894 001	
	EQ 125MG BASE/5ML		N050010 001	
	EQ 250MG BASE/5ML		A061894 002	
	EQ 250MG BASE/5ML		N050010 002	
SUSPENSION/DROPS;ORAL				
ILOSONE				
LILLY	EQ 100MG BASE/ML		A061894 003	
TABLET;ORAL				
ILOSONE				
LILLY	EQ 500MG BASE		A061896 001	
TABLET, CHEWABLE;ORAL				
ILOSONE				
DISTA	EQ 125MG BASE		A061895 001	
	EQ 250MG BASE		A061895 002	
ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL				
SUSPENSION;ORAL				
ILOSONE SULFA				
LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML		N050599 001	Sep 29, 1989
ERYTHROMYCIN ETHYLSUCCINATE				
GRANULE;ORAL				
PEDIAMYCIN				
ROSS LABS	EQ 200MG BASE/5ML		A062305 001	
SUSPENSION;ORAL				
E-MYCIN E				
PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML		A062198 001	
	EQ 400MG BASE/5ML		A062198 002	
E.E.S. 200				
ARBOR PHARMS LLC	EQ 200MG BASE/5ML **		A061639 001	
E.E.S. 400				
ARBOR PHARMS LLC	EQ 400MG BASE/5ML **		A061639 002	
ERYTHROMYCIN ETHYLSUCCINATE				
ALPHARMA US PHARMS	EQ 200MG BASE/5ML		A062200 001	
	EQ 400MG BASE/5ML		A062200 002	
DISTA	EQ 200MG BASE/5ML		A062177 001	
	EQ 400MG BASE/5ML		A062177 002	
NASKA	EQ 400MG BASE/5ML		A062674 001	Mar 10, 1987
PARKE DAVIS	EQ 200MG BASE/5ML		A062231 001	
	EQ 400MG BASE/5ML		A062231 002	
PHARMAFAIR	EQ 200MG BASE/5ML		A062559 001	Mar 15, 1985
	EQ 400MG BASE/5ML		A062558 001	Mar 15, 1985
PEDIAMYCIN				
ARBOR PHARMS LLC	EQ 200MG BASE/5ML		A062304 001	
PEDIAMYCIN 400				
ARBOR PHARMS LLC	EQ 400MG BASE/5ML		A062304 002	
WYAMYCIN E				
WYETH AYERST	EQ 200MG BASE/5ML		A062123 002	
	EQ 400MG BASE/5ML		A062123 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN ETHYLSUCCINATE				
SUSPENSION/DROPS;ORAL				
PEDIAMYCIN				
ROSS LABS	EQ 100MG BASE/2.5ML		A062305 002	
TABLET;ORAL				
E.E.S. 400				
ARBOR PHARMS LLC	EQ 400MG BASE		A061905 001	
ERYTHROMYCIN ETHYLSUCCINATE				
BARR	EQ 400MG BASE		A062256 001	
MYLAN	EQ 400MG BASE		A062847 001	Sep 14, 1988
TABLET, CHEWABLE;ORAL				
E.E.S.				
ARBOR PHARMS INC	EQ 200MG BASE		N050297 002	
ERYPED				
ARBOR PHARMS INC	EQ 200MG BASE		N050297 003	Jul 05, 1988
PEDIAMYCIN				
ROSS LABS	EQ 200MG BASE		A062306 001	
ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL				
GRANULE;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL				
BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML		A062759 001	May 20, 1988
ERYZOLE				
ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML		A062758 001	Jun 15, 1988
PEDIAZOLE				
ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML		N050529 001	
ERYTHROMYCIN GLUCEPTATE				
INJECTABLE;INJECTION				
ILOTYCIN GLUCEPTATE				
DISTA	EQ 250MG BASE/VIAL		N050370 001	
	EQ 500MG BASE/VIAL		N050370 002	
	EQ 1GM BASE/VIAL		N050370 003	
ERYTHROMYCIN LACTOBIONATE				
INJECTABLE;INJECTION				
ERYTHROCIN				
ABBOTT	EQ 500MG BASE/VIAL		A062586 001	Jan 04, 1988
	EQ 1GM BASE/VIAL		A062586 002	Jan 04, 1988
HOSPIRA	EQ 500MG BASE/VIAL		N050182 002	
	EQ 1GM BASE/VIAL		A062638 002	Oct 31, 1986
	EQ 1GM BASE/VIAL		N050182 003	
+	EQ 1GM BASE/VIAL		N050609 002	Sep 24, 1986
ERYTHROMYCIN				
ELKINS SINN	EQ 500MG BASE/VIAL		A062563 001	Mar 28, 1985
	EQ 1GM BASE/VIAL		A062563 002	Mar 28, 1985
ERYTHROMYCIN LACTOBIONATE				
ABRAXIS PHARM	EQ 500MG BASE/VIAL		A062604 001	Nov 24, 1986
	EQ 1GM BASE/VIAL		A062604 002	Nov 24, 1986
BAXTER HLTHCARE	EQ 500MG BASE/VIAL		A062993 001	May 09, 1989
	EQ 1GM BASE/VIAL		A062993 002	May 09, 1989
TEVA PARENTERAL	EQ 500MG BASE/VIAL		A063253 001	Jul 30, 1993
	EQ 1GM BASE/VIAL		A063253 002	Jul 30, 1993
ERYTHROMYCIN STEARATE				
TABLET;ORAL				
BRISTAMYCIN				
BRISTOL	EQ 250MG BASE		A061304 001	
	EQ 250MG BASE		A061887 001	
ERYPAR				
PARKE DAVIS	EQ 250MG BASE		A062032 001	
	EQ 500MG BASE		A062032 002	
WARNER CHILCOTT	EQ 250MG BASE		A062322 001	
ERYTHROCIN STEARATE				
ARBOR PHARMS LLC	EQ 125MG BASE		A060359 002	
	EQ 500MG BASE		A060359 003	
ERYTHROMYCIN STEARATE				
ANI PHARMS INC	EQ 250MG BASE		A061461 001	
	EQ 250MG BASE		A061591 001	
	EQ 500MG BASE		A061461 002	
	EQ 500MG BASE		A063179 001	May 15, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROMYCIN STEARATE

LEDERLE	EQ 250MG BASE	A062089	001	
	EQ 500MG BASE	A062089	002	
MYLAN	EQ 250MG BASE	A061505	001	
	EQ 500MG BASE	A061505	002	
PUREPAC PHARM	EQ 250MG BASE	A061743	001	
WATSON LABS	EQ 250MG BASE	A062121	002	
	EQ 500MG BASE	A062121	001	

ETHRIL 250

BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605	001	

ETHRIL 500

BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605	002	

PFIZER-E

PFIZER	EQ 250MG BASE	A061791	001	
	EQ 500MG BASE	A061791	002	

WYAMYCIN S

WYETH AYERST	EQ 250MG BASE	A061675	001	
	EQ 500MG BASE	A061675	002	

ESCITALOPRAM OXALATE

CAPSULE;ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC	EQ 5MG BASE	A077660	001	Jul 31, 2007
	EQ 10MG BASE	A077660	002	Jul 31, 2007
	EQ 20MG BASE	A077660	003	Jul 31, 2007

TABLET;ORAL

ESCITALOPRAM OXALATE

MYLAN	EQ 5MG BASE	A077550	001	May 14, 2015
	EQ 10MG BASE	A077550	002	May 14, 2015
	EQ 20MG BASE	A077550	003	May 14, 2015

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC

BAXTER HLTHCARE	10MG/ML	N019386	003	Aug 15, 1988
	20MG/ML	N019386	007	May 28, 2003

ESMOLOL HYDROCHLORIDE

AM REGENT	10MG/ML	A201126	001	Feb 20, 2015

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY	EQ 20MG BASE	A209647	001	Apr 10, 2019
	EQ 40MG BASE	A209647	002	Apr 10, 2019
HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018
	EQ 40MG BASE	A207265	001	May 18, 2018

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

P AND L	EQ 20MG BASE	A209202	001	Mar 05, 2019

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016
MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017
SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013

NEXIUM IV

+	ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL **	N021689	001	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

+	R2 PHARMA LLC	24.65MG	N202342	001	Aug 06, 2013
+		49.3MG	N202342	002	Aug 06, 2013

ESTAZOLAM
TABLET;ORAL
PROSOM
+ ABBOTT 1MG ** N019080 001 Dec 26, 1990
+ 2MG ** N019080 002 Dec 26, 1990

ESTRADIOL
FILM, EXTENDED RELEASE;TRANSDERMAL
ESCLIM
WOMEN FIRST HLTHCARE 0.025MG/24HR N020847 001 Aug 04, 1998
0.0375MG/24HR N020847 002 Aug 04, 1998
0.05MG/24HR N020847 003 Aug 04, 1998
0.075MG/24HR N020847 004 Aug 04, 1998
0.1MG/24HR N020847 005 Aug 04, 1998
ESTRADERM
+ NOVARTIS 0.05MG/24HR N019081 002 Sep 10, 1986
+ 0.1MG/24HR N019081 003 Sep 10, 1986
ESTRADIOL
ORTHO MCNEIL PHARM 0.05MG/24HR N021048 001 Sep 20, 1999
0.075MG/24HR N021048 002 Sep 20, 1999
0.1MG/24HR N021048 003 Sep 20, 1999
FEMPATCH
PARKE DAVIS 0.025MG/24HR N020417 001 Dec 03, 1996
VIVELLE
NOVARTIS 0.025MG/24HR N020323 005 Aug 16, 2000
0.0375MG/24HR N020323 001 Oct 28, 1994
0.05MG/24HR N020323 002 Oct 28, 1994
0.075MG/24HR N020323 003 Oct 28, 1994
0.1MG/24HR N020323 004 Oct 28, 1994
GEL;TOPICAL
ESTROGEL
ASCEND THERAPS US 0.06% N021166 001 Feb 09, 2004
TABLET;ORAL
ESTRACE
BRISTOL MYERS SQUIBB 0.5MG A081295 001 Jun 30, 1993
1MG A084499 001
2MG A084500 001
ESTRADIOL
LANNETT HOLDINGS INC 0.5MG A040138 001 Jan 30, 1998
1MG A040138 002 Jan 30, 1998
2MG A040138 003 Jan 30, 1998
USL PHARMA 0.5MG A040297 001 Apr 17, 2002
1MG A040297 002 Apr 17, 2002
2MG A040297 003 Apr 17, 2002
GYNODIOL
DURAMED PHARMS BARR 0.5MG A040212 001 Dec 29, 1997
1MG A040212 002 Dec 29, 1997
1.5MG A040212 003 Dec 29, 1997
2MG A040212 004 Dec 29, 1997
INNOFEM
NOVO NORDISK INC 0.5MG A040312 001 Nov 19, 1999
1MG A040312 002 Nov 19, 1999
2MG A040312 003 Nov 19, 1999
TABLET;VAGINAL
VAGIFEM
+ NOVO NORDISK INC 25MCG ** N020908 001 Mar 26, 1999

ESTRADIOL ACETATE
TABLET;ORAL
FEMTRACE
+ APIL 0.45MG N021633 001 Aug 20, 2004
+ 0.9MG N021633 002 Aug 20, 2004
+ 1.8MG N021633 003 Aug 20, 2004

ESTRADIOL CYPIONATE
INJECTABLE;INJECTION
DEPO-ESTRADIOL
PHARMACIA AND UPJOHN 1MG/ML A085470 001
3MG/ML A085470 002

ESTRADIOL CYPIONATE
INJECTABLE;INJECTION
ESTRADIOL CYPIONATE

	DR REDDYS	5MG/ML	A085620 001	

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
INJECTABLE;INTRAMUSCULAR
LUNELLE

	PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874 001	Oct 05, 2000

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE
INJECTABLE;INJECTION
DEPO-TESTADIOL

	PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968 001	

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

	WATSON LABS	2MG/ML;50MG/ML	A085603 001	Mar 13, 1986

ESTRADIOL HEMIHYDRATE
EMULSION;TOPICAL
ESTRASORB

+	EXELTIS USA INC	0.25%	N021371 001	Oct 09, 2003

ESTRADIOL VALERATE
INJECTABLE;INJECTION
ESTRADIOL VALERATE

	DR REDDYS	20MG/ML	A083547 001	
		40MG/ML	A083714 001	
	FOSUN PHARMA	10MG/ML	A040628 001	Oct 04, 2007
		20MG/ML	A040628 002	Oct 04, 2007
		40MG/ML	A040628 003	Oct 04, 2007
	WATSON LABS	10MG/ML	A083546 001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE
INJECTABLE;INJECTION
DITATE-DS

	SAVAGE LABS	8MG/ML;180MG/ML	A086423 001	

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

	WATSON LABS	4MG/ML;90MG/ML	A085865 001	
		8MG/ML;180MG/ML	A085860 001	

ESTRADIOL; NORETHINDRONE ACETATE
TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

	ACCORD HLTHCARE	1MG;0.5MG	A210233 001	Feb 28, 2018

ESTRADIOL; NORGESTIMATE
TABLET;ORAL
PREFEST

+	TEVA WOMENS	1MG,1MG;N/A,0.09MG **	N021040 001	Oct 22, 1999

ESTROGENS, CONJUGATED
TABLET;ORAL
PREMARIN

	WYETH PHARMS	2.5MG	N004782 002	

ESTROGENS, CONJUGATED SYNTHETIC A
CREAM;VAGINAL
SYNTHETIC CONJUGATED ESTROGENS A

	TEVA WOMENS	0.625MG/GM	N021788 001	Nov 28, 2008

TABLET;ORAL
CENESTIN

+	ASPEN	0.3MG **	N020992 001	Jun 21, 2002
+		0.45MG **	N020992 005	Feb 05, 2004
+		0.625MG **	N020992 002	Mar 24, 1999
+		0.9MG **	N020992 003	Mar 24, 1999
+		1.25MG **	N020992 004	Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B
TABLET;ORAL
ENJUVIA

	ASPEN	0.3MG	N021443 001	Dec 20, 2004
		0.45MG	N021443 002	Dec 20, 2004
		0.625MG **	N021443 003	May 10, 2004
		0.9MG	N021443 005	Apr 27, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTROGENS, CONJUGATED SYNTHETIC B				
TABLET;ORAL				
ENJUVIA				
	1.25MG **	N021443	004	May 10, 2004
ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE				
TABLET;ORAL-28				
PREMPHASE (PREMARIN;CYCRIN 14/14)				
WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303	002	Dec 30, 1994
PREMPRO (PREMARIN;CYCRIN)				
WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303	001	Dec 30, 1994
ESTROGENS, CONJUGATED; MEPROBAMATE				
TABLET;ORAL				
MILPREM-200				
MEDPOINTE PHARM HLC	0.45MG;200MG	N011045	002	
MILPREM-400				
MEDPOINTE PHARM HLC	0.45MG;400MG	N011045	001	
PMB 200				
WYETH AYERST	0.45MG;200MG	N010971	005	
PMB 400				
WYETH AYERST	0.45MG;400MG	N010971	003	
ESTROGENS, ESTERIFIED				
TABLET;ORAL				
AMNESTROGEN				
BRISTOL MYERS SQUIBB	0.3MG	A083266	001	
	0.625MG	A083266	002	
	1.25MG	A083266	003	
	2.5MG	A083266	004	
ESTERIFIED ESTROGENS				
PVT FORM	0.625MG	A083414	001	
	1.25MG	A083765	001	
	2.5MG	A085907	001	
SANDOZ	1.25MG	A085302	001	
ESTRATAB				
SOLVAY	0.3MG	A086715	001	
	0.625MG	A083209	001	
	1.25MG	A083856	001	
	2.5MG	A083857	001	
EVEX				
ROCHE PALO	0.625MG	A084215	001	
	1.25MG	A083376	002	
FEMOGEN				
PVT FORM	0.625MG	A085076	001	
	1.25MG	A085008	001	
	2.5MG	A085007	001	
ESTRONE				
INJECTABLE;INJECTION				
ESTROGENIC SUBSTANCE				
WYETH AYERST	2MG/ML	A083488	001	
ESTRONE				
DR REDDYS	5MG/ML	A085239	001	
WATSON LABS	2MG/ML	A083397	001	
NATURAL ESTROGENIC SUBSTANCE-ESTRONE				
WATSON LABS	2MG/ML	A085237	001	Nov 23, 1982
THEELIN				
PARKEDALE	1MG/ML	N003977	001	
	2MG/ML	N003977	002	
	5MG/ML	N003977	003	
ESTROPIPATE				
CREAM;VAGINAL				
OGEN				
PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001	
TABLET;ORAL				
ESTROPIPATE				
BARR	0.75MG	A040135	001	Nov 27, 1996
	1.5MG	A040135	002	Nov 27, 1996
	3MG	A040135	003	Nov 27, 1996
DURAMED PHARMS BARR	0.75MG	A040296	001	Nov 01, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ESTROPIPATE
TABLET;ORAL
ESTROPIPATE

	1.5MG	A040296	002	Nov 01, 1999
	3MG	A040296	003	Nov 01, 1999
MYLAN	3MG	A040359	003	Aug 26, 1999
WATSON LABS	0.75MG	A081213	001	Sep 23, 1993
	1.5MG	A081214	001	Sep 23, 1993
	6MG	A081216	001	Sep 23, 1993
WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993

OGEN .625

PHARMACIA AND UPJOHN	0.75MG	A083220	001	

OGEN 1.25

PHARMACIA AND UPJOHN	1.5MG	A083220	002	

OGEN 2.5

PHARMACIA AND UPJOHN	3MG	A083220	003	

ORTHO-EST

SUN PHARM INDS INC	0.75MG	A089567	001	Feb 27, 1991
	1.5MG	A089582	001	Jul 17, 1991

ESZOPICLONE
TABLET;ORAL
ESZOPICLONE

BRECKENRIDGE	1MG	A203087	001	May 08, 2019
	2MG	A203087	002	May 08, 2019
	3MG	A203087	003	May 08, 2019
WOCKHARDT LTD	1MG	A091165	001	Jul 14, 2011
	2MG	A091165	002	Jul 14, 2011
	3MG	A091165	003	Jul 14, 2011

ETHACRYNIC ACID
TABLET;ORAL
EDECRIN

BAUSCH	50MG	N016092	002	

ETHAMBUTOL HYDROCHLORIDE
TABLET;ORAL
MYAMBUTOL

STI PHARMA LLC	200MG	N016320	002	
	500MG	N016320	004	

ETHCHLORVYNOL
CAPSULE;ORAL
ETHCHLORVYNOL

BANNER PHARMACAPS	100MG	A084463	001	
	200MG	A084463	002	
	500MG	A084463	003	
	750MG	A084463	004	

PLACIDYL

ABBVIE	100MG	N010021	004	
	200MG	N010021	007	
	500MG	N010021	002	
	750MG	N010021	010	

ETHINAMATE
CAPSULE;ORAL
VALMID

DISTA	500MG	N009750	001	

ETHINYL ESTRADIOL
TABLET;ORAL
ESTINYL

SCHERING	0.02MG	N005292	001	
	0.05MG	N005292	002	
	0.5MG	N005292	003	

FEMINONE

PHARMACIA AND UPJOHN	0.05MG	N016649	001	

LYNORAL

ORGANON USA INC	0.01MG	N005490	003	
	0.05MG	N005490	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE					
TABLET;ORAL-21					
DEMULEN 1/35-21					
	GD SEARLE LLC	0.035MG;1MG **	N018168	001	
DEMULEN 1/50-21					
	GD SEARLE LLC	0.05MG;1MG	N016927	001	
ZOVIA 1/35E-21					
	WATSON PHARMS TEVA	0.035MG;1MG	A072720	001	Dec 30, 1991
ZOVIA 1/50E-21					
	WATSON LABS	0.05MG;1MG	A072722	001	Dec 30, 1991
TABLET;ORAL-28					
DEMULEN 1/35-28					
	GD SEARLE LLC	0.035MG;1MG **	N018160	001	
DEMULEN 1/50-28					
	GD SEARLE LLC	0.05MG;1MG **	N016936	001	
ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE					
TABLET;ORAL-28					
NORQUEST FE					
	GD SEARLE LLC	0.035MG;75MG;1MG	N018926	001	Jul 18, 1986
ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE					
TABLET;ORAL-28					
NORLESTRIN FE 1/50					
	PARKE DAVIS	0.05MG;75MG;1MG	N016766	001	
NORLESTRIN FE 2.5/50					
	PARKE DAVIS	0.05MG;75MG;2.5MG	N016854	001	
ETHINYL ESTRADIOL; LEVONORGESTREL					
TABLET;ORAL					
LYBREL					
+	WYETH PHARMS INC	0.02MG;0.09MG **	N021864	001	May 22, 2007
PREVEN EMERGENCY CONTRACEPTIVE KIT					
	TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998
TABLET;ORAL-21					
ALESSE					
+	CADENCE HEALTH	0.02MG;0.1MG **	N020683	001	Mar 27, 1997
AVIANE-21					
	DURAMED PHARMS BARR	0.02MG;0.1MG	A075796	002	Apr 30, 2001
ENPRESSE-21					
	DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809	001	Jul 16, 2001
LESSINA-21					
	BARR	0.02MG;0.1MG	A075803	001	Mar 20, 2002
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	001	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	BARR	0.02MG;0.1MG	A075862	001	Apr 29, 2003
LEVORA 0.15/30-21					
	WATSON LABS	0.03MG;0.15MG	A073592	001	Dec 13, 1993
NORDETTE-21					
	TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982
PORTIA-21					
	BARR	0.03MG;0.15MG	A075866	001	May 23, 2002
TRIPHASIL-21					
+	WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019192	001	Nov 01, 1984
TRIVORA-21					
	MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	001	Dec 18, 1997
TABLET;ORAL-28					
ALESSE					
+	CADENCE HEALTH	0.02MG;0.1MG **	N020683	002	Mar 27, 1997
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	002	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	BARR	0.02MG;0.1MG	A075862	002	Apr 29, 2003
	MYLAN LABS LTD	0.02MG;0.1MG	A202247	001	Dec 08, 2014
NORDETTE-28					
+	TEVA BRANDED PHARM	0.03MG;0.15MG **	N018782	001	Jul 21, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; LEVONORGESTREL					
TABLET;ORAL-28					
TRIPHASIL-28					
+	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019190	001	Nov 01, 1984
ETHINYL ESTRADIOL; NORELGESTROMIN					
FILM, EXTENDED RELEASE;TRANSDERMAL					
ORTHO EVRA					
+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR **	N021180	001	Nov 20, 2001
ETHINYL ESTRADIOL; NORETHINDRONE					
TABLET;ORAL-21					
BALZIVA-21					
	BARR	0.035MG;0.4MG	A076198	001	Apr 22, 2004
BREVICON 21-DAY					
	ALLERGAN	0.035MG;0.5MG	N017566	001	
GENCEPT 10/11-21					
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072694	001	Feb 28, 1992
MODICON 21					
	ORTHO MCNEIL PHARM	0.035MG;0.5MG **	N017488	001	
N.E.E. 1/35 21					
	LPI	0.035MG;1MG	A071541	001	Dec 14, 1987
NORCEPT-E 1/35 21					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb 09, 1989
NORETHIN 1/35E-21					
	WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010
		0.035MG;0.5MG	A070684	001	Jan 29, 1987
	WATSON PHARMS TEVA	0.035MG;1MG	A070685	001	Jan 29, 1987
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991
NORTREL 0.5/35-21					
	BARR	0.035MG;0.5MG	A072692	001	Feb 28, 1992
ORTHO-NOVUM 1/35-21					
	ORTHO MCNEIL PHARM	0.035MG;1MG **	N017489	002	
ORTHO-NOVUM 10/11-21					
+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG **	N018354	001	Jan 11, 1982
ORTHO-NOVUM 7/14-21					
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	001	Apr 04, 1984
ORTHO-NOVUM 7/7/7-21					
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N018985	001	Apr 04, 1984
OVCON-35					
+	WARNER CHILCOTT	0.035MG;0.4MG **	N018127	001	
OVCON-50					
	WARNER CHILCOTT	0.05MG;1MG	N018128	001	
TRI-NORINYL 21-DAY					
	MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984
TABLET;ORAL-28					
GENCEPT 10/11-28					
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072697	001	Feb 28, 1992
MODICON 28					
+	JANSSEN PHARMS	0.035MG;0.5MG	N017735	001	
N.E.E. 1/35 28					
	LPI	0.035MG;1MG	A071542	001	Dec 14, 1987
NORCEPT-E 1/35 28					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071546	001	Feb 09, 1989
NORETHIN 1/35E-28					
	WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	MYLAN LABS LTD	0.035MG;0.4MG	A200897	001	May 11, 2015
		0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A200486	001	Dec 28, 2015
		0.035MG;0.5MG	A200488	001	Oct 21, 2015
		0.035MG;1MG	A200489	001	Oct 21, 2015
		0.05MG;1MG	A203006	001	Aug 05, 2013
	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,	A076393	001	Feb 04, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28					
NORETHINDRONE AND ETHINYL ESTRADIOL		1MG			
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991
ORTHO-NOVUM 1/35-28					
+	JANSSEN PHARMS	0.035MG;1MG	N017919	002	
ORTHO-NOVUM 10/11-28					
+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N018354	002	Jan 11, 1982
ORTHO-NOVUM 7/14-28					
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	002	Apr 04, 1984
OVCON-35					
+	WARNER CHILCOTT LLC	0.035MG;0.4MG **	N017716	001	
OVCON-50					
	WARNER CHILCOTT LLC	0.05MG;1MG **	N017576	001	
TABLET, CHEWABLE;ORAL					
FEMCON FE					
+	APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL					
FEMHRT					
+	APIL	0.005MG;1MG **	N021065	002	Oct 15, 1999
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	MYLAN LABS LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	APOTEX	0.02MG;1MG	A208639	001	Mar 21, 2018
TABLET;ORAL-21					
ESTROSTEP 21					
+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **	N020130	001	Oct 09, 1996
NORLESTRIN 21 1/50					
	PARKE DAVIS	0.05MG;1MG	N016749	001	
NORLESTRIN 21 2.5/50					
	PARKE DAVIS	0.05MG;2.5MG	N016852	001	
TABLET;ORAL-28					
NORLESTRIN 28 1/50					
	PARKE DAVIS	0.05MG;1MG	N016723	001	
TABLET, CHEWABLE;ORAL					
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017
TABLET, CHEWABLE, TABLET;ORAL					
LO MINASTRIN FE					
+	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21					
ORTHO CYCLEN-21					
	JANSSEN PHARMS	0.035MG;0.25MG	N019653	001	Dec 29, 1989
ORTHO TRI-CYCLEN					
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	N019697	002	Jul 03, 1992
TABLET;ORAL-28					
NORGESTIMATE AND ETHINYL ESTRADIOL					
	MYLAN LABS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A202132	001	Sep 09, 2015
	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A090479	001	Mar 09, 2011
		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A076626	001	Aug 17, 2006
		0.035MG;0.25MG	A076627	001	Aug 17, 2006
ORTHO CYCLEN-28					
+	JANSSEN PHARMS	0.035MG;0.25MG	N019653	002	Dec 29, 1989

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21					
LO/OVRAL					
	CADENCE HEALTH	0.03MG;0.3MG	N017612	001	
LOW-OGESTREL-21					
	MAYNE PHARMA	0.03MG;0.3MG	A075288	001	Jul 28, 1999

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; NORGESTREL				
TABLET;ORAL-21				
OGESTREL 0.5/50-21				
	WATSON LABS	0.05MG;0.5MG	A075406 001	Dec 15, 1999
OVRAL				
	WYETH PHARMS	0.05MG;0.5MG	N016672 001	
TABLET;ORAL-28				
LO/OVRAL-28				
	WYETH PHARMS	0.03MG;0.3MG **	N017802 001	
NORGESTREL AND ETHINYL ESTRADIOL				
	MYLAN LABS LTD	0.03MG;0.3MG	A201828 001	Jun 21, 2016
		0.05MG;0.5MG	A202875 001	May 08, 2017
OVRAL-28				
	WYETH PHARMS	0.05MG;0.5MG	N016806 001	
ETHOPROPAZINE HYDROCHLORIDE				
TABLET;ORAL				
PARSIDOL				
	PARKE DAVIS	10MG	N009078 003	
		50MG	N009078 006	
		100MG	N009078 008	
ETHOSUXIMIDE				
SYRUP;ORAL				
ETHOSUXIMIDE				
	TEVA PHARMS	250MG/5ML	A081306 001	Jul 30, 1993
ETHOTOIN				
TABLET;ORAL				
PEGANONE				
	RECORDATI RARE	500MG	N010841 003	
ETHOXZOLAMIDE				
TABLET;ORAL				
CARDRASE				
	PHARMACIA AND UPJOHN	62.5MG	N011047 002	
		125MG	N011047 001	
ETHAMIDE				
	ALLERGAN	125MG	N016144 001	
ETHYLESTRENOL				
ELIXIR;ORAL				
MAXIBOLIN				
	ORGANON USA INC	2MG/5ML	N014006 002	
TABLET;ORAL				
MAXIBOLIN				
	ORGANON USA INC	2MG	N014005 002	
ETHYNODIOL DIACETATE; MESTRANOL				
TABLET;ORAL-20				
OVULEN				
	GD SEARLE LLC	1MG;0.1MG	N016029 002	
TABLET;ORAL-21				
OVULEN-21				
	GD SEARLE LLC	1MG;0.1MG	N016029 003	
TABLET;ORAL-28				
OVULEN-28				
	GD SEARLE LLC	1MG;0.1MG	N016705 001	
ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+	ASTRAZENECA	0.5% **	N017751 003	
+		1% **	N017751 005	
ETIDRONATE DISODIUM				
INJECTABLE;INJECTION				
DIDRONEL				
	MGI PHARMA INC	50MG/ML	N019545 001	Apr 20, 1987
TABLET;ORAL				
DIDRONEL				
+	APIL	200MG **	N017831 001	
+		400MG **	N017831 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ETIDRONATE DISODIUM					
TABLET;ORAL					
ETIDRONATE DISODIUM					
	MYLAN	200MG	A075800	001	Jan 24, 2003
		400MG	A075800	002	Jan 24, 2003
ETODOLAC					
CAPSULE;ORAL					
ETODOLAC					
	ANI PHARMS INC	200MG	A074840	001	Aug 29, 1997
		200MG	A074844	001	Dec 23, 1997
		200MG	A074899	001	Jul 08, 1997
		300MG	A074840	002	Aug 29, 1997
		300MG	A074844	002	Dec 23, 1997
		300MG	A074899	002	Jul 08, 1997
	CHARTWELL MOLECULES	200MG	A074842	001	Jul 17, 1997
		300MG	A074842	002	Jul 17, 1997
	ECI PHARMS LLC	300MG	A074929	001	Jan 30, 1998
	MYLAN	200MG	A074932	001	May 16, 1997
		200MG	A075071	001	Sep 30, 1998
		300MG	A074932	002	May 16, 1997
		300MG	A075071	002	Sep 30, 1998
	SANDOZ	200MG	A074942	001	Sep 30, 1997
		300MG	A074942	002	Sep 30, 1997
LODINE					
+	WYETH PHARMS INC	200MG **	N018922	002	Jan 31, 1991
+		300MG	N018922	003	Jan 31, 1991
TABLET;ORAL					
ETODOLAC					
	CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997
	ECI PHARMS LLC	400MG	A074927	001	Oct 30, 1997
	INVATECH	400MG	A074839	001	Jul 11, 1997
		400MG	A074846	001	Feb 28, 1997
	IVAX SUB TEVA PHARMS	400MG	A074883	001	Feb 28, 1997
		500MG	A074883	002	Nov 20, 1998
	MYLAN	400MG	A075012	001	Sep 30, 1998
		400MG	A075104	001	Feb 06, 1998
		500MG	A075012	002	Sep 30, 1998
		500MG	A075104	002	Nov 20, 1998
	OXFORD PHARMS	400MG	A074819	001	Feb 28, 1997
		500MG	A074819	002	Apr 28, 1998
	RANBAXY LABS LTD	400MG	A075226	001	Nov 24, 1998
		500MG	A075226	002	Nov 24, 1998
	TEVA	400MG	A074847	001	Apr 23, 1999
		500MG	A074847	002	Apr 23, 1999
	WATSON LABS	400MG	A074892	001	Apr 16, 1997
		400MG	A075069	001	Apr 16, 1998
		500MG	A074892	002	Oct 29, 1998
LODINE					
+	WYETH PHARMS INC	400MG **	N018922	004	Jul 29, 1993
+		500MG **	N018922	005	Jun 28, 1996
TABLET, EXTENDED RELEASE;ORAL					
ETODOLAC					
	ACTAVIS ELIZABETH	400MG	A075696	001	Jul 31, 2000
	ANI PHARMS INC	400MG	A075943	001	Jul 26, 2002
		500MG	A075943	002	Jul 26, 2002
		600MG	A075943	003	Jul 26, 2002
	WATSON LABS FLORIDA	400MG	A075829	001	Nov 30, 2001
		500MG	A075829	002	Nov 30, 2001
LODINE XL					
	WYETH PHARMS INC	400MG **	N020584	001	Oct 25, 1996
		500MG **	N020584	003	Jan 20, 1998
+		600MG **	N020584	002	Oct 25, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETOMIDATE				
INJECTABLE;INJECTION				
ETOMIDATE				
LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009
PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012
ETONOGESTREL				
IMPLANT;IMPLANTATION				
IMPLANON				
ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006
ETOPOSIDE				
CAPSULE;ORAL				
VEPESID				
+ DAVA PHARMS INC	50MG	N019557	001	Dec 30, 1986
+	100MG	N019557	002	Dec 30, 1986
INJECTABLE;INJECTION				
ETOPOSIDE				
HOSPIRA	20MG/ML	A074320	001	Aug 30, 1995
	20MG/ML	A074351	001	Aug 30, 1995
PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996
PIERRE FABRE	20MG/ML	A074813	001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510	001	Jun 29, 1995
TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994
WATSON LABS	20MG/ML	A074228	001	Oct 15, 1996
WATSON LABS INC	20MG/ML	A074968	001	Jan 09, 1998
TOPOSAR				
TEVA PARENTERAL	20MG/ML	A074166	001	Feb 27, 1995
VEPESID				
+ CORDEN PHARMA	20MG/ML **	N018768	001	Nov 10, 1983
ETOPOSIDE PHOSPHATE				
INJECTABLE;INJECTION				
ETOPOPHOS PRESERVATIVE FREE				
BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N020906	001	Feb 27, 1998
	EQ 1GM BASE/VIAL	N020906	002	Feb 27, 1998
ETRETINATE				
CAPSULE;ORAL				
TEGISON				
ROCHE	10MG	N019369	001	Sep 30, 1986
	25MG	N019369	002	Sep 30, 1986
EVANS BLUE				
INJECTABLE;INJECTION				
EVANS BLUE				
PARKE DAVIS	0.5% **	N008041	001	
EVEROLIMUS				
TABLET, FOR SUSPENSION;ORAL				
EVEROLIMUS				
MYLAN	2MG	A210130	001	Apr 19, 2019
	3MG	A210130	002	Apr 19, 2019
	5MG	A210130	003	Apr 19, 2019
EXEMESTANE				
TABLET;ORAL				
EXEMESTANE				
AMNEAL PHARMS	25MG	A206421	001	Dec 28, 2018
EZOGABINE				
TABLET;ORAL				
POTIGA				
+ GLAXOSMITHKLINE	50MG	N022345	001	Jun 10, 2011
+	200MG	N022345	002	Jun 10, 2011
+	300MG	N022345	003	Jun 10, 2011
+	400MG	N022345	004	Jun 10, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FAMCICLOVIR					
TABLET;ORAL					
FAMVIR					
+	NOVARTIS	125MG **	N020363	003	Dec 11, 1995
+		250MG **	N020363	001	Apr 26, 1996
+		500MG **	N020363	002	Jun 29, 1994
FAMOTIDINE					
FOR SUSPENSION;ORAL					
PEPCID					
+	SALIX PHARMS	40MG/5ML	N019527	001	Feb 02, 1987
INJECTABLE;INJECTION					
FAMOTIDINE					
	APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002
	APOTHECON	10MG/ML	A075707	001	Apr 16, 2001
	HOSPIRA	10MG/ML	A075705	001	Apr 16, 2001
		10MG/ML	A075870	001	Nov 23, 2001
		10MG/ML	A075905	001	Nov 23, 2001
	WEST-WARD PHARMS INT	10MG/ML	A075799	001	Apr 30, 2002
FAMOTIDINE PRESERVATIVE FREE					
	APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002
	APOTHECON	10MG/ML	A075708	001	Apr 16, 2001
	HOSPIRA	10MG/ML	A075669	001	Apr 16, 2001
	WEST-WARD PHARMS INT	10MG/ML	A075789	001	Apr 30, 2002
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)					
	APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER					
	ABBVIE	0.4MG/ML	A075729	001	Dec 17, 2001
PEPCID					
+	MERCK	10MG/ML **	N019510	001	Nov 04, 1986
PEPCID PRESERVATIVE FREE					
+	MERCK	10MG/ML **	N019510	004	Nov 04, 1986
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
+	MERCK SHARP DOHME	0.4MG/ML **	N020249	001	Feb 18, 1994
TABLET;ORAL					
FAMOTIDINE					
	ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001
		40MG	A075650	002	Sep 14, 2001
	APOTEX	10MG	A075610	001	Mar 12, 2002
	MYLAN	40MG	A075704	002	Apr 16, 2001
	MYLAN PHARMS INC	20MG	A075457	001	Apr 18, 2001
		40MG	A075457	002	Apr 18, 2001
	PLD ACQUISITIONS	20MG	A075302	001	Apr 16, 2001
		40MG	A075302	002	Apr 16, 2001
	SANDOZ	10MG	A076101	001	Oct 21, 2002
		20MG	A075607	001	May 10, 2001
		20MG	A075793	001	Apr 16, 2001
		40MG	A075607	002	May 10, 2001
		40MG	A075793	002	Apr 16, 2001
	SUN PHARM INDUSTRIES	20MG	A075639	002	Dec 12, 2001
		40MG	A075639	001	Dec 12, 2001
	WATSON LABS	10MG	A075404	001	Nov 28, 2001
		20MG	A075062	002	Apr 16, 2001
		40MG	A075062	001	Apr 16, 2001
TABLET, CHEWABLE;ORAL					
PEPCID AC					
+	J AND J CONSUMER INC	10MG **	N020801	001	Sep 24, 1998
TABLET, ORALLY DISINTEGRATING;ORAL					
FLUXID					
	UCB INC	20MG	N021712	001	Sep 24, 2004
		40MG	N021712	002	Sep 24, 2004
PEPCID RPD					
	MERCK	20MG	N020752	001	May 28, 1998
		40MG	N020752	002	May 28, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FELODIPINE				
TABLET, EXTENDED RELEASE;ORAL				
FELODIPINE				
MYLAN	2.5MG	A078855	001	Apr 17, 2008
	5MG	A078855	002	Apr 17, 2008
	10MG	A078855	003	Apr 17, 2008
WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012
	5MG	A091484	002	Aug 15, 2012
	10MG	A091484	003	Aug 15, 2012
PLENDIL				
+ ASTRAZENECA	2.5MG **	N019834	004	Sep 22, 1994
+	5MG **	N019834	001	Jul 25, 1991
+	10MG **	N019834	002	Jul 25, 1991
FENOFIBRATE				
CAPSULE;ORAL				
ANTARA (MICRONIZED)				
LUPIN ATLANTIS	87MG	N021695	002	Nov 30, 2004
FENOFIBRATE (MICRONIZED)				
NOVAST LABS	67MG	A207564	001	Apr 19, 2019
	134MG	A207564	002	Apr 19, 2019
	200MG	A207564	003	Apr 19, 2019
LIPIDIL				
ABBVIE	100MG	N019304	001	Dec 31, 1993
LIPOFEN				
CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006
TRICOR (MICRONIZED)				
+ ABBVIE	67MG **	N019304	002	Feb 09, 1998
+	134MG **	N019304	003	Jun 30, 1999
+	200MG **	N019304	004	Jun 30, 1999
TABLET;ORAL				
FENOFIBRATE				
GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018
	160MG	A210606	002	Aug 17, 2018
MYLAN	107MG	A076520	002	Dec 29, 2005
TRICOR				
+ ABBVIE INC	54MG **	N021203	001	Sep 04, 2001
+	160MG **	N021203	003	Sep 04, 2001
TRIGLIDE				
SKYEPHARMA AG	50MG	N021350	001	May 07, 2005
FENOLDOPAM MESYLATE				
INJECTABLE;INJECTION				
FENOLDOPAM MESYLATE				
LUITPOLD	EQ 10MG BASE/ML	A076656	001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826	001	Mar 07, 2007
FENOPROFEN CALCIUM				
CAPSULE;ORAL				
FENOPROFEN CALCIUM				
AM THERAP	EQ 200MG BASE	A072307	001	Aug 22, 1988
	EQ 300MG BASE	A072308	001	Aug 22, 1988
AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988
	EQ 300MG BASE	A072395	001	Oct 17, 1988
HALSEY	EQ 200MG BASE	A072355	001	Aug 17, 1988
	EQ 300MG BASE	A072356	001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22, 1988
	EQ 300MG BASE	A072438	001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17, 1988
	EQ 300MG BASE	A071738	001	Aug 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946	001	Apr 30, 1991
	EQ 300MG BASE	A072472	001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294	001	Aug 17, 1988
	EQ 200MG BASE	A072981	001	Aug 19, 1991
	EQ 300MG BASE	A072293	001	Aug 17, 1988
	EQ 300MG BASE	A072982	001	Aug 19, 1991
NALFON				
XSPIRE PHARMA	EQ 300MG BASE	N017604	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FENOPROFEN CALCIUM				
TABLET;ORAL				
FENOPROFEN CALCIUM				
AM THERAP	EQ 600MG BASE	A072309	001	Aug 17, 1988
ANI PHARMS INC	EQ 600MG BASE	A072274	001	May 02, 1988
AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326	001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357	001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988
PAR PHARM	EQ 600MG BASE	A072429	001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17, 1988
SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902	001	Dec 21, 1990
USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17, 1988
	EQ 600MG BASE	A072602	001	Oct 11, 1988
WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988
NALFON				
DISTA	EQ 600MG BASE	N017710	001	
FENTANYL				
FILM, EXTENDED RELEASE;TRANSDERMAL				
FENTANYL-100				
ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007
MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007
NOVEN	100MCG/HR	A077775	004	Oct 16, 2009
FENTANYL-25				
ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007
MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007
NOVEN	25MCG/HR	A077775	001	Oct 16, 2009
FENTANYL-50				
ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007
MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007
NOVEN	50MCG/HR	A077775	002	Oct 16, 2009
FENTANYL-75				
ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007
MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007
NOVEN	75MCG/HR	A077775	003	Oct 16, 2009
FENTANYL CITRATE				
FILM;BUCCAL				
ONSOLIS				
BDSI	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
	EQ 0.4MG BASE	N022266	002	Jul 16, 2009
	EQ 0.6MG BASE	N022266	003	Jul 16, 2009
	EQ 0.8MG BASE	N022266	004	Jul 16, 2009
	EQ 1.2MG BASE	N022266	005	Jul 16, 2009
INJECTABLE;INJECTION				
FENTANYL CITRATE				
ABBOTT	EQ 0.05MG BASE/ML	A070636	001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637	001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488	001	Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE				
DR REDDYS	EQ 0.05MG BASE/ML	A074917	001	Feb 03, 1998
SPRAY, METERED;NASAL				
LAZANDA				
+ BTCP PHARMA	EQ 0.3MG BASE	N022569	003	Dec 21, 2015
TABLET;BUCCAL, SUBLINGUAL				
FENTANYL CITRATE				
WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011
	EQ 0.2MG BASE	A079075	002	Jan 07, 2011
	EQ 0.4MG BASE	A079075	003	Jan 07, 2011
	EQ 0.6MG BASE	A079075	004	Jan 07, 2011
	EQ 0.8MG BASE	A079075	005	Jan 07, 2011
FENTORA				
+ CEPHALON	EQ 0.3MG BASE **	N021947	006	Mar 02, 2007
TABLET;SUBLINGUAL				
ABSTRAL				
+ SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011
+	EQ 0.2MG BASE	N022510	002	Jan 07, 2011
+	EQ 0.3MG BASE	N022510	003	Jan 07, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FENTANYL CITRATE				
TABLET;SUBLINGUAL				
ABSTRAL				
+	EQ 0.4MG BASE	N022510	004	Jan 07, 2011
+	EQ 0.6MG BASE	N022510	005	Jan 07, 2011
+	EQ 0.8MG BASE	N022510	006	Jan 07, 2011
FENTANYL CITRATE				
ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017
	EQ 0.2MG BASE	A207338	002	Nov 17, 2017
	EQ 0.3MG BASE	A207338	003	Nov 17, 2017
	EQ 0.4MG BASE	A207338	004	Nov 17, 2017
	EQ 0.6MG BASE	A207338	005	Nov 17, 2017
	EQ 0.8MG BASE	A207338	006	Nov 17, 2017
TROCHE/LOZENGE;ORAL				
FENTANYL				
CEPHALON	EQ 0.1MG BASE	N020195	007	Oct 30, 1995
	EQ 0.2MG BASE	N020195	001	Oct 04, 1993
	EQ 0.3MG BASE	N020195	002	Oct 04, 1993
	EQ 0.4MG BASE	N020195	003	Oct 04, 1993
TROCHE/LOZENGE;TRANSMUCOSAL				
FENTANYL CITRATE				
PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009
	EQ 0.4MG BASE	A077312	002	Oct 30, 2009
	EQ 0.6MG BASE	A077312	003	Oct 30, 2009
	EQ 0.8MG BASE	A077312	004	Oct 30, 2009
	EQ 1.2MG BASE	A077312	005	Oct 30, 2009
	EQ 1.6MG BASE	A077312	006	Oct 30, 2009
FENTANYL HYDROCHLORIDE				
SYSTEM;IONTOPHORESIS, TRANSDERMAL				
IONSYS				
+ THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006
FERRIC AMMONIUM CITRATE				
FOR SOLUTION;ORAL				
FERRISELTZ				
OTSUKA	600MG/PACKET	N020292	001	Oct 14, 1997
FERRIC PYROPHOSPHATE CITRATE				
SOLUTION;INTRAVENOUS				
TRIFERIC				
+ ROCKWELL MEDICAL INC	272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015
FERROUS CITRATE, FE-59				
INJECTABLE;INJECTION				
FERROUS CITRATE FE 59				
MALLINCKRODT	25uCi/ML	N016729	001	
FERROUS SULFATE; FOLIC ACID				
CAPSULE;ORAL				
FOLVRON				
LEDERLE	182MG;0.33MG	N006012	003	
FERUMOXIDES				
INJECTABLE;INJECTION				
FERIDEX I.V.				
AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996
FERUMOXSIL				
SUSPENSION;ORAL				
GASTROMARK				
AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996
FESOTERODINE FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
FESOTERODINE FUMARATE				
ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015
	8MG	A204827	002	Dec 10, 2015

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL					
ALLEGRA					
	SANOFI AVENTIS US	60MG **	N020625	001	Jul 25, 1996
FEXOFENADINE HYDROCHLORIDE					
	BARR	60MG	A076169	001	Jul 13, 2005
SUSPENSION;ORAL					
ALLEGRA					
+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006
CHILDREN'S ALLEGRA HIVES					
+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
	TARO	30MG/5ML	A208123	001	Nov 09, 2017
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
	TARO	30MG/5ML	A208123	002	Nov 09, 2017
FEXOFENADINE HYDROCHLORIDE					
	P AND L	30MG/5ML	A201311	001	Jul 25, 2012
TABLET;ORAL					
ALLEGRA HIVES					
+	SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011
+		180MG	N020872	009	Jan 24, 2011
CHILDREN'S ALLEGRA ALLERGY					
+	SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES					
+	SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
	MYLAN	30MG	A077081	004	Jul 21, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
	MYLAN	30MG	A077081	005	Jul 21, 2011
FEXOFENADINE HYDROCHLORIDE					
	MYLAN	30MG	A077081	002	Apr 11, 2008
TABLET, ORALLY DISINTEGRATING;ORAL					
CHILDREN'S ALLEGRA ALLERGY					
+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES					
+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
	DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
	DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	BARR	60MG;120MG	A076236	001	Apr 14, 2005
	IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010

FIBRINOGEN, I-125

INJECTABLE;INJECTION					
IBRIN					
	GE HEALTHCARE	154uCi/VIAL	N017879	001	
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR					
	ABBOTT	140uCi/ML	N017787	001	

FINAFLOXACIN

SUSPENSION/DROPS;OTIC					
XTORO					
+	MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014

FINASTERIDE

TABLET;ORAL					
FINASTERIDE					
	GEDEON RICHTER USA	5MG	A077251	001	Dec 22, 2006
	IVAX SUB TEVA PHARMS	5MG	A076340	001	Jun 19, 2006
	MYLAN	1MG	A078161	001	Nov 05, 2013
		5MG	A077578	001	Dec 18, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLAVOXATE HYDROCHLORIDE				
TABLET;ORAL				
FLAVOXATE HYDROCHLORIDE				
IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003
URISPAS				
ORTHO MCNEIL JANSSEN	100MG	N016769	001	
FLECAINIDE ACETATE				
TABLET;ORAL				
FLECAINIDE ACETATE				
ANI PHARMS INC	50MG	A076030	001	Oct 28, 2002
	100MG	A076030	002	Oct 28, 2002
	150MG	A076030	003	Oct 28, 2002
APOTEX INC	50MG	A079164	001	Jul 09, 2009
	100MG	A079164	002	Jul 09, 2009
	150MG	A079164	003	Jul 09, 2009
TAMBOCOR				
CNTY LINE PHARMS	200MG	N018830	002	Oct 31, 1985
FLORBETAPIR F-18				
SOLUTION;INTRAVENOUS				
AMYVID				
AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012
FLOXURIDINE				
INJECTABLE;INJECTION				
FLOXURIDINE				
LUITPOLD	500MG/VIAL	A203008	001	Nov 22, 2017
FUDR				
+ HOSPIRA	500MG/VIAL **	N016929	001	
FLUCONAZOLE				
FOR SUSPENSION;ORAL				
FLUCONAZOLE				
IVAX SUB TEVA PHARMS	50MG/5ML	A077523	001	Sep 12, 2007
	200MG/5ML	A077523	002	Sep 12, 2007
SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004
	200MG/5ML	A076332	002	Jul 29, 2004
TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006
	200MG/5ML	A076918	002	Dec 18, 2006
INJECTABLE;INJECTION				
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992
+	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994
DIFLUCAN IN SODIUM CHLORIDE 0.9%				
+ PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990
+	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990
+	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER				
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%				
DR REDDYS	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
DR REDDYS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005
HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005
TABLET;ORAL				
FLUCONAZOLE				
ANI PHARMS INC	50MG	A076086	001	Jul 29, 2004
	100MG	A076086	002	Jul 29, 2004
	150MG	A076086	003	Jul 29, 2004
	200MG	A076086	004	Jul 29, 2004
GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
	100MG	A076432	002	Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUCONAZOLE					
TABLET;ORAL					
FLUCONAZOLE					
		150MG	A076432	003	Jul 29, 2004
		200MG	A076432	004	Jul 29, 2004
	MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
		100MG	A076042	002	Jul 29, 2004
		150MG	A076042	003	Jul 29, 2004
		200MG	A076042	004	Jul 29, 2004
	PLIVA	50MG	A076424	001	Jul 29, 2004
		100MG	A076424	002	Jul 29, 2004
		150MG	A076424	003	Jul 29, 2004
		200MG	A076424	004	Jul 29, 2004
	RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
		100MG	A076386	002	Jul 29, 2004
		150MG	A076386	003	Jul 29, 2004
		200MG	A076386	004	Jul 29, 2004
	ROXANE	50MG	A076213	001	Jul 29, 2004
		100MG	A076213	002	Jul 29, 2004
		150MG	A076213	003	Jul 29, 2004
		200MG	A076213	004	Jul 29, 2004
FLUDARABINE PHOSPHATE					
INJECTABLE;INJECTION					
FLUDARA					
+	GENZYME CORP	50MG/VIAL **	N020038	001	Apr 18, 1991
FLUDARABINE PHOSPHATE					
	MYLAN LABS LTD	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011
TABLET;ORAL					
OFORTA					
	SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008
FLUDEOXYGLUCOSE F-18					
INJECTABLE;INJECTION					
FLUDEOXYGLUCOSE F18					
+	DOWNSTATE CLINCL	4-40mCi/ML **	N020306	001	Aug 19, 1994
+		4-90mCi/ML **	N020306	002	Sep 25, 2001
INJECTABLE;INTRAVENOUS					
FLUDEOXYGLUCOSE F18					
+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005
	MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015
	WEILL MEDCL COLL	10-100mCi/ML **	N021768	001	Aug 05, 2004
FLUDROCORTISONE ACETATE					
TABLET;ORAL					
FLORINEF					
+	CASPER PHARMA LLC	0.1MG **	N010060	001	
FLUMAZENIL					
INJECTABLE;INJECTION					
FLUMAZENIL					
	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004
		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004
	DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004
		1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004
	MYLAN LABS LTD	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008
ROMAZICON					
+	HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML) **	N020073	001	Dec 20, 1991
+		0.5MG/5ML (0.1MG/ML) **	N020073	002	Dec 20, 1991
FLUMETHASONE PIVALATE					
CREAM;TOPICAL					
LOCORTEN					
	NOVARTIS	0.03%	N016379	001	
FLUNISOLIDE					
AEROSOL, METERED;INHALATION					
AEROBID					
	ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984
AEROSPAN HFA					
+	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUNISOLIDE				
SPRAY, METERED;NASAL				
FLUNISOLIDE				
APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007
NASALIDE				
IVAX RES	0.025MG/SPRAY **	N018148	001	
NASAREL				
TEVA BRANDED PHARM	0.029MG/SPRAY	N020409	001	Mar 08, 1995
FLUOCINOLONE ACETONIDE				
CREAM;TOPICAL				
FLUOCET				
ALPHARMA US PHARMS	0.025%	A088360	001	Jan 16, 1984
FLUOCINOLONE ACETONIDE				
ACP NIMBLE	0.025%	A089525	001	Jul 26, 1988
ALPHARMA US PHARMS	0.01%	A088361	001	Jan 16, 1984
INVATECH	0.01%	A088047	001	Dec 16, 1982
	0.025%	A088045	001	Dec 16, 1982
PERRIGO NEW YORK	0.01%	A086810	001	Mar 04, 1982
	0.025%	A086811	001	Mar 04, 1982
PHARMAFAIR	0.01%	A088499	001	Aug 02, 1984
	0.025%	A088506	001	Aug 02, 1984
TARO	0.01%	A040035	001	Oct 31, 1994
	0.01%	A087102	001	Apr 27, 1982
	0.025%	A040042	001	Oct 31, 1994
USL PHARMA	0.01%	A088757	001	Feb 11, 1985
	0.025%	A088756	001	Mar 28, 1985
FLUONID				
ALLERGAN HERBERT	0.025%	A087156	002	Sep 06, 1984
FLUOTREX				
SAVAGE LABS	0.01%	A088174	001	May 06, 1983
	0.025%	A088173	001	Mar 09, 1983
SYNALAR-HP				
MEDIMETRIKS PHARMS	0.2%	N016161	002	
GEL;TOPICAL				
FLUONID				
ALLERGAN HERBERT	0.025%	A087300	001	May 27, 1982
OINTMENT;TOPICAL				
FLUOCINOLONE ACETONIDE				
PHARMADERM	0.025%	A088046	001	Dec 16, 1982
PHARMAFAIR	0.025%	A088507	001	Feb 27, 1984
USL PHARMA	0.025%	A088742	001	Feb 08, 1985
FLUONID				
ALLERGAN HERBERT	0.025%	A087157	001	Sep 06, 1984
FLUOTREX				
SAVAGE LABS	0.025%	A088172	001	Mar 09, 1983
SOLUTION;TOPICAL				
FLUOCINOLONE ACETONIDE				
ACP NIMBLE	0.01%	A207441	001	Sep 28, 2016
ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016
ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982
BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993
INVATECH	0.01%	A088048	001	Dec 16, 1982
MORTON GROVE	0.01%	A088312	001	Jan 27, 1984
PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984
FLUONID				
ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983
FLUOTREX				
SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983
FLUOCINONIDE				
CREAM;TOPICAL				
FLUOCINONIDE				
AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018
PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988
LIDEX				
+ CNTY LINE PHARMS	0.05%	N016908	002	
SOLUTION;TOPICAL				
FLUOCINONIDE				
TARO	0.05%	A072857	001	Aug 02, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOCINONIDE					
SOLUTION;TOPICAL					
FLUOCINONIDE					
	TEVA PHARMS	0.05%	A072522	001	Sep 28, 1990
FLUORESCEIN SODIUM					
INJECTABLE;INJECTION					
FUNDUSCEIN-25					
+	NOVARTIS	25% **	N017869	001	
FLUOROMETHOLONE					
CREAM;TOPICAL					
OXYLONE					
	PHARMACIA AND UPJOHN	0.025%	N011748	001	
SUSPENSION/DROPS;OPHTHALMIC					
FLUOR-OP					
	NOVARTIS	0.1%	A070185	001	Feb 27, 1986
FLUOROMETHOLONE ACETATE; TOBRAMYCIN					
SUSPENSION/DROPS;OPHTHALMIC					
TOBRASONE					
	EYEVANCE	0.1%;0.3%	N050628	001	Jul 21, 1989
FLUOROMETHOLONE; SULFACETAMIDE SODIUM					
SUSPENSION/DROPS;OPHTHALMIC					
FML-S					
	ALLERGAN	0.1%;10%	N019525	001	Sep 29, 1989
FLUOROURACIL					
INJECTABLE;INJECTION					
ADRUCIL					
	PHARMACIA AND UPJOHN	50MG/ML	A081222	001	Jun 28, 1991
+		50MG/ML	N017959	001	
	TEVA PARENTERAL	50MG/ML	A040023	001	Oct 18, 1991
		50MG/ML	A081225	001	Aug 28, 1991
FLUOROURACIL					
	ABIC	50MG/ML	A088929	001	Mar 04, 1986
	ABRAXIS PHARM	50MG/ML	A089152	001	Mar 21, 1986
		50MG/ML	A089428	001	Jan 12, 1987
		50MG/ML	A089519	001	Mar 12, 1987
	BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
	EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008
	FRESENIUS KABI USA	50MG/ML	A040291	001	Mar 24, 1999
		50MG/ML	A040379	001	Nov 15, 2000
	MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
	MYLAN LABS LTD	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012
		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012
	SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011
		5GM/100ML (50MG/ML)	A091299	002	May 02, 2011
	SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
		50MG/ML	A088767	001	Dec 28, 1984
		50MG/ML	A089434	001	Mar 26, 1987
	SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
+		500MG/10ML (50MG/ML) **	N012209	001	
+		2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016
SOLUTION;TOPICAL					
FLUOROPLEX					
	ELORAC	1%	N016765	001	
FLUOXETINE HYDROCHLORIDE					
CAPSULE;ORAL					
FLUOXETINE					
	SUN PHARM INDUSTRIES	EQ 10MG BASE	A075787	001	Jan 29, 2002
		EQ 20MG BASE	A075787	002	Jan 29, 2002
	WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
		EQ 20MG BASE	A075662	002	Jan 29, 2002
FLUOXETINE HYDROCHLORIDE					
	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008
		EQ 20MG BASE	A076287	002	May 20, 2008
	BARR	EQ 40MG BASE	A076251	001	May 18, 2005
	BEXIMCO PHARMS USA	EQ 10MG BASE	A075807	001	Jan 29, 2002
		EQ 20MG BASE	A075807	002	Jan 29, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL					
FLUOXETINE HYDROCHLORIDE					
	CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
		EQ 20MG BASE	A076022	002	Jan 30, 2002
	CELLTRION	EQ 10MG BASE	A078143	001	Jan 16, 2008
		EQ 20MG BASE	A078143	002	Jan 16, 2008
		EQ 40MG BASE	A078143	003	Jan 16, 2008
	CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002
		EQ 20MG BASE	A076165	002	Feb 01, 2002
	HERITAGE PHARMS INC	EQ 10MG BASE	A201336	001	Oct 01, 2012
		EQ 20MG BASE	A201336	002	Oct 01, 2012
		EQ 40MG BASE	A201336	003	Oct 01, 2012
	MYLAN	EQ 10MG BASE	A075207	001	Jan 30, 2002
		EQ 10MG BASE	A078045	001	Nov 17, 2008
		EQ 20MG BASE	A075207	002	Jan 30, 2002
		EQ 20MG BASE	A078045	002	Nov 17, 2008
		EQ 40MG BASE	A075207	003	May 25, 2007
	MYLAN PHARMS INC	EQ 10MG BASE	A075577	001	Jan 29, 2002
		EQ 20MG BASE	A075577	002	Jan 29, 2002
	PAR PHARM	EQ 10MG BASE	A076922	001	Dec 16, 2004
		EQ 20MG BASE	A076922	002	Dec 16, 2004
		EQ 40MG BASE	A076922	003	Dec 16, 2004
	SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008
		EQ 20MG BASE	A077469	002	Nov 17, 2008
PROZAC					
	ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999
SARAFEM					
+	ELI LILLY AND CO	EQ 10MG BASE **	N018936	007	Jul 06, 2000
+		EQ 20MG BASE **	N018936	008	Jul 06, 2000
CAPSULE, DELAYED REL PELLETS;ORAL					
FLUOXETINE HYDROCHLORIDE					
	BARR	EQ 90MG BASE	A076237	001	Mar 24, 2010
PROZAC WEEKLY					
+	LILLY	EQ 90MG BASE	N021235	001	Feb 26, 2001
SOLUTION;ORAL					
FLUOXETINE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009
	HI TECH PHARMA	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002
	LANNETT CO INC	EQ 20MG BASE/5ML	A076458	001	May 14, 2004
	NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002
PROZAC					
+	LILLY	EQ 20MG BASE/5ML **	N020101	001	Apr 24, 1991
TABLET;ORAL					
FLUOXETINE HYDROCHLORIDE					
	BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
	FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002
	IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
		EQ 40MG BASE	A075865	003	Aug 30, 2004
PROZAC					
+	LILLY	EQ 10MG BASE **	N020974	001	Mar 09, 1999
+		EQ 20MG BASE **	N020974	002	Mar 09, 1999

FLUOXYMESTERONE

TABLET;ORAL					
ANDROID-F					
	VALEANT PHARM INTL	10MG	A087196	001	
FLUOXYMESTERONE					
	VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
	WATSON LABS	2MG	A088260	001	Dec 06, 1983
		5MG	A088265	001	Dec 06, 1983
		10MG	A088309	001	Dec 06, 1983
HALOTESTIN					
	PHARMACIA AND UPJOHN	2MG	N010611	002	
		5MG	N010611	006	
		10MG	N010611	010	
ORA-TESTRYL					
	BRISTOL MYERS SQUIBB	2MG	N011359	001	
		5MG	N011359	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUPHENAZINE DECANOATE				
INJECTABLE;INJECTION				
FLUPHENAZINE DECANOATE				
HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
TEVA PARENTERAL	25MG/ML	A074795	001	Sep 10, 1996
PROLIXIN DECANOATE				
+ BRISTOL MYERS SQUIBB	25MG/ML **	N016727	001	
FLUPHENAZINE ENANTHATE				
INJECTABLE;INJECTION				
PROLIXIN ENANTHATE				
APOTHECON	25MG/ML **	N016110	001	
FLUPHENAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991
PERMITIL				
SCHERING	5MG/ML **	N016008	001	
PROLIXIN				
APOTHECON	5MG/ML	A070533	001	Nov 07, 1985
ELIXIR;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993
PROLIXIN				
+ APOTHECON	2.5MG/5ML **	N012145	003	
INJECTABLE;INJECTION				
PROLIXIN				
APOTHECON	2.5MG/ML **	N011751	005	
TABLET;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
WATSON LABS	1MG	A088555	001	Dec 18, 1987
	2.5MG	A088544	001	Dec 18, 1987
	5MG	A088527	001	Dec 18, 1987
	10MG	A088550	001	Dec 18, 1987
PERMITIL				
SCHERING	0.25MG	N012034	001	
	2.5MG	N012034	004	
	5MG	N012034	005	
	10MG	N012034	006	
PROLIXIN				
+ APOTHECON	1MG **	N011751	004	
+	2.5MG **	N011751	001	
+	5MG **	N011751	003	
+	10MG **	N011751	002	
TABLET, EXTENDED RELEASE;ORAL				
PERMITIL				
SCHERING	1MG	N012419	004	
FLUPREDNISOLONE				
TABLET;ORAL				
ALPHADROL				
PHARMACIA AND UPJOHN	1.5MG	N012259	002	
FLURANDRENOLIDE				
LOTION;TOPICAL				
FLURANDRENOLIDE				
ALPHARMA US PHARMS	0.05%	A087203	001	Apr 29, 1982
OINTMENT;TOPICAL				
CORDRAN				
+ ALMIRALL	0.025% **	N012806	004	
FLURANDRENOLIDE; NEOMYCIN SULFATE				
CREAM;TOPICAL				
CORDRAN N				
LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001	
OINTMENT;TOPICAL				
CORDRAN N				
LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLURAZEPAM HYDROCHLORIDE					
CAPSULE;ORAL					
DALMANE					
	VALEANT PHARM INTL	15MG **	N016721	001	
+		30MG **	N016721	002	
FLURAZEPAM HYDROCHLORIDE					
	AUROLIFE PHARMA LLC	15MG	A071717	002	Jul 31, 1991
		30MG	A071717	001	Jul 31, 1991
	HALSEY	15MG	A071808	001	Jan 07, 1988
		30MG	A071809	001	Jan 07, 1988
	HERITAGE PHARMA	15MG	A071205	001	Nov 25, 1986
		15MG	A072368	001	Mar 30, 1989
		30MG	A071068	001	Nov 25, 1986
		30MG	A072369	001	Mar 30, 1989
	HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986
	HIKMA PHARMS	30MG	A071108	001	Dec 08, 1986
	PAR PHARM	15MG	A070444	001	Mar 20, 1986
		30MG	A070445	001	Mar 20, 1986
	PUREPAC PHARM	15MG	A071927	001	Sep 09, 1987
		30MG	A071551	001	Sep 09, 1987
	SUN PHARM INDUSTRIES	15MG	A070454	001	Aug 04, 1986
		30MG	A070455	001	Aug 04, 1986
	SUPERPHARM	15MG	A071659	001	Aug 04, 1988
		30MG	A071660	001	Aug 04, 1988
	USL PHARMA	15MG	A070562	001	Jul 09, 1987
		30MG	A070563	001	Jul 09, 1987
	WARNER CHILCOTT	15MG	A071767	001	Dec 04, 1987
		30MG	A071768	001	Dec 04, 1987
FLURBIPROFEN					
TABLET;ORAL					
ANSAID					
	PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988
		100MG	N018766	003	Oct 31, 1988
FLURBIPROFEN					
	AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995
		100MG	A074448	002	Jul 28, 1995
	IVAX SUB TEVA PHARMS	50MG	A074411	001	May 31, 1995
		100MG	A074411	002	May 31, 1995
	PLIVA	50MG	A074647	001	Apr 01, 1997
		100MG	A074647	002	Apr 01, 1997
	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001
		100MG	A075058	002	Apr 27, 2001
	TEVA	50MG	A074405	002	May 24, 1995
		100MG	A074405	001	May 24, 1995
	THERAGEN	100MG	A074560	002	May 16, 1997
FLUTAMIDE					
CAPSULE;ORAL					
EULEXIN					
+	SCHERING	125MG	N018554	001	Jan 27, 1989
FLUTAMIDE					
	ACTAVIS LABS FL INC	125MG	A075820	001	Sep 18, 2001
	MYLAN	125MG	A076224	001	May 09, 2003
	YAOPHARMA CO LTD	125MG	A075818	001	Sep 18, 2001
FLUTEMETAMOL F-18					
INJECTABLE;INTRAVENOUS					
VIZAMYL					
+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013
FLUTICASONE PROPIONATE					
AEROSOL, METERED;INHALATION					
FLOVENT					
	GLAXOSMITHKLINE	0.044MG/INH	N020548	001	Mar 27, 1996
		0.11MG/INH	N020548	002	Mar 27, 1996
		0.22MG/INH	N020548	003	Mar 27, 1996
CREAM;TOPICAL					
CUTIVATE					
+	FOUGERA PHARMS	0.05% **	N019958	001	Dec 18, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUTICASONE PROPIONATE					
CREAM;TOPICAL					
FLUTICASONE PROPIONATE					
	NESHER PHARMS	0.05%	A076865	001	Sep 10, 2004
OINTMENT;TOPICAL					
CUTIVATE					
+	FOUGERA PHARMS	0.005%	N019957	001	Dec 14, 1990
FLUTICASONE PROPIONATE					
	FOUGERA PHARMS	0.005%	A076300	001	May 14, 2004
	TARO PHARM INDS	0.005%	A077145	001	Jun 14, 2005
POWDER;INHALATION					
ARMONAIR RESPICLICK					
+	TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017
+		0.113MG/INH	N208798	002	Jan 27, 2017
+		0.232MG/INH	N208798	003	Jan 27, 2017
FLOVENT					
	GLAXOSMITHKLINE	0.044MG/INH	N020549	001	Nov 07, 1997
		0.088MG/INH	N020549	002	Nov 07, 1997
		0.22MG/INH	N020549	003	Nov 07, 1997
SPRAY, METERED;NASAL					
FLONASE					
+	GLAXOSMITHKLINE	0.05MG/SPRAY **	N020121	001	Oct 19, 1994
FLUVASTATIN SODIUM					
CAPSULE;ORAL					
LESCOL					
+	NOVARTIS	EQ 20MG BASE **	N020261	001	Dec 31, 1993
+		EQ 40MG BASE **	N020261	002	Dec 31, 1993
TABLET, EXTENDED RELEASE;ORAL					
FLUVASTATIN SODIUM					
	MYLAN	EQ 80MG BASE	A202458	001	Sep 11, 2015
FLUVOXAMINE MALEATE					
CAPSULE, EXTENDED RELEASE;ORAL					
LUVOX CR					
+	JAZZ PHARMS	100MG **	N022033	001	Feb 28, 2008
+		150MG **	N022033	002	Feb 28, 2008
TABLET;ORAL					
FLUVOXAMINE MALEATE					
	ACTAVIS ELIZABETH	25MG	A075901	001	Dec 28, 2000
		50MG	A075901	002	Dec 28, 2000
		100MG	A075901	003	Dec 28, 2000
	ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001
		25MG	A075898	001	Mar 12, 2001
		50MG	A075897	002	Jan 25, 2001
		50MG	A075898	002	Mar 12, 2001
		100MG	A075897	003	Jan 25, 2001
		100MG	A075898	003	Mar 12, 2001
	ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006
		50MG	A075900	002	Feb 23, 2006
		100MG	A075900	003	Feb 23, 2006
	HERITAGE PHARMA	25MG	A075894	001	Apr 18, 2001
		50MG	A075894	002	Apr 18, 2001
		100MG	A075894	003	Apr 18, 2001
	MYLAN	25MG	A075889	001	Nov 29, 2000
		50MG	A075889	002	Nov 29, 2000
		50MG	A075950	001	Oct 15, 2001
		100MG	A075889	003	Nov 29, 2000
		100MG	A075950	002	Oct 15, 2001
	SUN PHARM INDUSTRIES	25MG	A076125	001	Apr 29, 2002
		50MG	A076125	002	Apr 29, 2002
		100MG	A076125	003	Apr 29, 2002
	SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
		50MG	A075899	002	Jan 17, 2001
		100MG	A075899	003	Jan 17, 2001
	UPSHER SMITH LABS	25MG	A075887	001	Jan 05, 2001
		50MG	A075887	002	Jan 05, 2001
		100MG	A075887	003	Jan 05, 2001
LUVOX					
+	SOLVAY	25MG **	N020243	001	Dec 05, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

FLUVOXAMINE MALEATE				
TABLET;ORAL				
LUVOX				
+	50MG **	N020243	002	Dec 05, 1994
+	100MG **	N020243	003	Dec 05, 1994
+	150MG **	N020243	004	Dec 05, 1994
FOLIC ACID				
INJECTABLE;INJECTION				
FOLIC ACID				
BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993
FOLVITE				
+ WYETH PHARMS INC	5MG/ML	N005897	008	
TABLET;ORAL				
FOLIC ACID				
BARR	1MG	A089177	001	Jan 08, 1986
CONTRACT PHARMACAL	1MG	A085061	001	
EVERYLIFE	1MG	A080755	001	
HALSEY	1MG	A083598	001	
IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
LANNETT	1MG	A080816	001	
LILLY	1MG	N006135	003	
MK LABS	1MG	A083526	001	
NEXGEN PHARMA INC	1MG	A084915	001	
PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
SUN PHARM INDUSTRIES	1MG	A040582	001	Jul 18, 2005
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET				
MISSION PHARMA	1MG	A087438	001	
FOLVITE				
WYETH PHARMS INC	1MG	N005897	004	
FOLLITROPIN ALFA/BETA				
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
FOLLISTIM				
ORGANON USA INC	75 IU/VIAL	N020582	001	Sep 29, 1997
	150 IU/VIAL	N020582	002	Sep 29, 1997
INJECTABLE;SUBCUTANEOUS				
FOLLISTIM AQ				
ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005
	150 IU/0.18ML	N021211	003	Feb 11, 2004
	150 IU/0.5ML	N021273	002	Aug 26, 2005
GONAL-F				
EMD SERONO	37.5 IU/VIAL	N020378	003	May 25, 2000
	37.5 IU/VIAL	N021765	001	Mar 25, 2004
	75 IU/VIAL	N020378	001	Sep 29, 1997
	150 IU/VIAL	N020378	002	Sep 29, 1997
	150 IU/VIAL	N021765	003	Mar 25, 2004
FOMEPIZOLE				
INJECTABLE;INJECTION				
ANTIZOL				
+ PAR PHARM INC	1.5GM/1.5ML (1GM/ML)	N020696	001	Dec 04, 1997
FOMEPIZOLE				
MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009

FOMIVIRSEN SODIUM
INJECTABLE;INJECTION
VITRAVENE PRESERVATIVE FREE

	NOVARTIS	6.6MG/ML	N020961	001	Aug 26, 1998

FORMOTEROL FUMARATE
POWDER;INHALATION
FORADIL

+	NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001

FORADIL CERTIHALER

	NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE
POWDER;INTRAVENOUS
EMEND

+	MERCK AND CO INC	EQ 115MG BASE/VIAL **	N022023	001	Jan 25, 2008

FOSCARNET SODIUM
INJECTABLE;INJECTION
FOSCARNET SODIUM

	HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005

FOSINOPRIL SODIUM
TABLET;ORAL
FOSINOPRIL SODIUM

	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004
		20MG	A076620	002	Oct 15, 2004
		40MG	A076620	003	Oct 15, 2004
	RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004
		20MG	A076580	002	Apr 23, 2004
		40MG	A076580	003	Apr 23, 2004
	UPSHER SMITH LABS	10MG	A076188	001	Oct 08, 2004
		20MG	A076188	002	Oct 08, 2004
		40MG	A076188	003	Oct 08, 2004
	WATSON LABS	10MG	A076987	001	Dec 23, 2004
		10MG	A077531	001	Aug 31, 2006
		20MG	A076987	002	Dec 23, 2004
		20MG	A077531	002	Aug 31, 2006
		40MG	A076987	003	Dec 23, 2004
		40MG	A077531	003	Aug 31, 2006

MONOPRIL

+	BRISTOL MYERS SQUIBB	10MG **	N019915	002	May 16, 1991
+		20MG **	N019915	003	May 16, 1991
+		40MG **	N019915	004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
TABLET;ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

	ANI PHARMS INC	10MG;12.5MG	A076608	001	Dec 03, 2004
		10MG;12.5MG	A077144	001	Aug 16, 2005
		20MG;12.5MG	A076608	002	Dec 03, 2004
		20MG;12.5MG	A077144	002	Aug 16, 2005
	MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006
		20MG;12.5MG	A077705	002	Aug 14, 2006
	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004
		20MG;12.5MG	A076739	002	Dec 17, 2004
	TEVA	10MG;12.5MG	A076945	001	Jul 05, 2006
		20MG;12.5MG	A076945	002	Jul 05, 2006

MONOPRIL-HCT

+	BRISTOL MYERS SQUIBB	10MG;12.5MG **	N020286	002	Nov 30, 1994
+		20MG;12.5MG **	N020286	001	Nov 30, 1994

FOSPHENYTOIN SODIUM
INJECTABLE;INJECTION
FOSPHENYTOIN SODIUM

	APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007
	DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007
	HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007
	LUITPOLD	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007
		EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FOSPROPOFOL DISODIUM				
SOLUTION;INTRAVENOUS				
LUSEDRA				
EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008
FURAZOLIDONE				
SUSPENSION;ORAL				
FUROXONE				
SHIRE	50MG/15ML	N011323	002	
TABLET;ORAL				
FUROXONE				
SHIRE	100MG	N011270	002	
FUROSEMIDE				
INJECTABLE;INJECTION				
FUROSEMIDE				
ABRAXIS PHARM	10MG/ML	N018507	001	Jul 30, 1982
	10MG/ML	N019036	001	Aug 13, 1984
ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986
ASTRAZENECA	10MG/ML	A070014	001	Sep 09, 1985
HOSPIRA	10MG/ML	A070578	001	Jul 08, 1987
	10MG/ML	A072080	001	Aug 13, 1991
	10MG/ML	A074337	001	Oct 31, 1994
IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985
	10MG/ML	A070096	001	Sep 09, 1985
INTL MEDICATION	10MG/ML	N018025	001	
+ LUITPOLD	10MG/ML **	N018579	001	Nov 30, 1983
MARSAM PHARMS LLC	10MG/ML	A074017	001	Jun 30, 1994
SMITH AND NEPHEW	10MG/ML	A070023	001	Feb 05, 1986
	10MG/ML	A070078	001	Feb 05, 1986
WARNER CHILCOTT	10MG/ML	N018420	001	Feb 26, 1982
WATSON LABS	10MG/ML	A070019	001	Sep 22, 1986
	10MG/ML	A070604	001	Jan 02, 1987
WEST-WARD PHARMS INT	10MG/ML	A071439	001	Sep 14, 1990
	10MG/ML	N018267	001	
WYETH AYERST	10MG/ML	N018670	001	Jul 20, 1982
LASIX				
+ SANOFI AVENTIS US	10MG/ML **	N016363	001	
SOLUTION;ORAL				
LASIX				
SANOFI AVENTIS US	10MG/ML	N017688	001	
TABLET;ORAL				
FUROSEMIDE				
ANI PHARMS INC	20MG	A071379	001	Jan 02, 1987
	40MG	A070413	001	Feb 26, 1986
	80MG	A071594	001	Feb 09, 1988
DAVA PHARMS INC	20MG	N018415	001	Jul 27, 1982
	40MG	N018415	002	Jul 27, 1982
	80MG	N018415	003	Nov 26, 1984
INTL MEDICATION	20MG	N018753	001	Feb 28, 1984
	40MG	N018753	002	Feb 28, 1984
KALAPHARM	20MG	N018868	001	Jun 28, 1983
	40MG	N018868	002	Jun 28, 1983
SANDOZ	40MG	N018750	002	Jul 30, 1984
SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014
	40MG	A091258	002	Apr 01, 2014
	40MG	N018790	001	Nov 29, 1983
	80MG	A091258	003	Apr 01, 2014
SUN PHARM INDUSTRIES	20MG	A070043	001	Sep 26, 1985
	80MG	A070100	001	Jan 26, 1988
SUPERPHARM	20MG	N018370	002	Jun 26, 1984
	40MG	N018370	001	Feb 10, 1983
WARNER CHILCOTT	20MG	N018419	001	Jan 31, 1983
	40MG	N018419	002	Jan 31, 1983
	80MG	N018419	003	Nov 13, 1984
WATSON LABS	20MG	A070412	001	Feb 26, 1986
	20MG	N018369	001	May 14, 1982
	40MG	A070450	001	Nov 22, 1985
	40MG	N018369	002	May 14, 1982
WATSON LABS TEVA	20MG	A070449	001	Nov 22, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FUROSEMIDE				
TABLET;ORAL				
FUROSEMIDE				
	80MG		A070528 001	Jan 07, 1986
GABAPENTIN				
CAPSULE;ORAL				
GABAPENTIN				
CSPC OUYI	100MG		A075477 001	Mar 23, 2005
	300MG		A075477 002	Mar 23, 2005
	400MG		A075477 003	Mar 23, 2005
HIKMA	100MG		A078150 001	Sep 25, 2007
	300MG		A078150 002	Sep 25, 2007
	400MG		A078150 003	Sep 25, 2007
SANDOZ	100MG		A075428 001	Jan 24, 2006
	100MG		A075539 001	Apr 06, 2005
	300MG		A075428 002	Jan 24, 2006
	300MG		A075539 002	Apr 06, 2005
	400MG		A075428 003	Jan 24, 2006
	400MG		A075539 003	Apr 06, 2005
SUN PHARM INDS LTD	100MG		A076606 001	Oct 07, 2005
	300MG		A076606 002	Oct 07, 2005
	400MG		A076606 003	Oct 07, 2005
SUN PHARM INDUSTRIES	100MG		A076537 001	Jun 30, 2005
	300MG		A076537 002	Jun 30, 2005
	400MG		A076537 003	Jun 30, 2005
WATSON LABS	100MG		A075485 003	May 11, 2007
	300MG		A075485 002	May 11, 2007
	400MG		A075485 001	May 11, 2007
TABLET;ORAL				
GABAPENTIN				
HIKMA PHARMS	600MG		A078782 001	Jul 21, 2011
	800MG		A078782 002	Jul 21, 2011
INVATECH	600MG		A076877 001	Jul 06, 2006
	800MG		A076877 002	Jul 06, 2006
IVAX SUB TEVA PHARMS	600MG		A076017 004	Apr 29, 2005
	800MG		A076017 005	Apr 29, 2005
LUPIN LTD	600MG		A209306 001	Aug 24, 2018
	800MG		A209306 002	Aug 24, 2018
RANBAXY	600MG		A076605 001	Sep 14, 2005
	800MG		A076605 002	Sep 14, 2005
SANDOZ	600MG		A076120 001	Jan 27, 2006
	800MG		A076120 002	Jan 27, 2006
TEVA	600MG		A075827 001	Dec 15, 2004
	800MG		A075827 002	Dec 15, 2004
GADODIAMIDE				
INJECTABLE;INJECTION				
OMNISCAN				
GE HEALTHCARE	14.35GM/50ML (287MG/ML)		N022066 001	Sep 05, 2007
GADOFOSVESET TRISODIUM				
SOLUTION;INTRAVENOUS				
ABLAVAR				
LANTHEUS MEDCL	2440MG/10ML (244MG/ML)		N021711 001	Dec 22, 2008
	3660MG/15ML (244MG/ML)		N021711 002	Dec 22, 2008
GADOPENTETATE DIMEGLUMINE				
INJECTABLE;INJECTION				
MAGNEVIST				
+ BAYER HLTHCARE	469.01MG/ML		N019596 001	Jun 02, 1988
+	469.01MG/ML		N021037 001	Mar 10, 2000
GADOVERSETAMIDE				
INJECTABLE;INJECTION				
OPTIMARK				
+ LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)		N020937 001	Dec 08, 1999
+	3309MG/10ML (330.9MG/ML)		N020937 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)		N020937 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)		N020937 004	Dec 08, 1999
+	16.545GM/50ML (330.9MG/ML)		N020975 001	Dec 08, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

GADOVERSETAMIDE
INJECTABLE;INJECTION
OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999

GALANTAMINE HYDROBROMIDE
CAPSULE, EXTENDED RELEASE;ORAL
GALANTAMINE HYDROBROMIDE

	IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009
		EQ 16MG BASE	A078484	002	May 27, 2009
		EQ 24MG BASE	A078484	003	May 27, 2009
	MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011
		EQ 16MG BASE	A090900	002	Jan 24, 2011
		EQ 24MG BASE	A090900	003	Jan 24, 2011

SOLUTION;ORAL
RAZADYNE

	JANSSEN PHARMS	4MG/ML **	N021224	001	Jun 22, 2001

TABLET;ORAL
GALANTAMINE HYDROBROMIDE

	HERITAGE PHARMA	EQ 4MG BASE	A077585	001	Sep 15, 2009
		EQ 4MG BASE	A077587	001	Jul 09, 2009
		EQ 8MG BASE	A077585	002	Sep 15, 2009
		EQ 8MG BASE	A077587	002	Jul 09, 2009
		EQ 12MG BASE	A077585	003	Sep 15, 2009
		EQ 12MG BASE	A077587	003	Jul 09, 2009
	MYLAN	EQ 4MG BASE	A077590	001	May 29, 2009
		EQ 4MG BASE	A077603	001	Aug 28, 2008
		EQ 8MG BASE	A077590	002	May 29, 2009
		EQ 8MG BASE	A077603	002	Aug 28, 2008
		EQ 12MG BASE	A077590	003	May 29, 2009
		EQ 12MG BASE	A077603	003	Aug 28, 2008

GALLAMINE TRIETHIODIDE
INJECTABLE;INJECTION
FLAXEDIL

	DAVIS AND GECK	20MG/ML	N007842	001	
		100MG/ML	N007842	002	

GALLIUM CITRATE GA-67
INJECTABLE;INJECTION
GALLIUM CITRATE GA 67

	GE HEALTHCARE	1mCi/ML	N017700	001	

NEOSCAN

	GE HEALTHCARE	2mCi/ML	N017655	001	

GALLIUM NITRATE
INJECTABLE;INJECTION
GANITE

	CHEPLAPHARM	25MG/ML **	N019961	002	Jan 17, 1991

GANCICLOVIR
CAPSULE;ORAL
CYTOVENE

+	ROCHE PALO	250MG **	N020460	001	Dec 22, 1994
+		500MG **	N020460	002	Dec 12, 1997

GANCICLOVIR

	RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003
		500MG	A076457	002	Jun 27, 2003

IMPLANT;IMPLANTATION
VITRASERT

	BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996

GANCICLOVIR SODIUM
INJECTABLE;INJECTION
GANCICLOVIR SODIUM

	CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001	Jun 20, 2019
	LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013
	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GATIFLOXACIN				
SOLUTION/DROPS;OPHTHALMIC				
GATIFLOXACIN				
APOTEX INC	0.3%	A079084	001	Aug 19, 2011
GEFITINIB				
TABLET;ORAL				
IRESSA				
ASTRAZENECA	250MG	N021399	001	May 05, 2003
GEMCITABINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
GEMCITABINE HYDROCHLORIDE				
ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016
	1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016
	2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016
ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011
	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011
	EQ 2GM BASE/VIAL	A079160	003	Jul 28, 2016
HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012
	EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012
INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019
	1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019
	2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019
LUITPOLD	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013
	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013
SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013
	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013
SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019
	EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019
GEMFIBROZIL				
CAPSULE;ORAL				
GEMFIBROZIL				
MYLAN	300MG	A073466	001	Jan 25, 1993
PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993
LOPID				
PFIZER PHARMS	200MG	N018422	001	
	300MG	N018422	002	
TABLET;ORAL				
GEMFIBROZIL				
MYLAN	600MG	A074452	001	Feb 16, 1995
PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994
SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008
WATSON LABS	600MG	A074156	001	Oct 24, 1994
	600MG	A074442	001	Apr 28, 1995
YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995
GEMTUZUMAB OZOGAMICIN				
INJECTABLE;INJECTION				
MYLOTARG				
WYETH PHARMS INC	5MG/VIAL	N021174	001	May 17, 2000
GENTAMICIN SULFATE				
CREAM;TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE **	A060462	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062458	001	Sep 01, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062471	001	Sep 27, 1983
FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984
PHARMADERM	EQ 1MG BASE/GM	A062530	001	Jul 05, 1984
TARO	EQ 0.1% BASE	A062427	001	May 26, 1983
INJECTABLE;INJECTION				
APOGEN				
KING PHARMS	EQ 10MG BASE/ML	A062289	001	
	EQ 40MG BASE/ML	A062289	002	
BRISTAGEN				
BRISTOL	EQ 40MG BASE/ML	A062288	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GARAMYCIN				
SCHERING	EQ 1MG BASE/ML **	A061716	002	
	EQ 10MG BASE/ML **	A061739	001	
	EQ 40MG BASE/ML **	A061716	001	
GENTAFAIR				
PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985
GENTAMICIN				
INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325	001	
	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982
GENTAMICIN SULFATE				
ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983
	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982
KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A062251	002	
	EQ 40MG BASE/ML	A062251	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814	004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814	005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814	006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814	007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814	008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814	009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814	010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814	011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814	012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814	013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814	014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414	002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414	004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414	005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062414	006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414	007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986

GENTAMICIN SULFATE

INJECTABLE;INJECTION				
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	EQ 90MG BASE/100ML	A062414	009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986
U-GENCIN				
PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	
INJECTABLE;INTRATHECAL				
GARAMYCIN				
+ SCHERING	EQ 2MG BASE/ML **	N050505	001	
OINTMENT;OPHTHALMIC				
GARAMYCIN				
SCHERING	EQ 0.3% BASE	N050425	001	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984
GENTAFAIR				
PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983
OINTMENT;TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE **	A060463	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984
SOLUTION/DROPS;OPHTHALMIC				
GARAMYCIN				
+ SCHERING	EQ 0.3% BASE **	N050039	002	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984
GENTAFAIR				
PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983
GENTAMICIN SULFATE				
ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985
PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988

GENTIAN VIOLET

SUPPOSITORY;VAGINAL				
GVS				
SAVAGE LABS	0.4%	A083513	001	
TAMPON;VAGINAL				
GENAPAX				
KEY PHARMS	5MG	A085017	001	

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS				
COPAXONE				
TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996

GLIMEPIRIDE

TABLET;ORAL				
GLIMEPIRIDE				
ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010
	2MG	A076995	002	Apr 27, 2010
	4MG	A076995	003	Apr 27, 2010
EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005
	2MG	A077274	002	Oct 06, 2005
	4MG	A077274	003	Oct 06, 2005
HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013
	2MG	A078952	002	Aug 01, 2013
	4MG	A078952	003	Aug 01, 2013
MYLAN	1MG	A077486	001	Feb 10, 2006
	2MG	A077486	002	Feb 10, 2006
	4MG	A077486	003	Feb 10, 2006
RANBAXY	3MG	A077366	001	Oct 06, 2005
	6MG	A077366	002	Oct 06, 2005
RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005
	2MG	A076875	002	Oct 06, 2005
	4MG	A076875	003	Oct 06, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

	8MG	A076875	004	Oct 06, 2005
TEVA	1MG	A076802	001	Oct 06, 2005
	2MG	A076802	002	Oct 06, 2005
	4MG	A076802	003	Oct 06, 2005
WATSON LABS	1MG	A077280	001	Feb 03, 2006
	2MG	A077280	002	Feb 03, 2006
	4MG	A077280	003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDARYL

+	SB PHARMCO	1MG;4MG **	N021700	001	Nov 23, 2005
+		2MG;4MG **	N021700	002	Nov 23, 2005
+		2MG;8MG **	N021700	004	Mar 30, 2007
+		4MG;4MG **	N021700	003	Nov 23, 2005
+		4MG;8MG **	N021700	005	Mar 30, 2007

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

TEVA PHARMS USA	1MG;4MG	A078709	001	Apr 01, 2016
	2MG;4MG	A078709	002	Apr 01, 2016
	2MG;8MG	A078709	004	Apr 01, 2016
	4MG;4MG	A078709	003	Apr 01, 2016
	4MG;8MG	A078709	005	Apr 01, 2016

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

ANI PHARMS INC	5MG	A074387	001	Mar 04, 1996
	5MG	A074497	001	Aug 31, 1995
	10MG	A074387	002	Mar 04, 1996
	10MG	A074497	002	Aug 31, 1995
BARR LABS INC	5MG	A074619	001	Apr 04, 1997
	10MG	A074619	002	Apr 04, 1997
BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995
	10MG	A074542	002	Jun 20, 1995
MYLAN	5MG	A074438	001	Jun 20, 1995
	10MG	A074438	002	Jun 20, 1995
OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994
	10MG	A074378	002	Nov 28, 1994
WATSON LABS	5MG	A074370	001	Nov 22, 1994
	10MG	A074370	002	Nov 22, 1994

GLUCOTROL

PFIZER	2.5MG	N017783	003	May 11, 1993

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

MYLAN	2.5MG	A202298	001	May 19, 2015
	5MG	A202298	002	May 19, 2015
	10MG	A202298	003	May 19, 2015

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

MYLAN	2.5MG;250MG	A078083	001	Apr 12, 2007
	2.5MG;500MG	A078083	002	Apr 12, 2007
	5MG;500MG	A078083	003	Apr 12, 2007
SUN PHARM INDS INC	2.5MG;250MG	A077620	001	Jan 11, 2008
	2.5MG;500MG	A077620	002	Jan 11, 2008
	5MG;500MG	A077620	003	Jan 11, 2008

METAGLIP

+	BRISTOL MYERS SQUIBB	2.5MG;250MG **	N021460	001	Oct 21, 2002
+		2.5MG;500MG **	N021460	002	Oct 21, 2002
+		5MG;500MG **	N021460	003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE				
INJECTABLE;INJECTION				
GLUCAGON				
+ LILLY	EQ 1MG BASE/VIAL **	N012122 001		
+	EQ 10MG BASE/VIAL **	N012122 002		
GLUTETHIMIDE				
CAPSULE;ORAL				
DORIDEN				
SANOFI AVENTIS US	500MG	N009519 008		
TABLET;ORAL				
DORIDEN				
SANOFI AVENTIS US	250MG	N009519 002		
	500MG	N009519 005		
GLUTETHIMIDE				
HALSEY	250MG	A089458 001	Oct 10, 1986	
	500MG	A089459 001	Oct 10, 1986	
LANNETT	250MG	A083475 001		
	500MG	A085571 001		
UCB INC	500MG	A085171 001		
UPSHER SMITH LABS	500MG	A083234 002		
VITARINE	500MG	A087297 001		
WATSON LABS	500MG	A084362 001		
	500MG	A085763 001		
GLYBURIDE				
TABLET;ORAL				
GLYBURIDE				
ACTAVIS ELIZABETH	1.5MG	A075947 001	Nov 14, 2002	
	3MG	A075947 002	Nov 14, 2002	
	6MG	A075947 003	Nov 14, 2002	
ORIENT PHARMA CO LTD	1.25MG	A206483 001	Feb 22, 2019	
	2.5MG	A206483 002	Feb 22, 2019	
	5MG	A206483 003	Feb 22, 2019	
GLYBURIDE (MICRONIZED)				
SANOFI AVENTIS US	1.5MG	N020055 001	Apr 17, 1992	
	3MG	N020055 002	Apr 17, 1992	
	6MG	N020055 003	Mar 08, 2000	
YAOPHARMA CO LTD	1.5MG	A075174 001	Jun 22, 1998	
	3MG	A075174 002	Jun 22, 1998	
GLYNASE				
+ PHARMACIA AND UPJOHN	4.5MG **	N020051 003	Sep 24, 1993	
MICRONASE				
+ PHARMACIA AND UPJOHN	1.25MG **	N017498 001	May 01, 1984	
	2.5MG	N017498 002	May 01, 1984	
+	5MG **	N017498 003	May 01, 1984	
GLYBURIDE; METFORMIN HYDROCHLORIDE				
TABLET;ORAL				
GLUCOVANCE				
+ BRISTOL MYERS SQUIBB	1.25MG;250MG **	N021178 001	Jul 31, 2000	
+	2.5MG;500MG **	N021178 002	Jul 31, 2000	
+	5MG;500MG **	N021178 003	Jul 31, 2000	
GLYBURIDE AND METFORMIN HYDROCHLORIDE				
HERITAGE PHARMS INC	1.25MG;250MG	A079009 001	Jun 03, 2009	
	2.5MG;500MG	A079009 002	Jun 03, 2009	
	5MG;500MG	A079009 003	Jun 03, 2009	
IMPAX LABS INC	1.25MG;250MG	A076731 001	Nov 19, 2004	
	2.5MG;500MG	A076731 002	Nov 19, 2004	
	5MG;500MG	A076731 003	Nov 19, 2004	
TEVA	1.25MG;250MG	A076821 001	Jan 27, 2005	
	2.5MG;500MG	A076821 002	Jan 27, 2005	
	5MG;500MG	A076821 003	Jan 27, 2005	
GLYCINE				
SOLUTION;IRRIGATION				
GLYCINE 1.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982	
HOSPIRA	1.5GM/100ML	N017633 001		

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLYCOPYRROLATE				
INJECTABLE;INJECTION				
GLYCOPYRROLATE				
ABRAXIS PHARM	0.2MG/ML	A088475	001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393	001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169	001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947	001	Jun 24, 1983
ROBINUL				
+ HIKMA	0.2MG/ML **	N017558	001	
ROBINS AH	0.2MG/ML	N014764	001	
TABLET;ORAL				
GLYCOPYRROLATE				
HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009
	2MG	A040836	002	Mar 05, 2009
RENATA	1MG	A040568	001	Dec 22, 2004
	2MG	A040568	002	Dec 22, 2004
WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	
ROBINUL				
+ CASPER PHARMA LLC	1MG **	N012827	001	
ROBINUL FORTE				
+ CASPER PHARMA LLC	2MG **	N012827	002	
GONADORELIN ACETATE				
INJECTABLE;INJECTION				
LUTREPULSE KIT				
FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989
GONADORELIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
FACTREL				
WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982
GONADOTROPIN, CHORIONIC				
INJECTABLE;INJECTION				
A.P.L.				
FERRING	5,000 UNITS/VIAL	N017055	001	
	10,000 UNITS/VIAL	N017055	002	
	20,000 UNITS/VIAL	N017055	003	
CHORIONIC GONADOTROPIN				
BEL MAR	5,000 UNITS/VIAL	N017054	001	
	10,000 UNITS/VIAL	N017054	002	
FERRING	2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
	15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016	004	
FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067	001	
	15,000 UNITS/VIAL	N017067	004	
	20,000 UNITS/VIAL	N017067	003	
FOLLUTEIN				
BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001	
GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
SOLUTION/DROPS;OPHTHALMIC				
NEO-POLYCIN				
DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN				
IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818	001	Oct 11, 1988
WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788	001	Jun 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN				
PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383	001	Aug 31, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GRANISETRON HYDROCHLORIDE					
INJECTABLE;INJECTION					
GRANISETRON HYDROCHLORIDE					
	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007
		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008
		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008
	LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010
	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008
	TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
	DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007
KYTRIL					
+	ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239	003	Sep 17, 2004
+		EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239	004	Mar 11, 1994
+		EQ 3MG BASE/ML **	N020239	001	Dec 29, 1993
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239	002	Mar 11, 1994
SOLUTION;ORAL					
GRANISOL					
	PEDIATRX	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008
KYTRIL					
+	ROCHE	EQ 2MG BASE/10ML **	N021238	001	Jun 27, 2001
TABLET;ORAL					
GRANISETRON HYDROCHLORIDE					
	BARR	EQ 1MG BASE	A078221	001	Dec 31, 2007
	EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007
	TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007
KYTRIL					
+	ROCHE	EQ 1MG BASE **	N020305	001	Mar 16, 1995
+		EQ 2MG BASE **	N020305	002	Jun 15, 1998
GREPAFLOXACIN HYDROCHLORIDE					
TABLET;ORAL					
RAXAR					
	OTSUKA	EQ 200MG BASE	N020695	001	Nov 06, 1997
		EQ 400MG BASE	N020695	002	May 14, 1998
		EQ 600MG BASE	N020695	003	May 14, 1998
GRISEOFULVIN, MICROCRYSTALLINE					
CAPSULE;ORAL					
GRISACTIN					
	WYETH AYERST	125MG	N050051	002	
		250MG	N050051	001	
SUSPENSION;ORAL					
GRIFULVIN V					
+	JOHNSON AND JOHNSON	125MG/5ML **	N050448	001	
TABLET;ORAL					
FULVICIN-U/F					
	CHARTWELL RX	250MG	A060569	002	
		500MG	A060569	001	
GRIFULVIN V					
	J AND J	125MG	A060618	001	
		250MG	A060618	002	
		500MG	A060618	003	
	VALEANT LUXEMBOURG	125MG	A062279	001	
		250MG **	A062279	002	
GRISACTIN					
	WYETH AYERST	500MG	A060212	001	
GRISEOFULVIN, MICROSIZE					
SUSPENSION;ORAL					
GRIFULVIN V					
	VALEANT LUXEMBOURG	125MG/5ML **	A062483	001	Jan 26, 1984
TABLET;ORAL					
GRIFULVIN V					
	VALEANT LUXEMBOURG	500MG	A062279	003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL				
FULVICIN P/G				
CHARTWELL RX	125MG	A061996	001	
	250MG	A061996	002	
FULVICIN P/G 165				
CHARTWELL RX	165MG	A061996	003	Apr 06, 1982
FULVICIN P/G 330				
CHARTWELL RX	330MG	A061996	004	Apr 06, 1982
GRISACTIN ULTRA				
WYETH AYERST	125MG	A062178	001	
	165MG	A062438	001	Nov 17, 1983
	250MG	A062178	002	
	330MG	A062438	002	Nov 17, 1983
ULTRAGRIS-165				
PLIVA	165MG	A062645	001	Jun 30, 1992
ULTRAGRIS-330				
PLIVA	330MG	A062646	001	Jun 30, 1992

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL				
GUAIFENESIN				
OHM LABS INC	600MG	A209254	001	Jul 16, 2018
	1.2GM	A209254	002	Jul 16, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
FLOWTUSS				
BKK PHARMS	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015
OBREDON				
+ SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001	Nov 14, 2014
TABLET;ORAL				
XTRELUS				
+ ECI PHARMS LLC	400MG;5MG	N208085	001	Apr 25, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
HYCOFENIX				
+ BKK PHARMS	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015

GUANABENZ ACETATE

TABLET;ORAL				
GUANABENZ ACETATE				
ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995
	EQ 4MG BASE	A074267	001	Jun 01, 1994
	EQ 8MG BASE	A074149	002	Apr 07, 1995
	EQ 8MG BASE	A074267	002	Jun 01, 1994
WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994
	EQ 8MG BASE	A074025	002	Feb 28, 1994
YAOPHARMA CO LTD	EQ 4MG BASE	A074517	001	Sep 30, 1998
	EQ 8MG BASE	A074517	002	Sep 30, 1998
WYTENSIN				
WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982
	EQ 8MG BASE	N018587	002	Sep 07, 1982
	EQ 16MG BASE	N018587	003	Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL				
HYLOREL				
PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982
	25MG	N018104	002	Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL				
GUANETHIDINE MONOSULFATE				
WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985
	EQ 25MG SULFATE	A086114	001	Mar 26, 1985
ISMELIN				
NOVARTIS	EQ 10MG SULFATE	N012329	001	
	EQ 25MG SULFATE	N012329	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
ESIMIL				
	NOVARTIS	10MG;25MG	N013553 001	
GUANFACINE HYDROCHLORIDE				
TABLET;ORAL				
GUANFACINE HYDROCHLORIDE				
	WATSON LABS	EQ 1MG BASE	A074762 001	Jun 25, 1997
		EQ 2MG BASE	A074762 002	Jun 25, 1997
TENEX				
+	PROMIUS PHARMA	EQ 1MG BASE	N019032 001	Oct 27, 1986
+		EQ 2MG BASE	N019032 002	Nov 07, 1988
		EQ 3MG BASE	N019032 003	Nov 07, 1988
TABLET, EXTENDED RELEASE;ORAL				
GUANFACINE HYDROCHLORIDE				
	IMPAX LABS INC	EQ 1MG BASE	A202238 001	Oct 20, 2015
		EQ 2MG BASE	A202238 002	Oct 20, 2015
		EQ 3MG BASE	A202238 003	Oct 20, 2015
		EQ 4MG BASE	A202238 004	Oct 20, 2015
	MYLAN	EQ 1MG BASE	A202578 001	Jun 02, 2015
		EQ 2MG BASE	A202578 002	Jun 02, 2015
		EQ 3MG BASE	A202578 003	Jun 02, 2015
		EQ 4MG BASE	A202578 004	Jun 02, 2015
HALAZEPAM				
TABLET;ORAL				
PAXIPAM				
	SCHERING	20MG	N017736 003	
		40MG	N017736 004	
HALCINONIDE				
CREAM;TOPICAL				
HALOG				
	WESTWOOD SQUIBB	0.025%	N017818 001	
HALOG-E				
	SUN PHARM INDS INC	0.1%	N018234 001	
OINTMENT;TOPICAL				
HALOG				
	BRISTOL MYERS SQUIBB	0.025%	N018125 001	
SOLUTION;TOPICAL				
HALOG				
	SUN PHARM INDS INC	0.1%	N017823 001	
HALOBETASOL PROPIONATE				
CREAM;TOPICAL				
ULTRAVATE				
+	SUN PHARM INDS INC	0.05%	N019967 001	Dec 27, 1990
OINTMENT;TOPICAL				
HALOBETASOL PROPIONATE				
	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004
HALOFANTRINE HYDROCHLORIDE				
TABLET;ORAL				
HALFAN				
	GLAXOSMITHKLINE	250MG	N020250 001	Jul 24, 1992
HALOPERIDOL				
TABLET;ORAL				
HALDOL				
+	ORTHO MCNEIL	0.5MG **	N015921 001	
+		1MG **	N015921 002	
+		2MG **	N015921 003	
+		5MG **	N015921 004	
+		10MG **	N015921 005	
+		20MG **	N015921 006	Feb 02, 1982
HALDOL SOLUTAB				
	ORTHO MCNEIL PHARM	1MG	N017079 001	
HALOPERIDOL				
	CYCLE PHARMS LTD	0.5MG	A071128 001	Feb 17, 1987
		1MG	A071129 001	Feb 17, 1987
		2MG	A071130 001	Feb 17, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HALOPERIDOL
TABLET;ORAL
HALOPERIDOL

	5MG	A071131	001	Feb 17, 1987
	10MG	A071132	001	May 12, 1987
	20MG	A071133	001	May 12, 1987
DURAMED PHARMS BARR	0.5MG	A071216	001	Dec 04, 1986
	1MG	A071217	001	Dec 04, 1986
	2MG	A071218	001	Dec 04, 1986
	5MG	A071219	001	Dec 04, 1986
	10MG	A071220	001	Jul 07, 1987
	20MG	A071221	001	Jul 07, 1987
LEDERLE	0.5MG	A072727	001	Sep 19, 1989
	1MG	A072728	001	Sep 19, 1989
	2MG	A072729	001	Sep 19, 1989
	5MG	A072730	001	Sep 19, 1989
	10MG	A072731	001	Sep 19, 1989
	20MG	A072732	001	Sep 19, 1989
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SANDOZ	2MG	A071208	001	Nov 17, 1986
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071235	002	Nov 03, 1986
	1MG	A071235	003	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071235	004	Nov 03, 1986
	10MG	A071235	005	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE
INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HALOPERIDOL LACTATE				
CONCENTRATE;ORAL				
HALDOL				
ORTHO MCNEIL	EQ 2MG BASE/ML **	N015922	001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987
TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988
HALOPERIDOL INTENSOL				
HIKMA	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988
INJECTABLE;INJECTION				
HALOPERIDOL				
ABRAXIS PHARM	EQ 5MG BASE/ML	A071187	001	Jan 20, 1987
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004
FOSUN PHARMA	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004
FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516	001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517	001	Feb 25, 1993
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802	001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864	001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713	001	May 17, 1988
	EQ 5MG BASE/ML	A070714	001	May 17, 1988
	EQ 5MG BASE/ML	A070744	001	May 17, 1988
SOLUTION;ORAL				
HALOPERIDOL LACTATE				
ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536	001	Nov 02, 1995
HALOPROGIN				
CREAM;TOPICAL				
HALOTEX				
WESTWOOD SQUIBB	1%	N016942	001	
SOLUTION;TOPICAL				
HALOTEX				
WESTWOOD SQUIBB	1%	N016943	001	
HALOTHANE				
LIQUID;INHALATION				
FLUOTHANE				
WYETH AYERST	99.99%	N011338	001	
HALOTHANE				
BH	99.99%	A084977	001	
HALOCARBON	99.99%	A080810	001	
HOSPIRA	99.99%	A083254	001	
HEPARIN CALCIUM				
INJECTABLE;INJECTION				
CALCIPARINE				
SANOFI AVENTIS US	25,000 UNITS/ML	N018237	001	
HEPARIN SODIUM				
INJECTABLE;INJECTION				
HEPARIN LOCK FLUSH				
HOSPIRA	100 UNITS/ML	N005264	010	
INTL MEDICATION	10 UNITS/ML	A086357	001	
	500 UNITS/ML	A086357	002	
LUITPOLD	10 UNITS/ML	A089063	001	Oct 09, 1985
	100 UNITS/ML	A089064	001	Oct 09, 1985
PARKE DAVIS	10 UNITS/ML	N017346	006	
SMITH AND NEPHEW	10 UNITS/ML	A087904	001	Apr 20, 1983
	10 UNITS/ML	A087958	001	Apr 20, 1983
	10 UNITS/ML	A088458	001	Jul 26, 1984
	10 UNITS/ML	A088580	001	Oct 25, 1984
	100 UNITS/ML	A087906	001	Apr 20, 1983
	100 UNITS/ML	A087959	001	Apr 20, 1983
	100 UNITS/ML	A088460	001	Jul 26, 1984
	100 UNITS/ML	A088581	001	Oct 25, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN LOCK FLUSH

SOLOPAK	10 UNITS/ML	A087903	001	Apr 20, 1983
	10 UNITS/ML	A088457	001	Oct 25, 1984
	100 UNITS/ML	A087905	001	Apr 20, 1983
	100 UNITS/ML	A088459	001	Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM	1,000 UNITS/ML	N017033	001	
	1,000 UNITS/ML	N017979	001	
	5,000 UNITS/ML	N017979	003	
	10,000 UNITS/ML	N017979	002	
AKORN	1,000 UNITS/ML	N017486	001	
	5,000 UNITS/ML	N017486	002	
	10,000 UNITS/ML	N017486	003	
	20,000 UNITS/ML	N017486	004	
	40,000 UNITS/ML	N017486	005	
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
	5,000 UNITS/ML	N017130	002	
	10,000 UNITS/ML	N017130	003	
	20,000 UNITS/ML	N017130	004	
DELL LABS	1,000 UNITS/ML	N017540	001	
	5,000 UNITS/ML	N017540	002	
	10,000 UNITS/ML	N017540	003	
	20,000 UNITS/ML	N017540	004	
	40,000 UNITS/ML	N017540	005	
DR REDDYS	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
	5,000 UNITS/ML	N017029	002	
	10,000 UNITS/ML	N017651	003	
	20,000 UNITS/ML	N017651	008	
HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
	10,000 UNITS/ML	A040095	001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521	001	
	10,000 UNITS/ML	N005521	002	
	20,000 UNITS/ML	N005521	004	
LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	
	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
PHARM SPEC	1,000 UNITS/ML	N017780	001	
	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	
	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM					
		10,000 UNITS/0.5ML	A087363	001	
	WATSON LABS INC	1,000 UNITS/ML	A040008	001	Oct 10, 1995
+	WEST-WARD PHARMS INT	1,000 UNITS/ML **	N017007	001	
+		2,500 UNITS/ML **	N017007	007	
+		5,000 UNITS/ML **	N017007	002	
+		5,000 UNITS/0.5ML **	N017007	010	
+		7,500 UNITS/ML **	N017007	003	
+		10,000 UNITS/ML **	N017007	004	
+		15,000 UNITS/ML **	N017007	005	
+		20,000 UNITS/ML **	N017007	006	
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%					
	HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%					
	HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
		10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
		10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%					
	HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
		5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
		10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%					
	HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
		10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
		10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
		5,000 UNITS/100ML	N019802	003	Jul 20, 1992
	HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%					
	HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
		100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM				
INJECTABLE;INJECTION				
HEPARIN SODIUM PRESERVATIVE FREE				
DR REDDYS	1,000 UNITS/ML	A089464	001	Jun 03, 1986
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986
PANHEPRIN				
HOSPIRA	1,000 UNITS/ML	N005264	004	
	5,000 UNITS/ML	N005264	006	
	10,000 UNITS/ML	N005264	007	
	20,000 UNITS/ML	N005264	008	
	40,000 UNITS/ML	N005264	009	
SODIUM HEPARIN				
ABRAXIS PHARM	5,000 UNITS/ML	N017033	002	
	10,000 UNITS/ML	N017033	003	
	20,000 UNITS/ML	N017033	004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036	001	Mar 04, 1988
HETACILLIN				
FOR SUSPENSION;ORAL				
VERSAPEN				
BRISTOL	EQ 112.5MG AMPICIL/ML	A061398	001	
	EQ 112.5MG AMPICIL/5ML	N050060	001	
	EQ 112.5MG AMPICIL/ML	N050060	003	
	EQ 225MG AMPICIL/5ML	A061398	002	
HETACILLIN POTASSIUM				
CAPSULE;ORAL				
VERSAPEN-K				
BRISTOL	EQ 225MG AMPICIL	A061396	001	
	EQ 450MG AMPICIL	A061396	002	
HEXACHLOROPHENE				
AEROSOL;TOPICAL				
SEPTISOL				
VESTAL LABS	0.23%	N017424	001	
TURGEX				
XTTRIUM	3%	N018375	001	
EMULSION;TOPICAL				
HEXA-GERM				
HUNTINGTON LABS	3%	N017411	001	
PHISOHEX				
SANOFI AVENTIS US	3%	N006882	001	
	3%	N008402	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEXACHLOROPHENE				
EMULSION;TOPICAL				
SOY-DOME				
	BAYER PHARMS	3%	N017405 001	
TURGEX				
	XTTRIUM	3%	N019055 001	Nov 30, 1984
SOAP;TOPICAL				
GAMOPHEN				
	ARBROOK	2%	N006270 003	
SOLUTION;TOPICAL				
DIAL				
	DIAL	0.25%	N017421 002	
GERMA-MEDICA				
	HUNTINGTON LABS	1%	N017412 001	
GERMA-MEDICA "MG"				
	HUNTINGTON LABS	0.25%	N017412 002	
SEPTI-SOFT				
	CALGON	0.25%	N017460 001	
SEPTISOL				
	VESTAL LABS	0.25%	N017423 001	
SPONGE;TOPICAL				
E-Z SCRUB				
	BECTON DICKINSON	450MG	N017452 001	
HEXASCRUB				
	PROF DSPLS	3%	N018363 001	
PHISO-SCRUB				
	SANOFI AVENTIS US	3%	N017446 001	
SCRUBTEAM SURGICAL SPONGEBRUSH				
	3M	330MG	N017413 001	
HEXAFLUORENIUM BROMIDE				
INJECTABLE;INJECTION				
MYLAXEN				
	MEDPOINTE PHARM HLC	20MG/ML	N009789 003	
HEXOCYCLIUM METHYLSULFATE				
TABLET;ORAL				
TRAL				
	ABBVIE	25MG	N010599 001	
HEXYLCAINE HYDROCHLORIDE				
SOLUTION;TOPICAL				
CYCLAINE				
	MERCK	5%	N008472 001	
HISTAMINE PHOSPHATE				
INJECTABLE;INJECTION				
HISTAMINE PHOSPHATE				
	LILLY	EQ 0.1MG BASE/ML	N000734 003	
		EQ 0.2MG BASE/ML	N000734 002	
		EQ 1MG BASE/ML	N000734 001	
HISTRELIN ACETATE				
INJECTABLE;INJECTION				
SUPPRELIN				
	SHIRE	EQ 0.2MG BASE/ML	N019836 001	Dec 24, 1991
		EQ 0.5MG BASE/ML	N019836 002	Dec 24, 1991
		EQ 1MG BASE/ML	N019836 003	Dec 24, 1991
HOMATROPINE METHYLBROMIDE				
TABLET;ORAL				
HOMAPIN-10				
	MISSION PHARMA	10MG	A086308 001	
HOMAPIN-5				
	MISSION PHARMA	5MG	A086309 001	
TABLET, CHEWABLE;ORAL				
EQUIPIN				
	MISSION PHARMA	3MG	A086310 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE				
SYRUP;ORAL				
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE				
	BRECKENRIDGE	1.5MG/5ML;5MG/5ML	A210663 001	Jun 11, 2019
	IVAX SUB TEVA PHARMS	1.5MG/5ML;5MG/5ML	A040285 001	Jul 19, 1999
	TORRENT	1.5MG/5ML;5MG/5ML	A204765 001	Mar 06, 2017
HYDROPANE				
	HALSEY	1.5MG/5ML;5MG/5ML	A088066 001	Jun 28, 1985
TABLET;ORAL				
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE				
	ACTAVIS ELIZABETH	1.5MG;5MG	A040295 001	Dec 01, 2000
HYCODAN				
+	GENUS	1.5MG;5MG **	N005213 001	Jul 26, 1988
HYALURONIDASE				
INJECTABLE;INJECTION				
HYDASE				
	AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005
VITRASE				
	BAUSCH AND LOMB	6,200 UNITS/VIAL	N021640 001	May 05, 2004
WYDASE				
	BAXTER HLTHCARE	150 UNITS/ML **	N006343 002	
		150 UNITS/VIAL **	N006343 006	
		1,500 UNITS/VIAL **	N006343 005	
HYDRALAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
APRESOLINE				
+	NOVARTIS	20MG/ML **	N008303 003	
HYDRALAZINE HYDROCHLORIDE				
	ABRAXIS PHARM	20MG/ML	A089532 001	Aug 11, 1987
	LUITPOLD	20MG/ML	A040136 001	Jun 30, 1997
	SMITH AND NEPHEW	20MG/ML	A088518 001	Apr 20, 1984
	SOLOPAK	20MG/ML	A088517 001	Aug 22, 1985
	TEVA PARENTERAL	20MG/ML	A040373 001	Feb 23, 2000
TABLET;ORAL				
APRESOLINE				
+	NOVARTIS	10MG **	N008303 004	
+		25MG **	N008303 001	
+		50MG **	N008303 002	
+		100MG **	N008303 005	
DRALZINE				
	TEVA	25MG	A084301 001	
HYDRALAZINE HYDROCHLORIDE				
	ACTAVIS ELIZABETH	25MG	A088560 001	Oct 04, 1984
		50MG	A088649 001	Oct 18, 1984
	ACTAVIS GRP PTC	10MG	A091679 001	Mar 04, 2013
		25MG	A091679 002	Mar 04, 2013
		50MG	A091679 003	Mar 04, 2013
		100MG	A091679 004	Mar 04, 2013
	ANDA REPOSITORY	10MG	A089359 001	Jul 25, 1986
		25MG	A089258 001	May 05, 1986
		50MG	A089259 001	May 05, 1986
		100MG	A088729 001	Apr 11, 1985
	ASCOT	25MG	A088310 001	Dec 19, 1984
		50MG	A088311 001	Dec 19, 1984
	CHARTWELL RX	10MG	A088846 001	Feb 26, 1985
		25MG	A088847 001	Feb 26, 1985
		50MG	A088848 001	Feb 26, 1985
		100MG	A088849 001	Feb 26, 1985
	HALSEY	10MG	A089218 001	Jan 22, 1986
		25MG	A089130 001	Jan 15, 1986
		50MG	A089222 001	Jan 22, 1986
		100MG	A089178 001	Jan 15, 1986
	HERITAGE PHARMS INC	10MG	A040858 001	Feb 26, 2010
		25MG	A040858 002	Feb 26, 2010
		50MG	A040858 003	Feb 26, 2010
		100MG	A040858 004	Feb 26, 2010
	IMPAX LABS	25MG	A084922 001	
		50MG	A084923 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	10MG	A084443 001	
	25MG	A084437 001	
	50MG	A084469 002	
	100MG	A084581 001	
MUTUAL PHARM	10MG	A088728 001	Apr 11, 1985
	25MG	A084106 002	
	50MG	A084107 002	
MYLAN	10MG	A090413 001	Dec 08, 2010
	25MG	A090413 002	Dec 08, 2010
	50MG	A090413 003	Dec 08, 2010
	100MG	A090413 004	Dec 08, 2010
PUREPAC PHARM	25MG	A088177 001	Jul 29, 1983
	50MG	A088178 001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671 001	May 01, 1984
	25MG	A088657 001	Jun 15, 1984
	50MG	A088652 001	May 08, 1984
	100MG	A088686 001	May 01, 1984
SUPERPHARM	10MG	A088787 001	Aug 28, 1984
	25MG	A088788 001	Aug 28, 1984
	50MG	A088789 001	Aug 28, 1984
UPSHER SMITH LABS	10MG	A083241 001	
	25MG	A083560 001	
	50MG	A083561 001	
	50MG	A085088 001	
USL PHARMA	25MG	A087780 001	Mar 29, 1982
	50MG	A087751 001	Mar 29, 1982
VANGARD	25MG	A087712 001	
	50MG	A087908 001	May 07, 1982
VITARINE	25MG	A086088 001	
WATSON LABS	25MG	A084504 001	
	25MG	A085532 002	May 24, 1982
	50MG	A084503 001	
	50MG	A085533 002	May 25, 1982
WEST WARD	25MG	A088240 001	May 27, 1983
	50MG	A088241 001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

APRESAZIDE

NOVARTIS	25MG;25MG	A084735 001	
	50MG;50MG	A084810 001	
	100MG;50MG	A084811 001	

HYDRA-ZIDE

PAR PHARM	100MG;50MG	A088961 001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG;25MG	A087608 001	Feb 08, 1982
	50MG;50MG	A087213 001	Feb 08, 1982
	100MG;50MG	A087609 001	Feb 08, 1982
SUPERPHARM	25MG;25MG	A089200 001	Feb 09, 1987
	50MG;50MG	A089201 001	Feb 09, 1987
WATSON LABS	25MG;25MG	A085457 001	Mar 04, 1982
	50MG;50MG	A085446 001	Mar 04, 1982
	100MG;50MG	A085440 001	Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG;50MG	A088358 001	Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG;25MG	A088356 001	Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG;50MG	A088357 001	Apr 10, 1984

TABLET;ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG;15MG	N012026 002	

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG;15MG	A085827 001	

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG;15MG	A085373 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE				
TABLET;ORAL				
CAM-AP-ES				
	CHARTWELL RX	25MG;15MG;0.1MG	A084897 001	
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE				
	IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291 001	
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE				
	MYLAN	25MG;15MG;0.1MG	A087085 001	
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE				
	WATSON LABS	25MG;15MG;0.1MG	A085771 001	
HYDRAP-ES				
	SANDOZ	25MG;15MG;0.1MG	A084876 001	
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE				
	WATSON LABS	25MG;15MG;0.1MG	A083770 001	
HYDROSERPINE PLUS (R-H-H)				
	IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877 001	
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
	SOLVAY	25MG;15MG;0.1MG	A088376 001	Oct 28, 1983
	SUN PHARM INDUSTRIES	25MG;15MG;0.1MG	A088570 001	Apr 10, 1984
	WATSON LABS	25MG;15MG;0.1MG	A085549 001	
		25MG;15MG;0.1MG	A087556 001	
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE				
	LEDERLE	25MG;15MG;0.1MG	A087709 001	May 13, 1982
SER-A-GEN				
	SOLVAY	25MG;15MG;0.1MG	A087210 001	
SER-AP-ES				
	NOVARTIS	25MG;15MG;0.1MG	N012193 005	
UNIPRES				
	SOLVAY	25MG;15MG;0.1MG	A085893 001	
		25MG;15MG;0.1MG	A086298 001	
HYDRALAZINE HYDROCHLORIDE; RESERPINE				
TABLET;ORAL				
DRALSERP				
	SANDOZ	25MG;0.1MG	A084617 001	
SERPASIL-APRESOLINE				
	NOVARTIS	25MG;0.1MG	N009296 004	
		50MG;0.2MG	N009296 002	
HYDROCHLOROTHIAZIDE				
CAPSULE;ORAL				
HYDROCHLOROTHIAZIDE				
	APOTEX	12.5MG	A078389 001	May 16, 2008
	HIKMA INTL PHARMS	12.5MG	A077885 001	Nov 26, 2007
	LANNETT CO INC	12.5MG	A091662 001	Jan 27, 2012
SOLUTION;ORAL				
HYDROCHLOROTHIAZIDE				
	MORTON GROVE	50MG/5ML	A089661 001	Jun 20, 1988
	ROXANE	50MG/5ML	A088587 001	Jul 02, 1984
HYDROCHLOROTHIAZIDE INTENSOL				
	ROXANE	100MG/ML	A088588 001	Jul 02, 1984
TABLET;ORAL				
ESIDRIX				
	NOVARTIS	25MG	N011793 005	
		50MG	N011793 008	
		100MG	N011793 009	
HYDRO-D				
	HALSEY	25MG	A086504 001	
		50MG	A083891 002	
HYDROCHLOROTHIAZIDE				
	ABC HOLDING	50MG	A085672 001	
	ACTAVIS ELIZABETH	25MG	A085054 002	
		50MG	A085208 001	
	ALRA	25MG	A086369 001	
		50MG	A083554 001	
	APOTEX	25MG	A040774 001	Oct 03, 2007
		50MG	A040774 002	Oct 03, 2007
	ASCOT	25MG	A087539 001	Feb 03, 1982
		50MG	A087540 001	Feb 03, 1982
	AUROLIFE PHARMA LLC	25MG	A083899 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

	50MG	A085219	001	
BARR	50MG	A084771	001	
CHARTWELL RX	25MG	A085683	001	
	50MG	A083965	001	
DAVA PHARMS INC	100MG	A087060	001	
ELKINS SINN	50MG	A085152	002	
HEATHER	50MG	A084135	001	
HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
IMPAX LABS	25MG	A084029	001	
	50MG	A083607	002	
	100MG	A085098	001	
INWOOD LABS	25MG	A084776	001	
	25MG	A085067	001	
	50MG	A084776	002	
IVAX SUB TEVA PHARMS	50MG	A084658	001	
	100MG	A085022	001	
JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
	50MG	A040809	002	Sep 04, 2007
LANNETT CO INC	25MG	A084325	001	
	50MG	A084324	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SOLVAY	25MG	A085323	001	
SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008
	25MG	A040810	001	Mar 27, 2007
	50MG	A040810	002	Mar 27, 2007
SUN PHARM INDUSTRIES	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A081189	001	Jan 24, 1992
	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WATSON LABS TEVA	50MG	A083232	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982
	50MG	A084912	001	

HYDRODIURIL

+ MERCK	25MG **	N011835	003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE					
TABLET;ORAL					
HYDRODIURIL					
+		50MG **	N011835	006	
+		100MG **	N011835	007	
ORETIC					
	ABBVIE	25MG	N011971	001	
		50MG	N011971	002	
ZIDE					
	SOLVAY	50MG	A083925	001	
HYDROCHLOROTHIAZIDE; IRBESARTAN					
TABLET;ORAL					
AVALIDE					
+	SANOFI AVENTIS US	12.5MG;75MG **	N020758	001	Sep 30, 1997
+		25MG;300MG **	N020758	004	Mar 15, 2005
IRBESARTAN AND HYDROCHLOROTHIAZIDE					
	APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012
		12.5MG;300MG	A201505	002	Oct 15, 2012
	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016
		12.5MG;300MG	A203036	002	Jan 15, 2016
		25MG;300MG	A203036	003	Jan 15, 2016
	MYLAN PHARMS INC	12.5MG;150MG	A077969	001	Sep 27, 2012
		12.5MG;300MG	A077969	002	Sep 27, 2012
		25MG;300MG	A077969	003	Jul 20, 2016
	TEVA	25MG;300MG	A077369	003	Mar 30, 2012
	WATSON LABS INC	12.5MG;150MG	A091539	001	Oct 22, 2012
		12.5MG;300MG	A091539	002	Oct 22, 2012
HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE					
TABLET;ORAL					
NORMOZIDE					
	SCHERING	25MG;100MG	N019046	001	Apr 06, 1987
		25MG;200MG	N019046	002	Apr 06, 1987
		25MG;300MG	N019046	003	Apr 06, 1987
		25MG;400MG	N019046	004	Apr 06, 1987
TRANDATE HCT					
	GLAXOSMITHKLINE	25MG;100MG	N019174	001	Apr 10, 1987
		25MG;200MG	N019174	002	Apr 10, 1987
		25MG;300MG	N019174	003	Apr 10, 1987
		25MG;400MG	N019174	004	Apr 10, 1987
HYDROCHLOROTHIAZIDE; LISINOPRIL					
TABLET;ORAL					
LISINOPRIL AND HYDROCHLOROTHIAZIDE					
	APOTEX	12.5MG;10MG	A076674	001	Oct 05, 2004
		12.5MG;20MG	A076674	002	Oct 05, 2004
		25MG;20MG	A076674	003	Oct 05, 2004
	HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002
		12.5MG;20MG	A075776	002	Jul 01, 2002
		25MG;20MG	A075776	003	Jul 01, 2002
	MYLAN	12.5MG;10MG	A076113	001	Jul 01, 2002
		12.5MG;20MG	A076113	002	Jul 01, 2002
		25MG;20MG	A076113	003	Jul 01, 2002
	SANDOZ	12.5MG;10MG	A075926	001	Jul 01, 2002
		12.5MG;20MG	A075926	002	Jul 01, 2002
		25MG;20MG	A075926	003	Jul 01, 2002
	TEVA	12.5MG;10MG	A075869	001	Jul 01, 2002
		12.5MG;20MG	A075869	002	Jul 01, 2002
		25MG;20MG	A075869	003	Jul 01, 2002
PRINZIDE					
+	MERCK	12.5MG;10MG **	N019778	003	Nov 18, 1993
+		12.5MG;20MG **	N019778	001	Feb 16, 1989
+		25MG;20MG **	N019778	002	Feb 16, 1989

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM					
TABLET;ORAL					
HYZAAR					
+	MERCK SHARP DOHME	12.5MG;50MG	N020387	001	Apr 28, 1995
+		25MG;100MG	N020387	002	Nov 10, 1998
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE					
	APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010
		12.5MG;100MG	A090150	002	Aug 11, 2010
		25MG;100MG	A090150	003	Oct 06, 2010
	WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011
		12.5MG;100MG	A200180	002	Jan 12, 2011
		25MG;100MG	A200180	003	Jan 12, 2011
HYDROCHLOROTHIAZIDE; METHYLDOPA					
TABLET;ORAL					
ALDORIL 15					
	MERCK	15MG;250MG	N013402	001	
ALDORIL 25					
	MERCK	25MG;250MG	N013402	002	
ALDORIL D30					
	MERCK	30MG;500MG	N013402	003	
ALDORIL D50					
	MERCK	50MG;500MG	N013402	004	
METHYLDOPA AND HYDROCHLOROTHIAZIDE					
	DAVA PHARMS INC	15MG;250MG	A072507	001	Jun 02, 1989
		25MG;250MG	A072508	001	Jun 02, 1989
		30MG;500MG	A072509	001	Jun 02, 1989
		50MG;500MG	A072510	001	Jun 02, 1989
	IVAX SUB TEVA PHARMS	15MG;250MG	A071458	001	Mar 08, 1988
		25MG;250MG	A071459	001	Mar 08, 1988
		30MG;500MG	A071460	001	Mar 08, 1988
		50MG;500MG	A071461	001	Mar 08, 1988
	PAR PHARM	15MG;250MG	A070616	001	Feb 02, 1987
		25MG;250MG	A070612	001	Feb 02, 1987
		30MG;500MG	A070613	001	Feb 02, 1987
		50MG;500MG	A070614	001	Feb 02, 1987
	PARKE DAVIS	15MG;250MG	A071897	001	Nov 23, 1987
		25MG;250MG	A071898	001	Nov 23, 1987
		30MG;500MG	A071899	001	Nov 23, 1987
		50MG;500MG	A071900	001	Nov 23, 1987
	PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
		25MG;250MG	A070688	001	Apr 24, 1986
		30MG;500MG	A070854	001	Oct 08, 1986
		50MG;500MG	A070689	001	Apr 24, 1986
	SANDOZ	15MG;250MG	A070829	001	Mar 09, 1987
		25MG;250MG	A070830	001	Mar 09, 1987
	TEVA	15MG;250MG	A071819	001	Apr 08, 1988
		25MG;250MG	A071820	001	Apr 08, 1988
		30MG;500MG	A071821	001	Apr 08, 1988
		50MG;500MG	A071822	001	Apr 08, 1988
	WATSON LABS	15MG;250MG	A070365	001	Mar 19, 1986
		15MG;250MG	A070958	001	Feb 06, 1989
		15MG;250MG	A071920	001	Aug 29, 1988
		25MG;250MG	A070366	001	Apr 16, 1986
		25MG;250MG	A070959	001	Jan 19, 1989
		25MG;250MG	A071921	001	Aug 29, 1988
		30MG;500MG	A070367	001	Mar 19, 1986
		30MG;500MG	A071069	001	Jan 19, 1989
		30MG;500MG	A071922	001	Aug 29, 1988
		50MG;500MG	A070368	001	Apr 16, 1986
		50MG;500MG	A070960	001	Feb 06, 1989
		50MG;500MG	A071923	001	Aug 29, 1988
	YAOPHARMA CO LTD	15MG;250MG	A070182	001	Jan 15, 1986
		25MG;250MG	A070183	001	Jan 15, 1986
		30MG;500MG	A070543	001	Jan 15, 1986
		50MG;500MG	A070544	001	Jan 15, 1986

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE					
TABLET;ORAL					
LOPRESSOR HCT					
+	US PHARMS HOLDINGS I	50MG;100MG **	N018303	003	Dec 31, 1984
HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE					
TABLET;ORAL					
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008
		12.5MG;15MG	A090096	002	Sep 25, 2008
		25MG;15MG	A090096	003	Sep 25, 2008
UNIRETIC					
	UCB INC	12.5MG;7.5MG **	N020729	001	Jun 27, 1997
		12.5MG;15MG **	N020729	003	Feb 14, 2002
		25MG;15MG **	N020729	002	Jun 27, 1997
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL					
TABLET;ORAL					
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE					
	ACCORD HLTHCARE	12.5MG;20MG	A209281	001	Feb 07, 2019
		12.5MG;40MG	A209281	002	Feb 07, 2019
		25MG;40MG	A209281	003	Feb 07, 2019
	MYLAN	12.5MG;20MG	A078827	001	Oct 26, 2016
		12.5MG;40MG	A078827	002	Oct 26, 2016
		25MG;40MG	A078827	003	Oct 26, 2016
	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017
		25MG;40MG	A200532	003	Apr 24, 2017
HYDROCHLOROTHIAZIDE; PINDOLOL					
TABLET;ORAL					
VISKAZIDE					
	NOVARTIS	25MG;5MG	N018872	001	Jul 22, 1987
		25MG;10MG	N018872	002	Jul 22, 1987
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
INDERIDE LA 120/50					
	WYETH AYERST	50MG;120MG	N019059	002	Jul 03, 1985
INDERIDE LA 160/50					
	WYETH AYERST	50MG;160MG	N019059	003	Jul 03, 1985
INDERIDE LA 80/50					
	WYETH AYERST	50MG;80MG	N019059	001	Jul 03, 1985
TABLET;ORAL					
INDERIDE-40/25					
+	WYETH PHARMS INC	25MG;40MG **	N018031	001	
INDERIDE-80/25					
+	WYETH PHARMS INC	25MG;80MG **	N018031	002	
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE					
	DURAMED PHARMS BARR	25MG;40MG	A071126	001	Mar 02, 1987
		25MG;80MG	A071127	001	Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	ACTAVIS ELIZABETH	25MG;40MG	A070851	001	May 15, 1986
		25MG;80MG	A070852	001	May 15, 1986
	ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986
		25MG;40MG	A072042	001	Mar 14, 1988
		25MG;80MG	A070705	001	Oct 01, 1986
		25MG;80MG	A072043	001	Mar 14, 1988
	IVAX SUB TEVA PHARMS	25MG;40MG	A071552	001	Dec 01, 1988
		25MG;80MG	A071553	001	Dec 01, 1988
	WARNER CHILCOTT	25MG;40MG	A071771	001	Jan 26, 1988
		25MG;80MG	A071772	001	Jan 26, 1988
	WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986
		25MG;40MG	A071498	001	Dec 18, 1991
		25MG;80MG	A070305	001	Apr 18, 1986
		25MG;80MG	A071501	001	Dec 18, 1991
	YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987
		25MG;80MG	A071061	001	Aug 26, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005
	12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005
	25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005
SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009
	12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009
	25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

H.R.-50

WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338	001	

HYDRO-RESERP

ABC HOLDING	50MG;0.125MG	A084714	002	Jun 29, 1982

HYDRO-SERP "25"

SANDOZ	25MG;0.125MG	A084827	001	

HYDRO-SERP "50"

SANDOZ	50MG;0.125MG	A085213	001	

HYDROCHLOROTHIAZIDE W/ RESERPINE

IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572	001	
	25MG;0.125MG	A083571	001	
	50MG;0.1MG	A083568	001	
	50MG;0.125MG	A083573	001	
PHARMERAL	25MG;0.125MG	A085421	001	
	50MG;0.125MG	A085420	001	
ROXANE	50MG;0.125MG	A084603	001	
WATSON LABS	25MG;0.125MG	A084466	001	
	25MG;0.125MG	A085317	001	
	25MG;0.125MG	A086330	002	
	50MG;0.125MG	A083666	001	
	50MG;0.125MG	A084467	001	
	50MG;0.125MG	A086331	001	

HYDROPRES 25

MERCK	25MG;0.125MG	N011958	002	

HYDROPRES 50

MERCK	50MG;0.125MG	N011958	003	

RESERPINE AND HYDROCHLOROTHIAZIDE

BARR	25MG;0.125MG	A084580	001	
	50MG;0.125MG	A084579	001	
SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984

RESERPINE AND HYDROCHLOROTHIAZIDE-50

WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984

SERPASIL-ESIDRIX #1

NOVARTIS	25MG;0.1MG	N011878	003	

SERPASIL-ESIDRIX #2

NOVARTIS	50MG;0.1MG	N011878	005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG;25MG	A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG;25MG	A087267	001	
PUREPAC PHARM	25MG;25MG	A087999	001	Nov 06, 1985
SUPERPHARM	25MG;25MG	A089137	001	Aug 26, 1985
WATSON LABS	25MG;25MG	A087398	001	
YAOPHARMA CO LTD	25MG;25MG	A086881	001	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

IVAX PHARMS	25MG;25MG	A087004	002	May 24, 1982
LEDERLE	25MG;25MG	A087511	001	
PARKE DAVIS	25MG;25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG;25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553	001	
USL PHARMA	25MG;25MG	A087651	001	
VANGARD	25MG;25MG	A087655	001	
WATSON LABS	25MG;25MG	A085974	001	
	25MG;25MG	A086026	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE				
TABLET;ORAL				
TIMOLIDE 10-25				
	MERCK	25MG;10MG	N018061 001	
HYDROCHLOROTHIAZIDE; TRIAMTERENE				
CAPSULE;ORAL				
DYAZIDE				
	GLAXOSMITHKLINE LLC	25MG;50MG	N016042 002	
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
	ANI PHARMS INC	25MG;37.5MG	A074970 001	Jan 06, 1998
		25MG;50MG	A074259 001	Mar 30, 1995
	CASI PHARMS INC	25MG;50MG	A073191 001	Jul 31, 1991
	NOVARTIS	25MG;37.5MG	A074857 001	Sep 09, 1997
	VITARINE	25MG;50MG	A071737 001	Feb 12, 1988
TABLET;ORAL				
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
	AM THERAP	50MG;75MG	A072022 001	Apr 17, 1988
	ANI PHARMS INC	50MG;75MG	A073467 001	Jan 31, 1996
	QUANTUM PHARMICS	50MG;75MG	A071980 001	Apr 17, 1988
	WATSON LABS	50MG;75MG	A071969 001	Apr 17, 1988
HYDROCHLOROTHIAZIDE; VALSARTAN				
TABLET;ORAL				
VALSARTAN AND HYDROCHLOROTHIAZIDE				
	APOTEX INC	12.5MG;80MG	A203026 001	Mar 21, 2013
		12.5MG;160MG	A203026 002	Mar 21, 2013
		12.5MG;320MG	A203026 003	Mar 21, 2013
		25MG;160MG	A203026 004	Mar 21, 2013
		25MG;320MG	A203026 005	Mar 21, 2013
	WATSON LABS TEVA	12.5MG;80MG	A091519 001	Mar 21, 2013
		12.5MG;160MG	A091519 002	Mar 21, 2013
		12.5MG;320MG	A091519 003	Mar 21, 2013
		25MG;160MG	A091519 004	Mar 21, 2013
		25MG;320MG	A091519 005	Mar 21, 2013
	ZYDUS PHARMS	12.5MG;80MG	A203000 001	Mar 15, 2019
		12.5MG;160MG	A203000 002	Mar 15, 2019
		12.5MG;320MG	A203000 003	Mar 15, 2019
		25MG;160MG	A203000 004	Mar 15, 2019
		25MG;320MG	A203000 005	Mar 15, 2019
HYDROCODONE BITARTRATE				
TABLET, EXTENDED RELEASE;ORAL				
VANTRELA ER				
+	TEVA BRANDED PHARM	15MG	N207975 001	Jan 17, 2017
+		30MG	N207975 002	Jan 17, 2017
+		45MG	N207975 003	Jan 17, 2017
+		60MG	N207975 004	Jan 17, 2017
+		90MG	N207975 005	Jan 17, 2017
HYDROCODONE BITARTRATE; IBUPROFEN				
TABLET;ORAL				
HYDROCODONE BITARTRATE AND IBUPROFEN				
	ANI PHARMS INC	5MG;200MG	A077454 001	Jun 23, 2010
	SUN PHARM INDS INC	2.5MG;200MG	A091633 001	May 28, 2013
		5MG;200MG	A091633 002	May 28, 2013
		7.5MG;200MG	A091633 003	May 28, 2013
		10MG;200MG	A091633 004	May 28, 2013
	TEVA	7.5MG;200MG	A076023 001	Apr 11, 2003
VICOPROFEN				
+	ABBVIE	7.5MG;200MG	N020716 001	Sep 23, 1997
HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE				
SYRUP;ORAL				
CODAMINE				
	ALPHARMA US PHARMS	5MG/5ML;25MG/5ML	A075103 001	Sep 29, 2000

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE				
SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
MAYNE PHARMA INC	5MG/5ML;60MG/5ML	A205658	001	Nov 17, 2015
PADDOCK LLC	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014
TORRENT	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019
TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014
REZIRA				
+ PERSION	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011
HYDROCORTAMATE HYDROCHLORIDE				
OINTMENT;TOPICAL				
MAGNACORT				
PFIZER	0.5%	N010554	001	
HYDROCORTISONE				
AEROSOL;TOPICAL				
AEROSEB-HC				
ALLERGAN HERBERT	0.5%	A085805	001	
CREAM;TOPICAL				
CORT-DOME				
BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	
DERMACORT				
MONARCH PHARMS	1%	A083011	002	
ELDECORT				
VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	
FLEXICORT				
WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982
H-CORT				
PHARM ASSOC	0.5%	A086823	001	
HC #1				
BAYER PHARMS	0.5%	A080438	001	
HC #4				
BAYER PHARMS	1%	A080438	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080482	003	
	1%	A080482	004	
HI-COR				
C AND M PHARMA	2.5%	A080483	001	
HYDROCORTISONE				
ALPHARMA US PHARMS	2.5%	A089754	001	Feb 01, 1989
ALTANA	0.5%	A080848	002	
	1%	A080848	003	
AMBIX	1%	A086080	001	
	2.5%	A086271	001	
EVERYLIFE	0.5%	A080452	001	
	1%	A080452	002	
G AND W LABS	1%	A084059	001	
INGRAM PHARM	0.5%	A080456	002	
	1%	A080456	003	
IVAX PHARMS	1%	A085733	001	
NASKA	1%	A089706	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084970	002	
	1%	A085026	001	
PHARMADERM	1%	A088845	001	Feb 27, 1986
	2.5%	A089413	001	Dec 16, 1986
PHARMAFAIR	1%	A087838	001	Jul 28, 1982
STIEFEL	1%	A086170	001	
SYOSSET	0.5%	A085527	001	
TARO	0.5%	A086154	001	
TARO PHARM INDS LTD	1%	A086155	001	
TEVA	0.5%	A080400	002	
	1%	A080400	003	
	1%	A085191	001	
	2.5%	A080400	004	
TOPIDERM	1%	A089273	001	Feb 17, 1989

HYDROCORTISONE				
CREAM;TOPICAL				
HYDROCORTISONE				
USL PHARMA	1%		A088027 001	Sep 27, 1983
	2.5%		A088029 001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%		A080496 002	
HYTONE				
VALEANT INTL	1% **		A080472 003	
	2.5% **		A080472 004	
NOGENIC HC				
IVAX PHARMS	1%		A087427 001	Apr 04, 1988
NUTRACORT				
BAUSCH	0.5%		A080442 002	
	1%		A080442 003	
PENECORT				
ALLERGAN HERBERT	1%		A088216 001	Jun 06, 1984
PROCTOCORT				
MONARCH PHARMS	1%		A083011 001	
SYNACORT				
MEDICIS	0.5%		A087459 001	
	1%		A087458 001	
	2.5%		A087457 001	
GEL;TOPICAL				
NUTRACORT				
HEALTHPOINT	1%		A084698 001	
PENECORT				
ALLERGAN HERBERT	1%		A088215 001	Jun 06, 1984
INJECTABLE;INJECTION				
CORTEF				
PHARMACIA AND UPJOHN	50MG/ML		N009864 001	
LOTION;TOPICAL				
ACTICORT				
BAKER NORTON	1%		A086535 001	
ALA-CORT				
CROWN LABS	1%		A083201 001	
BALNEOL-HC				
SOLVAY	1%		A088041 001	Dec 03, 1982
BETA-HC				
BETA DERMAC	1%		A089495 001	Jan 25, 1988
CETACORT				
BAUSCH	0.5%		A080426 002	
	1%		A080426 001	
CORT-DOME				
BAYER PHARMS	0.5%		N009895 003	
	1%		N009895 001	
DERMACORT				
SOLVAY	0.5%		A084573 002	
	1%		A086462 001	
EPICORT				
BLULINE	0.5%		A083219 002	
GLYCORT				
HERAN	1%		A087489 001	Oct 03, 1983
H-CORT				
PHARM ASSOC	0.5%		A086824 001	
HYDROCORTISONE				
ALPHARMA US PHARMS	0.5%		A087317 001	Jun 07, 1982
	1%		A087315 001	Jun 07, 1982
MERICON	0.5%		A085282 001	
	1%		A085282 002	Feb 26, 1987
NASKA	1%		A089705 001	Apr 25, 1988
PERRIGO NEW YORK	0.5%		A085662 001	
	1%		A085663 001	
TARO	1%		A089024 001	Feb 12, 1986
HYTONE				
VALEANT INTL	1% **		A080473 003	
	2.5% **		A080473 004	Nov 30, 1982
NUTRACORT				
DOW PHARM	0.5%		A080443 002	
	1%		A080443 003	

HYDROCORTISONE				
LOTION;TOPICAL				
NUTRACORT				
	2.5%	A087644	001	Aug 24, 1982
STIE-CORT				
PERRIGO CO	1%	A089066	001	Nov 25, 1985
OINTMENT;TOPICAL				
CORTRIL				
PFIZER GLOBAL	1%	N009176	001	
	2.5%	N009176	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080481	001	
	1%	A080481	002	
HYDROCORTISONE				
ALTANA	0.5%	A080489	002	
	1%	A080489	003	
AMBIX	1%	A086079	001	
	2.5%	A086272	001	
NASKA	1%	A089704	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969	003	
	1%	A085028	001	
PHARMADERM	1%	A088842	001	Feb 09, 1987
TARO	0.5%	A086256	001	
	2.5%	A040310	001	Dec 29, 2000
USL PHARMA	1%	A088061	001	Sep 27, 1983
	2.5%	A088039	001	Sep 27, 1983
HYTONE				
DERMIK LABS	1% **	A080474	003	
	2.5% **	A080474	004	
PENECORT				
ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984
POWDER;FOR RX COMPOUNDING				
H-CORT				
TORCH	100%	A087834	001	Mar 29, 1982
HYDRO-RX				
X GEN PHARMS	100%	A085982	001	
HYDROCORTISONE				
PADDOCK LLC	100%	A088082	001	Apr 08, 1983
SOLUTION;TOPICAL				
PENECORT				
ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984
TEXACORT				
MISSION PHARMA	1%	A080425	001	
TABLET;ORAL				
CORTRIL				
PFIZER	10MG	N009127	005	
	20MG	N009127	003	
HYDROCORTISONE				
BARR	20MG	A083999	001	
ELKINS SINN	20MG	A080624	001	
FERRANTE	10MG	A080568	001	
	20MG	A080568	002	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	
HYDROCORTONE				
MERCK	10MG	N008506	007	

HYDROCORTISONE				
TABLET;ORAL				
HYDROCORTONE				
	20MG		N008506 011	
TABLET;VAGINAL				
CORTRIL				
PFIPHARMECS	10MG		N009796 001	
HYDROCORTISONE ACETATE				
CREAM;TOPICAL				
HEMSOL-HC				
ABLE	1%		A081274 001	Jun 19, 1992
HYDROCORTISONE ACETATE				
CENCI	1%		A080419 001	Jan 25, 1982
FERNDALE LABS	2.5%		A040259 001	Jul 29, 1999
PARKE DAVIS	1%		A089914 001	Jan 03, 1989
PUREPAC PHARM	0.5%		A086050 001	
	1%		A086052 001	
MICORT-HC				
SEBELA IRELAND LTD	2%		A040398 001	Mar 29, 2002
INJECTABLE;INJECTION				
CORTEF ACETATE				
PHARMACIA AND UPJOHN	50MG/ML		N009378 002	
CORTRIL				
PFIZER	25MG/ML		N009164 001	
HYDROCORTISONE ACETATE				
AKORN	25MG/ML		N009637 001	
	50MG/ML		N009637 002	
BEL MAR	25MG/ML		A083739 001	
	50MG/ML		A083739 002	
WATSON LABS	25MG/ML		A083128 001	
	25MG/ML		A083759 001	
	50MG/ML		A083759 002	
	50MG/ML		A085214 001	
HYDROCORTONE				
MERCK	25MG/ML		N008228 001	
	50MG/ML		N008228 004	
LOTION;TOPICAL				
DRICORT				
INGRAM PHARM	0.5%		A086207 001	
OINTMENT;OPHTHALMIC				
HYDROCORTISONE ACETATE				
FERA PHARMS	0.5%		A080828 001	
OINTMENT;OPHTHALMIC, OTIC				
HYDROCORTONE				
MERCK	1.5%		N009018 003	
OINTMENT;TOPICAL				
CORTEF ACETATE				
PHARMACIA AND UPJOHN	1%		N008917 002	
+	2.5% **		N008917 001	
PASTE;TOPICAL				
ORABASE HCA				
COLGATE	0.5%		A083205 001	
POWDER;FOR RX COMPOUNDING				
HYDROCORTISONE ACETATE				
X GEN PHARMS	100%		A085981 001	
HYDROCORTISONE ACETATE; NEOMYCIN SULFATE				
CREAM;TOPICAL				
NEO-CORTEF				
PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM		A061049 001	
	2.5%;EQ 3.5MG BASE/GM		A061049 002	
OINTMENT;OPHTHALMIC				
NEO-CORTEF				
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM		A060610 001	
	1.5%;EQ 3.5MG BASE/GM		A060610 002	
OINTMENT;TOPICAL				
NEO-CORTEF				
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM		A060751 001	
	1%;EQ 3.5MG BASE/GM		A060751 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE				
OINTMENT;TOPICAL				
NEO-CORTEF				
	2.5%;EQ 3.5MG BASE/GM		A060751 003	
SUSPENSION/DROPS;OPHTHALMIC				
COR-OTICIN				
AKORN	1.5%;EQ 3.5MG BASE/ML		A060188 001	
NEO-CORTEF				
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML		A060612 002	
	1.5%;EQ 3.5MG BASE/ML		A060612 001	
HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE				
SUSPENSION;OPHTHALMIC				
TERRA-CORTRIL				
PFIZER	1.5%;EQ 5MG BASE/ML		A061016 001	
HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE				
AEROSOL, METERED;TOPICAL				
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%				
GENUS	1%;1%		A089440 001	May 17, 1988
LOTION;TOPICAL				
PRAMOSONE				
FERNDALE LABS	0.5%;1%		A083213 002	
HYDROCORTISONE ACETATE; UREA				
CREAM;TOPICAL				
CARMOL HC				
FOUGERA PHARMS	1%;10%		A080505 001	
HYDROCORTISONE BUTYRATE				
CREAM;TOPICAL				
LOCOID				
YAMANOUCHI	0.1%		N018795 001	Jan 07, 1983
OINTMENT;TOPICAL				
LOCOID				
YAMANOUCHI	0.1%		N019106 001	Jul 03, 1984
SOLUTION;TOPICAL				
LOCOID				
YAMANOUCHI	0.1%		N019819 001	Sep 15, 1988
HYDROCORTISONE CYPIONATE				
SUSPENSION;ORAL				
CORTEF				
PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML		N009900 001	
HYDROCORTISONE SODIUM PHOSPHATE				
INJECTABLE;INJECTION				
HYDROCORTONE				
MERCK	EQ 50MG BASE/ML		N012052 001	
HYDROCORTISONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
A-HYDROCORT				
ABBOTT	EQ 100MG BASE/VIAL		A085928 001	
	EQ 100MG BASE/VIAL		A089577 001	Apr 11, 1989
	EQ 250MG BASE/VIAL		A089578 001	Apr 11, 1989
	EQ 500MG BASE/VIAL		A089579 001	Apr 11, 1989
	EQ 1GM BASE/VIAL		A089580 001	Apr 11, 1989
HOSPIRA	EQ 100MG BASE/VIAL		A040666 001	Apr 06, 2006
	EQ 100MG BASE/VIAL		A085929 001	
	EQ 250MG BASE/VIAL		A085930 001	
	EQ 500MG BASE/VIAL		A085931 001	
	EQ 1GM BASE/VIAL		A085932 001	
HYDROCORTISONE SODIUM SUCCINATE				
ABRAXIS PHARM	EQ 100MG BASE/VIAL		A088667 001	Jun 08, 1984
	EQ 100MG BASE/VIAL		A088712 001	Jun 08, 1984
	EQ 250MG BASE/VIAL		A088668 001	Jun 08, 1984
	EQ 500MG BASE/VIAL		A088669 001	Jun 08, 1984
	EQ 1GM BASE/VIAL		A088670 001	Jun 08, 1984
BAXTER HLTHCARE	EQ 100MG BASE/VIAL		A086619 001	
	EQ 250MG BASE/VIAL		A087567 001	
	EQ 500MG BASE/VIAL		A087568 001	
	EQ 1GM BASE/VIAL		A087569 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION				
HYDROCORTISONE SODIUM SUCCINATE				
INTL MEDICATION	EQ 100MG BASE/VIAL	A087532	001	Mar 19, 1982
WATSON LABS	EQ 100MG BASE/VIAL	A084737	002	
	EQ 100MG BASE/VIAL	A084738	001	
	EQ 250MG BASE/VIAL	A084737	001	
	EQ 500MG BASE/VIAL	A084747	001	
	EQ 1GM BASE/VIAL	A084748	001	

HYDROCORTISONE VALERATE

CREAM;TOPICAL				
HYDROCORTISONE VALERATE				
ACP NIMBLE	0.2%	A074489	001	Aug 12, 1998
WESTCORT				
+ SUN PHARM INDS INC	0.2% **	N017950	001	
OINTMENT;TOPICAL				
HYDROCORTISONE VALERATE				
FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001
WESTCORT				
+ SUN PHARM INDS INC	0.2% **	N018726	001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORT-DOME				
BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237	006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237	005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
CORTISPORIN				
+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML **	N050479	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394	001	Sep 29, 1982
OTOCORT				
WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730	002	
SUSPENSION/DROPS;OPHTHALMIC				
CORTISPORIN				
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623	001	Sep 24, 1985
SUSPENSION/DROPS;OTIC				
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617	001	Sep 18, 1985
OTICAIR				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399	001	Nov 18, 1982
OTOBIONE				
SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816	001	
OTOCORT				
ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521	001	Jul 11, 1985
PEDIOTIC				
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
OTOBIOTIC				
SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302	001	
PYOCIDIN				
FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606	001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC				
ACHROMYCIN				
LEDERLE	1.5%;1%	N050272	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROCORTISONE; UREA				
CREAM;TOPICAL				
ALPHADERM				
	BIOGLAN	1%;10%	A086008 001	
CALMURID HC				
	PHARMACIA AND UPJOHN	1%;10%	A083947 001	
HYDROFLUMETHIAZIDE				
TABLET;ORAL				
DIUCARDIN				
	WYETH AYERST	50MG	A083383 001	
HYDROFLUMETHIAZIDE				
	PAR PHARM	50MG	A088850 001	May 31, 1985
	WATSON LABS	50MG	A088031 001	Apr 06, 1983
		50MG	A088528 001	Aug 15, 1984
SALURON				
+	SHIRE LLC	50MG	N011949 001	
HYDROFLUMETHIAZIDE; RESERPINE				
TABLET;ORAL				
HYDROFLUMETHIAZIDE AND RESERPINE				
	USL PHARMA	50MG;0.125MG	A088195 001	Oct 26, 1983
	WATSON LABS	25MG;0.125MG	A088127 001	Mar 22, 1983
		50MG;0.125MG	A088110 001	Mar 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE				
	IVAX PHARMS	50MG;0.125MG	A088932 001	Jan 11, 1985
	PAR PHARM	50MG;0.125MG	A088907 001	Sep 20, 1985
SALUTENSIN				
	SHIRE	50MG;0.125MG	N012359 003	
SALUTENSIN-DEMI				
	SHIRE	25MG;0.125MG	N012359 004	
HYDROGEN PEROXIDE				
SOLUTION;TOPICAL				
ESKATA				
+	ACLARIS	40%	N209305 001	Dec 14, 2017
HYDROMORPHONE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
PALLADONE				
	PURDUE PHARMA LP	12MG	N021044 001	Sep 24, 2004
		16MG	N021044 002	Sep 24, 2004
		24MG	N021044 003	Sep 24, 2004
		32MG	N021044 004	Sep 24, 2004
INJECTABLE;INJECTION				
DILAUDID				
+	FRESENIUS KABI USA	4MG/ML	N019034 005	Apr 30, 2009
DILAUDID-HP				
+	FRESENIUS KABI USA	10MG/ML	N019034 001	Jan 11, 1984
		250MG/VIAL	N019034 002	Aug 04, 1994
HYDROMORPHONE HYDROCHLORIDE				
	HOSPIRA	10MG/ML	A074598 001	Jun 19, 1997
	WATSON LABS	10MG/ML	A074317 001	Aug 23, 1995
TABLET;ORAL				
HYDROMORPHONE HYDROCHLORIDE				
	NESHER PHARMS	2MG	A077311 001	Nov 09, 2005
		4MG	A077311 002	Nov 09, 2005
		8MG	A077311 003	Nov 09, 2005
TABLET, EXTENDED RELEASE;ORAL				
EXALGO				
+	SPECGX LLC	8MG	N021217 001	Mar 01, 2010
+		12MG	N021217 002	Mar 01, 2010
+		16MG	N021217 003	Mar 01, 2010
+		32MG	N021217 004	Aug 24, 2012
HYDROMORPHONE HYDROCHLORIDE				
	ACTAVIS LABS FL INC	8MG	A202144 001	May 12, 2014
		12MG	A202144 002	May 12, 2014
		16MG	A202144 003	May 12, 2014
		32MG	A202144 004	Jun 30, 2016

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXOCOBALAMIN				
INJECTABLE;INJECTION				
ALPHAREDISOL				
MERCK	1MG/ML	A080778	001	
CYANOKIT				
SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006
HYDROXOCOBALAMIN				
ABRAXIS PHARM	1MG/ML	A084921	001	
WATSON LABS	1MG/ML	A085528	001	
HYDROXOMIN				
BEL MAR	1MG/ML	A084629	001	
HYDROXYAMPHETAMINE HYDROBROMIDE				
SOLUTION/DROPS;OPHTHALMIC				
PAREDRINE				
PHARMICS	1%	N000004	004	
HYDROXYCHLOROQUINE SULFATE				
TABLET;ORAL				
HYDROXYCHLOROQUINE SULFATE				
INVATECH	200MG	A040150	001	Jan 27, 1996
LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019
LUPIN LTD	200MG	A210543	001	Jul 06, 2018
HYDROXYPROGESTERONE CAPROATE				
INJECTABLE;INJECTION				
HYDROXYPROGESTERONE CAPROATE				
AKORN	125MG/ML	N018004	001	
ALLERGAN	125MG/ML	N017439	001	
	250MG/ML	N017439	002	
SOLUTION;INTRAMUSCULAR				
DELALUTIN				
+ BRISTOL MYERS SQUIBB	125MG/ML (125MG/ML) **	N010347	004	
+	125MG/ML (125MG/ML) **	N016911	001	
+	250MG/ML (250MG/ML) **	N010347	002	
+	250MG/ML (250MG/ML) **	N016911	002	
HYDROXYPROGESTERONE CAPROATE				
EUGIA PHARMA	1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019
HYDROXYSTILBAMIDINE ISETHIONATE				
INJECTABLE;INJECTION				
HYDROXYSTILBAMIDINE ISETHIONATE				
SANOFI AVENTIS US	225MG/AMP	N009166	001	
HYDROXYUREA				
CAPSULE;ORAL				
HYDROXYUREA				
BARR	250MG	A075143	002	Sep 21, 2000
BARR LABS INC	250MG	A075020	002	Jun 26, 2000
	500MG	A075020	001	Jul 30, 1998
ROXANE	500MG	A074476	001	Aug 18, 1995
TABLET;ORAL				
HYDROXYUREA				
BARR	1GM	A075734	001	Aug 29, 2000
HYDROXYZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HYDROXYZINE				
BAXTER HLTHCARE	50MG/ML	A085551	002	
HYDROXYZINE HYDROCHLORIDE				
ALTANA	25MG/ML	A087273	001	Apr 20, 1982
	50MG/ML	A087273	002	Apr 20, 1982
BAXTER HLTHCARE	25MG/ML	A085551	001	
DR REDDYS	50MG/ML	A085779	001	
FRESENIUS KABI USA	25MG/ML	A087329	001	
	25MG/ML	A088184	001	Mar 31, 1983
	50MG/ML	A087329	002	
	50MG/ML	A088185	001	Mar 31, 1983
HOSPIRA	25MG/ML	A087416	001	
	50MG/ML	A086821	001	
	50MG/ML	A087546	001	
PHARMAFAIR	25MG/ML	A088862	001	Feb 14, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROXYZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HYDROXYZINE HYDROCHLORIDE				
	25MG/ML	A089106	001	Feb 14, 1986
	50MG/ML	A088881	001	Feb 14, 1986
	50MG/ML	A089107	001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592	001	
SOLOPAK	25MG/ML	A086822	001	
	25MG/ML	A087591	001	
	50MG/ML	A087310	001	
	50MG/ML	A087593	001	
	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	
ORGATRAX				
ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	
VISTARIL				
+ PFIZER	25MG/ML **	N011111	001	
+	50MG/ML **	N011111	002	
SYRUP;ORAL				
ATARAX				
ROERIG	10MG/5ML **	N010485	001	
HYDROXYZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
ANIMA	10MG/5ML	A086880	001	
KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982
TORRENT	10MG/5ML	A210634	001	Feb 26, 2019
TABLET;ORAL				
ATARAX				
+ PFIZER	10MG **	N010392	001	
+	25MG **	N010392	004	
+	50MG **	N010392	006	
+	100MG **	N010392	005	
HYDROXYZINE HYDROCHLORIDE				
ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982
	25MG	A087871	003	Dec 20, 1982
	50MG	A087871	001	Dec 20, 1982
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
MYLAN	10MG	A091176	001	Jun 07, 2010
	25MG	A091176	002	Jun 07, 2010
	50MG	A091176	003	Jun 07, 2010
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE				
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985
SANDOZ	10MG	A087246	002	
	25MG	A085247	001	
	50MG	A087245	001	
SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008
	25MG	A040899	002	Jun 10, 2008
	50MG	A040899	003	Jun 10, 2008
SUN PHARM INDUSTRIES	10MG	A089381	001	May 19, 1986
	25MG	A089382	001	May 19, 1986
	50MG	A089383	001	May 19, 1986
	100MG	A087862	001	Apr 18, 1983
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
VINTAGE	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	10MG	A088348	001	Sep 15, 1983
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	25MG	A088349	001	Sep 15, 1983
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	
	50MG	A088350	001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HY-PAM "25"				
TEVA	EQ 25MG HYDROCHLORIDE	A088713	001	Mar 04, 1985
HYDROXYZINE PAMOATE				
BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991
DURAMED PHARMS BARR	EQ 25MG HYDROCHLORIDE	A088593	001	Feb 29, 1984
	EQ 50MG HYDROCHLORIDE	A088594	001	Feb 29, 1984
	EQ 100MG HYDROCHLORIDE	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HYDROCHLORIDE	A087761	001	Mar 05, 1982
	EQ 50MG HYDROCHLORIDE	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HYDROCHLORIDE	A087656	001	Jun 11, 1982
	EQ 25MG HYDROCHLORIDE	A089145	001	Mar 17, 1986
	EQ 50MG HYDROCHLORIDE	A087657	001	Jun 11, 1982
	EQ 50MG HYDROCHLORIDE	A089146	001	Mar 17, 1986
	EQ 100MG HYDROCHLORIDE	A087658	001	Jun 11, 1982
SANDOZ	EQ 50MG HYDROCHLORIDE	A081128	001	Jun 28, 1991
	EQ 100MG HYDROCHLORIDE	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HYDROCHLORIDE	A089031	001	Jan 02, 1987
	EQ 50MG HYDROCHLORIDE	A089032	001	Jan 02, 1987
	EQ 100MG HYDROCHLORIDE	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HYDROCHLORIDE	A088392	001	Sep 19, 1983
	EQ 50MG HYDROCHLORIDE	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HYDROCHLORIDE	A086698	001	
	EQ 25MG HYDROCHLORIDE	A086840	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A086695	001	
	EQ 50MG HYDROCHLORIDE	A086705	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A087767	001	Aug 16, 1982
	EQ 100MG HYDROCHLORIDE	A086697	001	
	EQ 100MG HYDROCHLORIDE	A086728	001	Oct 05, 1982
	EQ 100MG HYDROCHLORIDE	A087790	001	Aug 16, 1982
VISTARIL				
+ PFIZER	EQ 25MG HYDROCHLORIDE	N011459	002	
+	EQ 50MG HYDROCHLORIDE	N011459	004	
	EQ 100MG HYDROCHLORIDE **	N011459	006	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYZINE PAMOATE				
SUSPENSION;ORAL				
VISTARIL				
PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795 001		
IBANDRONATE SODIUM				
INJECTABLE;INTRAVENOUS				
IBANDRONATE SODIUM				
EMCURE PHARMS LTD	EQ 3MG BASE/3ML	A203987 001	Sep 02, 2014	
TABLET;ORAL				
BONIVA				
+ HOFFMANN LA ROCHE	EQ 2.5MG BASE **	N021455 001	May 16, 2003	
IBANDRONATE SODIUM				
MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	
SUN PHARM INDUSTRIES	EQ 150MG BASE	A078996 001	Aug 15, 2012	
IBUPROFEN				
CAPSULE;ORAL				
IBUPROFEN				
CONTRACT PHARMACAL	200MG	A074782 001	Jul 06, 1998	
STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469 001	Mar 28, 2018	
MIDOL				
BAYER	200MG **	A070626 001	Sep 02, 1987	
	200MG **	A071002 001	Sep 02, 1987	
SOLUTION;INTRAVENOUS				
CALDOLOR				
CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009	
SUSPENSION;ORAL				
CHILDREN'S ADVIL				
GLAXOSMITHKLINE	100MG/5ML	N019833 002	Sep 19, 1989	
CHILDREN'S ELIXSURE				
MOBERG PHARMA NORTH	100MG/5ML	N021604 001	Jan 07, 2004	
IBU				
ABBOTT	100MG/5ML	N019784 001	Dec 18, 1989	
IBUPROFEN				
GUARDIAN DRUG	100MG/5ML	A210149 001	Aug 17, 2018	
MOTRIN				
+ MCNEIL CONSUMER	100MG/5ML **	N019842 001	Sep 19, 1989	
SUSPENSION/DROPS;ORAL				
MOTRIN				
MCNEIL	40MG/ML	N020476 001	May 25, 1995	
PEDIATRIC ADVIL				
+ GLAXOSMITHKLINE	100MG/2.5ML	N020812 001	Jan 30, 1998	
TABLET;ORAL				
ACHES-N-PAIN				
LEDERLE	200MG	A071065 001	May 28, 1987	
CAP-PROFEN				
PERRIGO	200MG	A072097 001	Dec 08, 1987	
IBU				
BASF	400MG	A070083 001	Feb 22, 1985	
	400MG	N018197 001		
	600MG	A070088 001	Feb 08, 1985	
	600MG	A070099 001	Mar 29, 1985	
	800MG	A070745 001	Jul 23, 1986	
IBU-TAB				
ALRA	800MG	A071965 001	Aug 11, 1988	
IBUPRIN				
PLIVA	200MG	A071773 001	Jul 16, 1987	
IBUPROFEN				
ABBOTT	600MG	A070556 001	Jun 14, 1985	
	800MG	A071264 001	Jul 25, 1986	
ANI PHARMS INC	200MG	A071144 001	Jan 20, 1987	
	200MG	A072901 001	Dec 19, 1991	
	200MG	A072903 001	Dec 19, 1991	
AUROLIFE PHARMA LLC	300MG	A070736 002	Jun 12, 1986	
	400MG	A070736 003	Jun 12, 1986	
	600MG	A070736 001	Jun 12, 1986	
	800MG	A071938 001	Jan 14, 1988	
CONTRACT PHARMACAL	200MG	A071265 001	Oct 15, 1986	
	200MG	A071265 002	Sep 10, 1987	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN

TABLET;ORAL

IBUPROFEN

	200MG		A071735 001	Sep 10, 1987
	200MG		A073691 001	Feb 25, 1994
	200MG		A074931 001	Jul 20, 1998
HALSEY	200MG		A071027 001	Sep 29, 1987
	300MG		A071028 001	Mar 23, 1987
	400MG		A071029 001	Mar 23, 1987
	600MG		A071030 001	Mar 23, 1987
	800MG		A072137 001	Feb 05, 1988
HEC PHARM	400MG		A204062 001	Sep 10, 2018
	600MG		A204062 002	Sep 10, 2018
	800MG		A204062 003	Sep 10, 2018
IVAX SUB TEVA PHARMS	200MG		A071154 001	Oct 27, 1987
	200MG		A072040 001	Apr 29, 1988
	400MG		A071145 001	Sep 23, 1986
	600MG		A071146 001	Sep 23, 1986
	800MG		A071769 001	May 08, 1987
J AND J CONSUMER INC	400MG		A070081 001	Jun 16, 1986
LEDERLE	400MG		A070629 001	Sep 19, 1986
	600MG		A070630 001	Sep 19, 1986
LEINER	300MG		A071266 001	Oct 15, 1986
LNK	100MG		A076741 001	Jun 17, 2004
MCNEIL	600MG		A070476 001	Jun 16, 1986
MYLAN	200MG		A071870 001	May 05, 1988
	400MG		A070045 001	Sep 24, 1985
	600MG		A070057 001	Sep 24, 1985
	800MG		A071999 001	Dec 03, 1987
NORTHSTAR HLTHCARE	400MG		A078132 001	Sep 10, 2007
	600MG		A078132 002	Sep 10, 2007
	800MG		A078132 003	Sep 10, 2007
OHM LABS	400MG		A070818 001	Dec 26, 1985
P AND L DEV LLC	200MG		A070733 001	Sep 19, 1986
PAR PHARM	200MG		A071575 001	May 08, 1987
	300MG		A070328 001	Aug 06, 1985
	400MG		A070329 001	Aug 06, 1985
	600MG		A070330 001	Aug 06, 1985
	800MG		A070986 001	Jul 25, 1986
PERRIGO	200MG		A072098 001	Dec 08, 1987
PLIVA	400MG		A071666 001	Jun 18, 1987
	600MG		A071667 001	Jun 18, 1987
	800MG		A071668 001	Jun 18, 1987
PUREPAC PHARM	200MG		A071122 001	Oct 03, 1986
	200MG		A071664 001	Feb 03, 1987
	300MG		A071123 001	Sep 19, 1986
	400MG		A071124 001	Sep 19, 1986
	600MG		A071125 001	Sep 19, 1986
	800MG		A071964 001	Feb 01, 1988
SANDOZ	200MG		A071807 001	Feb 25, 1988
	200MG		A074525 001	Dec 15, 1995
	200MG		A074533 001	Dec 15, 1995
	400MG		A072064 001	Jan 14, 1988
	600MG		A072065 001	Jan 14, 1988
	800MG		A072169 001	Dec 11, 1987
SUN PHARM INDUSTRIES	200MG		A070493 001	Dec 24, 1985
	200MG		A070908 001	Sep 26, 1986
	200MG		A071462 001	Oct 02, 1986
	400MG		A070079 001	Jul 24, 1985
	600MG		A070080 001	Jul 24, 1985
	800MG		A071448 001	Feb 18, 1987
SUPERPHARM	600MG		A070709 001	Apr 25, 1986
TEVA	200MG		A073141 001	May 29, 1992
	400MG		A073343 001	Jun 30, 1992
	600MG		A073344 001	Jun 30, 1992
	800MG		A073345 001	Jun 30, 1992
VINTAGE PHARMS	200MG		A072249 001	Jan 10, 1989
	300MG		A071230 001	Oct 22, 1986
	400MG		A071231 001	Oct 22, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

IBUPROFEN

TABLET;ORAL					
IBUPROFEN					
	600MG		A071232	001	Oct 22, 1986
	800MG		A072004	001	Nov 18, 1987
WATSON LABS	200MG		A070435	001	Mar 05, 1986
	200MG		A071765	001	Sep 04, 1987
	200MG		A071905	001	Mar 08, 1988
	300MG		A071338	001	Dec 01, 1986
	400MG		A070038	001	Sep 06, 1985
	400MG		A070436	001	Aug 21, 1985
	600MG		A070041	001	Sep 06, 1985
	600MG		A070437	001	Aug 21, 1985
	800MG		A071547	001	Jul 02, 1987
	800MG		A071911	001	Oct 13, 1987
IBUPROHM					
OHM LABS	200MG		A071214	001	Dec 01, 1986
	400MG		A070469	001	Aug 29, 1985
MEDIPREN					
MCNEIL	200MG		A070475	001	Feb 06, 1986
	200MG		A071215	001	Jun 26, 1986
MIDOL					
BAYER	200MG		A070591	001	Sep 02, 1987
	200MG		A071001	001	Sep 02, 1987
MOTRIN					
+ MCNEIL CONSUMER	300MG **		N017463	003	
+	400MG **		N017463	002	
+	600MG **		N017463	004	
+	800MG **		N017463	005	May 22, 1985
MCNEIL PED	100MG		N020418	001	Nov 16, 1994
MOTRIN MIGRAINE PAIN					
J AND J CONSUMER INC	200MG		N019012	004	Feb 25, 2000
NUPRIN					
BRISTOL MYERS	200MG		A072035	001	Feb 16, 1988
	200MG		A072036	001	Feb 16, 1988
J AND J CONSUMER INC	200MG		N019012	001	May 18, 1984
	200MG		N019012	002	Jul 29, 1987
RUFEN					
BASF	600MG		N018197	002	Mar 05, 1984
TABLET, CHEWABLE;ORAL					
CHILDREN'S MOTRIN					
+ J AND J CONSUMER INC	50MG		N020601	001	Nov 15, 1996
IBUPROFEN					
PERRIGO	50MG		A076359	001	Jan 16, 2004
JUNIOR STRENGTH MOTRIN					
+ J AND J CONSUMER INC	100MG		N020601	003	Nov 15, 1996
MOTRIN					
MCNEIL PED	50MG		N020135	001	Nov 16, 1994
	100MG		N020135	002	Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL					
COMBUNOX					
FOREST LABS	400MG;5MG **		N021378	001	Nov 26, 2004
OXYCODONE HYDROCHLORIDE AND IBUPROFEN					
WATSON LABS	400MG;5MG		A078394	001	Nov 26, 2007

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL					
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
CONTRACT PHARMACAL	200MG;30MG		A075588	001	Apr 08, 2002

IBUTILIDE FUMARATE

INJECTABLE;INJECTION					
IBUTILIDE FUMARATE					
LUITPOLD	0.1MG/ML		A090240	001	Jan 11, 2010
MYLAN INSTITUTIONAL	0.1MG/ML		A090924	001	Jan 11, 2010

IDARUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
IDAMYCIN				
PHARMACIA AND UPJOHN	5MG/VIAL	N050661	002	Sep 27, 1990
	10MG/VIAL	N050661	001	Sep 27, 1990
	20MG/VIAL	N050661	003	Apr 25, 1995
IDARUBICIN HYDROCHLORIDE				
MYLAN LABS LTD	1MG/ML	A200144	001	Oct 11, 2012
SANDOZ	1MG/ML	A091293	001	Mar 29, 2011
TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002
	10MG/VIAL	A065037	002	May 01, 2002
	20MG/VIAL	A065037	001	May 01, 2002
IDOXURIDINE				
OINTMENT;OPHTHALMIC				
STOXIL				
GLAXOSMITHKLINE	0.5%	N015868	001	
SOLUTION/DROPS;OPHTHALMIC				
DENDRID				
+ ALCON	0.1%	N014169	001	
HERPLEX				
ALLERGAN	0.1%	N013935	002	
STOXIL				
GLAXOSMITHKLINE	0.1%	N013934	001	
IFOSFAMIDE				
INJECTABLE;INJECTION				
IFOSFAMIDE				
FRESENIUS KABI USA	1GM/20ML (50MG/ML)	A090181	001	Sep 22, 2009
	3GM/60ML (50MG/ML)	A090181	002	Sep 22, 2009
MYLAN LABS LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012
	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012
IFOSFAMIDE; MESNA				
INJECTABLE;INJECTION				
IFEX/MESNEX KIT				
BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N019763	003	Oct 10, 1992
	3GM/VIAL;100MG/ML	N019763	004	Oct 10, 1992
INJECTABLE;INTRAVENOUS				
IFOSFAMIDE/MESNA KIT				
TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002
	3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002
ILOPERIDONE				
TABLET;ORAL				
ILOPERIDONE				
INVENTIA	1MG	A207231	001	Nov 28, 2016
	2MG	A207231	002	Nov 28, 2016
	4MG	A207231	003	Nov 28, 2016
	6MG	A207231	004	Nov 28, 2016
	8MG	A207231	005	Nov 28, 2016
	10MG	A207231	006	Nov 28, 2016
	12MG	A207231	007	Nov 28, 2016
TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019
	2MG	A207098	002	Jul 22, 2019
	4MG	A207098	003	Jul 22, 2019
	6MG	A207098	004	Jul 22, 2019
	8MG	A207098	005	Jul 22, 2019
	10MG	A207098	006	Jul 22, 2019
	12MG	A207098	007	Jul 22, 2019
ILOPROST				
SOLUTION;INHALATION				
VENTAVIS				
ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IMATINIB MESYLATE				
CAPSULE;ORAL				
GLEEVEC				
+ NOVARTIS	EQ 50MG BASE **	N021335	001	May 10, 2001
+	EQ 100MG BASE **	N021335	002	May 10, 2001
TABLET;ORAL				
IMATINIB MESYLATE				
AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019
	EQ 400MG BASE	A207495	002	Feb 08, 2019
IMIPRAMINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
IMIPRAMINE HYDROCHLORIDE				
NOVARTIS	25MG/ML	A086765	001	
INJECTABLE;INJECTION				
TOFRANIL				
NOVARTIS	12.5MG/ML	N011838	002	
TABLET;ORAL				
IMIPRAMINE HYDROCHLORIDE				
LEDERLE	10MG	A086269	001	
	25MG	A086267	001	
	50MG	A086268	001	
LUPIN LTD	10MG	A090441	002	Mar 11, 2010
	25MG	A090441	003	Mar 11, 2010
	50MG	A090441	001	Mar 11, 2010
OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008
	25MG	A040751	002	Feb 28, 2008
	50MG	A040751	001	Feb 28, 2008
PAR PHARM	10MG	A089422	001	Jul 14, 1987
	25MG	A089497	001	Jul 14, 1987
ROXANE	10MG	A083799	001	
	25MG	A083799	002	
	50MG	A083799	003	
SANDOZ	10MG	A085200	001	
	25MG	A084869	002	
	50MG	A085133	001	
TEVA	10MG	A083729	001	
	25MG	A083729	004	
	50MG	A083729	003	
USL PHARMA	25MG	A087776	001	Feb 10, 1982
VANGARD	10MG	A088036	001	Nov 03, 1982
	25MG	A087619	001	Feb 09, 1982
	50MG	A087631	001	Jan 04, 1982
WATSON LABS	10MG	A085220	001	
	10MG	A085875	001	
	25MG	A084252	002	
	25MG	A085878	001	
	50MG	A085221	001	
	50MG	A085877	001	
WEST WARD	25MG	A088222	001	May 26, 1983
	50MG	A088223	001	May 26, 1983
JANIMINE				
ABBOTT	10MG	N017895	001	
	25MG	N017895	002	
	50MG	N017895	003	
PRAMINE				
ALRA	10MG	A083827	001	
	25MG	A083827	002	
	50MG	A083827	003	
PRESAMINE				
SANOFI AVENTIS US	10MG	N011836	006	
	25MG	N011836	003	
	50MG	N011836	007	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IMIPRAMINE PAMOATE					
CAPSULE;ORAL					
IMIPRAMINE PAMOATE					
	MYLAN PHARMS INC	EQ 75MG HYDROCHLORIDE	A202338	001	Jun 28, 2013
		EQ 100MG HYDROCHLORIDE	A202338	002	Jun 28, 2013
		EQ 125MG HYDROCHLORIDE	A202338	003	Jun 28, 2013
		EQ 150MG HYDROCHLORIDE	A202338	004	Jun 28, 2013
TOFRANIL-PM					
+	SPECGX LLC	EQ 75MG HYDROCHLORIDE **	N017090	001	
+		EQ 100MG HYDROCHLORIDE **	N017090	004	
+		EQ 125MG HYDROCHLORIDE **	N017090	003	
+		EQ 150MG HYDROCHLORIDE **	N017090	002	
IMIQUIMOD					
CREAM;TOPICAL					
IMIQUIMOD					
	ACP NIMBLE	5%	A200481	001	Apr 18, 2011
	STRIDES PHARMA	5%	A202002	001	Jun 24, 2014
INAMRINONE LACTATE					
INJECTABLE;INJECTION					
AMRINONE LACTATE					
	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542	001	May 10, 2000
	HOSPIRA	EQ 5MG BASE/ML	A074616	001	Aug 03, 1998
INOCOR					
	SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700	001	Jul 31, 1984
INDAPAMIDE					
TABLET;ORAL					
INDAPAMIDE					
	ANI PHARMS INC	1.25MG	A074498	002	Feb 12, 1998
		2.5MG	A074498	001	Oct 31, 1996
	MYLAN PHARMS INC	1.25MG	A075105	001	Jul 23, 1998
		2.5MG	A075105	002	Jul 23, 1998
	TEVA	1.25MG	A074665	001	Apr 04, 1997
		2.5MG	A074665	002	Apr 04, 1997
	WATSON LABS	1.25MG	A074585	001	Sep 26, 1996
		2.5MG	A074585	002	Sep 26, 1996
	YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996
		2.5MG	A074594	002	May 23, 1996
LOZOL					
+	SANOFI AVENTIS US	1.25MG **	N018538	002	Apr 29, 1993
+		2.5MG **	N018538	001	Jul 06, 1983
INDECAINIDE HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
DECABID					
	LILLY	EQ 50MG BASE	N019693	001	Dec 29, 1989
		EQ 75MG BASE	N019693	002	Dec 29, 1989
		EQ 100MG BASE	N019693	003	Dec 29, 1989
INDINAVIR SULFATE					
CAPSULE;ORAL					
CRIXIVAN					
	MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000
		EQ 333MG BASE	N020685	005	Dec 17, 1998
INDIUM IN-111 CHLORIDE					
INJECTABLE;INJECTION					
INDICLOR					
+	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992
INDOCYANINE GREEN					
INJECTABLE;INJECTION					
IC-GREEN					
	AKORN	10MG/VIAL **	N011525	003	
		40MG/VIAL **	N011525	004	
		50MG/VIAL **	N011525	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INDOMETHACIN					
CAPSULE;ORAL					
INDO-LEMMON					
	TEVA	25MG	A070266	001	Nov 07, 1985
		50MG	A070267	001	Nov 07, 1985
INDOCIN					
+	EGALET	25MG **	N016059	001	
+		50MG **	N016059	002	
INDOMETHACIN					
	ABLE	25MG	A076666	001	Dec 17, 2003
		50MG	A076666	002	Dec 17, 2003
	ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987
		50MG	A071149	001	Mar 18, 1987
	CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984
		50MG	A070651	001	Mar 05, 1986
		50MG	N018829	001	Aug 06, 1984
	CYCLE PHARMS LTD	25MG	A070353	001	Jun 18, 1985
		50MG	A070354	001	Jun 18, 1985
	DURAMED PHARMS BARR	25MG	A070326	001	Oct 18, 1985
		50MG	A070327	001	Oct 18, 1985
	HALSEY	25MG	A070782	001	Jun 03, 1987
		50MG	A070635	001	Jun 03, 1987
	IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
		50MG	N018730	002	May 04, 1984
	MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
		50MG	A070068	001	Oct 03, 1986
	MYLAN	25MG	N018858	001	Apr 20, 1984
		50MG	A070624	001	Sep 04, 1985
		50MG	N018858	002	Apr 20, 1984
	PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
		50MG	N018806	002	Nov 23, 1984
	PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
		50MG	A070592	001	Aug 11, 1986
	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013
		50MG	A091401	002	Mar 28, 2013
	SUN PHARM INDUSTRIES	25MG	A070900	002	Feb 09, 1987
		50MG	A070900	001	Feb 09, 1987
	SUPERPHARM	25MG	A070487	001	Oct 10, 1986
		50MG	A070488	001	Oct 10, 1986
	TEVA	25MG	A071342	001	Apr 18, 1988
		50MG	A071343	001	Apr 18, 1988
	WATSON LABS	25MG	A070529	001	Oct 18, 1985
		25MG	A070784	001	Aug 20, 1986
		25MG	A072996	001	Jul 31, 1991
		25MG	N018690	001	Jul 31, 1984
		50MG	A070530	001	Oct 18, 1985
		50MG	A070785	001	Aug 20, 1986
		50MG	A071635	001	May 18, 1987
		50MG	A072997	001	Jul 31, 1991
		50MG	N018690	002	Jul 31, 1984
CAPSULE, EXTENDED RELEASE;ORAL					
INDOCIN SR					
+	EGALET	75MG **	N018185	001	Feb 23, 1982
INDOMETHACIN					
	ABLE	75MG	A076114	001	Feb 06, 2002
	INWOOD LABS	75MG	A072410	001	Mar 15, 1989
	WATSON LABS INC	75MG	A202572	001	Dec 09, 2013
SUPPOSITORY;RECTAL					
INDOCIN					
+	EGALET	50MG **	N017814	001	Aug 13, 1984
SUSPENSION;ORAL					
INDOMETHACIN					
	HIKMA	25MG/5ML	A071412	001	Mar 18, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT					
INJECTABLE;SUBCUTANEOUS					
NOVOLOG MIX 50/50					
	NOVO NORDISK INC	50 UNITS/ML;50 UNITS/ML	N021810	001	Aug 26, 2008
NOVOLOG MIX 70/30 PENFILL					
	NOVO NORDISK INC	210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	002	Nov 01, 2001
		210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	003	Nov 01, 2001
INSULIN ASPART RECOMBINANT					
INJECTABLE;SUBCUTANEOUS					
NOVOLOG FLEXTOUCH					
+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013
NOVOLOG INNOLET					
	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	004	Apr 23, 2004
INSULIN ASPART; INSULIN DEGLUDEC					
SOLUTION;SUBCUTANEOUS					
RYZODEG 70/30					
+	NOVO	90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)	N203313	001	Sep 25, 2015
INSULIN DETEMIR RECOMBINANT					
INJECTABLE;SUBCUTANEOUS					
LEVEMIR FLEXPEN					
	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005
LEVEMIR INNOLET					
	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	003	Jun 16, 2005
LEVEMIR PENFILL					
	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	004	Jun 16, 2005
INSULIN GLULISINE RECOMBINANT					
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS					
APIDRA					
+	SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021629	002	Dec 20, 2005
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT					
INJECTABLE;INJECTION					
HUMALOG MIX 50/50 PEN					
	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	003	Dec 22, 1999
HUMALOG MIX 75/25 PEN					
	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	003	Dec 22, 1999
INSULIN LISPRO RECOMBINANT					
INJECTABLE;INJECTION					
HUMALOG PEN					
	LILLY	100 UNITS/ML	N020563	002	Aug 06, 1998
INSULIN PORK					
INJECTABLE;INJECTION					
ILETIN I					
	LILLY	500 UNITS/ML	N017931	001	
INSULIN					
	NOVO NORDISK INC	40 UNITS/ML	N017926	001	
REGULAR INSULIN					
	NOVO NORDISK INC	100 UNITS/ML	N017926	003	
INSULIN PURIFIED BEEF					
INJECTABLE;INJECTION					
REGULAR ILETIN II					
	LILLY	100 UNITS/ML	N018478	001	
INSULIN PURIFIED PORK					
INJECTABLE;INJECTION					
ILETIN II					
	LILLY	500 UNITS/ML	N018344	002	
REGULAR ILETIN II (PORK)					
	LILLY	100 UNITS/ML	N018344	001	
REGULAR PURIFIED PORK INSULIN					
	NOVO NORDISK INC	100 UNITS/ML	N018381	001	
VELOSULIN					
	NOVO NORDISK INC	100 UNITS/ML	N018193	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK				
INJECTABLE;INJECTION				
INSULIN NORDISK MIXTARD (PORK)				
	NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N018195 001	
INSULIN RECOMBINANT HUMAN				
INJECTABLE;INJECTION				
HUMULIN BR				
	LILLY	100 UNITS/ML	N019529 001	Apr 28, 1986
VELOSULIN BR				
	NOVO NORDISK INC	100 UNITS/ML	N021028 001	Jul 19, 1999
POWDER;INHALATION				
EXUBERA				
	PFIZER	1MG/INH	N021868 001	Jan 27, 2006
		3MG/INH	N021868 002	Jan 27, 2006
INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN				
INJECTABLE;INJECTION				
HUMULIN 50/50				
	LILLY	50 UNITS/ML;50 UNITS/ML	N020100 001	Apr 29, 1992
INSULIN RECOMBINANT PURIFIED HUMAN				
INJECTABLE;INJECTION				
NOVOLIN R				
	NOVO NORDISK INC	100 UNITS/ML	N018778 001	Aug 30, 1983
VELOSULIN BR HUMAN				
	NOVO NORDISK INC	100 UNITS/ML	N019450 001	May 30, 1986
INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN				
INJECTABLE;INJECTION				
MIXTARD HUMAN 70/30				
	BAYER PHARMS	30 UNITS/ML;70 UNITS/ML	N019585 001	Mar 11, 1988
NOVOLIN 70/30				
	NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019441 001	Jul 11, 1986
INSULIN SUSP ISOPHANE BEEF				
INJECTABLE;INJECTION				
NPH INSULIN				
	NOVO NORDISK INC	40 UNITS/ML	N017929 001	
		100 UNITS/ML	N017929 003	
INSULIN SUSP ISOPHANE BEEF/PORK				
INJECTABLE;INJECTION				
NPH ILETIN I (BEEF-PORK)				
	LILLY	40 UNITS/ML	N017936 001	
		100 UNITS/ML	N017936 002	
INSULIN SUSP ISOPHANE PURIFIED BEEF				
INJECTABLE;INJECTION				
NPH ILETIN II				
	LILLY	100 UNITS/ML	N018479 001	
INSULIN SUSP ISOPHANE PURIFIED PORK				
INJECTABLE;INJECTION				
INSULIN INSULATARD NPH NORDISK				
	NOVO NORDISK INC	100 UNITS/ML	N018194 001	
NPH ILETIN II (PORK)				
	LILLY	100 UNITS/ML	N018345 001	
NPH PURIFIED PORK ISOPHANE INSULIN				
	NOVO NORDISK INC	100 UNITS/ML	N018623 001	
INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN				
INJECTABLE;INJECTION				
INSULATARD NPH HUMAN				
	NOVO NORDISK INC	100 UNITS/ML	N019449 001	May 30, 1986
NOVOLIN N				
	NOVO NORDISK INC	100 UNITS/ML	N019065 001	Jan 23, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN SUSP PROTAMINE ZINC BEEF/PORK
INJECTABLE;INJECTION
PROTAMINE ZINC & ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N017932	001	
	100 UNITS/ML	N017932	002	

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF
INJECTABLE;INJECTION
PROTAMINE ZINC AND ILETIN II

LILLY	100 UNITS/ML	N018476	001	

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB	40 UNITS/ML	N017928	001	
	100 UNITS/ML	N017928	003	

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK
INJECTABLE;INJECTION
PROTAMINE ZINC AND ILETIN II (PORK)

LILLY	100 UNITS/ML	N018346	001	

INSULIN ZINC SUSP BEEF
INJECTABLE;INJECTION
LENTE INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017998	001	
	100 UNITS/ML	N017998	003	

INSULIN ZINC SUSP EXTENDED BEEF
INJECTABLE;INJECTION
ULTRALENTE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017997	003	

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF
INJECTABLE;INJECTION
ULTRALENTE

NOVO NORDISK INC	100 UNITS/ML	N018385	001	

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN
INJECTABLE;INJECTION
HUMULIN U

LILLY	40 UNITS/ML	N019571	001	Jun 10, 1987
	100 UNITS/ML	N019571	002	Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF
INJECTABLE;INJECTION
SEMILENTE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017996	003	

INSULIN ZINC SUSP PROMPT PURIFIED PORK
INJECTABLE;INJECTION
SEMILENTE

NOVO NORDISK INC	100 UNITS/ML	N018382	001	

INSULIN ZINC SUSP PURIFIED BEEF
INJECTABLE;INJECTION
LENTE ILETIN II

LILLY	100 UNITS/ML	N018477	001	

INSULIN ZINC SUSP PURIFIED BEEF/PORK
INJECTABLE;INJECTION
LENTARD

NOVO NORDISK INC	100 UNITS/ML	N018384	001	

INSULIN ZINC SUSP PURIFIED PORK
INJECTABLE;INJECTION
LENTE

NOVO NORDISK INC	100 UNITS/ML	N018383	001	

LENTE ILETIN II (PORK)

LILLY	100 UNITS/ML	N018347	001	

INSULIN ZINC SUSP RECOMBINANT HUMAN
INJECTABLE;INJECTION
HUMULIN L

LILLY	100 UNITS/ML	N019377	002	Sep 30, 1985

NOVOLIN L

NOVO NORDISK INC	100 UNITS/ML	N019965	001	Jun 25, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN
INJECTABLE;INJECTION
NOVOLIN L
NOVO NORDISK INC 100 UNITS/ML N018777 001 Aug 30, 1983

INULIN
INJECTABLE;INJECTION
INULIN AND SODIUM CHLORIDE
ISO TEX 100MG/ML N002282 001

INVERT SUGAR
INJECTABLE;INJECTION
TRAVERT 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10GM/100ML N016717 001

IOBENGUANE SULFATE I-131
INJECTABLE;INJECTION
IOBENGUANE SULFATE I 131
PHARMALUCENCE 2.3mCi/ML N020084 001 Mar 25, 1994

IOCETAMIC ACID
TABLET;ORAL
CHOLEBRINE
MALLINCKRODT 750MG N017129 001

IODAMIDE MEGLUMINE
INJECTABLE;INJECTION
RENOVUE-65
BRACCO 65% N017902 001
RENOVUE-DIP
BRACCO 24% N017903 001

IODIPAMIDE MEGLUMINE
INJECTABLE;INJECTION
CHOLOGRAFIN MEGLUMINE
BRACCO 10.3% N009321 007
\+ 52% N009321 003

IODIPAMIDE SODIUM
INJECTABLE;INJECTION
CHOLOGRAFIN SODIUM
BRACCO 20% N009321 001

IODIXANOL
INJECTABLE;INJECTION
VISIPAQUE 270
GE HEALTHCARE 55% N020808 001 Aug 29, 1997

IODOHIPPURATE SODIUM I-123
INJECTABLE;INJECTION
NEPHROFLOW
GE HEALTHCARE 1mCi/ML N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131
INJECTABLE;INJECTION
HIPPURAN I 131
MALLINCKRODT 0.25mCi/ML N016666 001
HIPPUTOPE
BRACCO 1-2mCi/VIAL N015419 002
IODOHIPPURATE SODIUM I 131
PHARMALUCENCE 0.2mCi/ML N017313 001

IODOXAMATE MEGLUMINE
INJECTABLE;INJECTION
CHOLOVUE
BRACCO 9.9% N018077 001
40.3% N018076 001

IOFETAMINE HYDROCHLORIDE I-123
INJECTABLE;INJECTION
SPECTAMINE
IMP 1mCi/ML N019432 001 Dec 24, 1987

IOHEXOL					
INJECTABLE;INJECTION					
OMNIPAQUE 210					
	GE HEALTHCARE	45.3%	N018956	006	Jun 30, 1989
SOLUTION;INJECTION, ORAL, RECTAL					
OMNIPAQUE 240					
	GE HEALTHCARE	51.8%	N020608	001	Oct 24, 1995
SOLUTION;URETHRAL					
OMNIPAQUE 70					
	GE HEALTHCARE	15.1%	N018956	007	Jun 01, 1994
IOPAMIDOL					
INJECTABLE;INJECTION					
IOPAMIDOL					
	BAXTER HLTHCARE	41%	A074629	001	Nov 06, 1996
		51%	A074629	004	Mar 31, 1998
		61%	A074629	002	Nov 06, 1996
		76%	A074629	003	Nov 06, 1996
	HOSPIRA	61%	A074734	001	Dec 10, 1996
		76%	A074734	002	Dec 10, 1996
IOPAMIDOL-200					
	COOK IMAGING	41%	A074881	001	Jul 28, 2000
	HOSPIRA	41%	A074898	001	Dec 30, 1997
IOPAMIDOL-200 IN PLASTIC CONTAINER					
	HOSPIRA	41%	A074636	001	Dec 30, 1997
IOPAMIDOL-250					
	COOK IMAGING	51%	A074881	002	Jul 28, 2000
	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997
	HOSPIRA	51%	A074898	002	Dec 30, 1997
		51%	A075005	001	Feb 24, 1998
IOPAMIDOL-250 IN PLASTIC CONTAINER					
	HOSPIRA	51%	A074636	002	Dec 30, 1997
IOPAMIDOL-300					
	ABBVIE	61%	A074638	001	Apr 30, 1997
	COOK IMAGING	61%	A074881	003	Jul 28, 2000
	FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997
	HOSPIRA	61%	A074898	003	Dec 30, 1997
		61%	A075005	002	Feb 24, 1998
IOPAMIDOL-300 IN PLASTIC CONTAINER					
	HOSPIRA	61%	A074636	003	Dec 30, 1997
		61%	A074637	001	Apr 03, 1997
IOPAMIDOL-370					
	COOK IMAGING	76%	A074881	004	Jul 28, 2000
	FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997
	HOSPIRA	76%	A074898	004	Dec 30, 1997
		76%	A075005	003	Feb 24, 1998
IOPAMIDOL-370 IN PLASTIC CONTAINER					
	HOSPIRA	76%	A074636	004	Dec 30, 1997
ISOVUE-128					
	BRACCO	26%	N018735	005	Oct 21, 1986
ISOVUE-200					
	BRACCO	41%	N020327	001	Oct 12, 1994
IOPANOIC ACID					
TABLET;ORAL					
TELEPAQUE					
	GE HEALTHCARE	500MG	N008032	001	
IOPHENDYLATE					
INJECTABLE;INJECTION					
PANTOPAQUE					
	ALCON	100%	N005319	001	
IOPROMIDE					
INJECTABLE;INJECTION					
ULTRAVIST (PHARMACY BULK)					
+	BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004
ULTRAVIST 150					
+	BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995
ULTRAVIST 240					
+	BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995

IOPROMIDE
INJECTABLE;INJECTION
ULTRAVIST 300 IN PLASTIC CONTAINER
\+ BAYER HLTHCARE 62.3% N020220 005 Nov 18, 2008

IOTHALAMATE MEGLUMINE
INJECTABLE;INJECTION
CONRAY 30
\+ LIEBEL-FLARSHEIM 30% N016983 001
CONRAY 43
\+ LIEBEL-FLARSHEIM 43% N013295 002

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM
INJECTABLE;INJECTION
VASCORAY
MALLINCKRODT 52%;26% N016783 001

IOTHALAMATE SODIUM
INJECTABLE;INJECTION
ANGIO-CONRAY
MALLINCKRODT 80% N013319 001
CONRAY 325
MALLINCKRODT 54.3% N017685 001
CONRAY 400
MALLINCKRODT 66.8% N014295 001

IOTROLAN
INJECTABLE;INTRATHECAL
OSMOVIST 190
BAYER HLTHCARE 40.6% N019580 001 Dec 07, 1989
OSMOVIST 240
BAYER HLTHCARE 51.3% N019580 002 Dec 07, 1989

IOVERSOL
INJECTABLE;INJECTION
OPTIRAY 160
LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988
OPTIRAY 240
LIEBEL-FLARSHEIM 51% N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM
INJECTABLE;INJECTION
HEXABRIX
GUERBET 39.3%;19.6% N018905 002 Jul 26, 1985

IOXILAN
INJECTABLE;INJECTION
OXILAN-300
GUERBET 62% N020316 001 Dec 21, 1995
OXILAN-350
GUERBET 73% N020316 002 Dec 21, 1995

IPODATE CALCIUM
GRANULE;ORAL
ORAGRAFIN CALCIUM
BRACCO 3GM/PACKET N012968 001

IPODATE SODIUM
CAPSULE;ORAL
BILIVIST
BAYER HLTHCARE 500MG A087768 001 Aug 11, 1982
ORAGRAFIN SODIUM
BRACCO 500MG N012967 001

IPRATROPIUM BROMIDE
AEROSOL, METERED;INHALATION
ATROVENT
BOEHRINGER INGELHEIM 0.018MG/INH N019085 001 Dec 29, 1986
SOLUTION;INHALATION
ATROVENT
\+ BOEHRINGER INGELHEIM 0.02% ** N020228 001 Sep 29, 1993
IPRATROPIUM BROMIDE
ACTAVIS MID ATLANTIC 0.02% A075111 001 Apr 22, 1999
APOTEX INC 0.02% A075441 001 Mar 28, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IPRATROPIUM BROMIDE				
SOLUTION;INHALATION				
IPRATROPIUM BROMIDE				
BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001
MYLAN SPECIALITY LP	0.02%	A074755	001	Jan 10, 1997
PHARMASCIENCE INC	0.02%	A075507	001	Jan 19, 2001
ROXANE	0.02%	A075867	001	Jul 22, 2002
TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000
SPRAY, METERED;NASAL				
ATROVENT				
+ BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995
+	0.042MG/SPRAY	N020394	001	Oct 20, 1995
IPRATROPIUM BROMIDE				
APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003
MYLAN SPECIALITY LP	0.021MG/SPRAY	A075552	001	Mar 31, 2003
	0.042MG/SPRAY	A075553	001	Mar 31, 2003
IRBESARTAN				
TABLET;ORAL				
IRBESARTAN				
AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015
	150MG	A203685	002	Dec 10, 2015
	300MG	A203685	003	Dec 10, 2015
APOTEX INC	75MG	A200832	001	Oct 15, 2012
	150MG	A200832	002	Oct 15, 2012
	300MG	A200832	003	Oct 15, 2012
MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012
	150MG	A200461	002	Sep 27, 2012
	300MG	A200461	003	Sep 27, 2012
WATSON LABS INC	75MG	A090720	001	Oct 12, 2012
	150MG	A090720	002	Oct 12, 2012
	300MG	A090720	003	Oct 12, 2012
IRINOTECAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
IRINOTECAN HYDROCHLORIDE				
FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008
SANDOZ	40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008
SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009
	100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009
SUN PHARMA GLOBAL	40MG/2ML (20MG/ML)	A078805	001	Apr 21, 2008
	100MG/5ML (20MG/ML)	A078805	002	Apr 21, 2008
IRON DEXTRAN				
INJECTABLE;INJECTION				
DEXFERRUM				
LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
IRON DEXTRAN				
SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	
PROFERDEX				
NEW RIVER	EQ 50MG IRON/ML	N017807	001	
IRON SUCROSE				
INJECTABLE;INTRAVENOUS				
VENOFER				
AM REGENT	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013
	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005
ISOETHARINE HYDROCHLORIDE				
SOLUTION;INHALATION				
BETA-2				
NEPHRON	1%	A086711	001	
BRONKOSOL				
SANOFI AVENTIS US	0.25%	N012339	009	
	1%	N012339	008	
ISOETHARINE HYDROCHLORIDE				
ALPHARMA US PHARMS	1%	A087101	001	
ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982
	0.062%	A089614	001	Jun 13, 1991
	0.125%	A087938	001	Nov 15, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ISOETHARINE HYDROCHLORIDE

SOLUTION;INHALATION				
ISOETHARINE HYDROCHLORIDE				
	0.125%	A089615	001	Jun 13, 1991
	0.167%	A088470	001	Mar 14, 1984
	0.167%	A089616	001	Jun 13, 1991
	0.2%	A088471	001	Mar 14, 1984
	0.2%	A089617	001	Jun 13, 1991
	0.25%	A088472	001	Mar 14, 1984
	0.25%	A089618	001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
	0.14%	A088145	001	Mar 26, 1984
	0.25%	A088146	001	Aug 01, 1983
DEY	0.08%	A088187	001	Dec 03, 1982
	0.1%	A087389	001	
	0.17%	A087390	001	
	0.25%	A088188	001	Dec 03, 1982
	1%	A086763	001	
INTL MEDICATION	0.077%	A086651	001	
	0.08%	A086651	002	
	0.1%	A086651	003	
	0.143%	A086651	004	
	0.167%	A086651	005	
	0.2%	A086651	006	
	0.25%	A086651	007	
	1%	A086651	008	
PARKE DAVIS	0.5%	A085997	001	
	1%	A085889	001	
ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED;INHALATION				
BRONKOMETER				
SANOFI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984

ISOFLURANE

LIQUID;INHALATION				
ISOFLURANE				
HOSPIRA	99.9%	A074097	001	Jan 25, 1993
WATSON LABS INC	99.9%	A074393	001	May 12, 1995

ISOFLUROPHATE

OINTMENT;OPHTHALMIC				
FLOROPRYL				
MERCK	0.025%	N010656	001	

ISONIAZID

INJECTABLE;INJECTION				
NYDRAZID				
SANDOZ	100MG/ML **	N008662	001	
RIMIFON				
ROCHE	25MG/ML	N008420	002	
	100MG/ML	N008420	003	
SYRUP;ORAL				
ISONIAZID				
ANDA REPOSITORY	50MG/5ML	A081118	001	Jul 21, 1997
LANIAZID				
LANNETT	50MG/5ML	A089243	001	Feb 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ISONIAZID

SYRUP;ORAL					
RIMIFON					
	ROCHE	50MG/5ML	N008420	001	
TABLET;ORAL					
DOW-ISONIAZID					
	DOW PHARM	300MG	A080330	002	
HYZYD					
	MEDPOINTE PHARM HLC	100MG	A080134	003	
		300MG	A080134	004	
INH					
	NOVARTIS	300MG	A080935	001	
ISONIAZID					
	DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
		300MG	A088119	001	Mar 17, 1983
	HALSEY	50MG	A083632	001	
	HIKMA INTL PHARMS	100MG	A080212	001	
		300MG	A087425	001	
	IMPAX LABS	100MG	A080153	001	
	IVAX SUB TEVA PHARMS	100MG	A080270	001	
		300MG	A083610	001	
	LILLY	100MG	N008499	002	
		300MG	N008499	003	
	MK LABS	100MG	A080941	001	
	NEXGEN PHARMA INC	100MG	A084050	001	
	PANRAY	50MG	N008428	001	
		100MG	N008428	002	
		300MG	N008428	003	
	PERRIGO	100MG	A083060	001	
	PHARMAVITE	100MG	A085091	001	
	PHOENIX LABS NY	50MG	A080368	001	
		100MG	A080368	002	
	PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
		100MG	A080132	004	Jul 14, 1982
+	SANDOZ	100MG	N008678	002	
+		300MG	N008678	003	
	SUN PHARM INDUSTRIES	100MG	A080136	001	
		300MG	A083633	001	
	WATSON LABS	50MG	A080522	001	
		100MG	A080401	001	
		100MG	A080523	001	
		100MG	A085790	001	
		300MG	A080521	001	
		300MG	A083178	001	
		300MG	A085784	001	
	WHITEWORTH TOWN PLSN	100MG	A080120	002	
LANIAZID					
	LANNETT	50MG	A080140	001	
		100MG	A080140	002	
		300MG	A089776	001	Jun 13, 1988
NYDRAZID					
	BRISTOL MYERS SQUIBB	100MG	N008392	003	
STANOZIDE					
	EVERYLIFE	100MG	A080126	001	
		300MG	A080126	002	

ISONIAZID; RIFAMPIN

CAPSULE;ORAL					
RIFAMPIN AND ISONIAZID					
	HIKMA INTL PHARMS	150MG;300MG	A065221	001	Jul 29, 2005

ISOPROPAMIDE IODIDE

TABLET;ORAL					
DARBID					
	GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001	

ISOPROPYL ALCOHOL				
SOLUTION;TOPICAL				
ZURAGARD				
+ ZUREX PHARMA	70% (10.5ML)	N210872	001	Apr 26, 2019
ISOPROTERENOL HYDROCHLORIDE				
AEROSOL, METERED;INHALATION				
ISOPROTERENOL HYDROCHLORIDE				
3M	0.12MG/INH	N010375	004	
ALPHARMA US PHARMS	0.12MG/INH	A085904	001	
ISUPREL				
SANOFI AVENTIS US	0.103MG/INH	N011178	001	
DISC;INHALATION				
NORISODRINE AEROTROL				
ABBOTT	0.25%	N016814	001	
INJECTABLE;INJECTION				
ISOPROTERENOL HYDROCHLORIDE				
ABRAXIS PHARM	0.2MG/ML	A083431	001	
BAXTER HLTHCARE	0.2MG/ML	A083486	001	
HOSPIRA	0.02MG/ML	A083283	001	
	0.2MG/ML	A083346	001	
INTL MEDICATION	0.2MG/ML	A083724	001	
SOLUTION;INHALATION				
AEROLONE				
LILLY	0.25%	N007245	001	
ISOPROTERENOL HYDROCHLORIDE				
ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
	0.062%	A087936	001	Nov 18, 1982
DEY	0.5%	A086764	001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994	001	
	0.5%	A085540	001	
ISUPREL				
SANOFI AVENTIS US	0.5%	N006327	002	
	1%	N006327	003	
VAPO-ISO				
FISONS	0.5%	N016813	001	
TABLET;RECTAL, SUBLINGUAL				
ISUPREL				
SANOFI AVENTIS US	10MG	N006328	001	
	15MG	N006328	002	
ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE				
AEROSOL, METERED;INHALATION				
DUO-MEDIHALER				
3M	0.16MG/INH;0.24MG/INH	N013296	001	
ISOPROTERENOL SULFATE				
AEROSOL, METERED;INHALATION				
MEDIHALER-ISO				
3M	0.08MG/INH	N010375	003	
POWDER;INHALATION				
NORISODRINE				
ABBVIE	10%	N006905	003	
	25%	N006905	002	
ISOSORBIDE				
SOLUTION;ORAL				
ISMOTIC				
ALCON	100GM/220ML	N017063	001	
ISOSORBIDE DINITRATE				
CAPSULE, EXTENDED RELEASE;ORAL				
ISORDIL				
WYETH AYERST	40MG	N012882	002	Jul 29, 1988
TABLET;ORAL				
ISORDIL				
+ BAUSCH	10MG **	N012093	002	Jul 29, 1988
+	20MG **	N012093	006	Jul 29, 1988
+	30MG **	N012093	005	Jul 29, 1988
ISOSORBIDE DINITRATE				
ANI PHARMS INC	10MG	A086032	001	Jan 07, 1988
SUN PHARM INDUSTRIES	5MG	A086166	002	Sep 19, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ISOSORBIDE DINITRATE					
TABLET;ORAL					
ISOSORBIDE DINITRATE					
		10MG	A086169	001	Sep 19, 1986
		20MG	A086167	001	Sep 19, 1986
		30MG	A087564	001	Sep 18, 1986
	SUPERPHARM	5MG	A089190	001	Feb 17, 1987
		10MG	A089191	001	Feb 17, 1987
		20MG	A089192	001	Feb 17, 1987
	WATSON LABS	5MG	A086034	001	Jan 06, 1988
SORBITRATE					
	ASTRAZENECA	5MG	N016192	001	Apr 01, 1996
		10MG	N016192	002	Apr 01, 1996
		20MG	A086405	002	Aug 21, 1990
		30MG	A088124	001	Aug 21, 1990
		40MG	A088125	001	Aug 21, 1990
TABLET;SUBLINGUAL					
ISORDIL					
+	BIOVAIL	2.5MG **	N012940	004	Jul 29, 1988
+		5MG **	N012940	003	Jul 29, 1988
+		10MG **	N012940	005	Jul 29, 1988
ISOSORBIDE DINITRATE					
	HIKMA INTL PHARMS	2.5MG	A086054	001	Oct 29, 1987
		5MG	A086055	001	Nov 02, 1987
	SANDOZ	2.5MG	A086225	001	Feb 19, 1988
		5MG	A086222	001	Feb 19, 1988
	SUN PHARM INDUSTRIES	2.5MG	A084204	001	Sep 18, 1986
		5MG	A086168	001	Sep 18, 1986
		10MG	A087545	001	Sep 18, 1986
	WATSON LABS	2.5MG **	A086033	001	Feb 26, 1988
	WATSON LABS TEVA	5MG **	A086031	001	Sep 29, 1987
SORBITRATE					
	ASTRAZENECA	2.5MG	N016191	002	Apr 01, 1996
		5MG	N016191	001	Apr 01, 1996
TABLET, CHEWABLE;ORAL					
SORBITRATE					
	ASTRAZENECA	5MG	N016776	002	Apr 01, 1996
		10MG	N016776	003	Apr 01, 1996
TABLET, EXTENDED RELEASE;ORAL					
ISORDIL					
	WYETH AYERST	40MG	N012882	001	Jul 29, 1988
ISOSORBIDE DINITRATE					
	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008
ISOSORBIDE MONONITRATE					
TABLET;ORAL					
ISMO					
	PROMIUS PHARMA	20MG	N019091	001	Dec 30, 1991
ISOSORBIDE MONONITRATE					
	ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998
TABLET, EXTENDED RELEASE;ORAL					
IMDUR					
+	SCHERING PLOUGH	30MG **	N020225	001	Aug 12, 1993
+		60MG **	N020225	002	Aug 12, 1993
+		120MG **	N020225	003	Mar 30, 1995
ISOSORBIDE MONONITRATE					
	ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017
		60MG	A209684	002	Oct 24, 2017
		120MG	A209684	003	Oct 24, 2017
	ACTAVIS ELIZABETH	30MG	A075306	001	Dec 31, 1998
		60MG	A075306	002	Dec 31, 1998
	ALKERMES GAINESVILLE	60MG	A075041	001	Sep 22, 1998
	IVAX SUB TEVA PHARMS	30MG	A075448	002	Aug 07, 2001
		60MG	A075448	001	Jun 19, 2000
		120MG	A075448	003	Aug 07, 2001
	SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOSULFAN BLUE				
INJECTABLE;INJECTION				
ISOSULFAN BLUE				
BELOTECA INC	1%	A210714	001	Jan 16, 2019
SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019
LYMPHAZURIN				
+ COVIDIEN	1% **	N018310	001	
ISOTRETINOIN				
CAPSULE;ORAL				
ACCUTANE				
+ HOFFMANN LA ROCHE	10MG **	N018662	002	May 07, 1982
+	20MG **	N018662	004	Mar 28, 1983
+	40MG **	N018662	003	May 07, 1982
SOTRET				
SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002
	20MG	A076041	002	Dec 24, 2002
	30MG	A076503	001	Jun 20, 2003
	40MG	A076041	003	Dec 24, 2002
ISRADIPINE				
CAPSULE;ORAL				
DYNACIRC				
+ SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990
+	5MG	N019546	002	Dec 20, 1990
TABLET, EXTENDED RELEASE;ORAL				
DYNACIRC CR				
+ GLAXOSMITHKLINE LLC	5MG **	N020336	001	Jun 01, 1994
+	10MG **	N020336	002	Jun 01, 1994
ISRADIPINE				
MYLAN	5MG	A201067	001	Nov 27, 2015
	10MG	A201067	002	Nov 27, 2015
ITRACONAZOLE				
INJECTABLE;INJECTION				
SPORANOX				
JANSSEN PHARMS	10MG/ML	N020966	001	Mar 30, 1999
IVERMECTIN				
TABLET;ORAL				
STROMECTOL				
MERCK SHARP DOHME	6MG	N050742	001	Nov 22, 1996
KANAMYCIN SULFATE				
CAPSULE;ORAL				
KANTREX				
APOTHECON	EQ 500MG BASE	A060516	001	
	EQ 500MG BASE	A061911	001	
	EQ 500MG BASE	A062726	001	Mar 06, 1987
INJECTABLE;INJECTION				
KANAMYCIN				
WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001	
	EQ 500MG BASE/2ML	A062324	002	
	EQ 1GM BASE/3ML	A062324	003	
KANAMYCIN SULFATE				
ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504	001	Apr 05, 1984
	EQ 500MG BASE/2ML	A062504	002	Apr 05, 1984
	EQ 1GM BASE/3ML	A062504	003	Apr 05, 1984
FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002
	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002
INTL MEDICATION	EQ 500MG BASE/2ML	A062466	001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466	002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML	A063021	001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022	001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025	001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668	001	May 07, 1987
	EQ 500MG BASE/2ML	A062672	001	May 07, 1987
	EQ 1GM BASE/3ML	A062669	001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605	003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605	001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605	002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092	001	Oct 11, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

KANAMYCIN SULFATE				
INJECTABLE;INJECTION				
KANAMYCIN SULFATE				
WATSON LABS	EQ 1GM BASE/3ML	A062520	003	May 09, 1985
KANTREX				
APOTHECON	EQ 75MG BASE/2ML	A061655	003	
	EQ 75MG BASE/2ML	A061901	003	
	EQ 75MG BASE/2ML	A062564	001	Sep 21, 1984
	EQ 500MG BASE/2ML	A061655	001	
	EQ 500MG BASE/2ML	A061901	001	
	EQ 500MG BASE/2ML	A062564	002	Sep 21, 1984
	EQ 1GM BASE/3ML	A061655	002	
	EQ 1GM BASE/3ML	A061901	002	
	EQ 1GM BASE/3ML	A062564	003	Sep 21, 1984
KLEBCIL				
KING PHARMS	EQ 75MG BASE/2ML	A062170	001	
	EQ 500MG BASE/2ML	A062170	002	
	EQ 1GM BASE/3ML	A062170	003	
KETOCONAZOLE				
CREAM;TOPICAL				
NIZORAL				
+ JANSSEN PHARMA	2% **	N019084	001	Dec 31, 1985
SUSPENSION;ORAL				
NIZORAL				
JANSSEN PHARMA	100MG/5ML	A070767	001	Nov 07, 1986
TABLET;ORAL				
KETOCONAZOLE				
AAIPHARMA LLC	200MG	A075341	001	Jul 27, 1999
HAVIX	200MG	A075912	001	Jan 10, 2002
HERITAGE PHARMA	200MG	A074971	001	Jun 15, 1999
	200MG	A075362	001	Jun 15, 1999
SUN PHARM INDUSTRIES	200MG	A075314	001	Jun 15, 1999
TEVA	200MG	A075273	001	Jun 15, 1999
NIZORAL				
+ JANSSEN PHARMS	200MG **	N018533	001	
KETOPROFEN				
CAPSULE;ORAL				
KETOPROFEN				
AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995
	75MG	A074024	002	Dec 29, 1995
MYLAN	50MG	A074035	002	Dec 31, 1996
	75MG	A074035	003	Dec 31, 1996
TEVA	25MG	A073515	001	Dec 22, 1992
ORUDIS				
+ WYETH AYERST	25MG **	N018754	001	Jul 31, 1987
+	50MG **	N018754	002	Jan 09, 1986
+	75MG **	N018754	003	Jan 09, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
KETOPROFEN				
ACTAVIS LABS FL INC	100MG	A075270	002	Mar 24, 1999
	150MG	A075270	003	Mar 24, 1999
	200MG	A075270	001	Mar 24, 1999
ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
MYLAN	100MG	A075679	003	Feb 20, 2002
	150MG	A075679	002	Feb 20, 2002
ORUVAIL				
+ WYETH PHARMS INC	100MG **	N019816	003	Feb 08, 1995
+	150MG **	N019816	002	Feb 08, 1995
+	200MG **	N019816	001	Sep 24, 1993
FILM;ORAL				
NEXCEDE				
NOVARTIS	12.5MG	N022470	001	Nov 25, 2009
TABLET;ORAL				
ACTRON				
BAYER	12.5MG	N020499	001	Oct 06, 1995
KETOPROFEN				
PERRIGO	12.5MG	A075364	001	Feb 07, 2002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

KETOPROFEN					
TABLET;ORAL					
ORUDIS KT					
+	WYETH CONS	12.5MG **	N020429	001	Oct 06, 1995
KETOROLAC TROMETHAMINE					
INJECTABLE;INJECTION					
KETOROLAC TROMETHAMINE					
	APOTEX INC	30MG/ML	A075626	001	Jul 24, 2001
		30MG/ML	A077201	001	Oct 14, 2005
	APOTHECON	15MG/ML	A075348	001	Nov 28, 2000
		30MG/ML	A075348	002	Nov 28, 2000
	BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001
		30MG/ML	A075631	001	Jun 29, 2001
	BEDFORD	15MG/ML	A075230	002	Oct 25, 1999
		30MG/ML	A075230	001	Oct 25, 1999
	GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
		30MG/ML	A076722	002	Jul 27, 2004
	HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997
		30MG/ML	A074801	002	Jun 05, 1997
	LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008
		30MG/ML	A078145	002	Jan 14, 2008
	MYLAN LABS LTD	15MG/ML	A078299	001	Jul 16, 2007
		15MG/ML	A201155	001	Aug 04, 2014
		30MG/ML	A078299	002	Jul 16, 2007
		30MG/ML	A201155	002	Aug 04, 2014
	SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004
	SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008
		30MG/ML	A078737	002	Oct 06, 2008
	WEST-WARD PHARMS INT	15MG/ML **	A075222	001	Apr 26, 1999
		15MG/ML	A075299	001	Nov 03, 1999
		30MG/ML **	A075222	002	Apr 26, 1999
		30MG/ML **	A075228	001	Apr 26, 1999
		30MG/ML	A075299	002	Nov 03, 1999
	WOCKHARDT	30MG/ML	A077943	001	Mar 27, 2007
TORADOL					
+	ROCHE PALO	15MG/ML **	N019698	001	Nov 30, 1989
+		30MG/ML **	N019698	002	Nov 30, 1989
SOLUTION/DROPS;OPHTHALMIC					
ACULAR PRESERVATIVE FREE					
	ALLERGAN	0.5%	N020811	001	Nov 03, 1997
KETOROLAC TROMETHAMINE					
	AKORN	0.45%	A203376	001	Feb 10, 2014
	AUROBINDO PHARMA LTD	0.4%	A205191	001	Nov 15, 2018
	SANDOZ INC	0.4%	A078721	001	Nov 05, 2009
TABLET;ORAL					
KETOROLAC TROMETHAMINE					
	CYCLE PHARMS LTD	10MG	A074790	001	Jun 26, 1997
	WATSON LABS	10MG	A074955	001	Sep 19, 1997
TORADOL					
+	ROCHE PALO	10MG **	N019645	001	Dec 20, 1991
KETOTIFEN FUMARATE					
SOLUTION/DROPS;OPHTHALMIC					
ZADITOR					
+	ALCON PHARMA	EQ 0.025% BASE **	N021066	002	Oct 19, 2006
KRYPTON, KR-81M					
GAS;INHALATION					
MPI KRYPTON 81M GENERATOR					
	GE HEALTHCARE	N/A	N018088	001	
L-GLUTAMINE					
FOR SOLUTION;ORAL					
NUTRESTORE					
+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LABETALOL HYDROCHLORIDE					
INJECTABLE;INJECTION					
LABETALOL HYDROCHLORIDE					
	AKORN INC	5MG/ML	A075524	001	Nov 29, 1999
	APOTHECON	5MG/ML	A075355	001	Nov 29, 1999
	BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002
	HOSPIRA	5MG/ML	A075242	001	Sep 30, 1999
	MYLAN ASI	5MG/ML	A079134	001	Feb 03, 2010
NORMODYNE					
	SCHERING	5MG/ML	N018686	001	Aug 01, 1984
TRANDATE					
+	SEBELA IRELAND LTD	5MG/ML **	N019425	001	Dec 31, 1985
TABLET;ORAL					
LABETALOL HYDROCHLORIDE					
	APOTHECON	100MG	A075223	001	Nov 20, 1998
		200MG	A075223	002	Nov 20, 1998
		300MG	A075223	003	Nov 20, 1998
	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998
		200MG	A074787	002	Aug 03, 1998
		300MG	A074787	003	Aug 03, 1998
	TEVA	100MG	A074989	001	Sep 30, 1998
		200MG	A074989	002	Sep 30, 1998
		300MG	A074989	003	Sep 30, 1998
NORMODYNE					
+	SCHERING	100MG **	N018687	001	Aug 31, 1987
+		200MG **	N018687	002	Aug 01, 1984
+		300MG **	N018687	003	Aug 01, 1984
+		400MG **	N018687	004	Aug 01, 1984
TRANDATE					
+	CNTY LINE PHARMS	400MG **	N018716	004	Aug 01, 1984
LACTULOSE					
SOLUTION;ORAL					
CHRONULAC					
+	SANOFI AVENTIS US	10GM/15ML **	N017884	001	
CONSTULOSE					
	ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988
DUPHALAC					
	SOLVAY	10GM/15ML	A072372	001	Mar 22, 1989
EVALOSE					
	TEVA PHARMS	10GM/15ML	A073497	001	May 28, 1993
LACTULOSE					
	ANI PHARMS	10GM/15ML	A078430	001	Nov 28, 2007
	MORTON GROVE	10GM/15ML	A071841	001	Sep 22, 1988
	PACO	10GM/15ML	A073160	001	Aug 25, 1992
	TORRENT	10GM/15ML	A207786	001	Jun 11, 2018
LAXILOSE					
	NOSTRUM LABS	10GM/15ML	A073686	001	May 28, 1993
SOLUTION;ORAL, RECTAL					
ACILAC					
	NOSTRUM LABS	10GM/15ML	A073685	001	May 28, 1993
CEPHULAC					
+	SANOFI AVENTIS US	10GM/15ML **	N017657	001	
GENERLAC					
	MORTON GROVE	10GM/15ML	A071842	001	Sep 27, 1988
HEPTALAC					
	TEVA PHARMS	10GM/15ML	A073504	001	May 28, 1993
LACTULOSE					
	ANI PHARMS	10GM/15ML	A090426	001	Nov 21, 2008
	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003
	PACO	10GM/15ML	A072029	001	Aug 25, 1992
	ROXANE	10GM/15ML	A073590	001	May 29, 1992
	SOLVAY	10GM/15ML	N017906	001	
	TORRENT	10GM/15ML	A203762	001	Mar 27, 2015
PORTALAC					
	SOLVAY	10GM/15ML	A072374	001	Mar 22, 1989

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LAMIVUDINE				
TABLET;ORAL				
LAMIVUDINE				
MYLAN	100MG	A204002	001	Dec 31, 2014
	150MG	A204528	001	Mar 04, 2016
	300MG	A204528	002	Mar 04, 2016
LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE				
TABLET;ORAL				
LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE				
+ MICRO LABS	150MG;200MG;300MG	N205626	001	Aug 13, 2018
LAMIVUDINE; RALTEGRAVIR POTASSIUM				
TABLET;ORAL				
DUTREBIS				
MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015
LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE				
TABLET;ORAL				
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE				
AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018
LAMIVUDINE; ZIDOVUDINE				
TABLET;ORAL				
LAMIVUDINE AND ZIDOVUDINE				
MYLAN	150MG;300MG	A079079	001	Aug 12, 2019
	150MG;300MG	A204005	001	Aug 28, 2014
PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017
TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011
LAMOTRIGINE				
TABLET;ORAL				
LAMICTAL				
+ GLAXOSMITHKLINE LLC	50MG **	N020241	006	Dec 27, 1994
+	250MG **	N020241	004	Dec 27, 1994
LAMOTRIGINE				
ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
	100MG	A078669	002	Apr 08, 2011
	150MG	A078669	003	Apr 08, 2011
	200MG	A078669	004	Apr 08, 2011
CELLTRION	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009
HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
	100MG	A078134	002	Apr 19, 2011
	150MG	A078134	003	Apr 19, 2011
	200MG	A078134	004	Apr 19, 2011
MYLAN	25MG	A077428	001	Jan 27, 2009
	100MG	A077428	002	Jan 27, 2009
	150MG	A077428	003	Jan 27, 2009
	200MG	A077428	004	Jan 27, 2009
MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
SANDOZ	25MG	A078645	001	Jan 27, 2009
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
TEVA	25MG	A076388	001	Aug 30, 2006
	100MG	A076388	002	Aug 30, 2006
	150MG	A076388	003	Aug 30, 2006
	200MG	A076388	004	Aug 30, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LAMOTRIGINE				
TABLET, CHEWABLE;ORAL				
LAMICTAL CD				
GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998
LAMOTRIGINE				
MYLAN	5MG	A076630	001	Jan 22, 2009
	25MG	A076630	002	Jan 22, 2009
SANDOZ	5MG	A078409	002	Jan 22, 2009
	25MG	A078409	003	Jan 22, 2009
TEVA	5MG	A076420	001	Jun 21, 2006
	25MG	A076420	002	Jun 21, 2006
TABLET, EXTENDED RELEASE;ORAL				
LAMOTRIGINE				
RUBICON	25MG	A202887	001	Jun 17, 2013
	50MG	A202887	002	Jun 17, 2013
LANSOPRAZOLE				
CAPSULE, DELAYED REL PELLETS;ORAL				
LANSOPRAZOLE				
AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016
	30MG	A203957	002	Oct 14, 2016
BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018
	30MG	A203964	002	Oct 17, 2018
KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013
	30MG	A091212	002	Sep 16, 2013
FOR SUSPENSION, DELAYED RELEASE;ORAL				
PREVACID				
TAKEDA PHARMS NA	15MG/PACKET	N021281	001	May 03, 2001
	30MG/PACKET	N021281	002	May 03, 2001
INJECTABLE;INTRAVENOUS				
PREVACID IV				
+ TAKEDA PHARMS NA	30MG/VIAL **	N021566	001	May 27, 2004
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
LANSOPRAZOLE				
ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010
	30MG	A078730	002	Oct 15, 2010
LANSOPRAZOLE; NAPROXEN				
CAPSULE, DELAYED REL PELLETS, TABLET;ORAL				
PREVACID NAPRAPAC 250 (COPACKAGED)				
+ TAKEDA PHARMS NA	15MG,N/A;N/A,250MG **	N021507	002	Nov 14, 2003
PREVACID NAPRAPAC 375 (COPACKAGED)				
TAKEDA PHARMS NA	15MG,N/A;N/A,375MG	N021507	003	Nov 14, 2003
PREVACID NAPRAPAC 500 (COPACKAGED)				
TAKEDA PHARMS NA	15MG,N/A;N/A,500MG	N021507	004	Nov 14, 2003
LANTHANUM CARBONATE				
TABLET, CHEWABLE;ORAL				
FOSRENOL				
SHIRE LLC	EQ 250MG BASE	N021468	001	Oct 26, 2004
LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX				
SOLUTION;TOPICAL				
VIRAC REX				
CHESEBROUGH PONDS	0.5%;1.8%	N011914	001	
LATANOPROST				
SOLUTION/DROPS;OPHTHALMIC				
LATANOPROST				
APOTEX INC	0.005%	A077697	001	Mar 22, 2011
LEFLUNOMIDE				
TABLET;ORAL				
LEFLUNOMIDE				
FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005
	20MG	A077087	002	Sep 13, 2005
SANDOZ	10MG	A077085	001	Sep 13, 2005
	20MG	A077085	002	Sep 13, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEPIRUDIN RECOMBINANT					
INJECTABLE;INJECTION					
REFLUDAN					
	BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998
LESINURAD					
TABLET;ORAL					
ZURAMPIC					
+	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015
LETROZOLE					
TABLET;ORAL					
LETROZOLE					
	ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011
	FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011
	IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011
	LANNETT CO INC	2.5MG	A091098	001	Jun 03, 2011
		2.5MG	A202048	001	Oct 29, 2014
	MYLAN	2.5MG	A078190	001	Dec 24, 2008
	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011
	SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011
LEUCOVORIN CALCIUM					
FOR SOLUTION;ORAL					
LEUCOVORIN CALCIUM					
	HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987
INJECTABLE;INJECTION					
LEUCOVORIN CALCIUM					
	ABIC	EQ 3MG BASE/ML	A089352	001	Jun 01, 1988
		EQ 50MG BASE/VIAL	A089353	001	Jun 01, 1988
	ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939	001	Dec 01, 1986
	ELKINS SINN	EQ 50MG BASE/VIAL	A070480	001	Jan 02, 1987
		EQ 100MG BASE/VIAL	A081224	001	Jun 03, 1994
+	HOSPIRA	EQ 3MG BASE/ML **	N008107	001	
+		EQ 50MG BASE/VIAL **	N008107	002	
+		EQ 100MG BASE/VIAL **	N008107	004	May 23, 1988
+		EQ 350MG BASE/VIAL **	N008107	005	Apr 05, 1989
	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018
	PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
	PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
		EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993
LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	AM REGENT	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
	HOSPIRA	EQ 10MG BASE/ML **	A040147	001	Jun 25, 1997
	TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999
WELLCOVORIN					
	GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
		EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
		EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
		EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989
TABLET;ORAL					
LEUCOVORIN CALCIUM					
	ANI PHARMS INC	EQ 15MG BASE	A075327	001	Mar 24, 1999
	EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997
		EQ 25MG BASE	A074544	002	Aug 28, 1997
	PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
		EQ 25MG BASE	A071598	001	Oct 14, 1987
	PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
		EQ 25MG BASE	A073101	001	Mar 28, 1997
	XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986
		EQ 10MG BASE	A071962	001	Nov 19, 1987
		EQ 15MG BASE	A071104	001	Mar 04, 1987
WELLCOVORIN					
+	GLAXOSMITHKLINE	EQ 5MG BASE **	N018342	001	Jul 08, 1983
+		EQ 25MG BASE **	N018342	002	Jul 08, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEUPROLIDE ACETATE					
FOR SUSPENSION;INTRAMUSCULAR					
LUTRATE DEPOT KIT					
+	GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018
IMPLANT;IMPLANTATION					
VIADUR					
	ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088	001	Mar 03, 2000
INJECTABLE;INJECTION					
LEUPROLIDE ACETATE					
	GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001
LUPRON					
+	ABBVIE ENDOCRINE INC	1MG/0.2ML **	N019010	001	Apr 09, 1985
LUPRON DEPOT					
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL **	N020011	001	Oct 22, 1990
LUPRON DEPOT-PED					
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL,7.5MG/VIAL **	N020263	003	Apr 16, 1993
+		7.5MG/VIAL,7.5MG/VIAL **	N020263	004	Apr 16, 1993
LEVALBUTEROL HYDROCHLORIDE					
SOLUTION;INHALATION					
LEVALBUTEROL HYDROCHLORIDE					
	MYLAN SPECIALITY LP	EQ 0.0103% BASE	A077800	001	Mar 15, 2013
		EQ 0.021% BASE	A077800	002	Mar 15, 2013
		EQ 0.042% BASE	A077800	003	Mar 15, 2013
LEVALLORPHAN TARTRATE					
INJECTABLE;INJECTION					
LORFAN					
	ROCHE	1MG/ML	N010423	001	
LEVAMISOLE HYDROCHLORIDE					
TABLET;ORAL					
ERGAMISOL					
	JANSSEN PHARMA	EQ 50MG BASE	N020035	001	Jun 18, 1990
LEVETIRACETAM					
INJECTABLE;INTRAVENOUS					
LEVETIRACETAM					
	AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018
	AM REGENT	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012
SOLUTION;ORAL					
LEVETIRACETAM					
	ACI HEALTHCARE LTD	100MG/ML	A078582	001	Jan 15, 2009
	APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011
TABLET;ORAL					
LEVETIRACETAM					
	ACTAVIS LABS FL INC	250MG	A077408	001	Mar 02, 2009
		500MG	A077408	002	Mar 02, 2009
		750MG	A077408	003	Mar 02, 2009
	FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009
		500MG	A077324	002	Jan 15, 2009
		750MG	A077324	003	Jan 15, 2009
		1GM	A077324	004	Jan 15, 2009
	MYLAN	250MG	A078731	001	Feb 10, 2009
		500MG	A078731	002	Feb 10, 2009
		750MG	A078731	003	Feb 10, 2009
		1GM	A078731	004	Feb 10, 2009
	WATSON LABS INC	250MG	A078797	002	Jan 15, 2009
		500MG	A078797	003	Jan 15, 2009
		750MG	A078797	004	Jan 15, 2009
		1GM	A078797	001	Jan 15, 2009
TABLET, EXTENDED RELEASE;ORAL					
LEVETIRACETAM					
	MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011
		750MG	A200475	002	Dec 19, 2011
		1GM	A200475	003	Dec 07, 2015
	SANDOZ	500MG	A091668	001	Nov 01, 2012
		750MG	A091668	002	Nov 01, 2012
	SUN PHARM INDUSTRIES	500MG	A091285	001	Sep 12, 2011
		750MG	A091285	002	Sep 12, 2011
	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LEVETIRACETAM				
TABLET, EXTENDED RELEASE;ORAL				
LEVETIRACETAM				
	750MG		A091291 002	Sep 12, 2011
LEVOBETAXOLOL HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
BETAXON				
ALCON PHARMS LTD	EQ 0.5% BASE		N021114 001	Feb 23, 2000
LEVOBUNOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
LEVOBUNOLOL HYDROCHLORIDE				
ALCON LABS INC	0.25%		A074851 001	Oct 28, 1996
APOTEX INC	0.25%		A075473 001	Aug 03, 2000
	0.5%		A075475 001	Aug 03, 2000
BAUSCH AND LOMB	0.25%		A074307 001	Mar 04, 1994
SANDOZ INC	0.5%		A074850 001	Oct 28, 1996
LEVOBUPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CHIROCAINE				
PURDUE PHARMA LP	EQ 2.5MG BASE/ML		N020997 001	Aug 05, 1999
	EQ 5MG BASE/ML		N020997 002	Aug 05, 1999
	EQ 7.5MG BASE/ML		N020997 003	Aug 05, 1999
LEVOCABASTINE HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
LIVOSTIN				
NOVARTIS	EQ 0.05% BASE		N020219 001	Nov 10, 1993
LEVOCARNITINE				
INJECTABLE;INJECTION				
LEVOCARNITINE				
TEVA PHARMS USA	200MG/ML		A075881 001	Mar 29, 2001
SOLUTION;ORAL				
CARNITOR				
LEADIANT BIOSCI INC	1GM/10ML		N018948 002	Apr 27, 1988
LEVOCETIRIZINE DIHYDROCHLORIDE				
TABLET;ORAL				
LEVOCETIRIZINE DIHYDROCHLORIDE				
FOSUN PHARMA	5MG		A090486 001	Mar 26, 2013
PERRIGO R AND D	5MG		A211983 001	Mar 28, 2019
LEVODOPA				
CAPSULE;ORAL				
BENDOPA				
VALEANT PHARM INTL	100MG		N016948 003	
	250MG		N016948 001	
	500MG		N016948 002	
DOPAR				
SHIRE	100MG		N016913 003	
	250MG		N016913 001	
	500MG		N016913 002	
LARODOPA				
ROCHE	100MG		N016912 002	
	250MG		N016912 001	
	500MG		N016912 006	
TABLET;ORAL				
DOPAR				
SHIRE	250MG		N016913 004	
	500MG		N016913 005	
LARODOPA				
ROCHE	100MG		N016912 005	
	250MG		N016912 003	
	500MG		N016912 004	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVOFLOXACIN					
INJECTABLE;INJECTION					
LEVAQUIN					
+	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996
+		EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **	N020635	002	Dec 20, 1996
+		EQ 500MG/100ML (EQ 5MG/ML) **	N020635	003	Dec 20, 1996
+		EQ 750MG/150ML (EQ 5MG/ML) **	N020635	005	Dec 20, 1996
LEVOFLOXACIN					
	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013
		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013
	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015
		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015
	MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011
		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011
	ZYDUS PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017
		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017
SOLUTION;ORAL					
LEVAQUIN					
+	JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004
SOLUTION/DROPS;OPHTHALMIC					
IQUIX					
+	SANTEN	1.5% **	N021571	001	Mar 01, 2004
LEVOFLOXACIN					
	APOTEX INC	0.5%	A078282	001	Dec 20, 2010
QUIXIN					
+	SANTEN	0.5% **	N021199	001	Aug 18, 2000
TABLET;ORAL					
LEVAQUIN					
+	JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996
+		500MG	N020634	002	Dec 20, 1996
+		750MG	N020634	003	Sep 08, 2000
LEVOFLOXACIN					
	MYLAN	250MG	A076276	001	Jun 20, 2011
		500MG	A076276	002	Jun 20, 2011
		750MG	A077097	001	Jun 20, 2011
	WATSON LABS INC	250MG	A201484	001	Nov 22, 2013
		500MG	A201484	002	Nov 22, 2013
		750MG	A201484	003	Nov 22, 2013
LEVOLEUCOVORIN CALCIUM					
POWDER;INTRAVENOUS					
LEVOLEUCOVORIN CALCIUM					
+	ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016
SOLUTION;INTRAVENOUS					
FUSILEV					
+	ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **	N020140	002	Apr 29, 2011
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **	N020140	003	Apr 29, 2011
LEVOLEUCOVORIN CALCIUM					
	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015
		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015
LEVOMEPROMAZINE					
INJECTABLE;INJECTION					
LEVOPROME					
	IMMUNEX	20MG/ML	N015865	001	
LEVOMETHADYL ACETATE HYDROCHLORIDE					
CONCENTRATE;ORAL					
ORLAAM					
+	ROXANE	10MG/ML **	N020315	001	Jul 09, 1993
LEVOMILNACIPRAN HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
LEVOMILNACIPRAN HYDROCHLORIDE					
	AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019
		EQ 40MG BASE	A210790	002	Feb 04, 2019
		EQ 80MG BASE	A210790	003	Feb 04, 2019
		EQ 120MG BASE	A210790	004	Feb 04, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
	SOLVAY	0.05MG/ML;2%	A085010 001	
CARBOCAINE W/ NEO-COBEFRIN				
	EASTMAN KODAK	0.05MG/ML;2%	N012125 002	
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
	SEPTODONT INC	0.05MG/ML;2%	A084697 001	
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
	BELMORA LLC	0.05MG/ML;2%	A084850 002	Oct 21, 1983
POLOCAINE W/ LEVONORDEFRIN				
	DENTSPLY PHARM	0.05MG/ML;2%	A089517 001	Apr 14, 1988
LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN				
	EASTMAN KODAK	0.05MG/ML;2%;0.4%	N008592 007	
LEVONORGESTREL				
IMPLANT;IMPLANTATION				
JADELLE				
+	POPULATION COUNCIL	75MG/IMPLANT **	N020544 001	Nov 01, 1996
LEVONORGESTREL				
	WYETH PHARMS INC	75MG/IMPLANT	N020627 001	Aug 15, 1996
NORPLANT				
	POPULATION COUNCIL	36MG/IMPLANT	N019897 001	Dec 10, 1990
NORPLANT SYSTEM IN PLASTIC CONTAINER				
	WYETH PHARMS INC	36MG/IMPLANT	N020088 001	Dec 10, 1990
TABLET;ORAL				
LEVONORGESTREL				
	ACCORD HLTHCARE	1.5MG	A207660 001	May 02, 2019
	ALVOGEN	1.5MG	A202246 001	Jun 05, 2015
	APOTEX	1.5MG	A205329 001	Sep 18, 2018
	FDN CONSUMER	0.75MG **	A078665 001	Aug 28, 2009
		1.5MG	A200670 001	Jul 12, 2012
	LOTUS PHARM CO LTD	0.75MG	A202684 001	Sep 02, 2016
	LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013
	WATSON LABS	0.75MG	A078666 001	Jun 24, 2009
PLAN B				
+	FDN CONSUMER	0.75MG **	N021045 001	Jul 28, 1999
+		0.75MG **	N021045 002	Aug 24, 2006
LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS				
CAPSULE;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE	N012928 006	
		EQ 100MG BASE	N012928 004	
SUSPENSION;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE/5ML	N012928 002	
LEVORPHANOL TARTRATE				
INJECTABLE;INJECTION				
LEVO-DROMORAN				
	VALEANT PHARM INTL	2MG/ML	N008719 001	Dec 19, 1991
TABLET;ORAL				
LEVO-DROMORAN				
+	VALEANT PHARM INTL	2MG **	N008720 001	Dec 19, 1991
LEVORPHANOL TARTRATE				
	SENTYNL THERAPS INC	1MG	A074278 002	Jun 18, 2018
LEVOTHYROXINE SODIUM				
POWDER;INTRAVENOUS				
LEVOTHYROXINE SODIUM				
	PAR STERILE PRODUCTS	200MCG/VIAL	A205366 001	Dec 07, 2015
TABLET;ORAL				
EUTHYROX				
	PROVELL	0.3MG	N021292 012	May 31, 2002
LEVOLET				
	GENUS LIFESCIENCES	0.025MG	N021137 001	Jun 06, 2003
		0.05MG	N021137 002	Jun 06, 2003
		0.075MG	N021137 003	Jun 06, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVOTHYROXINE SODIUM					
TABLET;ORAL					
LEVOLET					
		0.088MG	N021137	004	Jun 06, 2003
		0.1MG	N021137	005	Jun 06, 2003
		0.112MG	N021137	006	Jun 06, 2003
		0.125MG	N021137	007	Jun 06, 2003
		0.137MG	N021137	008	Jun 06, 2003
		0.15MG	N021137	009	Jun 06, 2003
		0.175MG	N021137	010	Jun 06, 2003
		0.2MG	N021137	011	Jun 06, 2003
		0.3MG	N021137	012	Jun 06, 2003
LEVOTHYROXINE SODIUM					
	AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019
		0.05MG	A210831	002	Feb 19, 2019
		0.075MG	A210831	003	Feb 19, 2019
		0.088MG	A210831	004	Feb 19, 2019
		0.1MG	A210831	005	Feb 19, 2019
		0.112MG	A210831	006	Feb 19, 2019
		0.125MG	A210831	007	Feb 19, 2019
		0.137MG	A210831	008	Feb 19, 2019
		0.15MG	A210831	009	Feb 19, 2019
		0.175MG	A210831	010	Feb 19, 2019
		0.2MG	A210831	011	Feb 19, 2019
		0.3MG	A210831	012	Feb 19, 2019
	MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005
		0.05MG	A076752	002	Jun 16, 2005
		0.075MG	A076752	003	Jun 16, 2005
		0.088MG	A076752	004	Jun 16, 2005
		0.1MG	A076752	005	Jun 16, 2005
		0.112MG	A076752	006	Jun 16, 2005
		0.125MG	A076752	007	Jun 16, 2005
		0.15MG	A076752	008	Jun 16, 2005
		0.175MG	A076752	009	Jun 16, 2005
		0.2MG	A076752	010	Jun 16, 2005
		0.3MG	A076752	011	Jun 16, 2005
LEVOXYL					
+	KING PHARMS	0.3MG **	N021301	012	May 25, 2001
LIDOCAINE					
AEROSOL;ORAL					
XYLOCAINE					
	ASTRAZENECA	10%	N014394	001	
FILM, EXTENDED RELEASE;BUCCAL					
DENTIPATCH					
	NOVEN	23MG/PATCH	N020575	001	May 21, 1996
OINTMENT;TOPICAL					
ALPHACAINE					
	CARLISLE	5%	A084944	001	
		5%	A084946	001	
		5%	A084947	001	
LIDOCAINE					
	BELMORA LLC	5%	A080210	001	
XYLOCAINE					
+	ASTRAZENECA	5% **	N008048	001	
PATCH;TOPICAL					
DENTIPATCH					
	NOVEN	46.1MG/PATCH	N020575	002	May 21, 1996
SOLUTION;TOPICAL					
XYLOCAINE					
	ASTRAZENECA	5%	N014127	001	
SUPPOSITORY;RECTAL					
XYLOCAINE					
	ASTRAZENECA	100MG	N013077	001	

LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALPHACAINE HYDROCHLORIDE				
CARLISLE	2%	A084721	001	
LIDOCAINE HYDROCHLORIDE				
ABBOTT	10%	A087980	001	Feb 02, 1983
	20%	A089362	001	May 25, 1988
ABRAXIS PHARM	1%	A080420	001	
	1%	A086761	001	
	1.5%	A080420	005	
	2%	A080420	002	
	2%	A080420	004	
	2%	A086761	002	
	2%	N017508	001	
	4%	N017508	002	
	20%	N017508	004	
AKORN	1%	A085037	001	
	2%	A085037	002	
BEL MAR	1%	A080710	001	
	2%	A080760	001	
BELMORA LLC	2%	A080504	001	
DELL LABS	1%	A083387	001	
	2%	A083388	001	
ELKINS SINN	0.5%	A085131	001	
	4%	A084626	001	
GD SEARLE LLC	1%	A083135	001	
	2%	A083135	002	
HOSPIRA	1%	A040013	001	Jun 23, 1995
	1.5%	A088330	001	May 17, 1984
	2%	A088331	001	May 17, 1984
	20%	A083158	003	
INTL MEDICATION	1%	N017701	002	
	2%	N017701	001	
	1GM/VIAL	N018543	001	
	2GM/VIAL	N018543	002	
LUITPOLD	1%	A080850	001	
	1%	A091564	001	Aug 14, 2015
	2%	A083198	001	
LYPHOMED	1%	A080390	001	
	2%	A080390	002	
MILES	1%	A080414	001	
	2%	A080414	002	
MYLAN LABS LTD	0.5%	A091056	001	Dec 08, 2010
	0.5%	A091058	001	Sep 30, 2010
	1%	A091056	002	Dec 08, 2010
	1%	A091058	002	Sep 30, 2010
	2%	A202242	001	Apr 11, 2014
WATSON LABS	1%	A080377	001	
	1%	A083627	001	
	2%	A080377	002	
	2%	A083627	002	
WEST-WARD PHARMS INT	1%	A080407	001	
	2%	A080407	002	
WYETH AYERST	1%	A083083	001	
	2%	A083083	002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	100MG/100ML	N018461	001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N018967	001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%				
HOSPIRA	200MG/100ML	A083158	005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	200MG/100ML	N018954	001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388	001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	400MG/100ML	N018967	002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%				
HOSPIRA	400MG/100ML	A083158	006	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	400MG/100ML	N018388	002	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	800MG/100ML	N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER					
	HOSPIRA	1.5%	A088326	001	Jul 31, 1984
		10%	A088367	001	Jul 31, 1984
		20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
	INTL MEDICATION	4%	N017702	002	
		20%	N017702	001	
	MYLAN LABS LTD	2%	A090665	001	Sep 27, 2010
	WEST-WARD PHARMS INT	1%	A084625	001	
		2%	A084625	002	
LIDOCATON					
	PHARMATON	2%	A084727	001	Aug 17, 1983
LIDOPEN					
	MERIDIAN MEDCL TECHN	10%	N017549	001	
XYLOCAINE					
	ASTRAZENECA	1%	N010418	005	
		1.5%	N010418	009	
		2%	N010418	007	
XYLOCAINE 4% PRESERVATIVE FREE					
+	FRESENIUS KABI USA	4%	N010417	001	
XYLOCAINE DENTAL					
	DENTSPLY PHARM	2%	N021380	001	
XYLOCAINE PRESERVATIVE FREE					
+	FRESENIUS KABI USA	1%	N016801	005	Jan 19, 1988
+		2%	N016801	001	
+		4%	N016801	002	
		10%	N016801	003	
+		20%	N016801	004	
INJECTABLE;SPINAL					
XYLOCAINE 1.5% W/ DEXTROSE 7.5%					
	FRESENIUS KABI USA	1.5%	N016297	001	
XYLOCAINE 5% W/ GLUCOSE 7.5%					
	ASTRAZENECA	5%	N010496	002	Jul 07, 1982
JELLY;TOPICAL					
ANESTACON					
	BIONPHARMA INC	2%	A080429	001	
LIDOCAINE HYDROCHLORIDE					
	ACP NIMBLE	2%	A081318	001	Apr 29, 1993
	WATSON LABS INC	2%	A040837	001	Mar 23, 2011
SOLUTION;ORAL					
LIDOCAINE HYDROCHLORIDE VISCOUS					
	ACTAVIS MID ATLANTIC	2%	A086578	001	
	INTL MEDICATION	2%	A086389	001	Feb 02, 1982
XYLOCAINE VISCOUS					
+	FRESENIUS KABI USA	2% **	N009470	001	
SOLUTION;TOPICAL					
LARYNGOTRACHEAL ANESTHESIA KIT					
	KENDALL IL	4%	A087931	001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE					
	PACO	4%	A089688	001	Jun 30, 1989
	WOCKHARDT BIO AG	4%	A087881	001	Nov 18, 1982
LTA II KIT					
	HOSPIRA	4%	A080409	001	
		4%	A088542	001	Jul 31, 1984
PEDIATRIC LTA KIT					
	ABBOTT	2%	A088572	001	Jul 31, 1984
	HOSPIRA	2%	A085995	001	
XYLOCAINE 4% PRESERVATIVE FREE					
+	FRESENIUS KABI USA	4%	N010417	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE				
INJECTABLE;INJECTION				
TERRAMYCIN				
PFIZER	2%;50MG/ML	A060567	001	
	2%;125MG/ML	A060567	002	
LIDOCAINE; PRILOCAINE				
DISC;TOPICAL				
EMLA				
ASTRAZENECA	2.5%;2.5%	N020962	001	Feb 04, 1998
LINCOMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
LINCOCIN				
PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316	001	
	EQ 500MG BASE	N050316	002	
INJECTABLE;INJECTION				
LINCOMYCIN HYDROCHLORIDE				
WATSON LABS	EQ 300MG BASE/ML	A063180	001	Apr 16, 1991
LINDANE				
CREAM;TOPICAL				
KWELL				
REED AND CARNRICK	1%	A084218	001	
	1%	N006309	001	
LOTION;TOPICAL				
GAMENE				
SOLA BARNES HIND	1%	A084989	001	
KWELL				
REED AND CARNRICK	1%	A084218	002	
	1%	N006309	003	
LINDANE				
WOCKHARDT	1%	A088190	001	Aug 16, 1984
SCABENE				
STIEFEL	1%	A086769	001	
SHAMPOO;TOPICAL				
GAMENE				
SOLA BARNES HIND	1%	A084988	001	
KWELL				
REED AND CARNRICK	1%	A084219	001	
	1%	N010718	001	
SCABENE				
STIEFEL	1%	A087940	001	Apr 08, 1983
LINEZOLID				
SOLUTION;INTRAVENOUS				
ZYVOX				
+ PHARMACIA AND UPJOHN	400MG/200ML (2MG/ML) **	N021131	002	Apr 18, 2000
TABLET;ORAL				
LINEZOLID				
MYLAN	600MG	A078845	001	Dec 21, 2015
ZYVOX				
+ PHARMACIA AND UPJOHN	400MG **	N021130	001	Apr 18, 2000
LIOTHYRONINE SODIUM				
TABLET;ORAL				
LIOTHYRONINE SODIUM				
MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009
	EQ 0.025MG BASE	A090326	002	Jul 14, 2009
	EQ 0.05MG BASE	A090326	003	Jul 14, 2009
SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016
	EQ 0.025MG BASE	A091382	002	Apr 20, 2016
	EQ 0.05MG BASE	A091382	003	Apr 20, 2016
TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018
	EQ 0.025MG BASE	A211510	002	Oct 26, 2018
	EQ 0.05MG BASE	A211510	003	Oct 26, 2018
WATSON LABS	EQ 0.025MG BASE	A085755	001	Jan 25, 1982
	EQ 0.05MG BASE	A085753	001	Feb 03, 1982

LIOTRIX (T4;T3)					
TABLET;ORAL					
EUTHROID-0.5					
	PARKE DAVIS	0.03MG;0.0075MG	N016680	001	
EUTHROID-1					
	PARKE DAVIS	0.06MG;0.015MG	N016680	002	
EUTHROID-2					
	PARKE DAVIS	0.12MG;0.03MG	N016680	003	
EUTHROID-3					
	PARKE DAVIS	0.18MG;0.045MG	N016680	004	
THYROLAR-0.25					
+	ALLERGAN	0.0125MG;0.0031MG	N016807	001	
THYROLAR-0.5					
+	ALLERGAN	0.025MG;0.0063MG	N016807	005	
THYROLAR-1					
+	ALLERGAN	0.05MG;0.0125MG	N016807	004	
THYROLAR-2					
+	ALLERGAN	0.1MG;0.025MG	N016807	002	
THYROLAR-3					
+	ALLERGAN	0.15MG;0.0375MG	N016807	003	
THYROLAR-5					
	ALLERGAN	0.25MG;0.0625MG	N016807	006	
LISINOPRIL					
TABLET;ORAL					
LISINOPRIL					
	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002
		5MG	A075752	002	Jul 01, 2002
		10MG	A075752	003	Jul 01, 2002
		20MG	A075752	004	Jul 01, 2002
		30MG	A075752	005	Jul 01, 2002
		40MG	A075752	006	Jul 01, 2002
	HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002
		5MG	A076063	002	Jul 01, 2002
		10MG	A076063	003	Jul 01, 2002
		20MG	A076063	004	Jul 01, 2002
		30MG	A076063	006	Jun 27, 2003
		40MG	A076063	005	Jul 01, 2002
	INVATECH	2.5MG	A075903	001	Jul 01, 2002
		2.5MG	A075999	001	Jul 01, 2002
		5MG	A075903	002	Jul 01, 2002
		5MG	A075999	002	Jul 01, 2002
		10MG	A075903	003	Jul 01, 2002
		10MG	A075999	003	Jul 01, 2002
		20MG	A075903	004	Jul 01, 2002
		20MG	A075999	004	Jul 01, 2002
		30MG	A075903	005	Jul 01, 2002
		30MG	A075999	005	Jul 01, 2002
		40MG	A075903	006	Jul 01, 2002
		40MG	A075999	006	Jul 01, 2002
	MYLAN	2.5MG	A076071	001	Jul 01, 2002
		5MG	A076071	002	Jul 01, 2002
		10MG	A076071	003	Jul 01, 2002
		20MG	A076071	004	Jul 01, 2002
		30MG	A076071	005	Jul 01, 2002
		40MG	A076071	006	Jul 01, 2002
	TEVA	2.5MG	A075783	001	Jul 01, 2002
		5MG	A075783	002	Jul 01, 2002
		10MG	A075783	003	Jul 01, 2002
		20MG	A075783	004	Jul 01, 2002
		30MG	A075783	005	Jul 01, 2002
		40MG	A075783	006	Jul 01, 2002
PRINIVIL					
	MERCK	2.5MG	N019558	006	Jan 28, 1994
		10MG	N019558	002	Dec 29, 1987
		20MG	N019558	003	Dec 29, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LITHIUM CARBONATE				
CAPSULE;ORAL				
ESKALITH				
NOVEN THERAP	300MG	N016860	001	
LITHIUM CARBONATE				
ABLE	150MG	A076823	001	Jun 29, 2004
	300MG	A076121	001	Sep 27, 2001
	300MG	A076823	002	Jun 29, 2004
	600MG	A076823	003	Jun 29, 2004
APOTEX INC	300MG	A076795	001	Nov 22, 2004
MYLAN	600MG	A078763	001	Apr 15, 2008
USL PHARMA	300MG	A072542	001	Feb 01, 1989
WATSON LABS	300MG	A070407	001	Mar 19, 1987
LITHONATE				
SOLVAY	300MG	N016782	001	
TABLET;ORAL				
ESKALITH				
JDS PHARMS	300MG	N017971	001	
LITHANE				
BAYER PHARMS	300MG	N018833	001	Jul 18, 1985
LITHIUM CARBONATE				
HIKMA INTL PHARMS	300MG	A078715	001	Dec 28, 2010
PFIZER	300MG	N016834	001	
LITHOTABS				
SOLVAY	300MG	N016980	001	
TABLET, EXTENDED RELEASE;ORAL				
ESKALITH CR				
JDS PHARMS	450MG **	N018152	001	Mar 29, 1982
LITHIUM CARBONATE				
ABLE	300MG	A076382	001	Apr 21, 2003
HERITAGE PHARMA	300MG	A076170	001	Jun 10, 2002
	450MG	A076366	001	Aug 21, 2003
HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003
LITHIUM CITRATE				
SYRUP;ORAL				
LITHONATE				
SOLVAY	EQ 300MG CARBONATE/5ML	N017672	001	
LOMEFLOXACIN HYDROCHLORIDE				
TABLET;ORAL				
MAXAQUIN				
PHARMACIA	EQ 400MG BASE	N020013	001	Feb 21, 1992
LOMUSTINE				
CAPSULE;ORAL				
GLEOSTINE				
+ CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014
LOPERAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
IMODIUM				
J AND J CONSUMER INC	2MG **	N017690	001	
+	2MG **	N017694	001	
LOPERAMIDE HYDROCHLORIDE				
ROXANE	2MG	A073080	001	Nov 27, 1991
TEVA	2MG	A073122	001	Aug 30, 1991
YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992
SOLUTION;ORAL				
IMODIUM				
JANSSEN PHARMS	1MG/5ML	N019037	001	Jul 31, 1984
LOPERAMIDE HYDROCHLORIDE				
ALLIED	1MG/5ML	A073079	001	Apr 30, 1992
ALPHARMA US PHARMS	1MG/5ML	A073187	001	Sep 15, 1992
DURAMED PHARMS BARR	1MG/5ML	A074991	001	Dec 29, 1997
TEVA	1MG/5ML	A073478	001	Jun 23, 1995
WATSON LABS	1MG/5ML	A073062	001	May 28, 1993
TABLET;ORAL				
LOPERAMIDE HYDROCHLORIDE				
ABLE	2MG	A073528	001	Nov 30, 1993
CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LOPERAMIDE HYDROCHLORIDE					
TABLET;ORAL					
LOPERAMIDE HYDROCHLORIDE					
	PERRIGO	2MG	A074194	001	Oct 30, 1992
TABLET, CHEWABLE;ORAL					
IMODIUM A-D EZ CHEWS					
+	J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997
LOPERAMIDE HYDROCHLORIDE; SIMETHICONE					
TABLET, CHEWABLE;ORAL					
IMODIUM MULTI-SYMPTOM RELIEF					
+	J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996
LOPINAVIR; RITONAVIR					
CAPSULE;ORAL					
KALETRA					
	ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000
LORACARBEF					
CAPSULE;ORAL					
LORABID					
	KING PHARMS	200MG	N050668	001	Dec 31, 1991
		400MG	N050668	002	Apr 05, 1996
FOR SUSPENSION;ORAL					
LORABID					
	KING PHARMS	100MG/5ML	N050667	001	Dec 31, 1991
		200MG/5ML	N050667	002	Dec 31, 1991
LORATADINE					
CAPSULE;ORAL					
LORATADINE					
	BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018
SYRUP;ORAL					
CLARITIN HIVES RELIEF					
+	BAYER HEALTHCARE LLC	1MG/ML **	N020641	003	Nov 19, 2003
LORATADINE					
	PHARM ASSOC	1MG/ML	A075565	001	Oct 05, 2004
	RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004
TABLET;ORAL					
LORATADINE					
	PERRIGO	10MG	N021512	001	Jun 24, 2004
LORATADINE; PSEUDOEPHEDRINE SULFATE					
TABLET, EXTENDED RELEASE;ORAL					
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
	HERITAGE PHARMA	5MG;120MG	A076208	001	Jan 28, 2004
LORAZEPAM					
INJECTABLE;INJECTION					
LORAZEPAM					
	AKORN	2MG/ML	A074974	001	Jul 23, 1998
	BEDFORD	2MG/ML	A077076	001	Jul 13, 2005
		4MG/ML	A077076	002	Jul 13, 2005
	DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
		4MG/ML	A074793	002	Mar 16, 2000
	DR REDDYS	1MG/0.5ML	A074551	003	Sep 12, 1996
		2MG/ML	A074535	001	Sep 12, 1996
		2MG/ML	A074551	001	Sep 12, 1996
		4MG/ML	A074535	002	Sep 12, 1996
		4MG/ML	A074551	002	Sep 12, 1996
	HOSPIRA	2MG/ML	A074280	001	May 27, 1994
		2MG/ML	A074300	001	Apr 12, 1994
		4MG/ML	A074280	002	May 27, 1994
		4MG/ML	A074300	003	Mar 19, 1997
	MYLAN ASI	2MG/ML	A200217	001	Apr 04, 2017
		2MG/ML	A200542	001	Apr 28, 2017
		4MG/ML	A200217	002	Apr 04, 2017
		4MG/ML	A200542	002	Apr 28, 2017
	WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994
		4MG/ML	A074276	002	Apr 15, 1994
	WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998
		4MG/ML	A074496	002	Sep 28, 1998

LORAZEPAM				
INJECTABLE;INJECTION				
LORAZEPAM PRESERVATIVE FREE				
BEDFORD LABS	2MG/ML	A077074	001	Jul 13, 2005
	4MG/ML	A077074	002	Jul 13, 2005
SOLUTION;ORAL				
LORAZEPAM				
ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997
TABLET;ORAL				
LORAZ				
QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985
LORAZEPAM				
AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
ANDA REPOSITORY	0.5MG	A072555	002	Mar 29, 1991
	1MG	A072555	003	Mar 29, 1991
	2MG	A072555	001	Mar 29, 1991
ANI PHARMS INC	0.5MG	A077396	001	Dec 13, 2006
	1MG	A077396	002	Dec 13, 2006
	2MG	A077396	003	Dec 13, 2006
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985
	2MG	A070474	001	Dec 10, 1985
MYLAN	0.5MG	A071591	002	Oct 13, 1987
	1MG	A071591	003	Oct 13, 1987
	2MG	A071591	001	Oct 13, 1987
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
SANDOZ	0.5MG	A071193	001	Apr 15, 1988
	1MG	A071194	001	Apr 15, 1988
	2MG	A071195	001	Apr 15, 1988
SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001
	1MG	A076045	002	Aug 29, 2001
	2MG	A076045	003	Aug 29, 2001
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	1MG	A071118	001	Jul 24, 1986
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986
LOSARTAN POTASSIUM				
TABLET;ORAL				
COZAAR				
+ MERCK SHARP DOHME	25MG	N020386	001	Apr 14, 1995
+	50MG	N020386	002	Apr 14, 1995
LOSARTAN POTASSIUM				
APOTEX CORP	25MG	A090790	001	Oct 06, 2010
	50MG	A090790	002	Oct 06, 2010
	100MG	A090790	003	Oct 06, 2010
HISUN PHARM HANGZHOU	25MG	A204795	001	Apr 04, 2019
	50MG	A204795	002	Apr 04, 2019
	100MG	A204795	003	Apr 04, 2019
TEVA	25MG	A076958	001	Apr 06, 2010
	50MG	A076958	002	Apr 06, 2010
	100MG	A076958	003	Apr 06, 2010

LOTEPREDNOL ETABONATE				
SUSPENSION/DROPS;OPHTHALMIC				
LOTEMAX				
PHARMOS	0.5%		N020841 001	Mar 09, 1998
LOVASTATIN				
TABLET;ORAL				
LOVASTATIN				
MYLAN	10MG		A075451 001	Dec 17, 2001
	10MG		A075935 001	Dec 17, 2001
	20MG		A075451 002	Dec 17, 2001
	20MG		A075935 002	Dec 17, 2001
	40MG		A075451 003	Dec 17, 2001
	40MG		A075935 003	Dec 17, 2001
SUN PHARM INDUSTRIES	10MG		A077520 001	Apr 14, 2006
	20MG		A077520 002	Apr 14, 2006
	40MG		A077520 003	Apr 14, 2006
MEVACOR				
+ MERCK	10MG **		N019643 002	Mar 28, 1991
+	20MG **		N019643 003	Aug 31, 1987
+	40MG **		N019643 004	Dec 14, 1988
TABLET, EXTENDED RELEASE;ORAL				
ALTOPREV				
COVIS PHARMA BV	10MG		N021316 001	Jun 26, 2002
LOXAPINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
LOXITANE C				
TEVA BRANDED PHARM	EQ 25MG BASE/ML		N017658 001	
INJECTABLE;INJECTION				
LOXITANE IM				
ACTAVIS LABS UT INC	EQ 50MG BASE/ML		N018039 001	
LOXAPINE SUCCINATE				
CAPSULE;ORAL				
LOXITANE				
+ TEVA BRANDED PHARM	EQ 5MG BASE **		N017525 001	
+	EQ 10MG BASE **		N017525 002	
+	EQ 25MG BASE **		N017525 003	
+	EQ 50MG BASE **		N017525 004	
TABLET;ORAL				
LOXITANE				
+ TEVA BRANDED PHARM	EQ 10MG BASE **		N017525 006	
+	EQ 25MG BASE **		N017525 007	
+	EQ 50MG BASE **		N017525 008	
LUCINACTANT				
SUSPENSION;INTRATRACHEAL				
SURFAXIN				
WINDTREE THERAP	8.5ML		N021746 001	Mar 06, 2012
LURASIDONE HYDROCHLORIDE				
TABLET;ORAL				
LURASIDONE HYDROCHLORIDE				
AMNEAL PHARMS CO	20MG		A208002 001	Jan 03, 2019
	40MG		A208002 002	Jan 03, 2019
	60MG		A208002 003	Jan 03, 2019
	80MG		A208002 004	Jan 03, 2019
	120MG		A208002 005	Jan 03, 2019
EMCURE PHARMS LTD	20MG		A208058 001	Sep 04, 2019
	40MG		A208058 002	Sep 04, 2019
	60MG		A208058 003	Sep 04, 2019
	80MG		A208058 004	Sep 04, 2019
INVAGEN PHARMS	20MG		A208028 001	Jan 03, 2019
	40MG		A208028 002	Jan 03, 2019
	60MG		A208028 003	Jan 03, 2019
	80MG		A208028 004	Jan 03, 2019
	120MG		A208028 005	Jan 03, 2019
LUPIN LTD	20MG		A208031 001	Jan 03, 2019
	40MG		A208031 002	Jan 03, 2019
	60MG		A208031 003	Jan 03, 2019
	80MG		A208031 004	Jan 03, 2019

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LURASIDONE HYDROCHLORIDE				
TABLET;ORAL				
LURASIDONE HYDROCHLORIDE				
	120MG	A208031	005	Jan 03, 2019
TEVA PHARMS USA	20MG	A208060	001	May 17, 2019
	40MG	A208060	002	May 17, 2019
	60MG	A208060	003	May 17, 2019
	80MG	A208060	004	May 17, 2019
	120MG	A208060	005	May 17, 2019
TORRENT	20MG	A208055	001	Jan 03, 2019
	40MG	A208055	002	Jan 03, 2019
	80MG	A208055	003	Jan 03, 2019
	120MG	A208055	004	Jan 03, 2019
ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019
	40MG	A208052	002	Mar 19, 2019
	60MG	A208052	003	Mar 19, 2019
	80MG	A208052	004	Mar 19, 2019
	120MG	A208052	005	Mar 19, 2019
LUTROPIN ALFA				
INJECTABLE;SUBCUTANEOUS				
LUVERIS				
EMD SERONO	75 IU/VIAL	N021322	001	Oct 08, 2004
LYPRESSIN				
SOLUTION;NASAL				
DIAPID				
NOVARTIS	0.185MG/ML	N016755	001	
MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
PLASMA-LYTE 56 IN PLASTIC CONTAINER				
BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE				
INJECTABLE;INJECTION				
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER				
B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019006	001	Apr 04, 1984
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE				
INJECTABLE;INJECTION				
ISOLYTE S IN PLASTIC CONTAINER				
B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018252	001	
SOLUTION;IRRIGATION				
PHYSIOSOL IN PLASTIC CONTAINER				
HOSPIRA INC	14MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	001	
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER				
HOSPIRA INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	002	Jul 08, 1982
SYNOVALYTE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N019326	001	Jan 25, 1985
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE				
TABLET;ORAL				
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE				
SANTARUS	343MG;20MG;750MG	N022456	001	Dec 04, 2009
	343MG;40MG;750MG	N022456	002	Dec 04, 2009
TABLET, CHEWABLE;ORAL				
ZEGERID				
SANTARUS	700MG;20MG;600MG	N021850	001	Mar 24, 2006
	700MG;40MG;600MG	N021850	002	Mar 24, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE				
SOLUTION;ORAL				
SUCLEAR				
+	BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM **	N203595 001	Jan 18, 2013
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE				
POWDER;ORAL				
COLPREP KIT				
+	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553 001	Dec 27, 2016
MALATHION				
LOTION;TOPICAL				
MALATHION				
	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009
OVIDE				
+	TARO PHARM INDS LTD	0.5%	N018613 001	Aug 02, 1982
MANGAFODIPIR TRISODIUM				
INJECTABLE;INJECTION				
TESLASCAN				
	IC TARGETS	37.9MG/ML	N020652 001	Nov 26, 1997
MANGANESE CHLORIDE TETRAHYDRATE				
FOR SOLUTION;ORAL				
LUMENHANCE				
	BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997
MANGANESE SULFATE				
INJECTABLE;INJECTION				
MANGANESE SULFATE				
	ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML	N019228 001	May 05, 1987
MANNITOL				
INJECTABLE;INJECTION				
MANNITOL 10%				
	B BRAUN	10GM/100ML	N016080 002	
	HOSPIRA	10GM/100ML	N016269 002	
	MILES	10GM/100ML	N016472 002	
MANNITOL 10% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	10GM/100ML	N019603 002	Jan 08, 1987
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER				
	B BRAUN	10GM/100ML	N016080 006	
MANNITOL 15%				
	B BRAUN	15GM/100ML	N016080 003	
	HOSPIRA	15GM/100ML	N016269 003	
	MILES	15GM/100ML	N016472 005	
MANNITOL 15% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	15GM/100ML	N019603 003	Jan 08, 1990
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%				
	B BRAUN	15GM/100ML	N016080 005	
MANNITOL 20%				
	B BRAUN	20GM/100ML	N014738 001	
		20GM/100ML	N016080 004	
	HOSPIRA	20GM/100ML	N016269 004	
	MILES	20GM/100ML	N016472 004	
MANNITOL 25%				
	ABRAXIS PHARM	12.5GM/50ML	A086754 001	
	HOSPIRA	12.5GM/50ML	N016269 005	
	IGI LABS INC	12.5GM/50ML	A089239 001	May 06, 1987
		12.5GM/50ML	A089240 001	May 06, 1987
	LUITPOLD	12.5GM/50ML	A087409 001	Jan 21, 1982
	MERCK	12.5GM/50ML	N005620 001	
	WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983
MANNITOL 5%				
	B BRAUN	5GM/100ML	N016080 001	
	HOSPIRA	5GM/100ML	N016269 001	
MANNITOL 5% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML	N019603 001	Jan 08, 1987

MANNITOL
INJECTABLE;INJECTION
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

	B BRAUN	5GM/100ML	N016080 007	

SOLUTION;IRRIGATION
RESECTISOL

	B BRAUN	5GM/100ML	N016704 002	

MANNITOL; SORBITOL
SOLUTION;IRRIGATION
SORBITOL-MANNITOL

	HOSPIRA	540MG/100ML;2.7GM/100ML	A080224 001	

SORBITOL-MANNITOL IN PLASTIC CONTAINER

	HOSPIRA	540MG/100ML;2.7GM/100ML	N017636 001	

MAPROTILINE HYDROCHLORIDE
TABLET;ORAL
LUDIOMIL

	NOVARTIS	25MG	N017543 001	
		50MG	N017543 002	
		75MG	N017543 003	Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

	AM THERAP	25MG	A072129 001	Jan 14, 1988
		50MG	A072130 001	Jan 14, 1988
		75MG	A072131 001	Jan 14, 1988
	HERITAGE PHARMA	25MG	A072162 001	Jun 01, 1988
	WATSON LABS	25MG	A071943 001	Dec 30, 1987
		50MG	A071944 001	Dec 30, 1987
		75MG	A071945 001	Dec 30, 1987
		75MG	A072164 001	Jun 01, 1988
	WATSON LABS TEVA	50MG	A072163 001	Jun 01, 1988

MASOPROCOL
CREAM;TOPICAL
ACTINEX

	UNIV AZ CANCER CTR	10%	N019940 001	Sep 04, 1992

MAZINDOL
TABLET;ORAL
MAZANOR

	WYETH AYERST	1MG	N017980 002	
		2MG	N017980 001	

SANOREX

+	HEXIM	1MG **	N017247 001	
+		2MG **	N017247 002	

MEBENDAZOLE
TABLET, CHEWABLE;ORAL
VERMOX

+	JANSSEN PHARMS	100MG **	N017481 001	
+		500MG	N208398 001	Oct 19, 2016

MEBUTAMATE
TABLET;ORAL
DORMATE

	MEDPOINTE PHARM HLC	600MG	N017374 001	

MECAMYLAMINE HYDROCHLORIDE
TABLET;ORAL
INVERSINE

+	TARGACEPT	2.5MG **	N010251 001	

MECASERMIN RINFABATE RECOMBINANT
INJECTABLE;SUBCUTANEOUS
IPLEX

	INSMED	36MG/0.6ML	N021884 001	Dec 12, 2005

MECHLORETHAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
MUSTARGEN

+	RECORDATI RARE	10MG/VIAL	N006695 001	

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

ABC HOLDING	12.5MG	A085253 001	
	25MG	A085252 001	
AMNEAL PHARMS	50MG	A201451 003	Feb 23, 2011
ANABOLIC	25MG	A085891 001	
ANI PHARMS INC	12.5MG	A084657 002	
	12.5MG	A085269 001	
	12.5MG	A088732 001	Dec 11, 1985
	25MG	A084657 001	
	25MG	A085740 001	
BUNDY	12.5MG	A084382 001	
	25MG	A084872 001	
IVAX SUB TEVA PHARMS	12.5MG	A083784 001	
KV PHARM	12.5MG	A085524 001	
	25MG	A085523 001	
MYLAN PHARMS INC	50MG	A202640 003	Sep 17, 2012
PAR PHARM	50MG	A089674 001	Mar 31, 1988
PLIVA	25MG	A088734 001	Dec 11, 1985
RISING	12.5MG	A040179 001	Jan 30, 1997
	25MG	A040179 002	Jan 30, 1997
SUPERPHARM	12.5MG	A089113 001	Aug 20, 1985
	25MG	A089114 001	Aug 20, 1985
UDL	12.5MG	A088256 001	Jun 13, 1983
	25MG	A088257 001	Jun 13, 1983
VANGARD	12.5MG	A087877 001	Apr 20, 1982
	25MG	A087620 001	Jan 04, 1982
WATSON LABS	12.5MG	A085195 001	

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	25MG	A084976 001	
NEXGEN PHARMA INC	25MG	A086392 001	
PLIVA	25MG	A088733 001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM;TOPICAL

MECLAN

JOHNSON AND JOHNSON	1%	N050518 001	

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLODIUM

QUANTUM PHARMICS	EQ 50MG BASE	A071380 001	Jul 14, 1987
	EQ 100MG BASE	A071381 001	Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP	EQ 50MG BASE	A071362 001	Feb 10, 1987
	EQ 100MG BASE	A071363 001	Feb 10, 1987
ANI PHARMS INC	EQ 50MG BASE	A071468 001	Apr 15, 1987
	EQ 100MG BASE	A071469 001	Apr 15, 1987
BARR	EQ 50MG BASE	A072848 001	Mar 20, 1989
	EQ 100MG BASE	A072809 001	Mar 20, 1989
FOSUN PHARMA	EQ 50MG BASE	A072262 001	Nov 29, 1988
	EQ 100MG BASE	A072263 001	Nov 29, 1988
PAR PHARM	EQ 50MG BASE	A072077 001	Mar 10, 1988
	EQ 100MG BASE	A072078 001	Mar 10, 1988
USL PHARMA	EQ 50MG BASE	A071007 001	Mar 25, 1988
	EQ 100MG BASE	A071008 001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710 001	Jun 15, 1988
	EQ 100MG BASE	A071684 001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400 001	Nov 25, 1986
	EQ 50MG BASE	A071640 001	Aug 11, 1987
	EQ 100MG BASE	A070401 001	Nov 25, 1986
	EQ 100MG BASE	A071641 001	Aug 11, 1987

MECLOMEN

PARKE DAVIS	EQ 50MG BASE	N018006 001	
	EQ 100MG BASE	N018006 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEDROXYPROGESTERONE ACETATE				
INJECTABLE;INJECTION				
DEPO-PROVERA				
+ PHARMACIA AND UPJOHN	100MG/ML **	N012541	002	
MEDROXYPROGESTERONE ACETATE				
CIPLA	150MG/ML	A210335	001	Jan 25, 2019
SANDOZ INC	150MG/ML	A078711	001	May 20, 2009
TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004
TABLET;ORAL				
AMEN				
AMARIN PHARMS	10MG	A083242	001	
CURRETAB				
SOLVAY	10MG	A085686	001	
CYCRIN				
ESI	2.5MG	A081239	001	Oct 30, 1992
	5MG	A081240	001	Oct 30, 1992
	10MG	A089386	001	Sep 09, 1987
MEDROXYPROGESTERONE ACETATE				
DURAMED PHARMS BARR	2.5MG	A040311	001	Dec 01, 1999
	5MG	A040311	002	Dec 01, 1999
	10MG	A040311	003	Dec 01, 1999
UPSHER SMITH LABS	10MG	A088484	001	Jul 26, 1984
MEDRYSONE				
SUSPENSION;OPHTHALMIC				
HMS				
ALLERGAN	1%	N016624	003	
MEFENAMIC ACID				
CAPSULE;ORAL				
MEFENAMIC ACID				
BRECKENRIDGE	250MG	A090359	001	Feb 05, 2013
MEFLOQUINE HYDROCHLORIDE				
TABLET;ORAL				
LARIAM				
+ ROCHE	250MG **	N019591	001	May 02, 1989
MEFLOQUINE HYDROCHLORIDE				
HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010
SANDOZ	250MG	A076175	001	Feb 20, 2002
US ARMY WALTER REED	250MG **	N019578	001	May 02, 1989
MEGESTROL ACETATE				
SUSPENSION;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	40MG/ML **	N020264	001	Sep 10, 1993
MEGESTROL ACETATE				
PHARM ASSOC	40MG/ML	A077404	001	Feb 16, 2006
TABLET;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	20MG **	N016979	001	
+	40MG **	N016979	002	
MEGESTROL ACETATE				
TEVA	40MG	A074745	001	Feb 27, 1998
USL PHARMA	20MG	A070646	001	Oct 02, 1987
	40MG	A070647	001	Oct 02, 1987
MELOXICAM				
SUSPENSION;ORAL				
MOBIC				
+ AVONDALE PHARMS	7.5MG/5ML **	N021530	001	Jun 01, 2004
TABLET;ORAL				
MELOXICAM				
ANDA REPOSITORY	7.5MG	A077935	001	Jul 19, 2006
	15MG	A077935	002	Jul 19, 2006
CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006
	15MG	A078039	002	Dec 14, 2006
HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006
	15MG	A077936	002	Jul 19, 2006
IMPAX LABS INC	7.5MG	A077930	001	Jul 19, 2006
	15MG	A077930	002	Jul 19, 2006
MYLAN	7.5MG	A077923	001	Jul 19, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MELOXICAM				
TABLET;ORAL				
MELOXICAM				
	7.5MG	A077934	001	Jul 20, 2006
	15MG	A077923	002	Jul 19, 2006
	15MG	A077934	002	Jul 20, 2006
ROXANE	7.5MG	A077925	001	Jul 19, 2006
	15MG	A077925	002	Jul 19, 2006
SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006
	15MG	A077937	002	Jul 19, 2006
YABAO PHARM	7.5MG	A077933	001	Jul 19, 2006
	15MG	A077933	002	Jul 19, 2006
MELPHALAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
MELPHALAN HYDROCHLORIDE				
MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009
US WORLDMEDS LLC	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019
MEMANTINE HYDROCHLORIDE				
SOLUTION;ORAL				
MEMANTINE HYDROCHLORIDE				
TORRENT	2MG/ML	A205446	001	Dec 07, 2015
NAMENDA				
+ ALLERGAN	2MG/ML	N021627	001	Apr 18, 2005
TABLET;ORAL				
MEMANTINE HYDROCHLORIDE				
APOTEX INC	5MG	A090244	001	Jul 11, 2018
	10MG	A090244	002	Jul 11, 2018
MYLAN	5MG	A079225	001	Jan 30, 2015
	10MG	A079225	002	Jan 30, 2015
ORCHID HLTHCARE	5MG	A090044	001	Mar 12, 2012
	10MG	A090044	002	Mar 12, 2012
MENADIOL SODIUM DIPHOSPHATE				
INJECTABLE;INJECTION				
KAPPADIONE				
LILLY	10MG/ML	N005725	001	
SYNKAYVITE				
ROCHE	5MG/ML	N003718	004	
	10MG/ML	N003718	006	
	37.5MG/ML	N003718	008	
TABLET;ORAL				
SYNKAYVITE				
ROCHE	5MG	N003718	010	
MENADIONE				
TABLET;ORAL				
MENADIONE				
LILLY	5MG	N002139	003	
MENOTROPINS (FSH;LH)				
INJECTABLE;INJECTION				
HUMEGON				
ORGANON USA INC	75 IU/VIAL;75 IU/VIAL	N020328	001	Sep 01, 1994
	150 IU/VIAL;150 IU/VIAL	N020328	002	Sep 01, 1994
MENOTROPINS				
FERRING	75 IU/VIAL;75 IU/VIAL	A073598	001	Jan 30, 1997
	150 IU/VIAL;150 IU/VIAL	A073599	001	Jan 30, 1997
PERGONAL				
SERONO	75 IU/AMP;75 IU/AMP	N017646	001	
	150 IU/AMP;150 IU/AMP	N017646	002	May 20, 1985
REPRONEX				
FERRING	150 IU/VIAL;150 IU/VIAL	N021047	002	Aug 27, 1999
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
REPRONEX				
FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999

MEPENZOLATE BROMIDE				
SOLUTION;ORAL				
CANTIL				
SANOFI AVENTIS US	25MG/5ML	N010679	004	
TABLET;ORAL				
CANTIL				
+ SANOFI AVENTIS US	25MG	N010679	003	
MEPERIDINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DEMEROL				
US PHARM HOLDINGS	25MG/ML	N005010	007	
	50MG/ML	N005010	002	
	75MG/ML	N005010	009	
	100MG/ML	N005010	003	
MEPERIDINE HYDROCHLORIDE				
ABBOTT	25MG/ML	A080388	001	
	50MG/ML	A080385	001	
	50MG/ML	A080387	001	
	75MG/ML	A080389	001	
	100MG/ML	A080386	001	
BAXTER HLTHCARE	25MG/ML	A088279	001	Jun 15, 1984
	50MG/ML	A088280	001	Jun 15, 1984
	75MG/ML	A088281	001	Jun 15, 1984
	100MG/ML	A088282	001	Jun 15, 1984
IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989
	50MG/ML	A089782	001	Mar 31, 1989
	50MG/ML	A089783	001	Mar 31, 1989
	50MG/ML	A089784	001	Mar 31, 1989
	75MG/ML	A089785	001	Mar 31, 1989
	100MG/ML	A089786	001	Mar 31, 1989
	100MG/ML	A089787	001	Mar 31, 1989
	100MG/ML	A089788	001	Mar 31, 1989
INTL MEDICATION	10MG/ML	A086332	001	
PARKE DAVIS	50MG/ML	A080364	002	
	75MG/ML	A080364	003	
	100MG/ML	A080364	001	
WATSON LABS	50MG/ML	A073444	001	Mar 17, 1992
	100MG/ML	A073445	001	Mar 17, 1992
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE				
HOSPIRA	10MG/ML	A040305	001	Mar 10, 1999
ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984
INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993
SPECGX LLC	10MG/ML	A040163	001	May 12, 1997
WATSON LABS	10MG/ML	A073443	001	Mar 17, 1992
SYRUP;ORAL				
DEMEROL				
US PHARM HOLDINGS	50MG/5ML **	N005010	005	
TABLET;ORAL				
DEMEROL				
+ US PHARM HOLDINGS	50MG	N005010	001	
+	100MG	N005010	004	
MEPERIDINE HYDROCHLORIDE				
ANDA REPOSITORY	50MG	A040893	001	Jun 24, 2009
	75MG	A040893	002	Jun 24, 2009
	100MG	A040893	003	Jun 24, 2009
	150MG	A040893	004	Jun 24, 2009
BARR	50MG	A088639	001	Jul 02, 1984
	100MG	A088640	001	Sep 19, 1984
DURAMED PHARMS BARR	50MG	A040318	001	Oct 05, 1999
	100MG	A040318	002	Oct 05, 1999
SPECGX LLC	50MG	A040352	001	Jun 13, 2000
	100MG	A040352	002	Jun 13, 2000
SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002
	100MG	A040446	002	Aug 08, 2002
SUN PHARM INDUSTRIES	50MG	A080448	001	
	100MG	A080448	002	
WATSON LABS	50MG	A040186	001	Jun 30, 1997
	100MG	A040186	002	Jun 30, 1997
WYETH AYERST	50MG	A080454	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MEPERGAN				
HIKMA	25MG/ML;25MG/ML		N011730 001	
MEPHENTERMINE SULFATE				
INJECTABLE;INJECTION				
WYAMINE SULFATE				
BAXTER HLTHCARE CORP	EQ 15MG BASE/ML		N008248 002	
	EQ 30MG BASE/ML		N008248 001	
MEPHENYTOIN				
TABLET;ORAL				
MESANTOIN				
+ NOVARTIS	100MG **		N006008 001	
MEPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE				
SOLVAY	3%		A084777 002	Apr 18, 1982
CARBOCAINE				
+ EASTMAN KODAK	3% **		N012125 003	
ISOCAINE HYDROCHLORIDE				
SEPTODONT INC	3%		A080925 001	
MEPIVACAINE HYDROCHLORIDE				
BELMORA LLC	3%		A083559 001	
HOSPIRA INC	3%		A040806 001	Apr 28, 2008
INTL MEDICATION SYS	1%		A087509 001	Oct 05, 1982
WATSON LABS	1%		A088769 001	Nov 20, 1984
	2%		A088770 001	Nov 20, 1984
POLOCAINE				
DENTSPLY PHARM	3%		A088653 001	Aug 21, 1984
MEPREDNISONE				
TABLET;ORAL				
BETAPAR				
SCHERING	4MG		N016053 002	
MEPROBAMATE				
CAPSULE;ORAL				
EQUANIL				
WYETH AYERST	400MG		N012455 002	
CAPSULE, EXTENDED RELEASE;ORAL				
MEPROSPAN				
MEDPOINTE PHARM HLC	200MG		N011284 001	
	400MG		N011284 002	
TABLET;ORAL				
AMOSENE				
FERNDALE LABS	400MG		A084030 001	
BAMATE				
ALRA	200MG		A080380 001	
	400MG		A080380 002	
EQUANIL				
WYETH AYERST	200MG		N010028 005	
	400MG		N010028 004	
MEPRIAM				
TEVA	400MG		N016069 001	
MEPROBAMATE				
AUROLIFE PHARMA LLC	400MG		A080655 001	
BARR	600MG		A084230 001	
ELKINS SINN	200MG		N015426 002	
	400MG		N015426 001	
HEATHER	400MG		N016928 003	
	600MG		A084329 001	
IMPAX LABS	200MG		N014322 002	
	400MG		N014322 001	
IVAX SUB TEVA PHARMS	200MG		N015438 001	
	400MG		N015438 002	
	600MG		A084181 001	
IVC INDS	400MG		A084153 001	
LANNETT	200MG		N014882 002	
	400MG		N014882 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

LEDERLE	400MG	A086299	001	
LEE KM	400MG	A089538	001	Nov 25, 1987
MALLARD	400MG	N015072	002	
MK LABS	200MG	N014368	004	
	400MG	N014368	002	
MYLAN	400MG	A083618	001	
NEXGEN PHARMA INC	200MG	A084220	001	
	400MG	A084589	001	
PARKE DAVIS	200MG	A084744	001	
	400MG	A084744	002	
PERRIGO	200MG	A084546	001	
	400MG	A084547	001	
PHARMAVITE	400MG	A084438	001	
PUREPAC PHARM	200MG	A084804	001	
	400MG	A084804	002	
PVT FORM	400MG	N014601	001	
ROXANE	600MG	A084332	001	
SANDOZ	200MG	N014547	002	
	400MG	N014547	001	
SCHERER LABS	400MG	A083343	001	
SOLVAY	200MG	A084435	001	
STANLABS PHARM	200MG	N014474	002	
	400MG	N014474	004	
SUN PHARM INDUSTRIES	200MG	A080699	001	
	400MG	A080699	002	
TABLICAPS	400MG	A083494	001	
TARO	200MG	A200998	001	May 23, 2011
	400MG	A200998	002	May 23, 2011
USL PHARMA	200MG	A087825	001	Mar 18, 1982
	400MG	A087826	001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139	006	
	400MG	N015139	005	
VANGARD	400MG	A088011	001	Jul 14, 1982
WATSON LABS	200MG	A085720	001	
	400MG	A085721	001	
	600MG	A084274	001	
	600MG	A085719	001	
WEST WARD	200MG	N015417	003	
	400MG	N015417	002	
WHITEWORTH TOWN PLSN	200MG	A083830	001	
	400MG	A083442	001	

MILTOWN

+ MEDPOINTE PHARM HLC	200MG **	N009698	004	
+	400MG **	N009698	002	
	600MG	A083919	001	

NEURAMATE

HALSEY	200MG	N014359	002	
	400MG	N014359	001	

TRANMEP

SOLVAY	400MG	A084369	001	
	400MG	N016249	001	

MEQUINOL; TRETINOIN

SOLUTION;TOPICAL

SOLAGE

ALMIRALL	2%;0.01%	N020922	001	Dec 10, 1999

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

HOSPIRA INC	500MG/VIAL	A090940	001	Jun 22, 2010
	1GM/VIAL	A090940	002	Jun 22, 2010
SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011
	1GM/VIAL	A091201	002	Mar 29, 2011

MERSALYL SODIUM; THEOPHYLLINE				
INJECTABLE;INJECTION				
MERSALYL-THEOPHYLLINE				
	WATSON LABS	100MG/ML;50MG/ML	A084875 001	
MESALAMINE				
ENEMA;RECTAL				
MESALAMINE				
	G AND W LABS INC	4GM/60ML	A076841 001	Sep 30, 2004
SUPPOSITORY;RECTAL				
CANASA				
	ALLERGAN	500MG	N021252 001	Jan 05, 2001
ROWASA				
+	MEDA PHARMS	500MG **	N019919 001	Dec 18, 1990
TABLET, DELAYED RELEASE;ORAL				
ASACOL				
	APIL	400MG	N019651 001	Jan 31, 1992
MESNA				
INJECTABLE;INTRAVENOUS				
MESNA				
	MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012
	MYLAN LABS LTD	100MG/ML	A203364 001	Jul 18, 2014
MESORIDAZINE BESYLATE				
CONCENTRATE;ORAL				
SERENTIL				
	NOVARTIS	EQ 25MG BASE/ML	N016997 001	
INJECTABLE;INJECTION				
SERENTIL				
	NOVARTIS	EQ 25MG BASE/ML	N016775 001	
TABLET;ORAL				
SERENTIL				
	NOVARTIS	EQ 10MG BASE	N016774 001	
		EQ 25MG BASE	N016774 002	
		EQ 50MG BASE	N016774 003	
		EQ 100MG BASE	N016774 004	
MESTRANOL; NORETHINDRONE				
TABLET;ORAL-20				
NORINYL				
	ACTAVIS LABS UT INC	0.1MG;2MG	N013625 004	
TABLET;ORAL-21				
NORETHIN 1/50M-21				
	HERITAGE PHARMA	0.05MG;1MG	A071539 001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070758 001	Jul 01, 1988
NORINYL 1+50 21-DAY				
	ACTAVIS LABS UT INC	0.05MG;1MG	N013625 002	
NORINYL 1+80 21-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016724 001	
ORTHO-NOVUM 1/50 21				
	ORTHO MCNEIL PHARM	0.05MG;1MG	N012728 004	
ORTHO-NOVUM 1/80 21				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 001	
ORTHO-NOVUM 10-21				
	ORTHO MCNEIL PHARM	0.06MG;10MG	N012728 001	
ORTHO-NOVUM 2-21				
	ORTHO MCNEIL PHARM	0.1MG;2MG	N012728 005	
TABLET;ORAL-28				
NORETHIN 1/50M-28				
	HERITAGE PHARMA	0.05MG;1MG	A071540 001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070759 001	Jul 01, 1988
NORINYL 1+50 28-DAY				
+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659 001	
NORINYL 1+80 28-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016725 001	
ORTHO-NOVUM 1/50 28				
	ORTHO MCNEIL JANSSEN	0.05MG;1MG	N016709 001	

MESTRANOL; NORETHINDRONE				
TABLET;ORAL-28				
ORTHO-NOVUM 1/80 28				
ORTHO MCNEIL PHARM	0.08MG;1MG	N016715	002	
MESTRANOL; NORETHYNODREL				
TABLET;ORAL				
ENOVID				
GD SEARLE LLC	0.075MG;5MG	N010976	008	
	0.15MG;9.85MG	N010976	005	
TABLET;ORAL-20				
ENOVID				
GD SEARLE LLC	0.075MG;5MG	N010976	004	
ENOVID-E				
GD SEARLE LLC	0.1MG;2.5MG	N010976	006	
TABLET;ORAL-21				
ENOVID-E 21				
GD SEARLE LLC	0.1MG;2.5MG	N010976	007	
METAPROTERENOL SULFATE				
AEROSOL, METERED;INHALATION				
ALUPENT				
BOEHRINGER INGELHEIM	0.65MG/INH	N016402	001	
SOLUTION;INHALATION				
ALUPENT				
BOEHRINGER INGELHEIM	0.4%	N018761	002	Oct 10, 1986
	0.6%	N018761	001	Jun 30, 1983
	5%	N017659	001	
METAPROTERENOL SULFATE				
APOTEX INC	0.4%	A075402	001	Feb 28, 2001
	0.6%	A075403	001	Feb 28, 2001
ASTRAZENECA	0.4%	A071275	001	Jul 27, 1988
	0.6%	A071018	001	Jul 27, 1988
DEY	0.33%	A071806	001	Aug 05, 1988
	0.5%	A071805	001	Aug 05, 1988
	5%	A070805	001	Aug 17, 1987
MYLAN SPECIALITY LP	0.4%	A071786	001	Aug 05, 1988
	0.6%	A070804	001	Aug 17, 1987
NEPHRON	0.4%	A071855	001	Jul 14, 1988
	0.6%	A071726	001	Jul 14, 1988
WOCKHARDT	0.4%	A075586	001	May 30, 2002
	0.6%	A075586	002	May 30, 2002
	5%	A072190	001	Jun 07, 1988
PROMETA				
MURO	5%	A073340	001	Mar 30, 1992
SYRUP;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG/5ML	N017571	001	
METAPROTERENOL SULFATE				
ACP NIMBLE	10MG/5ML	A072761	001	Feb 27, 1992
APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000
G AND W LABS INC	10MG/5ML	A073034	001	Aug 30, 1991
MORTON GROVE	10MG/5ML	A071656	001	Oct 13, 1987
WOCKHARDT	10MG/5ML	A074702	001	Mar 24, 1997
PROMETA				
MURO	10MG/5ML	A072023	001	Sep 15, 1988
TABLET;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG	N015874	002	
	20MG	N015874	001	
METAPROTERENOL SULFATE				
AM THERAP	10MG	A072054	001	Jun 23, 1988
	20MG	A072055	001	Jun 23, 1988
HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990
	20MG	A072520	001	Mar 30, 1990
PAR PHARM	10MG	A072024	001	Jun 28, 1988
	20MG	A072025	001	Jun 28, 1988
USL PHARMA	10MG	A071013	001	Jan 25, 1988
	20MG	A071014	001	Jan 25, 1988
WATSON LABS	10MG	A073013	001	Jan 31, 1991

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METAPROTERENOL SULFATE				
TABLET;ORAL				
METAPROTERENOL SULFATE				
	20MG		A072795 001	Jan 31, 1991
METARAMINOL BITARTRATE				
INJECTABLE;INJECTION				
ARAMINE				
+ MERCK	EQ 10MG BASE/ML **		N009509 002	Dec 22, 1987
METARAMINOL BITARTRATE				
ABRAXIS PHARM	EQ 10MG BASE/ML		A080431 001	
ELKINS SINN	EQ 10MG BASE/ML		A083363 001	
FRESENIUS KABI USA	EQ 10MG BASE/ML		A080722 001	
GD SEARLE LLC	EQ 10MG BASE/ML		A086418 001	
	EQ 20MG BASE/ML		A086418 002	
METAXALONE				
TABLET;ORAL				
METAXALONE				
+ PRIMUS PHARMS	640MG **		N022503 001	Jun 01, 2015
SKELAXIN				
+ KING PHARMS	400MG **		N013217 001	
METFORMIN HYDROCHLORIDE				
TABLET;ORAL				
GLUCOPHAGE				
+ EMD SERONO INC	500MG		N020357 001	Mar 03, 1995
+	625MG **		N020357 003	Nov 05, 1998
+	750MG **		N020357 004	Nov 05, 1998
+	850MG		N020357 002	Mar 03, 1995
+	1GM		N020357 005	Nov 05, 1998
METFORMIN HYDROCHLORIDE				
BARR	500MG		A075971 001	Jan 25, 2002
	850MG		A075971 002	Jan 25, 2002
	1GM		A075971 003	Jan 25, 2002
IPCA LABS LTD	500MG		A078422 001	Aug 06, 2007
	850MG		A078422 002	Aug 06, 2007
	1GM		A078422 003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG		A075975 001	Jan 24, 2002
	625MG		A075975 004	Jan 24, 2002
	750MG		A075975 005	Jan 24, 2002
	850MG		A075975 002	Jan 24, 2002
	1GM		A075975 003	Jan 24, 2002
MYLAN PHARMS INC	500MG		A075969 001	Jan 29, 2002
	850MG		A075969 002	Jan 29, 2002
	1GM		A075969 003	Jan 29, 2002
PROVIDENT PHARM	500MG		A077853 001	Jul 28, 2006
	850MG		A077853 002	Jul 28, 2006
	1GM		A077853 003	Jul 28, 2006
SANDOZ	500MG		A075985 001	Jan 25, 2002
	850MG		A075985 002	Jan 25, 2002
	1GM		A075985 003	Jan 25, 2002
SUN PHARM INDUSTRIES	500MG		A076038 001	Feb 21, 2002
	850MG		A076038 002	Feb 21, 2002
	1GM		A076038 003	Feb 21, 2002
SUNSHINE LAKE	500MG		A208999 001	Oct 12, 2018
	850MG		A208999 002	Oct 12, 2018
	1GM		A208999 003	Oct 12, 2018
TEVA	500MG		A076328 001	Dec 16, 2002
	850MG		A076328 002	Dec 16, 2002
	1GM		A076328 003	Dec 16, 2002
WATSON LABS	500MG		A075979 001	Jan 24, 2002
	850MG		A075979 002	Jan 24, 2002
	1GM		A075979 003	Jan 24, 2002
WATSON LABS FLORIDA	500MG		A075961 001	Jan 25, 2002
	850MG		A075961 002	Jan 25, 2002
	1GM		A075961 003	Jan 25, 2002
TABLET, EXTENDED RELEASE;ORAL				
FORTAMET				
+ ANDRX LABS LLC	500MG **		N021574 001	Apr 27, 2004
+	1GM **		N021574 002	Apr 27, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METFORMIN HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
GLUCOPHAGE XR					
+	EMD SERONO INC	500MG	N021202	001	Oct 13, 2000
+		750MG	N021202	004	Apr 11, 2003
METFORMIN HYDROCHLORIDE					
	ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004
		750MG	A076878	001	Apr 13, 2005
	BARR	500MG	A076496	001	Nov 25, 2005
	IMPAX LABS	500MG	A076249	001	Jul 30, 2004
		750MG	A076985	001	Sep 13, 2005
	IVAX SUB TEVA PHARMS	500MG	A076545	001	Dec 01, 2003
	MYLAN	500MG	A076650	001	Sep 13, 2005
		750MG	A077113	001	Sep 08, 2005
	RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004
		750MG	A077211	001	Jun 29, 2005
	SANDOZ	500MG	A076223	001	Dec 14, 2004
	SUN PHARM INDUSTRIES	500MG	A077124	001	Dec 21, 2005
	TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010
	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004
	YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018
		750MG	A211052	002	Sep 24, 2018
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE					
TABLET;ORAL					
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE					
	MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011
		850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011
TABLET, EXTENDED RELEASE;ORAL					
ACTOPLUS MET XR					
+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009
METFORMIN HYDROCHLORIDE; REPAGLINIDE					
TABLET;ORAL					
PRANDIMET					
+	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+		500MG;2MG	N022386	002	Jun 23, 2008
REPAGLINIDE AND METFORMIN HYDROCHLORIDE					
	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015
		500MG;2MG	A200624	002	Jul 15, 2015
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE					
TABLET;ORAL					
AVANDAMET					
+	SB PHARMCO	500MG;EQ 1MG BASE **	N021410	001	Oct 10, 2002
+		500MG;EQ 2MG BASE **	N021410	002	Oct 10, 2002
+		500MG;EQ 4MG BASE **	N021410	003	Oct 10, 2002
+		1GM;EQ 2MG BASE **	N021410	004	Aug 25, 2003
+		1GM;EQ 4MG BASE **	N021410	005	Aug 25, 2003
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE					
	TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014
		500MG;EQ 1MG BASE	A077337	005	May 19, 2017
		500MG;EQ 4MG BASE	A077337	002	May 07, 2014
		1GM;EQ 4MG BASE	A077337	004	May 07, 2014
		1GM;EQ 2MG BASE	A077337	003	May 07, 2014
METHACHOLINE CHLORIDE					
FOR SOLUTION;INHALATION					
PROVOCHOLINE					
+	METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016
METHACYCLINE HYDROCHLORIDE					
CAPSULE;ORAL					
RONDOMYCIN					
	MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001	
		EQ 280MG BASE	A060641	002	
SYRUP;ORAL					
RONDOMYCIN					
	MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHADONE HYDROCHLORIDE				
POWDER;FOR RX COMPOUNDING				
METHADONE HYDROCHLORIDE				
MALLINCKRODT INC	50GM/BOT		N006383 002	
	100GM/BOT		N006383 003	
	500GM/BOT		N006383 004	
SYRUP;ORAL				
DOLOPHINE HYDROCHLORIDE				
HIKMA	10MG/30ML		N006134 004	
TABLET;ORAL				
METHADONE HYDROCHLORIDE				
ROXANE	5MG		A088108 001	Mar 08, 1983
	10MG		A088109 001	Mar 08, 1983
	40MG		A074081 001	Apr 28, 1995
VISTAPHARM	5MG		A040241 001	May 29, 1998
TABLET, DISPERSIBLE;ORAL				
WESTADONE				
SANDOZ	2.5MG		N017108 001	
TABLET, EFFERVESCENT;ORAL				
WESTADONE				
SANDOZ	5MG		N017108 002	
	10MG		N017108 003	
	40MG		N017108 004	
METHAMPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
METHAMPEX				
TEVA	10MG		A083889 001	
METHAMPHETAMINE HYDROCHLORIDE				
ABLE	5MG		A040529 001	Feb 25, 2004
REXAR	5MG		A084931 001	
	10MG		A084931 002	
TEVA	5MG		A086359 001	
TABLET, EXTENDED RELEASE;ORAL				
DESOXYN				
RECORDATI RARE	5MG		N005378 004	
	10MG		N005378 003	
	15MG		N005378 005	
METHANTHELINE BROMIDE				
TABLET;ORAL				
BANTHINE				
SHIRE	50MG		N007390 001	
METHARBITAL				
TABLET;ORAL				
GEMONIL				
ABBVIE	100MG		N008322 001	
METHAZOLAMIDE				
TABLET;ORAL				
METHAZOLAMIDE				
APPLIED ANAL	25MG		A040011 001	Jul 17, 1997
	50MG		A040011 002	Jul 17, 1997
INVATECH	25MG		A040102 001	Aug 28, 1996
	50MG		A040102 002	Aug 28, 1996
MICRO LABS	25MG		A207438 001	Oct 05, 2018
	50MG		A207438 002	Oct 05, 2018
NEPTAZANE				
+ LEDERLE	25MG **		N011721 002	Nov 25, 1991
+	50MG **		N011721 001	
METHDILAZINE				
TABLET, CHEWABLE;ORAL				
TACARYL				
WESTWOOD SQUIBB	3.6MG		N011950 009	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METHDILAZINE HYDROCHLORIDE				
SYRUP;ORAL				
METHDILAZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	4MG/5ML	A087122	001	
TACARYL				
WESTWOOD SQUIBB	4MG/5ML	N011950	007	
TABLET;ORAL				
TACARYL				
WESTWOOD SQUIBB	8MG	N011950	006	
METHICILLIN SODIUM				
INJECTABLE;INJECTION				
STAPHCILLIN				
APOTHECON	EQ 900MG BASE/VIAL	A061449	001	
	EQ 900MG BASE/VIAL	N050117	001	
	EQ 3.6GM BASE/VIAL	A061449	002	
	EQ 3.6GM BASE/VIAL	N050117	002	
	EQ 5.4GM BASE/VIAL	A061449	003	
	EQ 5.4GM BASE/VIAL	N050117	003	
METHIMAZOLE				
TABLET;ORAL				
METHIMAZOLE				
ECI PHARMS LLC	15MG	A040619	003	Jul 12, 2005
	20MG	A040547	004	Feb 18, 2005
MYLAN	20MG	A040350	003	Jun 07, 2001
SUN PHARM INDS INC	5MG	A040870	001	Sep 25, 2007
	10MG	A040870	002	Sep 25, 2007
TAPAZOLE				
+ KING PHARMS	5MG **	N007517	002	
+	10MG **	N007517	004	
METHIXENE HYDROCHLORIDE				
TABLET;ORAL				
TREST				
NOVARTIS	1MG	N013420	001	
METHOCARBAMOL				
INJECTABLE;INJECTION				
METHOCARBAMOL				
DR REDDYS	100MG/ML	A086459	001	
MARSAM PHARMS LLC	100MG/ML	A089849	001	Dec 27, 1991
TABLET;ORAL				
DELAXIN				
FERNDALE LABS	500MG	A085454	001	
FORBAXIN				
FOREST LABS	750MG	A085136	001	
METHOCARBAMOL				
ABLE	500MG	A040413	001	Mar 17, 2003
	750MG	A040413	002	Mar 17, 2003
AM THERAP	500MG	A089417	001	Feb 11, 1987
	750MG	A089418	001	Feb 11, 1987
ANI PHARMS INC	500MG	A084277	001	
	750MG	A084276	002	
ASCOT	500MG	A087660	001	Oct 27, 1982
	750MG	A087661	001	Oct 27, 1982
CLONMEL HLTHCARE	500MG	A085961	001	
	750MG	A085963	001	
FOSUN PHARMA	500MG	A084616	001	
	750MG	A084615	001	
HEATHER	500MG	A084675	001	
	750MG	A084924	001	
IMPAX LABS	500MG	A084927	001	
	750MG	A084928	001	
INWOOD LABS	500MG	A085137	001	
IVAX SUB TEVA PHARMS	500MG	A084648	001	
	750MG	A084649	001	
KV PHARM	500MG	A085660	001	
	750MG	A085658	001	
LANNETT CO INC	500MG	A084756	002	Mar 31, 2003
	750MG	A084756	001	

METHOCARBAMOL					
TABLET;ORAL					
METHOCARBAMOL					
	MYLAN	500MG	A084259	001	
		750MG	A084323	001	
	NYLOS	750MG	A085033	001	
	PIONEER PHARMS	500MG	A088731	001	Dec 13, 1985
		750MG	A089082	001	Dec 13, 1985
	PURACAP PHARM	500MG	A084231	002	
		750MG	A084471	001	
	PUREPAC PHARM	500MG	A085718	001	
		750MG	A085718	002	
	ROXANE	500MG	A088646	001	Feb 29, 1984
		750MG	A088647	001	Feb 29, 1984
	SANDOZ	500MG	A087283	001	
		750MG	A087282	001	
	SOLVAY	500MG	A084448	001	
		750MG	A084449	001	
	SUN PHARM INDUSTRIES	500MG	A084488	001	
		750MG	A084486	001	
	SUPERPHARM	500MG	A087589	001	Jan 22, 1982
		750MG	A087590	001	Jan 22, 1982
	TABLICAPS	500MG	A084846	001	
	UPSHER SMITH	500MG	A087453	001	
		750MG	A087454	001	
	WATSON LABS	500MG	A083605	001	
		500MG	A085180	001	
		750MG	A083605	002	
		750MG	A085192	001	
ROBAXIN					
+	AUXILIUM PHARMS LLC	500MG	N011011	004	
METHOHEXITAL SODIUM					
INJECTABLE;INJECTION					
BREVITAL SODIUM					
	PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012
		5GM/VIAL	N011559	003	
METHOTREXATE					
SOLUTION;SUBCUTANEOUS					
OTREXUP					
+	ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014
OTREXUP PFS					
+	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017
+		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017
+		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017
+		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017
+		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017
+		25MG/ML (25MG/ML)	N204824	014	May 31, 2017
RASUVO					
+	MEDEXUS	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014
METHOTREXATE SODIUM					
INJECTABLE;INJECTION					
ABITREXATE					
	ABIC	EQ 25MG BASE/ML	A089161	001	Mar 10, 1987
		EQ 50MG BASE/VIAL	A089354	001	Jul 17, 1987
		EQ 100MG BASE/VIAL	A089355	001	Jul 17, 1987
		EQ 250MG BASE/VIAL	A089356	001	Jul 17, 1987
FOLEX					
	PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983
		EQ 50MG BASE/VIAL	A087695	002	Apr 08, 1983
		EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983
		EQ 250MG BASE/VIAL	A088954	001	Oct 24, 1985
FOLEX PFS					
	PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242	001	Aug 23, 1991
		EQ 25MG BASE/ML	A089180	001	Jan 03, 1986
METHOTREXATE LPF					
	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHOTREXATE SODIUM					
INJECTABLE;INJECTION					
METHOTREXATE PRESERVATIVE FREE					
	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **	N011719	013	Apr 13, 2005
		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005
METHOTREXATE SODIUM					
	ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323	001	Jun 13, 1986
		EQ 20MG BASE/VIAL	A088935	001	Oct 11, 1985
		EQ 25MG BASE/ML	A089263	001	Jun 13, 1986
		EQ 25MG BASE/ML	A089322	001	Jun 13, 1986
		EQ 50MG BASE/VIAL	A088936	001	Oct 11, 1985
		EQ 100MG BASE/VIAL	A088937	001	Oct 11, 1985
	FRESENIUS KABI USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999
	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004	
		EQ 20MG BASE/VIAL	N011719	001	
		EQ 25MG BASE/ML	N011719	005	
		EQ 50MG BASE/VIAL	N011719	003	
		EQ 100MG BASE/VIAL	N011719	006	
	NORBROOK	EQ 25MG BASE/ML	A088648	001	May 09, 1986
	PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158	001	Jul 08, 1988
METHOTREXATE SODIUM PRESERVATIVE FREE					
	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988
MEXATE					
	BRISTOL	EQ 20MG BASE/VIAL	A086358	001	
		EQ 50MG BASE/VIAL	A086358	002	
		EQ 100MG BASE/VIAL	A086358	003	
		EQ 250MG BASE/VIAL	A086358	004	
MEXATE-AQ					
	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985
MEXATE-AQ PRESERVED					
	BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887	001	Apr 14, 1989
TABLET;ORAL					
METHOTREXATE SODIUM					
	DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233	001	Jun 17, 1999
METHOXAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
VASOXYL					
	GLAXOSMITHKLINE	10MG/ML	N006772	002	
		20MG/ML	N006772	001	
METHOXSALEN					
CAPSULE;ORAL					
8-MOP					
+	VALEANT PHARM INTL	10MG	N009048	001	
METHOXSALEN					
	ANI PHARMS INC	10MG	A087781	001	Jun 08, 1982
LOTION;TOPICAL					
OXSORALEN					
+	VALEANT PHARM INTL	1%	N009048	002	
METHSCOPOLAMINE BROMIDE					
TABLET;ORAL					
METHSCOPOLAMINE BROMIDE					
	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011
		5MG	A040642	002	Dec 06, 2011
	PVT FORM	2.5MG	A080970	001	
	VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006
		5MG	A040624	002	Dec 28, 2006
PAMINE					
	FOUGERA PHARMS	2.5MG **	N008848	001	
PAMINE FORTE					
	FOUGERA PHARMS	5MG **	N008848	002	Mar 25, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHSUXIMIDE					
CAPSULE;ORAL					
CELONTIN					
+	PARKE DAVIS	150MG	N010596	007	
METHYCLOTHIAZIDE					
TABLET;ORAL					
AQUATENSEN					
	MEDPOINTE PHARM HLC	5MG	N017364	001	
ENDURON					
+	ABBVIE	2.5MG **	N012524	001	
+		5MG **	N012524	004	
METHYCLOTHIAZIDE					
	IVAX PHARMS	2.5MG	A087913	001	Jun 03, 1982
		5MG	A087786	001	May 18, 1982
	MYLAN	2.5MG	A087671	001	Aug 17, 1982
	MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982
	PAR PHARM	2.5MG	A089135	001	Feb 12, 1986
		5MG	A089136	001	Feb 12, 1986
	USL PHARMA	5MG	A088745	001	Mar 21, 1985
	WATSON LABS	2.5MG	A085487	001	Mar 11, 1982
		2.5MG	A088750	001	Sep 06, 1984
		5MG	A085476	001	Mar 11, 1982
		5MG	A088724	001	Sep 06, 1984
	YAOPHARMA CO LTD	2.5MG	A089835	001	Aug 18, 1988
		5MG	A089837	001	Aug 18, 1988
METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE					
TABLET;ORAL					
EUTRON					
	ABBOTT	5MG;25MG	N016047	001	
METHYCLOTHIAZIDE; RESERPINE					
TABLET;ORAL					
DIUTENSEN-R					
	MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708	005	
METHYL AMINOLEVULINATE HYDROCHLORIDE					
CREAM;TOPICAL					
METVIXIA					
	GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004
METHYLDOPA					
SUSPENSION;ORAL					
ALDOMET					
	MERCK	250MG/5ML	N018389	001	
TABLET;ORAL					
ALDOMET					
+	MERCK	125MG **	N013400	003	
+		250MG **	N013400	001	
+		500MG **	N013400	002	
METHYLDOPA					
	ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985
	DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
		500MG	A071009	001	Dec 16, 1986
	HALSEY	125MG	A071751	001	Mar 28, 1988
		250MG	A071752	001	Mar 28, 1988
		500MG	A071753	001	Mar 28, 1988
	PAR PHARM	125MG	A070535	001	Jan 02, 1987
		250MG	A070536	001	Jan 02, 1987
		500MG	A070537	001	Jan 02, 1987
	PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
		250MG	A070332	001	Apr 15, 1986
		500MG	A070333	001	Apr 15, 1986
	PLIVA	125MG	A072126	001	Jul 07, 1988
		250MG	A072127	001	Jul 07, 1988
		500MG	A072128	001	Jul 07, 1988
	PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
		250MG	A070750	001	Feb 07, 1986
		500MG	A070452	001	Feb 07, 1986
	ROXANE	125MG	A070192	001	Apr 25, 1986
		250MG	A070193	001	Apr 25, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLDOPA

TABLET;ORAL

METHYLDOPA

	500MG	A070194	001	Apr 25, 1986
SUN PHARM INDUSTRIES	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985
YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

ALDOMET

+ MERCK	50MG/ML **	N013401	001	

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHERGINE

+ EDISON THERAPS LLC	0.2MG **	N006035	003	

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

RITALIN LA

+ NOVARTIS	60MG **	N021284	005	Oct 27, 2014

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002
AUROLIFE PHARMA LLC	5MG	A209276	001	Oct 25, 2018
	10MG	A209276	002	Oct 25, 2018
	20MG	A209276	003	Oct 25, 2018
CEDIPROF INC	5MG	A208737	001	Feb 01, 2019
	10MG	A208737	002	Feb 01, 2019
	20MG	A208737	003	Feb 01, 2019
CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016
	10MG	A206840	002	Sep 15, 2016
	20MG	A206840	003	Sep 15, 2016
LANNETT CO INC	5MG	A086429	001	
	10MG	A085799	001	
	20MG	A086428	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METHYLPHENIDATE HYDROCHLORIDE					
TABLET, CHEWABLE;ORAL					
METHYLIN					
+	SPECGX LLC	2.5MG **	N021475	001	Apr 15, 2003
+		5MG **	N021475	002	Apr 15, 2003
+		10MG **	N021475	003	Apr 15, 2003
TABLET, EXTENDED RELEASE;ORAL					
METADATE ER					
	LANNETT CO INC	10MG	A040306	001	Oct 20, 1999
		20MG	A089601	001	Jun 01, 1988
METHYLPHENIDATE HYDROCHLORIDE					
	ABLE	20MG	A076032	001	May 09, 2001
	HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001
	PAR PHARM	36MG	A204659	001	Jul 15, 2019
		54MG	A204659	002	Jul 15, 2019
	WATSON LABS	20MG	A040410	001	Feb 09, 2001
RITALIN-SR					
+	NOVARTIS	20MG **	N018029	001	Mar 30, 1982
METHYLPREDNISOLONE					
TABLET;ORAL					
MEDROL					
	PHARMACIA AND UPJOHN	24MG	N011153	005	
METHYLPREDNISOLONE					
	HEATHER	4MG	A085650	001	
	INVATECH	4MG	A087341	001	
	LUPIN LTD	2MG	A209097	001	Feb 22, 2019
		4MG	A209097	002	Feb 22, 2019
		8MG	A209097	003	Feb 22, 2019
		16MG	A209097	004	Feb 22, 2019
		32MG	A209097	005	Feb 22, 2019
	NOVAST LABS	4MG	A210985	001	Jan 09, 2019
	PAR PHARM	16MG	A089207	001	Apr 25, 1988
		24MG	A089208	001	Apr 25, 1988
		32MG	A089209	001	Apr 25, 1988
	WATSON LABS	4MG	A086161	001	Feb 09, 1982
		16MG	A086159	001	Feb 09, 1982
METHYLPREDNISOLONE ACETATE					
ENEMA;RECTAL					
MEDROL					
	PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
INJECTABLE;INJECTION					
M-PREDROL					
	BEL MAR	40MG/ML	A086666	001	
		80MG/ML	A087135	001	
METHYLPREDNISOLONE ACETATE					
	AKORN	40MG/ML	A086903	001	Oct 20, 1982
		80MG/ML	A086903	002	Oct 20, 1982
	AMNEAL	40MG/ML	A210043	001	May 20, 2019
		80MG/ML	A210043	002	May 20, 2019
	WATSON LABS	20MG/ML	A085597	001	
		20MG/ML	A087248	001	
		40MG/ML	A085374	001	
		40MG/ML	A085600	001	
		80MG/ML	A085595	001	
		80MG/ML	A086507	001	
OINTMENT;TOPICAL					
MEDROL ACETATE					
	PHARMACIA AND UPJOHN	0.25%	N012421	001	
		1%	N012421	002	
METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE					
CREAM;TOPICAL					
NEO-MEDROL ACETATE					
	PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002	
		1%;EQ 3.5MG BASE/GM	A060611	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-METHAPRED				
	ABBOTT	EQ 40MG BASE/VIAL	A089573 001	Feb 22, 1991
		EQ 125MG BASE/VIAL	A089574 001	Feb 22, 1991
		EQ 500MG BASE/VIAL	A089575 001	Feb 22, 1991
		EQ 1GM BASE/VIAL	A089576 001	Feb 22, 1991
	HOSPIRA	EQ 40MG BASE/VIAL	A040664 001	Dec 20, 2005
		EQ 40MG BASE/VIAL	A085853 001	
		EQ 125MG BASE/VIAL	A040665 001	Dec 20, 2005
		EQ 125MG BASE/VIAL	A085855 001	
		EQ 500MG BASE/VIAL	A085854 001	
		EQ 500MG BASE/VIAL	A089173 001	Aug 18, 1987
		EQ 1GM BASE/VIAL	A085852 001	
		EQ 1GM BASE/VIAL	A089174 001	Aug 18, 1987
	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008
		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008
METHYLPREDNISOLONE				
	ELKINS SINN	EQ 125MG BASE/VIAL	A086906 002	
		EQ 500MG BASE/VIAL	A086906 003	
		EQ 1GM BASE/VIAL	A086906 004	
	ORGANON USA INC	EQ 500MG BASE/VIAL	A087535 001	Jun 25, 1982
		EQ 1GM BASE/VIAL	A087535 002	Jun 25, 1982
METHYLPREDNISOLONE SODIUM SUCCINATE				
	ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676 001	Jun 08, 1984
		EQ 40MG BASE/VIAL	A089143 001	Mar 28, 1986
		EQ 125MG BASE/VIAL	A088677 001	Jun 08, 1984
		EQ 125MG BASE/VIAL	A089144 001	Mar 28, 1986
		EQ 500MG BASE/VIAL	A088678 001	Jun 08, 1984
		EQ 500MG BASE/VIAL	A089186 001	Mar 28, 1986
		EQ 500MG BASE/VIAL	A089187 001	Mar 28, 1986
		EQ 1GM BASE/VIAL	A088679 001	Jun 08, 1984
		EQ 1GM BASE/VIAL	A089188 001	Mar 28, 1986
		EQ 1GM BASE/VIAL	A089189 001	Mar 28, 1986
	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007
		EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007
		EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007
		EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007
		EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007
		EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007
	ELKINS SINN	EQ 40MG BASE/VIAL	A086906 001	
	INTL MEDICATION	EQ 40MG BASE/VIAL	A087812 001	Feb 09, 1983
		EQ 125MG BASE/VIAL	A087813 001	Feb 09, 1983
		EQ 500MG BASE/VIAL	A087851 001	Feb 09, 1983
		EQ 1GM BASE/VIAL	A087852 001	Feb 09, 1983
	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992
		EQ 500MG BASE/VIAL	A081267 001	Nov 30, 1992
		EQ 1GM BASE/VIAL	A081268 001	Nov 30, 1992
	WATSON LABS	EQ 40MG BASE/VIAL	A086953 001	Jul 22, 1982
		EQ 125MG BASE/VIAL	A087030 001	Jul 22, 1982
		EQ 500MG BASE/VIAL	A088523 001	Jul 24, 1984
		EQ 1GM BASE/VIAL	A088524 001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC

NEO-MEDROL				
	PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645 001	

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE				
	HEATHER	10MG	A084967 001	
VIRILON				
	CHARTWELL	10MG	A087750 001	Nov 24, 1982

TABLET;BUCCAL

ANDROID 5				
	VALEANT PHARM INTL	5MG	A087222 001	
ORETON				
	SCHERING	10MG	A080281 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METHYLTESTOSTERONE				
TABLET;BUCCAL, SUBLINGUAL				
METANDREN				
NOVARTIS	5MG		N003240 004	
	10MG		N003240 001	
	10MG		N003240 005	
	25MG		N003240 003	
METHYLTESTOSTERONE				
IMPAX LABS	10MG		A084287 001	
LILLY	10MG		A080256 001	
	25MG		A080256 002	
PUREPAC PHARM	10MG		A080308 001	
	10MG		A080475 001	
	10MG		A080475 002	
	25MG		A080475 003	
PVT FORM	5MG		A083836 001	
TABLICAPS	10MG		A085125 001	
USL PHARMA	10MG		A080271 001	
TABLET;ORAL				
ANDROID 10				
VALEANT PHARMS NORTH	10MG		A086450 001	
METHYLTESTOSTERONE				
IMPAX LABS	25MG		A084310 001	
INWOOD LABS	10MG		A080839 001	
	25MG		A080973 001	
KV PHARM	10MG		A084312 001	
LANNETT	10MG		A087092 001	Nov 05, 1982
	25MG		A087111 001	Jan 27, 1983
PARKE DAVIS	10MG		A084244 001	
	25MG		A084241 001	
PUREPAC PHARM	10MG		A080309 001	
	25MG		A080310 001	
PVT FORM	5MG		A080214 001	
	10MG		A080214 002	
	25MG		A080214 003	
TABLICAPS	10MG		A080313 001	
	25MG		A085270 001	
WATSON LABS	10MG		A080933 001	
	25MG		A080931 001	
WEST WARD	10MG		A084331 001	
	25MG		A084331 002	
	25MG		A084642 001	
ORETON METHYL				
SCHERING	10MG		N003158 001	
	25MG		N003158 002	
METHYPRYLON				
CAPSULE;ORAL				
NOLUDAR				
ROCHE	300MG		N009660 008	
ELIXIR;ORAL				
NOLUDAR				
ROCHE	50MG/5ML		N009660 007	
TABLET;ORAL				
NOLUDAR				
ROCHE	50MG		N009660 002	
	200MG		N009660 004	
METHYSERGIDE MALEATE				
TABLET;ORAL				
SANSERT				
NOVARTIS	2MG		N012516 001	
METIPRANOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
METIPRANOLOL				
SANDOZ INC	0.3%		A075720 001	Aug 06, 2001
OPTIPRANOLOL				
+ BAUSCH AND LOMB	0.3%		N019907 001	Dec 29, 1989

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOCLOPRAMIDE HYDROCHLORIDE					
CONCENTRATE;ORAL					
METOCLOPRAMIDE INTENSOL					
	ROXANE	EQ 10MG BASE/ML	A072995	001	Jan 30, 1992
INJECTABLE;INJECTION					
METOCLOPRAMIDE HYDROCHLORIDE					
	BEDFORD	EQ 5MG BASE/ML	A072155	001	Mar 30, 1992
		EQ 5MG BASE/ML	A072244	001	Mar 30, 1992
		EQ 5MG BASE/ML	A072247	001	May 18, 1992
	HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
		EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
		EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
		EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
		EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
		EQ 5MG BASE/ML	A073117	001	Jan 17, 1991
		EQ 5MG BASE/ML	A074147	001	Aug 02, 1996
	LYPHOMED	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
	NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
	SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
		EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987
REGLAN					
	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862	001	
		EQ 10MG BASE/ML	N017862	004	May 28, 1987
SOLUTION;ORAL					
METOCLOPRAMIDE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
	LANNETT CO INC	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992
	MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
	PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
	ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
	TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
		EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993
REGLAN					
+	ROBINS AH	EQ 5MG BASE/5ML **	N018821	001	Mar 25, 1983
TABLET;ORAL					
CLOPRA					
	QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
		EQ 10MG BASE	A070294	001	Jul 29, 1985
CLOPRA-"YELLOW"					
	QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
MAXOLON					
	KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
METOCLOPRAMIDE HYDROCHLORIDE					
	CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
	HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
	INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
	MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
	NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374	001	Nov 30, 2007
		EQ 10MG BASE	A078374	002	Nov 30, 2007
	PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
	SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
		EQ 10MG BASE	A070850	001	Feb 03, 1987
	SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
	SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997
		EQ 10MG BASE	A071536	001	Apr 28, 1993
	SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
	USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
	WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
		EQ 10MG BASE	A070453	001	Jun 06, 1986
		EQ 10MG BASE	A070511	001	Jan 22, 1986
		EQ 10MG BASE	A070645	001	May 11, 1987
	YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995
		EQ 10MG BASE	A072215	001	Jan 30, 1990
		EQ 10MG BASE	A074478	002	Oct 05, 1995
TABLET, ORALLY DISINTEGRATING;ORAL					
METOZOLV ODT					
+	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009
+		EQ 10MG BASE **	N022246	002	Sep 04, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOCLOPRAMIDE HYDROCHLORIDE				
TABLET, ORALLY DISINTEGRATING;ORAL				
REGLAN ODT				
MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005
METOCURINE IODIDE				
INJECTABLE;INJECTION				
METUBINE IODIDE				
LILLY	2MG/ML	N006632	003	
METOLAZONE				
TABLET;ORAL				
DIULO				
GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	
METOLAZONE				
ANI PHARMS INC	2.5MG	A076600	001	Jan 06, 2004
	5MG	A076833	001	Mar 01, 2004
	10MG	A075543	003	Dec 24, 2003
ROXANE	10MG	A076482	002	Apr 29, 2004
WATSON LABS	10MG	A076891	001	Jul 21, 2004
MYKROX				
LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987
METOPROLOL FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
LOPRESSOR				
NOVARTIS	EQ 100MG TARTRATE	N019786	001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786	002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786	003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786	004	Dec 27, 1989
METOPROLOL SUCCINATE				
TABLET, EXTENDED RELEASE;ORAL				
METOPROLOL SUCCINATE				
NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176	001	May 14, 2008
	EQ 100MG TARTRATE	A076640	002	May 18, 2007
	EQ 200MG TARTRATE	A076640	001	May 18, 2007
SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969	002	May 18, 2007
	EQ 100MG TARTRATE	A076969	003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969	004	Mar 20, 2008
METOPROLOL TARTRATE				
INJECTABLE;INJECTION				
LOPRESSOR				
+ NOVARTIS	1MG/ML	N018704	001	Mar 30, 1984
METOPROLOL TARTRATE				
LUITPOLD	1MG/ML	A090386	001	Sep 30, 2009
	1MG/ML	A091307	001	Dec 29, 2010
WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993
TABLET;ORAL				
METOPROLOL TARTRATE				
APOTHECON	50MG	A074258	001	Jan 27, 1994
	100MG	A074258	002	Jan 27, 1994
MYLAN	50MG	A073666	001	Dec 21, 1993
	100MG	A073666	002	Dec 21, 1993
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994
RENATA	50MG	A074453	001	Apr 27, 1995
	100MG	A074453	002	Apr 27, 1995
SUN PHARM INDUSTRIES	25MG	A073654	002	Jul 15, 2009
	50MG	A073654	003	Dec 21, 1993
	100MG	A073654	001	Dec 21, 1993
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994
WATSON LABS	50MG	A074217	001	May 27, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOPROLOL TARTRATE				
TABLET;ORAL				
METOPROLOL TARTRATE				
	100MG	A074217	002	May 27, 1994
YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994
	100MG	A073289	001	Mar 25, 1994
METRIZAMIDE				
INJECTABLE;INJECTION				
AMIPAQUE				
GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983
METRONIDAZOLE				
CAPSULE;ORAL				
METRONIDAZOLE				
ABLE	375MG	A076505	001	Nov 13, 2003
INJECTABLE;INJECTION				
FLAGYL I.V. RTU IN PLASTIC CONTAINER				
PFIZER	500MG/100ML	N018353	002	
METRO I.V.				
B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
METRONIDAZOLE				
ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986
WEST-WARD PHARMS INT	500MG/100ML	N018907	001	Mar 30, 1984
TABLET;ORAL				
METROMIDOL				
LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996
METRONIDAZOLE				
ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983
FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982
	250MG	N018740	001	Oct 22, 1982
	500MG	N018620	002	Jun 02, 1983
	500MG	N018740	002	Oct 22, 1982
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	250MG	N018764	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984
	500MG	N018764	002	Dec 20, 1982
PROTOSTAT				
ORTHO MCNEIL PHARM	250MG	N018871	001	Mar 02, 1983
	500MG	N018871	002	Mar 02, 1983
SATRIC				
SAVAGE LABS	250MG	A070029	001	Mar 19, 1985
	500MG	A070731	001	Jun 08, 1987
TABLET, EXTENDED RELEASE;ORAL				
FLAGYL ER				
+ GD SEARLE LLC	750MG	N020868	001	Nov 26, 1997
METRONIDAZOLE				
ABLE	750MG	A076462	001	Jun 25, 2003
ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METRONIDAZOLE HYDROCHLORIDE				
INJECTABLE;INJECTION				
FLAGYL I.V.				
PFIZER	EQ 500MG BASE/VIAL **	N018353	001	
METRONIDAZOLE HYDROCHLORIDE				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295	001	Oct 15, 1985
METYRAPONE				
TABLET;ORAL				
METOPIRONE				
HRA PHARMA	250MG	N012911	001	
MEXILETINE HYDROCHLORIDE				
CAPSULE;ORAL				
MEXILETINE HYDROCHLORIDE				
ANI PHARMS INC	150MG	A074450	001	May 16, 1996
	200MG	A074450	002	May 16, 1996
	250MG	A074450	003	May 16, 1996
WATSON LABS	150MG	A074711	001	Feb 26, 1997
	150MG	A074865	001	Apr 13, 1998
	200MG	A074711	002	Feb 26, 1997
	200MG	A074865	002	Apr 13, 1998
	250MG	A074711	003	Feb 26, 1997
	250MG	A074865	003	Apr 13, 1998
MEXITIL				
+ BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
+	200MG	N018873	003	Dec 30, 1985
+	250MG	N018873	004	Dec 30, 1985
MEZLOCILLIN SODIUM MONOHYDRATE				
INJECTABLE;INJECTION				
MEZLIN				
BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988
MICONAZOLE				
INJECTABLE;INJECTION				
MONISTAT				
JANSSEN PHARMA	10MG/ML	N018040	001	
MICONAZOLE NITRATE				
CREAM;TOPICAL				
MONISTAT-DERM				
INSIGHT PHARMS	2%	N017494	001	
CREAM;VAGINAL				
MICONAZOLE NITRATE				
TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992
CREAM, SUPPOSITORY;TOPICAL, VAGINAL				
M-ZOLE 7 DUAL PACK				
ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997
MICONAZOLE 7 COMBINATION PACK				
ACP NIMBLE	2%,100MG	A076585	001	Mar 26, 2004
LOTION;TOPICAL				
MONISTAT-DERM				
INSIGHT PHARMS	2%	N017739	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MICONAZOLE NITRATE				
TAMPON;VAGINAL				
MONISTAT 5				
PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989
MIDAZOLAM HYDROCHLORIDE				
INJECTABLE;INJECTION				
MIDAZOLAM HYDROCHLORIDE				
AKORN INC	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000
APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004
WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008
	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008
	EQ 5MG BASE/ML	A078141	002	May 30, 2008
	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008
MIDOZALAM HYDROCHLORIDE				
MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011
	EQ 5MG BASE/ML	A090316	002	May 04, 2011
VERSED				
+ HLR	EQ 1MG BASE/ML **	N018654	002	May 26, 1987
+	EQ 5MG BASE/ML **	N018654	001	Dec 20, 1985
SYRUP;ORAL				
MIDAZOLAM HYDROCHLORIDE				
PHARM ASSOC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002
VERSED				
+ ROCHE	EQ 2MG BASE/ML **	N020942	001	Oct 15, 1998
MIDODRINE HYDROCHLORIDE				
TABLET;ORAL				
MIDODRINE HYDROCHLORIDE				
CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003
	5MG	A076514	002	Sep 11, 2003
	10MG	A076514	003	Jul 02, 2004
PROAMATINE				
+ SHIRE LLC	2.5MG **	N019815	001	Sep 06, 1996
+	5MG **	N019815	002	Sep 06, 1996
+	10MG **	N019815	003	Mar 20, 2002
MILNACIPRAN HYDROCHLORIDE				
TABLET;ORAL				
MILNACIPRAN HYDROCHLORIDE				
AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016
	25MG	A205081	002	Apr 22, 2016
	50MG	A205081	003	Apr 22, 2016
	100MG	A205081	004	Apr 22, 2016
USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016
	25MG	A205071	002	Jan 27, 2016
	50MG	A205071	003	Jan 27, 2016
	100MG	A205071	004	Jan 27, 2016

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MILRINONE LACTATE					
INJECTABLE;INJECTION					
MILRINONE LACTATE					
	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004
	GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190	001	Oct 31, 2006
	HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002
		EQ 1MG BASE/ML	A075884	001	May 28, 2002
	MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075852	001	May 28, 2002
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004
	BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002
	WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002
	WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005
PRIMACOR					
+	SANOFI AVENTIS US	EQ 1MG BASE/ML **	N019436	001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	SANOFI AVENTIS US	EQ 10MG BASE/100ML **	N020343	001	Aug 09, 1994
+		EQ 15MG BASE/100ML **	N020343	002	Aug 09, 1994
+		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) **	N020343	003	Aug 09, 1994
+		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) **	N020343	004	Aug 09, 1994
MINOCYCLINE HYDROCHLORIDE					
CAPSULE;ORAL					
MINOCIN					
+	BAUSCH	EQ 75MG BASE **	N050649	003	Feb 12, 2001
	TRIAX PHARMS	EQ 50MG BASE	N050315	002	
		EQ 100MG BASE	N050315	001	
CAPSULE, EXTENDED RELEASE;ORAL					
XIMINO					
	SUN PHARM INDS INC	EQ 67.5MG BASE	N201922	002	Jul 11, 2012
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012
INJECTABLE;INJECTION					
MINOCIN					
	LEDERLE	EQ 100MG BASE/VIAL	A062139	001	
SUSPENSION;ORAL					
MINOCIN					
	BAUSCH	EQ 50MG BASE/5ML	N050445	001	
TABLET;ORAL					
MINOCYCLINE HYDROCHLORIDE					
+	TRIAX PHARMS	EQ 50MG BASE **	N050451	003	Aug 10, 1982
+		EQ 100MG BASE **	N050451	002	Aug 10, 1982
TABLET, EXTENDED RELEASE;ORAL					
MINOCYCLINE HYDROCHLORIDE					
	BARR LABS INC	EQ 45MG BASE	A065485	001	Mar 17, 2009
		EQ 90MG BASE	A065485	002	Mar 17, 2009
		EQ 135MG BASE	A065485	003	Mar 17, 2009
	IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009
		EQ 90MG BASE	A090024	002	Feb 03, 2009
		EQ 135MG BASE	A090024	003	Feb 03, 2009
	MYLAN	EQ 55MG BASE	A203443	001	Aug 21, 2019
	MYLAN LABS LTD	EQ 65MG BASE	A201467	001	Jul 30, 2019
		EQ 115MG BASE	A201467	002	Jul 30, 2019
	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010
		EQ 90MG BASE	A090911	002	Jul 20, 2010
		EQ 135MG BASE	A090911	003	Jul 20, 2010
SOLODYN					
+	MEDICIS	EQ 45MG BASE **	N050808	001	May 08, 2006
+		EQ 90MG BASE **	N050808	002	May 08, 2006
+		EQ 135MG BASE **	N050808	003	May 08, 2006
MINOXIDIL					
SOLUTION;TOPICAL					
MINOXIDIL (FOR MEN)					
	APOTEX INC	2%	A074924	001	Apr 29, 1998
	BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
	COPLEY PHARM	2%	A074500	001	May 23, 1996
	SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
	TEVA	2%	A074589	001	Apr 05, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MINOXIDIL					
SOLUTION;TOPICAL					
MINOXIDIL (FOR WOMEN)					
	APOTEX INC	2%	A074924	002	Apr 29, 1998
	SIGHT PHARMS	2%	A074743	001	Oct 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
	APOTEX INC	5%	A075839	001	Oct 01, 2001
TABLET;ORAL					
LONITEN					
+	PHARMACIA AND UPJOHN	2.5MG **	N018154	001	
+		10MG **	N018154	003	
MINODYL					
	QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
		10MG	A071534	001	Mar 19, 1987
MINOXIDIL					
	ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
		10MG	A071796	001	Nov 10, 1987
	USL PHARMA	2.5MG	A071537	001	Dec 16, 1988
MIPOMERSEN SODIUM					
SOLUTION;SUBCUTANEOUS					
KYNAMRO					
+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013
MIRTAZAPINE					
TABLET;ORAL					
MIRTAZAPINE					
	ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
		15MG	A076308	001	Jun 20, 2003
		30MG	A076241	002	Jun 25, 2003
		30MG	A076308	002	Jun 20, 2003
		45MG	A076241	003	Jun 25, 2003
		45MG	A076308	003	Jun 20, 2003
	ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003
		30MG	A076336	002	Jun 20, 2003
		45MG	A076336	003	Jun 20, 2003
	IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
		30MG	A076244	002	Dec 22, 2003
		45MG	A076244	003	Dec 22, 2003
	MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003
		30MG	A076176	002	Jun 19, 2003
		45MG	A076176	003	Jun 19, 2003
	ROXANE	15MG	A076270	001	Jun 19, 2003
		30MG	A076270	002	Jun 19, 2003
		45MG	A076270	003	Jun 19, 2003
	UPSHER SMITH LABS	15MG	A076189	001	Jun 19, 2003
		30MG	A076189	002	Jun 19, 2003
		45MG	A076189	003	Jun 19, 2003
	WATSON LABS	15MG	A076312	001	Jun 19, 2003
		30MG	A076312	002	Jun 19, 2003
		45MG	A076312	003	Jun 19, 2003
REMERON					
+	ORGANON USA INC	45MG **	N020415	003	Mar 17, 1997
TABLET, ORALLY DISINTEGRATING;ORAL					
MIRTAZAPINE					
	ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
		15MG	A077959	001	Feb 14, 2011
		30MG	A076689	002	Aug 31, 2005
		30MG	A077959	002	Feb 14, 2011
		45MG	A076689	003	Aug 31, 2005
		45MG	A077959	003	Feb 14, 2011
	ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003
		30MG	A076307	002	Dec 17, 2003
		45MG	A076307	003	Feb 28, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MISOPROSTOL				
TABLET;ORAL				
MISOPROSTOL				
ANI PHARMS INC	0.1MG	A076095	001	Jul 10, 2002
	0.2MG	A076095	002	Jul 10, 2002
ZYDUS PHARMS	0.1MG	A210201	001	Jul 02, 2019
	0.2MG	A210201	002	Jul 02, 2019
MITOMYCIN				
INJECTABLE;INJECTION				
MITOMYCIN				
HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995
WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995
MITOZYTREX				
+ SUPERGEN	5MG/VIAL **	N050763	001	Nov 14, 2002
MUTAMYCIN				
+ BRISTOL	5MG/VIAL **	N050450	001	
+	20MG/VIAL **	N050450	002	
BRISTOL MYERS	5MG/VIAL	A062336	001	
	20MG/VIAL	A062336	002	
	40MG/VIAL	A062336	003	Mar 10, 1988
MITOXANTRONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MITOXANTRONE HYDROCHLORIDE				
FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008
MYLAN INSTITUTIONAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009
MYLAN LABS LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012
NOVANTRONE				
+ EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987
+	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **	N019297	002	Dec 23, 1987
+	EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **	N019297	003	Dec 23, 1987
MIVACURIUM CHLORIDE				
INJECTABLE;INJECTION				
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBVIE	EQ 0.5MG BASE/ML	N020098	002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098	003	Jan 22, 1992
MIVACURIUM CHLORIDE				
MYLAN LABS LTD	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009
SOLUTION;INTRAVENOUS				
MIVACRON				
+ ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **	N020098	001	Jan 22, 1992
+	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992
+	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992
MODAFINIL				
TABLET;ORAL				
MODAFINIL				
HIKMA PHARMS	100MG	A090543	001	Sep 26, 2012
	200MG	A090543	002	Sep 26, 2012
MOEXIPRIL HYDROCHLORIDE				
TABLET;ORAL				
UNIVASC				
UCB INC	7.5MG **	N020312	001	Apr 19, 1995
	15MG **	N020312	002	Apr 19, 1995
MOLINDONE HYDROCHLORIDE				
CAPSULE;ORAL				
MOBAN				
+ ENDO PHARMS	5MG **	N017111	001	
+	10MG **	N017111	002	
+	25MG **	N017111	003	
CONCENTRATE;ORAL				
MOBAN				
ENDO PHARMS	20MG/ML	N017938	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MOLINDONE HYDROCHLORIDE				
TABLET;ORAL				
MOBAN				
+ ENDO PHARMS	5MG **	N017111	004	
+	10MG **	N017111	005	
+	25MG **	N017111	006	
+	50MG **	N017111	007	
+	100MG **	N017111	008	
MOMETASONE FUROATE				
CREAM;TOPICAL				
ELOCON				
MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987
+	0.1%	N019625	002	Apr 19, 2013
OINTMENT;TOPICAL				
ELOCON				
+ MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987
MOMETASONE FUROATE				
TARO	0.1%	A076624	001	Dec 03, 2004
MONOBENZONE				
CREAM;TOPICAL				
BENOQUIN				
VALEANT PHARM INTL	20%	N008173	003	
MONOCTANOIN				
LIQUID;PERFUSION, BILIARY				
MOCTANIN				
ETHITEK	100%	N019368	001	Oct 29, 1985
MONTELUKAST SODIUM				
GRANULE;ORAL				
MONTELUKAST SODIUM				
MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012
TABLET;ORAL				
MONTELUKAST SODIUM				
APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012
MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012
VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012
TABLET, CHEWABLE;ORAL				
MONTELUKAST SODIUM				
APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012
	EQ 5MG BASE	A201508	002	Aug 03, 2012
MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012
	EQ 5MG BASE	A079142	002	Aug 03, 2012
VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012
	EQ 5MG BASE	A091588	002	Aug 03, 2012
MORICIZINE HYDROCHLORIDE				
TABLET;ORAL				
ETHMOZINE				
SHIRE	200MG	N019753	001	Jun 19, 1990
	250MG	N019753	002	Jun 19, 1990
	300MG	N019753	003	Jun 19, 1990
MORPHINE SULFATE				
CAPSULE, EXTENDED RELEASE;ORAL				
AVINZA				
KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002
	45MG	N021260	005	Dec 18, 2008
	60MG	N021260	002	Mar 20, 2002
	75MG	N021260	006	Dec 18, 2008
	90MG	N021260	003	Mar 20, 2002
	120MG	N021260	004	Mar 20, 2002
INJECTABLE;INJECTION				
ASTRAMORPH PF				
FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986
	0.5MG/ML	A071051	001	Oct 07, 1986
	1MG/ML	A071052	001	Oct 07, 1986
	1MG/ML	A071053	001	Oct 07, 1986
MORPHINE SULFATE				
+ HOSPIRA INC	15MG/ML	N202515	005	Nov 14, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MORPHINE SULFATE					
INJECTABLE;INJECTION					
MORPHINE SULFATE					
	ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992
+		5MG/ML	N019916	002	Oct 27, 2006
	SPECGX LLC	1MG/ML	N020631	001	Jul 03, 1996
		2MG/ML	N020631	002	Jul 03, 1996
	WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991
		0.5MG/ML	A073375	001	Sep 30, 1991
		1MG/ML	A073374	001	Sep 30, 1991
		1MG/ML	A073376	001	Sep 30, 1991
INJECTABLE, LIPOSOMAL;EPIDURAL					
DEPODUR					
	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004
		15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004
		20MG/2ML (10MG/ML)	N021671	003	May 18, 2004
SOLUTION;ORAL					
MORPHINE SULFATE					
	LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015
		20MG/5ML	A202310	001	Oct 30, 2015
		100MG/5ML	N201517	001	Jun 23, 2011
	VISTAPHARM	10MG/5ML	A201947	001	Jan 05, 2012
		20MG/5ML	A201947	002	Jan 05, 2012
TABLET, EXTENDED RELEASE;ORAL					
ARYMO ER					
+	ZYLA	15MG	N208603	001	Jan 09, 2017
+		30MG	N208603	002	Jan 09, 2017
+		60MG	N208603	003	Jan 09, 2017
MORPHINE SULFATE					
	EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016
		30MG	A091357	002	Jun 23, 2016
		60MG	A091357	003	Jun 23, 2016
		100MG	A091357	004	Jun 23, 2016
		200MG	A091357	005	Jun 23, 2016
	MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011
		30MG	A200824	002	Oct 18, 2011
		60MG	A200824	003	Oct 18, 2011
		100MG	A200824	004	Oct 18, 2011
		200MG	A200824	005	Oct 18, 2011
	SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016
		30MG	A205634	002	Aug 25, 2016
		60MG	A205634	003	Aug 25, 2016
		100MG	A205634	004	Aug 25, 2016
		200MG	A205634	005	Aug 25, 2016
	WATSON LABS	100MG	A075656	001	Jan 30, 2001
ORAMORPH SR					
	XANODYNE PHARMS INC	15MG	N019977	004	Nov 23, 1994
		30MG	N019977	001	Aug 15, 1991
		60MG	N019977	002	Aug 15, 1991
		100MG	N019977	003	Aug 15, 1991
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
EMBEDA					
+	ALPHARMA PHARMS	20MG;0.8MG	N022321	001	Aug 13, 2009
+		30MG;1.2MG	N022321	002	Aug 13, 2009
+		50MG;2MG	N022321	003	Aug 13, 2009
+		60MG;2.4MG	N022321	004	Aug 13, 2009
+		80MG;3.2MG	N022321	005	Aug 13, 2009
+		100MG;4MG	N022321	006	Aug 13, 2009
MOXALACTAM DISODIUM					
INJECTABLE;INJECTION					
MOXAM					
	LILLY	EQ 250MG BASE/VIAL	N050550	001	
		EQ 500MG BASE/VIAL	N050550	002	
		EQ 1GM BASE/VIAL	N050550	003	
		EQ 2GM BASE/VIAL	N050550	004	
		EQ 10GM BASE/VIAL	N050550	008	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MOXIFLOXACIN HYDROCHLORIDE					
SOLUTION;INTRAVENOUS					
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML) **	N021277	001	Nov 30, 2001
TABLET;ORAL					
MOXIFLOXACIN HYDROCHLORIDE					
	MYLAN	EQ 400MG BASE	A204635	001	Aug 31, 2015
	SUNSHINE LAKE	EQ 400MG BASE	A206295	001	Sep 28, 2018
MUPIROCIN					
OINTMENT;TOPICAL					
BACTROBAN					
+	GLAXOSMITHKLINE	2% **	N050591	001	Dec 31, 1987
MUPIROCIN CALCIUM					
CREAM;TOPICAL					
BACTROBAN					
+	GLAXOSMITHKLINE	EQ 2% BASE **	N050746	001	Dec 11, 1997
OINTMENT;NASAL					
BACTROBAN					
+	GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995
MYCOPHENOLATE MOFETIL					
CAPSULE;ORAL					
MYCOPHENOLATE MOFETIL					
	APOTEX CORP	250MG	A090419	001	Apr 22, 2009
	DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011
	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014
	ZYDUS PHARMS USA INC	250MG	A065433	001	May 04, 2009
TABLET;ORAL					
MYCOPHENOLATE MOFETIL					
	APOTEX	500MG	A090499	001	Apr 22, 2009
	DR REDDYS LABS LTD	500MG	A090464	001	Sep 13, 2010
	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014
	OXFORD PHARMS	500MG	A090606	001	Jul 16, 2010
	TEVA PHARMS	500MG	A065457	001	May 04, 2009
	ZYDUS PHARMS USA INC	500MG	A065477	001	May 04, 2009
NABUMETONE					
TABLET;ORAL					
NABUMETONE					
	COPLEY PHARM	750MG	A075179	001	Jun 06, 2000
	OXFORD PHARMS	500MG	A079093	001	Feb 27, 2009
		750MG	A079093	002	Feb 27, 2009
	SANDOZ	500MG	A075590	001	Feb 25, 2002
		750MG	A075590	002	Feb 25, 2002
RELAFEN					
+	SMITHKLINE BEECHAM	500MG **	N019583	001	Dec 24, 1991
+		750MG **	N019583	002	Dec 24, 1991
NADOLOL					
TABLET;ORAL					
CORGARD					
	US WORLDMEDS LLC	120MG	N018063	003	
		160MG	N018063	004	
NADOLOL					
	HERITAGE PHARMA	120MG	A074255	002	Jan 24, 1996
		160MG	A074255	003	Jan 24, 1996
	TEVA PHARMS	80MG	A074368	001	Aug 31, 1994
		120MG	A074368	002	Aug 31, 1994
		160MG	A074368	003	Aug 31, 1994
NAFCILLIN SODIUM					
CAPSULE;ORAL					
UNIPEN					
	WYETH AYERST	EQ 250MG BASE	N050111	001	
FOR SOLUTION;ORAL					
UNIPEN					
	WYETH AYERST	EQ 250MG BASE/5ML	N050199	001	
INJECTABLE;INJECTION					
NAFCILLIN SODIUM					
	APOTHECON	EQ 500MG BASE/VIAL	A061984	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAFCILLIN SODIUM				
INJECTABLE;INJECTION				
NAFCILLIN SODIUM				
	EQ 1GM BASE/VIAL	A061984	002	
	EQ 2GM BASE/VIAL	A061984	003	
	EQ 4GM BASE/VIAL	A061984	005	
MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014
	EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014
SANDOZ	EQ 500MG BASE/VIAL	A062527	001	Aug 02, 1984
WATSON LABS INC	EQ 500MG BASE/VIAL	A062844	001	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062844	002	Oct 26, 1988
	EQ 1.5GM BASE/VIAL	A062844	003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062844	004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062844	005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A063008	001	Sep 29, 1988
NALLPEN				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061999	001	
	EQ 1GM BASE/VIAL	A061999	002	
	EQ 1GM BASE/VIAL	A062755	001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A061999	003	
	EQ 2GM BASE/VIAL	A062755	002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A061999	004	
UNIPEN				
WYETH AYERST	EQ 500MG BASE/VIAL **	A062717	001	Dec 16, 1986
+	EQ 500MG BASE/VIAL **	N050320	001	
	EQ 1GM BASE/VIAL **	A062717	002	Dec 16, 1986
	EQ 2GM BASE/VIAL **	A062717	004	Dec 16, 1986
+	EQ 2GM BASE/VIAL **	N050320	003	
+	EQ 4GM BASE/VIAL **	N050320	004	
+	EQ 10GM BASE/VIAL **	N050320	005	
+	EQ 20GM BASE/VIAL **	N050320	006	
UNIPEN IN PLASTIC CONTAINER				
+ WYETH AYERST	EQ 1GM BASE/VIAL **	N050320	002	
TABLET;ORAL				
UNIPEN				
WYETH AYERST	EQ 500MG BASE	N050462	001	
NAFTIFINE HYDROCHLORIDE				
CREAM;TOPICAL				
NAFTIN				
+ SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988
GEL;TOPICAL				
NAFTIFINE HYDROCHLORIDE				
TARO	2%	A208201	001	Apr 10, 2019
NALBUPHINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NALBUPHINE				
ABRAXIS PHARM	10MG/ML	A070751	001	Jul 02, 1986
	20MG/ML	A070752	001	Sep 24, 1986
NALBUPHINE HYDROCHLORIDE				
ABBOTT	20MG/ML	A070917	001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200	001	Mar 12, 1993
DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998
	20MG/ML	A074471	002	Mar 19, 1998
IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989
	10MG/ML	A072071	001	Apr 10, 1989
	10MG/ML	A072072	001	Apr 10, 1989
	20MG/ML	A072073	001	Apr 10, 1989
	20MG/ML	A072074	001	Apr 10, 1989
	20MG/ML	A072075	001	Apr 10, 1989
NUBAIN				
+ PAR PHARM INC	10MG/ML **	N018024	001	
+	20MG/ML **	N018024	002	May 27, 1982

NALIDIXIC ACID					
SUSPENSION;ORAL					
NEGGRAM					
	SANOFI AVENTIS US	250MG/5ML	N017430	001	
TABLET;ORAL					
NALIDIXIC ACID					
	SUN PHARM INDUSTRIES	250MG	A070270	001	Jun 29, 1988
		500MG	A070271	001	Jun 29, 1988
		1GM	A070272	001	Jun 29, 1988
	WATSON LABS	250MG	A071936	001	Jun 29, 1988
		500MG	A072061	001	Jun 29, 1988
		1GM	A071919	001	Jun 29, 1988
NEGGRAM					
	SANOFI AVENTIS US	250MG	N014214	002	
		500MG	N014214	004	
		1GM	N014214	005	
NALMEFENE HYDROCHLORIDE					
INJECTABLE;INJECTION					
REVEX					
+	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML **	N020459	001	Apr 17, 1995
+		EQ 1MG BASE/ML **	N020459	002	Apr 17, 1995
NALOXONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
NALOXONE					
	WEST-WARD PHARMS INT	0.4MG/ML	A070298	001	Sep 24, 1986
		0.4MG/ML	A070496	001	Sep 24, 1986
	WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
		0.02MG/ML	A070189	001	Sep 24, 1986
		0.4MG/ML	A070190	001	Sep 24, 1986
		0.4MG/ML	A070191	001	Sep 24, 1986
NALOXONE HYDROCHLORIDE					
	ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
		0.02MG/ML	A070661	001	Nov 17, 1986
		0.4MG/ML	A070649	001	Nov 17, 1986
		1MG/ML	A071604	001	Dec 16, 1988
	ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
	EUROHLTH INTL SARL	0.02MG/ML	A071272	001	May 24, 1988
		1MG/ML	A071273	001	May 24, 1988
		1MG/ML	A071274	001	May 24, 1988
		1MG/ML	A071287	001	May 24, 1988
	HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
		0.02MG/ML	A070252	001	Jan 16, 1987
		0.02MG/ML	A070253	001	Jan 16, 1987
		0.4MG/ML	A070255	001	Jan 07, 1987
	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989
		0.02MG/ML	A072083	001	Apr 11, 1989
		0.02MG/ML	A072084	001	Apr 11, 1989
		0.02MG/ML	A072085	001	Apr 11, 1989
		0.4MG/ML	A072086	001	Apr 11, 1989
		0.4MG/ML	A072087	001	Apr 11, 1989
		0.4MG/ML	A072088	001	Apr 11, 1989
		0.4MG/ML	A072089	001	Apr 11, 1989
		0.4MG/ML	A072090	001	Apr 11, 1989
		1MG/ML	A072091	001	Apr 11, 1989
		1MG/ML	A072092	001	Apr 11, 1989
		1MG/ML	A072093	001	Apr 11, 1989
	INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
		1MG/ML	A072115	001	Apr 27, 1988
	MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
	SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
		0.4MG/ML	A071681	001	Nov 17, 1987
		0.4MG/ML	A071682	001	Nov 17, 1987
	SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
		0.4MG/ML	A071683	001	Nov 17, 1987
	VIRTUS PHARMS	0.4MG/ML	A207846	001	Dec 17, 2018
	WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN					
+	ADAPT	0.02MG/ML **	N016636	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NALOXONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
NARCAN					
+		0.4MG/ML **	N016636	001	
+		1MG/ML **	N016636	003	Jun 14, 1982
	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
		1MG/ML	A071084	001	Jul 28, 1988
		1MG/ML	A071311	001	Jul 28, 1988
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
EVZIO					
+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014
SPRAY, METERED;NASAL					
NALOXONE HYDROCHLORIDE					
	TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019
NARCAN					
+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
TARGINIQ					
+	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014
+		10MG;20MG	N205777	002	Jul 23, 2014
+		20MG;40MG	N205777	003	Jul 23, 2014
NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE					
TABLET;ORAL					
TALWIN NX					
	SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE **	N018733	001	Dec 16, 1982
NALTREXONE HYDROCHLORIDE					
TABLET;ORAL					
NALTREXONE HYDROCHLORIDE					
	FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000
REVIA					
	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
TROXYCA ER					
	PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016
		2.4MG;20MG	N207621	002	Aug 19, 2016
		3.6MG;30MG	N207621	003	Aug 19, 2016
		4.8MG;40MG	N207621	004	Aug 19, 2016
		7.2MG;60MG	N207621	005	Aug 19, 2016
		9.6MG;80MG	N207621	006	Aug 19, 2016
NANDROLONE DECANOATE					
INJECTABLE;INJECTION					
DECA-DURABOLIN					
	ASPEN GLOBAL INC	50MG/ML	N013132	001	Jun 12, 1986
		100MG/ML	N013132	002	Jun 12, 1986
+		200MG/ML **	N013132	003	Jun 12, 1986
NANDROLONE DECANOATE					
	ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
		200MG/ML	A088317	001	Oct 14, 1983
	AKORN	100MG/ML	A087519	001	Sep 28, 1983
	LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010
	WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
		50MG/ML	A087598	001	Oct 06, 1983
		50MG/ML	A088554	001	Feb 10, 1986
		100MG/ML	A086598	001	Jan 13, 1984
		100MG/ML	A087599	001	Oct 06, 1983
		200MG/ML	A088128	001	Dec 05, 1983
NANDROLONE PHENPROPIONATE					
INJECTABLE;INJECTION					
DURABOLIN					
	ORGANON USA INC	25MG/ML	N011891	001	
		50MG/ML	N011891	002	
NANDROLONE PHENPROPIONATE					
	WATSON LABS	25MG/ML	A086386	001	Jun 17, 1983
		50MG/ML	A087488	001	Jun 17, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

NAPHAZOLINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
ALBALON				
ALLERGAN	0.1% **	A080248	001	
NAFAZAIR				
BAUSCH AND LOMB	0.1%	A040073	001	May 25, 1994
PHARMAFAIR	0.1%	A088101	001	Apr 15, 1983
NAPHAZOLINE HYDROCHLORIDE				
AKORN INC	0.1%	A083590	001	
NAPHCON FORTE				
ALCON	0.1%	A080229	001	
OPCON				
BAUSCH AND LOMB	0.1%	A087506	001	
VASOCON				
NOVARTIS	0.1%	A080235	002	Mar 24, 1983
NAPROXEN				
TABLET;ORAL				
NAPROSYN				
+ ATNAHS PHARMA US	250MG	N017581	002	
+	375MG	N017581	003	
NAPROXEN				
CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995
	375MG	A074410	002	Apr 28, 1995
	500MG	A074410	003	Apr 28, 1995
DAVA PHARMS INC	250MG	A074105	001	Dec 21, 1993
	375MG	A074105	002	Dec 21, 1993
	500MG	A074105	003	Dec 21, 1993
FOSUN PHARMA	250MG	A074140	001	Dec 21, 1993
	375MG	A074140	002	Dec 21, 1993
	500MG	A074140	003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004
	375MG	A076494	002	Jan 14, 2004
	500MG	A076494	003	Jan 14, 2004
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995
	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995
PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074457	001	May 31, 1995
	375MG	A074457	002	May 31, 1995
	500MG	A074457	003	May 31, 1995
WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995
TABLET, DELAYED RELEASE;ORAL				
NAPROXEN				
ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998
	500MG	A074936	002	Feb 24, 1998
FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998
	500MG	A075061	002	Feb 18, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAPROXEN				
TABLET, DELAYED RELEASE;ORAL				
NAPROXEN				
MYLAN PHARMS INC	375MG	A075390	001	Apr 19, 2001
	500MG	A075390	002	Apr 19, 2001
NAPROXEN SODIUM				
TABLET;ORAL				
ANAPROX				
+ ATNAHS PHARMA US	EQ 250MG BASE **	N018164	001	
NAPROXEN SODIUM				
ABLE	EQ 250MG BASE	A076544	001	Aug 22, 2003
	EQ 500MG BASE	A076544	002	Aug 22, 2003
CONTRACT PHARMACAL	220MG	A074789	001	Feb 27, 1997
HAMILTON PHARMS	EQ 250MG BASE	A074106	001	Aug 31, 1993
	EQ 500MG BASE	A074106	002	Aug 31, 1993
HIKMA	EQ 250MG BASE	A074480	002	Feb 18, 1998
	EQ 500MG BASE	A074480	001	May 14, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230	001	Mar 14, 1995
	EQ 500MG BASE	A074230	002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367	001	Aug 31, 1994
	EQ 500MG BASE	A074367	002	Aug 31, 1994
PLD ACQUISITIONS LLC	220MG	A074646	001	Jan 13, 1997
PLIVA	EQ 250MG BASE	A074242	001	Jun 20, 1996
	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
SANDOZ	EQ 250MG BASE	A074162	001	Dec 21, 1993
	EQ 250MG BASE	A074495	001	Dec 05, 1994
	EQ 500MG BASE	A074162	002	Dec 21, 1993
	EQ 500MG BASE	A074495	002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 250MG BASE	A074455	001	May 31, 1995
	EQ 500MG BASE	A074195	002	Dec 21, 1993
	EQ 500MG BASE	A074455	002	May 31, 1995
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE				
TABLET;ORAL				
TREXIMET				
+ CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015
NARATRIPTAN HYDROCHLORIDE				
TABLET;ORAL				
NARATRIPTAN				
ANI PHARMS INC	EQ 1MG BASE	A078751	001	Jul 07, 2010
	EQ 2.5MG BASE	A078751	002	Jul 07, 2010
APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011
	EQ 2.5MG BASE	A091373	002	Apr 22, 2011
CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010
	EQ 2.5MG BASE	A090288	002	Jul 07, 2010
MYLAN PHARMS INC	EQ 1MG BASE	A202431	001	May 31, 2012
	EQ 2.5MG BASE	A202431	002	May 31, 2012
NATEGLINIDE				
TABLET;ORAL				
NATEGLINIDE				
TEVA PHARMS	60MG	A077467	001	Sep 09, 2009
	120MG	A077467	002	Sep 09, 2009
STARLIX				
+ NOVARTIS	60MG	N021204	001	Dec 22, 2000
+	120MG	N021204	002	Dec 22, 2000

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEBIVOLOL HYDROCHLORIDE				
TABLET;ORAL				
NEBIVOLOL HYDROCHLORIDE				
ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015
	EQ 5MG BASE	A203741	002	Jun 24, 2015
	EQ 10MG BASE	A203741	003	Jun 24, 2015
	EQ 20MG BASE	A203741	004	Jun 24, 2015
AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015
	EQ 5MG BASE	A203659	002	Apr 16, 2015
	EQ 10MG BASE	A203659	003	Apr 16, 2015
	EQ 20MG BASE	A203659	004	Apr 16, 2015
GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017
	EQ 5MG BASE	A203821	002	May 25, 2017
	EQ 10MG BASE	A203821	003	May 25, 2017
	EQ 20MG BASE	A203821	004	May 25, 2017
INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015
	EQ 5MG BASE	A203828	002	Jul 29, 2015
	EQ 10MG BASE	A203828	003	Jul 29, 2015
	EQ 20MG BASE	A203828	004	Jul 29, 2015
TORRENT	EQ 2.5MG BASE	A203966	001	Mar 02, 2018
	EQ 5MG BASE	A203966	002	Mar 02, 2018
	EQ 10MG BASE	A203966	003	Mar 02, 2018
	EQ 20MG BASE	A203966	004	Mar 02, 2018
WATSON LABS INC	EQ 2.5MG BASE	A203683	001	Nov 27, 2015
	EQ 5MG BASE	A203683	002	Nov 27, 2015
	EQ 10MG BASE	A203683	003	Nov 27, 2015
	EQ 20MG BASE	A203683	004	Nov 27, 2015
NEBIVOLOL HYDROCHLORIDE; VALSARTAN				
TABLET;ORAL				
BYVALSON				
+ ALLERGAN	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016
NEDOCROMIL SODIUM				
AEROSOL, METERED;INHALATION				
TILADE				
KING PHARMS LLC	1.75MG/INH	N019660	001	Dec 30, 1992
SOLUTION;INHALATION				
TILADE				
SANOFI AVENTIS US	0.5%	N020750	001	Oct 01, 1997
NEFAZODONE HYDROCHLORIDE				
TABLET;ORAL				
NEFAZODONE HYDROCHLORIDE				
ANI PHARMS INC	50MG	A076072	001	Sep 16, 2003
	100MG	A076072	002	Sep 16, 2003
	150MG	A076072	003	Sep 16, 2003
	200MG	A076072	004	Sep 16, 2003
	250MG	A076072	005	Sep 16, 2003
DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003
	100MG	A076309	002	Sep 16, 2003
	150MG	A076309	003	Sep 16, 2003
	200MG	A076309	004	Sep 16, 2003
	250MG	A076309	005	Sep 16, 2003
FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003
	100MG	A076302	002	Sep 16, 2003
	150MG	A076302	003	Sep 16, 2003
	200MG	A076302	004	Sep 16, 2003
	250MG	A076302	005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763	001	Sep 16, 2003
	100MG	A075763	002	Sep 16, 2003
	150MG	A075763	003	Sep 16, 2003
	200MG	A075763	004	Sep 16, 2003
	250MG	A075763	005	Sep 16, 2003
MYLAN	100MG	A076129	002	Sep 16, 2003
	150MG	A076129	003	Sep 16, 2003
	200MG	A076129	004	Sep 16, 2003
	250MG	A076129	005	Sep 16, 2003
ROXANE	50MG	A076196	001	Sep 16, 2003
	100MG	A076196	002	Sep 16, 2003
	150MG	A076196	003	Sep 16, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEFAZODONE HYDROCHLORIDE					
TABLET;ORAL					
NEFAZODONE HYDROCHLORIDE					
		200MG	A076196	004	Sep 16, 2003
		250MG	A076196	005	Sep 16, 2003
	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003
		100MG	A076409	002	Sep 16, 2003
		150MG	A076409	003	Sep 16, 2003
		200MG	A076409	004	Sep 16, 2003
		250MG	A076409	005	Sep 16, 2003
	WATSON LABS	100MG	A076073	002	Sep 16, 2003
		150MG	A076073	003	Sep 16, 2003
		200MG	A076073	004	Sep 16, 2003
		250MG	A076073	005	Sep 16, 2003
SERZONE					
+	BRISTOL MYERS SQUIBB	50MG **	N020152	001	Dec 22, 1994
+		100MG **	N020152	002	Dec 22, 1994
+		150MG **	N020152	003	Dec 22, 1994
+		200MG **	N020152	004	Dec 22, 1994
+		250MG **	N020152	005	Dec 22, 1994
+		300MG **	N020152	006	Dec 22, 1994
NELFINAVIR MESYLATE					
POWDER;ORAL					
VIRACEPT					
	AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997
NEOMYCIN SULFATE					
SOLUTION;ORAL					
MYCIFRADIN					
	PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285	001	
NEO-FRADIN					
	X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010	001	May 23, 2002
TABLET;ORAL					
MYCIFRADIN					
	PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520	001	
NEOBIOTIC					
	PFIZER	EQ 350MG BASE	A060475	001	
NEOMYCIN SULFATE					
	BRISTOL MYERS SQUIBB	500MG	A060365	001	
	LANNETT	500MG	A060607	001	
	LANNETT CO INC	500MG	A204435	001	Jun 10, 2016
	LILLY	500MG	A060385	001	
	ROXANE	500MG	A062173	001	
	SANDOZ	500MG	A061586	001	
NEOMYCIN SULFATE; POLYMYXIN B SULFATE					
CREAM;TOPICAL					
NEOSPORIN					
	GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176	002	Jan 14, 1985
OINTMENT;OPHTHALMIC					
STATROL					
	ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344	002	
SOLUTION;IRRIGATION					
NEOMYCIN AND POLYMYXIN B SULFATE					
	WATSON LABS	EQ 40MG BASE/ML;200,000 UNITS/ML	A062664	001	Apr 08, 1986
SOLUTION/DROPS;OPHTHALMIC					
STATROL					
	ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339	001	Nov 30, 1984
		EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456	001	
NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE					
SUSPENSION/DROPS;OPHTHALMIC					
POLY-PRED					
	ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEOMYCIN SULFATE; PREDNISOLONE ACETATE				
OINTMENT;OPHTHALMIC				
NEO-DELTA-CORTEF				
	PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039 002	
		EQ 3.5MG BASE/GM;0.5%	A061039 001	
SUSPENSION/DROPS;OPHTHALMIC				
NEO-DELTA-CORTEF				
	PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037 001	
NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE				
OINTMENT;OPHTHALMIC				
NEO-HYDELTRASOL				
	MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378 001	
NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE				
CREAM;TOPICAL				
MYTREX A				
	SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598 001	Jul 21, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE				
	FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600 001	Jul 21, 1986
	PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595 001	Jul 21, 1986
OINTMENT;TOPICAL				
MYTREX A				
	SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609 001	May 23, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE				
	FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608 001	May 23, 1986
	PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607 001	May 23, 1986
NESIRITIDE RECOMBINANT				
FOR SOLUTION;INTRAVENOUS				
NATRECOR				
+	SCIOS LLC	1.5MG/VIAL	N020920 001	Aug 10, 2001
NETILMICIN SULFATE				
INJECTABLE;INJECTION				
NETROMYCIN				
	SCHERING	EQ 10MG BASE/ML	N050544 001	Feb 28, 1983
		EQ 25MG BASE/ML	N050544 002	Feb 28, 1983
		EQ 100MG BASE/ML	N050544 003	Feb 28, 1983
NEVIRAPINE				
TABLET;ORAL				
NEVIRAPINE				
	APOTEX INC	200MG	A203021 001	May 22, 2012
	TECH ORGANIZED	200MG	A203176 001	May 22, 2012
TABLET, EXTENDED RELEASE;ORAL				
NEVIRAPINE				
	APOTEX	400MG	A205258 001	Apr 03, 2014
	CIPLA	400MG	A206448 001	Oct 15, 2015
	MYLAN	100MG	A206271 001	Nov 09, 2015
	TECH ORGANIZED	100MG	A207467 001	Jul 31, 2017
		400MG	A207467 002	Jul 31, 2017
NIACIN				
CAPSULE;ORAL				
WAMPOCAP				
	MEDPOINTE PHARM HLC	500MG	N011073 003	
TABLET;ORAL				
NIACIN				
	EVERYLIFE	500MG	A083203 001	
	HALSEY	500MG	A083453 001	
	HIKMA PHARMS	500MG	A083718 001	
	IMPAX LABS	500MG	A083115 001	
	IVAX SUB TEVA PHARMS	500MG	A083180 001	
	MK LABS	500MG	A083525 001	
	PUREPAC PHARM	500MG	A083271 001	
	SANDOZ	500MG	A083306 001	
	TABLICAPS	500MG	A084237 001	
	WATSON LABS	500MG	A083136 001	
		500MG	A083305 001	
		500MG	A085172 001	

NIACIN

TABLET;ORAL				
NICOLAR				
	SANOFI AVENTIS US	500MG	A083823 001	
TABLET, EXTENDED RELEASE;ORAL				
NIACIN				
	YICHANG HUMANWELL	500MG	A212017 001	Jun 10, 2019
		750MG	A212017 002	Jun 10, 2019
		1GM	A212017 003	Jun 10, 2019
NIASPAN				
	ABBVIE	375MG	N020381 001	Jul 28, 1997
NIASPAN TITRATION STARTER PACK				
	ABBVIE	375MG;500MG;750MG	N020381 005	Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION;ORAL				
TPN				
	INTL MINERALS	15MG/5ML;3.75MG/5ML;600MG/5ML	N008378 003	

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL				
CARDENE				
	CHIESI USA INC	20MG **	N019488 001	Dec 21, 1988
		30MG **	N019488 002	Dec 21, 1988
NICARDIPINE HYDROCHLORIDE				
	ANI PHARMS INC	20MG	A074439 001	Dec 10, 1996
		20MG	A074540 001	Oct 28, 1996
		20MG	A074670 001	Oct 28, 1996
		30MG	A074439 002	Dec 10, 1996
		30MG	A074540 002	Oct 28, 1996
		30MG	A074670 002	Oct 28, 1996
CAPSULE, EXTENDED RELEASE;ORAL				
CARDENE SR				
+	CHIESI USA INC	30MG **	N020005 001	Feb 21, 1992
+		45MG **	N020005 002	Feb 21, 1992
+		60MG **	N020005 003	Feb 21, 1992
INJECTABLE;INJECTION				
CARDENE				
+	CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734 001	Jan 30, 1992
NICARDIPINE HYDROCHLORIDE				
	LUITPOLD	25MG/10ML (2.5MG/ML)	A090534 001	Nov 17, 2009
	MYLAN INSTITUTIONAL	25MG/10ML (2.5MG/ML)	A090664 001	Nov 17, 2009
	NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125 001	Nov 17, 2009
	SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	N078405 001	Nov 17, 2009
	WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714 001	Dec 28, 2009
	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671 001	Nov 17, 2009
INJECTABLE;INTRAVENOUS				
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER				
+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734 005	Nov 07, 2008
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE				
	EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276 002	Apr 07, 2016
		40MG/200ML (0.2MG/ML)	N022276 003	Apr 07, 2016

NICLOSAMIDE

TABLET, CHEWABLE;ORAL				
NICLOCIDE				
	BAYER PHARMS	500MG	N018669 001	May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL				
NICOTROL				
	MCNEIL CONS	15MG/16HR	N020536 001	Jul 03, 1996
PROSTEP				
	AVEVA	11MG/24HR	N019983 003	Dec 23, 1998
		22MG/24HR	N019983 004	Dec 23, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NICOTINE POLACRILEX				
GUM, CHEWING;BUCCAL				
NICOTINE POLACRILEX				
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009
	EQ 4MG BASE	A077850	001	Feb 18, 2009
THRIVE				
GLAXOSMITHKLINE CONS	EQ 2MG BASE	A077658	001	Jun 19, 2007
	EQ 4MG BASE	A077656	001	Jun 19, 2007
NIFEDIPINE				
CAPSULE;ORAL				
ADALAT				
BAYER PHARMS	10MG	N019478	001	Nov 27, 1985
	20MG	N019478	002	Sep 17, 1986
NIFEDIPINE				
CHASE LABS NJ	10MG	A072409	001	Jul 04, 1990
	20MG	A073421	001	Jun 19, 1991
TEVA	10MG	A072651	001	Feb 19, 1992
PROCARDIA				
+ PFIZER	20MG **	N018482	002	Jul 24, 1986
TABLET, EXTENDED RELEASE;ORAL				
AFEDITAB CR				
WATSON LABS	60MG	A075659	001	Oct 26, 2001
WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000
NIFEDIPINE				
MARTEC USA LLC	90MG	A075414	003	Mar 23, 2004
MYLAN	30MG	A075108	001	Dec 17, 1999
	30MG	A090649	001	Jun 21, 2010
	60MG	A090649	002	Jun 21, 2010
	90MG	A090649	003	Jun 21, 2010
MYLAN LABS LTD	30MG	A090602	001	Sep 13, 2010
	60MG	A090602	002	Sep 13, 2010
	90MG	A090602	003	Sep 13, 2010
NILUTAMIDE				
TABLET;ORAL				
NILANDRON				
CONCORDIA	50MG	N020169	001	Sep 19, 1996
NIMODIPINE				
CAPSULE;ORAL				
NIMODIPINE				
SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007
NIMOTOP				
+ BAYER PHARMS	30MG **	N018869	001	Dec 28, 1988
NISOLDIPINE				
TABLET, EXTENDED RELEASE;ORAL				
SULAR				
+ COVIS PHARMA BV	10MG **	N020356	001	Feb 02, 1995
+	20MG **	N020356	002	Feb 02, 1995
+	25.5MG **	N020356	006	Jan 02, 2008
+	30MG **	N020356	003	Feb 02, 1995
+	40MG **	N020356	004	Feb 02, 1995
NITRIC OXIDE				
GAS;INHALATION				
INOMAX				
+ MALLINCKRODT HOSP	100PPM **	N020845	002	Dec 23, 1999
NITROFURANTOIN				
CAPSULE;ORAL				
NITROFURANTOIN				
WATSON LABS	50MG	A084326	001	
	100MG	A084326	002	
TABLET;ORAL				
FURADANTIN				
PROCTER AND GAMBLE	50MG	N008693	001	
	100MG	N008693	002	
FURALAN				
LANNETT	50MG	A080017	001	
	100MG	A080017	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

NITROFURANTOIN				
TABLET;ORAL				
NITROFURANTOIN				
ELKINS SINN	50MG	A080003	001	
	100MG	A080003	002	
IVAX SUB TEVA PHARMS	50MG	A080078	002	
	100MG	A080078	001	
SANDOZ	50MG	A080043	001	
	100MG	A080043	002	
WATSON LABS	50MG	A080447	001	
	50MG	A085797	001	
	100MG	A080447	002	
	100MG	A085796	001	
WHITEWORTH TOWN PLSN	100MG	A084085	002	
NITROFURANTOIN SODIUM				
INJECTABLE;INJECTION				
IVADANTIN				
PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402	001	
NITROFURANTOIN, MACROCRYSTALLINE				
CAPSULE;ORAL				
NITROFURANTOIN				
INVATECH	25MG	A074336	001	Jan 25, 1995
	50MG	A074336	002	Jan 25, 1995
	100MG	A074336	003	Jan 25, 1995
MYLAN	50MG	A074967	001	Jul 09, 1997
	100MG	A074967	002	Jul 09, 1997
	100MG	A077025	001	Aug 18, 2004
WATSON LABS	25MG	A073696	001	Dec 31, 1992
	50MG	A073696	002	Dec 31, 1992
	100MG	A073696	003	Dec 31, 1992
NITROFURANTOIN MACROCRYSTALLINE				
WATSON LABS	50MG	A070248	001	Jun 24, 1988
	100MG	A070249	001	Jun 24, 1988
NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE				
CAPSULE;ORAL				
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)				
RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005
NITROFURAZONE				
CREAM;TOPICAL				
FURACIN				
SHIRE	0.2%	A083789	001	
DRESSING;TOPICAL				
ACTIN-N				
SHERWOOD MEDCL	0.2%	N017343	001	
OINTMENT;TOPICAL				
FURACIN				
SHIRE	0.2%	N005795	001	
NITROFURAZONE				
AMBIX	0.2%	A086077	001	
LANNETT	0.2%	A084393	001	
PERRIGO NEW YORK	0.2%	A084968	001	
TARO	0.2%	A086156	001	
WENDT	0.2%	A086766	001	
POWDER;TOPICAL				
FURACIN				
SHIRE	0.2%	A083791	001	
SOLUTION;TOPICAL				
NITROFURAZONE				
PERRIGO NEW YORK	0.2%	A085130	001	
WENDT	0.2%	A087081	001	
NITROGLYCERIN				
AEROSOL;SUBLINGUAL				
NITROLINGUAL				
POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NITROGLYCERIN					
FILM, EXTENDED RELEASE;TRANSDERMAL					
MINITRAN					
	MEDICIS	0.4MG/HR	A089773	001	Aug 30, 1996
	VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996
		0.6MG/HR	A089774	001	Aug 30, 1996
	VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996
NITROGLYCERIN					
	LANNETT CO INC	0.2MG/HR	A075115	001	Aug 10, 2004
		0.4MG/HR	A075115	002	Aug 10, 2004
	MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999
		0.2MG/HR	A074992	003	Nov 12, 1999
		0.4MG/HR	A074992	002	Nov 12, 1999
		0.6MG/HR	A074992	001	Nov 12, 1999
TRANSDERM-NITRO					
+	NOVARTIS	0.1MG/HR **	N020144	001	Feb 27, 1996
+		0.2MG/HR **	N020144	002	Feb 27, 1996
+		0.4MG/HR **	N020144	003	Feb 27, 1996
+		0.6MG/HR **	N020144	004	Feb 27, 1996
+		0.8MG/HR **	N020144	005	Feb 27, 1996
INJECTABLE;INJECTION					
NITRO IV					
	POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983
NITRO-BID					
	SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982
		10MG/ML	A071159	001	Feb 28, 1990
NITROGLYCERIN					
	ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
		5MG/ML	A071203	001	May 08, 1987
+	HOSPIRA	5MG/ML **	N018531	001	
	INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
	LUITPOLD	5MG/ML	A071492	001	May 24, 1988
	SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
		5MG/ML	A070634	001	Jun 19, 1986
NITROGLYCERIN IN DEXTROSE 5%					
	HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
		10MG/100ML	A071846	001	Aug 31, 1990
		20MG/100ML	A071847	001	Aug 31, 1990
		40MG/100ML	A071848	001	Aug 31, 1990
NITROL					
	RORER	0.8MG/ML	N018774	001	Jan 19, 1983
NITRONAL					
	POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
NITROSTAT					
	PARKE DAVIS	0.8MG/ML	N018588	001	
		5MG/ML	A070863	001	Jan 08, 1987
		5MG/ML	N018588	002	Dec 23, 1983
		10MG/ML	A070871	001	Jan 08, 1987
		10MG/ML	A070872	001	Jan 08, 1987
TRIDIL					
	HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
		5MG/ML	N018537	001	
NIZATIDINE					
CAPSULE;ORAL					
AXID					
	SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
		300MG	N019508	002	Apr 12, 1988
NIZATIDINE					
	ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002
		150MG	A075668	001	Sep 12, 2002
		300MG	A075461	002	Jul 08, 2002
		300MG	A075668	002	Sep 12, 2002
	APOTEX INC	150MG	A076383	001	Jan 23, 2003
		300MG	A076383	002	Jan 23, 2003
	MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002
		300MG	A075934	002	Jul 09, 2002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NIZATIDINE					
SOLUTION;ORAL					
AXID					
+	BRAINTREE	15MG/ML **	N021494	001	May 25, 2004
NONOXYNOL-9					
AEROSOL;VAGINAL					
DELFEN					
	PERSONAL PRODS	12.5%	N014349	002	
NOREPINEPHRINE BITARTRATE					
INJECTABLE;INJECTION					
NOREPINEPHRINE BITARTRATE					
	METRICS PHARM	EQ 1MG BASE/ML	A040522	001	Sep 30, 2004
NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
RAVOCAINE AND NOVOCAIN W/ LEVOPHED					
	EASTMAN KODAK	EQ 0.033MG BASE/ML;2%;0.4%	N008592	003	
NORETHINDRONE					
TABLET;ORAL					
NORLUTIN					
	PARKE DAVIS	5MG	N010895	002	
TABLET;ORAL-28					
MICRONOR					
+	JANSSEN PHARMS	0.35MG	N016954	001	
NORETHINDRONE ACETATE					
TABLET;ORAL					
AYGESTIN					
+	DURAMED RES	5MG **	N018405	001	Apr 21, 1982
NORETHINDRONE ACETATE					
	AUROBINDO PHARMA LTD	5MG	A204236	001	Jan 08, 2016
NORLUTATE					
	PARKE DAVIS	5MG	N012184	002	
NORFLOXACIN					
SOLUTION/DROPS;OPHTHALMIC					
CHIBROXIN					
	MERCK	0.3%	N019757	001	Jun 17, 1991
TABLET;ORAL					
NOROXIN					
+	MERCK	400MG **	N019384	002	Oct 31, 1986
NORGESTREL					
TABLET;ORAL					
OPILL					
+	LABORATOIRE HRA	0.075MG	N017031	001	
NORTRIPTYLINE HYDROCHLORIDE					
CAPSULE;ORAL					
AVENTYL HYDROCHLORIDE					
	LILLY	EQ 10MG BASE	N014684	001	
		EQ 25MG BASE	N014684	002	
NORTRIPTYLINE HYDROCHLORIDE					
	ANI PHARMS INC	EQ 10MG BASE	A074054	001	Dec 31, 1992
		EQ 25MG BASE	A074054	002	Dec 31, 1992
		EQ 50MG BASE	A074054	003	Dec 31, 1992
		EQ 75MG BASE	A074054	004	Dec 31, 1992
	AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835	001	Jun 30, 1997
		EQ 25MG BASE	A074835	002	Jun 30, 1997
		EQ 50MG BASE	A074835	003	Jun 30, 1997
		EQ 75MG BASE	A074835	004	Jun 30, 1997
	MYLAN	EQ 10MG BASE	A074234	001	Jul 26, 1993
		EQ 25MG BASE	A074234	002	Jul 26, 1993
		EQ 50MG BASE	A074234	003	Jul 26, 1993
		EQ 75MG BASE	A074234	004	Jul 26, 1993
	TEVA	EQ 10MG BASE	A073667	001	Apr 11, 1996
		EQ 25MG BASE	A073667	002	Apr 11, 1996
		EQ 50MG BASE	A073667	003	Apr 11, 1996
		EQ 75MG BASE	A073667	004	Apr 11, 1996

NORTRIPTYLINE HYDROCHLORIDE				
SOLUTION;ORAL				
AVENTYL				
+ RANBAXY	EQ 10MG BASE/5ML **	N014685 001		
PAMELOR				
SPECGX LLC	EQ 10MG BASE/5ML	N018012 001		
NYSTATIN				
CREAM;TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/GM	A061810 001		
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060575 001		
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062387 001	Jul 29, 1982	
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061445 001		
NYSTATIN				
TARO	100,000 UNITS/GM	A062457 001	Jul 28, 1983	
LOTION;TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/ML	N050233 001		
OINTMENT;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060571 001		
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986	
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061444 001		
PASTILLE;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	200,000 UNITS	N050619 001	Apr 09, 1987	
POWDER;ORAL				
BARSTATIN 100				
BARLAN	100%	A062489 001	Apr 27, 1988	
NILSTAT				
+ DAVA PHARMS INC	100% **	N050576 001	Dec 22, 1983	
NYSTATIN				
PADDOCK LLC	100%	A062613 001	Nov 26, 1985	
POWDER;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060578 001		
NYSTATIN				
NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006	
SUPPOSITORY;VAGINAL				
NYSERT				
WARNER CHILCOTT	100,000 UNITS	N050478 001		
SUSPENSION;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/ML	A061533 001		
NILSTAT				
+ GLENMARK GENERICS	100,000 UNITS/ML **	N050299 001		
NYSTATIN				
ACP NIMBLE	100,000 UNITS/ML	A062776 001	Dec 17, 1987	
ALPHARMA US PHARMS	100,000 UNITS/ML	A062571 001	Oct 29, 1985	
G AND W LABS INC	100,000 UNITS/ML	A062349 001	Jul 14, 1982	
MORTON GROVE	100,000 UNITS/ML	A062835 001	Nov 19, 1987	
PHARMADERM	100,000 UNITS/ML	A062518 001	Jul 06, 1984	
PHARMAFAIR	100,000 UNITS/ML	A062541 001	Jan 16, 1985	
SOCORRO	100,000 UNITS/ML	A062832 001	Dec 27, 1991	
TEVA	100,000 UNITS/ML	A062670 001	Jun 18, 1987	
NYSTEX				
SAVAGE LABS	100,000 UNITS/ML	A062519 001	Jul 06, 1984	
TABLET;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	500,000 UNITS	A060574 001		
NILSTAT				
LEDERLE	500,000 UNITS	A061151 001		

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NYSTATIN				
TABLET;ORAL				
NYSTATIN				
QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984
SANDOZ	500,000 UNITS	A062065	001	
UPSHER SMITH LABS	500,000 UNITS	A062524	001	Nov 26, 1985
WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982
TABLET;VAGINAL				
KOROSTATIN				
HOLLAND RANTOS	100,000 UNITS	A061718	001	
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS	A060577	001	
NILSTAT				
LEDERLE	100,000 UNITS	A061325	001	
NYSTATIN				
FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983
ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985
PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984
SANDOZ	100,000 UNITS	A061965	001	
TEVA	100,000 UNITS	A062502	001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176	001	
NYSTATIN; TRIAMCINOLONE ACETONIDE				
CREAM;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%	A061954	002	Sep 20, 1985
MYCOLOG-II				
DELCOR ASSET CORP	100,000 UNITS/GM;0.1% **	A060576	002	May 01, 1985
MYLAN	100,000 UNITS/GM;0.1% **	A062606	001	May 15, 1985
MYTREX F				
SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597	001	Oct 08, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010	001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186	002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657	001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%	A062347	001	Mar 30, 1987
NYSTATIN TRIAMCINOLONE ACETONIDE				
PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985
OINTMENT;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%	A062045	002	Nov 26, 1985
MYCOLOG-II				
MYLAN	100,000 UNITS/GM;0.1% **	A060572	001	Jun 28, 1985
MYTREX F				
SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601	001	Oct 09, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
CROWN LABS INC	100,000 UNITS/GM;0.1%	A207731	001	Dec 26, 2017
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280	002	Oct 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656	001	Jul 30, 1986
ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018
NYSTATIN-TRIAMCINOLONE ACETONIDE				
PHARMADERM	100,000 UNITS/GM;0.1%	A062603	001	Oct 09, 1985
OCTREOTIDE ACETATE				
INJECTABLE;INJECTION				
OCTREOTIDE ACETATE				
HERITAGE PHARMS INC	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018
	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018
SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008
	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007
	EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008
	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007
	EQ 0.2MG BASE/ML	A077330	001	Mar 04, 2008
	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007
	EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008
	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007
	EQ 1MG BASE/ML	A077331	001	Mar 04, 2008
	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007
WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OCTREOTIDE ACETATE				
INJECTABLE;INJECTION				
OCTREOTIDE ACETATE				
	EQ 1MG BASE/ML	A090986	002	May 11, 2011
OCTREOTIDE ACETATE PRESERVATIVE FREE				
WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011
	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011
	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011
OFLOXACIN				
INJECTABLE;INJECTION				
FLOXIN				
ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992
	40MG/ML	N020087	003	Mar 31, 1992
FLOXIN IN DEXTROSE 5%				
ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992
	400MG/100ML	N020087	005	Mar 31, 1992
OFLOXACIN				
BEDFORD	40MG/ML	A075762	001	Jan 16, 2002
SOLUTION/DROPS;OPHTHALMIC				
OFLOXACIN				
SANDOZ	0.3%	A076848	001	Nov 25, 2008
SANDOZ INC	0.3%	A076231	001	May 14, 2004
SOLUTION/DROPS;OTIC				
FLOXIN OTIC				
+ DAIICHI	0.3% **	N020799	001	Dec 16, 1997
OFLOXACIN				
ALVOGEN	0.3%	A090395	001	Aug 11, 2009
SANDOZ INC	0.3%	A078222	001	Mar 17, 2008
TABLET;ORAL				
FLOXIN				
JANSSEN PHARMS	200MG **	N019735	001	Dec 28, 1990
	300MG **	N019735	002	Dec 28, 1990
	400MG **	N019735	003	Dec 28, 1990
OFLOXACIN				
LARKEN LABS	200MG	A076093	001	Sep 02, 2003
	300MG	A076093	002	Sep 02, 2003
	400MG	A076093	003	Sep 02, 2003
RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003
	300MG	A076220	002	Sep 02, 2003
	400MG	A076220	003	Sep 02, 2003
OLANZAPINE				
TABLET;ORAL				
OLANZAPINE				
AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016
	5MG	A206711	002	Aug 30, 2016
	7.5MG	A206711	003	Aug 30, 2016
	10MG	A206711	004	Aug 30, 2016
	15MG	A206711	005	Aug 30, 2016
	20MG	A206711	006	Aug 30, 2016
MYLAN	2.5MG	A076866	001	Apr 23, 2012
	5MG	A076866	002	Apr 23, 2012
	7.5MG	A076866	003	Apr 23, 2012
	10MG	A076866	004	Apr 23, 2012
	15MG	A076866	005	Apr 23, 2012
	20MG	A076866	006	Apr 23, 2012
SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018
	5MG	A206238	002	Nov 19, 2018
	7.5MG	A206238	003	Nov 19, 2018
	10MG	A206238	004	Nov 19, 2018
	15MG	A206238	005	Nov 19, 2018
	20MG	A206238	006	Nov 19, 2018
TABLET, ORALLY DISINTEGRATING;ORAL				
OLANZAPINE				
AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017
	10MG	A204320	002	May 30, 2017
	15MG	A204320	003	May 30, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OLANZAPINE					
TABLET, ORALLY DISINTEGRATING;ORAL					
OLANZAPINE					
		20MG	A204320	004	May 30, 2017
	HEC PHARM	5MG	A208146	001	Jul 02, 2018
		10MG	A208146	002	Jul 02, 2018
		15MG	A208146	003	Jul 02, 2018
		20MG	A208146	004	Jul 02, 2018
OLMESARTAN MEDOXOMIL					
TABLET;ORAL					
OLMESARTAN MEDOXOMIL					
	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017
		20MG	A091079	002	Apr 24, 2017
		40MG	A091079	003	Apr 24, 2017
OLOPATADINE HYDROCHLORIDE					
SOLUTION/DROPS;OPHTHALMIC					
OLOPATADINE HYDROCHLORIDE					
	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015
OMBITASVIR; PARITAPREVIR; RITONAVIR					
TABLET;ORAL					
TECHNIVIE					
+	ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015
OMEGA-3-ACID ETHYL ESTERS					
CAPSULE;ORAL					
OMEGA-3-ACID ETHYL ESTERS					
	PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014
	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019
	ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019
OMEGA-3-ACID ETHYL ESTERS TYPE A					
CAPSULE;ORAL					
OMTRYG					
+	OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014
OMEGA-3-CARBOXYLIC ACIDS					
CAPSULE;ORAL					
EPANOVA					
+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014
OMEPRAZOLE					
CAPSULE, DELAYED REL PELLETS;ORAL					
OMEPRAZOLE					
	LUPIN LTD	40MG	A202384	001	Aug 25, 2015
	MYLAN	10MG	A075876	001	May 29, 2003
		40MG	A075876	003	Jan 21, 2009
PRILOSEC					
+	ASTRAZENECA PHARMS	10MG **	N019810	003	Oct 05, 1995
+		20MG **	N019810	001	Sep 14, 1989
+		40MG **	N019810	002	Jan 15, 1998
TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE					
	APOTEX	20MG	A210070	001	Feb 11, 2019
OMEPRAZOLE; SODIUM BICARBONATE					
CAPSULE;ORAL					
OMEPRAZOLE AND SODIUM BICARBONATE					
	PAR PHARM	20MG;1.1GM	A078966	001	May 25, 2010
		40MG;1.1GM	A078966	002	May 25, 2010
ONDANSETRON					
TABLET, ORALLY DISINTEGRATING;ORAL					
ONDANSETRON					
	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006
		8MG	A077406	004	Dec 26, 2006
		16MG	A077406	001	Dec 26, 2006
		24MG	A077406	002	Dec 26, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ONDANSETRON				
TABLET, ORALLY DISINTEGRATING;ORAL				
ONDANSETRON				
NESHER PHARMS	4MG	A077717	001	Jun 25, 2007
	8MG	A077717	002	Jun 25, 2007
ONDANSETRON HYDROCHLORIDE				
INJECTABLE;INJECTION				
ONDANSETRON HYDROCHLORIDE				
APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
LANNETT CO INC	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010
	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006
	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008
MYLAN LABS LTD	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007
SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER				
HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE				
APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006
HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006
	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008
MYLAN LABS LTD	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A077173	001	Dec 26, 2006
TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008
TEVA	EQ 2MG BASE/ML	A076759	001	Nov 22, 2006
ZOFRAN				
+ NOVARTIS	EQ 2MG BASE/ML **	N020007	001	Jan 04, 1991
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER				
+ GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **	N020403	001	Jan 31, 1995
ZOFRAN PRESERVATIVE FREE				
+ NOVARTIS	EQ 2MG BASE/ML **	N020007	003	Dec 10, 1993
TABLET;ORAL				
ONDANSETRON HYDROCHLORIDE				
CHARTWELL MOLECULES	EQ 4MG BASE	A077303	001	Jun 25, 2007
	EQ 8MG BASE	A077303	002	Jun 25, 2007
	EQ 24MG BASE	A077303	004	Jun 25, 2007
HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007
	EQ 8MG BASE	A077545	002	Sep 06, 2007
	EQ 24MG BASE	A077545	003	Sep 06, 2007
MYLAN	EQ 24MG BASE	A076930	004	Jun 25, 2007
TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011
	EQ 8MG BASE	A077729	002	Mar 28, 2011
	EQ 24MG BASE	A077729	003	Mar 28, 2011
ORPHENADRINE CITRATE				
INJECTABLE;INJECTION				
NORFLEX				
+ TELIGENT	30MG/ML	N013055	001	
ORPHENADRINE CITRATE				
WATSON LABS	30MG/ML	A087062	001	
TABLET, EXTENDED RELEASE;ORAL				
NORFLEX				
+ MEDICIS	100MG	N012157	001	
ORPHENADRINE CITRATE				
ASCOT	100MG	A088067	001	Apr 06, 1983
SANDOZ	100MG	A085046	001	
WATSON LABS	100MG	A084303	001	
ORPHENADRINE HYDROCHLORIDE				
TABLET;ORAL				
DISIPAL				
3M	50MG	N010653	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OSELTAMIVIR PHOSPHATE				
FOR SUSPENSION;ORAL				
TAMIFLU				
ROCHE	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000
OXACILLIN SODIUM				
CAPSULE;ORAL				
BACTOCILL				
GLAXOSMITHKLINE	EQ 250MG BASE	A061336	001	
	EQ 250MG BASE	A062241	001	
	EQ 500MG BASE	A061336	002	
	EQ 500MG BASE	A062241	002	
OXACILLIN SODIUM				
ANI PHARMS INC	EQ 250MG BASE	A062222	001	
	EQ 500MG BASE	A062222	002	
APOTHECON	EQ 250MG BASE	A061450	002	
	EQ 500MG BASE	A061450	001	
PROSTAPHLIN				
APOTHECON	EQ 500MG BASE	N050118	002	
FOR SOLUTION;ORAL				
BACTOCILL				
GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321	001	
OXACILLIN SODIUM				
APOTHECON	EQ 250MG BASE/5ML	A061457	001	
TEVA	EQ 250MG BASE/5ML	A062252	001	
PROSTAPHLIN				
APOTHECON	EQ 250MG BASE/5ML	N050194	001	
INJECTABLE;INJECTION				
BACTOCILL				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL **	A061334	009	Mar 26, 1982
	EQ 1GM BASE/VIAL **	A061334	006	Mar 26, 1982
	EQ 1GM BASE/VIAL **	A062736	001	Dec 19, 1986
	EQ 2GM BASE/VIAL **	A061334	007	Mar 26, 1982
	EQ 2GM BASE/VIAL **	A062736	002	Dec 19, 1986
	EQ 4GM BASE/VIAL **	A061334	008	Mar 26, 1982
	EQ 10GM BASE/VIAL **	A061334	010	
OXACILLIN SODIUM				
+ APOTHECON	EQ 250MG BASE/VIAL **	N050195	001	
+	EQ 500MG BASE/VIAL **	N050195	002	
+	EQ 1GM BASE/VIAL **	N050195	003	
+	EQ 2GM BASE/VIAL **	N050195	004	
+	EQ 4GM BASE/VIAL **	N050195	005	
ELKINS SINN	EQ 250MG BASE/VIAL	A062711	001	Feb 03, 1989
	EQ 500MG BASE/VIAL	A062711	002	Feb 03, 1989
	EQ 1GM BASE/VIAL	A062711	003	Feb 03, 1989
	EQ 2GM BASE/VIAL	A062711	004	Feb 03, 1989
	EQ 4GM BASE/VIAL	A062711	005	Feb 03, 1989
	EQ 10GM BASE/VIAL	A062711	006	Feb 03, 1989
HOSPIRA INC	EQ 1GM BASE/VIAL	A203950	001	Dec 11, 2015
	EQ 2GM BASE/VIAL	A203950	002	Dec 11, 2015
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995
	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995
	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995
	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995
	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995
MYLAN LABS LTD	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014
	EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014
SANDOZ	EQ 250MG BASE/VIAL	A061490	001	
	EQ 500MG BASE/VIAL	A061490	002	
	EQ 1GM BASE/VIAL	A061490	003	
	EQ 2GM BASE/VIAL	A061490	004	
	EQ 10GM BASE/VIAL	A061490	006	May 09, 1991
WATSON LABS INC	EQ 250MG BASE/VIAL	A062856	001	Oct 26, 1988
	EQ 500MG BASE/VIAL	A062856	002	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062856	003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062856	004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062856	005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A062984	001	Sep 29, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXACILLIN SODIUM					
POWDER;INTRAVENOUS					
OXACILLIN SODIUM					
	SANDOZ	EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986
		EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986
OXALIPLATIN					
INJECTABLE;INTRAVENOUS					
ELOXATIN					
+	SANOFI AVENTIS US	50MG/VIAL **	N021492	001	Aug 09, 2002
+		100MG/VIAL **	N021492	002	Aug 09, 2002
+		200MG/40ML (5MG/ML) **	N021759	003	Nov 17, 2006
OXALIPLATIN					
	AM REGENT	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017
		100MG/20ML (5MG/ML)	A204378	002	May 12, 2017
	FRESENIUS KABI ONCOL	50MG/VIAL	A078810	001	Aug 07, 2009
		100MG/VIAL	A078810	002	Aug 07, 2009
	HOSPIRA INC	50MG/VIAL	A078815	001	Sep 30, 2009
		100MG/VIAL	A078815	002	Sep 30, 2009
	MYLAN LABS LTD	50MG/VIAL	A200979	001	Aug 08, 2012
		100MG/VIAL	A200979	002	Aug 08, 2012
		200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017
	SANDOZ	50MG/VIAL	A090849	001	Apr 28, 2011
		100MG/VIAL	A090849	002	Apr 28, 2011
	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009
		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009
	SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009
		50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014
		100MG/VIAL	A078818	002	Aug 07, 2009
		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014
		200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019
OXAMNIQUINE					
CAPSULE;ORAL					
VANSIL					
	PFIZER	250MG	N018069	001	
OXANDROLONE					
TABLET;ORAL					
OXANDRIN					
+	GEMINI LABS LLC	2.5MG	N013718	001	
+		10MG	N013718	002	Nov 05, 2001
OXANDROLONE					
	ROXANE	2.5MG	A077249	001	Jul 10, 2007
		10MG	A077249	002	Jul 10, 2007
	SANDOZ	2.5MG	A076897	001	Dec 01, 2006
		10MG	A076897	002	Dec 01, 2006
OXAPROZIN					
TABLET;ORAL					
OXAPROZIN					
	ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
	BEXIMCO PHARMS USA	600MG	A075842	001	Apr 12, 2001
	MYLAN	600MG	A075851	001	Aug 17, 2001
	MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
	SANDOZ	600MG	A075850	001	Apr 27, 2001
	SUN PHARM INDS INC	600MG	A075844	001	Jan 03, 2002
	WATSON LABS	600MG	A075848	001	Feb 09, 2001
OXAPROZIN POTASSIUM					
TABLET;ORAL					
DAYPRO ALTA					
	GD SEARLE	600MG	N020776	001	Oct 17, 2002
OXAZEPAM					
CAPSULE;ORAL					
OXAZEPAM					
	AM THERAP	10MG	A071955	001	Mar 03, 1988
		15MG	A071956	001	Mar 03, 1988
		30MG	A071957	001	Mar 03, 1988
	FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987
		15MG	A071026	003	Aug 10, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXAZEPAM				
CAPSULE;ORAL				
OXAZEPAM				
	30MG	A071026	001	Aug 10, 1987
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
WATSON LABS	15MG	A072953	001	Sep 28, 1990
	30MG	A072954	001	Sep 28, 1990
WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990
SERAX				
ALPHARMA US PHARMS	10MG **	N015539	002	
	15MG **	N015539	004	
	30MG **	N015539	006	
ZAXOPAM				
QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988
TABLET;ORAL				
OXAZEPAM				
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
SUN PHARM INDUSTRIES	15MG	A070683	001	Jan 16, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987
SERAX				
ALPHARMA US PHARMS	15MG **	N015539	008	
OXCARBAZEPINE				
TABLET;ORAL				
OXCARBAZEPINE				
ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007
	300MG	A078005	002	Dec 11, 2007
	600MG	A078005	003	Dec 11, 2007
JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010
	300MG	A090239	002	Jan 25, 2010
	600MG	A090239	003	Jan 25, 2010
OXPRENOLOL HYDROCHLORIDE				
CAPSULE;ORAL				
TRASICOR				
NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983
OXTRIPHYLLINE				
SOLUTION;ORAL				
CHOLEDYL				
PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984
OXTRIPHYLLINE				
MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983
SYRUP;ORAL				
CHOLEDYL				
PARKE DAVIS	50MG/5ML	N009268	011	
OXTRIPHYLLINE PEDIATRIC				
MORTON GROVE	50MG/5ML	A088242	001	Dec 05, 1983
TABLET, DELAYED RELEASE;ORAL				
CHOLEDYL				
PARKE DAVIS	100MG	N009268	003	
	200MG	N009268	007	
OXTRIPHYLLINE				
WATSON LABS	100MG	A087866	001	Aug 25, 1983
	200MG	A087835	001	Aug 25, 1983
TABLET, EXTENDED RELEASE;ORAL				
CHOLEDYL SA				
WARNER CHILCOTT LLC	400MG	A087863	001	May 24, 1983
	600MG	A086742	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYBUTYNIN					
FILM, EXTENDED RELEASE;TRANSDERMAL					
OXYBUTYNIN					
	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014
GEL, METERED;TRANSDERMAL					
GELNIQUE 3%					
+	ALLERGAN	3%	N202513	001	Dec 07, 2011
OXYBUTYNIN CHLORIDE					
GEL;TRANSDERMAL					
OXYBUTYNIN CHLORIDE					
	PAR PHARM INC	10% (100MG/PACKET)	A207329	001	May 31, 2018
SYRUP;ORAL					
DITROPAN					
+	ORTHO MCNEIL JANSSEN	5MG/5ML **	N018211	001	
OXYBUTYNIN CHLORIDE					
	ANDA REPOSITORY	5MG/5ML	A075039	001	Jan 29, 1999
	LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004
	PHARM ASSOC	5MG/5ML	A074997	001	Oct 15, 1997
TABLET;ORAL					
DITROPAN					
+	JANSSEN PHARMS	5MG **	N017577	001	
OXYBUTYNIN CHLORIDE					
	QUANTUM PHARMICS	5MG	A072296	001	Dec 08, 1988
	USL PHARMA	5MG	A070746	001	Mar 10, 1988
	WATSON LABS	5MG	A072485	001	Apr 19, 1989
TABLET, EXTENDED RELEASE;ORAL					
DITROPAN XL					
+	JANSSEN PHARMS	15MG **	N020897	003	Jun 22, 1999
OXYBUTYNIN CHLORIDE					
	MYLAN	5MG	A076702	001	Nov 09, 2006
OXYCODONE HYDROCHLORIDE					
SOLUTION;ORAL					
OXYCODONE HYDROCHLORIDE					
	LANNETT CO INC	100MG/5ML	A204085	001	Sep 09, 2014
TABLET;ORAL					
OXYCODONE HYDROCHLORIDE					
	VINTAGE PHARMS	5MG	A077712	003	Mar 02, 2009
		10MG	A077712	004	Apr 13, 2015
		15MG	A077712	001	Jan 31, 2007
		20MG	A077712	005	Apr 13, 2015
		30MG	A077712	002	Jan 31, 2007
ROXYBOND					
	INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017
		15MG	N209777	002	Apr 20, 2017
		30MG	N209777	003	Apr 20, 2017
TABLET, EXTENDED RELEASE;ORAL					
ROXICODONE					
	ROXANE	10MG	N020932	001	Oct 26, 1998
		30MG	N020932	002	Oct 26, 1998
OXYMETAZOLINE HYDROCHLORIDE					
SOLUTION/DROPS;OPHTHALMIC					
OCUCLEAR					
	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986
OXYMORPHONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
OPANA					
+	ENDO PHARMS	1MG/ML	N011707	002	
		1.5MG/ML	N011707	001	
SUPPOSITORY;RECTAL					
NUMORPHAN					
	ENDO PHARMS	5MG	N011738	004	
TABLET;ORAL					
OPANA					
+	ENDO PHARMS	5MG	N021611	001	Jun 22, 2006
+		10MG	N021611	002	Jun 22, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYMORPHONE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
OPANA ER				
ENDO PHARMS	5MG **	N021610	001	Jun 22, 2006
+	5MG	N201655	001	Dec 09, 2011
	7.5MG **	N021610	005	Feb 29, 2008
+	7.5MG	N201655	002	Dec 09, 2011
	10MG **	N021610	002	Jun 22, 2006
+	10MG	N201655	003	Dec 09, 2011
	15MG **	N021610	006	Feb 29, 2008
+	15MG	N201655	004	Dec 09, 2011
	20MG **	N021610	003	Jun 22, 2006
+	20MG	N201655	005	Dec 09, 2011
	30MG **	N021610	007	Feb 29, 2008
+	30MG	N201655	006	Dec 09, 2011
	40MG **	N021610	004	Jun 22, 2006
+	40MG	N201655	007	Dec 09, 2011
OXYMORPHONE HYDROCHLORIDE				
PAR PHARM	5MG	A200792	001	Oct 24, 2014
	7.5MG	A200792	002	Oct 24, 2014
	10MG	A200792	003	Oct 24, 2014
	15MG	A200792	004	Oct 24, 2014
	20MG	A200792	005	Oct 24, 2014
	30MG	A200792	006	Oct 24, 2014
	40MG	A200792	007	Oct 24, 2014
SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015
	7.5MG	A203506	002	Apr 24, 2015
	10MG	A203506	003	Apr 24, 2015
	15MG	A203506	004	Apr 24, 2015
	20MG	A203506	005	Apr 24, 2015
	30MG	A203506	006	Apr 24, 2015
	40MG	A203506	007	Apr 24, 2015
OXYPHENBUTAZONE				
TABLET;ORAL				
OXYPHENBUTAZONE				
WATSON LABS	100MG	A088399	001	Sep 17, 1984
TANDEARIL				
NOVARTIS	100MG	N012542	004	Sep 03, 1982
OXYPHENCYCLIMINE HYDROCHLORIDE				
TABLET;ORAL				
DARICON				
PFIZER	10MG	N011612	001	
OXYPHENONIUM BROMIDE				
TABLET;ORAL				
ANTRENYL				
NOVARTIS	5MG	N008492	002	
OXYTETRACYCLINE				
TABLET;ORAL				
TERRAMYCIN				
PFIZER	250MG	N050287	001	
OXYTETRACYCLINE CALCIUM				
SYRUP;ORAL				
TERRAMYCIN				
PFIZER	EQ 125MG BASE/5ML	A060595	001	
OXYTETRACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
OXY-KESSO-TETRA				
FERRANTE	EQ 250MG BASE	A060179	001	
OXYTETRACYCLINE HYDROCHLORIDE				
HIKMA PHARMS	EQ 250MG BASE	A060770	001	
IMPAX LABS	EQ 250MG BASE	A060760	001	
PROTER	EQ 250MG BASE	A060869	001	
PUREPAC PHARM	EQ 250MG BASE	A060634	001	
TERRAMYCIN				
PFIZER	EQ 125MG BASE	N050286	001	
	EQ 250MG BASE	N050286	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYTETRACYCLINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
TERRAMYCIN				
PFIZER	EQ 250MG BASE/VIAL	A060586	001	
	EQ 500MG BASE/VIAL	A060586	002	
OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
TERRAMYCIN W/ POLYMYXIN B SULFATE				
CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	N061015	001	
OINTMENT;OTIC				
TERRAMYCIN W/ POLYMYXIN				
PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061841	001	
TABLET;VAGINAL				
TERRAMYCIN-POLYMYXIN				
PFIZER	EQ 100MG BASE;100,000 UNITS	A061009	001	
OXYTOCIN				
INJECTABLE;INJECTION				
OXYTOCIN				
DR REDDYS	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008
	100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%				
+ ABBOTT	1USP UNITS/100ML **	N019185	004	Mar 29, 1985
+	2USP UNITS/100ML **	N019185	003	Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%				
+ ABBOTT	2USP UNITS/100ML **	N019185	002	Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%				
+ ABBOTT	1USP UNITS/100ML **	N019185	001	Mar 29, 1985
SYNTOCINON				
NOVARTIS	10USP UNITS/ML	N018245	001	
SOLUTION;NASAL				
SYNTOCINON				
RTRX	40USP UNITS/ML	N012285	001	
PACLITAXEL				
INJECTABLE;INJECTION				
PACLITAXEL				
ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004
	6MG/ML	A205720	001	Aug 17, 2018
HOSPIRA	6MG/ML	A076233	001	Aug 01, 2002
MYLAN	6MG/ML	A075278	001	Jan 25, 2002
PLIVA LACHEMA	6MG/ML	A077413	001	Mar 12, 2008
SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007
TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002
TAXOL				
+ HQ SPCLT PHARMA	6MG/ML	N020262	001	Dec 29, 1992
PALIPERIDONE				
TABLET, EXTENDED RELEASE;ORAL				
INVEGA				
+ JANSSEN PHARMS	12MG **	N021999	004	Dec 19, 2006
PALONOSETRON HYDROCHLORIDE				
CAPSULE;ORAL				
ALOXI				
+ HELSINN HLTHCARE	EQ 0.5MG BASE **	N022233	001	Aug 22, 2008
INJECTABLE;INTRAVENOUS				
PALONOSETRON HYDROCHLORIDE				
DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016
SOLUTION;INTRAVENOUS				
PALONOSETRON HYDROCHLORIDE				
DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016
	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PAMIDRONATE DISODIUM					
INJECTABLE;INJECTION					
AREDIA					
+	NOVARTIS	30MG/VIAL **	N020036	001	Oct 31, 1991
		60MG/VIAL	N020036	003	May 06, 1993
		90MG/VIAL	N020036	004	May 06, 1993
PAMIDRONATE DISODIUM					
	AESGEN	30MG/VIAL	A075594	001	May 06, 2002
		90MG/VIAL	A075594	002	May 06, 2002
	LUITPOLD	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008
		90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008
	MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009
		90MG/VIAL	A078300	002	Mar 10, 2009
	SUN PHARMA GLOBAL	30MG/VIAL	A077703	001	Dec 24, 2008
		90MG/VIAL	A077703	002	Dec 24, 2008
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)					
CAPSULE;ORAL					
COTAZYM					
	ORGANON USA INC	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N020580	001	Dec 09, 1996
CAPSULE, DELAYED RELEASE;ORAL					
ULTRESA					
+	FOREST LABS INC	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012
+		41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012
+		46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012
PANCURONIUM BROMIDE					
INJECTABLE;INJECTION					
PANCURONIUM BROMIDE					
	ELKINS SINN	1MG/ML	A072058	001	Mar 23, 1988
		2MG/ML	A072059	001	Mar 23, 1988
		2MG/ML	A072060	001	Mar 23, 1988
	HOSPIRA	2MG/ML	A072321	001	Jan 19, 1989
	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988
		2MG/ML	A072211	001	Mar 31, 1988
		2MG/ML	A072212	001	Mar 31, 1988
		2MG/ML	A072213	001	Mar 31, 1988
PAVULON					
+	ORGANON USA INC	1MG/ML	N017015	002	
+		2MG/ML	N017015	001	
PANTOPRAZOLE SODIUM					
INJECTABLE;IV (INFUSION)					
PANTOPRAZOLE SODIUM					
	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018
TABLET, DELAYED RELEASE;ORAL					
PANTOPRAZOLE SODIUM					
	SUN PHARM	EQ 20MG BASE	A077058	001	Sep 10, 2007
		EQ 40MG BASE	A077058	002	Sep 10, 2007
	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012
		EQ 40MG BASE	A200794	002	May 02, 2012
PARAMETHADIONE					
CAPSULE;ORAL					
PARADIONE					
	ABBVIE	150MG	N006800	003	
		300MG	N006800	001	
SOLUTION;ORAL					
PARADIONE					
	ABBVIE	300MG/ML	N006800	002	
PARAMETHASONE ACETATE					
TABLET;ORAL					
HALDRONE					
	LILLY	1MG	N012772	005	
		2MG	N012772	006	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PARGYLINE HYDROCHLORIDE
TABLET;ORAL
EUTONYL

ABBOTT	10MG	N013448	002	
	25MG	N013448	003	
	50MG	N013448	004	

PARICALCITOL
CAPSULE;ORAL
PARICALCITOL

LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016
	2MCG	A206710	002	Feb 24, 2016
	4MCG	A206710	003	Feb 24, 2016

ZEMPLAR

+	ABBVIE	4MCG **	N021606	003	May 26, 2005

PAROMOMYCIN SULFATE
CAPSULE;ORAL
HUMATIN

KING PFIZER	EQ 250MG BASE	A062310	001	
PARKEDALE	EQ 250MG BASE	A060521	001	

SYRUP;ORAL
HUMATIN

PARKE DAVIS	EQ 125MG BASE/5ML	A060522	001	

PAROXETINE HYDROCHLORIDE
CAPSULE;ORAL
PAXIL

+	APOTEX TECHNOLOGIES	EQ 10MG BASE **	N020885	001	Oct 09, 1998
+		EQ 20MG BASE **	N020885	002	Oct 09, 1998
+		EQ 30MG BASE **	N020885	003	Oct 09, 1998
+		EQ 40MG BASE **	N020885	004	Oct 09, 1998

SUSPENSION;ORAL
PAROXETINE HYDROCHLORIDE

APOTEX INC	EQ 10MG BASE/5ML	A077395	001	Dec 05, 2006

TABLET;ORAL
PAROXETINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 10MG BASE	A075716	001	Mar 08, 2004
	EQ 20MG BASE	A075716	002	Mar 08, 2004
	EQ 30MG BASE	A075716	003	Mar 08, 2004
	EQ 40MG BASE	A075716	004	Mar 08, 2004
ROXANE	EQ 10MG BASE	A078026	001	Jun 29, 2007
	EQ 20MG BASE	A078026	002	Jun 29, 2007
	EQ 30MG BASE	A078026	003	Jun 29, 2007
	EQ 40MG BASE	A078026	004	Jun 29, 2007
SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007
	EQ 20MG BASE	A078194	002	Jun 29, 2007
	EQ 30MG BASE	A078194	003	Jun 29, 2007
	EQ 40MG BASE	A078194	004	Jun 29, 2007
TEVA PHARMS	EQ 10MG BASE	A077082	001	Jun 29, 2007
	EQ 20MG BASE	A077082	002	Jun 29, 2007
	EQ 30MG BASE	A077082	003	Jun 29, 2007
	EQ 40MG BASE	A077082	004	Jun 29, 2007
UPSHER SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004
	EQ 20MG BASE	A075566	002	Mar 08, 2004
	EQ 30MG BASE	A075566	003	Mar 08, 2004
	EQ 40MG BASE	A075566	004	Mar 08, 2004

PAXIL

APOTEX TECHNOLOGIES	EQ 50MG BASE	N020031	004	Dec 29, 1992

PAZOPANIB HYDROCHLORIDE
TABLET;ORAL
VOTRIENT

NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009

PEGADEMASE BOVINE
INJECTABLE;INJECTION
ADAGEN

+	LEADIANT BIOSCI INC	250 UNITS/ML	N019818	001	Mar 21, 1990

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS				
OMONTYS				
TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012
OMONTYS PRESERVATIVE FREE				
TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012
	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012
	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012
	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC				
ALAMAST				
SANTEN	0.1%	N021079	001	Sep 24, 1999

PEMOLINE

TABLET;ORAL				
CYLERT				
ABBOTT	18.75MG	N016832	001	
	37.5MG	N016832	002	
	75MG	N016832	003	
PEMOLINE				
ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000
	37.5MG	A075595	002	Feb 28, 2000
	75MG	A075595	003	Feb 28, 2000
FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999
	37.5MG	A075286	002	Jun 30, 1999
	75MG	A075286	003	Jun 30, 1999
MALLINCKRODT	18.75MG	A075726	003	Mar 30, 2001
	37.5MG	A075726	002	Mar 30, 2001
	75MG	A075726	001	Mar 30, 2001
TEVA PHARMS	18.75MG	A075030	003	Feb 22, 2000
	37.5MG	A075030	001	Jan 29, 1999
	75MG	A075030	002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001	Apr 19, 2000
	37.5MG	A075328	002	Apr 19, 2000
	75MG	A075328	003	Apr 19, 2000
WATSON LABS	18.75MG	A075287	001	Jun 13, 2001
	37.5MG	A075287	002	Sep 18, 2000
	75MG	A075287	003	Sep 18, 2000
TABLET, CHEWABLE;ORAL				
CYLERT				
ABBOTT	37.5MG	N017703	001	
PEMOLINE				
ACTAVIS ELIZABETH	37.5MG	A075678	001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555	001	Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL				
LEVATOL				
+ AUXILIUM PHARMS LLC	10MG **	N018976	001	Dec 30, 1987
+	20MG **	N018976	004	Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL				
CUPRIMINE				
VALEANT PHARMS INTL	125MG	N019853	002	

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION				
BICILLIN L-A				
+ KING PHARMS LLC	300,000 UNITS/ML	N050141	003	
WYETH AYERST	300,000 UNITS/ML	N050131	001	
PERMAPEN				
CASPER PHARMA LLC	600,000 UNITS/ML	N060014	001	
SUSPENSION;ORAL				
BICILLIN				
WYETH AYERST	300,000 UNITS/5ML	N050126	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN G BENZATHINE				
TABLET;ORAL				
BICILLIN				
	WYETH AYERST	200,000 UNITS	N050128 001	
PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE				
INJECTABLE;INJECTION				
BICILLIN C-R				
+	KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138 002	
PENICILLIN G POTASSIUM				
FOR SOLUTION;ORAL				
PENICILLIN				
	TEVA	200,000 UNITS/5ML	A060307 002	
		400,000 UNITS/5ML	A060307 004	
PENICILLIN G POTASSIUM				
	MYLAN	200,000 UNITS/5ML	A060752 003	
		250,000 UNITS/5ML	A060752 002	
		400,000 UNITS/5ML	A060752 001	
	PUREPAC PHARM	250,000 UNITS/5ML	A061740 001	
		400,000 UNITS/5ML	A061740 002	
PENICILLIN-2				
	TEVA	250,000 UNITS/5ML	A060307 003	
PENTIDS '200'				
	APOTHECON	200,000 UNITS/5ML	A062149 001	
PENTIDS '400'				
	APOTHECON	400,000 UNITS/5ML	A062149 002	
PFIZERPEN G				
	PFIZER	400,000 UNITS/5ML	A060587 001	
INJECTABLE;INJECTION				
PENICILLIN G POTASSIUM				
	APOTHECON	1,000,000 UNITS/VIAL	A060362 001	
		5,000,000 UNITS/VIAL	A060362 003	
		10,000,000 UNITS/VIAL	A060362 004	
		20,000,000 UNITS/VIAL	A060362 002	
	CONSOLIDATED PHARM	500,000 UNITS/VIAL	A060806 001	
		1,000,000 UNITS/VIAL	A060806 002	
		5,000,000 UNITS/VIAL	A060806 003	
		10,000,000 UNITS/VIAL	A060806 004	
	LILLY	200,000 UNITS/VIAL	A060384 004	
		500,000 UNITS/VIAL	A060384 003	
		1,000,000 UNITS/VIAL	A060384 002	
		5,000,000 UNITS/VIAL	A060384 001	
		20,000,000 UNITS/VIAL	A060384 005	
		20,000,000 UNITS/VIAL	A060601 001	
	PARKE DAVIS	1,000,000 UNITS/VIAL	A062003 001	
		5,000,000 UNITS/VIAL	A062003 002	
	PFIZER	20,000,000 UNITS/VIAL	A060074 003	
	SANDOZ	1,000,000 UNITS/VIAL **	A065079 001	Aug 30, 2002
	WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001	Sep 13, 1988
		5,000,000 UNITS/VIAL	A062991 002	Sep 13, 1988
		10,000,000 UNITS/VIAL	A062991 003	Sep 13, 1988
		20,000,000 UNITS/VIAL	A062991 004	Sep 13, 1988
PFIZERPEN				
	PFIZER	1,000,000 UNITS/VIAL **	A060657 001	
TABLET;ORAL				
PENICILLIN G POTASSIUM				
	APOTHECON	250,000 UNITS	A060392 003	
	IVAX SUB TEVA PHARMS	400,000 UNITS	A060073 004	
	LILLY	250,000 UNITS	A060403 001	
	MYLAN	200,000 UNITS	A060781 001	
		250,000 UNITS	A060781 002	
		400,000 UNITS	A060781 003	
		500,000 UNITS	A060781 005	
		800,000 UNITS	A060781 004	
	PUREPAC PHARM	200,000 UNITS	A061588 001	
		250,000 UNITS	A061588 002	
		400,000 UNITS	A061588 003	
	TEVA	200,000 UNITS	A060306 001	
		250,000 UNITS	A060306 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN G POTASSIUM				
TABLET;ORAL				
PENICILLIN G POTASSIUM				
	400,000 UNITS		A060306 003	
	500,000 UNITS		A060306 004	
WYETH AYERST	200,000 UNITS		A060413 001	
	250,000 UNITS		A060413 002	
	400,000 UNITS		A060413 003	
PENTIDS '200'				
APOTHECON	200,000 UNITS		A062155 001	
PENTIDS '250'				
APOTHECON	250,000 UNITS		A062155 002	
PENTIDS '400'				
APOTHECON	400,000 UNITS		A060392 004	
	400,000 UNITS		A062155 003	
PENTIDS '800'				
APOTHECON	800,000 UNITS		A060392 005	
	800,000 UNITS		A062155 004	
PFIZERPEN G				
PFIZER	50,000 UNITS		A060075 001	
	100,000 UNITS		A060075 002	
	200,000 UNITS		A060075 003	
	250,000 UNITS		A060075 004	
	400,000 UNITS		A060075 005	
	800,000 UNITS		A060075 006	
PENICILLIN G PROCAINE				
INJECTABLE;INJECTION				
DURACILLIN A.S.				
LILLY	300,000 UNITS/ML		A060093 001	
PENICILLIN G PROCAINE				
CONSOLIDATED PHARM	300,000 UNITS/ML		A060800 001	
	600,000 UNITS/1.2ML		A060800 002	
PARKE DAVIS	300,000 UNITS/ML		A062029 001	
PFIZER	300,000 UNITS/VIAL		A060099 001	
	1,500,000 UNITS/VIAL		A060099 002	
PFIZERPEN-AS				
PFIZER	300,000 UNITS/ML		A060286 001	
	600,000 UNITS/ML		A060286 002	
PENICILLIN G SODIUM				
INJECTABLE;INJECTION				
PENICILLIN G SODIUM				
BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL		A061935 001	
COPANOS	5,000,000 UNITS/VIAL		A061051 001	
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL		A061046 001	
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
PENICILLIN G SODIUM				
WATSON LABS INC	5,000,000 UNITS/VIAL		A063014 001	Sep 13, 1988
PENICILLIN V				
FOR SUSPENSION;ORAL				
V-CILLIN				
LILLY	125MG/0.6ML		A060002 001	
PENICILLIN V POTASSIUM				
FOR SOLUTION;ORAL				
BEEPEN-VK				
GLAXOSMITHKLINE	EQ 125MG BASE/5ML		A062270 001	
	EQ 250MG BASE/5ML		A062270 002	
BETAPEN-VK				
APOTHECON	EQ 125MG BASE/5ML		A061149 001	
	EQ 250MG BASE/5ML		A061149 002	
LEDERCILLIN VK				
LEDERLE	EQ 125MG BASE/5ML		A060136 001	
	EQ 250MG BASE/5ML		A060136 002	
PEN-VEE K				
WYETH AYERST	EQ 125MG BASE/5ML		A060007 001	
	EQ 250MG BASE/5ML		A060007 002	
PENAPAR-VK				
PARKE DAVIS	EQ 125MG BASE/5ML		A062002 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL			
PENAPAR-VK			
	EQ 250MG BASE/5ML		A062002 002
PENICILLIN V POTASSIUM			
AM ANTIBIOTICS	EQ 125MG BASE/5ML		A061529 001
	EQ 250MG BASE/5ML		A061529 002
MYLAN	EQ 125MG BASE/5ML		A061624 002
	EQ 250MG BASE/5ML		A061624 001
PUREPAC PHARM	EQ 125MG BASE/5ML		A061758 001
	EQ 250MG BASE/5ML		A061758 002
PFIZERPEN VK			
PFIZER	EQ 125MG BASE/5ML		A061815 001
	EQ 250MG BASE/5ML		A061815 002
V-CILLIN K			
LILLY	EQ 125MG BASE/5ML		A060004 001
	EQ 250MG BASE/5ML		A060004 002
VEETIDS			
APOTHECON	EQ 125MG BASE/5ML		A061410 001
	EQ 250MG BASE/5ML		A061410 002
VEETIDS '125'			
APOTHECON	EQ 125MG BASE/5ML		A061206 001
	EQ 125MG BASE/5ML		A062153 001
VEETIDS '250'			
APOTHECON	EQ 250MG BASE/5ML		A061206 002
	EQ 250MG BASE/5ML		A062153 002
TABLET;ORAL			
BEEPEN-VK			
GLAXOSMITHKLINE	EQ 250MG BASE		A062273 001
	EQ 500MG BASE		A062273 002
BETAPEN-VK			
BRISTOL	EQ 250MG BASE		A061150 001
	EQ 500MG BASE		A061150 002
LEDERCILLIN VK			
LEDERLE	EQ 250MG BASE		A060134 001
	EQ 500MG BASE		A060134 002
PEN-VEE K			
WYETH AYERST	EQ 125MG BASE		A060006 001
	EQ 250MG BASE		A060006 002
	EQ 500MG BASE		A060006 003
PENAPAR-VK			
PARKE DAVIS	EQ 250MG BASE		A062001 001
	EQ 500MG BASE		A062001 002
PENICILLIN V POTASSIUM			
AM ANTIBIOTICS	EQ 250MG BASE		A061528 001
	EQ 500MG BASE		A061528 002
IVAX SUB TEVA PHARMS	EQ 125MG BASE		A060518 001
	EQ 250MG BASE		A060518 002
	EQ 500MG BASE		A060518 003
MYLAN	EQ 250MG BASE		A061530 001
	EQ 500MG BASE		A061530 002
PUREPAC PHARM	EQ 125MG BASE		A061571 001
	EQ 250MG BASE		A061571 002
	EQ 500MG BASE		A061571 003
PFIZERPEN VK			
PFIZER	EQ 250MG BASE		A061836 001
	EQ 500MG BASE		A061836 002
UTICILLIN VK			
PHARMACIA AND UPJOHN	EQ 250MG BASE		A061651 001
	EQ 500MG BASE		A061651 002
V-CILLIN K			
LILLY	EQ 125MG BASE **		A060003 001
	EQ 250MG BASE **		A060003 002
	EQ 500MG BASE **		A060003 003
VEETIDS			
APOTHECON	EQ 250MG BASE		A061411 001
	EQ 500MG BASE		A061411 002
VEETIDS '250'			
APOTHECON	EQ 250MG BASE		A061164 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN V POTASSIUM				
TABLET;ORAL				
VEETIDS '250'				
		EQ 250MG BASE	A062156 002	
VEETIDS '500'				
	APOTHECON	EQ 500MG BASE	A061164 002	
		EQ 500MG BASE	A062156 001	
PENTAGASTRIN				
INJECTABLE;INJECTION				
PEPTAVLON				
+	WYETH AYERST	0.25MG/ML **	N017048 001	
PENTAMIDINE ISETHIONATE				
FOR SOLUTION;INHALATION				
NEBUPENT				
	FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996
INJECTABLE;INJECTION				
PENTACARINAT				
	ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994
PENTAMIDINE ISETHIONATE				
	BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
	HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992
	WATSON LABS	300MG/VIAL	A074303 001	Aug 17, 1995
PENTAZOCINE HYDROCHLORIDE				
TABLET;ORAL				
TALWIN 50				
	SANOFI AVENTIS US	EQ 50MG BASE	N016732 001	
PENTAZOCINE LACTATE				
INJECTABLE;INJECTION				
TALWIN				
+	HOSPIRA	EQ 30MG BASE/ML	N016194 001	
PENTETATE CALCIUM TRISODIUM YB-169				
INJECTABLE;INJECTION				
YTTERBIUM YB 169 DTPA				
	3M	2mCi/ML	N017518 001	
PENTOBARBITAL				
ELIXIR;ORAL				
NEMBUTAL				
	OAK PHARMS	18.2MG/5ML	A083244 001	
PENTOBARBITAL SODIUM				
CAPSULE;ORAL				
NEMBUTAL SODIUM				
	OAK PHARMS	30MG	A084095 001	
		50MG	A084093 001	
		100MG	A083245 001	
PENTOBARBITAL SODIUM				
	LANNETT	50MG	A085937 001	
		100MG	A085915 001	
	VITARINE	100MG	A083284 001	
	WHITEWORTH TOWN PLSN	100MG	A083338 001	
SODIUM PENTOBARBITAL				
	ANABOLIC	100MG	A084590 001	
	ELKINS SINN	100MG	A083368 001	
	EVERYLIFE	100MG	A083259 001	
	HALSEY	100MG	A084677 001	
	IVAX SUB TEVA PHARMS	50MG	A083461 001	
		100MG	A083461 002	
	PARKE DAVIS	100MG	A084156 001	
	PERRIGO	100MG	A084560 001	
	PUREPAC PHARM	100MG	A083301 001	
	VALEANT PHARM INTL	100MG	A083264 001	
	WATSON LABS	100MG	A085791 001	
	WYETH AYERST	100MG	A083239 001	
INJECTABLE;INJECTION				
PENTOBARBITAL SODIUM				
	ELKINS SINN	50MG/ML	A083270 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION				
SODIUM PENTOBARBITAL				
	WYETH AYERST	50MG/ML	A083261 001	
SUPPOSITORY;RECTAL				
NEMBUTAL				
	OAK PHARMS	30MG	A083247 001	Jan 25, 1982
		60MG	A083247 002	Jan 25, 1982
		120MG	A083247 003	Jan 25, 1982
		200MG	A083247 004	Jan 25, 1982
TABLET;ORAL				
PENTOBARBITAL SODIUM				
	VITARINE	100MG	A083285 001	
SODIUM PENTOBARBITAL				
	NEXGEN PHARMA INC	100MG	A084238 001	

PENTOLINIUM TARTRATE

INJECTABLE;INJECTION				
ANSOLYSEN				
	WYETH AYERST	10MG/ML	N009372 001	

PENTOSTATIN

INJECTABLE;INJECTION				
PENTOSTATIN				
	MYLAN INSTITUTIONAL	10MG/VIAL	A203554 001	Sep 19, 2014

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL				
PENTOXIFYLLINE				
	ANI PHARMS INC	400MG	A074878 001	Jul 09, 1997
		400MG	A075107 001	Sep 04, 1998
		400MG	A075199 001	Sep 03, 1999
	HERITAGE PHARMS INC	400MG	A074877 001	Jul 08, 1997
	IMPAX LABS	400MG	A075093 001	Aug 10, 1999
	MYLAN	400MG	A074425 001	Jul 08, 1997
	PLIVA	400MG	A074874 001	May 25, 1999
TRENTAL				
+	US PHARM HOLDINGS	400MG **	N018631 001	Aug 30, 1984

PERFLUBRON

LIQUID;ORAL				
IMAGENT				
	ALLIANCE PHARM	100%	N020091 001	Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE;TOPICAL				
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS				
	US ARMY	50%;50%	N021084 001	Feb 17, 2000

PERGOLIDE MESYLATE

TABLET;ORAL				
PERGOLIDE MESYLATE				
	IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094 001	Sep 04, 2003
		EQ 0.25MG BASE	A076094 002	Sep 04, 2003
		EQ 1MG BASE	A076094 003	Sep 04, 2003
	PAR PHARM	EQ 0.05MG BASE	A076061 001	Nov 27, 2002
		EQ 0.25MG BASE	A076061 002	Nov 27, 2002
		EQ 1MG BASE	A076061 003	Nov 27, 2002
PERMAX				
	VALEANT PHARM INTL	EQ 0.05MG BASE	N019385 001	Dec 30, 1988
		EQ 0.25MG BASE	N019385 002	Dec 30, 1988
		EQ 1MG BASE	N019385 003	Dec 30, 1988

PERINDOPRIL ERBUMINE

TABLET;ORAL				
ACEON				
+	SYMPLMED PHARMS LLC	2MG	N020184 001	Dec 30, 1993
+		4MG	N020184 002	Dec 30, 1993
+		8MG	N020184 003	Dec 30, 1993
PERINDOPRIL ERBUMINE				
	ANI PHARMS INC	2MG	A078138 001	Nov 10, 2009
		4MG	A078138 002	Nov 10, 2009
		8MG	A078138 003	Nov 10, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PERINDOPRIL ERBUMINE

TABLET;ORAL				
PERINDOPRIL ERBUMINE				
APOTEX	2MG		A090463 001	Aug 30, 2010
	4MG		A090463 002	Aug 30, 2010
	8MG		A090463 003	Aug 30, 2010
LUPIN LTD	2MG		A078263 001	Jan 27, 2010
	4MG		A078263 002	Jan 27, 2010
	8MG		A078263 003	Jan 27, 2010

PERMETHRIN

LOTION;TOPICAL				
NIX				
GLAXOSMITHKLINE	1%		N019435 001	Mar 31, 1986

PERPHENAZINE

CONCENTRATE;ORAL				
PERPHENAZINE				
PHARM ASSOC	16MG/5ML		A040360 001	May 25, 2001
TRILAFON				
SCHERING	16MG/5ML		N011557 001	
INJECTABLE;INJECTION				
TRILAFON				
SCHERING	5MG/ML		N011213 002	
SYRUP;ORAL				
TRILAFON				
SCHERING	2MG/5ML		N011294 002	
TABLET;ORAL				
PERPHENAZINE				
ANI PHARMS INC	2MG		A089707 001	Sep 10, 1987
	4MG		A089708 001	Sep 10, 1987
	8MG		A089456 001	Sep 10, 1987
	16MG		A089457 001	Sep 10, 1987
TRILAFON				
+ SCHERING	2MG **		N010775 001	
+	4MG **		N010775 002	
+	8MG **		N010775 003	
+	16MG **		N010775 004	
TABLET, EXTENDED RELEASE;ORAL				
TRILAFON				
SCHERING	8MG		N011361 002	

PHENACEMIDE

TABLET;ORAL				
PHENURONE				
+ ABBVIE	500MG **		N007707 001	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET;ORAL				
AZO GANTANOL				
+ ROCHE	100MG;500MG **		N013294 001	Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL				
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE				
ABLE	200MG,N/A,N/A;N/A,800MG,160MG		N021105 001	Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET;ORAL				
AZO GANTRISIN				
+ ROCHE	50MG;500MG **		N019358 001	Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL				
PHENAZINE				
MAST MM	35MG		A086523 001	
	35MG		A086524 001	
	35MG		A086525 001	
PHENDIMETRAZINE TARTRATE				
SANDOZ	35MG		A085633 001	
	35MG		A085694 001	
	35MG		A085702 001	
VIRTUS PHARMS	35MG		A085695 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PHENDIMETRAZINE TARTRATE				
CAPSULE;ORAL				
PHENDIMETRAZINE TARTRATE				
VITARINE	35MG	A085634	001	
	35MG	A085645	001	
	35MG	A085670	001	
	35MG	A086403	001	
	35MG	A086408	001	
	35MG	A086410	001	
	35MG	A087424	001	
SPRX-3				
SOLVAY	35MG	A085897	001	
STATOBEX				
TEVA	35MG	A085507	001	
X-TROZINE				
SHIRE RICHWOOD	35MG	A087394	001	Sep 22, 1982
CAPSULE, EXTENDED RELEASE;ORAL				
BONTRIL				
VALEANT	105MG	A088021	001	Sep 21, 1982
MELFIAT-105				
NUMARK	105MG	A087487	001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
VIRTUS PHARMS	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET;ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
CHARTWELL RX	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
CHARTWELL RX	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	

PHENDIMETRAZINE TARTRATE
TABLET;ORAL
PHENDIMETRAZINE TARTRATE

	35MG		A084743 001
IVAX PHARMS	35MG		A085611 001
	35MG		A085612 001
IVAX SUB TEVA PHARMS	35MG		A083682 001
KV PHARM	35MG		A084138 001
	35MG		A084141 001
	35MG		A085525 001
MFG CHEMISTS	35MG		A085914 001
NEXGEN PHARMA INC	35MG		A086020 001
NUMARK	35MG		A083790 001
PVT FORM	35MG		A085199 001
	35MG		A085697 001
SANDOZ	35MG		A085402 001
	35MG		A085830 001
	35MG		A086370 001
SOLVAY	35MG		A083993 001
UPSHER SMITH LABS	35MG		A084399 001
USL PHARMA	35MG		A083805 001
	35MG		A084398 001
VIRTUS PHARMS	35MG		A085497 001
	35MG		A086365 001
VITARINE	35MG		A085519 001
	35MG		A086005 001
	35MG		A086106 001
WATSON LABS	35MG		A085767 001
	35MG		A085768 001
	35MG		A085770 001
	35MG		A085773 001

PLEGINE

WYETH AYERST	35MG **		N012248 001

STATOBEX

TEVA	35MG		A086013 001

STATOBEX-G

TEVA	35MG		A085095 001

X-TROZINE

SHIRE RICHWOOD	35MG		A086550 001
	35MG		A086551 001
	35MG		A086552 001
	35MG		A086553 001
	35MG		A086554 001

PHENINDIONE
TABLET;ORAL
HEDULIN

SANOFI AVENTIS US	50MG		N008767 002

PHENMETRAZINE HYDROCHLORIDE
TABLET;ORAL
PRELUDIN

BOEHRINGER INGELHEIM	25MG		N010460 005

TABLET, EXTENDED RELEASE;ORAL
PRELUDIN

BOEHRINGER INGELHEIM	50MG		N011752 004
	75MG		N011752 003

PHENOXYBENZAMINE HYDROCHLORIDE
CAPSULE;ORAL
DIBENZYLINE

+ CONCORDIA	10MG		N008708 001

PHENPROCOUMON
TABLET;ORAL
LIQUAMAR

ORGANON USA INC	3MG		N011228 001

PHENSUXIMIDE				
CAPSULE;ORAL				
MILONTIN				
PARKE DAVIS	500MG	N008855	004	
PHENTERMINE HYDROCHLORIDE				
CAPSULE;ORAL				
FASTIN				
GLAXOSMITHKLINE	30MG **	N017352	001	
OBESTIN-30				
FERNDALE LABS	30MG	A087144	001	
OBY-TRIM				
SHIRE RICHWOOD	30MG	A087764	001	Mar 18, 1982
ONA-MAST				
MAST MM	30MG	A086511	001	
	30MG	A086516	001	
PHENTERMINE HYDROCHLORIDE				
ABC HOLDING	30MG	A085411	001	
ABLE	15MG	A040497	001	Mar 13, 2003
	30MG	A040403	001	Aug 30, 2001
	30MG	A040427	001	Aug 30, 2001
CAMALL	15MG	A086735	001	
	30MG	A087226	001	
CHARTWELL RX	18.75MG	A088576	001	May 23, 1984
	30MG	A085417	001	
	30MG	A086732	002	
	30MG	A087215	001	
	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
ELITE LABS INC	15MG	A040460	001	Jan 14, 2003
	30MG	A040227	001	Jun 18, 1997
	30MG	A040448	001	Jan 22, 2003
IVAX PHARMS	30MG	A086329	001	
LANNETT CO INC	30MG	A091359	001	Jul 16, 2010
SANDOZ	30MG	A087208	001	
	30MG	A087223	001	
	37.5MG	A088414	001	Oct 19, 1983
SUN PHARM INDUSTRIES	37.5MG	A040527	001	Oct 23, 2003
TEVA	30MG	A086911	001	
	30MG	A087126	001	
	30MG	A087777	001	Nov 01, 1985
	30MG	A088612	001	Apr 04, 1984
	30MG	A088613	001	Apr 09, 1984
	30MG	A088614	001	Apr 09, 1984
TG UNITED INC	30MG	A040083	001	Mar 07, 1997
UPSHER SMITH LABS	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
USL PHARMA	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985
TABLET;ORAL				
ONA-MAST				
MAST MM	8MG	A086260	001	
PHENTERMINE HYDROCHLORIDE				
ABLE	37.5MG	A040402	001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
CHARTWELL RX	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
IVAX PHARMS	8MG	A085553	001	
NOVAST LABS	37.5MG	A091451	001	Sep 21, 2012
SANDOZ	8MG	A085671	001	
	8MG	A085689	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENTERMINE HYDROCHLORIDE				
TABLET;ORAL				
PHENTERMINE HYDROCHLORIDE				
SANDOZ INC	30MG	A088605	001	Sep 28, 1987
SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007
USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	
WATSON LABS	8MG	A085739	001	
TORA				
SOLVAY	8MG	A084035	001	
WILPO				
+ SANDOZ	8MG **	N012737	001	
TABLET, ORALLY DISINTEGRATING;ORAL				
SUPRENZA				
CITIUS PHARMS	15MG **	N202088	001	Jun 13, 2011
	30MG **	N202088	002	Jun 13, 2011
	37.5MG **	N202088	003	Mar 27, 2012
PHENTERMINE RESIN COMPLEX				
CAPSULE, EXTENDED RELEASE;ORAL				
IONAMIN				
UCB INC	EQ 15MG BASE **	N011613	004	
	EQ 30MG BASE **	N011613	002	
PHENTERMINE RESIN 30				
QUANTUM PHARMICS	EQ 30MG BASE	A089120	001	Feb 04, 1988
PHENTERMINE RESIN COMPLEX				
LANNETT CO INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
	EQ 30MG BASE	A040872	002	Jul 28, 2011
PHENTOLAMINE MESYLATE				
INJECTABLE;INJECTION				
REGITINE				
+ NOVARTIS	5MG/VIAL **	N008278	003	
PHENYL AMINOSALICYLATE				
POWDER;ORAL				
PHENY-PAS-TEBAMIN				
PHARM RES ASSOC	50%	N011695	002	
TABLET;ORAL				
PHENY-PAS-TEBAMIN				
PHARM RES ASSOC	500MG	N011695	003	
PHENYLBUTAZONE				
CAPSULE;ORAL				
AZOLID				
SANOFI AVENTIS US	100MG	A087260	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	009	
PHENYLBUTAZONE				
FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982
IVAX PHARMS	100MG	A088218	001	Jun 24, 1983
SUN PHARM INDUSTRIES	100MG	A088994	001	Dec 04, 1985
WATSON LABS	100MG	A087756	001	Dec 17, 1982
TABLET;ORAL				
AZOLID				
SANOFI AVENTIS US	100MG	A087091	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	008	
PHENYLBUTAZONE				
FOSUN PHARMA	100MG	A084339	001	
SUN PHARM INDUSTRIES	100MG	A088863	001	Dec 04, 1985
WATSON LABS	100MG	A086151	001	
	100MG	A087674	001	Apr 21, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE					
SYRUP;ORAL					
PHENERGAN VC					
+	ANI PHARMS	5MG/5ML;6.25MG/5ML **	N008604	003	Apr 02, 1984
PHERAZINE VC					
	HALSEY	5MG/5ML;6.25MG/5ML	A088868	001	Mar 02, 1987
PROMETH VC PLAIN					
	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984
PROMETHAZINE VC PLAIN					
	CENCI	5MG/5ML;6.25MG/5ML	A088815	001	Nov 22, 1985
	WOCKHARDT	5MG/5ML;6.25MG/5ML	A088897	001	Jan 04, 1985
PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE					
SOLUTION/DROPS;OPHTHALMIC					
PREFRIN-A					
	ALLERGAN	0.12%;0.1%	N007953	001	
PHENYTOIN					
SUSPENSION;ORAL					
DILANTIN-30					
	PARKE DAVIS	30MG/5ML	N008762	002	
PHENYTOIN					
	ACTAVIS MID ATLANTIC	125MG/5ML	A089892	001	Sep 25, 1992
PHENYTOIN SODIUM					
CAPSULE;ORAL					
DIPHENYLAN SODIUM					
	LANNETT	30MG PROMPT	A080857	001	
		100MG PROMPT	A080857	002	
EXTENDED PHENYTOIN SODIUM					
	ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003
		100MG EXTENDED	A089441	001	Dec 18, 1986
	SUN PHARM INDS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006
	WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007
	WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008
PHENYTEX					
	WATSON LABS	100MG EXTENDED	A088711	001	Dec 21, 1984
PHENYTOIN SODIUM					
	PHARMERAL	100MG PROMPT	A085435	001	
	WATSON LABS	100MG PROMPT	A085894	001	
PROMPT PHENYTOIN SODIUM					
	ANI PHARMS INC	100MG PROMPT	A080259	001	
	WATSON LABS	100MG PROMPT	A080905	001	
INJECTABLE;INJECTION					
DILANTIN					
	PARKE DAVIS	50MG/ML	N010151	001	
PHENYTOIN SODIUM					
	FRESENIUS KABI USA	50MG/ML	A089003	001	May 31, 1985
	HOSPIRA	50MG/ML	A089521	001	Mar 17, 1987
		50MG/ML	A089744	001	Dec 18, 1987
	LUITPOLD	50MG/ML	A040781	001	Dec 04, 2007
	MARSAM PHARMS LLC	50MG/ML	A089501	001	Oct 13, 1987
		50MG/ML	A089779	001	Nov 27, 1992
	SMITH AND NEPHEW	50MG/ML	A088519	001	Dec 19, 1984
		50MG/ML	A088521	001	Dec 18, 1984
	SOLOPAK	50MG/ML	A088520	001	Dec 17, 1984
	WARNER CHILCOTT	50MG/ML	A089900	001	Mar 30, 1990
	WATSON LABS	50MG/ML	A085434	001	
PHYTONADIONE					
INJECTABLE;INJECTION					
AQUAMEPHYTON					
+	TELIGENT	1MG/0.5ML **	N012223	002	
+		10MG/ML **	N012223	001	
KONAKION					
	ROCHE	1MG/0.5ML	N011745	001	
		10MG/ML	N011745	003	
PHYTONADIONE					
	GLAXOSMITHKLINE	1MG/0.5ML	A084060	001	
		10MG/ML	A084060	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHYTONADIONE					
INJECTABLE;INJECTION					
VITAMIN K1					
	HOSPIRA	10MG/ML	A087956	001	Jul 25, 1983
PILOCARPINE					
INSERT, EXTENDED RELEASE;OPHTHALMIC					
OCUSERT PILO-20					
	AKORN	5MG	N017431	001	
OCUSERT PILO-40					
	AKORN	11MG	N017548	001	
PILOCARPINE HYDROCHLORIDE					
GEL;OPHTHALMIC					
PILOPINE HS					
	ALCON	4%	N018796	001	Oct 01, 1984
PIMAVANSERIN TARTRATE					
TABLET;ORAL					
NUPLAZID					
+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016
PIMOZIDE					
TABLET;ORAL					
ORAP					
+	TEVA	1MG	N017473	003	Aug 27, 1997
+		2MG	N017473	001	Jul 31, 1984
PINACIDIL					
CAPSULE, EXTENDED RELEASE;ORAL					
PINDAC					
	LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
		25MG	N019456	002	Dec 28, 1989
PINDOLOL					
TABLET;ORAL					
PINDOLOL					
	ACP NIMBLE	5MG	A073661	001	Oct 31, 1993
		5MG	A073687	001	Feb 26, 1993
		5MG	A074123	001	Apr 17, 1997
		10MG	A073661	002	Oct 31, 1993
		10MG	A073687	002	Feb 26, 1993
		10MG	A074123	002	Apr 17, 1997
	MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992
		10MG	A074018	001	Sep 24, 1992
	NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
		10MG	A074474	002	Oct 28, 1996
	PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
		10MG	A074125	002	Apr 28, 1993
	WATSON LABS	5MG	A074437	001	Feb 27, 1995
		10MG	A074437	002	Feb 27, 1995
	ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017
		10MG	A209866	002	Aug 18, 2017
VISKEN					
+	NOVARTIS	5MG **	N018285	001	Sep 03, 1982
+		10MG **	N018285	002	Sep 03, 1982
PIPECURONIUM BROMIDE					
INJECTABLE;INJECTION					
ARDUAN					
	ORGANON USA INC	10MG/VIAL	N019638	001	Jun 26, 1990
PIPERACETAZINE					
TABLET;ORAL					
QUIDE					
	DOW PHARM	10MG	N013615	001	
		25MG	N013615	002	

PIPERACILLIN SODIUM				
INJECTABLE;INJECTION				
PIPRACIL				
	WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750 001	Oct 13, 1987
+		EQ 2GM BASE/VIAL **	N050545 002	
		EQ 3GM BASE/VIAL	A062750 002	Oct 13, 1987
+		EQ 3GM BASE/VIAL **	N050545 003	
		EQ 4GM BASE/VIAL	A062750 003	Oct 13, 1987
+		EQ 4GM BASE/VIAL **	N050545 004	
+		EQ 40GM BASE/VIAL **	N050545 006	Sep 30, 1985
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM				
INJECTABLE;INJECTION				
PIPERACILLIN AND TAZOBACTAM				
	ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287 001	Jul 29, 2019
		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287 002	Jul 29, 2019
		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287 003	Jul 29, 2019
	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386 001	Sep 15, 2009
		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386 002	Sep 15, 2009
		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386 003	Sep 15, 2009
		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446 001	Sep 15, 2009
PIPERAZINE CITRATE				
SYRUP;ORAL				
ANTEPAR				
	GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102 001	
BRYREL				
	SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796 001	
MULTIFUGE				
	BLULINE	EQ 500MG BASE/5ML	N009452 001	
PIPERAZINE CITRATE				
	ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774 001	
	LANNETT	EQ 500MG BASE/5ML	A080963 001	
	LUITPOLD	EQ 500MG BASE/5ML	A080671 001	
VERMIDOL				
	SOLVAY	EQ 500MG BASE/5ML	A080992 001	
TABLET;ORAL				
ANTEPAR				
	GLAXOSMITHKLINE	EQ 500MG BASE	N009102 003	
PIPERAZINE CITRATE				
	IMPAX LABS	EQ 250MG BASE	A080874 001	
PIPERONYL BUTOXIDE; PYRETHRINS				
AEROSOL;TOPICAL				
RID MOUSSE				
	BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000
PIPOBROMAN				
TABLET;ORAL				
VERCYTE				
	ABBOTT	10MG	N016245 001	
		25MG	N016245 002	
PIRBUTEROL ACETATE				
AEROSOL, METERED;INHALATION				
MAXAIR				
	BAUSCH	EQ 0.2MG BASE/INH	N019009 001	Dec 30, 1986
	MEDICIS	EQ 0.2MG BASE/INH	N020014 001	Nov 30, 1992
PIRFENIDONE				
TABLET;ORAL				
ESBRIET				
+	GENENTECH INC	534MG **	N208780 002	Jan 11, 2017
PIROXICAM				
CAPSULE;ORAL				
PIROXICAM				
	BRECKENRIDGE	10MG	A208991 001	Feb 21, 2018
		20MG	A208991 002	Feb 21, 2018
	CYCLE PHARMS LTD	10MG	A073651 001	Feb 26, 1993
		20MG	A073651 002	Feb 26, 1993
	EGIS	10MG	A074808 001	Jul 08, 1997
		20MG	A074808 002	Jul 08, 1997

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PIROXICAM					
CAPSULE;ORAL					
PIROXICAM					
IVAX SUB TEVA PHARMS	10MG		A074148	001	Jun 03, 1996
	20MG		A074148	002	Jun 03, 1996
MYLAN	10MG		A074043	001	Sep 22, 1992
	10MG		A074102	001	Jul 31, 1992
	20MG		A074043	002	Sep 22, 1992
	20MG		A074102	002	Jul 31, 1992
SCS	10MG		A074036	001	May 29, 1992
	20MG		A074036	002	May 29, 1992
SUN PHARM INDUSTRIES	10MG		A073536	002	Jan 23, 2008
	20MG		A073536	001	Mar 12, 1993
TEVA	10MG		A073637	001	Jan 28, 1994
	20MG		A073638	001	Jan 28, 1994
TEVA PHARMS	10MG		A074103	001	Aug 28, 1992
	20MG		A074103	002	Aug 28, 1992
WATSON LABS	10MG		A074287	001	May 16, 1996
	10MG		A074460	001	Sep 29, 1995
	20MG		A074287	002	May 16, 1996
	20MG		A074460	002	Sep 29, 1995
PITAVASTATIN CALCIUM					
TABLET;ORAL					
PITAVASTATIN CALCIUM					
MYLAN	EQ 1MG BASE		A206070	001	Apr 04, 2019
	EQ 2MG BASE		A206070	002	Apr 04, 2019
	EQ 4MG BASE		A206070	003	Apr 04, 2019
PITAVASTATIN MAGNESIUM					
TABLET;ORAL					
ZYPITAMAG					
+ MEDICURE	EQ 1MG BASE		N208379	001	Jul 14, 2017
PITAVASTATIN SODIUM					
TABLET;ORAL					
NIKITA					
+ LUPIN LTD	EQ 1MG BASE		N209875	001	Aug 04, 2017
+	EQ 2MG BASE		N209875	002	Aug 04, 2017
+	EQ 4MG BASE		N209875	003	Aug 04, 2017
PLICAMYCIN					
INJECTABLE;INJECTION					
MITHRACIN					
PFIZER	2.5MG/VIAL		N050109	001	
PODOFILOX					
SOLUTION;TOPICAL					
PODOFILOX					
BAUSCH AND LOMB INC	0.5%		A090184	001	Jul 21, 2010
POLYESTRADIOL PHOSPHATE					
INJECTABLE;INJECTION					
ESTRADURIN					
WYETH AYERST	40MG/AMP		N010753	001	
POLYETHYLENE GLYCOL 3350					
FOR SOLUTION;ORAL					
GLYCOLAX					
LANNETT CO INC	17GM/SCOOPFUL		A076652	001	Jul 02, 2004
	17GM/PACKET		A090600	001	Oct 06, 2009
	17GM/SCOOPFUL		A090600	002	Oct 06, 2009
POLYETHYLENE GLYCOL 3350					
BRECKENRIDGE PHARM	17GM/SCOOPFUL		A077736	001	May 26, 2006
NEXGEN PHARMA INC	17GM/SCOOPFUL		A077706	001	Sep 27, 2006
PADDOCK LLC	17GM/SCOOPFUL		A077893	001	May 26, 2006
	17GM/SCOOPFUL		A090567	001	Oct 15, 2009
TEVA PHARMS	17GM/SCOOPFUL		A077445	001	May 04, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409	001	Apr 02, 2010

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

CLENZ-LYTE

PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769	001	Jun 07, 2010

SOLUTION;ORAL

OCL

HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML	N019284	001	Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984
	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984
	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987
	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984

COLYTE-FLAVORED

MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991

GOLYTELY

+	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011	002	Jun 02, 1992

PEG 3350 AND ELECTROLYTES

MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712	001	Feb 25, 2010

FOR SUSPENSION;ORAL

CO-LAV

VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992

COLOVAGE

DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	A071320	001	Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A071278	001	Nov 21, 1988

GLYCOPREP

GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A072319	001	Dec 23, 1988

GO-EVAC

VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433	001	Apr 28, 1992

PEG-LYTE

SANDOZ	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073098	001	Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

AEROSPORIN

GLAXOSMITHKLINE	EQ 500,000 U BASE/VIAL	A062036	001

POLYMYXIN B SULFATE

WEST-WARD PHARMS INT	EQ 500,000 UNITS BASE/VIAL	A060716	001

POWDER;FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS	100,000,000 UNITS/BOT	A061578	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POLYMYXIN B SULFATE				
POWDER;FOR RX COMPOUNDING				
POLYMYXIN B SULFATE				
PADDOCK LLC	100,000,000 UNITS/BOT	A062455	001	Jul 27, 1983
POLYTHIAZIDE				
TABLET;ORAL				
RENESE				
PFIZER	1MG	N012845	001	
	2MG	N012845	002	
	4MG	N012845	003	
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
MINIZIDE				
PFIZER	0.5MG;EQ 1MG BASE	N017986	001	
	0.5MG;EQ 2MG BASE	N017986	002	
	0.5MG;EQ 5MG BASE	N017986	003	
POLYTHIAZIDE; RESERPINE				
TABLET;ORAL				
RENESE-R				
PFIZER	2MG;0.25MG	N013636	001	
POTASSIUM AMINOSALICYLATE				
CAPSULE;ORAL				
PASKALIUM				
GLENWOOD	500MG	N009395	004	
POWDER;ORAL				
POTASSIUM AMINOSALICYLATE				
HEXCEL	100%	A080098	001	
TABLET;ORAL				
PASKALIUM				
GLENWOOD	1GM	N009395	003	
POTASSIUM CHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
K-LEASE				
SAVAGE LABS	8MEQ	A073398	001	Jan 28, 1992
	10MEQ	A072427	001	Mar 28, 1990
POTASSIUM CHLORIDE				
NESHER PHARMS	10MEQ	A070980	001	Feb 17, 1987
TEVA	8MEQ	A073531	001	Apr 26, 1996
	10MEQ	A073532	001	Apr 26, 1996
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
MICRO-K LS				
KV PHARM	20MEQ/PACKET	N019561	003	Aug 26, 1988
INJECTABLE;INJECTION				
POTASSIUM CHLORIDE				
ABRAXIS PHARM	2MEQ/ML	A080204	001	
	2MEQ/ML	A084290	001	
	2MEQ/ML	A086713	001	
	2MEQ/ML	A086714	001	
	2MEQ/ML	A087787	001	Apr 20, 1982
	2MEQ/ML	A087885	001	Feb 03, 1983
AKORN	2MEQ/ML	A088286	001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203	001	
	2MEQ/ML	A085499	001	
FRESENIUS KABI USA	2MEQ/ML	A087817	001	Oct 20, 1982
GD SEARLE LLC	1MEQ/ML	A086219	001	
	2MEQ/ML	A086219	002	
	2MEQ/ML	A086220	002	
	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	
	1MEQ/ML	A083345	003	
	1.5MEQ/ML	A083345	001	
	2MEQ/ML	A083345	002	
	2.4MEQ/ML	A080205	004	
	3.2MEQ/ML	A080205	005	
INTL MEDICATION	2MEQ/ML	A083163	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

POTASSIUM CHLORIDE

INJECTABLE;INJECTION					
POTASSIUM CHLORIDE					
	LILLY	2MEQ/ML	N007865	002	
	LUITPOLD	2MEQ/ML	A080221	001	
		2MEQ/ML	A080736	001	
		2MEQ/ML	A087584	001	
		2MEQ/ML	A087585	001	
	MILES	1MEQ/ML	A080195	002	
		2MEQ/ML	A080195	001	
		3MEQ/ML	A080195	003	
		4MEQ/ML	A080195	004	
	PHARMA SERVE NY	2MEQ/ML	A086297	001	
		2MEQ/ML	A087362	001	Mar 08, 1983
	WATSON LABS	2MEQ/ML	A086208	001	
		2MEQ/ML	A089163	001	Mar 10, 1988
		2MEQ/ML	A089421	001	Jan 02, 1987
		3MEQ/ML	A086210	001	
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998
TABLET, EXTENDED RELEASE;ORAL					
K+10					
	FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
K+8					
	FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
KAON CL					
	SAVAGE LABS	6.7MEQ	N017046	001	
KAON CL-10					
	SAVAGE LABS	10MEQ	N017046	002	
KLOTRIX					
	APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE					
	COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
	NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
	PII	8MEQ	A206881	001	Jan 22, 2019
		10MEQ	A206630	001	Mar 29, 2019
		10MEQ	A206881	002	Jan 22, 2019
		10MEQ	A210097	001	Jun 17, 2019
		15MEQ	A206630	002	Mar 29, 2019
		20MEQ	A206630	003	Mar 29, 2019
		20MEQ	A210098	001	Apr 26, 2019
+	SCHERING	10MEQ **	N019439	002	Jun 13, 1986
+		20MEQ **	N019439	001	Jun 13, 1986
SLOW-K					
	NOVARTIS	8MEQ	N017476	002	
TEN-K					
	NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	37MG/100ML;900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	75MG/100ML;900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	110MG/100ML;900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	220MG/100ML;900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%					
+	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003	
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	300MG/100ML;900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER					
	B BRAUN	75MG/100ML;900MG/100ML	N018722	001	Nov 09, 1982
	BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
	B BRAUN	150MG/100ML;900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER					
	B BRAUN	220MG/100ML;900MG/100ML	N018722	003	Nov 09, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POTASSIUM CHLORIDE; SODIUM CHLORIDE					
INJECTABLE;INJECTION					
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	B BRAUN	300MG/100ML;900MG/100ML	N018722	004	Nov 09, 1982
POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE					
INJECTABLE;INJECTION					
THAM-E					
	HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025	001	
POTASSIUM CITRATE					
FOR SOLUTION;ORAL					
POTASSIUM CITRATE					
+	UT SW MEDCTR	10MEQ/PACKET **	N019647	002	Oct 13, 1988
+		20MEQ/PACKET **	N019647	001	Oct 13, 1988
POTASSIUM IODIDE					
SOLUTION;ORAL					
POTASSIUM IODIDE					
	ROXANE	1GM/ML **	N018551	001	Feb 19, 1982
TABLET;ORAL					
THYRO-BLOCK					
	MEDA PHARMS	130MG	N018307	001	
POTASSIUM PERCHLORATE					
CAPSULE;ORAL					
PERCHLORACAP					
	MALLINCKRODT	200MG	N017551	001	
POVIDONE-IODINE					
SOLUTION;TOPICAL					
E-Z PREP					
	CLINIPAD	10%	N019382	001	Jul 25, 1989
SPONGE;TOPICAL					
E-Z PREP					
	CLINIPAD	5%	N019382	002	Jul 25, 1989
E-Z PREP 220					
	CLINIPAD	5%	N019382	003	Jul 25, 1989
PRALIDOXIME CHLORIDE					
INJECTABLE;INJECTION					
PRALIDOXIME CHLORIDE					
	BAXTER HLTHCARE CORP	300MG/ML	N018799	001	Dec 13, 1982
TABLET;ORAL					
PROTOPAM CHLORIDE					
	WYETH AYERST	500MG	N014122	002	
PRAMIPEXOLE DIHYDROCHLORIDE					
TABLET;ORAL					
MIRAPEX					
	BOEHRINGER INGELHEIM	1.25MG	N020667	004	Jul 01, 1997
PRAMIPEXOLE DIHYDROCHLORIDE					
	HERITAGE PHARMA	0.125MG	A078551	001	Oct 08, 2010
		0.125MG	A090241	001	Oct 08, 2010
		0.125MG	A091254	001	Nov 30, 2010
		0.25MG	A078551	002	Oct 08, 2010
		0.25MG	A090241	002	Oct 08, 2010
		0.25MG	A091254	002	Nov 30, 2010
		0.5MG	A078551	003	Oct 08, 2010
		0.5MG	A090241	003	Oct 08, 2010
		0.5MG	A091254	003	Nov 30, 2010
		0.75MG	A090241	004	Oct 08, 2010
		0.75MG	A091254	004	Nov 30, 2010
		1MG	A078551	004	Oct 08, 2010
		1MG	A090241	005	Oct 08, 2010
		1MG	A091254	005	Nov 30, 2010
		1.5MG	A078551	005	Oct 08, 2010
		1.5MG	A090241	006	Oct 08, 2010
		1.5MG	A091254	006	Nov 30, 2010
	SANDOZ	0.125MG	A090190	001	Jul 06, 2010
		0.25MG	A090190	002	Jul 06, 2010
		0.5MG	A090190	003	Jul 06, 2010
		0.75MG	A090190	006	Oct 08, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PRAMIPEXOLE DIHYDROCHLORIDE				
TABLET;ORAL				
PRAMIPEXOLE DIHYDROCHLORIDE				
	1MG	A090190	004	Jul 06, 2010
	1.5MG	A090190	005	Jul 06, 2010
SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013
	0.25MG	A091683	002	Mar 27, 2013
	0.5MG	A091683	003	Mar 27, 2013
	0.75MG	A091683	004	Mar 27, 2013
	1MG	A091683	005	Mar 27, 2013
	1.5MG	A091683	006	Mar 27, 2013
PRAMLINTIDE ACETATE				
INJECTABLE;SUBCUTANEOUS				
SYMLIN				
ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005
PRAVASTATIN SODIUM				
TABLET;ORAL				
PRAVACHOL				
+ BRISTOL MYERS SQUIBB	10MG **	N019898	002	Oct 31, 1991
PRAVASTATIN SODIUM				
MYLAN	10MG	A077013	001	Oct 23, 2006
	20MG	A077013	002	Oct 23, 2006
	40MG	A077013	003	Oct 23, 2006
	80MG	A077013	004	Dec 28, 2007
PLIVA HRVATSKA DOO	10MG	A077730	001	Nov 21, 2006
	20MG	A077730	002	Nov 21, 2006
	30MG	A077730	003	Nov 21, 2006
	40MG	A077730	005	Nov 21, 2006
RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007
	20MG	A076445	002	Apr 23, 2007
	40MG	A076445	003	Apr 23, 2007
	80MG	A076445	004	Apr 23, 2007
PRAZEPAM				
CAPSULE;ORAL				
CENTRAX				
PARKE DAVIS	5MG	N018144	001	
	10MG	N018144	002	
	20MG	N018144	003	May 10, 1982
PRAZEPAM				
USL PHARMA	5MG	A070427	001	Nov 06, 1987
	10MG	A070428	001	Nov 06, 1987
TABLET;ORAL				
CENTRAX				
PARKE DAVIS	10MG	N017415	001	
PRAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
PRAZOSIN HYDROCHLORIDE				
AM THERAP	EQ 1MG BASE	A072782	001	May 16, 1989
	EQ 2MG BASE	A072783	001	May 16, 1989
	EQ 5MG BASE	A072784	001	May 16, 1989
ANI PHARMS INC	EQ 1MG BASE	A072577	002	May 16, 1989
	EQ 2MG BASE	A072577	001	May 16, 1989
	EQ 5MG BASE	A072577	003	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705	001	May 16, 1989
	EQ 2MG BASE	A072706	001	May 16, 1989
	EQ 5MG BASE	A072707	001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991	001	May 16, 1989
	EQ 2MG BASE	A072921	001	May 16, 1989
	EQ 5MG BASE	A072992	001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352	001	May 16, 1989
	EQ 2MG BASE	A072333	001	May 16, 1989
	EQ 5MG BASE	A072609	001	May 16, 1989
TABLET, EXTENDED RELEASE;ORAL				
MINIPRESS XL				
PFIZER	2.5MG	N019775	001	Jan 29, 1992
	5MG	N019775	002	Jan 29, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE				
CREAM;TOPICAL				
METI-DERM				
SCHERING	0.5%	N010209	002	
SYRUP;ORAL				
PREDNISOLONE				
IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999
NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001
	15MG/5ML	A040364	001	Apr 10, 2002
PHARM ASSOC	5MG/5ML	A040570	001	Aug 25, 2005
	15MG/5ML	A040571	001	Aug 25, 2005
TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192	001	May 28, 1998
PRELONE				
MURO	5MG/5ML	A089654	001	Jan 17, 1989
TABLET;ORAL				
CORTALONE				
HALSEY	1MG	A080304	003	
	2.5MG	A080304	002	
	5MG	A080304	001	
DELTA-CORTEF				
PHARMACIA AND UPJOHN	5MG	N009987	004	
FERNISOLONE-P				
FERNDALE LABS	5MG	A083941	001	
PREDNISOLONE				
AUROLIFE PHARMA LLC	5MG	A084773	001	
BARR	5MG	A084426	002	
BUNDY	5MG	A083675	001	
CHARTWELL RX	5MG	A084542	001	
ELKINS SINN	5MG	A080625	001	
EVERYLIFE	1MG	A084439	001	
	2.5MG	A084439	002	
	5MG	A084439	003	
FERRANTE	2.5MG	A080562	001	
	5MG	A080562	002	
FOSUN PHARMA	5MG	A080339	001	
HEATHER	5MG	A080326	001	
IMPAX LABS	5MG	A080780	001	
INWOOD LABS	5MG	A080748	001	
IVAX SUB TEVA PHARMS	5MG	A080378	001	
LANNETT	5MG	A080531	002	
MARSHALL PHARMA	5MG	A080307	001	
PANRAY	1MG	A080351	001	
	5MG	A080351	002	
PHOENIX LABS NY	5MG	A080322	001	
PUREPAC PHARM	5MG	A080325	001	
PVT FORM	5MG	A080211	001	
ROXANE	5MG	A080327	002	
SPERTI	1MG	A080358	001	
	2.5MG	A080358	002	
	5MG	A080358	003	
SUPERPHARM	5MG	A088892	001	Feb 26, 1985
TABLICAPS	5MG	A085170	001	
TEVA	5MG	A080398	001	
UDL	5MG	A087987	001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236	001	
VITARINE	5MG	A080534	001	
WATSON LABS	5MG	A085085	002	
	5MG	A085415	001	
	5MG	A085416	001	
WEST WARD	5MG	A080324	001	
WHITEWORTH TOWN PLSN	5MG	A080342	001	
STERANE				
PFIZER	5MG	N009996	001	

PREDNISOLONE ACETATE

INJECTABLE;INJECTION			
METICORTELONE			
SCHERING	25MG/ML	N010255 002	
PREDNISOLONE ACETATE			
AKORN	25MG/ML	A083032 001	
	50MG/ML	A084492 001	
BEL MAR	25MG/ML	A083738 001	
	50MG/ML	A083738 002	
CENT PHARMS	25MG/ML	A084717 001	
	50MG/ML	A084717 002	
WATSON LABS	25MG/ML	A083398 001	
	25MG/ML	A083654 001	
	40MG/ML	A083767 001	
	50MG/ML	A083764 001	
	50MG/ML	A085781 001	
STERANE			
PFIZER	25MG/ML	N011446 001	
SUSPENSION;ORAL			
FLO-PRED			
TARO	EQ 5MG BASE/5ML	N022067 001	Jan 17, 2008
	EQ 15MG BASE/5ML	N022067 002	Jan 17, 2008
SUSPENSION/DROPS;OPHTHALMIC			
ECONOPRED			
EYEVANCE	0.125%	N017468 001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC			
CETAPRED			
ALCON	0.25%;10%	A087771 001	Aug 06, 1993
METIMYD			
SCHERING	0.5%;10%	N010210 002	Sep 09, 1984
PREDSULFAIR			
PHARMAFAIR	0.5%;10%	A088032 001	Apr 15, 1983
VASOCIDIN			
NOVARTIS	0.5%;10%	A088791 001	Oct 05, 1984
SUSPENSION;OPHTHALMIC			
ISOPTO CETAPRED			
ALCON	0.25%;10%	A087547 001	
SUSPENSION/DROPS;OPHTHALMIC			
METIMYD			
SCHERING	0.5%;10%	N010210 001	
PREDAMIDE			
AKORN	0.5%;10%	A088059 001	Jul 29, 1983
PREDSULFAIR			
PHARMAFAIR	0.5%;10%	A088007 001	Apr 19, 1983
PREDSULFAIR II			
PHARMAFAIR	0.2%;10%	A088837 001	Dec 24, 1985
SULPHRIN			
BAUSCH AND LOMB	0.5%;10%	A088089 001	Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE;INJECTION			
HYDELTRASOL			
MERCK	EQ 20MG PHOSPHATE/ML	N011583 002	
PREDNISOLONE SODIUM PHOSPHATE			
WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517 001	
OINTMENT;OPHTHALMIC, OTIC			
HYDELTRASOL			
MERCK	EQ 0.25% PHOSPHATE	N011028 001	
SOLUTION;ORAL			
ORAPRED			
CONCORDIA PHARMS INC	EQ 15MG BASE/5ML **	A075117 001	Dec 14, 2000
PREDNISOLONE SODIUM PHOSPHATE			
AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345 001	Mar 10, 2009
MEDICIS PHARMS	EQ 15MG BASE/5ML	A075250 001	Jul 12, 2002
NESHER PHARMS	EQ 5MG BASE/5ML	A076982 001	May 24, 2005
	EQ 15MG BASE/5ML	A076988 001	May 24, 2005
PHARM ASSOC	EQ 5MG BASE/5ML	A076123 001	Dec 23, 2002
VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416 001	Oct 31, 2007

PREDNISOLONE SODIUM PHOSPHATE				
SOLUTION;ORAL				
PREDNISOLONE SODIUM PHOSPHATE				
	WE PHARMS	EQ 5MG BASE/5ML	A075181 001	Dec 23, 2002
SOLUTION/DROPS;OPHTHALMIC				
INFLAMASE FORTE				
	NOVARTIS	EQ 0.9% PHOSPHATE	A080751 002	
INFLAMASE MILD				
	NOVARTIS	EQ 0.11% PHOSPHATE	A080751 001	
METRETON				
	SCHERING	EQ 0.5% PHOSPHATE	A083834 001	
PREDAIR				
	PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415 001	Feb 29, 1984
PREDAIR FORTE				
	PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165 001	Mar 28, 1983
PREDNISOLONE SODIUM PHOSPHATE				
	AKORN	EQ 0.11% PHOSPHATE	A083358 001	
		EQ 0.9% PHOSPHATE	A083358 002	
	ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043 001	Oct 24, 1991
		EQ 0.9% PHOSPHATE	A081044 001	Oct 24, 1991
	BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065 001	Jul 29, 1994
	SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171 001	
		EQ 0.9% PHOSPHATE	A084168 001	
		EQ 0.9% PHOSPHATE	A084169 001	
		EQ 0.9% PHOSPHATE	A084172 001	
PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE				
	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630 001	May 27, 1993
SULSTER				
	AKORN	EQ 0.23% PHOSPHATE;10%	A074511 001	Jul 30, 1996
VASOCIDIN				
+	NOVARTIS	EQ 0.23% PHOSPHATE;10% **	N018988 001	Aug 26, 1988
PREDNISOLONE TEBUTATE				
INJECTABLE;INJECTION				
HYDELTRA-TBA				
	MERCK	20MG/ML	N010562 001	
PREDNISOLONE TEBUTATE				
	WATSON LABS	20MG/ML	A083362 001	Feb 17, 1984
PREDNISONE				
SOLUTION;ORAL				
PREDNISONE				
	WOCKHARDT	5MG/5ML	A089726 001	Aug 02, 1988
SYRUP;ORAL				
LIQUID PRED				
	MURO	5MG/5ML	A087611 002	Sep 07, 1982
TABLET;ORAL				
CORTAN				
	HALSEY	20MG	A087480 001	
DELTA-DOME				
	BAYER PHARMS	5MG	A080293 001	
DELTASONE				
+	PHARMACIA AND UPJOHN	2.5MG **	N009986 005	
+		5MG **	N009986 002	
+		10MG **	N009986 006	
+		20MG **	N009986 007	
+		50MG **	N009986 008	
FERNISONE				
	FERNDALE LABS	5MG	A083364 001	
METICORTEN				
+	SCHERING	1MG **	N009766 002	
+		5MG **	N009766 001	
ORASONE				
	SOLVAY	1MG	A083009 001	
		5MG	A083009 002	
		10MG	A083009 003	
		20MG	A083009 004	
		50MG	A085999 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PREDNISONE

TABLET;ORAL

PARACORT				
PARKE DAVIS	5MG	N010962	002	
PREDNICEN-M				
SCHWARZ PHARMA	5MG	A084655	001	
PREDNISONE				
AM THERAP	5MG	A089387	001	Nov 06, 1986
	10MG	A089388	001	Nov 06, 1986
	20MG	A089389	001	Nov 06, 1986
AMNEAL PHARMS NY	5MG	A089597	001	Oct 05, 1987
	10MG	A089598	001	Oct 05, 1987
	20MG	A089599	001	Oct 05, 1987
AUROLIFE PHARMA LLC	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
BUNDY	5MG	A083676	001	
CHARTWELL RX	5MG	A083059	001	
CONTRACT PHARMACAL	5MG	A080209	001	
DURAMED PHARMS BARR	5MG	A088394	001	Oct 04, 1983
	10MG	A088395	001	Oct 04, 1983
	20MG	A088396	001	Oct 04, 1983
ELKINS SINN	5MG	A080491	001	
	20MG	A085811	001	
EVERYLIFE	1MG	A084440	001	
	2.5MG	A084440	002	
	5MG	A084440	003	
FERRANTE	2.5MG	A080563	001	
	5MG	A080563	002	
HALSEY	5MG	A080300	001	
HEATHER	5MG	A080320	001	
	10MG	A084341	001	
	20MG	A084417	001	
	20MG	A085543	001	
	50MG	A086946	001	
HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010
	2.5MG	A040538	001	Jan 08, 2004
IMPAX LABS	5MG	A080782	001	
INWOOD LABS	1MG	A080328	001	
	2.5MG	A080306	001	
	5MG	A080279	001	
IVAX SUB TEVA PHARMS	5MG	A080283	001	
	10MG	A084133	001	
	20MG	A084134	001	
KV PHARM	5MG	A084236	001	
LANNETT	5MG	A080514	001	
	20MG	A084275	001	
LEDERLE	5MG	A086968	001	
MARSHALL PHARMA	5MG	A080301	001	
MUTUAL PHARM	5MG	A080701	001	
	10MG	A086595	001	
	20MG	A084634	001	
NYLOS	5MG	A085115	001	
PANRAY	1MG	A080350	001	
	2.5MG	A080350	002	
	5MG	A080350	003	
PHARMAVITE	5MG	A084662	002	
PHOENIX LABS NY	5MG	A080321	001	
	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
ROXANE	20MG	N017109	001	
	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
SCHERER LABS	5MG	A080371	001	

PREDNISONE
TABLET;ORAL
PREDNISONE

SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUN PHARM INDUSTRIES	50MG	A086596	001	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	

SERVISONE

LEDERLE	5MG	A080223	001	

PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CITANEST

+ ASTRAZENECA	1% **	N014763	004	
+	2% **	N014763	005	
+	3% **	N014763	003	

CITANEST PLAIN

+ ASTRAZENECA	4% **	N014763	007	

CITANEST PLAIN DENTAL

+ DENTSPLY PHARM	4%	N021382	001	

PRIMIDONE
SUSPENSION;ORAL
MYSOLINE

NURO PHARMA	250MG/5ML	N010401	001	

TABLET;ORAL
PRIMIDONE

DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008
HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006
IMPAX LABS	50MG	A040717	001	Feb 12, 2008
	250MG	A040717	002	Feb 12, 2008
WATSON LABS	250MG	A085052	001	

PROBENECID
TABLET;ORAL
BENEMID

+ MERCK	500MG **	N007898	004	

PROBENECID

IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984
LEDERLE	500MG	A086917	001	
WATSON LABS	500MG	A086150	002	Apr 23, 1982

PROBUCOL				
TABLET;ORAL				
LORELCO				
SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988
PROCAINAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS INC	250MG	A089219	001	Jul 01, 1986
	375MG	A089219	002	Jul 01, 1986
	500MG	A089219	003	Jul 01, 1986
ASCOT	250MG	A087542	001	Jan 08, 1982
	375MG	A087697	001	Mar 01, 1983
	500MG	A087543	001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604	001	
	375MG	A084595	001	
	500MG	A084606	001	
LANNETT	250MG	A083693	001	
	500MG	A084696	001	
LEDERLE	250MG	A086942	001	
	375MG	A086952	001	
	500MG	A086943	001	
ROXANE	250MG	A088989	001	Apr 26, 1985
	500MG	A088990	001	Apr 26, 1985
VANGARD	250MG	A087643	001	Jun 01, 1982
	500MG	A087875	001	Jun 01, 1982
WATSON LABS	250MG	A083287	001	
	250MG	A083795	001	
	250MG	A085167	001	
	375MG	A084403	001	
	375MG	A087020	001	
	500MG	A084280	001	
	500MG	A084357	001	
	500MG	A087021	001	
PROCAN				
PARKE DAVIS	250MG	A085804	001	
	375MG	A087502	001	
	500MG	A085079	001	
PROCAPAN				
PANRAY	250MG	A083553	002	
PRONESTYL				
+ APOTHECON	250MG **	N007335	001	
+	375MG **	N007335	004	
+	500MG **	N007335	003	
INJECTABLE;INJECTION				
PROCAINAMIDE HYDROCHLORIDE				
ABRAXIS PHARM	100MG/ML	A089415	001	Nov 17, 1986
	500MG/ML	A089416	001	Nov 17, 1986
HOSPIRA	500MG/ML	A089537	001	Aug 25, 1987
INTL MEDICATION	500MG/ML	A088637	001	Jul 31, 1984
PHARMAFAIR	100MG/ML	A088824	001	Nov 20, 1985
	500MG/ML	A088830	001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530	001	Mar 04, 1985
	500MG/ML	A088531	001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528	001	May 03, 1988
	500MG/ML	A089529	001	May 03, 1988
WATSON LABS	100MG/ML	A087079	001	
	500MG/ML	A087080	001	
WEST-WARD PHARMS INT	100MG/ML	A089029	001	Apr 17, 1986
	500MG/ML	A089030	001	Apr 17, 1986
PRONESTYL				
+ APOTHECON	100MG/ML **	N007335	002	
+	500MG/ML **	N007335	005	
TABLET;ORAL				
PRONESTYL				
APOTHECON	250MG	N017371	001	
	375MG	N017371	002	
	500MG	N017371	003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS INC	250MG	A088958	001	Dec 02, 1985
	250MG	A089369	001	Aug 14, 1987
	500MG	A088959	001	Dec 02, 1985
	500MG	A088974	001	Jul 22, 1985
	500MG	A089369	002	Jan 09, 1987
	750MG	A089369	003	Aug 14, 1987
	750MG	A089438	001	Mar 23, 1987
	1GM	A040111	001	Dec 13, 1996
INWOOD LABS	500MG	A089840	001	Mar 06, 1989
SANDOZ	500MG	A089284	001	Jun 23, 1986
WATSON LABS	250MG	A088533	001	Dec 03, 1984
	250MG	A089026	001	Oct 22, 1985
	500MG	A088534	001	Dec 03, 1984
	500MG	A089027	001	Oct 22, 1985
	750MG	A088535	001	Nov 03, 1984
	750MG	A089042	001	Oct 22, 1985
	1GM	A089520	001	Jan 15, 1987
PROCAN SR				
PARKE DAVIS	250MG	A086468	001	
PARKEDALE	500MG	A086065	001	
	750MG	A087510	001	Apr 01, 1982
	1GM	A088489	001	Jan 16, 1985
PROCANBID				
KING PHARMS	500MG	N020545	001	Jan 31, 1996
	1GM	N020545	002	Jan 31, 1996
PRONESTYL-SR				
APOTHECON	500MG	A087361	001	

PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

NOVOCAIN				
HOSPIRA	1%	A085362	003	
	2%	A085362	004	
	10%	A086797	001	
PROCAINE HYDROCHLORIDE				
ABRAXIS PHARM	1%	A080384	002	
	1%	A080421	001	
	2%	A080384	003	
	2%	A080421	002	
BEL MAR	1%	A080711	001	
	2%	A080756	001	
ELKINS SINN	1%	A083315	001	
	2%	A083315	002	
GD SEARLE LLC	1%	A086202	001	
	2%	A086202	002	
HOSPIRA	1%	A080416	001	
	2%	A080416	002	
MILES	1%	A080415	001	
	2%	A080415	002	
WATSON LABS	1%	A080658	001	
	1%	A083535	001	
	2%	A080658	002	
	2%	A083535	002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION

ACHROMYCIN				
LEDERLE	40MG/VIAL;100MG/VIAL	N050276	001	
	40MG/VIAL;250MG/VIAL	N050276	003	
TETRACYN				
PFIZER	40MG/VIAL;100MG/VIAL	A060285	002	
	40MG/VIAL;250MG/VIAL	A060285	003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE;INJECTION				
DICURIN PROCAINE				
LILLY	100MG/ML;50MG/ML	N008869	001	

PROCHLORPERAZINE

SUPPOSITORY;RECTAL				
COMPAZINE				
GLAXOSMITHKLINE	2.5MG **	N011127	003	
	5MG **	N011127	001	
	25MG **	N011127	002	
PROCHLORPERAZINE				
ABLE	2.5MG	A040407	001	Jul 11, 2001
	5MG	A040407	002	Jul 11, 2001
	25MG	A040407	003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001	
PROCHLORPERAZINE				
ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153	001	Jun 08, 1982
PROCHLORPERAZINE EDISYLATE				
MORTON GROVE	EQ 10MG BASE/ML	A088598	001	Oct 25, 1984
INJECTABLE;INJECTION				
COMPAZINE				
+ GLAXOSMITHKLINE	EQ 5MG BASE/ML **	N010742	002	
PROCHLORPERAZINE				
BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759	001	Oct 01, 1982
PROCHLORPERAZINE EDISYLATE				
HOSPIRA	EQ 5MG BASE/ML	A089703	001	Apr 07, 1988
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675	001	Dec 05, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251	001	Dec 04, 1986
TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003
WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089605	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089606	001	Jul 08, 1987
WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988
WYETH AYERST	EQ 5MG BASE/ML	A086348	001	
SYRUP;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001	
PROCHLORPERAZINE EDISYLATE				
ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982
MORTON GROVE	EQ 5MG BASE/5ML	A088597	001	Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 10MG BASE	N011000	001	
	EQ 10MG BASE	N021019	001	Oct 06, 1999
	EQ 15MG BASE	N011000	002	
	EQ 15MG BASE	N021019	002	Oct 06, 1999
	EQ 30MG BASE	N011000	003	
	EQ 75MG BASE	N011000	004	
TABLET;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 5MG BASE **	N010571	001	
	EQ 10MG BASE **	N010571	002	
	EQ 25MG BASE **	N010571	003	
PROCHLORPERAZINE				
WATSON LABS	EQ 5MG BASE	A085580	001	
	EQ 10MG BASE	A085178	001	
	EQ 25MG BASE	A085579	001	
PROCHLORPERAZINE MALEATE				
DURAMED PHARMS BARR	EQ 5MG BASE	A040207	001	May 01, 1997
	EQ 5MG BASE	A089484	001	Jan 20, 1987
	EQ 10MG BASE	A040207	002	May 01, 1997
	EQ 10MG BASE	A089485	001	Jan 20, 1987
	EQ 25MG BASE	A089486	001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162	001	Jan 20, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PROCHLORPERAZINE MALEATE				
TABLET;ORAL				
PROCHLORPERAZINE MALEATE				
	EQ 10MG BASE	A040162	002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101	003	Jul 19, 1996
TEVA PHARMS	EQ 5MG BASE	A040120	001	Jul 11, 1996
	EQ 10MG BASE	A040120	002	Jul 11, 1996
PROCYCLIDINE HYDROCHLORIDE				
TABLET;ORAL				
KEMADRIN				
MONARCH PHARMS	2MG	N009818	005	
	5MG	N009818	003	
PROGESTERONE				
CAPSULE;ORAL				
PROGESTERONE				
TEVA PHARMS	100MG	A202121	001	Feb 29, 2012
	200MG	A202121	002	Feb 29, 2012
PROMETRIUM				
VIRTUS PHARMS	300MG	N019781	003	Oct 15, 1999
INJECTABLE;INJECTION				
PROGESTERONE				
LILLY	25MG/ML	N009238	002	
	50MG/ML	N009238	001	
LUITPOLD	50MG/ML	A090845	001	Jun 22, 2009
INSERT, EXTENDED RELEASE;INTRAUTERINE				
PROGESTASERT				
ALZA	38MG	N017553	001	
PROMAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
SPARINE				
WYETH AYERST	30MG/ML	N010942	001	
	100MG/ML	N010942	004	
INJECTABLE;INJECTION				
PROMAZINE HYDROCHLORIDE				
WATSON LABS	25MG/ML	A084510	001	
	50MG/ML	A084517	001	
SPARINE				
BAXTER HLTHCARE CORP	25MG/ML	N010349	008	
	50MG/ML	N010349	006	
SYRUP;ORAL				
SPARINE				
WYETH AYERST	10MG/5ML	N010942	003	
TABLET;ORAL				
SPARINE				
WYETH AYERST	10MG	N010348	006	
	25MG	N010348	001	
	50MG	N010348	002	
	100MG	N010348	003	
	200MG	N010348	004	
PROMETHAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
PHENERGAN				
WYETH AYERST	25MG/ML	N008857	002	
	50MG/ML	N008857	003	
PROMETHAZINE HYDROCHLORIDE				
ABBOTT	25MG/ML	A084223	001	
	50MG/ML	A084222	001	
AKORN	25MG/ML	A083955	002	
	50MG/ML	A083955	001	
AM REGENT	25MG/ML	A040515	001	Mar 19, 2003
BEDFORD LABS	25MG/ML	A040524	001	Mar 17, 2004
	50MG/ML	A040524	002	Mar 17, 2004
HOSPIRA	25MG/ML	A040372	001	Jun 08, 2000
	50MG/ML	A040372	002	Jun 08, 2000
	50MG/ML	A083838	002	
MARSAM PHARMS LLC	25MG/ML	A089463	001	May 02, 1988
	50MG/ML	A089477	001	May 02, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROMETHAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
PROMETHAZINE HYDROCHLORIDE				
MYLAN INSTITUTIONAL	25MG/ML	A040471	001	Nov 21, 2002
SANDOZ	25MG/ML	A040593	001	Nov 08, 2006
	50MG/ML	A040593	002	Nov 08, 2006
TEVA PHARMS USA	25MG/ML **	A040454	001	Aug 22, 2002
	50MG/ML **	A040454	002	Aug 22, 2002
WATSON LABS	25MG/ML	A083532	001	
	25MG/ML	A084591	001	
	50MG/ML	A080629	002	
	50MG/ML	A083532	002	
WOCKHARDT	25MG/ML	A040785	001	Sep 26, 2008
	50MG/ML	A040785	002	Sep 26, 2008
ZIPAN-25				
ALTANA	25MG/ML	A083997	001	
ZIPAN-50				
ALTANA	50MG/ML	A083997	002	
SUPPOSITORY;RECTAL				
PHENERGAN				
+ MYLAN	12.5MG **	N010926	002	
+	25MG **	N010926	001	
+	50MG **	N011689	001	
PROMETHACON				
POLYMEDICA	25MG	A084901	001	
	50MG	A084902	001	
PROMETHAZINE HYDROCHLORIDE				
ABLE	12.5MG	A040504	001	Apr 11, 2003
	25MG	A040504	002	Apr 11, 2003
	50MG	A040449	001	Feb 27, 2003
SYRUP;ORAL				
MYMETHAZINE FORTIS				
USL PHARMA	25MG/5ML	A087996	001	Jan 18, 1983
PROMETH FORTIS				
ALPHARMA US PHARMS	25MG/5ML	A084772	001	
PROMETH PLAIN				
ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001	
PROMETHAZINE				
CENCI	6.25MG/5ML	A089013	001	Sep 20, 1985
PROMETHAZINE HYDROCHLORIDE				
KV PHARM	6.25MG/5ML	A085388	001	
	25MG/5ML	A085385	001	
PHARM ASSOC	6.25MG/5ML	A087518	001	
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395	001	
PROMETHAZINE HYDROCHLORIDE PLAIN				
+ ANI PHARMS	6.25MG/5ML **	N008381	004	Apr 18, 1984
+	25MG/5ML **	N008381	003	
TABLET;ORAL				
PHENERGAN				
+ DELCOR ASSET CORP	12.5MG **	N007935	002	
+	25MG **	N007935	003	
+	50MG **	N007935	004	
PROMETHAZINE HYDROCHLORIDE				
ABBOTT	12.5MG	A084160	001	
	25MG	A084166	001	
	50MG	A084539	001	
ABLE	12.5MG	A040558	001	Jul 01, 2004
	25MG	A040558	002	Jul 01, 2004
	50MG	A040558	003	Jul 01, 2004
IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008
	25MG	A040791	003	Feb 12, 2008
	25MG	A084214	002	Jul 07, 1982
	50MG	A040791	001	May 20, 2008
INVATECH	12.5MG	A084233	001	
	25MG	A085146	001	
	50MG	A085146	002	
IVAX SUB TEVA PHARMS	12.5MG	A083604	001	
	25MG	A083603	001	
	50MG	A083613	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL				
PROMETHAZINE HYDROCHLORIDE				
	LANNETT	12.5MG	A080949 001	
		25MG	A080949 002	
		50MG	A080949 003	
	MYLAN	12.5MG	A091054 001	Aug 30, 2011
		25MG	A091054 002	Aug 30, 2011
		50MG	A091054 003	Aug 30, 2011
	PVT FORM	12.5MG	A083214 001	
		25MG	A083658 001	
	SANDOZ	12.5MG	A084176 002	May 22, 2009
	SUN PHARM INDUSTRIES	12.5MG	A084555 001	
		25MG	A084554 001	
		50MG	A084557 001	
	TABLICAPS	12.5MG	A084080 001	
		25MG	A084027 001	
	TEVA	25MG	A089109 001	Sep 10, 1985
	WATSON LABS	12.5MG	A083401 001	
		12.5MG	A083712 001	
		12.5MG	A085986 001	
		25MG	A083204 001	
		25MG	A085684 001	
		50MG	A083403 001	
		50MG	A085664 001	
REMSED				
	BRISTOL MYERS SQUIBB	25MG	A083176 002	
		50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE

TABLET;ORAL				
PROPAFENONE HYDROCHLORIDE				
	NESHER PHARMS	150MG	A076193 001	Feb 07, 2002
		225MG	A076193 002	Feb 07, 2002
		300MG	A076193 003	Feb 07, 2002
RYTHMOL				
+	GLAXOSMITHKLINE LLC	150MG	N019151 001	Nov 27, 1989
+		225MG	N019151 003	Nov 20, 1992
+		300MG	N019151 002	Nov 27, 1989

PROPANTHELINE BROMIDE

INJECTABLE;INJECTION				
PRO-BANTHINE				
	GD SEARLE LLC	30MG/VIAL	N008843 001	
TABLET;ORAL				
PRO-BANTHINE				
+	SHIRE	7.5MG **	N008732 003	
+		15MG **	N008732 002	
PROPANTHELINE BROMIDE				
	ASCOT	15MG	A087663 001	Oct 25, 1982
	HEATHER	15MG	A085780 001	
	HIKMA	7.5MG	A080927 001	
	IMPAX LABS	15MG	A084541 002	
	MYLAN	15MG	A083706 001	
	PAR PHARM	15MG	A088377 001	Dec 08, 1983
	PVT FORM	15MG	A080977 001	
	SANDOZ	15MG	A080928 001	
	TABLICAPS	15MG	A084428 001	
	WATSON LABS	15MG	A083029 002	
		15MG	A083151 001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
KAINAIR				
	PHARMAFAIR	0.5%	A088087 001	Jun 07, 1983
OPHTHAINE				
+	APOTHECON	0.5% **	N008883 001	
OPHTHETIC				
+	ALLERGAN	0.5% **	N012583 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPARACAINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
PARACAINE				
OPTOPICS	0.5%	A087681	001	Aug 05, 1982
PROPARACAINE HYDROCHLORIDE				
SOLA BARNES HIND	0.5%	A084144	001	
	0.5%	A084151	001	
PROPIOLACTONE				
SOLUTION;IRRIGATION				
BETAPRONE				
FOREST LABS	N/A	N011657	001	
PROPIOMAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
LARGON				
WEST-WARD PHARMS INT	20MG/ML	N012382	002	
PROPOFOL				
INJECTABLE;INJECTION				
DIPRIVAN				
FRESENIUS KABI USA	10MG/ML	N019627	001	Oct 02, 1989
PROPOFOL				
TEVA PARENTERAL	10MG/ML	A075392	001	Sep 19, 2000
WEST-WARD PHARMS INT	10MG/ML	A074848	001	Apr 19, 2005
PROPOXYPHENE HYDROCHLORIDE				
CAPSULE;ORAL				
DARVON				
XANODYNE PHARM	32MG	N010997	001	
	65MG	N010997	003	
DOLENE				
HERITAGE PHARMS INC	65MG	A080530	001	
KESSO-GESIC				
MK LABS	65MG	A083544	001	
PROPHENE 65				
HALSEY	65MG	A083538	002	
PROPOXYPHENE HYDROCHLORIDE				
ALRA	65MG	A083184	001	
IMPAX LABS	65MG	A083317	001	
IVAX SUB TEVA PHARMS	32MG	A083597	001	
MUTUAL PHARM	65MG	A083186	001	
MYLAN	32MG	A083528	001	
	65MG	A040569	001	Dec 16, 2004
	65MG	A083299	001	
NEXGEN PHARMA INC	65MG	A083185	001	
PAR PHARM	65MG	A080269	001	
PUREPAC PHARM	65MG	A083278	001	
PVT FORM	32MG	A083464	001	
	65MG	A083113	001	
ROXANE	32MG	A083089	001	
	65MG	A083089	002	
SANDOZ	32MG	A084014	001	
	65MG	A083125	002	
	65MG	A083688	001	
	65MG	A083870	002	
	65MG	A086495	001	
TEVA	65MG	A088615	001	Oct 22, 1984
VALEANT PHARM INTL	65MG	A080783	001	
VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009
WATSON LABS	65MG	A080908	002	
	65MG	A085190	001	
WEST WARD	65MG	A083501	001	
WHITEWORTH TOWN PLSN	65MG	A084551	001	
PROPOXYPHENE HYDROCHLORIDE 65				
WARNER CHILCOTT	65MG	A083786	001	

PROPOXYPHENE NAPSYLATE

SUSPENSION;ORAL

DARVON-N

AAIPHARMA LLC	50MG/5ML	N016861	001	

TABLET;ORAL

DARVON-N

XANODYNE PHARM	100MG	N016862	002	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS	60MG	A072499	001	Apr 11, 1989
	80MG	A072500	001	Apr 11, 1989
	120MG	A072501	001	Apr 11, 1989
	160MG	A072502	001	Apr 11, 1989
MYLAN	60MG	A078022	001	Feb 15, 2007
	80MG	A078022	002	Feb 15, 2007
	120MG	A078022	003	Feb 15, 2007
	160MG	A078022	004	Feb 15, 2007
UPSHER SMITH LABS	60MG	A078311	001	Mar 06, 2009
	80MG	A078311	002	Mar 06, 2009
	120MG	A078311	003	Mar 06, 2009
	160MG	A078311	004	Mar 06, 2009

CONCENTRATE;ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE	80MG/ML	A071388	001	May 15, 1987

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

+ BAXTER HLTHCARE CORP	1MG/ML	N016419	001	
FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003
SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
	1MG/ML	A070137	001	Apr 15, 1986
SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986

SOLUTION;ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE	20MG/5ML	A071984	001	Mar 03, 1989
	40MG/5ML	A071985	001	Mar 03, 1989

SUSPENSION;ORAL

INDERAL

WYETH AYERST	10MG/ML	N019536	001	Dec 12, 1986

TABLET;ORAL

INDERAL

+ WYETH PHARMS	10MG **	N016418	001	
+	20MG **	N016418	003	
+	40MG **	N016418	002	
+	60MG **	N016418	009	Oct 18, 1982
+	80MG **	N016418	004	
+	90MG **	N016418	010	Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

ANI PHARMS INC	60MG	A071791	001	Jul 15, 1987
	90MG	A071977	001	Apr 06, 1988
DAVA PHARMS INC	10MG	A070125	001	Jul 30, 1985
	20MG	A070126	001	Jul 30, 1985
	40MG	A070127	001	Jul 30, 1985
	60MG	A071495	001	Dec 31, 1987
	80MG	A070128	001	Jul 30, 1985
	90MG	A071496	001	Dec 31, 1987
DURAMED PHARMS BARR	10MG	A070306	001	Sep 09, 1985
	20MG	A070307	001	Sep 09, 1985
	40MG	A070308	001	Sep 09, 1985
	60MG	A070309	001	Oct 01, 1986
	80MG	A070310	001	Sep 09, 1985
	90MG	A071327	001	Oct 01, 1986
INTERPHARM	10MG	A071368	001	May 05, 1987
	20MG	A071369	001	May 05, 1987
	40MG	A071370	001	May 05, 1987
	80MG	A071371	001	May 05, 1987
IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	60MG		A072068	001	Jul 29, 1988
	80MG		A072069	001	Jul 29, 1988
LEDERLE	10MG		A072117	001	Jun 23, 1988
	20MG		A072118	001	Jun 23, 1988
	40MG		A072119	001	Jun 23, 1988
	80MG		A072120	001	Jun 23, 1988
MYLAN	60MG		A072275	001	Jun 09, 1989
PAR PHARM	90MG		A071288	001	Oct 22, 1986
PUREPAC PHARM	10MG		A070814	001	Nov 03, 1986
	20MG		A070815	001	Nov 03, 1986
	40MG		A070816	001	Nov 03, 1986
	60MG		A070817	001	Nov 03, 1986
	80MG		A070757	001	Nov 03, 1986
ROXANE	10MG		A070516	001	Jul 07, 1986
	20MG		A070517	001	Jul 07, 1986
	40MG		A070518	001	Jul 07, 1986
	60MG		A070519	001	Sep 24, 1986
	80MG		A070520	001	Jul 07, 1986
	90MG		A070521	001	Sep 24, 1986
SANDOZ	10MG		A071658	001	Jul 05, 1988
	20MG		A071687	001	Jul 05, 1988
	40MG		A071688	001	Jul 05, 1988
	60MG		A072197	001	Jul 05, 1988
	80MG		A071689	001	Jul 05, 1988
	90MG		A072198	001	Jul 05, 1988
SCHERING	10MG		A070120	001	Aug 06, 1985
	20MG		A070121	001	Aug 06, 1985
	40MG		A070122	001	Aug 06, 1985
	60MG		A070123	001	Oct 29, 1986
	80MG		A070124	001	Aug 06, 1985
SUPERPHARM	10MG		A071515	001	Jun 08, 1988
	20MG		A071516	001	Jun 08, 1988
	40MG		A071517	001	Jun 08, 1988
	80MG		A071518	001	Jun 08, 1988
TEVA	10MG		A070232	001	Oct 07, 1987
	20MG		A070233	001	Jun 23, 1986
	40MG		A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG		A070438	001	Sep 15, 1986
	20MG		A070439	001	Sep 15, 1986
	40MG		A070440	001	Sep 15, 1986
	60MG		A070441	001	Sep 24, 1986
	80MG		A070442	001	Sep 15, 1986
WATSON LABS	10MG		A070140	001	Jul 30, 1985
	10MG		A070378	001	Mar 19, 1987
	20MG		A070141	001	Jul 30, 1985
	20MG		A070379	001	Mar 19, 1987
	40MG		A070142	001	Jul 30, 1985
	40MG		A070380	001	Mar 19, 1987
	60MG		A070143	001	Jan 15, 1987
	60MG		A070381	001	Mar 19, 1987
	60MG		A071098	001	Oct 06, 1986
	80MG		A070144	001	Jul 30, 1985
	80MG		A070382	001	Mar 19, 1987
	80MG		A070551	001	Jul 10, 1986
	90MG		A071183	001	Oct 06, 1986
	90MG		A071792	001	Jul 15, 1987
WATSON LABS TEVA	10MG		A070548	001	Jul 10, 1986
	20MG		A070549	001	Apr 11, 1986
	40MG		A070550	001	Apr 11, 1986
YAOPHARMA CO LTD	10MG		A070663	001	Jun 13, 1986
	20MG		A070664	001	Jun 13, 1986
	40MG		A070665	001	Jun 13, 1986
	60MG		A070666	001	Oct 10, 1986
	80MG		A070667	001	Jun 13, 1986

PROPYLIODONE

SUSPENSION;INTRATRACHEAL				
DIONOSIL AQUEOUS				
	GLAXOSMITHKLINE	50%	N009309 001	
DIONOSIL OILY				
	GLAXOSMITHKLINE	60%	N009309 002	

PROPYLTHIOURACIL

TABLET;ORAL				
PROPYLTHIOURACIL				
	ABBOTT	50MG	A084075 001	
	ANABOLIC	50MG	A080285 001	
	ANI PHARMS INC	50MG	A080215 001	
	CHARTWELL RX	50MG	A084543 001	
	HALSEY	50MG	A080015 001	
	IMPAX LABS	50MG	A080159 001	
	LANNETT	50MG	A080016 001	
	LILLY	50MG	N006213 001	
	QUAGEN	50MG	A080154 001	
	SUN PHARM INDUSTRIES	50MG	A083982 001	
	TABLICAPS	50MG	A080840 001	
	WATSON LABS	50MG	A080932 001	
		50MG	A085201 001	

PROTAMINE SULFATE

INJECTABLE;INJECTION				
PROTAMINE SULFATE				
+	LILLY	10MG/ML **	N006460 002	
	PHARMACIA AND UPJOHN	50MG/VIAL	N007413 001	
		250MG/VIAL	N007413 002	Aug 02, 1984
	WEST-WARD PHARMS INT	10MG/ML	A089474 001	Nov 05, 1986
		10MG/ML	A089475 001	Nov 05, 1986

PROTEIN HYDROLYSATE

INJECTABLE;INJECTION				
AMINOSOL 5%				
	ABBVIE	5%	N005932 012	Jan 31, 1985
HYPROTIGEN 5%				
	B BRAUN	5%	N006170 003	Jan 10, 1984

PROTIRELIN

INJECTABLE;INJECTION				
THYPINONE				
	ABBOTT	0.5MG/ML	N017638 001	
THYREL TRH				
	FERRING	0.5MG/ML	N018087 001	

PROTOKYLOL HYDROCHLORIDE

TABLET;ORAL				
VENTAIRE				
	SANOFI AVENTIS US	2MG	A083459 001	

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL				
VIVACTIL				
	TEVA WOMENS	5MG **	N016012 001	
		10MG **	N016012 002	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
NOVAFED				
	SANOFI AVENTIS US	120MG	N017603 001	
SUDAFED 12 HOUR				
+	GLAXOSMITHKLINE	120MG **	N017941 002	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
ACTIFED				
	GLAXOSMITHKLINE	120MG;5MG	N018996 001	Jun 17, 1985
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
	KV PHARM	120MG;5MG	A071798 001	Mar 16, 1989

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL				
ACTAHIST				
	CENCI	30MG/5ML;1.25MG/5ML	A088344 001	Feb 09, 1984
HISTAFED				
	CENCI	30MG/5ML;1.25MG/5ML	A088283 001	Apr 20, 1984
MYFED				
	USL PHARMA	30MG/5ML;1.25MG/5ML	A088116 001	Mar 04, 1983
TRILITRON				
	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	A088474 001	Feb 12, 1985
TABLET;ORAL				
ALLERFED				
	PVT FORM	60MG;2.5MG	A088860 001	Jan 31, 1985
CORPHED				
	FOSUN PHARMA	60MG;2.5MG	A088602 001	Apr 11, 1985
PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE				
	SANDOZ	60MG;2.5MG	A088193 001	May 17, 1983
TRILITRON				
	NEWTRON PHARMS	60MG;2.5MG	A088515 001	Jan 09, 1985
TRIPHED				
	TEVA	60MG;2.5MG	A088630 001	May 17, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE				
	WATSON LABS	60MG;2.5MG	A088318 002	Jan 13, 1984
	WEST WARD	60MG;2.5MG	A088117 001	Apr 19, 1983
TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
	IVAX SUB TEVA PHARMS	60MG;2.5MG	A085273 001	Dec 12, 1984
	SUPERPHARM	60MG;2.5MG	A088578 001	Feb 21, 1985
TABLET, EXTENDED RELEASE;ORAL				
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
	KV PHARM	120MG;5MG	A072758 001	Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL				
PSEUDO-12				
	UCB INC	EQ 60MG HYDROCHLORIDE/5ML	N019401 001	Jun 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
AFRINOL				
+	SCHERING PLOUGH	120MG	N018191 001	

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL				
PYRIDOSTIGMINE BROMIDE				
	ANI PHARMS INC	30MG	A040512 002	Jul 20, 2005
		60MG	A040512 001	Oct 08, 2003
	IMPAX LABS INC	60MG	A040457 001	Dec 26, 2002
	SOLVAY	30MG	A089572 001	Nov 27, 1990
	US ARMY	30MG	N020414 001	Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION				
HEXA-BETALIN				
	LILLY	100MG/ML	A080854 001	
PYRIDOXINE HYDROCHLORIDE				
	AKORN	100MG/ML	A087967 001	Oct 01, 1982
	BEL MAR	100MG/ML	A080761 001	
	DELL LABS	50MG/ML	A083771 001	
		100MG/ML	A083772 001	
	DR REDDYS	100MG/ML	A080572 001	
	ELKINS SINN	100MG/ML	A080581 001	
	LUITPOLD	100MG/ML	A080669 001	
	MYLAN INSTITUTIONAL	100MG/ML	A204879 001	Jul 14, 2016
	WATSON LABS	100MG/ML	A083760 001	

PYRILAMINE MALEATE

TABLET;ORAL				
PYRILAMINE MALEATE				
	IMPAX LABS	25MG	A080808 001	
	WATSON LABS	25MG	A085231 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PYRIMETHAMINE; SULFADOXINE				
TABLET;ORAL				
FANSIDAR				
ROCHE	25MG;500MG	N018557	001	
PYRITHIONE ZINC				
LOTION;TOPICAL				
HEAD & SHOULDERS CONDITIONER				
WARNER CHILCOTT	0.3%	N019412	002	Mar 10, 1986
PYRVINIUM PAMOATE				
SUSPENSION;ORAL				
POVAN				
PARKE DAVIS	EQ 50MG BASE/5ML	N011964	001	
TABLET;ORAL				
POVAN				
PARKE DAVIS	EQ 50MG BASE	N012485	002	
QUAZEPAM				
TABLET;ORAL				
DORAL				
GALT PHARMS	7.5MG	N018708	003	Feb 26, 1987
QUETIAPINE FUMARATE				
TABLET;ORAL				
QUETIAPINE FUMARATE				
ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013
	EQ 50MG BASE	A201762	002	Feb 27, 2013
	EQ 100MG BASE	A201762	003	Feb 27, 2013
	EQ 150MG BASE	A201762	004	Feb 27, 2013
	EQ 200MG BASE	A201762	005	Feb 27, 2013
	EQ 300MG BASE	A201762	006	Feb 27, 2013
	EQ 400MG BASE	A201762	007	Feb 27, 2013
MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012
SEROQUEL				
+ ASTRAZENECA PHARMS	EQ 150MG BASE **	N020639	004	Dec 20, 1998
TABLET, EXTENDED RELEASE;ORAL				
QUETIAPINE FUMARATE				
AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018
QUINAPRIL HYDROCHLORIDE				
TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE				
ACTAVIS ELIZABETH	EQ 5MG BASE	A076459	001	Dec 22, 2004
	EQ 10MG BASE	A076459	002	Dec 22, 2004
	EQ 20MG BASE	A076459	003	Dec 22, 2004
	EQ 40MG BASE	A076459	004	Dec 22, 2004
ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005
	EQ 10MG BASE	A076049	002	Jan 14, 2005
	EQ 20MG BASE	A076049	003	Jan 14, 2005
	EQ 40MG BASE	A076049	004	Jan 14, 2005
ANI PHARMS INC	EQ 5MG BASE	A075504	001	Aug 24, 2007
	EQ 10MG BASE	A075504	002	Aug 24, 2007
	EQ 20MG BASE	A075504	003	Aug 24, 2007
	EQ 40MG BASE	A075504	004	Aug 24, 2007
APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006
	EQ 10MG BASE	A076240	002	Jan 26, 2006
	EQ 20MG BASE	A076240	003	Jan 26, 2006
	EQ 40MG BASE	A076240	004	Jan 26, 2006
MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005
	EQ 10MG BASE	A076036	002	Jan 28, 2005
	EQ 20MG BASE	A076036	003	Jan 28, 2005
	EQ 40MG BASE	A076036	004	Jan 28, 2005
SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004
	EQ 5MG BASE	A090800	001	Jun 18, 2009
	EQ 10MG BASE	A076607	002	Dec 15, 2004
	EQ 10MG BASE	A090800	002	Jun 18, 2009
	EQ 20MG BASE	A076607	003	Dec 15, 2004
	EQ 20MG BASE	A090800	003	Jun 18, 2009
	EQ 40MG BASE	A076607	004	Dec 15, 2004
	EQ 40MG BASE	A090800	004	Jun 18, 2009
YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001	Mar 02, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

QUINAPRIL HYDROCHLORIDE				
TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE				
	EQ 10MG BASE		A076803 002	Mar 02, 2005
	EQ 20MG BASE		A076803 003	Mar 02, 2005
	EQ 40MG BASE		A076803 004	Mar 02, 2005
QUINESTROL				
TABLET;ORAL				
ESTROVIS				
PARKE DAVIS	0.1MG		N016768 002	
	0.2MG		N016768 003	
QUINETHAZONE				
TABLET;ORAL				
HYDROMOX				
LEDERLE	50MG		N013264 001	
QUINETHAZONE; RESERPINE				
TABLET;ORAL				
HYDROMOX R				
LEDERLE	50MG;0.125MG		N013927 001	
QUINIDINE GLUCONATE				
INJECTABLE;INJECTION				
QUINIDINE GLUCONATE				
+ LILLY	80MG/ML		N007529 002	Feb 10, 1989
TABLET;ORAL				
QUINACT				
BAYER HLTHCARE	266MG		A085978 001	
	400MG		A086099 001	
TABLET, EXTENDED RELEASE;ORAL				
DURAQUIN				
WARNER CHILCOTT	330MG		N017917 001	
QUINAGLUTE				
+ BAYER HLTHCARE	324MG		N016647 001	
QUINALAN				
LANNETT	324MG		A088081 001	Feb 10, 1986
QUINATIME				
WATSON LABS	324MG		A087448 001	
QUINIDINE GLUCONATE				
ANI PHARMS INC	324MG		A087810 001	Sep 29, 1982
ASCOT	324MG		A088582 001	Jun 17, 1985
AUROLIFE PHARMA LLC	324MG		A089894 001	Dec 15, 1988
CYCLE PHARMS LTD	324MG		A088431 001	Jan 06, 1984
HALSEY	324MG		A089476 001	Apr 10, 1987
SUPERPHARM	324MG		A089164 001	Nov 21, 1985
WATSON LABS	324MG		A087785 001	Jan 24, 1983
QUINIDINE POLYGALACTURONATE				
TABLET;ORAL				
CARDIOQUIN				
PHARM RES ASSOC	275MG		N011642 002	
QUINIDINE SULFATE				
CAPSULE;ORAL				
CIN-QUIN				
SOLVAY	200MG		A085296 001	
	300MG		A085297 001	
QUINIDINE SULFATE				
LILLY	200MG		A085103 001	
TABLET;ORAL				
CIN-QUIN				
SOLVAY	100MG		A085299 001	
	200MG		A084932 001	
	300MG		A085298 001	
QUINIDINE SULFATE				
BARR	200MG		A084177 001	
CONTRACT PHARMACAL	200MG		A083808 001	
CYCLE PHARMS LTD	200MG		A083640 001	
	300MG		A085632 001	
DAVA PHARMS INC	200MG		A087011 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

ELKINS SINN	200MG	A083622 001	
EVERYLIFE	200MG	A083439 001	
HALSEY	200MG	A083583 001	
HIKMA PHARMS	200MG	A083862 001	
IMPAX LABS	200MG	A083347 001	
IVAX SUB TEVA PHARMS	200MG	A084549 001	
KING PHARMS	200MG	A085175 001	
KV PHARM	200MG	A085276 001	
LANNETT	200MG	A083743 001	
LEDERLE	200MG	A086176 001	
LILLY	200MG	A085038 001	
PERRIGO	200MG	A085322 001	
PHARMAVITE	200MG	A084627 001	
PUREPAC PHARM	200MG	A084003 001	
SANDOZ	200MG	A084631 001	
	200MG	A084914 001	
	300MG	A089839 001	Sep 29, 1988
SCHERER LABS	200MG	A085068 001	
SUN PHARM INDUSTRIES	100MG	A081029 001	Apr 14, 1989
	200MG	A081030 001	Apr 14, 1989
	300MG	A081031 001	Apr 14, 1989
SUPERPHARM	200MG	A088973 001	Apr 10, 1985
USL PHARMA	200MG	A087837 001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393 001	
VANGARD	200MG	A087909 001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963 001	
WARNER CHILCOTT	200MG	A083879 001	
WATSON LABS	100MG	A085584 001	
	200MG	A085140 002	
WHITEWORTH TOWN PLSN	200MG	A085444 001	

QUINORA

KEY PHARMS	200MG	A083576 001	
SCHERING	300MG	A085222 001	

TABLET, EXTENDED RELEASE;ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796 002	

QUINIDINE SULFATE

ACP NIMBLE	300MG	A040045 001	Jun 30, 1994

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

MYLAN PHARMS INC	324MG	A202581 001	Dec 14, 2012

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

+	EISAI INC	10MG **	N020973 001	May 29, 2002

RABEPRAZOLE SODIUM

MYLAN	20MG	A076885 001	Nov 08, 2013

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513 001	Jun 18, 2008
	2.5MG	A077513 002	Jun 18, 2008
	5MG	A077513 003	Jun 18, 2008
	10MG	A077513 004	Jun 18, 2008
CIPLA	1.25MG	A077004 001	Aug 07, 2008
	2.5MG	A077004 002	Aug 07, 2008
	5MG	A077004 003	Aug 07, 2008
	10MG	A077004 004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009
	10MG	A078849 002	Mar 06, 2009
WATSON LABS	5MG	A076549 003	Oct 24, 2005
YAOPHARMA CO LTD	1.25MG	A077514 001	Jun 18, 2008
	2.5MG	A077514 002	Jun 18, 2008
	5MG	A077514 003	Jun 18, 2008

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RAMIPRIL					
CAPSULE;ORAL					
RAMIPRIL					
		10MG	A077514	004	Jun 18, 2008
TABLET;ORAL					
ALTACE					
+	KING PFIZER	1.25MG **	N022021	001	Feb 27, 2007
+		2.5MG **	N022021	002	Feb 27, 2007
+		5MG **	N022021	003	Feb 27, 2007
+		10MG **	N022021	004	Feb 27, 2007
RAMIPRIL					
	APOTEX	1.25MG	A091069	001	Dec 02, 2015
		2.5MG	A091069	002	Dec 02, 2015
		5MG	A091069	003	Dec 02, 2015
		10MG	A091069	004	Dec 02, 2015
	MYLAN PHARMS INC	1.25MG	A090650	001	Jun 30, 2011
		2.5MG	A090650	002	Jun 30, 2011
		5MG	A090650	003	Jun 30, 2011
		10MG	A090650	004	Jun 30, 2011
	ZYDUS PHARMS USA INC	1.25MG	A090697	001	Sep 24, 2009
		2.5MG	A090697	002	Sep 24, 2009
		5MG	A090697	003	Sep 24, 2009
		10MG	A090697	004	Sep 24, 2009
RANITIDINE BISMUTH CITRATE					
TABLET;ORAL					
TRITEC					
	GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996
RANITIDINE HYDROCHLORIDE					
CAPSULE;ORAL					
RANITIDINE HYDROCHLORIDE					
	MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000
		EQ 300MG BASE	A075564	002	Oct 27, 2000
	TEVA	EQ 150MG BASE	A075557	001	Oct 31, 2003
		EQ 300MG BASE	A075557	002	Oct 31, 2003
ZANTAC 150					
+	GLAXOSMITHKLINE	EQ 150MG BASE **	N020095	001	Mar 08, 1994
ZANTAC 300					
+	GLAXOSMITHKLINE	EQ 300MG BASE **	N020095	002	Mar 08, 1994
GRANULE, EFFERVESCENT;ORAL					
ZANTAC 150					
	GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994
INJECTABLE;INJECTION					
RANITIDINE HYDROCHLORIDE					
	BEDFORD	EQ 25MG BASE/ML	A074764	001	Nov 19, 2004
ZANTAC IN PLASTIC CONTAINER					
	TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991
		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986
SYRUP;ORAL					
RANITIDINE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007
	APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007
	RANBAXY	EQ 15MG BASE/ML	A078448	001	Dec 13, 2007
	TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009
	WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009
		EQ 15MG BASE/ML	A079212	001	Feb 23, 2009
ZANTAC					
+	GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988
TABLET;ORAL					
RANITIDINE HYDROCHLORIDE					
	ANI PHARMS INC	EQ 75MG BASE	A075212	001	Jan 14, 2000
		EQ 75MG BASE	A075296	001	Jan 14, 2000
		EQ 150MG BASE	A074488	001	Jul 31, 1997
		EQ 150MG BASE	A077426	001	Dec 19, 2005
		EQ 300MG BASE	A074488	002	Jul 31, 1997
		EQ 300MG BASE	A077426	002	Dec 19, 2005
	BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662	001	Aug 29, 1997
		EQ 300MG BASE	A074662	002	Aug 29, 1997
	CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RANITIDINE HYDROCHLORIDE				
TABLET;ORAL				
RANITIDINE HYDROCHLORIDE				
MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
	EQ 150MG BASE	A074023	001	Aug 22, 1997
	EQ 150MG BASE	A074552	001	Jul 30, 1998
	EQ 300MG BASE	A074023	002	Aug 22, 1997
	EQ 300MG BASE	A074552	002	Jul 30, 1998
RANBAXY	EQ 75MG BASE	A075254	001	Jan 14, 2000
	EQ 150MG BASE	A075000	001	Jan 30, 1998
	EQ 300MG BASE	A075000	002	Jan 30, 1998
SANDOZ	EQ 75MG BASE	A075519	001	Sep 26, 2002
SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000
	EQ 150MG BASE	A075439	001	Apr 19, 2000
	EQ 300MG BASE	A075439	002	Apr 19, 2000
WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997
	EQ 300MG BASE	A074864	002	Oct 20, 1997
WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008
	EQ 150MG BASE	A078653	001	Nov 26, 2007
	EQ 150MG BASE	A078701	001	Nov 12, 2009
	EQ 300MG BASE	A078701	002	Dec 11, 2009
ZANTAC 150				
+ GLAXO GRP LTD	EQ 150MG BASE **	N018703	001	Jun 09, 1983
ZANTAC 300				
+ GLAXO GRP LTD	EQ 300MG BASE **	N018703	002	Dec 09, 1985
TABLET, EFFERVESCENT;ORAL				
ZANTAC 150				
GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994
ZANTAC 25				
GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004
ZANTAC 75				
+ SANOFI US	EQ 75MG BASE **	N020745	001	Feb 26, 1998
RAPACURONIUM BROMIDE				
INJECTABLE;INJECTION				
RAPLON				
ORGANON USA INC	100MG/VIAL	N020984	001	Aug 18, 1999
	200MG/VIAL	N020984	002	Aug 18, 1999
RASAGILINE MESYLATE				
TABLET;ORAL				
RASAGILINE MESYLATE				
APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013
	EQ 1MG BASE	A201950	002	Sep 12, 2013
RAUWOLFIA SERPENTINA ROOT				
TABLET;ORAL				
HIWOLFIA				
BOWMAN PHARMS	50MG	N009276	003	
	50MG	N009276	005	
	100MG	N009276	004	
HYSERPIN				
PHYS PRODS VA	50MG	N010581	001	
KOGLUCOID				
PANRAY	50MG	N009278	001	
	100MG	N009278	002	
RAUDIXIN				
APOTHECON	50MG	N008842	001	
	100MG	N008842	002	
RAUSERPIN				
FERNDALE LABS	50MG	N009926	002	
	100MG	N009926	004	
RAUVAL				
PAL PAK	50MG	N009108	002	
	100MG	N009108	004	
RAUWOLFIA SERPENTINA				
BUNDY	50MG	N009477	001	
	100MG	N009477	002	
HALSEY	50MG	A080498	001	
	100MG	A080498	002	
IMPAX LABS	50MG	N009273	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RAUWOLFIA SERPENTINA ROOT				
TABLET;ORAL				
RAUWOLFIA SERPENTINA				
	100MG		N009273 002	
IVAX SUB TEVA PHARMS	50MG		N011521 001	
	100MG		N011521 002	
PUREPAC PHARM	50MG		A080842 001	
	100MG		A080842 002	
PVT FORM	50MG		A080583 001	
	100MG		A080583 002	
SOLVAY	50MG		A080500 001	
	100MG		A080500 002	
TABLICAPS	50MG		A083867 001	
	100MG		A083444 001	
VALEANT PHARM INTL	50MG		N009668 001	
	100MG		N009668 002	
WATSON LABS	50MG		A080907 001	
	100MG		A080914 001	
WOLFINA				
FOREST PHARMS	50MG		N009255 008	
	100MG		N009255 006	
REPAGLINIDE				
TABLET;ORAL				
PRANDIN				
+ GEMINI LABS LLC	0.5MG		N020741 001	Dec 22, 1997
+	1MG		N020741 002	Dec 22, 1997
+	2MG		N020741 003	Dec 22, 1997
REPAGLINIDE				
MYLAN	0.5MG		A090252 001	Aug 23, 2013
	1MG		A090252 002	Jan 22, 2014
	2MG		A090252 003	Jan 22, 2014
RESCINNAMINE				
CAPSULE;ORAL				
CINNASIL				
PANRAY	0.5MG		A084736 001	
TABLET;ORAL				
MODERIL				
PFIZER	0.25MG		N010686 003	
	0.5MG		N010686 006	
RESERPINE				
ELIXIR;ORAL				
SERPASIL				
NOVARTIS	0.2MG/4ML		N009115 005	
INJECTABLE;INJECTION				
SANDRIL				
LILLY	2.5MG/ML		N010012 001	
SERPASIL				
NOVARTIS	2.5MG/ML		N009434 002	
TABLET;ORAL				
HISERPIA				
BOWMAN PHARMS	0.1MG		N009631 002	
	0.25MG		N009631 004	
RAU-SED				
BRISTOL MYERS SQUIBB	0.1MG		N009357 001	
	0.25MG		N009357 004	
	0.5MG		N009357 006	
	1MG		N009357 008	
RESERPINE				
BARR	0.25MG		A080721 002	
BELL PHARMA	0.1MG		A083058 001	
	0.25MG		A083058 002	
BUNDY	0.1MG		N009663 001	
	0.25MG		N009663 003	
CYCLE PHARMS LTD	0.1MG		N009859 001	
	0.25MG		N009859 002	
ELKINS SINN	0.1MG		A083145 001	
	0.25MG		A083145 002	
EVERYLIFE	0.1MG		N010441 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

RESERPINE

TABLET;ORAL

RESERPINE					
		0.25MG	N010441	002	
		0.5MG	N010441	003	
		1MG	N010441	004	
	HALSEY	0.1MG	A080457	002	
		0.25MG	A080457	001	
		1MG	A080457	003	
	HIKMA INTL PHARMS	0.1MG	A080975	001	
		0.25MG	A080975	002	
		1MG	A080975	003	
	IMPAX LABS	0.1MG	N009627	001	
		0.25MG	N009627	002	
	IVAX SUB TEVA PHARMS	0.1MG	N011185	001	
		0.25MG	N011185	002	
	MARSHALL PHARMA	0.1MG	A080492	001	
		0.25MG	A080492	002	
	MK LABS	0.1MG	A080525	002	
		0.25MG	A080525	001	
	MYLAN	1MG	A084974	001	
	PHARMAVITE	0.25MG	A084663	001	
	PUREPAC PHARM	0.1MG	A080753	002	
		0.25MG	A080753	001	
	PVT FORM	0.1MG	A086117	001	
		0.25MG	A080582	001	
		0.25MG	A085775	001	
		1MG	A080582	002	
	REXALL	0.25MG	A080637	001	
+	SANDOZ	0.1MG	N009838	001	
+		0.25MG	N009838	002	
	SOLVAY	0.25MG	A080446	001	
	TABLICAPS	0.25MG	A085207	001	
	TEVA	0.1MG	A089020	001	Mar 07, 1985
		0.25MG	A089019	001	Mar 07, 1985
	VALEANT PHARM INTL	0.1MG	N009667	001	
		0.25MG	N009667	002	
	WATSON LABS	0.1MG	A080679	001	
		0.25MG	A080393	001	
		0.25MG	A085401	001	
		1MG	A080749	001	
	WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
		0.25MG	A080723	002	
		1MG	A080723	003	
SANDRIL					
	LILLY	0.1MG	N009376	004	
		0.25MG	N009376	001	
SERPALAN					
	LANNETT	0.1MG	N010124	001	
		0.25MG	N010124	002	
SERPANRAY					
	PANRAY	0.1MG	N009391	001	
		0.25MG	N009391	002	
		1MG	N009391	004	
SERPASIL					
	NOVARTIS	0.1MG	N009115	001	
		0.25MG	N009115	003	
		1MG	N009115	004	
SERPATE					
	VALE	0.1MG	N009453	001	
		0.25MG	N009453	002	
SERPIVITE					
	VITARINE	0.25MG	N009645	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RESERPINE; TRICHLORMETHIAZIDE				
TABLET;ORAL				
METATENSIN #2				
	SANOFI AVENTIS US	0.1MG;2MG	N012972 001	
METATENSIN #4				
	SANOFI AVENTIS US	0.1MG;4MG	N012972 002	
NAQUIVAL				
	SCHERING	0.1MG;4MG	N012265 003	
TRICHLORMETHIAZIDE W/ RESERPINE				
	WATSON LABS	0.1MG;4MG	A085248 001	
RIBAVIRIN				
CAPSULE;ORAL				
REBETOL				
	MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**	N020903 001	Jun 03, 1998
RIBAVIRIN				
	CASI PHARMS INC	200MG	A076192 001	Apr 06, 2004
SOLUTION;ORAL				
REBETOL				
+	SCHERING	40MG/ML	N021546 001	Jul 29, 2003
TABLET;ORAL				
COPEGUS				
	ROCHE	200MG **	N021511 001	Dec 03, 2002
		400MG **	N021511 002	Jun 21, 2005
RIBAVIRIN				
	HERITAGE PHARMA	200MG	A077053 001	Dec 05, 2005
RILUZOLE				
TABLET;ORAL				
RILUZOLE				
	DAITO PHARMS CO LTD	50MG	A204430 001	Oct 16, 2018
RIMANTADINE HYDROCHLORIDE				
SYRUP;ORAL				
FLUMADINE				
	FOREST LABS	50MG/5ML	N019650 001	Sep 17, 1993
TABLET;ORAL				
RIMANTADINE HYDROCHLORIDE				
	HERITAGE PHARMA	100MG	A076375 001	Jan 14, 2003
	IMPAX LABS INC	100MG	A075916 001	Nov 02, 2001
RIMEXOLONE				
SUSPENSION/DROPS;OPHTHALMIC				
VEXOL				
	EYEVANCE	1%	N020474 001	Dec 30, 1994
RISEDRONATE SODIUM				
TABLET;ORAL				
ACTONEL				
+	APIL	75MG **	N020835 004	Apr 16, 2007
RISEDRONATE SODIUM				
	HANGZHOU BINJIANG	35MG	A207516 001	Feb 15, 2019
	MYLAN	5MG	A200477 001	Nov 30, 2015
		30MG	A200477 002	Nov 30, 2015
		35MG	A200477 003	Nov 30, 2015
		75MG	A200477 004	Jun 10, 2014
		150MG	A200477 005	Jun 10, 2014
TABLET, DELAYED RELEASE;ORAL				
RISEDRONATE SODIUM				
	IMPAX LABS INC	35MG	A205066 001	Jun 29, 2018
	ZYDUS PHARMS	35MG	A203822 001	Sep 11, 2018
RISPERIDONE				
SOLUTION;ORAL				
RISPERIDONE				
	ANI PHARMS INC	1MG/ML	A076440 001	Jan 30, 2009
	LANNETT CO INC	1MG/ML	A202386 001	Jan 12, 2015
	PRECISION DOSE	1MG/ML	A076797 001	Jun 28, 2010
	TORRENT	1MG/ML	A078909 001	Jul 29, 2009
	WOCKHARDT	1MG/ML	A078744 001	Oct 08, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

RISPERIDONE

TABLET;ORAL

RISPERDAL

JANSSEN PHARMS	5MG	N020272	005	Dec 29, 1993

RISPERIDONE

HERITAGE PHARMA	0.25MG	A076228	001	Jun 30, 2008
	0.25MG	A077769	001	Oct 16, 2008
	0.5MG	A076228	002	Jun 30, 2008
	0.5MG	A077769	002	Oct 16, 2008
	1MG	A076228	003	Jun 30, 2008
	1MG	A077769	003	Oct 16, 2008
	2MG	A076228	004	Jun 30, 2008
	2MG	A077769	004	Oct 16, 2008
	3MG	A076228	005	Jun 30, 2008
	3MG	A077769	005	Oct 16, 2008
	4MG	A076228	006	Jun 30, 2008
	4MG	A077769	006	Oct 16, 2008
JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009
	0.5MG	A078828	002	Mar 23, 2009
	1MG	A078828	003	Mar 23, 2009
	2MG	A078828	004	Mar 23, 2009
	3MG	A078828	005	Mar 23, 2009
	4MG	A078828	006	Mar 23, 2009
RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010
	0.5MG	A077784	002	Jun 08, 2010
	1MG	A077784	003	Jun 08, 2010
	2MG	A077784	004	Jun 08, 2010
	3MG	A077784	005	Jun 08, 2010
	4MG	A077784	006	Jun 08, 2010
SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014
	0.5MG	A078036	002	Mar 10, 2014
	1MG	A078036	003	Mar 10, 2014
	2MG	A078036	004	Mar 10, 2014
	3MG	A078036	005	Mar 10, 2014
	4MG	A078036	006	Mar 10, 2014
SYNTHON PHARMS	0.25MG	A078187	001	Oct 22, 2009
	0.5MG	A078187	002	Oct 22, 2009
	1MG	A078187	003	Oct 22, 2009
	2MG	A078187	004	Oct 22, 2009
	3MG	A078187	005	Oct 22, 2009
	4MG	A078187	006	Oct 22, 2009
WATSON LABS	0.25MG	A077860	001	Dec 05, 2008
	0.5MG	A077860	002	Dec 05, 2008
	1MG	A077860	003	Dec 05, 2008
	2MG	A077860	004	Dec 05, 2008
	3MG	A077860	005	Dec 05, 2008
	4MG	A077860	006	Dec 05, 2008
WEST WARD PHARMS	0.25MG	A078740	001	May 29, 2009
	0.5MG	A078740	002	May 29, 2009
	1MG	A078740	003	May 29, 2009
	2MG	A078740	004	May 29, 2009
	3MG	A078740	005	May 29, 2009
	4MG	A078740	006	May 29, 2009

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013
	0.5MG	A091537	001	Mar 30, 2011
	1MG	A091537	002	Mar 30, 2011
	2MG	A091537	003	Mar 30, 2011
	3MG	A091537	004	Mar 30, 2011
	4MG	A091537	005	Mar 30, 2011

RITODRINE HYDROCHLORIDE

INJECTABLE;INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A071188	001	Jul 23, 1987
	15MG/ML	A071189	001	Jul 23, 1987
HOSPIRA	10MG/ML	A071618	001	Feb 28, 1991
	15MG/ML	A071619	001	Feb 28, 1991

RITODRINE HYDROCHLORIDE

INJECTABLE;INJECTION					
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	30MG/100ML	A071438	001	Jan 22, 1991
YUTOPAR					
	ASTRAZENECA	10MG/ML	N018580	001	
		15MG/ML	N018580	002	Sep 27, 1984
TABLET;ORAL					
YUTOPAR					
	ASTRAZENECA	10MG	N018555	001	

RITONAVIR

CAPSULE;ORAL					
NORVIR					
	ABBOTT	100MG	N020680	001	Mar 01, 1996
+	ABBVIE	100MG **	N020945	001	Jun 29, 1999

RIVASTIGMINE TARTRATE

CAPSULE;ORAL					
EXELON					
+	NOVARTIS	EQ 1.5MG BASE	N020823	003	Apr 21, 2000
+		EQ 3MG BASE	N020823	004	Apr 21, 2000
+		EQ 4.5MG BASE	N020823	005	Apr 21, 2000
+		EQ 6MG BASE	N020823	006	Apr 21, 2000
SOLUTION;ORAL					
EXELON					
	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000

RIZATRIPTAN BENZOATE

TABLET;ORAL					
MAXALT					
+	MERCK	EQ 5MG BASE **	N020864	001	Jun 29, 1998
RIZATRIPTAN BENZOATE					
	APOTEX INC	EQ 5MG BASE	A202244	001	Dec 31, 2012
		EQ 10MG BASE	A202244	002	Dec 31, 2012
TABLET, ORALLY DISINTEGRATING;ORAL					
MAXALT-MLT					
+	MERCK	EQ 5MG BASE **	N020865	001	Jun 29, 1998
RIZATRIPTAN BENZOATE					
	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013
		EQ 10MG BASE	A202477	002	Jul 01, 2013

ROCURONIUM BROMIDE

INJECTABLE;INJECTION					
ZEMURON					
+	ORGANON USA INC	50MG/5ML (10MG/ML) **	N020214	001	Mar 17, 1994
+		10MG/ML (10MG/ML) **	N020214	002	Mar 17, 1994
+		100MG/10ML (10MG/ML) **	N020214	003	Mar 17, 1994

ROFECOXIB

SUSPENSION;ORAL					
VIOXX					
	MERCK	12.5MG/5ML	N021052	001	May 20, 1999
		25MG/5ML	N021052	002	May 20, 1999
TABLET;ORAL					
VIOXX					
	MERCK	12.5MG	N021042	001	May 20, 1999
		25MG	N021042	002	May 20, 1999
		50MG	N021042	003	Feb 25, 2000

ROFLUMILAST

TABLET;ORAL					
ROFLUMILAST					
	MYLAN	500MCG	A208257	001	Jul 13, 2018

ROLAPITANT HYDROCHLORIDE

EMULSION;INTRAVENOUS					
VARUBI					
+	TERSERA THERAPS LLC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ROPINIROLE HYDROCHLORIDE				
TABLET;ORAL				
ROPINIROLE HYDROCHLORIDE				
ACP NIMBLE	EQ 0.25MG BASE	A077460	001	May 05, 2008
	EQ 0.5MG BASE	A077460	002	May 05, 2008
	EQ 1MG BASE	A077460	003	May 05, 2008
	EQ 2MG BASE	A077460	004	May 05, 2008
	EQ 3MG BASE	A077460	005	May 05, 2008
	EQ 4MG BASE	A077460	006	May 05, 2008
	EQ 5MG BASE	A077460	007	May 19, 2008
EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008
	EQ 0.5MG BASE	A078230	002	May 20, 2008
	EQ 1MG BASE	A078230	003	May 20, 2008
	EQ 2MG BASE	A078230	004	May 20, 2008
	EQ 3MG BASE	A078230	005	May 20, 2008
	EQ 4MG BASE	A078230	006	May 20, 2008
	EQ 5MG BASE	A078230	007	May 20, 2008
TABLET, EXTENDED RELEASE;ORAL				
REQUIP XL				
+ GLAXOSMITHKLINE LLC	EQ 3MG BASE **	N022008	002	Jun 13, 2008
+	EQ 4MG BASE	N022008	003	Jun 13, 2008
ROPINIROLE HYDROCHLORIDE				
MYLAN PHARMS INC	EQ 2MG BASE	A200462	001	Oct 15, 2012
	EQ 3MG BASE	A200462	002	Oct 15, 2012
	EQ 4MG BASE	A200462	003	Oct 15, 2012
	EQ 6MG BASE	A200462	004	Oct 15, 2012
	EQ 8MG BASE	A200462	005	Oct 15, 2012
	EQ 12MG BASE	A200462	006	Oct 15, 2012
ROPIVACAINE HYDROCHLORIDE				
SOLUTION;INJECTION				
NAROPIN				
FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998
	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996
ROSE BENGAL SODIUM I-131				
INJECTABLE;INJECTION				
ROBENGATOPE				
BRACCO	0.5mCi/VIAL	N016224	001	
	1mCi/VIAL	N016224	002	
	2mCi/VIAL	N016224	003	
SODIUM ROSE BENGAL I 131				
SORIN	0.5mCi/ML	N017318	001	
ROSIGLITAZONE MALEATE				
TABLET;ORAL				
AVANDIA				
+ SB PHARMCO	EQ 8MG BASE	N021071	004	May 25, 1999
ROSIGLITAZONE MALEATE				
ANI PHARMS INC	EQ 2MG BASE	A076747	001	Jan 25, 2013
	EQ 4MG BASE	A076747	002	Jan 25, 2013
	EQ 8MG BASE	A076747	003	Jan 25, 2013
ROSUVASTATIN CALCIUM				
TABLET;ORAL				
ROSUVASTATIN CALCIUM				
AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018
	10MG	A208850	002	Oct 16, 2018
	20MG	A208850	003	Oct 16, 2018
	40MG	A208850	004	Oct 16, 2018
MYLAN	5MG	A079161	001	Jul 19, 2016
	10MG	A079161	002	Jul 19, 2016
	20MG	A079161	003	Jul 19, 2016
	40MG	A079161	004	Jul 19, 2016
SCIEGEN PHARMS INC	5MG	A206381	001	Apr 24, 2019
	10MG	A206381	002	Apr 24, 2019
	20MG	A206381	003	Apr 24, 2019
	40MG	A206381	004	Apr 24, 2019
TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016
	10MG	A079166	002	Jul 19, 2016
	20MG	A079166	003	Jul 19, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ROSUVASTATIN CALCIUM				
TABLET;ORAL				
ROSUVASTATIN CALCIUM				
	40MG	A079166	004	Jul 19, 2016
UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019
	10MG	A207626	002	Apr 09, 2019
	20MG	A207626	003	Apr 09, 2019
	40MG	A207626	004	Apr 09, 2019
ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019
	10MG	A206513	002	Mar 01, 2019
	20MG	A206513	003	Mar 01, 2019
	40MG	A206513	004	Mar 01, 2019
RUFINAMIDE				
TABLET;ORAL				
BANZEL				
+ EISAI INC	100MG **	N021911	001	Nov 14, 2008
RUFINAMIDE				
MYLAN	200MG	A205095	001	May 16, 2016
	400MG	A205095	002	May 16, 2016
SAFFLOWER OIL				
INJECTABLE;INJECTION				
LIPOSYN 10%				
ABBOTT	10% (10GM/100ML)	N018203	001	
LIPOSYN 20%				
ABBOTT	20% (20GM/100ML)	N018614	001	
SAFFLOWER OIL; SOYBEAN OIL				
INJECTABLE;INJECTION				
LIPOSYN II 10%				
HOSPIRA	5%;5% (5GM/100ML)	N018997	001	Aug 27, 1984
LIPOSYN II 20%				
HOSPIRA	10%;10% (10GM/100ML)	N018991	001	Aug 27, 1984
SALMETEROL XINAFOATE				
AEROSOL, METERED;INHALATION				
SEREVENT				
GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236	001	Feb 04, 1994
SAPROPTERIN DIHYDROCHLORIDE				
POWDER;ORAL				
SAPROPTERIN DIHYDROCHLORIDE				
PAR PHARM INC	500MG/PACKET	A210027	001	Aug 20, 2019
TABLET;ORAL				
SAPROPTERIN DIHYDROCHLORIDE				
PAR PHARM INC	100MG	A207200	001	May 10, 2019
SAQUINAVIR				
CAPSULE;ORAL				
FORTOVASE				
+ HOFFMANN LA ROCHE	200MG **	N020828	001	Nov 07, 1997
SAQUINAVIR MESYLATE				
CAPSULE;ORAL				
INVIRASE				
+ HOFFMANN LA ROCHE	EQ 200MG BASE	N020628	001	Dec 06, 1995
SARALASIN ACETATE				
INJECTABLE;INJECTION				
SARENIN				
PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009	001	
SECOBARBITAL SODIUM				
CAPSULE;ORAL				
SECOBARBITAL SODIUM				
ANABOLIC	100MG	A084422	001	
BARR	100MG	A084225	001	
EVERYLIFE	100MG	A085895	001	
HALSEY	100MG	A084676	001	
IVAX PHARMS	100MG	A085869	001	
KV PHARM	100MG	A085285	001	
LANNETT	50MG	A085909	001	
	100MG	A085903	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

SECOBARBITAL SODIUM

CAPSULE;ORAL				
SECOBARBITAL SODIUM				
PARKE DAVIS	100MG		A084762 001	
PERRIGO	100MG		A084561 001	
PUREPAC PHARM	100MG		A085867 001	
VALEANT PHARM INTL	100MG		A085477 001	
VITARINE	100MG		A085898 001	
	100MG		A086273 001	
WATSON LABS	100MG		A085792 001	
WEST WARD	100MG		A084926 001	
WHITEWORTH TOWN PLSN	100MG		A085798 001	
WYETH AYERST	100MG		A086390 001	
INJECTABLE;INJECTION				
SECOBARBITAL SODIUM				
ELKINS SINN	100MG/VIAL		A083281 001	
WYETH AYERST	50MG/ML		A083262 001	
SECONAL SODIUM				
LILLY	50MG/ML		N007392 002	
SUPPOSITORY;RECTAL				
SECONAL SODIUM				
LILLY	30MG		A086530 001	
	60MG		A086530 002	
	120MG		A086530 003	
	200MG		A086530 004	

SECRETIN

INJECTABLE;INJECTION				
SECRETIN-FERRING				
FERRING	75CU/VIAL		N018290 001	

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION;INTRAVENOUS				
SECREFLO				
CHIRHOCLIN	16MCG/VIAL		N021136 001	Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL				
ELDEPRYL				
+ SOMERSET	5MG		N020647 001	May 15, 1996
SELEGILINE HYDROCHLORIDE				
LANNETT CO INC	5MG		A075145 001	Sep 15, 2003
TABLET;ORAL				
SELEGILINE HYDROCHLORIDE				
ACP NIMBLE	5MG		A074744 001	Jan 27, 1997
	5MG		A074756 001	Nov 25, 1998
ALLIED	5MG		A074672 001	Apr 01, 1997
CHARTWELL MOLECULES	5MG		A074565 001	Aug 02, 1996
	5MG		A074641 001	Aug 02, 1996
G AND W LABS INC	5MG		A074537 001	Aug 02, 1996
MYLAN	5MG		A074866 001	Nov 26, 1997
+ SOMERSET	5MG **		N019334 001	Jun 05, 1989

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL				
EXSEL				
ALLERGAN HERBERT	2.5%		A083892 001	
SELENIUM SULFIDE				
ACP NIMBLE	2.5%		A086209 001	
ACTAVIS MID ATLANTIC	2.5%		A084394 001	
IVAX PHARMS	2.5%		A085777 001	
SELSUN				
+ CHATTEM	2.5%		N007936 001	

SELENOMETHIONINE SE-75

INJECTABLE;INJECTION				
SELENOMETHIONINE SE 75				
GE HEALTHCARE	250uCi/ML		N017257 001	
MALLINCKRODT	100uCi/ML		N017098 001	
PHARMALUCENCE	500uCi/ML		N017322 001	

SELENOMETHIONINE SE-75				
INJECTABLE;INJECTION				
SETHOTOPE				
	BRACCO	85-550uCi/ML	N017047 001	
SERMORELIN ACETATE				
INJECTABLE;INJECTION				
GEREF				
+	EMD SERONO	EQ 0.05MG BASE/AMP **	N019863 001	Dec 28, 1990
+	EMD SERONO INC	EQ 0.5MG BASE/VIAL **	N020443 001	Sep 26, 1997
+		EQ 1MG BASE/VIAL **	N020443 002	Sep 26, 1997
SERTRALINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
SERTRALINE HYDROCHLORIDE				
	ACI HEALTHCARE LTD	EQ 20MG BASE/ML	A076934 001	Jun 30, 2006
	RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007
TABLET;ORAL				
SERTRALINE HYDROCHLORIDE				
	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881 001	Feb 06, 2007
		EQ 50MG BASE	A076881 002	Feb 06, 2007
		EQ 100MG BASE	A076881 003	Feb 06, 2007
	ANDA REPOSITORY	EQ 25MG BASE	A077818 001	Feb 06, 2007
		EQ 50MG BASE	A077818 002	Feb 06, 2007
		EQ 100MG BASE	A077818 003	Feb 06, 2007
	CADILA	EQ 25MG BASE	A077106 001	Feb 06, 2007
		EQ 50MG BASE	A077106 002	Feb 06, 2007
		EQ 100MG BASE	A077106 003	Feb 06, 2007
	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162 001	Feb 06, 2007
		EQ 50MG BASE	A077162 002	Feb 06, 2007
		EQ 100MG BASE	A077162 003	Feb 06, 2007
	FOSUN PHARMA	EQ 25MG BASE	A077713 001	Feb 06, 2007
		EQ 50MG BASE	A077713 002	Feb 06, 2007
		EQ 100MG BASE	A077713 003	Feb 06, 2007
	HERITAGE PHARMA	EQ 25MG BASE	A076465 001	Aug 11, 2006
		EQ 25MG BASE	A077299 001	Feb 06, 2007
		EQ 25MG BASE	A077345 001	Feb 06, 2007
		EQ 25MG BASE	A077663 001	Feb 06, 2007
		EQ 50MG BASE	A076465 002	Aug 11, 2006
		EQ 50MG BASE	A077299 002	Feb 06, 2007
		EQ 50MG BASE	A077345 002	Feb 06, 2007
		EQ 50MG BASE	A077663 002	Feb 06, 2007
		EQ 100MG BASE	A076465 003	Aug 11, 2006
		EQ 100MG BASE	A077299 003	Feb 06, 2007
		EQ 100MG BASE	A077345 003	Feb 06, 2007
		EQ 100MG BASE	A077663 003	Feb 06, 2007
	HIKMA PHARMS	EQ 25MG BASE	A077864 001	Aug 10, 2009
		EQ 50MG BASE	A077864 002	Aug 10, 2009
		EQ 100MG BASE	A077864 003	Aug 10, 2009
	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719 003	Jun 30, 2006
		EQ 50MG BASE	A075719 001	Jun 30, 2006
		EQ 100MG BASE	A075719 002	Jun 30, 2006
	MYLAN	EQ 25MG BASE	A076671 001	Feb 06, 2007
		EQ 50MG BASE	A076671 002	Feb 06, 2007
		EQ 100MG BASE	A076671 003	Feb 06, 2007
	MYLAN PHARMS INC	EQ 25MG BASE	A076540 001	Mar 20, 2007
		EQ 25MG BASE	A078626 001	Jan 31, 2008
		EQ 50MG BASE	A076540 002	Mar 20, 2007
		EQ 50MG BASE	A078626 002	Jan 31, 2008
		EQ 100MG BASE	A076540 003	Mar 20, 2007
		EQ 100MG BASE	A078626 003	Jan 31, 2008
	SCIEGEN PHARMS INC	EQ 25MG BASE	A076442 001	Apr 30, 2007
		EQ 50MG BASE	A076442 002	Apr 30, 2007
		EQ 100MG BASE	A076442 003	Apr 30, 2007
	SUN PHARM INDS (IN)	EQ 25MG BASE	A078108 001	Feb 06, 2007
		EQ 50MG BASE	A078108 002	Feb 06, 2007
		EQ 100MG BASE	A078108 003	Feb 06, 2007
ZOLOFT				
+	PFIZER	EQ 150MG BASE **	N019839 003	Dec 30, 1991
+		EQ 200MG BASE **	N019839 004	Dec 30, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SEVELAMER HYDROCHLORIDE				
CAPSULE;ORAL				
RENAGEL				
GENZYME	403MG	N020926	001	Oct 30, 1998
SIBUTRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
MERIDIA				
ABBOTT	5MG	N020632	001	Nov 22, 1997
	10MG	N020632	002	Nov 22, 1997
	15MG	N020632	003	Nov 22, 1997
SILDENAFIL CITRATE				
TABLET;ORAL				
SILDENAFIL CITRATE				
ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013
APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012
SILVER SULFADIAZINE				
CREAM;TOPICAL				
SSD AF				
DR REDDYS LA	1%	N018578	003	Jul 11, 1990
DRESSING;TOPICAL				
SILDAFLO				
FRANKLIN PHARMS	1%	N019608	001	Nov 30, 1989
SIMEPREVIR SODIUM				
CAPSULE;ORAL				
OLYSIO				
+ JANSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013
SIMETHICONE-CELLULOSE				
SUSPENSION;ORAL				
SONORX				
BRACCO	7.5MG/ML	N020773	001	Oct 29, 1998
SIMVASTATIN				
TABLET;ORAL				
SIMVASTATIN				
HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017
	20MG	A206557	002	Nov 13, 2017
	40MG	A206557	003	Nov 13, 2017
	80MG	A206557	004	Nov 13, 2017
IVAX SUB TEVA PHARMS	5MG	A076052	001	Jun 23, 2006
	10MG	A076052	002	Jun 23, 2006
	20MG	A076052	003	Jun 23, 2006
	40MG	A076052	004	Jun 23, 2006
	80MG	A076052	005	Dec 20, 2006
MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010
	10MG	A090868	002	Jun 08, 2010
	20MG	A090868	003	Jun 08, 2010
	40MG	A090868	004	Jun 08, 2010
	80MG	A090868	005	Jun 08, 2010
SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006
	10MG	A076285	002	Dec 20, 2006
	20MG	A076285	003	Dec 20, 2006
	40MG	A076285	004	Dec 20, 2006
	80MG	A076285	005	Jun 23, 2006
YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006
	10MG	A077766	002	Dec 20, 2006
	20MG	A077766	003	Dec 20, 2006
	40MG	A077766	004	Dec 20, 2006
	80MG	A077766	005	Dec 20, 2006
TABLET, ORALLY DISINTEGRATING;ORAL				
SIMVASTATIN				
SYNTHON PHARMS	10MG	N021961	001	Oct 09, 2007
	20MG	N021961	002	Oct 09, 2007
	40MG	N021961	003	Oct 09, 2007
	80MG	N021961	004	Oct 09, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SIMVASTATIN; SITAGLIPTIN PHOSPHATE					
TABLET;ORAL					
JUVISYNC					
+	MERCK SHARP DOHME	10MG;EQ 50MG BASE **	N202343	004	Sep 18, 2012
+		10MG;EQ 100MG BASE **	N202343	001	Oct 07, 2011
+		20MG;EQ 50MG BASE **	N202343	005	Sep 18, 2012
+		20MG;EQ 100MG BASE **	N202343	002	Oct 07, 2011
+		40MG;EQ 50MG BASE **	N202343	006	Sep 18, 2012
+		40MG;EQ 100MG BASE **	N202343	003	Oct 07, 2011
SIROLIMUS					
TABLET;ORAL					
RAPAMUNE					
+	PF PRISM CV	5MG **	N021110	003	Feb 23, 2004
SODIUM BENZOATE; SODIUM PHENYLACETATE					
SOLUTION;ORAL					
UCEPHAN					
	B BRAUN	100MG/ML;100MG/ML	N019530	001	Dec 23, 1987
SODIUM BICARBONATE					
INJECTABLE;INJECTION					
SODIUM BICARBONATE					
	HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017
SODIUM BICARBONATE IN PLASTIC CONTAINER					
+	ABBOTT	0.9MEQ/ML **	N019443	001	Jun 03, 1986
+		1MEQ/ML **	N019443	002	Jun 03, 1986
SODIUM BICARBONATE; TARTARIC ACID					
GRANULE, EFFERVESCENT;ORAL					
BAROS					
	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509	001	Aug 07, 1985
SODIUM CHLORIDE					
INJECTABLE;INJECTION					
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	ABRAXIS PHARM	9MG/ML	A088909	001	Feb 07, 1985
SODIUM CHLORIDE					
	ABBOTT	20GM/100ML	N017013	001	
	B BRAUN	20GM/100ML	N017038	001	
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	450MG/100ML	N018184	001	
	MILES	450MG/100ML	N018503	001	
SODIUM CHLORIDE 0.9%					
+	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012
+		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012
+		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012
+		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	ABBOTT	9MG/ML	N019218	001	Jul 13, 1984
+	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984
+	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
+	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012
	MILES	900MG/100ML	N018502	001	
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER					
+	ABRAXIS PHARM	234MG/ML **	N019329	001	Apr 22, 1987
SOLUTION;IRRIGATION					
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	450MG/100ML	N017864	001	
		450MG/100ML	N018497	001	Feb 19, 1982
	HOSPIRA	450MG/100ML	N017670	001	
		450MG/100ML	N018380	001	
SODIUM CHLORIDE IN PLASTIC CONTAINER					
	MILES	900MG/100ML	N018247	001	
SODIUM CHROMATE CR-51					
INJECTABLE;INJECTION					
CHROMITOPE SODIUM					
	BRACCO	2mCi/VIAL	N013993	002	
		200uCi/ML	N013993	001	
SODIUM CHROMATE CR 51					
	CURIUM	100uCi/ML	N016708	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM FLUORIDE F-18				
INJECTABLE;INTRAVENOUS				
FLUORINE F-18				
+ GE HEALTHCARE	2mCi/ML **	N017042	001	
SODIUM FLUORIDE F 18				
NIH NCI DCTD	10-200mCi/ML **	N022494	001	Jan 26, 2011
SODIUM FLUORIDE F-18				
UIHC PET IMAGING	10-200mCi/ML	A204462	001	Nov 17, 2015
UNIV TX MD ANDERSON	10-200mCi/ML	A203247	001	Dec 23, 2013
SODIUM FLUORIDE; TRICLOSAN				
PASTE;DENTAL				
COLGATE TOTAL				
+ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997
SODIUM IODIDE I-123				
CAPSULE;ORAL				
SODIUM IODIDE I 123				
CARDINAL HEALTH 418	400uCi	N018671	003	May 27, 1982
GE HEALTHCARE	100uCi	N017630	001	
SOLUTION;ORAL				
SODIUM IODIDE I 123				
GE HEALTHCARE	2mCi/ML **	N017630	002	
SODIUM IODIDE I-131				
CAPSULE;ORAL				
IODOTOPE				
BRACCO	1-130mCi	N010929	001	
	1-150mCi	N010929	003	
SODIUM IODIDE I 131				
CIS	50uCi	N017316	001	
	100uCi	N017316	002	
CURIUM	0.8-100mCi	N016515	002	
+	0.8-100mCi	N016517	001	
	15-100uCi	N016517	002	
JUBILANT DRAXIMAGE	2-200mCi	N021305	004	Nov 18, 2004
SOLUTION;ORAL				
HICON				
JUBILANT DRAXIMAGE	1-250mCi/0.25ML	N021305	002	Jan 24, 2003
	1-500mCi/0.5ML	N021305	003	Jan 24, 2003
	1-1000mCi/ML	N021305	005	Apr 04, 2006
IODOTOPE				
BRACCO	7-106mCi/BOT	N010929	002	
SODIUM IODIDE I 131				
CIS	50mCi/ML	N017315	001	
+ CURIUM	3.5-150mCi/VIAL	N016515	001	
SODIUM LACTATE				
INJECTABLE;INJECTION				
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER				
B BRAUN	1.87GM/100ML	N018186	001	
BAXTER HLTHCARE	1.87GM/100ML	N016692	001	
HOSPIRA	1.87GM/100ML	N018249	001	
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER				
B BRAUN	1.87GM/100ML	N020004	001	Apr 21, 1992
SODIUM MONOFLUOROPHOSPHATE				
GEL;DENTAL				
EXTRA-STRENGTH AIM				
CHESEBROUGH PONDS	1.2%	N019518	002	Aug 06, 1986
PASTE;DENTAL				
EXTRA-STRENGTH AIM				
CHESEBROUGH PONDS	1.2%	N019518	001	Jun 03, 1987
SODIUM NITROPRUSSIDE				
INJECTABLE;INJECTION				
NIPRIDE				
ROCHE	50MG/VIAL	N017546	001	
NITROPRESS				
ABBOTT	50MG/VIAL	A071555	001	Nov 16, 1987
+ ABBVIE	50MG/VIAL **	N018450	001	
HOSPIRA	50MG/VIAL	A070566	001	Jun 09, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM NITROPRUSSIDE					
INJECTABLE;INJECTION					
SODIUM NITROPRUSSIDE					
	ABRAXIS PHARM	50MG/VIAL	A070031	001	Jan 17, 1985
+	BAXTER HLTHCARE	50MG/VIAL **	N018581	001	Jul 28, 1982
	SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018
	TEVA PARENTERAL	25MG/ML	A073465	001	Mar 30, 1992
	VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018
SOLUTION;INTRAVENOUS					
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%					
+	EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017
SODIUM PHOSPHATE P-32					
SOLUTION;INJECTION, ORAL					
PHOSPHOTOPE					
	BRACCO	1-8mCi/VIAL	N010927	001	
SODIUM PHOSPHATE P 32					
	MALLINCKRODT	0.67mCi/ML	N011777	001	
		1.5mCi/VIAL	N011777	002	
SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE					
TABLET;ORAL					
VISICOL					
	SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE					
TABLET;ORAL					
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE					
	NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011
SODIUM POLYSTYRENE SULFONATE					
POWDER;ORAL, RECTAL					
KAYEXALATE					
+	CONCORDIA	453.6GM/BOT **	N011287	001	
SODIUM POLYSTYRENE SULFONATE					
	CITRUSPHRMA	454GM/BOT	A040909	001	Dec 03, 2008
	WOCKHARDT	453.6GM/BOT	A088786	001	Sep 11, 1984
SUSPENSION;ORAL, RECTAL					
SODIUM POLYSTYRENE SULFONATE					
	MORTON GROVE	15GM/60ML	A088717	001	Sep 11, 1984
	ROXANE	15GM/60ML	A088453	001	Nov 17, 1983
SODIUM SUCCINATE					
INJECTABLE;INJECTION					
SODIUM SUCCINATE					
	ELKINS SINN	30%	A080516	001	
SODIUM TETRADECYL SULFATE					
INJECTABLE;INJECTION					
SOTRADECOL					
+	ELKINS SINN	1% **	N005970	004	
+		3% **	N005970	005	
SODIUM THIOSULFATE					
INJECTABLE;INJECTION					
SODIUM THIOSULFATE					
	US ARMY	250MG/ML	N020166	001	Feb 14, 1992
SOMATREM					
INJECTABLE;INJECTION					
PROTROPIN					
	GENENTECH	5MG/VIAL	N019107	001	Oct 17, 1985
		10MG/VIAL	N019107	002	Oct 24, 1989
SOMATROPIN					
INJECTABLE;INJECTION					
ASELLACRIN 10					
	SERONO	10 IU/VIAL	N017726	001	
ASELLACRIN 2					
	SERONO	2 IU/VIAL	N017726	002	Jul 21, 1983
BIO-TROPIN					
	FERRING	4.8MG/VIAL	N019774	001	May 25, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SOMATROPIN					
INJECTABLE;INJECTION					
CRESCORMON					
	GENENTECH	4 IU/VIAL	N017992	001	
GENOTROPIN PRESERVATIVE FREE					
+	PHARMACIA	1.5MG/VIAL	N020280	004	Aug 24, 1995
NORDITROPIN					
	NOVO NORDISK INC	5MG/1.5ML	N021148	001	Jun 20, 2000
		10MG/1.5ML	N021148	002	Jun 20, 2000
		15MG/1.5ML	N021148	003	Jun 20, 2000
NORDITROPIN NORDIFLEX					
	NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004
		10MG/1.5ML	N021148	005	Oct 01, 2004
		15MG/1.5ML	N021148	006	Oct 01, 2004
		30MG/3ML	N021148	007	Mar 10, 2009
NUTROPIN					
	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993
		10MG/VIAL	N020168	002	Nov 17, 1993
NUTROPIN AQ					
	GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995
NUTROPIN AQ PEN					
+	GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002
+		20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008
SAIZEN					
	EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007
		6MG/VIAL	N019764	001	Oct 08, 1996
SEROSTIM					
	EMD SERONO	8.8MG/VIAL	N020604	004	Sep 06, 2001
INJECTABLE;SUBCUTANEOUS					
SEROSTIM LQ					
	EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005
SOMATROPIN RECOMBINANT					
INJECTABLE;INJECTION					
ACCRETROPIN					
	EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008
HUMATROPE					
	LILLY	2MG/VIAL	N019640	001	Jun 23, 1987
NORDITROPIN					
	NOVO NORDISK INC	4MG/VIAL	N019721	001	May 08, 1995
		8MG/VIAL	N019721	002	May 08, 1995
NUTROPIN DEPOT					
	GENENTECH	13.5MG/VIAL	N021075	001	Dec 22, 1999
		18MG/VIAL	N021075	002	Dec 22, 1999
		22.5MG/VIAL	N021075	003	Dec 22, 1999
VALTROPIN					
	LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007
ZORBTIVE					
	EMD SERONO	4MG/VIAL	N021597	001	Dec 01, 2003
		5MG/VIAL	N021597	002	Dec 01, 2003
		6MG/VIAL	N021597	003	Dec 01, 2003
SORBITOL					
SOLUTION;IRRIGATION					
SORBITOL 3% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	3GM/100ML	N018512	001	May 27, 1982
SOTALOL HYDROCHLORIDE					
TABLET;ORAL					
BETAPACE					
	COVIS PHARMA BV	320MG	N019865	004	Oct 30, 1992
BETAPACE AF					
	COVIS PHARMA BV	40MG	N021151	006	Apr 02, 2003
		60MG	N021151	007	Apr 02, 2003
		100MG	N021151	005	Mar 14, 2003
SOTALOL HYDROCHLORIDE					
	IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000
		120MG	A075663	002	Nov 07, 2000
		160MG	A075663	003	Nov 07, 2000
		240MG	A075663	004	Nov 07, 2000
	MYLAN	80MG	A075237	001	May 01, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

	80MG	A075725	001	Dec 19, 2000
	120MG	A075237	002	May 01, 2000
	120MG	A075725	002	Dec 19, 2000
	160MG	A075237	003	May 01, 2000
	160MG	A075725	003	Dec 19, 2000
	240MG	A075237	004	May 01, 2000
	240MG	A075725	004	Dec 19, 2000
SUN PHARM INDUSTRIES	80MG	A075515	001	Oct 15, 2001
	80MG	A076576	001	Apr 08, 2004
	120MG	A075515	004	Oct 15, 2001
	120MG	A076576	002	Apr 08, 2004
	160MG	A075515	002	Oct 15, 2001
	160MG	A076576	003	Apr 08, 2004
	240MG	A075515	003	Oct 15, 2001
TEVA	80MG	A076883	001	Jul 26, 2004
	120MG	A076883	002	Jul 26, 2004
	160MG	A076883	003	Jul 26, 2004
UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000
	120MG	A075366	002	May 01, 2000
	160MG	A075366	003	May 01, 2000
	240MG	A075366	004	May 01, 2000
WATSON LABS	80MG	A075238	001	Jul 13, 2000
	120MG	A075238	002	Jul 13, 2000
	160MG	A075238	003	Jul 13, 2000
	240MG	A075238	004	Jul 13, 2000

SOYBEAN OIL

INJECTABLE;INJECTION

LIPOSYN III 10%

HOSPIRA	10%	N018969	001	Sep 24, 1984

LIPOSYN III 20%

HOSPIRA	20%	N018970	001	Sep 25, 1984

LIPOSYN III 30%

HOSPIRA	30%	N020181	001	Jan 13, 1998

SOYACAL 10%

ALPHA THERA	10%	N018465	001	Jun 29, 1983

SOYACAL 20%

ALPHA THERA	20%	N018786	001	Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE	10%	N018660	001	Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE	20%	N018758	001	Feb 15, 1983

SPARFLOXACIN

TABLET;ORAL

ZAGAM

MYLAN	200MG	N020677	001	Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

TROBICIN

PFIZER	EQ 2GM BASE/VIAL	N050347	001	
	EQ 4GM BASE/VIAL	N050347	002	

SPIRAPRIL HYDROCHLORIDE

TABLET;ORAL

RENORMAX

SCHERING	3MG	N020240	001	Dec 29, 1994
	6MG	N020240	002	Dec 29, 1994
	12MG	N020240	003	Dec 29, 1994
	24MG	N020240	004	Dec 29, 1994

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006
	50MG	A040353	001	Jul 29, 1999
	100MG	A040353	002	Jul 29, 1999
ASCOT	25MG	A087687	001	Oct 20, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AUROBINDO PHARMA LTD	25MG	A202187	001	Mar 06, 2014
	50MG	A202187	002	Mar 06, 2014
	100MG	A202187	003	Mar 06, 2014
CASI PHARMS INC	25MG	A086809	001	
IVAX PHARMS	25MG	A087108	001	
LEDERLE	25MG	A087634	001	
MUTUAL PHARM	25MG	A087265	001	
MYLAN	25MG	A087086	001	
PUREPAC PHARM	25MG	A087998	001	Oct 14, 1983
	25MG	A088053	001	Aug 25, 1983
SUPERPHARM	25MG	A089364	001	Nov 07, 1986
UPSHER SMITH	25MG	A087554	001	
VANGARD	25MG	A087648	001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952	001	Nov 18, 1982
WATSON LABS	25MG	A086898	002	Mar 02, 1982
	25MG	A087078	001	

STANOZOLOL

TABLET;ORAL

WINSTROL

+	LUNDBECK INC	2MG	N012885	001	May 14, 1984

STAVUDINE

CAPSULE;ORAL

STAVUDINE

HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008
	20MG	A078957	002	Dec 29, 2008
	30MG	A078957	003	Dec 29, 2008
	40MG	A078957	004	Dec 29, 2008
MYLAN	15MG	A079069	001	Dec 29, 2008
	20MG	A079069	002	Dec 29, 2008
	30MG	A079069	003	Dec 29, 2008
	40MG	A079069	004	Dec 29, 2008
MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009
	40MG	A078775	002	Jan 05, 2009

ZERIT

BRISTOL MYERS SQUIBB	5MG	N020412	001	Jun 24, 1994

CAPSULE, EXTENDED RELEASE;ORAL

ZERIT XR

BRISTOL MYERS SQUIBB	37.5MG	N021453	001	Dec 31, 2002
	50MG	N021453	002	Dec 31, 2002
	75MG	N021453	003	Dec 31, 2002
	100MG	N021453	004	Dec 31, 2002

FOR SOLUTION;ORAL

STAVUDINE

AUROBINDO PHARMA	1MG/ML	A077774	001	Dec 29, 2008
CIPLA LTD	1MG/ML	A078030	001	Mar 20, 2009

ZERIT

+	BRISTOL-MYERS SQUIBB	1MG/ML	N020413	001	Sep 06, 1996

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%	A089099	001	Dec 29, 1987
	100%	A089100	001	Dec 29, 1987

STERILE WATER FOR INJECTION

+	HOSPIRA	100% (1ML)	N018801	001	Oct 27, 1982
	WEST-WARD PHARMS INT	100% (20ML)	A206369	002	Sep 02, 2015

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN	100%	N019077	001	Mar 02, 1984

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES	100%	N018246	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

STREPTOMYCIN SULFATE				
INJECTABLE;INJECTION				
STREPTOMYCIN SULFATE				
COPANOS	EQ 500MG BASE/ML	A060684	001	
LILLY	EQ 1GM BASE/VIAL	A060107	001	
	EQ 1GM BASE/2ML	A060404	001	
	EQ 5GM BASE/VIAL	A060107	002	
PFIZER	EQ 1GM BASE/VIAL **	A060076	001	
	EQ 1GM BASE/2.5ML	A060111	001	
	EQ 5GM BASE/VIAL **	A060076	002	
SUCCINYLCHOLINE CHLORIDE				
INJECTABLE;INJECTION				
ANECTINE				
SANDOZ INC	50MG/ML	N008453	003	
	500MG/VIAL	N008453	001	
	1GM/VIAL	N008453	004	
QUELICIN PRESERVATIVE FREE				
+ HOSPIRA	20MG/ML	N008845	001	
	50MG/ML	N008845	002	
	100MG/ML	N008845	004	
SUCCINYLCHOLINE CHLORIDE				
INTL MEDICATION	100MG/VIAL	A085400	001	Feb 04, 1982
ORGANON USA INC	20MG/ML	A080997	001	
SUCOSTRIN				
APOTHECON	20MG/ML	N008847	001	
	100MG/ML	N008847	003	
SUCRALFATE				
TABLET;ORAL				
SUCRALFATE				
NOSTRUM LABS INC	1GM	A074415	001	Jun 08, 1998
SUFENTANIL CITRATE				
INJECTABLE;INJECTION				
SUFENTANIL CITRATE				
WATSON LABS	EQ 0.05MG BASE/ML	A074406	001	Dec 15, 1995
SULFACETAMIDE SODIUM				
OINTMENT;OPHTHALMIC				
BLEPH-10				
ALLERGAN	10%	A084015	001	
CETAMIDE				
ALCON	10%	A080021	001	
SODIUM SULAMYD				
+ SCHERING	10% **	N005963	002	
SULFAIR 10				
PHARMAFAIR	10%	A088000	001	Dec 22, 1982
SOLUTION/DROPS;OPHTHALMIC				
BLEPH-30				
ALLERGAN	30%	A080028	002	
ISOPTO CETAMIDE				
ALCON	15%	A080020	002	
OCUSULF-10				
MIZA PHARMS USA	10%	A080660	001	
OCUSULF-30				
MIZA PHARMS USA	30%	A080660	002	
SODIUM SULAMYD				
+ SCHERING	10% **	N005963	001	
+	30% **	N005963	003	
SODIUM SULFACETAMIDE				
AKORN	10%	A083021	001	
	15%	A083021	002	
	30%	A083021	003	
SOLA BARNES HIND	10%	A084143	001	
	10%	A084145	001	
	30%	A084146	001	
	30%	A084147	001	
SULF-10				
NOVARTIS	10%	A080025	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

SULFACETAMIDE SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
SULF-15				
NOVARTIS	15%		A089047 001	Oct 31, 1995
SULFACEL-15				
OPTOPICS	15%		A080024 001	
SULFACETAMIDE SODIUM				
AKORN	30%		A040216 001	May 25, 1999
ALCON PHARMS LTD	30%		A089068 001	May 05, 1987
PHARMAFAIR	10%		A088947 001	May 17, 1985
SULFAIR 10				
PHARMAFAIR	10%		A087949 001	Dec 13, 1982
SULFAIR FORTE				
PHARMAFAIR	30%		A088385 001	Oct 13, 1983
SULFAIR-15				
PHARMAFAIR	15%		A088186 001	May 25, 1983
SULTEN-10				
BAUSCH AND LOMB	10%		A087818 001	Feb 03, 1983
SULFACYTINE				
TABLET;ORAL				
RENOQUID				
GLENWOOD	250MG		N017569 001	
SULFADIAZINE				
TABLET;ORAL				
SULFADIAZINE				
ABBVIE	300MG		N004125 005	
EVERYLIFE	500MG		A080088 001	
IMPAX LABS	500MG		A080081 001	
LANNETT	500MG		A080084 001	
LEDERLE	500MG		N004054 001	
+ LILLY	500MG		N004122 002	
SULFADIAZINE SODIUM				
INJECTABLE;INJECTION				
SULFADIAZINE SODIUM				
LEDERLE	250MG/ML		N004054 002	
SULFADIAZINE; SULFAMERAZINE				
SUSPENSION;ORAL				
SULFONAMIDES DUPLEX				
LILLY	250MG/5ML;250MG/5ML		N006317 007	
SULFAMETER				
TABLET;ORAL				
SULLA				
BAYER HLTHCARE	500MG		N016000 002	
SULFAMETHIZOLE				
TABLET;ORAL				
MICROSUL				
FOREST PHARMS	1GM		A086012 001	
PROKLAR				
FOREST PHARMS	500MG		A080273 001	
THIOSULFIL				
WYETH AYERST	250MG		N008565 001	
	500MG		N008565 004	
SULFAMETHOXAZOLE				
SUSPENSION;ORAL				
GANTANOL				
ROCHE	500MG/5ML		N013664 002	
TABLET;ORAL				
GANTANOL				
ROCHE	500MG		N012715 002	
GANTANOL-DS				
ROCHE	1GM		N012715 003	
SULFAMETHOXAZOLE				
ASCOT	500MG		A087662 001	Oct 20, 1982
AUROLIFE PHARMA LLC	500MG		A085844 001	
BARR	500MG		A087189 001	Jul 25, 1983
HEATHER	500MG		A086163 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

SULFAMETHOXAZOLE				
TABLET;ORAL				
SULFAMETHOXAZOLE				
WATSON LABS	500MG	A085053	001	
	1GM	A086000	001	
UROBAK				
SHIONOGI	500MG	A087307	001	
SULFAMETHOXAZOLE; TRIMETHOPRIM				
INJECTABLE;INJECTION				
BACTRIM				
+ SUN PHARM INDS INC	80MG/ML;16MG/ML **	N018374	001	
SEPTRA				
MONARCH PHARMS	80MG/ML;16MG/ML **	N018452	001	
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
ABRAXIS PHARM	80MG/ML;16MG/ML	A070223	001	Dec 29, 1987
BEDFORD	80MG/ML;16MG/ML	A072383	001	Apr 29, 1992
HOSPIRA	80MG/ML;16MG/ML	A073199	001	Sep 11, 1992
TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991
WATSON LABS	80MG/ML;16MG/ML	A071556	001	Dec 29, 1987
WEST-WARD PHARMS INT	80MG/ML;16MG/ML	A070627	001	Dec 29, 1987
	80MG/ML;16MG/ML	A070628	001	Dec 29, 1987
SUSPENSION;ORAL				
BACTRIM				
+ SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **	N017560	001	
BACTRIM PEDIATRIC				
SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **	N017560	002	
SEPTRA				
MONARCH PHARMS	200MG/5ML;40MG/5ML **	N017598	001	
SEPTRA GRAPE				
MONARCH PHARMS	200MG/5ML;40MG/5ML **	N017598	002	Feb 12, 1986
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
ANI PHARMS INC	200MG/5ML;40MG/5ML	A070028	001	Jun 02, 1987
TEVA	200MG/5ML;40MG/5ML	N018812	001	Jan 28, 1983
	200MG/5ML;40MG/5ML	N018812	002	Jun 10, 1983
SULFATRIM				
PHARM ASSOC	200MG/5ML;40MG/5ML	N018615	002	Jan 07, 1983
SULMEPRIM				
USL PHARMA	200MG/5ML;40MG/5ML	A070063	001	Aug 01, 1986
SULMEPRIM PEDIATRIC				
USL PHARMA	200MG/5ML;40MG/5ML	A070064	001	Aug 01, 1986
TRIMETH/SULFA				
ALPHARMA US PHARMS	200MG/5ML;40MG/5ML	A072289	001	May 23, 1988
	200MG/5ML;40MG/5ML	A072398	001	May 23, 1988
NASKA	200MG/5ML;40MG/5ML	A072399	001	May 23, 1988
TABLET;ORAL				
COTRIM				
TEVA	400MG;80MG	A070034	001	May 16, 1985
COTRIM D.S.				
TEVA	800MG;160MG	A070048	001	Mar 18, 1985
SULFAMETHOPRIM				
NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985
SULFAMETHOPRIM-DS				
NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
FOSUN PHARMA	400MG;80MG	A070889	001	Nov 13, 1986
	400MG;80MG	N018598	003	May 19, 1982
	800MG;160MG	A070890	001	Nov 13, 1986
HEATHER	400MG;80MG	N018946	001	Aug 10, 1984
	800MG;160MG	N018946	002	Aug 10, 1984
INTERPHARM	400MG;80MG	A071299	001	Oct 27, 1987
	800MG;160MG	A071300	001	Oct 27, 1987
MARTEC USA LLC	400MG;80MG	A072408	001	Dec 07, 1988
MUTUAL PHARM	400MG;80MG	A070006	001	Nov 14, 1984
PLIVA	400MG;80MG	A070215	001	Sep 10, 1985
	800MG;160MG	A070216	001	Sep 10, 1985
ROXANE	400MG;80MG	A072768	001	Aug 30, 1991
TEVA	400MG;80MG	N018242	001	
	800MG;160MG	N018242	002	
USL PHARMA	400MG;80MG	A070203	001	Nov 08, 1985

SULFAMETHOXAZOLE; TRIMETHOPRIM				
TABLET;ORAL				
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
	800MG;160MG	A070204	001	Nov 08, 1985
WATSON LABS	400MG;80MG	A070002	001	Nov 07, 1984
	400MG;80MG	N018852	001	May 09, 1983
	800MG;160MG	A070000	001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH				
FOSUN PHARMA	800MG;160MG	N018598	004	May 19, 1982
HERITAGE PHARMA	800MG;160MG	A070037	001	Jun 02, 1987
MARTEC USA LLC	800MG;160MG	A072417	001	Dec 07, 1988
MUTUAL PHARM	800MG;160MG	A070007	001	Nov 14, 1984
ROXANE	800MG;160MG	A072769	001	Aug 30, 1991
WATSON LABS	800MG;160MG	N018854	001	May 09, 1983
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH				
HERITAGE PHARMA	400MG;80MG	A070030	001	Jun 02, 1987
SULFATRIM-DS				
SUPERPHARM	800MG;160MG	A070066	001	Jun 24, 1985
SULFATRIM-SS				
SUPERPHARM	400MG;80MG	A070065	002	Jun 24, 1985
UROPLUS DS				
SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS				
SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987
SULFANILAMIDE				
CREAM;VAGINAL				
SULFANILAMIDE				
ACP NIMBLE	15%	A088718	001	Sep 19, 1985
SUPPOSITORY;VAGINAL				
AVC				
MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987
SULFAPHENAZOLE				
SUSPENSION;ORAL				
SULFABID				
PHARM RES ASSOC	500MG/5ML	N013093	001	
TABLET;ORAL				
SULFABID				
PURDUE FREDERICK	500MG	N013092	002	
SULFAPYRIDINE				
TABLET;ORAL				
SULFAPYRIDINE				
LILLY	500MG	N000159	001	
SULFASALAZINE				
SUSPENSION;ORAL				
AZULFIDINE				
PHARMACIA AND UPJOHN	250MG/5ML	N018605	001	
TABLET;ORAL				
S.A.S.-500				
SOLVAY	500MG	A083450	001	
SULFASALAZINE				
HERITAGE PHARMS INC	500MG	A080197	001	
SANDOZ	500MG	A086184	001	
SUN PHARM INDUSTRIES	500MG	A089590	001	Oct 19, 1987
SUPERPHARM	500MG	A089339	001	Oct 26, 1987
WATSON LABS	500MG	A084964	001	
	500MG	A087197	001	
TABLET, DELAYED RELEASE;ORAL				
SULFASALAZINE				
WATSON LABS	500MG	A088052	001	May 24, 1983
SULFINPYRAZONE				
CAPSULE;ORAL				
ANTURANE				
+ NOVARTIS	200MG **	N011556	004	
SULFINPYRAZONE				
BARR	200MG	A087666	001	Sep 17, 1982
IVAX PHARMS	200MG	A087770	001	Nov 19, 1982
PAR PHARM	200MG	A088934	001	Sep 06, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFINPYRAZONE				
CAPSULE;ORAL				
SULFINPYRAZONE				
VANGARD	200MG		A088666 001	Feb 17, 1984
TABLET;ORAL				
ANTURANE				
NOVARTIS	100MG **		N011556 003	
SULFINPYRAZONE				
BARR	100MG		A087665 001	Sep 17, 1982
IVAX PHARMS	100MG		A087769 001	Jun 01, 1982
PAR PHARM	100MG		A088933 001	Sep 06, 1985
WATSON LABS	100MG		A087667 001	May 26, 1982
SULFISOXAZOLE				
TABLET;ORAL				
GANTRISIN				
ROCHE	500MG		N006525 001	
SOSOL				
MK LABS	500MG		A080036 001	
SOXAZOLE				
ALRA	500MG		A080366 001	
SULFALAR				
PARKE DAVIS	500MG		A084955 001	
SULFISOXAZOLE				
ANI PHARMS INC	500MG		A080142 001	
AUROLIFE PHARMA LLC	500MG		A085628 001	
BARR	500MG		A084031 001	
HEATHER	500MG		A080189 001	
IMPAX LABS	500MG		A080109 001	
LANNETT	500MG		A080085 001	
LEDERLE	500MG		A087649 001	
PHARMERAL	500MG		A084385 001	
PUREPAC PHARM	500MG		A080087 001	
ROXANE	500MG		A080082 001	
VALEANT PHARM INTL	500MG		A080268 002	
VITARINE	500MG		A087332 001	
WATSON LABS	500MG		A085534 001	
WEST WARD	500MG		A080379 001	
SULSOXIN				
SOLVAY	500MG		A080040 001	
SULFISOXAZOLE ACETYL				
EMULSION;ORAL				
LIPO GANTRISIN				
ROCHE	EQ 1GM BASE/5ML		N009182 009	
SUSPENSION;ORAL				
GANTRISIN PEDIATRIC				
ROCHE	EQ 500MG BASE/5ML		N009182 004	
SYRUP;ORAL				
GANTRISIN				
ROCHE	EQ 500MG BASE/5ML		N009182 002	
SULFISOXAZOLE DIOLAMINE				
INJECTABLE;INJECTION				
GANTRISIN				
ROCHE	EQ 400MG BASE/ML		N006917 001	
OINTMENT;OPHTHALMIC				
GANTRISIN				
ROCHE	EQ 4% BASE		N008414 002	
SOLUTION/DROPS;OPHTHALMIC				
GANTRISIN				
ROCHE	EQ 4% BASE		N007757 002	
SULFISOXAZOLE DIOLAMINE				
SOLA BARNES HIND	EQ 4% BASE		A084148 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFOXONE SODIUM				
TABLET, DELAYED RELEASE;ORAL				
DIASONE SODIUM				
ABBVIE	165MG	N006044	003	
SULFUR				
POWDER;TOPICAL				
BENSULFOID				
POYTHRESS	33.32%	N002918	001	
SULINDAC				
TABLET;ORAL				
CLINORIL				
+ MERCK	150MG **	N017911	001	
+	200MG **	N017911	002	
SULINDAC				
ANI PHARMS INC	150MG	A072972	001	Feb 28, 1992
	200MG	A072973	001	Feb 28, 1992
EPIC PHARMA LLC	150MG	A073262	002	Sep 06, 1991
	200MG	A073262	001	Sep 06, 1991
FOSUN PHARMA	150MG	A072712	001	Aug 30, 1991
	200MG	A072713	001	Aug 30, 1991
SUMATRIPTAN				
SPRAY;NASAL				
IMITREX				
GLAXOSMITHKLINE	10MG/SPRAY	N020626	002	Aug 26, 1997
SUMATRIPTAN SUCCINATE				
INJECTABLE;SUBCUTANEOUS				
ALSUMA				
MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010
SUMATRIPTAN SUCCINATE				
FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079240	002	Sep 18, 2009
	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A079240	001	Sep 18, 2009
MYLAN LABS LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014
PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009
SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009
TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318	001	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318	002	Feb 06, 2009
TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009
ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010
SUMAVEL DOSEPRO				
+ ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013
+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009
SYSTEM;IONTOPHORESIS				
ZECUITY				
+ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013
TABLET;ORAL				
SUMATRIPTAN SUCCINATE				
FOSUN PHARMA	EQ 25MG BASE	A076976	001	Aug 10, 2009
	EQ 50MG BASE	A076976	002	Aug 10, 2009
	EQ 100MG BASE	A076976	003	Aug 10, 2009
HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013
	EQ 50MG BASE	A078298	002	May 21, 2013
	EQ 100MG BASE	A078298	003	May 21, 2013
MYLAN	EQ 25MG BASE	A077163	001	Nov 02, 2009
	EQ 50MG BASE	A077163	002	Nov 02, 2009
	EQ 100MG BASE	A077163	003	Nov 02, 2009
ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009
	EQ 50MG BASE	A078241	002	Aug 10, 2009
	EQ 100MG BASE	A078241	003	Aug 10, 2009
TEVA	EQ 25MG BASE	A076840	001	Feb 09, 2009
	EQ 50MG BASE	A076840	002	Feb 09, 2009
	EQ 100MG BASE	A076840	003	Feb 09, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SUPROFEN				
SOLUTION/DROPS;OPHTHALMIC				
PROFENAL				
ALCON	1%	N019387	001	Dec 23, 1988
SUTILAINS				
OINTMENT;TOPICAL				
TRAVASE				
+ ABBOTT	82,000 UNITS/GM **	N012828	001	
TACRINE HYDROCHLORIDE				
CAPSULE;ORAL				
COGNEX				
SHIONOGI INC	EQ 10MG BASE	N020070	001	Sep 09, 1993
	EQ 20MG BASE	N020070	002	Sep 09, 1993
	EQ 30MG BASE	N020070	003	Sep 09, 1993
	EQ 40MG BASE	N020070	004	Sep 09, 1993
TACROLIMUS				
CAPSULE;ORAL				
TACROLIMUS				
HERITAGE PHARMA	EQ 5MG BASE	A090402	001	Jul 01, 2010
TADALAFIL				
TABLET;ORAL				
TADALAFIL				
WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019
	5MG	A205885	002	Mar 29, 2019
	10MG	A205885	003	Mar 29, 2019
	20MG	A205885	004	Mar 29, 2019
TALBUTAL				
TABLET;ORAL				
LOTUSATE				
SANOFI AVENTIS US	120MG	N009410	005	
TAMOXIFEN CITRATE				
TABLET;ORAL				
NOLVADEX				
+ ASTRAZENECA	EQ 10MG BASE **	N017970	001	
+	EQ 20MG BASE **	N017970	002	Mar 21, 1994
TAMOXIFEN CITRATE				
ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003
	EQ 20MG BASE	A076179	002	Feb 20, 2003
AEGIS PHARMS	EQ 10MG BASE	A076398	001	Mar 31, 2003
	EQ 20MG BASE	A076398	002	Mar 31, 2003
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075740	001	Feb 20, 2003
	EQ 20MG BASE	A075740	002	Feb 20, 2003
PHARMACHEMIE	EQ 10MG BASE	A074539	001	Mar 31, 2003
ROXANE	EQ 10MG BASE	A076027	001	Feb 20, 2003
	EQ 20MG BASE	A076027	002	Feb 20, 2003
TEVA	EQ 10MG BASE	A074504	001	Apr 28, 2003
	EQ 20MG BASE	A074504	002	Apr 28, 2003
TAMSULOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
TAMSULOSIN HYDROCHLORIDE				
MYLAN	0.4MG	A090408	001	Apr 27, 2010
TAPENTADOL HYDROCHLORIDE				
SOLUTION;ORAL				
NUCYNTA				
+ ASSERTIO	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012
TAZAROTENE				
CREAM;TOPICAL				
TAZAROTENE				
FOUGERA PHARMS INC	0.1%	A211175	001	Jan 28, 2019

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE;INJECTION

TC 99M-LUNGAGGREGATE

GE HEALTHCARE	5mCi/ML	N017848	001	

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS	N/A	N017916	001	

AN-MAA

PHARMALUCENCE	N/A	N017792	001	

LUNGAGGREGATE REAGENT

GE HEALTHCARE	N/A	N017838	001	

MACROTEC

BRACCO	N/A	N017833	001	

PULMOLITE

+ JUBILANT DRAXIMAGE	N/A	N017776	001	

TECHNESCAN MAA

MALLINCKRODT	N/A	N017842	001	

TECHNETIUM TC 99M MAA

GE HEALTHCARE	N/A	N017773	001	

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE;INJECTION

MICROLITE

PHARMALUCENCE	N/A	N018263	001	Mar 25, 1983

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE;INJECTION

TECHNETIUM TC 99M HSA

GE HEALTHCARE	N/A	N017775	001	

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE;INJECTION

INSTANT MICROSPHERES

3M	N/A	N017832	001	

TECHNETIUM TC-99M APCITIDE

INJECTABLE;INJECTION

ACUTECT

CIS BIO INTL SA	N/A	N020887	001	Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE;INJECTION

NEO TECT KIT

CIS BIO INTL SA	N/A	N021012	001	Aug 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE;INJECTION

HEPATOLITE

PHARMALUCENCE	N/A	N018467	001	Mar 16, 1982

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE;INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE	N/A	N017653	001	

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE	N/A	N017667	001	

OSTEOSCAN

MALLINCKRODT	N/A	N017454	001	

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE	N/A	N017562	001	

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE;INJECTION

RENOTEC

BRACCO	N/A	N017045	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M GLUCEPTATE KIT				
INJECTABLE;INJECTION				
GLUCOSCAN				
	BRISTOL MYERS SQUIBB	N/A	N017907 001	
TECHNESCAN GLUCEPTATE				
	DRAXIMAGE	N/A	N018272 001	Jan 27, 1982
TECHNETIUM TC-99M LIDOFENIN KIT				
INJECTABLE;INJECTION				
TECHNESCAN HIDA				
	DRAXIMAGE	N/A	N018489 001	Oct 31, 1986
TECHNETIUM TC-99M MEDRONATE				
INJECTABLE;INJECTION				
DRAXIMAGE MDP-10				
	JUBILANT DRAXIMAGE	N/A	N018035 001	
TECHNETIUM TC-99M MEDRONATE KIT				
INJECTABLE;INJECTION				
AMERSCAN MDP KIT				
	GE HEALTHCARE	N/A	N018335 001	Aug 05, 1982
MDP-BRACCO				
	CARDINAL HEALTH 414	N/A	N018107 001	
OSTEOLITE				
	PHARMALUCENCE	N/A	N017972 001	
TECHNETIUM TC 99M MPI MDP				
	GE HEALTHCARE	N/A	N018141 001	
		N/A	N018141 002	Jun 12, 1989
TECHNETIUM TC-99M PENTETATE KIT				
INJECTABLE;INJECTION				
AN-DTPA				
	JUBILANT DRAXIMAGE	N/A	N017714 001	
MPI DTPA KIT - CHELATE				
	GE HEALTHCARE	N/A	N017255 001	
TECHNETIUM TC-99M PENTETATE KIT				
	GE HEALTHCARE	N/A	N017264 002	
TECHNETIUM TC-99M POLYPHOSPHATE KIT				
INJECTABLE;INJECTION				
SODIUM POLYPHOSPHATE-TIN KIT				
	GE HEALTHCARE	N/A	N017664 001	
TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT				
INJECTABLE;INJECTION				
PYROLITE				
	PHARMALUCENCE	N/A	N017684 001	
TECHNETIUM TC-99M PYROPHOSPHATE KIT				
INJECTABLE;INJECTION				
PHOSPHOTEC				
	BRACCO	N/A	N017680 001	
TECHNETIUM TC-99M RED BLOOD CELL KIT				
INJECTABLE;INJECTION				
RBC-SCAN				
	CADEMA	N/A	N020063 001	Jun 11, 1992
TECHNETIUM TC-99M SESTAMIBI KIT				
INJECTABLE;INJECTION				
MIRALUMA				
	LANTHEUS MEDCL	N/A	N019785 003	May 23, 1997
TECHNETIUM TC-99M SODIUM PERTECHNETATE				
SOLUTION;INJECTION, ORAL				
SODIUM PERTECHNETATE TC 99M				
+	GE HEALTHCARE	2-100mCi/ML **	N017471 001	
+	MALLINCKRODT	10-60mCi/ML **	N017725 001	
	PHARMALUCENCE	12mCi/ML	N017321 001	
		24mCi/ML	N017321 002	
		48mCi/ML	N017321 003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR				
SOLUTION;INJECTION, ORAL				
MINITEC				
	BRACCO	0.22-2.22 CI/GENERATOR	N017339 001	
SOLUTION;INTRAVENOUS				
TECHNELITE				
	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771 001	
ULTRA-TECHNEKOW FM				
	CURIUM	0.25-3 CI/GENERATOR	N017243 002	
SOLUTION;INTRAVENOUS, ORAL				
TECHNETIUM TC 99M GENERATOR				
+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693 002	Dec 13, 2013
		830-16600mCi/GENERATOR	N017693 001	
TECHNETIUM TC-99M SUCCIMER KIT				
INJECTABLE;INJECTION				
MPI DMSA KIDNEY REAGENT				
	GE HEALTHCARE	N/A	N017944 001	May 18, 1982
TECHNETIUM TC-99M SULFUR COLLOID				
SOLUTION;INJECTION, ORAL				
TECHNETIUM TC 99M SULFUR COLLOID				
	GE HEALTHCARE	4mCi/ML	N017456 001	
SOLUTION;ORAL				
TECHNETIUM TC 99M SULFUR COLLOID				
	MALLINCKRODT	3mCi/ML	N017724 001	
TECHNETIUM TC-99M SULFUR COLLOID KIT				
SOLUTION;INJECTION, ORAL				
TECHNECOLL				
	MALLINCKRODT	N/A	N017059 001	
TECHNETIUM TC 99M TSC				
	GE HEALTHCARE	N/A	N017784 001	
TESULOID				
	BRACCO	N/A	N016923 001	
TECHNETIUM TC-99M TEBOROXIME KIT				
INJECTABLE;INJECTION				
CARDIOTEC				
	BRACCO	N/A	N019928 001	Dec 19, 1990
TECHNETIUM TC-99M TETROFOSMIN KIT				
INJECTABLE;INJECTION				
MYOVIEW				
+	GE HEALTHCARE	N/A	N020372 001	Feb 09, 1996
TEGASEROD MALEATE				
TABLET;ORAL				
ZELNORM				
+	ALFASIGMA	EQ 2MG BASE	N021200 001	Jul 24, 2002
TELAPREVIR				
TABLET;ORAL				
INCIVEK				
	VERTEX PHARMS	375MG	N201917 001	May 23, 2011
TELAVANCIN HYDROCHLORIDE				
POWDER;INTRAVENOUS				
VIBATIV				
+	CUMBERLAND PHARMS	EQ 250MG BASE/VIAL	N022110 001	Sep 11, 2009
TELBIVUDINE				
SOLUTION;ORAL				
TYZEKA				
	NOVARTIS	100MG/5ML	N022154 001	Apr 28, 2009
TABLET;ORAL				
TYZEKA				
+	NOVARTIS	600MG	N022011 001	Oct 25, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TELITHROMYCIN					
TABLET;ORAL					
KETEK					
	SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005
		400MG	N021144	001	Apr 01, 2004
TELMISARTAN					
TABLET;ORAL					
TELMISARTAN					
	CIPLA	20MG	A078710	001	Jan 08, 2014
		40MG	A078710	002	Jan 08, 2014
		80MG	A078710	003	Jan 08, 2014
	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019
		40MG	A207843	002	Feb 19, 2019
		80MG	A207843	003	Feb 19, 2019
	MICRO LABS	20MG	A207016	001	Oct 03, 2017
		40MG	A207016	002	Oct 03, 2017
		80MG	A207016	003	Oct 03, 2017
TEMAZEPAM					
CAPSULE;ORAL					
TEMAZ					
	QUANTUM PHARMICS	15MG	A070564	001	Oct 15, 1985
		30MG	A070547	001	Oct 15, 1985
TEMAZEPAM					
	DURAMED PHARMS BARR	15MG	A071708	001	Sep 29, 1988
		30MG	A071709	001	Sep 29, 1988
	SUN PHARM INDUSTRIES	15MG	A071174	001	Jul 10, 1986
		30MG	A071175	001	Jul 10, 1986
	USL PHARMA	15MG	A070489	001	Jul 07, 1986
		30MG	A070490	001	Jul 07, 1986
	WATSON LABS	15MG	A070383	001	Mar 23, 1987
		15MG	A071446	001	May 21, 1993
		30MG	A070384	001	Mar 23, 1987
		30MG	A071447	001	May 21, 1993
TEMOZOLOMIDE					
CAPSULE;ORAL					
TEMOZOLOMIDE					
	APOTEX INC	5MG	A204159	001	Jul 05, 2018
		20MG	A204159	002	Jul 05, 2018
		100MG	A204159	003	Jul 05, 2018
		140MG	A204159	004	Jul 05, 2018
		180MG	A204159	005	Jul 05, 2018
		250MG	A204159	006	Jul 05, 2018
	LANNETT CO INC	5MG	A203898	001	Feb 10, 2016
		20MG	A203898	002	Feb 10, 2016
		100MG	A203898	003	Feb 10, 2016
		140MG	A203898	004	Feb 10, 2016
		180MG	A203898	005	Feb 10, 2016
		250MG	A203898	006	Feb 10, 2016
	MYLAN	5MG	A205227	001	Jun 29, 2016
		20MG	A205227	002	Jun 29, 2016
		100MG	A205227	003	Jun 29, 2016
		140MG	A205227	004	Jun 29, 2016
		180MG	A205227	005	Jun 29, 2016
		250MG	A205227	006	Jun 29, 2016
TENIPOSIDE					
INJECTABLE;INJECTION					
VUMON					
+	HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992
TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
TENOFOVIR DISOPROXIL FUMARATE					
	CHARTWELL	300MG	A206481	001	Jul 26, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TERAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
HYTRIN				
+ ABBOTT	EQ 1MG BASE **	N020347	001	Dec 14, 1994
+	EQ 2MG BASE **	N020347	002	Dec 14, 1994
+	EQ 5MG BASE **	N020347	003	Dec 14, 1994
+	EQ 10MG BASE **	N020347	004	Dec 14, 1994
TERAZOSIN HYDROCHLORIDE				
BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000
	EQ 2MG BASE	A075667	002	Jul 28, 2000
	EQ 5MG BASE	A075667	003	Jul 28, 2000
	EQ 10MG BASE	A075667	004	Jul 28, 2000
MYLAN TECHNOLOGIES	EQ 1MG BASE	A075384	001	Dec 01, 2000
	EQ 2MG BASE	A075384	002	Dec 01, 2000
	EQ 5MG BASE	A075384	003	Dec 01, 2000
	EQ 10MG BASE	A075384	004	Dec 01, 2000
RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002
	EQ 2MG BASE	A076021	002	Aug 22, 2002
	EQ 5MG BASE	A076021	003	Aug 22, 2002
	EQ 10MG BASE	A076021	004	Aug 22, 2002
TABLET;ORAL				
HYTRIN				
ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987
	EQ 2MG BASE	N019057	002	Aug 07, 1987
	EQ 5MG BASE	N019057	003	Aug 07, 1987
	EQ 10MG BASE	N019057	004	Aug 07, 1987
TERAZOSIN HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530	001	Apr 21, 2000
	EQ 2MG BASE	A074530	002	Apr 21, 2000
	EQ 5MG BASE	A074530	003	Apr 21, 2000
	EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315	001	Dec 31, 1998
	EQ 1MG BASE	A074657	001	Apr 28, 2000
	EQ 2MG BASE	A074315	002	Dec 31, 1998
	EQ 2MG BASE	A074657	002	Apr 28, 2000
	EQ 5MG BASE	A074315	003	Dec 31, 1998
	EQ 5MG BASE	A074657	003	Apr 28, 2000
	EQ 10MG BASE	A074315	004	Dec 31, 1998
	EQ 10MG BASE	A074657	004	Apr 28, 2000
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000
TERBINAFINE				
GEL;TOPICAL				
LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998
TERBINAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
LAMISIL				
NOVARTIS	1%	N020192	001	Dec 30, 1992
GRANULE;ORAL				
LAMISIL				
+ NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007
+	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007
SOLUTION;TOPICAL				
LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997
TABLET;ORAL				
TERBINAFINE HYDROCHLORIDE				
CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007
GEDEON RICHTER USA	EQ 250MG BASE	A077065	001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007
	EQ 250MG BASE	A077195	001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007
WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007

TERBUTALINE SULFATE				
AEROSOL, METERED;INHALATION				
BRETHAIRE				
NOVARTIS	0.2MG/INH	N018762	001	Aug 17, 1984
BRICANYL				
SANOFI AVENTIS US	0.2MG/INH	N018000	001	Mar 19, 1985
INJECTABLE;INJECTION				
BRETHINE				
+ PHARMACARE	1MG/ML **	N018571	001	
BRICANYL				
SANOFI AVENTIS US	1MG/ML	N017466	001	
TERBUTALINE SULFATE				
DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004
TABLET;ORAL				
BRICANYL				
SANOFI AVENTIS US	2.5MG	N017618	001	
	5MG	N017618	002	
TERCONAZOLE				
CREAM;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	0.8%	N019964	001	Feb 21, 1991
TERAZOL 7				
+ JANSSEN PHARMS	0.4%	N019579	001	Dec 31, 1987
SUPPOSITORY;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	80MG	N019641	001	May 24, 1988
TERCONAZOLE				
FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006
TERIFLUNOMIDE				
TABLET;ORAL				
TERIFLUNOMIDE				
AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018
	14MG	A209613	002	Sep 28, 2018
APOTEX	7MG	A209601	001	Nov 02, 2018
	14MG	A209601	002	Nov 02, 2018
AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018
	14MG	A209638	002	Oct 26, 2018
MSN	7MG	A209623	001	Apr 24, 2019
	14MG	A209623	002	Apr 24, 2019
TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018
	14MG	A209700	002	Sep 04, 2018
WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018
	14MG	A209549	002	Jul 27, 2018
ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018
	14MG	A209668	002	Nov 30, 2018
TERIPARATIDE ACETATE				
INJECTABLE;INJECTION				
PARATHAR				
SANOFI AVENTIS US	200 UNITS/VIAL	N019498	001	Dec 23, 1987
TERIPARATIDE RECOMBINANT HUMAN				
INJECTABLE;SUBCUTANEOUS				
FORTEO				
LILLY	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002
TESTOLACTONE				
INJECTABLE;INJECTION				
TESLAC				
BRISTOL MYERS SQUIBB	100MG/ML	N016119	001	
TABLET;ORAL				
TESLAC				
BRISTOL MYERS SQUIBB	50MG	N016118	001	
	250MG	N016118	002	

TESTOSTERONE					
FILM, EXTENDED RELEASE;TRANSDERMAL					
ANDRODERM					
	ALLERGAN	2.5MG/24HR	N020489	001	Sep 29, 1995
		5MG/24HR	N020489	002	May 02, 1997
TESTODERM					
	ALZA	4MG/24HR	N019762	001	Oct 12, 1993
		6MG/24HR	N019762	002	Oct 12, 1993
TESTODERM TTS					
	ALZA	5MG/24HR	N020791	001	Dec 18, 1997
GEL;TRANSDERMAL					
TESTOSTERONE					
	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012
		50MG/5GM PACKET	N202763	002	Feb 14, 2012
	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007
	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013
		50MG/5GM PACKET	N203098	003	Jan 31, 2013
GEL, METERED;TRANSDERMAL					
TESTOSTERONE					
	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013
INJECTABLE;INJECTION					
TESTOSTERONE					
	DR REDDYS	100MG/ML	A086417	001	Jul 07, 1983
	WATSON LABS	25MG/ML	A086420	001	May 10, 1983
		50MG/ML	A086419	001	Aug 23, 1983
SOLUTION, METERED;TRANSDERMAL					
AXIRON					
+	ELI LILLY AND CO	30MG/1.5ML ACTUATION **	N022504	001	Nov 23, 2010
TABLET, EXTENDED RELEASE;BUCCAL					
STRIANT					
+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003
TESTOSTERONE CYPIONATE					
INJECTABLE;INJECTION					
DEPO-TESTOSTERONE					
	PHARMACIA AND UPJOHN	50MG/ML	A085635	001	
TESTOSTERONE CYPIONATE					
	MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006
	WATSON LABS	100MG/ML	A084401	001	
		100MG/ML	A086029	001	
		200MG/ML	A084401	002	
TESTOSTERONE ENANTHATE					
INJECTABLE;INJECTION					
DELATESTRYL					
	ENDO PHARMS	200MG/ML	N009165	001	
+		200MG/ML	N009165	003	
TESTOSTERONE ENANTHATE					
	MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009
	WATSON LABS	100MG/ML	A083667	001	
		100MG/ML	A085599	001	
		200MG/ML	A083667	002	
TESTOSTERONE PROPIONATE					
INJECTABLE;INJECTION					
TESTOSTERONE PROPIONATE					
	BEL MAR	25MG/ML	A080741	001	
		50MG/ML	A080742	001	
		100MG/ML	A080743	001	
	ELKINS SINN	25MG/ML	A080276	001	
	LILLY	50MG/ML	A080254	002	
	WATSON LABS	25MG/ML	A080188	001	
		25MG/ML	A085490	001	
		50MG/ML	A080188	002	
		50MG/ML	A085490	002	
		100MG/ML	A080188	003	
		100MG/ML	A083595	003	

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BRISTACYCLINE				
	BRISTOL	250MG	A061658 001	
		250MG	A061888 001	
		500MG	A061658 002	
		500MG	A061888 002	
CYCLOPAR				
	WARNER CHILCOTT	250MG	A061725 001	
		250MG	A062175 001	
		250MG	A062332 001	
		500MG	A061725 002	
		500MG	A062332 002	
PANMYCIN				
	PHARMACIA AND UPJOHN	250MG	A060347 001	
RETET				
	SOLVAY	250MG	A061443 001	
		500MG	A061443 002	
ROBITET				
	WYETH AYERST	250MG	A061734 001	
		500MG	A061734 002	
SUMYCIN				
	APOTHECON	100MG	A060429 002	
		125MG	A060429 004	
		250MG	A060429 001	
		500MG	A060429 003	
TETRACHEL				
	ANGUS	250MG	A060343 001	
		500MG	A060343 003	
TETRACYCLINE HYDROCHLORIDE				
	ABBOTT	250MG	A061802 001	
		500MG	A061802 002	
	ANI PHARMS INC	250MG	A061471 001	
	ELKINS SINN	250MG	A060059 001	
	FERRANTE	125MG	A060173 001	
		250MG	A060173 002	
	HEATHER	250MG	A061148 001	
		500MG	A061148 002	
	HIKMA PHARMS	250MG	A060768 001	
		500MG	A060768 002	
	IMPAX LABS	100MG	A060469 002	
		250MG	A060469 001	
		500MG	A060469 003	
	IVAX SUB TEVA PHARMS	250MG	A060704 001	
		500MG	A060704 002	
	MAST MM	250MG	A062085 001	
	MYLAN	250MG	A060783 001	
		500MG	A060783 002	
	PUREPAC PHARM	250MG	A060290 001	
		500MG	A060290 002	
	PVT FORM	250MG	A062686 001	Jul 24, 1986
		500MG	A062686 002	Jul 24, 1986
	ROXANE	500MG	A061214 002	
	SUN PHARM INDUSTRIES	250MG	A060736 001	
		500MG	A060736 002	
	SUPERPHARM	250MG	A062540 001	Mar 21, 1985
		500MG	A062540 002	Mar 21, 1985
	VALEANT PHARM INTL	250MG	A060471 001	
		500MG	A060471 002	
	WARNER CHILCOTT	250MG	A062300 001	
		500MG	A062300 002	
	WATSON LABS	250MG	A062103 001	
		250MG	A062343 001	
		500MG	A062103 002	
		500MG	A062343 002	
	WYETH AYERST	250MG	A061685 001	
		500MG	A061685 002	
TETRACYN				
	PFIPHARMECS	250MG	A060082 003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TETRACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
TETRACYN				
	500MG		A060082 004	
FIBER, EXTENDED RELEASE;PERIODONTAL				
ACTISITE				
SCHIFF AND CO	12.7MG/FIBER		N050653 001	Mar 25, 1994
FOR SOLUTION;TOPICAL				
TOPICYCLINE				
SHIRE	2.2MG/ML		N050493 001	
INJECTABLE;INJECTION				
ACHROMYCIN				
LEDERLE	250MG/VIAL		N050273 002	
	500MG/VIAL		N050273 003	
TETRACYN				
PFIZER	250MG/VIAL		A060096 001	
	500MG/VIAL		A060096 002	
OINTMENT;OPHTHALMIC				
ACHROMYCIN				
STORZ	10MG/GM		N050266 001	
SUSPENSION;ORAL				
ACHROMYCIN V				
LEDERLE	125MG/5ML		N050263 002	
SUMYCIN				
PAR PHARM	125MG/5ML		A060400 001	
TETRACYCLINE HYDROCHLORIDE				
ALPHARMA US PHARMS	125MG/5ML		A060633 001	
FERRANTE	125MG/5ML		A060174 001	
PROTER	125MG/5ML		A060446 001	
PUREPAC PHARM	125MG/5ML		A060291 001	
TETRACYN				
PFIPHARMECS	125MG/5ML		A060095 001	
TETRAMED				
IVAX SUB TEVA PHARMS	125MG/5ML		A061468 001	
SUSPENSION/DROPS;OPHTHALMIC				
ACHROMYCIN				
STORZ	1%		N050268 001	
TABLET;ORAL				
PANMYCIN				
PHARMACIA AND UPJOHN	250MG		A061705 001	
	500MG		A061705 002	
SUMYCIN				
PAR PHARM	50MG		A061147 003	
	100MG		A061147 002	
	250MG		A061147 001	
	500MG		A061147 004	
TETRACYCLINE PHOSPHATE COMPLEX				
CAPSULE;ORAL				
TETREX				
BRISTOL	EQ 100MG HYDROCHLORIDE		A061653 001	
	EQ 250MG HYDROCHLORIDE		A061653 002	
	EQ 250MG HYDROCHLORIDE		A061889 002	
	EQ 250MG HYDROCHLORIDE		N050212 002	
	EQ 500MG HYDROCHLORIDE		A061653 003	
	EQ 500MG HYDROCHLORIDE		A061889 001	
	EQ 500MG HYDROCHLORIDE		N050212 003	
THALLOUS CHLORIDE TL-201				
INJECTABLE;INJECTION				
THALLOUS CHLORIDE TL 201				
BRACCO	1mCi/ML		N018548 001	Dec 30, 1982
TRACE LIFE	1mCi/ML		A075569 001	Nov 21, 2001
INJECTABLE;INTRAVENOUS				
THALLOUS CHLORIDE TL 201				
+ LANTHEUS MEDCL	2mCi/ML		N017806 002	Oct 09, 1998
MALLINKRODT NUCLEAR	2mCi/ML		A077698 001	Nov 09, 2006

THEOPHYLLINE

CAPSULE;ORAL				
BRONKODYL				
SANOFI AVENTIS US	100MG	A085264	001	
	200MG	A085264	002	
ELIXOPHYLLIN				
FOREST LABS	100MG	A085545	001	Jul 31, 1984
	200MG	A083921	001	Jul 31, 1984
SOMOPHYLLIN-T				
FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985
THEOPHYLLINE				
KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
AEROLATE III				
FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
AEROLATE JR				
FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
AEROLATE SR				
FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
ELIXOPHYLLIN SR				
FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985
SLO-BID				
SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985
SLO-PHYLLIN				
SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982
SOMOPHYLLIN-CRT				
GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985
THEO-DUR				
SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985
THEOBID				
WHITBY	260MG	A085983	001	Mar 20, 1985
THEOBID JR.				
WHITBY	130MG	A087854	001	Mar 20, 1985
THEOCLEAR L.A.-130				
SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982
THEOCLEAR L.A.-260				
SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982
THEOPHYL-SR				
ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985
THEOPHYLLINE				
CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985
HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995
INWOOD LABS	100MG	A040052	001	Feb 14, 1994
	125MG	A040052	002	Feb 14, 1994

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE					
CAPSULE, EXTENDED RELEASE;ORAL					
THEOPHYLLINE					
	200MG		A040052	003	Feb 14, 1994
	300MG		A040052	004	Feb 14, 1994
SANDOZ	260MG		A087462	001	May 11, 1982
THEOPHYLLINE-SR					
SCHERER RP	300MG		A088255	001	Jun 12, 1986
THEOVENT					
SCHERING	125MG		A087010	001	Jan 31, 1985
	250MG		A087910	001	Jan 31, 1985
ELIXIR;ORAL					
ELIXOMIN					
CENCI	80MG/15ML		A088303	001	Jan 25, 1984
LANOPHYLLIN					
LANNETT	80MG/15ML		A084578	001	
THEOLIXIR					
PANRAY	80MG/15ML		A084559	001	
THEOPHYL-225					
ORTHO MCNEIL PHARM	112.5MG/15ML		A086485	001	
THEOPHYLLINE					
ALPHARMA US PHARMS	80MG/15ML		A089223	001	May 27, 1988
CENCI	80MG/15ML		A087679	001	Apr 15, 1982
CHARTWELL RX	80MG/15ML		A085952	001	
HALSEY	80MG/15ML		A085169	001	
PHARM ASSOC	80MG/15ML		A086720	001	
PRECISION DOSE	80MG/15ML		A085863	001	
ROXANE	80MG/15ML		A084739	001	
TARO	80MG/15ML		A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML		A086748	001	
INJECTABLE;INJECTION					
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	40MG/100ML		N019083	001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	80MG/100ML		N019083	002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	160MG/100ML		N019083	003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	200MG/100ML		N019212	001	Nov 07, 1984
	200MG/100ML		N019826	004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	4MG/ML		N019212	003	Nov 07, 1984
	400MG/100ML		N019212	002	Nov 07, 1984
	400MG/100ML		N019826	005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER					
BAXTER HLTHCARE	4MG/ML		N018649	007	Jul 26, 1982
	40MG/100ML		N018649	001	Jul 26, 1982
	80MG/100ML		N018649	002	Jul 26, 1982
	160MG/100ML		N018649	003	Jul 26, 1982
	200MG/100ML		N018649	004	Jul 26, 1982
	320MG/100ML		N018649	006	Nov 13, 1985
	400MG/100ML		N018649	005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER					
+ HOSPIRA INC	4MG/ML		N019211	007	Dec 14, 1984
+	40MG/100ML		N019211	001	Dec 14, 1984
	80MG/100ML		N019211	002	Dec 14, 1984
+	160MG/100ML		N019211	003	Dec 14, 1984
	200MG/100ML		N019211	004	Dec 14, 1984
+	320MG/100ML		N019211	006	Jan 20, 1988
	400MG/100ML		N019211	005	Dec 14, 1984
SOLUTION;ORAL					
AEROLATE					
FLEMING PHARMS	150MG/15ML		A089141	001	Dec 03, 1986
THEOLAIR					
3M	80MG/15ML		A086107	001	
THEOPHYLLINE					
ROXANE	80MG/15ML		A087449	001	Sep 15, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

THEOPHYLLINE

SUSPENSION;ORAL				
ELIXICON				
FOREST LABS	100MG/5ML	A085502	001	
SYRUP;ORAL				
ACCURBRON				
SANOFI AVENTIS US	150MG/15ML	A088746	001	Nov 22, 1985
AQUAPHYLLIN				
FERNDALE LABS	80MG/15ML	A087917	001	Jan 18, 1983
SLO-PHYLLIN				
SANOFI AVENTIS US	80MG/15ML	A085187	001	
THEOCLEAR-80				
CENT PHARMS	80MG/15ML	A087095	001	Mar 01, 1982
THEOPHYLLINE				
ALPHARMA US PHARMS	80MG/15ML	A086001	001	
	150MG/15ML	A086545	001	
TABLET;ORAL				
QUIBRON-T				
MONARCH PHARMS	300MG	A088656	001	Aug 22, 1985
SLO-PHYLLIN				
SANOFI AVENTIS US	100MG	A085202	001	
	200MG	A085204	001	
THEOCLEAR-100				
CENT PHARMS	100MG	A085353	002	
THEOCLEAR-200				
CENT PHARMS	200MG	A085353	001	
THEOLAIR				
MEDICIS	125MG	A086399	001	
	250MG	A086399	002	
THEOPHYL-225				
ORTHO MCNEIL PHARM	225MG	A084726	001	
TABLET, CHEWABLE;ORAL				
THEOPHYL				
ORTHO MCNEIL PHARM	100MG	A086506	001	Sep 12, 1985
TABLET, EXTENDED RELEASE;ORAL				
DURAPHYL				
FOREST LABS	100MG	A088503	001	Apr 03, 1985
	200MG	A088504	001	Apr 03, 1985
	300MG	A088505	001	Apr 03, 1985
LABID				
WARNER CHILCOTT	250MG	A087225	001	
QUIBRON-T/SR				
MONARCH PHARMS	300MG	A087563	001	Jun 21, 1983
SUSTAIRE				
ROERIG	100MG	A085665	001	
	300MG	A085665	002	
T-PHYL				
PHARM RES ASSOC	200MG	A088253	001	Aug 17, 1983
THEO-DUR				
SCHERING	100MG	A085328	001	
	200MG	A086998	001	
	300MG	A085328	002	
	450MG	A089131	001	Jun 25, 1986
THEOCHRON				
NOSTRUM PHARMS LLC	300MG	A087400	002	Jan 11, 1983
THEOLAIR-SR				
3M	200MG	A088369	001	Jul 16, 1987
	250MG	A086363	002	Jul 16, 1987
	300MG	A088364	001	Jul 16, 1987
	500MG	A089132	001	Jul 16, 1987
THEOPHYLLINE				
ABLE	300MG	A040548	001	Apr 30, 2004
	400MG	A040543	001	Apr 27, 2004
	450MG	A040546	001	Apr 30, 2004
	600MG	A040539	001	Apr 27, 2004
HERITAGE PHARMA	450MG	A081236	001	Nov 09, 1992
INWOOD LABS	450MG	A040034	001	Apr 28, 1995
UNI-DUR				
SCHERING	400MG	A089822	001	Jan 04, 1995

THEOPHYLLINE				
TABLET, EXTENDED RELEASE;ORAL				
UNI-DUR				
	600MG		A089823 001	Jan 04, 1995
THEOPHYLLINE SODIUM GLYCINATE				
ELIXIR;ORAL				
SYNOPHYLATE				
CENT PHARMS	EQ 165MG BASE/15ML		N006333 008	
TABLET;ORAL				
ASBRON				
NOVARTIS	EQ 150MG BASE		A085148 001	
THIABENDAZOLE				
SUSPENSION;ORAL				
MINTEZOL				
MERCK SHARP DOHME	500MG/5ML		N016097 001	
TABLET, CHEWABLE;ORAL				
MINTEZOL				
MERCK SHARP DOHME	500MG		N016096 001	
THIAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
BETALIN S				
LILLY	100MG/ML		A080853 001	
THIAMINE HYDROCHLORIDE				
ABRAXIS PHARM	100MG/ML		A080509 001	
AKORN	100MG/ML		A087968 001	Oct 01, 1982
BEL MAR	100MG/ML		A080718 001	
	200MG/ML		A080712 001	
DELL LABS	100MG/ML		A083775 001	
DR REDDYS	100MG/ML		A080571 001	
	200MG/ML		A080571 002	
HOSPIRA	100MG/ML		A040079 001	May 03, 1996
LUITPOLD	100MG/ML		A080667 001	
PARKE DAVIS	100MG/ML		A080770 001	
WATSON LABS	100MG/ML		A083534 001	
	200MG/ML		A083534 002	
WEST-WARD PHARMS INT	100MG/ML		A080575 001	
WYETH AYERST	100MG/ML		A080553 001	
THIAMYLAL SODIUM				
INJECTABLE;INJECTION				
SURITAL				
PARKEDALE	1GM/VIAL		N007600 003	
	5GM/VIAL		N007600 005	
	10GM/VIAL		N007600 009	
THIETHYLPERAZINE MALATE				
INJECTABLE;INJECTION				
TORECAN				
NOVARTIS	5MG/ML		N012754 002	
THIETHYLPERAZINE MALEATE				
SUPPOSITORY;RECTAL				
TORECAN				
NOVARTIS	10MG		N013247 001	
TABLET;ORAL				
TORECAN				
NOVARTIS	10MG		N012753 001	
THIOPENTAL SODIUM				
SUSPENSION;RECTAL				
PENTOTHAL				
ABBOTT	400MG/GM		N011679 001	
THIORIDAZINE				
SUSPENSION;ORAL				
MELLARIL-S				
NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML **		N017923 001	
	EQ 100MG HYDROCHLORIDE/5ML **		N017923 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL					
MELLARIL					
	NOVARTIS	30MG/ML **	N011808	012	
		100MG/ML **	N011808	018	
THIORIDAZINE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	100MG/ML	A088229	001	Aug 23, 1983
	ALPHARMA US PHARMS	30MG/ML	A087766	001	Apr 26, 1983
	ANI PHARMS INC	30MG/ML	A089602	001	Nov 09, 1987
		100MG/ML	A089603	001	Nov 09, 1987
	HI TECH PHARMA	30MG/ML	A040125	001	Aug 16, 1996
		100MG/ML	A040126	001	Aug 16, 1996
	PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997
		100MG/ML	A040213	001	May 29, 1998
	SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
		100MG/ML	A088308	001	Nov 23, 1983
	WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
		100MG/ML	A088227	001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE INTENSOL					
	ROXANE	30MG/ML	A088941	001	Dec 16, 1985
		100MG/ML	A088942	001	Dec 16, 1985
TABLET;ORAL					
MELLARIL					
+	NOVARTIS	10MG **	N011808	003	
+		15MG **	N011808	016	
+		25MG **	N011808	006	
+		50MG **	N011808	011	
+		100MG **	N011808	009	
+		150MG **	N011808	017	
+		200MG **	N011808	015	
THIORIDAZINE HYDROCHLORIDE					
	ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983
		10MG	A088493	001	May 17, 1985
		15MG	A088271	001	Apr 14, 1983
		25MG	A088272	001	Apr 14, 1983
		50MG	A088194	001	Apr 14, 1983
		100MG	A088273	001	Oct 03, 1983
		100MG	A088456	001	May 17, 1985
	FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983
		15MG	A088132	001	Aug 30, 1983
		25MG	A088133	001	Aug 30, 1983
		50MG	A088134	001	Aug 30, 1983
		100MG	A088135	001	Nov 20, 1984
		150MG	A088136	001	Sep 17, 1986
		200MG	A088137	001	Sep 17, 1986
	HERITAGE PHARMA	10MG	A088476	001	Nov 08, 1983
		25MG	A088478	001	Nov 08, 1983
		50MG	A088479	001	Nov 08, 1983
		100MG	A088736	001	Jul 24, 1984
	MUTUAL PHARM	10MG	A088375	001	Nov 18, 1983
		25MG	A087264	001	Nov 18, 1983
		50MG	A088370	001	Nov 18, 1983
		100MG	A088379	001	Nov 16, 1983
	MYLAN	10MG	A088332	001	Jun 27, 1983
		25MG	A088333	001	Jun 27, 1983
		50MG	A088334	001	Jun 27, 1983
		100MG	A088335	001	Nov 18, 1983
	PAR PHARM	10MG	A088351	001	Dec 05, 1983
		15MG	A088352	001	Dec 05, 1983
		25MG	A088336	001	Dec 05, 1983
		50MG	A088322	001	Dec 05, 1983
		100MG	A088480	001	Dec 29, 1983
		150MG	A089764	001	Feb 09, 1988
		200MG	A089765	001	Feb 09, 1988
	ROXANE	10MG	A088663	001	Mar 15, 1984
		25MG	A088664	001	Mar 15, 1984
		50MG	A088665	001	Mar 15, 1984
		100MG	A089048	001	Feb 26, 1985
	SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

THIORIDAZINE HYDROCHLORIDE					
TABLET;ORAL					
THIORIDAZINE HYDROCHLORIDE					
		15MG	A088461	001	Nov 18, 1983
		25MG	A089953	003	Aug 01, 1986
		50MG	A089953	002	Aug 01, 1986
		100MG	A089953	001	Oct 07, 1988
		150MG	A088737	001	Sep 26, 1984
		200MG	A088738	001	Oct 16, 1984
	SUPERPHARM	10MG	A089103	001	Jul 02, 1985
		25MG	A089104	001	Jul 02, 1985
		50MG	A089105	001	Jul 02, 1985
	WATSON LABS	10MG	A088412	001	Sep 12, 1983
		10MG	A088561	001	May 11, 1984
		15MG	A088345	001	Jul 28, 1983
		15MG	A088562	001	May 11, 1984
		25MG	A088296	001	Jul 28, 1983
		25MG	A088755	001	Jul 24, 1984
		50MG	A088323	001	Jul 28, 1983
		50MG	A088563	001	May 11, 1984
		100MG	A088284	001	Aug 25, 1983
		100MG	A088564	001	May 11, 1984
		150MG	A088410	001	Mar 05, 1984
		150MG	A088869	001	Jun 28, 1985
		200MG	A088381	001	Mar 14, 1984
	WATSON LABS TEVA	15MG	A088477	001	Nov 08, 1983
		25MG	A088567	001	May 11, 1984
		200MG	A088872	001	Apr 26, 1985
	WEST WARD	10MG	A088658	001	Mar 26, 1984
		15MG	A088659	001	Mar 26, 1984
		25MG	A088660	001	Mar 26, 1984
		50MG	A088661	001	Mar 26, 1984
THIOTEPA					
INJECTABLE;INJECTION					
THIOPLEX					
+	IMMUNEX	15MG/VIAL **	N020058	001	Dec 22, 1994
THIOTEPA					
	FRESENIUS KABI USA	15MG/VIAL	A075698	001	Sep 20, 2001
	IMMUNEX	15MG/VIAL	N011683	001	
	TEVA PARENTERAL	15MG/VIAL **	A075730	001	Apr 20, 2001
		30MG/VIAL **	A075730	002	Apr 20, 2001
THIOTHIXENE					
CAPSULE;ORAL					
NAVANE					
+	PFIZER	1MG **	N016584	001	
+		2MG **	N016584	002	
+		5MG **	N016584	003	
+		10MG **	N016584	004	
+		20MG **	N016584	005	
THIOTHIXENE					
	AM THERAP	1MG	A071884	001	Aug 12, 1987
		2MG	A071885	001	Aug 12, 1987
		5MG	A071886	001	Aug 12, 1987
		10MG	A071887	001	Aug 12, 1987
		20MG	A072200	001	Dec 17, 1987
	HERITAGE PHARMA	1MG	A070600	001	Jun 05, 1987
		2MG	A070601	001	Jun 05, 1987
		5MG	A070602	001	Jun 05, 1987
		10MG	A070603	001	Jun 05, 1987
	SANDOZ	1MG	A071529	002	Jun 24, 1987
		2MG	A071529	003	Jun 24, 1987
		5MG	A071529	001	Jun 24, 1987
		10MG	A071529	004	Jun 24, 1987
	WATSON LABS	2MG	A071626	001	Jun 25, 1987
		5MG	A071627	001	Jun 25, 1987
		10MG	A071628	001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE				
CONCENTRATE;ORAL				
NAVANE				
PFIZER	EQ 5MG BASE/ML	N016758	001	
THIOTHIXENE HYDROCHLORIDE				
ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969	001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917	001	Sep 20, 1989
	EQ 5MG BASE/ML	A071939	001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184	001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554	001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL				
HIKMA	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992
INJECTABLE;INJECTION				
NAVANE				
PFIZER	EQ 2MG BASE/ML	N016904	001	
	EQ 10MG BASE/VIAL	N016904	002	
THYROGLOBULIN				
TABLET;ORAL				
PROLOID				
PARKE DAVIS	16MG	N002245	009	
	32MG	N002245	005	
	65MG	N002245	002	
	100MG	N002245	008	
	130MG	N002245	010	
	200MG	N002245	007	
	325MG	N002245	004	
THYROGLOBULIN				
IMPAX LABS	64.8MG	A080151	001	
THYROTROPIN				
INJECTABLE;INJECTION				
THYTROPAR				
SANOFI AVENTIS US	10 IU/VIAL	N008682	001	
TIAGABINE HYDROCHLORIDE				
TABLET;ORAL				
GABITRIL				
CEPHALON	6MG	N020646	006	Nov 29, 2005
	8MG	N020646	007	Nov 29, 2005
	10MG	N020646	008	Nov 29, 2005
	20MG	N020646	004	Sep 30, 1997
TICAGRELOR				
TABLET;ORAL				
TICAGRELOR				
AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019
WATSON LABS INC	60MG	A208390	001	Sep 04, 2018
	90MG	A208390	002	Sep 04, 2018
TICARCILLIN DISODIUM				
INJECTABLE;INJECTION				
TICAR				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497	001	
	EQ 3GM BASE/VIAL	A062690	001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497	002	
	EQ 6GM BASE/VIAL	N050497	003	
	EQ 20GM BASE/VIAL	N050497	004	
	EQ 30GM BASE/VIAL	N050497	005	Apr 04, 1984
TICLOPIDINE HYDROCHLORIDE				
TABLET;ORAL				
TICLID				
ROCHE PALO	125MG	N019979	001	Mar 24, 1993
	250MG	N019979	002	Oct 31, 1991
TICLOPIDINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999
MYLAN	250MG	A075161	001	Sep 13, 1999
	250MG	A075316	001	Nov 02, 1999
SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002
WATSON LABS	250MG	A075309	001	Apr 26, 2000
YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999

TICLOPIDINE HYDROCHLORIDE				
TABLET;ORAL				
TICLOPIDINE HYDROCHLORIDE				
	250MG	A075326	001	Aug 20, 1999
TILUDRONATE DISODIUM				
TABLET;ORAL				
SKELID				
+ SANOFI AVENTIS US	EQ 200MG BASE **	N020707	001	Mar 07, 1997
TIMOLOL MALEATE				
SOLUTION/DROPS;OPHTHALMIC				
TIMOLOL MALEATE				
AKORN	EQ 0.25% BASE	A074465	001	Mar 25, 1997
	EQ 0.25% BASE	A074515	001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000
	EQ 0.5% BASE	A075412	001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667	001	Mar 25, 1997
	EQ 0.5% BASE	A074668	001	Mar 25, 1997
TABLET;ORAL				
BLOCADREN				
+ MERCK	5MG **	N018017	001	
+	10MG **	N018017	002	
+	20MG **	N018017	004	
TIMOLOL MALEATE				
ANI PHARMS INC	5MG	A072917	001	Jul 31, 1991
	10MG	A072918	001	Jul 31, 1991
	20MG	A072919	001	Jul 31, 1991
QUANTUM PHARMICS	5MG	A072466	001	May 19, 1989
	10MG	A072467	001	May 19, 1989
	20MG	A072468	001	May 19, 1989
TEVA	5MG	A072648	001	Jun 16, 1993
	10MG	A072649	001	Jun 16, 1993
	20MG	A072650	001	Jun 16, 1993
USL PHARMA	5MG	A072001	001	Apr 11, 1989
	10MG	A072002	001	Apr 11, 1989
	20MG	A072003	001	Apr 11, 1989
WATSON LABS	5MG	A072269	001	Apr 11, 1989
	10MG	A072270	001	Apr 11, 1989
	20MG	A072271	001	Apr 11, 1989
YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989
	10MG	A072551	001	Apr 13, 1989
	20MG	A072552	001	Apr 13, 1989
TINZAPARIN SODIUM				
INJECTABLE;INJECTION				
INNOHEP				
LEO PHARMA AS	20,000 IU/ML	N020484	001	Jul 14, 2000
TIOCONAZOLE				
CREAM;TOPICAL				
TZ-3				
PFIZER	1%	N018682	001	Feb 18, 1983
TIROFIBAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
AGGRASTAT				
MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912	001	May 14, 1998
	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998
TIZANIDINE HYDROCHLORIDE				
TABLET;ORAL				
TIZANIDINE HYDROCHLORIDE				
ANI PHARMS INC	EQ 2MG BASE	A076283	001	Jul 12, 2002
	EQ 2MG BASE	A076284	001	Jul 03, 2002
	EQ 2MG BASE	A076321	001	Sep 30, 2004
	EQ 2MG BASE	A076371	001	Apr 09, 2003
	EQ 4MG BASE	A076283	002	Jul 12, 2002
	EQ 4MG BASE	A076284	002	Jul 03, 2002
	EQ 4MG BASE	A076321	002	Sep 30, 2004
	EQ 4MG BASE	A076371	002	Apr 09, 2003
MYLAN PHARMS INC	EQ 2MG BASE	A076282	001	Dec 16, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TIZANIDINE HYDROCHLORIDE				
TABLET;ORAL				
TIZANIDINE HYDROCHLORIDE				
	EQ 4MG BASE	A076282	002	Dec 16, 2003
PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017
	EQ 4MG BASE	A207170	002	Jan 26, 2017
ZANAFLEX				
+ COVIS PHARMA BV	EQ 2MG BASE **	N020397	002	Feb 04, 2000
TOBRAMYCIN				
SOLUTION;INHALATION				
TOBRAMYCIN				
TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019
SOLUTION/DROPS;OPHTHALMIC				
TOBRAMYCIN				
ALCON PHARMS LTD	0.3%	A063176	001	May 25, 1994
APOTEX INC	0.3%	A065087	001	Feb 25, 2002
TOBRAMYCIN SULFATE				
INJECTABLE;INJECTION				
NEBCIN				
LILLY	EQ 10MG BASE/ML	A062008	004	
	EQ 10MG BASE/ML	A062707	001	Apr 29, 1987
+	EQ 10MG BASE/ML **	N050477	005	
	EQ 40MG BASE/ML	A062008	001	
+	EQ 1.2GM BASE/VIAL **	N050519	001	
TOBRAMYCIN SULFATE				
APOTHECON	EQ 10MG BASE/ML	A064021	001	May 31, 1994
	EQ 40MG BASE/ML	A064021	002	May 31, 1994
	EQ 40MG BASE/ML	A064026	001	May 31, 1994
HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161	001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994
WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991
TOBRAMYCIN SULFATE (PHARMACY BULK)				
HOSPIRA	EQ 40MG BASE/ML **	A063116	001	May 18, 1992
TOCAINIDE HYDROCHLORIDE				
TABLET;ORAL				
TONOCARD				
ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984
TOLAZAMIDE				
TABLET;ORAL				
TOLAZAMIDE				
BARR	100MG	A070162	001	Jan 14, 1986
	250MG	A070163	001	Jan 14, 1986
	500MG	A070164	001	Jan 14, 1986
COSETTE	100MG	N018894	001	Nov 02, 1984
	250MG	N018894	002	Nov 02, 1984
	500MG	N018894	003	Nov 02, 1984
DURAMED PHARMS BARR	100MG	A070165	001	Jan 10, 1986
	250MG	A070166	001	Jan 10, 1986
	500MG	A070167	001	Jan 10, 1986
INTERPHARM	250MG	A071270	001	Sep 23, 1986
	500MG	A071271	001	Sep 23, 1986
PAR PHARM	100MG	A070159	001	Jan 06, 1986
	250MG	A070160	001	Jan 06, 1986
	500MG	A070161	001	Jan 06, 1986
SUN PHARM INDUSTRIES	100MG	A071357	001	Jul 16, 1987
	250MG	A071358	001	Jul 16, 1987
	500MG	A071359	001	Jul 16, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TOLAZAMIDE					
TABLET;ORAL					
TOLAZAMIDE					
	SUPERPHARM	250MG	A070763	001	Jun 16, 1986
		500MG	A070764	001	Jun 16, 1986
	USL PHARMA	100MG	A071355	001	Jan 11, 1988
		250MG	A070168	001	Apr 02, 1986
		500MG	A070169	001	Apr 02, 1986
	WATSON LABS	100MG	A070242	001	Aug 01, 1986
		100MG	A070513	001	Jan 09, 1986
		250MG	A070243	001	Aug 01, 1986
		250MG	A070514	001	Jan 09, 1986
		500MG	A070244	001	Aug 01, 1986
		500MG	A070515	001	Jan 09, 1986
	YAOPHARMA CO LTD	100MG	A071633	001	Dec 09, 1987
		250MG	A070289	001	Mar 13, 1986
		500MG	A070290	001	Mar 13, 1986
TOLINASE					
+	PHARMACIA AND UPJOHN	100MG **	N015500	002	
+		250MG **	N015500	004	
+		500MG **	N015500	005	
TOLAZOLINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
PRISCOLINE					
	NOVARTIS	25MG/ML	N006403	005	Feb 22, 1985
TOLBUTAMIDE					
TABLET;ORAL					
ORINASE					
	PHARMACIA AND UPJOHN	250MG **	N010670	002	
		500MG **	N010670	001	
TOLBUTAMIDE					
	ALRA	500MG	A086141	001	
	ANI PHARMS INC	500MG	A087093	001	
	ASCOT	500MG	A087541	001	Mar 01, 1983
	BARR	500MG	A087121	001	
	DAVA PHARMS INC	500MG	A086926	001	
	PARKE DAVIS	500MG	A086047	001	
	PUREPAC PHARM	500MG	A088950	001	Jun 17, 1985
	SANDOZ	500MG	N012678	001	
	SUPERPHARM	500MG	A088893	001	Nov 19, 1984
	VANGARD	500MG	A087876	001	Apr 20, 1982
	WATSON LABS	250MG	A089110	001	May 29, 1987
		500MG	A086109	001	
		500MG	A087318	001	
		500MG	A089111	001	May 29, 1987
	YAOPHARMA CO LTD	500MG	A086574	001	
TOLBUTAMIDE SODIUM					
INJECTABLE;INJECTION					
ORINASE DIAGNOSTIC					
	PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	
TOLCAPONE					
TABLET;ORAL					
TASMAR					
	BAUSCH	200MG	N020697	002	Jan 29, 1998
TOLMETIN SODIUM					
CAPSULE;ORAL					
TOLECTIN DS					
+	ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001	
TOLMETIN SODIUM					
	ANI PHARMS INC	EQ 400MG BASE	A073308	001	Jan 24, 1992
		EQ 400MG BASE	A073392	001	Jan 24, 1992
		EQ 400MG BASE	A073519	001	May 29, 1992
	FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992
	SUN PHARM INDUSTRIES	EQ 400MG BASE	A073311	001	Nov 27, 1991

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOLMETIN SODIUM				
TABLET;ORAL				
TOLECTIN				
+	ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628 001	
TOLECTIN 600				
+	ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628 002	Mar 08, 1989
TOLMETIN SODIUM				
	ACP NIMBLE	EQ 600MG BASE	A074399 001	Mar 28, 1996
		EQ 600MG BASE	A074729 001	Feb 27, 1997
	ANI PHARMS INC	EQ 600MG BASE	A073527 001	Jun 30, 1992
	FOSUN PHARMA	EQ 200MG BASE	A073588 001	Jul 31, 1992
		EQ 600MG BASE	A074002 001	Sep 27, 1993
	SUN PHARM INDUSTRIES	EQ 200MG BASE	A073310 001	Nov 27, 1991
TOLTERODINE TARTRATE				
TABLET;ORAL				
TOLTERODINE TARTRATE				
	APOTEX CORP	1MG	A200164 001	Sep 25, 2012
		2MG	A200164 002	Sep 25, 2012
TOLVAPTAN				
TABLET;ORAL				
SAMSCA				
+	OTSUKA AMERICA PHARM	60MG **	N022275 003	May 19, 2009
TOPIRAMATE				
CAPSULE;ORAL				
TOPAMAX SPRINKLE				
	JANSSEN PHARMS	50MG	N020844 003	Oct 26, 1998
TOPIRAMATE				
	BARR	15MG	A076448 001	Apr 15, 2009
		25MG	A076448 002	Apr 15, 2009
	FOSUN PHARMA	15MG	A079206 001	Oct 14, 2009
		25MG	A079206 002	Oct 14, 2009
	MYLAN	15MG	A078418 001	Oct 14, 2009
		25MG	A078418 002	Oct 14, 2009
TABLET;ORAL				
TOPAMAX				
	JANSSEN PHARMS	300MG	N020505 003	Dec 24, 1996
		400MG	N020505 006	Dec 24, 1996
TOPIRAMATE				
	ACTAVIS TOTOWA	25MG	A078637 001	Feb 27, 2013
		50MG	A078637 002	Feb 27, 2013
		100MG	A078637 003	Feb 27, 2013
		200MG	A078637 004	Feb 27, 2013
	BARR	25MG	A076315 001	Mar 27, 2009
		100MG	A076315 002	Mar 27, 2009
		200MG	A076315 003	Mar 27, 2009
	HIKMA PHARMS	25MG	A091185 001	Nov 25, 2013
		50MG	A091185 002	Nov 25, 2013
		100MG	A091185 003	Nov 25, 2013
		200MG	A091185 004	Nov 25, 2013
	LUPIN	25MG	A078410 001	Sep 11, 2013
		50MG	A078410 002	Sep 11, 2013
		100MG	A078410 003	Sep 11, 2013
		200MG	A078410 004	Sep 11, 2013
	MYLAN	25MG	A076314 001	Mar 27, 2009
		50MG	A076314 002	Mar 27, 2009
		100MG	A076314 003	Mar 27, 2009
		200MG	A076314 004	Mar 27, 2009
	PLIVA HRVATSKA DOO	25MG	A077905 001	Mar 30, 2009
		50MG	A077905 002	Mar 30, 2009
		100MG	A077905 003	Mar 30, 2009
		200MG	A077905 004	Mar 30, 2009
	ROXANE	25MG	A076306 001	Mar 27, 2009
		50MG	A076306 002	Mar 27, 2009
		100MG	A076306 003	Mar 27, 2009
		200MG	A076306 004	Mar 27, 2009
	WATSON LABS	25MG	A077643 001	Mar 27, 2009
		50MG	A077643 002	Mar 27, 2009
		100MG	A077643 003	Mar 27, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOPIRAMATE					
TABLET;ORAL					
TOPIRAMATE					
		200MG	A077643	004	Mar 27, 2009
	WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010
		50MG	A090353	002	Sep 01, 2010
		100MG	A090353	003	Sep 01, 2010
		200MG	A090353	004	Sep 01, 2010
TOPOTECAN HYDROCHLORIDE					
INJECTABLE;INJECTION					
TOPOTECAN HYDROCHLORIDE					
	FRESENIUS KABI USA	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010
	MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012
	SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013
SOLUTION;INTRAVENOUS					
TOPOTECAN					
+	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N200199	001	Feb 25, 2011
+		EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **	N200199	002	Feb 25, 2011
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N200199	003	Feb 25, 2011
TORSEMIDE					
INJECTABLE;INJECTION					
DEMADEX					
+	ROCHE	50MG/5ML (10MG/ML) **	N020137	002	Aug 23, 1993
+		20MG/2ML (10MG/ML) **	N020137	001	Aug 23, 1993
TORSEMIDE					
	AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010
		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010
	WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008
		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008
TABLET;ORAL					
TORSEMIDE					
	SUN PHARM INDS	5MG	A078478	001	Feb 26, 2008
		10MG	A078478	002	Feb 26, 2008
		20MG	A078478	003	Feb 26, 2008
		100MG	A078478	004	Feb 26, 2008
TRAMADOL HYDROCHLORIDE					
TABLET;ORAL					
TRAMADOL HYDROCHLORIDE					
	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013
	ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002
	ASTA	50MG	A075974	001	Jul 12, 2002
	FOSUN PHARMA	50MG	A075968	001	Jun 25, 2002
	IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002
	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002
	NORTHSTAR HLTHCARE	50MG	A078935	001	May 26, 2010
	POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019
	SPECGX LLC	50MG	A075983	001	Jun 25, 2002
	SUN PHARM INDUSTRIES	50MG	A076100	001	Jun 20, 2002
	WATSON LABS	50MG	A075962	001	Jun 24, 2002
ULTRAM					
	JANSSEN PHARMS	100MG	N020281	001	Mar 03, 1995
TABLET, EXTENDED RELEASE;ORAL					
RYZOLT					
+	PURDUE PHARMA	100MG **	N021745	001	Dec 30, 2008
+		200MG **	N021745	002	Dec 30, 2008
+		300MG **	N021745	003	Dec 30, 2008
TRAMADOL HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	100MG	A204421	001	Oct 20, 2015
		200MG	A204421	002	Oct 20, 2015
		300MG	A204421	003	Oct 20, 2015
	PAR PHARM INC	100MG	A078783	001	Nov 13, 2009
		200MG	A078783	002	Nov 13, 2009
		300MG	A078783	003	Sep 20, 2011
ULTRAM ER					
+	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005
+		200MG	N021692	002	Sep 08, 2005
+		300MG	N021692	003	Sep 08, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRAMADOL HYDROCHLORIDE					
TABLET, ORALLY DISINTEGRATING;ORAL					
RYBIX ODT					
	SHIONOGI INC	50MG	N021693	001	May 05, 2005
TRAMETINIB DIMETHYL SULFOXIDE					
TABLET;ORAL					
MEKINIST					
+	NOVARTIS	EQ 1MG	N204114	002	May 29, 2013
TRANDOLAPRIL					
TABLET;ORAL					
MAVIK					
+	ABBVIE	1MG **	N020528	001	Apr 26, 1996
+		2MG **	N020528	002	Apr 26, 1996
+		4MG **	N020528	003	Apr 26, 1996
TRANDOLAPRIL					
	CIPLA	1MG	A077307	002	Jun 12, 2007
		2MG	A077307	001	Jun 12, 2007
		4MG	A077307	003	Jun 12, 2007
	DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008
		2MG	A078493	002	Aug 25, 2008
		4MG	A078493	003	Aug 25, 2008
	EPIC PHARMA LLC	1MG	A077256	001	Jun 12, 2007
		2MG	A077256	002	Jun 12, 2007
		4MG	A077256	003	Jun 12, 2007
	INVAGEN PHARMS	1MG	A078320	001	Jun 12, 2007
		2MG	A078320	002	Jun 12, 2007
		4MG	A078320	003	Jun 12, 2007
	MYLAN	1MG	A078346	001	Apr 28, 2008
		2MG	A078346	002	Apr 28, 2008
		4MG	A078346	003	Apr 28, 2008
	WATSON LABS	1MG	A077805	001	Jun 12, 2007
		2MG	A077805	002	Jun 12, 2007
		4MG	A077805	003	Jun 12, 2007
TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
TARKA					
+	ABBVIE	1MG;240MG	N020591	003	Oct 22, 1996
TRANEXAMIC ACID					
INJECTABLE;INJECTION					
TRANEXAMIC ACID					
	VIRTUS PHARMS	100MG/ML	A202755	001	Feb 25, 2016
TABLET;ORAL					
CYKLOKAPRON					
	PHARMACIA AND UPJOHN	500MG	N019280	001	Dec 30, 1986
TRANEXAMIC ACID					
	AMERIGEN PHARMS LTD	650MG	A203256	001	Jul 25, 2016
TRAVOPROST					
SOLUTION/DROPS;OPHTHALMIC					
IZBA					
+	NOVARTIS	0.003% **	N204822	001	May 15, 2014
TRAVATAN					
+	ALCON PHARMS LTD	0.004% **	N021257	001	Mar 16, 2001
TRAZODONE HYDROCHLORIDE					
TABLET;ORAL					
DESYREL					
+	PRAGMA	50MG **	N018207	001	
+		100MG **	N018207	002	
+		150MG **	N018207	003	Mar 25, 1985
+		300MG **	N018207	004	Nov 07, 1988
TRAZODONE HYDROCHLORIDE					
	AM THERAP	50MG	A071139	001	Oct 29, 1986
		100MG	A071140	001	Oct 29, 1986
	AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990
	FOSUN PHARMA	100MG	A072483	001	Apr 30, 1990
	MYLAN	50MG	A071405	001	Feb 27, 1991
		100MG	A071406	001	Feb 27, 1991

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRAZODONE HYDROCHLORIDE				
TABLET;ORAL				
TRAZODONE HYDROCHLORIDE				
MYLAN PHARMS INC	50MG	A090514	001	Jun 02, 2009
	100MG	A090514	002	Jun 02, 2009
	150MG	A090514	003	Jun 02, 2009
	300MG	A090514	004	Jun 02, 2009
QUANTUM PHARMICS	100MG	A070921	001	Dec 01, 1986
TEVA	150MG	A074357	001	Apr 30, 1997
USL PHARMA	50MG	A070491	001	Apr 29, 1987
	100MG	A070492	001	Apr 29, 1987
WATSON LABS	50MG	A070857	001	Oct 10, 1986
	50MG	A071112	001	Nov 17, 1986
	100MG	A070858	001	Oct 10, 1986
	100MG	A071113	001	Nov 17, 1986
TRIALODINE				
QUANTUM PHARMICS	50MG	A070942	001	Dec 01, 1986
TABLET, EXTENDED RELEASE;ORAL				
OLEPTRO				
+ ANGELINI PHARMA	150MG **	N022411	001	Feb 02, 2010
+	300MG **	N022411	002	Feb 02, 2010
TRETINOIN				
CAPSULE;ORAL				
VESANOID				
+ CHEPLAPHARM	10MG **	N020438	001	Nov 22, 1995
CREAM;TOPICAL				
TRETINOIN				
ALLERGAN	0.0375%	A090098	001	Mar 22, 2010
	0.075%	A202209	001	Oct 11, 2012
SOLUTION;TOPICAL				
RETIN-A				
+ VALEANT INTL	0.05%	N016921	001	
TRETINOIN				
TEVA PHARMS	0.05%	A074873	001	Jun 19, 1998
WOCKHARDT	0.05%	A075260	001	Jan 25, 1999
SWAB;TOPICAL				
RETIN-A				
VALEANT INTL	0.05%	N016921	002	
TRIAMCINOLONE				
TABLET;ORAL				
ARISTOCORT				
ASTELLAS	1MG	N011161	009	
	2MG	N011161	004	
	4MG	N011161	007	
	8MG	N011161	011	
	16MG	N011161	010	
KENACORT				
DELCOR ASSET CORP	1MG	N011283	003	
	2MG	N011283	008	
	4MG	N011283	006	
	8MG	N011283	010	
TRIAMCINOLONE				
BARR	2MG	A084286	001	
	2MG	A084318	001	
	4MG	A084267	001	
	4MG	A084319	001	
	8MG	A084268	001	
	8MG	A084320	001	
IMPAX LABS	4MG	A084340	001	
IVAX SUB TEVA PHARMS	4MG	A083750	001	
MYLAN	2MG	A084406	001	
PUREPAC PHARM	2MG	A084020	002	
	4MG	A084020	003	
ROXANE	2MG	A084708	001	
	4MG	A084709	001	
	8MG	A084707	001	
SANDOZ	4MG	A085601	001	
TEVA	4MG	A084775	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIAMCINOLONE				
TABLET;ORAL				
TRIAMCINOLONE				
WATSON LABS	4MG	A084270	001	
	4MG	A085834	001	
TRIAMCINOLONE ACETONIDE				
AEROSOL, METERED;INHALATION				
AZMACORT				
ABBVIE	0.1MG/INH	N018117	001	Apr 23, 1982
AEROSOL, METERED;NASAL				
NASACORT				
SANOFI AVENTIS US	0.055MG/INH	N019798	001	Jul 11, 1991
CREAM;TOPICAL				
ARISTOCORT				
ASTELLAS	0.025%	A083017	003	
	0.1%	A083016	004	
	0.5%	A083015	002	
ARISTOCORT A				
ASTELLAS	0.025%	A083017	004	
	0.025%	A088818	001	Oct 16, 1984
	0.1%	A083016	005	
	0.1%	A088819	001	Oct 16, 1984
	0.5%	A083015	003	
	0.5%	A088820	001	Oct 16, 1984
FLUTEX				
IVAX PHARMS	0.025%	A085539	001	
	0.1%	A085539	002	
	0.5%	A085539	003	
KENALOG				
DELCOR ASSET CORP	0.5%	A083943	001	
KENALOG-H				
DELCOR ASSET CORP	0.1%	A086240	001	
TRIACET				
TEVA	0.025%	A084908	001	
	0.1%	A084908	002	
	0.5%	A084908	003	
TRIACORT				
SOLVAY	0.1%	A087113	001	
TRIAMCINOLONE ACETONIDE				
ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982
ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
AMBIX	0.025%	A087932	001	May 09, 1983
MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
	0.1%	A088095	001	Sep 01, 1983
	0.5%	A088096	001	Sep 01, 1983
PHARMADERM	0.025%	A087990	001	Jul 07, 1983
	0.1%	A087991	001	Jul 07, 1983
	0.5%	A087992	001	Jul 07, 1983
PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
	0.1%	A087912	001	Aug 10, 1982
	0.5%	A087922	001	Aug 10, 1982
TARO	0.025%	A040038	001	Oct 26, 1994
	0.025%	A086277	001	
	0.1%	A086276	001	
	0.5%	A086275	001	
TOPIDERM	0.025%	A089274	001	Feb 21, 1989
	0.1%	A089275	001	Feb 21, 1989
	0.5%	A089276	001	Feb 21, 1989
TRIATEX				
IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988
	0.1%	A087429	001	Nov 01, 1988
	0.5%	A087428	001	Nov 01, 1988
TRYMEX				
SAVAGE LABS	0.025%	A088196	001	Mar 25, 1983
	0.1%	A088197	001	Mar 25, 1983
	0.5%	A088198	001	Mar 25, 1983

TRIAMCINOLONE ACETONIDE					
GEL;TOPICAL					
ARISTOGEL					
	ASTELLAS	0.1%	A083380	001	
INJECTABLE;INJECTION					
TRIAMCINOLONE ACETONIDE					
	PARNELL	3MG/ML	N019503	001	Oct 16, 1987
	SANDOZ INC	10MG/ML	A090166	001	May 27, 2009
		40MG/ML	A090164	001	Jun 01, 2009
	WATSON LABS	40MG/ML	A085825	001	
INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL					
TRIVARIS					
+	ALLERGAN	8MG/0.1ML (8MG/0.1ML) **	N022220	001	Jun 16, 2008
LOTION;TOPICAL					
KENALOG					
	DELCOR ASSET CORP	0.025% **	A084343	001	
+		0.025% **	N011602	003	
		0.1% **	A084343	002	
+		0.1% **	N011602	001	
TRIAMCINOLONE ACETONIDE					
	ALPHARMA US PHARMS	0.025%	A087191	001	Sep 08, 1982
		0.1%	A087192	001	Sep 08, 1982
OINTMENT;TOPICAL					
ARISTOCORT					
	ASTELLAS	0.1%	A080750	004	
		0.5% **	A080745	002	
ARISTOCORT A					
	ASTELLAS	0.1%	A080750	003	
		0.1%	A088780	001	Oct 01, 1984
		0.5% **	A080745	003	
		0.5%	A088781	001	Oct 05, 1984
FLUTEX					
	IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988
		0.1%	A087377	001	Nov 01, 1988
		0.5%	A087376	001	Nov 01, 1988
KENALOG					
	DELCOR ASSET CORP	0.5% **	A083944	001	
TRIAMCINOLONE ACETONIDE					
	ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982
	ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
	MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
		0.1%	A088091	001	Sep 01, 1983
		0.5%	A088092	001	Sep 01, 1983
+	MYLAN	0.025% **	N011600	003	
+		0.1% **	N011600	001	
	PHARMADERM	0.025%	A088692	001	Aug 02, 1984
		0.1%	A088690	001	Aug 02, 1984
	TARO	0.025%	A040040	001	Sep 30, 1994
		0.025%	A040374	001	Jun 05, 2001
		0.1%	A087902	001	Dec 27, 1982
		0.5%	A040386	001	Jun 05, 2001
TRYMEX					
	SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984
		0.1%	A088691	001	Aug 02, 1984
PASTE;DENTAL					
KENALOG IN ORABASE					
+	DELCOR ASSET CORP	0.1% **	N012097	001	
ORALONE					
	TARO	0.1%	A071383	001	Jul 06, 1987
SPRAY, METERED;NASAL					
ALLERNAZE					
	LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000
NASACORT HFA					
	SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004
TRIAMCINOLONE ACETONIDE					
	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009

TRIAMCINOLONE DIACETATE

INJECTABLE;INJECTION				
ARISTOCORT				
	FOSUN PHARMA	25MG/ML	N011685 003	
+		40MG/ML **	N012802 001	
TRIAMCINOLONE DIACETATE				
	AKORN	25MG/ML	A085122 001	
		40MG/ML	A086394 001	
	WATSON LABS	40MG/ML	A084072 001	
		40MG/ML	A085529 001	
SYRUP;ORAL				
ARISTOCORT				
	ASTELLAS	2MG/5ML	N011960 004	
KENACORT				
	DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515 001	

TRIAZOLAM

TABLET;ORAL				
HALCION				
	PHARMACIA AND UPJOHN	0.5MG	N017892 002	Nov 15, 1982
TRIAZOLAM				
	WATSON LABS	0.125MG	A074445 001	Oct 20, 1995
		0.25MG	A074445 002	Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET;ORAL				
METAHYDRIN				
	SANOFI AVENTIS US	2MG	N012594 001	Jun 16, 1988
		4MG	N012594 002	Jun 16, 1988
NAQUA				
	SCHERING	2MG	N012265 001	
		4MG	N012265 002	
TRICHLOREX				
	LANNETT	4MG	A083436 001	
		4MG	A085630 001	
TRICHLORMAS				
	MAST MM	4MG	A086259 001	
TRICHLORMETHIAZIDE				
	CHARTWELL RX	4MG	A085568 001	
	IMPAX LABS	4MG	A083967 001	
	PAR PHARM	2MG	A087007 001	
		4MG	A087005 001	
	SANDOZ	4MG	A086171 001	
	WATSON LABS	2MG	A083847 001	
		2MG	A086458 001	
		4MG	A083462 001	
		4MG	A083855 001	
		4MG	A085962 001	

TRICLOFOS SODIUM

SOLUTION;ORAL				
TRICLOS				
	SANOFI AVENTIS US	1.5GM/15ML	N016830 001	
TABLET;ORAL				
TRICLOS				
	SANOFI AVENTIS US	750MG	N016809 002	

TRIDIHEXETHYL CHLORIDE

INJECTABLE;INJECTION				
PATHILON				
	LEDERLE	10MG/ML	N009729 001	
TABLET;ORAL				
PATHILON				
	LEDERLE	25MG	N009489 005	

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE;ORAL				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 10MG BASE/ML **	N011552 006	
TRIFLUOPERAZINE HYDROCHLORIDE				
	FOSUN PHARMA	EQ 10MG BASE/ML	A085787 001	Apr 15, 1982
	WOCKHARDT	EQ 10MG BASE/ML	A088143 001	Jul 26, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRIFLUOPERAZINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
STELAZINE					
+	GLAXOSMITHKLINE	EQ 2MG BASE/ML **	N011552	005	
TABLET;ORAL					
STELAZINE					
+	GLAXOSMITHKLINE	EQ 1MG BASE **	N011552	001	
+		EQ 2MG BASE **	N011552	002	
+		EQ 5MG BASE **	N011552	003	
+		EQ 10MG BASE **	N011552	004	
TRIFLUOPERAZINE HYDROCHLORIDE					
	DURAMED PHARMS BARR	EQ 1MG BASE	A088967	001	Apr 23, 1985
		EQ 2MG BASE	A088968	001	Apr 23, 1985
		EQ 5MG BASE	A088969	001	Apr 23, 1985
		EQ 10MG BASE	A088970	001	Apr 23, 1985
	INVATECH	EQ 1MG BASE	A040153	001	Oct 25, 1996
		EQ 2MG BASE	A040153	002	Oct 25, 1996
		EQ 5MG BASE	A040153	003	Oct 25, 1996
		EQ 10MG BASE	A040153	004	Oct 25, 1996
	IVAX PHARMS	EQ 1MG BASE	A087612	001	Nov 19, 1982
		EQ 2MG BASE	A087613	001	Nov 19, 1982
		EQ 5MG BASE	A087328	001	Nov 19, 1982
		EQ 10MG BASE	A087614	001	Nov 19, 1982
	WATSON LABS	EQ 1MG BASE	A085975	001	Jun 23, 1988
		EQ 2MG BASE	A085976	001	Jun 23, 1988
		EQ 5MG BASE	A085973	001	Jun 23, 1988
		EQ 10MG BASE	A088710	001	Jun 23, 1988
TRIFLUPROMAZINE					
SUSPENSION;ORAL					
VESPRIN					
	APOTHECON	EQ 50MG HYDROCHLORIDE/5ML	N011491	004	
TRIFLUPROMAZINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
VESPRIN					
	APOTHECON	3MG/ML	N011325	005	
		10MG/ML	N011325	004	
		20MG/ML	N011325	001	
TABLET;ORAL					
VESPRIN					
	BRISTOL MYERS SQUIBB	10MG	N011123	001	
		25MG	N011123	002	
		50MG	N011123	003	
TRIHEXYPHENIDYL HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
ARTANE					
	LEDERLE	5MG	N006773	010	
		5MG	N012947	001	
ELIXIR;ORAL					
ARTANE					
	LEDERLE	2MG/5ML	N006773	009	
TRIHEXYPHENIDYL HYDROCHLORIDE					
	PHARM VENTURES	2MG/5ML	A089514	001	Apr 07, 1989
TABLET;ORAL					
ARTANE					
+	LEDERLE	2MG **	N006773	005	
+		5MG **	N006773	003	
TREMIN					
	SCHERING	2MG	A080381	001	
		5MG	A080381	003	
TRIHEXYPHENIDYL HYDROCHLORIDE					
	HIKMA PHARMS	2MG	A040337	002	Feb 16, 2000
		5MG	A040337	001	Feb 16, 2000
	NYLOS	5MG	A085622	001	
	VANGARD	2MG	A088035	001	Jul 30, 1982
	WATSON LABS	2MG	A040184	001	Feb 06, 1998
		2MG	A085117	001	
		5MG	A040184	002	Feb 06, 1998
		5MG	A085105	001	

TRILOSTANE
CAPSULE;ORAL
MODRASTANE

BIOENVISION	30MG	N018719	002	Dec 31, 1984
	60MG	N018719	001	Dec 31, 1984

TRIMEPRAZINE TARTRATE
CAPSULE, EXTENDED RELEASE;ORAL
TEMARIL

ALLERGAN HERBERT	EQ 5MG BASE	N011316	004	

SYRUP;ORAL
TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316	003	

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015	001	Feb 18, 1982
MORTON GROVE	EQ 2.5MG BASE/5ML	A088285	001	Apr 11, 1985

TABLET;ORAL
TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE	N011316	001	

TRIMETHADIONE
CAPSULE;ORAL
TRIDIONE

ABBVIE	300MG	N005856	005	

SOLUTION;ORAL
TRIDIONE

ABBVIE	200MG/5ML	N005856	002	

TABLET;ORAL
TRIDIONE

+	ABBVIE	150MG	N005856	009	

TRIMETHAPHAN CAMSYLATE
INJECTABLE;INJECTION
ARFONAD

ROCHE	50MG/ML	N008983	001	

TRIMETHOBENZAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

AM REGENT	100MG/ML	A091330	001	Mar 08, 2011
HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960	001	Apr 04, 1986
	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AM REGENT	100MG/ML	A091329	001	Mar 08, 2011

TRIMETHOPRIM
TABLET;ORAL
PROLOPRIM

MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982

TRIMETHOPRIM

SUN PHARM INDUSTRIES	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986
TEVA	200MG **	A071259	001	Jun 18, 1987

TRIMPEX

ROCHE	100MG	N017952	001	

TRIMPEX 200

ROCHE	200MG	N017952	002	Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION;ORAL
PRIMSOL

ALLEGIS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995

TRIMETREXATE GLUCURONATE				
INJECTABLE;INJECTION				
NEUTREXIN				
MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N020326	001	Dec 17, 1993
	EQ 200MG BASE/VIAL	N020326	002	Jul 31, 1998
TRIMIPRAMINE MALEATE				
CAPSULE;ORAL				
SURMONTIL				
+ ODYSSEY PHARMS	EQ 25MG BASE	N016792	001	
+	EQ 50MG BASE	N016792	002	
+	EQ 100MG BASE	N016792	003	Sep 15, 1982
TRIMIPRAMINE MALEATE				
USL PHARMA	EQ 25MG BASE	A071283	001	Dec 08, 1987
	EQ 50MG BASE	A071284	001	Dec 08, 1987
	EQ 100MG BASE	A071285	001	Dec 08, 1987
TRIOXSALEN				
TABLET;ORAL				
TRISORALEN				
VALEANT PHARM INTL	5MG	N012697	001	
TRIPELENNAMINE CITRATE				
ELIXIR;ORAL				
PBZ				
NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML	N005914	004	
TRIPELENNAMINE HYDROCHLORIDE				
TABLET;ORAL				
PBZ				
NOVARTIS	25MG	A083149	001	
	50MG	N005914	002	
TRIPELENNAMINE HYDROCHLORIDE				
ANABOLIC	50MG	A083037	001	
BARR	50MG	A080744	001	
HEATHER	50MG	A083989	001	
IMPAX LABS	50MG	A080785	001	
LANNETT	50MG	A083557	001	
NYLOS	50MG	A085412	001	
PARKE DAVIS	25MG	A083625	001	
	50MG	A083626	001	
WATSON LABS	50MG	A080713	001	
	50MG	A080790	001	
	50MG	A085188	001	
TABLET, EXTENDED RELEASE;ORAL				
PBZ-SR				
NOVARTIS	50MG	N010533	002	
	100MG	N010533	001	
TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)				
CREAM;VAGINAL				
GYNE-SULF				
ACP NIMBLE	3.7%;2.86%;3.42%	A088607	001	Jun 09, 1986
SULTRIN				
ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N005794	001	
TRIPLE SULFA				
ALPHARMA US PHARMS	3.7%;2.86%;3.42%	A087864	001	Sep 01, 1982
FOUGERA	3.7%;2.86%;3.42%	A086424	001	
PERRIGO NEW YORK	3.7%;2.86%;3.42%	A087285	001	Nov 15, 1982
TRYSUL				
SAVAGE LABS	3.7%;2.86%;3.42%	A087887	001	Jul 23, 1982
VAGILIA				
ACP NIMBLE	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987
TABLET;VAGINAL				
SULTRIN				
ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG	N005794	002	
TRIPLE SULFA				
FOUGERA	184MG;143.75MG;172.5MG	A088463	001	Jan 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG	A088462	001	Jan 03, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIPROLIDINE HYDROCHLORIDE				
SYRUP;ORAL				
ACTIDIL				
GLAXOSMITHKLINE	1.25MG/5ML	N011496	002	Jul 01, 1983
MYIDYL				
USL PHARMA	1.25MG/5ML	A087963	001	Jan 18, 1983
TRIPROLIDINE HYDROCHLORIDE				
ALPHARMA US PHARMS	1.25MG/5ML	A085940	001	
HALSEY	1.25MG/5ML	A088735	001	Jan 17, 1985
PHARM ASSOC	1.25MG/5ML	A087514	001	Feb 10, 1982
TABLET;ORAL				
ACTIDIL				
GLAXOSMITHKLINE	2.5MG	N011110	002	Jul 01, 1983
TRIPROLIDINE HYDROCHLORIDE				
VITARINE	2.5MG	A085610	001	
WATSON LABS	2.5MG	A085094	001	
TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)				
SUSPENSION;ORAL				
LANTRISUL				
LANNETT	167MG/5ML;167MG/5ML;167MG/5ML	A080123	002	
NEOTRIZINE				
LILLY	167MG/5ML;167MG/5ML;167MG/5ML	N006317	012	
SULFALOID				
FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080100	001	
SULFOSE				
WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	A080013	002	
TERFONYL				
BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML	N006904	002	
TRIPLE SULFA				
ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080280	001	
TRIPLE SULFAS				
LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML	N006920	003	
TABLET;ORAL				
NEOTRIZINE				
LILLY	167MG;167MG;167MG	N006317	011	
SULFA-TRIPLE #2				
IMPAX LABS	167MG;167MG;167MG	A080079	001	
SULFALOID				
FOREST PHARMS	167MG;167MG;167MG	A080099	001	
SULFOSE				
WYETH AYERST	167MG;167MG;167MG	A080013	001	
TERFONYL				
BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904	001	
TRIPLE SULFA				
PUREPAC PHARM	167MG;167MG;167MG	A080086	001	
TRIPLE SULFAS				
LEDERLE	167MG;167MG;167MG	N006920	002	
TRIPLE SULFOID				
PAL PAK	167MG;167MG;167MG	A080094	001	
TROGLITAZONE				
TABLET;ORAL				
PRELAY				
SANKYO	200MG	N020719	001	Jan 29, 1997
	300MG	N020719	003	Aug 04, 1997
	400MG	N020719	002	Jan 29, 1997
REZULIN				
PFIZER PHARMS	200MG	N020720	001	Jan 29, 1997
	300MG	N020720	003	Aug 04, 1997
	400MG	N020720	002	Jan 29, 1997
TROLAMINE POLYPEPTIDE OLEATE CONDENSATE				
SOLUTION/DROPS;OTIC				
CERUMENEX				
PHARM RES ASSOC	10%	N011340	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TROLEANDOMYCIN				
CAPSULE;ORAL				
TAO				
	PFIZER	EQ 250MG BASE	N050336 002	
SUSPENSION;ORAL				
TAO				
	PFIZER	EQ 125MG BASE/5ML	N050332 001	
TROMETHAMINE				
INJECTABLE;INJECTION				
THAM				
+	HOSPIRA	3.6GM/100ML **	N013025 002	
TROPICAMIDE				
SOLUTION/DROPS;OPHTHALMIC				
MYDRIACYL				
	ALCON	0.5% **	N012111 002	
		1% **	N012111 004	
MYDRIAFAIR				
	PHARMAFAIR	0.5%	A088274 001	Sep 16, 1983
		1%	A088230 001	Sep 16, 1983
TROPICAMIDE				
	AKORN	1%	A088447 001	Aug 28, 1985
	ALCON PHARMS LTD	1%	A089172 001	Dec 28, 1990
	MIZA PHARMS USA	0.5%	A087636 001	Jul 30, 1982
		1%	A087637 001	Aug 09, 1982
	WATSON LABS	0.5%	A089171 001	Dec 28, 1990
TROSPIUM CHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
SANCTURA XR				
+	ALLERGAN	60MG **	N022103 001	Aug 03, 2007
TROSPIUM CHLORIDE				
	UPSHER SMITH LABS	60MG	A091635 001	Apr 29, 2015
TABLET;ORAL				
SANCTURA				
+	ALLERGAN	20MG **	N021595 001	May 28, 2004
TROVAFLOXACIN MESYLATE				
TABLET;ORAL				
TROVAN				
	PFIZER	EQ 100MG BASE	N020759 001	Dec 18, 1997
		EQ 200MG BASE	N020759 002	Dec 18, 1997
TUBOCURARINE CHLORIDE				
INJECTABLE;INJECTION				
TUBOCURARINE CHLORIDE				
	BRISTOL MYERS SQUIBB	3MG/ML	N005657 001	
	HOSPIRA	3MG/ML	N006095 001	
	LILLY	3MG/ML	N006325 001	
TYROPANOATE SODIUM				
CAPSULE;ORAL				
BILOPAQUE				
	GE HEALTHCARE	750MG	N013731 001	
UNOPROSTONE ISOPROPYL				
SOLUTION/DROPS;OPHTHALMIC				
RESCULA				
+	SUCAMPO PHARMA LLC	0.15% **	N021214 001	Aug 03, 2000
URACIL MUSTARD				
CAPSULE;ORAL				
URACIL MUSTARD				
	SHIRE	1MG	N012892 001	
UREA				
INJECTABLE;INJECTION				
STERILE UREA				
	HOSPIRA	40GM/VIAL	N017698 001	
UREAPHIL				
	HOSPIRA	40GM/VIAL	N012154 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

UREA C-13				
FOR SOLUTION;ORAL				
BREATHTEK UBT FOR H-PYLORI				
OTSUKA AMERICA	EQ 75MG/POUCH	N020586	002	May 10, 2001
HELICOSOL				
METABOLIC SOLUTIONS	125MG/VIAL	N021092	001	Dec 17, 1999
MERETEK UBT KIT (W/ PRANACTIN)				
OTSUKA AMERICA	125MG/VIAL	N020586	001	Sep 17, 1996
PYLORI-CHEK BREATH TEST				
DXS DEVICES	100MG/VIAL	N020900	001	Feb 04, 1999
UROFOLLITROPIN				
INJECTABLE;INTRAMUSCULAR				
METRODIN				
SERONO	75 IU/AMP	N019415	002	Sep 18, 1986
	150 IU/AMP	N019415	003	Sep 18, 1986
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
BRAVELLE				
+ FERRING	75 IU/VIAL	N021289	001	May 06, 2002
INJECTABLE;SUBCUTANEOUS				
FERTINEX				
SERONO	75 IU/AMP	N019415	005	Aug 23, 1996
	150 IU/AMP	N019415	004	Aug 23, 1996
UROKINASE				
INJECTABLE;INJECTION				
KINLYTIC				
MICROBIX BIOSYSTEMS	5,000 IU/VIAL	N021846	003	
	9,000 IU/VIAL	N021846	002	
	250,000 IU/VIAL	N021846	001	
URSODIOL				
CAPSULE;ORAL				
ACTIGALL				
ALLERGAN	150MG	N019594	001	Dec 31, 1987
URSODIOL				
IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006
TABLET;ORAL				
URSODIOL				
TEVA PHARMS USA	250MG	A079184	001	May 13, 2009
	500MG	A079184	002	May 13, 2009
VALACYCLOVIR HYDROCHLORIDE				
TABLET;ORAL				
VALACYCLOVIR HYDROCHLORIDE				
MYLAN	EQ 500MG BASE	A078070	001	May 24, 2010
	EQ 1GM BASE	A078070	002	May 24, 2010
WATSON LABS INC	EQ 500MG BASE	A090370	001	Mar 16, 2011
	EQ 1GM BASE	A090370	002	Mar 16, 2011
VALDECOXIB				
TABLET;ORAL				
BEXTRA				
GD SEARLE	10MG	N021341	002	Nov 16, 2001
	20MG	N021341	003	Nov 16, 2001
VALPROATE SODIUM				
INJECTABLE;INJECTION				
DEPACON				
+ ABBVIE	EQ 100MG BASE/ML	N020593	001	Dec 30, 1996
VALPROIC ACID				
CAPSULE;ORAL				
DEPAKENE				
+ ABBVIE	250MG	N018081	001	
VALPROIC ACID				
PAR PHARM	250MG	A070431	001	Feb 28, 1986
SCHERER RP	250MG	A070195	001	Jul 02, 1987
UPSHER SMITH LABS	250MG	A070631	001	Jun 11, 1987
CAPSULE, DELAYED RELEASE;ORAL				
STAVZOR				
+ BIONPHARMA INC	125MG **	N022152	001	Jul 29, 2008
+	250MG **	N022152	002	Jul 29, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VALPROIC ACID				
CAPSULE, DELAYED RELEASE;ORAL				
STAVZOR				
+	500MG **		N022152 003	Jul 29, 2008
SYRUP;ORAL				
DEPAKENE				
+ ABBVIE	250MG/5ML		N018082 001	
VALPROIC ACID				
ANI PHARMS INC	250MG/5ML		A073178 001	Aug 25, 1992
APOTEX	250MG/5ML		A077105 001	Jul 29, 2005
VALSARTAN				
CAPSULE;ORAL				
DIOVAN				
NOVARTIS	80MG		N020665 001	Dec 23, 1996
	160MG		N020665 002	Dec 23, 1996
SOLUTION;ORAL				
PREXXARTAN				
+ CARMEL BIOSCIENCES	20MG/5ML		N209139 001	Dec 19, 2017
+	80MG/20ML		N209139 002	Dec 19, 2017
TABLET;ORAL				
VALSARTAN				
TORRENT	40MG		A202728 001	Jan 05, 2015
	80MG		A202728 002	Jan 05, 2015
	160MG		A202728 003	Jan 05, 2015
	320MG		A202728 004	Jan 05, 2015
WATSON LABS INC	40MG		A090642 001	Jan 05, 2015
	80MG		A090642 002	Jan 05, 2015
	160MG		A090642 003	Jan 05, 2015
	320MG		A090642 004	Jan 05, 2015
VANCOMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
VANCOMYCIN HYDROCHLORIDE				
FRESENIUS KABI USA	EQ 125MG BASE		A065453 001	Jun 18, 2012
	EQ 250MG BASE		A065453 002	Jun 18, 2012
FOR SOLUTION;ORAL				
VANCOCIN HYDROCHLORIDE				
ANI PHARMS INC	EQ 500MG BASE/6ML		A061667 001	
VANCOLED				
LEDERLE	EQ 250MG BASE/5ML		A063321 002	Oct 15, 1993
	EQ 500MG BASE/6ML		A063321 003	Oct 15, 1993
INJECTABLE;INJECTION				
VANCOCIN HYDROCHLORIDE				
ANI PHARMS INC	EQ 500MG BASE/VIAL **		A060180 001	
	EQ 500MG BASE/VIAL		A062476 001	Mar 15, 1984
	EQ 500MG BASE/VIAL		A062716 001	Mar 13, 1987
	EQ 500MG BASE/VIAL **		A062812 001	Nov 17, 1987
	EQ 1GM BASE/VIAL **		A060180 002	Mar 21, 1986
	EQ 1GM BASE/VIAL		A062476 002	Mar 21, 1986
	EQ 1GM BASE/VIAL		A062716 002	Mar 13, 1987
	EQ 1GM BASE/VIAL **		A062812 002	Nov 17, 1987
	EQ 10GM BASE/VIAL **		A062812 003	Nov 17, 1987
VANCOLED				
WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL **		A062682 001	Jul 22, 1986
	EQ 1GM BASE/VIAL **		A062682 002	Mar 30, 1988
	EQ 2GM BASE/VIAL **		A062682 003	May 11, 1988
	EQ 5GM BASE/VIAL **		A062682 004	May 11, 1988
	EQ 10GM BASE/VIAL **		A062682 005	May 11, 1988
VANCOMYCIN HYDROCHLORIDE				
EMCURE PHARMS LTD	EQ 500MG BASE/VIAL		A202275 001	Oct 31, 2013
	EQ 1GM BASE/VIAL		A202275 002	Oct 31, 2013
	EQ 10GM BASE/VIAL		A202464 001	Oct 09, 2013
	EQ 5GM BASE/VIAL		A202274 001	Oct 31, 2013
HAINAN POLY PHARM	EQ 500MG BASE/VIAL		A212332 001	Jun 12, 2019
	EQ 1GM BASE/VIAL		A212332 002	Jun 12, 2019
MYLAN LABS LTD	EQ 10GM BASE/VIAL		A091469 001	Jul 01, 2011
TEVA PHARMS USA	EQ 500MG BASE/VIAL		A201251 001	Dec 23, 2015
	EQ 1GM BASE/VIAL		A201251 002	Dec 23, 2015
	EQ 5GM BASE/VIAL		A201250 001	Dec 23, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VANCOMYCIN HYDROCHLORIDE					
INJECTABLE;INJECTION					
VANCOMYCIN HYDROCHLORIDE					
		EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015
	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
		EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988
	XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015
		EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015
		EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015
		EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015
VANCOR					
	PHARMACIA AND UPJOHN	EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
		EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988
VARDENAFIL HYDROCHLORIDE					
TABLET;ORAL					
LEVITRA					
+	BAYER HLTHCARE	2.5MG **	N021400	003	Aug 19, 2003
VARDENAFIL HYDROCHLORIDE					
	AMNEAL PHARMS CO	5MG	A210738	001	Oct 31, 2018
		10MG	A210738	002	Oct 31, 2018
		20MG	A210738	003	Oct 31, 2018
VASOPRESSIN TANNATE					
INJECTABLE;INJECTION					
PITRESSIN TANNATE					
+	PARKE DAVIS	5PRESSOR UNITS/ML **	N003402	001	
VECURONIUM BROMIDE					
INJECTABLE;INJECTION					
NORCURON					
+	ORGANON USA INC	10MG/VIAL **	N018776	002	Apr 30, 1984
+		20MG/VIAL **	N018776	003	Jan 03, 1992
VECURONIUM BROMIDE					
	HOSPIRA	4MG/VIAL	A075558	001	Sep 11, 2001
	WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995
		20MG/VIAL	A074334	002	Aug 31, 1995
	WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999
		20MG/VIAL	A075218	002	Aug 23, 1999
VELAGLUCERASE ALFA					
POWDER;INTRAVENOUS					
VPRIV					
	SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575	002	Feb 26, 2010
VENLAFAXINE HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
EFFEXOR XR					
	WYETH PHARMS	EQ 100MG BASE	N020699	003	Oct 20, 1997
VENLAFAXINE HYDROCHLORIDE					
	ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012
		EQ 75MG BASE	A078087	002	Mar 16, 2012
		EQ 150MG BASE	A078087	003	Mar 16, 2012
	MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011
		EQ 75MG BASE	A078789	002	Jun 01, 2011
		EQ 150MG BASE	A078789	003	Jun 01, 2011
TABLET;ORAL					
EFFEXOR					
+	WYETH PHARMS INC	EQ 12.5MG BASE **	N020151	001	Dec 28, 1993
+		EQ 25MG BASE **	N020151	002	Dec 28, 1993
+		EQ 37.5MG BASE **	N020151	006	Dec 28, 1993
+		EQ 50MG BASE **	N020151	003	Dec 28, 1993
+		EQ 75MG BASE **	N020151	004	Dec 28, 1993
+		EQ 100MG BASE **	N020151	005	Dec 28, 1993
VENLAFAXINE HYDROCHLORIDE					
	FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008
		EQ 37.5MG BASE	A077515	002	Jun 13, 2008
		EQ 50MG BASE	A077515	003	Jun 13, 2008
		EQ 75MG BASE	A077515	004	Jun 13, 2008
		EQ 100MG BASE	A077515	005	Jun 13, 2008
	PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008
		EQ 37.5MG BASE	A078517	002	Jun 13, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VENLAFAXINE HYDROCHLORIDE					
TABLET;ORAL					
VENLAFAXINE HYDROCHLORIDE					
		EQ 50MG BASE	A078517	003	Jun 13, 2008
		EQ 75MG BASE	A078517	004	Jun 13, 2008
		EQ 100MG BASE	A078517	005	Jun 13, 2008
	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010
		EQ 37.5MG BASE	A090027	002	Aug 04, 2010
		EQ 50MG BASE	A090027	003	Aug 04, 2010
		EQ 75MG BASE	A090027	004	Aug 04, 2010
		EQ 100MG BASE	A090027	005	Aug 04, 2010
VERAPAMIL HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
VERAPAMIL HYDROCHLORIDE					
	MYLAN	100MG	A078306	001	Aug 09, 2007
		200MG	A078306	002	Aug 09, 2007
		300MG	A078306	003	Aug 09, 2007
INJECTABLE;INJECTION					
CALAN					
	GD SEARLE LLC	2.5MG/ML	N019038	001	Mar 30, 1984
ISOPTIN					
+	MT ADAMS	2.5MG/ML **	N018485	001	
VERAPAMIL HYDROCHLORIDE					
	ABRAXIS PHARM	2.5MG/ML	A070348	001	May 01, 1986
	BEDFORD	2.5MG/ML	A072888	001	Jul 28, 1995
	HOSPIRA	2.5MG/ML	A070577	001	Feb 02, 1987
		2.5MG/ML	A070739	001	May 06, 1987
		2.5MG/ML	A070740	001	May 06, 1987
	INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985
	LUITPOLD	2.5MG/ML	A070225	001	Nov 12, 1985
		2.5MG/ML	A070617	001	Nov 12, 1985
	MARSAM PHARMS LLC	2.5MG/ML	A072233	001	Feb 26, 1993
		2.5MG/ML	A073485	001	Sep 27, 1993
	SMITH AND NEPHEW	2.5MG/ML	A070696	001	Jul 31, 1987
		2.5MG/ML	A070697	001	Jul 31, 1987
	SOLOPAK	2.5MG/ML	A070695	001	Jul 31, 1987
TABLET;ORAL					
CALAN					
	GD SEARLE LLC	40MG	N018817	003	Feb 23, 1988
+		80MG	N018817	001	Sep 10, 1984
+		120MG	N018817	002	Sep 10, 1984
		160MG	N018817	004	Feb 23, 1988
ISOPTIN					
+	MT ADAMS	40MG	N018593	003	Nov 23, 1987
+		80MG	N018593	001	Mar 08, 1982
+		120MG	N018593	002	Mar 08, 1982
VERAPAMIL HYDROCHLORIDE					
	ACTAVIS ELIZABETH	80MG	A071019	001	Sep 24, 1986
		120MG	A070468	001	Sep 24, 1986
	MUTUAL PHARM	80MG	A070482	001	Sep 24, 1986
		120MG	A070483	001	Sep 24, 1986
	PLIVA	40MG	A072751	001	Feb 23, 1996
		80MG	A072124	001	Jan 26, 1989
		120MG	A072125	001	Jan 26, 1989
	SUN PHARM INDUSTRIES	80MG	A071489	002	Jan 13, 1988
		120MG	A071489	001	Jan 13, 1988
	WARNER CHILCOTT	80MG	A070340	001	Sep 24, 1986
		120MG	A070341	001	Sep 24, 1986
	WATSON LABS	40MG	A072799	001	Apr 28, 1989
		40MG	A072923	001	Jun 29, 1993
		80MG	A070855	001	Sep 24, 1986
		80MG	A071366	001	Oct 01, 1986
		120MG	A070856	001	Sep 24, 1986
		120MG	A071367	001	Oct 01, 1986
	YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992
		80MG	A071423	001	May 24, 1988
		120MG	A071424	001	May 25, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VERAPAMIL HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
CALAN SR				
+ PFIZER	180MG **	N019152	002	Dec 15, 1989
COVERA-HS				
GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996
	240MG	N020552	002	Feb 26, 1996
VERAPAMIL HYDROCHLORIDE				
APOTEX CORP	120MG	A200878	001	Apr 20, 2012
	180MG	A200878	002	Apr 20, 2012
	240MG	A200878	003	Apr 20, 2012
PLIVA	240MG	A072922	001	Mar 01, 1996
VERATRUM VIRIDE ROOT				
TABLET;ORAL				
VERTAVIS				
MEDPOINTE PHARM HLC	130CSR UNIT	N005691	002	
VIDARABINE				
INJECTABLE;INJECTION				
VIRA-A				
PARKEDALE	EQ 187.4MG BASE/ML	N050523	001	
OINTMENT;OPHTHALMIC				
VIRA-A				
PARKEDALE	3%	N050486	001	
VINBLASTINE SULFATE				
INJECTABLE;INJECTION				
VELBAN				
+ LILLY	10MG/VIAL	N012665	001	
VINBLASTINE SULFATE				
ABRAXIS PHARM	10MG/VIAL	A089011	001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565	001	Aug 18, 1987
VINCRISTINE SULFATE				
INJECTABLE;INJECTION				
ONCOVIN				
LILLY	1MG/VIAL	N014103	001	
	1MG/ML	N014103	003	Mar 07, 1984
	5MG/VIAL	N014103	002	
VINCASAR PFS				
TEVA PARENTERAL	1MG/ML	A071426	001	Jul 17, 1987
VINCREX				
BRISTOL MYERS SQUIBB	5MG/VIAL	A070867	001	Jul 12, 1988
VINCRISTINE SULFATE				
ABIC	1MG/ML	A070873	001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411	001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296	001	Dec 20, 2002
	1MG/ML	A076401	001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559	001	Apr 11, 1988
	2MG/VIAL	A071560	001	Apr 11, 1988
	5MG/VIAL	A071561	001	Apr 11, 1988
VINCRISTINE SULFATE PFS				
TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999
VINORELBINE TARTRATE				
INJECTABLE;INJECTION				
NAVELBINE				
+ PIERRE FABRE	EQ 10MG BASE/ML	N020388	001	Dec 23, 1994
VINORELBINE TARTRATE				
EBEWE PHARMA	EQ 10MG BASE/ML	A078408	001	Feb 13, 2008
HOSPIRA	EQ 10MG BASE/ML	A076827	001	Jun 02, 2005
MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012
NOVAST LABS	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019
VIOMYCIN SULFATE				
INJECTABLE;INJECTION				
VIOCIN SULFATE				
PFIZER	EQ 1GM BASE/VIAL	A061086	001	
	EQ 5GM BASE/VIAL	A061086	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VITAMIN A				
CAPSULE;ORAL				
AQUASOL A				
	ASTRAZENECA	25,000USP UNITS	A083080 002	
		50,000USP UNITS	A083080 001	
VITAMIN A				
	BANNER PHARMACAPS	50,000USP UNITS	A083973 001	
	CHASE CHEM	50,000 IU	A083351 001	
	EVERYLIFE	50,000 IU	A083134 001	
	IMPAX LABS	50,000USP UNITS	A080952 001	
	WEST WARD	50,000USP UNITS	A080985 001	
VITAMIN A PALMITATE				
CAPSULE;ORAL				
AFAXIN				
	STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187 001	
ALPHALIN				
	LILLY	EQ 50,000 UNITS BASE	A080883 001	
DEL-VI-A				
	DEL RAY LABS	EQ 50,000 UNITS BASE	A080830 001	
VI-DOM-A				
	BAYER PHARMS	EQ 50,000 UNITS BASE	A080972 001	
VITAMIN A				
	BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001	
	BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001	
	CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001	
		EQ 50,000 UNITS BASE	A083207 001	
	ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001	
	EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001	
		EQ 50,000 UNITS BASE	A083114 001	
	IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001	
		EQ 50,000 UNITS BASE	A080955 001	
	IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001	
		EQ 50,000 UNITS BASE	A083190 001	
	MK LABS	EQ 25,000 UNITS BASE	A083457 002	
		EQ 50,000 UNITS BASE	A083457 001	
	WEST WARD	EQ 50,000 UNITS BASE	A080967 001	
	WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001	
VITAMIN A PALMITATE				
	ARCUM	EQ 50,000 UNITS BASE	A083311 001	
		EQ 50,000 UNITS BASE	A083321 001	
	BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001	
		EQ 50,000 UNITS BASE	A083981 001	
VITAMIN A SOLUBILIZED				
	TEVA	EQ 50,000 UNITS BASE	A080921 001	
INJECTABLE;INJECTION				
VITAMIN A PALMITATE				
	BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001	
VORICONAZOLE				
FOR SUSPENSION;ORAL				
VORICONAZOLE				
	MYLAN PHARMS INC	200MG/5ML	A202361 001	May 28, 2013
TABLET;ORAL				
VORICONAZOLE				
	TEVA PHARMS	50MG	A091658 001	Apr 06, 2012
		200MG	A091658 002	Apr 06, 2012
VORTIOXETINE HYDROBROMIDE				
TABLET;ORAL				
TRINTELLIX				
+	TAKEDA PHARMS USA	EQ 15MG BASE **	N204447 003	Sep 30, 2013
WARFARIN POTASSIUM				
TABLET;ORAL				
ATHROMBIN-K				
	PHARM RES ASSOC	2MG	N011771 007	
		5MG	N011771 004	
		10MG	N011771 005	
		25MG	N011771 006	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

WARFARIN SODIUM				
INJECTABLE;INJECTION				
COUMADIN				
BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995
	50MG/VIAL	N009218	020	
	75MG/VIAL	N009218	012	
TABLET;ORAL				
ATHROMBIN				
PHARM RES ASSOC	5MG	N011771	003	
	10MG	N011771	002	
	25MG	N011771	001	
PANWARFIN				
ABBOTT	2MG	N017020	001	
	2.5MG	N017020	002	
	5MG	N017020	003	
	7.5MG	N017020	004	
	10MG	N017020	005	
WARFARIN SODIUM				
MYLAN	1MG	A040415	001	Sep 27, 2004
	2MG	A040415	002	Sep 27, 2004
	2.5MG	A040415	003	Sep 29, 2004
	3MG	A040415	004	Sep 27, 2004
	4MG	A040415	005	Sep 27, 2004
	5MG	A040415	006	Sep 27, 2004
	6MG	A040415	007	Sep 27, 2004
	7.5MG	A040415	008	Sep 27, 2004
	10MG	A040415	009	Sep 27, 2004
USL PHARMA	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985
WATSON LABS	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982
YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997
	5MG	A040196	005	Sep 30, 1997
	6MG	A040196	009	Jul 26, 2000
	7.5MG	A040196	006	Sep 30, 1997
	10MG	A040196	007	Sep 30, 1997
XENON XE-127				
GAS;INHALATION				
XENON XE 127				
MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982
XENON XE-133				
GAS;INHALATION				
XENON XE 133				
GE HEALTHCARE	1 CI/AMP	N017256	002	
	10mCi/VIAL	N017687	002	
	20mCi/VIAL	N017687	003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001	
	0.25-5 CI/AMP	N017550	003	
XENON XE 133-V.S.S.				
GE HEALTHCARE	10mCi/VIAL	N017687	001	
INJECTABLE;INJECTION				
XENON XE 133				
GE HEALTHCARE	1.3-1.7 CI/AMP	N017256	001	
LANTHEUS MEDCL	6.3mCi/ML	N017283	001	
SOLUTION;INHALATION, INJECTION				
XENEISOL				
MALLINCKRODT	18-25mCi/AMP	N017262	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

XYLOSE				
POWDER;ORAL				
XYLO-PFAN				
SAVAGE LABS	25GM/BOT	N017605	001	
XYLOSE				
LYNE	25GM/BOT	N018856	001	Mar 26, 1987
ZALCITABINE				
TABLET;ORAL				
HIVID				
ROCHE	0.375MG	N020199	001	Jun 19, 1992
	0.75MG	N020199	002	Jun 19, 1992
ZALEPLON				
CAPSULE;ORAL				
ZALEPLON				
MYLAN	5MG	A077238	001	Jun 06, 2008
	10MG	A077238	002	Jun 06, 2008
UPSHER SMITH LABS	5MG	A078095	001	Jun 06, 2008
	5MG	A078706	001	Jun 06, 2008
	10MG	A078095	002	Jun 06, 2008
	10MG	A078706	002	Jun 06, 2008
ZICONOTIDE ACETATE				
INJECTABLE;INTRATHECAL				
PRIALT				
TERSERA THERAPS LLC	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004
ZIDOVUDINE				
INJECTABLE;INJECTION				
ZIDOVUDINE				
LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013
LUITPOLD	10MG/ML	A091457	001	May 06, 2010
TABLET;ORAL				
RETROVIR				
VIIV HLTHCARE	200MG	N020518	001	Dec 19, 1995
+	300MG **	N020518	002	Oct 04, 1996
ZIDOVUDINE				
AUROBINDO PHARMA	60MG	N022294	001	Jul 23, 2009
HEC PHARM	300MG	A202058	001	Oct 07, 2011
MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011
RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005
ZILEUTON				
TABLET;ORAL				
ZYFLO				
CHIESI USA INC	300MG	N020471	001	Dec 09, 1996
ZINC SULFATE				
INJECTABLE;INJECTION				
ZINC SULFATE				
ABRAXIS PHARM	EQ 1MG ZINC/ML	N019229	002	May 05, 1987
ZIPRASIDONE HYDROCHLORIDE				
CAPSULE;ORAL				
ZIPRASIDONE HYDROCHLORIDE				
CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017
	EQ 40MG BASE	A208988	002	Aug 22, 2017
	EQ 60MG BASE	A208988	003	Aug 22, 2017
	EQ 80MG BASE	A208988	004	Aug 22, 2017
MYLAN	EQ 20MG BASE	A202395	001	Oct 10, 2013
	EQ 40MG BASE	A202395	002	Oct 10, 2013
	EQ 60MG BASE	A202395	003	Oct 10, 2013
	EQ 80MG BASE	A202395	004	Oct 10, 2013
SUSPENSION;ORAL				
GEODON				
PFIZER INC	EQ 10MG BASE/ML	N021483	001	Mar 29, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZOLEDRONIC ACID					
INJECTABLE;INTRAVENOUS					
ZOLEDRONIC ACID					
	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013
	DR REDDYS LABS LTD	EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018
	SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019
	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013
		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013
ZOMETA					
+	NOVARTIS	EQ 4MG BASE/VIAL **	N021223	001	Aug 20, 2001
ZOLMITRIPTAN					
TABLET;ORAL					
ZOLMITRIPTAN					
	ANI PHARMS INC	2.5MG	A090861	001	Mar 04, 2014
		5MG	A090861	002	Mar 04, 2014
	APOTEX INC	2.5MG	A202078	001	May 14, 2013
		5MG	A202078	002	May 14, 2013
	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015
		5MG	A203772	002	Sep 30, 2015
	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013
		5MG	A203186	002	May 14, 2013
	SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014
		5MG	A203476	002	Nov 13, 2014
TABLET, ORALLY DISINTEGRATING;ORAL					
ZOLMITRIPTAN					
	APOTEX INC	2.5MG	A202476	001	May 14, 2013
		5MG	A202476	002	May 14, 2013
	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015
		5MG	A204336	002	Oct 22, 2015
ZOLPIDEM TARTRATE					
TABLET;ORAL					
ZOLPIDEM TARTRATE					
	DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007
		10MG	A077985	002	Apr 23, 2007
	HIKMA	5MG	A078129	001	Apr 30, 2008
		10MG	A078129	002	Apr 30, 2008
	MYLAN	5MG	A076578	001	Apr 23, 2007
		10MG	A076578	002	Apr 23, 2007
	MYLAN PHARMS INC	5MG	A078016	001	Apr 23, 2007
		10MG	A078016	002	Apr 23, 2007
	STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007
		10MG	A076062	002	Apr 23, 2007
	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007
		10MG	A077359	002	Apr 23, 2007
	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007
		10MG	A078055	002	Apr 23, 2007
	SUN PHARM INDUSTRIES	5MG	A077288	001	Apr 23, 2007
		10MG	A077288	002	Apr 23, 2007
	SYNTHON PHARMS	5MG	A077540	001	Apr 23, 2007
		10MG	A077540	002	Apr 23, 2007
	WATSON LABS	5MG	A077773	001	Apr 23, 2007
		10MG	A077773	002	Apr 23, 2007
	WOCKHARDT	5MG	A078426	001	May 15, 2007
		10MG	A078426	002	May 15, 2007
TABLET;SUBLINGUAL					
INTERMEZZO					
+	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011
+		3.5MG	N022328	002	Nov 23, 2011
TABLET, EXTENDED RELEASE;ORAL					
ZOLPIDEM TARTRATE					
	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011
		12.5MG	A078483	002	Jun 06, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
TOVALT ODT					
	BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007
		10MG	N021412	002	Apr 25, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN					
+	SUNOVION PHARMS INC	50MG **	N020789	002	Aug 22, 2003
ZONISAMIDE					
	ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005
		25MG	A077641	003	Dec 22, 2005
		50MG	A077639	002	Dec 22, 2005
		50MG	A077641	002	Dec 22, 2005
		100MG	A077639	003	Dec 22, 2005
		100MG	A077641	001	Dec 22, 2005
	AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006
		50MG	A077645	003	Sep 29, 2006
		100MG	A077645	001	Dec 22, 2005
	EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007
		50MG	A077876	002	Feb 21, 2007
		100MG	A077876	003	Feb 21, 2007
	HERITAGE PHARMA	25MG	A077650	001	Apr 20, 2006
		50MG	A077650	002	Apr 20, 2006
		100MG	A077650	003	Apr 20, 2006
	MYLAN	25MG	A077637	001	Dec 22, 2005
		50MG	A077637	002	Dec 22, 2005
		100MG	A077637	003	Dec 22, 2005
	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005
		50MG	A077647	002	Dec 22, 2005
		100MG	A077647	003	Dec 22, 2005
	ROXANE	25MG	A077648	001	Dec 22, 2005
		50MG	A077648	002	Dec 22, 2005
		100MG	A077648	003	Dec 22, 2005
	SUN PHARM INDUSTRIES	25MG	A077635	001	Dec 22, 2005
		50MG	A077635	002	Dec 22, 2005
		100MG	A077635	003	Dec 22, 2005
	UPSHER SMITH LABS	25MG	A077644	001	Dec 22, 2005
		50MG	A077644	002	Dec 22, 2005
		100MG	A077644	003	Dec 22, 2005

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ABLYSINOL, ALCOHOL
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSORICA LD, ISOTRETINOIN
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCRUFER, FERRIC MALTOL
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICLATE, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE (OTC)
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIGUAT
ADENOSINE, ADENOSINE
ADHANSIA XR, METHYLPHENIDATE HYDROCHLORIDE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADLYXIN, LIXISENATIDE
ADMELOG, INSULIN LISPRO
ADMELOG SOLOSTAR, INSULIN LISPRO
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS ER, AMPHETAMINE
ADZENYS XR-ODT, AMPHETAMINE
AEMCOLO, RIFAMYCIN SODIUM
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AFREZZA, INSULIN RECOMBINANT HUMAN
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKLIEF, TRIFAROTENE
AKOVAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENDAZOLE, ALBENDAZOLE
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALIQOPA, COPANLISIB DIHYDROCHLORIDE
ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLZITAL, ACETAMINOPHEN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALTRENO, TRETINOIN
ALUNBRIG, BRIGATINIB
ALVESCO, CICLESONIDE
ALVIMOPAN, ALVIMOPAN
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ALYQ, TADALAFIL
AMABELZ, ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMBRISENTAN, AMBRISENTAN
AMCINONIDE, AMCINONIDE
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMYVID, FLORBETAPIR F-18
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANGIOMAX RTU, BIVALIRUDIN
ANNOVERA, ETHINYL ESTRADIOL
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANUSOL HC, HYDROCORTISONE
APADAZ, ACETAMINOPHEN
APIDRA, INSULIN GLULISINE RECOMBINANT
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIXABAN, APIXABAN
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARAKODA, TAFENOQUINE SUCCINATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARAZLO, TAZAROTENE
ARCAPTA NEOHALER, INDACATEROL MALEATE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIKAYCE KIT, AMIKACIN SULFATE
ARIMIDEX, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARISTADA, ARIPIPRAZOLE LAUROXIL
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ARTHROTEC, DICLOFENAC SODIUM
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASCOR, ASCORBIC ACID
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AURYXIA, FERRIC CITRATE
AUSTEDO, DEUTETRABENAZINE
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVEED, TESTOSTERONE UNDECANOATE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AVYCAZ, AVIBACTAM SODIUM
AXID AR, NIZATIDINE (OTC)
AXUMIN, FLUCICLOVINE F-18
AYUNA, ETHINYL ESTRADIOL
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZEDRA, IOBENGUANE I-131
AZELAIC ACID, AZELAIC ACID
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACIIM, BACITRACIN
BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALCOLTRA, ETHINYL ESTRADIOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALVERSA, ERDAFITINIB
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BAQSIMI, GLUCAGON
BARACLUDE, ENTECAVIR
BASAGLAR, INSULIN GLARGINE
BAXDELA, DELAFLOXACIN MEGLUMINE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BELSOMRA, SUVOREXANT
BELVIQ, LORCASERIN HYDROCHLORIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEVYXXA, BETRIXABAN
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BIJUVA, ESTRADIOL
BIKTARVY, BICTEGRAVIR SODIUM
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBSALICYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BONIVA, IBANDRONATE SODIUM
BONJESTA, DOXYLAMINE SUCCINATE
BONSITY, TERIPARATIDE RECOMBINANT HUMAN
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BOSULIF, BOSUTINIB MONOHYDRATE
BRAFTOVI, ENCORAFENIB
BREO ELLIPTA, FLUTICASONE FUROATE
BRETHINE, TERBUTALINE SULFATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRIDION, SUGAMMADEX SODIUM
BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRISDELLE, PAROXETINE MESYLATE
BRIVIACT, BRIVARACETAM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BROMSITE, BROMFENAC SODIUM
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BRUKINSA, ZANUBRUTINIB
BRYHALI, HALOBETASOL PROPIONATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON, EXENATIDE SYNTHETIC

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BYDUREON BCISE, EXENATIDE
BYDUREON PEN, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPLYTA, LUMATEPERONE TOSYLATE
CAPRELSA, VANDETANIB
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARFILZOMIB, CARFILZOMIB

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARMUSTINE, CARMUSTINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CEQUA, CYCLOSPORINE
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERINTA, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLBAM, CHOLIC ACID
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMDUO, LAMIVUDINE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CINVANTI, APREPITANT
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARISCAN, GADOTERATE MEGLUMINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLENPIQ, CITRIC ACID
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOLAR, CLOFARABINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOVIQUE, TRIENTINE HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
COLCRYS, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONJUPRI, LEVAMLODIPINE MALEATE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CONRAY, IOTHALAMATE MEGLUMINE
CONSENSI, AMLODIPINE BESYLATE
CONSTILAC, LACTULOSE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPIKTRA, DUVELISIB
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COUMADIN, WARFARIN SODIUM
COZAAR, LOSARTAN POTASSIUM
CREON, PANCRELIPASE (AMYLASE
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUBICIN RF, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CYONANZ, ETHINYL ESTRADIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOTEC, MISOPROSTOL
CYTOVENE, GANCICLOVIR SODIUM

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DALFAMPRIDINE, DALFAMPRIDINE
DALIRESP, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DAPTOMYCIN, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARUNAVIR, DARUNAVIR
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAURISMO, GLASDEGIB MALEATE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE
DDAVP, DESMOPRESSIN ACETATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DEFITELIO, DEFIBROTIDE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSTRIGO, DORAVIRINE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMADEX, TORSEMIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENAVIR, PENCICLOVIR
DEPAKOTE, DIVALPROEX SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMATOP, PREDNICARBATE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESCOVY, EMTRICITABINE
DESFERAL, DEFEROXAMINE MESYLATE
DESFLURANE, DESFLURANE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONATE, DESONIDE
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXILANT, DEXLANSOPRAZOLE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTENZA, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50%, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXYCU KIT, DEXAMETHASONE
DIABETA, GLYBURIDE
DIACOMIT, STIRIPENTOL
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOCETAXEL, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DOFETILDE, DOFETILIDE
DOFETILIDE, DOFETILIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOPTELET, AVATROMBOPAG MALEATE
DORAL, QUAZEPAM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVATO, DOLUTEGRAVIR SODIUM
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIA, HYDROXYUREA
DSUVIA, SUFENTANIL CITRATE
DUAC, BENZOYL PEROXIDE
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUOBRII, HALOBETASOL PROPIONATE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-37, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURLAZA, ASPIRIN
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DUVOID, BETHANECHOL CHLORIDE
DYANAVEL XR, AMPHETAMINE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCLOPRO, DYCLONINE HYDROCHLORIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGATEN, TRICLABENDAZOLE
EGRIFTA, TESAMORELIN ACETATE
ELCYS, CYSTEINE HYDROCHLORIDE
ELELYSO, TALIGLUCERASE ALFA
ELEPSIA XR, LEVETIRACETAM
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIFEMME, ETHINYL ESTRADIOL
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
ELURYNG, ETHINYL ESTRADIOL
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMFLAZA, DEFLAZACORT
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRICITABINE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENULOSE, LACTULOSE
ENVARSUS XR, TACROLIMUS
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDIOLEX, CANNABIDIOL
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
EPINEPHRINE (COPACKAGED), EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERLEADA, APALUTAMIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON
EUTHYROX, LEVOTHYROXINE SODIUM **
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVEKEO ODT, AMPHETAMINE SULFATE
EVEROLIMUS, EVEROLIMUS
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOMELA, MELPHALAN HYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVZIO (AUTOINJECTOR), NALOXONE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXEM FOAM KIT, AIR POLYMER-TYPE A
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXONDYS 51, ETEPLIRSEN
EXPAREL, BUPIVACAINE
EXSERVAN, RILUZOLE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODEXTRIN
EZALLOR, ROSUVASTATIN CALCIUM
EZETIMIBE, EZETIMIBE
EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
EZETIMIBE AND SIMVASTATIN, EZETIMIBE

**** F ****

FABIOR, TAZAROTENE
FACTIVE, GEMIFLOXACIN MESYLATE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FARXIGA, DAPAGLIFLOZIN
FARYDAK, PANOBINOSTAT LACTATE
FASLODEX, FULVESTRANT
FAYOSIM, ETHINYL ESTRADIOL
FEBUXOSTAT, FEBUXOSTAT
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERRIPROX, DEFERIPRONE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIASP, INSULIN ASPART
FIASP FLEXTOUCH, INSULIN ASPART
FIASP PENFILL, INSULIN ASPART
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL, ASPIRIN
FIORINAL W/CODEINE, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FIRMAGON, DEGARELIX ACETATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
FLAGYL, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLOLAN, EPOPROSTENOL SODIUM
FLOLIPID, SIMVASTATIN
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXURIDINE, FLOXURIDINE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCITE, FLUORESCEIN SODIUM
FLUORODOPA F18, FLUORODOPA F-18
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTESTA, TESTOSTERONE
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FULVESTRANT, FULVESTRANT
FURADANTIN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE
FYAVOLV, ETHINYL ESTRADIOL
FYCOMPA, PERAMPANEL

**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GADAVIST, GADOBUTROL
GALAFOLD, MIGALASTAT HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALLIUM DOTATOC GA 68, GALLIUM DOTATOC GA-68
GALZIN, ZINC ACETATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GANZYK-RTU, GANCICLOVIR
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOSYL, NITRIC OXIDE
GENOTROPIN, SOMATROPIN
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II ACETATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD HYDROCHLORIDE
GILOTRIF, AFATINIB DIMALEATE
GIVLAARI, GIVOSIRAN SODIUM
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLOPERBA, COLCHICINE
GLUCAGEN, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCOTROL, GLIPIZIDE
GLUCOTROL XL, GLIPIZIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GLYNASE, GLYBURIDE
GLYRX-PF, GLYCOPYRROLATE
GLYSET, MIGLITOL
GLYXAMBI, EMPAGLIFLOZIN
GOCOVRI, AMANTADINE HYDROCHLORIDE
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONITRO, NITROGLYCERIN
GOPRELTO, COCAINE HYDROCHLORIDE
GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUAIFENESIN, GUAIFENESIN (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
GVOKE HYPOPEN, GLUCAGON
GVOKE PFS, GLUCAGON
GYNAZOLE-1, BUTOCONAZOLE NITRATE

**** H ****

H.P. ACTHAR GEL, CORTICOTROPIN
HABITROL, NICOTINE (OTC)
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1/20, ETHINYL ESTRADIOL
HALAVEN, ERIBULIN MESYLATE
HALCINONIDE, HALCINONIDE
HALCION, TRIAZOLAM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HALOG, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HARVONI, LEDIPASVIR
HEATHER, NORETHINDRONE
HECTOROL, DOXERCALCIFEROL
HEMABATE, CARBOPROST TROMETHAMINE
HEMADY, DEXAMETHASONE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPSERA, ADEFOVIR DIPIVOXIL
HER STYLE, LEVONORGESTREL (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** H ****

HETLIOZ, TASIMELTEON
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HICON, SODIUM IODIDE I-131
HIPREX, METHENAMINE HIPPURATE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HORIZANT, GABAPENTIN ENACARBIL
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG TEMPO PEN, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R KWIKPEN, INSULIN HUMAN
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERON CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
HYSINGLA ER, HYDROCODONE BITARTRATE
HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBRANCE, PALBOCICLIB
IBSRELA, TENAPANOR HYDROCHLORIDE
IBU-TAB, IBUPROFEN
IBU-TAB 200, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN LYSINE, IBUPROFEN LYSINE
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** I ****

IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICATIBANT ACETATE, ICATIBANT ACETATE
ICLEVIA, ETHINYL ESTRADIOL
ICLUSIG, PONATINIB HYDROCHLORIDE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDHIFA, ENASIDENIB MESYLATE
IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
ILEVRO, NEPAFENAC
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPOYZ, CLOBETASOL PROPIONATE
IMURAN, AZATHIOPRINE
IMVEXXY, ESTRADIOL
INAPSINE, DROPERIDOL
INBRIJA, LEVODOPA
INCASSIA, NORETHINDRONE
INCRELEX, MECASERMIN RECOMBINANT
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANT'S ADVIL, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUGEM, GEMCITABINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGENOL MEBUTATE, INGENOL MEBUTATE
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INREBIC, FEDRATINIB HYDROCHLORIDE
INSPRA, EPLERENONE
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL

APPENDIX A - PRODUCT NAME INDEX

**** I ****

INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVELTYS, LOTEPREDNOL ETABONATE
INVIRASE, SAQUINAVIR MESYLATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISIBLOOM, DESOGESTREL
ISOFLURANE, ISOFLURANE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVERMECTIN, IVERMECTIN
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE

**** J ****

JADENU, DEFERASIROX
JADENU SPRINKLE, DEFERASIROX
JAIMIESS, ETHINYL ESTRADIOL
JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JATENZO, TESTOSTERONE UNDECANOATE
JEANATOPE, ALBUMIN IODINATED I-125 SERUM

APPENDIX A - PRODUCT NAME INDEX

**** J ****

JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE
JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE
JYNARQUE, TOLVAPTAN

**** K ****

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KADIAN, MORPHINE SULFATE
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KATERZIA, AMLODIPINE BENZOATE
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KELNOR, ETHINYL ESTRADIOL
KEMEYA, DROSPIRENONE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHAPZORY, LEVOLEUCOVORIN
KIMIDESS, DESOGESTREL
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** K ****

KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KORLYM, MIFEPRISTONE
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
KRINTAFEL, TAFENOQUINE SUCCINATE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYBELLA, DEOXYCHOLIC ACID
KYLEENA, LEVONORGESTREL
KYPROLIS, CARFILZOMIB
KYRA, DROSPIRENONE

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LANTUS, INSULIN GLARGINE RECOMBINANT
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACAFT, ALCAFTADINE
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LAZANDA, FENTANYL CITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LENVIMA, LENVATINIB MESYLATE
LERIBANE, ETHINYL ESTRADIOL
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVEMIR, INSULIN DETEMIR RECOMBINANT
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXETTE, HALOBETASOL PROPIONATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LILETTA, LEVONORGESTREL
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LINEZOLID, LINEZOLID
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPIODOL, ETHIODIZED OIL
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO SIMPESSE, ETHINYL ESTRADIOL
LO-MALMOREDE, ETHINYL ESTRADIOL
LO-ZUMANDIMINE, DROSPIRENONE
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOGILIA, ULIPRISTAL ACETATE
LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
LOMAIRA, PHENTERMINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
LONHALA MAGNAIR KIT, GLYCOPYRROLATE
LONSURF, TIPIRACIL HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORBRENA, LORLATINIB
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMIFY, BRIMONIDINE TARTRATE (OTC)
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPANETA PACK, LEUPROLIDE ACETATE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
LUTATHERA, LUTETIUM DOTATATE LU-177
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LUZU, LULICONAZOLE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNPARZA, OLAPARIB
LYRICA, PREGABALIN
LYRICA CR, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M.V.I. ADULT, ASCORBIC ACID
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
MACRILEN, MACIMORELIN ACETATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACUGEN, PEGAPTANIB SODIUM
MAFENIDE ACETATE, MAFENIDE ACETATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAKENA, HYDROXYPROGESTERONE CAPROATE
MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MALMOREDE, ETHINYL ESTRADIOL
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVENCLAD, CLADRIBINE
MAVYRET, GLECAPREVIR
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAYZENT, SIPONIMOD FUMARIC ACID
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE ES, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MEKTOVI, BINIMETINIB
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPURINE, MERCAPTOPURINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLDOPA, METHYLDOPA
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRO-K, POTASSIUM CHLORIDE
MICRO-K 10, POTASSIUM CHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIFEPRISTONE, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGLUSTAT, MIGLUSTAT
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRABEGRON, MIRABEGRON
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITIGO, MORPHINE SULFATE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHABOND ER, MORPHINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIDECTIN, MOXIDECTIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULPLETA, LUSUTROMBOPAG
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYDAYIS, AMPHETAMINE ASPARTATE
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MYSOLINE, PRIMIDONE
MYTESI, CROFELEMER
MYXREDLIN, INSULIN HUMAN
MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALOXONE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE
NATACYN, NATAMYCIN
NATAZIA, DIENOGEST
NATEGLINIDE, NATEGLINIDE
NATESTO, TESTOSTERONE
NATROBA, SPINOSAD
NAYZILAM, MIDAZOLAM
NEBUPENT, PENTAMIDINE ISETHIONATE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NEPHRAMINE 5.4%, AMINO ACIDS
NERLYNX, NERATINIB MALEATE

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXESTA FE, ETHINYL ESTRADIOL
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXPLANON, ETONOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILUTAMIDE, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITHIODOTE, SODIUM NITRITE
NITISINONE, NITISINONE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL, KETOCONAZOLE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOCDURNA, DESMOPRESSIN ACETATE
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORDITROPIN FLEXPRO, SOMATROPIN
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORITATE, METRONIDAZOLE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORTHERA, DROXIDOPA
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOURESS, CYSTEINE HYDROCHLORIDE
NOURIANZ, ISTRADEFYLLINE
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOXAFIL, POSACONAZOLE
NOXIVENT, NITRIC OXIDE
NUBEQA, DAROLUTAMIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUPLAZID, PIMAVANSERIN TARTRATE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN AQ NUSPIN, SOMATROPIN
NUVARING, ETHINYL ESTRADIOL
NUVESSA, METRONIDAZOLE
NUVIGIL, ARMODAFINIL
NUZYRA, OMADACYCLINE TOSYLATE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
NYMALIZE, NIMODIPINE
NYSTATIN, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTOP, NYSTATIN

**** O ****

OCALIVA, OBETICHOLIC ACID
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
ODEFSEY, EMTRICITABINE
ODOMZO, SONIDEGIB PHOSPHATE
OFEV, NINTEDANIB ESYLATE

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN 5, ESTROPIPATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUMIANT, BARICITINIB
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEGAVEN, FISH OIL TRIGLYCERIDES
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONMEL, ITRACONAZOLE
ONPATTRO, PATISIRAN SODIUM
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
ORABLOC, ARTICAINE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORALTAG, IOHEXOL
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORILISSA, ELAGOLIX SODIUM
ORKAMBI, IVACAFTOR
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORSYTHIA, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** O ****

ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORTIKOS, BUDESONIDE
ORVATEN, MIDODRINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OSENI, ALOGLIPTIN BENZOATE
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
OSPHENA, OSPEMIFENE
OTEZLA, APREMILAST
OTICAIR, HYDROCORTISONE
OTIPRIO, CIPROFLOXACIN
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
OTREXUP, METHOTREXATE
OVIDREL, CHORIOGONADOTROPIN ALFA
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXANDROLONE, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAYDO, OXYCODONE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
OXBRYTA, VOXELOTOR
OXCARBAZEPINE, OXCARBAZEPINE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
OXISTAT, OXICONAZOLE NITRATE
OXSORALEN-ULTRA, METHOXSALEN
OXTELLAR XR, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
OXYTROL, OXYBUTYNIN
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OZEMPIC, SEMAGLUTIDE
OZOBAX, BACLOFEN
OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
PACITAXEL, PACLITAXEL
PACLITAXEL, PACLITAXEL
PALIPERIDONE, PALIPERIDONE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCREAZE, PANCRELIPASE (AMYLASE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAGARD T 380A, COPPER

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROEX, CHLORHEXIDINE GLUCONATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PARSABIV, ETELCALCETIDE
PASER, AMINOSALICYLIC ACID
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PEGANONE, ETHOTOIN
PENICILLAMINE, PENICILLAMINE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID, FAMOTIDINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERSERIS KIT, RISPERIDONE
PERTZYE, PANCRELIPASE (AMYLASE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHILITH, ETHINYL ESTRADIOL
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PICATO, INGENOL MEBUTATE
PIFELTRO, DORAVIRINE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIMECROLIMUS, PIMECROLIMUS
PIMOZIDE, PIMOZIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIQRAY, ALPELISIB
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENVU, ASCORBIC ACID
PLIAGLIS, LIDOCAINE
PODOFILOX, PODOFILOX
POLMON, DEXCHLORPHENIRAMINE MALEATE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYTRIM, POLYMYXIN B SULFATE
POMALYST, POMALIDOMIDE
PONSTEL, MEFENAMIC ACID
PORTIA-28, ETHINYL ESTRADIOL
POSACONAZOLE, POSACONAZOLE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** P ****

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** P ****

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVACHOL, PRAVASTATIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZIQUANTEL, PRAZIQUANTEL
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PREDNISONE INTENSOL, PREDNISONE
PREGABALIN, PREGABALIN
PREGNYL, GONADOTROPIN, CHORIONIC
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRESTALIA, AMLODIPINE BESYLATE
PRETOMANID, PRETOMANID
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVYMIS, LETERMOVIR
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINIVIL, LISINOPRIL
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR DIGIHALER, ALBUTEROL SULFATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVAYBLUE, METHYLENE BLUE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PUR-WASH, PURIFIED WATER (OTC)
PURINETHOL, MERCAPTOPURINE
PURIXAN, MERCAPTOPURINE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYTEST, UREA, C-14
PYTEST KIT, UREA, C-14

**** Q ****

QBRELIS, LISINOPRIL
QBREXZA, GLYCOPYRRONIUM TOSYLATE
QMIIZ ODT, MELOXICAM
QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QTERN, DAPAGLIFLOZIN
QTERNMET XR, DAPAGLIFLOZIN
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUARTETTE, ETHINYL ESTRADIOL
QUASENSE, ETHINYL ESTRADIOL
QUDEXY XR, TOPIRAMATE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QUTENZA, CAPSAICIN
QUZYTTIR, CETIRIZINE HYDROCHLORIDE
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADICAVA, EDARAVONE
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE

APPENDIX A - PRODUCT NAME INDEX

**** R ****

RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYALDEE, CALCIFEDIOL
RAYOS, PREDNISONE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)
REBETOL, RIBAVIRIN
RECARBRIO, CILASTATIN SODIUM
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REDITREX, METHOTREXATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
REPREXAIN, HYDROCODONE BITARTRATE
REQUIP, ROPINIROLE HYDROCHLORIDE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPRAZOLE
REYATAZ, ATAZANAVIR SULFATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL DIMESYLATE
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** R ****

RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RINVOQ, UPADACITINIB
RIOMET, METFORMIN HYDROCHLORIDE
RIOMET ER, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROCALTROL, CALCITRIOL
ROCKLATAN, LATANOPROST
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
ROZLYTREK, ENTRECTINIB
RUBRACA, RUCAPARIB CAMSYLATE
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RUZURGI, AMIFAMPRIDINE
RYANODEX, DANTROLENE SODIUM
RYBELSUS, SEMAGLUTIDE
RYDAPT, MIDOSTAURIN
RYTARY, CARBIDOPA
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

**** S ****

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SAIZEN, SOMATROPIN
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL
SCENESSE, AFAMELANOTIDE
SCLEROSOL, TALC

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECONAL SODIUM, SECOBARBITAL SODIUM
SECUADO, ASENAPINE
SEEBRI, GLYCOPYRROLATE
SEGLUROMET, ERTUGLIFLOZIN
SEIZALAM, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIOUS ACID, SELENIOUS ACID
SELENIUM SULFIDE, SELENIUM SULFIDE
SELFEMRA, FLUOXETINE HYDROCHLORIDE
SELZENTRY, MARAVIROC
SEMPREX-D, ACRIVASTINE
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SERNIVO, BETAMETHASONE DIPROPIONATE
SEROMYCIN, CYCLOSERINE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SETLAKIN, ETHINYL ESTRADIOL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SEVOFLURANE, SEVOFLURANE
SEYSARA, SARECYCLINE HYDROCHLORIDE
SFROWASA, MESALAMINE
SIGNIFOR, PASIREOTIDE DIASPARTATE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIKLOS, HYDROXYUREA
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILODOSIN, SILODOSIN
SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINEMET CR, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINUVA, MOMETASONE FUROATE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN
SKYLA, LEVONORGESTREL
SLYND, DROSPIRENONE
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLIQUA 100/33, INSULIN GLARGINE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SPECTAZOLE, ECONAZOLE NITRATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SPY AGENT GREEN KIT, INDOCYANINE GREEN
SSD, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STAVUDINE, STAVUDINE
STAXYN, VARDENAFIL HYDROCHLORIDE
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN

APPENDIX A - PRODUCT NAME INDEX

**** S ****

STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNOSI, SOLRIAMFETOL
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SURVANTA, BERACTANT
SUSTIVA, EFAVIRENZ
SUSTOL, GRANISETRON
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYLEVIA, ETHINYL ESTRADIOL
SYMBICORT, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMDEKO (COPACKAGED), IVACAFTOR
SYMFI, EFAVIRENZ
SYMFI LO, EFAVIRENZ
SYMJEPI, EPINEPHRINE
SYMLIN, PRAMLINTIDE ACETATE
SYMPAZAN, CLOBAZAM
SYMPROIC, NALDEMEDINE TOSYLATE
SYMTUZA, COBICISTAT
SYNALAR, FLUOCINOLONE ACETONIDE
SYNAREL, NAFARELIN ACETATE
SYNDROS, DRONABINOL
SYNERA, LIDOCAINE
SYNERCID, DALFOPRISTIN

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SYNJARDY, EMPAGLIFLOZIN
SYNJARDY XR, EMPAGLIFLOZIN
SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TAFINLAR, DABRAFENIB MESYLATE
TAFLUPROST, TAFLUPROST
TAGAMET HB, CIMETIDINE (OTC)
TAGITOL V, BARIUM SULFATE
TAGRISSO, OSIMERTINIB MESYLATE
TALC, TALC
TALICIA, AMOXICILLIN
TALZENNA, TALAZOPARIB TOSYLATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAPAZOLE, METHIMAZOLE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASIGNA, NILOTINIB HYDROCHLORIDE
TASMAR, TOLCAPONE
TAVALISSE, FOSTAMATINIB DISODIUM
TAXOTERE, DOCETAXEL
TAYTULLA, ETHINYL ESTRADIOL
TAZAROTENE, TAZAROTENE
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEGSEDI, INOTERSEN SODIUM
TEKTURNA, ALISKIREN HEMIFUMARATE
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMIXYS, LAMIVUDINE
TEMODAR, TEMOZOLOMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TEPADINA, THIOTEPA
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIL, CARBAMAZEPINE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTRED, METHYLTESTOSTERONE
TETRABENAZINE, TETRABENAZINE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEXACORT, HYDROCORTISONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THEO-24, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOLA, TIOPRONIN
THIOLA EC, TIOPRONIN
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE
THYRO-TABS, LEVOTHYROXINE SODIUM **
THYROGEN, THYROTROPIN ALFA
THYROSAFE, POTASSIUM IODIDE (OTC)
THYROSHIELD, POTASSIUM IODIDE (OTC)
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TIBSOVO, IVOSIDENIB
TICAGRELOR, TICAGRELOR
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIGLUTIK KIT, RILUZOLE
TIKOSYN, DOFETILIDE
TIMOLOL, TIMOLOL
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM
TIS-U-SOL, MAGNESIUM SULFATE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TISSUEBLUE, BRILLIANT BLUE G
TIVICAY, DOLUTEGRAVIR SODIUM
TIVORBEX, INDOMETHACIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOLAK, FLUOROURACIL
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLCAPONE, TOLCAPONE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLSURA, ITRACONAZOLE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOSYMRA, SUMATRIPTAN
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOUJEO MAX SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPOXX, TECOVIRIMAT
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRESIBA, INSULIN DEGLUDEC
TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TREXIMET, NAPROXEN SODIUM
TREZIX, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETATE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE, TRIAMTERENE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRILYTE, POLYETHYLENE GLYCOL 3350
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
TRIOSTAT, LIOTHYRONINE SODIUM
TRIPTODUR KIT, TRIPTORELIN PAMOATE
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROKENDI XR, TOPIRAMATE
TROPHAMINE, AMINO ACIDS
TROPHAMINE 10%, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
TRULANCE, PLECANATIDE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TURALIO, PEXIDARTINIB HYDROCHLORIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUXARIN ER, CHLORPHENIRAMINE MALEATE
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
TWYNSTA, AMLODIPINE BESYLATE
TYBOST, COBICISTAT
TYDEMY, DROSPIRENONE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL, ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYMLOS, ABALOPARATIDE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TYVASO, TREPROSTINIL
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

U-CORT, HYDROCORTISONE ACETATE
UBRELVY, UBROGEPANT
UCERIS, BUDESONIDE
ULORIC, FEBUXOSTAT
ULTACAN, ARTICAINE HYDROCHLORIDE
ULTACAN FORTE, ARTICAINE HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UPTRAVI, SELEXIPAG
URECHOLINE, BETHANECHOL CHLORIDE
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UTIBRON, GLYCOPYRROLATE
UVADEX, METHOXSALEN

**** V ****

VABOMERE, MEROPENEM
VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALRUBICIN, VALRUBICIN
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE

APPENDIX A - PRODUCT NAME INDEX

**** V ****

VARIBAR THIN LIQUID, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZALORE, ASPIRIN (OTC)
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITEX CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIDEX, DIDANOSINE
VIDEX EC, DIDANOSINE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIENVA, ETHINYL ESTRADIOL
VIGABATRIN, VIGABATRIN
VIGADRONE, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIOKACE, PANCRELIPASE (AMYLASE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** V ****

VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTOGARD, URIDINE TRIACETATE
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITRAKVI, LAROTRECTINIB SULFATE
VITRASE, HYALURONIDASE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE-DOT, ESTRADIOL
VIVITROL, NALTREXONE
VIVLODEX, MELOXICAM
VIZAMYL, FLUTEMETAMOL F-18
VIZIMPRO, DACOMITINIB
VOGELXO, TESTOSTERONE
VOLNEA, DESOGESTREL
VOLTAREN, DICLOFENAC SODIUM
VORICONAZOLE, VORICONAZOLE
VOSEVI, SOFOSBUVIR
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOSPIRE ER, ALBUTEROL SULFATE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VPRIV, VELAGLUCERASE ALFA
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VUMERITY, DIROXIMEL FUMARATE
VUSION, MICONAZOLE NITRATE
VYFEMLA, ETHINYL ESTRADIOL
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE
VYONDYS 53, GOLODIRSEN
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
VYXEOS, CYTARABINE
VYZULTA, LATANOPROSTENE BUNOD

**** W ****

WAKIX, PITOLISANT HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WIXELA INHUB, FLUTICASONE PROPIONATE
WOMEN'S ROGAINE, MINOXIDIL (OTC)

**** X ****

XADAGO, SAFINAMIDE MESYLATE
XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARELTO, RIVAROXABAN
XATMEP, METHOTREXATE SODIUM
XELJANZ, TOFACITINIB CITRATE
XELJANZ XR, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XELPROS, LATANOPROST
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENLETA, LEFAMULIN ACETATE
XENON XE 133, XENON XE-133
XEPI, OZENOXACIN

APPENDIX A - PRODUCT NAME INDEX

**** X ****

XERAVA, ERAVACYCLINE DIHYDROCHLORIDE
XERESE, ACYCLOVIR
XERMELO, TELOTRISTAT ETIPRATE
XHANCE, FLUTICASONE PROPIONATE
XIFAXAN, RIFAXIMIN
XIGDUO XR, DAPAGLIFLOZIN
XIIDRA, LIFITEGRAST
XIMINO, MINOCYCLINE HYDROCHLORIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
XOFLUZA, BALOXAVIR MARBOXIL
XOLEGEL, KETOCONAZOLE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
XOSPATA, GILTERITINIB FUMARATE
XPOVIO, SELINEXOR
XTAMPZA ER, OXYCODONE
XTANDI, ENZALUTAMIDE
XULANE, ETHINYL ESTRADIOL
XULTOPHY 100/3.6, INSULIN DEGLUDEC
XURIDEN, URIDINE TRIACETATE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE
XYREM, SODIUM OXYBATE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

**** Y ****

YAELA, DROSPIRENONE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE
YONDELIS, TRABECTEDIN
YONSA, ABIRATERONE ACETATE
YOSPRALA, ASPIRIN
YUPELRI, REVEFENACIN
YUTIQ, FLUOCINOLONE ACETONIDE

**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC, RANITIDINE HYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZEGERID, OMEPRAZOLE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZEJULA, NIRAPARIB TOSYLATE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZELNORM, TEGASEROD MALEATE
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZEMDRI, PLAZOMICIN SULFATE
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZENPEP, PANCRELIPASE (AMYLASE
ZEPATIER, ELBASVIR
ZERBAXA, CEFTOLOZANE SULFATE
ZERIT, STAVUDINE
ZERVIATE, CETIRIZINE HYDROCHLORIDE
ZESTORETIC, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZINACEF, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC, ZOLEDRONIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMACTON, SOMATROPIN
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZTLIDO, LIDOCAINE
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZULRESSO, BREXANOLONE
ZUMANDIMINE, DROSPIRENONE
ZUPLENZ, ONDANSETRON
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYPITAMAG, PITAVASTATIN MAGNESIUM
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 3 ****

3D IMAGING DRUG

* 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M

* 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M DRUG DELIVERY

* 3M DRUG DELIVERY SYSTEMS
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

3M HEALTH CARE

* 3M HEALTH CARE INFECTION PREVENTION DIV
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)

**** 6 ****

60 DEGREES PHARMS

* 60 DEGREES PHARMACEUTICALS LLC
ARAKODA, TAFENOQUINE SUCCINATE

**** A ****

AAA USA INC

* ADVANCED ACCELERATOR APPLICATIONS USA INC
LUTATHERA, LUTETIUM DOTATATE LU-177
NETSPOT, GALLIUM DOTATATE GA-68

AAIPHARMA LLC

* AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE

* ABBVIE INC
ANDROGEL, TESTOSTERONE
CREON, PANCRELIPASE (AMYLASE
CYCLOSPORINE, CYCLOSPORINE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
MARINOL, DRONABINOL
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TRICOR, FENOFIBRATE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE

* ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

ABBVIE ENDOCRINE INC

* ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ABBVIE ENDOCRINE INC
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

ABBVIE INC

* ABBVIE INC
DUOPA, CARBIDOPA
MAVYRET, GLECAPREVIR
NORVIR, RITONAVIR
ORILISSA, ELAGOLIX SODIUM
RINVOQ, UPADACITINIB
VENCLEXTA, VENETOCLAX
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM

ABHAI INC

* ABHAI INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI LLC

* ABHAI LLC
ATOVAQUONE, ATOVAQUONE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEFLUNOMIDE, LEFLUNOMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
URSODIOL, URSODIOL

ABON PHARMS LLC

* ABON PHARMACEUTICALS LLC
CLOFARABINE, CLOFARABINE

ABRAXIS BIOSCIENCE

* ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

ABRAXIS PHARM

* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADIA PHARMS INC

* ACADIA PHARMACEUTICALS INC
NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS

* ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZACITIDINE, AZACITIDINE
BICALUTAMIDE, BICALUTAMIDE
BIVALIRUDIN, BIVALIRUDIN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
DALFAMPRIDINE, DALFAMPRIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ENTECAVIR, ENTECAVIR
EPLERENONE, EPLERENONE
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FINASTERIDE, FINASTERIDE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL, LISINOPRIL
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SPIRONOLACTONE, SPIRONOLACTONE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TERIFLUNOMIDE, TERIFLUNOMIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC USA
BUSULFAN, BUSULFAN
TIGECYCLINE, TIGECYCLINE

ACELLA

* ACELLA PHARMACEUTICALS LLC
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CICLOPIROX, CICLOPIROX
PHENYTOIN SODIUM, PHENYTOIN SODIUM

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
GABAPENTIN, GABAPENTIN

ACELRX PHARMS

* ACELRX PHARMACEUTICALS INC
DSUVIA, SUFENTANIL CITRATE

ACERUS

* ACERUS PHARMACEUTICALS CORP
NATESTO, TESTOSTERONE

ACI HEALTHCARE LTD

* ACI HEALTHCARE LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC PHARMS

* ACIC PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

ACORDA

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
INBRIJA, LEVODOPA

ACP NIMBLE

* ACP NIMBLE BUYER INC
ACEPHEN, ACETAMINOPHEN (OTC)
ACYCLOVIR, ACYCLOVIR
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
INDOMETHACIN, INDOMETHACIN
LIDOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MYKACET, NYSTATIN
NYSTATIN, NYSTATIN
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TAZAROTENE, TAZAROTENE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ACROTECH

* ACROTECH BIOPHARMA LLC
BELEODAQ, BELINOSTAT
EVOMELA, MELPHALAN HYDROCHLORIDE
FOLOTYN, PRALATREXATE
FUSILEV, LEVOLEUCOVORIN CALCIUM
KHAPZORY, LEVOLEUCOVORIN
MARQIBO KIT, VINCRISTINE SULFATE

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALBENDAZOLE, ALBENDAZOLE
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS ELIZABETH LLC
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALPRAZOLAM, ALPRAZOLAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
MORPHINE SULFATE, MORPHINE SULFATE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
METHOXSALEN, METHOXSALEN

ACTAVIS LABS

* ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

* ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
MESALAMINE, MESALAMINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ACTAVIS LABS FL INC

* ACTAVIS LABORATORIES FL INC
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTASTERIDE, DUTASTERIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
OMEPRAZOLE, OMEPRAZOLE
OXYCODONE AND ASPIRIN, ASPIRIN
PALIPERIDONE, PALIPERIDONE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISONE, PREDNISONE
RAMELTEON, RAMELTEON
RISPERIDONE, RISPERIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS LABORATORIES FL INC
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TETRABENAZINE, TETRABENAZINE
TRANEXAMIC ACID, TRANEXAMIC ACID
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
AZELAIC ACID, AZELAIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLONIDINE, CLONIDINE
FIORICET W/ CODEINE, ACETAMINOPHEN
LIDOCAINE, LIDOCAINE
PROGESTERONE, PROGESTERONE
TESTOSTERONE, TESTOSTERONE
* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PIMECROLIMUS, PIMECROLIMUS
TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

* ACTAVIS LLC
AZACITIDINE, AZACITIDINE
DAPSONE, DAPSONE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
* ACTAVIS LLC AN INDIRECT WHOLLY-OWNED SUB OF TEVA PHARMACEUTICALS USA INC
BUSULFAN, BUSULFAN
DOCETAXEL, DOCETAXEL
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
OXALIPLATIN, OXALIPLATIN

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ENULOSE, LACTULOSE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
LEVETIRACETAM, LEVETIRACETAM
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
VALNAC, BETAMETHASONE VALERATE
* ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
IBUPROFEN, IBUPROFEN
PERMETHRIN, PERMETHRIN (OTC)

ACTAVIS PHARMA

* ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
MICONAZOLE NITRATE, MICONAZOLE NITRATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
REPAGLINIDE, REPAGLINIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTAVIS TOTOWA TEVA
* ACTAVIS TOTOWA LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
FINASTERIDE, FINASTERIDE

ACTELION PHARMS
* ACTELION PHARMACEUTICALS LTD
TRACLEER, BOSENTAN

ACTELION PHARMS LTD
* ACTELION PHARMACEUTICALS LTD
OPSUMIT, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT

ACTIENT PHARMS
* ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE

ADAMAS PHARMA
* ADAMAS PHARMA LLC
GOCOVRI, AMANTADINE HYDROCHLORIDE

ADAMIS PHARMS CORP
* ADAMIS PHARMACEUTICALS CORP
SYMJEPI, EPINEPHRINE

ADAPT
* ADAPT PHARMA OPERATIONS LTD
NARCAN, NALOXONE HYDROCHLORIDE

ADARE PHARMS INC
* ADARE PHARMACEUTICALS INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ADDMEDICA SAS
* ADDMEDICA SAS
SIKLOS, HYDROXYUREA

ADHERA
* ADHERA THERAPEUTICS INC
PRESTALIA, AMLODIPINE BESYLATE

ADIENNE SA
* ADIENNE SA
TEPADINA, THIOTEPA

AEGERION
* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

AERIE PHARMS INC
* AERIE PHARMACEUTICALS INC
RHOPRESSA, NETARSUDIL DIMESYLATE
ROCKLATAN, LATANOPROST

AGIOS PHARMS INC
* AGIOS PHARMACEUTICALS INC
TIBSOVO, IVOSIDENIB

AGNITIO
* AGNITIO INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AGNITIO INC
ETHACRYNIC ACID, ETHACRYNIC ACID
TRIAMTERENE, TRIAMTERENE

AGOURON PHARMS

* AGOURON PHARMACEUTICALS LLC
VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC

* AILEX PHARMACEUTICALS LLC
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
CROMOLYN SODIUM, CROMOLYN SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CAPTOPRIL, CAPTOPRIL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTACAPONE, ENTACAPONE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

AKARX INC

* AKARX INC
DOPTELET, AVATROMBOPAG MALEATE

AKCEA THERAPS

* AKCEA THERAPEUTICS INC
TEGSEDI, INOTERSEN SODIUM

AKORN

* AKORN INC
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IC-GREEN, INDOCYANINE GREEN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LATANOPROST, LATANOPROST
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OFLOXACIN, OFLOXACIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PYRAZINAMIDE, PYRAZINAMIDE
RIFAMPIN, RIFAMPIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOLOL, TIMOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROPICACYL, TROPICAMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

AKORN INC

* AKORN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DRONABINOL, DRONABINOL
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
INAPSINE, DROPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALAN LABS INC
* ALAN LABORATORIES INC
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE

ALCON
* ALCON LABORATORIES INC
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
MIOSTAT, CARBACHOL
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

ALCON LABS
* ALCON LABORATORIES LTD
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

ALCON LABS INC
* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
FLUORESCITE, FLUORESCEIN SODIUM
ISOPTO ATROPINE, ATROPINE SULFATE

ALCON PHARMS LTD
* ALCON PHARMACEUTICALS LTD
BETADINE, POVIDONE-IODINE
ZADITOR, KETOTIFEN FUMARATE (OTC)

ALEMBIC LTD
* ALEMBIC LTD
LITHIUM CARBONATE, LITHIUM CARBONATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS LTD
* ALEMBIC PHARMACEUTICALS LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEMBIC PHARMACEUTICALS LTD
CELECOXIB, CELECOXIB
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEFERASIROX, DEFERASIROX
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DESVENLAFAXINE, DESVENLAFAXINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TERIFLUNOMIDE, TERIFLUNOMIDE
THEOPHYLLINE, THEOPHYLLINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRAVOPROST, TRAVOPROST
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ALEOR DERMACEUTICALS

* ALEOR DERMACEUTICALS LTD
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEOR DERMACEUTICALS LTD
DESONIDE, DESONIDE
LIDOCAINE, LIDOCAINE

ALEXZA PHARMS

* ALEXZA PHARMACEUTICALS INC
ADASUVE, LOXAPINE

ALFASIGMA

* ALFASIGMA USA INC
ZELNORM, TEGASEROD MALEATE

ALIGNSCIENCE PHARMA

* ALIGNSCIENCE PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
ILUVIEN, FLUOCINOLONE ACETONIDE

ALKALOIDA ZRT

* ALKALOIDA CHEMICAL CO ZRT
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

ALKEM

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CEFIXIME, CEFIXIME
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DEFERASIROX, DEFERASIROX
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALKEM LABORATORIES LTD
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN, VALSARTAN

ALKERMES
* ALKERMES INC
VIVITROL, NALTREXONE

ALKERMES INC
* ALKERMES INC
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTADA, ARIPIPRAZOLE LAUROXIL

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLEGIS
* ALLEGIS HOLDINGS LLC
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

ALLERGAN
* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
ZYMAXID, GATIFLOXACIN
* ALLERGAN INC
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
LASTACAFT, ALCAFTADINE
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTASIS, CYCLOSPORINE
TAZORAC, TAZAROTENE
ZYMAR, GATIFLOXACIN
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
OCUFEN, FLURBIPROFEN SODIUM
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
* ALLERGAN SALES LLC
ACTIGALL, URSODIOL
ALORA, ESTRADIOL
ANDRODERM, TESTOSTERONE
AVYCAZ, AVIBACTAM SODIUM
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALLERGAN SALES LLC
BREVICON 28-DAY, ETHINYL ESTRADIOL
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
CELEXA, CITALOPRAM HYDROBROMIDE
CONDYLOX, PODOFILOX
CRINONE, PROGESTERONE
DALVANCE, DALBAVANCIN HYDROCHLORIDE
ESTRACE, ESTRADIOL
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
GELNIQUE, OXYBUTYNIN CHLORIDE
INFED, IRON DEXTRAN
KADIAN, MORPHINE SULFATE
LEXAPRO, ESCITALOPRAM OXALATE
LINZESS, LINACLOTIDE
MICROZIDE, HYDROCHLOROTHIAZIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OXYTROL, OXYBUTYNIN
PYLERA, BISMUTH SUBCITRATE POTASSIUM
RAPAFLO, SILODOSIN
RECTIV, NITROGLYCERIN
SAPHRIS, ASENAPINE MALEATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
TEFLARO, CEFTAROLINE FOSAMIL
TRELSTAR, TRIPTORELIN PAMOATE
UBRELVY, UBROGEPANT
URSO 250, URSODIOL
URSO FORTE, URSODIOL
VIIBRYD, VILAZODONE HYDROCHLORIDE
VRAYLAR, CARIPRAZINE HYDROCHLORIDE

ALLERGAN HOLDINGS

* ALLERGAN HOLDINGS UNLTD CO
VIBERZI, ELUXADOLINE

ALLERQUEST

* ALLERQUEST LLC
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE

ALLIED

* ALLIED PHARMA INC
CARISOPRODOL, CARISOPRODOL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ALMIRALL

* ALMIRALL LLC
ACTICLATE, DOXYCYCLINE HYCLATE
ACZONE, DAPSONE
ALTABAX, RETAPAMULIN
AZELEX, AZELAIC ACID
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
FLUOROPLEX, FLUOROURACIL
SEYSARA, SARECYCLINE HYDROCHLORIDE
VELTIN, CLINDAMYCIN PHOSPHATE
VERDESO, DESONIDE
XOLEGEL, KETOCONAZOLE

ALNYLAM PHARMS INC

* ALNYLAM PHARMACEUTICALS INC
GIVLAARI, GIVOSIRAN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALNYLAM PHARMACEUTICALS INC
ONPATTRO, PATISIRAN SODIUM

ALRA

* ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN

* ALVOGEN GROUP HOLDINGS 2 LLC
DAPSONE, DAPSONE
ETHACRYNIC ACID, ETHACRYNIC ACID
OFLOXACIN, OFLOXACIN
* ALVOGEN GROUP HOLDINGS 3 LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE
* ALVOGEN GROUP HOLDINGS 4 LLC
THYRO-TABS, LEVOTHYROXINE SODIUM **
* ALVOGEN GROUP HOLDINGS LLC
ADALAT CC, NIFEDIPINE
* ALVOGEN INC
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
* ALVOGEN MALTA OPERATIONS LTD
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BONSITY, TERIPARATIDE RECOMBINANT HUMAN
BUDESONIDE, BUDESONIDE
CARBIDOPA, CARBIDOPA
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DISULFIRAM, DISULFIRAM
EXEMESTANE, EXEMESTANE
FELBAMATE, FELBAMATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MELPHALAN, MELPHALAN
NAPRELAN, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NEVIRAPINE, NEVIRAPINE
NITROGLYCERIN, NITROGLYCERIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIVASTIGMINE, RIVASTIGMINE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SPECTAZOLE, ECONAZOLE NITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
VORICONAZOLE, VORICONAZOLE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL

ALVOGEN INC

* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALVOGEN INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

ALVOGEN PINE BROOK

* ALVOGEN PINE BROOK LLC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

AM ANTIBIOTICS

* AMERICAN ANTIBIOTICS INC
AMOXICILLIN, AMOXICILLIN

AM REGENT

* AMERICAN REGENT INC
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
FOMEPIZOLE, FOMEPIZOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROXYPROGESTERON CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
INJECTAFER, FERRIC CARBOXYMALTOSE
METHOCARBAMOL, METHOCARBAMOL
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLANZAPINE, OLANZAPINE
SELENIOUS ACID, SELENIOUS ACID
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VENOFER, IRON SUCROSE
ZINC SULFATE, ZINC SULFATE

AMAG PHARMA USA

* AMAG PHARMA USA INC
MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MAKENA, HYDROXYPROGESTERONE CAPROATE

AMAG PHARMS INC

* AMAG PHARMACEUTICALS INC
FERAHEME, FERUMOXYTOL
INTRAROSA, PRASTERONE
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE

AMARIN PHARMS

* AMARIN PHARMACEUTICALS IRELAND LTD
VASCEPA, ICOSAPENT ETHYL

AMERIGEN PHARMS LTD

* AMERIGEN PHARMACEUTICALS LTD
BEXAROTENE, BEXAROTENE
CARBIDOPA, CARBIDOPA
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
INDAPAMIDE, INDAPAMIDE
MIGLUSTAT, MIGLUSTAT
PENICILLAMINE, PENICILLAMINE
RANOLAZINE, RANOLAZINE
TEMOZOLOMIDE, TEMOZOLOMIDE

AMGEN

* AMGEN INC
SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC

* AMGEN INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMGEN INC
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
OTEZLA, APREMILAST

AMICI

* AMICI PHARMACEUTICALS LLC
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM

AMICUS THERAPS US

* AMICUS THERAPEUTICS US INC
GALAFOLD, MIGALASTAT HYDROCHLORIDE

AMNEAL

* AMNEAL EU LTD
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BUSULFAN, BUSULFAN
CARMUSTINE, CARMUSTINE
CLOFARABINE, CLOFARABINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FULVESTRANT, FULVESTRANT
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OFLOXACIN, OFLOXACIN
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOVAQUONE, ATOVAQUONE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ENTECAVIR, ENTECAVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
FELBAMATE, FELBAMATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LORAZEPAM, LORAZEPAM
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN
NIZATIDINE, NIZATIDINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TEMOZOLOMIDE, TEMOZOLOMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
WARFARIN SODIUM, WARFARIN SODIUM

* AMNEAL PHARMACEUTICALS HOLDINGS GMBH
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CELECOXIB, CELECOXIB
DUTASTERIDE, DUTASTERIDE
EPTIFIBATIDE, EPTIFIBATIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PALIPERIDONE, PALIPERIDONE
PARICALCITOL, PARICALCITOL
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIVASTIGMINE, RIVASTIGMINE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SPIRONOLACTONE, SPIRONOLACTONE
TOBRAMYCIN, TOBRAMYCIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN

AMNEAL PHARMS CO

* AMNEAL PHARMACEUTICALS CO GMBH
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARGATROBAN, ARGATROBAN
BOSENTAN, BOSENTAN
BUMETANIDE, BUMETANIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOBAZAM, CLOBAZAM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHACRYNIC ACID, ETHACRYNIC ACID
ETODOLAC, ETODOLAC
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FUROSEMIDE, FUROSEMIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
NADOLOL, NADOLOL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PARICALCITOL, PARICALCITOL
PHYTONADIONE, PHYTONADIONE
PREGABALIN, PREGABALIN
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
URSODIOL, URSODIOL

AMNEAL PHARMS LLC

* AMNEAL PHARMACEUTICALS LLC
ACTIVELLA, ESTRADIOL
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AZATHIOPRINE, AZATHIOPRINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS LLC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
ELURYNG, ETHINYL ESTRADIOL
ESTRADIOL, ESTRADIOL
FENOFIBRATE, FENOFIBRATE
FLUOCINONIDE, FLUOCINONIDE
MESALAMINE, MESALAMINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RITONAVIR, RITONAVIR
SIROLIMUS, SIROLIMUS
SUCRALFATE, SUCRALFATE
TESTOSTERONE, TESTOSTERONE
TIGECYCLINE, TIGECYCLINE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
BEXAROTENE, BEXAROTENE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISOTRETINOIN, ISOTRETINOIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PROGESTERONE, PROGESTERONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
AMPHADASE, HYALURONIDASE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
CORTROSYN, COSYNTROPIN
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

AMRING PHARMS
* AMRING PHARMACEUTICALS INC
  ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
  LATANOPROST, LATANOPROST
  MESALAMINE, MESALAMINE
  NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
  NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
  NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
  SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

AMTA
* AMTA LABS LTD
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ANACOR PHARMS INC
* ANACOR PHARMACEUTICALS INC
  EUCRISA, CRISABOROLE
  KERYDIN, TAVABOROLE

ANBEX
* ANBEX INC
  IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB
* ANBISON LABORATORY CO LTD
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

ANCHEN PHARMS
* ANCHEN PHARMACEUTICALS INC
  ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
  FENOFIBRIC ACID, CHOLINE FENOFIBRATE
  FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
  LAMOTRIGINE, LAMOTRIGINE
  LEVETIRACETAM, LEVETIRACETAM
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  TRETINOIN, TRETINOIN
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ANCHEN PHARMACEUTICALS TAIWAN INC
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
* ANCHEN PHARMACEUTICALS, INC
  ALPRAZOLAM, ALPRAZOLAM
  CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN

ANDA REPOSITORY
* ANDA REPOSITORY LLC
  ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
  BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
  BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CICLOPIROX, CICLOPIROX
  CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
  CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
  DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
  FLAC, FLUOCINOLONE ACETONIDE
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  IMIQUIMOD, IMIQUIMOD
  ISONIAZID, ISONIAZID
  LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANDA REPOSITORY LLC
LEVETIRACETAM, LEVETIRACETAM
MOMETASONE FUROATE, MOMETASONE FUROATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PRIMIDONE, PRIMIDONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

ANDOR PHARMS
* ANDOR PHARMACEUTICALS LLC
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ANI PHARMS
* ANI PHARMACEUTICALS INC
CORTENEMA, HYDROCORTISONE
LUVOX, FLUVOXAMINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANI PHARMS INC
* ANI PHARMACEUTICALS INC
ARIMIDEX, ANASTROZOLE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
BRETHINE, TERBUTALINE SULFATE
CASODEX, BICALUTAMIDE
CHOLESTYRAMINE, CHOLESTYRAMINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ETODOLAC, ETODOLAC
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FELBAMATE, FELBAMATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
LITHOBID, LITHIUM CARBONATE
METHAZOLAMIDE, METHAZOLAMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NILUTAMIDE, NILUTAMIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PINDOLOL, PINDOLOL
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CITRATE, POTASSIUM CITRATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ANIMA
* ANIMA PHARMACEUTICALS PVT LTD
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
DEXAMETHASONE, DEXAMETHASONE

ANNORA
* ANNORA PHARMA PRIVATE LTD
LAMIVUDINE, LAMIVUDINE

ANNORA PHARMA
* ANNORA PHARMA PRIVATE LTD
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ANTARES PHARMA INC
* ANTARES PHARMA INC
OTREXUP, METHOTREXATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE

ANTIBIOTICE
* ANTIBIOTICE SA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANTIBIOTICE SA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

APEX PHARMS INC

* APEX PHARMACEUTICALS INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APGDI

* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ, MIRABEGRON

APIL

* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
DELZICOL, MESALAMINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
LO LOESTRIN FE, ETHINYL ESTRADIOL
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
MINASTRIN 24 FE, ETHINYL ESTRADIOL
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
SARAFEM, FLUOXETINE HYDROCHLORIDE
TAYTULLA, ETHINYL ESTRADIOL

APNAR PHARMA LP

* APNAR PHARMA LP
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APOLLO

* APOLLO PHARMACEUTICALS INC
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
TRANEXAMIC ACID, TRANEXAMIC ACID

APOPHARMA INC

* APOPHARMA INC
FERRIPROX, DEFERIPRONE

APOTEX

* APOTEX INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATOVAQUONE, ATOVAQUONE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BIVALIRUDIN, BIVALIRUDIN
BUSULFAN, BUSULFAN
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
CIMETIDINE, CIMETIDINE (OTC)
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ETODOLAC, ETODOLAC
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
ITRACONAZOLE, ITRACONAZOLE
LAMIVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

APOTEX CORP

* APOTEX CORP
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RILUZOLE, RILUZOLE

APOTEX INC

* APOTEX INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITONIN-SALMON, CALCITONIN SALMON
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DUTASTERIDE, DUTASTERIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIQUIMOD, IMIQUIMOD
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LOVASTATIN, LOVASTATIN
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC ETOBICOKE SITE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTZAC, DILTIAZEM HYDROCHLORIDE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
LEFLUNOMIDE, LEFLUNOMIDE
LISINOPRIL, LISINOPRIL
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
MIRTAZAPINE, MIRTAZAPINE
OXAPROZIN, OXAPROZIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
ZONISAMIDE, ZONISAMIDE

* APOTEX INC RICHMOND HILL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

* APOTEX INC.
DILTZAC, DILTIAZEM HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTEX TECHNOLOGIES

* APOTEX TECHNOLOGIES INC
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE

APP PHARMS

* APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO

* APPCO PHARMA LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BUDESONIDE, BUDESONIDE
HALOPERIDOL, HALOPERIDOL
METAXALONE, METAXALONE
MODAFINIL, MODAFINIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

APRECIA PHARMS

* APRECIA PHARMACEUTICALS LLC
SPRITAM, LEVETIRACETAM

APTAPHARMA INC

* APTAPHARMA INC
IBUPROFEN, IBUPROFEN (OTC)

AQUESTIVE THERAP

* AQUESTIVE THERAPEUTICS
EXSERVAN, RILUZOLE
SYMPAZAN, CLOBAZAM

ARBOR PHARMS LLC

* ARBOR PHARMACEUTICALS LLC
BIDIL, HYDRALAZINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
ERY-TAB, ERYTHROMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ARBOR PHARMACEUTICALS LLC
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
EVEKEO ODT, AMPHETAMINE SULFATE
EVEKEO, AMPHETAMINE SULFATE
GLIADEL, CARMUSTINE
HORIZANT, GABAPENTIN ENACARBIL
NYMALIZE, NIMODIPINE
SKLICE, IVERMECTIN
SOTYLIZE, SOTALOL HYDROCHLORIDE
TRIPTODUR KIT, TRIPTORELIN PAMOATE

ARCO PHARMS LLC
* ARCO PHARMACEUTICALS LLC
THYROSHIELD, POTASSIUM IODIDE (OTC)

ARDELYX INC
* ARDELYX INC
IBSRELA, TENAPANOR HYDROCHLORIDE

AREVA PHARMS
* AREVA PHARMACEUTICALS INC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD
* ARIAD PHARMACEUTICALS INC
ALUNBRIG, BRIGATINIB
ICLUSIG, PONATINIB HYDROCHLORIDE

ARISE
* ARISE PHARMACEUTICALS LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CHLORTHALIDONE, CHLORTHALIDONE
IBUPROFEN, IBUPROFEN (OTC)
LAMIVUDINE, LAMIVUDINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

ARMSTRONG PHARMS
* ARMSTRONG PHARMACEUTICALS INC
PRIMATENE MIST, EPINEPHRINE (OTC)

ARRAY BIOPHARMA INC
* ARRAY BIOPHARMA INC
BRAFTOVI, ENCORAFENIB
MEKTOVI, BINIMETINIB

ASCEND THERAPS US
* ASCEND THERAPEUTICS US LLC
BINOSTO, ALENDRONATE SODIUM
ESTROGEL, ESTRADIOL

ASCENT PHARMS INC
* ASCENT PHARMACEUTICALS INC
BENZONATATE, BENZONATATE
DUTASTERIDE, DUTASTERIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

ASPEN
* ASPEN PHARMA USA INC
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

ASPEN GLOBAL
* ASPEN GLOBAL INC
MYLERAN, BUSULFAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ASPEN GLOBAL INC
* ASPEN GLOBAL INC
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  CYCLESSA, DESOGESTREL
  HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
  LEUKERAN, CHLORAMBUCIL
  THIOGUANINE, THIOGUANINE

ASSERTIO
* ASSERTIO THERAPEUTICS INC
  CAMBIA, DICLOFENAC POTASSIUM
  GRALISE, GABAPENTIN
  ZIPSOR, DICLOFENAC POTASSIUM

ASTELLAS
* ASTELLAS PHARMA US INC
  AMBISOME, AMPHOTERICIN B
  ASTAGRAF XL, TACROLIMUS
  CRESEMBA, ISAVUCONAZONIUM SULFATE
  LEXISCAN, REGADENOSON
  MYCAMINE, MICAFUNGIN SODIUM
  PROGRAF, TACROLIMUS
  VESICARE, SOLIFENACIN SUCCINATE
  XOSPATA, GILTERITINIB FUMARATE
  XTANDI, ENZALUTAMIDE

ASTRAL
* ASTRAL STERITECH PVT LTD
  AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
  CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
  CEFTRIAXONE, CEFTRIAXONE SODIUM

ASTRAZENECA
* ASTRAZENECA LP
  PULMICORT FLEXHALER, BUDESONIDE
  SYMBICORT, BUDESONIDE
* ASTRAZENECA PHARMACEUTICALS LP
  FASLODEX, FULVESTRANT
  ZOMIG, ZOLMITRIPTAN
  ZOMIG-ZMT, ZOLMITRIPTAN
* ASTRAZENECA UK LTD
  CALQUENCE, ACALABRUTINIB
  SEROQUEL XR, QUETIAPINE FUMARATE

ASTRAZENECA AB
* ASTRAZENECA AB
  BYDUREON BCISE, EXENATIDE
  BYDUREON PEN, EXENATIDE SYNTHETIC
  BYDUREON, EXENATIDE SYNTHETIC
  BYETTA, EXENATIDE SYNTHETIC
  FARXIGA, DAPAGLIFLOZIN
  KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
  ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
  QTERN, DAPAGLIFLOZIN
  QTERNMET XR, DAPAGLIFLOZIN
  SYMLIN, PRAMLINTIDE ACETATE
  XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP
* ASTRAZENECA LP
  NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ASTRAZENECA PHARMS
* ASTRAZENECA PHARMACEUTICALS LP
  BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
  BRILINTA, TICAGRELOR
  DALIRESP, ROFLUMILAST
  IRESSA, GEFITINIB
  LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
  LYNPARZA, OLAPARIB
  MOVANTIK, NALOXEGOL OXALATE
  NEXIUM IV, ESOMEPRAZOLE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ASTRAZENECA PHARMACEUTICALS LP
NEXIUM, ESOMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PULMICORT RESPULES, BUDESONIDE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
SEROQUEL, QUETIAPINE FUMARATE
TAGRISSO, OSIMERTINIB MESYLATE

ATHEM
* ATHEM HOLDINGS LLC
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORTHALIDONE, CHLORTHALIDONE
FOLIC ACID, FOLIC ACID
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

ATHENA
* ATHENA BIOSCIENCES LLC
FIBRICOR, FENOFIBRIC ACID

ATHENEX
* ATHENEX PHARMACEUTICAL DIV
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

ATHENEX INC
* ATHENEX INC
BUSULFAN, BUSULFAN
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
VALPROATE SODIUM, VALPROATE SODIUM

ATLAS PHARMS LLC
* ATLAS PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ATNAHS PHARMA US
* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

ATON
* ATON PHARMA INC
LODOSYN, CARBIDOPA

AUCTA
* AUCTA PHARMACEUTICALS INC
VIGADRONE, VIGABATRIN

AUREX
* AUREX LABORATORIES LTD LIABILITY CO
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

AUROBINDO
* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

AUROBINDO PHARMA

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATENOLOL, ATENOLOL
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIBAVIRIN, RIBAVIRIN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRANDOLAPRIL, TRANDOLAPRIL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LEVOFLOXACIN, LEVOFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AFIRMELLE, ETHINYL ESTRADIOL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARIPIPRAZOLE, ARIPIPRAZOLE
ARMODAFINIL, ARMODAFINIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AYUNA, ETHINYL ESTRADIOL
AZITHROMYCIN, AZITHROMYCIN
BIVALIRUDIN, BIVALIRUDIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CARBIDOPA, CARBIDOPA
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
CYONANZ, ETHINYL ESTRADIOL
DALFAMPRIDINE, DALFAMPRIDINE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOFETILDE, DOFETILIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
EPTIFIBATIDE, EPTIFIBATIDE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESZOPICLONE, ESZOPICLONE
ETOMIDATE, ETOMIDATE
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ICLEVIA, ETHINYL ESTRADIOL
INCASSIA, NORETHINDRONE
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISOSULFAN BLUE, ISOSULFAN BLUE
KALLIGA, DESOGESTREL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LATANOPROST, LATANOPROST
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LO SIMPESSE, ETHINYL ESTRADIOL
LO-ZUMANDIMINE, DROSPIRENONE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
MILI, ETHINYL ESTRADIOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NEVIRAPINE, NEVIRAPINE
NEXESTA FE, ETHINYL ESTRADIOL
NIACIN, NIACIN
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SIMPESSE, ETHINYL ESTRADIOL
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TIGECYCLINE, TIGECYCLINE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-MILI, ETHINYL ESTRADIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLMITRIPTAN, ZOLMITRIPTAN
ZUMANDIMINE, DROSPIRENONE
* AUROBINDO PHARMA LTD INC
ZIDOVUDINE, ZIDOVUDINE

AUROLIFE PHARMA LLC

* AUROLIFE PHARMA LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DUTASTERIDE, DUTASTERIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA

* AUSTARPHARMA LLC
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE

AUSTARPHARMA LLC

* AUSTARPHARMA LLC
METHOCARBAMOL, METHOCARBAMOL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS INC

* AUXILIUM PHARMACEUTICALS INC
TESTOPEL, TESTOSTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUXILIUM PHARMACEUTICALS INC
THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC

* AUXILIUM PHARMACEUTICALS LLC
DILATRATE-SR, ISOSORBIDE DINITRATE
EDEX, ALPROSTADIL
ROBAXIN-750, METHOCARBAMOL
SEMPREX-D, ACRIVASTINE
TESTIM, TESTOSTERONE
THEO-24, THEOPHYLLINE

AVACOR PRODS

* AVACOR PRODUCTS LLC
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVADEL LEGACY

* AVADEL LEGACY PHARMACEUTICALS LLC
AKOVAZ, EPHEDRINE SULFATE
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
NOURESS, CYSTEINE HYDROCHLORIDE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

AVANIR PHARMS

* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEDRO INC

* AVEDRO INC
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

AVEMA PHARMA

* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT

* AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVERITAS

* AVERITAS PHARMA INC
QUTENZA, CAPSAICIN

AVET

* AVET PHARMACEUTICALS INC
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE

AVEVA

* AVEVA DRUG DELIVERY SYSTEMS INC
CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC

* AVID RADIOPHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18

AVION PHARMS

* AVION PHARMACEUTICALS LLC
BALCOLTRA, ETHINYL ESTRADIOL
GLOPERBA, COLCHICINE

AVONDALE PHARMS

* AVONDALE PHARMACEUTICALS LLC
NIACOR, NIACIN

AYTU

* AYTU BIOSCIENCE INC
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
KARBINAL ER, CARBINOXAMINE MALEATE
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
ZOLPIMIST, ZOLPIDEM TARTRATE

**** B ****

B BRAUN

* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC

* B BRAUN MEDICAL INC
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ

* BAJAJ MEDICAL LLC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

BARR

* BARR LABORATORIES INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARANELLE, ETHINYL ESTRADIOL
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALZIVA-28, ETHINYL ESTRADIOL
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
DANAZOL, DANAZOL
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DIPYRIDAMOLE, DIPYRIDAMOLE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DUTASTERIDE, DUTASTERIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
ISONIAZID, ISONIAZID
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BARR LABORATORIES INC
JUNEL FE 1/20, ETHINYL ESTRADIOL
KARIVA, DESOGESTREL
KELNOR, ETHINYL ESTRADIOL
LEFLUNOMIDE, LEFLUNOMIDE
LESSINA-28, ETHINYL ESTRADIOL
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
ONDANSETRON, ONDANSETRON
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PORTIA-28, ETHINYL ESTRADIOL
SPRINTEC, ETHINYL ESTRADIOL
TEMOZOLOMIDE, TEMOZOLOMIDE
TREXALL, METHOTREXATE SODIUM
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
WARFARIN SODIUM, WARFARIN SODIUM
* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS DIV TEVA

* BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
BUDESONIDE, BUDESONIDE

BARR LABS INC

* BARR LABORATORIES INC
ACITRETIN, ACITRETIN
CLOZAPINE, CLOZAPINE
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ESTRADIOL, ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
TRETINOIN, TRETINOIN
TRI LO SPRINTEC, ETHINYL ESTRADIOL

BAUSCH

* BAUSCH HEALTH AMERICAS INC
ACANYA, BENZOYL PEROXIDE
ARAZLO, TAZAROTENE
BENZACLIN, BENZOYL PEROXIDE
BRYHALI, HALOBETASOL PROPIONATE
DUOBRII, HALOBETASOL PROPIONATE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EFUDEX, FLUOROURACIL
JUBLIA, EFINACONAZOLE
LOCOID, HYDROCORTISONE BUTYRATE
MEPHYTON, PHYTONADIONE
ONEXTON, BENZOYL PEROXIDE
OXSORALEN-ULTRA, METHOXSALEN
SYPRINE, TRIENTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH HEALTH IRELAND LTD
ERTACZO, SERTACONAZOLE NITRATE
TARGRETIN, BEXAROTENE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
* BAUSCH HEALTH US LLC
ALDARA, IMIQUIMOD
ANCOBON, FLUCYTOSINE
ATIVAN, LORAZEPAM
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DEMSER, METYROSINE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
ELIDEL, PIMECROLIMUS
ISORDIL, ISOSORBIDE DINITRATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
LOCOID, HYDROCORTISONE BUTYRATE
LOPROX, CICLOPIROX
MESTINON, PYRIDOSTIGMINE BROMIDE
METROGEL-VAGINAL, METRONIDAZOLE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
TASMAR, TOLCAPONE
TIAZAC, DILTIAZEM HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
XERESE, ACYCLOVIR
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR
ZYCLARA, IMIQUIMOD

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTEPREDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPREDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TROPICAMIDE, TROPICAMIDE
VITRASE, HYALURONIDASE
VYZULTA, LATANOPROSTENE BUNOD
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPREDNOL ETABONATE
* BAUSCH AND LOMB PHARMACEUTICALS INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH AND LOMB PHARMACEUTICALS INC
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
BEPREVE, BEPOTASTINE BESILATE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTEMAX, LOTEPREDNOL ETABONATE
LUMIFY, BRIMONIDINE TARTRATE (OTC)

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
EXTRANEAL, ICODEXTRIN
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FORANE, ISOFLURANE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
IFEX, IFOSFAMIDE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NEXTERONE, AMIODARONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION
SUPRANE, DESFLURANE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
* BAXTER HEALTHCARE INTERNATI0NAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINOLIPID 20%, OLIVE OIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MYXREDLIN, INSULIN HUMAN
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

BAYER

* BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE

* BAYER HEALTHCARE PHARMACEUTICALS INC
ALIQOPA, COPANLISIB DIHYDROCHLORIDE
NUBEQA, DAROLUTAMIDE
VITRAKVI, LAROTRECTINIB SULFATE

BAYER HEALTHCARE LLC

* BAYER HEALTHCARE LLC
CHILDREN'S CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
ZEGERID OTC, OMEPRAZOLE (OTC)

BAYER HLTHCARE

* BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
* BAYER HEALTHCARE PHARMACEUTICALS INC
ADEMPAS, RIOCIGUAT
ANGELIQ, DROSPIRENONE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BILTRICIDE, PRAZIQUANTEL
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
EOVIST, GADOXETATE DISODIUM
GADAVIST, GADOBUTROL
KYLEENA, LEVONORGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAYER HEALTHCARE PHARMACEUTICALS INC
LEVITRA, VARDENAFIL HYDROCHLORIDE
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
NATAZIA, DIENOGEST
NEXAVAR, SORAFENIB TOSYLATE
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STAXYN, VARDENAFIL HYDROCHLORIDE
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
VITRAKVI, LAROTRECTINIB SULFATE
XOFIGO, RADIUM RA-223 DICHLORIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC
* BAYSHORE PHARMACEUTICALS LLC
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
PINDOLOL, PINDOLOL
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BDSI
* BIODELIVERY SCIENCES INTERNATIONAL INC
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
SYMPROIC, NALDEMEDINE TOSYLATE

BE PHARMS
* BE PHARMACEUTICALS AG
DAPTOMYCIN, DAPTOMYCIN
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

BECTON DICKINSON
* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO
* BECTON DICKINSON AND CO
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEIGENE
* BEIGENE USA INC
BRUKINSA, ZANUBRUTINIB

BEIJING YILING
* BEIJING YILING BIO-ENGEERING AND TECHNOLOGY CO LTD
ANASTROZOLE, ANASTROZOLE
LETROZOLE, LETROZOLE

BELCHER PHARMS
* BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN
DESLORATADINE, DESLORATADINE

BELCHER PHARMS LLC
* BELCHER PHARMACEUTICALS LLC
ABLYSINOL, ALCOHOL
CEFIXIME, CEFIXIME
EPINEPHRINE, EPINEPHRINE
MEFENAMIC ACID, MEFENAMIC ACID
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BELCHER PHARMACEUTICALS LLC
TACROLIMUS, TACROLIMUS

BELOTECA INC
* BELOTECA INC
DIAZEPAM, DIAZEPAM

BEXIMCO PHARMS USA
* BEXIMCO PHARMACEUTICALS USA INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NADOLOL, NADOLOL
RIBAVIRIN, RIBAVIRIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA
* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BIOCODEX SA
* BIOCODEX SA
DIACOMIT, STIRIPENTOL

BIOCON LIMITED
* BIOCON LIMITED
SIMVASTATIN, SIMVASTATIN

BIOCON LTD
* BIOCON LTD
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

BIOCRYST
* BIOCRYST PHARMACEUTICALS INC
RAPIVAB, PERAMIVIR

BIOFRONTERA
* BIOFRONTERA BIOSCIENCE GMBH
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN
* BIOGEN
VUMERITY, DIROXIMEL FUMARATE

BIOGEN IDEC
* BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

BIOGEN IDEC INC
* BIOGEN IDEC INC
TECFIDERA, DIMETHYL FUMARATE

BIOMARIN PHARM
* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIOMEDCL RES FDN
* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISANA
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC
* BIONPHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBAZAM, CLOBAZAM
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BIONPHARMA INC
DOFETILIDE, DOFETILIDE
DUTASTERIDE, DUTASTERIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NIMODIPINE, NIMODIPINE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
PROGESTERONE, PROGESTERONE
RUFINAMIDE, RUFINAMIDE
TETRABENAZINE, TETRABENAZINE
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL
ZONISAMIDE, ZONISAMIDE

BLAIREX
* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLUE EARTH
* BLUE EARTH DIAGNOSTICS LTD
AXUMIN, FLUCICLOVINE F-18

BOEHRINGER INGELHEIM
* BOEHRINGER INGELHEIM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
GILOTRIF, AFATINIB DIMALEATE
GLYXAMBI, EMPAGLIFLOZIN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
APTIVUS, TIPRANAVIR
ATROVENT HFA, IPRATROPIUM BROMIDE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
JARDIANCE, EMPAGLIFLOZIN
JENTADUETO XR, LINAGLIPTIN
JENTADUETO, LINAGLIPTIN
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MOBIC, MELOXICAM
OFEV, NINTEDANIB ESYLATE
PERSANTINE, DIPYRIDAMOLE
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRIVA, TIOTROPIUM BROMIDE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
SYNJARDY XR, EMPAGLIFLOZIN
SYNJARDY, EMPAGLIFLOZIN
TRADJENTA, LINAGLIPTIN
TWYNSTA, AMLODIPINE BESYLATE
VIRAMUNE XR, NEVIRAPINE
VIRAMUNE, NEVIRAPINE

BOSCOGEN
* BOSCOGEN INC
ARIPIPRAZOLE, ARIPIPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BOSCOGEN INC
CAPTOPRIL, CAPTOPRIL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

BPI LABS LLC

* BPI LABS LLC
ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READI-CAT 2, BARIUM SULFATE
TAGITOL V, BARIUM SULFATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE

BRAINTREE

* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE

BRECKENRIDGE

* BRECKENRIDGE PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
EXEMESTANE, EXEMESTANE
IMATINIB MESYLATE, IMATINIB MESYLATE
LEVETIRACETAM, LEVETIRACETAM
MEGESTROL ACETATE, MEGESTROL ACETATE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
OMEPRAZOLE, OMEPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BRECKENRIDGE PHARMACEUTICAL INC
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE, RIVASTIGMINE
ROFLUMILAST, ROFLUMILAST
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
CILOSTAZOL, CILOSTAZOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
LEVETIRACETAM, LEVETIRACETAM
MELOXICAM, MELOXICAM
OXCARBAZEPINE, OXCARBAZEPINE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
AMMONIA N 13, AMMONIA N-13

BRIGHTGENE

* BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD
ENTECAVIR, ENTECAVIR

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
PRAVACHOL, PRAVASTATIN SODIUM
* BRISTOL MYERS SQUIBB CO
DROXIA, HYDROXYUREA
HYDREA, HYDROXYUREA
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
VIDEX EC, DIDANOSINE
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN
ZERIT, STAVUDINE
* BRISTOL MYERS SQUIBB PHARMA CO
COUMADIN, WARFARIN SODIUM

BRISTOL-MYERS SQUIBB

* BRISTOL-MYERS SQUIBB CO
EVOTAZ, ATAZANAVIR SULFATE
VIDEX, DIDANOSINE

BTCP PHARMA

* BTCP PHARMA LLC
LAZANDA, FENTANYL CITRATE
SUBSYS, FENTANYL

BWXT ITG

* BWXT ITG CANADA INC
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

**** C ****

CADILA

* CADILA HEALTHCARE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CADILA HEALTHCARE LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELBAMATE, FELBAMATE
INDOMETHACIN, INDOMETHACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
NYSTATIN, NYSTATIN
PIROXICAM, PIROXICAM
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

CADILA PHARMS LTD
* CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
CELECOXIB, CELECOXIB
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NATEGLINIDE, NATEGLINIDE
OFLOXACIN, OFLOXACIN
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CADISTA PHARMS
* CADISTA PHARMACEUTICALS INC
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

CALL INC
* CALL INC DBA ROCHESTER PHARMACEUTICALS
ADAPALENE, ADAPALENE

CAPELLON PHARMS LLC
* CAPELLON PHARMACEUTICALS LLC
POLMON, DEXCHLORPHENIRAMINE MALEATE

CAPLIN
* CAPLIN STERILES LTD
GLYCOPYRROLATE, GLYCOPYRROLATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

CARDINAL HEALTH 414
* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

CARDINAL HEALTH 418
* CARDINAL HEALTH 418 INC
SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARIBE HOLDINGS
* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
GEMFIBROZIL, GEMFIBROZIL

CARLSBAD
* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

CARLSBAD TECHNOLOGY
* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR

CASI PHARMS INC
* CASI PHARMACEUTICALS INC
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CEFPROZIL, CEFPROZIL
CILOSTAZOL, CILOSTAZOL
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
ENTECAVIR, ENTECAVIR
HEPARIN SODIUM, HEPARIN SODIUM
LISINOPRIL, LISINOPRIL
METHIMAZOLE, METHIMAZOLE
NABUMETONE, NABUMETONE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

CASPER PHARMA LLC
* CASPER PHARMA LLC
ANTIVERT, MECLIZINE HYDROCHLORIDE
AQUASOL A, VITAMIN A PALMITATE
CASPORYN HC, HYDROCORTISONE
FURADANTIN, NITROFURANTOIN
NEOSPORIN, BACITRACIN ZINC
ZYLOPRIM, ALLOPURINOL

CATALENT
* CATALENT PHARMA SOLUTIONS LLC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
VALPROIC ACID, VALPROIC ACID

CATALYST PHARMS
* CATALYST PHARMACEUTICALS INC
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE

CEDIPROF INC
* CEDIPROF INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **

CELATOR PHARMS
* CELATOR PHARMACEUTICALS INC
VYXEOS, CYTARABINE

CELGENE
* CELGENE CORP
ISTODAX, ROMIDEPSIN
POMALYST, POMALIDOMIDE
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

CELGENE CORP
* CELGENE CORP
IDHIFA, ENASIDENIB MESYLATE

CELLTRION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CELLTRION INC
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FAMOTIDINE, FAMOTIDINE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TEMIXYS, LAMIVUDINE
ZONISAMIDE, ZONISAMIDE

CEPHALON
* CEPHALON INC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE
GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

CEYONE
* CEYONE PHARMA LLC
BUMETANIDE, BUMETANIDE

CHANGZHOU PHARM
* CHANGZHOU PHARMACEUTICAL FACTORY
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL
* CHARTWELL LIFE MOLECULES LLC
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
FLUCONAZOLE, FLUCONAZOLE

CHARTWELL LIFE SCI
* CHARTWELL LIFE SCIENCE LLC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHARTWELL MOLECULAR
* CHARTWELL MOLECULAR HOLDINGS LLC
CALCIUM ACETATE, CALCIUM ACETATE
CARVEDILOL, CARVEDILOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FOLIC ACID, FOLIC ACID
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
RAMIPRIL, RAMIPRIL
RISPERIDONE, RISPERIDONE

CHARTWELL MOLECULES
* CHARTWELL MOLECULES LLC
DISULFIRAM, DISULFIRAM
GEMFIBROZIL, GEMFIBROZIL
NABUMETONE, NABUMETONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX
* CHARTWELL RX SCIENCES LLC
CALCIUM ACETATE, CALCIUM ACETATE
CILOSTAZOL, CILOSTAZOL
DUVOID, BETHANECHOL CHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
INDOMETHACIN, INDOMETHACIN
LEVETIRACETAM, LEVETIRACETAM
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL RX SCIENCES LLC
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE

CHARTWELL TETRA
* CHARTWELL TETRA LLC
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM
* CHATTEM INC
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEMI SPA
* CHEMI SPA
DECITABINE, DECITABINE
TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR
* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

CHEMO RESEARCH SL
* CHEMO RESEARCH SL
BENZNIDAZOLE, BENZNIDAZOLE
NUVESSA, METRONIDAZOLE

CHEPLAPHARM
* CHEPLAPHARM ARZNEIMITTEL GMBH
CYTOVENE, GANCICLOVIR SODIUM
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
XENICAL, ORLISTAT

CHIESI USA INC
* CHIESI USA INC
BETHKIS, TOBRAMYCIN
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CLEVIPREX, CLEVIDIPINE
CUROSURF, PORACTANT ALFA
KENGREAL, CANGRELOR
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

CHILDRENS HOSP MI
* CHILDRENS HOSP MICHIGAN
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES
* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN
* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CINTEX SVCS
* CINTEX SERVICES LLC
FLURANDRENOLIDE, FLURANDRENOLIDE

CIPHER PHARMS INC
* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA
* CIPLA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CIPLA LTD
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BOSENTAN, BOSENTAN
BUDESONIDE, BUDESONIDE
CELECOXIB, CELECOXIB
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DECITABINE, DECITABINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE, EMTRICITABINE
ENTECAVIR, ENTECAVIR
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
FLUTAMIDE, FLUTAMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MELOXICAM, MELOXICAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREGABALIN, PREGABALIN
RANOLAZINE, RANOLAZINE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE, TESTOSTERONE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
ZIDOVUDINE, ZIDOVUDINE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

CIPLA LTD

* CIPLA LTD
ALBENDAZOLE, ALBENDAZOLE
CARBOPLATIN, CARBOPLATIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CIPLA USA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CIPLA USA INC
ZEMDRI, PLAZOMICIN SULFATE

CIRCASSIA
* CIRCASSIA LTD
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE

CLARUS
* CLARUS THERAPEUTICS INC
JATENZO, TESTOSTERONE UNDECANOATE

CLINIGEN
* CLINIGEN INC
ETHYOL, AMIFOSTINE
TOTECT, DEXRAZOXANE HYDROCHLORIDE

CLINIGEN HLTHCARE
* CLINIGEN HEALTHCARE LTD
FOSCAVIR, FOSCARNET SODIUM

CLIVUNEL INC
* CLINUVEL INC
SCENESSE, AFAMELANOTIDE

CLOVER PHARMS
* CLOVER PHARMACEUTICALS CORP
AMICAR, AMINOCAPROIC ACID

CLOVIS ONCOLOGY INC
* CLOVIS ONCOLOGY INC
RUBRACA, RUCAPARIB CAMSYLATE

CMP DEV LLC
* CMP DEVELOPMENT LLC
CAROSPIR, SPIRONOLACTONE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC

CMP PHARMA INC
* CMP PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CNTY LINE PHARMS
* COUNTY LINE PHARMACEUTICALS LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CICLOPIROX, CICLOPIROX
DYNACIN, MINOCYCLINE HYDROCHLORIDE
FLUOCINONIDE, FLUOCINONIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
TAMBOCOR, FLECAINIDE ACETATE
TRANDATE, LABETALOL HYDROCHLORIDE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
UREX, METHENAMINE HIPPURATE

COEPTIS
* COEPTIS PHARMACEUTICALS INC
CONSENSI, AMLODIPINE BESYLATE

COLGATE PALMOLIVE CO
* COLGATE PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE-PALMOLIVE CO
* COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC
* COLLEGIUM PHARMACEUTICAL INC
XTAMPZA ER, OXYCODONE

COMBE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)

CONCORD BIOTECH LTD
* CONCORD BIOTECH LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID

CONCORDIA
* CONCORDIA PHARMACEUTICALS INC
DUTOPROL, HYDROCHLOROTHIAZIDE
DYRENIUM, TRIAMTERENE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
PANRETIN, ALITRETINOIN
PARNATE, TRANYLCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
SALAGEN, PILOCARPINE HYDROCHLORIDE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

CONCORDIA PHARMS INC
* CONCORDIA PHARMACEUTICALS INC
KAPVAY, CLONIDINE HYDROCHLORIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE

CONTRACT PHARMACAL
* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

COOPERSURGICAL
* COOPERSURGICAL INC
PARAGARD T 380A, COPPER

CORCEPT THERAP
* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

CORDEN PHARMA
* CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE

COSETTE
* COSETTE PHARMACEUTICALS INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
MIGERGOT, CAFFEINE

COVIS PHARMA BV
* COVIS PHARMA BV
ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
OMNARIS, CICLESONIDE
PRILOSEC, OMEPRAZOLE MAGNESIUM
RILUTEK, RILUZOLE
SULAR, NISOLDIPINE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZETONNA, CICLESONIDE

CPDC
* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CPPI CV
* CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CROSSMEDIKA SA
* CROSSMEDIKA SA
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CROSSMEDIKA SA
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

CROWN LABS
* CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC
* CROWN LABORATORIES INC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

CSPC OUYI
* CSPC OUYI PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
CELECOXIB, CELECOXIB
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CONJUPRI, LEVAMLODIPINE MALEATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

CSPC OUYI PHARM CO
* CSPC OUYI PHARMACEUTICAL CO LTD
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CUBIST PHARMS
* CUBIST PHARMACEUTICALS INC
ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC
* CUBIST PHARMACEUTICALS LLC
CUBICIN RF, DAPTOMYCIN
CUBICIN, DAPTOMYCIN
DIFICID, FIDAXOMICIN
SIVEXTRO, TEDIZOLID PHOSPHATE
ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS
* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
REDITREX, METHOTREXATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VIBATIV, TELAVANCIN HYDROCHLORIDE

CURIUM
* CURIUM US LLC
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

CURRAX
* CURRAX PHARMACEUTICALS LLC
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
SILENOR, DOXEPIN HYDROCHLORIDE
TREXIMET, NAPROXEN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CUSTOPHARM INC
* CUSTOPHARM INC
ACETAMINOPHEN, ACETAMINOPHEN
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
VALRUBICIN, VALRUBICIN

CYCLE PHARMS LTD
* CYCLE PHARMACEUTICALS LTD
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NITYR, NITISINONE

**** D ****

DAEWOONG PHARM CO
* DAEWOONG PHARMACEUTICAL CO LTD
MEROPENEM, MEROPENEM

DAIICHI SANKYO
* DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO INC
* DAIICHI SANKYO INC
EVOXAC, CEVIMELINE HYDROCHLORIDE
MORPHABOND ER, MORPHINE SULFATE
SAVAYSA, EDOXABAN TOSYLATE
TURALIO, PEXIDARTINIB HYDROCHLORIDE
WELCHOL, COLESEVELAM HYDROCHLORIDE

DANCO LABS LLC
* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DAVA INTL INC
* DAVA INTERNATIONAL INC
ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC
* DAVA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
GLYBURIDE (MICRONIZED), GLYBURIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DBL PHARMS
* DBL PHARMACEUTICALS INC
METHOCARBAMOL, METHOCARBAMOL

DECATUR
* DECATUR MEMORIAL HOSP
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DECATUR MEMORIAL HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPO NF

* DEPO NF SUB LLC A SUB OF ASSERTIO THERAPEUTICS INC
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE

DEPROCO

* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMIRA INC

* DERMIRA INC
QBREXZA, GLYCOPYRRONIUM TOSYLATE

DEVA HOLDING AS

* DEVA HOLDING AS
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL LTD

* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
HEMADY, DEXAMETHASONE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
OMEPRAZOLE, OMEPRAZOLE (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

DFB ONCOLOGY LTD

* DFB ONCOLOGY LTD
DOCETAXEL, DOCETAXEL

DIAGNOSTIC GREEN

* DIAGNOSTIC GREEN GMBH
INDOCYANINE GREEN, INDOCYANINE GREEN

DIALYSIS SUPS

* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DIGESTIVE CARE INC

* DIGESTIVE CARE INC
PERTZYE, PANCRELIPASE (AMYLASE

DORC

* DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

* DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM

* DOW PHARMACEUTICAL SCIENCES
ALTRENO, TRETINOIN
ATRALIN, TRETINOIN

DR REDDYS

* DR REDDYS LABORATORIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES INC
NITROGLYCERIN, NITROGLYCERIN
PROGESTERONE, PROGESTERONE
PROPOFOL, PROPOFOL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE, TESTOSTERONE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* DR REDDYS LABORATORIES LTD
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZACITIDINE, AZACITIDINE
CARFILZOMIB, CARFILZOMIB
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OMEPRAZOLE, OMEPRAZOLE (OTC)
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TETRABENAZINE, TETRABENAZINE
THIOTEPA, THIOTEPA
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

DR REDDYS LA

* DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC

* DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* DR REDDYS LABORATORIES LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BIVALIRUDIN, BIVALIRUDIN
BORTEZOMIB, BORTEZOMIB
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOFARABINE, CLOFARABINE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOCETAXEL, DOCETAXEL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHYTONADIONE, PHYTONADIONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIROLIMUS, SIROLIMUS
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZAFIRLUKAST, ZAFIRLUKAST
ZENATANE, ISOTRETINOIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
HABITROL, NICOTINE (OTC)
MERCAPTOPURINE, MERCAPTOPURINE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
RAMELTEON, RAMELTEON
TOBRAMYCIN, TOBRAMYCIN

DRAXIMAGE

* DRAXIMAGE INC
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

DUCHESNAY

* DUCHESNAY INC
BONJESTA, DOXYLAMINE SUCCINATE
DICLEGIS, DOXYLAMINE SUCCINATE
OSPHENA, OSPEMIFENE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ENPRESSE-28, ETHINYL ESTRADIOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VELIVET, DESOGESTREL

DUSA

* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DUTCH OPHTHALMIC

* DUTCH OPHTHALMIC RESEARCH CENTER INTERNATIONAL BV
TISSUEBLUE, BRILLIANT BLUE G

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DOCTOR REDDYS LABORATORIES LTD
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ****

E5 PHARMA INC
* E5 PHARMA INC
DIAZOXIDE, DIAZOXIDE

EAGLE PHARMS
* EAGLE PHARMACEUTICALS INC
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
RYANODEX, DANTROLENE SODIUM

ECI PHARMS LLC
* ECI PHARMACEUTICALS LLC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LAMIVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
METHIMAZOLE, METHIMAZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
VALPROIC ACID, VALPROIC ACID

ECOLAB
* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR
* ECR PHARMACEUTICALS
DEXAMETHASONE, DEXAMETHASONE

ECR PHARMA
* ECR PHARMA
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS
* EDENBRIDGE PHARMACEUTICALS LLC
ALBENDAZOLE, ALBENDAZOLE
CARBIDOPA, CARBIDOPA
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ETHACRYNIC ACID, ETHACRYNIC ACID
ETODOLAC, ETODOLAC
IVERMECTIN, IVERMECTIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TINIDAZOLE, TINIDAZOLE

EDISON THERAPS LLC
* EDISON THERAPEUTICS LLC
METHERGINE, METHYLERGONOVINE MALEATE

EGALET
* EGALET US INC
INDOCIN, INDOMETHACIN

EI INC
* EI INC
THEROXIDIL, MINOXIDIL (OTC)

EISAI INC
* EISAI INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BELVIQ, LORCASERIN HYDROCHLORIDE
FYCOMPA, PERAMPANEL
HALAVEN, ERIBULIN MESYLATE
LENVIMA, LENVATINIB MESYLATE

ELI LILLY AND CO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ELI LILLY AND CO
BAQSIMI, GLUCAGON
BASAGLAR, INSULIN GLARGINE
EFFIENT, PRASUGREL HYDROCHLORIDE
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
OLUMIANT, BARICITINIB
PROZAC, FLUOXETINE HYDROCHLORIDE
VERZENIO, ABEMACICLIB

ELI LILLY CO

* ELI LILLY CO
ADCIRCA, TADALAFIL
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS

* ELITE LABORATORIES INC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC

* ELITE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
DANTROLENE SODIUM, DANTROLENE SODIUM
ISRADIPINE, ISRADIPINE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

ELYSIUM

* ELYSIUM PHARMACEUTICALS LTD
CALCITRIOL, CALCITRIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

EMCURE PHARMS

* EMCURE PHARMACEUTICALS LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS LTD

* EMCURE PHARMACEUTICALS LTD
ACARBOSE, ACARBOSE
AMIKACIN SULFATE, AMIKACIN SULFATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BICNU, CARMUSTINE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ETOMIDATE, ETOMIDATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RIFAMPIN, RIFAMPIN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRANEXAMIC ACID, TRANEXAMIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMD SERONO

* EMD SERONO INC
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F, FOLLITROPIN ALFA/BETA
OVIDREL, CHORIOGONADOTROPIN ALFA
SAIZEN, SOMATROPIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EMD SERONO INC
SEROSTIM, SOMATROPIN
ZORBTIVE, SOMATROPIN RECOMBINANT

EMD SERONO INC
* EMD SERONO INC
CETROTIDE, CETRORELIX
MAVENCLAD, CLADRIBINE

EMERALD INTL LTD
* EMERALD INTERNATIONAL LTD
BACLOFEN, BACLOFEN

EMMAUS MEDCL
* EMMAUS MEDICAL INC
ENDARI, L-GLUTAMINE

ENCORE DERMAT
* ENCORE DERMATOLOGY INC
IMPOYZ, CLOBETASOL PROPIONATE
SERNIVO, BETAMETHASONE DIPROPIONATE

ENCUBE
* ENCUBE ETHICALS PRIVATE LTD
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ENCUBE ETHICALS
* ENCUBE ETHICALS PVT LTD
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
PERMETHRIN, PERMETHRIN

ENDO PHARM
* ENDO PHARMACEUTICAL SOLUTIONS INC
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VANTAS, HISTRELIN ACETATE

ENDO PHARMS
* ENDO PHARMACEUTICALS INC
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
PERCODAN, ASPIRIN

ENDO PHARMS INC
* ENDO PHARMACEUTICALS INC
AVEED, TESTOSTERONE UNDECANOATE
COLY-MYCIN S, COLISTIN SULFATE
MEGACE ES, MEGESTROL ACETATE
NASCOBAL, CYANOCOBALAMIN
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

EPI HLTH
* EPI HEALTH LLC
CLODERM, CLOCORTOLONE PIVALATE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
SITAVIG, ACYCLOVIR

EPIC PHARMA
* EPIC PHARMA INC
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
* EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA INC
* EPIC PHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EPIC PHARMA INC
ESTRADIOL, ESTRADIOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AZITHROMYCIN, AZITHROMYCIN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GABAPENTIN, GABAPENTIN
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

ESPERO

* ESPERO BIOPHARMA INC
DURLAZA, ASPIRIN

ESSENTIAL ISOTOPES

* ESSENTIAL ISOTOPES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM

* ETHYPHARM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETHYPHARM USA CORP

* ETHYPHARM USA CORP
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETON PHARMS

* ETON PHARMACEUTICALS
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE

EUGIA PHARMA

* EUGIA PHARMA SPECIALITIES LTD
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN
PROGESTERONE, PROGESTERONE

EUROHLTH INTL SARL

* EUROHEALTH INTERNATIONAL SARL
DROPERIDOL, DROPERIDOL
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

EVUS

* EVUS HEALTH SOLUTIONS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EVUS HEALTH SOLUTIONS LLC
NITROMIST, NITROGLYCERIN

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
IDKIT:HP, CITRIC ACID

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

EXELA PHARMA SCS LLC

* EXELA PHARMA SCIENCES LLC
CAFFEINE CITRATE, CAFFEINE CITRATE
ELCYS, CYSTEINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GANZYK-RTU, GANCICLOVIR
GLYRX-PF, GLYCOPYRROLATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EXELIXIS

* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

* EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS USA INC

* EXELTIS USA INC
SLYND, DROSPIRENONE

EYEPOINT PHARMS

* EYEPOINT PHARMACEUTICALS INC
DEXYCU KIT, DEXAMETHASONE
YUTIQ, FLUOCINOLONE ACETONIDE

EYEVANCE

* EYEVANCE PHARMACEUTICALS LLC
FLAREX, FLUOROMETHOLONE ACETATE
ZERVIATE, CETIRIZINE HYDROCHLORIDE

EYWA

* EYWA PHARMA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

EYWA PHARMA

* EYWA PHARMA PTE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
BACLOFEN, BACLOFEN
URSODIOL, URSODIOL

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG TEMPO PEN, INSULIN LISPRO RECOMBINANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ELI LILLY AND CO
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R KWIKPEN, INSULIN HUMAN
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

**** F ****

FDC LTD
* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
OFLOXACIN, OFLOXACIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER
* FOUNDATION CONSUMER HEALTHCARE LLC
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN
* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUORODOPA F18, FLUORODOPA F-18

FERA PHARMS
* FERA PHARMACEUTICALS LLC
TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC
* FERA PHARMACEUTICALS LLC
DEXAMETHASONE, DEXAMETHASONE
GENTAMICIN SULFATE, GENTAMICIN SULFATE

FERRER INTERNACIONAL
* FERRER INTERNACIONAL SA
XEPI, OZENOXACIN

FERRING
* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE
MENOPUR, MENOTROPINS (FSH
MINIRIN, DESMOPRESSIN ACETATE
ZOMACTON, SOMATROPIN

FERRING PHARMS INC
* FERRING PHARMACEUTICALS INC
CERVIDIL, DINOPROSTONE
CLENPIQ, CITRIC ACID
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
LYSTEDA, TRANEXAMIC ACID
NOCDURNA, DESMOPRESSIN ACETATE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

FLAMINGO PHARMS
* FLAMINGO PHARMACEUTICALS LTD
METRONIDAZOLE, METRONIDAZOLE
PIROXICAM, PIROXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

FLEXION THERAPS INC
* FLEXION THERAPEUTICS INC
ZILRETTA, TRIAMCINOLONE ACETONIDE

FOAMIX
* FOAMIX PHARMACEUTICALS INC
AMZEEQ, MINOCYCLINE HYDROCHLORIDE

FOLDRX PHARMS
* FOLDRX PHARMACEUTICALS INC SUB PFIZER INC
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE

FOREST LABS LLC
* FOREST LABORATORIES LLC
NAMENDA XR, MEMANTINE HYDROCHLORIDE

FORTOVIA
* FORTOVIA THERAPEUTICS INC
ORAVIG, MICONAZOLE
SOLTAMOX, TAMOXIFEN CITRATE

FOSUN PHARMA
* FOSUN PHARMA USA INC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

FOUGERA PHARMS
* FOUGERA PHARMACEUTICALS INC
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMCINONIDE, AMCINONIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CUTIVATE, FLUTICASONE PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE
PANDEL, HYDROCORTISONE PROBUTATE
PREDNICARBATE, PREDNICARBATE
SOLARAZE, DICLOFENAC SODIUM
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC
* FOUGERA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FOUGERA PHARMACEUTICALS INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
TACROLIMUS, TACROLIMUS
TERCONAZOLE, TERCONAZOLE
VEREGEN, SINECATECHINS

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
* FRESENIUS KABI IPSUM SRL
NAFCILLIN SODIUM, NAFCILLIN SODIUM

FRESENIUS KABI

* FRESENIUS KABI ANTI INFECTIVES SRL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
* FRESENIUS KABI AUSTRIA GMBH
LACTULOSE, LACTULOSE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
ACETAMINOPHEN, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
ARGATROBAN, ARGATROBAN
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACITRACIN, BACITRACIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CEFOTETAN, CEFOTETAN DISODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OMEGAVEN, FISH OIL TRIGLYCERIDES
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FRONTIDA BIOPHARM

* FRONTIDA BIOPHARM INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

**** G ****

G AND W LABS INC

* G AND W LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

GALDERMA LABS

* GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE
* GALDERMA LABORATORIES LP
CAPEX, FLUOCINOLONE ACETONIDE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
DIFFERIN, ADAPALENE (OTC)
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
SOOLANTRA, IVERMECTIN
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

GALDERMA R AND D

* GALDERMA RESEARCH AND DEVELOPMENT INC
AKLIEF, TRIFAROTENE

GALEN SPECIALTY

* GALEN SPECIALTY PHARMA US LLC
SYNERA, LIDOCAINE

GALT PHARMS

* GALT PHARMACEUTICALS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GALT PHARMACEUTICALS LLC
DORAL, QUAZEPAM

GATE PHARMS
* GATE PHARMACEUTICALS
LINEZOLID, LINEZOLID

GD SEARLE
* GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

GD SEARLE LLC
* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CYTOTEC, MISOPROSTOL
FLAGYL, METRONIDAZOLE
INSPRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE
* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CLARISCAN, GADOTERATE MEGLUMINE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC
* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GENBIOPRO
* GENBIOPRO INC
MIFEPRISTONE, MIFEPRISTONE

GENENTECH
* GENENTECH INC
ERIVEDGE, VISMODEGIB
NUTROPIN AQ NUSPIN, SOMATROPIN

GENENTECH INC
* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
ESBRIET, PIRFENIDONE
ROZLYTREK, ENTRECTINIB
XOFLUZA, BALOXAVIR MARBOXIL

GENERICS
* GENERICS INTERNATIONAL VENTURES ENTERPRISES LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

GENEYORK PHARMS
* GENEYORK PHARMACEUTICALS GROUP LLC
PREDNISONE, PREDNISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

GENUS
* GENUS LIFESCIENCES INC
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
TIVORBEX, INDOMETHACIN

GENUS LIFESCIENCES
* GENUS LIFE SCIENCES INC
GOPRELTO, COCAINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
YOSPRALA, ASPIRIN

GENZYME
* GENZYME CORP
CEREZYME, IMIGLUCERASE
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
RENVELA, SEVELAMER CARBONATE
THYROGEN, THYROTROPIN ALFA

GENZYME CORP
* GENZYME CORP
CAPRELSA, VANDETANIB
CERDELGA, ELIGLUSTAT TARTRATE

GILEAD
* GILEAD SCIENCES INC
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

GILEAD SCIENCES
* GILEAD SCIENCES LLC
ATRIPLA, EFAVIRENZ

GILEAD SCIENCES INC
* GILEAD SCIENCES INC
BIKTARVY, BICTEGRAVIR SODIUM
COMPLERA, EMTRICITABINE
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
TYBOST, COBICISTAT
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VOSEVI, SOFOSBUVIR
ZYDELIG, IDELALISIB

GISKIT
* GISKIT BV
EXEM FOAM KIT, AIR POLYMER-TYPE A

GLAND PHARMA LTD
* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
AZITHROMYCIN, AZITHROMYCIN
BIMATOPROST, BIMATOPROST
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CYTARABINE, CYTARABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAND PHARMA LTD
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEROPENEM, MEROPENEM
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACITAXEL, PACLITAXEL
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLEDRONIC, ZOLEDRONIC ACID

GLASSHOUSE PHARMS

* GLASSHOUSE PHARMACEUTICALS LTD CANADA
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE

GLAXO GRP ENGLAND

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
FLOVENT HFA, FLUTICASONE PROPIONATE
* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREO ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
AVODART, DUTASTERIDE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
EPIVIR-HBV, LAMIVUDINE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAXOSMITHKLINE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
JALYN, DUTASTERIDE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
RELENZA, ZANAMIVIR
VALTREX, VALACYCLOVIR HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE

* GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ALAVERT, LORATADINE (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
INFANT'S ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)

* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
KRINTAFEL, TAFENOQUINE SUCCINATE
TRELEGY ELLIPTA, FLUTICASONE FUROATE

* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE

GLAXOSMITHKLINE CON

* GLAXOSMITHKLINE CONSUMER HEALTH
TRANSDERM SCOP, SCOPOLAMINE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
VOLTAREN, DICLOFENAC SODIUM

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
AMERGE, NARATRIPTAN HYDROCHLORIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
FLOLAN, EPOPROSTENOL SODIUM
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE
REQUIP XL, ROPINIROLE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAXOSMITHKLINE LLC
REQUIP, ROPINIROLE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

GLENMARK

* GLENMARK THERAPEUTICS INC USA
ECOZA, ECONAZOLE NITRATE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE
ADAPALENE, ADAPALENE (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
IMIQUIMOD, IMIQUIMOD
MOMETASONE FUROATE, MOMETASONE FUROATE
NIZATIDINE, NIZATIDINE
ZONISAMIDE, ZONISAMIDE
* GLENMARK GENERICS LIMITED
BRIELLYN, ETHINYL ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
* GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
HEATHER, NORETHINDRONE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LITHIUM CARBONATE, LITHIUM CARBONATE
MARLISSA, ETHINYL ESTRADIOL
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN, NAPROXEN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIORELE, DESOGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK GENERICS LTD
ZOLMITRIPTAN, ZOLMITRIPTAN
* GLENMARK GENERICS LTD INDIA
INDOMETHACIN, INDOMETHACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

* GLENMARK PHARMACEUTICALS INC
TERIFLUNOMIDE, TERIFLUNOMIDE
* GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN
* GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
* GLENMARK PHARMACEUTICALS SA
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ATOVAQUONE, ATOVAQUONE
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE, CALCIPOTRIENE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
LINEZOLID, LINEZOLID
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GLENMARK PHARMS INC

* GLENMARK PHARMACEUTICALS INC USA
CALCIPOTRIENE, CALCIPOTRIENE
FULVESTRANT, FULVESTRANT
LITHIUM CARBONATE, LITHIUM CARBONATE
MUPIROCIN, MUPIROCIN CALCIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

GLENMARK PHARMS LTD

* GLENMARK PHARMACEUTICALS LTD
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTRADIOL, ESTRADIOL
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
HAILEY FE 1/20, ETHINYL ESTRADIOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
INDOMETHACIN, INDOMETHACIN
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK PHARMACEUTICALS LTD
LIDOCAINE, LIDOCAINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXCARBAZEPINE, OXCARBAZEPINE
PIMECROLIMUS, PIMECROLIMUS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
RUFINAMIDE, RUFINAMIDE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
TACROLIMUS, TACROLIMUS
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VORICONAZOLE, VORICONAZOLE

GLENMARK PHARMS SA
* GLENMARK PHARMACEUTICALS SA SWITZERLAND
ACYCLOVIR, ACYCLOVIR
APREPITANT, APREPITANT
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
NITROGLYCERIN, NITROGLYCERIN

GLOBAL BLOOD THERAPS
* GLOBAL BLOOD THERAPEUTICS INC
OXBRYTA, VOXELOTOR

GRANULES INDIA
* GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRANULES INDIA LTD
* GRANULES INDIA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

GRANULES PHARMS
* GRANULES PHARMACEUTICALS INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

GRAVITI PHARMS
* GRAVITI PHARMACEUTICALS PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE

GUARDIAN DRUG

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GUARDIAN DRUG CO
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)

GUERBET
* GUERBET LLC
DOTAREM, GADOTERATE MEGLUMINE
LIPIODOL, ETHIODIZED OIL

GW RES LTD
* GW RESEARCH LTD
EPIDIOLEX, CANNABIDIOL

HANFORD GC
* GC HANFORD MANUFACTURING CO
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

POHL BOSKAMP
* G POHL BOSKAMP GMBH AND CO KG
GONITRO, NITROGLYCERIN

**** H ****

HAEMONETICS
* HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HAINAN POLY PHARM
* HAINAN POLY PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
EPTIFIBATIDE, EPTIFIBATIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
LEVETIRACETAM, LEVETIRACETAM
VORICONAZOLE, VORICONAZOLE

HALOCARBON PRODS
* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP
* HALOZYME THERAPEUTICS INC
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN PHARMA PLUS
* HAMELN PHARMA PLUS GMBH
PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM

HANGZHOU BINJIANG
* HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM

HANSAMED INC
* HANSAMED INC
ULTACAN FORTE, ARTICAINE HYDROCHLORIDE
ULTACAN, ARTICAINE HYDROCHLORIDE

HARMONY
* HARMONY BIOSCIENCES LLC
WAKIX, PITOLISANT HYDROCHLORIDE

HARRIS PHARM
* HARRIS PHARMACEUTICAL INC
FLUCONAZOLE, FLUCONAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HBT LABS INC
* HBT LABS INC
FULVESTRANT, FULVESTRANT

HEBEI CHANGSHAN
* HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

HEC PHARM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HEC PHARM USA INC
CLARITHROMYCIN, CLARITHROMYCIN
LEVOFLOXACIN, LEVOFLOXACIN
PRASUGREL, PRASUGREL HYDROCHLORIDE

HEC PHARM CO LTD

* HEC PHARM CO LTD
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

HELSINN

* HELSINN BIREX PHARMACEUTICALS LTD
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

HELSINN HLTHCARE

* HELSINN HEALTHCARE SA
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
NITROGLYCERIN, NITROGLYCERIN

HERITAGE LIFE

* HERITAGE LIFE SCIENCES BARBADOS INC
CLOZARIL, CLOZAPINE

HERITAGE PHARMA

* HERITAGE PHARMA LABS INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUNISAL, DIFLUNISAL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
INDOMETHACIN, INDOMETHACIN
LITHIUM CARBONATE, LITHIUM CARBONATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHYLDOPA, METHYLDOPA
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NADOLOL, NADOLOL
NIFEDIPINE, NIFEDIPINE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DUTASTERIDE, DUTASTERIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HERITAGE PHARMACEUTICALS INC
ETHOSUXIMIDE, ETHOSUXIMIDE
FELODIPINE, FELODIPINE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
KETOPROFEN, KETOPROFEN
LEFLUNOMIDE, LEFLUNOMIDE
METRONIDAZOLE, METRONIDAZOLE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NYSTATIN, NYSTATIN
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERON THERAPS INC

* HERON THERAPEUTICS INC
CINVANTI, APREPITANT
SUSTOL, GRANISETRON

HETERO LABS LTD

* HETERO LABS LTD
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

HETERO LABS LTD III

* HETERO LABS LTD UNIT III
ABACAVIR SULFATE, ABACAVIR SULFATE
ATOVAQUONE, ATOVAQUONE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBAZAM, CLOBAZAM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHOCARBAMOL, METHOCARBAMOL
NEVIRAPINE, NEVIRAPINE
OMEPRAZOLE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PREGABALIN, PREGABALIN
RITONAVIR, RITONAVIR
ROFLUMILAST, ROFLUMILAST
SIMVASTATIN, SIMVASTATIN
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TORSEMIDE, TORSEMIDE
ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
ACYCLOVIR, ACYCLOVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HETERO LABS LTD UNIT V
ARIPIPRAZOLE, ARIPIPRAZOLE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
FAMCICLOVIR, FAMCICLOVIR
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TETRABENAZINE, TETRABENAZINE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH

* HI-TECH PHARMACAL CO INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
IBUPROFEN, IBUPROFEN
MEGESTROL ACETATE, MEGESTROL ACETATE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
TRIFLURIDINE, TRIFLURIDINE

* HI-TECH PHARMACAL CO INC AN AKORN CO
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE

HI TECH PHARMA

* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CORMAX, CLOBETASOL PROPIONATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HI TECH PHARMACAL CO INC
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TIMOLOL MALEATE, TIMOLOL MALEATE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO

* HI TECH PHARMACAL CO INC
FLUNISOLIDE, FLUNISOLIDE
PREDNISOLONE, PREDNISOLONE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
FAMOTIDINE, FAMOTIDINE
GATIFLOXACIN, GATIFLOXACIN
LORAZEPAM, LORAZEPAM
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
LEVETIRACETAM, LEVETIRACETAM

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKMA

* HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM
* HIKMA FARMACEUTICA PORTUGAL SA
CEFOTETAN, CEFOTETAN DISODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
ETOMIDATE, ETOMIDATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
* HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
* HIKMA PHARMACEUTICALS INTERNATIONAL LTD
ATIVAN, LORAZEPAM
CAFCIT, CAFFEINE CITRATE
CIMETIDINE, CIMETIDINE
CODEINE SULFATE, CODEINE SULFATE
DIGOXIN, DIGOXIN
DOPRAM, DOXAPRAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HEPARIN SODIUM, HEPARIN SODIUM
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
MORPHINE SULFATE, MORPHINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS INTERNATIONAL LTD
ROBAXIN, METHOCARBAMOL
RUFINAMIDE, RUFINAMIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
* HIKMA PHARMACEUTICALS LLC
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
* HIKMA PHARMACEUTICALS USA INC
ACARBOSE, ACARBOSE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BOSENTAN, BOSENTAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
CLOBAZAM, CLOBAZAM
CLOTRIMAZOLE, CLOTRIMAZOLE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DALFAMPRIDINE, DALFAMPRIDINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DISULFIRAM, DISULFIRAM
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DUTASTERIDE, DUTASTERIDE
ESZOPICLONE, ESZOPICLONE
ETHACRYNIC ACID, ETHACRYNIC ACID
EVEROLIMUS, EVEROLIMUS
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FEBUXOSTAT, FEBUXOSTAT
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACTULOSE, LACTULOSE
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LORAZEPAM INTENSOL, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROXICET, ACETAMINOPHEN
RUFINAMIDE, RUFINAMIDE
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TETRABENAZINE, TETRABENAZINE
TINIDAZOLE, TINIDAZOLE
TORSEMIDE, TORSEMIDE
TRIAZOLAM, TRIAZOLAM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFOXITIN, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA FARMACEUTICA (PORTUGAL) SA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VALPROATE SODIUM, VALPROATE SODIUM

* HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

* HIKMA FARMACEUTICA PORTUGAL SA
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

* HIKMA FARMACEUTICA SA
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CORTISONE ACETATE, CORTISONE ACETATE
DIGOXIN, DIGOXIN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOCARBAMOL, METHOCARBAMOL
MITIGARE, COLCHICINE
PRIMIDONE, PRIMIDONE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GEMFIBROZIL, GEMFIBROZIL
LETROZOLE, LETROZOLE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
RIFAMPIN, RIFAMPIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

* HIKMA PHARMACEUTICALS CO LTD
PARICALCITOL, PARICALCITOL

* HIKMA PHARMACEUTICALS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS LLC
DANTROLENE SODIUM, DANTROLENE SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
FOLIC ACID, FOLIC ACID
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
OLANZAPINE, OLANZAPINE
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
ZALEPLON, ZALEPLON

HILL DERMAC
* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS
* HILL DERMACEUTICALS INC
TOLAK, FLUOROURACIL

HISAMITSU
* HISAMITSU PHARMACEUTICAL CO INC
SECUADO, ASENAPINE

HISAMITSU PHARM CO
* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU
* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
CLADRIBINE, CLADRIBINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
* HISUN PHARMACEUTICAL HANGZHOU CO LTD
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
DACTINOMYCIN, DACTINOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TICAGRELOR, TICAGRELOR

HLTHCARE
* HEALTHCARE PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL

HOFFMANN LA ROCHE
* HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE
* HOFFMANN-LA ROCHE INC
ALECENSA, ALECTINIB HYDROCHLORIDE
INVIRASE, SAQUINAVIR MESYLATE

HOPE PHARMS
* HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON
* HORIZON MEDICINES LLC
DUEXIS, FAMOTIDINE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
* HORIZON THERAPEUTICS IRELAND DAC
PENNSAID, DICLOFENAC SODIUM

HORIZON PHARMA USA
* HORIZON PHARMA USA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HORIZON PHARMA USA INC
PROCYSBI, CYSTEAMINE BITARTRATE
RAYOS, PREDNISONE

HORIZON THERAP

* HORIZON THERAPEUTICS LLC
BUPHENYL, SODIUM PHENYLBUTYRATE
RAVICTI, GLYCEROL PHENYLBUTYRATE

HOSPIRA

* HOSPIRA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50%, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. ADULT, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 25%, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROPOFOL, PROPOFOL
QUELICIN, SUCCINYLCHOLINE CHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TAZICEF, CEFTAZIDIME
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VITAMIN K1, PHYTONADIONE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
* HOSPIRA WORLDWIDE, INC
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NITROPRESS, SODIUM NITROPRUSSIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

* HOSPIRA INC
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BIVALIRUDIN, BIVALIRUDIN
BUSULFAN, BUSULFAN
CEFTRIAXONE, CEFTRIAXONE SODIUM
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DAPTOMYCIN, DAPTOMYCIN
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
EPINEPHRINE (COPACKAGED), EPINEPHRINE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NIPENT, PENTOSTATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PARICALCITOL, PARICALCITOL
SODIUM BICARBONATE, SODIUM BICARBONATE
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

* HOT SHOTS NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

* HQ SPECIALTY PHARMA CORP
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CISPLATIN, CISPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HQ SPECIALTY PHARMA CORP
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEROPENEM, MEROPENEM

HQ SPECIALITY PHARMA
* HQ SPECIALITY PHARMA LLC
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HRA PHARMA
* HRA PHARMA RARE DISEASES
LYSODREN, MITOTANE
METOPIRONE, METYRAPONE

HUMANWELL PURACAP
* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
DUTASTERIDE, DUTASTERIDE
IBUPROFEN, IBUPROFEN (OTC)

HUONS
* HUONS CO LTD
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE

ROCHE
* HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
FUZEON, ENFUVIRTIDE
KLONOPIN, CLONAZEPAM
TAMIFLU, OSELTAMIVIR PHOSPHATE
VALIUM, DIAZEPAM

SHUANGCHENG
* HAINAN SHUANGCHENG PHARMACEUTICALS CO LTD
BIVALIRUDIN, BIVALIRUDIN
PREGABALIN, PREGABALIN

**** I ****

ICHNOS
* ICHNOS SCIENCES SA
DEFERASIROX, DEFERASIROX

ICU MEDICAL INC
* ICU MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MORPHINE SULFATE, MORPHINE SULFATE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ICU MEDICAL INC
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

IDENTI PHARMS INC
* IDENTI PHARMACEUTICALS INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

IDT AUSTRALIA LTD
* IDT AUSTRALIA LTD
TEMOZOLOMIDE, TEMOZOLOMIDE

IMPACT
* IMPACT BIOMEDICINES INC A WHOLLY OWNED SUB OF CELGENE CORP
INREBIC, FEDRATINIB HYDROCHLORIDE

IMPAX
* IMPAX LABORATORIES LLC
ADRENACLICK, EPINEPHRINE

IMPAX LABS
* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
OMEPRAZOLE, OMEPRAZOLE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RILUZOLE, RILUZOLE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* IMPAX LABORATORIES INC
ACITRETIN, ACITRETIN
ALBENZA, ALBENDAZOLE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
EMVERM, MEBENDAZOLE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LAMOTRIGINE, LAMOTRIGINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
NABUMETONE, NABUMETONE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RYTARY, CARBIDOPA
SEVELAMER CARBONATE, SEVELAMER CARBONATE
URSODIOL, URSODIOL

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

INCYTE CORP

* INCYTE CORP
JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA

* INDICUS PHARMA LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LETROZOLE, LETROZOLE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDIVIOR INC

* INDIVIOR INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
PERSERIS KIT, RISPERIDONE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO REMEDIES

* INDOCO REMEDIES LTD
ALLOPURINOL, ALLOPURINOL
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
FEBUXOSTAT, FEBUXOSTAT
GLIMEPIRIDE, GLIMEPIRIDE
RASAGILINE MESYLATE, RASAGILINE MESYLATE

INFORLIFE

* INFORLIFE SA
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INFORLIFE SA
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS LLC
* INGENUS PHARMACEUTICALS LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CABERGOLINE, CABERGOLINE
CARBOPLATIN, CARBOPLATIN
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOFARABINE, CLOFARABINE
DECITABINE, DECITABINE
DOCETAXEL, DOCETAXEL
FLUOROURACIL, FLUOROURACIL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
OXALIPLATIN, OXALIPLATIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

INGENUS PHARMS NJ
* INGENUS PHARMACEUTICALS NJ LLC
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN

INNOGENIX
* INNOGENIX LLC
HALOPERIDOL, HALOPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

INSMED INC
* INSMED INC
ARIKAYCE KIT, AMIKACIN SULFATE

INST BIOCHEM
* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INSTITUT BIOCHIMIQUE
* INSTITUT BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM

INSYS DEV CO INC
* INSYS DEVELOPMENT CO INC
SYNDROS, DRONABINOL

INTAS PHARMS USA
* INTAS PHARMACEUTICALS USA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTELLIPHARMACEUTICS
* INTELLIPHARMACEUTICS CORP
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

INTERCEPT PHARMS INC
* INTERCEPT PHARMACEUTICALS INC
OCALIVA, OBETICHOLIC ACID

INTERGEL PHARM
* INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

INTERGEL PHARMS INC
* INTERGEL PHARMACEUTICALS INC
DUTASTERIDE, DUTASTERIDE

INTERPHARMA PRAHA AS
* INTERPHARMA PRAHA AS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INTERPHARMA PRAHA AS
ORALTAG, IOHEXOL

INTERSECT ENT INC

* INTERSECT ENT INC
SINUVA, MOMETASONE FUROATE

INTL MEDICATED

* INTERNATIONAL MEDICATED SYSTEMS LTD
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION

* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
LORAZEPAM, LORAZEPAM
SODIUM BICARBONATE, SODIUM BICARBONATE

INTRA-CELLULAR

* INTRA-CELLULAR THERAPIES INC
CAPLYTA, LUMATEPERONE TOSYLATE

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
OLANZAPINE, OLANZAPINE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INVAGEN PHARMACEUTICALS INC
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VIGABATRIN, VIGABATRIN
WARFARIN SODIUM, WARFARIN SODIUM
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

INVATECH
* INVATECH PHARMA SOLUTIONS LLC
DIVALPROEX SODIUM, DIVALPROEX SODIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

INVENTIA
* INVENTIA HEALTHCARE LTD
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PALIPERIDONE, PALIPERIDONE
TELMISARTAN, TELMISARTAN

INVENTIA HLTHCARE
* INVENTIA HEALTHCARE PRIVATE LTD
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

IONETIX
* IONETIX CORP
AMMONIA N 13, AMMONIA N-13

IPCA LABS LTD
* IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

IPR
* IPR PHARMACEUTICALS INC
CRESTOR, ROSUVASTATIN CALCIUM
ZOMIG, ZOLMITRIPTAN

IPSEN INC
* IPSEN BIOPHARMACEUTICALS INC
INCRELEX, MECASERMIN RECOMBINANT
ONIVYDE, IRINOTECAN HYDROCHLORIDE

IPSEN PHARMA
* IPSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

IRONSHORE PHARMS
* IRONSHORE PHARMACEUTICALS AND DEVELOPMENT INC
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

ISO TEX
* ISO TEX DIAGNOSTICS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ISO TEX DIAGNOSTICS INC
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX

* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

ITALFARMACO SPA

* ITALFARMACO SPA
TIGLUTIK KIT, RILUZOLE

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
VALSARTAN, VALSARTAN

IVAX PHARMS INC

* IVAX PHARMACEUTICALS INC
OLANZAPINE, OLANZAPINE

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DIAZEPAM, DIAZEPAM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OXAPROZIN, OXAPROZIN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ****

J AND J CONSUMER INC

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MOTRIN IB, IBUPROFEN (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
SINE-AID IB, IBUPROFEN (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TYLENOL, ACETAMINOPHEN (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JACOBUS

* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JACOBUS PHARMACEUTICAL CO
PASER, AMINOSALICYLIC ACID

JACOBUS PHARM CO INC

* JACOBUS PHARMACEUTICAL CO INC
RUZURGI, AMIFAMPRIDINE

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
BALVERSA, ERDAFITINIB
ERLEADA, APALUTAMIDE
ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-37, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVOKAMET XR, CANAGLIFLOZIN
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
NIZORAL, KETOCONAZOLE
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
TOPAMAX, TOPIRAMATE
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
EDURANT, RILPIVIRINE HYDROCHLORIDE
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
SYMTUZA, COBICISTAT
YONDELIS, TRABECTEDIN

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAZZ

* JAZZ PHARMACEUTICALS IRELAND LTD
SUNOSI, SOLRIAMFETOL

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
XYREM, SODIUM OXYBATE

JAZZ PHARMS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

JDP

* JDP THERAPEUTICS LLC
QUZYTTIR, CETIRIZINE HYDROCHLORIDE

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU HENGRUI MED

* JIANGSU HENGRUI MEDICINE CO LTD
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GABAPENTIN, GABAPENTIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN
THIOTEPA, THIOTEPA

JIANGXI BOYA SEEHOT

* JIANGXI BOYA SEEHOT PHARMACEUTICAL CO LTD
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

* JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)

JOURNEY

* JOURNEY MEDICAL CORP
EXELDERM, SULCONAZOLE NITRATE

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

* JUBILANT DRAXIMAGE INC
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
RUBY-FILL, RUBIDIUM CHLORIDE RB-82

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JUBILANT DRAXIMAGE INC
SODIUM IODIDE I 131, SODIUM IODIDE I-131
* JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
* JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

* JUBILANT GENERICS LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SPIRONOLACTONE, SPIRONOLACTONE
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ****

GRIFFEN

* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC

* KADMON PHARMACEUTICALS LLC
CLOVIQUE, TRIENTINE HYDROCHLORIDE
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

KAI PHARMS INC

* KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
PARSABIV, ETELCALCETIDE

KALA PHARMS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KALA PHARMACEUTICALS INC
INVELTYS, LOTEPREDNOL ETABONATE

KALEO INC
* KALEO INC
AUVI-Q, EPINEPHRINE
EVZIO (AUTOINJECTOR), NALOXONE HYDROCHLORIDE

KARYOPHARM THERAPS
* KARYOPHARM THERAPEUTICS INC
XPOVIO, SELINEXOR

KENTON
* KENTON CHEMICALS AND PHARMACEUTICALS CORP
ACYCLOVIR, ACYCLOVIR
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE

KERYX BIOPHARMS
* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

KETTERING MEDCTR
* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KING PHARMS
* KING PHARMACEUTICALS INC
SYNERCID, DALFOPRISTIN
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **
TUSSIGON, HOMATROPINE METHYLBROMIDE
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC A SUB OF PFIZER INC
SKELAXIN, METAXALONE

KING PHARMS LLC
* KING PHARMACEUTICALS LLC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CORZIDE, BENDROFLUMETHIAZIDE
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE
TAPAZOLE, METHIMAZOLE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

KNIGHT THERAPS
* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO
* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KRAMER
* KRAMER LABORATORIES INC
NIZORAL A-D, KETOCONAZOLE (OTC)

KREITCHMAN PET CTR
* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KVK TECH
* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KVK TECH INC
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC

* KVK TECH INC
APADAZ, ACETAMINOPHEN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
FARESTON, TOREMIFENE CITRATE
NOURIANZ, ISTRADEFYLLINE
SANCUSO, GRANISETRON

KYTHERA BIOPHARMS

* KYTHERA BIOPHARMACEUTICALS INC
KYBELLA, DEOXYCHOLIC ACID

**** L ****

L PERRIGO CO

* L PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARMA

* LA JOLLA PHARMA LLC
GIAPREZA, ANGIOTENSIN II ACETATE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LABORATORIOS GRIFOLS

* LABORATORIOS GRIFOLS SA
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABORATORIOS SALVAT

* LABORATORIOS SALVAT SA
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID

LANNETT CO INC

* LANNETT CO INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LANNETT CO INC
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CODEINE SULFATE, CODEINE SULFATE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DANAZOL, DANAZOL
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DRONABINOL, DRONABINOL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LACTULOSE, LACTULOSE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
NYSTATIN, NYSTATIN
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LANNETT CO INC
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN, SUMATRIPTAN
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THEOPHYLLINE, THEOPHYLLINE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
URSODIOL, URSODIOL
VALPROIC ACID, VALPROIC ACID
ZAROXOLYN, METOLAZONE

LANTHEUS MEDCL
* LANTHEUS MEDICAL IMAGING INC
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

LANTHEUS MEDICAL
* LANTHEUS MEDICAL IMAGING INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS
* LARKEN LABORATORIES INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

LARKEN LABS INC
* LARKEN LABORATORIES INC
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ALLZITAL, ACETAMINOPHEN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
DEXAMETHASONE, DEXAMETHASONE

LAURUS LABS LTD
* LAURUS LABS LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

LAVIPHARM LABS
* LAVIPHARM LABORATORIES INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

LEADIANT BIOSCI INC
* LEADIANT BIOSCIENCES INC
ABELCET, AMPHOTERICIN B
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING PHARMA LLC
* LEADING PHARMA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
NIFEDIPINE, NIFEDIPINE

LEO LABS
* LEO LABORATORIES LTD
PICATO, INGENOL MEBUTATE

LEO PHARMA AS
* LEO PHARMA AS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LEO PHARMA AS
DESONATE, DESONIDE
DOVONEX, CALCIPOTRIENE
ENSTILAR, BETAMETHASONE DIPROPIONATE
FINACEA, AZELAIC ACID
PROTOPIC, TACROLIMUS
TACLONEX, BETAMETHASONE DIPROPIONATE

LEXICON PHARMS INC

* LEXICON PHARMACEUTICALS INC
XERMELO, TELOTRISTAT ETIPRATE

LG CHEM LTD

* LG CHEM LTD
FACTIVE, GEMIFLOXACIN MESYLATE

LIEBEL-FLARSHEIM

* LIEBEL-FLARSHEIM CO LLC
CONRAY, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFE MOLECULAR

* LIFE MOLECULAR IMAGING SA
NEURACEQ, FLORBETABEN F-18

LIFEPHARMA

* LIFEPHARMA FZE
LACTULOSE, LACTULOSE

LNK

* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC

* LNK INTERNATIONAL INC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM
* LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT
CALCIUM ACETATE, CALCIUM ACETATE
LEVETIRACETAM, LEVETIRACETAM

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BUSULFAN, BUSULFAN
CAFFEINE CITRATE, CAFFEINE CITRATE
DROPERIDOL, DROPERIDOL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
NITROGLYCERIN, NITROGLYCERIN
TRANEXAMIC ACID, TRANEXAMIC ACID

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK NA LTD

* LUNDBECK NA LTD
NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC

* LUNDBECK PHARMACEUTICALS LLC
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

LUPIN

* LUPIN INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINARETIC, HYDROCHLOROTHIAZIDE
SOLOSEC, SECNIDAZOLE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
* LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
ANTARA (MICRONIZED), FENOFIBRATE
BUDESONIDE, BUDESONIDE
DESOXIMETASONE, DESOXIMETASONE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MIBELAS 24 FE, ETHINYL ESTRADIOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LUPIN LTD

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
* LUPIN LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
AMABELZ, ESTRADIOL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARMODAFINIL, ARMODAFINIL
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BEKYREE, DESOGESTREL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD
BIMATOPROST, BIMATOPROST
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CELECOXIB, CELECOXIB
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DAYSEE, ETHINYL ESTRADIOL
DECITABINE, DECITABINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENSKYCE, DESOGESTREL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
ETHACRYNIC ACID, ETHACRYNIC ACID
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FALLBACK SOLO, LEVONORGESTREL (OTC)
FAMOTIDINE, FAMOTIDINE
FAYOSIM, ETHINYL ESTRADIOL
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FYAVOLV, ETHINYL ESTRADIOL
GATIFLOXACIN, GATIFLOXACIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
JENCYCLA, NORETHINDRONE
KAITLIB FE, ETHINYL ESTRADIOL
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KURVELO, ETHINYL ESTRADIOL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NIACIN, NIACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD
NIKKI, DROSPIRENONE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
RIFABUTIN, RIFABUTIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SUPRAX, CEFIXIME
TADALAFIL, TADALAFIL
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TESTOSTERONE, TESTOSTERONE
TETRABENAZINE, TETRABENAZINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TYDEMY, DROSPIRENONE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VYFEMLA, ETHINYL ESTRADIOL
ZILEUTON, ZILEUTON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS

* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLORATADINE, DESLORATADINE
MELOXICAM, MELOXICAM
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIFAMPIN, RIFAMPIN
SUPRAX, CEFIXIME
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYMOL MEDCL

* LYMOL MEDICAL CORP
SCLEROSOL, TALC
TALC, TALC

LYNE

* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOCARNITINE, LEVOCARNITINE
NYSTATIN, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO

* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* L PERRIGO CO
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TAB-PROFEN, IBUPROFEN (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ****

MA GENERAL HOSP
* MASSACHUSETTS GENERAL HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD
* MACLEODS PHARMACEUTICALS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
FLUOCINONIDE, FLUOCINONIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MACLEODS PHARMACEUTICALS LTD
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAMCINOLONE ACETATE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

MAIA PHARMS INC

* MAIA PHARMACEUTICALS INC
ANGIOMAX RTU, BIVALIRUDIN
BACLOFEN, BACLOFEN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MAINPOINTE

* MAINPOINTE PHARMACEUTICALS LLC
TUXARIN ER, CHLORPHENIRAMINE MALEATE

MALLINCKRODT ARD

* MALLINCKRODT ARD INC
H.P. ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP

* MALLINCKRODT HOSP PRODUCTS IP LTD
INOMAX, NITRIC OXIDE
OFIRMEV, ACETAMINOPHEN
UVADEX, METHOXSALEN

MALLINKRODT NUCLEAR

* MALLINCKRODT NUCLEAR MEDICINE LLC
SODIUM IODIDE I 123, SODIUM IODIDE I-123
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

MANNKIND

* MANNKIND CORP
AFREZZA, INSULIN RECOMBINANT HUMAN

MARKSANS PHARMA

* MARKSANS PHARMA LTD
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
PARICALCITOL, PARICALCITOL

MARNEL PHARMS

* MARNEL PHARMACEUTICALS LLC
ALA-SCALP, HYDROCORTISONE
CROTAN, CROTAMITON

MAYER LABS INC

* MAYER LABORATORIES INC
TODAY, NONOXYNOL-9 (OTC)

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX MPC, DOXYCYCLINE HYCLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX, DOXYCYCLINE HYCLATE
ERYC, ERYTHROMYCIN
* MAYNE PHARMA LLC
BUDESONIDE, BUDESONIDE
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLARITHROMYCIN, CLARITHROMYCIN
CLONIDINE, CLONIDINE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ERRIN, NORETHINDRONE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
FABIOR, TAZAROTENE
FLUOROURACIL, FLUOROURACIL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEXETTE, HALOBETASOL PROPIONATE
LOW-OGESTREL-28, ETHINYL ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
SORILUX, CALCIPOTRIENE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TOLCAPONE, TOLCAPONE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIMETHOPRIM, TRIMETHOPRIM
TRIVORA-28, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL

MAYNE PHARMA INC

* MAYNE PHARMA INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
EXEMESTANE, EXEMESTANE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

MAYNE PHARMA INTL

* MAYNE PHARMA INTERNATIONAL PTY LTD
TOLSURA, ITRACONAZOLE

MCGUFF

* MCGUFF PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MCGUFF PHARMACEUTICALS INC
ASCOR, ASCORBIC ACID

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
IBUPROFEN, IBUPROFEN (OTC)

MCNEIL CONS
* MCNEIL CONSUMER HEALTHCARE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

MCPRF
* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MDGH
* MEDICINES DEVELOPMENT FOR GLOBAL HEALTH
MOXIDECTIN, MOXIDECTIN

MEDEFIL INC
* MEDEFIL INC
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

MEDEXUS
* MEDEXUS PHARMA INC
RASUVO, METHOTREXATE

MEDICINES360
* MEDICINES360
LILETTA, LEVONORGESTREL

MEDICIS
* MEDICIS PHARMACEUTICAL CORP
AMMONUL, SODIUM BENZOATE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
LUZU, LULICONAZOLE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
ZIANA, CLINDAMYCIN PHOSPHATE

MEDICURE
* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
ZYPITAMAG, PITAVASTATIN MAGNESIUM

MEDIMETRIKS PHARMS
* MEDIMETRIKS PHARMACEUTICALS INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE

MEDLINE INDUSTRIES
* MEDLINE INDUSTRIES INC
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)

MEDTECH PRODUCTS
* MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

MEITHEAL
* MEITHEAL PHARMACEUTICALS INC
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MEITHEAL PHARMACEUTICALS INC
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYTARABINE, CYTARABINE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

MELINTA
* MELINTA SUBSIDIARY CORP
BAXDELA, DELAFLOXACIN MEGLUMINE

MELINTA THERAP
* MELINTA THERAPEUTICS INC
ORBACTIV, ORITAVANCIN DIPHOSPHATE

MEM SLOAN-KETTERING
* MEMORIAL SLOAN-KETTERING CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK
* MERCK AND CO INC
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
FOSAMAX PLUS D, ALENDRONATE SODIUM
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
ZOLINZA, VORINOSTAT
* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
PRINIVIL, LISINOPRIL
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE

MERCK AND CO INC
* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE
FOSAMAX, ALENDRONATE SODIUM

MERCK SHARP DOHME
* MERCK SHARP AND DOHME CORP
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
BELSOMRA, SUVOREXANT
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
COZAAR, LOSARTAN POTASSIUM
CRIXIVAN, INDINAVIR SULFATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DULERA, FORMOTEROL FUMARATE
ELOCON, MOMETASONE FUROATE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
HYZAAR, HYDROCHLOROTHIAZIDE
INVANZ, ERTAPENEM SODIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISENTRESS, RALTEGRAVIR POTASSIUM
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUMET, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
LOTRISONE, BETAMETHASONE DIPROPIONATE
NASONEX, MOMETASONE FUROATE
NOXAFIL, POSACONAZOLE
PREVYMIS, LETERMOVIR
REBETOL, RIBAVIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MERCK SHARP AND DOHME CORP
SEGLUROMET, ERTUGLIFLOZIN
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STROMECTOL, IVERMECTIN
TEMODAR, TEMOZOLOMIDE
ZEPATIER, ELBASVIR

MERIDIAN MEDCL
* MERIDIAN MEDICAL TECHNOLOGIES INC
DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN
* MERIDIAN MEDICAL TECHNOLOGIES INC
ATROPEN, ATROPINE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
SEIZALAM, MIDAZOLAM HYDROCHLORIDE

MERRO PHARM
* MERRO PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS
* MERZ PHARMACEUTICALS LLC
CUVPOSA, GLYCOPYRROLATE

METACEL PHARMS LLC
* METACEL PHARMACEUTICALS LLC
OZOBAX, BACLOFEN

METHAPHARM
* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS
* METUCHEN PHARMACEUTICALS LLC
STENDRA, AVANAFIL

MICRO LABS
* MICRO LABS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
APIXABAN, APIXABAN
CAFFEINE CITRATE, CAFFEINE CITRATE
CELECOXIB, CELECOXIB
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DALFAMPRIDINE, DALFAMPRIDINE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PIROXICAM, PIROXICAM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
ROFLUMILAST, ROFLUMILAST
SIMVASTATIN, SIMVASTATIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TAFLUPROST, TAFLUPROST
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MICRO LABS LTD
* MICRO LABS LTD
NEVIRAPINE, NEVIRAPINE

MICRO LABS LTD INDIA
* MICRO LABS LTD INDIA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MICRO LABS LTD INDIA
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDATECH PHARMA US
* MIDATECH PHARMA US INC
ZUPLENZ, ONDANSETRON

MIDWEST MEDCL
* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
AMMONIA N 13, AMMONIA N-13
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART
* MIKART LLC
BENZONATATE, BENZONATATE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METHAZOLAMIDE, METHAZOLAMIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MILLENNIUM PHARMS
* MILLENNIUM PHARMACEUTICALS INC
NINLARO, IXAZOMIB CITRATE
VELCADE, BORTEZOMIB

MILLICENT
* MILLICENT HOLDINGS LTD
FEMRING, ESTRADIOL ACETATE

MIPS CRF
* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MISSION PHARMA
* MISSION PHARMACAL CO
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO
* MISSION PHARMACAL CO
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
THIOLA EC, TIOPRONIN

MITSUBISHI TANABE
* MITSUBISHI TANABE PHARMA CORP
RADICAVA, EDARAVONE

MLV
* MLV PHARMA LLC
ACETIC ACID, ACETIC ACID, GLACIAL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

MOBIUS THERAP
* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH
* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS
* MONARCH PHARMACEUTICALS LLC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC
* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MOUNTAIN
* MOUNTAIN LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE

MSD INTL
* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH
* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MSD MERCK CO
* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
DELSTRIGO, DORAVIRINE
EMEND, APREPITANT
PIFELTRO, DORAVIRINE
RECARBRIO, CILASTATIN SODIUM
SINGULAIR, MONTELUKAST SODIUM
ZOCOR, SIMVASTATIN

MSN
* MSN LABORATORIES PRIVATE LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CAPECITABINE, CAPECITABINE
CLOFARABINE, CLOFARABINE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
FEBUXOSTAT, FEBUXOSTAT
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

MURTY PHARMS
* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVZAT ILAC
* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MYLAN

* MYLAN PHARMACEUTICALS
  FENOFIBRATE, FENOFIBRATE
  METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  TRANEXAMIC ACID, TRANEXAMIC ACID
* MYLAN PHARMACEUTICALS INC
  ABIRATERONE ACETATE, ABIRATERONE ACETATE
  ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
  ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
  ACITRETIN, ACITRETIN
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  ALLOPURINOL, ALLOPURINOL
  ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
  ALPRAZOLAM, ALPRAZOLAM
  AMBRISENTAN, AMBRISENTAN
  AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
  AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
  AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  ANASTROZOLE, ANASTROZOLE
  APIXABAN, APIXABAN
  ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
  ATENOLOL AND CHLORTHALIDONE, ATENOLOL
  ATENOLOL, ATENOLOL
  ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
  AVITA, TRETINOIN
  AZATHIOPRINE, AZATHIOPRINE
  AZITHROMYCIN, AZITHROMYCIN
  BACLOFEN, BACLOFEN
  BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
  BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
  BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
  BICALUTAMIDE, BICALUTAMIDE
  BOSENTAN, BOSENTAN
  BROMFENAC SODIUM, BROMFENAC SODIUM
  BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
  BUDESONIDE, BUDESONIDE
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
  BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
  CABERGOLINE, CABERGOLINE
  CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
  CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
  CAPECITABINE, CAPECITABINE
  CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
  CAPTOPRIL, CAPTOPRIL
  CARBIDOPA AND LEVODOPA, CARBIDOPA
  CARVEDILOL, CARVEDILOL
  CELECOXIB, CELECOXIB
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
  CHLOROTHIAZIDE, CHLOROTHIAZIDE
  CHLORTHALIDONE, CHLORTHALIDONE
  CIMETIDINE, CIMETIDINE
  CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  CLOBAZAM, CLOBAZAM
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
  CLONAZEPAM, CLONAZEPAM
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
  CLOZAPINE, CLOZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
COLCHICINE, COLCHICINE
CYSTAGON, CYSTEAMINE BITARTRATE
DENAVIR, PENCICLOVIR
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
EFAVIRENZ, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIMITE, PERMETHRIN
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENTECAVIR, ENTECAVIR
EPLERENONE, EPLERENONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYGEL, ERYTHROMYCIN
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETOPOSIDE, ETOPOSIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXEMESTANE, EXEMESTANE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GATIFLOXACIN, GATIFLOXACIN
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALCINONIDE, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IMATINIB MESYLATE, IMATINIB MESYLATE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LITHIUM CARBONATE, LITHIUM CARBONATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LUXIQ, BETAMETHASONE VALERATE
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MENTAX, BUTENAFINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
NEVIRAPINE, NEVIRAPINE
NIACIN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NISOLDIPINE, NISOLDIPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUX E, CLOBETASOL PROPIONATE
OLUX, CLOBETASOL PROPIONATE
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PALIPERIDONE, PALIPERIDONE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENYTEK, PHENYTOIN SODIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
PREDNISONE, PREDNISONE
PREGABALIN, PREGABALIN
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULINDAC, SULINDAC
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SYMFI LO, EFAVIRENZ
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TETRABENAZINE, TETRABENAZINE
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAVOPROST, TRAVOPROST
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRILYTE, POLYETHYLENE GLYCOL 3350
URSODIOL, URSODIOL
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VUSION, MICONAZOLE NITRATE
WIXELA INHUB, FLUTICASONE PROPIONATE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONALON, DOXEPIN HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR

MYLAN ASI

* MYLAN ASI LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AZITHROMYCIN, AZITHROMYCIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN ASI LLC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
MYLERAN, BUSULFAN
SULFAMYLON, MAFENIDE ACETATE

* MYLAN INSTITUTIONAL LLC
ALOPRIM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CIDOFOVIR, CIDOFOVIR
COSYNTROPIN, COSYNTROPIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FOMEPIZOLE, FOMEPIZOLE
FULVESTRANT, FULVESTRANT
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ISOSULFAN BLUE, ISOSULFAN BLUE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM
MIACALCIN, CALCITONIN SALMON
PRETOMANID, PRETOMANID
YUPELRI, REVEFENACIN

MYLAN LABS

* MYLAN LABORATORIES LTD
NEVIRAPINE, NEVIRAPINE

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
ADENOSINE, ADENOSINE
AMIFOSTINE, AMIFOSTINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BUSULFAN, BUSULFAN
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CIMDUO, LAMIVUDINE
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
CYTARABINE, CYTARABINE
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DOCETAXEL, DOCETAXEL
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LAMIVUDINE, LAMIVUDINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MITOMYCIN, MITOMYCIN
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SYMFI, EFAVIRENZ
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
AMNESTEEM, ISOTRETINOIN
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AVITA, TRETINOIN
BACLOFEN, BACLOFEN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
ESZOPICLONE, ESZOPICLONE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ITRACONAZOLE, ITRACONAZOLE
LANSOPRAZOLE, LANSOPRAZOLE
LITHIUM CARBONATE, LITHIUM CARBONATE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
NABUMETONE, NABUMETONE
NEVIRAPINE, NEVIRAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYTOIN, PHENYTOIN
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRIAZOLAM, TRIAZOLAM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VORICONAZOLE, VORICONAZOLE
ZIDOVUDINE, ZIDOVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
NIZATIDINE, NIZATIDINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECIALITY LP

* MYLAN SPECIALTY LP
ACCUNEB, ALBUTEROL SULFATE
ANADROL-50, OXYMETHOLONE
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
AVC, SULFANILAMIDE
BUTISOL SODIUM, BUTABARBITAL SODIUM
CESAMET, NABILONE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DEMADEX, TORSEMIDE
DEPEN, PENICILLAMINE
DIPENTUM, OLSALAZINE SODIUM
DYMISTA, AZELASTINE HYDROCHLORIDE
EDLUAR, ZOLPIDEM TARTRATE
ELESTRIN, ESTRADIOL
EPIFOAM, HYDROCORTISONE ACETATE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
FELBATOL, FELBAMATE
GASTROCROM, CROMOLYN SODIUM
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MUSE, ALPROSTADIL
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL
TOBI PODHALER, TOBRAMYCIN
TOBI, TOBRAMYCIN

MYLAN SPECLT

* MYLAN SPECIALTY LP
PERFOROMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
RIVASTIGMINE, RIVASTIGMINE
SCOPOLAMINE, SCOPOLAMINE
XULANE, ETHINYL ESTRADIOL

**** N ****

NAARI PTE LTD

* NAARI PTE LTD
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

NABRIVA

* NABRIVA THERAPEUTICS IRELAND DAC
XENLETA, LEFAMULIN ACETATE

NALPROPION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NALPROPION PHARMACEUTICALS INC
CONTRAVE, BUPROPION HYDROCHLORIDE

NANG KUANG PHARM CO

* NANG KUANG PHARMACEUTICAL CO LTD
LINEZOLID, LINEZOLID

NANJING KING-FRIEND

* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

NAPO PHARMS INC

* NAPO PHARMACEUTICALS INC
MYTESI, CROFELEMER

NATCO PHARMA

* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
BOSENTAN, BOSENTAN
CARISOPRODOL, CARISOPRODOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
IMATINIB MESYLATE, IMATINIB MESYLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAVINTA LLC

* NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARMUSTINE, CARMUSTINE
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
METHOCARBAMOL, METHOCARBAMOL
RIBAVIRIN, RIBAVIRIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

NCM USA BRONX LLC

* NCM USA BRONX LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOPHARMA

* NEOPHARMA INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMOXIL, AMOXICILLIN
ANASTROZOLE, ANASTROZOLE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
IRBESARTAN, IRBESARTAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NEOPHARMA INC
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAROTID, AMOXICILLIN
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

NEOS THERAP INC
* NEOS THERAPEUTICS INC
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS
* NEOS THERAPEUTICS
ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC
* NEOS THERAPEUTICS INC
ADZENYS ER, AMPHETAMINE
COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON
* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BUDESONIDE, BUDESONIDE

NESHER PHARMS
* NESHER PHARMACEUTICALS USA LLC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

NEUROCRINE
* NEUROCRINE BIOSCIENCES INC
INGREZZA, VALBENAZINE TOSYLATE

NEXGEN PHARMA
* NEXGEN PHARMA INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC
* NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
NABUMETONE, NABUMETONE

NEXTWAVE
* NEXTWAVE PHARMACEUTICALS INC A SUB OF TRIS PHARMA INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXTWAVE PHARMS
* NEXTWAVE PHARMACEUTICALS INC
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS
* NEXUS PHARMACEUTICALS INC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
BUSULFAN, BUSULFAN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NEXUS PHARMACEUTICALS INC
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

NIAGARA PHARMS

* NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NODEN PHARMA

* NODEN PHARMA DAC
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TEKTURNA, ALISKIREN HEMIFUMARATE

NORATECH

* NORATECH PHARMACEUTICALS INC
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

NORTEC DEV ASSOC

* NORTEC DEVELOPMENT ASSOC INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHLAND

* NORTHLAND NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

NORTHSTAR HLTHCARE

* NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHSTAR MEDICAL

* NORTHSTAR MEDICAL RADIOISOTOPES LLC
RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

NORTON WATERFORD

* NORTON WATERFORD LTD
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NOSTRUM LABS INC

* NOSTRUM LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL, CARISOPRODOL
CLARITHROMYCIN, CLARITHROMYCIN
DAPSONE, DAPSONE
ELIXOPHYLLIN, THEOPHYLLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NABUMETONE, NABUMETONE
NITROFURANTOIN, NITROFURANTOIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE

NOVA LABS LTD

* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPURINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

NOVADAQ TECH

* NOVADAQ TECHNOLOGIES ULC
SPY AGENT GREEN KIT, INDOCYANINE GREEN

NOVARTIS

* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
ALOMIDE, LODOXAMIDE TROMETHAMINE
ARGATROBAN, ARGATROBAN
ARRANON, NELARABINE
AZOPT, BRINZOLAMIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
COARTEM, ARTEMETHER
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DUREZOL, DIFLUPREDNATE
EGATEN, TRICLABENDAZOLE
EXELON, RIVASTIGMINE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
GILENYA, FINGOLIMOD HYDROCHLORIDE
GLEEVEC, IMATINIB MESYLATE
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
ILEVRO, NEPAFENAC
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
JADENU SPRINKLE, DEFERASIROX
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KISQALI, RIBOCICLIB SUCCINATE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LESCOL XL, FLUVASTATIN SODIUM
LOTREL, AMLODIPINE BESYLATE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MAYZENT, SIPONIMOD FUMARIC ACID
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
NATACYN, NATAMYCIN
NEORAL, CYCLOSPORINE
NEVANAC, NEPAFENAC
OMNIPRED, PREDNISOLONE ACETATE
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PIQRAY, ALPELISIB
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMACTA, ELTROMBOPAG OLAMINE
RECLAST, ZOLEDRONIC ACID
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RYDAPT, MIDOSTAURIN
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIGNIFOR, PASIREOTIDE DIASPARTATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
SIMBRINZA, BRIMONIDINE TARTRATE
TAFINLAR, DABRAFENIB MESYLATE
TASIGNA, NILOTINIB HYDROCHLORIDE
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TOBRADEX ST, DEXAMETHASONE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRAVATAN Z, TRAVOPROST
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRILEPTAL, OXCARBAZEPINE
TYKERB, LAPATINIB DITOSYLATE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
VOTRIENT, PAZOPANIB HYDROCHLORIDE
XIIDRA, LIFITEGRAST
ZOFRAN ODT, ONDANSETRON
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOMETA, ZOLEDRONIC ACID
ZORTRESS, EVEROLIMUS
ZYKADIA, CERITINIB

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
ENTRESTO, SACUBITRIL
JADENU, DEFERASIROX

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
NORETHINDRONE, NORETHINDRONE
* NOVAST LABORATORIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
HER STYLE, LEVONORGESTREL (OTC)
INDOMETHACIN, INDOMETHACIN
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LERIBANE, ETHINYL ESTRADIOL
LIDOCAINE, LIDOCAINE
LO-MALMOREDE, ETHINYL ESTRADIOL
MAFENIDE ACETATE, MAFENIDE ACETATE
MALMOREDE, ETHINYL ESTRADIOL
MELAMISA, DROSPIRENONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NADOLOL, NADOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVAST LABORATORIES LTD
NIFEDIPINE, NIFEDIPINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE, NORETHINDRONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PIMTREA, DESOGESTREL
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PROBENECID AND COLCHICINE, COLCHICINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
SETLAKIN, ETHINYL ESTRADIOL
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLCAPONE, TOLCAPONE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
YAELA, DROSPIRENONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MONO-LINYAH, ETHINYL ESTRADIOL
PHILITH, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
WERA, ETHINYL ESTRADIOL

NOVATECH SA

* NOVATECH SA
STERITALC, TALC

NOVEL LABS INC

* NOVEL LABORATORIES INC
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
CALCIPOTRIENE, CALCIPOTRIENE
CARBIDOPA, CARBIDOPA
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FAMOTIDINE, FAMOTIDINE
FLUCYTOSINE, FLUCYTOSINE
FLUOCINONIDE, FLUOCINONIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MISOPROSTOL, MISOPROSTOL
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVEL LABORATORIES INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
TEMAZEPAM, TEMAZEPAM
TINIDAZOLE, TINIDAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMETHOPRIM, TRIMETHOPRIM
VORICONAZOLE, VORICONAZOLE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVELGENIX THERAPS
* NOVELGENIX THERAPEUTICS PVT LTD
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
VALPROIC ACID, VALPROIC ACID

NOVEN
* NOVEN PHARMACEUTICALS INC
MINIVELLE, ESTRADIOL

NOVEN PHARMS INC
* NOVEN PHARMACEUTICALS INC
COMBIPATCH, ESTRADIOL
DAYTRANA, METHYLPHENIDATE

NOVITIUM PHARMA
* NOVITIUM PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLOTRIMAZOLE, CLOTRIMAZOLE
DAPSONE, DAPSONE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCARNITINE, LEVOCARNITINE
NITISINONE, NITISINONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
THIOTHIXENE, THIOTHIXENE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NOVO
* NOVO NORDISK INC
FIASP FLEXTOUCH, INSULIN ASPART
FIASP PENFILL, INSULIN ASPART
FIASP, INSULIN ASPART
MACRILEN, MACIMORELIN ACETATE
OZEMPIC, SEMAGLUTIDE
RYBELSUS, SEMAGLUTIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
TRESIBA, INSULIN DEGLUDEC
XULTOPHY 100/3.6, INSULIN DEGLUDEC

NOVO NORDISK
* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE

NOVO NORDISK INC
* NOVO NORDISK INC
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
LEVEMIR, INSULIN DETEMIR RECOMBINANT
NORDITROPIN FLEXPRO, SOMATROPIN
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVO NORDISK INC
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL INC
* NOVOCOL INC
DYCLOPRO, DYCLONINE HYDROCHLORIDE

NPS PHARMS INC
* NPS PHARMACEUTICALS INC
GATTEX KIT, TEDUGLUTIDE RECOMBINANT

NUVO PHARM
* NUVO PHARMACEUTICAL INC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
FENOFIBRATE, FENOFIBRATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

NUVO PHARMS INC
* NUVO PHAMACEUTICALS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

NXDC
* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**** O ****

OAK PHARMS
* OAK PHARMACEUTICALS INC
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

OAK PHARMS AKORN
* OAK PHARMACEUTICALS INC SUB AKORN INC
COGENTIN, BENZTROPINE MESYLATE
DIURIL, CHLOROTHIAZIDE SODIUM

OAK PHARMS INC
* OAK PHARMACEUTICALS INC
ZIOPTAN, TAFLUPROST
* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
AZASITE, AZITHROMYCIN
BETIMOL, TIMOLOL
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

OCULAR THERAPEUTIX
* OCULAR THERAPEUTIX INC
DEXTENZA, DEXAMETHASONE

ODYSSEY PHARMS
* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
URECHOLINE, BETHANECHOL CHLORIDE

OHM
* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS
* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

OHM LABS INC
* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
VALSARTAN, VALSARTAN

OLTA PHARMS
* OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

OMEROS
* OMEROS CORP
OMIDRIA, KETOROLAC TROMETHAMINE

ONY
* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX THERAP
* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

OPKO IRELAND GLOBAL
* OPKO IRELAND GLOBAL HOLDINGS LTD
RAYALDEE, CALCIFEDIOL

OPTINOSE US INC
* OPTINOSE US INC
XHANCE, FLUTICASONE PROPIONATE

ORAPHARMA
* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE
* ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLMITRIPTAN, ZOLMITRIPTAN

OREXO US INC
* OREXO US INC
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON SUB MERCK
* ORGANON USA INC A SUB OF MERCK AND CO INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* ORGANON USA INC A SUB OF MERCK AND CO INC
BRIDION, SUGAMMADEX SODIUM
NUVARING, ETHINYL ESTRADIOL

ORGANON USA INC

* ORGANON USA INC
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
GANIRELIX ACETATE, GANIRELIX ACETATE
NEXPLANON, ETONOGESTREL
PREGNYL, GONADOTROPIN, CHORIONIC
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL
MIGLITOL, MIGLITOL
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ORION PHARMA

* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

ORIT LABS LLC

* ORIT LABORATORIES LLC
BENZONATATE, BENZONATATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
FENOFIBRATE, FENOFIBRATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVETIRACETAM, LEVETIRACETAM
METRONIDAZOLE, METRONIDAZOLE

ORPHAN EUROPE

* ORPHAN EUROPE SARL
CYSTADANE, BETAINE

OSI PHARMS

* OSI PHARMACEUTICALS LLC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA

* OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

OSMOTICA PHARM

* OSMOTICA PHARMACEUTICAL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
* OSMOTICA PHARMACEUTICAL CORP
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM US

* OSMOTICA PHARMACEUTICAL US LLC
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

OTONOMY INC

* OTONOMY INC
OTIPRIO, CIPROFLOXACIN

OTSUKA

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA PHARM

* OTSUKA AMERICA PHARMACEUTICAL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
DACOGEN, DECITABINE
JYNARQUE, TOLVAPTAN
REXULTI, BREXPIPRAZOLE

OUTLOOK PHARMS

* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OXFORD PHARMS

* OXFORD PHARMACEUTICALS LLC
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**** P ****

P AND L

* P AND L DEVELOPMENT LLC
ADAPALENE, ADAPALENE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DOCOSANOL, DOCOSANOL (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

P AND L DEV LLC

* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

PACIRA PHARMS INC
* PACIRA PHARMACEUTICALS INC
EXPAREL, BUPIVACAINE

PADDOCK LLC
* PADDOCK LABORATORIES LLC
ATOVAQUONE, ATOVAQUONE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REPAGLINIDE, REPAGLINIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

PANACEA BIOTEC LTD
* PANACEA BIOTEC LTD
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TACROLIMUS, TACROLIMUS

PAR FORM
* PAR FORMULATIONS PRIVATE LTD
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MAFENIDE ACETATE, MAFENIDE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM
* PAR PHARMACEUTICAL
EVEROLIMUS, EVEROLIMUS
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
* PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
CABERGOLINE, CABERGOLINE
CALCITONIN-SALMON, CALCITONIN SALMON
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR PHARMACEUTICAL INC
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESTAZOLAM, ESTAZOLAM
FLUTAMIDE, FLUTAMIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYUREA, HYDROXYUREA
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LAMOTRIGINE, LAMOTRIGINE
MEGESTROL ACETATE, MEGESTROL ACETATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXANDROLONE, OXANDROLONE
PIMOZIDE, PIMOZIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVOPROST, TRAVOPROST
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
ACCOLATE, ZAFIRLUKAST
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BOSENTAN, BOSENTAN
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOFETILIDE, DOFETILIDE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ETHACRYNIC ACID, ETHACRYNIC ACID
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
PENICILLAMINE, PENICILLAMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PRAZIQUANTEL, PRAZIQUANTEL
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLCAPONE, TOLCAPONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR PHARMACEUTICAL INC
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZILEUTON, ZILEUTON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
ADRENALIN, EPINEPHRINE
ARGATROBAN, ARGATROBAN
BREVITAL SODIUM, METHOHEXITAL SODIUM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
COLY-MYCIN M, COLISTIMETHATE SODIUM
CORPHEDRA, EPHEDRINE SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
KETALAR, KETAMINE HYDROCHLORIDE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PITOCIN, OXYTOCIN
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TREPROSTINIL, TREPROSTINIL
TRIOSTAT, LIOTHYRONINE SODIUM
VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK

* PARAGON BIOTECK INC
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC

* PARAPRO LLC
NATROBA, SPINOSAD

PARATEK PHARMS INC

* PARATEK PHARMACEUTICALS INC
NUZYRA, OMADACYCLINE TOSYLATE

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
CELONTIN, METHSUXIMIDE
CEREBYX, FOSPHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
ZARONTIN, ETHOSUXIMIDE

PARKE-DAVIS

* PARKE-DAVIS DIVISION OF PFIZER INC
DILANTIN, PHENYTOIN SODIUM
ZARONTIN, ETHOSUXIMIDE

PERRIGO

* PERRIGO CO
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
* PERRIGO LLC
DESLORATADINE, DESLORATADINE

PERRIGO CO

* PERRIGO CO OF TENESSEE INC
CICLOPIROX, CICLOPIROX
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

* PERRIGO CO TENNESSEE INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO CO TENNESSEE INC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

* PERRIGO ISRAEL PHARMACEUTICALS LTD
AMMONIUM LACTATE, AMMONIUM LACTATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
MINOXIDIL, MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NITROGLYCERIN, NITROGLYCERIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PERMETHRIN, PERMETHRIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
TERCONAZOLE, TERCONAZOLE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CENTANY, MUPIROCIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN (OTC)
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
CLINDESSE, CLINDAMYCIN PHOSPHATE
ENTOCORT EC, BUDESONIDE
EVAMIST, ESTRADIOL
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
TRETINOIN, TRETINOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY CO
LORATADINE, LORATADINE (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)

PERRIGO PHARMS CO

* PERRIGO PHARMACEUTICALS CO
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
NAPROXEN, NAPROXEN
SCOPOLAMINE, SCOPOLAMINE

PERRIGO R AND D

* PERRIGO R AND D CO
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ESTRADIOL, ESTRADIOL
FLURANDRENOLIDE, FLURANDRENOLIDE
INGENOL MEBUTATE, INGENOL MEBUTATE
METRONIDAZOLE, METRONIDAZOLE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERSION

* PERSION PHARMACEUTICALS LLC
ZOHYDRO ER, HYDROCODONE BITARTRATE

PETNET

* PETNET SOLUTIONS INC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
BOSULIF, BOSUTINIB MONOHYDRATE
CHANTIX, VARENICLINE TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PF PRISM CV
INLYTA, AXITINIB
LYRICA CR, PREGABALIN
LYRICA, PREGABALIN
PRISTIQ, DESVENLAFAXINE SUCCINATE
RAPAMUNE, SIROLIMUS
TORISEL, TEMSIROLIMUS
TYGACIL, TIGECYCLINE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE

PFIZER

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER INC
CADUET, AMLODIPINE BESYLATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CARDURA XL, DOXAZOSIN MESYLATE
ELELYSO, TALIGLUCERASE ALFA
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
LIPITOR, ATORVASTATIN CALCIUM
MERREM, MEROPENEM
NORVASC, AMLODIPINE BESYLATE
PROCARDIA, NIFEDIPINE
REVATIO, SILDENAFIL CITRATE
SONATA, ZALEPLON
TESSALON, BENZONATATE
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
ZITHROMAX, AZITHROMYCIN
* PFIZER LABORATORIES DIV PFIZER INC
CARDURA, DOXAZOSIN MESYLATE
FELDENE, PIROXICAM
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PFIZERPEN, PENICILLIN G POTASSIUM
PROCARDIA XL, NIFEDIPINE
UNASYN, AMPICILLIN SODIUM
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
* PFIZER PHARMACEUTICALS INC
DILANTIN, PHENYTOIN
ZOLOFT, SERTRALINE HYDROCHLORIDE
* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER INC

* PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
DAURISMO, GLASDEGIB MALEATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM
IBRANCE, PALBOCICLIB
LORBRENA, LORLATINIB
NICOTROL, NICOTINE
TALZENNA, TALAZOPARIB TOSYLATE
VIAGRA, SILDENAFIL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PFIZER INC
VIZIMPRO, DACOMITINIB
XELJANZ XR, TOFACITINIB CITRATE

PFIZER IRELAND

* PFIZER IRELAND PHARMACEUTICALS
RELPAX, ELETRIPTAN HYDROBROMIDE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* PHARMACEUTICAL ASSOCIATES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

PHARM SOURCING

* PHARMACEUTICAL SOURCING PARTNERS INC
MESALAMINE, MESALAMINE

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA

* PHARMACIA AND UPJOHN CO LLC
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN
GENOTROPIN, SOMATROPIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN
XANAX XR, ALPRAZOLAM

* PHARMACIA AND UPJOHN CO
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACITRACIN, BACITRACIN
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CORTEF, HYDROCORTISONE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
MEDROL, METHYLPREDNISOLONE
MYCOBUTIN, RIFABUTIN
NICOTROL, NICOTINE
OGEN 5, ESTROPIPATE
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMAVERT, PEGVISOMANT
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID

* PHARMACIA AND UPJOHN SUB PFIZER INC
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMACIA UPJOHN

* PHARMACIA AND UPJOHN CO A SUB OF PFIZER INC
COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE

PHARMACYCLICS INC

* PHARMACYCLICS INC
IMBRUVICA, IBRUTINIB

PHARMADAX INC

* PHARMADAX INC
GLYBURIDE, GLYBURIDE
LEVETIRACETAM, LEVETIRACETAM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

PHARMALUCENCE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PHARMALUCENCE INC
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT

PHARMASCIENCE INC
* PHARMASCIENCE INC
BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMAXIS LTD
* PHARMAXIS LTD
ARIDOL KIT, MANNITOL

PHOTOCURE ASA
* PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE DERMA
* PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL
* PIERREL S.P.A.
ORABLOC, ARTICAINE HYDROCHLORIDE

PII
* PHARMACEUTICS INTERNATIONAL INC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
HYDROCORTISONE, HYDROCORTISONE
ITRACONAZOLE, ITRACONAZOLE
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PINNACLE BIOLGS
* PINNACLE BIOLOGICS INC
PHOTOFRIN, PORFIMER SODIUM

PIRAMAL CRITICAL
* PIRAMAL CRITICAL CARE INC
GABLOFEN, BACLOFEN
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOFLURANE, ISOFLURANE
MITIGO, MORPHINE SULFATE
OXACILLIN SODIUM, OXACILLIN SODIUM
SOJOURN, SEVOFLURANE
* PIRAMAL CRITICAL CARE LTD
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

PIRAMAL ENT
* PIRAMAL ENTERPRISES LTD
ISOFLURANE, ISOFLURANE

PIRAMAL HLTHCARE UK
* PIRAMAL HEALTHCARE UK LTD
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DEFERASIROX, DEFERASIROX

PLD ACQUISITIONS
* PLD ACQUISITIONS LLC DBA AVEMA PHARMA SOLUTIONS
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

PLD ACQUISITIONS LLC
* PLD ACQUISITIONS LLC
LORATADINE, LORATADINE (OTC)
ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA
* PLIVA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIMETIDINE, CIMETIDINE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO
* PLIVA HRVATSKA DOO
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

PLIVA LACHEMA
* PLIVA LACHEMA AS
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

PLIVA PHARM IND
* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA
* PLX PHARMA INC
VAZALORE, ASPIRIN (OTC)

POHL BOSKAMP
* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS
* POLYGEN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

POLYMEDICA
* POLYMEDICA INDUSTRIES INC
NEOPAP, ACETAMINOPHEN (OTC)

PORTOLA PHARMS INC
* PORTOLA PHARMACEUTICALS INC
BEVYXXA, BETRIXABAN

POWDER PHARMS
* POWDER PHARMACEUTICALS INC
ZINGO, LIDOCAINE HYDROCHLORIDE

PRAGMA
* PRAGMA PHARMACEUTICALS LLC
KEFLEX, CEPHALEXIN

PRAXAIR DISTRIBUTION
* PRAXAIR DISTRIBUTION INC
NOXIVENT, NITRIC OXIDE

PRECISION DERMAT
* PRECISION DERMATOLOGY INC
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE

PRECISION DOSE INC
* PRECISION DOSE INC
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR
* PRECISION NUCLEAR LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
ARIPIPRAZOLE, ARIPIPRAZOLE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPTOPRIL, CAPTOPRIL
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOFETILIDE, DOFETILIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE, FENOFIBRATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NEVIRAPINE, NEVIRAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VORICONAZOLE, VORICONAZOLE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROGENICS PHARMS INC

* PROGENICS PHARMACEUTICALS INC
AZEDRA, IOBENGUANE I-131

PROVELL

* PROVELL PHARMACEUTICALS LLC
EUTHYROX, LEVOTHYROXINE SODIUM **

PROVENSIS

* PROVENSIS LTD
VARITHENA, POLIDOCANOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

PROVEPHARM SAS
* PROVEPHARM SAS
PROVAYBLUE, METHYLENE BLUE

PTC THERAP
* PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT

PULMOFLOW INC
* PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH
* PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

PURACAP PHARM
* PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC
* PURACAP PHARMACEUTICAL LLC
BENZONATATE, BENZONATATE
ERGOCALCIFEROL, ERGOCALCIFEROL
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE
* PURDUE GMP CENTER LLC
SEROMYCIN, CYCLOSERINE

PURDUE PHARMA LP
* PURDUE PHARMA LP
ADHANSIA XR, METHYLPHENIDATE HYDROCHLORIDE
BUTRANS, BUPRENORPHINE
HYSINGLA ER, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

**** Q ****

Q BIOMED
* Q BIOMED INC
METASTRON, STRONTIUM CHLORIDE SR-89
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

QILU
* QILU PHARMACEUTICAL CO LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

QINGDAO BAHEAL PHARM
* QINGDAO BAHEAL PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE
CELECOXIB, CELECOXIB
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

QOL MEDCL
* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Q ****

* QOL MEDICAL LLC
SUCRAID, SACROSIDASE

QUAGEN
* QUAGEN PHARMACEUTICALS LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

QUEEN HAMAMATSU PET
* QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**** R ****

R-PHARM US LLC
* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

RADIUS HEALTH INC
* RADIUS HEALTH INC
TYMLOS, ABALOPARATIDE

RB HLTH
* RB HEALTH US LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

RECIP
* RECIP AB
THYROSAFE, POTASSIUM IODIDE (OTC)

RECIPHARM
* RECIPHARM PHARMASERVICES PRIVATE LTD
FLUCYTOSINE, FLUCYTOSINE

RECORDATI RARE
* RECORDATI RARE DISEASES INC
CARBAGLU, CARGLUMIC ACID
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
INDOCIN, INDOMETHACIN SODIUM
NEOPROFEN, IBUPROFEN LYSINE
PEGANONE, ETHOTOIN
TRANXENE, CLORAZEPATE DIPOTASSIUM

RECRO GAINESVILLE
* RECRO GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

REDHILL
* REDHILL BIOPHARMA INC
AEMCOLO, RIFAMYCIN SODIUM
* REDHILL BIOPHARMA LTD
TALICIA, AMOXICILLIN

RELYPSA INC
* RELYPSA INC
VELTASSA, PATIROMER SORBITEX CALCIUM

REMPEX PHARMS
* REMPEX PHARMACEUTICALS
MINOCIN, MINOCYCLINE HYDROCHLORIDE
* REMPEX PHARMACEUTICALS A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS INC
VABOMERE, MEROPENEM

RENATA
* RENATA LTD
RISPERIDONE, RISPERIDONE

RHODES PHARMS
* RHODES PHARMACEUTICALS LP
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** R ****

* RHODES PHARMACEUTICALS LP
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

RICONPHARMA LLC

* RICONPHARMA LLC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CHLORTHALIDONE, CHLORTHALIDONE
DOFETILIDE, DOFETILIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

RIGEL PHARMS INC

* RIGEL PHARMACEUTICALS INC
TAVALISSE, FOSTAMATINIB DISODIUM

RISING

* RISING PHARMA HOLDINGS INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETIC ACID, ACETIC ACID, GLACIAL
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DOXERCALCIFEROL, DOXERCALCIFEROL
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE, HYDROCORTISONE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
METHIMAZOLE, METHIMAZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
PARICALCITOL, PARICALCITOL
PERPHENAZINE, PERPHENAZINE
PREGABALIN, PREGABALIN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RISPERIDONE, RISPERIDONE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZILEUTON, ZILEUTON

ROCHE PALO

* ROCHE PALO ALTO LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROCKWELL MEDICAL INC

* ROCKWELL MEDICAL INC
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

ROMARK

* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

ROUSES POINT PHARMS

* ROUSES POINT PHARMACEUTICALS LLC
LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** R ****

RTRX
* RETROPHIN INC
CHOLBAM, CHOLIC ACID

RUBICON
* RUBICON RESEARCH PRIVATE LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BACLOFEN, BACLOFEN
CARVEDILOL, CARVEDILOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LAMOTRIGINE, LAMOTRIGINE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

RXMTM THERAPS LLC
* RXMTM THERAPEUTICS LLC A WHOLLY OWNED SUB OF CUTISPHARMA INC
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE

**** S ****

SAGE PRODS
* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGE THERAP
* SAGE THERAPEUTICS INC
ZULRESSO, BREXANOLONE

SAGENT PHARMS
* SAGENT PHARMACEUTICALS INC
CAFFEINE CITRATE, CAFFEINE CITRATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT PHARMS INC
* SAGENT PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
FULVESTRANT, FULVESTRANT
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYDO, LIDOCAINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SAGENT PHARMACEUTICALS INC
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OXYTOCIN, OXYTOCIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PROPOFOL, PROPOFOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

SAI LIFE SCIENCES

* SAI LIFE SCIENCES LTD
DAPSONE, DAPSONE

SALIX

* SALIX PHARMACEUTICALS INC
FENOGLIDE, FENOFIBRATE
PLENVU, ASCORBIC ACID
RELISTOR, METHYLNALTREXONE BROMIDE
TRULANCE, PLECANATIDE
UCERIS, BUDESONIDE
ZEGERID, OMEPRAZOLE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC
ANUSOL HC, HYDROCORTISONE
DIURIL, CHLOROTHIAZIDE
MOVIPREP, ASCORBIC ACID
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
RELISTOR, METHYLNALTREXONE BROMIDE
XIFAXAN, RIFAXIMIN

SAMSON MEDCL

* SAMSON MEDICAL TECHNOLOGIES LLC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ

* SANDOZ
DOCETAXEL, DOCETAXEL
* SANDOZ INC
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
APREPITANT, APREPITANT
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFERGOT, CAFFEINE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARVEDILOL, CARVEDILOL
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLARITHROMYCIN, CLARITHROMYCIN
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NIZATIDINE, NIZATIDINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
OMNITROPE, SOMATROPIN
ONDANSETRON, ONDANSETRON
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXALIPLATIN, OXALIPLATIN
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SULFADIAZINE, SULFADIAZINE
TACROLIMUS, TACROLIMUS
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC

* SANDOZ CANADA INC
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INFUVITE PEDIATRIC, ASCORBIC ACID

SANDOZ INC

* SANDOZ INC
ACETAMINOPHEN, ACETAMINOPHEN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANGIOMAX, BIVALIRUDIN
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DECITABINE, DECITABINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EZETIMIBE, EZETIMIBE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FLUMAZENIL, FLUMAZENIL
FULVESTRANT, FULVESTRANT
GATIFLOXACIN, GATIFLOXACIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLATOPA, GLATIRAMER ACETATE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
ISONIAZID, ISONIAZID
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LATANOPROST, LATANOPROST
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
MAXITROL, DEXAMETHASONE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYDRIACYL, TROPICAMIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEVIRAPINE, NEVIRAPINE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QOLIANA, BRIMONIDINE TARTRATE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
REGONOL, PYRIDOSTIGMINE BROMIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TELMISARTAN, TELMISARTAN
TERIFLUNOMIDE, TERIFLUNOMIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
TOBREX, TOBRAMYCIN
TREPROSTINIL, TREPROSTINIL
TRIFLURIDINE, TRIFLURIDINE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANOCHEMIA CORP USA

* SANOCHEMIA CORP USA
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL

SANOFI

* SANOFI GENZYME
HECTOROL, DOXERCALCIFEROL
RENVELA, SEVELAMER CARBONATE

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL
* SANOFI AVENTIS US LLC
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DIABETA, GLYBURIDE
ELOXATIN, OXALIPLATIN
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FLOMAX, TAMSULOSIN HYDROCHLORIDE
GAVISCON, ALUMINUM HYDROXIDE (OTC)
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LANTUS, INSULIN GLARGINE RECOMBINANT
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NICODERM CQ, NICOTINE (OTC)
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TAXOTERE, DOCETAXEL
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

SANOFI US

* SANOFI US
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

SANOFI US SERVICES

* SANOFI US SERVICES INC
TOUJEO MAX SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT

SANOFI-AVENTIS US

* SANOFI-AVENTIS US LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANOFI-AVENTIS US LLC
ADLYXIN, LIXISENATIDE
ADMELOG SOLOSTAR, INSULIN LISPRO
ADMELOG, INSULIN LISPRO
SOLIQUA 100/33, INSULIN GLARGINE

SANOVEL ILAC
* SANOVEL ILAC SAN VE TIC AS
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

SANTARUS INC
* SANTARUS INC
GLUMETZA, METFORMIN HYDROCHLORIDE

SAOL THERAPS RES LTD
* SAOL THERAPEUTICS RESEARCH LTD
LIORESAL, BACLOFEN

SAPTALIS PHARMS
* SAPTALIS PHARMACEUTICALS LLC
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

SAREPTA THERAPS INC
* SAREPTA THERAPEUTICS INC
EXONDYS 51, ETEPLIRSEN
VYONDYS 53, GOLODIRSEN

SAVIOR LIFETEC CORP
* SAVIOR LIFETEC CORP
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM

SAWAI USA
* SAWAI USA INC
MIRABEGRON, MIRABEGRON
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

SB PHARMCO
* SB PHARMCO PUERTO RICO INC
AVANDIA, ROSIGLITAZONE MALEATE

SCHERING
* SCHERING CORP
INTEGRILIN, EPTIFIBATIDE
NOXAFIL, POSACONAZOLE

SCIECURE PHARMA INC
* SCIECURE PHARMA INC
BUDESONIDE, BUDESONIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

SCIEGEN PHARMS INC
* SCIEGEN PHARMACEUTICALS INC
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ETHACRYNIC ACID, ETHACRYNIC ACID
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SCIEGEN PHARMACEUTICALS INC
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

SCILEX PHARMS INC
* SCILEX PHARMACEUTICALS
ZTLIDO, LIDOCAINE

SCINOPHARM TAIWAN
* SCINOPHARM TAIWAN LTD
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM

SEBELA IRELAND LTD
* SEBELA IRELAND LTD
BRISDELLE, PAROXETINE MESYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
ONMEL, ITRACONAZOLE
PEXEVA, PAROXETINE MESYLATE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN

SECAN PHARMS
* SECAN PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM

SECURA
* SECURA BIO INC
FARYDAK, PANOBINOSTAT LACTATE

SENTYNL THERAPS INC
* SENTYNL THERAPEUTICS INC
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

SEPTODONT
* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

SEPTODONT HOLDING
* SEPTODONT HOLDING SAS
ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC
* SEPTODONT INC
LIDOCAINE, LIDOCAINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERB SA
* SERB SA
CYANOKIT, HYDROXOCOBALAMIN

SETON PHARM
* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SETON PHARMS
* SETON PHARMACEUTICALS LLC
CAPTOPRIL, CAPTOPRIL
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

SHANDONG
* SHANDONG NEW TIME PHARMACEUTICAL CO LTD
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

SHANDONG XINHUA
* SHANDONG XINHUA PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

SHANGHAI HENGRUI

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
DESFLURANE, DESFLURANE
SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW

* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

* SHERTECH LABORATORIES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHIELD TX

* SHIELD TX UK LTD
ACCRUFER, FERRIC MALTOL

SHILPA MEDICARE

* SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHILPA MEDICARE LTD

* SHILPA MEDICARE LTD
BUSULFAN, BUSULFAN
CAPECITABINE, CAPECITABINE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

SHIONOGI INC

* SHIONOGI INC
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
MULPLETA, LUSUTROMBOPAG
PONSTEL, MEFENAMIC ACID

SHIRE

* SHIRE DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE

SHIRE DEV LLC

* SHIRE DEVELOPMENT LLC
CARBATROL, CARBAMAZEPINE
FOSRENOL, LANTHANUM CARBONATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MYDAYIS, AMPHETAMINE ASPARTATE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

* SHIRE HUMAN GENETIC THERAPIES INC
VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

* SHIRE DEVELOPMENT LLC
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
FOSRENOL, LANTHANUM CARBONATE

SHIRE ORPHAN THERAP

* SHIRE ORPHAN THERAPIES LLC
FIRAZYR, ICATIBANT ACETATE

SIDMAK LABS INDIA

* SIDMAK LABORATORIES INDIA PVT LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGA TECHNOLOGIES

* SIGA TECHNOLOGIES INC
TPOXX, TECOVIRIMAT

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMBRISENTAN, AMBRISENTAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
DOFETILIDE, DOFETILIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NITROGLYCERIN, NITROGLYCERIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SILVERGATE PHARMS

* SILVERGATE PHARMACEUTICALS INC
EPANED, ENALAPRIL MALEATE
KATERZIA, AMLODIPINE BENZOATE
QBRELIS, LISINOPRIL
XATMEP, METHOTREXATE SODIUM

SINOTHERAPEUTICS INC

* SINOTHERAPEUTICS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

SKINMEDICA

* SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

* SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SLATE

* SLATE RUN PHARMACEUTICALS LLC
CILOSTAZOL, CILOSTAZOL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL

SLAYBACK PHARMA LLC

* SLAYBACK PHARMA LLC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

SMITHKLINE BEECHAM

* SMITHKLINE BEECHAM
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
* SMITHKLINE BEECHAM (CORK) LTD IRELAND
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL

SOAPCO

* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS
NIMODIPINE, NIMODIPINE
* SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
PROGESTERONE, PROGESTERONE

SOFIE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SOFIE CO DBA SOFIE
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
* SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SOMERSET

* SOMERSET PHARMACEUTICALS INC
EMSAM, SELEGILINE
* SOMERSET THERAPEUTICS LLC
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOMERSET THERAPS LLC

* SOMERSET THERAPEUTICS LLC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TROPICAMIDE, TROPICAMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SPARC

* SUN PHARMA ADVANCED RESEARCH CO LTD
ELEPSIA XR, LEVETIRACETAM

SPECGX LLC

* SPECGX LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SPECGX LLC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
ROXICODONE, OXYCODONE HYDROCHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE

SPECTRA MDCL DEVICES
* SPECTRA MEDICAL DEVICES INC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPECTRON MRC LLC
* SPECTRON MRC LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SPIL
* SUN PHARMA INDUSTRIES LTD
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

SPROUT PHARMS
* SPROUT PHARMACEUTICALS INC
ADDYI, FLIBANSERIN

SQUARE PHARMS LTD
* SQUARE PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
VALSARTAN, VALSARTAN

ST RENATUS
* ST RENATUS LLC
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH
* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STANDARD CHEM PHARM
* STANDARD CHEM AND PHARM CO LTD
RILUZOLE, RILUZOLE

STASON PHARMS
* STASON PHARMACEUTICALS INC
PURINETHOL, MERCAPTOPURINE

STI PHARMA LLC
* STI PHARMA LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CARMUSTINE, CARMUSTINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
THIOTEPA, THIOTEPA
TRIACIN-C, CODEINE PHOSPHATE

STIEFEL
* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

STIEFEL LABS INC
* STIEFEL LABORATORIES INC
SORIATANE, ACITRETIN

STRIDES PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STRIDES PHARMA GLOBAL PTE LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ACARBOSE, ACARBOSE
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBENDAZOLE, ALBENDAZOLE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZONATATE, BENZONATATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARISOPRODOL, CARISOPRODOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHOSUXIMIDE, ETHOSUXIMIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOCONAZOLE, KETOCONAZOLE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LIDOCAINE, LIDOCAINE
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOXSALEN, METHOXSALEN
METRONIDAZOLE, METRONIDAZOLE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NEVIRAPINE, NEVIRAPINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PIROXICAM, PIROXICAM
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TACROLIMUS, TACROLIMUS
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

STRONGBRIDGE US

* STRONGBRIDGE US INC
KEVEYIS, DICHLORPHENAMIDE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUN PHARM

* SUN PHARMACEUTICAL INDUSTRIES LTD
ABSORICA LD, ISOTRETINOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMBRISENTAN, AMBRISENTAN
AMIFOSTINE, AMIFOSTINE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BOSENTAN, BOSENTAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CERINTA, ETHINYL ESTRADIOL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DALFAMPRIDINE, DALFAMPRIDINE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESZOPICLONE, ESZOPICLONE
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GANIRELIX ACETATE, GANIRELIX ACETATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
INFUGEM, GEMCITABINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KEMEYA, DROSPIRENONE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KYRA, DROSPIRENONE
LANSOPRAZOLE, LANSOPRAZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE (OTC)
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANOLAZINE, RANOLAZINE
RIOMET ER, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SYLEVIA, ETHINYL ESTRADIOL
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TETRABENAZINE, TETRABENAZINE
TOBRAMYCIN, TOBRAMYCIN
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
ABSORICA, ISOTRETINOIN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
ERGOCALCIFEROL, ERGOCALCIFEROL
EURAX, CROTAMITON
FLUMADINE, RIMANTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
GLIPIZIDE, GLIPIZIDE
HALOG, HALCINONIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KENALOG, TRIAMCINOLONE ACETONIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
XIMINO, MINOCYCLINE HYDROCHLORIDE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DOXYCYCLINE, DOXYCYCLINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
RILUZOLE, RILUZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
RIOMET, METFORMIN HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TOPIRAMATE, TOPIRAMATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

SUN PHARM INDUSTRIES

* SUN PHARMACEUTICAL INDUSTRIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CHLORTHALIDONE, CHLORTHALIDONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FELODIPINE, FELODIPINE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUALAQUIN, QUININE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE

SUN PHARMA GLOBAL

* SUN PHARMA GLOBAL FZE
BROMSITE, BROMFENAC SODIUM
CEQUA, CYCLOSPORINE
DECITABINE, DECITABINE
DOCETAXEL, DOCETAXEL
DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
EZALLOR, ROSUVASTATIN CALCIUM
ODOMZO, SONIDEGIB PHOSPHATE
ORTIKOS, BUDESONIDE
XELPROS, LATANOPROST
YONSA, ABIRATERONE ACETATE

SUNGEN PHARMA

* SUNGEN PHARMA LLC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
LIDOCAINE, LIDOCAINE
METHYLPREDNISOLONE, METHYLPREDNISOLONE

SUNNY PHARMTECH INC

* SUNNY PHARMTECH INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUNNY PHARMTECH INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

SUNOVION
* SUNOVION PHARMACEUTICALS INC
BROVANA, ARFORMOTEROL TARTRATE
XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC
* SUNOVION PHARMACEUTICALS INC
APTIOM, ESLICARBAZEPINE ACETATE
ARCAPTA NEOHALER, INDACATEROL MALEATE
LATUDA, LURASIDONE HYDROCHLORIDE
LUNESTA, ESZOPICLONE
SEEBRI, GLYCOPYRROLATE
UTIBRON, GLYCOPYRROLATE
ZONEGRAN, ZONISAMIDE

SUNOVION RESP
* SUNOVION RESPIRATORY DEVELOPMENT INC
LONHALA MAGNAIR KIT, GLYCOPYRROLATE

SUNRISE PHARM INC
* SUNRISE PHARMACEUTICAL INC
NAPROXEN, NAPROXEN

SUNSHINE LAKE
* SUNSHINE LAKE PHARMA CO LTD
AZITHROMYCIN, AZITHROMYCIN
CLARITHROMYCIN, CLARITHROMYCIN
ENTACAPONE, ENTACAPONE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
TADALAFIL, TADALAFIL

SUNSTAR AMERICAS
* SUNSTAR AMERICAS INC
PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS
* SUPERNUS PHARMACEUTICALS INC
OXTELLAR XR, OXCARBAZEPINE
TROKENDI XR, TOPIRAMATE

SUVEN LIFE
* SUVEN LIFE SCIENCES LTD
MALATHION, MALATHION

SVC PHARMA
* SVC PHARMA LP
DRONABINOL, DRONABINOL

SWEDISH ORPHAN
* SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

SYNTHON PHARMS
* SYNTHON PHARMACEUTICALS INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

**** T ****

ACME LABS
* THE ACME LABORATORIES LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

GEN HOSP
* THE GENERAL HOSPITAL CORP
AMMONIA N 13, AMMONIA N-13

METHODIST HOSP RES
* THE METHODIST HOSP RESEARCH INSTITUTE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP
* THE RITEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* THE RITEDOSE CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAIHO ONCOLOGY

* TAIHO ONCOLOGY INC
LONSURF, TIPIRACIL HYDROCHLORIDE

TAKEDA PHARMS USA

* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
COLCRYS, COLCHICINE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
KAZANO, ALOGLIPTIN BENZOATE
NESINA, ALOGLIPTIN BENZOATE
OSENI, ALOGLIPTIN BENZOATE
PREVACID, LANSOPRAZOLE
ROZEREM, RAMELTEON
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
ULORIC, FEBUXOSTAT

TAMARANG

* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DESLORATADINE, DESLORATADINE
DESONIDE, DESONIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FELBAMATE, FELBAMATE
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PHENYTOIN, PHENYTOIN
TERIL, CARBAMAZEPINE
WARFARIN SODIUM, WARFARIN SODIUM

* TARO PHARMACEUTICALS USA INC
ACETIC ACID, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMMONIUM LACTATE, AMMONIUM LACTATE
AZELAIC ACID, AZELAIC ACID
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DAPSONE, DAPSONE
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOZOLE, KETOCONAZOLE
LIDOCAINE, LIDOCAINE
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PHENYTOIN, PHENYTOIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
U-CORT, HYDROCORTISONE ACETATE

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE

TARO PHARM INDS LTD

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
DESLORATADINE, DESLORATADINE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TOPICORT, DESOXIMETASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TARO PHARMS

* TARO PHARMACEUTICALS INC
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
PLIAGLIS, LIDOCAINE
TAZAROTENE, TAZAROTENE
TOPICORT, DESOXIMETASONE
TRETINOIN, TRETINOIN

TASMAN PHARMA

* TASMAN PHARMA INC
CLOTRIMAZOLE, CLOTRIMAZOLE
VERSACLOZ, CLOZAPINE

TCG FLUENT PHARMA

* TCG FLUENT PHARMA INVESTORS LP
FLOLIPID, SIMVASTATIN

TEIKOKU PHARMA

* TEIKOKU PHARMA USA INC
DOCETAXEL, DOCETAXEL

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TELIGENT

* TELIGENT OU
CEFOTAN, CEFOTETAN DISODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
ZANTAC, RANITIDINE HYDROCHLORIDE
ZINACEF, CEFUROXIME SODIUM

TELIGENT PHARMA INC

* TELIGENT PHARMA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE, FLUOCINONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE AND PRILOCAINE, LIDOCAINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TELIGENT PHARMA INC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TERSERA THERAPS LLC

* TERSERA THERAPEUTICS LLC
ERGOMAR, ERGOTAMINE TARTRATE
PRIALT, ZICONOTIDE ACETATE
QMIIZ ODT, MELOXICAM
VARUBI, ROLAPITANT HYDROCHLORIDE
ZOLADEX, GOSERELIN ACETATE

TESARO INC

* TESARO INC
ZEJULA, NIRAPARIB TOSYLATE

TETRAPHASE PHARMS

* TETRAPHASE PHARMACEUTICALS INC
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE

TEVA

* TEVA NEUROSCIENCE INC
AZILECT, RASAGILINE MESYLATE
* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CAPTOPRIL, CAPTOPRIL
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOR
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPITOL, CARBAMAZEPINE
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXAPROZIN, OXAPROZIN
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN-VK, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRELONE, PREDNISOLONE
RIBAVIRIN, RIBAVIRIN
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
AUSTEDO, DEUTETRABENAZINE
EMLA, LIDOCAINE
LOSEASONIQUE, ETHINYL ESTRADIOL
PROAIR DIGIHALER, ALBUTEROL SULFATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
PROGLYCEM, DIAZOXIDE
QNASL, BECLOMETHASONE DIPROPIONATE
QUARTETTE, ETHINYL ESTRADIOL
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM

* TEVA PHARMACEUTICAL INDUSTRIES LTD
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
AZITHROMYCIN, AZITHROMYCIN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FAMCICLOVIR, FAMCICLOVIR
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
ZALEPLON, ZALEPLON

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
SYNRIBO, OMACETAXINE MEPESUCCINATE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ACITRETIN, ACITRETIN
ADENOSINE, ADENOSINE
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALPROSTADIL, ALPROSTADIL
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUDESONIDE, BUDESONIDE
CARBOPLATIN, CARBOPLATIN
CLARAVIS, ISOTRETINOIN
CLOZAPINE, CLOZAPINE
COPAXONE, GLATIRAMER ACETATE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPTIFIBATIDE, EPTIFIBATIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GABAPENTIN, GABAPENTIN
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LINEZOLID, LINEZOLID
LOGILIA, ULIPRISTAL ACETATE
MESNA, MESNA
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TREPROSTINIL, TREPROSTINIL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VIGABATRIN, VIGABATRIN
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZANOSAR, STREPTOZOCIN
* TEVA PHARMACEUTICALS USA INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALYQ, TADALAFIL
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CAPECITABINE, CAPECITABINE
DAPTOMYCIN, DAPTOMYCIN
DARUNAVIR, DARUNAVIR
DEFERASIROX, DEFERASIROX
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL, ESTRADIOL
EVEROLIMUS, EVEROLIMUS
ICATIBANT ACETATE, ICATIBANT ACETATE
IVERMECTIN, IVERMECTIN
LIDOCAINE, LIDOCAINE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MESALAMINE, MESALAMINE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METRONIDAZOLE, METRONIDAZOLE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SELFEMRA, FLUOXETINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TEVA PHARMS USA INC

* TEVA PHARMACEUTICALS USA INC
FULVESTRANT, FULVESTRANT
POTASSIUM CITRATE, POTASSIUM CITRATE

THE FEINSTEIN INST

* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZONATATE, BENZONATATE
ISONIAZID, ISONIAZID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* THEPHARMANETWORK LLC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

THERAPEUTICSMD INC

* THERAPEUTICSMD INC
ANNOVERA, ETHINYL ESTRADIOL
BIJUVA, ESTRADIOL
IMVEXXY, ESTRADIOL

THERATECHNOLOGIES

* THERATECHNOLOGIES INC
EGRIFTA, TESAMORELIN ACETATE

TIANJIN TIANYAO

* TIANJIN TIANYAO PHARMACEUTICALS CO LTD
METHYLPREDNISOLONE, METHYLPREDNISOLONE

TIME-CAP LABS INC

* TIME-CAP LABORATORIES INC
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

TITAN PHARMS

* TITAN PHARMACEUTICALS INC
PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE

TOLMAR

* TOLMAR INC
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
ATRIDOX, DOXYCYCLINE HYCLATE
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
ELIGARD, LEUPROLIDE ACETATE

TOPROL

* TOPROL ACQUISITION LLC
TOPROL-XL, METOPROLOL SUCCINATE
ZONTIVITY, VORAPAXAR SULFATE

TORPHARM

* TORPHARM INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT

* TORRENT PHARMA INC
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
* TORRENT PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARIPIPRAZOLE, ARIPIPRAZOLE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TORRENT PHARMACEUTICALS LTD
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NYSTATIN, NYSTATIN
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TADALAFIL, TADALAFIL
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LIMITED
LEVOFLOXACIN, LEVOFLOXACIN
* TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* TORRENT PHARMACEUTICALS LTD.
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

TORRENT PHARMS LLC

* TORRENT PHARMACEUTICALS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
OLANZAPINE, OLANZAPINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
LEVETIRACETAM, LEVETIRACETAM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

TRIS PHARMA INC

* TRIS PHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TRIS PHARMA INC
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DYANAVEL XR, AMPHETAMINE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
IBUPROFEN, IBUPROFEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA
* TRUSTEES OF THE UNIV OF PENNSYLVANIA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TULEX PHARMS INC
* TULEX PHARMACEUTICALS INC
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

TWI PHARMS
* TWI PHARMACEUTICALS INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TESTOSTERONE, TESTOSTERONE
ZOLMITRIPTAN, ZOLMITRIPTAN

TWI PHARMS INC
* TWI PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** U ****

UCB INC
* UCB INC
BRIVIACT, BRIVARACETAM
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
NAYZILAM, MIDAZOLAM
NEUPRO, ROTIGOTINE
VIMPAT, LACOSAMIDE

UCLA BIOMEDICAL
* UCLA BIOMEDICAL CYCLOTRON
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RODIOPHARM
* UCSF RADIOPHARMACEUTICAL FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

UIHC PET IMAGING
* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
GALLIUM DOTATOC GA 68, GALLIUM DOTATOC GA-68

ULTRATAB LABS INC
* ULTRATAB LABORATORIES INC
IBUPROFEN, IBUPROFEN (OTC)

UMEDICA LABS PVT LTD
* UMEDICA LABORATORIES PRIVATE LTD
CELECOXIB, CELECOXIB
CHLORTHALIDONE, CHLORTHALIDONE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL

UNICHEM
* UNICHEM LABORATORIES LTD
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MELOXICAM, MELOXICAM
ZALEPLON, ZALEPLON

UNICHEM LABS LTD
* UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* UNICHEM LABORATORIES LTD
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PIROXICAM, PIROXICAM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN, VALSARTAN

UNICHEM PHARMS (USA)
* UNICHEM PHARMACEUTICALS (USA) INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIMARK REMEDIES LTD
* UNIMARK REMEDIES LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE PHARM LABS
* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
FLUCONAZOLE, FLUCONAZOLE
GLIPIZIDE, GLIPIZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TINIDAZOLE, TINIDAZOLE

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC
TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
ORENITRAM, TREPROSTINIL DIOLAMINE
REMODULIN, TREPROSTINIL
TYVASO, TREPROSTINIL

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX SW MEDCTR

* UNIV TEXAS SOUTHWESTERN MEDCTR
AMMONIA N 13, AMMONIA N-13

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES INC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE

* UPSHER SMITH LABORATORIES LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BEXAROTENE, BEXAROTENE
BUMETANIDE, BUMETANIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EXEMESTANE, EXEMESTANE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
JANTOVEN, WARFARIN SODIUM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UPSHER SMITH LABORATORIES LLC
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREVALITE, CHOLESTYRAMINE
QUDEXY XR, TOPIRAMATE
SORINE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TOSYMRA, SUMATRIPTAN
VOGELXO, TESTOSTERONE
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE

US PHARM HOLDINGS
* US PHARMACEUTICAL HOLDINGS II LLC
DRISDOL, ERGOCALCIFEROL
HIPREX, METHENAMINE HIPPURATE
LASIX, FUROSEMIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

US PHARMS HOLDINGS I
* US PHARMACEUTICALS HOLDINGS I LLC
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS
* US WORLDMEDS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

US WORLDMEDS LLC
* US WORLDMEDS LLC
CORGARD, NADOLOL
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
XADAGO, SAFINAMIDE MESYLATE

USPHARMA
* USPHARMA LTD
NITRO-DUR, NITROGLYCERIN

USPHARMA WINDLAS
* USPHARMA WINDLAS LLC
PRASUGREL, PRASUGREL HYDROCHLORIDE

USV
* USV PRIVATE LTD
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**** V ****

VALEANT
* VALEANT PHARMACEUTICALS INTERNATIONAL
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MYSOLINE, PRIMIDONE

VALEANT BERMUDA
* VALEANT INTERNATIONAL BERMUDA
DERMATOP E EMOLLIENT, PREDNICARBATE
PENLAC, CICLOPIROX
RETIN-A, TRETINOIN

VALEANT INTL
* VALEANT INTERNATIONAL BARBADOS SRL
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
* VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

VALEANT LUXEMBOURG
* VALEANT PHARMACEUTICALS LUXEMBOURG SARL
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL
* VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN

VALEANT PHARMS
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INC
* VALEANT PHARMACEUTICALS INTERNATIONAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

VALEANT PHARMS INTL
* VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
CUPRIMINE, PENICILLAMINE
LACRISERT, HYDROXYPROPYL CELLULOSE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
UCERIS, BUDESONIDE

VALEANT PHARMS LLC
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
MACUGEN, PEGAPTANIB SODIUM
TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
APLENZIN, BUPROPION HYDROBROMIDE
CARAC, FLUOROURACIL
DERMATOP, PREDNICARBATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
KLARON, SULFACETAMIDE SODIUM
NIFEDIPINE, NIFEDIPINE
NORITATE, METRONIDAZOLE
PEPCID, FAMOTIDINE
RENOVA, TRETINOIN
RETIN-A, TRETINOIN
SECONAL SODIUM, SECOBARBITAL SODIUM
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
XENAZINE, TETRABENAZINE

VALIDUS PHARMS
* VALIDUS PHARMACEUTICALS LLC
BUMEX, BUMETANIDE
EQUETRO, CARBAMAZEPINE
ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC
* VALIDUS PHARMACEUTICALS INC
MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC
* VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE
HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC
* VELOXIS PHARMACEUTICALS INC
ENVARSUS XR, TACROLIMUS

VERASTEM INC
* VERASTEM INC
COPIKTRA, DUVELISIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

VERO BIOTECH
* VERO BIOTECH
GENOSYL, NITRIC OXIDE

VEROSCIENCE
* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERTEX PHARMS
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR
SYMDEKO (COPACKAGED), IVACAFTOR
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR

VERTICAL PHARMS LLC
* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VGYAAN
* VGYAAN PHARMACEUTICALS LLC
NADOLOL, NADOLOL

VICURON
* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS
* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIV HLTHCARE
* VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
DOVATO, DOLUTEGRAVIR SODIUM
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
JULUCA, DOLUTEGRAVIR SODIUM
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE
* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS
* VINTAGE PHARMACEUTICALS
ALPRAZOLAM, ALPRAZOLAM
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

* VINTAGE PHARMACEUTICALS
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KIMIDESS, DESOGESTREL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
DIAZEPAM, DIAZEPAM
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LEVETIRACETAM, LEVETIRACETAM
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PERPHENAZINE, PERPHENAZINE
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SULFASALAZINE, SULFASALAZINE
TORSEMIDE, TORSEMIDE

VINTAGE PHARMS LLC
* VINTAGE PHARMACEUTICALS LLC
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
DUTASTERIDE, DUTASTERIDE
EMOQUETTE, DESOGESTREL
FELODIPINE, FELODIPINE
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
LETROZOLE, LETROZOLE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYZILRA, ETHINYL ESTRADIOL
ORSYTHIA, ETHINYL ESTRADIOL
PERCOCET, ACETAMINOPHEN
PREVIFEM, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL

VIOKACE
* VIOKACE LLC
VIOKACE, PANCRELIPASE (AMYLASE

VIRTUS PHARM
* VIRTUS PHARMACEUTICAL INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

VIRTUS PHARMS
* VIRTUS PHARMACEUTICALS LLC
DAPSONE, DAPSONE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROMETRIUM, PROGESTERONE

VISTA PHARMS
* VISTA PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

* VISTAPHARM INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CLOBAZAM, CLOBAZAM
DIGOXIN, DIGOXIN
FELBAMATE, FELBAMATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PREDNISOLONE, PREDNISOLONE
VALPROIC ACID, VALPROIC ACID

VITRUVIAS THERAP

* VITRUVIAS THERAPEUTICS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
* VITRUVIAS THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN

VIVUS

* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE

VIVUS INC

* VIVUS INC
PANCREAZE, PANCRELIPASE (AMYLASE

VKT PHARMA PVT LTD

* VKT PHARMA PRIVATE LTD
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

VPNA

* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

VYERA PHARMS LLC

* VYERA PHARMACEUTICALS LLC
DARAPRIM, PYRIMETHAMINE

**** W ****

WA UNIV SCH MED

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COL-PROBENECID, COLCHICINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MEPROBAMATE, MEPROBAMATE
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NABUMETONE, NABUMETONE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL
QUINIDINE SULFATE, QUINIDINE SULFATE
RAMIPRIL, RAMIPRIL
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
* WATSON LABS INC
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC

* WATSON LABORATORIES INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMMONIUM LACTATE, AMMONIUM LACTATE
BOSENTAN, BOSENTAN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
COLCHICINE, COLCHICINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
PENICILLAMINE, PENICILLAMINE
PERPHENAZINE, PERPHENAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPOFOL, PROPOFOL
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

WATSON LABS TEVA

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALVIMOPAN, ALVIMOPAN
BICALUTAMIDE, BICALUTAMIDE
BUPRENORPHINE, BUPRENORPHINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
GLIPIZIDE, GLIPIZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ISRADIPINE, ISRADIPINE
LEVOFLOXACIN, LEVOFLOXACIN
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PROBENECID, PROBENECID
SIMVASTATIN, SIMVASTATIN
TEMOZOLOMIDE, TEMOZOLOMIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

WATSON PHARMS INC

* WATSON PHARMACEUTICALS INC
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

WATSON PHARMS TEVA

* WATSON PHARMACEUTICALS INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
RIFAMPIN, RIFAMPIN

WELLSTAT THERAP

* WELLSTAT THERAPEUTICS CORP
VISTOGARD, URIDINE TRIACETATE
XURIDEN, URIDINE TRIACETATE

WES PHARMA INC

* WES PHARMA INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

WEST WARD

* WEST WARD PHARMACEUTICAL CORP
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARMS INT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMRINONE LACTATE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARBOPLATIN, CARBOPLATIN
CEFOXITIN, CEFOXITIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DURAMORPH PF, MORPHINE SULFATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFUMORPH, MORPHINE SULFATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MESNA, MESNA
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOSTATIN, PENTOSTATIN
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
THIOTEPA, THIOTEPA
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

WI MEDCL CYCLOTRON

* WISCONSIN MEDICAL CYCLOTRON LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL
NATEGLINIDE, NATEGLINIDE
PERPHENAZINE, PERPHENAZINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

WINDLAS HLTHCARE

* WINDLAS HEALTHCARE PVT LTD
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE

WOCKHARDT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WOCKHARDT LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AZITHROMYCIN, AZITHROMYCIN
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLARITHROMYCIN, CLARITHROMYCIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FAMOTIDINE, FAMOTIDINE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL, LISINOPRIL
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIACIN, NIACIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

WOCKHARDT BIO AG

* WOCKHARDT BIO AG
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BROMFED-DM, BROMPHENIRAMINE MALEATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOSPORINE, CYCLOSPORINE
DECITABINE, DECITABINE
DEXAMETHASONE, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FUROSEMIDE, FUROSEMIDE
GENERLAC, LACTULOSE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WOCKHARDT BIO AG
MEGESTROL ACETATE, MEGESTROL ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NYSTATIN, NYSTATIN
OXACILLIN SODIUM, OXACILLIN SODIUM
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID

WOCKHARDT LTD

* WOCKHARDT LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENTACAPONE, ENTACAPONE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA

* WOCKHARDT USA INC
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
* WOCKHARDT USA LLC
LANSOPRAZOLE, LANSOPRAZOLE

WOODWARD

* WOODWARD PHARMA SERVICES LLC
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE

WRASER PHARMS

* WRASER PHARMACEUTICALS LLC
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC

* WRASER PHARMACEUTICALS LLC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
TREZIX, ACETAMINOPHEN

WUSM CYCLOTRON

* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS

* WYETH PHARMACEUTICALS LLC
DUAVEE, BAZEDOXIFENE ACETATE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
TRECATOR, ETHIONAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WYETH PHARMACEUTICALS LLC
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM

**** X ****

X GEN PHARMS
* X GEN PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B
BACIIM, BACITRACIN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS
* X-GEN PHARMACEUTICALS INC
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

X-GEN PHARMS INC
* X-GEN PHARMACEUTICALS INC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DACTINOMYCIN, DACTINOMYCIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN LYSINE, IBUPROFEN LYSINE
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

XELLIA PHARMS APS
* XELLIA PHARMACEUTICALS APS
BACITRACIN, BACITRACIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

XERIS
* XERIS PHARMACEUTICALS INC
GVOKE HYPOPEN, GLUCAGON
GVOKE PFS, GLUCAGON

XIAMEN LP PHARM CO
* XIAMEN LP PHARMACUETICAL CO LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

XIROMED
* XIROMED PHARMA ESPANA SL
ALTAVERA, ETHINYL ESTRADIOL
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ELIFEMME, ETHINYL ESTRADIOL
ESTARYLLA, ETHINYL ESTRADIOL
FLUOCINONIDE, FLUOCINONIDE
INTROVALE, ETHINYL ESTRADIOL
ISIBLOOM, DESOGESTREL
JAIMIESS, ETHINYL ESTRADIOL
LANSOPRAZOLE, LANSOPRAZOLE
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORYNA, DROSPIRENONE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROGESTERONE, PROGESTERONE
SYEDA, DROSPIRENONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** X ****

* XIROMED PHARMA ESPANA SL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
VIENVA, ETHINYL ESTRADIOL
VOLNEA, DESOGESTREL

XSPIRE PHARMA
* XSPIRE PHARMA
NALFON, FENOPROFEN CALCIUM
* XSPIRE PHARMA LLC
DEXAMETHASONE, DEXAMETHASONE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

XTTRIUM
* XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

XTTRIUM LABS INC
* XTTRIUM LABORATORIES INC
LACTULOSE, LACTULOSE

**** Y ****

YABAO PHARM
* YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

YAOPHARMA CO LTD
* YAOPHARMA CO LTD
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YICHANG HUMANWELL
* YICHANG HUMANWELL PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

YILING PHARM LTD
* YILING PHARMACEUTICAL LTD
ACYCLOVIR, ACYCLOVIR
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FELODIPINE, FELODIPINE

YUNG SHIN PHARM
* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
FELODIPINE, FELODIPINE
MELOXICAM, MELOXICAM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**** Z ****

ZAMBON SPA
* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZENNOVA
* ZENNOVA LLC
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

ZENPEP
* ZENPEP LLC
ZENPEP, PANCRELIPASE (AMYLASE

ZHEJIANG HISUN PHARM
* ZHEJIANG HISUN PHARMACEUTICAL CO LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZHEJIANG JUTAI PHARM
* ZHEJIANG JUTAI PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

ZHEJIANG YONGTAI
* ZHEJIANG YONGTAI PHARMACEUTICAL CO LTD
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ZO SKIN HEALTH
* ZO SKIN HEALTH
TRETINOIN, TRETINOIN

ZYDUS
* ZYDUS WORLDWIDE DMCC
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEFLUNOMIDE, LEFLUNOMIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
URSODIOL, URSODIOL

ZYDUS HLTHCARE
* ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS NOVELTECH INC
* ZYDUS NOVELTECH INC
RIVASTIGMINE, RIVASTIGMINE

ZYDUS PHARMS
* ZYDUS PHARMACEUTICALS USA INC
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BOSENTAN, BOSENTAN
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
DESOXIMETASONE, DESOXIMETASONE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTECAVIR, ENTECAVIR
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
EXEMESTANE, EXEMESTANE
EZETIMIBE, EZETIMIBE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LINEZOLID, LINEZOLID
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RAMELTEON, RAMELTEON
SIROLIMUS, SIROLIMUS
SPIRONOLACTONE, SPIRONOLACTONE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TADALAFIL, TADALAFIL
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CARVEDILOL, CARVEDILOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OMEPRAZOLE, OMEPRAZOLE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYLA

* ZYLA LIFE SCIENCES US INC
OXAYDO, OXYCODONE HYDROCHLORIDE
SPRIX, KETOROLAC TROMETHAMINE
VIVLODEX, MELOXICAM
ZORVOLEX, DICLOFENAC

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL, FOAM
AEROSOL, METERED
BAR, CHEWABLE
CAPSULE
CAPSULE, DELAYED REL PELLETS
CAPSULE, DELAYED RELEASE
CAPSULE, EXTENDED RELEASE
CLOTH
CONCENTRATE
CREAM
CREAM, AUGMENTED
ELIXIR
EMULSION
ENEMA
FILM
FILM, EXTENDED RELEASE
FOAM
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, DELAYED RELEASE
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INJECTION, EXTENDED RELEASE
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
OIL
OIL/DROPS
OINTMENT
OINTMENT, AUGMENTED
PASTE
PATCH
PELLET
PELLETS
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION, EXTENDED RELEASE
SOLUTION, GEL FORMING/DROPS
SOLUTION, METERED
SOLUTION/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION, EXTENDED RELEASE
SUSPENSION, LIPOSOMAL
SUSPENSION/DROPS
SWAB
SYRUP
SYSTEM
SYSTEM, EXTENDED RELEASE
TABLET
TABLET, CHEWABLE
TABLET, DELAYED RELEASE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, EXTENDED RELEASE, CHEWABLE
TABLET, FOR SUSPENSION
TABLET, ORALLY DISINTEGRATING
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
TAPE
TROCHE/LOZENGE

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
DENTAL
ENDOCERVICAL
ENDOTRACHEAL
ENTERAL
IMPLANTATION
INHALATION
INJECTION
INTERSTITIAL
INTRA-ANAL
INTRA-ARTERIAL
INTRA-ARTICULAR
INTRACRANIAL
INTRADERMAL
INTRAMUSCULAR
INTRAOCULAR
INTRAOSSESOUS
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVENOUS
INTRAVESICAL
INTRAVITREAL
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION, CARDIAC
PERIODONTAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TRANSDERMAL
TRANSMUCOSAL
URETHRAL
VAGINAL

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ABBREVIATIONS

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
SC	SUBCUTANEOUS
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for periods of exclusivity and provides patent information that has been submitted to the Food and Drug Administration (FDA) concerning the listed drug products.

Exclusivity

This *Addendum* identifies:

- Drugs approved under section 505(c) of the FD&C Act that have qualified under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for five-year and three-year periods of exclusivity pursuant to Section 505(c)(3)(E)and Section 505(j)(5)(F)of the FD&C Act
- Drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act
- Drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act
- Drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for 180-day exclusivity pursuant to Section 505(j)(5)(B)(iv)of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j)(5)(B)(v) of the FD&C Act

This section is arranged in alphabetical order by established name of the active ingredient, followed by the proprietary name (brand name or trade name) of the drug product. Active ingredient headings for multiple ingredient fixed-combination drug products are arranged alphabetically.

Individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. Such descriptions of Orphan Drug Exclusivity were included beginning with the 38th edition of the Orange Book.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity.

Patent Information

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. In addition, patent information must be filed on Form FDA 3542 within 30 days of the date of approval of a Section 505(b) drug application.[1] FDA publishes certain information from Form FDA 3542 in the Orange Book after approval of the NDA or supplement.

The Orange Book includes the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder) for each newly listed patent to facilitate assessments of whether patent information is untimely filed with respect to a pending 505(b)(2) application or ANDA.[2]

The patents that FDA regards as covered by the statutory provisions for submission of patent information are:

- Patents that claim the drug substance (i.e., active ingredient(s))
- Drug product patents, which include formulation/composition patents
- Method-of-use patents that claim one or more approved methods of using the approved drug product

This information, as provided by the sponsor on Form FDA 3542, will be published as described above. An NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the Annual Edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

[1] Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see Section 505(x)(1) and (2) of the FD&C Act).

[2] See 21 CFR 314.50(i)(4) and 314.94(a)(12)(vi). The submission date for patent information is determined in accordance with 21 CFR 314.53(d)(5).

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ							
N 205551	001	8129385	Oct 05, 2027	DS DP			
		9242986	Dec 08, 2029	DS DP			
ABALOPARATIDE - TYMLOS							
N 208743	001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
		8148333	Nov 08, 2027	DP			
		8748382	Oct 03, 2027	U-2009			
ABEMACICLIB - VERZENIO							
N 208716	001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251			
ABEMACICLIB - VERZENIO							
N 208716	002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251			
ABEMACICLIB - VERZENIO							
N 208716	003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251			
ABEMACICLIB - VERZENIO							
N 208716	004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135			
		7855211	Dec 15, 2029	DS DP U-2251			
ABIRATERONE ACETATE - ZYTIGA							
N 202379	001					I-765	Feb 07, 2021
ABIRATERONE ACETATE - ZYTIGA							
N 202379	002	8822438	Aug 24, 2027	U-1579	Y	I-765	Feb 07, 2021
		8822438	Aug 24, 2027	U-1580	Y		
		8822438	Aug 24, 2027	U-2235	Y		
ABIRATERONE ACETATE - YONSA							
N 210308	001	10292990	May 20, 2034	U-2535			
		9889144	Mar 17, 2034	DP			
ACALABRUTINIB - CALQUENCE							
N 210259	001	10167291	Jul 01, 2036	DP U-2145		I-817	Nov 21, 2022
		10167291	Jul 01, 2036	DP U-2666		NCE	Oct 31, 2022
		10167291	Jul 01, 2036	DP U-2667		ODE-175	Oct 31, 2024
		10167291	Jul 01, 2036	DP U-2668		ODE-274	Nov 21, 2026
		10167291	Jul 01, 2036	DP U-2669			
		10167291	Jul 01, 2036	DP U-2670			
		10167291	Jul 01, 2036	DP U-2671			
		10239883	Jul 11, 2032	U-2666			
		10239883	Jul 11, 2032	U-2668			
		10272083	Jan 21, 2035	U-2519			
		10272083	Jan 21, 2035	U-2682			
		10272083	Jan 21, 2035	U-2683			
		10272083	Jan 21, 2035	U-2684			
		10272083	Jan 21, 2035	U-2685			
		10272083	Jan 21, 2035	U-2686			
		10272083	Jan 21, 2035	U-2687			
		7459554	Nov 24, 2026	DS			
		9290504	Jul 11, 2032	DS DP			
		9758524	Jul 11, 2032	U-2145			
		9796721	Jul 01, 2036	DS DP U-2145			
		9796721	Jul 01, 2036	DS DP U-2666			
		9796721	Jul 01, 2036	DS DP U-2667			
		9796721	Jul 01, 2036	DS DP U-2668			
		9796721	Jul 01, 2036	DS DP U-2669			
		9796721	Jul 01, 2036	DS DP U-2670			
		9796721	Jul 01, 2036	DS DP U-2671			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN - OFIRMEV								
N	022450	001	10383834	Nov 13, 2028	U-2262		M-196	Jan 27, 2020
			10383834	Nov 13, 2028	U-2621		PED	Jul 27, 2020
			6992218	Jun 06, 2021	DP			
			6992218*PED	Dec 06, 2021				
			9399012	Sep 11, 2031	U-2261			
			9399012	Sep 11, 2031	U-2262			
			9399012*PED	Mar 11, 2032				
			9610265	Nov 13, 2028	U-2263			
			9610265*PED	May 13, 2029				
			9987238	Nov 13, 2028	U-2261			
			9987238*PED	May 13, 2029				
ACETAMINOPHEN - ACETAMINOPHEN								
N	204767	001	8741959	Apr 19, 2030	DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ								
N	208653	001	8461137	Feb 22, 2031	DS DP			
			8748413	Jul 01, 2030	DS DP			
			8828978	Jul 01, 2030	DP			
			9132125	Jul 01, 2030	DS DP U-2249			
			9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ								
N	208653	002	8461137	Feb 22, 2031	DS DP			
			8748413	Jul 10, 2030	DS DP			
			8828978	Jul 01, 2030	DP			
			9132125	Jul 01, 2030	DS DP U-2249			
			9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ								
N	208653	003	8461137	Feb 22, 2031	DS DP			
			8748413	Jul 10, 2030	DS DP			
			8828978	Jul 01, 2030	DP			
			9132125	Jul 01, 2030	DS DP U-2249			
			9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR								
N	204031	001	6488962	Jun 20, 2020	DP			
			7976870	Jun 01, 2027	U-1498			
			8372432	Mar 11, 2029	DP U-1499			
			8377453	Nov 19, 2029	DP U-1499			
			8394408	Mar 11, 2029	DP			
			8597681	Dec 21, 2030	DP			
			8658631	May 16, 2032	DP			
			8668929	Mar 11, 2029	U-1499			
			8741885	May 16, 2032	DP U-1499			
			8980319	Dec 21, 2030	DP			
			8992975	May 16, 2032	DP			
			9050335	May 16, 2032	DP			
			9468636	May 16, 2032	U-1499			
ACETYLCYSTEINE - ACETADOTE								
N	021539	001	8148356	May 21, 2026	DP			
			8399445	Aug 24, 2025	U-1373			
			8653061	Aug 24, 2025	U-1373			
			8722738	Apr 06, 2032	U-1373			
			9327028	Jul 21, 2031	U-1839			
ACETYLCYSTEINE - CETYLEV								
N	207916	001	8747894	May 08, 2032	DP U-1373			
			9427421	May 08, 2032	DP			
			9561204	May 08, 2032	U-1373			
ACETYLCYSTEINE - CETYLEV								
N	207916	002	8747894	May 08, 2032	DP U-1373			
			9427421	May 08, 2032	DP			
			9561204	May 08, 2032	U-1373			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR								
N 202450	001	10034867	Jul 07, 2020		DP U-2513			
		10034867	Jul 07, 2020		DP U-2514			
		10085974	Mar 13, 2029		DP U-2513			
		6681768	Aug 07, 2022		DP			
		7078412	Jul 07, 2020	DS	DP U-2513			
		8051851	Apr 22, 2027		DP			
		9056100	Jul 07, 2020		DP U-2513			
		9333195	Jul 07, 2020		DP U-2513			
		RE46417	Feb 10, 2025	DS	DP U-2513			
ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR								
N 210595	001	10034867	Jul 07, 2020		DP U-2513		NC	Mar 29, 2022
		10034867	Jul 07, 2020		DP U-2514			
		10085974	Mar 13, 2029		DP U-2513			
		6681768	Aug 07, 2022		DP			
		7078412	Jul 07, 2020	DS	DP U-2513			
		7750023	Jul 07, 2020		DP U-2513			
		8051851	Apr 22, 2027		DP			
		8129405	Jul 07, 2020		DP U-2513			
		9056100	Jul 07, 2020		DP U-2513			
		9333195	Jul 07, 2020		DP U-2513			
		RE46417	Feb 10, 2025	DS	DP U-2513			
ACYCLOVIR - AVACLYR								
N 202408	001						ODE-235	Mar 29, 2026
ACYCLOVIR - SITAVIG								
N 203791	001	8592434	Jun 16, 2030		DP U-1460			
		8747896	Jun 03, 2027		DP U-1460			
		8791127	Mar 23, 2027		DP U-1460			
ACYCLOVIR; HYDROCORTISONE - XERESE								
N 022436	001	7223387	Nov 13, 2022		DP U-1006			
		7223387	Nov 13, 2022		DP U-1484			
ADAPALENE - DIFFERIN								
N 021753	001	7579377	Feb 23, 2025		U-818			
		7737181	Aug 29, 2024		DP			
		7834060	Mar 12, 2023		U-1078			
		7838558	Mar 12, 2023		DP			
		7868044	Mar 12, 2023		U-1078			
		8703820	Mar 12, 2023		U-1078			
ADAPALENE - DIFFERIN								
N 022502	001	7998467	May 31, 2028		DP U-1078			
		8435502	Sep 15, 2026		DP U-1078			
		8709392	Sep 15, 2026		DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO								
N 022320	001	7820186	Nov 23, 2025		DP			
		7964202	Sep 01, 2024		DP U-1078			
		8071644	Jul 18, 2027		DP U-1078			
		8080537	Jul 18, 2027		U-1078			
		8105618	Dec 23, 2022		U-1078			
		8129362	Jul 18, 2027		U-1078			
		8241649	Dec 23, 2022		DP			
		8445543	Jul 12, 2027		U-1078			
		8809305	Dec 23, 2022		U-1078			
		8936800	Dec 23, 2022		DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE								
N 207917	001	8445543	Dec 23, 2022		U-1078			
		8703820	Mar 12, 2023		U-1078			
		8729127	Mar 12, 2023		U-1078			
		8785420	Dec 23, 2022		U-1078			
		8809305	Dec 23, 2022		U-1078			
		8936800	Dec 23, 2022		DP U-1078			
		9381179	Mar 12, 2023		U-1078			
		9387187	Mar 12, 2023		U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE									
N	207917	001	9814690	Dec 23, 2022	DP	U-1078			
AFAMELANOTIDE - SCENESSE									
N	210797	001	10076555	Feb 11, 2025		U-2638		NCE	Oct 08, 2024
			8334265	Mar 11, 2029		U-2638		ODE-270	Oct 08, 2026
AFATINIB DIMALEATE - GILOTRIF									
N	201292	001	10004743	Jul 05, 2030	DP			I-763	Jan 12, 2021
			8426586	Oct 10, 2029	DS			ODE-115	Apr 15, 2023
			8545884	Dec 19, 2029	DP			ODE-230	Jan 12, 2025
			9539258	Nov 09, 2026		U-1950		ODE-50	Jul 12, 2020
			RE43431	Jan 22, 2022	DS				
AFATINIB DIMALEATE - GILOTRIF									
N	201292	002	10004743	Jul 05, 2030	DP			I-763	Jan 12, 2021
			8426586	Oct 10, 2029	DS			ODE-115	Apr 15, 2023
			8545884	Dec 19, 2029	DP			ODE-230	Jan 12, 2025
			9539258	Nov 09, 2026		U-1950		ODE-50	Jul 12, 2020
			RE43431	Jan 22, 2022	DS				
AFATINIB DIMALEATE - GILOTRIF									
N	201292	003	10004743	Jul 05, 2030	DP			I-763	Jan 12, 2021
			8426586	Oct 10, 2029	DS			ODE-115	Apr 15, 2023
			8545884	Dec 19, 2029	DP			ODE-230	Jan 12, 2025
			9539258	Nov 09, 2026		U-1950		ODE-50	Jul 12, 2020
			RE43431	Jan 22, 2022	DS				
AIR POLYMER-TYPE A - EXEM FOAM KIT									
N	212279	001	9034300	Oct 15, 2030	DP	U-2663		NCE	Nov 07, 2024
			9259494	May 04, 2035	DP	U-2663			
			9849199	Feb 11, 2036	DP				
ALBUMIN HUMAN - OPTISON									
N	020899	001	6723303	Apr 20, 2021	DP				
ALBUTEROL SULFATE - ACCUNEB									
N	020949	001	6702997	Dec 28, 2021		U-558			
ALBUTEROL SULFATE - ACCUNEB									
N	020949	002	6702997	Dec 28, 2021		U-558			
ALBUTEROL SULFATE - VENTOLIN HFA									
N	020983	001	7500444	Feb 26, 2026	DP				
			7500444*PED	Aug 26, 2026					
			7832351	Jun 19, 2023	DP				
			9861771	Oct 11, 2020	DP				
ALBUTEROL SULFATE - PROAIR HFA									
N	021457	001	10022509	May 18, 2031	DP				
			10022510	May 18, 2031	DP				
			10086156	May 18, 2031	DP				
			7105152	Sep 12, 2023	DP				
			8132712	Sep 07, 2028	DP				
			9463289	May 18, 2031	DP				
			9808587	May 18, 2031	DP				
ALBUTEROL SULFATE - PROAIR RESPICLICK									
N	205636	001	10022510	May 18, 2031	DP				
			10124131	May 18, 2031	DP				
			6701917	Jun 23, 2021	DP				
			6718972	Jun 23, 2021	DP				
			6748947	Jun 23, 2021	DP				
			6871646	Jun 23, 2021	DP				
			7540282	May 06, 2023	DP				
			8006690	Jun 23, 2021	DP				
			8651103	Mar 26, 2028	DP				
			8978966	Jan 13, 2032	DP				
			9216260	Jun 28, 2031	DP				
			9463288	May 19, 2025	DP				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALBUTEROL SULFATE - PROAIR RESPICLICK									
N 205636	001		9731087	May 18, 2031		DP			
ALBUTEROL SULFATE - PROAIR DIGIHALER									
N 205636	002		10022510	May 18, 2031		DP			
			10124131	May 18, 2031		DP			
			6701917	Jun 23, 2021		DP			
			6718972	Jun 23, 2021		DP			
			6748947	Jun 23, 2021		DP			
			6871646	Jun 23, 2021		DP			
			7540282	May 06, 2023		DP			
			8006690	Jun 23, 2021		DP			
			8651103	Mar 26, 2028		DP			
			8978966	Jan 13, 2032		DP			
			9216260	Jun 28, 2031		DP			
			9463288	May 19, 2025		DP			
			9731087	May 18, 2031		DP			
			9782550	Aug 28, 2035		DP			
			9782551	Aug 28, 2035		DP			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB									
N 020950	001		6632842	Dec 28, 2021		U-532			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT									
N 021747	001		6988496	Feb 23, 2020		DP			
			7284474	Aug 26, 2024		DP			
			7396341	Oct 10, 2026		DP			
			7837235	Mar 13, 2028		DP			
			7896264	May 26, 2025		DP			
			7988001	Aug 04, 2021		DP			
			8733341	Oct 16, 2030		DP			
			9027967	Mar 31, 2027		DP			
ALCAFTADINE - LASTACAFT									
N 022134	001		8664215	Dec 23, 2027		U-1493			
ALCOHOL - ABLYSINOL									
N 207987	001							ODE-192	Jun 21, 2025
ALCOHOL - ABLYSINOL									
N 207987	002							ODE-192	Jun 21, 2025
ALECTINIB HYDROCHLORIDE - ALECENSA									
N 208434	001		9126931	May 29, 2031		DS		I-756	Nov 06, 2020
			9365514	Mar 04, 2032		DP		NCE	Dec 11, 2020
			9440922	Jun 09, 2030		DP		ODE-105	Dec 11, 2022
								ODE-159	Nov 06, 2024
ALENDRONATE SODIUM - BINOSTO									
N 202344	001		7488496	Aug 11, 2023		DS DP			
			7964212	Mar 06, 2023		DS DP			
ALISKIREN HEMIFUMARATE - TEKTURNA									
N 021985	001		8617595	Feb 19, 2026		DP			
			8617595*PED	Aug 19, 2026					
ALISKIREN HEMIFUMARATE - TEKTURNA									
N 021985	002		8617595	Feb 19, 2026		DP			
			8617595*PED	Aug 19, 2026					
ALISKIREN HEMIFUMARATE - TEKTURNA									
N 210709	001							NP	Nov 14, 2020
								PED	May 14, 2021
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO									
N 022545	001		8613949	Dec 21, 2029		DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO									
N 022545	002		8613949	Dec 21, 2029		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N 022545	003		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N 022545	004		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	001		8183295	May 16, 2023	DP			
			8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	002		8183295	May 16, 2023	DP			
			8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	003		8183295	May 16, 2023	DP			
			8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	004		8183295	May 16, 2023	DP			
			8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	005		8183295	May 16, 2023	DP			
			8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N 022107	001		8618172	Jul 13, 2028	DP			
			9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N 022107	002		8618172	Jul 13, 2028	DP			
			9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N 022107	003		8618172	Jul 13, 2028	DP			
			9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N 022107	004		8618172	Jul 13, 2028	DP			
			9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA								
N 022217	001		8168616	Jul 03, 2026	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA								
N 022217	002		8168616	Jul 03, 2026	DP			
ALLOPURINOL; LESINURAD - DUZALLO								
N 209203	001		10183012	Nov 26, 2028			U-2104	
			8003681	Aug 25, 2025	DS			
			8084483	Aug 17, 2029			U-2104	
			8283369	Nov 26, 2028			U-2104	
			8357713	Nov 26, 2028	DP		U-2104	
			8546436	Feb 29, 2032	DS			
			8546437	Apr 29, 2029			U-2104	
			9216179	Aug 01, 2031			U-2104	
			9956205	Dec 28, 2031			U-2104	
ALLOPURINOL; LESINURAD - DUZALLO								
N 209203	002		10183012	Nov 26, 2028			U-2104	
			8003681	Aug 25, 2025	DS			
			8084483	Aug 17, 2029			U-2104	
			8283369	Nov 26, 2028			U-2104	
			8357713	Nov 26, 2028	DP		U-2104	
			8546436	Feb 29, 2032	DS			
			8546437	Apr 29, 2029			U-2104	
			9216179	Aug 01, 2031			U-2104	
			9956205	Dec 28, 2031			U-2104	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE - NESINA							
N 022271	001	7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Dec 02, 2025			U-1338	
		8288539	Mar 15, 2025	DS			
		8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA							
N 022271	002	7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Dec 02, 2025			U-1338	
		8288539	Mar 15, 2025	DS			
		8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA							
N 022271	003	7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Dec 02, 2025			U-1338	
		8288539	Mar 15, 2025	DS			
		8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO							
N 203414	001	7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Mar 15, 2025			U-1338	
		8288539	Jun 24, 2025	DS			
		8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO							
N 203414	002	7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Mar 15, 2025			U-1338	
		8288539	Jun 24, 2025	DS			
		8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	001	6329404	Jun 19, 2021	DP		U-1334	
		7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Mar 15, 2025			U-1338	
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	002	6329404	Jun 19, 2021	DP		U-1334	
		7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Mar 15, 2025			U-1338	
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	003	6329404	Jun 19, 2021	DP		U-1334	
		7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Mar 15, 2025			U-1338	
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	004	6329404	Jun 19, 2021	DP		U-1334	
		7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Mar 15, 2025			U-1338	
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	005	6329404	Jun 19, 2021	DP		U-1334	
		7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Mar 15, 2025			U-1338	
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	006	6329404	Jun 19, 2021	DP		U-1334	
		7807689	Jun 27, 2028	DS DP		U-1337	
		8173663	Mar 15, 2025			U-1338	
		8288539	Mar 15, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	006	8637079	Jun 04, 2029	DP			
ALPELISIB - PIQRAY							
N 212526	001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
		8476268	Sep 10, 2029	DS DP			
ALPELISIB - PIQRAY							
N 212526	002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
		8476268	Sep 10, 2029	DS DP			
ALPELISIB - PIQRAY							
N 212526	003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
		8476268	Sep 10, 2029	DS DP			
ALVIMOPAN - ENTEREG							
N 021775	001	6469030	Nov 29, 2020	U-879			
		8112290	Jul 31, 2030	U-1443	Y		
		8645160	Jun 18, 2029	U-1485	Y		
		8946262	Feb 12, 2030	U-1655			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	001	10154971	Dec 04, 2034	U-2459		I-769	Aug 24, 2020
		8389578	Jan 22, 2028	U-2105		ODE-153	Aug 24, 2024
		8741343	Dec 02, 2030	U-2106			
		8796337	Nov 23, 2025	U-2106			
		8889740	Nov 23, 2025	DP			
		8895614	Nov 23, 2025	DP			
		8895615	Nov 23, 2025	U-2106			
		8895616	Nov 23, 2025	U-2106			
		8895617	Nov 23, 2025	U-2106			
		8895618	Nov 23, 2025	DP			
		9867791	Dec 02, 2030	U-2106			
		9867792	Dec 02, 2030	U-2106			
		9867793	Dec 02, 2030	U-2106			
		9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	002	10154971	Dec 04, 2034	U-2459		I-769	Aug 24, 2020
		8389578	Jan 22, 2028	U-2105		ODE-153	Aug 24, 2024
		8741343	Dec 02, 2030	U-2106			
		8796337	Nov 23, 2025	U-2106			
		8889740	Nov 23, 2025	DP			
		8895614	Nov 23, 2025	DP			
		8895615	Nov 23, 2025	U-2106			
		8895616	Nov 23, 2025	U-2106			
		8895617	Nov 23, 2025	U-2106			
		8895618	Nov 23, 2025	DP			
		9867791	Dec 02, 2030	U-2106			
		9867792	Dec 02, 2030	U-2106			
		9867793	Dec 02, 2030	U-2106			
		9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	001	10213393	Feb 15, 2038	U-20			
		10213394	Feb 15, 2038	U-2497			
		10500170	Feb 15, 2038	U-20			
		10500171	Feb 15, 2038	U-2497			
		10500172	Feb 15, 2038	U-2497			
		10512617	Feb 15, 2038	U-2497			
		8252331	Mar 13, 2030	DP			
		8574626	Nov 28, 2025	DP U-20			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	002	10213393	Feb 15, 2038	U-20			
		10213394	Feb 15, 2038	U-2497			
		10500170	Feb 15, 2038	U-20			
		10500171	Feb 15, 2038	U-2497			
		10500172	Feb 15, 2038	U-2497			
		10512617	Feb 15, 2038	U-2497			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - OSMOLEX ER								
N 209410	002		8252331	Mar 13, 2030	DP			
			8574626	Nov 28, 2025	DP U-20			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER								
N 209410	003		10213393	Feb 15, 2038	U-20			
			10213394	Feb 15, 2038	U-2497			
			10500170	Feb 15, 2038	U-20			
			10500171	Feb 15, 2038	U-2497			
			10500172	Feb 15, 2038	U-2497			
			10512617	Feb 15, 2038	U-2497			
			8252331	Mar 13, 2030	DP			
			8574626	Nov 28, 2025	DP U-20			
AMBRISENTAN - LETAIRIS								
N 022081	001		8377933	Dec 11, 2027	U-1754			
			9474752	Dec 11, 2027	U-1754			
			9549926	Oct 14, 2031	U-1965			
AMBRISENTAN - LETAIRIS								
N 022081	002		8377933	Dec 11, 2027	U-1754			
			9474752	Dec 11, 2027	U-1754			
			9549926	Oct 14, 2031	U-1965			
AMIFAMPRIDINE - RUZURGI								
N 209321	001						ODE-244	May 06, 2026
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE								
N 208078	001						NCE	Nov 28, 2023
							ODE-223	Nov 28, 2025
AMIKACIN SULFATE - ARIKAYCE KIT								
N 207356	001		10251900	May 15, 2035	U-2414		ODE-214	Sep 28, 2025
			7718189	Jun 06, 2025	DP U-2415		GAIN	Sep 28, 2030
			8226975	Aug 15, 2028	DP			
			8632804	Dec 05, 2026	U-2416			
			8642075	Dec 05, 2026	DP			
			8679532	Dec 05, 2026	U-2415			
			8802137	Apr 08, 2024	DP U-2414			
			9566234	Jan 18, 2034	DP U-2415			
			9827317	Apr 08, 2024	DP U-2415			
			9895385	May 15, 2035	U-2417			
AMINOCAPROIC ACID - AMINOCAPROIC ACID								
A 212492	001						CGT	May 30, 2020
AMINOCAPROIC ACID - AMINOCAPROIC ACID								
A 212780	001						CGT	Feb 26, 2020
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN								
N 020965	001		10357567	Jan 12, 2038	U-804		I-766	Mar 09, 2021
AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN								
N 208630	001						ODE-146	Jun 06, 2024
AMIODARONE HYDROCHLORIDE - NEXTERONE								
N 022325	001		6869939	May 04, 2022	DP			
			7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE								
N 022325	002		6869939	May 04, 2022	DP			
			7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE								
N 022325	003		6869939	May 04, 2022	DP			
			7635773	Mar 13, 2029	DP			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE								
N 022026	001		6828339	Nov 20, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE								
N	022026	002	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE								
N	022026	003	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI								
N	210045	001	10350171	Jun 14, 2038	DP		NC	May 31, 2021
			9662315	May 22, 2029	DP U-2410			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI								
N	210045	002	10350171	Jun 14, 2038	DP		NC	May 31, 2021
			9662315	May 22, 2029	DP U-2410			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI								
N	210045	003	10350171	Jun 14, 2038	DP		NC	May 31, 2021
			9662315	May 22, 2029	DP U-2410			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT								
N	022314	001	8101599	May 16, 2023	DP			
			8475839	May 16, 2023	DP			
			8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT								
N	022314	002	8101599	May 16, 2023	DP			
			8475839	May 16, 2023	DP			
			8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT								
N	022314	003	8101599	May 16, 2023	DP			
			8475839	May 16, 2023	DP			
			8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT								
N	022314	004	8101599	May 16, 2023	DP			
			8475839	May 16, 2023	DP			
			8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT								
N	022314	005	8101599	May 16, 2023	DP			
			8475839	May 16, 2023	DP			
			8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA								
N	205003	001	6696481	Apr 15, 2023	DS DP U-3			
			7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA								
N	205003	002	6696481	Apr 15, 2023	DS DP U-3			
			7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA								
N	205003	003	6696481	Apr 15, 2023	DS DP U-3			
			7846961	Oct 05, 2029	DS DP U-3			
AMOXICILLIN - MOXATAG								
N	050813	001	6544555	Oct 13, 2020	DS DP U-897			
			6669948	Oct 13, 2020	DS DP U-897			
			6723341	Oct 13, 2020	DS DP U-897			
			8299052	May 07, 2027	U-1304			
			8357394	Dec 08, 2026	DP			
			8778924	Dec 08, 2026	DS DP U-897			
AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR								
N	050785	001	6746692	Apr 04, 2020	DP			
			6783773	Apr 04, 2020	DP			
			6878386	Apr 04, 2020	U-926			
			7217430	Apr 04, 2020	DP U-926			
			7250176	Apr 04, 2020	U-926			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA								
N 213004	001		10238606	Feb 12, 2034	DP			
			9050263	Feb 12, 2034	DP U-2660			
			9498445	Feb 12, 2034	DP U-2660			
			9603806	Feb 12, 2034	DP U-2660			
AMPHETAMINE - ADZENYS ER								
N 204325	001		8709491	Jun 28, 2032	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	001		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	002		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	003		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	004		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	005		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	006		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - DYANAVEL XR								
N 208147	001		10086087	Mar 15, 2027	DP			
			8062667	Mar 29, 2029	DP			
			8597684	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			8883217	Mar 15, 2027	DP			
			9675703	Mar 15, 2027	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10								
N 011522	007		6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20								
N 011522	008		6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5								
N 011522	009		6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30								
N 011522	010		6384020	Jul 06, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5								
N	011522	011	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5								
N	011522	012	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15								
N	011522	013	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	001	6913768	May 24, 2023	DP	U-2025	M-248	Sep 13, 2022
			8846100	Aug 24, 2029	DP		NP	Jun 20, 2020
			9173857	May 12, 2026		U-2025	PED	Mar 13, 2023
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	002	6913768	May 24, 2023	DP	U-2025	M-248	Sep 13, 2022
			8846100	Aug 24, 2029	DP		NP	Jun 20, 2020
			9173857	May 12, 2026		U-2025	PED	Mar 13, 2023
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	003	6913768	May 24, 2023	DP	U-2025	M-248	Sep 13, 2022
			8846100	Aug 24, 2029	DP		NP	Jun 20, 2020
			9173857	May 12, 2026		U-2025	PED	Mar 13, 2023
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	004	6913768	May 24, 2023	DP	U-2025	M-248	Sep 13, 2022
			8846100	Aug 24, 2029	DP		NP	Jun 20, 2020
			9173857	May 12, 2026		U-2025	PED	Mar 13, 2023
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	001	10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	002	10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	003	10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N	209905	004	10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
ANGIOTENSIN II ACETATE - GIAPREZA								
N	209360	001	10028995	Dec 18, 2034		U-2338	NCE	Dec 21, 2022
			10335451	Dec 16, 2029		U-2581		
			10493124	Dec 18, 2034		U-2679		
			10500247	Dec 16, 2029		U-2680		
			10500247	Dec 16, 2029		U-2681		
			9220745	Dec 18, 2034		U-2217		
			9220745	Dec 18, 2034		U-2218		
			9572856	Nov 20, 2030		U-2221		
			9867863	Dec 16, 2029		U-2231		
ANGIOTENSIN II ACETATE - GIAPREZA								
N	209360	002	10028995	Dec 18, 2034		U-2338	NCE	Dec 21, 2022
			10335451	Dec 16, 2029		U-2581		
			10493124	Dec 18, 2034		U-2679		
			10500247	Dec 16, 2029		U-2680		
			10500247	Dec 16, 2029		U-2681		
			9220745	Dec 18, 2034		U-2217		
			9220745	Dec 18, 2034		U-2218		
			9572856	Nov 20, 2030		U-2221		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ANGIOTENSIN II ACETATE - GIAPREZA							
N 209360	002	9867863	Dec 16, 2029	U-2231			
ANIDULAFUNGIN - ERAXIS							
N 021632	001	5965525	Feb 17, 2020	DS DP U-540			
		6960564	Apr 12, 2021	DP U-540			
		7709444	Apr 12, 2021	DP U-540			
ANIDULAFUNGIN - ERAXIS							
N 021632	002	5965525	Feb 17, 2020	DS DP U-540			
		6960564	Apr 12, 2021	DP U-540			
		7709444	Apr 12, 2021	DP U-540			
APALUTAMIDE - ERLEADA							
N 210951	001	10052314	Sep 23, 2033	U-2381		I-808	Sep 17, 2022
		10052314	Sep 23, 2033	U-2382		NCE	Feb 14, 2023
		8445507	Sep 15, 2030	DS DP U-2237			
		8445507	Sep 15, 2030	DS DP U-2624			
		8802689	Mar 27, 2027	U-2237			
		8802689	Mar 27, 2027	U-2624			
		9388159	Mar 27, 2027	DS DP			
		9481663	Jun 04, 2033	DS DP U-2237			
		9481663	Jun 04, 2033	DS DP U-2624			
		9884054	Sep 23, 2033	U-2237			
		9987261	Mar 27, 2027	DP			
APIXABAN - ELIQUIS							
N 202155	001	6967208	Nov 21, 2026	DS DP U-1167			
		6967208	Nov 21, 2026	DS DP U-1200			
		6967208	Nov 21, 2026	DS DP U-1301			
		6967208	Nov 21, 2026	DS DP U-1302			
		6967208	Nov 21, 2026	DS DP U-1323			
		6967208	Nov 21, 2026	DS DP U-1501			
		6967208	Nov 21, 2026	DS DP U-1502			
		6967208	Nov 21, 2026	DS DP U-1729			
		6967208	Nov 21, 2026	DS DP U-1730			
		9326945	Feb 24, 2031	DP			
APIXABAN - ELIQUIS							
N 202155	002	6967208	Nov 21, 2026	DS DP U-1200			
		6967208	Nov 21, 2026	DS DP U-1301			
		6967208	Nov 21, 2026	DS DP U-1302			
		6967208	Nov 21, 2026	DS DP U-1323			
		9326945	Feb 24, 2031	DP			
APREMILAST - OTEZLA							
N 205437	001	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
		10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
		6962940	Mar 19, 2023	U-1504			
		6962940	Mar 19, 2023	U-2656			
		6962940	Mar 19, 2023	U-2657			
		6962940	Mar 19, 2023	U-2658			
		7208516	Mar 19, 2023	U-1505			
		7427638	Feb 16, 2028	DS DP			
		7659302	Mar 19, 2023	U-1505			
		7659302	Mar 19, 2023	U-1595			
		7659302	Mar 19, 2023	U-2657			
		7659302	Mar 19, 2023	U-2658			
		7893101	Dec 09, 2023	DS DP			
		8455536	Mar 19, 2023	U-1505			
		8455536	Mar 19, 2023	U-1595			
		8455536	Mar 19, 2023	U-2657			
		8455536	Mar 19, 2023	U-2658			
		8802717	Mar 19, 2023	U-1561			
		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
		9018243	Mar 19, 2023	U-2656			
		9018243	Mar 19, 2023	U-2657			
		9018243	Mar 19, 2023	U-2658			
		9724330	Mar 19, 2023	U-1561			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA							
N 205437	001	9724330	Mar 19, 2023	U-1595			
		9724330	Mar 19, 2023	U-2656			
		9724330	Mar 19, 2023	U-2657			
		9724330	Mar 19, 2023	U-2658			
		9872854	May 29, 2034	U-2232			
		9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA							
N 205437	002	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
		10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
		6962940	Mar 19, 2023	U-1504			
		6962940	Mar 19, 2023	U-2656			
		6962940	Mar 19, 2023	U-2657			
		6962940	Mar 19, 2023	U-2658			
		7208516	Mar 19, 2023	U-1505			
		7427638	Feb 16, 2028	DS DP			
		7659302	Mar 19, 2023	U-1505			
		7659302	Mar 19, 2023	U-1595			
		7659302	Mar 19, 2023	U-2657			
		7659302	Mar 19, 2023	U-2658			
		7893101	Dec 09, 2023	DS DP			
		8455536	Mar 19, 2023	U-1505			
		8455536	Mar 19, 2023	U-1595			
		8455536	Mar 19, 2023	U-2657			
		8455536	Mar 19, 2023	U-2658			
		8802717	Mar 19, 2023	U-1561			
		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
		9018243	Mar 19, 2023	U-2656			
		9018243	Mar 19, 2023	U-2657			
		9018243	Mar 19, 2023	U-2658			
		9724330	Mar 19, 2023	U-1561			
		9724330	Mar 19, 2023	U-1595			
		9724330	Mar 19, 2023	U-2656			
		9724330	Mar 19, 2023	U-2657			
		9724330	Mar 19, 2023	U-2658			
		9872854	May 29, 2034	U-2232			
		9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA							
N 205437	003	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
		10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
		6962940	Mar 19, 2023	U-1504			
		6962940	Mar 19, 2023	U-2656			
		6962940	Mar 19, 2023	U-2657			
		6962940	Mar 19, 2023	U-2658			
		7208516	Mar 19, 2023	U-1505			
		7427638	Feb 16, 2028	DS DP			
		7659302	Mar 19, 2023	U-1505			
		7659302	Mar 19, 2023	U-1595			
		7659302	Mar 19, 2023	U-2657			
		7659302	Mar 19, 2023	U-2658			
		7893101	Dec 09, 2023	DS DP			
		8455536	Mar 19, 2023	U-1505			
		8455536	Mar 19, 2023	U-1595			
		8455536	Mar 19, 2023	U-2657			
		8455536	Mar 19, 2023	U-2658			
		8802717	Mar 19, 2023	U-1561			
		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
		9018243	Mar 19, 2023	U-2656			
		9018243	Mar 19, 2023	U-2657			
		9018243	Mar 19, 2023	U-2658			
		9724330	Mar 19, 2023	U-1561			
		9724330	Mar 19, 2023	U-1595			
		9724330	Mar 19, 2023	U-2656			
		9724330	Mar 19, 2023	U-2657			
		9724330	Mar 19, 2023	U-2658			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA								
N 205437	003		9872854	May 29, 2034	U-2232			
			9872854	May 29, 2034	U-2233			
APREPITANT - EMEND								
N 021549	001		8258132	Sep 26, 2027	DP U-1743			
			8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND								
N 021549	002		8258132	Sep 26, 2027	DP U-1743			
			8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND								
N 021549	003		8258132	Sep 26, 2027	DP U-1743			
			8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND								
N 207865	001		8258132	Sep 26, 2027	DP U-1916			
APREPITANT - CINVANTI								
N 209296	001		10500208	Sep 18, 2035	DP			
			9561229	Sep 18, 2035	DP U-2161			
			9808465	Sep 18, 2035	U-2161			
			9974742	Sep 18, 2035	DP			
			9974793	Sep 18, 2035	DP			
			9974794	Sep 18, 2035	DP U-2161			
ARFORMOTEROL TARTRATE - BROVANA								
N 021912	001		6472563	Nov 09, 2021	DS			
			6667344	Jun 22, 2021	DP			
			6720453	Nov 09, 2021	DS			
			6814953	Jun 22, 2021	U-793			
			7145036	Nov 09, 2021	DS			
			7348362	Jun 22, 2021	DP U-793			
			7462645	Jun 22, 2021	U-793			
			7465756	Jun 22, 2021	DP			
			7473710	Jun 22, 2021	U-793			
			7541385	Jun 22, 2021	U-793			
			8110706	Nov 09, 2021	DP			
ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE								
N 022434	001		7589106	Sep 26, 2027	DP U-1163			
			7687516	Sep 26, 2027	DP U-1164			
ARIPIPRAZOLE - ABILIFY								
N 021436	001		7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
			8017615	Jun 16, 2024	DP			
			8017615*PED	Dec 16, 2024				
			8580796	Sep 25, 2022	DS			
			8580796*PED	Mar 25, 2023				
			8642600	Jan 28, 2022	U-1492			
			8642600*PED	Jul 28, 2022				
			8642760	Sep 25, 2022	DS			
			8642760*PED	Mar 25, 2023				
			8759350	Mar 02, 2027	U-1529			
			9089567	Jan 28, 2022	U-543			
			9125939	Jul 28, 2026	U-1749			
			9359302	Sep 25, 2022	DS DP U-1859			
			9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY								
N 021436	002		7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
			8017615	Jun 16, 2024	DP			
			8017615*PED	Dec 16, 2024				
			8580796	Sep 25, 2022	DS			
			8580796*PED	Mar 25, 2023				
			8642600	Jan 28, 2022	U-1492			
			8642600*PED	Jul 28, 2022				
			8642760	Sep 25, 2022	DS			
			8642760*PED	Mar 25, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 002	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 003	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 004	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 005	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 006	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 006	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021713 001	6977257	Apr 24, 2022	DP		ODE-80	Dec 12, 2021
	6977257*PED	Oct 24, 2022				
	7053092	Jan 28, 2022	U-839			
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 002	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 003	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 004	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY							
N 021729	004	8580796*PED	Mar 25, 2023				
		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				
		8642760	Sep 25, 2022	DS			
		8642760*PED	Mar 25, 2023				
		9358207	Apr 12, 2020	DP			
		9359302	Sep 25, 2022	DS DP U-1859			
		9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY							
N 021729	005	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
		8017615	Jun 16, 2024	DP			
		8017615*PED	Dec 16, 2024				
		8518421	Jan 24, 2021	DP			
		8518421*PED	Jul 24, 2021				
		8580796	Sep 25, 2022	DS			
		8580796*PED	Mar 25, 2023				
		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				
		8642760	Sep 25, 2022	DS			
		8642760*PED	Mar 25, 2023				
		9358207	Apr 12, 2020	DP			
		9359302	Sep 25, 2022	DS DP U-1859			
		9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY							
N 021866	001	7115587	Jul 21, 2024	DP U-764		ODE-80	Dec 12, 2021
		7115587*PED	Jan 21, 2025				
		7550445	Jul 21, 2024	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	001	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
		8030313	Oct 19, 2024	U-1632			
		8030313	Oct 19, 2024	U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338427	Mar 15, 2025	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8399469	Jun 29, 2025	DS			
		8722679	Oct 19, 2024	DP			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
		9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	002	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
		8030313	Oct 19, 2024	U-1632			
		8030313	Oct 19, 2024	U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338427	Mar 15, 2025	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8399469	Jun 29, 2025	DS			
		8722679	Oct 19, 2024	DP			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
		9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	003	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
		8030313	Oct 19, 2024	U-1632			
		8030313	Oct 19, 2024	U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338427	Mar 15, 2025	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8399469	Jun 29, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	003	8722679	Oct 19, 2024	DP			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
		9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	004	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
		8030313	Oct 19, 2024	U-1632			
		8030313	Oct 19, 2024	U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338427	Mar 15, 2025	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8399469	Jun 29, 2025	DS			
		8722679	Oct 19, 2024	DP			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
		9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202	001	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
		7053092	Jan 28, 2022	U-1529			
		7978064	Sep 14, 2026	DP			
		8017615	Jun 16, 2024	DP			
		8114021	Jun 21, 2030	DP			
		8258962	Nov 25, 2030	DP			
		8545402	Apr 27, 2030	DP			
		8547248	Dec 18, 2030	DP U-2167			
		8580796	Sep 25, 2022	DS			
		8642760	Sep 25, 2022	DS			
		8674825	Apr 09, 2029	DP U-2170			
		8718193	Dec 05, 2029	DP			
		8759350	Mar 02, 2027	U-1529			
		8847766	Mar 29, 2030	DP U-2167			
		8945005	Aug 19, 2029	DP U-2167			
		8956288	Jul 06, 2029	DP U-2167			
		8961412	Nov 17, 2030	DP			
		9060708	Mar 05, 2029	DP			
		9089567	Jan 28, 2022	U-543			
		9119554	Dec 16, 2028	DP			
		9125939	Jul 28, 2026	U-1749			
		9149577	Dec 15, 2029	DP			
		9258035	Mar 05, 2029	DP			
		9268909	Oct 15, 2033	DP U-2168			
		9320455	Dec 15, 2031	DP			
		9359302	Sep 25, 2022	DS DP U-1529			
		9359302	Sep 25, 2022	DS DP U-1749			
		9359302	Sep 25, 2022	DS DP U-543			
		9387182	Dec 25, 2023	U-1529			
		9433371	Sep 15, 2029	DP			
		9444503	Nov 19, 2027	DP U-2169			
		9577864	Oct 03, 2033	DP U-2169			
		9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202	002	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
		7053092	Jan 28, 2022	U-1529			
		7978064	Sep 14, 2026	DP			
		8017615	Jun 16, 2024	DP			
		8114021	Jun 21, 2030	DP			
		8258962	Nov 25, 2030	DP			
		8545402	Apr 27, 2030	DP			
		8547248	Dec 18, 2030	DP U-2167			
		8580796	Sep 25, 2022	DS			
		8642760	Sep 25, 2022	DS			
		8674825	Apr 09, 2029	DP U-2170			
		8718193	Dec 05, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 002	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 004	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT							
N 209830	001	10016415	Sep 08, 2035	DP		NCE	Oct 05, 2020
		10112903	Jun 24, 2030	DS U-543			
		8431576	Oct 26, 2030	DS			
		8796276	Jun 24, 2030	U-543			
ARMODAFINIL - NUVIGIL							
N 021875	001	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL							
N 021875	002	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL							
N 021875	003	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL							
N 021875	004	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL							
N 021875	005	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARSENIC TRIOXIDE - TRISENOX							
N 021248	001					ODE-167	Jan 12, 2025
ARSENIC TRIOXIDE - TRISENOX							
N 021248	002					ODE-167	Jan 12, 2025
ASCORBIC ACID - ASCOR							
N 209112	001					ODE-160	Oct 02, 2024
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP							
N 021881	001	7169381	Sep 01, 2024	DS DP			
		7658914	Sep 01, 2024	DS DP			
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU							
N 209381	001	10016504	Sep 10, 2033	DP		NP	May 04, 2021
		8999313	Sep 10, 2033	DP			
		9326969	Sep 10, 2033	U-2310			
		9592252	Aug 11, 2032	DP U-2310			
		9707297	Sep 10, 2033	DP			
ASENAPINE - SECUADO							
N 212268	001	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
		9687474	Jul 25, 2033	DP			
ASENAPINE - SECUADO							
N 212268	002	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
		9687474	Jul 25, 2033	DP			
ASENAPINE - SECUADO							
N 212268	003	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
		9687474	Jul 25, 2033	DP			
ASENAPINE MALEATE - SAPHRIS							
N 022117	001	5763476	Jun 09, 2020	DP U-1960		D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961		I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1962			
		5763476	Jun 09, 2020	DP U-1963			
		5763476	Jun 09, 2020	DP U-326			
		5763476*PED	Dec 09, 2020				
		7741358	Apr 06, 2026	DS DP U-1064			
		7741358	Apr 06, 2026	DS DP U-1960			
		7741358	Apr 06, 2026	DS DP U-1961			
		7741358	Apr 06, 2026	DS DP U-1962			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASENAPINE MALEATE - SAPHRIS							
N 022117	001	7741358	Apr 06, 2026	DS DP U-1963			
		7741358*PED	Oct 06, 2026				
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS							
N 022117	002	5763476	Jun 09, 2020	DP U-1960		D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961		I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1962			
		5763476	Jun 09, 2020	DP U-1963			
		5763476	Jun 09, 2020	DP U-326			
		5763476*PED	Dec 09, 2020				
		7741358	Apr 06, 2026	DS DP U-1064			
		7741358	Apr 06, 2026	DS DP U-1960			
		7741358	Apr 06, 2026	DS DP U-1961			
		7741358	Apr 06, 2026	DS DP U-1962			
		7741358	Apr 06, 2026	DS DP U-1963			
		7741358*PED	Oct 06, 2026				
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS							
N 022117	003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
		5763476*PED	Dec 09, 2020				
		7741358	Apr 06, 2026	DS DP U-1893			
		7741358	Apr 06, 2026	DS DP U-1966			
		7741358*PED	Oct 06, 2026				
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASPIRIN - VAZALORE							
N 203697	001	8865187	Mar 23, 2022	DP			
		9101637	Mar 23, 2022	U-1731			
		9101637	Mar 23, 2022	U-1732			
		9101637	Mar 23, 2022	U-1733			
		9216150	Sep 29, 2032	DP			
		9226892	Sep 29, 2032	U-1731			
		9226892	Sep 29, 2032	U-1732			
		9226892	Sep 29, 2032	U-1733			
		9351984	Dec 19, 2021	DP			
ASPIRIN; OMEPRAZOLE - YOSPRALA							
N 205103	001	6926907	Feb 28, 2023	DP U-1902			
		8206741	Feb 28, 2023	DP U-1902			
		9364439	May 31, 2022	DP U-1902			
		9539214	Mar 13, 2033	U-1902			
		9987231	Jan 02, 2033	U-2324			
ASPIRIN; OMEPRAZOLE - YOSPRALA							
N 205103	002	6926907	Feb 28, 2023	DP U-1902			
		8206741	Feb 28, 2023	DP U-1902			
		9364439	May 31, 2022	DP U-1902			
		9539214	Mar 13, 2033	U-1902			
		9987231	Jan 02, 2033	U-2324			
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ							
N 206353	001	10039718	Oct 04, 2032	DP			
		8148374	Sep 03, 2029	DS DP U-1279			
ATORVASTATIN CALCIUM - LIPITOR							
N 020702	001					M-204	Jun 23, 2020
ATORVASTATIN CALCIUM - LIPITOR							
N 020702	002					M-204	Jun 23, 2020
AVANAFIL - STENDRA							
N 202276	001	6656935	Apr 27, 2025	DS DP U-155			
		7501409	May 05, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVANAFIL - STENDRA								
N 202276	001		6656935	Apr 27, 2025	DS DP U-155			
			7501409	May 05, 2023	DP			
AVANAFIL - STENDRA								
N 202276	002		6656935	Apr 27, 2025	DS DP U-155			
			7501409	May 05, 2023	DP			
AVANAFIL - STENDRA								
N 202276	003		6656935	Apr 27, 2025	DS DP U-155			
			7501409	May 05, 2023	DP			
AVATROMBOPAG MALEATE - DOPTELET								
N 210238	001		7638536	May 05, 2025	DS DP		I-802	Jun 26, 2022
			8338429	Jun 30, 2023	U-2577		NCE	May 21, 2023
			8765764	Jan 15, 2023	U-2314		ODE-246	Jun 26, 2026
			8765764	Jan 15, 2023	U-2578			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ								
N 206494	001		7112592	Feb 24, 2022	DS DP U-2244			
			7112592	Feb 24, 2022	DS DP U-2508			
			7112592	Feb 24, 2022	DS DP U-282			
			7612087	Nov 12, 2026	DP			
			8178554	Jul 24, 2021	DS DP U-2245			
			8178554	Jul 24, 2021	DS DP U-2509			
			8178554	Jul 24, 2021	DS DP U-282			
			8471025	Aug 12, 2031	DS			
			8835455	Oct 08, 2030	DP			
			8969566	Jun 15, 2032	DS			
			9284314	Jun 15, 2032	DS			
			9695122	Jun 15, 2032	DS			
AXITINIB - INLYTA								
N 202324	001		6534524	Apr 29, 2025	DS DP			
			7141581	Jun 30, 2020	U-1220			
			8791140	Dec 14, 2030	DS			
AXITINIB - INLYTA								
N 202324	002		6534524	Apr 29, 2025	DS DP			
			7141581	Jun 30, 2020	U-1220			
			8791140	Dec 14, 2030	DS			
AZELAIC ACID - FINACEA								
N 207071	001		10117812	Oct 18, 2027	DP U-1796			
			10322085	Oct 24, 2023	DP			
			7700076	Sep 18, 2027	DP			
			8435498	Mar 01, 2024	U-1727			
			8722021	Oct 24, 2023	DP			
			8900554	Oct 24, 2023	DP			
			9211259	Feb 28, 2029	U-1796			
			9265725	Dec 08, 2027	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO								
N 022203	001		8071073	Jun 04, 2028	DP			
			8518919	Nov 22, 2025	U-1430			
AZELASTINE HYDROCHLORIDE - ASTEPRO								
N 022203	002		8071073	Jun 04, 2028	DP			
			8518919	Nov 22, 2025	U-1430			
			9919050	Nov 22, 2025	DP			
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA								
N 202236	001		8163723	Aug 29, 2023	U-1667			
			8163723	Aug 29, 2023	U-644			
			8163723	Aug 29, 2023	U-707			
			8163723	Aug 29, 2023	U-77			
			8163723	Aug 29, 2023	U-81			
			8163723*PED	Feb 29, 2024				
			8168620	Feb 24, 2026	DP			
			9259428	Jun 13, 2023	U-644			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA							
N 202236	001	9259428*PED	Dec 13, 2023				
		9901585	Jun 13, 2023	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	001	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
		9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	002	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
		9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331	001	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
		9066936	Mar 26, 2028	DP			
		9169238	Feb 04, 2030	DP			
		9387249	Jul 01, 2031	U-3			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331	002	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
		9066936	Mar 26, 2028	DP			
		9169238	Feb 04, 2030	DP			
		9387249	Jul 01, 2031	U-3			
AZITHROMYCIN - ZMAX							
N 050797	001	6984403	Feb 14, 2024	DP U-282			
		7887844	Feb 14, 2024	DP			
AZTREONAM - CAYSTON							
N 050814	001	7208141	Dec 20, 2021	DP U-1031			
		7214364	Dec 20, 2021	DP			
		7427633	Dec 20, 2021	DP U-1031			
		8399496	Dec 20, 2021	DP U-1377			
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854	001	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
		8927710	May 05, 2031	DP		NCE	Oct 24, 2023
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854	002	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
		8927710	May 05, 2031	DP		NCE	Oct 24, 2023
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALSALAZIDE DISODIUM - COLAZAL							
N 020610	001	7452872	Aug 24, 2026	U-141			
		7625884	Aug 24, 2026	U-141			
BALSALAZIDE DISODIUM - GIAZO							
N 022205	001	7452872	Aug 24, 2026	U-1229			
		7625884	Aug 24, 2026	U-1229			
		8497256	Jun 23, 2031	U-1229			
		9192616	Aug 02, 2026	U-1229			
BARICITINIB - OLUMIANT							
N 207924	001	8158616	Jun 08, 2030	DS DP		NCE	May 31, 2023
		8420629	Mar 10, 2029	U-247			
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE							
N 022247	001	6479535	May 06, 2024	DP U-594			
		6479535	May 06, 2024	DP U-904			
		7683051	Mar 10, 2027	DS DP U-594			
		7683051	Mar 10, 2027	DS DP U-904			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BECLOMETHASONE DIPROPIONATE - QVAR 80							
N 020911	001	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		9463289	May 18, 2031	DP			
		9808587	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR 40							
N 020911	002	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		9463289	May 18, 2031	DP			
		9808587	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QNASL							
N 202813	001	10188811	Oct 21, 2031	DP			
		7780038	Jan 24, 2027	DP			
BECLOMETHASONE DIPROPIONATE - QNASL							
N 202813	002	10188811	Oct 21, 2031	DP			
		7780038	Jan 24, 2027	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	001	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		7637260	Aug 25, 2020	DP			
		8132712	Sep 07, 2028	DP			
		8931476	Jul 17, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	002	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		7637260	Aug 25, 2020	DP			
		8132712	Sep 07, 2028	DP			
		8931476	Jul 17, 2031	DP			
BEDAQUILINE FUMARATE - SIRTURO							
N 204384	001	7498343	Dec 01, 2026	DS DP U-1321		NPP	Aug 09, 2022
		8546428	Mar 19, 2029	DS DP U-1321		ODE-251	Aug 09, 2026
BELINOSTAT - BELEODAQ							
N 206256	001	6888027	Sep 27, 2021	DS DP U-1544		ODE-68	Jul 03, 2021
		8835501	Oct 27, 2027	DP			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	001	8436190	Oct 26, 2030	DP			
		8436190*PED	Apr 26, 2031				
		8445524	Mar 26, 2029	DS DP U-1402			
		8445524*PED	Sep 26, 2029				
		8609863	Jan 12, 2026	DP			
		8609863*PED	Jul 12, 2026				
		8669279	Mar 26, 2029	DP U-1402			
		8669279*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
		8883836	Mar 26, 2029	DP U-1402			
		8883836*PED	Sep 26, 2029				
		8895756	Jan 12, 2026	DP			
		8895756*PED	Jul 12, 2026				
		9533955	Mar 26, 2029	DP U-1949			
		9533955	Mar 26, 2029	DP U-1952			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	002	8436190	Oct 26, 2030	DP			
		8436190*PED	Apr 26, 2031				
		8445524	Mar 26, 2029	DS DP U-1402			
		8445524*PED	Sep 26, 2029				
		8609863	Jan 12, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	002	8609863*PED	Jul 12, 2026				
		8669279	Mar 26, 2029	DP U-1402			
		8669279*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
		8883836	Mar 26, 2029	DP U-1402			
		8883836*PED	Sep 26, 2029				
		8895756	Jan 12, 2026	DP			
		8895756*PED	Jul 12, 2026				
		9533955	Mar 26, 2029	DP U-1949			
		9533955	Mar 26, 2029	DP U-1952			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	003	8344006	Sep 23, 2029	DP U-1402			
		8344006*PED	Mar 23, 2030				
		8445524	Mar 26, 2029	DS			
		8445524*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	004	8344006	Sep 23, 2029	DP U-1402			
		8344006*PED	Mar 23, 2030				
		8445524	Mar 26, 2029	DS			
		8445524*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO							
N 205580	001	10010533	Jan 28, 2031	DP			
		8609707	Aug 11, 2031	DP U-1971			
		8609707	Aug 11, 2031	DP U-1972			
		8791270	Jan 12, 2026	DP U-1971			
		8791270	Jan 12, 2026	DP U-1972			
		9265831	Jan 28, 2031	DP			
		9572796	Jan 28, 2031	DP U-1971			
		9572796	Jan 28, 2031	DP U-1972			
		9572797	Jan 28, 2031	U-1971			
		9572797	Jan 28, 2031	U-1972			
BENDAMUSTINE HYDROCHLORIDE - BENDEKA							
N 208194	001	10010533	Jan 28, 2031	DP		ODE-179	Dec 07, 2022
		10052385	Mar 15, 2033	U-1971			
		10052385	Mar 15, 2033	U-1972			
		8609707	Aug 11, 2031	DP U-1542			
		8791270	Jan 12, 2026	DP U-1790			
		9000021	Mar 15, 2033	U-1542			
		9034908	Mar 15, 2033	U-1542			
		9144568	Mar 15, 2033	U-1542			
		9265831	Jan 28, 2031	DP			
		9572796	Jan 28, 2031	DP U-1971			
		9572796	Jan 28, 2031	DP U-1972			
		9572797	Jan 28, 2031	U-1971			
		9572797	Jan 28, 2031	U-1972			
		9572887	Mar 15, 2033	U-1971			
		9572887	Mar 15, 2033	U-1972			
		9579384	Mar 15, 2033	U-1971			
		9579384	Mar 15, 2033	U-1972			
		9597397	Mar 15, 2033	U-1971			
		9597397	Mar 15, 2033	U-1972			
		9597398	Mar 15, 2033	U-1971			
		9597399	Mar 15, 2033	U-1971			
		9597399	Mar 15, 2033	U-1972			
BENZNIDAZOLE - BENZNIDAZOLE							
N 209570	001					NCE	Aug 29, 2022
						ODE-154	Aug 29, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENZNIDAZOLE - BENZNIDAZOLE								
N 209570	002						NCE	Aug 29, 2022
							ODE-154	Aug 29, 2024
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA								
N 050819	001	10220049	Jun 03, 2029		DP U-916			
		8288434	Aug 05, 2029		DP U-124			
		8663699	Jun 03, 2029		U-124			
		8895070	Jun 03, 2029		U-124			
		9078870	Jun 03, 2029		DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON								
N 050819	002	10137142	Jun 03, 2029		DP U-916			
		10220049	Jun 03, 2029		DP U-916			
		8288434	Aug 05, 2029		DP U-1033			
		8288434	Aug 05, 2029		DP U-124			
		8288434	Aug 05, 2029		DP U-134			
		8288434	Aug 05, 2029		DP U-818			
		8288434	Aug 05, 2029		DP U-916			
		8288434	Aug 05, 2029		DP U-921			
		9504704	Jun 03, 2029		DP U-124			
		9504704	Jun 03, 2029		DP U-134			
		9504704	Jun 03, 2029		DP U-818			
		9504704	Jun 03, 2029		DP U-916			
		9561208	Jun 03, 2029		DP U-916			
BENZYL ALCOHOL - ULESFIA								
N 022129	001	6793931	Jul 11, 2022		DP U-970			
		7294342	May 19, 2024		U-970			
BEPOTASTINE BESILATE - BEPREVE								
N 022288	001	8784789	Sep 05, 2024		DP			
		8877168	Jul 30, 2023		DP			
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE								
N 022308	001	6685958	Jun 29, 2021		DP U-80			
		8415342	Nov 07, 2030		U-80			
		8481526	Jan 09, 2031	DS				
		8604020	Mar 12, 2030		DP			
		8937062	Nov 13, 2029		U-80			
BETAMETHASONE DIPROPIONATE - SERNIVO								
N 208079	001	10179137	Aug 31, 2030		DP U-1858			
		9364485	Aug 31, 2030		DP U-1858			
		9433630	Aug 31, 2030		DP U-1858			
		9439911	Aug 31, 2030		DP U-1858			
		9655907	Aug 31, 2030		DP U-1858			
		9775851	Aug 31, 2030		DP U-1858			
		9877974	Aug 31, 2030		DP U-1858			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX								
N 021852	001	6753013	Jan 27, 2020		DP U-193			
		6753013	Jan 27, 2020		DP U-88			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX								
N 022185	001	6753013	Jan 27, 2020		DP U-1761		NPP	Jul 25, 2022
		6753013	Jan 27, 2020		DP U-193		PED	Jan 25, 2023
		6753013	Jan 27, 2020		DP U-88			
		6787529	Jan 27, 2020		DP U-1761			
		6787529	Jan 27, 2020		DP U-193			
		6787529	Jan 27, 2020		DP U-88			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR								
N 207589	001	10130640	Jun 10, 2031		DP		NPP	Jul 30, 2022
		10130640*PED	Dec 10, 2031				PED	Jan 30, 2023
		6753013	Jan 27, 2020		DP U-1761			
		6753013	Jan 27, 2020		DP U-2627			
		9119781	Jun 10, 2031		DP U-1761			
		9119781	Jun 10, 2031		DP U-2627			
		9119781*PED	Dec 10, 2031					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR							
N 207589	001	9566286	Jun 10, 2031	DP			
BETRIXABAN - BEVYXXA							
N 208383	001	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502			
		6376515	Sep 15, 2020	DS DP U-2029			
		6376515	Sep 15, 2020	DS DP U-2030			
		6835739	Sep 15, 2020	DS DP			
		7598276	Nov 08, 2026	DS			
		8404724	Mar 29, 2031	DP U-2034			
		8518977	Sep 15, 2020	DS			
		8557852	Sep 08, 2028	U-1167			
		8557852	Sep 08, 2028	U-2030			
		8691847	Sep 15, 2020	DS DP U-2029			
		8691847	Sep 15, 2020	DS DP U-2035			
		8987463	Dec 28, 2030	DP			
		9555023	Nov 07, 2026	U-1502			
		9629831	Sep 15, 2020	U-1167			
		9629831	Sep 15, 2020	U-1502			
		9629831	Sep 15, 2020	U-2030			
		9629831	Sep 15, 2020	U-2035			
BETRIXABAN - BEVYXXA							
N 208383	002	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502			
		6376515	Sep 15, 2020	DS DP U-2029			
		6376515	Sep 15, 2020	DS DP U-2030			
		6835739	Sep 15, 2020	DS DP			
		7598276	Nov 08, 2026	DS			
		8404724	Mar 29, 2031	DP U-2034			
		8518977	Sep 15, 2020	DS			
		8557852	Sep 08, 2028	U-1167			
		8557852	Sep 08, 2028	U-2030			
		8691847	Sep 15, 2020	DS DP U-2029			
		8691847	Sep 15, 2020	DS DP U-2035			
		8987463	Dec 28, 2030	DP			
		9555023	Nov 07, 2026	U-1502			
		9629831	Sep 15, 2020	U-1167			
		9629831	Sep 15, 2020	U-1502			
		9629831	Sep 15, 2020	U-2030			
		9629831	Sep 15, 2020	U-2035			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY							
N 210251	001	10385067	Jun 19, 2035	U-257		NCE	Feb 07, 2023
		6642245	Nov 04, 2020	U-257		NPP	Jun 18, 2022
		6703396	Mar 09, 2021	DS DP		ODE-256	Jun 18, 2026
		7390791	May 07, 2022	DS DP			
		7803788	Feb 02, 2022	U-257			
		8754065	Aug 15, 2032	DS DP U-257			
		9216996	Dec 19, 2033	DS DP			
		9296769	Aug 15, 2032	DS DP U-257			
		9708342	Jun 19, 2035	DS DP			
		9732092	Dec 19, 2033	DS DP			
BIMATOPROST - LUMIGAN							
N 022184	001	7851504	Jun 13, 2027	DS DP			
		8278353	Mar 16, 2025	DP			
		8299118	Mar 16, 2025	U-1295			
		8309605	Mar 16, 2025	U-1293			
		8309605	Mar 16, 2025	U-1294			
		8338479	Mar 16, 2025	DP U-1295			
		8524777	Mar 16, 2025	U-1235			
		8586630	Mar 16, 2025	U-1458			
		8772338	Mar 16, 2025	DP U-1528			
		8933120	Mar 16, 2025	DP			
		8933127	Mar 16, 2025	DP			
		9155716	Mar 16, 2025	DP U-1528			
		9241918	Mar 16, 2025	DP U-1814			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BIMATOPROST - LATISSE							
N 022369	001	8038988	Aug 25, 2023	DS DP U-1208			
		8101161	May 25, 2024	U-1217			
		8101161	May 25, 2024	U-1218			
		8263054	Jan 15, 2023	U-1277			
		8541466	Jan 31, 2021	U-1217			
		8632760	Jan 15, 2023	U-1487			
		8758733	Jan 15, 2023	U-1487			
		8906962	Jan 31, 2021	U-1217			
		8986715	Jan 15, 2023	U-1217			
		9216183	Jan 15, 2023	U-1487			
		9226931	Jan 15, 2023	U-1799			
		9579270	Jan 31, 2021	U-1975			
BINIMETINIB - MEKTOVI							
N 210498	001	10005761	Aug 27, 2030	U-2331		NCE	Jun 27, 2023
		7777050	Mar 13, 2023	DS DP		ODE-194	Jun 27, 2025
		8178693	Mar 13, 2023	DS DP			
		8193229	Mar 13, 2023	U-2330			
		8513293	Mar 13, 2023	U-2331			
		9314464	Jul 04, 2031	U-2332			
		9562016	Oct 18, 2033	DS DP			
		9593100	Aug 27, 2030	DP			
		9598376	Oct 18, 2033	U-2330			
		9850229	Aug 27, 2030	U-2333			
		9980944	Oct 18, 2033	U-2334			
BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY							
N 021551	003	7291324	Oct 22, 2022	U-837			
BIVALIRUDIN - ANGIOMAX							
N 020873	001	7582727	Jul 27, 2028	DP			
		7598343	Jul 27, 2028	DP			
BOCEPREVIR - VICTRELIS							
N 202258	001	7772178	Nov 11, 2027	DP U-1128			
		8119602	Mar 17, 2027	U-1233			
		RE43298	Dec 22, 2024	DS DP U-1128			
BORTEZOMIB - VELCADE							
N 021602	001	6713446	Jan 25, 2022	DS DP		ODE-76	Oct 08, 2021
		6713446*PED	Jul 25, 2022			PED	Apr 08, 2022
		6958319	Jan 25, 2022	DS DP			
		6958319*PED	Jul 25, 2022				
BORTEZOMIB - BORTEZOMIB							
N 205004	001	8962572	Nov 03, 2032	DP			
BOSENTAN - TRACLEER							
N 021290	001					NPP	Sep 05, 2020
BOSENTAN - TRACLEER							
N 021290	002					NPP	Sep 05, 2020
BOSENTAN - TRACLEER							
N 209279	001	7959945	Dec 28, 2027	DP		NP	Sep 05, 2020
		8309126	May 15, 2026	DP		ODE-161	Sep 05, 2024
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	001	7417148	Dec 11, 2025	U-1283		I-759	Dec 19, 2020
		7767678	Nov 23, 2026	DS DP		ODE-163	Dec 19, 2024
		7919625	Dec 11, 2025	DP			
		RE42376	Apr 13, 2024	DS			
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	002	7417148	Dec 11, 2025	U-1283		I-759	Dec 19, 2020
		7767678	Nov 23, 2026	DS DP		ODE-163	Dec 19, 2024
		7919625	Dec 11, 2025	DP			
		RE42376	Apr 13, 2024	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	003	7417148	Dec 11, 2025	U-1283		I-759	Dec 19, 2020
		7767678	Nov 23, 2026	DS DP		ODE-163	Dec 19, 2024
		7919625	Dec 11, 2025	DP			
		RE42376	Apr 13, 2024	DS			
BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)							
N 210557	001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
		6579968	Jun 28, 2020	DS DP			
		6794489	Jun 28, 2020	DS DP			
		9352013	Nov 05, 2033	U-2568			
		9700592	Nov 05, 2033	U-2568			
BREXANOLONE - ZULRESSO							
N 211371	001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
		10251894	Nov 27, 2033	U-2552			
		10322139	Jan 23, 2033	DP			
		7635773	Mar 13, 2029	DP			
		8410077	Mar 13, 2029	DP			
		9200088	Mar 13, 2029	DP			
		9750822	Mar 13, 2029	DP			
BREXPIPRAZOLE - REXULTI							
N 205422	001	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	Apr 12, 2026	DS			
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	002	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	Apr 12, 2026	DS			
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	003	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	Apr 12, 2026	DS			
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	004	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	Apr 12, 2026	DS			
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	005	10307419	Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	Apr 12, 2026	DS			
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	006	7888362	Apr 12, 2026	DS		NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIGATINIB - ALUNBRIG							
N 208772	001	10385078	Nov 10, 2035	DS DP U-1927		NCE	Apr 28, 2022
		9012462	Jul 31, 2030	DS		ODE-142	Apr 28, 2024
		9273077	May 21, 2029	U-1927			
		9611283	Apr 10, 2034	U-1927			
BRIGATINIB - ALUNBRIG							
N 208772	002	10385078	Nov 10, 2035	DS DP U-1927		NCE	Apr 28, 2022
		9012462	Jul 31, 2030	DS		ODE-142	Apr 28, 2024
		9273077	May 21, 2029	U-1927			
		9611283	Apr 10, 2034	U-1927			
BRIGATINIB - ALUNBRIG							
N 208772	003	10385078	Nov 10, 2035	DS DP U-1927		NCE	Apr 28, 2022
		9012462	Jul 31, 2030	DS		ODE-142	Apr 28, 2024
		9273077	May 21, 2029	U-1927			
		9611283	Apr 10, 2034	U-1927			
BRIMONIDINE TARTRATE - ALPHAGAN P							
N 021262	001	6562873	Jul 10, 2021				
		6627210	Jul 18, 2021	DP			
		6641834	Jul 28, 2021	DP			
		6673337	Jul 26, 2021	DP			
		9295641	Jul 10, 2021	U-1833			
		9295641*PED	Jan 10, 2022				
BRIMONIDINE TARTRATE - QOLIANA							
N 021764	001	7265117	Aug 19, 2025	DP			
BRIMONIDINE TARTRATE - ALPHAGAN P							
N 021770	001	10307368	Jul 10, 2021	DP			
		6562873	Jul 10, 2021	DP			
		6627210	Jul 18, 2021	DP			
		6641834	Jul 28, 2021	DP			
		6673337	Jul 26, 2021	DP			
		8858961	Sep 02, 2023	DP			
		8858961*PED	Mar 02, 2024				
		9295641	Jul 10, 2021	U-1833			
		9295641*PED	Jan 10, 2022				
		9687443	Jul 10, 2021	DP			
		9687443*PED	Jan 10, 2022				
BRIMONIDINE TARTRATE - MIRVASO							
N 204708	001	10201517	Jun 13, 2031	DP			
		7439241	Aug 25, 2025	U-1428			
		8053427	Jun 13, 2031	DP U-1428			
		8163725	Jun 13, 2031	DP			
		8231885	May 24, 2025	DP			
		8410102	May 24, 2025	U-1428			
		8426410	May 24, 2025	U-1428			
		8513247	Mar 25, 2031	DP U-1428			
		8513249	Mar 25, 2031	DP U-1428			
		8859551	May 25, 2024	U-1428			
		9861631	Mar 25, 2031	U-1428			
		9861632	Mar 25, 2031	U-1428			
BRIMONIDINE TARTRATE - LUMIFY							
N 208144	001	8293742	Jul 14, 2030	U-2222		NP	Dec 22, 2020
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA							
N 204251	001	9044484	Oct 30, 2030	DP			
		9421265	Jun 17, 2030	DP			
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN							
N 021398	001	7030149	Apr 19, 2022	U-849			
		7320976	Apr 19, 2022	U-849			
		7323463	Jan 19, 2023	DP	Y		
		7642258	Apr 19, 2022	DS DP U-1024			
		8133890	Apr 19, 2022	U-1235			
		8354409	Apr 19, 2022	DP U-1371			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN							
N 021398	001	8748425	Apr 19, 2022	DP U-1524			
		9474751	Apr 19, 2022	DP U-1524			
		9770453	Apr 19, 2022	DP U-2131			
		9907801	Apr 19, 2022	DP U-2239			
		9907802	Apr 19, 2022	DP U-2240			
BRIVARACETAM - BRIVIACT							
N 205836	001	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
		6911461	Feb 21, 2021	DS DP U-2295			
		8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT							
N 205836	002	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
		6911461	Feb 21, 2021	DS DP U-2295			
		8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT							
N 205836	003	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
		6911461	Feb 21, 2021	DS DP U-2295			
		8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT							
N 205836	004	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
		6911461	Feb 21, 2021	DS DP U-2295			
		8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT							
N 205836	005	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
		6911461	Feb 21, 2021	DS DP U-2295			
		8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT							
N 205837	001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
		6784197	Feb 21, 2021	DS DP U-2130			
		6911461	Feb 21, 2021	DS DP U-1815			
		6911461	Feb 21, 2021	DS DP U-2130			
		8492416	Feb 21, 2021	U-1815			
		8492416	Feb 21, 2021	U-2130			
BRIVARACETAM - BRIVIACT							
N 205838	001	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
		6911461	Feb 21, 2021	DS DP U-2295			
		8492416	Feb 21, 2021	U-2295			
BROMFENAC SODIUM - PROLENSA							
N 203168	001	10085958	Nov 19, 2032	DP			
		8129431	Sep 11, 2025	DS DP			
		8669290	Jan 16, 2024	DP			
		8754131	Jan 16, 2024	DP			
		8871813	Jan 16, 2024	DP			
		8927606	Jan 16, 2024	U-100			
		8927606	Jan 16, 2024	U-1095			
		8927606	Jan 16, 2024	U-810			
		9144609	Jan 16, 2024	DP			
		9517220	Nov 11, 2033	U-1933			
		9561277	Jan 16, 2024	U-1933			
BROMFENAC SODIUM - BROMSITE							
N 206911	001	8778999	Aug 07, 2029	DP U-1834			
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866	001	7888310	Jul 25, 2023	U-1433			
		8137992	Jul 25, 2023	U-1433			
		8137993	Jul 25, 2023	U-1433			
		8137994	Jul 25, 2023	U-1433			
		8431155	Apr 30, 2032	DP U-976			
		8613947	Apr 30, 2032	DP U-976			
		8877708	Jun 07, 2030	DP U-1706			
		9192576	Apr 30, 2032	DP U-976			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866	001	9352025	Jun 07, 2030	U-2111			
		9352025	Jun 07, 2030	U-2112			
		9352025	Jun 07, 2030	U-2113			
		9352025	Jun 07, 2030	U-2114			
		9352025	Jun 07, 2030	U-2115			
		9352025	Jun 07, 2030	U-2116			
		9352025	Jun 07, 2030	U-2117			
		9352025	Jun 07, 2030	U-2118			
		9352025	Jun 07, 2030	U-2119			
		9522117	Apr 30, 2032	DP U-1939			
		9522117	Apr 30, 2032	DP U-976			
		9700555	Apr 30, 2032	DP U-2183			
		9700555	Apr 30, 2032	DP U-2184			
		9700555	Apr 30, 2032	DP U-2185			
		9700555	Apr 30, 2032	DP U-2186			
		9700555	Apr 30, 2032	DP U-2187			
		9700555	Apr 30, 2032	DP U-2188			
		9700555	Apr 30, 2032	DP U-2189			
		9700555	Apr 30, 2032	DP U-2190			
		9700555	Apr 30, 2032	DP U-2191			
		9700555	Apr 30, 2032	DP U-2192			
		9700555	Apr 30, 2032	DP U-2193			
		9700555	Apr 30, 2032	DP U-2194			
		9700555	Apr 30, 2032	DP U-2195			
		9700555	Apr 30, 2032	DP U-2196			
		9700555	Apr 30, 2032	DP U-2197			
		9700555	Apr 30, 2032	DP U-2198			
		9895422	Jun 07, 2030	U-2114			
		9895422	Jun 07, 2030	U-2116			
		9895422	Jun 07, 2030	U-2281			
		9895422	Jun 07, 2030	U-2282			
		9895422	Jun 07, 2030	U-2283			
		9895422	Jun 07, 2030	U-2284			
		9895422	Jun 07, 2030	U-2285			
		9895422	Jun 07, 2030	U-2286			
		9895422	Jun 07, 2030	U-2287			
		9993474	Apr 30, 2032	U-2384			
		9993474	Apr 30, 2032	U-2385			
		9993474	Apr 30, 2032	U-2386			
		9993474	Apr 30, 2032	U-2387			
		9993474	Apr 30, 2032	U-2388			
		9993474	Apr 30, 2032	U-2389			
		9993474	Apr 30, 2032	U-2390			
		9993474	Apr 30, 2032	U-2391			
		9993474	Apr 30, 2032	U-2392			
		9993474	Apr 30, 2032	U-2393			
BUDESONIDE - UCERIS							
N 203634	001	10064878	Jun 09, 2020	DP U-1325			
		10105374	Jun 09, 2020	DP U-1325			
		10143698	Jun 09, 2020	DP U-1325			
		10307375	Sep 07, 2031	DP			
		7410651	Jun 09, 2020	DP U-1325			
		7431943	Jun 09, 2020	DP			
		8293273	Jun 09, 2020	DP			
		8784888	Jun 09, 2020	DP			
		8895064	Sep 07, 2031	DP			
		9132093	Sep 07, 2031	DP			
		9192581	Sep 07, 2031	DP U-1325			
		9320716	Jun 09, 2020	DP U-1325			
		9532954	Jun 09, 2020	DP U-1325			
		RE43799	Jun 09, 2020	DP U-1325			
BUDESONIDE - ORTIKOS							
N 211929	001	10172802	Sep 09, 2036	U-2554			
		9707182	Sep 09, 2036	DP U-2554			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE - ORTIKOS							
N 211929	002	10172802	Sep 09, 2036	U-2554			
		9707182	Sep 09, 2036	DP U-2554			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	001	10166247	Jan 29, 2023	DP U-2001		M-210	Sep 11, 2020
		10166247	Jan 29, 2023	DP U-2002		M-214	Dec 20, 2020
		10166247	Jan 29, 2023	DP U-2122		NPP	Jan 27, 2020
		10166247*PED	Jul 29, 2023			PED	Jul 27, 2020
		7587988	Apr 10, 2026	DP			
		7587988*PED	Oct 10, 2026				
		7759328	Jan 29, 2023	DP U-2001			
		7759328	Jan 29, 2023	DP U-2002			
		7759328	Jan 29, 2023	DP U-2122			
		7759328*PED	Jul 29, 2023				
		7967011	Aug 11, 2021	DP			
		7967011*PED	Feb 11, 2022				
		8143239	Jan 29, 2023	DP U-2001			
		8143239	Jan 29, 2023	DP U-2002			
		8143239	Jan 29, 2023	DP U-2122			
		8143239*PED	Jul 29, 2023				
		8387615	Mar 26, 2027	DP			
		8387615*PED	Sep 26, 2027				
		8528545	Oct 16, 2028	DP			
		8528545*PED	Apr 16, 2029				
		8575137	Jan 29, 2023	DP U-2001			
		8575137	Jan 29, 2023	DP U-2002			
		8575137	Jan 29, 2023	DP U-2122			
		8575137*PED	Jul 29, 2023				
		8616196	Apr 07, 2029	DP			
		8616196*PED	Oct 07, 2029				
		8875699	Nov 10, 2024	DP			
		8875699*PED	May 10, 2025				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	002	10166247	Jan 29, 2023	DP U-2001		M-210	Sep 11, 2020
		10166247	Jan 29, 2023	DP U-2002		M-214	Dec 20, 2020
		10166247	Jan 29, 2023	DP U-2122			
		10166247*PED	Jul 29, 2023				
		7587988	Apr 10, 2026	DP			
		7587988*PED	Oct 10, 2026				
		7759328	Jan 29, 2023	DP U-2001			
		7759328	Jan 29, 2023	DP U-2002			
		7759328	Jan 29, 2023	DP U-2122			
		7759328*PED	Jul 29, 2023				
		7967011	Aug 11, 2021	DP			
		7967011*PED	Feb 11, 2022				
		8143239	Jan 29, 2023	DP U-2001			
		8143239	Jan 29, 2023	DP U-2002			
		8143239	Jan 29, 2023	DP U-2122			
		8143239*PED	Jul 29, 2023				
		8387615	Mar 26, 2027	DP			
		8387615*PED	Sep 26, 2027				
		8528545	Oct 16, 2028	DP			
		8528545*PED	Apr 16, 2029				
		8575137	Jan 29, 2023	DP U-2001			
		8575137	Jan 29, 2023	DP U-2002			
		8575137	Jan 29, 2023	DP U-2122			
		8575137*PED	Jul 29, 2023				
		8616196	Apr 07, 2029	DP			
		8616196*PED	Oct 07, 2029				
		8875699	Nov 10, 2024	DP			
		8875699*PED	May 10, 2025				
BUPIVACAINE - EXPAREL							
N 022496	001	9585838	Dec 24, 2021	DP		I-771	Apr 06, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE - EXPAREL						
N 022496 002	9585838	Dec 24, 2021	DP		I-771	Apr 06, 2021
BUPRENORPHINE - BUTRANS						
N 021306 001					M-250	Oct 13, 2020
BUPRENORPHINE - BUTRANS						
N 021306 002					M-250	Oct 13, 2020
BUPRENORPHINE - BUTRANS						
N 021306 003					M-250	Oct 13, 2020
BUPRENORPHINE - BUTRANS						
N 021306 004					M-250	Oct 13, 2020
BUPRENORPHINE - BUTRANS						
N 021306 005					M-250	Oct 13, 2020
BUPRENORPHINE - SUBLOCADE						
N 209819 001	10198218	Jun 06, 2031	U-2489		NP	Nov 30, 2020
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE - SUBLOCADE						
N 209819 002	10198218	Jun 06, 2031	U-2489		NP	Nov 30, 2020
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE						
N 204442 001	7736665	Apr 25, 2024	U-1878			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 001	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	002	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	003	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	004	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	005	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	006	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	007	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE								
N	022410	001	10285910	Oct 11, 2022	DP			
			8017150	Feb 13, 2023	DP			
			8475832	Mar 26, 2030	DP U-1411			
			8603514	Apr 03, 2024	DP U-1464			
			9687454	Aug 07, 2029	DP U-1464			
			9855221	Feb 14, 2022	DP			
			9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE								
N	022410	002	10285910	Oct 11, 2022	DP			
			8017150	Feb 13, 2023	DP			
			8475832	Mar 26, 2030	DP U-1411			
			8603514	Apr 03, 2024	DP U-1464			
			9687454	Aug 07, 2029	DP U-1464			
			9855221	Feb 14, 2022	DP			
			9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE								
N	022410	003	10285910	Oct 11, 2022	DP			
			8017150	Feb 13, 2023	DP			
			8475832	Mar 26, 2030	DP U-1411			
			8603514	Apr 03, 2024	DP U-1464			
			9687454	Aug 07, 2029	DP U-1464			
			9855221	Feb 14, 2022	DP			
			9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE								
N	022410	004	10285910	Oct 11, 2022	DP			
			8017150	Feb 13, 2023	DP			
			8475832	Mar 26, 2030	DP U-1411			
			8603514	Apr 03, 2024	DP U-1464			
			9687454	Aug 07, 2029	DP U-1464			
			9855221	Feb 14, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE								
N 022410	004		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	001		8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	002		8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	003		8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	004		8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	005		8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	006		8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP	Y		
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N 205637	001		7579019	Jan 22, 2020			U-1521	
			8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N 205637	002		7579019	Jan 22, 2020			U-1521	
			8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N 205637	003		7579019	Jan 22, 2020			U-1521	
			8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	
BUPROPION HYDROBROMIDE - APLENZIN								
N 022108	001		7241805	Jun 27, 2026	DP			
			7569610	Jun 27, 2026			U-997	
			7572935	Jun 27, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 001	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROCHLORIDE - FORFIVO XL						
N 022497 001	7674479	Jun 25, 2027	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			
	7375111	Mar 26, 2025	DP			
	7462626	Jul 20, 2024	U-1583			
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027	U-1584			
	8722085	Nov 08, 2027	U-1585			
	8815889	Jul 20, 2024	U-1586			
	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
	9125868	Nov 08, 2027	U-1585			
	9248123	Jan 13, 2032	U-1808			
CABAZITAXEL - JEVTANA KIT						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			M-209	Sep 14, 2020
	7241907	Dec 10, 2025	DS		PED	Nov 17, 2020
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 001	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 002	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-760	Dec 19, 2020
	10039757	Jul 18, 2031	U-1480		I-792	Jan 14, 2022
	7579473	Aug 14, 2026	DS DP		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1220			
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOZANTINIB S-MALATE - CABOMETYX								
N 208692	001		9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX								
N 208692	002		10034873	Jul 18, 2031	U-2488		I-760	Dec 19, 2020
			10039757	Jul 18, 2031	U-1480		I-792	Jan 14, 2022
			7579473	Aug 14, 2026	DS DP		ODE-227	Jan 14, 2026
			8497284	Sep 24, 2024	U-1220			
			8497284	Sep 24, 2024	U-1480			
			8497284	Sep 24, 2024	U-2488			
			8877776	Oct 08, 2030	DS DP			
			9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX								
N 208692	003		10034873	Jul 18, 2031	U-2488		I-760	Dec 19, 2020
			10039757	Jul 18, 2031	U-1480		I-792	Jan 14, 2022
			7579473	Aug 14, 2026	DS DP		ODE-227	Jan 14, 2026
			8497284	Sep 24, 2024	U-1220			
			8497284	Sep 24, 2024	U-1480			
			8497284	Sep 24, 2024	U-2488			
			8877776	Oct 08, 2030	DS DP			
			9724342	Jul 09, 2033	DP			
CALCIFEDIOL - RAYALDEE								
N 208010	001		10213442	Feb 02, 2027	DP			
			10300078	Mar 14, 2034	DP			
			10357502	Mar 14, 2034	DP			
			6582727	Aug 22, 2020	DP			
			8207149	Apr 25, 2028	U-1871			
			8361488	Jul 19, 2028	DP			
			8426391	Aug 27, 2028	U-1872			
			8778373	Apr 25, 2028	U-1873			
			8906410	Feb 02, 2027	DP			
			9408858	Apr 25, 2028	U-1888			
			9498486	Apr 25, 2028	U-1920			
			9861644	Mar 14, 2034	DP			
			9925147	Apr 25, 2028	DP U-2255			
			9925147	Apr 25, 2028	DP U-2256			
			9925147	Apr 25, 2028	DP U-2257			
			9925147	Apr 25, 2028	DP U-2258			
			9925147	Apr 25, 2028	DP U-2259			
			9943530	Feb 02, 2027	U-2274			
CALCIPOTRIENE - SORILUX								
N 022563	001		8263580	May 07, 2028	DP U-1280			
			8263580	May 07, 2028	DP U-2662			
			8629128	May 26, 2026	DP U-1280			
			8629128	May 26, 2026	DP U-1767			
			8629128	May 26, 2026	DP U-2662			
CALCITONIN SALMON RECOMBINANT - FORTICAL								
N 021406	001		6440392	Feb 02, 2021	DP U-227			
			RE40812	Feb 02, 2021	DP			
			RE43580	Feb 02, 2021	DP U-227			
CALCIUM ACETATE - PHOSLO								
N 021160	002		6576665	Apr 03, 2021				
CALCIUM ACETATE - PHOSLO GELCAPS								
N 021160	003		6576665	Apr 03, 2021				
			6875445	Jul 30, 2021	DP			
CALCIUM ACETATE - PHOSLYRA								
N 022581	001		8591938	Feb 23, 2030	DP U-1469			
			8592480	Jul 20, 2027	U-1469			
			9089528	Jul 20, 2027	U-1469			
CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE								
N 020958	001		6814978	Aug 26, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL							
N 022193	001	7084130	Nov 29, 2021	DP U-891			
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
N 207026	001					ODE-85	Jan 13, 2022
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
N 207026	002					ODE-85	Jan 13, 2022
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE							
N 210906	001	10130646	Jul 25, 2037	DP			
		10342813	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE							
N 210906	002	10130646	Jul 25, 2037	DP			
		10342813	Jul 25, 2037	DP			
CANAGLIFLOZIN - INVOKANA							
N 204042	001	7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-2632		I-809	Sep 27, 2022
		7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-2632			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-2632			
		8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN - INVOKANA							
N 204042	002	7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-2632		I-809	Sep 27, 2022
		7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-2632			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-2632			
		8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	001	7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	002	7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	003	7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	003	8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	004	7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	001	6723340	Oct 25, 2021	DP		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-2441			
		7943582	Feb 26, 2029	DS DP U-493			
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	002	7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493			
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	003	6723340	Oct 25, 2021	DP		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-2441			
		7943582	Feb 26, 2029	DS DP U-493			
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	004	7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493			
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANGRELOR - KENGREAL							
N 204958	001	10039780	Jul 10, 2035	U-2260		NCE	Jun 22, 2020
		6130208	Jun 29, 2023	DP U-1715			
		8680052	Mar 09, 2033	U-1715			
		9295687	Jul 10, 2035	DP			
		9427448	Nov 10, 2030	U-1926			
		9439921	Jul 10, 2035	DP			
		9700575	Jul 10, 2035	DP			
		9925265	May 13, 2029	U-2260			
CANNABIDIOL - EPIDIOLEX							
N 210365	001	10092525	Jun 17, 2035	U-2427		NCE	Sep 28, 2023
		10111840	Jun 17, 2035	U-2442		ODE-216	Sep 28, 2025
		10111840	Jun 17, 2035	U-2443			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANNABIDIOL - EPIDIOLEX								
N 210365	001		10137095	Jun 17, 2035	U-2454			
			10137095	Jun 17, 2035	U-2455			
			10195159	May 07, 2022	DS			
			9949937	Jun 17, 2035	U-2421			
			9956183	Jun 17, 2035	U-2422			
			9956183	Jun 17, 2035	U-2423			
			9956184	Jun 17, 2035	U-2424			
			9956185	Jun 17, 2035	U-2425			
			9956186	Jun 17, 2035	U-2426			
CAPSAICIN - QUTENZA								
N 022395	001		10034841	Sep 06, 2025	DP			
			10463598	Sep 05, 2023	DP			
			6239180	Jun 04, 2021	DP			
			8263059	Sep 05, 2023	U-2705			
			8821920	Mar 26, 2030	DP			
			8889113	Sep 05, 2023	U-2705			
			9226903	Dec 15, 2028	DP			
CARBAMAZEPINE - EQUETRO								
N 021710	001		6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO								
N 021710	002		6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO								
N 021710	003		6977253	May 19, 2024	U-693			
CARBAMAZEPINE - CARNEXIV								
N 206030	001		7635773	Mar 13, 2029	DP		ODE-124	Oct 07, 2023
			8410077	Mar 13, 2029	DP			
			9493582	Feb 27, 2033	DP			
			9629797	Nov 10, 2028	U-2004			
			9629797	Nov 10, 2028	U-2005			
			9629797	Nov 10, 2028	U-2006			
			9750822	Mar 13, 2029	DP			
			9770407	Nov 10, 2028	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50								
N 021485	001		6500867	Jun 29, 2020	DP U-219			
			6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100								
N 021485	002		6500867	Jun 29, 2020	DP U-219			
			6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150								
N 021485	003		6500867	Jun 29, 2020	DP U-219			
			6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200								
N 021485	004		6500867	Jun 29, 2020	DP U-219			
			6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75								
N 021485	005		6500867	Jun 29, 2020	DP U-219			
			6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125								
N 021485	006		6500867	Jun 29, 2020	DP U-219			
			6797732	Jun 29, 2020	DP			
CARBIDOPA; LEVODOPA - RYTARY								
N 203312	001		7094427	May 29, 2022	DP U-1645	Y		
			8377474	Dec 26, 2028	DP U-1645			
			8377474	Dec 26, 2028	DP U-219			
			8454998	Dec 26, 2028	DP U-1645			
			8454998	Dec 26, 2028	DP U-1646			
			8454998	Dec 26, 2028	DP U-1647			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	001	8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	002	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	003	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	004	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - DUOPA							
N 203952	001					ODE-84	Jan 09, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBINOXAMINE MALEATE - KARBINAL ER							
N 022556	001	8062667	Mar 29, 2029	DP			
		9522191	Jun 15, 2027	DP			
CARFILZOMIB - KYPROLIS							
N 202714	001	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP			
		7491704	Apr 14, 2025	U-1260			
		7737112	Dec 07, 2027	DP			
		8129346	Apr 14, 2025	U-1260			
		8207125	Apr 14, 2025	DS DP			
		8207126	Apr 14, 2025	DP			
		8207127	Apr 14, 2025	U-1260			
		8207297	Apr 14, 2025	DS DP			
		9493582	Feb 27, 2033	DP			
		9511109	Oct 21, 2029	U-1924			
CARFILZOMIB - KYPROLIS							
N 202714	002	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP			
		7491704	Apr 14, 2025	U-1260			
		7737112	Dec 07, 2027	DP			
		8129346	Apr 14, 2025	U-1260			
		8207125	Apr 14, 2025	DS DP			
		8207126	Apr 14, 2025	DP			
		8207127	Apr 14, 2025	U-1260			
		8207297	Apr 14, 2025	DS DP			
		9493582	Feb 27, 2033	DP			
		9511109	Oct 21, 2029	U-1924			
CARFILZOMIB - KYPROLIS							
N 202714	003	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP			
		7491704	Apr 14, 2025	U-2319			
		7491704	Apr 14, 2025	U-2320			
		7737112	Dec 07, 2027	DP			
		8129346	Apr 14, 2025	U-2319			
		8129346	Apr 14, 2025	U-2320			
		8207125	Apr 14, 2025	DS DP			
		8207126	Apr 14, 2025	DP			
		8207127	Apr 14, 2025	U-2319			
		8207127	Apr 14, 2025	U-2320			
		8207297	Apr 14, 2025	DS DP			
		9493582	Feb 27, 2033	DP			
		9511109	Oct 21, 2029	U-1924			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	001	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543		M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544		NCE	Sep 17, 2020
		7737142	Sep 17, 2029	DS DP U-2545			
		7943621	Dec 16, 2028	DS DP			
		RE47350	Jul 16, 2029	U-1750			
		RE47350	Jul 16, 2029	U-2543			
		RE47350	Jul 16, 2029	U-2544			
		RE47350	Jul 16, 2029	U-2545			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	002	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543		M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544		NCE	Sep 17, 2020
		7737142	Sep 17, 2029	DS DP U-2545			
		7943621	Dec 16, 2028	DS DP			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	003	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543		M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544		NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	004	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543		M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544		NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	001	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	002	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	003	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	004	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE							
N 206110	001	9636407	Dec 21, 2032	DP			
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE							
N 206110	002	9636407	Dec 21, 2032	DP			
CEFIDEROCOL SULFATE TOSYLATE - FETROJA							
N 209445	001	10004750	Sep 03, 2035	DS DP		NCE	Nov 14, 2024
		9238657	Nov 19, 2031	DS DP U-282		GAIN	Nov 14, 2029
		9949982	Sep 03, 2035	DP			
CEFIXIME - SUPRAX							
N 202091	001	9233112	Dec 14, 2028	DP U-1676			
CEFTAROLINE FOSAMIL - TEFLARO							
N 200327	001	6417175	Apr 11, 2022	DS DP U-1676			
		6906055	Dec 15, 2021	DS DP			
		7419973	Dec 15, 2021	DP			
		8247400	Feb 10, 2031	DP U-282			
		9629861	Sep 21, 2030	DP			
CEFTAROLINE FOSAMIL - TEFLARO							
N 200327	002	6417175	Apr 11, 2022	DS DP U-1676			
		6906055	Dec 15, 2021	DS DP			
		7419973	Dec 15, 2021	DP			
		8247400	Feb 10, 2031	DP U-282			
		9629861	Sep 21, 2030	DP			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA							
N 206829	001	10028963	Sep 07, 2032	U-2565		NCE	Dec 19, 2019
		10028963	Sep 07, 2032	U-2566		GAIN	Dec 19, 2024
		10125149	Aug 14, 2035	DP			
		10376496	Sep 09, 2034	U-2610			
		10376496	Sep 09, 2034	U-2611			
		10420841	Mar 14, 2034	U-1672			
		10420841	Mar 14, 2034	U-2631			
		7129232	May 15, 2028	DS DP U-1676			
		7129232	May 15, 2028	DS DP U-36			
		8476425	Sep 27, 2032	DS			
		8685957	Sep 27, 2032	DS U-36			
		8906898	May 28, 2034	DS DP			
		8968753	Mar 14, 2034	U-1672			
		8968753	Mar 14, 2034	U-1673			
		9320740	Mar 14, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA								
N 206829	001	9724353	Sep 07, 2032		U-2565			
		9724353	Sep 07, 2032		U-2566			
		9872906	Mar 14, 2034		DP			
CERITINIB - ZYKADIA								
N 205755	001	7153964	Feb 26, 2021	DS	DP		M-199	May 26, 2020
		7893074	Apr 25, 2026	DS	DP		ODE-145	May 26, 2024
		7964592	Jan 13, 2027	DS	DP		ODE-66	Apr 29, 2021
		8039479	Jun 29, 2030	DS	DP			
		8188276	Jan 31, 2023	DS	DP			
		8377921	Nov 20, 2027		U-1179			
		8399450	Nov 20, 2027	DS	DP			
		8703787	Feb 02, 2032		U-1179			
		8835430	Jan 31, 2023	DS	DP			
		9018204	Jan 31, 2023	DS	DP			
		9309229	Jan 18, 2032	DS	DP			
		9416112	Jan 31, 2023	DS	DP			
CERITINIB - ZYKADIA								
N 211225	001	7153964	Feb 26, 2021	DS	DP			
		7893074	Apr 25, 2026	DS	DP			
		7964592	Jan 13, 2027	DS	DP			
		8039479	Jun 29, 2030	DS	DP			
		8188276	Jan 31, 2023	DS	DP			
		8377921	Nov 20, 2027		U-1179			
		8399450	Nov 20, 2027	DS	DP			
		8703787	Feb 02, 2032		U-1179			
		8835430	Jan 31, 2023	DS	DP			
		9018204	Jan 31, 2023	DS	DP			
		9309229	Jan 18, 2032	DS	DP			
		9416112	Jan 31, 2023	DS	DP			
CETIRIZINE HYDROCHLORIDE - ZERVIATE								
N 208694	001	8829005	Mar 15, 2030		U-1680		NDF	May 30, 2020
		8829005*PED	Sep 15, 2030				PED	Nov 30, 2020
		9254286	Jul 09, 2032		DP			
		9254286*PED	Jan 09, 2033					
		9750684	Mar 15, 2030		DP			
		9993471	Mar 15, 2030		U-1680			
CETIRIZINE HYDROCHLORIDE - QUZYTTIR								
N 211415	001	8263581	Feb 28, 2030		U-2635		NP	Oct 04, 2022
		8314083	Feb 28, 2030		U-2634			
		8513259	Feb 11, 2030		U-2636			
		9119771	Feb 11, 2030		U-2635			
		9180090	Feb 11, 2030		U-2635			
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR								
N 021150	002	7014867	Jun 10, 2022		DP			
		7226614	Jun 10, 2022		U-295			
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE								
N 021669	001	7066916	Feb 17, 2024		U-737			
		7427574	Apr 25, 2026		DP			
		7595021	May 12, 2023		DP U-1022			
		7717889	Feb 27, 2025		DP U-1022			
		7935093	Oct 02, 2027		DP U-1022			
CHLORHEXIDINE GLUCONATE - READYPREP CHG								
N 207964	001						NP	Nov 20, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP								
N 020832	001	6536975	Nov 10, 2020		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N 020832	002	6729786	Mar 14, 2023		DP			
		6991394	Jan 31, 2024		DP			
		7182536	Dec 30, 2023		DP			
		7241065	Mar 14, 2023		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N	020832	002	7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP								
N	020832	004	6536975	Nov 10, 2020	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N	020832	005	6536975	Nov 10, 2020	DP			
			6729786	Mar 14, 2023	DP			
			7241065	Mar 14, 2023	DP			
			7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP								
N	020832	006	6991394	Jan 31, 2024	DP			
			7182536	Dec 30, 2023	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N	020832	007	6536975	Nov 10, 2020	DP			
			6729786	Mar 14, 2023	DP			
			7241065	Mar 14, 2023	DP			
			7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB								
N	021524	001					M-221	Feb 14, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK								
N	021524	002					M-221	Feb 14, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK								
N	021524	003					M-221	Feb 14, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP								
N	208288	001	8623935	Jul 26, 2029	DP U-1022		NP	Aug 08, 2021
CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL								
N	208791	001	8969412	Sep 05, 2026	DP U-2609		NP	Sep 26, 2020
			9504666	Dec 11, 2033	DP			
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - TUXARIN ER								
N	206323	001	9066942	Jan 03, 2032	U-1716			
			9107921	Jan 03, 2032	DP			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS								
N	021441	001	7863287	Feb 28, 2027	DP			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS								
N	021587	001	10238640	May 25, 2024	DP			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR								
N	207768	001	8062667	Mar 29, 2029	DP			
			8790700	Mar 15, 2027	DP			
CHLORZOXAZONE - CHLORZOXAZONE								
A	212253	001					CGT	May 25, 2020
CHLORZOXAZONE - CHLORZOXAZONE								
A	212253	002					CGT	May 25, 2020
CHOLIC ACID - CHOLBAM								
N	205750	001					NCE	Mar 17, 2020
							ODE-91	Mar 17, 2022
CHOLIC ACID - CHOLBAM								
N	205750	002					NCE	Mar 17, 2020
							ODE-91	Mar 17, 2022
CHOLINE FENOFIBRATE - TRILIPIX								
N	022224	001	7259186	Jan 07, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHOLINE FENOFIBRATE - TRILIPIX								
N	022224	002	7259186	Jan 07, 2025	DS			
CHORIOGONADOTROPIN ALFA - OVIDREL								
N	021149	002	6706681	Mar 16, 2021	DP			
CICLESONIDE - ALVESCO								
N	021658	002	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - ALVESCO								
N	021658	003	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - OMNARIS								
N	022004	001	6767901	Oct 21, 2020	DP			
			8371292	Feb 01, 2028	U-1356			
			8383611	Oct 20, 2020	DP			
CICLESONIDE - ZETONNA								
N	202129	001	8371292	Feb 01, 2028	U-1357			
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO								
N	212819	001	8487093	Nov 19, 2029	DS DP U-2586			
			8487093	Nov 19, 2029	DS DP U-2587			
CINACALCET HYDROCHLORIDE - SENSIPAR								
N	021688	001	7829595	Sep 22, 2026	DP U-1098		M-200	May 23, 2020
			9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
CINACALCET HYDROCHLORIDE - SENSIPAR								
N	021688	002	7829595	Sep 22, 2026	DP U-1098		M-200	May 23, 2020
			9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
CINACALCET HYDROCHLORIDE - SENSIPAR								
N	021688	003	7829595	Sep 22, 2026	DP U-1098		M-200	May 23, 2020
			9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
CIPROFLOXACIN - OTIPRIO								
N	207986	001	8318817	Apr 27, 2030	U-1792		I-770	Mar 02, 2021
			9205048	Apr 21, 2029	U-1793			
			9220796	Jul 01, 2035	DP			
			9233068	Dec 11, 2029	DP			
			9603796	Apr 21, 2029	DS DP U-2252			
CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR								
N	021744	001	6488962	Jun 20, 2020	DP			
CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL								
N	208251	001	8932610	Mar 24, 2030	DP U-1578			
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR								
N	021473	001	7709022	Jun 23, 2021	DP			
			8187632	Jun 23, 2021	DP			
			8187632*PED	Dec 23, 2021				
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR								
N	021473	002	7709022	Jun 23, 2021	DP			
			8187632	Jun 23, 2021	DP			
			8187632*PED	Dec 23, 2021				
CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX								
N	021537	001	6284804	Aug 10, 2020				
			6359016	Aug 10, 2020				
			8846650	Jun 04, 2025	DP U-1578			
			9149486	Sep 13, 2022	DP U-1578			
			9345714	Sep 13, 2022	DP U-1578			
			9402805	Sep 13, 2022	DP U-1578			
			9402805	Sep 13, 2022	DP U-1679			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK									
N 202535	001		8450338	Oct 10, 2028		DP		NPP	Aug 15, 2021
			8481083	Oct 10, 2028		DP			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ									
N 209589	001		9827231	Jun 26, 2034		DP U-2162			
CLADRIBINE - MAVENCLAD									
N 022561	001		7713947	Oct 16, 2026		U-2520		NP	Mar 29, 2022
			7888328	Apr 11, 2024		DP U-2521			
			8377903	May 31, 2026		U-2522			
			8785415	Apr 11, 2024		DP U-2523			
CLEVIDIPINE - CLEVIPREX									
N 022156	001		10010537	Oct 10, 2031		DP			
			5856346	Jan 05, 2021	DS	DP U-893			
			8658676	Oct 10, 2031		DP			
CLEVIDIPINE - CLEVIPREX									
N 022156	002		10010537	Oct 10, 2031		DP			
			5856346	Jan 05, 2021	DS	DP U-893			
			8658676	Oct 10, 2031		DP			
CLEVIDIPINE - CLEVIPREX									
N 022156	003		10010537	Oct 10, 2031		DP			
			5856346	Jan 05, 2021	DS	DP U-893			
			8658676	Oct 10, 2031		DP			
CLINDAMYCIN PHOSPHATE - CLEOCIN									
N 050767	001		6495157	Jul 20, 2020		DP			
CLINDAMYCIN PHOSPHATE - CLINDAGEL									
N 050782	001		6387383	Aug 03, 2020		DP U-818			
CLINDAMYCIN PHOSPHATE - CLINDESSE									
N 050793	001		6899890	Apr 27, 2023		DP U-137			
			9789057	Dec 02, 2026		DP U-137			
CLINDAMYCIN PHOSPHATE - EVOCLIN									
N 050801	001		7141237	Feb 03, 2024		DP			
			7374747	Jan 23, 2024		DP U-921			
CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA									
N 050802	001		6387383	Aug 03, 2020		DP U-916			
CLOBAZAM - SYMPAZAN									
N 210833	001		8603514	Apr 03, 2024		DP			
			8765167	Feb 20, 2024		DP			
CLOBAZAM - SYMPAZAN									
N 210833	002		8603514	Apr 03, 2024		DP			
			8765167	Feb 20, 2024		DP			
CLOBAZAM - SYMPAZAN									
N 210833	003		8603514	Apr 03, 2024		DP			
			8765167	Feb 20, 2024		DP			
CLOBETASOL PROPIONATE - CLOBEX									
N 021644	001		7700081	Jan 03, 2022		U-1044			
CLOBETASOL PROPIONATE - OLUX E									
N 022013	001		8460641	Nov 05, 2028		DP U-1410			
			8962000	Aug 31, 2025		DP U-1410			
CLOBETASOL PROPIONATE - IMPOYZ									
N 209483	001		10064875	Aug 31, 2030		DP U-1408		NP	Nov 28, 2020
			10064875	Aug 31, 2030		DP U-1858			
			10064875	Aug 31, 2030		DP U-193			
			10064875	Aug 31, 2030		DP U-742			
			10064875	Aug 31, 2030		DP U-88			
			9855334	Mar 11, 2035		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLOBETASOL PROPIONATE - IMPOYZ								
N 209483	001	9956231	Aug 31, 2030		DP U-1408			
		9956231	Aug 31, 2030		DP U-1761			
		9956231	Aug 31, 2030		DP U-1858			
		9956231	Aug 31, 2030		DP U-193			
		9956231	Aug 31, 2030		DP U-742			
		9956231	Aug 31, 2030		DP U-88			
CLOZAPINE - VERSACLOZ								
N 203479	001	8057811	May 01, 2028		DP			
COBICISTAT - TYBOST								
N 203094	001	10039718	Oct 04, 2032		DP		NPP	Aug 22, 2022
		8148374	Sep 03, 2029	DS	DP U-1279		ODE-260	Aug 22, 2026
COBICISTAT; DARUNAVIR - PREZCOBIX								
N 205395	001	10039718	Oct 04, 2032		DP			
		7700645	Dec 26, 2026	DS	DP			
		7700645*PED	Jun 26, 2027					
		8148374	Sep 03, 2029	DS	DP U-1279			
		8518987	Feb 16, 2024	DS	DP			
		8518987*PED	Aug 16, 2024					
COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA								
N 210455	001	10039718	Oct 04, 2032		DP		NC	Jul 17, 2020
		6642245	Nov 04, 2020		U-2352		NCE	Nov 05, 2020
		6703396	Mar 09, 2021	DS	DP			
		7390791	May 07, 2022	DS	DP			
		7700645	Dec 26, 2026	DS	DP			
		7803788	Feb 02, 2022		U-2352			
		8148374	Sep 03, 2029	DS	DP U-2353			
		8148374	Sep 03, 2029	DS	DP U-2364			
		8148374	Sep 03, 2029	DS	DP U-2365			
		8518987	Feb 16, 2024	DS	DP			
		8754065	Aug 15, 2032	DS	DP U-2352			
		9296769	Aug 15, 2032	DS	DP U-2352			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA								
N 207561	001	10039718	Oct 04, 2032		DP		D-173	Dec 10, 2021
		6642245	Nov 04, 2020		U-257		NCE	Nov 05, 2020
		6642245*PED	May 04, 2021				NPP	Sep 25, 2020
		6703396	Mar 09, 2021	DS	DP			
		6703396*PED	Sep 09, 2021					
		7176220	Aug 27, 2026	DS	DP U-257			
		7390791	May 07, 2022	DS	DP			
		7635704	Oct 26, 2026	DS	DP U-257			
		7803788	Feb 02, 2022		U-257			
		8148374	Sep 03, 2029	DS	DP U-1279			
		8633219	Apr 24, 2030		DP U-257			
		8754065	Aug 15, 2032	DS	DP U-257			
		8981103	Oct 26, 2026	DS	DP			
		9296769	Aug 15, 2032	DS	DP U-257			
		9891239	Sep 03, 2029		DP U-257			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD								
N 203100	001	10039718	Oct 04, 2032		DP		NPP	Jan 27, 2020
		6642245	Nov 04, 2020		U-257			
		6703396	Mar 09, 2021	DS	DP			
		7176220	Aug 27, 2026	DS	DP U-257			
		7635704	Oct 26, 2026	DS	DP U-257			
		8148374	Sep 03, 2029	DS	DP U-1279			
		8592397	Jan 13, 2024		DP U-257			
		8633219	Apr 24, 2030		DP U-257			
		8716264	Jan 13, 2024		DP U-257			
		8981103	Oct 26, 2026	DS	DP			
		9457036	Jan 13, 2024		DP U-257			
		9744181	Jan 13, 2024		DP U-257			
		9891239	Sep 03, 2029		DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COBIMETINIB FUMARATE - COTELLIC							
N 206192	001	10478400	Jun 29, 2036	DS DP U-1776		NCE	Nov 10, 2020
		7803839	Feb 01, 2027	DS DP		ODE-101	Nov 10, 2022
		8362002	Oct 05, 2026	U-1776			
COCAINE HYDROCHLORIDE - GOPRELTO							
N 209963	001	10016407	Feb 07, 2037	U-2329		NCE	Dec 14, 2022
		10149843	Feb 07, 2037	U-2478			
		10149843	Feb 07, 2037	U-2479			
		10231961	Feb 07, 2037	DP			
		10413505	Feb 07, 2037	U-2479			
		10420760	Feb 07, 2037	U-2478			
		9867815	Feb 07, 2037	U-2225			
		9867815	Feb 07, 2037	U-2226			
		9867815	Feb 07, 2037	U-2227			
COLCHICINE - COLCRYS							
N 022352	001	7601758	Feb 10, 2029	U-1007			
		7619004	Dec 03, 2028	U-1020			
		7820681	Feb 17, 2029	U-1020			
		7906519	Feb 17, 2029	U-1116			
		7915269	Feb 17, 2029	U-1007			
		7935731	Dec 03, 2028	U-1116			
		7964647	Oct 06, 2028	U-1007			
		7964648	Oct 06, 2028	U-1161			
		7981938	Oct 06, 2028	U-1166			
		8093296	Oct 06, 2028	U-1007			
		8093297	Oct 06, 2028	U-1161			
		8093298	Oct 06, 2028	U-1116			
		8097655	Oct 06, 2028	U-1020			
		8415395	Oct 06, 2028	U-1007			
		8415396	Oct 06, 2028	U-1007			
		8440721	Feb 17, 2029	U-1007			
		8440722	Feb 17, 2029	U-1020			
COLCHICINE - MITIGARE							
N 204820	001	8927607	Aug 22, 2033	U-1020			
		9399036	Aug 22, 2033	U-1020			
		9555029	Aug 22, 2033	U-1020			
		9675613	Aug 22, 2033	U-1020			
		9789108	Aug 22, 2033	U-1020			
COLCHICINE - GLOPERBA							
N 210942	001	10226423	Dec 20, 2037	DP			
		9907751	Nov 22, 2036	DP			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 021176	001	7229613	Apr 17, 2022	U-851			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 022362	001	7229613	Apr 17, 2022	U-493			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 022362	002	7229613	Apr 17, 2022	U-493			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 210895	001	7229613	Apr 17, 2022	U-2516			
COPANLISIB DIHYDROCHLORIDE - ALIQOPA							
N 209936	001	10383876	Mar 29, 2032	DS DP		NCE	Sep 14, 2022
		7511041	May 13, 2024	DS DP		ODE-155	Sep 14, 2024
		9636344	Mar 29, 2032	U-2124			
		RE46856	Oct 22, 2029	DS DP U-2124			
CRISABOROLE - EUCRISA							
N 207695	001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
		8168614	Jan 20, 2030	U-1932			
		8501712	Feb 16, 2027	U-1932			
		9682092	Feb 16, 2027	U-1932			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CRIZOTINIB - XALKORI							
N 202570	001	7230098	Aug 26, 2025	DS		ODE-111	Mar 11, 2023
		7825137	May 12, 2027	U-1179			
		7858643	Oct 08, 2029	DS DP			
		8217057	Nov 06, 2029	DS DP			
		8785632	Mar 01, 2025	DS			
CRIZOTINIB - XALKORI							
N 202570	002	7230098	Aug 26, 2025	DS		ODE-111	Mar 11, 2023
		7825137	May 12, 2027	U-1179			
		7858643	Oct 08, 2029	DS DP			
		8217057	Nov 06, 2029	DS DP			
		8785632	Mar 01, 2025	DS			
CROFELEMER - MYTESI							
N 202292	001	7341744	Jun 02, 2022	DP U-1319			
		8962680	Oct 31, 2031	U-1319			
		9585868	Oct 31, 2031	U-1319			
CYANOCOBALAMIN - NASCOBAL							
N 021642	001	7229636	Aug 01, 2024	DP U-817			
		7404489	Mar 12, 2024	DP			
		7879349	Aug 01, 2024	DP U-1152			
		8003353	Aug 01, 2024	U-817			
		8940714	Feb 26, 2024	U-1152			
		9415007	Jul 28, 2024	U-1896			
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX							
N 021777	001	7387793	Feb 26, 2025	DP			
		7544372	Nov 14, 2023	U-979			
		7790199	Nov 14, 2023	DP			
		7820203	Nov 14, 2023	DP			
		7829121	Nov 14, 2023	U-1088			
		8877245	Nov 14, 2023	U-979			
		9375410	Nov 14, 2023	U-1088			
		9399025	Nov 14, 2023	DP U-979			
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX							
N 021777	002	7387793	Feb 26, 2025	DP			
		7544372	Nov 14, 2023	U-979			
		7790199	Nov 14, 2023	DP			
		7820203	Nov 14, 2023	DP			
		7829121	Nov 14, 2023	U-1088			
		8877245	Nov 14, 2023	U-979			
		9375410	Nov 14, 2023	U-1088			
		9399025	Nov 14, 2023	DP U-979			
CYCLOSPORINE - RESTASIS							
N 050790	001	8629111	Aug 27, 2024	DP			
		8633162	Aug 27, 2024	U-1479			
		8642556	Aug 27, 2024	DP			
		8648048	Aug 27, 2024	U-1483			
		8685930	Aug 27, 2024	DP			
		9248191	Aug 27, 2024	U-1479			
CYCLOSPORINE - RESTASIS MULTIDOSE							
N 050790	002	8292129	Feb 25, 2031	DP			
		8561859	Apr 16, 2032	DP			
		8629111	Aug 27, 2024	DP			
		8633162	Aug 27, 2024	U-1479			
		8642556	Aug 27, 2024	DP			
		8648048	Aug 27, 2024	U-1483			
		8685930	Aug 27, 2024	DP			
		9248191	Aug 27, 2024	U-1479			
		9669974	May 11, 2034	DP			
		9676525	Feb 07, 2034	DP			
CYCLOSPORINE - CEQUA							
N 210913	001	10441630	Aug 23, 2033	DP			
		8980839	Aug 23, 2033	DP U-1483			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYCLOSPORINE - CEQUA							
N 210913	001	9937225	Aug 23, 2033	DP U-1483			
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	001	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
		10328037	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
		8026284	Sep 22, 2027	U-1399		ODE-45	Apr 30, 2020
		8026284*PED	Mar 22, 2028			ODE-97	Aug 14, 2022
		9173851	Jun 17, 2034	DP		PED	Oct 30, 2020
		9173851*PED	Dec 17, 2034			PED	Jun 22, 2021
		9192590	Jan 26, 2027	U-1399		PED	Feb 14, 2023
		9192590*PED	Jul 26, 2027				
		9198882	Jan 26, 2027	U-1399			
		9198882*PED	Jul 26, 2027				
		9233077	Jun 17, 2034	DP			
		9233077*PED	Dec 17, 2034				
		9925156	Jan 26, 2027	DS DP U-1399			
		9925157	Jan 26, 2027	DS DP U-1399			
		9925158	Jan 26, 2027	DS DP U-1399			
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	002	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
		10328037	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
		8026284	Sep 22, 2027	U-1399		ODE-45	Apr 30, 2020
		8026284*PED	Mar 22, 2028			ODE-97	Aug 14, 2022
		9173851	Jun 17, 2034	DP		PED	Oct 30, 2020
		9173851*PED	Dec 17, 2034			PED	Jun 22, 2021
		9192590	Jan 26, 2027	U-1399		PED	Feb 14, 2023
		9192590*PED	Jul 26, 2027				
		9198882	Jan 26, 2027	U-1399			
		9198882*PED	Jul 26, 2027				
		9233077	Jun 17, 2034	DP			
		9233077*PED	Dec 17, 2034				
		9925156	Jan 26, 2027	DS DP U-1399			
		9925157	Jan 26, 2027	DS DP U-1399			
		9925158	Jan 26, 2027	DS DP U-1399			
CYSTEINE HYDROCHLORIDE - ELCYS							
N 210660	001	10478453	Jan 15, 2039	DP			
CYTARABINE; DAUNORUBICIN - VYXEOS							
N 209401	001	10028912	Sep 29, 2034	DP U-2341		NP	Aug 03, 2020
		10028912	Sep 29, 2034	DP U-2342			
		10166184	Oct 15, 2032	DP U-2341			
		7850990	Jan 23, 2027	DP U-2090			
		8022279	Sep 14, 2027	DP U-2090			
		8092828	Apr 01, 2029	U-2090			
		8431806	Apr 22, 2025	DP U-2090			
		8518437	Jun 07, 2026	DP			
		9271931	Jan 23, 2027	DP			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	001	6087380	Dec 28, 2021	DS DP U-1931			
		7866474	Aug 31, 2027	DP	Y		
		7932273	Sep 07, 2025	DS DP			
		9034822	Jan 20, 2031	U-1759			
		9925174	Jun 14, 2023	DP			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	002	6087380	Dec 28, 2021	DS DP U-1931			
		7866474	Aug 31, 2027	DP	Y		
		7932273	Sep 07, 2025	DS DP			
		9034822	Jan 20, 2031	U-1759			
		9925174	Jun 14, 2023	DP			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	003	6087380	Dec 28, 2021	DS DP U-1931			
		7866474	Aug 31, 2027	DP	Y		
		7932273	Sep 07, 2025	DS DP			
		9034822	Jan 20, 2031	U-1759			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	003	9925174	Jun 14, 2023	DP			
DABRAFENIB MESYLATE - TAFINLAR							
N 202806	001	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
		7994185	Jan 20, 2030	DS DP U-2031		I-778	Apr 30, 2021
		7994185	Jan 20, 2030	DS DP U-2032		I-781	May 04, 2021
		7994185	Jan 20, 2030	DS DP U-2296		M-246	Oct 06, 2022
		8415345	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
		8415345	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
		8415345	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
		8415345	Jan 20, 2030	DS DP U-2296		ODE-47	May 29, 2020
		8703781	Oct 15, 2030	DS DP U-1713		ODE-58	Jan 09, 2021
		8703781	Oct 15, 2030	DS DP U-2032			
		8703781	Oct 15, 2030	DS DP U-2296			
		8703781	Oct 15, 2030	DS DP U-2297			
		8703781	Oct 15, 2030	DS DP U-2298			
		8835443	Jun 10, 2025	U-2026			
		8835443	Jun 10, 2025	U-2027			
		8835443	Jun 10, 2025	U-2296			
		8835443	Jun 10, 2025	U-2298			
		8952018	Oct 15, 2030	U-2027			
		9233956	May 04, 2029	U-1811			
		9233956	May 04, 2029	U-2031			
		9233956	May 04, 2029	U-2032			
		9233956	May 04, 2029	U-2296			
		9233956	May 04, 2029	U-2297			
DABRAFENIB MESYLATE - TAFINLAR							
N 202806	002	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
		7994185	Jan 20, 2030	DS DP U-2031		I-778	Apr 30, 2021
		7994185	Jan 20, 2030	DS DP U-2032		I-781	May 04, 2021
		7994185	Jan 20, 2030	DS DP U-2296		M-246	Oct 06, 2022
		8415345	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
		8415345	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
		8415345	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
		8415345	Jan 20, 2030	DS DP U-2296		ODE-47	May 29, 2020
		8703781	Oct 15, 2030	DS DP U-1713		ODE-58	Jan 09, 2021
		8703781	Oct 15, 2030	DS DP U-2032			
		8703781	Oct 15, 2030	DS DP U-2296			
		8703781	Oct 15, 2030	DS DP U-2297			
		8703781	Oct 15, 2030	DS DP U-2298			
		8835443	Jun 10, 2025	U-2026			
		8835443	Jun 10, 2025	U-2027			
		8835443	Jun 10, 2025	U-2296			
		8835443	Jun 10, 2025	U-2298			
		8952018	Oct 15, 2030	U-2027			
		9233956	May 04, 2029	U-1811			
		9233956	May 04, 2029	U-2031			
		9233956	May 04, 2029	U-2032			
		9233956	May 04, 2029	U-2296			
		9233956	May 04, 2029	U-2297			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	001	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
		8629171	Jun 13, 2031	DS DP U-1724			
		8642025	Aug 11, 2027	DS DP U-1724			
		8642025	Aug 11, 2027	DS DP U-1725			
		8900566	Aug 08, 2027	U-1724			
		8900566	Aug 08, 2027	U-1725			
		9421192	Aug 08, 2027	DS U-1724			
		9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	002	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
		8629171	Jun 13, 2031	DS DP U-1724			
		8642025	Aug 11, 2027	DS DP U-1724			
		8642025	Aug 11, 2027	DS DP U-1725			
		8900566	Aug 08, 2027	U-1724			
		8900566	Aug 08, 2027	U-1725			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	002	9421192	Aug 08, 2027	DS U-1724			
		9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	003	9421192	Aug 08, 2027	DS U-1724			
		9421192	Aug 08, 2027	DS U-1725			
DACOMITINIB - VIZIMPRO							
N 211288	001	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
						ODE-213	Sep 27, 2025
DACOMITINIB - VIZIMPRO							
N 211288	002	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
						ODE-213	Sep 27, 2025
DACOMITINIB - VIZIMPRO							
N 211288	003	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
						ODE-213	Sep 27, 2025
DALBAVANCIN HYDROCHLORIDE - DALVANCE							
N 021883	001	6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
		7115564	Nov 14, 2023	DP		GAIN	May 23, 2024
		7119061	Nov 14, 2023	DP			
		8143212	Nov 14, 2023	U-1517			
DALFAMPRIDINE - AMPYRA							
N 022250	001	8007826	May 26, 2027	U-1030	Y		
		8354437	Dec 22, 2026	U-1030	Y		
		8440703	Apr 08, 2025	U-1030	Y		
DALTEPARIN SODIUM - FRAGMIN							
N 020287	001					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	002					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	003					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	004					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	005					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	006					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	007					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	008					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	009					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	010					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN							
N 020287	011					NPP	May 16, 2022
DANTROLENE SODIUM - RYANODEX							
N 205579	001	7758890	Jul 01, 2025	DP		ODE-69	Jul 22, 2021
		8110225	Dec 24, 2022	DP			
		8604072	Dec 24, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DANTROLENE SODIUM - RYANODEX							
N 205579	001	8685460	Feb 15, 2023	U-1546			
		9884044	Jun 13, 2022	DP U-1546			
DAPAGLIFLOZIN - FARXIGA							
N 202293	001	6414126	Oct 04, 2020	DS DP U-2139		M-212	Oct 20, 2020
		6414126	Oct 04, 2020	DS DP U-493		M-238	Feb 22, 2022
		6515117	Oct 04, 2020	DS DP U-2139			
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7456254	Jun 30, 2025	DP U-2139			
		7851502	Aug 19, 2028	DP			
		7919598	Dec 16, 2029	DS			
		8221786	Mar 21, 2028	DP			
		8329648	Aug 18, 2026	U-2139			
		8329648	Aug 18, 2026	U-2212			
		8329648	Aug 18, 2026	U-2213			
		8361972	Mar 21, 2028	U-2139			
		8361972	Mar 21, 2028	U-493			
		8431685	Apr 13, 2025	DP U-2139			
		8461105	Apr 13, 2025	DP U-2139			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		8716251	Mar 21, 2028	DP			
		8721615	Jan 18, 2030	DP	Y		
		8906851	Aug 18, 2026	U-2139			
		9198925	Oct 04, 2020	U-2139			
		9198925	Oct 04, 2020	U-493			
		9238076	Apr 15, 2024	DP U-2139			
DAPAGLIFLOZIN - FARXIGA							
N 202293	002	6414126	Oct 04, 2020	DS DP U-2139		M-212	Oct 20, 2020
		6414126	Oct 04, 2020	DS DP U-493		M-238	Feb 22, 2022
		6515117	Oct 04, 2020	DS DP U-2139			
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7456254	Jun 30, 2025	DP U-2139			
		7851502	Aug 19, 2028	DP			
		7919598	Dec 16, 2029	DS			
		8221786	Mar 21, 2028	DP			
		8329648	Aug 18, 2026	U-2139			
		8329648	Aug 18, 2026	U-2212			
		8329648	Aug 18, 2026	U-2213			
		8361972	Mar 21, 2028	U-2139			
		8361972	Mar 21, 2028	U-493			
		8431685	Apr 13, 2025	DP U-2139			
		8461105	Apr 13, 2025	DP U-2139			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		8716251	Mar 21, 2028	DP			
		8721615	Jan 18, 2030	DP	Y		
		8906851	Aug 18, 2026	U-2139			
		9198925	Oct 04, 2020	U-2139			
		9198925	Oct 04, 2020	U-493			
		9238076	Apr 15, 2024	DP U-2139			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	001	6414126	Oct 04, 2020	DS DP U-493			
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	002	6414126	Oct 04, 2020	DS DP U-493			
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	002	7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	003	6414126	Oct 04, 2020	DS DP U-493			
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	004	6414126	Oct 04, 2020	DS DP U-493			
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	005	6414126	Oct 04, 2020	DS DP U-493			
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR							
N 210874	001	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8628799	Jul 13, 2025	DP			
		8716251	Mar 21, 2028	DP			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
		RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR							
N 210874	002	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8628799	Jul 13, 2025	DP			
		8716251	Mar 21, 2028	DP			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
		RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR							
N 210874	003	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8628799	Jul 13, 2025	DP			
		8716251	Mar 21, 2028	DP			
		9198925	Oct 04, 2020	U-493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR							
N 210874	003	9616028	Nov 12, 2030	DP			
		RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR							
N 210874	004	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8628799	Jul 13, 2025	DP			
		8716251	Mar 21, 2028	DP			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
		RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN							
N 209091	001	6414126	Oct 04, 2020	DS DP U-493		I-804	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493		NC	Feb 27, 2020
		6936590	Oct 04, 2020	U-1976			
		6936590	Oct 04, 2020	U-1977			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8221786	Mar 21, 2028	DP			
		8361972	Mar 21, 2028	U-1976			
		8361972	Mar 21, 2028	U-1977			
		8361972	Mar 21, 2028	U-493			
		8501698	Jun 20, 2027	DP U-1976			
		8501698	Jun 20, 2027	DP U-1977			
		8501698	Jun 20, 2027	DP U-493			
		8628799	Jul 13, 2025	DP			
		8716251	Mar 21, 2028	DP			
		9198925	Oct 04, 2020	U-1976			
		9198925	Oct 04, 2020	U-1977			
		9198925	Oct 04, 2020	U-493			
		RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN							
N 209091	002	6414126	Oct 04, 2020	DS DP U-493		NS	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8221786	Mar 21, 2028	DP			
		8361972	Mar 21, 2028	U-493			
		8501698	Jun 20, 2027	DP U-493			
		8628799	Jul 13, 2025	DP			
		8716251	Mar 21, 2028	DP			
		9198925	Oct 04, 2020	U-493			
		RE44186	Jul 31, 2023	DS DP U-493			
DAPSONE - ACZONE							
N 207154	001	9161926	Nov 18, 2033	DP		NPP	Sep 10, 2022
		9517219	Nov 18, 2033	U-1033			
DAPTOMYCIN - DAPTOMYCIN							
A 212667	001					CGT	Jan 12, 2020
DAPTOMYCIN - CUBICIN							
N 021572	002	8003673	Sep 04, 2028	U-1180		M-211	Sep 01, 2020
						NPP	Mar 29, 2020
DAPTOMYCIN - CUBICIN RF							
N 021572	003	9138456	Nov 23, 2030	DP		M-211	Sep 01, 2020
						NPP	Mar 29, 2020
DAROLUTAMIDE - NUBEQA							
N 212099	001	10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
		10383853	Jan 28, 2036	DS			
		8975254	Oct 27, 2030	DS DP U-2605			
		9657003	Oct 27, 2030	DS DP U-2605			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAROLUTAMIDE - NUBEQA								
N 212099	001		10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
			10383853	Jan 28, 2036	DS			
			8975254	Oct 27, 2030	DS DP U-2605			
			9657003	Oct 27, 2030	DS DP U-2605			
DARUNAVIR - PREZISTA								
N 021976	001		7700645	Dec 26, 2026	DS DP			
			8518987	Feb 16, 2024	DS DP			
			8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA								
N 021976	002		7700645	Dec 26, 2026	DS DP			
			8518987	Feb 16, 2024	DS DP			
			8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA								
N 021976	003		7700645	Dec 26, 2026	DS DP			
			8518987	Feb 16, 2024	DS DP			
			8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA								
N 021976	004		7700645	Dec 26, 2026	DS DP			
			8518987	Feb 16, 2024	DS DP			
			8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA								
N 021976	005		7700645	Dec 26, 2026	DS DP			
			8518987	Feb 16, 2024	DS DP			
			8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA								
N 021976	006		7700645	Dec 26, 2026	DS DP			
			8518987	Feb 16, 2024	DS DP			
			8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA								
N 202895	001		7700645	Dec 26, 2026	DS DP			
			8518987	Feb 16, 2024	DS DP			
			8518987*PED	Aug 16, 2024				
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)								
N 206619	001		10201542	Oct 18, 2033	DP U-1753			
			7364752	Nov 10, 2020	DP			
			8188104	May 17, 2029	DS DP U-1636			
			8268349	Aug 25, 2024	DP			
			8399015	Aug 25, 2024	DP			
			8420596	Apr 10, 2031	DS DP			
			8466159	Sep 04, 2032	U-1637			
			8492386	Sep 04, 2032	U-1840			
			8501238	Sep 17, 2028	DS DP U-1636			
			8642538	Sep 10, 2029	DS DP U-1638			
			8680106	Sep 04, 2032	U-1637			
			8685984	Sep 04, 2032	U-1840			
			8686026	Jun 09, 2031	DP			
			8691938	Apr 13, 2032	DS DP			
			9006387	Jun 10, 2030	U-1687			
			9044480	Apr 10, 2031	U-1638			
			9139536	Nov 09, 2028	U-1753			
			9629841	Oct 18, 2033	DP U-1753			
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR								
N 208624	001		10105365	Jan 02, 2035	DP U-1889			
			10201541	May 17, 2032	DP			
			10201584	May 17, 2032	U-1889			
			7364752	Nov 10, 2020	DP			
			8188104	May 17, 2029	DS DP U-1636			
			8268349	Aug 25, 2024	DP			
			8399015	Aug 25, 2024	DP			
			8420596	Apr 10, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR							
N 208624	001	8466159	Sep 04, 2032	U-1637			
		8492386	Sep 04, 2032	U-1840			
		8501238	Sep 17, 2028	DS DP U-1636			
		8642538	Sep 10, 2029	DS DP U-1638			
		8680106	Sep 04, 2032	U-1637			
		8685984	Sep 04, 2032	U-1840			
		8686026	Jun 09, 2031	DP			
		8691938	Apr 13, 2032	DS DP			
		9006387	Jun 10, 2030	U-1687			
		9044480	Apr 10, 2031	U-1638			
		9139536	Nov 09, 2028	U-1753			
		9333204	Jan 02, 2035	DP U-1889			
		9744170	Jan 02, 2035	DP U-1889			
DASATINIB - SPRYCEL							
N 021986	001	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
		6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
		6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
		7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
		7125875	Apr 13, 2020	U-780		PED	May 09, 2021
		7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
		7153856	Apr 28, 2020	U-780		PED	May 09, 2025
		7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
		7491725	Mar 28, 2026	DS DP			
		7491725*PED	Sep 28, 2026				
		8680103	Feb 04, 2025	DP			
		8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL							
N 021986	002	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
		6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
		6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
		7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
		7125875	Apr 13, 2020	U-780		PED	May 09, 2021
		7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
		7153856	Apr 28, 2020	U-780		PED	May 09, 2025
		7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
		7491725	Mar 28, 2026	DS DP			
		7491725*PED	Sep 28, 2026				
		8680103	Feb 04, 2025	DP			
		8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL							
N 021986	003	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
		6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
		6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
		7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
		7125875	Apr 13, 2020	U-780		PED	May 09, 2021
		7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
		7153856	Apr 28, 2020	U-780		PED	May 09, 2025
		7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
		7491725	Mar 28, 2026	DS DP			
		7491725*PED	Sep 28, 2026				
		8680103	Feb 04, 2025	DP			
		8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL							
N 021986	004	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
		6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
		6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
		7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
		7125875	Apr 13, 2020	U-780		PED	May 09, 2021
		7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
		7153856	Apr 28, 2020	U-780		PED	May 09, 2025
		7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
		7491725	Mar 28, 2026	DS DP			
		7491725*PED	Sep 28, 2026				
		8680103	Feb 04, 2025	DP			
		8680103*PED	Aug 04, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - SPRYCEL						
N 021986 004	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL						
N 021986 005	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL						
N 021986 006	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
DEFERASIROX - DEFERASIROX						
A 208697 002					PC	Jun 14, 2020
DEFERASIROX - EXJADE						
N 021882 001					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020
DEFERASIROX - EXJADE						
N 021882 002					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020
DEFERASIROX - EXJADE						
N 021882 003					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020
DEFERASIROX - JADENU						
N 206910 001	9283209	Nov 21, 2034	DS DP		M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020
DEFERASIROX - JADENU						
N 206910 002	9283209	Nov 21, 2034	DS DP		M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFERASIROX - JADENU							
N 206910	003	9283209	Nov 21, 2034	DS DP		M-239	Dec 12, 2021
						M-241	Jul 24, 2022
						ODE-39	Jan 23, 2020
DEFERASIROX - JADENU SPRINKLE							
N 207968	001					M-239	Dec 12, 2021
						M-241	Jul 24, 2022
DEFERASIROX - JADENU SPRINKLE							
N 207968	002					M-239	Dec 12, 2021
						M-241	Jul 24, 2022
DEFERASIROX - JADENU SPRINKLE							
N 207968	003					M-239	Dec 12, 2021
						M-241	Jul 24, 2022
DEFERIPRONE - FERRIPROX							
N 021825	001	7049328	Jun 28, 2021	U-735			
DEFERIPRONE - FERRIPROX							
N 208030	001	7049328	Jun 28, 2021	U-735			
		8703156	Oct 29, 2029	DP U-735			
DEFERIPRONE - FERRIPROX							
N 208030	002	7049328	Jun 28, 2021	U-735			
		8703156	Oct 29, 2029	DP U-735			
DEFIBROTIDE SODIUM - DEFITELIO							
N 208114	001					NCE	Mar 30, 2021
						ODE-112	Mar 30, 2023
DEFLAZACORT - EMFLAZA							
N 208684	001					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
						ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA							
N 208684	002					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
						ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA							
N 208684	003					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
						ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA							
N 208684	004					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
						ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA							
N 208685	001					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
						ODE-252	Jun 07, 2026
DEGARELIX ACETATE - FIRMAGON							
N 022201	001	5925730	May 18, 2021	DS DP U-943			
		9415085	Apr 27, 2032	U-1895			
		9579359	Feb 10, 2029	U-1978			
DEGARELIX ACETATE - FIRMAGON							
N 022201	002	5925730	May 18, 2021	DS DP U-943			
		9415085	Apr 27, 2032	U-1895			
		9579359	Feb 10, 2029	U-1978			
DELAFLOXACIN MEGLUMINE - BAXDELA							
N 208610	001	7728143	Nov 20, 2027	DS		I-815	Oct 24, 2022
		8252813	Oct 02, 2026	DP U-2028		NCE	Jun 19, 2022
		8273892	Aug 06, 2026	DS		GAIN	Jun 19, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DELAFLOXACIN MEGLUMINE - BAXDELA									
N 208610	001		8648093	Oct 07, 2025		DP U-2028			
			8871938	Sep 23, 2029	DS				
			8969569	Oct 07, 2025		DP U-2028			
			9539250	Oct 07, 2025	DS	DP U-2028			
			RE46617	Dec 28, 2029	DS				
DELAFLOXACIN MEGLUMINE - BAXDELA									
N 208611	001		7635773	Mar 13, 2029		DP		I-815	Oct 24, 2022
			7728143	Nov 20, 2027	DS			NCE	Jun 19, 2022
			8252813	Oct 02, 2026		DP U-2028		GAIN	Jun 19, 2027
			8273892	Aug 06, 2026	DS				
			8410077	Mar 13, 2029		DP			
			8648093	Oct 07, 2025		DP U-2028			
			8871938	Sep 23, 2029	DS				
			9200088	Mar 13, 2029		DP			
			9493582	Feb 27, 2033		DP			
			9539250	Oct 07, 2025	DS	DP U-2028			
			9750822	Mar 13, 2029		DP			
			RE46617	Dec 28, 2029	DS				
DEOXYCHOLIC ACID - KYBELLA									
N 206333	001		7622130	Dec 10, 2027		U-1690			
			7754230	Dec 10, 2027		U-1690			
			8101593	Mar 02, 2030		DP			
			8242294	May 16, 2028	DS				
			8298556	Aug 03, 2025		U-1690			
			8367649	Mar 02, 2030		DP			
			8461140	Feb 21, 2028		DP			
			8546367	Feb 21, 2028		DP U-1690			
			8653058	Mar 02, 2030		DP			
			8846066	Feb 08, 2025		U-1690			
			8883770	Feb 21, 2028		DP			
			9522155	Feb 21, 2028		DP U-1940			
			9636349	Feb 21, 2028		U-1940			
			9949986	Feb 21, 2028		U-1940			
DESLORATADINE - CLARINEX									
N 021312	001		7618649	Dec 19, 2020		DP U-1017			
DESLORATADINE - CLARINEX									
N 021312	002		7618649	Dec 19, 2020		DP U-1017			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR									
N 021313	001		6709676	Feb 18, 2021		DP U-707			
			7618649	Dec 19, 2020		DP U-1017			
			8187630	Dec 19, 2020		DP U-1017			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR									
N 021605	001		6979463	Mar 28, 2022		DP			
			7618649	Dec 19, 2020		DP U-1017			
			7820199	Mar 28, 2022		DP			
DESMOPRESSIN ACETATE - NOCDURNA									
N 022517	001		10307459	May 07, 2023		DP		NP	Jun 21, 2021
			7560429	Feb 02, 2024		DP U-2326			
			7947654	Dec 29, 2023		DP			
			8802624	Dec 29, 2023		U-2326			
			9220747	May 07, 2023		U-2326			
			9504647	May 07, 2023		DP U-2326			
			9919025	May 07, 2023		U-2326			
			9974826	Apr 13, 2030		U-2326			
DESMOPRESSIN ACETATE - NOCDURNA									
N 022517	002		10137167	May 21, 2029		U-2327		NP	Jun 21, 2021
			10307459	May 07, 2023		DP			
			7560429	Feb 02, 2024		DP U-2326			
			7947654	Dec 29, 2023		DP			
			8802624	Dec 29, 2023		U-2326			
			9220747	May 07, 2023		U-2326			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESMOPRESSIN ACETATE - NOCDURNA							
N 022517	002	9504647	May 07, 2023	DP U-2326			
		9919025	May 07, 2023	U-2326			
		9974826	Apr 13, 2030	U-2327			
DESMOPRESSIN ACETATE - NOCTIVA							
N 201656	001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980			
		7799761	Sep 26, 2024	DP			
		9539302	Jun 15, 2030	DP			
DESMOPRESSIN ACETATE - NOCTIVA							
N 201656	002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980			
		9539302	Jun 15, 2030	DP			
DESONIDE - DESONATE							
N 021844	001	6387383	Aug 03, 2020	DS DP U-783			
DESONIDE - VERDESO							
N 021978	001	8460641	Aug 13, 2027	DP U-1412			
		8962000	Aug 31, 2025	DP U-1412			
		9492384	Aug 31, 2025	DP U-1412			
DESOXIMETASONE - TOPICORT							
N 204141	001	8277780	Sep 01, 2028	DP U-1408			
		8715624	May 26, 2026	DP U-1408			
DESVENLAFAXINE SUCCINATE - PRISTIQ							
N 021992	001	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860			
		8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ							
N 021992	002	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860			
		8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ							
N 021992	003	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860			
		8269040	Jul 05, 2027	DS			
DEUTETRABENAZINE - AUSTEDO							
N 208082	001	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846			
		9550780	Sep 18, 2033	DS DP U-1995			
		9814708	Sep 18, 2033	DP			
DEUTETRABENAZINE - AUSTEDO							
N 208082	002	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846			
		9550780	Sep 18, 2033	DS DP U-1995			
		9814708	Sep 18, 2033	DP			
DEUTETRABENAZINE - AUSTEDO							
N 208082	003	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846			
		9550780	Sep 18, 2033	DS DP U-1995			
		9814708	Sep 18, 2033	DP			
DEXAMETHASONE - OZURDEX							
N 022315	001	10076526	Jan 09, 2023	DP			
		6726918	Oct 20, 2020	DP U-1204			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXAMETHASONE - OZURDEX							
N 022315	001	6726918	Oct 20, 2020	DP U-1205			
		6899717	Nov 01, 2023	U-1206			
		7033605	Oct 20, 2020	DP			
		7767223	Nov 28, 2021	DP			
		8034366	Jan 09, 2023	DP U-1204			
		8034366	Jan 09, 2023	DP U-1205			
		8034370	Jan 09, 2023	DP			
		8043628	Oct 20, 2020	U-1205			
		8063031	Oct 20, 2020	DP			
		8088407	Oct 20, 2020	U-1205			
		8506987	Jan 09, 2023	U-1204			
		8506987	Jan 09, 2023	U-1205			
		9012437	Oct 20, 2020	U-1205			
		9192511	Jan 09, 2023	DP			
		9283178	Oct 20, 2020	U-1205			
		9592242	Oct 20, 2020	U-1989			
		9592242	Oct 20, 2020	U-1990			
		9775849	Oct 20, 2020	U-1989			
		9775849	Oct 20, 2020	U-1990			
DEXAMETHASONE - DEXTENZA							
N 208742	001	8409606	May 14, 2030	DP		I-800	Jun 20, 2022
		8563027	Feb 12, 2030	U-2487		NP	Nov 30, 2021
		9254267	Sep 11, 2024	DP			
DEXAMETHASONE - DEXYCU KIT							
N 208912	001	10022502	Sep 12, 2020	U-2340		NP	Feb 09, 2021
		10028965	May 23, 2034	U-2340			
		10159683	May 23, 2034	DP			
		6960346	Jul 03, 2023	DP			
		7560120	Sep 05, 2022	DP			
DEXAMETHASONE - HEMADY							
N 211379	001					ODE-271	Oct 03, 2026
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST							
N 050818	001	7795316	Aug 03, 2028	DP U-1082			
		8101582	Dec 19, 2027	DP U-1082			
		8450287	Dec 19, 2027	DP			
DEXLANSOPRAZOLE - DEXILANT							
N 022287	001	6462058	Jun 15, 2020	DS DP U-949			
		6462058	Jun 15, 2020	DS DP U-950			
		6462058	Jun 15, 2020	DS DP U-951			
		6664276	Jan 30, 2023	DS DP U-1507			
		6664276	Jan 30, 2023	DS DP U-949			
		6664276	Jan 30, 2023	DS DP U-950			
		6664276	Jan 30, 2023	DS DP U-951			
		6664276*PED	Jul 30, 2023				
		6939971	Jun 15, 2020	U-949			
		6939971	Jun 15, 2020	U-950			
		6939971	Jun 15, 2020	U-951			
		7285668	Jun 15, 2020	DS			
		7790755	Aug 02, 2026	DP			
		8105626	Sep 27, 2026	DP			
		8173158	Mar 17, 2030	U-949			
		8173158	Mar 17, 2030	U-950			
		8173158	Mar 17, 2030	U-951			
		8461187	Jan 17, 2026	DP			
		8461187*PED	Jul 17, 2026				
		8722084	Oct 15, 2023	DP			
		8722084*PED	Apr 15, 2024				
		8784885	Oct 15, 2023	DP U-1552			
		8784885	Oct 15, 2023	DP U-1553			
		8784885	Oct 15, 2023	DP U-1554			
		8784885*PED	Apr 15, 2024				
		8871273	Jan 11, 2028	DP			
		9011926	Feb 24, 2026	DP			
		9145389	Jun 15, 2020	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT SOLUTAB						
N 208056 001	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 002	10016396	Jan 04, 2032	DP			
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N	021038	002	9320712*PED	Jul 04, 2032				
			9616049	Jan 04, 2032	DP			
			9616049*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N	021038	003	10016396	Jan 04, 2032	DP			
			8242158	Jan 04, 2032	DP			
			8242158*PED	Jul 04, 2032				
			8338470	Jan 04, 2032	DP			
			8338470*PED	Jul 04, 2032				
			8455527	Jan 04, 2032	U-421			
			8455527*PED	Jul 04, 2032				
			8648106	Jan 04, 2032	DP			
			8648106*PED	Jul 04, 2032				
			9320712	Jan 04, 2032	DP			
			9320712*PED	Jul 04, 2032				
			9616049	Jan 04, 2032	DP			
			9616049*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N	021038	004	8242158	Jan 04, 2032	DP			
			8242158*PED	Jul 04, 2032				
			8338470	Jan 04, 2032	DP			
			8338470*PED	Jul 04, 2032				
			8455527	Jan 04, 2032	U-421			
			8455527*PED	Jul 04, 2032				
			8648106	Jan 04, 2032	DP			
			8648106*PED	Jul 04, 2032				
			9320712	Jan 04, 2032	DP			
			9320712*PED	Jul 04, 2032				
			9616049	Jan 04, 2032	DP			
			9616049*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE								
N	206628	003	9649296	Apr 20, 2036	DP			
			9717796	Apr 20, 2036	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE								
N	206628	004	9649296	Apr 20, 2036	DP			
			9717796	Apr 20, 2036	DP			
DEXRAZOXANE HYDROCHLORIDE - TOTECT								
N	022025	001	6727253	Mar 13, 2020	U-829			
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM								
N	021620	001	6372252	Apr 28, 2020	DP			
			6955821	Apr 28, 2020	DP		U-685	
			7838032	Apr 28, 2020	DP			
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM								
N	021620	002	6372252	Apr 28, 2020	DP			
			6955821	Apr 28, 2020	DP		U-685	
			7838032	Apr 28, 2020	DP			
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA								
N	021879	001	7659282	Aug 13, 2026	U-1093			
			8227484	Jul 17, 2023	U-1093			
DIAZOXIDE - DIAZOXIDE								
A	211050	001					CGT	Jun 17, 2020
DICHLORPHENAMIDE - KEVEYIS								
N	011366	002					ODE-96	Aug 07, 2022
DICLOFENAC - ZORVOLEX								
N	204592	001	8679544	Apr 23, 2030	DP			
			8999387	Apr 23, 2030	U-55			
			9017721	Apr 23, 2030	DP			
			9173854	Apr 23, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC - ZORVOLEX							
N 204592	001	9180095	Apr 23, 2030	U-55			
		9180096	Apr 23, 2030	DP			
		9186328	Apr 23, 2030	U-55			
DICLOFENAC - ZORVOLEX							
N 204592	002	8679544	Apr 23, 2030	DP			
		8999387	Apr 23, 2030	U-55			
		9017721	Apr 23, 2030	DP			
		9173854	Apr 23, 2030	DP			
		9180095	Apr 23, 2030	U-55			
		9180096	Apr 23, 2030	DP			
		9186328	Apr 23, 2030	U-55			
DICLOFENAC EPOLAMINE - LICART							
N 206976	001					NP	Dec 19, 2021
DICLOFENAC POTASSIUM - CAMBIA							
N 022165	001	7759394	Jun 16, 2026	DS DP U-436			
		8097651	Jun 16, 2026	DS DP U-436			
		8927604	Jun 16, 2026	U-436			
		9827197	Jun 16, 2026	DP			
DICLOFENAC POTASSIUM - ZIPSOR							
N 022202	001	7662858	Feb 24, 2029	U-1035			
		7884095	Feb 24, 2029	U-1111			
		7939518	Feb 24, 2029	U-980			
		8110606	Feb 24, 2029	U-980			
		8623920	Feb 24, 2029	U-1482			
		9561200	Feb 24, 2029	U-1482			
DICLOFENAC SODIUM - PENNSAID							
N 020947	001	8217078	Jul 10, 2029	U-1248			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8618164	Jul 10, 2029	U-1477			
		8741956	Jul 10, 2029	U-1435			
DICLOFENAC SODIUM - DYLOJECT							
N 022396	001	8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID							
N 204623	001	8217078	Jul 10, 2029	U-1477			
		8252838	Apr 21, 2028	DP U-1489			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8563613	Oct 17, 2027	DP U-1488			
		8618164	Jul 10, 2029	U-1477			
		8741956	Jul 10, 2029	U-1435			
		8871809	Oct 17, 2027	U-1614			
		9066913	Oct 17, 2027	DP U-1488			
		9101591	Oct 17, 2027	DP U-1488			
		9132110	Oct 17, 2027	U-1488			
		9168304	Oct 17, 2027	DP			
		9168305	Oct 17, 2027	U-1488			
		9220784	Oct 17, 2027	U-1488			
		9339551	Oct 17, 2027	U-1488			
		9339552	Oct 17, 2027	DP U-1488			
		9370501	Jul 10, 2029	U-1614			
		9375412	Jul 10, 2029	U-1614			
		9415029	Jul 10, 2029	U-1614			
		9539335	Oct 17, 2027	U-1614			
DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA							
N 022252	001	8071577	May 13, 2026	DP U-1			
		8153616	Jan 30, 2028	U-1240			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIGOXIN - DIGOXIN								
A 213000	001						CGT	Apr 01, 2020
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA								
N 021392	001		6923984	Feb 25, 2021	DP			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA								
N 021392	002		6923984	Feb 25, 2021	DP			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA								
N 021392	003		6923984	Feb 25, 2021	DP			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA								
N 021392	004		6923984	Feb 25, 2021	DP			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA								
N 021392	005		6923984	Feb 25, 2021	DP			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA								
N 021392	006		6923984	Feb 25, 2021	DP			
DIMETHYL FUMARATE - TECFIDERA								
N 204063	001		7619001	Jun 20, 2020	U-1384			
			8399514	Feb 07, 2028	U-1384			
DIMETHYL FUMARATE - TECFIDERA								
N 204063	002		7619001	Jun 20, 2020	U-1384			
			8399514	Feb 07, 2028	U-1384			
DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM								
N 021394	001		8263647	May 30, 2022	DP			
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM								
N 021393	001		8883849	Jan 17, 2022	U-1618			
			9155718	Jan 17, 2022	DP			
DIROXIMEL FUMARATE - VUMERITY								
N 211855	001		10080733	Sep 20, 2033	DS DP U-1384			
			8669281	Sep 20, 2033	DS DP			
			9090558	Sep 20, 2033	U-1384			
DOCETAXEL - DOCETAXEL								
N 205934	001		8940786	Sep 30, 2033	DP U-1789			
			9308195	Sep 30, 2033	DP			
			9763880	Sep 30, 2033	U-2558			
			9763880	Sep 30, 2033	U-2559			
			9763880	Sep 30, 2033	U-2560			
			9763880	Sep 30, 2033	U-2561			
			9763880	Sep 30, 2033	U-2562			
			9763880	Sep 30, 2033	U-2563			
			9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL								
N 205934	002		8940786	Sep 30, 2033	DP U-1789			
			9308195	Sep 30, 2033	DP			
			9763880	Sep 30, 2033	U-2558			
			9763880	Sep 30, 2033	U-2559			
			9763880	Sep 30, 2033	U-2560			
			9763880	Sep 30, 2033	U-2561			
			9763880	Sep 30, 2033	U-2562			
			9763880	Sep 30, 2033	U-2563			
			9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL								
N 205934	003		8940786	Sep 30, 2033	DP U-1789			
			9308195	Sep 30, 2033	DP			
			9763880	Sep 30, 2033	U-2558			
			9763880	Sep 30, 2033	U-2559			
			9763880	Sep 30, 2033	U-2560			
			9763880	Sep 30, 2033	U-2561			
			9763880	Sep 30, 2033	U-2562			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOCETAXEL - DOCETAXEL							
N 205934	003	9763880	Sep 30, 2033	U-2563			
		9763880	Sep 30, 2033	U-2564			
DOLUTEGRAVIR SODIUM - TIVICAY							
N 204790	001	8129385	Oct 05, 2027	DS DP		I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM - TIVICAY							
N 204790	002	8129385	Oct 05, 2027	DS DP		I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM - TIVICAY							
N 204790	003	8129385	Oct 05, 2027	DS DP		I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO							
N 211994	001	8129385	Oct 05, 2027	DS DP		NC	Apr 08, 2022
		9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA							
N 210192	001	10426780	Jan 24, 2031	DS DP U-257		NC	Nov 21, 2020
		6838464	Feb 26, 2021	DS DP			
		7125879	Apr 21, 2025	DS DP U-257			
		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			
		8129385	Oct 05, 2027	DS DP			
		9242986	Dec 08, 2029	DS DP			
DONEPEZIL HYDROCHLORIDE - ARICEPT							
N 022568	001	8481565	Oct 04, 2026	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	001	8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	002	8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	002	8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	003	8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	004	8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DORAVIRINE - PIFELTRO							
N 210806	001	8486975	Oct 07, 2031	DS DP U-2394		NCE	Aug 30, 2023
		8486975	Oct 07, 2031	DS DP U-2630			
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO							
N 210807	001	8486975	Oct 07, 2031	DS DP U-2395		I-806	Sep 19, 2022
		8486975	Oct 07, 2031	DS DP U-2629		NCE	Aug 30, 2023
DORIPENEM - DORIBAX							
N 022106	001	8247402	Mar 30, 2021	DS DP			
DORIPENEM - DORIBAX							
N 022106	002	8247402	Mar 30, 2021	DS DP			
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036	001	10238620	May 18, 2027	U-620			
		6211229	Feb 17, 2020	U-620			
		7915307	Aug 24, 2027	U-620			
		8513299	Sep 07, 2030	U-620			
		9107898	May 01, 2028	U-620			
		9486437	May 18, 2027	U-620			
		9532971	Jun 01, 2029	DP			
		9572814	Jul 20, 2027	U-620			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOXEPIN HYDROCHLORIDE - SILENOR								
N 022036	001		9861607	May 18, 2027	U-620			
			9907780	Apr 11, 2028	DP			
DOXEPIN HYDROCHLORIDE - SILENOR								
N 022036	002		10238620	May 18, 2027	U-620			
			6211229	Feb 17, 2020	U-620			
			7915307	Aug 24, 2027	U-620			
			8513299	Sep 07, 2030	U-620			
			9107898	May 01, 2028	U-620			
			9486437	May 18, 2027	U-620			
			9532971	Jun 01, 2029	DP			
			9572814	Jul 20, 2027	U-620			
			9861607	May 18, 2027	U-620			
			9907780	Apr 11, 2028	DP			
DOXYCYCLINE - ORACEA								
N 050805	001		10058564	Apr 05, 2022	U-1063			
			7211267	Apr 05, 2022	U-925			
			7232572	Apr 05, 2022	U-925			
			7749532	Dec 19, 2027	DP U-1063			
			8206740	Dec 24, 2025	DP U-925			
			8394405	Apr 07, 2024	DP U-925			
			8394406	Apr 07, 2024	DP U-925			
			8470364	Apr 07, 2024	DP U-925			
			8603506	Apr 05, 2022	U-1063			
			8709478	Apr 07, 2024	U-1063			
			9241946	Apr 05, 2022	U-1063			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	001		6958161	Dec 15, 2022	DP U-918			
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	002		6958161	Dec 15, 2022	DP U-918			
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	003		6958161	Dec 15, 2022	DP U-918			
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	004		6958161	Dec 15, 2022	DP U-918			
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	005		6958161	Dec 15, 2022	DP U-918			
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	006		6958161	Dec 15, 2022	DP U-918			
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX MPC								
N 050795	007		6958161	Dec 15, 2022	DP U-918			
			8715724	Feb 03, 2028	DP			
			9295652	Oct 23, 2034	DP U-918			
			9446057	Dec 23, 2034	DP U-918			
			9511031	Oct 23, 2034	DP			
DOXYCYCLINE HYCLATE - DORYX MPC								
N 050795	008		6958161	Dec 15, 2022	DP U-918			
			8715724	Feb 03, 2028	DP			
			9295652	Oct 23, 2034	DP U-918			
			9446057	Dec 23, 2034	DP U-918			
			9511031	Oct 23, 2034	DP			
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS								
N 021876	001		6340695	Jun 21, 2021	DP U-1382			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA							
N 209661	001	9089489	Feb 18, 2033	DP U-1382			
		9375404	Feb 18, 2033	DP U-1382			
		9526703	Feb 18, 2033	DP U-1382			
		9937132	Feb 18, 2033	DP U-1382			
DRONABINOL - SYNDROS							
N 205525	001	10265293	Aug 06, 2028	DS DP			
		8222292	Aug 06, 2028	DS DP			
		9345771	Aug 06, 2028	DS DP			
DRONEDARONE HYDROCHLORIDE - MULTAQ							
N 022425	001	8410167	Apr 16, 2029	U-1387			
		8410167	Apr 16, 2029	U-1388			
		8602215	Jun 30, 2031	U-1473			
		9107900	Apr 16, 2029	U-1726			
		9107900	Apr 16, 2029	U-1728			
DROSPIRENONE - SLYND							
N 211367	001	10179140	Jun 28, 2031	U-2553		NP	May 23, 2022
		9603860	Jun 28, 2031	U-2553			
DROSPIRENONE; ESTRADIOL - ANGELIQ							
N 021355	001	8906890	Oct 22, 2031	DP			
DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN							
N 021098	001	6787531	Aug 31, 2020	DP			
DROSPIRENONE; ETHINYL ESTRADIOL - YAZ							
N 021676	001	6787531	Aug 31, 2020	DP			
		6958326	Dec 20, 2021	DP			
		7163931	Dec 20, 2021	U-1			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ							
N 022532	001	6441168	Jul 30, 2022	DS			
		6958326	Dec 20, 2021	DP			
		7163931	Mar 03, 2022	U-1			
		8617597	Feb 08, 2030	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL							
N 022574	001	6441168	Apr 17, 2020	DS			
		6958326	Dec 20, 2021	DP			
		7163931	Mar 03, 2022	U-1			
		8617597	Feb 08, 2030	DP			
DROXIDOPA - NORTHERA							
N 203202	001					ODE-61	Feb 18, 2021
DROXIDOPA - NORTHERA							
N 203202	002					ODE-61	Feb 18, 2021
DROXIDOPA - NORTHERA							
N 203202	003					ODE-61	Feb 18, 2021
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516	001	10413525	Apr 13, 2037	DP			
		9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516	002	10413525	Apr 13, 2037	DP			
		9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516	003	10413525	Apr 13, 2037	DP			
		9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516	004	10413525	Apr 13, 2037	DP			
		9839626	Apr 13, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DUVELISIB - COPIKTRA							
N 211155	001	8193182	Feb 13, 2030	DS		NCE	Sep 24, 2023
		9216982	Jan 05, 2029	U-2412		ODE-208	Sep 24, 2025
		9216982	Jan 05, 2029	U-2413		ODE-209	Sep 24, 2025
		9840505	Jan 10, 2032	U-2412			
		9840505	Jan 10, 2032	U-2413			
		RE46621	May 17, 2032	DS DP			
DUVELISIB - COPIKTRA							
N 211155	002	8193182	Feb 13, 2030	DS		NCE	Sep 24, 2023
		9216982	Jan 05, 2029	U-2412		ODE-208	Sep 24, 2025
		9216982	Jan 05, 2029	U-2413		ODE-209	Sep 24, 2025
		9840505	Jan 10, 2032	U-2412			
		9840505	Jan 10, 2032	U-2413			
		RE46621	May 17, 2032	DS DP			
ECONAZOLE NITRATE - ECOZA							
N 205175	001	10071054	Aug 08, 2031	DP			
EDARAVONE - RADICAVA							
N 209176	001	6933310	Nov 13, 2020	U-2013		NCE	May 05, 2022
						ODE-144	May 05, 2024
EDARAVONE - RADICAVA							
N 209176	002	6933310	Nov 13, 2020	U-2013		NCE	May 05, 2022
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	001	7365205	Jun 12, 2023	DS		M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	002	7365205	Jun 12, 2023	DS		M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	003	7365205	Jun 12, 2023	DS		M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP		NCE	Jan 08, 2020
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA							
N 021937	001	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-750			
		6703396	Mar 09, 2021	DS DP			
		8592397	Jan 13, 2024	DP U-1170			
		8592397	Jan 13, 2024	DP U-750			
		8598185	Apr 28, 2029	DP			
		8716264	Jan 13, 2024	DP U-257			
		9018192	Jun 13, 2026	U-1170			
		9018192	Jun 13, 2026	U-750			
		9457036	Jan 13, 2024	DP U-257			
		9545414	Jun 13, 2026	DP U-1170			
		9545414	Jun 13, 2026	DP U-750			
		9744181	Jan 13, 2024	DP U-257			
EFINACONAZOLE - JUBLIA							
N 203567	001	10105444	Jul 08, 2030	DP			
		10512640	Jan 03, 2028	U-1969			
		7214506	Oct 05, 2021	U-281			
		8039494	Jul 08, 2030	U-281			
		8486978	Oct 24, 2030	DP			
		9302009	Oct 24, 2030	DP			
		9566272	Jan 03, 2028	U-1969			
		9662394	Oct 02, 2034	DP			
		9861698	Jul 08, 2030	DP			
		9877955	Jan 03, 2028	U-1969			
ELAGOLIX SODIUM - ORILISSA							
N 210450	001	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
		7056927	Sep 10, 2024	DS DP			
		7176211	Jul 06, 2024	U-2360			
		7179815	Mar 07, 2021	U-2360			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELAGOLIX SODIUM - ORILISSA							
N 210450	001	7419983	Jul 06, 2024	DS DP U-2360			
		7462625	Jan 25, 2021	DS DP U-2360			
ELAGOLIX SODIUM - ORILISSA							
N 210450	002	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
		7056927	Sep 10, 2024	DS DP			
		7176211	Jul 06, 2024	U-2360			
		7179815	Mar 07, 2021	U-2360			
		7419983	Jul 06, 2024	DS DP U-2360			
		7462625	Jan 25, 2021	DS DP U-2360			
ELBASVIR; GRAZOPREVIR - ZEPATIER							
N 208261	001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
		8871759	May 04, 2031	DS DP U-1813			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)							
N 212273	001	10022352	Apr 09, 2027	DP U-2651		NCE	Feb 12, 2023
		10081621	Mar 25, 2031	DP U-2652		NCE	Oct 21, 2024
		10239867	Apr 09, 2027	DS DP U-2653		ODE-275	Oct 21, 2026
		7495103	May 20, 2027	DS DP			
		7645789	May 01, 2027	DS DP			
		7776905	Jun 03, 2027	DS DP			
		8324242	Aug 05, 2027	U-2645			
		8354427	Jul 06, 2026	U-2646			
		8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-2645			
		8598181	May 01, 2027	U-2645			
		8623905	May 01, 2027	DS DP			
		8629162	Jun 24, 2025	U-2648			
		8754224	Dec 28, 2026	DS DP			
		9012496	Jul 15, 2033	U-2649			
		9670163	Dec 28, 2026	DP U-2650			
		9931334	Dec 28, 2026	DP U-2650			
		9974781	Apr 09, 2027	DP U-2645			
ELIGLUSTAT TARTRATE - CERDELGA							
N 205494	001	6916802	Apr 29, 2022	DS U-1571		ODE-73	Aug 19, 2021
		7196205	Jun 26, 2026	DS			
		7253185	Apr 29, 2022	DP			
		7615573	Apr 29, 2022	U-1571			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	001	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
		7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
		7160870*PED	May 20, 2023			PED	Feb 26, 2022
		7332481	May 24, 2021	U-1306			
		7332481	May 24, 2021	U-2451			
		7332481*PED	Nov 24, 2021				
		7452874	May 24, 2021	DS DP			
		7452874*PED	Nov 24, 2021				
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-2451			
		7473686*PED	Nov 24, 2021				
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-2451			
		7547719	Jul 13, 2025	DS DP U-2452			
		7547719*PED	Jan 13, 2026				
		7790704	May 24, 2021	U-1306			
		7790704	May 24, 2021	U-2451			
		7790704*PED	Nov 24, 2021				
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-2451			
		7795293*PED	Nov 21, 2023				
		8052993	Aug 01, 2027	DP U-1306			
		8052993	Aug 01, 2027	DP U-1575			
		8052993	Aug 01, 2027	DP U-2451			
		8052993	Aug 01, 2027	DP U-930			
		8052993*PED	Feb 01, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 005	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1575		ODE-75	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1714		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	005	7452874	May 24, 2021	DS DP U-1714			
		7452874*PED	Nov 24, 2021				
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-1575			
		7473686	May 24, 2021	DS DP U-1714			
		7473686	May 24, 2021	DS DP U-930			
		7473686*PED	Nov 24, 2021				
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-930			
		7547719*PED	Jan 13, 2026				
		7790704	May 24, 2021	U-1306			
		7790704	May 24, 2021	U-1575			
		7790704	May 24, 2021	U-930			
		7790704*PED	Nov 24, 2021				
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1575			
		7795293	May 21, 2023	U-930			
		7795293*PED	Nov 21, 2023				
ELTROMBOPAG OLAMINE - PROMACTA KIT							
N 207027	001	7160870	Nov 20, 2022	DS DP U-1306		ODE-74	Aug 26, 2021
		7160870	Nov 20, 2022	DS DP U-1736		PED	Feb 26, 2022
		7160870*PED	May 20, 2023				
		7332481	May 24, 2021	U-1306			
		7332481	May 24, 2021	U-1736			
		7332481*PED	Nov 24, 2021				
		7452874	May 24, 2021	DS DP			
		7452874*PED	Nov 24, 2021				
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-1736			
		7473686*PED	Nov 24, 2021				
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-1736			
		7547719	Jul 13, 2025	DS DP U-2452			
		7547719*PED	Jan 13, 2026				
		7790704	May 24, 2021	U-1306			
		7790704	May 24, 2021	U-1736			
		7790704*PED	Nov 24, 2021				
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1736			
		7795293*PED	Nov 24, 2023				
ELTROMBOPAG OLAMINE - PROMACTA KIT							
N 207027	002	7160870	Nov 20, 2022	DS DP U-1306			
		7160870	Nov 20, 2022	DS DP U-1736			
		7160870*PED	May 20, 2023				
		7332481	May 24, 2021	U-1306			
		7332481	May 24, 2021	U-1736			
		7332481*PED	Nov 24, 2021				
		7452874	May 24, 2021	DS DP			
		7452874*PED	Nov 24, 2021				
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-1736			
		7473686*PED	Nov 24, 2021				
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-1736			
		7547719	Jul 13, 2025	DS DP U-2452			
		7547719*PED	Jan 13, 2026				
		7790704	May 24, 2021	U-1306			
		7790704	May 24, 2021	U-1736			
		7790704*PED	Nov 24, 2021				
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1736			
		7795293*PED	Nov 21, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELUXADOLINE - VIBERZI							
N 206940	001	10188632	Mar 14, 2033	DP		NCE	May 27, 2020
		10213415	Mar 14, 2025	DS U-2152			
		7741356	Mar 25, 2028	DS DP			
		7786158	Mar 14, 2025	DS			
		8344011	Mar 14, 2025	U-1709			
		8609709	Mar 14, 2025	DS			
		8691860	Jul 07, 2028	DS U-1709			
		8772325	Mar 14, 2025	U-1709			
		9115091	Jul 07, 2028	DS DP U-1738			
		9205076	Mar 14, 2025	U-1709			
		9364489	Jul 07, 2028	U-1709			
		9675587	Mar 14, 2033	DP			
		9700542	Mar 14, 2025	DP			
		9789125	Jul 07, 2028	DP U-1709			
		9789125	Jul 07, 2028	DP U-2152			
ELUXADOLINE - VIBERZI							
N 206940	002	10188632	Mar 14, 2033	DP		NCE	May 27, 2020
		10213415	Mar 14, 2025	DS U-2152			
		7741356	Mar 25, 2028	DS DP			
		7786158	Mar 14, 2025	DS			
		8344011	Mar 14, 2025	U-1709			
		8609709	Mar 14, 2025	DS			
		8691860	Jul 07, 2028	DS U-1709			
		8772325	Mar 14, 2025	U-1709			
		9115091	Jul 07, 2028	DS DP U-1738			
		9205076	Mar 14, 2025	U-1709			
		9364489	Jul 07, 2028	U-1709			
		9675587	Mar 14, 2033	DP			
		9700542	Mar 14, 2025	DP			
		9789125	Jul 07, 2028	DP U-1709			
		9789125	Jul 07, 2028	DP U-2152			
ELVITEGRAVIR - VITEKTA							
N 203093	001	7176220	Aug 27, 2026	DS DP U-257			
		7635704	Oct 26, 2026	DS DP U-257			
		8981103	Oct 26, 2026	DS DP			
ELVITEGRAVIR - VITEKTA							
N 203093	002	7176220	Aug 27, 2026	DS DP U-257			
		7635704	Oct 26, 2026	DS DP U-257			
		8981103	Oct 26, 2026	DS DP			
EMPAGLIFLOZIN - JARDIANCE							
N 204629	001	10258637	Apr 03, 2034	U-2290			
		10406172	Jun 15, 2030	U-1652			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8551957	Oct 14, 2029	U-1651			
		9949997	May 17, 2034	U-2292			
		9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN - JARDIANCE							
N 204629	002	10258637	Apr 03, 2034	U-2290			
		10406172	Jun 15, 2030	U-1652			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8551957	Oct 14, 2029	U-1651			
		9949997	May 17, 2034	U-2292			
		9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073	001	10258637	Apr 03, 2034	U-2290			
		10406172	Jun 15, 2030	U-1652			
		7407955	May 02, 2025	DS DP			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8119648	Aug 12, 2023	U-1651			
		8178541	Aug 12, 2023	DP U-1653			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073	001	8178541	Aug 12, 2023	DP		U-1654	
		8551957	Oct 14, 2029	DP		U-1651	
		8673927	May 04, 2027			U-1652	
		8883805	Nov 26, 2025	DP			
		9173859	May 04, 2027	DP		U-1772	
		9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073	002	10258637	Apr 03, 2034			U-2290	
		10406172	Jun 15, 2030			U-1652	
		7407955	May 02, 2025	DS DP			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8119648	Aug 12, 2023			U-1651	
		8178541	Aug 12, 2023	DP		U-1653	
		8178541	Aug 12, 2023	DP		U-1654	
		8551957	Oct 14, 2029	DP		U-1651	
		8673927	May 04, 2027			U-1652	
		8883805	Nov 26, 2025	DP			
		9173859	May 04, 2027	DP		U-1772	
		9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	001	10258637	Apr 03, 2034			U-2290	
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	002	10258637	Apr 03, 2034			U-2290	
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	003	10258637	Apr 03, 2034			U-2290	
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	004	10258637	Apr 03, 2034			U-2290	
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	001	10258637	Apr 03, 2034			U-2290	
		6488962	Jun 20, 2020	DP			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	002	10258637	Apr 03, 2034			U-2290	
		6488962	Jun 20, 2020	DP			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	003	10258637	Apr 03, 2034			U-2290	
		6488962	Jun 20, 2020	DP			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	004	10258637	Apr 03, 2034			U-2290	
		6488962	Jun 20, 2020	DP			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034			U-2290	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR								
N 208658	004		10258637	Apr 03, 2034	U-2290			
			6488962	Jun 20, 2020	DP			
			7579449	Nov 05, 2025	DS			
			7713938	Apr 15, 2027	DS DP			
			9949998	Jun 11, 2034	U-2290			
EMTRICITABINE - EMTRIVA								
N 021500	001		6642245	Nov 04, 2020	U-257			
			6642245	Nov 04, 2020	U-541			
			6703396	Mar 09, 2021	DS DP			
EMTRICITABINE - EMTRIVA								
N 021896	001		6642245	Nov 04, 2020	U-257			
			6703396	Mar 09, 2021	DS DP			
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY								
N 208351	001		6642245	Nov 04, 2020	U-257		M-206	Aug 21, 2020
			6642245*PED	May 04, 2021			M-207	Aug 21, 2020
			6703396	Mar 09, 2021	DS DP		NCE	Nov 05, 2020
			6703396*PED	Sep 09, 2021				
			6838464	Feb 26, 2021	DS DP			
			7125879	Apr 21, 2025	DS DP U-257			
			7390791	May 07, 2022	DS DP			
			7803788	Feb 02, 2022	U-257			
			8080551	Apr 11, 2023	DS DP			
			8101629	Aug 09, 2022	DP			
			8754065	Aug 15, 2032	DS DP U-257			
			9296769	Aug 15, 2032	DS DP U-257			
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA								
N 202123	001		6642245	Nov 04, 2020	U-257			
			6703396	Mar 09, 2021	DS DP			
			6838464	Feb 26, 2021	DS DP			
			7125879	Apr 21, 2025	DS DP U-257			
			8080551	Apr 11, 2023	DS DP			
			8101629	Aug 09, 2022	DP			
			8592397	Jan 13, 2024	DP U-257			
			8716264	Jan 13, 2024	DP U-257			
			8841310	Dec 09, 2025	DP U-257			
			9457036	Jan 13, 2024	DP U-257			
			9744181	Jan 13, 2024	DP U-257			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY								
N 208215	001		6642245	Nov 04, 2020	U-1663		I-812	Oct 03, 2022
			6642245*PED	May 04, 2021			NCE	Nov 05, 2020
			6703396	Mar 09, 2021	DS DP		NPP	Sep 25, 2020
			6703396*PED	Sep 09, 2021				
			7390791	May 07, 2022	DS DP			
			7803788	Feb 02, 2022	U-1663			
			8754065	Aug 15, 2032	DS DP U-1259			
			8754065	Aug 15, 2032	DS DP U-1663			
			8754065	Aug 15, 2032	DS DP U-257			
			9296769	Aug 15, 2032	DS DP U-1259			
			9296769	Aug 15, 2032	DS DP U-1663			
			9296769	Aug 15, 2032	DS DP U-257			
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA								
N 021752	001		6642245	Nov 04, 2020	U-1170			
			6642245	Nov 04, 2020	U-248			
			6642245	Nov 04, 2020	U-541			
			6703396	Mar 09, 2021	DS DP			
			8592397	Jan 13, 2024	DP U-1170			
			8592397	Jan 13, 2024	DP U-248			
			8592397	Jan 13, 2024	DP U-541			
			8716264	Jan 13, 2024	DP U-257			
			9457036	Jan 13, 2024	DP U-257			
			9744181	Jan 13, 2024	DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	002	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-248			
		6642245	Nov 04, 2020	U-541			
		6642245*PED	May 04, 2021				
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	003	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-248			
		6642245	Nov 04, 2020	U-541			
		6642245*PED	May 04, 2021				
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	004	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-248			
		6642245	Nov 04, 2020	U-541			
		6642245*PED	May 04, 2021				
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
ENALAPRIL MALEATE - EPANED KIT							
N 204308	001	8568747	Nov 06, 2032	DP			
		8778366	Nov 06, 2032	U-1723			
		8778366	Nov 06, 2032	U-185			
		8778366	Nov 06, 2032	U-1892			
		8778366	Nov 06, 2032	U-3			
		8778366	Nov 06, 2032	U-71			
		9855214	Nov 06, 2032	DP			
		9968553	Nov 06, 2032	U-1723			
		9968553	Nov 06, 2032	U-185			
		9968553	Nov 06, 2032	U-1892			
		9968553	Nov 06, 2032	U-3			
		9968553	Nov 06, 2032	U-71			
ENALAPRIL MALEATE - EPANED							
N 208686	001	10039745	Mar 25, 2036	DP			
		10154987	Mar 25, 2036	U-1723			
		10154987	Mar 25, 2036	U-185			
		10154987	Mar 25, 2036	U-1892			
		10154987	Mar 25, 2036	U-3			
		10154987	Mar 25, 2036	U-71			
		9669008	Mar 25, 2036	DP			
		9808442	Mar 25, 2036	U-1723			
		9808442	Mar 25, 2036	U-185			
		9808442	Mar 25, 2036	U-1892			
		9808442	Mar 25, 2036	U-3			
		9808442	Mar 25, 2036	U-71			
ENASIDENIB MESYLATE - IDHIFA							
N 209606	001	10093654	Aug 01, 2034	DS DP U-2087		NCE	Aug 01, 2022
		10294215	Jan 07, 2033	DP U-2087		ODE-151	Aug 01, 2024
		9512107	Jan 07, 2033	DS DP U-2087			
		9732062	Sep 16, 2034	DS			
		9738625	Aug 01, 2034	DS			
ENASIDENIB MESYLATE - IDHIFA							
N 209606	002	10093654	Aug 01, 2034	DS DP U-2087		NCE	Aug 01, 2022
		10294215	Jan 07, 2033	DP U-2087		ODE-151	Aug 01, 2024
		9512107	Jan 07, 2033	DS DP U-2087			
		9732062	Sep 16, 2034	DS			
		9738625	Aug 01, 2034	DS			
ENCORAFENIB - BRAFTOVI							
N 210496	001	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
		8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
		8541575	Feb 26, 2030	DS DP U-2335			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENCORAFENIB - BRAFTOVI							
N 210496	001	8946250	Jul 23, 2029	DS DP			
		9314464	Jul 04, 2031	U-2336			
		9387208	Nov 21, 2032	DP			
		9593099	Aug 27, 2030	DS			
		9593100	Aug 27, 2030	DP			
		9763941	Nov 21, 2032	U-2335			
		9850229	Aug 27, 2030	U-2337			
		9850230	Aug 27, 2030	U-2334			
ENCORAFENIB - BRAFTOVI							
N 210496	002	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
		8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
		8541575	Feb 26, 2030	DS DP U-2335			
		8946250	Jul 23, 2029	DS DP			
		9314464	Jul 04, 2031	U-2336			
		9387208	Nov 21, 2032	DP			
		9593099	Aug 27, 2030	DS			
		9593100	Aug 27, 2030	DP			
		9763941	Nov 21, 2032	U-2335			
		9850229	Aug 27, 2030	U-2337			
		9850230	Aug 27, 2030	U-2334			
ENTRECTINIB - ROZLYTREK							
N 212725	001	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
		10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
		10398693	Jul 18, 2038	DP			
		8299057	Mar 01, 2029	DS DP			
		8673893	Jul 08, 2028	U-2617			
		8673893	Jul 08, 2028	U-2618			
		9029356	Jul 08, 2028	DS DP			
		9085558	Jul 08, 2028	DP			
		9085565	May 22, 2033	DS DP			
		9255087	Jul 08, 2028	U-2617			
		9255087	Jul 08, 2028	U-2618			
		9616059	Jul 08, 2028	U-2618			
		9649306	May 22, 2033	U-2617			
		9649306	May 22, 2033	U-2618			
ENTRECTINIB - ROZLYTREK							
N 212725	002	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
		10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
		10398693	Jul 18, 2038	DP			
		8299057	Mar 01, 2029	DS DP			
		8673893	Jul 08, 2028	U-2617			
		8673893	Jul 08, 2028	U-2618			
		9029356	Jul 08, 2028	DS DP			
		9085558	Jul 08, 2028	DP			
		9085565	May 22, 2033	DS DP			
		9255087	Jul 08, 2028	U-2617			
		9255087	Jul 08, 2028	U-2618			
		9616059	Jul 08, 2028	U-2618			
		9649306	May 22, 2033	U-2617			
		9649306	May 22, 2033	U-2618			
ENZALUTAMIDE - XTANDI							
N 203415	001	7709517	Aug 13, 2027	DS DP		I-786	Jul 13, 2021
		8183274	Aug 24, 2026	U-1281		I-808	Dec 16, 2022
		8183274	Aug 24, 2026	U-1588			
		8183274	Aug 24, 2026	U-2345			
		9126941	May 15, 2026	U-1588			
		9126941	May 15, 2026	U-2345			
EPINEPHRINE - EPIPEN							
N 019430	001	7449012	Sep 11, 2025	DP			
		7794432	Sep 11, 2025	DP			
		8048035	Sep 11, 2025	DP			
		8870827	Sep 11, 2025	DP			
		9586010	Sep 11, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - EPIPEN JR.							
N 019430	002	7449012	Sep 11, 2025	DP			
		7794432	Sep 11, 2025	DP			
		8048035	Sep 11, 2025	DP			
		8870827	Sep 11, 2025	DP			
		9586010	Sep 11, 2025	DP			
EPINEPHRINE - TWINJECT 0.3							
N 020800	001	7297136	Jan 18, 2025	DP			
		7621891	Feb 04, 2025	DP			
EPINEPHRINE - TWINJECT 0.15							
N 020800	002	7297136	Jan 18, 2025	DP			
		7621891	Feb 04, 2025	DP			
EPINEPHRINE - ADRENACLICK							
N 020800	003	10166344	Jan 21, 2025	DP			
		7905352	Apr 12, 2027	DP			
EPINEPHRINE - ADRENACLICK							
N 020800	004	10166344	Jan 21, 2025	DP			
		7905352	Apr 12, 2027	DP			
EPINEPHRINE - AUVI-Q							
N 201739	001	10314977	Nov 23, 2024	DP			
		10335549	Apr 30, 2025	DP			
		7731686	Jun 01, 2026	DP			
		7731690	Jan 15, 2025	DP			
		7749194	Oct 30, 2028	DP			
		7918823	Nov 23, 2024	DP			
		7947017	Mar 12, 2028	DP			
		8016788	Mar 21, 2025	DP			
		8021344	Nov 02, 2029	DP			
		8206360	Feb 27, 2027	DP			
		8226610	Apr 10, 2029	DP			
		8231573	Nov 25, 2028	DP			
		8313466	Nov 23, 2024	DP			
		8361029	Nov 23, 2024	DP			
		8425462	Nov 23, 2024	DP			
		8608698	Nov 23, 2024	DP			
		8920377	Nov 23, 2024	DP			
		8926594	Mar 31, 2026	DP			
		9056170	Nov 23, 2024	DP			
		9149579	Jul 19, 2025			U-1758	
		9238108	Feb 20, 2027	DP			
		9259539	Feb 01, 2026	DP			
		9278182	Feb 01, 2026	DP			
		9724471	May 23, 2027	DP		U-2092	
		9737669	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q							
N 201739	002	10314977	Nov 23, 2024	DP			
		10335549	Apr 30, 2025	DP			
		7731686	Jun 01, 2026	DP			
		7731690	Jan 15, 2025	DP			
		7749194	Oct 30, 2028	DP			
		7918823	Nov 23, 2024	DP			
		7947017	Mar 12, 2028	DP			
		8016788	Mar 21, 2025	DP			
		8021344	Nov 02, 2029	DP			
		8206360	Feb 27, 2027	DP			
		8226610	Apr 10, 2029	DP			
		8231573	Nov 25, 2028	DP			
		8313466	Nov 23, 2024	DP			
		8361029	Nov 23, 2024	DP			
		8425462	Nov 23, 2024	DP			
		8608698	Nov 23, 2024	DP			
		8920377	Nov 23, 2024	DP			
		8926594	Mar 31, 2026	DP			
		9056170	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q									
N 201739	002		9149579	Jul 19, 2025		U-1758			
			9238108	Feb 20, 2027		DP			
			9259539	Feb 01, 2026		DP			
			9278182	Feb 01, 2026		DP			
			9724471	May 23, 2027		DP U-2092			
			9737669	Nov 23, 2024		DP			
EPINEPHRINE - AUVI-Q									
N 201739	003		10314977	Nov 23, 2024		DP			
			10335549	Apr 30, 2025		DP			
			7731686	Jun 01, 2026		DP			
			7731690	Jan 15, 2025		DP			
			7749194	Oct 30, 2028		DP			
			7918823	Nov 23, 2024		DP			
			7947017	Mar 12, 2028		DP			
			8016788	Mar 21, 2025		DP			
			8021344	Nov 02, 2029		DP			
			8206360	Feb 27, 2027		DP			
			8226610	Apr 10, 2029		DP			
			8231573	Nov 25, 2028		DP			
			8313466	Nov 23, 2024		DP			
			8361029	Nov 23, 2024		DP			
			8425462	Nov 23, 2024		DP			
			8608698	Nov 23, 2024		DP			
			8920377	Nov 23, 2024		DP			
			8926594	Mar 31, 2026		DP			
			9056170	Nov 23, 2024		DP			
			9149579	Jul 19, 2025		U-1758			
			9238108	Feb 20, 2027		DP			
			9259539	Feb 01, 2026		DP			
			9278182	Feb 01, 2026		DP			
			9724471	May 23, 2027		DP U-2092			
			9737669	Nov 23, 2024		DP			
			9833573	Nov 23, 2024		U-2172			
EPINEPHRINE - ADRENALIN									
N 204200	001		9119876	Mar 13, 2035		DP			
			9295657	Mar 13, 2035		U-1829			
EPINEPHRINE - ADRENALIN									
N 204640	001		10130592	Mar 13, 2035		DP			
			9119876	Mar 13, 2035		DP			
			9295657	Mar 13, 2035		U-1829			
EPINEPHRINE - EPINEPHRINE									
N 205029	001		10004700	Aug 14, 2034		DP U-2325			
			10039728	Aug 14, 2034		U-1828			
			9283197	Aug 15, 2034		DP U-1828			
			9283197	Aug 15, 2034		DP U-1829			
			9283197	Aug 15, 2034		DP U-1830			
EPINEPHRINE - PRIMATENE MIST									
N 205920	001		8367734	Jan 26, 2026		DP		NP	Nov 07, 2021
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT									
N 021504	001		6629968	Jun 30, 2020	DS	DP			
			6635045	Jun 29, 2021	DS	DP			
EPOPROSTENOL SODIUM - VELETRI									
N 022260	001		8318802	Mar 15, 2027		DP			
			8598227	Feb 02, 2027					
EPOPROSTENOL SODIUM - VELETRI									
N 022260	002		8318802	Mar 15, 2027		DP			
			8598227	Feb 02, 2027					
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA									
N 211109	001		8796245	Aug 07, 2029		U-2380		NCE	Aug 27, 2023
			8906887	Dec 28, 2030		DP		GAIN	Aug 27, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA								
N	211109	001	8796245	Aug 07, 2029	U-2380		NCE	Aug 27, 2023
			8906887	Dec 28, 2030	DP		GAIN	Aug 27, 2028
ERDAFITINIB - BALVERSA								
N	212018	001	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
			9464071	Apr 28, 2031	U-2518			
			9902714	Mar 26, 2035	DP			
ERDAFITINIB - BALVERSA								
N	212018	002	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
			9464071	Apr 28, 2031	U-2518			
			9902714	Mar 26, 2035	DP			
ERDAFITINIB - BALVERSA								
N	212018	003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
			9464071	Apr 28, 2031	U-2518			
			9902714	Mar 26, 2035	DP			
ERIBULIN MESYLATE - HALAVEN								
N	201532	001	6214865	Jul 20, 2023	DS		ODE-107	Jan 28, 2023
			8097648	Jan 22, 2021	U-1096			
			RE46965	Jan 08, 2027	DP			
ERLOTINIB HYDROCHLORIDE - TARCEVA								
N	021743	001	6900221	Nov 09, 2020	DS DP U-1046			
			6900221	Nov 09, 2020	DS DP U-1403			
			6900221	Nov 09, 2020	DS DP U-659			
			6900221	Nov 09, 2020	DS DP U-875			
			6900221*PED	May 09, 2021				
			7087613	Nov 09, 2020	U-1045			
			7087613	Nov 09, 2020	U-1403			
			7087613	Nov 09, 2020	U-659			
			7087613*PED	May 09, 2021				
ERLOTINIB HYDROCHLORIDE - TARCEVA								
N	021743	002	6900221	Nov 09, 2020	DS DP U-1046			
			6900221	Nov 09, 2020	DS DP U-1403			
			6900221	Nov 09, 2020	DS DP U-659			
			6900221	Nov 09, 2020	DS DP U-875			
			6900221*PED	May 09, 2021				
			7087613	Nov 09, 2020	U-1045			
			7087613	Nov 09, 2020	U-1403			
			7087613	Nov 09, 2020	U-659			
			7087613*PED	May 09, 2021				
ERLOTINIB HYDROCHLORIDE - TARCEVA								
N	021743	003	6900221	Nov 09, 2020	DS DP U-1046			
			6900221	Nov 09, 2020	DS DP U-1403			
			6900221	Nov 09, 2020	DS DP U-659			
			6900221	Nov 09, 2020	DS DP U-875			
			6900221*PED	May 09, 2021				
			7087613	Nov 09, 2020	U-1045			
			7087613	Nov 09, 2020	U-1403			
			7087613	Nov 09, 2020	U-659			
			7087613*PED	May 09, 2021				
ERTUGLIFLOZIN - STEGLATRO								
N	209803	001	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
ERTUGLIFLOZIN - STEGLATRO								
N	209803	002	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET								
N	209806	001	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
			9308204	Oct 21, 2030	DP			
			9439902	Oct 21, 2030	U-2214			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET									
N	209806	002	8080580	Jul 13, 2030	DS	DP U-2214		NCE	Dec 19, 2022
			9308204	Oct 21, 2030		DP			
			9439902	Oct 21, 2030		U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET									
N	209806	003	8080580	Jul 13, 2030	DS	DP U-2214		NCE	Dec 19, 2022
			9308204	Oct 21, 2030		DP			
			9439902	Oct 21, 2030		U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET									
N	209806	004	8080580	Jul 13, 2030	DS	DP U-2214		NCE	Dec 19, 2022
			9308204	Oct 21, 2030		DP			
			9439902	Oct 21, 2030		U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN									
N	209805	001	6699871	Jul 26, 2022	DS	DP U-2214		NCE	Dec 19, 2022
			7326708	Nov 24, 2026	DS	DP U-2214			
			8080580	Jul 13, 2030	DS	DP U-2214			
			9308204	Oct 21, 2030		DP			
			9439901	Oct 21, 2030		U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN									
N	209805	002	6699871	Jul 26, 2022	DS	DP U-2214		NCE	Dec 19, 2022
			7326708	Nov 24, 2026	DS	DP U-2214			
			8080580	Jul 13, 2030	DS	DP U-2214			
			9308204	Oct 21, 2030		DP			
			9439901	Oct 21, 2030		U-2214			
ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE									
A	211991	001						CGT	May 09, 2020
ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE									
A	211991	002						CGT	May 09, 2020
ESCITALOPRAM OXALATE - LEXAPRO									
N	021323	001	6916941	Aug 12, 2022	DS	DP			
			7420069	Aug 12, 2022		DP			
ESCITALOPRAM OXALATE - LEXAPRO									
N	021323	002	6916941	Aug 12, 2022	DS	DP			
			7420069	Aug 12, 2022		DP			
ESCITALOPRAM OXALATE - LEXAPRO									
N	021323	003	6916941	Aug 12, 2022	DS	DP			
			7420069	Aug 12, 2022		DP			
ESKETAMINE HYDROCHLORIDE - SPRAVATO									
N	211243	001	8785500	Jul 09, 2031		U-2502		NCE*	Mar 05, 2024
			9592207	Mar 20, 2027		U-2502			
ESLICARBAZEPINE ACETATE - APTIOM									
N	022416	001	5753646	Jun 27, 2021	DS	DP U-2041			
			8372431	Apr 17, 2030		DP			
			9206135	Apr 21, 2026	DS				
			9566244	Oct 23, 2028		DP			
			9643929	Apr 21, 2026		DP			
			9750747	Aug 24, 2032		U-2041			
			9750747	Aug 24, 2032		U-2121			
			9763954	Sep 13, 2028		U-2123			
ESLICARBAZEPINE ACETATE - APTIOM									
N	022416	002	5753646	Jun 27, 2021	DS	DP U-2041			
			8372431	Apr 17, 2030		DP			
			9206135	Apr 21, 2026	DS				
			9566244	Oct 23, 2028		DP			
			9643929	Apr 21, 2026		DP			
			9750747	Aug 24, 2032		U-2041			
			9750747	Aug 24, 2032		U-2121			
			9763954	Sep 13, 2028		U-2123			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM									
N 022416	003		5753646	Jun 27, 2021	DS	DP U-2041			
			8372431	Apr 17, 2030		DP			
			9206135	Apr 21, 2026	DS				
			9566244	Oct 23, 2028		DP			
			9643929	Apr 21, 2026		DP			
			9750747	Aug 24, 2032		U-2041			
			9750747	Aug 24, 2032		U-2121			
			9763954	Sep 13, 2028		U-2123			
ESLICARBAZEPINE ACETATE - APTIOM									
N 022416	004		5753646	Jun 27, 2021	DS	DP U-2041			
			8372431	Apr 17, 2030		DP			
			9206135	Apr 21, 2026	DS				
			9566244	Oct 23, 2028		DP			
			9643929	Apr 21, 2026		DP			
			9750747	Aug 24, 2032		U-2041			
			9750747	Aug 24, 2032		U-2121			
			9763954	Sep 13, 2028		U-2123			
ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER									
N 019386	004		6310094	Jan 12, 2021					
			6528540	Jan 12, 2021					
ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER									
N 019386	005		6310094	Jan 12, 2021					
			6528540	Jan 12, 2021					
ESMOLOL HYDROCHLORIDE - BREVIBLOC									
N 019386	006		6310094	Jan 12, 2021					
			6528540	Jan 12, 2021					
ESMOLOL HYDROCHLORIDE - BREVIBLOC									
N 019386	007		6310094	Jan 12, 2021					
			6528540	Jan 12, 2021					
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER									
N 205703	001		6310094	Jan 12, 2021		DP			
			6528540	Jan 12, 2021		DP			
			8829054	Mar 15, 2033		DP			
			8835505	Mar 15, 2033		DP			
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER									
N 205703	002		6310094	Jan 12, 2021		DP			
			6528540	Jan 12, 2021		DP			
			8829054	Mar 15, 2033		DP			
			8835505	Mar 15, 2033		DP			
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR									
N 204655	001		6428810*PED	May 03, 2020					
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR									
N 207920	001		6428810*PED	May 03, 2020					
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO									
N 022511	001		6926907	Feb 28, 2023		DP U-1052		NPP	Jul 06, 2020
			8557285	May 31, 2022		DP			
			8852636	May 31, 2022		DP U-1052			
			8858996	May 31, 2022		DP U-1052			
			8945621	Oct 17, 2031		U-1661			
			9161920	May 31, 2022		U-1760			
			9198888	May 31, 2022		U-1781			
			9220698	Mar 10, 2031		U-1781			
			9345695	May 31, 2022		DP			
			9393208	Sep 03, 2029		U-1781			
			9707181	May 31, 2022		DP			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO									
N 022511	002		6926907	Feb 28, 2023		DP U-1052		NPP	Jul 06, 2020
			8557285	May 31, 2022		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	002	8852636	May 31, 2022	DP U-1052			
		8858996	May 31, 2022	DP U-1052			
		8945621	Oct 17, 2031	U-1661			
		9161920	May 31, 2022	U-1760			
		9198888	May 31, 2022	U-1781			
		9345695	May 31, 2022	DP			
		9393208	Sep 03, 2029	U-1781			
		9707181	May 31, 2022	DP			
ESTRADIOL - VAGIFEM							
N 020908	002	7018992	Sep 17, 2022	U-1023			
ESTRADIOL - ELESTRIN							
N 021813	001	7198801	Jun 25, 2022	DP			
		7470433	Aug 03, 2021	DP			
ESTRADIOL - EVAMIST							
N 022014	001	6978945	Jul 31, 2022	DP			
ESTRADIOL - MINIVELLE							
N 203752	001	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028	U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	002	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028	U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	003	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028	U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	004	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028	U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	005	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9724310	Jul 10, 2028	DS DP			
		9730900	Jul 10, 2028	DP U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - IMVEXXY							
N 208564	001	10258630	Dec 20, 2033	U-2316		NP	May 29, 2021
		10258630	Dec 20, 2033	U-2317			
		10398708	Dec 20, 2033	U-2317			
		10398708	Dec 20, 2033	U-2614			
		10471072	Jun 18, 2033	U-2316			
		10471072	Jun 18, 2033	U-2317			
		9180091	Dec 20, 2033	DP U-2316			
		9180091	Dec 20, 2033	DP U-2317			
		9289382	Nov 21, 2032	DP			
ESTRADIOL - IMVEXXY							
N 208564	002	10258630	Dec 20, 2033	U-2316		NP	May 29, 2021
		10258630	Dec 20, 2033	U-2317			
		10398708	Dec 20, 2033	U-2317			
		10398708	Dec 20, 2033	U-2614			
		10471072	Jun 18, 2033	U-2316			
		10471072	Jun 18, 2033	U-2317			
		9180091	Dec 20, 2033	DP U-2316			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - IMVEXXY								
N 208564	002		9180091	Dec 20, 2033	DP U-2317			
			9289382	Nov 21, 2032	DP			
ESTRADIOL ACETATE - FEMTRACE								
N 021633	001		6962908	Dec 21, 2021	DP			
			7572779	Oct 02, 2025	U-904			
			7799771	Dec 21, 2021	DP			
ESTRADIOL ACETATE - FEMTRACE								
N 021633	002		6962908	Dec 21, 2021	DP			
			7572779	Oct 02, 2025	U-904			
			7799771	Dec 21, 2021	DP			
ESTRADIOL ACETATE - FEMTRACE								
N 021633	003		6962908	Dec 21, 2021	DP			
			7572779	Oct 02, 2025	U-904			
			7799771	Dec 21, 2021	DP			
ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST								
N 021040	001		6747019	Mar 20, 2020	U-311			
			7320970	Mar 30, 2020	DP U-844			
ESTRADIOL; PROGESTERONE - BIJUVA								
N 210132	001		10052386	Nov 21, 2032	DP		NP	Oct 28, 2021
			10206932	Nov 21, 2032	U-2439			
			8633178	Nov 21, 2032	DP			
			8846648	Nov 21, 2032	U-2439			
			8846649	Nov 21, 2032	DP U-2439			
			8987237	Nov 21, 2032	DP			
			8993548	Nov 21, 2032	DP			
			8993549	Nov 21, 2032	DP			
			9006222	Nov 21, 2032	DP U-2439			
			9114145	Nov 21, 2032	U-2439			
			9114146	Nov 21, 2032	DP U-2439			
			9301920	Nov 21, 2032	DP U-2439			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
N 021443	001		6660726	Mar 08, 2021	DS DP U-904			
			6660726	Mar 08, 2021	DS DP U-905			
			6855703	Feb 12, 2021	DS DP U-904			
			6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
N 021443	002		6660726	Mar 08, 2021	DS DP U-904			
			6660726	Mar 08, 2021	DS DP U-905			
			6855703	Feb 12, 2021	DS DP U-904			
			6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
N 021443	003		6660726	Mar 08, 2021	DS DP U-904			
			6660726	Mar 08, 2021	DS DP U-905			
			6855703	Feb 12, 2021	DS DP U-904			
			6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
N 021443	004		6660726	Mar 08, 2021	DS DP U-904			
			6660726	Mar 08, 2021	DS DP U-905			
			6855703	Feb 12, 2021	DS DP U-904			
			6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
N 021443	005		6660726	Mar 08, 2021	DS DP U-904			
			6660726	Mar 08, 2021	DS DP U-905			
			6855703	Feb 12, 2021	DS DP U-904			
			6855703	Feb 12, 2021	DS DP U-905			
ETELCALCETIDE - PARSABIV								
N 208325	001		10344765	Jun 27, 2034	DP		NCE	Feb 07, 2022
			8377880	Jul 29, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETELCALCETIDE - PARSABIV							
N 208325	001	8999932	Jul 29, 2030	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV							
N 208325	002	10344765	Jun 27, 2034	DP		NCE	Feb 07, 2022
		8377880	Jul 29, 2030	DS DP			
		8999932	Jul 29, 2030	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV							
N 208325	003	10344765	Jun 27, 2034	DP		NCE	Feb 07, 2022
		8377880	Jul 29, 2030	DS DP			
		8999932	Jul 29, 2030	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETEPLIRSEN - EXONDYS 51							
N 206488	001	10337003	Mar 14, 2034	U-1918		NCE	Sep 19, 2021
		10364431	Mar 14, 2034	U-1918		ODE-122	Sep 19, 2023
		10364431	Mar 14, 2034	U-1919			
		8486907	Jun 28, 2025	U-1904	Y		
		9018368	Jun 28, 2025	DS DP			
		9243245	Oct 27, 2028	DS U-2097			
		9243245	Oct 27, 2028	DS U-2098			
		9416361	May 04, 2021	DS			
		9506058	Mar 14, 2034	U-1918			
		9506058	Mar 14, 2034	U-1919			
		RE47751	Jun 28, 2025	U-1918			
		RE47751	Jun 28, 2025	U-2664			
		RE47751	Jun 28, 2025	U-2673			
		RE47751	Jun 28, 2025	U-2674			
		RE47769	Jun 28, 2025	DP			
ETEPLIRSEN - EXONDYS 51							
N 206488	002	10337003	Mar 14, 2034	U-1918		NCE	Sep 19, 2021
		10364431	Mar 14, 2034	U-1918		ODE-122	Sep 19, 2023
		10364431	Mar 14, 2034	U-1919			
		8486907	Jun 28, 2025	U-1904	Y		
		9018368	Jun 28, 2025	DS DP			
		9243245	Oct 27, 2028	DS U-2097			
		9243245	Oct 27, 2028	DS U-2098			
		9416361	May 04, 2021	DS			
		9506058	Mar 14, 2034	U-1918			
		9506058	Mar 14, 2034	U-1919			
		RE47751	Jun 28, 2025	U-1918			
		RE47751	Jun 28, 2025	U-2664			
		RE47751	Jun 28, 2025	U-2673			
		RE47751	Jun 28, 2025	U-2674			
		RE47769	Jun 28, 2025	DP			
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE							
N 021840	001	7320969	Jan 30, 2024	U-828			
		7615545	Jun 15, 2023	U-1			
		7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT							
N 020946	001	6156742	Dec 05, 2020	U-374			
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE							
N 022262	001	7615545	Jun 15, 2023	U-1			
		7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE							
N 204061	001	8415332	Mar 11, 2029	DP			
		8450299	Oct 07, 2025	U-1			
ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA							
N 208612	001	6716814	Aug 16, 2021	DS DP			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE							
N 022501	001	7704984	Feb 02, 2029	U-1090			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - TAYTULLA							
N 204426	001	6652880	Mar 29, 2020	DP			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE							
N 204654	001	7704984	Feb 02, 2029	U-1			
ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA							
N 209627	001					NCE	Aug 10, 2023
ETHIODIZED OIL - LIPIODOL							
N 009190	001					ODE-64	Apr 04, 2021
ETONOGESTREL - IMPLANON							
N 021529	001	9757552	Jul 28, 2030	DP U-1			
ETONOGESTREL - NEXPLANON							
N 021529	002	8722037	Sep 28, 2027	DP			
		8888745	Aug 28, 2026	DP			
		9757552	Jul 28, 2030	DP U-1			
ETRAVIRINE - INTELENCE							
N 022187	001	6878717*PED	May 05, 2020			NPP	Jul 16, 2021
		7037917	Dec 13, 2020	DS DP U-1016		PED	Jan 16, 2022
		7037917	Dec 13, 2020	DS DP U-1237			
		7037917	Dec 13, 2020	DS DP U-2354			
		7037917	Dec 13, 2020	DS DP U-256			
		7037917*PED	Jun 13, 2021				
		8003789*PED	May 01, 2020				
ETRAVIRINE - INTELENCE							
N 022187	002	6878717*PED	May 05, 2020			NPP	Jul 16, 2021
		7037917	Dec 13, 2020	DS DP U-1016		PED	Jan 16, 2022
		7037917	Dec 13, 2020	DS DP U-1237			
		7037917	Dec 13, 2020	DS DP U-2354			
		7037917	Dec 13, 2020	DS DP U-256			
		7037917*PED	Jun 13, 2021				
		8003789*PED	May 01, 2020				
ETRAVIRINE - INTELENCE							
N 022187	003	6878717*PED	May 05, 2020			NPP	Jul 16, 2021
		7037917	Dec 13, 2020	DS DP U-1237		PED	Jan 16, 2022
		7037917	Dec 13, 2020	DS DP U-2354			
		7037917*PED	Jun 13, 2021				
		8003789*PED	May 01, 2020				
EVEROLIMUS - ZORTRESS							
N 021560	001	5665772*PED	Mar 09, 2020				
EVEROLIMUS - ZORTRESS							
N 021560	002	5665772*PED	Mar 09, 2020				
EVEROLIMUS - ZORTRESS							
N 021560	003	5665772*PED	Mar 09, 2020				
EVEROLIMUS - AFINITOR							
N 022334	001	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
		8410131*PED	May 01, 2026				
		8436010	Feb 22, 2022	U-1396			
		8436010*PED	Aug 22, 2022				
		8778962	Feb 18, 2022	U-1541			
		8778962*PED	Aug 18, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR						
N 022334 001	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 002	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 003	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 004	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 001	8617598	Sep 27, 2022	DP		I-773	Apr 10, 2021
	8617598*PED	Mar 27, 2023			ODE-169	Apr 10, 2025
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 002	8617598	Sep 27, 2022	DP		I-773	Apr 10, 2021
	8617598*PED	Mar 27, 2023			ODE-169	Apr 10, 2025
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 003	8617598	Sep 27, 2022	DP		I-773	Apr 10, 2021
	8617598*PED	Mar 27, 2023			ODE-169	Apr 10, 2025
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EXENATIDE - BYDUREON BCISE						
N 209210 001	6414126	Oct 04, 2020	U-2588		NP	Oct 20, 2020
	6479065	Aug 10, 2020	DP			
	6515117	Oct 04, 2020	U-2588			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE - BYDUREON BCISE							
N 209210	001	8329648	Aug 18, 2026	U-2588			
		8329648	Aug 18, 2026	U-2589			
		8329648	Aug 18, 2026	U-2590			
		8329648	Aug 18, 2026	U-2593			
		8329648	Aug 18, 2026	U-2594			
		8329648	Aug 18, 2026	U-2595			
		8329648	Aug 18, 2026	U-2596			
		8361972	Mar 21, 2028	U-2588			
		8431685	Apr 13, 2025	DP U-2589			
		8431685	Apr 13, 2025	DP U-2590			
		8431685	Apr 13, 2025	DP U-2597			
		8431685	Apr 13, 2025	DP U-2598			
		8461105	Apr 13, 2025	DP U-2589			
		8461105	Apr 13, 2025	DP U-2590			
		8461105	Apr 13, 2025	DP U-2597			
		8461105	Apr 13, 2025	DP U-2598			
		8501698	Jun 20, 2027	U-2588			
		8895033	Oct 04, 2030	DP U-2589			
		8895033	Oct 04, 2030	DP U-2590			
		8895033	Oct 04, 2030	DP U-2597			
		8895033	Oct 04, 2030	DP U-2600			
		8895033	Oct 04, 2030	DP U-2601			
		8895033	Oct 04, 2030	DP U-2602			
		8906851	Aug 18, 2026	U-2589			
		8906851	Aug 18, 2026	U-2590			
		8906851	Aug 18, 2026	U-2593			
		8906851	Aug 18, 2026	U-2597			
		9198925	Oct 04, 2020	U-2588			
		9238076	Apr 15, 2024	DP U-2589			
		9238076	Apr 15, 2024	DP U-2590			
		9238076	Apr 15, 2024	DP U-2597			
		9238076	Apr 15, 2024	DP U-2599			
		9884092	Aug 18, 2026	U-2589			
		9884092	Aug 18, 2026	U-2590			
		9884092	Aug 18, 2026	U-2593			
		9884092	Aug 18, 2026	U-2594			
		9884092	Aug 18, 2026	U-2595			
		9884092	Aug 18, 2026	U-2596			
		9884092	Aug 18, 2026	U-2597			
EXENATIDE SYNTHETIC - BYETTA							
N 021773	001	6872700	Jan 14, 2020	U-654			
		6902744	Jan 14, 2020	DP			
EXENATIDE SYNTHETIC - BYETTA							
N 021773	002	6872700	Jan 14, 2020	U-654			
		6902744	Jan 14, 2020	DP			
EXENATIDE SYNTHETIC - BYDUREON							
N 022200	001	6414126	Oct 04, 2020	DS DP U-2139		M-212	Oct 20, 2020
		6414126	Oct 04, 2020	DS DP U-493		M-224	Apr 02, 2021
		6479065	Aug 10, 2020	DP			
		6495164	May 25, 2020	DP			
		6515117	Oct 04, 2020	DS DP U-2139			
		6515117	Oct 04, 2020	DS DP U-493			
		6667061	May 25, 2020	DP			
		6824822	Oct 09, 2022	DP			
		6872700	Jan 14, 2020	U-2288			
		6872700	Jan 14, 2020	U-654			
		6936590	Oct 04, 2020	U-493			
		7223440	Aug 31, 2021	DP			
		7456254	Jun 30, 2025	DP U-1223			
		7563871	Apr 15, 2024	DP			
		7612176	Apr 13, 2025	DP U-1223			
		7851502	Aug 19, 2028	DP			
		7919598	Dec 16, 2029	DS			
		8221786	Mar 21, 2028	DP			
		8329648	Aug 18, 2026	U-1313			
		8361972	Mar 21, 2028	U-2139			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON							
N 022200	001	8361972	Mar 21, 2028	U-493			
		8431685	Apr 13, 2025	DP U-412			
		8461105	Apr 13, 2025	DP U-412			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		8716251	Mar 21, 2028	DP			
		8906851	Aug 18, 2026	U-1313			
		9198925	Oct 04, 2020	U-2139			
		9198925	Oct 04, 2020	U-493			
		9238076	Apr 15, 2024	DP U-412			
		9884092	Aug 18, 2026	U-1313			
		9884092	Aug 18, 2026	U-2154			
		9884092	Aug 18, 2026	U-2155			
		9884092	Aug 18, 2026	U-2156			
EXENATIDE SYNTHETIC - BYDUREON PEN							
N 022200	002	6414126	Oct 04, 2020	DS DP U-2139		M-224	Apr 02, 2021
		6414126	Oct 04, 2020	DS DP U-493			
		6479065	Aug 10, 2020	DP			
		6495164	May 25, 2020	DP			
		6515117	Oct 04, 2020	DS DP U-2139			
		6515117	Oct 04, 2020	DS DP U-493			
		6667061	May 25, 2020	DP			
		6824822	Oct 09, 2022	DP			
		6872700	Jan 14, 2020	U-2288			
		6872700	Jan 14, 2020	U-654			
		6936590	Oct 04, 2020	U-493			
		7223440	Aug 31, 2021	DP			
		7456254	Jun 30, 2025	DP U-1223			
		7563871	Apr 15, 2024	DP			
		7612176	Apr 13, 2025	DP U-1223			
		7851502	Aug 19, 2028	DP			
		7919598	Dec 16, 2029	DS			
		8216180	Jan 12, 2028	DP			
		8221786	Mar 21, 2028	DP			
		8329648	Aug 18, 2026	U-1313			
		8361972	Mar 21, 2028	U-2139			
		8361972	Mar 21, 2028	U-493			
		8431685	Apr 13, 2025	DP U-412			
		8439864	Mar 25, 2028	DP			
		8461105	Apr 13, 2025	DP U-412			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		8690837	May 19, 2029	DP			
		8716251	Mar 21, 2028	DP			
		8721615	Jan 18, 2030	DP			
		8758292	Nov 12, 2027	DP			
		8827963	Feb 04, 2029	DP			
		8906851	Aug 18, 2026	U-1313			
		8998876	Jan 07, 2030	DP			
		9198925	Oct 04, 2020	U-2139			
		9198925	Oct 04, 2020	U-493			
		9238076	Apr 15, 2024	DP U-412			
		9320853	Mar 25, 2028	DP			
		9884092	Aug 18, 2026	U-1313			
		9884092	Aug 18, 2026	U-2154			
		9884092	Aug 18, 2026	U-2155			
		9884092	Aug 18, 2026	U-2156			
EZETIMIBE - ZETIA							
N 021445	001	7030106	Jan 25, 2022	DP			
		7612058	Oct 30, 2025	U-1027			
		7612058	Oct 30, 2025	U-1173			
		7612058*PED	Apr 30, 2026				
FAMOTIDINE - PEPCID AC							
N 020801	002	6814978	Aug 26, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FAMOTIDINE; IBUPROFEN - DUEXIS							
N 022519	001	8067033	Jul 18, 2026	DP			
		8067451	Jul 18, 2026	DP U-1196			
		8309127	Jul 18, 2026	DP			
		8318202	Jul 18, 2026	DP			
		8449910	Jul 18, 2026	DP			
		8501228	Jul 18, 2026	U-1196			
FEBUXOSTAT - ULORIC							
N 021856	001	7361676	Mar 08, 2024	DP		M-205	Aug 15, 2020
		8372872	Sep 08, 2031	U-1346			
		9107912	Sep 08, 2031	U-1346			
FEBUXOSTAT - ULORIC							
N 021856	002	7361676	Mar 08, 2024	DP		M-205	Aug 15, 2020
		8372872	Sep 08, 2031	U-1346			
		9107912	Sep 08, 2031	U-1346			
FEDRATINIB HYDROCHLORIDE - INREBIC							
N 212327	001	10391094	Jun 04, 2032	DP U-2607		NCE	Aug 16, 2024
		7528143	Dec 16, 2026	DS		ODE-259	Aug 16, 2026
		7825246	Dec 16, 2026	DS			
		8138199	Jun 30, 2028	U-2607			
FENOFIBRATE - TRIGLIDE							
N 021350	001	6696084	Sep 11, 2021	DS DP U-680			
FENOFIBRATE - TRIGLIDE							
N 021350	002	6696084	Sep 11, 2021	DS DP U-680			
FENOFIBRATE - TRICOR							
N 021656	001	6375986	Sep 21, 2020	DP U-615			
		7276249	Feb 21, 2023	DP			
		7320802	Feb 21, 2023	U-847			
FENOFIBRATE - TRICOR							
N 021656	002	6375986	Sep 21, 2020	DP U-615			
		7276249	Feb 21, 2023	DP			
		7320802	Feb 21, 2023	U-847			
FENOFIBRATE - ANTARA (MICRONIZED)							
N 021695	001	7101574	Aug 20, 2020	DS DP			
		7863331	Aug 08, 2020	U-1106			
		7863331	Aug 08, 2020	U-1107			
FENOFIBRATE - ANTARA (MICRONIZED)							
N 021695	003	7101574	Aug 20, 2020	DS DP			
		7863331	Aug 08, 2020	U-1106			
		7863331	Aug 08, 2020	U-1107			
FENOFIBRATE - ANTARA (MICRONIZED)							
N 021695	004	8026281	Apr 22, 2025	U-1447			
		8026281	Apr 22, 2025	U-1448			
FENOFIBRATE - ANTARA (MICRONIZED)							
N 021695	005	8026281	Apr 22, 2025	U-1447			
		8026281	Apr 22, 2025	U-1448			
		9314447	May 31, 2033	DP U-1447			
		9314447	May 31, 2033	DP U-1448			
FENOFIBRATE - FENOGLIDE							
N 022118	001	7658944	Dec 09, 2024	DP			
		8124125	Oct 01, 2024	DP U-1234			
		8481078	Oct 01, 2024	DP U-1416			
		9173847	Oct 01, 2024	DP			
FENOFIBRATE - FENOGLIDE							
N 022118	002	7658944	Dec 09, 2024	DP			
		8124125	Oct 01, 2024	DP U-1234			
		8481078	Oct 01, 2024	DP U-1416			
		9173847	Oct 01, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRATE - FENOGLIDE							
N 022118	002	7658944	Dec 09, 2024	DP			
		8124125	Oct 01, 2024	DP		U-1234	
		8481078	Oct 01, 2024	DP		U-1416	
		9173847	Oct 01, 2024	DP			
FENOFIBRIC ACID - FIBRICOR							
N 022418	001	7569612	Aug 20, 2027			U-1000	
		7741373	Aug 20, 2027			U-1059	
		7741374	Aug 20, 2027			U-1060	
		7741374	Aug 20, 2027			U-1061	
		7915247	Aug 20, 2027			U-1000	
		7915247	Aug 20, 2027			U-1059	
		7915247	Aug 20, 2027			U-1061	
FENOFIBRIC ACID - FIBRICOR							
N 022418	002	7569612	Aug 20, 2027			U-1000	
		7741373	Aug 20, 2027			U-1059	
		7741374	Aug 20, 2027			U-1060	
		7741374	Aug 20, 2027			U-1061	
		7915247	Aug 20, 2027			U-1000	
		7915247	Aug 20, 2027			U-1059	
		7915247	Aug 20, 2027			U-1061	
FENTANYL - SUBSYS							
N 202788	001	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030			U-55	
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP		U-55	
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP		U-55	
		9642797	Jan 25, 2027	DP		U-55	
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	002	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030			U-55	
		8835460	Jan 25, 2027	DP		U-55	
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP		U-55	
		9642797	Jan 25, 2027	DP		U-55	
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	003	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030			U-55	
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP		U-55	
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP		U-55	
		9642797	Jan 25, 2027	DP		U-55	
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	004	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030			U-55	
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP		U-55	
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP		U-55	
		9642797	Jan 25, 2027	DP		U-55	
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	005	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL - SUBSYS								
N	202788	005	8486973	Apr 27, 2030	U-55			
			8835460	Jan 25, 2027	DP U-55			
			9241935	Jan 25, 2027	DP			
			9289387	Jan 25, 2027	DP U-55			
			9642797	Jan 25, 2027	DP U-55			
			9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS								
N	202788	006	10016403	Jan 25, 2027	DP			
			8486972	Apr 27, 2030	DP			
			8486973	Apr 27, 2030	U-55			
			8835459	Jan 25, 2027	DP			
			8835460	Jan 25, 2027	DP U-55			
			9241935	Jan 25, 2027	DP			
			9289387	Jan 25, 2027	DP U-55			
			9642797	Jan 25, 2027	DP U-55			
			9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS								
N	202788	007	10016403	Jan 25, 2027	DP			
			8486972	Apr 27, 2030	DP			
			8486973	Apr 27, 2030	U-55			
			8835459	Jan 25, 2027	DP			
			8835460	Jan 25, 2027	DP U-55			
			9241935	Jan 25, 2027	DP			
			9289387	Jan 25, 2027	DP U-55			
			9642797	Jan 25, 2027	DP U-55			
			9642844	Jan 25, 2027	DP			
FENTANYL CITRATE - FENTORA								
N	021947	001	7862832	Jun 15, 2028	DP			
			7862833	Jun 15, 2028	DP			
			8092832	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA								
N	021947	002	7862832	Jun 15, 2028	DP			
			7862833	Jun 15, 2028	DP			
			8092832	Dec 30, 2024	DP			
			8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA								
N	021947	003	7862832	Jun 15, 2028	DP			
			7862833	Jun 15, 2028	DP			
			8092832	Dec 30, 2024	DP			
			8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA								
N	021947	004	7862832	Jun 15, 2028	DP			
			7862833	Jun 15, 2028	DP			
			8092832	Dec 30, 2024	DP			
			8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA								
N	021947	005	7862832	Jun 15, 2028	DP			
			7862833	Jun 15, 2028	DP			
			8092832	Dec 30, 2024	DP			
			8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - ONSOLIS								
N	022266	001	7579019	Jan 22, 2020	U-767			
			9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS								
N	022266	002	7579019	Jan 22, 2020	U-767			
			9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS								
N	022266	003	7579019	Jan 22, 2020	U-767			
			9597288	Jul 23, 2027	DP U-767			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - ONSOLIS								
N 022266	003	7579019	Jan 22, 2020		U-767			
		9597288	Jul 23, 2027		DP U-767			
FENTANYL CITRATE - ONSOLIS								
N 022266	004	7579019	Jan 22, 2020		U-767			
		9597288	Jul 23, 2027		DP U-767			
FENTANYL CITRATE - ONSOLIS								
N 022266	005	7579019	Jan 22, 2020		U-767			
		9597288	Jul 23, 2027		DP U-767			
FENTANYL CITRATE - LAZANDA								
N 022569	001	8216604	Oct 03, 2024		U-767			
		8889176	Jan 16, 2024		U-767			
		9078814	Jan 08, 2024		DP			
		9731869	Jan 26, 2032		DP			
		9814705	Jan 08, 2024		DP			
FENTANYL CITRATE - LAZANDA								
N 022569	002	8216604	Oct 03, 2024		U-767			
		8889176	Jan 16, 2024		U-767			
		9078814	Jan 08, 2024		DP			
		9731869	Jan 26, 2032		DP			
		9814705	Jan 08, 2024		DP			
FENTANYL CITRATE - LAZANDA								
N 022569	003	9731869	Jan 26, 2032		DP			
		9814705	Jan 08, 2024		DP			
FENTANYL HYDROCHLORIDE - IONSYS								
N 021338	001	6881208	Apr 19, 2022		U-736			
		6975902	Apr 01, 2024		DP			
		8301238	Sep 30, 2031		DP			
		8428708	May 21, 2032		U-736			
		8428709	Jun 11, 2032		DP U-736			
		8781571	Mar 31, 2032		DP U-736			
		9095706	Feb 03, 2033		DP			
		9364656	Sep 30, 2031		U-736			
		9731121	Oct 17, 2031		DP			
FERRIC CARBOXYMALTOSE - INJECTAFER								
N 203565	001	7612109	Feb 05, 2024	DS	DP			
		7754702	Feb 15, 2028		DP U-1432			
		7754702	Feb 15, 2028		DP U-2555			
		7754702	Feb 15, 2028		DP U-2556			
		7754702	Feb 15, 2028		DP U-2557			
		8895612	Jan 08, 2027		DP U-1620			
		9376505	Oct 20, 2023	DS	DP			
FERRIC CITRATE - AURYXIA								
N 205874	001	10300039	Jul 21, 2030		U-2549		I-790	Nov 06, 2020
		5753706	Feb 03, 2020		DP U-1577			
		7767851	Feb 18, 2024	DS	DP			
		8093423	Apr 21, 2026		U-1577			
		8299298	Feb 18, 2024		DP			
		8338642	Feb 18, 2024	DS	DP U-1577			
		8609896	Feb 18, 2024		DP			
		8754257	Feb 18, 2024		DP			
		8754258	Feb 18, 2024		DP			
		8846976	Feb 18, 2024		U-1577			
		8901349	Feb 18, 2024		U-1577			
		9050316	Feb 18, 2024		U-1577			
		9328133	Feb 18, 2024	DS	DP U-1577			
		9387191	Jul 21, 2030		DP			
		9757416	Feb 18, 2024	DS	DP U-1577			
FERRIC MALTOL - ACCRUFER								
N 212320	001	10179120	Jan 06, 2035		U-2603		NCE	Jul 25, 2024
		9248148	Mar 29, 2031		U-2603			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC MALTOL - ACCRUFER							
N 212320	001	9802973	Oct 23, 2035	DS DP U-2603			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC							
N 206317	001	7816404	Apr 17, 2029	DP U-1656			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC							
N 208551	001	7816404	Apr 17, 2029	U-1656			
		7857977	Sep 08, 2027	U-1656			
FERUMOXYTOL - FERAHEME							
N 022180	001	6599498	Jun 30, 2023	DS DP		I-767	Feb 02, 2021
		7553479	Mar 08, 2020	DS DP			
		7871597	Mar 08, 2020	DS DP			
		8501158	Mar 08, 2020	U-1422			
		8591864	Mar 08, 2020	DP			
		8926947	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ							
N 022030	001	6858650	Jul 03, 2022	DS U-913			
		7807715	Jun 07, 2027	DP U-913			
		8088398	Jun 07, 2027	DP U-913			
		8501723	Jun 07, 2027	DP			
FESOTERODINE FUMARATE - TOVIAZ							
N 022030	002	6858650	Jul 03, 2022	DS U-913			
		7807715	Jun 07, 2027	DP U-913			
		8088398	Jun 07, 2027	DP U-913			
		8501723	Jun 07, 2027	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY							
N 021909	002	6723348	Nov 26, 2021	DP U-1466			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES							
N 021909	003	6723348	Nov 26, 2021	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY							
N 201373	001	8933097	Aug 02, 2030	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES							
N 201373	002	8933097	Aug 02, 2030	DP			
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION							
N 021704	002	6613357	Dec 25, 2020	DP U-1159			
FIDAXOMICIN - DIFICID							
N 201699	001	7378508	Jul 31, 2027	DS DP			
		7863249	Jul 31, 2027	DS DP			
		7906489	Mar 04, 2027	U-319			
		8586551	Jul 15, 2023	DS DP			
		8586551*PED	Jan 15, 2024				
		8859510	Jul 31, 2027	U-319			
		8859510*PED	Jan 31, 2028				
FINAFLOXACIN - XTORO							
N 206307	001	8536167	Aug 08, 2031	U-1679			
		9119859	Jul 02, 2030	U-1679			
		9504691	Nov 21, 2033	DP U-1679			
FINGOLIMOD HYDROCHLORIDE - GILENYA							
N 022527	001	8324283	Mar 29, 2026	DP		NPP	May 11, 2021
		8324283*PED	Sep 29, 2026			PED	Nov 11, 2021
		9187405	Jun 25, 2027	U-2613			
		9187405*PED	Dec 25, 2027				
FINGOLIMOD HYDROCHLORIDE - GILENYA							
N 022527	002	9592208	Mar 30, 2032	DP U-2315		NS	May 11, 2021
		9592208*PED	Sep 30, 2032			PED	Nov 11, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FISH OIL TRIGLYCERIDES - OMEGAVEN								
N 210589	001		10350186	Nov 05, 2024	U-2585		NCE	Jul 27, 2023
			9566260	Jul 11, 2025	DP U-2366		ODE-202	Jul 27, 2025
			9629821	Jul 11, 2025	DP U-2367			
FISH OIL TRIGLYCERIDES - OMEGAVEN								
N 210589	002		10350186	Nov 05, 2024	U-2585		NCE	Jul 27, 2023
			9566260	Jul 11, 2025	DP U-2366		ODE-202	Jul 27, 2025
			9629821	Jul 11, 2025	DP U-2367			
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%								
N 207648	001						NCE	Jul 13, 2021
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%								
N 207648	002						NCE	Jul 13, 2021
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%								
N 207648	003						NCE	Jul 13, 2021
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%								
N 207648	004						NCE	Jul 13, 2021
FLIBANSERIN - ADDYI								
N 022526	001		7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
			7420057	Aug 01, 2022	DS DP			
			8227471	May 09, 2023	U-1734			
			9468639	Oct 16, 2022	U-1734			
FLORBETABEN F-18 - NEURACEQ								
N 204677	001		7807135	Mar 18, 2029	DS DP U-1497			
FLORBETAPIR F-18 - AMYVID								
N 202008	001		7687052	Apr 30, 2027	DS DP			
			8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID								
N 202008	002		7687052	Apr 30, 2027	DS DP			
			8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID								
N 202008	003		7687052	Apr 30, 2027	DS DP			
			8506929	Apr 30, 2027	DS DP U-1423			
FLUCICLOVINE F-18 - AXUMIN								
N 208054	001		10010632	Nov 28, 2026	DP		NCE	May 27, 2021
			10124079	Dec 30, 2035	U-2450			
			5808146	Nov 09, 2020	DS			
			9387266	Nov 28, 2026	U-1879			
FLUDARABINE PHOSPHATE - OFORTA								
N 022273	001		7148207	Dec 20, 2022	DP U-944			
FLUOCINOLONE ACETONIDE - ILUVIEN								
N 201923	001		6375972	Apr 26, 2020	DP U-1597			
			8871241	Aug 12, 2027	DP			
FLUOCINOLONE ACETONIDE - YUTIQ								
N 210331	001		6375972	Apr 26, 2020	DP U-708		NP	Nov 12, 2021
			8574613	Apr 26, 2020	DP			
			8574659	Apr 26, 2020	DP			
			8871241	Aug 12, 2027	DP			
			9192579	Apr 26, 2020	DP			
			9849085	Apr 26, 2020	U-708			
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA								
N 021112	001		7915243	Sep 08, 2023	DP			
			7939516	Sep 08, 2023	DP			
			8247395	Oct 25, 2022	DP			
			8653053	Oct 25, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUOCINONIDE - VANOS							
N 021758	001	6765001	Dec 21, 2021	DP			
		7220424	Jan 07, 2023	U-861			
		7794738	Sep 11, 2022	U-1084			
		8232264	Mar 09, 2023	DP			
FLUORODOPA F-18 - FLUORODOPA F18							
N 200655	001					NCE	Oct 10, 2024
						W	Oct 10, 2024
FLUOROURACIL - CARAC							
N 020985	001	6670335	Jun 02, 2021	DP U-68			
FLUOROURACIL - TOLAK							
N 022259	001	7169401	Jul 18, 2023	DP			
FLUTEMETAMOL F-18 - VIZAMYL							
N 203137	001	7270800	Sep 03, 2025	DS DP U-336			
		7351401	Jan 24, 2023	DS DP U-336			
		8236282	May 21, 2024	DS DP			
		8691185	Jan 24, 2023	U-336			
		8916131	Sep 16, 2028	DP			
FLUTEMETAMOL F-18 - VIZAMYL							
N 203137	002	7270800	Sep 03, 2025	DS DP U-336			
		7351401	Jan 24, 2023	DS DP U-336			
		8236282	May 21, 2024	DS DP			
		8691185	Jan 24, 2023	U-336			
		8916131	Sep 16, 2028	DP			
FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF							
N 022051	002	6858596	Aug 03, 2021	DP U-1890			
		7101866	Aug 03, 2021	DS DP U-1890			
		7541350	Aug 03, 2021	DP U-1890			
		8062264	Apr 05, 2026	DP			
		8147461	Oct 15, 2028	DP			
		8347879	Jul 15, 2028	DP			
		8752543	Apr 05, 2026	DP			
		9320862	Nov 06, 2024	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA							
N 205625	001	7101866	Aug 03, 2021	DS DP U-1559		NPP	May 17, 2021
		7629335	Aug 03, 2021	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8201556	Feb 05, 2029	DP			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA							
N 205625	002	7101866	Aug 03, 2021	DS DP U-1559			
		7629335	Aug 03, 2021	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8201556	Feb 05, 2029	DP			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA							
N 205625	003	7101866	Aug 03, 2021	DS DP U-2349		NS	May 17, 2021
		7629335	Aug 03, 2021	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8201556	Feb 05, 2029	DP			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA								
N 209482	001	6537983	Aug 03, 2021		DP U-2125		I-775	Apr 24, 2021
		6759398	Aug 03, 2021		DP U-2125			
		6878698	Aug 03, 2021		U-2134			
		7101866	Aug 03, 2021	DS	DP U-2126			
		7439393	May 21, 2025	DS	DP U-2127			
		7488827	Dec 18, 2027	DS	DP			
		7498440	Apr 27, 2025	DS	DP			
		7629335	Aug 03, 2021		DP			
		7776895	Sep 11, 2022		DP			
		8113199	Oct 23, 2027		DP			
		8161968	Feb 05, 2028		DP			
		8183257	Jul 27, 2025		U-2128			
		8309572	Apr 27, 2025		U-2129			
		8511304	Jun 14, 2027		DP			
		8534281	Mar 08, 2030		DP			
		8746242	Oct 11, 2030		DP			
		9333310	Oct 02, 2027		DP			
		9750726	Nov 29, 2030		DP			
		RE44874	Mar 23, 2023	DS	DP U-2127			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	001	6537983	Aug 03, 2021		DP U-1401		M-202	May 15, 2020
		6537983	Aug 03, 2021		DP U-1691			
		6759398	Aug 03, 2021		DP U-1401			
		6759398	Aug 03, 2021		DP U-1691			
		6878698	Aug 03, 2021		U-1401			
		7101866	Aug 03, 2021	DS	DP U-1401			
		7101866	Aug 03, 2021	DS	DP U-1691			
		7439393	May 21, 2025	DS	DP U-1401			
		7439393	May 21, 2025	DS	DP U-1691			
		7439393	May 21, 2025	DS	DP U-2099			
		7439393	May 21, 2025	DS	DP U-2100			
		7629335	Aug 03, 2021		DP			
		7776895	Sep 11, 2022		DP			
		8113199	Oct 23, 2027		DP			
		8161968	Feb 05, 2028		DP			
		8511304	Jun 14, 2027		DP U-1424			
		8511304	Jun 14, 2027		DP U-1691			
		8534281	Mar 08, 2030		DP			
		8746242	Oct 11, 2030		DP			
		9333310	Oct 02, 2027		DP			
		RE44874	Mar 23, 2023	DS	DP U-1548			
		RE44874	Mar 23, 2023	DS	DP U-1691			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	002	6537983	Aug 03, 2021		DP U-1691		M-202	May 15, 2020
		6759398	Aug 03, 2021		DP U-1691			
		7101866	Aug 03, 2021	DS	DP U-1691			
		7439393	May 21, 2025	DS	DP U-1691			
		7439393	May 21, 2025	DS	DP U-2099			
		7439393	May 21, 2025	DS	DP U-2100			
		7629335	Aug 03, 2021		DP			
		7776895	Sep 11, 2022		DP			
		8113199	Oct 23, 2027		DP			
		8161968	Feb 05, 2028		DP			
		8511304	Jun 14, 2027		DP U-1691			
		8534281	Mar 08, 2030		DP			
		8746242	Oct 11, 2030		DP			
		9333310	Oct 02, 2027		DP			
		RE44874	Mar 23, 2023	DS	DP U-1691			
FLUTICASONE PROPIONATE - FLOVENT HFA								
N 021433	001	7500444	Feb 26, 2026		DP			
		7500444*PED	Aug 26, 2026					
		7832351	Jun 19, 2023		DP			
		9861771	Oct 11, 2020		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT HFA							
N 021433	002	6743413	Jun 01, 2021	U-581	Y		
		7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
		9861771	Oct 11, 2020	DP			
FLUTICASONE PROPIONATE - FLOVENT HFA							
N 021433	003	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
		9861771	Oct 11, 2020	DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK							
N 208798	001	10022510	May 18, 2031	DP		NP	Jan 27, 2020
		10124131	May 18, 2031	DP			
		10195375	Feb 14, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
		8714149	Feb 25, 2032	DP			
		8978966	Jan 13, 2032	DP			
		9216260	Jun 28, 2031	DP			
		9463288	May 19, 2025	DP			
		9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK							
N 208798	002	10022510	May 18, 2031	DP		NP	Jan 27, 2020
		10124131	May 18, 2031	DP			
		10195375	Feb 14, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
		8714149	Feb 25, 2032	DP			
		8978966	Jan 13, 2032	DP			
		9216260	Jun 28, 2031	DP			
		9463288	May 19, 2025	DP			
		9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK							
N 208798	003	10022510	May 18, 2031	DP		NP	Jan 27, 2020
		10124131	May 18, 2031	DP			
		10195375	Feb 14, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
		8714149	Feb 25, 2032	DP			
		8978966	Jan 13, 2032	DP			
		9216260	Jun 28, 2031	DP			
		9463288	May 19, 2025	DP			
		9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - XHANCE							
N 209022	001	10076614	Oct 20, 2034	DP		NP	Sep 18, 2020
		10076615	Jul 30, 2029	U-2133			
		10124132	Mar 06, 2027	DP U-2133			
		10179216	Jul 08, 2033	DP U-2133			
		10252010	Feb 07, 2031	DP			
		10300229	Jul 07, 2035	DP U-2133			
		10478574	Nov 04, 2033	U-2133			
		6715485	Mar 03, 2020	DP			
		7975690	Dec 29, 2025	U-2133			
		8327844	Oct 08, 2023	U-2133			
		8522778	May 11, 2022	DP			
		8550073	Oct 22, 2029	DP			
		8555878	Mar 20, 2020	DP			
		8978647	Aug 06, 2030	DP			
		9072857	Apr 10, 2021	DP			
		9468727	Jul 30, 2020	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50							
N 021077	001					M-214	Dec 20, 2020
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50							
N 021077	002					M-214	Dec 20, 2020
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50							
N 021077	003					M-214	Dec 20, 2020
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	001	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
		9861771	Oct 11, 2020	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	002	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
		9861771	Oct 11, 2020	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	003	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
		9861771	Oct 11, 2020	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	001	10022510	May 18, 2031	DP		NP	Jan 27, 2020
		10124131	May 18, 2031	DP			
		10195375	Feb 14, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
		8714149	Feb 25, 2032	DP			
		8978966	Jan 13, 2032	DP			
		9066957	Oct 06, 2034	DP U-645			
		9216260	Jun 28, 2031	DP			
		9415008	Oct 06, 2034	DP U-645			
		9463288	May 19, 2025	DP			
		9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			
		9987229	Sep 01, 2024	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	002	10022510	May 18, 2031	DP		NP	Jan 27, 2020
		10124131	May 18, 2031	DP			
		10195375	Feb 14, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	002	6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
		8714149	Feb 25, 2032	DP			
		8978966	Jan 13, 2032	DP			
		9066957	Oct 06, 2034	DP U-645			
		9216260	Jun 28, 2031	DP			
		9463288	May 19, 2025	DP			
		9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			
		9987229	Sep 01, 2024	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	003	10022510	May 18, 2031	DP		NP	Jan 27, 2020
		10124131	May 18, 2031	DP			
		10195375	Feb 14, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
		8714149	Feb 25, 2032	DP			
		8978966	Jan 13, 2032	DP			
		9066957	Oct 06, 2034	DP U-645			
		9216260	Jun 28, 2031	DP			
		9463288	May 19, 2025	DP			
		9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			
		9987229	Sep 01, 2024	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER							
N 208799	004	10022510	May 18, 2031	DP			
		10124131	May 18, 2031	DP			
		10195375	Feb 14, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
		8714149	Feb 25, 2032	DP			
		8978966	Jan 13, 2032	DP			
		9066957	Oct 06, 2034	DP U-645			
		9216260	Jun 28, 2031	DP			
		9415008	Oct 06, 2034	DP U-645			
		9463288	May 19, 2025	DP			
		9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			
		9782550	Aug 28, 2035	DP			
		9782551	Aug 28, 2035	DP			
		9987229	Sep 01, 2024	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER							
N 208799	005	10022510	May 18, 2031	DP			
		10124131	May 18, 2031	DP			
		10195375	Feb 14, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER								
N 208799	005		8651103	Mar 26, 2028	DP			
			8714149	Feb 25, 2032	DP			
			8978966	Jan 13, 2032	DP			
			9066957	Oct 06, 2034	DP		U-645	
			9216260	Jun 28, 2031	DP			
			9463288	May 19, 2025	DP			
			9616024	Sep 01, 2024	DP			
			9731087	May 18, 2031	DP			
			9782550	Aug 28, 2035	DP			
			9782551	Aug 28, 2035	DP			
			9987229	Sep 01, 2024	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER								
N 208799	006		10022510	May 18, 2031	DP			
			10124131	May 18, 2031	DP			
			10195375	Feb 14, 2031	DP			
			6701917	Jun 23, 2021	DP			
			6718972	Jun 23, 2021	DP			
			6748947	Jun 23, 2021	DP			
			6871646	Jun 23, 2021	DP			
			7540282	May 06, 2023	DP			
			8006690	Jun 23, 2021	DP			
			8651103	Mar 26, 2028	DP			
			8714149	Feb 25, 2032	DP			
			8978966	Jan 13, 2032	DP			
			9066957	Oct 06, 2034	DP		U-645	
			9216260	Jun 28, 2031	DP			
			9463288	May 19, 2025	DP			
			9616024	Sep 01, 2024	DP			
			9731087	May 18, 2031	DP			
			9782550	Aug 28, 2035	DP			
			9782551	Aug 28, 2035	DP			
			9987229	Sep 01, 2024	DP			
FLUVASTATIN SODIUM - LESCOL XL								
N 021192	001		6242003	Apr 13, 2020				
FLUVOXAMINE MALEATE - LUVOX CR								
N 022033	001		7465462	May 10, 2020	DP		U-929	
FLUVOXAMINE MALEATE - LUVOX CR								
N 022033	002		7465462	May 10, 2020	DP		U-929	
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT								
N 021684	001		7741268	Apr 02, 2024	DP			
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT								
N 021684	002		7741268	Apr 02, 2024	DP			
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT								
N 021684	003		7741268	Apr 02, 2024	DP			
FOMEPIZOLE - ANTIZOL								
N 020696	001		7553863	Jun 30, 2027	DS DP			
FORMOTEROL FUMARATE - FORADIL								
N 020831	001		6887459	Nov 28, 2020			U-762	
FORMOTEROL FUMARATE - PERFOROMIST								
N 022007	001		6667344	Jun 22, 2021	DP			
			6814953	Jun 22, 2021	DP		U-813	
			7348362	Jun 22, 2021	DP			
			7462645	Jun 22, 2021	DP		U-813	
			8623922	Jun 22, 2021	DP			
			9730890	Jun 22, 2021	DP			
FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE								
N 208294	001		8324266	May 28, 2030			U-2546	
			8703806	May 28, 2030			U-2546	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE							
N 208294	001	8808713	May 28, 2030	DP U-2546			
		8815258	Mar 17, 2031	U-2546			
		9415009	May 28, 2030	U-2546			
		9463161	May 28, 2030	DP U-2546			
FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA							
N 022518	001	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
		7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
		7566705	May 21, 2020	DP U-1068			
		7566705*PED	Nov 21, 2020				
FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA							
N 022518	002	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
		7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
		7566705	May 21, 2020	DP U-1068			
		7566705*PED	Nov 21, 2020				
FOSAPREPITANT DIMEGLUMINE - EMEND							
N 022023	001					NPP	Apr 03, 2021
						PED	Oct 03, 2021
FOSAPREPITANT DIMEGLUMINE - EMEND							
N 022023	002					NPP	Apr 03, 2021
						PED	Oct 03, 2021
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 210493	001	10208073	May 23, 2032	U-2301		NCE	Apr 19, 2023
		8426450	May 23, 2032	DS DP			
		8895586	May 23, 2032	U-2301			
		9186357	Nov 18, 2030	U-2301			
		9403772	May 23, 2032	DS U-2301			
		9908907	May 23, 2032	DS DP			
FOSPROPOFOL DISODIUM - LUSEDRA							
N 022244	001	6204257	Jul 01, 2022	DS DP U-945			
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294			
		8163902	Jun 17, 2026	DS U-2294			
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			
		8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026	U-2294			
		8951504	Jul 27, 2032	U-2294			
		9266912	Jan 19, 2026	U-2294			
		9283238	Jun 17, 2026	U-2294			
		9737554	Jan 19, 2026	DP			
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294			
		8163902	Jun 17, 2026	DS U-2294			
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			
		8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026	U-2294			
		8951504	Jul 27, 2032	U-2294			
		9266912	Jan 19, 2026	U-2294			
		9283238	Jun 17, 2026	U-2294			
		9737554	Jan 19, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FULVESTRANT - FASLODEX							
N 021344	001	6774122	Jan 09, 2021	U-1826		I-749	Aug 25, 2020
		6774122	Jan 09, 2021	U-2108			
		6774122	Jan 09, 2021	U-2163			
		6774122	Jan 09, 2021	U-2504			
		6774122	Jan 09, 2021	U-596			
		6774122*PED	Jul 09, 2021				
		7456160	Jan 09, 2021	U-1826			
		7456160	Jan 09, 2021	U-2108			
		7456160	Jan 09, 2021	U-2163			
		7456160	Jan 09, 2021	U-2504			
		7456160	Jan 09, 2021	U-596			
		7456160*PED	Jul 09, 2021				
		8329680	Jan 09, 2021	U-1826			
		8329680	Jan 09, 2021	U-2108			
		8329680	Jan 09, 2021	U-2163			
		8329680	Jan 09, 2021	U-2504			
		8329680	Jan 09, 2021	U-596			
		8329680*PED	Jul 09, 2021				
		8466139	Jan 09, 2021	U-1826			
		8466139	Jan 09, 2021	U-2108			
		8466139	Jan 09, 2021	U-2163			
		8466139	Jan 09, 2021	U-2504			
		8466139	Jan 09, 2021	U-596			
		8466139*PED	Jul 09, 2021				
FULVESTRANT - FULVESTRANT							
N 210326	001	10188663	Feb 14, 2034	DP U-2540			
		9271990	May 17, 2034	DP U-2540			
		9833459	Feb 14, 2034	DP U-2540			
GABAPENTIN - NEURONTIN							
N 021129	001	7256216	May 28, 2022	DP			
GABAPENTIN - GRALISE							
N 022544	001	6488962	Jun 20, 2020	DP			
		6723340	Oct 25, 2021	DP			
		7438927	Feb 26, 2024	U-1114			
		7731989	Oct 25, 2022	DP			
		8192756	Oct 25, 2022	DP U-1114			
		8252332	Oct 25, 2022	DP U-1114			
		8333992	Oct 25, 2022	DP U-1114			
GABAPENTIN - GRALISE							
N 022544	002	6488962	Jun 20, 2020	DP			
		6723340	Oct 25, 2021	DP			
		7438927	Feb 26, 2024	U-1114			
		7731989	Oct 25, 2022	DP			
		8192756	Oct 25, 2022	DP U-1114			
		8252332	Oct 25, 2022	DP U-1114			
		8333992	Oct 25, 2022	DP U-1114			
GABAPENTIN ENACARBIL - HORIZANT							
N 022399	001	6818787	Apr 06, 2025	DS DP			
		8026279	Nov 10, 2026	DS DP			
		8048917	Nov 06, 2022	DS DP U-1247			
		8114909	Apr 11, 2026	U-1231			
		8686034	Jan 24, 2025	U-1231			
		8686034	Jan 24, 2025	U-1247			
		8795725	Jun 10, 2029	DP U-1231			
		8795725	Jun 10, 2029	DP U-1247			
GABAPENTIN ENACARBIL - HORIZANT							
N 022399	002	6818787	Apr 06, 2025	DS DP			
		8026279	Nov 10, 2026	DS DP			
		8048917	Nov 06, 2022	DS DP U-1247			
		8114909	Apr 11, 2026	U-1231			
		8686034	Jan 24, 2025	U-1231			
		8686034	Jan 24, 2025	U-1247			
		8795725	Jun 10, 2029	DP U-1231			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 002	8795725	Jun 10, 2029	DP U-1247			
GADOBUTROL - GADAVIST						
N 201277 001					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 002					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 003					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 004					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 005					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119		I-801	Jul 12, 2022
GADOFOSVESET TRISODIUM - ABLAVAR						
N 021711 001	6676929	May 04, 2020	DP			
GADOFOSVESET TRISODIUM - ABLAVAR						
N 021711 002	6676929	May 04, 2020	DP			
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 001					NPP	Aug 25, 2020
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 002					NPP	Aug 25, 2020
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 003					NPP	Aug 25, 2020
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 004					NPP	Aug 25, 2020
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 005					NPP	Aug 25, 2020
GADOXETATE DISODIUM - EOVIST						
N 022090 001	6039931	Nov 13, 2021	U-1239			
GADOXETATE DISODIUM - EOVIST						
N 022090 002	6039931	Nov 13, 2021	U-1239			
GALLIUM DOTATATE GA-68 - NETSPOT						
N 208547 001	9375498	Aug 10, 2032	DP		NCE	Jun 01, 2021
					ODE-120	Jun 01, 2023
GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68						
N 210828 001					NCE	Aug 21, 2024
					W	Aug 21, 2024
GANCICLOVIR - GANZYK-RTU						
N 209347 001	9486530	Sep 02, 2034	DP			
GATIFLOXACIN - ZYMAR						
N 021493 001	6333045*PED	Feb 20, 2020				
GEFITINIB - IRESSA						
N 206995 001					ODE-95	Jul 13, 2022
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 001	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 002	9241948	Jul 01, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GEMCITABINE HYDROCHLORIDE - INFUGEM								
N 208313	003		9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM								
N 208313	004		9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM								
N 208313	005		9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM								
N 208313	006		9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM								
N 208313	007		9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM								
N 208313	008		9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM								
N 208313	009		9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM								
N 208313	010		9241948	Jul 01, 2033	DP			
GILTERITINIB FUMARATE - XOSPATA								
N 211349	001		8969336	Jan 27, 2031	DS DP		NCE	Nov 28, 2023
			9487491	Jul 28, 2030	U-2456		ODE-222	Nov 28, 2025
GIVOSIRAN SODIUM - GIVLAARI								
N 212194	001		10119143	Oct 03, 2034	DS DP U-2672		NCE	Nov 20, 2024
			10125364	Mar 15, 2033	DS DP U-2672		ODE-273	Nov 20, 2026
			10131907	Aug 24, 2028	DS DP U-2672			
			10273477	Mar 08, 2024	DS			
			8106022	Dec 12, 2029	DS DP U-2672			
			8546143	Jan 09, 2022	DS U-2672			
			8828956	Dec 04, 2028	DS DP U-2672			
			9133461	May 14, 2033	DS DP U-2672			
			9150605	Aug 28, 2025	DS DP			
			9631193	Mar 15, 2033	U-2672			
			9708610	Jan 01, 2024	DS DP U-2672			
			9708615	Mar 08, 2024	DS			
GLASDEGIB MALEATE - DAURISMO								
N 210656	001		10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
			8148401	Jan 30, 2031	DS DP		ODE-224	Nov 21, 2025
			8431597	Jun 29, 2028	DP			
GLASDEGIB MALEATE - DAURISMO								
N 210656	002		10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
			8148401	Jan 30, 2031	DS DP		ODE-224	Nov 21, 2025
			8431597	Jun 29, 2028	DP			
GLATIRAMER ACETATE - COPAXONE								
N 020622	003		8232250	Aug 19, 2030	U-441			
			8399413	Aug 19, 2030	U-441			
			8969302	Aug 19, 2030	U-441			
			9155776	Aug 19, 2030	U-441			
			9402874	Aug 19, 2030	U-441			
GLECAPREVIR; PIBRENTASVIR - MAVYRET								
N 209394	001		10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
			10028937	Jun 10, 2030	U-2532		M-230	Aug 06, 2021
			10039754	Jun 10, 2030	U-2141		NCE	Aug 03, 2022
			10039754	Jun 10, 2030	U-2532		NPP	Apr 30, 2022
			10286029	Mar 14, 2034	U-2532		ODE-232	Apr 30, 2026
			8648037	Jan 19, 2032	DS DP U-2141		ODE-233	Apr 30, 2026
			8648037	Jan 19, 2032	DS DP U-2532			
			8937150	May 18, 2032	DS DP			
			9321807	Jun 05, 2035	DS			
			9586978	Jun 10, 2030	U-2141			
			9586978	Jun 10, 2030	U-2532			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLECAPREVIR; PIBRENTASVIR - MAVYRET							
N 209394	001	10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
		10028937	Jun 10, 2030	U-2532		M-230	Aug 06, 2021
		10039754	Jun 10, 2030	U-2141		NCE	Aug 03, 2022
		10039754	Jun 10, 2030	U-2532		NPP	Apr 30, 2022
		10286029	Mar 14, 2034	U-2532		ODE-232	Apr 30, 2026
		8648037	Jan 19, 2032	DS DP U-2141		ODE-233	Apr 30, 2026
		8648037	Jan 19, 2032	DS DP U-2532			
		8937150	May 18, 2032	DS DP			
		9321807	Jun 05, 2035	DS			
		9586978	Jun 10, 2030	U-2141			
		9586978	Jun 10, 2030	U-2532			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT							
N 021925	001	7700128	Jan 30, 2027	DP			
		8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT							
N 021925	002	7700128	Jan 30, 2027	DP			
		8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	001	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	002	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	003	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	004	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	005	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLUCAGON - BAQSIMI							
N 210134	001	10213487	Feb 16, 2036	DP U-2604		NP	Jul 24, 2022
		6938798	Jan 03, 2022	DP			
GLUCAGON - GVOKE PFS							
N 212097	001					NP	Sep 10, 2022
GLUCAGON - GVOKE PFS							
N 212097	002					NP	Sep 10, 2022
GLUCAGON - GVOKE HYPOPEN							
N 212097	003					NP	Sep 10, 2022
GLUCAGON - GVOKE HYPOPEN							
N 212097	004					NP	Sep 10, 2022
GLYCEROL PHENYLBUTYRATE - RAVICTI							
N 203284	001	10045958	Sep 22, 2030	U-1816		NPP	Apr 28, 2020
		10045959	Sep 22, 2030	U-1816		ODE-157	Apr 28, 2024
		10183002	Sep 22, 2030	U-1816		ODE-42	Feb 01, 2020
		10183003	Sep 22, 2030	U-1816			
		10183004	Sep 22, 2030	U-1816			
		10183005	Sep 22, 2030	U-1816			
		10183006	Sep 22, 2030	U-1816			
		8404215	Mar 09, 2032	U-1383			
		8642012	Sep 22, 2030	U-1383			
		9095559	Mar 09, 2032	U-1383			
		9254278	Mar 09, 2032	U-1816			
		9326966	Mar 09, 2032	U-1816			
		9561197	Sep 22, 2030	U-1383			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLYCEROL PHENYLBUTYRATE - RAVICTI								
N 203284	001		9962359	Sep 22, 2030	U-1816			
			9999608	Sep 22, 2030	U-1816			
GLYCOPYRROLATE - CUVPOSA								
N 022571	001		7638552	Aug 20, 2023	U-1076			
			7816396	Aug 20, 2023	U-1076			
GLYCOPYRROLATE - SEEBRI								
N 207923	001		7229607	Apr 09, 2021	U-1773			
			7736670	Jun 27, 2021	DP			
			8029768	Apr 09, 2021	U-1773			
			8048451	Jun 27, 2021	DP			
			8182838	Oct 20, 2028	DP			
			8303991	Jun 27, 2021	DP			
			8435567	Jun 27, 2021	DP			
			8479730	Oct 11, 2028	DP			
			8580306	Jun 27, 2021	DP			
			8956661	Jun 27, 2021	DP			
			9931304	Jun 27, 2021	DP			
			9962338	Jun 27, 2021	DP			
GLYCOPYRROLATE - LONHALA MAGNAIR KIT								
N 208437	001		10376661	Sep 14, 2035	DP		NP	Dec 05, 2020
			6962151	Oct 27, 2020	DP			
			7316067	Sep 06, 2022	DP			
			7458372	Nov 18, 2024	DP			
			7931212	Nov 25, 2025	DP			
			8511581	Nov 08, 2023	DP			
			9168556	Sep 01, 2032	DP			
			9265900	Dec 07, 2028	DP			
			9604018	May 16, 2033	DP			
			9789270	Oct 30, 2030	DP			
GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON								
N 207930	001		6878721	Feb 25, 2025	DS DP U-1773			
			7229607	Apr 09, 2021	U-1773			
			7736670	Jun 27, 2021	DP			
			7820694	Jun 02, 2020	DP U-1773			
			8029768	Apr 09, 2021	U-1773			
			8048451	Jun 27, 2021	DP			
			8067437	Jun 02, 2020	U-1773			
			8182838	Oct 20, 2028	DP			
			8283362	Jun 02, 2020	DP U-1773			
			8303991	Jun 27, 2021	DP			
			8435567	Jun 27, 2021	DP			
			8479730	Oct 11, 2028	DP			
			8580306	Jun 27, 2021	DP			
			8658673	Jun 02, 2020	DP U-1773			
			8796307	Jun 02, 2020	DP			
			8956661	Jun 27, 2021	DP			
			9931304	Jun 27, 2021	DP			
			9962338	Jun 27, 2021	DP			
GLYCOPYRRONIUM TOSYLATE - QBREXZA								
N 210361	001		10004717	Feb 28, 2033	DP U-2398			
			10052267	Oct 17, 2028	DP U-2398			
			6433003	Apr 10, 2020	U-2398			
			8618160	Dec 10, 2029	DP U-2398			
			8859610	Feb 28, 2033	DP U-2398			
			9259414	Feb 28, 2033	U-2398			
			9744105	Jul 18, 2030	DP U-2398			
GOLODIRSEN - VYONDYS 53								
N 211970	001		10227590	Jun 28, 2025	DS DP		NCE	Dec 12, 2024
			10266827	Jun 28, 2025	U-2675			
			10421966	Jun 28, 2025	DS DP			
			9024007	Jun 28, 2025	DS DP			
			9416361	May 04, 2021	DS			
			9994851	Jun 28, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GOLODIRSEN - VYONDYS 53							
N 211970	001	RE47691	Jun 28, 2025	DP			
GOSERELIN ACETATE - ZOLADEX							
N 019726	001	7118552	Apr 13, 2022	DP			
		7220247	Apr 09, 2022	DP			
		7500964	Feb 26, 2021	DP			
GOSERELIN ACETATE - ZOLADEX							
N 020578	001	7118552	Apr 13, 2022	DP			
		7220247	Apr 09, 2022	DP			
		7500964	Feb 26, 2021	DP			
GRANISETRON - SANCUSO							
N 022198	001	7608282	Jan 22, 2025	DP		U-1011	
GRANISETRON - SUSTOL							
N 022445	001	10357570	Sep 28, 2024			U-2253	
		6613355	Jun 28, 2021	DP			
		6790458	May 11, 2021	DP			
		8252304	Sep 28, 2024	DP			
		8252305	Sep 28, 2024			U-1891	
		8715710	Sep 28, 2024	DP			
		9913910	Sep 28, 2024			U-2253	
GUAIFENESIN - MUCINEX							
N 021282	001	6372252	Apr 28, 2020			U-489	
		6955821	Apr 28, 2020	DP		U-489	
		7838032	Apr 28, 2020	DP			
GUAIFENESIN - MUCINEX							
N 021282	002	6372252	Apr 28, 2020			U-489	
		6955821	Apr 28, 2020	DP		U-489	
		7838032	Apr 28, 2020	DP			
GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON							
N 205474	001	10105324	Nov 13, 2035	DS DP		U-2023	
		9549907	Nov 13, 2035	DS DP		U-2023	
		9808431	Nov 13, 2035	DS DP		U-2023	
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D							
N 021585	001	6372252	Apr 28, 2020	DP			
		6955821	Apr 28, 2020	DP		U-686	
		7838032	Apr 28, 2020	DP			
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D							
N 021585	002	6372252	Apr 28, 2020	DP			
		6955821	Apr 28, 2020	DP		U-686	
		7838032	Apr 28, 2020	DP			
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	001	6287599	Dec 20, 2020	DP			
		6287599*PED	Jun 20, 2021				
		6811794	Jul 04, 2022	DP		U-494	
		6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	002	6287599	Dec 20, 2020	DP			
		6287599*PED	Jun 20, 2021				
		6811794	Jul 04, 2022	DP		U-494	
		6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	003	6287599	Dec 20, 2020	DP			
		6287599*PED	Jun 20, 2021				
		6811794	Jul 04, 2022	DP		U-494	
		6811794*PED	Jan 04, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GUANFACINE HYDROCHLORIDE - INTUNIV								
N	022037	004	6287599	Dec 20, 2020	DP			
			6287599*PED	Jun 20, 2021				
			6811794	Jul 04, 2022	DP U-494			
			6811794*PED	Jan 04, 2023				
HALOBETASOL PROPIONATE - ULTRAVATE								
N	208183	001	8962028	Jun 19, 2033	DP U-1775			
HALOBETASOL PROPIONATE - BRYHALI								
N	209355	001	10478502	Nov 02, 2031	DP U-2625		NP	Nov 06, 2021
			6517847	Aug 03, 2020	DP			
			8809307	Nov 02, 2031	DP			
HALOBETASOL PROPIONATE - LEXETTE								
N	210566	001					NDF	May 24, 2021
HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII								
N	209354	001	10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
			10426787	Jun 06, 2036	U-2625			
			10478502	Nov 02, 2031	DP U-2625			
			6517847	Aug 03, 2020	DP			
			8809307	Nov 02, 2031	DP			
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT								
N	022555	001	7348361	Nov 06, 2020	DP U-1087		M-220	Feb 15, 2021
			7348361	Nov 06, 2020	DP U-2250			
HISTRELIN ACETATE - SUPPRELIN LA								
N	022058	001	8062652	Jun 16, 2026	U-1197			
HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT								
N	021859	001	7767429	Sep 23, 2027	DS DP			
HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL								
N	020727	001	6465463	Sep 08, 2020	U-71			
			6784177	Sep 08, 2020	U-71			
HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT								
N	021162	001	6358986	Jan 10, 2020				
HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT								
N	021162	002	6358986	Jan 10, 2020				
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N	202880	001	10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N	202880	002	10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N 202880	002		9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N 202880	003		10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N 202880	004		10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N 202880	005		10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N 202880	006		10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	006	9421200	Jul 25, 2033			U-1810	
		9433619	Jul 25, 2033			U-1810	
		9452163	Sep 12, 2034			U-55	
		9486451	Sep 12, 2034			U-55	
		9610286	Jul 25, 2033			U-1810	
		9713611	Sep 12, 2034	DP		U-55	
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	001	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		6733783	Oct 30, 2021	DP		U-1556	
		8309060	Nov 20, 2023	DP		U-1556	
		8361499	Oct 30, 2021	DP			
		8529948	Aug 06, 2022	DP			
		8551520	Oct 30, 2021	DP			
		8647667	Oct 30, 2021	DP			
		8808740	Dec 21, 2031	DP		U-1556	
		9023401	Oct 30, 2020	DP			
		9056052	Oct 30, 2020	DP			
		9060940	Oct 30, 2020			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9198863	Oct 30, 2020	DP			
		9205056	Oct 30, 2020	DP			
		9289391	Oct 30, 2020	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9517236	Oct 30, 2020	DP			
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9572804	Oct 30, 2020	DP			
		9669023	Oct 30, 2020	DP			
		9669024	Oct 30, 2020	DP			
		9675610	Jun 16, 2023	DP			
		9675611	Oct 30, 2020			U-1556	
		9682077	Oct 30, 2020			U-1556	
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			
		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	002	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		6733783	Oct 30, 2021	DP		U-1556	
		8309060	Nov 20, 2023	DP		U-1556	
		8361499	Oct 30, 2021	DP			
		8529948	Aug 06, 2022	DP			
		8551520	Oct 30, 2021	DP			
		8647667	Oct 30, 2021	DP			
		8808740	Dec 21, 2031	DP		U-1556	
		9023401	Oct 30, 2020	DP			
		9056052	Oct 30, 2020	DP			
		9060940	Oct 30, 2020			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9198863	Oct 30, 2020	DP			
		9205056	Oct 30, 2020	DP			
		9289391	Oct 30, 2020	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER								
N	206627	002	9492389	Aug 24, 2027	DP			
			9492390	Aug 24, 2027	U-1556			
			9492391	Aug 24, 2027	U-1556			
			9517236	Oct 30, 2020	DP			
			9545380	Aug 24, 2027	U-1556			
			9572779	Dec 21, 2031	DP			
			9572804	Oct 30, 2020	DP			
			9669023	Oct 30, 2020	DP			
			9669024	Oct 30, 2020	DP			
			9675610	Jun 16, 2023	DP			
			9675611	Oct 30, 2020	U-1556			
			9682077	Oct 30, 2020	U-1556			
			9750703	Dec 21, 2031	DP			
			9763933	Aug 24, 2027	DP			
			9770416	Aug 24, 2027	DP			
			9775809	Aug 24, 2027	DP			
			9861584	Dec 21, 2031	DP			
			9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER								
N	206627	003	10130591	Nov 20, 2023	DP	U-1819		
			10369109	Jun 16, 2023	DP			
			6733783	Oct 30, 2021	DP	U-1556		
			8309060	Nov 20, 2023	DP	U-1556		
			8361499	Oct 30, 2021	DP			
			8529948	Aug 06, 2022	DP			
			8551520	Oct 30, 2021	DP			
			8647667	Oct 30, 2021	DP			
			8808740	Dec 21, 2031	DP	U-1556		
			9023401	Oct 30, 2020	DP			
			9056052	Oct 30, 2020	DP			
			9060940	Oct 30, 2020	U-1556			
			9084816	Aug 24, 2027	DP			
			9095614	Aug 24, 2027	U-1556			
			9095615	Aug 24, 2027	DP			
			9198863	Oct 30, 2020	DP			
			9205056	Oct 30, 2020	DP			
			9289391	Oct 30, 2020	DP			
			9486412	Aug 24, 2027	DP			
			9486413	Aug 24, 2027	DP			
			9492389	Aug 24, 2027	DP			
			9492390	Aug 24, 2027	U-1556			
			9492391	Aug 24, 2027	U-1556			
			9517236	Oct 30, 2020	DP			
			9545380	Aug 24, 2027	U-1556			
			9572779	Dec 21, 2031	DP			
			9572804	Oct 30, 2020	DP			
			9669023	Oct 30, 2020	DP			
			9669024	Oct 30, 2020	DP			
			9675610	Jun 16, 2023	DP			
			9675611	Oct 30, 2020	U-1556			
			9682077	Oct 30, 2020	U-1556			
			9750703	Dec 21, 2031	DP			
			9763933	Aug 24, 2027	DP			
			9770416	Aug 24, 2027	DP			
			9775809	Aug 24, 2027	DP			
			9861584	Dec 21, 2031	DP			
			9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER								
N	206627	004	10130591	Nov 20, 2023	DP	U-1819		
			10369109	Jun 16, 2023	DP			
			6733783	Oct 30, 2021	DP	U-1556		
			8309060	Nov 20, 2023	DP	U-1556		
			8361499	Oct 30, 2021	DP			
			8529948	Aug 06, 2022	DP			
			8551520	Oct 30, 2021	DP			
			8647667	Oct 30, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	004	8808740	Dec 21, 2031	DP		U-1556	
		9023401	Oct 30, 2020	DP			
		9056052	Oct 30, 2020	DP			
		9060940	Oct 30, 2020			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9198863	Oct 30, 2020	DP			
		9205056	Oct 30, 2020	DP			
		9289391	Oct 30, 2020	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9517236	Oct 30, 2020	DP			
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9572804	Oct 30, 2020	DP			
		9669023	Oct 30, 2020	DP			
		9669024	Oct 30, 2020	DP			
		9675610	Jun 16, 2023	DP			
		9675611	Oct 30, 2020			U-1556	
		9682077	Oct 30, 2020			U-1556	
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			
		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	005	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		6733783	Oct 30, 2021	DP		U-1556	
		8309060	Nov 20, 2023	DP		U-1556	
		8361499	Oct 30, 2021	DP			
		8529948	Aug 06, 2022	DP			
		8551520	Oct 30, 2021	DP			
		8647667	Oct 30, 2021	DP			
		8808740	Dec 21, 2031	DP		U-1556	
		9056052	Oct 30, 2020	DP			
		9060940	Oct 30, 2020			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9198863	Oct 30, 2020	DP			
		9205056	Oct 30, 2020	DP			
		9289391	Oct 30, 2020	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9517236	Oct 30, 2020	DP			
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9572804	Oct 30, 2020	DP			
		9669023	Oct 30, 2020	DP			
		9669024	Oct 30, 2020	DP			
		9675610	Jun 16, 2023	DP			
		9675611	Oct 30, 2020			U-1556	
		9682077	Oct 30, 2020			U-1556	
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER								
N 206627	005		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER								
N 206627	006		10130591	Nov 20, 2023	DP		U-1819	
			10369109	Jun 16, 2023	DP			
			6733783	Oct 30, 2021	DP		U-1556	
			8309060	Nov 20, 2023	DP		U-1556	
			8361499	Oct 30, 2021	DP			
			8529948	Aug 06, 2022	DP			
			8551520	Oct 30, 2021	DP			
			8647667	Oct 30, 2021	DP			
			8808740	Dec 21, 2031	DP		U-1556	
			9056052	Oct 30, 2020	DP			
			9060940	Oct 30, 2020			U-1556	
			9084816	Aug 24, 2027	DP			
			9095614	Aug 24, 2027			U-1556	
			9095615	Aug 24, 2027	DP			
			9198863	Oct 30, 2020	DP			
			9205056	Oct 30, 2020	DP			
			9289391	Oct 30, 2020	DP			
			9486412	Aug 24, 2027	DP			
			9486413	Aug 24, 2027	DP			
			9492389	Aug 24, 2027	DP			
			9492390	Aug 24, 2027			U-1556	
			9492391	Aug 24, 2027			U-1556	
			9517236	Oct 30, 2020	DP			
			9545380	Aug 24, 2027			U-1556	
			9572779	Dec 21, 2031	DP			
			9572804	Oct 30, 2020	DP			
			9669023	Oct 30, 2020	DP			
			9669024	Oct 30, 2020	DP			
			9675610	Jun 16, 2023	DP			
			9675611	Oct 30, 2020			U-1556	
			9682077	Oct 30, 2020			U-1556	
			9750703	Dec 21, 2031	DP			
			9763933	Aug 24, 2027	DP			
			9770416	Aug 24, 2027	DP			
			9775809	Aug 24, 2027	DP			
			9861584	Dec 21, 2031	DP			
			9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER								
N 206627	007		10130591	Nov 20, 2023	DP		U-1819	
			10369109	Jun 16, 2023	DP			
			6733783	Oct 30, 2021	DP		U-1556	
			8309060	Nov 20, 2023	DP		U-1556	
			8361499	Oct 30, 2021	DP			
			8529948	Aug 06, 2022	DP			
			8551520	Oct 30, 2021	DP			
			8647667	Oct 30, 2021	DP			
			8808740	Dec 21, 2031	DP		U-1556	
			9056052	Oct 30, 2020	DP			
			9060940	Oct 30, 2020			U-1556	
			9084816	Aug 24, 2027	DP			
			9095614	Aug 24, 2027			U-1556	
			9095615	Aug 24, 2027	DP			
			9198863	Oct 30, 2020	DP			
			9205056	Oct 30, 2020	DP			
			9289391	Oct 30, 2020	DP			
			9486412	Aug 24, 2027	DP			
			9486413	Aug 24, 2027	DP			
			9492389	Aug 24, 2027	DP			
			9492390	Aug 24, 2027			U-1556	
			9492391	Aug 24, 2027			U-1556	
			9517236	Oct 30, 2020	DP			
			9545380	Aug 24, 2027			U-1556	
			9572779	Dec 21, 2031	DP			
			9572804	Oct 30, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER									
N 206627	007		9669023	Oct 30, 2020		DP			
			9669024	Oct 30, 2020		DP			
			9675610	Jun 16, 2023		DP			
			9675611	Oct 30, 2020		U-1556			
			9682077	Oct 30, 2020		U-1556			
			9750703	Dec 21, 2031		DP			
			9763933	Aug 24, 2027		DP			
			9770416	Aug 24, 2027		DP			
			9775809	Aug 24, 2027		DP			
			9861584	Dec 21, 2031		DP			
			9872837	Dec 21, 2031		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	001		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	002		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	003		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	004		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	005		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCORTISONE BUTYRATE - LOCOID									
N 022076	001		7378405	Dec 19, 2026		DP			
			7981877	Jan 23, 2025		DP			
HYDROGEN PEROXIDE - ESKATA									
N 209305	001		10098910	Apr 21, 2035		DP U-2205		NP	Dec 14, 2020
			7381427	Jun 08, 2022		U-2205			
			9675639	Jul 04, 2035		DP U-2205			
			9980983	Apr 21, 2035		U-2205			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP									
N 019034	001		6589960	Nov 09, 2020		DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP									
N 019034	002		6589960	Nov 09, 2020		DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N 019034	003		6589960	Nov 09, 2020	DS	DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N 019034	004		6589960	Nov 09, 2020	DS	DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROMORPHONE HYDROCHLORIDE - DILAUDID								
N 019034	005		6589960	Nov 09, 2020	DS DP			
			9248229	Mar 12, 2034	DP			
			9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID								
N 019891	001		6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID								
N 019892	001		6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID								
N 019892	002		6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID								
N 019892	003		6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE								
N 021044	001		6589960	Nov 09, 2020	DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE								
N 021044	002		6589960	Nov 09, 2020	DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE								
N 021044	003		6589960	Nov 09, 2020	DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE								
N 021044	004		6589960	Nov 09, 2020	DP			
HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)								
N 021945	004		10471075	May 02, 2036	U-2236			
			8021335	Oct 04, 2026	DP			
			8562564	Jan 24, 2026	DP			
			9180259	Jan 24, 2026	DP			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			
			9789257	Feb 11, 2034	DP			
			9844558	May 02, 2036	U-2236			
HYDROXYUREA - SIKLOS								
N 208843	001						NP	Dec 21, 2020
							ODE-177	Dec 21, 2024
HYDROXYUREA - SIKLOS								
N 208843	002						NP	Dec 21, 2020
							ODE-177	Dec 21, 2024
IBANDRONATE SODIUM - BONIVA								
N 021455	002		7192938	May 06, 2023	U-798			
			7410957	May 06, 2023	U-887			
			7718634	May 06, 2023	U-642			
IBRUTINIB - IMBRUVICA								
N 205552	001		10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
			10004746	Jun 03, 2031	U-1946		I-741	Jan 18, 2020
			10004746	Jun 03, 2031	U-2241		I-753	Aug 02, 2020
			10004746	Jun 03, 2031	U-2242		M-236	Jan 25, 2022
			10016435	Jun 03, 2031	U-1650		ODE-109	Mar 04, 2023
			10106548	Jun 03, 2033	DS DP		ODE-117	May 06, 2023
			10125140	Jun 03, 2033	DS DP		ODE-128	Jan 18, 2024
			10294231	Jun 03, 2033	DP		ODE-152	Aug 02, 2024
			10294232	Jun 03, 2033	DP		ODE-55	Nov 13, 2020
			10463668	Oct 24, 2034	U-2654		ODE-60	Feb 12, 2021
			10478439	Jun 03, 2031	U-1456		ODE-72	Jul 28, 2021
			10478439	Jun 03, 2031	U-1650		ODE-86	Jan 29, 2022
			10478439	Jun 03, 2031	U-1684			
			10478439	Jun 03, 2031	U-1946			
			10478439	Jun 03, 2031	U-1947			
			10478439	Jun 03, 2031	U-2241			
			10478439	Jun 03, 2031	U-2242			
			10478439	Jun 03, 2031	U-2665			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
	9181257	Dec 28, 2026	DS DP			
	9296753	Oct 30, 2033	DS DP			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 205552 002	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10294231	Jun 03, 2033	DP			
	10294232	Jun 03, 2033	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 001	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 002	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 003	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 004	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 210563	004	8497277	Dec 28, 2026			U-1947	
		8497277	Dec 28, 2026			U-2241	
		8497277	Dec 28, 2026			U-2242	
		8563563	Apr 26, 2027			U-1491	
		8563563	Apr 26, 2027			U-1650	
		8563563	Apr 26, 2027			U-1946	
		8563563	Apr 26, 2027			U-2241	
		8563563	Apr 26, 2027			U-2242	
		8697711	Dec 28, 2026	DS DP			
		8703780	Dec 28, 2026			U-1491	
		8703780	Dec 28, 2026			U-2242	
		8735403	Dec 28, 2026	DS DP			
		8754090	Jun 03, 2031			U-1456	
		8754091	Dec 28, 2026	DP			
		8952015	Dec 28, 2026			U-1456	
		8952015	Dec 28, 2026			U-1491	
		8952015	Dec 28, 2026			U-1650	
		8952015	Dec 28, 2026			U-1946	
		8952015	Dec 28, 2026			U-1947	
		8952015	Dec 28, 2026			U-2241	
		8952015	Dec 28, 2026			U-2242	
		8957079	Dec 28, 2026	DS DP			
		8999999	Jun 03, 2031			U-1491	
		8999999	Jun 03, 2031			U-1946	
		8999999	Jun 03, 2031			U-2241	
		8999999	Jun 03, 2031			U-2242	
		9125889	Jun 03, 2031			U-1650	
		9181257	Dec 28, 2026	DS			
		9296753	Oct 30, 2033	DS			
		9655857	Mar 03, 2036	DP			
		9725455	Jun 03, 2033	DS			
		9795604	Oct 24, 2034			U-2150	
		9801881	Jun 03, 2031			U-1491	
		9801881	Jun 03, 2031			U-2242	
		9801883	Jun 03, 2031			U-2159	
		9801883	Jun 03, 2031			U-2243	
		9814721	Jun 03, 2031			U-1947	
IBUPROFEN - CHILDREN'S ADVIL-FLAVORED							
N 020589	002	10238640	May 25, 2024	DP			
IBUPROFEN - CALDOLOR							
N 022348	001	6727286	Nov 27, 2021	DP		U-981	
IBUPROFEN - CALDOLOR							
N 022348	002	6727286	Nov 27, 2021	DP		U-981	
		8735452	Sep 30, 2029			U-981	
		8871810	Sep 30, 2029			U-981	
		9012508	Sep 14, 2030			U-981	
		9114068	Sep 30, 2029			U-1735	
		9138404	Sep 30, 2029			U-1756	
		9295639	Sep 30, 2029			U-1756	
		9649284	Sep 30, 2029			U-2018	
IBUPROFEN - CALDOLOR							
N 022348	003	8735452	Sep 30, 2029			U-981	
		8871810	Sep 30, 2029			U-981	
		9012508	Sep 14, 2030			U-981	
		9072661	Mar 16, 2032			U-2264	
		9072710	Mar 16, 2032			U-2266	
IBUPROFEN LYSINE - NEOPROFEN							
N 021903	001	6342530	Nov 14, 2020	DP		U-1127	
		6342530	Nov 14, 2020	DP		U-794	
		6344479	Mar 20, 2021	DS DP		U-794	Y
		8415337	Mar 02, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	10010517	Apr 29, 2030	U-2690		I-819	Dec 13, 2022
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8455472	Jun 15, 2030	U-2690			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8618166	Apr 29, 2030	U-2689			
	8623406	Apr 29, 2030	U-1478			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	10010517	Apr 29, 2030	U-2690		I-819	Dec 13, 2022
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA							
N 202057	002	8367652	Feb 09, 2030	U-1287			
		8377920	Feb 09, 2030	U-1287			
		8399446	Feb 09, 2030	U-1287			
		8410086	Jun 15, 2030	U-2688			
		8415335	Feb 09, 2030	U-1287			
		8426399	Feb 09, 2030	U-1287			
		8440650	Feb 09, 2030	U-1287			
		8445003	Apr 29, 2030	U-1287			
		8445013	Apr 29, 2030	U-1287			
		8454994	Apr 29, 2030	U-2689			
		8501225	Apr 29, 2030	U-1287			
		8518929	Apr 29, 2030	U-1287			
		8524698	Apr 29, 2030	U-1287			
		8546372	Apr 29, 2030	U-1287			
		8551521	Apr 29, 2030	U-1287			
		8563608	Apr 29, 2030	U-1287			
		8617593	Apr 29, 2030	U-1287			
		8617593	Apr 29, 2030	U-2691			
		8617594	Apr 29, 2030	U-1287			
		8623406	Apr 29, 2030	U-1287			
		8623406	Apr 29, 2030	U-2692			
		8642077	Apr 29, 2030	U-2693			
		8669245	Jun 15, 2030	U-2694			
		8680144	Feb 09, 2030	U-2695			
		8691871	Apr 29, 2030	U-2689			
		8703185	Apr 29, 2030	U-2691			
		8709475	Apr 29, 2030	U-2689			
		8710041	Jun 15, 2030	U-2690			
		9198892	Sep 25, 2027	U-2706			
		9603826	Jun 28, 2033	U-2696			
		9610272	Jun 28, 2033	U-2697			
		9623001	Jun 28, 2033	U-2698			
		9693984	Jun 28, 2033	U-2697			
		9693985	Jun 28, 2033	U-2696			
		9693986	Jun 28, 2033	U-2698			
		9700537	May 31, 2027	U-2707			
		9918954	Jun 28, 2033	U-2699			
IDELALISIB - ZYDELIG							
N 205858	001	6800620	Apr 24, 2021	DS U-1560		ODE-70	Jul 23, 2021
		6949535	Apr 24, 2021	DS U-1560		ODE-71	Jul 23, 2021
		8138195	Apr 24, 2021	DS DP U-1549			
		8492389	Apr 24, 2021	DS DP			
		8637533	Apr 24, 2021	DS DP			
		8865730	Mar 05, 2033	DS DP U-1615			
		8980901	May 12, 2025	U-1678			
		9149477	May 12, 2025	U-1757			
		9469643	Sep 02, 2033	DS			
		9492449	Mar 11, 2030	U-1914			
		RE44599	Jul 21, 2025	U-1558			
		RE44599	Jul 21, 2025	U-1615			
		RE44638	Aug 05, 2025	DS DP			
IDELALISIB - ZYDELIG							
N 205858	002	6800620	Apr 24, 2021	DS U-1560		ODE-70	Jul 23, 2021
		6949535	Apr 24, 2021	DS U-1560		ODE-71	Jul 23, 2021
		8138195	Apr 24, 2021	DS DP U-1549			
		8492389	Apr 24, 2021	DS DP			
		8637533	Apr 24, 2021	DS DP			
		8865730	Mar 05, 2033	DS DP U-1615			
		8980901	May 12, 2025	U-1678			
		9149477	May 12, 2025	U-1757			
		9469643	Sep 02, 2033	DS			
		9492449	Mar 11, 2030	U-1914			
		RE44599	Jul 21, 2025	U-1558			
		RE44599	Jul 21, 2025	U-1615			
		RE44638	Aug 05, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 001	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 002	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 003	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 004	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 005	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 006	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 007	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 007	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
IMATINIB MESYLATE - GLEEVEC						
N 021335 001	6958335	Dec 19, 2021	U-791			
IMATINIB MESYLATE - GLEEVEC						
N 021335 002	6958335	Dec 19, 2021	U-791			
IMATINIB MESYLATE - GLEEVEC						
N 021588 001	6958335	Dec 19, 2021	U-1883		ODE-40	Jan 25, 2020
	6958335	Dec 19, 2021	U-791			
	6958335*PED	Jun 19, 2022				
IMATINIB MESYLATE - GLEEVEC						
N 021588 002	6958335	Dec 19, 2021	U-1883		ODE-40	Jan 25, 2020
	6958335	Dec 19, 2021	U-791			
	6958335*PED	Jun 19, 2022				
IMIQUIMOD - ALDARA						
N 020723 001	7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
IMIQUIMOD - ZYCLARA						
N 022483 001	10238644	Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-1455			
	8598196	Aug 18, 2029	U-172			
IMIQUIMOD - ZYCLARA						
N 022483 002	8222270	Dec 11, 2029	U-68			
INDACATEROL MALEATE - ARCAPTA NEOHALER						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
	8658673	Jun 02, 2020	DS DP U-1168			
	8796307	Jun 02, 2020	DS DP			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 001	6689761	Feb 10, 2021	U-554			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 003	6689761	Feb 10, 2021	U-554			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 005	6689761	Feb 10, 2021	U-554			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 006	6689761	Feb 10, 2021	U-554			
INDOCYANINE GREEN - SPY AGENT GREEN KIT						
N 211580 001	6915154	Aug 01, 2021	U-2460		NP	Nov 21, 2021
	7881777	Sep 22, 2021	U-2461			
	8185176	Jun 04, 2028	U-2462			
	8406860	Apr 09, 2029	U-2463			
	8647605	Feb 11, 2029	U-2464			
	8647605	Feb 11, 2029	U-2468			
	8892190	Aug 11, 2020	U-2465			
	9421280	Nov 24, 2025	U-2466			
	9421280	Nov 24, 2025	U-2467			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INDOMETHACIN - TIVORBEX							
N 204768	001	8734847	Apr 23, 2030	DP			
		8992982	Apr 23, 2030	DP			
		9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX							
N 204768	002	8734847	Apr 23, 2030	DP			
		8992982	Apr 23, 2030	DP			
		9089471	Apr 23, 2030	U-55			
INGENOL MEBUTATE - PICATO							
N 202833	001	7410656	Oct 10, 2020	U-1222			
		8278292	Jul 06, 2027	DP			
		8372827	Dec 18, 2026	DP			
		8372828	Dec 18, 2026	DP			
		8377919	Dec 18, 2026	DP			
		8536163	Dec 18, 2026	U-1440			
		8716271	Dec 18, 2026	U-1440			
		8735375	Dec 18, 2026	U-1440			
		9789078	May 15, 2033	U-2138			
		9820959	Dec 18, 2026	DP U-1440			
		9833428	Dec 18, 2026	DP			
		9833429	Dec 18, 2026	DP			
		9861603	Dec 18, 2026	U-1440			
INGENOL MEBUTATE - PICATO							
N 202833	002	7410656	Oct 10, 2020	U-1222			
		8278292	Jul 06, 2027	DP			
		8372827	Dec 18, 2026	DP			
		8372828	Dec 18, 2026	DP			
		8377919	Dec 18, 2026	DP			
		8536163	Dec 18, 2026	U-1440			
		8716271	Dec 18, 2026	U-1440			
		8735375	Dec 18, 2026	U-1440			
		9820959	Dec 18, 2026	DP U-1440			
		9833428	Dec 18, 2026	DP			
		9833429	Dec 18, 2026	DP			
		9861603	Dec 18, 2026	U-1440			
INOTERSEN SODIUM - TEGSEDI							
N 211172	001	7015315	Mar 21, 2023	DS		NCE	Oct 05, 2023
		7101993	Sep 05, 2023	DS		ODE-212	Oct 05, 2025
		8101743	Apr 01, 2025	DS DP			
		8697860	Apr 29, 2031	DP			
		9061044	Apr 29, 2031	DS			
		9399774	Apr 29, 2031	U-2430			
INSULIN ASPART - FIASP							
N 208751	001	8324157	Jun 25, 2030	DP		M-247	Oct 21, 2022
						NP	Sep 29, 2020
						NPP	Dec 19, 2022
INSULIN ASPART - FIASP FLEXTOUCH							
N 208751	002	10220155	Jul 17, 2026	DP		NP	Sep 29, 2020
		10357616	Jan 20, 2026	DP		NPP	Dec 19, 2022
		10376652	Jan 20, 2026	DP			
		6899699	Jan 02, 2022	DP			
		7762994	May 23, 2024	DP			
		8324157	Jun 25, 2030	DP			
		8579869	Jun 30, 2023	DP			
		8672898	Jan 02, 2022	DP			
		8684969	Oct 20, 2025	DP			
		8920383	Jul 17, 2026	DP			
		9108002	Jan 20, 2026	DP			
		9132239	Feb 01, 2032	DP			
		9457154	Jan 20, 2026	DP			
		9486588	Jan 02, 2022	DP			
		9616180	Jan 20, 2026	DP			
		9687611	Feb 27, 2027	DP			
		9775953	Jul 17, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN ASPART - FIASP FLEXTOUCH									
N 208751	002		9861757	Jan 20, 2026		DP			
			RE46363	Aug 03, 2026		DP			
INSULIN ASPART - FIASP PENFILL									
N 208751	003							NPP	Dec 19, 2022
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN									
N 021172	004		7762994	May 23, 2024		DP			
			8579869	Jun 30, 2023		DP			
			9265893	Sep 23, 2032		DP			
			RE41956	Jan 21, 2021		DP			
INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL									
N 020986	002		7762994	May 23, 2024		DP			
			8579869	Jun 30, 2023		DP			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN									
N 020986	003		7762994	May 23, 2024		DP			
			8579869	Jun 30, 2023		DP			
			9265893	Sep 23, 2032		DP			
			RE41956	Jan 21, 2021		DP			
INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET									
N 020986	004		RE41956	Jan 21, 2021		DP			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH									
N 020986	005		10220155	Jul 17, 2026		DP			
			10357616	Jan 20, 2026		DP			
			10376652	Jan 20, 2026		DP			
			6899699	Jan 02, 2022		DP			
			7762994	May 23, 2024		DP			
			8579869	Jun 30, 2023		DP			
			8672898	Jan 02, 2022		DP			
			8684969	Oct 20, 2025		DP			
			8920383	Jul 17, 2026		DP			
			9108002	Jan 20, 2026		DP			
			9132239	Feb 01, 2032		DP			
			9457154	Sep 27, 2027		DP			
			9486588	Jan 02, 2022		DP			
			9616180	Jan 20, 2026		DP			
			9687611	Feb 27, 2027		DP			
			9775953	Jul 17, 2026		DP			
			9861757	Jan 20, 2026		DP			
			RE46363	Aug 03, 2026		DP			
INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30									
N 203313	001		10220155	Jul 17, 2026		DP		NCE	Sep 25, 2020
			10357616	Jan 20, 2026		DP			
			10376652	Jan 20, 2026		DP			
			6899699	Jan 02, 2022		DP			
			7615532	Jun 28, 2029	DS	DP			
			7762994	May 23, 2024		DP			
			8579869	Jun 30, 2023		DP			
			8672898	Jan 02, 2022		DP			
			8684969	Oct 20, 2025		DP			
			8920383	Jul 17, 2026		DP			
			9108002	Jan 20, 2026		DP			
			9132239	Feb 01, 2032		DP			
			9457154	Sep 27, 2027		DP			
			9486588	Jan 02, 2022		DP			
			9616180	Jan 20, 2026		DP			
			9687611	Feb 27, 2027		DP			
			9775953	Jul 17, 2026		DP			
			9861757	Jan 20, 2026		DP			
			9884094	May 01, 2033		U-2238			
			RE46363	Aug 03, 2026		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN DEGLUDEC - TRESIBA						
N 203314 001	10220155	Jul 17, 2026	DP		NCE	Sep 25, 2020
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
INSULIN DEGLUDEC - TRESIBA						
N 203314 002	10220155	Jul 17, 2026	DP		NCE	Sep 25, 2020
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
INSULIN DEGLUDEC - TRESIBA						
N 203314 003	10376652	Jan 20, 2026	DP			
	7615532	Jun 28, 2029	DS DP			
INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6						
N 208583 001	10220155	Jul 17, 2026	DP		M-242	Aug 08, 2022
	10357616	Jan 20, 2026	DP		NCE	Sep 25, 2020
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6								
N 208583	001		9775953	Jul 17, 2026	DP			
			9861757	Jan 20, 2026	DP			
			RE46363	Aug 03, 2026	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN								
N 021536	002		9265893	Sep 23, 2032	DP			
			RE41956	Jan 21, 2021	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH								
N 021536	005		10220155	Jul 17, 2026	DP			
			10357616	Jan 20, 2026	DP			
			10376652	Jan 20, 2026	DP			
			6899699	Jan 02, 2022	DP			
			7686786	Aug 03, 2026	DP			
			7762994	May 23, 2024	DP			
			8579869	Jun 30, 2023	DP			
			8672898	Jan 02, 2022	DP			
			8684969	Oct 20, 2025	DP			
			8920383	Jul 17, 2026	DP			
			9108002	Jan 20, 2026	DP			
			9132239	Feb 01, 2032	DP			
			9457154	Sep 27, 2027	DP			
			9486588	Jan 02, 2022	DP			
			9616180	Jan 20, 2026	DP			
			9687611	Feb 27, 2027	DP			
			9775953	Jul 17, 2026	DP			
			9861757	Jan 20, 2026	DP			
			RE46363	Aug 03, 2026	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS								
N 021081	001		7476652	Jul 23, 2023	DP			
			7713930	Jun 13, 2023	DP			
			7918833	Sep 23, 2027	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR								
N 021081	002		8512297	Sep 15, 2024	DP			
			8556864	Mar 03, 2024	DP			
			8603044	Mar 02, 2024	DP			
			8679069	Apr 12, 2025	DP			
			8992486	Jun 05, 2024	DP			
			9011391	Mar 26, 2024	U-1832			
			9233211	Mar 02, 2024	DP			
			9408979	Mar 02, 2024	DP			
			9526844	Mar 02, 2024	DP			
			9533105	Aug 17, 2024	DP			
			9561331	Aug 28, 2024	DP			
			9604008	Mar 02, 2024	DP			
			9604009	Aug 16, 2024	DP			
			9610409	Mar 02, 2024	DP			
			9623189	Aug 19, 2024	DP			
			9717852	Apr 08, 2033	DP			
			9775954	Mar 02, 2024	DP			
			9827379	Mar 02, 2024	DP U-2146			
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR								
N 206538	001		10369291	Sep 16, 2035	DP		NPP	Nov 26, 2022
			7918833	Sep 23, 2027	DP			
			7918833*PED	Mar 23, 2028				
			8512297	Sep 15, 2024	DP			
			8556864	Mar 03, 2024	DP			
			8603044	Mar 02, 2024	DP			
			8679069	Apr 12, 2025	DP			
			8992486	Jun 05, 2024	DP			
			9011391	Mar 26, 2024	U-1832			
			9233211	Mar 02, 2024	DP			
			9345750	May 18, 2031	DP U-1855			
			9408979	Mar 02, 2024	DP			
			9526844	Mar 02, 2024	DP			
			9533105	Aug 17, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR							
N 206538	001	9561331	Aug 28, 2024	DP			
		9604008	Mar 02, 2024	DP			
		9604009	Aug 16, 2024	DP			
		9610409	Mar 02, 2024	DP			
		9623189	Aug 19, 2024	DP			
		9775954	Mar 02, 2024	DP			
		9827379	Mar 02, 2024	DP U-2146			
INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR							
N 206538	002	10369291	Sep 16, 2035	DP		NPP	Nov 26, 2022
		7918833	Sep 23, 2027	DP			
		8512297	Sep 15, 2024	DP			
		8556864	Mar 03, 2024	DP			
		8603044	Mar 02, 2024	DP			
		8679069	Apr 12, 2025	DP			
		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP U-1832			
		9233211	Mar 02, 2024	DP			
		9345750	May 18, 2031	DP U-1855			
		9408979	Mar 02, 2024	DP			
		9526844	Mar 02, 2024	DP			
		9533105	Aug 17, 2024	DP			
		9561331	Aug 28, 2024	DP			
		9604008	Mar 02, 2024	DP			
		9604009	Aug 16, 2024	DP			
		9610409	Mar 02, 2024	DP			
		9623189	Aug 19, 2024	DP			
		9775954	Mar 02, 2024	DP			
		9827379	Mar 02, 2024	DP U-2146			
INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33							
N 208673	001	10029011	Nov 11, 2030	DP		NCE	Jul 27, 2021
		10117909	Oct 09, 2029	DP			
		7918833	Sep 23, 2027	DP			
		8512297	Sep 15, 2024	DP			
		8556864	Mar 03, 2024	DP			
		8603044	Mar 02, 2024	DP			
		8679069	Apr 12, 2025	DP			
		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	U-1923			
		9011391	Mar 26, 2024	U-2496			
		9233211	Mar 02, 2024	DP			
		9408979	Mar 02, 2024	DP			
		9526764	Oct 09, 2029	DP			
		9526844	Mar 02, 2024	DP			
		9533105	Aug 17, 2024	DP			
		9561331	Aug 28, 2024	DP			
		9604008	Mar 02, 2024	DP			
		9604009	Aug 16, 2024	DP			
		9610409	Mar 02, 2024	DP			
		9623189	Aug 19, 2024	DP			
		9707176	Nov 11, 2030	DP			
		9717852	Apr 08, 2033	DP			
		9775954	Mar 02, 2024	DP			
		9821032	May 09, 2032	U-2182			
		9827379	Mar 02, 2024	DP U-2146			
		9950039	Dec 10, 2035	U-2277			
		9950039	Dec 10, 2035	U-2278			
		9950039	Dec 10, 2035	U-2279			
		RE45313	Jul 12, 2020	DS DP			
INSULIN GLULISINE RECOMBINANT - APIDRA							
N 021629	001	6960561	Jan 25, 2023	DP U-471			
		7452860	Mar 22, 2022	DP			
		7696162	Mar 22, 2022	DP U-471			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN GLULISINE RECOMBINANT - APIDRA								
N	021629	002	6960561	Jan 25, 2023	DP U-471			
			7452860	Mar 22, 2022	DP			
			7696162	Mar 22, 2022	DP U-471			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR								
N	021629	003	6960561	Jan 25, 2023	DP U-471			
			7452860	Mar 22, 2022	DP			
			7696162	Mar 22, 2022	DP U-471			
			7918833	Sep 23, 2027	DP			
			8512297	Sep 15, 2024	DP			
			8556864	Mar 03, 2024	DP			
			8603044	Mar 02, 2024	DP			
			8679069	Apr 12, 2025	DP			
			8992486	Jun 05, 2024	DP			
			9011391	Mar 26, 2024	U-1832			
			9233211	Mar 02, 2024	DP			
			9408979	Mar 02, 2024	DP			
			9526844	Mar 02, 2024	DP			
			9533105	Aug 17, 2024	DP			
			9561331	Aug 28, 2024	DP			
			9604008	Mar 02, 2024	DP			
			9604009	Aug 16, 2024	DP			
			9610409	Mar 02, 2024	DP			
			9623189	Aug 19, 2024	DP			
			9717852	Apr 08, 2033	DP			
			9775954	Mar 02, 2024	DP			
			9827379	Mar 02, 2024	DP U-2146			
INSULIN HUMAN - HUMULIN R								
N	018780	004	7291132	Aug 09, 2024	DP			
INSULIN LISPRO - ADMELOG								
N	209196	001					NP	Dec 11, 2020
INSULIN LISPRO - ADMELOG SOLOSTAR								
N	209196	002	7918833	Sep 23, 2027	DP		NP	Dec 11, 2020
			8512297	Sep 15, 2024	DP			
			8556864	Mar 03, 2024	DP			
			8603044	Mar 02, 2024	DP			
			8679069	Apr 12, 2025	DP			
			8992486	Jun 05, 2024	DP			
			9011391	Mar 26, 2024	DP U-1832			
			9233211	Mar 02, 2024	DP			
			9408979	Mar 02, 2024	DP			
			9526844	Mar 02, 2024	DP			
			9533105	Aug 17, 2024	DP			
			9561331	Aug 28, 2024	DP			
			9604008	Mar 02, 2024	DP			
			9604009	Aug 16, 2024	DP			
			9610409	Mar 02, 2024	DP			
			9623189	Aug 19, 2024	DP			
			9717852	Apr 08, 2033	DP			
			9775954	Mar 02, 2024	DP			
			9827379	Mar 04, 2024	DP U-2146			
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN								
N	021017	002	7291132	Aug 09, 2024	DP			
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN								
N	021018	002	7291132	Aug 09, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN								
N	020563	003	7291132	Aug 09, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN								
N	205747	001	7291132	Aug 09, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - EXUBERA								
N 021868	001		6582728	Jun 24, 2020	DP			
INSULIN RECOMBINANT HUMAN - EXUBERA								
N 021868	002		6582728	Jun 24, 2020	DP			
INSULIN RECOMBINANT HUMAN - AFREZZA								
N 022472	001		10046031	Aug 11, 2029			U-2383	
			10201672	Aug 02, 2030	DP			
			10342938	Jun 12, 2029	DP			
			10500159	Nov 02, 2030	DP			
			6444226	Jun 29, 2020	DP		U-1534	
			6652885	Jun 29, 2020			U-1535	
			7305986	Jan 16, 2023	DP			
			7464706	Mar 02, 2023	DP			
			7648960	Jun 29, 2020			U-1535	
			7943178	Jun 29, 2020	DP		U-1535	
			7943572	Aug 10, 2026			U-1539	
			8119593	Aug 11, 2029			U-1537	
			8146588	Apr 24, 2023	DP			
			8156936	Jan 16, 2023	DP			
			8215300	Nov 24, 2022	DP			
			8258095	Aug 11, 2029			U-1537	
			8389470	Jun 29, 2020	DP		U-1621	
			8424518	Oct 17, 2031	DP			
			8485180	Mar 25, 2030	DP			
			8499757	Feb 19, 2032	DP			
			8551528	Jun 11, 2030	DP			
			8623817	Sep 18, 2029			U-1537	
			8636001	Jul 12, 2032	DP			
			8729019	Dec 26, 2028	DP			
			8734845	Jun 11, 2030	DP			
			8778403	Jun 11, 2030	DP		U-1538	
			8889099	Jun 29, 2020	DP		U-1621	
			8912193	Jun 12, 2029	DP		U-1538	
			8950397	Jul 20, 2021	DP			
			9192675	Jun 12, 2029	DP		U-1788	
			9283193	Sep 14, 2026	DP			
			9339615	Oct 20, 2029	DP			
			9358352	Feb 15, 2031	DP		U-1861	
			9393372	Jul 04, 2029	DP			
			9446133	Jun 12, 2029	DP		U-1861	
			9511198	Feb 16, 2030			U-1929	
			9511198	Feb 16, 2030			U-1930	
			9597374	Oct 08, 2031			U-1987	
			9662461	Jun 12, 2029	DP		U-2019	
			9717689	Sep 14, 2026	DP			
			9943571	Aug 11, 2029			U-1537	
INSULIN RECOMBINANT HUMAN - AFREZZA								
N 022472	002		10046031	Aug 11, 2029			U-2383	
			10201672	Aug 02, 2030	DP			
			10342938	Jun 12, 2029	DP			
			10500159	Nov 02, 2030	DP			
			6444226	Jun 29, 2020	DP		U-1534	
			6652885	Jun 29, 2020			U-1535	
			7305986	Jan 16, 2023	DP			
			7464706	Mar 02, 2023	DP			
			7648960	Jun 29, 2020			U-1535	
			7943178	Jun 29, 2020	DP		U-1535	
			7943572	Aug 10, 2026			U-1539	
			8119593	Aug 11, 2029			U-1537	
			8146588	Apr 24, 2023	DP			
			8156936	Jan 16, 2023	DP			
			8215300	Nov 24, 2022	DP			
			8258095	Aug 11, 2029			U-1537	
			8389470	Jun 29, 2020	DP		U-1621	
			8424518	Oct 17, 2031	DP			
			8485180	Mar 25, 2030	DP			
			8499757	Feb 19, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 002	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029			U-1537	
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP		U-1538	
	8889099	Jun 29, 2020	DP		U-1621	
	8912193	Jun 12, 2029	DP		U-1538	
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP		U-1788	
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP		U-1861	
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP		U-1861	
	9511198	Feb 16, 2030			U-1929	
	9511198	Feb 16, 2030			U-1930	
	9597374	Oct 08, 2031			U-1987	
	9662461	Jun 12, 2029	DP		U-2019	
	9717689	Sep 14, 2026	DP			
	9943571	Aug 11, 2029			U-1537	
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 003	10046031	Aug 11, 2029			U-2383	
	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
	10500159	Nov 02, 2030	DP			
	6444226	Jun 29, 2020	DP		U-1534	
	6652885	Jun 29, 2020			U-1535	
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020			U-1535	
	7943178	Jun 29, 2020	DP		U-1535	
	7943572	Aug 10, 2026			U-1539	
	8119593	Aug 11, 2029			U-1537	
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029			U-1537	
	8389470	Jun 29, 2020	DP		U-1621	
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029			U-1537	
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP		U-1538	
	8889099	Jun 29, 2020	DP		U-1621	
	8912193	Jun 12, 2029	DP		U-1538	
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP		U-1788	
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP		U-1861	
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP		U-1861	
	9511198	Feb 16, 2030			U-1929	
	9511198	Feb 16, 2030			U-1930	
	9597374	Oct 08, 2031			U-1987	
	9662461	Jun 12, 2029	DP		U-2019	
	9717689	Sep 14, 2026	DP			
	9943571	Aug 11, 2029			U-1537	
INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30						
N 019717 001	7291132	Aug 09, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN							
N 019717	002	7291132	Aug 09, 2024	DP			
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N							
N 018781	001	7291132	Aug 09, 2024	DP			
IOBENGUANE I-131 - AZEDRA							
N 209607	001					NP	Jul 30, 2021
						ODE-204	Jul 30, 2025
IODIXANOL - VISIPAQUE 320							
N 020351	002					I-752	Apr 05, 2020
IODIXANOL - VISIPAQUE 320							
N 020808	002					I-752	Apr 05, 2020
IPRATROPIUM BROMIDE - ATROVENT HFA							
N 021527	001	6739333	May 26, 2020	DP			
		6983743	May 26, 2020	DP			
		8474447	Jan 17, 2030	DP			
IRINOTECAN HYDROCHLORIDE - CAMPTOSAR							
N 020571	001	6403569	Apr 28, 2020	U-449			
		6794370	May 01, 2020	U-606			
IRINOTECAN HYDROCHLORIDE - CAMPTOSAR							
N 020571	002	6403569	Apr 28, 2020	U-449			
		6794370	May 01, 2020	U-606			
IRINOTECAN HYDROCHLORIDE - ONIVYDE							
N 207793	001	10456360	Oct 15, 2036	DP		ODE-99	Oct 22, 2022
		8147867	Aug 29, 2028	DS DP			
		8329213	May 02, 2025	DS DP			
		8703181	May 02, 2025	U-1434			
		8992970	May 02, 2025	DS DP			
		9339497	Jun 12, 2033	U-1848			
		9364473	Jun 12, 2033	U-1856			
		9452162	Jun 12, 2033	U-1899			
		9492442	Jun 12, 2033	U-1848			
		9492442	Jun 12, 2033	U-1899			
		9492442	Jun 12, 2033	U-1917			
		9717724	Jun 12, 2033	U-1848			
		9717724	Jun 12, 2033	U-2091			
		9724303	May 02, 2025	DS DP			
		9730891	May 02, 2025	U-1848			
		9782349	May 02, 2025	DS DP			
ISAVUCONAZONIUM SULFATE - CRESEMBA							
N 207500	001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
		7459561	Oct 31, 2020	DS		ODE-90	Mar 06, 2022
						GAIN	Mar 06, 2025
						GAIN	Mar 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA							
N 207501	001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
		7459561	Oct 31, 2020	DS		ODE-90	Mar 06, 2022
						GAIN	Mar 06, 2025
						GAIN	Mar 06, 2027
ISOPROPYL ALCOHOL - ZURAGARD							
N 210872	001					NP	Apr 26, 2022
ISOTRETINOIN - ABSORICA							
N 021951	001	7435427	Sep 21, 2021	DP			
		8367102	Sep 21, 2021	U-1347			
		8952064	Sep 21, 2021	DP			
		9078925	Sep 21, 2021	DP			
		9089534	Sep 21, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISOTRETINOIN - ABSORICA						
N 021951 002	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 003	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 004	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 001	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 002	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 003	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 004	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 005	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 006	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISTRADEFYLLINE - NOURIANZ						
N 022075 001	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	U-2623			
	7727994	Jan 18, 2023	U-2623			
	8318201	Sep 05, 2027	DP			
ISTRADEFYLLINE - NOURIANZ						
N 022075 002	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	U-2623			
	7727994	Jan 18, 2023	U-2623			
	8318201	Sep 05, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ITRACONAZOLE - ONMEL						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
ITRACONAZOLE - TOLSURA						
N 208901 001	10463740	Jun 21, 2033	DP U-2453			
	8771739	Jul 25, 2023	DP			
	8921374	Jun 21, 2033	DP			
	9272046	Jun 21, 2033	DP			
	9713642	Jun 21, 2033	U-2453			
IVABRADINE - CORLANOR						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694		NP	Apr 22, 2022
	7867996	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7879842	Feb 22, 2026	DS DP U-1694		PED	Oct 15, 2020
					PED	Oct 22, 2022
					PED	Oct 22, 2026
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
IVACAFTOR - KALYDECO						
N 203188 001	7495103	May 20, 2027	DS DP		NPP	Jul 31, 2020
	8324242	Aug 05, 2027	U-1311		ODE-186	Feb 21, 2021
	8324242	Aug 05, 2027	U-1906		ODE-187	Dec 29, 2021
	8354427	Jul 06, 2026	U-1311		ODE-189	Jul 31, 2024
	8354427	Jul 06, 2026	U-1905		ODE-190	May 17, 2024
	8410274	Dec 28, 2026	DP		ODE-199	Aug 15, 2025
	8629162	Jun 24, 2025	U-2234			
	8754224	Dec 28, 2026	DS DP			
	9670163	Dec 28, 2026	DP U-1311			
IVACAFTOR - KALYDECO						
N 203188 002					NPP	Jul 31, 2020
					ODE-186	Feb 21, 2021
					ODE-187	Dec 29, 2021
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024
					ODE-199	Aug 15, 2025
IVACAFTOR - KALYDECO						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 001	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
IVACAFTOR - KALYDECO						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
IVACAFTOR - KALYDECO						
N 207925 003	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
		10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
		10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
		10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
		10081621	Mar 25, 2031	DP U-2420			
		10081621	Mar 25, 2031	DP U-2571			
		10206877	Apr 14, 2035	DP U-2498			
		10206877	Apr 14, 2035	DP U-2570			
		10239867	Apr 09, 2027	DS DP U-2512			
		10239867	Apr 09, 2027	DS DP U-2569			
		7495103	May 20, 2027	DS DP			
		7645789	May 01, 2027	DS DP			
		7776905	Jun 03, 2027	DS DP			
		8324242	Aug 05, 2027	U-2246			
		8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-2246			
		8598181	May 01, 2027	U-2246			
		8623905	May 01, 2027	DS DP			
		8629162	Jun 24, 2025	U-2247			
		8754224	Dec 28, 2026	DS DP			
		9012496	Jul 15, 2033	U-2248			
		9670163	Dec 28, 2026	DP U-2246			
		9931334	Dec 28, 2026	DP U-2275			
		9931334	Dec 28, 2026	DP U-2575			
		9974781	Apr 09, 2027	DP U-2318			
		9974781	Apr 09, 2027	DP U-2574			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001	10076513	Dec 04, 2028	DP U-2411		M-218	Jan 25, 2021
		7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-1973		ODE-123	Sep 28, 2023
		8324242	Aug 05, 2027	U-1311		ODE-93	Jul 02, 2022
		8324242	Aug 05, 2027	U-1911			
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-1718			
		8716338	Sep 20, 2030	DP U-1910			
		8741933	Nov 08, 2026	U-1717			
		8741933	Nov 08, 2026	U-1909			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-1717			
		8846718	Dec 04, 2028	U-1908			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-1908			
		9192606	Sep 29, 2029	DP U-1912			
		9216969	Nov 08, 2026	DS DP			
		9670163	Dec 28, 2026	DP U-1911			
		9931334	Dec 28, 2026	DP U-2276			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	002	7495103	May 20, 2027	DS DP		M-218	Jan 25, 2021
		7973038	Nov 08, 2026	U-1973		NCE	Jul 02, 2020
		8324242	Aug 05, 2027	U-1911		ODE-123	Sep 28, 2023
		8410274	Dec 28, 2026	DP		ODE-93	Jul 02, 2022
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-1910			
		8741933	Nov 08, 2026	U-1909			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-1908			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-1908			
		9192606	Sep 29, 2029	DP U-1912			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-1911			
		9931334	Dec 28, 2026	DP U-2276			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-2374		NP	Aug 07, 2021
		8324242	Aug 05, 2027	U-2374		ODE-195	Aug 07, 2025
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-2396			
		8741933	Nov 08, 2026	U-2374			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-2375			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-2375			
		9192606	Sep 29, 2029	DP U-2397			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-2376			
		9931334	Dec 28, 2026	DP U-2376			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	002	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-2374		NP	Aug 07, 2021
		8324242	Aug 05, 2027	U-2374		ODE-195	Aug 07, 2025
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-2396			
		8741933	Nov 08, 2026	U-2374			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-2375			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-2375			
		9192606	Sep 29, 2029	DP U-2397			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-2376			
		9931334	Dec 28, 2026	DP U-2376			
IVERMECTIN - IVERMECTIN							
A 210019	001					PC	Apr 11, 2020
IVERMECTIN - SKLICE							
N 202736	001	8791153	Oct 12, 2027	DP			
		8927595	Oct 12, 2027	U-1782			
IVERMECTIN - SOOLANTRA							
N 206255	001	10206939	Mar 13, 2034	U-1631			
		7550440	Apr 22, 2024	DP U-1631			
		8080530	Apr 22, 2024	DP U-1631			
		8093219	Apr 22, 2024	DP U-1631			
		8415311	Apr 22, 2024	DP U-1631			
		8470788	Apr 22, 2024	DP U-1631			
		8815816	Apr 22, 2024	DP U-1631			
		9089587	Mar 13, 2034	U-1631			
		9233117	Mar 13, 2034	U-1631			
		9233118	Mar 13, 2034	U-1631			
		9782425	Mar 13, 2034	U-1631			
IVOSIDENIB - TIBSOVO							
N 211192	001	10449184	Mar 13, 2035	DP		I-816	May 02, 2022
		9474779	Aug 19, 2033	DS DP U-2350		NCE	Jul 20, 2023
		9474779	Aug 19, 2033	DS DP U-2533		ODE-203	Jul 20, 2025
		9474779	Aug 19, 2033	DS DP U-2534		ODE-242	May 02, 2026
		9850277	Jan 18, 2033	DS DP U-2350			
		9850277	Jan 18, 2033	DS DP U-2533			
		9850277	Jan 18, 2033	DS DP U-2534			
		9968595	Mar 13, 2035	DP U-2351			
		9968595	Mar 13, 2035	DP U-2533			
		9968595	Mar 13, 2035	DP U-2534			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT							
N 022065	001	6670384	Jan 23, 2022	DP U-959			
		6670384	Jan 23, 2022	DP U-960			
		7022330	Jan 23, 2022	DP U-958			
		7312237	Aug 21, 2024	U-965			
		RE41393	Feb 08, 2022	U-961			
		RE41911	Sep 28, 2020	DS DP U-961			
IXABEPILONE - IXEMPRA KIT							
N 022065	002	6670384	Jan 23, 2022	DP U-959			
		6670384	Jan 23, 2022	DP U-960			
		7022330	Jan 23, 2022	DP U-958			
		7312237	Aug 21, 2024	U-965			
		RE41393	Feb 08, 2022	U-961			
		RE41911	Sep 28, 2020	DS DP U-961			
IXAZOMIB CITRATE - NINLARO							
N 208462	001	7442830	Nov 20, 2029	DS DP U-2434		NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP		ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434			
		8530694	Aug 06, 2027	DS DP U-2434			
		8546608	Aug 12, 2024	DS			
		8859504	Jun 16, 2029	DS DP			
		8871745	Aug 06, 2027	U-2434			
		9175017	Jun 16, 2029	U-2434			
		9233115	Aug 12, 2024	U-2434			
IXAZOMIB CITRATE - NINLARO							
N 208462	002	7442830	Nov 20, 2029	DS DP U-2434		NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP		ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434			
		8530694	Aug 06, 2027	DS DP U-2434			
		8546608	Aug 12, 2024	DS			
		8859504	Jun 16, 2029	DS DP			
		8871745	Aug 06, 2027	U-2434			
		9175017	Jun 16, 2029	U-2434			
		9233115	Aug 12, 2024	U-2434			
IXAZOMIB CITRATE - NINLARO							
N 208462	003	7442830	Nov 20, 2029	DS DP U-2434		NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP		ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434			
		8530694	Aug 06, 2027	DS DP U-2434			
		8546608	Aug 12, 2024	DS			
		8859504	Jun 16, 2029	DS DP			
		8871745	Aug 06, 2027	U-2434			
		9175017	Jun 16, 2029	U-2434			
		9233115	Aug 12, 2024	U-2434			
KETOCONAZOLE - XOLEGEL							
N 021946	001	8232276	Nov 24, 2020	DP			
KETOROLAC TROMETHAMINE - ACULAR LS							
N 021528	001	8008338	May 24, 2027	DS DP U-1181			
		8207215	May 28, 2024	U-1251			
		8377982	May 28, 2024	U-1363			
		8377982*PED	Nov 28, 2024				
		8541463	May 28, 2024	U-1441			
		8541463*PED	Nov 28, 2024				
		8648107	May 28, 2024	DP			
		8906950	May 28, 2024	U-1626			
		8946281	May 28, 2024	U-1662			
		9216167	May 28, 2024	U-1800			
KETOROLAC TROMETHAMINE - ACUVAIL							
N 022427	001	7842714	Aug 15, 2029	DS DP			
		8512717	Mar 07, 2028	DP			
		8992952	Aug 05, 2024	DP			
		9192571	Mar 07, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA							
N 205388	001	8173707	Jul 30, 2023	U-1518		NPP	Dec 08, 2020
		8173707*PED	Jan 30, 2024			PED	Jun 08, 2021
		8586633	Jul 30, 2023	DP			
		8586633*PED	Jan 30, 2024				
		9066856	Oct 23, 2033	DP			
		9066856*PED	Apr 23, 2034				
		9278101	Jul 30, 2023	U-1518			
		9278101*PED	Jan 30, 2024				
		9399040	Jul 30, 2023	DP			
		9399040*PED	Jan 30, 2024				
		9486406	Oct 23, 2033	DP			
		9486406*PED	Apr 23, 2034				
		9855246	Oct 23, 2033	DP			
L-GLUTAMINE - ENDARI							
N 208587	001					I-748	Jul 07, 2020
						ODE-150	Jul 07, 2024
LACOSAMIDE - VIMPAT							
N 022253	001	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LACOSAMIDE - VIMPAT							
N 022253	002	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LACOSAMIDE - VIMPAT							
N 022253	003	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LACOSAMIDE - VIMPAT							
N 022253	004	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LACOSAMIDE - VIMPAT							
N 022254	001	RE38551	Mar 17, 2022	DS DP U-1565		M-217	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-1568			
LACOSAMIDE - VIMPAT							
N 022255	001	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS							
N 206510	001	7169780	Oct 03, 2023	DS DP			
		7169780*PED	Apr 03, 2024				
		7217713	Oct 21, 2022	U-1663			
		7217713*PED	Apr 21, 2023				
		7435734	Oct 21, 2022	U-1663			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-1663			
		7754731*PED	Sep 11, 2029				
		7820660	Apr 25, 2023	DS			
LAMOTRIGINE - LAMICTAL XR							
N 022115	001	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	002	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	003	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	004	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL XR								
N	022115	005	8637512	Jun 14, 2028	DP			
			9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR								
N	022115	006	8637512	Jun 14, 2028	DP			
			9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL ODT								
N	022251	001	7919115	Jan 04, 2029	DS DP			
			8840925	Jul 02, 2028	DP U-1596			
			9339504	Jul 02, 2028	DP U-1596			
LAMOTRIGINE - LAMICTAL ODT								
N	022251	004	7919115	Jan 04, 2029	DS DP			
			8840925	Jul 02, 2028	DP U-1596			
			9339504	Jul 02, 2028	DP U-1596			
LANREOTIDE ACETATE - SOMATULINE DEPOT								
N	022074	001	5595760	Mar 08, 2020	DP U-831		I-754	Sep 15, 2020
							ODE-156	Sep 15, 2024
							ODE-82	Dec 16, 2021
LANREOTIDE ACETATE - SOMATULINE DEPOT								
N	022074	002	5595760	Mar 08, 2020	DP U-831		I-754	Sep 15, 2020
							ODE-156	Sep 15, 2024
							ODE-82	Dec 16, 2021
LANREOTIDE ACETATE - SOMATULINE DEPOT								
N	022074	003	5595760	Mar 08, 2020	DP U-831		I-754	Sep 15, 2020
							ODE-156	Sep 15, 2024
							ODE-82	Dec 16, 2021
LANSOPRAZOLE - PREVACID IV								
N	021566	001	7396841	Aug 17, 2021	DP U-947			
LANTHANUM CARBONATE - FOSRENOL								
N	021468	001	7381428	Aug 26, 2024	U-890			
			7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL								
N	021468	002	7381428	Aug 26, 2024	U-890			
			7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL								
N	021468	003	7381428	Aug 26, 2024	U-890			
			7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL								
N	021468	004	7381428	Aug 26, 2024	U-890			
			7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL								
N	204734	001	7465465	Aug 26, 2024	DP			
			8980327	Dec 01, 2030	DP			
			9023397	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL								
N	204734	002	7465465	Aug 26, 2024	DP			
			8980327	Dec 01, 2030	DP			
			9023397	Dec 01, 2030	DP			
LAPATINIB DITOSYLATE - TYKERB								
N	022059	001	6713485	Sep 29, 2020	DS DP U-1429		M-235	Dec 06, 2021
			6713485	Sep 29, 2020	DS DP U-800			
			7157466	Nov 19, 2021	DS DP			
			8821927	Sep 18, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAROTRECTINIB SULFATE - VITRAKVI							
N 210861	001	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
		10047097	Oct 21, 2029	U-2474		ODE-215	Nov 26, 2025
		10172861	Nov 16, 2035	DS DP		ODE-220	Nov 26, 2025
		10285993	Nov 16, 2035	U-2470		ODE-221	Nov 26, 2025
		8513263	Dec 23, 2029	DS DP			
		8865698	Oct 21, 2029	U-2469			
		9127013	Oct 21, 2029	DS DP			
		9447104	Oct 21, 2029	U-2470			
		9676783	Oct 21, 2029	U-2469			
		9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB SULFATE - VITRAKVI							
N 210861	002	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
		10047097	Oct 21, 2029	U-2474		ODE-215	Nov 26, 2025
		10172861	Nov 16, 2035	DS DP		ODE-220	Nov 26, 2025
		10285993	Nov 16, 2035	U-2470		ODE-221	Nov 26, 2025
		8513263	Dec 23, 2029	DS DP			
		8865698	Oct 21, 2029	U-2469			
		9127013	Oct 21, 2029	DS DP			
		9447104	Oct 21, 2029	U-2470			
		9676783	Oct 21, 2029	U-2469			
		9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB SULFATE - VITRAKVI							
N 211710	001	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
		10045991	Apr 04, 2037	U-2473		ODE-215	Nov 26, 2025
		10047097	Oct 21, 2029	U-2474		ODE-220	Nov 26, 2025
		10137127	Apr 04, 2037	DP		ODE-221	Nov 26, 2025
		10172861	Nov 16, 2035	DS			
		8513263	Dec 23, 2029	DS DP			
		8865698	Oct 21, 2029	U-2469			
		9127013	Oct 21, 2029	DS DP			
		9447104	Oct 21, 2029	U-2470			
		9676783	Oct 21, 2029	U-2469			
		9782414	Nov 16, 2035	U-2471			
LATANOPROST - XELPROS							
N 206185	001	9539262	Oct 15, 2028	U-2400			
		9629852	Sep 12, 2029	DP			
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN							
N 208259	001	10174017	Jan 27, 2030	DS DP U-1524		NC	Mar 12, 2022
		8394826	Nov 10, 2030	DS DP U-1524		NCE	Dec 18, 2022
		8450344	Jul 11, 2026	DS DP U-1524			
		9096569	Jul 11, 2026	DS DP U-1524			
		9415043	Mar 14, 2034	DS			
		9931336	Mar 14, 2034	DS DP U-1524			
		9993470	Mar 14, 2034	DS DP U-1524			
LATANOPROSTENE BUNOD - VYZULTA							
N 207795	001	7273946	Oct 03, 2025	DS DP U-2144			
		7629345	Jan 05, 2025	DP U-2144			
		7910767	Jan 05, 2025	DS DP U-2144			
		8058467	Jan 05, 2025	DS U-2144			
LEDIPASVIR; SOFOSBUVIR - HARVONI							
N 205834	001	10039779	Jan 30, 2034	DS DP U-2369		D-177	Nov 15, 2022
		10039779	Jan 30, 2034	DS DP U-2370		NPP	Apr 07, 2020
		10039779*PED	Jul 30, 2034			ODE-136	Apr 07, 2024
		10456414	Sep 14, 2032	DP		PED	Oct 07, 2024
		7964580	Mar 26, 2029	DS DP U-1470			
		7964580*PED	Sep 26, 2029				
		8088368	May 12, 2030	DS DP			
		8088368*PED	Nov 12, 2030				
		8273341	May 12, 2030	U-1470			
		8273341*PED	Nov 12, 2030				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI							
N 205834	001	8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8822430	May 12, 2030	DS DP U-1470			
		8822430*PED	Nov 12, 2030				
		8841278	May 12, 2030	DP U-1470			
		8841278*PED	Nov 12, 2030				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9393256	Sep 14, 2032	U-1470			
		9393256*PED	Mar 14, 2033				
		9511056	May 12, 2030	DP U-1470			
		9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI							
N 205834	002	10039779	Jan 30, 2034	DS DP U-1470		D-177	Nov 15, 2022
		10039779*PED	Jul 30, 2034				
		10456414	Sep 14, 2032	DP			
		7964580	Mar 26, 2029	DS DP U-1470			
		7964580*PED	Sep 26, 2029				
		8088368	May 12, 2030	DS DP			
		8088368*PED	Nov 12, 2030				
		8273341	May 12, 2030	U-1470			
		8273341*PED	Nov 12, 2030				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8822430	May 12, 2030	DS DP U-1470			
		8822430*PED	Nov 12, 2030				
		8841278	May 12, 2030	DP U-1470			
		8841278*PED	Nov 12, 2030				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9393256	Sep 14, 2032	U-1470			
		9393256*PED	Mar 14, 2033				
		9511056	May 12, 2030	U-1470			
		9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI							
N 212477	001	10456414	Sep 14, 2032	DP		D-177	Nov 15, 2022
		7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
		7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
		8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
		8088368*PED	Nov 12, 2030				
		8273341	May 12, 2030	U-1470			
		8273341*PED	Nov 12, 2030				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 001	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 002	10456414	Sep 14, 2032	DP		D-177	Nov 15, 2022
	7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
	8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEFAMULIN ACETATE - XENLETA						
N 211672 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
	9120727	May 23, 2031	DS DP			
LEFAMULIN ACETATE - XENLETA						
N 211673 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 001	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 002	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 003	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 003	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 004	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 005	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 006	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID							
N 021880	006	9056120	Apr 11, 2023	U-1982			
		9101621	May 15, 2023	U-1985			
		9101622	May 15, 2023	U-1986			
		9155730	May 15, 2023	U-2550			
		9393238	May 15, 2023	U-2550			
LENVATINIB MESYLATE - LENVIMA							
N 206947	001	10259791	Aug 26, 2035	DS		I-787	Aug 15, 2021
		10407393	Aug 26, 2035	DS		I-807	Sep 17, 2022
		7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP		ODE-196	Aug 15, 2025
		9006256	Jul 27, 2027	U-1695		ODE-87	Feb 13, 2022
LENVATINIB MESYLATE - LENVIMA							
N 206947	002	10259791	Aug 26, 2035	DS		I-787	Aug 15, 2021
		10407393	Aug 26, 2035	DS		I-807	Sep 17, 2022
		7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP		ODE-196	Aug 15, 2025
		9006256	Jul 27, 2027	U-1695		ODE-87	Feb 13, 2022
LESINURAD - ZURAMPIC							
N 207988	001	10183012	Nov 26, 2028	U-2311		NCE	Dec 22, 2020
		8003681	Aug 25, 2025	DS			
		8084483	Aug 17, 2029	U-1801			
		8283369	Nov 26, 2028	U-1802			
		8283369	Nov 26, 2028	U-1804			
		8357713	Nov 26, 2028	DP U-1801			
		8357713	Nov 26, 2028	DP U-1802			
		8357713	Nov 26, 2028	DP U-1803			
		8546436	Feb 29, 2032	DS DP			
		8546437	Apr 29, 2029	U-1803			
		9216179	Aug 01, 2031	U-1806			
		9956205	Dec 28, 2031	U-2311			
LETERMOVIR - PREVYMIS							
N 209939	001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209939	002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209940	001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209940	002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)							
N 209935	001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
		8415355	Feb 19, 2031	DS DP			
		8685980	May 25, 2030	DS DP			
		8962630	Dec 09, 2029	U-2505			
		9193732	Nov 09, 2031	DS DP			
		9416136	Aug 20, 2029	U-2505			
		9868739	Nov 09, 2031	U-2505			
LEUPROLIDE ACETATE - LUPRON DEPOT							
N 020517	003	8815801	Jun 28, 2022	DP			
		8921326	Feb 05, 2031	DP U-1666			
LEUPROLIDE ACETATE - ELIGARD							
N 021343	001	6626870	Mar 27, 2020	DP			
LEUPROLIDE ACETATE - ELIGARD							
N 021379	001	6626870	Mar 27, 2020	DP			
		8470359	Oct 15, 2023	DS DP U-621			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEUPROLIDE ACETATE - ELIGARD									
N 021379	001		8840916	Nov 13, 2020		DP			
			9539333	Nov 13, 2020	DS	DP U-621			
LEUPROLIDE ACETATE - ELIGARD									
N 021488	001		6626870	Mar 27, 2020		DP			
			8470359	Oct 15, 2023	DS	DP U-621			
			8840916	Nov 13, 2020		DP			
			9539333	Nov 13, 2020	DS	DP U-621			
LEUPROLIDE ACETATE - ELIGARD									
N 021731	001		6626870	Mar 27, 2020		DP			
			8470359	Oct 15, 2023	DS	DP U-621			
			8840916	Nov 13, 2020		DP			
			9539333	Nov 13, 2020	DS	DP U-621			
			9914802	Nov 13, 2020	DS	DP U-1666			
LEUPROLIDE ACETATE - LUTRATE DEPOT KIT									
N 205054	001		9789064	Dec 15, 2020		DP			
LEVALBUTEROL HYDROCHLORIDE - XOPENEX									
N 020837	001		6451289	Mar 21, 2021					
LEVALBUTEROL HYDROCHLORIDE - XOPENEX									
N 020837	002		6451289	Mar 21, 2021					
LEVALBUTEROL HYDROCHLORIDE - XOPENEX									
N 020837	003		6451289	Mar 21, 2021					
LEVALBUTEROL HYDROCHLORIDE - XOPENEX									
N 020837	004		6451289	Mar 21, 2021		DP			
LEVALBUTEROL TARTRATE - XOPENEX HFA									
N 021730	001		7256310	Oct 08, 2024	DS	DP U-636			
			8765153	Dec 08, 2023		DP			
LEVETIRACETAM - KEPPRA									
N 021035	001		8802142	Jun 07, 2031		DP			
			8802142*PED	Dec 07, 2031					
LEVETIRACETAM - KEPPRA									
N 021035	002		8802142	Jun 07, 2031		DP			
			8802142*PED	Dec 07, 2031					
LEVETIRACETAM - KEPPRA									
N 021035	003		8802142	Jun 07, 2031		DP			
			8802142*PED	Dec 07, 2031					
LEVETIRACETAM - KEPPRA									
N 021035	004		8802142	Jun 07, 2031		DP			
			8802142*PED	Dec 07, 2031					
LEVETIRACETAM - KEPPRA XR									
N 022285	001		7858122	Sep 17, 2028		DP			
LEVETIRACETAM - KEPPRA XR									
N 022285	002		7858122	Sep 17, 2028		DP			
LEVETIRACETAM - ELEPSIA XR									
N 204417	001		8163306	Sep 03, 2027		DP			
			8425938	Feb 22, 2026		DP			
			8431156	Oct 31, 2027		DP			
			8470367	Oct 31, 2027		DP			
			8535717	Feb 22, 2026		DP			
LEVETIRACETAM - ELEPSIA XR									
N 204417	002		8163306	Sep 03, 2027		DP			
			8425938	Feb 22, 2026		DP			
			8431156	Oct 31, 2027		DP			
			8470367	Oct 31, 2027		DP			
			8535717	Feb 22, 2026		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVETIRACETAM - ELEPSIA XR								
N	204417	002	8163306	Sep 03, 2027	DP			
			8425938	Feb 22, 2026	DP			
			8431156	Oct 31, 2027	DP			
			8470367	Oct 31, 2027	DP			
			8535717	Feb 22, 2026	DP			
LEVETIRACETAM - SPRITAM								
N	207958	001	9339489	Mar 14, 2034	DP U-1850			
			9669009	Mar 14, 2034	U-1850			
			9669009	Mar 14, 2034	U-2021			
			9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM								
N	207958	002	9339489	Mar 14, 2034	DP U-1850			
			9669009	Mar 14, 2034	U-1850			
			9669009	Mar 14, 2034	U-2021			
			9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM								
N	207958	003	9339489	Mar 14, 2034	DP U-1850			
			9669009	Mar 14, 2034	U-1850			
			9669009	Mar 14, 2034	U-2021			
			9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM								
N	207958	004	9339489	Mar 14, 2034	DP U-1850			
			9669009	Mar 14, 2034	U-1850			
			9669009	Mar 14, 2034	U-2021			
			9669009	Mar 14, 2034	U-2022			
LEVOCARNITINE - LEVOCARNITINE								
A	211676	001					CGT	Apr 13, 2020
LEVOCARNITINE - LEVOCARNITINE SF								
A	211676	002					CGT	Apr 13, 2020
LEVOCARNITINE - CARNITOR								
N	020182	001	6335369	Jan 18, 2021	U-433			
			6429230	Jan 18, 2021	U-433			
			6696493	Jan 18, 2021	U-433			
LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR								
N	209090	001	8633194	Oct 16, 2027	DP			
LEVODOPA - INBRIJA								
N	209184	001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
			6613308	Sep 19, 2020	U-2484			
			6858199	Nov 04, 2021	U-2485			
			6921528	Jun 19, 2020	U-2485			
			6979437	Sep 19, 2020	U-2484			
			7146978	Apr 16, 2021	U-2486			
			7182961	Feb 22, 2024	DP			
			7384649	Nov 20, 2022	DP			
			7556798	Nov 04, 2021	U-2485			
			8404276	Mar 19, 2023	U-2484			
			8545878	Nov 16, 2032	DP			
			8586093	Mar 19, 2023	U-2484			
			8628754	Jun 19, 2020	U-2485			
			8685442	Nov 16, 2032	DP			
			8945612	Nov 16, 2032	DP			
			9155699	Mar 19, 2023	DP			
			9393210	Nov 16, 2032	DP			
			RE43711	Feb 03, 2029	U-2484			
LEVOFLOXACIN - LEVAQUIN								
N	021721	001	6806256	Feb 26, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOLEUCOVORIN CALCIUM - FUSILEV								
N	020140	001	6500829	Mar 07, 2022	DS DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV								
N	020140	002	6500829	Mar 07, 2022	DS DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV								
N	020140	003	6500829	Mar 07, 2022	DS DP			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA								
N	204168	001	8481598	Mar 02, 2031	U-839		M-249	Oct 07, 2022
			8865937	May 23, 2032	DS DP			
			RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA								
N	204168	002	8481598	Mar 02, 2031	U-839		M-249	Oct 07, 2022
			8865937	May 23, 2032	DS DP			
			RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA								
N	204168	003	8481598	Mar 02, 2031	U-839		M-249	Oct 07, 2022
			8865937	May 23, 2032	DS DP			
			RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA								
N	204168	004	8481598	Mar 02, 2031	U-839		M-249	Oct 07, 2022
			8865937	May 23, 2032	DS DP			
			RE43879	Jun 03, 2023	U-839			
LEVONORGESTREL - MIRENA								
N	021225	001	9615965	Sep 16, 2029	DP U-2003			
			9668912	Apr 01, 2031	DP			
LEVONORGESTREL - SKYLA								
N	203159	001	7252839	Nov 13, 2023	DP			
			9615965	Sep 16, 2029	DP U-2003			
			9668912	Apr 01, 2031	DP			
LEVONORGESTREL - LILETTA								
N	206229	001	10028858	Mar 22, 2034	DP U-2348			
LEVONORGESTREL - KYLEENA								
N	208224	001	7252839	Nov 13, 2023	DP			
			9615965	Sep 16, 2029	DP U-2003			
			9668912	Apr 01, 2031	DP			
LEVOTHYROXINE SODIUM - LEVOXYL								
N	021301	001	6555581	Feb 15, 2022				
			7067148	Feb 15, 2022	DP			
			7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL								
N	021301	002	6555581	Feb 15, 2022				
			7067148	Feb 15, 2022	DP			
			7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL								
N	021301	003	6555581	Feb 15, 2022				
			7067148	Feb 15, 2022	DP			
			7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL								
N	021301	004	6555581	Feb 15, 2022				
			7067148	Feb 15, 2022	DP			
			7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL								
N	021301	005	6555581	Feb 15, 2022				
			7067148	Feb 15, 2022	DP			
			7101569	Oct 02, 2023	U-759			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 001	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 002	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 003	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 004	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 005	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 006	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 007	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 008	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 009	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 010	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 011	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	002	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	003	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	004	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	005	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	006	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	007	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	008	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	009	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	010	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	011	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	012	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	013	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM								
N	202231	001	9006289	Oct 03, 2032	DP			
			9168238	Aug 29, 2032	DP			
			9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM								
N	202231	002	9006289	Oct 03, 2032	DP			
			9168238	Aug 29, 2032	DP			
			9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM								
N	202231	003	9006289	Oct 03, 2032	DP			
			9168238	Aug 29, 2032	DP			
			9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM								
N	210632	001	10398669	Dec 01, 2036	DP			
			9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM								
N	210632	002	10398669	Dec 01, 2036	DP			
			9782376	Dec 01, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM							
N 210632	003	10398669	Dec 01, 2036	DP			
		9782376	Dec 01, 2036	DP			
LIDOCAINE - ZTLIDO							
N 207962	001	9283174	May 10, 2031	DP		NP	Feb 28, 2021
		9925264	May 10, 2031	DP U-2267			
		9931403	May 10, 2031	DP			
LIDOCAINE HYDROCHLORIDE - ZINGO							
N 022114	001	8540665	Oct 22, 2029	U-1438			
		9358338	Apr 27, 2035	U-1870			
		9370622	Sep 28, 2035	U-1870			
LIDOCAINE HYDROCHLORIDE - AKTEN							
N 022221	001	8759401	Jul 24, 2026	DP U-1523			
LIDOCAINE; TETRACAINE - SYNERA							
N 021623	001	6465709	Jul 07, 2020	DP			
LIDOCAINE; TETRACAINE - PLIAGLIS							
N 021717	001	10350180	Jan 14, 2031	DP			
LIFITEGRAST - XIIDRA							
N 208073	001	10124000	Nov 05, 2024	U-1900		NCE	Jul 11, 2021
		7314938	Mar 10, 2025	DS DP			
		7745460	Nov 05, 2024	DS DP U-1880			
		7790743	Nov 05, 2024	U-1880			
		7928122	Nov 05, 2024	DS DP			
		8084047	May 17, 2026	DS DP			
		8168655	May 09, 2029	U-1880			
		8367701	Apr 15, 2029	DP U-1880			
		8592450	May 17, 2026	U-1880			
		8927574	Nov 12, 2030	DP			
		9085553	Jul 25, 2033	DP			
		9216174	Nov 05, 2024	DP			
		9353088	Oct 21, 2030	DP			
		9447077	Apr 15, 2029	U-1900			
		9890141	Oct 21, 2030	DS			
LINACLOTIDE - LINZESS							
N 202811	001	7304036	Aug 30, 2026	DS DP U-1278			
		7304036	Aug 30, 2026	DS DP U-1516			
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			
		8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1278			
		8748573	Oct 30, 2031	U-1515			
		8748573	Oct 30, 2031	U-1516			
		8802628	Oct 30, 2031	DP			
		8933030	Feb 17, 2031	DP			
		9708371	Aug 16, 2033	DP U-1515			
		9708371	Aug 16, 2033	DP U-1516			
LINACLOTIDE - LINZESS							
N 202811	002	7304036	Aug 30, 2026	DS DP U-1278			
		7304036	Aug 30, 2026	DS DP U-1516			
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			
		8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1278			
		8748573	Oct 30, 2031	U-1515			
		8748573	Oct 30, 2031	U-1516			
		8802628	Oct 30, 2031	DP			
		8933030	Feb 17, 2031	DP			
		9708371	Aug 16, 2033	DP U-1515			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINACLOTIDE - LINZESS							
N 202811	003	7304036	Aug 30, 2026	DS DP U-1516		NS	Jan 25, 2020
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			
		8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1516			
		8933030	Feb 17, 2031	DP U-1516			
		9708371	Aug 16, 2033	DP U-1516			
LINAGLIPTIN - TRADJENTA							
N 201280	001	10034877	Aug 05, 2029	U-2347			
		7407955	May 02, 2025	DS DP			
		8119648	Aug 12, 2023	U-1270			
		8119648	Aug 12, 2023	U-774			
		8178541	Aug 12, 2023	U-1244			
		8178541	Aug 12, 2023	U-1245			
		8178541	Aug 12, 2023	U-1270			
		8178541	Aug 12, 2023	U-775			
		8673927	May 04, 2027	U-1503			
		8846695	Jun 04, 2030	U-1503	Y		
		8853156	Mar 05, 2031	U-1642			
		8883805	Nov 26, 2025	DP			
		9173859	May 04, 2027	DP U-1503			
		9173859	May 04, 2027	DP U-1768			
		9486526	Aug 05, 2029	U-1915			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	001	10022379	Apr 02, 2029	U-2339			
		7407955	May 02, 2025	DS DP			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-775			
		8673927	May 04, 2027	U-1503			
		8846695	Jun 04, 2030	U-1503			
		8883805	Nov 26, 2025	DP			
		9155705	May 21, 2030	DP			
		9173859	May 04, 2027	DP U-1503			
		9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	002	10022379	Apr 02, 2029	U-2339			
		7407955	May 02, 2025	DS DP			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-775			
		8673927	May 04, 2027	U-1503			
		8846695	Jun 04, 2030	U-1503			
		8883805	Nov 26, 2025	DP			
		9155705	May 21, 2030	DP			
		9173859	May 04, 2027	DP U-1503			
		9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	003	10022379	Apr 02, 2029	U-2339			
		7407955	May 02, 2025	DS DP			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-775			
		8673927	May 04, 2027	U-1503			
		8846695	Jun 04, 2030	U-1503	Y		
		8883805	Nov 26, 2025	DP			
		9155705	May 21, 2030	DP			
		9173859	May 04, 2027	DP U-1503			
		9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR							
N 208026	001	10022379	Apr 02, 2029	U-2339			
		6488962	Jun 20, 2020	DP			
		7407955	May 02, 2025	DS DP			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-1853			
		8673927	May 04, 2027	U-1503			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR									
N 208026	001	8883805	Nov 26, 2025		DP				
		9155705	May 21, 2030		DP				
		9173859	May 04, 2027		DP	U-1503			
		9415016	Apr 02, 2029		DP				
		9555001	Mar 06, 2033		DP	U-1967			
		9555001	Mar 06, 2033		DP	U-1968			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR									
N 208026	002	10022379	Apr 02, 2029			U-2339			
		6488962	Jun 20, 2020		DP				
		7407955	May 02, 2025	DS	DP				
		8119648	Aug 12, 2023			U-802			
		8178541	Aug 12, 2023		DP	U-1853			
		8673927	May 04, 2027			U-1503			
		8883805	Nov 26, 2025		DP				
		9155705	May 21, 2030		DP				
		9173859	May 04, 2027		DP	U-1503			
		9415016	Apr 02, 2029		DP				
		9555001	Mar 06, 2033		DP	U-1967			
		9555001	Mar 06, 2033		DP	U-1968			
LINEZOLID - ZYVOX									
N 021130	001	6514529	Mar 15, 2021		DP				
		6559305	Jan 29, 2021	DS					
LINEZOLID - ZYVOX									
N 021130	002	6514529	Mar 15, 2021		DP				
		6559305	Jan 29, 2021	DS					
LINEZOLID - ZYVOX									
N 021131	001	6559305	Jan 29, 2021	DS					
LINEZOLID - ZYVOX									
N 021131	002	6559305	Jan 29, 2021	DS					
		6559305*PED	Jul 29, 2021						
LINEZOLID - ZYVOX									
N 021131	003	6559305	Jan 29, 2021	DS					
		6559305*PED	Jul 29, 2021						
LINEZOLID - ZYVOX									
N 021132	001	6559305	Jan 29, 2021	DS					
LIRAGLUTIDE RECOMBINANT - VICTOZA									
N 022341	001	6268343	Aug 22, 2022	DS	DP	U-968		I-750	Aug 25, 2020
		6268343*PED	Feb 22, 2023					NPP	Jun 17, 2022
		7762994	May 23, 2024		DP			PED	Dec 17, 2022
		7762994*PED	Nov 23, 2024						
		8114833	Aug 13, 2025	DS	DP				
		8114833*PED	Feb 13, 2026						
		8579869	Jun 30, 2023		DP				
		8579869*PED	Dec 30, 2023						
		8846618	Jun 27, 2022		DP				
		8846618*PED	Dec 27, 2022						
		9265893	Sep 23, 2032		DP				
		9265893*PED	Mar 23, 2033						
		9968659	Jan 09, 2037			U-2313			
		9968659*PED	Jul 09, 2037						
		RE41956	Jan 21, 2021		DP				
		RE41956*PED	Jul 21, 2021						
LIRAGLUTIDE RECOMBINANT - SAXENDA									
N 206321	001	10220155	Jul 17, 2026		DP				
		10220155*PED	Jan 17, 2027						
		10357616	Jan 20, 2026		DP				
		10376652	Jan 20, 2026		DP				
		6268343	Aug 22, 2022	DS	DP	U-1255			
		6268343*PED	Feb 22, 2023						
		6899699	Jan 01, 2022		DP				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIRAGLUTIDE RECOMBINANT - SAXENDA							
N 206321	001	6899699*PED	Jul 01, 2022				
		7762994	May 23, 2024	DP			
		7762994*PED	Nov 23, 2024				
		8114833	Aug 13, 2025	DP			
		8114833*PED	Feb 13, 2026				
		8579869	Jun 30, 2023	DP			
		8579869*PED	Dec 30, 2023				
		8672898	Jan 02, 2022	DP			
		8672898*PED	Jul 02, 2022				
		8684969	Oct 20, 2025	DP			
		8684969*PED	Apr 20, 2026				
		8846618	Jun 27, 2022	DP			
		8846618*PED	Dec 27, 2022				
		8920383	Jul 17, 2026	DP			
		8920383*PED	Jan 17, 2027				
		9108002	Jan 26, 2026	DP			
		9108002*PED	Jul 26, 2026				
		9132239	Feb 01, 2032	DP			
		9132239*PED	Aug 01, 2032				
		9457154	Sep 27, 2027	DP			
		9457154*PED	Mar 27, 2028				
		9486588	Jan 02, 2022	DP			
		9486588*PED	Jul 02, 2022				
		9616180	Jan 20, 2026	DP			
		9616180*PED	Jul 20, 2026				
		9687611	Feb 27, 2027	DP			
		9687611*PED	Aug 27, 2027				
		9775953	Jul 17, 2026	DP			
		9775953*PED	Jan 17, 2027				
		9861757	Jan 20, 2026	DP			
		9861757*PED	Jul 20, 2026				
		9968659	Jan 09, 2037			U-2438	
		9968659*PED	Jul 09, 2037				
		RE46363	Aug 03, 2026	DP			
		RE46363*PED	Feb 03, 2027				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	001	7105486	Feb 24, 2023			U-727	
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS			
		7659253	Feb 24, 2023	DS DP		U-727	
		7659254	Feb 24, 2023			U-1034	
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023			U-727	
		7671030	Feb 24, 2023	DP		U-727	
		7671031	Feb 24, 2023			U-727	
		7674774	Feb 24, 2023	DP		U-842	
		7678770	Feb 24, 2023			U-842	
		7678771	Feb 24, 2023	DP		U-842	
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP		U-842	
		7700561	Feb 24, 2023	DP			
		7713936	Feb 24, 2023			U-727	
		7718619	Feb 24, 2023	DP		U-842	
		7723305	Feb 24, 2023	DP		U-842	
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	002	7105486	Feb 24, 2023			U-727	
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS			
		7659253	Feb 24, 2023	DS DP		U-727	
		7659254	Feb 24, 2023			U-1034	
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023			U-727	
		7671030	Feb 24, 2023	DP		U-727	
		7671031	Feb 24, 2023			U-727	
		7674774	Feb 24, 2023	DP		U-842	
		7678770	Feb 24, 2023			U-842	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE								
N	021977	002	7678771	Feb 24, 2023	DP U-842			
			7687466	Feb 24, 2023	DP			
			7687467	Feb 24, 2023	DP U-842			
			7700561	Feb 24, 2023	DP			
			7713936	Feb 24, 2023	U-727			
			7718619	Feb 24, 2023	DP U-842			
			7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE								
N	021977	003	7105486	Feb 24, 2023	U-727			
			7223735	Feb 24, 2023	DP			
			7655630	Feb 24, 2023	DS			
			7659253	Feb 24, 2023	DS DP U-727			
			7659254	Feb 24, 2023	U-1034			
			7662787	Feb 24, 2023	DS			
			7662788	Feb 24, 2023	U-727			
			7671030	Feb 24, 2023	DP U-727			
			7671031	Feb 24, 2023	U-727			
			7674774	Feb 24, 2023	DP U-842			
			7678770	Feb 24, 2023	U-842			
			7678771	Feb 24, 2023	DP U-842			
			7687466	Feb 24, 2023	DP			
			7687467	Feb 24, 2023	DP U-842			
			7700561	Feb 24, 2023	DP			
			7713936	Feb 24, 2023	U-727			
			7718619	Feb 24, 2023	DP U-842			
			7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE								
N	021977	004	7105486	Feb 24, 2023	U-727			
			7105486	Feb 24, 2023	U-842			
			7223735	Feb 24, 2023	DP			
			7655630	Feb 24, 2023	DS			
			7659253	Feb 24, 2023	DS DP U-727			
			7659254	Feb 24, 2023	U-1034			
			7662787	Feb 24, 2023	DS			
			7662788	Feb 24, 2023	U-727			
			7671030	Feb 24, 2023	DP U-727			
			7671031	Feb 24, 2023	U-727			
			7674774	Feb 24, 2023	DP U-842			
			7678770	Feb 24, 2023	U-842			
			7678771	Feb 24, 2023	DP U-842			
			7687466	Feb 24, 2023	DP			
			7687467	Feb 24, 2023	DP U-842			
			7700561	Feb 24, 2023	DP			
			7713936	Feb 24, 2023	U-727			
			7718619	Feb 24, 2023	DP U-842			
			7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE								
N	021977	005	7105486	Feb 24, 2023	U-842			
			7223735	Feb 24, 2023	DP			
			7655630	Feb 24, 2023	DS			
			7659253	Feb 24, 2023	DS DP U-727			
			7659254	Feb 24, 2023	U-1034			
			7662787	Feb 24, 2023	DS			
			7662788	Feb 24, 2023	U-727			
			7671030	Feb 24, 2023	DP U-727			
			7671031	Feb 24, 2023	U-727			
			7674774	Feb 24, 2023	DP U-842			
			7678770	Feb 24, 2023	U-842			
			7678771	Feb 24, 2023	DP U-842			
			7687466	Feb 24, 2023	DP			
			7687467	Feb 24, 2023	DP U-842			
			7700561	Feb 24, 2023	DP			
			7713936	Feb 24, 2023	U-727			
			7718619	Feb 24, 2023	DP U-842			
			7723305	Feb 24, 2023	DP U-842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	006	7105486	Feb 24, 2023	U-727			
		7105486	Feb 24, 2023	U-842			
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-1034			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-842			
		7678770	Feb 24, 2023	U-842			
		7678771	Feb 24, 2023	DP U-842			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-842			
		7700561	Feb 24, 2023	DP			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-842			
		7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	007	7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-1034			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-842			
		7678770	Feb 24, 2023	U-842			
		7678771	Feb 24, 2023	DP			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-842			
		7700561	Feb 24, 2023	DP			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	001	7105486	Feb 24, 2023	U-727			
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS DP			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-727			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-727			
		7678770	Feb 24, 2023	U-727			
		7678771	Feb 24, 2023	DP U-727			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-727			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-727			
		7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	002	7105486	Feb 24, 2023	U-727			
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS DP			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-727			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-727			
		7678770	Feb 24, 2023	U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	002	7678771	Feb 24, 2023	DP U-727			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-727			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-727			
		7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	003	7105486	Feb 24, 2023	U-727			
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS DP			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-727			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-727			
		7678770	Feb 24, 2023	U-727			
		7678771	Feb 24, 2023	DP U-727			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-727			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-727			
		7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	004	7105486	Feb 24, 2023	U-727			
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS DP			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-727			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-727			
		7678770	Feb 24, 2023	U-727			
		7678771	Feb 24, 2023	DP U-727			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-727			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-727			
		7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	005	7105486	Feb 24, 2023	U-727			
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS DP			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-727			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-727			
		7678770	Feb 24, 2023	U-727			
		7678771	Feb 24, 2023	DP U-727			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-727			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-727			
		7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	006	7105486	Feb 24, 2023	U-727			
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS DP			
		7659253	Feb 24, 2023	DS DP U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 006	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
LISINOPRIL - QBRELIS						
N 208401 001	10039800	Nov 06, 2035	U-1723			
	10039800	Nov 06, 2035	U-185			
	10039800	Nov 06, 2035	U-1864			
	10039800	Nov 06, 2035	U-1991			
	10039800	Nov 06, 2035	U-3			
	10039800	Nov 06, 2035	U-71			
	10039800	Nov 06, 2035	U-8			
	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035	U-1723			
	10406199	Nov 06, 2035	U-185			
	10406199	Nov 06, 2035	U-1864			
	10406199	Nov 06, 2035	U-1991			
	10406199	Nov 06, 2035	U-3			
	10406199	Nov 06, 2035	U-71			
	10406199	Nov 06, 2035	U-8			
	9463183	Nov 06, 2035	DP			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-8			
	9814751	Nov 06, 2035	DP			
LIXISENATIDE - ADLYXIN						
N 208471 001	10028910	Nov 11, 2030	DP		NCE	Jul 27, 2021
	10201663	Mar 10, 2034	DP			
	8475414	Dec 28, 2030	DP U-1881			
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9440029	Jan 30, 2032	DP			
	9511193	Jan 19, 2032	DP			
	9707176	Nov 11, 2030	DP			
	9821032	May 09, 2032	U-2200			
	9855388	Apr 24, 2029	DP U-1881			
	9981013	Aug 30, 2030	U-2297			
	RE45313	Jul 12, 2020	DS DP			
LIXISENATIDE - ADLYXIN						
N 208471 002	10028910	Nov 11, 2030	DP		NCE	Jul 27, 2021
	10201663	Mar 10, 2034	DP			
	8475414	Dec 28, 2030	DP U-1881			
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9440029	Jan 30, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIXISENATIDE - ADLYXIN							
N 208471	002	9511193	Jan 19, 2032	DP			
		9707176	Nov 11, 2030	DP			
		9821032	May 09, 2032	U-2200			
		9855388	Apr 24, 2029	DP U-1881			
		9981013	Aug 30, 2030	U-2297			
		RE45313	Jul 12, 2020	DS DP			
LOFEXIDINE HYDROCHLORIDE - LUCEMYRA							
N 209229	001					NCE	May 16, 2023
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	001	10016404	Mar 07, 2025	U-1316			
		5712279	Feb 21, 2020	DS DP U-1317			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	002	10016404	Mar 07, 2025	U-1316			
		5712279	Feb 21, 2020	DS DP U-1317			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	003	10016404	Mar 07, 2025	U-1316			
		5712279	Feb 21, 2020	DS DP U-1317			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	004	10016404	Mar 07, 2025	U-1316			
		5712279	Feb 21, 2020	DS DP U-1317			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	005	10016404	Mar 07, 2025	U-1316			
		5712279	Feb 21, 2020	DS DP U-1317			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	006	10016404	Mar 07, 2025	U-1316			
		5712279	Feb 21, 2020	DS DP U-1317			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	006	10016404	Mar 07, 2025	U-1316			
		5712279	Feb 21, 2020	DS DP U-1317			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS							
N 020448	001	6814978	Aug 26, 2021	DP			
LOPINAVIR; RITONAVIR - KALETRA							
N 021226	001	7141593	May 22, 2020	DP			
		7432294	May 22, 2020	DP			
LOPINAVIR; RITONAVIR - KALETRA							
N 021251	001	6911214	Nov 28, 2021	DP U-895			
		8501219	Nov 28, 2021	DP			
LOPINAVIR; RITONAVIR - KALETRA							
N 021906	001	7364752	Nov 10, 2020	DP U-688			
		8025899	Dec 14, 2027	DP			
		8025899*PED	Jun 14, 2028				
		8268349	Aug 25, 2024	DP			
		8309613	Dec 24, 2024	U-688			
		8377952	Oct 22, 2027	U-1372			
		8377952*PED	Apr 22, 2028				
		8399015	Aug 25, 2024	DP			
		8399015*PED	Feb 25, 2025				
		8470347	Sep 17, 2026	DP			
		8470347*PED	Mar 17, 2027				
		8691878	Aug 25, 2024	U-1513			
		8691878*PED	Feb 25, 2025				
LOPINAVIR; RITONAVIR - KALETRA							
N 021906	002	7364752	Nov 10, 2020	DP U-688			
		8025899	Dec 14, 2027	DP			
		8025899*PED	Jun 14, 2028				
		8268349	Aug 25, 2024	DP			
		8309613	Dec 24, 2024	U-688			
		8377952	Oct 22, 2027	U-1372			
		8377952*PED	Apr 22, 2028				
		8399015	Aug 25, 2024	DP			
		8399015*PED	Feb 25, 2025				
		8470347	Sep 17, 2026	DP			
		8470347*PED	Mar 17, 2027				
		8691878	Aug 25, 2024	U-1513			
		8691878*PED	Feb 25, 2025				
LORCASERIN HYDROCHLORIDE - BELVIQ							
N 022529	001	6953787	Apr 10, 2023	DS DP U-1252			
		6953787	Apr 10, 2023	DS DP U-1253			
		6953787	Apr 10, 2023	DS DP U-1254			
		6953787	Apr 10, 2023	DS DP U-1255			
		7514422	Apr 10, 2023	U-1252			
		7514422	Apr 10, 2023	U-1253			
		7514422	Apr 10, 2023	U-1254			
		7514422	Apr 10, 2023	U-1255			
		7977329	Apr 10, 2023	DS DP U-1252			
		7977329	Apr 10, 2023	DS DP U-1253			
		7977329	Apr 10, 2023	DS DP U-1254			
		7977329	Apr 10, 2023	DS DP U-1255			
		8168624	Apr 18, 2029	DS DP			
		8207158	Apr 10, 2023	U-1252			
		8207158	Apr 10, 2023	U-1253			
		8207158	Apr 10, 2023	U-1254			
		8207158	Apr 10, 2023	U-1255			
		8273734	Apr 10, 2023	U-1254			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LORCASERIN HYDROCHLORIDE - BELVIQ							
N 022529	001	8273734	Apr 10, 2023	U-1255			
		8367657	Apr 10, 2023	DS DP U-1252			
		8367657	Apr 10, 2023	DS DP U-1253			
		8367657	Apr 10, 2023	DS DP U-1254			
		8367657	Apr 10, 2023	DS DP U-1255			
		8546379	Apr 10, 2023	DS DP U-1252			
		8546379	Apr 10, 2023	DS DP U-1253			
		8546379	Apr 10, 2023	DS DP U-1254			
		8546379	Apr 10, 2023	DS DP U-1255			
		8575149	Apr 10, 2023	U-1452			
		8697686	Dec 20, 2025	DS DP			
		8946207	Jun 16, 2024	DP			
		8980881	Dec 20, 2025	U-1252			
		8980881	Dec 20, 2025	U-1253			
		8980881	Dec 20, 2025	U-1254			
		8980881	Dec 20, 2025	U-1255			
		8999970	Feb 07, 2033	U-1688			
		8999970	Feb 07, 2033	U-1689			
		8999970	Feb 07, 2033	U-1692			
		9169213	Dec 06, 2032	U-1762			
		9169213	Dec 06, 2032	U-1763			
		9169213	Dec 06, 2032	U-1764			
		9169213	Dec 06, 2032	U-1765			
		9770455	Aug 31, 2031	U-2110			
LORCASERIN HYDROCHLORIDE - BELVIQ XR							
N 208524	001	10226471	Aug 31, 2031	DP			
		10463676	Aug 31, 2031	U-2661			
		6953787	Apr 10, 2023	DS DP U-1252			
		6953787	Apr 10, 2023	DS DP U-1253			
		6953787	Apr 10, 2023	DS DP U-1254			
		6953787	Apr 10, 2023	DS DP U-1255			
		7514422	Apr 10, 2023	U-1252			
		7514422	Apr 10, 2023	U-1253			
		7514422	Apr 10, 2023	U-1254			
		7514422	Apr 10, 2023	U-1255			
		7977329	Apr 10, 2023	DS DP U-1252			
		7977329	Apr 10, 2023	DS DP U-1253			
		7977329	Apr 10, 2023	DS DP U-1254			
		7977329	Apr 10, 2023	DS DP U-1255			
		8168624	Apr 18, 2029	DS DP			
		8207158	Apr 10, 2023	U-1252			
		8207158	Apr 10, 2023	U-1253			
		8207158	Apr 10, 2023	U-1254			
		8207158	Apr 10, 2023	U-1255			
		8273734	Apr 10, 2023	U-1254			
		8273734	Apr 10, 2023	U-1255			
		8367657	Apr 10, 2023	DS DP U-1252			
		8367657	Apr 10, 2023	DS DP U-1253			
		8367657	Apr 10, 2023	DS DP U-1254			
		8367657	Apr 10, 2023	DS DP U-1255			
		8546379	Apr 10, 2023	DS DP U-1252			
		8546379	Apr 10, 2023	DS DP U-1253			
		8546379	Apr 10, 2023	DS DP U-1254			
		8546379	Apr 10, 2023	DS DP U-1255			
		8575149	Apr 10, 2023	U-1452			
		8697686	Dec 20, 2025	DS DP			
		8946207	Jun 16, 2024	DP			
		8980881	Dec 20, 2025	U-1252			
		8980881	Dec 20, 2025	U-1253			
		8980881	Dec 20, 2025	U-1254			
		8980881	Dec 20, 2025	U-1255			
		8999970	Feb 07, 2033	U-1688			
		8999970	Feb 07, 2033	U-1689			
		8999970	Feb 07, 2033	U-1692			
		9169213	Dec 06, 2032	U-1884			
		9169213	Dec 06, 2032	U-1885			
		9169213	Dec 06, 2032	U-1886			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LORCASERIN HYDROCHLORIDE - BELVIQ XR							
N 208524	001	9169213	Dec 06, 2032	U-1887			
		9770455	Aug 31, 2031	U-2110			
LORLATINIB - LORBRENA							
N 210868	001	10420749	Jul 27, 2036	DS DP U-2633		NCE	Nov 02, 2023
		8680111	Mar 05, 2033	DS DP		ODE-217	Nov 02, 2025
						ODE-218	Nov 02, 2025
						ODE-219	Nov 02, 2025
LORLATINIB - LORBRENA							
N 210868	002	10420749	Jul 27, 2036	DS DP U-2633		NCE	Nov 02, 2023
		8680111	Mar 05, 2033	DS DP		ODE-217	Nov 02, 2025
						ODE-218	Nov 02, 2025
						ODE-219	Nov 02, 2025
LOTEPREDNOL ETABONATE - LOTEMAX							
N 202872	001					M-229	Jul 20, 2021
LOTEPREDNOL ETABONATE - LOTEMAX SM							
N 208219	001					NS	Feb 22, 2022
LOTEPREDNOL ETABONATE - INVELTYS							
N 210565	001	10058511	May 03, 2033	DP U-2492		NP	Aug 22, 2021
		9056057	May 03, 2033	DP U-2491			
		9393213	May 03, 2033	DP			
		9532955	May 03, 2033	U-2491			
		9737491	May 03, 2033	U-2492			
		9827191	May 03, 2033	DP U-2493			
LOXAPINE - ADASUVE							
N 022549	001	6716416	May 20, 2022	DP			
		7052679	Oct 26, 2021	DP			
		7078020	Oct 26, 2021	DP U-1375			
		7090830	Oct 26, 2021	DP			
		7458374	Aug 18, 2024	DP			
		7537009	Oct 28, 2024	DP			
		7585493	Oct 26, 2021	DP			
		7601337	Oct 26, 2021	DP			
		8074644	Jul 25, 2022	DP			
		8173107	Oct 26, 2021	DP			
		8235037	Oct 26, 2021	DP			
		8387612	Oct 23, 2026	DP			
		8955512	Oct 26, 2021	DP			
		8991387	May 21, 2024	DP			
		9370629	May 20, 2024	DP			
		9439907	Oct 26, 2021	DP			
		9440034	Oct 26, 2021	DP			
		9687487	Oct 26, 2021	DS DP			
LUBIPROSTONE - AMITIZA							
N 021908	001	6414016	Sep 05, 2020	U-1392		M-225	Apr 26, 2021
		6414016	Sep 05, 2020	U-717			
		6583174	Oct 16, 2020	DP			
		6982283	Dec 04, 2022	U-1391			
		7064148	Aug 30, 2022	U-1404			
		7064148	Aug 30, 2022	U-739			
		7417067	Oct 16, 2020	DP			
		8026393	Oct 25, 2027	DP			
		8071613	Sep 05, 2020	U-1203			
		8071613	Sep 05, 2020	U-1393			
		8088934	May 18, 2021	DS			
		8097649	Oct 16, 2020	DP			
		8097653	Nov 14, 2022	U-1214			
		8097653	Nov 14, 2022	U-1394			
		8114890	Sep 05, 2020	DP			
		8338639	Jan 23, 2027	DP			
		8389542	Nov 14, 2022	DP U-1345			
		8389542	Nov 14, 2022	DP U-1395			
		8748481	Sep 01, 2025	U-1520			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUBIPROSTONE - AMITIZA						
N 021908 001	8779187	Jan 23, 2027	DP			
LUBIPROSTONE - AMITIZA						
N 021908 002	6414016	Sep 05, 2020	U-874		M-225	Apr 26, 2021
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-873			
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024	U-1085			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1202			
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
LULICONAZOLE - LUZU						
N 204153 001	5900488	Jan 18, 2020	DS DP		NPP	Feb 20, 2021
	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	8729085	May 26, 2026	DP		M-195	Jan 27, 2020
	8729085*PED	Nov 26, 2026			NPP	Jan 27, 2020
	8883794	May 26, 2026	DP		NPP	Mar 05, 2021
	8883794*PED	Nov 26, 2026			PED	Jul 27, 2020
	9174975	Feb 20, 2024	U-1770		PED	Jul 27, 2020
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 002	8729085	May 26, 2026	DP		NPP	Jan 27, 2020
	8729085*PED	Nov 26, 2026			NPP	Mar 05, 2021
	8883794	May 26, 2026	DP		PED	Jul 27, 2020
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003	8729085	May 26, 2026	DP		M-195	Jan 27, 2020
	8729085*PED	Nov 26, 2026			NPP	Jan 27, 2020
	8883794	May 26, 2026	DP		NPP	Mar 05, 2021
	8883794*PED	Nov 26, 2026			PED	Jul 27, 2020
	9174975	Feb 20, 2024	U-1770		PED	Jul 27, 2020
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	003	9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			
		9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	004	8729085	May 26, 2026	DP			
		8729085*PED	Nov 26, 2026				
		8883794	May 26, 2026	DP			
		8883794*PED	Nov 26, 2026				
		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031	U-1822			
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			
		9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	005	8729085	May 26, 2026	DP		M-195	Jan 27, 2020
		8729085*PED	Nov 26, 2026			NPP	Jan 27, 2020
		8883794	May 26, 2026	DP		NPP	Mar 05, 2021
		8883794*PED	Nov 26, 2026			PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770		PED	Jul 27, 2020
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031	U-1822			
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			
		9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LUSUTROMBOPAG - MULPLETA							
N 210923	001	7601746	Sep 05, 2024	DS DP U-2344		NCE	Jul 31, 2023
		8530668	Jan 21, 2030	DS DP			
		8889722	Jul 29, 2028	DS DP			
		9427402	Sep 29, 2031	DP			
LUTETIUM DOTATATE LU-177 - LUTATHERA							
N 208700	001					NCE	Jan 26, 2023
						ODE-166	Jan 26, 2025
MACIMORELIN ACETATE - MACRILEN							
N 205598	001	6861409	Aug 01, 2022	DS DP U-2220		NCE	Dec 20, 2022
		8192719	Oct 12, 2027	U-2220		ODE-170	Dec 20, 2024
MACITENTAN - OPSUMIT							
N 204410	001	7094781	Dec 05, 2025	DS DP		ODE-54	Oct 18, 2020
		8268847	Apr 18, 2029	U-1446			
		8367685	Oct 04, 2028	DP U-1445			
		9265762	May 29, 2027	DP U-1820			
MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25							
N 021910	001	7300674	Mar 04, 2023	DP U-785			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT									
N 022372	001		6946149	Mar 07, 2023		DP U-837			
MALATHION - OVIDE									
N 018613	001		7560445	Feb 01, 2027	DS	DP U-986			
			7977324	Aug 14, 2026		DP			
MARAVIROC - SELZENTRY									
N 022128	001		6667314	Aug 06, 2021	DS	DP U-824			
			7368460	Nov 25, 2022		U-824			
			7576097	May 25, 2021	DS				
MARAVIROC - SELZENTRY									
N 022128	002		6667314	Aug 06, 2021	DS	DP U-824			
			7368460	Nov 25, 2022		U-824			
			7576097	May 25, 2021	DS				
MARAVIROC - SELZENTRY									
N 022128	003		6667314	Aug 06, 2021	DS	DP U-824			
			7368460	Nov 25, 2022		U-824			
			7576097	May 25, 2021	DS				
MARAVIROC - SELZENTRY									
N 022128	004		6667314	Aug 06, 2021	DS	DP U-824			
			7368460	Nov 25, 2022		U-824			
			7576097	May 25, 2021	DS				
MARAVIROC - SELZENTRY									
N 208984	001		6667314	Aug 06, 2021	DS	DP U-824			
			7368460	Nov 25, 2022		U-824			
			7576097	May 25, 2021	DS				
MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR									
N 202317	001		7838564	Mar 07, 2026		DP		ODE-51	Aug 23, 2020
			7872050	Jul 08, 2029		U-1427			
			8450375	Mar 07, 2026		DP			
			8501818	Mar 07, 2026		DP			
			8501819	Mar 07, 2026		U-1427			
			9382191	Mar 07, 2026		DP			
MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104									
N 021583	001		6495534	May 15, 2020		DP			
MEGESTROL ACETATE - MEGACE ES									
N 021778	001		6592903	Sep 21, 2020		DP			
			7101576	Apr 22, 2024		U-755			
			9040088	Apr 22, 2024		U-755			
			9101540	Apr 22, 2024		DP U-755			
			9101549	Apr 22, 2024		U-755			
			9107827	Apr 22, 2024		U-755			
MELOXICAM - VIVLODEX									
N 207233	001		9526734	Mar 31, 2033		DP			
			9649318	Mar 31, 2035		DP			
			9808468	Mar 31, 2035		U-2160			
			9808468	Mar 31, 2035		U-2165			
MELOXICAM - VIVLODEX									
N 207233	002		9526734	Mar 31, 2033		DP			
			9649318	Mar 31, 2035		DP			
			9808468	Mar 31, 2035		U-2160			
			9808468	Mar 31, 2035		U-2165			
MELOXICAM - QMIIZ ODT									
N 211210	001		8545879	Aug 31, 2030		DP			
MELOXICAM - QMIIZ ODT									
N 211210	002		8545879	Aug 31, 2030		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELPHALAN HYDROCHLORIDE - EVOMELA								
N	207155	001	10040872	Jan 30, 2034	DP		ODE-110	Mar 10, 2023
			8410077	Mar 13, 2029	DP			
			9200088	Mar 13, 2029	DP			
			9493582	Feb 27, 2033	DP			
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N	022525	001	8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
			8168209	Nov 22, 2025	DP			
			8168209*PED	May 22, 2026				
			8173708	Nov 22, 2025	U-539			
			8173708*PED	May 22, 2026				
			8283379	Nov 22, 2025	U-539			
			8283379*PED	May 22, 2026				
			8329752	Nov 22, 2025	DP			
			8329752*PED	May 22, 2026				
			8362085	Nov 22, 2025	U-539			
			8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N	022525	002	8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
			8168209	Nov 22, 2025	DP			
			8168209*PED	May 22, 2026				
			8173708	Nov 22, 2025	U-539			
			8173708*PED	May 22, 2026				
			8283379	Nov 22, 2025	U-539			
			8283379*PED	May 22, 2026				
			8329752	Nov 22, 2025	DP			
			8329752*PED	May 22, 2026				
			8362085	Nov 22, 2025	U-539			
			8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N	022525	003	8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
			8168209	Nov 22, 2025	DP			
			8168209*PED	May 22, 2026				
			8173708	Nov 22, 2025	U-539			
			8173708*PED	May 22, 2026				
			8283379	Nov 22, 2025	U-539			
			8283379*PED	May 22, 2026				
			8329752	Nov 22, 2025	DP			
			8329752*PED	May 22, 2026				
			8362085	Nov 22, 2025	U-539			
			8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N	022525	004	8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
			8168209	Nov 22, 2025	DP			
			8168209*PED	May 22, 2026				
			8173708	Nov 22, 2025	U-539			
			8173708*PED	May 22, 2026				
			8283379	Nov 22, 2025	U-539			
			8283379*PED	May 22, 2026				
			8329752	Nov 22, 2025	DP			
			8329752*PED	May 22, 2026				
			8362085	Nov 22, 2025	U-539			
			8362085*PED	May 22, 2026				
			8598233	Nov 22, 2025	DP			
			8598233*PED	May 22, 2026				
MENTHOL; METHYL SALICYLATE - SALONPAS								
N	022029	001	8809615	Jan 03, 2030	DP			
			9233184	Aug 01, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MENTHOL; METHYL SALICYLATE - SALONPAS							
N 022029	002	8809615	Jan 03, 2030	DP			
		9233184	Aug 01, 2027	DP			
MEQUINOL; TRETINOIN - SOLAGE							
N 020922	001	6353029	Aug 24, 2020				
MERCAPTOPURINE - PURIXAN							
N 205919	001					ODE-65	Apr 28, 2021
MEROPENEM; VABORBACTAM - VABOMERE							
N 209776	001	10172874	Aug 08, 2031	DP			
		10183034	Aug 08, 2031	U-2490			
		8680136	Aug 17, 2031	DS DP			
		9694025	Aug 08, 2031	U-2120			
MESALAMINE - SFROWASA							
N 019618	002	7645801	Jul 24, 2027	DS DP			
MESALAMINE - CANASA							
N 021252	002	8217083	Jun 06, 2028	DP			
		8436051	Jun 06, 2028	DP			
MESALAMINE - ASACOL HD							
N 021830	001	6893662	Nov 15, 2021	DP U-141			
		8580302	Nov 15, 2021	DP			
		9089492	Nov 15, 2021	DP			
MESALAMINE - LIALDA							
N 022000	001	6773720	Jun 08, 2020	DP			
MESALAMINE - APRISO							
N 022301	001	8865688	May 01, 2030	U-1310			
MESALAMINE - DELZICOL							
N 204412	001	6649180	Apr 13, 2020	DP			
METAXALONE - SKELAXIN							
N 013217	003	7122566	Feb 06, 2026	U-915			
		7714006	Dec 03, 2021	U-1050			
METFORMIN HYDROCHLORIDE - FORTAMET							
N 021574	001	6790459	Mar 17, 2021	U-604			
		6866866	Mar 17, 2021	DP			
METFORMIN HYDROCHLORIDE - FORTAMET							
N 021574	002	6790459	Mar 17, 2021	U-604			
		6866866	Mar 17, 2021	DP			
METFORMIN HYDROCHLORIDE - RIOMET							
N 021591	001	6890957	Aug 07, 2021	DP			
METFORMIN HYDROCHLORIDE - GLUMETZA							
N 021748	001	6488962	Jun 20, 2020	DS DP			
		6723340	Oct 25, 2021	DS DP			
METFORMIN HYDROCHLORIDE - GLUMETZA							
N 021748	002	7780987	Mar 23, 2025	DS DP			
		8323692	Mar 30, 2023	DP			
METFORMIN HYDROCHLORIDE - RIOMET ER							
N 212595	001	9962336	May 01, 2035	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET							
N 021842	001	9101660	Jan 22, 2027	DP			
		9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET							
N 021842	002	9101660	Jan 22, 2027	DP			
		9320714	Feb 03, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR								
N	022024	001	6790459	Mar 17, 2021	U-974			
			6866866	Mar 17, 2021	DP			
			7785627	Jul 31, 2026	DP			
			7959946	Jul 31, 2026	DP			
			8470368	Sep 19, 2023	DP			
			8668931	Sep 19, 2023	DP			
			9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR								
N	022024	002	6790459	Mar 17, 2021	U-974			
			6866866	Mar 17, 2021	DP			
			7785627	Jul 31, 2026	DP			
			7959946	Jul 31, 2026	DP			
			8470368	Sep 19, 2023	DP			
			8668931	Sep 19, 2023	DP			
			9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
N	021410	001	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
N	021410	002	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
N	021410	003	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
N	021410	004	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
N	021410	005	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR								
N	200678	001	8628799	Jul 13, 2025	DP		M-198	Feb 27, 2020
			9339472	Jul 13, 2025	DP			
			RE44186	Jul 31, 2023	DS DP U-1097			
			RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR								
N	200678	002	8628799	Jul 13, 2025	DP		M-198	Feb 27, 2020
			9339472	Jul 13, 2025	DP			
			RE44186	Jul 31, 2023	DS DP U-1097			
			RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR								
N	200678	003	8628799	Jul 13, 2025	DP		M-198	Feb 27, 2020
			9339472	Jul 13, 2025	DP			
			RE44186	Jul 31, 2023	DS DP U-1097			
			RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET								
N	022044	001	6699871	Jul 26, 2022	DS DP U-802			
			7125873	Jul 26, 2022	DP U-1036			
			7125873	Jul 26, 2022	DP U-1038			
			7125873	Jul 26, 2022	DP U-803			
			7326708	Nov 24, 2026	DS DP U-802			
			8414921	Jul 21, 2028	DP U-1036			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET								
N	022044	002	6699871	Jul 26, 2022	DS DP U-802			
			7125873	Jul 26, 2022	DP U-1036			
			7125873	Jul 26, 2022	DP U-1038			
			7125873	Jul 26, 2022	DP U-803			
			7326708	Nov 24, 2026	DS DP U-802			
			8414921	Jul 21, 2028	DP U-1036			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR								
N	202270	001	6699871	Jul 26, 2022	DS DP U-1227			
			7125873	Jul 26, 2022	DP U-1227			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR								
N	202270	001	7326708	Nov 24, 2026	DS DP U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR								
N	202270	002	6699871	Jul 26, 2022	DS DP U-1227			
			7125873	Jul 26, 2022	DP U-1227			
			7326708	Nov 24, 2026	DS DP U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR								
N	202270	003	6699871	Jul 26, 2022	DS DP U-1227			
			7125873	Jul 26, 2022	DP U-1227			
			7326708	Nov 24, 2026	DS DP U-1227			
METHOTREXATE - OTREXUP								
N	204824	001	6746429	Apr 12, 2020	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			
			9421333	Mar 19, 2030	DP U-1442			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP								
N	204824	002	6746429	Apr 12, 2020	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			
			9421333	Mar 19, 2030	DP U-1442			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP								
N	204824	003	6746429	Apr 12, 2020	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			
			9421333	Mar 19, 2030	DP U-1442			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP								
N	204824	004	6746429	Apr 12, 2020	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			
			9421333	Mar 19, 2030	DP U-1442			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP								
N	204824	005	6746429	Apr 12, 2020	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			
			9421333	Mar 19, 2030	DP U-1442			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
METHOTREXATE - RASUVO						
N 205776 001	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 002	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 003	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 004	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 005	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 006	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 007	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 008	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 009	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 010	8664231	Jun 01, 2029	U-1442			
METHOTREXATE SODIUM - XATMEP						
N 208400 001	10231927	Jan 02, 2033	U-1349		ODE-137	Apr 25, 2024
	10231927	Jan 02, 2033	U-1699		ODE-138	Apr 25, 2024
	9259427	Jan 02, 2033	DP			
	9855215	Jan 02, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLENE BLUE - PROVAYBLUE							
N 204630	001					ODE-113	Apr 08, 2023
METHYLNALTREXONE BROMIDE - RELISTOR							
N 021964	001	10376584	Apr 08, 2024	DP U-1185			
		8247425	Dec 31, 2030	U-1185			
		8420663	Sep 30, 2029	U-1185			
		8552025	Apr 08, 2024	DP			
		8822490	Sep 30, 2029	DP U-1185			
		9180125	Sep 30, 2029	DP U-1185			
		9492445	Sep 30, 2029	DP U-1185			
		9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR							
N 021964	002	10376584	Apr 08, 2024	DP U-1185			
		8247425	Dec 31, 2030	U-1185			
		8420663	Sep 30, 2029	U-1185			
		8552025	Apr 08, 2024	DP			
		8822490	Sep 30, 2029	DP U-1185			
		9180125	Sep 30, 2029	DP U-1185			
		9492445	Sep 30, 2029	DP U-1185			
		9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR							
N 021964	003	10376584	Apr 08, 2024	DP U-1185			
		8247425	Dec 31, 2030	U-1185			
		8420663	Sep 30, 2029	U-1185			
		8552025	Apr 08, 2024	DP			
		8822490	Sep 30, 2029	DP U-1185			
		9180125	Sep 30, 2029	DP U-1185			
		9492445	Sep 30, 2029	DP U-1185			
		9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR							
N 208271	001	10307417	Mar 10, 2031	DP			
		10376505	Mar 10, 2031	DP			
		8420663	Sep 30, 2029	U-1185			
		8524276	Mar 10, 2031	DP			
		8956651	Mar 10, 2031	DP			
		9180125	Sep 30, 2029	DP U-1185			
		9314461	Mar 10, 2031	DP			
		9492445	Sep 30, 2029	DP U-1185			
		9724343	Sep 30, 2029	DP U-1185			
METHYLPHENIDATE - DAYTRANA							
N 021514	001	8632802	Oct 07, 2025	DP			
		9034370	Oct 07, 2025	DP			
		9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA							
N 021514	002	8632802	Oct 07, 2025	DP			
		9034370	Oct 07, 2025	DP			
		9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA							
N 021514	003	8632802	Oct 07, 2025	DP			
		9034370	Oct 07, 2025	DP			
		9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA							
N 021514	004	8632802	Oct 07, 2025	DP			
		9034370	Oct 07, 2025	DP			
		9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - COTEMPLA XR-ODT							
N 205489	001	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
		9072680	Jun 28, 2032	DP			
		9089496	Jun 28, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE - COTEMPLA XR-ODT								
N	205489	002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
			9072680	Jun 28, 2032	DP			
			9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT								
N	205489	003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
			9072680	Jun 28, 2032	DP			
			9089496	Jun 28, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD								
N	021259	001	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD								
N	021259	002	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD								
N	021259	003	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD								
N	021259	004	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN								
N	021419	001	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN								
N	021419	002	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR								
N	202100	001	8062667	Mar 29, 2029	DP			
			8287903	Feb 15, 2031	DP			
			8465765	Feb 15, 2031	DP U-1415			
			8563033	Feb 15, 2031	DP U-1415			
			8778390	Feb 15, 2031	DP U-1543			
			8956649	Feb 15, 2031	DP U-1665			
			9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR								
N	205831	001	10039719*PED	Jun 16, 2020				
			6419960*PED	Jun 16, 2020				
			7083808*PED	Jun 16, 2020				
			7247318*PED	Jun 16, 2020				
			7438930*PED	Jun 16, 2020				
			8580310*PED	Jun 16, 2020				
			9066869*PED	Jun 16, 2020				
			9801823*PED	Jun 16, 2020				
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR								
N	205831	002	10039719*PED	Jun 16, 2020				
			6419960*PED	Jun 16, 2020				
			7083808*PED	Jun 16, 2020				
			7247318*PED	Jun 16, 2020				
			7438930*PED	Jun 16, 2020				
			8580310*PED	Jun 16, 2020				
			9066869*PED	Jun 16, 2020				
			9801823*PED	Jun 16, 2020				
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR								
N	205831	003	10039719*PED	Jun 16, 2020				
			6419960*PED	Jun 16, 2020				
			7083808*PED	Jun 16, 2020				
			7247318*PED	Jun 16, 2020				
			7438930*PED	Jun 16, 2020				
			8580310*PED	Jun 16, 2020				
			9066869*PED	Jun 16, 2020				
			9801823*PED	Jun 16, 2020				
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR								
N	205831	004	10039719*PED	Jun 16, 2020				
			6419960*PED	Jun 16, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR								
N	205831	004	7083808*PED	Jun 16, 2020				
			7247318*PED	Jun 16, 2020				
			7438930*PED	Jun 16, 2020				
			8580310*PED	Jun 16, 2020				
			9066869*PED	Jun 16, 2020				
			9801823*PED	Jun 16, 2020				
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR								
N	205831	005	10039719*PED	Jun 16, 2020				
			6419960*PED	Jun 16, 2020				
			7083808*PED	Jun 16, 2020				
			7247318*PED	Jun 16, 2020				
			7438930*PED	Jun 16, 2020				
			8580310*PED	Jun 16, 2020				
			9066869*PED	Jun 16, 2020				
			9801823*PED	Jun 16, 2020				
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR								
N	205831	006	10039719*PED	Jun 16, 2020				
			6419960*PED	Jun 16, 2020				
			7083808*PED	Jun 16, 2020				
			7247318*PED	Jun 16, 2020				
			7438930*PED	Jun 16, 2020				
			8580310*PED	Jun 16, 2020				
			9066869*PED	Jun 16, 2020				
			9801823*PED	Jun 16, 2020				
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR								
N	205831	007	10039719*PED	Jun 16, 2020				
			6419960*PED	Jun 16, 2020				
			7083808*PED	Jun 16, 2020				
			7247318*PED	Jun 16, 2020				
			7438930*PED	Jun 16, 2020				
			8580310*PED	Jun 16, 2020				
			9066869*PED	Jun 16, 2020				
			9801823*PED	Jun 16, 2020				
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER								
N	207960	001	8202537	Mar 15, 2027	DP			
			8287903	Feb 15, 2031	DP			
			8999386	Aug 14, 2033	DP			
			9295642	Aug 14, 2033	DP U-1827			
			9545399	Aug 14, 2033	DP U-1827			
			9844544	Aug 14, 2033	DP U-2203			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER								
N	207960	002	8202537	Mar 15, 2027	DP			
			8287903	Feb 15, 2031	DP			
			8999386	Aug 14, 2033	DP			
			9295642	Aug 14, 2033	DP U-1827			
			9545399	Aug 14, 2033	DP U-1827			
			9844544	Aug 14, 2033	DP U-2203			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER								
N	207960	003	8202537	Mar 15, 2027	DP			
			8287903	Feb 15, 2031	DP			
			8999386	Aug 14, 2033	DP			
			9295642	Aug 14, 2033	DP U-1827			
			9545399	Aug 14, 2033	DP U-1827			
			9844544	Aug 14, 2033	DP U-2203			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM								
N	209311	001	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
			10292937	Mar 23, 2032	U-2357			
			8916588	Mar 23, 2032	U-2357			
			8927010	Mar 23, 2032	DP			
			9023389	Mar 23, 2032	DP			
			9028868	Mar 23, 2032	U-2357			
			9034902	Mar 23, 2032	U-2357			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	001	9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	002	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
		10292937	Mar 23, 2032	U-2357			
		8916588	Mar 23, 2032	U-2357			
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	003	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
		10292937	Mar 23, 2032	U-2357			
		8916588	Mar 23, 2032	U-2357			
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	004	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
		10292937	Mar 23, 2032	U-2357			
		8916588	Mar 23, 2032	U-2357			
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	005	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
		10292937	Mar 23, 2032	U-2357			
		8916588	Mar 23, 2032	U-2357			
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR							
N 212038	001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
		10292938	Oct 30, 2035	DP			
		10292939	Oct 30, 2035	DP U-2357			
		10449159	Oct 30, 2035	U-2357			
		10500162	Oct 30, 2035	U-2357			
		10507186	Oct 30, 2035	DP			
		10512612	Oct 30, 2035	DP			
		10512613	Oct 30, 2035	U-2357			
		9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR							
N 212038	002	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
		10292938	Oct 30, 2035	DP			
		10292939	Oct 30, 2035	DP U-2357			
		10449159	Oct 30, 2035	U-2357			
		10500162	Oct 30, 2035	U-2357			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR							
N 212038	002	10507186	Oct 30, 2035	DP			
		10512612	Oct 30, 2035	DP			
		10512613	Oct 30, 2035	U-2357			
		9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR							
N 212038	003	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
		10292938	Oct 30, 2035	DP			
		10292939	Oct 30, 2035	DP U-2357			
		10449159	Oct 30, 2035	U-2357			
		10500162	Oct 30, 2035	U-2357			
		10507186	Oct 30, 2035	DP			
		10512612	Oct 30, 2035	DP			
		10512613	Oct 30, 2035	U-2357			
		9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR							
N 212038	004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
		10292938	Oct 30, 2035	DP			
		10292939	Oct 30, 2035	DP U-2357			
		10449159	Oct 30, 2035	U-2357			
		10500162	Oct 30, 2035	U-2357			
		10507186	Oct 30, 2035	DP			
		10512612	Oct 30, 2035	DP			
		10512613	Oct 30, 2035	U-2357			
		9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR							
N 212038	005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
		10292938	Oct 30, 2035	DP			
		10292939	Oct 30, 2035	DP U-2357			
		10449159	Oct 30, 2035	U-2357			
		10500162	Oct 30, 2035	U-2357			
		10507186	Oct 30, 2035	DP			
		10512612	Oct 30, 2035	DP			
		10512613	Oct 30, 2035	U-2357			
		9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR							
N 212038	006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
		10292938	Oct 30, 2035	DP			
		10292939	Oct 30, 2035	DP U-2357			
		10449159	Oct 30, 2035	U-2357			
		10500162	Oct 30, 2035	U-2357			
		10507186	Oct 30, 2035	DP			
		10512612	Oct 30, 2035	DP			
		10512613	Oct 30, 2035	U-2357			
		9974752	Oct 30, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE							
N 210428	001	9504655	Jul 09, 2035	DP			
		9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE							
N 210428	002	9504655	Jul 09, 2035	DP			
		9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE							
N 210428	003	9504655	Jul 09, 2035	DP			
		9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE							
N 210428	004	9504655	Jul 09, 2035	DP			
		9700530	Jul 09, 2035	DP			
METRONIDAZOLE - METROGEL							
N 021789	001	6881726	Feb 21, 2022	DP U-743			
		7348317	Feb 21, 2022	DP U-743			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METRONIDAZOLE - VANDAZOLE								
N	021806	001	7456207	Sep 22, 2024	DP			
METRONIDAZOLE - NUVESSA								
N	205223	001	10238634	Jun 28, 2032	DP			
			7893097	Feb 19, 2028	DP			
			8658678	Jun 27, 2028	U-1682			
			8877792	Feb 02, 2028	DP			
			8946276	Jun 28, 2032	U-1664			
			9198858	Jun 28, 2032	U-1664			
MICAFUNGIN SODIUM - MYCAMINE								
N	021506	002	6774104	Jan 08, 2021	DP U-650			
			6774104	Jan 08, 2021	DP U-845			
			6774104*PED	Jul 08, 2021				
MICAFUNGIN SODIUM - MYCAMINE								
N	021506	003	6774104	Jan 08, 2021	DP U-650			
			6774104	Jan 08, 2021	DP U-845			
			6774104*PED	Jul 08, 2021				
MICONAZOLE - ORAVIG								
N	022404	001	6916485	Sep 11, 2022	DP U-1051			
			7651698	Sep 11, 2022	U-1051			
			8518442	Sep 11, 2022	DP			
MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK								
N	021308	001	6153635	Nov 28, 2020		Y		
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION								
N	021026	001	8147852	Mar 30, 2028	U-1426			
MIDAZOLAM - NAYZILAM								
N	211321	001	8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
			8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
			9289432	Jan 18, 2028	DP U-2526			
			9687495	Jan 18, 2028	DP U-2526			
MIDAZOLAM HYDROCHLORIDE - SEIZALAM								
N	209566	001					ODE-207	Sep 14, 2025
MIDOSTAURIN - RYDAPT								
N	207997	001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
			8222244	Oct 29, 2022	U-2007		ODE-140	Apr 28, 2024
			8575146	Dec 02, 2030	U-2008		ODE-141	Apr 28, 2024
MIFEPRISTONE - KORLYM								
N	202107	001	10006924	Aug 12, 2036	U-1643			
			10151763	Jan 18, 2037	U-1643			
			10166242	Apr 20, 2036	U-1643			
			10166243	Apr 20, 2036	U-1643			
			10195214	Jun 19, 2037	U-1643			
			10231983	Aug 22, 2038	U-1643			
			10314850	Aug 22, 2038	U-1643			
			10495650	Aug 12, 2036	U-1643			
			10500216	Mar 05, 2033	U-1643			
			8921348	Aug 27, 2028	U-1643			
			9829495	Aug 15, 2036	U-1643			
			9943526	Apr 20, 2036	U-1643			
MIGALASTAT HYDROCHLORIDE - GALAFOLD								
N	208623	001	10076514	Mar 15, 2037	U-2371		NCE	Aug 10, 2023
			10251873	May 30, 2038	U-2371		ODE-205	Aug 10, 2025
			10383864	May 16, 2027	U-2371			
			10406143	May 16, 2027	U-2371			
			10471053	May 30, 2038	U-2371			
			8592362	Feb 12, 2029	U-2371			
			9000011	May 16, 2027	U-2371			
			9095584	Feb 12, 2029	U-2371			
			9480682	May 16, 2027	U-2371			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIGALASTAT HYDROCHLORIDE - GALAFOLD								
N 208623	001		9987263	May 16, 2027	U-2371			
			9999618	Apr 28, 2028	U-2372			
			9999618	Apr 28, 2028	U-2373			
MILNACIPRAN HYDROCHLORIDE - SAVELLA								
N 022256	001		6602911	Jan 14, 2023	U-882			
			6992110	Nov 05, 2021	U-882			
			7888342	Nov 05, 2021	U-882			
			7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA								
N 022256	002		6602911	Jan 14, 2023	U-882			
			6992110	Nov 05, 2021	U-882			
			7888342	Nov 05, 2021	U-882			
			7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA								
N 022256	003		6602911	Jan 14, 2023	U-882			
			6992110	Nov 05, 2021	U-882			
			7888342	Nov 05, 2021	U-882			
			7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA								
N 022256	004		6602911	Jan 14, 2023	U-882			
			6992110	Nov 05, 2021	U-882			
			7888342	Nov 05, 2021	U-882			
			7994220	Sep 19, 2029	U-819			
MILTEFOSINE - IMPAVIDO								
N 204684	001						ODE-63	Mar 19, 2021
MINOCYCLINE HYDROCHLORIDE - MINOCIN								
N 050444	001		9084802	May 12, 2031	U-282			
			9278105	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - ARESTIN								
N 050781	001		6682348	Mar 29, 2022	DP			
			7699609	Mar 29, 2022	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	001		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	002		7541347	Apr 02, 2027	U-917			
			7544373	Apr 02, 2027	DP			
			7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	003		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	004		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
			9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	005		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN							
N 050808	005	8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-1078			
		9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN							
N 050808	006	7790705	Jun 24, 2025	U-1078			
		7919483	Mar 07, 2027	U-1078			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-1078			
		8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN							
N 050808	007	7790705	Jun 24, 2025	U-1078			
		7919483	Mar 07, 2027	U-1078			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-1078			
		8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN							
N 050808	008	7790705	Jun 24, 2025	U-1078			
		7919483	Mar 07, 2027	U-1078			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-1078			
		8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - XIMINO							
N 201922	001	7541347	Apr 02, 2027	U-917			
		7544373	Apr 02, 2027	DP			
		7790705	Jun 24, 2025	U-124			
		7919483	Mar 07, 2027	U-124			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO							
N 201922	003	7541347	Apr 02, 2027	U-917			
		7544373	Apr 02, 2027	DP			
		7790705	Jun 24, 2025	U-124			
		7919483	Mar 07, 2027	U-124			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO							
N 201922	005	7541347	Apr 02, 2027	U-917			
		7544373	Apr 02, 2027	DP			
		7790705	Jun 24, 2025	U-124			
		7919483	Mar 07, 2027	U-124			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - AMZEEQ							
N 212379	001	10086080	Oct 01, 2030	U-2647			
		10137200	Oct 01, 2030	U-2647			
		10213512	Oct 01, 2030	DP U-2647			
		10265404	Oct 01, 2030	DP			
		10398641	Sep 08, 2037	U-2647			
		8865139	Oct 01, 2030	DP U-2647			
		8945516	Oct 01, 2030	DP			
		8992896	Oct 01, 2030	DP U-2647			
		9675700	Oct 01, 2030	DP U-2647			
MIPOMERSEN SODIUM - KYNAMRO							
N 203568	001	7015315	Mar 21, 2023	DS		ODE-41	Jan 29, 2020
		7101993	Sep 05, 2023	DS			
		7407943	Aug 01, 2021	U-1353			
		7511131	Jan 29, 2027	DS			
MIRABEGRON - MYRBETRIQ							
N 202611	001	6346532	Mar 27, 2022	DS DP		I-777	Apr 27, 2021
		6562375	Aug 01, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIRABEGRON - MYRBETRIQ								
N 202611	001	7342117	Nov 04, 2023	DS				
		7982049	Nov 04, 2023	DP				
		8772315	Oct 30, 2028		U-2300			
		8835474	Nov 04, 2023		U-1527			
		RE44872	Nov 04, 2023		U-1527			
MIRABEGRON - MYRBETRIQ								
N 202611	002	6346532	Mar 27, 2022	DS	DP		I-777	Apr 27, 2021
		6562375	Aug 01, 2020		DP			
		7342117	Nov 04, 2023	DS				
		7982049	Nov 04, 2023		DP			
		8772315	Oct 30, 2028		U-2300			
		8835474	Nov 04, 2023		U-1527			
		RE44872	Nov 04, 2023		U-1527			
MITOMYCIN - MITOSOL								
N 022572	001	7806265	Feb 01, 2029		DP			
		8186511	Jul 19, 2026		DP			
		9205075	Jul 19, 2026		DP			
		9539241	Jan 02, 2028	DS	DP	U-2095		
		9649428	May 21, 2029			U-2095		
MODAFINIL - PROVIGIL								
N 020717	001	7297346	Nov 29, 2023		DP			
MODAFINIL - PROVIGIL								
N 020717	002	7297346	Nov 29, 2023		DP			
MOMETASONE FUROATE - SINUVA								
N 209310	001	10232152	Nov 24, 2034		DP	U-2272	NP	Dec 08, 2020
		10357640	Oct 03, 2031			U-2272		
		10406332	Mar 13, 2034		DP			
		7544192	Nov 29, 2026			U-2272		
		7662141	Mar 12, 2024			U-2272		
		7713255	Mar 12, 2024			U-2272		
		7951130	Mar 12, 2024			U-2272		
		7951131	Mar 12, 2024			U-2272		
		7951133	Mar 12, 2024			U-2272		
		8025635	Jun 12, 2027		DP	U-2272		
		8109918	Mar 12, 2024			U-2272		
		8763222	Feb 08, 2032		DP			
		9585681	Apr 04, 2026			U-2272		
MONTELUKAST SODIUM - SINGULAIR								
N 021409	001	8007830	Oct 24, 2022		DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	001	9072781	Mar 12, 2034		DP			
		9192608	Mar 12, 2034			U-43		
		9192608	Mar 12, 2034			U-55		
		9248229	Mar 12, 2034		DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	002	9072781	Mar 12, 2034		DP			
		9192608	Mar 12, 2034			U-43		
		9192608	Mar 12, 2034			U-55		
		9248229	Mar 12, 2034		DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	003	9072781	Mar 12, 2034		DP			
		9192608	Mar 12, 2034			U-43		
		9192608	Mar 12, 2034			U-55		
		9248229	Mar 12, 2034		DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	004	9072781	Mar 12, 2034		DP			
		9192608	Mar 12, 2034			U-43		
		9192608	Mar 12, 2034			U-55		
		9248229	Mar 12, 2034		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE - MORPHINE SULFATE								
N	204223	004	9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N	204223	005	9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHABOND ER								
N	206544	001	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N	206544	002	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N	206544	003	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N	206544	004	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - ARYMO ER								
N	208603	001	9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER								
N	208603	002	9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER								
N	208603	003	9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N	022321	001	7682633	Jun 19, 2027	U-1510			
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027	U-1510			
			8623418	Nov 07, 2029	U-1640			
			8685443	Jul 03, 2025	U-1508			
			8685444	Jul 03, 2025	DP			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N	022321	002	7682633	Jun 19, 2027	U-1510			
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027	U-1510			
			8623418	Nov 07, 2029	U-1640			
			8685443	Jul 03, 2025	U-1508			
			8685444	Jul 03, 2025	DP			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N	022321	003	7682633	Jun 19, 2027	U-1510			
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027	U-1510			
			8623418	Nov 07, 2029	U-1640			
			8685443	Jul 03, 2025	U-1508			
			8685444	Jul 03, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA									
N 022321	003		8846104	Jun 19, 2027		DP			
			8877247	Jun 19, 2027		DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA									
N 022321	004		7682633	Jun 19, 2027		U-1510			
			7682634	Jun 19, 2027		DP			
			7815934	Dec 12, 2027		DP			
			8158156	Jun 19, 2027		U-1510			
			8623418	Nov 07, 2029		U-1640			
			8685443	Jul 03, 2025		U-1508			
			8685444	Jul 03, 2025		DP			
			8846104	Jun 19, 2027		DP			
			8877247	Jun 19, 2027		DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA									
N 022321	005		7682633	Jun 19, 2027		U-1510			
			7682634	Jun 19, 2027		DP			
			7815934	Dec 12, 2027		DP			
			8158156	Jun 19, 2027		U-1510			
			8623418	Nov 07, 2029		U-1640			
			8685443	Jul 03, 2025		U-1508			
			8685444	Jul 03, 2025		DP			
			8846104	Jun 19, 2027		DP			
			8877247	Jun 19, 2027		DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA									
N 022321	006		7682633	Jun 19, 2027		U-1510			
			7682634	Jun 19, 2027		DP			
			7815934	Dec 12, 2027		DP			
			8158156	Jun 19, 2027		U-1510			
			8623418	Nov 07, 2029		U-1640			
			8685443	Jul 03, 2025		U-1508			
			8685444	Jul 03, 2025		DP			
			8846104	Jun 19, 2027		DP			
			8877247	Jun 19, 2027		DP			
MOXIDECTIN - MOXIDECTIN									
N 210867	001							NCE	Jun 13, 2023
								ODE-193	Jun 13, 2025
MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER									
N 021277	001		6548079	Jul 25, 2020		DP U-298			
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA									
N 022428	001		8450311	May 29, 2029		DP			
			9114168	May 29, 2029		DP			
NAFTIFINE HYDROCHLORIDE - NAFTIN									
N 204286	001		10166205	Jan 31, 2033		DP			
			10166206	Jan 31, 2033		DP			
			8778365	Jan 31, 2033		DP			
			9161914	Jan 31, 2033		U-540			
NALDEMEDINE TOSYLATE - SYMPROIC									
N 208854	001		9108975	Nov 11, 2031	DS	DP		NCE	Mar 23, 2022
			RE46365	Jan 11, 2028	DS	DP			
			RE46375	Oct 05, 2026	DS	DP U-1185			
NALOXEGOL OXALATE - MOVANTIK									
N 204760	001		7056500	Jun 29, 2024		DP U-1185			
			7662365	Oct 18, 2022	DS	DP			
			7786133	Dec 19, 2027	DS	DP			
			8067431	Dec 16, 2024		U-1185			
			8617530	Oct 18, 2022		U-1185			
			9012469	Apr 02, 2032	DS	DP			
NALOXEGOL OXALATE - MOVANTIK									
N 204760	002		7056500	Jun 29, 2024		DP U-1185			
			7662365	Oct 18, 2022	DS	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXEGOL OXALATE - MOVANTIK						
N 204760 002	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
	9012469	Apr 02, 2032	DS DP			
NALOXONE HYDROCHLORIDE - EVZIO						
N 205787 001	10143972	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9517307	Jul 18, 2034	DP U-1925			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE - NARCAN						
N 208411 001	10085937	Mar 16, 2035	U-1903			
	9211253	Mar 16, 2035	DP			
	9468747	Mar 16, 2035	DP U-1903			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
	9775838	Mar 16, 2035	U-1903			
NALOXONE HYDROCHLORIDE - NARCAN						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
	9707226	Mar 16, 2035	DP U-1903			
NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)							
N 209862	001	8627816	Feb 04, 2032	DP			
		8926594	Mar 31, 2026	DP			
		8939943	Feb 28, 2031	DP			
		9022022	Feb 28, 2031	DP			
		9056170	Nov 23, 2024	DP			
		9238108	Feb 20, 2027	DP			
		9278182	Feb 01, 2026	DP			
		9474869	Feb 28, 2031	DP		U-1907	
		9517307	Jul 18, 2034	DP		U-1925	
		9724471	May 23, 2027	DP		U-2092	
		9737669	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	001	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
		9555000	Apr 04, 2023	DP		U-1556	
		9907793	Apr 04, 2023	DP		U-1556	
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	002	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
		9555000	Apr 04, 2023	DP		U-1556	
		9907793	Apr 04, 2023	DP		U-1556	
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	003	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
NALTREXONE - VIVITROL							
N 021897	001	6264987	May 19, 2020	DP			
		6379704	May 19, 2020	DP			
		6495164	May 25, 2020	DP			
		6534092	May 19, 2020	DP			
		6667061	May 25, 2020	DP			
		7799345	May 25, 2020	DP			
		7919499	Oct 15, 2029			U-1123	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALTREXONE - VIVITROL								
N 021897	001		7919499	Oct 15, 2029	U-1124			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	001		7815934	Dec 12, 2027	DP			
			8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	002		7815934	Dec 12, 2027	DP			
			8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	003		7815934	Dec 12, 2027	DP			
			8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	004		7815934	Dec 12, 2027	DP			
			8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	005		7815934	Dec 12, 2027	DP			
			8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	006		7815934	Dec 12, 2027	DP			
			8685443	Jul 03, 2025	U-1508			
NAPROXEN SODIUM - NAPROXEN SODIUM								
N 021920	001		10022344	Mar 03, 2026	DP U-1731			
			10022344	Mar 03, 2026	DP U-1732			
			10028925	Mar 03, 2026	DP U-1731			
			10028925	Mar 03, 2026	DP U-1732			
			9693978	Mar 03, 2026	DP			
			9693979	Mar 03, 2026	DP			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET								
N 021926	001		7332183	Oct 02, 2025	DP U-867			
			7332183*PED	Apr 02, 2026				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET								
N 021926	002		7332183	Oct 02, 2025	DP U-1719			
			7332183*PED	Apr 02, 2026				
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC								
N 021742	002		6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC								
N 021742	003		6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC								
N 021742	004		6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC								
N 021742	005		6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON								
N 206302	001		7803838	Aug 29, 2026	DP			
			7838552	Oct 04, 2027	U-185			
NEPAFENAC - NEVANAC								
N 021862	001		7834059	Jan 31, 2027	U-1095			
			8071648	Dec 02, 2025	DP			
			8324281	Dec 02, 2025	DP			
NEPAFENAC - ILEVRO								
N 203491	001		7947295	Jun 08, 2024	DP			
			8921337	Mar 31, 2032	DP			
			9662398	Dec 01, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NERATINIB MALEATE - NERLYNX							
N 208051	001	10035788	Oct 15, 2028	U-2043		NCE	Jul 17, 2022
		7399865	Dec 29, 2025	DS DP			
		7982043	Oct 08, 2025	U-2043			
		8518446	Nov 20, 2030	DP U-2043			
		8790708	Nov 05, 2030	DP U-2043			
		9139558	Oct 15, 2028	U-2043			
		9211291	Mar 24, 2030	U-2043			
		9630946	Oct 15, 2028	U-2043			
NETARSUDIL DIMESYLATE - RHOPRESSA							
N 208254	001	10174017	Jan 27, 2030	DS DP U-1524		NCE	Dec 18, 2022
		8394826	Nov 10, 2030	DS DP U-1524			
		8450344	Jul 11, 2026	DS DP U-1524			
		9096569	Jul 11, 2026	DS DP U-1524			
		9415043	Mar 14, 2034	DS			
		9931336	Mar 14, 2034	DS DP U-1524			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 205718	001	10233154	Sep 25, 2035	DS			
		6297375	Feb 22, 2020	DS			
		8623826	Nov 18, 2030	U-2293			
		8951969	Nov 18, 2030	DP			
		9186357	Nov 18, 2030	U-2293			
		9271975	Sep 09, 2031	U-2293			
		9943515	Nov 18, 2030	U-2293			
		9951016	Sep 25, 2035	DS DP			
NEVIRAPINE - VIRAMUNE XR							
N 201152	001	8460704	Mar 12, 2029	U-1409			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER							
N 019734	002	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER							
N 019734	003	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER							
N 019734	004	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER							
N 019734	005	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICOTINE - NICODERM CQ							
N 020165	004	8075911	May 22, 2021	DP			
		8663680	Feb 13, 2020	DP			
		8999379	Feb 13, 2020	U-1686			
NICOTINE - NICODERM CQ							
N 020165	005	8075911	May 22, 2021	DP			
		8663680	Feb 13, 2020	DP			
		8999379	Feb 13, 2020	U-1686			
NICOTINE - NICODERM CQ							
N 020165	006	8075911	May 22, 2021	DP			
		8663680	Feb 13, 2020	DP			
		8999379	Feb 13, 2020	U-1686			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICOTINE POLACRILEX - NICORETTE							
N 018612	002	8323683	Apr 30, 2028				
NICOTINE POLACRILEX - NICORETTE							
N 020066	002	8323683	Apr 30, 2028	DP			
NICOTINE POLACRILEX - NICORETTE							
N 022360	001	8501164	Jun 14, 2029	DP			
		8940772	Apr 30, 2029	DP			
NICOTINE POLACRILEX - NICORETTE							
N 022360	002	8501164	Jun 14, 2029	DP			
		8940772	Apr 30, 2029	DP			
NILOTINIB HYDROCHLORIDE - TASIGNA							
N 022068	001	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
		7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
		8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
		8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
		8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
		8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
		8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
		8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
		8415363	Jul 18, 2026	DS DP U-1407			
		8415363*PED	Jan 18, 2027				
		8501760	Jul 18, 2026	DS DP			
		8501760*PED	Jan 18, 2027				
		9061029	Apr 07, 2032	DP U-1374			
		9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA							
N 022068	002	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
		7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
		8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
		8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
		8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
		8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
		8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
		8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
		8415363	Jul 18, 2026	DS DP U-1407			
		8415363*PED	Jan 18, 2027				
		8501760	Jul 18, 2026	DS DP			
		8501760*PED	Jan 18, 2027				
		9061029	Apr 07, 2032	DP U-1374			
		9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA							
N 022068	003	7169791	Jul 04, 2023	DS DP U-836		NPP	Mar 22, 2021
		7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
		8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025
		8163904*PED	Feb 23, 2029			PED	Sep 22, 2021
		8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
		8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
		8389537	Jul 18, 2026	DS DP U-1374			
		8389537*PED	Jan 18, 2027				
		8415363	Jul 18, 2026	DS DP U-1407			
		8415363*PED	Jan 18, 2027				
		8501760	Jul 18, 2026	DS DP			
		8501760*PED	Jan 18, 2027				
		9061029	Apr 07, 2032	DS DP U-1374			
		9061029*PED	Oct 07, 2032				
NIMODIPINE - NYMALIZE							
N 203340	001					ODE-46	May 10, 2020
NINTEDANIB ESYLATE - OFEV							
N 205832	001	10105323	Jun 04, 2029	DP		I-805	Sep 06, 2022
		10154990	Dec 20, 2025	U-2620		ODE-261	Sep 06, 2026
		6762180	Oct 03, 2020	DS DP		ODE-77	Oct 15, 2021
		7119093	Feb 21, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NINTEDANIB ESYLATE - OFEV							
N 205832	001	7989474	Apr 06, 2024	U-1677			
		9907756	Jun 07, 2029	DP			
NINTEDANIB ESYLATE - OFEV							
N 205832	002	10105323	Jun 04, 2029	DP		I-805	Sep 06, 2022
		10154990	Dec 20, 2025	U-2620		ODE-261	Sep 06, 2026
		6762180	Oct 03, 2020	DS DP		ODE-77	Oct 15, 2021
		7119093	Feb 21, 2024	DS DP			
		7989474	Apr 06, 2024	U-1677			
		9907756	Jun 07, 2029	DP			
NIRAPARIB TOSYLATE - ZEJULA							
N 208447	001	8071579	Aug 12, 2027	U-2655		I-813	Oct 23, 2022
		8071623	Mar 22, 2030	DS DP		I-814	Oct 23, 2022
		8143241	Aug 12, 2027	U-2655		NCE	Mar 27, 2022
		8436185	Apr 24, 2029	DS		ODE-133	Mar 27, 2024
		8859562	Aug 04, 2031	U-2655		ODE-277	Oct 23, 2026
						ODE-278	Oct 23, 2026
NITISINONE - ORFADIN							
N 021232	001					D-169	Sep 01, 2020
NITISINONE - ORFADIN							
N 021232	002					D-169	Sep 01, 2020
NITISINONE - ORFADIN							
N 021232	003					D-169	Sep 01, 2020
NITISINONE - ORFADIN							
N 021232	004					D-169	Sep 01, 2020
NITISINONE - ORFADIN							
N 206356	001	9301932	Feb 28, 2033	DP U-1836		D-169	Sep 01, 2020
NITISINONE - NITYR							
N 209449	001	10328029	Jan 05, 2035	DP U-1836			
NITISINONE - NITYR							
N 209449	002	10328029	Jan 05, 2035	DP U-1836			
NITISINONE - NITYR							
N 209449	003	10328029	Jan 05, 2035	DP U-1836			
NITRIC OXIDE - INOMAX							
N 020845	002	8282966	Jun 30, 2029	U-1286			
		8291904	Jan 06, 2031	DP U-1226			
		8293284	Jun 30, 2029	U-1286			
		8431163	Jun 30, 2029	U-1286			
		8431163*PED	Dec 30, 2029				
		8573209	Jan 06, 2031	DP			
		8573209*PED	Jul 06, 2031				
		8573210	Jan 06, 2031	DP U-1453			
		8573210*PED	Jul 06, 2031				
		8776794	Jan 06, 2031	DP U-1226			
		8776794*PED	Jul 06, 2031				
		8776795	Jan 06, 2031	DP U-1226			
		8776795*PED	Jul 06, 2031				
		8795741	Jun 30, 2029	U-1286			
		8795741*PED	Dec 30, 2029				
		8846112	Jun 30, 2029	U-1286			
		8846112*PED	Dec 30, 2029				
NITRIC OXIDE - INOMAX							
N 020845	003	8282966	Jun 30, 2029	U-1286			
		8291904	Jan 06, 2031	DP U-1226			
		8293284	Jun 30, 2029	U-1286			
		8431163	Jun 30, 2029	U-1286			
		8431163*PED	Dec 30, 2029				
		8573209	Jan 06, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITRIC OXIDE - INOMAX							
N 020845	003	8573209*PED	Jul 06, 2031				
		8573210	Jan 06, 2031	DP U-1453			
		8573210*PED	Jul 06, 2031				
		8776794	Jan 06, 2031	DP U-1226			
		8776794*PED	Jul 06, 2031				
		8776795	Jan 06, 2031	DP U-1226			
		8776795*PED	Jul 06, 2031				
		8795741	Jun 30, 2029	U-1286			
		8795741*PED	Dec 30, 2029				
		8846112	Jun 30, 2029	U-1286			
		8846112*PED	Dec 30, 2029				
		9265911	Jan 06, 2031	DP U-1824			
		9265911*PED	Jul 06, 2031				
		9279794	Feb 19, 2034	DP U-1823			
		9279794*PED	Aug 19, 2034				
		9295802	Jan 06, 2031	DP U-1226			
		9295802*PED	Jul 06, 2031				
		9408993	Jan 06, 2031	DP U-1824			
		9408993*PED	Jul 06, 2031				
		9770570	May 03, 2036	U-2148			
		9770570*PED	Nov 03, 2036				
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY							
N 018705	002	7872049	Mar 12, 2029	DP U-2223			
NITROGLYCERIN - GONITRO							
N 208424	001	9101592	Mar 11, 2032	DP			
NIZATIDINE - AXID							
N 021494	001	6930119	Jul 17, 2022	DP			
NUSINERSEN SODIUM - SPINRAZA							
N 209531	001	10266822	Dec 05, 2025	DP U-1942		M-226	May 14, 2021
		10266822	Dec 05, 2025	DP U-1943		NCE	Dec 23, 2021
		10266822	Dec 05, 2025	DP U-1944		ODE-127	Dec 23, 2023
		10436802	Sep 11, 2035	U-1941			
		10436802	Sep 11, 2035	U-1942			
		10436802	Sep 11, 2035	U-1943			
		10436802	Sep 11, 2035	U-1944			
		10436802	Sep 11, 2035	U-2093			
		10436802	Sep 11, 2035	U-2094			
		7101993	Sep 05, 2023	DS			
		7838657	Jul 11, 2027	DS			
		8110560	Dec 05, 2025	U-1942			
		8110560	Dec 05, 2025	U-1943			
		8110560	Dec 05, 2025	U-1944			
		8361977	May 27, 2030	DS DP			
		8980853	Nov 24, 2030	U-1941			
		9717750	Jun 17, 2030	U-1942			
		9717750	Jun 17, 2030	U-1943			
		9717750	Jun 17, 2030	U-2093			
		9717750	Jun 17, 2030	U-2094			
		9926559	Jan 09, 2034	U-1943			
OBETICHOLIC ACID - OCALIVA							
N 207999	001	10047117	Sep 06, 2033	U-1854		NCE	May 27, 2021
		10052337	Apr 26, 2036	DP		ODE-119	May 27, 2023
		10174073	Jun 17, 2033	DS			
		7138390	Nov 16, 2022	DS DP			
		8058267	Feb 21, 2022	U-1854			
		8377916	Feb 21, 2022	U-1854			
		9238673	Jun 17, 2033	DP			
OBETICHOLIC ACID - OCALIVA							
N 207999	002	10047117	Sep 06, 2033	U-1854		NCE	May 27, 2021
		10052337	Apr 26, 2036	DP		ODE-119	May 27, 2023
		10174073	Jun 17, 2033	DS			
		7138390	Nov 16, 2022	DS DP			
		8058267	Feb 21, 2022	U-1854			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OBETICHOLIC ACID - OCALIVA							
N 207999	002	8377916	Feb 21, 2022	U-1854			
		9238673	Jun 17, 2033	DP			
OLAPARIB - LYNPARZA							
N 206162	001	7151102	Apr 29, 2022	DS DP		ODE-83	Dec 19, 2021
		7449464	Oct 11, 2024	DS DP			
		7981889	Oct 11, 2024	DS DP			
		8143241	Aug 12, 2027	U-1634			
		8247416	Sep 24, 2028	DS			
		8859562	Aug 04, 2031	U-1634			
		8912187	Mar 12, 2024	U-1634			
OLAPARIB - LYNPARZA							
N 208558	001	7151102	Apr 29, 2022	DS DP		I-762	Jan 12, 2021
		7449464	Oct 11, 2024	DS DP		I-776	Dec 19, 2021
		7981889	Oct 11, 2024	DS DP		I-818	Dec 27, 2022
		8143241	Aug 12, 2027	U-2101		NP	Aug 17, 2020
		8143241	Aug 12, 2027	U-2103		ODE-180	Aug 17, 2024
		8143241	Aug 12, 2027	U-2480		ODE-181	Aug 17, 2024
		8143241	Aug 12, 2027	U-2481		ODE-226	Dec 19, 2025
		8143241	Aug 12, 2027	U-2482		ODE-83	Dec 19, 2021
		8143241	Aug 12, 2027	U-2483			
		8475842	Dec 31, 2029	DP			
		8859562	Aug 04, 2031	U-2101			
		8859562	Aug 04, 2031	U-2480			
		8859562	Aug 04, 2031	U-2481			
		8859562	Aug 04, 2031	U-2482			
		8859562	Aug 04, 2031	U-2483			
		8912187	Mar 12, 2024	U-2101			
		8912187	Mar 12, 2024	U-2480			
		8912187	Mar 12, 2024	U-2481			
		8912187	Mar 12, 2024	U-2482			
		8912187	Mar 12, 2024	U-2483			
OLAPARIB - LYNPARZA							
N 208558	002	7151102	Apr 29, 2022	DS DP		I-762	Jan 12, 2021
		7449464	Oct 11, 2024	DS DP		I-776	Dec 19, 2021
		7981889	Oct 11, 2024	DS DP		I-818	Dec 27, 2022
		8143241	Aug 12, 2027	U-2101		NP	Aug 17, 2020
		8143241	Aug 12, 2027	U-2103		ODE-180	Aug 17, 2024
		8143241	Aug 12, 2027	U-2480		ODE-181	Aug 17, 2024
		8143241	Aug 12, 2027	U-2481		ODE-226	Dec 19, 2025
		8143241	Aug 12, 2027	U-2482		ODE-83	Dec 19, 2021
		8143241	Aug 12, 2027	U-2483			
		8475842	Dec 31, 2029	DP			
		8859562	Aug 04, 2031	U-2101			
		8859562	Aug 04, 2031	U-2480			
		8859562	Aug 04, 2031	U-2481			
		8859562	Aug 04, 2031	U-2482			
		8859562	Aug 04, 2031	U-2483			
		8912187	Mar 12, 2024	U-2101			
		8912187	Mar 12, 2024	U-2480			
		8912187	Mar 12, 2024	U-2481			
		8912187	Mar 12, 2024	U-2482			
		8912187	Mar 12, 2024	U-2483			
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT							
N 203108	001	6988496	Feb 23, 2020	DP U-1547			
		7056916	Dec 07, 2023	DS DP			
		7220742	May 12, 2025	DS DP U-1547			
		7284474	Aug 26, 2024	DP			
		7396341	Oct 10, 2026	DP U-1547			
		7491719	Nov 10, 2023	DS DP			
		7727984	Jan 19, 2027	DS			
		7786111	Nov 10, 2023	DP			
		7837235	Mar 13, 2028	DP			
		7896264	May 26, 2025	DP			
		7988001	Aug 04, 2021	DP			
		8034809	May 12, 2025	U-1547			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT							
N 203108	001	8044046	Nov 10, 2023	U-1547			
		8733341	Oct 16, 2030	DP			
		9027967	Mar 31, 2027	DP			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT							
N 206756	001	6988496	Feb 23, 2020	DP		M-233	Oct 05, 2021
		6988496*PED	Aug 23, 2020				
		7056916	Dec 07, 2023	DS DP			
		7220742	May 12, 2025	DS DP U-1703			
		7284474	Aug 26, 2024	DP			
		7284474*PED	Feb 26, 2025				
		7396341	Oct 10, 2026	DP			
		7396341*PED	Apr 10, 2027				
		7491719	Nov 10, 2023	DS DP			
		7727984	Jan 19, 2027	DS			
		7786111	Nov 10, 2023	DP			
		7837235	Mar 13, 2028	DP			
		7837235*PED	Sep 13, 2028				
		7896264	May 26, 2025	DP			
		7988001	Aug 04, 2021	DP			
		8034809	May 12, 2025	U-1702			
		8044046	Nov 10, 2023	U-1702			
		8733341	Oct 16, 2030	DP			
		9027967	Mar 31, 2027	DP			
OLOPATADINE HYDROCHLORIDE - PATADAY							
N 021545	001	6995186	Nov 12, 2023	DP U-765			
		7402609	Jun 19, 2022	DP			
OLOPATADINE HYDROCHLORIDE - PATANASE							
N 021861	001	7977376	Feb 02, 2023	DP			
		8399508	Sep 17, 2022	U-726			
		8399508*PED	Mar 17, 2023				
OLOPATADINE HYDROCHLORIDE - PAZEO							
N 206276	001	8791154	May 19, 2032	DP U-1680			
		9533053	May 19, 2032	DP			
OMACETAXINE MEPESUCCINATE - SYNRIBO							
N 203585	001	6987103	Oct 26, 2026	U-1300			
OMADACYCLINE TOSYLATE - NUZYRA							
N 209816	001	10111890	Aug 03, 2037	U-2444		NCE	Oct 02, 2023
		10124014	Mar 05, 2029	U-2449		GAIN	Oct 02, 2028
		10383884	Oct 31, 2037	U-2576			
		7326696	Sep 24, 2023	DS			
		7553828	Jun 02, 2023	DS			
		8383610	Sep 23, 2030	DS			
		9265740	Mar 05, 2029	U-1569			
		9314475	Mar 18, 2031	DP			
		9365500	Jun 29, 2021	U-1569			
		9365500	Jun 29, 2021	U-2576			
		9724358	Mar 05, 2029	U-1569			
OMADACYCLINE TOSYLATE - NUZYRA							
N 209817	001	10124014	Mar 05, 2029	U-2449		NCE	Oct 02, 2023
		10383884	Oct 31, 2037	U-2576		GAIN	Oct 02, 2028
		7326696	Sep 24, 2023	DS			
		7553828	Jun 02, 2023	DS			
		9265740	Mar 05, 2029	DP			
		9365500	Jun 29, 2021	U-1569			
		9365500	Jun 29, 2021	U-2576			
		9724358	Mar 05, 2029	U-1569			
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE							
N 207931	001	7148359*PED	Jan 19, 2020				
		7364752	Nov 10, 2020	DP			
		7364752*PED	May 10, 2021				
		8268349	Aug 25, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE							
N 207931	001	8268349*PED	Feb 25, 2025				
		8399015	Aug 25, 2024	DP			
		8399015*PED	Feb 25, 2025				
		8420596	Apr 10, 2031	DS DP			
		8420596*PED	Oct 10, 2031				
		8642538	Sep 10, 2029	DS DP U-1638			
		8686026	Jun 09, 2031	DP			
		8691938	Apr 13, 2032	DS DP			
		9006387	Jun 10, 2030	U-1687			
		9044480	Apr 10, 2031	U-1638			
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA							
N 205060	001	10117844	Jan 04, 2033	U-2447			
		5792795	May 13, 2020	DP			
		5948818	May 13, 2020	DP			
		7960370	Dec 20, 2026	DP			
		8383678	Feb 07, 2025	DP U-1511			
		9012501	Feb 07, 2025	DP U-1511			
		9050308	Jan 04, 2033	U-1511			
		9050309	Jan 04, 2033	DS			
		9132112	Feb 07, 2025	DP U-1511			
OMEPRAZOLE - OMEPRAZOLE							
N 022032	001	9023391	Aug 16, 2025	DP			
OMEPRAZOLE - OMEPRAZOLE							
N 209400	001	10076494	Dec 08, 2036	DP			
ONDANSETRON - ZUPLENZ							
N 022524	001	8580830	Nov 23, 2029	DP			
		9095577	Jul 13, 2030	DP			
ONDANSETRON - ZUPLENZ							
N 022524	002	8580830	Nov 23, 2029	DP			
		9095577	Jul 13, 2030	DP			
ORITAVANCIN DIPHOSPHATE - ORBACTIV							
N 206334	001	5840684	Nov 24, 2020	DS DP U-1569		NCE	Aug 06, 2019
		8420592	Aug 29, 2029	U-1570		GAIN	Aug 06, 2024
		9649352	Jul 16, 2035	DP			
		9682061	Apr 26, 2030	U-1569			
OSIMERTINIB MESYLATE - TAGRISSO							
N 208065	001	10183020	Jan 02, 2035	DP U-1777		I-774	Apr 18, 2021
		10183020	Jan 02, 2035	DP U-2289		NCE	Nov 13, 2020
		8946235	Aug 08, 2032	DS DP U-1777		ODE-102	Nov 13, 2022
		8946235	Aug 08, 2032	DS DP U-2289		ODE-176	Apr 18, 2025
		9732058	Jul 25, 2032	DS DP U-1777			
		9732058	Jul 25, 2032	DS DP U-2289			
OSIMERTINIB MESYLATE - TAGRISSO							
N 208065	002	10183020	Jan 02, 2035	DP U-1777		I-774	Apr 18, 2021
		10183020	Jan 02, 2035	DP U-2289		NCE	Nov 13, 2020
		8946235	Aug 08, 2032	DS DP U-1777		ODE-102	Nov 13, 2022
		8946235	Aug 08, 2032	DS DP U-2289		ODE-176	Apr 18, 2025
		9732058	Jul 25, 2032	DS DP U-1777			
		9732058	Jul 25, 2032	DS DP U-2289			
OSPEMIFENE - OSPHENA							
N 203505	001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
		6245819	Jul 21, 2025	U-905			
		8236861	Aug 11, 2026	U-1369			
		8236861	Aug 11, 2026	U-1370			
		8236861	Aug 11, 2026	U-905			
		8470890	Feb 13, 2024	U-1369			
		8470890	Feb 13, 2024	U-1370			
		8470890	Feb 13, 2024	U-905			
		8642079	Jul 09, 2028	DP			
		8772353	Feb 13, 2024	U-1369			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OSPEMIFENE - OSPHENA							
N 203505	001	8772353	Feb 13, 2024	U-1370			
		8772353	Feb 13, 2024	U-905			
		9241915	Feb 13, 2024	U-1369			
		9241915	Feb 13, 2024	U-1370			
		9241915	Feb 13, 2024	U-905			
		9566252	Jul 21, 2020	U-1370			
		9855224	Feb 13, 2024	U-1369			
		9855224	Feb 13, 2024	U-1370			
		9855224	Feb 13, 2024	U-905			
OXCARBAZEPINE - TRILEPTAL							
N 021285	001	8119148	Dec 19, 2020	DP U-724			
OXCARBAZEPINE - OXTELLAR XR							
N 202810	001	10220042	Apr 13, 2027	U-2501			
		7722898	Apr 13, 2027	DP			
		7910131	Apr 13, 2027	U-2041			
		8617600	Apr 13, 2027	DP			
		8821930	Apr 13, 2027	DP			
		9119791	Apr 13, 2027	U-2041			
		9351975	Apr 13, 2027	DP			
		9370525	Apr 13, 2027	DP			
		9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR							
N 202810	002	10220042	Apr 13, 2027	U-2501			
		7722898	Apr 13, 2027	DP			
		7910131	Apr 13, 2027	U-2041			
		8617600	Apr 13, 2027	DP			
		8821930	Apr 13, 2027	DP			
		9119791	Apr 13, 2027	U-2041			
		9351975	Apr 13, 2027	DP			
		9370525	Apr 13, 2027	DP			
		9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR							
N 202810	003	10220042	Apr 13, 2027	U-2501			
		7722898	Apr 13, 2027	DP			
		7910131	Apr 13, 2027	U-2041			
		8617600	Apr 13, 2027	DP			
		8821930	Apr 13, 2027	DP			
		9119791	Apr 13, 2027	U-2041			
		9351975	Apr 13, 2027	DP			
		9370525	Apr 13, 2027	DP			
		9855278	Apr 13, 2027	DP			
OXYBUTYNIN - OXYTROL							
N 021351	002	6743441	Apr 26, 2020	DP U-318			
		7081249	Apr 26, 2020	DP U-318			
		7081250	Apr 26, 2020	DP U-318			
		7081251	Apr 26, 2020	DP U-318			
		7081252	Apr 26, 2020	DP U-318			
		7179483	Apr 26, 2020	DS DP U-318			
OXYBUTYNIN - OXYTROL FOR WOMEN							
N 202211	001	6743441	Apr 26, 2020	DP U-1329			
		7081249	Apr 26, 2020	DP U-1329			
		7081250	Apr 26, 2020	DP U-1329			
		7081251	Apr 26, 2020	DP U-1329			
		7081252	Apr 26, 2020	DP U-1329			
		7179483	Apr 26, 2020	U-1329			
OXYBUTYNIN - GELNIQUE 3%							
N 202513	001	7029694	Apr 26, 2020	DP U-318			
		7179483	Apr 26, 2020	U-318			
		7198801	Jun 25, 2022	DP			
		8241662	Apr 26, 2020	U-318			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYBUTYNIN CHLORIDE - GELNIQUE							
N 022204	001	10272061	Apr 26, 2020	U-2525			
		10449173	Nov 06, 2029	DP U-2637			
		7029694	Apr 26, 2020	DP U-318			
		7179483	Apr 26, 2020	U-318			
		8241662	Apr 26, 2020	U-318			
		8920392	Mar 26, 2031	U-1644			
		9259388	Nov 06, 2029	U-1644			
OXYCODONE - XTAMPZA ER							
N 208090	001	10004729	Dec 10, 2030	DP U-1556			
		10188644	Sep 02, 2036	DP U-1556			
		10525052	Jul 07, 2023	DP U-1556			
		10525053	Jul 07, 2023	DP			
		7399488	Mar 24, 2025	DP			
		7771707	Mar 24, 2025	DP			
		8449909	Mar 24, 2025	DP			
		8557291	Mar 21, 2025	DP			
		8758813	Jun 10, 2025	U-1556			
		8840928	Jul 07, 2023	DP U-1556			
		9044398	Jul 07, 2023	DP			
		9248195	Jul 07, 2023	U-1556			
		9592200	Jul 07, 2023	DP			
		9682075	Dec 10, 2030	DP U-1556			
		9737530	Sep 02, 2036	DP U-1556			
		9763883	Jul 07, 2023	DP			
		9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER							
N 208090	002	10004729	Dec 10, 2030	DP U-1556			
		10188644	Sep 02, 2036	DP U-1556			
		10525052	Jul 07, 2023	DP U-1556			
		10525053	Jul 07, 2023	DP			
		7399488	Mar 24, 2025	DP			
		7771707	Mar 24, 2025	DP			
		8449909	Mar 24, 2025	DP			
		8557291	Mar 21, 2025	DP			
		8758813	Jun 10, 2025	U-1556			
		8840928	Jul 07, 2023	DP U-1556			
		9044398	Jul 07, 2023	DP			
		9248195	Jul 07, 2023	U-1556			
		9592200	Jul 07, 2023	DP			
		9682075	Dec 10, 2030	DP U-1556			
		9737530	Sep 02, 2036	DP U-1556			
		9763883	Jul 07, 2023	DP			
		9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER							
N 208090	003	10004729	Dec 10, 2030	DP U-1556			
		10188644	Sep 02, 2036	DP U-1556			
		10525052	Jul 07, 2023	DP U-1556			
		10525053	Jul 07, 2023	DP			
		7399488	Mar 24, 2025	DP			
		7771707	Mar 24, 2025	DP			
		8449909	Mar 24, 2025	DP			
		8557291	Mar 21, 2025	DP			
		8758813	Jun 10, 2025	U-1556			
		8840928	Jul 07, 2023	DP U-1556			
		9044398	Jul 07, 2023	DP			
		9248195	Jul 07, 2023	U-1556			
		9592200	Jul 07, 2023	DP			
		9682075	Dec 10, 2030	DP U-1556			
		9737530	Sep 02, 2036	DP U-1556			
		9763883	Jul 07, 2023	DP			
		9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER							
N 208090	004	10004729	Dec 10, 2030	DP U-1556			
		10188644	Sep 02, 2036	DP U-1556			
		10525052	Jul 07, 2023	DP U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE - XTAMPZA ER							
N 208090	004	10525053	Jul 07, 2023	DP			
		7399488	Mar 24, 2025	DP			
		7771707	Mar 24, 2025	DP			
		8449909	Mar 24, 2025	DP			
		8557291	Mar 21, 2025	DP			
		8758813	Jun 10, 2025	U-1556			
		8840928	Jul 07, 2023	DP U-1556			
		9044398	Jul 07, 2023	DP			
		9248195	Jul 07, 2023	U-1556			
		9592200	Jul 07, 2023	DP			
		9682075	Dec 10, 2030	DP U-1556			
		9737530	Sep 02, 2036	DP U-1556			
		9763883	Jul 07, 2023	DP			
		9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER							
N 208090	005	10004729	Dec 10, 2030	DP U-1556			
		10188644	Sep 02, 2036	DP U-1556			
		10525052	Jul 07, 2023	DP U-1556			
		10525053	Jul 07, 2023	DP			
		7399488	Mar 24, 2025	DP			
		7771707	Mar 24, 2025	DP			
		8449909	Mar 24, 2025	DP			
		8557291	Mar 21, 2025	DP			
		8758813	Jun 10, 2025	U-1556			
		8840928	Jul 07, 2023	DP U-1556			
		9044398	Jul 07, 2023	DP			
		9248195	Jul 07, 2023	U-1556			
		9592200	Jul 07, 2023	DP			
		9682075	Dec 10, 2030	DP U-1556			
		9737530	Sep 02, 2036	DP U-1556			
		9763883	Jul 07, 2023	DP			
		9968598	Sep 02, 2036	DP U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	001	10130591	Nov 20, 2023	DP U-1819			
		10369109	Jun 16, 2023	DP			
		10407434	Mar 30, 2025	DS			
		7674799	Mar 30, 2025	DP		Y	
		7674800	Mar 30, 2025	DS		Y	
		7683072	Mar 30, 2025	DS		Y	
		7776314	Apr 19, 2025	DP		Y	
		8309060	Nov 20, 2023	DP U-1556			
		8808741	Aug 24, 2027	U-1556			
		8894987	Mar 29, 2030	DP			
		8894988	Aug 24, 2027	DP			
		9060976	Aug 06, 2022	DP		Y	
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027	U-1556			
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027	U-1556			
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	002	10130591	Nov 20, 2023	DP U-1819			
		10369109	Jun 16, 2023	DP			
		10407434	Mar 30, 2025	DS			
		7674799	Mar 30, 2025	DP		Y	
		7674800	Mar 30, 2025	DS		Y	
		7683072	Mar 30, 2025	DS		Y	
		7776314	Apr 19, 2025	DP		Y	
		8309060	Nov 20, 2023	DP U-1556			
		8808741	Aug 24, 2027	U-1556			
		8894987	Mar 29, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	002	8894988	Aug 24, 2027	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027	U-1556			
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027	U-1556			
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	003	10130591	Nov 20, 2023	DP U-1819			
		10369109	Jun 16, 2023	DP			
		10407434	Mar 30, 2025	DS			
		7674799	Mar 30, 2025	DP		Y	
		7674800	Mar 30, 2025	DS		Y	
		7683072	Mar 30, 2025	DS		Y	
		7776314	Apr 19, 2025	DP		Y	
		8309060	Nov 20, 2023	DP U-1556			
		8808741	Aug 24, 2027	U-1556			
		8894987	Mar 29, 2030	DP			
		8894988	Aug 24, 2027	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027	U-1556			
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027	U-1556			
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	004	10130591	Nov 20, 2023	DP U-1819			
		10369109	Jun 16, 2023	DP			
		10407434	Mar 30, 2025	DS			
		8309060	Nov 20, 2023	DP U-1556			
		8808741	Aug 24, 2027	U-1556			
		8894987	Mar 29, 2030	DP			
		8894988	Aug 24, 2027	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027	U-1556			
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027	U-1556			
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	005	10130591	Nov 20, 2023	DP U-1819			
		10369109	Jun 16, 2023	DP			
		10407434	Mar 30, 2025	DS			
		8309060	Nov 20, 2023	DP U-1556			
		8808741	Aug 24, 2027	U-1556			
		8894988	Aug 24, 2027	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027	U-1556			
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027	U-1556			
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	005	9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	006	10130591	Nov 20, 2023	DP U-1819			
		10369109	Jun 16, 2023	DP			
		10407434	Mar 30, 2025	DS			
		8309060	Nov 20, 2023	DP U-1556			
		8808741	Aug 24, 2027	U-1556			
		8894988	Aug 24, 2027	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027	U-1556			
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027	U-1556			
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	007	10130591	Nov 20, 2023	DP U-1819			
		10369109	Jun 16, 2023	DP			
		10407434	Mar 30, 2025	DS			
		8309060	Nov 20, 2023	DP U-1556			
		8808741	Aug 24, 2027	U-1556			
		8894988	Aug 24, 2027	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027	U-1556			
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027	U-1556			
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO							
N 202080	001	7201920	Mar 16, 2025	DP			
		7510726	Nov 26, 2023	DP			
		7981439	Nov 26, 2023	DP			
		8409616	Nov 26, 2023	DP			
		8637540	Nov 26, 2023	DP			
		9492443	May 26, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO							
N 202080	002	7201920	Mar 16, 2025	DP			
		7510726	Nov 26, 2023	DP			
		7981439	Nov 26, 2023	DP			
		8409616	Nov 26, 2023	DP			
		8637540	Nov 26, 2023	DP			
		9492443	May 26, 2024	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND							
N 209777	001	10314788	Aug 12, 2028	DP		NP	Apr 20, 2020
		7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND							
N 209777	002	10314788	Aug 12, 2028	DP		NP	Apr 20, 2020
		7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND							
N 209777	003	10314788	Aug 12, 2028	DP		NP	Apr 20, 2020
		7955619	Aug 12, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMETAZOLINE HYDROCHLORIDE - RHOFADE								
N 208552	001		10335391	Jun 11, 2035	U-2567		NP	Jan 18, 2020
			7812049	May 02, 2028	U-1959			
			8420688	Aug 02, 2024	U-1959			
			8815929	Jan 22, 2024	U-1959			
			8883838	Dec 01, 2031	DP			
			9974773	Jun 11, 2035	U-2306			
OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE								
N 208032	001		6413499	Mar 20, 2020	U-1876			
			8580282	Apr 02, 2030	DP U-1876			
			9308191	Apr 02, 2030	DP U-1876			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	001		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	002		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	003		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	004		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	005		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	006		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	007		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	001		7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	002		7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	003		7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	004		7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	004	8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	005	7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	006	7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	007	7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OZENOXACIN - XEPI								
N	208945	001	6335447	Apr 06, 2020	DS		NCE	Dec 11, 2022
			9180200	Jan 29, 2032	DP U-805			
			9399014	Dec 15, 2029	U-805			
PACLITAXEL - ABRAXANE								
N	021660	001	7758891	Feb 21, 2026	U-1434		ODE-52	Sep 06, 2020
			7758891*PED	Aug 21, 2026			PED	Mar 06, 2021
			7820788	Oct 27, 2024	DP U-1092			
			7820788	Oct 27, 2024	DP U-1290			
			7820788	Oct 27, 2024	DP U-1434			
			7820788*PED	Apr 27, 2025				
			7923536	Dec 09, 2023	U-1117			
			7923536	Dec 09, 2023	U-1290			
			7923536	Dec 09, 2023	U-1434			
			7923536*PED	Jun 09, 2024				
			8034375	Aug 13, 2026	U-1290			
			8138229	Dec 09, 2023	DP U-1092			
			8138229	Dec 09, 2023	DP U-1290			
			8138229	Dec 09, 2023	DP U-1434			
			8138229*PED	Jun 09, 2024				
			8268348	Feb 21, 2026	U-1290			
			8314156	Dec 09, 2023	U-1290			
			8314156	Dec 09, 2023	U-1434			
			8314156*PED	Jun 09, 2024				
			8853260	Oct 10, 2020	DP U-1092			
			8853260	Oct 10, 2020	DP U-1290			
			8853260	Oct 10, 2020	DP U-1434			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PACLITAXEL - ABRAXANE							
N 021660	001	8853260*PED	Apr 10, 2021				
		9101543	Feb 21, 2026	U-1434			
		9101543*PED	Aug 21, 2026				
		9393318	Mar 04, 2032	U-1290			
		9393318*PED	Sep 04, 2032				
		9511046	Jan 12, 2034	U-1434			
		9511046*PED	Jul 12, 2034				
		9597409	Mar 04, 2032	U-1290			
		9597409*PED	Sep 04, 2032				
PALBOCICLIB - IBRANCE							
N 207103	001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1998			
		7456168	Jan 16, 2023	U-2515			
		RE47739	Jan 16, 2023	DS DP			
PALBOCICLIB - IBRANCE							
N 207103	002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1998			
		7456168	Jan 16, 2023	U-2515			
		RE47739	Jan 16, 2023	DS DP			
PALBOCICLIB - IBRANCE							
N 207103	003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1998			
		7456168	Jan 16, 2023	U-2515			
		RE47739	Jan 16, 2023	DS DP			
PALBOCICLIB - IBRANCE							
N 212436	001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-2515			
		RE47739	Jan 16, 2023	DS DP			
PALBOCICLIB - IBRANCE							
N 212436	002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-2515			
		RE47739	Jan 16, 2023	DS DP			
PALBOCICLIB - IBRANCE							
N 212436	003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-2515			
		RE47739	Jan 16, 2023	DS DP			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	001	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	002	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	003	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	004	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	005	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	001	10143693	Apr 05, 2036	U-2457			
		10143693	Apr 05, 2036	U-2458			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE PALMITATE - INVEGA TRINZA								
N 207946	002		10143693	Apr 05, 2036	U-2457			
			10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA								
N 207946	003		10143693	Apr 05, 2036	U-2457			
			10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA								
N 207946	004		10143693	Apr 05, 2036	U-2457			
			10143693	Apr 05, 2036	U-2458			
PALONOSETRON HYDROCHLORIDE - ALOXI								
N 021372	001		7947724	Jan 30, 2024	DP			
			7947724*PED	Jul 30, 2024				
			7947725	Jan 30, 2024	DP			
			7947725*PED	Jul 30, 2024				
			7960424	Jan 30, 2024	DP			
			7960424*PED	Jul 30, 2024				
			8518981	Jan 30, 2024	DP			
			8518981*PED	Jul 30, 2024				
			8598218	Jan 30, 2024	DP			
			8598218*PED	Jul 30, 2024				
			8598219	Jan 30, 2024	DP			
			8598219*PED	Jul 30, 2024				
			8729094	Jan 30, 2024	DP		U-528	
			8729094*PED	Jul 30, 2024				
			9066980	Jan 30, 2024	DP		U-528	
			9066980*PED	Jul 30, 2024				
			9125905	Jan 30, 2024	DP			
			9125905*PED	Jul 30, 2024				
			9173942	Jan 30, 2024	DP			
			9173942*PED	Jul 30, 2024				
			9439854	Jan 30, 2024	DP			
			9439854*PED	Jul 30, 2024				
			9457020	Jan 30, 2024	DP			
			9457020*PED	Jul 30, 2024				
			9457021	Jan 30, 2024	DP			
			9457021*PED	Jul 30, 2024				
PALONOSETRON HYDROCHLORIDE - ALOXI								
N 021372	002		7947724	Jan 30, 2024	DP			
			7947724*PED	Jul 30, 2024				
			7947725	Jan 30, 2024	DP			
			7947725*PED	Jul 30, 2024				
			7960424	Jan 30, 2024	DP			
			7960424*PED	Jul 30, 2024				
			8518981	Jan 30, 2024	DP			
			8518981*PED	Jul 30, 2024				
			8598218	Jan 30, 2024	DP			
			8598218*PED	Jul 30, 2024				
			9173942	Jan 30, 2024	DP			
			9173942*PED	Jul 30, 2024				
			9439854	Jan 30, 2024	DP			
			9439854*PED	Jul 30, 2024				
			9457020	Jan 30, 2024	DP			
			9457020*PED	Jul 30, 2024				
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP								
N 022210	001		7658918	Feb 20, 2028	DP			
			8221747	Feb 20, 2028	DP			
			8246950	Feb 20, 2028	U-1274			
			8562978	Feb 20, 2028	DP			
			8562979	Feb 20, 2028	DP		U-1274	
			8562980	Feb 20, 2028	DP		U-1274	
			8562981	Feb 20, 2028	U-1274			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP							
N 022210	002	7658918	Feb 20, 2028	DP			
		8221747	Feb 20, 2028	DP			
		8246950	Feb 20, 2028	U-1274			
		8562978	Feb 20, 2028	DP			
		8562979	Feb 20, 2028	DP U-1274			
		8562980	Feb 20, 2028	DP U-1274			
		8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP							
N 022210	003	7658918	Feb 20, 2028	DP			
		8221747	Feb 20, 2028	DP			
		8246950	Feb 20, 2028	U-1274			
		8562978	Feb 20, 2028	DP			
		8562979	Feb 20, 2028	DP U-1274			
		8562980	Feb 20, 2028	DP U-1274			
		8562981	Feb 20, 2028				
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP							
N 022210	004	7658918	Feb 20, 2028	DP			
		8221747	Feb 20, 2028	DP			
		8246950	Feb 20, 2028	U-1274			
		8562978	Feb 20, 2028	DP			
		8562979	Feb 20, 2028	DP U-1274			
		8562980	Feb 20, 2028	DP U-1274			
		8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP							
N 022210	005	8221747	Feb 20, 2028	DP			
		8562978	Feb 20, 2028	DP			
		8562979	Feb 20, 2028	DP U-1274			
		8562980	Feb 20, 2028	DP U-1274			
		8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP							
N 022210	006	8221747	Feb 20, 2028	DP			
		8562978	Feb 20, 2028	DP			
		8562979	Feb 20, 2028	DP U-1274			
		8562980	Feb 20, 2028	DP U-1274			
		8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP							
N 022210	007	8221747	Feb 20, 2028	DP			
		8562978	Feb 20, 2028	DP			
		8562979	Feb 20, 2028	DP U-1274			
		8562980	Feb 20, 2028	DP U-1274			
		8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE							
N 022523	005	8221747	Feb 20, 2028	DP			
		8562978	Feb 20, 2028	DP			
		8562979	Feb 20, 2028	DP U-1274			
		8562980	Feb 20, 2028	DP U-1274			
		8562981	Feb 20, 2028	DP U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON							
N 020725	001	9198871	Feb 07, 2030	DP U-1787			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON							
N 020725	002	9198871	Feb 07, 2030	DP U-1787			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON							
N 020725	003	9198871	Feb 07, 2030	DP U-1787			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON							
N 020725	004	9198871	Feb 07, 2030	DP U-1787			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON							
N 020725	005	9198871	Feb 07, 2030	DP U-1787			
PANOBINOSTAT LACTATE - FARYDAK							
N 205353	001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669			
		7989494	Jan 17, 2028	DS DP			
		8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK							
N 205353	002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669			
		7989494	Jan 17, 2028	DS DP			
		8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK							
N 205353	003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669			
		7989494	Jan 17, 2028	DS DP			
		8883842	Jun 13, 2028	U-1669			
PANTOPRAZOLE SODIUM - PROTONIX IV							
N 020988	001	6780881	Nov 17, 2021	DP			
		7351723	Nov 17, 2021	DP			
		8754108	Nov 17, 2021	DP			
		8754108*PED	May 17, 2022				
PANTOPRAZOLE SODIUM - PROTONIX							
N 022020	001	7544370	Jun 07, 2026	DP			
		7550153	Sep 30, 2024	U-859			
		7553498	Sep 30, 2024	U-859			
		7838027	Sep 30, 2024	DP U-859			
PARICALCITOL - ZEMPLAR							
N 021606	001					ODE-125	Oct 18, 2023
PARICALCITOL - ZEMPLAR							
N 021606	002					ODE-125	Oct 18, 2023
PARICALCITOL - ZEMPLAR							
N 021606	003					ODE-125	Oct 18, 2023
PAROXETINE MESYLATE - PEXEVA							
N 021299	001	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA							
N 021299	002	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA							
N 021299	003	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA							
N 021299	004	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - BRISDELLE							
N 204516	001	7598271	May 04, 2025	DS			
		8658663	Apr 06, 2029	DS DP U-904			
		8946251	Aug 04, 2026	DS DP U-904			
		9393237	Aug 04, 2026	U-904			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	001	7473761	Dec 14, 2026	DS DP			
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	002	7473761	Dec 14, 2026	DS DP			
		8299209	Dec 27, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	002	7473761	Dec 14, 2026	DS DP			
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	003	7473761	Dec 14, 2026	DS DP			
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	001	7473761	Dec 14, 2026	DS DP		I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268	Jun 29, 2025
		8822637	Aug 06, 2023	U-1629		ODE-81	Dec 15, 2021
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	002	7473761	Dec 14, 2026	DS DP		I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268	Jun 29, 2025
		8822637	Aug 06, 2023	U-1629		ODE-81	Dec 15, 2021
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	003	7473761	Dec 14, 2026	DS DP		I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268	Jun 29, 2025
		8822637	Aug 06, 2023	U-1629		ODE-81	Dec 15, 2021
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	004	7473761	Dec 14, 2026	DS DP		I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268	Jun 29, 2025
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	005	7473761	Dec 14, 2026	DS DP		I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-268	Jun 29, 2025
		9351923	May 23, 2028	DP			
PATIROMER SORBITEX CALCIUM - VELTASSA							
N 205739	001	10485821	Mar 30, 2024	U-1766		NCE	Oct 21, 2020
		7556799	Feb 27, 2025	U-1766			
		8147873	Jun 20, 2028	DP			
		8216560	Mar 14, 2027	U-1766			
		8282913	May 29, 2027	DP			
		8287847	Mar 30, 2024	U-1766			
		8337824	May 29, 2030	DS U-1766			
		8475780	Mar 30, 2024	U-1766			
		8778324	Mar 30, 2024	U-1766			
		8889115	Mar 30, 2024	U-1766			
		9492476	Oct 08, 2033	U-1766			
		9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA							
N 205739	002	10485821	Mar 30, 2024	U-1766		NCE	Oct 21, 2020
		7556799	Feb 27, 2025	U-1766			
		8147873	Jun 20, 2028	DP			
		8216560	Mar 14, 2027	U-1766			
		8282913	May 29, 2027	DP			
		8287847	Mar 30, 2024	U-1766			
		8337824	May 29, 2030	DS U-1766			
		8475780	Mar 30, 2024	U-1766			
		8778324	Mar 30, 2024	U-1766			
		8889115	Mar 30, 2024	U-1766			
		9492476	Oct 08, 2033	U-1766			
		9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA							
N 205739	003	10485821	Mar 30, 2024	U-1766		NCE	Oct 21, 2020
		7556799	Feb 27, 2025	U-1766			
		8147873	Jun 20, 2028	DP			
		8216560	Mar 14, 2027	U-1766			
		8282913	May 29, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PATIROMER SORBITEX CALCIUM - VELTASSA							
N 205739	003	8287847	Mar 30, 2024	U-1766			
		8337824	May 29, 2030	DS U-1766			
		8475780	Mar 30, 2024	U-1766			
		8778324	Mar 30, 2024	U-1766			
		8889115	Mar 30, 2024	U-1766			
		9492476	Oct 08, 2033	U-1766			
		9925212	Oct 08, 2033	U-1766			
PATISIRAN SODIUM - ONPATTRO							
N 210922	001	8058069	Apr 15, 2029	DP		NCE	Aug 10, 2023
		8158601	Nov 10, 2030	DP U-2378		ODE-197	Aug 10, 2025
		8168775	Oct 20, 2029	DS DP U-2378			
		8334373	May 27, 2025	DS DP			
		8362231	Mar 30, 2021	DS DP			
		8372968	Mar 30, 2021	DS DP			
		8492359	Apr 15, 2029	DP			
		8552171	Mar 30, 2021	DS DP			
		8642076	Oct 03, 2027	DP			
		8741866	Oct 20, 2029	U-2378			
		8778902	Mar 30, 2021	U-2378			
		8802644	Oct 21, 2030	DP U-2378			
		8822668	Apr 15, 2029	DP U-2378			
		8895718	Mar 30, 2021	DS DP			
		8895721	Mar 30, 2021	DS DP			
		9193753	Mar 30, 2021	U-2378			
		9234196	Oct 20, 2029	DP U-2378			
		9364435	Apr 15, 2029	DP U-2378			
		9567582	Mar 30, 2021	DS DP			
		9943538	Nov 04, 2023	DP			
		9943539	Nov 04, 2023	DP			
PAZOPANIB HYDROCHLORIDE - VOTRIENT							
N 022465	001	7105530	Oct 19, 2023	DS DP			
		7262203	Dec 19, 2021	DS DP			
		8114885	Dec 19, 2021	DS DP			
PAZOPANIB HYDROCHLORIDE - VOTRIENT							
N 022465	002	7105530	Oct 19, 2023	DS DP			
		7262203	Dec 19, 2021	DS DP			
		8114885	Dec 19, 2021	DS DP			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	001	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	002	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	003	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	004	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE								
N	202799	004	7550433	Jun 02, 2026	U-1238			
			7919118	May 12, 2024	DS DP			
			7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE								
N	202799	005	7084245	May 12, 2024	DS DP U-1238			
			7414105	May 12, 2024	DS DP U-1238			
			7528104	May 12, 2024	DS DP			
			7550433	Jun 02, 2026	U-1238			
			7919118	May 12, 2024	DS DP			
			7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE								
N	202799	006	7084245	May 12, 2024	DS DP U-1238			
			7414105	May 12, 2024	DS DP U-1238			
			7528104	May 12, 2024	DS DP			
			7550433	Jun 02, 2026	U-1238			
			7919118	May 12, 2024	DS DP			
			7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS								
N	202799	007	7084245	May 12, 2024	DS DP U-1238			
			7414105	May 12, 2024	DS DP U-1238			
			7528104	May 12, 2024	DS DP			
			7550433	Jun 02, 2026	U-1238			
			7919118	May 12, 2024	DS DP			
			7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS								
N	202799	008	7084245	May 12, 2024	DS DP U-1238			
			7414105	May 12, 2024	DS DP U-1238			
			7528104	May 12, 2024	DS DP			
			7550433	Jun 02, 2026	U-1238			
			7919118	May 12, 2024	DS DP			
			7919461	Jun 02, 2026	U-1238			
PEMETREXED DISODIUM - ALIMTA								
N	021462	001	7772209	Nov 24, 2021	U-1296			
PEMETREXED DISODIUM - ALIMTA								
N	021462	002	7772209	Nov 24, 2021	U-1296			
PENCICLOVIR - DENAVIR								
N	020629	001	6579981	Jun 17, 2020	U-501			
PERAMIVIR - RAPIVAB								
N	206426	001	10391075	Feb 12, 2027	U-2622		NPP	Sep 20, 2020
			6562861	Dec 16, 2023	DS			
			8778997	May 07, 2027	U-1627			
			8778997	May 07, 2027	U-2622			
PERAMPANEL - FYCOMPA								
N	202834	001	6949571	Jun 08, 2021	DS DP U-106			
			6949571	Jun 08, 2021	DS DP U-2088			
			6949571	Jun 08, 2021	DS DP U-2089			
			6949571	Jun 08, 2021	DS DP U-2428			
			6949571	Jun 08, 2021	DS DP U-2429			
			8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N	202834	002	6949571	Jun 08, 2021	DS DP U-106			
			6949571	Jun 08, 2021	DS DP U-2088			
			6949571	Jun 08, 2021	DS DP U-2089			
			6949571	Jun 08, 2021	DS DP U-2428			
			6949571	Jun 08, 2021	DS DP U-2429			
			8772497	Jul 01, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMPANEL - FYCOMPA								
N 202834	003		6949571	Jun 08, 2021	DS DP U-106			
			6949571	Jun 08, 2021	DS DP U-2088			
			6949571	Jun 08, 2021	DS DP U-2089			
			6949571	Jun 08, 2021	DS DP U-2428			
			6949571	Jun 08, 2021	DS DP U-2429			
			8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 202834	004		6949571	Jun 08, 2021	DS DP U-106			
			6949571	Jun 08, 2021	DS DP U-2088			
			6949571	Jun 08, 2021	DS DP U-2089			
			6949571	Jun 08, 2021	DS DP U-2428			
			6949571	Jun 08, 2021	DS DP U-2429			
			8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 202834	005		6949571	Jun 08, 2021	DS DP U-106			
			6949571	Jun 08, 2021	DS DP U-2088			
			6949571	Jun 08, 2021	DS DP U-2089			
			6949571	Jun 08, 2021	DS DP U-2428			
			6949571	Jun 08, 2021	DS DP U-2429			
			8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 202834	006		6949571	Jun 08, 2021	DS DP U-106			
			6949571	Jun 08, 2021	DS DP U-2088			
			6949571	Jun 08, 2021	DS DP U-2089			
			6949571	Jun 08, 2021	DS DP U-2428			
			6949571	Jun 08, 2021	DS DP U-2429			
			8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 208277	001		6949571	Jun 08, 2021	DS DP U-106			
			6949571	Jun 08, 2021	DS DP U-2088			
			6949571	Jun 08, 2021	DS DP U-2089			
			6949571	Jun 08, 2021	DS DP U-2428			
			6949571	Jun 08, 2021	DS DP U-2429			
			8772497	Jul 01, 2026	DS			
PERFLUTREN - DEFINITY								
N 021064	001		9789210	Mar 16, 2037	U-665			
PEXIDARTINIB HYDROCHLORIDE - TURALIO								
N 211810	001		10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
			10435404	Jul 24, 2038	DP		ODE-250	Aug 02, 2026
			7893075	Oct 13, 2028	DS			
			8404700	Nov 21, 2027	DS			
			8461169	Apr 19, 2028	U-2606			
			8722702	Nov 21, 2027	DS			
			9169250	Nov 21, 2027	DS			
			9358235	Jun 08, 2033	U-2606			
			9802932	May 05, 2036	DS			
PHENTERMINE HYDROCHLORIDE - SUPRENZA								
N 202088	001		8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA								
N 202088	002		8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA								
N 202088	003		8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA								
N 022580	001		7056890	Jun 14, 2020	DP U-1262			
			7553818	Jun 14, 2020	U-1262			
			7659256	Jun 14, 2020	DP U-1262			
			7674776	Jun 14, 2020	DP U-1262			
			8580298	May 15, 2029	DP			
			8580299	Jun 14, 2029	U-1262			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	001	8895057	Jun 09, 2028	U-1262			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	002	7056890	Jun 14, 2020	DP U-1262			
		7553818	Jun 14, 2020	U-1262			
		7659256	Jun 14, 2020	DP U-1262			
		7674776	Jun 14, 2020	DP U-1262			
		8580298	May 15, 2029	DP			
		8580299	Jun 14, 2029	U-1262			
		8895057	Jun 09, 2028	U-1262			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	003	7056890	Jun 14, 2020	DP U-1262			
		7553818	Jun 14, 2020	U-1262			
		7659256	Jun 14, 2020	DP U-1262			
		7674776	Jun 14, 2020	DP U-1262			
		8580298	May 15, 2029	DP			
		8580299	Jun 14, 2029	U-1262			
		8895057	Jun 09, 2028	U-1262			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	004	7056890	Jun 14, 2020	DP U-1262			
		7553818	Jun 14, 2020	U-1262			
		7659256	Jun 14, 2020	DP U-1262			
		7674776	Jun 14, 2020	DP U-1262			
		8580298	May 15, 2029	DP			
		8580299	Jun 14, 2029	U-1262			
		8895057	Jun 09, 2028	U-1262			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			
PHENTOLAMINE MESYLATE - ORAVERSE							
N 022159	001	6764678	May 11, 2021	U-967			
		6872390	May 11, 2021	DP			
		7229630	Jun 20, 2023	DP			
		7569230	Oct 17, 2023	U-967			
		7575757	Apr 21, 2025	DP			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE							
N 203510	001	8859623	Nov 14, 2033	U-1594			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE							
N 203510	002	8859623	Nov 14, 2033	U-1594			
PIMAVANSERIN TARTRATE - NUPLAZID							
N 207318	001	10028944	Jan 15, 2024	U-1974		NCE	Apr 29, 2021
		6756393	Mar 06, 2021	DS DP			
		6815458	Mar 06, 2021	DS DP U-1843			
		7115634	Oct 06, 2021	DS DP			
		7601740	Jun 17, 2027	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7858789	Dec 13, 2020	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8110574	Dec 13, 2020	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9296694	Mar 06, 2021	DS DP			
		9566271	Jan 15, 2024	U-1974			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIMAVANSERIN TARTRATE - NUPLAZID							
N 207318	001	9765053	Jul 27, 2022	U-1974			
PIMAVANSERIN TARTRATE - NUPLAZID							
N 207318	002	10028944	Jan 15, 2024	U-1974		NCE	Apr 29, 2021
		10517860	Mar 23, 2037	U-1974			
		6756393	Mar 06, 2021	DS DP			
		6815458	Mar 06, 2021	DS DP U-1843			
		7115634	Oct 06, 2021	DS DP			
		7601740	Jun 17, 2027	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7858789	Dec 13, 2020	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8110574	Dec 13, 2020	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9296694	Mar 06, 2021	DS DP			
		9566271	Jan 15, 2024	U-1974			
		9765053	Jul 27, 2022	U-1974			
PIMAVANSERIN TARTRATE - NUPLAZID							
N 210793	001	10028944	Jan 15, 2024	U-1974		NCE	Apr 29, 2021
		10449185	Aug 27, 2038	DP			
		6756393	Mar 06, 2021	DS DP			
		6815458	Mar 06, 2021	DS DP U-1843			
		7115634	Oct 06, 2021	DS DP			
		7601740	Jun 17, 2027	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7858789	Dec 13, 2020	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8110574	Dec 13, 2020	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9296694	Mar 06, 2021	DS DP			
		9566271	Jan 15, 2024	U-1974			
		9765053	Jul 27, 2022	U-1974			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	001	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	002	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	003	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	004	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	001	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	002	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	003	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIRFENIDONE - ESBRIET							
N 022535	001	7566729	Apr 22, 2029	U-1600		ODE-77	Oct 15, 2021
		7635707	Apr 22, 2029	U-1609			
		7696236	Dec 18, 2027	U-1601			
		7767225	Sep 22, 2026	DP U-1602			
		7767700	Dec 18, 2027	U-1601			
		7816383	Jan 08, 2030	U-1603			
		7910610	Jan 08, 2030	U-1604			
		7988994	Sep 22, 2026	DP U-1602			
		8013002	Jan 08, 2030	U-1603			
		8084475	Jan 08, 2030	U-1605			
		8318780	Jan 08, 2030	U-1606			
		8383150	Sep 22, 2026	DP U-2361			
		8420674	Dec 18, 2027	DP U-1608			
		8592462	Apr 22, 2029	U-1609			
		8609701	Apr 22, 2029	U-1610			
		8648098	Jan 08, 2030	U-1611			
		8753679	Sep 22, 2026	DP U-1602			
		8754109	Jan 08, 2030	U-1612			
		8778947	Aug 30, 2033	U-1613			
PIRFENIDONE - ESBRIET							
N 208780	001	10188637	Mar 28, 2037	DP		ODE-77	Oct 15, 2021
		7566729	Apr 22, 2029	U-2077			
		7566729	Apr 22, 2029	U-2078			
		7635707	Apr 22, 2029	U-2072			
		7635707	Apr 22, 2029	U-2073			
		7635707	Apr 22, 2029	U-2074			
		7635707	Apr 22, 2029	U-2075			
		7635707	Apr 22, 2029	U-2076			
		7635707	Apr 22, 2029	U-2083			
		7767700	Dec 18, 2027	U-2080			
		7816383	Jan 08, 2030	U-2042			
		7816383	Jan 08, 2030	U-2050			
		7910610	Jan 08, 2030	U-2048			
		7910610	Jan 08, 2030	U-2049			
		8013002	Jan 08, 2030	U-2047			
		8013002	Jan 08, 2030	U-2082			
		8084475	Jan 08, 2030	U-2052			
		8084475	Jan 08, 2030	U-2054			
		8318780	Jan 08, 2030	U-2046			
		8318780	Jan 08, 2030	U-2081			
		8383150	Sep 22, 2026	DP U-2361			
		8420674	Dec 18, 2027	U-2079			
		8592462	Apr 22, 2029	U-2055			
		8592462	Apr 22, 2029	U-2056			
		8592462	Apr 22, 2029	U-2057			
		8592462	Apr 22, 2029	U-2058			
		8592462	Apr 22, 2029	U-2059			
		8592462	Apr 22, 2029	U-2060			
		8592462	Apr 22, 2029	U-2061			
		8592462	Apr 22, 2029	U-2062			
		8592462	Apr 22, 2029	U-2063			
		8609701	Apr 22, 2029	U-2064			
		8609701	Apr 22, 2029	U-2065			
		8609701	Apr 22, 2029	U-2066			
		8609701	Apr 22, 2029	U-2067			
		8609701	Apr 22, 2029	U-2068			
		8609701	Apr 22, 2029	U-2069			
		8609701	Apr 22, 2029	U-2070			
		8648098	Jan 08, 2030	U-2051			
		8648098	Jan 08, 2030	U-2052			
		8754109	Jan 08, 2030	U-2053			
		8778947	Aug 30, 2033	U-2044			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 208780 001	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
PIRFENIDONE - ESBRIET						
N 208780 002	10188637	Mar 28, 2037	DP		ODE-77	Oct 15, 2021
	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
PIRFENIDONE - ESBRIET						
N 208780 003	10188637	Mar 28, 2037	DP		ODE-77	Oct 15, 2021
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET							
N 208780	003	8318780	Jan 08, 2030	U-2046			
		8318780	Jan 08, 2030	U-2081			
		8383150	Sep 22, 2026	DP U-2361			
		8420674	Dec 18, 2027	U-2079			
		8592462	Apr 22, 2029	U-2055			
		8592462	Apr 22, 2029	U-2056			
		8592462	Apr 22, 2029	U-2057			
		8592462	Apr 22, 2029	U-2058			
		8592462	Apr 22, 2029	U-2059			
		8592462	Apr 22, 2029	U-2060			
		8592462	Apr 22, 2029	U-2061			
		8592462	Apr 22, 2029	U-2062			
		8592462	Apr 22, 2029	U-2063			
		8609701	Apr 22, 2029	U-2064			
		8609701	Apr 22, 2029	U-2065			
		8609701	Apr 22, 2029	U-2066			
		8609701	Apr 22, 2029	U-2067			
		8609701	Apr 22, 2029	U-2068			
		8609701	Apr 22, 2029	U-2069			
		8609701	Apr 22, 2029	U-2070			
		8648098	Jan 08, 2030	U-2051			
		8648098	Jan 08, 2030	U-2052			
		8754109	Jan 08, 2030	U-2053			
		8778947	Aug 30, 2033	U-2044			
		8778947	Aug 30, 2033	U-2045			
		9561217	Jan 25, 2022	DP			
PITAVASTATIN CALCIUM - LIVALO							
N 022363	001	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
		5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
		7022713	Feb 19, 2024	U-998			
		7022713*PED	Aug 19, 2024				
		8557993	Feb 02, 2024	DP			
		8557993*PED	Aug 02, 2024				
PITAVASTATIN CALCIUM - LIVALO							
N 022363	002	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
		5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
		7022713	Feb 19, 2024	U-998			
		7022713*PED	Aug 19, 2024				
		8557993	Feb 02, 2024	DP			
		8557993*PED	Aug 02, 2024				
PITAVASTATIN CALCIUM - LIVALO							
N 022363	003	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
		5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
		7022713	Feb 19, 2024	U-998			
		7022713*PED	Aug 19, 2024				
		8557993	Feb 02, 2024	DP			
		8557993*PED	Aug 02, 2024				
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	001	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	002	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	003	8829186	Jan 19, 2031	DS DP			
PITOLISANT HYDROCHLORIDE - WAKIX							
N 211150	001	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
		7910605	Sep 23, 2022	U-1101		ODE-255	Aug 14, 2026
		8207197	Feb 25, 2029	DS DP			
		8354430	Feb 26, 2026	U-1101			
		8486947	Sep 26, 2029	U-1101			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PITOLISANT HYDROCHLORIDE - WAKIX							
N 211150	002	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
		7910605	Sep 23, 2022	U-1101		ODE-255	Aug 14, 2026
		8207197	Feb 25, 2029	DS DP			
		8354430	Feb 26, 2026	U-1101			
		8486947	Sep 26, 2029	U-1101			
PLAZOMICIN SULFATE - ZEMDRI							
N 210303	001	8383596	Jun 02, 2031	DS U-2328		NCE	Jun 25, 2023
		8822424	Nov 21, 2028	DP		GAIN	Jun 25, 2028
		9266919	Nov 21, 2028	U-2328			
		9688711	Nov 21, 2028	DS U-2328			
PLECANATIDE - TRULANCE							
N 208745	001	10011637	Jun 05, 2034	DS		I-764	Jan 24, 2021
		7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
		7799897	Jun 09, 2022	DS			
		8637451	Mar 28, 2022	U-1964			
		9610321	Sep 15, 2031	U-1999			
		9610321	Sep 15, 2031	U-2230			
		9616097	Jul 02, 2032	DP			
		9919024	Sep 15, 2031	U-1999			
		9919024	Sep 15, 2031	U-2230			
		9925231	Sep 15, 2031	DP			
PLERIXAFOR - MOZOBIL							
N 022311	001	6987102	Jul 22, 2023	U-936			
		7897590	Jul 22, 2023	U-936			
POLIDOCANOL - VARITHENA							
N 205098	001	6572873	May 26, 2020	U-1461			
		6846412	Jul 19, 2022	DP			
		6942165	May 26, 2020	DP			
		7025290	May 26, 2020	DP U-1461			
		7357336	May 26, 2020	U-1461			
		7604185	May 26, 2020	DS DP U-1462			
		7731986	Nov 17, 2024	DS DP U-1463			
		7814943	Nov 19, 2027	DP U-1461			
		7842282	May 26, 2020	U-1461			
		7842283	May 26, 2020	DP			
		8122917	Sep 09, 2024	DP			
		8323677	May 26, 2020	DS			
		8734833	May 26, 2020	DS DP			
		9480652	May 12, 2032	DP			
POMALIDOMIDE - POMALYST							
N 204026	001	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361			
		6755784	Oct 23, 2020	U-1361			
		8198262	Jun 17, 2025	U-1360			
		8198262	Jun 17, 2025	U-2254			
		8315886	Oct 23, 2020	U-1361			
		8626531	Oct 23, 2020	U-1361			
		8673939	May 15, 2023	U-1360			
		8673939	May 15, 2023	U-2254			
		8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8828427	Jun 21, 2031	DS DP			
		9993467	May 19, 2030	DP			
POMALIDOMIDE - POMALYST							
N 204026	002	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361			
		6755784	Oct 23, 2020	U-1361			
		8198262	Jun 17, 2025	U-1360			
		8198262	Jun 17, 2025	U-2254			
		8315886	Oct 23, 2020	U-1361			
		8626531	Oct 23, 2020	U-1361			
		8673939	May 15, 2023	U-1360			
		8673939	May 15, 2023	U-2254			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POMALIDOMIDE - POMALYST							
N 204026	002	8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8828427	Jun 21, 2031	DS DP			
		9993467	May 19, 2030	DP			
POMALIDOMIDE - POMALYST							
N 204026	003	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361			
		6755784	Oct 23, 2020	U-1361			
		8198262	Jun 17, 2025	U-1360			
		8198262	Jun 17, 2025	U-2254			
		8315886	Oct 23, 2020	U-1361			
		8626531	Oct 23, 2020	U-1361			
		8673939	May 15, 2023	U-1360			
		8673939	May 15, 2023	U-2254			
		8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8828427	Jun 21, 2031	DS DP			
		9993467	May 19, 2030	DP			
POMALIDOMIDE - POMALYST							
N 204026	004	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361			
		6755784	Oct 23, 2020	U-1361			
		8198262	Jun 17, 2025	U-1360			
		8198262	Jun 17, 2025	U-2254			
		8315886	Oct 23, 2020	U-1361			
		8626531	Oct 23, 2020	U-1361			
		8673939	May 15, 2023	U-1360			
		8673939	May 15, 2023	U-2254			
		8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8828427	Jun 21, 2031	DS DP			
		9993467	May 19, 2030	DP			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469	001	8114874	Dec 22, 2026	DS DP			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
		9029533	Dec 22, 2026	U-836			
		9493470	Dec 12, 2033	DS DP U-1700			
		9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469	002	8114874	Dec 22, 2026	DS DP			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
		9029533	Dec 22, 2026	U-836			
		9493470	Dec 12, 2033	DS DP U-1700			
		9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469	003	8114874	Dec 22, 2026	DS DP			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
		9029533	Dec 22, 2026	U-836			
		9493470	Dec 12, 2033	DS DP U-1700			
		9493470	Dec 12, 2033	DS DP U-1948			
POSACONAZOLE - NOXAFIL							
N 022003	001	8263600	Apr 01, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POSACONAZOLE - NOXAFIL								
N 205596	001		10117951	Mar 13, 2029	DP			
			8410077	Mar 13, 2029	DP			
			9023790	Jul 04, 2031	DP U-1698			
			9358297	Jun 24, 2031	DP U-1454			
			9493582	Feb 27, 2033	DP			
			9750822	Mar 13, 2029	DP			
PRALATREXATE - FOLOTYN								
N 022468	001		6028071	Jul 16, 2022	DS DP U-1004			
			7622470	May 31, 2025	U-1015			
			8299078	May 31, 2025	U-1004			
PRALATREXATE - FOLOTYN								
N 022468	002		6028071	Jul 16, 2022	DS DP U-1004			
			7622470	May 31, 2025	U-1015			
			8299078	May 31, 2025	U-1004			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	001		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	002		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	003		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	004		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	005		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	006		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	007		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRASTERONE - INTRAROSA								
N 208470	001		8268806	Mar 19, 2031	DP		NCE	Nov 16, 2021
			8629129	Aug 07, 2028	DP			
			8957054	Aug 07, 2028	U-1922			
PREDNISOLONE ACETATE - FLO-PRED								
N 022067	001		7799331	Oct 11, 2028	DP U-1068			
			7799331	Oct 11, 2028	DP U-139			
PREDNISOLONE ACETATE - FLO-PRED								
N 022067	002		7799331	Oct 11, 2028	DP U-1068			
			7799331	Oct 11, 2028	DP U-139			
PREDNISONE - RAYOS								
N 202020	001		6488960	Mar 14, 2020	DP U-1267			
			6677326	Mar 14, 2020	DP U-1268			
			8309124	Apr 23, 2024	U-1292			
			8394407	Apr 23, 2024	DP U-1362			
			9040085	Apr 23, 2024	U-1362			
			9186332	Apr 23, 2024	U-1362			
			9504699	Aug 03, 2027	U-1362			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREDNISONE - RAYOS						
N 202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREDNISONE - RAYOS						
N 202020 003	8168218	Jan 07, 2028	DP U-1269			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREGABALIN - LYRICA						
N 021446 001					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA						
N 021446 002					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA						
N 021446 003					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA						
N 021446 004					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA						
N 021446 005					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA						
N 021446 006					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA						
N 021446 007					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA						
N 021446 008					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA						
N 022488 001					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREGABALIN - LYRICA						
N 022488 001					NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
PREGABALIN - LYRICA CR						
N 209501 001	10022447	Nov 02, 2026	U-2136		NP	Oct 11, 2020
	10022447	Nov 02, 2026	U-2137		PED	Apr 11, 2021
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PREGABALIN - LYRICA CR						
N 209501 002	10022447	Nov 02, 2026	U-2136		NP	Oct 11, 2020
	10022447	Nov 02, 2026	U-2137		PED	Apr 11, 2021
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PREGABALIN - LYRICA CR						
N 209501 003	10022447	Nov 02, 2026	U-2136		NP	Oct 11, 2020
	10022447	Nov 02, 2026	U-2137		PED	Apr 11, 2021
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PRETOMANID - PRETOMANID						
N 212862 001					NCE	Aug 14, 2024
					ODE-253	Aug 14, 2026
					GAIN	Aug 14, 2029
PROPOFOL - DIPRIVAN						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL						
N 021438 001	6500454	Oct 04, 2021	DP			
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL						
N 021438 002	6500454	Oct 04, 2021	DP			
PROPRANOLOL HYDROCHLORIDE - HEMANGEOL						
N 205410 001	8338489	Oct 16, 2028	U-1496		ODE-62	Mar 14, 2021
	8987262	Oct 16, 2028	U-1988			
PRUCALOPRIDE SUCCINATE - MOTEGRITY						
N 210166 001					NCE	Dec 14, 2023
PRUCALOPRIDE SUCCINATE - MOTEGRITY						
N 210166 002					NCE	Dec 14, 2023
QUAZEPAM - DORAL						
N 018708 001	7608616	Jun 03, 2028	U-1012			
QUAZEPAM - DORAL						
N 018708 003	7608616	Jun 03, 2028	U-1012			
RADIUM RA-223 DICHLORIDE - XOFIGO						
N 203971 001	6635234	Nov 17, 2022	U-2271			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RALTEGRAVIR POTASSIUM - ISENTRESS								
N 022145	001	7169780		Oct 03, 2023	DS DP		D-167	May 26, 2020
		7169780*PED		Apr 03, 2024			NPP	Nov 22, 2020
		7217713		Oct 21, 2022	U-257		PED	Nov 26, 2020
		7217713*PED		Apr 21, 2023			PED	May 22, 2021
		7435734		Oct 21, 2022	U-257			
		7435734		Oct 21, 2022	U-900			
		7435734*PED		Apr 21, 2023				
		7754731		Mar 11, 2029	DS DP U-257			
		7754731*PED		Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS HD								
N 022145	002	7169780		Oct 03, 2023	DS DP		NPP	Nov 22, 2020
		7169780*PED		Apr 03, 2024			NS	May 26, 2020
		7217713		Oct 21, 2022	U-257		PED	Nov 26, 2020
		7217713*PED		Apr 21, 2023			PED	May 22, 2021
		7435734		Oct 21, 2022	U-257			
		7435734		Oct 21, 2022	U-900			
		7435734*PED		Apr 21, 2023				
		7754731		Mar 11, 2029	DS DP U-257			
		7754731*PED		Sep 11, 2029				
		9649311		Oct 21, 2030	DP			
		9649311*PED		Apr 21, 2031				
RALTEGRAVIR POTASSIUM - ISENTRESS								
N 203045	001	7169780		Oct 03, 2023	DS DP		NPP	Nov 22, 2020
		7169780*PED		Apr 03, 2024			PED	May 22, 2021
		7217713		Oct 21, 2022	U-257			
		7217713*PED		Apr 21, 2023				
		7435734		Oct 21, 2022	U-257			
		7435734*PED		Apr 21, 2023				
		7754731		Mar 11, 2029	DS DP U-257			
		7754731*PED		Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS								
N 203045	002	7169780		Oct 03, 2023	DS DP		NPP	Nov 22, 2020
		7169780*PED		Apr 03, 2024			PED	May 22, 2021
		7217713		Oct 21, 2022	U-257			
		7217713*PED		Apr 21, 2023				
		7435734		Oct 21, 2022	U-257			
		7435734*PED		Apr 21, 2023				
		7754731		Mar 11, 2029	DS DP U-257			
		7754731*PED		Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS								
N 205786	001	7169780		Oct 03, 2023	DS DP		NPP	Nov 22, 2020
		7169780*PED		Apr 03, 2024			PED	May 22, 2021
		7217713		Oct 21, 2022	U-257			
		7217713*PED		Apr 21, 2023				
		7435734		Oct 21, 2022	U-257			
		7435734*PED		Apr 21, 2023				
		7754731		Mar 11, 2029	DS DP U-257			
		7754731*PED		Sep 11, 2029				
RAMELTEON - ROZEREM								
N 021782	001	10098866		Nov 16, 2021	DP U-2433			
RAMIPRIL - ALTACE								
N 019901	001	7368469		Aug 30, 2020	U-871			
RAMIPRIL - ALTACE								
N 019901	002	7368469		Aug 30, 2020	U-871			
RAMIPRIL - ALTACE								
N 019901	003	7368469		Aug 30, 2020	U-871			
RAMIPRIL - ALTACE								
N 019901	004	7368469		Aug 30, 2020	U-871			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RAMIPRIL - ALTACE								
N	022021	001	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE								
N	022021	002	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE								
N	022021	003	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE								
N	022021	004	7368469	Aug 30, 2020	U-871			
RASAGILINE MESYLATE - AZILECT								
N	021641	001	7572834	Dec 05, 2026	DP			
			7815942	Aug 27, 2027	DS DP U-219			
RASAGILINE MESYLATE - AZILECT								
N	021641	002	7572834	Dec 05, 2026	DP			
			7815942	Aug 27, 2027	DS DP U-219			
REGADENOSON - LEXISCAN								
N	022161	001	6403567	Apr 10, 2022	DS DP U-869		M-194	Jan 17, 2020
			8106183	Feb 02, 2027	DS			
			RE47301	Feb 02, 2027	DP			
REGORAFENIB - STIVARGA								
N	203085	001	7351834	Jun 28, 2022	DS		I-744	Apr 27, 2020
			8637553	Feb 16, 2031	DS DP		ODE-139	Apr 27, 2024
			8680124	Jun 02, 2030	U-1506		ODE-44	Feb 25, 2020
			9458107	Apr 08, 2031	DP			
			9957232	Jul 09, 2032	DS			
RETAPAMULIN - ALTABAX								
N	022055	001	7875630	Feb 14, 2027	DS			
			8207191	Aug 30, 2024	U-805			
			RE43390	Apr 12, 2021	DS DP U-805			
REVEFENACIN - YUPELRI								
N	210598	001	10106503	Mar 10, 2025	U-2440		NCE	Nov 09, 2023
			10343995	Mar 10, 2025	U-2440			
			7288657	Dec 23, 2025	DS			
			7491736	Mar 10, 2025	U-2440			
			7521041	Mar 10, 2025	U-2440			
			7550595	Mar 10, 2025	DP			
			7585879	Mar 10, 2025	DS DP U-2440			
			7910608	Mar 10, 2025	DS DP			
			8034946	Mar 10, 2025	DP			
			8053448	Mar 10, 2025	U-2440			
			8273894	Mar 10, 2025	DP			
			8541451	Aug 25, 2031	DS			
			9765028	Jul 14, 2030	DS			
RIBAVIRIN - REBETOL								
N	021546	001	6790837	Apr 05, 2023	DP			
RIBOCICLIB SUCCINATE - KISQALI								
N	209092	001	8324225	Jun 17, 2028	DS DP		I-783	Jul 18, 2021
			8415355	Feb 19, 2031	DS DP		I-784	Jul 18, 2021
			8685980	May 25, 2030	DS DP		NCE	Mar 13, 2022
			8962630	Dec 09, 2029	U-1981			
			8962630	Dec 09, 2029	U-2355			
			8962630	Dec 09, 2029	U-2356			
			9193732	Nov 09, 2031	DS DP			
			9416136	Aug 20, 2029	U-1981			
			9416136	Aug 20, 2029	U-2355			
			9416136	Aug 20, 2029	U-2356			
			9868739	Nov 09, 2031	U-1981			
			9868739	Nov 09, 2031	U-2355			
			9868739	Nov 09, 2031	U-2356			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA							
N 203324	001					ODE-116	Apr 15, 2023
						ODE-121	Jul 15, 2023
RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%							
N 203324	002					ODE-116	Apr 15, 2023
						ODE-121	Jul 15, 2023
RIFAMYCIN SODIUM - AEMCOLO							
N 210910	001	8263120	May 03, 2025	DP			
		8486446	May 03, 2025	DP			
		8529945	May 03, 2025	DP			
		8741948	May 03, 2025	DP U-2448			
RIFAXIMIN - XIFAXAN							
N 021361	001	7045620	Jun 19, 2024	DS DP			
		7612199	Jun 19, 2024	DS DP			
		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
		7928115	Jul 24, 2029	U-1121			
		8158644	Jun 19, 2024	DP			
		8158781	Jun 19, 2024	DS			
		8193196	Sep 02, 2027	DS DP			
		8518949	Feb 27, 2026	DP			
		8741904	Feb 27, 2026	DS U-1526			
		8835452	Jun 19, 2024	DS DP			
		8853231	Jun 19, 2024	DP			
		9271968	Feb 27, 2026	DP			
RIFAXIMIN - XIFAXAN							
N 022554	001	10314828	Oct 02, 2029	U-1481			
		10335397	Oct 02, 2029	U-2579			
		10456384	Feb 26, 2029	U-2643			
		10456384	Feb 26, 2029	U-2644			
		7045620	Jun 19, 2024	DS			
		7612199	Jun 19, 2024	DS DP			
		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
		7915275	Feb 23, 2025	U-1707			
		7915275	Feb 23, 2025	U-1708			
		8158644	Jun 19, 2024	DP			
		8158781	Jun 19, 2024	DS			
		8193196	Sep 02, 2027	DS DP U-1707			
		8193196	Sep 02, 2027	DS DP U-1708			
		8309569	Jul 18, 2029	U-1707			
		8309569	Jul 18, 2029	U-1708			
		8518949	Feb 27, 2026	DP			
		8642573	Oct 02, 2029	U-1481			
		8741904	Feb 27, 2026	DS U-1526			
		8741904	Feb 27, 2026	DS U-1707			
		8741904	Feb 27, 2026	DS U-1708			
		8829017	Jul 24, 2029	U-1562			
		8835452	Jun 19, 2024	DS DP			
		8853231	Jun 19, 2024	DP			
		8946252	Jul 24, 2029	U-1481			
		8969398	Oct 02, 2029	U-1481			
		9271968	Feb 27, 2026	DP			
		9421195	Mar 10, 2030	U-1481			
		9629828	Jul 24, 2029	U-1994			
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N 202022	001	6838464	Feb 26, 2021	DS DP		M-223	Feb 01, 2021
		7125879	Apr 21, 2025	DS DP U-1153			
		7125879	Apr 21, 2025	DS DP U-1307			
		7125879	Apr 21, 2025	DS DP U-1740			
		7638522	Apr 14, 2023	DP			
		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RILUZOLE - TIGLUTIK KIT							
N 209080	001	8765150	Mar 12, 2029	DP U-2401			
RIOCIGUAT - ADEMPAS							
N 204819	001	7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
RIOCIGUAT - ADEMPAS							
N 204819	002	7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
RIOCIGUAT - ADEMPAS							
N 204819	003	7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
RIOCIGUAT - ADEMPAS							
N 204819	004	7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
RIOCIGUAT - ADEMPAS							
N 204819	005	7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
RISEDRONATE SODIUM - ACTONEL							
N 020835	005	7192938	May 06, 2023	U-353			
		7718634	May 06, 2023	U-662			
RISEDRONATE SODIUM - ATELVIA							
N 022560	001	7645459	Jan 09, 2028	DP U-662			
		7645460	Jan 09, 2028	DP U-662			
		8246989	Jan 16, 2026	DP			
RISPERIDONE - RISPERDAL CONSTA							
N 021346	001	6667061	May 25, 2020	DP			
RISPERIDONE - RISPERDAL CONSTA							
N 021346	002	6667061	May 25, 2020	DP			
RISPERIDONE - RISPERDAL CONSTA							
N 021346	003	6667061	May 25, 2020	DP			
RISPERIDONE - PERSERIS KIT							
N 210655	001	10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
		10058554	Sep 26, 2026	U-2363			
		10376590	Feb 13, 2028	U-2608			
		10406160	Jun 26, 2026	DP U-2608			
		9180197	Feb 13, 2028	DP			
		9186413	Feb 13, 2028	U-543			
		9597402	Sep 26, 2026	DP			
RISPERIDONE - PERSERIS KIT							
N 210655	002	10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
		10058554	Sep 26, 2026	U-2363			
		10376590	Feb 13, 2028	U-2608			
		10406160	Jun 26, 2026	DP U-2608			
		9180197	Feb 13, 2028	DP			
		9186413	Feb 13, 2028	U-543			
		9597402	Sep 26, 2026	DP			
RITONAVIR - NORVIR							
N 020945	001	7141593	May 22, 2020	DP			
		7432294	May 22, 2020	DP			
RITONAVIR - NORVIR							
N 022417	001	7364752	Nov 10, 2020	DP U-688			
		8268349	Aug 25, 2024	DP			
		8399015	Aug 25, 2024	DP			
		8399015*PED	Feb 25, 2025				
		8470347	Sep 17, 2026	DP			
		8470347*PED	Mar 17, 2027				
		8691878	Aug 25, 2024	U-688			
		8691878*PED	Feb 25, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RITONAVIR - NORVIR						
N 209512 001					ODE-184	Jun 07, 2024
RIVAROXABAN - XARELTO						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301		D-168	Oct 27, 2020
	7157456	Aug 28, 2024	DS DP U-1302		I-810	Oct 11, 2022
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	7592339	Dec 11, 2020	U-2142			
	7592339	Dec 11, 2020	U-2640			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
RIVAROXABAN - XARELTO						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301		I-810	Oct 11, 2022
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
RIVAROXABAN - XARELTO						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301		I-810	Oct 11, 2022
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
RIVAROXABAN - XARELTO						
N 022406 004	7157456	Aug 28, 2024	DS DP		I-810	Oct 11, 2022
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-2435			
	9415053	Nov 13, 2024	DP U-2435			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO							
N 022406	004	7157456	Aug 28, 2024	DS DP		I-810	Oct 11, 2022
		7585860	Dec 11, 2020	DS			
		7592339	Dec 11, 2020	U-2435			
		9415053	Nov 13, 2024	DP U-2435			
ROFLUMILAST - DALIRESP							
N 022522	001	5712298	Jan 27, 2020	DS DP U-1115		D-171	Jan 23, 2021
		8431154	Feb 19, 2023	DP		M-208	Aug 31, 2020
		8536206	Mar 08, 2024	U-1115			
		8604064	Mar 08, 2024	U-1115			
		8618142	Mar 08, 2024	DP			
		9468598	Feb 19, 2023	DP			
ROFLUMILAST - DALIRESP							
N 022522	002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
		8431154	Feb 19, 2023	DP			
		8536206	Mar 08, 2024	U-1115			
		8604064	Mar 08, 2024	U-1115			
		8618142	Mar 08, 2024	DP			
		9468598	Feb 19, 2023	DP			
ROLAPITANT HYDROCHLORIDE - VARUBI							
N 206500	001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
		7563801	Apr 04, 2027	DP			
		7981905	Apr 04, 2027	U-1741			
		8178550	Apr 04, 2027	DS DP			
		8361500	Oct 09, 2029	DP			
		8404702	Apr 04, 2027	U-1741			
		8470842	Jan 18, 2029	U-1741			
		8796299	Dec 17, 2022	U-1741			
ROLAPITANT HYDROCHLORIDE - VARUBI							
N 208399	001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
		7981905	Apr 04, 2027	U-1741			
		8178550	Apr 04, 2027	DS DP			
		8404702	Apr 04, 2027	U-1741			
		8470842	Jan 18, 2029	U-1741			
		8796299	Dec 17, 2022	U-1741			
		9101615	Jul 14, 2032	U-1741			
ROMIDEPSIN - ISTODAX							
N 022393	001	7608280	Aug 22, 2021	DS			
		7611724	Aug 22, 2021	DS			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	001	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	002	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	003	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	004	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	005	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	006	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROPIVACAINE HYDROCHLORIDE - NAROPIN							
N 020533	006	7828787	Oct 18, 2025	DP			
		7857802	Nov 28, 2026	DP			
		8118802	May 18, 2023	DP			
		8162915	May 23, 2024	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN							
N 020533	007	7828787	Oct 18, 2025	DP			
		7857802	Nov 28, 2026	DP			
		8118802	May 18, 2023	DP			
		8162915	May 23, 2024	DP			
ROSIGLITAZONE MALEATE - AVANDIA							
N 021071	002	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
ROSIGLITAZONE MALEATE - AVANDIA							
N 021071	003	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
ROSIGLITAZONE MALEATE - AVANDIA							
N 021071	004	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	002	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
		6858618	Dec 17, 2021	U-1032			
		6858618	Dec 17, 2021	U-1807			
		6858618	Dec 17, 2021	U-618			
		6858618*PED	Jun 17, 2022				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	003	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
		6858618	Dec 17, 2021	U-1032			
		6858618	Dec 17, 2021	U-1807			
		6858618	Dec 17, 2021	U-618			
		6858618*PED	Jun 17, 2022				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	004	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
		6858618	Dec 17, 2021	U-1032			
		6858618	Dec 17, 2021	U-1807			
		6858618	Dec 17, 2021	U-618			
		6858618*PED	Jun 17, 2022				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	005	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
		6858618	Dec 17, 2021	U-618			
ROSUVASTATIN CALCIUM - EZALLOR							
N 208647	001	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR							
N 208647	002	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR							
N 208647	003	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR							
N 208647	004	10413543	Feb 12, 2036	DP			
ROTIGOTINE - NEUPRO							
N 021829	001	10130589	Dec 22, 2030	DP			
		10350174	Dec 22, 2030	DP			
		6699498	Nov 27, 2020	DP			
		6884434	Mar 30, 2021	DP			
		8246979	Sep 01, 2027	DP U-1272			
		8246979	Sep 01, 2027	DP U-1273			
		8246980	Nov 27, 2025	DP			
		8617591	Jul 22, 2023	DP U-1474			
		9925150	Mar 01, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROTIGOTINE - NEUPRO						
N 021829 001	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 002	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 003	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 004	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 005	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 006	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001	10130636	Aug 17, 2035	U-2012		I-772	Apr 06, 2021
	10130636	Aug 17, 2035	U-2101		NCE	Dec 19, 2021
	10130636	Aug 17, 2035	U-2273		ODE-126	Dec 19, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001	10278974	Feb 10, 2031	DP		ODE-168	Apr 06, 2025
	6495541	Jan 10, 2021	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	10130636	Aug 17, 2035	U-2012		I-772	Apr 06, 2021
	10130636	Aug 17, 2035	U-2101		NCE	Dec 19, 2021
	10130636	Aug 17, 2035	U-2273		ODE-126	Dec 19, 2023
	10278974	Feb 10, 2031	DP		ODE-168	Apr 06, 2025
	6495541	Jan 10, 2021	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 003	10130636	Aug 17, 2035	U-2012		I-772	Apr 06, 2021
	10130636	Aug 17, 2035	U-2101		NCE	Dec 19, 2021
	10130636	Aug 17, 2035	U-2273		ODE-126	Dec 19, 2023
	10278974	Feb 10, 2031	DP		ODE-168	Apr 06, 2025
	6495541	Jan 10, 2021	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA							
N 209115	003	8143241	Aug 12, 2027	U-2101			
		8143241	Aug 12, 2027	U-2273			
		8754072	Feb 10, 2031	DS DP			
		8859562	Aug 04, 2031	U-2012			
		8859562	Aug 04, 2031	U-2101			
		8859562	Aug 04, 2031	U-2273			
		9045487	Feb 10, 2031	DS DP			
		9861638	Feb 10, 2031	U-2012			
		9861638	Feb 10, 2031	U-2101			
		9861638	Feb 10, 2031	U-2273			
		9987285	Aug 17, 2035	DP			
RUFINAMIDE - BANZEL							
N 021911	001	6740669	Nov 14, 2022	DS DP			
		6740669*PED	May 14, 2023				
RUFINAMIDE - BANZEL							
N 021911	002	6740669	Nov 14, 2022	DS DP			
		6740669*PED	May 14, 2023				
RUFINAMIDE - BANZEL							
N 021911	003	6740669	Nov 14, 2022	DS DP			
		6740669*PED	May 14, 2023				
RUFINAMIDE - BANZEL							
N 201367	001	6740669	Nov 14, 2022	DS DP			
		6740669*PED	May 14, 2023				
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	001	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP U-1201		ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP U-1622		ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
		9814722	Dec 12, 2026	U-2536			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	002	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP U-1201		ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP U-1622		ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
		9814722	Dec 12, 2026	U-2536			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	003	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP U-1201		ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP U-1622		ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
		9814722	Dec 12, 2026	U-2536			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	004	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP U-1201		ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP U-1622		ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
		9814722	Dec 12, 2026	U-2536			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	005	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP U-1201		ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP U-1622		ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
		9814722	Dec 12, 2026	U-2536			
SACROSIDASE - SUCRAID							
N 020772	001	9255261	Feb 07, 2034	DS DP			
		9469847	Feb 07, 2034	DS DP			
		9849161	Feb 07, 2034	DS DP			
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620	001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
		7468390*PED	May 27, 2024			NPP	Oct 01, 2022
		8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
		8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
		8404744	Jan 14, 2023	DP			
		8404744*PED	Jul 14, 2023				
		8796331	Jan 14, 2023	U-1723			
		8796331*PED	Jul 14, 2023				
		8877938	May 27, 2027	DS DP			
		8877938*PED	Nov 27, 2027				
		9388134	Nov 08, 2026	U-1723			
		9388134*PED	May 08, 2027				
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620	002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
		7468390*PED	May 27, 2024			NPP	Oct 01, 2022
		8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
		8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
		8404744	Jan 14, 2023	DP			
		8404744*PED	Jul 14, 2023				
		8796331	Jan 14, 2023	U-1723			
		8796331*PED	Jul 14, 2023				
		8877938	May 27, 2027	DS DP			
		8877938*PED	Nov 27, 2027				
		9388134	Nov 08, 2026	U-1723			
		9388134*PED	May 08, 2027				
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620	003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
		7468390*PED	May 27, 2024			NPP	Oct 01, 2022
		8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
		8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
		8404744	Jan 14, 2023	DP			
		8404744*PED	Jul 14, 2023				
		8796331	Jan 14, 2023	U-1723			
		8796331*PED	Jul 14, 2023				
		8877938	May 27, 2027	DS DP			
		8877938*PED	Nov 27, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620	003	9388134	Nov 08, 2026	U-1723			
		9388134*PED	May 08, 2027				
SAFINAMIDE MESYLATE - XADAGO							
N 207145	001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
		8278485	Jun 08, 2027	DS U-1993			
		8283380	Sep 01, 2027	U-1993			
SAFINAMIDE MESYLATE - XADAGO							
N 207145	002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
		8278485	Jun 08, 2027	DS U-1993			
		8283380	Sep 01, 2027	U-1993			
SAPROPTERIN DIHYDROCHLORIDE - KUVAN							
N 022181	001	7566462	Nov 16, 2025	DP			
		7566462*PED	May 16, 2026				
		7566714	Nov 17, 2024	U-989			
		7566714*PED	May 17, 2025				
		7612073	Nov 17, 2024	U-1010			
		7612073*PED	May 17, 2025				
		7727987	Nov 17, 2024	DP			
		7727987*PED	May 17, 2025				
		7947681	Nov 17, 2024	U-1156	Y		
		7947681*PED	May 17, 2025				
		8003126	Nov 16, 2025				
		8003126*PED	May 16, 2026				
		8067416	Nov 17, 2024	U-989			
		8067416*PED	May 17, 2025				
		8318745	Nov 17, 2024	DP			
		8318745*PED	May 17, 2025				
		9433624	Nov 17, 2024	U-1589			
		RE43797	Nov 17, 2024	U-1156			
		RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN							
N 205065	001	7566714	Nov 17, 2024	U-1589			
		7566714*PED	May 17, 2025				
		7612073	Nov 17, 2024	U-1010			
		7612073*PED	May 17, 2025				
		8067416	Nov 17, 2024	U-1589			
		8067416*PED	May 17, 2025				
		9216178	Nov 01, 2032	DP			
		9433624	Nov 17, 2024	U-1589			
		RE43797	Nov 17, 2024	U-1590			
		RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN							
N 205065	002	7566714	Nov 17, 2024	U-1589			
		7566714*PED	May 17, 2025				
		7612073	Nov 17, 2024	U-1010			
		7612073*PED	May 17, 2025				
		8067416	Nov 17, 2024	U-1589			
		8067416*PED	May 17, 2025				
		9216178	Nov 01, 2032	DP			
		9433624	Nov 17, 2024	U-1589			
		RE43797	Nov 17, 2024	U-1590			
		RE43797*PED	May 17, 2025				
SARECYCLINE HYDROCHLORIDE - SEYSARA							
N 209521	001	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
		8513223	Dec 07, 2029	U-2406			
		9255068	Feb 09, 2033	DS DP U-2407			
		9255068	Feb 09, 2033	DS DP U-2408			
		9481639	Aug 10, 2028	U-2409			
SARECYCLINE HYDROCHLORIDE - SEYSARA							
N 209521	002	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
		8513223	Dec 07, 2029	U-2406			
		9255068	Feb 09, 2033	DS DP U-2407			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SARECYCLINE HYDROCHLORIDE - SEYSARA							
N 209521	002	9255068	Feb 09, 2033	DS DP U-2408			
		9481639	Aug 10, 2028	U-2409			
SARECYCLINE HYDROCHLORIDE - SEYSARA							
N 209521	003	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
		8513223	Dec 07, 2029	U-2406			
		9255068	Feb 09, 2033	DS DP U-2407			
		9255068	Feb 09, 2033	DS DP U-2408			
		9481639	Aug 10, 2028	U-2409			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA							
N 022350	001	7951400	Nov 30, 2028	DP		M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-1837			
		RE44186	Jul 31, 2023	DS DP U-995			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA							
N 022350	002	7951400	Nov 30, 2028	DP		M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-1837			
		RE44186	Jul 31, 2023	DS DP U-995			
SECNIDAZOLE - SOLOSEC							
N 209363	001	10335390	Sep 04, 2035	U-2583		NCE	Sep 15, 2022
						GAIN	Sep 15, 2027
SELENIOUS ACID - SELENIOUS ACID							
N 209379	001					NCE	Apr 30, 2024
SELEXIPAG - UPTRAVI							
N 207947	001	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	002	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	003	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	004	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	005	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	006	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	007	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEXIPAG - UPTRAVI						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELINEXOR - XPOVIO						
N 212306 001	8999996	Sep 15, 2032	DS DP		NCE	Jul 03, 2024
	9079865	Jul 26, 2032	U-2584		ODE-257	Jul 03, 2026
	9714226	Jul 26, 2032	DS DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 001	10220155	Jul 17, 2026	DP		NCE	Dec 05, 2022
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Jan 29, 2029	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 001	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 002	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 003	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SERTRALINE HYDROCHLORIDE - ZOLOFT						
N 020990 001	7067555*PED	Apr 11, 2020				
SEVELAMER CARBONATE - RENVELA						
N 022127 001	7985418	Oct 27, 2025	DP			
SEVELAMER CARBONATE - RENVELA						
N 022318 001	9095509	Dec 06, 2030	DP			
SEVELAMER CARBONATE - RENVELA						
N 022318 002	9095509	Dec 06, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEVELAMER HYDROCHLORIDE - RENAGEL								
N 021179	001		6733780	Oct 18, 2020	DP			
SEVELAMER HYDROCHLORIDE - RENAGEL								
N 021179	002		6733780	Oct 18, 2020	DP			
SIMEPREVIR SODIUM - OLYSIO								
N 205123	001		7671032	May 19, 2025	DS DP			
			8148399	Sep 05, 2029	DS DP		U-1467	
			8349869	Jul 28, 2026	DS DP		U-1467	
			8741926	Jul 28, 2026	DS		U-1467	
			8754106	Jul 28, 2026	DS		U-1467	
			9040562	Jul 28, 2026	DS DP		U-1467	
			9353103	Jul 28, 2026			U-1467	
			9623022	Jul 28, 2026			U-1467	
			9856265	Jul 28, 2026	DS DP		U-1467	
SIMVASTATIN - FLOLIPID								
N 206679	001		10300041	Apr 26, 2027	DP			
			9597289	Feb 23, 2030	DP			
SIMVASTATIN - FLOLIPID								
N 206679	002		10300041	Apr 26, 2027	DP			
			9597289	Feb 23, 2030	DP			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC								
N 202343	001		6699871	Jul 26, 2022	DS DP		U-1188	
			7125873	Jul 26, 2022	DP		U-1189	
			7125873	Jul 26, 2022	DP		U-1190	
			7125873	Jul 26, 2022	DP		U-1192	
			7125873	Jul 26, 2022	DP		U-1193	
			7326708	Apr 11, 2026	DS DP		U-1188	
			8168637	Jun 26, 2022	DP		U-1188	
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC								
N 202343	002		6699871	Jul 26, 2022	DS DP		U-1188	
			7125873	Jul 26, 2022	DP		U-1189	
			7125873	Jul 26, 2022	DP		U-1190	
			7125873	Jul 26, 2022	DP		U-1192	
			7125873	Jul 26, 2022	DP		U-1193	
			7326708	Apr 11, 2026	DS DP		U-1188	
			8168637	Jun 26, 2022	DP		U-1188	
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC								
N 202343	003		6699871	Jul 26, 2022	DS DP		U-1188	
			7125873	Jul 26, 2022	DP		U-1189	
			7125873	Jul 26, 2022	DP		U-1190	
			7125873	Jul 26, 2022	DP		U-1192	
			7125873	Jul 26, 2022	DP		U-1193	
			7326708	Apr 11, 2026	DS DP		U-1188	
			8168637	Jun 26, 2022	DP		U-1188	
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC								
N 202343	004		6699871	Jul 26, 2022	DS DP		U-1188	
			7125873	Jul 26, 2022	DP		U-1189	
			7125873	Jul 26, 2022	DP		U-1190	
			7125873	Jul 26, 2022	DP		U-1192	
			7125873	Jul 26, 2022	DP		U-1193	
			7326708	Apr 11, 2026	DS DP		U-1188	
			8168637	Jun 26, 2022	DP		U-1188	
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC								
N 202343	005		6699871	Jul 26, 2022	DS DP		U-1188	
			7125873	Jul 26, 2022	DP		U-1189	
			7125873	Jul 26, 2022	DP		U-1190	
			7125873	Jul 26, 2022	DP		U-1192	
			7125873	Jul 26, 2022	DP		U-1193	
			7326708	Apr 11, 2026	DS DP		U-1188	
			8168637	Jun 26, 2022	DP		U-1188	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC							
N 202343	006	6699871	Jul 26, 2022	DS DP U-1188			
		7125873	Jul 26, 2022	DP U-1189			
		7125873	Jul 26, 2022	DP U-1190			
		7125873	Jul 26, 2022	DP U-1192			
		7125873	Jul 26, 2022	DP U-1193			
		7326708	Apr 11, 2026	DS DP U-1188			
		8168637	Jun 26, 2022	DP U-1188			
SINCALIDE - KINEVAC							
N 017697	001	6803046	Aug 16, 2022	DP			
SINECATECHINS - VEREGEN							
N 021902	001	10434059	Nov 18, 2022	DP U-172			
		5795911	Oct 31, 2020	U-172			
		7858662	Oct 02, 2026	DP U-172			
		9770406	Jul 12, 2025	DP U-172			
SIPONIMOD FUMARIC ACID - MAYZENT							
N 209884	001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
		8492441	Nov 30, 2030	U-2511			
SIPONIMOD FUMARIC ACID - MAYZENT							
N 209884	002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
		8492441	Nov 30, 2030	U-2511			
SIROLIMUS - RAPAMUNE							
N 021083	001					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110	001					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110	002					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110	003					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110	004					ODE-92	May 28, 2022
SITAGLIPTIN PHOSPHATE - JANUVIA							
N 021995	001	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
		7125873	Jul 26, 2022	U-1036			
		7125873	Jul 26, 2022	U-1037			
		7125873	Jul 26, 2022	U-1038			
		7125873	Jul 26, 2022	U-775			
		7326708	Nov 24, 2026	DS DP U-802			
SITAGLIPTIN PHOSPHATE - JANUVIA							
N 021995	002	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
		7125873	Jul 26, 2022	U-1036			
		7125873	Jul 26, 2022	U-1037			
		7125873	Jul 26, 2022	U-1038			
		7125873	Jul 26, 2022	U-775			
		7326708	Nov 24, 2026	DS DP U-802			
SITAGLIPTIN PHOSPHATE - JANUVIA							
N 021995	003	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
		7125873	Jul 26, 2022	U-1036			
		7125873	Jul 26, 2022	U-1037			
		7125873	Jul 26, 2022	U-1038			
		7125873	Jul 26, 2022	U-775			
		7326708	Nov 24, 2026	DS DP U-802			
SODIUM NITRITE - SODIUM NITRITE							
N 203922	001	8568793	Dec 24, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE							
N 201444	001	8496973	Mar 29, 2031	DS DP U-1419			
		8568793	Dec 24, 2031	DS DP			
		9345724	Mar 29, 2031	DS DP U-2015			
		9585912	Mar 29, 2031	DS DP			
SODIUM OXYBATE - XYREM							
N 021196	001	10213400	Mar 15, 2033	U-2499		NPP	Oct 26, 2021
		6780889	Jul 04, 2020	DP		ODE-231	Oct 26, 2025
		6780889*PED	Jan 04, 2021			PED	Apr 26, 2022
		7262219	Jul 04, 2020	DP			
		7262219*PED	Jan 04, 2021				
		7668730	Jun 16, 2024	U-1110	Y		
		7668730*PED	Dec 16, 2024				
		7851506*PED	Jun 22, 2020				
		8263650*PED	Jun 22, 2020				
		8324275*PED	Jun 22, 2020				
		8731963	Dec 17, 2022	U-1110			
		8731963*PED	Jun 17, 2023				
		8772306	Mar 15, 2033	U-1532			
		8772306*PED	Sep 15, 2033				
		8859619*PED	Jun 22, 2020				
		8952062*PED	Jun 22, 2020				
		9050302	Mar 15, 2033	U-1532			
		9050302*PED	Sep 15, 2033				
		9486426	Mar 15, 2033	U-1532			
		9486426*PED	Sep 15, 2033				
		9539330*PED	Jun 22, 2020				
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP							
N 021892	001	7687075	Jun 22, 2028	DS DP			
SODIUM THIOSULFATE - SODIUM THIOSULFATE							
N 203923	001	8496973	Mar 29, 2031	DS DP U-1419			
		9345724	Mar 29, 2031	DS DP U-2015			
		9585912	Mar 29, 2031	DS DP			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA							
N 207078	001	10300087	Oct 14, 2035	DS U-2312		NCE	May 18, 2023
		10335432	Feb 10, 2032	U-2312			
		10398730	Feb 10, 2032	U-2312			
		10413569	Feb 10, 2032	DS			
		8802152	Apr 19, 2032	DS			
		8808750	Feb 10, 2032	U-2312			
		8877255	Oct 22, 2033	DS			
		9592253	Oct 14, 2035	DS U-2312			
		9844567	Feb 10, 2032	U-2312			
		9861658	Feb 10, 2032	U-2312			
		9913860	Oct 22, 2033	DS U-2312			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA							
N 207078	002	10300087	Oct 14, 2035	DS U-2312		NCE	May 18, 2023
		10398730	Feb 10, 2032	U-2312			
		10413569	Feb 10, 2032	DS			
		8802152	Apr 19, 2032	DS			
		8808750	Feb 10, 2032	U-2312			
		8877255	Oct 22, 2033	DS			
		9592253	Oct 14, 2035	DS U-2312			
		9844567	Feb 10, 2032	U-2312			
		9861658	Feb 10, 2032	U-2312			
		9913860	Oct 22, 2033	DS U-2312			
SOFOSBUVIR - SOVALDI							
N 204671	001	7964580	Mar 26, 2029	DS DP U-1470		NPP	Apr 07, 2020
		7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
		8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR - SOVALDI							
N 204671	001	8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9549941	Mar 26, 2029	U-1958			
		9549941*PED	Sep 26, 2029				
SOFOSBUVIR - SOVALDI							
N 204671	002	7964580	Mar 26, 2029	DS DP U-1470			
		7964580*PED	Sep 26, 2029				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
SOFOSBUVIR - SOVALDI							
N 212480	001	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
		7964580*PED	Sep 26, 2029				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
SOFOSBUVIR - SOVALDI							
N 212480	002	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
		7964580*PED	Sep 26, 2029				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 208341	001	10086011	Jan 30, 2034	U-1470		D-177	Nov 15, 2022
		7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
		7964580*PED	Sep 26, 2029			NPP	Aug 01, 2020
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8575135	Nov 16, 2032	DS DP U-1470			
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		8921341	Nov 16, 2032	DS DP U-1470			
		8940718	Nov 16, 2032	DS DP U-1470			
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9757406	Jan 30, 2034	DP			
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI							
N 209195	001	7964580	Mar 26, 2029	DS DP U-2039		NCE	Jul 18, 2022
		7964580	Mar 26, 2029	DS DP U-2040			
		7964580*PED	Sep 26, 2029				
		8334270	Mar 21, 2028	DS DP U-2039			
		8334270	Mar 21, 2028	DS DP U-2040			
		8334270*PED	Sep 21, 2028				
		8575135	Nov 05, 2033	DS DP U-2039			
		8575135	Nov 05, 2033	DS DP U-2040			
		8580765	Mar 21, 2028	DS DP U-2039			
		8580765	Mar 21, 2028	DS DP U-2040			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-2039			
		8618076	Dec 11, 2030	DS DP U-2040			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-2039			
		8633309	Mar 26, 2029	DS DP U-2040			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	DS DP U-2039			
		8735372	Mar 21, 2028	DS DP U-2040			
		8889159	Mar 26, 2029	DS DP U-2039			
		8889159	Mar 26, 2029	DS DP U-2040			
		8889159*PED	Sep 26, 2029				
		8921341	Nov 16, 2032	DS DP U-2039			
		8921341	Nov 16, 2032	DS DP U-2040			
		8940718	Nov 16, 2032	DS DP U-2039			
		8940718	Nov 16, 2032	DS DP U-2040			
		9085573	Mar 21, 2028	DS DP U-2039			
		9085573	Mar 21, 2028	DS DP U-2040			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-2039			
		9284342	Sep 13, 2030	DS DP U-2040			
		9284342*PED	Mar 13, 2031				
		9296782	Jul 17, 2034	DS DP			
		9585906	Mar 21, 2028	DS DP U-2039			
		9585906	Mar 21, 2028	DS DP U-2040			
		9868745	Nov 16, 2032	DS DP			
SOLRIAMFETOL - SUNOSI							
N 211230	001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
		10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
		8440715	Aug 25, 2027	U-2548			
		8877806	Jun 07, 2026	U-2548			
		9604917	Jun 07, 2026	U-2548			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOLRIAMFETOL - SUNOSI								
N 211230	002		10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
			10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
			8440715	Aug 25, 2027	U-2548			
			8877806	Jun 07, 2026	U-2548			
			9604917	Jun 07, 2026	U-2548			
SOMATROPIN - NORDITROPIN NORDIFLEX								
N 021148	004		RE41956	Jan 21, 2021	DP			
SOMATROPIN - NORDITROPIN NORDIFLEX								
N 021148	005		RE41956	Jan 21, 2021	DP			
SOMATROPIN - NORDITROPIN NORDIFLEX								
N 021148	006		RE41956	Jan 21, 2021	DP			
SOMATROPIN - NORDITROPIN NORDIFLEX								
N 021148	007		RE41956	Jan 21, 2021	DP			
SOMATROPIN - NORDITROPIN FLEXPRO								
N 021148	008		10220155	Jul 17, 2026	DP			
			10357616	Jan 20, 2026	DP			
			10376652	Jan 20, 2026	DP			
			6899699	Jan 02, 2022	DP			
			7762994	May 23, 2024	DP			
			8579869	Jun 30, 2023	DP			
			8672898	Jan 02, 2022	DP			
			8684969	Oct 20, 2025	DP			
			8920383	Jul 17, 2026	DP			
			9108002	Jan 20, 2026	DP			
			9132239	Feb 01, 2032	DP			
			9457154	Sep 27, 2027	DP			
			9486588	Jan 02, 2022	DP			
			9616180	Jan 20, 2026	DP			
			9687611	Feb 27, 2027	DP			
			9775953	Jul 17, 2026	DP			
			9861757	Jan 20, 2026	DP			
			RE46363	Aug 03, 2026	DP			
SOMATROPIN - NORDITROPIN FLEXPRO								
N 021148	009		10220155	Jul 17, 2026	DP			
			10357616	Jan 20, 2026	DP			
			10376652	Jan 20, 2026	DP			
			6899699	Jan 02, 2022	DP			
			7762994	May 23, 2024	DP			
			8579869	Jun 30, 2023	DP			
			8672898	Jan 02, 2022	DP			
			8684969	Oct 20, 2025	DP			
			8920383	Jul 17, 2026	DP			
			9108002	Jan 20, 2026	DP			
			9132239	Feb 01, 2032	DP			
			9457154	Sep 27, 2027	DP			
			9486588	Jan 02, 2022	DP			
			9616180	Jan 20, 2026	DP			
			9687611	Feb 27, 2027	DP			
			9775953	Jul 17, 2026	DP			
			9861757	Jan 20, 2026	DP			
			RE46363	Aug 03, 2026	DP			
SOMATROPIN - NORDITROPIN FLEXPRO								
N 021148	010		10220155	Jul 17, 2026	DP			
			10357616	Jan 20, 2026	DP			
			10376652	Jan 20, 2026	DP			
			6899699	Jan 02, 2022	DP			
			7762994	May 23, 2024	DP			
			8579869	Jun 30, 2023	DP			
			8672898	Jan 02, 2022	DP			
			8684969	Oct 20, 2025	DP			
			8920383	Jul 17, 2026	DP			
			9108002	Jan 20, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN - NORDITROPIN FLEXPRO						
N 021148 010	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SOMATROPIN - NORDITROPIN FLEXPRO						
N 021148 011	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SONIDEGIB PHOSPHATE - ODOMZO						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
SORAFENIB TOSYLATE - NEXAVAR						
N 021923 001	7235576	Jan 12, 2020	DS DP		ODE-56	Nov 22, 2020
	7351834	Jan 12, 2020	DS			
	7897623	Jan 12, 2020	DP			
	8124630	Jan 12, 2020	U-1459			
	8618141	Feb 11, 2023	U-1480			
	8841330	Jan 12, 2020	U-1696			
	8877933	Dec 24, 2027	DS DP U-1624			
	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
SOTALOL HYDROCHLORIDE - SOTYLIZE						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
	9724297	Aug 31, 2035	DP U-2096			
SPINOSAD - NATROBA						
N 022408 001	6063771	Jul 25, 2023	DP U-1670			
	7030095	Jul 02, 2021	DP U-1105			
SPIRONOLACTONE - CAROSPIR						
N 209478 001	10493083	Oct 28, 2036	DP			
	9757394	Oct 28, 2036	DP U-2109			
STAVUDINE - ZERIT XR						
N 021453 001	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR						
N 021453 002	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR						
N 021453 003	7135465	Feb 18, 2023	DP U-167			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
STAVUDINE - ZERIT XR						
N 021453 004	7135465	Feb 18, 2023	DP U-167			
STIRIPENTOL - DIACOMIT						
N 206709 001					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT						
N 206709 002					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT						
N 207223 001					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT						
N 207223 002					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
SUCROFERRIC OXYHYDROXIDE - VELPHORO						
N 205109 001	6174442	Jun 12, 2020	DS U-1468			
	9561251	Jan 23, 2030	DP U-1468			
SUFENTANIL CITRATE - DSUVIA						
N 209128 001	10245228	Jan 05, 2027	DP U-1351		NP	Nov 02, 2021
	10342762	Jan 05, 2027	DP			
	10507180	Jan 05, 2027	DP U-1351			
	8202535	Oct 22, 2030	U-1351			
	8226978	Jan 05, 2027	DP U-1351			
	8231900	Jan 05, 2027	DP			
	8252328	Jan 05, 2027	DP			
	8252329	Jan 05, 2027	DP			
	8535714	Jan 05, 2027	DP U-1351			
	8574189	Mar 16, 2030	DP			
	8778393	Jan 05, 2027	U-1351			
	8778394	Jan 05, 2027	U-1351			
	8865211	Jan 05, 2027	U-1351			
	8865743	Oct 22, 2030	U-1351			
	8945592	Jul 29, 2031	DP			
	9320710	Jan 05, 2027	U-1351			
	9744129	Jan 05, 2027	DP			
SUGAMMADEX SODIUM - BRIDION						
N 022225 001	6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
SUGAMMADEX SODIUM - BRIDION						
N 022225 002	6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON						
N 203684 001	10232061	Jul 06, 2038	DP		NPP	Nov 13, 2022
	10335502	Jul 06, 2038	DP			
SUMATRIPTAN - TOSYMRA						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N 022239 001	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO								
N 022239	001		8267903	Mar 18, 2023	DP			
			8287489	Dec 06, 2024	DP			
			8343130	Oct 18, 2022	DP			
			8491524	Nov 21, 2022	DP			
SUMATRIPTAN SUCCINATE - ALSUMA								
N 022377	001		7811254	Aug 26, 2027	DP U-1083			
SUMATRIPTAN SUCCINATE - ZECUITY								
N 202278	001		6745071	Feb 21, 2023	DP			
			7973058	Apr 12, 2027	U-1328			
			8155737	Apr 12, 2027	U-1328			
			8366600	Apr 21, 2029	U-1327			
			8470853	Apr 12, 2027	U-1328			
			8597272	Apr 12, 2027	DP			
			8983594	Nov 19, 2030	DP U-1328			
			9272137	Sep 07, 2027	DP			
			9327114	Oct 08, 2032	DP U-1328			
			9427578	Apr 12, 2027	DP U-1328			
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL								
N 206099	001		10076614	Oct 20, 2034	DP			
			10076615	Jul 30, 2029	U-2010			
			10076615	Jul 30, 2029	U-2011			
			10076615	Jul 30, 2029	U-2404			
			10124132	Mar 06, 2027	DP U-1719			
			10124132	Mar 06, 2027	DP U-2010			
			10124132	Mar 06, 2027	DP U-2011			
			10398859	Dec 19, 2027	DP			
			10478574	Nov 04, 2033	U-2404			
			6715485	Mar 03, 2020	DP			
			7975690	Aug 18, 2025	DP U-1809			
			8047202	Jul 02, 2023	DP			
			8327844	Oct 03, 2023	U-1809			
			8550073	Oct 22, 2029	DP			
			8555877	Mar 03, 2020	DP			
			8590530	Sep 15, 2025	DP U-1809			
			8875704	Apr 07, 2028	DP U-1809			
			8899229	Aug 18, 2030	DP			
			8978647	Dec 06, 2030	DP			
			9108015	Sep 15, 2025	DP			
			9119932	Apr 23, 2024	DP			
			9649456	Oct 21, 2030	DP U-1719			
			9649456	Oct 21, 2030	DP U-2010			
			9649456	Oct 21, 2030	DP U-2011			
SUNITINIB MALATE - SUTENT								
N 021938	001		6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
			6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
			6573293*PED	Aug 15, 2021				
			7125905	Feb 15, 2021	DS DP			
			7125905*PED	Aug 15, 2021				
			7211600	Dec 22, 2020	U-883			
			7211600*PED	Jun 22, 2021				
SUNITINIB MALATE - SUTENT								
N 021938	002		6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
			6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
			6573293*PED	Aug 15, 2021				
			7125905	Feb 15, 2021	DS DP			
			7125905*PED	Aug 15, 2021				
			7211600	Dec 22, 2020	U-883			
			7211600*PED	Jun 22, 2021				
SUNITINIB MALATE - SUTENT								
N 021938	003		6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
			6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
			6573293*PED	Aug 15, 2021				
			7125905	Feb 15, 2021	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUNITINIB MALATE - SUTENT							
N 021938	003	7125905*PED	Aug 15, 2021				
		7211600	Dec 22, 2020	U-883			
		7211600*PED	Jun 22, 2021				
SUNITINIB MALATE - SUTENT							
N 021938	004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
		6573293*PED	Aug 15, 2021				
		7125905	Feb 15, 2021	DS DP			
		7125905*PED	Aug 15, 2021				
		7211600	Dec 22, 2020	U-883			
		7211600*PED	Jun 22, 2021				
SUVOREXANT - BELSOMRA							
N 204569	001	10098892	May 29, 2033	DP			
		7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA							
N 204569	002	10098892	May 29, 2033	DP			
		7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA							
N 204569	003	10098892	May 29, 2033	DP			
		7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA							
N 204569	004	10098892	May 29, 2033	DP			
		7951797	Nov 20, 2029	DS DP U-620			
TACROLIMUS - ENVARSUS XR							
N 206406	001	10166190	May 30, 2028	DP		ODE-94	Jul 10, 2022
		7994214	Aug 30, 2024	DP			
		8486993	Aug 30, 2024	DP U-1752			
		8586084	Aug 30, 2024	U-1752			
		8591946	Aug 30, 2024	DP			
		8617599	Aug 30, 2024	DP			
		8623410	Aug 30, 2024	DP			
		8623411	Aug 30, 2024	U-1752			
		8644239	Aug 30, 2028	DP U-2677			
		8644239	Aug 30, 2028	DP U-2678			
		8664239	May 30, 2028	U-1752			
		8685998	Aug 30, 2028	DP U-1752			
		8685998	Aug 30, 2028	DP U-2677			
		8685998	Aug 30, 2028	DP U-2678			
		8889185	Aug 30, 2024	U-1752			
		8889186	Aug 30, 2024	U-1752			
		9161907	Aug 30, 2024	DP U-1752			
		9549918	May 30, 2028	DP			
		9757362	Aug 30, 2024	DP			
		9763920	Aug 30, 2024	DP			
TACROLIMUS - ENVARSUS XR							
N 206406	002	10166190	May 30, 2028	DP		ODE-94	Jul 10, 2022
		7994214	Aug 30, 2024	DP			
		8486993	Aug 30, 2024	DP U-1752			
		8586084	Aug 30, 2024	U-1752			
		8591946	Aug 30, 2024	DP			
		8617599	Aug 30, 2024	DP			
		8623410	Aug 30, 2024	DP			
		8623411	Aug 30, 2024	U-1752			
		8644239	Aug 30, 2028	DP U-2677			
		8644239	Aug 30, 2028	DP U-2678			
		8664239	May 30, 2028	U-1752			
		8685998	Aug 30, 2028	DP U-1752			
		8685998	Aug 30, 2028	DP U-2677			
		8685998	Aug 30, 2028	DP U-2678			
		8889185	Aug 30, 2024	U-1752			
		8889186	Aug 30, 2024	U-1752			
		9161907	Aug 30, 2024	DP U-1752			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - ENVARSUS XR						
N 206406 002	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 003	10166190	May 30, 2028	DP		ODE-94	Jul 10, 2022
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8644239	Aug 30, 2028	DP U-2677			
	8644239	Aug 30, 2028	DP U-2678			
	8664239	May 30, 2028	U-1752			
	8685998	Aug 30, 2028	DP U-1752			
	8685998	Aug 30, 2028	DP U-2677			
	8685998	Aug 30, 2028	DP U-2678			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
TACROLIMUS - PROGRAF						
N 210115 001					ODE-269	May 24, 2025
TACROLIMUS - PROGRAF						
N 210115 002					ODE-269	May 24, 2025
TADALAFIL - CIALIS						
N 021368 001	6943166	Apr 26, 2020	U-1184		M-219	Feb 15, 2021
	6943166	Apr 26, 2020	U-155		PED	Aug 15, 2021
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
TADALAFIL - CIALIS						
N 021368 002	6943166	Apr 26, 2020	U-155		M-219	Feb 15, 2021
	6943166	Apr 26, 2020	U-614		PED	Aug 15, 2021
	6943166*PED	Oct 26, 2020				
TADALAFIL - CIALIS						
N 021368 003	6943166	Apr 26, 2020	U-614		M-219	Feb 15, 2021
	6943166*PED	Oct 26, 2020			PED	Aug 15, 2021
TADALAFIL - CIALIS						
N 021368 004	6943166	Apr 26, 2020	U-155		M-219	Feb 15, 2021
	6943166*PED	Oct 26, 2020			PED	Aug 15, 2021
TAFAMIDIS - VYNDAMAX						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
TAFAMIDIS MEGLUMINE - VYNDAQEL						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
TAFENOQUINE SUCCINATE - ARAKODA						
N 210607 001	10342791	Dec 02, 2035	U-2582		NCE	Jul 20, 2023
					NP	Aug 08, 2021
TAFENOQUINE SUCCINATE - KRINTAFEL						
N 210795 001					NCE	Jul 20, 2023
					ODE-201	Jul 20, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAFLUPROST - ZIOPTAN							
N 202514	001	5886035	Dec 18, 2022	DS DP U-778			
		9999593	May 28, 2029	DP			
TALAZOPARIB TOSYLATE - TALZENNA							
N 211651	001	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
		8012976	Oct 19, 2029	DS DP			
		8420650	Jul 27, 2029	DS DP			
		8735392	Oct 20, 2031	DS DP			
		9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA							
N 211651	002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
		8012976	Oct 19, 2029	DS DP			
		8420650	Jul 27, 2029	DS DP			
		8735392	Oct 20, 2031	DS DP			
		9820985	Jul 27, 2029	U-2437			
TALC - STERITALC							
N 205555	001					ODE-143	May 01, 2024
						ODE-191	May 01, 2024
TALC - STERITALC							
N 205555	002					ODE-143	May 01, 2024
						ODE-191	May 01, 2024
TALC - STERITALC							
N 205555	003					ODE-143	May 01, 2024
						ODE-191	May 01, 2024
TALIGLUCERASE ALFA - ELELYSO							
N 022458	001	8227230	Feb 24, 2024	DS DP			
		8741620	Feb 24, 2024	DS DP			
		8790641	Oct 18, 2025	U-1564			
		8790641	Oct 18, 2025	U-1574			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 022304	001	7994364	Jun 27, 2025	DS DP U-931			
		RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 022304	002	7994364	Jun 27, 2025	DS DP U-931			
		RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 022304	003	7994364	Jun 27, 2025	DS DP U-931			
		RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	001	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	002	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	002	RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	003	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	004	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	005	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 203794	001	7994364	Jun 27, 2025	DS DP U-1289			
		RE39593	Aug 05, 2022	DS DP U-1289			
TASIMELTEON - HETLIOZ							
N 205677	001	10071977	Feb 12, 2035	DS DP		ODE-59	Jan 31, 2021
		10149829	Jan 25, 2033	U-2477			
		10376487	Jul 27, 2035	U-2615			
		10449176	Jan 25, 2033	U-2149			
		5856529	Dec 09, 2022	DS DP U-2149			
		9060995	Jan 25, 2033	U-1710			
		9539234	Jan 25, 2033	U-1934			
		9549913	Jan 25, 2033	U-1486			
		9730910	May 17, 2034	U-2085			
		9855241	Jan 25, 2033	U-2149			
		RE46604	Jan 25, 2033	U-2147			
TAVABOROLE - KERYDIN							
N 204427	001	7582621	May 26, 2027	U-2016	Y		
		7582621*PED	Nov 26, 2027				
		9549938	Feb 16, 2026	U-1951			
		9549938*PED	Aug 16, 2026				
		9566289	Feb 16, 2026	DP			
		9566289*PED	Aug 16, 2026				
		9566290	Feb 16, 2026	U-1970			
		9566290*PED	Aug 16, 2026				
		9572823	Feb 16, 2026	U-1970			
		9572823*PED	Aug 16, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAZAROTENE - FABIOR							
N 202428	001	8808716	Feb 24, 2030	DP			
TAZAROTENE - ARAZLO							
N 211882	001	6517847	Aug 03, 2020	DP U-2368		NP	Dec 18, 2022
TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML							
N 020372	002	9549999	Mar 10, 2030	DP			
TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT							
N 202207	001	6409990	May 12, 2020	DS		ODE-67	Jun 13, 2021
		9439985	Sep 27, 2033	DS DP			
TECOVIRIMAT - TPOXX							
N 208627	001	7737168	May 03, 2027	U-2346		NCE	Jul 13, 2023
		8039504	Jul 23, 2027	DP		ODE-200	Jul 13, 2025
		8124643	Jun 18, 2024	DS DP			
		8530509	Jun 18, 2024	DP			
		8802714	Jun 18, 2024	U-2346			
		9339466	Mar 23, 2031	DS DP			
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205435	001	10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
		10442829	Feb 03, 2030	DS		GAIN	Jun 20, 2024
		7816379	Feb 23, 2028	DS DP U-282			
		8420676	Feb 23, 2028	DS DP U-282			
		8426389	Dec 31, 2030	DS DP U-282			
		9624250	Feb 03, 2030	DS DP U-2507			
		9988406	Feb 03, 2030	DP			
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205436	001	10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
		10442829	Feb 03, 2030	DS		GAIN	Jun 20, 2024
		7816379	Feb 23, 2028	DS DP U-282			
		8420676	Feb 23, 2028	DS DP U-282			
		8426389	Dec 31, 2030	DS DP U-282			
		9624250	Feb 03, 2030	DS DP U-2507			
		9988406	Feb 03, 2030	DP			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT							
N 203441	001	5789379	Apr 14, 2020	DS DP U-1320		ODE-240	May 16, 2026
		5789379*PED	Oct 14, 2020				
		7056886	Sep 18, 2022	DP U-1320			
		7056886*PED	Mar 18, 2023				
		7847061	Nov 01, 2025	U-1320			
		7847061*PED	May 01, 2026				
		9060992	Nov 01, 2025	U-1320			
		9060992*PED	May 01, 2026				
		9539310	Nov 01, 2025	U-1320			
		9539310*PED	May 01, 2026				
		9545434	Nov 01, 2025	U-1320			
		9545434*PED	May 01, 2026				
		9545435	Nov 01, 2025	U-1320			
		9545435*PED	May 01, 2026				
		9555079	Nov 01, 2025	U-1320			
		9555079*PED	May 01, 2026				
		9572867	Nov 01, 2025	U-1320			
		9572867*PED	May 01, 2026				
		9592273	Nov 01, 2025	U-1320			
		9592273*PED	May 01, 2026				
		9592274	Nov 01, 2025	U-1320			
		9592274*PED	May 01, 2026				
		9968655	Nov 01, 2025	U-2308			
		9968655*PED	May 01, 2026				
		9968656	Nov 01, 2025	U-2308			
		9968656*PED	May 01, 2026				
		9968658	Nov 01, 2025	U-1320			
		9968658*PED	May 01, 2026				
		9974835	Nov 01, 2025	U-1320			
		9974835*PED	May 01, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TEDUGLUTIDE RECOMBINANT - GATTEX KIT								
N 203441	001		9974837	Nov 01, 2025	U-1320			
			9974837*PED	May 01, 2026				
			9981014	Nov 01, 2025	U-1320			
			9981014*PED	May 01, 2026				
			9981016	Nov 01, 2025	U-1320			
			9981016*PED	May 01, 2026				
			9987334	Nov 01, 2025	U-1320			
			9987334*PED	May 01, 2026				
			9987335	Nov 01, 2025	U-1320			
			9987335*PED	May 01, 2026				
			9993528	Nov 01, 2025	U-1320			
			9993528*PED	May 01, 2026				
TELAPREVIR - INCIVEK								
N 201917	001		7820671	Feb 25, 2025	DS DP			
			8431615	May 30, 2028	U-1398			
			8529882	Aug 31, 2021	U-1398			
TELAVANCIN HYDROCHLORIDE - VIBATIV								
N 022110	001		6635618	Sep 11, 2023	DS DP U-728			
			6858584	Aug 24, 2022	DP			
			6872701	Jun 05, 2021	DP			
			7008923	May 06, 2021	U-1005			
			7208471	May 01, 2021	DS DP			
			7351691	May 01, 2021	DS DP U-728			
			7531623	Jan 01, 2027	DS			
			7544364	May 01, 2021	DP			
			7700550	May 01, 2021	U-282			
			8101575	May 01, 2021	DP			
			8158580	May 01, 2021	DP			
TELAVANCIN HYDROCHLORIDE - VIBATIV								
N 022110	002		6635618	Sep 11, 2023	DS DP U-728			
			6858584	Aug 24, 2022	DP			
			6872701	Jun 05, 2021	DP			
			7008923	May 06, 2021	U-1005			
			7208471	May 01, 2021	DS DP			
			7351691	May 01, 2021	DS DP U-728			
			7531623	Jan 01, 2027	DS			
			7544364	May 01, 2021	DP			
			7700550	May 01, 2021	U-282			
			8101575	May 01, 2021	DP			
			8158580	May 01, 2021	DP			
TELBIVUDINE - TYZEKA								
N 022011	001		6569837	Oct 25, 2020	U-782			
			6569837	Oct 25, 2020	U-999			
			7589079	Sep 11, 2023	DS DP U-999			
			7858594	Sep 11, 2023	DS DP U-999			
TELBIVUDINE - TYZEKA								
N 022154	001		6569837	Oct 25, 2020	U-999			
			7858594	Sep 11, 2023	DS DP U-999			
TELMISARTAN - MICARDIS								
N 020850	001		6358986	Jan 10, 2020				
TELMISARTAN - MICARDIS								
N 020850	002		6358986	Jan 10, 2020				
			7998953	Jun 06, 2020	U-1177			
			8003679	Oct 06, 2022	U-1176			
TELMISARTAN - MICARDIS								
N 020850	003		6358986	Jan 10, 2020				
TELOTRISTAT ETIPRATE - XERMELO								
N 208794	001		7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
			7709493	Dec 11, 2027	DS U-1979		ODE-132	Feb 28, 2024
			7968559	Dec 11, 2027	U-1979			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TELOTRISTAT ETIPRATE - XERMELO							
N 208794	001	8193204	Feb 27, 2031	DS			
		8653094	Dec 19, 2028	U-1979			
TEMOZOLOMIDE - TEMODAR							
N 022277	001	6987108	Sep 08, 2023	DP			
		7786118	Feb 21, 2023	DP			
		8623868	Feb 21, 2023	DP			
TEMSIROLIMUS - TORISEL							
N 022088	001	8026276	Jan 20, 2026	DP			
		8299116	Jul 25, 2023	DP			
		8455539	Jul 25, 2023	DP			
		8455539*PED	Jan 25, 2024				
		8722700	Jul 25, 2023	DP			
		8722700*PED	Jan 25, 2024				
		8791097	May 10, 2032	U-1550			
		8791097	May 10, 2032	U-1551			
		8791097*PED	Nov 10, 2032				
TENAPANOR HYDROCHLORIDE - IBSRELA							
N 211801	001	8541448	Dec 30, 2029	DS DP		NCE	Sep 12, 2024
		8969377	Dec 30, 2029	DS DP			
		9006281	May 02, 2030	U-2626			
		9408840	Dec 30, 2029	U-2626			
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY							
N 208464	001	7390791	May 07, 2022	DS DP		NCE	Nov 05, 2020
		7803788	Feb 02, 2022	U-999			
		8754065	Aug 15, 2032	DS DP U-999			
		9296769	Aug 15, 2032	DS DP U-999			
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 021356	001					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 021356	002					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 021356	003					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 021356	004					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 022577	001					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TERIFLUNOMIDE - AUBAGIO							
N 202992	001	6794410	Sep 12, 2026	U-1285			
		8802735	Sep 14, 2030	DP			
		9186346	Feb 04, 2034	U-1786			
TERIFLUNOMIDE - AUBAGIO							
N 202992	002	6794410	Sep 12, 2026	U-1285			
		8802735	Sep 14, 2030	DP			
		9186346	Feb 04, 2034	U-1786			
TERIPARATIDE RECOMBINANT HUMAN - FORTEO							
N 021318	001	7517334	Mar 25, 2025	DP			
TERIPARATIDE RECOMBINANT HUMAN - FORTEO							
N 021318	002	7517334	Mar 25, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESAMORELIN ACETATE - EGRIFTA						
N 022505 001	5861379	May 26, 2020	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
	8314066	Aug 14, 2023	U-1100			
	8435945	Aug 14, 2023	U-1100			
TESAMORELIN ACETATE - EGRIFTA						
N 022505 002	5861379	May 26, 2020	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
	8314066	Aug 14, 2023	U-1100			
	8435945	Aug 14, 2023	U-1100			
TESTOSTERONE - ANDROGEL						
N 021015 001	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL						
N 021015 002	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL						
N 021015 003	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - TESTIM						
N 021454 001	7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
	7935690	Apr 21, 2023	U-1009			
	8063029	Apr 21, 2023	U-843			
	8178518	Apr 21, 2023	DP			
TESTOSTERONE - ANDROGEL						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - ANDROGEL						
N 022309 002	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - AXIRON						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Sep 27, 2027	U-1390			
	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
	9289586	Feb 26, 2027	U-1390			
TESTOSTERONE - VOGELXO						
N 204399 002	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - VOGELXO						
N 204399 003	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - NATESTO						
N 205488 001	8574622	Feb 04, 2024	DP			
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 001	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 002	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)							
N 209863	003	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
		8562564	Jan 24, 2026	DP			
		9180259	Jan 24, 2026	DP			
		9533102	Jan 24, 2026	DP			
		9629959	Jan 24, 2026	DP			
		9744302	Nov 19, 2035	DP			
		9950125	Sep 04, 2036	DP U-2418			
TESTOSTERONE UNDECANOATE - AVEED							
N 022219	001	7718640	Mar 14, 2027	DP			
		8338395	Feb 27, 2026	U-1500			
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089	001	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
		8492369	Dec 20, 2030	DP U-2506			
		8778916	Apr 12, 2030	DP			
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089	002	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
		8492369	Dec 20, 2030	DP U-2506			
		8778916	Apr 12, 2030	DP			
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089	003	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
		8492369	Dec 20, 2030	DP U-2506			
		8778916	Apr 12, 2030	DP			
THALIDOMIDE - THALOMID							
N 020785	001	6315720	Oct 23, 2020	U-442			
		6315720	Oct 23, 2020	U-731			
		6561977	Oct 23, 2020	U-371			
		6561977	Oct 23, 2020	U-731			
		6755784	Oct 23, 2020	U-371			
		6755784	Oct 23, 2020	U-731			
		6869399	Oct 23, 2020	U-371			
		6869399	Oct 23, 2020	U-731			
		6869399	Oct 23, 2020	U-732			
		6869399	Oct 23, 2020	U-733			
		7141018	Oct 23, 2020	U-371			
		7141018	Oct 23, 2020	U-731			
		7141018	Oct 23, 2020	U-732			
		7141018	Oct 23, 2020	U-733			
		7230012	Dec 09, 2023	DP			
		7959566	Oct 23, 2020	U-1155			
		8315886	Oct 23, 2020	U-1249			
		8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID							
N 020785	002	6315720	Oct 23, 2020	U-442			
		6315720	Oct 23, 2020	U-731			
		6561977	Oct 23, 2020	U-371			
		6561977	Oct 23, 2020	U-731			
		6755784	Oct 23, 2020	U-371			
		6755784	Oct 23, 2020	U-731			
		6869399	Oct 23, 2020	U-371			
		6869399	Oct 23, 2020	U-731			
		6869399	Oct 23, 2020	U-732			
		6869399	Oct 23, 2020	U-733			
		7141018	Oct 23, 2020	U-371			
		7141018	Oct 23, 2020	U-731			
		7141018	Oct 23, 2020	U-732			
		7141018	Oct 23, 2020	U-733			
		7230012	Dec 09, 2023	DP			
		7959566	Oct 23, 2020	U-1155			
		8315886	Oct 23, 2020	U-1249			
		8626531	Oct 23, 2020	U-1465			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID							
N 020785	003	6315720	Oct 23, 2020	U-442			
		6315720	Oct 23, 2020	U-731			
		6561977	Oct 23, 2020	U-371			
		6561977	Oct 23, 2020	U-731			
		6755784	Oct 23, 2020	U-371			
		6755784	Oct 23, 2020	U-731			
		6869399	Oct 23, 2020	U-371			
		6869399	Oct 23, 2020	U-731			
		6869399	Oct 23, 2020	U-732			
		6869399	Oct 23, 2020	U-733			
		7141018	Oct 23, 2020	U-371			
		7141018	Oct 23, 2020	U-731			
		7141018	Oct 23, 2020	U-732			
		7141018	Oct 23, 2020	U-733			
		7230012	Dec 09, 2023	DP			
		7959566	Oct 23, 2020	U-1155			
		8315886	Oct 23, 2020	U-1249			
		8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID							
N 020785	004	6315720	Oct 23, 2020	U-731			
		6561977	Oct 23, 2020	U-731			
		6755784	Oct 23, 2020	U-731			
		6869399	Oct 23, 2020	U-731			
		7141018	Oct 23, 2020	U-731			
		7959566	Oct 23, 2020	U-1155			
		8315886	Oct 23, 2020	U-1249			
		8626531	Oct 23, 2020	U-1465			
THIOTEPA - TEPADINA							
N 208264	001					I-747	Jan 26, 2020
						ODE-129	Jan 26, 2024
THIOTEPA - TEPADINA							
N 208264	002					I-747	Jan 26, 2020
						ODE-129	Jan 26, 2024
TICAGRELOR - BRILINTA							
N 022433	001	10300065	Jan 27, 2036	U-2541			
		10300065	Jan 27, 2036	U-2542			
		7265124	Jul 09, 2021	DS DP U-1171			
		7265124	Jul 09, 2021	DS DP U-1860			
		7265124	Jul 09, 2021	DS DP U-1868			
		7265124	Jul 09, 2021	DS DP U-1869			
		8425934	Apr 17, 2030	DP			
		RE46276	Oct 30, 2024	DS DP U-1935			
		RE46276	Oct 30, 2024	DS DP U-1936			
		RE46276	Oct 30, 2024	DS DP U-1937			
		RE46276	Oct 30, 2024	DS DP U-1938			
TICAGRELOR - BRILINTA							
N 022433	002	10300065	Jan 27, 2036	U-2541			
		10300065	Jan 27, 2036	U-2542			
		7265124	Jul 09, 2021	DS DP U-1171			
		7265124	Jul 09, 2021	DS DP U-1860			
		7265124	Jul 09, 2021	DS DP U-1868			
		7265124	Jul 09, 2021	DS DP U-1869			
		8425934	Apr 17, 2030	DP			
		RE46276	Oct 30, 2024	DS DP U-1935			
		RE46276	Oct 30, 2024	DS DP U-1936			
		RE46276	Oct 30, 2024	DS DP U-1937			
		RE46276	Oct 30, 2024	DS DP U-1938			
TIGECYCLINE - TYGACIL							
N 021821	001	7879828	Feb 05, 2029	DP			
		8372995	Oct 08, 2030	DP			
		8975242	Oct 24, 2028	DP			
		9254328	Mar 13, 2026	DP			
		9694078	Mar 13, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIGECYCLINE - TYGACIL							
N 021821	001	7879828	Feb 05, 2029	DP			
		8372995	Oct 08, 2030	DP			
		8975242	Oct 24, 2028	DP			
		9254328	Mar 13, 2026	DP			
		9694078	Mar 13, 2026	DP			
TIGECYCLINE - TIGECYCLINE							
N 211158	001	9855335	Apr 07, 2033	DP			
TIOPRONIN - THIOLA							
N 019569	001					ODE-267	Jun 28, 2026
TIOTROPIUM BROMIDE - SPIRIVA							
N 021395	001	6777423	Sep 24, 2021	DS DP			
		6777423*PED	Mar 24, 2022				
		6908928	Sep 24, 2021	DS DP U-566			
		6908928	Sep 24, 2021	DS DP U-762			
		6908928*PED	Mar 24, 2022				
		7070800	Jan 22, 2022	DP U-566			
		7070800*PED	Jul 22, 2022				
		7309707	Sep 24, 2021	DS DP			
		7309707*PED	Mar 24, 2022				
		7642268	Sep 24, 2021	DS DP			
		7642268*PED	Mar 24, 2022				
		7694676	Mar 12, 2027	DP			
		7694676*PED	Sep 12, 2027				
		8022082	Jan 19, 2026	DP U-1186			
		8022082*PED	Jul 19, 2026				
		9010323	Apr 19, 2030	DP			
		RE38912	Oct 11, 2021	DP			
		RE38912*PED	Apr 11, 2022				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936	001	6988496	Feb 23, 2020	DP		NPP	Feb 15, 2020
		6988496*PED	Aug 23, 2020			PED	Aug 15, 2020
		7284474	Aug 26, 2024	DP			
		7284474*PED	Feb 26, 2025				
		7396341	Oct 10, 2026	DP			
		7396341*PED	Apr 10, 2027				
		7837235	Mar 13, 2028	DP			
		7837235*PED	Sep 13, 2028				
		7896264	May 26, 2025	DP			
		7896264*PED	Nov 26, 2025				
		7988001	Aug 04, 2021	DP			
		7988001*PED	Feb 04, 2022				
		8733341	Oct 16, 2030	DP			
		8733341*PED	Apr 16, 2031				
		9027967	Mar 31, 2027	DP			
		9027967*PED	Oct 01, 2027				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936	002	6988496	Feb 23, 2020	DP		NPP	Feb 15, 2020
		6988496*PED	Aug 23, 2020			PED	Aug 15, 2020
		7284474	Aug 26, 2024	DP			
		7284474*PED	Feb 26, 2025				
		7396341	Oct 10, 2026	DP			
		7396341*PED	Apr 10, 2027				
		7837235	Mar 13, 2028	DP			
		7837235*PED	Sep 13, 2028				
		7896264	May 26, 2025	DP			
		7896264*PED	Nov 26, 2025				
		7988001	Aug 04, 2021	DP			
		7988001*PED	Feb 04, 2022				
		8733341	Oct 16, 2030	DP			
		8733341*PED	Apr 16, 2031				
		9027967	Mar 31, 2027	DP			
		9027967*PED	Oct 01, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	001	10456399	Feb 03, 2037	U-2642		I-794	Feb 22, 2022
		10457666	Jun 17, 2034	DS DP		NCE	Sep 22, 2020
		6479500	Mar 16, 2020	U-1751		ODE-229	Feb 22, 2026
		9527833	Jun 17, 2034	DS DP			
		RE46284	Dec 16, 2026	U-1751			
		RE46284	Dec 16, 2026	U-2503			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	002	10456399	Feb 03, 2037	U-2642		I-794	Feb 22, 2022
		10457666	Jun 17, 2034	DS DP		NCE	Sep 22, 2020
		6479500	Mar 16, 2020	U-1751		ODE-229	Feb 22, 2026
		9527833	Jun 17, 2034	DS DP			
		RE46284	Dec 16, 2026	U-1751			
		RE46284	Dec 16, 2026	U-2503			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020912	001	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020912	002	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	001	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	002	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	003	6770660	May 01, 2023	U-1444			
TOBRAMYCIN - TOBI PODHALER							
N 201688	001	10207066	Nov 04, 2030	DP U-909			
		7368102	Dec 19, 2022	DP U-909			
		7442388	May 10, 2020	DP			
		7516741	Jan 11, 2024	DP			
		7559325	Oct 27, 2025	DP			
		8069851	Sep 24, 2024	DP			
		8349294	May 10, 2020	DP			
		8664187	Jun 20, 2025	U-909			
		8715623	Dec 19, 2022	DP U-909			
		8869794	Sep 12, 2028	DP U-909			
		9421166	Dec 19, 2022	DP U-909			
TOBRAMYCIN - BETHKIS							
N 201820	001	6987094	Sep 22, 2022	DP			
		7696178	Sep 22, 2022	DP			
		7939502	Jun 14, 2022	U-1324			
TOFACITINIB CITRATE - XELJANZ							
N 203214	001	6956041	Dec 08, 2020	DP		I-761	Dec 14, 2020
		6965027	Mar 25, 2023	DS		I-780	May 30, 2021
		7091208	Dec 08, 2020	U-247			
		7265221	Dec 08, 2020	DS			
		7301023	May 23, 2022	DS			
		7842699	Dec 08, 2020	U-2322			
		RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ							
N 203214	002	6956041	Dec 08, 2020	DP		I-780	May 30, 2021
		6965027	Mar 25, 2023	DS			
		7265221	Dec 08, 2020	DS			
		7301023	May 23, 2022	DS			
		7842699	Dec 08, 2020	U-2322			
		RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ XR							
N 208246	001	6956041	Dec 08, 2020	DP		I-761	Dec 14, 2020
		6965027	Mar 25, 2023	DS			
		7091208	Dec 08, 2020	U-247			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOFACITINIB CITRATE - XELJANZ XR								
N	208246	001	7265221	Dec 08, 2020	DS			
			7301023	May 23, 2022	DS			
			7842699	Dec 08, 2020	U-2322			
			9937181	Mar 14, 2034	DP			
			RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ XR								
N	208246	002	6956041	Dec 08, 2020	DP			
			6965027	Mar 25, 2023	DS			
			7265221	Dec 08, 2020	DS			
			7301023	May 23, 2022	DS			
			7842699	Dec 08, 2020	U-2322			
			RE41783	Dec 08, 2025	DS			
TOLTERODINE TARTRATE - DETROL LA								
N	021228	001	6911217*PED	May 11, 2020				
TOLTERODINE TARTRATE - DETROL LA								
N	021228	002	6911217*PED	May 11, 2020				
TOLVAPTAN - SAMSCA								
N	022275	001	5753677	May 19, 2020	U-978			
			8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA								
N	022275	002	5753677	May 19, 2020	U-978			
			8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA								
N	022275	003	5753677	May 19, 2020	U-978			
			8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE								
N	204441	001	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
			8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOLVAPTAN - JYNARQUE								
N	204441	002	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
			8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOLVAPTAN - JYNARQUE								
N	204441	003	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
			8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOLVAPTAN - JYNARQUE								
N	204441	004	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
			8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOLVAPTAN - JYNARQUE								
N	204441	005	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
			8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOPIRAMATE - TROKENDI XR								
N	201635	001	10314790	Nov 16, 2027	DP U-1675			
			10314790	Nov 16, 2027	DP U-1992			
			8298576	Apr 04, 2028	DP U-106			
			8298576	Apr 04, 2028	DP U-1992			
			8298580	Nov 16, 2027	DP U-106			
			8298580	Nov 16, 2027	DP U-1992			
			8663683	Nov 16, 2027	DP U-106			
			8663683	Nov 16, 2027	DP U-1992			
			8877248	Nov 16, 2027	DP U-106			
			8877248	Nov 16, 2027	DP U-1992			
			8889191	Nov 16, 2027	U-106			
			8889191	Nov 16, 2027	U-1992			
			8992989	Nov 16, 2027	DP U-1675			
			8992989	Nov 16, 2027	DP U-1992			
			9549940	Nov 16, 2027	DP U-1675			
			9549940	Nov 16, 2027	DP U-1992			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 001	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 004	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - QUDEXY XR						
N 205122 001	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 002	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 003	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 004	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 005	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N 020981 001	8158645	Dec 10, 2024	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N 020981 002	8158645	Dec 10, 2024	DP			
TRABECTEDIN - YONDELIS						
N 207953 001	8895557	Jan 07, 2028	DP		M-232	Jun 29, 2021
	8895557*PED	Jul 07, 2028			NCE	Oct 23, 2020
					ODE-100	Oct 23, 2022
					PED	Apr 23, 2021
					PED	Dec 29, 2021
					PED	Apr 23, 2023
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 001	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 002	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 003	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - CONZIP						
N 022370 001	7858118	Apr 11, 2022	DP U-1104			
TRAMADOL HYDROCHLORIDE - CONZIP						
N 022370 002	7858118	Apr 11, 2022	DP U-1104			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMADOL HYDROCHLORIDE - CONZIP							
N 022370	003	7858118	Apr 11, 2022	DP U-1104			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114	001	7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
		8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
		8703781	Oct 15, 2030	DS DP U-2020		M-246	Oct 06, 2022
		8703781	Oct 15, 2030	DS DP U-2037		ODE-148	Jun 22, 2024
		8703781	Oct 15, 2030	DS DP U-2302		ODE-182	Apr 30, 2025
		8703781	Oct 15, 2030	DS DP U-2305		ODE-183	May 04, 2025
		8835443	Jun 10, 2025	U-1581		ODE-48	May 29, 2020
		8835443	Jun 10, 2025	U-1582		ODE-57	Jan 08, 2021
		8835443	Jun 10, 2025	U-2020			
		8835443	Jun 10, 2025	U-2037			
		8835443	Jun 10, 2025	U-2302			
		8835443	Jun 10, 2025	U-2305			
		8952018	Oct 15, 2030	U-2020			
		9155706	Jan 28, 2032	DP			
		9271941	Jan 28, 2032	DP			
		9399021	Jan 28, 2032	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114	002	7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
		8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
		8703781	Oct 15, 2030	DS DP U-2020		M-246	Oct 06, 2022
		8703781	Oct 15, 2030	DS DP U-2037		ODE-148	Jun 22, 2024
		8703781	Oct 15, 2030	DS DP U-2302		ODE-182	Apr 30, 2025
		8703781	Oct 15, 2030	DS DP U-2305		ODE-183	May 04, 2025
		8835443	Jun 10, 2025	U-1581		ODE-48	May 29, 2020
		8835443	Jun 10, 2025	U-1582		ODE-57	Jan 08, 2021
		8835443	Jun 10, 2025	U-2020			
		8835443	Jun 10, 2025	U-2037			
		8835443	Jun 10, 2025	U-2302			
		8835443	Jun 10, 2025	U-2305			
		8952018	Oct 15, 2030	U-2020			
		9155706	Jan 28, 2032	DP			
		9271941	Jan 28, 2032	DP			
		9399021	Jan 28, 2032	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114	003	7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
		8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
		8703781	Oct 15, 2030	DS DP U-2020		M-246	Oct 06, 2022
		8703781	Oct 15, 2030	DS DP U-2037		ODE-148	Jun 22, 2024
		8703781	Oct 15, 2030	DS DP U-2302		ODE-182	Apr 30, 2025
		8703781	Oct 15, 2030	DS DP U-2305		ODE-183	May 04, 2025
		8835443	Jun 10, 2025	U-1581		ODE-48	May 29, 2020
		8835443	Jun 10, 2025	U-1582		ODE-57	Jan 08, 2021
		8835443	Jun 10, 2025	U-2020			
		8835443	Jun 10, 2025	U-2037			
		8835443	Jun 10, 2025	U-2302			
		8835443	Jun 10, 2025	U-2305			
		8952018	Oct 15, 2030	U-2020			
		9155706	Jan 28, 2032	DP			
		9271941	Jan 28, 2032	DP			
		9399021	Jan 28, 2032	DP			
TRANEXAMIC ACID - LYSTEDA							
N 022430	001	7947739	Mar 04, 2025	DP			
		8022106	Mar 04, 2025	U-1182			
		8273795	Mar 04, 2025	U-1182			
		8487005	Mar 04, 2025	DP U-1182			
		8791160	Mar 04, 2025	DP U-1182			
		8809394	Mar 04, 2025	DP U-1182			
		8957113	Mar 04, 2025	DP U-1182			
		9060939	Mar 04, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAVOPROST - TRAVATAN Z								
N 021994	001		8268299	Oct 13, 2029	DP			
			8323630	Sep 20, 2027	DP			
			8388941	Sep 20, 2027	DP			
TRAVOPROST - IZBA								
N 204822	001		8178582	Oct 10, 2029	DP			
			8722735	Oct 10, 2029	DP			
			8754123	May 19, 2029	DP			
			9144561	Mar 13, 2029	DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	001		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	002		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	003		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	004		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO								
N 022411	001		6607748	Jun 29, 2020	DP			
			7829120	Mar 27, 2027	DP		U-796	
			8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO								
N 022411	002		6607748	Jun 29, 2020	DP			
			7829120	Mar 27, 2027	DP		U-796	
			8133893	Mar 13, 2029	DS DP			
TREPROSTINIL - REMODULIN								
N 021272	001		10076505	Dec 16, 2024	DP			
			7999007	Mar 29, 2029	DP		U-1437	
			8653137	Sep 05, 2028			U-1437	
			8658694	Sep 05, 2028			U-1437	
			9199908	May 24, 2024			U-1771	
			9593066	Dec 15, 2028	DS			
			9604901	Dec 15, 2028	DS			
			9713599	Dec 16, 2024			U-2036	
TREPROSTINIL - REMODULIN								
N 021272	002		10076505	Dec 16, 2024	DP			
			7999007	Mar 29, 2029	DP		U-1437	
			8653137	Sep 05, 2028			U-1437	
			8658694	Sep 05, 2028			U-1437	
			9199908	May 24, 2024			U-1771	
			9593066	Dec 15, 2028	DS			
			9604901	Dec 15, 2028	DS			
			9713599	Dec 16, 2024			U-2036	
TREPROSTINIL - REMODULIN								
N 021272	003		10076505	Dec 16, 2024	DP			
			7999007	Mar 29, 2029	DP		U-1437	
			8653137	Sep 05, 2028			U-1437	
			8658694	Sep 05, 2028			U-1437	
			9199908	May 24, 2024			U-1771	
			9593066	Dec 15, 2028	DS			
			9604901	Dec 15, 2028	DS			
			9713599	Dec 16, 2024			U-2036	
TREPROSTINIL - REMODULIN								
N 021272	004		10076505	Dec 16, 2024	DP			
			7999007	Mar 29, 2029	DP		U-1437	
			8653137	Sep 05, 2028			U-1437	
			8658694	Sep 05, 2028			U-1437	
			9199908	May 24, 2024			U-1771	
			9593066	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - REMODULIN							
N 021272	004	9604901	Dec 15, 2028	DS			
		9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - TYVASO							
N 022387	001	8497393	Dec 15, 2028	DS	Y		
		9339507	Mar 10, 2028	DP			
		9358240	May 05, 2028	U-1849			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN							
N 208276	001	10076505	Dec 16, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
		9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN							
N 208276	002	10076505	Dec 16, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
		9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN							
N 208276	003	10076505	Dec 16, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
		9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN							
N 208276	004	10076505	Dec 16, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
		9713599	Dec 16, 2024	U-2036			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	001	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
		7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	002	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
		7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			
		8497393	Dec 15, 2028	DS	Y		
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	003	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
		7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	003	8497393	Dec 15, 2028	DS	Y		
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	004	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
		7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			
		8497393	Dec 15, 2028	DS	Y		
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	005	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
		7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TRETINOIN - RENOVA							
N 021108	001	6531141	Mar 07, 2020				
TRETINOIN - ALTRENO							
N 209353	001	6517847	Aug 03, 2020	DP U-2368		NDF	Aug 23, 2021
TRIAMCINOLONE ACETONIDE - TRIAMCINOLONE ACETONIDE							
A 212384	001					CGT	May 30, 2020
TRIAMCINOLONE ACETONIDE - TRIESENCE							
N 022048	001	6395294	Jan 13, 2020	DP U-846			
		8128960	Dec 17, 2029	DP			
		8211880	Mar 10, 2029	U-1257			
		8211880	Mar 10, 2029	U-1258			
TRIAMCINOLONE ACETONIDE - ZILRETTA							
N 208845	001	8828440	Aug 04, 2031	DP		NP	Oct 06, 2020
		9555048	Aug 04, 2031	U-2151			
TRICLABENDAZOLE - EGATEN							
N 208711	001					NCE	Feb 13, 2024
						ODE-228	Feb 13, 2026
TRIFAROTENE - AKLIEF							
N 211527	001	7807708	Oct 01, 2026	DS DP		NCE	Oct 04, 2024
		8227507	Dec 21, 2025	U-818			
		8470871	Dec 21, 2025	U-2639			
		9084778	May 30, 2033	DP U-134			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRIPTORELIN PAMOATE - TRELSTAR							
N 022437	001	10166181	Feb 10, 2029	DP			
TRIPTORELIN PAMOATE - TRIPTODUR KIT							
N 208956	001	10166181	Feb 10, 2029	DP		NP	Jun 29, 2020
						ODE-149	Jun 29, 2024
UBROGEPANT - UBRELVY							
N 211765	001					NCE	Dec 23, 2024
UBROGEPANT - UBRELVY							
N 211765	002					NCE	Dec 23, 2024
ULIPRISTAL ACETATE - ELLA							
N 022474	001	10159681	Apr 13, 2030	U-2510			
		8426392	Jun 12, 2030	U-1389			
		8512745	Jun 02, 2030	DP			
		8735380	Feb 20, 2029	DP			
		8962603	Jun 12, 2030	U-1657			
		9283233	Apr 13, 2030	U-1821			
		9844510	Dec 08, 2028	DP			
UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA							
N 205382	001	7488827	Dec 18, 2027	DS DP			
		7498440	Apr 27, 2025	DS DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8183257	Jul 27, 2025	U-1476			
		8201556	Feb 05, 2029	DP			
		8309572	Apr 27, 2025	U-1476			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA							
N 203975	001	7439393	May 21, 2025	DS DP U-1476		M-245	Jun 09, 2022
		7488827	Dec 18, 2027	DS DP			
		7498440	Apr 27, 2025	DS DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8183257	Jul 27, 2025	U-1476			
		8309572	Apr 27, 2025	U-1476			
		8511304	Jun 14, 2027	DP U-1476			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		9750726	Nov 29, 2030	DP			
		RE44874	Mar 23, 2023	DS DP U-1476			
UNOPROSTONE ISOPROPYL - RESCULA							
N 021214	001	6458836	Jul 09, 2021	U-1315			
		6458836	Jul 09, 2021	U-333			
UPADACITINIB - RINVOQ							
N 211675	001	8962629	Jan 15, 2031	DS U-2616		NCE	Aug 16, 2024
		9951080	Oct 17, 2036	DS DP			
		9963459	Oct 17, 2036	DP			
		RE47221	Dec 01, 2030	DS			
URIDINE TRIACETATE - VISTOGARD							
N 208159	001	6258795	Jul 10, 2023	DP		NCE	Sep 04, 2020
		7776838	Aug 17, 2027	U-1791		ODE-104	Dec 11, 2022
URIDINE TRIACETATE - XURIDEN							
N 208169	001	6258795	Jul 10, 2023	DP		NCE	Sep 04, 2020
						ODE-98	Sep 04, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALBENAZINE TOSYLATE - INGREZZA							
N 209241	001	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
		8039627	Oct 06, 2029	DS DP			
		8357697	Nov 08, 2027	U-1995			
VALBENAZINE TOSYLATE - INGREZZA							
N 209241	002	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
		8039627	Oct 06, 2029	DS DP			
		8357697	Nov 08, 2027	U-1995			
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE							
N 022257	001	8889109	Dec 11, 2027	DP			
		9642911	Dec 11, 2027	DP			
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT							
N 208910	001	10493028	Mar 13, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT							
N 208910	002	10493028	Mar 13, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	001	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	002	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	003	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	004	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
VANDETANIB - CAPRELSA							
N 022405	001	7173038	Aug 14, 2021	DS DP			
		8067427	Aug 08, 2028	DP			
		8642608	Feb 06, 2022	U-1490			
		RE42353	Jun 27, 2022	DS DP			
VANDETANIB - CAPRELSA							
N 022405	002	7173038	Aug 14, 2021	DS DP			
		8067427	Aug 08, 2028	DP			
		8642608	Feb 06, 2022	U-1490			
		RE42353	Jun 27, 2022	DS DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	001	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	002	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	003	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	004	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - STAXYN							
N 200179	001	8613950	Dec 23, 2028	DP			
VARENICLINE TARTRATE - CHANTIX							
N 021928	001	6410550	May 10, 2020	DS DP U-56		M-237	Feb 22, 2022
		6410550*PED	Nov 10, 2020			PED	Aug 22, 2022
		6890927	May 06, 2022	DS DP U-56			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VARENICLINE TARTRATE - CHANTIX							
N 021928	001	6890927*PED	Nov 06, 2022				
		7265119	Aug 03, 2022	DS DP U-56			
		7265119*PED	Feb 03, 2023				
VARENICLINE TARTRATE - CHANTIX							
N 021928	002	6410550	May 10, 2020	DS DP U-56		M-237	Feb 22, 2022
		6410550*PED	Nov 10, 2020			PED	Aug 22, 2022
		6890927	May 06, 2022	DS DP U-56			
		6890927*PED	Nov 06, 2022				
		7265119	Aug 03, 2022	DS DP U-56			
		7265119*PED	Feb 03, 2023				
VASOPRESSIN - VASOSTRICT							
N 204485	001	9375478	Jan 30, 2035	U-1857			
		9687526	Jan 30, 2035	U-1857			
		9744209	Jan 30, 2035	U-1857			
		9744239	Jan 30, 2035	U-1857			
		9750785	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT							
N 204485	002	9375478	Jan 30, 2035	U-1857			
		9687526	Jan 30, 2035	U-1857			
		9744209	Jan 30, 2035	U-1857			
		9744239	Jan 30, 2035	U-1857			
		9750785	Jan 30, 2035	DP			
		9937223	Jan 30, 2035	U-1857			
VEMURAFENIB - ZELBORAF							
N 202429	001	7504509	Oct 22, 2026	DS DP		I-757	Nov 06, 2020
		7863288	Jun 20, 2029	DS DP		ODE-158	Nov 06, 2024
		8143271	Jun 21, 2026	DS DP			
		8470818	Aug 02, 2026	U-1418			
		8470818	Aug 02, 2026	U-2164			
		8741920	Jul 27, 2030	DS DP			
		9447089	Jun 06, 2032	DP			
VENETOCLAX - VENCLEXTA							
N 208573	001	8546399	Jun 27, 2031	DS DP		I-782	Jun 08, 2021
		9174982	May 26, 2030	U-2323		I-789	Nov 21, 2021
		9174982	May 26, 2030	U-2445		I-795	May 15, 2022
		9174982	May 26, 2030	U-2446		M-228	Jun 08, 2021
		9174982	May 26, 2030	U-2537		NCE	Apr 11, 2021
		9539251	Sep 06, 2033	U-2538		ODE-114	Apr 11, 2023
						ODE-185	Jun 08, 2025
						ODE-211	Nov 21, 2025
						ODE-239	May 15, 2026
VENETOCLAX - VENCLEXTA							
N 208573	002	8546399	Jun 27, 2031	DS DP		I-782	Jun 08, 2021
		9174982	May 26, 2030	U-2323		I-789	Nov 21, 2021
		9174982	May 26, 2030	U-2445		I-795	May 15, 2022
		9174982	May 26, 2030	U-2446		M-228	Jun 08, 2021
		9174982	May 26, 2030	U-2537		NCE	Apr 11, 2021
		9539251	Sep 06, 2033	U-2538		ODE-114	Apr 11, 2023
						ODE-185	Jun 08, 2025
						ODE-211	Nov 21, 2025
						ODE-239	May 15, 2026
VENETOCLAX - VENCLEXTA							
N 208573	003	8546399	Jun 27, 2031	DS DP		I-782	Jun 08, 2021
		9174982	May 26, 2030	U-2323		I-789	Nov 21, 2021
		9174982	May 26, 2030	U-2445		I-795	May 15, 2022
		9174982	May 26, 2030	U-2446		M-228	Jun 08, 2021
		9174982	May 26, 2030	U-2537		NCE	Apr 11, 2021
		9539251	Sep 06, 2033	U-2538		ODE-114	Apr 11, 2023
						ODE-185	Jun 08, 2025
						ODE-211	Nov 21, 2025
						ODE-239	May 15, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	001	7834020	Jun 05, 2022	DS DP U-839			
		8193195	Jun 05, 2022	U-839			
		8236804	Jun 05, 2022	U-839			
		8673921	Jun 05, 2022	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	002	7834020	Jun 05, 2022	DS DP U-839			
		8193195	Jun 05, 2022	U-839			
		8236804	Jun 05, 2022	U-839			
		8673921	Jun 05, 2022	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	003	7834020	Jun 05, 2022	DS DP U-839			
		8193195	Jun 05, 2022	U-839			
		8236804	Jun 05, 2022	U-839			
		8673921	Jun 05, 2022	DS DP			
VINCRISTINE SULFATE - MARQIBO KIT							
N 202497	001	6723338	Mar 31, 2020	U-1271			
		7247316	Sep 25, 2020	DP			
		7887836	Mar 31, 2020	U-1271			
VISMODEGIB - ERIVEDGE							
N 203388	001	7888364	Nov 11, 2028	DS DP			
		9278961	Dec 15, 2028	U-1825			
VORAPAXAR SULFATE - ZONTIVITY							
N 204886	001	7235567	Jun 13, 2021	DS DP			
		7304078	Apr 06, 2024	DS DP U-1512			
		7713999	May 30, 2024	DS DP U-2291			
VORICONAZOLE - VFEND							
N 021266	001					NPP	Jan 29, 2022
VORICONAZOLE - VFEND							
N 021266	002					NPP	Jan 29, 2022
VORICONAZOLE - VFEND							
N 021267	001					NPP	Jan 29, 2022
VORICONAZOLE - VFEND							
N 021630	001					NPP	Jan 29, 2022
VORINOSTAT - ZOLINZA							
N 021991	001	7399787	Feb 09, 2025	U-892			
		7456219	Mar 11, 2027	DS			
		7652069	Mar 04, 2023	DP			
		7732490	Mar 04, 2023	U-892			
		7851509	Feb 21, 2024	DP U-892			
		8067472	Mar 04, 2023	U-892			
		8093295	May 16, 2026	DP			
		8101663	Mar 04, 2023	U-892			
		8450372	Mar 18, 2028	U-892			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	001	7144884	Jun 17, 2026	DS DP U-1439		M-227	May 02, 2021
		8476279	Oct 02, 2022	DP U-1439		M-234	Oct 19, 2021
		8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	002	7144884	Jun 17, 2026	DS DP U-1439		M-227	May 02, 2021
		8476279	Oct 02, 2022	DP U-1439		M-234	Oct 19, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	002	8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	003	7144884	Jun 17, 2026	DS DP U-1439		M-227	May 02, 2021
		8476279	Oct 02, 2022	DP U-1439		M-234	Oct 19, 2021
		8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	004	7144884	Jun 17, 2026	DS DP U-1439		M-227	May 02, 2021
		8476279	Oct 02, 2022	DP U-1439		M-234	Oct 19, 2021
		8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			
VOXELOTOR - OXBRYTA							
N 213137	001					NCE	Nov 25, 2024
ZANUBRUTINIB - BRUKINSA							
N 213217	001	9447106	Apr 22, 2034	DS DP U-2145		NCE	Nov 14, 2024
						ODE-276	Nov 14, 2026
ZICONOTIDE ACETATE - PRIALT							
N 021060	001	8653033	Oct 01, 2024	U-48			
		8653033	Oct 01, 2024	U-55			
		8765680	Oct 01, 2024	U-48			
		8765680	Oct 01, 2024	U-55			
		9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT							
N 021060	002	8653033	Oct 01, 2024	U-48			
		8653033	Oct 01, 2024	U-55			
		8765680	Oct 01, 2024	U-48			
		8765680	Oct 01, 2024	U-55			
		9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT							
N 021060	003	8653033	Oct 01, 2024	U-48			
		8653033	Oct 01, 2024	U-55			
		8765680	Oct 01, 2024	U-48			
		8765680	Oct 01, 2024	U-55			
		9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT							
N 021060	004	8653033	Oct 01, 2024	U-48			
		8653033	Oct 01, 2024	U-55			
		8765680	Oct 01, 2024	U-48			
		8765680	Oct 01, 2024	U-55			
		9707270	Oct 01, 2024	U-2084			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZIPRASIDONE HYDROCHLORIDE - GEODON								
N	021483	001	7175855	May 18, 2020	DP			
ZOLEDRONIC ACID - ZOMETA								
N	021223	002	8324189	May 29, 2025			U-1308	
			8324189	May 29, 2025			U-1309	
			8324189	May 29, 2025			U-53	
ZOLEDRONIC ACID - ZOMETA								
N	021223	003	7932241	Feb 05, 2028	DP			
			8324189	May 29, 2025			U-1308	
			8324189	May 29, 2025			U-1309	
			8324189	May 29, 2025			U-53	
ZOLEDRONIC ACID - RECLAST								
N	021817	001	7932241	Feb 05, 2028	DP			
			8052987	Oct 27, 2023			U-1199	
ZOLMITRIPTAN - ZOMIG								
N	021450	003	6750237	Nov 28, 2020	DP			
			6750237*PED	May 28, 2021				
			7220767	Nov 28, 2020	DP			
			7220767*PED	May 28, 2021				
ZOLMITRIPTAN - ZOMIG								
N	021450	004	6750237	Nov 28, 2020	DP			
			7220767	Nov 28, 2020	DP			
ZOLPIDEM TARTRATE - EDLUAR								
N	021997	001	9265720	Feb 25, 2031			U-674	
			9597281	Apr 06, 2027			U-674	
ZOLPIDEM TARTRATE - EDLUAR								
N	021997	002	9265720	Feb 25, 2031			U-674	
			9597281	Apr 06, 2027			U-674	
ZOLPIDEM TARTRATE - ZOLPIMIST								
N	022196	001	8236285	Aug 07, 2032	DS DP		U-70	
ZOLPIDEM TARTRATE - INTERMEZZO								
N	022328	001	7658945	Apr 15, 2027	DP		U-1194	
			7682628	Feb 16, 2025			U-1194	
			8242131	Aug 20, 2029			U-1266	
			8252809	Feb 16, 2025	DP			
ZOLPIDEM TARTRATE - INTERMEZZO								
N	022328	002	7658945	Apr 15, 2027	DP		U-1194	
			7682628	Feb 16, 2025			U-1194	
			8242131	Aug 20, 2029			U-1266	
			8252809	Feb 16, 2025	DP			

PATENT AND EXCLUSIVITY TERMS

PATENT & EXCLUSIVITY ABBREVIATIONS

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN

EXCLUSIVITY DOSING SCHEDULE

D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING
D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY

EXCLUSIVITY DOSING SCHEDULE

D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
D-90	ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
D-91	ALTERNATE INTERMITTENT DOSING REGIMEN

EXCLUSIVITY DOSING SCHEDULE

D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION

EXCLUSIVITY DOSING SCHEDULE

D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.
D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP

EXCLUSIVITY DOSING SCHEDULE

D-150	1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
D-151	DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
D-152	DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
D-153	IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
D-154	ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
D-155	SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-156	DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
D-157	UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
D-158	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
D-159	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
D-160	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
D-161	DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
D-162	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
D-163	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
D-164	UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
D-165	DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
D-166	BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY
D-167	ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAIVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY
D-168	NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
D-169	ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE
D-170	TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
D-171	REVISED DOSING TO INCLUDE UP-TITRATION AS A STRATEGY TO IMPROVE TOLERABILITY AND THEREBY REDUCE TREATMENT DISCONTINUATION FOR ROFLUMILAST MAINTENANCE DOSAGE OF 500 MCG DAILY
D-172	ADDITION OF A ONCE WEEKLY DOSING REGIMEN FOR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE

EXCLUSIVITY DOSING SCHEDULE

	RECEIVED ONE TO THREE LINES OF THERAPY
D-173	DOSING RECOMMENDATION FOR THE USE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED DOSE COMBINATION IN HIV-1 INFECTED ADULT PATIENTS WITH END-STAGE-RENAL DISEASE WHO ARE RECEIVING CHRONIC HEMODIALYSIS
D-174	MODIFICATIONS TO THE EXISTING DOSING REGIMEN TO ALLOW FOR TREATMENT INTERRUPTIONS OF UP TO 8 WEEKS FOR INTOLERABLE ADVERSE REACTIONS
D-175	EIGHT-WEEK DOSING REGIMEN FOR THE TREATMENT OF GENOTYPES 1, 2, 3, 4, 5, AND 6, CHRONIC HEPATITIS C VIRUS INFECTION IN TREATMENT-NAIVE SUBJECTS WITH COMPENSATED CIRRHOSIS BASED ON THE RESULTS FROM THE EXPEDITION-8 STUDY
D-176	IBRUTINIB IN COMBINATION WITH RITUXIMAB
D-177	INFORMATION ADDED TO THE DOSIG SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS
D-178	INFORMATION ADDED TO THE DOSING SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS

	EXCLUSIVITY INDICATION
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS

	EXCLUSIVITY INDICATION
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER

	EXCLUSIVITY INDICATION
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUKOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES

	EXCLUSIVITY INDICATION
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONYCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES

	EXCLUSIVITY INDICATION
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONYCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS

	EXCLUSIVITY INDICATION
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

	EXCLUSIVITY INDICATION
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
I-250	PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
I-251	TREATMENT OF GENERALIZED ANXIETY DISORDER
I-252	NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
I-253	COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
I-254	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
I-255	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
I-256	USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
I-257	TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
I-258	FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
I-259	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-260	EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

	EXCLUSIVITY INDICATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS

	EXCLUSIVITY INDICATION
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN

	EXCLUSIVITY INDICATION
	PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE

	EXCLUSIVITY INDICATION
	PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
I-387	ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
I-388	TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-389	SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS

EXCLUSIVITY INDICATION

I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....

I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY

I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL

I-393 CHRONIC BACTERIAL PROSTATITIS

I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES

I-395 TO IMPROVE PHYSICAL FUNCTION

I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION

I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY

I-398 IDIOPATHIC SHORT STATURE

I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS

I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER

I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA

I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS

I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE

I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY

I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN

I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)

I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION

I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)

I-409 ESOPHAGEAL CANDIDIASIS

I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS

I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS

I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS

I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY

I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS

	EXCLUSIVITY INDICATION
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
I-432	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
I-433	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
I-434	PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
I-435	CHRONIC IDIOPATHIC CONSTIPATION
I-436	FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
I-437	TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-438	EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
I-439	USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
I-440	FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
I-441	USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
I-442	USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
I-443	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
I-444	USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM

	EXCLUSIVITY INDICATION
	TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS
I-445	TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
I-446	EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
I-447	USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
I-448	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
I-449	TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
I-450	TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
I-451	MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
I-452	EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
I-453	USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
I-454	MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
I-455	MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
I-456	TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
I-457	TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
I-458	USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
I-459	NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
I-460	TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
I-461	USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
I-462	LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
I-463	TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
I-464	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
I-465	PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
I-466	FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
I-467	USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
I-468	USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
I-469	RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
I-470	DIABETIC PERIPHERAL NEUROPATHIC PAIN

	EXCLUSIVITY INDICATION
I-471	INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
I-472	USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
I-473	USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
I-474	TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
I-475	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
I-476	TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
I-477	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
I-478	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
I-479	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
I-480	PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
I-481	INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-482	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
I-483	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-484	FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
I-485	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-486	ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
I-487	INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
I-488	MAINTENANCE THERAPY IN BIPOLAR I DISORDER
I-489	FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
I-490	FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
I-491	INFLUENZA PROPHYLAXIS
I-492	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
I-493	ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
I-494	CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
I-495	ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
I-496	LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
I-497	PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
I-498	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-499	USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF

EXCLUSIVITY INDICATION

	PLATINUM-BASED THERAPY
I-500	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETENT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
I-502	FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
I-503	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-504	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
I-505	TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
I-506	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-507	ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-508	PREMENSTRUAL DYSPHONIC DISORDER
I-509	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
I-510	ADULT DERMATOFIBROSARCOMA PROTUBERANS (DFSP)
I-511	ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
I-512	ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
I-513	ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
I-514	ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
I-515	PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
I-516	PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-517	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
I-518	TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
I-519	USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-520	USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
I-521	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
I-522	TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
I-523	USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
I-524	GENERALIZED ANXIETY DISORDER (GAD)
I-525	USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
I-526	TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
I-527	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-528	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

	EXCLUSIVITY INDICATION
I-529	TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
I-530	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
I-531	MAINTENANCE TREATMENT OF SCHIZOPHRENIA
I-532	TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
I-533	ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
I-534	EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
I-535	MANAGEMENT OF FIBROMYALGIA
I-536	FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
I-537	LONG TERM TREATMENT OF PANIC DISORDER
I-538	SHORT TERM TREATMENT OF PANIC DISORDER
I-539	REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
I-540	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
I-541	TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
I-542	EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
I-543	USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-544	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-545	ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
I-546	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
I-547	ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
I-548	SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
I-549	USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-550	TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
I-551	TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
I-552	ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
I-553	FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-554	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
I-555	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
I-556	PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
I-557	USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
I-558	MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-559	ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
I-560	MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX

EXCLUSIVITY INDICATION

I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)

	EXCLUSIVITY INDICATION
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
I-605	ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
I-606	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
I-607	INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
I-608	REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
I-610	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-611	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
I-612	MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
I-613	MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
I-614	SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
I-615	MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-616	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
I-617	MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
I-618	ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
I-619	INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
I-620	FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
I-621	PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
I-622	ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER

	EXCLUSIVITY INDICATION
I-623	TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
I-624	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
I-625	PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
I-626	RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-627	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
I-628	MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
I-629	ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-630	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
I-631	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
I-632	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
I-633	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-634	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
I-635	ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
I-636	TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
I-637	USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
I-638	FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
I-639	TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
I-640	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-641	TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-642	TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-643	REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
I-644	MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
I-645	MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
I-646	SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
I-647	SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
I-648	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
I-649	TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
I-650	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
I-651	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
I-652	MANAGEMENT OF POSTHERPETIC NEURALGIA
I-653	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
I-654	MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE

	EXCLUSIVITY INDICATION
I-655	TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
I-656	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
I-657	PLAQUE PSORIASIS OF THE SCALP
I-658	FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
I-659	PLAQUE PSORIASIS OF THE BODY
I-660	TREATMENT OF DEEP VEIN THROMBOSIS
I-661	TREATMENT OF PULMONARY EMBOLISM
I-662	REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
I-663	IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
I-664	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
I-665	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
I-666	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
I-667	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
I-668	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
I-669	SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
I-670	TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
I-671	FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-672	USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
I-673	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
I-674	TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
I-675	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-676	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
I-677	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
I-678	TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-679	RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

EXCLUSIVITY INDICATION

I-680	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-681	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
I-682	TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
I-683	TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
I-684	PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
I-685	EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
I-686	INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
I-687	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
I-688	GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
I-689	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
I-690	INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
I-691	INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
I-692	INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
I-693	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
I-694	TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
I-695	REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
I-696	USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
I-697	FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
I-698	SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
I-699	FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
I-700	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
I-701	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL
I-702	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
I-703	MODERATE TO SEVERE BINGE EATING DISORDER (BED)
I-704	EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN
I-705	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
I-706	EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-707	POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
I-708	DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
I-709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

EXCLUSIVITY INDICATION

I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.

I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.

I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY

I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE

I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION

I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.

I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY

I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4

I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY

I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.

I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.

I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.

I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.

I-723 AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY

I-724 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE

I-725 TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.

I-726 EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION

I-727 EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL

I-728 EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS

I-729 PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

I-730 NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY

I-731 FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE

I-732 TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS

I-733 USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN

I-734 EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC

EXCLUSIVITY INDICATION

THERAPY.

I-735 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE

I-736 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)

I-737 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION

I-738 REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS

I-739 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE

I-740 EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE

I-741 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY

I-742 TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA

I-743 INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665

I-744 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

I-745 MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.

I-746 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS

I-747 FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA

I-748 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER

I-749 MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY

I-750 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE

I-751 TREATMENT OF TARDIVE DYSKINESIA

I-752 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE

I-753 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY

I-754 TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME

I-755 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY

I-756 EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB

I-757 TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

I-758 FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV

I-759 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)

	EXCLUSIVITY INDICATION
I-760	FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
I-761	TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
I-762	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING
I-763	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-764	TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
I-765	ABIRATERONE ACETATE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
I-766	TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR
I-767	TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON
I-768	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
I-769	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
I-770	TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
I-771	REVISION OF THE INDICATION SECTION OF THE PACKAGE INSERT REGARDING AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
I-772	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
I-773	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGE 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
I-774	TO ALLOW FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS, AS DETECTED BY AN FDA APPROVED TEST
I-775	REVISED INDICATION FOR FIXED-DOSE COMBINATION OF FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL TO TREAT AIRFLOW OBSTRUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TO REDUCE COPD EXACERBATIONS IN PTS WITH HISTORY OF EXACERBATIONS
I-776	FIRSTLINE MAINTENANCE TX IN PTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE, SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO FIRSTLINE PLATINUM-BASED CHEMOTHERAPY
I-777	CO-ADMINISTRATION THERAPY OF MIRABEGRON WITH SOLIFENACIN SUCCINATE FOR TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
I-778	DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
I-779	USE OF TOLVAPTAN TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
I-780	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
I-781	DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

EXCLUSIVITY INDICATION

I-782 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-783 EXPANDED INDICATION TO INCLUDE RIBOCICLIB WITH AN AROMATASE INHIBITOR IN PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY

I-784 RIBOCICLIB WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY

I-785 TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE

I-786 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

I-787 FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

I-788 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)

I-789 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

I-790 USE OF FERRIC CITRATE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH CKD NOT ON DIALYSIS

I-791 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY

I-792 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

I-793 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE

I-794 TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY

I-795 VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

I-796 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)

I-797 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)

I-798 TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION)

I-799 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER

I-800 TREATMENT OF OCULAR INFLAMMATION FOLLOWING OPHTHALMIC SURGERY

I-801 USE IN CARDIAC MRI TO ASSESS MYOCARDIAL PERFUSION (STRESS, REST) AND LATE GADOLINIUM ENHANCEMENT IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE (CAD)

I-802 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

I-803 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE

I-804 EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

I-805 SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

I-806 EXPANDED INDICATION FOR PTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HX OF TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W RESISTANCE TO DORAVIRINE, LAMIVUDINE OR TENOFOVIR

EXCLUSIVITY INDICATION

	DISOPROXIL FUMARATE
I-807	TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
I-808	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
I-809	TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY
I-810	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
I-811	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS AND ARE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS
I-812	FOR USE IN AT RISK ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF HIV-1 INFECTION FROM SEXUAL ACQUISITION, EXCLUDING INDIVIDUALS AT RISK FROM RECEPTIVE VAGINAL SEX
I-813	TX OF ADULT PTS W/ ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY POSITIVE STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
I-814	TX OF ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY DEFINED BY POSITIVE STATUS GENOMIC INSTABILITY & WHO HAVE PROGRESSED >6MO AFTER RESPONSE TO LAST PLATINUM-BASED CHEMO
I-815	TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
I-816	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
I-817	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
I-818	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
I-819	ADJUNCT TO MAX TOLERATED STATIN TX TO REDUCE RISK OF MI, STROKE, CORONARY REVASCULARIZATION, & UNSTABLE ANGINA REQUIRING HOSPITALIZATION IN ADULTS W/ ELEVATED TG LEVELS & ESTABLISHED CV DISEASE OR DIABETES MELLITUS & 2+ RISK FACTORS FOR CV DISEASE
I-820	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION

EXCLUSIVITY MISCELLANEOUS

	INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
M-30	CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
M-31	INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
M-32	ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
M-33	INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
M-34	EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-35	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
M-36	ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
M-37	INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE

EXCLUSIVITY MISCELLANEOUS

	SUBSECTIONS
M-38	SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
M-39	FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
M-40	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
M-41	REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
M-42	ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
M-43	INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
M-44	CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
M-45	INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
M-46	PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
M-47	PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
M-48	CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
M-49	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
M-50	NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
M-51	INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
M-52	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
M-53	FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
M-54	INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
M-55	INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
M-56	INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
M-57	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
M-58	CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
M-59	RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
M-60	CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
M-61	REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-62	CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES

EXCLUSIVITY MISCELLANEOUS

M-63	DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
M-64	CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
M-65	ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
M-66	USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
M-67	INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
M-68	DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
M-69	RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
M-70	PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
M-71	REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
M-72	INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
M-73	NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
M-74	REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
M-75	PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
M-76	REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
M-77	USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
M-78	CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
M-79	LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
M-80	ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
M-81	ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOTOXICOSIS)
M-82	LABELING REVISIONS RELATED TO CLINICAL STUDIES
M-83	ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
M-84	STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
M-85	INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
M-86	LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
M-87	INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
M-88	ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
M-89	PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
M-90	LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND

EXCLUSIVITY MISCELLANEOUS

	CHILDREN AGES 1-12
M-91	UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
M-92	UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
M-93	EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
M-94	INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
M-95	INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
M-96	UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97	LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98	NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
M-99	ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATIENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
M-100	INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
M-101	INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
M-102	INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
M-103	SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
M-104	INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
M-105	NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
M-106	ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
M-107	INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
M-108	CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
M-109	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-110	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-111	LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
M-112	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
M-113	LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS

EXCLUSIVITY MISCELLANEOUS

M-114	CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
M-115	REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
M-116	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
M-117	ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
M-118	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
M-119	LABELING CHANGES REGARDING MISSED DOSES
M-120	CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
M-121	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
M-122	LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
M-123	UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
M-124	LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
M-125	LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
M-126	UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
M-127	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
M-128	CLINICAL TRIAL STUDY RESULTS
M-129	RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
M-130	ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
M-131	INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
M-132	REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
M-133	INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
M-134	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
M-135	ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
M-136	ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS
M-137	LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
M-138	INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
M-139	INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
M-140	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
M-141	REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
M-142	ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY
M-143	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER

EXCLUSIVITY MISCELLANEOUS

M-144	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
M-145	ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
M-146	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
M-147	OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
M-148	LABELING CHANGES BASED ON STUDY H80-EW-GWDM
M-149	INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
M-150	ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
M-151	REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
M-152	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
M-153	ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
M-154	UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
M-155	ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
M-156	UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
M-157	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
M-158	UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
M-159	ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
M-160	UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
M-161	UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
M-162	INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
M-163	INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
M-164	REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
M-165	PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)"
M-166	UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS

EXCLUSIVITY MISCELLANEOUS

M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".

M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)

M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.

M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL

M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS

M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS

M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN

M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES

M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT

M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE

M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS

M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS

M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA

M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"

M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM

M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES

M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS

M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232

M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING

M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)

M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES

M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE

EXCLUSIVITY MISCELLANEOUS

LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS

M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2

M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS

M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA

M-194 INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE

M-195 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17

M-196 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1

M-197 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR

M-198 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN

M-199 INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.

M-200 CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.

M-201 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.

M-202 INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.

M-203 PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569

M-204 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

M-205 INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT

M-206 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY

M-207 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY

M-208 INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

M-209 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY

M-210 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

M-211 PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE

M-212 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC

EXCLUSIVITY MISCELLANEOUS

CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE

M-213 INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

M-214 INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS

M-215 INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED

M-216 UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER

M-217 INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING

M-218 ADDITIONAL INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS AGED 6 THROUGH 11 YEARS (TRIAL 4)

M-219 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS 7 TO 14 YEARS OF AGE WITH DUCHENNE MUSCULAR DYSTROPHY

M-220 ADDITIONAL INFORMATION ADDED TO THE LABELING FROM STUDY PC B308/13 REGARDING THE USE OF BLUE LIGHT CYSTOSCOPY WITH CYSVIEW AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY

M-221 DRUG FACTS LABELING CHANGES UNDER THE DIRECTIONS HEADING TO REVISE THE STATED PREPARATION TIME OF A DRY SITE FROM 120 SECONDS SCRUBBING AND 90 SECONDS DRYING TO 30 SECONDS SCRUBBING AND 30 SECONDS DRYING

M-222 ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1

M-223 INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)

M-224 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF EXENATIDE EXTENDED RELEASE AS ADD-ON IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN GLARGINE WITH OR WITHOUT METFORMIN

M-225 REVISIONS TO SECTION 8.4 OF THE PRESCRIBING INFORMATION TO INCLUDE A SAFETY AND EFFICACY STUDY IN PEDIATRIC PATIENTS AGES >=6 YEARS TO <18 YEARS WITH CHRONIC IDIOPATHIC CONSTIPATION

M-226 CHANGES TO THE LABELING BASED ON RESULTS FROM A CONTROLLED CLINICAL TRIAL IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY

M-227 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER

M-228 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX

M-229 REVISED LABELING TO INCORPORATE THE PEDIATRIC USE OF LOTEPREDNOL ETABONATE GEL IN PATIENTS FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY

M-230 REVISIONS TO THE GLECAPREVIR/PIBRENTASVIR COMBINATION PRODUCT PRESCRIBING INFORMATION TO INCLUDE SAFETY AND EFFICACY DATA FROM THE HCV/HIV-1 COINFECTION STUDY M14-730 AND FROM THE LIVER AND RENAL TRANSPLANT STUDY M13-596

M-231 REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION (SECTION 8.3) OF THE PACKAGE INSERT WITH THE RESULTS OF CLINICAL TRIAL WV25651, CONDUCTED TO EVALUATE THE EFFECT OF VALGANCYCLOVIR ON SPERMATOGENESIS AND TO FULFILL PMR 1670-3

M-232 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES

M-233 INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS

M-234 UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS

M-235 INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY LAP016A2307 TO

EXCLUSIVITY MISCELLANEOUS

	FULFILL POSTMARKETING STUDY REQUIREMENT 1586-1
M-236	INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
M-237	INFORMATION ADDED TO LABELING TO DESCRIBE A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN ADOLESCENT SMOKERS
M-238	INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
M-239	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD
M-240	INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES
M-241	INFORMATION ADDED TO THE LABELING FOR SAFETY & EFFICACY STUDY ENTITLED, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) & TRANSFUSIONAL IRON OVERLOAD
M-242	INFORMATION ADDED TO THE LABELING REGARDING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC/LIRAGLUTIDE VS INSULIN GLARGINE IN PTS W/ TYPE 2 DIABETES INADEQUATELY CONTROLLED ON SGLT2I WITH OR WITHOUT ORAL ANTIDIABETIC THERAPIES
M-243	INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER
M-244	INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
M-245	ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIAL
M-246	ADDITION OF STUDY BRF117277, A NON-RANDOMIZED, OPEN-LABEL, MULTI-CENTER, MULTI-COHORT TRIAL OF DABRAFENIB PLUS TRAMETINIB IN SUBJECTS WITH BRAF MUTATION-POSITIVE MELANOMA THAT HAS METASTASIZED TO THE BRAIN
M-247	REVISIONS TO THE LABELING REGARDING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AS A CONDITION OF USE FOR INSULIN ASPART
M-248	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
M-249	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY LVM-MD-15 TO FULFILL POSTMARKETING COMMITMENT 1943-4
M-250	REVISIONS TO THE PEDIATRIC USE SECTION TO INCLUDE AN OPEN-LABEL CLINICAL TRIAL TO FULFILL PMR 1655-1

ORPHAN DRUG EXCLUSIVITY

ODE-1	TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)
ODE-2	FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
ODE-3	TO TREAT INFANTILE SPASMS
ODE-4	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION
ODE-5	FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING
ODE-6	FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA

ORPHAN DRUG EXCLUSIVITY

ODE-7	TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
ODE-8	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
ODE-9	TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-10	FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
ODE-11	TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-12	TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-13	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-14	TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER
ODE-15	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST
ODE-16	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
ODE-17	ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER
ODE-18	ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME INPATIENTS 2 YEARS OF AGE OR OLDER
ODE-19	TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
ODE-20	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE.
ODE-21	AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY
ODE-22	FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
ODE-23	ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
ODE-24	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
ODE-25	MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS.
ODE-26	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
ODE-27	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
ODE-28	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
ODE-29	LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
ODE-30	TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY
ODE-31	TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
ODE-32	TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
ODE-33	TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
ODE-34	TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS

ORPHAN DRUG EXCLUSIVITY

	NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-35	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.
ODE-36	ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
ODE-37	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-38	PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
ODE-39	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
ODE-40	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
ODE-41	ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
ODE-42	USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-43	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
ODE-44	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
ODE-45	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER.
ODE-46	IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
ODE-47	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
ODE-48	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
ODE-49	TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
ODE-50	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
ODE-51	TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
ODE-52	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
ODE-53	TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.
ODE-54	TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENED PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT).
ODE-55	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-56	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE

ORPHAN DRUG EXCLUSIVITY

	TREATMENT.
ODE-57	TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-58	DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-59	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
ODE-60	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-61	TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
ODE-62	TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.
ODE-63	TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
ODE-64	SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
ODE-65	TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
ODE-66	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
ODE-67	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
ODE-68	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
ODE-69	TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
ODE-70	RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
ODE-71	RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-72	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-73	LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
ODE-74	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
ODE-75	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
ODE-76	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
ODE-77	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
ODE-78	TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.
ODE-79	TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
ODE-80	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
ODE-81	TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION

ORPHAN DRUG EXCLUSIVITY

ODE-82	TREATMENT OF PATIENTS WITH UNRESECTABLE,WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
ODE-83	USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-84	TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
ODE-85	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
ODE-86	TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
ODE-87	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
ODE-88	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
ODE-89	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
ODE-90	TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
ODE-91	TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
ODE-92	TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
ODE-93	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
ODE-94	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-95	FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-96	TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
ODE-97	TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
ODE-98	TREATMENT OF HEREDITARY OROTIC ACIDURIA
ODE-99	FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
ODE-100	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-101	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
ODE-102	FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
ODE-103	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-104	EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
ODE-105	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-106	FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
ODE-107	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE

ORPHAN DRUG EXCLUSIVITY

	RECEIVED A PRIOR ANTHRACYCLNE-CONTAINING REGIMEN
ODE-108	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-109	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
ODE-110	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
ODE-111	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
ODE-112	FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
ODE-113	FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
ODE-114	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-115	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-116	TREATMENT OF PROGRESSIVE KERATOCONUS
ODE-117	FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-118	AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
ODE-119	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
ODE-120	FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
ODE-121	TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
ODE-122	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
ODE-123	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-124	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
ODE-125	INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
ODE-126	AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
ODE-127	TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
ODE-128	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
ODE-129	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
ODE-130	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
ODE-131	TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
ODE-132	TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG

ORPHAN DRUG EXCLUSIVITY

	(SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
ODE-133	INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-134	TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
ODE-135	TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-136	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-137	TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
ODE-138	TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEOMOTHERAPY MAINTENANCE REGIMEN
ODE-139	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
ODE-140	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
ODE-141	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
ODE-142	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-143	TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
ODE-144	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ODE-145	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
ODE-146	OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
ODE-147	DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-148	TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-149	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
ODE-150	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
ODE-151	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-152	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
ODE-153	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
ODE-154	FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
ODE-155	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-156	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY

ORPHAN DRUG EXCLUSIVITY

ODE-157	FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS >=2 MONTHS AND < 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-158	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
ODE-159	FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-160	FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
ODE-161	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY
ODE-162	TREATMENT OF NEPHROPATHIC CYSTINOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE TO LESS THAN 2 YEARS OF AGE
ODE-163	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
ODE-164	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
ODE-165	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
ODE-166	TREATMENT OF SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS IN ADULTS
ODE-167	ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
ODE-168	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-169	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
ODE-170	FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
ODE-171	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
ODE-172	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
ODE-173	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-174	FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-175	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-176	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
ODE-177	TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS
ODE-178	INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

ORPHAN DRUG EXCLUSIVITY

ODE-179	TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
ODE-180	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-181	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-182	TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
ODE-183	TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
ODE-184	INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH HIV-1 INFECTION
ODE-185	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-186	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R
ODE-187	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
ODE-188	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGES 2 TO LESS THAN 6 YEARS WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, AND R117H
ODE-189	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T
ODE-190	TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N
ODE-191	TO DECREASE THE RECURRENCE OF MALIGNANT PLEURAL EFFUSIONS IN SYMPTOMATIC PATIENTS FOLLOWING MAXIMAL DRAINAGE OF THE PLEURAL EFFUSION
ODE-192	INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
ODE-193	INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
ODE-194	ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-195	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-196	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
ODE-197	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-198	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
ODE-199	THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-200	INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG

ORPHAN DRUG EXCLUSIVITY

ODE-201	INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
ODE-202	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS IN PEDIATRIC PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)
ODE-203	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-204	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
ODE-205	INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA
ODE-206	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-207	TREATMENT OF STATUS EPILEPTICUS IN ADULTS
ODE-208	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
ODE-209	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-210	INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
ODE-211	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-212	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-213	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-214	TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
ODE-215	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
ODE-216	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-217	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DIESASE
ODE-218	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-219	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-220	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY
ODE-221	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED

ORPHAN DRUG EXCLUSIVITY

	FOLLOWING TREATMENT
ODE-222	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WHO HAVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-223	INDICATED FOR THE TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN ADULTS
ODE-224	INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >=75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-225	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
ODE-226	MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
ODE-227	INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
ODE-228	INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
ODE-229	TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
ODE-230	FIRST-LINE TREATMENT OF METASTATIC NONSMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-231	INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
ODE-232	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)
ODE-233	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
ODE-234	INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE
ODE-235	INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
ODE-236	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-237	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
ODE-238	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
ODE-239	TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-240	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-241	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
ODE-242	TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO ARE >=75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-243	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE

ORPHAN DRUG EXCLUSIVITY

	AND OLDER
ODE-244	TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN PATIENTS 6 TO LESS THAN 17 YEARS OF AGE
ODE-245	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
ODE-246	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-247	TX OF PTS W/ CYSTIC FIBROSIS (CF) AGE 6 TO <12 YRS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR W/ AT LEAST 1 MUTATION IN CF TRANSMEMBRANE CONDUCTANCE REGULATORY GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
ODE-248	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
ODE-249	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGE 6 YEARS TO LESS THAN 12 YEARS WHO ARE HOMOZYGOUS FOR F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR GENE THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-250	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
ODE-251	INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
ODE-252	TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
ODE-253	INDICATED AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OF ADULTS WITH PULMONARY EXTENSIVELY DRUG RESISTANT (XDR) OR TREATMENT-INTOLERANT OR NONRESPONSIVE MULTIDRUG-RESISTANT (MDR) TUBERCULOSIS (TB)
ODE-254	INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
ODE-255	INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
ODE-256	FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF
ODE-257	IN COMBO W/ DEXAMETHASONE FOR ADULTS W/ RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO RECEIVED AT LEAST 4 PRIOR THERAPIES AND REFRACTORY TO AT LEAST 2 PROTEASOME INHIBITORS, AT LEAST 2 IMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY
ODE-258	FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-259	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
ODE-260	INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
ODE-261	INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
ODE-262	TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-263	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-264	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS

ORPHAN DRUG EXCLUSIVITY

	OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-265	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ROS1-POSITIVE
ODE-266	ADULT & PED >=12YRS OLD W/ SOLID TUMORS THAT HAVE NTRK W/O KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY & HAVE EITHER PROGRESSED FOLLOWING TX OR HAVE NO SATISFACTORY ALTERNATIVE TX
ODE-267	INDICATED IN COMBINATION WITH HIGH FLUID INTAKE, ALKALI, AND DIET MODIFICATION, FOR THE PREVENTION OF CYSTINE STONE FORMATION IN PEDIATRIC PATIENTS 20KG TO 9 YEARS OF AGE W/SEVERE HOMOZYGOUS CYSTINURIA, WHO ARE NOT RESPONSIVE TO THESE MEASURES ALONE
ODE-268	INDICATED FOR TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-269	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANT, LIVER TRANSPLANTS, AND HEART TRANSPLANT, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-270	INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
ODE-271	INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
ODE-272	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
ODE-273	INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)
ODE-274	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-275	INDICATED FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
ODE-276	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-277	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
ODE-278	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY GENOMIC INSTABILITY & PROGRESSED >6 MONTHS AFTER RESPONSE TO THE LAST PLATINUM-BASED CHEMOTHERAPY

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE

PATENT USE

	CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY

PATENT USE

U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

PATENT USE

U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
U-109	ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121	METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122	A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123	METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124	TREATMENT OF ACNE
U-125	TREATMENT NEUROGENERATIVE DISEASES
U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHOD FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS

PATENT USE

U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT

PATENT USE

U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO

PATENT USE

	FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS

PATENT USE

U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)

PATENT USE

U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE

PATENT USE

U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION

PATENT USE

U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS

PATENT USE

U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHOMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABILIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES

PATENT USE

U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION
U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG

PATENT USE

U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	TREATMENT OF MIGRAINE
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY
U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN

PATENT USE

U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI
U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION
U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT
U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO

PATENT USE

	BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516	METHOD OF TREATING A PSYCHOTIC DISEASE
U-517	STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518	OBSESSIVE COMPULSIVE DISORDER
U-519	POST OPERATIVE NAUSEA AND VOMITING
U-520	PREMENOPAUSAL OSTEOPOROSIS
U-521	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522	TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523	METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524	METHOD OF TREATING DIARRHEA
U-525	METHOD OF TREATING PARASITIC INFECTIONS
U-526	METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527	METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528	PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529	ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530	TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531	TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532	TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533	ERECTILE DYSFUNCTION
U-534	HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS

PATENT USE

U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS
U-541	METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542	METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543	TREATMENT OF SCHIZOPHRENIA
U-544	TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545	METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546	USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547	MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
U-548	A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549	USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551	METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552	TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553	MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
U-554	TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
U-555	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556	USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-558	INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
U-559	METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
U-560	METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
U-561	COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
U-562	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-563	MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
U-564	TREATMENT OF HIV IN CONCOMITANT THERAPY
U-565	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
U-566	FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-567	METHOD OF TREATING INFERTILITY
U-568	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
U-569	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
U-570	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
U-571	TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

PATENT USE

U-572	INTENSIVE CARE UNIT SEDATION
U-573	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574	PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-575	LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
U-576	ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
U-577	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
U-578	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
U-579	TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580	TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
U-581	METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
U-582	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
U-583	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
U-584	SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
U-585	TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586	AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
U-587	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
U-588	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-589	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
U-590	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
U-591	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
U-592	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-593	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-594	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595	35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-596	TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-597	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE

PATENT USE

U-598	PROPHYLACTIC TREATMENT OF MIGRAINE
U-599	METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
U-600	A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
U-601	TREATMENT OF BIPOLAR DISORDER
U-602	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
U-603	METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
U-604	METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
U-605	TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
U-606	USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
U-607	CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
U-608	USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
U-609	USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
U-610	ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
U-611	METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
U-612	TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-613	REDUCTION OF SERUM PHOSPHATE
U-614	TREATMENT OF SEXUAL DYSFUNCTION
U-615	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-616	MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
U-617	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-618	USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
U-619	TREATMENT OF MALIGNANT NEOPLASM
U-620	TREATMENT OF INSOMNIA
U-621	METHOD OF TREATING CANCER
U-622	TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
U-623	SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
U-624	REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
U-625	ALLERGIC RHINITIS OR NASAL POLYPS
U-626	CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
U-627	TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
U-628	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

PATENT USE

U-629	METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
U-630	TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
U-631	TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
U-632	METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
U-633	METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
U-634	METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
U-635	TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
U-636	TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
U-637	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
U-638	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
U-639	TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
U-640	USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA
U-641	USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
U-642	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-643	THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
U-644	TREATMENT OF SEASONAL ALLERGIC RHINITIS
U-645	TREATMENT OF ASTHMA
U-646	METHOD OF TREATING OTITIS
U-647	TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-648	THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
U-649	A METHOD FOR TREATING A TUMOR DISEASE
U-650	TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
U-651	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
U-652	TREATMENT OF CARDIAC ARRHYTHMIA
U-653	STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
U-654	LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
U-655	TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
U-656	REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-657	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-658	TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
U-659	TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
U-660	TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE

PATENT USE

U-661	TREATMENT OF SEIZURE DISORDER
U-662	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-663	THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
U-664	TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
U-665	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
U-666	METHOD OF TREATING ADHD
U-667	MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
U-668	LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
U-669	INDICATION OF TYPE II DIABETES
U-670	TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
U-671	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
U-672	TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
U-673	METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
U-674	METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
U-675	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
U-676	METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
U-677	A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
U-678	METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-679	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-680	A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
U-681	TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-682	NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-683	PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
U-684	TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-685	EXPECTORANT AND COUGH SUPPRESSANT
U-686	EXPECTORANT AND NASAL DECONGESTANT
U-687	REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-688	TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-689	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-690	TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-691	USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-692	USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
U-693	THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE

PATENT USE

	OPTIMAL CLINICAL RESPONSE.
U-694	LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
U-695	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-696	TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-697	A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-698	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
U-699	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-700	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-701	TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
U-702	TOPICAL AEROSOL HAIR REGROWTH TREATMENT
U-703	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
U-704	METHOD OF ADMINISTERING INSULIN VIA INHALATION
U-705	TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
U-706	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
U-707	ALLERGIC RHINITIS
U-708	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-709	METHOD OF COMBATING BACTERIA IN A PATIENT
U-710	A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
U-711	ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-712	A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
U-713	TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
U-714	TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
U-715	FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
U-716	THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
U-717	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-718	TREATMENT OF FUNGAL INFECTIONS
U-719	TREATENT OF PSYCHOSIS
U-720	TREATMENT OF NEUROLEPTIC DISEASES
U-721	TREATMENT OF INFLUENZA
U-722	PROPHYLAXIS OF INFLUENZA
U-723	PROPHYLACTIC TREATMENT OF MIGRAINE
U-724	METHOD OF TREATING SEIZURES
U-725	ALLERGIC RHINITIS AND URTICARIA
U-726	ALLERGIC RHINITIS

PATENT USE

U-727	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-728	METHOD FOR TREATING BACTERIAL INFECTION
U-729	TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-730	USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
U-731	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-732	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
U-733	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
U-734	FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
U-735	METHOD OF TREATING CHRONIC IRON OVERLOAD
U-736	METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
U-737	DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
U-738	INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
U-739	METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
U-740	FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
U-741	COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
U-742	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
U-743	ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
U-744	TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
U-745	TREATMENT OR PREVENTION OF EMESIS
U-746	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-747	PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-748	A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
U-749	METHOD OF CONTRACEPTION
U-750	TREATMENT OF HIV-1 INFECTION IN ADULTS
U-751	ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
U-752	SUNSCREEN
U-753	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
U-754	USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
U-755	TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
U-756	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-757	USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
U-758	TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
U-759	METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
U-760	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-761	TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
U-762	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-763	ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION

PATENT USE

U-764	TREATMENT OF SCHIZOPHRENIA
U-765	METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
U-766	TREATMENT OF SEIZURES
U-767	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
U-768	A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
U-769	REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-770	LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-771	METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
U-772	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
U-773	PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-774	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-775	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
U-776	TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
U-777	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-778	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-779	A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
U-780	A METHOD FOR THE TREATMENT OF CANCER
U-781	FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
U-782	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
U-783	DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
U-784	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
U-785	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
U-786	PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
U-787	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
U-788	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
U-789	TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
U-790	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
U-791	GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
U-792	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-793	FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY

PATENT USE

	DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-794	CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
U-795	METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
U-796	METHOD OF TREATING DEPRESSION
U-797	METHOD OF TREATING ANXIETY
U-798	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
U-799	METHOD FOR INHIBITING SEROTONIN UPTAKE
U-800	TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
U-801	METHOD OF TREATING CANCER
U-802	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-803	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
U-804	TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
U-805	TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
U-806	INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
U-807	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
U-808	THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
U-809	TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
U-810	METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
U-811	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
U-812	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-813	MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-814	TREATMENT OF SCHIZOPHRENIA
U-815	TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
U-816	DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
U-817	NASAL ADMINISTRATION OF CYANOCOBALAMIN
U-818	TOPICAL TREATMENT OF ACNE VULGARIS
U-819	MANAGEMENT OF FIBROMYALGIA
U-820	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
U-821	METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
U-822	USE IN LIPID MANAGEMENT
U-823	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
U-824	METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
U-825	USE FOR PREVENTION OF BREAST CANCER
U-826	RELIEF OF MODERATE TO SEVERE PAIN

PATENT USE

U-827	USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
U-828	PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-829	TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
U-830	TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
U-831	METHOD OF ADMINISTERING LANREOTIDE ACETATE
U-832	ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
U-833	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
U-834	INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
U-835	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
U-836	A METHOD FOR THE TREATMENT OF LEUKEMIAS
U-837	GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
U-838	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
U-839	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-840	TREATMENT FOR TYPE 2 DIABETES MELLITUS
U-841	INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
U-842	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
U-843	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-844	PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
U-845	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
U-846	USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
U-847	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-848	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-849	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
U-850	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-851	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-852	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-853	TREATMENT OR PREVENTION OF EMESIS
U-854	PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
U-855	METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
U-856	SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-857	INHIBITION OF TRANSPLANT REJECTION
U-858	PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS

PATENT USE

U-859	EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
U-860	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
U-861	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-862	ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
U-863	TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
U-864	PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-865	TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
U-866	THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
U-867	TREATMENT OF MIGRAINE
U-868	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
U-869	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-870	METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
U-871	METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
U-872	TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-873	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
U-874	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-875	FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
U-876	TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-877	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
U-878	A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
U-879	A METHOD OF TREATING OR PREVENTING ILEUS
U-880	ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-881	TREATMENT OF NON-SMALL CELL LUNG CANCER
U-882	MANAGEMENT OF FIBROMYALGIA (FM)
U-883	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
U-884	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
U-885	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
U-886	ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
U-887	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-888	FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
U-889	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
U-890	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-891	USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE

PATENT USE

U-892	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
U-893	CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
U-894	TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
U-895	TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-896	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
U-897	METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
U-898	USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
U-899	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-900	INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
U-901	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
U-902	USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
U-903	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
U-904	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
U-905	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
U-906	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
U-907	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
U-908	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
U-909	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-910	TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
U-911	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
U-912	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-913	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
U-914	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-915	TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-916	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
U-917	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-918	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
U-919	FOR THE TREATMENT OF DERMATITIS
U-920	STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
U-921	TREATMENT OF ACNE VULGARIS
U-922	FOR THE TREATMENT OF FUNGAL INFECTIONS
U-923	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

PATENT USE

U-924	TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
U-925	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-926	MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
U-927	METHOD FOR INCREASING TEAR PRODUCTION
U-928	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-929	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
U-930	TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
U-931	RELIEF OF MODERATE TO SEVERE ACUTE PAIN
U-932	PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
U-933	FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-934	IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
U-935	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
U-936	USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
U-937	TREATMENT OF PROSTATE CANCER
U-938	TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-939	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-940	METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
U-941	METHOD TO TREAT OVARIAN CANCER
U-942	METHOD TO TREAT MULTIPLE MYELOMA
U-943	GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
U-944	TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-945	SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
U-946	TREATMENT OF BREAST CANCER
U-947	WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS
U-948	TREATMENT OF DIABETES MELLITUS
U-949	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
U-950	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
U-951	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
U-952	USE AS AN ANALGESIC
U-953	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-954	CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
U-955	PROPHYLACTIC TREATMENT OF MIGRAINE
U-956	TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE

PATENT USE

U-957	A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
U-958	METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
U-959	METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
U-960	METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
U-961	METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
U-962	SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-963	PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-964	ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-965	USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
U-966	TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
U-967	A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
U-968	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-969	TREATMENT OF MIGRAINE
U-970	TOPICAL TREATMENT OF LICE INFESTATIONS
U-971	INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
U-972	MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
U-973	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
U-974	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-975	TREATMENT OF PULMONARY HYPERTENSION
U-976	IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
U-977	TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
U-978	METHOD OF TREATING HYPONATREMIA
U-979	RELIEF OF MUSCLE SPASM
U-980	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-981	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-982	A METHOD OF TREATING OSTEOPOROSIS
U-983	METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
U-984	METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
U-985	TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-986	TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

PATENT USE

U-987	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
U-988	TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
U-989	FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-990	TREATMENT OF PROTOZOAL INFECTION
U-991	TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
U-992	REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
U-993	METHOD OF TREATING INFERTILITY
U-994	METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
U-995	METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
U-996	AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA
U-997	TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
U-998	ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
U-999	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
U-1000	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
U-1001	METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
U-1002	METHOD OF TREATING INFLAMMATORY CONDITIONS
U-1003	A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
U-1004	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1005	METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
U-1006	NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
U-1007	METHOD OF TREATING GOUT FLARES
U-1008	APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
U-1009	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-1010	TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
U-1011	USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
U-1012	METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
U-1013	METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1014	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1015	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1016	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
U-1017	A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-1018	TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

PATENT USE

U-1019	TREATMENT OF PULMONARY HYPERTENSION
U-1020	METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
U-1021	SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
U-1022	FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
U-1023	TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
U-1024	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
U-1025	TREATING FREQUENT HEARTBURN
U-1026	A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
U-1027	REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
U-1028	A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
U-1029	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
U-1030	IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
U-1031	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1032	USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
U-1033	TOPICAL TREATMENT OF ACNE VULGARIS
U-1034	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
U-1035	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1036	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
U-1037	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
U-1038	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
U-1039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
U-1040	INHIBITION OF THROMBIN IN A PATIENT
U-1041	TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
U-1042	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-1043	MANAGEMENT OF MODERATE TO SEVERE PAIN
U-1044	TOPICAL TREATMENT OF SCALP PSORIASIS
U-1045	MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY
U-1046	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
U-1047	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
U-1048	WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
U-1049	PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
U-1050	USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-1051	TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-1052	RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1053	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1054	ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS

PATENT USE

U-1055	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
U-1056	TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1057	TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1058	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-1059	ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
U-1060	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS
U-1061	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
U-1062	ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
U-1063	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-1064	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-1065	METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-1066	METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
U-1067	TREATMENT OF CANCER
U-1068	TREATMENT OF ASTHMA
U-1069	A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1070	A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE
U-1071	METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
U-1072	THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
U-1073	USE FOR THE TREATMENT OF ASTHMA AND COPD
U-1074	USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
U-1075	USE FOR THE TREATMENT OF ASTHMA
U-1076	REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
U-1077	PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION
U-1078	TREATMENT OF ACNE
U-1079	REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1080	METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
U-1081	LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1082	USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
U-1083	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
U-1084	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-1085	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
U-1086	TREATMENT OF AUTOIMMUNE DISEASE
U-1087	DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

PATENT USE

U-1088	RELIEF OF MUSCLE SPASM
U-1089	INHIBITION OF THROMBIN
U-1090	LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-1091	ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
U-1092	TREATMENT OF BREAST CANCER
U-1093	TREATMENT OF PSEUDOBULBAR AFFECT
U-1094	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
U-1095	METHOD OF TREATING OCULAR INFLAMMATION
U-1096	TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
U-1097	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
U-1098	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
U-1099	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1100	REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
U-1101	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1102	METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
U-1103	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1104	USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
U-1105	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
U-1106	TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
U-1107	TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
U-1108	TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
U-1109	TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-1110	METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1111	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1112	METHOD OF MR IMAGING OF A MAMMAL
U-1113	TREATMENT AND PROPHYLAXIS OF INFLUENZA
U-1114	TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
U-1115	TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
U-1116	METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
U-1117	TREATMENT OF BREAST CANCER
U-1118	USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-1119	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-1120	TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
U-1121	METHOD OF TREATING TRAVELERS' DIARRHEA
U-1122	TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
U-1123	TREATMENT OF ALCOHOL DEPENDENCE

PATENT USE

U-1124	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
U-1125	METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
U-1126	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
U-1127	TREATMENT OF PATENT DUCTUS ARTERIOSUS
U-1128	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
U-1129	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1130	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1131	TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1132	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1133	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1134	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1135	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
U-1136	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1137	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1138	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1139	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1140	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1141	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1142	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1143	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1144	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1145	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1146	REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1147	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1148	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1149	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1150	TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C

PATENT USE

U-1151	TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
U-1152	CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
U-1153	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
U-1154	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
U-1155	USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
U-1156	TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
U-1157	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1158	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1159	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-1160	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
U-1161	FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
U-1162	TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
U-1163	METHOD OF TREATING THROMBOSIS
U-1164	METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
U-1165	USE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1166	A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
U-1167	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
U-1168	THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-1169	MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
U-1170	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1171	REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
U-1172	TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
U-1173	TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
U-1174	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176	TREATMENT OR PREVENTION OF STROKE
U-1177	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178	RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179	TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

PATENT USE

U-1180	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183	A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184	TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
U-1185	TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186	ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187	TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191	METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)
U-1192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194	METHOD FOR TREATING INSOMNIA
U-1195	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196	RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198	RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
U-1199	TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200	REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204	TREATMENT OF UVEITIS
U-1205	TREATMENT OF MACULAR EDEMA
U-1206	DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207	INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS
U-1208	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-1209	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER

PATENT USE

U-1210	USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
U-1211	USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1212	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1213	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
U-1214	METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1215	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1216	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1217	METHOD OF INCREASING HAIR GROWTH
U-1218	METHOD OF STIMULATING HAIR GROWTH
U-1219	METHOD OF INCREASING THE NUMBER OF HAIRS
U-1220	TREATMENT OF RENAL CELL CARCINOMA
U-1221	TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
U-1222	TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
U-1223	METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
U-1224	REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
U-1225	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
U-1226	A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
U-1227	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
U-1228	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
U-1229	TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
U-1230	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
U-1231	TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
U-1232	USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN
U-1233	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

PATENT USE

U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM

PATENT USE

U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
U-1274	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
U-1275	TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1277	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
U-1278	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
U-1279	TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-1280	USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
U-1281	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
U-1282	PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
U-1283	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
U-1284	A METHOD OF TREATING A NEOPLASM
U-1285	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
U-1286	A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
U-1287	METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1288	TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
U-1289	MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
U-1290	TREATMENT OF LUNG CANCER
U-1291	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-1292	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
U-1293	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1294	METHOD OF TREATING GLAUCOMA IN A PATIENT
U-1295	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1296	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
U-1297	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
U-1298	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
U-1299	TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1300	TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1301	TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
U-1302	TREATMENT OF PULMONARY EMBOLISM (PE)
U-1303	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
U-1304	USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
U-1305	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
U-1306	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

PATENT USE

U-1307	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1308	MULTIPLE MYELOMA
U-1309	BONE METASTASES
U-1310	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
U-1311	METHOD OF TREATING CYSTIC FIBROSIS
U-1312	USE FOR THE TREATMENT OF HYPERGLYCEMIA
U-1313	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1314	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1315	THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-1316	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1317	TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1318	TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1319	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
U-1320	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-1321	TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
U-1322	METHOD OF REDUCING OCULAR HYPERTENSION
U-1323	REDUCING THE RISK OF STROKE
U-1324	MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
U-1325	INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
U-1326	METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
U-1327	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
U-1328	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
U-1329	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
U-1330	METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1331	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1332	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1333	METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
U-1334	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1335	METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
U-1336	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE

PATENT USE

	INHIBITOR AND METFORMIN
U-1337	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
U-1338	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
U-1339	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1340	METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1341	METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1342	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1343	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1344	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
U-1345	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1346	USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
U-1347	TREATMENT OF A SKIN DISORDER
U-1348	TREATMENT OF OSTEOARTHRITIS
U-1349	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
U-1350	TREATMENT OF ANKYLOSING SPONDYLITIS
U-1351	TREATMENT OF ACUTE PAIN
U-1352	TREATMENT OF PRIMARY DYSMENORRHEA
U-1353	ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1354	INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
U-1355	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1356	TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
U-1357	TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1358	TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
U-1359	USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1360	USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1361	USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
U-1362	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

PATENT USE

U-1363	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
U-1364	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1365	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
U-1366	TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
U-1367	METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
U-1368	TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
U-1369	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
U-1370	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
U-1371	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
U-1372	ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
U-1373	METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
U-1374	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
U-1375	ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
U-1376	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-1377	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1378	TREATMENT OF A NITROGEN METABOLISM DISORDER
U-1379	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1380	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
U-1381	USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1382	TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
U-1383	DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
U-1384	METHOD OF TREATING MULTIPLE SCLEROSIS
U-1385	METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
U-1386	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1388	TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1389	ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
U-1391	METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION

PATENT USE

U-1393	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1394	METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396	TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
U-1397	USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
U-1398	METHOD OF TREATING CHRONIC HEPATITIS C
U-1399	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
U-1400	FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1401	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
U-1402	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
U-1403	FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
U-1404	METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
U-1405	THERAPEUTIC TREATMENT OF BONE METASTASES
U-1406	TREATMENT OF MELANOMA
U-1407	TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
U-1408	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-1409	TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
U-1410	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
U-1411	THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1412	TREATMENT OF ATOPIC DERMATITIS
U-1413	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
U-1414	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
U-1415	TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
U-1416	USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
U-1417	USE FOR TREATMENT OF HELICOBACTER INFECTIONS
U-1418	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
U-1419	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
U-1420	METHOD OF ONCE A DAY ADMINISTRATION
U-1421	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
U-1422	METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
U-1423	AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET)

PATENT USE

	IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1424	LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1425	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1426	USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
U-1427	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
U-1428	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
U-1429	TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
U-1430	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-1431	METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
U-1432	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
U-1433	IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1434	TREATMENT OF PANCREATIC CANCER
U-1435	COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
U-1436	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
U-1437	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
U-1438	ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1439	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
U-1440	USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
U-1441	A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
U-1442	SUBCUTANEOUS INJECTION OF METHOTREXATE
U-1443	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1444	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
U-1445	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1446	METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
U-1447	TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
U-1448	TREATING SEVERE HYPERTRIGLYCERIDEMIA
U-1449	METHOD OF ALLEVIATING A SKIN CONDITION
U-1450	TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
U-1451	APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH

PATENT USE

	EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
U-1452	METHOD FOR CHRONIC WEIGHT MANAGEMENT
U-1453	A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1454	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1455	TREATMENT OF PERIANAL WARTS
U-1456	TREATMENT OF MANTLE CELL LYMPHOMA
U-1457	A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
U-1458	A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1459	TREATMENT OF CARCINOMA OF THE THYROID
U-1460	TREATMENT OF HERPES LABIALIS
U-1461	A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
U-1462	A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
U-1463	A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
U-1464	TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
U-1465	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
U-1466	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1467	METHOD OF TREATING HEPATITIS C
U-1468	CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
U-1469	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
U-1470	FOR THE TREATMENT OF HEPATITIS C
U-1471	A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
U-1472	INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-1473	MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
U-1474	A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
U-1475	USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
U-1476	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
U-1477	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE
U-1478	METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1479	INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1480	TREATMENT OF ADVANCED RENAL CELL CARCINOMA
U-1481	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1482	DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1483	INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

PATENT USE

U-1484	COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
U-1485	TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1486	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
U-1487	METHOD OF INCREASING EYELASH GROWTH
U-1488	USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
U-1489	USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
U-1490	FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
U-1491	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1492	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1493	METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1494	SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1495	RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
U-1496	METHOD TO TREAT HEMANGIOMA.
U-1497	NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1498	METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
U-1499	MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-1500	TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
U-1501	PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
U-1502	PROPHYLAXIS OF PULMONARY EMBOLISM
U-1503	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1504	USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
U-1505	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1506	TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
U-1507	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1508	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
U-1509	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
U-1510	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
U-1511	TREATMENT OF HYPERTRIGLYCERIDEMIA
U-1512	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1513	TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-1514	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
U-1515	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
U-1516	METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
U-1517	TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.

PATENT USE

U-1518	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
U-1519	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
U-1520	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
U-1521	MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1522	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
U-1523	METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
U-1524	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
U-1525	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1526	THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1527	FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-1528	A METHOD OF LOWERING INTRAOCULAR PRESSURE
U-1529	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1530	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
U-1531	METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
U-1532	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
U-1533	PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1534	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
U-1535	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
U-1536	ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1537	TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
U-1538	ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
U-1539	PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
U-1540	BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1541	TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
U-1542	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
U-1543	TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
U-1544	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
U-1545	A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
U-1546	FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
U-1547	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
U-1548	FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

PATENT USE

U-1549	FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
U-1550	METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
U-1551	METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.
U-1552	FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
U-1553	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1554	FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
U-1555	MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1556	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1557	A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
U-1558	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
U-1559	INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
U-1560	A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
U-1561	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1562	TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
U-1563	A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
U-1564	A METHOD OF TREATING GAUCHER'S DISEASE
U-1565	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1566	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-1567	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
U-1568	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1569	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
U-1570	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
U-1571	TREATMENT OF GAUCHER DISEASE TYPE 1
U-1572	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
U-1573	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
U-1574	A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
U-1575	PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
U-1576	TREATMENT OF LEUKEMIA
U-1577	CONTROL OF SERUM PHOSPHOROUS LEVELS
U-1578	TREATMENT OF ACUTE OTITIS MEDIA
U-1579	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1580	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL

PATENT USE

	CHEMOTHERAPY
U-1581	IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
U-1582	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
U-1583	FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1584	USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
U-1585	USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
U-1586	FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
U-1587	SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
U-1588	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
U-1589	METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-1590	KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
U-1591	TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
U-1592	TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-1593	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
U-1594	DILATION OF THE PUPIL
U-1595	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
U-1596	LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
U-1597	TREATMENT OF DIABETIC MACULAR EDEMA
U-1598	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
U-1599	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-1600	DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1601	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1602	METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
U-1603	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-1604	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
U-1605	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1606	METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
U-1607	METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
U-1608	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
U-1609	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1610	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE
U-1611	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
U-1612	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING

PATENT USE

	SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1613	DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN
U-1614	USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN
U-1615	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1616	NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1617	METHOD OF TREATING MEDULLARY THYROID CANCER
U-1618	A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT
U-1619	TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1620	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.
U-1621	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.
U-1622	FOR THE TREATMENT OF POLYCYTHEMIA VERA
U-1623	USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.
U-1624	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
U-1625	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
U-1626	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
U-1627	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
U-1628	METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
U-1629	METHOD OF TREATING ACROMEGALY
U-1630	TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
U-1631	TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
U-1632	TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1633	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1634	TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
U-1635	USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
U-1636	USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
U-1637	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
U-1638	TREATMENT OF HCV INFECTION USING PARITAPREVIR
U-1639	USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1640	TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1641	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-1642	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
U-1643	TREATING CUSHING'S SYNDROME

PATENT USE

U-1644	TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
U-1645	TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1646	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1647	TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1648	TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1649	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
U-1650	TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
U-1651	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1652	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
U-1653	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
U-1654	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
U-1655	A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
U-1656	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
U-1657	METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99
U-1658	TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN
U-1659	MANAGEMENT OF PAIN
U-1660	TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-1661	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
U-1662	A METHOD OF TREATING OCULAR PAIN
U-1663	TREATMENT OF HIV-1 INFECTION
U-1664	TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
U-1665	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1
U-1666	PALLIATIVE TREATMENT OF PROSTATE CANCER
U-1667	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS
U-1668	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
U-1669	TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
U-1670	NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.
U-1671	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS
U-1672	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
U-1673	TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
U-1674	DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1675	USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

PATENT USE

U-1676	METHODS FOR TREATING BACTERIAL INFECTIONS
U-1677	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
U-1678	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1679	TREATMENT OF ACUTE OTITIS EXTERNA
U-1680	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1681	TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
U-1682	TREATMENT OF BACTERIAL VAGINOSIS
U-1683	TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-1684	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1685	DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1686	A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
U-1687	TREATMENT OF HCV INFECTION USING OMBITASVIR
U-1688	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1689	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1690	METHOD FOR REDUCTION OF SUBMENTAL FAT
U-1691	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
U-1692	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1693	METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1694	A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
U-1695	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
U-1696	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
U-1697	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.
U-1698	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1699	A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
U-1700	A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
U-1701	A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
U-1702	TREATMENT OF COPD
U-1703	TREATMENT OF RESPIRATORY COMPLAINTS
U-1704	USE FOR TREATMENT IN PATIENTS WITH DIABETES
U-1705	USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA
U-1706	TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE
U-1707	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
U-1708	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
U-1709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
U-1710	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
U-1711	FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL

PATENT USE

U-1712	MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1713	TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1714	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1715	P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
U-1716	TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
U-1717	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
U-1718	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
U-1719	ACUTE TREATMENT OF MIGRAINE
U-1720	METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
U-1721	USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
U-1722	TREATMENT OF BASAL CELL CARCINOMA
U-1723	TREATMENT OF HEART FAILURE
U-1724	METHOD OF INHIBITING HEPATITIS C VIRUS
U-1725	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
U-1726	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1727	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1728	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1729	REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
U-1730	REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
U-1731	TEMPORARY RELIEF OF MINOR ACHES AND PAINS
U-1732	TEMPORARY REDUCTION OF FEVER
U-1733	TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
U-1734	USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-1735	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL
U-1736	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1737	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
U-1738	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-1739	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1740	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY

PATENT USE

U-1741	PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1742	ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1743	FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
U-1744	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
U-1746	MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY
U-1747	FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD
U-1748	FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1749	ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-1750	TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-1751	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-1752	PROPHYLAXIS OF ORGAN REJECTION
U-1753	TREATMENT OF HCV INFECTION USING DASABUVIR
U-1754	FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
U-1755	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
U-1756	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-1757	INHIBITION ON PI3K KINASE
U-1758	METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
U-1759	METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB
U-1760	RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT
U-1761	PLAQUE PSORIASIS
U-1762	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1763	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1764	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1765	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1766	TREATMENT OF HYPERKALEMIA
U-1767	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
U-1768	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
U-1769	TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE
U-1770	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA
U-1771	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION
U-1772	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

PATENT USE

U-1773	LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1774	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE
U-1775	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
U-1776	METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA
U-1777	TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
U-1778	METHOD FOR TREATING MULTIPLE MYELOMA
U-1779	METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS
U-1780	METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
U-1781	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
U-1782	FOR HEAD LICE INFESTATIONS
U-1783	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED
U-1784	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED
U-1785	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED
U-1786	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE
U-1787	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY
U-1788	TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN
U-1789	METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
U-1790	FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA
U-1791	EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS
U-1792	TREATMENT OF OTIC INFECTION OR INFLAMMATION
U-1793	TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1794	REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK
U-1795	REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
U-1796	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1797	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
U-1798	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN
U-1799	METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
U-1800	A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
U-1801	REDUCTION OF SERUM URIC ACID LEVELS
U-1802	TREATMENT OF GOUT
U-1803	TREATMENT OF HYPERURICEMIA
U-1804	ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT

PATENT USE

U-1805	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
U-1806	COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
U-1807	TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
U-1808	USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
U-1809	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
U-1810	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
U-1811	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
U-1812	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
U-1813	TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
U-1814	METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
U-1815	TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-1816	TREATMENT OF A UREA CYCLE DISORDER
U-1817	PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-1818	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1819	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1820	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1821	METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-1822	TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
U-1823	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
U-1824	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1825	METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
U-1826	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1827	A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
U-1828	INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-1829	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
U-1830	INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
U-1831	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
U-1832	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1833	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA

PATENT USE

	OR OCULAR HYPERTENSION
U-1834	TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY
U-1835	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-1836	TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
U-1837	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
U-1838	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
U-1839	COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
U-1840	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
U-1841	USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1842	METHOD OF TREATING EPILEPSY
U-1843	TREATMENT OF PSYCHOSIS
U-1844	TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
U-1845	TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
U-1846	TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
U-1847	METHOD OF TREATING A BACTERIAL INFECTION
U-1848	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1849	METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-1850	METHOD OF ADMINISTERING LEVETIRACETAM
U-1851	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1852	METHOD OF TREATING TYPE 2 DIABETES
U-1853	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
U-1854	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
U-1855	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
U-1856	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-1857	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
U-1858	TREATMENT OF PLAQUE PSORIASIS
U-1859	TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1860	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1861	USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
U-1862	TREATMENT OF POST-MYOCARDIAL INFARCTION
U-1863	TREATMENT OF STROKE
U-1864	TREATMENT OF MYOCARDIAL INFARCTION

PATENT USE

U-1865	TREATMENT OF THROMBOTIC STROKE
U-1866	TREATMENT OF STABLE AND UNSTABLE ANGINA
U-1867	METHOD OF INHIBITING PLATELET AGGREGATION
U-1868	TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
U-1869	TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
U-1870	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1871	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D
U-1872	USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY
U-1873	ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE
U-1874	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8
U-1875	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3
U-1876	METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH
U-1877	METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL
U-1878	FOR OPIOID DEPENDENCE
U-1879	METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
U-1880	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1881	IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
U-1882	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY
U-1883	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
U-1884	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1885	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1886	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1887	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1888	USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE
U-1889	TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
U-1890	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
U-1891	TREATMENT OR PREVENTION OF NAUSEA AND VOMITING
U-1892	METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
U-1893	METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
U-1894	COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

PATENT USE

U-1895	METHOD OF TREATING PROSTATE CANCER
U-1896	SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
U-1897	METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1898	METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1899	TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1900	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1901	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
U-1902	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-1903	USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
U-1904	(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1905	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1906	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1907	USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
U-1908	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
U-1909	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR
U-1910	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
U-1911	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
U-1912	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606
U-1913	TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1914	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1915	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
U-1916	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)
U-1917	TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1918	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1919	RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1920	USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
U-1921	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT

PATENT USE

U-1922	INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
U-1923	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1924	KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-1925	USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL
U-1926	METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
U-1927	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
U-1928	RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
U-1929	TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
U-1930	METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
U-1931	PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE
U-1932	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
U-1933	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY
U-1934	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-1935	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
U-1936	TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1937	TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1938	TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1939	ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
U-1940	IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
U-1941	TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY
U-1942	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
U-1943	TREATMENT OF SPINAL MUSCULAR ATROPHY
U-1944	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
U-1945	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.
U-1946	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
U-1947	TREATMENT OF MARGINAL ZONE LYMPHOMA
U-1948	A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA
U-1949	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

PATENT USE

U-1950	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
U-1951	TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL
U-1952	FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1953	REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1954	TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1955	TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1956	FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1957	PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1958	FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN
U-1959	TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-1960	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-1961	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
U-1962	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
U-1963	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
U-1964	ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
U-1965	FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3
U-1966	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
U-1967	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1968	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1969	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
U-1970	TREATMENT OF ONYCHOMYCHOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES
U-1971	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-1972	FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1973	METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
U-1974	TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
U-1975	METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST

PATENT USE

U-1976	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
U-1977	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
U-1978	TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
U-1979	THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
U-1980	A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-1981	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-1982	USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
U-1983	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
U-1984	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
U-1985	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
U-1986	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
U-1987	METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
U-1988	METHOD TO TREAT INFANTILE HEMANGIOMA
U-1989	INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-1990	INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
U-1991	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
U-1992	USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
U-1993	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-1994	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
U-1995	TREATMENT OF TARDIVE DYSKINESIA
U-1996	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1997	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN
U-1998	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1999	CHRONIC IDIOPATHIC CONSTIPATION
U-2000	MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2001	USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2002	USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2003	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM

PATENT USE

U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY
U-2005	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
U-2006	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
U-2007	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
U-2008	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
U-2009	METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
U-2010	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
U-2011	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
U-2012	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2013	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
U-2014	A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
U-2015	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-2016	TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
U-2017	TREATMENT OF OPIOID DEPENDENCE
U-2018	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-2019	METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
U-2020	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2021	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
U-2022	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
U-2023	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
U-2024	METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
U-2025	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-2026	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2027	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
U-2028	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
U-2029	PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
U-2030	PROPHYLAXIS OF VENOUS THROMBOSIS
U-2031	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST

PATENT USE

U-2032	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2033	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
U-2034	INHIBITING COAGULATION
U-2035	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
U-2036	A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
U-2037	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
U-2038	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2039	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
U-2040	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
U-2041	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2042	DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2043	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
U-2044	DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2045	ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2046	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
U-2047	ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2048	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2049	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2050	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2051	DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2052	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2053	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2054	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2055	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2056	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY

PATENT USE

	ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2057	DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2058	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF
U-2059	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF
U-2060	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF
U-2061	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2062	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF
U-2063	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2064	DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2065	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2066	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE
U-2067	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2068	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE
U-2069	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2070	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY
U-2071	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2072	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2073	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF
U-2074	DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2075	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
U-2076	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

PATENT USE

U-2077	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF
U-2078	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2079	PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
U-2080	PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
U-2081	DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE
U-2082	MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2083	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF
U-2084	TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE
U-2085	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
U-2086	A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
U-2087	TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
U-2088	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
U-2089	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
U-2090	FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2091	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-2092	METHOD FOR CONFIRMING DOSE DELIVERY
U-2093	TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
U-2094	TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
U-2095	MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
U-2096	SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
U-2097	TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2098	INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2099	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
U-2100	INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER

PATENT USE

U-2101	MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-2102	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
U-2103	MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-2104	TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
U-2105	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2106	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2107	TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
U-2108	TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
U-2109	CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE
U-2110	METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION
U-2111	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
U-2112	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
U-2113	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
U-2114	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
U-2115	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10
U-2116	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
U-2117	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
U-2118	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
U-2119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN

PATENT USE

	SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
U-2120	TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2121	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
U-2122	USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2123	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
U-2124	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
U-2125	THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
U-2126	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2127	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2128	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
U-2129	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
U-2130	TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-2131	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2132	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
U-2133	METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
U-2134	THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR
U-2135	AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
U-2136	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-2137	TREATMENT OF POSTHERPETIC NEURALGIA
U-2138	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
U-2139	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
U-2140	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2141	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2142	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
U-2143	AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2144	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2145	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

PATENT USE

U-2146	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE
U-2147	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
U-2148	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITIRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE
U-2149	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
U-2150	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2151	METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
U-2152	TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-2153	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2154	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2155	REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2156	REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2157	TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE
U-2158	DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION
U-2159	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
U-2160	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
U-2161	TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
U-2162	FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY
U-2163	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-2164	ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
U-2165	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
U-2166	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-2167	METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2168	METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2169	METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2170	METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2171	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
U-2172	METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)
U-2173	TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE
U-2174	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2175	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY
U-2176	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE
U-2177	TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE

PATENT USE

U-2178	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION
U-2179	IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION
U-2180	TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE
U-2181	TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE
U-2182	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2183	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13
U-2184	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14
U-2185	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27
U-2186	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28
U-2187	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39
U-2188	ADJUNCT TO DIET AND EXECRISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40
U-2189	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52
U-2190	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53
U-2191	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64
U-2192	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65
U-2193	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75
U-2194	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76
U-2195	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87
U-2196	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88
U-2197	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99
U-2198	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100
U-2199	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA
U-2200	COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2201	TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN

PATENT USE

	BIPOLAR DISORDER
U-2202	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2203	A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
U-2204	TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-2205	TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
U-2206	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE
U-2207	TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2208	TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
U-2209	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2210	TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE
U-2211	TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE
U-2212	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2213	REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2214	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
U-2215	ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2216	ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2217	TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2218	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2219	TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
U-2220	A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN
U-2221	TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2222	RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
U-2223	METHOD OF TREATING ANGINA PECTORIS
U-2224	TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2225	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
U-2226	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
U-2227	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
U-2228	TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
U-2229	IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION
U-2230	IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
U-2231	TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN

PATENT USE

	ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2232	TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE
U-2233	TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT
U-2234	USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2235	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
U-2236	REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
U-2237	TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2238	METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY
U-2239	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2240	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
U-2241	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2242	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-2243	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2244	A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNENUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2245	A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2246	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2247	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2248	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
U-2249	MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-2250	DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-2251	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2252	THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
U-2253	PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY
U-2254	USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY
U-2255	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE

PATENT USE

	LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS
U-2256	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2257	TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2258	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2259	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2260	METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION
U-2261	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2262	MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
U-2263	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS
U-2264	METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2265	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND PEDIATRIC PATIENTS
U-2266	METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2267	METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA
U-2268	DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2269	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2270	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2271	THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
U-2272	TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT
U-2273	A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2274	MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D
U-2275	TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
U-2276	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2277	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE
U-2278	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN

PATENT USE

U-2279	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG
U-2280	ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES
U-2281	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2282	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2
U-2283	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7
U-2284	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8
U-2285	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11
U-2286	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14
U-2287	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19
U-2288	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY
U-2289	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
U-2290	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2291	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
U-2292	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2293	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
U-2294	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-2295	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2296	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2297	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15
U-2298	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC)

PATENT USE

	WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
U-2299	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION
U-2300	USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-2301	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY
U-2302	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2303	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2304	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION
U-2305	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
U-2306	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-2307	TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
U-2308	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-2309	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
U-2310	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
U-2311	TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE
U-2312	TREATMENT OF HYPERKALEMIA IN ADULTS
U-2313	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
U-2314	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET
U-2315	TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD
U-2316	TREATMENT OF DYSPAREUNIA
U-2317	TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
U-2318	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2319	KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-2320	KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
U-2321	A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
U-2322	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
U-2323	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

PATENT USE

U-2324	FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-2325	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
U-2326	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-2327	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
U-2328	METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS
U-2329	METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
U-2330	METHOD OF TREATING MELANOMA
U-2331	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
U-2332	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2333	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2334	TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2335	TREATMENT OF MELANOMA
U-2336	TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2337	INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2338	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
U-2339	USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
U-2340	TREATMENT OF POSTOPERATIVE INFLAMMATION
U-2341	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2342	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2343	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2344	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE
U-2345	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
U-2346	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
U-2347	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
U-2348	A METHOD FOR PREVENTION OF PREGNANCY
U-2349	FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER
U-2350	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
U-2351	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION

PATENT USE

U-2352	TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2353	TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2354	COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV
U-2355	IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
U-2356	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
U-2357	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-2358	TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
U-2359	TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2360	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
U-2361	METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS
U-2362	TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2363	ADMINISTRATION OF RISPERIDONE
U-2364	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2365	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2366	TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12
U-2367	USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE
U-2368	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
U-2369	FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
U-2370	FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS
U-2371	THE TREATMENT OF FABRY PATIENTS
U-2372	A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2373	A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYLCERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2374	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
U-2375	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR
U-2376	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-2377	USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY

PATENT USE

U-2378	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
U-2379	USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING OPHTHALMIC SURGERY
U-2380	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
U-2381	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2382	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2383	METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPBTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
U-2384	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10
U-2385	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11
U-2386	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19
U-2387	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20
U-2388	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28
U-2389	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29
U-2390	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41
U-2391	ADJUNCT TO DIET AND EXCERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42
U-2392	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50
U-2393	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51
U-2394	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2395	FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2396	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR
U-2397	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606
U-2398	TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
U-2399	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S PATENT 10058546

PATENT USE

U-2400	REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2401	A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1
U-2402	TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION
U-2403	TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE
U-2404	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
U-2405	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2406	A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2407	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2408	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2409	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
U-2410	TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE
U-2411	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR
U-2412	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
U-2413	FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
U-2414	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN
U-2415	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2416	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN
U-2417	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2418	METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY
U-2419	METHOD OF OPERATING AN INJECTION DEVICE
U-2420	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2421	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2422	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2423	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2424	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2425	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2426	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME

PATENT USE

U-2427	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2428	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
U-2429	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2430	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
U-2431	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS
U-2432	LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2433	METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA
U-2434	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2435	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD
U-2436	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
U-2437	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
U-2438	CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
U-2439	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
U-2440	FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2441	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2442	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2443	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2444	TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION
U-2445	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-2446	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2447	TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
U-2448	TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS
U-2449	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION
U-2450	POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
U-2451	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-2452	COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
U-2453	TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS
U-2454	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2455	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME

PATENT USE

U-2456	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
U-2457	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
U-2458	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
U-2459	TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2460	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2461	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2462	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2463	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2464	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2465	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2466	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2467	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2468	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2469	METHOD OF TREATING CANCEROUS SOLID TUMORS
U-2470	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2471	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT
U-2472	METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2473	METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION
U-2474	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
U-2475	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT
U-2476	USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE
U-2477	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-2478	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES
U-2479	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES
U-2480	MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
U-2481	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY

PATENT USE

U-2482	TREATMENT OF HR-NEGATIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
U-2483	TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2484	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
U-2485	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
U-2486	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER
U-2487	DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY
U-2488	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
U-2489	TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER
U-2490	TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
U-2491	A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
U-2492	A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
U-2493	A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT
U-2494	INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING
U-2495	VENTRICULAR FIBRILLATION
U-2496	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-2497	TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS
U-2498	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2499	METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM
U-2500	USE OF A DELIVERY DEVICE TO DELIVER A BIOEQUIVALENT DOSE OF A NALOXONE COMPOSITION VIA A NEEDLE
U-2501	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2502	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-2503	TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPIATE, HER2/NEU-TARGETED THERAPY
U-2504	TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH RIBOCICLIB AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
U-2505	TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2506	METHOD OF TREATING TESTOSTERONE DEFICIENCY
U-2507	METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA

PATENT USE

U-2508	A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2509	A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2510	A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-2511	A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
U-2512	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
U-2513	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2514	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2515	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-2516	A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2517	A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2518	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-2519	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2520	TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
U-2521	TREATMENT OF MS WITH A TABLET WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE AND HYDROXYPROPYL-B-CYCLODEXTRIN AND (B) AMORPHOUS FREE CLADRIBINE AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, CLADRIBINE/CYCLODEXTRIN 1:10-1:16 W/W
U-2522	TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
U-2523	TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W/O SIGN. AMOUNTS OF CRYST. 2CDA
U-2524	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
U-2525	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY OR URGE INCONTINENCE
U-2526	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2527	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

PATENT USE

U-2528	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
U-2529	TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION REPSONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2530	TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO < 6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2531	TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
U-2532	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
U-2533	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
U-2534	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
U-2535	USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER
U-2536	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
U-2537	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
U-2538	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
U-2539	IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER
U-2540	TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
U-2541	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
U-2542	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
U-2543	TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE
U-2544	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-2545	TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE
U-2546	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2547	METHOD OF PROVIDING CONTRACEPTION IN A WOMAN HAVING A BMI OF 25 KG/M2 OR MORE WITH RESULTANT LIMITED BLEEDING EVENTS PER TREATMENT CYCLE
U-2548	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
U-2549	CONTROL OF SERUM PHOSPHORUS LEVELS
U-2550	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
U-2551	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
U-2552	METHOD OF TREATING POSTPARTUM DEPRESSION
U-2553	PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
U-2554	TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON

PATENT USE

U-2555	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-2556	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2557	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
U-2558	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
U-2559	USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
U-2560	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
U-2561	USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
U-2562	TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
U-2563	TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
U-2564	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
U-2565	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
U-2566	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
U-2567	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT
U-2568	TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-2569	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
U-2570	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2571	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2572	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546
U-2573	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2574	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2575	TREATING CYSTIC FIBROSIS PATIENTS AGES 6 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
U-2576	TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

PATENT USE

U-2577	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAS HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-2578	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE
U-2579	REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
U-2580	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
U-2581	TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
U-2582	FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE
U-2583	TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN
U-2584	XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES
U-2585	TREATMENT OF PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS IN PATIENTS UNDER THE AGE OF 12
U-2586	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
U-2587	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
U-2588	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
U-2589	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
U-2590	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
U-2591	LOWERING PLASMA GLUCAGON IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
U-2592	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2593	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2594	REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2595	REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2596	REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2597	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
U-2598	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN INJECTABLE SUSTAINED RELEASE FORMULATION OF EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
U-2599	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS

PATENT USE

U-2600	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2601	STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2602	DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2603	METHOD OF TREATING IRON DEFICIENCY
U-2604	TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
U-2605	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
U-2606	TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
U-2607	TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS
U-2608	METHOD OF TREATING SCHIZOPHRENIA
U-2609	A METHOD FOR INDUCING A REGIONAL ANAESTHESIA VIA INTRATHECAL ADMINISTRATION OF A PATENTED PRESERVATIVE FREE SOLUTION FOR INJECTION (WITH A SPECIFIC COMPOSITION, PH, OSMOLALITY AND DENSITY) CONTAINING 9-11 MG/ML CHLOROPROCAINE HCL
U-2610	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2611	TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2612	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN PATIENTS 10 YEARS OF AGE AND OLDER
U-2613	TREATMENT OF RELAPSING-REMITTING SCLEROSIS (MS)
U-2614	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA
U-2615	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-2616	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE
U-2617	TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER
U-2618	TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2619	TREATMENT OF ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2620	USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
U-2621	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN
U-2622	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
U-2623	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
U-2624	TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
U-2625	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
U-2626	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR
U-2627	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
U-2628	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
U-2629	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO

PATENT USE

U-2630	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
U-2631	TREATMENT OF COMPLICATED URINARY TRACT INFECTION
U-2632	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2633	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER, PROGRESSED ON: CRIZOTINIB + AT LEAST 1 OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB, OR CERITINIB AS FIRST ALK INHIBITOR FOR METASTATIC DISEASE.
U-2634	METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
U-2635	TREATMENT OF ACUTE URTICARIA
U-2636	METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
U-2637	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
U-2638	INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
U-2639	METHOD OF ACTIVATING RARGAMMA RECEPTOR
U-2640	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
U-2641	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2642	METHOD OF TREATING CANCER BY DETECTING A CREATININE CLEARANCE OF A PATIENT AND ADMINISTERING LONSURF
U-2643	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
U-2644	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
U-2645	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2646	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE ONE F508DEL MUTATION AND ONE R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2647	TREATMENT OF NON-NODULAR ACNE VULGARIS
U-2648	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2649	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
U-2650	TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AMORPHOUS IVACAFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-2651	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2652	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-2653	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF

PATENT USE

	ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2654	TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2655	A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS
U-2656	TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
U-2657	TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
U-2658	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE
U-2659	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE
U-2660	TREATMENT OF H. PYLORI INFECTION IN ADULTS
U-2661	CHRONIC WEIGHT MANAGEMENT IN ADULT PATIENTS USING AN EXTENDED RELEASE TABLET CONTAINING LORCARSERIN HYDROCHLORIDE HEMIHYDRATE
U-2662	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
U-2663	USE IN SONOHYSTEROSALPINOGRAPHY TO ASSESS FALLOPIAN TUBE PATENCY
U-2664	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY INDUCING SKIPPING OF EXON 51
U-2665	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2666	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-2667	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA
U-2668	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2669	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2670	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
U-2671	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2672	TREATMENT OF ACUTE HEPATIC PORPHYRIA
U-2673	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY CORRECTING A DEFECTIVE GENE FOR DYSTROPHIN
U-2674	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION
U-2675	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
U-2676	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1 TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2
U-2677	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
U-2678	PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
U-2679	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE
U-2680	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION
U-2681	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP
U-2682	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING

PATENT USE

	100MG OF ACALABRUTINIB TWICE DAILY
U-2683	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
U-2684	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
U-2685	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
U-2686	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2687	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2688	USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2689	USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG/DL) AND ON STATIN THERAPY
U-2690	USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2691	USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2692	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2693	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2694	USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2695	USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2696	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION, AND UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2697	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2698	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2699	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
U-2700	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY
U-2701	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2702	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
U-2703	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT (CV DEATH, CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND DIABETES MELLITUS

PATENT USE

U-2704	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND AT LEAST ONE RISK FACTOR FOR CARDIOVASCULAR DISEASE
U-2705	METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA
U-2706	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY
U-2707	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA
U-2708	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER